<SEC-DOCUMENT>0000875045-20-000005.txt : 20200206
<SEC-HEADER>0000875045-20-000005.hdr.sgml : 20200206
<ACCEPTANCE-DATETIME>20200206163239
ACCESSION NUMBER:		0000875045-20-000005
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		190
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200206
DATE AS OF CHANGE:		20200206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		20583107

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>biib-20191231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:34EC581D374D58D1BE89CE1852F4C110,x:31b9914e8b2641aabe18eafa592dfe26-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:biib="http://www.biogenidec.com/20191231" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonFraction decimals="2" unitRef="usd" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="biib:AverageStockPriceOnGrantDateInDollarsMaximum" id="Fact-E1DADEECA96329DE235D6F38B875BAB9-wk-Fact-E1DADEECA96329DE235D6F38B875BAB9">267.88</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usd" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="biib:AverageStockPriceOnGrantDateInDollarsMaximum" id="Fact-527FABF924E06DF975726F38B873BC9A-wk-Fact-527FABF924E06DF975726F38B873BC9A">346.76</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usd" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="biib:AverageStockPriceOnGrantDateInDollarsMaximum" id="Fact-8AE57826EEE2EB0602D96F38B872E835-wk-Fact-8AE57826EEE2EB0602D96F38B872E835">331.18</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usd" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="biib:AverageStockPriceOnGrantDateInDollarsMinimum" id="Fact-24E5D42CE847B29554036F38B8795FC9-wk-Fact-24E5D42CE847B29554036F38B8795FC9">263.18</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usd" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="biib:AverageStockPriceOnGrantDateInDollarsMinimum" id="Fact-A7DAE5BD4AD52B2198CA6F38B86F7587-wk-Fact-A7DAE5BD4AD52B2198CA6F38B86F7587">279.47</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usd" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="biib:AverageStockPriceOnGrantDateInDollarsMinimum" id="Fact-3A5DE464808C2798DA176F38B871BD09-wk-Fact-3A5DE464808C2798DA176F38B871BD09">228.59</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:CompensationExpenseOverPurchasePeriod" id="Fact-A03F848351BE481BF8D16F38B7A5DB76-wk-Fact-A03F848351BE481BF8D16F38B7A5DB76">The fair value of the look-back provision plus the 15% discount</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:EstimatedUsefulLivesOfLeaseholdImprovements" id="Fact-62C72C917F54368B79356F38B7A54CBB-wk-Fact-62C72C917F54368B79356F38B7A54CBB">Lesser of the useful life or the term of the respective lease</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="Fact-6110EA3B8640BF0D62D66F38B8B35502-wk-Fact-6110EA3B8640BF0D62D66F38B8B35502">Indefinite</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="Fact-DCC86966D94742959D726F38B8B2452D-wk-Fact-DCC86966D94742959D726F38B8B2452D">Indefinite</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:PaymentTermsOfAccountsReceivable" id="Fact-5F142DCE72FD5134700E6F38B7A2E496-wk-Fact-5F142DCE72FD5134700E6F38B7A2E496">30 to 90 days</ix:nonNumeric><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2017Q4_srt_ProductOrServiceAxis_biib_RituxanMember" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" id="Fact-9E5D1C690A1B3B1254016F38B82B06AD-wk-Fact-9E5D1C690A1B3B1254016F38B82B06AD">0.375</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_RituxanMember" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" id="Fact-6FCE829BB6F09C994EAD6F38B89242A5-wk-Fact-6FCE829BB6F09C994EAD6F38B89242A5">0.375</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH" name="biib:PercentageOfMinimumInvestmentReturn" id="Fact-B2C25DE9246FE9F1ADDE6F38B8279589-wk-Fact-B2C25DE9246FE9F1ADDE6F38B8279589">0.0100</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:PurchasePriceOfCommonStockUnderEspp" id="Fact-699918F11E4708DEF9106F38B7A47F0D-wk-Fact-699918F11E4708DEF9106F38B7A47F0D">85% of the lower of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:AmendmentFlag" id="Fact-601138F62D1C8D2958846F38B8C1504E-wk-Fact-601138F62D1C8D2958846F38B8C1504E" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-06B7887BD1A8B23C3B886F38B8C441C5-wk-Fact-06B7887BD1A8B23C3B886F38B8C441C5">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-4B124B26183E6D03F6586F38B8C36512-wk-Fact-4B124B26183E6D03F6586F38B8C36512">FY</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalYearFocus" id="Fact-6E1016268B067DD34AA26F38B8BFB35A-wk-Fact-6E1016268B067DD34AA26F38B8BFB35A">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:EntityCentralIndexKey" id="Fact-3FEAB178574D22E242196F38B8BF2AA2-wk-Fact-3FEAB178574D22E242196F38B8BF2AA2">0000875045</ix:nonNumeric><ix:nonFraction decimals="4" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-85A1AFF0B49581B25B366F38B7D90BF4-wk-Fact-85A1AFF0B49581B25B366F38B7D90BF4">0.0005</ix:nonFraction><ix:nonFraction decimals="4" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-5DFC402E0126967CB4006F38B7D77431-wk-Fact-5DFC402E0126967CB4006F38B7D77431">0.0005</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-5EA23C2207BDD738691E6F38B83B4DE9-wk-Fact-5EA23C2207BDD738691E6F38B83B4DE9">0.052</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-1D0ADB12ADA663D2040D6F38B8425926-wk-Fact-1D0ADB12ADA663D2040D6F38B8425926">0.0405</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-67D0AE3558AB50F5D08A6F38B840B179-wk-Fact-67D0AE3558AB50F5D08A6F38B840B179">0.03625</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-FABA99D64585208CA56D6F38B83EB03B-wk-Fact-FABA99D64585208CA56D6F38B83EB03B">0.029</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-81600C9A0651D20828876F38B8B223F0-wk-Fact-81600C9A0651D20828876F38B8B223F0">P28Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-6E15AF8386CB79E957DD6F38B8B4A42A-wk-Fact-6E15AF8386CB79E957DD6F38B8B4A42A">P4Y</ix:nonNumeric><ix:nonFraction decimals="3" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-AA88748079D9B380E8496F38B7D98433-wk-Fact-AA88748079D9B380E8496F38B7D98433">0.001</ix:nonFraction><ix:nonFraction decimals="3" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-86DCC857F67C7F46C9BD6F38B7D8C446-wk-Fact-86DCC857F67C7F46C9BD6F38B7D8C446">0.001</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-EEE9BF4E254006CC2C9E6F38B7A29AFF-wk-Fact-EEE9BF4E254006CC2C9E6F38B7A29AFF">P40Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-13C488D9E41343A8B7EE6F38B7A33BF4-wk-Fact-13C488D9E41343A8B7EE6F38B7A33BF4">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-153CC06D6EA62F0A52336F38B7A40C82-wk-Fact-153CC06D6EA62F0A52336F38B7A40C82">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-FD08B729ECF2C081B08A6F38B7A4D731-wk-Fact-FD08B729ECF2C081B08A6F38B7A4D731">P20Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-FE61D96427A39BE025246F38B7A27545-wk-Fact-FE61D96427A39BE025246F38B7A27545">P15Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-86BC2A4465AAC25075FC6F38B7A581F3-wk-Fact-86BC2A4465AAC25075FC6F38B7A581F3">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-DBE47407B1C4535086796F38B7A56FDC-wk-Fact-DBE47407B1C4535086796F38B7A56FDC">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-AFC93C3C3D190267E7DE6F38B7A3B32B-wk-Fact-AFC93C3C3D190267E7DE6F38B7A3B32B">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs" id="Fact-2EE1844C4B58DBE8170B6F38B866C2C5-wk-Fact-2EE1844C4B58DBE8170B6F38B866C2C5">0</ix:nonNumeric><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-6D8C27F9216C433740646F38B88A79F9-wk-Fact-6D8C27F9216C433740646F38B88A79F9">0.356</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-D237F246AF8DB7B950F96F38B88A1D9B-wk-Fact-D237F246AF8DB7B950F96F38B88A1D9B">0.330</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-4344324549D84AC1B9FD6F38B886F120-wk-Fact-4344324549D84AC1B9FD6F38B886F120">0.324</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-D9A4DFE51F184DEB18246F38B887C4B8-wk-Fact-D9A4DFE51F184DEB18246F38B887C4B8">0.275</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-6D281EE0B4EB38A5923E6F38B878089C-wk-Fact-6D281EE0B4EB38A5923E6F38B878089C">0.336</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-7656A5517DB6D5E1671B6F38B876F2CF-wk-Fact-7656A5517DB6D5E1671B6F38B876F2CF">0.312</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-3782FE58C378859235B86F38B86FCEFF-wk-Fact-3782FE58C378859235B86F38B86FCEFF">0.016</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-941E760E735BA19EC38F6F38B86EB083-wk-Fact-941E760E735BA19EC38F6F38B86EB083">0.023</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" id="Fact-A61344F03DC3C8D92A306F38B885CF7F-wk-Fact-A61344F03DC3C8D92A306F38B885CF7F">0.025</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-3CD5599D57576D94FB7B6F38B87A4BE9-wk-Fact-3CD5599D57576D94FB7B6F38B87A4BE9">0.009</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-B5F6CE3CDF4ACECF48676F38B8707903-wk-Fact-B5F6CE3CDF4ACECF48676F38B8707903">0.019</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="Fact-5320006E980F782C8B846F38B87C5B0F-wk-Fact-5320006E980F782C8B846F38B87C5B0F">0.025</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact-734743511DAD63D802D36F38B82ED381-wk-Fact-734743511DAD63D802D36F38B82ED381">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact-99CAF33D20DB4421C94B6F38B82E7DBD-wk-Fact-99CAF33D20DB4421C94B6F38B82E7DBD">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact-8A010BA93697EF84D0E16F38B7EA0C22-wk-Fact-8A010BA93697EF84D0E16F38B7EA0C22">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:TreasuryStockShares" id="Fact-ACA1E382C836063D0E616F38B7D9045D-wk-Fact-ACA1E382C836063D0E616F38B7D9045D">23800000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:TreasuryStockShares" id="Fact-CC5ECDE03E80FD890D4B6F38B7D86F9D-wk-Fact-CC5ECDE03E80FD890D4B6F38B7D86F9D">23800000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="biib-20191231.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-02-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredIncomeTaxChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DeferredIncomeTaxChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_biib_DeferredtaxliabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:KaryopharmMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:AliveGenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:AliveGenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:KaryopharmMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_RemedyPharmaceuticalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:RemedyPharmaceuticalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SobiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SobiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SobiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:WorkinprocessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_PLSRMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:PLSRMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD_srt_ProductOrServiceAxis_biib_VUMERITYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q1_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BG00011Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-01</xbrli:startDate>
			<xbrli:endDate>2015-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2012Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2010Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-10-01</xbrli:startDate>
			<xbrli:endDate>2010-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2012Q1_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_biib_SubleaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">biib:SubleaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_biib_SubleaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">biib:SubleaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:OperatingleaseassetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4creditfacility_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4creditfacility_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-28</xbrli:startDate>
			<xbrli:endDate>2020-01-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_biib_UndesignatedPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:UndesignatedPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_biib_SeriesXPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:SeriesXPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_DirectorsPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:DirectorsPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4QTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_biib_ForeignearningstypeAxis_biib_OtherForeignEarningsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:OtherForeignEarningsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_biib_ForeignearningstypeAxis_biib_ForeignearningsintheformofcashandcashequivalentsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:ForeignearningsintheformofcashandcashequivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_biib_PrepaidtaxesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:PrepaidtaxesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DeferredTaxAssetLiabilityTypeAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_biib_CumulativeSalesLevelAxis_biib_TwentybillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:TwentybillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SixteenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4QTD_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SixteenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_FifteenbillionMemberMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:FifteenbillionMemberMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2012Q1Feb_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-01</xbrli:startDate>
			<xbrli:endDate>2012-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_StatementGeographicalAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_srt_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2012Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_NewAntiCd20Member_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_NewAntiCd20Member_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2013Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_TypeOfArrangementAxis_biib_IPerianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IPerianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q1_srt_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-07-01</xbrli:startDate>
			<xbrli:endDate>2013-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_country_BR">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-04-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_ExpectedPaymentTimelineofMilestoneAxis_biib_TwelvemonthsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ExpectedPaymentTimelineofMilestoneAxis">biib:TwelvemonthsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_TwentybillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:TwentybillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_CommercialMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:CommercialMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Pfizer_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="KRW">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Plan">
		<xbrli:measure>biib:Plan</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Increment">
		<xbrli:measure>biib:Increment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51074274e3506-wk-Fact-18648B692AB2CAE6B5BE6F38B8007958" toRefs="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51074274e1962-wk-Fact-25F8D9680520642A20556F38B7A877D9" toRefs="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51064427e3498-wk-Fact-4F1B1F369F645FCAB5E06F38B89EFA30" toRefs="TextSelection-7DBF3EF78F81D359A1B66F38B8E4EC02-0-wk-Footnote-7DBF3EF78F81D359A1B66F38B8E4EC02_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51064427e5013-wk-Fact-607BA5807AAC7AE99C9D6F38B7FC34A8" toRefs="TextSelection-6E4BA122DC3EE32976BC6F38B8E4D29B-0-wk-Footnote-6E4BA122DC3EE32976BC6F38B8E4D29B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51074274e3525-wk-Fact-7D710B0C70644267D7476F38B819CD33" toRefs="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51074274e2039-wk-Fact-90B4B0BBDC335E1D98E66F38B7AEC3AF" toRefs="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51074274e2020-wk-Fact-9E8DAB667FD08FF8AE916F38B7ACD38A" toRefs="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51064427e3517-wk-Fact-9ECB7064E915716669C46F38B829E7BC d51064427e3889-wk-Fact-9ECB7064E915716669C46F38B829E7BC" toRefs="TextSelection-7DBF3EF78F81D359A1B66F38B8E4EC02-0-wk-Footnote-7DBF3EF78F81D359A1B66F38B8E4EC02_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51064427e4878-wk-Fact-A2BEB14B74EE13ECC3C46F38B87B88DB" toRefs="TextSelection-6E4BA122DC3EE32976BC6F38B8E4D29B-0-wk-Footnote-6E4BA122DC3EE32976BC6F38B8E4D29B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51074274e3487-wk-Fact-AD7947C887768A97332A6F38B805214D" toRefs="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51064427e4468-wk-Fact-B089A6B821E5A82ACA5F6F38B8043D78" toRefs="TextSelection-7DBF3EF78F81D359A1B66F38B8E4EC02-0-wk-Footnote-7DBF3EF78F81D359A1B66F38B8E4EC02_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51074274e3545-wk-Fact-D6A590AF10C4643FB6FE6F38B80C7506" toRefs="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51074274e3564-wk-Fact-E3357B8FDA69C56A09186F38B7FDB839" toRefs="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51064427e4859-wk-Fact-E86D1CE0A120BCF496176F38B80DB12E" toRefs="TextSelection-6E4BA122DC3EE32976BC6F38B8E4D29B-0-wk-Footnote-6E4BA122DC3EE32976BC6F38B8E4D29B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51074274e1981-wk-Fact-F03991FB13B63561F4C96F38B7CC50F3" toRefs="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d51074274e2000-wk-Fact-F1ACA004E23D51D9B4726F38B7B6E740" toRefs="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"></ix:relationship></ix:resources></ix:header></div><div><a id="sC9B727AFD67F5E2EAC710EA097F08E8A"></a></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</span></div><div style="line-height:100%;text-align:center;font-size:18pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;</span><span><ix:nonNumeric id="d50957966e1302-wk-Fact-8A0BD13F9654E1708EB06F47CA3D88E7" name="dei:DocumentType" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">10-K</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:100%;text-align:left;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:14pt;"><span style="font-family:Arial Unicode MS;font-size:14pt;"><span><ix:nonNumeric id="d50957966e1320-wk-Fact-8AC584334697CA5AF6676F5D16084FB9" name="dei:DocumentAnnualReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:42px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the fiscal year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d50957966e1330-wk-Fact-E2F33040799E665984FC6F52E5F164F8" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q4YTD" format="ixt:datemonthdayyearen">December 31, 2019</ix:nonNumeric></span></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:100%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:100%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">or</span></div><div style="line-height:100%;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:14pt;"><span style="font-family:Arial Unicode MS;font-size:14pt;"><span><ix:nonNumeric id="d50957966e1352-wk-Fact-3459CEEEFAC318EF53C96F64AD8D9C87" name="dei:DocumentTransitionReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission file number:&#160;</span><span><ix:nonNumeric id="d50957966e1362-wk-Fact-8FF2256FFD63083C31126F65B4DA690C" name="dei:EntityFileNumber" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">0-19311</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;"><img src="biogenlogo2020a01.jpg" alt="biogenlogo2020a01.jpg" style="height:42px;width:128px;"></img></div><div style="line-height:100%;text-align:center;font-size:24pt;"><span><ix:nonNumeric id="d50957966e1371-wk-Fact-F4886CD50E944D3BFD496F66BB5F74FE" name="dei:EntityRegistrantName" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;"> </span></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d50957966e1393-wk-Fact-D5FDEF9463C34BF02A4A6F678B37A423" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q4YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d50957966e1403-wk-Fact-6B38EB0D7BD444EC36416F686F26055F" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q4YTD">33-0112644</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d50957966e1422-wk-Fact-6DAE157B31DF5216E6506F693C13B591" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">225 Binney Street</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d50957966e1427-wk-Fact-27902AF61E711D4CAF786F6D76C3DCA7" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">Cambridge</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d50957966e1432-wk-Fact-7154533D5E89DEEF68CA6F6E0C00FF91" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">MA</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d50957966e1437-wk-Fact-334900A350D58FFCC3E46F6ED17D95B3" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">02142</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d50957966e1445-wk-Fact-C5C2D35F6513E1BABC0C6F6F7BCC6CF0" name="dei:CityAreaCode" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">617</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">)&#160;</span><span><ix:nonNumeric id="d50957966e1450-wk-Fact-C31EF1664673F29BE8A46F6FF7852803" name="dei:LocalPhoneNumber" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">679-2000</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</span></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.81481481481482%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Title of Each Class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Name of Each Exchange Where Registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d50957966e1509-wk-Fact-2E56A7F1386DB9728FA16F74B8D83F0E" name="dei:Security12bTitle" contextRef="FD2019Q4YTD">Common Stock, $0.0005&#160;par value</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d50957966e1519-wk-Fact-8F2E3B31C107204E37026F76272291CD" name="dei:TradingSymbol" contextRef="FD2019Q4YTD">BIIB</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">The</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d50957966e1534-wk-Fact-9BE6B29D477F3BD46FA16F772CDA80AE" name="dei:SecurityExchangeName" contextRef="FD2019Q4YTD" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">None</span></div><div style="line-height:100%;padding-top:5px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d50957966e1545-wk-Fact-41EE8623BDCA627FCB916F79BEF375CE" name="dei:EntityWellKnownSeasonedIssuer" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:100%;padding-top:5px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d50957966e1564-wk-Fact-03EB33628C68E360B7E66F7B2F40FFF8" name="dei:EntityVoluntaryFilers" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">No</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span></div><div style="line-height:100%;padding-top:5px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d50957966e1574-wk-Fact-86E93BC8EFB70DC13E2E6F7BF17D195D" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:100%;padding-top:5px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d50957966e1588-wk-Fact-FDFC56682816F3A7F6E66F7CD4C6C400" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:100%;padding-top:5px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="line-height:100%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:24%;"></td><td style="width:3%;"></td><td style="width:39%;"></td><td style="width:31%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d50957966e1619-wk-Fact-1D339E7308DF24AA5BC56F88ABA10583" name="dei:EntityFilerCategory" contextRef="FD2019Q4YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">x</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d50957966e1665-wk-Fact-452C19F066A64736E2FF6F8946356071" name="dei:EntitySmallBusiness" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d50957966e1691-wk-Fact-11BA7DFC965395B933626F8997BE0D1A" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d50957966e1701-wk-Fact-DB8A85D06B8CE086F5F26F8D70A120E1" name="dei:EntityShellCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) computed by reference to the price at which the common stock was last sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d50957966e1711-wk-Fact-10A120009520C03707E26F38B7B34CD4" name="dei:EntityPublicFloat" contextRef="FI2019Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">43,010,112,437</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;4, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the registrant had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50957966e1722-wk-Fact-F0A469027FF5A7D7626D6F38B7B72BFD" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2019Q4SharesOutstanding" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">174,064,011</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock, $0.0005&#160;par value, outstanding.</span></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Portions of the definitive proxy statement for our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this report.</span></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s9BA39E4D1C415CF592B019C4847E2A7F"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">ANNUAL REPORT ON FORM&#160;10-K</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Year Ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">TABLE OF CONTENTS</span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:76%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s06BEA940A3235F70A697756DB4C7D45C"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;I</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBB11A173FBC258CEA789272E5FF7B95F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBB11A173FBC258CEA789272E5FF7B95F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Business</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBB11A173FBC258CEA789272E5FF7B95F">1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s12D04E5FF9455A22921BC51F6CDD8456"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s12D04E5FF9455A22921BC51F6CDD8456"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s12D04E5FF9455A22921BC51F6CDD8456">33</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1427BFBEDF605FF887B947A13B9FCBEA"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1B.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1427BFBEDF605FF887B947A13B9FCBEA"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unresolved Staff Comments</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1427BFBEDF605FF887B947A13B9FCBEA">48</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s764E11D3C33B5E219872C6F463F20B00"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s764E11D3C33B5E219872C6F463F20B00"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Properties</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s764E11D3C33B5E219872C6F463F20B00">48</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s2DA15E2C0A5950C5B0D9405F5AF76E3B"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s2DA15E2C0A5950C5B0D9405F5AF76E3B"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s2DA15E2C0A5950C5B0D9405F5AF76E3B">49</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s7FEF9BFBD32357B8B8DC12BC0A18F9EC"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s7FEF9BFBD32357B8B8DC12BC0A18F9EC"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s7FEF9BFBD32357B8B8DC12BC0A18F9EC">49</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#sCC880C9055425AA286429B4E353FF968"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;II</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s8D15A8B0B7C751F895D9607AEBD1077F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 5.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s8D15A8B0B7C751F895D9607AEBD1077F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s8D15A8B0B7C751F895D9607AEBD1077F">50</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s53518B7B8E4B5F35B532D2DEF336FD1C"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s53518B7B8E4B5F35B532D2DEF336FD1C"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selected Financial Data</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s53518B7B8E4B5F35B532D2DEF336FD1C">52</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE31BAA7BAB4A5EF394B812AFB8336190"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 7.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE31BAA7BAB4A5EF394B812AFB8336190"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE31BAA7BAB4A5EF394B812AFB8336190">55</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5B65AF34E43F5E6CBB32796E8DA1D59D"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 7A.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5B65AF34E43F5E6CBB32796E8DA1D59D"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5B65AF34E43F5E6CBB32796E8DA1D59D">86</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s25D3F174C5C25E5191124E4035FF41C5"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 8.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s25D3F174C5C25E5191124E4035FF41C5"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements and Supplementary Data</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s25D3F174C5C25E5191124E4035FF41C5">88</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1BEAC78354CC51C59225AFFAB359E71B"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1BEAC78354CC51C59225AFFAB359E71B"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1BEAC78354CC51C59225AFFAB359E71B">88</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFF2848B3ED115BAEA9389921DFB1C2CB"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9A.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFF2848B3ED115BAEA9389921DFB1C2CB"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFF2848B3ED115BAEA9389921DFB1C2CB">88</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD64C8A7D444A562D86F8B85A9B701047"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9B.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD64C8A7D444A562D86F8B85A9B701047"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Information</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD64C8A7D444A562D86F8B85A9B701047">89</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s4134C6EB1658550C9E619F58314EE047"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;III</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s476AAACF3B8354239CF346B4EAF6E0BB"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 10.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s476AAACF3B8354239CF346B4EAF6E0BB"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Directors, Executive Officers and Corporate Governance</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s476AAACF3B8354239CF346B4EAF6E0BB">90</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s4FB207C7F3A654F7B100D4469F6EDCB3"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 11.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s4FB207C7F3A654F7B100D4469F6EDCB3"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Compensation</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s4FB207C7F3A654F7B100D4469F6EDCB3">90</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sEC9A18032A775CDA9773B1097E61F799"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 12.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sEC9A18032A775CDA9773B1097E61F799"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sEC9A18032A775CDA9773B1097E61F799">90</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s39E1D3E99B155EFF90B00E0CD73EE80F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 13.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s39E1D3E99B155EFF90B00E0CD73EE80F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s39E1D3E99B155EFF90B00E0CD73EE80F">90</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDBE941E4C6CB536993EC5F0C13EC4453"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 14.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDBE941E4C6CB536993EC5F0C13EC4453"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Principal Accountant Fees and Services</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDBE941E4C6CB536993EC5F0C13EC4453">90</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#sACD2232777E05562B9938EF24C78D202"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;IV</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA8A12005879F5E9F9683D83027128802"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;15.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA8A12005879F5E9F9683D83027128802"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exhibits and Financial Statement Schedules</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA8A12005879F5E9F9683D83027128802">91</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE2CB510631A55C398EA798A7D52C8FFC"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 16.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE2CB510631A55C398EA798A7D52C8FFC"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form 10-K Summary</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE2CB510631A55C398EA798A7D52C8FFC">91</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s16FDF2DBB88E58939B769B4367E8A1AE"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Signatures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s16FDF2DBB88E58939B769B4367E8A1AE">95</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE4D3A870A9AF5A41BA9D0C2A8FE36F60"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE4D3A870A9AF5A41BA9D0C2A8FE36F60">F- 1</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s131DB2520BBB57BBA8AE99E5FF3B32FF"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; "goal," &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expenses; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete, including increased competition from generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our plans and investments in our core and emerging growth areas, as well as implementation of our corporate strategy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intention to commit resources relating to research and development programs and business development opportunities, as well as the potential benefits and results of, and the anticipated timing to complete, certain business development transactions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filings and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities and activities in new or existing manufacturing facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.) departure from the European Union (E.U.);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws, including the Swiss Federal Act on Tax Reform and AHV Financing, regulatory requirements, judicial decisions and accounting standards.</span></div></td></tr></table><div><br/></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div><a id="s87DBAB85A0A35A94B1690BCD8CC66A3E"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in this report to:</span></div><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;text-indent:0px;"><span style="padding-top:12px;text-align:left;font-family:Franklin Gothic Book,sans-serif;font-size:10pt;padding-right:17px;">&#8226;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries;</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">"ELOCTATE" refers to both ELOCTATE (the trade name for Antihemophilic Factor (recombinant), Fc Fusion Protein in the U.S., Canada and Japan) and ELOCTA (the trade name for Antihemophilic Factor (recombinant), Fc Fusion Protein in the E.U.).</span></div></td></tr></table><div><a id="s02C697BCF25058A1AC3F831FF106A4EE"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174;, VUMERITY&#174; and ZINBRYTA&#174; are registered trademarks of Biogen. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FLIXABI</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FUMADERM</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and IMRALDI</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">are trademarks of Biogen. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX&#174;, ELOCTATE&#174;, ENBREL&#174;, EYLEA&#174;, FAMPYRA</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, GAZYVA&#174;, HUMIRA&#174;, LUCENTIS&#174;, OCREVUS&#174;, REMICADE&#174;, SkySTAR</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and other trademarks referenced in this report are the property of their respective owners.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s06BEA940A3235F70A697756DB4C7D45C"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I</span></div><div><a id="sBB11A173FBC258CEA789272E5FF7B95F"></a></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1. &#160;&#160;&#160;&#160;Business</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><img src="bubbles20192.jpg" alt="bubbles20192.jpg" style="height:193px;width:318px;"></img></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We also introduced the first approved treatment for SMA and are continuing to pursue research and development for potential advancements in the treatment of SMA, including a muscle enhancement program, novel antisense oligonucleotide (ASO) drug candidates and an oral splicing modulator. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, ALS, Parkinson's disease, choroideremia (CHM), X-linked retinitis pigmentosa (XLRP), systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), cognitive impairment associated with schizophrenia (CIAS), stroke, epilepsy and pain.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell  BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE0AABD4BC9685212BCFCE6E3F6CF48C8"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Key Business Developments</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of key developments affecting our business since the beginning of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisitions, collaborative and other relationships discussed below, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Note 19,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Investments in Variable Interest Entities,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions, Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration. In October 2019 we amended this agreement to add an additional discovery program.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of this acquisition, we added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM Corporation (FUJIFILM). </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Samsung Bioepis</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. We also acquired an option to extend our existing commercial agreement with Samsung Bioepis for BENEPALI, IMRALDI and FLIXABI in Europe and obtained exclusive rights to commercialize these products in China.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB080 Option Exercise</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we exercised our option with Ionis Pharmaceuticals, Inc. (Ionis) and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO), an investigational treatment for AD.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pfizer Inc.</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2020 we entered into an agreement to acquire PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). In particular, we plan to develop the Phase 1 asset for the treatment of sundowning in AD and irregular sleep wake rhythm disorder (ISWRD) in Parkinson&#8217;s disease. This transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S. We expect this transaction to close in the first quarter of 2020.</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Key Developments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">VUMERITY</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 the U.S. Food and Drug Administration (FDA) approved VUMERITY for the treatment of RMS. The FDA approval of VUMERITY was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway. It included interim exposure and safety findings from EVOLVE-MS-1, an ongoing, Phase 3, single-arm, open label, two-year safety study evaluating VUMERITY in patients with relapsing remitting MS (RRMS), and data from pharmacokinetic bridging studies comparing VUMERITY and TECFIDERA to establish bioequivalence, and relied, in part, on the FDA's findings of safety and efficacy for TECFIDERA. In November 2019 VUMERITY became available in the U.S.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab (A&#946; mAb)</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 we and our collaboration partner Eisai Co., Ltd. (Eisai) announced that we plan to pursue regulatory approval for aducanumab, our anti-amyloid beta antibody candidate for the potential treatment of AD, in the U.S.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2019 Share Repurchase Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program). Our March 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our March 2019 Share Repurchase Program will be retired.</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program). Our December 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our December 2019 Share Repurchase Program will be retired.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Board of Directors Update</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 stockholders elected two new independent directors, William A. Hawkins and Jesus B. Mantas, to Biogen's Board of Directors, who are each serving for a one-year term until the 2020 annual meeting of stockholders and their successors are duly elected and qualified.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Management Changes</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2019 we announced the following management changes:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The appointment of Alfred Sandrock, Jr., M.D., Ph.D. as Executive Vice President, Research and Development; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The appointment of Alphonse Galdes, Ph.D., as Executive Vice President, Pharmaceutical Operations and Technology.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on these and our other executive officers, please read the subsection entitled "Information about our Executive Officers" included in this report.</span></div><div><a id="s409A59AEBCBE5C07B5CEB4FF0789D071"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product and Pipeline Developments</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Core Growth Areas</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Multiple Sclerosis and Neuroimmunology</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">TECFIDERA (dimethyl fumarate)</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2019, at the 71</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA, we presented re-analyzed pooled images from the Phase 3 DEFINE and CONFIRM studies that showed that treatment with TECFIDERA significantly slowed the rate of whole brain volume loss by 35.9% during the second year of treatment compared to placebo.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019, at the 35</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Congress of the European Committee for Treatment and Research in MS (ECTRIMS) and 24</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Annual Conference of Rehabilitation in MS in Stockholm, Sweden, we presented new 10-year results from the ongoing Phase 3 ENDORSE extension study and comparative effectiveness analyses of TECFIDERA that support the consistent, long-term benefits of treatment with TECFIDERA.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">TYSABRI (natalizumab)</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 the first patient was enrolled in the global Phase 3b NOVA study evaluating the efficacy and safety of extended interval dosing (EID; every six weeks) for natalizumab compared to standard interval dosing in patients with RMS.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2019, at the 71</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> annual meeting of the AAN in Philadelphia, PA, we presented updated safety analyses from the TOUCH database safety analysis evaluating EID of natalizumab (of approximately every six weeks) compared to every four-week dosing based on the TOUCH prescribing program database.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019, at the 35</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Congress of ECTRIMS and 24</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Annual Conference of Rehabilitation in MS in Stockholm, Sweden, we presented new data from the observational, open-label, single-arm STRIVE study that support the real-world long-term effectiveness of TYSABRI in patients with early RMS, who are within three years from diagnosis and are anti-JC virus antibody negative.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">AVONEX (interferon beta-1a) and PLEGRIDY (peginterferon beta-1a)</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019, at the 35</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Congress of ECTRIMS and 24</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Annual Conference of Rehabilitation in MS in Stockholm, Sweden, we presented new data from two real-world observational studies that provide further support that exposure to interferon beta treatment, including AVONEX and PLEGRIDY, before conception and/or during pregnancy is not expected to have an adverse effect on pregnancy or infant growth outcomes.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 the European Medicines Agency (EMA) updated the summaries of product characteristics for AVONEX and PLEGRIDY to remove pregnancy contraindications and, where clinically needed, to allow use during pregnancy and breastfeeding in women with RMS.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">VUMERITY (diroximel fumarate; DRF)</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2019, at the 71</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> annual meeting of the AAN in Philadelphia, PA, we presented updated safety and exploratory efficacy results from the ongoing open-label EVOLVE-MS-1 study of VUMERITY in RMS.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2019 we presented new interim data from the EVOLVE-MS-1 study at the annual meeting of the Consortium of Multiple Sclerosis Centers in Seattle, WA. These data indicated that VUMERITY was generally well tolerated and significantly reduced disease activity in newly diagnosed RMS patients and those previously treated with interferons or glatiramer acetate. Treatment discontinuations due to gastrointestinal events occurred at a low rate over one year.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 we and Alkermes plc announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of VUMERITY for RMS, compared to TECFIDERA. VUMERITY was statistically superior to TECFIDERA on the study's pre-specified primary endpoint, with patients treated with VUMERITY self-reporting significantly fewer days of key gastrointestinal symptoms with intensity scores &#8805; 2 on the Individual Gastrointestinal Symptom and Impact Scale, as compared to TECFIDERA (p=0.0003).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019, at the 35</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Congress of ECTRIMS and 24</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Annual Conference of Rehabilitation in MS in Stockholm, Sweden, we presented interim data from the Phase 3 EVOLVE-MS-1 study that support the potential of VUMERITY as a novel oral fumarate.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2019, at the 27</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Annual Meeting of the European Charcot Foundation in Italy, we presented results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed gastrointestinal tolerability of VUMERITY compared to TECFIDERA.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB091 (BTK inhibitor)</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2019 the first participant was dosed in the Phase 1 study of BIIB091 in MS.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 dosing began for the final multiple ascending dose cohort in the Phase 1 study of BIIB091 in MS.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Alzheimer's Disease and Dementia</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Aducanumab (A&#946; mAb)</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we and our collaboration partner Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 we and our collaboration partner Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S. and that the Phase 3 EMERGE study met its primary endpoint showing a significant reduction in clinical decline. We believe that results from a subset of patients in the Phase 3 ENGAGE study who received sufficient exposure to high dose aducanumab support the findings from EMERGE. The decision to file is based on a new analysis, conducted in consultation with the FDA, of a larger dataset from the Phase 3 EMERGE and ENGAGE trials that were discontinued in March 2019 following a futility analysis.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019, at the 12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Clinical Trials on Alzheimer's Disease annual meeting in San Diego, CA, we presented topline results from the Phase 3 EMERGE and ENGAGE trials of aducanumab.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BAN2401 (A&#946; mAb)</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2019 our collaboration partner Eisai dosed the first patient in the global Phase 3 study (Clarity AD) of BAN2401 in early AD.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB092 (gosuranemab)</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019 we completed enrollment of the Phase 2 study of gosuranemab for early AD.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neuromuscular Disorders</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">SPINRAZA (nusinersen)</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2019 SPINRAZA was approved by the China National Medical Products Association for the treatment of 5q SMA.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2019 we presented new data illustrating the rapidly progressive nature of SMA in adults, adolescents and older children. We also presented data from the NURTURE study, highlighting the benefits of pre-symptomatic treatment and findings on the role of neurofilament as a potential biomarker for predicting motor function in SMA. These data were presented at the Muscular Dystrophy Association Clinical and Scientific Conference in Orlando, FL.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2019 data from CS2/CS12, an open-label study of the safety and tolerability of SPINRAZA in individuals with later-onset SMA, were published in the peer-reviewed journal </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Neurology</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the medical journal of the AAN. The data showed that individuals with later-onset SMA, treated with SPINRAZA, regained motor function that had been previously lost and that treatment stabilized their disease activity leading to improvements in activities of daily living.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2019, at the 71</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> annual meeting of the AAN in Philadelphia, PA, we presented data from the NURTURE study that demonstrated that pre-symptomatic infants with SMA treated with SPINRAZA over three years achieved motor milestones that are more consistent with normal childhood development, as well as interim results from the ENDEAR/CHERISH/SHINE open-label extension study that showed that treatment with SPINRAZA, particularly when initiated earlier, leads to progressive motor milestone improvements and increased survival rates for individuals with infantile-onset SMA.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2019 The National Institute for Health and Care Excellence (NICE) in the U.K. recommended funding for SPINRAZA on the National Health Service. The positive recommendation is for the treatment of infants, children and adults with 5q SMA, including pre-symptomatic and symptomatic SMA Types 1, 2 and 3.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June and July 2019 we presented new results from the NURTURE study, adding data to the longest study of SMA in pre-symptomatic infants (n=25). The data reported, after up to 45.1 months of analysis, continued to demonstrate efficacy and safety in patients treated pre-symptomatically with SPINRAZA in comparison to the natural history of SMA. These new data also showed that patients treated with SPINRAZA had continuous improvement, with the majority of patients achieving motor milestones within timeframes consistent with normal development. These data were presented at the Cure SMA Annual SMA Conference in Anaheim, CA and the 5</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Congress of the European Academy of Neurology in Oslo, Norway.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019 we announced that we plan to initiate DEVOTE, a new Phase 2/3 study evaluating whether a higher dose of SPINRAZA can offer even greater efficacy in treating SMA, as well as the safety and tolerability of SPINRAZA, when administered at a higher dose.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019 we presented new data further demonstrating the safety and efficacy of treatment with SPINRAZA in individuals with later-onset SMA at the 13</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Congress of the European Paediatric Neurology Society in Athens, Greece. An integrated analysis from SHINE, an open-label extension study for patients with SMA who participated in prior SPINRAZA studies, found that children with later-onset SMA (Type 2 or Type 3) experienced improvements or stabilization in one or more measures of motor function for up to nearly six years, in contrast to the expected decline observed in natural history cohorts.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 the journal </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Neuromuscular Disorders</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> published data from NURTURE, the first study investigating a treatment targeting the underlying cause of SMA in infants treated pre-symptomatically. Data from the NURTURE study demonstrated that infants who initiated treatment with SPINRAZA prior to the onset of clinical symptoms attained unparalleled results compared to the natural history of the disease. These published results from the NURTURE study were previously presented at the 2019 Cure SMA Annual </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:54px;padding-top:12px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SMA Conference in Anaheim, CA and the 5</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Congress of the European Academy of Neurology in Oslo, Norway.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB067 (tofersen) - ALS</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 the first patient was dosed in the Phase 3 VALOR study of tofersen in adults with ALS with a confirmed superdioxide dismutate 1 (SOD1) mutation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2019 we presented interim results of the Phase 1/2 study of tofersen. The data demonstrated a statistically significant reduction in SOD1 protein levels and a numerical trend towards slowing of clinical decline in SOD1-ALS patients treated with tofersen compared to placebo. The data were presented at the 71</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> annual meeting of the AAN in Philadelphia, PA and The European Network for the Cure of ALS meeting in Tours, France.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB100 (XPO1 inhibitor) - ALS</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 the first patient was dosed in the Phase 1 study of BIIB100 in sporadic ALS.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Movement Disorders</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB054 (cinpanemab) - Parkinson's Disease</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2019 we completed enrollment of the Phase 2 study of BIIB054 for Parkinson's disease.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB094 (ION859) - Parkinson's Disease</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 the first patient in the Phase 1 study of BIIB094, an ASO targeting leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease, was dosed.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Ophthalmology</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB111 (timrepigene emparvovec) - CHM</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2019 we completed enrollment of the Phase 3 STAR study of timrepigene emparvovec for CHM.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Emerging Growth Areas</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Immunology</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Dapirolizumab Pegol (anti-CD40L) - SLE</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 our collaboration partner UCB presented interim results from the Phase 2b study of dapirolizumab pegol (DZP) in patients with active SLE despite standard-of-care treatment. The primary endpoint of the study, which was to demonstrate a dose response at 24 weeks on the British Isles Lupus Assessment Group-based Composite Lupus Assessment (p=0.07), was not met. The study did demonstrate consistent and potentially meaningful improvements for the majority of clinical endpoints in patients treated with DZP compared with placebo. In addition, biomarker data demonstrated evidence of proof of biology. DZP was well tolerated and demonstrated an acceptable safety profile. The data were presented at the European Congress of Rheumatology (EULAR) 2019 in Madrid, Spain.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB059 (anti-BDCA2) - CLE/SLE</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2019 we completed enrollment of the Phase 2 LILAC study of BIIB059 for CLE and SLE.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we announced positive top-line results from the Phase 2 LILAC study evaluating the efficacy and safety of BIIB059 in CLE and SLE. The CLE part of the study met its primary endpoint (p&lt;0.001) by demonstrating a dose response of BIIB059 on the percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at week 16 in individuals with CLE. Study participants with CLE treated with 50 mg, 150 mg and 450 mg of BIIB059 experienced reductions in CLASI-A scores of 40.9% (p=0.008), 48.0% (p=0.001) and 42.5% (p=0.001), respectively, versus 14.5% with placebo. CLASI-A is a well-defined and reliable outcome measure that has been shown to detect meaningful change in CLE skin disease activity.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:54px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The SLE part of the study also met its primary endpoint of reducing disease activity in individuals with SLE as measured by change from baseline in total active joint count at week 24 (treatment difference = -3.4 for BIIB059 450 mg versus placebo, p=0.037). Total active joint count is the total number of tender or swollen </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:54px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">joints, with joint involvement being a common symptom in people with SLE. In addition, improvements in skin disease and overall disease activity were consistently observed across multiple secondary endpoints.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurocognitive Disorders</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB104 (AMPA) - CIAS</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 the FDA granted BIIB104 fast track designation for CIAS.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acute Neurology</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB093 (glibenclamide IV) - Brain Contusion</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 we dosed the first patient in the Phase 2 study of BIIB093 for brain contusion.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Biosimilars</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Samsung Bioepis - Biogen's Joint Venture with Samsung BioLogics</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 we presented real-world evidence confirming the safety and efficacy of BENEPALI, IMRALDI and FLIXABI and the high adherence of patients to treatment. The data were presented at EULAR 2019 in Madrid, Spain.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 we presented new data highlighting real-world evidence confirming the safety and efficacy of IMRALDI and FLIXABI for patients with inflammatory bowel disease. These data were presented at the United European Gastroenterology Week 2019 in Barcelona, Spain.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Genentech Relationship</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-CD20 Therapies</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">GAZYVA (obinutuzumab)</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 Roche announced positive topline results for NOBILITY, a Phase 2 study investigating the safety and efficacy of GAZYVA for adults with proliferative lupus nephritis. The study met its primary endpoint, showing GAZYVA, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrated enhanced efficacy compared to placebo plus standard of care alone in achieving complete renal response at one year. In addition, GAZYVA met key secondary endpoints showing improved overall renal responses (complete and partial renal response) and serologic markers of disease activity as compared to placebo.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019 Roche announced that the FDA granted breakthrough therapy designation to GAZYVA for adults with lupus nephritis. This designation was granted based on data from the Phase 2 NOBILITY study in adult patients with proliferative lupus nephritis, as discussed above.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Discontinued Programs</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 we discontinued the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis (IPF) due to safety concerns.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019 we and our collaboration partner Eisai announced the decision to discontinue the global Phase 3 studies (MISSION AD1 and MISSION AD2) of the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in patients with early AD.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we announced that the Phase 2 PASSPORT study investigating gosuranemab in individuals with progressive supranuclear palsy (PSP) did not meet its primary endpoint. Based on these results, we discontinued development of gosuranemab in PSP and other primary tauopathies. Safety results of the Phase 2 PASSPORT study were generally consistent with previous studies of gosuranemab. We will continue our ongoing Phase 2 TANGO study of gosuranemab for mild cognitive impairment due to AD or mild AD, given differences in disease pathology.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="s94405D25A48C55408F52A5F19E61AC93"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Marketed Products</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following graph shows our revenues by product and revenues from anti-CD20 therapeutic programs for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;"><img src="marketedproductsrev.jpg" alt="marketedproductsrev.jpg" style="height:508px;width:666px;"></img></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Interferon includes product revenues from AVONEX and PLEGRIDY.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">For 2019, 2018 and 2017 other includes product revenues from FAMPYRA, FUMADERM, BENEPALI and FLIXABI. For 2019 and 2018 other also includes product revenues from IMRALDI, which was launched in Europe in October 2018. For 2019 other also includes product revenues from VUMERITY, which was available in the U.S. in November 2019. For 2018 and 2017 other also includes product revenues from ZINBRYTA, which was voluntary withdrawn from the market in March 2018. For 2017 other also includes product revenues from ALPROLIX and ELOCTATE through January 31, 2017. No product revenues for ALPROLIX and ELOCTATE were recognized subsequent to February 1, 2017, the effective date of the spin-off of our hemophilia business.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Anti-CD20 therapeutic programs include revenues from RITUXAN, RITUXAN HYCELA, GAZYVA and OCREVUS.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales for TECFIDERA, AVONEX and TYSABRI as well as our share of pre-tax profits in the U.S. for RITUXAN each accounted for more than 10% of our total revenues for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Product sales for SPINRAZA also accounted for more than 10% of our total revenues for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional financial information about our product and other revenues and geographic areas where we operate, please read Note 4, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and Note&#160;24, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report and Item&#160;6. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Selected Financial Data </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Item 7. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management's Discussion and Analysis of Financial Condition and Results of Operations </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">included in this report. A discussion of the risks attendant to our operations is set forth in Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis and Neuroimmunology</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, leading to a loss of muscle control, paralysis and, in some cases, death. Patients with active RMS experience an uneven pattern of disease progression characterized by periods of stability that are interrupted by flare-ups of the disease after which the patient returns to a new baseline of functioning. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our MS products and major markets are as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Collaborator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="tecfidera.jpg" alt="tecfidera.jpg" style="height:37px;width:172px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RMS in the U.S.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RRMS in the E.U.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="avonex.jpg" alt="avonex.jpg" style="height:49px;width:134px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RMS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="plegridy.jpg" alt="plegridy.jpg" style="height:77px;width:128px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RMS in the U.S.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RRMS in the E.U.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="tysabri.jpg" alt="tysabri.jpg" style="height:62px;width:114px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RMS</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RRMS in the E.U.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Crohn's disease in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="vumerity-logoa03.jpg" alt="vumerity-logoa03.jpg" style="height:56px;width:140px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RMS in the U.S.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="fampyra.jpg" alt="fampyra.jpg" style="height:37px;width:133px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Walking ability for patients with MS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acorda Therapeutics, Inc. (Acorda)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Neuromuscular Disorders</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SMA is characterized by loss of motor neurons in the spinal cord and lower brain stem, resulting in severe and progressive muscular atrophy and weakness. Ultimately, individuals with the most severe type of SMA can become paralyzed and have difficulty performing the basic functions of life, like breathing and swallowing. Due to a deletion or mutations in the SMN1 gene, people with SMA do not produce enough survival motor neuron (SMN) protein, which is critical to the survival of the neurons that control muscles. The severity of SMA correlates with the amount of SMN protein. People with Type 1 SMA, the most severe life-threatening form, produce very little SMN protein and do not achieve the ability to sit without support, and typically do not live beyond two years of age without respiratory support and nutritional interventions. People with Type 2 and Type 3 SMA produce greater amounts of SMN protein and have less severe, but still life-altering, forms of SMA. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our SMA product and major markets are as follows: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Collaborator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><img src="spinrazalogonewa01.jpg" alt="spinrazalogonewa01.jpg" style="height:80px;width:160px;"></img><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SMA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Brazil</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Turkey</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Ionis, please read Note&#160;18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars are a group of biologic medicines that are similar to currently available biologic therapies known as originators. Under our agreement with Samsung Bioepis, we commercialize three anti-tumor necrosis factor (TNF) biosimilars in certain countries in Europe: BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE. Additionally, we have exclusive rights to commercialize BENEPALI, IMRALDI and FLIXABI in China and two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current biosimilar products and major markets are as follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="benepalia04.jpg" alt="benepalia04.jpg" style="height:74px;width:173px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rheumatoid arthritis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Juvenile idiopathic arthritis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Psoriatic arthritis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Axial spondyloarthritis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plaque psoriasis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paediatric plaque psoriasis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="imraldi.jpg" alt="imraldi.jpg" style="height:89px;width:173px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rheumatoid arthritis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Juvenile idiopathic arthritis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Axial spondyloarthritis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Psoriatic arthritis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Psoriasis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paediatric plaque psoriasis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hidradenitis suppurativa </span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adolescent hidradenitis suppurativa</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Crohn&#8217;s disease</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paediatric Crohn's disease</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ulcerative colitis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Uveitis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paediatric Uveitis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="flixabi.jpg" alt="flixabi.jpg" style="height:85px;width:162px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rheumatoid arthritis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Crohn&#8217;s disease</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paediatric Crohn&#8217;s disease</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ulcerative colitis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paediatric ulcerative colitis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ankylosing spondylitis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Psoriatic arthritis</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Psoriasis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note&#160;18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech Relationships</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have agreements with Genentech that entitle us to certain business and financial rights with respect to RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS and other potential anti-CD20 therapies. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current anti-CD20 therapeutic programs and major markets are as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="rituxan.jpg" alt="rituxan.jpg" style="height:46px;width:128px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-Hodgkin's lymphoma</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CLL</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rheumatoid arthritis</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Two forms of ANCA-associated vasculitis</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pemphigus vulgaris</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="rituxanhycelalogo300x87.jpg" alt="rituxanhycelalogo300x87.jpg" style="height:48px;width:165px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-Hodgkin's lymphoma</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CLL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="gazyva.jpg" alt="gazyva.jpg" style="height:73px;width:97px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In combination with chlorambucil for previously untreated CLL</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Follicular lymphoma</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In combination with chemotherapy followed by GAZYVA alone for previously untreated follicular lymphoma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="ocrevus.jpg" alt="ocrevus.jpg" style="height:49px;width:165px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RMS</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">PPMS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australia</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and Note&#160;18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Collaborator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="fumaderm.jpg" alt="fumaderm.jpg" style="height:45px;width:116px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Moderate to severe plaque psoriasis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><a id="sCC57476974D458DAB1C7B4B970D68274"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Patient Support and Access</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We interact with patients, advocacy organizations and healthcare societies in order to gain insights into unmet needs. The insights gained from these engagements help us support patients with services, programs and applications that are designed to help patients lead better lives. Among other things, we provide customer service and other related programs for our products, such as disease and product specific websites, insurance research services, financial assistance programs and the facilitation of the procurement of our marketed products. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are dedicated to helping patients obtain access to our therapies. Our patient representatives have access to a suite of financial assistance tools. With those tools, we help patients understand their insurance coverage and, if needed, help patients compare and select new insurance options and programs. In the U.S., we have established programs that provide co-pay assistance or free marketed product for qualified uninsured or underinsured patients, based on specific eligibility criteria. We also provide charitable contributions to independent charitable organizations that assist patients with out-of-pocket expenses associated with their therapy.</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Marketing and Distribution</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales Force and Marketing</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We promote our products worldwide, including in the U.S., most of the major countries of the E.U. and Japan, primarily through our own sales forces and marketing groups. In some countries, particularly in areas where we continue to expand into new geographic areas, we partner with third parties. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN, RITUXAN HYCELA, GAZYVA and OCREVUS are marketed by the Roche Group and its sublicensees.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We commercialize BENEPALI, IMRALDI and FLIXABI in collaboration with Samsung Bioepis in certain countries in Europe.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We focus our sales and marketing efforts on specialist physicians in private practice or at major medical centers. We use customary industry practices to market our products and to educate physicians, such as sales representatives calling on individual physicians, advertisements, professional symposia, direct mail, public relations and other methods. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Distribution Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We distribute our products in the U.S. principally through wholesale distributors of pharmaceutical products, mail order specialty distributors or shipping service providers. In other countries, the distribution of our products varies from country to country, including through wholesale distributors of pharmaceutical products and third-party distribution partners who are responsible for most marketing and distribution activities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN, RITUXAN HYCELA, GAZYVA and OCREVUS are distributed by the Roche Group and its sublicensees.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We distribute BENEPALI, IMRALDI and FLIXABI in certain countries in Europe and have exclusive rights to distribute these products in China.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our product sales to two wholesale distributors, AmerisourceBergen and McKesson, each accounted for more than 10% of our total revenues for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and on a combined basis, accounted for approximately 47%, 50% and 56% of our gross product revenues for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information, please read Note 4, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div><a id="s8B142B3C6CB25A8DBFFA833AEDEBDF63"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Patents and Other Proprietary Rights</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patents are important to obtaining and protecting exclusive rights in our products and product candidates. We regularly seek patent protection in the U.S.&#160;and in selected countries outside the U.S.&#160;for inventions originating from our research and development efforts. In addition, we license rights to various patents and patent applications. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.&#160;patents, as well as most foreign patents, are generally effective for 20&#160;years from the date the earliest application was filed; however, U.S.&#160;patents that issue on applications filed before June&#160;8, 1995,&#160;may be effective until 17&#160;years from the issue date, if that is later than the 20-year date. In some cases, the patent term may be extended to recapture a portion of the term lost during regulatory review of the claimed therapeutic or, in the case of the U.S., because of U.S.&#160;Patent and Trademark Office (USPTO) delays in prosecuting the application. Specifically, in the U.S., under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, a patent that covers a drug approved by the FDA may be eligible for patent term extension (for up to 5 years, but not beyond a total of </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14 years from the date of product approval) as compensation for patent term lost during the FDA regulatory review process. The duration and extension of the term of foreign patents varies, in accordance with local law. For example, supplementary protection certificates (SPCs) on some of our products have been granted in a number of European countries, compensating in part for delays in obtaining marketing approval.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory exclusivity, which may consist of regulatory data protection and market protection, also can provide meaningful protection for our products. Regulatory data protection provides to the holder of a drug or biologic marketing authorization, for a set period of time, the exclusive use of the proprietary pre-clinical and clinical data that it created at significant cost and submitted to the applicable regulatory authority to obtain approval of its product. After the applicable set period of time, third parties are then permitted to rely upon such data to file for approval of their abbreviated applications for, and to market (subject to any applicable market protection), their generic drugs and biosimilars referencing such data. Market protection provides to the holder of a drug or biologic marketing authorization the exclusive right to commercialize its product for a set period of time, thereby preventing the commercialization of another product containing the same active ingredient(s) during that period. Although the World Trade Organization's agreement on trade-related aspects of intellectual property rights (TRIPS) requires signatory countries to provide regulatory exclusivity to innovative pharmaceutical products, implementation and enforcement varies widely from country to country.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely upon other forms of unpatented confidential information to remain competitive. We protect such information principally through </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">confidentiality agreements with our employees, consultants, outside scientific collaborators, scientists whose research we sponsor and other advisers. In the case of our employees, these agreements also provide, in compliance with relevant law, that inventions and other intellectual property conceived by such employees during their employment shall be our exclusive property.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our trademarks are important to us and are generally covered by trademark applications or registrations in the USPTO and the patent or trademark offices of other countries. We also use trademarks licensed from third parties, such as the trademark FAMPYRA, which we license from Acorda. Trademark protection varies in accordance with local law, and continues in some countries as long as the trademark is used and in other countries as long as the trademark is registered. Trademark registrations generally are for fixed but renewable terms.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our Patent Portfolio </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes our patents in the U.S. and Europe that we currently consider of primary importance to our marketed products, including the territory, patent number, general subject matter and expected expiration dates. Except as otherwise noted, the expected expiration dates include any granted patent term extensions and issued SPCs. In some instances, there are later-expiring patents relating to our products directed to, among other things, particular forms or compositions, methods of manufacturing or use of the drug in the treatment of particular diseases or conditions. We also continue to pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our products that may, if issued, extend exclusivity beyond the expiration of the patents listed in the table.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Territory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Patent No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">General Subject Matter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Patent </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Expiration</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,619,001</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,399,514</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2028</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1131065</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Formulations of dialkyl fumarates and their use for treating autoimmune diseases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2137537</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of use</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2028</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">AVONEX and PLEGRIDY</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,588,755</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Use of recombinant beta interferon for immunomodulation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">PLEGRIDY</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,446,173</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon beta-1a</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2022</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,524,660</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,017,733</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon beta-1a</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1656952</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon-beta-1a and uses thereof</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(5)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1476181</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon-beta-1a and uses thereof</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(6)</sup></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TYSABRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">6,602,503</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Humanized recombinant antibodies; nucleic acids and host cells; processes for production; therapeutic compositions; methods of use</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,807,167</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">9,493,567</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">0804237</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Humanized immunoglobulins; nucleic acids; pharmaceutical compositions; medical uses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(7)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1485127</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of use </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2676967</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of use</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">FAMPYRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1732548</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Sustained-release aminopyridine compositions for increasing walking speed in patients with MS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(8)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2377536</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Sustained-release aminopyridine compositions for treating MS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(9)</sup></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">VUMERITY</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,669,281</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Compounds and pharmaceutical compositions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2033</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">9,090,558</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2033</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">10,080,733</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Crystalline forms, pharmaceutical compositions and methods of treatment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2033</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">SPINRAZA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,101,993</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Oligonucleotides containing 2&#8217;-O-modified purines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,838,657</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">SMA treatment via targeting of SMN2 splice site inhibitory sequences</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,110,560</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">SMA treatment via targeting of SMN2 splice site inhibitory sequences</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,361,977</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,980,853</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">9,717,750</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">9,926,559</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2034</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">10,266,822</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">SMA treatment via targeting of SMN2 splice site inhibitory sequences</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">10,436,802</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Methods for Treating Spinal Muscular Atrophy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2035</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1910395</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(10)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2548560</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(11)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">3305302</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">3308788</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Footnotes follow on next page.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">In addition to patent protection, certain of our products are entitled to regulatory exclusivity in the U.S. and the E.U. expected until the dates set forth below:</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:2%;"></td><td style="width:21%;"></td><td style="width:2%;"></td><td style="width:55%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Territory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Expected Expiration</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">PLEGRIDY</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">FAMPYRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2021</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">SPINRAZA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2029</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">For additional information, please read Note 20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Litigation</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, to our consolidated financial statements included in this report.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2024. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent was revoked in a European opposition. This decision is being appealed. This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2029.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(5)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2024.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(6)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2028.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(7)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Reflects SPCs granted in most European countries and pediatric extension in some countries.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(8)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2026.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(9)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2026.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(10)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2031.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(11)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2031.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The existence of patents does not guarantee our right to practice the patented technology or commercialize the patented product. Patents relating to pharmaceutical, biopharmaceutical and biotechnology products, compounds and processes, such as those that cover our existing products, compounds and processes and those that we will likely file in the future, do not always provide complete or adequate protection. Litigation, interferences, oppositions, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our patents, regulatory exclusivities or other proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We also face challenges to our patents, regulatory exclusivities or other proprietary rights covering our products by manufacturers of generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways. A discussion of certain risks and uncertainties that may affect our patent position, regulatory exclusivities or other proprietary rights is set forth in Item 1A.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report, and a discussion of legal proceedings related to certain patents described above is set forth in Note&#160;20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF2112EB76AB952E0BDE833F3EAA3E2E5"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Competition</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition in the biopharmaceutical industry is intense and comes from many sources, including biotechnology and pharmaceutical companies. Many of our competitors, certain of whom have substantially greater financial, marketing, research and development and other resources than we do, are working to develop or have commercialized products similar to or competitive with those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that competition and leadership in the industry is based on managerial and technological excellence and innovation as well as establishing patent and other proprietary positions through research and development. The achievement of a leadership position also depends largely upon our ability to maximize the approval, acceptance and use of products resulting from research and the availability of adequate financial resources to fund facilities, equipment, personnel, clinical testing, manufacturing and marketing. Another key aspect of remaining competitive within the industry is recruiting and retaining leading scientists and technicians. We believe that we have been successful in attracting and retaining skilled and experienced scientific personnel.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition among products approved for sale may be based, among other things, on patent position, product efficacy, safety, convenience/delivery devices, reliability, availability and price. In addition, early entry of a new pharmaceutical product into the market may have important advantages in gaining product acceptance and market share. Accordingly, the relative speed with which we can develop products, complete the testing and approval process and supply commercial quantities of products will have a significant impact on our competitive position.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The introduction of new products or technologies, including the development of new processes or technologies by competitors or new information about existing products or technologies, results in increased competition for our marketed products and pricing pressure on our marketed products. The development of new or improved treatment options or standards of care or cures for the diseases our products treat reduces and could eliminate the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also face increased competitive pressures from the introduction of generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products, which may significantly reduce both the price that we are able to charge for our products and the volume of products we sell. In addition, when a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional information about the competition that our marketed products face is set forth below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and VUMERITY each compete with one or more of the following products as well as generic and biosimilar versions of such products: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:2%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Competing Product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Competitor</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">AUBAGIO (teriflunomide)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sanofi Genzyme</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">BETASERON/BETAFERON (interferon-beta-1b)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Bayer Group</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">COPAXONE </span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(glatiramer acetate)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Teva Pharmaceuticals Industries Ltd.</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">EXTAVIA </span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(interferon-beta-1b)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Novartis AG</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">GILENYA (fingolimod)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Novartis AG</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">GLATOPA (glatiramer acetate)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sandoz, a division of Novartis AG</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">LEMTRADA (alemtuzumab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sanofi Genzyme</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">MAVENCLAD (cladribine)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">EMD Serono</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">MAYZENT (siponimod)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Novartis AG</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">OCREVUS (ocrelizumab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Genentech</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">REBIF </span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(interferon-beta-1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">EMD Serono</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA is indicated as a treatment to improve walking in adult patients with MS who have a walking disability and is the first treatment that addresses this unmet medical need with demonstrated efficacy in people with all types of MS. FAMPYRA is currently the only therapy approved to improve walking in patients with MS. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition in the MS market is intense.&#160;Along with us, a number of companies are working to develop additional treatments for MS that may in the future compete with our MS products. One such product that was approved in the U.S. in 2017 and in the E.U. in 2018 is OCREVUS, a treatment for RMS and PPMS that was developed by Genentech. While we have a financial interest in OCREVUS, future sales of our MS products may be adversely affected if </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">OCREVUS continues to gain market share, or if other MS products that we or our competitors are developing are commercialized</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Future sales may also be negatively impacted</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">by</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of generics, prodrugs of existing therapies, biosimilars of existing products or products approved under abbreviated regulatory pathways.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We face competition from a new gene therapy product that was approved in the U.S. in May 2019 for the treatment of SMA. Additionally, we are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential oral products. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Psoriasis</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM competes with several different types of therapies in the psoriasis market within Germany, including oral systemics such as methotrexate and cyclosporine.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI, IMRALDI and FLIXABI, the three biosimilar products we currently commercialize in certain countries in Europe for Samsung Bioepis, compete with their reference products, ENBREL, HUMIRA and REMICADE, respectively, as well as other biosimilars of those reference products. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech Relationships in Other Indications</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN, RITUXAN HYCELA and GAZYVA in Oncology</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN, RITUXAN HYCELA and GAZYVA compete with a number of therapies in the oncology market, including TREANDA (bendamustine HCL), ARZERRA (ofatumumab), IMBRUVICA (ibrutinib) and ZYDELIG (idelalisib). </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also expect that over time RITUXAN HYCELA and GAZYVA will increasingly compete with RITUXAN in the oncology market. In addition, we are aware of anti-CD20 molecules, including biosimilar products, in development that if successfully developed and approved, could compete with RITUXAN, RITUXAN HYCELA and GAZYVA in the oncology market. The introduction of a biosimilar product can result in a significant reduction in net sales for the relevant product, as other manufacturers typically offer their versions at lower prices. In November 2019 and January 2020 biosimilar products referencing </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN were launched in the U.S. and this could adversely affect the pre-tax profits of our collaboration arrangements with Genentech, which could, in turn adversely affect our co-promotion profits in the U.S. in future years.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN in Rheumatoid Arthritis</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN competes with several different types of therapies in the rheumatoid arthritis market, including, among others, traditional disease-modifying anti-rheumatic drugs such as steroids, methotrexate and cyclosporine, TNF inhibitors, ORENCIA (abatacept), ACTEMRA (tocilizumab) and XELJANZ (tofacitinib).</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also aware of other products, including biosimilars, in development that, if approved, may compete with RITUXAN in the rheumatoid arthritis market. </span></div><div><a id="s07B62600DE1C5E739D04F9FF81E84B4D"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Research and Development Programs</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A commitment to research is fundamental to our mission. Our research efforts are focused on better understanding the underlying biology of diseases so we can discover and deliver treatments that have the potential to make a real difference in the lives of patients with high unmet medical needs. By applying our expertise in biologics and our growing capabilities in small molecule, antisense, gene therapy, gene editing and other technologies, we target specific medical needs where we believe new or better treatments are needed.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated. As part of our ongoing research and development efforts, we have devoted significant resources to conducting clinical studies to advance the development of new pharmaceutical products and technologies and to explore the utility of our existing products in treating disorders beyond those currently approved in their labels.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our research and development expense included in our consolidated statements of income, please read Item 7. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management's Discussion and Analysis of Financial Condition and Results of Operations </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The table below highlights our current research and development programs that are in clinical trials and the current phase of such programs. Drug development involves a high degree of risk and investment, and the status, timing and scope of our development programs are subject to change. Important factors that could adversely affect our drug development efforts are discussed in Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report. </span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:8%;"></td><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:3%;"></td><td style="width:6%;"></td><td style="width:6%;"></td></tr><tr><td rowspan="31" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Core Growth Areas</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">MS and Neuroimmunology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Opicinumab (anti-LINGO) - MS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB061 (oral remyelination) - MS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB091 (BTK inhibitor) - MS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td rowspan="9" style="vertical-align:middle;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Alzheimer's Disease and Dementia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Aducanumab (A&#946; mAb)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">*</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- Alzheimer's</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BAN2401 (A&#946; mAb)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">*</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- Alzheimer's</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB092 (gosuranemab) - Alzheimer's</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB076 (anti-tau mAb) - Alzheimer's</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB080 (tau ASO) - Alzheimer's</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td rowspan="7" style="vertical-align:middle;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Neuromuscular Disorders, </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">including SMA and ALS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB067 (tofersen) - ALS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB078 (IONIS-C9</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- ALS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB110 (ActRIIA/B ligand trap) - SMA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB100 (XP01 inhibitor) - ALS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Movement Disorders, </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">including Parkinson's Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB054 (cinpanemab) - Parkinson's</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB094 (ION859)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- Parkinson's</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Ophthalmology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB111 (timrepigene emparvovec) - CHM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB112 (RPGR gene therapy) - XLRP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2/3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td rowspan="20" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Emerging Growth Areas</span></div></td><td rowspan="3" style="vertical-align:middle;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Immunology / Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Dapirolizumab pegol (anti-CD40L)* - SLE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB059 (anti-BDCA2) - CLE/SLE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#def3c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Neurocognitive Disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#def3c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB104 (AMPA) - CIAS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td rowspan="7" style="vertical-align:middle;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Acute Neurology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB093 (glibenclamide IV) - LHI</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#94;</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;Stroke</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">TMS-007</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- Acute Ischemic Stroke</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Natalizumab - Epilepsy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB093 (glibenclamide IV) - Brain Contusion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#def3c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#def3c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB074 (vixotrigine) - Trigeminal Neuralgia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#def3c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB074 (vixotrigine) - Small Fiber Neuropathy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#def3c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB095 (Nav 1.7) - Neuropathic Pain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biosimilars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">SB11 (referencing LUCENTIS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Collaboration program</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"># Option agreement</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#94; Large Hemispheric Infarction (LHI)</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information about certain of our agreements with collaborators and other third parties, please read the subsection entitled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Business Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> below and Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD1622B99653154AFAF19E04F3419092E"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Business Relationships</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of our business strategy, we establish business relationships, including entering into licenses, joint ventures and collaborative arrangements with other companies, universities and medical research institutions, to assist in the clinical development and/or commercialization of certain of our products and product candidates and to provide support for our research programs. We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business from other companies, universities and medical research institutions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Below is a brief description of certain business relationships and collaborations that expand our pipeline and provide us with certain rights to existing and potential new products and technologies. For additional information on certain of these relationships, including their ongoing financial and accounting impact on our business, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Acorda to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Alkermes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive license and collaboration agreement with Alkermes for VUMERITY, which was approved for the treatment of RMS in the U.S. in October 2019 and became available in the U.S. in November 2019. Under this agreement, we received an exclusive, worldwide license to develop and commercialize VUMERITY. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for the development and potential commercialization of BIIB092 (gosuranemab), a phase 2 investigational therapy with potential in AD. Under this agreement, we received worldwide rights to gosuranemab and are responsible for the full development and potential commercialization of gosuranemab in AD. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai to jointly develop and commercialize BAN2401, an Eisai product candidate for the potential treatment of AD. Eisai serves as the global operational and regulatory </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. Upon marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have a collaboration agreement with Eisai to jointly develop and commercialize aducanumab (the Aducanumab Collaboration Agreement). Under the Aducanumab Collaboration Agreement, the two companies will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech, Inc. (Roche Group)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have collaboration arrangements with Genentech which entitle us to certain business and financial rights with respect to RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS and other potential anti-CD20 therapies. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive, worldwide option and collaboration agreement with Ionis relating to the development and commercialization of antisense therapeutics for up to three gene targets. Under a separate collaboration and license agreement with Ionis, we have an exclusive, worldwide license to develop and commercialize SPINRAZA for the treatment of SMA. We also have a 10-year exclusive collaboration agreement with Ionis to develop novel ASO drug candidates for a broad range of neurological diseases, which we refer to as the 2018 Ionis Agreement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we have research collaboration agreements with Ionis under which both companies perform discovery level research and will develop and commercialize new ASO drug candidates for the potential treatment of SMA and additional antisense or other therapeutics for the potential treatment of neurological diseases.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Neurimmune SubOne AG</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all licensed products.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Samsung BioLogics established a joint venture, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;We also have an agreement with Samsung Bioepis to commercialize, over a 10-year term, 3 anti-TNF biosimilar product candidates in Europe and, in the case of BENEPALI, Japan.&#160;Under this agreement, we are commercializing BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. </span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. We also acquired an option to extend our existing commercial agreement with Samsung Bioepis for BENEPALI, IMRALDI and FLIXABI in Europe and obtained exclusive rights to commercialize these products in China.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our joint venture and commercialization agreements with Samsung Bioepis, we license certain of our proprietary technology to Samsung Bioepis in connection with Samsung Bioepis' development, manufacture and commercialization of its biosimilar products. We also provide technical development and technology transfer services to Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and research and development services agreement with Skyhawk pursuant to which the companies are leveraging Skyhawk&#8217;s SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TMS Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive option agreement with TMS Co., Ltd. (TMS) granting us the option to acquire TMS-007, a plasminogen activator with a novel mechanism of action associated with breaking down blood clots which is in Phase 2 development in Japan, and backup compounds for the treatment of stroke.</span></div><div><a id="s9C878F8BD673553A8B663DD56B2C3039"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Regulatory</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current and contemplated activities and the products, technologies and processes that result from </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">such activities are subject to substantial government regulation.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation of Pharmaceuticals</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Approval and Post-Approval Regulation in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">APPROVAL PROCESS</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Before new pharmaceutical products may be sold in the U.S., preclinical studies and clinical trials of the products must be conducted and the results submitted to the FDA for approval. With limited exceptions, the FDA requires companies to register both pre-approval and post-approval clinical trials and disclose clinical trial results in public databases. Failure to register a trial or disclose study results within the required time periods could result in penalties, including civil monetary penalties. Clinical trial programs must establish efficacy, determine an appropriate dose and dosing regimen and define the conditions for safe use. This is a high-risk process that requires stepwise clinical studies in which the candidate product must successfully meet predetermined endpoints. The results of the preclinical and clinical testing of a product are then submitted to the FDA in the form of a Biologics License Application (BLA) or a NDA. In response to a BLA or NDA, the FDA may grant marketing approval, request additional information or deny the application if it determines the application does not provide an adequate basis for approval.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development and receipt of regulatory approval takes a number of years, involves the expenditure of substantial resources and depends on a number of factors, including the severity of the disease in question, the availability of suitable alternative treatments, potential safety signals observed in preclinical or clinical tests and the risks and benefits of the product as demonstrated in clinical trials. The FDA has substantial discretion in the product approval process, and it is impossible to predict with any certainty whether and when the FDA will grant marketing approval. The agency may require the sponsor of a BLA or NDA to conduct additional clinical studies or to provide other scientific or technical information about the product, and these additional requirements may lead to unanticipated delays or expenses. Furthermore, even if a product is approved, the approval may be subject to limitations based on the FDA's interpretation of the existing pre-clinical and/or clinical data. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA has developed four distinct approaches intended to facilitate the development and expedite the regulatory review of therapeutically important drugs, especially when the drugs are the first available treatment or have advantages over existing </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">treatments: accelerated approval, fast track, breakthrough therapy and priority review.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Accelerated Approval</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant &#8220;accelerated approval&#8221; to products that treat serious or life-threatening illnesses and that provide meaningful therapeutic benefits to patients over existing treatments. Under this pathway, the FDA may approve a product based on surrogate endpoints or clinical endpoints other than survival or irreversible morbidity. When approval is based on surrogate endpoints or clinical endpoints other than survival or morbidity, the sponsor will be required to provide the FDA with confirmatory data post-approval to verify and describe clinical benefit. Under the FDA's accelerated approval regulations, if the FDA concludes that a drug that has been shown to be effective can be safely used only if distribution or use is restricted, it may require certain post-marketing restrictions to assure safe use. In addition, for products approved under accelerated approval, sponsors may be required to submit all copies of their promotional materials, including advertisements, to the FDA at least 30 days prior to initial dissemination. The FDA may withdraw approval if, for instance, post-marketing studies fail to verify clinical benefit, it becomes clear that restrictions on the distribution of the product are inadequate to ensure its safe use or if a sponsor fails to comply with the conditions of the accelerated approval.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fast Track</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant "fast track" status to products that treat a serious condition and have data demonstrating the potential to address an unmet medical need or a drug that has been designated as a qualified infectious disease product.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Breakthrough Therapy</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant &#8220;breakthrough therapy&#8221; status to drugs designed to treat, alone or in combination with another drug or drugs, a serious or life-threatening disease or condition and for which preliminary clinical evidence suggests a substantial improvement over existing therapies based on a clinically significant endpoint. Breakthrough therapy status entitles the sponsor to earlier and more frequent meetings with the FDA regarding the development of nonclinical and clinical data and permits the FDA to offer product development or regulatory advice for the purpose of shortening the time to product approval. Breakthrough therapy status does not guarantee that a product will be eligible for priority review and does not ensure FDA approval.</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Priority Review</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: &#8220;Priority review&#8221; only applies to applications (original or efficacy supplement) for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, diagnosis or prevention of a serious condition. Priority review may also be granted for any supplement that proposes a labeling change due to studies completed in response to a written request from the FDA for pediatric studies, for an application for a drug that has been designated as a qualified infectious disease product or for any application or supplement for a drug submitted with a priority review voucher.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 the FDA issued a rare pediatric disease priority review voucher to us in connection with the approval of SPINRAZA. </span></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">POST-MARKETING STUDIES</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of the approval pathway employed, the FDA may require a sponsor to conduct additional post-marketing studies as a condition of approval to provide data on safety and effectiveness. If a sponsor fails to conduct the required studies, the FDA may withdraw its approval. In addition, if the FDA concludes that a drug that has been shown to be effective can be safely used only if distribution or use is restricted, it can mandate post-marketing restrictions to assure safe use. In such a case, the sponsor may be required to establish rigorous systems to assure use of the product under safe conditions. These systems are usually referred to as Risk Evaluation and Mitigation Strategies (REMS). The FDA can impose financial penalties for failing to comply with certain post-marketing commitments, including REMS. In addition, any changes to an approved REMS must be reviewed and approved by the FDA prior to implementation.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">ADVERSE EVENT REPORTING</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor information on side effects and adverse events reported during clinical studies and after marketing approval and report such information and events to regulatory agencies. Non-compliance with the FDA's safety reporting requirements may result in civil or criminal penalties. Side effects or adverse events that are reported during clinical trials can delay, impede or prevent marketing approval. Based on new safety information that emerges after approval, the FDA can mandate product labeling changes, impose a new REMS or the addition of elements to an existing REMS, require new post-marketing studies (including additional clinical trials) or suspend or withdraw approval of the product. These requirements may affect our ability to maintain marketing approval of our products or require us to </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">make significant expenditures to obtain or maintain such approvals.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">APPROVAL OF CHANGES TO AN APPROVED PRODUCT</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we seek to make certain types of changes to an approved product, such as adding a new indication, making certain manufacturing changes or changing manufacturers or suppliers of certain ingredients or components, the FDA will need to review and approve such changes in advance. In the case of a new indication, we are required to demonstrate with additional clinical data that the product is safe and effective for a use other than what was initially approved. FDA regulatory review may result in denial or modification of the planned changes, or requirements to conduct additional tests or evaluations that can substantially delay or increase the cost of the planned changes.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">REGULATION OF PRODUCT ADVERTISING AND PROMOTION</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA regulates all advertising and promotion activities and communications for products under its jurisdiction both before and after approval. Pursuant to FDA guidance, a company can make safety and efficacy claims from data either in or consistent with the label. However, physicians may prescribe legally available drugs for uses that are not described in the drug's labeling. Such off-label prescribing is common across medical specialties, and often reflect a physician's belief that the off-label use is the best treatment for patients. The FDA does not regulate the behavior of physicians in their choice of treatments, but FDA regulations do impose stringent restrictions on manufacturers' communications regarding off-label uses. Failure to comply with applicable FDA requirements may subject a company to adverse publicity, enforcement action by the FDA, corrective advertising and the full range of civil and criminal penalties available to the government.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Regulation of Combination Products</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Combination products are defined by the FDA to include products comprising two or more regulated components (e.g., a biologic and a device). Biologics and devices each have their own regulatory requirements, and combination products may have additional requirements. Some of our marketed products meet this definition and are regulated under this framework and similar regulations outside the U.S., and we expect that some of our pipeline product candidates may be evaluated for regulatory approval under this framework as well. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 new regulations governing medical devices (MDR) and in-vitro diagnostic medical devices (IVDR) entered into force in the E.U. although these </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">are not expected to fully apply until May 2020 with respect to the MDR regulations and May 2022 with respect to the IVDR regulations. All products covered by these regulations will be required to comply with them at the end of the transitional periods. These regulations introduce new requirements, including for clinical investigation of certain classifications of medical devices, require increased regulatory scrutiny, enhance the requirements for post market surveillance and vigilance and provide for greater transparency. These regulations also change the requirements for assessment of the medical device components of integral drug-device combination products, necessitating assessment of the device components under both the medical device and medicinal product regulatory regimes.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Approval and Post-Approval Regulation Outside the U.S.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We market our products in numerous jurisdictions outside the U.S. Most of these jurisdictions have product approval and post-approval regulatory processes that are similar in principle to those in the U.S. In Europe, for example, where a substantial part of our ex-U.S. efforts are focused, there are several routes for marketing approval, depending on the type of product for which approval is sought. Under the centralized procedure, a company submits a single application to the EMA. The marketing authorization application is similar to the NDA or BLA in the U.S. and is evaluated by the Committee for Medicinal Products for Human Use (CHMP), the expert scientific committee of the EMA responsible for human medicines. If the CHMP determines that the marketing authorization application fulfills the requirements for quality, safety and efficacy and that the medicine has a positive benefit risk balance, it will adopt a positive opinion recommending the granting of the marketing authorization by the European Commission (EC). The CHMP opinion is not binding, but is typically adopted by the EC. A marketing authorization application approved by the EC is valid in all member states of the E.U. The centralized procedure is required for all biological products, orphan medicinal products and new treatments for neurodegenerative disorders, and it is available for certain other products, including those which constitute a significant therapeutic, scientific or technical innovation.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the centralized procedure, the European regulatory framework includes the following options for regulatory review and approval in E.U. member states: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a national procedure, where the first application is made to the competent authority in one E.U. country only; </span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a decentralized procedure, where applicants submit identical applications to several E.U. countries and receive simultaneous approval, if the medicine has not yet been authorized in any E.U. country; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a mutual recognition procedure, where applicants that have a medicine authorized in one E.U. country can apply for mutual recognition of this authorization in other E.U. countries. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As in the U.S., the E.U. also has distinct approaches intended to optimize the regulatory pathways for therapeutically important drugs, including the Priority Medicines Evaluation Scheme (PRIME), accelerated assessment and conditional marketing authorization. PRIME is intended to provide additional support to medicine developers throughout the development process. Regulatory review timelines in the E.U. may be truncated under accelerated assessment for products that address an unmet medical need. In addition, conditional marketing  authorizations may be granted for such products in the interest of public health, where the benefit of immediate availability outweighs the risk of less comprehensive data than normally required. Conditional marketing authorizations are valid for one year and can be renewed annually. The marketing authorization holder is required to complete specific obligations (ongoing or new studies and, in some cases, additional activities) with a view to providing comprehensive data confirming that the benefit risk balance is positive. Once comprehensive data on the product have been obtained, the marketing authorization may be converted into a standard marketing authorization.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Aside from the U.S. and E.U., there are countries in other regions where it is possible to receive an "accelerated" review whereby the national regulatory authority will commit to truncated review timelines for products that meet specific medical needs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. there is detailed legislation on pharmacovigilance and extensive guidance on good pharmacovigilance practices. A failure to comply with E.U. pharmacovigilance obligations may result in significant financial penalties for the marketing authorization holder.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of the approval process employed, various parties share responsibilities for the monitoring, detection and evaluation of adverse events post-approval, including national competent authorities, the EMA, the EC and the marketing authorization holder. The EMA&#8217;s Pharmacovigilance Risk Assessment Committee is responsible for assessing and monitoring the safety of human medicines and makes recommendations on product safety issues. Marketing authorization holders have </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">an obligation to inform regulatory agencies of any new information which may influence the evaluation of benefits and risks of the medicinal product concerned. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., E.U. and other jurisdictions, regulatory agencies, including the FDA, conduct periodic inspections of NDA and BLA holders to assess their compliance with pharmacovigilance obligations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Good Manufacturing Practices</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory agencies regulate and inspect equipment, facilities and processes used in the manufacturing and testing of pharmaceutical and biologic products prior to approving a product. If, after receiving approval from regulatory agencies, a company makes a material change in manufacturing equipment, location or process, additional regulatory review and approval may be required. We also must adhere to current Good Manufacturing Practices (cGMP) and product-specific regulations enforced by regulatory agencies following product approval. The FDA, the EMA and other regulatory agencies also conduct periodic visits to re-inspect equipment, facilities and processes following the initial approval of a product. If, as a result of these inspections, it is determined that our equipment, facilities or processes do not comply with applicable regulations and conditions of product approval, regulatory agencies may seek civil, criminal or administrative sanctions or remedies against us, including significant financial penalties and the suspension of our manufacturing operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Good Clinical Practices</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA, the EMA and other regulatory agencies promulgate regulations and standards for designing, conducting, monitoring, auditing and reporting the results of clinical trials to ensure that the data and results are accurate and that the rights and welfare of trial participants are adequately protected (commonly referred to as current Good Clinical Practices (cGCP)). Regulatory agencies enforce cGCP through periodic inspections of trial sponsors, principal investigators and trial sites, contract research organizations (CROs) and institutional review boards. If our studies fail to comply with applicable cGCP guidelines, the clinical data generated in our clinical trials may be deemed unreliable and relevant regulatory agencies may require us to perform additional clinical trials before approving our marketing applications. Noncompliance can also result in civil or criminal sanctions. We rely on third parties, including CROs, to carry out many of our clinical trial-related activities. Failure of such third parties to comply with cGCP can likewise result in rejection of our clinical trial data or other sanctions.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2014 the EC adopted a new Clinical Trial Regulation, which was effective in June 2014 but is not expected to apply until 2021. The regulation harmonizes the procedures for assessment and governance of clinical trials throughout the E.U. and will require that information on the authorization, conduct and results of each clinical trial conducted in the E.U. be publicly available.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Approval of Biosimilars </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Patient Protection and Affordable Care Act (PPACA) amended the Public Health Service Act (PHSA) to authorize the FDA to approve biological products, referred to as biosimilars or follow-on biologics, that are shown to be "highly similar" to previously approved biological products based upon potentially abbreviated data packages.&#160;The biosimilar must show it has no clinically meaningful differences in terms of safety and effectiveness from the reference product, and only minor differences in clinically inactive components are allowable in biosimilar products. The approval pathway for biosimilars does, however, grant a biologics manufacturer a 12-year period of exclusivity from the date of approval of its biological product before biosimilar competition can be introduced. There is uncertainty, however, as the approval framework for biosimilars originally was enacted as part of the PPACA. There have been, and there are likely to continue to be, federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. If the PPACA is repealed, substantially modified or invalidated, it is unclear what, if any, impact such action would have on biosimilar regulation.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A biosimilars approval pathway has been in place in the E.U. since 2003. The EMA has issued a number of scientific and product specific biosimilar guidelines, including requirements for approving biosimilars containing monoclonal antibodies. In the E.U., biosimilars are generally approved under the centralized procedure. The approval pathway allows sponsors of a biosimilar to seek and obtain regulatory approval based in part on reliance on the clinical trial data of an innovator product to which the biosimilar has been demonstrated, through comprehensive comparability studies, to be &#8220;similar.&#8221; In many cases, this allows biosimilars to be brought to market without conducting the full complement of clinical trials typically required for novel biologic drugs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Orphan Drug Act</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the U.S.&#160;Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a &#8220;rare disease or condition,&#8221; which generally is a disease or condition that affects fewer than 200,000 individuals in the U.S.&#160;If a product which has an orphan drug designation subsequently </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">receives an initial FDA approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, i.e., the FDA may not approve any other applications to market the same drug for the same indication for a period of seven years following marketing approval, except in certain very limited circumstances, such as if the later product is shown to be clinically superior to the orphan product. Legislation similar to the U.S.&#160;Orphan Drug Act has been enacted in other countries to encourage the research, development and marketing of medicines to treat, prevent or diagnose rare diseases. In the E.U., medicinal products that receive and maintain an orphan designation are entitled to 10 years of market exclusivity following approval, protocol assistance and access to the centralized procedure for marketing authorization. SPINRAZA has been granted orphan drug designation in the U.S., E.U. and Japan.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation Pertaining to Pricing and Reimbursement</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In both domestic and foreign markets, sales of our products depend, to a significant extent, on the availability and amount of reimbursement by third-party payors, including governments, private health plans and other organizations. Substantial uncertainty exists regarding the pricing and reimbursement of our products, and drug prices continue to receive significant scrutiny. Governments may regulate coverage, reimbursement and pricing of our products to control cost or affect utilization of our products. Challenges to our pricing strategies, by either government or private stakeholders, could harm our business. The U.S.&#160;and foreign governments have enacted and regularly consider additional reform measures that affect health care coverage and costs. Private health plans may also seek to manage cost and utilization by implementing coverage and reimbursement limitations. Other payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities and private health insurers, seek price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, may impose restrictions on access, coverage or pricing of particular drugs based on perceived value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Within the U.S.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Medicaid</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Medicaid is a joint federal and state program that is administered by the states for low income and disabled beneficiaries. Under the Medicaid Drug Rebate Program, we are required to pay a rebate for each unit of product reimbursed by the state Medicaid programs. The amount of the rebate is established by law and is adjusted upward if the average manufacturer price (AMP) increases more than inflation </span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:6px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(measured by the Consumer Price Index&#160;- Urban). The rebate amount is calculated each quarter based on our report of current AMP and best price for each of our products to the Centers for Medicare&#160;&amp; Medicaid Services (CMS). The requirements for calculating AMP and best price are complex. We are required to report any revisions to AMP or best price previously reported within a certain period, which revisions could affect our rebate liability for prior quarters. In addition, if we fail to provide information timely or we are found to have knowingly submitted false information to the government, the statute governing the Medicaid Drug Rebate Program provides for civil monetary penalties.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Medicare</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Medicare is a federal program that is administered by the federal government. The program covers individuals age&#160;65 and over as well as those with certain disabilities. Medicare Part&#160;B generally covers drugs that must be administered by physicians or other health care practitioners, are provided in connection with certain durable medical equipment or are certain oral anti-cancer drugs and certain oral immunosuppressive drugs. Medicare Part B pays for such drugs under a payment methodology based on the average sales price (ASP) of the drugs. Manufacturers, including us, are required to provide ASP information to the CMS on a quarterly basis. The manufacturer-submitted information is used to calculate Medicare payment rates. If a manufacturer is found to have made a misrepresentation in the reporting of ASP, the governing statute provides for civil monetary penalties.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicare Part D provides coverage to enrolled Medicare patients for self-administered drugs (i.e., drugs that are not administered by a physician). Medicare Part D is administered by private prescription drug plans approved by the U.S. government. Each drug plan establishes its own Medicare Part D formulary for prescription drug coverage and pricing, which the drug plan may modify from time-to-time. The prescription drug plans negotiate pricing with manufacturers and pharmacies, and may condition formulary placement on the availability of manufacturer discounts. In addition, manufacturers, including us, are required to provide to the CMS a discount of up to 70% on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries reach the coverage gap in their drug benefits.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Federal Agency Discounted Pricing</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Our products are subject to discounted pricing when purchased by federal agencies via the Federal </span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supply Schedule (FSS). FSS participation is required for our products to be covered and reimbursed by the Veterans Administration (VA), Department of Defense, Coast Guard and Public Health Service (PHS). Coverage under Medicaid, Medicare and the PHS pharmaceutical pricing program is also conditioned upon FSS participation. FSS pricing is intended not to exceed the price that we charge our most-favored non-federal customer for a product. In addition, prices for drugs purchased by the VA, Department of Defense (including drugs purchased by military personnel and dependents through the TriCare retail pharmacy program), Coast Guard and PHS are subject to a cap on pricing equal to 76% of the non-federal average manufacturer price (non-FAMP). An additional discount applies if non-FAMP increases more than inflation (measured by the Consumer Price Index&#160;- Urban). In addition, if we fail to provide information timely or we are found to have knowingly submitted false information to the government, the governing statute provides for civil monetary penalties.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">340B Discounted Pricing</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: To maintain coverage of our products under the Medicaid Drug Rebate Program and Medicare Part B, we are required to extend significant discounts to certain covered entities that purchase products under Section 340B of the PHS pharmaceutical pricing program. Purchasers eligible for discounts include hospitals that serve a disproportionate share of financially needy patients, community health clinics and other entities that receive certain types of grants under the PHSA. For all of our products, we must agree to charge a price that will not exceed the amount determined under statute (the &#8220;ceiling price&#8221;) when we sell outpatient drugs to these covered entities. In addition, we may, but are not required to, offer these covered entities a price lower than the 340B ceiling price. The 340B discount formula is based on AMP and is generally similar to the level of rebates calculated under the Medicaid Drug Rebate Program. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Outside the U.S.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outside the U.S., our products are paid for by a variety of payors, with governments being the primary source of payment. Governments may determine or influence reimbursement of products and may also set prices or otherwise regulate pricing. Negotiating prices with governmental authorities can delay commercialization of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing and reference pricing (i.e., referencing prices in other countries and using </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">those reference prices to set a price). Budgetary pressures in many countries are continuing to cause governments to consider or implement various cost-containment measures, such as price freezes, increased price cuts and rebates and expanded generic substitution and patient cost-sharing. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation Pertaining to Sales and Marketing</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claims laws. Anti-kickback laws generally prohibit a prescription drug manufacturer from soliciting, offering, receiving or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. There is therefore a possibility that our practices might be challenged under anti-kickback or similar laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, for payment to third-party payors (including Medicare and Medicaid), claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services. Our activities relating to the sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and exclusion from federal health care programs (including Medicare and Medicaid). In the U.S., federal and state authorities are paying increased attention to enforcement of these laws within the pharmaceutical industry and private individuals have been active in alleging violations of the laws and bringing suits on behalf of the government under the federal civil False Claims Act. If we were subject to allegations concerning, or were convicted of violating, these laws, our business could be harmed.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Laws and regulations have been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers. The laws and regulations generally limit financial interactions between manufacturers and health care providers or require disclosure to the government and public of such interactions. The laws include federal &#8220;sunshine&#8221; provisions. The sunshine provisions apply to pharmaceutical manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government (for re-disclosure to the public) certain payments made to physicians and certain other healthcare practitioners or to teaching hospitals. State laws may also require </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disclosure of pharmaceutical pricing information and marketing expenditures. Many of these laws and regulations contain ambiguous requirements. Given the lack of clarity in laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations. Outside the U.S., other countries have implemented requirements for disclosure of financial interactions with healthcare providers and additional countries may consider or implement such laws.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Regulations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Foreign Anti-Corruption</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to various federal and foreign laws that govern our international business practices with respect to payments to government officials. Those laws include the U.S.&#160;Foreign Corrupt Practices Act (FCPA), which prohibits U.S.&#160;companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect their transactions and to devise and maintain an adequate system of internal accounting controls.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The laws to which we are subject also include the U.K. Bribery Act 2010 (Bribery Act), which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official and failing to have adequate procedures to prevent employees and other agents from giving bribes. U.S. companies that conduct business in the U.K. generally will be subject to the Bribery Act. Penalties under the Bribery Act include significant fines for companies and criminal sanctions for corporate officers under certain circumstances.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">NIH Guidelines</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We seek to conduct research at our U.S. facilities in compliance with the current U.S.&#160;National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines). By local ordinance, we are required to, among other things, comply with the NIH Guidelines in relation to our facilities in Research Triangle Park (RTP), NC and are required to operate pursuant to certain permits.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Laws</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our present and future business has been and will continue to be subject to various other laws and </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">regulations. Various laws, regulations and recommendations relating to data privacy and protection, safe working conditions, laboratory practices, the experimental use of animals and the purchase, storage, movement, import, export and use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research work are or may be applicable to our activities. Certain agreements entered into by us involving exclusive license rights may be subject to national or international antitrust regulatory control, the effect of which cannot be predicted. The extent of government regulation, which might result from future legislation or administrative action, cannot accurately be predicted.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The European Parliament and the Council of the European Union adopted a comprehensive general data privacy regulation (GDPR) in 2016 to replace the current E.U. Data Protection Directive and related country-specific legislation. The GDPR took effect in May 2018 and governs the collection and use of personal data in the E.U. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the E.U. to the U.S., provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20.0 million or 4% of the annual global revenues of the infringer, whichever is greater.</span></div><div><a id="s5341F36E5F3958EDB3C3D294CA0B8EA4"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Environmental Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We strive to comply in all material respects with applicable laws and regulations concerning the environment. While it is impossible to predict accurately the future costs associated with environmental compliance and potential remediation activities, compliance with environmental laws is not expected to require significant capital expenditures and has not had, and is not expected to have, a material adverse effect on our operations or competitive position.</span></div><div><a id="s279F2554E069523CB6C7D5577A02A843"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Manufacturing</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are committed to ensuring an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. We believe that our manufacturing facilities, together with the third-party contract manufacturing organizations we outsource to, currently provide sufficient capacity </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">for our products and to Samsung Bioepis, our joint venture that develops, manufactures and markets biosimilar products, and other strategic contract manufacturing partners. In order to support our drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing Facilities</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our drug substance manufacturing facility includes:</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Drug Substance Manufactured</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">RTP, NC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">AVONEX</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">PLEGRIDY</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">TYSABRI</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Other*</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-12px;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Other includes products manufactured for contract manufacturing partners.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our drug substance manufacturing facility, we have a drug product manufacturing facility and supporting infrastructure in RTP, NC, including a parenteral facility and an oral solid dose products manufacturing facility. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The parenteral facility adds capabilities and capacity for filling biologics into vials and is principally used for filling product candidates. The oral solid dose products facility can supplement our outsourced small molecule manufacturing capabilities, including the manufacture of TECFIDERA.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have an oligonucleotide synthesis manufacturing facility in RTP, NC. This facility gives us the capability to manufacture ASO drugs like SPINRAZA as well as our other ASO candidates currently in our clinical pipeline.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which we expect to be partially operational by the end of 2020. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is responsible for all worldwide manufacturing activities for bulk RITUXAN, RITUXAN HYCELA and GAZYVA and has sourced the manufacture of certain bulk RITUXAN, RITUXAN HYCELA and GAZYVA requirements to a third party. Acorda supplies FAMPYRA to us pursuant to its supply agreement with Alkermes, Inc. and Ionis supplies the active pharmaceutical ingredient (API) for SPINRAZA. Alkermes currently supplies VUMERITY to us pursuant to our supply agreement with Alkermes. In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes pursuant to which we have the election, </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">following a transition period, to manufacture VUMERITY or have manufacturing transitioned to a third party.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Third-Party Suppliers and Manufacturers</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We principally use third parties to manufacture the API and the final product for our small molecule products and product candidates, including TECFIDERA and FUMADERM, and the final drug product for our large molecule products and, to a lesser extent, product candidates. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We source all of our fill-finish and the majority of final product assembly and storage operations for our products, along with a substantial part of our label and packaging operations, to a concentrated group of third-party contract manufacturing organizations. Raw materials, delivery devices, such as syringes and auto-injectors, and other supplies required for the production of our products and product candidates are procured from various third-party suppliers and manufacturers in quantities adequate to meet our needs. Continuity of supply of such raw materials, devices and supplies is assured using a strategy of dual sourcing where possible or by a risk-based inventory strategy. Our third-party service providers, suppliers and manufacturers may be subject to routine cGMP inspections by the FDA or comparable agencies in other jurisdictions and undergo assessment and certification by our quality management group.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8BF8F26C302655BC8912F945EB3F66C7"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Our Employees</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately 7,400 employees worldwide.</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Information about our Executive Officers (as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">February&#160;6, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Officer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Current Position</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Age</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year Joined Biogen</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michel Vounatsos</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Susan H. Alexander</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Chief Legal Officer and Secretary</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2006</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Jeffrey D. Capello</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Alphonse Galdes, Ph.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Pharmaceutical Operations and Technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1995</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Ginger Gregory, Ph.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and Chief Human Resources Officer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Chirfi Guindo</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Global Product Strategy and Commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Daniel Karp</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Corporate Development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Robin C. Kramer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Chief Accounting Officer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Alfred W. Sandrock, Jr., M.D., Ph.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Research and Development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1998</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michel Vounatsos</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Vounatsos has served as our Chief Executive Officer and as a member of our Board of Directors since January 2017. Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President, Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck &amp; Co., Inc. (Merck), a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line and Merck Customer Centricity. In this role, he led Merck&#8217;s global primary care business unit, a role which encompassed Merck&#8217;s cardiology-metabolic, general medicine, women&#8217;s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company&#8217;s relationships with key constituents, including the most significant providers, payors and retailers and the world&#8217;s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company. Mr. Vounatsos currently serves on the advisory board of Tsinghua University School of Pharmaceutical Sciences, on the Supervisory Board of Liryc, the Electrophysiology and Heart Modeling Institute at the University of Bordeaux, on the board of directors of N-Lorem Foundation and as a member of the MIT Presidential CEO Advisory Board.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Universite Victor Segalen, Bordeaux II, France, C.S.C.T. Certificate in Medicine</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">HEC School of Management - Paris, M.B.A.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Susan H. Alexander</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ms. Alexander has served as our Executive Vice President, Chief Legal Officer and Secretary since April 2018. Prior to that, Ms. Alexander served as our Executive Vice President, Chief Legal, Corporate Services and Secretary from March 2017 to March 2018, as our Executive Vice President, Chief Legal Officer and Secretary from December 2011 to March 2017 and as our Executive Vice President, General Counsel and Corporate Secretary from 2006 to December 2011. Prior to joining Biogen, Ms.&#160;Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company, from 2003 to January 2006. From 2001 to 2003 Ms.&#160;Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001 Ms.&#160;Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms.&#160;Alexander was a partner at the law firms of Hinckley, Allen&#160;&amp; Snyder and Fine&#160;&amp; Ambrogne. </span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Public Company Boards</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Invacare Corporation, a medical and healthcare product company</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Wellesley College, B.A.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston University School of Law, J.D.</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Jeffrey D. Capello</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Capello has served as our Executive Vice President and Chief Financial Officer since December 2017 and served as our Chief Accounting Officer from July 2018 to November 2018. Prior to joining Biogen, Mr. Capello served as the Chief Financial Officer of Beacon Health Options, Inc., a behavioral health company, with responsibility for finance, human resources, information technology, real estate and procurement from October 2016 until November 2017. From July 2015 until September 2016 Mr. Capello was the founder and Chief Executive Officer of Monomoy Advisors, which focuses on helping companies drive shareholder value. From July 2014 until June 2015 Mr. Capello served as the Executive Vice President and Chief Financial Officer of Ortho-Clinical Diagnostics, an in-vitro diagnostics company that was acquired by the Carlyle Group from Johnson &amp; Johnson, with responsibility for global finance and business development. From March 2010 to December 2013 Mr. Capello served as Chief Financial Officer and Executive Vice President of Boston Scientific Corporation (Boston Scientific), a medical device company, where he was responsible for the worldwide management of Boston Scientific&#8217;s finance, information systems, business development and corporate strategy functions. Mr. Capello joined Boston Scientific in June 2008 and served as Senior Vice President and Chief Accounting Officer until March 2010. From 2006 to 2008 he was the Senior Vice President and Chief Financial Officer with responsibilities for global finance and business development at PerkinElmer, Inc. (PerkinElmer), a life sciences tool company. Previously, he served as PerkinElmer&#8217;s Vice President of Finance, Corporate Controller, Treasurer and Chief Accounting Officer from 2001 to 2006. Prior to his tenure at PerkinElmer, Mr. Capello was a Partner at PricewaterhouseCoopers LLP, both in the U.S. and in the Netherlands.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Vermont, B.S. Business Administration</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard Business School, M.B.A.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Alphonse Galdes, Ph.D.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Galdes has served as our Executive Vice President, Pharmaceutical Operations and Technology since September 2019. Since joining Biogen in 1995, Dr. Galdes has held several senior executive positions, including most recently as Senior Vice President, Asset Development and Portfolio Management from November 2015 to September 2019 and Senior Vice President, Technical Development from October 2010 to November 2015. Dr. Galdes was a Rhodes Scholar at Oxford University and performed post-doctoral research work at the Department of Biological Chemistry at Harvard Medical School.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Malta, B.Sc. Chemistry and Biology</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Malta, M.Sc. Biochemistry</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Oxford University, Ph.D. Biochemistry</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Ginger Gregory, Ph.D.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Gregory has served as our Executive Vice President and Chief Human Resources Officer since July 2017. Prior to joining Biogen, Dr. Gregory served as Executive Vice President and Chief Human Resources Officer at Shire PLC, a global specialty biopharmaceutical company, from February 2014 to April 2017. Prior to that, Dr. Gregory held executive-level human resources positions for several multinational companies across a variety of industries, including Dunkin&#8217; Brands Group Inc., a restaurant holding company, where she served as Chief Human Resource Officer, Novartis AG, a pharmaceutical company, where she was the division head of Human Resources for Novartis Vaccines and Diagnostics, Novartis Consumer Health and Novartis Institutes of BioMedical Research and Novo Nordisk A/S, a pharmaceutical company, where she served as Senior Vice President, Corporate People &amp; Organization at the company&#8217;s headquarters in Copenhagen, Denmark. Earlier in her career, Dr. Gregory held a variety of human resources generalist and specialist positions at BMS, a pharmaceutical company, and served as a consultant with Booz Allen &amp; Hamilton, an information technology consulting company, in the area of organization change and effectiveness.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Massachusetts, B.A. Psychology</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The George Washington University, Ph.D. Psychology</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Chirfi Guindo</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Guindo has served as our Executive Vice President, Global Product Strategy and Commercialization since February 2019. Prior to that, Mr. Guindo served as our Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation from November 2017 to February 2019. Prior to joining Biogen, Mr. Guindo spent 27 years in the global pharmaceutical industry and has held several leadership positions at Merck, a pharmaceutical company, in Canada, the U.S., France, Africa and the Netherlands. He worked in several disciplines including Finance, Sales &amp; Marketing, General Management and Global Strategy/Product Development in specialty, acute and hospital care. Most recently Mr. Guindo was Vice President and Managing Director and President and Managing Director of Merck Canada from October 2014 to November 2017. From January 2011 to October 2014, he was Vice President and General Manager, Global HIV Franchise at Merck.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ecole Central de Paris (France), Engineering</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stern School of Business, New York University, M.B.A. Finance/Economics</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Daniel Karp</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Karp has served as our Executive Vice President, Corporate Development since June 2018. Prior to joining Biogen, Mr. Karp held a number of positions of increasing responsibility at Pfizer, a biopharmaceutical company, including as Vice President, Worldwide Business Development and Head of Business Development for Worldwide Research and Development from May 2016 to June 2018, as Vice President, Worldwide Business Development and BD Lead for Pfizer Vaccines, Oncology and Consumer Healthcare from January 2014 to May 2016, as Senior Director, Worldwide Business Development from December 2010 to December 2013, as Director, Worldwide Business Development from January 2008 to December 2010, as Senior Manager, Worldwide Business Development from May 2007 to December 2007 and as Manager, U.S. Business Development from July 2006 to April 2007. Prior to that, Mr. Karp held roles in healthcare and life sciences strategy consulting.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Duke University, B.S. Biology</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Wharton School of the University of Pennsylvania, M.B.A.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Robin C. Kramer</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ms. Kramer has served as our Vice President, Chief Accounting Officer since November 2018. Prior to joining Biogen, Ms. Kramer served as the Senior Vice President and Chief Accounting Officer of Hertz Global Holdings, Inc., a car rental company, from May 2014 to November 2018. Prior to that, Ms. Kramer was an audit partner at Deloitte &amp; Touche LLP (Deloitte), a professional services firm, from 2007 to 2014, including serving in Deloitte's National Office Accounting Standards and Communications Group from 2007 to 2010. From 2005 to 2007 Ms. Kramer served as Chief Accounting Officer of Fisher Scientific International, Inc., a laboratory supply and biotechnology company, and from 2004 to 2005 Ms. Kramer served as Director, External Reporting, Accounting and Control for the Gillette Company, a personal care company. Ms. Kramer also held partner positions in the public accounting firms of Ernst &amp; Young LLP and Arthur Anderson LLP. Ms. Kramer is a licensed certified public accountant (CPA) in Massachusetts. She is a member of the Massachusetts Society of CPAs and the American Institute of CPAs and served as a Board Member for the Massachusetts State Board of Accountancy from September 2011 to December 2015.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Salem State University, B.B.A. Accounting</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Alfred W. Sandrock, Jr., M.D., Ph.D.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Sandrock has served as our Executive Vice President, Research and Development since September 2019. Prior to that, Dr. Sandrock served as our Chief Medical Officer from October 2017 to January 2020, as our Executive Vice President, Chief Medical Officer Neurology and Neurodegeneration from October 2015 to October 2017, as our Chief Medical Officer and Group Senior Vice President from April 2013 to October 2015 and as our Chief Medical Officer and Senior Vice President of Development Sciences from February 2012 to April 2013. Prior to that, Dr. Sandrock held several other senior executive positions since joining Biogen in 1998, including Senior Vice President of Neurology Research and Development and Vice President of Clinical Development, Neurology.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Public Company Boards</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Neurocrine Biosciences, Inc., a life sciences company</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stanford University, B.A. Human Biology</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard Medical School, M.D. </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard University, Ph.D. Neurobiology</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Wingdings;font-size:6pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts General Hospital, internship in Medicine, residency and chief residency in Neurology and clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography)</span></div></td></tr></table></div></div><div><a id="sBDDD9AC622EF556196D84471EED1ED0E"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Available Information</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our principal executive offices are located at 225 Binney Street, Cambridge, MA 02142 and our telephone number is (617)&#160;679-2000. Our website address is www.biogen.com. We make available free of charge through the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> section of our website our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the U.S. Securities and Exchange Commission (SEC). We include our website address in this report only as an inactive textual reference and do not intend it to be an active link to our website. The contents of our website are not incorporated into this report.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><a id="s12D04E5FF9455A22921BC51F6CDD8456"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;1A. &#160;&#160;&#160;&#160;Risk Factors</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our products. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. Additionally, a significant portion of our revenues are concentrated on sales of our products in increasingly competitive markets. Any of the following negative developments relating to any of our  products or any of our anti-CD20 therapeutic programs may adversely affect our revenues and results of operations or could cause a decline in our stock price: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition or changes in, or implementation of, reimbursement policies and practices of payors and other third parties; or </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA has been approved by, among others, the FDA, the EC and the Japanese Ministry of Health, Labor and Welfare, and is in the early stages of commercial launch in certain markets.&#160;In addition to risks associated with new product launches and the other factors described in these </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ability to successfully commercialize SPINRAZA may be adversely affected due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of a new gene therapy product that was approved in the U.S. in May 2019 for the treatment of SMA, and other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential oral products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within certain SMA markets, which may impact our ability to develop additional relationships with the associated medical and scientific community; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the lack of readiness of healthcare providers within certain SMA markets to treat patients with SMA.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:54px;padding-top:12px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products varies significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may not only limit the revenues from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. In addition, competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products or treatments brought to market by our competitors could cause revenues for our products to decrease due to potential price reductions and lower sales volumes. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, increasingly seek ways to reduce their costs. Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients. Such measures include more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Payors also increasingly seek price discounts or rebates in connection with the placement of our products on their formularies or those they manage and control costs by imposing restrictions on access to or usage of our products, such as by requiring prior authorization or step therapy. Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Ultimately, additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection afforded to our products and processes in the U.S. and in other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. Under the Hatch-Waxman Act, a manufacturer may file an Abbreviated New Drug Application, seeking approval of a generic copy of an approved innovator product, or a NDA under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, which may be for a new or improved version of the original innovator product. The manufacturers are allowed to rely on the safety and efficacy data of the innovator's product, may not need to conduct clinical trials, can market a competing version of a product after the expiration or loss of patent exclusivity or the expiration or loss of regulatory exclusivity and often charge significantly lower prices. Upon the expiration or loss of patent protection or the expiration or loss of regulatory exclusivity for a product, a major portion of revenues for that product may be reduced in a short period of time. When others exploit our inventions, the expected benefit from them are reduced. Furthermore, our products may be determined to </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">infringe patents or other intellectual property rights held by third parties, which could result in financial, legal, business or reputational harm to us.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenues for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our patents, regulatory exclusivities or other proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reviews, administrative challenges or other similar types of proceedings are unpredictable and are often protracted, expensive and distracting to management. Negative outcomes of such proceedings adversely affect the validity and scope of our patent or other proprietary rights. Settlements of Hatch-Waxman litigation typically result in reducing the period of patent protection, accelerating reduction in revenue from affected products. Adverse outcomes in intellectual property litigation also could hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon the successful development of additional indications for our existing products as well as the successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung BioLogics or licenses or acquisitions from third parties. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of uncertainty and risk. Only a small number of research and development programs result in the commercialization of a product. Furthermore, the development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the ASO platform and gene therapy, may present additional challenges and risks, including obtaining regulatory approval from the FDA and other regulatory agencies that have limited experience with the development of such therapies. In addition, clinical trial data are subject to differing interpretations and, even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, may limit the scope of the approval or may deny approval altogether. Consequently, it may be difficult to predict the time and cost of product development of novel approaches for the treatment of diseases. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing and research and development and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition in many markets from generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways.&#160;Generic versions of drugs, biosimilars, prodrugs and products approved under abbreviated regulatory pathways are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenues. In addition, when a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, including TECFIDERA, our business could be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of biosimilars, follow-on products, generic versions of branded MS products, prodrugs or products approved under abbreviated regulatory pathways, which would be significantly less costly than our products to bring to market and would be offered for sale at lower prices, and could result in a significant percentage of the sales of our products being lost to such biosimilars, follow-on products, generic versions of branded MS products, prodrugs or products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the off-label use by physicians of therapies indicated for other conditions to treat MS patients; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract and maintain new and current patients to our therapies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products, generic or biosimilars of our MS products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products or generic or biosimilars of our MS products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the SMA market, we face competition from a new gene therapy product that was approved in the U.S. in May 2019 for the treatment of SMA. Additionally, we are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential oral products. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives, external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations, or the disposition of certain of our assets or operations. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have in the past made, and may continue to make, significant operating and capital expenditures for potential new products in our pipeline prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement. Furthermore, if we decide to dispose of certain of our assets or operations, we are not certain that we will be able to identify a suitable counterparty or if we will be able to reach agreement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may fail to initiate or complete transactions for many reasons and we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with cGCP. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in liabilities, loss of revenues, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges or other adverse impacts on our results of operations. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy (PML) or liver injury in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data to operate our business. Our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). A breakdown, invasion, corruption, destruction or breach of our technology systems, including the cloud technologies that we utilize, and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems, including the cloud technologies that we utilize, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems, including the cloud technologies that we utilize, may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks could also include supply chain attacks, which could cause a delay in the manufacturing of our products or products produced for contract manufacturing. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies could heighten these and other operational risks, and any failure by cloud technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators, joint venture partners and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative and other third-party relationships, including joint venture partners, for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships, including joint venture partners, subjects us to a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborators, joint venture partners or third parties devote to our programs, products or product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise under an agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators, joint venture partners or other third parties, and the underlying agreement with our collaborators, joint venture partners or other third parties may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third parties fail to perform; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborators, joint venture partners or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third-party relationships, joint ventures and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of products under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborators, joint venture partners or other third parties to comply with applicable laws, regulatory requirements and/or applicable contractual obligations in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators, joint venture partners or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any improper conduct or actions on the part of our collaborators, joint venture partners or other third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, or revenues from products could decline and/or we may not realize the anticipated benefits of the collaboration arrangements and/or joint ventures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the PPACA have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the PHSA. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenues and may continue to adversely affect our revenues and results of operations in the future.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have experienced changes in management and other key personnel in critical functions across our organization in recent years. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. Further, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change emphasis on our existing business programs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Further, certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we partner or collaborate with or acquire in emerging markets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates that may adversely impact our revenues, net income and value of certain of our investments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">diverse data privacy and protection requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the Bribery Act, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effects of the implementation of the U.K.&#8217;s departure from the E.U., known as Brexit;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of tariffs or embargoes and other trade restrictions, including the recent tariffs imposed by the U.S. and China and the possibility of additional tariffs or other trade restrictions relating to trade between the two countries; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of public health epidemics on employees and the global economy, such as the coronavirus currently impacting China and elsewhere.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the FCPA prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe we currently have sufficient large-scale manufacturing capacity to meet our near-term manufacturing requirements. However, in order to support our drug development pipeline, in 2015 we made the decision to expand our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity would be required. We expect the Solothurn manufacturing facility to be partially operational by the end of 2020; however, there can be no assurance that we will be able to meet our expected timeline. If there are delays in bringing the Solothurn manufacturing facility online, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we have made significant investments in connection with the building of this manufacturing facility with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity would have a negative effect on our financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with cGMP.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures, cyber-attacks and numerous other factors. In addition, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which we expect to be partially operational by the end of 2020. However, there can be no assurance that we will be able to meet our expected timeline. If there are delays in bring </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:54px;padding-top:12px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the Solothurn manufacturing facility online, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilars, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. In addition, following the divestiture of our Hiller&#248;d, Denmark manufacturing operations, we are dependent on FUJIFILM for the manufacture of biosimilar products. If Samsung Bioepis, FUJIFILM or other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Ability to Provide Adequate Supply.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Manufacturing biosimilars is complex.&#160;If we encounter any manufacturing or supply chain difficulties, we may be unable to meet higher than anticipated demand. In addition, following the divestiture of our Hiller&#248;d, Denmark manufacturing operations, we are dependent on FUJIFILM for the manufacture of biosimilar products. FUJIFILM may not perform their obligations in a timely and cost effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area; and</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Legal and Regulatory Requirements.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Any improper conduct or actions on the part of Samsung Bioepis or our joint venture partner, Samsung BioLogics, could damage our reputation and be distracting to management. In particular, Samsung BioLogics is currently subject to an ongoing criminal investigation, which may impact the operations of Samsung Bioepis and its business or divert the attention of the Samsung Bioepis management team from its ongoing operations and business. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilar products, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, as Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including in-process research and development (IPR&amp;D) and other intangible assets; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions, divestitures and other business development activities; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">failure to meet certain contractual commitments, including, for example, the minimum batch production commitment guarantees we have provided as part of the transaction with FUJIFILM.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates (including withholding taxes) in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws either prospectively or retrospectively (including by regulation). Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">statements.</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries and collaborations to immediate U.S. taxation as global intangible low-taxed income (GILTI) or Subpart F income, and includes base erosion prevention measures on U.S. earnings and the reduced effective tax rate on income that comes from U.S. exports, called Foreign Derived Intangible Income. These changes became effective in 2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). The Transition Toll Tax will be paid over an eight-year period, which started in 2018, and will not accrue interest. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimates concerning the impact of the 2017 Tax Act on our accounting and on our business remain subject to developing interpretations of the provisions of the 2017 Tax Act. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial condition. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Swiss Federal Act on Tax Reform and AHV Financing (TRAF) will result in significant changes to the Swiss cantonal income tax system. These changes include the elimination of historic favorable cantonal tax regimes, the introduction of a patent box regime and the introduction of a research and development super deduction. The TRAF also provides for transitional rules to lessen the immediate impact of the elimination of the favorable cantonal tax regimes. These changes became effective on January 1, 2020. In response to the TRAF, each canton must enact cantonal tax reform to comply with the framework provided by the TRAF and are also expected to lower the statutory tax rate to compensate for the elimination of the historic favorable cantonal tax regimes. We will account for the impact of the TRAF and the specific cantonal tax reform changes in the period in which each canton in which we operate enacts the cantonal tax reform. Zug, a canton in which we operate, enacted cantonal tax reform in the third quarter of 2019 and Solothurn, another canton in which we operate, will hold a public referendum on the enactment of cantonal tax reform on February 9, 2020. Upon the enactment of Zug cantonal tax reform, we were required to remeasure our Swiss deferred tax assets and liabilities, to account for the elimination of the historic favorable cantonal tax regimes, the impact of the transitional rules and the change in the statutory cantonal tax rate. Further remeasurement of our Swiss deferred tax assets and liabilities could have a significant impact on our income tax provision in the period of enactment.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the enactment of some or all of the recommendations set forth or that may be forthcoming in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate an owned or leased property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the value of collateral underlying the securities included in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time our Board of Directors authorizes share repurchase programs, including our March 2019 Share Repurchase Program and our December 2019 Share Repurchase Program. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our agreements applicable to the repurchase of shares. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our 2019 share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption in the past, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders.&#160;Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </span></div><div><a id="s1427BFBEDF605FF887B947A13B9FCBEA"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;1B. &#160;&#160;&#160;&#160;Unresolved Staff Comments</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</span></div><div><a id="s764E11D3C33B5E219872C6F463F20B00"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;2. &#160;&#160;&#160;&#160;Properties</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Below is a summary of our owned and leased properties as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Massachusetts</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In Cambridge, MA we own approximately 508,000&#160;square feet of real estate space, consisting of a building that houses a research laboratory and a cogeneration plant totaling approximately 263,000&#160;square feet and a building that contains research, development and quality laboratories totaling approximately 245,000&#160;square feet.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we lease a total of approximately 1,157,000&#160;square feet in Massachusetts, which is summarized as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">800,000&#160;square feet in Cambridge, MA, which is comprised of offices for our corporate headquarters and other administrative and development functions and laboratories, of which 289,000 square feet is subleased by multiple companies for general office space, laboratories and manufacturing facilities; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">357,000&#160;square feet of office space in Weston, MA, of which 174,000 square feet is subleased through the remaining term of our lease agreement.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Massachusetts lease agreements expire at various dates through the year 2028.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">North Carolina</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In RTP, NC we own approximately 1,022,000&#160;square feet of real estate space, which is summarized as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">357,000&#160;square feet of laboratory and office space;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">188,000 square foot multi-purpose facility, including an ASO manufacturing suite and administrative space;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">175,000&#160;square feet related to a large-scale biologics manufacturing facility;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">105,000&#160;square feet related to a small-scale biologics manufacturing facility;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84,000&#160;square feet of warehouse space and utilities;&#160;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70,000 square feet related to a parenteral fill-finish facility; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43,000&#160;square feet related to a large-scale purification facility.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we lease approximately 40,000 square feet of warehouse space in Durham, NC. </span></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Switzerland</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space.  </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other International</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease office space in Baar, Switzerland, our international headquarters; the U.K.; Germany; France; Denmark and numerous other countries. Our international lease agreements expire at various dates through the year 2030.</span></div><div><a id="s2DA15E2C0A5950C5B0D9405F5AF76E3B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;3. &#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal matters as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div><a id="s7FEF9BFBD32357B8B8DC12BC0A18F9EC"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;4. &#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Not applicable.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><a id="sCC880C9055425AA286429B4E353FF968"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;II</span></div><div><a id="s8D15A8B0B7C751F895D9607AEBD1077F"></a></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;5. &#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Market and Stockholder Information</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our common stock trades on The Nasdaq Global Select Market under the symbol &#8220;BIIB.&#8221; As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;4, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, there were approximately 540 shareholders of record of our common stock.</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Dividends</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not paid cash dividends since our inception. While we historically have not paid cash dividends and do not have a current intention to pay cash dividends, we continually review our capital allocation strategies, including, among other things, payment of cash dividends, share repurchases and acquisitions.</span></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> The following table summarizes our common stock repurchase activity during the fourth quarter of 2019:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:18%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced Programs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs ($ in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,215,407</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">238.71</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,215,407</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,604.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">November 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,550,825</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">292.01</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,550,825</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,151.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,928,634</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">297.99</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,928,634</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,279.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,694,866</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">272.01</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our December 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our December 2019 Share Repurchase Program will be retired. We did not repurchase shares of our common stock under our December 2019 Share Repurchase Program during the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our March 2019 Share Repurchase Program, which is a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock. Our March 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our March 2019 Share Repurchase Program will be retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.7 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Performance Graph</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The performance graph below compares the five-year cumulative total stockholder return on our common stock, the Nasdaq Pharmaceutical Index, the S&amp;P 500 Index and the Nasdaq Biotechnology Index.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. In connection with the spin-off, each Biogen shareholder received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. For additional information on the spin-off of our hemophilia business, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 (2018 Form 10-K).</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The performance graph below assumes the investment of $100.00 on December&#160;31, 2014, in our common stock and each of the three indexes, with dividends being reinvested. Our stock prices have been adjusted for the effect of the spin-off of our hemophilia business. The five-year cumulative total stockholder return for Biogen does not reflect the reinvestment by Biogen shareholders of the distribution they received in connection with the spin-off of our hemophilia business or any subsequent increase or decrease in value of Bioverativ stock subsequent to the spin-off. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The stock price performance in the graph below is not necessarily indicative of future price performance.</span></div><div style="line-height:120%;text-align:left;"><img src="stockperfgraph.jpg" alt="stockperfgraph.jpg" style="height:480px;width:613px;"></img></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.25</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$83.54</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$101.74</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.11</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$94.77</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nasdaq Pharmaceutical Index</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$105.43</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.29</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.23</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$134.11</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$153.57</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">S&amp;P 500 Index</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$101.38</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.51</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$138.29</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$132.23</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$173.86</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nasdaq Biotechnology Index</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.77</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$87.91</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$106.95</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$97.47</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$121.94</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information included under the heading </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Performance Graph</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is &#8220;furnished&#8221; and not &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be &#8220;soliciting material&#8221; subject to Regulation&#160;14A or incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><a id="s53518B7B8E4B5F35B532D2DEF336FD1C"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6. &#160;&#160;&#160;&#160;Selected Financial Data</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SELECTED FINANCIAL DATA</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="20" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:18px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are summarized as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Results of Operations </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,379.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,886.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,290.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,980.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">707.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">585.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14,377.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13,452.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,273.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,448.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,763.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,335.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,564.3</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,928.1</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,297.1</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,872.8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,042.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,888.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,345.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,151.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">83.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(217.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(218.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(123.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,125.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,899.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,128.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,933.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,767.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,158.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,425.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,458.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,237.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,161.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">79.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,888.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,474.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,670.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,695.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,593.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to noncontrolling interests, net of tax </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(5)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,888.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,430.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Diluted Earnings Per Share </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(6)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.42</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.58</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.92</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.93</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.34</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating diluted earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">187.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">205.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="20" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Financial Condition </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,884.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,913.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,746.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,724.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,188.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27,234.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25,288.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23,652.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22,876.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19,504.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable, less current portion </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(7)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,459.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,935.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,512.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,521.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(6)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13,343.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13,039.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,612.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,140.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,372.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the following notes, the financial data included within the tables above should be read in conjunction with our consolidated financial statements and related notes and Item 7. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report and our previously filed Annual Reports on Form&#160;10-K.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">On February 1, 2017, we completed the spin-off of our hemophilia business. Our consolidated results of operations and financial condition reflect the financial results of our hemophilia business for all periods through January 31, 2017. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Product revenues, net reflect the impact of the following product launches:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Commercial sales of VUMERITY in the U.S. began in the fourth quarter of 2019.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Commercial sales of SPINRAZA in the U.S. began in the fourth quarter of 2016 and in rest of world markets beginning in the first quarter of 2017.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Under our collaboration agreement with AbbVie Inc. (AbbVie), we began to recognize revenues on sales of ZINBRYTA to third parties in the E.U. in the third quarter of 2016. In March 2018 we and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for RMS.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Under our commercial agreement with Samsung Bioepis, we began to recognize revenues on sales of BENEPALI and FLIXABI to third parties in certain countries in Europe in the first and third quarters of 2016, respectively, and began to recognize revenues on sales of IMRALDI to third parties in certain countries in Europe in the fourth quarter of 2018. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">We stopped recognizing revenues from ALPROLIX and ELOCTATE effective February 1, 2017, upon the completion of the spin-off of our hemophilia business.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total cost and expenses included the following charges:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Pre-tax research and development expenses related to upfront and milestone payments made upon entering into strategic agreements or achievement of specified development milestones totaling $253.8 million, $602.7 million, $494.0 million, $167.6 million and $158.2 million in 2019, 2018, 2017, 2016 and 2015, respectively. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Impairment charges related to certain acquired intangible assets totaling $215.9 million, $366.1 million, $359.4 million and $12.2 million in 2019, 2018, 2017 and 2016, respectively. For additional information, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, to our consolidated financial statements included in this report.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Pre-tax research and development expenses of $486.2 million in 2018 related to the 2018 Ionis Agreement. For additional information on our collaboration arrangements with Ionis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, to our consolidated financial statements included in this report.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Pre-tax charges to acquired IPR&amp;D totaling $112.5 million and $120.0 million in 2018 and 2017, respectively, for upfront payments made upon the closing of our asset purchase transactions, as the underlying assets had not yet reached technological feasibility.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Pre-tax charge of $454.8 million in 2016 related to our January 2017 settlement and license agreement with Forward Pharma A/S (Forward Pharma).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Pre-tax restructuring and other exit-related costs totaling $1.5 million, $12.0 million, $0.9 million, $103.6 million and $93.4 million in 2019, 2018, 2017, 2016 and 2015, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income tax expense included the following activities:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income tax expense in 2019 reflects a benefit of approximately $205.0 million related to an internal reorganization of certain intellectual property rights and the impact of the enactment of a new taxing regime in the country and certain cantons of Switzerland, which we refer to as Swiss Tax Reform, offset by a $68.9 million tax expense related to the divestiture of our subsidiary that owned our Hiller&#248;d, Denmark manufacturing operations. For additional information, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Income Taxes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, to our consolidated financial statements included in this report.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income tax expense in 2018 reflects a net increase to expense of approximately $125.0 million recognized upon finalization of our estimates related to the Transition Toll Tax, the remeasurement of our deferred tax assets and liabilities, the impact of electing to record deferred taxes on GILTI and other aspects of the 2017 Tax Act. For additional information, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Income Taxes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, to our consolidated financial statements included in this report.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income tax expense in 2017 includes a $1,173.6 million estimate pursuant to SEC Staff Accounting Bulletin No. 118. Our estimate included $989.6 million associated with the Transition Toll Tax and $184.0 million related to the impact of remeasuring our deferred tax balances to reflect the new federal statutory rate and other changes to U.S. tax law.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(5)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net income (loss) attributable to noncontrolling interests, net of tax included the following activities:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Pre-tax charges of $50.0 million and $150.0 million for the years ended December 31, 2018 and 2017, respectively, for payments made under the terms of the Neurimmune Agreement in exchange for reductions in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">A pre-tax charge of $60.0 million for the year ended December 31, 2015, for a milestone payment due to Neurimmune upon the enrollment of the first patient in a Phase 3 study of aducanumab.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:48px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">For additional information on our collaboration arrangement with Neurimmune, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Investments in Variable Interest Entities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, to our consolidated financial statements included in this report.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(6)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total Biogen Inc. shareholders' equity reflects the repurchase of approximately 63.4 million shares of our common stock at a cost of approximately $17.6 billion between December 31, 2015 and December 31, 2019:</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">During 2019 we repurchased and retired approximately 14.7 million and 8.9 million shares of our common stock at a cost of approximately $3.7 billion and $2.1 billion under our March 2019 Share Repurchase Program and our 2018 Share Repurchase Program, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">During 2018 we repurchased and retired approximately 4.3 million and 10.5 million shares of our common stock at a cost of approximately $1.4 billion and $3.0 billion under our 2018 Share Repurchase Program and a program authorized by our Board of Directors in July 2016 for the repurchase of up to $5.0 billion of our common stock (2016 Share Repurchase Program), respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">During 2017 we repurchased and retired approximately 3.7 million shares of our common stock at a cost of approximately $1.0 billion under our 2016 Share Repurchase Program.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">During 2017 we repurchased approximately 1.2 million shares of our common stock at a cost of $365.4 million under a program authorized by our Board of Directors in February 2011 for the repurchase of up to 20.0 million shares of our common stock. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">During 2016 we repurchased and retired approximately 3.3 million shares of our common stock at a cost of approximately $1.0 billion under our 2016 Share Repurchase Program.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">During 2015 we repurchased and retired approximately 16.8 million shares of our common stock at a cost of $5.0 billion under a program authorized by our Board of Directors in May 2015 for the repurchase of up to $5.0 billion of our common stock.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(7)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Notes payable, less current portion reflect:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Our 2017 repayment of our 6.875% Senior Notes that were issued in 2008 with an aggregate principal amount of $550.0 million; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">The issuance of our senior unsecured notes for an aggregate principal amount of $6.0 billion in September 2015.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE31BAA7BAB4A5EF394B812AFB8336190"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;7. &#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our consolidated financial statements and the accompanying notes beginning on page&#160;F-1 of this report. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For our discussion of the year ended December 31, 2018, compared to the year ended December 31, 2017, please read Item 7. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> located in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include MS and neuroimmunology; AD and dementia; neuromuscular disorders, including SMA and ALS; movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and reduce the cost burden for healthcare systems. Through Samsung Bioepis, our joint venture with Samsung BioLogics Co., Ltd., we market and sell  BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products continue to face increasing competitive pressures from the introduction of generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products, which may significantly reduce both the price that we are able to charge for our products and the volume of products we sell. In addition, when </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.&#160;</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to&#160;the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures as well as the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our competition and pricing risks that could negatively impact our product sales, please read Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and Item 7A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Brexit</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the U.K. electorate voted in a referendum to voluntarily depart from the E.U., known as Brexit. In March 2017 the U.K. government formally notified the European Council of its intention to leave the E.U. and began to negotiate the terms of its withdrawal and outline the future relationship between the U.K. and the E.U. upon exit, which occurred on January 31, 2020. Following the U.K.&#8217;s departure, there is now a transition period during which existing arrangements will remain in place until the end of 2020, allowing detailed discussions on the future relationship between the U.K. and the E.U. to take place.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The potential impact on our results of operations and liquidity resulting from Brexit remains unclear. The actual effects of Brexit will depend upon many factors and significant uncertainty remains with respect to the future relationship between the U.K. and the E.U. The final outcome of the discussions during the transition period may impact certain of our research, commercial and general business operations in the U.K. and the E.U., including the approval and supply of our products. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compliance with any resulting regulatory mandates may prove challenging and the macroeconomic impact on our sales and consolidated results of operations from these developments remains unknown. We do not, however, expect Brexit to have a material impact on our consolidated results of operations as approximately 3.5%, 3.3% and 3.2% of our total product revenues in 2019, 2018 and 2017, respectively, were derived from U.K. sales.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have implemented measures to meet E.U. legal and regulatory requirements and to continue to modify our business operations to prepare for the finalization of the terms of the U.K.'s separation from the E.U. However, we cannot predict the direction Brexit-related developments will take nor the impact of those developments on our European operations and the economies of the markets where we operate. Therefore, we will continue to monitor for developments in this area and assess any potential impact on our business and results of operations.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;"><img src="finhighlights.jpg" alt="finhighlights.jpg" style="height:433px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.42</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 45.6% over $21.58 in the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Results of Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our net income and diluted earnings per share attributable to Biogen Inc. for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$14,377.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">6.9%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over $13,452.9 million in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$11,379.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">4.5%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over $10,886.8 million in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to a 21.6% increase in revenues from SPINRAZA and a 35.4% increase in revenues from our biosimilar business. Product revenues, net, compared to the same period in 2018, further reflects the unfavorable impact of foreign currency exchange of $53.0 million.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2,290.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">15.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over $1,980.2 million in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to an increase in royalty revenues on sales of OCREVUS.</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$707.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">20.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over $585.9 million in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to higher revenues from our manufacturing and supply agreement with Bioverativ, partially offset by lower revenues from other contract manufacturing agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$7,335.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">3.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from $7,564.3 million in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was primarily due to:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">12.2%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease in research and development expense, primarily due to the $482.6 million net charge recognized in 2018 upon the closing of the 2018 Ionis Agreement; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">34.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease in amortization and impairment of acquired intangible assets, primarily due to the $366.1 million impairment charges recognized in 2018, which lowered amortization expense in subsequent periods, partially offset by the $215.9 million impairment charges recognized in 2019; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a net change in (gain) loss on fair value remeasurement of contingent consideration, primarily due to the gain recognized on the remeasurement of our continent consideration obligation related to the Phase 2b study of BG00011 for the potential treatment of IPF. </span></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This decrease was partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">12.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase in selling, general and administrative expenses, primarily due to increased commercial and medical investments as well as the timing of spend on selling, general and administrative expense; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">7.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase in cost of sales, primarily due to our sales in 2019 to Bioverativ of hemophilia-related inventory on hand as of December 31, 2018, and an increase in sales of products within our biosimilar business. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. was favorably impacted by a decrease in our effective tax rate to 16.3% for the year ended </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from 24.2% for </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due in part to an internal reorganization of certain intellectual property rights, the impact of Swiss Tax Reform and the 2018 unfavorable impacts of U.S. Tax Reform.</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Condition, Liquidity and Capital Resources</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generated </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$7,078.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net cash flows from operations for </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were primarily driven by earnings. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities totaled approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$5,884.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We repurchased and retired approximately 23.6 million shares of our common stock at a cost of approximately $5.8 billion during 2019 under our March 2019 Share Repurchase Program and our 2018 Share Repurchase Program.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions, Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisitions, collaborative and other relationships discussed below, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. In connection with this agreement, we made an upfront payment of $74.0 million to Skyhawk. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration. In October 2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of $15.0 million.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 we completed our acquisition of all of the outstanding shares of NST, a clinical-stage gene therapy company focused on AAV treatments for inherited retinal disorders. As a result of this acquisition, we added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111, which is in Phase 3 development for the potential treatment of CHM, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of XLRP, which is a rare inherited retinal disease with no currently approved treatments.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the acquisition, we paid NST shareholders $25.50 in cash for each issued and outstanding NST share, which totaled $847.6 million.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. Upon the closing of this transaction, we received approximately $881.9 million in cash, which may be adjusted based on other contractual terms. In addition, we sold to FUJIFILM $41.8 million of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Samsung Bioepis</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. We also acquired an option to extend our existing commercial agreement with Samsung Bioepis for BENEPALI, IMRALDI and FLIXABI in Europe and obtained exclusive rights to commercialize these products in China. In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB080 Option Exercise</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080, an investigational treatment for AD.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pfizer Inc.</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2020 we entered into an agreement to acquire PF-05251749, a novel CNS-penetrant small molecule inhibitor of CK1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer. In particular, we plan to develop the Phase 1 asset for the treatment of sundowning in AD and ISWRD in Parkinson&#8217;s disease. This transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S. We expect this transaction to close in the first quarter of 2020.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Key Developments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">VUMERITY</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under the terms of the license and collaboration agreement with Alkermes, we made milestone payments totaling $155.0 million to Alkermes following the FDA's approval of VUMERITY. In November 2019 VUMERITY became available in the U.S.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 we and our collaboration partner Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S. and that the Phase 3 EMERGE study met its primary endpoint showing a significant reduction in clinical decline. We believe that results from a subset of patients in the Phase 3 ENGAGE study who received sufficient exposure to high dose aducanumab support findings from EMERGE. The decision to file is based on a new analysis, conducted in consultation with the FDA, of a larger dataset from the Phase 3 EMERGE and ENGAGE trials that were discontinued in March 2019 following a futility analysis.</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our plans to file for regulatory approval for aducanumab, please read the </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">subsection entitled "Financial Condition, Liquidity and Capital Resources" included below.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Elenbecestat</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019 we and our collaboration partner Eisai announced the decision to discontinue the global Phase 3 studies (MISSION AD1 and MISSION AD2) of the investigational oral BACE inhibitor elenbecestat in patients with early AD.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2019 Share Repurchase Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our March 2019 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our March 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our March 2019 Share Repurchase Program will be retired.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our December 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our December 2019 Share Repurchase Program will be retired.</span></div></div></div><div><a id="s6CF0735BB5B15701B81A8F82F3911E77"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019 compared to 2018</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018 compared to 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,713.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,800.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,017.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,666.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,086.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,337.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,379.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,886.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,290.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,980.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">707.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">585.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">20.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14,377.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13,452.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,273.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019 compared to 2018</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018 compared to 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,432.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,274.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,214.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,101.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,363.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,645.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,892.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,864.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,973.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">VUMERITY</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">97.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(100.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(97.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,529.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,595.2</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,977.2</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,097.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,724.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">883.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">486.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">485.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">184.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,001.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">68.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">380.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">738.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">545.1</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">379.8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(43.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Hemophilia product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.4</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,379.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,886.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Interferon includes AVONEX and PLEGRIDY.</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1F7279E8C28D5E07A08F8FA9287A6085"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</span></div><div style="line-height:120%;text-align:left;"><img src="tecfiderarev.jpg" alt="tecfiderarev.jpg" style="height:306px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 1.6% increase in U.S. TECFIDERA revenues was primarily due to a slight net price increase, offset by a small decrease in unit sales volume. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 10.3% increase in rest of world TECFIDERA revenues was primarily due to increases in unit sales volume of 14%, primarily related to our European and Japanese markets, and the favorable impact of foreign currency exchange of $16.5 million, partially offset by pricing reductions in certain European countries.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2020 the U.S. Patent Trial and Appeal Board (PTAB) decided that our U.S. Patent No. 8,399,514 (the &#8216;514 Patent) is patentable. The &#8216;514 Patent covers treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. This decision may be appealed. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The &#8216;514 Patent has also been challenged pursuant to the Hatch-Waxman Act in the U.S. District Courts of Delaware (the Delaware action) and West Virginia (the West Virginia action). We are awaiting a decision in the Delaware action and the trial in the West Virginia action is ongoing. If we receive an adverse judgment in either U.S. District Court action, we will appeal but we may face generic competition while our appeal is pending. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will face TECFIDERA generic competition if an adverse PTAB or U.S. District Court decision is reached on appeal. In addition, we have entered into settlement agreements with some of the defendants in the Delaware action and we now anticipate TECFIDERA generic competition before the &#8216;514 Patent expires in February 2028. Generic competition </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">is expected to have an adverse impact on our TECFIDERA sales and our results of operations. For additional information, please read Note 20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate an increase in TECFIDERA demand in rest of world in 2020, compared to 2019, notwithstanding the increasing competition from additional treatments for MS. We expect volume growth in our rest of world markets to offset volume declines in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX and PLEGRIDY</span></div><div style="line-height:120%;text-align:left;"><img src="interferonrev.jpg" alt="interferonrev.jpg" style="height:306px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 14.5% decrease in U.S. Interferon revenues was primarily due to a decrease in Interferon unit sales volumes of 13%, which was primarily attributable to patients transitioning to other MS therapies and a net price decrease. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 2.8% decrease in rest of world Interferon revenues was primarily due to pricing reductions in certain European countries. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that Interferon revenues will continue to decline in both the U.S. and rest of world markets in 2020, compared to 2019, as a result of increasing competition from our other MS products as well as other treatments for MS, including biosimilars, and pricing reductions in certain European markets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> U.S. AVONEX revenues totaled $1,202.1 million, $1,420.2 million and $1,593.6 million, respectively.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> rest of world AVONEX revenues totaled $463.8 million, $495.3 million and $557.9 million, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">PLEGRIDY</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> U.S. PLEGRIDY revenues totaled $224.5 million, $248.1 million and $295.5 million, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> rest of world PLEGRIDY revenues totaled $211.4 million, $199.4 million and $198.8 million, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</span></div><div style="line-height:120%;text-align:left;"><img src="tysabrirev.jpg" alt="tysabrirev.jpg" style="height:306px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 1.6% increase in U.S. TYSABRI revenues was primarily due to price increases, partially offset by a decrease in unit sales volumes of 4%. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 1.4% increase in rest of world TYSABRI revenues was primarily due to an increase in unit sales volumes of 3%.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate TYSABRI demand to be stable on a global basis in 2020, compared to 2019, with expected volume declines in the U.S. due to increasing competition from additional treatments for MS, including OCREVUS, offset by volume growth in our rest of world markets, net of price reductions in certain rest of world countries.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;text-align:left;text-indent:18px;"><img src="spinrazarev.jpg" alt="spinrazarev.jpg" style="height:306px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 9.3% increase in U.S. SPINRAZA revenues was primarily due to increases in unit sales volume of 9%.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 33.7% increase in rest of world SPINRAZA revenues was primarily due to an increase in unit sales volumes of 69%, partially offset by the unfavorable impact of foreign currency exchange of $43.5 million.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that the rate at which SPINRAZA revenues will grow will moderate in 2020, compared to 2019, primarily due to a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We face competition from a new gene therapy product that was approved in the U.S. in May 2019 for the treatment of SMA. Additionally, we are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential oral products. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Ionis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">BENEPALI, IMRALDI and FLIXABI</span></div><div style="line-height:120%;"><img src="biosimilarsrev.jpg" alt="biosimilarsrev.jpg" style="height:306px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 35.4% increase in biosimilar revenues was primarily due to the launch of IMRALDI in the fourth quarter of 2018, partially offset by the unfavorable impact of foreign currency exchange of $27.8 million.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2020 we expect strong revenue growth for our biosimilars business, primarily driven by the continued launch of IMRALDI in Europe, partially offset by price reductions in certain European countries.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilars, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. We also acquired an option to extend our existing commercial agreement with Samsung Bioepis for BENEPALI, IMRALDI and FLIXABI in Europe and obtained exclusive rights to commercialize these products in China.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="s9CD2A1DFFAF955A8B7909B3DF06E7C22"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech Inc. (Roche Group)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;"><img src="anticd20revenue.jpg" alt="anticd20revenue.jpg" style="height:366px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,747.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,484.3</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,206.9</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">622.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">669.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">755.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,124.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,814.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,451.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,542.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,431.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,316.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN annual pre-tax co-promotion profits in the U.S. in excess of $50.0 million decreased to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter of 2017 as gross sales of GAZYVA in the U.S. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">for the preceding 12-month period exceeded </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues, net was primarily due to increased net sales of RITUXAN in the U.S. of 5.0%, which reflects an increase in unit sales volume of 3%, and selling price increases, partially offset by higher rates in discounts and allowances.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in U.S. product revenues, net over 2018 also reflects an increase in GAZYVA unit sales volume of 21%.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in collaboration costs and expenses was primarily due to lower cost of sales and lower selling and marketing costs on RITUXAN and lower Branded Pharmaceutical Drug fee expenses for RITUXAN and GAZYVA.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are aware of anti-CD20 molecules, including biosimilar products, in development that if successfully developed and approved, could compete with RITUXAN and GAZYVA in the oncology market. The introduction of a biosimilar product can result in a significant reduction in net sales for the relevant product, as other manufacturers typically offer their versions at lower prices. In November 2019 and January 2020 biosimilar products referencing RITUXAN were launched in the U.S. and this could adversely affect the pre-tax profits of our collaboration arrangements with Genentech, which could, in turn, adversely affect our co-promotion profits in the U.S. in future years.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs consist of royalty revenues on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in other revenues from anti-CD20 therapeutic programs was primarily due to the sales growth of OCREVUS. Royalty revenues recognized on sales of OCREVUS for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled $687.5 million, $478.3 million and $159.3 million, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">OCREVUS royalty revenues are based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FDA approved OCREVUS for the treatment of RMS and PPMS. Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24% if annual net sales exceed $900.0 million. There will be a 50% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we receive a gross 3% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS has been approved for the treatment of RMS and PPMS in the E.U. and certain other countries. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read Note&#160;18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div></div></div><div><a id="sBC6C7BCA008A55EE95F5DB77D1AF0974"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For The Years </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019 compared to 2018</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018 compared to 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.5</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">140.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">601.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">498.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">323.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">707.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">585.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships primarily include revenues from our technical development services and manufacturing agreements with Samsung Bioepis and royalty revenues on biosimilar products from Samsung Bioepis. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$106.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the services described above provided to Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborative and other relationships, including revenues recognized under our technical development services and manufacturing agreements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Royalty and Corporate Revenues</span></div><div style="line-height:120%;text-align:left;"><img src="otherrev.jpg" alt="otherrev.jpg" style="height:306px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenues primarily from amounts earned under contract manufacturing agreements.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in other royalty and corporate revenues was primarily due to $383.2 million in revenues recognized in 2019 under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, compared to $206.7 million recognized in 2018. The increase in Bioverativ revenues in 2019 over the prior year period was due to our sales in 2019 of hemophilia-related inventory on hand as of December 31, 2018. The increase in corporate revenues was partially offset by the reduction in royalty revenues due to the expiration of certain of our patents and a reduction in revenues from contract manufacturing agreements, other than Bioverativ, as discussed above.</span></div><div><a id="s4B5EBD6313F65B7C9CAC3B29906EB876"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</span></div><div style="line-height:120%;text-align:center;"><img src="reservesdisandallow.jpg" alt="reservesdisandallow.jpg" style="height:328px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reserves for discounts and allowances as a percentage of gross product revenues were 24.3%, 23.7% and 22.0%, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounts were relatively consistent.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment assistance (copay), VA and PHS discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to higher managed care rebates and governmental rebates in the U.S. as well as higher governmental rebates and allowances in the rest of world, due in part to an increase in SPINRAZA sales volumes worldwide.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return reserves were relatively consistent. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenue reserves, please read Note 4, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><a id="s83CB78FA59AD5A99BE4DF2ADF5642FFF"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019 compared to 2018</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018 compared to 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,955.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,816.3</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,630.0</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,280.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,597.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,253.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(12.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,374.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,106.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,933.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">489.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">814.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(34.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">241.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">185.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(63.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">417.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(119.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(100.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(87.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,335.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,564.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,928.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</span></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s7D4503968C91569C909460426C098252"></a></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets (Cost of Sales)</span></div><div style="line-height:120%;text-align:left;"><img src="cogs.jpg" alt="cogs.jpg" style="height:306px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, as a percentage of total revenues, were 13.6%, 13.5% and 13.3% for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily due to our sale in 2019 to Bioverativ of hemophilia-related inventory on hand as of December 31, 2018, with a cost basis totaling $184.5 million pursuant to the terms of the manufacturing and supply agreement with Bioverativ </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">entered into in connection with the spin-off of our hemophilia business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, the increase in product cost of sales was attributable to an increase in sales of products within our biosimilar business and an increase in inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons, partially offset by lower cost of sales from our contract manufacturing agreements, except Bioverativ, as discussed above. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$52.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$76.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in royalty cost of sales was primarily due to a decrease in royalties payable on sales of TYSABRI resulting from the expiration of certain third party royalties, partially offset by increased royalties payable on higher sales of SPINRAZA and IMRALDI.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6AD5DC3575F057B2A2B98B6AE66E906D"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;"><img src="researchanddevelopment.jpg" alt="researchanddevelopment.jpg" style="height:693px;width:317px;"></img></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;"><img src="researchanddev.jpg" alt="researchanddev.jpg" style="height:365px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in research and development expense was primarily due to a decrease in milestone and upfront expenses and a decrease in other research and development costs. These decreases were partially offset by increases in costs incurred in connection with our early stage programs and marketed products.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Milestone and Upfront Expenses</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> includes:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$63.0 million charge to research and development expense upon the completion of a transaction with Samsung Bioepis to secure the exclusive rights to commercialize two potential ophthalmology biosimilar products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million charge to research and development expense upon the exercise of our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB080; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.5 million charge to research and development expense consisting of a $38.5 million charge upon the entering into a collaboration and research and development services agreement with Skyhawk and an approximately $8.0 million charge upon entering into an amendment to this agreement to add an additional discovery program.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> includes:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$486.2 million net charge to research and development expense upon the closing of the 2018 Ionis Agreement; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.0 million charge to research and development expense upon the exercise of our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize tofersen in ALS.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These payments are classified as research and development expense as the programs they relate to had not achieved regulatory approval as of the payment date.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information about these collaboration arrangements, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Early Stage Programs</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in spending related to our early stage programs was primarily due to an increase in costs associated with:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">gosuranemab in PSP and AD pursuant to our license agreement with BMS;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">cinpanemab in Parkinson's disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB112 in XLRP;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB104 in CIAS; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB078 (IONIS-C9</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) in ALS; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB091 in MS;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB110 (ActRIIA/B ligand trap) in SMA; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our decision in September 2019 to discontinue the Phase 2b study of BG00011 for the potential treatment of IPF, for which we incurred a one-time close out charge of approximately $10.0 million.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These increases were partially offset by a decrease in costs associated with:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the development of vixotrigine (BIIB074) in trigeminal neuralgia (TGN);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tofersen in ALS, which was advanced to a late stage program in the first quarter of 2019;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our decision in December 2018 to discontinue development of BIIB087, an investigational AAV-based gene therapy for the potential treatment of X-linked retinoschisis, and BIIB088, an investigational AAV-based gene therapy for the potential treatment of XLRP, upon the termination of our collaboration agreement with Applied Genetic Technologies Corporation; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB093 in LHI, which was advanced to a late stage program in the third quarter of 2018.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Late Stage Programs</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in spending associated with our late stage programs was primarily due to a decrease in spending related to the discontinuation of the global Phase 3 trials, ENGAGE and EMERGE, of aducanumab, net of Eisai reimbursement. This decrease was partially offset by increases in spending related to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of the termination costs of approximately $48.0 million resulting from the decision to discontinue the global Phase 3 studies of elenbecestat in AD;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BAN2401 in early AD pursuant to our collaboration arrangement with Eisai, which was advanced to a late stage program in the first quarter of 2019;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tofersen in ALS, which was advanced to a late stage program in the first quarter of 2019; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB093 in LHI, which was advanced to a late stage program in the third quarter of 2018; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB111 in CHM.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</span></div><div style="line-height:120%;"><img src="sellinggeneralandadmin.jpg" alt="sellinggeneralandadmin.jpg" style="height:240px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in selling, general and administrative expenses was primarily due to increased commercial and medical investments as well as the timing of spend on selling, general and administrative expense.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2020 we expect selling, general and administrative costs, including increases in headcount and other commercial infrastructure, to significantly increase as we support pre-launch activities associated with the potential regulatory approval of aducanumab.</span></div><div><a id="s717BF603927C59F0876C7AF6DCAEA59F"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization and Impairment of Acquired Intangible Assets</span></div><div style="line-height:120%;"><img src="amortofacquireintang.jpg" alt="amortofacquireintang.jpg" style="height:240px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and other programs acquired through business combinations. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets for the year ended December 31, 2019, was impacted by the 2019 impairment charges of $215.9 million related to certain IPR&amp;D assets associated with the Phase 2b study of BG00011 for the potential treatment of IPF, which was discontinued in the third quarter of 2019. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets for the year ended December 31, 2018, was impacted by the 2018 impairment charges of $189.3 million related to certain IPR&amp;D assets associated with our vixotrigine program and $176.8 million related to our intangible assets associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets, excluding impairment charges, totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$381.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$455.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets, excluding impairment charges, was primarily due to a lower rate of amortization for acquired intangible assets, primarily due to prior year impairments.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D related to Business Combinations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">BG00011</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF due to safety concerns. As a result, we recognized an impairment charge of approximately $215.9 million during the third quarter of 2019 to reduce the fair value of the IPR&amp;D intangible asset to zero. We also adjusted the value of our contingent consideration obligations related to this asset resulting in a gain of $61.2 million in the third quarter of 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Vixotrigine</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the potential treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR. As a result, we recognized an impairment charge of approximately $60.0 million during the third quarter of 2018 to reduce the fair value of the related IPR&amp;D intangible asset to zero. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN as we awaited the outcome of ongoing interactions with the FDA regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy. We reassessed the fair value of the TGN program using reduced expected lifetime revenues, higher expected clinical development costs and lower cumulative probability of success. As a result of that reassessment, we recognized an impairment charge of $129.3 million during the third quarter of 2018 to reduce the fair value of the TGN IPR&amp;D intangible asset to $41.8 million. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The TGN program has experienced numerous delays in development in the periods since we acquired the program and the fair value of this asset is not significantly in excess of carrying value. In addition, we are currently testing vixotrigine in another mid-stage clinical trial, in a different neuropathic pain indication, for which we also have an IPR&amp;D asset. Data from that trial is expected in the first half of 2020. This data may affect the economic value of vixotrigine and the IPR&amp;D assets for one or both programs could be impaired if assumptions used in determining their fair value change.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenues and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates and prioritization of these programs may result in a significant change to our valuation of our IPR&amp;D assets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA License Rights</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;$1.25 billion&#160;in cash, of which $795.2 million was recorded within intangible assets in the first quarter of 2017. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We had an intellectual property dispute with Forward Pharma in the U.S. concerning intellectual property related to TECFIDERA. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded a $328.2 million impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute and continued to amortize the remaining net book value of the U.S. intangible asset in our consolidated statements of income utilizing an economic consumption model. The U.S. Court of Appeals for the Federal Circuit upheld the USPTO's March 2017 ruling and in January 2019 denied Forward Pharma&#8217;s petition for rehearing. We evaluated the recoverability of the U.S. asset based upon these most recent developments and recorded a $176.8 million impairment charge in the fourth quarter of 2018 to reduce the remaining net book value of the U.S. asset to zero.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an intellectual property dispute with Forward Pharma in the E.U. concerning intellectual property related to TECFIDERA. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the European Patent Office (EPO) revoked Forward Pharma&#8217;s European Patent No. 2 801 355. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for June 2020. Based upon our assessment of this ruling, we continue to amortize the remaining net book value of the rest of world intangible asset in our consolidated statements of income utilizing an economic consumption model. The remaining net book value of the TECFIDERA rest of world intangible asset as of December 31, 2019, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$36.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the dispute with Forward Pharma in the E.U., please read Note 20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the amortization and impairment of acquired intangible assets, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div><a id="s2496B44D756956F6923230550C4E5AA2"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit (Loss) Sharing</span></div><div style="line-height:120%;"><img src="collaborationprofitshare.jpg" alt="collaborationprofitshare.jpg" style="height:240px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing primarily includes Samsung Bioepis' 50% share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recognized a net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$241.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$187.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis&#8217; </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits. The increases in profit-sharing expense for the comparative periods were primarily due to increased collaboration profits resulting from increased biosimilar sales.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="s0770639BC2A852D1BE4F0DB4911DBE12"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss on Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;"><img src="lossondivestitureofdenmark.jpg" alt="lossondivestitureofdenmark.jpg" style="height:240px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. Upon the closing of this transaction, we received approximately $881.9 million in cash, which may be adjusted based on other contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees and have accrued for this obligation. We may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this transaction, we recognized a total net loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$164.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated statements of income. This loss included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$95.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded in loss on divestiture of Hiller&#248;d, Denmark manufacturing operations. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and our estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$114.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. We also recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this transaction. During the fourth quarter of 2019 we recorded a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in our estimate of the future minimum batch commitment utilizing our current manufacturing forecast, which reflects the impact of forecasted aducanumab batches, resulting in a reduction in the pre-tax loss on divestiture from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$95.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$55.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the adverse commitment is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div><a id="sE920994682795F92A047B73836C2BC99"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div style="line-height:120%;"><img src="fvremeasurementcc.jpg" alt="fvremeasurementcc.jpg" style="height:240px;width:317px;"></img></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The gain on fair value remeasurement of contingent consideration for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of IPF, partially offset by changes in the probability and expected timing of achievement of certain developmental milestones, a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The gain on fair value remeasurement of contingent consideration for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was primarily due to delays in the expected timing of achievement of milestones related to our vixotrigine program for the potential treatment of TGN and an increase in discount rates used to revalue our contingent consideration liabilities, partially offset by the passage of time. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The loss on fair value remeasurement of contingent consideration for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was primarily due to the increase in the probability of achieving certain developmental milestones based upon the progression of the underlying clinical programs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our IPR&amp;D intangible assets related to our discontinued BG00011 program for the potential treatment of IPF and our vixotrigine program for the potential treatment of TGN, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</span></div></div><hr style="page-break-after:always"></hr><div><a id="s17D3A32CC8E355B1BF984AF1C6495D27"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</span></div><div style="line-height:120%;"><img src="acquirediprd.jpg" alt="acquirediprd.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB110 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we acquired BIIB110 and ALG-802 from AliveGen Inc. (AliveGen). BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. In connection with the closing of this transaction, we made an upfront payment of $27.5 million to AliveGen, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB110 has not yet reached technological feasibility.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB104 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we acquired BIIB104 from Pfizer. BIIB104 is a first-in-class, Phase 2b AMPA receptor potentiator for CIAS. In connection with the closing of this transaction, we made an upfront payment of $75.0 million to Pfizer, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB104 has not yet reached technological feasibility.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB100 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired BIIB100 from Kayropharm Therapeutics Inc. (Karyopharm). BIIB100 is a Phase 1 investigational oral compound for the treatment of certain neurological and neurodegenerative diseases, primarily in ALS. In connection with the closing of this transaction, we made an upfront payment of $10.0 million to Karyopharm, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB100 has not yet reached technological feasibility.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB093 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 we acquired BIIB093 from Remedy Pharmaceuticals Inc. (Remedy). In connection with the closing of this transaction, we made an upfront payment of $120.0 million to Remedy, which was </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB093 had not yet reached technological feasibility. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisitions of BIIB110, BIIB104, BIIB100 and BIIB093, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div><a id="sE0FB660ACDCA5B52B01D364EEA3194AB"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</span></div><div style="line-height:120%;"><img src="otherincomeexpense.jpg" alt="otherincomeexpense.jpg" style="height:240px;width:317px;"></img></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective January 1, 2018, other income (expense) reflects the recognition of net gains (losses) recorded in relation to changes in the fair value of our strategic investments following our adoption of Accounting Standards Update (ASU) No. 2016-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Prior to the adoption of this standard, we recognized changes in fair value of our strategic investment in accumulated other comprehensive income (loss), net. Changes in the fair value of our strategic investments could have a significant impact on our results of operations in any given period. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net primarily reflects net gains totaling $204.7 million recognized on our investments related to our holdings in equity and debt securities, compared to net gains totaling $119.5 million in 2018. The net gains recognized during the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily reflect an increase in the fair value in our investment in Ionis common stock from December 31, 2018, partially offset by the net loss recognized on our sale of a portion of our investment in Ionis common stock during the second and third quarters of 2019 reflecting the decrease in the fair value of the shares sold from March 31, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from our sale of a portion of our investment in Ionis common stock during the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled approximately </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$382.0 million. The original cost basis upon acquisition in June 2018 for the shares sold during the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled approximately $312.5 million.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains recognized on our investments related to our holdings in equity and debt securities for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflects an increase in the fair value of an investment in a non-marketable equity security from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that was realized for a net gain of approximately $87.7 million upon sale in the second quarter of 2019.</span></div><div><a id="sC903BE8D8C585C689CD09A3774AB8E3A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</span></div><div style="line-height:120%;"><img src="incometaxprovision.jpg" alt="incometaxprovision.jpg" style="height:338px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights and the impact of Swiss Tax Reform. This decrease was partially offset by a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense related to the divestiture of our subsidiary that owned our Hiller&#248;d, Denmark manufacturing operations. We also had a higher effective tax rate in 2018 resulting from the unfavorable effects of the 2017 Tax Act and our sale of inventory, the tax effect of which had been included within prepaid taxes at </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our uncertain tax positions and income tax rate reconciliation for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div><a id="s2B36E3119F6857D6A572FC7378C01026"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity in Loss of Investee, Net of Tax</span></div><div style="line-height:120%;"><img src="equityinlossofinvestee.jpg" alt="equityinlossofinvestee.jpg" style="height:240px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately 49.9%</span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended December 31, 2019, equity in loss of investee, net of tax reflects our share of losses totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and amortization of basis differences totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$78.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div><a id="sA46E6B5D8E4655848BC7F5C4F421F9D5"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Noncontrolling Interests, Net of Tax</span></div><div style="line-height:120%;"><img src="nci.jpg" alt="nci.jpg" style="height:240px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> net income attributable to noncontrolling interests, net of tax, was primarily related to a $50.0 million pre-tax payment made to Neurimmune to reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by 5%. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> net income attributable to noncontrolling interests, net of tax, was primarily related to a $150.0 million pre-tax payment made to Neurimmune to reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by 15%.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Neurimmune, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1D9984F686775D719AAB103C447457E4"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019 compared to 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,913.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,224.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">137.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,562.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,313.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,408.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,375.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,884.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,913.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,495.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,459.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(24.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,954.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working Capital:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,381.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,640.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,863.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,295.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,518.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,345.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</span></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s219B99167180576B9BE6D794729A2A2B"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$7.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in net cash flows provided by operating activities, net of: </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;"> in total net payments for income taxes; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$74.0 million upfront payment made to Skyhawk upon entering into a collaboration and research and development services agreement; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$5.9 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for share repurchases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$923.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in proceeds received on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, including the sale of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$744.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment made for our acquisition of NST, net of cash acquired;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$479.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in proceeds received on sales of strategic investments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$514.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for purchases of property, plant and equipment; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the final contingent payment made to former shareholders of Fumapharm AG and holders of their rights; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;">$155.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in payments made to Alkermes following the FDA's approval of VUMERITY.</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$6.2 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in net cash flows provided by operating activities, net of:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total net payments for income taxes; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$375.0 million in an upfront payment made to Ionis upon the closing of the 2018 Ionis Agreement and a $162.1 million expense reflecting the premium paid for the purchase of Ionis common stock; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$4.4 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for share repurchases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$770.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for purchases of property, plant and equipment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$676.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment made to Samsung BioLogics upon the closing of the share purchase transaction increasing our ownership percentage in Samsung Bioepis to approximately 49.9%;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$462.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment made to Ionis reflecting the fair value of the Ionis common stock purchased upon the closing the 2018 Ionis Agreement; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$112.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in payments made for the acquisitions of BIIB100, BIIB104 and BIIB110.</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. We expect our operating expenditures, particularly those related to research and development, clinical trials, commercialization of new products and international expansion to continue to grow. However, we expect to continue funding our current and planned operating requirements principally through our cash flows from operations, as well as our existing cash resources. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 we and our collaboration partner Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S. We plan to actively commit funds to developing our commercialization program for aducanumab so that we would be in a position to launch aducanumab if we receive regulatory approval. If we do not receive regulatory approval or are unable to successfully commercialize aducanumab, our financial condition, business and operations may be adversely affected.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read Item 1A. R</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">isk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and Item 7A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had cash, cash equivalents and marketable securities totaling approximately $5.9 billion compared to approximately $4.9 billion as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The net increase in cash, cash equivalents and marketable securities at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to cash flows from operations, cash received upon the divestiture of our Hiller&#248;d, Denmark manufacturing operations, net proceeds from marketable securities and proceeds from sales of strategic investments, partially offset by cash used for share repurchases, cash used for our acquisition of NST, net purchases of property, plant and equipment, contingent payments made to former shareholders of Fumapharm AG and holders of their rights and upfront and milestone payments made to Alkermes and Skyhawk. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets in our consolidated balance sheet as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes the carrying value of our investment in Samsung Bioepis of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$580.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and $680.6 million, respectively. As Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment. Investments in other assets, as of December 31, 2019 and 2018, also includes the fair value of our investment in Ionis common stock of $329.6 million and $563.8 million, respectively, which is subject to certain holding period restrictions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report. For additional information on our collaboration arrangements with Ionis, Samsung Bioepis, Alkermes and Skyhawk, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2022;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2025; and</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15,&#160;2045.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These Senior Notes were issued at discount and are amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair values of our outstanding borrowings as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Credit Facility</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we entered into a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we were permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility included a financial covenant that required us not to exceed a maximum consolidated leverage ratio. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding borrowings and were in compliance with all covenants under this facility. This credit facility was replaced with the new revolving credit facility entered into in January 2020, as discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2020 Credit Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility entered into in August 2015.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital is defined as current assets less current liabilities. The change in working capital at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects an increase in total current assets of $740.9 million and an increase in total current liabilities of $1,568.6 million. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net increase in total current assets was primarily driven by an increase in net cash, cash equivalents and marketable securities, as described above, offset by a decrease in inventory resulting from our sale of hemophilia-related inventory to Bioverativ.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net increase in total current liabilities was primarily due to the reclassification of $1.5 billion of our Senior Notes to current liabilities from notes payable, as these Senior Notes are due within one year. This increase was partially offset by a reduction in accrued expenses and other. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net decrease in accrued expenses and other was primarily related to a decrease in the accrual of contingent payments related to FUMADERM and TECFIDERA and a decrease in the accrual for construction in progress, partially offset by the accrual of the $100.0 million upfront payment to Samsung Bioepis, which was paid in January 2020.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our December 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our December 2019 Share Repurchase Program will be retired. We did not repurchase shares of our common stock under our December 2019 Share Repurchase Program during the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our March 2019 Share Repurchase Program, which is a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock. Our March 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our March 2019 Share Repurchase Program will be retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.7 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized our 2018 Share Repurchase Program, which was a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock. Our 2018 Share Repurchase Program was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized our 2016 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock. Our 2016 Share Repurchase Program was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</span></div></div><hr style="page-break-after:always"></hr><div><a id="s80BE8E55BED75A29B883430998EAD55B"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019 compared to 2018</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018 compared to 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,078.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,187.7</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,551.0</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by (used in) investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">470.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,046.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,963.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(123.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(30.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5,860.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,472.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,380.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s8B25713746BA5110BBCAD8C3C1D9AA6D"></a></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">non-cash operating items such as depreciation and amortization, impairment charges, unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net cash flows provided by operating activities increased primarily due to higher net income.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows provided by investing activities was primarily due to a decrease in contingent payments made to former shareholders of Fumapharm AG and holders of their rights, the proceeds received upon the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the proceeds received on our sales of strategic investments and the $462.9 million payment made to Ionis reflecting the fair value of the Ionis common stock purchased upon the closing of the 2018 Ionis Agreement in the prior year comparative period. This increase was partially offset by a decrease in net proceeds related to marketable securities, the cash used for our acquisition of NST and $155.0 million in milestone payments made to Alkermes following the FDA's approval of VUMERITY, which was recorded as an intangible asset during the fourth quarter of 2019. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in financing activities was primarily due to an increase in cash used for share repurchases. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFDBB9311C4D15062A7EA9980CCAE9178"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our contractual obligations as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Payments Due by Period</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Less&#160;than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1 Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1 to 3</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">3 to 5</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">After</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">5&#160;Years</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cancellable operating leases (1), (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">372.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">105.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">89.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">116.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term debt obligations (3)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,792.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,730.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,387.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">323.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,350.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase and other obligations (4)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,013.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">266.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">183.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">329.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Defined benefit obligation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">102.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">102.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total contractual obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,280.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,057.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,676.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">742.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,804.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="sB69E4049F20A543CB58593E00EA43616"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease properties and equipment for use in our operations. Amounts reflected within the table above detail future minimum rental commitments under non-cancelable operating leases as of December&#160;31 for each of the periods presented. In addition to the minimum rental commitments, these leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Obligations are presented net of sublease income expected to be received for the vacated small-scale biologics manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term debt obligations are related to our Senior Notes, including principal and interest payments. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase and other obligations primarily include  </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$697.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the remaining payments on the Transition Toll Tax, contractual commitments to our suppliers, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$52.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contractual commitments for the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$8.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the fair value of net liabilities on derivative contracts. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Payments</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation plc, full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net commercial sales up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net commercial sales that exceed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net commercial sales of SPINRAZA using a tiered royalty rate between 11% and 15%, which are recorded as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">VUMERITY</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes, we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of 15%, which are recorded as cost of sales in our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. For additional information on our collaboration arrangement with Alkermes, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Holdings Limited (Convergence) and Biogen International Neuroscience GmbH (BIN), we agreed to make additional payments based upon the achievement of certain milestone events. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence and BIN occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue the remaining obligations each reporting period. We may pay up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$735.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestones related to these acquisitions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, the Fumapharm Products). We were required to make contingent payments to former shareholders of Fumapharm AG and holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement, until such time as the cumulative sales level reached </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments were due. During the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we paid the final </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment as we achieved the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales level related to the Fumapharm Products in the fourth quarter of 2018.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.8 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in development milestones, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in regulatory milestones and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$430.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of milestone payments in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the regulatory filing with the FDA for approval of aducanumab and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if aducanumab is launched in the U.S. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated balance sheet for expenditures incurred by CROs as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$514.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cancellable future commitments based on existing CRO contracts as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees and have accrued for this obligation. We may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$136.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net liabilities associated with uncertain tax positions. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the Transition Toll Tax. Of the amounts accrued as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to an approximately $87.0 million carryforward of taxes paid in relation to the company's 2017 tax return. The Transition Toll Tax will be paid over an eight-year period, which started in 2018, and will not accrue interest. For additional information on the Transition Toll Tax, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div><a id="s3B53B6AD5F35582A86E22D028EB8BC5F"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards and their expected impact on our consolidated financial statements or disclosures, please read Note&#160;1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div><a id="s3C1DADB5C359507784571929AACA064C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Legal Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal matters as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Policies and Estimates</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(U.S.&#160;GAAP), requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates. Other significant accounting policies are outlined in Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under Financial Accounting Standards Board (FASB) Accounting Standards Codification 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenues, please read Note 4, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired Intangible Assets, including IPR&amp;D</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we purchase a business, the acquired IPR&amp;D is measured at fair value, capitalized as an intangible asset and tested for impairment at least annually, as of October 31, until commercialization, after which time the IPR&amp;D is amortized over its estimated useful life. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have acquired, and expect to continue to acquire, intangible assets through the acquisition of biotechnology companies or through the consolidation of variable interest entities. These intangible assets primarily consist of technology associated with human therapeutic products and IPR&amp;D product candidates. When significant identifiable intangible assets are acquired, we generally engage an independent third-party valuation firm to assist in determining the fair values of these assets as of the acquisition date. Management will determine the fair value of less significant identifiable intangible assets acquired. Discounted cash flow models are typically used in these valuations, and these models require the use of significant estimates and assumptions including but not limited to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">estimating the timing of and expected costs to complete the in-process projects;</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">projecting regulatory approvals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">estimating future cash flows from product sales resulting from completed products and in process projects;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">developing appropriate discount rates and probability rates by project.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe the fair values assigned to the intangible assets acquired are based upon reasonable estimates and assumptions given available facts and circumstances as of the acquisition dates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If these projects are not successfully developed, the sales and profitability of the company may be adversely affected in future periods. Additionally, the value of the acquired intangible assets may become impaired. No assurance can be given that the underlying assumptions used to estimate expected project sales, development costs or profitability, or the events associated with such projects, will transpire as estimated.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment and Amortization of Long-lived Assets and Accounting for Goodwill</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Long-lived Assets Other than Goodwill</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used include property, plant and equipment as well as intangible assets, including IPR&amp;D and trademarks. Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above under </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquired Intangible Assets, including IPR&amp;D</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in the estimates and assumptions used in determining the fair value of our acquired IPR&amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have previously been impaired, including our vixotrigine program for the treatment of neuropathic pain, such as TGN, could become further impaired in the future.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most significant intangible assets are our acquired and in-licensed rights and patents. Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elan and obtaining the fair value of the U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property, including Forward Pharma&#8217;s intellectual property related to TECFIDERA. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY or TECFIDERA (rest of world) products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the impairment charges related to our long-lived assets during </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Goodwill</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill relates largely to amounts that arose in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003 and amounts that were paid in connection with the acquisition of Fumapharm AG. Our goodwill balances represent the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess our goodwill balance within our single reporting unit annually, as of October&#160;31, and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable to determine whether any impairment in this asset may exist and, if so, the extent of such impairment. We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We completed our required annual impairment test in the fourth quarters of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and determined in each of those periods that the carrying value of goodwill was not impaired. In each year, the fair value of our reporting unit, which includes goodwill, was significantly in excess of the carrying value of our reporting unit.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">revalue the remaining obligations and record increases or decreases in their fair value as an adjustment to contingent consideration expense in our consolidated statements of income. Changes in the fair value of our contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates and achievement and timing of any cumulative sales-based and development milestones or changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions described above, could have a material impact on the amount of contingent consideration expense we record in any given period.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We prepare and file income tax returns based on our interpretation of each jurisdiction&#8217;s tax laws and regulations. In preparing our consolidated financial statements, we estimate our income tax liability in each of the jurisdictions in which we operate by estimating our actual current tax expense together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred tax assets and liabilities, which are included in our consolidated balance sheets. Upon our election in the fourth quarter of 2018 to record deferred taxes for GILTI, we have included amounts related to U.S. GILTI taxes within temporary difference. Significant management judgment is required in assessing the realizability of our deferred tax assets. In performing this assessment, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial accounting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and the effects of tax planning strategies. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Our liabilities for uncertain tax positions can be relieved only if the contingency becomes legally extinguished, through either payment to the taxing authority or the expiration of the statute of limitations, the recognition of the benefits associated with the position meet the &#8220;more-likely-than-not&#8221; threshold or the liability becomes effectively settled through the examination process. We consider matters to be effectively settled once the taxing authority has completed all of its required or expected examination procedures, including all appeals and administrative reviews, we have no plans to appeal or litigate any aspect of the tax position and we believe that it is highly unlikely that the taxing authority would examine or re-examine the related tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div><a id="s5B65AF34E43F5E6CBB32796E8DA1D59D"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks that may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Japanese yen and South Korean won.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenues will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expenses, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenues and expenses will increase when reported in U.S. dollars.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100%, which indicated that Argentina&#8217;s economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of December 31, 2019, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15 months</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 9, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in this report.  </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of foreign currency exchange rate changes on revenues and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">are reported as operating activities in our consolidated statements of cash flows.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our consolidated statements of cash flows.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $265.0 million and $290.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Hedge Program</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. dollar and South Korean won as a result of exercising our option to increase our ownership percentage in Samsung Bioepis to approximately 49.9%. We entered into foreign currency forward contracts to manage the foreign currency risk with our forward contracts used to hedge changes in the spot rate over the next 10 months. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement would result in a hypothetical decrease in fair value of approximately $43.0 million and $64.0 million, respectively. The estimated fair value was determined by measuring the impact of the hypothetical spot rate movement on outstanding forward contracts.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $21.0 million and $19.0 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8&#160;million. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in certain international markets in which we operate have implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the way our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our consolidated financial position or results of operations. There is also </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, impose restrictions on the coverage of certain drugs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition in many markets from generic versions, biosimilars and prodrugs of existing products as well as products approved under abbreviated regulatory pathways.&#160;Such products are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenues. In addition, when a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="s25D3F174C5C25E5191124E4035FF41C5"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information required by this Item&#160;8 is contained on pages F-1 through F-82 of this report and is incorporated herein by reference.</span></div><div><a id="s1BEAC78354CC51C59225AFFAB359E71B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</span></div><div><a id="sFF2848B3ED115BAEA9389921DFB1C2CB"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers and effected by a company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S.&#160;GAAP. Our internal control over financial reporting includes those policies and procedures that:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S.&#160;GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our management assessed the effectiveness of our internal control over financial reporting as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control&#160;&#8212; Integrated Framework.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our assessment, our management has concluded that, as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our internal control over financial reporting is effective based on those criteria.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The effectiveness of our internal control over financial reporting as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, has been audited by PricewaterhouseCoopers LLP, an </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">independent registered public accounting firm, as stated in their attestation report, which is included herein.</span></div><div><a id="sD64C8A7D444A562D86F8B85A9B701047"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4134C6EB1658550C9E619F58314EE047"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;III</span></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s476AAACF3B8354239CF346B4EAF6E0BB"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information concerning our executive officers is set forth under the heading </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Information about our Executive Officers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in Item 1 of this report. The text of our code of business conduct, which includes the code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions, is posted on our website, www.biogen.com, under the &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Corporate Governance</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; subsection of the &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of the site. We intend to make all required disclosures regarding any amendments to, or waivers from, provisions of our code of business conduct at the same location of our website. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to the remainder of this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Proposal&#160;1&#160;- Election of Directors,&#8221; &#8220;Corporate Governance at Biogen&#8221; </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Miscellaneous&#160;- Stockholder Proposals</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> annual meeting of stockholders.</span></div><div><a id="s4FB207C7F3A654F7B100D4469F6EDCB3"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Executive Compensation Matters</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Corporate Governance at Biogen&#8221;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contained in the proxy statement for our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> annual meeting of stockholders.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><a id="sEC9A18032A775CDA9773B1097E61F799"></a></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Stock Ownership&#8221;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Equity Compensation Plan Information&#8221;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contained in the proxy statement for our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> annual meeting of stockholders.</span></div><div><a id="s39E1D3E99B155EFF90B00E0CD73EE80F"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Certain Relationships and Related Person Transactions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Corporate Governance at Biogen</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> annual meeting of stockholders.</span></div><div><a id="sDBE941E4C6CB536993EC5F0C13EC4453"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accountant Fees and Services</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the section entitled &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Proposal&#160;2&#160;- Ratification of the Selection of our Independent Registered Public Accounting Firm</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> annual meeting of stockholders.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90</span></div></div><hr style="page-break-after:always"></hr><div><a id="sACD2232777E05562B9938EF24C78D202"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;IV</span></div><div><a id="sA8A12005879F5E9F9683D83027128802"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;15. &#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">a. &#160;&#160;&#160;&#160;(1)&#160;Consolidated Financial Statements:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following financial statements are filed as part of this report:</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:37%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Financial Statements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page&#160;Number</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-3</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Balance Sheets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-4</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-5</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-6</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-9</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-80</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain totals may not sum due to rounding.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;(2) Exhibits</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed on the Exhibit&#160;Index beginning on page&#160;92, which is incorporated herein by reference, are filed or furnished as part of this report or are incorporated into this report by reference.</span></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(3) Financial Statement Schedules</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Schedules are omitted because they are not applicable, or are not required, or because the information is included in the consolidated financial statements and notes thereto.</span></div><div><a id="sE2CB510631A55C398EA798A7D52C8FFC"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;16. &#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Not applicable.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91</span></div></div><hr style="page-break-after:always"></hr><div><a id="s414200C5E4335ACFADCAF0BAFF36A735"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:center;-sec-extract:summary;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT INDEX</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:7%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1&#8224;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504513000010/apa.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset Purchase Agreement among Biogen Idec International Holding Ltd., Elan Pharma International Limited and Elan Pharmaceuticals, Inc., dated as of February 5, 2013. Filed as Exhibit 2.1 to our Current Report on Form 8-K/A filed on February 12, 2013.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000007/ex21_separationxagreement.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Separation Agreement between Biogen Inc. and Bioverativ Inc. dated as of January 31, 2017. Filed as Exhibit 2.1 to our Current Report on Form 8-K filed on February 2, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312512312222/d362642dex31.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amended and Restated Certificate of Incorporation, as amended. Filed as Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504515000008/biib-2015x327xexhibit31.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certificate of Amendment to the Certificate of Incorporation. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on March 27, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312517200127/d406783dex31.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fourth Amended and Restated Bylaws. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on June 9, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312512312222/d362642dex31.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reference is made to Exhibit 3.1 for a description of the rights, preferences and privileges of our Series A Preferred Stock and Series X Junior Participating Preferred Stock.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312515320650/d78596dex41.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indenture between Biogen Inc. and U.S. Bank National Association, dated as of September 15, 2015. Filed as Exhibit 4.1 to our Current Report on Form 8-K filed on September 16, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312515320650/d78596dex42.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">First Supplemental Indenture between Biogen Inc. and U.S. Bank National Association, dated September 15, 2015. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on September 16, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.4+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20191231xex44.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Description of Securities.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504515000028/creditagreement2015biogen.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit Agreement between Biogen Inc., Bank of America, N.A., Goldman Sachs Bank USA and other lenders party thereto, dated August 28, 2015. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on September 1, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312520022940/d854655dex101.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit Agreement, dated as of January 28, 2020, among Biogen Inc., Bank of America, N.A., as administrative agent, swing ling lender and the L/C issuer, and the other lenders party thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on February 3, 2020.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3&#8224;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012311009300/b83162exv10w5.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Second Amended and Restated Collaboration Agreement between Biogen Idec Inc. and Genentech, Inc., dated as of October 18, 2010. Filed as Exhibit 10.5 to our Annual Report on Form 10-K for the year ended December 31, 2010.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.4&#8224;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012311009300/b83162exv10w6.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter Agreement regarding GA101 financial terms between Biogen Idec Inc. and Genentech, Inc., dated October 18, 2010. Filed as Exhibit 10.6 to our Annual Report on Form 10-K for the year ended December 31, 2010.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095015717000082/ex10-1.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement and License Agreement, dated January 17, 2017, between Biogen Swiss Manufacturing GmbH, Biogen International Holdings ltd., Forward Pharma A/S and other parties thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on February 1, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.6*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312517139450/d43428ddef14a.htm#toc43428_63"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2017 Omnibus Equity Plan. Filed as Appendix B to our Definitive Proxy Statement on Schedule 14A filed on April 26, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit102.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of restricted stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.8*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit103.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of market stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.9*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit104.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.4 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.10*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit105.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of cash-settled performance unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.5 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.11*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1010.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement (cash-settled) under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.10 to our Annual Report on Form 10-K for the year ended December 31, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.12*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1011.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.11 to our Annual Report on Form 10-K for the year ended December 31, 2017.</span></a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:7%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.13*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000010/biib-2018331xex101.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.14*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000010/biib-2018331xex102.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement (cash settled) under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.15*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000010/biib-2018331xex103.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of restricted stock unit award agreement (2018 one-time transition grant) under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.16*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000029/biib-2019630xex101.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of market stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019). Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.17*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000029/biib-2019630xex102.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019). Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.18*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000029/biib-2019630xex103.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement (cash settled) under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019). Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.19*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000011/biib-2014331xex101.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. 2008 Amended and Restated Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.20*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000011/biib-2014331xex102.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.21*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000011/biib-2014331xex103.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of market stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.22*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508005246/b71469biexv10w1.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of restricted stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 1, 2008.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.23*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508005246/b71469biexv10w2.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of nonqualified stock option award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Current Report on Form 8-K filed on August 1, 2008.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.24*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012310036233/b79987exv10w1.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of cash-settled performance shares award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.25*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504515000014/biib-2015331xex101.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2006 Non-Employee Directors Equity Plan, as amended. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.26*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312515159387/d786327ddef14a.htm#toc786327_57"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2015 Employee Stock Purchase Plan. Filed as Appendix A to our Definitive Proxy Statement on Schedule 14A filed on April 30, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.27*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508003542/b67068dfdefc14a.htm#152"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. 2008 Performance-Based Management Incentive Plan. Filed as Appendix B to our Definitive Proxy Statement on Schedule 14A filed on May 8, 2008.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.28*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000017/biib-2019331xex101.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2019 Form of Performance-Based Management Incentive Plan.&#160;Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.29*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013504001180/b48790biexv10w13.txt"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Voluntary Executive Supplemental Savings Plan, as amended and restated effective January 1, 2004. Filed as Exhibit 10.13 to our Annual Report on Form 10-K for the year ended December 31, 2003.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.30*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000042/biib-20151231xex1023.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Supplemental Savings Plan, as amended. Filed as Exhibit 10.23 to our Annual Report on Form 10-K for the year ended December 31, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.31*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000042/biib-20151231xex1024.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Voluntary Board of Directors Savings Plan, as amended. Filed as Exhibit 10.24 to our Annual Report on Form 10-K for the year ended December 31, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.32*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000029/biib-2019630xex104.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective June 19, 2019. Filed as Exhibit 10.4 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.33*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000006/biib-20181231xex1031.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Annual Retainer Summary for Board of Directors. Filed as Exhibit 10.31 to our Annual Report on Form 10-K for the year ended December 31, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.34*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000041/biib-2019930xex101.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Annual Retainer Summary for Board of Directors (effective January 1, 2020). Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019.</span></a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:6%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.35*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012311057276/b86869exv10w1.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of indemnification agreement for directors and executive officers. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on June 7, 2011.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.36*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000076/biogenemploymentagreementf.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employment Agreement between Biogen Inc. and Michel Vounatsos dated December 18, 2016 and effective as of January 6, 2017. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on December 19, 2016.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.37*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1031.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Jeffrey Capello dated November 14, 2017. Filed as Exhibit 10.31 to our Annual Report on Form 10-K for the year ended December 31, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.38*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1033.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Michael Ehlers dated April 16, 2016. Filed as Exhibit 10.33 to our Annual Report on Form 10-K for the year ended December 31, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.39*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012310010528/b77985exv10w58.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Susan Alexander dated December 13, 2005. Filed as Exhibit 10.58 to our Annual Report on Form 10-K for the year ended December 31, 2009.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.40*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000010/biib-2018331xex104.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement for Paul McKenzie dated December 14, 2015. Filed as Exhibit 10.4 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20191231xex21.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subsidiaries.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20191231xex23.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20191231xex311.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20191231xex312.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20191231xex321.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flows, (v) the Consolidated Statements of Equity and (vi) Notes to Consolidated Financial Statements.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management contract or compensatory plan or arrangement.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8224;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Confidential treatment has been granted or requested with respect to portions of this exhibit.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Filed herewith.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;++</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furnished herewith.</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">94</span></div></div><hr style="page-break-after:always"></hr><div><a id="s16FDF2DBB88E58939B769B4367E8A1AE"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="line-height:120%;font-size:18pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;">&#160;</span></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:316px;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:50px;"></td><td style="width:265px;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">BIOGEN INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;M</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHEL</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;V</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OUNATSOS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:42%;"></td><td style="width:3%;"></td><td style="width:34%;"></td><td style="width:3%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Name</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Capacity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Date</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;M</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHEL</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;V</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OUNATSOS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director&#160;and&#160;Chief&#160;Executive&#160;Officer (principal&#160;executive&#160;officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;J</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">EFFREY </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">D</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">C</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">APELLO</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive&#160;Vice&#160;President and Chief Financial Officer (principal financial officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;R</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OBIN</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;C. K</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">RAMER</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Chief Accounting Officer (principal accounting officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robin C. Kramer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TELIOS</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;P</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">APADOPOULOS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director&#160;and&#160;Chairman&#160;of&#160;the&#160;Board&#160;of Directors</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stelios Papadopoulos</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">LEXANDER </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">J</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">D</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ENNER</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Alexander J. Denner</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;C</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AROLINE</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;D. D</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ORSA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Caroline D. Dorsa</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;W</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ILLIAM</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;A. H</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AWKINS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">William A. Hawkins</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;N</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ANCY</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;L. L</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">EAMING</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nancy L. Leaming</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;J</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ESUS</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;B. M</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ANTAS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February 6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jesus B. Mantas</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;R</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHARD </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">C</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">M</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ULLIGAN</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Richard C. Mulligan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;R</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OBERT</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;W. P</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ANGIA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robert W. Pangia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;B</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">RIAN</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;S. P</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OSNER</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Brian S. Posner</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;E</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">RIC</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;K. R</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OWINSKY</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eric K. Rowinsky</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;L</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">YNN</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">CHENK</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Lynn Schenk</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TEPHEN</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;A. S</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">HERWIN</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stephen A. Sherwin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">96</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE4D3A870A9AF5A41BA9D0C2A8FE36F60"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:37%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page&#160;Number</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-2</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Balance Sheets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-4</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-5</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-6</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-9</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-80</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:300px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 1</span></div></div><hr style="page-break-after:always"></hr><div><a id="s488358A78E4F531C85E89BA9183E0787"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions, except per share amounts)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e1508-wk-Fact-F1FBA38FF669B88E1D976F38B82CDF1B" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11,379.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1527-wk-Fact-7B6205D978C9C04E48296F38B81CF51A" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10,886.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1546-wk-Fact-A0A85755BDDAAFF80DF16F38B7A963B8" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10,354.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e1562-wk-Fact-6DB6BA0B8C715A0D0D4B6F38B8607F57" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,290.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1581-wk-Fact-5DE8AC0444CC0844782E6F38B82AE6AA" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,980.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1600-wk-Fact-3A0656DB95083450147A6F38B824BC8E" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,559.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e1621-wk-Fact-00E0A71FFA7A5B6582ED6F38B7ACA093" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">707.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1640-wk-Fact-F0C4D670DC0F193457D96F38B8622365" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">585.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1659-wk-Fact-5D3FED1ADFF25AE90C656F38B87CF3D8" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">360.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e1680-wk-Fact-E32397F18F6693CE30CB6F38B869063E" name="us-gaap:Revenues" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14,377.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1699-wk-Fact-6346545FE8014FEB58A26F38B7BCE6BD" name="us-gaap:Revenues" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,452.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1718-wk-Fact-96627728E852FC579E846F38B8727293" name="us-gaap:Revenues" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,273.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e1801-wk-Fact-F31EB1813F669E0C4CE46F38B81939B6" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,955.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1820-wk-Fact-5836028879FCD1E33D2B6F38B81DC6AF" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,816.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1839-wk-Fact-436BEFF0AD5D83B1CFDD6F38B827BEB2" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,630.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e1860-wk-Fact-249B537F1C6F398F9F736F38B883F9E8" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,280.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1879-wk-Fact-CB3AC2C9EB0A3573A6A06F38B841157E" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,597.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1898-wk-Fact-8C04E99A6A84512CB5786F38B83C630B" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,253.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e1919-wk-Fact-7B2DF81CED7650C3660D6F38B7AEC578" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,374.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1938-wk-Fact-DC74F299D202669E73136F38B8048B00" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,106.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1957-wk-Fact-B05147F5608E5C0110656F38B815661A" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,933.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e1979-wk-Fact-79F73778C54DE73C4DD76F38B881C966" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">489.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e1998-wk-Fact-81104360B4FDD747DCD66F38B87FA895" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">747.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2017-wk-Fact-0248BA74606E7D1238426F38B833F6BA" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">814.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2038-wk-Fact-18F0A3FB37E3A7A494966F38B87AD564" name="biib:CollaborationProfitSharing" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">241.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2057-wk-Fact-8CFFC23D5AD1C81925E76F38B80A2DFD" name="biib:CollaborationProfitSharing" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">185.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2076-wk-Fact-768B3C497523BB8A323D6F38B867F91A" name="biib:CollaborationProfitSharing" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2097-wk-Fact-2E1848792728A1D7E2B57019220BE327" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2116-wk-Fact-7ECF992C3975B52D113870194B2D32B5" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2135-wk-Fact-D95679811100D0E7E32C70196C35ACAE" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d50997257e2156-wk-Fact-1823324BEE5AA206F4236F38B832A514" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d50997257e2176-wk-Fact-977CCFE1B549EEAAE2F26F38B8745977" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2196-wk-Fact-98699FC9CF903005B5E56F38B7ABD2C2" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">62.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2217-wk-Fact-8083CD7170BB88E868B56F38B7C72176" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2236-wk-Fact-17423E27B848A85AD4AE6F38B820B150" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2255-wk-Fact-44EAC57204C4C05B290C6F38B884AC7E" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2276-wk-Fact-5A8618CA47536F9730136F38B7B89C8B" name="us-gaap:RestructuringCharges" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2295-wk-Fact-B80C88B842F78DFE31EF6F38B818E106" name="us-gaap:RestructuringCharges" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2314-wk-Fact-997495A4CAD8A36FB4E26F38B826DFBB" name="us-gaap:RestructuringCharges" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2335-wk-Fact-F5F281DF9D0C5B1D58116F38B805F247" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,335.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2354-wk-Fact-7EC25CE695A7A4812C316F38B7AD746A" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,564.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2373-wk-Fact-EB3F161724E402F63C156F38B7C88B14" name="us-gaap:CostsAndExpenses" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,928.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2394-wk-Fact-A79AB0F2F1ED0BC79F866F38B7C805F3" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,042.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2413-wk-Fact-926F44026F3FFC9248AC6F38B800FCAC" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,888.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2432-wk-Fact-9E58A29345FB56EB3CDE6F38B7A7E08A" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,345.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2453-wk-Fact-30D3E4734FFCCDECF81C6F38B832E9CF" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2472-wk-Fact-1E1CCAC95E8FE4A0F3CC6F38B873F8AA" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d50997257e2491-wk-Fact-0B37CAFFF87FFF67E1CA6F38B7DCE800" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">217.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2513-wk-Fact-037FDB9132CFC80955486F38B80DC31A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,125.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2532-wk-Fact-CEA622036210CBAE55336F38B7C2C044" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,899.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2551-wk-Fact-68291FC0C112D97457DA6F38B7DD4BB7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,128.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2572-wk-Fact-D772848546D678B1763B6F38B837CC03" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,158.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2591-wk-Fact-2FDAAAEDBE81F99A2C786F38B89FE50C" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,425.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2610-wk-Fact-297A0CBBF5B99106D4D26F38B7FC8B8D" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,458.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2632-wk-Fact-2A57B951C0BA4E68F8936F38B82EF936" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">79.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2651-wk-Fact-91D14DB26E2AF98F5DF46F38B8756C34" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2670-wk-Fact-A9714C9669A2DB1BC04A6F38B8195CF4" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2691-wk-Fact-C3E3738B6B2880EEE0C26F38B86F41E2" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,888.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2710-wk-Fact-697504B55D319C5C89A06F38B813740F" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,474.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2729-wk-Fact-11271C2D6390C500664E6F38B7B1785A" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,670.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to noncontrolling interests, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2750-wk-Fact-1900219E0FB7A5328D086F38B7FAC097" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2769-wk-Fact-E8E5FA73540BFEE969DC6F38B88214FB" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2788-wk-Fact-161AB1A997B7E3DA22CF6F38B89B9F1E" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2814-wk-Fact-409F06146EDA2C5A1FA56F38B82DE39D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,888.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2833-wk-Fact-D75E3BB69A698B5537196F38B831D83C" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,430.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2852-wk-Fact-029151C37D9A5DCBB4476F38B8229A45" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,539.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2935-wk-Fact-A79B8DD2B8E528E3782E6F38B808C78D" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">31.47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2954-wk-Fact-EC8AD5EF20EED04CF1636F38B8861C2A" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e2973-wk-Fact-1309CB0E98D1AEAAED8B6F38B837AD26" name="us-gaap:EarningsPerShareBasic" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e2994-wk-Fact-F8BA2307E5D05CF7F3896F38B7C21B4F" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">31.42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e3013-wk-Fact-5A9680F29B9835BE41B06F38B82F13BD" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e3032-wk-Fact-AC1A9E20C32DB8C75C6E6F38B7A31203" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e3110-wk-Fact-1969AB1F17EC7BCE4FB56F38B7B8CA9B" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">187.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e3129-wk-Fact-5907C0CD0AE9671001886F38B828BCF3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">204.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e3148-wk-Fact-699EE9018111D1CC3A906F38B80EA6F3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">212.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d50997257e3169-wk-Fact-9C26193DB3CDD8FB9C8B6F38B8899F39" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">187.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e3188-wk-Fact-4176A55C9C6E8FB2BE6A6F38B7A4B71D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">205.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d50997257e3207-wk-Fact-BDF045D316347ECE0A996F38B87BB71A" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">213.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:120px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 2</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA48F89167352527C8D3834BEA078C909"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001034e1445-wk-Fact-409F06146EDA2C5A1FA56F38B82DE39D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,888.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e1464-wk-Fact-D75E3BB69A698B5537196F38B831D83C" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,430.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e1483-wk-Fact-029151C37D9A5DCBB4476F38B8229A45" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,539.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001034e1623-wk-Fact-036AE0A9F02C9CF5CCE66F38B81AF793" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51001034e1642-wk-Fact-E2BF01DADDB2DDB253656F38B81672D1" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51001034e1662-wk-Fact-22620E07DDA09BF57ACF6F38B8196E38" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: reclassification adjustment for (gains) losses included in net income, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51001034e1684-wk-Fact-850FB1BD118ACA44C9D66F38B819DD6F" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e1704-wk-Fact-158B897DA936D844E43D6F38B8100B61" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e1723-wk-Fact-186A8E31C983D57A2BE46F38B8174F8A" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001034e1744-wk-Fact-23E718C96C1F7D1EFA1C6F38B81A332F" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51001034e1763-wk-Fact-82BCB771BD1EBE85B00B6F38B86381BD" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e1783-wk-Fact-980B5C73304B4432C5D26F38B8628EF0" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001034e1866-wk-Fact-72F9B7E4B0E1E8A262AA6F38B8187145" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e1885-wk-Fact-768879F371477FBF53096F38B80E0DB3" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">97.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51001034e1904-wk-Fact-BD0BC5A2ADA7F06BF7026F38B81A5C38" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">193.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: reclassification adjustment for (gains) losses included in net income, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51001034e1926-wk-Fact-6569365DC95E5054B5696F38B80E341B" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">115.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e1946-wk-Fact-F829005F80D75D746CB96F38B8611030" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">41.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e1965-wk-Fact-5C1A5042825B6AB15DB56F38B86EF660" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51001034e1987-wk-Fact-58F1A7C851B29908A75F6F38B80F8124" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">26.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2007-wk-Fact-CAF379F238DF11937A766F38B817DB96" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">139.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51001034e2026-wk-Fact-F7B9347038E39989A61B6F38B885B658" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">162.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) recognized during the period, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001034e2110-wk-Fact-085DEE816DF81F31649E6F38B8148634" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2129-wk-Fact-65E3E9BC59BCE7A697106F38B86A342A" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2148-wk-Fact-C6684478E53F26F446A76F38B861D8CB" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: reclassification adjustment for (gains) losses included in net income, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51001034e2169-wk-Fact-DE48FCAAECC6C1C392296F38B81B9578" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51001034e2189-wk-Fact-EB54C7BF5C1E6F59DC676F38B80FF675" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2209-wk-Fact-081830A5CD7E691CD34E6F38B861C060" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedges, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001034e2230-wk-Fact-FCA6B8EFE0F2484309866F38B8104433" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2249-wk-Fact-AD4CB6818D39FC290C2F6F38B81A9BFE" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2268-wk-Fact-AD6832FDCF7B55A0E55C6F38B8165837" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51001034e2289-wk-Fact-77779DF3D5AEA2320E5B6F38B81A5CF3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2309-wk-Fact-80172A32A65847926D416F38B8168295" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51001034e2328-wk-Fact-C713801FE6BC787A0CFA6F38B85E8929" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001034e2350-wk-Fact-656A298293E90F3F8D096F38B863F838" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">103.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51001034e2369-wk-Fact-ADE602B01FDC1A89FCED6F38B80E4CFE" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">67.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2389-wk-Fact-2FBD302A263A0B7D0BEF6F38B8637B5D" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">158.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001034e2410-wk-Fact-D065EF4A97DD7AA72ECF6F38B85F566B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">105.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2429-wk-Fact-3FFFEF07DFDCE1143CF16F38B81442EC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2448-wk-Fact-DAF3185409661071AF2B6F38B80DA8BC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001034e2469-wk-Fact-A2D5BAF327BB6898B0C76F38B8158571" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,993.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2488-wk-Fact-13ED8A39D11AE02272036F38B86B8D5E" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,507.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2507-wk-Fact-72AE9FEE19B228C5CA406F38B8632119" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,540.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51001034e2528-wk-Fact-4A88EA1036E45A6BB6556F38B810DFBF" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2548-wk-Fact-F24257C6912EE59FAE036F38B8144963" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2567-wk-Fact-2E945A5EFA82EB9E24136F38B8178C5C" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001034e2593-wk-Fact-67C0C1B1314ABCDB93F36F38B8182C91" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,993.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2612-wk-Fact-E9FE404441B42C8D4A326F38B862B50F" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,550.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001034e2631-wk-Fact-E01AAF7679D745D8EFD46F38B81785C4" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,671.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 3</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB3FC2700DA395DB0B1F9F0A2C258E4EB"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions, except per share amounts)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1480-wk-Fact-1F183EDFDE14BD1665F76F38B8C78A4F" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,913.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1499-wk-Fact-B402A4E49B32DDD763566F38B838CB79" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,224.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1514-wk-Fact-5D3894AA12B159647C9C6F38B8C18A7C" name="us-gaap:AvailableForSaleSecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,562.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1533-wk-Fact-7805FBAA57741DCE7CBC6F38B8B5C084" name="us-gaap:AvailableForSaleSecuritiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,313.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1553-wk-Fact-8D13454B6972B4D73FFB6F38B8B6120C" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,880.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1572-wk-Fact-D5ADBF8AD760EE88B7BE6F38B8BECAA8" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,958.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1592-wk-Fact-32D40AC6CF18100B88736F38B8C7335F" name="biib:DueFromUnconsolidatedJointBusiness" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">590.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1611-wk-Fact-74A98A29053CE4F6BDA96F38B8B662C1" name="biib:DueFromUnconsolidatedJointBusiness" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">526.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1631-wk-Fact-26F6B410F20D465D19666F38B8C27FA2" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">804.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1650-wk-Fact-8C4A1D272C17C1AD6F426F38B8C3B56F" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">929.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1670-wk-Fact-EFB3265B4305DF9AAD2A6F38B8AD763C" name="us-gaap:OtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">631.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1689-wk-Fact-349E6AD4888A84D1E7F66F38B83F1C50" name="us-gaap:OtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">687.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1709-wk-Fact-4DA9948E5664D6D862B86F38B8B9AEF8" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,381.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1728-wk-Fact-D186B9D28E2E1CF9CC046F38B8C42A59" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,640.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1749-wk-Fact-2986E5682008DC2FAEA06F38B8C277D9" name="us-gaap:AvailableForSaleSecuritiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1768-wk-Fact-C117801EC02801861D686F38B83BC1C5" name="us-gaap:AvailableForSaleSecuritiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,375.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1788-wk-Fact-CF1C2504DA7602F237C56F38B8445161" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,247.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1807-wk-Fact-366250CBE4B1855EC9FF6F38B83E3B1B" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,601.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1827-wk-Fact-95391A476E38CC55D450E85D6C8B15E7" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">427.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1846-wk-Fact-A9E19B8C55ED48705AC7E85D6DCCE9E8" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1866-wk-Fact-4AD21CB6B4B90431AF316F38B8BC8BF4" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,527.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1885-wk-Fact-0B06E7AFD52116E2A95B6F38B8B9E33F" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,120.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1905-wk-Fact-0B1007097B5E08446E1E6F38B840631D" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,757.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1924-wk-Fact-E7AAD5AF93A3B138C23D6F38B839DA15" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,706.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1944-wk-Fact-60EC76FA353894EECB236F38B8B6C3F6" name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,232.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e1963-wk-Fact-AFB3FFACBACC4E72C02F6F38B84277F6" name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,153.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e1983-wk-Fact-411CE66892D435FC7FB76F38B83D1251" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,252.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2002-wk-Fact-C768E5E9137F08726E626F38B8B30520" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,690.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2027-wk-Fact-0B0D7B37366B0014A0F36F38B83BECFB" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27,234.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2046-wk-Fact-644C724D76997259EF696F38B8BE093A" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25,288.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2148-wk-Fact-E03C31AEBF983BAF370A6F38B83EEB28" name="us-gaap:DebtCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,495.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2167-wk-Fact-A5C816CFC4616E30647F6F38B83C6A09" name="us-gaap:DebtCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2183-wk-Fact-E6307D6AD7D6708EC20C6F38B8C0EE3E" name="us-gaap:TaxesPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2202-wk-Fact-A541F02EAEEFBC121D796F38B8AEF68C" name="us-gaap:TaxesPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2222-wk-Fact-157D8C3481B5747B40DF6F38B7A2AF9C" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">530.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2241-wk-Fact-64359EE7A1009F1987726F38B83EA3DC" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">370.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2261-wk-Fact-BDC01B59134555A3997B6F38B8B552E2" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,765.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2280-wk-Fact-90574151EADDD2E79EBF6F38B8439367" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,861.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2300-wk-Fact-70416AC8671D942151196F38B8C37C72" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,863.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2319-wk-Fact-725A00ED306314158A066F38B83D6A7F" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,295.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2339-wk-Fact-95D2C560A678B1EACADD6F38B8BDFC71" name="us-gaap:LongTermDebt" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,459.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2358-wk-Fact-CAE61D364EA39551186E6F38B8C4B9E5" name="us-gaap:LongTermDebt" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,936.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2378-wk-Fact-3A8FA7EC9AB9E31C8A0C6F38B8AECDBE" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,810.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2397-wk-Fact-AF3291890E788E56CFA26F38B8B279CB" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,636.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2417-wk-Fact-BD941F941CAD0B19CB3BE85E0BA7189C" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">412.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2436-wk-Fact-A5C2C3DC4144BB1F5F14E85E0D615639" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2456-wk-Fact-FEE7C166F066CB6B97C56F38B8BCBDFD" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,348.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2475-wk-Fact-020D28AEA8A1984F186F6F38B8C2FBCF" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,389.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2495-wk-Fact-6CF1DF5B7EEDCBFB71AE6F38B8B913E1" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,895.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2514-wk-Fact-4C5322C471F747C960D06F38B8C872C7" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,257.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2534-wk-Fact-89147172F22905F20F616F38B8BB7BD3" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2552-wk-Fact-A0E43DF219EADE5F54BE6F38B8B14C7A" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2654-wk-Fact-90D450E388D8C0D2F2176F38B83BA6A3" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2673-wk-Fact-830C505FAD6F5F8EA4F76F38B83C4EAB" name="us-gaap:PreferredStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2693-wk-Fact-8EFD8D4FF6F2358C8A4D6F38B83A95E5" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2712-wk-Fact-473042731EFBFF89C9C76F38B839E4AE" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2732-wk-Fact-B6FD7CE60F4817CDE6D76F38B8401DD3" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2751-wk-Fact-7FC06C33EE058E10D0F86F38B8BF0E98" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51001180e2771-wk-Fact-262FECE5A3392F04B8F36F38B8C7C408" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">135.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51001180e2791-wk-Fact-85A952828CB37D9B77516F38B8B27C3F" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2812-wk-Fact-61EAE81C54FFEDB4AD576F38B8B2E4C1" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,455.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2831-wk-Fact-3AE2378285645E37DA366F38B8B87CFB" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,257.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51001180e2851-wk-Fact-1F5E05E7ECE9B8E9663E6F38B8BC02DD" name="us-gaap:TreasuryStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51001180e2871-wk-Fact-B8498D34D3DCF278F79A6F38B8BEF886" name="us-gaap:TreasuryStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2892-wk-Fact-5784C3342553B2982B496F38B8C6A7D0" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,343.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2911-wk-Fact-ABC0C61D4C7DF5163AEB6F38B8BBCD37" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,039.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51001180e2931-wk-Fact-C067636497E1287B08576F38B8C365BD" name="us-gaap:MinorityInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51001180e2951-wk-Fact-5A5612F8391AED46D17A6F38B8C1E160" name="us-gaap:MinorityInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e2972-wk-Fact-E27B78E7E3A5AB66D9E76F38B84668E0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,339.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e2991-wk-Fact-3CB4C3695BCE2D0BFC186F38B8B4EFC2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,031.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51001180e3016-wk-Fact-0F5AC0816DAEC603849D6F38B8BA9613" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27,234.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51001180e3035-wk-Fact-76A4EDC8B35F3DF03EDC6F38B8C1F81B" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25,288.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 4</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFB642602F50E5CFF839AA1984BA8A94E"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">For the Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e1507-wk-Fact-C3E3738B6B2880EEE0C26F38B86F41E2" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,888.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1526-wk-Fact-697504B55D319C5C89A06F38B813740F" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,474.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1545-wk-Fact-11271C2D6390C500664E6F38B7B1785A" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,670.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and impairments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e1623-wk-Fact-9F317AAA796E544D450C6F38B7C21FFB" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">680.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1642-wk-Fact-A01969903A5AB3CDF5E36F38B7B87E83" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,016.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1661-wk-Fact-E48762A5362956E4A6F06F38B7B77F84" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,081.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e1682-wk-Fact-8083CD7170BB88E868B56F38B7C72176" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1701-wk-Fact-17423E27B848A85AD4AE6F38B820B150" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1720-wk-Fact-44EAC57204C4C05B290C6F38B884AC7E" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e1741-wk-Fact-1A811E630801EA6218816F38B7BEDB3E" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">182.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1760-wk-Fact-C59DD2F2BE7B48ACB8A36F38B7C40CE5" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">157.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1779-wk-Fact-E96F49E60A88D191F5456F38B868F049" name="us-gaap:ShareBasedCompensation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">128.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e1800-wk-Fact-7C31084FEFA28114DCAB6F38B864D055" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">67.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1819-wk-Fact-15E7585669CC1C2CBDC96F38B86FDC03" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">108.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1838-wk-Fact-AA985A4C7305479DFAD86F38B7C27564" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">91.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51007189e1859-wk-Fact-1823324BEE5AA206F4236F38B832A514" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e1879-wk-Fact-977CCFE1B549EEAAE2F26F38B8745977" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1899-wk-Fact-98699FC9CF903005B5E56F38B7ABD2C2" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">62.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e1920-wk-Fact-449CB1C38658B96F0B32702A6FD27FC1" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">55.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1939-wk-Fact-031FE57F4CD6143FA88D702A711D0319" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e1958-wk-Fact-4F2E88D9EA10D834AEBC702A733556A8" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e1980-wk-Fact-65A959FDD7161E1D47256F38B8745FF9" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">69.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e1999-wk-Fact-7538CE22CD7EF7BC1BD66F38B86F88CE" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2019-wk-Fact-862B182E47ACC274FB026F38B7BB54E4" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">162.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities, net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e2102-wk-Fact-B659C7CB89E531CB336F6F38B87048E0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">68.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2121-wk-Fact-CEF792B8E5CDB003A2156F38B7C658F8" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">205.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2141-wk-Fact-AEF5F9EAE45D73BAF3046F38B7C0A9E5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">435.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51007189e2163-wk-Fact-B06309CAA3F7B48BEAB96F38B7BBD7BC" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2183-wk-Fact-FA9BC9B82681B1CD6BAA6F38B7BE61DB" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2202-wk-Fact-9AEFBC358E3F4DF143156F38B8656111" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">232.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51007189e2224-wk-Fact-AD27F47DE869A6583EE86F38B86751D6" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2244-wk-Fact-BFE944E2874ECC49B6BE6F38B7C40C1D" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2264-wk-Fact-20289F6533314EC2245C6F38B7B74DB7" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">94.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e2286-wk-Fact-5C87F5F1B69BB7100A396F38B85FFE0C" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">240.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2305-wk-Fact-8A162E103A33BEC2464C6F38B862D580" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">465.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2324-wk-Fact-CF31E47F5618546D9EF16F38B86C36D8" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">227.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax assets and liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e2346-wk-Fact-7D417649EF6FB7299BE56F38B7B51FE0" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2365-wk-Fact-314F4041AF93F9CA4DC46F38B7B795A4" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">321.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2384-wk-Fact-42A8F80D9CDDF989C7A36F38B8798B8C" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,303.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51007189e2405-wk-Fact-6470012F61FD41C52B4A6F38B7B35B70" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">43.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2425-wk-Fact-C8F1A4DB634CBA6DEAF56F38B7B23F03" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">135.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2445-wk-Fact-1DA332A1C998985B82626F38B7BC741B" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">79.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e2467-wk-Fact-DD78F0561C2C078BC6C06F38B7C4DE29" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,078.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2486-wk-Fact-F2E5DE33CB2C655CA5146F38B7C2A789" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,187.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2505-wk-Fact-98EE686DF7096618BDFC6F38B7B9D389" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,551.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales and maturities of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e2588-wk-Fact-9B2BAA05E503864359F46F38B864558E" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,007.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2607-wk-Fact-91236B58E7640EF128CE6F38B7B34236" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9,173.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2626-wk-Fact-D3A23249D5697F1852396F38B7BFFC17" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,565.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51007189e2648-wk-Fact-4C68BC47649C1BEDB6796F38B86C620E" name="us-gaap:PaymentsToAcquireAvailableForSaleSecurities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,252.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2668-wk-Fact-43864AB7F367BEC8CB266F38B7B7DE5B" name="us-gaap:PaymentsToAcquireAvailableForSaleSecurities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,694.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2688-wk-Fact-D4B8F07D51F93EAE064C6F38B86585D6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecurities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,355.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration related to Fumapharm AG acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51007189e2710-wk-Fact-5E52FA6D936ABFBDD72C6F38B7B418A6" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2730-wk-Fact-A3ED243CAB7D69E02C186F38B7C799D8" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,500.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2750-wk-Fact-4D39337611F4E739AA156F38B7B4DEDC" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,200.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition of Nightstar Therapeutics plc, net of cash acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51007189e2772-wk-Fact-B3F3DED935484FDB31CCE85FE2E5CFE9" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">744.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2792-wk-Fact-25FA12D62D0DC4BF016CE85FE511BD49" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2811-wk-Fact-357439D0C8C388C30CD4E85FE746CDDA" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e2832-wk-Fact-747B36455DA4C02BB05FE85FE7BA7257" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">923.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2851-wk-Fact-3556A3D0E26975B63737E85FE84B02C3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e2870-wk-Fact-65BB47BFE5EAE92961F3E85FE989E27C" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e2891-wk-Fact-B48678F8D726B3BD2EEB6F38B8650C01" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2910-wk-Fact-9BE248533C0B2242410B6F38B86296E1" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2930-wk-Fact-F05C8B2C70F5E87F066F6F38B7BAABD2" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51007189e2952-wk-Fact-38E0EFAA85842E5BC05E6F38B878A308" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">514.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2972-wk-Fact-1575B781F30213FFEAA66F38B864B389" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">770.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e2992-wk-Fact-66C0C90B949CD69B1FEC6F38B86B5B73" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">867.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisitions of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51007189e3014-wk-Fact-1B13AF395A441265574E6F38B7C87917" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">155.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3034-wk-Fact-F0A85357FE625601CC2F6F38B8798D2F" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3054-wk-Fact-F052F57799815F2A29246F38B7B9D93E" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">975.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase of Ionis Pharmaceuticals, Inc. stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3076-wk-Fact-EF2A48E55DCF47CD34D96F38B8787822" name="us-gaap:PaymentsToAcquireOtherInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3095-wk-Fact-0591D97BDE0EE9E1145D6F38B868CBD7" name="us-gaap:PaymentsToAcquireOtherInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">462.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e3115-wk-Fact-BE6D47613A51669C34166F38B87AECB8" name="us-gaap:PaymentsToAcquireOtherInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investment in Samsung Bioepis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3136-wk-Fact-2B041933338397072C1D6F38B7C650A8" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3155-wk-Fact-56AE50267B9E75B542206F38B871E659" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e3175-wk-Fact-2D715DE442451A4B2D5B6F38B8733414" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales of strategic investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3196-wk-Fact-9647933C724E3158CEEAE8605DEC3679" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">479.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e3215-wk-Fact-6D0E1729EF84810FC5F3E8605FDB3FBE" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e3234-wk-Fact-8C04290EE3D1C6718370E86061E63329" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3255-wk-Fact-B37D1DDBF5355A5E9D856F38B7C86378" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">27.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e3274-wk-Fact-08994F80B22E8720DF866F38B7BFB5AC" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3293-wk-Fact-41E69C07DAC08E1FFD7D6F38B7B860E4" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by (used in) investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3316-wk-Fact-C861526D9C529998F7F56F38B87B56DF" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">470.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3335-wk-Fact-2B64996FC864C4CB7F056F38B7C5C649" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,046.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3355-wk-Fact-64F4A50A8C7E564F686D6F38B87B1589" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,963.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of treasury stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51007189e3439-wk-Fact-DBDCE8E038F5A0BEB2896F38B7C7295A" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,868.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3459-wk-Fact-51A36D29CEDD709084E26F38B7C1A09B" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,352.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3479-wk-Fact-1EDE0510D32C1A1B87566F38B7BE982E" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,365.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net contribution (distribution) to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3501-wk-Fact-5541F8E1DC128D1E97CA6F38B87336D0" name="us-gaap:PaymentsToMinorityShareholders" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3520-wk-Fact-36421408DAD2A68EB4B56F38B869B8F1" name="us-gaap:PaymentsToMinorityShareholders" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3540-wk-Fact-9DF56AB117278D77F5856F38B87733CB" name="us-gaap:PaymentsToMinorityShareholders" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">134.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repayments of borrowings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3562-wk-Fact-38CA70517A8BFC890A8A6F38B8640CA3" name="us-gaap:RepaymentsOfDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3581-wk-Fact-9AE83ED9BB882A5E31076F38B7BA21FA" name="us-gaap:RepaymentsOfDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3601-wk-Fact-3FDAD86BD7C7C5BB43E16F38B86981FA" name="us-gaap:RepaymentsOfDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">560.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash contribution to Bioverativ, Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3623-wk-Fact-50CDFAC5A8F402BE1F176F38B86AEF49" name="us-gaap:PaymentsOfCapitalDistribution" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e3642-wk-Fact-1A8962550E6653E7B5846F38B86C9D02" name="us-gaap:PaymentsOfCapitalDistribution" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3661-wk-Fact-3E089A53FF95A00D23F56F38B86DE827" name="us-gaap:PaymentsOfCapitalDistribution" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">302.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3683-wk-Fact-BC9F6486AF65F795A6A76F38B864CDBF" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3702-wk-Fact-1CC5D67510E7F7D718F56F38B7B3987C" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3722-wk-Fact-8DA102F7283160FDB2F66F38B7B5A88D" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3744-wk-Fact-FF6BCD881A2410D97BEA6F38B874F541" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3763-wk-Fact-60BC6FDF615D07063CBB6F38B86D6581" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3783-wk-Fact-39EE9C45F78744F025F76F38B7C3D0CA" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">13.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51007189e3805-wk-Fact-F93416FD66A9D8FD7F286F38B86E7D15" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5,860.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3825-wk-Fact-73C98F381A9A802F7CD76F38B7BD3586" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4,472.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3845-wk-Fact-3391BFD9FEE4D4BCB3DB6F38B7BC1DB6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,380.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3867-wk-Fact-DA2298296EC21724ABD26F38B7B3BE98" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,688.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3886-wk-Fact-B94D83286461806D9D686F38B8777B0B" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">330.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3906-wk-Fact-12258EE9E52A93DEB5D06F38B7C55548" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">792.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3928-wk-Fact-392834188991A47ED5A76F38B7C62BA4" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51007189e3947-wk-Fact-4222BFF6621838727A446F38B874BD6D" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">18.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e3967-wk-Fact-2D564E4A9446367C189B6F38B8751D23" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, beginning of the year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e3989-wk-Fact-B402A4E49B32DDD763566F38B838CB79" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,224.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e4008-wk-Fact-80BFDA7146A775C44BE06F38B8660DF1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,573.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e4027-wk-Fact-906F465F35CDF3F0FBD96F38B87215EE" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,326.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, end of the year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51007189e4053-wk-Fact-1F183EDFDE14BD1665F76F38B8C78A4F" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,913.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e4072-wk-Fact-B402A4E49B32DDD763566F38B838CB79" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,224.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51007189e4091-wk-Fact-80BFDA7146A775C44BE06F38B8660DF1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,573.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 5</span></div></div><hr style="page-break-after:always"></hr><div><a id="s19EFDFA5B8EA53B3ACB67DBBC5F2D5E9"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.91666666666666%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:10%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e1843-wk-Fact-FC6BD39B73491F0771E96F38B7C48259" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e1862-wk-Fact-12411F493663665C481B6F38B7AE8F90" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e1876-wk-Fact-9C5AD0C83D1E22701F2D6F38B88FEE4B" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">221.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e1896-wk-Fact-D0D7319D5AA69096D4096F38B7BFEDA4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e1915-wk-Fact-5A0843BFA954605F22C16F38B7C7A6EE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e1934-wk-Fact-D9A111AF560E38CA94966F38B7B8C128" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e1955-wk-Fact-A13A847A72CA16A4EF8C6F38B88C56EE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,257.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e1969-wk-Fact-AAB3BBD7C2DAA204DE6C6F38B7B43D09" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e1989-wk-Fact-C25C9B8B2D2AA699B5276F38B7BBE94A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e2010-wk-Fact-ABC0C61D4C7DF5163AEB6F38B8BBCD37" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,039.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e2029-wk-Fact-34F4954DA06ACA92FB976F38B7C02975" name="us-gaap:MinorityInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e2049-wk-Fact-3CB4C3695BCE2D0BFC186F38B8B4EFC2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,031.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e2177-wk-Fact-68E8E865C41C38D9112D6F38B7B94D24" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,888.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e2232-wk-Fact-409F06146EDA2C5A1FA56F38B82DE39D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,888.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e2251-wk-Fact-1787ACAA578B0F24D5506F38B7BA0886" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e2270-wk-Fact-C3E3738B6B2880EEE0C26F38B86F41E2" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,888.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e2382-wk-Fact-9E2D38129642A883439E6F38B7B1D9D9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">105.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e2458-wk-Fact-D065EF4A97DD7AA72ECF6F38B85F566B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">105.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e2477-wk-Fact-0F0C45BABB91FC77FB5B6F38B88D6612" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e2497-wk-Fact-596E86F9CDF4F8C52B756F38B7BE1409" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">104.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Capital contribution by noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e2686-wk-Fact-DCB5BFF6946C6676AF916F38B88EB503" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e2705-wk-Fact-36F7B33FA7F3FA7073BB6F38B7B41E3E" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e2724-wk-Fact-409293DD07607E05EE636F38B7B5AAE8" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e2877-wk-Fact-16BCE9E5B23F30F172376F38B7C1AC08" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e2892-wk-Fact-32548F6D031B8B1990166F38B7B2CE43" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,720.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e2913-wk-Fact-D6A1E3FDDFFE78444EAB6F38B7C19B99" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,720.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e2953-wk-Fact-D6A1E3FDDFFE78444EAB6F38B7C19B99" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,720.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e3010-wk-Fact-283DBFC1C9312B5C5DFB6F38B7B95B88" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3026-wk-Fact-57201F8897F0F6EEB68E6F38B7B4E6D8" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e3045-wk-Fact-D0064842CD711BCAA8146F38B7B5118D" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e3086-wk-Fact-AE9EDC54A0A6ADB02B2B6F38B7BD5F2A" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,599.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3106-wk-Fact-8CC8973B0434B74FE4446F38B7B60001" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3120-wk-Fact-8C55871DF7B9A306B4EA6F38B7BCA81D" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,720.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3140-wk-Fact-B8692957C4584F603E846F38B7B26CDD" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3179-wk-Fact-B8692957C4584F603E846F38B7B26CDD" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e3332-wk-Fact-F3CA4D4490CE7F4C990D6F38B88E760F" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e3347-wk-Fact-8803384DCB38FFD8CD086F38B7BD1540" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e3368-wk-Fact-742DD781FD1D0934345D6F38B7C7BACB" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e3408-wk-Fact-742DD781FD1D0934345D6F38B7C7BACB" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e3465-wk-Fact-8929CB2D5485F6A69A0A6F38B7B4A367" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3481-wk-Fact-70889EF7E1168A55BD876F38B7B90C35" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e3500-wk-Fact-1DCE07891E1F4D7631246F38B7B7E472" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">110.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e3541-wk-Fact-7926CD3F1690D7285DF56F38B7C03A33" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,036.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3561-wk-Fact-FDCF0305A794EC365FE66F38B7C38E2A" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3575-wk-Fact-D0BF822130FB09F0C5FE6F38B7C33B6A" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3595-wk-Fact-7251DB06C6F9757CB5FF6F38B7B2B48A" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3634-wk-Fact-7251DB06C6F9757CB5FF6F38B7B2B48A" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3690-wk-Fact-3CA56DF928B38105CB516F38B7C66627" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3705-wk-Fact-B8DA4CA054F4DD800C6E6F38B7B40779" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3724-wk-Fact-2EA47AAC0D74F6302AEC6F38B7BC6F4B" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3764-wk-Fact-865139B6689C1E58AF48704FB84AB569" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3819-wk-Fact-35500CDAF2981EA9525E6F38B7AE4854" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3858-wk-Fact-35500CDAF2981EA9525E6F38B7AE4854" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock award plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3915-wk-Fact-41366450D8ACD916761F6F38B7C7F059" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3930-wk-Fact-3F824C5D06F4125EEDCD6F38B7B68461" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e3949-wk-Fact-FBDBAD377D97578AAE276F38B7C5D8B0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e3989-wk-Fact-94B91508B97EC4AE3DC7704FB6D6720C" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">53.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e4045-wk-Fact-F467A8211DAC2F43FECE6F38B7B81897" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">53.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e4085-wk-Fact-F467A8211DAC2F43FECE6F38B7B81897" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">53.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Compensation related to share-based payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e4178-wk-Fact-AC009E45F0FF8755A28B6F38B7C9366D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">191.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e4274-wk-Fact-AF5A93CA6CDB2ABC9CA26F38B89029DB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">191.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e4313-wk-Fact-AF5A93CA6CDB2ABC9CA26F38B89029DB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">191.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e4334-wk-Fact-D707CBC1CE8CCE3C21EA6F38B8905FEC" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e4353-wk-Fact-53918B50FD97547ECEEA6F38B88D9C39" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e4367-wk-Fact-2CB51A211F1BF0B5F3736F38B7B13F39" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">198.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e4387-wk-Fact-3357A56FBC7ABE47C9106F38B7AF6548" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e4406-wk-Fact-3DC3833E3C7F4D639B646F38B7B1AD45" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e4425-wk-Fact-27B78241165E74F361586F38B7AF85C1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">135.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e4446-wk-Fact-65E2CC87B286D0DBBA0B6F38B7C5E657" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,455.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e4460-wk-Fact-F95FC732B4AFA5C8407C6F38B88CBFFF" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e4480-wk-Fact-9BEE3CB0E201DEDD1EB46F38B7BA4D6D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e4501-wk-Fact-5784C3342553B2982B496F38B8C6A7D0" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,343.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d51023978e4520-wk-Fact-CB551408B665B05A357B6F38B7B03C36" name="us-gaap:MinorityInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d51023978e4540-wk-Fact-E27B78E7E3A5AB66D9E76F38B84668E0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,339.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 6</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:13%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5121-wk-Fact-0886C1D4B8AB865F3CD06F38B7E46B34" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5140-wk-Fact-03DEADBCAD46914CF4F06F38B7D531CC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5154-wk-Fact-C13E27745B490825AA1F6F38B7CE25A1" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">235.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5174-wk-Fact-52639BD98AA93C0EB4036F38B7E35AEB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5193-wk-Fact-C750753F5AA372874A1B6F38B7E1E7E8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">97.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e5212-wk-Fact-F4A56A3A303C51E837676F38B7D955AA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">318.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5233-wk-Fact-A93126C2F82E7A3B20636F38B7E6B801" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15,810.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e5247-wk-Fact-661A3C0DCE4765F146886F38B7DCFB0E" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e5267-wk-Fact-A55654119174A11F647C6F38B7DB1CB3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5288-wk-Fact-36FECCDF9D50D85B76656F38B7E45CF3" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,612.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e5307-wk-Fact-D13879B48E9022EC4D7D6F38B7D89A58" name="us-gaap:MinorityInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5327-wk-Fact-80594C8122A490FC351A6F38B7D2FC06" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,598.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5455-wk-Fact-8C366C83E15D49CC1ECD6F38B7D3A4B4" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,430.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5510-wk-Fact-D75E3BB69A698B5537196F38B831D83C" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,430.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5529-wk-Fact-2651FB05B09233E88B256F38B7DBB4C0" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5548-wk-Fact-697504B55D319C5C89A06F38B813740F" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,474.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5660-wk-Fact-2067F4D14B744B2D41076F38B7CD6912" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5736-wk-Fact-3FFFEF07DFDCE1143CF16F38B81442EC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e5755-wk-Fact-A480E5CE5B06849E52266F38B7E02B46" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5775-wk-Fact-A03A1753D060A8971AF46F38B7E60287" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">76.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital contribution by noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5964-wk-Fact-FB2D9D52BF31AB371CEE6F38B7D568EA" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e5983-wk-Fact-02EE46D930F1ED3557B86F38B7D90B74" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e6002-wk-Fact-20C298F6BEB40565C4C46F38B7CDD57F" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e6191-wk-Fact-37C43954921C599396CA70568DF5DE2F" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6210-wk-Fact-69DC196773D870C8C1DD6F38B7D84CC5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6230-wk-Fact-D3ECBD278C317A2CB11D6F38B7D168F4" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6384-wk-Fact-73305A4F4F5E62C2B5C06F38B7D67E91" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6399-wk-Fact-25825FA2B84C8B1EE0096F38B7D15627" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,352.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6420-wk-Fact-4EE3A1B4E0157649FB6E6F38B7CE3806" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,352.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6460-wk-Fact-4EE3A1B4E0157649FB6E6F38B7CE3806" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,352.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6517-wk-Fact-E6BE2390B5AE4F131A8A6F38B7DEBD9C" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e6533-wk-Fact-1B2C7F775C9C1A9C472F6F38B7DE77F4" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6552-wk-Fact-870FFFE2E908113E06636F38B7D985C3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">92.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6593-wk-Fact-B4ABB9396B0720B578946F38B7D024F8" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,259.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e6613-wk-Fact-86F5951AF31EC0F490AA6F38B7D6E336" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e6627-wk-Fact-586B60655108632C7D246F38B7D5F4A7" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,352.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e6647-wk-Fact-69633AB2142E42903C916F38B7D0B26A" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e6686-wk-Fact-69633AB2142E42903C916F38B7D0B26A" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6839-wk-Fact-956208B46B55066FC1386F38B7DFD78C" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6854-wk-Fact-83D923F803F5409DB02C6F38B7E57C09" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6875-wk-Fact-D7AB953A47BC17DC8C1E6F38B7CD70FC" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6915-wk-Fact-5238B1DADDD936CFEAFC6F38B7DD4CB8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e6972-wk-Fact-3E3088E5F4B09DEB09966F38B7D32C08" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e6988-wk-Fact-5333541CC49EABABB9F46F38B7E20BD6" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e7007-wk-Fact-3DE131CE57525E0022906F38B7D849A2" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">171.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e7048-wk-Fact-0AAEF901F2822B0F01E37059808F2985" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,828.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7068-wk-Fact-74E86CC0A17E26AE2FD3705982AC16C7" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7082-wk-Fact-2BD0EA05BF8DE4588403705985A2D9BE" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7102-wk-Fact-EF3CCCCCAE831F3679756F38B7D71DBD" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7141-wk-Fact-EF3CCCCCAE831F3679756F38B7D71DBD" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7198-wk-Fact-5B54512E2377006387716F38B7E84358" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7213-wk-Fact-4005CD58FBAB4132EDCB6F38B7DC8B03" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7232-wk-Fact-ED8F63D55778AF7189E06F38B7E16145" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7328-wk-Fact-E0E38D282EE87BA8269E6F38B7D38808" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7367-wk-Fact-E0E38D282EE87BA8269E6F38B7D38808" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7423-wk-Fact-8DC3660624E05CCBA288705A84C92515" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7438-wk-Fact-6F141D11FC100555FD28705A8635943B" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e7457-wk-Fact-9FCF1E5EE2DD934C018E6F38B7DD1DA5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e7554-wk-Fact-6CDAB4B7BB39BF18B3556F38B7E6AF3E" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e7594-wk-Fact-6CDAB4B7BB39BF18B3556F38B7E6AF3E" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation related to share-based payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7687-wk-Fact-801B0D428C27F2581CC1705B8EFD6FD8" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">168.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7783-wk-Fact-CB0C79BAA35FE78702876F38B7E3D400" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">168.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7822-wk-Fact-CB0C79BAA35FE78702876F38B7E3D400" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">168.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adoption of new accounting guidance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7934-wk-Fact-021F31C03C5221590FED705F51A8D852" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e7954-wk-Fact-A7DBCF21A5815F5F0D186F38B7CF6B0F" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">104.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8009-wk-Fact-EB93AA6C2C429B96187A6F38B7D618B4" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8048-wk-Fact-EB93AA6C2C429B96187A6F38B7D618B4" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8069-wk-Fact-FC6BD39B73491F0771E96F38B7C48259" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8088-wk-Fact-12411F493663665C481B6F38B7AE8F90" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8102-wk-Fact-9C5AD0C83D1E22701F2D6F38B88FEE4B" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">221.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8122-wk-Fact-D0D7319D5AA69096D4096F38B7BFEDA4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8141-wk-Fact-5A0843BFA954605F22C16F38B7C7A6EE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e8160-wk-Fact-D9A111AF560E38CA94966F38B7B8C128" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8181-wk-Fact-A13A847A72CA16A4EF8C6F38B88C56EE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,257.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e8195-wk-Fact-AAB3BBD7C2DAA204DE6C6F38B7B43D09" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e8215-wk-Fact-C25C9B8B2D2AA699B5276F38B7BBE94A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8236-wk-Fact-ABC0C61D4C7DF5163AEB6F38B8BBCD37" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,039.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e8255-wk-Fact-34F4954DA06ACA92FB976F38B7C02975" name="us-gaap:MinorityInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8275-wk-Fact-3CB4C3695BCE2D0BFC186F38B8B4EFC2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,031.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 7</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8849-wk-Fact-8F5C3C45E1E9BD2374D66F38B7F321AD" name="us-gaap:SharesIssued" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8868-wk-Fact-747A0F9127B6CCE61D276F38B7F35514" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8882-wk-Fact-ADF9AC0B6C877F0358806F38B82CC6A6" name="us-gaap:SharesIssued" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">238.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8902-wk-Fact-CDB85ECA23D3AB0B68226F38B7F5C96C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8921-wk-Fact-B1CD54FE9F38B1C08E5E6F38B82CC11B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e8940-wk-Fact-B9875DACED8DC67D83116F38B7F5EA33" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">319.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e8961-wk-Fact-30268C24E8A59C69E4EB6F38B83354FF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15,071.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e8975-wk-Fact-3B53CFC6BB638AEB9FAC6F38B8324484" name="us-gaap:SharesIssued" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">22.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e8995-wk-Fact-BDC3DD8AD19867C6C1376F38B82BDE4A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,611.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9016-wk-Fact-1F045D43A0E5359FD2356F38B7F0BBC3" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,140.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e9035-wk-Fact-019E683D47BA697F2D0C6F38B83674BC" name="us-gaap:MinorityInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9055-wk-Fact-5E5620C312817FB09DAF6F38B7F714F9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,128.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9183-wk-Fact-06611EA785D40EC668BA6F38B82F5B3E" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,539.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9238-wk-Fact-029151C37D9A5DCBB4476F38B8229A45" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,539.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9257-wk-Fact-1D2683E70CA35B372F2A6F38B82DC2E1" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9276-wk-Fact-11271C2D6390C500664E6F38B7B1785A" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,670.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9388-wk-Fact-8C3F29C774F4A3815E606F38B829DC74" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9464-wk-Fact-DAF3185409661071AF2B6F38B80DA8BC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9483-wk-Fact-DE80286E6A70EC3C59A96F38B8334602" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9502-wk-Fact-4B79072BDE22BA60E2BE6F38B7EEBCD9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital contribution to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9691-wk-Fact-C4875D7DDBB8C97C8AB36F38B82ADF80" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9710-wk-Fact-541D7BE3ADC98B39D4AB6F38B7F41F28" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e9729-wk-Fact-93F094A0BF31508500566F38B82A04EA" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin_Gothic_Book;font-size:8pt;"><span><ix:nonFraction id="d51023978e9918-wk-Fact-148DB9F0D59F9148013270653ECC95BB" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e9937-wk-Fact-E4AFDA0136EA7D8ECF1F6F38B82A9149" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e9957-wk-Fact-E65FD5FBB08404BDC3656F38B832B441" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10111-wk-Fact-59F8879B05862FBC7F077066C880543F" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10126-wk-Fact-B2F432CFE860D0FB1FB47066CC22A78F" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10147-wk-Fact-061D830C94F821DDA1506F38B82DBAD0" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10187-wk-Fact-061D830C94F821DDA1506F38B82DBAD0" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10244-wk-Fact-687A766E726C7B24C6AA7067AA93863B" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e10260-wk-Fact-5A09E6312B71636065D67067AF9C3317" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10279-wk-Fact-11C44FA4BE3B2C8E4CEA7067B47EE7CA" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10320-wk-Fact-AFE9592753AA02AAABF77067BB0075AE" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">964.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e10340-wk-Fact-61B524345985C3AD6DD06F38B82F63FC" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e10354-wk-Fact-B99A8876BF4EBCEA5A1B6F38B8294D42" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e10374-wk-Fact-594EB43D3443905048CD6F38B83112C6" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e10413-wk-Fact-594EB43D3443905048CD6F38B83112C6" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2011 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10565-wk-Fact-F6724E09EE7FC8445EC06F38B8349C89" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10580-wk-Fact-A68BDB24BDA277AF98EF6F38B82DBBBE" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">365.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10601-wk-Fact-9DD635C1632F8A8B601C6F38B8352615" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">365.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10641-wk-Fact-9DD635C1632F8A8B601C6F38B8352615" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">365.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e10698-wk-Fact-6DBA67E1D2A9DD4AC8006F38B8329B6F" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e10713-wk-Fact-07CB553EE7FF10B090846F38B82C1FF8" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e10732-wk-Fact-325D6834206767B1A5916F38B7F28810" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e10828-wk-Fact-6F478638806535FF11366F38B83108DA" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e10867-wk-Fact-6F478638806535FF11366F38B83108DA" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e10924-wk-Fact-49D243369062EFA992C36F38B7EF0777" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e10939-wk-Fact-A40008494073408D69A86F38B834C45B" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10958-wk-Fact-6914A52621E737ACAC3C6F38B830F20A" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e10999-wk-Fact-021604712AED861A6B736F38B82E2BBE" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e11055-wk-Fact-7ADCCC58C69D0AEC769A6F38B82DD6EC" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e11095-wk-Fact-7ADCCC58C69D0AEC769A6F38B82DD6EC" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation related to share-based payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11188-wk-Fact-1388A48FDD68A817F9356F38B7F64767" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">138.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11284-wk-Fact-1B9F01A41CA665B313546F38B7F23D1F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">138.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11323-wk-Fact-1B9F01A41CA665B313546F38B7F23D1F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">138.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e11456-wk-Fact-368FBF3D3A4830C37DC97071B5C5FC34" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">852.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e11512-wk-Fact-368FBF3D3A4830C37DC97071B5C5FC34" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">852.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e11552-wk-Fact-368FBF3D3A4830C37DC97071B5C5FC34" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">852.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11686-wk-Fact-D3899ACF1C5DD76971FA70610ED8BD72" name="biib:StockholdersEquityTaxBenefitExpense" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11741-wk-Fact-54026962E7FD89FA1DEA6F38B82B0A78" name="biib:StockholdersEquityTaxBenefitExpense" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">17.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11780-wk-Fact-6CCE522EFA3648933A9B6F38B83011C7" name="biib:StockholdersEquityTaxBenefitExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">17.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11801-wk-Fact-0886C1D4B8AB865F3CD06F38B7E46B34" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11820-wk-Fact-03DEADBCAD46914CF4F06F38B7D531CC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11834-wk-Fact-C13E27745B490825AA1F6F38B7CE25A1" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">235.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11854-wk-Fact-52639BD98AA93C0EB4036F38B7E35AEB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11873-wk-Fact-C750753F5AA372874A1B6F38B7E1E7E8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">97.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e11892-wk-Fact-F4A56A3A303C51E837676F38B7D955AA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">318.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11913-wk-Fact-A93126C2F82E7A3B20636F38B7E6B801" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15,810.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e11927-wk-Fact-661A3C0DCE4765F146886F38B7DCFB0E" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e11947-wk-Fact-A55654119174A11F647C6F38B7DB1CB3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e11968-wk-Fact-36FECCDF9D50D85B76656F38B7E45CF3" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,612.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51023978e11987-wk-Fact-D13879B48E9022EC4D7D6F38B7D89A58" name="us-gaap:MinorityInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51023978e12007-wk-Fact-80594C8122A490FC351A6F38B7D2FC06" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,598.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 8</span></div></div><hr style="page-break-after:always"></hr><div><a id="s36554B383E105E0EA9B416FD3DCCFF8D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div><a id="s9FB652FCB5CA5E8880D92E3573ADE90C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-0-wk-Fact-C6AF55507CF2F2CE1EC86F38B84190AC" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-1" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-2"><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:BusinessOverviewPolicyTextBlock" id="TextSelection-5FB78FAF711B145EA4916F38B8DCA3EE-0-wk-Fact-DFF35CDBD026F8F4BF2D6F38B8429FE0" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-E91CD00ED7A7C22D21D86F38B8DFDAF5-0-wk-Fact-E5F3CF50E846E415A4866F38B8417C93" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51036666e1347-wk-Fact-B51F226A28E138CC87D36F38B84D317B" name="biib:InterestInSubsidiary" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-2" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-3"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:UseOfEstimates" id="TextSelection-229ECB1F5983B47BEF716F38B8DA3574-0-wk-Fact-FBF4FC766C3E889E1E116F38B8413FB6" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This standard became effective for us on January 1, 2018, and was adopted using the modified retrospective method. The adoption of this standard as of January 1, 2018, did not change our revenue recognition.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">W<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="TextSelection-4612B92134120E57E50D6F38B8DD3191-0-wk-Fact-6E3068D75466F10C72626F38B84EED50" continuedAt="TextSelection-4612B92134120E57E50D6F38B8DD3191-1" escape="true">e recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under the FASB Accounting Standards Codification (ASC) 606, </ix:nonNumeric></span><ix:continuation id="TextSelection-4612B92134120E57E50D6F38B8DD3191-1" continuedAt="TextSelection-4612B92134120E57E50D6F38B8DD3191-2"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</span></ix:continuation></div><ix:continuation id="TextSelection-4612B92134120E57E50D6F38B8DD3191-2" continuedAt="TextSelection-4612B92134120E57E50D6F38B8DD3191-3"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the United States (U.S.), we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-4612B92134120E57E50D6F38B8DD3191-3" continuedAt="TextSelection-4612B92134120E57E50D6F38B8DD3191-4"><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-3" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-4"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates, non-U.S. pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a </span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-4612B92134120E57E50D6F38B8DD3191-4" continuedAt="TextSelection-4612B92134120E57E50D6F38B8DD3191-5"><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-4" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-5"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration with Genentech is within the scope of ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Agreements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech and the Roche Group. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates that are based on information received from Genentech and Roche. These estimates are subject to change and actual results may differ. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Genentech, please read Note&#160;18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Royalty Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and other third parties and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech and Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-5" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-6"><ix:continuation id="TextSelection-4612B92134120E57E50D6F38B8DD3191-5" continuedAt="TextSelection-4612B92134120E57E50D6F38B8DD3191-6"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Corporate Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"><ix:continuation id="TextSelection-4612B92134120E57E50D6F38B8DD3191-6"></ix:continuation>Fair Value Measurements</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="TextSelection-526A1BE0ED2E1668EBEB6F38B8DD73DD-0-wk-Fact-2D2DB7630D37A02DAC576F38B84F00F5" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Assets and Liabilities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="TextSelection-ED8506B883BD4310FC396F38B8DCD3DF-0-wk-Fact-E19D0E522C04F68E444A6F38B847FB6D" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounts Receivable</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ReceivablesPolicyTextBlock" id="TextSelection-E48462F90ADD8398F7FA6F38B8DD8672-0-wk-Fact-2D1A7EBD71C494030DA66F38B83F374D" continuedAt="TextSelection-E48462F90ADD8398F7FA6F38B8DD8672-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within </span><span style="font-family:Franklin Gothic Book,sans-serif;">30 to 90 days</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-6" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-7"><ix:continuation id="TextSelection-E48462F90ADD8398F7FA6F38B8DD8672-1"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We provide reserves against accounts receivable for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ConcentrationRiskCreditRisk" id="TextSelection-BE13A326763589E11E9A6F38B8DFC218-0-wk-Fact-458AEEFDFC538B8817DE6F38B847F389" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Marketable Securities and Other Investments</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InvestmentPolicyTextBlock" id="TextSelection-85AEF28D9ECEEC93418C6F38B8DF4F14-0-wk-Fact-82DA0B446A759DA949726F38B844B3FB" continuedAt="TextSelection-85AEF28D9ECEEC93418C6F38B8DF4F14-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities and Venture Capital Funds</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Marketable Debt Securities for Other-than-Temporary Impairments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-7" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-8"><ix:continuation id="TextSelection-85AEF28D9ECEEC93418C6F38B8DF4F14-1"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Equity Method of Accounting</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EquityMethodInvestmentsPolicy" id="TextSelection-58D6B934244A71EFA26E6F38B8DA5910-0-wk-Fact-07FB11C8245D50EF4B816F38B83F5A19" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our consolidated statements of income our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Inventory</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InventoryPolicyTextBlock" id="TextSelection-B4CD9C493290CFF5DB316F38B8DC6312-0-wk-Fact-151F6839A74ACC5887416F38B84AE9AD" continuedAt="TextSelection-B4CD9C493290CFF5DB316F38B8DC6312-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At each reporting period we review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-8" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-9"><ix:continuation id="TextSelection-B4CD9C493290CFF5DB316F38B8DC6312-1"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Property, Plant and Equipment</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="TextSelection-7C6EDE1D68E5669729D96F38B8DD466B-0-wk-Fact-FEE492222B4EBF843EC06F38B83F5B62" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </span><span style="font-family:Franklin Gothic Book,sans-serif;">three to five years</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" id="TextSelection-0456031171C9C7B3D5BE6F38B8DD9CFF-0-wk-Fact-5747030CAADA4194E8966F38B849625D" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Leases</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeLeasesPolicyTextBlock" id="TextSelection-03902514FE18354A67B67086E8EFD225-0-wk-Fact-2DA24DDCFAE617F81342708902278BD1" continuedAt="TextSelection-03902514FE18354A67B67086E8EFD225-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-10, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvement for Lessors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and ASU No. 2019-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Codification Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-9" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-10"><ix:continuation id="TextSelection-03902514FE18354A67B67086E8EFD225-1"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis in our consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51036666e2037-wk-Fact-FD54D2082F0EC999FDCA707FE56A3FD7" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">463.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a corresponding operating lease liability of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51036666e2041-wk-Fact-4B8EB3579A1CE9B976E67083394AEAC0" name="us-gaap:OperatingLeaseLiability" contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">526.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are included in our consolidated balance sheets. The adoption of the new leasing standards did not have an impact on our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our consolidated balance sheets. Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the adoption of the new leasing standards, please read Note 11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="TextSelection-976E879F7336CA28B7A06F38B8DD63BF-0-wk-Fact-DBEEA948824D9252F3EF6F38B84CBC03" continuedAt="TextSelection-976E879F7336CA28B7A06F38B8DD63BF-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of completed technology (comprised of acquired and in-licensed rights and patents, developed technology, out-licensed patents), in-process research and development (IPR&amp;D) acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also include our rest of world license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-10" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-11"><ix:continuation id="TextSelection-976E879F7336CA28B7A06F38B8DD63BF-1"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and IPR&amp;D prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired In-process Research and Development (IPR&amp;D)</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="TextSelection-1702C2A0CC24C2EB85576F38B8DBB3FF-0-wk-Fact-627187BBA600F4047F7A6F38B847EF75" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the potential treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="TextSelection-3AEDFC223B7C86FBEB626F38B8DE737F-0-wk-Fact-3C5194FF93F83C8999A46F38B8489990" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but is reviewed for impairment. Goodwill is reviewed for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&#160;24, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="TextSelection-6A53B5804CA37149EACF6F38B8DD3637-0-wk-Fact-B14187411D9B66E80DE76F38B84C1F85" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-11" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-12"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BusinessCombinationsPolicy" id="TextSelection-080B2420FC03FFE52B176F38B8DBEDCA-0-wk-Fact-30D34E129BB1CCA9640D6F38B84F35E6" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. </span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Derivative Instruments and Hedging Activities</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DerivativesPolicyTextBlock" id="TextSelection-347366D80B70B59701976F38B8DE0940-0-wk-Fact-C6317E04DECEEC87A1EF6F38B84FA2C4" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cash Flow and Fair Value Derivative Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Derivative Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our derivative instruments and hedging activities, please read Note 9, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Translation of Foreign Currencies</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="TextSelection-BCE616ABE6DD6B6A0A956F38B8DBCEB2-0-wk-Fact-6473D4BA672CF43BBFB36F38B84A2F01" continuedAt="TextSelection-BCE616ABE6DD6B6A0A956F38B8DBCEB2-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-12" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-13"><ix:continuation id="TextSelection-BCE616ABE6DD6B6A0A956F38B8DBCEB2-1"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Cost of Sales</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:RoyaltyCostofSalesPolicyTextBlock" id="TextSelection-8486721CFB427D6F63AE6F38B8DC7F7F-0-wk-Fact-E1EF5BB5CBCC1DC2E2186F38B8454ACE" escape="true">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.</ix:nonNumeric> </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Share-Based Compensation</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="TextSelection-512E4B81667DBEB8D0A56F38B8DA1294-0-wk-Fact-D50F80BCCF8F204446BF6F38B848EF00" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). Compensation expense is recognized based on the estimated fair value of the awards at grant date. We recognize compensation expense for the number of awards expected to vest after taking into consideration an estimate of award forfeitures over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of PSUs that settle in stock are based upon the stock price on the date of grant. Compensation expense is recognized for the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-13" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-14"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development Expenses</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="TextSelection-438844A82D50452CC5EF6F38B8DD001E-0-wk-Fact-D80E11A91593CD2E313D6F38B83F700E" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses and upfront fees and milestones paid to third-party collaborators. Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="TextSelection-02AF5B7D697DD27AEB1D6F38B8DC8F08-0-wk-Fact-5C7FDBE4B2431CC4EF2A6F38B84920A1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51036666e2398-wk-Fact-F81F350DB92916E843356F38B84E816D" name="us-gaap:AdvertisingExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">79.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51036666e2402-wk-Fact-4AFAB95BD8A23F38B0736F38B84B90B9" name="us-gaap:AdvertisingExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">90.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51036666e2407-wk-Fact-2A967406F0C1D109E2756F38B84BA6BD" name="us-gaap:AdvertisingExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxPolicyTextBlock" id="TextSelection-0CA105AB31CC754F766A6F38B8DE2712-0-wk-Fact-F831BA4C535BA3D499A46F38B8418622" continuedAt="TextSelection-0CA105AB31CC754F766A6F38B8DE2712-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The income tax consequences from the intra-entity transfers of inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the inventory is sold to a third party.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16,&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51036666e2447-wk-Fact-B731234716BE94F35167FC24C706A84B" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredIncomeTaxChargesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">0.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, offset by a corresponding net increase to retained earnings of approximately&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51036666e2451-wk-Fact-AA09A7F3E7B9E543D186FC2A4A300063" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">0.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51036666e2455-wk-Fact-514B72584F113CB8EF3EFC2B76296BAE" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_biib_DeferredtaxliabilityMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">0.4</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;with a corresponding reduction to </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-14" continuedAt="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-15"><ix:continuation id="TextSelection-0CA105AB31CC754F766A6F38B8DE2712-1"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our retained earnings as these differences are related to intra-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingencies</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="TextSelection-EE9A1C76879ADDBCD91A6F38B8DF2471-0-wk-Fact-4CC2F9186EA432BA36A06F38B84314DE" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. </span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Earnings per Share</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EarningsPerSharePolicyTextBlock" id="TextSelection-ACBB4B1562FED648703B6F38B8DE3DE8-0-wk-Fact-7573B255B5DE6D7779916F38B847B8EC" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-A4B5BC575EF4381FA2126F38B8DDD3B2-0-wk-Fact-270D728EF47334CD036C6F38B8425E79" continuedAt="TextSelection-A4B5BC575EF4381FA2126F38B8DDD3B2-1" escape="true">rom time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</ix:nonNumeric></span></div><ix:continuation id="TextSelection-A4B5BC575EF4381FA2126F38B8DDD3B2-1" continuedAt="TextSelection-A4B5BC575EF4381FA2126F38B8DDD3B2-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued the new leasing standards to increase transparency and comparability among organizations related to their leasing activities. For additional information on the adoption of the new leasing standards, please read the section titled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Lease </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">above, and Note 11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on the composition of our investment portfolio, accounts receivable and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards are not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-A4B5BC575EF4381FA2126F38B8DDD3B2-2"><ix:continuation id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-15"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Debt Securities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020. The adoption of this standard will not have a material impact on our disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FASB issued ASU No. 2018-16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard became effective for us on January 1, 2019, and did not have an impact on our consolidated results of operations or financial position.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> This standard makes targeted improvements for collaborative arrangements as follows: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. The adoption of this standard did not have a material impact on our consolidated financial position, results of operations and related disclosures.</span></div></ix:continuation></ix:continuation><div><a id="s856F569999455FCCAD596CC213E55A34"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="TextSelection-CBC6979DD13E1240A2C76F38B8DF18F4-0-wk-Fact-B00139C06603A18CB7B86F38B81EF5D6" continuedAt="TextSelection-CBC6979DD13E1240A2C76F38B8DF18F4-1" escape="true">&#160;&#160;&#160;&#160;Acquisitions</ix:nonNumeric></span></div><ix:continuation id="TextSelection-CBC6979DD13E1240A2C76F38B8DF18F4-1" continuedAt="TextSelection-CBC6979DD13E1240A2C76F38B8DF18F4-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. As a result of this acquisition, we added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-CBC6979DD13E1240A2C76F38B8DF18F4-2" continuedAt="TextSelection-CBC6979DD13E1240A2C76F38B8DF18F4-3"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the acquisition, we paid NST shareholders </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1301-wk-Fact-87A79CBC26146B5B02DF7ED5975AFD8A" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">25.50</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1305-wk-Fact-BD679BAC683C3BF72B757ED63BF7452C" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">847.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1309-wk-Fact-BCF10C77947A99F4F8DD7ED685C30FB1" name="us-gaap:OtherPaymentsToAcquireBusinesses" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for equity compensation, which is attributable to pre-combination services and is reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1313-wk-Fact-CE62EAAB9B912242D46C7ED81421F20D" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1317-wk-Fact-F67C75A789F9727D76D67ED96BC76A4A" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recognized as a charge to selling, general and administrative expense with the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1322-wk-Fact-86B091481203272C918C7ED9B644335B" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a charge to research and development expense in our consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We finalized purchase accounting for this acquisition in the fourth quarter of 2019. The following table summarizes the fair values of the separately identifiable assets acquired and liabilities assumed:</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="TextSelection-D6FDFA07009C738CD95E7EDAC335DFDD-0-wk-Fact-67B67180AEE82E3BCBCD7EDAF551425D" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51004110e1376-wk-Fact-A69B380F158C715F8AA57EE119CB9859" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51004110e1391-wk-Fact-258C860583CB3EAE79377EE15A9486D1" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51004110e1411-wk-Fact-82604D074397E99D730A7EE181675AC1" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">700.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51004110e1431-wk-Fact-4B28A3E3556855D1ED5D7EE1A58C5933" name="us-gaap:Goodwill" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">117.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d51004110e1451-wk-Fact-C8DAF36AAE5AE163FFC97EE1CA1DA9BC" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51004110e1472-wk-Fact-F996B37F911A6B9CB2797EE1EF9CF960" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51004110e1497-wk-Fact-CF11A036F39E4C2D297A7EE2134DB9A3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">852.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of the IPR&amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51004110e1508-wk-Fact-F0008C0FF84DCD6358DB7EE76FBE1C12" name="biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">12.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with BIIB111. The fair value associated with BIIB111 was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1512-wk-Fact-59D17427E05415CAE83C7EE6E2305AF9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">480.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have recorded an additional IPR&amp;D asset related to BIIB112 of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1516-wk-Fact-16D30E8145816579B4B67EE71C9FA449" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have recognized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets, which have no tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for GILTI. Goodwill that is tax deductible for GILTI purposes is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1523-wk-Fact-ED9FFCF1D2282A32C02D7EE7BC70BB37" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our consolidated statements of income. Subsequent to June 7, 2019, the acquisition date, our results of operations include the results of operations of NST.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB100 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired BIIB100 (XP01 inhibitor) from Karyopharm Therapeutics Inc. (Karyopharm). BIIB100 is a Phase 1 investigational oral compound for the treatment of certain neurological and neurodegenerative diseases, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1540-wk-Fact-2B07C6A0EAB8D12E9C486F38B8201F89" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Karyopharm, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB100 had not yet reached technological feasibility. We may also pay Karyopharm up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1544-wk-Fact-61F677BF746AE3FCF8206F38B81F399F" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">207.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as tiered royalties on potential net commercial sales in the mid-single digit to low-teen percentages. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-CBC6979DD13E1240A2C76F38B8DF18F4-3" continuedAt="TextSelection-CBC6979DD13E1240A2C76F38B8DF18F4-4"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB104 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we acquired BIIB104 (AMPA) from Pfizer Inc. (Pfizer). BIIB104 is a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1557-wk-Fact-B73E9F9149B60E7A00846F38B81FA7CC" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Pfizer, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB104 had not yet reached technological feasibility. We may also pay Pfizer up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1561-wk-Fact-32EF7D1B556445EBA9046F38B8212F8D" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">515.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the low to mid-teen percentages. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TMS Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we entered into an exclusive option agreement with TMS Co., Ltd. (TMS) granting us the option to acquire TMS-007, a plasminogen activator with a novel mechanism of action associated with breaking down blood clots, which is in Phase 2 development in Japan, and backup compounds for the treatment of stroke. In exchange for the purchase option, we made a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1571-wk-Fact-76FF4C3B95913B1B5A2E6F38B820C94B" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment to TMS, which was recorded as research and development expense in our consolidated statements of income as TMS-007 had not yet reached technological feasibility. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we exercise the purchase option, we will make an additional payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1578-wk-Fact-ADD13EB686B15E95ED926F38B81E1838" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon closing of the asset acquisition, which will be recorded as acquired IPR&amp;D expense in our consolidated statements of income as TMS-007 will not have reached technological feasibility at that time. In addition, we may pay TMS up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1582-wk-Fact-4FC75C2379EEC9FBCADC6F38B81F1AB2" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">335.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the high-single digit to low-teen percentages. If we exercise the purchase option, consummation of the asset acquisition may be subject to the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB110 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we acquired BIIB110 (ActRIIA/B ligand trap) and ALG-802 from AliveGen Inc. (AliveGen).&#160;BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. We initially plan to study BIIB110 in multiple neuromuscular indications, including SMA and ALS. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1595-wk-Fact-771C25E8188CAD91CD726F38B81F1A30" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to AliveGen, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB110 had not yet reached technological feasibility. We may also pay AliveGen up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1599-wk-Fact-0D209DC0E8BA2D277CCF6F38B8217DC9" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">535.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and commercialization milestones.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB093 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 we acquired BIIB093 (glibencamide IV) from Remedy Pharmaceuticals Inc. (Remedy). BIIB093 is in a Phase 3 study for large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) granted BIIB093 orphan drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 fast track designation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are responsible for the future development and commercialization of BIIB093 and Remedy may share in the cost of development for the target indication for BIIB093 in LHI stroke.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><ix:continuation id="TextSelection-CBC6979DD13E1240A2C76F38B8DF18F4-4" continuedAt="TextSelection-CBC6979DD13E1240A2C76F38B8DF18F4-5"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as we did not acquire any employees from Remedy nor did we acquire any significant processes required in the development of BIIB093. In connection with the closing of this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51004110e1616-wk-Fact-7C3FA50C178600D388ED6F38B820D42B" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_RemedyPharmaceuticalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.0</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-CBC6979DD13E1240A2C76F38B8DF18F4-5"> to Remedy, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB093 had not yet reached technological feasibility. We may also pay Remedy certain development and sales based milestone payments that are substantially payable upon or after regulatory approval, as well as royalties on potential net commercial sales.</ix:continuation> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 25</span></div></div><hr style="page-break-after:always"></hr><div><a id="s7652C99E08E65D7893DE2EB14605D380"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;Divestitures</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="TextSelection-6207EDEF5A6EDB000B1A6F38B8DFC435-0-wk-Fact-08B6D2842F607D1A44226F38B878311C" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM Corporation (FUJIFILM). Upon the closing of this transaction, we received approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51007415e1296-wk-Fact-27EA9DE3604CB7A8CAFA7EF86BCE840F" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">881.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, which may be adjusted based on other contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51007415e1303-wk-Fact-994A71B05DC0C10DA6977EFB1890BB20" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2019Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees and have accrued for this obligation. We may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this transaction, we recognized a total net loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51007415e1316-wk-Fact-C512769E94DAD5B118357EFD5604D7D3" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">164.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated statements of income. This loss included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51007415e1320-wk-Fact-6206447488C50EAA0D3D7EFE82A6B7CC" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">95.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded in loss on divestiture of Hiller&#248;d, Denmark manufacturing operations. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51007415e1324-wk-Fact-34C97FE393A15D423D807F007801A7DC" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and our estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51007415e1328-wk-Fact-10A78FAED36F0E9DB584E86F82C97371" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2019Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">114.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. We also recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51007415e1332-wk-Fact-7DD7E13C219FC7B4D1AE7F012B0335CA" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this transaction. During the fourth quarter of 2019 we recorded a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51007415e1337-wk-Fact-680A2949DD1C33225AE8E8704D7CBB50" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" contextRef="FD2019Q4QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in our estimate of the future minimum batch commitment utilizing our current manufacturing forecast, which reflects the impact of forecasted aducanumab batches, resulting in a reduction in the pre-tax loss on divestiture from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51007415e1341-wk-Fact-6206447488C50EAA0D3D7EFE82A6B7CC" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">95.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51007415e1345-wk-Fact-25731977E8E1923A8E3DE870A27E5A14" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sold to FUJIFILM </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51007415e1352-wk-Fact-7B67356AE4C6F2044AE67F01D86E0CE7" name="biib:InventoryrawmaterialssoldtoFUJIFILM" contextRef="I2019Q3Denmark" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the adverse commitment is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 26</span></div></div><hr style="page-break-after:always"></hr><div><a id="s51FDB302D69F58E3A95F7A952BA7F601"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-70BC8E95AFE27EB79C366F38B8E0B1B1-0-wk-Fact-B56C3DDD09EFB06F29DC6F38B7D41263" continuedAt="TextSelection-70BC8E95AFE27EB79C366F38B8E0B1B1-1" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="TextSelection-70BC8E95AFE27EB79C366F38B8E0B1B1-1" continuedAt="TextSelection-70BC8E95AFE27EB79C366F38B8E0B1B1-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="TextSelection-9480294ACAA90466835A6F38B8E07ED5-0-wk-Fact-0F0EADBFB6A8A6B5CF7D6F38B7CFBACB" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2110-wk-Fact-7178F7ECE2E8F56E08A06F38B8541ED7" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,306.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2129-wk-Fact-7EF5073E34FA11118B256F38B837386B" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,126.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2148-wk-Fact-BCD410BEDDA3E97A774A6F38B89E9365" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,432.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2168-wk-Fact-E774B0EFAAFB7BAF76E46F38B8AB1412" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,253.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2187-wk-Fact-28E1368E449182293C046F38B850AB49" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,020.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2207-wk-Fact-6C076252D70E55462C066F38B8AB8BDE" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,274.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2226-wk-Fact-69D618FB522F322CD6206F38B8489900" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,294.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2245-wk-Fact-19AF842B0A3547F2B74B6F38B8A81C5A" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">920.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2265-wk-Fact-8532C1CA9122300BB9346F38B855A197" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,214.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2280-wk-Fact-C9D00A1D3DA8814BEF436F38B8A19E4A" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,426.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2299-wk-Fact-D246160A5EBECF776B8C6F38B846D26F" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">675.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2318-wk-Fact-BFD6B5E6012E423899A66F38B8A0631D" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,101.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2338-wk-Fact-CF63614DF1A99675C25E6F38B83D89C0" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,668.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2357-wk-Fact-1F34CCAADCF6D0D1A1CE6F38B8AC918F" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">694.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2376-wk-Fact-87FEDFBFC34F2CBF19196F38B89FC4FD" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,363.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2396-wk-Fact-7A7107DD41A37CAF21B66F38B89CE292" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,889.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2415-wk-Fact-087395A8FEB9289E01F06F38B855013E" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">756.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2435-wk-Fact-FDEBEBFB11DD9F83A10D6F38B846D785" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,645.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2455-wk-Fact-6FFE0F9E1BD388E264516F38B83B0EE9" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,041.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2474-wk-Fact-981BDCC3DC7C07AE2E736F38B8A0AFE8" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">850.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2493-wk-Fact-7964346AAB80C3F7196E6F38B8AA2B20" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,892.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2513-wk-Fact-893E7531F927F0336FBB6F38B84E90B3" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,025.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2532-wk-Fact-3098CD42B17958D530796F38B83EB3FB" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">839.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2551-wk-Fact-630F890706B31D75C9906F38B84BA5E4" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,864.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2571-wk-Fact-44698503DF8F3807C0946F38B854904B" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,113.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2590-wk-Fact-8CB95461A7A4EE4364926F38B842B36D" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">859.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2610-wk-Fact-F8C2676E0917361E4F216F38B8A766E8" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,973.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">VUMERITY</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2630-wk-Fact-D1B96FC294061CE18A4DE8733EA1ADDA" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2649-wk-Fact-3A83CDE025A9577BB627E8734109493D" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2668-wk-Fact-BB343842B86CAFA0210BE873437B4DF3" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2688-wk-Fact-BEBCF796CD96EE563D2FE87345707D1B" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2707-wk-Fact-63765EBCBA2DD3A0D2B7E87347D845BD" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2726-wk-Fact-97624A8A3A23EC00C779E8734A52C620" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2746-wk-Fact-49383F53A8FA45B5AC4BE8734C4677E7" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2765-wk-Fact-47B14953EEDE7D46DA78E8734EADDF2A" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2785-wk-Fact-587520D80F04B0A3451BE87351275B96" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2805-wk-Fact-A9D93BDED7FD663918B46F38B840D5C8" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2824-wk-Fact-E56C85A610C096D955846F38B84A1E45" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">97.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2843-wk-Fact-2CD61E5D5F15DE0F701C6F38B8A1427F" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">97.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2863-wk-Fact-FBAC51A55B525C65EE9E6F38B839D35C" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2882-wk-Fact-846BC48484CE6B3755A66F38B8AB70C6" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">92.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2901-wk-Fact-56F9563F6D3125EB88FD6F38B84F15A8" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">92.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2921-wk-Fact-48A40101726EB69A0B736F38B84C2F77" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2940-wk-Fact-0666315F19323315166C6F38B8A564C4" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">91.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e2960-wk-Fact-5CE00C2F48BBE2B5E3AD6F38B8A56504" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">91.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2980-wk-Fact-FD1B9F4E6879A74F7D5A6F38B841269F" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e2999-wk-Fact-B85B3F4D03DE5193F31D6F38B8533CA0" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e3018-wk-Fact-AF7E4474FC3158821EBC6F38B84DB649" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3038-wk-Fact-8B52002C0AA5B42EF6446F38B89C32DE" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3057-wk-Fact-314DB7EE1940650BD3266F38B8AB5355" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3076-wk-Fact-827F967916D4315CC3E66F38B857DAD4" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3096-wk-Fact-633898C07050AE5610DE6F38B8A24B9D" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3115-wk-Fact-9AE66B8E642AC36F1ADE6F38B8A11AB1" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3135-wk-Fact-4650A6B5A762EBC9C2976F38B8A4B3A0" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS Product Revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e3155-wk-Fact-F195E1EC8ED28689E8366F38B8AC6376" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,780.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e3174-wk-Fact-5714B817FBA2361D71686F38B84F2F94" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,748.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e3193-wk-Fact-83E0947CDDEC5CDDBEB36F38B8A86451" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,529.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3213-wk-Fact-85B07E50F6083E80A3466F38B83871A8" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,946.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3232-wk-Fact-F808B4766C0E2E1F55296F38B837B592" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,648.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3251-wk-Fact-642538AB9FBB204C8D4B6F38B8ACA635" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,595.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3271-wk-Fact-3432B61F6A97B0B236506F38B849DEFA" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,296.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3290-wk-Fact-FCFCA77FD020F91DB4C86F38B840EAC0" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,680.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3310-wk-Fact-0138E25D800678A85E416F38B8A70656" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,977.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e3699-wk-Fact-969824CFFEEA7B45CB4E6F38B840AA9B" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">933.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e3718-wk-Fact-10CEB08D0414FD1054166F38B8AAA640" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,163.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e3737-wk-Fact-8E61C5D97516A10EAAA36F38B89DB152" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,097.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3757-wk-Fact-7E1E771E7FE7124A5A146F38B858452F" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">854.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3776-wk-Fact-E4B225B6380CB42493526F38B89F299E" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">870.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3795-wk-Fact-06349855CEE6CBAF9C546F38B8A6AA7D" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,724.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3815-wk-Fact-2838B8F012123786F80F6F38B843EAD5" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">657.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3834-wk-Fact-95A708AD9372607553FD6F38B8490B20" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">226.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e3854-wk-Fact-21ADC2404D6F977648066F38B89E310E" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">883.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e4242-wk-Fact-1B3734F7E6FF26D8C5F76F38B84ADF6E" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e4261-wk-Fact-711EDED6F8A4F6BE32346F38B8479476" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">486.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e4280-wk-Fact-22A7D3D6C162A23114496F38B84A97EF" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">486.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4300-wk-Fact-C63524C709AD88F7A6FD6F38B8A0F9B2" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4319-wk-Fact-3EDF123DF168D9E112546F38B84251EB" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">485.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4338-wk-Fact-B0232DB960246F65C8F16F38B8AC3007" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">485.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4358-wk-Fact-137970766800E834C4BC6F38B8ADDB9A" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4377-wk-Fact-470D8EE6BC1ABE7B1F946F38B8394139" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">370.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4397-wk-Fact-00E75C2CE55924708BD56F38B845AC1F" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">370.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e4417-wk-Fact-E4528FB59CDB06C7F6596F38B837969F" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e4436-wk-Fact-17CA8FA2624735F12D7E6F38B89C960D" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">184.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e4455-wk-Fact-7CF29032C4491FE8C4AC93CA0EE139FB" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">184.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4475-wk-Fact-43E17EB736CBEE0D88F56F38B8AA09D0" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4494-wk-Fact-1039995D8C96C0984B326F38B848D6CC" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4513-wk-Fact-86E344CFD95A06FA298593CA50577A1C" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4533-wk-Fact-25C4C43A696F34DA0C5A6F38B8A2A50C" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4552-wk-Fact-08B90C4658E140B0B2756F38B89C2507" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4572-wk-Fact-9029280CBBA3314E11DB93CA7E35DE76" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e4592-wk-Fact-E893ECE2AD3B7E60DA1A6F38B847835C" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e4611-wk-Fact-491D22F8A9F7E4060D056F38B83D4007" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e4630-wk-Fact-B185EA9C40B4D4F5DAA76F38B89D88AF" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4650-wk-Fact-254C46441D4F7BE1CA9C6F38B84138E6" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4669-wk-Fact-8EA51C673D11E6431F6C6F38B8561583" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4688-wk-Fact-8502F49E7AD44B2566856F38B842DC87" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4708-wk-Fact-C733A3C18E14F9773B5F6F38B8A78598" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4727-wk-Fact-02AD391F6F7C94E78ADC6F38B851AF4D" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4747-wk-Fact-CB65433CC48753DB72DA6F38B852E3C1" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e4767-wk-Fact-DC78B706D2B9E2411BA26F38B84310BC" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e4786-wk-Fact-1201F017A49BBAA608B96F38B8482900" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">738.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e4805-wk-Fact-2F917D991B1833F4ED2A6F38B850B40B" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">738.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4825-wk-Fact-E00653BCA67F9A701C5C6F38B8584492" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4844-wk-Fact-140266E38F85D9033E966F38B8AC5C36" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">545.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4863-wk-Fact-8F308751B2A4931FF9196F38B8523276" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">545.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4883-wk-Fact-E0EF5C9090DF50D179CD6F38B850B9D9" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4902-wk-Fact-0D9BF2E2D2B320A142666F38B84CC1B9" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">379.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e4922-wk-Fact-9807BBA5D0267FC5D7C76F38B8A3EE8A" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">379.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e5311-wk-Fact-868DBD07789EDFCA6D6C6F38B84CF1BF" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e5330-wk-Fact-CFAA484D6EACFCB7D28D6F38B854EECD" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e5349-wk-Fact-9EA18A071FA86CFA9C9B6F38B83EBB00" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e5369-wk-Fact-C9884796EC6F2B319DCE6F38B8A55F3D" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e5388-wk-Fact-7702DA027A7BA4C9DE396F38B8504B7C" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e5407-wk-Fact-B5D3FE6C77BB94DD7A476F38B84F4C18" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e5427-wk-Fact-BEBED064BBAF13E2161F6F38B89D3CE4" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e5446-wk-Fact-BA182DF5D3411FF3595F6F38B8485735" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e5466-wk-Fact-C264FD3C1FC17E8E126B6F38B8407721" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e5854-wk-Fact-7E045E2FCCE87D5EF5216F38B8A28056" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e5873-wk-Fact-AE1B22DC7C26C1FADBF06F38B83A2E87" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e5892-wk-Fact-FD5A8E196D5C96F123346F38B8A2593D" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e5912-wk-Fact-481DC4EBC294AC8261326F38B83CF5BF" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e5931-wk-Fact-50F08CF7707F3BF9C0CE6F38B8A5E86E" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e5950-wk-Fact-1FDFC5717EACA77C36896F38B8467A5A" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e5970-wk-Fact-C458C2240F5FF26B82676F38B84D38D8" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e5989-wk-Fact-33566A04BE05B220B8386F38B8533D19" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6009-wk-Fact-469032FB2607D925670E6F38B8A328AC" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e6029-wk-Fact-BC4A27EADBD4713E0CAE6F38B83DABCA" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e6048-wk-Fact-15C1A916923E32CDEAD56F38B84B3AE0" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e6067-wk-Fact-719FBA0AF483D751A30D6F38B8A8EBF2" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6087-wk-Fact-01A174DB54FCDB30C5436F38B8A43863" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6106-wk-Fact-F3E403AAF46FBEB1496C6F38B84DA03A" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6125-wk-Fact-099A36DE28A9D45111D86F38B852EEC9" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6145-wk-Fact-47FA694F1D66D8F80F656F38B8A656E5" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6164-wk-Fact-C46A212B9154F02ADAAE6F38B844820C" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6184-wk-Fact-452255477FCCBAC36EDB6F38B84DACCF" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Hemophilia product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e6204-wk-Fact-51038E5E04FCB94F836E6F38B8AA1931" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e6223-wk-Fact-513B5CD79F09E8E550386F38B843F9C1" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e6242-wk-Fact-104590C7188B6920EE6E6F38B83D7677" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6262-wk-Fact-1E49E52ADF04EC5D3F2D6F38B8372877" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6281-wk-Fact-E5626ED7D6CB030440F26F38B8A414FE" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6300-wk-Fact-348EADC13053EA8A72FE6F38B83CB548" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6320-wk-Fact-ACBC9FA87EC1ABF415CA6F38B84AF0ED" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6339-wk-Fact-6941617A07683B02C6256F38B857FDDF" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6359-wk-Fact-1EFF99EC168CB8E933B66F38B83B205A" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e6568-wk-Fact-8B42590D2AE4D7B90D5A6F38B83ADC6B" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,713.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e6587-wk-Fact-BCA71A3F159546C947596F38B8A552F7" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,666.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e6606-wk-Fact-F1FBA38FF669B88E1D976F38B82CDF1B" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11,379.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6626-wk-Fact-5384BFFD347C612F45386F38B8517C44" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,800.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6645-wk-Fact-DA7D01CBC8D84725300E6F38B89FAAFB" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,086.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6665-wk-Fact-7B6205D978C9C04E48296F38B81CF51A" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10,886.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6684-wk-Fact-279DB18511D84B5AD04A6F38B8A819C5" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,017.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6703-wk-Fact-C390E028FC22AE0CC39C6F38B840045E" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,337.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d51031806e6723-wk-Fact-A0A85755BDDAAFF80DF16F38B7A963B8" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10,354.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e6737-wk-Fact-E1DC77899CA180C007446F38B7CFA906" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e6741-wk-Fact-BDF0173A84F573BCAC686F38B7D399C5" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e6749-wk-Fact-FDCC363E917377C951356F38B7D26F96" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2018Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e6753-wk-Fact-B386C9FB6E650706AAC06F38B7D324C5" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2018Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e6762-wk-Fact-3497DED074498C52B4FC6F38B7D0519B" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">34</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e6766-wk-Fact-0D6484122065A63253336F38B7D1FDD5" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e6781-wk-Fact-3BF5C3BCEC00B76C7AA16F38B7CE1504" name="biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" contextRef="FI2019Q4_biib_MajorDistributorAxis_biib_DistributorOneMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">24.1</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e6785-wk-Fact-CDBB450B5A86B10052676F38B7D05D4E" name="biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" contextRef="FI2019Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">13.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net accounts receivable associated with our product sales, as compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e6789-wk-Fact-553F8ECB319EB233D11B6F38B7D58795" name="biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" contextRef="FI2018Q4_biib_MajorDistributorAxis_biib_DistributorOneMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">27.7</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e6793-wk-Fact-1CCE6E02877ED1F149D26F38B7D253EA" name="biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" contextRef="FI2018Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">15.6</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-70BC8E95AFE27EB79C366F38B8E0B1B1-2" continuedAt="TextSelection-70BC8E95AFE27EB79C366F38B8E0B1B1-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="TextSelection-65A5FD682DBB94372F2E6F38B8DF0878-0-wk-Fact-F5C1149F28E89263E7E56F38B7CF1A5D" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7019-wk-Fact-8A9FA3DBACC07E8F72896F38B7C91625" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7038-wk-Fact-79A7D730F6B06E25F5666F38B89D0D7E" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">888.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7057-wk-Fact-87C468842B59399AECDA6F38B8AD129D" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7077-wk-Fact-3E4AC112B64B6AB6576A6F38B7A3C8B2" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,051.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7092-wk-Fact-ADEF6A24E22C27F4C0C76F38B85A4F9F" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">666.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7111-wk-Fact-0EF84F87EB4BE24ED5866F38B85DFC19" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,011.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7130-wk-Fact-7918091EA9B0A5A90A826F38B85B3EDF" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7150-wk-Fact-4E9BC5FF9D53688268956F38B85832C6" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,698.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7170-wk-Fact-92DE238C7225EF4158BC6F38B859A897" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51031806e7189-wk-Fact-28F007448A95EBC00A586F38B85CF5C2" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">54.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7209-wk-Fact-3F84CA51FF2BB074F4E36F38B88FE47C" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51031806e7229-wk-Fact-F016752F3BCB36A7239C6F38B8592922" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51031806e7250-wk-Fact-001105F50119E81B8FCB6F38B85C20A2" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">535.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51031806e7270-wk-Fact-082CC9D897975E81FBE66F38B88F6874" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,242.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51031806e7290-wk-Fact-BA796D8196DC485D19C66F38B88FA417" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51031806e7311-wk-Fact-B4D20E61498F88F869B76F38B85C60DB" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,778.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51031806e7332-wk-Fact-D659A76D66CFFC23418D6F38B88EFF7E" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51031806e7352-wk-Fact-7DD37661EA45CE932DA36F38B88D5765" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">576.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51031806e7372-wk-Fact-0CB7A2255824C17E17026F38B88DCF22" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51031806e7393-wk-Fact-6E2594A9A1686D7CFB9F6F38B859D9BE" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">724.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7419-wk-Fact-234A584500B6138FF4426F38B85ADC81" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7438-wk-Fact-C277ECD3C56D4DCB92896F38B85937EA" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,027.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7457-wk-Fact-D443961612D1F37D9C8D6F38B88CF725" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e7477-wk-Fact-8FCA815A8432989B0C476F38B85D916C" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,198.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e7690-wk-Fact-A3B5EB49BDB9642F21216F38B8AE1126" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e7709-wk-Fact-F8FB02F259A4C849D20E6F38B7B16265" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">606.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e7728-wk-Fact-725101FDAF5D5B5EE9046F38B7CFB816" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e7748-wk-Fact-62C9CCF20D5EBA9BEE1B6F38B8A5EBD2" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">761.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e7763-wk-Fact-05897C73EFBDCDAB3FE16F38B8062729" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">679.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e7782-wk-Fact-78503854A7992EC92DAA6F38B845B733" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,686.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e7801-wk-Fact-67AF24074B393E49D6EC6F38B89BA940" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e7821-wk-Fact-02D8942802EF783000F76F38B843D773" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,389.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e7841-wk-Fact-792CE882BF360DAAA1FB6F38B8AD6AC1" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e7861-wk-Fact-D5F502F5FDA21EF314F36F38B84830C8" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e7881-wk-Fact-CAB62E1A5365663019476F38B80920B9" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e7902-wk-Fact-002464A079952E84F1E06F38B8843652" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e7923-wk-Fact-EED2B404CCE8057BCC4A6F38B889145E" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">551.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e7943-wk-Fact-061C6E9B319E087D90566F38B810295E" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,887.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e7963-wk-Fact-82D2367CC5432D7D9CEB6F38B7ADAF47" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e7984-wk-Fact-A11AE8C60D6185A85AC16F38B8A27509" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,440.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8005-wk-Fact-31FE67F8A9DEDC6C90A06F38B81C0478" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8025-wk-Fact-2FC15730D71DA76C0CFC6F38B8938B56" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">506.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8045-wk-Fact-DA3FD5C5771E6C287EE56F38B7F6C630" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8066-wk-Fact-9CEB9913060033D680996F38B8C635E7" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">646.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8092-wk-Fact-8A9FA3DBACC07E8F72896F38B7C91625" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8111-wk-Fact-79A7D730F6B06E25F5666F38B89D0D7E" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">888.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8130-wk-Fact-87C468842B59399AECDA6F38B8AD129D" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8150-wk-Fact-3E4AC112B64B6AB6576A6F38B7A3C8B2" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,051.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8361-wk-Fact-030F4CD51D3F6EB116226F38B7DEDF0A" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8380-wk-Fact-A47FEFD554FC7FA2AFC36F38B7D62E13" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">482.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8399-wk-Fact-06A1569401039B2745E56F38B7D816F4" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8419-wk-Fact-196068BFBBDD76DA0DE96F38B7DCB8F9" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2016Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">605.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8434-wk-Fact-2E5795BE191D586CDFD86F38B7DD065E" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">583.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8453-wk-Fact-3DC03A11EACE31EABAD36F38B7DE30AA" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,307.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8472-wk-Fact-6E75F5FED2995B4D47EF6F38B7DB714B" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8492-wk-Fact-B1FF02E77436FC2E279D6F38B7DA95A2" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,917.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8512-wk-Fact-DCFB2B6F64AFE602BB856F38B7D99489" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8532-wk-Fact-42B8D9900839DD64F6426F38B7DC2698" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">15.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8551-wk-Fact-1EA7F2CFFB94951B9D586F38B7D73CBC" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8572-wk-Fact-89106EC5EE704A3F8B446F38B7DE941E" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8592-wk-Fact-AA68AD01E0CED3A783316F38B7D77D21" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">475.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8612-wk-Fact-2B6335B01DBA1E84E99A6F38B7D9D2AE" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,756.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8632-wk-Fact-8DE44C836FEB57B07C6C6F38B7DD0BB6" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8653-wk-Fact-4ADC89F64F60FC5BC1506F38B7DE84BA" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,232.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8674-wk-Fact-A298CC9B2B0A6D59AD366F38B7DB5A51" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8694-wk-Fact-530018D21CF10484BF6A6F38B7D9EF65" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">442.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8714-wk-Fact-69A47D51F11389F0DB346F38B7DB12B8" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e8735-wk-Fact-5A1EE19821AB7E6631C96F38B7D6D9F0" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">534.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8761-wk-Fact-A3B5EB49BDB9642F21216F38B8AE1126" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8780-wk-Fact-F8FB02F259A4C849D20E6F38B7B16265" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">606.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8799-wk-Fact-725101FDAF5D5B5EE9046F38B7CFB816" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8819-wk-Fact-62C9CCF20D5EBA9BEE1B6F38B8A5EBD2" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">761.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="TextSelection-729A6DC70A834596B0D76F38B8E03739-0-wk-Fact-F67DE55115249D1B05086F38B7D06501" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e8957-wk-Fact-EDD2DB46CDE06F3C80E96F38B85DE649" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">197.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e8976-wk-Fact-4B0FA7C18E26D6A05A026F38B85EDDE2" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">176.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e8991-wk-Fact-95236321ECF2BFF56EC16F38B85CEE98" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,001.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9010-wk-Fact-1FE860E51A66C4BD686F6F38B85CFD98" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">874.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e9035-wk-Fact-8FCA815A8432989B0C476F38B85D916C" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,198.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9054-wk-Fact-3E4AC112B64B6AB6576A6F38B7A3C8B2" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,051.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="TextSelection-638E06587C1F10CAAFCD6F38B8E02F7C-0-wk-Fact-D5A9FB3D9AB158FBE9E46F38B7CE9A2D" continuedAt="TextSelection-7B1B6F66AB5E252F0AAC6F38B8E77FBD-0" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e9230-wk-Fact-26337B82AAEF05E73A3E6F38B85F0A00" name="biib:ShareOfCoPromotionProfits" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,542.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9249-wk-Fact-B6C3F88418A5E2EE809B6F38B8628501" name="biib:ShareOfCoPromotionProfits" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,431.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9268-wk-Fact-2DFFF43C74572858F7716F38B862D03C" name="biib:ShareOfCoPromotionProfits" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,316.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e9284-wk-Fact-B81242FED25624534B936F38B8676A8A" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">748.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9303-wk-Fact-FB06AB0BDFB9774258446F38B8615CE3" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">548.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9322-wk-Fact-EE4AEC4BFD0DED5E11FC6F38B85F5D20" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">242.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51031806e9348-wk-Fact-6DB6BA0B8C715A0D0D4B6F38B8607F57" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,290.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9367-wk-Fact-5DE8AC0444CC0844782E6F38B82AE6AA" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,980.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9386-wk-Fact-3A0656DB95083450147A6F38B824BC8E" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,559.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9399-wk-Fact-77C6EE89DB0D429BD2826F38B7D19259" name="biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">16</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9403-wk-Fact-F8CAE99BE14A27F718C56F38B7D4FDE9" name="biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9407-wk-Fact-E9F18636260A1ABA5F5E6F38B7D3E7A3" name="biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our total revenues in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are derived from our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-70BC8E95AFE27EB79C366F38B8E0B1B1-3"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:OtherrevenuesTableTextBlock" id="TextSelection-8C0ADF7C45713CB35C766F38B8E0335B-0-wk-Fact-00ADD7CF61EF3DA1F56A6F38B7D42149" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51031806e9655-wk-Fact-4C382510ABFD169D06076F38B81BC097" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e9674-wk-Fact-8E85EC7E039C29B352A46F38B838A94B" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51031806e9694-wk-Fact-F2A2DA8DFCD0FE44D3006F38B817260B" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">16.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development services and manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51031806e9711-wk-Fact-9C6F8620EFB92534924C6F38B81B790F" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9730-wk-Fact-D98AB683F00560D115956F38B8180CE8" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">96.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9749-wk-Fact-451BC7676B153AC2F9D46F38B817A7C0" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Swedish Orphan Biovitrum AB (Sobi) and royalties from Sobi on sales of ELOCTA and ALPROLIX</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51031806e9770-wk-Fact-BC230EB7D860876E9F856F38B83772D5" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9789-wk-Fact-C57B6BD867FF7B4640876F38B8193C6F" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9808-wk-Fact-57A6F603F561C56782EE6F38B81B5038" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51031806e9891-wk-Fact-6DEF235C43079255766D6F38B81AFE42" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9910-wk-Fact-3BA33591AF6A2EFEC48B6F38B81A04B0" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9929-wk-Fact-53FF036340A563D1B1086F38B81A8157" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51031806e9950-wk-Fact-A11D430804BAB190CC8E6F38B817B7C1" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">584.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9969-wk-Fact-8F29895CB4BD28E2DF4F6F38B818F0BD" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">459.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e9988-wk-Fact-FB7300F2763967631B9A6F38B819D90D" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">253.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51031806e10014-wk-Fact-00E0A71FFA7A5B6582ED6F38B7ACA093" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">707.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e10033-wk-Fact-F0C4D670DC0F193457D96F38B8622365" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">585.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51031806e10052-wk-Fact-5D3FED1ADFF25AE90C656F38B87CF3D8" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">360.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic customers, including Bioverativ Inc. (Bioverativ). During the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51031806e10076-wk-Fact-8711D748E93BCF1DE1F07F0BBDAA434B" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">383.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51031806e10080-wk-Fact-6A7B1A646BAC100755617F0C17101529" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">206.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51031806e10085-wk-Fact-4BCF78733E175B27C3217F0C543D4B61" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we will license certain of our manufacturing-related intellectual property to the customer. We will be eligible to receive </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51031806e10092-wk-Fact-28D3BE14DB3FB3A79BFE7F0D47D39D08" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in a series of three payments. The first payment is due upon a regulatory achievement related to the customer's product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We expect the regulatory achievement to occur in 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with AbbVie Inc. (AbbVie) and Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:continuation><div><a id="s6923FADCDA5B52CCB4AFA894A431AD4A"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-5A01C0CCF8D0FD9461346F38B8E0D4DB-0-wk-Fact-39E39E9D5DA713830DF96F38B7DE9329" continuedAt="TextSelection-5A01C0CCF8D0FD9461346F38B8E0D4DB-1" escape="true">&#160;&#160;&#160;&#160;Inventory</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-55ECB43DF7CEACC8FF876F38B8E04257-0-wk-Fact-7924AFE8409EAEDABF6B6F38B7DF8884" escape="true"><ix:continuation id="TextSelection-5A01C0CCF8D0FD9461346F38B8E0D4DB-1" continuedAt="TextSelection-5A01C0CCF8D0FD9461346F38B8E0D4DB-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51008168e1413-wk-Fact-90CD31E27EE2393C377A6F38B7D734CC" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">169.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51008168e1432-wk-Fact-6AB07456E0D537CEEA996F38B7D80BDA" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">196.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51008168e1447-wk-Fact-6591E1D4F7E20493F29F6F38B7DB76E2" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">460.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51008168e1466-wk-Fact-007259F61199871542A76F38B7DF8974" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">606.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51008168e1486-wk-Fact-3C6C4DCD7ADE40FCA6416F38B7DEEC50" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51008168e1505-wk-Fact-28E893FE7C0BFEAE60A36F38B7E0624D" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51008168e1530-wk-Fact-DF17104FDCA763B760176F38B7D6FA5B" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">804.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51008168e1549-wk-Fact-BF2415D4BD7E9816F0596F38B7DA7C7F" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">936.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51008168e1651-wk-Fact-26F6B410F20D465D19666F38B8C27FA2" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">804.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51008168e1670-wk-Fact-8C4A1D272C17C1AD6F426F38B8C3B56F" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">929.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51008168e1685-wk-Fact-AC0DDA02A7F652BE02696F38B7D8D45D" name="us-gaap:InventoryNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51008168e1704-wk-Fact-049FFF4E5B821BBC12EF6F38B7D78A2D" name="us-gaap:InventoryNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51008168e1729-wk-Fact-DF17104FDCA763B760176F38B7D6FA5B" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">804.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51008168e1748-wk-Fact-BF2415D4BD7E9816F0596F38B7DA7C7F" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">936.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-5A01C0CCF8D0FD9461346F38B8E0D4DB-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2019 we sold to Bioverativ hemophilia-related inventory on hand as of December 31, 2018, with a cost basis totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51008168e1771-wk-Fact-AE180E85B6D1ADF24A22D10AC85EF07A" name="biib:InventorysoldtoBioverativcost" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">184.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> pursuant to the terms of the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51008168e1781-wk-Fact-BE860C7BC2B63CB66F1F6F38B7E38CE6" name="us-gaap:InventoryWriteDown" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51008168e1785-wk-Fact-28B7F0251CE7E29184A36F38B7DD62DF" name="us-gaap:InventoryWriteDown" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51008168e1789-wk-Fact-B065744EEC1FFCD04F3D6F38B7DF69EC" name="us-gaap:InventoryWriteDown" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included the sale of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51008168e1812-wk-Fact-B750035E8C7689BE23DD7F75AD606980" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" contextRef="I2019Q3Denmark_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of work in process inventory.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sold to FUJIFILM approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51008168e1819-wk-Fact-7B67356AE4C6F2044AE67F01D86E0CE7" name="biib:InventoryrawmaterialssoldtoFUJIFILM" contextRef="I2019Q3Denmark" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:continuation><div><a id="s5475BED69E895B219C1C84AE8EF7F28B"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="TextSelection-99BD60AB4ED2AABE17936F38B8E13EAD-0-wk-Fact-27CE6DFCA6B12E79B93D6F38B8B09302" continuedAt="TextSelection-99BD60AB4ED2AABE17936F38B8E13EAD-1" escape="true">&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="TextSelection-99BD60AB4ED2AABE17936F38B8E13EAD-1" continuedAt="TextSelection-99BD60AB4ED2AABE17936F38B8E13EAD-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="TextSelection-C939E9154435C068A8E46F38B8E16AAA-0-wk-Fact-35165718CDEE76B7403A6F38B8312EEA" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:20%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-28 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e1635-wk-Fact-5045C1667BFDB7F4A6446F38B7E197CC" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,379.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51024678e1654-wk-Fact-20A8E4232234AAE424EB6F38B7DC7954" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,881.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e1675-wk-Fact-53F472F6525C248BDD756F38B80BCEEE" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,497.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e1694-wk-Fact-B71A68581363D3A4EC056F38B7E217EE" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,187.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51024678e1713-wk-Fact-DDF87F45F2B80791E2666F38B8857B3B" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,607.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e1734-wk-Fact-34E907057BF3D13FBA226F38B83C3DA7" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,580.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e1759-wk-Fact-8C410B396EF78F024FDE6F38B8749112" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">965.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e1778-wk-Fact-0FFBD3D5F524EC2262766F38B7E92401" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e1798-wk-Fact-8C410B396EF78F024FDE6F38B8749112" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">965.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e1817-wk-Fact-5EAFAAB3B2572C26BBA06F38B7EA7D38" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">476.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e1836-wk-Fact-F86AF0E3D50420C8D0CC6F38B80D6733" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e1856-wk-Fact-5EAFAAB3B2572C26BBA06F38B7EA7D38" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">476.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and trade names</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e1886-wk-Fact-143ECF7427AA746C048C6F38B8464756" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e1905-wk-Fact-10ABBE83A8CD22353A3D6F38B84E6240" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e1925-wk-Fact-143ECF7427AA746C048C6F38B8464756" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e1944-wk-Fact-1F10FFA1F2C8C13051306F38B8206FF5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e1963-wk-Fact-F1D7727F1F9A9CBF64B26F38B7E00E1F" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e1983-wk-Fact-1F10FFA1F2C8C13051306F38B8206FF5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e2018-wk-Fact-FC57B6818DAB358EB31C6F38B86B69CD" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51024678e2037-wk-Fact-20A8E4232234AAE424EB6F38B7DC7954" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,881.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e2058-wk-Fact-4AD21CB6B4B90431AF316F38B8BC8BF4" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,527.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e2077-wk-Fact-99E7A6571B58CD4405F86F38B7BBCE7A" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,727.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51024678e2096-wk-Fact-DDF87F45F2B80791E2666F38B8857B3B" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,607.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e2117-wk-Fact-0B06E7AFD52116E2A95B6F38B8B9E33F" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,120.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Amortization and Impairments</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2139-wk-Fact-79F73778C54DE73C4DD76F38B881C966" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">489.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2143-wk-Fact-81104360B4FDD747DCD66F38B87FA895" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">747.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2147-wk-Fact-0248BA74606E7D1238426F38B833F6BA" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">814.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Amortization of acquired intangible assets, excluding impairment charges, totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2164-wk-Fact-D74A6CDB288794BC843EE882FF86C7CA" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">274.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2168-wk-Fact-80A6F7EEED667976781BE88369CFD305" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">381.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2172-wk-Fact-2C139FCC0AA67C2038C4E883A392B032" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">455.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The decrease in amortization of acquired intangible assets, excluding impairment charges, over the three years was primarily due to a lower rate of amortization for acquired intangible assets, primarily due to prior year impairments.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization and impairments of acquired intangible assets reflects the impact of a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2196-wk-Fact-C90610768443E1F0F6317F831C0B9606" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge to reduce the fair value of IPR&amp;D assets associated with BG00011 (STX-100) to zero, as discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the impact of impairment charges related to certain IPR&amp;D assets associated with our vixotrigine program totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2207-wk-Fact-6D50742932615A5BE2716F38B844A09D" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">189.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflect the impact of impairment charges of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2222-wk-Fact-A4EB1ECE5775B27307D9E884A2D18D59" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">176.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2226-wk-Fact-7597E590B93FBF39E3386F38B81E1927" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">328.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our intangible </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-99BD60AB4ED2AABE17936F38B8E13EAD-2" continuedAt="TextSelection-99BD60AB4ED2AABE17936F38B8E13EAD-3"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">assets associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Completed Technology</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan. The net book value of the TYSABRI asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2244-wk-Fact-A9F80EBA5C2DA997D16C6F38B8AF1792" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology also includes </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2251-wk-Fact-FAF3E384D38C467CBFA2E884F0FC95D7" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="FD2019Q4QTD_srt_ProductOrServiceAxis_biib_VUMERITYMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">155.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), following the approval of VUMERITY in the U.S. in October 2019, technology related to our AVONEX product, which we recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003, our rest of world license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below, and other amounts related to our other marketed products and other programs acquired through business combinations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">TECFIDERA License Rights</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2261-wk-Fact-13472D8C1D1B9AD94363E88565015CFA" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="FD2017Q1QTD" unitRef="usd" decimals="-7" scale="9" format="ixt:numdotdecimal">1.25</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2265-wk-Fact-8C83B763FE15C49AD3ECE885D34DF5DF" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q1_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">795.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded within intangible assets in the first quarter of 2017. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We had an intellectual property dispute with Forward Pharma in the U.S. concerning intellectual property related to TECFIDERA. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2275-wk-Fact-7597E590B93FBF39E3386F38B81E1927" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">328.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute and continued to amortize the remaining net book value of the U.S. intangible asset in our consolidated statements of income utilizing an economic consumption model. The U.S. Court of Appeals for the Federal Circuit upheld the U.S. Patent and Trademark Office&#8217;s March 2017 ruling and in January 2019 denied Forward Pharma's petition for rehearing. We evaluated the recoverability of the U.S. asset based upon these most recent developments and recorded a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2279-wk-Fact-A4EB1ECE5775B27307D9E884A2D18D59" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">176.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge in the fourth quarter of 2018 to reduce the remaining net book value of the U.S. asset to zero.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an intellectual property dispute with Forward Pharma in the European Union (E.U.) concerning intellectual property related to TECFIDERA. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the European Patent Office (EPO) revoked Forward Pharma&#8217;s European Patent No. 2 801 355. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for June 2020. Based upon our assessment of this ruling, we continue to amortize the remaining net book value of the rest of world intangible asset in our consolidated statements of income utilizing an economic consumption model. The remaining net book value of the TECFIDERA rest of world intangible asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2293-wk-Fact-E4C1FC14499CDABFA6306F38B81DCCAE" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the dispute with Forward Pharma in the E.U., please read Note 20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D Related to Business Combinations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life and amortize these amounts based upon an economic consumption method. The carrying value associated with our IPR&amp;D assets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Limited (Convergence), Stromedix Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN) in 2019, 2015, 2012 and 2010, respectively. IPR&amp;D balances include adjustments related to foreign currency exchange rate fluctuations.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-99BD60AB4ED2AABE17936F38B8E13EAD-3" continuedAt="TextSelection-99BD60AB4ED2AABE17936F38B8E13EAD-4"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long-range planning cycle, which was most recently updated in the second quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&#160;&#160;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of NST in June 2019, we acquired IPR&amp;D programs with an estimated fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2329-wk-Fact-82604D074397E99D730A7EE181675AC1" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">700.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">BG00011</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of idiopathic pulmonary fibrosis (IPF) due to safety concerns. As a result, we recognized an impairment charge of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2343-wk-Fact-C90610768443E1F0F6317F831C0B9606" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2019 to reduce the fair value of the IPR&amp;D intangible asset to zero. We also adjusted the value of our contingent consideration obligations related to this asset resulting in a gain of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2347-wk-Fact-96B220D7911BA8C5D11B7F8F096174C3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter of 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Vixotrigine</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the potential treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR. As a result, we recognized an impairment charge of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2357-wk-Fact-6B94FF0E1EF87647F2456F38B81FA37B" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_PLSRMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2018 to reduce the fair value of the related IPR&amp;D intangible asset to zero. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN as we awaited the outcome of ongoing interactions with the FDA regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy. We reassessed the fair value of the TGN program using reduced expected lifetime revenues, higher expected clinical development costs and lower cumulative probability of success. As a result of that reassessment, we recognized an impairment charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2364-wk-Fact-62518CD3536763C588746F38B8229656" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">129.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2018 to reduce the fair value of the TGN IPR&amp;D intangible asset to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2368-wk-Fact-92077CE971E61FD7333E6F38B8AF7674" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q3_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The IPR&amp;D impairment charges were included in amortization and impairment of acquired intangible assets and the gain resulting from the remeasurement of our contingent consideration obligation was recorded in (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income. The fair value of the intangible assets and contingent consideration obligations were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues, costs and probabilities of success.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the second quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="TextSelection-9C8568245F5583FE04CA6F38B8E0A841-0-wk-Fact-4F83D5382DABAFFA03906F38B8B1EE25" continuedAt="TextSelection-9C8568245F5583FE04CA6F38B8E0A841-1" escape="true">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9C8568245F5583FE04CA6F38B8E0A841-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e2443-wk-Fact-200089F11B8DA6B74B1D6F38B7F70E07" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e2458-wk-Fact-0F163071339723968F596F38B7F8F5C1" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e2478-wk-Fact-395237A1C58F7524DD016F38B7F70B84" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">225.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e2498-wk-Fact-61656FE5DD1FDCA426E56F38B7F85E81" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">230.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e2518-wk-Fact-747F3B69343A6D3953D56F38B7F78A97" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-99BD60AB4ED2AABE17936F38B8E13EAD-4" continuedAt="TextSelection-99BD60AB4ED2AABE17936F38B8E13EAD-5"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfGoodwillTextBlock" id="TextSelection-7EB297BCF3C73DE434486F38B8E1B425-0-wk-Fact-3D58A57FA90251447EE66F38B7C59CA4" escape="true"><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e2665-wk-Fact-E7AAD5AF93A3B138C23D6F38B839DA15" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,706.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e2684-wk-Fact-0953C5B7CA793B642E7F6F38B875B561" name="us-gaap:Goodwill" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,632.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e2699-wk-Fact-71020C1F7736B6CF6FC66F38B7AFB71D" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">117.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e2718-wk-Fact-E0120A450E5719C33F066F38B87FFF71" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,080.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51024678e2738-wk-Fact-70778140A835211D559A6F38B8C700DB" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e2758-wk-Fact-3F4BF4DDAF919884DABA6F38B7A73815" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e2778-wk-Fact-666206ACF5FD1CF8210E6F38B7AF1BAD" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51024678e2797-wk-Fact-3BE55DA4EB7A677936746F38B7A3DB52" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51024678e2823-wk-Fact-0B1007097B5E08446E1E6F38B840631D" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,757.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e2842-wk-Fact-E7AAD5AF93A3B138C23D6F38B839DA15" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,706.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase to goodwill during </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase to goodwill during </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2876-wk-Fact-B14BB1896D500B5349FE6F38B8285E65" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestones achieved (exclusive of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2880-wk-Fact-B7E679FB7C54BDBC9E4C6F38B8383EBD" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">119.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in tax benefits) and payable to the former shareholders of Fumapharm AG and holders of their rights. In the fourth quarter of 2018 we achieved the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2884-wk-Fact-52F3177A7113406F4A0D6F38B8263878" name="biib:CumulativeSalesLevel" contextRef="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">20.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales level threshold and accrued the final contingent payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51024678e2888-wk-Fact-00B4683AD08C54F6AB9A0C84CED65C99" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to FUMADERM and TECFIDERA (together, the Fumapharm Products), which was paid in the first quarter of 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The elimination of goodwill represents an allocation based upon the relative fair value of our Hiller&#248;d, Denmark manufacturing operations at the divestiture date. In connection with the divestiture of our Hiller&#248;d, Denmark manufacturing operations, our remaining goodwill was reviewed for impairment, and based upon this review, no impairments were recognized. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51024678e2906-wk-Fact-75282F562CB5B1A31AA16F38B8685406" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill. </span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-99BD60AB4ED2AABE17936F38B8E13EAD-5">Other includes changes related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div><a id="s242EFA8E1BEA5A3DB777E361DD44D639"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-17926427357AC9421FAF6F38B8E1A3F8-0-wk-Fact-39C1B03C36FAA051D4B46F38B8682FFE" continuedAt="TextSelection-17926427357AC9421FAF6F38B8E1A3F8-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-D18453EBD284594A49C06F38B8E12CD3-0-wk-Fact-382434371F926A3C1E126F38B8842AE2" continuedAt="TextSelection-D18453EBD284594A49C06F38B8E12CD3-1" escape="true"><ix:continuation id="TextSelection-17926427357AC9421FAF6F38B8E1A3F8-1" continuedAt="TextSelection-17926427357AC9421FAF6F38B8E1A3F8-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1538-wk-Fact-EC9258146D77A8509D4A6F38B85AB46E" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,541.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1557-wk-Fact-C0EDD3E1836D4F554E976F38B8512EB6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1576-wk-Fact-F6993B6A07451D31C2816F38B852F514" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,541.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1596-wk-Fact-D9D82276CB0A34D035ED6F38B84D887D" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1693-wk-Fact-EE2725F5ABCD06330BDB6F38B850343B" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,695.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1712-wk-Fact-7DDF33C226B4FEA28B356F38B890358B" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1731-wk-Fact-C1B61E94DB40BA9C1EF86F38B84FA38C" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,695.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1751-wk-Fact-0AB90965DA3A51E629136F38B8520920" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1771-wk-Fact-BB81D28A818D61B7F9C56F38B853BBCB" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,013.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1790-wk-Fact-ECE628EF0E7F5557F9EA6F38B85436D4" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1809-wk-Fact-C47E75F1901532A2D33E6F38B88DA9FF" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,013.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1829-wk-Fact-73A593FB899D23F0F6FA6F38B85E868A" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1849-wk-Fact-CDC833E9D8E5798F6C086F38B85A1A4E" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">261.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1868-wk-Fact-0E0227789BD7E61B7CBE6F38B85350F1" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1887-wk-Fact-38B96DB4487EB6D0D6506F38B88F5211" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">261.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1907-wk-Fact-AFA9B75D9FCFA0C4CD4E6F38B855801F" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1927-wk-Fact-75BD645E58686BC7DF086F38B88E19D3" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">337.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1946-wk-Fact-148D6A4A23ED02B89C5F6F38B84C8D5C" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1965-wk-Fact-82305A531B9DADFE49596F38B892A48C" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">329.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e1985-wk-Fact-8080A8035109E43370386F38B8563DF1" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2005-wk-Fact-FC186D031C3543E76EDD6F38B85939A1" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2024-wk-Fact-27E2FED8EF080B4CEF2C6F38B852EDCE" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2043-wk-Fact-569815B4283E15978A5D6F38B8507840" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2063-wk-Fact-D382C2D4C27C1B6563F36F38B88FD6DC" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2083-wk-Fact-F49B5B9071D0CE36CFCB6F38B851A3D9" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2102-wk-Fact-152F682FD573AD841C476F38B84C7C97" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2121-wk-Fact-7C26DE24B15654FB9BA76F38B88F8D37" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2141-wk-Fact-5F904C78B213E79C53C16F38B8911ED8" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2166-wk-Fact-BBAF8FE2318EE27C5ECB6F38B85B60F7" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,920.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2185-wk-Fact-C689AE60EC7AFC7E85BC6F38B84ED892" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2204-wk-Fact-FFDDF10B2C1E2AAA6A206F38B84F3259" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,912.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2224-wk-Fact-4D7CEA22B015CD4196D66F38B85209EB" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2327-wk-Fact-8C6CF39828C652CAA4A06F38B88EF8CD" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2346-wk-Fact-6334288060FBC89E46266F38B85A34FC" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2365-wk-Fact-0FD9268BA3776F2B89016F38B851368A" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2385-wk-Fact-E76ACDF87C147D10A42C6F38B854110E" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2400-wk-Fact-A10F6A8B85523CF3F7F86F38B84D8473" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2419-wk-Fact-C12EE914E4EAC5A9C0656F38B84C0FE8" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2438-wk-Fact-67DE65816E41FA577CCB6F38B851EBC9" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2458-wk-Fact-98019CA6F4F46E58F06A6F38B84EAD9F" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2483-wk-Fact-C330140DBC1BE65A98526F38B8540F0A" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">354.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2502-wk-Fact-BE5B60068B92D653D43A6F38B851DCA9" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2521-wk-Fact-55BFF459F1207C4E5E6B6F38B8501D48" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e2541-wk-Fact-51F232D0E20F8EB1419C6F38B85416BC" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-17926427357AC9421FAF6F38B8E1A3F8-2" continuedAt="TextSelection-17926427357AC9421FAF6F38B8E1A3F8-3"><ix:continuation id="TextSelection-D18453EBD284594A49C06F38B8E12CD3-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e2782-wk-Fact-7066379BD1A122AE212C6F38B7FF4D18" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e2801-wk-Fact-1FC555EC02578EFE4E236F38B7A5D468" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e2820-wk-Fact-A18D399B01FAF16D4A736F38B7F4F29D" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e2840-wk-Fact-AEC23130A93B349F00636F38B7FA8322" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e2937-wk-Fact-DC0AECE32297AC1D00136F38B8153FBA" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,459.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e2956-wk-Fact-632D7F1114B4609849D36F38B80FE9AF" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e2975-wk-Fact-CB17C242A467DB7596436F38B8853B59" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,459.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e2995-wk-Fact-F0814ACED7E8DBD5D5436F38B810DDE0" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3015-wk-Fact-FD6242F3725B6137E3E96F38B8B9F6F1" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">969.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3034-wk-Fact-655F2172AC92567F2F5B6F38B7ADB408" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3053-wk-Fact-EDBEA891E156890AEE0B6F38B7B2B15A" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">969.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3073-wk-Fact-4614A717FC48F3D890BE6F38B8B0297B" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3093-wk-Fact-8DFC21527B6A71EF8CC56F38B809EA4D" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3112-wk-Fact-A3C922C7F774CC6E33986F38B8B528FB" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3131-wk-Fact-1EEBD29C1636DC3AD73A6F38B7F6FC21" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3151-wk-Fact-3C29A0E494BD1CCE09066F38B7B0DAB0" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3171-wk-Fact-02629FE4358DD9094CCE6F38B7ACADD3" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">615.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3190-wk-Fact-18F308766DE279481A656F38B7A8867C" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3209-wk-Fact-C615210C0C666FD0FB676F38B866E20F" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">563.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3229-wk-Fact-EDB6E812C8742BD336E46F38B7B2ABA8" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3249-wk-Fact-61EC83DAACBFB9B470886F38B7E4DB90" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3268-wk-Fact-544258B85EA2A94192166F38B8839BA6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3287-wk-Fact-140AE2CF9DDD5779CDA56F38B80F5E13" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3307-wk-Fact-2CC73AD2FCBFD5E279876F38B7AECD84" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3327-wk-Fact-2F2C777FB878339C66176F38B7B3A968" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3346-wk-Fact-FA109492FEBA88B300696F38B8116A5C" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3365-wk-Fact-C22AADAA8DBB01CE21DE6F38B813B895" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3385-wk-Fact-F4AF2B25A8E7DCC31D826F38B8BE8F7B" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3410-wk-Fact-AA67EA863E25380A58166F38B7A76C3B" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,102.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3429-wk-Fact-BE71513E9CA27ADFC3866F38B810644A" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3448-wk-Fact-81EDECD226AA6FBF647F6F38B7B3CF78" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,050.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3468-wk-Fact-30E8FDFFD51F491BA6236F38B7B5B93D" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3571-wk-Fact-03E95DF04DD8C94FACFC6F38B7AC6B61" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3590-wk-Fact-24A4920ADE5088A089046F38B80D45A2" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3609-wk-Fact-5D8FBC53D5A9017C794D6F38B7E5F1B1" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3629-wk-Fact-E78A97B2CE06EC055E3D6F38B7AB700A" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3644-wk-Fact-4CBE27413C3EDEA117916F38B7AB7C4F" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3663-wk-Fact-C6760C7C98C35A581B576F38B816A4D7" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3682-wk-Fact-9EA89F642293CDE2C3466F38B7A8EB74" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3702-wk-Fact-A7480D911796580F012E6F38B883744D" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3727-wk-Fact-E21BB8206966B528A1A96F38B7B96660" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">434.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3746-wk-Fact-F33FB8DF7F99068F43606F38B7A7707B" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3765-wk-Fact-1B00161C63AA6B85F13F6F38B80E7CA4" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3785-wk-Fact-581739A6C39ADF7DBDB96F38B800E5CF" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </span><span><ix:nonNumeric id="d51035532e3803-wk-Fact-4D4C5D0C76D36F50A349F0A34ECC1A00" name="us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">no</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or transfers between fair value measurement levels during the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our collaboration arrangements with Ionis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="TextSelection-BE2A1D4443B5D4661F4F6F38B8E1C53A-0-wk-Fact-B0702C79A1D818C1BAF56F38B7E83F89" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e3955-wk-Fact-C42B399BF1898948B2D86F38B891F112" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,509.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e3974-wk-Fact-B3B52DE23849508B0B4E6F38B8913386" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,489.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e3989-wk-Fact-D2B809557FDB244752996F38B8947CAC" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,038.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e4008-wk-Fact-05177D675BB7590DA7426F38B89015AE" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,000.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e4028-wk-Fact-4E62F59C14B398A4E6BD6F38B89235A4" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,897.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e4047-wk-Fact-BDFDE0697E29B5C39B0B6F38B8901FF9" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,745.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e4067-wk-Fact-D76875A72D97919255A46F38B8928CA8" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,107.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e4086-wk-Fact-739E99003183BF386DF16F38B8901AF8" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,802.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e4111-wk-Fact-B67478805A82134060856F38B892A4C8" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,553.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e4130-wk-Fact-69AB32B1F3AAD4D403D96F38B890B442" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,037.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix and BIN in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="TextSelection-F8B83E8D25CA0D0309176F38B8E19FEE-0-wk-Fact-C60548148E5F11FC19416F38B81DD489" continuedAt="TextSelection-F8B83E8D25CA0D0309176F38B8E19FEE-1" escape="true">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F8B83E8D25CA0D0309176F38B8E19FEE-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e4271-wk-Fact-4CBE27413C3EDEA117916F38B7AB7C4F" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e4290-wk-Fact-E13D65BE0BFFDEB212A06F38B83B8926" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">523.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51035532e4305-wk-Fact-1823324BEE5AA206F4236F38B832A514" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51035532e4325-wk-Fact-977CCFE1B549EEAAE2F26F38B8745977" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e4346-wk-Fact-1C082769A24C4F5A17026F38B83DA9E5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51035532e4365-wk-Fact-6B14B2072094EAE02A5D6F38B83CD501" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">101.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51035532e4391-wk-Fact-A10F6A8B85523CF3F7F86F38B84D8473" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e4410-wk-Fact-4CBE27413C3EDEA117916F38B7AB7C4F" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4438-wk-Fact-0107656A82B694AD32DF6F38B8315091" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">197.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4442-wk-Fact-572C4D0ED257CDB07A6E6F38B81D2A82" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2018Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">265.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-17926427357AC9421FAF6F38B8E1A3F8-3" continuedAt="TextSelection-17926427357AC9421FAF6F38B8E1A3F8-4"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of IPF resulting in a reduction of our contingent consideration obligations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4456-wk-Fact-96B220D7911BA8C5D11B7F8F096174C3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, partially offset by changes in the probability and expected timing of achievement of certain developmental milestones, a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of achievement of milestones related to the TGN program and an increase in discount rates used to revalue our contingent consideration liabilities, partially offset by the passage of time. For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, payments and other reflects an </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4471-wk-Fact-920EF404A5465C38E5D86F38B824C4C0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">81.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment made to the former shareholders of Stromedix. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of the contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Convergence Pharmaceuticals Holdings Limited</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4488-wk-Fact-30E2D56393376CCAD3CF6F38B82E36B2" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">274.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4500-wk-Fact-BE914F8B9FEE22331A776F38B81E88FB" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">244.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4504-wk-Fact-867A7DC3CFA3B0DF94256F38B8226B63" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">246.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash flow projections of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4509-wk-Fact-54A6AF67038662FE8BCE6F38B8A1038C" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">400.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e4513-wk-Fact-1D4B0CA927D10DE2CE256F38B8246AE3" name="biib:FairValueMeasurementInputs" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.1</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in our contingent consideration obligation was primarily due to changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones, partially offset by a decrease in discount rates used to revalue our contingent consideration liabilities and the passage of time. Accrued expenses and other in our consolidated balances sheets include </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4528-wk-Fact-06F8823C5C30121355FB6F38B859ABAE" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as we expect to make the payment within one year.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Stromedix Inc.</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Stromedix in March 2012 we recorded a contingent consideration obligation of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4538-wk-Fact-724C1824631E20BDD6C76F38B86D0976" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="FD2012Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">122.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF due to safety concerns. As a result, we adjusted the fair value of this contingent consideration obligation to zero, resulting in a gain of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4542-wk-Fact-96B220D7911BA8C5D11B7F8F096174C3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter of 2019. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4550-wk-Fact-793CC6F3B179192134706F38B88D3F53" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen Idec International Neuroscience GmbH</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4561-wk-Fact-B8D8A4EABED9B5C813466F38B84B025D" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="FD2010Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4573-wk-Fact-9F894064E55EE73F5EA86F38B7E64F02" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">101.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4577-wk-Fact-49A54CE2D062190C77266F38B85A20C6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash outflow projections of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4582-wk-Fact-DB35B8C424CD465606046F38B82E6ED4" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">335.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51035532e4586-wk-Fact-8A658ABCA5EFAB81986B6F38B82A37A9" name="biib:FairValueMeasurementInputs" contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.3</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in our contingent consideration obligation was primarily due to changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones, a decrease in discount rates used to revalue our contingent consideration liabilities and the passage of time. No amounts are reflected as a current liability in our consolidated balance sheets at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as we do not expect to make a payment in the next year.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired IPR&amp;D</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of the acquired IPR&amp;D assets were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. These assets are tested for impairment annually until commercialization, after which time the acquired </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-17926427357AC9421FAF6F38B8E1A3F8-4"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D will be amortized over its estimated useful life using the economic consumption method. In connection with our acquisition of Stromedix, we recognized a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4614-wk-Fact-FE43F80CB27D3FFF9E0D93D1315B1342" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="FI2012Q1_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">219.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> acquired IPR&amp;D intangible asset. During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF due to safety concerns and recognized an impairment charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4618-wk-Fact-C90610768443E1F0F6317F831C0B9606" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reduce the fair value of the IPR&amp;D intangible asset to zero. In connection with our acquisition of Convergence we recognized a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4622-wk-Fact-76351957F1E1DE2032BB6F38B7E3ACBA" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">424.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> acquired IPR&amp;D intangible asset. During the third quarter of 2018 we recognized impairment charges related to certain IPR&amp;D assets associated with our vixotrigine program totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51035532e4626-wk-Fact-6D50742932615A5BE2716F38B844A09D" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">189.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our IPR&amp;D intangible assets, including a discussion of our most significant assumptions, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:continuation><div><a id="sD33AFA39AB0A5D43BA196AC92DE04D40"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="TextSelection-C333F93EB0D11B0846F16F38B8E2A9CE-0-wk-Fact-E143E08BEEF1049774636F38B8B46C63" continuedAt="TextSelection-C333F93EB0D11B0846F16F38B8E2A9CE-1" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-C333F93EB0D11B0846F16F38B8E2A9CE-1" continuedAt="TextSelection-C333F93EB0D11B0846F16F38B8E2A9CE-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="TextSelection-B5F7DFAC0C3D284D63E56F38B8E196EF-0-wk-Fact-E55C97626BB3026608AC6F38B8B75180" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </span><span><ix:nonNumeric id="d51044137e1304-wk-Fact-8231AA510DC926D15A2D6F38B8B1428F" name="us-gaap:DebtInstrumentMaturityDateDescription" contextRef="FD2019Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">less than 90&#160;days</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1424-wk-Fact-BD1F39C0A6E101800CF06F38B8029320" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">384.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e1443-wk-Fact-DF3C5F781F9601E153906F38B7FE33BE" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">231.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1458-wk-Fact-DD6060CCFB1172CE3C8A6F38B8047EC4" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">368.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e1477-wk-Fact-4D359C9051066803D9AE6F38B7FC0023" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1497-wk-Fact-995379A87E623A9C8B356F38B7FF1B2D" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,628.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e1516-wk-Fact-BC251230685EC89EFFA16F38B7FEA342" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">279.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1536-wk-Fact-8E93462D8487551B1DC66F38B803C15B" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">159.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e1555-wk-Fact-A22A1FC75E3FB4DD217E6F38B8030BA2" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">194.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1580-wk-Fact-357953AE9799FBE6CE586F38B7FD6616" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,541.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e1599-wk-Fact-72F8FDC4D34E0E09E26F6F38B7FD5F30" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities gains (losses) are recorded in other income (expense), net in our consolidated statements of income. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="TextSelection-5A72E2605693FD043BEE6F38B8E2854D-0-wk-Fact-C5D1DA78D6A047029F2B6F38B8B5AECD" continuedAt="TextSelection-5A72E2605693FD043BEE6F38B8E2854D-1" escape="true">The following tables summarize our marketable debt and equity securities, classified as available for sale:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-5A72E2605693FD043BEE6F38B8E2854D-1" continuedAt="TextSelection-5A72E2605693FD043BEE6F38B8E2854D-2"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1847-wk-Fact-499BCBCDFA7161162B7B6F38B8C2A23D" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,057.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1866-wk-Fact-E1640AC93A688483020D6F38B8BB439D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1885-wk-Fact-2BF9EE5393947905DEF16F38B8BD1C98" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1905-wk-Fact-72BE606195F640491DD36F38B8B733F8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,058.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1920-wk-Fact-DCA62FB5A695DF208DC96F38B8BE8ABF" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">633.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1939-wk-Fact-F2F305B920B30862AAA46F38B8BB8F9D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1958-wk-Fact-0EAED0B47CFCBAD00CCC6F38B8BE2693" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e1978-wk-Fact-8BFED5455B9C725819236F38B8B8CD8D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">636.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2080-wk-Fact-B5ECD264FC84041711ED6F38B8B78097" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">502.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2099-wk-Fact-D9610289F4D33C55FFF56F38B8B603A4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2118-wk-Fact-0125DCCA5F45BBCC43246F38B8B6FCFA" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2138-wk-Fact-AC67B65856A432CC36C66F38B8BB83A8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">503.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2158-wk-Fact-61A5E1A99439DE57C5E36F38B8BC9487" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">510.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2177-wk-Fact-FADD5F5B48CAB54CDBE86F38B8BDC234" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51044137e2196-wk-Fact-B4D502692B65FBEA76216F38B8B9F58E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2217-wk-Fact-399A53AA1C7B57A139E36F38B8BD97DD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">510.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2319-wk-Fact-037C5769F3CB157047D56F38B8BC38A5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2338-wk-Fact-EEDBF86DFD6E6DF594F16F38B8B72B9E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2357-wk-Fact-ADF496AAE7893D618D8C6F38B8B8FB8F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2377-wk-Fact-B48911120D075BFD3A9D6F38B8B815DB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2397-wk-Fact-D451502CBFF668E854066F38B8B6FB61" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2416-wk-Fact-FFDB8024DA8C692EDFF96F38B8B7614D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51044137e2435-wk-Fact-A025048BE07F39FDF5336F38B8BA1A78" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2456-wk-Fact-0BB584C0303018C7AD6C6F38B8BC7BC3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2481-wk-Fact-F9D36A0CB178A1F1D6766F38B7EC70D8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,965.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2500-wk-Fact-A6EDAB71C71AC15906D46F38B8BACFAD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51044137e2519-wk-Fact-8750CE4F362D33737E1C6F38B8BA7F39" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2540-wk-Fact-09218CCAD46CA9CF6A4C6F38B86B23BF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,970.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2561-wk-Fact-CDB6C6B5B81A1C186FCB6F38B8B865A5" name="us-gaap:EquitySecuritiesFvNiCost" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">218.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2580-wk-Fact-C5F1FB95DB08B92097976F38B8B8D668" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51044137e2599-wk-Fact-B5A9831670533F21DE9C6F38B8BCD2CB" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e2620-wk-Fact-26E2C7EA882598294EFC6F38B8BA256B" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">337.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-C333F93EB0D11B0846F16F38B8E2A9CE-2" continuedAt="TextSelection-C333F93EB0D11B0846F16F38B8E2A9CE-3"><ix:continuation id="TextSelection-5A72E2605693FD043BEE6F38B8E2854D-2"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e2846-wk-Fact-80F3CAB0D5F744F370C36F38B89EE9AD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,608.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e2865-wk-Fact-360611FC5D942991413A6F38B89E8CA6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044137e2884-wk-Fact-E89DE0338FD1F58C5B656F38B89893ED" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e2905-wk-Fact-CB2E3F7E5FE62BF1896A6F38B8A20697" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,607.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e2920-wk-Fact-F1D6C18E812A0BF007336F38B89ED934" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">854.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e2939-wk-Fact-81D0D887B4A7804D91F06F38B89D15D5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044137e2958-wk-Fact-DC230E025AEB8132D23C6F38B89F5719" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e2979-wk-Fact-45B824EA7434337FF27B6F38B892D649" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">851.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3081-wk-Fact-FA72D75A8CCEEF7E57196F38B89E2253" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">706.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3100-wk-Fact-1BC4EBAA2F4F4EA705906F38B892D761" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044137e3119-wk-Fact-6ABEA62478C33DF326A56F38B89611FE" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3140-wk-Fact-4F0323AC2FDD3D7A3BF56F38B8940D02" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3160-wk-Fact-38F396ADBA1C8634B5636F38B89C4151" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">264.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3179-wk-Fact-5868C1668606EF0682106F38B89389A2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044137e3198-wk-Fact-B46981E1891E0618C6D36F38B89BD766" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3219-wk-Fact-27B11F2D7A6A920E511A6F38B8953529" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">263.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3321-wk-Fact-EEAED65C2D12FC36748A6F38B898A436" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3340-wk-Fact-904214979D307A17D3416F38B895E2A7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3359-wk-Fact-20A25FC23E278823D8DC6F38B896123C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3379-wk-Fact-CDEA0C0C71658E6E63056F38B8972AF7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3399-wk-Fact-54D22EFA48C2C609B7FA6F38B8A0B5B8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3418-wk-Fact-200BCC83220232E9105C6F38B895A6C8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044137e3437-wk-Fact-2918168DB16D901EFC366F38B897C5E2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3458-wk-Fact-7F1A94F3577CE236BC216F38B8A0EB34" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3483-wk-Fact-8011E5D75A472C102B556F38B86C2B35" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,694.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3502-wk-Fact-9658045F6AE0A83E6BCA6F38B896BA8B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044137e3521-wk-Fact-344C4E37506D463167EE6F38B893B426" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3542-wk-Fact-DA378162924C6E8185866F38B867BA25" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,689.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3563-wk-Fact-9A1781D4961FADC5DD8F6F38B8A04118" name="us-gaap:EquitySecuritiesFvNiCost" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">496.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3582-wk-Fact-1F943AC009C6CA9CB8306F38B89C969E" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044137e3601-wk-Fact-EA583EB5D882938547046F38B89F85AC" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3622-wk-Fact-4A497BE42A7A0770B68A6F38B89F6DDF" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">615.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-E99A927E3431E726A7196F38B8E24431-0-wk-Fact-D097DFA1546017030E2A6F38B8B62ED1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e3860-wk-Fact-8E7C177DAA02C71040B26F38B86AD9EF" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,562.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e3879-wk-Fact-88C164EEF8973C79F5206F38B86A35F6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,560.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3898-wk-Fact-EBE178038FF6C4118D6D6F38B86B3749" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,313.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3918-wk-Fact-DAD4020BCE622F9576F56F38B8674CC9" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,314.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e3933-wk-Fact-4945B89ECB0F351F61A36F38B86B73CB" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,234.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e3952-wk-Fact-CEE7E030A0D8B5A888B56F38B869CCA1" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,230.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3971-wk-Fact-E25B7DE7CFEC25358FB16F38B8603BE6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,232.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e3991-wk-Fact-7937243CF0F75852BFF56F38B8691A7F" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,235.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e4011-wk-Fact-6A0F20E0E0A5CDFE5E426F38B86912AC" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">173.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e4030-wk-Fact-1D77144E73C658D1A2126F38B7EDDC04" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">173.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4049-wk-Fact-59F5101A3A2879A604296F38B86CC09D" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">143.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4069-wk-Fact-0166A7986CBB236C34DA6F38B8658555" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">143.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e4094-wk-Fact-09218CCAD46CA9CF6A4C6F38B86B23BF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,970.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e4113-wk-Fact-F9D36A0CB178A1F1D6766F38B7EC70D8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,965.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4132-wk-Fact-DA378162924C6E8185866F38B867BA25" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,689.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4152-wk-Fact-8011E5D75A472C102B556F38B86C2B35" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,694.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51044137e4179-wk-Fact-F3EC85F2D74FFA7E1C696F38B8B296F4" name="biib:AverageMaturityOfMarketableSecurities" contextRef="FD2019Q4YTD" format="ixt-sec:durmonth">14</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;months and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51044137e4183-wk-Fact-9217D82551BA1B54B6CE6F38B8B48AE5" name="biib:AverageMaturityOfMarketableSecurities" contextRef="FD2018Q4YTD" format="ixt-sec:durmonth">12</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="TextSelection-021208C0A949526AE3736F38B8E1D49E-0-wk-Fact-0B7A6EB4995D768455936F38B8B379DB" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e4359-wk-Fact-9B2BAA05E503864359F46F38B864558E" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,007.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4378-wk-Fact-91236B58E7640EF128CE6F38B7B34236" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9,173.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4397-wk-Fact-D3A23249D5697F1852396F38B7BFFC17" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,565.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e4418-wk-Fact-3B95433C7554C0E3DCC46F38B7B110E9" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedGains" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4437-wk-Fact-FCAFA4592669D8A91F486F38B7B0CD63" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedGains" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4456-wk-Fact-E33EA6F236DF1BABE4076F38B7B2BDC5" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedGains" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044137e4477-wk-Fact-4CCC5518040988ACF0376F38B7B359BF" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4496-wk-Fact-BE272356E0A1EA689E236F38B7B03644" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4515-wk-Fact-976E7CF53C8B41C98F856F38B7B0841C" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to impairments recognized on certain of our available-for-sale marketable debt securities, sales of agency mortgage-backed securities, corporate bonds and government securities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044137e4561-wk-Fact-21A754B118FC5CD829BA6F38B8B7A9E2" name="biib:StrategicInvestmentPortfolio" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">393.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044137e4565-wk-Fact-281E4FDF61B6472841496F38B8B5CBBA" name="biib:StrategicInvestmentPortfolio" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-C333F93EB0D11B0846F16F38B8E2A9CE-3"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">  Our investments in equity securities include shares of Ionis common stock acquired in June 2018. This investment is classified as a Level 2 marketable security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effect of the holding period restrictions on our investment in Ionis common stock valuation are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends. The remainder of our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in our strategic investment portfolio for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily reflects our sale of a portion of our investment in Ionis common stock for approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044137e4586-wk-Fact-4585A0C5F296BA0EF92B7FC68D2C8F95" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">382.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as well as our sale of our investment in a non-marketable equity security, partially offset by an increase in the fair value of our remaining investment in Ionis common stock.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the June 2018 investment in Ionis common stock, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we exercised our option under our joint venture agreement with Samsung BioLogics to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4604-wk-Fact-DAB0787A25553AB213926F38B8B69EFC" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4608-wk-Fact-A46E758D060B3483184A6F38B8B7D2D3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4612-wk-Fact-1D9B164B83DF3A938B3E6F38B8B5E5B9" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044137e4616-wk-Fact-5DB725E3C58F19FD80EA6F38B8B392CA" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4631-wk-Fact-8B25F35DD4B8B6D130EE7FC9A21CE66B" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">670.8</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044137e4635-wk-Fact-F7C51D85CEA56380D0337FC9E125D2A2" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">580.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044137e4639-wk-Fact-D54A0203BB298D1A86707FCA1DE4971F" name="us-gaap:EquityMethodInvestments" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044137e4644-wk-Fact-17DCA88187EFC9B166DA7FCA47FC4B95" name="us-gaap:EquityMethodInvestments" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">680.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets within our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:continuation><div><a id="sFE0FB77F8F785FCE8214C3EF77DF587B"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="TextSelection-31C5FA1C9BF71F15525D6F38B8E26774-0-wk-Fact-68D27276F7646A4F03CE6F38B7BFB595" continuedAt="TextSelection-31C5FA1C9BF71F15525D6F38B8E26774-1" escape="true">Derivative Instruments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-31C5FA1C9BF71F15525D6F38B8E26774-1" continuedAt="TextSelection-31C5FA1C9BF71F15525D6F38B8E26774-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51044295e1309-wk-Fact-322A8E363F8F4AC741F86F38B84945FB" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durmonth">1</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51044295e1313-wk-Fact-9DA025E88F4CEAA204886F38B7C1912E" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durmonth">15</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51044295e1317-wk-Fact-4445A6B770DAC40FBF306F38B8191CC7" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durmonth">1</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51044295e1322-wk-Fact-B166FDEC738C790EC53B6F38B7C0A4E8" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durmonth">12</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-31C5FA1C9BF71F15525D6F38B8E26774-2" continuedAt="TextSelection-31C5FA1C9BF71F15525D6F38B8E26774-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="TextSelection-4EC23AA84A35C9473B546F38B8E28F6E-0-wk-Fact-6C8EE6B0C078BAD9BD196F38B8142FD2" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e1450-wk-Fact-01060BEB3FFC6FDD9D0E6F38B7E66D87" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,892.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e1469-wk-Fact-C8FBC61236F0662265186F38B7E5606D" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,701.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e1484-wk-Fact-D465D1CEFCFF502D43D06F38B820F35C" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e1503-wk-Fact-28316E0CC9131D1BDF7D6F38B821B736" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e1523-wk-Fact-10DB29D0D2ACF88E58236F38B7ED0212" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e1542-wk-Fact-55B3847AAA7DF49559B56F38B7E6409C" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e1562-wk-Fact-5959E939060246CD68866F38B7EBB0F9" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e1581-wk-Fact-77897E8B689D13A798146F38B81D01B8" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">98.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e1601-wk-Fact-774F3E6DE4491836CC566F38B7E5EC7A" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e1620-wk-Fact-FBC0DBD746BC13CDDEBB6F38B7E99DEE" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">92.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e1645-wk-Fact-5B690B9CCC4A5E092FFA6F38B81CDF26" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,892.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e1664-wk-Fact-D25A1ADD28720BAD4E6A6F38B81C5438" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,239.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e1683-wk-Fact-D75AFD411EE46F08ACAC6F38B8993659" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e1693-wk-Fact-7D74CD4B51C415DEDD1E6F38B8115C73" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">27.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e1701-wk-Fact-98A1BCDDBBC2EE8EA0286F38B89FD15D" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">113.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We expect the net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e1710-wk-Fact-D75AFD411EE46F08ACAC6F38B8993659" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51044295e1714-wk-Fact-96309B39BDAAF66576016F38B89A9A52" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2019Q4YTD" format="ixt-sec:durmonth">15</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e1718-wk-Fact-A5F8F43BA2744D4183DC7FDF53B0299B" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2019Q4YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of these gains are expected to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51044295e1722-wk-Fact-E09D9C5760AA1B45491D7FDFC94A9A06" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2019Q4YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember" format="ixt-sec:durmonth">12</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="TextSelection-8FCDEE5F9B9BEF14AB586F38B8E2E680-0-wk-Fact-BB404B549937FA3C058E6F38B89BA2E3" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e2087-wk-Fact-5260522B2CD0BCFADAAF6F38B895D3B4" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">118.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044295e2106-wk-Fact-D42E285B8893C20236697FE3A907F9B8" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">42.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e2137-wk-Fact-A036F55C47EED3316C056F38B89704D2" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e2156-wk-Fact-C7119B5AA91BF351B91F7FE42522B7A5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51044295e2181-wk-Fact-A63AA220535E48DF3CEA6F38B89740CE" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e2201-wk-Fact-DA2F3E9D47228ED394387FE3AE7DD78E" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e2231-wk-Fact-423CCDCB7D50A90D707D6F38B8989411" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044295e2250-wk-Fact-1DC9C850823BA1BB48A87FE42A290F7E" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized Directly into Net Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044295e2472-wk-Fact-9D4CBD668A22CCF2DF1A6F38B7B8ABB3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">32.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e2502-wk-Fact-5C003B6F019CF448767C6F38B7B897A5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e2527-wk-Fact-6A8CECD39C48F1B630B26F38B7BB5B4E" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044295e2556-wk-Fact-814B4029D7DAE9F381136F38B7BE2A46" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Swap Contracts</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e2585-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, as described in Note 12, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements, we entered into interest rate swaps with an aggregate notional amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e2593-wk-Fact-91634FBD8864B002F6BA6F38B805EA5A" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">675.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e2597-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. The carrying value of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e2601-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e2614-wk-Fact-9D14185955890E7019747FF3DD7958FA" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e2618-wk-Fact-318271C910C842B5982C7FE5B4A322B8" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e2622-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our consolidated statements of income. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-31C5FA1C9BF71F15525D6F38B8E26774-3" continuedAt="TextSelection-31C5FA1C9BF71F15525D6F38B8E26774-4"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e2632-wk-Fact-DAB0787A25553AB213926F38B8B69EFC" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e2636-wk-Fact-A46E758D060B3483184A6F38B8B7D2D3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e2640-wk-Fact-1D9B164B83DF3A938B3E6F38B8B5E5B9" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e2644-wk-Fact-5DB725E3C58F19FD80EA6F38B8B392CA" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate these currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51044295e2655-wk-Fact-DF2BDBB8970976C6E4F26F38B89F1AE7" name="us-gaap:DerivativeTermOfContract" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" format="ixt-sec:durmonth">10</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e2659-wk-Fact-3178A6E613BDE080179B7FE8DCDCECF4" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e2663-wk-Fact-82EFE079072AC128382F6F38B7C47C93" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e2676-wk-Fact-2BB9F9545D64078F5B5D7FE90C425A93" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e2680-wk-Fact-A89E9C631799C85213276F38B80E93D7" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-E571C744E817334A4F746F38B8E260E2-0-wk-Fact-CEC27C0A941BCE574AD36F38B7C21D85" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of our net investment hedges in our consolidated financial statements:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51044295e3212-wk-Fact-29FEB4AE3F94AEBB937F7FEDB1AE4E7B" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044295e3231-wk-Fact-3CBA00191B363CB2E3E57FEDE96562ED" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51044295e3262-wk-Fact-A5C28CFDE1FB3632C9D07FEFA6057756" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e3281-wk-Fact-C1157379E3EC9063E8B47FEFCDE19CE6" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51044295e3311-wk-Fact-9C67F2B02D3E94F8D9B87FF069EFBCB1" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e3330-wk-Fact-546CFE2C88A2882395047FF08CC03A8C" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e3363-wk-Fact-FA3AF1C953859101D3A56F38B80C7CD9" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">793.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e3367-wk-Fact-ADB46BC448BE107A13646F38B8096BC5" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">735.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e3371-wk-Fact-83B9DCA80B7E3348A6D16F38B7BF4413" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e3376-wk-Fact-5CD833AC352FD4AABED36F38B817E110" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044295e3380-wk-Fact-6113D2CEAC14628723796F38B818ABC0" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recorded as a component of other income (expense), net, for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivative Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="TextSelection-821FDF2E9F0DAD91AAA66F38B8E23A78-0-wk-Fact-E0008F9442FAD27741DD6F38B7C8BB93" escape="true"><ix:continuation id="TextSelection-31C5FA1C9BF71F15525D6F38B8E26774-4"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br/>As of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br/>As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e3573-wk-Fact-5B3355CCF2387046704F6F38B8360FD9" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e3592-wk-Fact-131E482AD083DEA7EB927FF47BCE3FF8" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e3627-wk-Fact-58E214ACCAB56FD047A76F38B834C61C" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e3646-wk-Fact-8C9312E633030F7ACD497FF483800B72" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e3681-wk-Fact-C968C9C18AA1750428DDE8A9A2526617" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e3700-wk-Fact-3B20DED08C9C19115855E8AA194DA7A2" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Net Investment Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e3791-wk-Fact-4DE8D84271D5CA1BA8CEE8AB1620F687" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e3810-wk-Fact-89880E7343C312FC8187E8AD626F7892" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e3901-wk-Fact-9D14185955890E7019747FF3DD7958FA" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e3920-wk-Fact-ECBD79681239A276DA737FF487B5E566" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e3955-wk-Fact-8C2D3ACDED3B8964DCB96F38B8360841" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e3974-wk-Fact-318271C910C842B5982C7FE5B4A322B8" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivative Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e4066-wk-Fact-108A7C9507D9361A6F876F38B8361CC2" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e4085-wk-Fact-FC5D1258F8E394E7C27F7FF48C686004" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044295e4120-wk-Fact-0B8B27042BA58742D28A6F38B83688AC" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044295e4139-wk-Fact-A1DB114E40FC36CD7ADF7FF490D291B6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div><a id="s66BEBE8F128059BC8713BFE3F32EFB73"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-5A065778407496A902036F38B8E3209A-0-wk-Fact-583FED3EF6F479C4F2FC6F38B86D775F" continuedAt="TextSelection-5A065778407496A902036F38B8E3209A-1" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="TextSelection-5A065778407496A902036F38B8E3209A-1" continuedAt="TextSelection-5A065778407496A902036F38B8E3209A-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-BBDC0E14965AF1D1D8FF6F38B8E3C430-0-wk-Fact-2EBF8AF6C6A2C7F240776F38B86C9010" continuedAt="TextSelection-BBDC0E14965AF1D1D8FF6F38B8E3C430-1" escape="true">Components of property, plant and equipment, net are summarized as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BBDC0E14965AF1D1D8FF6F38B8E3C430-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044285e1414-wk-Fact-4B49484BBFA4A6FCA3D36F38B805104F" name="us-gaap:Land" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">118.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044285e1433-wk-Fact-6BE2BD1A669AEE9100D16F38B7FB8F25" name="us-gaap:Land" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">144.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044285e1448-wk-Fact-7BDD6D60FC8F781E52FC6F38B7F9578F" name="us-gaap:BuildingsAndImprovementsGross" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">835.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044285e1467-wk-Fact-1A742A393FBFA7C01FE16F38B809798A" name="us-gaap:BuildingsAndImprovementsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,282.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044285e1487-wk-Fact-D24E333490A428E38D996F38B8063617" name="us-gaap:LeaseholdImprovementsGross" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">99.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044285e1506-wk-Fact-0DC1EF657D2F114AF7AA6F38B8074924" name="us-gaap:LeaseholdImprovementsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">94.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044285e1526-wk-Fact-3B68992FE1A598E60B6D6F38B7FE701C" name="us-gaap:MachineryAndEquipmentGross" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">844.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044285e1545-wk-Fact-B217FB97E6FF9A3C46F06F38B8061029" name="us-gaap:MachineryAndEquipmentGross" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,258.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044285e1565-wk-Fact-621204C2730CA9AC6A346F38B804A4D8" name="biib:ComputerSoftwareAndHardware" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">798.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044285e1584-wk-Fact-50185CBC3B73771789F46F38B80554E0" name="biib:ComputerSoftwareAndHardware" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">798.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044285e1604-wk-Fact-6B928379857C30DCD69F6F38B805F28B" name="us-gaap:FurnitureAndFixturesGross" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044285e1623-wk-Fact-F9184F78DDE45846EE276F38B7FFFE0F" name="us-gaap:FurnitureAndFixturesGross" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044285e1643-wk-Fact-3F3D01122035916260A86F38B8074B57" name="us-gaap:ConstructionInProgressGross" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,084.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044285e1662-wk-Fact-D750FA2C509ABF560CDD6F38B7F8299B" name="us-gaap:ConstructionInProgressGross" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,758.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044285e1682-wk-Fact-A988179B5A4A50D9029E6F38B7FA7DF9" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,838.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044285e1701-wk-Fact-18F5FDAB35FE9A151BE46F38B8000255" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,398.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51044285e1721-wk-Fact-48854B5A0D08098CE00C6F38B7FC4889" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,590.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51044285e1741-wk-Fact-31CD5C9D5B66334623C96F38B80A11EF" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,797.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51044285e1768-wk-Fact-CF1C2504DA7602F237C56F38B8445161" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,247.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51044285e1787-wk-Fact-366250CBE4B1855EC9FF6F38B83E3B1B" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,601.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation expense totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044285e1806-wk-Fact-E6AC2228D96AB11FAC5A6F38B86EDBA5" name="us-gaap:Depreciation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">190.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044285e1810-wk-Fact-4167CA96464ED73233176F38B86F4840" name="us-gaap:Depreciation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">269.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044285e1814-wk-Fact-5A0679B5555AF4201F236F38B8703906" name="us-gaap:Depreciation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">266.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we capitalized interest costs related to construction in progress totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044285e1846-wk-Fact-54FA55EDE8C97A3A61D66F38B86CF92D" name="us-gaap:InterestCostsCapitalized" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044285e1850-wk-Fact-9168C76B52E9B46B008C6F38B86E3F8B" name="us-gaap:InterestCostsCapitalized" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">54.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044285e1855-wk-Fact-20FD69DACAAEE20F65066F38B86FE9EA" name="us-gaap:InterestCostsCapitalized" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The increase in capitalized interest costs is primarily due to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, as discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Manufacturing Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044285e1873-wk-Fact-DCA742D8727EF6C110DC6F38B86E4271" name="us-gaap:ConstructionInProgressGross" contextRef="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.9</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044285e1877-wk-Fact-03000C2CA37F755F47206F38B871C590" name="us-gaap:ConstructionInProgressGross" contextRef="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.6</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-5A065778407496A902036F38B8E3209A-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044285e1894-wk-Fact-8A855AA40548BDD58AFE7FFA8BDE6119" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">631.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of property, plant and equipment, which was primarily comprised of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044285e1898-wk-Fact-45EE7F87D5BEF4AA169D7FFAD1A78A2C" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">312.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for buildings and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51044285e1902-wk-Fact-5C77A015F4A117A204F97FFB16A4C7A0" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">287.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for machinery and equipment. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:continuation><div><a id="s0dea3f00862a456da7948839aa0a2542"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-43A723FF06F4D4F7BD9BD256EB02EA17-0-wk-Fact-0E7EE0AC3F393CD7E015D25831F6E61D" continuedAt="TextSelection-43A723FF06F4D4F7BD9BD256EB02EA17-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="TextSelection-43A723FF06F4D4F7BD9BD256EB02EA17-1" continuedAt="TextSelection-43A723FF06F4D4F7BD9BD256EB02EA17-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease real estate, including laboratory and office space, and certain equipment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our leases have remaining lease terms ranging from less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51053068e1291-wk-Fact-98B103000C2354954A1DD25B8DAA9804" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51053068e1295-wk-Fact-C747ECF84F93AF17D27BD25D069E9418" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51053068e1299-wk-Fact-F49053B600A739414845D25E634C5BBA" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51053068e1303-wk-Fact-43DC8C4EC87A088951D9D25EC9CD3C9E" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen">six years</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51053068e1310-wk-Fact-325DF0C214489ABB5100D25F33858CEC" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_biib_SubleaseMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51053068e1314-wk-Fact-F31E080003FAE333EF0DD25F8FEF399A" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_biib_SubleaseMember" format="ixt-sec:durwordsen">nine years</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our subleases do not include an option to renew as they are coterminous with our operating leases.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:LesseeLeaseTableTableTextBlock" id="TextSelection-4732EE9A28730427D90FD2605903A336-0-wk-Fact-421B44518408CD64825AD262FABA93E2" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All of our leases qualify as operating leases. The following table summarizes the presentation in our consolidated balance sheets of our operating leases:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:41%;"></td><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1421-wk-Fact-FF6A7E1776F83C7A2D34D2657F134BC1" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">427.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1513-wk-Fact-138158BBE8B16C663BCCD267F943D212" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">73.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1538-wk-Fact-F0E5F5917B249CC4F8E6D268506563F2" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">412.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1573-wk-Fact-AD7CC2919CAEAFB3317ED27287CE9B7B" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">486.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-B1E6980692F0814E3037D269F5909227-0-wk-Fact-6BF9C981D75DC0B63261D26A17861D93" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of lease costs in our consolidated statements of income:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:41%;"></td><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the year ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1684-wk-Fact-E7EAB52CF08ACA66B1C8D26B5E4DA964" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1709-wk-Fact-EB31B3B8CD8116B07A1CD26B639EFDC0" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">84.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1739-wk-Fact-D1B3F6139ED547983EB6D26C3EB4AD33" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1769-wk-Fact-5438E2817981411124A4D26C3E806F38" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d51053068e1799-wk-Fact-F4FFEA457BF335D62736D26BB07929EC" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d51053068e1830-wk-Fact-0737D4062FEBE63A8C49D26BB3B5066E" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1866-wk-Fact-9B475C9DE28C7BFC7248D26D3E7D7D59" name="us-gaap:LeaseCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">86.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-43A723FF06F4D4F7BD9BD256EB02EA17-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Variable lease cost primarily related to operating expenses, taxes and insurance associated with our operating leases. As these costs are generally variable in nature, they are not included in the measurement of the operating lease asset and related lease liability.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-EBE2C51FF2B1DE2D897DD296468B3FE6-0-wk-Fact-C6B8F51C34C0FCCE69DFD29655E67564" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The minimum lease payments for the next five years and thereafter is expected to be as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1929-wk-Fact-325DB683CCCC3F3A1E95D27278B22168" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1944-wk-Fact-A33843634D22D121E0C5D27279CD6129" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1964-wk-Fact-C94182E27AD58B92D66AD2727AFBC849" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e1984-wk-Fact-C7CED10EF6BF06225152D2727C8E2D24" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">72.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e2004-wk-Fact-436B831B80AD7C621E1BD2727E11D345" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e2024-wk-Fact-663AE6F5A00DA383205AD272819532B1" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">158.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e2049-wk-Fact-20D97C274D5756C7D9CED27283C357EA" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">544.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e2064-wk-Fact-34DE3CB4391A7D254B13D27285EA5ECB" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e2089-wk-Fact-AD7CC2919CAEAFB3317ED27287CE9B7B" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">486.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="TextSelection-1A6A5459CD9F15B3F0D4D298717E3CE7-0-wk-Fact-95D18213C26B3A8A4F26D29880FC7251" continuedAt="TextSelection-1A6A5459CD9F15B3F0D4D298717E3CE7-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the five years and total thereafter as of December&#160;31, 2018, were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2296-wk-Fact-F448D524BB6C29BABB0BD285F180843C" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2315-wk-Fact-BD37721BE5760CE16941D285F4B3E6C5" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2334-wk-Fact-E65DF6F80C316715AC2ED285F8103315" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2354-wk-Fact-C134D2DCDEC1D134EC69D285FB29E17F" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2373-wk-Fact-26034169EA8E41FECE04D285FE6987A5" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2393-wk-Fact-C72105749996343CBEBBD28601A28DAB" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2412-wk-Fact-D27ADF44B904D08F9065D286050BB5C7" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">601.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51053068e2429-wk-Fact-197543281BAF214CAE83D286070B363C" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51053068e2449-wk-Fact-A1F3A611D2BEA4BB0093D2860B6CF75E" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51053068e2469-wk-Fact-905C9AF2725D9142C22AD2860E8FDA55" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51053068e2490-wk-Fact-F260C39FC952F5A5D6DDD2861135FC79" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51053068e2510-wk-Fact-563B5CB3AC9659E0D256D28613061385" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51053068e2530-wk-Fact-20388E6104F2DEBAE0A8D28615AA9673" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51053068e2551-wk-Fact-BA7D0A8595160868FD70D2861884AB31" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">182.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2577-wk-Fact-1A8B7EFC82003ABECC8DD2861A412721" name="biib:NetMinimumLeasePaymentsWithInOneYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2596-wk-Fact-97E7DE7EA108EC818068D2861F2B04F5" name="biib:NetMinimumLeasePaymentsWithInTwoYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2615-wk-Fact-2509EC043A89283223F5D2862057FC94" name="biib:NetMinimumLeasePaymentsWithInThreeYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2635-wk-Fact-487E6DB50BB15185A1ABD28622049F3C" name="biib:NetMinimumLeasePaymentsWithInFourYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2654-wk-Fact-507288293ED2543D7FECD28623850110" name="biib:NetMinimumLeasePaymentsWithInFiveYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2674-wk-Fact-8AD4395FFBA587A8A1F2D28625FE405F" name="biib:NetMinimumLeasePaymentsThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">156.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51053068e2693-wk-Fact-3B65BBB1394F99B9E0A0D28628C87F37" name="biib:NetMinimumLeasePayments" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">418.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-1A6A5459CD9F15B3F0D4D298717E3CE7-1" continuedAt="TextSelection-1A6A5459CD9F15B3F0D4D298717E3CE7-2"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-1A6A5459CD9F15B3F0D4D298717E3CE7-2"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </span></div></ix:continuation></td></tr></table><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" id="TextSelection-220A65F40BB0FEFF642BE8B0D9C0447A-0-wk-Fact-254228B0E2533195F093E8B132B665C6" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:83%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term in years</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonNumeric id="d51053068e2748-wk-Fact-B185DDB0D8D082FEC49EE8B1DEBE1587" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q4" format="ixt-sec:duryear">7.07</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e2763-wk-Fact-02809B82CC15FE28F9A8E8B1E03EA9CA" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q4" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock" id="TextSelection-3D28474708AB7D3C55F2E8B2F25F7C0F-0-wk-Fact-A9B0DC1A734E72159153E8B30CBA9305" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our consolidated statements of cash flows is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the year ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e2843-wk-Fact-3424A5BA918C9E081E4CE8B3C067116C" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">93.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51053068e2863-wk-Fact-E88D20030A558670E804E8B3C22CE54A" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 43</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD4C619F1D7455FB799213AD600E66891"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-6283D8B98CF253E607C86F38B8E3BDCC-0-wk-Fact-22BA89BB527A24EDD0C16F38B8C5857B" continuedAt="TextSelection-6283D8B98CF253E607C86F38B8E3BDCC-1" escape="true">Indebtedness</ix:nonNumeric></span></div><ix:continuation id="TextSelection-6283D8B98CF253E607C86F38B8E3BDCC-1" continuedAt="TextSelection-6283D8B98CF253E607C86F38B8E3BDCC-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDebtTableTextBlock" id="TextSelection-7D284A2F47DAEF2676396F38B8E36381-0-wk-Fact-E12F5BC37DE0C6DC1B686F38B8BFDEF5" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e1455-wk-Fact-B15F90F1B71E3C1809497FFD88156156" name="us-gaap:NotesPayableCurrent" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,495.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046405e1474-wk-Fact-A1047D9C168DA653CB937FFDAB2CD98D" name="us-gaap:NotesPayableCurrent" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e1494-wk-Fact-E03C31AEBF983BAF370A6F38B83EEB28" name="us-gaap:DebtCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,495.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046405e1513-wk-Fact-A5C816CFC4616E30647F6F38B83C6A09" name="us-gaap:DebtCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e1569-wk-Fact-FC236BB80FF0F420C1A16F38B80A1E2A" name="us-gaap:LongTermNotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046405e1588-wk-Fact-EB614431FC5BD5386DF06F38B8084B73" name="us-gaap:LongTermNotesPayable" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,480.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e1608-wk-Fact-D3B5F99A599AE23341726F38B80DC998" name="us-gaap:LongTermNotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">996.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046405e1627-wk-Fact-8370C4172702E53DEADA6F38B811BADE" name="us-gaap:LongTermNotesPayable" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">995.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e1647-wk-Fact-9DCC3C01439D32D6DE5C6F38B80FEFB5" name="us-gaap:LongTermNotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,739.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046405e1666-wk-Fact-140B7DF2A89B4109EED76F38B8165890" name="us-gaap:LongTermNotesPayable" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,737.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e1686-wk-Fact-20CAA2D36A64BED55F856F38B8063F0C" name="us-gaap:LongTermNotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,722.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046405e1705-wk-Fact-22DA3FF05C0248C3F3526F38B806CC70" name="us-gaap:LongTermNotesPayable" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,722.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e1730-wk-Fact-95D2C560A678B1EACADD6F38B8BDFC71" name="us-gaap:LongTermDebt" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,459.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046405e1749-wk-Fact-CAE61D364EA39551186E6F38B8C4B9E5" name="us-gaap:LongTermDebt" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,936.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Senior Notes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51046405e1781-wk-Fact-0F42613126F00D906B776F38B8C2BD33" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span><ix:nonFraction id="d51046405e1785-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020, valued at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span><ix:nonFraction id="d51046405e1789-wk-Fact-02689282C3EF9AFEBEB06F38B8C2F271" name="biib:PercentageParValueOfSeniorNotes" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">99.792</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51046405e1798-wk-Fact-E934BAB45B9706213CE06F38B8C18FB2" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span><ix:nonFraction id="d51046405e1802-wk-Fact-E0443512FEBBE52824A96F38B8C29E2A" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.625</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2022, valued at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span><ix:nonFraction id="d51046405e1806-wk-Fact-DFD920FC86A191811D876F38B8C46C9D" name="biib:PercentageParValueOfSeniorNotes" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">99.920</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51046405e1815-wk-Fact-E4527FF9ED756B4B100B6F38B8BE51E3" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-7" scale="9" format="ixt:numdotdecimal">1.75</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span><ix:nonFraction id="d51046405e1819-wk-Fact-FC4C4141291E4F6C42D66F38B8C68612" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">4.05</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2025, valued at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span><ix:nonFraction id="d51046405e1823-wk-Fact-0A3388434B06C530B3286F38B8C8DBAD" name="biib:PercentageParValueOfSeniorNotes" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">99.764</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51046405e1832-wk-Fact-AF1FE49802A1E6EA17C86F38B8BE8C1B" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-7" scale="9" format="ixt:numdotdecimal">1.75</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span><ix:nonFraction id="d51046405e1836-wk-Fact-8565C05E209F8F450DC66F38B8C7F518" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">5.20</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15,&#160;2045, valued at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span><ix:nonFraction id="d51046405e1840-wk-Fact-A90FDA8FE1B2A18A5CB56F38B8C111DF" name="biib:PercentageParValueOfSeniorNotes" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">99.294</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The costs associated with these offerings of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51046405e1847-wk-Fact-163EE2E3AC8A618105F46F38B8C5BA76" name="us-gaap:PaymentsOfFinancingCosts" contextRef="FD2015Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheets. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These notes are senior unsecured obligations. These Senior Notes may be redeemed at our option at any time at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046405e1854-wk-Fact-92E9208DA2B62EF6ECD56F38B8C7003F" name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="FD2019Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued interest and a specified make-whole amount. These Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046405e1858-wk-Fact-27C3C0642E3C19801B0C6F38B8BF4F0C" name="biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" contextRef="FD2019Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">101</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046405e1866-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes offering due in 2020, we entered into interest rate swap contracts. The carrying value of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046405e1870-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51046405e1882-wk-Fact-605D61DB6321AE9F9AD86F38B8C4442A" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51046405e1887-wk-Fact-F1581EDDBFA2F3E913D06F38B7A2983A" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to changes in the fair value of these contracts. For additional information on our interest rate contracts, please read Note 9, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Credit Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we entered into a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51046405e1901-wk-Fact-C446A5D9C854BCD587A26F38B8C4C209" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="FI2015Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span><ix:nonNumeric id="d51046405e1905-wk-Fact-76841EF437B0D8571B3E6F38B8C67A4D" name="us-gaap:LineOfCreditFacilityDescription" contextRef="FD2015Q4YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">five</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we were permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility included a financial covenant that required us not to exceed a maximum consolidated leverage ratio. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046405e1914-wk-Fact-934F02061E603F0702F96F38B8C626F3" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2020 we entered into a new </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51046405e1921-wk-Fact-73DC378EC219BD1563FAEC7E7FAC4555" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="I2019Q4creditfacility_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span><ix:nonNumeric id="d51046405e1925-wk-Fact-8D917A5C058323C8C36FF1EE60E38D68" name="us-gaap:LineOfCreditFacilityDescription" contextRef="D2019Q4creditfacility_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"><span style="font-family:Franklin Gothic Book,sans-serif;">five</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility that replaced the credit facility entered into in August 2015. For additional information, please read Note 26, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-6283D8B98CF253E607C86F38B8E3BDCC-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Maturity</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="TextSelection-BCD0F32A7FDF8AAFDCF76F38B8E39766-0-wk-Fact-1C5AD54819A016628FCD6F38B8C5F69B" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments due under our debt arrangements are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e1994-wk-Fact-20533A4401F8EC49847A800D03B9F56E" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,500.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e2009-wk-Fact-684DEFAC9641121FE678800D0382D985" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e2029-wk-Fact-BE2FA3CFE945C192DCF2800D03D830E9" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e2049-wk-Fact-0B54A89F822A9A5D659A800D04042FC7" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e2069-wk-Fact-084EC2EC01BD47FFFFBD800D03A0B35B" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e2089-wk-Fact-DBA1BA49741A60135A9A800D03F4D263" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,500.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046405e2114-wk-Fact-9F59954044E7007AB12B6F38B872D031" name="us-gaap:LongTermNotesPayable" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our debt is disclosed in Note&#160;7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</span></div></ix:continuation><div><a id="s307742391A31540CAA373880DF4DAD83"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13.&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-4E5D23502DD4F5C1360C6F38B8E31FA6-0-wk-Fact-8C61B09CC6F7BC2443C46F38B839FB10" continuedAt="TextSelection-4E5D23502DD4F5C1360C6F38B8E31FA6-1" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="TextSelection-4E5D23502DD4F5C1360C6F38B8E31FA6-1" continuedAt="TextSelection-4E5D23502DD4F5C1360C6F38B8E31FA6-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Preferred Stock</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1303-wk-Fact-D79D91C6A2D5A75569146F38B8A8B83F" name="us-gaap:PreferredStockSharesAuthorized" contextRef="FI2019Q4" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares of Preferred Stock authorized, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1307-wk-Fact-98CAA0605D2A84C43ADF6F38B8ADCEE9" name="us-gaap:PreferredStockSharesAuthorized" contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" unitRef="shares" decimals="-4" scale="6" format="ixt:numdotdecimal">1.75</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are authorized as Series A, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1311-wk-Fact-3733D51B55A8696C85946F38B83A4F7F" name="us-gaap:PreferredStockSharesAuthorized" contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_biib_SeriesXPreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are authorized as Series X junior participating and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1315-wk-Fact-BE42894C1739BB2ED9D66F38B8A983FF" name="us-gaap:PreferredStockSharesAuthorized" contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_biib_UndesignatedPreferredStockMember" unitRef="shares" decimals="-4" scale="6" format="ixt:numdotdecimal">5.25</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Common Stock</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:SummaryOfCommonStockTableTextBlock" id="TextSelection-3C10B2DCA2989F75F8C26F38B8E3A568-0-wk-Fact-D5E7A39AA0E2E248B9506F38B83DCCA9" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:13%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">As of December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e1676-wk-Fact-5A92707C43F82506E5216F38B8540FA0" name="us-gaap:CommonStockSharesAuthorized" contextRef="FI2019Q4" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e1690-wk-Fact-31883891660A7A0437D46F38B855FD64" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q4" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">198.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e1704-wk-Fact-CC50B950451110D3CA3B6F38B85396AF" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q4" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">174.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1718-wk-Fact-EDA8A7A0D4281E431C636F38B85B8528" name="us-gaap:CommonStockSharesAuthorized" contextRef="FI2018Q4" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1733-wk-Fact-0A2980EE743D28411E9B6F38B85BC10E" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q4" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">221.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1747-wk-Fact-B10B4F9BBC03C6C5C4EE6F38B85552EA" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q4" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">197.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1761-wk-Fact-F2D81868B89E4B71DD6A6F38B85501DD" name="us-gaap:CommonStockSharesAuthorized" contextRef="FI2017Q4" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1776-wk-Fact-14AB024F22AD87BD1CA36F38B8586D04" name="us-gaap:CommonStockSharesIssued" contextRef="FI2017Q4" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">235.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1790-wk-Fact-AF25FA45AF16B77A2FF56F38B8537A6C" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2017Q4" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">211.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51051987e1812-wk-Fact-7B9C0D8AF720AFE79E1CE8B6319F5D57" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (December 2019 Share Repurchase Program). Our December 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our December 2019 Share Repurchase Program will be retired. We did not repurchase shares of our common stock under our December 2019 Share Repurchase Program during the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51051987e1823-wk-Fact-5B658F307BDA3C44B4BA6F38B8AD1B06" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (March 2019 Share Repurchase Program). Our March 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our March 2019 Share Repurchase Program will be retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1827-wk-Fact-FB6AC0B45C6B499F86096F38B8ACCC32" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51051987e1831-wk-Fact-2B4E10B158798D3B3F006F38B83E2D0F" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.7</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51051987e1842-wk-Fact-13436D827A1A1F4478DC8010EDBAF4B4" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1846-wk-Fact-8706F5DAD179D43BBC086F38B8AB2700" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1850-wk-Fact-8832B6AD62AFCD028A2D6F38B847A986" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51051987e1854-wk-Fact-DCD343A2BEB5045F50DD6F38B8A7CF3E" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.1</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51051987e1858-wk-Fact-12342286F9FC1F7EA0356F38B8442EEF" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51051987e1874-wk-Fact-817AE393230274773B806F38B8A7A489" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-4E5D23502DD4F5C1360C6F38B8E31FA6-2" continuedAt="TextSelection-4E5D23502DD4F5C1360C6F38B8E31FA6-3"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1882-wk-Fact-89EC87E59F7C976A5D63801782306245" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e1886-wk-Fact-6057C9D23FA36429E6178017EF6CDAF8" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51051987e1890-wk-Fact-56FF7E99664C2BB0C436801817D23142" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51051987e1894-wk-Fact-F562C0311FCAEA2C9214801890A383BD" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts paid to repurchase shares in excess of their par value are allocated between additional paid-in capital and retained earnings, with payments in excess of our additional paid-in-capital balance recorded as a reduction to retained earnings.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-1512C5E42CC278C4647E93D9D84794A2-0-wk-Fact-9B50A09A9D9096764B8F93DD504B60FF" continuedAt="TextSelection-1512C5E42CC278C4647E93D9D84794A2-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2087-wk-Fact-178748512BCFA1C379B693E2D4388F8E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2107-wk-Fact-7B69EC771B3E6E1AB62093E2D750DBF1" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2126-wk-Fact-6843D6299757B934C99693E2D9ED6021" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2146-wk-Fact-895AC5822916CE06895193E2DCFD2C2F" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2166-wk-Fact-5BA8F3C93A182973AC7893E2E042F1A6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">243.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2187-wk-Fact-85A952828CB37D9B77516F38B8B27C3F" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2203-wk-Fact-C51E95C1BF0FF19CB4EE93E36D6DEEE9" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2222-wk-Fact-F2474D0E574279166C0593E36FBDBB18" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2241-wk-Fact-D9215D63C3DBA9AD82AB93E371DB0ABD" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2261-wk-Fact-A242EA9CEEFD24B9AE4593E373CFA97E" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2281-wk-Fact-0766AFC4E6DE932685A393E376C294D5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">103.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2300-wk-Fact-57B9F76C4674F2C06D0B93E378B8B805" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">230.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2321-wk-Fact-F788E9346BE01BFAEAF393E3797F6784" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2341-wk-Fact-F65A959DDC48207B00EA93E37B725000" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">115.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2361-wk-Fact-E32B640B4EE06960ED0693E37D62A5F9" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2382-wk-Fact-0F82510384CB56A7178393E37F55C521" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2401-wk-Fact-DB1DA0462637EB3A4D6393E381484D63" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2420-wk-Fact-72B63C63D1CDE0E9F72B93E3833F3516" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">125.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2442-wk-Fact-5F015F13891E413F21BA93E383FB7A17" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2461-wk-Fact-0C117B8A724C9C861CE393E3861182F4" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">26.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2481-wk-Fact-7757B0D69E90628D878793E3881F758F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2501-wk-Fact-BAA061D55CC34503AEE193E38A123643" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2521-wk-Fact-9C0560EF60F68E76FC1C93E38C14D2E7" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">103.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2540-wk-Fact-D065EF4A97DD7AA72ECF6F38B85F566B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">105.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2566-wk-Fact-70A9DB0651B9F60974E193E30D7A671F" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2585-wk-Fact-8D884594A5A5D95C1A9893E30F9F0DB2" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e2604-wk-Fact-2C52629334D62FF5AB8393E3119854AA" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2624-wk-Fact-FDDEACAFB6D66B0144E193E313862167" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">32.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2644-wk-Fact-6A7C963BF18DF642FC6B93E3157BCD7A" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">139.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e2665-wk-Fact-262FECE5A3392F04B8F36F38B8C7C408" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">135.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e2842-wk-Fact-07D495ABFF6039A18136941B494B2A22" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e2862-wk-Fact-FE977B54EDE7A9CF2098941B4BB9E5D4" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">104.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e2882-wk-Fact-895997288D6D64219932941B4E2EF4CF" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e2902-wk-Fact-5018F694E1B8D5355537941B50C8F979" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">36.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e2922-wk-Fact-C0FB69BC90E1B56F1934941B53628DDB" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">175.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e2943-wk-Fact-A6E46D76F34C55D88CC8941B55CC5CBE" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">318.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU 2016-01</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e2959-wk-Fact-658A94750EB1D69E11F39418DE48866E" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e2978-wk-Fact-BD6FF3399C6562B753F89418E4C27318" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e2997-wk-Fact-E9ADEE488E668494B9C69418E8FB17B0" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3017-wk-Fact-731C1B94716F134C85649418ED587143" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3036-wk-Fact-F2610B0C258F502051619418F14551E9" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3055-wk-Fact-563DC78A92E8A93225719418F52CCDD8" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3076-wk-Fact-9D3C39963A95A1DD3CD2941930EC3140" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3096-wk-Fact-CD08B7F90C0778171626941933A31A3B" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">104.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3116-wk-Fact-A0134F9E1C741E7A8DD4941936409639" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="0" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3136-wk-Fact-6A379A6848F3D361526194193A26C373" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">36.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3156-wk-Fact-F4BC8557A2A2ECD85CE094193CC09493" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">175.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3176-wk-Fact-618AB2E321B713DEA5B094193F5B390F" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">316.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3198-wk-Fact-CB2E2D178F3FADBA9E02941982488C02" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3218-wk-Fact-C5CFFF4684CF6B7677A2941984B2CBDC" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">97.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3237-wk-Fact-40D1C6E26CE2E33CB6AF9419872A8673" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3257-wk-Fact-9CCBFDEDEE603CE47D679419899735E2" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3276-wk-Fact-573F5569E4722D7E112194198C1019FF" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">67.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3296-wk-Fact-6F3EC5CAB9A43FF0240B94198E754933" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3317-wk-Fact-F00ECF603588EE58C33F94198F6F5869" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3336-wk-Fact-116C306A7E5739C4A5189419923EB93C" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3355-wk-Fact-47F7CF754C6ED8994F629419952ECB4E" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3376-wk-Fact-561639E1D23D773BC3E694199796B125" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3395-wk-Fact-5BB19077D2110F8FD86694199A6429E5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3414-wk-Fact-0201F6255D9B9731182594199CC726A6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3435-wk-Fact-B95F34D42CB9B0EF443094199DFF21A4" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3455-wk-Fact-2BED97F6EBE772FF736D9419A12FBEFF" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">139.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3474-wk-Fact-5843D0CA8CF34CA20D3B9419A3F62F1E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3494-wk-Fact-C9A8CA2C87EC6AEBE5E99419A68B17D7" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3513-wk-Fact-E6B5E760AFD0AE23BD0D9419A9D29DDA" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">67.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3533-wk-Fact-3FFFEF07DFDCE1143CF16F38B81442EC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3559-wk-Fact-178748512BCFA1C379B693E2D4388F8E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3579-wk-Fact-7B69EC771B3E6E1AB62093E2D750DBF1" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3598-wk-Fact-6843D6299757B934C99693E2D9ED6021" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3618-wk-Fact-895AC5822916CE06895193E2DCFD2C2F" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3638-wk-Fact-5BA8F3C93A182973AC7893E2E042F1A6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">243.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3659-wk-Fact-85A952828CB37D9B77516F38B8B27C3F" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-4E5D23502DD4F5C1360C6F38B8E31FA6-3"><ix:continuation id="TextSelection-1512C5E42CC278C4647E93D9D84794A2-1"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3836-wk-Fact-4C8A5B38537622477E78941AC9E38458" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3856-wk-Fact-E814EC0FF67BAE36ABB8941ACC4EB86D" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3875-wk-Fact-7C5196AA257EEF081E92941ACEE68D4E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3895-wk-Fact-0FD8D50BF909B9016CA0941AD181454F" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">32.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3915-wk-Fact-07F183B7054D476CE03C941AD3FAAEFF" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">334.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3936-wk-Fact-C4A62DEFE59259832965941AD69B964B" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2016Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">319.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3952-wk-Fact-BB6EFE3D3423D6C7AAC5941B804FBB3D" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e3972-wk-Fact-6EC5CCE9F62338099816941B82BD6151" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">193.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e3992-wk-Fact-C651569856E77135970C941B86514330" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4012-wk-Fact-E660B6217267DBFFD1DA941B896B64D4" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4032-wk-Fact-8600E5F798A22BE2810C941B8C0AB6DA" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">158.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4051-wk-Fact-0A0F554323ACF9A4EAED941B8EC35849" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">42.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4073-wk-Fact-72D9BB3271867555F035941B8FC3E386" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4092-wk-Fact-CB2589EEF05F68ABD3EE941B9259B117" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4111-wk-Fact-FEAD22787E7E02DA1BCC941B94F1938A" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4131-wk-Fact-88ABB94E91FD5450E00A941B978C9CF4" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4150-wk-Fact-E89B250F169BB85C81EE941B998063A6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4169-wk-Fact-DBF10CB8F64B5205176D941B9C1C2D58" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4190-wk-Fact-441A06FDCFC0868D2CFD941B9D1662EF" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4209-wk-Fact-FC48A91DD98C59EDCC8D941B9FB0FC14" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">162.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4229-wk-Fact-978715A59DD6FD7E26BA941BA24B9275" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4249-wk-Fact-3047E24625691847B508941BA4E5079A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4269-wk-Fact-493FD0DBE7F972326F32941BA75D7BA2" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">158.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4288-wk-Fact-DAF3185409661071AF2B6F38B80DA8BC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4314-wk-Fact-07D495ABFF6039A18136941B494B2A22" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4334-wk-Fact-FE977B54EDE7A9CF2098941B4BB9E5D4" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">104.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4354-wk-Fact-895997288D6D64219932941B4E2EF4CF" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4374-wk-Fact-5018F694E1B8D5355537941B50C8F979" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">36.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4394-wk-Fact-C0FB69BC90E1B56F1934941B53628DDB" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">175.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4415-wk-Fact-A6E46D76F34C55D88CC8941B55CC5CBE" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">318.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="TextSelection-EE9F3D043A73CF2A447793E031A34F76-0-wk-Fact-6792ECB53088202F5AFE93E09F0C81BE" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e4712-wk-Fact-54D121CA477BAEB35479941F6A66B57D" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4731-wk-Fact-C5204CAB23A4798797FC94275EAD3512" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4752-wk-Fact-4A2DBD7C2A0336E1F6D794280378C462" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">19.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e4783-wk-Fact-7385455619DEF5D6A684941F6E54BBCF" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4803-wk-Fact-BB01F54623AC0F97231C9427619B3D80" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e4823-wk-Fact-5072DC54AB4D9CAA7570942806BBA88F" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e4935-wk-Fact-BEC66000A2CB4EC06261941F72938A2E" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">118.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4954-wk-Fact-16F49252555A74CF249D942764AC84FB" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">42.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e4975-wk-Fact-090B19977163AF3B35A794280AC485D1" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">32.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e5011-wk-Fact-1982D6C33B97D658B64F941F76081F9D" name="us-gaap:OperatingExpenses" contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e5031-wk-Fact-7460358F3BD45B4ACA36942767F03A6C" name="us-gaap:OperatingExpenses" contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e5051-wk-Fact-A259D465D8968892612094280DCC3480" name="us-gaap:OperatingExpenses" contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e5086-wk-Fact-8F22CC3A412CF24B3781941F796F4C93" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e5105-wk-Fact-BCC500546C941AE8E3AB94276B94A7FE" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e5125-wk-Fact-8FE747E8CB16B2D41B32942810791F76" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51051987e5160-wk-Fact-870CD408467ABBCF2A36941F7CCCB813" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e5180-wk-Fact-075E5B7B1449DEB324D194276F23BEA1" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e5200-wk-Fact-9CDF945993C2E9EEFA4E9428146187F4" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e5313-wk-Fact-38282520213A514E8E9E941F82324BDB" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e5332-wk-Fact-8F568474A86415FD9337942772AE1CD9" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51051987e5352-wk-Fact-03675CE962CB85DAA68F9428174DA493" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51051987e5469-wk-Fact-9DB89B1746185ECA2275941F8AC37E3B" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e5488-wk-Fact-5F31DEE26DCD4B5BD70794277ACD107E" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">47.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51051987e5509-wk-Fact-7410252D9B358428F6CB94281D5D5C54" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">44.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><a id="s2C7DE4EDCCE0527AA86A85EC54A16CBA"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-34F97D9F7E1A61E404CA6F38B8E3153C-0-wk-Fact-45F9DB28866826D2B1426F38B7E62D2F" continuedAt="TextSelection-34F97D9F7E1A61E404CA6F38B8E3153C-1" escape="true">Earnings&#160;per Share</ix:nonNumeric></span></div><ix:continuation id="TextSelection-34F97D9F7E1A61E404CA6F38B8E3153C-1" continuedAt="TextSelection-34F97D9F7E1A61E404CA6F38B8E3153C-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-B2C9529A0DAD009DF57A6F38B8E329D7-0-wk-Fact-10B42F0A0DC7EA5039D56F38B7E2F72A" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046400e1523-wk-Fact-409F06146EDA2C5A1FA56F38B82DE39D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,888.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e1542-wk-Fact-D75E3BB69A698B5537196F38B831D83C" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,430.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e1561-wk-Fact-029151C37D9A5DCBB4476F38B8229A45" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,539.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046400e1639-wk-Fact-1969AB1F17EC7BCE4FB56F38B7B8CA9B" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">187.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e1658-wk-Fact-5907C0CD0AE9671001886F38B828BCF3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">204.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e1677-wk-Fact-699EE9018111D1CC3A906F38B80EA6F3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">212.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046400e1760-wk-Fact-3E14C3A9898CA93B736F6F38B89AB3DC" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e1779-wk-Fact-3F82DD404E7B8472DFC26F38B8925F13" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e1798-wk-Fact-39F40B3990A378800B306F38B89C5615" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046400e1819-wk-Fact-45FECC33B84B76ED5B986F38B8A0D460" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e1838-wk-Fact-AEAA52268159CD4CE5626F38B8A5391F" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e1857-wk-Fact-3162A1744EC5226544156F38B892BD57" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046400e1878-wk-Fact-2C548FA9FA0FAE820D7F6F38B85284AE" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e1897-wk-Fact-BA6B4E84300F981C201C6F38B89B836D" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e1916-wk-Fact-63F28142EBF3663844A96F38B895BA00" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046400e1937-wk-Fact-37CC05F29D372DD5E8A16F38B8A5FF8B" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e1956-wk-Fact-2C8A010A4389F3969E5E6F38B8AC985D" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e1975-wk-Fact-8F202F0C15B8A7A4ACE96F38B8AB9848" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046400e1997-wk-Fact-8CA2D641896DAA16E2CE6F38B7A837D6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e2016-wk-Fact-7183DAA7FA0ADDEAD2616F38B84BC9AA" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e2035-wk-Fact-5F0CB5C6EF0AB00189616F38B8AA7909" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51046400e2056-wk-Fact-9C26193DB3CDD8FB9C8B6F38B8899F39" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">187.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e2075-wk-Fact-4176A55C9C6E8FB2BE6A6F38B7A4B71D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">205.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e2094-wk-Fact-BDF045D316347ECE0A996F38B87BB71A" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">213.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-34F97D9F7E1A61E404CA6F38B8E3153C-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Earnings per share for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects, on a weighted average basis, the repurchase of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e2134-wk-Fact-8D6FF6737C2327B196A56F38B7E32E9B" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e2138-wk-Fact-A7D6E527CFE244BE3DAA6F38B7E7ED8F" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">14.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51046400e2143-wk-Fact-D404ED6D582D89FFF6656F38B7E0ED7E" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock, respectively, under our March 2019, 2018 and 2016 Share Repurchase Programs.</span></div></ix:continuation><div><a id="s5962379A3CC45F0FAECF1FBF0C0F0DE3"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-0-wk-Fact-DA6DF5E033A0759F17856F38B7CE8464" continuedAt="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-1" escape="true">Share-Based Payments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-1" continuedAt="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Expense</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-ABA33A557B4D9126332E6F38B8E55CC0-0-wk-Fact-5D446A58D85E6810F4FB6F38B7E4DAB3" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e1463-wk-Fact-C922D916B58FEFA23D0E6F38B8143DBF" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">77.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e1482-wk-Fact-D618F66F3E981AC7924D6F38B81B169A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e1501-wk-Fact-FFDA31967CDBE4C30AB96F38B80717D8" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e1517-wk-Fact-9A5F370A85DDE8BE45FF6F38B81CF3D1" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e1536-wk-Fact-562BBC3F1D7C8933A7B36F38B82ED00D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">105.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e1555-wk-Fact-C6FA636FBAB903C58E386F38B827DD00" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">95.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e1576-wk-Fact-8B3171C4274A546EDCA86F38B7F9C16D" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">225.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e1595-wk-Fact-54510C3888EE45A844256F38B825BBE9" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">181.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e1614-wk-Fact-EE0CD247BF1D9F82DECD6F38B7F5FC51" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">169.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e1635-wk-Fact-7061327E7AB7741ACFB96F38B81BB062" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51064427e1655-wk-Fact-9AE20A75B8882ADFEE256F38B823558A" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51064427e1675-wk-Fact-5C646CC93220E93D672D6F38B7F35D70" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e1697-wk-Fact-D021E3ABEB7B41FE371E6F38B80DF396" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">216.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e1716-wk-Fact-FF777E45E6F8CA8C999B6F38B7FDE5A6" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">170.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e1735-wk-Fact-9F6535C3ECBA176AA3296F38B80811D8" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e1756-wk-Fact-1F24B9F99EB57A66D2026F38B83053AA" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51064427e1776-wk-Fact-BA23EDC78AD5FF4D46166F38B7FA3BE4" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51064427e1796-wk-Fact-978A75625295FF7309116F38B82B2963" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e1823-wk-Fact-915F4D8C6F2550003B5A6F38B810B047" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">180.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e1842-wk-Fact-434297DF9F7949D844786F38B821D069" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">142.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e1861-wk-Fact-748B8BE3668FE4F546886F38B82B162A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">117.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="TextSelection-6995D26B5C680CBF9C8C6F38B8E55A68-0-wk-Fact-6C83D6D43AD797CE8B906F38B84DE68A" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2046-wk-Fact-FF47A0BFFBB40E31C4026F38B81578C5" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2065-wk-Fact-6818B27E3D83AD21D0136F38B7E79A5B" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2084-wk-Fact-5786DECBF34BD272D8326F38B824693D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2100-wk-Fact-9A72D65EA029C2FC982D6F38B7D439CB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">134.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2119-wk-Fact-4D16389809F0FC61C29F6F38B7FC6C47" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">126.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2138-wk-Fact-4576FE68CEDDBACB358C6F38B7CB61F8" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2159-wk-Fact-36D505C37F9F0707642A6F38B7FE04C6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2178-wk-Fact-4B8EBC42050D315BEDB26F38B7CB53D4" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2197-wk-Fact-28AB811D140475E2C4BD6F38B80C61E4" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2218-wk-Fact-BD786C5ABD9928B3C47C6F38B815A558" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2237-wk-Fact-CBE4A395CF0D8EA9B5EB6F38B7D3BDEB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2256-wk-Fact-2DD72CA6169948AF943A6F38B7F3C293" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2277-wk-Fact-D1D3D736F620F31C599C6F38B7E5734E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2296-wk-Fact-6063A14C11004029EA6F6F38B808052F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2315-wk-Fact-41207B4540E34DF84C486F38B7F45ED8" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2336-wk-Fact-0DF50BC8476D2B886F5C6F38B81C0B06" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2355-wk-Fact-A8D151C6E31CC0E810D66F38B7F70E5E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2374-wk-Fact-7EC347940DCD48F3C2666F38B7E8B381" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2395-wk-Fact-527A592769461A2B136A6F38B7E6A3B0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2414-wk-Fact-17A3EA923FAE9471A1F96F38B7FA5F52" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2433-wk-Fact-305C7119B0B0D6B630346F38B7D4070F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NST stock options</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2454-wk-Fact-172F3F921774D1B166F0944CD0F65A4E" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2473-wk-Fact-B71F2CC8992DBEF8A2DA944CFB29F2E1" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2492-wk-Fact-BAED40554C69D9A61B7E944D219E0221" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2513-wk-Fact-8B3171C4274A546EDCA86F38B7F9C16D" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">225.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2532-wk-Fact-54510C3888EE45A844256F38B825BBE9" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">181.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2551-wk-Fact-EE0CD247BF1D9F82DECD6F38B7F5FC51" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">169.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e2573-wk-Fact-7061327E7AB7741ACFB96F38B81BB062" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51064427e2593-wk-Fact-9AE20A75B8882ADFEE256F38B823558A" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51064427e2613-wk-Fact-5C646CC93220E93D672D6F38B7F35D70" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2640-wk-Fact-D021E3ABEB7B41FE371E6F38B80DF396" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">216.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2659-wk-Fact-FF777E45E6F8CA8C999B6F38B7FDE5A6" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">170.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2678-wk-Fact-9F6535C3ECBA176AA3296F38B80811D8" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, unrecognized compensation cost related to unvested share-based compensation was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e2702-wk-Fact-D9E9FBC431D1B18C74466F38B85E9C3B" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">210.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51064427e2706-wk-Fact-E60D91BBE3EEFA7A68576F38B7ECABBB" name="biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">1.9</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Plans</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2716-wk-Fact-97DECEBFF0902871C1296F38B8386AD7" name="biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" contextRef="FD2019Q4YTD" unitRef="Plan" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP). </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Directors Plan</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2006 our shareholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2006 Directors Plan. We have reserved a total of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2726-wk-Fact-A322F0C7CAE044925A296F38B85F2046" name="biib:NumberOfSharesOfCommonStockForIssuance" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_DirectorsPlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-2" continuedAt="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-3"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a </span><span><ix:nonNumeric id="d51064427e2734-wk-Fact-BB4E9B18885D67C0ED356F38B838ED01" name="biib:RatioOfNumberOfSharesReservedUnderPlan" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_DirectorsPlanMember"><span style="font-family:Franklin Gothic Book,sans-serif;">1.5-to-1</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Omnibus Plan</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2017 Omnibus Equity Plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e2745-wk-Fact-0BA892FD0CEDA877082B6F38B81C320F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="FI2017Q2_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2008 Omnibus Equity Plan as of June 7, 2017, or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017, are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&#160;</span><span><ix:nonNumeric id="d51064427e2749-wk-Fact-A906DDC7957F1D33F7A46F38B858BCF5" name="biib:RatioOfNumberOfSharesReservedUnderPlan" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember"><span style="font-family:Franklin Gothic Book,sans-serif;">1.5-to-1</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;ratio.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a 10-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all outstanding options were exercisable.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-8829F4033081A42157536F38B8E64402-0-wk-Fact-B6F20196A0837ED1F79C6F38B7E8E186" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2850-wk-Fact-53E39B02B39DBEE7CE5F6F38B85C8EF0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">27,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2869-wk-Fact-70E2D2874738ECA713326F38B859CB3D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">53.82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2884-wk-Fact-98A5FEF334055CFE47C66F38B7EA7C84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2903-wk-Fact-340D89B8336E79B114656F38B7E8ADE8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e2918-wk-Fact-0EC02343C5D0A7CEF6616F38B85E2ECF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2938-wk-Fact-A0CE7062B0440F70C8796F38B84907C8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">50.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2953-wk-Fact-C1DE462F7D6C535647B16F38B7EBEAC2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2019Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2972-wk-Fact-DEE1F8947598FD74DDF46F38B88B25B1" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e2987-wk-Fact-19A652CBBED3248EC4606F38B834021F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">12,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e3006-wk-Fact-5D8C7A679D3329FE4F406F38B7E9A0F6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">58.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total intrinsic values of options exercised in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e3037-wk-Fact-E157BCB3B37F5CE45CC76F38B85BAAE6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e3041-wk-Fact-2EE2E28457B6C059D2586F38B7E4D7D7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e3046-wk-Fact-3E4FD9FE67DE98FAF6E96F38B8438607" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic values of options outstanding as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e3054-wk-Fact-19AEAF3E0F2B812115816F38B846FAEC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The weighted average remaining contractual term for options outstanding as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51064427e3062-wk-Fact-B1F40E8EE87ED50C35CC6F38B8573C0A" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">0.2</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;years. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" id="TextSelection-2DEAF2173AF6230F8FE76F38B8E5E40F-0-wk-Fact-CB345E0D3830958CA2D46F38B8646B64" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e3234-wk-Fact-28D2B8E36C08CD93F5766F38B8C1ADCC" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3253-wk-Fact-C1A6D9DBA8BF960DD6CA6F38B8C1CA41" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3272-wk-Fact-D8FAFC9B199E2B4C98666F38B7CFE133" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e3293-wk-Fact-CB7AEAEA5B4BE251E8EC6F38B8BF2C86" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3312-wk-Fact-508DF8FC6ECB1FA135E86F38B8C53B8E" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3331-wk-Fact-025DF0FDFEB2A4098D636F38B8C44F30" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Market Stock Units (MSUs)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees prior to 2014 vested in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3355-wk-Fact-2722D1624C9AE10CA4F26F38B860466D" name="biib:NumberOfEqualAnnualIncrements" contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="Increment" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3359-wk-Fact-BA4D3214B32D3F463ACE6F38B8627507" name="biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3363-wk-Fact-F0C4380BDBC9E3CC22516F38B80777E5" name="biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">150</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on actual stock performance. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-3" continuedAt="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-4"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees in 2014 and thereafter vest in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3370-wk-Fact-E5040A4CD8DE00B2D2646F38B7E5979E" name="biib:NumberOfEqualAnnualIncrements" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="Increment" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3374-wk-Fact-E78332A274D2E5AB26286F38B8158F1C" name="biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3378-wk-Fact-60B47D9C51EB6837B1506F38B865647C" name="biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">200</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on actual stock performance. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:ScheduleOfMarketStockUnitsActivityTableTextBlock" id="TextSelection-5D5DB79CBAA1942BC12D6F38B8E56EF8-0-wk-Fact-549075D5A0002475A3156F38B7E8CE9F" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e3464-wk-Fact-1C8395DA70B2A9104F6C6F38B7E39853" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">180,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e3483-wk-Fact-DA5044E573BB62D9089F6F38B8998C4A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">371.32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e3498-wk-Fact-4F1B1F369F645FCAB5E06F38B89EFA30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">147,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e3517-wk-Fact-9ECB7064E915716669C46F38B829E7BC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">378.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e3532-wk-Fact-68A3733CE3D50B1519A06F38B8A24461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">101,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e3552-wk-Fact-E2AB938B33018F780EE26F38B7E57340" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">356.71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e3567-wk-Fact-54ED05CD4563CEC483C36F38B8A269E7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">43,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e3587-wk-Fact-279307FF36F0573DAB476F38B89304F1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">388.68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e3602-wk-Fact-F19F4A496734EDDC4E0A6F38B7E70EF0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">183,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e3621-wk-Fact-476D467B761CD93FB37D6F38B82F7637" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">378.09</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-7DBF3EF78F81D359A1B66F38B8E4EC02-0-wk-Footnote-7DBF3EF78F81D359A1B66F38B8E4EC02_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted during 2019 include awards granted in conjunction with our annual awards made in February 2019 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2019 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2018, 2017 and 2016.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51064427e3665-wk-Fact-53EFE783EAD85B76A8FA6F38B84686AF" name="biib:NumberOfDaysForCalculationOfAverageClosingStockPrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" format="ixt-sec:durday">30</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price on the date of grant for MSUs, expected volatility of our stock price, risk-free rates of return and expected dividend yield.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">T<ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" id="TextSelection-B18DDD8B61AFC145F5636F38B8E479EE-0-wk-Fact-3CB94B70ACB531D0F5D36F38B85A0F70" continuedAt="TextSelection-B18DDD8B61AFC145F5636F38B8E479EE-1" escape="true">he assumptions used in our valuation are summarized as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B18DDD8B61AFC145F5636F38B8E479EE-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:44%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e3765-wk-Fact-C39F45D35190FA2BD9026F38B8301A32" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3775-wk-Fact-64501121A84C9DC23BF66F38B82DAF77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3785-wk-Fact-BF42A68D25A45EDE267B6F38B82A4F0F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.2% - 33.6%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.5% - 32.4%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.0% - 35.6%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.46% - 2.53%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9% - 2.3%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9% - 1.6%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$228.59 - $331.18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$279.47 - $346.76</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$263.18 - $267.88</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>$<ix:nonFraction id="d51064427e3889-wk-Fact-9ECB7064E915716669C46F38B829E7BC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">378.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e3899-wk-Fact-D8DDCF53FD3C69463D566F38B82F9D06" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">378.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e3909-wk-Fact-4C7CBB88ADB7D61992006F38B82C0ACA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">382.59</ix:nonFraction></span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of MSUs vested in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e3936-wk-Fact-86B7CEB9A6E8E900FC9B6F38B817E463" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e3940-wk-Fact-98EA283ADA24D4CE984E6F38B856134F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e3945-wk-Fact-C679A98255842BC995FF6F38B85F718E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Settled Performance Units (CSPUs)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CSPUs awarded to employees vest in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3956-wk-Fact-0BB7C67757E825523A406F38B7D1EB26" name="biib:NumberOfEqualAnnualIncrements" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="Increment" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3960-wk-Fact-34E10E045B53C0EB4EC06F38B7E746D4" name="biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e3964-wk-Fact-01E3912C107ABBA133496F38B7E8C8C7" name="biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">200</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs are classified as liability awards and will be settled in cash based on the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51064427e3968-wk-Fact-A7629355C3DC0E0A65F86F38B7CEA480" name="biib:NumberOfDaysForCalculationOfAverageClosingStockPrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" format="ixt-sec:durday">30</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-4" continuedAt="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-5"><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" id="TextSelection-4677AB063A3DF49666826F38B8E5E47A-0-wk-Fact-51210B2110A2D5878D766F38B7CCB113" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4027-wk-Fact-A7477ACA4DFB73072E4F6F38B888235E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">50,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4042-wk-Fact-B2AB1654C6C9E45C3FE56F38B8955470" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="shares" decimals="INF" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e4057-wk-Fact-97444E16795C011BA1C76F38B890091A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">33,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e4073-wk-Fact-AB693AAE5A6B8FBB6B7A6F38B88669D7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">4,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4089-wk-Fact-B6FC8A90A77461C6DABE6F38B8866FCF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">13,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cash paid in settlement of CSPUs vested in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e4128-wk-Fact-C1C8D2FF47C7358C64D66F38B85ECBD0" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e4132-wk-Fact-A7625857EA260083E9D66F38B84AD16E" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e4137-wk-Fact-D77CC0E80F4F8EF7262A6F38B7E639D2" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance-vested Restricted Stock Units (PUs)</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">PUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e4147-wk-Fact-45F705999FB7B255551C6F38B85DB2B3" name="biib:NumberOfEqualAnnualIncrements" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Increment" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e4151-wk-Fact-0E629A35D8D2FDBAC23F6F38B85222AC" name="biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e4155-wk-Fact-44EC9332C926D2A9E2696F38B7CB1EAC" name="biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">200</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51064427e4159-wk-Fact-E0B08A77A7EB951769686F38B7EC1EDA" name="biib:NumberOfDaysForCalculationOfAverageClosingStockPrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt-sec:durday">30</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:PerformanceunitsactivityTableTextBlock" id="TextSelection-A0F47EC8AF36F08713846F38B8E6D5CE-0-wk-Fact-CDBCF06F669C0DFF78F96F38B83FEAE7" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4212-wk-Fact-5D738431E6B0640650D36F38B7EADB64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">48,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4227-wk-Fact-178A9FB5811957F1E3206F38B7E913F2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e4242-wk-Fact-8F65EFFE6EA0B59DEC0F6F38B7E4ED2E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">33,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e4258-wk-Fact-88944F7E8428361225D86F38B7E27EBB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">4,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4274-wk-Fact-17A4AD567165210541106F38B7EAD75D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">11,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All PUs that vested in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were settled in cash totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e4308-wk-Fact-E6C051DE16452B467AA76F38B85D31B8" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e4312-wk-Fact-06AF65B25DDDD5332C616F38B7CA0D0D" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e4317-wk-Fact-62E533FC673DF438DAFF6F38B7D0D5BB" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance Stock Units (PSUs)</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">PSUs Settled in Stock</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018 we began granting awards for performance-vested RSUs that will settle in stock. PSUs awarded to employees have a three-year performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of cumulative three-year performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Participants may ultimately earn between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e4334-wk-Fact-BC58F528399BE8E673F76F38B8586123" name="biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e4338-wk-Fact-6815093DD9E2225A7F9A6F38B84A0A04" name="biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">200</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-5" continuedAt="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-6"><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:PerformanceStockUnitsSettledinStockTableTextBlock" id="TextSelection-5EDAC8FB81402AE3095C6F38B8E409A2-0-wk-Fact-F8EEEEF5C04CDFEC70C76F38B7D309ED" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PSUs that settle in stock activity:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4415-wk-Fact-DC74A22A9C5CF874E2F86F38B80B280F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">60,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4434-wk-Fact-3E1BDE3778C9B8846FE66F38B7FF16CB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">317.26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4449-wk-Fact-E6B44BF27A8218CBDB316F38B80A7BFE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">77,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4468-wk-Fact-B089A6B821E5A82ACA5F6F38B8043D78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">316.28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4483-wk-Fact-07D417C2DD6D2349C2236F38B8088D4C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4502-wk-Fact-FECA44E5E9369A58A6256F38B7FE4D65" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e4517-wk-Fact-0E27AC6844410186DF816F38B8076183" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">26,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4537-wk-Fact-5FF072EA40E53B412D436F38B805956E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">318.11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4552-wk-Fact-21D9EEB57C8B81975A986F38B800B160" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">111,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4571-wk-Fact-D81570F131E4F91864A86F38B7FD1CDE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">316.39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PSUs settled in stock granted in 2019 include awards granted in conjunction with our annual awards made in February 2019 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">PSUs Settled in Cash</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018 we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have three performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of three annual performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Participants may ultimately earn between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e4601-wk-Fact-EE467F4818885B4ABCF36F38B83ECE7D" name="biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e4605-wk-Fact-4D3365D46D74B763092D6F38B8172E7B" name="biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">200</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs are classified as liability awards and will be settled in cash based on the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51064427e4609-wk-Fact-6E902BEBB4BDC065C59B6F38B7E80670" name="biib:NumberOfDaysForCalculationOfAverageClosingStockPrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" format="ixt-sec:durday">30</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through the vesting date, once the actual vested and earned number of PSUs is determined. Since no shares are issued, these awards do not dilute equity.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:PerformanceStockUnitsSettledinCashTableTextBlock" id="TextSelection-6ADE1629F8D3A4FE9C616F38B8E5FD05-0-wk-Fact-84254DC1F5EF703F54DB6F38B83EC749" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PSUs that settle in cash activity:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:83%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4652-wk-Fact-BA919EE2C778FB1C8D9C6F38B8BA7660" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">40,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4667-wk-Fact-D2C5B78117DF5BA6F4CA6F38B7F2C88F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">63,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e4682-wk-Fact-10D174C5D09D544C3BDF6F38B8C0F09A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e4698-wk-Fact-0AC9D94E1AD28EE9A91E6F38B7F4B6F9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4714-wk-Fact-2F35CB83578AA6D9E5A96F38B7F8EA50" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">82,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PSUs settled in cash granted in 2019 include awards granted in conjunction with our annual awards made in February 2019 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Time-Vested Restricted Stock Units (RSUs)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs awarded to employees generally vest no sooner than </span><span style="font-family:Franklin Gothic Book,sans-serif;">one-third per year over three years</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-6"><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock" id="TextSelection-9672EAFAA506674613B46F38B8E5D6E0-0-wk-Fact-001C065AE58F8BD532A16F38B845CF13" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4825-wk-Fact-C19263F98BEC96BACF586F38B8745AD2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">903,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4844-wk-Fact-BE97DDD53A99867F18FD6F38B8753E52" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">303.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4859-wk-Fact-E86D1CE0A120BCF496176F38B80DB12E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">602,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4878-wk-Fact-A2BEB14B74EE13ECC3C46F38B87B88DB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">304.44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e4893-wk-Fact-62D4F9FF93274D5C52236F38B891CA64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">416,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4913-wk-Fact-71C2C55015FC332ED5E86F38B87103B2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">294.71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51064427e4928-wk-Fact-8DD013F8BFBBCE2336496F38B8104318" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">151,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4948-wk-Fact-B90C1DAA899DC8E99CEF6F38B8BDFDF5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">311.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4963-wk-Fact-E5DE6EEA546C5EDF1D2A6F38B863D9D8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">938,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e4982-wk-Fact-AC8802F47110652E27396F38B812ED68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">306.55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-6E4BA122DC3EE32976BC6F38B8E4D29B-0-wk-Footnote-6E4BA122DC3EE32976BC6F38B8E4D29B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2019 primarily represent RSUs granted in conjunction with our annual awards made in February 2019 and awards made in conjunction with the hiring of new employees. RSUs granted in 2019 also include approximately </span><span style="font-family:Franklin Gothic Book;font-size:9pt;"><span><ix:nonFraction id="d51064427e5013-wk-Fact-607BA5807AAC7AE99C9D6F38B7FC34A8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,000</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> RSUs granted to our Board of Directors.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs granted in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> had weighted average grant date fair values of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e5036-wk-Fact-58BFCB2553BA5BFAF57A6F38B7F6F569" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">316.32</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e5040-wk-Fact-F976A3B9036513CD33B76F38B8562CC1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">293.41</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of RSUs vested in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e5064-wk-Fact-A0904F4433BD188763D16F38B857A591" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e5068-wk-Fact-839FD07AFB0F8759459B6F38B84773F1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">111.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064427e5073-wk-Fact-2166256C00BFAC597E046F38B7D08B93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015 our shareholders approved the 2015 ESPP. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e5083-wk-Fact-D2767D36571F6FA495C26F38B85B0C8F" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" id="TextSelection-EA3C3CEDF4D2A42EC1DA6F38B8E5EF55-0-wk-Fact-950AE6A3F1EB56C83D656F38B838C717" escape="true"><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e5250-wk-Fact-47B389D096C1443776C66F38B8107F60" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">204,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e5269-wk-Fact-CB390249688740D2237E6F38B8148ACA" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">170,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e5288-wk-Fact-34461C5F12C3B31864C56F38B815B731" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">167,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51064427e5314-wk-Fact-CA41435A97D666695B0B6F38B80E0ADB" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e5333-wk-Fact-4139C1C3B3EE90400BE26F38B8147EF1" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064427e5352-wk-Fact-4C50BA076A1732EB37C66F38B813E0A6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="s814981C6C2B9557A932D59338FD5C839"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-4DA6B191511715A8114C6F38B8E60B13-0-wk-Fact-88AC1A04F8B2F4BD38796F38B7A6D37A" continuedAt="TextSelection-4DA6B191511715A8114C6F38B8E60B13-1" escape="true">&#160;&#160;&#160;&#160;Income Taxes</ix:nonNumeric></span></div><ix:continuation id="TextSelection-4DA6B191511715A8114C6F38B8E60B13-1" continuedAt="TextSelection-4DA6B191511715A8114C6F38B8E60B13-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Tax Expense</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="TextSelection-E043A5C322EBAC858C606F38B8E619A0-0-wk-Fact-0C585A59587886FFB97F6F38B8B0B584" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e1525-wk-Fact-97DD3255C2BDF679F11A6F38B7A57D74" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,725.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e1544-wk-Fact-3975C9AC3921344880396F38B87C828C" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,877.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e1563-wk-Fact-E83BB60678D8829947466F38B86601AB" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,540.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e1579-wk-Fact-56B0163FA259911C6FE06F38B8B81FD7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,400.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e1598-wk-Fact-D255D63334B1DCF5C8996F38B8B15215" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,022.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e1617-wk-Fact-74EFDB175FE9C6843B4A6F38B8B52700" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,588.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e1643-wk-Fact-037FDB9132CFC80955486F38B80DC31A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,125.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e1662-wk-Fact-CEA622036210CBAE55336F38B7C2C044" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,899.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e1681-wk-Fact-68291FC0C112D97457DA6F38B7DD4BB7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,128.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e1826-wk-Fact-DE3A2A0A5EE9C325988B6F38B7AA7A89" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">947.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e1845-wk-Fact-EBDE76E464C0C13C53EB6F38B8BDF2C5" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,131.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e1864-wk-Fact-2DCE46EB8C1E141938FC6F38B889B028" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,201.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e1880-wk-Fact-31413CF7A9812FDE308A6F38B7A8C876" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e1899-wk-Fact-9F8604320F39675BA1CD6F38B860D1FF" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e1918-wk-Fact-6A7640C2E516651606786F38B8AFD467" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e1939-wk-Fact-3A59225FB2492EB6E06E6F38B8B076B9" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">84.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e1958-wk-Fact-C7EFC5F1F7C7AAE1C0516F38B87E3338" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">140.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e1977-wk-Fact-CA8B8708EFFE5E90A0056F38B887B516" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">108.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e1999-wk-Fact-93A2CA0144A6EBF443CA6F38B8B055D5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,090.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2018-wk-Fact-6B0573C592FE253693E36F38B86B9C7C" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,317.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2037-wk-Fact-ECDCAE5C5D0D0B6542466F38B879CBB3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,367.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e2125-wk-Fact-646EEB59905489B571E26F38B869ED88" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,143.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e2144-wk-Fact-2B3F15C20007669E5F5B6F38B7A98384" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">62.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2164-wk-Fact-DF212C12FCD728BF21B16F38B8B941BE" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">241.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e2180-wk-Fact-A2272F18AE1DA0F204C86F38B7A83B36" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e2200-wk-Fact-6047BEF02B04CC40CB696F38B8C3F563" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2220-wk-Fact-73AA159C8BDE75BD6B376F38B7C353EE" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e2241-wk-Fact-98E81378DDE2B9FBC91A6F38B87B20BA" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1,074.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2261-wk-Fact-CFEB7783D75421F028966F38B8C0B521" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">177.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e2280-wk-Fact-29B2E5C7B4902366CBDC6F38B7A60D13" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">159.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e2302-wk-Fact-7C31084FEFA28114DCAB6F38B864D055" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">67.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2321-wk-Fact-15E7585669CC1C2CBDC96F38B86FDC03" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">108.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2340-wk-Fact-AA985A4C7305479DFAD86F38B7C27564" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">91.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e2366-wk-Fact-D772848546D678B1763B6F38B837CC03" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,158.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2385-wk-Fact-2FDAAAEDBE81F99A2C786F38B89FE50C" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,425.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2404-wk-Fact-297A0CBBF5B99106D4D26F38B7FC8B8D" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,458.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-4DA6B191511715A8114C6F38B8E60B13-2" continuedAt="TextSelection-4DA6B191511715A8114C6F38B8E60B13-3"><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2017 Tax Act</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2427-wk-Fact-70B479AAC24A525935106F38B88111E8" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2431-wk-Fact-964C41E5BAFF81993B036F38B7B1194F" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries and collaborations to immediate U.S. taxation as GILTI or Subpart F income, and includes base erosion prevention measures on U.S. earnings and the reduced effective tax rate on income that comes from U.S. exports, called Foreign Derived Intangible Income. These changes became effective in 2018. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2017 we recognized within our provision for income taxes a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2438-wk-Fact-F4F0D1C36591CEA9D6F06F38B8AFC00D" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> estimate pursuant to the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 118. Our estimate included an amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2442-wk-Fact-5EAC5E8CB8B583D310216F38B7B4551F" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">989.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax), as discussed below, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2446-wk-Fact-DD89308EA5D44145ED3D6F38B8B5EB64" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" contextRef="FD2017Q4QTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">184.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the impact of remeasuring our deferred tax balances to reflect the new federal statutory rate and other changes to U.S. tax law. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended December 31, 2018, we recognized a net reduction of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2453-wk-Fact-F28A34897708EEE639296F38B7A48216" name="biib:Reductionindeferredtaxliabilityundistributedforeignearnings" contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our estimated Transition Toll Tax, an expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2457-wk-Fact-95CA1639175DCBB9B9D96F38B8B0DCA0" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to remeasure our deferred tax balances, an expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2461-wk-Fact-570282B9EBEE8CB3C20D6F38B8C7A8FD" name="biib:DeferredtaxliabilitiesGILTItaxcalculation" contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">135.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to establishing deferred taxes for GILTI and an expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2465-wk-Fact-2606B358E0C2B7C076B26F38B8B0033F" name="us-gaap:OtherTaxExpenseBenefit" contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect other aspects of the 2017 Tax Act.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Transition Toll Tax</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax. The Transition Toll Tax was assessed on our share of our foreign corporations' accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2475-wk-Fact-32F7BCF55DD8411DDF826F38B8B078DE" name="biib:TransitionTollTaxRepatriationTaxRate" contextRef="FI2017Q4_biib_ForeignearningstypeAxis_biib_ForeignearningsintheformofcashandcashequivalentsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">15.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and all other earnings were taxed at a rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2479-wk-Fact-ACD03A6750E57F9BB4846F38B8B514BE" name="biib:TransitionTollTaxRepatriationTaxRate" contextRef="FI2017Q4_biib_ForeignearningstypeAxis_biib_OtherForeignEarningsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">8.0</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2494-wk-Fact-52C5D7094068BA7F90B96F38B8C0633D" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">697.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the Transition Toll Tax. Of the amounts accrued as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to an approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2502-wk-Fact-AD9B60635BB64EC20E84D152089FDEEB" name="us-gaap:IncomeTaxesPaid" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> carryforward of taxes paid in relation to the company's 2017 tax return. The Transition Toll Tax will be paid over an eight--year period, which started in 2018, and does not accrue interest.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unremitted Earnings</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At December 31, 2019, we considered our earnings not to be permanently reinvested outside the U.S. and therefore recorded deferred tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. Other than for earnings, we are permanently reinvested for book/tax basis differences of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2513-wk-Fact-D59DFCF02A0901DBDA23FC2E91368956" name="biib:Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" contextRef="FI2019Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of December 31, 2019, primarily arising through the impacts of purchase accounting. These permanently reinvested basis differences could reverse through sales of the foreign subsidiaries, as well as various other events, none of which were considered probable as of December 31, 2019. The residual U.S. tax liability, if these differences reverse, would be between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2517-wk-Fact-B45BDA5E60CF0C82C39AFC2FB25DFB6A" name="biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">0.3</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2521-wk-Fact-6DD37D671D9965452540FC308A139EBF" name="biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">0.4</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of December 31, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Article 20 Procedure of ZINBRYTA</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017 the European Medicines Agency initiated a review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury. As a result of the Article 20 Procedure of ZINBRYTA, for the year ended December 31, 2017, we recognized a net impairment charge on certain tax assets related to ZINBRYTA reflected within income tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2531-wk-Fact-0221C7625B0B85BB983B6F38B7A389F9" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This charge reflected the write-off of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2535-wk-Fact-436D63CDAA4F7906CCF36F38B7ADEE47" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_biib_PrepaidtaxesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">142.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to prepaid taxes, which was partially offset by the recognition of an unrecorded deferred tax benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e2539-wk-Fact-455C43561EC0E646D11C6F38B7B0B5DB" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">93.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our collaboration arrangement with AbbVie, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-4DA6B191511715A8114C6F38B8E60B13-3" continuedAt="TextSelection-4DA6B191511715A8114C6F38B8E60B13-4"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilitie<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="TextSelection-4973455FAB516DAF7FD36F38B8E63C6B-0-wk-Fact-20837A0D7F89FFF497D76F38B7C4D61B" continuedAt="TextSelection-4973455FAB516DAF7FD36F38B8E63C6B-1" escape="true">s</ix:nonNumeric></span></div><ix:continuation id="TextSelection-4973455FAB516DAF7FD36F38B8E63C6B-1"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e2713-wk-Fact-16EC0A3CF085551C5B626F38B858FBF7" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2732-wk-Fact-C9F59C72AADD891E9AD26F38B7ECEA92" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">102.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves and accruals</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e2747-wk-Fact-5B4EA01EFF58A89270CA6F38B8446C16" name="us-gaap:DeferredTaxAssetsInventory" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">162.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2766-wk-Fact-397664E3A5D081A2263B6F38B84B841F" name="us-gaap:DeferredTaxAssetsInventory" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">163.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e2786-wk-Fact-5EB6015C5472673176836F38B849C5C9" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,380.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2805-wk-Fact-E4BE326B0E89DE253EBE6F38B8387ED3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,298.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e2825-wk-Fact-A09602DEA5E5C954519A6F38B8421746" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">130.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2844-wk-Fact-0C5DA9D442BC1C5923146F38B7EB5297" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">213.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e2864-wk-Fact-16A6C004B9B328EA998A6F38B85F0908" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2883-wk-Fact-68850645CAF9CCDC748B6F38B8673B71" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e2903-wk-Fact-19EEBCCCAB42517C84F06F38B84812E1" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">103.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e2922-wk-Fact-5170640CB73AD2784A096F38B84A8965" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e2942-wk-Fact-762A01BA35E74570BB0D6F38B86CE6C8" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e2962-wk-Fact-9A23ACC46298D163A6FC6F38B868F978" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e2988-wk-Fact-940B6E43E7B37D8C63466F38B841C6DC" name="us-gaap:DeferredTaxAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,905.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3007-wk-Fact-6AACC70561E6F97141D86F38B7EB650B" name="us-gaap:DeferredTaxAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,823.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e3069-wk-Fact-F262955AB6A852EE15D36F38B85CD285" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">350.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e3089-wk-Fact-1B1976732BFA422CBF826F38B7E86C9E" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">232.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e3105-wk-Fact-6497D6494E0F1755C7D06F38B849922C" name="biib:DeferredtaxliabilitiesGILTItaxcalculation" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1,381.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e3125-wk-Fact-707B18E38D5CA08D1CD76F38B7ED988B" name="biib:DeferredtaxliabilitiesGILTItaxcalculation" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">544.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e3146-wk-Fact-FBEE45F2DF7CB9BACF906F38B7EB9D05" name="biib:DeferredTaxLiabilitiesTaxCreditCarryforwards" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1,617.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e3166-wk-Fact-9ABDCFC10A5A1DEA25226F38B85F9F10" name="biib:DeferredTaxLiabilitiesTaxCreditCarryforwards" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1,425.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e3187-wk-Fact-3EF9DF482D4D62B2DCBC6F38B8393EE4" name="biib:DeferredTaxLiabilitiesDepreciationAmortizationOther" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">135.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e3207-wk-Fact-377CE05F36C5E2F93FAF6F38B8596798" name="biib:DeferredTaxLiabilitiesDepreciationAmortizationOther" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">102.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e3233-wk-Fact-02014614BD7DDA3BF39D6F38B85349B7" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,484.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e3253-wk-Fact-030A1BEE9F279EE71D176F38B85E2855" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,305.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intra-entity sales of inventory. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total deferred charges and prepaid taxes were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e3281-wk-Fact-31EFDE55C1D24E1AF2686F38B7A818B9" name="biib:Totaldeferredchargesandprepaidtaxes" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">243.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e3285-wk-Fact-AABC1E5B8E2DAEF3C49D6F38B8B8779D" name="biib:Totaldeferredchargesandprepaidtaxes" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">239.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rat<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="TextSelection-F289736B160DA1D44C266F38B8E6496B-0-wk-Fact-7D4E93A70ED5F331F7D46F38B7A99968" continuedAt="TextSelection-F289736B160DA1D44C266F38B8E6496B-1" escape="true">e</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F289736B160DA1D44C266F38B8E6496B-1"><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:55%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e3420-wk-Fact-5AB65E54E6ED753A97286F38B86A45C8" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3435-wk-Fact-83B09769B7AA78058C616F38B85EC330" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3450-wk-Fact-70B479AAC24A525935106F38B88111E8" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">35.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e3466-wk-Fact-926B9BF83222A3F446966F38B89E5835" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3480-wk-Fact-601B8D2D7BC01C5C097E6F38B8A14DE9" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3494-wk-Fact-88651EC52BC6F05A0CB86F38B870AF05" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e3509-wk-Fact-FA9A558EA5E6EC27C8356F38B871AA63" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e3524-wk-Fact-721359E7B2C9C9CE6AED6F38B7B251BD" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e3539-wk-Fact-7EAAFEDA265C69E49F126F38B85E8045" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">11.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e3555-wk-Fact-FB124E6754FDDC88CC316F38B8A8D8D5" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e3570-wk-Fact-3F01D31134776FD9A2F86F38B88929F0" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e3585-wk-Fact-356D6DDC944080E81DA56F38B8611998" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e3601-wk-Fact-F8790B0E4C4645295FB46F38B87DB9C1" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3615-wk-Fact-68C383DCBFF43CA7388F6F38B7C18A2B" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3629-wk-Fact-1A5EB239771B15E719CA6F38B891F4B5" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Divestiture of Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e3644-wk-Fact-2F34BDE0C6F486007D3AFC325A1748A8" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3658-wk-Fact-4D33A815C2D29FEF8597FC325C90EF02" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3672-wk-Fact-5A71A2B2EE69CD85BEE1FC325FD1B0D6" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Internal reorganization of certain intellectual property rights</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e3687-wk-Fact-72B56EE923FD022F1F74FC32D923FB70" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3702-wk-Fact-39FFF3CC878998F488F0FC32DBE4D9E3" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3716-wk-Fact-621794DC7AED53291CD8FC32DDCC458B" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e3731-wk-Fact-2EC086FEB0B7B5DC78596F38B869E74B" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3745-wk-Fact-D7D73339E6424F8F42F96F38B85D5EE8" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3759-wk-Fact-2F5C0605538ED33785C76F38B861D7D5" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e3774-wk-Fact-6742C652BCD109F261216F38B7B7FA52" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3788-wk-Fact-AF9608F45B0981A225756F38B87AC347" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3802-wk-Fact-D4C9E1BD8D5DE1F1C1AD6F38B896F7BA" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S. tax reform</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e3818-wk-Fact-0587D865B836AC81849B6F38B8A6E562" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3832-wk-Fact-93BA252969E48801D5856F38B887FAC7" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3846-wk-Fact-D89EE90BA083174049A76F38B855DABD" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">22.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss tax reform</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e3861-wk-Fact-AC75FDDA482AD23E414DFC334FAFC7FA" name="biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3876-wk-Fact-B0FE0CA0B791ED99366FFC3351AAE511" name="biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3890-wk-Fact-2B90E70AF63F58C74900FC335343371E" name="biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e3905-wk-Fact-B8B4A1514F45B78096346F38B86D71E5" name="biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3919-wk-Fact-DB85FF57400AB512649E6F38B894C141" name="biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e3933-wk-Fact-1E6F9F929AABB17352746F38B8972549" name="biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment of ZINBRYTA related tax assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e3949-wk-Fact-949FC4CC836E235F807B6F38B87ACE77" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3963-wk-Fact-F82628F3EED443F7ADDA6F38B86AE879" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e3977-wk-Fact-AFC434AE531F81CD46C06F38B864B8BD" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e3992-wk-Fact-AA6623E1119A08930BE86F38B8A4875B" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4007-wk-Fact-EDFBDE8B3772D65674456F38B89A5C63" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4021-wk-Fact-35E969BC343232E771F06F38B874509C" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e4036-wk-Fact-90B8848C5FD113D9C68C6F38B865B932" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">16.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4051-wk-Fact-AF4164AAC639B94B05996F38B862D248" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">24.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4066-wk-Fact-FA643C28819C0460819D6F38B8675469" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">47.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Changes in Tax Rate</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights and the impact of the enactment of a new taxing regime in the country and certain cantons of Switzerland. This decrease was partially offset by a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4098-wk-Fact-7DD7E13C219FC7B4D1AE7F012B0335CA" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense related to the divestiture of our subsidiary that owned our Hiller&#248;d, Denmark manufacturing operations. We also had a higher effective tax rate in 2018 resulting from the unfavorable effects of </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-4DA6B191511715A8114C6F38B8E60B13-4" continuedAt="TextSelection-4DA6B191511715A8114C6F38B8E60B13-5"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the 2017 Tax Act and our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Although we are recognizing a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write-off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the internal reorganization of certain intellectual property rights, we recorded a deferred tax asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4111-wk-Fact-61163ADE25D807E7EECDD15B0AD703FC" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2019Q4_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">754.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4115-wk-Fact-B877199C18D25F0A7EBFD15B4BC95EE9" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="FI2019Q4_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">603.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the enactment of the 2017 Tax Act. The effects of an overall reduction in the federal statutory rate in the U.S. were partially offset by the elimination of the manufacturing deduction, the imposition of the GILTI tax on international earnings, our recording of deferred taxes on GILTI in 2018, limits on the deductibility of certain benefits on executive compensation and a reduction in the tax benefit associated with the Orphan Drug Credit, all resulting from the 2017 Tax Act, and a change in accounting rules related to recording the tax impacts of intra-entity transactions. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Attributes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4144-wk-Fact-51A20F9CC38DFBED4FD06F38B7C5053C" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4148-wk-Fact-F6AFC41F5586E1D0A7FE6F38B7A3F0E6" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which begin to expire in 2022. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4152-wk-Fact-668DE660CDCA76B2D6026F38B8B30549" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that begin to expire in 2020. For state income tax purposes, we had research and investment credit carry forwards of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4156-wk-Fact-3531BEBE380FD43695086F38B7AFD27A" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that begin to expire in 2020. For foreign income tax purposes, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4161-wk-Fact-0A3DC3D42DA6B4D28F736F38B8C75622" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,773.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net operating loss carryforwards that begin to expire in 2025.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxe<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="TextSelection-5B11A01FC9DD37801EBE6F38B8E6679A-0-wk-Fact-1D21FF544C3C654959B96F38B7A585EE" continuedAt="TextSelection-5B11A01FC9DD37801EBE6F38B8E6679A-1" escape="true">s</ix:nonNumeric></span></div><ix:continuation id="TextSelection-5B11A01FC9DD37801EBE6F38B8E6679A-1"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e4350-wk-Fact-AB10E54D109DDBC561266F38B7FA3A6B" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">114.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4369-wk-Fact-FF0F2B63D3EA661B77306F38B7FB01CC" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4388-wk-Fact-349189CE5FAC281F17B06F38B7F703AD" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2016Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e4404-wk-Fact-FC2880A8916EC8F47B286F38B7FB4716" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4423-wk-Fact-9539A77778B89AEA65556F38B80A3E15" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4442-wk-Fact-1DF81E43CEB65862627B6F38B7FACB6C" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e4463-wk-Fact-CFDC88F42BD89B0B03906F38B7F94E41" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4482-wk-Fact-A9F96A2C9665D9D8203C6F38B7F8727E" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4501-wk-Fact-0F1FFBF057F3650EFA2C6F38B80B836E" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e4522-wk-Fact-0721083B9094C73C03466F38B7F9A81D" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e4542-wk-Fact-DBE683CF335380DC296E6F38B7FBB64B" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e4562-wk-Fact-53BE0118CF50045ECCFB6F38B80C1CBD" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51060145e4584-wk-Fact-2406579DE5E709708ADC6F38B7FE50F0" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e4604-wk-Fact-598DCA08D826185F05806F38B809916A" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51060145e4624-wk-Fact-F198E84EBF9574B45FEC6F38B808171A" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement refund (payment)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e4646-wk-Fact-EC584DDDBDA72427591F6F38B7F9EDC2" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4665-wk-Fact-8F3F5AD37C6546D383D06F38B809C121" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4684-wk-Fact-26EC59C24555B8E11E636F38B7F9820F" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51060145e4710-wk-Fact-EF493EE8E9EC92C2670F6F38B7FDBD03" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">129.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4729-wk-Fact-AB10E54D109DDBC561266F38B7FA3A6B" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">114.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51060145e4748-wk-Fact-FF0F2B63D3EA661B77306F38B7FB01CC" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our 2017 activity reflects a refund received from a state related to the settlement of an uncertain tax position.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-4DA6B191511715A8114C6F38B8E60B13-5"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in the balance of unrecognized tax benefits as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4781-wk-Fact-2935EEB95A1B81FE0A1E6F38B7A6C75D" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">122.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4785-wk-Fact-D3DF7A5C2F4B3465B44E6F38B8B9D34E" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4790-wk-Fact-28D1D158D54CD3FE56CD6F38B7C2C2BB" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize potential interest and penalties related to unrecognized tax benefits in income tax expense. In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recognized a net interest expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4809-wk-Fact-0EA46F30C069CC16D83D6F38B7A856F2" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4813-wk-Fact-98651094EB3215501A816F38B7A603BB" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4818-wk-Fact-75EB74161C54271B76AB6F38B7A2B406" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We have accrued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4822-wk-Fact-C308FA8DC5FEA9337AD06F38B7A672DB" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4826-wk-Fact-D0DE7D0BFD688FF2DF686F38B7A6F1F2" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the payment of interest and penalties as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Accounting for Uncertainty in Income Taxes</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, in connection with the spin-off of our hemophilia business, we distributed all of the then outstanding shares of Bioverativ common stock to Biogen shareholders pursuant to a separation agreement. In March 2018 Bioverativ was acquired by Sanofi S.A. (Sanofi) and is now an indirect wholly-owned subsidiary of Sanofi. The spin-off of our hemophilia business was intended to qualify for tax-free treatment to Biogen and its shareholders under the Internal Revenue Code. Our 2017 tax return remains open to audit. Bioverativ and Sanofi agreed to indemnify us for certain potential liabilities that may arise. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Federal and State Uncertain Tax Positions</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51060145e4853-wk-Fact-E768FD74A6B755573EABFC37B29ABA00" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div></ix:continuation><div><a id="s299C5FC87E24570ABEE58A5D72BCBE58"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="TextSelection-AF019DEBDCA1085723246F38B8E64AB0-0-wk-Fact-65BD57164ED9C0FB3C376F38B7F44A23" continuedAt="TextSelection-AF019DEBDCA1085723246F38B8E64AB0-1" escape="true">Other Consolidated Financial Statement Detail</ix:nonNumeric></span></div><ix:continuation id="TextSelection-AF019DEBDCA1085723246F38B8E64AB0-1" continuedAt="TextSelection-AF019DEBDCA1085723246F38B8E64AB0-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Supplemental Cash Flow Information</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="TextSelection-301BC8F1DE83051280B46F38B8E6DF41-0-wk-Fact-81160F6F89BF21BE54416F38B8C6E41D" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:51%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e1538-wk-Fact-3B03BC9A70F88E7B20476F38B88AD059" name="us-gaap:InterestPaidNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">244.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e1557-wk-Fact-AA66E144B518F61D07CE6F38B88BFA64" name="us-gaap:InterestPaidNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">243.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e1576-wk-Fact-4428291704869D02AFA16F38B88B806E" name="us-gaap:InterestPaidNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">281.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e1597-wk-Fact-2FA61DF1A7D45D46FC286F38B889CA04" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,064.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e1616-wk-Fact-1D84891FFEFF3D3240466F38B88A79AF" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,007.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e1635-wk-Fact-8120DA83F7CCE87809186F38B88A8A5F" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,066.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-cash Operating, Investing and Financing Activity</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2018 we accrued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51055572e1658-wk-Fact-756B1B0E00D6B85859926F38B8BF2B5A" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2018Q4QTD_biib_CumulativeSalesLevelAxis_biib_TwentybillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51055572e1662-wk-Fact-52F3177A7113406F4A0D6F38B8263878" name="biib:CumulativeSalesLevel" contextRef="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">20.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of the Fumapharm Products, which was paid in the first quarter of 2019. In the fourth quarter of 2017 we accrued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51055572e1666-wk-Fact-1D13164F44F2C95774536F38B8BEBD1E" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2017Q4QTD_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">600.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51055572e1670-wk-Fact-59063DE70B104946D9C36F38B8BF6A8D" name="biib:CumulativeSalesLevel" contextRef="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_FifteenbillionMemberMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">15.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51055572e1674-wk-Fact-24FF9E356FF94A2E12036F38B7EF18C9" name="biib:CumulativeSalesLevel" contextRef="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">16.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of the Fumapharm Products, which was paid in the first quarter of 2018. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51055572e1681-wk-Fact-944BD814856D14F96A656F38B8BDDC7D" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" contextRef="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51055572e1685-wk-Fact-5FE6F3423667647EBE6B6F38B8C5666A" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" contextRef="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information on the construction of our manufacturing facility in Solothurn, Switzerland, please read Note 10,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Property, Plant and Equipment,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-AF019DEBDCA1085723246F38B8E64AB0-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="TextSelection-F41A9DF256F315AB85696F38B8E6EAFE-0-wk-Fact-AE6B3FEDFFFFD7EBD0506F38B7EE3024" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e1872-wk-Fact-85B874E7E62A9101904F6F38B8742F9F" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e1891-wk-Fact-0A117E36A421D3D76EF96F38B83810FF" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e1910-wk-Fact-5A1406495907EB020B106F38B86F6156" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">78.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51055572e1926-wk-Fact-3EA70472CEE6A4EE94E56F38B875ACBE" name="us-gaap:InterestExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">187.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51055572e1946-wk-Fact-1534B4E7B5A8B2A414996F38B8363E97" name="us-gaap:InterestExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">200.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51055572e1966-wk-Fact-5F35E4DFA17CCF71225D6F38B882F056" name="us-gaap:InterestExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">250.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e1988-wk-Fact-BB569C88A55CBE4E87686F38B875D085" name="us-gaap:GainLossOnSaleOfInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">204.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2007-wk-Fact-4FA1482C5BA6E328AEE56F38B82F9734" name="us-gaap:GainLossOnSaleOfInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">119.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51055572e2026-wk-Fact-0F3B9152E08008909C026F38B8318B83" name="us-gaap:GainLossOnSaleOfInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">36.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51055572e2048-wk-Fact-639D520FEB7E6862ECF76F38B835B8C4" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51055572e2068-wk-Fact-37145F1FC591319D816E6F38B832153E" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2088-wk-Fact-90ADE57319FE76E8F42E6F38B83AD9B6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(<ix:nonFraction id="d51055572e2109-wk-Fact-FF9550E5E3EF2F8D02966F38B8337367" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">47.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51055572e2129-wk-Fact-53E4E27123F2766429F76F38B872AF63" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51055572e2149-wk-Fact-B08A6FF70F6D2A4FDE4D6F38B83380E3" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e2176-wk-Fact-30D3E4734FFCCDECF81C6F38B832E9CF" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2195-wk-Fact-1E1CCAC95E8FE4A0F3CC6F38B873F8AA" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51055572e2214-wk-Fact-0B37CAFFF87FFF67E1CA6F38B7DCE800" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">217.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:GainLossOnInvestmentsTextBlock" id="TextSelection-3187FB28D55B05D13E26D1452B029EF1-0-wk-Fact-994621E207C2B0E41975D145970D4E3F" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e2408-wk-Fact-13F44DF9426E85BDF0F6D146DA277C3B" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">200.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2427-wk-Fact-2EBB35116AEFBCF728C2D14710567E67" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51055572e2446-wk-Fact-2C9CA874145B994202FCD14730C1B823" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">19.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e2468-wk-Fact-645143363FDF2D8BECE5D146DBFEC6BC" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51055572e2487-wk-Fact-01E54A92BB165870A1DED1471152634C" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2507-wk-Fact-97AE98E6E634AD3CC1F8D14731EFFB4B" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period on equity securities held as of December 31</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e2528-wk-Fact-605E5B86437522F7BCB6D146DD6CDC58" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2547-wk-Fact-759879636059F1182545D1471250FB18" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">128.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d51055572e2566-wk-Fact-6697C3D3636FA7224390D147330E7F6F" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">19.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="TextSelection-6E9449BBA1D866400F4F6F38B8E6752B-0-wk-Fact-7C621D6B5EE7DA477DB86F38B8C613BA" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e2701-wk-Fact-95236321ECF2BFF56EC16F38B85CEE98" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,001.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2720-wk-Fact-1FE860E51A66C4BD686F6F38B85CFD98" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">874.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e2735-wk-Fact-414B60AB8BD95FAE15316F38B868EF90" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">309.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2754-wk-Fact-78C6956C594728149DC36F38B8734A5B" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">320.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e2774-wk-Fact-04C37D51933A184113346F38B8735F30" name="biib:Collaborationexpensesaccrual" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">281.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2793-wk-Fact-DB9DFDEEA8CEDBEE297C6F38B7D3A399" name="biib:Collaborationexpensesaccrual" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">261.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e2813-wk-Fact-35921CBA415099C6A3106F38B86DCDBA" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2832-wk-Fact-E1E091172F781958E9146F38B7EBAB19" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">224.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e2852-wk-Fact-92247D7B4EA77638028E6F38B87B4117" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2871-wk-Fact-01C21F6EE35A9311D0D66F38B86E4C71" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">444.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e2891-wk-Fact-74FE5404FACBD8A74C016F38B7D43993" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">78.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2910-wk-Fact-4932976258F68F1A43716F38B87250C8" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e2930-wk-Fact-89BE674B1B83BA3AD10E6F38B7D351E2" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">726.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2949-wk-Fact-582F5182862F03E22FF36F38B8701293" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">609.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51055572e2974-wk-Fact-BDC01B59134555A3997B6F38B8B552E2" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,765.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51055572e2993-wk-Fact-90574151EADDD2E79EBF6F38B8439367" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,861.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51055572e3021-wk-Fact-FEE7C166F066CB6B97C56F38B8BCBDFD" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,348.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51055572e3025-wk-Fact-020D28AEA8A1984F186F6F38B8C2FBCF" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,389.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and include accrued income taxes totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51055572e3037-wk-Fact-B1FECD0EAF4155BDE1806F38B7F44DF3" name="us-gaap:AccruedIncomeTaxesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">803.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51055572e3042-wk-Fact-15E26C14508A094955CA6F38B7F063DE" name="us-gaap:AccruedIncomeTaxesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">791.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div></ix:continuation><div><a id="s39944B92372B5C03B63A39E29D8C627D"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-0-wk-Fact-FF17E955EB440724F2546F38B826C590" continuedAt="TextSelection-0248CB847CE55149846C6F38B8E8AA98-1" escape="true">Collaborative and Other Relationships</ix:nonNumeric></span></div><ix:continuation id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-1" continuedAt="TextSelection-0248CB847CE55149846C6F38B8E8AA98-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-2" continuedAt="TextSelection-0248CB847CE55149846C6F38B8E8AA98-3"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depending on the collaborative arrangement, we may record funding receivable or payable balances with our collaboration partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaborative arrangements are discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech, Inc. (Roche Group)</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration arrangements will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#8217;s offer or purchase Genentech&#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN, as well as all development and commercialization activities as follows:</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">U.S.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Canada</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">GAZYVA</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">OCREVUS</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FDA approved OCREVUS for the treatment of RMS and PPMS. Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1342-wk-Fact-664E32782AC86EDCCA856F38B89A2198" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_RangeAxis_srt_MinimumMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">13.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and increasing up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1346-wk-Fact-3B2DD34F96F98E3539906F38B8791AF3" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_RangeAxis_srt_MaximumMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">24</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if annual net sales exceed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e1350-wk-Fact-449A12C7A3815C3873996F38B8A37D3D" name="biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">900.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. There will be a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1354-wk-Fact-1C035B2428FED589E6CC6F38B89625E2" name="biib:Reductioninroyaltyrate" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we receive a gross </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1361-wk-Fact-57062AC12104FB9BD0076F38B83059B0" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_StatementGeographicalAxis_us-gaap_ForeignCountryMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51071008e1365-wk-Fact-2F94F8439CB3688155EA6F38B8324FC8" name="biib:PeriodOfCollaborationAgreement" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember" format="ixt-sec:duryear">11</ix:nonNumeric> years</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS has been approved for the treatment of RMS and PPMS in the E.U. and certain other countries. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-3" continuedAt="TextSelection-0248CB847CE55149846C6F38B8E8AA98-4"><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Profit-sharing Formulas</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">RITUXAN Profit Share</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1381-wk-Fact-E793B5096FFC945F0D926F38B880CC0D" name="biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_RituxanMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share on the first </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e1385-wk-Fact-9CBF23E3E580D390FD5D6F38B8860C7A" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of co-promotion operating profits earned each calendar year. <ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:CoPromotionProfitSharingFormulaTableTextBlock" id="TextSelection-18A47850A3E822186C736F38B8E83241-0-wk-Fact-4CF2A4C620AD6776B3E56F38B7A4CA60" continuedAt="TextSelection-18A47850A3E822186C736F38B8E83241-1" escape="true">Our share of annual co-promotion profits in excess of </ix:nonNumeric></span><ix:continuation id="TextSelection-18A47850A3E822186C736F38B8E83241-1" continuedAt="TextSelection-18A47850A3E822186C736F38B8E83241-2"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e1393-wk-Fact-9CBF23E3E580D390FD5D6F38B8860C7A" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</span></ix:continuation></div><ix:continuation id="TextSelection-18A47850A3E822186C736F38B8E83241-2" continuedAt="TextSelection-18A47850A3E822186C736F38B8E83241-3"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e1422-wk-Fact-7359C2203FF6BF4198606F38B879CBC4" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_RituxanMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">40.0</ix:nonFraction></span></span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e1438-wk-Fact-8B0154F97582BA43BDE56F38B87FE35E" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_RituxanMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">39.0</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e1454-wk-Fact-E7B224C78A4F9ED8640D6F38B87EB52D" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_RituxanMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">37.5</ix:nonFraction></span></span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e1470-wk-Fact-7D85B91793C9E93100B56F38B8720B03" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_RituxanMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">35.0</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</span></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e1487-wk-Fact-A737849F68ECB6E002456F38B89A84D5" name="biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e1491-wk-Fact-986DB9D28CA2E91154136F38B80BDF48" name="biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e1500-wk-Fact-A7874FAF6F77A9CADDCA6F38B8A45B84" name="biib:SalesTriggerGrossSalesThreshold" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-18A47850A3E822186C736F38B8E83241-3"></ix:continuation>Our share of RITUXAN pre-tax profits in the U.S. decreased from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1515-wk-Fact-4EAA23903F08FD6756A76F38B896B796" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" contextRef="FI2016Q1_srt_ProductOrServiceAxis_biib_RituxanMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">39</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1519-wk-Fact-93DD129F7CEFE369F6786F38B8946116" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" contextRef="FI2017Q3_srt_ProductOrServiceAxis_biib_RituxanMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">37.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12-month period exceeded </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e1523-wk-Fact-A737849F68ECB6E002456F38B89A84D5" name="biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1530-wk-Fact-DF3F625F69C63173D78B6F38B892663B" name="biib:Futurepercentageofcopromotionoperatingprofits" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_NewAntiCd20Member_srt_RangeAxis_srt_MinimumMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1534-wk-Fact-C34BEA8AC19A84FDE2836F38B82231D1" name="biib:Futurepercentageofcopromotionoperatingprofits" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_NewAntiCd20Member_srt_RangeAxis_srt_MaximumMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">37.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on certain events.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GAZYVA Profit Share</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax profit-sharing formula for GAZYVA provides for a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1544-wk-Fact-91A763299E1F13047A5E6F38B82A1F99" name="biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share on the first </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e1548-wk-Fact-9CBF23E3E580D390FD5D6F38B8860C7A" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating profits earned each calendar year. <ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:PretaxProfitSharingFormulaTableTextBlock" id="TextSelection-060EC7F63A0E7D21888D6F38B8E7E87A-0-wk-Fact-2EFA8F144910027FBE2C6F38B8846E8A" continuedAt="TextSelection-060EC7F63A0E7D21888D6F38B8E7E87A-1" escape="true">Our share of annual profits in excess of </ix:nonNumeric></span><ix:continuation id="TextSelection-060EC7F63A0E7D21888D6F38B8E7E87A-1" continuedAt="TextSelection-060EC7F63A0E7D21888D6F38B8E7E87A-2"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e1556-wk-Fact-9CBF23E3E580D390FD5D6F38B8860C7A" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</span></ix:continuation></div><ix:continuation id="TextSelection-060EC7F63A0E7D21888D6F38B8E7E87A-2"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e1583-wk-Fact-4D81637F5B65639300426F38B825BC36" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">39.0</ix:nonFraction></span></span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e1599-wk-Fact-BA91171A3F17E1E48BC86F38B82C8787" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">37.5</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e1615-wk-Fact-F68E5E429E6096D786666F38B825D8ED" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">35.0</ix:nonFraction></span></span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of GAZYVA operating profits in 2019 and 2018 was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1634-wk-Fact-BA91171A3F17E1E48BC86F38B82C8787" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">37.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> our share of operating profits on GAZYVA was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1642-wk-Fact-6B1F43032B2FD7F291C36F38B8A30846" name="biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" contextRef="FI2017Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><ix:continuation id="TextSelection-7B1B6F66AB5E252F0AAC6F38B8E77FBD-0"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e1821-wk-Fact-26337B82AAEF05E73A3E6F38B85F0A00" name="biib:ShareOfCoPromotionProfits" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,542.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1840-wk-Fact-B6C3F88418A5E2EE809B6F38B8628501" name="biib:ShareOfCoPromotionProfits" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,431.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1859-wk-Fact-2DFFF43C74572858F7716F38B862D03C" name="biib:ShareOfCoPromotionProfits" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,316.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e1875-wk-Fact-B81242FED25624534B936F38B8676A8A" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">748.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1894-wk-Fact-FB06AB0BDFB9774258446F38B8615CE3" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">548.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1913-wk-Fact-EE4AEC4BFD0DED5E11FC6F38B85F5D20" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">242.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e1939-wk-Fact-6DB6BA0B8C715A0D0D4B6F38B8607F57" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,290.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1958-wk-Fact-5DE8AC0444CC0844782E6F38B82AE6AA" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,980.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e1977-wk-Fact-3A0656DB95083450147A6F38B824BC8E" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,559.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-4" continuedAt="TextSelection-0248CB847CE55149846C6F38B8E8AA98-5"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2012 we entered into a collaboration and license agreement with Ionis pursuant to which we have an exclusive, worldwide license to develop and commercialize SPINRAZA for the treatment of SMA. SPINRAZA was approved for the treatment of SMA in the U.S., E.U. and Japan in December 2016, June 2017 and July 2017, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized product revenues of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2115-wk-Fact-742BB14C0FCC481D8AB66F38B82D0ED2" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,097.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2119-wk-Fact-2E407703B7BA9CD6B5516F38B8C79046" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,724.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2124-wk-Fact-1CFE1EA12F70B469F5D56F38B7CBFF41" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">883.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, on our sales of SPINRAZA. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2128-wk-Fact-97EF098C978E67239F5E6F38B88B6DA7" name="biib:PercentageOfRoyaltiesAsPerCollaboration" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2132-wk-Fact-279649C450172DB898E46F38B897EA2C" name="biib:PercentageOfRoyaltiesAsPerCollaboration" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2149-wk-Fact-A219CFD621E22B7F12AF6F38B7F3E17F" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">293.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2153-wk-Fact-7A519F41BC3ACB0F79206F38B87D1FE0" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">238.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2157-wk-Fact-86F65F329274A9652C786F38B7C6EEA6" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we made milestone payments to Ionis totaling&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2168-wk-Fact-D8DAE9CEDFCC00FF18426F38B8967349" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;related to the marketing approvals discussed above, which were capitalized in intangible assets, net in our consolidated balance sheets.  </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Antisense Therapeutics</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three gene targets. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, Ionis is responsible for global development of any product candidate</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2190-wk-Fact-AA7FA5569A6872F3C7156F38B881416F" name="biib:LicenseFee" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2194-wk-Fact-7748D63CFAE1FF483FC36F38B88BF578" name="biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">130.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if we successfully develop the product candidate after option exercise. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2205-wk-Fact-4FC046DF40102C366D1C6F38B7FCF597" name="biib:Upfrontpaymentforcollaborationagreement" contextRef="FI2012Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis and agreed to make potential additional payments, prior to licensing, of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2209-wk-Fact-4E5EB29B68A37C265D6F6F38B7C60A78" name="biib:AdditionalMilestonePayment" contextRef="FI2012Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 we recognized this </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2213-wk-Fact-F2B8134F1C39001A0A416F38B7B96561" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone upon the selection of BIIB080 (tau ASO), which is currently in Phase 1 development for the potential treatment of AD. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080. In connection with the option exercise, we made a payment of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2220-wk-Fact-5B5420AD288ECBE73C13EC7114B5ABC1" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to Ionis, which was recorded as research and development expense in our consolidated statements of income. Future payments may include additional milestone payments of up to&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2224-wk-Fact-25DC7FFD4791A31458DCECA062432E53" name="biib:AdditionalMilestonePayment" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">155.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;and royalties on future sales of in the low- to mid-teens if we successfully develop the product candidate after option exercise.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2018 Ionis Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we closed a </span><span><ix:nonNumeric id="d51071008e2234-wk-Fact-B3665494D7856B968E2B6F38B82EDF2F" name="biib:Termofcollaborationagreement" contextRef="FD2018Q2QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"><span style="font-family:Franklin Gothic Book,sans-serif;">10</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year exclusive collaboration agreement with Ionis to develop novel antisense oligonucleotide (ASO) drug candidates for a broad range of neurological diseases (2018 Ionis Agreement) for a total payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2239-wk-Fact-076A2D6FE46F438716566F38B8A3F008" name="biib:Totalpaymenttoentercollaborationagreement" contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2243-wk-Fact-A31264209A135F8935066F38B8980997" name="biib:Upfrontpaymentforcollaborationagreement" contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">375.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and the purchase of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2247-wk-Fact-6D745E4F584CBC62896A6F38B89ADA6C" name="biib:Investmentincommonstocksharespurchased" contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">11.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of Ionis common stock at a cost of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2251-wk-Fact-4764836B123DE4FED2616F38B8A63CD0" name="biib:Purchaseofcommonstock" contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">625.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon closing, we recorded </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2258-wk-Fact-04DBE02A65A3F7BD798F6F38B7C4730B" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="FI2018Q2_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2262-wk-Fact-A31264209A135F8935066F38B8980997" name="biib:Upfrontpaymentforcollaborationagreement" contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">375.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment as prepaid services in our consolidated balance sheets and recognized the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2266-wk-Fact-258760E5EE54092130EA6F38B7BEE376" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q2QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">324.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as research and development expense in our consolidated statements of income. The amount recorded as prepaid services represented the value of the employee resources committed to the arrangement to provide research and discovery services over the term of the agreement.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-5" continuedAt="TextSelection-0248CB847CE55149846C6F38B8E8AA98-6"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2273-wk-Fact-6D745E4F584CBC62896A6F38B89ADA6C" name="biib:Investmentincommonstocksharespurchased" contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">11.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of Ionis common stock were purchased at a premium to their fair value at the transaction closing date. The premium consisted of acquiring the shares at a price above the fair value based on the trailing 10-day weighted-average close price prior to entering into the 2018 Ionis Agreement in April 2018 and the effect of certain holding period restrictions. We recorded an asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2277-wk-Fact-342A2C8FE26F3A83D8CF6F38B8A7FC04" name="biib:Investmentincommonstockvalue" contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">462.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in investments and other assets in our consolidated balance sheets reflecting the fair value of the common stock as of the purchase date and a charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2281-wk-Fact-65A5C54CC3B28292F9056F38B87A34EC" name="biib:Premiumonpurchaseofcommonstock" contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">162.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to research and development expense in our consolidated statements of income in the second quarter of 2018 reflecting the premium paid for the common stock. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Ionis common stock is remeasured each reporting period. Changes in the fair value of our investment in Ionis common stock, including the effect of the holding period restrictions, are reflected in other income (expense), net in our consolidated statements of income. For additional information on the fair value of our investment in Ionis common stock, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have the option to license therapies arising out of this agreement and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2295-wk-Fact-4011947F1F92C272DDBC6F38B80BA3F1" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2299-wk-Fact-D60C6251150446495CCD6F38B87F5A52" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">270.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for each program, depending on the indication plus an annual license fee, as well as royalties on potential net commercial sales.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we incurred milestones of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2310-wk-Fact-115C3D81A706BBC517E4F1F9B0DB81D5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the advancement of neurological targets identified under this agreement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2017 SMA Collaboration Agreement</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2017 we entered into a collaboration agreement with Ionis to identify new ASO drug candidates for the potential treatment of SMA. Under this agreement, we have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of such therapies.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2324-wk-Fact-E7BEC9109BD1FCC29A616F38B896409D" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment to Ionis and we may pay Ionis up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2328-wk-Fact-E33B7AB296AC4150F7ED6F38B87DCC9B" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and regulatory milestone payments if new drug candidates advance to marketing approval. Upon commercialization, we may also pay Ionis up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2332-wk-Fact-32D4211CDCB16562773D6F38B8A4A03B" name="biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">800.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2013 Long-term Strategic Research Agreement</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2013 we entered into a </span><span><ix:nonNumeric id="d51071008e2342-wk-Fact-7A316ACB9A0063AC60446F38B81E01DC" name="biib:Termofcollaborationagreement" contextRef="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"><span style="font-family:Franklin Gothic Book,sans-serif;">six</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the potential treatment of neurological diseases.&#160;Under this agreement, Ionis performs research on a set of neurological targets identified within the agreement. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis is eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us under the terms of the agreement. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For non-ALS antisense product candidates, Ionis is responsible for global development through the completion of a Phase 2 trial and we provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2353-wk-Fact-AA7FA5569A6872F3C7156F38B881416F" name="biib:LicenseFee" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2357-wk-Fact-7748D63CFAE1FF483FC36F38B88BF578" name="biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">130.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (tofersen), an investigational treatment for ALS with superoxide dismutase 1 (SOD1) mutations. In connection with the option exercise, we made a payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2364-wk-Fact-F1B44D408396DB2DB4B46F38B8357A14" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis, which was recorded as research and development in our consolidated statements of income. Future payments may include potential post-licensing milestone payments of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2368-wk-Fact-324AFBEA52048AAC06456F38B89B269C" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and royalties in the low to mid-teen percentages on potential annual worldwide net sales. We are solely responsible for the costs and expenses related to the development, manufacturing and commercialization of tofersen following the option exercise. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-6" continuedAt="TextSelection-0248CB847CE55149846C6F38B8E8AA98-7"><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ending </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we incurred milestones of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2387-wk-Fact-095BF1856EBFD7DA54A56F38B7BEA159" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2391-wk-Fact-9D3CB2C3CD0078914B146F38B899B336" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2396-wk-Fact-F732D92A9D3C624DC4A76F38B81C117B" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of programs under this agreement, which were recorded as research and development expense in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates for the potential treatment of AD, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor (the BAN2401 and Elenbecestat Collaboration). </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019 we and Eisai announced the decision to discontinue the global Phase 3 studies (MISSION AD1 and MISSION AD2) of elenbecestat in early AD. As a result of this decision, in the third quarter of 2019, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2413-wk-Fact-D5DA5C521F4F7074EC20D19B904E5B8B" name="us-gaap:LossOnContractTermination" contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our share of the termination of various clinical trials and research and development contracts incurred under the BAN2401 and Elenbecestat Collaboration.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. Upon marketing approval we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for early AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" id="TextSelection-B088616852F49CBD7EEC6F38B8E74EAB-0-wk-Fact-FCA19E4AF57F2B41E7526F38B86E6E2F" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e2588-wk-Fact-08C727694376BA512CAF6F38B7E96617" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">348.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2607-wk-Fact-C1D31F1EB158B04C54696F38B7E8453A" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">232.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2626-wk-Fact-8E638E97A4C4DB13850F6F38B7EE4C5B" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">146.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e2647-wk-Fact-8F25270C0284E5A65D036F38B7EA96A3" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2666-wk-Fact-934314B5FF60EA4C86A86F38B7F59D8E" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">116.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2685-wk-Fact-881149773F0324EB5F9B6F38B7EB20A5" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e2768-wk-Fact-221F350006AE51CE2502F1FB21DE5FF9" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2787-wk-Fact-49AD674CE0EEF2F1C14DF1FB2849667E" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2806-wk-Fact-C20AACFDAEEAED825894F1FB2D2CC43A" name="biib:Expenseincurredbythecollaboration" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51071008e2827-wk-Fact-B84B0CAB357B865CF6FCF1FB31305DAB" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2846-wk-Fact-9F4F135F6E08C7180AEEF1FB37B733D2" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2865-wk-Fact-61A7790C60DA35C33F84F1FB3C4213F6" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, the two companies will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early AD. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 63</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-7" continuedAt="TextSelection-0248CB847CE55149846C6F38B8E8AA98-8"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">study met its pre-specified primary and secondary endpoints. In October 2019 we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2891-wk-Fact-27475C4DD98D739E17186F38B88B53D7" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of aducanumab development expense incurred and beginning January 1, 2019, is reimbursing us for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2895-wk-Fact-C993143E7D1D855941D46F38B89D8ABE" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of aducanumab development expense incurred. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e2902-wk-Fact-012BCC0F7C02381025AFD19F5113AAD6" name="us-gaap:LossOnContractTermination" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the termination of various clinical trials and research and development contracts net of the expected </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2906-wk-Fact-C993143E7D1D855941D46F38B89D8ABE" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. We will receive a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2914-wk-Fact-1E94605F3E4F72190F746F38B7AAB657" name="biib:Biogenshareofcopromotionprofitsorlosses" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">55</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in the U.S., a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2918-wk-Fact-A658ABD84A392E0E1B5B6F38B89CC72F" name="biib:Biogenshareofcopromotionprofitsorlosses" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">68.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in the E.U. and a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e2922-wk-Fact-B8D56377C0E6C7C837C86F38B8A2F806" name="biib:Biogenshareofcopromotionprofitsorlosses" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The two companies will continue to share equally in the potential profits (losses) in rest of world markets. Sales and marketing expense incurred before commercialization are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="TextSelection-20FB1F64C46A96A4AEB56F38B8E70C33-0-wk-Fact-06154BE7726237EF17B06F38B8297C5A" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51071008e3088-wk-Fact-8730AA714286FEFCB36F6F38B7CD4B14" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">179.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3107-wk-Fact-8185424F24C92C16B9CF6F38B7EACB8C" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">264.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3126-wk-Fact-8EA7422CDF24C79C4D0D6F38B7EB078E" name="biib:Expenseincurredbythecollaboration" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">268.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51071008e3147-wk-Fact-A94D14CE5744FEBB5F906F38B7CFDCCB" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">98.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3166-wk-Fact-2FD63AB0181A85FE3C676F38B7ED1818" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">234.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3185-wk-Fact-9EC598074DF125146F4D6F38B7CE7BF7" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">268.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51071008e3268-wk-Fact-0D328B3AAF9E457C39B66F38B7CC2A40" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3287-wk-Fact-971A1F6FEF7C4FFE050E6F38B7D209E6" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3306-wk-Fact-C0660FEE6809279BC14B6F38B7ECE569" name="biib:Expenseincurredbythecollaboration" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d51071008e3327-wk-Fact-9608C93BECBFCEBAD20F6F38B7D1B610" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3346-wk-Fact-8ED2F2BE7D52C6B05AA26F38B7EA4A1C" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3365-wk-Fact-8182FAF2A9369FF03EC56F38B7D59AF8" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.  </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-Tau Option</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Alkermes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes for VUMERITY, a novel fumarate for the treatment of RMS. In October 2019 the FDA approved VUMERITY in the U.S. for the treatment of RMS. In November 2019 VUMERITY became available in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received an exclusive, worldwide license to develop and commercialize VUMERITY and we pay Alkermes a royalty of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3400-wk-Fact-EA384A9F7FD60A71FCC5F1FCECA48C09" name="biib:PercentageOfRoyaltiesAsPerCollaboration" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on worldwide net commercial sales of VUMERITY. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Alkermes is eligible to receive royalties in the high-single digits to sub-teen double digits of annual net commercial sales upon successful development and commercialization of new product candidates, other than VUMERITY, developed under the exclusive license from Alkermes. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3410-wk-Fact-03E5BA08D7A20108DD7B6F38B8808AC3" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment to Alkermes representing our share of VUMERITY development costs already incurred in 2017. Beginning in 2018 we became responsible for all </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 64</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-8" continuedAt="TextSelection-0248CB847CE55149846C6F38B8E8AA98-9"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">development expenses related to VUMERITY. In December 2017 we also recognized a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3418-wk-Fact-A06FB396768E5D3CD6A46F38B87DCC49" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> expense, which was paid to Alkermes in 2018, enabling the continuation of the agreement to develop VUMERITY. Both the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3422-wk-Fact-03E5BA08D7A20108DD7B6F38B8808AC3" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3426-wk-Fact-A06FB396768E5D3CD6A46F38B87DCC49" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> continuation payment were recorded as research and development expense in our consolidated financial statements during the year ended December 31, 2017. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2019, following the FDA's approval of VUMERITY, we paid Alkermes </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3433-wk-Fact-FCE856802EFC015AD7B46F38B891AD08" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">155.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments, which were recorded in intangible assets in our consolidated balance sheets and will be amortized over the useful life of the product. For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3449-wk-Fact-1ADE24E20015E7D5646ED1AB7ECBA186" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">53.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3454-wk-Fact-66FF91986D5968388DC16F38B829FAF5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3458-wk-Fact-821E328A9F393893776F6F38B87E92C2" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in research and development expense in our consolidated statements of income related to this collaboration.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Alkermes currently supplies VUMERITY to us pursuant to a supply agreement with Alkermes. In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes pursuant to which we have the election, following a transition period, to manufacture VUMERITY or have manufacturing transitioned to a third party in exchange for an increase in the royalty rate on worldwide net commercial sales of VUMERITY that is manufactured by us or our designee.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for the development and potential commercialization of BIIB092 (gosuranemab), an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received worldwide rights to gosuranemab and are responsible for the full development and potential commercialization of gosuranemab in AD and progressive supranuclear palsy (PSP). </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we announced that the Phase 2 PASSPORT study investigating gosuranemab in individuals with PSP did not meet its primary endpoint. Based on these results, we discontinued development of gosuranemab in PSP and other primary tauopathies. We will continue our ongoing Phase 2 TANGO study of gosuranemab for mild cognitive impairment due to AD or mild AD, given differences in disease pathology.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3480-wk-Fact-00C45A5666966A71BAE06F38B8711AD1" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to BMS and assumed all remaining obligations to the former shareholders of iPierian, Inc. (iPierian) related to BMS&#8217;s acquisition of iPierian in 2014. In June 2017 we recognized a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3484-wk-Fact-0A3D2802844EB1BB9FF66F38B8A7E063" name="biib:DevelopmentalMilestonePayment" contextRef="FI2017Q2_us-gaap_TypeOfArrangementAxis_biib_IPerianMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 PASSPORT study of gosuranemab for PSP.  Both the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3488-wk-Fact-00C45A5666966A71BAE06F38B8711AD1" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment and the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3492-wk-Fact-0A3D2802844EB1BB9FF66F38B8A7E063" name="biib:DevelopmentalMilestonePayment" contextRef="FI2017Q2_us-gaap_TypeOfArrangementAxis_biib_IPerianMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone payment were recorded as research and development expense in our consolidated statements of income for the year ended December 31, 2017.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may pay BMS up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3499-wk-Fact-B0DEA4B56A9D4FB261FBF20168391F57" name="biib:AdditionalMilestonePayment" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">360.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments, and potential royalties, and we may pay the former shareholders of iPierian up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3503-wk-Fact-43C971A8EAD8F70AD746F2021F2D7827" name="biib:AdditionalMilestonePayment" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IPerianMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">370.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestone payments as well as potential royalties on net commercial sales.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3518-wk-Fact-9AA1A01020D70ED8B5616F38B89730ED" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">144.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3522-wk-Fact-859993C783D50BEBF8ADD1ACD753209C" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">97.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in research and development expense in our consolidated statements of income related to this collaboration.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and we may pay potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. The next expected milestone would be </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3536-wk-Fact-EA5A1C060FDD0C7B4E366F38B897B4F5" name="biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due if ex-U.S. net sales reach </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3540-wk-Fact-F1A66207600FA29F87416F38B822EB42" name="biib:ForeignSalesRequiredToTriggerMilestone" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over a period of four consecutive quarters. Royalty payments are recognized in cost of sales within our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 65</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-9" continuedAt="TextSelection-0248CB847CE55149846C6F38B8E8AA98-10"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">agreement between Acorda and Alkermes Inc., who acquired Elan Drug Technologies, the original party to the license with Acorda. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ending </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3565-wk-Fact-404E03712136CD77DE8C6F38B8316AE4" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3569-wk-Fact-B78CCBC6AB2F035AA4EC6F38B8819922" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3574-wk-Fact-4AAD0D6C41920063614E6F38B87670E0" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie for the development and commercialization of ZINBRYTA, which was approved for the treatment of RMS in the U.S. in May 2016 and in the E.U. in July 2016. The collaboration began selling ZINBRYTA in the third quarter of 2016. In March 2018 we and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for RMS.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we and AbbVie conducted ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories, where development and commercialization costs and profits were shared equally.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We were responsible for manufacturing and research and development activities and recorded these activities within their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures received from AbbVie.&#160;For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the collaboration incurred </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3602-wk-Fact-6C7BA2D242BBD1C886F06F38B7B55975" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3606-wk-Fact-811A9D6FFBA7E278CE7E6F38B8AD05DB" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3611-wk-Fact-838CE9149DE37C8CB94B6F38B7BCA4D3" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for research and development activities, respectively, for which we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3615-wk-Fact-86F35087C76273AF20236F38B8851B4E" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3619-wk-Fact-0989A631126306480E926F38B874BEE7" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3623-wk-Fact-F48B96524831F4EC11236F38B87D93D8" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie recognized revenues on sales to third parties and we recognized our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3633-wk-Fact-2191C1A3A8C54C5C63EE6F38B8258F6C" name="biib:Biogenshareofcopromotionprofitsorlosses" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of the co-promotion losses on ZINBRYTA in the U.S. for the year ended December 31, 2019, was immaterial. For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenues from collaborative and other relationships, a component of other revenues, of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3649-wk-Fact-A7E4C562D06F7A04E3316F38B825053D" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3653-wk-Fact-BCDA72483413293F7B436F38B827A94C" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">16.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect our share of the overall net losses within the collaboration for each of those years.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3674-wk-Fact-7C46030F7669AFFAE93DD20C8E341E38" name="biib:AdditionalMilestonePayment" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.4</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as potential royalties on net commercial sales.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3681-wk-Fact-F5DEECDD7C73D0E65496D20CEDFEAD5D" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3685-wk-Fact-675472E800A67B0C8E6ED20D97FD89D3" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our consolidated statements of income and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3689-wk-Fact-2A81369EB46647C60CEBD20DF59D652B" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our consolidated balance sheets and will be expensed as the services are provided. In October 2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3693-wk-Fact-362EF62B33BE7B5BF910F2039EC4019E" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3697-wk-Fact-BBE3B55DE6D14BDAF8C7F203E0AB050F" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3702-wk-Fact-2675EAA9CC3E6040330BF20421FBD7E2" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into several research, discovery and other related arrangements that resulted in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3724-wk-Fact-6D4B8D7E8024F3B20AD66F38B87AFA9E" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3728-wk-Fact-3085C0C30A9779E2D0CA6F38B871232E" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3733-wk-Fact-2123162CC5D7890D21F26F38B899081F" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, recorded as research and development expense in our consolidated statements of income. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 66</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-10" continuedAt="TextSelection-0248CB847CE55149846C6F38B8E8AA98-11"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis Co., Ltd.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;Samsung BioLogics contributed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3746-wk-Fact-8D87ED9DE334715630F56F38B8772C98" name="biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement" contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">280.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3750-wk-Fact-852C58676DA1E4B247F16F38B80BF322" name="biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement" contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">250.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3754-wk-Fact-D55A9A2E83B0312B678D6F38B89A2E7D" name="biib:JointVentureOwnerShipPercentageByThirdParty" contextRef="D2012Q1Feb_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> stake in Samsung Bioepis and we contributed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3758-wk-Fact-D24397B89D145D635BB66F38B8C6A74C" name="us-gaap:EquityMethodInvestments" contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">49.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3762-wk-Fact-DBCF0FB220053BD05F626F38B87E87D7" name="us-gaap:EquityMethodInvestments" contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3767-wk-Fact-6CE8293C111EFE1740776F38B87F1A04" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ownership interest.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3771-wk-Fact-DAB0787A25553AB213926F38B8B69EFC" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflected the effect of previous equity financings in which we did not participate, to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3775-wk-Fact-A46E758D060B3483184A6F38B8B7D2D3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3779-wk-Fact-1D9B164B83DF3A938B3E6F38B8B5E5B9" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3783-wk-Fact-5DB725E3C58F19FD80EA6F38B8B392CA" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics.&#160;As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3792-wk-Fact-A46E758D060B3483184A6F38B8B7D2D3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3803-wk-Fact-771D05291C8CC40C81F7D21AA9F83E54" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">675</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3807-wk-Fact-081E3F1AC50849F244ACD21B53D44884" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to inventory, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3811-wk-Fact-AAE6B857D798A53D01CDD21A418C492A" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">615</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to developed technology and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3815-wk-Fact-F4F967EFE1EE2E9ABF6AD21BC7A877F6" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to IPR&amp;D. A deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3819-wk-Fact-0A7EE883B67066DBBBEED21C263442F3" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51071008e3824-wk-Fact-E0D08ADEFD56849B949BD21D8B30E561" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember" format="ixt-sec:duryear">1.5</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51071008e3828-wk-Fact-DAB312106952D76CA981D21DF6687E5D" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years, respectively, one quarter in arrears.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized losses on our investment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3842-wk-Fact-23936DA0DC5001F1DADAD220C9D581A5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">79.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These losses reflect our share of losses totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3846-wk-Fact-66154A9606CEC9C41FE3D2217F28B5AE" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and amortization of basis differences totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3850-wk-Fact-CAB0D45948C3549C78A5D2228CB00F92" name="us-gaap:AdjustmentForAmortization" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">78.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3865-wk-Fact-8B25F35DD4B8B6D130EE7FC9A21CE66B" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">670.8</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3869-wk-Fact-F7C51D85CEA56380D0337FC9E125D2A2" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">580.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3873-wk-Fact-D54A0203BB298D1A86707FCA1DE4971F" name="us-gaap:EquityMethodInvestments" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3878-wk-Fact-17DCA88187EFC9B166DA7FCA47FC4B95" name="us-gaap:EquityMethodInvestments" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">680.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets within our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2019 Transaction</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3891-wk-Fact-8D6B653F907874A6E197D22634175528" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Samsung Bioepis in January 2020, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3895-wk-Fact-5B7F3DDADDBB4C47F3B2EC6DE68C4672" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our consolidated statements of income and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3899-wk-Fact-6791AF70FA77FE74B14AF2095DC411E0" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as an intangible asset in our consolidated balance sheets. Additionally, we may pay Samsung Bioepis up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3903-wk-Fact-C0B4C53773E14CED851CD22804A64D7A" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">210.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development, regulatory and sales-based milestones, including a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3907-wk-Fact-6828886166CEFE3ED2D5F20AAF8C3EF6" name="biib:AdditionalMilestonePayment" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> development milestone that we may pay in 2020. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also acquired an option to extend the term of our current European commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3914-wk-Fact-A432E54702AD34B8591ED22D5CE08289" name="biib:ContractOptionExerciseFee" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and obtained exclusive rights to commercialize these products in China. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 67</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-11" continuedAt="TextSelection-0248CB847CE55149846C6F38B8E8AA98-12"><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2013 Commercial Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2013 pursuant to our rights under the joint venture agreement with Samsung BioLogics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, 3 anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of BENEPALI, Japan.&#160;As discussed above, we have an option to extend this agreement by an additional five years. Under this agreement, we have made upfront and clinical development milestone payments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3924-wk-Fact-56AFCE20C54A6CC5AFB76F38B81D22A3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2013Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3928-wk-Fact-A1667191ABA6F8419ED26F38B80703C6" name="biib:AdditionalMilestonePayment" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept biosimilar referencing ENBREL, received regulatory approval in the E.U. in August 2017, May 2016 and January 2016, respectively, and we capitalized the related milestone payments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3932-wk-Fact-66EB9FA5174B08DB1DB86F38B87381C7" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as intangible assets, net in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we and Samsung Bioepis announced an agreement with AbbVie related to the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. We began to recognize revenues on sales of IMRALDI to third parties in Europe in the fourth quarter of 2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3946-wk-Fact-48EABB5BCC628031C5326F38B87E15F5" name="biib:EquityMethodInvestmentsExpectedProfitShare" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3962-wk-Fact-C2712DE5284CD67B98766F38B81C2AA2" name="biib:CollaborationProfitSharing" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">241.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3967-wk-Fact-B982771564D71C98A85B6F38B8931CE6" name="biib:CollaborationProfitSharing" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">187.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e3971-wk-Fact-788368E24B5EC46BB2316F38B86F0577" name="biib:CollaborationProfitSharing" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">111.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e3975-wk-Fact-48EABB5BCC628031C5326F38B87E15F5" name="biib:EquityMethodInvestmentsExpectedProfitShare" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development and analytical development. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019 FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under the technical development services and manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e4016-wk-Fact-BC915FE1FECB54CF4E056F38B87E9E6F" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e4020-wk-Fact-EBD00976BEE6C60D674C6F38B7FF634D" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">96.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e4025-wk-Fact-4921D7BE0122CF1814FF6F38B8C44381" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues under the license, technical development services and manufacturing agreements, which is reflected in revenues from collaborative and other relationships, as a component of other revenues in our consolidated statements of income. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 68</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-12"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts receivable from Samsung Bioepis related to the agreements discussed above were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e4032-wk-Fact-2B38C81BAE0E01F3BCE0F21A9F57496B" name="us-gaap:DueFromRelatedParties" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51071008e4036-wk-Fact-00A318E352F4AC8DCCEEF21B6D75E60E" name="us-gaap:DueFromRelatedParties" contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">116.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Amounts payable to Samsung Bioepis as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisted of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e4053-wk-Fact-9A423FB5FF6E75EB561CF21C3A27ADBA" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment related to the 2019 transaction we completed in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as discussed above. Amounts payable to Samsung Bioepis as of December 31, 2018, were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51071008e4061-wk-Fact-9F81F1F89FD292CA48CEF21E1C5BAE54" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></ix:continuation><div><a id="s68B8E0CAA8EF5E0F8C0981D79D069579"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="TextSelection-7B876764000A21D7A8636F38B8E81C06-0-wk-Fact-265CB486E69B573024BF6F38B8333118" continuedAt="TextSelection-7B876764000A21D7A8636F38B8E81C06-1" escape="true">Investments in Variable Interest Entities</ix:nonNumeric></span></div><ix:continuation id="TextSelection-7B876764000A21D7A8636F38B8E81C06-1" continuedAt="TextSelection-7B876764000A21D7A8636F38B8E81C06-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab, our anti-amyloid beta antibody candidate for the potential treatment of AD (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all licensed products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of the Neurimmune Agreement and made a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51057336e1314-wk-Fact-DB65AC15292FB71121BAD13ADCB80CEC" name="us-gaap:PaymentsToMinorityShareholders" contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune in exchange for a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51057336e1318-wk-Fact-1DCD443E7C1D275CAD15D13A87F52F6D" name="biib:Reductioninroyaltyratepayableoncommercialsales" contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51057336e1322-wk-Fact-C19630D92012165D1FC7D13BABFED104" name="us-gaap:PaymentsToMinorityShareholders" contextRef="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51057336e1326-wk-Fact-FBC8A0F6B8DBADA5A65FD13B517B54B9" name="biib:Additionalreductioninroyaltyratepayableoncommercialsales" contextRef="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, under the terms of the Neurimmune Agreement, we would be required to pay Neurimmune a milestone payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51057336e1333-wk-Fact-3D02CF3B8FE89CC2BA34E8C5607DA162" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the regulatory filing with the FDA for approval of aducanumab and a milestone payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51057336e1337-wk-Fact-E00CAFA5C5E3AF54FE19E8C6DE164BFA" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if aducanumab is launched in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai. For additional information on our collaboration arrangements with Eisai, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 69</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-7B876764000A21D7A8636F38B8E81C06-2" continuedAt="TextSelection-7B876764000A21D7A8636F38B8E81C06-3"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51057336e1392-wk-Fact-2F8ED388D78B448BDED46F38B881BB49" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51057336e1396-wk-Fact-A285A36E7B203AE01A146F38B83D8AC9" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-7B876764000A21D7A8636F38B8E81C06-3">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.</ix:continuation> </span></div><div><a id="s8AC1C58081CB5C2ABD44FF28EC9373F8"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">20.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="TextSelection-8876274B241FF251AD046F38B8E896C5-0-wk-Fact-4953CBD6F753103A31DA6F38B7ABCE40" continuedAt="TextSelection-8876274B241FF251AD046F38B8E896C5-1" escape="true">Litigation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-8876274B241FF251AD046F38B8E896C5-1" continuedAt="TextSelection-8876274B241FF251AD046F38B8E896C5-2"><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing on the merits has been scheduled. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. In Italy, Fresenius Kabi has surrendered the Italian counterpart of the &#8216;510 Patent and has moved to dismiss its infringement action. A hearing in the proceeding in Germany has not yet been set but is expected to occur after a decision on our pending opposition to the &#8216;510 patent in the EPO.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 70</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8876274B241FF251AD046F38B8E896C5-2" continuedAt="TextSelection-8876274B241FF251AD046F38B8E896C5-3"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">'667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom (U.K.) counterpart of the '667 Patent. In January 2020 the U.K. court revoked the patent.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. Gedeon Richter filed a separate action for infringement in the same court and a hearing in both cases has been set for May 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss in the pending IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Dispute with Former Convergence Shareholders</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51059462e1346-wk-Fact-5F60A55BB9859C24F44DEC440B3F8272" name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">200.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of our U.S. Patent No. 8,399,514 (the '514 Patent), which covers treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. Sawai USA, Inc. and Sawai Pharmaceutical Co. Ltd. were later joined as petitioners, but in January 2020 the PTAB terminated their involvement in the proceeding. A hearing on Mylan&#8217;s petition was held in November 2019 and on February 5, 2020, the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, 2018 and 2019 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shipla Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia. The litigation against Aurobindo Pharma U.S.A., Inc., Glenmark Pharmaceuticals Ltd. and Sawai USA was dismissed in the fourth quarter of 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial against the remaining Delaware Defendants was held in the Delaware Court in December 2019 and we are awaiting a decision.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial is ongoing in the West Virginia action against Mylan.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into settlement agreements with some of the Delaware Defendants and we now anticipate market entry of a generic product equivalent to TECFIDERA before the &#8216;514 Patent expires in February 2028.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we filed an action under the Hatch-Waxman Act against Banner Life Sciences LLC (Banner) for infringement of our U.S. Patent No. 7,619,001 (the &#8216;001 patent) expiring on June 20, 2020, and claiming treatment of MS with dimethyl fumarate or methyl hydrogen fumarate or a combination thereof. In January 2020 the </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 71</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8876274B241FF251AD046F38B8E896C5-3" continuedAt="TextSelection-8876274B241FF251AD046F38B8E896C5-4"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware Court entered judgment that Banner&#8217;s drug product does not infringe the &#8216;001 patent. We have appealed the decision.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the EPO revoked our European patent number 2 137 537 (the '537 Patent), which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing has been set for March 2020. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for June 2020. For additional information regarding this matter, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish '263 Patent), corresponding to our European Patent Number 1 485 127 (the E.U. '127 Patent) and covering administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. No hearing on the merits has been set in this matter.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and a hearing has been set for July 2020 in our appeal in the German action. No date for a hearing on the merits has been set in the Italian action.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. EMD Serono and Pfizer filed an appeal in the U.S. Court of Appeals for the Federal Circuit and oral argument is scheduled for March 2020. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We are cooperating with the investigation and have participated in preliminary discussions with the government regarding potential resolution of aspects of the matter. We have accrued the amount of our best estimate of the minimum probable loss in this matter.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 72</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8876274B241FF251AD046F38B8E896C5-4"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51059462e1435-wk-Fact-9A0003D48F79424514B26F38B7ACECC8" name="us-gaap:LossContingencyEstimateOfPossibleLoss" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_country_BR" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties. We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending. We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div><a id="s886D2AC5205954ABB2E701B8335DD0D7"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">21.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-2EB05FD7772AEE7F87646F38B8E8B06E-0-wk-Fact-D65571CBE05A3241BE026F38B8B0601D" continuedAt="TextSelection-2EB05FD7772AEE7F87646F38B8E8B06E-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-2EB05FD7772AEE7F87646F38B8E8B06E-1" continuedAt="TextSelection-2EB05FD7772AEE7F87646F38B8E8B06E-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Payments</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064727e1301-wk-Fact-EBD6EC500D1CE98116AF6F38B88CA3B4" name="biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net commercial sales up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1305-wk-Fact-B00C4DF317BBBD5BD22F6F38B891ABDD" name="biib:FutureContingentPaymentThreshold" contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064727e1309-wk-Fact-4BF71588B4E62170C4756F38B8B2396A" name="biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net commercial sales that exceed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1313-wk-Fact-B00C4DF317BBBD5BD22F6F38B891ABDD" name="biib:FutureContingentPaymentThreshold" contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net commercial sales of SPINRAZA using a tiered royalty rate between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064727e1323-wk-Fact-97EF098C978E67239F5E6F38B88B6DA7" name="biib:PercentageOfRoyaltiesAsPerCollaboration" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064727e1327-wk-Fact-279649C450172DB898E46F38B897EA2C" name="biib:PercentageOfRoyaltiesAsPerCollaboration" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recorded as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">VUMERITY</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes, we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51064727e1341-wk-Fact-1F987F6C8DFF43FB8511EC47C08D492A" name="biib:PercentageOfRoyaltiesAsPerCollaboration" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recorded as cost of sales in our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. For additional information on our collaboration arrangement with Alkermes, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence and BIN occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue the remaining obligations each reporting period. We may pay up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1358-wk-Fact-48B032DD5B2856DA9FB16F38B889F3F1" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">735.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestones related to these acquisitions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired the Fumapharm Products. We were required to make contingent payments to former shareholders of Fumapharm AG and holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement, until such time as the cumulative sales level reached </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1369-wk-Fact-52F3177A7113406F4A0D6F38B8263878" name="biib:CumulativeSalesLevel" contextRef="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">20.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments were due. During the first </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 73</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-2EB05FD7772AEE7F87646F38B8E8B06E-2"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we paid the final </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1380-wk-Fact-00B4683AD08C54F6AB9A0C84CED65C99" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment as we achieved the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1384-wk-Fact-A9129AACC76F7855A4456F38B8AF7A68" name="biib:CumulativeSalesLevel" contextRef="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_TwentybillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">20.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2018.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1398-wk-Fact-0776212560941C81146F6F38B8AD1A2F" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">6.8</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1402-wk-Fact-ED218F9DC433A7A7EB2E6F38B8B287BD" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in development milestones, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1406-wk-Fact-D116F0DF4FB64DA0B1EC6F38B8B06C4A" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in regulatory milestones and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1410-wk-Fact-21D2290D413A9581BC386F38B8AECE53" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_CommercialMilestonesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.2</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1422-wk-Fact-640ECF8E8C001804904AEC60BE836EFD" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_ExpectedPaymentTimelineofMilestoneAxis_biib_TwelvemonthsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">430.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of milestone payments in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1430-wk-Fact-3D02CF3B8FE89CC2BA34E8C5607DA162" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the regulatory filing with the FDA for approval of aducanumab and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1434-wk-Fact-E00CAFA5C5E3AF54FE19E8C6DE164BFA" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if aducanumab is launched in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1448-wk-Fact-6ECB94B0B79FC17F81356F38B8AF3F26" name="biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated balance sheet for expenditures incurred by CROs as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1456-wk-Fact-427D34D688E05363331A6F38B88A5E5F" name="us-gaap:OtherCommitment" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">514.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cancellable future commitments based on existing CRO contracts as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1467-wk-Fact-994A71B05DC0C10DA6977EFB1890BB20" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2019Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees and have accrued for this obligation. We may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1481-wk-Fact-C7E36954AFAACB148FC26F38B8AF9E42" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">136.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net liabilities associated with uncertain tax positions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1497-wk-Fact-52C5D7094068BA7F90B96F38B8C0633D" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">697.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the Transition Toll Tax. Of the amounts accrued as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to an approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1505-wk-Fact-AD9B60635BB64EC20E84D152089FDEEB" name="us-gaap:IncomeTaxesPaid" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> carryforward of taxes paid in relation to the company's 2017 tax return. The Transition Toll Tax will be paid over an eight-year period, which started in 2018, and will not accrue interest. For additional information on the Transition Toll Tax, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Manufacturing Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51064727e1524-wk-Fact-8304BC3025AB413DB9796F38B8B439C7" name="us-gaap:OtherCommitment" contextRef="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the construction of this facility.</span></div></ix:continuation><div><a id="sDD1C264737F75B61B4A4B01A6B071508"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">22.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:GuaranteesTextBlock" id="TextSelection-319FC8E7471B5DC248EB6F38B8E902D0-0-wk-Fact-736467A969D1A652D48D6F38B8AB41C1" continuedAt="TextSelection-319FC8E7471B5DC248EB6F38B8E902D0-1" escape="true">Guarantees</ix:nonNumeric></span></div><ix:continuation id="TextSelection-319FC8E7471B5DC248EB6F38B8E902D0-1" continuedAt="TextSelection-319FC8E7471B5DC248EB6F38B8E902D0-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not have significant liabilities recorded for guarantees.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 74</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-319FC8E7471B5DC248EB6F38B8E902D0-2"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></ix:continuation><div><a id="sD943D452240C5F30AD40424EB96477AA"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">23.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="TextSelection-BF963FD87C8E6D8ECE9C6F38B8E98819-0-wk-Fact-C4CF9E5CCC7ECA210AA06F38B8246515" continuedAt="TextSelection-BF963FD87C8E6D8ECE9C6F38B8E98819-1" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BF963FD87C8E6D8ECE9C6F38B8E98819-1"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">401(k) Savings Plan</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d51065270e1301-wk-Fact-D99AE47FEDE29B147F406F38B828E78F" name="biib:MinimumQualifyingAgeForEmployeeBenefitPlan" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember" format="ixt-sec:duryear">21</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense related to our 401(k) Savings Plan totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1308-wk-Fact-2E5F4C79981B241F8DCE6F38B829D7C0" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1312-wk-Fact-41354BEFF3BB0C99A1536F38B8201A0D" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1316-wk-Fact-2D32663DAD4837DDFA396F38B827A668" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Compensation Plan</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1347-wk-Fact-E889EFC3A3310103639E6F38B822557A" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">114.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1351-wk-Fact-A132796A6954B3C105286F38B8263E5E" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pension Plans</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51065270e1364-wk-Fact-9A1CA8ED200CCB8610066F38B81E6760" name="biib:PercentageOfMinimumInvestmentReturn" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.00</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. Minimum employee contributions are based on the respective employee&#8217;s age, salary and gender. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the Swiss plan had an unfunded net pension obligation of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1389-wk-Fact-E2A045DD696104A293146F38B829807C" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_CH" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1393-wk-Fact-988C1184F51B0AB919FE6F38B826B7E1" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_CH" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and plan assets that totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1397-wk-Fact-2F546F8BE84A22804D5A6F38B8227E61" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_CH" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1401-wk-Fact-1F7B5CD82F6ED33806C66F38B829E39D" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_CH" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">93.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recognized expense totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1418-wk-Fact-8FCD4D08FB01F06A3CE86F38B8264779" name="us-gaap:PensionExpense" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1422-wk-Fact-7D10F49F8A3712EE94F06F38B8216318" name="us-gaap:PensionExpense" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1426-wk-Fact-467FA76AD3EFD859682F6F38B826458B" name="us-gaap:PensionExpense" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our Swiss plan, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1431-wk-Fact-9D388FF5167A764EC2316F38B8252FCC" name="us-gaap:PensionExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_CH" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1435-wk-Fact-4B7F8E051E7FA2E3E7606F38B82B5093" name="us-gaap:PensionExpense" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_CH" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1439-wk-Fact-CEECC964429512646C546F38B8276795" name="us-gaap:PensionExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_CH" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, was included in other income (expense), net.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The obligations under the German plans are unfunded and totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1446-wk-Fact-59C31D551F404845C4406F38B81D04CC" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_DE" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1450-wk-Fact-37EB30B842EC92FC31EE6F38B82BA711" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_DE" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net periodic pension cost related to the German plans totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1462-wk-Fact-C4E45D0B969CFFBC14D96F38B81FE739" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_DE" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1467-wk-Fact-587FF54E95EAF8EC9EE66F38B82314C9" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_DE" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1471-wk-Fact-6677DE611C0506DF504F6F38B82CEB12" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_DE" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1487-wk-Fact-A43A4B6D95C63703CB7C6F38B826825B" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_DE" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1492-wk-Fact-8A580C55F0C7511AF4206F38B82B4512" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_DE" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065270e1496-wk-Fact-9F4E6AA1D7C74586523A6F38B824591B" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_DE" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, was included in other income (expense), net.</span></div></ix:continuation><div><a id="s4BFC5CF886DE5208A34D3AC8BCDDF7B2"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">24.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SegmentReportingDisclosureTextBlock" id="TextSelection-53DB1FAEA6598AC06C406F38B8E94F53-0-wk-Fact-34D95C94DA9019DD33176F38B7EDB16C" continuedAt="TextSelection-53DB1FAEA6598AC06C406F38B8E94F53-1" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="TextSelection-53DB1FAEA6598AC06C406F38B8E94F53-1" continuedAt="TextSelection-53DB1FAEA6598AC06C406F38B8E94F53-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e1295-wk-Fact-5427CEDDEB92B1321B7E6F38B7EE85C9" name="us-gaap:NumberOfReportableSegments" contextRef="FD2019Q4YTD" unitRef="segment" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 75</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-53DB1FAEA6598AC06C406F38B8E94F53-2"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adjacencies. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Geographic Information</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="TextSelection-F8710783B40C5BD386EA6F38B8E9268A-0-wk-Fact-471B90E542382DD739876F38B7E92817" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1484-wk-Fact-8B42590D2AE4D7B90D5A6F38B83ADC6B" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,713.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1503-wk-Fact-D1ADF5271EB4D920B3206F38B7EF8761" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,794.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1522-wk-Fact-5CC1C47027CEEF72393D6F38B8800726" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">320.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1542-wk-Fact-24E1AAE4BDA8525977496F38B883BD1B" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">551.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1561-wk-Fact-F1FBA38FF669B88E1D976F38B82CDF1B" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11,379.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1581-wk-Fact-302877AADF4727E157716F38B7F2F23B" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,211.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1600-wk-Fact-0329A2785D6301B120826F38B8839B92" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1619-wk-Fact-A5FDB089B5DEB2A7936B6F38B7F1490C" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1639-wk-Fact-ABD1723A5EDA5BDEBBAA6F38B7F51F9F" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">78.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1658-wk-Fact-6DB6BA0B8C715A0D0D4B6F38B8607F57" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,290.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1678-wk-Fact-9F4CABFBF61C08C7E87A6F38B7F6DA17" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">585.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1697-wk-Fact-7A3EB7F7BE97023681FB6F38B7EF2D8F" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1716-wk-Fact-1D2439D2FBE31142DE6F6F38B7E96A09" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1736-wk-Fact-095C88231DD51BB72BFC6F38B7ED5F77" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1755-wk-Fact-00E0A71FFA7A5B6582ED6F38B7ACA093" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">707.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1775-wk-Fact-5F5DB3E2272AB8BEF9F96F38B7F78461" name="us-gaap:NoncurrentAssets" contextRef="FI2019Q4_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,493.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1794-wk-Fact-1A401C3F874F7BFDEBD76F38B881CC25" name="us-gaap:NoncurrentAssets" contextRef="FI2019Q4_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,162.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1813-wk-Fact-91065B372CF805CC59FF6F38B7EF344F" name="us-gaap:NoncurrentAssets" contextRef="FI2019Q4_srt_StatementGeographicalAxis_srt_AsiaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1833-wk-Fact-76AAB65B2A55E8CEFC946F38B7EEB45D" name="us-gaap:NoncurrentAssets" contextRef="FI2019Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51067797e1852-wk-Fact-94DC29CEE3F92F740CE96F38B7EFC59F" name="us-gaap:NoncurrentAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,674.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2076-wk-Fact-5384BFFD347C612F45386F38B8517C44" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,800.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2095-wk-Fact-275AB4FFDCA5EF8F689B6F38B7CD7319" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,370.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2114-wk-Fact-CD016954D7E8676A16366F38B7F9715C" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">281.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2134-wk-Fact-61E59191AAEF81EB2BA06F38B7EBAD21" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">434.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2153-wk-Fact-7B6205D978C9C04E48296F38B81CF51A" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10,886.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2173-wk-Fact-5EF752A227592086471A6F38B87F0557" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,903.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2192-wk-Fact-15A53D11F6DA96A745546F38B7DC71EE" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2211-wk-Fact-DE1BAE8DA3A43AE8551F6F38B88B779F" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2231-wk-Fact-6C130D9355AF505EBF086F38B882B79C" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2250-wk-Fact-5DE8AC0444CC0844782E6F38B82AE6AA" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,980.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2270-wk-Fact-264EFC1D21AB90A284476F38B7FB0CF4" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">457.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2289-wk-Fact-3C1DF127DC9DD578F87F6F38B88664AA" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2308-wk-Fact-A2A68834ABB36C86D7606F38B88EEA07" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">96.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2328-wk-Fact-1A0C6809BDA4753FC6A96F38B8811066" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2347-wk-Fact-F0C4D670DC0F193457D96F38B8622365" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">585.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2367-wk-Fact-7562A42A473089BD40D56F38B7F97076" name="us-gaap:NoncurrentAssets" contextRef="FI2018Q4_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,152.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2386-wk-Fact-652DA8F43F88D798C7256F38B7ECEA29" name="us-gaap:NoncurrentAssets" contextRef="FI2018Q4_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,442.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2405-wk-Fact-BB01A963345C013E206E6F38B884948F" name="us-gaap:NoncurrentAssets" contextRef="FI2018Q4_srt_StatementGeographicalAxis_srt_AsiaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2425-wk-Fact-027982AD79AD29EA6B406F38B88477E9" name="us-gaap:NoncurrentAssets" contextRef="FI2018Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2444-wk-Fact-9E56EA3F4D5FC1518D1A6F38B7F207CD" name="us-gaap:NoncurrentAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,601.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2017 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2669-wk-Fact-279DB18511D84B5AD04A6F38B8A819C5" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,017.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2688-wk-Fact-642975C3D6C28123A4726F38B7F0826F" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,844.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2707-wk-Fact-C77115557CCAA3ADDCF76F38B8826FEB" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2727-wk-Fact-DBCBE5F70B3B9DB8CAED6F38B7F35AE4" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">332.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2746-wk-Fact-A0A85755BDDAAFF80DF16F38B7A963B8" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10,354.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2766-wk-Fact-F9ECA47F2C0B0325F8336F38B7EFDED1" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,475.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2785-wk-Fact-D75FB3B1F832C8532F786F38B7F0CFC4" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2804-wk-Fact-4532B72CFBDDC394485E6F38B7F43FC2" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2824-wk-Fact-B3FA4B00BA644CBFEC916F38B7EBF4EC" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2843-wk-Fact-3A0656DB95083450147A6F38B824BC8E" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,559.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2863-wk-Fact-C53B45C269C2189708726F38B7CCB94E" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">249.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2882-wk-Fact-3863DF20D8ACF33505CF6F38B7CB577F" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">67.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2901-wk-Fact-28CEEDFEA5E04BAE6DA36F38B8832E29" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2921-wk-Fact-11818BB1ECD914C093916F38B7FBFD70" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2940-wk-Fact-5D3FED1ADFF25AE90C656F38B87CF3D8" name="us-gaap:Revenues" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">360.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2960-wk-Fact-62338B2EAF4D1924647A6F38B7EDF103" name="us-gaap:NoncurrentAssets" contextRef="FI2017Q4_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,226.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2979-wk-Fact-3CB99C6F8CFD6C286D416F38B886F312" name="us-gaap:NoncurrentAssets" contextRef="FI2017Q4_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,948.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e2998-wk-Fact-88452907363C618AE3066F38B7EF3679" name="us-gaap:NoncurrentAssets" contextRef="FI2017Q4_srt_StatementGeographicalAxis_srt_AsiaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e3018-wk-Fact-B29D8B95A58F749477E56F38B7CC2615" name="us-gaap:NoncurrentAssets" contextRef="FI2017Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51067797e3037-wk-Fact-541578B691FC636CFB606F38B7F05BBB" name="us-gaap:NoncurrentAssets" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,182.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51067797e3077-wk-Fact-85205AFED49CBF44EB4F6F38B7F6230C" name="us-gaap:NoncurrentAssets" contextRef="FI2019Q4_srt_StatementGeographicalAxis_biib_SolothurnMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,028.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51067797e3081-wk-Fact-4278D722BE0FAE4D2DE56F38B7EE3A42" name="us-gaap:NoncurrentAssets" contextRef="FI2018Q4_srt_StatementGeographicalAxis_biib_SolothurnMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,748.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51067797e3086-wk-Fact-EBA944AC55EF018982E26F38B7ED4E8A" name="us-gaap:NoncurrentAssets" contextRef="FI2017Q4_srt_StatementGeographicalAxis_biib_SolothurnMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,215.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51067797e3101-wk-Fact-BFF966C5B2B9276781EE6F38B7E9DCB8" name="us-gaap:NoncurrentAssets" contextRef="FI2018Q4_srt_StatementGeographicalAxis_country_DK" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">646.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51067797e3105-wk-Fact-67CE26E1B85ECCC0E5F36F38B7D53E68" name="us-gaap:NoncurrentAssets" contextRef="FI2017Q4_srt_StatementGeographicalAxis_country_DK" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">707.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to our manufacturing facility in Hiller&#248;d, Denmark.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read Note 10, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 76</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE7B9134075DB53C1AAD831287357ECA2"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">25.&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="TextSelection-0E9B45DD7372ACAFCAF06F38B8EB6324-0-wk-Fact-301FD8665A37A02D43E26F38B87A2460" continuedAt="TextSelection-0E9B45DD7372ACAFCAF06F38B8EB6324-1" escape="true">&#160;&#160;&#160;&#160;Quarterly Financial Data (Unaudited)</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="TextSelection-C3B13C8C0EC18BE3BCAD6F38B8EB31A7-0-wk-Fact-D70888FD5EA151BDDD0A6F38B88310D2" continuedAt="TextSelection-C3B13C8C0EC18BE3BCAD6F38B8EB31A7-1" escape="true"><ix:continuation id="TextSelection-0E9B45DD7372ACAFCAF06F38B8EB6324-1" continuedAt="TextSelection-0E9B45DD7372ACAFCAF06F38B8EB6324-2"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1572-wk-Fact-AD5FB9CCB325CF9421AD6F38B7ADD3B3" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,680.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1591-wk-Fact-3C99DBEE0A70FF128ED76F38B7CACC9F" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,880.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1610-wk-Fact-FDA2283986F94F8989176F38B7AB9F87" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,894.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1630-wk-Fact-EBC222CFB76BCEF4797C6F38B7A77F5E" name="us-gaap:Revenues" contextRef="FD2019Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,924.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1649-wk-Fact-F1FBA38FF669B88E1D976F38B82CDF1B" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11,379.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1669-wk-Fact-D841D758A9AE1491D7356F38B7C01877" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">517.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1688-wk-Fact-F3EA7407820C3A25AB6F6F38B7CA41D9" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">576.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1707-wk-Fact-22090CFFFD2F9FA335B86F38B7BB91AA" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">595.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1727-wk-Fact-FCD514F0CFE43F1D8E326F38B7A99E9C" name="us-gaap:Revenues" contextRef="FD2019Q4QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">600.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1746-wk-Fact-6DB6BA0B8C715A0D0D4B6F38B8607F57" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,290.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1766-wk-Fact-4DC688EC5AC5B079BF716F38B7CD1745" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">292.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1785-wk-Fact-0A77A8237921432958FA6F38B7C77344" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1804-wk-Fact-FCC559336DD4CB3730296F38B7BCDB0F" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1824-wk-Fact-433EF916C4F31B981FF06F38B7A95047" name="us-gaap:Revenues" contextRef="FD2019Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">145.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1843-wk-Fact-00E0A71FFA7A5B6582ED6F38B7ACA093" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">707.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1863-wk-Fact-E66159CAA272F56A28B96F38B7AC2603" name="us-gaap:Revenues" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,489.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1882-wk-Fact-9D67E0FD29235C9445926F38B7CC811D" name="us-gaap:Revenues" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,616.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1901-wk-Fact-6D5131DB8D61F9BDE8A06F38B7AC54F3" name="us-gaap:Revenues" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,600.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1921-wk-Fact-08548BD7E3A5566F20A56F38B7C55A3A" name="us-gaap:Revenues" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,671.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1940-wk-Fact-E32397F18F6693CE30CB6F38B869063E" name="us-gaap:Revenues" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14,377.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1962-wk-Fact-25F8D9680520642A20556F38B7A877D9" name="us-gaap:GrossProfit" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,887.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e1981-wk-Fact-F03991FB13B63561F4C96F38B7CC50F3" name="us-gaap:GrossProfit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,140.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2000-wk-Fact-F1ACA004E23D51D9B4726F38B7B6E740" name="us-gaap:GrossProfit" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,170.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2020-wk-Fact-9E8DAB667FD08FF8AE916F38B7ACD38A" name="us-gaap:GrossProfit" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,224.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2039-wk-Fact-90B4B0BBDC335E1D98E66F38B7AEC3AF" name="us-gaap:GrossProfit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,422.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2061-wk-Fact-5CB2738E0B2538DCF1A06F38B7BDC8F2" name="us-gaap:ProfitLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2080-wk-Fact-ECEAB4B119829BAB3C906F38B7CB668E" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2099-wk-Fact-F395A257B7F590399F956F38B7C9A1C5" name="us-gaap:ProfitLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,545.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2119-wk-Fact-C434E596792007D163776F38B7CBD190" name="us-gaap:ProfitLoss" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,439.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2138-wk-Fact-C3E3738B6B2880EEE0C26F38B86F41E2" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,888.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2160-wk-Fact-83DF4A1F2393A5ED88726F38B7AD3519" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2179-wk-Fact-36F36E7386F02C65EC8B6F38B7C94661" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2198-wk-Fact-1986ED84E54A9B7C58D26F38B7CDA200" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,545.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2218-wk-Fact-4471A1E7D022C2980A646F38B7CAF15E" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,439.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2237-wk-Fact-409F06146EDA2C5A1FA56F38B82DE39D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,888.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2359-wk-Fact-3BDD6A35F238782207506F38B7CDF5F9" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2378-wk-Fact-DA7D41C4F4E182D8EF5C6F38B7AB5E58" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2397-wk-Fact-3C2FC0561FB7CC6CFDC56F38B7AAB1AE" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2417-wk-Fact-4AD7D09A973C86BFE6946F38B7C98EE1" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2436-wk-Fact-A79B8DD2B8E528E3782E6F38B808C78D" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">31.47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2457-wk-Fact-47CFB0CD5C2C762DBF116F38B7ABFBA2" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2476-wk-Fact-37082D66FD70F1D412346F38B7CDBE64" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2495-wk-Fact-7FD2F26F5947521C8BE36F38B7A7294D" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2515-wk-Fact-A048BB136DDC540916CA6F38B7B1E593" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2534-wk-Fact-F8BA2307E5D05CF7F3896F38B7C21B4F" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">31.42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2651-wk-Fact-C6761C1F1CA74A16822D6F38B7C91E98" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">196.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2670-wk-Fact-6A2AD75D2054CFC71F016F38B7A72D25" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2689-wk-Fact-BE3C899C712E77415DE86F38B7C5EB92" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">184.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2709-wk-Fact-35A1AFB52B56E89DDAA56F38B7C9F202" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q4QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">177.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2728-wk-Fact-1969AB1F17EC7BCE4FB56F38B7B8CA9B" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">187.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2748-wk-Fact-DBEA22B774F16B3CFEF86F38B7A9DC71" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">197.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2767-wk-Fact-BF07F8E164232369C7C36F38B7AAABC9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2786-wk-Fact-AD5DBA1463EBDCBB74A26F38B7B6C73D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">184.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2806-wk-Fact-7ECACBA61073B2ED940C6F38B7C845F8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q4QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">178.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span><ix:nonFraction id="d51074274e2825-wk-Fact-9C26193DB3CDD8FB9C8B6F38B8899F39" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">187.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3097-wk-Fact-30F3E12D536F79AABFFC6F38B808B357" name="us-gaap:Revenues" contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,523.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3116-wk-Fact-AD919574D17CAEC27DA66F38B811E3DB" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,757.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3135-wk-Fact-68103C672778227924356F38B80874D8" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,780.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3155-wk-Fact-8B326E9A26F264AC12086F38B818E2B6" name="us-gaap:Revenues" contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,825.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3174-wk-Fact-7B6205D978C9C04E48296F38B81CF51A" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10,886.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3194-wk-Fact-28863BD8E6798AE49A656F38B80C388D" name="us-gaap:Revenues" contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">443.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3213-wk-Fact-E59C624DCFB464B0C7676F38B7F81774" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">490.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3232-wk-Fact-60E3C8FDE3B55903D8066F38B7FDB782" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">511.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3252-wk-Fact-0AA8E5171B27F12CD62A6F38B810AB32" name="us-gaap:Revenues" contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">534.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3271-wk-Fact-5DE8AC0444CC0844782E6F38B82AE6AA" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,980.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3291-wk-Fact-9011AE068F8ECE15B8D66F38B7FA7F68" name="us-gaap:Revenues" contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">164.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3310-wk-Fact-5E718DE99528EB752B886F38B7EAD1AF" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">108.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3329-wk-Fact-EFD2F43A1450A1C22FFB6F38B8169DE3" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">147.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3349-wk-Fact-34D2C07DC74D44E6CFF26F38B80B737A" name="us-gaap:Revenues" contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">165.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3368-wk-Fact-F0C4D670DC0F193457D96F38B8622365" name="us-gaap:Revenues" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">585.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3388-wk-Fact-1EA16D36EE1AE4411D1A6F38B8049268" name="us-gaap:Revenues" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,131.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3407-wk-Fact-078C4341C813F11836146F38B80DCE38" name="us-gaap:Revenues" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,356.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3426-wk-Fact-EAF9B9FE03252FD9A1A96F38B80F27BB" name="us-gaap:Revenues" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,439.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3446-wk-Fact-9CB27597215A4E7FAA6E6F38B8076EFC" name="us-gaap:Revenues" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,526.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3465-wk-Fact-6346545FE8014FEB58A26F38B7BCE6BD" name="us-gaap:Revenues" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,452.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3487-wk-Fact-AD7947C887768A97332A6F38B805214D" name="us-gaap:GrossProfit" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,685.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3506-wk-Fact-18648B692AB2CAE6B5BE6F38B8007958" name="us-gaap:GrossProfit" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,935.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3525-wk-Fact-7D710B0C70644267D7476F38B819CD33" name="us-gaap:GrossProfit" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,978.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3545-wk-Fact-D6A590AF10C4643FB6FE6F38B80C7506" name="us-gaap:GrossProfit" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,037.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3564-wk-Fact-E3357B8FDA69C56A09186F38B7FDB839" name="us-gaap:GrossProfit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11,636.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3586-wk-Fact-B3AB723FE175911FB07E6F38B7F0F805" name="us-gaap:ProfitLoss" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,171.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3605-wk-Fact-B068B7126E3159FA2C536F38B7F131A2" name="us-gaap:ProfitLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">915.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3624-wk-Fact-9BCABB355017EF845B056F38B805C907" name="us-gaap:ProfitLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,442.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3644-wk-Fact-15605FE8BC1CD2C9C6FB6F38B7F481A7" name="us-gaap:ProfitLoss" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">944.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3663-wk-Fact-697504B55D319C5C89A06F38B813740F" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,474.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3685-wk-Fact-5EF51A0A02802EFFDD366F38B7F6849E" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,172.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3704-wk-Fact-3C07468CEC439713990D6F38B7F382D1" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">866.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3723-wk-Fact-9CD666CAB27461A1B8E16F38B7FA6F36" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,444.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3743-wk-Fact-DA01565E8E45737ED7AA6F38B8073EB8" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">946.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3762-wk-Fact-D75E3BB69A698B5537196F38B831D83C" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,430.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3884-wk-Fact-49623268A504D41A981F6F38B7F8EAED" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3903-wk-Fact-7651DAC439D825E8B7696F38B80AB9B3" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3922-wk-Fact-42ADC5E897592FF8E0116F38B7FBE91C" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3942-wk-Fact-C5188F0B4EB3254B954E6F38B7EE313D" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.74</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3961-wk-Fact-EC8AD5EF20EED04CF1636F38B8861C2A" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e3982-wk-Fact-63A9F4036D89356E74106F38B80D5031" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4001-wk-Fact-AB60636A4671D09F83616F38B7F7151E" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4020-wk-Fact-B7F190E431DEB44184906F38B7F65C34" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4040-wk-Fact-765F9120D917446BE64C6F38B7FFE2A9" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4059-wk-Fact-5A9680F29B9835BE41B06F38B82F13BD" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4176-wk-Fact-FC7932016DEFEE7A5FE56F38B7F71979" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">211.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4195-wk-Fact-FAC98350780596AD28B36F38B7FEEF4D" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">207.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4214-wk-Fact-1404B31D802E46C921166F38B7FC8939" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">201.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4234-wk-Fact-CCE787442430278832B76F38B809CE0D" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q4QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">199.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4253-wk-Fact-5907C0CD0AE9671001886F38B828BCF3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">204.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4273-wk-Fact-FCC9E03DC1CC9B6D20486F38B7FFF632" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">211.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4292-wk-Fact-8E0B84ECF7BC81FC318B6F38B8068B61" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">207.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4311-wk-Fact-29B19561644BD9FBA27C6F38B80EB30B" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">201.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4331-wk-Fact-ED85616D28DB679E267D6F38B7FE4555" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q4QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">200.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d51074274e4350-wk-Fact-4176A55C9C6E8FB2BE6A6F38B7A4B71D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">205.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><ix:footnote id="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets</ix:footnote>.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for 2019 include:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax gains (losses) related to changes in the fair value of our strategic investments of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4389-wk-Fact-155FE2BAD93CE4C5E7FFEC6A378D9D8B" name="us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">376.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>($<ix:nonFraction id="d51074274e4393-wk-Fact-D8CC00D4F94E0F4E5663EC6A6676F50F" name="us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">174.2</ix:nonFraction>) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>($<ix:nonFraction id="d51074274e4397-wk-Fact-9E1231F3AE2514DA1497EC6AD45D429C" name="us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.6</ix:nonFraction>) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4401-wk-Fact-D64BD4428891C56FC7E5EC6B140B2265" name="us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second, third and fourth quarters, respectively.</span></div></td></tr></table></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 77</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-C3B13C8C0EC18BE3BCAD6F38B8EB31A7-1" continuedAt="TextSelection-C3B13C8C0EC18BE3BCAD6F38B8EB31A7-2"><ix:continuation id="TextSelection-0E9B45DD7372ACAFCAF06F38B8EB6324-2" continuedAt="TextSelection-0E9B45DD7372ACAFCAF06F38B8EB6324-3"><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment charges related to certain intangible assets of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4412-wk-Fact-C90610768443E1F0F6317F831C0B9606" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter. For additional information, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A total net loss in our consolidated statements of income of approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4427-wk-Fact-DE24E0AAB8C57FA871FDEC6C42D0446D" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">124.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the sale of all the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This loss included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4431-wk-Fact-25731977E8E1923A8E3DE870A27E5A14" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a tax expense of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4435-wk-Fact-7DD7E13C219FC7B4D1AE7F012B0335CA" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this transaction. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read, Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An expense of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4450-wk-Fact-5B7F3DDADDBB4C47F3B2EC6DE68C4672" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded in research and development expense in our consolidated statements of income in the fourth quarter as we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. We also acquired an option to extend our existing commercial agreement with Samsung Bioepis for BENEPALI, IMRALDI and FLIXABI in Europe and obtained exclusive rights to commercialize these products in China. For additional information, please read, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Losses (gains) related to the adjustments to the fair values of our contingent consideration obligations of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4465-wk-Fact-E98DDFB941B88644DF5AEC6F35091D0E" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(<ix:nonFraction id="d51074274e4469-wk-Fact-091B0E5A2669AC634033EC6F6FBA0AFD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(<ix:nonFraction id="d51074274e4473-wk-Fact-9AADE74D209FBE4C7C31EC6FA9A4D575" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.8</ix:nonFraction>) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4477-wk-Fact-39B3894DFAD25F5F286DEC6FDFEFE899" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second, third and fourth quarters, respectively. For additional information on the valuation of our contingent consideration obligations, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A payment of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4493-wk-Fact-5B5420AD288ECBE73C13EC7114B5ABC1" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis in the fourth quarter, as we exercised our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB080. For additional information, please read, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A payment of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4509-wk-Fact-675472E800A67B0C8E6ED20D97FD89D3" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk in the first quarter as we entered into a collaboration and research and development services agreement with Skyhawk pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. For additional information, please read, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for 2018 include:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax (losses) gains related to changes in the fair value of our strategic investments of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(<ix:nonFraction id="d51074274e4536-wk-Fact-2D6CDBC84B55379E429B6F38B87C088F" name="us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.4</ix:nonFraction>) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4540-wk-Fact-4C456391CD220B575E856F38B87EAF3F" name="us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4544-wk-Fact-B32F5C599F3E116FB95D6F38B87D1AC5" name="us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">141.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(<ix:nonFraction id="d51074274e4548-wk-Fact-B8B418E02662408D4B7B6F38B883B16D" name="us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.2</ix:nonFraction>) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second, third and fourth quarters, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax charges to acquired IPR&amp;D of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4561-wk-Fact-2B07C6A0EAB8D12E9C486F38B8201F89" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4565-wk-Fact-B73E9F9149B60E7A00846F38B81FA7CC" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4569-wk-Fact-771C25E8188CAD91CD726F38B81F1A30" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second and third quarters, respectively, for upfront payments made upon closing of asset purchase transactions. For additional information, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax research and development expenses for the second quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4587-wk-Fact-8669B37D8C8580A46D1C6F38B8809639" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q2QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">486.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the 2018 Ionis Agreement. For additional information, please read, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax charge to noncontrolling interests of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4611-wk-Fact-C19630D92012165D1FC7D13BABFED104" name="us-gaap:PaymentsToMinorityShareholders" contextRef="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the second quarter for a payment to Neurimmune in exchange for a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span><ix:nonFraction id="d51074274e4615-wk-Fact-FBC8A0F6B8DBADA5A65FD13B517B54B9" name="biib:Additionalreductioninroyaltyratepayableoncommercialsales" contextRef="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. For additional information, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment charges related to certain intangible assets of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4636-wk-Fact-6D50742932615A5BE2716F38B844A09D" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">189.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4640-wk-Fact-A4EB1ECE5775B27307D9E884A2D18D59" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">176.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third and fourth quarters, respectively. For additional information, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Losses (gains) related to the adjustments to the fair values of our contingent consideration obligations of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(<ix:nonFraction id="d51074274e4655-wk-Fact-EB896C80A9671BCA5721D12053D79915" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction>) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4659-wk-Fact-0E6A160C0EA0B920DE1CD1208205BF21" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(<ix:nonFraction id="d51074274e4663-wk-Fact-911C3BA01E60604047B3D120EB28908F" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.9</ix:nonFraction>) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4667-wk-Fact-04824CD0E3AC2599621AD121286C67CD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">79.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second, third and fourth quarters, </span></div></td></tr></table></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 78</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-C3B13C8C0EC18BE3BCAD6F38B8EB31A7-2" continuedAt="TextSelection-C3B13C8C0EC18BE3BCAD6F38B8EB31A7-3"><ix:continuation id="TextSelection-0E9B45DD7372ACAFCAF06F38B8EB6324-3" continuedAt="TextSelection-0E9B45DD7372ACAFCAF06F38B8EB6324-4"><div style="line-height:120%;padding-left:48px;padding-top:12px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">respectively. For additional information, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase to income tax expense of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4704-wk-Fact-570282B9EBEE8CB3C20D6F38B8C7A8FD" name="biib:DeferredtaxliabilitiesGILTItaxcalculation" contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">135.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the fourth quarter reflecting the impact of electing to record deferred taxes on GILTI. For additional information, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-C3B13C8C0EC18BE3BCAD6F38B8EB31A7-3" continuedAt="TextSelection-C3B13C8C0EC18BE3BCAD6F38B8EB31A7-4"><ix:continuation id="TextSelection-0E9B45DD7372ACAFCAF06F38B8EB6324-4" continuedAt="TextSelection-0E9B45DD7372ACAFCAF06F38B8EB6324-5"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-C3B13C8C0EC18BE3BCAD6F38B8EB31A7-4"><ix:continuation id="TextSelection-0E9B45DD7372ACAFCAF06F38B8EB6324-5"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An upfront payment of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$<ix:nonFraction id="d51074274e4725-wk-Fact-F1B44D408396DB2DB4B46F38B8357A14" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis, as we exercised our option in the fourth quarter to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize tofersen. For additional information, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></ix:continuation></ix:continuation></td></tr></table><div><a id="sB4521EB671445936B590519C81ED2AB8"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">26.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SubsequentEventsTextBlock" id="TextSelection-60D6DDE9EC14655A4F336F38B8EB7E1B-0-wk-Fact-21BB5138DD21BD5FC02D6F38B81FA1E9" continuedAt="TextSelection-60D6DDE9EC14655A4F336F38B8EB7E1B-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="TextSelection-60D6DDE9EC14655A4F336F38B8EB7E1B-1"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pfizer Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2020 we entered into an agreement to acquire PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer. In particular, we plan to develop the Phase 1 asset for the treatment of sundowning in AD and irregular sleep wake rhythm disorder in Parkinson&#8217;s disease. In connection with the closing of this transaction, we will make an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065666e1294-wk-Fact-DEDB8924A8ADBD1698EDEC78CD31B93A" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="D2019Q4Pfizer_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Pfizer, which will be recorded as acquired IPR&amp;D in our consolidated statements of income as PF-05251749 has not yet reached technological feasibility. We may also pay Pfizer up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065666e1298-wk-Fact-7DD6B4AE19422BE7FF2AEC7C94B46FE3" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="D2019Q4Pfizer_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">635.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This transaction will be accounted for as an asset acquisition and is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S. We expect the transaction to close in the first quarter of 2020.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2020 Credit Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2020 we entered into a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d51065666e1311-wk-Fact-73DC378EC219BD1563FAEC7E7FAC4555" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="I2019Q4creditfacility_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span><ix:nonNumeric id="d51065666e1315-wk-Fact-8D917A5C058323C8C36FF1EE60E38D68" name="us-gaap:LineOfCreditFacilityDescription" contextRef="D2019Q4creditfacility_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"><span style="font-family:Franklin Gothic Book,sans-serif;">five</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility entered into in August 2015.</span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 79</span></div></div><hr style="page-break-after:always"></hr><div><a id="s65C1074486305E8E930DD9C99D7393F8"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">To the Board of Directors and Shareholders of Biogen Inc.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Biogen Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2019 and 2018, and the related consolidated statements of income, comprehensive income, equity and cash flows for each of the three years in the period ended December 31, 2019, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 31, 2019, based on criteria established in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework (2013)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").  </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework (2013)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> issued by the COSO.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Changes in Accounting Principles</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As discussed in Note 1 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019 and the manner in which it accounts for income taxes for intra-entity transfers of assets other than inventory in 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Basis for Opinions</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.  </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 80</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Critical Audit Matters</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reserves for Medicaid and Managed Care Rebates </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described in Notes 1 and 4 to the consolidated financial statements, the Company recognized revenue from product sales net of reserves, including Medicaid and managed care rebates. Within Accrued expenses and other, total contractual adjustments amounted to $1,027.3 million as of December 31, 2019. This balance primarily includes provisions for Medicaid and managed care rebates in the U.S. Medicaid rebates relate to the Company&#8217;s estimated obligations to states under established reimbursement arrangements. The Company&#8217;s liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end. Managed care rebates represent the Company&#8217;s obligations to third parties, primarily pharmacy benefit managers.  Managed care rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual of the managed care rebate is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period. As disclosed by management, the Medicaid and managed care estimates reflect historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The principal considerations for our determination that performing procedures relating to reserves for Medicaid and managed care rebates is a critical audit matter are there was significant judgment by management due to the significant measurement uncertainty involved in developing these reserves, as the reserves are based on assumptions developed using historical experience, current contractual requirements, specific known market events and payment patterns. This in turn led to a high degree of auditor judgment, subjectivity and effort in applying procedures related to these assumptions.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements.  These procedures included testing the effectiveness of controls relating to the reserves for Medicaid and managed care rebates, including controls over the assumptions used to estimate these rebate reserves. These procedures also included, among others, (i) developing an independent estimate of the rebate reserves by utilizing third party data related to product demand, data related to price changes, the terms of the specific rebate programs, the historical trend of actual rebate claims paid and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 81</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s9BA39E4D1C415CF592B019C4847E2A7F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consideration of contractual requirement changes and market events; (ii) comparing the independent estimate to management&#8217;s estimate, and (iii) testing rebate claims paid by the Company, including evaluating the claims for consistency with the contractual terms of the Company&#8217;s rebate agreements.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/PricewaterhouseCoopers LLP</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston, Massachusetts</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have served as the Company's auditor since 2003.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 82</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>biib-20191231xex44.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s18666dde353e42c59bdc7a43c3dffd3e"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit 4.4</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REGISTERED PURSUANT TO SECTION 12 OF THE </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2019, Biogen Inc. (the &#8220;Company&#8221;) has five classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;): (1) Common Stock; (2) 2.900% Senior Notes due 2020; (3) 3.625% Senior Notes due 2022; (4) 4.050% Senior Notes due 2025; and (5) 5.200% Senior Notes due 2045.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">_____________________________________________________________________________________________</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Common Stock</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following description of our Common Stock is a summary and does not purport to be complete. It is</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation, as amended (the &#8220;Certificate of Incorporation&#8221;), and our Fourth Amended and Restated Bylaws (the &#8220;Bylaws&#8221;), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.4 is a part. We encourage you to</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">read our Certificate of Incorporation, our Bylaws and the applicable provisions of the General Corporation Law of Delaware for additional information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authorized Capital Stock</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our authorized capital stock consists of 1,000,000,000 shares of Common Stock, par value $0.0005 per share, and 8,000,000 shares of Preferred Stock, par value $0.001 per share.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Voting Rights</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of Common Stock are entitled to one vote per share on all matters voted on by the stockholders, including the election of directors. Our Common Stock does not have cumulative voting rights.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividend Rights</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to the rights of holders of all classes of stock at the time outstanding having prior rights as to dividends, if any, the holders of Common Stock are entitled to receive dividends, if any, as may be declared from time to time by the Board of Directors in its discretion out of funds legally available for the payment of dividends.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidation Rights</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to any preferential rights of outstanding shares of Preferred Stock, if any, holders of Common Stock will share ratably in all assets legally available for distribution to our stockholders in the event of liquidation, dissolution or winding up of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Rights and Preferences</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Common Stock has no sinking fund or redemption provisions or preemptive, conversion or exchange rights. Holders of Common Stock may act by unanimous written consent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Listing</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Common Stock is traded on The Nasdaq Stock Market LLC under the trading symbol &#8220;BIIB.&#8221;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Notes</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following description of our 2.900% Senior Notes due 2020 (the &#8220;notes due 2020&#8221;), the 3.625% Senior Notes due 2022 (the &#8220;notes due 2022&#8221;), the 4.050% Senior Notes due 2025 (the &#8220;notes due 2025&#8221;) and the 5.200% Senior Notes due 2045 (the &#8220;notes due 2045&#8221; and together with the notes due 2020, the notes due 2022 and the notes due 2025, the &#8220;notes&#8221;), is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the indenture, dated as of September 15, 2015 (the &#8220;Base Indenture&#8221;), between Biogen Inc. and U.S. Bank National Association, as trustee, as supplemented by the first supplemental indenture dated as of September 15, 2015 (the Base Indenture, as supplemented by the fist supplemental indentures, the &#8220;Indenture&#8221;), which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this Exhibit 4.4 is a part.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We encourage you to read the above referenced Indenture, as supplemented, for additional information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As used in this Description of Notes, the terms &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and other similar references refer only to Biogen Inc. and not to any of its subsidiaries.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notes due 2020 were initially limited to $1,500,000,000 aggregate principal amount. The maturity date of the notes due 2020 is September 15, 2020.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notes due 2022 were initially limited to $1,000,000,000 aggregate principal amount. The maturity date of the notes due 2022 is September 15, 2022.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notes due 2025 were initially limited to $1,750,000,000 aggregate principal amount. The maturity date of the notes due 2025 is September 15, 2025.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notes due 2045 were initially limited to $1,750,000,000 aggregate principal amount. The maturity date of the notes due 2045 is September 15, 2045.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may from time to time, without notice to or the consent of the holders or beneficial owners of the notes, create and issue additional notes of any of the series having the same ranking and the same interest rate, maturity and other terms as the notes of the applicable series. Any additional notes and the notes of such series will generally constitute a single series under the Indenture, provided that if the additional notes are not fungible with the notes of such series for U.S. federal income tax purposes, the additional notes will have a separate CUSIP number.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest and Principal</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notes due 2020 bear interest at a fixed interest rate of 2.900%. The notes due 2022 bear interest at a fixed interest rate of 3.625%. The notes due 2025 bear interest at a fixed interest rate of 4.050%.  The notes due 2045 bear interest at a fixed interest rate of 5.200%. Interest on the notes is payable semiannually on March 15 and September 15 of each year to holders of record at the close of business on the March 1 or September 1, whether or not a business day, immediately before the applicable interest payment date. The amount of interest payable on the notes is computed on the basis of a 360-day year consisting of twelve 30-day months.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notes were issued only in fully registered form, without coupons, in denominations of $2,000 and integral multiples of $1,000 in excess thereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any interest payment date or the maturity date of the notes is not a business day, then the related payment of interest and/or principal payable on such date will be paid on the next succeeding business day with the same force and effect as if made on such interest payment date or maturity date and no further interest will accrue in respect of the delay. The term &#8220;business day&#8221; means any day other than a Saturday, a Sunday or any other day on which banking institutions in The City of New York are authorized or required by law, regulation or executive order to close.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ranking</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notes are senior unsecured obligations and rank equal in right of payment with our other existing and future senior unsecured obligations, and senior in right of payment to any of our future subordinated indebtedness.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notes are effectively subordinated to any secured obligations of ours to the extent of the value of the assets securing such obligations. The notes are structurally subordinated to all existing and future obligations of our subsidiaries, including claims with respect to trade payables. This means that holders of the notes have a junior position to the claims of creditors of our direct and indirect subsidiaries on the assets and earnings of such subsidiaries.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Optional Redemption</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Optional redemption of notes due 2020</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time and from time to time, the notes due 2020 are redeemable, as a whole or in part, at our option, on at least 30 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2020, at a redemption price equal to the greater of:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% of principal amount of the notes due 2020 to be redeemed, or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the sum of the present values of the remaining scheduled payments of interest and principal thereon (exclusive of interest accrued and unpaid to, but not including, the date of redemption) discounted to the date of redemption on a semiannual basis, assuming a 360-day year consisting of twelve 30-day months, at the Treasury Rate (as defined below) plus 20 basis points,</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">plus, in either case, accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Optional redemption of notes due 2022</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time and from time to time, the notes due 2022 are redeemable, as a whole or in part, at our option, on at least 30 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2022, at a redemption price equal to the greater of:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% of principal amount of the notes due 2022 to be redeemed, or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the sum of the present values of the remaining scheduled payments of interest and principal thereon (exclusive of interest accrued and unpaid to, but not including, the date of redemption) discounted to the date of redemption on a semiannual basis, assuming a 360-day year consisting of twelve 30-day months, at the Treasury Rate plus 25 basis points,</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">plus, in either case, accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Optional redemption of notes due 2025</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time and from time to time prior to June 15, 2025 (the date that is three months prior to maturity), the notes due 2025 are redeemable, as a whole or in part, at our option, on at least 30 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2025, at a redemption price equal to the greater of:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% of principal amount of the notes due 2025 to be redeemed, or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the sum of the present values of the remaining scheduled payments of interest and principal thereon (exclusive of interest accrued and unpaid to, but not including, the date of redemption) discounted to the date of redemption on a semiannual basis, assuming a 360-day year consisting of twelve 30-day months, at the Treasury Rate plus 30 basis points,</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">plus, in either case, accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On or after June 15, 2025 (the date that is three months before maturity), the notes due 2025 may be redeemed, as a whole or in part, at our option, on at least 30 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2025, at a redemption price equal to 100% of the principal amount of the notes due 2025 to be redeemed on the redemption date plus accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Optional redemption of notes due 2045</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time and from time to time prior to March 15, 2045 (the date that is six months prior to maturity), the notes due 2045 are redeemable, as a whole or in part, at our option, on at least 30 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2045, at a redemption price equal to the greater of:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% of principal amount of the notes due 2045 to be redeemed, or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the sum of the present values of the remaining scheduled payments of interest and principal thereon (exclusive of interest accrued and unpaid to, but not including, the date of redemption) discounted to the date of redemption on a semiannual basis, assuming a 360-day year consisting of twelve 30-day months, at the Treasury Rate plus 35 basis points,</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">plus, in either case, accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On or after March 15, 2045 (the date that is six months before maturity), the notes due 2045 may be redeemed, as a whole or in part, at our option, on at least 30 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2045, at a redemption price equal to 100% of the principal amount of the notes due 2045 to be redeemed on the redemption date plus accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Comparable Treasury Issue&#8221; means the United States Treasury security or securities selected by an Independent Investment Banker (as defined below) as having an actual or interpolated maturity comparable to the remaining term of the notes of the applicable series to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of a comparable maturity to the remaining term of such notes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Comparable Treasury Price&#8221; means, with respect to any notes of a series on any redemption date, (A)&#160;the average of the Reference Treasury Dealer Quotations (as defined below) for such redemption date, after excluding the highest and lowest such Reference Treasury Dealer Quotations, or (B)&#160;if the Independent Investment Banker obtains fewer than four such Reference Treasury Dealer Quotations, the average of all such quotations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Independent Investment Banker&#8221; means one of the Reference Treasury Dealers (as defined below) appointed by us.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Reference Treasury Dealer&#8221; means each of Goldman, Sachs&#160;&amp; Co. and Merrill Lynch, Pierce, Fenner&#160;&amp; Smith Incorporated or their respective affiliates, which are primary U.S. Government securities dealers in The City of New York, and their respective successors plus three other primary U.S. Government securities dealers in The City of New York selected by us; provided, however, that if any of the foregoing or their affiliates shall cease to be a primary U.S. Government securities dealer in The City of New York (a &#8220;Primary Treasury Dealer&#8221;), we will substitute therefor another Primary Treasury Dealer.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Reference Treasury Dealer Quotations&#8221; means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the applicable Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the trustee by the Reference Treasury Dealers at 3:30 p.m. New York time on the third business day preceding such redemption date.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Treasury Rate&#8221; means, with respect to any redemption date, the rate per annum equal to the semiannual equivalent yield to maturity or interpolated (on a day count basis) of the Comparable Treasury Issue, assuming a price for the applicable Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the applicable Comparable Treasury Price for such redemption date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On and after the redemption date for the notes of the applicable series, interest will cease to accrue on the notes of that series or any portion thereof called for redemption, unless we default in the payment of the redemption price. On or before the redemption date for the notes of that series, we will deposit with a paying agent, or the trustee, funds sufficient to pay the redemption price of and accrued and unpaid interest on such notes to be redeemed on such date. If less than all of the notes of a series are to be redeemed, the notes of that series to be redeemed will be selected by DTC (as defined below) in accordance with its standard procedures. If the notes to be redeemed are not global notes then held by DTC, or DTC prescribes no method of selection, the trustee will select the notes to be redeemed on a pro rata basis, by lot, or by any other method the trustee deems fair and appropriate and subject to and otherwise in accordance with the procedures of DTC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change of Control</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a Change of Control Triggering Event (as defined below) occurs with respect to the notes of a series, unless we have exercised our option to redeem the notes of such series as described above, we will be required to make an offer (the &#8220;Change of Control Offer&#8221;) to each holder of the notes of such series to repurchase all or any part of that holder&#8217;s notes of such series on the terms set forth in such notes. In the Change of Control Offer, we will be required to offer payment in cash equal to 101% of the aggregate principal amount of notes repurchased, plus accrued and unpaid interest, if any, on the notes repurchased to but not including the date of repurchase (the &#8220;Change of Control Payment&#8221;). With respect to the notes of each series, within 30 days following any Change of Control Triggering Event or, at our option, prior to any Change of Control (as defined below), but after public announcement of the transaction that constitutes or may constitute the Change of Control, a notice will be mailed to holders of the notes of the applicable series describing the transaction that constitutes or may constitute the Change of Control Triggering Event and offering to repurchase the notes of such series on the date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is mailed or, if the notice is mailed prior to the Change of Control, no earlier than 30 days and no later than 60 days from the date on which the Change of Control Triggering Event occurs (the &#8220;Change of Control Payment Date&#8221;). The notice will, if mailed prior to the date of consummation of the Change of Control, state that the offer to purchase is conditioned on the Change of Control Triggering Event occurring on or prior to the Change of Control Payment Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Change of Control Payment Date, we will, to the extent lawful:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">accept for payment all notes or portions of notes properly tendered pursuant to the Change of Control Offer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">deposit with the paying agent an amount equal to the Change of Control Payment in respect of all notes or portions of notes properly tendered; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">deliver or cause to be delivered to the trustee the notes properly accepted together with an officers&#8217; certificate stating the aggregate principal amount of notes or portions of notes being repurchased.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will not be required to make a Change of Control Offer upon the occurrence of a Change of Control Triggering Event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for an offer made by us and the third party repurchases all notes properly tendered and not withdrawn under its offer. In addition, we will not repurchase any notes if there has occurred and is continuing on the Change of Control Payment Date an event of default under the Indenture, other than a default in the payment of the Change of Control Payment upon a Change of Control Triggering Event.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will comply in all material respects with the requirements of Rule 14e-1 under the Exchange Act and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the notes as a result of a Change of Control Triggering Event. To the extent that the provisions of any </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">such securities laws or regulations conflict with the Change of Control Offer provisions of the notes, we will comply with those securities laws and regulations and will not be deemed to have breached our obligations under the Change of Control Offer provisions of the notes by virtue of any such conflict.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of the Change of Control Offer provisions of the notes, the following terms will be applicable:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Change of Control&#8221; means the occurrence of any of the following: (1)&#160;the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any &#8220;person&#8221; (as that term is used in Section&#160;13(d) of the Exchange Act) (other than us or one of our Subsidiaries (as defined below)) becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of more than 50% of our Voting Stock (as defined below) or other Voting Stock into which our Voting Stock is reclassified, consolidated, exchanged or changed, measured by voting power rather than number of shares; provided, however, that a Person (as defined below) shall not be deemed beneficial owner of, or to own beneficially, (A)&#160;any securities tendered pursuant to a tender or exchange offer made by or on behalf of such Person or any of such Person&#8217;s affiliates until such tendered securities are accepted for purchase or exchange thereunder, or (B)&#160;any securities if such beneficial ownership (i)&#160;arises solely as a result of a revocable proxy delivered in response to a proxy or consent solicitation made pursuant to the applicable rules and regulations under the Exchange Act, and (ii)&#160;is not also then reportable on Schedule&#160;13D (or any successor schedule) under the Exchange Act; (2)&#160;the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more series of related transactions, of all or substantially all of our assets and the assets of our Subsidiaries, taken as a whole, to one or more &#8220;persons&#8221; (as that term is used in Section&#160;13(d) of the Exchange Act) (other than to us or one of our Subsidiaries) (a &#8220;Transferee&#8221;), provided, however, that none of the circumstances in this clause&#160;(2) will be a Change of Control if the persons that beneficially own our Voting Stock immediately prior to the transaction own, directly or indirectly, shares representing a majority of the total Voting Stock as measured by voting power rather than number of shares of the Transferee; (3)&#160;we consolidate with, or merge with or into, any &#8220;person&#8221; (as that term is used in Section&#160;13(d) of the Exchange Act) or any such Person consolidates with, or merges with or into, us, in either case, pursuant to a transaction in which any of our outstanding Voting Stock or the Voting Stock of such other Person is converted into or exchanged for cash, securities or other property, other than pursuant to a transaction in which shares of our Voting Stock outstanding immediately prior to the transaction constitute, or are converted into or exchanged for, a majority of the Voting Stock of the surviving Person immediately after giving effect to such transaction; or (4)&#160;the adoption of a plan relating to our liquidation or dissolution.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Change of Control Triggering Event&#8221; means the occurrence of both a Change of Control and a Rating Event (as defined below).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Investment Grade Rating&#8221; means a rating equal to or higher than Baa3 (or the equivalent) by Moody&#8217;s (as defined below) and BBB- (or the equivalent) by S&amp;P (as defined below), and the equivalent investment grade credit rating from any additional rating agency or Rating Agencies (as defined below) selected by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Moody&#8217;s&#8221; means Moody&#8217;s Investors Service, Inc., or any successor thereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Rating Agencies&#8221; means (1)&#160;each of Moody&#8217;s and S&amp;P and (2)&#160;if any of Moody&#8217;s and S&amp;P ceases to rate the notes or fails to make a rating of the notes publicly available for reasons outside of our control, a &#8220;nationally recognized statistical rating organization&#8221; within the meaning of Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act selected by us (as certified by a resolution of our board of directors) and which is reasonably acceptable to the trustee as a replacement agency for Moody&#8217;s or S&amp;P, or both of them, as the case may be.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Rating Event&#8221; means (A)&#160;with respect to the notes due 2020, the rating on such notes is lowered by each of the Rating Agencies and such notes are rated below an Investment Grade Rating by each of the Rating Agencies, (B)&#160;with respect to the notes due 2022, the rating on such notes is lowered by each of the Rating Agencies and such notes are rated below an Investment Grade Rating by each of the Rating Agencies, (C)&#160;with respect to the notes due 2025, the rating on such notes is lowered by each of the Rating Agencies and such notes are rated below an Investment Grade Rating by each of the Rating Agencies and (D)&#160;with respect to the notes due 2045, the rating on such notes is lowered by each of the Rating Agencies and such notes are rated below an Investment Grade Rating by each of the Rating Agencies, in each case, on any day during the period commencing on the earlier of the date of the first public notice of the occurrence </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of a Change of Control or our intention to effect a Change of Control and ending 60 days following consummation of such Change of Control (which period will be extended so long as the rating of the applicable series of notes is under publicly announced consideration for a possible downgrade by any of the Rating Agencies).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;S&amp;P&#8221; means Standard&#160;&amp; Poor&#8217;s Rating Services, a Standard&#160;&amp; Poor&#8217;s Financial Services LLC business, or any successor thereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Voting Stock&#8221; means, with respect to any specified &#8220;person&#8221; (as that term is used in Section&#160;13(d) of the Exchange Act) as of any date, the capital stock of such person that is at the time entitled to vote generally in the election of the board of directors of such person.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sinking Fund</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notes are not be entitled to the benefit of any sinking fund.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Limitation on Liens</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than as provided under &#8220;-Exempted Liens and Sale and Leaseback Transactions,&#8221; we will not, and will not permit any Subsidiary of ours to, create or assume any Indebtedness (as defined below) secured by any Lien (as defined below) on any of our or their respective Properties (as defined below) unless the notes are secured by such Lien equally and ratably with, or prior to, the Indebtedness secured by such Lien. This restriction does not apply to Indebtedness that is secured by:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens existing on the date of the issuance of the notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens securing only the notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens on Property or shares of stock in respect of Indebtedness of a Person existing at the time such Person becomes a Subsidiary of ours or is merged into or consolidated with, or its assets are acquired by, us or any Subsidiary of ours (provided that such Lien was not incurred in anticipation of such transaction and was in existence prior to such transaction) so long as such Lien does not extend to any other Property and the Indebtedness so secured is not increased;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens to secure Indebtedness incurred for the purpose of all or any part of a Property&#8217;s purchase price or cost of construction or additions, repairs, alterations or other improvements; provided that (1)&#160;the principal amount of any Indebtedness secured by such Lien does not exceed 100% of such Property&#8217;s purchase price or cost, (2)&#160;such Lien does not extend to or cover any other Property other than the Property so purchased, constructed or on which such additions, repairs, alterations or other improvements were so made and (3)&#160;such Lien is incurred prior to or within 270 days after the acquisition of such Property or the completion of construction or such additions, repairs, alterations or other improvements and the full operation of such Property thereafter;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens in favor of the U.S. or any state thereof, or any instrumentality of either, to secure certain payments pursuant to any contract or statute;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens for taxes or assessments or other governmental charges or levies which are not overdue for a period exceeding 60 days unless such Liens are being contested in good faith and for which adequate reserves are being maintained, to the extent required by generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">title exceptions, easements, licenses, leases and other similar Liens that are not consensual and that do not materially impair the use of the Property subject thereto;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens to secure obligations under worker&#8217;s compensation laws, unemployment compensation, old-age pensions and other social security benefits or similar legislation;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens arising out of legal proceedings, including Liens arising out of judgments or awards;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warehousemen&#8217;s, materialmen&#8217;s, carrier&#8217;s, landlord&#8217;s and other similar Liens for sums not overdue for a period exceeding 60 days unless such Liens are being contested in good faith and for which adequate reserves are being maintained, to the extent required by generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens incurred to secure the performance of statutory obligations, surety or appeal bonds, performance or return-of-money bonds, insurance, self-insurance or other obligations of a like nature incurred in the ordinary course of business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens that are rights of set-off relating to the establishment of depository relations with banks not given in connection with the issuance of Indebtedness;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens on the assets of a special purpose Subsidiary resulting from securitization transactions with respect to accounts receivable, royalties and similar assets included in such securitization transactions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens upon specific items of inventory or other goods and proceeds of any Person securing such Person&#8217;s obligations in respect of bankers&#8217; acceptances issued or created for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens securing reimbursement obligations with respect to letters of credit that encumber documents and other Property relating to such letters of credit and the products and proceeds thereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens on key-man life insurance policies granted to secure our Indebtedness against the cash surrender value thereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens encumbering customary initial deposits and margin deposits and other Liens in the ordinary course of business, in each case securing Hedging Obligations (as defined below) and forward contract, option, futures contracts, futures options or similar agreements or arrangements designed to protect us or any of our Subsidiaries from fluctuations in interest rates, currencies or the price of commodities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into by us or any of our Subsidiaries in the ordinary course of business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens in our favor or the favor of any of our Subsidiaries; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liens to secure any extension, renewal, refinancing or refunding (or successive extensions, renewals, refinancings or refundings), in whole or in part, of any Indebtedness secured by Liens referred to in the foregoing bullets or Liens created in connection with any amendment, consent or waiver relating to such Indebtedness, so long as such Lien does not extend to any other Property and the Indebtedness so secured does not exceed the fair market value (as determined by our board of directors) of the assets subject to such Liens at the time of such extension, renewal, refinancing or refunding, or such amendment, consent or waiver, as the case may be.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Limitation on Sale and Leaseback Transactions</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than as provided under &#8220;-Exempted Liens and Sale and Leaseback Transactions,&#8221; we will not, and will not permit any of our Subsidiaries to, enter into any Sale and Leaseback Transaction (as defined below) with respect to any of our or their respective Properties, the acquisition or completion of construction and commencement of full operations of which has occurred more than 270 days prior thereto, unless:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">such transaction was entered into prior to the first issue date of the notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">such transaction was for the sale and leasing back to us of any Property by one of our Subsidiaries;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or such Subsidiary would be entitled to incur Indebtedness secured by a mortgage on the Property to be leased in an amount equal to the Attributable Debt (as defined below) with respect to such Sale and Leaseback Transaction without equally and ratably securing the notes pursuant to the first paragraph of &#8220;-Limitation on Liens&#8221; above;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the lease is for a period not in excess of five years, including renewal rights; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or the Subsidiary, prior to or within 270 days after the sale of such Property in connection with the Sale and Leaseback Transaction is completed, applies the net cash proceeds of the sale of the Property leased to:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the retirement of the notes or debt of ours ranking equally with the notes or to the retirement of any debt of a Subsidiary of ours, or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the acquisition of different property, facilities or equipment or the expansion of our existing business, including the acquisition of other businesses.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exempted Liens and Sale and Leaseback Transactions</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the restrictions described under the headings &#8220;-Limitation on Liens&#8221; or &#8220;-Limitation on Sale and Leaseback Transactions,&#8221; we or any Subsidiary of ours may create or assume any Liens or enter into any Sale and Leaseback Transactions not otherwise permitted as described above, if the sum of the following does not exceed 10% of Consolidated Total Assets (as defined below):</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the outstanding Indebtedness secured by such Liens (not including any Liens permitted under &#8220;-Limitation on Liens&#8221; which amount does not include any Liens permitted under the provisions of this &#8220;-Exempted Liens and Sale and Leaseback Transactions&#8221;); plus</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all Attributable Debt in respect of such Sale and Leaseback Transaction entered into (not including any Sale and Leaseback Transactions permitted under &#8220;-Limitation on Sale and Leaseback Transactions&#8221; which amount does not include any Sale and Leaseback Transactions permitted under the provisions of this &#8220;-Exempted Liens and Sale and Leaseback Transactions&#8221;),</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">measured, in each case, at the time such Lien is incurred or any such Sale and Leaseback Transaction is entered into by us or such Subsidiary of ours.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Merger, Consolidation or Sale of Assets</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may merge or consolidate with another Person and may sell, transfer or lease all or substantially all of our assets to another Person if all the following conditions are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the merger, consolidation or sale of assets must not cause an event of default. See &#8220;-Events of Default.&#8221; An event of default for this purpose would also include any event that would be an event of default if the notice or time requirements were disregarded;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we are not the surviving entity, the Person we would merge or consolidate with, or sell all or substantially all of our assets to, must be organized under the laws of the U.S., any state thereof or the District of Columbia;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we are not the surviving entity, the Person we would merge or consolidate with, or sell all or substantially all of our assets to, must expressly assume by supplemental Indenture all of our obligations under the notes and the Indenture; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we must deliver specific certification and documents to the trustee.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Events of Default</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The term &#8220;event of default&#8221; in respect of each series of the notes means any of the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we do not pay the principal of or any premium on the notes of that series on its due date;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we do not pay interest on the notes of that series within 30 days of its due date whether at maturity, upon redemption or upon acceleration (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent for application to pay such interest prior to the expiration of the 30-day period);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we remain in breach of a covenant in respect of the notes of that series for 90 days after we receive a written notice of default in accordance with the provisions of the Indenture stating we are in breach and requiring that we remedy the breach; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">certain events of bankruptcy, insolvency or reorganization occur with respect to us or any significant Subsidiary of ours.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an event of default (other than due to certain events in bankruptcy, insolvency or reorganization) with respect to the notes of a series has occurred and has not been cured, the trustee or the holders of at least 25% in aggregate principal amount of the notes of that series may, by a notice in writing to us (and to the trustee if given by the holders), declare the entire principal amount (and premium, if any) of, and all the accrued and unpaid interest on the notes of that series to be due and immediately payable. This is called a declaration of acceleration of maturity. If an event of default with respect to the notes of any of the series occurs because of certain events in bankruptcy, insolvency or reorganization relating to us, the principal amount of the notes of that series will be automatically accelerated, without any action by the trustee or any holder. Holders of a majority in aggregate principal amount of the notes of a series may also waive certain past defaults under the Indenture on behalf of all of the holders of the notes of that series. A declaration of acceleration of maturity with respect to the notes of a series may be canceled, under specific circumstances, by the holders of at least a majority in aggregate principal amount of the notes of that series.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any securities are outstanding under the Indenture, the Indenture requires us, within 120&#160;days after the end of each fiscal year, to furnish to the trustee a statement as to our compliance with the Indenture. The trustee will generally give the holders of notes notice within 90&#160;days of the occurrence of an event of default known to the trustee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except in cases of default, where the trustee has some special duties, the trustee is not required to take any action under the Indenture at the request of any of the holders unless the holders offer the trustee indemnity or security satisfactory to it. If indemnity or security satisfactory to the trustee is provided, the holders of a majority in aggregate principal amount of the notes of the applicable series may, with respect to the notes of that series, direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee. The trustee may refuse to follow those directions in certain circumstances. No delay or omission in exercising any right or remedy will be treated as a waiver of the right, remedy or event of default.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before you are allowed to bypass the trustee and bring a lawsuit or other formal legal action or take other steps to enforce your rights or protect your interests relating to the notes of the applicable series, the following must occur:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">you must give the trustee written notice that an event of default has occurred and remains uncured;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the holders of at least 25% in aggregate principal amount of the outstanding notes of that series must make a written request that the trustee take action because of the default and must offer the trustee indemnity or security satisfactory to it against the cost and other liabilities of taking that action;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the trustee must not have taken action for 60 days after receipt of the above notice and offer of indemnity; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">holders of a majority in aggregate principal amount of the notes of that series must not have given the trustee a direction inconsistent with the above notice.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">However, you are entitled at any time to bring a lawsuit for the payment of money due on your notes on or after the due date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Defeasance</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Full Defeasance</font><font style="font-family:inherit;font-size:10pt;">. If the Internal Revenue Service issues a ruling or there is a change in applicable U.S. federal tax law, as described below, we can legally release ourselves from any payment or other obligations on the notes, called &#8220;full defeasance,&#8221; if we put in place the following other arrangements for you to be repaid:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we must deposit in trust for your benefit and the benefit of all other registered holders of the notes, money, U.S. government or U.S. government agency notes or bonds or a combination thereof that will generate enough cash to make interest, principal and any other payments on the notes on their various due dates including, possibly, their earliest redemption date; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we must deliver to the trustee a legal opinion confirming that you will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the full defeasance and that you will not be taxed on the notes any differently than if the full defeasance had not occurred.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we accomplish full defeasance, as described above, you would have to rely solely on the trust deposit for repayment on the notes</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.&#160;</font><font style="font-family:inherit;font-size:10pt;">You could not look to us for repayment in the unlikely event of any shortfall</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.&#160;</font><font style="font-family:inherit;font-size:10pt;">Conversely, the trust deposit would most likely be protected from claims of our lenders and other creditors if we ever become bankrupt or insolvent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Covenant Defeasance.&#160;</font><font style="font-family:inherit;font-size:10pt;">We can be released from the restrictive covenants in the notes if we make the arrangements described below</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.&#160;</font><font style="font-family:inherit;font-size:10pt;">This is called &#8220;covenant defeasance.&#8221; In that event, the registered holders of the notes would lose the protection of those restrictive covenants but would gain the protection of having money and securities set aside in trust to repay the notes</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.&#160;</font><font style="font-family:inherit;font-size:10pt;">In order to achieve covenant defeasance, we must do the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we must deposit in trust for your benefit and the benefit of all other registered holders of the notes, money, U.S. government or U.S. government agency notes or bonds or a combination thereof that will generate enough cash to make interest, principal and any other payments on the notes on their various due dates, including their earliest possible redemption date; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we must deliver to the trustee a legal opinion confirming that under current U.S. federal income tax law the registered holders of the notes will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the covenant defeasance and that the registered holders of the notes will not be taxed on the notes any differently than if the covenant defeasance had not occurred.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we accomplish covenant defeasance, the following provisions of the Indenture and the notes would no longer apply unless otherwise specified:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our promises regarding conduct of our business and other matters and any other covenants applicable to the series of notes; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the definition of an event of default as a breach of such covenants.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we accomplish covenant defeasance, you can still look to us for repayment of the notes if there were a shortfall in the trust deposit</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.&#160;</font><font style="font-family:inherit;font-size:10pt;">In fact, if one of the remaining events of default occurred (such as our bankruptcy) and the notes become immediately due and payable, there may be such a shortfall</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.&#160;</font><font style="font-family:inherit;font-size:10pt;">Depending on the event causing the default, of course, you may not be able to obtain payment of the shortfall.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to exercise either full defeasance or covenant defeasance, we must comply with certain conditions, and no event or condition can exist that would prevent us from making payments of principal, premium and interest, if any, on the notes of such series on the date the irrevocable deposit is made or at any time during the period ending on the 91</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;day after the deposit date.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notices</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the notes, we and the trustee will send notices regarding the notes only to registered holders, using their addresses as listed in the list of registered holders.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Modification or Waiver</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generally may modify and amend the Indenture with the consent of the holders of at least a majority in aggregate principal amount of the outstanding notes of the affected series. However, we may not make any modification or amendment without the consent of each holder of the notes of the affected series if such action would:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">change the stated maturity of, or the principal of or premium or interest on, the notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce any amounts due on the notes or payable upon acceleration of the maturity of the notes following a default;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adversely affect any right of repayment at the holder&#8217;s option;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">change the place (except as otherwise described in this prospectus supplement) or currency of payment on the notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">modify the notes to contractually subordinate the notes in right of payment to other Indebtedness;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce the percentage of holders of notes whose consent is needed to modify or amend the Indenture;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce the percentage of holders of notes whose consent is needed to waive compliance with certain provisions of the Indenture or to waive certain defaults; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">modify any other aspect of the provisions of the Indenture dealing with modification and waiver except to increase the voting requirements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except for certain specified provisions, the holders of at least a majority in aggregate principal amount of the outstanding notes of the affected series may, on behalf of the holders of all the notes of that series, waive our compliance with certain provisions of the Indenture. The holders of a majority in aggregate principal amount of the outstanding notes of the affected series may, on behalf of the holders of all the notes of such series, waive any past default under the Indenture with respect to that series and its consequences, except a default in the payment of the principal of or premium or interest on any notes of that series or in respect of a covenant or provision which cannot be modified or amended without the consent of the holder of each outstanding note of that series; provided however that the holders of a majority in aggregate principal amount of the outstanding notes of the affected series may rescind an acceleration and its consequences, including any payment default that resulted from such acceleration.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the foregoing, without the consent of any holder of notes of a series, we may amend or supplement the Indenture or the notes for among other reasons:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to cure any ambiguity, defect or inconsistency provided such amendment or supplement does not adversely affect the rights of any holder of notes of that series;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to comply with the covenant described under &#8220;-Merger, Consolidation or Sale of Assets;&#8221;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to appoint a successor trustee with respect to the notes and to add to or change any of the provisions of the Indenture necessary to provide for the administration of the trusts in the Indenture by more than one trustee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to comply with the requirements of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) in order to maintain the qualification of the Indenture under the Trust Indenture Act of 1939;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to make any change that would not adversely affect the rights of any holder of notes of that series;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to provide for the issuance of any additional notes as permitted by the Indenture; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to conform the Indenture or the notes to the description thereof set forth in the prospectus supplement and in the accompanying prospectus.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Satisfaction and Discharge</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Indenture will cease to be of further effect, and we will be deemed to have satisfied and discharged the Indenture with respect to the notes, when the following conditions have been satisfied:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all notes not previously delivered to the trustee for cancellation have become due and payable or will become due and payable at their stated maturity or on a redemption date within one year;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we deposit with the trustee, in trust, funds sufficient to pay the entire indebtedness on the notes that had not been previously delivered for cancellation, for the principal and interest to the date of the deposit (for notes that have become due and payable) or to the stated maturity or the redemption date, as the case may be (for notes that have not become due and payable);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have paid or caused to be paid all other sums payable under the Indenture; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have delivered to the trustee an officers&#8217; certificate and opinion of counsel, each stating that we have complied with all these conditions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will remain obligated to provide for registration of transfer and exchange and to provide notices of redemption.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Trustee</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trustee is U.S. Bank National Association. U.S. Bank National Association is also the initial paying agent and registrar for the notes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Indenture provides that, except during the continuance of an event of default under the Indenture, the trustee under the Indenture will perform only such duties as are specifically set forth in the Indenture</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.&#160;</font><font style="font-family:inherit;font-size:10pt;">Under the Indenture, the holders of a majority in outstanding aggregate principal amount of the notes will have the right to direct the time, method and place of conducting any proceeding or exercising any remedy available to the trustee under the Indenture, subject to certain exceptions</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.&#160;</font><font style="font-family:inherit;font-size:10pt;">If an event of default has occurred and is continuing, the trustee under the Indenture will exercise such rights and powers vested in it under the Indenture and is obligated to use the same degree of care and skill in its exercise as a prudent person would exercise under the circumstances in the conduct of such person&#8217;s own affairs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Indenture and provisions of the Trust Indenture Act incorporated by reference in the Indenture contain limitations on the rights of the trustee under such Indenture, should it become a creditor of our company, to obtain payment of claims in certain cases or to realize on certain Property received by it in respect of any such claims, as security or otherwise</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.&#160;</font><font style="font-family:inherit;font-size:10pt;">The trustee under the Indenture is permitted to engage in other transactions</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.&#160;</font><font style="font-family:inherit;font-size:10pt;">However, if the trustee under the Indenture acquires any prohibited conflicting interest, it must eliminate the conflict or resign.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trustee may resign or be removed and a successor trustee may be appointed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Governing Law</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Indenture and the notes will be governed by, and construed in accordance with, the laws of the State of New York.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Definitions</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following definitions are applicable to this Description of Notes:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Attributable Debt&#8221; means, with respect to a Sale and Leaseback Transaction, an amount equal to the lesser of (1)&#160;the fair market value of the Property (as determined in good faith by our board of directors); and (2)&#160;the present value of the total net amount of rent payments to be made under the lease during its remaining term, discounted at the rate of interest set forth or implicit in the terms of the lease, compounded semi-annually. The calculation of the present value of the total net amount of rent payments is subject to adjustments specified in the Indenture.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Capitalized Lease&#8221; means any obligation of a Person to pay rent or other amounts incurred with respect to real property or equipment acquired or leased by such Person and used in its business that is required to be recorded as a capital lease in accordance with generally accepted accounting principles.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Consolidated Total Assets&#8221; means, with respect to any Person as of any date, the amount of total assets as shown on the consolidated balance sheet of such Person for the most recent fiscal quarter for which financial statements have been filed with the SEC, prepared in accordance with accounting principles generally accepted in the United States.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Hedging Obligations&#8221; means, with respect to any specified Person, the obligations of such Person under:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">interest rate swap agreements (whether from fixed to floating or from floating to fixed), interest rate cap agreements and interest rate collar agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other agreements or arrangements designed to manage interest rates or interest rate risk;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other agreements or arrangements designed to protect such Person against fluctuations in currency exchange rates or commodity prices.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Indebtedness&#8221; of any Person means, without duplication (1)&#160;any obligation of such Person for money borrowed, (2)&#160;any obligation of such Person evidenced by bonds, debentures, notes or other similar instruments, (3)&#160;any reimbursement obligation of such Person in respect of letters of credit or other similar instruments which support financial obligations which would otherwise become Indebtedness, and (4)&#160;any obligation of such Person under Capitalized Leases;&#160;provided, however</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">,</font><font style="font-family:inherit;font-size:10pt;">&#160;that &#8220;Indebtedness&#8221; of such Person shall not include any obligation of such Person to any Subsidiary of such Person or to any Person with respect to which such Person is a Subsidiary.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Lien&#8221; means any pledge, mortgage, lien, encumbrance or other security interest.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Person&#8221; means any individual, corporation, limited liability company, partnership, joint venture, association, joint stock company, trust, unincorporated organization or government or any agency or political subdivision thereof or other similar entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Property&#8221; means any property or asset, whether real, personal or mixed or tangible or intangible.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Sale and Leaseback Transaction&#8221; means any arrangement with any Person providing for the leasing by us or any Subsidiary of ours of any Property that has been or is to be sold or transferred by us or such Subsidiary, as the case may be, to such Person.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Subsidiary&#8221; of any Person means (1)&#160;a corporation, a majority of the outstanding Voting Stock of which is, at the time, directly or indirectly, owned by such Person by one or more Subsidiaries of such Person, or by such Person and one or more Subsidiaries thereof or (2)&#160;any other Person (other than a corporation), including, without limitation, a partnership or joint venture, in which such Person, one or more Subsidiaries thereof or such Person and one or more Subsidiaries thereof, directly or indirectly, at the date of determination thereof, has at least majority ownership interest entitled to vote in the election of directors, managers or trustees thereof (or other Person performing similar functions).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Global Notes: Book-Entry System</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Global Notes</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notes of each series is represented by one or more fully registered global notes, without interest coupons, was deposited upon issuance with the trustee as custodian for The Depository Trust Company (&#8220;DTC&#8221;), and registered in the name of Cede&#160;&amp; Co. or its nominee, in each case, for credit to an account of a direct or indirect participant as described below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as set forth below, the global notes may be transferred, in whole and not in part, only to another nominee of DTC or to a successor of DTC or its nominee. Beneficial interests in the global notes may not be</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:inherit;font-size:10pt;">exchanged for definitive notes in registered certificated form (&#8220;certificated notes&#8221;) except in limited circumstances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfers of beneficial interests in the global notes are subject to the applicable rules and procedures of DTC and its direct or indirect participants, which may change.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notes may be presented for registration of transfer and exchange at the offices of the trustee as set forth in the Indenture.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Certain Book Entry Procedures for the Global Notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All interests in the global notes will be subject to the operations and procedures of DTC, Euroclear Bank, S.A./N.V. and Clearstream Luxembourg,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;soci&#233;t&#233; anonyme</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">399160_1 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>3
<FILENAME>biib-20191231xex21.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDC7220603D37556FB8E24FD3F3B6296F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 21</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a list of subsidiaries of Biogen Inc. as of December 31, 2019, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SUBSIDIARY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Foundation Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen MA Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Realty Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Realty Limited Partnership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Limited Partnership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (RTP) Realty LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Chesapeake LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding I LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding II LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Manufacturing Holding LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen New Ventures Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen SRO Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Therapeutics Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Pacific LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. West Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conforma Therapeutics Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stromedix, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nightstar, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Argentina) SRL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Argentina</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Australia PTY Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Austria GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Austria</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Belgium N.V./S.A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International Holding Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bermuda</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Brasil Produtos Farmaceuticos LTDA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Brazil</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Canada Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Chile Spa</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chile</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Biotechnology (Shanghai) Co., Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">China</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Colombia S.A.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Colombia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Czech Republic) s.r.o.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Czech Republic</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) A/S</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) Manufacturing ApS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding APS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) New Manufacturing ApS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Finland OY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen France S.A.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Hong Kong Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hong Kong</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Hungary KFT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hungary</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Biotech India Pvt. Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">India</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec (Ireland) Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nightstar Europa Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ireland</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Italia SRL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Japan Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Korea</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Korea</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Luxembourg Holding SARL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Mexico S. DE R.L. DE C.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mexico</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Mexico Servicios, S. DE R.L. DE C.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mexico</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen NZ Biopharma Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">New Zealand</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Norway AS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Norway</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Poland Sp. z.o.o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Poland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Portugal Sociedade Farmaceutica, Unipessoal, Lda.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Singapore) Pte Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Slovakia s.r.o.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Slovak Republic</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Pharma, farmacevtska in biotehnoloska druzba d.o.o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Slovenia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Spain, S.L.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Sweden AB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sweden</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International Neuroscience GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Management Services GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Swiss Investments GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Swiss Manufacturing GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Switzerland AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Switzerland Holdings GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eidetica Biopharma GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Taiwan Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taiwan</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen B.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Netherlands</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Netherlands B.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Netherlands</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Research Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Convergence Pharmaceuticals Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Convergence Pharmaceuticals Holdings Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Old Convergence Pharmaceuticals Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Panion Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Silver Acquisition Co. Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nightstar Therapeutics Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nightstar Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tungsten Bidco Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Uruguay SA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Uruguay</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>biib-20191231xex23.htm
<DESCRIPTION>EXHIBIT 23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF79D389486F85F5BA94326EDD8E7F065"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 23</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-218799, 333-205254, 333-128339, 333-152456, 333-140817 and 333-170133) of Biogen Inc. of our report dated February 6, 2020 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10&#8209;K.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ PricewaterhouseCoopers LLP </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston, Massachusetts</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February 6, 2020</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>biib-20191231xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEBF0976AE66D53588D2B9BD89B89A201"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Michel Vounatsos, certify that:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this annual report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">c) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:76%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: February&#160;6, 2020</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>biib-20191231xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s915A3E7D9F0F5E8AABA7E5DD1240E14E"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Jeffrey Capello, certify that:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this annual report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">d) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:68%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: February&#160;6, 2020</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;Jeffrey Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Finance</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer (principal financial officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>biib-20191231xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5998E68C479159DBB159E0A15381E24B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Annual Report on Form 10-K for the year ended December&#160;31, 2019 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: February&#160;6, 2020</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos &#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: February 6, 2020</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Jeffrey Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey Capello</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Finance and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>biib-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20191231" xmlns:biib="http://www.biogenidec.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2102100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionsDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails">
        <link:definition>2402402 - Disclosure - Acquisitions Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDetailsTextual" roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual">
        <link:definition>2402403 - Disclosure - Acquisitions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" roleURI="http://www.biogenidec.com/role/AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables">
        <link:definition>2302301 - Disclosure - Acquisitions Schedule of separately identifiable assets acquired and liabilities assumed (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2124100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsAbbvieDetails2" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2">
        <link:definition>2424404 - Disclosure - Collaborative and Other Relationships - AbbVie (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1">
        <link:definition>2424403 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Eisai (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetailsTextual" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual">
        <link:definition>2424405 - Disclosure - Collaborative and Other Relationships (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsGenentechDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails">
        <link:definition>2424402 - Disclosure - Collaborative and Other Relationships - Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables">
        <link:definition>2324301 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies">
        <link:definition>2127100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual">
        <link:definition>2427402 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2327301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets">
        <link:definition>1003000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1003501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1002000 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncomeCalc2" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncomeCalc2">
        <link:definition>1002000 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfEquity" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity">
        <link:definition>1005000 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfIncome" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome">
        <link:definition>1001000 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2114100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsCashFlowHedgesDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails">
        <link:definition>2414402 - Disclosure - Derivative Instruments Cash Flow Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1">
        <link:definition>2414403 - Disclosure - Derivative Instruments Derivative Instruments Net Investment Hedges (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual">
        <link:definition>2414405 - Disclosure - Derivative Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsInterestRateSwapDetails2" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2">
        <link:definition>2414404 - Disclosure - Derivative Instruments Interest Rate Swap (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2314301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDivestitures" roleURI="http://www.biogenidec.com/role/DivestituresDivestitures">
        <link:definition>2107100 - Disclosure - Divestitures Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDivestituresDetailsTextual" roleURI="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual">
        <link:definition>2407401 - Disclosure - Divestitures Divestitures (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2120100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2420402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2320301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans">
        <link:definition>2129100 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails1" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1">
        <link:definition>2429402 - Disclosure - Employee Benefit Plans (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansEmployeeBenefitPlansDetails" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails">
        <link:definition>2429401 - Disclosure - Employee Benefit Plans Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2119100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2419405 - Disclosure - Equity Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2319302 - Disclosure - Equity Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.biogenidec.com/role/EquityDetails">
        <link:definition>2419403 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>2419406 - Disclosure - Equity Reclassification out of Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.biogenidec.com/role/EquityTables">
        <link:definition>2319301 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2112100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2412402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2412403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2412404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2412405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2312301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2113100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2413402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2413403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2413404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2413405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1">
        <link:definition>2413406 - Disclosure - Financial Instruments (Details Textual 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2">
        <link:definition>2413407 - Disclosure - Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2313301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Guarantees" roleURI="http://www.biogenidec.com/role/Guarantees">
        <link:definition>2128100 - Disclosure - Guarantees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2122100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2422402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails1" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1">
        <link:definition>2422403 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails2" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2">
        <link:definition>2422404 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails3" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3">
        <link:definition>2422405 - Disclosure - Income Taxes (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2422406 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2322301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>2117100 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2417402 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails1" roleURI="http://www.biogenidec.com/role/IndebtednessDetails1">
        <link:definition>2417403 - Disclosure - Indebtedness (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetailsTextual" roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual">
        <link:definition>2417404 - Disclosure - Indebtedness (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessTables" roleURI="http://www.biogenidec.com/role/IndebtednessTables">
        <link:definition>2317301 - Disclosure - Indebtedness (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2111100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2411402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2411403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2311301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2110100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2410402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetailsTextual" roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual">
        <link:definition>2410403 - Disclosure - Inventory (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2310301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2125100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2425401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeases" roleURI="http://www.biogenidec.com/role/LeasesLeases">
        <link:definition>2116100 - Disclosure - Leases Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasesDetails" roleURI="http://www.biogenidec.com/role/LeasesLeasesDetails">
        <link:definition>2416402 - Disclosure - Leases Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasesDetailsTextual" roleURI="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual">
        <link:definition>2416403 - Disclosure - Leases Leases (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasesTables" roleURI="http://www.biogenidec.com/role/LeasesLeasesTables">
        <link:definition>2316301 - Disclosure - Leases Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2126100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationLitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails">
        <link:definition>2426401 - Disclosure - Litigation Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2123100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2423402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual">
        <link:definition>2423403 - Disclosure - Other Consolidated Financial Statement Detail (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2323301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment">
        <link:definition>2115100 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2415402 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetailsTextual" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual">
        <link:definition>2415403 - Disclosure - Property, Plant and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentTables" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables">
        <link:definition>2315301 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2131100 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetails" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails">
        <link:definition>2431402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetailsTextual" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual">
        <link:definition>2431403 - Disclosure - Quarterly Financial Data (Unaudited) (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2331301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>2109100 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesByProductDetails" roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails">
        <link:definition>2409402 - Disclosure - Revenues by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetailsTextual" roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual">
        <link:definition>2409407 - Disclosure - Revenues (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>2409406 - Disclosure - Revenues Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesForDiscountsAndAllowancesDetails1" roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1">
        <link:definition>2409403 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesForDiscountsAndAllowancesDetails2" roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2">
        <link:definition>2409404 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails">
        <link:definition>2409405 - Disclosure - Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2309301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.biogenidec.com/role/SegmentInformation">
        <link:definition>2130100 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.biogenidec.com/role/SegmentInformationDetails">
        <link:definition>2430402 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetailsTextual" roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual">
        <link:definition>2430403 - Disclosure - Segment Information (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.biogenidec.com/role/SegmentInformationTables">
        <link:definition>2330301 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2121100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2421402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2421403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails10" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10">
        <link:definition>2421412 - Disclosure - Share-Based Payments (Details 10)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails11" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11">
        <link:definition>2421413 - Disclosure - Share-Based Payments (Details 11)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails2" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2">
        <link:definition>2421404 - Disclosure - Share-Based Payments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails3" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3">
        <link:definition>2421405 - Disclosure - Share-Based Payments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails4" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4">
        <link:definition>2421406 - Disclosure - Share-Based Payments (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails5" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5">
        <link:definition>2421407 - Disclosure - Share-Based Payments (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails6" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6">
        <link:definition>2421408 - Disclosure - Share-Based Payments (Details 6)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails7" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7">
        <link:definition>2421409 - Disclosure - Share-Based Payments (Details 7)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails8" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8">
        <link:definition>2421410 - Disclosure - Share-Based Payments (Details 8)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails9" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9">
        <link:definition>2421411 - Disclosure - Share-Based Payments (Details 9)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetailsTextual" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual">
        <link:definition>2421414 - Disclosure - Share-Based Payments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2321301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>2419404 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsSubsequentEvents" roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents">
        <link:definition>2133100 - Disclosure - Subsequent Events Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsSubsequentEventsDetails" roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails">
        <link:definition>2433401 - Disclosure - Subsequent Events Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401403 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A2011ShareRepurchaseProgramMember" name="A2011ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2015ESPPMember" name="A2015ESPPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2016ShareRepurchaseProgramMember" name="A2016ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2017OmnibusEquityPlanMember" name="A2017OmnibusEquityPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2018ShareRepurchaseProgramMember" name="A2018ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ALPROLIXMember" name="ALPROLIXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AbbVieMember" name="AbbVieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" name="AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_AccumulatedOtherComprehensiveIncomeLossAbstract" name="AccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AcordaMember" name="AcordaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Additionalreductioninroyaltyratepayableoncommercialsales" name="Additionalreductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AducanumabMember" name="AducanumabMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AliveGenMember" name="AliveGenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AlkermesMember" name="AlkermesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AmortizationandImpairmentofAcquiredIntangibleAssets" name="AmortizationandImpairmentofAcquiredIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" name="AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AverageStockPriceOnGrantDateInDollarsMaximum" name="AverageStockPriceOnGrantDateInDollarsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_AverageStockPriceOnGrantDateInDollarsMinimum" name="AverageStockPriceOnGrantDateInDollarsMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BENEPALIMember" name="BENEPALIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BG00011Member" name="BG00011Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB111Member" name="BIIB111Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB112Member" name="BIIB112Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BiogenIdecInternationalNeuroscienceMember" name="BiogenIdecInternationalNeuroscienceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogenshareofcopromotionprofitsorlosses" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiosimilarsMember" name="BiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BioverativMember" name="BioverativMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BristolMyersSquibbMember" name="BristolMyersSquibbMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BusinessTextualAbstract" name="BusinessTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesAbstract" name="CashSettledPerformanceSharesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" name="CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CoPromotionProfitSharingFormulaAbstract" name="CoPromotionProfitSharingFormulaAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CoPromotionProfitSharingFormulaTableTextBlock" name="CoPromotionProfitSharingFormulaTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CollaborationProfitSharing" name="CollaborationProfitSharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Collaborationexpensesaccrual" name="Collaborationexpensesaccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CollaborationsTextualAbstract" name="CollaborationsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CommercialMilestonesMember" name="CommercialMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CommitmentsAndContingenciesTextualAbstract" name="CommitmentsAndContingenciesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CompensationExpenseOverPurchasePeriod" name="CompensationExpenseOverPurchasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ComputerSoftwareAndHardware" name="ComputerSoftwareAndHardware" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ContractOptionExerciseFee" name="ContractOptionExerciseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ConvergencePharmaceuticalsMember" name="ConvergencePharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CumulativeSalesLevel" name="CumulativeSalesLevel" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelAxis" name="CumulativeSalesLevelAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelDomain" name="CumulativeSalesLevelDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" name="DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_December2019ShareRepurchaseProgramMember" name="December2019ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DeferredTaxAssetLiabilityTypeAxis" name="DeferredTaxAssetLiabilityTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DeferredTaxAssetLiabilityTypeDomain" name="DeferredTaxAssetLiabilityTypeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" name="DeferredTaxLiabilitiesDepreciationAmortizationOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" name="DeferredTaxLiabilitiesTaxCreditCarryforwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_DeferredtaxliabilitiesGILTItaxcalculation" name="DeferredtaxliabilitiesGILTItaxcalculation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" name="Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DeferredtaxliabilityMember" name="DeferredtaxliabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DenmarkManufacturingOperationsMember" name="DenmarkManufacturingOperationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DenominatorAbstract" name="DenominatorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityAxis" name="DerivativeMaturityAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityDomain" name="DerivativeMaturityDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DevelopmentalMilestonePayment" name="DevelopmentalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DirectorsPlanMember" name="DirectorsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorOneMember" name="DistributorOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorTwoMember" name="DistributorTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DivestituresAbstract" name="DivestituresAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DueFromUnconsolidatedJointBusiness" name="DueFromUnconsolidatedJointBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_E2609andBAN2401Member" name="E2609andBAN2401Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ELOCTATEMember" name="ELOCTATEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EachAdditionalOneBillionUpToTwentyBillionMember" name="EachAdditionalOneBillionUpToTwentyBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EarningsPerShareTextualAbstract" name="EarningsPerShareTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" name="EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" name="EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" name="EffectiveIncomeTaxRateReconciliationManufacturingDeduction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveTaxRateReconciliationGILTItax" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeBenefitPlansTextualAbstract" name="EmployeeBenefitPlansTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_EquityMethodInvestmentsExpectedProfitShare" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_EstimatedUsefulLivesOfLeaseholdImprovements" name="EstimatedUsefulLivesOfLeaseholdImprovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" name="ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" name="ExpectedLicenseFeeAndRegulatoryMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ExpectedPaymentTimelineofMilestoneAxis" name="ExpectedPaymentTimelineofMilestoneAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ExpectedPaymentTimelineofMilestoneDomain" name="ExpectedPaymentTimelineofMilestoneDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ExpenseIncurredByCollaboration" name="ExpenseIncurredByCollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Expenseincurredbythecollaboration" name="Expenseincurredbythecollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Expensereflectedwithinstatementsofincome" name="Expensereflectedwithinstatementsofincome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FAMPYRAMember" name="FAMPYRAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FLIXABIMember" name="FLIXABIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FUMADERMMember" name="FUMADERMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" name="FairValueIndefiniteLivedIntangibleAssetsDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_FairValueMeasurementInputs" name="FairValueMeasurementInputs" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_FifteenbillionMemberMember" name="FifteenbillionMemberMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FinancialInstrumentsTextualAbstract" name="FinancialInstrumentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ForeignSalesRequiredToTriggerMilestone" name="ForeignSalesRequiredToTriggerMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ForeignearningsintheformofcashandcashequivalentsMember" name="ForeignearningsintheformofcashandcashequivalentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ForeignearningstypeAxis" name="ForeignearningstypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ForeignearningstypeDomain" name="ForeignearningstypeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FumapharmAgMember" name="FumapharmAgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesAxis" name="FutureContingentMilestoneTypesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesDomain" name="FutureContingentMilestoneTypesDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" name="FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" name="FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureContingentPaymentThreshold" name="FutureContingentPaymentThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" name="FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Futurepercentageofcopromotionoperatingprofits" name="Futurepercentageofcopromotionoperatingprofits" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GAZYVAMember" name="GAZYVAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_HemophiliaProductsMember" name="HemophiliaProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IMRALDIMember" name="IMRALDIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IPerianMember" name="IPerianMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IncomeTaxesTextualAbstract" name="IncomeTaxesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" name="IntangibleAssetsAndGoodwillAdditionalTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InterferonMember" name="InterferonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InventoryrawmaterialssoldtoFUJIFILM" name="InventoryrawmaterialssoldtoFUJIFILM" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InventorysoldtoBioverativcost" name="InventorysoldtoBioverativcost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentInVariableInterestEntitiesTextualAbstract" name="InvestmentInVariableInterestEntitiesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Investmentincommonstocksharespurchased" name="Investmentincommonstocksharespurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_Investmentincommonstockvalue" name="Investmentincommonstockvalue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" name="InvestmentsByThirdPartyInJointVentureAsPerAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IonisPharmaceuticalsMember" name="IonisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_JointVentureOwnerShipPercentageByThirdParty" name="JointVentureOwnerShipPercentageByThirdParty" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_KaryopharmMember" name="KaryopharmMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_LesseeLeaseTableTableTextBlock" name="LesseeLeaseTableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_LicenseFee" name="LicenseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_LongtermoperatingleaseliabilitiesMember" name="LongtermoperatingleaseliabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MSProductRevenuesMember" name="MSProductRevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MajorDistributorAxis" name="MajorDistributorAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MajorDistributorDomain" name="MajorDistributorDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_March2019ShareRepurchaseProgramMember" name="March2019ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsActivityAbstract" name="MarketStockUnitsActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" name="MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MinimumQualifyingAgeForEmployeeBenefitPlan" name="MinimumQualifyingAgeForEmployeeBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" name="MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NetMinimumLeasePayments" name="NetMinimumLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsThereafter" name="NetMinimumLeasePaymentsThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFiveYear" name="NetMinimumLeasePaymentsWithInFiveYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFourYear" name="NetMinimumLeasePaymentsWithInFourYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInOneYear" name="NetMinimumLeasePaymentsWithInOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInThreeYear" name="NetMinimumLeasePaymentsWithInThreeYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInTwoYear" name="NetMinimumLeasePaymentsWithInTwoYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_NeurimmuneMember" name="NeurimmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NewAntiCd20Member" name="NewAntiCd20Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NightstarMember" name="NightstarMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" name="NumberOfDaysForCalculationOfAverageClosingStockPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfEqualAnnualIncrements" name="NumberOfEqualAnnualIncrements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" name="NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfSharesOfCommonStockForIssuance" name="NumberOfSharesOfCommonStockForIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NumeratorAbstract" name="NumeratorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OCREVUSMember" name="OCREVUSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OperatingleaseassetsMember" name="OperatingleaseassetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" name="OperatingleasesupplementalcashflowdisclosureTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" name="OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherForeignEarningsMember" name="OtherForeignEarningsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OthercorporaterevenuesMember" name="OthercorporaterevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherresearchanddiscoveryMember" name="OtherresearchanddiscoveryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesTableTextBlock" name="OtherrevenuesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PLSRMember" name="PLSRMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentTermsOfAccountsReceivable" name="PaymentTermsOfAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" name="PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfMinimumInvestmentReturn" name="PercentageOfMinimumInvestmentReturn" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfRoyaltiesAsPerCollaboration" name="PercentageOfRoyaltiesAsPerCollaboration" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageParValueOfSeniorNotes" name="PercentageParValueOfSeniorNotes" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" name="PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinCashAbstract" name="PerformanceStockUnitsSettledinCashAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinCashMember" name="PerformanceStockUnitsSettledinCashMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PerformanceStockUnitsSettledinCashTableTextBlock" name="PerformanceStockUnitsSettledinCashTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinStockAbstract" name="PerformanceStockUnitsSettledinStockAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinStockMember" name="PerformanceStockUnitsSettledinStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PerformanceStockUnitsSettledinStockTableTextBlock" name="PerformanceStockUnitsSettledinStockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceUnitsMember" name="PerformanceUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PerformanceunitsactivityTableTextBlock" name="PerformanceunitsactivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PeriodOfCollaborationAgreement" name="PeriodOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PfizerMember" name="PfizerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PostacquisitionequitycompensationMember" name="PostacquisitionequitycompensationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Premiumonpurchaseofcommonstock" name="Premiumonpurchaseofcommonstock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PrepaidtaxesMember" name="PrepaidtaxesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PretaxProfitSharingFormulaTableTextBlock" name="PretaxProfitSharingFormulaTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ProceedsFromMarketableDebtSecuritiesAbstract" name="ProceedsFromMarketableDebtSecuritiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PurchasePriceOfCommonStockUnderEspp" name="PurchasePriceOfCommonStockUnderEspp" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Purchaseofcommonstock" name="Purchaseofcommonstock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_RatioOfNumberOfSharesReservedUnderPlan" name="RatioOfNumberOfSharesReservedUnderPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract" name="ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductionindeferredtaxliabilityundistributedforeignearnings" name="Reductionindeferredtaxliabilityundistributedforeignearnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductioninroyaltyrate" name="Reductioninroyaltyrate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductioninroyaltyratepayableoncommercialsales" name="Reductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RegulatoryApprovalMilestoneMember" name="RegulatoryApprovalMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RemedyPharmaceuticalMember" name="RemedyPharmaceuticalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ResearchanddevelopmentassetAxis" name="ResearchanddevelopmentassetAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ResearchanddevelopmentassetDomain" name="ResearchanddevelopmentassetDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReserveforCashDiscountsMember" name="ReserveforCashDiscountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" name="ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_RestrictedStockUnitsActivityAbstract" name="RestrictedStockUnitsActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RevenuesFromUnconsolidatedJointBusinessAbstract" name="RevenuesFromUnconsolidatedJointBusinessAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" name="RevenuesInPercentageFromAntiCD20TherapeuticPrograms" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_Revenuesfromanticd20therapeuticprogramsMember" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RituxanMember" name="RituxanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RocheGroupGenentechMember" name="RocheGroupGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RoyaltyCostofSalesPolicyTextBlock" name="RoyaltyCostofSalesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" name="Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SOD1Member" name="SOD1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SPINRAZAMember" name="SPINRAZAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SalesTriggerGrossSalesThreshold" name="SalesTriggerGrossSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" name="ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" name="ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" name="ScheduleOfDevelopmentMilestoneAndCollaborationTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" name="ScheduleOfMarketStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" name="SegmentGeographicalGroupsOfCountriesGroupOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SegmentInformationTextualAbstract" name="SegmentInformationTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SeriesXPreferredStockMember" name="SeriesXPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShareBasedPaymentsTextualAbstract" name="ShareBasedPaymentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareOfCoPromotionProfits" name="ShareOfCoPromotionProfits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" name="SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShorttermderivativeMember" name="ShorttermderivativeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SixteenbillionMember" name="SixteenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SkyhawkTherapeuticsMember" name="SkyhawkTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SobiMember" name="SobiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnMember" name="SolothurnMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionActivityAbstract" name="StockOptionActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StockholdersEquityTaxBenefitExpense" name="StockholdersEquityTaxBenefitExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StromedixMember" name="StromedixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SubleaseMember" name="SubleaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" name="SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfCommonStockTableTextBlock" name="SummaryOfCommonStockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TGNMember" name="TGNMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TMSMember" name="TMSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" name="TaxBenefitAndCashReceivedFromStockOptionAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TaxcontingencyAbstract" name="TaxcontingencyAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Termofcollaborationagreement" name="Termofcollaborationagreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" name="ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" name="ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" name="TimeVestedRestrictedStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Totaldeferredchargesandprepaidtaxes" name="Totaldeferredchargesandprepaidtaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_Totalpaymenttoentercollaborationagreement" name="Totalpaymenttoentercollaborationagreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_TransitionTollTaxRepatriationTaxRate" name="TransitionTollTaxRepatriationTaxRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_TwelvemonthsMember" name="TwelvemonthsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TwentybillionMember" name="TwentybillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_U.S.2017TaxActMember" name="U.S.2017TaxActMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Upfrontpaymentforcollaborationagreement" name="Upfrontpaymentforcollaborationagreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_VUMERITYMember" name="VUMERITYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ValuationOfGrantedStockUnitsAbstract" name="ValuationOfGrantedStockUnitsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" name="WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_WorkinprocessMember" name="WorkinprocessMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>biib-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20191231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:href="biib-20191231.xsd#AcquisitionsAcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20191231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20191231.xsd#AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20191231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncomeCalc2" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncomeCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20191231.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails" xlink:href="biib-20191231.xsd#DerivativeInstrumentsCashFlowHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:href="biib-20191231.xsd#DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20191231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2" xlink:href="biib-20191231.xsd#DerivativeInstrumentsInterestRateSwapDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20191231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20191231.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual" xlink:href="biib-20191231.xsd#DivestituresDivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20191231.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20191231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20191231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20191231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:href="biib-20191231.xsd#EmployeeBenefitPlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:href="biib-20191231.xsd#EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20191231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20191231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20191231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20191231.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" xlink:href="biib-20191231.xsd#EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20191231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20191231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20191231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20191231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20191231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20191231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20191231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20191231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20191231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20191231.xsd#Guarantees" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20191231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20191231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20191231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20191231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20191231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20191231.xsd#Indebtedness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20191231.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20191231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20191231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20191231.xsd#IndebtednessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20191231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20191231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20191231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20191231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20191231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20191231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20191231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20191231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20191231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20191231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeases" xlink:href="biib-20191231.xsd#LeasesLeases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesDetails" xlink:href="biib-20191231.xsd#LeasesLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual" xlink:href="biib-20191231.xsd#LeasesLeasesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesTables" xlink:href="biib-20191231.xsd#LeasesLeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20191231.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:href="biib-20191231.xsd#LitigationLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20191231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20191231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20191231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20191231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20191231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20191231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20191231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20191231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20191231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20191231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20191231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20191231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:href="biib-20191231.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20191231.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20191231.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:href="biib-20191231.xsd#RevenuesOtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20191231.xsd#RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20191231.xsd#RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20191231.xsd#RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20191231.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20191231.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20191231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20191231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20191231.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20191231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails10" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails11" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20191231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20191231.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20191231.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20191231.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20191231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_e7486c7f-4b4f-6b90-afb9-63828afa66f9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_e7486c7f-4b4f-6b90-afb9-63828afa66f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_31e9d92a-989e-d017-15f9-6f38eabc27b2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_31e9d92a-989e-d017-15f9-6f38eabc27b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_fc98a957-80da-2344-7ed0-5b5c2c583d7a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_fc98a957-80da-2344-7ed0-5b5c2c583d7a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_93dd97fc-33af-32aa-9307-74029660459f" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_93dd97fc-33af-32aa-9307-74029660459f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_1417330d-29f9-c4e9-abb6-2898d623f603" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_DebtCurrent_1417330d-29f9-c4e9-abb6-2898d623f603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_aec86b81-11aa-859e-2a56-c42f4bdc8086" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_aec86b81-11aa-859e-2a56-c42f4bdc8086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_df7a9a28-7283-3e32-f63c-be1460b14d64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_df7a9a28-7283-3e32-f63c-be1460b14d64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f804297-91a1-3939-541d-a39b6288c9f9" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f804297-91a1-3939-541d-a39b6288c9f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_e7dfe01f-f85d-50a3-e5ae-55f159760a1f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_e7dfe01f-f85d-50a3-e5ae-55f159760a1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_1292ec45-46d1-e31e-9b88-8085df9cd4b2" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfDebt_1292ec45-46d1-e31e-9b88-8085df9cd4b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_93150703-969c-98cb-9165-c45c6016b964" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_93150703-969c-98cb-9165-c45c6016b964" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_a73d82d7-3d54-5ea8-2d2f-c40454b71639" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_a73d82d7-3d54-5ea8-2d2f-c40454b71639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_df7a9a28-7283-3e32-f63c-be1460b14d64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_b978ae77-fef7-cb46-afee-f23498c1fbe0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_b978ae77-fef7-cb46-afee-f23498c1fbe0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c609427e-97a7-37ff-0264-613508cb64bd" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c609427e-97a7-37ff-0264-613508cb64bd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6abb14d9-7978-302d-af6b-dbfc88f76bf2" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6abb14d9-7978-302d-af6b-dbfc88f76bf2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6d7a72cc-b15d-447c-3b26-c3564dc5b0b1" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6d7a72cc-b15d-447c-3b26-c3564dc5b0b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8644689e-88a2-9828-8c4d-126d8957ca8f" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8644689e-88a2-9828-8c4d-126d8957ca8f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_483713d8-e500-be9d-d173-6b5e26416fef" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_483713d8-e500-be9d-d173-6b5e26416fef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_06da844c-6ee0-0b1d-0eaf-6f589c92b21e" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_06da844c-6ee0-0b1d-0eaf-6f589c92b21e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_c4ba6750-a0ad-e402-704f-a43919d1eea3" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_c4ba6750-a0ad-e402-704f-a43919d1eea3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5cf64b6-8899-5a9a-328a-4f0a312ae378" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5cf64b6-8899-5a9a-328a-4f0a312ae378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_df7a9a28-7283-3e32-f63c-be1460b14d64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_cda04db3-0cc7-8cee-c106-c75d14634c49" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_cda04db3-0cc7-8cee-c106-c75d14634c49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2d3aea93-0685-7648-d025-abd4b91cbb46" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2d3aea93-0685-7648-d025-abd4b91cbb46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6933b079-472c-4409-d821-646ed2de772d" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6933b079-472c-4409-d821-646ed2de772d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06dfb931-62f3-bab4-4c41-dbf77bf8befd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06dfb931-62f3-bab4-4c41-dbf77bf8befd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06dfb931-62f3-bab4-4c41-dbf77bf8befd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_dea146b3-6d50-c215-7c85-641051f14bf2" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06dfb931-62f3-bab4-4c41-dbf77bf8befd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_dea146b3-6d50-c215-7c85-641051f14bf2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2efcb6ae-5d3a-652c-5e64-2f0332c3d5a3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2efcb6ae-5d3a-652c-5e64-2f0332c3d5a3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_397a475b-0af5-f3eb-f91e-9518c9a0cfd9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2efcb6ae-5d3a-652c-5e64-2f0332c3d5a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_397a475b-0af5-f3eb-f91e-9518c9a0cfd9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_93de04c3-ace0-a2f0-c272-f037b3709822" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2efcb6ae-5d3a-652c-5e64-2f0332c3d5a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_93de04c3-ace0-a2f0-c272-f037b3709822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_4aa12f65-c01e-b69d-e1f7-33b49edb7292" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_4aa12f65-c01e-b69d-e1f7-33b49edb7292" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_d883dcbc-2c6d-ac38-1d62-4c53193397a0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_4aa12f65-c01e-b69d-e1f7-33b49edb7292" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_d883dcbc-2c6d-ac38-1d62-4c53193397a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_274f35cc-71aa-a80a-4a1a-2898d2a2633b" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_4aa12f65-c01e-b69d-e1f7-33b49edb7292" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_274f35cc-71aa-a80a-4a1a-2898d2a2633b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_bfbc3edc-1edc-bfc6-c7b6-fb403917e31e" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_bfbc3edc-1edc-bfc6-c7b6-fb403917e31e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncomeCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5D425CE47FECBE98C99D6F399D593C52_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_5D425CE47FECBE98C99D6F399D593C52_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5D425CE47FECBE98C99D6F399D593C52_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_5D425CE47FECBE98C99D6F399D593C52_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5D425CE47FECBE98C99D6F399D593C52_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5D425CE47FECBE98C99D6F399D593C52_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5D425CE47FECBE98C99D6F399D593C52_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_c1a26ca9-fcd0-2c79-894e-6f38eec2d2ea" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_c1a26ca9-fcd0-2c79-894e-6f38eec2d2ea" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_4a0b2506-7b27-c41c-9c14-6f38e880cc1b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_biib_CollaborationProfitSharing_4a0b2506-7b27-c41c-9c14-6f38e880cc1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_b15190d2-1e17-e470-df7e-3ace9efbe89b" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_b15190d2-1e17-e470-df7e-3ace9efbe89b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_86dec120-3352-31c8-fc61-55992f948bdd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_86dec120-3352-31c8-fc61-55992f948bdd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_90854703-859b-2c45-aef2-d270627b3141" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_90854703-859b-2c45-aef2-d270627b3141" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_103b152e-0ae8-d915-6e3d-c66b85fd9d6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_103b152e-0ae8-d915-6e3d-c66b85fd9d6e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_343e33a1-c19a-6390-98c6-16cc97a33d05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2612293f-3433-3583-52e7-9d30e9028da1" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_343e33a1-c19a-6390-98c6-16cc97a33d05" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2612293f-3433-3583-52e7-9d30e9028da1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e12f97e0-5d92-eafd-b37a-c60f8d5e47e4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_343e33a1-c19a-6390-98c6-16cc97a33d05" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e12f97e0-5d92-eafd-b37a-c60f8d5e47e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c88e6350-e26e-969b-2f36-fb6881edab88" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_343e33a1-c19a-6390-98c6-16cc97a33d05" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c88e6350-e26e-969b-2f36-fb6881edab88" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2689b18d-c088-f9d0-8533-bbbc6703e3ca" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2689b18d-c088-f9d0-8533-bbbc6703e3ca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec915ab0-b06c-8246-6113-1ffd431b1e4b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec915ab0-b06c-8246-6113-1ffd431b1e4b" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_9438dacf-8de4-0934-65dd-f625b08c8172" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_9438dacf-8de4-0934-65dd-f625b08c8172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_f9649554-34c6-3259-f927-f625b09bb302" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_f9649554-34c6-3259-f927-f625b09bb302" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_dbb037c2-04c0-fa14-65e6-8ccd12d2a855" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_dbb037c2-04c0-fa14-65e6-8ccd12d2a855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8caef893-a841-2be2-863f-e20b53026f02" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8caef893-a841-2be2-863f-e20b53026f02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3ce82195-ed3e-f261-3529-b3a868ecf6c4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3ce82195-ed3e-f261-3529-b3a868ecf6c4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89ebd542-78ee-71d0-be95-65de1bb3ef82" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89ebd542-78ee-71d0-be95-65de1bb3ef82" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5da8fd5a-89f1-3049-e781-200c2d180554" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5da8fd5a-89f1-3049-e781-200c2d180554" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_b47060f0-1353-84f4-cc63-6f38ec646a01" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_b47060f0-1353-84f4-cc63-6f38ec646a01" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" xlink:label="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_79e8a206-11b0-b4b9-d62b-6f38ee996d89" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_79e8a206-11b0-b4b9-d62b-6f38ee996d89" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_7a51efb9-ec38-accc-c5ad-6f38e7662fb1" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_7a51efb9-ec38-accc-c5ad-6f38e7662fb1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9fd2e560-0aac-aea4-6be8-8b4e4e77d184" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9fd2e560-0aac-aea4-6be8-8b4e4e77d184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_76823e13-ff55-7cd2-ec5d-7dac1fd75cd9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_76823e13-ff55-7cd2-ec5d-7dac1fd75cd9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e1ccc1eb-ffbd-3ad3-bc7a-09819cccad11" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e1ccc1eb-ffbd-3ad3-bc7a-09819cccad11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_de5e795f-0165-d088-d22e-d01ff8d44317" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_de5e795f-0165-d088-d22e-d01ff8d44317" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa285cf0-c43f-6ef0-a0f2-c37d958f2fe4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa285cf0-c43f-6ef0-a0f2-c37d958f2fe4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_760e1cd1-b180-e0c4-17a8-eef24284a1cb" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_760e1cd1-b180-e0c4-17a8-eef24284a1cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_460bb6a1-555b-7f84-cef9-01aaeb67cc93" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_460bb6a1-555b-7f84-cef9-01aaeb67cc93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_f596c6d8-b215-4d64-bb21-cb6128455f52" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_f596c6d8-b215-4d64-bb21-cb6128455f52" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9F3325E0F11F9E0FAFA50AFCD3C2B8CB" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9F3325E0F11F9E0FAFA50AFCD3C2B8CB" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_9fa82ab8-0dc2-a508-316e-f625b06c48a9" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_9fa82ab8-0dc2-a508-316e-f625b06c48a9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_631ea6c6-f758-7a94-e1aa-04c5f19d6b4b" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_631ea6c6-f758-7a94-e1aa-04c5f19d6b4b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dde8ff73-3704-2d19-f167-45cf9c0efbb7" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dde8ff73-3704-2d19-f167-45cf9c0efbb7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_920576679DDD81DAD2CCDF9E7A4FF3B7" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_920576679DDD81DAD2CCDF9E7A4FF3B7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_cd6482bd-69ec-0791-6926-6f38ec1393a0" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_cd6482bd-69ec-0791-6926-6f38ec1393a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_31eb113d-20c2-89b0-7b2e-dd6b121a4c90" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_31eb113d-20c2-89b0-7b2e-dd6b121a4c90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c16a0eb3-02da-6ea0-91e7-3203372f71fd" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c16a0eb3-02da-6ea0-91e7-3203372f71fd" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_622e5770-f948-044b-c6fe-ee319e65b163" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b14a8305-c528-44ac-6db7-45b0f6f6ddc6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_622e5770-f948-044b-c6fe-ee319e65b163" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b14a8305-c528-44ac-6db7-45b0f6f6ddc6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ce3ac95b-761b-7fbc-3779-1bdfd056c71f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_622e5770-f948-044b-c6fe-ee319e65b163" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ce3ac95b-761b-7fbc-3779-1bdfd056c71f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d39bb101-f79f-a162-9929-01083e9d64b5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_622e5770-f948-044b-c6fe-ee319e65b163" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d39bb101-f79f-a162-9929-01083e9d64b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_73238937-86a2-9126-69f0-c70629155ebe" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_622e5770-f948-044b-c6fe-ee319e65b163" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_73238937-86a2-9126-69f0-c70629155ebe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a170264f-50ba-a4bb-6d22-ec86b5249633" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_622e5770-f948-044b-c6fe-ee319e65b163" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a170264f-50ba-a4bb-6d22-ec86b5249633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_da82f4c2-6e6f-ccde-a6bf-f559322a3267" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_622e5770-f948-044b-c6fe-ee319e65b163" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_da82f4c2-6e6f-ccde-a6bf-f559322a3267" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:type="arc" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20191231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a142eb63-af8d-4212-6321-d7c0ac27f958" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a142eb63-af8d-4212-6321-d7c0ac27f958" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesLeases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_8d3a9604-12a6-9f8a-2166-f625b1186579" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_8d3a9604-12a6-9f8a-2166-f625b1186579" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_1b3378b2-4516-3e25-8b78-2fea6fcc17f4" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_8d3a9604-12a6-9f8a-2166-f625b1186579" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_1b3378b2-4516-3e25-8b78-2fea6fcc17f4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4644c36b-2591-5821-1391-f625b166fb31" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4cf71329-74d6-54f3-cadb-acb7f1063f36" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4644c36b-2591-5821-1391-f625b166fb31" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4cf71329-74d6-54f3-cadb-acb7f1063f36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1614e10d-239d-dd27-f21f-6bf70cc45577" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4644c36b-2591-5821-1391-f625b166fb31" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1614e10d-239d-dd27-f21f-6bf70cc45577" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_c8e43ccd-2663-8a3a-34ae-f625b157f11e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e71cbb67-0324-15b7-66dc-376e90f3ca60" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_c8e43ccd-2663-8a3a-34ae-f625b157f11e" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e71cbb67-0324-15b7-66dc-376e90f3ca60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_9457929d-79a2-8c41-ff57-afe7f61ce807" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_c8e43ccd-2663-8a3a-34ae-f625b157f11e" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_9457929d-79a2-8c41-ff57-afe7f61ce807" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_e87c6669-8f1b-0b93-4ac0-f625b0f97077" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_832fb73d-9886-a0dd-5905-8e2ec54304d6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_e87c6669-8f1b-0b93-4ac0-f625b0f97077" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_832fb73d-9886-a0dd-5905-8e2ec54304d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_12928cf4-7bc8-1112-408f-6e02bd1f135d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_e87c6669-8f1b-0b93-4ac0-f625b0f97077" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_12928cf4-7bc8-1112-408f-6e02bd1f135d" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_ee837b39-c135-31a6-5f3f-f625b0ab8a62" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_ee837b39-c135-31a6-5f3f-f625b0ab8a62" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2e5128aa-6caf-7804-0014-2a8148a0b9de" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_ee837b39-c135-31a6-5f3f-f625b0ab8a62" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2e5128aa-6caf-7804-0014-2a8148a0b9de" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_f67e4a70-063a-7e63-7c03-f625b0ca3e13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1f2c68db-a374-1412-5f1f-4edca1431bbb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_f67e4a70-063a-7e63-7c03-f625b0ca3e13" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1f2c68db-a374-1412-5f1f-4edca1431bbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_d4de5958-df21-732d-46e4-0fb9b9ce81e1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_f67e4a70-063a-7e63-7c03-f625b0ca3e13" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_d4de5958-df21-732d-46e4-0fb9b9ce81e1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_828e5d61-3893-c6ba-834e-f625b0ab217a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_828e5d61-3893-c6ba-834e-f625b0ab217a" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_59c79d0c-ed63-b2bc-685a-f7e81a18ac39" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_828e5d61-3893-c6ba-834e-f625b0ab217a" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_59c79d0c-ed63-b2bc-685a-f7e81a18ac39" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_74f31f5f-ec6e-8caa-8038-0fd6f6455756" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_74f31f5f-ec6e-8caa-8038-0fd6f6455756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_96cf6261-5089-1df3-fbfc-c8c8918673b4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_96cf6261-5089-1df3-fbfc-c8c8918673b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="locator" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_008d078c-9a2a-722c-5c77-985ebb0cef73" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:to="loc_us-gaap_Land_008d078c-9a2a-722c-5c77-985ebb0cef73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_f1ca2698-ef44-aef0-3195-46d5b5f09667" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_f1ca2698-ef44-aef0-3195-46d5b5f09667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_23f8c30f-5a5c-2d11-0a3e-76f10a253777" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_23f8c30f-5a5c-2d11-0a3e-76f10a253777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_4f9f456f-b99f-98cb-4c0d-8686ab07bcd2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_4f9f456f-b99f-98cb-4c0d-8686ab07bcd2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_d512219e-e15e-b574-8882-6f38eb746a26" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:to="loc_biib_ComputerSoftwareAndHardware_d512219e-e15e-b574-8882-6f38eb746a26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_053b77b2-7a64-6db0-1196-000438fdd452" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_053b77b2-7a64-6db0-1196-000438fdd452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_849c20f4-7842-f86b-ff81-0b112bbf996c" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:to="loc_us-gaap_ConstructionInProgressGross_849c20f4-7842-f86b-ff81-0b112bbf996c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_bfbc9b8b-4c07-a9b6-40a8-f625b09bc6d8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:to="loc_biib_ShareOfCoPromotionProfits_bfbc9b8b-4c07-a9b6-40a8-f625b09bc6d8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_f5cdd8c1-efb2-02d5-8ff1-f625b118866a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_f5cdd8c1-efb2-02d5-8ff1-f625b118866a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>biib-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20191231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:href="biib-20191231.xsd#AcquisitionsAcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20191231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20191231.xsd#AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20191231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20191231.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails" xlink:href="biib-20191231.xsd#DerivativeInstrumentsCashFlowHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:href="biib-20191231.xsd#DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20191231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2" xlink:href="biib-20191231.xsd#DerivativeInstrumentsInterestRateSwapDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20191231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20191231.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual" xlink:href="biib-20191231.xsd#DivestituresDivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20191231.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20191231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20191231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20191231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:href="biib-20191231.xsd#EmployeeBenefitPlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:href="biib-20191231.xsd#EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20191231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20191231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20191231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20191231.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" xlink:href="biib-20191231.xsd#EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20191231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20191231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20191231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20191231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20191231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20191231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20191231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20191231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20191231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20191231.xsd#Guarantees" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20191231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20191231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20191231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20191231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20191231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20191231.xsd#Indebtedness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20191231.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20191231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20191231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20191231.xsd#IndebtednessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20191231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20191231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20191231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20191231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20191231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20191231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20191231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20191231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20191231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20191231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeases" xlink:href="biib-20191231.xsd#LeasesLeases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesDetails" xlink:href="biib-20191231.xsd#LeasesLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual" xlink:href="biib-20191231.xsd#LeasesLeasesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesTables" xlink:href="biib-20191231.xsd#LeasesLeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20191231.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:href="biib-20191231.xsd#LitigationLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20191231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20191231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20191231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20191231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20191231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20191231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20191231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20191231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20191231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20191231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20191231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20191231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:href="biib-20191231.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20191231.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20191231.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:href="biib-20191231.xsd#RevenuesOtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20191231.xsd#RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20191231.xsd#RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20191231.xsd#RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20191231.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20191231.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20191231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20191231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20191231.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20191231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails10" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails11" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20191231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20191231.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20191231.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20191231.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20191231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_CB2DBEC03BEA476312BC7EE95248DC82" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B3C5D01540D1470C7EEA7EE9523865C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CB2DBEC03BEA476312BC7EE95248DC82" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B3C5D01540D1470C7EEA7EE9523865C7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_D0DA36BA57175089FA067EE95248B418" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B3C5D01540D1470C7EEA7EE9523865C7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_D0DA36BA57175089FA067EE95248B418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B37F83443BC9224C63187EE952487FD1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D0DA36BA57175089FA067EE95248B418" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B37F83443BC9224C63187EE952487FD1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B37F83443BC9224C63187EE952487FD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D0DA36BA57175089FA067EE95248B418" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B37F83443BC9224C63187EE952487FD1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_E46EF508CCFAF221FC6A7EE952484E0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B37F83443BC9224C63187EE952487FD1" xlink:to="loc_biib_NightstarMember_E46EF508CCFAF221FC6A7EE952484E0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3C7F99E427DE7603EB407EE95248A274" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CB2DBEC03BEA476312BC7EE95248DC82" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3C7F99E427DE7603EB407EE95248A274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_BB1C62AA144222D892407EE952483E77" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CB2DBEC03BEA476312BC7EE95248DC82" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_BB1C62AA144222D892407EE952483E77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_300C4AA2878DF36F4DB47EE95248B00A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CB2DBEC03BEA476312BC7EE95248DC82" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_300C4AA2878DF36F4DB47EE95248B00A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_9142F7AE8B9D45CE07257EE9524882DE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CB2DBEC03BEA476312BC7EE95248DC82" xlink:to="loc_us-gaap_Goodwill_9142F7AE8B9D45CE07257EE9524882DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_E1BB7E2EC00B62EE75FA7EE95248D9C8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CB2DBEC03BEA476312BC7EE95248DC82" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_E1BB7E2EC00B62EE75FA7EE95248D9C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_193D95298327FEA0D7B17EE95248A6F8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CB2DBEC03BEA476312BC7EE95248DC82" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_193D95298327FEA0D7B17EE95248A6F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9DDCC474F2DDE92AD52E7EE95248DC67" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CB2DBEC03BEA476312BC7EE95248DC82" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9DDCC474F2DDE92AD52E7EE95248DC67" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:to="loc_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:to="loc_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_DBFB88954106433D9BE57ED98440998A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_DBFB88954106433D9BE57ED98440998A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_649F9CC8E6EC121CCFFA7ED984406621_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_DBFB88954106433D9BE57ED98440998A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_649F9CC8E6EC121CCFFA7ED984406621_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_649F9CC8E6EC121CCFFA7ED984406621" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_DBFB88954106433D9BE57ED98440998A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_649F9CC8E6EC121CCFFA7ED984406621" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9F71C0BDD627AE6A5DC57ED98460A139" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_649F9CC8E6EC121CCFFA7ED984406621" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9F71C0BDD627AE6A5DC57ED98460A139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4B6D9A5F7D3225D455947ED9CBA5A5A8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_649F9CC8E6EC121CCFFA7ED984406621" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4B6D9A5F7D3225D455947ED9CBA5A5A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC" xlink:to="loc_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7" xlink:to="loc_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="loc_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="loc_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="loc_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TMSMember" xlink:label="loc_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="loc_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AliveGenMember" xlink:label="loc_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="loc_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="loc_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_F8E07E8C4E30EB156FE57ED5BA74526D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_F8E07E8C4E30EB156FE57ED5BA74526D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A69CD9EA7B01048CC6A67ED6538575A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_A69CD9EA7B01048CC6A67ED6538575A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_56A76BF6AF0C0080FC227ED69B9B16A1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_56A76BF6AF0C0080FC227ED69B9B16A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8E01BEB067C57E0A4A0E7ED82955CF01" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8E01BEB067C57E0A4A0E7ED82955CF01" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F2FA0FF2B4D553E12F8E7EE6FAFD8BA6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F2FA0FF2B4D553E12F8E7EE6FAFD8BA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_E4EDEF447F00AF99A88F7EE7D6AA22C2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_E4EDEF447F00AF99A88F7EE7D6AA22C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_6B8B2507B4087A7A4F617ED42E283848" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_6B8B2507B4087A7A4F617ED42E283848" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_12517474A7234EE10C037ED42E291BE6" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_12517474A7234EE10C037ED42E291BE6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4637E252184832A8465CFCF51D25CDBE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4637E252184832A8465CFCF51D25CDBE" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_387F467AC2195A681E49FCF51D22C809" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:to="loc_srt_MajorCustomersAxis_387F467AC2195A681E49FCF51D22C809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_80C75762F240635EFD24FCF51D229101_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_387F467AC2195A681E49FCF51D22C809" xlink:to="loc_srt_NameOfMajorCustomerDomain_80C75762F240635EFD24FCF51D229101_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_80C75762F240635EFD24FCF51D229101" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_387F467AC2195A681E49FCF51D22C809" xlink:to="loc_srt_NameOfMajorCustomerDomain_80C75762F240635EFD24FCF51D229101" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_249860D07BB1CCD13DADFCF51D23BB32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_80C75762F240635EFD24FCF51D229101" xlink:to="loc_biib_AbbVieMember_249860D07BB1CCD13DADFCF51D23BB32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_3CEAAEC85B5302EBF204FCF51D238748" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:to="loc_srt_ProductOrServiceAxis_3CEAAEC85B5302EBF204FCF51D238748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7ED744B3E9C0E718E111FCF51D2365B9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3CEAAEC85B5302EBF204FCF51D238748" xlink:to="loc_srt_ProductsAndServicesDomain_7ED744B3E9C0E718E111FCF51D2365B9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7ED744B3E9C0E718E111FCF51D2365B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3CEAAEC85B5302EBF204FCF51D238748" xlink:to="loc_srt_ProductsAndServicesDomain_7ED744B3E9C0E718E111FCF51D2365B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_D76F03824941315A33A0FCF51D230DF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7ED744B3E9C0E718E111FCF51D2365B9" xlink:to="loc_us-gaap_ProductMember_D76F03824941315A33A0FCF51D230DF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_7A043674B659A7CCFE67FCF51D24D89B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:to="loc_srt_StatementGeographicalAxis_7A043674B659A7CCFE67FCF51D24D89B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_DA7DF8FAFE096CE21B2CFCF51D247890_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7A043674B659A7CCFE67FCF51D24D89B" xlink:to="loc_srt_SegmentGeographicalDomain_DA7DF8FAFE096CE21B2CFCF51D247890_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_DA7DF8FAFE096CE21B2CFCF51D247890" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7A043674B659A7CCFE67FCF51D24D89B" xlink:to="loc_srt_SegmentGeographicalDomain_DA7DF8FAFE096CE21B2CFCF51D247890" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_FC6B16D73541CA71BBB8FCF51D24F650" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_DA7DF8FAFE096CE21B2CFCF51D247890" xlink:to="loc_country_US_FC6B16D73541CA71BBB8FCF51D24F650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_07BEB9794700603C484AFCF51D244EC3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:to="loc_us-gaap_TypeOfArrangementAxis_07BEB9794700603C484AFCF51D244EC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3F57C727BDDE3C450A7FCF51D24A546_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_07BEB9794700603C484AFCF51D244EC3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3F57C727BDDE3C450A7FCF51D24A546_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3F57C727BDDE3C450A7FCF51D24A546" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_07BEB9794700603C484AFCF51D244EC3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3F57C727BDDE3C450A7FCF51D24A546" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_27E2A93B02AE6FE44C67FCF51D25D3A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3F57C727BDDE3C450A7FCF51D24A546" xlink:to="loc_biib_AbbVieMember_27E2A93B02AE6FE44C67FCF51D25D3A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_CCC0C44FF004449D0770FCF51D253F51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4637E252184832A8465CFCF51D25CDBE" xlink:to="loc_us-gaap_Revenues_CCC0C44FF004449D0770FCF51D253F51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_CB2D7F5653856E75B7FEFCF51D26933A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4637E252184832A8465CFCF51D25CDBE" xlink:to="loc_us-gaap_CostsAndExpenses_CB2D7F5653856E75B7FEFCF51D26933A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8DF81A039108E07DA1C1F1F26A4D5A30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8DF81A039108E07DA1C1F1F26A4D5A30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CEA34C5F2D892CB0BE88F1F26A4D0594_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8DF81A039108E07DA1C1F1F26A4D5A30" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_CEA34C5F2D892CB0BE88F1F26A4D0594_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CEA34C5F2D892CB0BE88F1F26A4D0594" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8DF81A039108E07DA1C1F1F26A4D5A30" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_CEA34C5F2D892CB0BE88F1F26A4D0594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_465798FF027B9E3D9159F1F26A4DA91F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CEA34C5F2D892CB0BE88F1F26A4D0594" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_465798FF027B9E3D9159F1F26A4DA91F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22BA5A40DF95E34FAA02F1F26A4DC6D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CEA34C5F2D892CB0BE88F1F26A4D0594" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22BA5A40DF95E34FAA02F1F26A4DC6D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_51EFDC26ED20FDA10D77F1F26A4DDA7A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:to="loc_srt_ProductOrServiceAxis_51EFDC26ED20FDA10D77F1F26A4DDA7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3E0953EB882E036CD93AF1F26A4D37AC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_51EFDC26ED20FDA10D77F1F26A4DDA7A" xlink:to="loc_srt_ProductsAndServicesDomain_3E0953EB882E036CD93AF1F26A4D37AC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3E0953EB882E036CD93AF1F26A4D37AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_51EFDC26ED20FDA10D77F1F26A4DDA7A" xlink:to="loc_srt_ProductsAndServicesDomain_3E0953EB882E036CD93AF1F26A4D37AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3E0953EB882E036CD93AF1F26A4D37AC" xlink:to="loc_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC" xlink:to="loc_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:to="loc_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:to="loc_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_BACA7FB0A419D09F03500B3C2020A3E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_BACA7FB0A419D09F03500B3C2020A3E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_730A4171580F2552FA9F0B3C20208B7A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_BACA7FB0A419D09F03500B3C2020A3E8" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_730A4171580F2552FA9F0B3C20208B7A_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_730A4171580F2552FA9F0B3C20208B7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_BACA7FB0A419D09F03500B3C2020A3E8" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_730A4171580F2552FA9F0B3C20208B7A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_84F26CAD51238C0E6B3C0B3C20208317" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_730A4171580F2552FA9F0B3C20208B7A" xlink:to="loc_biib_DevelopmentMilestonesMember_84F26CAD51238C0E6B3C0B3C20208317" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_ADDBC92866C6615F363B0B3C2020E9D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:to="loc_us-gaap_InventoriesMember_ADDBC92866C6615F363B0B3C2020E9D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_B8F1DA537F2C7F4B2F190B3C20202DC0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_B8F1DA537F2C7F4B2F190B3C20202DC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9B7DBD77242F961C95DD0B3C2020505D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9B7DBD77242F961C95DD0B3C2020505D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:to="loc_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_098059C64C43A57F58870B3C202036B0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_srt_MajorCustomersAxis_098059C64C43A57F58870B3C202036B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_29E37A322AD2BE75A9D50B3C2020EF3C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_098059C64C43A57F58870B3C202036B0" xlink:to="loc_srt_NameOfMajorCustomerDomain_29E37A322AD2BE75A9D50B3C2020EF3C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_29E37A322AD2BE75A9D50B3C2020EF3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_098059C64C43A57F58870B3C202036B0" xlink:to="loc_srt_NameOfMajorCustomerDomain_29E37A322AD2BE75A9D50B3C2020EF3C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_29E37A322AD2BE75A9D50B3C2020EF3C" xlink:to="loc_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_D1B1F11EB630DD9F7A960B3C20206D06" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_srt_StatementGeographicalAxis_D1B1F11EB630DD9F7A960B3C20206D06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_D1B1F11EB630DD9F7A960B3C20206D06" xlink:to="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_D1B1F11EB630DD9F7A960B3C20206D06" xlink:to="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_823A66E6EB49E849381A0B3C20202117" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A" xlink:to="loc_country_US_823A66E6EB49E849381A0B3C20202117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_CDED27190B79CD166B630B3C20202ACB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A" xlink:to="loc_us-gaap_ForeignCountryMember_CDED27190B79CD166B630B3C20202ACB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_D2E408C6944F72A1BC0C0B3C20200378" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A" xlink:to="loc_us-gaap_EuropeanUnionMember_D2E408C6944F72A1BC0C0B3C20200378" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_C1D2D51C1DEE93328E4D0B3C2020B902" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A" xlink:to="loc_country_JP_C1D2D51C1DEE93328E4D0B3C2020B902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6842A0EF85006625791B0B3C20205D2D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6842A0EF85006625791B0B3C20205D2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7D69C326772C1A78B2910B3C20206D7C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6842A0EF85006625791B0B3C20205D2D" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7D69C326772C1A78B2910B3C20206D7C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7D69C326772C1A78B2910B3C20206D7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6842A0EF85006625791B0B3C20205D2D" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7D69C326772C1A78B2910B3C20206D7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F96FC84302C506C368AB0B3C202007CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7D69C326772C1A78B2910B3C20206D7C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F96FC84302C506C368AB0B3C202007CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C60AC04363985B40EFDA0B3C20209A76" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7D69C326772C1A78B2910B3C20206D7C" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C60AC04363985B40EFDA0B3C20209A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E949A4647AAD46AA5620B3C20201CBA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E949A4647AAD46AA5620B3C20201CBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0B343F00FFFEC916AC8C0B3C20206523_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E949A4647AAD46AA5620B3C20201CBA" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0B343F00FFFEC916AC8C0B3C20206523_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0B343F00FFFEC916AC8C0B3C20206523" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E949A4647AAD46AA5620B3C20201CBA" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0B343F00FFFEC916AC8C0B3C20206523" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_83F5824C8D6887CA62B80B3C202062DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0B343F00FFFEC916AC8C0B3C20206523" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_83F5824C8D6887CA62B80B3C202062DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_564BFAD34FBF18856EF90B3C2020CA63" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_srt_ProductOrServiceAxis_564BFAD34FBF18856EF90B3C2020CA63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_564BFAD34FBF18856EF90B3C2020CA63" xlink:to="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_564BFAD34FBF18856EF90B3C2020CA63" xlink:to="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_92AE60DF9FB2DE9C8E8C0B3C2020942E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_RituxanMember_92AE60DF9FB2DE9C8E8C0B3C2020942E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_DC5FEC4AC71B5FCEB0D00B3C2020383D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_GAZYVAMember_DC5FEC4AC71B5FCEB0D00B3C2020383D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OCREVUSMember" xlink:label="loc_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_324EB2272BD3294AA7B10B3C20302D25" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_ZINBRYTAMember_324EB2272BD3294AA7B10B3C20302D25" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_8907C7E70F3C9E7D67C10B3C2030D1F7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_SPINRAZAMember_8907C7E70F3C9E7D67C10B3C2030D1F7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_VUMERITYMember" xlink:label="loc_biib_VUMERITYMember_AF50F6914F342EF7724E0B3C20308082" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_VUMERITYMember_AF50F6914F342EF7724E0B3C20308082" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_79AA70EE71B1D432A28F0B3C2030563D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_BiosimilarsMember_79AA70EE71B1D432A28F0B3C2030563D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_B3E73EEA4E2E97E6903D0B3C20306857" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_IMRALDIMember_B3E73EEA4E2E97E6903D0B3C20306857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1EA6CFC3268463B3A2BC0B3C203076AF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1EA6CFC3268463B3A2BC0B3C203076AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1EA6CFC3268463B3A2BC0B3C203076AF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1EA6CFC3268463B3A2BC0B3C203076AF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_1FA327EBE731DA83995A0B3C2030DF24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_RocheGroupGenentechMember_1FA327EBE731DA83995A0B3C2030DF24" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_E2F4F88CDE28376C1B790B3C20307AF2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_EisaiMember_E2F4F88CDE28376C1B790B3C20307AF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_C2808FCFC85132D72C110B3C20305E5B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_AbbVieMember_C2808FCFC85132D72C110B3C20305E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5D390AD3BE3532993AD80B3C2030510C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5D390AD3BE3532993AD80B3C2030510C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_1D32A339AE16E2E9AD9F0B3C2030E100" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_1D32A339AE16E2E9AD9F0B3C2030E100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_828AA7145EA5619CAA250B3C2030DA8D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_srt_RangeAxis_828AA7145EA5619CAA250B3C2030DA8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_AEB33BC9CA4237AC84E00B3C20304F8D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_828AA7145EA5619CAA250B3C2030DA8D" xlink:to="loc_srt_RangeMember_AEB33BC9CA4237AC84E00B3C20304F8D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_AEB33BC9CA4237AC84E00B3C20304F8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_828AA7145EA5619CAA250B3C2030DA8D" xlink:to="loc_srt_RangeMember_AEB33BC9CA4237AC84E00B3C20304F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4FC5938D67CC5BEFD2890B3C20303AA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_AEB33BC9CA4237AC84E00B3C20304F8D" xlink:to="loc_srt_MinimumMember_4FC5938D67CC5BEFD2890B3C20303AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_AB32493DABA89B2729840B3C20308D5E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_AEB33BC9CA4237AC84E00B3C20304F8D" xlink:to="loc_srt_MaximumMember_AB32493DABA89B2729840B3C20308D5E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_3764C0EC69C98A0FE35B0B3C2030A76C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_ShareOfCoPromotionProfits_3764C0EC69C98A0FE35B0B3C2030A76C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_CB3AD999EC163BDCBE180B3C2030705B" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_CB3AD999EC163BDCBE180B3C2030705B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5F7A3D25B6E00A2C1E0C0B3C2030EA4C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5F7A3D25B6E00A2C1E0C0B3C2030EA4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_09E5439C8F3E348A4B4D0B3C20304B1B" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_09E5439C8F3E348A4B4D0B3C20304B1B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ContractOptionExerciseFee" xlink:label="loc_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B8C1CE7350202A681FE30B3C20301B01" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B8C1CE7350202A681FE30B3C20301B01" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0B4D7FCC780B1BC65A670B3C20305FFB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0B4D7FCC780B1BC65A670B3C20305FFB" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B304B5055596BED91C8B0B3C203020B3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B304B5055596BED91C8B0B3C203020B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_752788BD774A6EC4C69B0B3C2030E0D5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_ExpenseIncurredByCollaboration_752788BD774A6EC4C69B0B3C2030E0D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F1F518C4E8628AC339D80B3C20309A5C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_Revenues_F1F518C4E8628AC339D80B3C20309A5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_95E5CF3DFB513234C61E0B3C20304C0C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_95E5CF3DFB513234C61E0B3C20304C0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_23EFF3B3256AABBFC7A00B3C2030B143" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_23EFF3B3256AABBFC7A00B3C2030B143" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_D0C907119CAC70FBFFC10B3C20307EBC" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_CollaborationProfitSharing_D0C907119CAC70FBFFC10B3C20307EBC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_521FA37A354C34ADE1490B3C203096EA" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_521FA37A354C34ADE1490B3C203096EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Upfrontpaymentforcollaborationagreement" xlink:label="loc_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_FB4D61C29C0E6C3D52A20B3C203053FD" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_FB4D61C29C0E6C3D52A20B3C203053FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Totalpaymenttoentercollaborationagreement" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_95A37109A17493D065ED0B3C2030272D" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_95A37109A17493D065ED0B3C2030272D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_3DF7E39CEC13F9D4542C0B3C203093ED" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_3DF7E39CEC13F9D4542C0B3C203093ED" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Investmentincommonstockvalue" xlink:label="loc_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_AB34543CB2F1D9B48D820B3C203020D0" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_AB34543CB2F1D9B48D820B3C203020D0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4027F16708EE8AEDBDAC0B3C20303240" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_EquityMethodInvestments_4027F16708EE8AEDBDAC0B3C20303240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3176B4E946D42EE6DD1F0B3C20307A21" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3176B4E946D42EE6DD1F0B3C20307A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_1BA6ED2497F506020F820B3C2030BE44" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_1BA6ED2497F506020F820B3C2030BE44" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_AE526C1A2878CFECDB040B3C2030FE36" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_AE526C1A2878CFECDB040B3C2030FE36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_98E671063FEF44E8BF0C0B3C20300097" xlink:type="locator" />
    <link:definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_98E671063FEF44E8BF0C0B3C20300097" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_25020910B6D4D3DB292D0B3C20307C5E" xlink:type="locator" />
    <link:definitionArc order="38" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_25020910B6D4D3DB292D0B3C20307C5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_11CC593C2EFF90684AC10B3C20309816" xlink:type="locator" />
    <link:definitionArc order="39" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_11CC593C2EFF90684AC10B3C20309816" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_54F60E4641006BA0C1FC0B3C20308454" xlink:type="locator" />
    <link:definitionArc order="40" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_AdjustmentForAmortization_54F60E4641006BA0C1FC0B3C20308454" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93" xlink:type="locator" />
    <link:definitionArc order="41" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_95FF046140269C5DE06E0B3C2030B36C" xlink:type="locator" />
    <link:definitionArc order="42" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_LossOnContractTermination_95FF046140269C5DE06E0B3C2030B36C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_5E1EFE1FFB3BCB4C95950B3C203072F5" xlink:type="locator" />
    <link:definitionArc order="43" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Expenseincurredbythecollaboration_5E1EFE1FFB3BCB4C95950B3C203072F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_B8912505B94BC53128FA0B3C2030BF72" xlink:type="locator" />
    <link:definitionArc order="44" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_DueFromRelatedParties_B8912505B94BC53128FA0B3C2030BF72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8A3B2B2883FF90C0C6D60B3C20300100" xlink:type="locator" />
    <link:definitionArc order="45" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8A3B2B2883FF90C0C6D60B3C20300100" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51EBE9AC80F3AE0B99BCF00F36C4BFEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_727D901A5FB74D66C3AAF00F36C1FEA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51EBE9AC80F3AE0B99BCF00F36C4BFEC" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_727D901A5FB74D66C3AAF00F36C1FEA1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_46A6A4E30871665884BEF00F36C17898" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_727D901A5FB74D66C3AAF00F36C1FEA1" xlink:to="loc_srt_ProductOrServiceAxis_46A6A4E30871665884BEF00F36C17898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F8FCBAA5AD72EE9EE0E8F00F36C2FE99_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_46A6A4E30871665884BEF00F36C17898" xlink:to="loc_srt_ProductsAndServicesDomain_F8FCBAA5AD72EE9EE0E8F00F36C2FE99_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F8FCBAA5AD72EE9EE0E8F00F36C2FE99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_46A6A4E30871665884BEF00F36C17898" xlink:to="loc_srt_ProductsAndServicesDomain_F8FCBAA5AD72EE9EE0E8F00F36C2FE99" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F8FCBAA5AD72EE9EE0E8F00F36C2FE99" xlink:to="loc_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F8FCBAA5AD72EE9EE0E8F00F36C2FE99" xlink:to="loc_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_262F0CEAB18C3718DF9CF00F36C3D46D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F8FCBAA5AD72EE9EE0E8F00F36C2FE99" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_262F0CEAB18C3718DF9CF00F36C3D46D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_0B8EA3190773A2C827DEF00F36C3420D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_727D901A5FB74D66C3AAF00F36C1FEA1" xlink:to="loc_srt_MajorCustomersAxis_0B8EA3190773A2C827DEF00F36C3420D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_F3B5A32ECE135D84232BF00F36C355A0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0B8EA3190773A2C827DEF00F36C3420D" xlink:to="loc_srt_NameOfMajorCustomerDomain_F3B5A32ECE135D84232BF00F36C355A0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_F3B5A32ECE135D84232BF00F36C355A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0B8EA3190773A2C827DEF00F36C3420D" xlink:to="loc_srt_NameOfMajorCustomerDomain_F3B5A32ECE135D84232BF00F36C355A0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_F3B5A32ECE135D84232BF00F36C355A0" xlink:to="loc_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51EBE9AC80F3AE0B99BCF00F36C4BFEC" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51EBE9AC80F3AE0B99BCF00F36C4BFEC" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:to="loc_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_10321BAE1D167A6CCCC1F00F36C673FE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:to="loc_us-gaap_Revenues_10321BAE1D167A6CCCC1F00F36C673FE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TwelvemonthsMember" xlink:label="loc_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA" xlink:to="loc_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FC399BC972538FBE9B3A0C8675A3F82A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FC399BC972538FBE9B3A0C8675A3F82A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CD241BD07C80E6E3A1B00C8675A3AFC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FC399BC972538FBE9B3A0C8675A3F82A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CD241BD07C80E6E3A1B00C8675A3AFC6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CD241BD07C80E6E3A1B00C8675A3AFC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FC399BC972538FBE9B3A0C8675A3F82A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CD241BD07C80E6E3A1B00C8675A3AFC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_BEAC4C3606A02BFEC7DE0C8675A46C16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CD241BD07C80E6E3A1B00C8675A3AFC6" xlink:to="loc_biib_IonisPharmaceuticalsMember_BEAC4C3606A02BFEC7DE0C8675A46C16" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_C3E9841707CA70C87B950C8675A493FB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CD241BD07C80E6E3A1B00C8675A3AFC6" xlink:to="loc_biib_AlkermesMember_C3E9841707CA70C87B950C8675A493FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_958A7371D6D241B0E6650C8675A4AD31" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_srt_RangeAxis_958A7371D6D241B0E6650C8675A4AD31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_51398EBF26685CC0F82D0C8675A42FA0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_958A7371D6D241B0E6650C8675A4AD31" xlink:to="loc_srt_RangeMember_51398EBF26685CC0F82D0C8675A42FA0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_51398EBF26685CC0F82D0C8675A42FA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_958A7371D6D241B0E6650C8675A4AD31" xlink:to="loc_srt_RangeMember_51398EBF26685CC0F82D0C8675A42FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_AC37227E93ACE8C815330C8675A594F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_51398EBF26685CC0F82D0C8675A42FA0" xlink:to="loc_srt_MinimumMember_AC37227E93ACE8C815330C8675A594F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_27EB4AABEC00D601FB510C8675A553C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_51398EBF26685CC0F82D0C8675A42FA0" xlink:to="loc_srt_MaximumMember_27EB4AABEC00D601FB510C8675A553C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_599A727C1026C82FF4190C8675A55C54" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_599A727C1026C82FF4190C8675A55C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_AE7717B62E20457CE5720C8675A501D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_599A727C1026C82FF4190C8675A55C54" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_AE7717B62E20457CE5720C8675A501D5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_AE7717B62E20457CE5720C8675A501D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_599A727C1026C82FF4190C8675A55C54" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_AE7717B62E20457CE5720C8675A501D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_EFA37BFC1200796029F90C8675A6F657" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_AE7717B62E20457CE5720C8675A501D5" xlink:to="loc_biib_U.S.2017TaxActMember_EFA37BFC1200796029F90C8675A6F657" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_90D3EC5150789A31481E0C8675A66DB1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_90D3EC5150789A31481E0C8675A66DB1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_8F699D3890771B58BA870C8675A620E4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_90D3EC5150789A31481E0C8675A66DB1" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_8F699D3890771B58BA870C8675A620E4_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_8F699D3890771B58BA870C8675A620E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_90D3EC5150789A31481E0C8675A66DB1" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_8F699D3890771B58BA870C8675A620E4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_A7CE8C05483BD2B7B7C80C8675A7A165" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_8F699D3890771B58BA870C8675A620E4" xlink:to="loc_biib_DevelopmentMilestonesMember_A7CE8C05483BD2B7B7C80C8675A7A165" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_8F699D3890771B58BA870C8675A620E4" xlink:to="loc_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CommercialMilestonesMember" xlink:label="loc_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_8F699D3890771B58BA870C8675A620E4" xlink:to="loc_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:to="loc_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:to="loc_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TwentybillionMember" xlink:label="loc_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:to="loc_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_40B139320C27DDA358D60C8675A9359E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_srt_ProductOrServiceAxis_40B139320C27DDA358D60C8675A9359E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_639932BB2B860C9981F50C8675A972B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_40B139320C27DDA358D60C8675A9359E" xlink:to="loc_srt_ProductsAndServicesDomain_639932BB2B860C9981F50C8675A972B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_639932BB2B860C9981F50C8675A972B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_40B139320C27DDA358D60C8675A9359E" xlink:to="loc_srt_ProductsAndServicesDomain_639932BB2B860C9981F50C8675A972B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_563DB2F8814468F9E9E20C8675A9AF54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_639932BB2B860C9981F50C8675A972B5" xlink:to="loc_biib_SPINRAZAMember_563DB2F8814468F9E9E20C8675A9AF54" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_VUMERITYMember" xlink:label="loc_biib_VUMERITYMember_E83080ED6B1E35CC22BF0C8675A97FA2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_639932BB2B860C9981F50C8675A972B5" xlink:to="loc_biib_VUMERITYMember_E83080ED6B1E35CC22BF0C8675A97FA2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_E5A94913727D42AD34B80C8675AAE1E4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_639932BB2B860C9981F50C8675A972B5" xlink:to="loc_biib_TecfideraMember_E5A94913727D42AD34B80C8675AAE1E4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_989137F31FA9025A00960C8675AAA060" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_biib_FacilityLocationAxis_989137F31FA9025A00960C8675AAA060" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_3DACC39F80CDF170BEEA0C8675AA7922_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_989137F31FA9025A00960C8675AAA060" xlink:to="loc_biib_FacilityLocationDomain_3DACC39F80CDF170BEEA0C8675AA7922_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_3DACC39F80CDF170BEEA0C8675AA7922" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_989137F31FA9025A00960C8675AAA060" xlink:to="loc_biib_FacilityLocationDomain_3DACC39F80CDF170BEEA0C8675AA7922" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_07BFE713C77214DAC74E0C8675AA3028" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_3DACC39F80CDF170BEEA0C8675AA7922" xlink:to="loc_biib_SolothurnMember_07BFE713C77214DAC74E0C8675AA3028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_25280FFB5437A0D638420C8675ABFB03" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_25280FFB5437A0D638420C8675ABFB03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1D56ECBBD22D6363161B0C8675ABDD8F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_25280FFB5437A0D638420C8675ABFB03" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1D56ECBBD22D6363161B0C8675ABDD8F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1D56ECBBD22D6363161B0C8675ABDD8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_25280FFB5437A0D638420C8675ABFB03" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1D56ECBBD22D6363161B0C8675ABDD8F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_D33FF1948BF80725440F0C8675ABDF4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1D56ECBBD22D6363161B0C8675ABDD8F" xlink:to="loc_biib_TysabriProductMember_D33FF1948BF80725440F0C8675ABDF4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1D56ECBBD22D6363161B0C8675ABDD8F" xlink:to="loc_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_BD8B6305BDC4974D28230C8675AC85E9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_BD8B6305BDC4974D28230C8675AC85E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_47EF24F136988FDBF13E0C8675ADE249" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_47EF24F136988FDBF13E0C8675ADE249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_04026269389511B527AA0C8675AD585A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_04026269389511B527AA0C8675AD585A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E2F70F9C5EF27BFD6ED10C8675AD089A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_E2F70F9C5EF27BFD6ED10C8675AD089A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_56A2DC5509C0855A46D90C8675AD6E85" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_56A2DC5509C0855A46D90C8675AD6E85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_70B2B6F155C7B69D7C870C8675ADF508" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_OtherCommitment_70B2B6F155C7B69D7C870C8675ADF508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_62AB39EC69AE865AC8290C8675AE1194" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_62AB39EC69AE865AC8290C8675AE1194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_E9D8F6CB3F4B554390980C8675AE3FB0" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_IncomeTaxesPaid_E9D8F6CB3F4B554390980C8675AE3FB0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C" xlink:to="loc_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C" xlink:to="loc_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_9F4402D13E5FDD9D700AFC3A1AA484DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_9F4402D13E5FDD9D700AFC3A1AA484DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B" xlink:to="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B" xlink:to="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_C4375E6364C2B4355E0DFC3A1AA43AB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_PreferredStockMember_C4375E6364C2B4355E0DFC3A1AA43AB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E7C06F9E6E7D41E7429DFC3A1AA42698" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_CommonStockMember_E7C06F9E6E7D41E7429DFC3A1AA42698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_A21B83E125BDC9555F0AFC3A1AA4D068" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_A21B83E125BDC9555F0AFC3A1AA4D068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C46CC3C7E0D90F3BB6B8FC3A1AA47CF8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C46CC3C7E0D90F3BB6B8FC3A1AA47CF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_04C09F95F67BD0D32151FC3A1AA41430" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_RetainedEarningsMember_04C09F95F67BD0D32151FC3A1AA41430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_4ABC7EB50155A502EAECFC3A1AA41B23" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_TreasuryStockMember_4ABC7EB50155A502EAECFC3A1AA41B23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_670CADE989A15E35A2D7FC3A1AA4F96A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_NoncontrollingInterestMember_670CADE989A15E35A2D7FC3A1AA4F96A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_5532691B3A488C1C2FF7FC3A1AA4762B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_ParentMember_5532691B3A488C1C2FF7FC3A1AA4762B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB32A3894630873F786FC3A1AB46139" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB32A3894630873F786FC3A1AB46139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4C93207A6E5E245764E9FC3A1AB43D8D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockholdersEquity_4C93207A6E5E245764E9FC3A1AB43D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_2E15A1D4FEBC09ED6CFFFC3A1AB47067" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_MinorityInterest_2E15A1D4FEBC09ED6CFFFC3A1AB47067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_B9B0262A2B43E7B66E88FC3A1AB484D0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_SharesIssued_B9B0262A2B43E7B66E88FC3A1AB484D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4858CC1E45875A9107AEFC3A1AB4A425" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_NetIncomeLoss_4858CC1E45875A9107AEFC3A1AB4A425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_22888303E59B2FFF7834FC3A1AB47B99" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_22888303E59B2FFF7834FC3A1AB47B99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_CAF51F9886BCB1ABA082FC3A1AB45B66" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_ProfitLoss_CAF51F9886BCB1ABA082FC3A1AB45B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CC568D04A9FB478026CDFC3A1AB42813" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CC568D04A9FB478026CDFC3A1AB42813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C5ED636AAD22A6E12521FC3A1AB40E40" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C5ED636AAD22A6E12521FC3A1AB40E40" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E101F1DBE02AD2F9F07AFC3A1AB458E7" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E101F1DBE02AD2F9F07AFC3A1AB458E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_CE6D75ACCE181763AB5DFC3A1AB4B747" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_CE6D75ACCE181763AB5DFC3A1AB4B747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_1B18C36EA1557B3EE622FC3A1AB4B392" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_1B18C36EA1557B3EE622FC3A1AB4B392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_3878C856A7FED6942C68FC3A1AB4FF0D" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_3878C856A7FED6942C68FC3A1AB4FF0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_DACA7007DC250FBD6F6AFC3A1AB4D5C0" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_DACA7007DC250FBD6F6AFC3A1AB4D5C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECE4BE041B7411EF9D19FC3A1AB47A9D" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECE4BE041B7411EF9D19FC3A1AB47A9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45AEFB62A5939A5EF084FC3A1AB4DDB1" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45AEFB62A5939A5EF084FC3A1AB4DDB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_049478C623265A8E26A8FC3A1AB425A6" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_049478C623265A8E26A8FC3A1AB425A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_719AACFB26E98D1AC2C5FC3A1AB46515" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_719AACFB26E98D1AC2C5FC3A1AB46515" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_86385E395690BB29072EFC3A1AB4F697" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_86385E395690BB29072EFC3A1AB4F697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_323C80A1B7AE067ACDA8FC3A1AB42352" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockholdersEquityOther_323C80A1B7AE067ACDA8FC3A1AB42352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_C20D6B1759FAE3C4EB5AFC3A1AB434D2" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_C20D6B1759FAE3C4EB5AFC3A1AB434D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_StockholdersEquityTaxBenefitExpense" xlink:label="loc_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_651E6848693DE0AB5F53FC3A1AF37A96" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EB27FDCBCAEE09B40213FC3A1AE3D5A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_651E6848693DE0AB5F53FC3A1AF37A96" xlink:to="loc_us-gaap_StatementTable_EB27FDCBCAEE09B40213FC3A1AE3D5A0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F4192C737649B3F55621FC3A1AE3CA1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_EB27FDCBCAEE09B40213FC3A1AE3D5A0" xlink:to="loc_srt_ProductOrServiceAxis_F4192C737649B3F55621FC3A1AE3CA1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E432062CB68C3D182EB4FC3A1AE38FF6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_F4192C737649B3F55621FC3A1AE3CA1B" xlink:to="loc_srt_ProductsAndServicesDomain_E432062CB68C3D182EB4FC3A1AE38FF6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E432062CB68C3D182EB4FC3A1AE38FF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_F4192C737649B3F55621FC3A1AE3CA1B" xlink:to="loc_srt_ProductsAndServicesDomain_E432062CB68C3D182EB4FC3A1AE38FF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_D9A91F858E49BBBD5EE6FC3A1AF3B7D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E432062CB68C3D182EB4FC3A1AE38FF6" xlink:to="loc_us-gaap_ProductMember_D9A91F858E49BBBD5EE6FC3A1AF3B7D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3E0B5EBB3131ED1F69C3FC3A1AF36B8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E432062CB68C3D182EB4FC3A1AE38FF6" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3E0B5EBB3131ED1F69C3FC3A1AF36B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_94AC3E4886E3409182B9FC3A1AF31BC3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E432062CB68C3D182EB4FC3A1AE38FF6" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_94AC3E4886E3409182B9FC3A1AF31BC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C6EF5871A366ACBAD91EFC3A1AF3D62E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_651E6848693DE0AB5F53FC3A1AF37A96" xlink:to="loc_us-gaap_Revenues_C6EF5871A366ACBAD91EFC3A1AF3D62E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA" xlink:to="loc_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA" xlink:to="loc_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:to="loc_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:to="loc_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_F7143801E83BC5B123EB7F76C6A0DE9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272" xlink:to="loc_us-gaap_ForeignExchangeContractMember_F7143801E83BC5B123EB7F76C6A0DE9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_7FD49F6F171BAE669FB37F76C6A0F189" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:to="loc_us-gaap_SalesMember_7FD49F6F171BAE669FB37F76C6A0F189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_D9CF03CF35B366E3338A7F76C6A0BDBD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_D9CF03CF35B366E3338A7F76C6A0BDBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_F8D065D1277BBF1B838D7F76C6A0308D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:to="loc_us-gaap_OperatingExpenseMember_F8D065D1277BBF1B838D7F76C6A0308D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_39FCD8D0CBEECF3556BD7F76C6A041ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_39FCD8D0CBEECF3556BD7F76C6A041ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_43F17C9C58440E46239E7F76C6A09471" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_43F17C9C58440E46239E7F76C6A09471" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_B58A1967EC9B168BCC757F76C690C225" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_B58A1967EC9B168BCC757F76C690C225" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_B58A1967EC9B168BCC757F76C690C225" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B71AFAE27DBDDFF3B6C87F76C69015CF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_B58A1967EC9B168BCC757F76C690C225" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B71AFAE27DBDDFF3B6C87F76C69015CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B71AFAE27DBDDFF3B6C87F76C69015CF" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B71AFAE27DBDDFF3B6C87F76C69015CF" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3F69C43F9C61E4EDCF327F76C6905B43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3F69C43F9C61E4EDCF327F76C6905B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_C4A6182E74E9F16A6F967F76C6A08541" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_B58A1967EC9B168BCC757F76C690C225" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_C4A6182E74E9F16A6F967F76C6A08541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_55ACF24C3BC414F092387F76C6A0B847_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_C4A6182E74E9F16A6F967F76C6A08541" xlink:to="loc_us-gaap_HedgingRelationshipDomain_55ACF24C3BC414F092387F76C6A0B847_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_55ACF24C3BC414F092387F76C6A0B847" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_C4A6182E74E9F16A6F967F76C6A08541" xlink:to="loc_us-gaap_HedgingRelationshipDomain_55ACF24C3BC414F092387F76C6A0B847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_3E6205DF1A52677B47A87F76C6A038B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_55ACF24C3BC414F092387F76C6A0B847" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_3E6205DF1A52677B47A87F76C6A038B7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_FB0030892F62A131B32F7F76C6A08AED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_FB0030892F62A131B32F7F76C6A08AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7CDA26968851201A7C007F76C6A033AE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7CDA26968851201A7C007F76C6A033AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_99BE826E7C45D4A6BCEC7F76C6A00943" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_DerivativeTermOfContract_99BE826E7C45D4A6BCEC7F76C6A00943" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_BDF6744AB5B6C371FA4E7F76C6A015F4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_BDF6744AB5B6C371FA4E7F76C6A015F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_BBFB57BFF247A49314E67FEAC476EC4C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_BBFB57BFF247A49314E67FEAC476EC4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_14EEC61E0822B099E5797FEDB19A4E0C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_14EEC61E0822B099E5797FEDB19A4E0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_92DF02E344F51A04EF377FF069DC6D1A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_92DF02E344F51A04EF377FF069DC6D1A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_0711FB78A5D2ECD964E9FCF51ED3B44B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0711FB78A5D2ECD964E9FCF51ED3B44B" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:to="loc_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:to="loc_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:to="loc_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440" xlink:to="loc_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:to="loc_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC" xlink:to="loc_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC" xlink:to="loc_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_CDD1CF693055B98DA2B9FCF51ED0F24A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:to="loc_srt_MinimumMember_CDD1CF693055B98DA2B9FCF51ED0F24A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5003142FEFA747B56A16FCF51ED0D674" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:to="loc_srt_MaximumMember_5003142FEFA747B56A16FCF51ED0D674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:to="loc_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_DF893C7C6FE6A28233FAFCF51ED176DC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_DF893C7C6FE6A28233FAFCF51ED176DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_94F8528B4EA491FD9B2DFCF51ED15C49_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_DF893C7C6FE6A28233FAFCF51ED176DC" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_94F8528B4EA491FD9B2DFCF51ED15C49_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_94F8528B4EA491FD9B2DFCF51ED15C49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_DF893C7C6FE6A28233FAFCF51ED176DC" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_94F8528B4EA491FD9B2DFCF51ED15C49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_8C7BE29FC35140420308FCF51ED1A4FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94F8528B4EA491FD9B2DFCF51ED15C49" xlink:to="loc_us-gaap_ForeignExchangeContractMember_8C7BE29FC35140420308FCF51ED1A4FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_6D8CA0B25D65E8B800F8FCF51ED2F858" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94F8528B4EA491FD9B2DFCF51ED15C49" xlink:to="loc_us-gaap_InterestRateSwapMember_6D8CA0B25D65E8B800F8FCF51ED2F858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_C205A9E4B83A52F77C7AFCF51ED2DF40" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:to="loc_us-gaap_HedgingDesignationAxis_C205A9E4B83A52F77C7AFCF51ED2DF40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_76807C3342A7A5022579FCF51ED24B87_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_C205A9E4B83A52F77C7AFCF51ED2DF40" xlink:to="loc_us-gaap_HedgingDesignationDomain_76807C3342A7A5022579FCF51ED24B87_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_76807C3342A7A5022579FCF51ED24B87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_C205A9E4B83A52F77C7AFCF51ED2DF40" xlink:to="loc_us-gaap_HedgingDesignationDomain_76807C3342A7A5022579FCF51ED24B87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9D92629E3A9B9D1F8F3BFCF51ED2C5A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_76807C3342A7A5022579FCF51ED24B87" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9D92629E3A9B9D1F8F3BFCF51ED2C5A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_235E3BAB8A6AEFAE248AFCF51ED341B3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_76807C3342A7A5022579FCF51ED24B87" xlink:to="loc_us-gaap_NondesignatedMember_235E3BAB8A6AEFAE248AFCF51ED341B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D1CD098DC668F62AEFFFFCF51ED38001" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0711FB78A5D2ECD964E9FCF51ED3B44B" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D1CD098DC668F62AEFFFFCF51ED38001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_892C105917ABD6F23757FCF51ED3BD85" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0711FB78A5D2ECD964E9FCF51ED3B44B" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_892C105917ABD6F23757FCF51ED3BD85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76F54A915B22B31BB774FCF51ED31186" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0711FB78A5D2ECD964E9FCF51ED3B44B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76F54A915B22B31BB774FCF51ED31186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_BAD03AC5E4BB35A1BDA4FD20C407B0BD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0711FB78A5D2ECD964E9FCF51ED3B44B" xlink:to="loc_us-gaap_DerivativeNotionalAmount_BAD03AC5E4BB35A1BDA4FD20C407B0BD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4A902EF704F0F376CC07FD17F6580A6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4A902EF704F0F376CC07FD17F6580A6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_A2C2DAF1974FD831B44BFD17F65B57AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4A902EF704F0F376CC07FD17F6580A6F" xlink:to="loc_us-gaap_HedgingRelationshipDomain_A2C2DAF1974FD831B44BFD17F65B57AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_A2C2DAF1974FD831B44BFD17F65B57AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4A902EF704F0F376CC07FD17F6580A6F" xlink:to="loc_us-gaap_HedgingRelationshipDomain_A2C2DAF1974FD831B44BFD17F65B57AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_E8936D94F20BCDB64EB1FD18A113E297" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A2C2DAF1974FD831B44BFD17F65B57AF" xlink:to="loc_us-gaap_CashFlowHedgingMember_E8936D94F20BCDB64EB1FD18A113E297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_67E6394D081243CD5B60FD1ADE9C7657" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A2C2DAF1974FD831B44BFD17F65B57AF" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_67E6394D081243CD5B60FD1ADE9C7657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_47673DA298D702070E1CFD1C05396984" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A2C2DAF1974FD831B44BFD17F65B57AF" xlink:to="loc_us-gaap_FairValueHedgingMember_47673DA298D702070E1CFD1C05396984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:to="loc_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831" xlink:to="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831" xlink:to="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_014E7BBE8633CA0EAF3CFCF51EDC643B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:to="loc_currency_EUR_014E7BBE8633CA0EAF3CFCF51EDC643B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_E63FE173CD98770E57CBFCF51EDC1331" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:to="loc_currency_GBP_E63FE173CD98770E57CBFCF51EDC1331" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_661B095833E0EF874A49FCF51EDC661C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:to="loc_currency_CHF_661B095833E0EF874A49FCF51EDC661C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_E677BDEB8AAF39400771FCF51EDDC84A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:to="loc_currency_CAD_E677BDEB8AAF39400771FCF51EDDC84A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_F79C256AB33910A52E4DFCF51EDDE183" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:to="loc_currency_JPY_F79C256AB33910A52E4DFCF51EDDE183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5F57E7024D385844C9A2FCF51EDD7258" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5F57E7024D385844C9A2FCF51EDD7258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_43879CE4DCD046A79DE2FCF51EDDE7EC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5F57E7024D385844C9A2FCF51EDD7258" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_43879CE4DCD046A79DE2FCF51EDDE7EC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_43879CE4DCD046A79DE2FCF51EDDE7EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5F57E7024D385844C9A2FCF51EDD7258" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_43879CE4DCD046A79DE2FCF51EDDE7EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_BDE5CF715DB16822DD60FCF51EDDA1B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_43879CE4DCD046A79DE2FCF51EDDE7EC" xlink:to="loc_us-gaap_ForeignExchangeContractMember_BDE5CF715DB16822DD60FCF51EDDA1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_2A52826E1666B86FB9EAFCF51EDE0FC4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_43879CE4DCD046A79DE2FCF51EDDE7EC" xlink:to="loc_us-gaap_InterestRateSwapMember_2A52826E1666B86FB9EAFCF51EDE0FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_6AB22CD1F508566098E1FCF51EDE8EFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_6AB22CD1F508566098E1FCF51EDE8EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_6FBA81798B549164DB04FCF51EDFF9C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_6FBA81798B549164DB04FCF51EDFF9C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9268C4C0875B50CD57CCFCF51EDF3DC9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9268C4C0875B50CD57CCFCF51EDF3DC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:to="loc_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB" xlink:to="loc_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB" xlink:to="loc_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_BD5AE0DFF3DC5565DE58FD06B3E33926" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_BD5AE0DFF3DC5565DE58FD06B3E33926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_3948356665010DCDA2B6FCF51EE07FDB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:to="loc_us-gaap_NondesignatedMember_3948356665010DCDA2B6FCF51EE07FDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_B9A54997FB803079A8EBFD217CD1E0E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:to="loc_us-gaap_DerivativeNotionalAmount_B9A54997FB803079A8EBFD217CD1E0E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_AF727BB1A58436465A41FCF51EE1F90A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_AF727BB1A58436465A41FCF51EE1F90A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_47D6640545E2E5025D0AFCF51EE1DD57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_AF727BB1A58436465A41FCF51EE1F90A" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_47D6640545E2E5025D0AFCF51EE1DD57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_95EDAA1E76883AF40471FCF51EE1AD38" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_AF727BB1A58436465A41FCF51EE1F90A" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_95EDAA1E76883AF40471FCF51EE1AD38" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6791A90EE8A42190CD9BE86FAF549B39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6791A90EE8A42190CD9BE86FAF549B39" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29BAE72C836AA0BFF7D5E86FAF54CD28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6791A90EE8A42190CD9BE86FAF549B39" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29BAE72C836AA0BFF7D5E86FAF54CD28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_14993D6F0E850BF0A6F6E86FAF54216B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29BAE72C836AA0BFF7D5E86FAF54CD28" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_14993D6F0E850BF0A6F6E86FAF54216B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_14993D6F0E850BF0A6F6E86FAF54216B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29BAE72C836AA0BFF7D5E86FAF54CD28" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_14993D6F0E850BF0A6F6E86FAF54216B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_65329C889463359F023BE86FAF54DC4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_14993D6F0E850BF0A6F6E86FAF54216B" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_65329C889463359F023BE86FAF54DC4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E3594119CB6FB5F85FFCE86FAF554690" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E3594119CB6FB5F85FFCE86FAF554690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_10E9541C698A0047E28CE86FAF550D2D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_10E9541C698A0047E28CE86FAF550D2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_F138BC84321FF9AC4B02E86FAF55C71E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_F138BC84321FF9AC4B02E86FAF55C71E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_494306C850B7F75882DFE86FAF56A922" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_494306C850B7F75882DFE86FAF56A922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7F2FF7C0DB4B02E1EC27E86FAF560F4E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7F2FF7C0DB4B02E1EC27E86FAF560F4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5ABA8686DD864D533267E86FAF560C14" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5ABA8686DD864D533267E86FAF560C14" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_25293F9025DE851D65C2E86FAF5627B4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_25293F9025DE851D65C2E86FAF5627B4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_DA0D1F8D2AE148901FBC6F399F1B8D87" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_DA0D1F8D2AE148901FBC6F399F1B8D87" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_B166F44B91908207BBCD6F399F1BB179" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:to="loc_biib_MarketStockUnitsMember_B166F44B91908207BBCD6F399F1BB179" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_BB243EC4EED46BCFD8CE6F399F1BC1A7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_BB243EC4EED46BCFD8CE6F399F1BC1A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:to="loc_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7E8FD03632804502F0426F399F1C1846" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185" xlink:to="loc_us-gaap_NetIncomeLoss_7E8FD03632804502F0426F399F1C1846" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:to="loc_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40DF59820B73F944DA5E6F399F1DF763" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40DF59820B73F944DA5E6F399F1DF763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F65164270B49FA7871746F399F1D2E31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F65164270B49FA7871746F399F1D2E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_AAA3F08ACC01968679FD6F399F1D65DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_AAA3F08ACC01968679FD6F399F1D65DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4A482ADF86C095345CFD6F399F1ED3B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4A482ADF86C095345CFD6F399F1ED3B3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_4119A5B68DDFCE8697AC0B73C6A477E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422" xlink:to="loc_us-gaap_ForeignPlanMember_4119A5B68DDFCE8697AC0B73C6A477E1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="loc_country_DE_73FF253340714FCD5DA90B73C6A417E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_4119A5B68DDFCE8697AC0B73C6A477E1" xlink:to="loc_country_DE_73FF253340714FCD5DA90B73C6A417E6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CH" xlink:label="loc_country_CH_9A9E29E888914059A01B0B73C6A479BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_4119A5B68DDFCE8697AC0B73C6A477E1" xlink:to="loc_country_CH_9A9E29E888914059A01B0B73C6A479BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_86C266BE2E1B0CEC94A80B3C1FD27085" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_86C266BE2E1B0CEC94A80B3C1FD27085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DE567B09FF1508FFFE8A0B3C1FD205FB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_86C266BE2E1B0CEC94A80B3C1FD27085" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DE567B09FF1508FFFE8A0B3C1FD205FB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DE567B09FF1508FFFE8A0B3C1FD205FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_86C266BE2E1B0CEC94A80B3C1FD27085" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DE567B09FF1508FFFE8A0B3C1FD205FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B5EB7E24897F5FA82D470B3C1FD27A97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DE567B09FF1508FFFE8A0B3C1FD205FB" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B5EB7E24897F5FA82D470B3C1FD27A97" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88" xlink:to="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:to="loc_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6F06D4C0F7F04030A1060B3C1FD2DE3C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6F06D4C0F7F04030A1060B3C1FD2DE3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_232F421636FD0AB3784A0B3C1FD26067" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_232F421636FD0AB3784A0B3C1FD26067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_3AC99CC2E4557EAB0A980B3C1FD23222" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:to="loc_us-gaap_PensionExpense_3AC99CC2E4557EAB0A980B3C1FD23222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6274612FB58D71C8A7040B3C1FE25D45" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6274612FB58D71C8A7040B3C1FE25D45" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:to="loc_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_4DC6859EE83859CC348CFCF51CA18AD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:to="loc_us-gaap_DomesticPlanMember_4DC6859EE83859CC348CFCF51CA18AD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_858891173BDC975B182AFCF51CA1169D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_858891173BDC975B182AFCF51CA1169D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:to="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_3DD9981BA31F6B510465FCF51CA18256" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_3DD9981BA31F6B510465FCF51CA18256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_061FE137DDDF00D172D8FCF51CA284D1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_061FE137DDDF00D172D8FCF51CA284D1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748885FAC453D7BAE281FCF51E4C1F9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748885FAC453D7BAE281FCF51E4C1F9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_FBEFEC0ACF51C956A932FCF51E4D6104_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748885FAC453D7BAE281FCF51E4C1F9D" xlink:to="loc_us-gaap_TypeOfAdoptionMember_FBEFEC0ACF51C956A932FCF51E4D6104_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_FBEFEC0ACF51C956A932FCF51E4D6104" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748885FAC453D7BAE281FCF51E4C1F9D" xlink:to="loc_us-gaap_TypeOfAdoptionMember_FBEFEC0ACF51C956A932FCF51E4D6104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_5EF9A7B102101C7C3E3AFCF51E4D5580" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_FBEFEC0ACF51C956A932FCF51E4D6104" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_5EF9A7B102101C7C3E3AFCF51E4D5580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_DAAB36172F696FE703F6FCF51E4DFA66" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_DAAB36172F696FE703F6FCF51E4DFA66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DAAB36172F696FE703F6FCF51E4DFA66" xlink:to="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DAAB36172F696FE703F6FCF51E4DFA66" xlink:to="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DCF86F0D64CE42FA98CFCF51E4E19E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DCF86F0D64CE42FA98CFCF51E4E19E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3C4E288DBB3A96F90506FCF51E4E575C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3C4E288DBB3A96F90506FCF51E4E575C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_97942934CDCB218E6E0CFCF51E4E6C67" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_97942934CDCB218E6E0CFCF51E4E6C67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5241D20AA32E176DF82DFCF51E4E7DFC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5241D20AA32E176DF82DFCF51E4E7DFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_CFAA33F7913F38B2C732FCF51E4FEE8E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_CFAA33F7913F38B2C732FCF51E4FEE8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2AC2D3CD97A20D2C319EFCF51E4FFD75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2AC2D3CD97A20D2C319EFCF51E4FFD75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_C45D0098DEA6AF63F5C5FCF51E4F1A2F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_C45D0098DEA6AF63F5C5FCF51E4F1A2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5AD3E2CE2663BFACF617FCF51E4FCD1E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5AD3E2CE2663BFACF617FCF51E4FCD1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_41AFED24E93890957FBAFCF51E4F1E89" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_41AFED24E93890957FBAFCF51E4F1E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_00BA3780CB3C49BB928BFCF51E50C336" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_00BA3780CB3C49BB928BFCF51E50C336" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_26B64CA9B690B064174FFCF51E44B57A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_26B64CA9B690B064174FFCF51E44B57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C071B50B43823FAED850FCF51E44D149_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_26B64CA9B690B064174FFCF51E44B57A" xlink:to="loc_us-gaap_EquityComponentDomain_C071B50B43823FAED850FCF51E44D149_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C071B50B43823FAED850FCF51E44D149" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_26B64CA9B690B064174FFCF51E44B57A" xlink:to="loc_us-gaap_EquityComponentDomain_C071B50B43823FAED850FCF51E44D149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8D760EEE4BB2CD1FF440FCF51E44D477" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C071B50B43823FAED850FCF51E44D149" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8D760EEE4BB2CD1FF440FCF51E44D477" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D01F10FC796B0465679BFCF51E45B24B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C071B50B43823FAED850FCF51E44D149" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D01F10FC796B0465679BFCF51E45B24B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_EC6DFBC041794EB7A541FCF51E45F11D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C071B50B43823FAED850FCF51E44D149" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_EC6DFBC041794EB7A541FCF51E45F11D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A22D9350B948C1FD7A6FCF51E4535CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A22D9350B948C1FD7A6FCF51E4535CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_96DA66D08907455E3706FCF51E4636AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_96DA66D08907455E3706FCF51E4636AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_F69921F7B154C90B73F3FCF51E46457D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_F69921F7B154C90B73F3FCF51E46457D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5CDF02389BD70F33310AFCF51E468181" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:to="loc_us-gaap_Revenues_5CDF02389BD70F33310AFCF51E468181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3AE8E22E0BBB1E81374FFCF51E46FBDD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:to="loc_us-gaap_OperatingExpenses_3AE8E22E0BBB1E81374FFCF51E46FBDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D4C9A6B4B9E80E7BB23BFCF51E4741E2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:to="loc_us-gaap_NetIncomeLoss_D4C9A6B4B9E80E7BB23BFCF51E4741E2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_C26BDD3D526082D95603EBFB64E8EFCA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_C26BDD3D526082D95603EBFB64E8EFCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_32003C2D6B0D310474C4EBFB64E90248" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_32003C2D6B0D310474C4EBFB64E90248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_718ECE50FEBCF2F0FD60EBFB64E918A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_718ECE50FEBCF2F0FD60EBFB64E918A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1235BF5FCF487927B70AEBFB64E9A2C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1235BF5FCF487927B70AEBFB64E9A2C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_E82F99E651F8A4E90522EBFB64EA327A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_E82F99E651F8A4E90522EBFB64EA327A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4C8E7C2B0B9AB1C1871FEBFB64EAA18F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E82F99E651F8A4E90522EBFB64EA327A" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4C8E7C2B0B9AB1C1871FEBFB64EAA18F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4C8E7C2B0B9AB1C1871FEBFB64EAA18F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E82F99E651F8A4E90522EBFB64EA327A" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4C8E7C2B0B9AB1C1871FEBFB64EAA18F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1482D77C60D8C8FF5197EBFB64EA3852" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4C8E7C2B0B9AB1C1871FEBFB64EAA18F" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1482D77C60D8C8FF5197EBFB64EA3852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_A40EB02CE02CFCA61202EBFB64EAD567" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4C8E7C2B0B9AB1C1871FEBFB64EAA18F" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_A40EB02CE02CFCA61202EBFB64EAD567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_06627DD37309F7E43A22EBFB64EB6804" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4C8E7C2B0B9AB1C1871FEBFB64EAA18F" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_06627DD37309F7E43A22EBFB64EB6804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37BA4839912EE68A143BEBFB64EB4534" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37BA4839912EE68A143BEBFB64EB4534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_69E614826357E50DF8DCEBFB64EC2371" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="loc_us-gaap_AvailableForSaleSecurities_69E614826357E50DF8DCEBFB64EC2371" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8458D3903978F644EA49EBFB64EC5EAC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8458D3903978F644EA49EBFB64EC5EAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2DC1B8B613F0A3DA9BAFEBFB64EC170A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2DC1B8B613F0A3DA9BAFEBFB64EC170A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_658C91AA145D0331D42EEBFB64EC6EDB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_658C91AA145D0331D42EEBFB64EC6EDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2186D794D2BEFC0E3B5CEBFB64EDE70C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2186D794D2BEFC0E3B5CEBFB64EDE70C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_175442E78CF9A3AEA8ECEBFB64ED6E35" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_175442E78CF9A3AEA8ECEBFB64ED6E35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6CE84CCF729BEE6E78E0EBFB64EDD8BA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_6CE84CCF729BEE6E78E0EBFB64EDD8BA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_971DE5F211CD7B9FFA11E873AD9AE6DC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A8BE974354387C1B57B2E873AD9ADA84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_971DE5F211CD7B9FFA11E873AD9AE6DC" xlink:to="loc_us-gaap_DebtInstrumentTable_A8BE974354387C1B57B2E873AD9ADA84" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F986F900F5FF9E8F8537E873AD9A0EAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A8BE974354387C1B57B2E873AD9ADA84" xlink:to="loc_us-gaap_DebtInstrumentAxis_F986F900F5FF9E8F8537E873AD9A0EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F986F900F5FF9E8F8537E873AD9A0EAD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F986F900F5FF9E8F8537E873AD9A0EAD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_A62E3D865F21A78CD63EE873AD9A5F18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_A62E3D865F21A78CD63EE873AD9A5F18" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_730E05647D20B1F2B202E873AD9A44B0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_730E05647D20B1F2B202E873AD9A44B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A18D7E60EB50719C5A9BE873AD9A7F88" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A18D7E60EB50719C5A9BE873AD9A7F88" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_C4412ADD82B36458AFA4E873AD9A45F5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_C4412ADD82B36458AFA4E873AD9A45F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_32EC11195EC7A3212ED1E873AD9A4CAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_971DE5F211CD7B9FFA11E873AD9AE6DC" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_32EC11195EC7A3212ED1E873AD9A4CAB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DEEC8C81AF63B30C23CD6F399EAA2389" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6D387A485259DCF55A326F399EA9AB47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DEEC8C81AF63B30C23CD6F399EAA2389" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6D387A485259DCF55A326F399EA9AB47" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BCDAB4126762D05511BD6F399EA9D854" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6D387A485259DCF55A326F399EA9AB47" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BCDAB4126762D05511BD6F399EA9D854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_337B4B6F110BDA7709FA6F399EA973B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BCDAB4126762D05511BD6F399EA9D854" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_337B4B6F110BDA7709FA6F399EA973B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_337B4B6F110BDA7709FA6F399EA973B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BCDAB4126762D05511BD6F399EA9D854" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_337B4B6F110BDA7709FA6F399EA973B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_872E6A8ACD33C6EF94306F399EA9C04C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_337B4B6F110BDA7709FA6F399EA973B6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_872E6A8ACD33C6EF94306F399EA9C04C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6CF2A865719D17B05DE16F399EAAADD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DEEC8C81AF63B30C23CD6F399EAA2389" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6CF2A865719D17B05DE16F399EAAADD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_585D02AD677B7759C7736F399EAA6097" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DEEC8C81AF63B30C23CD6F399EAA2389" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_585D02AD677B7759C7736F399EAA6097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_40EB591766FB9B7241636F399EAB357D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DEEC8C81AF63B30C23CD6F399EAA2389" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_40EB591766FB9B7241636F399EAB357D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_EF352E609F592645B681E873AD8AA518" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_EF352E609F592645B681E873AD8AA518" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_A2C72E0BC9D48312EF95E873AD8AAAC2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_EF352E609F592645B681E873AD8AA518" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_A2C72E0BC9D48312EF95E873AD8AAAC2_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_A2C72E0BC9D48312EF95E873AD8AAAC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_EF352E609F592645B681E873AD8AA518" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_A2C72E0BC9D48312EF95E873AD8AAAC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BG00011Member" xlink:label="loc_biib_BG00011Member_483FB84CC1DA2FE582BCE873AD8A15DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_A2C72E0BC9D48312EF95E873AD8AAAC2" xlink:to="loc_biib_BG00011Member_483FB84CC1DA2FE582BCE873AD8A15DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_0347DBCE7462B7A412D7E873AD8A2987" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_0347DBCE7462B7A412D7E873AD8A2987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_855484A0EB35CCEED932E873AD8A91C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_855484A0EB35CCEED932E873AD8A91C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_B6AA51B095FF28CEC988E873AD8A7575" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_B6AA51B095FF28CEC988E873AD8A7575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2995EEE97ECF31402B5EE873AD8A6862" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:to="loc_us-gaap_DebtInstrumentAxis_2995EEE97ECF31402B5EE873AD8A6862" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2995EEE97ECF31402B5EE873AD8A6862" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2995EEE97ECF31402B5EE873AD8A6862" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6D809FD96CC24EEBADCAE873AD8A7C49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6D809FD96CC24EEBADCAE873AD8A7C49" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_79325BD4194C1198DBE7E873AD8ABFA3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_79325BD4194C1198DBE7E873AD8ABFA3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_14C1C4AF086C413372B5E873AD8A77A2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_14C1C4AF086C413372B5E873AD8A77A2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3F8B087E4C121BADED0FE873AD8A5597" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3F8B087E4C121BADED0FE873AD8A5597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CF402E7F8B1647360D60E873AD8A2157" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CF402E7F8B1647360D60E873AD8A2157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A21BAB65D20BA66D093E873AD8ADCD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CF402E7F8B1647360D60E873AD8A2157" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A21BAB65D20BA66D093E873AD8ADCD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A21BAB65D20BA66D093E873AD8ADCD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CF402E7F8B1647360D60E873AD8A2157" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A21BAB65D20BA66D093E873AD8ADCD0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A21BAB65D20BA66D093E873AD8ADCD0" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A21BAB65D20BA66D093E873AD8ADCD0" xlink:to="loc_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A21BAB65D20BA66D093E873AD8ADCD0" xlink:to="loc_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs" xlink:label="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_AFE841192446D853D238E873AD9A09A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_AFE841192446D853D238E873AD9A09A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_967B0CA067B7429E3884E873AD9A86D6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_967B0CA067B7429E3884E873AD9A86D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_E1242CB4C1D51600AD61E873AD9A32A2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_E1242CB4C1D51600AD61E873AD9A32A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A9FC4DB22636D653B6AEE873AD9AABF8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A9FC4DB22636D653B6AEE873AD9AABF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_395E4D9733375CB6DF53E873AD9A8136" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_395E4D9733375CB6DF53E873AD9A8136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DD274952E341CE5C73E6E873AD9A09F5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DD274952E341CE5C73E6E873AD9A09F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_025177102C1DB9BD7658E873AD9AB0BE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_025177102C1DB9BD7658E873AD9AB0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4BF2B886B44358E5FF0FE873AD9A87FE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4BF2B886B44358E5FF0FE873AD9A87FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FairValueMeasurementInputs" xlink:label="loc_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_AFA259B66C1C13FF484DE873AD9ACA95" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_AFA259B66C1C13FF484DE873AD9ACA95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_776C7E63E089D4C15602E873AD9A294C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_776C7E63E089D4C15602E873AD9A294C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7F35F239481A40789AE9E873AD9A4E6C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7F35F239481A40789AE9E873AD9A4E6C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85" xlink:to="loc_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_98E4188C66D8494B76086F399EB85EF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:to="loc_us-gaap_CommercialPaperMember_98E4188C66D8494B76086F399EB85EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_CFEB9608B1D83E789AFD6F399EB87485" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_CFEB9608B1D83E789AFD6F399EB87485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C444C0807F609F8BD87C6F399EB8BFCC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:to="loc_us-gaap_MoneyMarketFundsMember_C444C0807F609F8BD87C6F399EB8BFCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_A06F2D4BD11528351A496F399EB85660" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:to="loc_us-gaap_DebtSecuritiesMember_A06F2D4BD11528351A496F399EB85660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_C79C2B62E809432475C56F399EB94BBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_C79C2B62E809432475C56F399EB94BBC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_B73F9DDE2E2EDECD899D7F76C6D5320F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773" xlink:to="loc_us-gaap_FinancialInstrumentAxis_B73F9DDE2E2EDECD899D7F76C6D5320F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_B73F9DDE2E2EDECD899D7F76C6D5320F" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_B73F9DDE2E2EDECD899D7F76C6D5320F" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_A86CDFC187FC4A6FF6087F76C6D5EF03" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_us-gaap_EquitySecuritiesMember_A86CDFC187FC4A6FF6087F76C6D5EF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0752CE820F3F05ECD187FAC218E898E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0752CE820F3F05ECD187FAC218E898E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_305B034C4AB8F89C65207FABBF013B93" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_305B034C4AB8F89C65207FABBF013B93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11A5235A8FB8EAC36AA47FAB1712E81F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11A5235A8FB8EAC36AA47FAB1712E81F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9FB416F45B51DCF73A5D7FA90F607F7C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9FB416F45B51DCF73A5D7FA90F607F7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_888618C0BB619ED201107FB45820143E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_888618C0BB619ED201107FB45820143E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_666FD81453DDBDAC2D4F7FB4584F7BB0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_666FD81453DDBDAC2D4F7FB4584F7BB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5C1F1FA0A98A562C476C7FB45877AA03" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5C1F1FA0A98A562C476C7FB45877AA03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0A7026CFCCCD25D22E7A7FB40C9E1ABC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0A7026CFCCCD25D22E7A7FB40C9E1ABC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_08B2BACC24B6A25BFDE1FC3A19BA3812" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_08B2BACC24B6A25BFDE1FC3A19BA3812" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4BEBF7C789E23EC4F8C1FC3A19BAA3C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_08B2BACC24B6A25BFDE1FC3A19BA3812" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4BEBF7C789E23EC4F8C1FC3A19BAA3C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4BEBF7C789E23EC4F8C1FC3A19BAA3C3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4BEBF7C789E23EC4F8C1FC3A19BAA3C3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_80FD52A6FCF2FE47164EFC3A19BA42DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_80FD52A6FCF2FE47164EFC3A19BA42DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F05D912938CABB5CCC94FC3A19BA9258" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_08B2BACC24B6A25BFDE1FC3A19BA3812" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F05D912938CABB5CCC94FC3A19BA9258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D05A5BE1CBB35D0FF9BCFC3A19BAFCEF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F05D912938CABB5CCC94FC3A19BA9258" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D05A5BE1CBB35D0FF9BCFC3A19BAFCEF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D05A5BE1CBB35D0FF9BCFC3A19BAFCEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F05D912938CABB5CCC94FC3A19BA9258" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D05A5BE1CBB35D0FF9BCFC3A19BAFCEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_2B34C5DD5F9455464E0EFC3A19BA1D56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D05A5BE1CBB35D0FF9BCFC3A19BAFCEF" xlink:to="loc_biib_IonisPharmaceuticalsMember_2B34C5DD5F9455464E0EFC3A19BA1D56" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_A7AFBF441A4270A55E56FC3A19BA5D12" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D05A5BE1CBB35D0FF9BCFC3A19BAFCEF" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_A7AFBF441A4270A55E56FC3A19BA5D12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_08B2BACC24B6A25BFDE1FC3A19BA3812" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3" xlink:to="loc_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_B13FC37463FE1B0CC699FC3A19BAEBC1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_B13FC37463FE1B0CC699FC3A19BAEBC1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_3644A1D374467E4E0B68FC3A19BACD5F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_3644A1D374467E4E0B68FC3A19BACD5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_35E44149D4DB150278B7FC3A19BA1DB3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_35E44149D4DB150278B7FC3A19BA1DB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B1ACBED11838736703F5FC3A19BA7E83" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B1ACBED11838736703F5FC3A19BA7E83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_1A9DCFD64C4186C63139FC3A19BAABDA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_us-gaap_EquityMethodInvestments_1A9DCFD64C4186C63139FC3A19BAABDA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxAssetLiabilityTypeAxis" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxAssetLiabilityTypeDomain" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxAssetLiabilityTypeDomain" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_F33C2354A9F5F5CA0402FC2E5A248C17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906" xlink:to="loc_us-gaap_IntellectualPropertyMember_F33C2354A9F5F5CA0402FC2E5A248C17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92D156BDFE80A879BF6DFC2E5A242667" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92D156BDFE80A879BF6DFC2E5A242667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55FF26E228CC7F3DDB37FC2E5A249A4C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92D156BDFE80A879BF6DFC2E5A242667" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55FF26E228CC7F3DDB37FC2E5A249A4C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55FF26E228CC7F3DDB37FC2E5A249A4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92D156BDFE80A879BF6DFC2E5A242667" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55FF26E228CC7F3DDB37FC2E5A249A4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_1DD19DE79809871BD4EBFC2E5A25A65A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55FF26E228CC7F3DDB37FC2E5A249A4C" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_1DD19DE79809871BD4EBFC2E5A25A65A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_35B1147684B88425791BFC2E5A2561FB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_35B1147684B88425791BFC2E5A2561FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A4AFBAB9253D1930B8F6FC2E5A25B447_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_35B1147684B88425791BFC2E5A2561FB" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A4AFBAB9253D1930B8F6FC2E5A25B447_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A4AFBAB9253D1930B8F6FC2E5A25B447" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_35B1147684B88425791BFC2E5A2561FB" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A4AFBAB9253D1930B8F6FC2E5A25B447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_BF898951A137ED0C61A1FC2E5A26ECBE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_srt_RangeAxis_BF898951A137ED0C61A1FC2E5A26ECBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_ECACDDAE620F726853BDFC2E5A26E3D0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_BF898951A137ED0C61A1FC2E5A26ECBE" xlink:to="loc_srt_RangeMember_ECACDDAE620F726853BDFC2E5A26E3D0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_ECACDDAE620F726853BDFC2E5A26E3D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_BF898951A137ED0C61A1FC2E5A26ECBE" xlink:to="loc_srt_RangeMember_ECACDDAE620F726853BDFC2E5A26E3D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9795BA3263F7C6116F3DFC2E5A269EBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ECACDDAE620F726853BDFC2E5A26E3D0" xlink:to="loc_srt_MinimumMember_9795BA3263F7C6116F3DFC2E5A269EBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_542FF01F46C3353A62C3FC2E5A26876D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ECACDDAE620F726853BDFC2E5A26E3D0" xlink:to="loc_srt_MaximumMember_542FF01F46C3353A62C3FC2E5A26876D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2FBC865AB46BC7C69992FC2E5A27510E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_srt_ProductOrServiceAxis_2FBC865AB46BC7C69992FC2E5A27510E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_849FCF6BB4BE352E348AFC2E5A279DDE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2FBC865AB46BC7C69992FC2E5A27510E" xlink:to="loc_srt_ProductsAndServicesDomain_849FCF6BB4BE352E348AFC2E5A279DDE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_849FCF6BB4BE352E348AFC2E5A279DDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2FBC865AB46BC7C69992FC2E5A27510E" xlink:to="loc_srt_ProductsAndServicesDomain_849FCF6BB4BE352E348AFC2E5A279DDE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_CE83B57D54B8E665EAEBFC2E5A277F02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_849FCF6BB4BE352E348AFC2E5A279DDE" xlink:to="loc_biib_ZINBRYTAMember_CE83B57D54B8E665EAEBFC2E5A277F02" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignearningstypeAxis" xlink:label="loc_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:to="loc_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:to="loc_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:to="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherForeignEarningsMember" xlink:label="loc_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:to="loc_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7CBE99324B5B3568EF72FC2E5A2E23EF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7CBE99324B5B3568EF72FC2E5A2E23EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_E91F766D27387371C822FC2E5A2E2B70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7CBE99324B5B3568EF72FC2E5A2E23EF" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_E91F766D27387371C822FC2E5A2E2B70_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_E91F766D27387371C822FC2E5A2E2B70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7CBE99324B5B3568EF72FC2E5A2E23EF" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_E91F766D27387371C822FC2E5A2E2B70" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_4E6F91EE576A0FF8DC94FC2E5A2E2255" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_E91F766D27387371C822FC2E5A2E2B70" xlink:to="loc_biib_DeferredtaxliabilityMember_4E6F91EE576A0FF8DC94FC2E5A2E2255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1EB89FAE06941FCE8289FC2E5A2F1BCA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_E91F766D27387371C822FC2E5A2E2B70" xlink:to="loc_us-gaap_RetainedEarningsMember_1EB89FAE06941FCE8289FC2E5A2F1BCA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PrepaidtaxesMember" xlink:label="loc_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_E91F766D27387371C822FC2E5A2E2B70" xlink:to="loc_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_1D1954CEE8DA0A13D2F6FC2E5A2F85EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:to="loc_us-gaap_GeneralBusinessMember_1D1954CEE8DA0A13D2F6FC2E5A2F85EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_97CE2EABD63F3E74FFBCFC2E5A30711D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:to="loc_us-gaap_ResearchMember_97CE2EABD63F3E74FFBCFC2E5A30711D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:to="loc_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_6F93A458E0B86893794CFC2E5A307C06" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:to="loc_us-gaap_DomesticCountryMember_6F93A458E0B86893794CFC2E5A307C06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5915F6DDAFFA6C154C4FFC2E5A31CE9C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5915F6DDAFFA6C154C4FFC2E5A31CE9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_74A4548EB9AE62F1A6CCFC2E5A3165AF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:to="loc_us-gaap_ForeignCountryMember_74A4548EB9AE62F1A6CCFC2E5A3165AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_A4F6B35FC5A842BD086BFC2E5A312376" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_A4F6B35FC5A842BD086BFC2E5A312376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_93853395B54A494DD1D2FC2E5A32710D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_93853395B54A494DD1D2FC2E5A32710D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1B9C1DDEEC7C860EE2A6FC2E5A32DF40" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1B9C1DDEEC7C860EE2A6FC2E5A32DF40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B69478896DE2F63D68F6FC2E5A324535" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B69478896DE2F63D68F6FC2E5A324535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F2879DA82B042DCC6F45FC2E5A325751" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F2879DA82B042DCC6F45FC2E5A325751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ECE14781248ECFF957E2FC2E5A32EA64" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ECE14781248ECFF957E2FC2E5A32EA64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ECC4F8648B52888F5187FC2E5A33E274" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ECC4F8648B52888F5187FC2E5A33E274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_08DC23A049597E5DE7BBFC2E5A337186" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_IncomeTaxesPaid_08DC23A049597E5DE7BBFC2E5A337186" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" xlink:label="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" xlink:label="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TransitionTollTaxRepatriationTaxRate" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E0F8EFB11FBF2846931DFC2E5A336583" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E0F8EFB11FBF2846931DFC2E5A336583" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Reductionindeferredtaxliabilityundistributedforeignearnings" xlink:label="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_054C22239EB1D70D5F1FFC2E5A34A456" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_OtherTaxExpenseBenefit_054C22239EB1D70D5F1FFC2E5A34A456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_15611CD785CD1CFEF885FC2E5A34CB81" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_15611CD785CD1CFEF885FC2E5A34CB81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_DE5E582365435F2E8315FC2E5A34BD5F" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_DE5E582365435F2E8315FC2E5A34BD5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_72B0E30BCE32EFF94DF1FC2E5A344A40" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_OperatingLossCarryforwards_72B0E30BCE32EFF94DF1FC2E5A344A40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1022A6B4A5BF8605F1B4FC2E5A34E862" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1022A6B4A5BF8605F1B4FC2E5A34E862" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_B034043B1F469AAFBA6DFC2E5A34670A" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_B034043B1F469AAFBA6DFC2E5A34670A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D306F1D80365E677B41EFC2E5A35A647" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D306F1D80365E677B41EFC2E5A35A647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20E7BF62CAB2488FA5F5FC37ACE198D4" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20E7BF62CAB2488FA5F5FC37ACE198D4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C9CFE8E93008D6A9F2DFF00F38159619" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F907B13D150FEED31915F00F3813C14D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C9CFE8E93008D6A9F2DFF00F38159619" xlink:to="loc_us-gaap_DebtInstrumentTable_F907B13D150FEED31915F00F3813C14D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8BDA1A398B10F321CB54F00F3813B558" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_F907B13D150FEED31915F00F3813C14D" xlink:to="loc_us-gaap_DebtInstrumentAxis_8BDA1A398B10F321CB54F00F3813B558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8BDA1A398B10F321CB54F00F3813B558" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8BDA1A398B10F321CB54F00F3813B558" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_9EBAB6502EAEAC5B481AF00F3814E36C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_9EBAB6502EAEAC5B481AF00F3814E36C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_751FFE294E9163DCFD65F00F381415F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_751FFE294E9163DCFD65F00F381415F5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_BAF022B2291C2AD0EDEDF00F38156FE7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_BAF022B2291C2AD0EDEDF00F38156FE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4030F40EEEB082AD2CFAF00F381524C2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4030F40EEEB082AD2CFAF00F381524C2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_89D1DC334253A8BD894AF00F3815F826" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_89D1DC334253A8BD894AF00F3815F826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C9CFE8E93008D6A9F2DFF00F38159619" xlink:to="loc_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_C18F41094145CF079986F00F38157531" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:to="loc_us-gaap_NotesPayableCurrent_C18F41094145CF079986F00F38157531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_A8ADA52EC03F2D1E0717F00F38189469" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:to="loc_us-gaap_DebtCurrent_A8ADA52EC03F2D1E0717F00F38189469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C9CFE8E93008D6A9F2DFF00F38159619" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_CBCEE2BEFF18FD0876A2F00F3818693F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:to="loc_us-gaap_LongTermNotesPayable_CBCEE2BEFF18FD0876A2F00F3818693F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6B5A87F134AAD5F0B5FBF00F3818FE0B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:to="loc_us-gaap_LongTermDebt_6B5A87F134AAD5F0B5FBF00F3818FE0B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_FD28AF7C73A7C541EADB0B3C231E370D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242" xlink:to="loc_us-gaap_SubsequentEventMember_FD28AF7C73A7C541EADB0B3C231E370D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6EDF2FCDB88B54489AEC0B3C232E5A01" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6EDF2FCDB88B54489AEC0B3C232E5A01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6326263E3C7CC9328EFA0B3C232E2086_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6EDF2FCDB88B54489AEC0B3C232E5A01" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6326263E3C7CC9328EFA0B3C232E2086_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6326263E3C7CC9328EFA0B3C232E2086" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6EDF2FCDB88B54489AEC0B3C232E5A01" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6326263E3C7CC9328EFA0B3C232E2086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_3E6C25A7BE67F7B7EFE80B3C232E43F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6326263E3C7CC9328EFA0B3C232E2086" xlink:to="loc_us-gaap_InterestRateSwapMember_3E6C25A7BE67F7B7EFE80B3C232E43F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F2B2F0D8914CCBD536290B3C232ECFED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:to="loc_us-gaap_DebtInstrumentAxis_F2B2F0D8914CCBD536290B3C232ECFED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F2B2F0D8914CCBD536290B3C232ECFED" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F2B2F0D8914CCBD536290B3C232ECFED" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_559A7E55D2C3E95762150B3C232E1572" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_559A7E55D2C3E95762150B3C232E1572" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_A8F339E924FC8BAA858A0B3C232EC60D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_A8F339E924FC8BAA858A0B3C232EC60D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A69A05CCD2B5E28309B0B3C232EE208" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A69A05CCD2B5E28309B0B3C232EE208" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_5BB7956CE38397C0873B0B3C232EDB83" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_5BB7956CE38397C0873B0B3C232EDB83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_58C1D31AA50272755CEA0B3C232E3B49" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_58C1D31AA50272755CEA0B3C232E3B49" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0FCA38F99B21BD99AC550B3C232E89C1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0FCA38F99B21BD99AC550B3C232E89C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7D6B46AFB6ED59FD6F8F0B3C232E7B1C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7D6B46AFB6ED59FD6F8F0B3C232E7B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_E4FF5C461D33E50B5DCF0B9C8A39BF22" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_LineOfCreditFacilityDescription_E4FF5C461D33E50B5DCF0B9C8A39BF22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_E8CB8246AA486AA07A190B3C232E6AA7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_E8CB8246AA486AA07A190B3C232E6AA7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_76407525B0365CCDB91DFCF51F7DBDD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_76407525B0365CCDB91DFCF51F7DBDD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_134E101D3A5C85D0F645FCF51F7DDD4C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_76407525B0365CCDB91DFCF51F7DBDD2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_134E101D3A5C85D0F645FCF51F7DDD4C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_134E101D3A5C85D0F645FCF51F7DDD4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_76407525B0365CCDB91DFCF51F7DBDD2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_134E101D3A5C85D0F645FCF51F7DDD4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_203940631C3A6E7A5DF4FCF51F7DB208" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_134E101D3A5C85D0F645FCF51F7DDD4C" xlink:to="loc_biib_NightstarMember_203940631C3A6E7A5DF4FCF51F7DB208" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_4B826B7702C5462D1BA8FCF51F7E101E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_4B826B7702C5462D1BA8FCF51F7E101E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_EC784515999C192AC081FCF51F7E3B53_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_4B826B7702C5462D1BA8FCF51F7E101E" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_EC784515999C192AC081FCF51F7E3B53_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_EC784515999C192AC081FCF51F7E3B53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_4B826B7702C5462D1BA8FCF51F7E101E" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_EC784515999C192AC081FCF51F7E3B53" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BG00011Member" xlink:label="loc_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_EC784515999C192AC081FCF51F7E3B53" xlink:to="loc_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PLSRMember" xlink:label="loc_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_EC784515999C192AC081FCF51F7E3B53" xlink:to="loc_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_EC784515999C192AC081FCF51F7E3B53" xlink:to="loc_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9251078E39100A12459BFCF51F7F080E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:to="loc_srt_ProductOrServiceAxis_9251078E39100A12459BFCF51F7F080E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9251078E39100A12459BFCF51F7F080E" xlink:to="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9251078E39100A12459BFCF51F7F080E" xlink:to="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_8849DF30D8155E7A3A37FCF51F8031E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:to="loc_biib_TysabriProductMember_8849DF30D8155E7A3A37FCF51F8031E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_VUMERITYMember" xlink:label="loc_biib_VUMERITYMember_C2A9FDE7D34A28255B45FCF51F80F2DD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:to="loc_biib_VUMERITYMember_C2A9FDE7D34A28255B45FCF51F80F2DD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_5C4FB99CF7A218362071FCF51F8093C8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:to="loc_biib_SPINRAZAMember_5C4FB99CF7A218362071FCF51F8093C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_EED837B9E57DA4DF2405FCF51F807224" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:to="loc_biib_BiosimilarsMember_EED837B9E57DA4DF2405FCF51F807224" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_206D1A0429FB55ACC504FCF51F806139" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:to="loc_biib_TecfideraMember_206D1A0429FB55ACC504FCF51F806139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_72B8E1D3D68F3FE67655FCF51F81E9FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_72B8E1D3D68F3FE67655FCF51F81E9FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_5F2C0F36CDEEA36DA9FBFCF51F815625" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_5F2C0F36CDEEA36DA9FBFCF51F815625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_151DA301A4A60C153A9DFCF51F81576E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:to="loc_srt_RangeAxis_151DA301A4A60C153A9DFCF51F81576E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_E27C6048FA62C7527215FCF51F817322_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_151DA301A4A60C153A9DFCF51F81576E" xlink:to="loc_srt_RangeMember_E27C6048FA62C7527215FCF51F817322_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_E27C6048FA62C7527215FCF51F817322" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_151DA301A4A60C153A9DFCF51F81576E" xlink:to="loc_srt_RangeMember_E27C6048FA62C7527215FCF51F817322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_232E00D7CF22FD253827FCF51F82B2C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_E27C6048FA62C7527215FCF51F817322" xlink:to="loc_srt_MinimumMember_232E00D7CF22FD253827FCF51F82B2C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_EB83D1059AD8EDC179F5FCF51F82812F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_E27C6048FA62C7527215FCF51F817322" xlink:to="loc_srt_MaximumMember_EB83D1059AD8EDC179F5FCF51F82812F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_F229BA92FB8B211AD58AFCF51F828CA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_F229BA92FB8B211AD58AFCF51F828CA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_BAB7784D54E7EF3298A3FCF51F83A307" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_BAB7784D54E7EF3298A3FCF51F83A307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99C4A2AAF55AD6E65CB3FCF51F83AEDE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99C4A2AAF55AD6E65CB3FCF51F83AEDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3AE7CB2C2CE7DD4B455DFCF51F830E0C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3AE7CB2C2CE7DD4B455DFCF51F830E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_CD49AD57C3096E21C3CBFCF51F83676B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_CD49AD57C3096E21C3CBFCF51F83676B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_45F32F86A8C14D72480BFCF51F847603" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_45F32F86A8C14D72480BFCF51F847603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0BDE10682FD4629E985EFCF51F84E9B6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0BDE10682FD4629E985EFCF51F84E9B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_E59358DC0C1E3E696D83FCF51F84941A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_E59358DC0C1E3E696D83FCF51F84941A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_879D477B171E50232EE1FCF51F84CB36" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_879D477B171E50232EE1FCF51F84CB36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A232030F076F86B102CEFCF51F84E075" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A232030F076F86B102CEFCF51F84E075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1A973E4B90425708205DFCF51F852464" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1A973E4B90425708205DFCF51F852464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_871B3DDA8DBD03527E10FCF51F85E0B1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_871B3DDA8DBD03527E10FCF51F85E0B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_829F61D5344AEB9F83B5FCF51F85521C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_829F61D5344AEB9F83B5FCF51F85521C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9311943C280046D9D0B1FCF51F852ABD" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9311943C280046D9D0B1FCF51F852ABD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6E3331026AF044C11E8EFCF51F854EC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6E3331026AF044C11E8EFCF51F854EC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_303FD833FE0888D30D83FCF51F854E28" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_303FD833FE0888D30D83FCF51F854E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E9D513755AD4AE3D9185FCF51F869E64" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E9D513755AD4AE3D9185FCF51F869E64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2D734BD8674B2F59050AFCF51F86DBDF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2D734BD8674B2F59050AFCF51F86DBDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_063184F72774378E606BFCF51F86A359" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_063184F72774378E606BFCF51F86A359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_C97176491EFDE6EA8AE8FCF51F864FDF" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_C97176491EFDE6EA8AE8FCF51F864FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_FBAAEB2138F963CC58EDFCF51F86B7ED" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_FBAAEB2138F963CC58EDFCF51F86B7ED" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_A4EA2395A75DFDC2C53A0C848E2E1ED6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:to="loc_biib_CumulativeSalesLevelAxis_A4EA2395A75DFDC2C53A0C848E2E1ED6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_56AB8522388FECFF24C60C848E2E5CC8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_A4EA2395A75DFDC2C53A0C848E2E1ED6" xlink:to="loc_biib_CumulativeSalesLevelDomain_56AB8522388FECFF24C60C848E2E5CC8_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_56AB8522388FECFF24C60C848E2E5CC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_A4EA2395A75DFDC2C53A0C848E2E1ED6" xlink:to="loc_biib_CumulativeSalesLevelDomain_56AB8522388FECFF24C60C848E2E5CC8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5AEA6CA3A7ECAC3DF21F0C848E2E7052" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_56AB8522388FECFF24C60C848E2E5CC8" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5AEA6CA3A7ECAC3DF21F0C848E2E7052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F031355F8C6BBEC49C790C848E2F9971" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F031355F8C6BBEC49C790C848E2F9971" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25DC85836D0FC50D7BB40C848E2F9D35_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F031355F8C6BBEC49C790C848E2F9971" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25DC85836D0FC50D7BB40C848E2F9D35_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25DC85836D0FC50D7BB40C848E2F9D35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F031355F8C6BBEC49C790C848E2F9971" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25DC85836D0FC50D7BB40C848E2F9D35" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_F651084DE53152A8F3A40C848E2F93DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25DC85836D0FC50D7BB40C848E2F9D35" xlink:to="loc_biib_BioverativMember_F651084DE53152A8F3A40C848E2F93DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_43903B6FEE79F37787880C848E2F744E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_43903B6FEE79F37787880C848E2F744E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33DB105FFB8CA75FA75B0C848E30C9C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43903B6FEE79F37787880C848E2F744E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33DB105FFB8CA75FA75B0C848E30C9C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33DB105FFB8CA75FA75B0C848E30C9C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43903B6FEE79F37787880C848E2F744E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33DB105FFB8CA75FA75B0C848E30C9C9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_F665E16285F01584EB770C848E303D45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33DB105FFB8CA75FA75B0C848E30C9C9" xlink:to="loc_biib_FumapharmAgMember_F665E16285F01584EB770C848E303D45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_53E7BAF3BBFD12B37F870C848E30C7BC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:to="loc_srt_ProductOrServiceAxis_53E7BAF3BBFD12B37F870C848E30C7BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_406B0B6C8D034172DF430C848E302051_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_53E7BAF3BBFD12B37F870C848E30C7BC" xlink:to="loc_srt_ProductsAndServicesDomain_406B0B6C8D034172DF430C848E302051_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_406B0B6C8D034172DF430C848E302051" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_53E7BAF3BBFD12B37F870C848E30C7BC" xlink:to="loc_srt_ProductsAndServicesDomain_406B0B6C8D034172DF430C848E302051" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_FBC61B6DE460E4883C9B0C848E312592" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_406B0B6C8D034172DF430C848E302051" xlink:to="loc_biib_TecfideraMember_FBC61B6DE460E4883C9B0C848E312592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9C47D01E412A7AC583AD0C848E316B6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9C47D01E412A7AC583AD0C848E316B6D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_6C7CD0C025A00B61B9A90C848E32EC00" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:to="loc_biib_CumulativeSalesLevel_6C7CD0C025A00B61B9A90C848E32EC00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7ED958CCFF802D2F6E040C848E32B614" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7ED958CCFF802D2F6E040C848E32B614" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_9C9887D6E78B4FF6134BF00F392CF9D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:to="loc_srt_MajorCustomersAxis_9C9887D6E78B4FF6134BF00F392CF9D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_222325D1D5F0286DB0B1F00F392C6DDD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9C9887D6E78B4FF6134BF00F392CF9D8" xlink:to="loc_srt_NameOfMajorCustomerDomain_222325D1D5F0286DB0B1F00F392C6DDD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_222325D1D5F0286DB0B1F00F392C6DDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9C9887D6E78B4FF6134BF00F392CF9D8" xlink:to="loc_srt_NameOfMajorCustomerDomain_222325D1D5F0286DB0B1F00F392C6DDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_777C47CCF24B806AB08FF00F392CD560" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_222325D1D5F0286DB0B1F00F392C6DDD" xlink:to="loc_biib_BioverativMember_777C47CCF24B806AB08FF00F392CD560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE" xlink:to="loc_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F71A3510D271F7D1EF15F00F392D5E4E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F71A3510D271F7D1EF15F00F392D5E4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1721172AD8D98B14F35FF00F392E1CA5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F71A3510D271F7D1EF15F00F392D5E4E" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1721172AD8D98B14F35FF00F392E1CA5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1721172AD8D98B14F35FF00F392E1CA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F71A3510D271F7D1EF15F00F392D5E4E" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1721172AD8D98B14F35FF00F392E1CA5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_2D7C109B706B5710AA9AF00F392EF1A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1721172AD8D98B14F35FF00F392E1CA5" xlink:to="loc_biib_BioverativMember_2D7C109B706B5710AA9AF00F392EF1A4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InventorysoldtoBioverativcost" xlink:label="loc_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:to="loc_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2EA3D7A82980566890C8F00F392F6FAB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2EA3D7A82980566890C8F00F392F6FAB" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_7277F86E3EEC14963696E8C959AC07CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_7277F86E3EEC14963696E8C959AC07CE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_AA5EC6CAA08283892F53E8C959ADE8E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_7277F86E3EEC14963696E8C959AC07CE" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_AA5EC6CAA08283892F53E8C959ADE8E7_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_AA5EC6CAA08283892F53E8C959ADE8E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_7277F86E3EEC14963696E8C959AC07CE" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_AA5EC6CAA08283892F53E8C959ADE8E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_4C9366955522F95CE31CE8C978842DDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_AA5EC6CAA08283892F53E8C959ADE8E7" xlink:to="loc_biib_RegulatoryMilestonesMember_4C9366955522F95CE31CE8C978842DDE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RegulatoryApprovalMilestoneMember" xlink:label="loc_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_AA5EC6CAA08283892F53E8C959ADE8E7" xlink:to="loc_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F" xlink:to="loc_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_D04778A35D30B2A98CFDE873AB617B1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_D04778A35D30B2A98CFDE873AB617B1D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_36D71F5F83A106E131AAE8C9599AE97F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_36D71F5F83A106E131AAE8C9599AE97F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesLeases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_490578E17F08AB2D7EA1E873ACFE41A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_StatementTable_490578E17F08AB2D7EA1E873ACFE41A9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_79E7677A4D3BE6ECBBA6E873ACFED211" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_490578E17F08AB2D7EA1E873ACFE41A9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_79E7677A4D3BE6ECBBA6E873ACFED211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_128431542480760D54B0E873ACFE02EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_79E7677A4D3BE6ECBBA6E873ACFED211" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_128431542480760D54B0E873ACFE02EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_128431542480760D54B0E873ACFE02EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_79E7677A4D3BE6ECBBA6E873ACFED211" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_128431542480760D54B0E873ACFE02EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4C0C920495FE3C231937E873ACFE381E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_128431542480760D54B0E873ACFE02EF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4C0C920495FE3C231937E873ACFE381E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6EEF44064F9553CE800CE873ACFEE932" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_128431542480760D54B0E873ACFE02EF" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6EEF44064F9553CE800CE873ACFEE932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_688F9C3CCA0E03128F16E873ACFE49F3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_128431542480760D54B0E873ACFE02EF" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_688F9C3CCA0E03128F16E873ACFE49F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4B31DAD7EBD2667858BEE873ACFE4F89" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_490578E17F08AB2D7EA1E873ACFE41A9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4B31DAD7EBD2667858BEE873ACFE4F89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_114D20B357D865220FACE873ACFE6C93_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4B31DAD7EBD2667858BEE873ACFE4F89" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_114D20B357D865220FACE873ACFE6C93_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_114D20B357D865220FACE873ACFE6C93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4B31DAD7EBD2667858BEE873ACFE4F89" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_114D20B357D865220FACE873ACFE6C93" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OperatingleaseassetsMember" xlink:label="loc_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_114D20B357D865220FACE873ACFE6C93" xlink:to="loc_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_655CA9D5362DE5C0A745E873ACFE119D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_114D20B357D865220FACE873ACFE6C93" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_655CA9D5362DE5C0A745E873ACFE119D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_114D20B357D865220FACE873ACFE6C93" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E3DFE77C75FFAFA29F27E873ACFE0F26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_E3DFE77C75FFAFA29F27E873ACFE0F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_A57A2E631B44004D08E6E873ACFED1CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_A57A2E631B44004D08E6E873ACFED1CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1DA6DEB86E9504AC7F1DE873ACFE00D0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1DA6DEB86E9504AC7F1DE873ACFE00D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_41DD7E9C9416E60AE3DAE873ACFE623C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseLiability_41DD7E9C9416E60AE3DAE873ACFE623C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_A0AAFC451DCF66B94E88E873ACFEE554" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseCost_A0AAFC451DCF66B94E88E873ACFEE554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_38B5618B7FB4C4014B6DE873ACFEB867" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_VariableLeaseCost_38B5618B7FB4C4014B6DE873ACFEB867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_C8DF49B509F66D2295B7E873ACFE1D2C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_C8DF49B509F66D2295B7E873ACFE1D2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_4146C61A9D009224884EE873ACFE4709" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LeaseCost_4146C61A9D009224884EE873ACFE4709" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0D5C0ABEB1A24CA818BBE873ACFE0025" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0D5C0ABEB1A24CA818BBE873ACFE0025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8D02DB6BDCA841E314CEE873ACFEFF8B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8D02DB6BDCA841E314CEE873ACFEFF8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_A9F8D5A07239E0C4986EE873ACFE6087" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_A9F8D5A07239E0C4986EE873ACFE6087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12634B2A6D58CF51EB87E873ACFE6BC4" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12634B2A6D58CF51EB87E873ACFE6BC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E9C2C54AC791981B5785E873ACFE052C" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E9C2C54AC791981B5785E873ACFE052C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_EC5E29C41E15FE62D7F8E873ACFEA899" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_EC5E29C41E15FE62D7F8E873ACFEA899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50871FF0B2E4A1AB8CB7E873ACFE5C80" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50871FF0B2E4A1AB8CB7E873ACFE5C80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ECB2AC2DD6555BFDFC7CE873ACFEED28" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ECB2AC2DD6555BFDFC7CE873ACFEED28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_944C1400F71AE4D7CEBBE873ACFE0A98" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_944C1400F71AE4D7CEBBE873ACFE0A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_754A59424AAA3453C12BE873ACFE6704" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_754A59424AAA3453C12BE873ACFE6704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_88A184F73226FA0F2690E873ACFE6A79" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_88A184F73226FA0F2690E873ACFE6A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_694B2DD4EAFF69B067AEE873ACFEBE4D" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_694B2DD4EAFF69B067AEE873ACFEBE4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_BEF3E8FCCB751566D088E873ACFE05F5" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_BEF3E8FCCB751566D088E873ACFE05F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_46792EE4582066F1DC99E873ACFE30D2" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_46792EE4582066F1DC99E873ACFE30D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_91B010E801E6713C03CBE873ACFE12AD" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_91B010E801E6713C03CBE873ACFE12AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_02513600D9BB7B76F0E3E873ACFE7378" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_02513600D9BB7B76F0E3E873ACFE7378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7EF337BF8354CE05BC4BE873ACFE6070" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7EF337BF8354CE05BC4BE873ACFE6070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_95A1DEF2CACE49C9D83BE873AD0D6D12" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_95A1DEF2CACE49C9D83BE873AD0D6D12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_5857B058FEC9F360BE0CE873AD0D8929" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_5857B058FEC9F360BE0CE873AD0D8929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_99A836EB41F10721FE35E873AD0DD9AD" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_99A836EB41F10721FE35E873AD0DD9AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_A4C2A3D62418A61136ABE873AD0D2853" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_A4C2A3D62418A61136ABE873AD0D2853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_F81D905374E0C0533986E873AD0DCA3D" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_F81D905374E0C0533986E873AD0DCA3D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D" xlink:type="locator" />
    <link:definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5567F9123F004B5D3547E8B1DE72FF82" xlink:type="locator" />
    <link:definitionArc order="38" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5567F9123F004B5D3547E8B1DE72FF82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6F9D0F4F48E08F68BD32E8B1DFF2FC3C" xlink:type="locator" />
    <link:definitionArc order="39" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6F9D0F4F48E08F68BD32E8B1DFF2FC3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_75E1E4279E68E8758DB4E8B3C011F458" xlink:type="locator" />
    <link:definitionArc order="40" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasePayments_75E1E4279E68E8758DB4E8B3C011F458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2DD2A954B517177A6EA0E8B3C1D10B82" xlink:type="locator" />
    <link:definitionArc order="41" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2DD2A954B517177A6EA0E8B3C1D10B82" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SubleaseMember" xlink:label="loc_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64" xlink:to="loc_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9120121AADCC4B603E110B39D4A1168B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:to="loc_srt_RangeAxis_9120121AADCC4B603E110B39D4A1168B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_E966BC536E298113CA9F0B39D4A28704_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9120121AADCC4B603E110B39D4A1168B" xlink:to="loc_srt_RangeMember_E966BC536E298113CA9F0B39D4A28704_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_E966BC536E298113CA9F0B39D4A28704" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9120121AADCC4B603E110B39D4A1168B" xlink:to="loc_srt_RangeMember_E966BC536E298113CA9F0B39D4A28704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D4E014255C054EEB27640B39D4A26B44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_E966BC536E298113CA9F0B39D4A28704" xlink:to="loc_srt_MinimumMember_D4E014255C054EEB27640B39D4A26B44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_379D2E905D13C2B05E230B39D4A37839" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_E966BC536E298113CA9F0B39D4A28704" xlink:to="loc_srt_MaximumMember_379D2E905D13C2B05E230B39D4A37839" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_AD9C523BE4768E0EA2270B39D4A304B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_AD9C523BE4768E0EA2270B39D4A304B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_A5F1B34B1434DA34DB400B39D4A3E838" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_A5F1B34B1434DA34DB400B39D4A3E838" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_543A7FE06C00EF633127EC4300D915A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_543A7FE06C00EF633127EC4300D915A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_B651D1D6B5D8A170C3C1EC4300DAA390_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_543A7FE06C00EF633127EC4300D915A3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_B651D1D6B5D8A170C3C1EC4300DAA390_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_B651D1D6B5D8A170C3C1EC4300DAA390" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_543A7FE06C00EF633127EC4300D915A3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_B651D1D6B5D8A170C3C1EC4300DAA390" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_108E8F80FA8FF0778A0AEC4300DA8BB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_B651D1D6B5D8A170C3C1EC4300DAA390" xlink:to="loc_country_BR_108E8F80FA8FF0778A0AEC4300DA8BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_6AFFEC1B939E58D0078BEC440AE23982" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_6AFFEC1B939E58D0078BEC440AE23982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_E1BC5CD438C1823810C2EC4300DBABC0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_E1BC5CD438C1823810C2EC4300DBABC0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5DC326937AD3DA3DEF50FC3A1872237A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9F8F065BD098388A9225FC3A18627124" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5DC326937AD3DA3DEF50FC3A1872237A" xlink:to="loc_us-gaap_StatementTable_9F8F065BD098388A9225FC3A18627124" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6CF21327CFE33A339B82FC3A18721648" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9F8F065BD098388A9225FC3A18627124" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6CF21327CFE33A339B82FC3A18721648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_59A608DD3DBB4320633BFC3A18721547_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6CF21327CFE33A339B82FC3A18721648" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_59A608DD3DBB4320633BFC3A18721547_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_59A608DD3DBB4320633BFC3A18721547" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6CF21327CFE33A339B82FC3A18721648" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_59A608DD3DBB4320633BFC3A18721547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_86CBB46F7E11496FD5E0FC3A187241E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_59A608DD3DBB4320633BFC3A18721547" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_86CBB46F7E11496FD5E0FC3A187241E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_8CAC97D3CCD6F6BD2737FC3A1872C3C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5DC326937AD3DA3DEF50FC3A1872237A" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_8CAC97D3CCD6F6BD2737FC3A1872C3C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_2BFC332CFB441C21072EFC3A1872D6CE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5DC326937AD3DA3DEF50FC3A1872237A" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_2BFC332CFB441C21072EFC3A1872D6CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855D1A624C8EE961EFC7FC3A1872939B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5DC326937AD3DA3DEF50FC3A1872237A" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855D1A624C8EE961EFC7FC3A1872939B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_5E3027DCF91EF51B6B60E873ABC55E7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:to="loc_srt_ProductOrServiceAxis_5E3027DCF91EF51B6B60E873ABC55E7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2EAB86EEC61F13DF4CA4E873ABC5DDDF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5E3027DCF91EF51B6B60E873ABC55E7C" xlink:to="loc_srt_ProductsAndServicesDomain_2EAB86EEC61F13DF4CA4E873ABC5DDDF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2EAB86EEC61F13DF4CA4E873ABC5DDDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5E3027DCF91EF51B6B60E873ABC55E7C" xlink:to="loc_srt_ProductsAndServicesDomain_2EAB86EEC61F13DF4CA4E873ABC5DDDF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_FE0EC6D428FD15777A8FE873ABC5AA6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2EAB86EEC61F13DF4CA4E873ABC5DDDF" xlink:to="loc_biib_TecfideraMember_FE0EC6D428FD15777A8FE873ABC5AA6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_82A24D08BAF77CD498E7E873ABC50D64" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_82A24D08BAF77CD498E7E873ABC50D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88356E8861828208B497E873ABC53693_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_82A24D08BAF77CD498E7E873ABC50D64" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88356E8861828208B497E873ABC53693_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88356E8861828208B497E873ABC53693" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_82A24D08BAF77CD498E7E873ABC50D64" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88356E8861828208B497E873ABC53693" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_3D7F692A7AF3AB51EC98E873ABC5437A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88356E8861828208B497E873ABC53693" xlink:to="loc_biib_FumapharmAgMember_3D7F692A7AF3AB51EC98E873ABC5437A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_83EA04AAC86E96535942E873ABC5AEDE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:to="loc_biib_FacilityLocationAxis_83EA04AAC86E96535942E873ABC5AEDE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_68FF1792F9E22558B2C9E873ABC5EFC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_83EA04AAC86E96535942E873ABC5AEDE" xlink:to="loc_biib_FacilityLocationDomain_68FF1792F9E22558B2C9E873ABC5EFC6_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_68FF1792F9E22558B2C9E873ABC5EFC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_83EA04AAC86E96535942E873ABC5AEDE" xlink:to="loc_biib_FacilityLocationDomain_68FF1792F9E22558B2C9E873ABC5EFC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_724B9F3D5F54DB6B6E14E873ABC5A5B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_68FF1792F9E22558B2C9E873ABC5EFC6" xlink:to="loc_biib_SolothurnMember_724B9F3D5F54DB6B6E14E873ABC5A5B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_4D53438EE94D0165652BE873ABC5FA88" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:to="loc_biib_CumulativeSalesLevelAxis_4D53438EE94D0165652BE873ABC5FA88" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_4D53438EE94D0165652BE873ABC5FA88" xlink:to="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_4D53438EE94D0165652BE873ABC5FA88" xlink:to="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TwentybillionMember" xlink:label="loc_biib_TwentybillionMember_A2682074F9EEA6A79DAEE873ABC5AFAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0" xlink:to="loc_biib_TwentybillionMember_A2682074F9EEA6A79DAEE873ABC5AFAD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_B0EAA1FA9686FDF1B010E873ABC52BED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_B0EAA1FA9686FDF1B010E873ABC52BED" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0" xlink:to="loc_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0" xlink:to="loc_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_D0DA91D4460C6654BFD1E873ABC5AA56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_D0DA91D4460C6654BFD1E873ABC5AA56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_0438348BF2FDD8FB9CF7E873ABC569CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_0438348BF2FDD8FB9CF7E873ABC569CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_17D448A297A3ADFA8A07E873ABC5E83C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:to="loc_biib_CumulativeSalesLevel_17D448A297A3ADFA8A07E873ABC5E83C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_F5B46AB79A83500B56BDE873ABC535F2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_F5B46AB79A83500B56BDE873ABC535F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1469D5365E6242E58C53E873ABC56A3F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1469D5365E6242E58C53E873ABC56A3F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_C96E33F52FAE49F936287FFAEC8567FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:to="loc_us-gaap_BuildingMember_C96E33F52FAE49F936287FFAEC8567FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_51C92F43A0116072DB397FFB36F0C9CE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_51C92F43A0116072DB397FFB36F0C9CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:to="loc_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:to="loc_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:to="loc_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D" xlink:to="loc_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_907D1C2AF1C36C707B5B7F76C671DCCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:to="loc_us-gaap_Depreciation_907D1C2AF1C36C707B5B7F76C671DCCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_F9F1C3E4B42004EEA1327F76C671BA2F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:to="loc_us-gaap_InterestCostsCapitalized_F9F1C3E4B42004EEA1327F76C671BA2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_FBF8572BE4CC3A94101F7F76C6717CBB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:to="loc_us-gaap_ConstructionInProgressGross_FBF8572BE4CC3A94101F7F76C6717CBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_765C96E64FF77D0080197FFAB1EFCA53" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_765C96E64FF77D0080197FFAB1EFCA53" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3F81135A15C490F9A91F6F39A048315F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_27FAA747D78312BA4AA26F39A04619B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3F81135A15C490F9A91F6F39A048315F" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_27FAA747D78312BA4AA26F39A04619B3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_59C78CF8977ECF4B02186F39A0472822" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27FAA747D78312BA4AA26F39A04619B3" xlink:to="loc_srt_ProductOrServiceAxis_59C78CF8977ECF4B02186F39A0472822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9AC57711B7E2F340A8136F39A0476D70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_59C78CF8977ECF4B02186F39A0472822" xlink:to="loc_srt_ProductsAndServicesDomain_9AC57711B7E2F340A8136F39A0476D70_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9AC57711B7E2F340A8136F39A0476D70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_59C78CF8977ECF4B02186F39A0472822" xlink:to="loc_srt_ProductsAndServicesDomain_9AC57711B7E2F340A8136F39A0476D70" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9AC57711B7E2F340A8136F39A0476D70" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_2643F74D19A408D5E66A6F39A048CD7A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9AC57711B7E2F340A8136F39A0476D70" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_2643F74D19A408D5E66A6F39A048CD7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_1A1E666DAB38CF24A11B6F39A04873E3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9AC57711B7E2F340A8136F39A0476D70" xlink:to="loc_us-gaap_ProductMember_1A1E666DAB38CF24A11B6F39A04873E3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20191231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A77E4F566767A457F6D2FC3A17979752" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A77E4F566767A457F6D2FC3A17979752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_782464A21A1BF2AB927CFC3A17984B22_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A77E4F566767A457F6D2FC3A17979752" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_782464A21A1BF2AB927CFC3A17984B22_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_782464A21A1BF2AB927CFC3A17984B22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A77E4F566767A457F6D2FC3A17979752" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_782464A21A1BF2AB927CFC3A17984B22" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_ADA73E29628A52259661FC3A1798A465" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_782464A21A1BF2AB927CFC3A17984B22" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_ADA73E29628A52259661FC3A1798A465" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_E5B0ADF56B074519F84FFC3A1798355B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_E5B0ADF56B074519F84FFC3A1798355B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0288AB0B3012E8081D98FC3A17984B36_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_E5B0ADF56B074519F84FFC3A1798355B" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0288AB0B3012E8081D98FC3A17984B36_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0288AB0B3012E8081D98FC3A17984B36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_E5B0ADF56B074519F84FFC3A1798355B" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0288AB0B3012E8081D98FC3A17984B36" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_86875B747532992E12F7FC3A1799FAA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0288AB0B3012E8081D98FC3A17984B36" xlink:to="loc_biib_U.S.2017TaxActMember_86875B747532992E12F7FC3A1799FAA2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_00C86E83C3F05EBBB374FC3A1799377D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_00C86E83C3F05EBBB374FC3A1799377D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_DD337D3B70EF3B82DDB8FC3A17990C92_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_00C86E83C3F05EBBB374FC3A1799377D" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_DD337D3B70EF3B82DDB8FC3A17990C92_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_DD337D3B70EF3B82DDB8FC3A17990C92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_00C86E83C3F05EBBB374FC3A1799377D" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_DD337D3B70EF3B82DDB8FC3A17990C92" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_9D0EB4AC7FF024F6FA2FFC3A1799CB97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_DD337D3B70EF3B82DDB8FC3A17990C92" xlink:to="loc_biib_TGNMember_9D0EB4AC7FF024F6FA2FFC3A1799CB97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_15FF5E1420DCA9652C5DFC3A179AD764" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_15FF5E1420DCA9652C5DFC3A179AD764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FE074D6C26273955778FC3A179ACB34_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_15FF5E1420DCA9652C5DFC3A179AD764" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FE074D6C26273955778FC3A179ACB34_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FE074D6C26273955778FC3A179ACB34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_15FF5E1420DCA9652C5DFC3A179AD764" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FE074D6C26273955778FC3A179ACB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_A42E187680BF0E8C1853FC3A179A4022" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FE074D6C26273955778FC3A179ACB34" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_A42E187680BF0E8C1853FC3A179A4022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B381797A03D5F5C9D2C1FC3A179AA539" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B381797A03D5F5C9D2C1FC3A179AA539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B381797A03D5F5C9D2C1FC3A179AA539" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B381797A03D5F5C9D2C1FC3A179AA539" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_55618CB645B7EA5ADB7EFC3A179BE7CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9" xlink:to="loc_biib_KaryopharmMember_55618CB645B7EA5ADB7EFC3A179BE7CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_37726A80A4C1B80AA5F3FC3A179BE4A1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9" xlink:to="loc_biib_RemedyPharmaceuticalMember_37726A80A4C1B80AA5F3FC3A179BE4A1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_81ACAD00C595DC453EFDFC3A179B89B4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9" xlink:to="loc_biib_PfizerMember_81ACAD00C595DC453EFDFC3A179B89B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AliveGenMember" xlink:label="loc_biib_AliveGenMember_838FE5EC0E6DD5B0F786FC3A179B7813" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9" xlink:to="loc_biib_AliveGenMember_838FE5EC0E6DD5B0F786FC3A179B7813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1788FE979747B97121D9FC3A179CF9C1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_srt_ProductOrServiceAxis_1788FE979747B97121D9FC3A179CF9C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_406FFBA6478455AD2FF8FC3A179C65CF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1788FE979747B97121D9FC3A179CF9C1" xlink:to="loc_srt_ProductsAndServicesDomain_406FFBA6478455AD2FF8FC3A179C65CF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_406FFBA6478455AD2FF8FC3A179C65CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1788FE979747B97121D9FC3A179CF9C1" xlink:to="loc_srt_ProductsAndServicesDomain_406FFBA6478455AD2FF8FC3A179C65CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_1BC28D0B9B6A60EA8C37FC3A179C48BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_406FFBA6478455AD2FF8FC3A179C65CF" xlink:to="loc_biib_TecfideraMember_1BC28D0B9B6A60EA8C37FC3A179C48BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ADFCA3AA0AFC6B2202E4FC3A179C7422" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ADFCA3AA0AFC6B2202E4FC3A179C7422" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D71EDCD684CD04B85867FC3A179C0DD5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ADFCA3AA0AFC6B2202E4FC3A179C7422" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D71EDCD684CD04B85867FC3A179C0DD5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D71EDCD684CD04B85867FC3A179C0DD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ADFCA3AA0AFC6B2202E4FC3A179C7422" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D71EDCD684CD04B85867FC3A179C0DD5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_E2071C7811ED200DDFA3FC3A179DA687" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D71EDCD684CD04B85867FC3A179C0DD5" xlink:to="loc_biib_NeurimmuneMember_E2071C7811ED200DDFA3FC3A179DA687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BBC9F285D055BF9DCE4EFC3A179DD931" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_BBC9F285D055BF9DCE4EFC3A179DD931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BBC9F285D055BF9DCE4EFC3A179DD931" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BBC9F285D055BF9DCE4EFC3A179DD931" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_949C0B44EAC803ACD95FFC3A179E5958" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_949C0B44EAC803ACD95FFC3A179E5958" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_15C20145FD79DB535662FC3A179EE6C7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:to="loc_biib_BristolMyersSquibbMember_15C20145FD79DB535662FC3A179EE6C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_3C071247635F9DE021A1FC3A179E6184" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:to="loc_biib_IPerianMember_3C071247635F9DE021A1FC3A179E6184" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_4180B476DB7AEA8725F8FC3A179EF1D7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:to="loc_biib_AlkermesMember_4180B476DB7AEA8725F8FC3A179EF1D7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_BB1796A23D19F865E805FC3A179EFFBD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:to="loc_biib_IonisPharmaceuticalsMember_BB1796A23D19F865E805FC3A179EFFBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_922FB68B988028B1937FFC3A179F5B8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_922FB68B988028B1937FFC3A179F5B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_381CAEB6C4FB0D14AA06FC3A179F64B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_381CAEB6C4FB0D14AA06FC3A179F64B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_5FE3B171817E79229461FC3A179F574D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_5FE3B171817E79229461FC3A179F574D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_CB1316D7C0C0CF2D837DFC3A179FC217" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_CB1316D7C0C0CF2D837DFC3A179FC217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2724D14226DF92401615FC3A179FD78B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2724D14226DF92401615FC3A179FD78B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_0A4BD8D4B20C33719211FC3A179F6DF2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_Premiumonpurchaseofcommonstock_0A4BD8D4B20C33719211FC3A179F6DF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_5854327560B598FD61AAFC3A17A0F372" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_Investmentincommonstocksharespurchased_5854327560B598FD61AAFC3A17A0F372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_10F204D9E826FEA3FADFFC3A17A0C334" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_10F204D9E826FEA3FADFFC3A17A0C334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_2C0634AC2F886188810AFC3A17A00A5C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_2C0634AC2F886188810AFC3A17A00A5C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_35BA3D66C0F4B1449D29FC3A17A0EF29" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_35BA3D66C0F4B1449D29FC3A17A0EF29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_B50B69753336142E6B28FC3A17A08C54" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_B50B69753336142E6B28FC3A17A08C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7DF439D026BC9DE60A25FC3A17A0ADD0" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7DF439D026BC9DE60A25FC3A17A0ADD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_DC2BA30A5F9EA813EF02FC3A17A1D53A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_DC2BA30A5F9EA813EF02FC3A17A1D53A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B9B62B5FA9DD1ABA24ACFC3A17A1E936" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B9B62B5FA9DD1ABA24ACFC3A17A1E936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_0CAB5094E5AB59813A9EFC3A17A1B29A" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_0CAB5094E5AB59813A9EFC3A17A1B29A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_A69630C5BBD701F4ED41FC3A17A123D6" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_DevelopmentalMilestonePayment_A69630C5BBD701F4ED41FC3A17A123D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_62E598B2094A8F55F93EFC3A17A19138" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_62E598B2094A8F55F93EFC3A17A19138" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_9231B4B056DE318B710CFC3A17A1C942" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_9231B4B056DE318B710CFC3A17A1C942" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_955E180E027D1EEF0B02FC3A17A23EF7" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_955E180E027D1EEF0B02FC3A17A23EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B325F27DCD6B812010A6FC3A17A2A0A8" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_B325F27DCD6B812010A6FC3A17A2A0A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_60129104E5B2FBB22BF2FC3A17A29461" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_60129104E5B2FBB22BF2FC3A17A29461" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_F8A7198ADC02254FC4A4E873428F07AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7BA2B61FF9EBEF0DB910E873428A16BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_F8A7198ADC02254FC4A4E873428F07AA" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7BA2B61FF9EBEF0DB910E873428A16BA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7BA2B61FF9EBEF0DB910E873428A16BA" xlink:to="loc_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1" xlink:to="loc_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1" xlink:to="loc_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_FF0D5E65AA014DDDEABDE873428B4061" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:to="loc_country_US_FF0D5E65AA014DDDEABDE873428B4061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_9F0E61B82C7F54701087E873428C6AA2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:to="loc_us-gaap_NonUsMember_9F0E61B82C7F54701087E873428C6AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_D655646973D9DB1FC9D2E873428C6F80" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7BA2B61FF9EBEF0DB910E873428A16BA" xlink:to="loc_srt_ProductOrServiceAxis_D655646973D9DB1FC9D2E873428C6F80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_D655646973D9DB1FC9D2E873428C6F80" xlink:to="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_D655646973D9DB1FC9D2E873428C6F80" xlink:to="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_VUMERITYMember" xlink:label="loc_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_947586215250769E2F8BE873428E258F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_IMRALDIMember_947586215250769E2F8BE873428E258F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_BC6D8D0E389CCD20070CE873428FD90D" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_us-gaap_ProductMember_BC6D8D0E389CCD20070CE873428FD90D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F1B2B553AFA1D3264F3DE873428FB615" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_F8A7198ADC02254FC4A4E873428F07AA" xlink:to="loc_us-gaap_Revenues_F1B2B553AFA1D3264F3DE873428FB615" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:to="loc_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B" xlink:to="loc_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B" xlink:to="loc_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_20B3E02BFDDBEBCC0B4C80C3141E94A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_20B3E02BFDDBEBCC0B4C80C3141E94A4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:to="loc_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:to="loc_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45" xlink:to="loc_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45" xlink:to="loc_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8" xlink:to="loc_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:to="loc_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:to="loc_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:to="loc_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:to="loc_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:to="loc_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_AF1812CB9C3FE3BF328380C31420B708" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:to="loc_us-gaap_Revenues_AF1812CB9C3FE3BF328380C31420B708" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:to="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:to="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_D4ED0827FDF08CFFD20980C31421396D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_D4ED0827FDF08CFFD20980C31421396D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6FCCC6081F5BD36A65DC6F399D9290CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_B09B18BC0E3B6F5A3BAF6F399D8E88C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6FCCC6081F5BD36A65DC6F399D9290CC" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_B09B18BC0E3B6F5A3BAF6F399D8E88C5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8D0CAFF55543FEF406E96F399D8F7B82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_B09B18BC0E3B6F5A3BAF6F399D8E88C5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8D0CAFF55543FEF406E96F399D8F7B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_641FB7B0A68E9F19C54C6F399D8FF971_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8D0CAFF55543FEF406E96F399D8F7B82" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_641FB7B0A68E9F19C54C6F399D8FF971_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_641FB7B0A68E9F19C54C6F399D8FF971" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8D0CAFF55543FEF406E96F399D8F7B82" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_641FB7B0A68E9F19C54C6F399D8FF971" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_CC5F1DD744EACEFFD9A36F399D8FDE1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_641FB7B0A68E9F19C54C6F399D8FF971" xlink:to="loc_us-gaap_CollaborativeArrangementMember_CC5F1DD744EACEFFD9A36F399D8FDE1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7D7972BFA672F654B5006F399D8F08BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_B09B18BC0E3B6F5A3BAF6F399D8E88C5" xlink:to="loc_srt_ProductOrServiceAxis_7D7972BFA672F654B5006F399D8F08BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CF061C5D81ED707964A66F399D909548_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7D7972BFA672F654B5006F399D8F08BF" xlink:to="loc_srt_ProductsAndServicesDomain_CF061C5D81ED707964A66F399D909548_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CF061C5D81ED707964A66F399D909548" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7D7972BFA672F654B5006F399D8F08BF" xlink:to="loc_srt_ProductsAndServicesDomain_CF061C5D81ED707964A66F399D909548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_684A24D7BAFC6CA1E5376F399D90F400" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CF061C5D81ED707964A66F399D909548" xlink:to="loc_us-gaap_RoyaltyMember_684A24D7BAFC6CA1E5376F399D90F400" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_83EEE6329D3858CF959A6F399D904877" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CF061C5D81ED707964A66F399D909548" xlink:to="loc_biib_OthercorporaterevenuesMember_83EEE6329D3858CF959A6F399D904877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_8CBBB7215A2BF152EF6B6F399D90F6DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CF061C5D81ED707964A66F399D909548" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_8CBBB7215A2BF152EF6B6F399D90F6DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_BC750DCEAE281EB27EA96F399D91417C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_B09B18BC0E3B6F5A3BAF6F399D8E88C5" xlink:to="loc_srt_MajorCustomersAxis_BC750DCEAE281EB27EA96F399D91417C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_4F71A64DAB5A00C276F76F399D91AFF6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_BC750DCEAE281EB27EA96F399D91417C" xlink:to="loc_srt_NameOfMajorCustomerDomain_4F71A64DAB5A00C276F76F399D91AFF6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_4F71A64DAB5A00C276F76F399D91AFF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_BC750DCEAE281EB27EA96F399D91417C" xlink:to="loc_srt_NameOfMajorCustomerDomain_4F71A64DAB5A00C276F76F399D91AFF6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_4D4DD8B22BB84FCA3C2D6F399D91F196" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4F71A64DAB5A00C276F76F399D91AFF6" xlink:to="loc_biib_AbbVieMember_4D4DD8B22BB84FCA3C2D6F399D91F196" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_F8F44EB3EF8FEB062F816F399D9103A3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4F71A64DAB5A00C276F76F399D91AFF6" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_F8F44EB3EF8FEB062F816F399D9103A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SobiMember" xlink:label="loc_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4F71A64DAB5A00C276F76F399D91AFF6" xlink:to="loc_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A90F2C1493A337CF22D36F399D9240AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6FCCC6081F5BD36A65DC6F399D9290CC" xlink:to="loc_us-gaap_Revenues_A90F2C1493A337CF22D36F399D9240AE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:to="loc_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:to="loc_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_447F237B1ACB0AE10B346F399D9D2FB9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_447F237B1ACB0AE10B346F399D9D2FB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_FFBF6E47C183648CF50E6F399D9DF670" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_FFBF6E47C183648CF50E6F399D9DF670" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F2F566F470465FA51238EBFB6554A733" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C1D0534E59F24422F72BEBFB655324F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_F2F566F470465FA51238EBFB6554A733" xlink:to="loc_us-gaap_StatementTable_C1D0534E59F24422F72BEBFB655324F1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4E2E15EF66F8885F53DCEBFB65532E0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_C1D0534E59F24422F72BEBFB655324F1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4E2E15EF66F8885F53DCEBFB65532E0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1CD5791E223777F2860EEBFB65549283_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4E2E15EF66F8885F53DCEBFB65532E0B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1CD5791E223777F2860EEBFB65549283_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1CD5791E223777F2860EEBFB65549283" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4E2E15EF66F8885F53DCEBFB65532E0B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1CD5791E223777F2860EEBFB65549283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_3E5508FA311281F4BDA1EBFB6554A4D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1CD5791E223777F2860EEBFB65549283" xlink:to="loc_us-gaap_AccountsReceivableMember_3E5508FA311281F4BDA1EBFB6554A4D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_02B953A0C9E40C8E215FEBFB6554B2F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1CD5791E223777F2860EEBFB65549283" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_02B953A0C9E40C8E215FEBFB6554B2F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_874CE536535B2FBD3BFCEBFB65554850" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F2F566F470465FA51238EBFB6554A733" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_874CE536535B2FBD3BFCEBFB65554850" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9E4C2B0ABE7C702DE774EBFB654F6776" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_57A21FDCC68F2A672D9CEBFB654D77BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9E4C2B0ABE7C702DE774EBFB654F6776" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_57A21FDCC68F2A672D9CEBFB654D77BB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_404D508B033C3659DA61EBFB654D6046" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57A21FDCC68F2A672D9CEBFB654D77BB" xlink:to="loc_srt_ProductOrServiceAxis_404D508B033C3659DA61EBFB654D6046" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_676D7D18D411925BE3E9EBFB654EC8B9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_404D508B033C3659DA61EBFB654D6046" xlink:to="loc_srt_ProductsAndServicesDomain_676D7D18D411925BE3E9EBFB654EC8B9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_676D7D18D411925BE3E9EBFB654EC8B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_404D508B033C3659DA61EBFB654D6046" xlink:to="loc_srt_ProductsAndServicesDomain_676D7D18D411925BE3E9EBFB654EC8B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_5A3D0EA4783CAD379847EBFB654E1FE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_676D7D18D411925BE3E9EBFB654EC8B9" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_5A3D0EA4783CAD379847EBFB654E1FE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F6EF022D576C028257C3EBFB654E2C62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57A21FDCC68F2A672D9CEBFB654D77BB" xlink:to="loc_srt_MajorCustomersAxis_F6EF022D576C028257C3EBFB654E2C62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_289CF8EE9CED077DBF4CEBFB654E97D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_F6EF022D576C028257C3EBFB654E2C62" xlink:to="loc_srt_NameOfMajorCustomerDomain_289CF8EE9CED077DBF4CEBFB654E97D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_289CF8EE9CED077DBF4CEBFB654E97D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_F6EF022D576C028257C3EBFB654E2C62" xlink:to="loc_srt_NameOfMajorCustomerDomain_289CF8EE9CED077DBF4CEBFB654E97D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_94D2177E193BA214DBB5EBFB654F8789" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_289CF8EE9CED077DBF4CEBFB654E97D8" xlink:to="loc_biib_RocheGroupGenentechMember_94D2177E193BA214DBB5EBFB654F8789" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_D51224B907020A16BA52EBFB654FC691" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9E4C2B0ABE7C702DE774EBFB654F6776" xlink:to="loc_biib_ShareOfCoPromotionProfits_D51224B907020A16BA52EBFB654FC691" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_FF573D5169811D5E8C2AEBFB65509A99" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9E4C2B0ABE7C702DE774EBFB654F6776" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_FF573D5169811D5E8C2AEBFB65509A99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_522D979D50AEAB98BB23EBFB6550834C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9E4C2B0ABE7C702DE774EBFB654F6776" xlink:to="loc_us-gaap_Revenues_522D979D50AEAB98BB23EBFB6550834C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_871BA838FF3DCBCB377D6F399F3C2060" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:to="loc_srt_ProductOrServiceAxis_871BA838FF3DCBCB377D6F399F3C2060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2811CA576BA2E0F6EF2C6F399F3DDCD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_871BA838FF3DCBCB377D6F399F3C2060" xlink:to="loc_srt_ProductsAndServicesDomain_2811CA576BA2E0F6EF2C6F399F3DDCD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2811CA576BA2E0F6EF2C6F399F3DDCD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_871BA838FF3DCBCB377D6F399F3C2060" xlink:to="loc_srt_ProductsAndServicesDomain_2811CA576BA2E0F6EF2C6F399F3DDCD0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_4ABB1E2DE503ADDFD05A6F399F3D14A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2811CA576BA2E0F6EF2C6F399F3DDCD0" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_4ABB1E2DE503ADDFD05A6F399F3D14A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_C31B8C46022F09B8968B6F399F3DE4CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2811CA576BA2E0F6EF2C6F399F3DDCD0" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_C31B8C46022F09B8968B6F399F3DE4CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C7193636C5F26F6B3CA56F399F3E402A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2811CA576BA2E0F6EF2C6F399F3DDCD0" xlink:to="loc_us-gaap_ProductMember_C7193636C5F26F6B3CA56F399F3E402A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_3FEEF1F6F1C57C52B9B56F399F3EE9E8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:to="loc_srt_StatementGeographicalAxis_3FEEF1F6F1C57C52B9B56F399F3EE9E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3FEEF1F6F1C57C52B9B56F399F3EE9E8" xlink:to="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3FEEF1F6F1C57C52B9B56F399F3EE9E8" xlink:to="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_EEE8EDBC1130D2FBC8626F399F3ECDDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C" xlink:to="loc_country_US_EEE8EDBC1130D2FBC8626F399F3ECDDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_E685D50E9D3D9924C8256F399F3FC02D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C" xlink:to="loc_srt_EuropeMember_E685D50E9D3D9924C8256F399F3FC02D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AsiaMember" xlink:label="loc_srt_AsiaMember_C7A53B77D1E59F0C741B6F399F3F2785" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C" xlink:to="loc_srt_AsiaMember_C7A53B77D1E59F0C741B6F399F3F2785" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C" xlink:to="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D1B5425077D93882D2736F399F3F5AEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:to="loc_us-gaap_Revenues_D1B5425077D93882D2736F399F3F5AEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_0771042926CD2840EBA56F399F40E8DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE" xlink:to="loc_us-gaap_NoncurrentAssets_0771042926CD2840EBA56F399F40E8DA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C04A8E1B7BB78C31E29A6F399CEEA4CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373" xlink:to="loc_srt_StatementGeographicalAxis_C04A8E1B7BB78C31E29A6F399CEEA4CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_367F80542D5DF762E0CC6F399CEE2D0C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_C04A8E1B7BB78C31E29A6F399CEEA4CD" xlink:to="loc_srt_SegmentGeographicalDomain_367F80542D5DF762E0CC6F399CEE2D0C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_367F80542D5DF762E0CC6F399CEE2D0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_C04A8E1B7BB78C31E29A6F399CEEA4CD" xlink:to="loc_srt_SegmentGeographicalDomain_367F80542D5DF762E0CC6F399CEE2D0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_337CB376827C283DAC946F399CEF8D95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_367F80542D5DF762E0CC6F399CEE2D0C" xlink:to="loc_biib_SolothurnMember_337CB376827C283DAC946F399CEF8D95" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DK" xlink:label="loc_country_DK_8EC6ED8A58D8C5E7388C6F399CEFCCE2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_367F80542D5DF762E0CC6F399CEE2D0C" xlink:to="loc_country_DK_8EC6ED8A58D8C5E7388C6F399CEFCCE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_BD66FF12412E140067436F399CF0EF77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F" xlink:to="loc_us-gaap_NoncurrentAssets_BD66FF12412E140067436F399CF0EF77" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A8233584663BB4503E41FCF51E230D13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A8233584663BB4503E41FCF51E230D13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80B751A859FF79ADC357FCF51E233758_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A8233584663BB4503E41FCF51E230D13" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80B751A859FF79ADC357FCF51E233758_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80B751A859FF79ADC357FCF51E233758" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A8233584663BB4503E41FCF51E230D13" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80B751A859FF79ADC357FCF51E233758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09850FB7E0803DA9F158FCF51E237CA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80B751A859FF79ADC357FCF51E233758" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09850FB7E0803DA9F158FCF51E237CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_876A8DF836F496DF39BBFCF51E24A959" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80B751A859FF79ADC357FCF51E233758" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_876A8DF836F496DF39BBFCF51E24A959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_AA84C4FFB04E19862F01FCF51E2480A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80B751A859FF79ADC357FCF51E233758" xlink:to="loc_us-gaap_ParentMember_AA84C4FFB04E19862F01FCF51E2480A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0D19BA83033FBB264F41FCF51E2591CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0D19BA83033FBB264F41FCF51E2591CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5A012E23C12280B99B9AFCF51E254C58" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5A012E23C12280B99B9AFCF51E254C58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07606E2A130856CD8293FCF51E2520D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07606E2A130856CD8293FCF51E2520D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_02969091478B2CD04385FCF51E25BE14" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_02969091478B2CD04385FCF51E25BE14" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_035C892B48C6642EF3D7EBFB62DD8780" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4F942A9C4E635196CAF9EBFB62D9E851" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_035C892B48C6642EF3D7EBFB62DD8780" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4F942A9C4E635196CAF9EBFB62D9E851" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_251858CEF1ADBB4E70CEEBFB62D97248" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4F942A9C4E635196CAF9EBFB62D9E851" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_251858CEF1ADBB4E70CEEBFB62D97248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_628534270ACBFF79B151EBFB62D939AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_251858CEF1ADBB4E70CEEBFB62D97248" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_628534270ACBFF79B151EBFB62D939AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_628534270ACBFF79B151EBFB62D939AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_251858CEF1ADBB4E70CEEBFB62D97248" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_628534270ACBFF79B151EBFB62D939AF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_7D2D1F8194003A3B3B63EBFB62DAEC47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_628534270ACBFF79B151EBFB62D939AF" xlink:to="loc_biib_NightstarMember_7D2D1F8194003A3B3B63EBFB62DAEC47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_43317E6CCB234A782AA5EBFB62DAA57C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4F942A9C4E635196CAF9EBFB62D9E851" xlink:to="loc_us-gaap_AwardTypeAxis_43317E6CCB234A782AA5EBFB62DAA57C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E63F50E90C666A3AFD2FEBFB62DA4FEC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_43317E6CCB234A782AA5EBFB62DAA57C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E63F50E90C666A3AFD2FEBFB62DA4FEC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E63F50E90C666A3AFD2FEBFB62DA4FEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_43317E6CCB234A782AA5EBFB62DAA57C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E63F50E90C666A3AFD2FEBFB62DA4FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_560B7138D11AA0C7F08BEBFB62DAE7A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E63F50E90C666A3AFD2FEBFB62DA4FEC" xlink:to="loc_us-gaap_EmployeeStockOptionMember_560B7138D11AA0C7F08BEBFB62DAE7A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2FC8E91EF5D282C9D036EBFB62DBE20F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4F942A9C4E635196CAF9EBFB62D9E851" xlink:to="loc_us-gaap_PlanNameAxis_2FC8E91EF5D282C9D036EBFB62DBE20F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2FC8E91EF5D282C9D036EBFB62DBE20F" xlink:to="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2FC8E91EF5D282C9D036EBFB62DBE20F" xlink:to="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_D2F7A39FEB0C56CA9780EBFB62DBCA69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_MarketStockUnitsMember_D2F7A39FEB0C56CA9780EBFB62DBCA69" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_0E6F55073595924690D7EBFB62DCA083" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_0E6F55073595924690D7EBFB62DCA083" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_DD1294171CF6594D1973EBFB62DC3E12" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_CashSettledPerformanceSharesMember_DD1294171CF6594D1973EBFB62DC3E12" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceUnitsMember" xlink:label="loc_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_FB9D183B048C2CE234CCEBFB62DC9F28" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_FB9D183B048C2CE234CCEBFB62DC9F28" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_ADB5B8BE811D000B0B80EBFB62DC04F9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_ADB5B8BE811D000B0B80EBFB62DC04F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_035C892B48C6642EF3D7EBFB62DD8780" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E28F7804B5897EF8EF20EBFB62DDCD3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_E28F7804B5897EF8EF20EBFB62DDCD3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_66FF5A9CFDFFE068CD8AEBFB62DDFEAA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_66FF5A9CFDFFE068CD8AEBFB62DDFEAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_52A2C43DBA9E7A626B3EEBFB62DDF9FE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_52A2C43DBA9E7A626B3EEBFB62DDF9FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BF8DA39D8AE39664FF83EBFB62DEED6E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BF8DA39D8AE39664FF83EBFB62DEED6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_6BAD343434EEFAF12F15EBFB62DE2784" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_6BAD343434EEFAF12F15EBFB62DE2784" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C4817071974FEC64C1CF6F399CE05030" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C697FCAB33F9A3A5B86F399CDF10C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C4817071974FEC64C1CF6F399CE05030" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C697FCAB33F9A3A5B86F399CDF10C4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_27C19EFD1DA1025832136F399CDF4029" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C697FCAB33F9A3A5B86F399CDF10C4" xlink:to="loc_us-gaap_AwardTypeAxis_27C19EFD1DA1025832136F399CDF4029" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03C3C86DBEB0415294936F399CDFE111_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_27C19EFD1DA1025832136F399CDF4029" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03C3C86DBEB0415294936F399CDFE111_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03C3C86DBEB0415294936F399CDFE111" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_27C19EFD1DA1025832136F399CDF4029" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03C3C86DBEB0415294936F399CDFE111" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_5FA34A7F0A5F8E4C527C6F399CE03E08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03C3C86DBEB0415294936F399CDFE111" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_5FA34A7F0A5F8E4C527C6F399CE03E08" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C4817071974FEC64C1CF6F399CE05030" xlink:to="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_72B0B4DE47EFB8D7A7886F399CE1A3CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_72B0B4DE47EFB8D7A7886F399CE1A3CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10FE2FC376B9CF8307776F399CE1BFD7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10FE2FC376B9CF8307776F399CE1BFD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2E11807333DE71E23DF56F399CE1F6D7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2E11807333DE71E23DF56F399CE1F6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3A3ECA430C263533B9076F399CE13BF1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3A3ECA430C263533B9076F399CE13BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CCFE25F1066202CF092C6F399CE13D75" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CCFE25F1066202CF092C6F399CE13D75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9AFE370C27E7DA6435E86F399CE1CE0B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9AFE370C27E7DA6435E86F399CE1CE0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D59B2E339EE72E01486D6F399CE2618C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D59B2E339EE72E01486D6F399CE2618C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_87174E48CC0CE7F7BD586F399CE2F6D8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_87174E48CC0CE7F7BD586F399CE2F6D8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589" xlink:to="loc_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B" xlink:to="loc_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B" xlink:to="loc_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9" xlink:to="loc_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5E3B3FBC385F751614936F399DDCC3BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5E3B3FBC385F751614936F399DDCC3BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_BC50E7CA1E8BFF841DFD6F399DDC5231" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_BC50E7CA1E8BFF841DFD6F399DDC5231" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36954BFC78290CE1DA6B6F399F110D4D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8FA0138D82DA4C75F9236F399F10BC03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36954BFC78290CE1DA6B6F399F110D4D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8FA0138D82DA4C75F9236F399F10BC03" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_653302EF6DEA9DC239166F399F1135CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8FA0138D82DA4C75F9236F399F10BC03" xlink:to="loc_us-gaap_AwardTypeAxis_653302EF6DEA9DC239166F399F1135CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E33537A7FB2333A8FA206F399F111558_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_653302EF6DEA9DC239166F399F1135CA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E33537A7FB2333A8FA206F399F111558_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E33537A7FB2333A8FA206F399F111558" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_653302EF6DEA9DC239166F399F1135CA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E33537A7FB2333A8FA206F399F111558" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_F8FE76FB6BB498E0AF8A6F399F1109CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E33537A7FB2333A8FA206F399F111558" xlink:to="loc_biib_MarketStockUnitsMember_F8FE76FB6BB498E0AF8A6F399F1109CD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36954BFC78290CE1DA6B6F399F110D4D" xlink:to="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_778DE6C7AC5E44599D836F399F120532" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_778DE6C7AC5E44599D836F399F120532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_392FB96822B8C39A92326F399F124A6D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_392FB96822B8C39A92326F399F124A6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FFABCB7E4B25A4E55C9C6F399F12F751" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FFABCB7E4B25A4E55C9C6F399F12F751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D2AE943DB82E96B28FDC6F399F130BB9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D2AE943DB82E96B28FDC6F399F130BB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3D39BC0D77FE407B5CC56F399F133371" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3D39BC0D77FE407B5CC56F399F133371" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FD345F9027BAD8911CA16F399F1327EB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FD345F9027BAD8911CA16F399F1327EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_55B1E51C3227F830E6916F399F13FDDE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_55B1E51C3227F830E6916F399F13FDDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_234FBE3030EC388EA4256F399F13BBAC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_234FBE3030EC388EA4256F399F13BBAC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9A20F5433DE4FC6049F56F399F48B269" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909E30A6906B96EE03C46F399F4545B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9A20F5433DE4FC6049F56F399F48B269" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909E30A6906B96EE03C46F399F4545B5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6E8BADF445B47809FDE46F399F46B87E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909E30A6906B96EE03C46F399F4545B5" xlink:to="loc_us-gaap_AwardTypeAxis_6E8BADF445B47809FDE46F399F46B87E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91103A31601B88EDA5256F399F463DFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6E8BADF445B47809FDE46F399F46B87E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91103A31601B88EDA5256F399F463DFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91103A31601B88EDA5256F399F463DFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6E8BADF445B47809FDE46F399F46B87E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91103A31601B88EDA5256F399F463DFE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_3A9481D9FFE4819A6B076F399F464268" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91103A31601B88EDA5256F399F463DFE" xlink:to="loc_biib_MarketStockUnitsMember_3A9481D9FFE4819A6B076F399F464268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_95B26ABFBD60E4C45D816F399F47A8FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909E30A6906B96EE03C46F399F4545B5" xlink:to="loc_srt_RangeAxis_95B26ABFBD60E4C45D816F399F47A8FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_45E0F996DC59783E57CD6F399F47C643_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_95B26ABFBD60E4C45D816F399F47A8FF" xlink:to="loc_srt_RangeMember_45E0F996DC59783E57CD6F399F47C643_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_45E0F996DC59783E57CD6F399F47C643" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_95B26ABFBD60E4C45D816F399F47A8FF" xlink:to="loc_srt_RangeMember_45E0F996DC59783E57CD6F399F47C643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_97014AC760D84319BF186F399F475DB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45E0F996DC59783E57CD6F399F47C643" xlink:to="loc_srt_MinimumMember_97014AC760D84319BF186F399F475DB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_09E122FBF45BC208DA116F399F48EEA5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45E0F996DC59783E57CD6F399F47C643" xlink:to="loc_srt_MaximumMember_09E122FBF45BC208DA116F399F48EEA5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9A20F5433DE4FC6049F56F399F48B269" xlink:to="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EE21EC35B5BE075CE1186F399F48E5F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EE21EC35B5BE075CE1186F399F48E5F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953332ED30B5BAB67D4D6F399F487A17" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953332ED30B5BAB67D4D6F399F487A17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_F52CCF3033F6D9E26B506F399F498059" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_F52CCF3033F6D9E26B506F399F498059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8573CB215B62DE9053F56F399F49D5D5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8573CB215B62DE9053F56F399F49D5D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA47FCC44D96F04470086F399F499A9A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA47FCC44D96F04470086F399F499A9A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D" xlink:to="loc_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C" xlink:to="loc_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B" xlink:to="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_809F3E9C09005A14D4026F39A0150319" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_809F3E9C09005A14D4026F39A0150319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92D43A6D19A4FB44B7756F39A016005D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92D43A6D19A4FB44B7756F39A016005D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_208F535582AF2B14A23C6F39A016921C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_208F535582AF2B14A23C6F39A016921C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A70C66F7461AFCA554DF6F39A016E5EE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A70C66F7461AFCA554DF6F39A016E5EE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722AA941CA197C25C1776F399BDAC022" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722AA941CA197C25C1776F399BDAC022" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E206DA9898D34AABBE616F399BDABA76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722AA941CA197C25C1776F399BDAC022" xlink:to="loc_us-gaap_AwardTypeAxis_E206DA9898D34AABBE616F399BDABA76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4CB03B67026F42581A6F399BDA7B83_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_E206DA9898D34AABBE616F399BDABA76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4CB03B67026F42581A6F399BDA7B83_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4CB03B67026F42581A6F399BDA7B83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_E206DA9898D34AABBE616F399BDABA76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4CB03B67026F42581A6F399BDA7B83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_8107BB91A8790397FBF36F399BDA0112" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4CB03B67026F42581A6F399BDA7B83" xlink:to="loc_us-gaap_PerformanceSharesMember_8107BB91A8790397FBF36F399BDA0112" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_86A5DF7601E45E288ABE6F399BDB8986" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_86A5DF7601E45E288ABE6F399BDB8986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_795B4EC0DB3DB5EA184E6F399BDBD116" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_795B4EC0DB3DB5EA184E6F399BDBD116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A2ED4FB1B0BD46D214C86F399BDCBA85" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A2ED4FB1B0BD46D214C86F399BDCBA85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_DE1FB3D08900938B038C6F399BDC61E7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_DE1FB3D08900938B038C6F399BDC61E7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81586881E5EED6DFA03D6F399FC0F828" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4FB5A032FD0EF90755DB6F399FBEDD47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81586881E5EED6DFA03D6F399FC0F828" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4FB5A032FD0EF90755DB6F399FBEDD47" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_F87065B028AC9B0ED97B6F399FBF1806" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4FB5A032FD0EF90755DB6F399FBEDD47" xlink:to="loc_us-gaap_PlanNameAxis_F87065B028AC9B0ED97B6F399FBF1806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_73A9C353D5CF9501FC766F399FBF1D0D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_F87065B028AC9B0ED97B6F399FBF1806" xlink:to="loc_us-gaap_PlanNameDomain_73A9C353D5CF9501FC766F399FBF1D0D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_73A9C353D5CF9501FC766F399FBF1D0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_F87065B028AC9B0ED97B6F399FBF1806" xlink:to="loc_us-gaap_PlanNameDomain_73A9C353D5CF9501FC766F399FBF1D0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_73A9C353D5CF9501FC766F399FBF1D0D" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D9DE04525233E438C87D6F399FBF9B2B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4FB5A032FD0EF90755DB6F399FBEDD47" xlink:to="loc_us-gaap_AwardTypeAxis_D9DE04525233E438C87D6F399FBF9B2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20A6E5BEDD9D7955D0116F399FC0CAD5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_D9DE04525233E438C87D6F399FBF9B2B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20A6E5BEDD9D7955D0116F399FC0CAD5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20A6E5BEDD9D7955D0116F399FC0CAD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_D9DE04525233E438C87D6F399FBF9B2B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20A6E5BEDD9D7955D0116F399FC0CAD5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_BE410A1CA2B64C4A5CEF6F399FC0843C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20A6E5BEDD9D7955D0116F399FC0CAD5" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_BE410A1CA2B64C4A5CEF6F399FC0843C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockAbstract" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81586881E5EED6DFA03D6F399FC0F828" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_76EFD4B4C1CC5F75E1CA6F399FC185FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_76EFD4B4C1CC5F75E1CA6F399FC185FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4683940800E0621383A46F399FC1B20E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4683940800E0621383A46F399FC1B20E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4765706D1FF791853EDB6F399FC1A448" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4765706D1FF791853EDB6F399FC1A448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93FE0045BC5DC2CE747E6F399FC11F1D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93FE0045BC5DC2CE747E6F399FC11F1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_71C4E284A492A78AB2826F399FC1983B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_71C4E284A492A78AB2826F399FC1983B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0F916F64ED215EE134436F399FC2AB8E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0F916F64ED215EE134436F399FC2AB8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C51D6EC97F76676820776F399FC2EFC1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C51D6EC97F76676820776F399FC2EFC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_B1F621C44549F22B322B6F399FC23021" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_B1F621C44549F22B322B6F399FC23021" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C15B703BBB0EEA6FC29FCF51DDEB247" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D31FF48EF75F04E2F56AFCF51DDD71DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C15B703BBB0EEA6FC29FCF51DDEB247" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D31FF48EF75F04E2F56AFCF51DDD71DE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D8EE457C620444DB1DA2FCF51DDDD88F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D31FF48EF75F04E2F56AFCF51DDD71DE" xlink:to="loc_us-gaap_AwardTypeAxis_D8EE457C620444DB1DA2FCF51DDDD88F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85A38C2366BB4BDF2D9BFCF51DDD099A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_D8EE457C620444DB1DA2FCF51DDDD88F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85A38C2366BB4BDF2D9BFCF51DDD099A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85A38C2366BB4BDF2D9BFCF51DDD099A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_D8EE457C620444DB1DA2FCF51DDDD88F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85A38C2366BB4BDF2D9BFCF51DDD099A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_B8DE1274A6D2F91F9FBFFCF51DDE1FDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85A38C2366BB4BDF2D9BFCF51DDD099A" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_B8DE1274A6D2F91F9FBFFCF51DDE1FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_FAA24562CE11903C7A01FCF51DDED423" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C15B703BBB0EEA6FC29FCF51DDEB247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_FAA24562CE11903C7A01FCF51DDED423" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinCashAbstract" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C15B703BBB0EEA6FC29FCF51DDEB247" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1CE62FB52743225D32A7FCF51DDF7EDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1CE62FB52743225D32A7FCF51DDF7EDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2EB4B52BAB1236DF6958FCF51DDF65E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2EB4B52BAB1236DF6958FCF51DDF65E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2CC9015285BF0D478FC8FCF51DDF60D1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2CC9015285BF0D478FC8FCF51DDF60D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_797283BA7DFE3C20F793FCF51DDFDB21" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_797283BA7DFE3C20F793FCF51DDFDB21" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15AE3AD67F81B8677BBF6F399CB3D937" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15AE3AD67F81B8677BBF6F399CB3D937" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_F30043A7043B6A7532C66F399CB43991" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15AE3AD67F81B8677BBF6F399CB3D937" xlink:to="loc_us-gaap_PlanNameAxis_F30043A7043B6A7532C66F399CB43991" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C3ADDB4E2321444B54896F399CB48CD3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_F30043A7043B6A7532C66F399CB43991" xlink:to="loc_us-gaap_PlanNameDomain_C3ADDB4E2321444B54896F399CB48CD3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C3ADDB4E2321444B54896F399CB48CD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_F30043A7043B6A7532C66F399CB43991" xlink:to="loc_us-gaap_PlanNameDomain_C3ADDB4E2321444B54896F399CB48CD3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_C3ADDB4E2321444B54896F399CB48CD3" xlink:to="loc_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2017OmnibusEquityPlanMember" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_C3ADDB4E2321444B54896F399CB48CD3" xlink:to="loc_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15AE3AD67F81B8677BBF6F399CB3D937" xlink:to="loc_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_D5679BB9E8FDAE6073F66F399CB65B2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7" xlink:to="loc_srt_DirectorMember_D5679BB9E8FDAE6073F66F399CB65B2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_06BBAC47295BB93BBEE46F399CB61F87" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15AE3AD67F81B8677BBF6F399CB3D937" xlink:to="loc_us-gaap_AwardTypeAxis_06BBAC47295BB93BBEE46F399CB61F87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_06BBAC47295BB93BBEE46F399CB61F87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_06BBAC47295BB93BBEE46F399CB61F87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:to="loc_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_DD6261A2FD2B951E02A96F399CB7492F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:to="loc_biib_CashSettledPerformanceSharesMember_DD6261A2FD2B951E02A96F399CB7492F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_B14C84DD0BBE836C0C976F399CB73FAE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:to="loc_us-gaap_PerformanceSharesMember_B14C84DD0BBE836C0C976F399CB73FAE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_401A947C6216047A94196F399CB7EFF2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_401A947C6216047A94196F399CB7EFF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9B442170D6ADA2962D526F399CB90B95" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9B442170D6ADA2962D526F399CB90B95" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D29A534A0E624B1077726F399CB9FEE7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D29A534A0E624B1077726F399CB9FEE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_BE566431A83556CF0E276F399CBAA094" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_BE566431A83556CF0E276F399CBAA094" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_3737AB3168DFB7789A596F399CBA8932" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_3737AB3168DFB7789A596F399CBA8932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D06C31F5CC7E1C229C876F399CBA1FCE" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D06C31F5CC7E1C229C876F399CBA1FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3B7E4C063E8A352794016F399CBA0B48" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3B7E4C063E8A352794016F399CBA0B48" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_684B2DC1AD4CD55CF822E873ACBFDBC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_684B2DC1AD4CD55CF822E873ACBFDBC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_684B2DC1AD4CD55CF822E873ACBFDBC9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_684B2DC1AD4CD55CF822E873ACBFDBC9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_F4D288B4B1A43000F3FAE873ACBFA68F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_F4D288B4B1A43000F3FAE873ACBFA68F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_0B59C31C4B1624180C72E873ACBF95F1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_0B59C31C4B1624180C72E873ACBF95F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_9E3E12E3A5F83F590EE9E873ACBF7245" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_9E3E12E3A5F83F590EE9E873ACBF7245" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_6F606FE313D40F115BFDE873ACBFD257" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_6F606FE313D40F115BFDE873ACBFD257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A" xlink:to="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A" xlink:to="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_330C83B2708A80F90B60E873ACBF1BE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_330C83B2708A80F90B60E873ACBF1BE2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:to="loc_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:to="loc_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B249F38F6F8C1AAB32A5E873ACBF939C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_B249F38F6F8C1AAB32A5E873ACBF939C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3543452836150D58EB25E873ACBF3BF0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3543452836150D58EB25E873ACBF3BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_F246D26C20FE24AED397E873ACBF353A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_F246D26C20FE24AED397E873ACBF353A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_081E5CFDB3E3BB203849E873ACBF8A2C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_081E5CFDB3E3BB203849E873ACBF8A2C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:to="loc_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0600A8CA17EF6AA08B3A0B3C1F98D102" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0600A8CA17EF6AA08B3A0B3C1F98D102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1B68D8F3062D30573B290B3C1F996FC4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0600A8CA17EF6AA08B3A0B3C1F98D102" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1B68D8F3062D30573B290B3C1F996FC4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1B68D8F3062D30573B290B3C1F996FC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0600A8CA17EF6AA08B3A0B3C1F98D102" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1B68D8F3062D30573B290B3C1F996FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_D377C98BAC4FBC7B7A780B3C1F990C98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1B68D8F3062D30573B290B3C1F996FC4" xlink:to="loc_us-gaap_SubsequentEventMember_D377C98BAC4FBC7B7A780B3C1F990C98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_6F69E6E720D43D00AFEC0B3C1F99DFD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_6F69E6E720D43D00AFEC0B3C1F99DFD9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D038CE6DB4F4A306F86A0B3C1F9A37AC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D038CE6DB4F4A306F86A0B3C1F9A37AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_40E4E3D2AD58C14B06F80B3C1F9AD701" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_40E4E3D2AD58C14B06F80B3C1F9AD701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_8323D2F58B34123CCAC90B9E5C870E8B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:to="loc_us-gaap_LineOfCreditFacilityDescription_8323D2F58B34123CCAC90B9E5C870E8B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18620954367782881F59FC2463CCC0F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18620954367782881F59FC2463CCC0F5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7EA1D7D2954F04EB8C80FC2463C543B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7EA1D7D2954F04EB8C80FC2463C543B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_6518FECAEBFCA3BF6091FC2463C6F2CD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7EA1D7D2954F04EB8C80FC2463C543B9" xlink:to="loc_us-gaap_AccountingGuidanceMember_6518FECAEBFCA3BF6091FC2463C6F2CD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_6518FECAEBFCA3BF6091FC2463C6F2CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7EA1D7D2954F04EB8C80FC2463C543B9" xlink:to="loc_us-gaap_AccountingGuidanceMember_6518FECAEBFCA3BF6091FC2463C6F2CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_6382394C48D005E35F06FC2463C649F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_6518FECAEBFCA3BF6091FC2463C6F2CD" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_6382394C48D005E35F06FC2463C649F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6584138A2E4F73F3DBCDFC2463C85268" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6584138A2E4F73F3DBCDFC2463C85268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_DC013624B43C8B5B4254FC2463C83316_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6584138A2E4F73F3DBCDFC2463C85268" xlink:to="loc_us-gaap_TypeOfAdoptionMember_DC013624B43C8B5B4254FC2463C83316_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_DC013624B43C8B5B4254FC2463C83316" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6584138A2E4F73F3DBCDFC2463C85268" xlink:to="loc_us-gaap_TypeOfAdoptionMember_DC013624B43C8B5B4254FC2463C83316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_26C41B6798609932D3A9FC295782A3E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_DC013624B43C8B5B4254FC2463C83316" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_26C41B6798609932D3A9FC295782A3E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_39DD9BDADD3DE50B717FFC2463C86B48" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_39DD9BDADD3DE50B717FFC2463C86B48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_39DD9BDADD3DE50B717FFC2463C86B48" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_39DD9BDADD3DE50B717FFC2463C86B48" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxChargesMember" xlink:label="loc_us-gaap_DeferredIncomeTaxChargesMember_38801FA6779059BE369EFC29C976C572" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E" xlink:to="loc_us-gaap_DeferredIncomeTaxChargesMember_38801FA6779059BE369EFC29C976C572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7962E335CA31AB7E4636FC2463C90113" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E" xlink:to="loc_us-gaap_RetainedEarningsMember_7962E335CA31AB7E4636FC2463C90113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4907D5F9C11B165735F8FC2463C98F37" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4907D5F9C11B165735F8FC2463C98F37" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_2B95E7685E00E1126997FC2463C94051" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E" xlink:to="loc_biib_DeferredtaxliabilityMember_2B95E7685E00E1126997FC2463C94051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_74DF322FF6949C6CC062FC2463CABBB3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:to="loc_srt_RangeAxis_74DF322FF6949C6CC062FC2463CABBB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BCDF88C3BFF3FB93CC27FC2463CA1E23_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_74DF322FF6949C6CC062FC2463CABBB3" xlink:to="loc_srt_RangeMember_BCDF88C3BFF3FB93CC27FC2463CA1E23_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BCDF88C3BFF3FB93CC27FC2463CA1E23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_74DF322FF6949C6CC062FC2463CABBB3" xlink:to="loc_srt_RangeMember_BCDF88C3BFF3FB93CC27FC2463CA1E23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9BD6F1A705A91073745CFC2463CADF2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BCDF88C3BFF3FB93CC27FC2463CA1E23" xlink:to="loc_srt_MinimumMember_9BD6F1A705A91073745CFC2463CADF2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_B04F75BF7681365F09F8FC2463CAE253" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BCDF88C3BFF3FB93CC27FC2463CA1E23" xlink:to="loc_srt_MaximumMember_B04F75BF7681365F09F8FC2463CAE253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D49B6C630E37721B6C46FC2463CAA1A5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D49B6C630E37721B6C46FC2463CAA1A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D49B6C630E37721B6C46FC2463CAA1A5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D49B6C630E37721B6C46FC2463CAA1A5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_C9AF6D3D4720BEEDC857FC2463CBAABA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E" xlink:to="loc_us-gaap_BuildingMember_C9AF6D3D4720BEEDC857FC2463CBAABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_A7ADD691BE2BD5A8BF7BFC2463CB9FE2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_A7ADD691BE2BD5A8BF7BFC2463CB9FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_8F703BC3EB2075922078FC2463CB831D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_8F703BC3EB2075922078FC2463CB831D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_CCC4150870D79D48D434FC2463CBA20C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E" xlink:to="loc_us-gaap_ComputerEquipmentMember_CCC4150870D79D48D434FC2463CBA20C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8789096846115C885EECFC24C6E7F738" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18620954367782881F59FC2463CCC0F5" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8789096846115C885EECFC24C6E7F738" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_B67759E26A14E49A1B66FC2463CC3616" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18620954367782881F59FC2463CCC0F5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_B67759E26A14E49A1B66FC2463CC3616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_DF5844490077E1334C5DFC2463CC1962" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18620954367782881F59FC2463CCC0F5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_DF5844490077E1334C5DFC2463CC1962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_12F45B96C4950EC16621FC2463CCC907" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18620954367782881F59FC2463CCC0F5" xlink:to="loc_us-gaap_OperatingLeaseLiability_12F45B96C4950EC16621FC2463CCC907" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>biib-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_E5D424CB8592A485B9976F399E5FDA64_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_E5D424CB8592A485B9976F399E5FDA64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E5D424CB8592A485B9976F399E5FDA64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E5D424CB8592A485B9976F399E5FDA64" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_E5D424CB8592A485B9976F399E5FDA64" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51AD544315CA1E7532C26F399E5F8801_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51AD544315CA1E7532C26F399E5F8801" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51AD544315CA1E7532C26F399E5F8801_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51AD544315CA1E7532C26F399E5F8801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51AD544315CA1E7532C26F399E5F8801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51AD544315CA1E7532C26F399E5F8801" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51AD544315CA1E7532C26F399E5F8801" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8E5F7B3C49B8C654F7137F76C6A0178B_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8E5F7B3C49B8C654F7137F76C6A0178B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8E5F7B3C49B8C654F7137F76C6A0178B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8E5F7B3C49B8C654F7137F76C6A0178B" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8E5F7B3C49B8C654F7137F76C6A0178B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:to="lab_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8" xlink:to="lab_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701" xlink:to="lab_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument Risk [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_F7143801E83BC5B123EB7F76C6A0DE9C_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_F7143801E83BC5B123EB7F76C6A0DE9C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_F7143801E83BC5B123EB7F76C6A0DE9C_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_F7143801E83BC5B123EB7F76C6A0DE9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_F7143801E83BC5B123EB7F76C6A0DE9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_F7143801E83BC5B123EB7F76C6A0DE9C" xlink:to="lab_us-gaap_ForeignExchangeContractMember_F7143801E83BC5B123EB7F76C6A0DE9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_7FD49F6F171BAE669FB37F76C6A0F189_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_7FD49F6F171BAE669FB37F76C6A0F189" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_7FD49F6F171BAE669FB37F76C6A0F189_label_en-US" xlink:label="lab_us-gaap_SalesMember_7FD49F6F171BAE669FB37F76C6A0F189" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_7FD49F6F171BAE669FB37F76C6A0F189" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_7FD49F6F171BAE669FB37F76C6A0F189" xlink:to="lab_us-gaap_SalesMember_7FD49F6F171BAE669FB37F76C6A0F189" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_D9CF03CF35B366E3338A7F76C6A0BDBD_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_D9CF03CF35B366E3338A7F76C6A0BDBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_D9CF03CF35B366E3338A7F76C6A0BDBD_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_D9CF03CF35B366E3338A7F76C6A0BDBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_D9CF03CF35B366E3338A7F76C6A0BDBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_D9CF03CF35B366E3338A7F76C6A0BDBD" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_D9CF03CF35B366E3338A7F76C6A0BDBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_F8D065D1277BBF1B838D7F76C6A0308D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_F8D065D1277BBF1B838D7F76C6A0308D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_F8D065D1277BBF1B838D7F76C6A0308D_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_F8D065D1277BBF1B838D7F76C6A0308D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_F8D065D1277BBF1B838D7F76C6A0308D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_F8D065D1277BBF1B838D7F76C6A0308D" xlink:to="lab_us-gaap_OperatingExpenseMember_F8D065D1277BBF1B838D7F76C6A0308D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_39FCD8D0CBEECF3556BD7F76C6A041ED_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_39FCD8D0CBEECF3556BD7F76C6A041ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in operating income for the settlement of certain effective cash flow hedge instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_39FCD8D0CBEECF3556BD7F76C6A041ED_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_39FCD8D0CBEECF3556BD7F76C6A041ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_39FCD8D0CBEECF3556BD7F76C6A041ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_39FCD8D0CBEECF3556BD7F76C6A041ED" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_39FCD8D0CBEECF3556BD7F76C6A041ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_43F17C9C58440E46239E7F76C6A09471_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_43F17C9C58440E46239E7F76C6A09471" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in net income of foreign currency forward contracts, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_43F17C9C58440E46239E7F76C6A09471_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_43F17C9C58440E46239E7F76C6A09471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_43F17C9C58440E46239E7F76C6A09471" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_43F17C9C58440E46239E7F76C6A09471" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_43F17C9C58440E46239E7F76C6A09471" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_FA32B8BEE1F82ADC1C8D80C3141D21A6_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract_FA32B8BEE1F82ADC1C8D80C3141D21A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_FA32B8BEE1F82ADC1C8D80C3141D21A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_FA32B8BEE1F82ADC1C8D80C3141D21A6" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract_FA32B8BEE1F82ADC1C8D80C3141D21A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B" xlink:to="lab_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:to="lab_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_20B3E02BFDDBEBCC0B4C80C3141E94A4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_20B3E02BFDDBEBCC0B4C80C3141E94A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_20B3E02BFDDBEBCC0B4C80C3141E94A4_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_20B3E02BFDDBEBCC0B4C80C3141E94A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_20B3E02BFDDBEBCC0B4C80C3141E94A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_20B3E02BFDDBEBCC0B4C80C3141E94A4" xlink:to="lab_us-gaap_ProductAndServiceOtherMember_20B3E02BFDDBEBCC0B4C80C3141E94A4" xlink:type="arc" />
    <link:label id="lab_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34" xlink:to="lab_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45" xlink:to="lab_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8" xlink:to="lab_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8" xlink:type="arc" />
    <link:label id="lab_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392_terseLabel_en-US" xlink:label="lab_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392_label_en-US" xlink:label="lab_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:label id="lab_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392_documentation_en-US" xlink:label="lab_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392" xlink:to="lab_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392" xlink:type="arc" />
    <link:label id="lab_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8_terseLabel_en-US" xlink:label="lab_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Distributor [Axis]</link:label>
    <link:label id="lab_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8_label_en-US" xlink:label="lab_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Distributor [Axis]</link:label>
    <link:label id="lab_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8_documentation_en-US" xlink:label="lab_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Distributor.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:to="lab_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:type="arc" />
    <link:label id="lab_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8_terseLabel_en-US" xlink:label="lab_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Distributor [Domain]</link:label>
    <link:label id="lab_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8_label_en-US" xlink:label="lab_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Distributor [Domain]</link:label>
    <link:label id="lab_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8_documentation_en-US" xlink:label="lab_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Distributor.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:to="lab_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0_label_en-US" xlink:label="lab_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0_documentation_en-US" xlink:label="lab_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0" xlink:to="lab_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671_label_en-US" xlink:label="lab_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671" xlink:to="lab_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_AF1812CB9C3FE3BF328380C31420B708_netLabel_en-US" xlink:label="lab_us-gaap_Revenues_AF1812CB9C3FE3BF328380C31420B708" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_AF1812CB9C3FE3BF328380C31420B708_label_en-US" xlink:label="lab_us-gaap_Revenues_AF1812CB9C3FE3BF328380C31420B708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_AF1812CB9C3FE3BF328380C31420B708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_AF1812CB9C3FE3BF328380C31420B708" xlink:to="lab_us-gaap_Revenues_AF1812CB9C3FE3BF328380C31420B708" xlink:type="arc" />
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenue from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2" xlink:type="arc" />
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53_terseLabel_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage receivables of wholesale distributor accounted in consolidated receivables</link:label>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53_label_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Receivables Of Wholesale Distributor Accounted In Consolidated Receivables</link:label>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53_documentation_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage receivables of wholesale distributor accounted in consolidated receivables.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53" xlink:to="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8_terseLabel_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues In Percentage From Anti-CD20 Therapeutic Programs</link:label>
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8_label_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues In Percentage From Anti-CD20 Therapeutic Programs</link:label>
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8_documentation_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues In Percentage From Anti-CD20 Therapeutic Programs</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8" xlink:to="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_D4ED0827FDF08CFFD20980C31421396D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_D4ED0827FDF08CFFD20980C31421396D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_D4ED0827FDF08CFFD20980C31421396D_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_D4ED0827FDF08CFFD20980C31421396D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_D4ED0827FDF08CFFD20980C31421396D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_D4ED0827FDF08CFFD20980C31421396D" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_D4ED0827FDF08CFFD20980C31421396D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_1762CED55F54D54327A06F399DA07436_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_1762CED55F54D54327A06F399DA07436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1762CED55F54D54327A06F399DA07436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1762CED55F54D54327A06F399DA07436" xlink:to="lab_us-gaap_SubsequentEventsAbstract_1762CED55F54D54327A06F399DA07436" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_9AF030FC4A362F4209A36F399DA10E4B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_9AF030FC4A362F4209A36F399DA10E4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_9AF030FC4A362F4209A36F399DA10E4B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_9AF030FC4A362F4209A36F399DA10E4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_9AF030FC4A362F4209A36F399DA10E4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_9AF030FC4A362F4209A36F399DA10E4B" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_9AF030FC4A362F4209A36F399DA10E4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D630E832D5746276EB2280C31396DD86_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D630E832D5746276EB2280C31396DD86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D630E832D5746276EB2280C31396DD86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D630E832D5746276EB2280C31396DD86" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D630E832D5746276EB2280C31396DD86" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_A86B848BA8CE6132F7FF80C313967A17_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_A86B848BA8CE6132F7FF80C313967A17" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_A86B848BA8CE6132F7FF80C313967A17_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_A86B848BA8CE6132F7FF80C313967A17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_A86B848BA8CE6132F7FF80C313967A17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_A86B848BA8CE6132F7FF80C313967A17" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_A86B848BA8CE6132F7FF80C313967A17" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8A267B1EB322E2D2E10780C31396DC11_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8A267B1EB322E2D2E10780C31396DC11" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8A267B1EB322E2D2E10780C31396DC11_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8A267B1EB322E2D2E10780C31396DC11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8A267B1EB322E2D2E10780C31396DC11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8A267B1EB322E2D2E10780C31396DC11" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8A267B1EB322E2D2E10780C31396DC11" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_34DA635D2A3944A1756380C313979CBF_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_34DA635D2A3944A1756380C313979CBF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_34DA635D2A3944A1756380C313979CBF_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_34DA635D2A3944A1756380C313979CBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_34DA635D2A3944A1756380C313979CBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_34DA635D2A3944A1756380C313979CBF" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_34DA635D2A3944A1756380C313979CBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3D3A3FD5827FC8DA0D7280C31397EF83_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3D3A3FD5827FC8DA0D7280C31397EF83" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3D3A3FD5827FC8DA0D7280C31397EF83_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3D3A3FD5827FC8DA0D7280C31397EF83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3D3A3FD5827FC8DA0D7280C31397EF83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3D3A3FD5827FC8DA0D7280C31397EF83" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3D3A3FD5827FC8DA0D7280C31397EF83" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_6D4B0F62DA8C6EF21BB180C313979C73_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_6D4B0F62DA8C6EF21BB180C313979C73" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, Estimated Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_6D4B0F62DA8C6EF21BB180C313979C73_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_6D4B0F62DA8C6EF21BB180C313979C73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_6D4B0F62DA8C6EF21BB180C313979C73_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_6D4B0F62DA8C6EF21BB180C313979C73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_6D4B0F62DA8C6EF21BB180C313979C73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_6D4B0F62DA8C6EF21BB180C313979C73" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_6D4B0F62DA8C6EF21BB180C313979C73" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_637A2CC10198BD3DD63780C313970E52_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_637A2CC10198BD3DD63780C313970E52" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_637A2CC10198BD3DD63780C313970E52_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_637A2CC10198BD3DD63780C313970E52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_637A2CC10198BD3DD63780C313970E52_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_637A2CC10198BD3DD63780C313970E52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_637A2CC10198BD3DD63780C313970E52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_637A2CC10198BD3DD63780C313970E52" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_637A2CC10198BD3DD63780C313970E52" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1B1E8F5FE5FD7A20197580C313978686_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1B1E8F5FE5FD7A20197580C313978686" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1B1E8F5FE5FD7A20197580C313978686_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1B1E8F5FE5FD7A20197580C313978686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1B1E8F5FE5FD7A20197580C313978686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1B1E8F5FE5FD7A20197580C313978686" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1B1E8F5FE5FD7A20197580C313978686" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7B920EFE2E812202CAFD80C31397F2FA_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7B920EFE2E812202CAFD80C31397F2FA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7B920EFE2E812202CAFD80C31397F2FA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7B920EFE2E812202CAFD80C31397F2FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7B920EFE2E812202CAFD80C31397F2FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7B920EFE2E812202CAFD80C31397F2FA" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7B920EFE2E812202CAFD80C31397F2FA" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614_verboseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_B71AFAE27DBDDFF3B6C87F76C69015CF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_B71AFAE27DBDDFF3B6C87F76C69015CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B71AFAE27DBDDFF3B6C87F76C69015CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B71AFAE27DBDDFF3B6C87F76C69015CF" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_B71AFAE27DBDDFF3B6C87F76C69015CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_3E6205DF1A52677B47A87F76C6A038B7_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_3E6205DF1A52677B47A87F76C6A038B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedge</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_3E6205DF1A52677B47A87F76C6A038B7_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_3E6205DF1A52677B47A87F76C6A038B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_3E6205DF1A52677B47A87F76C6A038B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember_3E6205DF1A52677B47A87F76C6A038B7" xlink:to="lab_us-gaap_NetInvestmentHedgingMember_3E6205DF1A52677B47A87F76C6A038B7" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis, ownership percentage before additional purchase transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_FB0030892F62A131B32F7F76C6A08AED_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_FB0030892F62A131B32F7F76C6A08AED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_FB0030892F62A131B32F7F76C6A08AED_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_FB0030892F62A131B32F7F76C6A08AED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_FB0030892F62A131B32F7F76C6A08AED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_FB0030892F62A131B32F7F76C6A08AED" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_FB0030892F62A131B32F7F76C6A08AED" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_7CDA26968851201A7C007F76C6A033AE_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_7CDA26968851201A7C007F76C6A033AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to increase investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_7CDA26968851201A7C007F76C6A033AE_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_7CDA26968851201A7C007F76C6A033AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7CDA26968851201A7C007F76C6A033AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7CDA26968851201A7C007F76C6A033AE" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_7CDA26968851201A7C007F76C6A033AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeTermOfContract_99BE826E7C45D4A6BCEC7F76C6A00943_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_99BE826E7C45D4A6BCEC7F76C6A00943" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward contracts duration</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_99BE826E7C45D4A6BCEC7F76C6A00943_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_99BE826E7C45D4A6BCEC7F76C6A00943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_99BE826E7C45D4A6BCEC7F76C6A00943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract_99BE826E7C45D4A6BCEC7F76C6A00943" xlink:to="lab_us-gaap_DerivativeTermOfContract_99BE826E7C45D4A6BCEC7F76C6A00943" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_BDF6744AB5B6C371FA4E7F76C6A015F4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_BDF6744AB5B6C371FA4E7F76C6A015F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on net investment hedge in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_BDF6744AB5B6C371FA4E7F76C6A015F4_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_BDF6744AB5B6C371FA4E7F76C6A015F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_BDF6744AB5B6C371FA4E7F76C6A015F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_BDF6744AB5B6C371FA4E7F76C6A015F4" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_BDF6744AB5B6C371FA4E7F76C6A015F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_BBFB57BFF247A49314E67FEAC476EC4C_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_BBFB57BFF247A49314E67FEAC476EC4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative qualifying as hedge, excluded component, after tax</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_BBFB57BFF247A49314E67FEAC476EC4C_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_BBFB57BFF247A49314E67FEAC476EC4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_BBFB57BFF247A49314E67FEAC476EC4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_BBFB57BFF247A49314E67FEAC476EC4C" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_BBFB57BFF247A49314E67FEAC476EC4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_14EEC61E0822B099E5797FEDB19A4E0C_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_14EEC61E0822B099E5797FEDB19A4E0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_14EEC61E0822B099E5797FEDB19A4E0C_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_14EEC61E0822B099E5797FEDB19A4E0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_14EEC61E0822B099E5797FEDB19A4E0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_14EEC61E0822B099E5797FEDB19A4E0C" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_14EEC61E0822B099E5797FEDB19A4E0C" xlink:type="arc" />
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7BAEA7140F8ACB5BE13A6F399DA37087_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7BAEA7140F8ACB5BE13A6F399DA37087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7BAEA7140F8ACB5BE13A6F399DA37087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7BAEA7140F8ACB5BE13A6F399DA37087" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7BAEA7140F8ACB5BE13A6F399DA37087" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1B5D70B6C124F91D8AD56F399DA34E15_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1B5D70B6C124F91D8AD56F399DA34E15" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1B5D70B6C124F91D8AD56F399DA34E15_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1B5D70B6C124F91D8AD56F399DA34E15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1B5D70B6C124F91D8AD56F399DA34E15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1B5D70B6C124F91D8AD56F399DA34E15" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1B5D70B6C124F91D8AD56F399DA34E15" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1" xlink:to="lab_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:to="lab_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:type="arc" />
    <link:label id="lab_country_US_FF0D5E65AA014DDDEABDE873428B4061_terseLabel_en-US" xlink:label="lab_country_US_FF0D5E65AA014DDDEABDE873428B4061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S</link:label>
    <link:label id="lab_country_US_FF0D5E65AA014DDDEABDE873428B4061_label_en-US" xlink:label="lab_country_US_FF0D5E65AA014DDDEABDE873428B4061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_FF0D5E65AA014DDDEABDE873428B4061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_FF0D5E65AA014DDDEABDE873428B4061" xlink:to="lab_country_US_FF0D5E65AA014DDDEABDE873428B4061" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_9F0E61B82C7F54701087E873428C6AA2_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_9F0E61B82C7F54701087E873428C6AA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_us-gaap_NonUsMember_9F0E61B82C7F54701087E873428C6AA2_label_en-US" xlink:label="lab_us-gaap_NonUsMember_9F0E61B82C7F54701087E873428C6AA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_9F0E61B82C7F54701087E873428C6AA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_9F0E61B82C7F54701087E873428C6AA2" xlink:to="lab_us-gaap_NonUsMember_9F0E61B82C7F54701087E873428C6AA2" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4_label_en-US" xlink:label="lab_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4_documentation_en-US" xlink:label="lab_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4" xlink:to="lab_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4" xlink:type="arc" />
    <link:label id="lab_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE_terseLabel_en-US" xlink:label="lab_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE_label_en-US" xlink:label="lab_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE_documentation_en-US" xlink:label="lab_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE" xlink:to="lab_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA_label_en-US" xlink:label="lab_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA" xlink:to="lab_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA" xlink:type="arc" />
    <link:label id="lab_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC_terseLabel_en-US" xlink:label="lab_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VUMERITY</link:label>
    <link:label id="lab_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC_label_en-US" xlink:label="lab_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VUMERITY [Member]</link:label>
    <link:label id="lab_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC_documentation_en-US" xlink:label="lab_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VUMERITY [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_VUMERITYMember" xlink:label="loc_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC" xlink:to="lab_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC" xlink:type="arc" />
    <link:label id="lab_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230_label_en-US" xlink:label="lab_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230" xlink:to="lab_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD" xlink:to="lab_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD" xlink:type="arc" />
    <link:label id="lab_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194" xlink:to="lab_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194" xlink:type="arc" />
    <link:label id="lab_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E_label_en-US" xlink:label="lab_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E" xlink:to="lab_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E" xlink:type="arc" />
    <link:label id="lab_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F_label_en-US" xlink:label="lab_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F_documentation_en-US" xlink:label="lab_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F" xlink:to="lab_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F" xlink:type="arc" />
    <link:label id="lab_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B_label_en-US" xlink:label="lab_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B_documentation_en-US" xlink:label="lab_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B" xlink:to="lab_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B" xlink:type="arc" />
    <link:label id="lab_biib_IMRALDIMember_947586215250769E2F8BE873428E258F_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember_947586215250769E2F8BE873428E258F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_947586215250769E2F8BE873428E258F_label_en-US" xlink:label="lab_biib_IMRALDIMember_947586215250769E2F8BE873428E258F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_947586215250769E2F8BE873428E258F_documentation_en-US" xlink:label="lab_biib_IMRALDIMember_947586215250769E2F8BE873428E258F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_947586215250769E2F8BE873428E258F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember_947586215250769E2F8BE873428E258F" xlink:to="lab_biib_IMRALDIMember_947586215250769E2F8BE873428E258F" xlink:type="arc" />
    <link:label id="lab_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5_label_en-US" xlink:label="lab_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5" xlink:to="lab_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5" xlink:type="arc" />
    <link:label id="lab_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F_label_en-US" xlink:label="lab_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F_documentation_en-US" xlink:label="lab_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F" xlink:to="lab_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F" xlink:type="arc" />
    <link:label id="lab_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E_terseLabel_en-US" xlink:label="lab_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ELOCTATE</link:label>
    <link:label id="lab_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E_label_en-US" xlink:label="lab_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:label id="lab_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E_documentation_en-US" xlink:label="lab_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E" xlink:to="lab_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E" xlink:type="arc" />
    <link:label id="lab_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6_terseLabel_en-US" xlink:label="lab_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALPROLIX</link:label>
    <link:label id="lab_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6_label_en-US" xlink:label="lab_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALPROLIX [Member]</link:label>
    <link:label id="lab_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6_documentation_en-US" xlink:label="lab_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ALPROLIX [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6" xlink:to="lab_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6" xlink:type="arc" />
    <link:label id="lab_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C_terseLabel_en-US" xlink:label="lab_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia Products</link:label>
    <link:label id="lab_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C_label_en-US" xlink:label="lab_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hemophilia Products [Member]</link:label>
    <link:label id="lab_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C_documentation_en-US" xlink:label="lab_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hemophilia Products</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C" xlink:to="lab_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_BC6D8D0E389CCD20070CE873428FD90D_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_BC6D8D0E389CCD20070CE873428FD90D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_BC6D8D0E389CCD20070CE873428FD90D_label_en-US" xlink:label="lab_us-gaap_ProductMember_BC6D8D0E389CCD20070CE873428FD90D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_BC6D8D0E389CCD20070CE873428FD90D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_BC6D8D0E389CCD20070CE873428FD90D" xlink:to="lab_us-gaap_ProductMember_BC6D8D0E389CCD20070CE873428FD90D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_F1B2B553AFA1D3264F3DE873428FB615_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_F1B2B553AFA1D3264F3DE873428FB615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F1B2B553AFA1D3264F3DE873428FB615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_F1B2B553AFA1D3264F3DE873428FB615" xlink:to="lab_us-gaap_Revenues_F1B2B553AFA1D3264F3DE873428FB615" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowHedgingMember_E8936D94F20BCDB64EB1FD18A113E297_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_E8936D94F20BCDB64EB1FD18A113E297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedge</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_E8936D94F20BCDB64EB1FD18A113E297_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_E8936D94F20BCDB64EB1FD18A113E297" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_E8936D94F20BCDB64EB1FD18A113E297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember_E8936D94F20BCDB64EB1FD18A113E297" xlink:to="lab_us-gaap_CashFlowHedgingMember_E8936D94F20BCDB64EB1FD18A113E297" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueHedgingMember_47673DA298D702070E1CFD1C05396984_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember_47673DA298D702070E1CFD1C05396984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hedge</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_47673DA298D702070E1CFD1C05396984_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember_47673DA298D702070E1CFD1C05396984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_47673DA298D702070E1CFD1C05396984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember_47673DA298D702070E1CFD1C05396984" xlink:to="lab_us-gaap_FairValueHedgingMember_47673DA298D702070E1CFD1C05396984" xlink:type="arc" />
    <link:label id="lab_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831_label_en-US" xlink:label="lab_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831" xlink:to="lab_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:to="lab_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:type="arc" />
    <link:label id="lab_currency_EUR_014E7BBE8633CA0EAF3CFCF51EDC643B_verboseLabel_en-US" xlink:label="lab_currency_EUR_014E7BBE8633CA0EAF3CFCF51EDC643B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_014E7BBE8633CA0EAF3CFCF51EDC643B_label_en-US" xlink:label="lab_currency_EUR_014E7BBE8633CA0EAF3CFCF51EDC643B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_014E7BBE8633CA0EAF3CFCF51EDC643B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_014E7BBE8633CA0EAF3CFCF51EDC643B" xlink:to="lab_currency_EUR_014E7BBE8633CA0EAF3CFCF51EDC643B" xlink:type="arc" />
    <link:label id="lab_currency_GBP_E63FE173CD98770E57CBFCF51EDC1331_terseLabel_en-US" xlink:label="lab_currency_GBP_E63FE173CD98770E57CBFCF51EDC1331" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound sterling</link:label>
    <link:label id="lab_currency_GBP_E63FE173CD98770E57CBFCF51EDC1331_label_en-US" xlink:label="lab_currency_GBP_E63FE173CD98770E57CBFCF51EDC1331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_E63FE173CD98770E57CBFCF51EDC1331" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_E63FE173CD98770E57CBFCF51EDC1331" xlink:to="lab_currency_GBP_E63FE173CD98770E57CBFCF51EDC1331" xlink:type="arc" />
    <link:label id="lab_currency_CHF_661B095833E0EF874A49FCF51EDC661C_terseLabel_en-US" xlink:label="lab_currency_CHF_661B095833E0EF874A49FCF51EDC661C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss francs</link:label>
    <link:label id="lab_currency_CHF_661B095833E0EF874A49FCF51EDC661C_label_en-US" xlink:label="lab_currency_CHF_661B095833E0EF874A49FCF51EDC661C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_661B095833E0EF874A49FCF51EDC661C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_661B095833E0EF874A49FCF51EDC661C" xlink:to="lab_currency_CHF_661B095833E0EF874A49FCF51EDC661C" xlink:type="arc" />
    <link:label id="lab_currency_CAD_E677BDEB8AAF39400771FCF51EDDC84A_verboseLabel_en-US" xlink:label="lab_currency_CAD_E677BDEB8AAF39400771FCF51EDDC84A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_E677BDEB8AAF39400771FCF51EDDC84A_label_en-US" xlink:label="lab_currency_CAD_E677BDEB8AAF39400771FCF51EDDC84A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_E677BDEB8AAF39400771FCF51EDDC84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_E677BDEB8AAF39400771FCF51EDDC84A" xlink:to="lab_currency_CAD_E677BDEB8AAF39400771FCF51EDDC84A" xlink:type="arc" />
    <link:label id="lab_currency_JPY_F79C256AB33910A52E4DFCF51EDDE183_terseLabel_en-US" xlink:label="lab_currency_JPY_F79C256AB33910A52E4DFCF51EDDE183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_F79C256AB33910A52E4DFCF51EDDE183_label_en-US" xlink:label="lab_currency_JPY_F79C256AB33910A52E4DFCF51EDDE183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_F79C256AB33910A52E4DFCF51EDDE183" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY_F79C256AB33910A52E4DFCF51EDDE183" xlink:to="lab_currency_JPY_F79C256AB33910A52E4DFCF51EDDE183" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_2A52826E1666B86FB9EAFCF51EDE0FC4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_2A52826E1666B86FB9EAFCF51EDE0FC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_2A52826E1666B86FB9EAFCF51EDE0FC4_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_2A52826E1666B86FB9EAFCF51EDE0FC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_2A52826E1666B86FB9EAFCF51EDE0FC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_2A52826E1666B86FB9EAFCF51EDE0FC4" xlink:to="lab_us-gaap_InterestRateSwapMember_2A52826E1666B86FB9EAFCF51EDE0FC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_6AB22CD1F508566098E1FCF51EDE8EFE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_6AB22CD1F508566098E1FCF51EDE8EFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_6AB22CD1F508566098E1FCF51EDE8EFE_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_6AB22CD1F508566098E1FCF51EDE8EFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_6AB22CD1F508566098E1FCF51EDE8EFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_6AB22CD1F508566098E1FCF51EDE8EFE" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_6AB22CD1F508566098E1FCF51EDE8EFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_6FBA81798B549164DB04FCF51EDFF9C5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_6FBA81798B549164DB04FCF51EDFF9C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_6FBA81798B549164DB04FCF51EDFF9C5_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_6FBA81798B549164DB04FCF51EDFF9C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_6FBA81798B549164DB04FCF51EDFF9C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_6FBA81798B549164DB04FCF51EDFF9C5" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_6FBA81798B549164DB04FCF51EDFF9C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9268C4C0875B50CD57CCFCF51EDF3DC9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9268C4C0875B50CD57CCFCF51EDF3DC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9268C4C0875B50CD57CCFCF51EDF3DC9_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9268C4C0875B50CD57CCFCF51EDF3DC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9268C4C0875B50CD57CCFCF51EDF3DC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9268C4C0875B50CD57CCFCF51EDF3DC9" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9268C4C0875B50CD57CCFCF51EDF3DC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB" xlink:to="lab_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:to="lab_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_BD5AE0DFF3DC5565DE58FD06B3E33926_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_BD5AE0DFF3DC5565DE58FD06B3E33926" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_BD5AE0DFF3DC5565DE58FD06B3E33926_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_BD5AE0DFF3DC5565DE58FD06B3E33926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_BD5AE0DFF3DC5565DE58FD06B3E33926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_BD5AE0DFF3DC5565DE58FD06B3E33926" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_BD5AE0DFF3DC5565DE58FD06B3E33926" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_3948356665010DCDA2B6FCF51EE07FDB_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_3948356665010DCDA2B6FCF51EE07FDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_3948356665010DCDA2B6FCF51EE07FDB_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_3948356665010DCDA2B6FCF51EE07FDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_3948356665010DCDA2B6FCF51EE07FDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_3948356665010DCDA2B6FCF51EE07FDB" xlink:to="lab_us-gaap_NondesignatedMember_3948356665010DCDA2B6FCF51EE07FDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_B9A54997FB803079A8EBFD217CD1E0E7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount_B9A54997FB803079A8EBFD217CD1E0E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_B9A54997FB803079A8EBFD217CD1E0E7_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount_B9A54997FB803079A8EBFD217CD1E0E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_B9A54997FB803079A8EBFD217CD1E0E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount_B9A54997FB803079A8EBFD217CD1E0E7" xlink:to="lab_us-gaap_DerivativeNotionalAmount_B9A54997FB803079A8EBFD217CD1E0E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_47D6640545E2E5025D0AFCF51EE1DD57_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_47D6640545E2E5025D0AFCF51EE1DD57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_47D6640545E2E5025D0AFCF51EE1DD57_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_47D6640545E2E5025D0AFCF51EE1DD57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_47D6640545E2E5025D0AFCF51EE1DD57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_47D6640545E2E5025D0AFCF51EE1DD57" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_47D6640545E2E5025D0AFCF51EE1DD57" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_95EDAA1E76883AF40471FCF51EE1AD38_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_95EDAA1E76883AF40471FCF51EE1AD38" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_95EDAA1E76883AF40471FCF51EE1AD38_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_95EDAA1E76883AF40471FCF51EE1AD38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_95EDAA1E76883AF40471FCF51EE1AD38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_95EDAA1E76883AF40471FCF51EE1AD38" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_95EDAA1E76883AF40471FCF51EE1AD38" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89EA1E07CC59DA67195AEBFB60DA95BF_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89EA1E07CC59DA67195AEBFB60DA95BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89EA1E07CC59DA67195AEBFB60DA95BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89EA1E07CC59DA67195AEBFB60DA95BF" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89EA1E07CC59DA67195AEBFB60DA95BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_357C2EE3DC202BA3EBEEEBFB60DA561B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_357C2EE3DC202BA3EBEEEBFB60DA561B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under non-cancelable leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_357C2EE3DC202BA3EBEEEBFB60DA561B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_357C2EE3DC202BA3EBEEEBFB60DA561B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_357C2EE3DC202BA3EBEEEBFB60DA561B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_357C2EE3DC202BA3EBEEEBFB60DA561B" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_357C2EE3DC202BA3EBEEEBFB60DA561B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_80A023CDF9764605FB826F399D7BF1F6_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_80A023CDF9764605FB826F399D7BF1F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_80A023CDF9764605FB826F399D7BF1F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_80A023CDF9764605FB826F399D7BF1F6" xlink:to="lab_us-gaap_DebtDisclosureAbstract_80A023CDF9764605FB826F399D7BF1F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_C07B0F77D3C1C36811E16F399D7BE830_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_C07B0F77D3C1C36811E16F399D7BE830" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_C07B0F77D3C1C36811E16F399D7BE830_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_C07B0F77D3C1C36811E16F399D7BE830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_C07B0F77D3C1C36811E16F399D7BE830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_C07B0F77D3C1C36811E16F399D7BE830" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_C07B0F77D3C1C36811E16F399D7BE830" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6D782341AEEA9511DE326F39A00DF6D9_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6D782341AEEA9511DE326F39A00DF6D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6D782341AEEA9511DE326F39A00DF6D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6D782341AEEA9511DE326F39A00DF6D9" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6D782341AEEA9511DE326F39A00DF6D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_56D574BC3F1FC826ACC76F39A00D5575_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_56D574BC3F1FC826ACC76F39A00D5575" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_56D574BC3F1FC826ACC76F39A00D5575_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_56D574BC3F1FC826ACC76F39A00D5575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_56D574BC3F1FC826ACC76F39A00D5575" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_56D574BC3F1FC826ACC76F39A00D5575" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_56D574BC3F1FC826ACC76F39A00D5575" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_991CB63B197596250C7B6F399DB2DBAA_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_991CB63B197596250C7B6F399DB2DBAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_991CB63B197596250C7B6F399DB2DBAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_991CB63B197596250C7B6F399DB2DBAA" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_991CB63B197596250C7B6F399DB2DBAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_76D8608020FC274AFCA36F399DB216D4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_76D8608020FC274AFCA36F399DB216D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_76D8608020FC274AFCA36F399DB216D4_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_76D8608020FC274AFCA36F399DB216D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_76D8608020FC274AFCA36F399DB216D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_76D8608020FC274AFCA36F399DB216D4" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_76D8608020FC274AFCA36F399DB216D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_465798FF027B9E3D9159F1F26A4DA91F_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_465798FF027B9E3D9159F1F26A4DA91F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_465798FF027B9E3D9159F1F26A4DA91F_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_465798FF027B9E3D9159F1F26A4DA91F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_465798FF027B9E3D9159F1F26A4DA91F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_465798FF027B9E3D9159F1F26A4DA91F" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_465798FF027B9E3D9159F1F26A4DA91F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22BA5A40DF95E34FAA02F1F26A4DC6D5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22BA5A40DF95E34FAA02F1F26A4DC6D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22BA5A40DF95E34FAA02F1F26A4DC6D5_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22BA5A40DF95E34FAA02F1F26A4DC6D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22BA5A40DF95E34FAA02F1F26A4DC6D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22BA5A40DF95E34FAA02F1F26A4DC6D5" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22BA5A40DF95E34FAA02F1F26A4DC6D5" xlink:type="arc" />
    <link:label id="lab_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC_terseLabel_en-US" xlink:label="lab_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aducanumab</link:label>
    <link:label id="lab_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC_label_en-US" xlink:label="lab_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC_documentation_en-US" xlink:label="lab_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC" xlink:to="lab_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746" xlink:to="lab_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7_label_en-US" xlink:label="lab_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7_documentation_en-US" xlink:label="lab_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7" xlink:to="lab_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements and non-collaborative arrangement transactions</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:type="arc" />
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BAN2401 and Elenbecestat R&amp;D expense incurred by collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D" xlink:to="lab_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D" xlink:type="arc" />
    <link:label id="lab_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aducanumab expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA" xlink:to="lab_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA" xlink:type="arc" />
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of expense reflected within our consolidation statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_C96E33F52FAE49F936287FFAEC8567FD_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_C96E33F52FAE49F936287FFAEC8567FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_C96E33F52FAE49F936287FFAEC8567FD_label_en-US" xlink:label="lab_us-gaap_BuildingMember_C96E33F52FAE49F936287FFAEC8567FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_C96E33F52FAE49F936287FFAEC8567FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_C96E33F52FAE49F936287FFAEC8567FD" xlink:to="lab_us-gaap_BuildingMember_C96E33F52FAE49F936287FFAEC8567FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_51C92F43A0116072DB397FFB36F0C9CE_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_51C92F43A0116072DB397FFB36F0C9CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_51C92F43A0116072DB397FFB36F0C9CE_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_51C92F43A0116072DB397FFB36F0C9CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_51C92F43A0116072DB397FFB36F0C9CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_51C92F43A0116072DB397FFB36F0C9CE" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_51C92F43A0116072DB397FFB36F0C9CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8" xlink:type="arc" />
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54_terseLabel_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54_label_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54_documentation_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54" xlink:to="lab_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:to="lab_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D" xlink:to="lab_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6_terseLabel_en-US" xlink:label="lab_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn</link:label>
    <link:label id="lab_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6_label_en-US" xlink:label="lab_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn [Member]</link:label>
    <link:label id="lab_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6_documentation_en-US" xlink:label="lab_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6" xlink:to="lab_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_907D1C2AF1C36C707B5B7F76C671DCCB_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_907D1C2AF1C36C707B5B7F76C671DCCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_907D1C2AF1C36C707B5B7F76C671DCCB_label_en-US" xlink:label="lab_us-gaap_Depreciation_907D1C2AF1C36C707B5B7F76C671DCCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_907D1C2AF1C36C707B5B7F76C671DCCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_907D1C2AF1C36C707B5B7F76C671DCCB" xlink:to="lab_us-gaap_Depreciation_907D1C2AF1C36C707B5B7F76C671DCCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestCostsCapitalized_F9F1C3E4B42004EEA1327F76C671BA2F_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_F9F1C3E4B42004EEA1327F76C671BA2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_F9F1C3E4B42004EEA1327F76C671BA2F_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_F9F1C3E4B42004EEA1327F76C671BA2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_F9F1C3E4B42004EEA1327F76C671BA2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized_F9F1C3E4B42004EEA1327F76C671BA2F" xlink:to="lab_us-gaap_InterestCostsCapitalized_F9F1C3E4B42004EEA1327F76C671BA2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_FBF8572BE4CC3A94101F7F76C6717CBB_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_FBF8572BE4CC3A94101F7F76C6717CBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_FBF8572BE4CC3A94101F7F76C6717CBB_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_FBF8572BE4CC3A94101F7F76C6717CBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_FBF8572BE4CC3A94101F7F76C6717CBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_FBF8572BE4CC3A94101F7F76C6717CBB" xlink:to="lab_us-gaap_ConstructionInProgressGross_FBF8572BE4CC3A94101F7F76C6717CBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_765C96E64FF77D0080197FFAB1EFCA53_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_765C96E64FF77D0080197FFAB1EFCA53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment sold to Fujifilm</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_765C96E64FF77D0080197FFAB1EFCA53_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_765C96E64FF77D0080197FFAB1EFCA53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_765C96E64FF77D0080197FFAB1EFCA53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_765C96E64FF77D0080197FFAB1EFCA53" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_765C96E64FF77D0080197FFAB1EFCA53" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_FB3FD8DB451F8AD74AF76F399EF1E645_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_FB3FD8DB451F8AD74AF76F399EF1E645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FB3FD8DB451F8AD74AF76F399EF1E645" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FB3FD8DB451F8AD74AF76F399EF1E645" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_FB3FD8DB451F8AD74AF76F399EF1E645" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0FFEE4D83CBD5249ADB06F399EF1BD45_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0FFEE4D83CBD5249ADB06F399EF1BD45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0FFEE4D83CBD5249ADB06F399EF1BD45_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0FFEE4D83CBD5249ADB06F399EF1BD45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0FFEE4D83CBD5249ADB06F399EF1BD45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0FFEE4D83CBD5249ADB06F399EF1BD45" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0FFEE4D83CBD5249ADB06F399EF1BD45" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_10D116A8FE9E4825D5036F399E6B315A_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_10D116A8FE9E4825D5036F399E6B315A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_10D116A8FE9E4825D5036F399E6B315A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_10D116A8FE9E4825D5036F399E6B315A" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_10D116A8FE9E4825D5036F399E6B315A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_3E4796A7D6A30354B83A6F399E6B05E7_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_3E4796A7D6A30354B83A6F399E6B05E7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_3E4796A7D6A30354B83A6F399E6B05E7_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_3E4796A7D6A30354B83A6F399E6B05E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_3E4796A7D6A30354B83A6F399E6B05E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_3E4796A7D6A30354B83A6F399E6B05E7" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_3E4796A7D6A30354B83A6F399E6B05E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B5A0CE3A7F0D4A644F786F399EEC8382_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B5A0CE3A7F0D4A644F786F399EEC8382" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B5A0CE3A7F0D4A644F786F399EEC8382_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B5A0CE3A7F0D4A644F786F399EEC8382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B5A0CE3A7F0D4A644F786F399EEC8382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B5A0CE3A7F0D4A644F786F399EEC8382" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B5A0CE3A7F0D4A644F786F399EEC8382" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5E5C5827E38591C2D70F6F39A014A6D3_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5E5C5827E38591C2D70F6F39A014A6D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5E5C5827E38591C2D70F6F39A014A6D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5E5C5827E38591C2D70F6F39A014A6D3" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5E5C5827E38591C2D70F6F39A014A6D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A" xlink:to="lab_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance units</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60" xlink:to="lab_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348_verboseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Settled Performance Shares [Abstract]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:to="lab_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_809F3E9C09005A14D4026F39A0150319_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_809F3E9C09005A14D4026F39A0150319" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Unvested, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_809F3E9C09005A14D4026F39A0150319_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_809F3E9C09005A14D4026F39A0150319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_809F3E9C09005A14D4026F39A0150319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_809F3E9C09005A14D4026F39A0150319" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_809F3E9C09005A14D4026F39A0150319" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92D43A6D19A4FB44B7756F39A016005D_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92D43A6D19A4FB44B7756F39A016005D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92D43A6D19A4FB44B7756F39A016005D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92D43A6D19A4FB44B7756F39A016005D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92D43A6D19A4FB44B7756F39A016005D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92D43A6D19A4FB44B7756F39A016005D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92D43A6D19A4FB44B7756F39A016005D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_208F535582AF2B14A23C6F39A016921C_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_208F535582AF2B14A23C6F39A016921C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_208F535582AF2B14A23C6F39A016921C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_208F535582AF2B14A23C6F39A016921C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_208F535582AF2B14A23C6F39A016921C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_208F535582AF2B14A23C6F39A016921C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_208F535582AF2B14A23C6F39A016921C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A70C66F7461AFCA554DF6F39A016E5EE_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A70C66F7461AFCA554DF6F39A016E5EE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A70C66F7461AFCA554DF6F39A016E5EE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A70C66F7461AFCA554DF6F39A016E5EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A70C66F7461AFCA554DF6F39A016E5EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A70C66F7461AFCA554DF6F39A016E5EE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A70C66F7461AFCA554DF6F39A016E5EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7834DB2A29C7B53AC9DB6F39A0160FE7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7834DB2A29C7B53AC9DB6F39A0160FE7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Unvested, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7834DB2A29C7B53AC9DB6F39A0160FE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7834DB2A29C7B53AC9DB6F39A0160FE7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7834DB2A29C7B53AC9DB6F39A0160FE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_F2642BFA2069A8FE80007ED42E208053_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_F2642BFA2069A8FE80007ED42E208053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F2642BFA2069A8FE80007ED42E208053" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F2642BFA2069A8FE80007ED42E208053" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_F2642BFA2069A8FE80007ED42E208053" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:type="arc" />
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:to="lab_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:type="arc" />
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Research and development asset [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:to="lab_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:type="arc" />
    <link:label id="lab_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1_terseLabel_en-US" xlink:label="lab_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB111</link:label>
    <link:label id="lab_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1_label_en-US" xlink:label="lab_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:label id="lab_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1_documentation_en-US" xlink:label="lab_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1" xlink:to="lab_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1" xlink:type="arc" />
    <link:label id="lab_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183_terseLabel_en-US" xlink:label="lab_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB112</link:label>
    <link:label id="lab_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183_label_en-US" xlink:label="lab_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183_documentation_en-US" xlink:label="lab_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183" xlink:to="lab_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC" xlink:type="arc" />
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338_terseLabel_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338_label_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338_documentation_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338" xlink:to="lab_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7" xlink:type="arc" />
    <link:label id="lab_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F_terseLabel_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Milestones</link:label>
    <link:label id="lab_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F_label_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F_documentation_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F" xlink:to="lab_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:type="arc" />
    <link:label id="lab_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B_terseLabel_en-US" xlink:label="lab_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nightstar</link:label>
    <link:label id="lab_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B_label_en-US" xlink:label="lab_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:label id="lab_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B_documentation_en-US" xlink:label="lab_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B" xlink:to="lab_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B" xlink:type="arc" />
    <link:label id="lab_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC_terseLabel_en-US" xlink:label="lab_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Karyopharm</link:label>
    <link:label id="lab_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC_label_en-US" xlink:label="lab_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Karyopharm [Member]</link:label>
    <link:label id="lab_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC_documentation_en-US" xlink:label="lab_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Karyopharm [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC" xlink:to="lab_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC" xlink:type="arc" />
    <link:label id="lab_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0_terseLabel_en-US" xlink:label="lab_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0_label_en-US" xlink:label="lab_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0_documentation_en-US" xlink:label="lab_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0" xlink:to="lab_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0" xlink:type="arc" />
    <link:label id="lab_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5_terseLabel_en-US" xlink:label="lab_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TMS</link:label>
    <link:label id="lab_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5_label_en-US" xlink:label="lab_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TMS [Member]</link:label>
    <link:label id="lab_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5_documentation_en-US" xlink:label="lab_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TMS [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_TMSMember" xlink:label="loc_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5" xlink:to="lab_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5" xlink:type="arc" />
    <link:label id="lab_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E_terseLabel_en-US" xlink:label="lab_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AliveGen</link:label>
    <link:label id="lab_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E_label_en-US" xlink:label="lab_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AliveGen [Member]</link:label>
    <link:label id="lab_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E_documentation_en-US" xlink:label="lab_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AliveGen [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AliveGenMember" xlink:label="loc_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E" xlink:to="lab_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E" xlink:type="arc" />
    <link:label id="lab_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675_terseLabel_en-US" xlink:label="lab_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remedy Pharmaceutical</link:label>
    <link:label id="lab_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675_label_en-US" xlink:label="lab_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remedy Pharmaceutical [Member]</link:label>
    <link:label id="lab_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675_documentation_en-US" xlink:label="lab_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remedy Pharmaceutical [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675" xlink:to="lab_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_F8E07E8C4E30EB156FE57ED5BA74526D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_F8E07E8C4E30EB156FE57ED5BA74526D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_F8E07E8C4E30EB156FE57ED5BA74526D_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_F8E07E8C4E30EB156FE57ED5BA74526D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_F8E07E8C4E30EB156FE57ED5BA74526D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_F8E07E8C4E30EB156FE57ED5BA74526D" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_F8E07E8C4E30EB156FE57ED5BA74526D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_A69CD9EA7B01048CC6A67ED6538575A4_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_A69CD9EA7B01048CC6A67ED6538575A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total transaction value</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_A69CD9EA7B01048CC6A67ED6538575A4_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_A69CD9EA7B01048CC6A67ED6538575A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A69CD9EA7B01048CC6A67ED6538575A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_A69CD9EA7B01048CC6A67ED6538575A4" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_A69CD9EA7B01048CC6A67ED6538575A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_56A76BF6AF0C0080FC227ED69B9B16A1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses_56A76BF6AF0C0080FC227ED69B9B16A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for pre-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_56A76BF6AF0C0080FC227ED69B9B16A1_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses_56A76BF6AF0C0080FC227ED69B9B16A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_56A76BF6AF0C0080FC227ED69B9B16A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses_56A76BF6AF0C0080FC227ED69B9B16A1" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses_56A76BF6AF0C0080FC227ED69B9B16A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8E01BEB067C57E0A4A0E7ED82955CF01_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8E01BEB067C57E0A4A0E7ED82955CF01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair-value post-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8E01BEB067C57E0A4A0E7ED82955CF01_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8E01BEB067C57E0A4A0E7ED82955CF01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8E01BEB067C57E0A4A0E7ED82955CF01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8E01BEB067C57E0A4A0E7ED82955CF01" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8E01BEB067C57E0A4A0E7ED82955CF01" xlink:type="arc" />
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808_terseLabel_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, in-process research and development, discount rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808_label_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808_documentation_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808" xlink:to="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F2FA0FF2B4D553E12F8E7EE6FAFD8BA6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F2FA0FF2B4D553E12F8E7EE6FAFD8BA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F2FA0FF2B4D553E12F8E7EE6FAFD8BA6_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F2FA0FF2B4D553E12F8E7EE6FAFD8BA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F2FA0FF2B4D553E12F8E7EE6FAFD8BA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F2FA0FF2B4D553E12F8E7EE6FAFD8BA6" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F2FA0FF2B4D553E12F8E7EE6FAFD8BA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_E4EDEF447F00AF99A88F7EE7D6AA22C2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_E4EDEF447F00AF99A88F7EE7D6AA22C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, goodwill</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_E4EDEF447F00AF99A88F7EE7D6AA22C2_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_E4EDEF447F00AF99A88F7EE7D6AA22C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_E4EDEF447F00AF99A88F7EE7D6AA22C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_E4EDEF447F00AF99A88F7EE7D6AA22C2" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_E4EDEF447F00AF99A88F7EE7D6AA22C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_6B8B2507B4087A7A4F617ED42E283848_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_6B8B2507B4087A7A4F617ED42E283848" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_6B8B2507B4087A7A4F617ED42E283848_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_6B8B2507B4087A7A4F617ED42E283848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_6B8B2507B4087A7A4F617ED42E283848" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_6B8B2507B4087A7A4F617ED42E283848" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_6B8B2507B4087A7A4F617ED42E283848" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_12517474A7234EE10C037ED42E291BE6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_12517474A7234EE10C037ED42E291BE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense asset acquired</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_12517474A7234EE10C037ED42E291BE6_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_12517474A7234EE10C037ED42E291BE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_12517474A7234EE10C037ED42E291BE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_12517474A7234EE10C037ED42E291BE6" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_12517474A7234EE10C037ED42E291BE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_1B5C347A888440790AB7F00F392BC449_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_1B5C347A888440790AB7F00F392BC449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1B5C347A888440790AB7F00F392BC449" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1B5C347A888440790AB7F00F392BC449" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_1B5C347A888440790AB7F00F392BC449" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE" xlink:type="arc" />
    <link:label id="lab_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81_terseLabel_en-US" xlink:label="lab_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81_label_en-US" xlink:label="lab_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work-in-process [Member]</link:label>
    <link:label id="lab_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81_documentation_en-US" xlink:label="lab_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81" xlink:to="lab_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:to="lab_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:type="arc" />
    <link:label id="lab_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008_terseLabel_en-US" xlink:label="lab_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory sold to Bioverativ, cost</link:label>
    <link:label id="lab_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008_label_en-US" xlink:label="lab_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory sold to Bioverativ, cost</link:label>
    <link:label id="lab_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008_documentation_en-US" xlink:label="lab_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory sold to Bioverativ, cost</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_InventorysoldtoBioverativcost" xlink:label="loc_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008" xlink:to="lab_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2EA3D7A82980566890C8F00F392F6FAB_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2EA3D7A82980566890C8F00F392F6FAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory work-in-process sold to FUJIFILM</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2EA3D7A82980566890C8F00F392F6FAB_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2EA3D7A82980566890C8F00F392F6FAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2EA3D7A82980566890C8F00F392F6FAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2EA3D7A82980566890C8F00F392F6FAB" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2EA3D7A82980566890C8F00F392F6FAB" xlink:type="arc" />
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85_terseLabel_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85_label_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85_documentation_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85" xlink:to="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_C8630E2E95A40CB4BC40F00F392F2E1A_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_C8630E2E95A40CB4BC40F00F392F2E1A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Write-downs on excess, obsolete, unmarketable or other inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_C8630E2E95A40CB4BC40F00F392F2E1A_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_C8630E2E95A40CB4BC40F00F392F2E1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_C8630E2E95A40CB4BC40F00F392F2E1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_C8630E2E95A40CB4BC40F00F392F2E1A" xlink:to="lab_us-gaap_InventoryWriteDown_C8630E2E95A40CB4BC40F00F392F2E1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_DF533F80074DCB3D2E256F39A00F6ADB_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_DF533F80074DCB3D2E256F39A00F6ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_DF533F80074DCB3D2E256F39A00F6ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DF533F80074DCB3D2E256F39A00F6ADB" xlink:to="lab_us-gaap_EarningsPerShareAbstract_DF533F80074DCB3D2E256F39A00F6ADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7B27D76DD763055BB02A6F39A00F7D02_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_7B27D76DD763055BB02A6F39A00F7D02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7B27D76DD763055BB02A6F39A00F7D02_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_7B27D76DD763055BB02A6F39A00F7D02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7B27D76DD763055BB02A6F39A00F7D02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_7B27D76DD763055BB02A6F39A00F7D02" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_7B27D76DD763055BB02A6F39A00F7D02" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_98D987302EE33D87072E6F39A046E7C2_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_98D987302EE33D87072E6F39A046E7C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_98D987302EE33D87072E6F39A046E7C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_98D987302EE33D87072E6F39A046E7C2" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_98D987302EE33D87072E6F39A046E7C2" xlink:type="arc" />
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699" xlink:type="arc" />
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775_terseLabel_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775_label_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:to="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_C2773479C0BD87B2E34D6F39A049D44A_verboseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_C2773479C0BD87B2E34D6F39A049D44A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_C2773479C0BD87B2E34D6F39A049D44A_label_en-US" xlink:label="lab_us-gaap_GrossProfit_C2773479C0BD87B2E34D6F39A049D44A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_C2773479C0BD87B2E34D6F39A049D44A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_C2773479C0BD87B2E34D6F39A049D44A" xlink:to="lab_us-gaap_GrossProfit_C2773479C0BD87B2E34D6F39A049D44A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_542201AD023CB81F9EC46F39A0495855_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_542201AD023CB81F9EC46F39A0495855" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_542201AD023CB81F9EC46F39A0495855_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_542201AD023CB81F9EC46F39A0495855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_542201AD023CB81F9EC46F39A0495855" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_542201AD023CB81F9EC46F39A0495855" xlink:to="lab_us-gaap_ProfitLoss_542201AD023CB81F9EC46F39A0495855" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_0F2F5DBD85D9417979E56F39A049AA52_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0F2F5DBD85D9417979E56F39A049AA52" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Idec Inc</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0F2F5DBD85D9417979E56F39A049AA52_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0F2F5DBD85D9417979E56F39A049AA52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0F2F5DBD85D9417979E56F39A049AA52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_0F2F5DBD85D9417979E56F39A049AA52" xlink:to="lab_us-gaap_NetIncomeLoss_0F2F5DBD85D9417979E56F39A049AA52" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_86007CA20B54F25467C56F39A049F5F6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_86007CA20B54F25467C56F39A049F5F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_86007CA20B54F25467C56F39A049F5F6_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_86007CA20B54F25467C56F39A049F5F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_86007CA20B54F25467C56F39A049F5F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_86007CA20B54F25467C56F39A049F5F6" xlink:to="lab_us-gaap_EarningsPerShareBasic_86007CA20B54F25467C56F39A049F5F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_DFB2FF9169272A01A8376F39A0493E5A_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_DFB2FF9169272A01A8376F39A0493E5A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_DFB2FF9169272A01A8376F39A0493E5A_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_DFB2FF9169272A01A8376F39A0493E5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_DFB2FF9169272A01A8376F39A0493E5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_DFB2FF9169272A01A8376F39A0493E5A" xlink:to="lab_us-gaap_EarningsPerShareDiluted_DFB2FF9169272A01A8376F39A0493E5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_22F68EE1CB0A269B358F6F39A04AF952_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_22F68EE1CB0A269B358F6F39A04AF952" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_22F68EE1CB0A269B358F6F39A04AF952_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_22F68EE1CB0A269B358F6F39A04AF952" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_22F68EE1CB0A269B358F6F39A04AF952" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_22F68EE1CB0A269B358F6F39A04AF952" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_22F68EE1CB0A269B358F6F39A04AF952" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B4A612A5D4742E186D286F39A04ABD08_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B4A612A5D4742E186D286F39A04ABD08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B4A612A5D4742E186D286F39A04ABD08_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B4A612A5D4742E186D286F39A04ABD08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B4A612A5D4742E186D286F39A04ABD08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B4A612A5D4742E186D286F39A04ABD08" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B4A612A5D4742E186D286F39A04ABD08" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_50F58CB8CB450AA6EBA4FC3A1AA42C66_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_50F58CB8CB450AA6EBA4FC3A1AA42C66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_50F58CB8CB450AA6EBA4FC3A1AA42C66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_50F58CB8CB450AA6EBA4FC3A1AA42C66" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_50F58CB8CB450AA6EBA4FC3A1AA42C66" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A_label_en-US" xlink:label="lab_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:to="lab_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C_terseLabel_en-US" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C_label_en-US" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C" xlink:to="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Guidance [Domain]</link:label>
    <link:label id="lab_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479_label_en-US" xlink:label="lab_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Guidance [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479" xlink:to="lab_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_9F4402D13E5FDD9D700AFC3A1AA484DF_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_9F4402D13E5FDD9D700AFC3A1AA484DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_9F4402D13E5FDD9D700AFC3A1AA484DF_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_9F4402D13E5FDD9D700AFC3A1AA484DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_9F4402D13E5FDD9D700AFC3A1AA484DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member_9F4402D13E5FDD9D700AFC3A1AA484DF" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member_9F4402D13E5FDD9D700AFC3A1AA484DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:type="arc" />
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7_terseLabel_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7_label_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7_documentation_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7" xlink:to="lab_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7" xlink:type="arc" />
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2_terseLabel_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2_label_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2_documentation_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2" xlink:to="lab_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2" xlink:type="arc" />
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17_terseLabel_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17_label_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17_documentation_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17" xlink:to="lab_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17" xlink:type="arc" />
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3_terseLabel_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3_label_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3_documentation_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3" xlink:to="lab_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="lab_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_C4375E6364C2B4355E0DFC3A1AA43AB8_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_C4375E6364C2B4355E0DFC3A1AA43AB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_C4375E6364C2B4355E0DFC3A1AA43AB8_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_C4375E6364C2B4355E0DFC3A1AA43AB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_C4375E6364C2B4355E0DFC3A1AA43AB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_C4375E6364C2B4355E0DFC3A1AA43AB8" xlink:to="lab_us-gaap_PreferredStockMember_C4375E6364C2B4355E0DFC3A1AA43AB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_E7C06F9E6E7D41E7429DFC3A1AA42698_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_E7C06F9E6E7D41E7429DFC3A1AA42698" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_E7C06F9E6E7D41E7429DFC3A1AA42698_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_E7C06F9E6E7D41E7429DFC3A1AA42698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E7C06F9E6E7D41E7429DFC3A1AA42698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_E7C06F9E6E7D41E7429DFC3A1AA42698" xlink:to="lab_us-gaap_CommonStockMember_E7C06F9E6E7D41E7429DFC3A1AA42698" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_A21B83E125BDC9555F0AFC3A1AA4D068_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_A21B83E125BDC9555F0AFC3A1AA4D068" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_A21B83E125BDC9555F0AFC3A1AA4D068_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_A21B83E125BDC9555F0AFC3A1AA4D068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_A21B83E125BDC9555F0AFC3A1AA4D068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_A21B83E125BDC9555F0AFC3A1AA4D068" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_A21B83E125BDC9555F0AFC3A1AA4D068" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C46CC3C7E0D90F3BB6B8FC3A1AA47CF8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C46CC3C7E0D90F3BB6B8FC3A1AA47CF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C46CC3C7E0D90F3BB6B8FC3A1AA47CF8_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C46CC3C7E0D90F3BB6B8FC3A1AA47CF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C46CC3C7E0D90F3BB6B8FC3A1AA47CF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C46CC3C7E0D90F3BB6B8FC3A1AA47CF8" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C46CC3C7E0D90F3BB6B8FC3A1AA47CF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_04C09F95F67BD0D32151FC3A1AA41430_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_04C09F95F67BD0D32151FC3A1AA41430" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_04C09F95F67BD0D32151FC3A1AA41430_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_04C09F95F67BD0D32151FC3A1AA41430" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_04C09F95F67BD0D32151FC3A1AA41430" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_04C09F95F67BD0D32151FC3A1AA41430" xlink:to="lab_us-gaap_RetainedEarningsMember_04C09F95F67BD0D32151FC3A1AA41430" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_4ABC7EB50155A502EAECFC3A1AA41B23_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_4ABC7EB50155A502EAECFC3A1AA41B23" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_4ABC7EB50155A502EAECFC3A1AA41B23_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_4ABC7EB50155A502EAECFC3A1AA41B23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_4ABC7EB50155A502EAECFC3A1AA41B23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_4ABC7EB50155A502EAECFC3A1AA41B23" xlink:to="lab_us-gaap_TreasuryStockMember_4ABC7EB50155A502EAECFC3A1AA41B23" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_670CADE989A15E35A2D7FC3A1AA4F96A_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_670CADE989A15E35A2D7FC3A1AA4F96A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_670CADE989A15E35A2D7FC3A1AA4F96A_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_670CADE989A15E35A2D7FC3A1AA4F96A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_670CADE989A15E35A2D7FC3A1AA4F96A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_670CADE989A15E35A2D7FC3A1AA4F96A" xlink:to="lab_us-gaap_NoncontrollingInterestMember_670CADE989A15E35A2D7FC3A1AA4F96A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_5532691B3A488C1C2FF7FC3A1AA4762B_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_5532691B3A488C1C2FF7FC3A1AA4762B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_5532691B3A488C1C2FF7FC3A1AA4762B_label_en-US" xlink:label="lab_us-gaap_ParentMember_5532691B3A488C1C2FF7FC3A1AA4762B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_5532691B3A488C1C2FF7FC3A1AA4762B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_5532691B3A488C1C2FF7FC3A1AA4762B" xlink:to="lab_us-gaap_ParentMember_5532691B3A488C1C2FF7FC3A1AA4762B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="lab_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB32A3894630873F786FC3A1AB46139_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB32A3894630873F786FC3A1AB46139" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB32A3894630873F786FC3A1AB46139_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB32A3894630873F786FC3A1AB46139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB32A3894630873F786FC3A1AB46139" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB32A3894630873F786FC3A1AB46139" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB32A3894630873F786FC3A1AB46139" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_4C93207A6E5E245764E9FC3A1AB43D8D_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_4C93207A6E5E245764E9FC3A1AB43D8D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4C93207A6E5E245764E9FC3A1AB43D8D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_4C93207A6E5E245764E9FC3A1AB43D8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4C93207A6E5E245764E9FC3A1AB43D8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_4C93207A6E5E245764E9FC3A1AB43D8D" xlink:to="lab_us-gaap_StockholdersEquity_4C93207A6E5E245764E9FC3A1AB43D8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_2E15A1D4FEBC09ED6CFFFC3A1AB47067_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_2E15A1D4FEBC09ED6CFFFC3A1AB47067" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_2E15A1D4FEBC09ED6CFFFC3A1AB47067_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_2E15A1D4FEBC09ED6CFFFC3A1AB47067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_2E15A1D4FEBC09ED6CFFFC3A1AB47067" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_2E15A1D4FEBC09ED6CFFFC3A1AB47067" xlink:to="lab_us-gaap_MinorityInterest_2E15A1D4FEBC09ED6CFFFC3A1AB47067" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_B9B0262A2B43E7B66E88FC3A1AB484D0_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_B9B0262A2B43E7B66E88FC3A1AB484D0" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesIssued_B9B0262A2B43E7B66E88FC3A1AB484D0_label_en-US" xlink:label="lab_us-gaap_SharesIssued_B9B0262A2B43E7B66E88FC3A1AB484D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_B9B0262A2B43E7B66E88FC3A1AB484D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_B9B0262A2B43E7B66E88FC3A1AB484D0" xlink:to="lab_us-gaap_SharesIssued_B9B0262A2B43E7B66E88FC3A1AB484D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_4858CC1E45875A9107AEFC3A1AB4A425_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_4858CC1E45875A9107AEFC3A1AB4A425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4858CC1E45875A9107AEFC3A1AB4A425" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_4858CC1E45875A9107AEFC3A1AB4A425" xlink:to="lab_us-gaap_NetIncomeLoss_4858CC1E45875A9107AEFC3A1AB4A425" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_22888303E59B2FFF7834FC3A1AB47B99_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_22888303E59B2FFF7834FC3A1AB47B99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_22888303E59B2FFF7834FC3A1AB47B99_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_22888303E59B2FFF7834FC3A1AB47B99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_22888303E59B2FFF7834FC3A1AB47B99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_22888303E59B2FFF7834FC3A1AB47B99" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_22888303E59B2FFF7834FC3A1AB47B99" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CC568D04A9FB478026CDFC3A1AB42813_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CC568D04A9FB478026CDFC3A1AB42813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CC568D04A9FB478026CDFC3A1AB42813_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CC568D04A9FB478026CDFC3A1AB42813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CC568D04A9FB478026CDFC3A1AB42813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CC568D04A9FB478026CDFC3A1AB42813" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CC568D04A9FB478026CDFC3A1AB42813" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C5ED636AAD22A6E12521FC3A1AB40E40_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C5ED636AAD22A6E12521FC3A1AB40E40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C5ED636AAD22A6E12521FC3A1AB40E40_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C5ED636AAD22A6E12521FC3A1AB40E40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C5ED636AAD22A6E12521FC3A1AB40E40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C5ED636AAD22A6E12521FC3A1AB40E40" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C5ED636AAD22A6E12521FC3A1AB40E40" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution by noncontrolling interest</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E101F1DBE02AD2F9F07AFC3A1AB458E7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E101F1DBE02AD2F9F07AFC3A1AB458E7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Distribution to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E101F1DBE02AD2F9F07AFC3A1AB458E7_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E101F1DBE02AD2F9F07AFC3A1AB458E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E101F1DBE02AD2F9F07AFC3A1AB458E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E101F1DBE02AD2F9F07AFC3A1AB458E7" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E101F1DBE02AD2F9F07AFC3A1AB458E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_CE6D75ACCE181763AB5DFC3A1AB4B747_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_CE6D75ACCE181763AB5DFC3A1AB4B747" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_CE6D75ACCE181763AB5DFC3A1AB4B747_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_CE6D75ACCE181763AB5DFC3A1AB4B747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_CE6D75ACCE181763AB5DFC3A1AB4B747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_CE6D75ACCE181763AB5DFC3A1AB4B747" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_CE6D75ACCE181763AB5DFC3A1AB4B747" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_1B18C36EA1557B3EE622FC3A1AB4B392_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_1B18C36EA1557B3EE622FC3A1AB4B392" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_1B18C36EA1557B3EE622FC3A1AB4B392_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_1B18C36EA1557B3EE622FC3A1AB4B392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_1B18C36EA1557B3EE622FC3A1AB4B392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_1B18C36EA1557B3EE622FC3A1AB4B392" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_1B18C36EA1557B3EE622FC3A1AB4B392" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_3878C856A7FED6942C68FC3A1AB4FF0D_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_3878C856A7FED6942C68FC3A1AB4FF0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_3878C856A7FED6942C68FC3A1AB4FF0D_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_3878C856A7FED6942C68FC3A1AB4FF0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_3878C856A7FED6942C68FC3A1AB4FF0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_3878C856A7FED6942C68FC3A1AB4FF0D" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_3878C856A7FED6942C68FC3A1AB4FF0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_DACA7007DC250FBD6F6AFC3A1AB4D5C0_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_DACA7007DC250FBD6F6AFC3A1AB4D5C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_DACA7007DC250FBD6F6AFC3A1AB4D5C0_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_DACA7007DC250FBD6F6AFC3A1AB4D5C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_DACA7007DC250FBD6F6AFC3A1AB4D5C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_DACA7007DC250FBD6F6AFC3A1AB4D5C0" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_DACA7007DC250FBD6F6AFC3A1AB4D5C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECE4BE041B7411EF9D19FC3A1AB47A9D_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECE4BE041B7411EF9D19FC3A1AB47A9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECE4BE041B7411EF9D19FC3A1AB47A9D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECE4BE041B7411EF9D19FC3A1AB47A9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECE4BE041B7411EF9D19FC3A1AB47A9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECE4BE041B7411EF9D19FC3A1AB47A9D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECE4BE041B7411EF9D19FC3A1AB47A9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45AEFB62A5939A5EF084FC3A1AB4DDB1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45AEFB62A5939A5EF084FC3A1AB4DDB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock options and stock purchase plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45AEFB62A5939A5EF084FC3A1AB4DDB1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45AEFB62A5939A5EF084FC3A1AB4DDB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45AEFB62A5939A5EF084FC3A1AB4DDB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45AEFB62A5939A5EF084FC3A1AB4DDB1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45AEFB62A5939A5EF084FC3A1AB4DDB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_049478C623265A8E26A8FC3A1AB425A6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_049478C623265A8E26A8FC3A1AB425A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_049478C623265A8E26A8FC3A1AB425A6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_049478C623265A8E26A8FC3A1AB425A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_049478C623265A8E26A8FC3A1AB425A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_049478C623265A8E26A8FC3A1AB425A6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_049478C623265A8E26A8FC3A1AB425A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_719AACFB26E98D1AC2C5FC3A1AB46515_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_719AACFB26E98D1AC2C5FC3A1AB46515" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_719AACFB26E98D1AC2C5FC3A1AB46515_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_719AACFB26E98D1AC2C5FC3A1AB46515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_719AACFB26E98D1AC2C5FC3A1AB46515" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_719AACFB26E98D1AC2C5FC3A1AB46515" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_719AACFB26E98D1AC2C5FC3A1AB46515" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_86385E395690BB29072EFC3A1AB4F697_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_86385E395690BB29072EFC3A1AB4F697" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_86385E395690BB29072EFC3A1AB4F697_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_86385E395690BB29072EFC3A1AB4F697" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_86385E395690BB29072EFC3A1AB4F697" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_86385E395690BB29072EFC3A1AB4F697" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_86385E395690BB29072EFC3A1AB4F697" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityOther_323C80A1B7AE067ACDA8FC3A1AB42352_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_323C80A1B7AE067ACDA8FC3A1AB42352" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of new accounting guidance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_323C80A1B7AE067ACDA8FC3A1AB42352_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_323C80A1B7AE067ACDA8FC3A1AB42352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_323C80A1B7AE067ACDA8FC3A1AB42352" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther_323C80A1B7AE067ACDA8FC3A1AB42352" xlink:to="lab_us-gaap_StockholdersEquityOther_323C80A1B7AE067ACDA8FC3A1AB42352" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_C20D6B1759FAE3C4EB5AFC3A1AB434D2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_C20D6B1759FAE3C4EB5AFC3A1AB434D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia spin-off adjustment</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_C20D6B1759FAE3C4EB5AFC3A1AB434D2_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_C20D6B1759FAE3C4EB5AFC3A1AB434D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Spinoff Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_C20D6B1759FAE3C4EB5AFC3A1AB434D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_C20D6B1759FAE3C4EB5AFC3A1AB434D2" xlink:to="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_C20D6B1759FAE3C4EB5AFC3A1AB434D2" xlink:type="arc" />
    <link:label id="lab_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB_terseLabel_en-US" xlink:label="lab_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB_label_en-US" xlink:label="lab_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity, Tax Benefit (Expense)</link:label>
    <link:label id="lab_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB_documentation_en-US" xlink:label="lab_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders Equity, Tax Benefit (Expense)</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_StockholdersEquityTaxBenefitExpense" xlink:label="loc_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB" xlink:to="lab_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_66707D7FD5DA2096E29BFC3A1AB41812_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_66707D7FD5DA2096E29BFC3A1AB41812" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_66707D7FD5DA2096E29BFC3A1AB41812" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_66707D7FD5DA2096E29BFC3A1AB41812" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_66707D7FD5DA2096E29BFC3A1AB41812" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_AC0E5AD23A9F0F379A30FC3A1AB470AE_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_AC0E5AD23A9F0F379A30FC3A1AB470AE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_AC0E5AD23A9F0F379A30FC3A1AB470AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_AC0E5AD23A9F0F379A30FC3A1AB470AE" xlink:to="lab_us-gaap_StockholdersEquity_AC0E5AD23A9F0F379A30FC3A1AB470AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_D676A0B64131E91A66E2FC3A1AB452CB_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_D676A0B64131E91A66E2FC3A1AB452CB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_D676A0B64131E91A66E2FC3A1AB452CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_D676A0B64131E91A66E2FC3A1AB452CB" xlink:to="lab_us-gaap_MinorityInterest_D676A0B64131E91A66E2FC3A1AB452CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_AC06F04D6521DCA52999FC3A1AB46204_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_AC06F04D6521DCA52999FC3A1AB46204" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_AC06F04D6521DCA52999FC3A1AB46204" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_AC06F04D6521DCA52999FC3A1AB46204" xlink:to="lab_us-gaap_SharesIssued_AC06F04D6521DCA52999FC3A1AB46204" xlink:type="arc" />
    <link:label id="lab_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3_terseLabel_en-US" xlink:label="lab_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GAZYVA</link:label>
    <link:label id="lab_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3_label_en-US" xlink:label="lab_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:label id="lab_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3_documentation_en-US" xlink:label="lab_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3" xlink:to="lab_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3" xlink:type="arc" />
    <link:label id="lab_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC_terseLabel_en-US" xlink:label="lab_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RITUXAN</link:label>
    <link:label id="lab_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC_label_en-US" xlink:label="lab_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RITUXAN [Member]</link:label>
    <link:label id="lab_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC_documentation_en-US" xlink:label="lab_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RITUXAN.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC" xlink:to="lab_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE" xlink:to="lab_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Abstract]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:to="lab_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Until GAZYVA First Non-CLL FDA Approval</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option one.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After First GA101 Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two [Abstract]</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Until First GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option one.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After First Threshold Date and until Second Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option two.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After Second Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option three.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A_verboseLabel_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A_label_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues From Unconsolidated Joint Business [Abstract]</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A_documentation_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:to="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6_verboseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6" xlink:to="lab_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_10321BAE1D167A6CCCC1F00F36C673FE_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_10321BAE1D167A6CCCC1F00F36C673FE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_10321BAE1D167A6CCCC1F00F36C673FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_10321BAE1D167A6CCCC1F00F36C673FE" xlink:to="lab_us-gaap_Revenues_10321BAE1D167A6CCCC1F00F36C673FE" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:to="lab_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440" xlink:to="lab_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440" xlink:type="arc" />
    <link:label id="lab_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9" xlink:to="lab_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC_label_en-US" xlink:label="lab_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC" xlink:to="lab_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE_terseLabel_en-US" xlink:label="lab_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE_label_en-US" xlink:label="lab_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:to="lab_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_CDD1CF693055B98DA2B9FCF51ED0F24A_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember_CDD1CF693055B98DA2B9FCF51ED0F24A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_CDD1CF693055B98DA2B9FCF51ED0F24A_label_en-US" xlink:label="lab_srt_MinimumMember_CDD1CF693055B98DA2B9FCF51ED0F24A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_CDD1CF693055B98DA2B9FCF51ED0F24A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_CDD1CF693055B98DA2B9FCF51ED0F24A" xlink:to="lab_srt_MinimumMember_CDD1CF693055B98DA2B9FCF51ED0F24A" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_5003142FEFA747B56A16FCF51ED0D674_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember_5003142FEFA747B56A16FCF51ED0D674" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_5003142FEFA747B56A16FCF51ED0D674_label_en-US" xlink:label="lab_srt_MaximumMember_5003142FEFA747B56A16FCF51ED0D674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5003142FEFA747B56A16FCF51ED0D674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_5003142FEFA747B56A16FCF51ED0D674" xlink:to="lab_srt_MaximumMember_5003142FEFA747B56A16FCF51ED0D674" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2" xlink:to="lab_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.90% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D1CD098DC668F62AEFFFFCF51ED38001_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D1CD098DC668F62AEFFFFCF51ED38001" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D1CD098DC668F62AEFFFFCF51ED38001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D1CD098DC668F62AEFFFFCF51ED38001" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D1CD098DC668F62AEFFFFCF51ED38001" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_892C105917ABD6F23757FCF51ED3BD85_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_892C105917ABD6F23757FCF51ED3BD85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_892C105917ABD6F23757FCF51ED3BD85_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_892C105917ABD6F23757FCF51ED3BD85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_892C105917ABD6F23757FCF51ED3BD85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_892C105917ABD6F23757FCF51ED3BD85" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_892C105917ABD6F23757FCF51ED3BD85" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_76F54A915B22B31BB774FCF51ED31186_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_76F54A915B22B31BB774FCF51ED31186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_76F54A915B22B31BB774FCF51ED31186_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_76F54A915B22B31BB774FCF51ED31186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76F54A915B22B31BB774FCF51ED31186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76F54A915B22B31BB774FCF51ED31186" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_76F54A915B22B31BB774FCF51ED31186" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_BE856A7776C037A7B703FCF51ED4C9D7_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_BE856A7776C037A7B703FCF51ED4C9D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_BE856A7776C037A7B703FCF51ED4C9D7_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_BE856A7776C037A7B703FCF51ED4C9D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_BE856A7776C037A7B703FCF51ED4C9D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_BE856A7776C037A7B703FCF51ED4C9D7" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_BE856A7776C037A7B703FCF51ED4C9D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_C29BEF69BC9ED02998516F399CEE6BD3_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_C29BEF69BC9ED02998516F399CEE6BD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_C29BEF69BC9ED02998516F399CEE6BD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_C29BEF69BC9ED02998516F399CEE6BD3" xlink:to="lab_us-gaap_SegmentReportingAbstract_C29BEF69BC9ED02998516F399CEE6BD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373" xlink:type="arc" />
    <link:label id="lab_country_DK_8EC6ED8A58D8C5E7388C6F399CEFCCE2_terseLabel_en-US" xlink:label="lab_country_DK_8EC6ED8A58D8C5E7388C6F399CEFCCE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DENMARK</link:label>
    <link:label id="lab_country_DK_8EC6ED8A58D8C5E7388C6F399CEFCCE2_label_en-US" xlink:label="lab_country_DK_8EC6ED8A58D8C5E7388C6F399CEFCCE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DENMARK</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DK" xlink:label="loc_country_DK_8EC6ED8A58D8C5E7388C6F399CEFCCE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DK_8EC6ED8A58D8C5E7388C6F399CEFCCE2" xlink:to="lab_country_DK_8EC6ED8A58D8C5E7388C6F399CEFCCE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncurrentAssets_BD66FF12412E140067436F399CF0EF77_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_BD66FF12412E140067436F399CF0EF77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets related to operations in Denmark</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_BD66FF12412E140067436F399CF0EF77_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_BD66FF12412E140067436F399CF0EF77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_BD66FF12412E140067436F399CF0EF77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_BD66FF12412E140067436F399CF0EF77" xlink:to="lab_us-gaap_NoncurrentAssets_BD66FF12412E140067436F399CF0EF77" xlink:type="arc" />
    <link:label id="lab_biib_SegmentInformationTextualAbstract_222C464E3685750793946F399CF060F4_verboseLabel_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_222C464E3685750793946F399CF060F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_SegmentInformationTextualAbstract_222C464E3685750793946F399CF060F4_label_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_222C464E3685750793946F399CF060F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Information (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_SegmentInformationTextualAbstract_222C464E3685750793946F399CF060F4_documentation_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_222C464E3685750793946F399CF060F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment Information.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SegmentInformationTextualAbstract" xlink:label="loc_biib_SegmentInformationTextualAbstract_222C464E3685750793946F399CF060F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SegmentInformationTextualAbstract_222C464E3685750793946F399CF060F4" xlink:to="lab_biib_SegmentInformationTextualAbstract_222C464E3685750793946F399CF060F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_D250ED67E5009D79AD7A6F399CF0FF6F_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_D250ED67E5009D79AD7A6F399CF0FF6F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segment</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_D250ED67E5009D79AD7A6F399CF0FF6F_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_D250ED67E5009D79AD7A6F399CF0FF6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_D250ED67E5009D79AD7A6F399CF0FF6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_D250ED67E5009D79AD7A6F399CF0FF6F" xlink:to="lab_us-gaap_NumberOfReportableSegments_D250ED67E5009D79AD7A6F399CF0FF6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_26CECD6D6746F6ED8AF6800B02AEDFAE_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_26CECD6D6746F6ED8AF6800B02AEDFAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_26CECD6D6746F6ED8AF6800B02AEDFAE_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_26CECD6D6746F6ED8AF6800B02AEDFAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_26CECD6D6746F6ED8AF6800B02AEDFAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_26CECD6D6746F6ED8AF6800B02AEDFAE" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_26CECD6D6746F6ED8AF6800B02AEDFAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0544836166B8F0AA52F4800B02AEAFDB_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0544836166B8F0AA52F4800B02AEAFDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0544836166B8F0AA52F4800B02AEAFDB_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0544836166B8F0AA52F4800B02AEAFDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0544836166B8F0AA52F4800B02AEAFDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0544836166B8F0AA52F4800B02AEAFDB" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0544836166B8F0AA52F4800B02AEAFDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D06C991D88BDC7A90F15800B02AEDDAB_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D06C991D88BDC7A90F15800B02AEDDAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D06C991D88BDC7A90F15800B02AEDDAB_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D06C991D88BDC7A90F15800B02AEDDAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D06C991D88BDC7A90F15800B02AEDDAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D06C991D88BDC7A90F15800B02AEDDAB" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D06C991D88BDC7A90F15800B02AEDDAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4AB17EB915D3D820A835800B02AE8716_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4AB17EB915D3D820A835800B02AE8716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4AB17EB915D3D820A835800B02AE8716_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4AB17EB915D3D820A835800B02AE8716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4AB17EB915D3D820A835800B02AE8716" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4AB17EB915D3D820A835800B02AE8716" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4AB17EB915D3D820A835800B02AE8716" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_C5E884BFE24807858CD0800B02AE37DA_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_C5E884BFE24807858CD0800B02AE37DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_C5E884BFE24807858CD0800B02AE37DA_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_C5E884BFE24807858CD0800B02AE37DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_C5E884BFE24807858CD0800B02AE37DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_C5E884BFE24807858CD0800B02AE37DA" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_C5E884BFE24807858CD0800B02AE37DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_E000952C395A54F066A7800B02AEC2E6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_E000952C395A54F066A7800B02AEC2E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_E000952C395A54F066A7800B02AEC2E6_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_E000952C395A54F066A7800B02AEC2E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_E000952C395A54F066A7800B02AEC2E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_E000952C395A54F066A7800B02AEC2E6" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_E000952C395A54F066A7800B02AEC2E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_A4401F71A679A67D6B6E800B02AEE415_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_A4401F71A679A67D6B6E800B02AEE415" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_A4401F71A679A67D6B6E800B02AEE415_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_A4401F71A679A67D6B6E800B02AEE415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_A4401F71A679A67D6B6E800B02AEE415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_A4401F71A679A67D6B6E800B02AEE415" xlink:to="lab_us-gaap_LongTermNotesPayable_A4401F71A679A67D6B6E800B02AEE415" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="lab_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_C6EF5871A366ACBAD91EFC3A1AF3D62E_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_C6EF5871A366ACBAD91EFC3A1AF3D62E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C6EF5871A366ACBAD91EFC3A1AF3D62E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_C6EF5871A366ACBAD91EFC3A1AF3D62E" xlink:to="lab_us-gaap_Revenues_C6EF5871A366ACBAD91EFC3A1AF3D62E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_B762688192737C811FDAFC3A1AF378C1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_B762688192737C811FDAFC3A1AF378C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_B762688192737C811FDAFC3A1AF378C1_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_B762688192737C811FDAFC3A1AF378C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_B762688192737C811FDAFC3A1AF378C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_B762688192737C811FDAFC3A1AF378C1" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_B762688192737C811FDAFC3A1AF378C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_033E3246820EAB7C5C05FC3A1AF32B7C_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_033E3246820EAB7C5C05FC3A1AF32B7C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_033E3246820EAB7C5C05FC3A1AF32B7C_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_033E3246820EAB7C5C05FC3A1AF32B7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_033E3246820EAB7C5C05FC3A1AF32B7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_033E3246820EAB7C5C05FC3A1AF32B7C" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_033E3246820EAB7C5C05FC3A1AF32B7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_73A77A9707F04B9977F2FC3A1AF3DA74_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_73A77A9707F04B9977F2FC3A1AF3DA74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_73A77A9707F04B9977F2FC3A1AF3DA74_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_73A77A9707F04B9977F2FC3A1AF3DA74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_73A77A9707F04B9977F2FC3A1AF3DA74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_73A77A9707F04B9977F2FC3A1AF3DA74" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_73A77A9707F04B9977F2FC3A1AF3DA74" xlink:type="arc" />
    <link:label id="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_DEAC7146074712F5BFC2FC3A1AF32E7E_terseLabel_en-US" xlink:label="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_DEAC7146074712F5BFC2FC3A1AF32E7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_DEAC7146074712F5BFC2FC3A1AF32E7E_label_en-US" xlink:label="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_DEAC7146074712F5BFC2FC3A1AF32E7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_DEAC7146074712F5BFC2FC3A1AF32E7E_documentation_en-US" xlink:label="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_DEAC7146074712F5BFC2FC3A1AF32E7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_DEAC7146074712F5BFC2FC3A1AF32E7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_DEAC7146074712F5BFC2FC3A1AF32E7E" xlink:to="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_DEAC7146074712F5BFC2FC3A1AF32E7E" xlink:type="arc" />
    <link:label id="lab_biib_CollaborationProfitSharing_024F2E7942C51467EBAFFC3A1AF3085B_terseLabel_en-US" xlink:label="lab_biib_CollaborationProfitSharing_024F2E7942C51467EBAFFC3A1AF3085B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharing_024F2E7942C51467EBAFFC3A1AF3085B_label_en-US" xlink:label="lab_biib_CollaborationProfitSharing_024F2E7942C51467EBAFFC3A1AF3085B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharing_024F2E7942C51467EBAFFC3A1AF3085B_documentation_en-US" xlink:label="lab_biib_CollaborationProfitSharing_024F2E7942C51467EBAFFC3A1AF3085B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_024F2E7942C51467EBAFFC3A1AF3085B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationProfitSharing_024F2E7942C51467EBAFFC3A1AF3085B" xlink:to="lab_biib_CollaborationProfitSharing_024F2E7942C51467EBAFFC3A1AF3085B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_9662E8C4F5581A5E3CB0FC3A1AF3051B_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_9662E8C4F5581A5E3CB0FC3A1AF3051B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_9662E8C4F5581A5E3CB0FC3A1AF3051B_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_9662E8C4F5581A5E3CB0FC3A1AF3051B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_9662E8C4F5581A5E3CB0FC3A1AF3051B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_9662E8C4F5581A5E3CB0FC3A1AF3051B" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_9662E8C4F5581A5E3CB0FC3A1AF3051B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4BAD0D54A2150B1EAE06FC3A1AF374DD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4BAD0D54A2150B1EAE06FC3A1AF374DD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4BAD0D54A2150B1EAE06FC3A1AF374DD_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4BAD0D54A2150B1EAE06FC3A1AF374DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4BAD0D54A2150B1EAE06FC3A1AF374DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4BAD0D54A2150B1EAE06FC3A1AF374DD" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4BAD0D54A2150B1EAE06FC3A1AF374DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_1C8015306298D9EE38F7FC3A1AF35DBB_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_1C8015306298D9EE38F7FC3A1AF35DBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_1C8015306298D9EE38F7FC3A1AF35DBB_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_1C8015306298D9EE38F7FC3A1AF35DBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1C8015306298D9EE38F7FC3A1AF35DBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_1C8015306298D9EE38F7FC3A1AF35DBB" xlink:to="lab_us-gaap_RestructuringCharges_1C8015306298D9EE38F7FC3A1AF35DBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_4A7CFE37BA5736A14AAFFC3A1AF36283_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_4A7CFE37BA5736A14AAFFC3A1AF36283" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_4A7CFE37BA5736A14AAFFC3A1AF36283_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_4A7CFE37BA5736A14AAFFC3A1AF36283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_4A7CFE37BA5736A14AAFFC3A1AF36283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_4A7CFE37BA5736A14AAFFC3A1AF36283" xlink:to="lab_us-gaap_CostsAndExpenses_4A7CFE37BA5736A14AAFFC3A1AF36283" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_32E8EF0686EB6153CA64FC3A1AF3B3B3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_32E8EF0686EB6153CA64FC3A1AF3B3B3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_32E8EF0686EB6153CA64FC3A1AF3B3B3_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_32E8EF0686EB6153CA64FC3A1AF3B3B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_32E8EF0686EB6153CA64FC3A1AF3B3B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_32E8EF0686EB6153CA64FC3A1AF3B3B3" xlink:to="lab_us-gaap_OperatingIncomeLoss_32E8EF0686EB6153CA64FC3A1AF3B3B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1A36B6B5200193CA3ED2FC3A1AF31021_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1A36B6B5200193CA3ED2FC3A1AF31021" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1A36B6B5200193CA3ED2FC3A1AF31021_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1A36B6B5200193CA3ED2FC3A1AF31021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1A36B6B5200193CA3ED2FC3A1AF31021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1A36B6B5200193CA3ED2FC3A1AF31021" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1A36B6B5200193CA3ED2FC3A1AF31021" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DAD037E1E4F0BEE9528BFC3A1AF369D3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DAD037E1E4F0BEE9528BFC3A1AF369D3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DAD037E1E4F0BEE9528BFC3A1AF369D3_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DAD037E1E4F0BEE9528BFC3A1AF369D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DAD037E1E4F0BEE9528BFC3A1AF369D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DAD037E1E4F0BEE9528BFC3A1AF369D3" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DAD037E1E4F0BEE9528BFC3A1AF369D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_A2DF3F0DBCB04C059D80FC3A1AF39DFC_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_A2DF3F0DBCB04C059D80FC3A1AF39DFC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_A2DF3F0DBCB04C059D80FC3A1AF39DFC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_A2DF3F0DBCB04C059D80FC3A1AF39DFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A2DF3F0DBCB04C059D80FC3A1AF39DFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_A2DF3F0DBCB04C059D80FC3A1AF39DFC" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_A2DF3F0DBCB04C059D80FC3A1AF39DFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_916E1D33C12079DD6BD0FC3A1AF38C1E_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_916E1D33C12079DD6BD0FC3A1AF38C1E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_916E1D33C12079DD6BD0FC3A1AF38C1E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_916E1D33C12079DD6BD0FC3A1AF38C1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_916E1D33C12079DD6BD0FC3A1AF38C1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_916E1D33C12079DD6BD0FC3A1AF38C1E" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_916E1D33C12079DD6BD0FC3A1AF38C1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_BDB5C779AA5F40F08888FC3A1AF3ADC9_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_BDB5C779AA5F40F08888FC3A1AF3ADC9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_BDB5C779AA5F40F08888FC3A1AF3ADC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_BDB5C779AA5F40F08888FC3A1AF3ADC9" xlink:to="lab_us-gaap_ProfitLoss_BDB5C779AA5F40F08888FC3A1AF3ADC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_757294C4735855C6C0CCFC3A1AF35EE0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_757294C4735855C6C0CCFC3A1AF35EE0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_757294C4735855C6C0CCFC3A1AF35EE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_757294C4735855C6C0CCFC3A1AF35EE0" xlink:to="lab_us-gaap_NetIncomeLoss_757294C4735855C6C0CCFC3A1AF35EE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_755DFD10A4775E3E26E7FC3A1AF3D677_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_755DFD10A4775E3E26E7FC3A1AF3D677" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_755DFD10A4775E3E26E7FC3A1AF3D677" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_755DFD10A4775E3E26E7FC3A1AF3D677" xlink:to="lab_us-gaap_EarningsPerShareAbstract_755DFD10A4775E3E26E7FC3A1AF3D677" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EB12AA9831F85409BCD7FC3A1AF3D5D4_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EB12AA9831F85409BCD7FC3A1AF3D5D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EB12AA9831F85409BCD7FC3A1AF3D5D4_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EB12AA9831F85409BCD7FC3A1AF3D5D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EB12AA9831F85409BCD7FC3A1AF3D5D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EB12AA9831F85409BCD7FC3A1AF3D5D4" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EB12AA9831F85409BCD7FC3A1AF3D5D4" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157_verboseLabel_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157_label_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Activity [Abstract]</link:label>
    <link:label id="lab_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157_documentation_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock option activity.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_StockOptionActivityAbstract" xlink:label="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:to="lab_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8635A0AF593385C3FE0D6F399EB10C58_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8635A0AF593385C3FE0D6F399EB10C58" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8635A0AF593385C3FE0D6F399EB10C58_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8635A0AF593385C3FE0D6F399EB10C58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8635A0AF593385C3FE0D6F399EB10C58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8635A0AF593385C3FE0D6F399EB10C58" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8635A0AF593385C3FE0D6F399EB10C58" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_617ADFE190AD798F5BB16F399EB1627F_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_617ADFE190AD798F5BB16F399EB1627F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_617ADFE190AD798F5BB16F399EB1627F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_617ADFE190AD798F5BB16F399EB1627F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_617ADFE190AD798F5BB16F399EB1627F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_617ADFE190AD798F5BB16F399EB1627F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_617ADFE190AD798F5BB16F399EB1627F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9A593C5BEE1DE32FF9F06F399EB2527D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9A593C5BEE1DE32FF9F06F399EB2527D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9A593C5BEE1DE32FF9F06F399EB2527D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9A593C5BEE1DE32FF9F06F399EB2527D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9A593C5BEE1DE32FF9F06F399EB2527D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9A593C5BEE1DE32FF9F06F399EB2527D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9A593C5BEE1DE32FF9F06F399EB2527D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3976AD88C15DA7D4D9C56F399EB2ACA1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3976AD88C15DA7D4D9C56F399EB2ACA1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3976AD88C15DA7D4D9C56F399EB2ACA1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3976AD88C15DA7D4D9C56F399EB2ACA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3976AD88C15DA7D4D9C56F399EB2ACA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3976AD88C15DA7D4D9C56F399EB2ACA1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3976AD88C15DA7D4D9C56F399EB2ACA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_528DB2782480C027FD066F399EB22FDE_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_528DB2782480C027FD066F399EB22FDE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_528DB2782480C027FD066F399EB22FDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_528DB2782480C027FD066F399EB22FDE" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_528DB2782480C027FD066F399EB22FDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2159FE4C179F854F14D76F399EB2325F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2159FE4C179F854F14D76F399EB2325F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2159FE4C179F854F14D76F399EB2325F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2159FE4C179F854F14D76F399EB2325F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2159FE4C179F854F14D76F399EB2325F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2159FE4C179F854F14D76F399EB2325F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2159FE4C179F854F14D76F399EB2325F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D1DC00C73CE3A6CC1FD36F399EB2E08D_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D1DC00C73CE3A6CC1FD36F399EB2E08D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D1DC00C73CE3A6CC1FD36F399EB2E08D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D1DC00C73CE3A6CC1FD36F399EB2E08D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D1DC00C73CE3A6CC1FD36F399EB2E08D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D1DC00C73CE3A6CC1FD36F399EB2E08D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D1DC00C73CE3A6CC1FD36F399EB2E08D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4DD13199228F360035706F399EB2C557_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4DD13199228F360035706F399EB2C557" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4DD13199228F360035706F399EB2C557_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4DD13199228F360035706F399EB2C557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4DD13199228F360035706F399EB2C557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4DD13199228F360035706F399EB2C557" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4DD13199228F360035706F399EB2C557" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CFFCD355FE690D7B29AF6F399EB383F3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CFFCD355FE690D7B29AF6F399EB383F3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Outstanding shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CFFCD355FE690D7B29AF6F399EB383F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CFFCD355FE690D7B29AF6F399EB383F3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CFFCD355FE690D7B29AF6F399EB383F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76AE2983BDB6931E5B766F399EB37984_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76AE2983BDB6931E5B766F399EB37984" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76AE2983BDB6931E5B766F399EB37984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76AE2983BDB6931E5B766F399EB37984" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76AE2983BDB6931E5B766F399EB37984" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_49503DA4D5A3092ECA9B6F399CA191CD_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_49503DA4D5A3092ECA9B6F399CA191CD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_49503DA4D5A3092ECA9B6F399CA191CD_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_49503DA4D5A3092ECA9B6F399CA191CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_49503DA4D5A3092ECA9B6F399CA191CD_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_49503DA4D5A3092ECA9B6F399CA191CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_49503DA4D5A3092ECA9B6F399CA191CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_49503DA4D5A3092ECA9B6F399CA191CD" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_49503DA4D5A3092ECA9B6F399CA191CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B7BDE8D77D6F2FE5630C6F399CA1A237_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B7BDE8D77D6F2FE5630C6F399CA1A237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B7BDE8D77D6F2FE5630C6F399CA1A237_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B7BDE8D77D6F2FE5630C6F399CA1A237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B7BDE8D77D6F2FE5630C6F399CA1A237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B7BDE8D77D6F2FE5630C6F399CA1A237" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B7BDE8D77D6F2FE5630C6F399CA1A237" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_3BDED41DC86EDB39EF756F399CA19B2E_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_3BDED41DC86EDB39EF756F399CA19B2E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_3BDED41DC86EDB39EF756F399CA19B2E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_3BDED41DC86EDB39EF756F399CA19B2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_3BDED41DC86EDB39EF756F399CA19B2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_3BDED41DC86EDB39EF756F399CA19B2E" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_3BDED41DC86EDB39EF756F399CA19B2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589" xlink:to="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B" xlink:to="lab_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9" xlink:to="lab_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9" xlink:type="arc" />
    <link:label id="lab_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7_terseLabel_en-US" xlink:label="lab_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 ESPP</link:label>
    <link:label id="lab_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7_label_en-US" xlink:label="lab_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:label id="lab_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7_documentation_en-US" xlink:label="lab_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7" xlink:to="lab_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5E3B3FBC385F751614936F399DDCC3BC_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5E3B3FBC385F751614936F399DDCC3BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5E3B3FBC385F751614936F399DDCC3BC_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5E3B3FBC385F751614936F399DDCC3BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5E3B3FBC385F751614936F399DDCC3BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5E3B3FBC385F751614936F399DDCC3BC" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5E3B3FBC385F751614936F399DDCC3BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_BC50E7CA1E8BFF841DFD6F399DDC5231_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_BC50E7CA1E8BFF841DFD6F399DDC5231" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_BC50E7CA1E8BFF841DFD6F399DDC5231_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_BC50E7CA1E8BFF841DFD6F399DDC5231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_BC50E7CA1E8BFF841DFD6F399DDC5231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_BC50E7CA1E8BFF841DFD6F399DDC5231" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_BC50E7CA1E8BFF841DFD6F399DDC5231" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_ADDBC92866C6615F363B0B3C2020E9D9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_ADDBC92866C6615F363B0B3C2020E9D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_ADDBC92866C6615F363B0B3C2020E9D9_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_ADDBC92866C6615F363B0B3C2020E9D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_ADDBC92866C6615F363B0B3C2020E9D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_ADDBC92866C6615F363B0B3C2020E9D9" xlink:to="lab_us-gaap_InventoriesMember_ADDBC92866C6615F363B0B3C2020E9D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_B8F1DA537F2C7F4B2F190B3C20202DC0_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_B8F1DA537F2C7F4B2F190B3C20202DC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Completed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_B8F1DA537F2C7F4B2F190B3C20202DC0_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_B8F1DA537F2C7F4B2F190B3C20202DC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_B8F1DA537F2C7F4B2F190B3C20202DC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_B8F1DA537F2C7F4B2F190B3C20202DC0" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_B8F1DA537F2C7F4B2F190B3C20202DC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_9B7DBD77242F961C95DD0B3C2020505D_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_9B7DBD77242F961C95DD0B3C2020505D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_9B7DBD77242F961C95DD0B3C2020505D_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_9B7DBD77242F961C95DD0B3C2020505D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9B7DBD77242F961C95DD0B3C2020505D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_9B7DBD77242F961C95DD0B3C2020505D" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_9B7DBD77242F961C95DD0B3C2020505D" xlink:type="arc" />
    <link:label id="lab_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14_label_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14" xlink:to="lab_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14" xlink:type="arc" />
    <link:label id="lab_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576_terseLabel_en-US" xlink:label="lab_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576_label_en-US" xlink:label="lab_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576_documentation_en-US" xlink:label="lab_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576" xlink:to="lab_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_CDED27190B79CD166B630B3C20202ACB_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_CDED27190B79CD166B630B3C20202ACB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outside the U.S</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_CDED27190B79CD166B630B3C20202ACB_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_CDED27190B79CD166B630B3C20202ACB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_CDED27190B79CD166B630B3C20202ACB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_CDED27190B79CD166B630B3C20202ACB" xlink:to="lab_us-gaap_ForeignCountryMember_CDED27190B79CD166B630B3C20202ACB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeanUnionMember_D2E408C6944F72A1BC0C0B3C20200378_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_D2E408C6944F72A1BC0C0B3C20200378" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_D2E408C6944F72A1BC0C0B3C20200378_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_D2E408C6944F72A1BC0C0B3C20200378" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_D2E408C6944F72A1BC0C0B3C20200378" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember_D2E408C6944F72A1BC0C0B3C20200378" xlink:to="lab_us-gaap_EuropeanUnionMember_D2E408C6944F72A1BC0C0B3C20200378" xlink:type="arc" />
    <link:label id="lab_country_JP_C1D2D51C1DEE93328E4D0B3C2020B902_terseLabel_en-US" xlink:label="lab_country_JP_C1D2D51C1DEE93328E4D0B3C2020B902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:label id="lab_country_JP_C1D2D51C1DEE93328E4D0B3C2020B902_label_en-US" xlink:label="lab_country_JP_C1D2D51C1DEE93328E4D0B3C2020B902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_C1D2D51C1DEE93328E4D0B3C2020B902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_C1D2D51C1DEE93328E4D0B3C2020B902" xlink:to="lab_country_JP_C1D2D51C1DEE93328E4D0B3C2020B902" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C60AC04363985B40EFDA0B3C20209A76_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C60AC04363985B40EFDA0B3C20209A76" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C60AC04363985B40EFDA0B3C20209A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C60AC04363985B40EFDA0B3C20209A76" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C60AC04363985B40EFDA0B3C20209A76" xlink:type="arc" />
    <link:label id="lab_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F" xlink:to="lab_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F" xlink:type="arc" />
    <link:label id="lab_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68_verboseLabel_en-US" xlink:label="lab_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">New Anti-CD20</link:label>
    <link:label id="lab_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68_label_en-US" xlink:label="lab_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Anti Cd20 [Member]</link:label>
    <link:label id="lab_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68_documentation_en-US" xlink:label="lab_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Anti-CD20.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68" xlink:to="lab_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68" xlink:type="arc" />
    <link:label id="lab_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D_verboseLabel_en-US" xlink:label="lab_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">OCREVUS</link:label>
    <link:label id="lab_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D_label_en-US" xlink:label="lab_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCREVUS [Member]</link:label>
    <link:label id="lab_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D_documentation_en-US" xlink:label="lab_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OCREVUS</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_OCREVUSMember" xlink:label="loc_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D" xlink:to="lab_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D" xlink:type="arc" />
    <link:label id="lab_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3_terseLabel_en-US" xlink:label="lab_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOD1</link:label>
    <link:label id="lab_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3_label_en-US" xlink:label="lab_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SOD1 [Member]</link:label>
    <link:label id="lab_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3_documentation_en-US" xlink:label="lab_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SOD1 [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3" xlink:to="lab_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_1FA327EBE731DA83995A0B3C2030DF24_verboseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_1FA327EBE731DA83995A0B3C2030DF24" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_1FA327EBE731DA83995A0B3C2030DF24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_1FA327EBE731DA83995A0B3C2030DF24" xlink:to="lab_biib_RocheGroupGenentechMember_1FA327EBE731DA83995A0B3C2030DF24" xlink:type="arc" />
    <link:label id="lab_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D" xlink:to="lab_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D" xlink:type="arc" />
    <link:label id="lab_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65_terseLabel_en-US" xlink:label="lab_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alkermes</link:label>
    <link:label id="lab_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65_label_en-US" xlink:label="lab_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alkermes [Member]</link:label>
    <link:label id="lab_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65_documentation_en-US" xlink:label="lab_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alkermes [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65" xlink:to="lab_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65" xlink:type="arc" />
    <link:label id="lab_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8_terseLabel_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:label id="lab_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8_label_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:label id="lab_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8_documentation_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8" xlink:to="lab_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8" xlink:type="arc" />
    <link:label id="lab_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA_terseLabel_en-US" xlink:label="lab_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">iPerian</link:label>
    <link:label id="lab_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA_label_en-US" xlink:label="lab_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">iPerian [Member]</link:label>
    <link:label id="lab_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA_documentation_en-US" xlink:label="lab_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">iPerian [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA" xlink:to="lab_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA" xlink:type="arc" />
    <link:label id="lab_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077_terseLabel_en-US" xlink:label="lab_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acorda</link:label>
    <link:label id="lab_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077_label_en-US" xlink:label="lab_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acorda [Member]</link:label>
    <link:label id="lab_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077_documentation_en-US" xlink:label="lab_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acorda.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077" xlink:to="lab_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077" xlink:type="arc" />
    <link:label id="lab_biib_AbbVieMember_C2808FCFC85132D72C110B3C20305E5B_verboseLabel_en-US" xlink:label="lab_biib_AbbVieMember_C2808FCFC85132D72C110B3C20305E5B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_C2808FCFC85132D72C110B3C20305E5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbVieMember_C2808FCFC85132D72C110B3C20305E5B" xlink:to="lab_biib_AbbVieMember_C2808FCFC85132D72C110B3C20305E5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_5D390AD3BE3532993AD80B3C2030510C_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_5D390AD3BE3532993AD80B3C2030510C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_5D390AD3BE3532993AD80B3C2030510C_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_5D390AD3BE3532993AD80B3C2030510C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5D390AD3BE3532993AD80B3C2030510C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_5D390AD3BE3532993AD80B3C2030510C" xlink:to="lab_us-gaap_CollaborativeArrangementMember_5D390AD3BE3532993AD80B3C2030510C" xlink:type="arc" />
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834_terseLabel_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834_label_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834_documentation_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834" xlink:to="lab_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834" xlink:type="arc" />
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430" xlink:to="lab_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430" xlink:type="arc" />
    <link:label id="lab_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F_verboseLabel_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships (Textual)</link:label>
    <link:label id="lab_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F_label_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborations (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F_documentation_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborations.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="lab_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:type="arc" />
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609_verboseLabel_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of ocrelizumab</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609_label_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Percentage To Be Received On Sale Of Product</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609_documentation_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of product.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609" xlink:to="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609" xlink:type="arc" />
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14_terseLabel_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14_label_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14_documentation_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14" xlink:to="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14" xlink:type="arc" />
    <link:label id="lab_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899_label_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899" xlink:to="lab_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899" xlink:type="arc" />
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41_verboseLabel_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Period of collaboration agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41_label_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41_documentation_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41" xlink:to="lab_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Co promotion Operating Profits first fifty million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits First Fifty Million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits first fifty million.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52_label_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52_documentation_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52" xlink:to="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52" xlink:type="arc" />
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E" xlink:to="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E" xlink:type="arc" />
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales to be achieved in any twelve consecutive months under option one.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434" xlink:to="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434" xlink:type="arc" />
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A_terseLabel_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A_label_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A_documentation_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales trigger gross sales threshold.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A" xlink:to="lab_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A" xlink:type="arc" />
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78_terseLabel_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78_label_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78_documentation_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78" xlink:to="lab_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9_verboseLabel_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments when certain sales threshold is met</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9_label_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Additional Milestone Payments When Meeting Certain Sales Threshold</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9_documentation_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments when meeting certain sales threshold.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9" xlink:to="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9" xlink:type="arc" />
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6_verboseLabel_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign sales required to trigger milestone</link:label>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6_label_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Sales Required To Trigger Milestone</link:label>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6_documentation_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign sales required to trigger milestone.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6" xlink:to="lab_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_09E5439C8F3E348A4B4D0B3C20304B1B_verboseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_09E5439C8F3E348A4B4D0B3C20304B1B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_09E5439C8F3E348A4B4D0B3C20304B1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_09E5439C8F3E348A4B4D0B3C20304B1B" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_09E5439C8F3E348A4B4D0B3C20304B1B" xlink:type="arc" />
    <link:label id="lab_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ContractOptionExerciseFee" xlink:label="loc_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C" xlink:to="lab_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B8C1CE7350202A681FE30B3C20301B01_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B8C1CE7350202A681FE30B3C20301B01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Until First GAZYVA Threshold Date</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B8C1CE7350202A681FE30B3C20301B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B8C1CE7350202A681FE30B3C20301B01" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B8C1CE7350202A681FE30B3C20301B01" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0B4D7FCC780B1BC65A670B3C20305FFB_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0B4D7FCC780B1BC65A670B3C20305FFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Until GAZYVA First Non-CLL FDA Approval</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0B4D7FCC780B1BC65A670B3C20305FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0B4D7FCC780B1BC65A670B3C20305FFB" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0B4D7FCC780B1BC65A670B3C20305FFB" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B304B5055596BED91C8B0B3C203020B3_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B304B5055596BED91C8B0B3C203020B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After First Threshold Date and until Second Threshold Date</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B304B5055596BED91C8B0B3C203020B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B304B5055596BED91C8B0B3C203020B3" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B304B5055596BED91C8B0B3C203020B3" xlink:type="arc" />
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_95E5CF3DFB513234C61E0B3C20304C0C_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_95E5CF3DFB513234C61E0B3C20304C0C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of Sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_95E5CF3DFB513234C61E0B3C20304C0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_95E5CF3DFB513234C61E0B3C20304C0C" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_95E5CF3DFB513234C61E0B3C20304C0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_23EFF3B3256AABBFC7A00B3C2030B143_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_23EFF3B3256AABBFC7A00B3C2030B143" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_23EFF3B3256AABBFC7A00B3C2030B143_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_23EFF3B3256AABBFC7A00B3C2030B143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_23EFF3B3256AABBFC7A00B3C2030B143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_23EFF3B3256AABBFC7A00B3C2030B143" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_23EFF3B3256AABBFC7A00B3C2030B143" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC_terseLabel_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Of Royalties As Per Collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC_label_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Royalties As Per Collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC_documentation_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of royalties as per collaboration.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC" xlink:to="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_521FA37A354C34ADE1490B3C203096EA_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_521FA37A354C34ADE1490B3C203096EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_521FA37A354C34ADE1490B3C203096EA_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_521FA37A354C34ADE1490B3C203096EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_521FA37A354C34ADE1490B3C203096EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_521FA37A354C34ADE1490B3C203096EA" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_521FA37A354C34ADE1490B3C203096EA" xlink:type="arc" />
    <link:label id="lab_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB_terseLabel_en-US" xlink:label="lab_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB_label_en-US" xlink:label="lab_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB_documentation_en-US" xlink:label="lab_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB" xlink:to="lab_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680_terseLabel_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected License Fee And Regulatory Milestone Payments</link:label>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680_label_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected License Fee And Regulatory Milestone Payments</link:label>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680_documentation_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected license fee and regulatory milestone payments.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680" xlink:to="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680" xlink:type="arc" />
    <link:label id="lab_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE_terseLabel_en-US" xlink:label="lab_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment for collaboration agreement</link:label>
    <link:label id="lab_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE_label_en-US" xlink:label="lab_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront payment for collaboration agreement</link:label>
    <link:label id="lab_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE_documentation_en-US" xlink:label="lab_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront payment for collaboration agreement</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Upfrontpaymentforcollaborationagreement" xlink:label="loc_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE" xlink:to="lab_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE" xlink:type="arc" />
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4_terseLabel_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4_label_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4_documentation_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4" xlink:to="lab_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4" xlink:type="arc" />
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC" xlink:to="lab_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC" xlink:type="arc" />
    <link:label id="lab_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6" xlink:to="lab_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6" xlink:type="arc" />
    <link:label id="lab_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76_terseLabel_en-US" xlink:label="lab_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total payment to enter collaboration agreement</link:label>
    <link:label id="lab_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76_label_en-US" xlink:label="lab_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total payment to enter collaboration agreement</link:label>
    <link:label id="lab_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76_documentation_en-US" xlink:label="lab_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total payment to enter collaboration agreement</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Totalpaymenttoentercollaborationagreement" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76" xlink:to="lab_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_95A37109A17493D065ED0B3C2030272D_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_95A37109A17493D065ED0B3C2030272D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and discovery services</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_95A37109A17493D065ED0B3C2030272D_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_95A37109A17493D065ED0B3C2030272D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_95A37109A17493D065ED0B3C2030272D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_95A37109A17493D065ED0B3C2030272D" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets_95A37109A17493D065ED0B3C2030272D" xlink:type="arc" />
    <link:label id="lab_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554_terseLabel_en-US" xlink:label="lab_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developmental Milestone Payment</link:label>
    <link:label id="lab_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554_label_en-US" xlink:label="lab_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developmental Milestone Payment</link:label>
    <link:label id="lab_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554_documentation_en-US" xlink:label="lab_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developmental Milestone Payment</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554" xlink:to="lab_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554" xlink:type="arc" />
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8_verboseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment, approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8" xlink:type="arc" />
    <link:label id="lab_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA_terseLabel_en-US" xlink:label="lab_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA_label_en-US" xlink:label="lab_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA_documentation_en-US" xlink:label="lab_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA" xlink:to="lab_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA" xlink:type="arc" />
    <link:label id="lab_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3_terseLabel_en-US" xlink:label="lab_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium on purchase of common stock</link:label>
    <link:label id="lab_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3_label_en-US" xlink:label="lab_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium on purchase of common stock</link:label>
    <link:label id="lab_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3_documentation_en-US" xlink:label="lab_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premium on purchase of common stock</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3" xlink:to="lab_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3" xlink:type="arc" />
    <link:label id="lab_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19_terseLabel_en-US" xlink:label="lab_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in common stock, value</link:label>
    <link:label id="lab_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19_label_en-US" xlink:label="lab_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in common stock, value</link:label>
    <link:label id="lab_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19_documentation_en-US" xlink:label="lab_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in common stock, value</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Investmentincommonstockvalue" xlink:label="loc_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19" xlink:to="lab_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_AB34543CB2F1D9B48D820B3C203020D0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_AB34543CB2F1D9B48D820B3C203020D0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_AB34543CB2F1D9B48D820B3C203020D0_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_AB34543CB2F1D9B48D820B3C203020D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_AB34543CB2F1D9B48D820B3C203020D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_AB34543CB2F1D9B48D820B3C203020D0" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_AB34543CB2F1D9B48D820B3C203020D0" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474_terseLabel_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474_label_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474_documentation_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments by third party in joint venture as per agreement</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474" xlink:to="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474" xlink:type="arc" />
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445_terseLabel_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint Venture Owner Ship Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445_label_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint Venture Owner Ship Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445_documentation_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Joint venture owner ship percentage by third party.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445" xlink:to="lab_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_4027F16708EE8AEDBDAC0B3C20303240_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_4027F16708EE8AEDBDAC0B3C20303240" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_4027F16708EE8AEDBDAC0B3C20303240_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_4027F16708EE8AEDBDAC0B3C20303240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4027F16708EE8AEDBDAC0B3C20303240" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_4027F16708EE8AEDBDAC0B3C20303240" xlink:to="lab_us-gaap_EquityMethodInvestments_4027F16708EE8AEDBDAC0B3C20303240" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_1BA6ED2497F506020F820B3C2030BE44_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_1BA6ED2497F506020F820B3C2030BE44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_1BA6ED2497F506020F820B3C2030BE44_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_1BA6ED2497F506020F820B3C2030BE44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_1BA6ED2497F506020F820B3C2030BE44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_1BA6ED2497F506020F820B3C2030BE44" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_1BA6ED2497F506020F820B3C2030BE44" xlink:type="arc" />
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_AE526C1A2878CFECDB040B3C2030FE36_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_AE526C1A2878CFECDB040B3C2030FE36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_AE526C1A2878CFECDB040B3C2030FE36_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_AE526C1A2878CFECDB040B3C2030FE36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_AE526C1A2878CFECDB040B3C2030FE36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_AE526C1A2878CFECDB040B3C2030FE36" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_AE526C1A2878CFECDB040B3C2030FE36" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_11CC593C2EFF90684AC10B3C20309816_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_11CC593C2EFF90684AC10B3C20309816" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_11CC593C2EFF90684AC10B3C20309816" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_11CC593C2EFF90684AC10B3C20309816" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_11CC593C2EFF90684AC10B3C20309816" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentForAmortization_54F60E4641006BA0C1FC0B3C20308454_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_54F60E4641006BA0C1FC0B3C20308454" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_54F60E4641006BA0C1FC0B3C20308454_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_54F60E4641006BA0C1FC0B3C20308454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_54F60E4641006BA0C1FC0B3C20308454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization_54F60E4641006BA0C1FC0B3C20308454" xlink:to="lab_us-gaap_AdjustmentForAmortization_54F60E4641006BA0C1FC0B3C20308454" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossOnContractTermination_95FF046140269C5DE06E0B3C2030B36C_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination_95FF046140269C5DE06E0B3C2030B36C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_95FF046140269C5DE06E0B3C2030B36C_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination_95FF046140269C5DE06E0B3C2030B36C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_95FF046140269C5DE06E0B3C2030B36C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination_95FF046140269C5DE06E0B3C2030B36C" xlink:to="lab_us-gaap_LossOnContractTermination_95FF046140269C5DE06E0B3C2030B36C" xlink:type="arc" />
    <link:label id="lab_biib_Expenseincurredbythecollaboration_5E1EFE1FFB3BCB4C95950B3C203072F5_verboseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_5E1EFE1FFB3BCB4C95950B3C203072F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">BAN2401 and Elenbecestat expense incurred by the collaboration</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_5E1EFE1FFB3BCB4C95950B3C203072F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration_5E1EFE1FFB3BCB4C95950B3C203072F5" xlink:to="lab_biib_Expenseincurredbythecollaboration_5E1EFE1FFB3BCB4C95950B3C203072F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedParties_B8912505B94BC53128FA0B3C2030BF72_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties_B8912505B94BC53128FA0B3C2030BF72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due from Related Parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_B8912505B94BC53128FA0B3C2030BF72_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties_B8912505B94BC53128FA0B3C2030BF72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_B8912505B94BC53128FA0B3C2030BF72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties_B8912505B94BC53128FA0B3C2030BF72" xlink:to="lab_us-gaap_DueFromRelatedParties_B8912505B94BC53128FA0B3C2030BF72" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8A3B2B2883FF90C0C6D60B3C20300100_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8A3B2B2883FF90C0C6D60B3C20300100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8A3B2B2883FF90C0C6D60B3C20300100_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8A3B2B2883FF90C0C6D60B3C20300100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8A3B2B2883FF90C0C6D60B3C20300100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8A3B2B2883FF90C0C6D60B3C20300100" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8A3B2B2883FF90C0C6D60B3C20300100" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_F204F29AECFA8220D32FE873ACFE3186_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_F204F29AECFA8220D32FE873ACFE3186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_F204F29AECFA8220D32FE873ACFE3186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_F204F29AECFA8220D32FE873ACFE3186" xlink:to="lab_us-gaap_LeasesAbstract_F204F29AECFA8220D32FE873ACFE3186" xlink:type="arc" />
    <link:label id="lab_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392_terseLabel_en-US" xlink:label="lab_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets [Member]</link:label>
    <link:label id="lab_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392_label_en-US" xlink:label="lab_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease assets [Member]</link:label>
    <link:label id="lab_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392_documentation_en-US" xlink:label="lab_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease assets [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_OperatingleaseassetsMember" xlink:label="loc_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392" xlink:to="lab_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392" xlink:type="arc" />
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4_terseLabel_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities [Member]</link:label>
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4_label_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities [Member]</link:label>
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4_documentation_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4" xlink:to="lab_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_E3DFE77C75FFAFA29F27E873ACFE0F26_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_E3DFE77C75FFAFA29F27E873ACFE0F26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_E3DFE77C75FFAFA29F27E873ACFE0F26_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_E3DFE77C75FFAFA29F27E873ACFE0F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E3DFE77C75FFAFA29F27E873ACFE0F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_E3DFE77C75FFAFA29F27E873ACFE0F26" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_E3DFE77C75FFAFA29F27E873ACFE0F26" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_A57A2E631B44004D08E6E873ACFED1CB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_A57A2E631B44004D08E6E873ACFED1CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_A57A2E631B44004D08E6E873ACFED1CB_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_A57A2E631B44004D08E6E873ACFED1CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_A57A2E631B44004D08E6E873ACFED1CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_A57A2E631B44004D08E6E873ACFED1CB" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_A57A2E631B44004D08E6E873ACFED1CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1DA6DEB86E9504AC7F1DE873ACFE00D0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1DA6DEB86E9504AC7F1DE873ACFE00D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1DA6DEB86E9504AC7F1DE873ACFE00D0_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1DA6DEB86E9504AC7F1DE873ACFE00D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1DA6DEB86E9504AC7F1DE873ACFE00D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1DA6DEB86E9504AC7F1DE873ACFE00D0" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1DA6DEB86E9504AC7F1DE873ACFE00D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_41DD7E9C9416E60AE3DAE873ACFE623C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_41DD7E9C9416E60AE3DAE873ACFE623C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_41DD7E9C9416E60AE3DAE873ACFE623C_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_41DD7E9C9416E60AE3DAE873ACFE623C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_41DD7E9C9416E60AE3DAE873ACFE623C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_41DD7E9C9416E60AE3DAE873ACFE623C" xlink:to="lab_us-gaap_OperatingLeaseLiability_41DD7E9C9416E60AE3DAE873ACFE623C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_A0AAFC451DCF66B94E88E873ACFEE554_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_A0AAFC451DCF66B94E88E873ACFEE554" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_A0AAFC451DCF66B94E88E873ACFEE554_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_A0AAFC451DCF66B94E88E873ACFEE554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_A0AAFC451DCF66B94E88E873ACFEE554" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_A0AAFC451DCF66B94E88E873ACFEE554" xlink:to="lab_us-gaap_OperatingLeaseCost_A0AAFC451DCF66B94E88E873ACFEE554" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_38B5618B7FB4C4014B6DE873ACFEB867_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_38B5618B7FB4C4014B6DE873ACFEB867" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_38B5618B7FB4C4014B6DE873ACFEB867_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_38B5618B7FB4C4014B6DE873ACFEB867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_38B5618B7FB4C4014B6DE873ACFEB867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_38B5618B7FB4C4014B6DE873ACFEB867" xlink:to="lab_us-gaap_VariableLeaseCost_38B5618B7FB4C4014B6DE873ACFEB867" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_C8DF49B509F66D2295B7E873ACFE1D2C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_C8DF49B509F66D2295B7E873ACFE1D2C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_C8DF49B509F66D2295B7E873ACFE1D2C_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_C8DF49B509F66D2295B7E873ACFE1D2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Income Statement, Sublease Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_C8DF49B509F66D2295B7E873ACFE1D2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_C8DF49B509F66D2295B7E873ACFE1D2C" xlink:to="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_C8DF49B509F66D2295B7E873ACFE1D2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_4146C61A9D009224884EE873ACFE4709_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_4146C61A9D009224884EE873ACFE4709" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_4146C61A9D009224884EE873ACFE4709_label_en-US" xlink:label="lab_us-gaap_LeaseCost_4146C61A9D009224884EE873ACFE4709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_4146C61A9D009224884EE873ACFE4709" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_4146C61A9D009224884EE873ACFE4709" xlink:to="lab_us-gaap_LeaseCost_4146C61A9D009224884EE873ACFE4709" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0D5C0ABEB1A24CA818BBE873ACFE0025_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0D5C0ABEB1A24CA818BBE873ACFE0025" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0D5C0ABEB1A24CA818BBE873ACFE0025_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0D5C0ABEB1A24CA818BBE873ACFE0025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0D5C0ABEB1A24CA818BBE873ACFE0025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0D5C0ABEB1A24CA818BBE873ACFE0025" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0D5C0ABEB1A24CA818BBE873ACFE0025" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8D02DB6BDCA841E314CEE873ACFEFF8B_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8D02DB6BDCA841E314CEE873ACFEFF8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8D02DB6BDCA841E314CEE873ACFEFF8B_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8D02DB6BDCA841E314CEE873ACFEFF8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8D02DB6BDCA841E314CEE873ACFEFF8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8D02DB6BDCA841E314CEE873ACFEFF8B" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8D02DB6BDCA841E314CEE873ACFEFF8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_A9F8D5A07239E0C4986EE873ACFE6087_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_A9F8D5A07239E0C4986EE873ACFE6087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_A9F8D5A07239E0C4986EE873ACFE6087_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_A9F8D5A07239E0C4986EE873ACFE6087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_A9F8D5A07239E0C4986EE873ACFE6087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_A9F8D5A07239E0C4986EE873ACFE6087" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_A9F8D5A07239E0C4986EE873ACFE6087" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12634B2A6D58CF51EB87E873ACFE6BC4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12634B2A6D58CF51EB87E873ACFE6BC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12634B2A6D58CF51EB87E873ACFE6BC4_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12634B2A6D58CF51EB87E873ACFE6BC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12634B2A6D58CF51EB87E873ACFE6BC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12634B2A6D58CF51EB87E873ACFE6BC4" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12634B2A6D58CF51EB87E873ACFE6BC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E9C2C54AC791981B5785E873ACFE052C_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E9C2C54AC791981B5785E873ACFE052C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E9C2C54AC791981B5785E873ACFE052C_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E9C2C54AC791981B5785E873ACFE052C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E9C2C54AC791981B5785E873ACFE052C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E9C2C54AC791981B5785E873ACFE052C" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E9C2C54AC791981B5785E873ACFE052C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_EC5E29C41E15FE62D7F8E873ACFEA899_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_EC5E29C41E15FE62D7F8E873ACFEA899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_EC5E29C41E15FE62D7F8E873ACFEA899_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_EC5E29C41E15FE62D7F8E873ACFEA899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_EC5E29C41E15FE62D7F8E873ACFEA899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_EC5E29C41E15FE62D7F8E873ACFEA899" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_EC5E29C41E15FE62D7F8E873ACFEA899" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50871FF0B2E4A1AB8CB7E873ACFE5C80_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50871FF0B2E4A1AB8CB7E873ACFE5C80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50871FF0B2E4A1AB8CB7E873ACFE5C80_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50871FF0B2E4A1AB8CB7E873ACFE5C80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50871FF0B2E4A1AB8CB7E873ACFE5C80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50871FF0B2E4A1AB8CB7E873ACFE5C80" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50871FF0B2E4A1AB8CB7E873ACFE5C80" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ECB2AC2DD6555BFDFC7CE873ACFEED28_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ECB2AC2DD6555BFDFC7CE873ACFEED28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ECB2AC2DD6555BFDFC7CE873ACFEED28_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ECB2AC2DD6555BFDFC7CE873ACFEED28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ECB2AC2DD6555BFDFC7CE873ACFEED28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ECB2AC2DD6555BFDFC7CE873ACFEED28" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ECB2AC2DD6555BFDFC7CE873ACFEED28" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_944C1400F71AE4D7CEBBE873ACFE0A98_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_944C1400F71AE4D7CEBBE873ACFE0A98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_944C1400F71AE4D7CEBBE873ACFE0A98_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_944C1400F71AE4D7CEBBE873ACFE0A98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_944C1400F71AE4D7CEBBE873ACFE0A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_944C1400F71AE4D7CEBBE873ACFE0A98" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_944C1400F71AE4D7CEBBE873ACFE0A98" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_754A59424AAA3453C12BE873ACFE6704_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_754A59424AAA3453C12BE873ACFE6704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_754A59424AAA3453C12BE873ACFE6704_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_754A59424AAA3453C12BE873ACFE6704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_754A59424AAA3453C12BE873ACFE6704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_754A59424AAA3453C12BE873ACFE6704" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_754A59424AAA3453C12BE873ACFE6704" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_88A184F73226FA0F2690E873ACFE6A79_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_88A184F73226FA0F2690E873ACFE6A79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_88A184F73226FA0F2690E873ACFE6A79_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_88A184F73226FA0F2690E873ACFE6A79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_88A184F73226FA0F2690E873ACFE6A79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_88A184F73226FA0F2690E873ACFE6A79" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_88A184F73226FA0F2690E873ACFE6A79" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_694B2DD4EAFF69B067AEE873ACFEBE4D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_694B2DD4EAFF69B067AEE873ACFEBE4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_694B2DD4EAFF69B067AEE873ACFEBE4D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_694B2DD4EAFF69B067AEE873ACFEBE4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_694B2DD4EAFF69B067AEE873ACFEBE4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_694B2DD4EAFF69B067AEE873ACFEBE4D" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_694B2DD4EAFF69B067AEE873ACFEBE4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_BEF3E8FCCB751566D088E873ACFE05F5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_BEF3E8FCCB751566D088E873ACFE05F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_BEF3E8FCCB751566D088E873ACFE05F5_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_BEF3E8FCCB751566D088E873ACFE05F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_BEF3E8FCCB751566D088E873ACFE05F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_BEF3E8FCCB751566D088E873ACFE05F5" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_BEF3E8FCCB751566D088E873ACFE05F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_46792EE4582066F1DC99E873ACFE30D2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_46792EE4582066F1DC99E873ACFE30D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_46792EE4582066F1DC99E873ACFE30D2_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_46792EE4582066F1DC99E873ACFE30D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_46792EE4582066F1DC99E873ACFE30D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_46792EE4582066F1DC99E873ACFE30D2" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_46792EE4582066F1DC99E873ACFE30D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_91B010E801E6713C03CBE873ACFE12AD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_91B010E801E6713C03CBE873ACFE12AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_91B010E801E6713C03CBE873ACFE12AD_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_91B010E801E6713C03CBE873ACFE12AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_91B010E801E6713C03CBE873ACFE12AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_91B010E801E6713C03CBE873ACFE12AD" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_91B010E801E6713C03CBE873ACFE12AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_02513600D9BB7B76F0E3E873ACFE7378_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_02513600D9BB7B76F0E3E873ACFE7378" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2019</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_02513600D9BB7B76F0E3E873ACFE7378_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_02513600D9BB7B76F0E3E873ACFE7378" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_02513600D9BB7B76F0E3E873ACFE7378" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_02513600D9BB7B76F0E3E873ACFE7378" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_02513600D9BB7B76F0E3E873ACFE7378" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7EF337BF8354CE05BC4BE873ACFE6070_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7EF337BF8354CE05BC4BE873ACFE6070" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2020</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7EF337BF8354CE05BC4BE873ACFE6070_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7EF337BF8354CE05BC4BE873ACFE6070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7EF337BF8354CE05BC4BE873ACFE6070" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7EF337BF8354CE05BC4BE873ACFE6070" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7EF337BF8354CE05BC4BE873ACFE6070" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_95A1DEF2CACE49C9D83BE873AD0D6D12_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_95A1DEF2CACE49C9D83BE873AD0D6D12" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2021</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_95A1DEF2CACE49C9D83BE873AD0D6D12_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_95A1DEF2CACE49C9D83BE873AD0D6D12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_95A1DEF2CACE49C9D83BE873AD0D6D12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_95A1DEF2CACE49C9D83BE873AD0D6D12" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_95A1DEF2CACE49C9D83BE873AD0D6D12" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_5857B058FEC9F360BE0CE873AD0D8929_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_5857B058FEC9F360BE0CE873AD0D8929" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2022</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_5857B058FEC9F360BE0CE873AD0D8929_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_5857B058FEC9F360BE0CE873AD0D8929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_5857B058FEC9F360BE0CE873AD0D8929" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_5857B058FEC9F360BE0CE873AD0D8929" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_5857B058FEC9F360BE0CE873AD0D8929" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_99A836EB41F10721FE35E873AD0DD9AD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_99A836EB41F10721FE35E873AD0DD9AD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">ACS 840 - Sublease income, 2023</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_99A836EB41F10721FE35E873AD0DD9AD_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_99A836EB41F10721FE35E873AD0DD9AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_99A836EB41F10721FE35E873AD0DD9AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_99A836EB41F10721FE35E873AD0DD9AD" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_99A836EB41F10721FE35E873AD0DD9AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_A4C2A3D62418A61136ABE873AD0D2853_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_A4C2A3D62418A61136ABE873AD0D2853" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, thereafter</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_A4C2A3D62418A61136ABE873AD0D2853_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_A4C2A3D62418A61136ABE873AD0D2853" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_A4C2A3D62418A61136ABE873AD0D2853" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_A4C2A3D62418A61136ABE873AD0D2853" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_A4C2A3D62418A61136ABE873AD0D2853" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_F81D905374E0C0533986E873AD0DCA3D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_F81D905374E0C0533986E873AD0DCA3D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, total</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_F81D905374E0C0533986E873AD0DCA3D_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_F81D905374E0C0533986E873AD0DCA3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_F81D905374E0C0533986E873AD0DCA3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_F81D905374E0C0533986E873AD0DCA3D" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_F81D905374E0C0533986E873AD0DCA3D" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2019</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In One Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in one year.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2020</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Two Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in two year.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2021</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Three Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in three year.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2022</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Four Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in four year.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2023</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Five Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in five year.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments Thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments thereafter.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95" xlink:to="lab_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, total</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D_label_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments total.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D" xlink:to="lab_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5567F9123F004B5D3547E8B1DE72FF82_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5567F9123F004B5D3547E8B1DE72FF82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5567F9123F004B5D3547E8B1DE72FF82_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5567F9123F004B5D3547E8B1DE72FF82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5567F9123F004B5D3547E8B1DE72FF82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5567F9123F004B5D3547E8B1DE72FF82" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5567F9123F004B5D3547E8B1DE72FF82" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6F9D0F4F48E08F68BD32E8B1DFF2FC3C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6F9D0F4F48E08F68BD32E8B1DFF2FC3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6F9D0F4F48E08F68BD32E8B1DFF2FC3C_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6F9D0F4F48E08F68BD32E8B1DFF2FC3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6F9D0F4F48E08F68BD32E8B1DFF2FC3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6F9D0F4F48E08F68BD32E8B1DFF2FC3C" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6F9D0F4F48E08F68BD32E8B1DFF2FC3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_75E1E4279E68E8758DB4E8B3C011F458_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_75E1E4279E68E8758DB4E8B3C011F458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_75E1E4279E68E8758DB4E8B3C011F458_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_75E1E4279E68E8758DB4E8B3C011F458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_75E1E4279E68E8758DB4E8B3C011F458" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_75E1E4279E68E8758DB4E8B3C011F458" xlink:to="lab_us-gaap_OperatingLeasePayments_75E1E4279E68E8758DB4E8B3C011F458" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2DD2A954B517177A6EA0E8B3C1D10B82_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2DD2A954B517177A6EA0E8B3C1D10B82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2DD2A954B517177A6EA0E8B3C1D10B82_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2DD2A954B517177A6EA0E8B3C1D10B82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2DD2A954B517177A6EA0E8B3C1D10B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2DD2A954B517177A6EA0E8B3C1D10B82" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2DD2A954B517177A6EA0E8B3C1D10B82" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_8107BB91A8790397FBF36F399BDA0112_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_8107BB91A8790397FBF36F399BDA0112" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_8107BB91A8790397FBF36F399BDA0112_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_8107BB91A8790397FBF36F399BDA0112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_8107BB91A8790397FBF36F399BDA0112" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_8107BB91A8790397FBF36F399BDA0112" xlink:to="lab_us-gaap_PerformanceSharesMember_8107BB91A8790397FBF36F399BDA0112" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_50D8A74DF85B18B9E2A5D10B833431F7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_50D8A74DF85B18B9E2A5D10B833431F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_50D8A74DF85B18B9E2A5D10B833431F7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_50D8A74DF85B18B9E2A5D10B833431F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_50D8A74DF85B18B9E2A5D10B833431F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_50D8A74DF85B18B9E2A5D10B833431F7" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_50D8A74DF85B18B9E2A5D10B833431F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D147678F407F2C2D76CDD10B83346C33_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D147678F407F2C2D76CDD10B83346C33" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D147678F407F2C2D76CDD10B83346C33_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D147678F407F2C2D76CDD10B83346C33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D147678F407F2C2D76CDD10B83346C33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D147678F407F2C2D76CDD10B83346C33" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D147678F407F2C2D76CDD10B83346C33" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_7BCB364F54A65EE84726D145EC5319C4_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock_7BCB364F54A65EE84726D145EC5319C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_7BCB364F54A65EE84726D145EC5319C4_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock_7BCB364F54A65EE84726D145EC5319C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_7BCB364F54A65EE84726D145EC5319C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock_7BCB364F54A65EE84726D145EC5319C4" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock_7BCB364F54A65EE84726D145EC5319C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6121155DFB9E4E4360E7D10B83346CAE_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6121155DFB9E4E4360E7D10B83346CAE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6121155DFB9E4E4360E7D10B83346CAE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6121155DFB9E4E4360E7D10B83346CAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6121155DFB9E4E4360E7D10B83346CAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6121155DFB9E4E4360E7D10B83346CAE" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6121155DFB9E4E4360E7D10B83346CAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_8C0CB99E44C5C47F0A836F399D71AC26_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_8C0CB99E44C5C47F0A836F399D71AC26" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Geographic information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_8C0CB99E44C5C47F0A836F399D71AC26_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_8C0CB99E44C5C47F0A836F399D71AC26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_8C0CB99E44C5C47F0A836F399D71AC26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_8C0CB99E44C5C47F0A836F399D71AC26" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_8C0CB99E44C5C47F0A836F399D71AC26" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_B956F7164DD77BE031C76F399F7EF4DF_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_B956F7164DD77BE031C76F399F7EF4DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_B956F7164DD77BE031C76F399F7EF4DF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_B956F7164DD77BE031C76F399F7EF4DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_B956F7164DD77BE031C76F399F7EF4DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_B956F7164DD77BE031C76F399F7EF4DF" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_B956F7164DD77BE031C76F399F7EF4DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_04F23D9069CE9B6134E36F399F7EE913_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_04F23D9069CE9B6134E36F399F7EE913" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities including strategic investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_04F23D9069CE9B6134E36F399F7EE913_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_04F23D9069CE9B6134E36F399F7EE913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_04F23D9069CE9B6134E36F399F7EE913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_04F23D9069CE9B6134E36F399F7EE913" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_04F23D9069CE9B6134E36F399F7EE913" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_21AE70E3C438906F13226F399F7E2CA8_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_21AE70E3C438906F13226F399F7E2CA8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: Available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_21AE70E3C438906F13226F399F7E2CA8_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_21AE70E3C438906F13226F399F7E2CA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_21AE70E3C438906F13226F399F7E2CA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_21AE70E3C438906F13226F399F7E2CA8" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_21AE70E3C438906F13226F399F7E2CA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B7C6C403FF2DB543046F6F399F7E0AB4_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B7C6C403FF2DB543046F6F399F7E0AB4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable securities, excluding strategic investments</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B7C6C403FF2DB543046F6F399F7E0AB4_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B7C6C403FF2DB543046F6F399F7E0AB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B7C6C403FF2DB543046F6F399F7E0AB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B7C6C403FF2DB543046F6F399F7E0AB4" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B7C6C403FF2DB543046F6F399F7E0AB4" xlink:type="arc" />
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_1BEC6A8F13335943C714E873AD0DB8E0_terseLabel_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock_1BEC6A8F13335943C714E873AD0DB8E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of operating leases</link:label>
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_1BEC6A8F13335943C714E873AD0DB8E0_label_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock_1BEC6A8F13335943C714E873AD0DB8E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Lease Table [Table Text Block]</link:label>
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_1BEC6A8F13335943C714E873AD0DB8E0_documentation_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock_1BEC6A8F13335943C714E873AD0DB8E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee Lease Table [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_LesseeLeaseTableTableTextBlock" xlink:label="loc_biib_LesseeLeaseTableTableTextBlock_1BEC6A8F13335943C714E873AD0DB8E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LesseeLeaseTableTableTextBlock_1BEC6A8F13335943C714E873AD0DB8E0" xlink:to="lab_biib_LesseeLeaseTableTableTextBlock_1BEC6A8F13335943C714E873AD0DB8E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_B3F802B96FA03D33036CE873AD0DABDB_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_B3F802B96FA03D33036CE873AD0DABDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_B3F802B96FA03D33036CE873AD0DABDB_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_B3F802B96FA03D33036CE873AD0DABDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_B3F802B96FA03D33036CE873AD0DABDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_B3F802B96FA03D33036CE873AD0DABDB" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_B3F802B96FA03D33036CE873AD0DABDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D73672C802748C3893A2E873AD0D403B_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D73672C802748C3893A2E873AD0D403B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D73672C802748C3893A2E873AD0D403B_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D73672C802748C3893A2E873AD0D403B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D73672C802748C3893A2E873AD0D403B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D73672C802748C3893A2E873AD0D403B" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D73672C802748C3893A2E873AD0D403B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E2DFF5B44550308F38B3E873AD0D6986_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E2DFF5B44550308F38B3E873AD0D6986" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E2DFF5B44550308F38B3E873AD0D6986" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E2DFF5B44550308F38B3E873AD0D6986" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E2DFF5B44550308F38B3E873AD0D6986" xlink:type="arc" />
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_CF863AD0C22CFF2873B1E8B29E768752_terseLabel_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_CF863AD0C22CFF2873B1E8B29E768752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease weighted average remaining term and discount rate [Table Text Block]</link:label>
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_CF863AD0C22CFF2873B1E8B29E768752_label_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_CF863AD0C22CFF2873B1E8B29E768752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease weighted average remaining term and discount rate [Table Text Block]</link:label>
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_CF863AD0C22CFF2873B1E8B29E768752_documentation_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_CF863AD0C22CFF2873B1E8B29E768752" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease weighted average remaining term and discount rate [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:label="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_CF863AD0C22CFF2873B1E8B29E768752" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_CF863AD0C22CFF2873B1E8B29E768752" xlink:to="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_CF863AD0C22CFF2873B1E8B29E768752" xlink:type="arc" />
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_9BE62EA19BE1DC75EA34E8B33A9C23D8_terseLabel_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_9BE62EA19BE1DC75EA34E8B33A9C23D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease supplemental cash flow disclosure [Table Text Block]</link:label>
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_9BE62EA19BE1DC75EA34E8B33A9C23D8_label_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_9BE62EA19BE1DC75EA34E8B33A9C23D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease supplemental cash flow disclosure [Table Text Block]</link:label>
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_9BE62EA19BE1DC75EA34E8B33A9C23D8_documentation_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_9BE62EA19BE1DC75EA34E8B33A9C23D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease supplemental cash flow disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:label="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_9BE62EA19BE1DC75EA34E8B33A9C23D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_9BE62EA19BE1DC75EA34E8B33A9C23D8" xlink:to="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_9BE62EA19BE1DC75EA34E8B33A9C23D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3F03AC4D62F499CD16536F399D5363F6_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3F03AC4D62F499CD16536F399D5363F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3F03AC4D62F499CD16536F399D5363F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3F03AC4D62F499CD16536F399D5363F6" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3F03AC4D62F499CD16536F399D5363F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09EEEF588D9A5189F85C6F399D54C1E0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09EEEF588D9A5189F85C6F399D54C1E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09EEEF588D9A5189F85C6F399D54C1E0_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09EEEF588D9A5189F85C6F399D54C1E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09EEEF588D9A5189F85C6F399D54C1E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09EEEF588D9A5189F85C6F399D54C1E0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09EEEF588D9A5189F85C6F399D54C1E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_C0E2504275BB88FED1A36F399D548B26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_C0E2504275BB88FED1A36F399D548B26" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: reclassification adjustment for (gains) losses included in net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_C0E2504275BB88FED1A36F399D548B26_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_C0E2504275BB88FED1A36F399D548B26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_C0E2504275BB88FED1A36F399D548B26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_C0E2504275BB88FED1A36F399D548B26" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_C0E2504275BB88FED1A36F399D548B26" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8569CF4AE21E4AC2D33C6F399D550A2D_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8569CF4AE21E4AC2D33C6F399D550A2D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8569CF4AE21E4AC2D33C6F399D550A2D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8569CF4AE21E4AC2D33C6F399D550A2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8569CF4AE21E4AC2D33C6F399D550A2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8569CF4AE21E4AC2D33C6F399D550A2D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8569CF4AE21E4AC2D33C6F399D550A2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_CCE1DD51C7AD9F7B9A226F399D551526_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_CCE1DD51C7AD9F7B9A226F399D551526" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_CCE1DD51C7AD9F7B9A226F399D551526_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_CCE1DD51C7AD9F7B9A226F399D551526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_CCE1DD51C7AD9F7B9A226F399D551526" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_CCE1DD51C7AD9F7B9A226F399D551526" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_CCE1DD51C7AD9F7B9A226F399D551526" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_68F1846C57AA432E16946F399D557758_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_68F1846C57AA432E16946F399D557758" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: reclassification adjustment for (gains) losses included in net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_68F1846C57AA432E16946F399D557758_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_68F1846C57AA432E16946F399D557758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_68F1846C57AA432E16946F399D557758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_68F1846C57AA432E16946F399D557758" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_68F1846C57AA432E16946F399D557758" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_75A4C7148F8CE6E760696F399D554892_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_75A4C7148F8CE6E760696F399D554892" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_75A4C7148F8CE6E760696F399D554892_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_75A4C7148F8CE6E760696F399D554892" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_75A4C7148F8CE6E760696F399D554892" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_75A4C7148F8CE6E760696F399D554892" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_75A4C7148F8CE6E760696F399D554892" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_86EC54384807C3A59E116F399D55691C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_86EC54384807C3A59E116F399D55691C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (Losses) on net investment hedge recognized during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_86EC54384807C3A59E116F399D55691C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_86EC54384807C3A59E116F399D55691C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_86EC54384807C3A59E116F399D55691C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_86EC54384807C3A59E116F399D55691C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_86EC54384807C3A59E116F399D55691C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_ECEB4AC79C2DDF2561C76F399D552C20_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_ECEB4AC79C2DDF2561C76F399D552C20" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Reclassification of net investment hedge forward points amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_ECEB4AC79C2DDF2561C76F399D552C20_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_ECEB4AC79C2DDF2561C76F399D552C20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_ECEB4AC79C2DDF2561C76F399D552C20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_ECEB4AC79C2DDF2561C76F399D552C20" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_ECEB4AC79C2DDF2561C76F399D552C20" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_A7D4E5ACC258EF887F7A6F399D56E2DF_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_A7D4E5ACC258EF887F7A6F399D56E2DF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_A7D4E5ACC258EF887F7A6F399D56E2DF_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_A7D4E5ACC258EF887F7A6F399D56E2DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_A7D4E5ACC258EF887F7A6F399D56E2DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_A7D4E5ACC258EF887F7A6F399D56E2DF" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_A7D4E5ACC258EF887F7A6F399D56E2DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_865EAE280BE1BE6ED1646F399D565A19_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_865EAE280BE1BE6ED1646F399D565A19" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_865EAE280BE1BE6ED1646F399D565A19_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_865EAE280BE1BE6ED1646F399D565A19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_865EAE280BE1BE6ED1646F399D565A19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_865EAE280BE1BE6ED1646F399D565A19" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_865EAE280BE1BE6ED1646F399D565A19" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCB07ACF6599B83A990D6F399D56A549_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCB07ACF6599B83A990D6F399D56A549" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCB07ACF6599B83A990D6F399D56A549_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCB07ACF6599B83A990D6F399D56A549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCB07ACF6599B83A990D6F399D56A549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCB07ACF6599B83A990D6F399D56A549" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCB07ACF6599B83A990D6F399D56A549" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_FAB86024FAD2460AF7576F399D561D2E_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_FAB86024FAD2460AF7576F399D561D2E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_FAB86024FAD2460AF7576F399D561D2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_FAB86024FAD2460AF7576F399D561D2E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_FAB86024FAD2460AF7576F399D561D2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ABBF25B38E2922B762176F399D5647EA_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_ABBF25B38E2922B762176F399D5647EA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ABBF25B38E2922B762176F399D5647EA_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_ABBF25B38E2922B762176F399D5647EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ABBF25B38E2922B762176F399D5647EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ABBF25B38E2922B762176F399D5647EA" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_ABBF25B38E2922B762176F399D5647EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AD2578D963CDA19DDB1C6F399D5773CA_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AD2578D963CDA19DDB1C6F399D5773CA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AD2578D963CDA19DDB1C6F399D5773CA_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AD2578D963CDA19DDB1C6F399D5773CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AD2578D963CDA19DDB1C6F399D5773CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AD2578D963CDA19DDB1C6F399D5773CA" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AD2578D963CDA19DDB1C6F399D5773CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EEBD0296AC073CDF2AE26F399D57D963_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EEBD0296AC073CDF2AE26F399D57D963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EEBD0296AC073CDF2AE26F399D57D963_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EEBD0296AC073CDF2AE26F399D57D963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EEBD0296AC073CDF2AE26F399D57D963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EEBD0296AC073CDF2AE26F399D57D963" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EEBD0296AC073CDF2AE26F399D57D963" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_346E789792DF7BA15A206F399CEA32C2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_346E789792DF7BA15A206F399CEA32C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_346E789792DF7BA15A206F399CEA32C2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_346E789792DF7BA15A206F399CEA32C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_346E789792DF7BA15A206F399CEA32C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_346E789792DF7BA15A206F399CEA32C2" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_346E789792DF7BA15A206F399CEA32C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3C7F99E427DE7603EB407EE95248A274_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3C7F99E427DE7603EB407EE95248A274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3C7F99E427DE7603EB407EE95248A274_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3C7F99E427DE7603EB407EE95248A274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3C7F99E427DE7603EB407EE95248A274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3C7F99E427DE7603EB407EE95248A274" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3C7F99E427DE7603EB407EE95248A274" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_BB1C62AA144222D892407EE952483E77_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_BB1C62AA144222D892407EE952483E77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_BB1C62AA144222D892407EE952483E77_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_BB1C62AA144222D892407EE952483E77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_BB1C62AA144222D892407EE952483E77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_BB1C62AA144222D892407EE952483E77" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_BB1C62AA144222D892407EE952483E77" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_9142F7AE8B9D45CE07257EE9524882DE_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_9142F7AE8B9D45CE07257EE9524882DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_9142F7AE8B9D45CE07257EE9524882DE_label_en-US" xlink:label="lab_us-gaap_Goodwill_9142F7AE8B9D45CE07257EE9524882DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_9142F7AE8B9D45CE07257EE9524882DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_9142F7AE8B9D45CE07257EE9524882DE" xlink:to="lab_us-gaap_Goodwill_9142F7AE8B9D45CE07257EE9524882DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_E1BB7E2EC00B62EE75FA7EE95248D9C8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_E1BB7E2EC00B62EE75FA7EE95248D9C8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_E1BB7E2EC00B62EE75FA7EE95248D9C8_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_E1BB7E2EC00B62EE75FA7EE95248D9C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_E1BB7E2EC00B62EE75FA7EE95248D9C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_E1BB7E2EC00B62EE75FA7EE95248D9C8" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_E1BB7E2EC00B62EE75FA7EE95248D9C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_193D95298327FEA0D7B17EE95248A6F8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_193D95298327FEA0D7B17EE95248A6F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_193D95298327FEA0D7B17EE95248A6F8_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_193D95298327FEA0D7B17EE95248A6F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_193D95298327FEA0D7B17EE95248A6F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_193D95298327FEA0D7B17EE95248A6F8" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_193D95298327FEA0D7B17EE95248A6F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9DDCC474F2DDE92AD52E7EE95248DC67_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9DDCC474F2DDE92AD52E7EE95248DC67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9DDCC474F2DDE92AD52E7EE95248DC67_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9DDCC474F2DDE92AD52E7EE95248DC67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9DDCC474F2DDE92AD52E7EE95248DC67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9DDCC474F2DDE92AD52E7EE95248DC67" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9DDCC474F2DDE92AD52E7EE95248DC67" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_C33517CAB72F898294AE6F399C1C7C20_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_C33517CAB72F898294AE6F399C1C7C20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Indebtedness</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_C33517CAB72F898294AE6F399C1C7C20_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_C33517CAB72F898294AE6F399C1C7C20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_C33517CAB72F898294AE6F399C1C7C20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_C33517CAB72F898294AE6F399C1C7C20" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_C33517CAB72F898294AE6F399C1C7C20" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AB4330DCD3EEBDC69D306F399C1C3A52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AB4330DCD3EEBDC69D306F399C1C3A52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AB4330DCD3EEBDC69D306F399C1C3A52_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AB4330DCD3EEBDC69D306F399C1C3A52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AB4330DCD3EEBDC69D306F399C1C3A52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AB4330DCD3EEBDC69D306F399C1C3A52" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AB4330DCD3EEBDC69D306F399C1C3A52" xlink:type="arc" />
    <link:label id="lab_biib_AccumulatedOtherComprehensiveIncomeLossAbstract_924100C12F2782EF6DA493DCFFCAF48B_label_en-US" xlink:label="lab_biib_AccumulatedOtherComprehensiveIncomeLossAbstract_924100C12F2782EF6DA493DCFFCAF48B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_AccumulatedOtherComprehensiveIncomeLossAbstract_924100C12F2782EF6DA493DCFFCAF48B_documentation_en-US" xlink:label="lab_biib_AccumulatedOtherComprehensiveIncomeLossAbstract_924100C12F2782EF6DA493DCFFCAF48B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_AccumulatedOtherComprehensiveIncomeLossAbstract_924100C12F2782EF6DA493DCFFCAF48B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccumulatedOtherComprehensiveIncomeLossAbstract_924100C12F2782EF6DA493DCFFCAF48B" xlink:to="lab_biib_AccumulatedOtherComprehensiveIncomeLossAbstract_924100C12F2782EF6DA493DCFFCAF48B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BB3AF0BF154EF834DB6E93DD5027F341_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BB3AF0BF154EF834DB6E93DD5027F341" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BB3AF0BF154EF834DB6E93DD5027F341_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BB3AF0BF154EF834DB6E93DD5027F341" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BB3AF0BF154EF834DB6E93DD5027F341" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BB3AF0BF154EF834DB6E93DD5027F341" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BB3AF0BF154EF834DB6E93DD5027F341" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_1D0BCCB60551F54CCD7393E09E1E737C_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_1D0BCCB60551F54CCD7393E09E1E737C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_1D0BCCB60551F54CCD7393E09E1E737C_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_1D0BCCB60551F54CCD7393E09E1E737C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_1D0BCCB60551F54CCD7393E09E1E737C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_1D0BCCB60551F54CCD7393E09E1E737C" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_1D0BCCB60551F54CCD7393E09E1E737C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C62C3C06A0AB24DCAC9A6F399D606100_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C62C3C06A0AB24DCAC9A6F399D606100" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C62C3C06A0AB24DCAC9A6F399D606100_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C62C3C06A0AB24DCAC9A6F399D606100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C62C3C06A0AB24DCAC9A6F399D606100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C62C3C06A0AB24DCAC9A6F399D606100" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C62C3C06A0AB24DCAC9A6F399D606100" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Abstract]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Abstract]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockAbstract" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4683940800E0621383A46F399FC1B20E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4683940800E0621383A46F399FC1B20E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4683940800E0621383A46F399FC1B20E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4683940800E0621383A46F399FC1B20E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4683940800E0621383A46F399FC1B20E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4683940800E0621383A46F399FC1B20E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4683940800E0621383A46F399FC1B20E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93FE0045BC5DC2CE747E6F399FC11F1D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93FE0045BC5DC2CE747E6F399FC11F1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93FE0045BC5DC2CE747E6F399FC11F1D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93FE0045BC5DC2CE747E6F399FC11F1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93FE0045BC5DC2CE747E6F399FC11F1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93FE0045BC5DC2CE747E6F399FC11F1D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93FE0045BC5DC2CE747E6F399FC11F1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0F916F64ED215EE134436F399FC2AB8E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0F916F64ED215EE134436F399FC2AB8E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0F916F64ED215EE134436F399FC2AB8E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0F916F64ED215EE134436F399FC2AB8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0F916F64ED215EE134436F399FC2AB8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0F916F64ED215EE134436F399FC2AB8E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0F916F64ED215EE134436F399FC2AB8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_B1F621C44549F22B322B6F399FC23021_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_B1F621C44549F22B322B6F399FC23021" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_B1F621C44549F22B322B6F399FC23021_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_B1F621C44549F22B322B6F399FC23021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_B1F621C44549F22B322B6F399FC23021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_B1F621C44549F22B322B6F399FC23021" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_B1F621C44549F22B322B6F399FC23021" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DAB1B479F56129FBB9686F399FC21D37_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DAB1B479F56129FBB9686F399FC21D37" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DAB1B479F56129FBB9686F399FC21D37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DAB1B479F56129FBB9686F399FC21D37" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DAB1B479F56129FBB9686F399FC21D37" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8030C1B5691DBF3FC6196F399E3860AF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8030C1B5691DBF3FC6196F399E3860AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8030C1B5691DBF3FC6196F399E3860AF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8030C1B5691DBF3FC6196F399E3860AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8030C1B5691DBF3FC6196F399E3860AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8030C1B5691DBF3FC6196F399E3860AF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8030C1B5691DBF3FC6196F399E3860AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_15ED3A862FDB700C62576F39A040F116_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_15ED3A862FDB700C62576F39A040F116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_15ED3A862FDB700C62576F39A040F116" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_15ED3A862FDB700C62576F39A040F116" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_15ED3A862FDB700C62576F39A040F116" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_7421F1092E5EE311F15E6F39A04070F7_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_7421F1092E5EE311F15E6F39A04070F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_7421F1092E5EE311F15E6F39A04070F7_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_7421F1092E5EE311F15E6F39A04070F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7421F1092E5EE311F15E6F39A04070F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7421F1092E5EE311F15E6F39A04070F7" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_7421F1092E5EE311F15E6F39A04070F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ACF3AB91C1FF80BFA49D6F39A041BD4A_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_ACF3AB91C1FF80BFA49D6F39A041BD4A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ACF3AB91C1FF80BFA49D6F39A041BD4A_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_ACF3AB91C1FF80BFA49D6F39A041BD4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ACF3AB91C1FF80BFA49D6F39A041BD4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_ACF3AB91C1FF80BFA49D6F39A041BD4A" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_ACF3AB91C1FF80BFA49D6F39A041BD4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_360BEF045222D851E2BD6F39A041F37E_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_360BEF045222D851E2BD6F39A041F37E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_360BEF045222D851E2BD6F39A041F37E_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_360BEF045222D851E2BD6F39A041F37E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_360BEF045222D851E2BD6F39A041F37E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_360BEF045222D851E2BD6F39A041F37E" xlink:to="lab_us-gaap_TreasuryStockShares_360BEF045222D851E2BD6F39A041F37E" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_817BE4BA24B9EB77552BEBFB6553D34C_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract_817BE4BA24B9EB77552BEBFB6553D34C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_817BE4BA24B9EB77552BEBFB6553D34C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_817BE4BA24B9EB77552BEBFB6553D34C" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract_817BE4BA24B9EB77552BEBFB6553D34C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_3E5508FA311281F4BDA1EBFB6554A4D8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_3E5508FA311281F4BDA1EBFB6554A4D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_3E5508FA311281F4BDA1EBFB6554A4D8_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_3E5508FA311281F4BDA1EBFB6554A4D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_3E5508FA311281F4BDA1EBFB6554A4D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_3E5508FA311281F4BDA1EBFB6554A4D8" xlink:to="lab_us-gaap_AccountsReceivableMember_3E5508FA311281F4BDA1EBFB6554A4D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_02B953A0C9E40C8E215FEBFB6554B2F1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_02B953A0C9E40C8E215FEBFB6554B2F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_02B953A0C9E40C8E215FEBFB6554B2F1_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_02B953A0C9E40C8E215FEBFB6554B2F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_02B953A0C9E40C8E215FEBFB6554B2F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_02B953A0C9E40C8E215FEBFB6554B2F1" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_02B953A0C9E40C8E215FEBFB6554B2F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_874CE536535B2FBD3BFCEBFB65554850_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_874CE536535B2FBD3BFCEBFB65554850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_874CE536535B2FBD3BFCEBFB65554850_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_874CE536535B2FBD3BFCEBFB65554850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_874CE536535B2FBD3BFCEBFB65554850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_874CE536535B2FBD3BFCEBFB65554850" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_874CE536535B2FBD3BFCEBFB65554850" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_A8CC65A2949E9BE041E36F399EEF59CA_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_A8CC65A2949E9BE041E36F399EEF59CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_A8CC65A2949E9BE041E36F399EEF59CA_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_A8CC65A2949E9BE041E36F399EEF59CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_A8CC65A2949E9BE041E36F399EEF59CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_A8CC65A2949E9BE041E36F399EEF59CA" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_A8CC65A2949E9BE041E36F399EEF59CA" xlink:type="arc" />
    <link:label id="lab_biib_DivestituresAbstract_8427159146DD24F72434E86FAF5338B0_label_en-US" xlink:label="lab_biib_DivestituresAbstract_8427159146DD24F72434E86FAF5338B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_8427159146DD24F72434E86FAF5338B0_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract_8427159146DD24F72434E86FAF5338B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_8427159146DD24F72434E86FAF5338B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract_8427159146DD24F72434E86FAF5338B0" xlink:to="lab_biib_DivestituresAbstract_8427159146DD24F72434E86FAF5338B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E3594119CB6FB5F85FFCE86FAF554690_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E3594119CB6FB5F85FFCE86FAF554690" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received for sale of Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E3594119CB6FB5F85FFCE86FAF554690_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E3594119CB6FB5F85FFCE86FAF554690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E3594119CB6FB5F85FFCE86FAF554690" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E3594119CB6FB5F85FFCE86FAF554690" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E3594119CB6FB5F85FFCE86FAF554690" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_10E9541C698A0047E28CE86FAF550D2D_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_10E9541C698A0047E28CE86FAF550D2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum batch production for Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_10E9541C698A0047E28CE86FAF550D2D_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_10E9541C698A0047E28CE86FAF550D2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_10E9541C698A0047E28CE86FAF550D2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_10E9541C698A0047E28CE86FAF550D2D" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_10E9541C698A0047E28CE86FAF550D2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_F138BC84321FF9AC4B02E86FAF55C71E_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_F138BC84321FF9AC4B02E86FAF55C71E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_F138BC84321FF9AC4B02E86FAF55C71E_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_F138BC84321FF9AC4B02E86FAF55C71E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_F138BC84321FF9AC4B02E86FAF55C71E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_F138BC84321FF9AC4B02E86FAF55C71E" xlink:to="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_F138BC84321FF9AC4B02E86FAF55C71E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7F2FF7C0DB4B02E1EC27E86FAF560F4E_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7F2FF7C0DB4B02E1EC27E86FAF560F4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected costs to sell disposal group</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7F2FF7C0DB4B02E1EC27E86FAF560F4E_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7F2FF7C0DB4B02E1EC27E86FAF560F4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7F2FF7C0DB4B02E1EC27E86FAF560F4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7F2FF7C0DB4B02E1EC27E86FAF560F4E" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7F2FF7C0DB4B02E1EC27E86FAF560F4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5ABA8686DD864D533267E86FAF560C14_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5ABA8686DD864D533267E86FAF560C14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense on disposal group</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5ABA8686DD864D533267E86FAF560C14_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5ABA8686DD864D533267E86FAF560C14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5ABA8686DD864D533267E86FAF560C14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5ABA8686DD864D533267E86FAF560C14" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5ABA8686DD864D533267E86FAF560C14" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_095B15C512B0135BDB12FC2E5A23FC7B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_095B15C512B0135BDB12FC2E5A23FC7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_095B15C512B0135BDB12FC2E5A23FC7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_095B15C512B0135BDB12FC2E5A23FC7B" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_095B15C512B0135BDB12FC2E5A23FC7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC_label_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxAssetLiabilityTypeAxis" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:to="lab_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Domain]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906_label_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Domain]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxAssetLiabilityTypeDomain" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906" xlink:to="lab_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntellectualPropertyMember_F33C2354A9F5F5CA0402FC2E5A248C17_terseLabel_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember_F33C2354A9F5F5CA0402FC2E5A248C17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual Property</link:label>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_F33C2354A9F5F5CA0402FC2E5A248C17_label_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember_F33C2354A9F5F5CA0402FC2E5A248C17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_F33C2354A9F5F5CA0402FC2E5A248C17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_F33C2354A9F5F5CA0402FC2E5A248C17" xlink:to="lab_us-gaap_IntellectualPropertyMember_F33C2354A9F5F5CA0402FC2E5A248C17" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647" xlink:to="lab_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647" xlink:type="arc" />
    <link:label id="lab_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739_terseLabel_en-US" xlink:label="lab_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:label id="lab_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739_label_en-US" xlink:label="lab_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:label id="lab_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739_documentation_en-US" xlink:label="lab_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignearningstypeAxis" xlink:label="loc_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:to="lab_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:type="arc" />
    <link:label id="lab_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740_terseLabel_en-US" xlink:label="lab_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Domain]</link:label>
    <link:label id="lab_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740_label_en-US" xlink:label="lab_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Domain]</link:label>
    <link:label id="lab_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740_documentation_en-US" xlink:label="lab_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Foreign earnings type [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:to="lab_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:type="arc" />
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF_terseLabel_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings in the form of cash and cash equivalents</link:label>
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF_label_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign earnings in the form of cash and cash equivalents [Member]</link:label>
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF_documentation_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign earnings in the form of cash and cash equivalents [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF" xlink:to="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF" xlink:type="arc" />
    <link:label id="lab_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070_terseLabel_en-US" xlink:label="lab_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Foreign Earnings</link:label>
    <link:label id="lab_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070_label_en-US" xlink:label="lab_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Foreign Earnings [Member]</link:label>
    <link:label id="lab_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070_documentation_en-US" xlink:label="lab_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Foreign Earnings [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherForeignEarningsMember" xlink:label="loc_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070" xlink:to="lab_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_1EB89FAE06941FCE8289FC2E5A2F1BCA_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_1EB89FAE06941FCE8289FC2E5A2F1BCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1EB89FAE06941FCE8289FC2E5A2F1BCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_1EB89FAE06941FCE8289FC2E5A2F1BCA" xlink:to="lab_us-gaap_RetainedEarningsMember_1EB89FAE06941FCE8289FC2E5A2F1BCA" xlink:type="arc" />
    <link:label id="lab_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51_terseLabel_en-US" xlink:label="lab_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51_label_en-US" xlink:label="lab_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid taxes [Member]</link:label>
    <link:label id="lab_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51_documentation_en-US" xlink:label="lab_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid taxes [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PrepaidtaxesMember" xlink:label="loc_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51" xlink:to="lab_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralBusinessMember_1D1954CEE8DA0A13D2F6FC2E5A2F85EC_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember_1D1954CEE8DA0A13D2F6FC2E5A2F85EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Business</link:label>
    <link:label id="lab_us-gaap_GeneralBusinessMember_1D1954CEE8DA0A13D2F6FC2E5A2F85EC_label_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember_1D1954CEE8DA0A13D2F6FC2E5A2F85EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Business Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_1D1954CEE8DA0A13D2F6FC2E5A2F85EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralBusinessMember_1D1954CEE8DA0A13D2F6FC2E5A2F85EC" xlink:to="lab_us-gaap_GeneralBusinessMember_1D1954CEE8DA0A13D2F6FC2E5A2F85EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_97CE2EABD63F3E74FFBCFC2E5A30711D_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_97CE2EABD63F3E74FFBCFC2E5A30711D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research</link:label>
    <link:label id="lab_us-gaap_ResearchMember_97CE2EABD63F3E74FFBCFC2E5A30711D_label_en-US" xlink:label="lab_us-gaap_ResearchMember_97CE2EABD63F3E74FFBCFC2E5A30711D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_97CE2EABD63F3E74FFBCFC2E5A30711D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_97CE2EABD63F3E74FFBCFC2E5A30711D" xlink:to="lab_us-gaap_ResearchMember_97CE2EABD63F3E74FFBCFC2E5A30711D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:type="arc" />
    <link:label id="lab_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8_terseLabel_en-US" xlink:label="lab_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Tax Act</link:label>
    <link:label id="lab_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8_label_en-US" xlink:label="lab_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. 2017 Tax Act [Member]</link:label>
    <link:label id="lab_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8_documentation_en-US" xlink:label="lab_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">U.S. 2017 Tax Act</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8" xlink:to="lab_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_6F93A458E0B86893794CFC2E5A307C06_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_6F93A458E0B86893794CFC2E5A307C06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Country</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_6F93A458E0B86893794CFC2E5A307C06_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_6F93A458E0B86893794CFC2E5A307C06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_6F93A458E0B86893794CFC2E5A307C06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_6F93A458E0B86893794CFC2E5A307C06" xlink:to="lab_us-gaap_DomesticCountryMember_6F93A458E0B86893794CFC2E5A307C06" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_5915F6DDAFFA6C154C4FFC2E5A31CE9C_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_5915F6DDAFFA6C154C4FFC2E5A31CE9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_5915F6DDAFFA6C154C4FFC2E5A31CE9C_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_5915F6DDAFFA6C154C4FFC2E5A31CE9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5915F6DDAFFA6C154C4FFC2E5A31CE9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_5915F6DDAFFA6C154C4FFC2E5A31CE9C" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_5915F6DDAFFA6C154C4FFC2E5A31CE9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_74A4548EB9AE62F1A6CCFC2E5A3165AF_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_74A4548EB9AE62F1A6CCFC2E5A3165AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_74A4548EB9AE62F1A6CCFC2E5A3165AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_74A4548EB9AE62F1A6CCFC2E5A3165AF" xlink:to="lab_us-gaap_ForeignCountryMember_74A4548EB9AE62F1A6CCFC2E5A3165AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_A4F6B35FC5A842BD086BFC2E5A312376_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_A4F6B35FC5A842BD086BFC2E5A312376" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_A4F6B35FC5A842BD086BFC2E5A312376_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_A4F6B35FC5A842BD086BFC2E5A312376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_A4F6B35FC5A842BD086BFC2E5A312376" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther_A4F6B35FC5A842BD086BFC2E5A312376" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther_A4F6B35FC5A842BD086BFC2E5A312376" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_1B9C1DDEEC7C860EE2A6FC2E5A32DF40_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_1B9C1DDEEC7C860EE2A6FC2E5A32DF40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_1B9C1DDEEC7C860EE2A6FC2E5A32DF40_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_1B9C1DDEEC7C860EE2A6FC2E5A32DF40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1B9C1DDEEC7C860EE2A6FC2E5A32DF40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_1B9C1DDEEC7C860EE2A6FC2E5A32DF40" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_1B9C1DDEEC7C860EE2A6FC2E5A32DF40" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B69478896DE2F63D68F6FC2E5A324535_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B69478896DE2F63D68F6FC2E5A324535" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B69478896DE2F63D68F6FC2E5A324535_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B69478896DE2F63D68F6FC2E5A324535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B69478896DE2F63D68F6FC2E5A324535" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B69478896DE2F63D68F6FC2E5A324535" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B69478896DE2F63D68F6FC2E5A324535" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F2879DA82B042DCC6F45FC2E5A325751_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F2879DA82B042DCC6F45FC2E5A325751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F2879DA82B042DCC6F45FC2E5A325751_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F2879DA82B042DCC6F45FC2E5A325751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F2879DA82B042DCC6F45FC2E5A325751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F2879DA82B042DCC6F45FC2E5A325751" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F2879DA82B042DCC6F45FC2E5A325751" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ECE14781248ECFF957E2FC2E5A32EA64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_ECE14781248ECFF957E2FC2E5A32EA64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ECE14781248ECFF957E2FC2E5A32EA64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ECE14781248ECFF957E2FC2E5A32EA64" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_ECE14781248ECFF957E2FC2E5A32EA64" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ECC4F8648B52888F5187FC2E5A33E274_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ECC4F8648B52888F5187FC2E5A33E274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition toll tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ECC4F8648B52888F5187FC2E5A33E274_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ECC4F8648B52888F5187FC2E5A33E274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ECC4F8648B52888F5187FC2E5A33E274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ECC4F8648B52888F5187FC2E5A33E274" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ECC4F8648B52888F5187FC2E5A33E274" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaid_08DC23A049597E5DE7BBFC2E5A337186_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_08DC23A049597E5DE7BBFC2E5A337186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_08DC23A049597E5DE7BBFC2E5A337186_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_08DC23A049597E5DE7BBFC2E5A337186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_08DC23A049597E5DE7BBFC2E5A337186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_08DC23A049597E5DE7BBFC2E5A337186" xlink:to="lab_us-gaap_IncomeTaxesPaid_08DC23A049597E5DE7BBFC2E5A337186" xlink:type="arc" />
    <link:label id="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49_terseLabel_en-US" xlink:label="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</link:label>
    <link:label id="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49_label_en-US" xlink:label="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</link:label>
    <link:label id="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49_documentation_en-US" xlink:label="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" xlink:label="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49" xlink:to="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49" xlink:type="arc" />
    <link:label id="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B_terseLabel_en-US" xlink:label="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</link:label>
    <link:label id="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B_label_en-US" xlink:label="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</link:label>
    <link:label id="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B_documentation_en-US" xlink:label="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" xlink:label="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B" xlink:to="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B" xlink:type="arc" />
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898_terseLabel_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition Toll Tax repatriation tax rate</link:label>
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898_label_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transition Toll Tax Repatriation Tax Rate</link:label>
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898_documentation_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transition Toll Tax Repatriation Tax Rate</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_TransitionTollTaxRepatriationTaxRate" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898" xlink:to="lab_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E0F8EFB11FBF2846931DFC2E5A336583_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E0F8EFB11FBF2846931DFC2E5A336583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E0F8EFB11FBF2846931DFC2E5A336583_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E0F8EFB11FBF2846931DFC2E5A336583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E0F8EFB11FBF2846931DFC2E5A336583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E0F8EFB11FBF2846931DFC2E5A336583" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E0F8EFB11FBF2846931DFC2E5A336583" xlink:type="arc" />
    <link:label id="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6_terseLabel_en-US" xlink:label="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in deferred tax liability, undistributed foreign earnings</link:label>
    <link:label id="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6_label_en-US" xlink:label="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in deferred tax liability, undistributed foreign earnings</link:label>
    <link:label id="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6_documentation_en-US" xlink:label="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in deferred tax liability, undistributed foreign earnings</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Reductionindeferredtaxliabilityundistributedforeignearnings" xlink:label="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6" xlink:to="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6" xlink:type="arc" />
    <link:label id="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD_label_en-US" xlink:label="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, GILTI tax calculation</link:label>
    <link:label id="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, GILTI tax calculation</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD" xlink:to="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherTaxExpenseBenefit_054C22239EB1D70D5F1FFC2E5A34A456_terseLabel_en-US" xlink:label="lab_us-gaap_OtherTaxExpenseBenefit_054C22239EB1D70D5F1FFC2E5A34A456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherTaxExpenseBenefit_054C22239EB1D70D5F1FFC2E5A34A456_label_en-US" xlink:label="lab_us-gaap_OtherTaxExpenseBenefit_054C22239EB1D70D5F1FFC2E5A34A456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_054C22239EB1D70D5F1FFC2E5A34A456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherTaxExpenseBenefit_054C22239EB1D70D5F1FFC2E5A34A456" xlink:to="lab_us-gaap_OtherTaxExpenseBenefit_054C22239EB1D70D5F1FFC2E5A34A456" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_15611CD785CD1CFEF885FC2E5A34CB81_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_15611CD785CD1CFEF885FC2E5A34CB81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net impairment on certain tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_15611CD785CD1CFEF885FC2E5A34CB81_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_15611CD785CD1CFEF885FC2E5A34CB81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_15611CD785CD1CFEF885FC2E5A34CB81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_15611CD785CD1CFEF885FC2E5A34CB81" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_15611CD785CD1CFEF885FC2E5A34CB81" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_72B0E30BCE32EFF94DF1FC2E5A344A40_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_72B0E30BCE32EFF94DF1FC2E5A344A40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_72B0E30BCE32EFF94DF1FC2E5A344A40_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_72B0E30BCE32EFF94DF1FC2E5A344A40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_72B0E30BCE32EFF94DF1FC2E5A344A40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_72B0E30BCE32EFF94DF1FC2E5A344A40" xlink:to="lab_us-gaap_OperatingLossCarryforwards_72B0E30BCE32EFF94DF1FC2E5A344A40" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_1022A6B4A5BF8605F1B4FC2E5A34E862_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_1022A6B4A5BF8605F1B4FC2E5A34E862" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_1022A6B4A5BF8605F1B4FC2E5A34E862_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_1022A6B4A5BF8605F1B4FC2E5A34E862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1022A6B4A5BF8605F1B4FC2E5A34E862" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_1022A6B4A5BF8605F1B4FC2E5A34E862" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_1022A6B4A5BF8605F1B4FC2E5A34E862" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_B034043B1F469AAFBA6DFC2E5A34670A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_B034043B1F469AAFBA6DFC2E5A34670A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_B034043B1F469AAFBA6DFC2E5A34670A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_B034043B1F469AAFBA6DFC2E5A34670A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_B034043B1F469AAFBA6DFC2E5A34670A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_B034043B1F469AAFBA6DFC2E5A34670A" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_B034043B1F469AAFBA6DFC2E5A34670A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D306F1D80365E677B41EFC2E5A35A647_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D306F1D80365E677B41EFC2E5A35A647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect of new accounting principle in period of adoption</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D306F1D80365E677B41EFC2E5A35A647_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D306F1D80365E677B41EFC2E5A35A647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D306F1D80365E677B41EFC2E5A35A647" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D306F1D80365E677B41EFC2E5A35A647" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D306F1D80365E677B41EFC2E5A35A647" xlink:type="arc" />
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20E7BF62CAB2488FA5F5FC37ACE198D4_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20E7BF62CAB2488FA5F5FC37ACE198D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20E7BF62CAB2488FA5F5FC37ACE198D4_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20E7BF62CAB2488FA5F5FC37ACE198D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20E7BF62CAB2488FA5F5FC37ACE198D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20E7BF62CAB2488FA5F5FC37ACE198D4" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20E7BF62CAB2488FA5F5FC37ACE198D4" xlink:type="arc" />
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7_verboseLabel_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes (Textual)</link:label>
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7_label_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7_documentation_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_IncomeTaxesTextualAbstract" xlink:label="loc_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7" xlink:to="lab_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7" xlink:type="arc" />
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_184BC14E9F5FC160D20EFC2E5A358E38_terseLabel_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_184BC14E9F5FC160D20EFC2E5A358E38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_184BC14E9F5FC160D20EFC2E5A358E38_label_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_184BC14E9F5FC160D20EFC2E5A358E38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_184BC14E9F5FC160D20EFC2E5A358E38_documentation_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_184BC14E9F5FC160D20EFC2E5A358E38" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Totaldeferredchargesandprepaidtaxes" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_184BC14E9F5FC160D20EFC2E5A358E38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Totaldeferredchargesandprepaidtaxes_184BC14E9F5FC160D20EFC2E5A358E38" xlink:to="lab_biib_Totaldeferredchargesandprepaidtaxes_184BC14E9F5FC160D20EFC2E5A358E38" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1046B7E8087A1AFBA9A3FC2E5A35C5A8_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1046B7E8087A1AFBA9A3FC2E5A35C5A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1046B7E8087A1AFBA9A3FC2E5A35C5A8_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1046B7E8087A1AFBA9A3FC2E5A35C5A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1046B7E8087A1AFBA9A3FC2E5A35C5A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1046B7E8087A1AFBA9A3FC2E5A35C5A8" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1046B7E8087A1AFBA9A3FC2E5A35C5A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_186E8A67DBAE6790415DFC2E5A35E484_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_186E8A67DBAE6790415DFC2E5A35E484" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_186E8A67DBAE6790415DFC2E5A35E484_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_186E8A67DBAE6790415DFC2E5A35E484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_186E8A67DBAE6790415DFC2E5A35E484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_186E8A67DBAE6790415DFC2E5A35E484" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_186E8A67DBAE6790415DFC2E5A35E484" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2D72B1CF82A04C32898AFC2E5A3BB377_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2D72B1CF82A04C32898AFC2E5A3BB377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2D72B1CF82A04C32898AFC2E5A3BB377_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2D72B1CF82A04C32898AFC2E5A3BB377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2D72B1CF82A04C32898AFC2E5A3BB377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2D72B1CF82A04C32898AFC2E5A3BB377" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2D72B1CF82A04C32898AFC2E5A3BB377" xlink:type="arc" />
    <link:label id="lab_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5_verboseLabel_en-US" xlink:label="lab_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Directors Plan</link:label>
    <link:label id="lab_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5_label_en-US" xlink:label="lab_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Directors Plan [Member]</link:label>
    <link:label id="lab_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5_documentation_en-US" xlink:label="lab_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Directors plan.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5" xlink:to="lab_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5" xlink:type="arc" />
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03_terseLabel_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Omnibus Equity Plan</link:label>
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03_label_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Omnibus Equity Plan [Member]</link:label>
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03_documentation_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Omnibus Equity Plan</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_A2017OmnibusEquityPlanMember" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03" xlink:to="lab_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03" xlink:type="arc" />
    <link:label id="lab_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9" xlink:to="lab_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9" xlink:type="arc" />
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7" xlink:type="arc" />
    <link:label id="lab_srt_DirectorMember_D5679BB9E8FDAE6073F66F399CB65B2A_terseLabel_en-US" xlink:label="lab_srt_DirectorMember_D5679BB9E8FDAE6073F66F399CB65B2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_D5679BB9E8FDAE6073F66F399CB65B2A_label_en-US" xlink:label="lab_srt_DirectorMember_D5679BB9E8FDAE6073F66F399CB65B2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_D5679BB9E8FDAE6073F66F399CB65B2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_D5679BB9E8FDAE6073F66F399CB65B2A" xlink:to="lab_srt_DirectorMember_D5679BB9E8FDAE6073F66F399CB65B2A" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E" xlink:to="lab_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A_verboseLabel_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total number of shares of common stock for issuance</link:label>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A_label_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Of Common Stock For Issuance</link:label>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A_documentation_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total number of shares of common stock for issuance.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A" xlink:to="lab_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A" xlink:type="arc" />
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0_verboseLabel_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ratio of total number of shares reserved under the plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0_label_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ratio Of Number Of Shares Reserved Under Plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0_documentation_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ratio of total number of shares reserved under the plan.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0" xlink:to="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9B442170D6ADA2962D526F399CB90B95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9B442170D6ADA2962D526F399CB90B95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omnibus Plan number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9B442170D6ADA2962D526F399CB90B95_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9B442170D6ADA2962D526F399CB90B95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9B442170D6ADA2962D526F399CB90B95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9B442170D6ADA2962D526F399CB90B95" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9B442170D6ADA2962D526F399CB90B95" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3_verboseLabel_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of equal annual increments</link:label>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3_label_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Equal Annual Increments</link:label>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3_documentation_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of equal annual increments.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3" xlink:to="lab_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3" xlink:type="arc" />
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6_verboseLabel_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6_label_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6_documentation_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6" xlink:to="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6" xlink:type="arc" />
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92_verboseLabel_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92_label_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92_documentation_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92" xlink:to="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D29A534A0E624B1077726F399CB9FEE7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D29A534A0E624B1077726F399CB9FEE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D29A534A0E624B1077726F399CB9FEE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D29A534A0E624B1077726F399CB9FEE7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D29A534A0E624B1077726F399CB9FEE7" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23_verboseLabel_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of days for calculation of average closing stock price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23_label_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Days For Calculation Of Average Closing Stock Price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23_documentation_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of days for calculation of average closing stock price.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23" xlink:to="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_BE566431A83556CF0E276F399CBAA094_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_BE566431A83556CF0E276F399CBAA094" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of vested awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_BE566431A83556CF0E276F399CBAA094_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_BE566431A83556CF0E276F399CBAA094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_BE566431A83556CF0E276F399CBAA094" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_BE566431A83556CF0E276F399CBAA094" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_BE566431A83556CF0E276F399CBAA094" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_3737AB3168DFB7789A596F399CBA8932_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_3737AB3168DFB7789A596F399CBA8932" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash in settlement of CSPS awards upon vesting</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_3737AB3168DFB7789A596F399CBA8932_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_3737AB3168DFB7789A596F399CBA8932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Cash Used to Settle Award</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_3737AB3168DFB7789A596F399CBA8932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_3737AB3168DFB7789A596F399CBA8932" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_3737AB3168DFB7789A596F399CBA8932" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758_terseLabel_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payments (Textual)</link:label>
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758_label_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758_documentation_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Payments.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareBasedPaymentsTextualAbstract" xlink:label="loc_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:to="lab_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_D6BC66805968867364456F399CBAAE23_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_D6BC66805968867364456F399CBAAE23" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to unvested share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_D6BC66805968867364456F399CBAAE23_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_D6BC66805968867364456F399CBAAE23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_D6BC66805968867364456F399CBAAE23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_D6BC66805968867364456F399CBAAE23" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_D6BC66805968867364456F399CBAAE23" xlink:type="arc" />
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_F8B044BB70AFF3B2BBA46F399CBBE914_verboseLabel_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_F8B044BB70AFF3B2BBA46F399CBBE914" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period to recognize the cost of unvested awards</link:label>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_F8B044BB70AFF3B2BBA46F399CBBE914_label_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_F8B044BB70AFF3B2BBA46F399CBBE914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Period To Recognize Cost Of Nonvested Awards</link:label>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_F8B044BB70AFF3B2BBA46F399CBBE914_documentation_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_F8B044BB70AFF3B2BBA46F399CBBE914" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-average period to recognize the cost of nonvested awards.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_F8B044BB70AFF3B2BBA46F399CBBE914" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_F8B044BB70AFF3B2BBA46F399CBBE914" xlink:to="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_F8B044BB70AFF3B2BBA46F399CBBE914" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_BD9DD8DEABCE2B96B1A96F399CBBB34C_verboseLabel_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_BD9DD8DEABCE2B96B1A96F399CBBB34C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of share-based compensation plans pursuant to which awards are currently being made</link:label>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_BD9DD8DEABCE2B96B1A96F399CBBB34C_label_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_BD9DD8DEABCE2B96B1A96F399CBBB34C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Based Compensation Plans Pursuant To Which Awards Are Currently Being Made</link:label>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_BD9DD8DEABCE2B96B1A96F399CBBB34C_documentation_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_BD9DD8DEABCE2B96B1A96F399CBBB34C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of share-based compensation plans pursuant to which awards are currently being made.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_BD9DD8DEABCE2B96B1A96F399CBBB34C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_BD9DD8DEABCE2B96B1A96F399CBBB34C" xlink:to="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_BD9DD8DEABCE2B96B1A96F399CBBB34C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B38E70B48DD8942AA45C6F399CBB2AD6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B38E70B48DD8942AA45C6F399CBB2AD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares granted under stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B38E70B48DD8942AA45C6F399CBB2AD6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B38E70B48DD8942AA45C6F399CBB2AD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B38E70B48DD8942AA45C6F399CBB2AD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B38E70B48DD8942AA45C6F399CBB2AD6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B38E70B48DD8942AA45C6F399CBB2AD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6683C8D0E80BBD4897A26F399CBB9815_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6683C8D0E80BBD4897A26F399CBB9815" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6683C8D0E80BBD4897A26F399CBB9815_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6683C8D0E80BBD4897A26F399CBB9815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6683C8D0E80BBD4897A26F399CBB9815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6683C8D0E80BBD4897A26F399CBB9815" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6683C8D0E80BBD4897A26F399CBB9815" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B89401158B9E1A86BBB86F399CBB488E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B89401158B9E1A86BBB86F399CBB488E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic values of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B89401158B9E1A86BBB86F399CBB488E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B89401158B9E1A86BBB86F399CBB488E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B89401158B9E1A86BBB86F399CBB488E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B89401158B9E1A86BBB86F399CBB488E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B89401158B9E1A86BBB86F399CBB488E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_CBA83ED8F1CA7C6A67E66F399CBCBB26_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_CBA83ED8F1CA7C6A67E66F399CBCBB26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_CBA83ED8F1CA7C6A67E66F399CBCBB26_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_CBA83ED8F1CA7C6A67E66F399CBCBB26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_CBA83ED8F1CA7C6A67E66F399CBCBB26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_CBA83ED8F1CA7C6A67E66F399CBCBB26" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_CBA83ED8F1CA7C6A67E66F399CBCBB26" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_6C6FAF4E840D0CC78776E873ACBF4E08_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_6C6FAF4E840D0CC78776E873ACBF4E08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6C6FAF4E840D0CC78776E873ACBF4E08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_6C6FAF4E840D0CC78776E873ACBF4E08" xlink:to="lab_us-gaap_EquityAbstract_6C6FAF4E840D0CC78776E873ACBF4E08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:type="arc" />
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A_terseLabel_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A_label_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A_documentation_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A" xlink:to="lab_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A" xlink:to="lab_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:to="lab_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_330C83B2708A80F90B60E873ACBF1BE2_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_330C83B2708A80F90B60E873ACBF1BE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_330C83B2708A80F90B60E873ACBF1BE2_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_330C83B2708A80F90B60E873ACBF1BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_330C83B2708A80F90B60E873ACBF1BE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_330C83B2708A80F90B60E873ACBF1BE2" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_330C83B2708A80F90B60E873ACBF1BE2" xlink:type="arc" />
    <link:label id="lab_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700_terseLabel_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series X junior participating</link:label>
    <link:label id="lab_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700_label_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series X Preferred Stock [Member]</link:label>
    <link:label id="lab_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700_documentation_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series X preferred stock.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700" xlink:to="lab_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700" xlink:type="arc" />
    <link:label id="lab_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8_terseLabel_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated</link:label>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8_label_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8_documentation_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8" xlink:to="lab_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:to="lab_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_B249F38F6F8C1AAB32A5E873ACBF939C_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B249F38F6F8C1AAB32A5E873ACBF939C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_B249F38F6F8C1AAB32A5E873ACBF939C_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B249F38F6F8C1AAB32A5E873ACBF939C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B249F38F6F8C1AAB32A5E873ACBF939C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_B249F38F6F8C1AAB32A5E873ACBF939C" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_B249F38F6F8C1AAB32A5E873ACBF939C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3543452836150D58EB25E873ACBF3BF0_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3543452836150D58EB25E873ACBF3BF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized amount of share repurchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3543452836150D58EB25E873ACBF3BF0_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3543452836150D58EB25E873ACBF3BF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3543452836150D58EB25E873ACBF3BF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3543452836150D58EB25E873ACBF3BF0" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3543452836150D58EB25E873ACBF3BF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_F246D26C20FE24AED397E873ACBF353A_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_F246D26C20FE24AED397E873ACBF353A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_F246D26C20FE24AED397E873ACBF353A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_F246D26C20FE24AED397E873ACBF353A" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_F246D26C20FE24AED397E873ACBF353A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_081E5CFDB3E3BB203849E873ACBF8A2C_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_081E5CFDB3E3BB203849E873ACBF8A2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_081E5CFDB3E3BB203849E873ACBF8A2C_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_081E5CFDB3E3BB203849E873ACBF8A2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_081E5CFDB3E3BB203849E873ACBF8A2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_081E5CFDB3E3BB203849E873ACBF8A2C" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_081E5CFDB3E3BB203849E873ACBF8A2C" xlink:type="arc" />
    <link:label id="lab_biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract_9B453CE2B7682F3A6AC0FCF51E437988_label_en-US" xlink:label="lab_biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract_9B453CE2B7682F3A6AC0FCF51E437988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract_9B453CE2B7682F3A6AC0FCF51E437988_documentation_en-US" xlink:label="lab_biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract_9B453CE2B7682F3A6AC0FCF51E437988" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract" xlink:label="loc_biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract_9B453CE2B7682F3A6AC0FCF51E437988" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract_9B453CE2B7682F3A6AC0FCF51E437988" xlink:to="lab_biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract_9B453CE2B7682F3A6AC0FCF51E437988" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8D760EEE4BB2CD1FF440FCF51E44D477_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8D760EEE4BB2CD1FF440FCF51E44D477" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains (Losses) on Securities Available for Sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8D760EEE4BB2CD1FF440FCF51E44D477_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8D760EEE4BB2CD1FF440FCF51E44D477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8D760EEE4BB2CD1FF440FCF51E44D477" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8D760EEE4BB2CD1FF440FCF51E44D477" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8D760EEE4BB2CD1FF440FCF51E44D477" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D01F10FC796B0465679BFCF51E45B24B_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D01F10FC796B0465679BFCF51E45B24B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains (Losses) on Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D01F10FC796B0465679BFCF51E45B24B_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D01F10FC796B0465679BFCF51E45B24B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D01F10FC796B0465679BFCF51E45B24B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D01F10FC796B0465679BFCF51E45B24B" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D01F10FC796B0465679BFCF51E45B24B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_EC6DFBC041794EB7A541FCF51E45F11D_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_EC6DFBC041794EB7A541FCF51E45F11D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (Losses) on Net Investment Hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_EC6DFBC041794EB7A541FCF51E45F11D_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_EC6DFBC041794EB7A541FCF51E45F11D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_EC6DFBC041794EB7A541FCF51E45F11D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_EC6DFBC041794EB7A541FCF51E45F11D" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_EC6DFBC041794EB7A541FCF51E45F11D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A22D9350B948C1FD7A6FCF51E4535CF_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A22D9350B948C1FD7A6FCF51E4535CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A22D9350B948C1FD7A6FCF51E4535CF_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A22D9350B948C1FD7A6FCF51E4535CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A22D9350B948C1FD7A6FCF51E4535CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A22D9350B948C1FD7A6FCF51E4535CF" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A22D9350B948C1FD7A6FCF51E4535CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_96DA66D08907455E3706FCF51E4636AF_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_96DA66D08907455E3706FCF51E4636AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_96DA66D08907455E3706FCF51E4636AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_96DA66D08907455E3706FCF51E4636AF" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_96DA66D08907455E3706FCF51E4636AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_3AE8E22E0BBB1E81374FFCF51E46FBDD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_3AE8E22E0BBB1E81374FFCF51E46FBDD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_3AE8E22E0BBB1E81374FFCF51E46FBDD_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_3AE8E22E0BBB1E81374FFCF51E46FBDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3AE8E22E0BBB1E81374FFCF51E46FBDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_3AE8E22E0BBB1E81374FFCF51E46FBDD" xlink:to="lab_us-gaap_OperatingExpenses_3AE8E22E0BBB1E81374FFCF51E46FBDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_A15A0FAFDE819298CC396F399F8A59E2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_A15A0FAFDE819298CC396F399F8A59E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_A15A0FAFDE819298CC396F399F8A59E2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_A15A0FAFDE819298CC396F399F8A59E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_A15A0FAFDE819298CC396F399F8A59E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_A15A0FAFDE819298CC396F399F8A59E2" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_A15A0FAFDE819298CC396F399F8A59E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9980BBD7E9A6EA3807BE6F399D6C2FD6_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9980BBD7E9A6EA3807BE6F399D6C2FD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9980BBD7E9A6EA3807BE6F399D6C2FD6_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9980BBD7E9A6EA3807BE6F399D6C2FD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9980BBD7E9A6EA3807BE6F399D6C2FD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9980BBD7E9A6EA3807BE6F399D6C2FD6" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9980BBD7E9A6EA3807BE6F399D6C2FD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:to="lab_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_FD28AF7C73A7C541EADB0B3C231E370D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_FD28AF7C73A7C541EADB0B3C231E370D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_FD28AF7C73A7C541EADB0B3C231E370D_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_FD28AF7C73A7C541EADB0B3C231E370D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_FD28AF7C73A7C541EADB0B3C231E370D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_FD28AF7C73A7C541EADB0B3C231E370D" xlink:to="lab_us-gaap_SubsequentEventMember_FD28AF7C73A7C541EADB0B3C231E370D" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.05% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.20% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="lab_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_A8F339E924FC8BAA858A0B3C232EC60D_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_A8F339E924FC8BAA858A0B3C232EC60D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_A8F339E924FC8BAA858A0B3C232EC60D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_A8F339E924FC8BAA858A0B3C232EC60D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_A8F339E924FC8BAA858A0B3C232EC60D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_A8F339E924FC8BAA858A0B3C232EC60D" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_A8F339E924FC8BAA858A0B3C232EC60D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A69A05CCD2B5E28309B0B3C232EE208_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A69A05CCD2B5E28309B0B3C232EE208" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on senior notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A69A05CCD2B5E28309B0B3C232EE208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A69A05CCD2B5E28309B0B3C232EE208" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A69A05CCD2B5E28309B0B3C232EE208" xlink:type="arc" />
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2_verboseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Redemption percentage par value of senior notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2" xlink:to="lab_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_5BB7956CE38397C0873B0B3C232EDB83_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_5BB7956CE38397C0873B0B3C232EDB83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs associated with the Senior Notes offerings</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_5BB7956CE38397C0873B0B3C232EDB83_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_5BB7956CE38397C0873B0B3C232EDB83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_5BB7956CE38397C0873B0B3C232EDB83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_5BB7956CE38397C0873B0B3C232EDB83" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_5BB7956CE38397C0873B0B3C232EDB83" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_58C1D31AA50272755CEA0B3C232E3B49_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_58C1D31AA50272755CEA0B3C232E3B49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemptions percentage of 2015 notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_58C1D31AA50272755CEA0B3C232E3B49_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_58C1D31AA50272755CEA0B3C232E3B49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_58C1D31AA50272755CEA0B3C232E3B49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_58C1D31AA50272755CEA0B3C232E3B49" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_58C1D31AA50272755CEA0B3C232E3B49" xlink:type="arc" />
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption percentage for change in control provision on the 2015 Senior Notes</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB_label_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB_documentation_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB" xlink:to="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0FCA38F99B21BD99AC550B3C232E89C1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0FCA38F99B21BD99AC550B3C232E89C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap, liability, fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0FCA38F99B21BD99AC550B3C232E89C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0FCA38F99B21BD99AC550B3C232E89C1" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0FCA38F99B21BD99AC550B3C232E89C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7D6B46AFB6ED59FD6F8F0B3C232E7B1C_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7D6B46AFB6ED59FD6F8F0B3C232E7B1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior unsecured revolving credit facility maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7D6B46AFB6ED59FD6F8F0B3C232E7B1C_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7D6B46AFB6ED59FD6F8F0B3C232E7B1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7D6B46AFB6ED59FD6F8F0B3C232E7B1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7D6B46AFB6ED59FD6F8F0B3C232E7B1C" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7D6B46AFB6ED59FD6F8F0B3C232E7B1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityDescription_E4FF5C461D33E50B5DCF0B9C8A39BF22_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityDescription_E4FF5C461D33E50B5DCF0B9C8A39BF22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityDescription_E4FF5C461D33E50B5DCF0B9C8A39BF22_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityDescription_E4FF5C461D33E50B5DCF0B9C8A39BF22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_E4FF5C461D33E50B5DCF0B9C8A39BF22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityDescription_E4FF5C461D33E50B5DCF0B9C8A39BF22" xlink:to="lab_us-gaap_LineOfCreditFacilityDescription_E4FF5C461D33E50B5DCF0B9C8A39BF22" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_E8CB8246AA486AA07A190B3C232E6AA7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_E8CB8246AA486AA07A190B3C232E6AA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount outstanding under the credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_E8CB8246AA486AA07A190B3C232E6AA7_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_E8CB8246AA486AA07A190B3C232E6AA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_E8CB8246AA486AA07A190B3C232E6AA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_E8CB8246AA486AA07A190B3C232E6AA7" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_E8CB8246AA486AA07A190B3C232E6AA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_DD0A0517A3F9BEAC95FF6F399D75B525_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_DD0A0517A3F9BEAC95FF6F399D75B525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_DD0A0517A3F9BEAC95FF6F399D75B525_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_DD0A0517A3F9BEAC95FF6F399D75B525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_DD0A0517A3F9BEAC95FF6F399D75B525" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_DD0A0517A3F9BEAC95FF6F399D75B525" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_DD0A0517A3F9BEAC95FF6F399D75B525" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AE48FF78635234ABF26F6F399D75C67B_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AE48FF78635234ABF26F6F399D75C67B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of change in reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AE48FF78635234ABF26F6F399D75C67B_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AE48FF78635234ABF26F6F399D75C67B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AE48FF78635234ABF26F6F399D75C67B_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AE48FF78635234ABF26F6F399D75C67B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AE48FF78635234ABF26F6F399D75C67B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AE48FF78635234ABF26F6F399D75C67B" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AE48FF78635234ABF26F6F399D75C67B" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_43D2B6C12951218E927E6F399D755706_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_43D2B6C12951218E927E6F399D755706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in consolidated balance sheet</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_43D2B6C12951218E927E6F399D755706_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_43D2B6C12951218E927E6F399D755706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_43D2B6C12951218E927E6F399D755706_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_43D2B6C12951218E927E6F399D755706" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_43D2B6C12951218E927E6F399D755706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_43D2B6C12951218E927E6F399D755706" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_43D2B6C12951218E927E6F399D755706" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F2CDFE9B0EB05F5FCE2C6F399D750140_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F2CDFE9B0EB05F5FCE2C6F399D750140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F2CDFE9B0EB05F5FCE2C6F399D750140_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F2CDFE9B0EB05F5FCE2C6F399D750140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F2CDFE9B0EB05F5FCE2C6F399D750140_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F2CDFE9B0EB05F5FCE2C6F399D750140" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F2CDFE9B0EB05F5FCE2C6F399D750140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F2CDFE9B0EB05F5FCE2C6F399D750140" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F2CDFE9B0EB05F5FCE2C6F399D750140" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_5E261A95A33CB250AA2E6F399D76C99E_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_5E261A95A33CB250AA2E6F399D76C99E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_5E261A95A33CB250AA2E6F399D76C99E_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_5E261A95A33CB250AA2E6F399D76C99E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_5E261A95A33CB250AA2E6F399D76C99E_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_5E261A95A33CB250AA2E6F399D76C99E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_5E261A95A33CB250AA2E6F399D76C99E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock_5E261A95A33CB250AA2E6F399D76C99E" xlink:to="lab_biib_OtherrevenuesTableTextBlock_5E261A95A33CB250AA2E6F399D76C99E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_09850FB7E0803DA9F158FCF51E237CA3_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_09850FB7E0803DA9F158FCF51E237CA3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09850FB7E0803DA9F158FCF51E237CA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09850FB7E0803DA9F158FCF51E237CA3" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_09850FB7E0803DA9F158FCF51E237CA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_AA84C4FFB04E19862F01FCF51E2480A6_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_AA84C4FFB04E19862F01FCF51E2480A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_AA84C4FFB04E19862F01FCF51E2480A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_AA84C4FFB04E19862F01FCF51E2480A6" xlink:to="lab_us-gaap_ParentMember_AA84C4FFB04E19862F01FCF51E2480A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0D19BA83033FBB264F41FCF51E2591CC_negatedLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0D19BA83033FBB264F41FCF51E2591CC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0D19BA83033FBB264F41FCF51E2591CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_0D19BA83033FBB264F41FCF51E2591CC" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0D19BA83033FBB264F41FCF51E2591CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5A012E23C12280B99B9AFCF51E254C58_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5A012E23C12280B99B9AFCF51E254C58" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5A012E23C12280B99B9AFCF51E254C58_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5A012E23C12280B99B9AFCF51E254C58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5A012E23C12280B99B9AFCF51E254C58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5A012E23C12280B99B9AFCF51E254C58" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5A012E23C12280B99B9AFCF51E254C58" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07606E2A130856CD8293FCF51E2520D5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07606E2A130856CD8293FCF51E2520D5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07606E2A130856CD8293FCF51E2520D5_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07606E2A130856CD8293FCF51E2520D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07606E2A130856CD8293FCF51E2520D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07606E2A130856CD8293FCF51E2520D5" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07606E2A130856CD8293FCF51E2520D5" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_02969091478B2CD04385FCF51E25BE14_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_02969091478B2CD04385FCF51E25BE14" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_02969091478B2CD04385FCF51E25BE14_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_02969091478B2CD04385FCF51E25BE14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_02969091478B2CD04385FCF51E25BE14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_02969091478B2CD04385FCF51E25BE14" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_02969091478B2CD04385FCF51E25BE14" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E_terseLabel_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E_label_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E_documentation_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:to="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA_terseLabel_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Payment Timeline of Milestone [Domain]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA_label_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Payment Timeline of Milestone [Domain]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA_documentation_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA" xlink:to="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA" xlink:type="arc" />
    <link:label id="lab_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2_terseLabel_en-US" xlink:label="lab_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Twelve months</link:label>
    <link:label id="lab_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2_label_en-US" xlink:label="lab_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twelve months [Member]</link:label>
    <link:label id="lab_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2_documentation_en-US" xlink:label="lab_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twelve months [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_TwelvemonthsMember" xlink:label="loc_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2" xlink:to="lab_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2" xlink:type="arc" />
    <link:label id="lab_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D" xlink:to="lab_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D" xlink:type="arc" />
    <link:label id="lab_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5_terseLabel_en-US" xlink:label="lab_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5_label_en-US" xlink:label="lab_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5_documentation_en-US" xlink:label="lab_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CommercialMilestonesMember" xlink:label="loc_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5" xlink:to="lab_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:to="lab_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:to="lab_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:type="arc" />
    <link:label id="lab_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5_terseLabel_en-US" xlink:label="lab_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Twenty billion</link:label>
    <link:label id="lab_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5_label_en-US" xlink:label="lab_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty billion [Member]</link:label>
    <link:label id="lab_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5_documentation_en-US" xlink:label="lab_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty billion [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_TwentybillionMember" xlink:label="loc_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5" xlink:to="lab_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5" xlink:type="arc" />
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E_terseLabel_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E_label_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E_documentation_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E" xlink:to="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E" xlink:type="arc" />
    <link:label id="lab_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40_terseLabel_en-US" xlink:label="lab_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumapharm AG</link:label>
    <link:label id="lab_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40_label_en-US" xlink:label="lab_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:label id="lab_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40_documentation_en-US" xlink:label="lab_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40" xlink:to="lab_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC" xlink:to="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9_label_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9" xlink:to="lab_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A" xlink:to="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_47EF24F136988FDBF13E0C8675ADE249_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_47EF24F136988FDBF13E0C8675ADE249" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum contingent consideration in the form of development and approval milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_47EF24F136988FDBF13E0C8675ADE249_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_47EF24F136988FDBF13E0C8675ADE249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_47EF24F136988FDBF13E0C8675ADE249" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_47EF24F136988FDBF13E0C8675ADE249" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_47EF24F136988FDBF13E0C8675ADE249" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_04026269389511B527AA0C8675AD585A_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_04026269389511B527AA0C8675AD585A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount paid in cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_04026269389511B527AA0C8675AD585A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_04026269389511B527AA0C8675AD585A" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_04026269389511B527AA0C8675AD585A" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761_label_en-US" xlink:label="lab_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761" xlink:to="lab_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_E2F70F9C5EF27BFD6ED10C8675AD089A_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_E2F70F9C5EF27BFD6ED10C8675AD089A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_E2F70F9C5EF27BFD6ED10C8675AD089A_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_E2F70F9C5EF27BFD6ED10C8675AD089A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E2F70F9C5EF27BFD6ED10C8675AD089A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_E2F70F9C5EF27BFD6ED10C8675AD089A" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_E2F70F9C5EF27BFD6ED10C8675AD089A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_70B2B6F155C7B69D7C870C8675ADF508_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_70B2B6F155C7B69D7C870C8675ADF508" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cancellable future commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_70B2B6F155C7B69D7C870C8675ADF508_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_70B2B6F155C7B69D7C870C8675ADF508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_70B2B6F155C7B69D7C870C8675ADF508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_70B2B6F155C7B69D7C870C8675ADF508" xlink:to="lab_us-gaap_OtherCommitment_70B2B6F155C7B69D7C870C8675ADF508" xlink:type="arc" />
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC_terseLabel_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies (Textual)</link:label>
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC_label_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC_documentation_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC" xlink:to="lab_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC" xlink:type="arc" />
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_59AAB09B87486E0C04DD0C8675AE0DAB_verboseLabel_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_59AAB09B87486E0C04DD0C8675AE0DAB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_59AAB09B87486E0C04DD0C8675AE0DAB_label_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_59AAB09B87486E0C04DD0C8675AE0DAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses On Funding Commitment Related To Clinical Research</link:label>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_59AAB09B87486E0C04DD0C8675AE0DAB_documentation_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_59AAB09B87486E0C04DD0C8675AE0DAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued expenses on funding commitment related to clinical research.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_59AAB09B87486E0C04DD0C8675AE0DAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_59AAB09B87486E0C04DD0C8675AE0DAB" xlink:to="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_59AAB09B87486E0C04DD0C8675AE0DAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A82F05A3745288165E660C8675AE18B1_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A82F05A3745288165E660C8675AE18B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities associated with uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A82F05A3745288165E660C8675AE18B1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A82F05A3745288165E660C8675AE18B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A82F05A3745288165E660C8675AE18B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A82F05A3745288165E660C8675AE18B1" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A82F05A3745288165E660C8675AE18B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CDEB69CB410F7315B5326F399D95A744_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CDEB69CB410F7315B5326F399D95A744" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income tax provision and the income tax expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CDEB69CB410F7315B5326F399D95A744_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CDEB69CB410F7315B5326F399D95A744" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CDEB69CB410F7315B5326F399D95A744" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CDEB69CB410F7315B5326F399D95A744" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CDEB69CB410F7315B5326F399D95A744" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F18667504AAA4114FE5D6F399D95C220_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F18667504AAA4114FE5D6F399D95C220" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F18667504AAA4114FE5D6F399D95C220_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F18667504AAA4114FE5D6F399D95C220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F18667504AAA4114FE5D6F399D95C220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F18667504AAA4114FE5D6F399D95C220" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F18667504AAA4114FE5D6F399D95C220" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_DEA2261607C74EF36D0D6F399D9563E6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_DEA2261607C74EF36D0D6F399D9563E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_DEA2261607C74EF36D0D6F399D9563E6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_DEA2261607C74EF36D0D6F399D9563E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_DEA2261607C74EF36D0D6F399D9563E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_DEA2261607C74EF36D0D6F399D9563E6" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_DEA2261607C74EF36D0D6F399D9563E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CCFBC1C6EEC2E4DC5C246F399D966C25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CCFBC1C6EEC2E4DC5C246F399D966C25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of beginning and ending amount of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CCFBC1C6EEC2E4DC5C246F399D966C25_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CCFBC1C6EEC2E4DC5C246F399D966C25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CCFBC1C6EEC2E4DC5C246F399D966C25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CCFBC1C6EEC2E4DC5C246F399D966C25" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CCFBC1C6EEC2E4DC5C246F399D966C25" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C34133B412ADFA60CB8A6F399C1F6D76_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C34133B412ADFA60CB8A6F399C1F6D76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C34133B412ADFA60CB8A6F399C1F6D76_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C34133B412ADFA60CB8A6F399C1F6D76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_C34133B412ADFA60CB8A6F399C1F6D76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_C34133B412ADFA60CB8A6F399C1F6D76" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C34133B412ADFA60CB8A6F399C1F6D76" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_09F017090E1693AFED4A6F399C1F7A19_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_09F017090E1693AFED4A6F399C1F7A19" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_09F017090E1693AFED4A6F399C1F7A19_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_09F017090E1693AFED4A6F399C1F7A19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_09F017090E1693AFED4A6F399C1F7A19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_09F017090E1693AFED4A6F399C1F7A19" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_09F017090E1693AFED4A6F399C1F7A19" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units activity</link:label>
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC_label_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units Activity [Abstract]</link:label>
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units activity.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="lab_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D2AE943DB82E96B28FDC6F399F130BB9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D2AE943DB82E96B28FDC6F399F130BB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D2AE943DB82E96B28FDC6F399F130BB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D2AE943DB82E96B28FDC6F399F130BB9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D2AE943DB82E96B28FDC6F399F130BB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_8CAC97D3CCD6F6BD2737FC3A1872C3C3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_8CAC97D3CCD6F6BD2737FC3A1872C3C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_8CAC97D3CCD6F6BD2737FC3A1872C3C3_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_8CAC97D3CCD6F6BD2737FC3A1872C3C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_8CAC97D3CCD6F6BD2737FC3A1872C3C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_8CAC97D3CCD6F6BD2737FC3A1872C3C3" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss_8CAC97D3CCD6F6BD2737FC3A1872C3C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_2BFC332CFB441C21072EFC3A1872D6CE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_2BFC332CFB441C21072EFC3A1872D6CE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_2BFC332CFB441C21072EFC3A1872D6CE_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_2BFC332CFB441C21072EFC3A1872D6CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_2BFC332CFB441C21072EFC3A1872D6CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_2BFC332CFB441C21072EFC3A1872D6CE" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_2BFC332CFB441C21072EFC3A1872D6CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855D1A624C8EE961EFC7FC3A1872939B_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855D1A624C8EE961EFC7FC3A1872939B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855D1A624C8EE961EFC7FC3A1872939B_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855D1A624C8EE961EFC7FC3A1872939B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855D1A624C8EE961EFC7FC3A1872939B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855D1A624C8EE961EFC7FC3A1872939B" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855D1A624C8EE961EFC7FC3A1872939B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7FC88EE673233B7EB3EBFC3A1872A8AE_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_7FC88EE673233B7EB3EBFC3A1872A8AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Paid During the Year</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7FC88EE673233B7EB3EBFC3A1872A8AE_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_7FC88EE673233B7EB3EBFC3A1872A8AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7FC88EE673233B7EB3EBFC3A1872A8AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7FC88EE673233B7EB3EBFC3A1872A8AE" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_7FC88EE673233B7EB3EBFC3A1872A8AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_53F1809CAB777D65FEA6FC3A18721727_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_53F1809CAB777D65FEA6FC3A18721727" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_53F1809CAB777D65FEA6FC3A18721727_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_53F1809CAB777D65FEA6FC3A18721727" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_53F1809CAB777D65FEA6FC3A18721727" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_53F1809CAB777D65FEA6FC3A18721727" xlink:to="lab_us-gaap_InterestPaidNet_53F1809CAB777D65FEA6FC3A18721727" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_7DEFD1825E50CBCE72ACFC3A1872D310_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_7DEFD1825E50CBCE72ACFC3A1872D310" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_7DEFD1825E50CBCE72ACFC3A1872D310_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_7DEFD1825E50CBCE72ACFC3A1872D310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_7DEFD1825E50CBCE72ACFC3A1872D310" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_7DEFD1825E50CBCE72ACFC3A1872D310" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_7DEFD1825E50CBCE72ACFC3A1872D310" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_0F919C80ECC285FDDCE0FC3A1872DCC0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_0F919C80ECC285FDDCE0FC3A1872DCC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_0F919C80ECC285FDDCE0FC3A1872DCC0_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_0F919C80ECC285FDDCE0FC3A1872DCC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0F919C80ECC285FDDCE0FC3A1872DCC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_0F919C80ECC285FDDCE0FC3A1872DCC0" xlink:to="lab_us-gaap_InvestmentIncomeInterest_0F919C80ECC285FDDCE0FC3A1872DCC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_926E98E00C6FABFA6DEBFC3A18728BC0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_926E98E00C6FABFA6DEBFC3A18728BC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_926E98E00C6FABFA6DEBFC3A18728BC0_label_en-US" xlink:label="lab_us-gaap_InterestExpense_926E98E00C6FABFA6DEBFC3A18728BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_926E98E00C6FABFA6DEBFC3A18728BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_926E98E00C6FABFA6DEBFC3A18728BC0" xlink:to="lab_us-gaap_InterestExpense_926E98E00C6FABFA6DEBFC3A18728BC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_38745D4E6F4B6CA30A63FC3A1872DB27_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_38745D4E6F4B6CA30A63FC3A1872DB27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_38745D4E6F4B6CA30A63FC3A1872DB27_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_38745D4E6F4B6CA30A63FC3A1872DB27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_38745D4E6F4B6CA30A63FC3A1872DB27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments_38745D4E6F4B6CA30A63FC3A1872DB27" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments_38745D4E6F4B6CA30A63FC3A1872DB27" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ED4DED4BBB46612EAFFFFC3A1872BCB0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ED4DED4BBB46612EAFFFFC3A1872BCB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ED4DED4BBB46612EAFFFFC3A1872BCB0_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ED4DED4BBB46612EAFFFFC3A1872BCB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ED4DED4BBB46612EAFFFFC3A1872BCB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ED4DED4BBB46612EAFFFFC3A1872BCB0" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ED4DED4BBB46612EAFFFFC3A1872BCB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_C6E9A436BA423BD2CA01FC3A1872927D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_C6E9A436BA423BD2CA01FC3A1872927D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_C6E9A436BA423BD2CA01FC3A1872927D_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_C6E9A436BA423BD2CA01FC3A1872927D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C6E9A436BA423BD2CA01FC3A1872927D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_C6E9A436BA423BD2CA01FC3A1872927D" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_C6E9A436BA423BD2CA01FC3A1872927D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_27877418B5532E70C7B6FC3A1872CC17_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_27877418B5532E70C7B6FC3A1872CC17" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_27877418B5532E70C7B6FC3A1872CC17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_27877418B5532E70C7B6FC3A1872CC17" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_27877418B5532E70C7B6FC3A1872CC17" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_622A087D5388A2E403BAFC3A1872E7B8_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_622A087D5388A2E403BAFC3A1872E7B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_622A087D5388A2E403BAFC3A1872E7B8_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_622A087D5388A2E403BAFC3A1872E7B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_622A087D5388A2E403BAFC3A1872E7B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_622A087D5388A2E403BAFC3A1872E7B8" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_622A087D5388A2E403BAFC3A1872E7B8" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationexpensesaccrual_E7EC3470AA5C1769C21DFC3A18727AF8_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_E7EC3470AA5C1769C21DFC3A18727AF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_E7EC3470AA5C1769C21DFC3A18727AF8_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_E7EC3470AA5C1769C21DFC3A18727AF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_E7EC3470AA5C1769C21DFC3A18727AF8_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_E7EC3470AA5C1769C21DFC3A18727AF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_E7EC3470AA5C1769C21DFC3A18727AF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual_E7EC3470AA5C1769C21DFC3A18727AF8" xlink:to="lab_biib_Collaborationexpensesaccrual_E7EC3470AA5C1769C21DFC3A18727AF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_B8BD913397B4311D9D87FC3A18728E52_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_B8BD913397B4311D9D87FC3A18728E52" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_B8BD913397B4311D9D87FC3A18728E52_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_B8BD913397B4311D9D87FC3A18728E52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_B8BD913397B4311D9D87FC3A18728E52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_B8BD913397B4311D9D87FC3A18728E52" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_B8BD913397B4311D9D87FC3A18728E52" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F7EBB47AA5D66B6BADCFFC3A1872E62C_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F7EBB47AA5D66B6BADCFFC3A1872E62C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F7EBB47AA5D66B6BADCFFC3A1872E62C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F7EBB47AA5D66B6BADCFFC3A1872E62C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F7EBB47AA5D66B6BADCFFC3A1872E62C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F7EBB47AA5D66B6BADCFFC3A1872E62C" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F7EBB47AA5D66B6BADCFFC3A1872E62C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_8414056FB10AC5129EEEFC3A187280CB_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_8414056FB10AC5129EEEFC3A187280CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_8414056FB10AC5129EEEFC3A187280CB_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_8414056FB10AC5129EEEFC3A187280CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_8414056FB10AC5129EEEFC3A187280CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_8414056FB10AC5129EEEFC3A187280CB" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_8414056FB10AC5129EEEFC3A187280CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A2647F50B8E0B73699DCFC3A1872F19E_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A2647F50B8E0B73699DCFC3A1872F19E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A2647F50B8E0B73699DCFC3A1872F19E_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A2647F50B8E0B73699DCFC3A1872F19E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_A2647F50B8E0B73699DCFC3A1872F19E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_A2647F50B8E0B73699DCFC3A1872F19E" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A2647F50B8E0B73699DCFC3A1872F19E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_2E880DC6DFC3C24ED509FC3A1872F6F5_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_2E880DC6DFC3C24ED509FC3A1872F6F5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_2E880DC6DFC3C24ED509FC3A1872F6F5_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_2E880DC6DFC3C24ED509FC3A1872F6F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2E880DC6DFC3C24ED509FC3A1872F6F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_2E880DC6DFC3C24ED509FC3A1872F6F5" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_2E880DC6DFC3C24ED509FC3A1872F6F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_C394FF17AAC7C842BF856F399C1A4EC9_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_C394FF17AAC7C842BF856F399C1A4EC9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_C394FF17AAC7C842BF856F399C1A4EC9_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_C394FF17AAC7C842BF856F399C1A4EC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_C394FF17AAC7C842BF856F399C1A4EC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_C394FF17AAC7C842BF856F399C1A4EC9" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_C394FF17AAC7C842BF856F399C1A4EC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_AF618E4C5FAC4FF5A208FCF51C9F2969_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_AF618E4C5FAC4FF5A208FCF51C9F2969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_AF618E4C5FAC4FF5A208FCF51C9F2969" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_AF618E4C5FAC4FF5A208FCF51C9F2969" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_AF618E4C5FAC4FF5A208FCF51C9F2969" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8" xlink:to="lab_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55" xlink:to="lab_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:to="lab_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticPlanMember_4DC6859EE83859CC348CFCF51CA18AD9_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember_4DC6859EE83859CC348CFCF51CA18AD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_4DC6859EE83859CC348CFCF51CA18AD9_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember_4DC6859EE83859CC348CFCF51CA18AD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_4DC6859EE83859CC348CFCF51CA18AD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember_4DC6859EE83859CC348CFCF51CA18AD9" xlink:to="lab_us-gaap_DomesticPlanMember_4DC6859EE83859CC348CFCF51CA18AD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_858891173BDC975B182AFCF51CA1169D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_858891173BDC975B182AFCF51CA1169D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_858891173BDC975B182AFCF51CA1169D_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_858891173BDC975B182AFCF51CA1169D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_858891173BDC975B182AFCF51CA1169D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_858891173BDC975B182AFCF51CA1169D" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_858891173BDC975B182AFCF51CA1169D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:type="arc" />
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6_terseLabel_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum Qualifying Age For Employee Benefit Plan</link:label>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6_label_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Qualifying Age For Employee Benefit Plan</link:label>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6_documentation_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum qualifying age for employee benefit plan.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6" xlink:to="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_3DD9981BA31F6B510465FCF51CA18256_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_3DD9981BA31F6B510465FCF51CA18256" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses related to savings plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_3DD9981BA31F6B510465FCF51CA18256_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_3DD9981BA31F6B510465FCF51CA18256" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_3DD9981BA31F6B510465FCF51CA18256" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_3DD9981BA31F6B510465FCF51CA18256" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_3DD9981BA31F6B510465FCF51CA18256" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_061FE137DDDF00D172D8FCF51CA284D1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_061FE137DDDF00D172D8FCF51CA284D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_061FE137DDDF00D172D8FCF51CA284D1_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_061FE137DDDF00D172D8FCF51CA284D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_061FE137DDDF00D172D8FCF51CA284D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_061FE137DDDF00D172D8FCF51CA284D1" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_061FE137DDDF00D172D8FCF51CA284D1" xlink:type="arc" />
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE_terseLabel_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments (Textual)</link:label>
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE_label_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE_documentation_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FinancialInstrumentsTextualAbstract" xlink:label="loc_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE" xlink:to="lab_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_13320F5162DF8A3976346F399EC68E02_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_13320F5162DF8A3976346F399EC68E02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Original maturities of commercial paper and short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_13320F5162DF8A3976346F399EC68E02_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_13320F5162DF8A3976346F399EC68E02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_13320F5162DF8A3976346F399EC68E02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateDescription_13320F5162DF8A3976346F399EC68E02" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateDescription_13320F5162DF8A3976346F399EC68E02" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_8BAAFC4D5A9888D4C68F6F399EC79BF6_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_8BAAFC4D5A9888D4C68F6F399EC79BF6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_8BAAFC4D5A9888D4C68F6F399EC79BF6_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_8BAAFC4D5A9888D4C68F6F399EC79BF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_8BAAFC4D5A9888D4C68F6F399EC79BF6_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_8BAAFC4D5A9888D4C68F6F399EC79BF6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_8BAAFC4D5A9888D4C68F6F399EC79BF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_8BAAFC4D5A9888D4C68F6F399EC79BF6" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_8BAAFC4D5A9888D4C68F6F399EC79BF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_C26BDD3D526082D95603EBFB64E8EFCA_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_C26BDD3D526082D95603EBFB64E8EFCA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_C26BDD3D526082D95603EBFB64E8EFCA_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_C26BDD3D526082D95603EBFB64E8EFCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_C26BDD3D526082D95603EBFB64E8EFCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_C26BDD3D526082D95603EBFB64E8EFCA" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_C26BDD3D526082D95603EBFB64E8EFCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_32003C2D6B0D310474C4EBFB64E90248_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_32003C2D6B0D310474C4EBFB64E90248" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_32003C2D6B0D310474C4EBFB64E90248_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_32003C2D6B0D310474C4EBFB64E90248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_32003C2D6B0D310474C4EBFB64E90248" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_32003C2D6B0D310474C4EBFB64E90248" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_32003C2D6B0D310474C4EBFB64E90248" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_718ECE50FEBCF2F0FD60EBFB64E918A6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_718ECE50FEBCF2F0FD60EBFB64E918A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_718ECE50FEBCF2F0FD60EBFB64E918A6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_718ECE50FEBCF2F0FD60EBFB64E918A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_718ECE50FEBCF2F0FD60EBFB64E918A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_718ECE50FEBCF2F0FD60EBFB64E918A6" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_718ECE50FEBCF2F0FD60EBFB64E918A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1235BF5FCF487927B70AEBFB64E9A2C5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_1235BF5FCF487927B70AEBFB64E9A2C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1235BF5FCF487927B70AEBFB64E9A2C5_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_1235BF5FCF487927B70AEBFB64E9A2C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1235BF5FCF487927B70AEBFB64E9A2C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_1235BF5FCF487927B70AEBFB64E9A2C5" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_1235BF5FCF487927B70AEBFB64E9A2C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_1482D77C60D8C8FF5197EBFB64EA3852_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_1482D77C60D8C8FF5197EBFB64EA3852" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_1482D77C60D8C8FF5197EBFB64EA3852_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_1482D77C60D8C8FF5197EBFB64EA3852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1482D77C60D8C8FF5197EBFB64EA3852" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_1482D77C60D8C8FF5197EBFB64EA3852" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_1482D77C60D8C8FF5197EBFB64EA3852" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_A40EB02CE02CFCA61202EBFB64EAD567_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_A40EB02CE02CFCA61202EBFB64EAD567" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_A40EB02CE02CFCA61202EBFB64EAD567_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_A40EB02CE02CFCA61202EBFB64EAD567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_A40EB02CE02CFCA61202EBFB64EAD567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_A40EB02CE02CFCA61202EBFB64EAD567" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_A40EB02CE02CFCA61202EBFB64EAD567" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_06627DD37309F7E43A22EBFB64EB6804_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_06627DD37309F7E43A22EBFB64EB6804" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_06627DD37309F7E43A22EBFB64EB6804_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_06627DD37309F7E43A22EBFB64EB6804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_06627DD37309F7E43A22EBFB64EB6804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_06627DD37309F7E43A22EBFB64EB6804" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_06627DD37309F7E43A22EBFB64EB6804" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37BA4839912EE68A143BEBFB64EB4534_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37BA4839912EE68A143BEBFB64EB4534" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37BA4839912EE68A143BEBFB64EB4534_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37BA4839912EE68A143BEBFB64EB4534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37BA4839912EE68A143BEBFB64EB4534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37BA4839912EE68A143BEBFB64EB4534" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37BA4839912EE68A143BEBFB64EB4534" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_69E614826357E50DF8DCEBFB64EC2371_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_69E614826357E50DF8DCEBFB64EC2371" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_69E614826357E50DF8DCEBFB64EC2371_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_69E614826357E50DF8DCEBFB64EC2371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_69E614826357E50DF8DCEBFB64EC2371" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_69E614826357E50DF8DCEBFB64EC2371" xlink:to="lab_us-gaap_AvailableForSaleSecurities_69E614826357E50DF8DCEBFB64EC2371" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_8458D3903978F644EA49EBFB64EC5EAC_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_8458D3903978F644EA49EBFB64EC5EAC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_8458D3903978F644EA49EBFB64EC5EAC_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_8458D3903978F644EA49EBFB64EC5EAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8458D3903978F644EA49EBFB64EC5EAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_8458D3903978F644EA49EBFB64EC5EAC" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_8458D3903978F644EA49EBFB64EC5EAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2DC1B8B613F0A3DA9BAFEBFB64EC170A_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2DC1B8B613F0A3DA9BAFEBFB64EC170A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2DC1B8B613F0A3DA9BAFEBFB64EC170A_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2DC1B8B613F0A3DA9BAFEBFB64EC170A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2DC1B8B613F0A3DA9BAFEBFB64EC170A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2DC1B8B613F0A3DA9BAFEBFB64EC170A" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2DC1B8B613F0A3DA9BAFEBFB64EC170A" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_658C91AA145D0331D42EEBFB64EC6EDB_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_658C91AA145D0331D42EEBFB64EC6EDB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_658C91AA145D0331D42EEBFB64EC6EDB_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_658C91AA145D0331D42EEBFB64EC6EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_658C91AA145D0331D42EEBFB64EC6EDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_658C91AA145D0331D42EEBFB64EC6EDB" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_658C91AA145D0331D42EEBFB64EC6EDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2186D794D2BEFC0E3B5CEBFB64EDE70C_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2186D794D2BEFC0E3B5CEBFB64EDE70C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2186D794D2BEFC0E3B5CEBFB64EDE70C_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2186D794D2BEFC0E3B5CEBFB64EDE70C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2186D794D2BEFC0E3B5CEBFB64EDE70C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2186D794D2BEFC0E3B5CEBFB64EDE70C" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2186D794D2BEFC0E3B5CEBFB64EDE70C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_175442E78CF9A3AEA8ECEBFB64ED6E35_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_175442E78CF9A3AEA8ECEBFB64ED6E35" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_175442E78CF9A3AEA8ECEBFB64ED6E35_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_175442E78CF9A3AEA8ECEBFB64ED6E35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_175442E78CF9A3AEA8ECEBFB64ED6E35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_175442E78CF9A3AEA8ECEBFB64ED6E35" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_175442E78CF9A3AEA8ECEBFB64ED6E35" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_6CE84CCF729BEE6E78E0EBFB64EDD8BA_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_6CE84CCF729BEE6E78E0EBFB64EDD8BA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_6CE84CCF729BEE6E78E0EBFB64EDD8BA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_6CE84CCF729BEE6E78E0EBFB64EDD8BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6CE84CCF729BEE6E78E0EBFB64EDD8BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6CE84CCF729BEE6E78E0EBFB64EDD8BA" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_6CE84CCF729BEE6E78E0EBFB64EDD8BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:type="arc" />
    <link:label id="lab_country_US_EEE8EDBC1130D2FBC8626F399F3ECDDE_verboseLabel_en-US" xlink:label="lab_country_US_EEE8EDBC1130D2FBC8626F399F3ECDDE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_EEE8EDBC1130D2FBC8626F399F3ECDDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_EEE8EDBC1130D2FBC8626F399F3ECDDE" xlink:to="lab_country_US_EEE8EDBC1130D2FBC8626F399F3ECDDE" xlink:type="arc" />
    <link:label id="lab_srt_EuropeMember_E685D50E9D3D9924C8256F399F3FC02D_terseLabel_en-US" xlink:label="lab_srt_EuropeMember_E685D50E9D3D9924C8256F399F3FC02D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_E685D50E9D3D9924C8256F399F3FC02D_label_en-US" xlink:label="lab_srt_EuropeMember_E685D50E9D3D9924C8256F399F3FC02D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_E685D50E9D3D9924C8256F399F3FC02D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember_E685D50E9D3D9924C8256F399F3FC02D" xlink:to="lab_srt_EuropeMember_E685D50E9D3D9924C8256F399F3FC02D" xlink:type="arc" />
    <link:label id="lab_srt_AsiaMember_C7A53B77D1E59F0C741B6F399F3F2785_terseLabel_en-US" xlink:label="lab_srt_AsiaMember_C7A53B77D1E59F0C741B6F399F3F2785" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asia</link:label>
    <link:label id="lab_srt_AsiaMember_C7A53B77D1E59F0C741B6F399F3F2785_label_en-US" xlink:label="lab_srt_AsiaMember_C7A53B77D1E59F0C741B6F399F3F2785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AsiaMember" xlink:label="loc_srt_AsiaMember_C7A53B77D1E59F0C741B6F399F3F2785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaMember_C7A53B77D1E59F0C741B6F399F3F2785" xlink:to="lab_srt_AsiaMember_C7A53B77D1E59F0C741B6F399F3F2785" xlink:type="arc" />
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F_verboseLabel_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F_label_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Geographical Groups Of Countries Group Other [Member]</link:label>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F_documentation_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment geographical groups of countries group other.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F" xlink:to="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Geographic information</link:label>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE_label_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments, Geographical Areas [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE" xlink:to="lab_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncurrentAssets_0771042926CD2840EBA56F399F40E8DA_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_0771042926CD2840EBA56F399F40E8DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_0771042926CD2840EBA56F399F40E8DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_0771042926CD2840EBA56F399F40E8DA" xlink:to="lab_us-gaap_NoncurrentAssets_0771042926CD2840EBA56F399F40E8DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_22AF96D24E41ECB34DF26F399FB2845F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_22AF96D24E41ECB34DF26F399FB2845F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_22AF96D24E41ECB34DF26F399FB2845F_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_22AF96D24E41ECB34DF26F399FB2845F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_22AF96D24E41ECB34DF26F399FB2845F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_22AF96D24E41ECB34DF26F399FB2845F" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_22AF96D24E41ECB34DF26F399FB2845F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_060FB8265220918137746F399FB38F17_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_060FB8265220918137746F399FB38F17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes (benefit):</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_060FB8265220918137746F399FB38F17_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_060FB8265220918137746F399FB38F17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_060FB8265220918137746F399FB38F17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_060FB8265220918137746F399FB38F17" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_060FB8265220918137746F399FB38F17" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_47DFE464196F229B165B6F399FB35310_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_47DFE464196F229B165B6F399FB35310" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_47DFE464196F229B165B6F399FB35310_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_47DFE464196F229B165B6F399FB35310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_47DFE464196F229B165B6F399FB35310" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_47DFE464196F229B165B6F399FB35310" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_47DFE464196F229B165B6F399FB35310" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B83ECD063A05BFCA45066F399FB381AA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B83ECD063A05BFCA45066F399FB381AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B83ECD063A05BFCA45066F399FB381AA_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B83ECD063A05BFCA45066F399FB381AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B83ECD063A05BFCA45066F399FB381AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B83ECD063A05BFCA45066F399FB381AA" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B83ECD063A05BFCA45066F399FB381AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_DBA2802CB18201D2E2676F399FB40CF8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_DBA2802CB18201D2E2676F399FB40CF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit):</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_DBA2802CB18201D2E2676F399FB40CF8_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_DBA2802CB18201D2E2676F399FB40CF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_DBA2802CB18201D2E2676F399FB40CF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_DBA2802CB18201D2E2676F399FB40CF8" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_DBA2802CB18201D2E2676F399FB40CF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_FDD7F27129C947D1A69E6F399FB43407_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_FDD7F27129C947D1A69E6F399FB43407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_FDD7F27129C947D1A69E6F399FB43407_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_FDD7F27129C947D1A69E6F399FB43407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_FDD7F27129C947D1A69E6F399FB43407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_FDD7F27129C947D1A69E6F399FB43407" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_FDD7F27129C947D1A69E6F399FB43407" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6EFD3B50D51DF27D3FB36F399FB423A0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6EFD3B50D51DF27D3FB36F399FB423A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6EFD3B50D51DF27D3FB36F399FB423A0_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6EFD3B50D51DF27D3FB36F399FB423A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6EFD3B50D51DF27D3FB36F399FB423A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6EFD3B50D51DF27D3FB36F399FB423A0" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6EFD3B50D51DF27D3FB36F399FB423A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_F3C88ECC6CA7ACA0A8D16F399FB5F2EE_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_F3C88ECC6CA7ACA0A8D16F399FB5F2EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_F3C88ECC6CA7ACA0A8D16F399FB5F2EE_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_F3C88ECC6CA7ACA0A8D16F399FB5F2EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_F3C88ECC6CA7ACA0A8D16F399FB5F2EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_F3C88ECC6CA7ACA0A8D16F399FB5F2EE" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_F3C88ECC6CA7ACA0A8D16F399FB5F2EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_975D5D89965BFA064C866F399FB57A98_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_975D5D89965BFA064C866F399FB57A98" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_975D5D89965BFA064C866F399FB57A98_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_975D5D89965BFA064C866F399FB57A98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_975D5D89965BFA064C866F399FB57A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_975D5D89965BFA064C866F399FB57A98" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_975D5D89965BFA064C866F399FB57A98" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_49966E34A050D5322AA76F399FB5190A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_49966E34A050D5322AA76F399FB5190A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_49966E34A050D5322AA76F399FB5190A_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_49966E34A050D5322AA76F399FB5190A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_49966E34A050D5322AA76F399FB5190A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_49966E34A050D5322AA76F399FB5190A" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_49966E34A050D5322AA76F399FB5190A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98B160F3FB46DC17C4816F399FB5B3B4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98B160F3FB46DC17C4816F399FB5B3B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98B160F3FB46DC17C4816F399FB5B3B4_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98B160F3FB46DC17C4816F399FB5B3B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98B160F3FB46DC17C4816F399FB5B3B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98B160F3FB46DC17C4816F399FB5B3B4" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98B160F3FB46DC17C4816F399FB5B3B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AD8205022ABDF0B5FA746F399FB6DEFA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AD8205022ABDF0B5FA746F399FB6DEFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AD8205022ABDF0B5FA746F399FB6DEFA_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AD8205022ABDF0B5FA746F399FB6DEFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AD8205022ABDF0B5FA746F399FB6DEFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AD8205022ABDF0B5FA746F399FB6DEFA" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AD8205022ABDF0B5FA746F399FB6DEFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_73A78476AB95122EB43B6F399FB6BF6B_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_73A78476AB95122EB43B6F399FB6BF6B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_73A78476AB95122EB43B6F399FB6BF6B_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_73A78476AB95122EB43B6F399FB6BF6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_73A78476AB95122EB43B6F399FB6BF6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_73A78476AB95122EB43B6F399FB6BF6B" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_73A78476AB95122EB43B6F399FB6BF6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E4CE4BDBC8F0EEDDCE2A6F399FB6B5E4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E4CE4BDBC8F0EEDDCE2A6F399FB6B5E4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E4CE4BDBC8F0EEDDCE2A6F399FB6B5E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_E4CE4BDBC8F0EEDDCE2A6F399FB6B5E4" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_E4CE4BDBC8F0EEDDCE2A6F399FB6B5E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_54DE7FB347C304E82993800B02AEFD6D_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_54DE7FB347C304E82993800B02AEFD6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_54DE7FB347C304E82993800B02AEFD6D_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_54DE7FB347C304E82993800B02AEFD6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_54DE7FB347C304E82993800B02AEFD6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_54DE7FB347C304E82993800B02AEFD6D" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_54DE7FB347C304E82993800B02AEFD6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_B8D2723890D72EA973C4800B02AE5769_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_B8D2723890D72EA973C4800B02AE5769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_B8D2723890D72EA973C4800B02AE5769_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_B8D2723890D72EA973C4800B02AE5769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_B8D2723890D72EA973C4800B02AE5769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_B8D2723890D72EA973C4800B02AE5769" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_B8D2723890D72EA973C4800B02AE5769" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_E65195AC1CB06D264F02800B02AE4433_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_E65195AC1CB06D264F02800B02AE4433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_E65195AC1CB06D264F02800B02AE4433_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_E65195AC1CB06D264F02800B02AE4433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_E65195AC1CB06D264F02800B02AE4433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_E65195AC1CB06D264F02800B02AE4433" xlink:to="lab_us-gaap_CommonStockSharesIssued_E65195AC1CB06D264F02800B02AE4433" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_38E9C655CE286C6EDD78800B02AECD9A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_38E9C655CE286C6EDD78800B02AECD9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_38E9C655CE286C6EDD78800B02AECD9A_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_38E9C655CE286C6EDD78800B02AECD9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_38E9C655CE286C6EDD78800B02AECD9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_38E9C655CE286C6EDD78800B02AECD9A" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_38E9C655CE286C6EDD78800B02AECD9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:type="arc" />
    <link:label id="lab_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3_terseLabel_en-US" xlink:label="lab_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Approval Milestone</link:label>
    <link:label id="lab_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3_label_en-US" xlink:label="lab_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:label id="lab_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3_documentation_en-US" xlink:label="lab_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RegulatoryApprovalMilestoneMember" xlink:label="loc_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3" xlink:to="lab_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities by Classification of Entity [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455_verboseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455_label_en-US" xlink:label="lab_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455" xlink:to="lab_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_D04778A35D30B2A98CFDE873AB617B1D_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_D04778A35D30B2A98CFDE873AB617B1D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment to Neurimmune</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_D04778A35D30B2A98CFDE873AB617B1D_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_D04778A35D30B2A98CFDE873AB617B1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_D04778A35D30B2A98CFDE873AB617B1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_D04778A35D30B2A98CFDE873AB617B1D" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_D04778A35D30B2A98CFDE873AB617B1D" xlink:type="arc" />
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF_terseLabel_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF_label_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF_documentation_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF" xlink:to="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF" xlink:type="arc" />
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_36D71F5F83A106E131AAE8C9599AE97F_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_36D71F5F83A106E131AAE8C9599AE97F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_36D71F5F83A106E131AAE8C9599AE97F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_36D71F5F83A106E131AAE8C9599AE97F" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_36D71F5F83A106E131AAE8C9599AE97F" xlink:type="arc" />
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8_label_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8" xlink:to="lab_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual)</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85_label_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85_documentation_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85" xlink:to="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:type="arc" />
    <link:label id="lab_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44_terseLabel_en-US" xlink:label="lab_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BG00011</link:label>
    <link:label id="lab_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44_label_en-US" xlink:label="lab_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BG00011 [Member]</link:label>
    <link:label id="lab_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44_documentation_en-US" xlink:label="lab_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BG00011</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_BG00011Member" xlink:label="loc_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44" xlink:to="lab_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44" xlink:type="arc" />
    <link:label id="lab_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C_terseLabel_en-US" xlink:label="lab_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PLSR</link:label>
    <link:label id="lab_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C_label_en-US" xlink:label="lab_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PLSR [Member]</link:label>
    <link:label id="lab_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C_documentation_en-US" xlink:label="lab_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PLSR</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PLSRMember" xlink:label="loc_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C" xlink:to="lab_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C" xlink:type="arc" />
    <link:label id="lab_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061_terseLabel_en-US" xlink:label="lab_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TGN</link:label>
    <link:label id="lab_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061_label_en-US" xlink:label="lab_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061_documentation_en-US" xlink:label="lab_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TGN</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061" xlink:to="lab_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_5F2C0F36CDEEA36DA9FBFCF51F815625_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_5F2C0F36CDEEA36DA9FBFCF51F815625" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and trade names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_5F2C0F36CDEEA36DA9FBFCF51F815625_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_5F2C0F36CDEEA36DA9FBFCF51F815625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_5F2C0F36CDEEA36DA9FBFCF51F815625" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_5F2C0F36CDEEA36DA9FBFCF51F815625" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_5F2C0F36CDEEA36DA9FBFCF51F815625" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_F229BA92FB8B211AD58AFCF51F828CA8_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_F229BA92FB8B211AD58AFCF51F828CA8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (In Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_F229BA92FB8B211AD58AFCF51F828CA8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_F229BA92FB8B211AD58AFCF51F828CA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_F229BA92FB8B211AD58AFCF51F828CA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_F229BA92FB8B211AD58AFCF51F828CA8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_F229BA92FB8B211AD58AFCF51F828CA8" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_BAB7784D54E7EF3298A3FCF51F83A307_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_BAB7784D54E7EF3298A3FCF51F83A307" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_BAB7784D54E7EF3298A3FCF51F83A307_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_BAB7784D54E7EF3298A3FCF51F83A307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_BAB7784D54E7EF3298A3FCF51F83A307" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_BAB7784D54E7EF3298A3FCF51F83A307" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_BAB7784D54E7EF3298A3FCF51F83A307" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99C4A2AAF55AD6E65CB3FCF51F83AEDE_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99C4A2AAF55AD6E65CB3FCF51F83AEDE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99C4A2AAF55AD6E65CB3FCF51F83AEDE_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99C4A2AAF55AD6E65CB3FCF51F83AEDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99C4A2AAF55AD6E65CB3FCF51F83AEDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99C4A2AAF55AD6E65CB3FCF51F83AEDE" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99C4A2AAF55AD6E65CB3FCF51F83AEDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3AE7CB2C2CE7DD4B455DFCF51F830E0C_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3AE7CB2C2CE7DD4B455DFCF51F830E0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3AE7CB2C2CE7DD4B455DFCF51F830E0C_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3AE7CB2C2CE7DD4B455DFCF51F830E0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3AE7CB2C2CE7DD4B455DFCF51F830E0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3AE7CB2C2CE7DD4B455DFCF51F830E0C" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3AE7CB2C2CE7DD4B455DFCF51F830E0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_CD49AD57C3096E21C3CBFCF51F83676B_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_CD49AD57C3096E21C3CBFCF51F83676B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_CD49AD57C3096E21C3CBFCF51F83676B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_CD49AD57C3096E21C3CBFCF51F83676B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_CD49AD57C3096E21C3CBFCF51F83676B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_CD49AD57C3096E21C3CBFCF51F83676B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_CD49AD57C3096E21C3CBFCF51F83676B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_45F32F86A8C14D72480BFCF51F847603_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_45F32F86A8C14D72480BFCF51F847603" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_45F32F86A8C14D72480BFCF51F847603_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_45F32F86A8C14D72480BFCF51F847603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_45F32F86A8C14D72480BFCF51F847603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_45F32F86A8C14D72480BFCF51F847603" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_45F32F86A8C14D72480BFCF51F847603" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0BDE10682FD4629E985EFCF51F84E9B6_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0BDE10682FD4629E985EFCF51F84E9B6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0BDE10682FD4629E985EFCF51F84E9B6_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0BDE10682FD4629E985EFCF51F84E9B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0BDE10682FD4629E985EFCF51F84E9B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0BDE10682FD4629E985EFCF51F84E9B6" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0BDE10682FD4629E985EFCF51F84E9B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A232030F076F86B102CEFCF51F84E075_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A232030F076F86B102CEFCF51F84E075" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of in-licensed patent</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A232030F076F86B102CEFCF51F84E075_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A232030F076F86B102CEFCF51F84E075" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A232030F076F86B102CEFCF51F84E075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A232030F076F86B102CEFCF51F84E075" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A232030F076F86B102CEFCF51F84E075" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1A973E4B90425708205DFCF51F852464_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1A973E4B90425708205DFCF51F852464" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1A973E4B90425708205DFCF51F852464_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1A973E4B90425708205DFCF51F852464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1A973E4B90425708205DFCF51F852464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1A973E4B90425708205DFCF51F852464" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1A973E4B90425708205DFCF51F852464" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_871B3DDA8DBD03527E10FCF51F85E0B1_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_871B3DDA8DBD03527E10FCF51F85E0B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_871B3DDA8DBD03527E10FCF51F85E0B1_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_871B3DDA8DBD03527E10FCF51F85E0B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_871B3DDA8DBD03527E10FCF51F85E0B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_871B3DDA8DBD03527E10FCF51F85E0B1" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_871B3DDA8DBD03527E10FCF51F85E0B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9311943C280046D9D0B1FCF51F852ABD_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9311943C280046D9D0B1FCF51F852ABD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9311943C280046D9D0B1FCF51F852ABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9311943C280046D9D0B1FCF51F852ABD" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9311943C280046D9D0B1FCF51F852ABD" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Additional Textual)</link:label>
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D_label_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets And Goodwill (Additional Textual) [Abstract]</link:label>
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill additional.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:to="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6E3331026AF044C11E8EFCF51F854EC8_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6E3331026AF044C11E8EFCF51F854EC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6E3331026AF044C11E8EFCF51F854EC8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6E3331026AF044C11E8EFCF51F854EC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6E3331026AF044C11E8EFCF51F854EC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6E3331026AF044C11E8EFCF51F854EC8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6E3331026AF044C11E8EFCF51F854EC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_303FD833FE0888D30D83FCF51F854E28_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_303FD833FE0888D30D83FCF51F854E28" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_303FD833FE0888D30D83FCF51F854E28_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_303FD833FE0888D30D83FCF51F854E28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_303FD833FE0888D30D83FCF51F854E28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_303FD833FE0888D30D83FCF51F854E28" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_303FD833FE0888D30D83FCF51F854E28" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E9D513755AD4AE3D9185FCF51F869E64_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E9D513755AD4AE3D9185FCF51F869E64" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E9D513755AD4AE3D9185FCF51F869E64_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E9D513755AD4AE3D9185FCF51F869E64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E9D513755AD4AE3D9185FCF51F869E64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E9D513755AD4AE3D9185FCF51F869E64" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E9D513755AD4AE3D9185FCF51F869E64" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2D734BD8674B2F59050AFCF51F86DBDF_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2D734BD8674B2F59050AFCF51F86DBDF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2D734BD8674B2F59050AFCF51F86DBDF_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2D734BD8674B2F59050AFCF51F86DBDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2D734BD8674B2F59050AFCF51F86DBDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2D734BD8674B2F59050AFCF51F86DBDF" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2D734BD8674B2F59050AFCF51F86DBDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_063184F72774378E606BFCF51F86A359_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_063184F72774378E606BFCF51F86A359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_063184F72774378E606BFCF51F86A359_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_063184F72774378E606BFCF51F86A359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_063184F72774378E606BFCF51F86A359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_063184F72774378E606BFCF51F86A359" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_063184F72774378E606BFCF51F86A359" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_FBAAEB2138F963CC58EDFCF51F86B7ED_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_FBAAEB2138F963CC58EDFCF51F86B7ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment made to Forward Pharma</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_FBAAEB2138F963CC58EDFCF51F86B7ED_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_FBAAEB2138F963CC58EDFCF51F86B7ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_FBAAEB2138F963CC58EDFCF51F86B7ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_FBAAEB2138F963CC58EDFCF51F86B7ED" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_FBAAEB2138F963CC58EDFCF51F86B7ED" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7_label_en-US" xlink:label="lab_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="lab_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_B4BF5AF3C35858B2086616203EC4EB87_terseLabel_en-US" xlink:label="lab_dei_DocumentType_B4BF5AF3C35858B2086616203EC4EB87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_B4BF5AF3C35858B2086616203EC4EB87_label_en-US" xlink:label="lab_dei_DocumentType_B4BF5AF3C35858B2086616203EC4EB87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_B4BF5AF3C35858B2086616203EC4EB87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_B4BF5AF3C35858B2086616203EC4EB87" xlink:to="lab_dei_DocumentType_B4BF5AF3C35858B2086616203EC4EB87" xlink:type="arc" />
    <link:label id="lab_dei_DocumentAnnualReport_49D824E877E80BCC467C16203EC4F257_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport_49D824E877E80BCC467C16203EC4F257" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_49D824E877E80BCC467C16203EC4F257_label_en-US" xlink:label="lab_dei_DocumentAnnualReport_49D824E877E80BCC467C16203EC4F257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_49D824E877E80BCC467C16203EC4F257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_49D824E877E80BCC467C16203EC4F257" xlink:to="lab_dei_DocumentAnnualReport_49D824E877E80BCC467C16203EC4F257" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_312C308E01707949C61A16203EC4BF14_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_312C308E01707949C61A16203EC4BF14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_312C308E01707949C61A16203EC4BF14_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_312C308E01707949C61A16203EC4BF14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_312C308E01707949C61A16203EC4BF14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_312C308E01707949C61A16203EC4BF14" xlink:to="lab_dei_DocumentPeriodEndDate_312C308E01707949C61A16203EC4BF14" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_34DC106B60949B486BA916203EC58A08_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_34DC106B60949B486BA916203EC58A08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_34DC106B60949B486BA916203EC58A08_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_34DC106B60949B486BA916203EC58A08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_34DC106B60949B486BA916203EC58A08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_34DC106B60949B486BA916203EC58A08" xlink:to="lab_dei_DocumentTransitionReport_34DC106B60949B486BA916203EC58A08" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_7429B4B67497A681470616203EC5AA0C_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_7429B4B67497A681470616203EC5AA0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_7429B4B67497A681470616203EC5AA0C_label_en-US" xlink:label="lab_dei_EntityFileNumber_7429B4B67497A681470616203EC5AA0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_7429B4B67497A681470616203EC5AA0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_7429B4B67497A681470616203EC5AA0C" xlink:to="lab_dei_EntityFileNumber_7429B4B67497A681470616203EC5AA0C" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_CF472858A50BC712751C16203EC50838_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_CF472858A50BC712751C16203EC50838" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_CF472858A50BC712751C16203EC50838_label_en-US" xlink:label="lab_dei_EntityRegistrantName_CF472858A50BC712751C16203EC50838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_CF472858A50BC712751C16203EC50838" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_CF472858A50BC712751C16203EC50838" xlink:to="lab_dei_EntityRegistrantName_CF472858A50BC712751C16203EC50838" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_868B6025ECD53F50174F16203EC58566_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_868B6025ECD53F50174F16203EC58566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_868B6025ECD53F50174F16203EC58566_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_868B6025ECD53F50174F16203EC58566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_868B6025ECD53F50174F16203EC58566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_868B6025ECD53F50174F16203EC58566" xlink:to="lab_dei_EntityIncorporationStateCountryCode_868B6025ECD53F50174F16203EC58566" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_97C57CAE8BDAB35E92FA16203EC543E8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_97C57CAE8BDAB35E92FA16203EC543E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_97C57CAE8BDAB35E92FA16203EC543E8_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_97C57CAE8BDAB35E92FA16203EC543E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_97C57CAE8BDAB35E92FA16203EC543E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_97C57CAE8BDAB35E92FA16203EC543E8" xlink:to="lab_dei_EntityTaxIdentificationNumber_97C57CAE8BDAB35E92FA16203EC543E8" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_0C67F73B75681DF2483C16203EC54F3E_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_0C67F73B75681DF2483C16203EC54F3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_0C67F73B75681DF2483C16203EC54F3E_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_0C67F73B75681DF2483C16203EC54F3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_0C67F73B75681DF2483C16203EC54F3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_0C67F73B75681DF2483C16203EC54F3E" xlink:to="lab_dei_EntityAddressAddressLine1_0C67F73B75681DF2483C16203EC54F3E" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_C2C37F35084BFA3EF95216203EC6EE71_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_C2C37F35084BFA3EF95216203EC6EE71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_C2C37F35084BFA3EF95216203EC6EE71_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_C2C37F35084BFA3EF95216203EC6EE71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_C2C37F35084BFA3EF95216203EC6EE71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_C2C37F35084BFA3EF95216203EC6EE71" xlink:to="lab_dei_EntityAddressCityOrTown_C2C37F35084BFA3EF95216203EC6EE71" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_32E8FC8450836488459016203EC679C6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_32E8FC8450836488459016203EC679C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_32E8FC8450836488459016203EC679C6_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_32E8FC8450836488459016203EC679C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_32E8FC8450836488459016203EC679C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_32E8FC8450836488459016203EC679C6" xlink:to="lab_dei_EntityAddressStateOrProvince_32E8FC8450836488459016203EC679C6" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_52411D920280D999EDE316203EC69D9D_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_52411D920280D999EDE316203EC69D9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_52411D920280D999EDE316203EC69D9D_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_52411D920280D999EDE316203EC69D9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_52411D920280D999EDE316203EC69D9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_52411D920280D999EDE316203EC69D9D" xlink:to="lab_dei_EntityAddressPostalZipCode_52411D920280D999EDE316203EC69D9D" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_4DD43C09D1403B5115BC16203EC68326_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_4DD43C09D1403B5115BC16203EC68326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_4DD43C09D1403B5115BC16203EC68326_label_en-US" xlink:label="lab_dei_CityAreaCode_4DD43C09D1403B5115BC16203EC68326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_4DD43C09D1403B5115BC16203EC68326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_4DD43C09D1403B5115BC16203EC68326" xlink:to="lab_dei_CityAreaCode_4DD43C09D1403B5115BC16203EC68326" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_520E177E587A0EBC570816203EC6D624_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_520E177E587A0EBC570816203EC6D624" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_520E177E587A0EBC570816203EC6D624_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_520E177E587A0EBC570816203EC6D624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_520E177E587A0EBC570816203EC6D624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_520E177E587A0EBC570816203EC6D624" xlink:to="lab_dei_LocalPhoneNumber_520E177E587A0EBC570816203EC6D624" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_BD17A69517D0815A5C1916203EC67842_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_BD17A69517D0815A5C1916203EC67842" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_BD17A69517D0815A5C1916203EC67842_label_en-US" xlink:label="lab_dei_Security12bTitle_BD17A69517D0815A5C1916203EC67842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_BD17A69517D0815A5C1916203EC67842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_BD17A69517D0815A5C1916203EC67842" xlink:to="lab_dei_Security12bTitle_BD17A69517D0815A5C1916203EC67842" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_591C686A080EFB1520F116203EC7ADB7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_591C686A080EFB1520F116203EC7ADB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_591C686A080EFB1520F116203EC7ADB7_label_en-US" xlink:label="lab_dei_TradingSymbol_591C686A080EFB1520F116203EC7ADB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_591C686A080EFB1520F116203EC7ADB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_591C686A080EFB1520F116203EC7ADB7" xlink:to="lab_dei_TradingSymbol_591C686A080EFB1520F116203EC7ADB7" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_09659E6742B90359BE0416203EC76FD3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_09659E6742B90359BE0416203EC76FD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_09659E6742B90359BE0416203EC76FD3_label_en-US" xlink:label="lab_dei_SecurityExchangeName_09659E6742B90359BE0416203EC76FD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_09659E6742B90359BE0416203EC76FD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_09659E6742B90359BE0416203EC76FD3" xlink:to="lab_dei_SecurityExchangeName_09659E6742B90359BE0416203EC76FD3" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_0558EA3E4BDEB8DD74F716203EC75123_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0558EA3E4BDEB8DD74F716203EC75123" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_0558EA3E4BDEB8DD74F716203EC75123_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0558EA3E4BDEB8DD74F716203EC75123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0558EA3E4BDEB8DD74F716203EC75123" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_0558EA3E4BDEB8DD74F716203EC75123" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0558EA3E4BDEB8DD74F716203EC75123" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_546FD0343B9981149DC316203EC70129_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_546FD0343B9981149DC316203EC70129" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_546FD0343B9981149DC316203EC70129_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_546FD0343B9981149DC316203EC70129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_546FD0343B9981149DC316203EC70129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_546FD0343B9981149DC316203EC70129" xlink:to="lab_dei_EntityVoluntaryFilers_546FD0343B9981149DC316203EC70129" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_9B045F9887981037E2E916203EC765B6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_9B045F9887981037E2E916203EC765B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9B045F9887981037E2E916203EC765B6_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_9B045F9887981037E2E916203EC765B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9B045F9887981037E2E916203EC765B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_9B045F9887981037E2E916203EC765B6" xlink:to="lab_dei_EntityCurrentReportingStatus_9B045F9887981037E2E916203EC765B6" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_34B98215D91B5B9CB3671640771E9A8C_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_34B98215D91B5B9CB3671640771E9A8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_34B98215D91B5B9CB3671640771E9A8C_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_34B98215D91B5B9CB3671640771E9A8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_34B98215D91B5B9CB3671640771E9A8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_34B98215D91B5B9CB3671640771E9A8C" xlink:to="lab_dei_EntityInteractiveDataCurrent_34B98215D91B5B9CB3671640771E9A8C" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_85DC6C48FF67BDCBB44E16203EC8E5EF_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_85DC6C48FF67BDCBB44E16203EC8E5EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_85DC6C48FF67BDCBB44E16203EC8E5EF_label_en-US" xlink:label="lab_dei_EntityFilerCategory_85DC6C48FF67BDCBB44E16203EC8E5EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_85DC6C48FF67BDCBB44E16203EC8E5EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_85DC6C48FF67BDCBB44E16203EC8E5EF" xlink:to="lab_dei_EntityFilerCategory_85DC6C48FF67BDCBB44E16203EC8E5EF" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_4F990CA4AF5989183E1D16203EC832D4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_4F990CA4AF5989183E1D16203EC832D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_4F990CA4AF5989183E1D16203EC832D4_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_4F990CA4AF5989183E1D16203EC832D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_4F990CA4AF5989183E1D16203EC832D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_4F990CA4AF5989183E1D16203EC832D4" xlink:to="lab_dei_EntitySmallBusiness_4F990CA4AF5989183E1D16203EC832D4" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6F9119F5E97219879D7216203EC827C4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_6F9119F5E97219879D7216203EC827C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6F9119F5E97219879D7216203EC827C4_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_6F9119F5E97219879D7216203EC827C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_6F9119F5E97219879D7216203EC827C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_6F9119F5E97219879D7216203EC827C4" xlink:to="lab_dei_EntityEmergingGrowthCompany_6F9119F5E97219879D7216203EC827C4" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_A86DFBF5FCEAF615BC2816203EC82C80_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_A86DFBF5FCEAF615BC2816203EC82C80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_A86DFBF5FCEAF615BC2816203EC82C80_label_en-US" xlink:label="lab_dei_EntityShellCompany_A86DFBF5FCEAF615BC2816203EC82C80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_A86DFBF5FCEAF615BC2816203EC82C80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_A86DFBF5FCEAF615BC2816203EC82C80" xlink:to="lab_dei_EntityShellCompany_A86DFBF5FCEAF615BC2816203EC82C80" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_02AB94B10D101AB04B6316203EC84DDE_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_02AB94B10D101AB04B6316203EC84DDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_02AB94B10D101AB04B6316203EC84DDE_label_en-US" xlink:label="lab_dei_EntityPublicFloat_02AB94B10D101AB04B6316203EC84DDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_02AB94B10D101AB04B6316203EC84DDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_02AB94B10D101AB04B6316203EC84DDE" xlink:to="lab_dei_EntityPublicFloat_02AB94B10D101AB04B6316203EC84DDE" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3BC6008371F5B13D1B8316203EC8D2A4_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_3BC6008371F5B13D1B8316203EC8D2A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3BC6008371F5B13D1B8316203EC8D2A4_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_3BC6008371F5B13D1B8316203EC8D2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3BC6008371F5B13D1B8316203EC8D2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_3BC6008371F5B13D1B8316203EC8D2A4" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_3BC6008371F5B13D1B8316203EC8D2A4" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_D48DC8AE36914FDD1F3016203EC93797_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_D48DC8AE36914FDD1F3016203EC93797" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_D48DC8AE36914FDD1F3016203EC93797_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_D48DC8AE36914FDD1F3016203EC93797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_D48DC8AE36914FDD1F3016203EC93797" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_D48DC8AE36914FDD1F3016203EC93797" xlink:to="lab_dei_EntityCentralIndexKey_D48DC8AE36914FDD1F3016203EC93797" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_21B35CA7F0A783C3B68B16203EC9D5A7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_21B35CA7F0A783C3B68B16203EC9D5A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_21B35CA7F0A783C3B68B16203EC9D5A7_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_21B35CA7F0A783C3B68B16203EC9D5A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_21B35CA7F0A783C3B68B16203EC9D5A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_21B35CA7F0A783C3B68B16203EC9D5A7" xlink:to="lab_dei_CurrentFiscalYearEndDate_21B35CA7F0A783C3B68B16203EC9D5A7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_095D17B772D414AA5E0116203EC9FA28_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_095D17B772D414AA5E0116203EC9FA28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_095D17B772D414AA5E0116203EC9FA28_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_095D17B772D414AA5E0116203EC9FA28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_095D17B772D414AA5E0116203EC9FA28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_095D17B772D414AA5E0116203EC9FA28" xlink:to="lab_dei_DocumentFiscalYearFocus_095D17B772D414AA5E0116203EC9FA28" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A1A03846EB84C622E08316203EC90715_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A1A03846EB84C622E08316203EC90715" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A1A03846EB84C622E08316203EC90715_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A1A03846EB84C622E08316203EC90715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A1A03846EB84C622E08316203EC90715" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_A1A03846EB84C622E08316203EC90715" xlink:to="lab_dei_DocumentFiscalPeriodFocus_A1A03846EB84C622E08316203EC90715" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_0FA9798B03AE21DF016A16203EC94B85_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_0FA9798B03AE21DF016A16203EC94B85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_0FA9798B03AE21DF016A16203EC94B85_label_en-US" xlink:label="lab_dei_AmendmentFlag_0FA9798B03AE21DF016A16203EC94B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_0FA9798B03AE21DF016A16203EC94B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_0FA9798B03AE21DF016A16203EC94B85" xlink:to="lab_dei_AmendmentFlag_0FA9798B03AE21DF016A16203EC94B85" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97E0B2C5B625B4E06BAD7EF7C7E766EF_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97E0B2C5B625B4E06BAD7EF7C7E766EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97E0B2C5B625B4E06BAD7EF7C7E766EF_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97E0B2C5B625B4E06BAD7EF7C7E766EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97E0B2C5B625B4E06BAD7EF7C7E766EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97E0B2C5B625B4E06BAD7EF7C7E766EF" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97E0B2C5B625B4E06BAD7EF7C7E766EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_5B609531B3C68A8E94A46F399E842315_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_5B609531B3C68A8E94A46F399E842315" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_5B609531B3C68A8E94A46F399E842315_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_5B609531B3C68A8E94A46F399E842315" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_5B609531B3C68A8E94A46F399E842315" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_5B609531B3C68A8E94A46F399E842315" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_5B609531B3C68A8E94A46F399E842315" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A7CFB981D65C925382F86F399E849B21_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A7CFB981D65C925382F86F399E849B21" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as cash flow hedging instruments on our consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A7CFB981D65C925382F86F399E849B21_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A7CFB981D65C925382F86F399E849B21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A7CFB981D65C925382F86F399E849B21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A7CFB981D65C925382F86F399E849B21" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A7CFB981D65C925382F86F399E849B21" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_389CB70F0405AEF3C6CC6F399E844541_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_389CB70F0405AEF3C6CC6F399E844541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_389CB70F0405AEF3C6CC6F399E844541_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_389CB70F0405AEF3C6CC6F399E844541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_389CB70F0405AEF3C6CC6F399E844541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_389CB70F0405AEF3C6CC6F399E844541" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_389CB70F0405AEF3C6CC6F399E844541" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_AC9490D58B82CB09010A6F399E856B3C_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_AC9490D58B82CB09010A6F399E856B3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the fair value for our outstanding derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_AC9490D58B82CB09010A6F399E856B3C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_AC9490D58B82CB09010A6F399E856B3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_AC9490D58B82CB09010A6F399E856B3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_AC9490D58B82CB09010A6F399E856B3C" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_AC9490D58B82CB09010A6F399E856B3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_482170283663C1BB2327FC2E5FA00252_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_482170283663C1BB2327FC2E5FA00252" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_482170283663C1BB2327FC2E5FA00252" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_482170283663C1BB2327FC2E5FA00252" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_482170283663C1BB2327FC2E5FA00252" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0AFA7FBFA3DB296D528FFC2E5FA0DA4B_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0AFA7FBFA3DB296D528FFC2E5FA0DA4B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0AFA7FBFA3DB296D528FFC2E5FA0DA4B_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0AFA7FBFA3DB296D528FFC2E5FA0DA4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0AFA7FBFA3DB296D528FFC2E5FA0DA4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0AFA7FBFA3DB296D528FFC2E5FA0DA4B" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0AFA7FBFA3DB296D528FFC2E5FA0DA4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_45424BAB8751B220F447FC2E5FA13EEF_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_45424BAB8751B220F447FC2E5FA13EEF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_45424BAB8751B220F447FC2E5FA13EEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_45424BAB8751B220F447FC2E5FA13EEF" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_45424BAB8751B220F447FC2E5FA13EEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5967DC985C3EF5CEA1A7FC2E5FA1CB35_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5967DC985C3EF5CEA1A7FC2E5FA1CB35" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5967DC985C3EF5CEA1A7FC2E5FA1CB35_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5967DC985C3EF5CEA1A7FC2E5FA1CB35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5967DC985C3EF5CEA1A7FC2E5FA1CB35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5967DC985C3EF5CEA1A7FC2E5FA1CB35" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5967DC985C3EF5CEA1A7FC2E5FA1CB35" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_DE447DCF45B7711BBD7CFC2E5FA130D5_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_DE447DCF45B7711BBD7CFC2E5FA130D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_DE447DCF45B7711BBD7CFC2E5FA130D5_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_DE447DCF45B7711BBD7CFC2E5FA130D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_DE447DCF45B7711BBD7CFC2E5FA130D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_DE447DCF45B7711BBD7CFC2E5FA130D5" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_DE447DCF45B7711BBD7CFC2E5FA130D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_F102A4B53E09E6F7F066FC325D898E88_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_F102A4B53E09E6F7F066FC325D898E88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_F102A4B53E09E6F7F066FC325D898E88_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_F102A4B53E09E6F7F066FC325D898E88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_F102A4B53E09E6F7F066FC325D898E88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_F102A4B53E09E6F7F066FC325D898E88" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_F102A4B53E09E6F7F066FC325D898E88" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9CEBCA6E50C8DACDB3F5FC32D902B293_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9CEBCA6E50C8DACDB3F5FC32D902B293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9CEBCA6E50C8DACDB3F5FC32D902B293_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9CEBCA6E50C8DACDB3F5FC32D902B293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9CEBCA6E50C8DACDB3F5FC32D902B293_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9CEBCA6E50C8DACDB3F5FC32D902B293" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9CEBCA6E50C8DACDB3F5FC32D902B293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9CEBCA6E50C8DACDB3F5FC32D902B293" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9CEBCA6E50C8DACDB3F5FC32D902B293" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5BED8D29536269D12EA6FC2E5FA1CAA9_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5BED8D29536269D12EA6FC2E5FA1CAA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5BED8D29536269D12EA6FC2E5FA1CAA9_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5BED8D29536269D12EA6FC2E5FA1CAA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5BED8D29536269D12EA6FC2E5FA1CAA9_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5BED8D29536269D12EA6FC2E5FA1CAA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5BED8D29536269D12EA6FC2E5FA1CAA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5BED8D29536269D12EA6FC2E5FA1CAA9" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5BED8D29536269D12EA6FC2E5FA1CAA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6812DEADC1AB42BD486BFC2E5FA17291_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6812DEADC1AB42BD486BFC2E5FA17291" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Tax Act</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6812DEADC1AB42BD486BFC2E5FA17291_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6812DEADC1AB42BD486BFC2E5FA17291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6812DEADC1AB42BD486BFC2E5FA17291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6812DEADC1AB42BD486BFC2E5FA17291" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6812DEADC1AB42BD486BFC2E5FA17291" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_503DF4D9466ED5CE9BBBFC334F9469D4_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_503DF4D9466ED5CE9BBBFC334F9469D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_503DF4D9466ED5CE9BBBFC334F9469D4_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_503DF4D9466ED5CE9BBBFC334F9469D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_503DF4D9466ED5CE9BBBFC334F9469D4_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_503DF4D9466ED5CE9BBBFC334F9469D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_503DF4D9466ED5CE9BBBFC334F9469D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_503DF4D9466ED5CE9BBBFC334F9469D4" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_503DF4D9466ED5CE9BBBFC334F9469D4" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_EDA683A225F334D6CB5BFC2E5FA1EC8B_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_EDA683A225F334D6CB5BFC2E5FA1EC8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_EDA683A225F334D6CB5BFC2E5FA1EC8B_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_EDA683A225F334D6CB5BFC2E5FA1EC8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_EDA683A225F334D6CB5BFC2E5FA1EC8B_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_EDA683A225F334D6CB5BFC2E5FA1EC8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_EDA683A225F334D6CB5BFC2E5FA1EC8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax_EDA683A225F334D6CB5BFC2E5FA1EC8B" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax_EDA683A225F334D6CB5BFC2E5FA1EC8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_8176674ED970D7092F07FC2E5FA22953_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_8176674ED970D7092F07FC2E5FA22953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of ZINBRYTA related tax assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_8176674ED970D7092F07FC2E5FA22953_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_8176674ED970D7092F07FC2E5FA22953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_8176674ED970D7092F07FC2E5FA22953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_8176674ED970D7092F07FC2E5FA22953" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_8176674ED970D7092F07FC2E5FA22953" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E1B76BAEE3A347E5CAD3FC2E5FA2C771_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E1B76BAEE3A347E5CAD3FC2E5FA2C771" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E1B76BAEE3A347E5CAD3FC2E5FA2C771_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E1B76BAEE3A347E5CAD3FC2E5FA2C771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E1B76BAEE3A347E5CAD3FC2E5FA2C771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E1B76BAEE3A347E5CAD3FC2E5FA2C771" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E1B76BAEE3A347E5CAD3FC2E5FA2C771" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4E1781971D4EAB6ECF49FC2E5FA22B56_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4E1781971D4EAB6ECF49FC2E5FA22B56" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4E1781971D4EAB6ECF49FC2E5FA22B56_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4E1781971D4EAB6ECF49FC2E5FA22B56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4E1781971D4EAB6ECF49FC2E5FA22B56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4E1781971D4EAB6ECF49FC2E5FA22B56" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4E1781971D4EAB6ECF49FC2E5FA22B56" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F06B566DCB898CE949CBFC2E5FA26B93_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F06B566DCB898CE949CBFC2E5FA26B93" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F06B566DCB898CE949CBFC2E5FA26B93_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F06B566DCB898CE949CBFC2E5FA26B93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F06B566DCB898CE949CBFC2E5FA26B93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F06B566DCB898CE949CBFC2E5FA26B93" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F06B566DCB898CE949CBFC2E5FA26B93" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_9EBAB6502EAEAC5B481AF00F3814E36C_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_9EBAB6502EAEAC5B481AF00F3814E36C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note payable to Fumedica</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_9EBAB6502EAEAC5B481AF00F3814E36C_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_9EBAB6502EAEAC5B481AF00F3814E36C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_9EBAB6502EAEAC5B481AF00F3814E36C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember_9EBAB6502EAEAC5B481AF00F3814E36C" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember_9EBAB6502EAEAC5B481AF00F3814E36C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:to="lab_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_C18F41094145CF079986F00F38157531_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_C18F41094145CF079986F00F38157531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.900% Senior Notes due September 15, 2020</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_C18F41094145CF079986F00F38157531_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_C18F41094145CF079986F00F38157531" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_C18F41094145CF079986F00F38157531" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_C18F41094145CF079986F00F38157531" xlink:to="lab_us-gaap_NotesPayableCurrent_C18F41094145CF079986F00F38157531" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_A8ADA52EC03F2D1E0717F00F38189469_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_A8ADA52EC03F2D1E0717F00F38189469" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_A8ADA52EC03F2D1E0717F00F38189469_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_A8ADA52EC03F2D1E0717F00F38189469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_A8ADA52EC03F2D1E0717F00F38189469" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_A8ADA52EC03F2D1E0717F00F38189469" xlink:to="lab_us-gaap_DebtCurrent_A8ADA52EC03F2D1E0717F00F38189469" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_CBCEE2BEFF18FD0876A2F00F3818693F_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_CBCEE2BEFF18FD0876A2F00F3818693F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current notes payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_CBCEE2BEFF18FD0876A2F00F3818693F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_CBCEE2BEFF18FD0876A2F00F3818693F" xlink:to="lab_us-gaap_LongTermNotesPayable_CBCEE2BEFF18FD0876A2F00F3818693F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_6B5A87F134AAD5F0B5FBF00F3818FE0B_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_6B5A87F134AAD5F0B5FBF00F3818FE0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_6B5A87F134AAD5F0B5FBF00F3818FE0B_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_6B5A87F134AAD5F0B5FBF00F3818FE0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6B5A87F134AAD5F0B5FBF00F3818FE0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_6B5A87F134AAD5F0B5FBF00F3818FE0B" xlink:to="lab_us-gaap_LongTermDebt_6B5A87F134AAD5F0B5FBF00F3818FE0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776" xlink:to="lab_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_24B3EB896C662C3DA4F56F399DC7FD94_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_24B3EB896C662C3DA4F56F399DC7FD94" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_24B3EB896C662C3DA4F56F399DC7FD94_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_24B3EB896C662C3DA4F56F399DC7FD94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_24B3EB896C662C3DA4F56F399DC7FD94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_24B3EB896C662C3DA4F56F399DC7FD94" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_24B3EB896C662C3DA4F56F399DC7FD94" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_635E5C71271BC40FC2496F399DC76444_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_635E5C71271BC40FC2496F399DC76444" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_635E5C71271BC40FC2496F399DC76444_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_635E5C71271BC40FC2496F399DC76444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_635E5C71271BC40FC2496F399DC76444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_635E5C71271BC40FC2496F399DC76444" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_635E5C71271BC40FC2496F399DC76444" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_937DD558DBE8B66B2EE26F399DC74118_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_937DD558DBE8B66B2EE26F399DC74118" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_937DD558DBE8B66B2EE26F399DC74118_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_937DD558DBE8B66B2EE26F399DC74118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_937DD558DBE8B66B2EE26F399DC74118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_937DD558DBE8B66B2EE26F399DC74118" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_937DD558DBE8B66B2EE26F399DC74118" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_506562273EE5C78EEE266F399DC72257_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_506562273EE5C78EEE266F399DC72257" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_506562273EE5C78EEE266F399DC72257_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_506562273EE5C78EEE266F399DC72257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_506562273EE5C78EEE266F399DC72257_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_506562273EE5C78EEE266F399DC72257" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_506562273EE5C78EEE266F399DC72257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_506562273EE5C78EEE266F399DC72257" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_506562273EE5C78EEE266F399DC72257" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_EDE58A62B7188CFA9E086F399DC7ACB0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_EDE58A62B7188CFA9E086F399DC7ACB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_EDE58A62B7188CFA9E086F399DC7ACB0_label_en-US" xlink:label="lab_us-gaap_InventoryNet_EDE58A62B7188CFA9E086F399DC7ACB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_EDE58A62B7188CFA9E086F399DC7ACB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_EDE58A62B7188CFA9E086F399DC7ACB0" xlink:to="lab_us-gaap_InventoryNet_EDE58A62B7188CFA9E086F399DC7ACB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_F740B0BB43A011D2729D6F399DC842E3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_F740B0BB43A011D2729D6F399DC842E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_F740B0BB43A011D2729D6F399DC842E3_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_F740B0BB43A011D2729D6F399DC842E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_F740B0BB43A011D2729D6F399DC842E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_F740B0BB43A011D2729D6F399DC842E3" xlink:to="lab_us-gaap_InventoryNoncurrent_F740B0BB43A011D2729D6F399DC842E3" xlink:type="arc" />
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091_verboseLabel_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091_label_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Activity [Abstract]</link:label>
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091_documentation_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted stock units activity.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="lab_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:to="lab_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7ED958CCFF802D2F6E040C848E32B614_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7ED958CCFF802D2F6E040C848E32B614" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7ED958CCFF802D2F6E040C848E32B614_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7ED958CCFF802D2F6E040C848E32B614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7ED958CCFF802D2F6E040C848E32B614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7ED958CCFF802D2F6E040C848E32B614" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7ED958CCFF802D2F6E040C848E32B614" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC" xlink:to="lab_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_86A960CE55EEC427BF8A0C848E32817D_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_86A960CE55EEC427BF8A0C848E32817D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_86A960CE55EEC427BF8A0C848E32817D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_86A960CE55EEC427BF8A0C848E32817D" xlink:to="lab_us-gaap_Goodwill_86A960CE55EEC427BF8A0C848E32817D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_817ADA97CE5061FD542A0C848E33E102_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_817ADA97CE5061FD542A0C848E33E102" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_817ADA97CE5061FD542A0C848E33E102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_817ADA97CE5061FD542A0C848E33E102" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_817ADA97CE5061FD542A0C848E33E102" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_72CCF47F5D2160E3CFB80C848E33CD55_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_72CCF47F5D2160E3CFB80C848E33CD55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_72CCF47F5D2160E3CFB80C848E33CD55_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_72CCF47F5D2160E3CFB80C848E33CD55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_72CCF47F5D2160E3CFB80C848E33CD55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_72CCF47F5D2160E3CFB80C848E33CD55" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_72CCF47F5D2160E3CFB80C848E33CD55" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_BD5B24E2701CD445CEE20C848E346077_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_BD5B24E2701CD445CEE20C848E346077" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_BD5B24E2701CD445CEE20C848E346077_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_BD5B24E2701CD445CEE20C848E346077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_BD5B24E2701CD445CEE20C848E346077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_BD5B24E2701CD445CEE20C848E346077" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_BD5B24E2701CD445CEE20C848E346077" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_CCED0CFDA1F8553A9E950C848E342AF4_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_CCED0CFDA1F8553A9E950C848E342AF4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_CCED0CFDA1F8553A9E950C848E342AF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_CCED0CFDA1F8553A9E950C848E342AF4" xlink:to="lab_us-gaap_Goodwill_CCED0CFDA1F8553A9E950C848E342AF4" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:type="arc" />
    <link:label id="lab_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA" xlink:to="lab_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93" xlink:to="lab_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_447F237B1ACB0AE10B346F399D9D2FB9_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_447F237B1ACB0AE10B346F399D9D2FB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_447F237B1ACB0AE10B346F399D9D2FB9_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_447F237B1ACB0AE10B346F399D9D2FB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_447F237B1ACB0AE10B346F399D9D2FB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_447F237B1ACB0AE10B346F399D9D2FB9" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_447F237B1ACB0AE10B346F399D9D2FB9" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_FFBF6E47C183648CF50E6F399D9DF670_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_FFBF6E47C183648CF50E6F399D9DF670" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_FFBF6E47C183648CF50E6F399D9DF670" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_FFBF6E47C183648CF50E6F399D9DF670" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_FFBF6E47C183648CF50E6F399D9DF670" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current provisions relating to sales in current year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087_negatedTerseLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Adjustments relating to prior years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571_negatedTerseLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments/returns related to sales in current year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6_negatedTerseLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments/returns related to sales in prior years</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_463D2E5C60D262FD27686F399D9EE8E2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_463D2E5C60D262FD27686F399D9EE8E2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_463D2E5C60D262FD27686F399D9EE8E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_463D2E5C60D262FD27686F399D9EE8E2" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_463D2E5C60D262FD27686F399D9EE8E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_CB2D7F5653856E75B7FEFCF51D26933A_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_CB2D7F5653856E75B7FEFCF51D26933A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_CB2D7F5653856E75B7FEFCF51D26933A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_CB2D7F5653856E75B7FEFCF51D26933A" xlink:to="lab_us-gaap_CostsAndExpenses_CB2D7F5653856E75B7FEFCF51D26933A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_CF5EF3FF0E723E6F0A1D7019AF4FD2A1_terseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_CF5EF3FF0E723E6F0A1D7019AF4FD2A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_CF5EF3FF0E723E6F0A1D7019AF4FD2A1_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_CF5EF3FF0E723E6F0A1D7019AF4FD2A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_CF5EF3FF0E723E6F0A1D7019AF4FD2A1_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_CF5EF3FF0E723E6F0A1D7019AF4FD2A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_CF5EF3FF0E723E6F0A1D7019AF4FD2A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_CF5EF3FF0E723E6F0A1D7019AF4FD2A1" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_CF5EF3FF0E723E6F0A1D7019AF4FD2A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_0C757194C62CBA76D04E7019AF4F6334_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0C757194C62CBA76D04E7019AF4F6334" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_0C757194C62CBA76D04E7019AF4F6334_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0C757194C62CBA76D04E7019AF4F6334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0C757194C62CBA76D04E7019AF4F6334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_0C757194C62CBA76D04E7019AF4F6334" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_0C757194C62CBA76D04E7019AF4F6334" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_1F9B7776DB2761B7DDFD7019AF4FF261_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_1F9B7776DB2761B7DDFD7019AF4FF261" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_1F9B7776DB2761B7DDFD7019AF4FF261_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_1F9B7776DB2761B7DDFD7019AF4FF261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1F9B7776DB2761B7DDFD7019AF4FF261" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_1F9B7776DB2761B7DDFD7019AF4FF261" xlink:to="lab_us-gaap_UseOfEstimates_1F9B7776DB2761B7DDFD7019AF4FF261" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_116EC1773F7AFDB7D4BE7019AF4F75EF_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_116EC1773F7AFDB7D4BE7019AF4F75EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_116EC1773F7AFDB7D4BE7019AF4F75EF_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_116EC1773F7AFDB7D4BE7019AF4F75EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_116EC1773F7AFDB7D4BE7019AF4F75EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_116EC1773F7AFDB7D4BE7019AF4F75EF" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_116EC1773F7AFDB7D4BE7019AF4F75EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_CEAE85CAF7378B53E29D7019AF4F5E4E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_CEAE85CAF7378B53E29D7019AF4F5E4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_CEAE85CAF7378B53E29D7019AF4F5E4E_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_CEAE85CAF7378B53E29D7019AF4F5E4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_CEAE85CAF7378B53E29D7019AF4F5E4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_CEAE85CAF7378B53E29D7019AF4F5E4E" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_CEAE85CAF7378B53E29D7019AF4F5E4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6F66702407DD97F599F77019AF4F821D_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6F66702407DD97F599F77019AF4F821D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6F66702407DD97F599F77019AF4F821D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6F66702407DD97F599F77019AF4F821D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6F66702407DD97F599F77019AF4F821D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6F66702407DD97F599F77019AF4F821D" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6F66702407DD97F599F77019AF4F821D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_64A98698905CC48282BD7019AF4FC270_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_64A98698905CC48282BD7019AF4FC270" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_64A98698905CC48282BD7019AF4FC270_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_64A98698905CC48282BD7019AF4FC270" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_64A98698905CC48282BD7019AF4FC270" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock_64A98698905CC48282BD7019AF4FC270" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock_64A98698905CC48282BD7019AF4FC270" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_68E78CB35B049FB29E4F7019AF4FFF78_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_68E78CB35B049FB29E4F7019AF4FFF78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_68E78CB35B049FB29E4F7019AF4FFF78_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_68E78CB35B049FB29E4F7019AF4FFF78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_68E78CB35B049FB29E4F7019AF4FFF78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_68E78CB35B049FB29E4F7019AF4FFF78" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_68E78CB35B049FB29E4F7019AF4FFF78" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_204008D0330754AC54157019AF4F0F1B_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_204008D0330754AC54157019AF4F0F1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Other Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_204008D0330754AC54157019AF4F0F1B_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_204008D0330754AC54157019AF4F0F1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_204008D0330754AC54157019AF4F0F1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_204008D0330754AC54157019AF4F0F1B" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_204008D0330754AC54157019AF4F0F1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_E24E92A6F7BF7825E80F7019AF4F95CB_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_E24E92A6F7BF7825E80F7019AF4F95CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method of Accounting</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_E24E92A6F7BF7825E80F7019AF4F95CB_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_E24E92A6F7BF7825E80F7019AF4F95CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_E24E92A6F7BF7825E80F7019AF4F95CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy_E24E92A6F7BF7825E80F7019AF4F95CB" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy_E24E92A6F7BF7825E80F7019AF4F95CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_04D43B431A9D556BB6927019AF4FC1F7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_04D43B431A9D556BB6927019AF4FC1F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_04D43B431A9D556BB6927019AF4FC1F7_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_04D43B431A9D556BB6927019AF4FC1F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_04D43B431A9D556BB6927019AF4FC1F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_04D43B431A9D556BB6927019AF4FC1F7" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_04D43B431A9D556BB6927019AF4FC1F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6F5B011F855FF205C5007019AF4F71B5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6F5B011F855FF205C5007019AF4F71B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6F5B011F855FF205C5007019AF4F71B5_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6F5B011F855FF205C5007019AF4F71B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6F5B011F855FF205C5007019AF4F71B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6F5B011F855FF205C5007019AF4F71B5" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6F5B011F855FF205C5007019AF4F71B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_599C72A0044479ED26127089020E61F5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_599C72A0044479ED26127089020E61F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_599C72A0044479ED26127089020E61F5_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_599C72A0044479ED26127089020E61F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_599C72A0044479ED26127089020E61F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_599C72A0044479ED26127089020E61F5" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_599C72A0044479ED26127089020E61F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_B1552A28A72864977F717019AF4F8A64_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_B1552A28A72864977F717019AF4F8A64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_B1552A28A72864977F717019AF4F8A64_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_B1552A28A72864977F717019AF4F8A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_B1552A28A72864977F717019AF4F8A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_B1552A28A72864977F717019AF4F8A64" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_B1552A28A72864977F717019AF4F8A64" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_16C2196C0F0E3F6DBA137019AF4F9FA9_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_16C2196C0F0E3F6DBA137019AF4F9FA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired In-process Research and Development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_16C2196C0F0E3F6DBA137019AF4F9FA9_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_16C2196C0F0E3F6DBA137019AF4F9FA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_16C2196C0F0E3F6DBA137019AF4F9FA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_16C2196C0F0E3F6DBA137019AF4F9FA9" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_16C2196C0F0E3F6DBA137019AF4F9FA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D67AEEFE7B06315ADBA07019AF4F5543_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D67AEEFE7B06315ADBA07019AF4F5543" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D67AEEFE7B06315ADBA07019AF4F5543_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D67AEEFE7B06315ADBA07019AF4F5543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D67AEEFE7B06315ADBA07019AF4F5543" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D67AEEFE7B06315ADBA07019AF4F5543" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D67AEEFE7B06315ADBA07019AF4F5543" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_239D3490837228177E137019AF4F3042_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_239D3490837228177E137019AF4F3042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_239D3490837228177E137019AF4F3042_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_239D3490837228177E137019AF4F3042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_239D3490837228177E137019AF4F3042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_239D3490837228177E137019AF4F3042" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_239D3490837228177E137019AF4F3042" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_C844033A516592B70A867019AF4F7635_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_C844033A516592B70A867019AF4F7635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_C844033A516592B70A867019AF4F7635_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_C844033A516592B70A867019AF4F7635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_C844033A516592B70A867019AF4F7635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_C844033A516592B70A867019AF4F7635" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_C844033A516592B70A867019AF4F7635" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_87954A02134D3FEB50447019AF4F703D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_87954A02134D3FEB50447019AF4F703D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_87954A02134D3FEB50447019AF4F703D_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_87954A02134D3FEB50447019AF4F703D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_87954A02134D3FEB50447019AF4F703D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_87954A02134D3FEB50447019AF4F703D" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_87954A02134D3FEB50447019AF4F703D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9D8F32120DB095B52E337019AF4F2ECA_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9D8F32120DB095B52E337019AF4F2ECA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation of Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9D8F32120DB095B52E337019AF4F2ECA_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9D8F32120DB095B52E337019AF4F2ECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9D8F32120DB095B52E337019AF4F2ECA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9D8F32120DB095B52E337019AF4F2ECA" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9D8F32120DB095B52E337019AF4F2ECA" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B20929B6E122D6178C057019AF4FA8E1_terseLabel_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B20929B6E122D6178C057019AF4FA8E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales</link:label>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B20929B6E122D6178C057019AF4FA8E1_label_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B20929B6E122D6178C057019AF4FA8E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales [Policy Text Block]</link:label>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B20929B6E122D6178C057019AF4FA8E1_documentation_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B20929B6E122D6178C057019AF4FA8E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales [Policy Text Block]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RoyaltyCostofSalesPolicyTextBlock" xlink:label="loc_biib_RoyaltyCostofSalesPolicyTextBlock_B20929B6E122D6178C057019AF4FA8E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyCostofSalesPolicyTextBlock_B20929B6E122D6178C057019AF4FA8E1" xlink:to="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B20929B6E122D6178C057019AF4FA8E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_BA52980ADADF2554CCE97019AF4F57CE_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_BA52980ADADF2554CCE97019AF4F57CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting for Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_BA52980ADADF2554CCE97019AF4F57CE_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_BA52980ADADF2554CCE97019AF4F57CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_BA52980ADADF2554CCE97019AF4F57CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_BA52980ADADF2554CCE97019AF4F57CE" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_BA52980ADADF2554CCE97019AF4F57CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_D3F42D77A2A0E788AE5F7019AF4FE46C_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_D3F42D77A2A0E788AE5F7019AF4FE46C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_D3F42D77A2A0E788AE5F7019AF4FE46C_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_D3F42D77A2A0E788AE5F7019AF4FE46C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_D3F42D77A2A0E788AE5F7019AF4FE46C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_D3F42D77A2A0E788AE5F7019AF4FE46C" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_D3F42D77A2A0E788AE5F7019AF4FE46C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D4132723B7E32385C1347019AF4FE85E_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D4132723B7E32385C1347019AF4FE85E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D4132723B7E32385C1347019AF4FE85E_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D4132723B7E32385C1347019AF4FE85E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D4132723B7E32385C1347019AF4FE85E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D4132723B7E32385C1347019AF4FE85E" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D4132723B7E32385C1347019AF4FE85E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_4A271E1CC6DD5495AD997019AF4FAB12_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_4A271E1CC6DD5495AD997019AF4FAB12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_4A271E1CC6DD5495AD997019AF4FAB12_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_4A271E1CC6DD5495AD997019AF4FAB12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_4A271E1CC6DD5495AD997019AF4FAB12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_4A271E1CC6DD5495AD997019AF4FAB12" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_4A271E1CC6DD5495AD997019AF4FAB12" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_C8305C80C103EB4C98CD7019AF4FFB1D_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_C8305C80C103EB4C98CD7019AF4FFB1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_C8305C80C103EB4C98CD7019AF4FFB1D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_C8305C80C103EB4C98CD7019AF4FFB1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_C8305C80C103EB4C98CD7019AF4FFB1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_C8305C80C103EB4C98CD7019AF4FFB1D" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_C8305C80C103EB4C98CD7019AF4FFB1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_C10B2807FA58FCDDAEBF7019AF4FB932_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_C10B2807FA58FCDDAEBF7019AF4FB932" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_C10B2807FA58FCDDAEBF7019AF4FB932_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_C10B2807FA58FCDDAEBF7019AF4FB932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_C10B2807FA58FCDDAEBF7019AF4FB932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_C10B2807FA58FCDDAEBF7019AF4FB932" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_C10B2807FA58FCDDAEBF7019AF4FB932" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92AD923AFDC71CC88EB47019AF4F9041_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92AD923AFDC71CC88EB47019AF4F9041" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92AD923AFDC71CC88EB47019AF4F9041_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92AD923AFDC71CC88EB47019AF4F9041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92AD923AFDC71CC88EB47019AF4F9041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92AD923AFDC71CC88EB47019AF4F9041" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92AD923AFDC71CC88EB47019AF4F9041" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F" xlink:to="lab_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_98E4188C66D8494B76086F399EB85EF3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_98E4188C66D8494B76086F399EB85EF3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_98E4188C66D8494B76086F399EB85EF3_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_98E4188C66D8494B76086F399EB85EF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_98E4188C66D8494B76086F399EB85EF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_98E4188C66D8494B76086F399EB85EF3" xlink:to="lab_us-gaap_CommercialPaperMember_98E4188C66D8494B76086F399EB85EF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_CFEB9608B1D83E789AFD6F399EB87485_verboseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_CFEB9608B1D83E789AFD6F399EB87485" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overnight Reverse Repurchase Agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_CFEB9608B1D83E789AFD6F399EB87485_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_CFEB9608B1D83E789AFD6F399EB87485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_CFEB9608B1D83E789AFD6F399EB87485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_CFEB9608B1D83E789AFD6F399EB87485" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_CFEB9608B1D83E789AFD6F399EB87485" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_C444C0807F609F8BD87C6F399EB8BFCC_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_C444C0807F609F8BD87C6F399EB8BFCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_C444C0807F609F8BD87C6F399EB8BFCC_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_C444C0807F609F8BD87C6F399EB8BFCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C444C0807F609F8BD87C6F399EB8BFCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_C444C0807F609F8BD87C6F399EB8BFCC" xlink:to="lab_us-gaap_MoneyMarketFundsMember_C444C0807F609F8BD87C6F399EB8BFCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_A06F2D4BD11528351A496F399EB85660_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_A06F2D4BD11528351A496F399EB85660" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_A06F2D4BD11528351A496F399EB85660_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_A06F2D4BD11528351A496F399EB85660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_A06F2D4BD11528351A496F399EB85660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_A06F2D4BD11528351A496F399EB85660" xlink:to="lab_us-gaap_DebtSecuritiesMember_A06F2D4BD11528351A496F399EB85660" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_C79C2B62E809432475C56F399EB94BBC_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_C79C2B62E809432475C56F399EB94BBC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_C79C2B62E809432475C56F399EB94BBC_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_C79C2B62E809432475C56F399EB94BBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_C79C2B62E809432475C56F399EB94BBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_C79C2B62E809432475C56F399EB94BBC" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_C79C2B62E809432475C56F399EB94BBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5241D20AA32E176DF82DFCF51E4E7DFC_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5241D20AA32E176DF82DFCF51E4E7DFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded Status of Post Retirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5241D20AA32E176DF82DFCF51E4E7DFC_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5241D20AA32E176DF82DFCF51E4E7DFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5241D20AA32E176DF82DFCF51E4E7DFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5241D20AA32E176DF82DFCF51E4E7DFC" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5241D20AA32E176DF82DFCF51E4E7DFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_CFAA33F7913F38B2C732FCF51E4FEE8E_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_CFAA33F7913F38B2C732FCF51E4FEE8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_CFAA33F7913F38B2C732FCF51E4FEE8E_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_CFAA33F7913F38B2C732FCF51E4FEE8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_CFAA33F7913F38B2C732FCF51E4FEE8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_CFAA33F7913F38B2C732FCF51E4FEE8E" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_CFAA33F7913F38B2C732FCF51E4FEE8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2AC2D3CD97A20D2C319EFCF51E4FFD75_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2AC2D3CD97A20D2C319EFCF51E4FFD75" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax Beginning Balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2AC2D3CD97A20D2C319EFCF51E4FFD75_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2AC2D3CD97A20D2C319EFCF51E4FFD75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2AC2D3CD97A20D2C319EFCF51E4FFD75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2AC2D3CD97A20D2C319EFCF51E4FFD75" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2AC2D3CD97A20D2C319EFCF51E4FFD75" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2D5028AFEF4A282ED88DFD2651ED0D9C_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2D5028AFEF4A282ED88DFD2651ED0D9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2D5028AFEF4A282ED88DFD2651ED0D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2D5028AFEF4A282ED88DFD2651ED0D9C" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2D5028AFEF4A282ED88DFD2651ED0D9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5AD3E2CE2663BFACF617FCF51E4FCD1E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5AD3E2CE2663BFACF617FCF51E4FCD1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5AD3E2CE2663BFACF617FCF51E4FCD1E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5AD3E2CE2663BFACF617FCF51E4FCD1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5AD3E2CE2663BFACF617FCF51E4FCD1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5AD3E2CE2663BFACF617FCF51E4FCD1E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5AD3E2CE2663BFACF617FCF51E4FCD1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_41AFED24E93890957FBAFCF51E4F1E89_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_41AFED24E93890957FBAFCF51E4F1E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts Reclassified From Accumulated Other Comprehensive Income, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_41AFED24E93890957FBAFCF51E4F1E89_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_41AFED24E93890957FBAFCF51E4F1E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_41AFED24E93890957FBAFCF51E4F1E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_41AFED24E93890957FBAFCF51E4F1E89" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_41AFED24E93890957FBAFCF51E4F1E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_008BD7E2B381653DE441FCF51E509BB5_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_008BD7E2B381653DE441FCF51E509BB5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_008BD7E2B381653DE441FCF51E509BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_008BD7E2B381653DE441FCF51E509BB5" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_008BD7E2B381653DE441FCF51E509BB5" xlink:type="arc" />
    <link:label id="lab_biib_TaxcontingencyAbstract_AC9BDE994B016C53D013EC4300D87B77_label_en-US" xlink:label="lab_biib_TaxcontingencyAbstract_AC9BDE994B016C53D013EC4300D87B77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax contingency [Abstract]</link:label>
    <link:label id="lab_biib_TaxcontingencyAbstract_AC9BDE994B016C53D013EC4300D87B77_documentation_en-US" xlink:label="lab_biib_TaxcontingencyAbstract_AC9BDE994B016C53D013EC4300D87B77" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax contingency [Abstract]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_TaxcontingencyAbstract" xlink:label="loc_biib_TaxcontingencyAbstract_AC9BDE994B016C53D013EC4300D87B77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TaxcontingencyAbstract_AC9BDE994B016C53D013EC4300D87B77" xlink:to="lab_biib_TaxcontingencyAbstract_AC9BDE994B016C53D013EC4300D87B77" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274" xlink:type="arc" />
    <link:label id="lab_country_BR_108E8F80FA8FF0778A0AEC4300DA8BB5_terseLabel_en-US" xlink:label="lab_country_BR_108E8F80FA8FF0778A0AEC4300DA8BB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BRAZIL</link:label>
    <link:label id="lab_country_BR_108E8F80FA8FF0778A0AEC4300DA8BB5_label_en-US" xlink:label="lab_country_BR_108E8F80FA8FF0778A0AEC4300DA8BB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_108E8F80FA8FF0778A0AEC4300DA8BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR_108E8F80FA8FF0778A0AEC4300DA8BB5" xlink:to="lab_country_BR_108E8F80FA8FF0778A0AEC4300DA8BB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_6AFFEC1B939E58D0078BEC440AE23982_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_6AFFEC1B939E58D0078BEC440AE23982" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Claims Asserted</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_6AFFEC1B939E58D0078BEC440AE23982_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_6AFFEC1B939E58D0078BEC440AE23982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_6AFFEC1B939E58D0078BEC440AE23982" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue_6AFFEC1B939E58D0078BEC440AE23982" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue_6AFFEC1B939E58D0078BEC440AE23982" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_E1BC5CD438C1823810C2EC4300DBABC0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_E1BC5CD438C1823810C2EC4300DBABC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Tax Assessment</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_E1BC5CD438C1823810C2EC4300DBABC0_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_E1BC5CD438C1823810C2EC4300DBABC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_E1BC5CD438C1823810C2EC4300DBABC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_E1BC5CD438C1823810C2EC4300DBABC0" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_E1BC5CD438C1823810C2EC4300DBABC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6DFD581652036D61F45F6F399E71A3BC_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6DFD581652036D61F45F6F399E71A3BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6DFD581652036D61F45F6F399E71A3BC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6DFD581652036D61F45F6F399E71A3BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6DFD581652036D61F45F6F399E71A3BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6DFD581652036D61F45F6F399E71A3BC" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6DFD581652036D61F45F6F399E71A3BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_51775A19077107D3CB906F399E71FA20_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_51775A19077107D3CB906F399E71FA20" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_51775A19077107D3CB906F399E71FA20_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_51775A19077107D3CB906F399E71FA20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_51775A19077107D3CB906F399E71FA20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_51775A19077107D3CB906F399E71FA20" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_51775A19077107D3CB906F399E71FA20" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4F91B154C47DDD1FCF6F6F399E71814C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4F91B154C47DDD1FCF6F6F399E71814C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4F91B154C47DDD1FCF6F6F399E71814C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4F91B154C47DDD1FCF6F6F399E71814C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4F91B154C47DDD1FCF6F6F399E71814C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4F91B154C47DDD1FCF6F6F399E71814C" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4F91B154C47DDD1FCF6F6F399E71814C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_C4607895FD9573036E436F399E71D2F8_terseLabel_en-US" xlink:label="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_C4607895FD9573036E436F399E71D2F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option exercises</link:label>
    <link:label id="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_C4607895FD9573036E436F399E71D2F8_label_en-US" xlink:label="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_C4607895FD9573036E436F399E71D2F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Proceeds Received and Tax Benefit from Share-based Payment Awards [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:label="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_C4607895FD9573036E436F399E71D2F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_C4607895FD9573036E436F399E71D2F8" xlink:to="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_C4607895FD9573036E436F399E71D2F8" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_B6824F5849B237A5243D6F399E71B0B1_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_B6824F5849B237A5243D6F399E71B0B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market stock units activity</link:label>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_B6824F5849B237A5243D6F399E71B0B1_label_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_B6824F5849B237A5243D6F399E71B0B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Market Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_B6824F5849B237A5243D6F399E71B0B1_documentation_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_B6824F5849B237A5243D6F399E71B0B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Market Stock Units Activity.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_B6824F5849B237A5243D6F399E71B0B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_B6824F5849B237A5243D6F399E71B0B1" xlink:to="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_B6824F5849B237A5243D6F399E71B0B1" xlink:type="arc" />
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_C2D15D789C70C6FB24F76F399E72E714_terseLabel_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_C2D15D789C70C6FB24F76F399E72E714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units</link:label>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_C2D15D789C70C6FB24F76F399E72E714_label_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_C2D15D789C70C6FB24F76F399E72E714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assumptions Used In Valuation Of Market Based Stock Units [Table Text Block]</link:label>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_C2D15D789C70C6FB24F76F399E72E714_documentation_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_C2D15D789C70C6FB24F76F399E72E714" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:label="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_C2D15D789C70C6FB24F76F399E72E714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_C2D15D789C70C6FB24F76F399E72E714" xlink:to="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_C2D15D789C70C6FB24F76F399E72E714" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_F73EE6EC791DC6CCAA0E6F399E726E8A_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_F73EE6EC791DC6CCAA0E6F399E726E8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares activity</link:label>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_F73EE6EC791DC6CCAA0E6F399E726E8A_label_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_F73EE6EC791DC6CCAA0E6F399E726E8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Cash Settled Performance Shares Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_F73EE6EC791DC6CCAA0E6F399E726E8A_documentation_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_F73EE6EC791DC6CCAA0E6F399E726E8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Cash Settled Performance Shares Activity.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_F73EE6EC791DC6CCAA0E6F399E726E8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_F73EE6EC791DC6CCAA0E6F399E726E8A" xlink:to="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_F73EE6EC791DC6CCAA0E6F399E726E8A" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_8B49BED9E3100F4ABCD16F399E72FEE0_terseLabel_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_8B49BED9E3100F4ABCD16F399E72FEE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units activity</link:label>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_8B49BED9E3100F4ABCD16F399E72FEE0_label_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_8B49BED9E3100F4ABCD16F399E72FEE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance units activity [Table Text Block]</link:label>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_8B49BED9E3100F4ABCD16F399E72FEE0_documentation_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_8B49BED9E3100F4ABCD16F399E72FEE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance units activity [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceunitsactivityTableTextBlock" xlink:label="loc_biib_PerformanceunitsactivityTableTextBlock_8B49BED9E3100F4ABCD16F399E72FEE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceunitsactivityTableTextBlock_8B49BED9E3100F4ABCD16F399E72FEE0" xlink:to="lab_biib_PerformanceunitsactivityTableTextBlock_8B49BED9E3100F4ABCD16F399E72FEE0" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_26962FCD0706CE2DFD146F399E7226C3_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_26962FCD0706CE2DFD146F399E7226C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock activity</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_26962FCD0706CE2DFD146F399E7226C3_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_26962FCD0706CE2DFD146F399E7226C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Table Text Block]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_26962FCD0706CE2DFD146F399E7226C3_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_26962FCD0706CE2DFD146F399E7226C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockTableTextBlock" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockTableTextBlock_26962FCD0706CE2DFD146F399E7226C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockTableTextBlock_26962FCD0706CE2DFD146F399E7226C3" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_26962FCD0706CE2DFD146F399E7226C3" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_BE8D719AD02AD1F577F66F399E72AF30_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_BE8D719AD02AD1F577F66F399E72AF30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash activity</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_BE8D719AD02AD1F577F66F399E72AF30_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_BE8D719AD02AD1F577F66F399E72AF30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Table Text Block]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_BE8D719AD02AD1F577F66F399E72AF30_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_BE8D719AD02AD1F577F66F399E72AF30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinCashTableTextBlock" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashTableTextBlock_BE8D719AD02AD1F577F66F399E72AF30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashTableTextBlock_BE8D719AD02AD1F577F66F399E72AF30" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_BE8D719AD02AD1F577F66F399E72AF30" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_8776D1C8E6FEFC7B73C96F399E72D22F_terseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_8776D1C8E6FEFC7B73C96F399E72D22F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units activity</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_8776D1C8E6FEFC7B73C96F399E72D22F_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_8776D1C8E6FEFC7B73C96F399E72D22F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_8776D1C8E6FEFC7B73C96F399E72D22F_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_8776D1C8E6FEFC7B73C96F399E72D22F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units Activity.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_8776D1C8E6FEFC7B73C96F399E72D22F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_8776D1C8E6FEFC7B73C96F399E72D22F" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_8776D1C8E6FEFC7B73C96F399E72D22F" xlink:type="arc" />
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_7E9F100AB96A97E3A5606F399E73B044_terseLabel_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_7E9F100AB96A97E3A5606F399E73B044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_7E9F100AB96A97E3A5606F399E73B044_label_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_7E9F100AB96A97E3A5606F399E73B044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Under Employee Stock Purchase Plan [Table Text Block]</link:label>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_7E9F100AB96A97E3A5606F399E73B044_documentation_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_7E9F100AB96A97E3A5606F399E73B044" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:label="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_7E9F100AB96A97E3A5606F399E73B044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_7E9F100AB96A97E3A5606F399E73B044" xlink:to="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_7E9F100AB96A97E3A5606F399E73B044" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6BD222897294AC6B19E76F399DDEED0A_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_6BD222897294AC6B19E76F399DDEED0A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6BD222897294AC6B19E76F399DDEED0A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_6BD222897294AC6B19E76F399DDEED0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_6BD222897294AC6B19E76F399DDEED0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_6BD222897294AC6B19E76F399DDEED0A" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_6BD222897294AC6B19E76F399DDEED0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_367BFE9460D1C7E75F086F399D784396_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_367BFE9460D1C7E75F086F399D784396" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_367BFE9460D1C7E75F086F399D784396_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_367BFE9460D1C7E75F086F399D784396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_367BFE9460D1C7E75F086F399D784396" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_367BFE9460D1C7E75F086F399D784396" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_367BFE9460D1C7E75F086F399D784396" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_144BA1A44C6F5CD5A7E96F399D781F47_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_144BA1A44C6F5CD5A7E96F399D781F47" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_144BA1A44C6F5CD5A7E96F399D781F47_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_144BA1A44C6F5CD5A7E96F399D781F47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_144BA1A44C6F5CD5A7E96F399D781F47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_144BA1A44C6F5CD5A7E96F399D781F47" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_144BA1A44C6F5CD5A7E96F399D781F47" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_93AD33FE62F3141DF8E66F399D79BBF8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_93AD33FE62F3141DF8E66F399D79BBF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_93AD33FE62F3141DF8E66F399D79BBF8_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_93AD33FE62F3141DF8E66F399D79BBF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_93AD33FE62F3141DF8E66F399D79BBF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_93AD33FE62F3141DF8E66F399D79BBF8" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_93AD33FE62F3141DF8E66F399D79BBF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_E39DAB699B0B28EC4F18EBFB61B26EC6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_E39DAB699B0B28EC4F18EBFB61B26EC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_E39DAB699B0B28EC4F18EBFB61B26EC6_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_E39DAB699B0B28EC4F18EBFB61B26EC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_E39DAB699B0B28EC4F18EBFB61B26EC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_E39DAB699B0B28EC4F18EBFB61B26EC6" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_E39DAB699B0B28EC4F18EBFB61B26EC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_2BD9D81F55D81FEC9884EBFB61B2AC9D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_2BD9D81F55D81FEC9884EBFB61B2AC9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, other reserves, and accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_2BD9D81F55D81FEC9884EBFB61B2AC9D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_2BD9D81F55D81FEC9884EBFB61B2AC9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_2BD9D81F55D81FEC9884EBFB61B2AC9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory_2BD9D81F55D81FEC9884EBFB61B2AC9D" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory_2BD9D81F55D81FEC9884EBFB61B2AC9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_178C0A334B0860884847EBFB61B3ED49_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_178C0A334B0860884847EBFB61B3ED49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_178C0A334B0860884847EBFB61B3ED49_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_178C0A334B0860884847EBFB61B3ED49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_178C0A334B0860884847EBFB61B3ED49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_178C0A334B0860884847EBFB61B3ED49" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_178C0A334B0860884847EBFB61B3ED49" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_94F248C939B7D19C0EAEEBFB61B37F97_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_94F248C939B7D19C0EAEEBFB61B37F97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_94F248C939B7D19C0EAEEBFB61B37F97_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_94F248C939B7D19C0EAEEBFB61B37F97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_94F248C939B7D19C0EAEEBFB61B37F97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_94F248C939B7D19C0EAEEBFB61B37F97" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_94F248C939B7D19C0EAEEBFB61B37F97" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C8BF7B37F53528EAC7DBEBFB61B3CE9F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C8BF7B37F53528EAC7DBEBFB61B3CE9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C8BF7B37F53528EAC7DBEBFB61B3CE9F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C8BF7B37F53528EAC7DBEBFB61B3CE9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C8BF7B37F53528EAC7DBEBFB61B3CE9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C8BF7B37F53528EAC7DBEBFB61B3CE9F" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C8BF7B37F53528EAC7DBEBFB61B3CE9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D98300A2175568B73927EBFB61B89C41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D98300A2175568B73927EBFB61B89C41" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D98300A2175568B73927EBFB61B89C41_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D98300A2175568B73927EBFB61B89C41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_D98300A2175568B73927EBFB61B89C41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_D98300A2175568B73927EBFB61B89C41" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D98300A2175568B73927EBFB61B89C41" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_7CBFB071201BCFB7518DEBFB61B8B28D_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_7CBFB071201BCFB7518DEBFB61B8B28D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_7CBFB071201BCFB7518DEBFB61B8B28D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_7CBFB071201BCFB7518DEBFB61B8B28D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7CBFB071201BCFB7518DEBFB61B8B28D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_7CBFB071201BCFB7518DEBFB61B8B28D" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_7CBFB071201BCFB7518DEBFB61B8B28D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_74C6715067AF1C0D3F08EBFB61B90ADD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_74C6715067AF1C0D3F08EBFB61B90ADD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_74C6715067AF1C0D3F08EBFB61B90ADD_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_74C6715067AF1C0D3F08EBFB61B90ADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_74C6715067AF1C0D3F08EBFB61B90ADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_74C6715067AF1C0D3F08EBFB61B90ADD" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_74C6715067AF1C0D3F08EBFB61B90ADD" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_90C59406AB1B6C7FAD7DEBFB61B930F3_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_90C59406AB1B6C7FAD7DEBFB61B930F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Tax Credit Carryforwards</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_90C59406AB1B6C7FAD7DEBFB61B930F3_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_90C59406AB1B6C7FAD7DEBFB61B930F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Tax Credit Carryforwards</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_90C59406AB1B6C7FAD7DEBFB61B930F3_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_90C59406AB1B6C7FAD7DEBFB61B930F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" xlink:label="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_90C59406AB1B6C7FAD7DEBFB61B930F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_90C59406AB1B6C7FAD7DEBFB61B930F3" xlink:to="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_90C59406AB1B6C7FAD7DEBFB61B930F3" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_C6975885EB4C55AF3681EBFB61B99340_negatedTerseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_C6975885EB4C55AF3681EBFB61B99340" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and other</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_C6975885EB4C55AF3681EBFB61B99340_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_C6975885EB4C55AF3681EBFB61B99340" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Depreciation Amortization Other</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_C6975885EB4C55AF3681EBFB61B99340_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_C6975885EB4C55AF3681EBFB61B99340" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities depreciation amortization other.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_C6975885EB4C55AF3681EBFB61B99340" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_C6975885EB4C55AF3681EBFB61B99340" xlink:to="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_C6975885EB4C55AF3681EBFB61B99340" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_50AD7B3D1C5D7A93CDC5EBFB61B9BBBE_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_50AD7B3D1C5D7A93CDC5EBFB61B9BBBE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_50AD7B3D1C5D7A93CDC5EBFB61B9BBBE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_50AD7B3D1C5D7A93CDC5EBFB61B9BBBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_50AD7B3D1C5D7A93CDC5EBFB61B9BBBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_50AD7B3D1C5D7A93CDC5EBFB61B9BBBE" xlink:to="lab_us-gaap_DeferredTaxLiabilities_50AD7B3D1C5D7A93CDC5EBFB61B9BBBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the beginning and ending of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_D4161830F0D095B90D80FCF51D924770_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_D4161830F0D095B90D80FCF51D924770" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_D4161830F0D095B90D80FCF51D924770_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_D4161830F0D095B90D80FCF51D924770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_D4161830F0D095B90D80FCF51D924770" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_D4161830F0D095B90D80FCF51D924770" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_D4161830F0D095B90D80FCF51D924770" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A9BC68982AFC45800E89FCF51D92134A_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A9BC68982AFC45800E89FCF51D92134A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions based on tax positions related to the current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A9BC68982AFC45800E89FCF51D92134A_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A9BC68982AFC45800E89FCF51D92134A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A9BC68982AFC45800E89FCF51D92134A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A9BC68982AFC45800E89FCF51D92134A" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A9BC68982AFC45800E89FCF51D92134A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E6AEABA9D4A51B7B781DFCF51D93C2D0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E6AEABA9D4A51B7B781DFCF51D93C2D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions for tax positions of prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E6AEABA9D4A51B7B781DFCF51D93C2D0_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E6AEABA9D4A51B7B781DFCF51D93C2D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E6AEABA9D4A51B7B781DFCF51D93C2D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E6AEABA9D4A51B7B781DFCF51D93C2D0" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E6AEABA9D4A51B7B781DFCF51D93C2D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A2432103FF78EC79B1D3FCF51D93695A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A2432103FF78EC79B1D3FCF51D93695A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reductions for tax positions of prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A2432103FF78EC79B1D3FCF51D93695A_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A2432103FF78EC79B1D3FCF51D93695A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A2432103FF78EC79B1D3FCF51D93695A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A2432103FF78EC79B1D3FCF51D93695A" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A2432103FF78EC79B1D3FCF51D93695A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4040966636102C77B870FCF51D9353E8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4040966636102C77B870FCF51D9353E8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Statute expirations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4040966636102C77B870FCF51D9353E8_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4040966636102C77B870FCF51D9353E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4040966636102C77B870FCF51D9353E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4040966636102C77B870FCF51D9353E8" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4040966636102C77B870FCF51D9353E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0B9D29198CCDA50FCF81FCF51D934AC3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0B9D29198CCDA50FCF81FCF51D934AC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0B9D29198CCDA50FCF81FCF51D934AC3_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0B9D29198CCDA50FCF81FCF51D934AC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0B9D29198CCDA50FCF81FCF51D934AC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0B9D29198CCDA50FCF81FCF51D934AC3" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0B9D29198CCDA50FCF81FCF51D934AC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_8744CE8CDC94B5D73985FCF51D93E225_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_8744CE8CDC94B5D73985FCF51D93E225" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8744CE8CDC94B5D73985FCF51D93E225" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_8744CE8CDC94B5D73985FCF51D93E225" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_8744CE8CDC94B5D73985FCF51D93E225" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:type="arc" />
    <link:label id="lab_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185_verboseLabel_en-US" xlink:label="lab_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185_label_en-US" xlink:label="lab_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185_documentation_en-US" xlink:label="lab_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185" xlink:to="lab_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185" xlink:type="arc" />
    <link:label id="lab_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B_verboseLabel_en-US" xlink:label="lab_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B_label_en-US" xlink:label="lab_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B_documentation_en-US" xlink:label="lab_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:to="lab_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40DF59820B73F944DA5E6F399F1DF763_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40DF59820B73F944DA5E6F399F1DF763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40DF59820B73F944DA5E6F399F1DF763" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40DF59820B73F944DA5E6F399F1DF763" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40DF59820B73F944DA5E6F399F1DF763" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F65164270B49FA7871746F399F1D2E31_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F65164270B49FA7871746F399F1D2E31" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F65164270B49FA7871746F399F1D2E31_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F65164270B49FA7871746F399F1D2E31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F65164270B49FA7871746F399F1D2E31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F65164270B49FA7871746F399F1D2E31" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F65164270B49FA7871746F399F1D2E31" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_AAA3F08ACC01968679FD6F399F1D65DB_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_AAA3F08ACC01968679FD6F399F1D65DB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_AAA3F08ACC01968679FD6F399F1D65DB_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_AAA3F08ACC01968679FD6F399F1D65DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_AAA3F08ACC01968679FD6F399F1D65DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_AAA3F08ACC01968679FD6F399F1D65DB" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_AAA3F08ACC01968679FD6F399F1D65DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4A482ADF86C095345CFD6F399F1ED3B3_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4A482ADF86C095345CFD6F399F1ED3B3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4A482ADF86C095345CFD6F399F1ED3B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4A482ADF86C095345CFD6F399F1ED3B3" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4A482ADF86C095345CFD6F399F1ED3B3" xlink:type="arc" />
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_503EF4B8223E17E2E38B6F399F1EB982_terseLabel_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_503EF4B8223E17E2E38B6F399F1EB982" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share (Textual)</link:label>
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_503EF4B8223E17E2E38B6F399F1EB982_label_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_503EF4B8223E17E2E38B6F399F1EB982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_503EF4B8223E17E2E38B6F399F1EB982_documentation_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_503EF4B8223E17E2E38B6F399F1EB982" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings per share.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EarningsPerShareTextualAbstract" xlink:label="loc_biib_EarningsPerShareTextualAbstract_503EF4B8223E17E2E38B6F399F1EB982" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EarningsPerShareTextualAbstract_503EF4B8223E17E2E38B6F399F1EB982" xlink:to="lab_biib_EarningsPerShareTextualAbstract_503EF4B8223E17E2E38B6F399F1EB982" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_58C9E271E389F05412816F399F1E8424_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_58C9E271E389F05412816F399F1E8424" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_58C9E271E389F05412816F399F1E8424_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_58C9E271E389F05412816F399F1E8424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_58C9E271E389F05412816F399F1E8424" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_58C9E271E389F05412816F399F1E8424" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_58C9E271E389F05412816F399F1E8424" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64" xlink:type="arc" />
    <link:label id="lab_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD_terseLabel_en-US" xlink:label="lab_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease</link:label>
    <link:label id="lab_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD_label_en-US" xlink:label="lab_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease [Member]</link:label>
    <link:label id="lab_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD_documentation_en-US" xlink:label="lab_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublease [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SubleaseMember" xlink:label="loc_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD" xlink:to="lab_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_AD9C523BE4768E0EA2270B39D4A304B4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_AD9C523BE4768E0EA2270B39D4A304B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_AD9C523BE4768E0EA2270B39D4A304B4_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_AD9C523BE4768E0EA2270B39D4A304B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_AD9C523BE4768E0EA2270B39D4A304B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_AD9C523BE4768E0EA2270B39D4A304B4" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_AD9C523BE4768E0EA2270B39D4A304B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_A5F1B34B1434DA34DB400B39D4A3E838_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_A5F1B34B1434DA34DB400B39D4A3E838" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_A5F1B34B1434DA34DB400B39D4A3E838_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_A5F1B34B1434DA34DB400B39D4A3E838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_A5F1B34B1434DA34DB400B39D4A3E838" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_A5F1B34B1434DA34DB400B39D4A3E838" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_A5F1B34B1434DA34DB400B39D4A3E838" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_52D77E20D6F11199A2246F399E870ECE_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_52D77E20D6F11199A2246F399E870ECE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_52D77E20D6F11199A2246F399E870ECE_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_52D77E20D6F11199A2246F399E870ECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_52D77E20D6F11199A2246F399E870ECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_52D77E20D6F11199A2246F399E870ECE" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_52D77E20D6F11199A2246F399E870ECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_BEA1FA3BAEDC742448456F399ED4B14E_verboseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_BEA1FA3BAEDC742448456F399ED4B14E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_BEA1FA3BAEDC742448456F399ED4B14E_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_BEA1FA3BAEDC742448456F399ED4B14E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_BEA1FA3BAEDC742448456F399ED4B14E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_BEA1FA3BAEDC742448456F399ED4B14E" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_BEA1FA3BAEDC742448456F399ED4B14E" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_762B2655F23542EB19A96F399D3D1793_terseLabel_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_762B2655F23542EB19A96F399D3D1793" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of common stock</link:label>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_762B2655F23542EB19A96F399D3D1793_label_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_762B2655F23542EB19A96F399D3D1793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Common Stock [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_762B2655F23542EB19A96F399D3D1793_documentation_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_762B2655F23542EB19A96F399D3D1793" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of common stock.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SummaryOfCommonStockTableTextBlock" xlink:label="loc_biib_SummaryOfCommonStockTableTextBlock_762B2655F23542EB19A96F399D3D1793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfCommonStockTableTextBlock_762B2655F23542EB19A96F399D3D1793" xlink:to="lab_biib_SummaryOfCommonStockTableTextBlock_762B2655F23542EB19A96F399D3D1793" xlink:type="arc" />
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE_verboseLabel_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Marketable Debt Securities</link:label>
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE_label_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Marketable Debt Securities [Abstract]</link:label>
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE_documentation_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ProceedsFromMarketableDebtSecuritiesAbstract" xlink:label="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE" xlink:to="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5BF059C3E3C1B7C12FE76F399E1F9B48_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5BF059C3E3C1B7C12FE76F399E1F9B48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5BF059C3E3C1B7C12FE76F399E1F9B48_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5BF059C3E3C1B7C12FE76F399E1F9B48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5BF059C3E3C1B7C12FE76F399E1F9B48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5BF059C3E3C1B7C12FE76F399E1F9B48" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5BF059C3E3C1B7C12FE76F399E1F9B48" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_B69C0BF3415EE13702CF6F399E20A7EE_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_B69C0BF3415EE13702CF6F399E20A7EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_B69C0BF3415EE13702CF6F399E20A7EE_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_B69C0BF3415EE13702CF6F399E20A7EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_B69C0BF3415EE13702CF6F399E20A7EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_B69C0BF3415EE13702CF6F399E20A7EE" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_B69C0BF3415EE13702CF6F399E20A7EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_4A74DB5DCE3F6B2414E06F399E20048D_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_4A74DB5DCE3F6B2414E06F399E20048D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_4A74DB5DCE3F6B2414E06F399E20048D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_4A74DB5DCE3F6B2414E06F399E20048D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_4A74DB5DCE3F6B2414E06F399E20048D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_4A74DB5DCE3F6B2414E06F399E20048D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_4A74DB5DCE3F6B2414E06F399E20048D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_E70450EA624BE50C9DF06F399BDE5BA6_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_E70450EA624BE50C9DF06F399BDE5BA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_E70450EA624BE50C9DF06F399BDE5BA6_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_E70450EA624BE50C9DF06F399BDE5BA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_E70450EA624BE50C9DF06F399BDE5BA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_E70450EA624BE50C9DF06F399BDE5BA6" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_E70450EA624BE50C9DF06F399BDE5BA6" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Abstract]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Abstract]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinCashAbstract" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:type="arc" />
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A_verboseLabel_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units</link:label>
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A_label_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation of Granted Stock Units [Abstract]</link:label>
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A_documentation_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation of granted stock units.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="lab_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EE21EC35B5BE075CE1186F399F48E5F8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EE21EC35B5BE075CE1186F399F48E5F8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EE21EC35B5BE075CE1186F399F48E5F8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EE21EC35B5BE075CE1186F399F48E5F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EE21EC35B5BE075CE1186F399F48E5F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EE21EC35B5BE075CE1186F399F48E5F8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EE21EC35B5BE075CE1186F399F48E5F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953332ED30B5BAB67D4D6F399F487A17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953332ED30B5BAB67D4D6F399F487A17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953332ED30B5BAB67D4D6F399F487A17_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953332ED30B5BAB67D4D6F399F487A17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953332ED30B5BAB67D4D6F399F487A17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953332ED30B5BAB67D4D6F399F487A17" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953332ED30B5BAB67D4D6F399F487A17" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_F52CCF3033F6D9E26B506F399F498059_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_F52CCF3033F6D9E26B506F399F498059" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum range of risk-free interest rates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_F52CCF3033F6D9E26B506F399F498059_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_F52CCF3033F6D9E26B506F399F498059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_F52CCF3033F6D9E26B506F399F498059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_F52CCF3033F6D9E26B506F399F498059" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_F52CCF3033F6D9E26B506F399F498059" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8573CB215B62DE9053F56F399F49D5D5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8573CB215B62DE9053F56F399F49D5D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum range of risk-free interest rates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8573CB215B62DE9053F56F399F49D5D5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8573CB215B62DE9053F56F399F49D5D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8573CB215B62DE9053F56F399F49D5D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8573CB215B62DE9053F56F399F49D5D5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8573CB215B62DE9053F56F399F49D5D5" xlink:type="arc" />
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA_verboseLabel_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average stock price on grant date minimum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA_label_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Stock Price On Grant Date In Dollars Minimum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA_documentation_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average stock price on grant date in dollars minimum.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA" xlink:to="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA" xlink:type="arc" />
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5_verboseLabel_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average stock price on grant date maximum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5_label_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Stock Price On Grant Date In Dollars Maximum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5_documentation_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average stock price on grant date in dollars maximum.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5" xlink:to="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_995DAC78466CDC7055076F399E905ED2_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_995DAC78466CDC7055076F399E905ED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_995DAC78466CDC7055076F399E905ED2_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_995DAC78466CDC7055076F399E905ED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_995DAC78466CDC7055076F399E905ED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_995DAC78466CDC7055076F399E905ED2" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_995DAC78466CDC7055076F399E905ED2" xlink:type="arc" />
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665_verboseLabel_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option</link:label>
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665_label_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Benefit And Cash Received From Stock Option [Abstract]</link:label>
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665_documentation_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" xlink:label="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665" xlink:to="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0D6139820484741AF68E6F399FF01878_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0D6139820484741AF68E6F399FF01878" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit realized for stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0D6139820484741AF68E6F399FF01878_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0D6139820484741AF68E6F399FF01878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0D6139820484741AF68E6F399FF01878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0D6139820484741AF68E6F399FF01878" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0D6139820484741AF68E6F399FF01878" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_27906880B5954BD0D5D96F399FF0094D_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_27906880B5954BD0D5D96F399FF0094D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_27906880B5954BD0D5D96F399FF0094D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_27906880B5954BD0D5D96F399FF0094D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_27906880B5954BD0D5D96F399FF0094D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_27906880B5954BD0D5D96F399FF0094D" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_27906880B5954BD0D5D96F399FF0094D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignPlanMember_4119A5B68DDFCE8697AC0B73C6A477E1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_4119A5B68DDFCE8697AC0B73C6A477E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_4119A5B68DDFCE8697AC0B73C6A477E1_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_4119A5B68DDFCE8697AC0B73C6A477E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_4119A5B68DDFCE8697AC0B73C6A477E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember_4119A5B68DDFCE8697AC0B73C6A477E1" xlink:to="lab_us-gaap_ForeignPlanMember_4119A5B68DDFCE8697AC0B73C6A477E1" xlink:type="arc" />
    <link:label id="lab_country_DE_73FF253340714FCD5DA90B73C6A417E6_terseLabel_en-US" xlink:label="lab_country_DE_73FF253340714FCD5DA90B73C6A417E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:label id="lab_country_DE_73FF253340714FCD5DA90B73C6A417E6_label_en-US" xlink:label="lab_country_DE_73FF253340714FCD5DA90B73C6A417E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="loc_country_DE_73FF253340714FCD5DA90B73C6A417E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE_73FF253340714FCD5DA90B73C6A417E6" xlink:to="lab_country_DE_73FF253340714FCD5DA90B73C6A417E6" xlink:type="arc" />
    <link:label id="lab_country_CH_9A9E29E888914059A01B0B73C6A479BA_terseLabel_en-US" xlink:label="lab_country_CH_9A9E29E888914059A01B0B73C6A479BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:label id="lab_country_CH_9A9E29E888914059A01B0B73C6A479BA_label_en-US" xlink:label="lab_country_CH_9A9E29E888914059A01B0B73C6A479BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CH" xlink:label="loc_country_CH_9A9E29E888914059A01B0B73C6A479BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH_9A9E29E888914059A01B0B73C6A479BA" xlink:to="lab_country_CH_9A9E29E888914059A01B0B73C6A479BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7_verboseLabel_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7_label_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7_documentation_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee benefit plans.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:to="lab_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of minimum investment return</link:label>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019_label_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Minimum Investment Return</link:label>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019_documentation_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of minimum investment return.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019" xlink:to="lab_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6F06D4C0F7F04030A1060B3C1FD2DE3C_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6F06D4C0F7F04030A1060B3C1FD2DE3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unfunded net pension</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6F06D4C0F7F04030A1060B3C1FD2DE3C_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6F06D4C0F7F04030A1060B3C1FD2DE3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6F06D4C0F7F04030A1060B3C1FD2DE3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6F06D4C0F7F04030A1060B3C1FD2DE3C" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6F06D4C0F7F04030A1060B3C1FD2DE3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_232F421636FD0AB3784A0B3C1FD26067_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_232F421636FD0AB3784A0B3C1FD26067" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_232F421636FD0AB3784A0B3C1FD26067_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_232F421636FD0AB3784A0B3C1FD26067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_232F421636FD0AB3784A0B3C1FD26067" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation_232F421636FD0AB3784A0B3C1FD26067" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation_232F421636FD0AB3784A0B3C1FD26067" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionExpense_3AC99CC2E4557EAB0A980B3C1FD23222_terseLabel_en-US" xlink:label="lab_us-gaap_PensionExpense_3AC99CC2E4557EAB0A980B3C1FD23222" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Cost (Reversal of Cost)</link:label>
    <link:label id="lab_us-gaap_PensionExpense_3AC99CC2E4557EAB0A980B3C1FD23222_label_en-US" xlink:label="lab_us-gaap_PensionExpense_3AC99CC2E4557EAB0A980B3C1FD23222" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Cost (Reversal of Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_3AC99CC2E4557EAB0A980B3C1FD23222" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionExpense_3AC99CC2E4557EAB0A980B3C1FD23222" xlink:to="lab_us-gaap_PensionExpense_3AC99CC2E4557EAB0A980B3C1FD23222" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6274612FB58D71C8A7040B3C1FE25D45_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6274612FB58D71C8A7040B3C1FE25D45" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Periodic pension cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6274612FB58D71C8A7040B3C1FE25D45_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6274612FB58D71C8A7040B3C1FE25D45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6274612FB58D71C8A7040B3C1FE25D45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6274612FB58D71C8A7040B3C1FE25D45" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6274612FB58D71C8A7040B3C1FE25D45" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_99EE89616A02560779E66F399D6FCC22_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_99EE89616A02560779E66F399D6FCC22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment estimated useful lives</link:label>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_99EE89616A02560779E66F399D6FCC22_label_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_99EE89616A02560779E66F399D6FCC22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_99EE89616A02560779E66F399D6FCC22_documentation_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_99EE89616A02560779E66F399D6FCC22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of property plant and equipment useful lives.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_99EE89616A02560779E66F399D6FCC22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_99EE89616A02560779E66F399D6FCC22" xlink:to="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_99EE89616A02560779E66F399D6FCC22" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_560B7138D11AA0C7F08BEBFB62DAE7A7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_560B7138D11AA0C7F08BEBFB62DAE7A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_560B7138D11AA0C7F08BEBFB62DAE7A7_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_560B7138D11AA0C7F08BEBFB62DAE7A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_560B7138D11AA0C7F08BEBFB62DAE7A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_560B7138D11AA0C7F08BEBFB62DAE7A7" xlink:to="lab_us-gaap_EmployeeStockOptionMember_560B7138D11AA0C7F08BEBFB62DAE7A7" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5_terseLabel_en-US" xlink:label="lab_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Units</link:label>
    <link:label id="lab_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5_label_en-US" xlink:label="lab_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:label id="lab_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5_documentation_en-US" xlink:label="lab_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceUnitsMember" xlink:label="loc_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5" xlink:to="lab_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_E28F7804B5897EF8EF20EBFB62DDCD3C_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_E28F7804B5897EF8EF20EBFB62DDCD3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E28F7804B5897EF8EF20EBFB62DDCD3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_E28F7804B5897EF8EF20EBFB62DDCD3C" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_E28F7804B5897EF8EF20EBFB62DDCD3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_6382394C48D005E35F06FC2463C649F8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_6382394C48D005E35F06FC2463C649F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_6382394C48D005E35F06FC2463C649F8_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_6382394C48D005E35F06FC2463C649F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_6382394C48D005E35F06FC2463C649F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_6382394C48D005E35F06FC2463C649F8" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_6382394C48D005E35F06FC2463C649F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201616Member_26C41B6798609932D3A9FC295782A3E6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member_26C41B6798609932D3A9FC295782A3E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-16</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201616Member_26C41B6798609932D3A9FC295782A3E6_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member_26C41B6798609932D3A9FC295782A3E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-16 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_26C41B6798609932D3A9FC295782A3E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201616Member_26C41B6798609932D3A9FC295782A3E6" xlink:to="lab_us-gaap_AccountingStandardsUpdate201616Member_26C41B6798609932D3A9FC295782A3E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxChargesMember_38801FA6779059BE369EFC29C976C572_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxChargesMember_38801FA6779059BE369EFC29C976C572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Charge</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxChargesMember_38801FA6779059BE369EFC29C976C572_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxChargesMember_38801FA6779059BE369EFC29C976C572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Charge [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxChargesMember" xlink:label="loc_us-gaap_DeferredIncomeTaxChargesMember_38801FA6779059BE369EFC29C976C572" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxChargesMember_38801FA6779059BE369EFC29C976C572" xlink:to="lab_us-gaap_DeferredIncomeTaxChargesMember_38801FA6779059BE369EFC29C976C572" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_A7ADD691BE2BD5A8BF7BFC2463CB9FE2_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_A7ADD691BE2BD5A8BF7BFC2463CB9FE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_A7ADD691BE2BD5A8BF7BFC2463CB9FE2_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_A7ADD691BE2BD5A8BF7BFC2463CB9FE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_A7ADD691BE2BD5A8BF7BFC2463CB9FE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_A7ADD691BE2BD5A8BF7BFC2463CB9FE2" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_A7ADD691BE2BD5A8BF7BFC2463CB9FE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_CCC4150870D79D48D434FC2463CBA20C_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_CCC4150870D79D48D434FC2463CBA20C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_CCC4150870D79D48D434FC2463CBA20C_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_CCC4150870D79D48D434FC2463CBA20C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_CCC4150870D79D48D434FC2463CBA20C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_CCC4150870D79D48D434FC2463CBA20C" xlink:to="lab_us-gaap_ComputerEquipmentMember_CCC4150870D79D48D434FC2463CBA20C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_B67759E26A14E49A1B66FC2463CC3616_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_B67759E26A14E49A1B66FC2463CC3616" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_B67759E26A14E49A1B66FC2463CC3616_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_B67759E26A14E49A1B66FC2463CC3616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_B67759E26A14E49A1B66FC2463CC3616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_B67759E26A14E49A1B66FC2463CC3616" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_B67759E26A14E49A1B66FC2463CC3616" xlink:type="arc" />
    <link:label id="lab_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A_terseLabel_en-US" xlink:label="lab_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business (Textual)</link:label>
    <link:label id="lab_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A_label_en-US" xlink:label="lab_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A_documentation_en-US" xlink:label="lab_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_BusinessTextualAbstract" xlink:label="loc_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:to="lab_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_5B5D0911D9E23531747AFC2463D24074_terseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_5B5D0911D9E23531747AFC2463D24074" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_5B5D0911D9E23531747AFC2463D24074_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_5B5D0911D9E23531747AFC2463D24074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_5B5D0911D9E23531747AFC2463D24074_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_5B5D0911D9E23531747AFC2463D24074" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_5B5D0911D9E23531747AFC2463D24074" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_5B5D0911D9E23531747AFC2463D24074" xlink:to="lab_biib_InterestInSubsidiary_5B5D0911D9E23531747AFC2463D24074" xlink:type="arc" />
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_11CDF1194997B644D336FC2463D27CB5_verboseLabel_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_11CDF1194997B644D336FC2463D27CB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment terms of accounts receivable arising from product sales</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_11CDF1194997B644D336FC2463D27CB5_label_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_11CDF1194997B644D336FC2463D27CB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Terms Of Accounts Receivable</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_11CDF1194997B644D336FC2463D27CB5_documentation_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_11CDF1194997B644D336FC2463D27CB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment  terms of accounts receivable.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PaymentTermsOfAccountsReceivable" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_11CDF1194997B644D336FC2463D27CB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentTermsOfAccountsReceivable_11CDF1194997B644D336FC2463D27CB5" xlink:to="lab_biib_PaymentTermsOfAccountsReceivable_11CDF1194997B644D336FC2463D27CB5" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_58D760B443603FBDBF89FC2463D26E2A_terseLabel_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_58D760B443603FBDBF89FC2463D26E2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives of leasehold improvements</link:label>
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_58D760B443603FBDBF89FC2463D26E2A_label_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_58D760B443603FBDBF89FC2463D26E2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives Of Leasehold Improvements</link:label>
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_58D760B443603FBDBF89FC2463D26E2A_documentation_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_58D760B443603FBDBF89FC2463D26E2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated useful lives of leasehold improvements.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_EstimatedUsefulLivesOfLeaseholdImprovements" xlink:label="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_58D760B443603FBDBF89FC2463D26E2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_58D760B443603FBDBF89FC2463D26E2A" xlink:to="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_58D760B443603FBDBF89FC2463D26E2A" xlink:type="arc" />
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_B0E744993E2227570F65FC2463D21D55_terseLabel_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_B0E744993E2227570F65FC2463D21D55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock under ESPP</link:label>
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_B0E744993E2227570F65FC2463D21D55_label_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_B0E744993E2227570F65FC2463D21D55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Price Of Common Stock Under ESPP</link:label>
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_B0E744993E2227570F65FC2463D21D55_documentation_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_B0E744993E2227570F65FC2463D21D55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Price Of Common Stock Under ESPP.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PurchasePriceOfCommonStockUnderEspp" xlink:label="loc_biib_PurchasePriceOfCommonStockUnderEspp_B0E744993E2227570F65FC2463D21D55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PurchasePriceOfCommonStockUnderEspp_B0E744993E2227570F65FC2463D21D55" xlink:to="lab_biib_PurchasePriceOfCommonStockUnderEspp_B0E744993E2227570F65FC2463D21D55" xlink:type="arc" />
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_0FBBCEDC0ED8D62FB11EFC2463D30B28_terseLabel_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_0FBBCEDC0ED8D62FB11EFC2463D30B28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense over purchase period</link:label>
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_0FBBCEDC0ED8D62FB11EFC2463D30B28_label_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_0FBBCEDC0ED8D62FB11EFC2463D30B28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Expense Over Purchase Period</link:label>
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_0FBBCEDC0ED8D62FB11EFC2463D30B28_documentation_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_0FBBCEDC0ED8D62FB11EFC2463D30B28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation expense over purchase period.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CompensationExpenseOverPurchasePeriod" xlink:label="loc_biib_CompensationExpenseOverPurchasePeriod_0FBBCEDC0ED8D62FB11EFC2463D30B28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CompensationExpenseOverPurchasePeriod_0FBBCEDC0ED8D62FB11EFC2463D30B28" xlink:to="lab_biib_CompensationExpenseOverPurchasePeriod_0FBBCEDC0ED8D62FB11EFC2463D30B28" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingExpense_63EABB1C943653305183FC2463D337A1_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_63EABB1C943653305183FC2463D337A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_63EABB1C943653305183FC2463D337A1_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_63EABB1C943653305183FC2463D337A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_63EABB1C943653305183FC2463D337A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_63EABB1C943653305183FC2463D337A1" xlink:to="lab_us-gaap_AdvertisingExpense_63EABB1C943653305183FC2463D337A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteesAbstract_8ECA4B9EB3534038F84F6F39A0182556_label_en-US" xlink:label="lab_us-gaap_GuaranteesAbstract_8ECA4B9EB3534038F84F6F39A0182556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="loc_us-gaap_GuaranteesAbstract_8ECA4B9EB3534038F84F6F39A0182556" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesAbstract_8ECA4B9EB3534038F84F6F39A0182556" xlink:to="lab_us-gaap_GuaranteesAbstract_8ECA4B9EB3534038F84F6F39A0182556" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteesTextBlock_EC7600E55BD76241A3E56F39A0181CD2_verboseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock_EC7600E55BD76241A3E56F39A0181CD2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteesTextBlock_EC7600E55BD76241A3E56F39A0181CD2_label_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock_EC7600E55BD76241A3E56F39A0181CD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GuaranteesTextBlock" xlink:label="loc_us-gaap_GuaranteesTextBlock_EC7600E55BD76241A3E56F39A0181CD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesTextBlock_EC7600E55BD76241A3E56F39A0181CD2" xlink:to="lab_us-gaap_GuaranteesTextBlock_EC7600E55BD76241A3E56F39A0181CD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117" xlink:to="lab_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:to="lab_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_32EC11195EC7A3212ED1E873AD9A4CAB_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_32EC11195EC7A3212ED1E873AD9A4CAB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_32EC11195EC7A3212ED1E873AD9A4CAB_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_32EC11195EC7A3212ED1E873AD9A4CAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_32EC11195EC7A3212ED1E873AD9A4CAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_32EC11195EC7A3212ED1E873AD9A4CAB" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_32EC11195EC7A3212ED1E873AD9A4CAB" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4BEBF7C789E23EC4F8C1FC3A19BAA3C3_verboseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4BEBF7C789E23EC4F8C1FC3A19BAA3C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4BEBF7C789E23EC4F8C1FC3A19BAA3C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4BEBF7C789E23EC4F8C1FC3A19BAA3C3" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4BEBF7C789E23EC4F8C1FC3A19BAA3C3" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49" xlink:to="lab_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF" xlink:to="lab_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E" xlink:to="lab_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_B13FC37463FE1B0CC699FC3A19BAEBC1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_B13FC37463FE1B0CC699FC3A19BAEBC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of Ionis common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_B13FC37463FE1B0CC699FC3A19BAEBC1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_B13FC37463FE1B0CC699FC3A19BAEBC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities, Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_B13FC37463FE1B0CC699FC3A19BAEBC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_B13FC37463FE1B0CC699FC3A19BAEBC1" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_B13FC37463FE1B0CC699FC3A19BAEBC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_0347DBCE7462B7A412D7E873AD8A2987_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_0347DBCE7462B7A412D7E873AD8A2987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_0347DBCE7462B7A412D7E873AD8A2987_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_0347DBCE7462B7A412D7E873AD8A2987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_0347DBCE7462B7A412D7E873AD8A2987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember_0347DBCE7462B7A412D7E873AD8A2987" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember_0347DBCE7462B7A412D7E873AD8A2987" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:type="arc" />
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09_terseLabel_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09_label_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09_documentation_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09" xlink:to="lab_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09" xlink:type="arc" />
    <link:label id="lab_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A_verboseLabel_en-US" xlink:label="lab_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stromedix, Inc.</link:label>
    <link:label id="lab_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A_label_en-US" xlink:label="lab_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stromedix [Member]</link:label>
    <link:label id="lab_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A_documentation_en-US" xlink:label="lab_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stromedix.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A" xlink:to="lab_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A" xlink:type="arc" />
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD_terseLabel_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec International Neuroscience GmbH</link:label>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD_label_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Idec International Neuroscience Member</link:label>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD_documentation_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen idec international neuroscience.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD" xlink:to="lab_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_AFE841192446D853D238E873AD9A09A2_terseLabel_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_AFE841192446D853D238E873AD9A09A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements, changes in valuation techniques</link:label>
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_AFE841192446D853D238E873AD9A09A2_label_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_AFE841192446D853D238E873AD9A09A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servicing Asset at Fair Value, Description of Changes in Valuation Inputs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs" xlink:label="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_AFE841192446D853D238E873AD9A09A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_AFE841192446D853D238E873AD9A09A2" xlink:to="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_AFE841192446D853D238E873AD9A09A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_E1242CB4C1D51600AD61E873AD9A32A2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_E1242CB4C1D51600AD61E873AD9A32A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_E1242CB4C1D51600AD61E873AD9A32A2_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_E1242CB4C1D51600AD61E873AD9A32A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_E1242CB4C1D51600AD61E873AD9A32A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_E1242CB4C1D51600AD61E873AD9A32A2" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_E1242CB4C1D51600AD61E873AD9A32A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A9FC4DB22636D653B6AEE873AD9AABF8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A9FC4DB22636D653B6AEE873AD9AABF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A9FC4DB22636D653B6AEE873AD9AABF8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A9FC4DB22636D653B6AEE873AD9AABF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A9FC4DB22636D653B6AEE873AD9AABF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A9FC4DB22636D653B6AEE873AD9AABF8" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A9FC4DB22636D653B6AEE873AD9AABF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_395E4D9733375CB6DF53E873AD9A8136_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_395E4D9733375CB6DF53E873AD9A8136" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_395E4D9733375CB6DF53E873AD9A8136_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_395E4D9733375CB6DF53E873AD9A8136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_395E4D9733375CB6DF53E873AD9A8136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_395E4D9733375CB6DF53E873AD9A8136" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_395E4D9733375CB6DF53E873AD9A8136" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DD274952E341CE5C73E6E873AD9A09F5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DD274952E341CE5C73E6E873AD9A09F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on fair value remeasurement of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DD274952E341CE5C73E6E873AD9A09F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DD274952E341CE5C73E6E873AD9A09F5" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DD274952E341CE5C73E6E873AD9A09F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_025177102C1DB9BD7658E873AD9AB0BE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_025177102C1DB9BD7658E873AD9AB0BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_025177102C1DB9BD7658E873AD9AB0BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_025177102C1DB9BD7658E873AD9AB0BE" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_025177102C1DB9BD7658E873AD9AB0BE" xlink:type="arc" />
    <link:label id="lab_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C_terseLabel_en-US" xlink:label="lab_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement and measurement inputs, recurring and nonrecurring</link:label>
    <link:label id="lab_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C_label_en-US" xlink:label="lab_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs</link:label>
    <link:label id="lab_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C_documentation_en-US" xlink:label="lab_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FairValueMeasurementInputs" xlink:label="loc_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C" xlink:to="lab_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C" xlink:type="arc" />
    <link:label id="lab_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229_terseLabel_en-US" xlink:label="lab_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fifteen billion</link:label>
    <link:label id="lab_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229_label_en-US" xlink:label="lab_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fifteen billion [Member] [Member]</link:label>
    <link:label id="lab_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229_documentation_en-US" xlink:label="lab_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fifteen billion [Member] [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229" xlink:to="lab_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229" xlink:type="arc" />
    <link:label id="lab_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042_terseLabel_en-US" xlink:label="lab_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sixteen billion</link:label>
    <link:label id="lab_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042_label_en-US" xlink:label="lab_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sixteen billion [Member]</link:label>
    <link:label id="lab_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042_documentation_en-US" xlink:label="lab_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sixteen billion [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042" xlink:to="lab_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_D0DA91D4460C6654BFD1E873ABC5AA56_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_D0DA91D4460C6654BFD1E873ABC5AA56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_D0DA91D4460C6654BFD1E873ABC5AA56_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_D0DA91D4460C6654BFD1E873ABC5AA56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_D0DA91D4460C6654BFD1E873ABC5AA56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_D0DA91D4460C6654BFD1E873ABC5AA56" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_D0DA91D4460C6654BFD1E873ABC5AA56" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_1469D5365E6242E58C53E873ABC56A3F_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_1469D5365E6242E58C53E873ABC56A3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_1469D5365E6242E58C53E873ABC56A3F_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_1469D5365E6242E58C53E873ABC56A3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1469D5365E6242E58C53E873ABC56A3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1469D5365E6242E58C53E873ABC56A3F" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent_1469D5365E6242E58C53E873ABC56A3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyMember_684A24D7BAFC6CA1E5376F399D90F400_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember_684A24D7BAFC6CA1E5376F399D90F400" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_684A24D7BAFC6CA1E5376F399D90F400_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember_684A24D7BAFC6CA1E5376F399D90F400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_684A24D7BAFC6CA1E5376F399D90F400" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember_684A24D7BAFC6CA1E5376F399D90F400" xlink:to="lab_us-gaap_RoyaltyMember_684A24D7BAFC6CA1E5376F399D90F400" xlink:type="arc" />
    <link:label id="lab_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61_terseLabel_en-US" xlink:label="lab_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sobi</link:label>
    <link:label id="lab_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61_label_en-US" xlink:label="lab_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sobi [Member]</link:label>
    <link:label id="lab_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61_documentation_en-US" xlink:label="lab_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sobi [Member]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SobiMember" xlink:label="loc_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61" xlink:to="lab_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61" xlink:type="arc" />
    <link:label id="lab_us-gaap_Land_165C9D109E1ADD5B1E736F399BFF8F61_terseLabel_en-US" xlink:label="lab_us-gaap_Land_165C9D109E1ADD5B1E736F399BFF8F61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_165C9D109E1ADD5B1E736F399BFF8F61_label_en-US" xlink:label="lab_us-gaap_Land_165C9D109E1ADD5B1E736F399BFF8F61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_165C9D109E1ADD5B1E736F399BFF8F61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land_165C9D109E1ADD5B1E736F399BFF8F61" xlink:to="lab_us-gaap_Land_165C9D109E1ADD5B1E736F399BFF8F61" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_5A0674A657C9D031B5DB6F399C00DC92_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross_5A0674A657C9D031B5DB6F399C00DC92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_5A0674A657C9D031B5DB6F399C00DC92_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross_5A0674A657C9D031B5DB6F399C00DC92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_5A0674A657C9D031B5DB6F399C00DC92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross_5A0674A657C9D031B5DB6F399C00DC92" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross_5A0674A657C9D031B5DB6F399C00DC92" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_C26E8DC718DF6F2FDEF56F399C00387E_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross_C26E8DC718DF6F2FDEF56F399C00387E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_C26E8DC718DF6F2FDEF56F399C00387E_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross_C26E8DC718DF6F2FDEF56F399C00387E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_C26E8DC718DF6F2FDEF56F399C00387E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross_C26E8DC718DF6F2FDEF56F399C00387E" xlink:to="lab_us-gaap_LeaseholdImprovementsGross_C26E8DC718DF6F2FDEF56F399C00387E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_17E85222530846C297856F399C003F33_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross_17E85222530846C297856F399C003F33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_17E85222530846C297856F399C003F33_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross_17E85222530846C297856F399C003F33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_17E85222530846C297856F399C003F33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross_17E85222530846C297856F399C003F33" xlink:to="lab_us-gaap_MachineryAndEquipmentGross_17E85222530846C297856F399C003F33" xlink:type="arc" />
    <link:label id="lab_biib_ComputerSoftwareAndHardware_2F9AA4D37067352C07016F399C00E087_terseLabel_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_2F9AA4D37067352C07016F399C00E087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_2F9AA4D37067352C07016F399C00E087_label_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_2F9AA4D37067352C07016F399C00E087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_2F9AA4D37067352C07016F399C00E087_documentation_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_2F9AA4D37067352C07016F399C00E087" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_2F9AA4D37067352C07016F399C00E087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ComputerSoftwareAndHardware_2F9AA4D37067352C07016F399C00E087" xlink:to="lab_biib_ComputerSoftwareAndHardware_2F9AA4D37067352C07016F399C00E087" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_6218B658823395CC7D396F399C00C4DA_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_6218B658823395CC7D396F399C00C4DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_6218B658823395CC7D396F399C00C4DA_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_6218B658823395CC7D396F399C00C4DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_6218B658823395CC7D396F399C00C4DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesGross_6218B658823395CC7D396F399C00C4DA" xlink:to="lab_us-gaap_FurnitureAndFixturesGross_6218B658823395CC7D396F399C00C4DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_D5F634E2C1CDF89777016F399C01F362_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_D5F634E2C1CDF89777016F399C01F362" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_D5F634E2C1CDF89777016F399C01F362_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_D5F634E2C1CDF89777016F399C01F362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_D5F634E2C1CDF89777016F399C01F362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_D5F634E2C1CDF89777016F399C01F362" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_D5F634E2C1CDF89777016F399C01F362" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A68F86372C509116889C6F399C01FBA1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A68F86372C509116889C6F399C01FBA1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A68F86372C509116889C6F399C01FBA1_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A68F86372C509116889C6F399C01FBA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A68F86372C509116889C6F399C01FBA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A68F86372C509116889C6F399C01FBA1" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A68F86372C509116889C6F399C01FBA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2DAD4A970A5204755D8D6F399C01AEBC_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2DAD4A970A5204755D8D6F399C01AEBC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2DAD4A970A5204755D8D6F399C01AEBC_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2DAD4A970A5204755D8D6F399C01AEBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2DAD4A970A5204755D8D6F399C01AEBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2DAD4A970A5204755D8D6F399C01AEBC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_2DAD4A970A5204755D8D6F399C01AEBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_71D8523B7555FBB8FB3CD25A59C010DE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_71D8523B7555FBB8FB3CD25A59C010DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_71D8523B7555FBB8FB3CD25A59C010DE_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_71D8523B7555FBB8FB3CD25A59C010DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_71D8523B7555FBB8FB3CD25A59C010DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_71D8523B7555FBB8FB3CD25A59C010DE" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_71D8523B7555FBB8FB3CD25A59C010DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E9AAFD3272CD70A4A60A6F399CE50585_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E9AAFD3272CD70A4A60A6F399CE50585" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E9AAFD3272CD70A4A60A6F399CE50585_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E9AAFD3272CD70A4A60A6F399CE50585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E9AAFD3272CD70A4A60A6F399CE50585" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E9AAFD3272CD70A4A60A6F399CE50585" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E9AAFD3272CD70A4A60A6F399CE50585" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:to="lab_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:to="lab_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B846B6164E5CE0F25609FC3A1AD33DF2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B846B6164E5CE0F25609FC3A1AD33DF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B846B6164E5CE0F25609FC3A1AD33DF2_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B846B6164E5CE0F25609FC3A1AD33DF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B846B6164E5CE0F25609FC3A1AD33DF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B846B6164E5CE0F25609FC3A1AD33DF2" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B846B6164E5CE0F25609FC3A1AD33DF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_E1F55611C1C8A219B20CFC3A1AD331A3_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_E1F55611C1C8A219B20CFC3A1AD331A3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_E1F55611C1C8A219B20CFC3A1AD331A3_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_E1F55611C1C8A219B20CFC3A1AD331A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_E1F55611C1C8A219B20CFC3A1AD331A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_E1F55611C1C8A219B20CFC3A1AD331A3" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_E1F55611C1C8A219B20CFC3A1AD331A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_C5EED5CDF0351F4435D0FC3A1AD3BFFA_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_C5EED5CDF0351F4435D0FC3A1AD3BFFA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_C5EED5CDF0351F4435D0FC3A1AD3BFFA_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_C5EED5CDF0351F4435D0FC3A1AD3BFFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_C5EED5CDF0351F4435D0FC3A1AD3BFFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_C5EED5CDF0351F4435D0FC3A1AD3BFFA" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_C5EED5CDF0351F4435D0FC3A1AD3BFFA" xlink:type="arc" />
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_97C0CB64BEE3F353B0A2FC3A1AD3BD22_verboseLabel_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_97C0CB64BEE3F353B0A2FC3A1AD3BD22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_97C0CB64BEE3F353B0A2FC3A1AD3BD22_label_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_97C0CB64BEE3F353B0A2FC3A1AD3BD22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from unconsolidated joint business</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_97C0CB64BEE3F353B0A2FC3A1AD3BD22_documentation_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_97C0CB64BEE3F353B0A2FC3A1AD3BD22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_97C0CB64BEE3F353B0A2FC3A1AD3BD22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DueFromUnconsolidatedJointBusiness_97C0CB64BEE3F353B0A2FC3A1AD3BD22" xlink:to="lab_biib_DueFromUnconsolidatedJointBusiness_97C0CB64BEE3F353B0A2FC3A1AD3BD22" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_E1923DCA6596C9D05CE6FC3A1AD3ED24_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_E1923DCA6596C9D05CE6FC3A1AD3ED24" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E1923DCA6596C9D05CE6FC3A1AD3ED24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_E1923DCA6596C9D05CE6FC3A1AD3ED24" xlink:to="lab_us-gaap_InventoryNet_E1923DCA6596C9D05CE6FC3A1AD3ED24" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_60AFAACF9C6CC3354D71FC3A1AD36B41_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_60AFAACF9C6CC3354D71FC3A1AD36B41" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_60AFAACF9C6CC3354D71FC3A1AD36B41_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_60AFAACF9C6CC3354D71FC3A1AD36B41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_60AFAACF9C6CC3354D71FC3A1AD36B41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_60AFAACF9C6CC3354D71FC3A1AD36B41" xlink:to="lab_us-gaap_OtherAssetsCurrent_60AFAACF9C6CC3354D71FC3A1AD36B41" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_351AFB8DA153B103FD0EFC3A1AD34298_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_351AFB8DA153B103FD0EFC3A1AD34298" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_351AFB8DA153B103FD0EFC3A1AD34298_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_351AFB8DA153B103FD0EFC3A1AD34298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_351AFB8DA153B103FD0EFC3A1AD34298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_351AFB8DA153B103FD0EFC3A1AD34298" xlink:to="lab_us-gaap_AssetsCurrent_351AFB8DA153B103FD0EFC3A1AD34298" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_B985B6FC8EDA7FF6DEFEFC3A1AD33B54_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_B985B6FC8EDA7FF6DEFEFC3A1AD33B54" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_B985B6FC8EDA7FF6DEFEFC3A1AD33B54_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_B985B6FC8EDA7FF6DEFEFC3A1AD33B54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_B985B6FC8EDA7FF6DEFEFC3A1AD33B54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_B985B6FC8EDA7FF6DEFEFC3A1AD33B54" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_B985B6FC8EDA7FF6DEFEFC3A1AD33B54" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_71771300A98B74C4C085FC3A1AD39898_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_71771300A98B74C4C085FC3A1AD39898" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_71771300A98B74C4C085FC3A1AD39898" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_71771300A98B74C4C085FC3A1AD39898" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_71771300A98B74C4C085FC3A1AD39898" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5AD0F64B96A6DB3870B0FC3A1AD3AB6D_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5AD0F64B96A6DB3870B0FC3A1AD3AB6D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5AD0F64B96A6DB3870B0FC3A1AD3AB6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5AD0F64B96A6DB3870B0FC3A1AD3AB6D" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5AD0F64B96A6DB3870B0FC3A1AD3AB6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_FA415BA1A05C5E73EADDFC3A1AD3EC8D_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_FA415BA1A05C5E73EADDFC3A1AD3EC8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_FA415BA1A05C5E73EADDFC3A1AD3EC8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_FA415BA1A05C5E73EADDFC3A1AD3EC8D" xlink:to="lab_us-gaap_Goodwill_FA415BA1A05C5E73EADDFC3A1AD3EC8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8D4807FEC6181C99AC0FFC3A1AD3FE93_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8D4807FEC6181C99AC0FFC3A1AD3FE93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8D4807FEC6181C99AC0FFC3A1AD3FE93_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8D4807FEC6181C99AC0FFC3A1AD3FE93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8D4807FEC6181C99AC0FFC3A1AD3FE93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8D4807FEC6181C99AC0FFC3A1AD3FE93" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8D4807FEC6181C99AC0FFC3A1AD3FE93" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9A4BBAA18D1995157EE5FC3A1AD30484_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_9A4BBAA18D1995157EE5FC3A1AD30484" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9A4BBAA18D1995157EE5FC3A1AD30484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_9A4BBAA18D1995157EE5FC3A1AD30484" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_9A4BBAA18D1995157EE5FC3A1AD30484" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_970537FF1EF9E101658FFC3A1AD33032_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_970537FF1EF9E101658FFC3A1AD33032" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_970537FF1EF9E101658FFC3A1AD33032_label_en-US" xlink:label="lab_us-gaap_Assets_970537FF1EF9E101658FFC3A1AD33032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_970537FF1EF9E101658FFC3A1AD33032" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_970537FF1EF9E101658FFC3A1AD33032" xlink:to="lab_us-gaap_Assets_970537FF1EF9E101658FFC3A1AD33032" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_C2E6AA164880BB7E746AFC3A1AD3DCA8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_C2E6AA164880BB7E746AFC3A1AD3DCA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_C2E6AA164880BB7E746AFC3A1AD3DCA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_C2E6AA164880BB7E746AFC3A1AD3DCA8" xlink:to="lab_us-gaap_DebtCurrent_C2E6AA164880BB7E746AFC3A1AD3DCA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_580D950B046F49E27B65FC3A1AD36D3E_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_580D950B046F49E27B65FC3A1AD36D3E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_580D950B046F49E27B65FC3A1AD36D3E_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_580D950B046F49E27B65FC3A1AD36D3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_580D950B046F49E27B65FC3A1AD36D3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_580D950B046F49E27B65FC3A1AD36D3E" xlink:to="lab_us-gaap_TaxesPayableCurrent_580D950B046F49E27B65FC3A1AD36D3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_CFFDE1FB3984767A3874FC3A1AD3A81A_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_CFFDE1FB3984767A3874FC3A1AD3A81A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_CFFDE1FB3984767A3874FC3A1AD3A81A_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_CFFDE1FB3984767A3874FC3A1AD3A81A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_CFFDE1FB3984767A3874FC3A1AD3A81A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_CFFDE1FB3984767A3874FC3A1AD3A81A" xlink:to="lab_us-gaap_AccountsPayableCurrent_CFFDE1FB3984767A3874FC3A1AD3A81A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_80FAEE39F15E87EEA2CCFC3A1AD3FDA5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_80FAEE39F15E87EEA2CCFC3A1AD3FDA5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_80FAEE39F15E87EEA2CCFC3A1AD3FDA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_80FAEE39F15E87EEA2CCFC3A1AD3FDA5" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_80FAEE39F15E87EEA2CCFC3A1AD3FDA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3ED089FD7359BFE81C40FC3A1AD3CCA3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_3ED089FD7359BFE81C40FC3A1AD3CCA3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3ED089FD7359BFE81C40FC3A1AD3CCA3_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_3ED089FD7359BFE81C40FC3A1AD3CCA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_3ED089FD7359BFE81C40FC3A1AD3CCA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_3ED089FD7359BFE81C40FC3A1AD3CCA3" xlink:to="lab_us-gaap_LiabilitiesCurrent_3ED089FD7359BFE81C40FC3A1AD3CCA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_7A07141997D75D1E1DA4FC3A1AD3915D_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_7A07141997D75D1E1DA4FC3A1AD3915D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7A07141997D75D1E1DA4FC3A1AD3915D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_7A07141997D75D1E1DA4FC3A1AD3915D" xlink:to="lab_us-gaap_LongTermDebt_7A07141997D75D1E1DA4FC3A1AD3915D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_42DE2478FABA2EA3FAF5FC3A1AD301F5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_42DE2478FABA2EA3FAF5FC3A1AD301F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_42DE2478FABA2EA3FAF5FC3A1AD301F5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_42DE2478FABA2EA3FAF5FC3A1AD301F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_42DE2478FABA2EA3FAF5FC3A1AD301F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_42DE2478FABA2EA3FAF5FC3A1AD301F5" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_42DE2478FABA2EA3FAF5FC3A1AD301F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8D748A478462A4EC2131FC3A1AD3AE2A_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8D748A478462A4EC2131FC3A1AD3AE2A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8D748A478462A4EC2131FC3A1AD3AE2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8D748A478462A4EC2131FC3A1AD3AE2A" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_8D748A478462A4EC2131FC3A1AD3AE2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_756939E94C1CF14EDF9BFC3A1AD3101E_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_756939E94C1CF14EDF9BFC3A1AD3101E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_756939E94C1CF14EDF9BFC3A1AD3101E_label_en-US" xlink:label="lab_us-gaap_Liabilities_756939E94C1CF14EDF9BFC3A1AD3101E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_756939E94C1CF14EDF9BFC3A1AD3101E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_756939E94C1CF14EDF9BFC3A1AD3101E" xlink:to="lab_us-gaap_Liabilities_756939E94C1CF14EDF9BFC3A1AD3101E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ADD1ABFFA31A81D0448DFC3A1AD3622F_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_ADD1ABFFA31A81D0448DFC3A1AD3622F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ADD1ABFFA31A81D0448DFC3A1AD3622F_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_ADD1ABFFA31A81D0448DFC3A1AD3622F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ADD1ABFFA31A81D0448DFC3A1AD3622F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_ADD1ABFFA31A81D0448DFC3A1AD3622F" xlink:to="lab_us-gaap_CommitmentsAndContingencies_ADD1ABFFA31A81D0448DFC3A1AD3622F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1963D985E748C5C785E0FC3A1AD38F25_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1963D985E748C5C785E0FC3A1AD38F25" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1963D985E748C5C785E0FC3A1AD38F25_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1963D985E748C5C785E0FC3A1AD38F25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1963D985E748C5C785E0FC3A1AD38F25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1963D985E748C5C785E0FC3A1AD38F25" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1963D985E748C5C785E0FC3A1AD38F25" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_31D4A1151874A49F3ABAFC3A1AD3A426_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_31D4A1151874A49F3ABAFC3A1AD3A426" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_31D4A1151874A49F3ABAFC3A1AD3A426_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_31D4A1151874A49F3ABAFC3A1AD3A426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_31D4A1151874A49F3ABAFC3A1AD3A426" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_31D4A1151874A49F3ABAFC3A1AD3A426" xlink:to="lab_us-gaap_PreferredStockValue_31D4A1151874A49F3ABAFC3A1AD3A426" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_C2335DB03065E992A10CFC3A1AD3D06B_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_C2335DB03065E992A10CFC3A1AD3D06B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_C2335DB03065E992A10CFC3A1AD3D06B_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_C2335DB03065E992A10CFC3A1AD3D06B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_C2335DB03065E992A10CFC3A1AD3D06B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_C2335DB03065E992A10CFC3A1AD3D06B" xlink:to="lab_us-gaap_CommonStockValue_C2335DB03065E992A10CFC3A1AD3D06B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_9DA4A33CD2DA9D2FA48FFC3A1AD3BD56_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_9DA4A33CD2DA9D2FA48FFC3A1AD3BD56" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_9DA4A33CD2DA9D2FA48FFC3A1AD3BD56_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_9DA4A33CD2DA9D2FA48FFC3A1AD3BD56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9DA4A33CD2DA9D2FA48FFC3A1AD3BD56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_9DA4A33CD2DA9D2FA48FFC3A1AD3BD56" xlink:to="lab_us-gaap_AdditionalPaidInCapital_9DA4A33CD2DA9D2FA48FFC3A1AD3BD56" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_69122C51AF93BE882D8CFC3A1AD38E49_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_69122C51AF93BE882D8CFC3A1AD38E49" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_69122C51AF93BE882D8CFC3A1AD38E49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_69122C51AF93BE882D8CFC3A1AD38E49" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_69122C51AF93BE882D8CFC3A1AD38E49" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D1213AE2154363B83E5EFC3A1AD343E0_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D1213AE2154363B83E5EFC3A1AD343E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D1213AE2154363B83E5EFC3A1AD343E0_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D1213AE2154363B83E5EFC3A1AD343E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D1213AE2154363B83E5EFC3A1AD343E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D1213AE2154363B83E5EFC3A1AD343E0" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D1213AE2154363B83E5EFC3A1AD343E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_02DCC45CF9B742817AF4FC3A1AD3B496_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_02DCC45CF9B742817AF4FC3A1AD3B496" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_02DCC45CF9B742817AF4FC3A1AD3B496_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_02DCC45CF9B742817AF4FC3A1AD3B496" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_02DCC45CF9B742817AF4FC3A1AD3B496" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_02DCC45CF9B742817AF4FC3A1AD3B496" xlink:to="lab_us-gaap_TreasuryStockValue_02DCC45CF9B742817AF4FC3A1AD3B496" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_327E19C705D2D1E6B773FC3A1AD31E2E_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_327E19C705D2D1E6B773FC3A1AD31E2E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_327E19C705D2D1E6B773FC3A1AD31E2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_327E19C705D2D1E6B773FC3A1AD31E2E" xlink:to="lab_us-gaap_StockholdersEquity_327E19C705D2D1E6B773FC3A1AD31E2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_343C3AC0234DFA2D36BBFC3A1AD3AF01_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_343C3AC0234DFA2D36BBFC3A1AD3AF01" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_343C3AC0234DFA2D36BBFC3A1AD3AF01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_343C3AC0234DFA2D36BBFC3A1AD3AF01" xlink:to="lab_us-gaap_MinorityInterest_343C3AC0234DFA2D36BBFC3A1AD3AF01" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB45A3F2AAB8899A45DFC3A1AD349FE_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB45A3F2AAB8899A45DFC3A1AD349FE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB45A3F2AAB8899A45DFC3A1AD349FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB45A3F2AAB8899A45DFC3A1AD349FE" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB45A3F2AAB8899A45DFC3A1AD349FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_F4A1254452EA2D86DDC1FC3A1AD3F728_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_F4A1254452EA2D86DDC1FC3A1AD3F728" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_F4A1254452EA2D86DDC1FC3A1AD3F728_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_F4A1254452EA2D86DDC1FC3A1AD3F728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_F4A1254452EA2D86DDC1FC3A1AD3F728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_F4A1254452EA2D86DDC1FC3A1AD3F728" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_F4A1254452EA2D86DDC1FC3A1AD3F728" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ECB996C5A6C5FFE91BB2F00EC112EC82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ECB996C5A6C5FFE91BB2F00EC112EC82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identified assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ECB996C5A6C5FFE91BB2F00EC112EC82_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ECB996C5A6C5FFE91BB2F00EC112EC82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ECB996C5A6C5FFE91BB2F00EC112EC82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ECB996C5A6C5FFE91BB2F00EC112EC82" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ECB996C5A6C5FFE91BB2F00EC112EC82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_A86CDFC187FC4A6FF6087F76C6D5EF03_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_A86CDFC187FC4A6FF6087F76C6D5EF03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_A86CDFC187FC4A6FF6087F76C6D5EF03_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_A86CDFC187FC4A6FF6087F76C6D5EF03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_A86CDFC187FC4A6FF6087F76C6D5EF03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_A86CDFC187FC4A6FF6087F76C6D5EF03" xlink:to="lab_us-gaap_EquitySecuritiesMember_A86CDFC187FC4A6FF6087F76C6D5EF03" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_305B034C4AB8F89C65207FABBF013B93_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_305B034C4AB8F89C65207FABBF013B93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_305B034C4AB8F89C65207FABBF013B93_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_305B034C4AB8F89C65207FABBF013B93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_305B034C4AB8F89C65207FABBF013B93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_305B034C4AB8F89C65207FABBF013B93" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_305B034C4AB8F89C65207FABBF013B93" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11A5235A8FB8EAC36AA47FAB1712E81F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11A5235A8FB8EAC36AA47FAB1712E81F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11A5235A8FB8EAC36AA47FAB1712E81F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11A5235A8FB8EAC36AA47FAB1712E81F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11A5235A8FB8EAC36AA47FAB1712E81F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11A5235A8FB8EAC36AA47FAB1712E81F" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11A5235A8FB8EAC36AA47FAB1712E81F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9FB416F45B51DCF73A5D7FA90F607F7C_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9FB416F45B51DCF73A5D7FA90F607F7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9FB416F45B51DCF73A5D7FA90F607F7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9FB416F45B51DCF73A5D7FA90F607F7C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9FB416F45B51DCF73A5D7FA90F607F7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_888618C0BB619ED201107FB45820143E_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost_888618C0BB619ED201107FB45820143E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_888618C0BB619ED201107FB45820143E_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost_888618C0BB619ED201107FB45820143E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_888618C0BB619ED201107FB45820143E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_888618C0BB619ED201107FB45820143E" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost_888618C0BB619ED201107FB45820143E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_666FD81453DDBDAC2D4F7FB4584F7BB0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_666FD81453DDBDAC2D4F7FB4584F7BB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_666FD81453DDBDAC2D4F7FB4584F7BB0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_666FD81453DDBDAC2D4F7FB4584F7BB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_666FD81453DDBDAC2D4F7FB4584F7BB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_666FD81453DDBDAC2D4F7FB4584F7BB0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_666FD81453DDBDAC2D4F7FB4584F7BB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5C1F1FA0A98A562C476C7FB45877AA03_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5C1F1FA0A98A562C476C7FB45877AA03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5C1F1FA0A98A562C476C7FB45877AA03_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5C1F1FA0A98A562C476C7FB45877AA03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5C1F1FA0A98A562C476C7FB45877AA03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5C1F1FA0A98A562C476C7FB45877AA03" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5C1F1FA0A98A562C476C7FB45877AA03" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_0A7026CFCCCD25D22E7A7FB40C9E1ABC_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_0A7026CFCCCD25D22E7A7FB40C9E1ABC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_0A7026CFCCCD25D22E7A7FB40C9E1ABC_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_0A7026CFCCCD25D22E7A7FB40C9E1ABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0A7026CFCCCD25D22E7A7FB40C9E1ABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi_0A7026CFCCCD25D22E7A7FB40C9E1ABC" xlink:to="lab_us-gaap_EquitySecuritiesFvNi_0A7026CFCCCD25D22E7A7FB40C9E1ABC" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_925814BA09ABA34F0DD3F1F26A5DC393_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_925814BA09ABA34F0DD3F1F26A5DC393" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_925814BA09ABA34F0DD3F1F26A5DC393_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_925814BA09ABA34F0DD3F1F26A5DC393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_925814BA09ABA34F0DD3F1F26A5DC393_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_925814BA09ABA34F0DD3F1F26A5DC393" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_925814BA09ABA34F0DD3F1F26A5DC393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_925814BA09ABA34F0DD3F1F26A5DC393" xlink:to="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_925814BA09ABA34F0DD3F1F26A5DC393" xlink:type="arc" />
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_D757569114AC63BBAA14F1F26A5D2E15_terseLabel_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_D757569114AC63BBAA14F1F26A5D2E15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pretax profit sharing formula</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_D757569114AC63BBAA14F1F26A5D2E15_label_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_D757569114AC63BBAA14F1F26A5D2E15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_D757569114AC63BBAA14F1F26A5D2E15_documentation_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_D757569114AC63BBAA14F1F26A5D2E15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_PretaxProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_D757569114AC63BBAA14F1F26A5D2E15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxProfitSharingFormulaTableTextBlock_D757569114AC63BBAA14F1F26A5D2E15" xlink:to="lab_biib_PretaxProfitSharingFormulaTableTextBlock_D757569114AC63BBAA14F1F26A5D2E15" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_43F0ECCAB386A80A1867F1F26A5D1FE7_verboseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_43F0ECCAB386A80A1867F1F26A5D1FE7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_43F0ECCAB386A80A1867F1F26A5D1FE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_43F0ECCAB386A80A1867F1F26A5D1FE7" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_43F0ECCAB386A80A1867F1F26A5D1FE7" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_C22D9AF96E670BA48AB0F1F26A5D0CC5_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_C22D9AF96E670BA48AB0F1F26A5D0CC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to BAN2401 and Elenbecestat collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_C22D9AF96E670BA48AB0F1F26A5D0CC5_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_C22D9AF96E670BA48AB0F1F26A5D0CC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_C22D9AF96E670BA48AB0F1F26A5D0CC5_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_C22D9AF96E670BA48AB0F1F26A5D0CC5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_C22D9AF96E670BA48AB0F1F26A5D0CC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_C22D9AF96E670BA48AB0F1F26A5D0CC5" xlink:to="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_C22D9AF96E670BA48AB0F1F26A5D0CC5" xlink:type="arc" />
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_F4F2477B04D6FFF80E42F1F26A5D9150_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_F4F2477B04D6FFF80E42F1F26A5D9150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to Aducanumab collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_F4F2477B04D6FFF80E42F1F26A5D9150_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_F4F2477B04D6FFF80E42F1F26A5D9150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_F4F2477B04D6FFF80E42F1F26A5D9150_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_F4F2477B04D6FFF80E42F1F26A5D9150" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_F4F2477B04D6FFF80E42F1F26A5D9150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_F4F2477B04D6FFF80E42F1F26A5D9150" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_F4F2477B04D6FFF80E42F1F26A5D9150" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B581507722790BF0C4306F399F345320_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B581507722790BF0C4306F399F345320" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B581507722790BF0C4306F399F345320_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B581507722790BF0C4306F399F345320" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B581507722790BF0C4306F399F345320" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B581507722790BF0C4306F399F345320" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B581507722790BF0C4306F399F345320" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28AB8B37140901BBDD421B9F87F364A9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28AB8B37140901BBDD421B9F87F364A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28AB8B37140901BBDD421B9F87F364A9_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28AB8B37140901BBDD421B9F87F364A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28AB8B37140901BBDD421B9F87F364A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28AB8B37140901BBDD421B9F87F364A9" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28AB8B37140901BBDD421B9F87F364A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_FC68DFF1C4D0C44D16E31B9F87F33901_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_FC68DFF1C4D0C44D16E31B9F87F33901" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairments</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_FC68DFF1C4D0C44D16E31B9F87F33901_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_FC68DFF1C4D0C44D16E31B9F87F33901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_FC68DFF1C4D0C44D16E31B9F87F33901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_FC68DFF1C4D0C44D16E31B9F87F33901" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_FC68DFF1C4D0C44D16E31B9F87F33901" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_FDF07AE89C305179DC861B9F87F3BD3B_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_FDF07AE89C305179DC861B9F87F3BD3B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_FDF07AE89C305179DC861B9F87F3BD3B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_FDF07AE89C305179DC861B9F87F3BD3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_FDF07AE89C305179DC861B9F87F3BD3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_FDF07AE89C305179DC861B9F87F3BD3B" xlink:to="lab_us-gaap_ShareBasedCompensation_FDF07AE89C305179DC861B9F87F3BD3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_658EF7E132193C8FD59B1B9F87F35F47_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_658EF7E132193C8FD59B1B9F87F35F47" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_658EF7E132193C8FD59B1B9F87F35F47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_658EF7E132193C8FD59B1B9F87F35F47" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_658EF7E132193C8FD59B1B9F87F35F47" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_95A3A245EAD803DAE5491B9F87F37AFB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_95A3A245EAD803DAE5491B9F87F37AFB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_95A3A245EAD803DAE5491B9F87F37AFB_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_95A3A245EAD803DAE5491B9F87F37AFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_95A3A245EAD803DAE5491B9F87F37AFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_95A3A245EAD803DAE5491B9F87F37AFB" xlink:to="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_95A3A245EAD803DAE5491B9F87F37AFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_51A4C9686468A6F14DAF1B9F87F34493_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_51A4C9686468A6F14DAF1B9F87F34493" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_51A4C9686468A6F14DAF1B9F87F34493" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_51A4C9686468A6F14DAF1B9F87F34493" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_51A4C9686468A6F14DAF1B9F87F34493" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_FD04AF33D79DB7ECB4EE1B9F87F3A11C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_FD04AF33D79DB7ECB4EE1B9F87F3A11C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_FD04AF33D79DB7ECB4EE1B9F87F3A11C_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_FD04AF33D79DB7ECB4EE1B9F87F3A11C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_FD04AF33D79DB7ECB4EE1B9F87F3A11C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_FD04AF33D79DB7ECB4EE1B9F87F3A11C" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_FD04AF33D79DB7ECB4EE1B9F87F3A11C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_FEC6F15DE403E1DB840A1B9F87F3D448_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_FEC6F15DE403E1DB840A1B9F87F3D448" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_FEC6F15DE403E1DB840A1B9F87F3D448_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_FEC6F15DE403E1DB840A1B9F87F3D448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_FEC6F15DE403E1DB840A1B9F87F3D448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_FEC6F15DE403E1DB840A1B9F87F3D448" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_FEC6F15DE403E1DB840A1B9F87F3D448" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7833ED98181E9FB975651B9F87F35A08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7833ED98181E9FB975651B9F87F35A08" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7833ED98181E9FB975651B9F87F35A08_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7833ED98181E9FB975651B9F87F35A08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7833ED98181E9FB975651B9F87F35A08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7833ED98181E9FB975651B9F87F35A08" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7833ED98181E9FB975651B9F87F35A08" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_B0052F6D74E036B9ED731B9F88021091_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_B0052F6D74E036B9ED731B9F88021091" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_B0052F6D74E036B9ED731B9F88021091_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_B0052F6D74E036B9ED731B9F88021091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_B0052F6D74E036B9ED731B9F88021091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_B0052F6D74E036B9ED731B9F88021091" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_B0052F6D74E036B9ED731B9F88021091" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_23F51238266C4D01CF701B9F8802B07B_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_23F51238266C4D01CF701B9F8802B07B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_23F51238266C4D01CF701B9F8802B07B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_23F51238266C4D01CF701B9F8802B07B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_23F51238266C4D01CF701B9F8802B07B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_23F51238266C4D01CF701B9F8802B07B" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_23F51238266C4D01CF701B9F8802B07B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A3AE637A72B6D4BCAFE01B9F8802630D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A3AE637A72B6D4BCAFE01B9F8802630D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A3AE637A72B6D4BCAFE01B9F8802630D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A3AE637A72B6D4BCAFE01B9F8802630D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A3AE637A72B6D4BCAFE01B9F8802630D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A3AE637A72B6D4BCAFE01B9F8802630D" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A3AE637A72B6D4BCAFE01B9F8802630D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DA8F361905604996F2811B9F88022ACB_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DA8F361905604996F2811B9F88022ACB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DA8F361905604996F2811B9F88022ACB_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DA8F361905604996F2811B9F88022ACB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DA8F361905604996F2811B9F88022ACB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DA8F361905604996F2811B9F88022ACB" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DA8F361905604996F2811B9F88022ACB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_742DDF52BC18581F3E801B9F880232C1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_742DDF52BC18581F3E801B9F880232C1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_742DDF52BC18581F3E801B9F880232C1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_742DDF52BC18581F3E801B9F880232C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_742DDF52BC18581F3E801B9F880232C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_742DDF52BC18581F3E801B9F880232C1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_742DDF52BC18581F3E801B9F880232C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76627EB2DE21165779931B9F88028716_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76627EB2DE21165779931B9F88028716" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76627EB2DE21165779931B9F88028716" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76627EB2DE21165779931B9F88028716" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76627EB2DE21165779931B9F88028716" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_397BDBCB6B0017F804241B9F8802499D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_397BDBCB6B0017F804241B9F8802499D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_397BDBCB6B0017F804241B9F8802499D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_397BDBCB6B0017F804241B9F8802499D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_397BDBCB6B0017F804241B9F8802499D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_397BDBCB6B0017F804241B9F8802499D" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_397BDBCB6B0017F804241B9F8802499D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_9003BCA6B88CA39A90F71B9F88023ABB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_9003BCA6B88CA39A90F71B9F88023ABB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_9003BCA6B88CA39A90F71B9F88023ABB_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_9003BCA6B88CA39A90F71B9F88023ABB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_9003BCA6B88CA39A90F71B9F88023ABB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_9003BCA6B88CA39A90F71B9F88023ABB" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_9003BCA6B88CA39A90F71B9F88023ABB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_79E9260896A97CCFF2891B9F88024662_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_79E9260896A97CCFF2891B9F88024662" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_79E9260896A97CCFF2891B9F88024662_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_79E9260896A97CCFF2891B9F88024662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_79E9260896A97CCFF2891B9F88024662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_79E9260896A97CCFF2891B9F88024662" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_79E9260896A97CCFF2891B9F88024662" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_A4E44D03E3775BAB33C21B9F8802BCFD_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_A4E44D03E3775BAB33C21B9F8802BCFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_A4E44D03E3775BAB33C21B9F8802BCFD_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_A4E44D03E3775BAB33C21B9F8802BCFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_A4E44D03E3775BAB33C21B9F8802BCFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_A4E44D03E3775BAB33C21B9F8802BCFD" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_A4E44D03E3775BAB33C21B9F8802BCFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7C6C62E9EC34A7B7A1D31B9F880294CD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7C6C62E9EC34A7B7A1D31B9F880294CD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7C6C62E9EC34A7B7A1D31B9F880294CD_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7C6C62E9EC34A7B7A1D31B9F880294CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7C6C62E9EC34A7B7A1D31B9F880294CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7C6C62E9EC34A7B7A1D31B9F880294CD" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7C6C62E9EC34A7B7A1D31B9F880294CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0B0A07E75BD1811A02F31B9F8802B3CE_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0B0A07E75BD1811A02F31B9F8802B3CE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0B0A07E75BD1811A02F31B9F8802B3CE_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0B0A07E75BD1811A02F31B9F8802B3CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0B0A07E75BD1811A02F31B9F8802B3CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0B0A07E75BD1811A02F31B9F8802B3CE" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0B0A07E75BD1811A02F31B9F8802B3CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_1791949D48D2064FF4C71B9F8802DDE8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_1791949D48D2064FF4C71B9F8802DDE8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_1791949D48D2064FF4C71B9F8802DDE8_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_1791949D48D2064FF4C71B9F8802DDE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1791949D48D2064FF4C71B9F8802DDE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1791949D48D2064FF4C71B9F8802DDE8" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_1791949D48D2064FF4C71B9F8802DDE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_422DADE406605C8445231B9F88026514_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments_422DADE406605C8445231B9F88026514" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_422DADE406605C8445231B9F88026514_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments_422DADE406605C8445231B9F88026514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_422DADE406605C8445231B9F88026514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments_422DADE406605C8445231B9F88026514" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments_422DADE406605C8445231B9F88026514" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_8AB77F8B69B887332ACD1B9F880253D3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_8AB77F8B69B887332ACD1B9F880253D3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments to increase investment in Samsung Bioepis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_8AB77F8B69B887332ACD1B9F880253D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_8AB77F8B69B887332ACD1B9F880253D3" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_8AB77F8B69B887332ACD1B9F880253D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_0892F3CCDC82983132D31B9F880214EE_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_0892F3CCDC82983132D31B9F880214EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities, Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_0892F3CCDC82983132D31B9F880214EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_0892F3CCDC82983132D31B9F880214EE" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_0892F3CCDC82983132D31B9F880214EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_AAAB526504F628B0CD991B9F8802BBA4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_AAAB526504F628B0CD991B9F8802BBA4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_AAAB526504F628B0CD991B9F8802BBA4_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_AAAB526504F628B0CD991B9F8802BBA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_AAAB526504F628B0CD991B9F8802BBA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_AAAB526504F628B0CD991B9F8802BBA4" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_AAAB526504F628B0CD991B9F8802BBA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_01622FD19CD48004E2181B9F8802A719_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_01622FD19CD48004E2181B9F8802A719" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_01622FD19CD48004E2181B9F8802A719_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_01622FD19CD48004E2181B9F8802A719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01622FD19CD48004E2181B9F8802A719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01622FD19CD48004E2181B9F8802A719" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_01622FD19CD48004E2181B9F8802A719" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5ED38F15249E960D845F1B9F88024C34_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5ED38F15249E960D845F1B9F88024C34" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5ED38F15249E960D845F1B9F88024C34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5ED38F15249E960D845F1B9F88024C34" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5ED38F15249E960D845F1B9F88024C34" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_B36AFB77163E5377D3861B9F880268EB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_B36AFB77163E5377D3861B9F880268EB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net contribution (distribution) to noncontrolling interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_B36AFB77163E5377D3861B9F880268EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_B36AFB77163E5377D3861B9F880268EB" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_B36AFB77163E5377D3861B9F880268EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_CC9D9F595D65BF655B8F1B9F880226A3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_CC9D9F595D65BF655B8F1B9F880226A3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_CC9D9F595D65BF655B8F1B9F880226A3_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_CC9D9F595D65BF655B8F1B9F880226A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_CC9D9F595D65BF655B8F1B9F880226A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_CC9D9F595D65BF655B8F1B9F880226A3" xlink:to="lab_us-gaap_RepaymentsOfDebt_CC9D9F595D65BF655B8F1B9F880226A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_59E518EB08098BDB63971B9F88027500_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution_59E518EB08098BDB63971B9F88027500" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net cash contribution to Bioverativ, Inc.</link:label>
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_59E518EB08098BDB63971B9F88027500_label_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution_59E518EB08098BDB63971B9F88027500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Capital Distribution</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_59E518EB08098BDB63971B9F88027500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfCapitalDistribution_59E518EB08098BDB63971B9F88027500" xlink:to="lab_us-gaap_PaymentsOfCapitalDistribution_59E518EB08098BDB63971B9F88027500" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_A41F6B87BF6E05B7FF2A1B9F88021D49_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_A41F6B87BF6E05B7FF2A1B9F88021D49" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_A41F6B87BF6E05B7FF2A1B9F88021D49_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_A41F6B87BF6E05B7FF2A1B9F88021D49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_A41F6B87BF6E05B7FF2A1B9F88021D49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets_A41F6B87BF6E05B7FF2A1B9F88021D49" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets_A41F6B87BF6E05B7FF2A1B9F88021D49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_848A7F9326659554CF2C1B9F88028674_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_848A7F9326659554CF2C1B9F88028674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_848A7F9326659554CF2C1B9F88028674_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_848A7F9326659554CF2C1B9F88028674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_848A7F9326659554CF2C1B9F88028674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_848A7F9326659554CF2C1B9F88028674" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_848A7F9326659554CF2C1B9F88028674" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_235911BDEC41C722892C1B9F8802F65A_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_235911BDEC41C722892C1B9F8802F65A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_235911BDEC41C722892C1B9F8802F65A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_235911BDEC41C722892C1B9F8802F65A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_235911BDEC41C722892C1B9F8802F65A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_235911BDEC41C722892C1B9F8802F65A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_235911BDEC41C722892C1B9F8802F65A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E1FC98E8EFC993806EAF1B9F8802A10E_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E1FC98E8EFC993806EAF1B9F8802A10E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E1FC98E8EFC993806EAF1B9F8802A10E_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E1FC98E8EFC993806EAF1B9F8802A10E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E1FC98E8EFC993806EAF1B9F8802A10E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E1FC98E8EFC993806EAF1B9F8802A10E" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E1FC98E8EFC993806EAF1B9F8802A10E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9F26047324892DE85A0F1B9F88022C08_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9F26047324892DE85A0F1B9F88022C08" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9F26047324892DE85A0F1B9F88022C08_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9F26047324892DE85A0F1B9F88022C08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9F26047324892DE85A0F1B9F88022C08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9F26047324892DE85A0F1B9F88022C08" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9F26047324892DE85A0F1B9F88022C08" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC3B1A8C0E05B91D1A7A1B9F88021A4E_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC3B1A8C0E05B91D1A7A1B9F88021A4E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC3B1A8C0E05B91D1A7A1B9F88021A4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC3B1A8C0E05B91D1A7A1B9F88021A4E" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC3B1A8C0E05B91D1A7A1B9F88021A4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_015AAE81C04967A0016D1B9F8802116D_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_015AAE81C04967A0016D1B9F8802116D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_015AAE81C04967A0016D1B9F8802116D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_015AAE81C04967A0016D1B9F8802116D" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_015AAE81C04967A0016D1B9F8802116D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67CD8AB7D6A5CD40CBE76F399CE81A90_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67CD8AB7D6A5CD40CBE76F399CE81A90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67CD8AB7D6A5CD40CBE76F399CE81A90_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67CD8AB7D6A5CD40CBE76F399CE81A90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67CD8AB7D6A5CD40CBE76F399CE81A90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67CD8AB7D6A5CD40CBE76F399CE81A90" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67CD8AB7D6A5CD40CBE76F399CE81A90" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_872E6A8ACD33C6EF94306F399EA9C04C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_872E6A8ACD33C6EF94306F399EA9C04C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_872E6A8ACD33C6EF94306F399EA9C04C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_872E6A8ACD33C6EF94306F399EA9C04C" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_872E6A8ACD33C6EF94306F399EA9C04C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6CF2A865719D17B05DE16F399EAAADD2_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6CF2A865719D17B05DE16F399EAAADD2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6CF2A865719D17B05DE16F399EAAADD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6CF2A865719D17B05DE16F399EAAADD2" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6CF2A865719D17B05DE16F399EAAADD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_40EB591766FB9B7241636F399EAB357D_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_40EB591766FB9B7241636F399EAB357D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_40EB591766FB9B7241636F399EAB357D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_40EB591766FB9B7241636F399EAB357D" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_40EB591766FB9B7241636F399EAB357D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8EF343E362703C20BEA96F399EAB5BD0_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8EF343E362703C20BEA96F399EAB5BD0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8EF343E362703C20BEA96F399EAB5BD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8EF343E362703C20BEA96F399EAB5BD0" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8EF343E362703C20BEA96F399EAB5BD0" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Table]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F_label_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Table]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F_documentation_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of development milestone and collaboration.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ADFCA3AA0AFC6B2202E4FC3A179C7422_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ADFCA3AA0AFC6B2202E4FC3A179C7422" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ADFCA3AA0AFC6B2202E4FC3A179C7422" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ADFCA3AA0AFC6B2202E4FC3A179C7422" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ADFCA3AA0AFC6B2202E4FC3A179C7422" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_E2071C7811ED200DDFA3FC3A179DA687_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_E2071C7811ED200DDFA3FC3A179DA687" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_E2071C7811ED200DDFA3FC3A179DA687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_E2071C7811ED200DDFA3FC3A179DA687" xlink:to="lab_biib_NeurimmuneMember_E2071C7811ED200DDFA3FC3A179DA687" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Line Items]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2_label_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Line Items]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2_documentation_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration.</link:label>
    <link:loc xlink:href="biib-20191231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_922FB68B988028B1937FFC3A179F5B8C_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_922FB68B988028B1937FFC3A179F5B8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on strategic investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_922FB68B988028B1937FFC3A179F5B8C_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_922FB68B988028B1937FFC3A179F5B8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Marketable Securities, Cost Method Investments, and Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_922FB68B988028B1937FFC3A179F5B8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_922FB68B988028B1937FFC3A179F5B8C" xlink:to="lab_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_922FB68B988028B1937FFC3A179F5B8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_381CAEB6C4FB0D14AA06FC3A179F64B4_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_381CAEB6C4FB0D14AA06FC3A179F64B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense on 2018 Ionis Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_381CAEB6C4FB0D14AA06FC3A179F64B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_381CAEB6C4FB0D14AA06FC3A179F64B4" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_381CAEB6C4FB0D14AA06FC3A179F64B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_2C0634AC2F886188810AFC3A17A00A5C_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_2C0634AC2F886188810AFC3A17A00A5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_2C0634AC2F886188810AFC3A17A00A5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_2C0634AC2F886188810AFC3A17A00A5C" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_2C0634AC2F886188810AFC3A17A00A5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_6473408ACF496F91CE9A6F39A0323E0E_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_6473408ACF496F91CE9A6F39A0323E0E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_6473408ACF496F91CE9A6F39A0323E0E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_6473408ACF496F91CE9A6F39A0323E0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_6473408ACF496F91CE9A6F39A0323E0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_6473408ACF496F91CE9A6F39A0323E0E" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_6473408ACF496F91CE9A6F39A0323E0E" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>biib-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20191231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:href="biib-20191231.xsd#AcquisitionsAcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20191231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20191231.xsd#AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20191231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20191231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20191231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20191231.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails" xlink:href="biib-20191231.xsd#DerivativeInstrumentsCashFlowHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:href="biib-20191231.xsd#DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20191231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2" xlink:href="biib-20191231.xsd#DerivativeInstrumentsInterestRateSwapDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20191231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20191231.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual" xlink:href="biib-20191231.xsd#DivestituresDivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20191231.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20191231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20191231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20191231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:href="biib-20191231.xsd#EmployeeBenefitPlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:href="biib-20191231.xsd#EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20191231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20191231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20191231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20191231.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" xlink:href="biib-20191231.xsd#EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20191231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20191231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20191231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20191231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20191231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20191231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20191231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20191231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20191231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20191231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20191231.xsd#Guarantees" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20191231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20191231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20191231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20191231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20191231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20191231.xsd#Indebtedness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20191231.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20191231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20191231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20191231.xsd#IndebtednessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20191231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20191231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20191231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20191231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20191231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20191231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20191231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20191231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20191231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20191231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeases" xlink:href="biib-20191231.xsd#LeasesLeases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesDetails" xlink:href="biib-20191231.xsd#LeasesLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual" xlink:href="biib-20191231.xsd#LeasesLeasesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesTables" xlink:href="biib-20191231.xsd#LeasesLeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20191231.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:href="biib-20191231.xsd#LitigationLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20191231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20191231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20191231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20191231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20191231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20191231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20191231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20191231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20191231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20191231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20191231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20191231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:href="biib-20191231.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20191231.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20191231.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:href="biib-20191231.xsd#RevenuesOtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20191231.xsd#RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20191231.xsd#RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20191231.xsd#RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20191231.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20191231.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20191231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20191231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20191231.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20191231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails10" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails11" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20191231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20191231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20191231.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20191231.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20191231.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20191231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_EA71DBD0CFFF4E348D456F39A032061C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_6473408ACF496F91CE9A6F39A0323E0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_EA71DBD0CFFF4E348D456F39A032061C" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_6473408ACF496F91CE9A6F39A0323E0E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_687787A0985DDE4BB6547EE9523816A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_96063C7B66E30D126C827EE0FEFC7652" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_687787A0985DDE4BB6547EE9523816A7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_96063C7B66E30D126C827EE0FEFC7652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7E15DF0E36FD1C089D487EE0FF029568" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_96063C7B66E30D126C827EE0FEFC7652" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7E15DF0E36FD1C089D487EE0FF029568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F82870882F1F0232EDB37EE0FF035136" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7E15DF0E36FD1C089D487EE0FF029568" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F82870882F1F0232EDB37EE0FF035136" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_CB2F5DE390AEE4F688957EE11B50B6D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F82870882F1F0232EDB37EE0FF035136" xlink:to="loc_biib_NightstarMember_CB2F5DE390AEE4F688957EE11B50B6D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_DF960DB011632AD13BB97EE0FF0896B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_96063C7B66E30D126C827EE0FEFC7652" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_DF960DB011632AD13BB97EE0FF0896B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_366275879B357FB10A3A7EE1192612D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DF960DB011632AD13BB97EE0FF0896B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_366275879B357FB10A3A7EE1192612D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_CB2B5908A0C323C488027EE15A7852A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DF960DB011632AD13BB97EE0FF0896B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_CB2B5908A0C323C488027EE15A7852A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_39EFC57A48A244BA4EF27EE180CCC8E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DF960DB011632AD13BB97EE0FF0896B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_39EFC57A48A244BA4EF27EE180CCC8E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0818CFBF579217D1CE287EE1A57C48A2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DF960DB011632AD13BB97EE0FF0896B7" xlink:to="loc_us-gaap_Goodwill_0818CFBF579217D1CE287EE1A57C48A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_CD74F0DE4CD26F3C13037EE1C9E8FED5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DF960DB011632AD13BB97EE0FF0896B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_CD74F0DE4CD26F3C13037EE1C9E8FED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_0881F00C2B72848F442D7EE1EF88B1EF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DF960DB011632AD13BB97EE0FF0896B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_0881F00C2B72848F442D7EE1EF88B1EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_06C8B034486D4A5CB2877EE2130E0892" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DF960DB011632AD13BB97EE0FF0896B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_06C8B034486D4A5CB2877EE2130E0892" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F2642BFA2069A8FE80007ED42E208053" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F2642BFA2069A8FE80007ED42E208053" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_B3E639623B0DE21DE9187EE6FB3B665C" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:to="loc_biib_BIIB111Member_3601149FFB7C0D14BA3E7EE6FBB803A1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_CAC200F42D38C24332A47EE6FB3BC809" xlink:to="loc_biib_BIIB112Member_9EAD71C34FF9EFF8336E7EE738123183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_DBFB88954106433D9BE57ED98440998A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_DBFB88954106433D9BE57ED98440998A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_649F9CC8E6EC121CCFFA7ED984406621" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_DBFB88954106433D9BE57ED98440998A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_649F9CC8E6EC121CCFFA7ED984406621" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9F71C0BDD627AE6A5DC57ED98460A139" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_649F9CC8E6EC121CCFFA7ED984406621" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9F71C0BDD627AE6A5DC57ED98460A139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4B6D9A5F7D3225D455947ED9CBA5A5A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_649F9CC8E6EC121CCFFA7ED984406621" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4B6D9A5F7D3225D455947ED9CBA5A5A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_1118F36B0E760A2E6B5B7ED829658494" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_36B06C33F892B6A050FB7ED92B4F4BEC" xlink:to="loc_biib_PostacquisitionequitycompensationMember_7FB17792B2E01650324E7ED829752338" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_A20A35DA97277AB0CE017ED42E21C7E0" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_E6E6F4E945D436FC3D687ED42E21E0C7" xlink:to="loc_biib_DevelopmentMilestonesMember_B7233BD7DB3E54E7D4267ED42E21115F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8E678FCA7559748121737ED42E225531" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="loc_biib_NightstarMember_919F64654187F8669CED7ED5BAB7E62B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="loc_biib_KaryopharmMember_B9317DAC6C650CFD12137ED42E22D3EC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="loc_biib_PfizerMember_2FFE4230C941630FC27A7ED42E22C2D0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TMSMember" xlink:label="loc_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="loc_biib_TMSMember_C8EA0F633176D787B82D7ED42E2258D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AliveGenMember" xlink:label="loc_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="loc_biib_AliveGenMember_100AE640AA196216E5B67ED42E231D3E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B16EC1EB2AB559245A3A7ED42E225D0A" xlink:to="loc_biib_RemedyPharmaceuticalMember_81D568D75A4741FE4A027ED42E28C675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9F6A0895F8F0290CF7927ED42E20BC8A" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_F8E07E8C4E30EB156FE57ED5BA74526D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_F8E07E8C4E30EB156FE57ED5BA74526D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A69CD9EA7B01048CC6A67ED6538575A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_A69CD9EA7B01048CC6A67ED6538575A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_56A76BF6AF0C0080FC227ED69B9B16A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_56A76BF6AF0C0080FC227ED69B9B16A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8E01BEB067C57E0A4A0E7ED82955CF01" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8E01BEB067C57E0A4A0E7ED82955CF01" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_3E2290CC56BF64F7B6607EE78BD40808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F2FA0FF2B4D553E12F8E7EE6FAFD8BA6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F2FA0FF2B4D553E12F8E7EE6FAFD8BA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_E4EDEF447F00AF99A88F7EE7D6AA22C2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_E4EDEF447F00AF99A88F7EE7D6AA22C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_6B8B2507B4087A7A4F617ED42E283848" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_6B8B2507B4087A7A4F617ED42E283848" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4B32796B1F15C8294CFA7ED42E29E0DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_12517474A7234EE10C037ED42E291BE6" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2EF3F36256A48DD8E5097ED42E288500" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_12517474A7234EE10C037ED42E291BE6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_33D6DB8FCEDA8109A69AF00E8B03D6BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ECB996C5A6C5FFE91BB2F00EC112EC82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_33D6DB8FCEDA8109A69AF00E8B03D6BF" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ECB996C5A6C5FFE91BB2F00EC112EC82" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0291B98BB462970C1F1C6F399D6CF85D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9980BBD7E9A6EA3807BE6F399D6C2FD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0291B98BB462970C1F1C6F399D6CF85D" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9980BBD7E9A6EA3807BE6F399D6C2FD6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DBD398736FA0C53B50A4FCF51D2121DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DBD398736FA0C53B50A4FCF51D2121DF" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_387F467AC2195A681E49FCF51D22C809" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:to="loc_srt_MajorCustomersAxis_387F467AC2195A681E49FCF51D22C809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_80C75762F240635EFD24FCF51D229101" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_387F467AC2195A681E49FCF51D22C809" xlink:to="loc_srt_NameOfMajorCustomerDomain_80C75762F240635EFD24FCF51D229101" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_249860D07BB1CCD13DADFCF51D23BB32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_80C75762F240635EFD24FCF51D229101" xlink:to="loc_biib_AbbVieMember_249860D07BB1CCD13DADFCF51D23BB32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_3CEAAEC85B5302EBF204FCF51D238748" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:to="loc_srt_ProductOrServiceAxis_3CEAAEC85B5302EBF204FCF51D238748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7ED744B3E9C0E718E111FCF51D2365B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3CEAAEC85B5302EBF204FCF51D238748" xlink:to="loc_srt_ProductsAndServicesDomain_7ED744B3E9C0E718E111FCF51D2365B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_D76F03824941315A33A0FCF51D230DF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7ED744B3E9C0E718E111FCF51D2365B9" xlink:to="loc_us-gaap_ProductMember_D76F03824941315A33A0FCF51D230DF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_7A043674B659A7CCFE67FCF51D24D89B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:to="loc_srt_StatementGeographicalAxis_7A043674B659A7CCFE67FCF51D24D89B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_DA7DF8FAFE096CE21B2CFCF51D247890" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7A043674B659A7CCFE67FCF51D24D89B" xlink:to="loc_srt_SegmentGeographicalDomain_DA7DF8FAFE096CE21B2CFCF51D247890" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_FC6B16D73541CA71BBB8FCF51D24F650" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_DA7DF8FAFE096CE21B2CFCF51D247890" xlink:to="loc_country_US_FC6B16D73541CA71BBB8FCF51D24F650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_07BEB9794700603C484AFCF51D244EC3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:to="loc_us-gaap_TypeOfArrangementAxis_07BEB9794700603C484AFCF51D244EC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3F57C727BDDE3C450A7FCF51D24A546" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_07BEB9794700603C484AFCF51D244EC3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3F57C727BDDE3C450A7FCF51D24A546" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_27E2A93B02AE6FE44C67FCF51D25D3A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3F57C727BDDE3C450A7FCF51D24A546" xlink:to="loc_biib_AbbVieMember_27E2A93B02AE6FE44C67FCF51D25D3A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4637E252184832A8465CFCF51D25CDBE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6A5CA27658B4C54C9958FCF51D222271" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4637E252184832A8465CFCF51D25CDBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_CCC0C44FF004449D0770FCF51D253F51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4637E252184832A8465CFCF51D25CDBE" xlink:to="loc_us-gaap_Revenues_CCC0C44FF004449D0770FCF51D253F51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_CB2D7F5653856E75B7FEFCF51D26933A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4637E252184832A8465CFCF51D25CDBE" xlink:to="loc_us-gaap_CostsAndExpenses_CB2D7F5653856E75B7FEFCF51D26933A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FD6A1C88910DF0D9E2ADF1F26A4D2EB5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FD6A1C88910DF0D9E2ADF1F26A4D2EB5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8DF81A039108E07DA1C1F1F26A4D5A30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8DF81A039108E07DA1C1F1F26A4D5A30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CEA34C5F2D892CB0BE88F1F26A4D0594" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8DF81A039108E07DA1C1F1F26A4D5A30" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_CEA34C5F2D892CB0BE88F1F26A4D0594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_465798FF027B9E3D9159F1F26A4DA91F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CEA34C5F2D892CB0BE88F1F26A4D0594" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_465798FF027B9E3D9159F1F26A4DA91F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22BA5A40DF95E34FAA02F1F26A4DC6D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CEA34C5F2D892CB0BE88F1F26A4D0594" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22BA5A40DF95E34FAA02F1F26A4DC6D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_51EFDC26ED20FDA10D77F1F26A4DDA7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:to="loc_srt_ProductOrServiceAxis_51EFDC26ED20FDA10D77F1F26A4DDA7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3E0953EB882E036CD93AF1F26A4D37AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_51EFDC26ED20FDA10D77F1F26A4DDA7A" xlink:to="loc_srt_ProductsAndServicesDomain_3E0953EB882E036CD93AF1F26A4D37AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3E0953EB882E036CD93AF1F26A4D37AC" xlink:to="loc_biib_AducanumabMember_7D0669B7B468678FB38FF1F26A4D64CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_51D7CA94CC47D8BBF9F6F1F26A4DC746" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CCC5FBC0F4A9551B1FB1F1F26A4D56CC" xlink:to="loc_biib_EisaiMember_B60832F7D148E98EA216F1F26A4DE0F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_77046713376AF331689BF1F26A4D32B6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_C24431C9584AE20D98EAF212402DB9B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:to="loc_biib_ExpenseIncurredByCollaboration_E8B8A6C5E5AC8B17A467F1F26A4D2C0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:to="loc_biib_Expenseincurredbythecollaboration_6B8CC37473969D92FDD2F1F26A4D3FEA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_065E8B657F9E9CD52601F1F26A4DDA90" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_9CAFBE05997B1935978AF1F26A4D8513" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AF2935C559F012E906880B3C20208A69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AF2935C559F012E906880B3C20208A69" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_BACA7FB0A419D09F03500B3C2020A3E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_BACA7FB0A419D09F03500B3C2020A3E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_730A4171580F2552FA9F0B3C20208B7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_BACA7FB0A419D09F03500B3C2020A3E8" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_730A4171580F2552FA9F0B3C20208B7A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_84F26CAD51238C0E6B3C0B3C20208317" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_730A4171580F2552FA9F0B3C20208B7A" xlink:to="loc_biib_DevelopmentMilestonesMember_84F26CAD51238C0E6B3C0B3C20208317" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E06A8196586BE1BF33E80B3C20207BF0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_ADDBC92866C6615F363B0B3C2020E9D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:to="loc_us-gaap_InventoriesMember_ADDBC92866C6615F363B0B3C2020E9D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_B8F1DA537F2C7F4B2F190B3C20202DC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_B8F1DA537F2C7F4B2F190B3C20202DC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9B7DBD77242F961C95DD0B3C2020505D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9B7DBD77242F961C95DD0B3C2020505D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804BEE754EAE8180E0ED0B3C202044F7" xlink:to="loc_biib_DeferredtaxliabilityMember_7E34EBFB97AB5EA0E3540B3C2020BE14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_098059C64C43A57F58870B3C202036B0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_srt_MajorCustomersAxis_098059C64C43A57F58870B3C202036B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_29E37A322AD2BE75A9D50B3C2020EF3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_098059C64C43A57F58870B3C202036B0" xlink:to="loc_srt_NameOfMajorCustomerDomain_29E37A322AD2BE75A9D50B3C2020EF3C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_29E37A322AD2BE75A9D50B3C2020EF3C" xlink:to="loc_biib_AbbVieMember_E3D5C1CD21B9CBF2028C0B3C2020B576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_45F9917533368780B3320B3C2020EFD9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D185C2CDEC222D9B4E180B3C2020D807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_D1B1F11EB630DD9F7A960B3C20206D06" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_srt_StatementGeographicalAxis_D1B1F11EB630DD9F7A960B3C20206D06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_D1B1F11EB630DD9F7A960B3C20206D06" xlink:to="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_823A66E6EB49E849381A0B3C20202117" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A" xlink:to="loc_country_US_823A66E6EB49E849381A0B3C20202117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_CDED27190B79CD166B630B3C20202ACB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A" xlink:to="loc_us-gaap_ForeignCountryMember_CDED27190B79CD166B630B3C20202ACB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_D2E408C6944F72A1BC0C0B3C20200378" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A" xlink:to="loc_us-gaap_EuropeanUnionMember_D2E408C6944F72A1BC0C0B3C20200378" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_C1D2D51C1DEE93328E4D0B3C2020B902" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_29B54B85A9A0CFACB8710B3C2020A43A" xlink:to="loc_country_JP_C1D2D51C1DEE93328E4D0B3C2020B902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6842A0EF85006625791B0B3C20205D2D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6842A0EF85006625791B0B3C20205D2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7D69C326772C1A78B2910B3C20206D7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6842A0EF85006625791B0B3C20205D2D" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7D69C326772C1A78B2910B3C20206D7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F96FC84302C506C368AB0B3C202007CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7D69C326772C1A78B2910B3C20206D7C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F96FC84302C506C368AB0B3C202007CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C60AC04363985B40EFDA0B3C20209A76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7D69C326772C1A78B2910B3C20206D7C" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C60AC04363985B40EFDA0B3C20209A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E949A4647AAD46AA5620B3C20201CBA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E949A4647AAD46AA5620B3C20201CBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0B343F00FFFEC916AC8C0B3C20206523" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E949A4647AAD46AA5620B3C20201CBA" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0B343F00FFFEC916AC8C0B3C20206523" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_83F5824C8D6887CA62B80B3C202062DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0B343F00FFFEC916AC8C0B3C20206523" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_83F5824C8D6887CA62B80B3C202062DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_564BFAD34FBF18856EF90B3C2020CA63" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_srt_ProductOrServiceAxis_564BFAD34FBF18856EF90B3C2020CA63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_564BFAD34FBF18856EF90B3C2020CA63" xlink:to="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_E2609andBAN2401Member_B842E64B05D76E2F65FF0B3C2020EC6F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_92AE60DF9FB2DE9C8E8C0B3C2020942E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_RituxanMember_92AE60DF9FB2DE9C8E8C0B3C2020942E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_DC5FEC4AC71B5FCEB0D00B3C2020383D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_GAZYVAMember_DC5FEC4AC71B5FCEB0D00B3C2020383D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_NewAntiCd20Member_3289469AC91D0254A94D0B3C2030DC68" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OCREVUSMember" xlink:label="loc_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_OCREVUSMember_4C0A7FBAA8A5C204DEC00B3C20307B2D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_324EB2272BD3294AA7B10B3C20302D25" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_ZINBRYTAMember_324EB2272BD3294AA7B10B3C20302D25" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_8907C7E70F3C9E7D67C10B3C2030D1F7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_SPINRAZAMember_8907C7E70F3C9E7D67C10B3C2030D1F7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_SOD1Member_D1014463228ECDCF940C0B3C20302CE3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_VUMERITYMember" xlink:label="loc_biib_VUMERITYMember_AF50F6914F342EF7724E0B3C20308082" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_VUMERITYMember_AF50F6914F342EF7724E0B3C20308082" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_79AA70EE71B1D432A28F0B3C2030563D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_BiosimilarsMember_79AA70EE71B1D432A28F0B3C2030563D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_B3E73EEA4E2E97E6903D0B3C20306857" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E92A6749C02789492A350B3C20207406" xlink:to="loc_biib_IMRALDIMember_B3E73EEA4E2E97E6903D0B3C20306857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1EA6CFC3268463B3A2BC0B3C203076AF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1EA6CFC3268463B3A2BC0B3C203076AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1EA6CFC3268463B3A2BC0B3C203076AF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_1FA327EBE731DA83995A0B3C2030DF24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_RocheGroupGenentechMember_1FA327EBE731DA83995A0B3C2030DF24" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_IonisPharmaceuticalsMember_0957043EA4CF48C1602E0B3C2030A63D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_E2F4F88CDE28376C1B790B3C20307AF2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_EisaiMember_E2F4F88CDE28376C1B790B3C20307AF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_AlkermesMember_2881634A49D6CC6DFCC30B3C2030DA65" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_BristolMyersSquibbMember_BAF5F6804FE815A7873F0B3C203082E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_IPerianMember_421E7934387E13A44F470B3C20308FBA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_AcordaMember_0EA5E7B71FE2A1C459A00B3C2030C077" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_C2808FCFC85132D72C110B3C20305E5B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_AbbVieMember_C2808FCFC85132D72C110B3C20305E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5D390AD3BE3532993AD80B3C2030510C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5D390AD3BE3532993AD80B3C2030510C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_SkyhawkTherapeuticsMember_65CB72D713C4748F63600B3C20303834" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_OtherresearchanddiscoveryMember_3E46A96E62EB060503650B3C20309430" xlink:type="arc" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6208B4E79DFB3B3C5E7B0B3C20303C37" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_83F5824C8D6887CA62B80B3C202062DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_828AA7145EA5619CAA250B3C2030DA8D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_srt_RangeAxis_828AA7145EA5619CAA250B3C2030DA8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_AEB33BC9CA4237AC84E00B3C20304F8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_828AA7145EA5619CAA250B3C2030DA8D" xlink:to="loc_srt_RangeMember_AEB33BC9CA4237AC84E00B3C20304F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4FC5938D67CC5BEFD2890B3C20303AA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_AEB33BC9CA4237AC84E00B3C20304F8D" xlink:to="loc_srt_MinimumMember_4FC5938D67CC5BEFD2890B3C20303AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_AB32493DABA89B2729840B3C20308D5E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_AEB33BC9CA4237AC84E00B3C20304F8D" xlink:to="loc_srt_MaximumMember_AB32493DABA89B2729840B3C20308D5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84AB38801A7847DEA9530B3C2020A618" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_B410A25A1DABD73F808C0B3C20307609" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_DFCF7A0F80F7422900030B3C20305C14" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_Reductioninroyaltyrate_1C146D2920AD76AE29250B3C20309899" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_PeriodOfCollaborationAgreement_A279F7B21E1643782F070B3C20307E41" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_6780A4EB0B8FDF50D3E30B3C203023B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_7662223DAE06D23151730B3C20306C52" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_F0267D8B0220C8C8A0750B3C20302E9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_7C284B13916E05795C9B0B3C2030E434" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_C40196D4C62FA7403F740B3C2030B33A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_Futurepercentageofcopromotionoperatingprofits_BC70762190C818D7A8250B3C20306D78" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_3764C0EC69C98A0FE35B0B3C2030A76C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_ShareOfCoPromotionProfits_3764C0EC69C98A0FE35B0B3C2030A76C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_CB3AD999EC163BDCBE180B3C2030705B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_CB3AD999EC163BDCBE180B3C2030705B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_739BF1AA48F9E833F2BC0B3C2030A4F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_ForeignSalesRequiredToTriggerMilestone_E61E8D6E7CB52FE8B7620B3C203037A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5F7A3D25B6E00A2C1E0C0B3C2030EA4C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5F7A3D25B6E00A2C1E0C0B3C2030EA4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_09E5439C8F3E348A4B4D0B3C20304B1B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_09E5439C8F3E348A4B4D0B3C20304B1B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ContractOptionExerciseFee" xlink:label="loc_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_54A02E8B3CA6698B9D0E0B3C2030E60F" xlink:to="loc_biib_ContractOptionExerciseFee_E59484994F7AAA4824A40B3C20300F8C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B8C1CE7350202A681FE30B3C20301B01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B8C1CE7350202A681FE30B3C20301B01" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0B4D7FCC780B1BC65A670B3C20305FFB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0B4D7FCC780B1BC65A670B3C20305FFB" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B304B5055596BED91C8B0B3C203020B3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B304B5055596BED91C8B0B3C203020B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_752788BD774A6EC4C69B0B3C2030E0D5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_ExpenseIncurredByCollaboration_752788BD774A6EC4C69B0B3C2030E0D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_6011B13E54FB676C14F10B3C20305EA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F1F518C4E8628AC339D80B3C20309A5C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_Revenues_F1F518C4E8628AC339D80B3C20309A5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_95E5CF3DFB513234C61E0B3C20304C0C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_95E5CF3DFB513234C61E0B3C20304C0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_23EFF3B3256AABBFC7A00B3C2030B143" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_23EFF3B3256AABBFC7A00B3C2030B143" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_D0C907119CAC70FBFFC10B3C20307EBC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_CollaborationProfitSharing_D0C907119CAC70FBFFC10B3C20307EBC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_28EDEFA417FE2B169E3D0B3C203031AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_521FA37A354C34ADE1490B3C203096EA" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_521FA37A354C34ADE1490B3C203096EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_LicenseFee_6236885919DE7F6F92AD0B3C2030C6FB" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B49BDF4A342DD65AA0F70B3C2030A680" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Upfrontpaymentforcollaborationagreement" xlink:label="loc_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Upfrontpaymentforcollaborationagreement_B23E4FAD32859913FFC60B3C2030C0FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Investmentincommonstocksharespurchased_104C5F4261E97402D9680B3C2030FAF4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_722B46D575BD6C8A24680B3C2030B878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_FB4D61C29C0E6C3D52A20B3C203053FD" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_FB4D61C29C0E6C3D52A20B3C203053FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_AdditionalMilestonePayment_628EE8509701482C942D0B3C203098DC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Termofcollaborationagreement_6711D3C39FAD3B6622120B3C2030B6C6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Totalpaymenttoentercollaborationagreement" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Totalpaymenttoentercollaborationagreement_9D990BD29C643837C8E80B3C20307F76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_95A37109A17493D065ED0B3C2030272D" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_95A37109A17493D065ED0B3C2030272D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_3DF7E39CEC13F9D4542C0B3C203093ED" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_3DF7E39CEC13F9D4542C0B3C203093ED" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_DevelopmentalMilestonePayment_ABB492743636CDADEBCD0B3C20303554" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_751913153EF24FC8C6490B3C2030B7B8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Purchaseofcommonstock_374A0702DACEE114FDD40B3C20308ECA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Premiumonpurchaseofcommonstock_A23000926EDFD6E350FA0B3C203084A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Investmentincommonstockvalue" xlink:label="loc_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Investmentincommonstockvalue_30AB2AC1048410E0918B0B3C20303B19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_AB34543CB2F1D9B48D820B3C203020D0" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_AB34543CB2F1D9B48D820B3C203020D0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_B69E69D5DAF6165E63480B3C2030E474" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_F051963C280AABB1177D0B3C2030F445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4027F16708EE8AEDBDAC0B3C20303240" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_EquityMethodInvestments_4027F16708EE8AEDBDAC0B3C20303240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3176B4E946D42EE6DD1F0B3C20307A21" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3176B4E946D42EE6DD1F0B3C20307A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_1BA6ED2497F506020F820B3C2030BE44" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_1BA6ED2497F506020F820B3C2030BE44" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_3F53462D39CB16FE9AC60B3C2030E436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_AE526C1A2878CFECDB040B3C2030FE36" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_AE526C1A2878CFECDB040B3C2030FE36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_98E671063FEF44E8BF0C0B3C20300097" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_98E671063FEF44E8BF0C0B3C20300097" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_25020910B6D4D3DB292D0B3C20307C5E" xlink:type="locator" />
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_25020910B6D4D3DB292D0B3C20307C5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_11CC593C2EFF90684AC10B3C20309816" xlink:type="locator" />
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_11CC593C2EFF90684AC10B3C20309816" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_54F60E4641006BA0C1FC0B3C20308454" xlink:type="locator" />
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_AdjustmentForAmortization_54F60E4641006BA0C1FC0B3C20308454" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93" xlink:type="locator" />
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_39BBDC9BA64D7EDDF8580B3C20307C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_95FF046140269C5DE06E0B3C2030B36C" xlink:type="locator" />
    <link:presentationArc order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_LossOnContractTermination_95FF046140269C5DE06E0B3C2030B36C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_5E1EFE1FFB3BCB4C95950B3C203072F5" xlink:type="locator" />
    <link:presentationArc order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_biib_Expenseincurredbythecollaboration_5E1EFE1FFB3BCB4C95950B3C203072F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_B8912505B94BC53128FA0B3C2030BF72" xlink:type="locator" />
    <link:presentationArc order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_DueFromRelatedParties_B8912505B94BC53128FA0B3C2030BF72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8A3B2B2883FF90C0C6D60B3C20300100" xlink:type="locator" />
    <link:presentationArc order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C6A091A7CFD5499E6470B3C2030BE41" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8A3B2B2883FF90C0C6D60B3C20300100" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31B0D3A4769255C41B20F00F36C189E4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_727D901A5FB74D66C3AAF00F36C1FEA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31B0D3A4769255C41B20F00F36C189E4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_727D901A5FB74D66C3AAF00F36C1FEA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_46A6A4E30871665884BEF00F36C17898" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_727D901A5FB74D66C3AAF00F36C1FEA1" xlink:to="loc_srt_ProductOrServiceAxis_46A6A4E30871665884BEF00F36C17898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F8FCBAA5AD72EE9EE0E8F00F36C2FE99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_46A6A4E30871665884BEF00F36C17898" xlink:to="loc_srt_ProductsAndServicesDomain_F8FCBAA5AD72EE9EE0E8F00F36C2FE99" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F8FCBAA5AD72EE9EE0E8F00F36C2FE99" xlink:to="loc_biib_GAZYVAMember_ACADCF2335962542CFE8F00F36C27FE3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F8FCBAA5AD72EE9EE0E8F00F36C2FE99" xlink:to="loc_biib_RituxanMember_D1356CF7B9853639D5FBF00F36C237AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_262F0CEAB18C3718DF9CF00F36C3D46D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F8FCBAA5AD72EE9EE0E8F00F36C2FE99" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_262F0CEAB18C3718DF9CF00F36C3D46D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_0B8EA3190773A2C827DEF00F36C3420D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_727D901A5FB74D66C3AAF00F36C1FEA1" xlink:to="loc_srt_MajorCustomersAxis_0B8EA3190773A2C827DEF00F36C3420D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_F3B5A32ECE135D84232BF00F36C355A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0B8EA3190773A2C827DEF00F36C3420D" xlink:to="loc_srt_NameOfMajorCustomerDomain_F3B5A32ECE135D84232BF00F36C355A0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_F3B5A32ECE135D84232BF00F36C355A0" xlink:to="loc_biib_RocheGroupGenentechMember_827F2EF43DBC748700BEF00F36C390DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51EBE9AC80F3AE0B99BCF00F36C4BFEC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_727D901A5FB74D66C3AAF00F36C1FEA1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51EBE9AC80F3AE0B99BCF00F36C4BFEC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51EBE9AC80F3AE0B99BCF00F36C4BFEC" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_5199A6D63CFE3FFF9152F00F36C493B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_3C56BC5A6E8AC9BF61ACF00F36C40D33" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_E1C1997B50194079AD2AF00F36C40993" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_CA7AD2744FA2F704D165F00F36C57A73" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_C0D3D04FD95ECAD0F9DDF00F36C40C44" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_7BEB2E686527A09C8BFCF00F36C5C214" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51EBE9AC80F3AE0B99BCF00F36C4BFEC" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:to="loc_biib_ShareOfCoPromotionProfits_44F2533A659C4188F370F00F36C658F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0B0555556D469509A104F00F36C62548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_10321BAE1D167A6CCCC1F00F36C673FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_781CC9263CC7DC86E07FF00F36C5C66A" xlink:to="loc_us-gaap_Revenues_10321BAE1D167A6CCCC1F00F36C673FE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0D2DD81CB9FC8BB98A80F1F26A5D5686" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_925814BA09ABA34F0DD3F1F26A5DC393" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0D2DD81CB9FC8BB98A80F1F26A5D5686" xlink:to="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_925814BA09ABA34F0DD3F1F26A5DC393" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PretaxProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_D757569114AC63BBAA14F1F26A5D2E15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0D2DD81CB9FC8BB98A80F1F26A5D5686" xlink:to="loc_biib_PretaxProfitSharingFormulaTableTextBlock_D757569114AC63BBAA14F1F26A5D2E15" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_43F0ECCAB386A80A1867F1F26A5D1FE7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0D2DD81CB9FC8BB98A80F1F26A5D5686" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_43F0ECCAB386A80A1867F1F26A5D1FE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_C22D9AF96E670BA48AB0F1F26A5D0CC5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0D2DD81CB9FC8BB98A80F1F26A5D5686" xlink:to="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_C22D9AF96E670BA48AB0F1F26A5D0CC5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_F4F2477B04D6FFF80E42F1F26A5D9150" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0D2DD81CB9FC8BB98A80F1F26A5D5686" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_F4F2477B04D6FFF80E42F1F26A5D9150" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85E0396D4654A138682A6F399E87EC60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_52D77E20D6F11199A2246F399E870ECE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85E0396D4654A138682A6F399E87EC60" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_52D77E20D6F11199A2246F399E870ECE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CD55AA012C7D4AC611C40C8675A22B75" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CD55AA012C7D4AC611C40C8675A22B75" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_F39122BC54BE30178DCF0C8675A2AD2E" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TwelvemonthsMember" xlink:label="loc_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_274847A16BB4EA5C11A80C8675A3C8EA" xlink:to="loc_biib_TwelvemonthsMember_2934F2E319544553ECA50C8675A346F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FC399BC972538FBE9B3A0C8675A3F82A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FC399BC972538FBE9B3A0C8675A3F82A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CD241BD07C80E6E3A1B00C8675A3AFC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FC399BC972538FBE9B3A0C8675A3F82A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CD241BD07C80E6E3A1B00C8675A3AFC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_BEAC4C3606A02BFEC7DE0C8675A46C16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CD241BD07C80E6E3A1B00C8675A3AFC6" xlink:to="loc_biib_IonisPharmaceuticalsMember_BEAC4C3606A02BFEC7DE0C8675A46C16" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_C3E9841707CA70C87B950C8675A493FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CD241BD07C80E6E3A1B00C8675A3AFC6" xlink:to="loc_biib_AlkermesMember_C3E9841707CA70C87B950C8675A493FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_958A7371D6D241B0E6650C8675A4AD31" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_srt_RangeAxis_958A7371D6D241B0E6650C8675A4AD31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_51398EBF26685CC0F82D0C8675A42FA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_958A7371D6D241B0E6650C8675A4AD31" xlink:to="loc_srt_RangeMember_51398EBF26685CC0F82D0C8675A42FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_AC37227E93ACE8C815330C8675A594F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_51398EBF26685CC0F82D0C8675A42FA0" xlink:to="loc_srt_MinimumMember_AC37227E93ACE8C815330C8675A594F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_27EB4AABEC00D601FB510C8675A553C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_51398EBF26685CC0F82D0C8675A42FA0" xlink:to="loc_srt_MaximumMember_27EB4AABEC00D601FB510C8675A553C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_599A727C1026C82FF4190C8675A55C54" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_599A727C1026C82FF4190C8675A55C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_AE7717B62E20457CE5720C8675A501D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_599A727C1026C82FF4190C8675A55C54" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_AE7717B62E20457CE5720C8675A501D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_EFA37BFC1200796029F90C8675A6F657" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_AE7717B62E20457CE5720C8675A501D5" xlink:to="loc_biib_U.S.2017TaxActMember_EFA37BFC1200796029F90C8675A6F657" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_90D3EC5150789A31481E0C8675A66DB1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_90D3EC5150789A31481E0C8675A66DB1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_8F699D3890771B58BA870C8675A620E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_90D3EC5150789A31481E0C8675A66DB1" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_8F699D3890771B58BA870C8675A620E4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_A7CE8C05483BD2B7B7C80C8675A7A165" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_8F699D3890771B58BA870C8675A620E4" xlink:to="loc_biib_DevelopmentMilestonesMember_A7CE8C05483BD2B7B7C80C8675A7A165" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_8F699D3890771B58BA870C8675A620E4" xlink:to="loc_biib_RegulatoryMilestonesMember_0DBC1872F029FA0400D70C8675A73E0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CommercialMilestonesMember" xlink:label="loc_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_8F699D3890771B58BA870C8675A620E4" xlink:to="loc_biib_CommercialMilestonesMember_F14C051F7C3E58FE0A470C8675A81DE5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_267CDBB1374C09D2F8E10C8675A8C09A" xlink:to="loc_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TwentybillionMember" xlink:label="loc_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:to="loc_biib_TwentybillionMember_D17745E6DED6519661620C8675A896E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_B69BF5C3860D55A5AAAA0C8675A84DFF" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_CCC05966A7752E35EDCD0C8675A8960E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_40B139320C27DDA358D60C8675A9359E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_srt_ProductOrServiceAxis_40B139320C27DDA358D60C8675A9359E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_639932BB2B860C9981F50C8675A972B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_40B139320C27DDA358D60C8675A9359E" xlink:to="loc_srt_ProductsAndServicesDomain_639932BB2B860C9981F50C8675A972B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_563DB2F8814468F9E9E20C8675A9AF54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_639932BB2B860C9981F50C8675A972B5" xlink:to="loc_biib_SPINRAZAMember_563DB2F8814468F9E9E20C8675A9AF54" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_VUMERITYMember" xlink:label="loc_biib_VUMERITYMember_E83080ED6B1E35CC22BF0C8675A97FA2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_639932BB2B860C9981F50C8675A972B5" xlink:to="loc_biib_VUMERITYMember_E83080ED6B1E35CC22BF0C8675A97FA2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_E5A94913727D42AD34B80C8675AAE1E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_639932BB2B860C9981F50C8675A972B5" xlink:to="loc_biib_TecfideraMember_E5A94913727D42AD34B80C8675AAE1E4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_989137F31FA9025A00960C8675AAA060" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_biib_FacilityLocationAxis_989137F31FA9025A00960C8675AAA060" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_3DACC39F80CDF170BEEA0C8675AA7922" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_989137F31FA9025A00960C8675AAA060" xlink:to="loc_biib_FacilityLocationDomain_3DACC39F80CDF170BEEA0C8675AA7922" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_07BFE713C77214DAC74E0C8675AA3028" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_3DACC39F80CDF170BEEA0C8675AA7922" xlink:to="loc_biib_SolothurnMember_07BFE713C77214DAC74E0C8675AA3028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_25280FFB5437A0D638420C8675ABFB03" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_25280FFB5437A0D638420C8675ABFB03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1D56ECBBD22D6363161B0C8675ABDD8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_25280FFB5437A0D638420C8675ABFB03" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1D56ECBBD22D6363161B0C8675ABDD8F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_D33FF1948BF80725440F0C8675ABDF4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1D56ECBBD22D6363161B0C8675ABDD8F" xlink:to="loc_biib_TysabriProductMember_D33FF1948BF80725440F0C8675ABDF4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1D56ECBBD22D6363161B0C8675ABDD8F" xlink:to="loc_biib_FumapharmAgMember_7B0B90B2B66C0A4CC47F0C8675ABEB40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7D57EFC27E50A49FE8FD0C8675A248EA" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_F113774D48D67E396F1E0C8675AC5BCC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_biib_FutureContingentPaymentThreshold_8E3A8BB3CD3C93E507100C8675AC20E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_BD8B6305BDC4974D28230C8675AC85E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_BD8B6305BDC4974D28230C8675AC85E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_D0E118AC43D362B6DD110C8675AC286A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_47EF24F136988FDBF13E0C8675ADE249" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_47EF24F136988FDBF13E0C8675ADE249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_04026269389511B527AA0C8675AD585A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_04026269389511B527AA0C8675AD585A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_biib_CumulativeSalesLevel_EBD65F3F3C95F6C35ECC0C8675AD7761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E2F70F9C5EF27BFD6ED10C8675AD089A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_E2F70F9C5EF27BFD6ED10C8675AD089A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_56A2DC5509C0855A46D90C8675AD6E85" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_56A2DC5509C0855A46D90C8675AD6E85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_70B2B6F155C7B69D7C870C8675ADF508" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_OtherCommitment_70B2B6F155C7B69D7C870C8675ADF508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_62AB39EC69AE865AC8290C8675AE1194" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_62AB39EC69AE865AC8290C8675AE1194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_E9D8F6CB3F4B554390980C8675AE3FB0" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E588AD844368BAEB0CC30C8675AC9FEE" xlink:to="loc_us-gaap_IncomeTaxesPaid_E9D8F6CB3F4B554390980C8675AE3FB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E40E7029562D92AFD3630C8675AEE27D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CD55AA012C7D4AC611C40C8675A22B75" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E40E7029562D92AFD3630C8675AEE27D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CD55AA012C7D4AC611C40C8675A22B75" xlink:to="loc_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_59AAB09B87486E0C04DD0C8675AE0DAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC" xlink:to="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_59AAB09B87486E0C04DD0C8675AE0DAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A82F05A3745288165E660C8675AE18B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_24FD96BF5D1A593D000A0C8675AE61BC" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A82F05A3745288165E660C8675AE18B1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89EA1E07CC59DA67195AEBFB60DA95BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_357C2EE3DC202BA3EBEEEBFB60DA561B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89EA1E07CC59DA67195AEBFB60DA95BF" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_357C2EE3DC202BA3EBEEEBFB60DA561B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6AA9560CB6AAAAA4E1ABFC3A1AD3C7AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6AA9560CB6AAAAA4E1ABFC3A1AD3C7AD" xlink:to="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:to="loc_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B846B6164E5CE0F25609FC3A1AD33DF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B846B6164E5CE0F25609FC3A1AD33DF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_E1F55611C1C8A219B20CFC3A1AD331A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_E1F55611C1C8A219B20CFC3A1AD331A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_C5EED5CDF0351F4435D0FC3A1AD3BFFA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_C5EED5CDF0351F4435D0FC3A1AD3BFFA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_97C0CB64BEE3F353B0A2FC3A1AD3BD22" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_97C0CB64BEE3F353B0A2FC3A1AD3BD22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E1923DCA6596C9D05CE6FC3A1AD3ED24" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:to="loc_us-gaap_InventoryNet_E1923DCA6596C9D05CE6FC3A1AD3ED24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_60AFAACF9C6CC3354D71FC3A1AD36B41" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:to="loc_us-gaap_OtherAssetsCurrent_60AFAACF9C6CC3354D71FC3A1AD36B41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_351AFB8DA153B103FD0EFC3A1AD34298" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_FEFF48CFF0A08814F46DFC3A1AD34565" xlink:to="loc_us-gaap_AssetsCurrent_351AFB8DA153B103FD0EFC3A1AD34298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_B985B6FC8EDA7FF6DEFEFC3A1AD33B54" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_B985B6FC8EDA7FF6DEFEFC3A1AD33B54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_71771300A98B74C4C085FC3A1AD39898" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_71771300A98B74C4C085FC3A1AD39898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0DB5B99508AE65CE3ED8FC3A1AD3DE69" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0DB5B99508AE65CE3ED8FC3A1AD3DE69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5AD0F64B96A6DB3870B0FC3A1AD3AB6D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5AD0F64B96A6DB3870B0FC3A1AD3AB6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_FA415BA1A05C5E73EADDFC3A1AD3EC8D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:to="loc_us-gaap_Goodwill_FA415BA1A05C5E73EADDFC3A1AD3EC8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8D4807FEC6181C99AC0FFC3A1AD3FE93" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8D4807FEC6181C99AC0FFC3A1AD3FE93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9A4BBAA18D1995157EE5FC3A1AD30484" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9A4BBAA18D1995157EE5FC3A1AD30484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_970537FF1EF9E101658FFC3A1AD33032" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB73AC8AF2F229C097E6FC3A1AD39A99" xlink:to="loc_us-gaap_Assets_970537FF1EF9E101658FFC3A1AD33032" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6AA9560CB6AAAAA4E1ABFC3A1AD3C7AD" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_C2E6AA164880BB7E746AFC3A1AD3DCA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED" xlink:to="loc_us-gaap_DebtCurrent_C2E6AA164880BB7E746AFC3A1AD3DCA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_580D950B046F49E27B65FC3A1AD36D3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED" xlink:to="loc_us-gaap_TaxesPayableCurrent_580D950B046F49E27B65FC3A1AD36D3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_CFFDE1FB3984767A3874FC3A1AD3A81A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED" xlink:to="loc_us-gaap_AccountsPayableCurrent_CFFDE1FB3984767A3874FC3A1AD3A81A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_80FAEE39F15E87EEA2CCFC3A1AD3FDA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_80FAEE39F15E87EEA2CCFC3A1AD3FDA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_3ED089FD7359BFE81C40FC3A1AD3CCA3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B905EB45CDC89FFA95E9FC3A1AD3DAED" xlink:to="loc_us-gaap_LiabilitiesCurrent_3ED089FD7359BFE81C40FC3A1AD3CCA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7A07141997D75D1E1DA4FC3A1AD3915D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:to="loc_us-gaap_LongTermDebt_7A07141997D75D1E1DA4FC3A1AD3915D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_42DE2478FABA2EA3FAF5FC3A1AD301F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_42DE2478FABA2EA3FAF5FC3A1AD301F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2DE2AEE21F2E89FB0197FC3A1AD3EE58" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2DE2AEE21F2E89FB0197FC3A1AD3EE58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8D748A478462A4EC2131FC3A1AD3AE2A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8D748A478462A4EC2131FC3A1AD3AE2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_756939E94C1CF14EDF9BFC3A1AD3101E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:to="loc_us-gaap_Liabilities_756939E94C1CF14EDF9BFC3A1AD3101E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ADD1ABFFA31A81D0448DFC3A1AD3622F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ADD1ABFFA31A81D0448DFC3A1AD3622F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1963D985E748C5C785E0FC3A1AD38F25" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1963D985E748C5C785E0FC3A1AD38F25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1963D985E748C5C785E0FC3A1AD38F25" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_31D4A1151874A49F3ABAFC3A1AD3A426" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:to="loc_us-gaap_PreferredStockValue_31D4A1151874A49F3ABAFC3A1AD3A426" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_C2335DB03065E992A10CFC3A1AD3D06B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:to="loc_us-gaap_CommonStockValue_C2335DB03065E992A10CFC3A1AD3D06B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9DA4A33CD2DA9D2FA48FFC3A1AD3BD56" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9DA4A33CD2DA9D2FA48FFC3A1AD3BD56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_69122C51AF93BE882D8CFC3A1AD38E49" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_69122C51AF93BE882D8CFC3A1AD38E49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D1213AE2154363B83E5EFC3A1AD343E0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D1213AE2154363B83E5EFC3A1AD343E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_02DCC45CF9B742817AF4FC3A1AD3B496" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:to="loc_us-gaap_TreasuryStockValue_02DCC45CF9B742817AF4FC3A1AD3B496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_327E19C705D2D1E6B773FC3A1AD31E2E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0296DC6046B3E7410CB4FC3A1AD3D815" xlink:to="loc_us-gaap_StockholdersEquity_327E19C705D2D1E6B773FC3A1AD31E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_343C3AC0234DFA2D36BBFC3A1AD3AF01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1963D985E748C5C785E0FC3A1AD38F25" xlink:to="loc_us-gaap_MinorityInterest_343C3AC0234DFA2D36BBFC3A1AD3AF01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB45A3F2AAB8899A45DFC3A1AD349FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1963D985E748C5C785E0FC3A1AD38F25" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB45A3F2AAB8899A45DFC3A1AD349FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_F4A1254452EA2D86DDC1FC3A1AD3F728" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DC1B768225D705BE3C1CFC3A1AD3B8CF" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_F4A1254452EA2D86DDC1FC3A1AD3F728" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_15ED3A862FDB700C62576F39A040F116" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7421F1092E5EE311F15E6F39A04070F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_15ED3A862FDB700C62576F39A040F116" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7421F1092E5EE311F15E6F39A04070F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ACF3AB91C1FF80BFA49D6F39A041BD4A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_15ED3A862FDB700C62576F39A040F116" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ACF3AB91C1FF80BFA49D6F39A041BD4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_360BEF045222D851E2BD6F39A041F37E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_15ED3A862FDB700C62576F39A040F116" xlink:to="loc_us-gaap_TreasuryStockShares_360BEF045222D851E2BD6F39A041F37E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28AB8B37140901BBDD421B9F87F364A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28AB8B37140901BBDD421B9F87F364A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_4D27BE20F761A66A6D5B1B9F87F313D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28AB8B37140901BBDD421B9F87F364A9" xlink:to="loc_us-gaap_ProfitLoss_4D27BE20F761A66A6D5B1B9F87F313D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28AB8B37140901BBDD421B9F87F364A9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_FC68DFF1C4D0C44D16E31B9F87F33901" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_FC68DFF1C4D0C44D16E31B9F87F33901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_1309BA1CF83AD67D747B1B9F87F3529F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_1309BA1CF83AD67D747B1B9F87F3529F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_FDF07AE89C305179DC861B9F87F3BD3B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:to="loc_us-gaap_ShareBasedCompensation_FDF07AE89C305179DC861B9F87F3BD3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_658EF7E132193C8FD59B1B9F87F35F47" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_658EF7E132193C8FD59B1B9F87F35F47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A6B775BADF660C9F0FF41B9F87F3B00C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A6B775BADF660C9F0FF41B9F87F3B00C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_95A3A245EAD803DAE5491B9F87F37AFB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_95A3A245EAD803DAE5491B9F87F37AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_51A4C9686468A6F14DAF1B9F87F34493" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_51A4C9686468A6F14DAF1B9F87F34493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_FD04AF33D79DB7ECB4EE1B9F87F3A11C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_FD04AF33D79DB7ECB4EE1B9F87F3A11C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_FEC6F15DE403E1DB840A1B9F87F3D448" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_FEC6F15DE403E1DB840A1B9F87F3D448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7833ED98181E9FB975651B9F87F35A08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7833ED98181E9FB975651B9F87F35A08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_B0052F6D74E036B9ED731B9F88021091" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_B0052F6D74E036B9ED731B9F88021091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_23F51238266C4D01CF701B9F8802B07B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_23F51238266C4D01CF701B9F8802B07B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A3AE637A72B6D4BCAFE01B9F8802630D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A3AE637A72B6D4BCAFE01B9F8802630D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DA8F361905604996F2811B9F88022ACB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3842AADF36355EEDE1A31B9F87F3FC8D" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DA8F361905604996F2811B9F88022ACB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_742DDF52BC18581F3E801B9F880232C1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D5B7CC108A39E372552A1B9F87F3BA22" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_742DDF52BC18581F3E801B9F880232C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76627EB2DE21165779931B9F88028716" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76627EB2DE21165779931B9F88028716" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_397BDBCB6B0017F804241B9F8802499D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_397BDBCB6B0017F804241B9F8802499D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_9003BCA6B88CA39A90F71B9F88023ABB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_9003BCA6B88CA39A90F71B9F88023ABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_79E9260896A97CCFF2891B9F88024662" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_79E9260896A97CCFF2891B9F88024662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_A4E44D03E3775BAB33C21B9F8802BCFD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_A4E44D03E3775BAB33C21B9F8802BCFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7C6C62E9EC34A7B7A1D31B9F880294CD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7C6C62E9EC34A7B7A1D31B9F880294CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0B0A07E75BD1811A02F31B9F8802B3CE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0B0A07E75BD1811A02F31B9F8802B3CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1791949D48D2064FF4C71B9F8802DDE8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1791949D48D2064FF4C71B9F8802DDE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_422DADE406605C8445231B9F88026514" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_422DADE406605C8445231B9F88026514" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_8AB77F8B69B887332ACD1B9F880253D3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_8AB77F8B69B887332ACD1B9F880253D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_0892F3CCDC82983132D31B9F880214EE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_0892F3CCDC82983132D31B9F880214EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_AAAB526504F628B0CD991B9F8802BBA4" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_AAAB526504F628B0CD991B9F8802BBA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01622FD19CD48004E2181B9F8802A719" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4DB29DD345FAE28C92A51B9F8802E836" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01622FD19CD48004E2181B9F8802A719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5ED38F15249E960D845F1B9F88024C34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5ED38F15249E960D845F1B9F88024C34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_B36AFB77163E5377D3861B9F880268EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_B36AFB77163E5377D3861B9F880268EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_CC9D9F595D65BF655B8F1B9F880226A3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:to="loc_us-gaap_RepaymentsOfDebt_CC9D9F595D65BF655B8F1B9F880226A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_59E518EB08098BDB63971B9F88027500" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_59E518EB08098BDB63971B9F88027500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_A41F6B87BF6E05B7FF2A1B9F88021D49" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_A41F6B87BF6E05B7FF2A1B9F88021D49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_848A7F9326659554CF2C1B9F88028674" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_848A7F9326659554CF2C1B9F88028674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_235911BDEC41C722892C1B9F8802F65A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8DBC2F50B5A56D333E121B9F88025D21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_235911BDEC41C722892C1B9F8802F65A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E1FC98E8EFC993806EAF1B9F8802A10E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E1FC98E8EFC993806EAF1B9F8802A10E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9F26047324892DE85A0F1B9F88022C08" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9F26047324892DE85A0F1B9F88022C08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC3B1A8C0E05B91D1A7A1B9F88021A4E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DC3B1A8C0E05B91D1A7A1B9F88021A4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_015AAE81C04967A0016D1B9F8802116D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82179E76C0480DCC332C1B9F87F32D47" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_015AAE81C04967A0016D1B9F8802116D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3F03AC4D62F499CD16536F399D5363F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_89218AAA56BC74303F406F399D536896" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3F03AC4D62F499CD16536F399D5363F6" xlink:to="loc_us-gaap_NetIncomeLoss_89218AAA56BC74303F406F399D536896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3F03AC4D62F499CD16536F399D5363F6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09EEEF588D9A5189F85C6F399D54C1E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09EEEF588D9A5189F85C6F399D54C1E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_C0E2504275BB88FED1A36F399D548B26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_C0E2504275BB88FED1A36F399D548B26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8569CF4AE21E4AC2D33C6F399D550A2D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8569CF4AE21E4AC2D33C6F399D550A2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_CCE1DD51C7AD9F7B9A226F399D551526" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_CCE1DD51C7AD9F7B9A226F399D551526" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_68F1846C57AA432E16946F399D557758" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_68F1846C57AA432E16946F399D557758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_75A4C7148F8CE6E760696F399D554892" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_75A4C7148F8CE6E760696F399D554892" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_86EC54384807C3A59E116F399D55691C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_86EC54384807C3A59E116F399D55691C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_ECEB4AC79C2DDF2561C76F399D552C20" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_ECEB4AC79C2DDF2561C76F399D552C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_A7D4E5ACC258EF887F7A6F399D56E2DF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_A7D4E5ACC258EF887F7A6F399D56E2DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_865EAE280BE1BE6ED1646F399D565A19" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_865EAE280BE1BE6ED1646F399D565A19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCB07ACF6599B83A990D6F399D56A549" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCB07ACF6599B83A990D6F399D56A549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_FAB86024FAD2460AF7576F399D561D2E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_FAB86024FAD2460AF7576F399D561D2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ABBF25B38E2922B762176F399D5647EA" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ABBF25B38E2922B762176F399D5647EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AD2578D963CDA19DDB1C6F399D5773CA" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AD2578D963CDA19DDB1C6F399D5773CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EEBD0296AC073CDF2AE26F399D57D963" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_E4CFEE8B5AFC1BF9DEC26F399D547DDA" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EEBD0296AC073CDF2AE26F399D57D963" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_50F58CB8CB450AA6EBA4FC3A1AA42C66" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_50F58CB8CB450AA6EBA4FC3A1AA42C66" xlink:to="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_AD556217525BC58FB09BFC3A1AA43D4C" xlink:to="loc_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_9F4402D13E5FDD9D700AFC3A1AA484DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_474388D8FDB9450D8B7FFC3A1AA47479" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_9F4402D13E5FDD9D700AFC3A1AA484DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_203478FC1ABA92FA97C0FC3A1AA45451" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_31D2E19D08A0B3FBE34EFC3A1AA404A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_316064DE1A6B8754DB90FC3A1AA483D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_DFD6F5CC82F9186B937AFC3A1AA42B17" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_3B3FCD7CD84925AE61A5FC3A1AA40119" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_FB7B2A279E4CE1CBA11FFC3A1AA4A6B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AC2B09B012166913C51EFC3A1AA47D7B" xlink:to="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_C4375E6364C2B4355E0DFC3A1AA43AB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_PreferredStockMember_C4375E6364C2B4355E0DFC3A1AA43AB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E7C06F9E6E7D41E7429DFC3A1AA42698" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_CommonStockMember_E7C06F9E6E7D41E7429DFC3A1AA42698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_A21B83E125BDC9555F0AFC3A1AA4D068" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_A21B83E125BDC9555F0AFC3A1AA4D068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C46CC3C7E0D90F3BB6B8FC3A1AA47CF8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C46CC3C7E0D90F3BB6B8FC3A1AA47CF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_04C09F95F67BD0D32151FC3A1AA41430" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_RetainedEarningsMember_04C09F95F67BD0D32151FC3A1AA41430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_4ABC7EB50155A502EAECFC3A1AA41B23" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_TreasuryStockMember_4ABC7EB50155A502EAECFC3A1AA41B23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_670CADE989A15E35A2D7FC3A1AA4F96A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_NoncontrollingInterestMember_670CADE989A15E35A2D7FC3A1AA4F96A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_5532691B3A488C1C2FF7FC3A1AA4762B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_24A9AB8FCA73CC4477B0FC3A1AA4973E" xlink:to="loc_us-gaap_ParentMember_5532691B3A488C1C2FF7FC3A1AA4762B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_192CBF14A15A645A1214FC3A1AA4179A" xlink:to="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB32A3894630873F786FC3A1AB46139" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1CB32A3894630873F786FC3A1AB46139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4C93207A6E5E245764E9FC3A1AB43D8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockholdersEquity_4C93207A6E5E245764E9FC3A1AB43D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_2E15A1D4FEBC09ED6CFFFC3A1AB47067" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_MinorityInterest_2E15A1D4FEBC09ED6CFFFC3A1AB47067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_B9B0262A2B43E7B66E88FC3A1AB484D0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_SharesIssued_B9B0262A2B43E7B66E88FC3A1AB484D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4858CC1E45875A9107AEFC3A1AB4A425" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_NetIncomeLoss_4858CC1E45875A9107AEFC3A1AB4A425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_22888303E59B2FFF7834FC3A1AB47B99" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_22888303E59B2FFF7834FC3A1AB47B99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_CAF51F9886BCB1ABA082FC3A1AB45B66" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_ProfitLoss_CAF51F9886BCB1ABA082FC3A1AB45B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CC568D04A9FB478026CDFC3A1AB42813" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CC568D04A9FB478026CDFC3A1AB42813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C5ED636AAD22A6E12521FC3A1AB40E40" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C5ED636AAD22A6E12521FC3A1AB40E40" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_19A54657C72213F161C9FC3A1AB4AD25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E101F1DBE02AD2F9F07AFC3A1AB458E7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E101F1DBE02AD2F9F07AFC3A1AB458E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_CE6D75ACCE181763AB5DFC3A1AB4B747" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_CE6D75ACCE181763AB5DFC3A1AB4B747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_1B18C36EA1557B3EE622FC3A1AB4B392" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_1B18C36EA1557B3EE622FC3A1AB4B392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_3878C856A7FED6942C68FC3A1AB4FF0D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_3878C856A7FED6942C68FC3A1AB4FF0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_DACA7007DC250FBD6F6AFC3A1AB4D5C0" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_DACA7007DC250FBD6F6AFC3A1AB4D5C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECE4BE041B7411EF9D19FC3A1AB47A9D" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECE4BE041B7411EF9D19FC3A1AB47A9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45AEFB62A5939A5EF084FC3A1AB4DDB1" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45AEFB62A5939A5EF084FC3A1AB4DDB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_049478C623265A8E26A8FC3A1AB425A6" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_049478C623265A8E26A8FC3A1AB425A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_719AACFB26E98D1AC2C5FC3A1AB46515" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_719AACFB26E98D1AC2C5FC3A1AB46515" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_86385E395690BB29072EFC3A1AB4F697" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_86385E395690BB29072EFC3A1AB4F697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_323C80A1B7AE067ACDA8FC3A1AB42352" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockholdersEquityOther_323C80A1B7AE067ACDA8FC3A1AB42352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_C20D6B1759FAE3C4EB5AFC3A1AB434D2" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_C20D6B1759FAE3C4EB5AFC3A1AB434D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_StockholdersEquityTaxBenefitExpense" xlink:label="loc_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_biib_StockholdersEquityTaxBenefitExpense_1F21FFE749D2B99E8697FC3A1AB49CFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_66707D7FD5DA2096E29BFC3A1AB41812" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_66707D7FD5DA2096E29BFC3A1AB41812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_AC0E5AD23A9F0F379A30FC3A1AB470AE" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_StockholdersEquity_AC0E5AD23A9F0F379A30FC3A1AB470AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_D676A0B64131E91A66E2FC3A1AB452CB" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_MinorityInterest_D676A0B64131E91A66E2FC3A1AB452CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_AC06F04D6521DCA52999FC3A1AB46204" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEFE1886051159C065B4FC3A1AA4BE8F" xlink:to="loc_us-gaap_SharesIssued_AC06F04D6521DCA52999FC3A1AB46204" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EB27FDCBCAEE09B40213FC3A1AE3D5A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="loc_us-gaap_StatementTable_EB27FDCBCAEE09B40213FC3A1AE3D5A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F4192C737649B3F55621FC3A1AE3CA1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EB27FDCBCAEE09B40213FC3A1AE3D5A0" xlink:to="loc_srt_ProductOrServiceAxis_F4192C737649B3F55621FC3A1AE3CA1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E432062CB68C3D182EB4FC3A1AE38FF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_F4192C737649B3F55621FC3A1AE3CA1B" xlink:to="loc_srt_ProductsAndServicesDomain_E432062CB68C3D182EB4FC3A1AE38FF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_D9A91F858E49BBBD5EE6FC3A1AF3B7D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E432062CB68C3D182EB4FC3A1AE38FF6" xlink:to="loc_us-gaap_ProductMember_D9A91F858E49BBBD5EE6FC3A1AF3B7D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3E0B5EBB3131ED1F69C3FC3A1AF36B8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E432062CB68C3D182EB4FC3A1AE38FF6" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3E0B5EBB3131ED1F69C3FC3A1AF36B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_94AC3E4886E3409182B9FC3A1AF31BC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E432062CB68C3D182EB4FC3A1AE38FF6" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_94AC3E4886E3409182B9FC3A1AF31BC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_651E6848693DE0AB5F53FC3A1AF37A96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EB27FDCBCAEE09B40213FC3A1AE3D5A0" xlink:to="loc_us-gaap_StatementLineItems_651E6848693DE0AB5F53FC3A1AF37A96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C6EF5871A366ACBAD91EFC3A1AF3D62E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_651E6848693DE0AB5F53FC3A1AF37A96" xlink:to="loc_us-gaap_Revenues_C6EF5871A366ACBAD91EFC3A1AF3D62E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_B762688192737C811FDAFC3A1AF378C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_B762688192737C811FDAFC3A1AF378C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_033E3246820EAB7C5C05FC3A1AF32B7C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_033E3246820EAB7C5C05FC3A1AF32B7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_73A77A9707F04B9977F2FC3A1AF3DA74" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_73A77A9707F04B9977F2FC3A1AF3DA74" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_DEAC7146074712F5BFC2FC3A1AF32E7E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_DEAC7146074712F5BFC2FC3A1AF32E7E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_024F2E7942C51467EBAFFC3A1AF3085B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:to="loc_biib_CollaborationProfitSharing_024F2E7942C51467EBAFFC3A1AF3085B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_9662E8C4F5581A5E3CB0FC3A1AF3051B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_9662E8C4F5581A5E3CB0FC3A1AF3051B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_40D8DE9997FCF5D5F892FC3A1AF3A139" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_40D8DE9997FCF5D5F892FC3A1AF3A139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4BAD0D54A2150B1EAE06FC3A1AF374DD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4BAD0D54A2150B1EAE06FC3A1AF374DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1C8015306298D9EE38F7FC3A1AF35DBB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:to="loc_us-gaap_RestructuringCharges_1C8015306298D9EE38F7FC3A1AF35DBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_4A7CFE37BA5736A14AAFFC3A1AF36283" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AA0C5C35A3A62DFD1A13FC3A1AF31E77" xlink:to="loc_us-gaap_CostsAndExpenses_4A7CFE37BA5736A14AAFFC3A1AF36283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_32E8EF0686EB6153CA64FC3A1AF3B3B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="loc_us-gaap_OperatingIncomeLoss_32E8EF0686EB6153CA64FC3A1AF3B3B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1A36B6B5200193CA3ED2FC3A1AF31021" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1A36B6B5200193CA3ED2FC3A1AF31021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DAD037E1E4F0BEE9528BFC3A1AF369D3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DAD037E1E4F0BEE9528BFC3A1AF369D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A2DF3F0DBCB04C059D80FC3A1AF39DFC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_A2DF3F0DBCB04C059D80FC3A1AF39DFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_916E1D33C12079DD6BD0FC3A1AF38C1E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_916E1D33C12079DD6BD0FC3A1AF38C1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_BDB5C779AA5F40F08888FC3A1AF3ADC9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="loc_us-gaap_ProfitLoss_BDB5C779AA5F40F08888FC3A1AF3ADC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_69E3BB35215116DC803BFC3A1AF357D5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_69E3BB35215116DC803BFC3A1AF357D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_757294C4735855C6C0CCFC3A1AF35EE0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="loc_us-gaap_NetIncomeLoss_757294C4735855C6C0CCFC3A1AF35EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_755DFD10A4775E3E26E7FC3A1AF3D677" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="loc_us-gaap_EarningsPerShareAbstract_755DFD10A4775E3E26E7FC3A1AF3D677" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_42302C4BF1F532D2446CFC3A1AF371A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_755DFD10A4775E3E26E7FC3A1AF3D677" xlink:to="loc_us-gaap_EarningsPerShareBasic_42302C4BF1F532D2446CFC3A1AF371A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C62074CE0F9C223A11B3FC3A1AF316FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_755DFD10A4775E3E26E7FC3A1AF3D677" xlink:to="loc_us-gaap_EarningsPerShareDiluted_C62074CE0F9C223A11B3FC3A1AF316FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EB12AA9831F85409BCD7FC3A1AF3D5D4" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DFEB5268FBD23F7AD2DBFC3A1AE354A9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EB12AA9831F85409BCD7FC3A1AF3D5D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FD4DB1B4D55EF4E19B86FC3A1AF34776" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EB12AA9831F85409BCD7FC3A1AF3D5D4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FD4DB1B4D55EF4E19B86FC3A1AF34776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_084C477E2A2D7E2366A8FC3A1AF31A38" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EB12AA9831F85409BCD7FC3A1AF3D5D4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_084C477E2A2D7E2366A8FC3A1AF31A38" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_B4BF5AF3C35858B2086616203EC4EB87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_DocumentType_B4BF5AF3C35858B2086616203EC4EB87" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_49D824E877E80BCC467C16203EC4F257" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_DocumentAnnualReport_49D824E877E80BCC467C16203EC4F257" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_312C308E01707949C61A16203EC4BF14" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_DocumentPeriodEndDate_312C308E01707949C61A16203EC4BF14" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_34DC106B60949B486BA916203EC58A08" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_DocumentTransitionReport_34DC106B60949B486BA916203EC58A08" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_7429B4B67497A681470616203EC5AA0C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityFileNumber_7429B4B67497A681470616203EC5AA0C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_CF472858A50BC712751C16203EC50838" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityRegistrantName_CF472858A50BC712751C16203EC50838" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_868B6025ECD53F50174F16203EC58566" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_868B6025ECD53F50174F16203EC58566" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_97C57CAE8BDAB35E92FA16203EC543E8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityTaxIdentificationNumber_97C57CAE8BDAB35E92FA16203EC543E8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_0C67F73B75681DF2483C16203EC54F3E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityAddressAddressLine1_0C67F73B75681DF2483C16203EC54F3E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_C2C37F35084BFA3EF95216203EC6EE71" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityAddressCityOrTown_C2C37F35084BFA3EF95216203EC6EE71" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_32E8FC8450836488459016203EC679C6" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityAddressStateOrProvince_32E8FC8450836488459016203EC679C6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_52411D920280D999EDE316203EC69D9D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityAddressPostalZipCode_52411D920280D999EDE316203EC69D9D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_4DD43C09D1403B5115BC16203EC68326" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_CityAreaCode_4DD43C09D1403B5115BC16203EC68326" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_520E177E587A0EBC570816203EC6D624" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_LocalPhoneNumber_520E177E587A0EBC570816203EC6D624" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_BD17A69517D0815A5C1916203EC67842" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_Security12bTitle_BD17A69517D0815A5C1916203EC67842" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_591C686A080EFB1520F116203EC7ADB7" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_TradingSymbol_591C686A080EFB1520F116203EC7ADB7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_09659E6742B90359BE0416203EC76FD3" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_SecurityExchangeName_09659E6742B90359BE0416203EC76FD3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0558EA3E4BDEB8DD74F716203EC75123" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0558EA3E4BDEB8DD74F716203EC75123" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_546FD0343B9981149DC316203EC70129" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityVoluntaryFilers_546FD0343B9981149DC316203EC70129" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9B045F9887981037E2E916203EC765B6" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityCurrentReportingStatus_9B045F9887981037E2E916203EC765B6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_34B98215D91B5B9CB3671640771E9A8C" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityInteractiveDataCurrent_34B98215D91B5B9CB3671640771E9A8C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_85DC6C48FF67BDCBB44E16203EC8E5EF" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityFilerCategory_85DC6C48FF67BDCBB44E16203EC8E5EF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_4F990CA4AF5989183E1D16203EC832D4" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntitySmallBusiness_4F990CA4AF5989183E1D16203EC832D4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_6F9119F5E97219879D7216203EC827C4" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityEmergingGrowthCompany_6F9119F5E97219879D7216203EC827C4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_A86DFBF5FCEAF615BC2816203EC82C80" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityShellCompany_A86DFBF5FCEAF615BC2816203EC82C80" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_02AB94B10D101AB04B6316203EC84DDE" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityPublicFloat_02AB94B10D101AB04B6316203EC84DDE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3BC6008371F5B13D1B8316203EC8D2A4" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3BC6008371F5B13D1B8316203EC8D2A4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_D48DC8AE36914FDD1F3016203EC93797" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_EntityCentralIndexKey_D48DC8AE36914FDD1F3016203EC93797" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_21B35CA7F0A783C3B68B16203EC9D5A7" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_CurrentFiscalYearEndDate_21B35CA7F0A783C3B68B16203EC9D5A7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_095D17B772D414AA5E0116203EC9FA28" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_DocumentFiscalYearFocus_095D17B772D414AA5E0116203EC9FA28" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A1A03846EB84C622E08316203EC90715" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_A1A03846EB84C622E08316203EC90715" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_0FA9798B03AE21DF016A16203EC94B85" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFFFCB74AFFF7B41BDEC16203EBF43B7" xlink:to="loc_dei_AmendmentFlag_0FA9798B03AE21DF016A16203EC94B85" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8981C87507688FD65E996F399EEC89FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B5A0CE3A7F0D4A644F786F399EEC8382" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8981C87507688FD65E996F399EEC89FB" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B5A0CE3A7F0D4A644F786F399EEC8382" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8E5F7B3C49B8C654F7137F76C6A0178B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8E5F7B3C49B8C654F7137F76C6A0178B" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D867A205490C0B2922CB7F76C6A075FA" xlink:to="loc_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:to="loc_biib_CashflowsrevenueMember_13EEE0384AFFDEE3B44C7F76C6A088A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_B99EFCF1E10140C07EE77F76C6A09B9A" xlink:to="loc_biib_CashflowsoperatingexpensesMember_96C4B98059D26C7B3E177F76C6A02701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5BD710A8F4E2BA1F06EB7F76C6A009ED" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_F7143801E83BC5B123EB7F76C6A0DE9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ECFAD630F7B0EC512EEB7F76C6A08272" xlink:to="loc_us-gaap_ForeignExchangeContractMember_F7143801E83BC5B123EB7F76C6A0DE9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_926DAEE396A52D0C98947F76C6A0F581" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_7FD49F6F171BAE669FB37F76C6A0F189" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:to="loc_us-gaap_SalesMember_7FD49F6F171BAE669FB37F76C6A0F189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_D9CF03CF35B366E3338A7F76C6A0BDBD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_D9CF03CF35B366E3338A7F76C6A0BDBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_F8D065D1277BBF1B838D7F76C6A0308D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6C22D7D990FC15B23B457F76C6A0E82E" xlink:to="loc_us-gaap_OperatingExpenseMember_F8D065D1277BBF1B838D7F76C6A0308D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5BAB08B6E9B46549137E7F76C6A0E8E5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C543897AE2FCCA8630FD7F76C6A0A66D" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_39FCD8D0CBEECF3556BD7F76C6A041ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_39FCD8D0CBEECF3556BD7F76C6A041ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_43F17C9C58440E46239E7F76C6A09471" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_04390B8BF4F5D7BC714C7F76C6A0DB50" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_43F17C9C58440E46239E7F76C6A09471" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7FE502C684D437FC8FDF7F76C690BC02" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_B58A1967EC9B168BCC757F76C690C225" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7FE502C684D437FC8FDF7F76C690BC02" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_B58A1967EC9B168BCC757F76C690C225" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_B58A1967EC9B168BCC757F76C690C225" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_AB16608A528535DA7C757F76C690D769" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_E45F3B498A681956084D7F76C6901614" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5D66190222C25D38A6117F76C690C115" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B71AFAE27DBDDFF3B6C87F76C69015CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_B58A1967EC9B168BCC757F76C690C225" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B71AFAE27DBDDFF3B6C87F76C69015CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B71AFAE27DBDDFF3B6C87F76C69015CF" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3F69C43F9C61E4EDCF327F76C6905B43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C8F62AD0A07FB9E45E377F76C690E218" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3F69C43F9C61E4EDCF327F76C6905B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_C4A6182E74E9F16A6F967F76C6A08541" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_B58A1967EC9B168BCC757F76C690C225" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_C4A6182E74E9F16A6F967F76C6A08541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_55ACF24C3BC414F092387F76C6A0B847" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_C4A6182E74E9F16A6F967F76C6A08541" xlink:to="loc_us-gaap_HedgingRelationshipDomain_55ACF24C3BC414F092387F76C6A0B847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_3E6205DF1A52677B47A87F76C6A038B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_55ACF24C3BC414F092387F76C6A0B847" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_3E6205DF1A52677B47A87F76C6A038B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_B58A1967EC9B168BCC757F76C690C225" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E6146AD1F4A82FDEB83E7F76C6A0EA91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_FB0030892F62A131B32F7F76C6A08AED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_FB0030892F62A131B32F7F76C6A08AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7CDA26968851201A7C007F76C6A033AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7CDA26968851201A7C007F76C6A033AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_99BE826E7C45D4A6BCEC7F76C6A00943" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_DerivativeTermOfContract_99BE826E7C45D4A6BCEC7F76C6A00943" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_BDF6744AB5B6C371FA4E7F76C6A015F4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_BDF6744AB5B6C371FA4E7F76C6A015F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_BBFB57BFF247A49314E67FEAC476EC4C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_BBFB57BFF247A49314E67FEAC476EC4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_14EEC61E0822B099E5797FEDB19A4E0C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_14EEC61E0822B099E5797FEDB19A4E0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_3EBA5BD160DC553A8C9C7FEFA5DEF99D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_92DF02E344F51A04EF377FF069DC6D1A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_B5040303C09696BD036E7F76C6A0A487" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_92DF02E344F51A04EF377FF069DC6D1A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9E0A2A4B7173827D26B7FCF51ECE2F2E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9E0A2A4B7173827D26B7FCF51ECE2F2E" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:to="loc_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_05652C75FE9A5CD6CB7EFCF51ECF7B57" xlink:to="loc_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_DDB61ED64A27E97B552BFCF51ECF4440" xlink:to="loc_biib_ShorttermderivativeMember_E878BC34E8FAB4CD4481FCF51ECFC9B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:to="loc_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_A10A45153FD9DE45AF45FCF51ECF61FC" xlink:to="loc_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_CDD1CF693055B98DA2B9FCF51ED0F24A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:to="loc_srt_MinimumMember_CDD1CF693055B98DA2B9FCF51ED0F24A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5003142FEFA747B56A16FCF51ED0D674" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_FEDD361157DE5CE7E025FCF51ED0ACFE" xlink:to="loc_srt_MaximumMember_5003142FEFA747B56A16FCF51ED0D674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:to="loc_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7BE633505D4ACF94CA5BFCF51ED00DD2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DF44F63A2223CD2BC16DFCF51ED0EC7A" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6B703845B5BDEA0FCED3FCF51ED1FF0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_DF893C7C6FE6A28233FAFCF51ED176DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_DF893C7C6FE6A28233FAFCF51ED176DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_94F8528B4EA491FD9B2DFCF51ED15C49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_DF893C7C6FE6A28233FAFCF51ED176DC" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_94F8528B4EA491FD9B2DFCF51ED15C49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_8C7BE29FC35140420308FCF51ED1A4FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94F8528B4EA491FD9B2DFCF51ED15C49" xlink:to="loc_us-gaap_ForeignExchangeContractMember_8C7BE29FC35140420308FCF51ED1A4FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_6D8CA0B25D65E8B800F8FCF51ED2F858" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94F8528B4EA491FD9B2DFCF51ED15C49" xlink:to="loc_us-gaap_InterestRateSwapMember_6D8CA0B25D65E8B800F8FCF51ED2F858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_C205A9E4B83A52F77C7AFCF51ED2DF40" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:to="loc_us-gaap_HedgingDesignationAxis_C205A9E4B83A52F77C7AFCF51ED2DF40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_76807C3342A7A5022579FCF51ED24B87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_C205A9E4B83A52F77C7AFCF51ED2DF40" xlink:to="loc_us-gaap_HedgingDesignationDomain_76807C3342A7A5022579FCF51ED24B87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9D92629E3A9B9D1F8F3BFCF51ED2C5A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_76807C3342A7A5022579FCF51ED24B87" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9D92629E3A9B9D1F8F3BFCF51ED2C5A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_235E3BAB8A6AEFAE248AFCF51ED341B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_76807C3342A7A5022579FCF51ED24B87" xlink:to="loc_us-gaap_NondesignatedMember_235E3BAB8A6AEFAE248AFCF51ED341B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_0711FB78A5D2ECD964E9FCF51ED3B44B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0397925C39B868E04526FCF51ECEAA58" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_0711FB78A5D2ECD964E9FCF51ED3B44B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D1CD098DC668F62AEFFFFCF51ED38001" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0711FB78A5D2ECD964E9FCF51ED3B44B" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D1CD098DC668F62AEFFFFCF51ED38001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_892C105917ABD6F23757FCF51ED3BD85" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0711FB78A5D2ECD964E9FCF51ED3B44B" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_892C105917ABD6F23757FCF51ED3BD85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76F54A915B22B31BB774FCF51ED31186" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0711FB78A5D2ECD964E9FCF51ED3B44B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76F54A915B22B31BB774FCF51ED31186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_BAD03AC5E4BB35A1BDA4FD20C407B0BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0711FB78A5D2ECD964E9FCF51ED3B44B" xlink:to="loc_us-gaap_DerivativeNotionalAmount_BAD03AC5E4BB35A1BDA4FD20C407B0BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_BE856A7776C037A7B703FCF51ED4C9D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9E0A2A4B7173827D26B7FCF51ECE2F2E" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_BE856A7776C037A7B703FCF51ED4C9D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4B55BB180FD65F568600FCF51EDB0400" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4B55BB180FD65F568600FCF51EDB0400" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4A902EF704F0F376CC07FD17F6580A6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4A902EF704F0F376CC07FD17F6580A6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_A2C2DAF1974FD831B44BFD17F65B57AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4A902EF704F0F376CC07FD17F6580A6F" xlink:to="loc_us-gaap_HedgingRelationshipDomain_A2C2DAF1974FD831B44BFD17F65B57AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_E8936D94F20BCDB64EB1FD18A113E297" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A2C2DAF1974FD831B44BFD17F65B57AF" xlink:to="loc_us-gaap_CashFlowHedgingMember_E8936D94F20BCDB64EB1FD18A113E297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_67E6394D081243CD5B60FD1ADE9C7657" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A2C2DAF1974FD831B44BFD17F65B57AF" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_67E6394D081243CD5B60FD1ADE9C7657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_47673DA298D702070E1CFD1C05396984" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A2C2DAF1974FD831B44BFD17F65B57AF" xlink:to="loc_us-gaap_FairValueHedgingMember_47673DA298D702070E1CFD1C05396984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:to="loc_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_C0B2F841AF868064FF4DFCF51EDB2831" xlink:to="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_014E7BBE8633CA0EAF3CFCF51EDC643B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:to="loc_currency_EUR_014E7BBE8633CA0EAF3CFCF51EDC643B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_E63FE173CD98770E57CBFCF51EDC1331" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:to="loc_currency_GBP_E63FE173CD98770E57CBFCF51EDC1331" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_661B095833E0EF874A49FCF51EDC661C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:to="loc_currency_CHF_661B095833E0EF874A49FCF51EDC661C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_E677BDEB8AAF39400771FCF51EDDC84A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:to="loc_currency_CAD_E677BDEB8AAF39400771FCF51EDDC84A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_F79C256AB33910A52E4DFCF51EDDE183" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8609054DD6AB096147F4FCF51EDCF956" xlink:to="loc_currency_JPY_F79C256AB33910A52E4DFCF51EDDE183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5F57E7024D385844C9A2FCF51EDD7258" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5F57E7024D385844C9A2FCF51EDD7258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_43879CE4DCD046A79DE2FCF51EDDE7EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5F57E7024D385844C9A2FCF51EDD7258" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_43879CE4DCD046A79DE2FCF51EDDE7EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_BDE5CF715DB16822DD60FCF51EDDA1B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_43879CE4DCD046A79DE2FCF51EDDE7EC" xlink:to="loc_us-gaap_ForeignExchangeContractMember_BDE5CF715DB16822DD60FCF51EDDA1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_2A52826E1666B86FB9EAFCF51EDE0FC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_43879CE4DCD046A79DE2FCF51EDDE7EC" xlink:to="loc_us-gaap_InterestRateSwapMember_2A52826E1666B86FB9EAFCF51EDE0FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8D2F268C8B14DCEE1EECFCF51EDEA1AE" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_6AB22CD1F508566098E1FCF51EDE8EFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_6AB22CD1F508566098E1FCF51EDE8EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_6FBA81798B549164DB04FCF51EDFF9C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_6FBA81798B549164DB04FCF51EDFF9C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9268C4C0875B50CD57CCFCF51EDF3DC9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6CCA086C7A59B3EA5304FCF51EDEE7C2" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9268C4C0875B50CD57CCFCF51EDF3DC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:to="loc_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_622019781C0FDE18D9E1FCF51EDFB0EB" xlink:to="loc_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_BD5AE0DFF3DC5565DE58FD06B3E33926" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_BD5AE0DFF3DC5565DE58FD06B3E33926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_3948356665010DCDA2B6FCF51EE07FDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_66988424B8762780C2FEFCF51EDFE4B4" xlink:to="loc_us-gaap_NondesignatedMember_3948356665010DCDA2B6FCF51EE07FDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2A0A531CEAAFD4A1CE4BFCF51EDBC5EB" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_B9A54997FB803079A8EBFD217CD1E0E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:to="loc_us-gaap_DerivativeNotionalAmount_B9A54997FB803079A8EBFD217CD1E0E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_AF727BB1A58436465A41FCF51EE1F90A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_31108D5A1A53676F77C1FCF51EE09ABF" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_AF727BB1A58436465A41FCF51EE1F90A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_47D6640545E2E5025D0AFCF51EE1DD57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_AF727BB1A58436465A41FCF51EE1F90A" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_47D6640545E2E5025D0AFCF51EE1DD57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_95EDAA1E76883AF40471FCF51EE1AD38" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_AF727BB1A58436465A41FCF51EE1F90A" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_95EDAA1E76883AF40471FCF51EE1AD38" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A8505970A4742888A0316F399E8482B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_5B609531B3C68A8E94A46F399E842315" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A8505970A4742888A0316F399E8482B9" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_5B609531B3C68A8E94A46F399E842315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A7CFB981D65C925382F86F399E849B21" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A8505970A4742888A0316F399E8482B9" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A7CFB981D65C925382F86F399E849B21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_389CB70F0405AEF3C6CC6F399E844541" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A8505970A4742888A0316F399E8482B9" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_389CB70F0405AEF3C6CC6F399E844541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_AC9490D58B82CB09010A6F399E856B3C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A8505970A4742888A0316F399E8482B9" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_AC9490D58B82CB09010A6F399E856B3C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended">
    <link:loc xlink:href="biib-20191231.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_5783BC4EA9869573CBB17EF7C7D90FE8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97E0B2C5B625B4E06BAD7EF7C7E766EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_5783BC4EA9869573CBB17EF7C7D90FE8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97E0B2C5B625B4E06BAD7EF7C7E766EF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20191231.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_8427159146DD24F72434E86FAF5338B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6791A90EE8A42190CD9BE86FAF549B39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_8427159146DD24F72434E86FAF5338B0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6791A90EE8A42190CD9BE86FAF549B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29BAE72C836AA0BFF7D5E86FAF54CD28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6791A90EE8A42190CD9BE86FAF549B39" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29BAE72C836AA0BFF7D5E86FAF54CD28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_14993D6F0E850BF0A6F6E86FAF54216B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29BAE72C836AA0BFF7D5E86FAF54CD28" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_14993D6F0E850BF0A6F6E86FAF54216B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_65329C889463359F023BE86FAF54DC4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_14993D6F0E850BF0A6F6E86FAF54216B" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_65329C889463359F023BE86FAF54DC4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6791A90EE8A42190CD9BE86FAF549B39" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E3594119CB6FB5F85FFCE86FAF554690" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E3594119CB6FB5F85FFCE86FAF554690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_10E9541C698A0047E28CE86FAF550D2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_10E9541C698A0047E28CE86FAF550D2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_F138BC84321FF9AC4B02E86FAF55C71E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_F138BC84321FF9AC4B02E86FAF55C71E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_494306C850B7F75882DFE86FAF56A922" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_494306C850B7F75882DFE86FAF56A922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7F2FF7C0DB4B02E1EC27E86FAF560F4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7F2FF7C0DB4B02E1EC27E86FAF560F4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5ABA8686DD864D533267E86FAF560C14" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5ABA8686DD864D533267E86FAF560C14" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_25293F9025DE851D65C2E86FAF5627B4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F68315783398F0522A9BE86FAF55B193" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_25293F9025DE851D65C2E86FAF5627B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_DF533F80074DCB3D2E256F39A00F6ADB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7B27D76DD763055BB02A6F39A00F7D02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DF533F80074DCB3D2E256F39A00F6ADB" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7B27D76DD763055BB02A6F39A00F7D02" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_68A45F559ECC6D28AA736F399F19F279" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_68A45F559ECC6D28AA736F399F19F279" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1332BBB4CFEA9D14BAFA6F399F1A10E1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A428D7E218E0FA28BDB46F399F1AD9FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_DA0D1F8D2AE148901FBC6F399F1B8D87" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_DA0D1F8D2AE148901FBC6F399F1B8D87" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_B166F44B91908207BBCD6F399F1BB179" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:to="loc_biib_MarketStockUnitsMember_B166F44B91908207BBCD6F399F1BB179" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_BB243EC4EED46BCFD8CE6F399F1BC1A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242ADC78A1538DE3968C6F399F1AE609" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_BB243EC4EED46BCFD8CE6F399F1BC1A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D24AFBEF7313FF8F5E6F399F1AAEE8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_DB52EA82E3C744FD0CA56F399F1BC1E3" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:to="loc_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7E8FD03632804502F0426F399F1C1846" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_NumeratorAbstract_316810B3DAE2DF23CB676F399F1C2185" xlink:to="loc_us-gaap_NetIncomeLoss_7E8FD03632804502F0426F399F1C1846" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_EF206DFB3274915C36B26F399F1CA54B" xlink:to="loc_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40DF59820B73F944DA5E6F399F1DF763" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40DF59820B73F944DA5E6F399F1DF763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F65164270B49FA7871746F399F1D2E31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F65164270B49FA7871746F399F1D2E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_AAA3F08ACC01968679FD6F399F1D65DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_C7F563CBA7654D1B1E4D6F399F1D2FB7" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_AAA3F08ACC01968679FD6F399F1D65DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4A482ADF86C095345CFD6F399F1ED3B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_A18B458C7C89FDCF380E6F399F1C232B" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4A482ADF86C095345CFD6F399F1ED3B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EarningsPerShareTextualAbstract" xlink:label="loc_biib_EarningsPerShareTextualAbstract_503EF4B8223E17E2E38B6F399F1EB982" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_68A45F559ECC6D28AA736F399F19F279" xlink:to="loc_biib_EarningsPerShareTextualAbstract_503EF4B8223E17E2E38B6F399F1EB982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_58C9E271E389F05412816F399F1E8424" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EarningsPerShareTextualAbstract_503EF4B8223E17E2E38B6F399F1EB982" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_58C9E271E389F05412816F399F1E8424" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_404F274EFAB7E980DE276F399D5F8394" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C62C3C06A0AB24DCAC9A6F399D606100" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_404F274EFAB7E980DE276F399D5F8394" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C62C3C06A0AB24DCAC9A6F399D606100" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_F199692216DBFC3B527C6F399BDE3465" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_E70450EA624BE50C9DF06F399BDE5BA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_F199692216DBFC3B527C6F399BDE3465" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_E70450EA624BE50C9DF06F399BDE5BA6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_54270F33D2F194D30B620B3C1FD2BBC7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_54270F33D2F194D30B620B3C1FD2BBC7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_3C78F42C762DAEB6E9BE0B55F99F176F" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_FE8DCDB7EE1242D71A570B7371771853" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_B9817A8DD0C1096497F70B767CFE9422" xlink:to="loc_us-gaap_ForeignPlanMember_FE8DCDB7EE1242D71A570B7371771853" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="loc_country_DE_84428133EDB9BBFA87200B58B70F423C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_FE8DCDB7EE1242D71A570B7371771853" xlink:to="loc_country_DE_84428133EDB9BBFA87200B58B70F423C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CH" xlink:label="loc_country_CH_7A74F631FD2C04BC73E50B563501F629" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_FE8DCDB7EE1242D71A570B7371771853" xlink:to="loc_country_CH_7A74F631FD2C04BC73E50B563501F629" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_86C266BE2E1B0CEC94A80B3C1FD27085" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_86C266BE2E1B0CEC94A80B3C1FD27085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DE567B09FF1508FFFE8A0B3C1FD205FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_86C266BE2E1B0CEC94A80B3C1FD27085" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DE567B09FF1508FFFE8A0B3C1FD205FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B5EB7E24897F5FA82D470B3C1FD27A97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DE567B09FF1508FFFE8A0B3C1FD205FB" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B5EB7E24897F5FA82D470B3C1FD27A97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_EC8D8A0D86A6AC1B13B80B3C1FD25116" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_E3692299992317777F410B3C1FD2BD88" xlink:to="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:to="loc_biib_PercentageOfMinimumInvestmentReturn_C77F3640BBA27A827EF30B3C1FD20019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6F06D4C0F7F04030A1060B3C1FD2DE3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6F06D4C0F7F04030A1060B3C1FD2DE3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_232F421636FD0AB3784A0B3C1FD26067" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_232F421636FD0AB3784A0B3C1FD26067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_3AC99CC2E4557EAB0A980B3C1FD23222" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:to="loc_us-gaap_PensionExpense_3AC99CC2E4557EAB0A980B3C1FD23222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6274612FB58D71C8A7040B3C1FE25D45" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_5FC301D7A009FCCDC0EE0B3C1FD28EE7" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6274612FB58D71C8A7040B3C1FE25D45" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_AF618E4C5FAC4FF5A208FCF51C9F2969" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_AF618E4C5FAC4FF5A208FCF51C9F2969" xlink:to="loc_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0C7B5E0EE52F55C18530FCF51CA0AD55" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_4DC6859EE83859CC348CFCF51CA18AD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:to="loc_us-gaap_DomesticPlanMember_4DC6859EE83859CC348CFCF51CA18AD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_858891173BDC975B182AFCF51CA1169D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9685F0603158157AC808FCF51CA0A481" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_858891173BDC975B182AFCF51CA1169D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_E8D9EFB13B95648A3E88FCF51CA04FC8" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:to="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_12F01D67BABFA95E26DBFCF51CA16BA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_3DD9981BA31F6B510465FCF51CA18256" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_3DD9981BA31F6B510465FCF51CA18256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_061FE137DDDF00D172D8FCF51CA284D1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0743063076B92F4C6DADFCF51CA18574" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_061FE137DDDF00D172D8FCF51CA284D1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0E28E42B16D1B11FEFBE6F399CE76BFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67CD8AB7D6A5CD40CBE76F399CE81A90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0E28E42B16D1B11FEFBE6F399CE76BFA" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67CD8AB7D6A5CD40CBE76F399CE81A90" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20191231.xsd#biib_AccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_AccumulatedOtherComprehensiveIncomeLossAbstract_6D09A3AA9B22D316909EFCF51E4CDEB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AccumulatedOtherComprehensiveIncomeLossAbstract_6D09A3AA9B22D316909EFCF51E4CDEB2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748885FAC453D7BAE281FCF51E4C1F9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748885FAC453D7BAE281FCF51E4C1F9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_FBEFEC0ACF51C956A932FCF51E4D6104" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748885FAC453D7BAE281FCF51E4C1F9D" xlink:to="loc_us-gaap_TypeOfAdoptionMember_FBEFEC0ACF51C956A932FCF51E4D6104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_5EF9A7B102101C7C3E3AFCF51E4D5580" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_FBEFEC0ACF51C956A932FCF51E4D6104" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_5EF9A7B102101C7C3E3AFCF51E4D5580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_DAAB36172F696FE703F6FCF51E4DFA66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_DAAB36172F696FE703F6FCF51E4DFA66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DAAB36172F696FE703F6FCF51E4DFA66" xlink:to="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DCF86F0D64CE42FA98CFCF51E4E19E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DCF86F0D64CE42FA98CFCF51E4E19E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3C4E288DBB3A96F90506FCF51E4E575C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3C4E288DBB3A96F90506FCF51E4E575C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_97942934CDCB218E6E0CFCF51E4E6C67" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_97942934CDCB218E6E0CFCF51E4E6C67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5241D20AA32E176DF82DFCF51E4E7DFC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5241D20AA32E176DF82DFCF51E4E7DFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_CFAA33F7913F38B2C732FCF51E4FEE8E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E80B1435FE2CA2F36846FCF51E4D8A00" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_CFAA33F7913F38B2C732FCF51E4FEE8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8CB7353F727AD691A768FCF51E4C7D32" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2AC2D3CD97A20D2C319EFCF51E4FFD75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2AC2D3CD97A20D2C319EFCF51E4FFD75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_C45D0098DEA6AF63F5C5FCF51E4F1A2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_C45D0098DEA6AF63F5C5FCF51E4F1A2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2D5028AFEF4A282ED88DFD2651ED0D9C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2D5028AFEF4A282ED88DFD2651ED0D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5AD3E2CE2663BFACF617FCF51E4FCD1E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5AD3E2CE2663BFACF617FCF51E4FCD1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_41AFED24E93890957FBAFCF51E4F1E89" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_41AFED24E93890957FBAFCF51E4F1E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_00BA3780CB3C49BB928BFCF51E50C336" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_00BA3780CB3C49BB928BFCF51E50C336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_008BD7E2B381653DE441FCF51E509BB5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_76A32AD8832FEB2A21C2FCF51E4F403D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_008BD7E2B381653DE441FCF51E509BB5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="biib-20191231.xsd#biib_AccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_AccumulatedOtherComprehensiveIncomeLossAbstract_924100C12F2782EF6DA493DCFFCAF48B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BB3AF0BF154EF834DB6E93DD5027F341" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AccumulatedOtherComprehensiveIncomeLossAbstract_924100C12F2782EF6DA493DCFFCAF48B" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BB3AF0BF154EF834DB6E93DD5027F341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_1D0BCCB60551F54CCD7393E09E1E737C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AccumulatedOtherComprehensiveIncomeLossAbstract_924100C12F2782EF6DA493DCFFCAF48B" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_1D0BCCB60551F54CCD7393E09E1E737C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D60C0BD0E490ECC99B55800B02AE1B54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_54DE7FB347C304E82993800B02AEFD6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D60C0BD0E490ECC99B55800B02AE1B54" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_54DE7FB347C304E82993800B02AEFD6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_B8D2723890D72EA973C4800B02AE5769" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_54DE7FB347C304E82993800B02AEFD6D" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_B8D2723890D72EA973C4800B02AE5769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_E65195AC1CB06D264F02800B02AE4433" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_54DE7FB347C304E82993800B02AEFD6D" xlink:to="loc_us-gaap_CommonStockSharesIssued_E65195AC1CB06D264F02800B02AE4433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_38E9C655CE286C6EDD78800B02AECD9A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_54DE7FB347C304E82993800B02AEFD6D" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_38E9C655CE286C6EDD78800B02AECD9A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20191231.xsd#biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract" xlink:label="loc_biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract_9B453CE2B7682F3A6AC0FCF51E437988" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract_9B453CE2B7682F3A6AC0FCF51E437988" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_26B64CA9B690B064174FFCF51E44B57A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_26B64CA9B690B064174FFCF51E44B57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C071B50B43823FAED850FCF51E44D149" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_26B64CA9B690B064174FFCF51E44B57A" xlink:to="loc_us-gaap_EquityComponentDomain_C071B50B43823FAED850FCF51E44D149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8D760EEE4BB2CD1FF440FCF51E44D477" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C071B50B43823FAED850FCF51E44D149" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8D760EEE4BB2CD1FF440FCF51E44D477" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D01F10FC796B0465679BFCF51E45B24B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C071B50B43823FAED850FCF51E44D149" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D01F10FC796B0465679BFCF51E45B24B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_EC6DFBC041794EB7A541FCF51E45F11D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C071B50B43823FAED850FCF51E44D149" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_EC6DFBC041794EB7A541FCF51E45F11D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46CD3D750984EB0E5DD1FCF51E45AD65" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A22D9350B948C1FD7A6FCF51E4535CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_BF40A1D5BA04BAE09DBCFCF51E455C22" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A22D9350B948C1FD7A6FCF51E4535CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9D3D8DCF313A9521F0F1FCF51E439AE9" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_96DA66D08907455E3706FCF51E4636AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_96DA66D08907455E3706FCF51E4636AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_F69921F7B154C90B73F3FCF51E46457D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_F69921F7B154C90B73F3FCF51E46457D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5CDF02389BD70F33310AFCF51E468181" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:to="loc_us-gaap_Revenues_5CDF02389BD70F33310AFCF51E468181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3AE8E22E0BBB1E81374FFCF51E46FBDD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:to="loc_us-gaap_OperatingExpenses_3AE8E22E0BBB1E81374FFCF51E46FBDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D4C9A6B4B9E80E7BB23BFCF51E4741E2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_99726906008CED7EA447FCF51E468E18" xlink:to="loc_us-gaap_NetIncomeLoss_D4C9A6B4B9E80E7BB23BFCF51E4741E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_384F452904FFAF1889A56F399D3C896E" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SummaryOfCommonStockTableTextBlock" xlink:label="loc_biib_SummaryOfCommonStockTableTextBlock_762B2655F23542EB19A96F399D3D1793" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_384F452904FFAF1889A56F399D3C896E" xlink:to="loc_biib_SummaryOfCommonStockTableTextBlock_762B2655F23542EB19A96F399D3D1793" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_991CB63B197596250C7B6F399DB2DBAA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_76D8608020FC274AFCA36F399DB216D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_991CB63B197596250C7B6F399DB2DBAA" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_76D8608020FC274AFCA36F399DB216D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_F18C2BD20A600DD61C77EBFB64E71F90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_F18C2BD20A600DD61C77EBFB64E71F90" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F1780A38AAE01AFCF41EBFB64E821D7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_C26BDD3D526082D95603EBFB64E8EFCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_C26BDD3D526082D95603EBFB64E8EFCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_32003C2D6B0D310474C4EBFB64E90248" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_32003C2D6B0D310474C4EBFB64E90248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_718ECE50FEBCF2F0FD60EBFB64E918A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EBA07E468B42746E2396EBFB64E86121" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_718ECE50FEBCF2F0FD60EBFB64E918A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_F1733A86343AFF467F25EBFB64E9D6EF" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1235BF5FCF487927B70AEBFB64E9A2C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_14276AB9C8730FB56BE9EBFB64E9C885" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1235BF5FCF487927B70AEBFB64E9A2C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_E82F99E651F8A4E90522EBFB64EA327A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_E82F99E651F8A4E90522EBFB64EA327A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4C8E7C2B0B9AB1C1871FEBFB64EAA18F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E82F99E651F8A4E90522EBFB64EA327A" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4C8E7C2B0B9AB1C1871FEBFB64EAA18F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1482D77C60D8C8FF5197EBFB64EA3852" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4C8E7C2B0B9AB1C1871FEBFB64EAA18F" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1482D77C60D8C8FF5197EBFB64EA3852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_A40EB02CE02CFCA61202EBFB64EAD567" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4C8E7C2B0B9AB1C1871FEBFB64EAA18F" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_A40EB02CE02CFCA61202EBFB64EAD567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_06627DD37309F7E43A22EBFB64EB6804" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4C8E7C2B0B9AB1C1871FEBFB64EAA18F" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_06627DD37309F7E43A22EBFB64EB6804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F1409F90F79CFAD0AE75EBFB64E8B4EC" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14A5C41833ED0B5C065DEBFB64EB2716" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37BA4839912EE68A143BEBFB64EB4534" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37BA4839912EE68A143BEBFB64EB4534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_69E614826357E50DF8DCEBFB64EC2371" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="loc_us-gaap_AvailableForSaleSecurities_69E614826357E50DF8DCEBFB64EC2371" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8458D3903978F644EA49EBFB64EC5EAC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8458D3903978F644EA49EBFB64EC5EAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2DC1B8B613F0A3DA9BAFEBFB64EC170A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2DC1B8B613F0A3DA9BAFEBFB64EC170A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E29413B08AC5E36FC02DEBFB64ECC5A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_658C91AA145D0331D42EEBFB64EC6EDB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3BAF0A0F8D223362B3DDEBFB64EB03B2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_658C91AA145D0331D42EEBFB64EC6EDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_96D4C4310B60FF7552AAEBFB64EBD1FE" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2186D794D2BEFC0E3B5CEBFB64EDE70C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2186D794D2BEFC0E3B5CEBFB64EDE70C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_175442E78CF9A3AEA8ECEBFB64ED6E35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_175442E78CF9A3AEA8ECEBFB64ED6E35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6CE84CCF729BEE6E78E0EBFB64EDD8BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2C293F3B43231D1CE3C1EBFB64ECDB2E" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_6CE84CCF729BEE6E78E0EBFB64EDD8BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3855B08E89B084F53A7EE873AD9A91DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A8BE974354387C1B57B2E873AD9ADA84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3855B08E89B084F53A7EE873AD9A91DB" xlink:to="loc_us-gaap_DebtInstrumentTable_A8BE974354387C1B57B2E873AD9ADA84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F986F900F5FF9E8F8537E873AD9A0EAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A8BE974354387C1B57B2E873AD9ADA84" xlink:to="loc_us-gaap_DebtInstrumentAxis_F986F900F5FF9E8F8537E873AD9A0EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F986F900F5FF9E8F8537E873AD9A0EAD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_A62E3D865F21A78CD63EE873AD9A5F18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_A62E3D865F21A78CD63EE873AD9A5F18" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_730E05647D20B1F2B202E873AD9A44B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_730E05647D20B1F2B202E873AD9A44B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A18D7E60EB50719C5A9BE873AD9A7F88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A18D7E60EB50719C5A9BE873AD9A7F88" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_C4412ADD82B36458AFA4E873AD9A45F5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2F8893A381156C10D4E1E873AD9A4A34" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_C4412ADD82B36458AFA4E873AD9A45F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_971DE5F211CD7B9FFA11E873AD9AE6DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A8BE974354387C1B57B2E873AD9ADA84" xlink:to="loc_us-gaap_DebtInstrumentLineItems_971DE5F211CD7B9FFA11E873AD9AE6DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_32EC11195EC7A3212ED1E873AD9A4CAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_971DE5F211CD7B9FFA11E873AD9AE6DC" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_32EC11195EC7A3212ED1E873AD9A4CAB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_F6A65677C2DDB1AB9A736F399EA87F95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6D387A485259DCF55A326F399EA9AB47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_F6A65677C2DDB1AB9A736F399EA87F95" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6D387A485259DCF55A326F399EA9AB47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BCDAB4126762D05511BD6F399EA9D854" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6D387A485259DCF55A326F399EA9AB47" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BCDAB4126762D05511BD6F399EA9D854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_337B4B6F110BDA7709FA6F399EA973B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BCDAB4126762D05511BD6F399EA9D854" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_337B4B6F110BDA7709FA6F399EA973B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_872E6A8ACD33C6EF94306F399EA9C04C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_337B4B6F110BDA7709FA6F399EA973B6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_872E6A8ACD33C6EF94306F399EA9C04C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DEEC8C81AF63B30C23CD6F399EAA2389" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6D387A485259DCF55A326F399EA9AB47" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DEEC8C81AF63B30C23CD6F399EAA2389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6CF2A865719D17B05DE16F399EAAADD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DEEC8C81AF63B30C23CD6F399EAA2389" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6CF2A865719D17B05DE16F399EAAADD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_585D02AD677B7759C7736F399EAA6097" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DEEC8C81AF63B30C23CD6F399EAA2389" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_585D02AD677B7759C7736F399EAA6097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_40EB591766FB9B7241636F399EAB357D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DEEC8C81AF63B30C23CD6F399EAA2389" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_40EB591766FB9B7241636F399EAB357D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8EF343E362703C20BEA96F399EAB5BD0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DEEC8C81AF63B30C23CD6F399EAA2389" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8EF343E362703C20BEA96F399EAB5BD0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_860ADBE86915A4956E12E873AD8A4C02" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_860ADBE86915A4956E12E873AD8A4C02" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_EF352E609F592645B681E873AD8AA518" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_EF352E609F592645B681E873AD8AA518" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_A2C72E0BC9D48312EF95E873AD8AAAC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_EF352E609F592645B681E873AD8AA518" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_A2C72E0BC9D48312EF95E873AD8AAAC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BG00011Member" xlink:label="loc_biib_BG00011Member_483FB84CC1DA2FE582BCE873AD8A15DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_A2C72E0BC9D48312EF95E873AD8AAAC2" xlink:to="loc_biib_BG00011Member_483FB84CC1DA2FE582BCE873AD8A15DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0C45E49E0BA3BDE81713E873AD8A90D6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_0347DBCE7462B7A412D7E873AD8A2987" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_16843F5A8BEBD00D9057E873AD8A7360" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_0347DBCE7462B7A412D7E873AD8A2987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_D418D2CF731A1197C142E873AD8A607C" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_855484A0EB35CCEED932E873AD8A91C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_855484A0EB35CCEED932E873AD8A91C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_B6AA51B095FF28CEC988E873AD8A7575" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_A05EF0E606C532797618E873AD8AD41B" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_B6AA51B095FF28CEC988E873AD8A7575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2995EEE97ECF31402B5EE873AD8A6862" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:to="loc_us-gaap_DebtInstrumentAxis_2995EEE97ECF31402B5EE873AD8A6862" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2995EEE97ECF31402B5EE873AD8A6862" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6D809FD96CC24EEBADCAE873AD8A7C49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6D809FD96CC24EEBADCAE873AD8A7C49" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_79325BD4194C1198DBE7E873AD8ABFA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_79325BD4194C1198DBE7E873AD8ABFA3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_14C1C4AF086C413372B5E873AD8A77A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_14C1C4AF086C413372B5E873AD8A77A2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3F8B087E4C121BADED0FE873AD8A5597" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DB9E4F7F371E3FC4D8EEE873AD8A6C87" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3F8B087E4C121BADED0FE873AD8A5597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CF402E7F8B1647360D60E873AD8A2157" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CF402E7F8B1647360D60E873AD8A2157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A21BAB65D20BA66D093E873AD8ADCD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CF402E7F8B1647360D60E873AD8A2157" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A21BAB65D20BA66D093E873AD8ADCD0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A21BAB65D20BA66D093E873AD8ADCD0" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_D13C30643C3EE21EF576E873AD8A4A09" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A21BAB65D20BA66D093E873AD8ADCD0" xlink:to="loc_biib_StromedixMember_D266DEACDA0BD6AD7044E873AD8AA30A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A21BAB65D20BA66D093E873AD8ADCD0" xlink:to="loc_biib_BiogenIdecInternationalNeuroscienceMember_C5417856E62F6A2B3C5EE873AD8A42CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A7FD33259584F956DCE2E873AD8A976D" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs" xlink:label="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_AFE841192446D853D238E873AD9A09A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_AFE841192446D853D238E873AD9A09A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_967B0CA067B7429E3884E873AD9A86D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_967B0CA067B7429E3884E873AD9A86D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_E1242CB4C1D51600AD61E873AD9A32A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_E1242CB4C1D51600AD61E873AD9A32A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A9FC4DB22636D653B6AEE873AD9AABF8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A9FC4DB22636D653B6AEE873AD9AABF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_395E4D9733375CB6DF53E873AD9A8136" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_395E4D9733375CB6DF53E873AD9A8136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DD274952E341CE5C73E6E873AD9A09F5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DD274952E341CE5C73E6E873AD9A09F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_025177102C1DB9BD7658E873AD9AB0BE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_025177102C1DB9BD7658E873AD9AB0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4BF2B886B44358E5FF0FE873AD9A87FE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4BF2B886B44358E5FF0FE873AD9A87FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FairValueMeasurementInputs" xlink:label="loc_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_biib_FairValueMeasurementInputs_80CD8D2E14BD7C7EDC4CE873AD9AAC2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_AFA259B66C1C13FF484DE873AD9ACA95" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_AFA259B66C1C13FF484DE873AD9ACA95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_776C7E63E089D4C15602E873AD9A294C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_776C7E63E089D4C15602E873AD9A294C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7F35F239481A40789AE9E873AD9A4E6C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_320A18B97EA129BA412CE873AD9A1E3E" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7F35F239481A40789AE9E873AD9A4E6C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2F14658EDD54EAEEB7206F399D788DA9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_367BFE9460D1C7E75F086F399D784396" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2F14658EDD54EAEEB7206F399D788DA9" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_367BFE9460D1C7E75F086F399D784396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_144BA1A44C6F5CD5A7E96F399D781F47" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2F14658EDD54EAEEB7206F399D788DA9" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_144BA1A44C6F5CD5A7E96F399D781F47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_93AD33FE62F3141DF8E66F399D79BBF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2F14658EDD54EAEEB7206F399D788DA9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_93AD33FE62F3141DF8E66F399D79BBF8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3BC2C933CCEBF5F761446F399CE5EA8D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E9AAFD3272CD70A4A60A6F399CE50585" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3BC2C933CCEBF5F761446F399CE5EA8D" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E9AAFD3272CD70A4A60A6F399CE50585" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_60F2B689DD8CD46DA9836F399EB73AE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_60F2B689DD8CD46DA9836F399EB73AE2" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85" xlink:to="loc_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_47E08BB48455C25F4EF96F399EB7307F" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_98E4188C66D8494B76086F399EB85EF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:to="loc_us-gaap_CommercialPaperMember_98E4188C66D8494B76086F399EB85EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_CFEB9608B1D83E789AFD6F399EB87485" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_CFEB9608B1D83E789AFD6F399EB87485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C444C0807F609F8BD87C6F399EB8BFCC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:to="loc_us-gaap_MoneyMarketFundsMember_C444C0807F609F8BD87C6F399EB8BFCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_A06F2D4BD11528351A496F399EB85660" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_37CC24236D3B32515FC26F399EB7E24D" xlink:to="loc_us-gaap_DebtSecuritiesMember_A06F2D4BD11528351A496F399EB85660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B4D95F7AA55D2B39FE7A6F399EB72C85" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3D7AC74456BC3EBFC65C6F399EB80851" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_C79C2B62E809432475C56F399EB94BBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E25DDDA1015CB677BC686F399EB97F8D" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_C79C2B62E809432475C56F399EB94BBC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1C3F36927B5998F499D47F76C6D5C2E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1C3F36927B5998F499D47F76C6D5C2E5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_B73F9DDE2E2EDECD899D7F76C6D5320F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773" xlink:to="loc_us-gaap_FinancialInstrumentAxis_B73F9DDE2E2EDECD899D7F76C6D5320F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_B73F9DDE2E2EDECD899D7F76C6D5320F" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_D3C4B0979BBC544F3C0C7F76C6D5F27F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_481BA5139C5210902E3B7F76C6D51789" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_0A6B3A7846433C086D7A7F76C6D503BB" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_BDCE3638AEE949A470DB7F76C6D5D2E1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_1CA5EDD4E6DE34C1077A7F76C6D54E78" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61D9FFADC33FF7AF7FBD7F76C6D5752B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_A86CDFC187FC4A6FF6087F76C6D5EF03" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B71D286B6EF05D9E7F627F76C6D56925" xlink:to="loc_us-gaap_EquitySecuritiesMember_A86CDFC187FC4A6FF6087F76C6D5EF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_756CE89B7025825FA9F17F76C6D5C773" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FD27010C3B127F11B0C47F76C6D59674" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0752CE820F3F05ECD187FAC218E898E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0752CE820F3F05ECD187FAC218E898E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_305B034C4AB8F89C65207FABBF013B93" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_305B034C4AB8F89C65207FABBF013B93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11A5235A8FB8EAC36AA47FAB1712E81F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11A5235A8FB8EAC36AA47FAB1712E81F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9FB416F45B51DCF73A5D7FA90F607F7C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9FB416F45B51DCF73A5D7FA90F607F7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_888618C0BB619ED201107FB45820143E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_888618C0BB619ED201107FB45820143E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_666FD81453DDBDAC2D4F7FB4584F7BB0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_666FD81453DDBDAC2D4F7FB4584F7BB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5C1F1FA0A98A562C476C7FB45877AA03" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5C1F1FA0A98A562C476C7FB45877AA03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0A7026CFCCCD25D22E7A7FB40C9E1ABC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_BAF623ECB269B4E2029F7F76C6D5F88E" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0A7026CFCCCD25D22E7A7FB40C9E1ABC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D630E832D5746276EB2280C31396DD86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D630E832D5746276EB2280C31396DD86" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_A86B848BA8CE6132F7FF80C313967A17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_A86B848BA8CE6132F7FF80C313967A17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8A267B1EB322E2D2E10780C31396DC11" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8A267B1EB322E2D2E10780C31396DC11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_34DA635D2A3944A1756380C313979CBF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_34DA635D2A3944A1756380C313979CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3D3A3FD5827FC8DA0D7280C31397EF83" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3D3A3FD5827FC8DA0D7280C31397EF83" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_6D4B0F62DA8C6EF21BB180C313979C73" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_6D4B0F62DA8C6EF21BB180C313979C73" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_637A2CC10198BD3DD63780C313970E52" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_637A2CC10198BD3DD63780C313970E52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1B1E8F5FE5FD7A20197580C313978686" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1B1E8F5FE5FD7A20197580C313978686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7B920EFE2E812202CAFD80C31397F2FA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4AABE13E57C053CC071580C31396D2C2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7B920EFE2E812202CAFD80C31397F2FA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9105D4FBDC2A7C37FC966F399E1E7E0B" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ProceedsFromMarketableDebtSecuritiesAbstract" xlink:label="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9105D4FBDC2A7C37FC966F399E1E7E0B" xlink:to="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5BF059C3E3C1B7C12FE76F399E1F9B48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5BF059C3E3C1B7C12FE76F399E1F9B48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_B69C0BF3415EE13702CF6F399E20A7EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_B69C0BF3415EE13702CF6F399E20A7EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_4A74DB5DCE3F6B2414E06F399E20048D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_D6E97CB26BCAE1F4EE126F399E1F35EE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_4A74DB5DCE3F6B2414E06F399E20048D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_67F921AA9ECF05CF6CD16F399EC6A9F4" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FinancialInstrumentsTextualAbstract" xlink:label="loc_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_67F921AA9ECF05CF6CD16F399EC6A9F4" xlink:to="loc_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_13320F5162DF8A3976346F399EC68E02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_13320F5162DF8A3976346F399EC68E02" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_8BAAFC4D5A9888D4C68F6F399EC79BF6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_E48A144674F64C41F5816F399EC62AAE" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_8BAAFC4D5A9888D4C68F6F399EC79BF6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_61CDDFA3B70F6174B8A0FC3A19BA5D4F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_08B2BACC24B6A25BFDE1FC3A19BA3812" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_61CDDFA3B70F6174B8A0FC3A19BA5D4F" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_08B2BACC24B6A25BFDE1FC3A19BA3812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4BEBF7C789E23EC4F8C1FC3A19BAA3C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_08B2BACC24B6A25BFDE1FC3A19BA3812" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4BEBF7C789E23EC4F8C1FC3A19BAA3C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4BEBF7C789E23EC4F8C1FC3A19BAA3C3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_80FD52A6FCF2FE47164EFC3A19BA42DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_03A60C47324867C736A5FC3A19BABCB4" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_80FD52A6FCF2FE47164EFC3A19BA42DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F05D912938CABB5CCC94FC3A19BA9258" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_08B2BACC24B6A25BFDE1FC3A19BA3812" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F05D912938CABB5CCC94FC3A19BA9258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D05A5BE1CBB35D0FF9BCFC3A19BAFCEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F05D912938CABB5CCC94FC3A19BA9258" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D05A5BE1CBB35D0FF9BCFC3A19BAFCEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_2B34C5DD5F9455464E0EFC3A19BA1D56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D05A5BE1CBB35D0FF9BCFC3A19BAFCEF" xlink:to="loc_biib_IonisPharmaceuticalsMember_2B34C5DD5F9455464E0EFC3A19BA1D56" xlink:type="arc" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D05A5BE1CBB35D0FF9BCFC3A19BAFCEF" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_80FD52A6FCF2FE47164EFC3A19BA42DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_08B2BACC24B6A25BFDE1FC3A19BA3812" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5795CD560116EA4C3F92FC3A19BA9F49" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9830CB8D979810575AE6FC3A19BA10A3" xlink:to="loc_biib_StrategicInvestmentsMember_BAC90291C41EB232D001FC3A19BAF7DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_08B2BACC24B6A25BFDE1FC3A19BA3812" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_biib_StrategicInvestmentPortfolio_D4C33173D69818C2C069FC3A19BA0B4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_B13FC37463FE1B0CC699FC3A19BAEBC1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_B13FC37463FE1B0CC699FC3A19BAEBC1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_3644A1D374467E4E0B68FC3A19BACD5F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_3644A1D374467E4E0B68FC3A19BACD5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_35E44149D4DB150278B7FC3A19BA1DB3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_35E44149D4DB150278B7FC3A19BA1DB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B1ACBED11838736703F5FC3A19BA7E83" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B1ACBED11838736703F5FC3A19BA7E83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_1A9DCFD64C4186C63139FC3A19BAABDA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D0E018545593FF586FFBFC3A19BA6548" xlink:to="loc_us-gaap_EquityMethodInvestments_1A9DCFD64C4186C63139FC3A19BAABDA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_32FA022909E631EF66CE6F399F7E24E1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_B956F7164DD77BE031C76F399F7EF4DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_32FA022909E631EF66CE6F399F7E24E1" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_B956F7164DD77BE031C76F399F7EF4DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_04F23D9069CE9B6134E36F399F7EE913" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_32FA022909E631EF66CE6F399F7E24E1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_04F23D9069CE9B6134E36F399F7EE913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_21AE70E3C438906F13226F399F7E2CA8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_32FA022909E631EF66CE6F399F7E24E1" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_21AE70E3C438906F13226F399F7E2CA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B7C6C403FF2DB543046F6F399F7E0AB4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_32FA022909E631EF66CE6F399F7E24E1" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B7C6C403FF2DB543046F6F399F7E0AB4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="loc_us-gaap_GuaranteesAbstract_8ECA4B9EB3534038F84F6F39A0182556" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GuaranteesTextBlock" xlink:label="loc_us-gaap_GuaranteesTextBlock_EC7600E55BD76241A3E56F39A0181CD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteesAbstract_8ECA4B9EB3534038F84F6F39A0182556" xlink:to="loc_us-gaap_GuaranteesTextBlock_EC7600E55BD76241A3E56F39A0181CD2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_34B38F8C1183D8378BAE6F399DDE6B2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_6BD222897294AC6B19E76F399DDEED0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34B38F8C1183D8378BAE6F399DDE6B2F" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_6BD222897294AC6B19E76F399DDEED0A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_30A5DB090D8C27DC63E66F399FB24BFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_22AF96D24E41ECB34DF26F399FB2845F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30A5DB090D8C27DC63E66F399FB24BFA" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_22AF96D24E41ECB34DF26F399FB2845F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_060FB8265220918137746F399FB38F17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_22AF96D24E41ECB34DF26F399FB2845F" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_060FB8265220918137746F399FB38F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_47DFE464196F229B165B6F399FB35310" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_060FB8265220918137746F399FB38F17" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_47DFE464196F229B165B6F399FB35310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B83ECD063A05BFCA45066F399FB381AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_060FB8265220918137746F399FB38F17" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B83ECD063A05BFCA45066F399FB381AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_918EC520739AA06CEC286F399FB32AC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_060FB8265220918137746F399FB38F17" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_918EC520739AA06CEC286F399FB32AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_DBA2802CB18201D2E2676F399FB40CF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_22AF96D24E41ECB34DF26F399FB2845F" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_DBA2802CB18201D2E2676F399FB40CF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_DBA2802CB18201D2E2676F399FB40CF8" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_FDD7F27129C947D1A69E6F399FB43407" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_FDD7F27129C947D1A69E6F399FB43407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6EFD3B50D51DF27D3FB36F399FB423A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6EFD3B50D51DF27D3FB36F399FB423A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_F3C88ECC6CA7ACA0A8D16F399FB5F2EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_F3C88ECC6CA7ACA0A8D16F399FB5F2EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_975D5D89965BFA064C866F399FB57A98" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F9DB87946304E40F2B2D6F399FB4CD0E" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_975D5D89965BFA064C866F399FB57A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_DBA2802CB18201D2E2676F399FB40CF8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_49966E34A050D5322AA76F399FB5190A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_49966E34A050D5322AA76F399FB5190A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98B160F3FB46DC17C4816F399FB5B3B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98B160F3FB46DC17C4816F399FB5B3B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AD8205022ABDF0B5FA746F399FB6DEFA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AD8205022ABDF0B5FA746F399FB6DEFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_73A78476AB95122EB43B6F399FB6BF6B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2C38C381D332523C61836F399FB590FB" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_73A78476AB95122EB43B6F399FB6BF6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E4CE4BDBC8F0EEDDCE2A6F399FB6B5E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_22AF96D24E41ECB34DF26F399FB2845F" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E4CE4BDBC8F0EEDDCE2A6F399FB6B5E4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FA2D7BAF911F3E7C08B1EBFB61B23C7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FA2D7BAF911F3E7C08B1EBFB61B23C7A" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_E39DAB699B0B28EC4F18EBFB61B26EC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_E39DAB699B0B28EC4F18EBFB61B26EC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_2BD9D81F55D81FEC9884EBFB61B2AC9D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_2BD9D81F55D81FEC9884EBFB61B2AC9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_178C0A334B0860884847EBFB61B3ED49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_178C0A334B0860884847EBFB61B3ED49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_94F248C939B7D19C0EAEEBFB61B37F97" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_94F248C939B7D19C0EAEEBFB61B37F97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C8BF7B37F53528EAC7DBEBFB61B3CE9F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C8BF7B37F53528EAC7DBEBFB61B3CE9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_F6D4FEC2112B91611090EBFB61B351D1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_F6D4FEC2112B91611090EBFB61B351D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_D98300A2175568B73927EBFB61B89C41" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_D98300A2175568B73927EBFB61B89C41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7CBFB071201BCFB7518DEBFB61B8B28D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7CBFB071201BCFB7518DEBFB61B8B28D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_74C6715067AF1C0D3F08EBFB61B90ADD" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_74C6715067AF1C0D3F08EBFB61B90ADD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_D1863B25AB139A94D273EBFB61B9500C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_D1863B25AB139A94D273EBFB61B9500C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" xlink:label="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_90C59406AB1B6C7FAD7DEBFB61B930F3" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_90C59406AB1B6C7FAD7DEBFB61B930F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_C6975885EB4C55AF3681EBFB61B99340" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_C6975885EB4C55AF3681EBFB61B99340" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_50AD7B3D1C5D7A93CDC5EBFB61B9BBBE" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6E152A9A4B29A5970F46EBFB61B20953" xlink:to="loc_us-gaap_DeferredTaxLiabilities_50AD7B3D1C5D7A93CDC5EBFB61B9BBBE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CB85AB8C7C44C1D0087CFC2E5FA07176" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CB85AB8C7C44C1D0087CFC2E5FA07176" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_482170283663C1BB2327FC2E5FA00252" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_482170283663C1BB2327FC2E5FA00252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0AFA7FBFA3DB296D528FFC2E5FA0DA4B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0AFA7FBFA3DB296D528FFC2E5FA0DA4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_45424BAB8751B220F447FC2E5FA13EEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_45424BAB8751B220F447FC2E5FA13EEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5967DC985C3EF5CEA1A7FC2E5FA1CB35" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5967DC985C3EF5CEA1A7FC2E5FA1CB35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_DE447DCF45B7711BBD7CFC2E5FA130D5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_DE447DCF45B7711BBD7CFC2E5FA130D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_F102A4B53E09E6F7F066FC325D898E88" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_F102A4B53E09E6F7F066FC325D898E88" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9CEBCA6E50C8DACDB3F5FC32D902B293" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9CEBCA6E50C8DACDB3F5FC32D902B293" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5BED8D29536269D12EA6FC2E5FA1CAA9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5BED8D29536269D12EA6FC2E5FA1CAA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6812DEADC1AB42BD486BFC2E5FA17291" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6812DEADC1AB42BD486BFC2E5FA17291" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_503DF4D9466ED5CE9BBBFC334F9469D4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_503DF4D9466ED5CE9BBBFC334F9469D4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_EDA683A225F334D6CB5BFC2E5FA1EC8B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_EDA683A225F334D6CB5BFC2E5FA1EC8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_8176674ED970D7092F07FC2E5FA22953" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_8176674ED970D7092F07FC2E5FA22953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E1B76BAEE3A347E5CAD3FC2E5FA2C771" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E1B76BAEE3A347E5CAD3FC2E5FA2C771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4E1781971D4EAB6ECF49FC2E5FA22B56" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4E1781971D4EAB6ECF49FC2E5FA22B56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F06B566DCB898CE949CBFC2E5FA26B93" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5E814DF97AD9B82AE9A8FC2E5FA0151B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F06B566DCB898CE949CBFC2E5FA26B93" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F81C2DEB358ACFC334C2FCF51D92DB23" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F81C2DEB358ACFC334C2FCF51D92DB23" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_D4161830F0D095B90D80FCF51D924770" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_D4161830F0D095B90D80FCF51D924770" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A9BC68982AFC45800E89FCF51D92134A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A9BC68982AFC45800E89FCF51D92134A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E6AEABA9D4A51B7B781DFCF51D93C2D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E6AEABA9D4A51B7B781DFCF51D93C2D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A2432103FF78EC79B1D3FCF51D93695A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A2432103FF78EC79B1D3FCF51D93695A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4040966636102C77B870FCF51D9353E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4040966636102C77B870FCF51D9353E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0B9D29198CCDA50FCF81FCF51D934AC3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0B9D29198CCDA50FCF81FCF51D934AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8744CE8CDC94B5D73985FCF51D93E225" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_47CAD0F4E2765C619B96FCF51D920EC2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8744CE8CDC94B5D73985FCF51D93E225" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_095B15C512B0135BDB12FC2E5A23FC7B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_095B15C512B0135BDB12FC2E5A23FC7B" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxAssetLiabilityTypeAxis" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredTaxAssetLiabilityTypeDomain" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_D34E83E3639E216DE22CFC2E5A2341AC" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_F33C2354A9F5F5CA0402FC2E5A248C17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeDomain_94F632107299D9685FB1FC2E5A241906" xlink:to="loc_us-gaap_IntellectualPropertyMember_F33C2354A9F5F5CA0402FC2E5A248C17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92D156BDFE80A879BF6DFC2E5A242667" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92D156BDFE80A879BF6DFC2E5A242667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55FF26E228CC7F3DDB37FC2E5A249A4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92D156BDFE80A879BF6DFC2E5A242667" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55FF26E228CC7F3DDB37FC2E5A249A4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_1DD19DE79809871BD4EBFC2E5A25A65A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55FF26E228CC7F3DDB37FC2E5A249A4C" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_1DD19DE79809871BD4EBFC2E5A25A65A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_35B1147684B88425791BFC2E5A2561FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_35B1147684B88425791BFC2E5A2561FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A4AFBAB9253D1930B8F6FC2E5A25B447" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_35B1147684B88425791BFC2E5A2561FB" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A4AFBAB9253D1930B8F6FC2E5A25B447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_BF898951A137ED0C61A1FC2E5A26ECBE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_srt_RangeAxis_BF898951A137ED0C61A1FC2E5A26ECBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_ECACDDAE620F726853BDFC2E5A26E3D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_BF898951A137ED0C61A1FC2E5A26ECBE" xlink:to="loc_srt_RangeMember_ECACDDAE620F726853BDFC2E5A26E3D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9795BA3263F7C6116F3DFC2E5A269EBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ECACDDAE620F726853BDFC2E5A26E3D0" xlink:to="loc_srt_MinimumMember_9795BA3263F7C6116F3DFC2E5A269EBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_542FF01F46C3353A62C3FC2E5A26876D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ECACDDAE620F726853BDFC2E5A26E3D0" xlink:to="loc_srt_MaximumMember_542FF01F46C3353A62C3FC2E5A26876D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4C02428514827DCFF59FFC2E5A265FEE" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7B00DE8D07AEA68F8F8DFC2E5A265647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2FBC865AB46BC7C69992FC2E5A27510E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_srt_ProductOrServiceAxis_2FBC865AB46BC7C69992FC2E5A27510E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_849FCF6BB4BE352E348AFC2E5A279DDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2FBC865AB46BC7C69992FC2E5A27510E" xlink:to="loc_srt_ProductsAndServicesDomain_849FCF6BB4BE352E348AFC2E5A279DDE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_CE83B57D54B8E665EAEBFC2E5A277F02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_849FCF6BB4BE352E348AFC2E5A279DDE" xlink:to="loc_biib_ZINBRYTAMember_CE83B57D54B8E665EAEBFC2E5A277F02" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignearningstypeAxis" xlink:label="loc_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeAxis_FAE1357004DEC96D543FFC2E5A2D1739" xlink:to="loc_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:to="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_40A62F5FE2251C5ED138FC2E5A2D5DEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherForeignEarningsMember" xlink:label="loc_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeDomain_03FD17AEB5099087469BFC2E5A2D8740" xlink:to="loc_biib_OtherForeignEarningsMember_B3E32DCE424C246415F5FC2E5A2DC070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7CBE99324B5B3568EF72FC2E5A2E23EF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7CBE99324B5B3568EF72FC2E5A2E23EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_E91F766D27387371C822FC2E5A2E2B70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7CBE99324B5B3568EF72FC2E5A2E23EF" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_E91F766D27387371C822FC2E5A2E2B70" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_4E6F91EE576A0FF8DC94FC2E5A2E2255" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_E91F766D27387371C822FC2E5A2E2B70" xlink:to="loc_biib_DeferredtaxliabilityMember_4E6F91EE576A0FF8DC94FC2E5A2E2255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1EB89FAE06941FCE8289FC2E5A2F1BCA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_E91F766D27387371C822FC2E5A2E2B70" xlink:to="loc_us-gaap_RetainedEarningsMember_1EB89FAE06941FCE8289FC2E5A2F1BCA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PrepaidtaxesMember" xlink:label="loc_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_E91F766D27387371C822FC2E5A2E2B70" xlink:to="loc_biib_PrepaidtaxesMember_3B40FCEAE896E768748FFC2E5A2F3D51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2BB0882C2E35DC60A5FAFC2E5A2F3D91" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_1D1954CEE8DA0A13D2F6FC2E5A2F85EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:to="loc_us-gaap_GeneralBusinessMember_1D1954CEE8DA0A13D2F6FC2E5A2F85EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_97CE2EABD63F3E74FFBCFC2E5A30711D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_D6F5A0939E6B72DD75E3FC2E5A2F5B90" xlink:to="loc_us-gaap_ResearchMember_97CE2EABD63F3E74FFBCFC2E5A30711D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8A87698719CCC5DD9E22FC2E5A305D07" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:to="loc_biib_U.S.2017TaxActMember_0B8BD2532AD6E6A0F37BFC2E5A3060B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_6F93A458E0B86893794CFC2E5A307C06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:to="loc_us-gaap_DomesticCountryMember_6F93A458E0B86893794CFC2E5A307C06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5915F6DDAFFA6C154C4FFC2E5A31CE9C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5915F6DDAFFA6C154C4FFC2E5A31CE9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_74A4548EB9AE62F1A6CCFC2E5A3165AF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812774151CF2E1FE6F29FC2E5A30C144" xlink:to="loc_us-gaap_ForeignCountryMember_74A4548EB9AE62F1A6CCFC2E5A3165AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6646C1C0D02ED1210A30FC2E5A236042" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_A4F6B35FC5A842BD086BFC2E5A312376" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_A4F6B35FC5A842BD086BFC2E5A312376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_93853395B54A494DD1D2FC2E5A32710D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_93853395B54A494DD1D2FC2E5A32710D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1B9C1DDEEC7C860EE2A6FC2E5A32DF40" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1B9C1DDEEC7C860EE2A6FC2E5A32DF40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B69478896DE2F63D68F6FC2E5A324535" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B69478896DE2F63D68F6FC2E5A324535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F2879DA82B042DCC6F45FC2E5A325751" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F2879DA82B042DCC6F45FC2E5A325751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ECE14781248ECFF957E2FC2E5A32EA64" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ECE14781248ECFF957E2FC2E5A32EA64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ECC4F8648B52888F5187FC2E5A33E274" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ECC4F8648B52888F5187FC2E5A33E274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_08DC23A049597E5DE7BBFC2E5A337186" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_IncomeTaxesPaid_08DC23A049597E5DE7BBFC2E5A337186" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" xlink:label="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_A766B21F9957ABF9D925FC2E8FF36B49" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" xlink:label="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_9477F51618890E477676FC2FB23EE81B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TransitionTollTaxRepatriationTaxRate" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_biib_TransitionTollTaxRepatriationTaxRate_6B803A3E69DEA1A15FF6FC2E5A335898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E0F8EFB11FBF2846931DFC2E5A336583" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E0F8EFB11FBF2846931DFC2E5A336583" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Reductionindeferredtaxliabilityundistributedforeignearnings" xlink:label="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_C908933E491557E598B7FC2E5A33ECE6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_0F430C6063A12AC14181FC2E5A3301AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_054C22239EB1D70D5F1FFC2E5A34A456" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_OtherTaxExpenseBenefit_054C22239EB1D70D5F1FFC2E5A34A456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_15611CD785CD1CFEF885FC2E5A34CB81" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_15611CD785CD1CFEF885FC2E5A34CB81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_DE5E582365435F2E8315FC2E5A34BD5F" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_DE5E582365435F2E8315FC2E5A34BD5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_72B0E30BCE32EFF94DF1FC2E5A344A40" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_OperatingLossCarryforwards_72B0E30BCE32EFF94DF1FC2E5A344A40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1022A6B4A5BF8605F1B4FC2E5A34E862" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1022A6B4A5BF8605F1B4FC2E5A34E862" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_B034043B1F469AAFBA6DFC2E5A34670A" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_B034043B1F469AAFBA6DFC2E5A34670A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D306F1D80365E677B41EFC2E5A35A647" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_D306F1D80365E677B41EFC2E5A35A647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20E7BF62CAB2488FA5F5FC37ACE198D4" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_E02DF114FE5AB15FA401FC2E5A31133A" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20E7BF62CAB2488FA5F5FC37ACE198D4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IncomeTaxesTextualAbstract" xlink:label="loc_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_095B15C512B0135BDB12FC2E5A23FC7B" xlink:to="loc_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Totaldeferredchargesandprepaidtaxes" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_184BC14E9F5FC160D20EFC2E5A358E38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7" xlink:to="loc_biib_Totaldeferredchargesandprepaidtaxes_184BC14E9F5FC160D20EFC2E5A358E38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1046B7E8087A1AFBA9A3FC2E5A35C5A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1046B7E8087A1AFBA9A3FC2E5A35C5A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_186E8A67DBAE6790415DFC2E5A35E484" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_186E8A67DBAE6790415DFC2E5A35E484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2D72B1CF82A04C32898AFC2E5A3BB377" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_B73793D09DF3D6FD568FFC2E5A3515C7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2D72B1CF82A04C32898AFC2E5A3BB377" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_36638E5DAEF5BF3AA8A66F399D9501E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CDEB69CB410F7315B5326F399D95A744" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_36638E5DAEF5BF3AA8A66F399D9501E9" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CDEB69CB410F7315B5326F399D95A744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F18667504AAA4114FE5D6F399D95C220" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_36638E5DAEF5BF3AA8A66F399D9501E9" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F18667504AAA4114FE5D6F399D95C220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_DEA2261607C74EF36D0D6F399D9563E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_36638E5DAEF5BF3AA8A66F399D9501E9" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_DEA2261607C74EF36D0D6F399D9563E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CCFBC1C6EEC2E4DC5C246F399D966C25" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_36638E5DAEF5BF3AA8A66F399D9501E9" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CCFBC1C6EEC2E4DC5C246F399D966C25" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_80A023CDF9764605FB826F399D7BF1F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_C07B0F77D3C1C36811E16F399D7BE830" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_80A023CDF9764605FB826F399D7BF1F6" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_C07B0F77D3C1C36811E16F399D7BE830" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_947B2DFD0F4A51AB66ABF00F38131B64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F907B13D150FEED31915F00F3813C14D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_947B2DFD0F4A51AB66ABF00F38131B64" xlink:to="loc_us-gaap_DebtInstrumentTable_F907B13D150FEED31915F00F3813C14D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8BDA1A398B10F321CB54F00F3813B558" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F907B13D150FEED31915F00F3813C14D" xlink:to="loc_us-gaap_DebtInstrumentAxis_8BDA1A398B10F321CB54F00F3813B558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8BDA1A398B10F321CB54F00F3813B558" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_9EBAB6502EAEAC5B481AF00F3814E36C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_9EBAB6502EAEAC5B481AF00F3814E36C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_751FFE294E9163DCFD65F00F381415F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_751FFE294E9163DCFD65F00F381415F5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_BAF022B2291C2AD0EDEDF00F38156FE7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_BAF022B2291C2AD0EDEDF00F38156FE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4030F40EEEB082AD2CFAF00F381524C2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4030F40EEEB082AD2CFAF00F381524C2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_89D1DC334253A8BD894AF00F3815F826" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BD30F8DF20CAAA68AB2AF00F38145E00" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_89D1DC334253A8BD894AF00F3815F826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C9CFE8E93008D6A9F2DFF00F38159619" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F907B13D150FEED31915F00F3813C14D" xlink:to="loc_us-gaap_DebtInstrumentLineItems_C9CFE8E93008D6A9F2DFF00F38159619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C9CFE8E93008D6A9F2DFF00F38159619" xlink:to="loc_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_C18F41094145CF079986F00F38157531" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:to="loc_us-gaap_NotesPayableCurrent_C18F41094145CF079986F00F38157531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_A8ADA52EC03F2D1E0717F00F38189469" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_DAD09A4DB672EE1FABC5F00F38154A82" xlink:to="loc_us-gaap_DebtCurrent_A8ADA52EC03F2D1E0717F00F38189469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C9CFE8E93008D6A9F2DFF00F38159619" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_CBCEE2BEFF18FD0876A2F00F3818693F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:to="loc_us-gaap_LongTermNotesPayable_CBCEE2BEFF18FD0876A2F00F3818693F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6B5A87F134AAD5F0B5FBF00F3818FE0B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_A9CFFC0832D85C46B794F00F3818B027" xlink:to="loc_us-gaap_LongTermDebt_6B5A87F134AAD5F0B5FBF00F3818FE0B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0C43B8A24851EDAE2A8C800B02AE0CCC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0C43B8A24851EDAE2A8C800B02AE0CCC" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_26CECD6D6746F6ED8AF6800B02AEDFAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_26CECD6D6746F6ED8AF6800B02AEDFAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0544836166B8F0AA52F4800B02AEAFDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0544836166B8F0AA52F4800B02AEAFDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D06C991D88BDC7A90F15800B02AEDDAB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D06C991D88BDC7A90F15800B02AEDDAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4AB17EB915D3D820A835800B02AE8716" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4AB17EB915D3D820A835800B02AE8716" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_C5E884BFE24807858CD0800B02AE37DA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_C5E884BFE24807858CD0800B02AE37DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_E000952C395A54F066A7800B02AEC2E6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_E000952C395A54F066A7800B02AEC2E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_A4401F71A679A67D6B6E800B02AEE415" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8526F4FD785F91F6537B800B02AE4298" xlink:to="loc_us-gaap_LongTermNotesPayable_A4401F71A679A67D6B6E800B02AEE415" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8C3F94026A8F4AF0731F0B3C231E7F2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8C3F94026A8F4AF0731F0B3C231E7F2D" xlink:to="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_26E9E7F046D2C8986DD10B3C231E1E0F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_FD28AF7C73A7C541EADB0B3C231E370D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6A7292EAA73F7F2D69030B3C231EE242" xlink:to="loc_us-gaap_SubsequentEventMember_FD28AF7C73A7C541EADB0B3C231E370D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6EDF2FCDB88B54489AEC0B3C232E5A01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6EDF2FCDB88B54489AEC0B3C232E5A01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6326263E3C7CC9328EFA0B3C232E2086" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6EDF2FCDB88B54489AEC0B3C232E5A01" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6326263E3C7CC9328EFA0B3C232E2086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_3E6C25A7BE67F7B7EFE80B3C232E43F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6326263E3C7CC9328EFA0B3C232E2086" xlink:to="loc_us-gaap_InterestRateSwapMember_3E6C25A7BE67F7B7EFE80B3C232E43F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F2B2F0D8914CCBD536290B3C232ECFED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:to="loc_us-gaap_DebtInstrumentAxis_F2B2F0D8914CCBD536290B3C232ECFED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F2B2F0D8914CCBD536290B3C232ECFED" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_559A7E55D2C3E95762150B3C232E1572" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_559A7E55D2C3E95762150B3C232E1572" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_197F93EC26DF633324A10B3C232ECA2F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8C9CE0045D77D47B963C0B3C232EF56B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E2DCCF9206229A768A00B3C232E1117" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_40F3E23A354C9AFE66800B3C232EF7B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_56D0C82C58571F59E1FB0B3C231ECAE7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_A8F339E924FC8BAA858A0B3C232EC60D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_A8F339E924FC8BAA858A0B3C232EC60D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A69A05CCD2B5E28309B0B3C232EE208" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A69A05CCD2B5E28309B0B3C232EE208" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_6412DC413D87A51B1A190B3C232EA7E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_5BB7956CE38397C0873B0B3C232EDB83" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_5BB7956CE38397C0873B0B3C232EDB83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_58C1D31AA50272755CEA0B3C232E3B49" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_58C1D31AA50272755CEA0B3C232E3B49" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1F9683A52A73334456D20B3C232EEADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0FCA38F99B21BD99AC550B3C232E89C1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0FCA38F99B21BD99AC550B3C232E89C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7D6B46AFB6ED59FD6F8F0B3C232E7B1C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7D6B46AFB6ED59FD6F8F0B3C232E7B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_E4FF5C461D33E50B5DCF0B9C8A39BF22" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_LineOfCreditFacilityDescription_E4FF5C461D33E50B5DCF0B9C8A39BF22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_E8CB8246AA486AA07A190B3C232E6AA7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2AD16DB1449B2865AF870B3C232ECD3C" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_E8CB8246AA486AA07A190B3C232E6AA7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3D35FCE098484E418FAA6F399C1C4AFB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_C33517CAB72F898294AE6F399C1C7C20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3D35FCE098484E418FAA6F399C1C4AFB" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_C33517CAB72F898294AE6F399C1C7C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AB4330DCD3EEBDC69D306F399C1C3A52" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3D35FCE098484E418FAA6F399C1C4AFB" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AB4330DCD3EEBDC69D306F399C1C3A52" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6D782341AEEA9511DE326F39A00DF6D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_56D574BC3F1FC826ACC76F39A00D5575" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6D782341AEEA9511DE326F39A00DF6D9" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_56D574BC3F1FC826ACC76F39A00D5575" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5D80618F0C17A5A34DBAFCF51F7C0E07" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5D80618F0C17A5A34DBAFCF51F7C0E07" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_76407525B0365CCDB91DFCF51F7DBDD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_76407525B0365CCDB91DFCF51F7DBDD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_134E101D3A5C85D0F645FCF51F7DDD4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_76407525B0365CCDB91DFCF51F7DBDD2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_134E101D3A5C85D0F645FCF51F7DDD4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_203940631C3A6E7A5DF4FCF51F7DB208" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_134E101D3A5C85D0F645FCF51F7DDD4C" xlink:to="loc_biib_NightstarMember_203940631C3A6E7A5DF4FCF51F7DB208" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_4B826B7702C5462D1BA8FCF51F7E101E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_4B826B7702C5462D1BA8FCF51F7E101E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_EC784515999C192AC081FCF51F7E3B53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_4B826B7702C5462D1BA8FCF51F7E101E" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_EC784515999C192AC081FCF51F7E3B53" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BG00011Member" xlink:label="loc_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_EC784515999C192AC081FCF51F7E3B53" xlink:to="loc_biib_BG00011Member_B04C3C8EECF31144FF4BFCF51F7E3C44" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PLSRMember" xlink:label="loc_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_EC784515999C192AC081FCF51F7E3B53" xlink:to="loc_biib_PLSRMember_F39B7BB3A595BA70B09FFCF51F7E6A1C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_EC784515999C192AC081FCF51F7E3B53" xlink:to="loc_biib_TGNMember_B201510ACD49629E89E0FCF51F7F1061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9251078E39100A12459BFCF51F7F080E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:to="loc_srt_ProductOrServiceAxis_9251078E39100A12459BFCF51F7F080E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9251078E39100A12459BFCF51F7F080E" xlink:to="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_8849DF30D8155E7A3A37FCF51F8031E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:to="loc_biib_TysabriProductMember_8849DF30D8155E7A3A37FCF51F8031E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_VUMERITYMember" xlink:label="loc_biib_VUMERITYMember_C2A9FDE7D34A28255B45FCF51F80F2DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:to="loc_biib_VUMERITYMember_C2A9FDE7D34A28255B45FCF51F80F2DD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_5C4FB99CF7A218362071FCF51F8093C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:to="loc_biib_SPINRAZAMember_5C4FB99CF7A218362071FCF51F8093C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_EED837B9E57DA4DF2405FCF51F807224" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:to="loc_biib_BiosimilarsMember_EED837B9E57DA4DF2405FCF51F807224" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_206D1A0429FB55ACC504FCF51F806139" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_EC701DAEEB7433F19FE9FCF51F7F0D42" xlink:to="loc_biib_TecfideraMember_206D1A0429FB55ACC504FCF51F806139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C7138F25E068EABDFA8DFCF51F809D5F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_72B8E1D3D68F3FE67655FCF51F81E9FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_72B8E1D3D68F3FE67655FCF51F81E9FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_5F2C0F36CDEEA36DA9FBFCF51F815625" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5F40AA65C1DD8E5DCEAFFCF51F811086" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_5F2C0F36CDEEA36DA9FBFCF51F815625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_151DA301A4A60C153A9DFCF51F81576E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:to="loc_srt_RangeAxis_151DA301A4A60C153A9DFCF51F81576E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_E27C6048FA62C7527215FCF51F817322" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_151DA301A4A60C153A9DFCF51F81576E" xlink:to="loc_srt_RangeMember_E27C6048FA62C7527215FCF51F817322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_232E00D7CF22FD253827FCF51F82B2C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_E27C6048FA62C7527215FCF51F817322" xlink:to="loc_srt_MinimumMember_232E00D7CF22FD253827FCF51F82B2C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_EB83D1059AD8EDC179F5FCF51F82812F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_E27C6048FA62C7527215FCF51F817322" xlink:to="loc_srt_MaximumMember_EB83D1059AD8EDC179F5FCF51F82812F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9DAA5055CF1BBEB01848FCF51F7C2089" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_F229BA92FB8B211AD58AFCF51F828CA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_F229BA92FB8B211AD58AFCF51F828CA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_E661DB3000BA7B6A20BDFCF51F8372DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_BAB7784D54E7EF3298A3FCF51F83A307" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_BAB7784D54E7EF3298A3FCF51F83A307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99C4A2AAF55AD6E65CB3FCF51F83AEDE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99C4A2AAF55AD6E65CB3FCF51F83AEDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3AE7CB2C2CE7DD4B455DFCF51F830E0C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3AE7CB2C2CE7DD4B455DFCF51F830E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_CD49AD57C3096E21C3CBFCF51F83676B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_CD49AD57C3096E21C3CBFCF51F83676B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_45F32F86A8C14D72480BFCF51F847603" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_45F32F86A8C14D72480BFCF51F847603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0BDE10682FD4629E985EFCF51F84E9B6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5E7335EDB6228899429FCF51F82938E" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0BDE10682FD4629E985EFCF51F84E9B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_E59358DC0C1E3E696D83FCF51F84941A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_E59358DC0C1E3E696D83FCF51F84941A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_879D477B171E50232EE1FCF51F84CB36" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_879D477B171E50232EE1FCF51F84CB36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A232030F076F86B102CEFCF51F84E075" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A232030F076F86B102CEFCF51F84E075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1A973E4B90425708205DFCF51F852464" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1A973E4B90425708205DFCF51F852464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_871B3DDA8DBD03527E10FCF51F85E0B1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_871B3DDA8DBD03527E10FCF51F85E0B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_829F61D5344AEB9F83B5FCF51F85521C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_829F61D5344AEB9F83B5FCF51F85521C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9311943C280046D9D0B1FCF51F852ABD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9311943C280046D9D0B1FCF51F852ABD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6E3331026AF044C11E8EFCF51F854EC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6E3331026AF044C11E8EFCF51F854EC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_303FD833FE0888D30D83FCF51F854E28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_303FD833FE0888D30D83FCF51F854E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E9D513755AD4AE3D9185FCF51F869E64" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E9D513755AD4AE3D9185FCF51F869E64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2D734BD8674B2F59050AFCF51F86DBDF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2D734BD8674B2F59050AFCF51F86DBDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_063184F72774378E606BFCF51F86A359" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_99B96BA4838519314B87FCF51F857F8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_063184F72774378E606BFCF51F86A359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_C97176491EFDE6EA8AE8FCF51F864FDF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_C97176491EFDE6EA8AE8FCF51F864FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_FBAAEB2138F963CC58EDFCF51F86B7ED" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22D4024EF40B9EAAACA7FCF51F82EC7A" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_FBAAEB2138F963CC58EDFCF51F86B7ED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41555218FCE45357F1150C848E2D45AB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41555218FCE45357F1150C848E2D45AB" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_A4EA2395A75DFDC2C53A0C848E2E1ED6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:to="loc_biib_CumulativeSalesLevelAxis_A4EA2395A75DFDC2C53A0C848E2E1ED6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_56AB8522388FECFF24C60C848E2E5CC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_A4EA2395A75DFDC2C53A0C848E2E1ED6" xlink:to="loc_biib_CumulativeSalesLevelDomain_56AB8522388FECFF24C60C848E2E5CC8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5AEA6CA3A7ECAC3DF21F0C848E2E7052" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_56AB8522388FECFF24C60C848E2E5CC8" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5AEA6CA3A7ECAC3DF21F0C848E2E7052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F031355F8C6BBEC49C790C848E2F9971" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F031355F8C6BBEC49C790C848E2F9971" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25DC85836D0FC50D7BB40C848E2F9D35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F031355F8C6BBEC49C790C848E2F9971" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25DC85836D0FC50D7BB40C848E2F9D35" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_F651084DE53152A8F3A40C848E2F93DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25DC85836D0FC50D7BB40C848E2F9D35" xlink:to="loc_biib_BioverativMember_F651084DE53152A8F3A40C848E2F93DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_43903B6FEE79F37787880C848E2F744E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_43903B6FEE79F37787880C848E2F744E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33DB105FFB8CA75FA75B0C848E30C9C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43903B6FEE79F37787880C848E2F744E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33DB105FFB8CA75FA75B0C848E30C9C9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_F665E16285F01584EB770C848E303D45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33DB105FFB8CA75FA75B0C848E30C9C9" xlink:to="loc_biib_FumapharmAgMember_F665E16285F01584EB770C848E303D45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_53E7BAF3BBFD12B37F870C848E30C7BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:to="loc_srt_ProductOrServiceAxis_53E7BAF3BBFD12B37F870C848E30C7BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_406B0B6C8D034172DF430C848E302051" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_53E7BAF3BBFD12B37F870C848E30C7BC" xlink:to="loc_srt_ProductsAndServicesDomain_406B0B6C8D034172DF430C848E302051" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_FBC61B6DE460E4883C9B0C848E312592" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_406B0B6C8D034172DF430C848E302051" xlink:to="loc_biib_TecfideraMember_FBC61B6DE460E4883C9B0C848E312592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DCAC07F6704E47FA6340C848E2D32D2" xlink:to="loc_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9C47D01E412A7AC583AD0C848E316B6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9C47D01E412A7AC583AD0C848E316B6D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_6C7CD0C025A00B61B9A90C848E32EC00" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:to="loc_biib_CumulativeSalesLevel_6C7CD0C025A00B61B9A90C848E32EC00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7ED958CCFF802D2F6E040C848E32B614" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_FF5205688CE8AB2157170C848E314C01" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7ED958CCFF802D2F6E040C848E32B614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41555218FCE45357F1150C848E2D45AB" xlink:to="loc_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_86A960CE55EEC427BF8A0C848E32817D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC" xlink:to="loc_us-gaap_Goodwill_86A960CE55EEC427BF8A0C848E32817D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_817ADA97CE5061FD542A0C848E33E102" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_817ADA97CE5061FD542A0C848E33E102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_72CCF47F5D2160E3CFB80C848E33CD55" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_72CCF47F5D2160E3CFB80C848E33CD55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_BD5B24E2701CD445CEE20C848E346077" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_BD5B24E2701CD445CEE20C848E346077" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_CCED0CFDA1F8553A9E950C848E342AF4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8174CEFE47D6060449CB0C848E326AAC" xlink:to="loc_us-gaap_Goodwill_CCED0CFDA1F8553A9E950C848E342AF4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05A8EC1CD7FF8D5A52806F399CA1E5DF" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_49503DA4D5A3092ECA9B6F399CA191CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05A8EC1CD7FF8D5A52806F399CA1E5DF" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_49503DA4D5A3092ECA9B6F399CA191CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B7BDE8D77D6F2FE5630C6F399CA1A237" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05A8EC1CD7FF8D5A52806F399CA1E5DF" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_B7BDE8D77D6F2FE5630C6F399CA1A237" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_3BDED41DC86EDB39EF756F399CA19B2E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05A8EC1CD7FF8D5A52806F399CA1E5DF" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_3BDED41DC86EDB39EF756F399CA19B2E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3E2FCBCD42A63DED97916F399EEE0678" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_A8CC65A2949E9BE041E36F399EEF59CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3E2FCBCD42A63DED97916F399EEE0678" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_A8CC65A2949E9BE041E36F399EEF59CA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9427E9BECD6A18E1BCA56F399DC66E5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9427E9BECD6A18E1BCA56F399DC66E5C" xlink:to="loc_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_24B3EB896C662C3DA4F56F399DC7FD94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_24B3EB896C662C3DA4F56F399DC7FD94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_635E5C71271BC40FC2496F399DC76444" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_635E5C71271BC40FC2496F399DC76444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_937DD558DBE8B66B2EE26F399DC74118" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_937DD558DBE8B66B2EE26F399DC74118" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_506562273EE5C78EEE266F399DC72257" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DA803790C28D4DEB3AA86F399DC69776" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_506562273EE5C78EEE266F399DC72257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_EDE58A62B7188CFA9E086F399DC7ACB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9427E9BECD6A18E1BCA56F399DC66E5C" xlink:to="loc_us-gaap_InventoryNet_EDE58A62B7188CFA9E086F399DC7ACB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_F740B0BB43A011D2729D6F399DC842E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9427E9BECD6A18E1BCA56F399DC66E5C" xlink:to="loc_us-gaap_InventoryNoncurrent_F740B0BB43A011D2729D6F399DC842E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1B5C347A888440790AB7F00F392BC449" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1B5C347A888440790AB7F00F392BC449" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_9C9887D6E78B4FF6134BF00F392CF9D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:to="loc_srt_MajorCustomersAxis_9C9887D6E78B4FF6134BF00F392CF9D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_222325D1D5F0286DB0B1F00F392C6DDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9C9887D6E78B4FF6134BF00F392CF9D8" xlink:to="loc_srt_NameOfMajorCustomerDomain_222325D1D5F0286DB0B1F00F392C6DDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_777C47CCF24B806AB08FF00F392CD560" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_222325D1D5F0286DB0B1F00F392C6DDD" xlink:to="loc_biib_BioverativMember_777C47CCF24B806AB08FF00F392CD560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_877592DF2A2555E2DBF6F00F392DAF5E" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ED97B447F67D4B99F6F0F00F392DDDFE" xlink:to="loc_biib_WorkinprocessMember_13A79D2FD5D7A1E2F5B1F00F392D4E81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F71A3510D271F7D1EF15F00F392D5E4E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F71A3510D271F7D1EF15F00F392D5E4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1721172AD8D98B14F35FF00F392E1CA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F71A3510D271F7D1EF15F00F392D5E4E" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1721172AD8D98B14F35FF00F392E1CA5" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1721172AD8D98B14F35FF00F392E1CA5" xlink:to="loc_biib_BioverativMember_777C47CCF24B806AB08FF00F392CD560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_735F6C703FC6FD08FB1BF00F392C0079" xlink:to="loc_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InventorysoldtoBioverativcost" xlink:label="loc_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:to="loc_biib_InventorysoldtoBioverativcost_1DD960547D95507225A0F00F392EE008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2EA3D7A82980566890C8F00F392F6FAB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2EA3D7A82980566890C8F00F392F6FAB" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_3309C5981D23301A4287F00F392EE9C7" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_164690624655152D379FF00F392FDF85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_C8630E2E95A40CB4BC40F00F392F2E1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1B5C347A888440790AB7F00F392BC449" xlink:to="loc_us-gaap_InventoryWriteDown_C8630E2E95A40CB4BC40F00F392F2E1A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_F878B4C4BE7D967FF9206F399CEA0BAA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_346E789792DF7BA15A206F399CEA32C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F878B4C4BE7D967FF9206F399CEA0BAA" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_346E789792DF7BA15A206F399CEA32C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:href="biib-20191231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_C34133B412ADFA60CB8A6F399C1F6D76" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_09F017090E1693AFED4A6F399C1F7A19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_C34133B412ADFA60CB8A6F399C1F6D76" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_09F017090E1693AFED4A6F399C1F7A19" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20191231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_65A0D9043A7BD42213EEE873AB6062AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_65A0D9043A7BD42213EEE873AB6062AE" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_7277F86E3EEC14963696E8C959AC07CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_7277F86E3EEC14963696E8C959AC07CE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_AA5EC6CAA08283892F53E8C959ADE8E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_7277F86E3EEC14963696E8C959AC07CE" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_AA5EC6CAA08283892F53E8C959ADE8E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_4C9366955522F95CE31CE8C978842DDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_AA5EC6CAA08283892F53E8C959ADE8E7" xlink:to="loc_biib_RegulatoryMilestonesMember_4C9366955522F95CE31CE8C978842DDE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RegulatoryApprovalMilestoneMember" xlink:label="loc_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_AA5EC6CAA08283892F53E8C959ADE8E7" xlink:to="loc_biib_RegulatoryApprovalMilestoneMember_CA6700F10482993C62C6E8C959CB30D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_FCF5FD3665DE57AD00B8E873AB604888" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D9D598F0DB836317D678E873AB60485F" xlink:to="loc_biib_NeurimmuneMember_B97A4C794A3FA61A3410E873AB612455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_912259FF5FF5B5493E9BE873AB60AAF1" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_D04778A35D30B2A98CFDE873AB617B1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_D04778A35D30B2A98CFDE873AB617B1D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_05185CF9A5DE43EA89C1E873AB62E9BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_36D71F5F83A106E131AAE8C9599AE97F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_36D71F5F83A106E131AAE8C9599AE97F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_1E475EA5765FCFF07873E873AB6242C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D08FC901AB8F10618C79E873AB612DF2" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_0B2A52B130674AC212E7E873AB622E85" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_52F02CA66B2B856AEB05E873AB627550" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesLeases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_7D433213FF483E125985D257879ADDCE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_71D8523B7555FBB8FB3CD25A59C010DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7D433213FF483E125985D257879ADDCE" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_71D8523B7555FBB8FB3CD25A59C010DE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_F204F29AECFA8220D32FE873ACFE3186" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_490578E17F08AB2D7EA1E873ACFE41A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_F204F29AECFA8220D32FE873ACFE3186" xlink:to="loc_us-gaap_StatementTable_490578E17F08AB2D7EA1E873ACFE41A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_79E7677A4D3BE6ECBBA6E873ACFED211" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_490578E17F08AB2D7EA1E873ACFE41A9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_79E7677A4D3BE6ECBBA6E873ACFED211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_128431542480760D54B0E873ACFE02EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_79E7677A4D3BE6ECBBA6E873ACFED211" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_128431542480760D54B0E873ACFE02EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4C0C920495FE3C231937E873ACFE381E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_128431542480760D54B0E873ACFE02EF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4C0C920495FE3C231937E873ACFE381E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6EEF44064F9553CE800CE873ACFEE932" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_128431542480760D54B0E873ACFE02EF" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6EEF44064F9553CE800CE873ACFEE932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_688F9C3CCA0E03128F16E873ACFE49F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_128431542480760D54B0E873ACFE02EF" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_688F9C3CCA0E03128F16E873ACFE49F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4B31DAD7EBD2667858BEE873ACFE4F89" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_490578E17F08AB2D7EA1E873ACFE41A9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4B31DAD7EBD2667858BEE873ACFE4F89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_114D20B357D865220FACE873ACFE6C93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4B31DAD7EBD2667858BEE873ACFE4F89" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_114D20B357D865220FACE873ACFE6C93" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OperatingleaseassetsMember" xlink:label="loc_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_114D20B357D865220FACE873ACFE6C93" xlink:to="loc_biib_OperatingleaseassetsMember_6A3BC7A896DAC4F8C6A5E873ACFE2392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_655CA9D5362DE5C0A745E873ACFE119D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_114D20B357D865220FACE873ACFE6C93" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_655CA9D5362DE5C0A745E873ACFE119D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_114D20B357D865220FACE873ACFE6C93" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_01211CC99ABBE5E6B36BE873ACFE89E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_490578E17F08AB2D7EA1E873ACFE41A9" xlink:to="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E3DFE77C75FFAFA29F27E873ACFE0F26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_E3DFE77C75FFAFA29F27E873ACFE0F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_A57A2E631B44004D08E6E873ACFED1CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_A57A2E631B44004D08E6E873ACFED1CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1DA6DEB86E9504AC7F1DE873ACFE00D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1DA6DEB86E9504AC7F1DE873ACFE00D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_41DD7E9C9416E60AE3DAE873ACFE623C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseLiability_41DD7E9C9416E60AE3DAE873ACFE623C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_A0AAFC451DCF66B94E88E873ACFEE554" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseCost_A0AAFC451DCF66B94E88E873ACFEE554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_38B5618B7FB4C4014B6DE873ACFEB867" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_VariableLeaseCost_38B5618B7FB4C4014B6DE873ACFEB867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_C8DF49B509F66D2295B7E873ACFE1D2C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_C8DF49B509F66D2295B7E873ACFE1D2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_4146C61A9D009224884EE873ACFE4709" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LeaseCost_4146C61A9D009224884EE873ACFE4709" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0D5C0ABEB1A24CA818BBE873ACFE0025" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0D5C0ABEB1A24CA818BBE873ACFE0025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8D02DB6BDCA841E314CEE873ACFEFF8B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8D02DB6BDCA841E314CEE873ACFEFF8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_A9F8D5A07239E0C4986EE873ACFE6087" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_A9F8D5A07239E0C4986EE873ACFE6087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12634B2A6D58CF51EB87E873ACFE6BC4" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12634B2A6D58CF51EB87E873ACFE6BC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E9C2C54AC791981B5785E873ACFE052C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E9C2C54AC791981B5785E873ACFE052C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_EC5E29C41E15FE62D7F8E873ACFEA899" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_EC5E29C41E15FE62D7F8E873ACFEA899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50871FF0B2E4A1AB8CB7E873ACFE5C80" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50871FF0B2E4A1AB8CB7E873ACFE5C80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ECB2AC2DD6555BFDFC7CE873ACFEED28" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ECB2AC2DD6555BFDFC7CE873ACFEED28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_944C1400F71AE4D7CEBBE873ACFE0A98" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_944C1400F71AE4D7CEBBE873ACFE0A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_754A59424AAA3453C12BE873ACFE6704" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_754A59424AAA3453C12BE873ACFE6704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_88A184F73226FA0F2690E873ACFE6A79" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_88A184F73226FA0F2690E873ACFE6A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_694B2DD4EAFF69B067AEE873ACFEBE4D" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_694B2DD4EAFF69B067AEE873ACFEBE4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_BEF3E8FCCB751566D088E873ACFE05F5" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_BEF3E8FCCB751566D088E873ACFE05F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_46792EE4582066F1DC99E873ACFE30D2" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_46792EE4582066F1DC99E873ACFE30D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_91B010E801E6713C03CBE873ACFE12AD" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_91B010E801E6713C03CBE873ACFE12AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_02513600D9BB7B76F0E3E873ACFE7378" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_02513600D9BB7B76F0E3E873ACFE7378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7EF337BF8354CE05BC4BE873ACFE6070" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7EF337BF8354CE05BC4BE873ACFE6070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_95A1DEF2CACE49C9D83BE873AD0D6D12" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_95A1DEF2CACE49C9D83BE873AD0D6D12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_5857B058FEC9F360BE0CE873AD0D8929" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_5857B058FEC9F360BE0CE873AD0D8929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_99A836EB41F10721FE35E873AD0DD9AD" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_99A836EB41F10721FE35E873AD0DD9AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_A4C2A3D62418A61136ABE873AD0D2853" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_A4C2A3D62418A61136ABE873AD0D2853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_F81D905374E0C0533986E873AD0DCA3D" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_F81D905374E0C0533986E873AD0DCA3D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4B259D52F71AA5CA4B7CE873AD0DF1B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_664846064B5D3FF0E8EDE873AD0DC561" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_2DEE28C6438945D7E316E873AD0D4038" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFourYear_7AFE6CFE373EB1E51D5BE873AD0DFFB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_25CAB77D7E0B0F3DCB68E873AD0DCA19" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePaymentsThereafter_AD35614D110C53A3AA17E873AD0D6B95" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_biib_NetMinimumLeasePayments_10AD58ECE8150C3B26A6E873AD0DD12D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5567F9123F004B5D3547E8B1DE72FF82" xlink:type="locator" />
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5567F9123F004B5D3547E8B1DE72FF82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6F9D0F4F48E08F68BD32E8B1DFF2FC3C" xlink:type="locator" />
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6F9D0F4F48E08F68BD32E8B1DFF2FC3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_75E1E4279E68E8758DB4E8B3C011F458" xlink:type="locator" />
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_OperatingLeasePayments_75E1E4279E68E8758DB4E8B3C011F458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2DD2A954B517177A6EA0E8B3C1D10B82" xlink:type="locator" />
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DED9879E296D5E1BDF41E873ACFE51FB" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2DD2A954B517177A6EA0E8B3C1D10B82" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_68D6B649DDA5D0E306C30B39D4900013" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_68D6B649DDA5D0E306C30B39D4900013" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_8251B20F5E805CFB516B0B3A7FE59793" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SubleaseMember" xlink:label="loc_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_F5AE2E02254B84F3D3280B3BFDAFFC64" xlink:to="loc_biib_SubleaseMember_BF224695489F359DE5CA0B3AF3B690AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9120121AADCC4B603E110B39D4A1168B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:to="loc_srt_RangeAxis_9120121AADCC4B603E110B39D4A1168B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_E966BC536E298113CA9F0B39D4A28704" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9120121AADCC4B603E110B39D4A1168B" xlink:to="loc_srt_RangeMember_E966BC536E298113CA9F0B39D4A28704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D4E014255C054EEB27640B39D4A26B44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_E966BC536E298113CA9F0B39D4A28704" xlink:to="loc_srt_MinimumMember_D4E014255C054EEB27640B39D4A26B44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_379D2E905D13C2B05E230B39D4A37839" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_E966BC536E298113CA9F0B39D4A28704" xlink:to="loc_srt_MaximumMember_379D2E905D13C2B05E230B39D4A37839" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6C5AFDFC513A5E42C22D0B39D4A0C96A" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_AD9C523BE4768E0EA2270B39D4A304B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_AD9C523BE4768E0EA2270B39D4A304B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_A5F1B34B1434DA34DB400B39D4A3E838" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_DB740C4CD028EEFB65CE0B39D4A3D384" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_A5F1B34B1434DA34DB400B39D4A3E838" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_06B2B9F3BB99F0211496E873AD0D705D" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_LesseeLeaseTableTableTextBlock" xlink:label="loc_biib_LesseeLeaseTableTableTextBlock_1BEC6A8F13335943C714E873AD0DB8E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_06B2B9F3BB99F0211496E873AD0D705D" xlink:to="loc_biib_LesseeLeaseTableTableTextBlock_1BEC6A8F13335943C714E873AD0DB8E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_B3F802B96FA03D33036CE873AD0DABDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_06B2B9F3BB99F0211496E873AD0D705D" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_B3F802B96FA03D33036CE873AD0DABDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D73672C802748C3893A2E873AD0D403B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_06B2B9F3BB99F0211496E873AD0D705D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D73672C802748C3893A2E873AD0D403B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E2DFF5B44550308F38B3E873AD0D6986" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_06B2B9F3BB99F0211496E873AD0D705D" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E2DFF5B44550308F38B3E873AD0D6986" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:label="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_CF863AD0C22CFF2873B1E8B29E768752" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_06B2B9F3BB99F0211496E873AD0D705D" xlink:to="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_CF863AD0C22CFF2873B1E8B29E768752" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:label="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_9BE62EA19BE1DC75EA34E8B33A9C23D8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_06B2B9F3BB99F0211496E873AD0D705D" xlink:to="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_9BE62EA19BE1DC75EA34E8B33A9C23D8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_10D116A8FE9E4825D5036F399E6B315A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_3E4796A7D6A30354B83A6F399E6B05E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_10D116A8FE9E4825D5036F399E6B315A" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_3E4796A7D6A30354B83A6F399E6B05E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20191231.xsd#biib_TaxcontingencyAbstract" xlink:label="loc_biib_TaxcontingencyAbstract_AC9BDE994B016C53D013EC4300D87B77" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxcontingencyAbstract_AC9BDE994B016C53D013EC4300D87B77" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_543A7FE06C00EF633127EC4300D915A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_543A7FE06C00EF633127EC4300D915A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_B651D1D6B5D8A170C3C1EC4300DAA390" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_543A7FE06C00EF633127EC4300D915A3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_B651D1D6B5D8A170C3C1EC4300DAA390" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_108E8F80FA8FF0778A0AEC4300DA8BB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_B651D1D6B5D8A170C3C1EC4300DAA390" xlink:to="loc_country_BR_108E8F80FA8FF0778A0AEC4300DA8BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_21FF9099A66DC98FA99FEC4300D8B274" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_6AFFEC1B939E58D0078BEC440AE23982" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_6AFFEC1B939E58D0078BEC440AE23982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_E1BC5CD438C1823810C2EC4300DBABC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_C04D9E0634C629A568A3EC4300DA2A8A" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_E1BC5CD438C1823810C2EC4300DBABC0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7BAEA7140F8ACB5BE13A6F399DA37087" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1B5D70B6C124F91D8AD56F399DA34E15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7BAEA7140F8ACB5BE13A6F399DA37087" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1B5D70B6C124F91D8AD56F399DA34E15" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45346AC9564B1FCC1640FC3A1862E800" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9F8F065BD098388A9225FC3A18627124" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45346AC9564B1FCC1640FC3A1862E800" xlink:to="loc_us-gaap_StatementTable_9F8F065BD098388A9225FC3A18627124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6CF21327CFE33A339B82FC3A18721648" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9F8F065BD098388A9225FC3A18627124" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6CF21327CFE33A339B82FC3A18721648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_59A608DD3DBB4320633BFC3A18721547" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6CF21327CFE33A339B82FC3A18721648" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_59A608DD3DBB4320633BFC3A18721547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_86CBB46F7E11496FD5E0FC3A187241E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_59A608DD3DBB4320633BFC3A18721547" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_86CBB46F7E11496FD5E0FC3A187241E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5DC326937AD3DA3DEF50FC3A1872237A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9F8F065BD098388A9225FC3A18627124" xlink:to="loc_us-gaap_StatementLineItems_5DC326937AD3DA3DEF50FC3A1872237A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_8CAC97D3CCD6F6BD2737FC3A1872C3C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5DC326937AD3DA3DEF50FC3A1872237A" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_8CAC97D3CCD6F6BD2737FC3A1872C3C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_2BFC332CFB441C21072EFC3A1872D6CE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5DC326937AD3DA3DEF50FC3A1872237A" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_2BFC332CFB441C21072EFC3A1872D6CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855D1A624C8EE961EFC7FC3A1872939B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5DC326937AD3DA3DEF50FC3A1872237A" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855D1A624C8EE961EFC7FC3A1872939B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7FC88EE673233B7EB3EBFC3A1872A8AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45346AC9564B1FCC1640FC3A1862E800" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7FC88EE673233B7EB3EBFC3A1872A8AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_53F1809CAB777D65FEA6FC3A18721727" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7FC88EE673233B7EB3EBFC3A1872A8AE" xlink:to="loc_us-gaap_InterestPaidNet_53F1809CAB777D65FEA6FC3A18721727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_7DEFD1825E50CBCE72ACFC3A1872D310" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7FC88EE673233B7EB3EBFC3A1872A8AE" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_7DEFD1825E50CBCE72ACFC3A1872D310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418" xlink:type="locator" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45346AC9564B1FCC1640FC3A1862E800" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0F919C80ECC285FDDCE0FC3A1872DCC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0F919C80ECC285FDDCE0FC3A1872DCC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_926E98E00C6FABFA6DEBFC3A18728BC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418" xlink:to="loc_us-gaap_InterestExpense_926E98E00C6FABFA6DEBFC3A18728BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_38745D4E6F4B6CA30A63FC3A1872DB27" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_38745D4E6F4B6CA30A63FC3A1872DB27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ED4DED4BBB46612EAFFFFC3A1872BCB0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ED4DED4BBB46612EAFFFFC3A1872BCB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C6E9A436BA423BD2CA01FC3A1872927D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_C6E9A436BA423BD2CA01FC3A1872927D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_27877418B5532E70C7B6FC3A1872CC17" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_18700E0CCE49B5C21EE6FC3A1872C418" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_27877418B5532E70C7B6FC3A1872CC17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:type="locator" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45346AC9564B1FCC1640FC3A1862E800" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_895BE09EE6E8E766B7C7FC3A1872C1BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_895BE09EE6E8E766B7C7FC3A1872C1BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_622A087D5388A2E403BAFC3A1872E7B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_622A087D5388A2E403BAFC3A1872E7B8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_E7EC3470AA5C1769C21DFC3A18727AF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:to="loc_biib_Collaborationexpensesaccrual_E7EC3470AA5C1769C21DFC3A18727AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_B8BD913397B4311D9D87FC3A18728E52" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_B8BD913397B4311D9D87FC3A18728E52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F7EBB47AA5D66B6BADCFFC3A1872E62C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F7EBB47AA5D66B6BADCFFC3A1872E62C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_8414056FB10AC5129EEEFC3A187280CB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_8414056FB10AC5129EEEFC3A187280CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_A2647F50B8E0B73699DCFC3A1872F19E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_A2647F50B8E0B73699DCFC3A1872F19E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2E880DC6DFC3C24ED509FC3A1872F6F5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_D6A05156D08EDAA8C393FC3A18725FE6" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2E880DC6DFC3C24ED509FC3A1872F6F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FAE88DE216454907D9E6E873ABC5CEED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FAE88DE216454907D9E6E873ABC5CEED" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_5E3027DCF91EF51B6B60E873ABC55E7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:to="loc_srt_ProductOrServiceAxis_5E3027DCF91EF51B6B60E873ABC55E7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2EAB86EEC61F13DF4CA4E873ABC5DDDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5E3027DCF91EF51B6B60E873ABC55E7C" xlink:to="loc_srt_ProductsAndServicesDomain_2EAB86EEC61F13DF4CA4E873ABC5DDDF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_FE0EC6D428FD15777A8FE873ABC5AA6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2EAB86EEC61F13DF4CA4E873ABC5DDDF" xlink:to="loc_biib_TecfideraMember_FE0EC6D428FD15777A8FE873ABC5AA6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_82A24D08BAF77CD498E7E873ABC50D64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_82A24D08BAF77CD498E7E873ABC50D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88356E8861828208B497E873ABC53693" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_82A24D08BAF77CD498E7E873ABC50D64" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88356E8861828208B497E873ABC53693" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_3D7F692A7AF3AB51EC98E873ABC5437A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88356E8861828208B497E873ABC53693" xlink:to="loc_biib_FumapharmAgMember_3D7F692A7AF3AB51EC98E873ABC5437A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_83EA04AAC86E96535942E873ABC5AEDE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:to="loc_biib_FacilityLocationAxis_83EA04AAC86E96535942E873ABC5AEDE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_68FF1792F9E22558B2C9E873ABC5EFC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_83EA04AAC86E96535942E873ABC5AEDE" xlink:to="loc_biib_FacilityLocationDomain_68FF1792F9E22558B2C9E873ABC5EFC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_724B9F3D5F54DB6B6E14E873ABC5A5B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_68FF1792F9E22558B2C9E873ABC5EFC6" xlink:to="loc_biib_SolothurnMember_724B9F3D5F54DB6B6E14E873ABC5A5B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_4D53438EE94D0165652BE873ABC5FA88" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:to="loc_biib_CumulativeSalesLevelAxis_4D53438EE94D0165652BE873ABC5FA88" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_4D53438EE94D0165652BE873ABC5FA88" xlink:to="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TwentybillionMember" xlink:label="loc_biib_TwentybillionMember_A2682074F9EEA6A79DAEE873ABC5AFAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0" xlink:to="loc_biib_TwentybillionMember_A2682074F9EEA6A79DAEE873ABC5AFAD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_B0EAA1FA9686FDF1B010E873ABC52BED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_B0EAA1FA9686FDF1B010E873ABC52BED" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0" xlink:to="loc_biib_FifteenbillionMemberMember_E5B43EEEA6D31C31DC11E873ABC58229" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_A7D2979595801A223DF6E873ABC545B0" xlink:to="loc_biib_SixteenbillionMember_5C92FE5C061F7B3E1217E873ABC57042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE63A10FEB48837C3F36E873ABC5CBCE" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_D0DA91D4460C6654BFD1E873ABC5AA56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_D0DA91D4460C6654BFD1E873ABC5AA56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_0438348BF2FDD8FB9CF7E873ABC569CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_0438348BF2FDD8FB9CF7E873ABC569CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_17D448A297A3ADFA8A07E873ABC5E83C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:to="loc_biib_CumulativeSalesLevel_17D448A297A3ADFA8A07E873ABC5E83C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_F5B46AB79A83500B56BDE873ABC535F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_F5B46AB79A83500B56BDE873ABC535F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1469D5365E6242E58C53E873ABC56A3F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DA23259A23FA8B4EDF93E873ABC54614" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1469D5365E6242E58C53E873ABC56A3F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87426EE94294A3B652E9D10B83346BFE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_50D8A74DF85B18B9E2A5D10B833431F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87426EE94294A3B652E9D10B83346BFE" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_50D8A74DF85B18B9E2A5D10B833431F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D147678F407F2C2D76CDD10B83346C33" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87426EE94294A3B652E9D10B83346BFE" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D147678F407F2C2D76CDD10B83346C33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_7BCB364F54A65EE84726D145EC5319C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87426EE94294A3B652E9D10B83346BFE" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_7BCB364F54A65EE84726D145EC5319C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6121155DFB9E4E4360E7D10B83346CAE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87426EE94294A3B652E9D10B83346BFE" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6121155DFB9E4E4360E7D10B83346CAE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E5D424CB8592A485B9976F399E5FDA64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51AD544315CA1E7532C26F399E5F8801" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E5D424CB8592A485B9976F399E5FDA64" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51AD544315CA1E7532C26F399E5F8801" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CECF48665E9F1F566ADB6F399BFFEAF9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_165C9D109E1ADD5B1E736F399BFF8F61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CECF48665E9F1F566ADB6F399BFFEAF9" xlink:to="loc_us-gaap_Land_165C9D109E1ADD5B1E736F399BFF8F61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_5A0674A657C9D031B5DB6F399C00DC92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CECF48665E9F1F566ADB6F399BFFEAF9" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_5A0674A657C9D031B5DB6F399C00DC92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_C26E8DC718DF6F2FDEF56F399C00387E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CECF48665E9F1F566ADB6F399BFFEAF9" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_C26E8DC718DF6F2FDEF56F399C00387E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_17E85222530846C297856F399C003F33" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CECF48665E9F1F566ADB6F399BFFEAF9" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_17E85222530846C297856F399C003F33" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_2F9AA4D37067352C07016F399C00E087" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CECF48665E9F1F566ADB6F399BFFEAF9" xlink:to="loc_biib_ComputerSoftwareAndHardware_2F9AA4D37067352C07016F399C00E087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_6218B658823395CC7D396F399C00C4DA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CECF48665E9F1F566ADB6F399BFFEAF9" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_6218B658823395CC7D396F399C00C4DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_28C3C5E3A407B3C22C2A6F399C011631" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CECF48665E9F1F566ADB6F399BFFEAF9" xlink:to="loc_us-gaap_ConstructionInProgressGross_28C3C5E3A407B3C22C2A6F399C011631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_D5F634E2C1CDF89777016F399C01F362" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CECF48665E9F1F566ADB6F399BFFEAF9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_D5F634E2C1CDF89777016F399C01F362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A68F86372C509116889C6F399C01FBA1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CECF48665E9F1F566ADB6F399BFFEAF9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A68F86372C509116889C6F399C01FBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2DAD4A970A5204755D8D6F399C01AEBC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CECF48665E9F1F566ADB6F399BFFEAF9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2DAD4A970A5204755D8D6F399C01AEBC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1CDD17B3DB70F7619B237F76C661FE0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1CDD17B3DB70F7619B237F76C661FE0C" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A148C600E3839704921A7FFAEC453CE0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_C96E33F52FAE49F936287FFAEC8567FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:to="loc_us-gaap_BuildingMember_C96E33F52FAE49F936287FFAEC8567FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_51C92F43A0116072DB397FFB36F0C9CE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_896D4BFA1E456D14FA4A7FFAEC4544D1" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_51C92F43A0116072DB397FFB36F0C9CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EC4EE275FD81755F33997FFAB2A3E5E9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_175FB4D8D2A179214BDF7FFAB2A4C0C8" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_6EF4CE954EC10AE590A37FFAB2DBCE54" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:to="loc_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_04B6B21089D56B2609EE7F76C6613D97" xlink:to="loc_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_6C1C71831023915067027F76C671191D" xlink:to="loc_biib_SolothurnMember_54A69D3C59EFEB7B44C97F76C671DBE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40DBD61ABD60AF44D5DA7F76C6619B52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_907D1C2AF1C36C707B5B7F76C671DCCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:to="loc_us-gaap_Depreciation_907D1C2AF1C36C707B5B7F76C671DCCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_F9F1C3E4B42004EEA1327F76C671BA2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:to="loc_us-gaap_InterestCostsCapitalized_F9F1C3E4B42004EEA1327F76C671BA2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_FBF8572BE4CC3A94101F7F76C6717CBB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:to="loc_us-gaap_ConstructionInProgressGross_FBF8572BE4CC3A94101F7F76C6717CBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_765C96E64FF77D0080197FFAB1EFCA53" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53745339C931A6140A5D7F76C671B0CC" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_765C96E64FF77D0080197FFAB1EFCA53" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4E503C45F88DEF0BFBB06F399E37DF9C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8030C1B5691DBF3FC6196F399E3860AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4E503C45F88DEF0BFBB06F399E37DF9C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8030C1B5691DBF3FC6196F399E3860AF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D6FA79D0D1896659833F6F399ED4FCF9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_BEA1FA3BAEDC742448456F399ED4B14E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D6FA79D0D1896659833F6F399ED4FCF9" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_BEA1FA3BAEDC742448456F399ED4B14E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_98D987302EE33D87072E6F39A046E7C2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_27FAA747D78312BA4AA26F39A04619B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_98D987302EE33D87072E6F39A046E7C2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_27FAA747D78312BA4AA26F39A04619B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_59C78CF8977ECF4B02186F39A0472822" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27FAA747D78312BA4AA26F39A04619B3" xlink:to="loc_srt_ProductOrServiceAxis_59C78CF8977ECF4B02186F39A0472822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9AC57711B7E2F340A8136F39A0476D70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_59C78CF8977ECF4B02186F39A0472822" xlink:to="loc_srt_ProductsAndServicesDomain_9AC57711B7E2F340A8136F39A0476D70" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9AC57711B7E2F340A8136F39A0476D70" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_AA0540AD4B99AF15AF186F39A0472699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_2643F74D19A408D5E66A6F39A048CD7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9AC57711B7E2F340A8136F39A0476D70" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_2643F74D19A408D5E66A6F39A048CD7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_1A1E666DAB38CF24A11B6F39A04873E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9AC57711B7E2F340A8136F39A0476D70" xlink:to="loc_us-gaap_ProductMember_1A1E666DAB38CF24A11B6F39A04873E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3F81135A15C490F9A91F6F39A048315F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27FAA747D78312BA4AA26F39A04619B3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3F81135A15C490F9A91F6F39A048315F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_98D987302EE33D87072E6F39A046E7C2" xlink:to="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_10391DDEDBA1E3B9C2056F39A04899BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:to="loc_us-gaap_Revenues_10391DDEDBA1E3B9C2056F39A04899BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_C2773479C0BD87B2E34D6F39A049D44A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:to="loc_us-gaap_GrossProfit_C2773479C0BD87B2E34D6F39A049D44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_542201AD023CB81F9EC46F39A0495855" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:to="loc_us-gaap_ProfitLoss_542201AD023CB81F9EC46F39A0495855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0F2F5DBD85D9417979E56F39A049AA52" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:to="loc_us-gaap_NetIncomeLoss_0F2F5DBD85D9417979E56F39A049AA52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_86007CA20B54F25467C56F39A049F5F6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:to="loc_us-gaap_EarningsPerShareBasic_86007CA20B54F25467C56F39A049F5F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_DFB2FF9169272A01A8376F39A0493E5A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:to="loc_us-gaap_EarningsPerShareDiluted_DFB2FF9169272A01A8376F39A0493E5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_22F68EE1CB0A269B358F6F39A04AF952" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_22F68EE1CB0A269B358F6F39A04AF952" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B4A612A5D4742E186D286F39A04ABD08" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_19F9E2C9281424B9F7E36F39A0485775" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B4A612A5D4742E186D286F39A04ABD08" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4F6BDDC44C3251CE2684FC3A1797A3B5" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4F6BDDC44C3251CE2684FC3A1797A3B5" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A77E4F566767A457F6D2FC3A17979752" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A77E4F566767A457F6D2FC3A17979752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_782464A21A1BF2AB927CFC3A17984B22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A77E4F566767A457F6D2FC3A17979752" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_782464A21A1BF2AB927CFC3A17984B22" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_ADA73E29628A52259661FC3A1798A465" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_782464A21A1BF2AB927CFC3A17984B22" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_ADA73E29628A52259661FC3A1798A465" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_E5B0ADF56B074519F84FFC3A1798355B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_E5B0ADF56B074519F84FFC3A1798355B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0288AB0B3012E8081D98FC3A17984B36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_E5B0ADF56B074519F84FFC3A1798355B" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0288AB0B3012E8081D98FC3A17984B36" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_86875B747532992E12F7FC3A1799FAA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0288AB0B3012E8081D98FC3A17984B36" xlink:to="loc_biib_U.S.2017TaxActMember_86875B747532992E12F7FC3A1799FAA2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_00C86E83C3F05EBBB374FC3A1799377D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_00C86E83C3F05EBBB374FC3A1799377D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_DD337D3B70EF3B82DDB8FC3A17990C92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_00C86E83C3F05EBBB374FC3A1799377D" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_DD337D3B70EF3B82DDB8FC3A17990C92" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_9D0EB4AC7FF024F6FA2FFC3A1799CB97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_DD337D3B70EF3B82DDB8FC3A17990C92" xlink:to="loc_biib_TGNMember_9D0EB4AC7FF024F6FA2FFC3A1799CB97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_15FF5E1420DCA9652C5DFC3A179AD764" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_15FF5E1420DCA9652C5DFC3A179AD764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FE074D6C26273955778FC3A179ACB34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_15FF5E1420DCA9652C5DFC3A179AD764" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FE074D6C26273955778FC3A179ACB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_A42E187680BF0E8C1853FC3A179A4022" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FE074D6C26273955778FC3A179ACB34" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_A42E187680BF0E8C1853FC3A179A4022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B381797A03D5F5C9D2C1FC3A179AA539" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B381797A03D5F5C9D2C1FC3A179AA539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B381797A03D5F5C9D2C1FC3A179AA539" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_55618CB645B7EA5ADB7EFC3A179BE7CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9" xlink:to="loc_biib_KaryopharmMember_55618CB645B7EA5ADB7EFC3A179BE7CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_37726A80A4C1B80AA5F3FC3A179BE4A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9" xlink:to="loc_biib_RemedyPharmaceuticalMember_37726A80A4C1B80AA5F3FC3A179BE4A1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_81ACAD00C595DC453EFDFC3A179B89B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9" xlink:to="loc_biib_PfizerMember_81ACAD00C595DC453EFDFC3A179B89B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AliveGenMember" xlink:label="loc_biib_AliveGenMember_838FE5EC0E6DD5B0F786FC3A179B7813" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558F4E8E383CE8597C9FFC3A179BADD9" xlink:to="loc_biib_AliveGenMember_838FE5EC0E6DD5B0F786FC3A179B7813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1788FE979747B97121D9FC3A179CF9C1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_srt_ProductOrServiceAxis_1788FE979747B97121D9FC3A179CF9C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_406FFBA6478455AD2FF8FC3A179C65CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1788FE979747B97121D9FC3A179CF9C1" xlink:to="loc_srt_ProductsAndServicesDomain_406FFBA6478455AD2FF8FC3A179C65CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_1BC28D0B9B6A60EA8C37FC3A179C48BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_406FFBA6478455AD2FF8FC3A179C65CF" xlink:to="loc_biib_TecfideraMember_1BC28D0B9B6A60EA8C37FC3A179C48BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ADFCA3AA0AFC6B2202E4FC3A179C7422" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ADFCA3AA0AFC6B2202E4FC3A179C7422" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D71EDCD684CD04B85867FC3A179C0DD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_ADFCA3AA0AFC6B2202E4FC3A179C7422" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D71EDCD684CD04B85867FC3A179C0DD5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_E2071C7811ED200DDFA3FC3A179DA687" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_D71EDCD684CD04B85867FC3A179C0DD5" xlink:to="loc_biib_NeurimmuneMember_E2071C7811ED200DDFA3FC3A179DA687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BBC9F285D055BF9DCE4EFC3A179DD931" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_BBC9F285D055BF9DCE4EFC3A179DD931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BBC9F285D055BF9DCE4EFC3A179DD931" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_949C0B44EAC803ACD95FFC3A179E5958" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_949C0B44EAC803ACD95FFC3A179E5958" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_15C20145FD79DB535662FC3A179EE6C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:to="loc_biib_BristolMyersSquibbMember_15C20145FD79DB535662FC3A179EE6C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_3C071247635F9DE021A1FC3A179E6184" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:to="loc_biib_IPerianMember_3C071247635F9DE021A1FC3A179E6184" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_4180B476DB7AEA8725F8FC3A179EF1D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:to="loc_biib_AlkermesMember_4180B476DB7AEA8725F8FC3A179EF1D7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_BB1796A23D19F865E805FC3A179EFFBD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97D3232A59AAAEE1E458FC3A179DDE82" xlink:to="loc_biib_IonisPharmaceuticalsMember_BB1796A23D19F865E805FC3A179EFFBD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_D37F80C9013A53A2DE53FC3A1797FB1F" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_922FB68B988028B1937FFC3A179F5B8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_922FB68B988028B1937FFC3A179F5B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_381CAEB6C4FB0D14AA06FC3A179F64B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_381CAEB6C4FB0D14AA06FC3A179F64B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_5FE3B171817E79229461FC3A179F574D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_5FE3B171817E79229461FC3A179F574D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_CB1316D7C0C0CF2D837DFC3A179FC217" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_CB1316D7C0C0CF2D837DFC3A179FC217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2724D14226DF92401615FC3A179FD78B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2724D14226DF92401615FC3A179FD78B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_0A4BD8D4B20C33719211FC3A179F6DF2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_Premiumonpurchaseofcommonstock_0A4BD8D4B20C33719211FC3A179F6DF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_5854327560B598FD61AAFC3A17A0F372" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_Investmentincommonstocksharespurchased_5854327560B598FD61AAFC3A17A0F372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_10F204D9E826FEA3FADFFC3A17A0C334" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_10F204D9E826FEA3FADFFC3A17A0C334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_2C0634AC2F886188810AFC3A17A00A5C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_2C0634AC2F886188810AFC3A17A00A5C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_35BA3D66C0F4B1449D29FC3A17A0EF29" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_35BA3D66C0F4B1449D29FC3A17A0EF29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_B50B69753336142E6B28FC3A17A08C54" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_B50B69753336142E6B28FC3A17A08C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7DF439D026BC9DE60A25FC3A17A0ADD0" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7DF439D026BC9DE60A25FC3A17A0ADD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_DC2BA30A5F9EA813EF02FC3A17A1D53A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_DC2BA30A5F9EA813EF02FC3A17A1D53A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B9B62B5FA9DD1ABA24ACFC3A17A1E936" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B9B62B5FA9DD1ABA24ACFC3A17A1E936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_0CAB5094E5AB59813A9EFC3A17A1B29A" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_0CAB5094E5AB59813A9EFC3A17A1B29A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_A69630C5BBD701F4ED41FC3A17A123D6" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_DevelopmentalMilestonePayment_A69630C5BBD701F4ED41FC3A17A123D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_62E598B2094A8F55F93EFC3A17A19138" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_62E598B2094A8F55F93EFC3A17A19138" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_9231B4B056DE318B710CFC3A17A1C942" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_9231B4B056DE318B710CFC3A17A1C942" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_955E180E027D1EEF0B02FC3A17A23EF7" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_955E180E027D1EEF0B02FC3A17A23EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B325F27DCD6B812010A6FC3A17A2A0A8" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_B325F27DCD6B812010A6FC3A17A2A0A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_60129104E5B2FBB22BF2FC3A17A29461" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_D2F5BE107F669F7C5BF5FC3A179E37E2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_60129104E5B2FBB22BF2FC3A17A29461" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8F060A1080423834229C6F399F8A6256" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_A15A0FAFDE819298CC396F399F8A59E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8F060A1080423834229C6F399F8A6256" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_A15A0FAFDE819298CC396F399F8A59E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FB3FD8DB451F8AD74AF76F399EF1E645" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0FFEE4D83CBD5249ADB06F399EF1BD45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FB3FD8DB451F8AD74AF76F399EF1E645" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0FFEE4D83CBD5249ADB06F399EF1BD45" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_580A74696491C4B94FBCE873428AF119" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7BA2B61FF9EBEF0DB910E873428A16BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_580A74696491C4B94FBCE873428AF119" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7BA2B61FF9EBEF0DB910E873428A16BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7BA2B61FF9EBEF0DB910E873428A16BA" xlink:to="loc_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2940CE49F53170A3F895E873428BD4B1" xlink:to="loc_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_FF0D5E65AA014DDDEABDE873428B4061" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:to="loc_country_US_FF0D5E65AA014DDDEABDE873428B4061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_9F0E61B82C7F54701087E873428C6AA2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_E6D956977F1C2B55CCCDE873428B6B09" xlink:to="loc_us-gaap_NonUsMember_9F0E61B82C7F54701087E873428C6AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_D655646973D9DB1FC9D2E873428C6F80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7BA2B61FF9EBEF0DB910E873428A16BA" xlink:to="loc_srt_ProductOrServiceAxis_D655646973D9DB1FC9D2E873428C6F80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_D655646973D9DB1FC9D2E873428C6F80" xlink:to="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_TecfideraMember_259F9BA73D26546D48C1E873428CECC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_InterferonMember_9D64C4051542C862569EE873428DA5DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_TysabriProductMember_F731ACB5CD2783947514E873428DA3CA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_VUMERITYMember" xlink:label="loc_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_VUMERITYMember_4A31E5E0EE63E4A060BEE873816122AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_FAMPYRAMember_C099A3EDD98BF3261544E873428DC230" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_ZINBRYTAMember_B2E5F3E2F3EB0783F6AAE873428D36BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_MSProductRevenuesMember_EE50F00DC90621CB9DBFE873428D0194" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_SPINRAZAMember_B335CD41098A4DE71CEDE873428D149E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_BENEPALIMember_34BB795EBC12095AA9E1E873428E428F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_FLIXABIMember_2B3FE5D84DE2727A7274E873428E4F4B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_947586215250769E2F8BE873428E258F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_IMRALDIMember_947586215250769E2F8BE873428E258F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_BiosimilarsMember_E75EDEF92A66820F5658E873428E70C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_FUMADERMMember_72970967B36717429D1CE873428E8C3F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_ELOCTATEMember_FDD7B194D4A83DEB5556E873428E843E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_ALPROLIXMember_78F90BA0EAAE2A6AD428E873428F35C6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_biib_HemophiliaProductsMember_673B09D9F46D91D71172E873428FE03C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_BC6D8D0E389CCD20070CE873428FD90D" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5862D56BF00675535D4E873428C3B4D" xlink:to="loc_us-gaap_ProductMember_BC6D8D0E389CCD20070CE873428FD90D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_F8A7198ADC02254FC4A4E873428F07AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7BA2B61FF9EBEF0DB910E873428A16BA" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_F8A7198ADC02254FC4A4E873428F07AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F1B2B553AFA1D3264F3DE873428FB615" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_F8A7198ADC02254FC4A4E873428F07AA" xlink:to="loc_us-gaap_Revenues_F1B2B553AFA1D3264F3DE873428FB615" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_FA32B8BEE1F82ADC1C8D80C3141D21A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_FA32B8BEE1F82ADC1C8D80C3141D21A6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:to="loc_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_63506B44A6D36E48D6BF80C3141D7D2B" xlink:to="loc_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_20B3E02BFDDBEBCC0B4C80C3141E94A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_20B3E02BFDDBEBCC0B4C80C3141E94A4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_50EB6BD9ED07172103DD80C3141ECB8F" xlink:to="loc_biib_OthercorporaterevenuesMember_EAECE9B6C204CEB1E34080C3141E8A34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:to="loc_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_F01DDAC26AB14E1025C780C3141EAE45" xlink:to="loc_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B11DCBFC65BC588F94D580C3141E85A8" xlink:to="loc_biib_BioverativMember_A0A42A68E6A7E31C683780C3141F1392" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:to="loc_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorAxis_A1398F2057E7F710F2D480C3141FC8B8" xlink:to="loc_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:to="loc_biib_DistributorOneMember_850A9A1D93E9E77ED04A80C3141F78E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_364E05E1EE89B1AD40F580C3141F5AD8" xlink:to="loc_biib_DistributorTwoMember_F6C26EF9E3EA78E9997880C31420E671" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9994184487DEDAFB79C480C3141D4C01" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_AF1812CB9C3FE3BF328380C31420B708" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:to="loc_us-gaap_Revenues_AF1812CB9C3FE3BF328380C31420B708" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_630182F79AD35F24128780C31420B6D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:to="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_228B9FBB179F2E8A74DA80C314209B53" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:to="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_EF7398E66B1E7E1458C280C3142147D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_D4ED0827FDF08CFFD20980C31421396D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9168C22F1FC47DEBE3E380C31420F9D6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_D4ED0827FDF08CFFD20980C31421396D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F654DF78D345CED56DDE6F399D8E0974" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_B09B18BC0E3B6F5A3BAF6F399D8E88C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F654DF78D345CED56DDE6F399D8E0974" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_B09B18BC0E3B6F5A3BAF6F399D8E88C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8D0CAFF55543FEF406E96F399D8F7B82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_B09B18BC0E3B6F5A3BAF6F399D8E88C5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8D0CAFF55543FEF406E96F399D8F7B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_641FB7B0A68E9F19C54C6F399D8FF971" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8D0CAFF55543FEF406E96F399D8F7B82" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_641FB7B0A68E9F19C54C6F399D8FF971" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_CC5F1DD744EACEFFD9A36F399D8FDE1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_641FB7B0A68E9F19C54C6F399D8FF971" xlink:to="loc_us-gaap_CollaborativeArrangementMember_CC5F1DD744EACEFFD9A36F399D8FDE1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7D7972BFA672F654B5006F399D8F08BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_B09B18BC0E3B6F5A3BAF6F399D8E88C5" xlink:to="loc_srt_ProductOrServiceAxis_7D7972BFA672F654B5006F399D8F08BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CF061C5D81ED707964A66F399D909548" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7D7972BFA672F654B5006F399D8F08BF" xlink:to="loc_srt_ProductsAndServicesDomain_CF061C5D81ED707964A66F399D909548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_684A24D7BAFC6CA1E5376F399D90F400" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CF061C5D81ED707964A66F399D909548" xlink:to="loc_us-gaap_RoyaltyMember_684A24D7BAFC6CA1E5376F399D90F400" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_83EEE6329D3858CF959A6F399D904877" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CF061C5D81ED707964A66F399D909548" xlink:to="loc_biib_OthercorporaterevenuesMember_83EEE6329D3858CF959A6F399D904877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_8CBBB7215A2BF152EF6B6F399D90F6DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CF061C5D81ED707964A66F399D909548" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_8CBBB7215A2BF152EF6B6F399D90F6DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_BC750DCEAE281EB27EA96F399D91417C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_B09B18BC0E3B6F5A3BAF6F399D8E88C5" xlink:to="loc_srt_MajorCustomersAxis_BC750DCEAE281EB27EA96F399D91417C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_4F71A64DAB5A00C276F76F399D91AFF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_BC750DCEAE281EB27EA96F399D91417C" xlink:to="loc_srt_NameOfMajorCustomerDomain_4F71A64DAB5A00C276F76F399D91AFF6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_4D4DD8B22BB84FCA3C2D6F399D91F196" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4F71A64DAB5A00C276F76F399D91AFF6" xlink:to="loc_biib_AbbVieMember_4D4DD8B22BB84FCA3C2D6F399D91F196" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_F8F44EB3EF8FEB062F816F399D9103A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4F71A64DAB5A00C276F76F399D91AFF6" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_F8F44EB3EF8FEB062F816F399D9103A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SobiMember" xlink:label="loc_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4F71A64DAB5A00C276F76F399D91AFF6" xlink:to="loc_biib_SobiMember_D6916FEFA09A63EE37A96F399D92DC61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6FCCC6081F5BD36A65DC6F399D9290CC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_B09B18BC0E3B6F5A3BAF6F399D8E88C5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6FCCC6081F5BD36A65DC6F399D9290CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A90F2C1493A337CF22D36F399D9240AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6FCCC6081F5BD36A65DC6F399D9290CC" xlink:to="loc_us-gaap_Revenues_A90F2C1493A337CF22D36F399D9240AE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_E5B79A7AE0DEAE03D5E06F399D9B31E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_E5B79A7AE0DEAE03D5E06F399D9B31E0" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5343D04E09745230FD3B6F399D9C62CB" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:to="loc_biib_ReserveforCashDiscountsMember_C01765789DBF08BE1D7C6F399D9C16CA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:to="loc_biib_ContractualAdjustmentsMember_39E0A914167297E413EE6F399D9C3E93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_447F237B1ACB0AE10B346F399D9D2FB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_DDDDF52B48BD46342B296F399D9CE2C5" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_447F237B1ACB0AE10B346F399D9D2FB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_CCD67A6C6AB2AA32B3176F399D9B1A29" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F1EF3940F44571A242A96F399D9DADE9" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_FFBF6E47C183648CF50E6F399D9DF670" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_FFBF6E47C183648CF50E6F399D9DF670" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_08DC39B556CB7ED92EC26F399D9EFADC" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3C42CD1168022DFD7E0A6F399D9E7087" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_05825D66FFC462ACA1F16F399D9E0571" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_EC093E217F0F4B612EF06F399D9EBBA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_463D2E5C60D262FD27686F399D9EE8E2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_80AC7BE4B4005DBCCD7B6F399D9D7A48" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_463D2E5C60D262FD27686F399D9EE8E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_817BE4BA24B9EB77552BEBFB6553D34C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C1D0534E59F24422F72BEBFB655324F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_817BE4BA24B9EB77552BEBFB6553D34C" xlink:to="loc_us-gaap_StatementTable_C1D0534E59F24422F72BEBFB655324F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4E2E15EF66F8885F53DCEBFB65532E0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C1D0534E59F24422F72BEBFB655324F1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4E2E15EF66F8885F53DCEBFB65532E0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1CD5791E223777F2860EEBFB65549283" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4E2E15EF66F8885F53DCEBFB65532E0B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1CD5791E223777F2860EEBFB65549283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_3E5508FA311281F4BDA1EBFB6554A4D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1CD5791E223777F2860EEBFB65549283" xlink:to="loc_us-gaap_AccountsReceivableMember_3E5508FA311281F4BDA1EBFB6554A4D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_02B953A0C9E40C8E215FEBFB6554B2F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1CD5791E223777F2860EEBFB65549283" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_02B953A0C9E40C8E215FEBFB6554B2F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F2F566F470465FA51238EBFB6554A733" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C1D0534E59F24422F72BEBFB655324F1" xlink:to="loc_us-gaap_StatementLineItems_F2F566F470465FA51238EBFB6554A733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_874CE536535B2FBD3BFCEBFB65554850" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F2F566F470465FA51238EBFB6554A733" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_874CE536535B2FBD3BFCEBFB65554850" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_CBC2FB2D69CAAD8BAA69EBFB654D866E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_57A21FDCC68F2A672D9CEBFB654D77BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_CBC2FB2D69CAAD8BAA69EBFB654D866E" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_57A21FDCC68F2A672D9CEBFB654D77BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_404D508B033C3659DA61EBFB654D6046" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57A21FDCC68F2A672D9CEBFB654D77BB" xlink:to="loc_srt_ProductOrServiceAxis_404D508B033C3659DA61EBFB654D6046" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_676D7D18D411925BE3E9EBFB654EC8B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_404D508B033C3659DA61EBFB654D6046" xlink:to="loc_srt_ProductsAndServicesDomain_676D7D18D411925BE3E9EBFB654EC8B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_5A3D0EA4783CAD379847EBFB654E1FE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_676D7D18D411925BE3E9EBFB654EC8B9" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_5A3D0EA4783CAD379847EBFB654E1FE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F6EF022D576C028257C3EBFB654E2C62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57A21FDCC68F2A672D9CEBFB654D77BB" xlink:to="loc_srt_MajorCustomersAxis_F6EF022D576C028257C3EBFB654E2C62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_289CF8EE9CED077DBF4CEBFB654E97D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_F6EF022D576C028257C3EBFB654E2C62" xlink:to="loc_srt_NameOfMajorCustomerDomain_289CF8EE9CED077DBF4CEBFB654E97D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_94D2177E193BA214DBB5EBFB654F8789" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_289CF8EE9CED077DBF4CEBFB654E97D8" xlink:to="loc_biib_RocheGroupGenentechMember_94D2177E193BA214DBB5EBFB654F8789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9E4C2B0ABE7C702DE774EBFB654F6776" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57A21FDCC68F2A672D9CEBFB654D77BB" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9E4C2B0ABE7C702DE774EBFB654F6776" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_D51224B907020A16BA52EBFB654FC691" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9E4C2B0ABE7C702DE774EBFB654F6776" xlink:to="loc_biib_ShareOfCoPromotionProfits_D51224B907020A16BA52EBFB654FC691" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_FF573D5169811D5E8C2AEBFB65509A99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9E4C2B0ABE7C702DE774EBFB654F6776" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_FF573D5169811D5E8C2AEBFB65509A99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_522D979D50AEAB98BB23EBFB6550834C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9E4C2B0ABE7C702DE774EBFB654F6776" xlink:to="loc_us-gaap_Revenues_522D979D50AEAB98BB23EBFB6550834C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C68ABE26ED6FBB7740706F399D75C0CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_DD0A0517A3F9BEAC95FF6F399D75B525" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C68ABE26ED6FBB7740706F399D75C0CC" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_DD0A0517A3F9BEAC95FF6F399D75B525" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AE48FF78635234ABF26F6F399D75C67B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C68ABE26ED6FBB7740706F399D75C0CC" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AE48FF78635234ABF26F6F399D75C67B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_43D2B6C12951218E927E6F399D755706" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C68ABE26ED6FBB7740706F399D75C0CC" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_43D2B6C12951218E927E6F399D755706" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F2CDFE9B0EB05F5FCE2C6F399D750140" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C68ABE26ED6FBB7740706F399D75C0CC" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F2CDFE9B0EB05F5FCE2C6F399D750140" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_5E261A95A33CB250AA2E6F399D76C99E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C68ABE26ED6FBB7740706F399D75C0CC" xlink:to="loc_biib_OtherrevenuesTableTextBlock_5E261A95A33CB250AA2E6F399D76C99E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_51920BC1A7B9BD754D8C6F399C19B49E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_C394FF17AAC7C842BF856F399C1A4EC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_51920BC1A7B9BD754D8C6F399C19B49E" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_C394FF17AAC7C842BF856F399C1A4EC9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_ABE05F2543D3269926206F399F3C09B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ABE05F2543D3269926206F399F3C09B5" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_871BA838FF3DCBCB377D6F399F3C2060" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:to="loc_srt_ProductOrServiceAxis_871BA838FF3DCBCB377D6F399F3C2060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2811CA576BA2E0F6EF2C6F399F3DDCD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_871BA838FF3DCBCB377D6F399F3C2060" xlink:to="loc_srt_ProductsAndServicesDomain_2811CA576BA2E0F6EF2C6F399F3DDCD0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_4ABB1E2DE503ADDFD05A6F399F3D14A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2811CA576BA2E0F6EF2C6F399F3DDCD0" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_4ABB1E2DE503ADDFD05A6F399F3D14A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_C31B8C46022F09B8968B6F399F3DE4CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2811CA576BA2E0F6EF2C6F399F3DDCD0" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_C31B8C46022F09B8968B6F399F3DE4CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C7193636C5F26F6B3CA56F399F3E402A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2811CA576BA2E0F6EF2C6F399F3DDCD0" xlink:to="loc_us-gaap_ProductMember_C7193636C5F26F6B3CA56F399F3E402A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_3FEEF1F6F1C57C52B9B56F399F3EE9E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:to="loc_srt_StatementGeographicalAxis_3FEEF1F6F1C57C52B9B56F399F3EE9E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3FEEF1F6F1C57C52B9B56F399F3EE9E8" xlink:to="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_EEE8EDBC1130D2FBC8626F399F3ECDDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C" xlink:to="loc_country_US_EEE8EDBC1130D2FBC8626F399F3ECDDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_E685D50E9D3D9924C8256F399F3FC02D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C" xlink:to="loc_srt_EuropeMember_E685D50E9D3D9924C8256F399F3FC02D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AsiaMember" xlink:label="loc_srt_AsiaMember_C7A53B77D1E59F0C741B6F399F3F2785" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C" xlink:to="loc_srt_AsiaMember_C7A53B77D1E59F0C741B6F399F3F2785" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_CAD89C9371FA1EB811696F399F3E809C" xlink:to="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_7C88DA00ABE6299F428B6F399F3F563F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_F134930CB874E269B8376F399F3C1F27" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D1B5425077D93882D2736F399F3F5AEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:to="loc_us-gaap_Revenues_D1B5425077D93882D2736F399F3F5AEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5A16E773007D1C4C7D986F399F3F07B3" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_0771042926CD2840EBA56F399F40E8DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_9C9C00984BAB01A2F3C16F399F40AFFE" xlink:to="loc_us-gaap_NoncurrentAssets_0771042926CD2840EBA56F399F40E8DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_C29BEF69BC9ED02998516F399CEE6BD3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_C29BEF69BC9ED02998516F399CEE6BD3" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C04A8E1B7BB78C31E29A6F399CEEA4CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373" xlink:to="loc_srt_StatementGeographicalAxis_C04A8E1B7BB78C31E29A6F399CEEA4CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_367F80542D5DF762E0CC6F399CEE2D0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_C04A8E1B7BB78C31E29A6F399CEEA4CD" xlink:to="loc_srt_SegmentGeographicalDomain_367F80542D5DF762E0CC6F399CEE2D0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_337CB376827C283DAC946F399CEF8D95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_367F80542D5DF762E0CC6F399CEE2D0C" xlink:to="loc_biib_SolothurnMember_337CB376827C283DAC946F399CEF8D95" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DK" xlink:label="loc_country_DK_8EC6ED8A58D8C5E7388C6F399CEFCCE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_367F80542D5DF762E0CC6F399CEE2D0C" xlink:to="loc_country_DK_8EC6ED8A58D8C5E7388C6F399CEFCCE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56262F14A2F33A32855E6F399CEEF373" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_BD66FF12412E140067436F399CF0EF77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_B924EAED831E303BC5D96F399CEF505F" xlink:to="loc_us-gaap_NoncurrentAssets_BD66FF12412E140067436F399CF0EF77" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SegmentInformationTextualAbstract" xlink:label="loc_biib_SegmentInformationTextualAbstract_222C464E3685750793946F399CF060F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_C29BEF69BC9ED02998516F399CEE6BD3" xlink:to="loc_biib_SegmentInformationTextualAbstract_222C464E3685750793946F399CF060F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_D250ED67E5009D79AD7A6F399CF0FF6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SegmentInformationTextualAbstract_222C464E3685750793946F399CF060F4" xlink:to="loc_us-gaap_NumberOfReportableSegments_D250ED67E5009D79AD7A6F399CF0FF6F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_8C1EF35E790908D069C56F399D71FBAF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_8C0CB99E44C5C47F0A836F399D71AC26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8C1EF35E790908D069C56F399D71FBAF" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_8C0CB99E44C5C47F0A836F399D71AC26" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D16461C991597DEB285B6F399F345B32" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B581507722790BF0C4306F399F345320" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D16461C991597DEB285B6F399F345B32" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B581507722790BF0C4306F399F345320" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F1E65E997489A5F53BDBFCF51E22D4D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F1E65E997489A5F53BDBFCF51E22D4D0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A8233584663BB4503E41FCF51E230D13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A8233584663BB4503E41FCF51E230D13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80B751A859FF79ADC357FCF51E233758" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A8233584663BB4503E41FCF51E230D13" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80B751A859FF79ADC357FCF51E233758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09850FB7E0803DA9F158FCF51E237CA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80B751A859FF79ADC357FCF51E233758" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09850FB7E0803DA9F158FCF51E237CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_876A8DF836F496DF39BBFCF51E24A959" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80B751A859FF79ADC357FCF51E233758" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_876A8DF836F496DF39BBFCF51E24A959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_AA84C4FFB04E19862F01FCF51E2480A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80B751A859FF79ADC357FCF51E233758" xlink:to="loc_us-gaap_ParentMember_AA84C4FFB04E19862F01FCF51E2480A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5269D44FA09CA8B7F29BFCF51E233FC7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8FC5B38E4D43975EF75EFCF51E249102" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0D19BA83033FBB264F41FCF51E2591CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0D19BA83033FBB264F41FCF51E2591CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5A012E23C12280B99B9AFCF51E254C58" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5A012E23C12280B99B9AFCF51E254C58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07606E2A130856CD8293FCF51E2520D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07606E2A130856CD8293FCF51E2520D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_BF4C2008B15361EE33B7FCF51E25B083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_02969091478B2CD04385FCF51E25BE14" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_F1CE262DAF9E822ED0FCFCF51E247C50" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_02969091478B2CD04385FCF51E25BE14" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B03076D8F80EEC64C964EBFB62D89353" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4F942A9C4E635196CAF9EBFB62D9E851" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B03076D8F80EEC64C964EBFB62D89353" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4F942A9C4E635196CAF9EBFB62D9E851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_251858CEF1ADBB4E70CEEBFB62D97248" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4F942A9C4E635196CAF9EBFB62D9E851" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_251858CEF1ADBB4E70CEEBFB62D97248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_628534270ACBFF79B151EBFB62D939AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_251858CEF1ADBB4E70CEEBFB62D97248" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_628534270ACBFF79B151EBFB62D939AF" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_7D2D1F8194003A3B3B63EBFB62DAEC47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_628534270ACBFF79B151EBFB62D939AF" xlink:to="loc_biib_NightstarMember_7D2D1F8194003A3B3B63EBFB62DAEC47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_43317E6CCB234A782AA5EBFB62DAA57C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4F942A9C4E635196CAF9EBFB62D9E851" xlink:to="loc_us-gaap_AwardTypeAxis_43317E6CCB234A782AA5EBFB62DAA57C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E63F50E90C666A3AFD2FEBFB62DA4FEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_43317E6CCB234A782AA5EBFB62DAA57C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E63F50E90C666A3AFD2FEBFB62DA4FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_560B7138D11AA0C7F08BEBFB62DAE7A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E63F50E90C666A3AFD2FEBFB62DA4FEC" xlink:to="loc_us-gaap_EmployeeStockOptionMember_560B7138D11AA0C7F08BEBFB62DAE7A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2FC8E91EF5D282C9D036EBFB62DBE20F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4F942A9C4E635196CAF9EBFB62D9E851" xlink:to="loc_us-gaap_PlanNameAxis_2FC8E91EF5D282C9D036EBFB62DBE20F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2FC8E91EF5D282C9D036EBFB62DBE20F" xlink:to="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_D2F7A39FEB0C56CA9780EBFB62DBCA69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_MarketStockUnitsMember_D2F7A39FEB0C56CA9780EBFB62DBCA69" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_0E6F55073595924690D7EBFB62DCA083" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_0E6F55073595924690D7EBFB62DCA083" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_DD1294171CF6594D1973EBFB62DC3E12" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_CashSettledPerformanceSharesMember_DD1294171CF6594D1973EBFB62DC3E12" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceUnitsMember" xlink:label="loc_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_PerformanceUnitsMember_590E90C5FC72189A2767EBFB62DC5BF5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_FB9D183B048C2CE234CCEBFB62DC9F28" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_FB9D183B048C2CE234CCEBFB62DC9F28" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_ADB5B8BE811D000B0B80EBFB62DC04F9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_ADB5B8BE811D000B0B80EBFB62DC04F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_FF2437AA63CFEE602AE1EBFB62DB19F4" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_3B0DF3ED43A194A41B0EEBFB62DC58EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_035C892B48C6642EF3D7EBFB62DD8780" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4F942A9C4E635196CAF9EBFB62D9E851" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_035C892B48C6642EF3D7EBFB62DD8780" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_035C892B48C6642EF3D7EBFB62DD8780" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E28F7804B5897EF8EF20EBFB62DDCD3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_E28F7804B5897EF8EF20EBFB62DDCD3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_66FF5A9CFDFFE068CD8AEBFB62DDFEAA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_66FF5A9CFDFFE068CD8AEBFB62DDFEAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_52A2C43DBA9E7A626B3EEBFB62DDF9FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_52A2C43DBA9E7A626B3EEBFB62DDF9FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BF8DA39D8AE39664FF83EBFB62DEED6E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BF8DA39D8AE39664FF83EBFB62DEED6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_6BAD343434EEFAF12F15EBFB62DE2784" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_F1DE48FB63AC5FC8DCE1EBFB62DD7C11" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_6BAD343434EEFAF12F15EBFB62DE2784" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13E279FADB61749DA17D6F399CDE55F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C697FCAB33F9A3A5B86F399CDF10C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13E279FADB61749DA17D6F399CDE55F0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C697FCAB33F9A3A5B86F399CDF10C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_27C19EFD1DA1025832136F399CDF4029" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C697FCAB33F9A3A5B86F399CDF10C4" xlink:to="loc_us-gaap_AwardTypeAxis_27C19EFD1DA1025832136F399CDF4029" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03C3C86DBEB0415294936F399CDFE111" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_27C19EFD1DA1025832136F399CDF4029" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03C3C86DBEB0415294936F399CDFE111" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_5FA34A7F0A5F8E4C527C6F399CE03E08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03C3C86DBEB0415294936F399CDFE111" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_5FA34A7F0A5F8E4C527C6F399CE03E08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C4817071974FEC64C1CF6F399CE05030" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C697FCAB33F9A3A5B86F399CDF10C4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C4817071974FEC64C1CF6F399CE05030" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C4817071974FEC64C1CF6F399CE05030" xlink:to="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_72B0B4DE47EFB8D7A7886F399CE1A3CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_72B0B4DE47EFB8D7A7886F399CE1A3CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10FE2FC376B9CF8307776F399CE1BFD7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10FE2FC376B9CF8307776F399CE1BFD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2E11807333DE71E23DF56F399CE1F6D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2E11807333DE71E23DF56F399CE1F6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3A3ECA430C263533B9076F399CE13BF1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3A3ECA430C263533B9076F399CE13BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CCFE25F1066202CF092C6F399CE13D75" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CCFE25F1066202CF092C6F399CE13D75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9AFE370C27E7DA6435E86F399CE1CE0B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9AFE370C27E7DA6435E86F399CE1CE0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D59B2E339EE72E01486D6F399CE2618C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D59B2E339EE72E01486D6F399CE2618C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_87174E48CC0CE7F7BD586F399CE2F6D8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_87174E48CC0CE7F7BD586F399CE2F6D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00381BB34A530B4914846F399CE2480F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00381BB34A530B4914846F399CE2480F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C86967BEF022E7CAF3B66F399CE20425" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_0B740A5477682CA3402D6F399CE0D091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C86967BEF022E7CAF3B66F399CE20425" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923F7037D7DFD681E0C06F399DDABFEB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923F7037D7DFD681E0C06F399DDABFEB" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589" xlink:to="loc_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_535CEEC9E1E09B170DE46F399DDB1C0B" xlink:to="loc_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0FCBDC504BA826DDE3CE6F399DDB4FD9" xlink:to="loc_biib_A2015ESPPMember_1EDE2526FEC3703613E86F399DDB76D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_DAD09F0F919C71459B6E6F399DDB5589" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5E3B3FBC385F751614936F399DDCC3BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5E3B3FBC385F751614936F399DDCC3BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_BC50E7CA1E8BFF841DFD6F399DDC5231" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_80BA7FE2F2F3E6CE44E16F399DDC3C9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_BC50E7CA1E8BFF841DFD6F399DDC5231" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4454C33C0E71DA44313A6F399EB15C60" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_StockOptionActivityAbstract" xlink:label="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4454C33C0E71DA44313A6F399EB15C60" xlink:to="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8635A0AF593385C3FE0D6F399EB10C58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8635A0AF593385C3FE0D6F399EB10C58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_617ADFE190AD798F5BB16F399EB1627F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_617ADFE190AD798F5BB16F399EB1627F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9A593C5BEE1DE32FF9F06F399EB2527D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9A593C5BEE1DE32FF9F06F399EB2527D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3976AD88C15DA7D4D9C56F399EB2ACA1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3976AD88C15DA7D4D9C56F399EB2ACA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_528DB2782480C027FD066F399EB22FDE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_528DB2782480C027FD066F399EB22FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2159FE4C179F854F14D76F399EB2325F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2159FE4C179F854F14D76F399EB2325F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D1DC00C73CE3A6CC1FD36F399EB2E08D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D1DC00C73CE3A6CC1FD36F399EB2E08D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4DD13199228F360035706F399EB2C557" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4DD13199228F360035706F399EB2C557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CFFCD355FE690D7B29AF6F399EB383F3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CFFCD355FE690D7B29AF6F399EB383F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76AE2983BDB6931E5B766F399EB37984" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1B5C1DE480C808064D26F399EB1D157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76AE2983BDB6931E5B766F399EB37984" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_66505C672543D56A8EFA6F399FEF8AFB" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" xlink:label="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_66505C672543D56A8EFA6F399FEF8AFB" xlink:to="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0D6139820484741AF68E6F399FF01878" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0D6139820484741AF68E6F399FF01878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_27906880B5954BD0D5D96F399FF0094D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_BE2A51D7096009F46D176F399FEF6665" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_27906880B5954BD0D5D96F399FF0094D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_487E4F6329B174C0107F6F399F10A366" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8FA0138D82DA4C75F9236F399F10BC03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_487E4F6329B174C0107F6F399F10A366" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8FA0138D82DA4C75F9236F399F10BC03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_653302EF6DEA9DC239166F399F1135CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8FA0138D82DA4C75F9236F399F10BC03" xlink:to="loc_us-gaap_AwardTypeAxis_653302EF6DEA9DC239166F399F1135CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E33537A7FB2333A8FA206F399F111558" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_653302EF6DEA9DC239166F399F1135CA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E33537A7FB2333A8FA206F399F111558" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_F8FE76FB6BB498E0AF8A6F399F1109CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E33537A7FB2333A8FA206F399F111558" xlink:to="loc_biib_MarketStockUnitsMember_F8FE76FB6BB498E0AF8A6F399F1109CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36954BFC78290CE1DA6B6F399F110D4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8FA0138D82DA4C75F9236F399F10BC03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36954BFC78290CE1DA6B6F399F110D4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36954BFC78290CE1DA6B6F399F110D4D" xlink:to="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_778DE6C7AC5E44599D836F399F120532" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_778DE6C7AC5E44599D836F399F120532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_392FB96822B8C39A92326F399F124A6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_392FB96822B8C39A92326F399F124A6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FFABCB7E4B25A4E55C9C6F399F12F751" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FFABCB7E4B25A4E55C9C6F399F12F751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D2AE943DB82E96B28FDC6F399F130BB9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D2AE943DB82E96B28FDC6F399F130BB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3D39BC0D77FE407B5CC56F399F133371" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3D39BC0D77FE407B5CC56F399F133371" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FD345F9027BAD8911CA16F399F1327EB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FD345F9027BAD8911CA16F399F1327EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_55B1E51C3227F830E6916F399F13FDDE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_55B1E51C3227F830E6916F399F13FDDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_234FBE3030EC388EA4256F399F13BBAC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_234FBE3030EC388EA4256F399F13BBAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_CE6452DEB4765FAF0ACA6F399F13E7D2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_CE6452DEB4765FAF0ACA6F399F13E7D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_001F408D50FA2F7E17426F399F14608C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_64EBCEB41C7320C023B76F399F1230DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_001F408D50FA2F7E17426F399F14608C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_697EAF580CD58CC3FBF36F399F451D40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909E30A6906B96EE03C46F399F4545B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_697EAF580CD58CC3FBF36F399F451D40" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909E30A6906B96EE03C46F399F4545B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6E8BADF445B47809FDE46F399F46B87E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909E30A6906B96EE03C46F399F4545B5" xlink:to="loc_us-gaap_AwardTypeAxis_6E8BADF445B47809FDE46F399F46B87E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91103A31601B88EDA5256F399F463DFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6E8BADF445B47809FDE46F399F46B87E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91103A31601B88EDA5256F399F463DFE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_3A9481D9FFE4819A6B076F399F464268" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91103A31601B88EDA5256F399F463DFE" xlink:to="loc_biib_MarketStockUnitsMember_3A9481D9FFE4819A6B076F399F464268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_95B26ABFBD60E4C45D816F399F47A8FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909E30A6906B96EE03C46F399F4545B5" xlink:to="loc_srt_RangeAxis_95B26ABFBD60E4C45D816F399F47A8FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_45E0F996DC59783E57CD6F399F47C643" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_95B26ABFBD60E4C45D816F399F47A8FF" xlink:to="loc_srt_RangeMember_45E0F996DC59783E57CD6F399F47C643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_97014AC760D84319BF186F399F475DB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45E0F996DC59783E57CD6F399F47C643" xlink:to="loc_srt_MinimumMember_97014AC760D84319BF186F399F475DB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_09E122FBF45BC208DA116F399F48EEA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45E0F996DC59783E57CD6F399F47C643" xlink:to="loc_srt_MaximumMember_09E122FBF45BC208DA116F399F48EEA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9A20F5433DE4FC6049F56F399F48B269" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909E30A6906B96EE03C46F399F4545B5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9A20F5433DE4FC6049F56F399F48B269" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9A20F5433DE4FC6049F56F399F48B269" xlink:to="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EE21EC35B5BE075CE1186F399F48E5F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EE21EC35B5BE075CE1186F399F48E5F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953332ED30B5BAB67D4D6F399F487A17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953332ED30B5BAB67D4D6F399F487A17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_F52CCF3033F6D9E26B506F399F498059" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_F52CCF3033F6D9E26B506F399F498059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8573CB215B62DE9053F56F399F49D5D5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8573CB215B62DE9053F56F399F49D5D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_34EF1B3C1980A86540E56F399F491CBA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_B89FEE59CC47C6A47AF96F399F490FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA47FCC44D96F04470086F399F499A9A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FA3297BA2DF8814875496F399F48F41A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA47FCC44D96F04470086F399F499A9A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5E5C5827E38591C2D70F6F39A014A6D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5E5C5827E38591C2D70F6F39A014A6D3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D" xlink:to="loc_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_A064BAB360850A390DEA6F39A0141B1A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A02C5A2ACFF0E6FE268E6F39A014910C" xlink:to="loc_biib_CashSettledPerformanceSharesMember_17DAF94041F69E3B097E6F39A014BE60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E289674A789B02FAF0CD6F39A014A84D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606EB6980869E3549AFF6F39A015A22B" xlink:to="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_809F3E9C09005A14D4026F39A0150319" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_809F3E9C09005A14D4026F39A0150319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92D43A6D19A4FB44B7756F39A016005D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92D43A6D19A4FB44B7756F39A016005D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_208F535582AF2B14A23C6F39A016921C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_208F535582AF2B14A23C6F39A016921C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A70C66F7461AFCA554DF6F39A016E5EE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A70C66F7461AFCA554DF6F39A016E5EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7834DB2A29C7B53AC9DB6F39A0160FE7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_A487104FAE34A0F098E06F39A0150348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7834DB2A29C7B53AC9DB6F39A0160FE7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6E3C24915E6D972FA4E36F399BD9580C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722AA941CA197C25C1776F399BDAC022" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6E3C24915E6D972FA4E36F399BD9580C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722AA941CA197C25C1776F399BDAC022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E206DA9898D34AABBE616F399BDABA76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722AA941CA197C25C1776F399BDAC022" xlink:to="loc_us-gaap_AwardTypeAxis_E206DA9898D34AABBE616F399BDABA76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4CB03B67026F42581A6F399BDA7B83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_E206DA9898D34AABBE616F399BDABA76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4CB03B67026F42581A6F399BDA7B83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_8107BB91A8790397FBF36F399BDA0112" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4CB03B67026F42581A6F399BDA7B83" xlink:to="loc_us-gaap_PerformanceSharesMember_8107BB91A8790397FBF36F399BDA0112" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722AA941CA197C25C1776F399BDAC022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_86A5DF7601E45E288ABE6F399BDB8986" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_86A5DF7601E45E288ABE6F399BDB8986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_795B4EC0DB3DB5EA184E6F399BDBD116" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_795B4EC0DB3DB5EA184E6F399BDBD116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A2ED4FB1B0BD46D214C86F399BDCBA85" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A2ED4FB1B0BD46D214C86F399BDCBA85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_DE1FB3D08900938B038C6F399BDC61E7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_DE1FB3D08900938B038C6F399BDC61E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_57E9E2E081280722D67E6F399BDC525D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BA1663C254A3B1E805056F399BDBC8BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_57E9E2E081280722D67E6F399BDC525D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EBB4BA71043BA2F7B2556F399FBE0207" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4FB5A032FD0EF90755DB6F399FBEDD47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EBB4BA71043BA2F7B2556F399FBE0207" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4FB5A032FD0EF90755DB6F399FBEDD47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_F87065B028AC9B0ED97B6F399FBF1806" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4FB5A032FD0EF90755DB6F399FBEDD47" xlink:to="loc_us-gaap_PlanNameAxis_F87065B028AC9B0ED97B6F399FBF1806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_73A9C353D5CF9501FC766F399FBF1D0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_F87065B028AC9B0ED97B6F399FBF1806" xlink:to="loc_us-gaap_PlanNameDomain_73A9C353D5CF9501FC766F399FBF1D0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_73A9C353D5CF9501FC766F399FBF1D0D" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D9DE04525233E438C87D6F399FBF9B2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4FB5A032FD0EF90755DB6F399FBEDD47" xlink:to="loc_us-gaap_AwardTypeAxis_D9DE04525233E438C87D6F399FBF9B2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20A6E5BEDD9D7955D0116F399FC0CAD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_D9DE04525233E438C87D6F399FBF9B2B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20A6E5BEDD9D7955D0116F399FC0CAD5" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20A6E5BEDD9D7955D0116F399FC0CAD5" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_EBD23E8AA3C1099071606F399FBFE93C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81586881E5EED6DFA03D6F399FC0F828" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4FB5A032FD0EF90755DB6F399FBEDD47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81586881E5EED6DFA03D6F399FC0F828" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockAbstract" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81586881E5EED6DFA03D6F399FC0F828" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_76EFD4B4C1CC5F75E1CA6F399FC185FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_76EFD4B4C1CC5F75E1CA6F399FC185FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4683940800E0621383A46F399FC1B20E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4683940800E0621383A46F399FC1B20E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4765706D1FF791853EDB6F399FC1A448" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4765706D1FF791853EDB6F399FC1A448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93FE0045BC5DC2CE747E6F399FC11F1D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93FE0045BC5DC2CE747E6F399FC11F1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_71C4E284A492A78AB2826F399FC1983B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_71C4E284A492A78AB2826F399FC1983B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0F916F64ED215EE134436F399FC2AB8E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0F916F64ED215EE134436F399FC2AB8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C51D6EC97F76676820776F399FC2EFC1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C51D6EC97F76676820776F399FC2EFC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_B1F621C44549F22B322B6F399FC23021" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_B1F621C44549F22B322B6F399FC23021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_185C6E47EE59CFC3C5856F399FC2FBF6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_185C6E47EE59CFC3C5856F399FC2FBF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DAB1B479F56129FBB9686F399FC21D37" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_EDB975BBC5011F1E49DD6F399FC0E13F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DAB1B479F56129FBB9686F399FC21D37" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DF93EAEC20E7A8E362FFCF51DDDE0E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D31FF48EF75F04E2F56AFCF51DDD71DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DF93EAEC20E7A8E362FFCF51DDDE0E9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D31FF48EF75F04E2F56AFCF51DDD71DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D8EE457C620444DB1DA2FCF51DDDD88F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D31FF48EF75F04E2F56AFCF51DDD71DE" xlink:to="loc_us-gaap_AwardTypeAxis_D8EE457C620444DB1DA2FCF51DDDD88F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85A38C2366BB4BDF2D9BFCF51DDD099A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_D8EE457C620444DB1DA2FCF51DDDD88F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85A38C2366BB4BDF2D9BFCF51DDD099A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_B8DE1274A6D2F91F9FBFFCF51DDE1FDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85A38C2366BB4BDF2D9BFCF51DDD099A" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_B8DE1274A6D2F91F9FBFFCF51DDE1FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C15B703BBB0EEA6FC29FCF51DDEB247" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D31FF48EF75F04E2F56AFCF51DDD71DE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C15B703BBB0EEA6FC29FCF51DDEB247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_FAA24562CE11903C7A01FCF51DDED423" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C15B703BBB0EEA6FC29FCF51DDEB247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_FAA24562CE11903C7A01FCF51DDED423" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinCashAbstract" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C15B703BBB0EEA6FC29FCF51DDEB247" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1CE62FB52743225D32A7FCF51DDF7EDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1CE62FB52743225D32A7FCF51DDF7EDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2EB4B52BAB1236DF6958FCF51DDF65E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2EB4B52BAB1236DF6958FCF51DDF65E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2CC9015285BF0D478FC8FCF51DDF60D1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2CC9015285BF0D478FC8FCF51DDF60D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_797283BA7DFE3C20F793FCF51DDFDB21" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_797283BA7DFE3C20F793FCF51DDFDB21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F7B263AA61798E7CE15EFCF51DDFFB90" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_0011E9610121AA3CE993FCF51DDE23A5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F7B263AA61798E7CE15EFCF51DDFFB90" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5CB1768F8AAFF73B055A6F399CB347BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15AE3AD67F81B8677BBF6F399CB3D937" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5CB1768F8AAFF73B055A6F399CB347BA" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15AE3AD67F81B8677BBF6F399CB3D937" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_F30043A7043B6A7532C66F399CB43991" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15AE3AD67F81B8677BBF6F399CB3D937" xlink:to="loc_us-gaap_PlanNameAxis_F30043A7043B6A7532C66F399CB43991" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C3ADDB4E2321444B54896F399CB48CD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_F30043A7043B6A7532C66F399CB43991" xlink:to="loc_us-gaap_PlanNameDomain_C3ADDB4E2321444B54896F399CB48CD3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_C3ADDB4E2321444B54896F399CB48CD3" xlink:to="loc_biib_DirectorsPlanMember_7D811943CC5012C220286F399CB44EF5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2017OmnibusEquityPlanMember" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_C3ADDB4E2321444B54896F399CB48CD3" xlink:to="loc_biib_A2017OmnibusEquityPlanMember_2D560F16081B4F0643606F399CB5EC03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15AE3AD67F81B8677BBF6F399CB3D937" xlink:to="loc_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_A6DB6B9F2D200B0A4D0C6F399CB5DAC9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_D5679BB9E8FDAE6073F66F399CB65B2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_DA08DAA8D9C39B0B0B196F399CB55AC7" xlink:to="loc_srt_DirectorMember_D5679BB9E8FDAE6073F66F399CB65B2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_06BBAC47295BB93BBEE46F399CB61F87" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15AE3AD67F81B8677BBF6F399CB3D937" xlink:to="loc_us-gaap_AwardTypeAxis_06BBAC47295BB93BBEE46F399CB61F87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_06BBAC47295BB93BBEE46F399CB61F87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:to="loc_biib_MarketStockUnitsMember_E0314BEC7299AA0278776F399CB6C04E" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_DD6261A2FD2B951E02A96F399CB7492F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:to="loc_biib_CashSettledPerformanceSharesMember_DD6261A2FD2B951E02A96F399CB7492F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_B14C84DD0BBE836C0C976F399CB73FAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:to="loc_us-gaap_PerformanceSharesMember_B14C84DD0BBE836C0C976F399CB73FAE" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_401A947C6216047A94196F399CB7EFF2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_401A947C6216047A94196F399CB7EFF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_30C36CB2942B85A80DE86F399CB8F602" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4ED6BFBC5C7A002B7A26F399CB6FCCE" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_3C714B15542B3D2238F26F399CB87C02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15AE3AD67F81B8677BBF6F399CB3D937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_biib_NumberOfSharesOfCommonStockForIssuance_95C0BE814F909EA419F96F399CB8F44A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_9F564EBDDF6F7B14DEB86F399CB8D2B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9B442170D6ADA2962D526F399CB90B95" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9B442170D6ADA2962D526F399CB90B95" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_biib_NumberOfEqualAnnualIncrements_C25542B13CAD12F2E7DF6F399CB9BFA3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_5CD4CEC8B20DF3571A926F399CB9DBB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_C7E65FC34E2CCAFC53716F399CB93B92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D29A534A0E624B1077726F399CB9FEE7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D29A534A0E624B1077726F399CB9FEE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_20E46FD186A9AB3BFD8F6F399CB9DB23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_BE566431A83556CF0E276F399CBAA094" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_BE566431A83556CF0E276F399CBAA094" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_3737AB3168DFB7789A596F399CBA8932" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_3737AB3168DFB7789A596F399CBA8932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D06C31F5CC7E1C229C876F399CBA1FCE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D06C31F5CC7E1C229C876F399CBA1FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3B7E4C063E8A352794016F399CBA0B48" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_708DE51789F96DF691086F399CB8EB21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3B7E4C063E8A352794016F399CBA0B48" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ShareBasedPaymentsTextualAbstract" xlink:label="loc_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5CB1768F8AAFF73B055A6F399CB347BA" xlink:to="loc_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_D6BC66805968867364456F399CBAAE23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_D6BC66805968867364456F399CBAAE23" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_F8B044BB70AFF3B2BBA46F399CBBE914" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:to="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_F8B044BB70AFF3B2BBA46F399CBBE914" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_BD9DD8DEABCE2B96B1A96F399CBBB34C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:to="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_BD9DD8DEABCE2B96B1A96F399CBBB34C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B38E70B48DD8942AA45C6F399CBB2AD6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B38E70B48DD8942AA45C6F399CBB2AD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6683C8D0E80BBD4897A26F399CBB9815" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6683C8D0E80BBD4897A26F399CBB9815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B89401158B9E1A86BBB86F399CBB488E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B89401158B9E1A86BBB86F399CBB488E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_CBA83ED8F1CA7C6A67E66F399CBCBB26" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_67E1D57CD207FC38DAFC6F399CBAE758" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_CBA83ED8F1CA7C6A67E66F399CBCBB26" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6DFD581652036D61F45F6F399E71A3BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6DFD581652036D61F45F6F399E71A3BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_51775A19077107D3CB906F399E71FA20" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_51775A19077107D3CB906F399E71FA20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4F91B154C47DDD1FCF6F6F399E71814C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4F91B154C47DDD1FCF6F6F399E71814C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:label="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_C4607895FD9573036E436F399E71D2F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:to="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_C4607895FD9573036E436F399E71D2F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_B6824F5849B237A5243D6F399E71B0B1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:to="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_B6824F5849B237A5243D6F399E71B0B1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:label="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_C2D15D789C70C6FB24F76F399E72E714" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:to="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_C2D15D789C70C6FB24F76F399E72E714" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_F73EE6EC791DC6CCAA0E6F399E726E8A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:to="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_F73EE6EC791DC6CCAA0E6F399E726E8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceunitsactivityTableTextBlock" xlink:label="loc_biib_PerformanceunitsactivityTableTextBlock_8B49BED9E3100F4ABCD16F399E72FEE0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:to="loc_biib_PerformanceunitsactivityTableTextBlock_8B49BED9E3100F4ABCD16F399E72FEE0" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinStockTableTextBlock" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockTableTextBlock_26962FCD0706CE2DFD146F399E7226C3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockTableTextBlock_26962FCD0706CE2DFD146F399E7226C3" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PerformanceStockUnitsSettledinCashTableTextBlock" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashTableTextBlock_BE8D719AD02AD1F577F66F399E72AF30" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashTableTextBlock_BE8D719AD02AD1F577F66F399E72AF30" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_8776D1C8E6FEFC7B73C96F399E72D22F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_8776D1C8E6FEFC7B73C96F399E72D22F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:label="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_7E9F100AB96A97E3A5606F399E73B044" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469E9422DAC7064A94BD6F399E70248C" xlink:to="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_7E9F100AB96A97E3A5606F399E73B044" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6C6FAF4E840D0CC78776E873ACBF4E08" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6C6FAF4E840D0CC78776E873ACBF4E08" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_684B2DC1AD4CD55CF822E873ACBFDBC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_684B2DC1AD4CD55CF822E873ACBFDBC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_684B2DC1AD4CD55CF822E873ACBFDBC9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_238B486C45ADB0BB2377E8B71348841A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_F4D288B4B1A43000F3FAE873ACBFA68F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_F4D288B4B1A43000F3FAE873ACBFA68F" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_0B59C31C4B1624180C72E873ACBF95F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_0B59C31C4B1624180C72E873ACBF95F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_9E3E12E3A5F83F590EE9E873ACBF7245" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_9E3E12E3A5F83F590EE9E873ACBF7245" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_6F606FE313D40F115BFDE873ACBFD257" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_19A3C95DDC64F4711D5AE873ACBFB4F5" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_6F606FE313D40F115BFDE873ACBFD257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4893957BDCC107FCA0BAE873ACBF5E1A" xlink:to="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_330C83B2708A80F90B60E873ACBF1BE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_330C83B2708A80F90B60E873ACBF1BE2" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:to="loc_biib_SeriesXPreferredStockMember_6E3571D75626451B066CE873ACBFC700" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B455F3F1651BDE6115F4E873ACBF5F37" xlink:to="loc_biib_UndesignatedPreferredStockMember_70AFA067AECB0B82EDDAE873ACBFDCE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CD3C8B13DA186FC3B000E873ACBFA1FF" xlink:to="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B249F38F6F8C1AAB32A5E873ACBF939C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_B249F38F6F8C1AAB32A5E873ACBF939C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3543452836150D58EB25E873ACBF3BF0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3543452836150D58EB25E873ACBF3BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_F246D26C20FE24AED397E873ACBF353A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_F246D26C20FE24AED397E873ACBF353A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_081E5CFDB3E3BB203849E873ACBF8A2C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9AA332F3E4B9FBD74B3E873ACBF0F95" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_081E5CFDB3E3BB203849E873ACBF8A2C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1762CED55F54D54327A06F399DA07436" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_9AF030FC4A362F4209A36F399DA10E4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1762CED55F54D54327A06F399DA07436" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_9AF030FC4A362F4209A36F399DA10E4B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5CC31809D4B22C9E6B8A0B3C1F98B09C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5CC31809D4B22C9E6B8A0B3C1F98B09C" xlink:to="loc_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0600A8CA17EF6AA08B3A0B3C1F98D102" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0600A8CA17EF6AA08B3A0B3C1F98D102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1B68D8F3062D30573B290B3C1F996FC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0600A8CA17EF6AA08B3A0B3C1F98D102" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1B68D8F3062D30573B290B3C1F996FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_D377C98BAC4FBC7B7A780B3C1F990C98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1B68D8F3062D30573B290B3C1F996FC4" xlink:to="loc_us-gaap_SubsequentEventMember_D377C98BAC4FBC7B7A780B3C1F990C98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_166339826B11C5FFDBDF0B3C1F983117" xlink:to="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_6F69E6E720D43D00AFEC0B3C1F99DFD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_6F69E6E720D43D00AFEC0B3C1F99DFD9" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D038CE6DB4F4A306F86A0B3C1F9A37AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D038CE6DB4F4A306F86A0B3C1F9A37AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_40E4E3D2AD58C14B06F80B3C1F9AD701" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_40E4E3D2AD58C14B06F80B3C1F9AD701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_8323D2F58B34123CCAC90B9E5C870E8B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_68FA8350F6814B53B9EA0B3C1F997DA1" xlink:to="loc_us-gaap_LineOfCreditFacilityDescription_8323D2F58B34123CCAC90B9E5C870E8B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_A334ACB3AC74D289B03C6F399E9066DE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_995DAC78466CDC7055076F399E905ED2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A334ACB3AC74D289B03C6F399E9066DE" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_995DAC78466CDC7055076F399E905ED2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_32FA8F73C30E61BAFF09FC2463B4A142" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_32FA8F73C30E61BAFF09FC2463B4A142" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7EA1D7D2954F04EB8C80FC2463C543B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7EA1D7D2954F04EB8C80FC2463C543B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_6518FECAEBFCA3BF6091FC2463C6F2CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7EA1D7D2954F04EB8C80FC2463C543B9" xlink:to="loc_us-gaap_AccountingGuidanceMember_6518FECAEBFCA3BF6091FC2463C6F2CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_6382394C48D005E35F06FC2463C649F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_6518FECAEBFCA3BF6091FC2463C6F2CD" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_6382394C48D005E35F06FC2463C649F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6584138A2E4F73F3DBCDFC2463C85268" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6584138A2E4F73F3DBCDFC2463C85268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_DC013624B43C8B5B4254FC2463C83316" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6584138A2E4F73F3DBCDFC2463C85268" xlink:to="loc_us-gaap_TypeOfAdoptionMember_DC013624B43C8B5B4254FC2463C83316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_26C41B6798609932D3A9FC295782A3E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_DC013624B43C8B5B4254FC2463C83316" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_26C41B6798609932D3A9FC295782A3E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_39DD9BDADD3DE50B717FFC2463C86B48" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_39DD9BDADD3DE50B717FFC2463C86B48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_39DD9BDADD3DE50B717FFC2463C86B48" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxChargesMember" xlink:label="loc_us-gaap_DeferredIncomeTaxChargesMember_38801FA6779059BE369EFC29C976C572" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E" xlink:to="loc_us-gaap_DeferredIncomeTaxChargesMember_38801FA6779059BE369EFC29C976C572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7962E335CA31AB7E4636FC2463C90113" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E" xlink:to="loc_us-gaap_RetainedEarningsMember_7962E335CA31AB7E4636FC2463C90113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4907D5F9C11B165735F8FC2463C98F37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4907D5F9C11B165735F8FC2463C98F37" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_2B95E7685E00E1126997FC2463C94051" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0130CF9C2A6B2703F7AAFC2463C90A2E" xlink:to="loc_biib_DeferredtaxliabilityMember_2B95E7685E00E1126997FC2463C94051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_74DF322FF6949C6CC062FC2463CABBB3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:to="loc_srt_RangeAxis_74DF322FF6949C6CC062FC2463CABBB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BCDF88C3BFF3FB93CC27FC2463CA1E23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_74DF322FF6949C6CC062FC2463CABBB3" xlink:to="loc_srt_RangeMember_BCDF88C3BFF3FB93CC27FC2463CA1E23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9BD6F1A705A91073745CFC2463CADF2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BCDF88C3BFF3FB93CC27FC2463CA1E23" xlink:to="loc_srt_MinimumMember_9BD6F1A705A91073745CFC2463CADF2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_B04F75BF7681365F09F8FC2463CAE253" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BCDF88C3BFF3FB93CC27FC2463CA1E23" xlink:to="loc_srt_MaximumMember_B04F75BF7681365F09F8FC2463CAE253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D49B6C630E37721B6C46FC2463CAA1A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D49B6C630E37721B6C46FC2463CAA1A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D49B6C630E37721B6C46FC2463CAA1A5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_C9AF6D3D4720BEEDC857FC2463CBAABA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E" xlink:to="loc_us-gaap_BuildingMember_C9AF6D3D4720BEEDC857FC2463CBAABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_A7ADD691BE2BD5A8BF7BFC2463CB9FE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_A7ADD691BE2BD5A8BF7BFC2463CB9FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_8F703BC3EB2075922078FC2463CB831D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_8F703BC3EB2075922078FC2463CB831D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_CCC4150870D79D48D434FC2463CBA20C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD41E1518F7885FF892CFC2463CBC06E" xlink:to="loc_us-gaap_ComputerEquipmentMember_CCC4150870D79D48D434FC2463CBA20C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18620954367782881F59FC2463CCC0F5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8046E7DA89F06EA313E5FC2463C44941" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18620954367782881F59FC2463CCC0F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8789096846115C885EECFC24C6E7F738" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18620954367782881F59FC2463CCC0F5" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8789096846115C885EECFC24C6E7F738" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_B67759E26A14E49A1B66FC2463CC3616" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18620954367782881F59FC2463CCC0F5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_B67759E26A14E49A1B66FC2463CC3616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_DF5844490077E1334C5DFC2463CC1962" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18620954367782881F59FC2463CCC0F5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_DF5844490077E1334C5DFC2463CC1962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_12F45B96C4950EC16621FC2463CCC907" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18620954367782881F59FC2463CCC0F5" xlink:to="loc_us-gaap_OperatingLeaseLiability_12F45B96C4950EC16621FC2463CCC907" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BusinessTextualAbstract" xlink:label="loc_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_32FA8F73C30E61BAFF09FC2463B4A142" xlink:to="loc_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_5B5D0911D9E23531747AFC2463D24074" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:to="loc_biib_InterestInSubsidiary_5B5D0911D9E23531747AFC2463D24074" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PaymentTermsOfAccountsReceivable" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_11CDF1194997B644D336FC2463D27CB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:to="loc_biib_PaymentTermsOfAccountsReceivable_11CDF1194997B644D336FC2463D27CB5" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_EstimatedUsefulLivesOfLeaseholdImprovements" xlink:label="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_58D760B443603FBDBF89FC2463D26E2A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:to="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_58D760B443603FBDBF89FC2463D26E2A" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_PurchasePriceOfCommonStockUnderEspp" xlink:label="loc_biib_PurchasePriceOfCommonStockUnderEspp_B0E744993E2227570F65FC2463D21D55" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:to="loc_biib_PurchasePriceOfCommonStockUnderEspp_B0E744993E2227570F65FC2463D21D55" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_CompensationExpenseOverPurchasePeriod" xlink:label="loc_biib_CompensationExpenseOverPurchasePeriod_0FBBCEDC0ED8D62FB11EFC2463D30B28" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:to="loc_biib_CompensationExpenseOverPurchasePeriod_0FBBCEDC0ED8D62FB11EFC2463D30B28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_63EABB1C943653305183FC2463D337A1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_7026F660ABD0E347CACDFC2463CC004A" xlink:to="loc_us-gaap_AdvertisingExpense_63EABB1C943653305183FC2463D337A1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_CF5EF3FF0E723E6F0A1D7019AF4FD2A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_CF5EF3FF0E723E6F0A1D7019AF4FD2A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0C757194C62CBA76D04E7019AF4F6334" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_0C757194C62CBA76D04E7019AF4F6334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1F9B7776DB2761B7DDFD7019AF4FF261" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_UseOfEstimates_1F9B7776DB2761B7DDFD7019AF4FF261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_116EC1773F7AFDB7D4BE7019AF4F75EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_116EC1773F7AFDB7D4BE7019AF4F75EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_CEAE85CAF7378B53E29D7019AF4F5E4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_CEAE85CAF7378B53E29D7019AF4F5E4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6F66702407DD97F599F77019AF4F821D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6F66702407DD97F599F77019AF4F821D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_64A98698905CC48282BD7019AF4FC270" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_64A98698905CC48282BD7019AF4FC270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_68E78CB35B049FB29E4F7019AF4FFF78" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_68E78CB35B049FB29E4F7019AF4FFF78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_204008D0330754AC54157019AF4F0F1B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_204008D0330754AC54157019AF4F0F1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_E24E92A6F7BF7825E80F7019AF4F95CB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_E24E92A6F7BF7825E80F7019AF4F95CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_04D43B431A9D556BB6927019AF4FC1F7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_04D43B431A9D556BB6927019AF4FC1F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6F5B011F855FF205C5007019AF4F71B5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6F5B011F855FF205C5007019AF4F71B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_599C72A0044479ED26127089020E61F5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_599C72A0044479ED26127089020E61F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_B1552A28A72864977F717019AF4F8A64" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_B1552A28A72864977F717019AF4F8A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_16C2196C0F0E3F6DBA137019AF4F9FA9" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_16C2196C0F0E3F6DBA137019AF4F9FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D67AEEFE7B06315ADBA07019AF4F5543" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D67AEEFE7B06315ADBA07019AF4F5543" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_239D3490837228177E137019AF4F3042" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_239D3490837228177E137019AF4F3042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_C844033A516592B70A867019AF4F7635" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_C844033A516592B70A867019AF4F7635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_87954A02134D3FEB50447019AF4F703D" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_87954A02134D3FEB50447019AF4F703D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9D8F32120DB095B52E337019AF4F2ECA" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9D8F32120DB095B52E337019AF4F2ECA" xlink:type="arc" />
    <link:loc xlink:href="biib-20191231.xsd#biib_RoyaltyCostofSalesPolicyTextBlock" xlink:label="loc_biib_RoyaltyCostofSalesPolicyTextBlock_B20929B6E122D6178C057019AF4FA8E1" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_biib_RoyaltyCostofSalesPolicyTextBlock_B20929B6E122D6178C057019AF4FA8E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_BA52980ADADF2554CCE97019AF4F57CE" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_BA52980ADADF2554CCE97019AF4F57CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_D3F42D77A2A0E788AE5F7019AF4FE46C" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_D3F42D77A2A0E788AE5F7019AF4FE46C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D4132723B7E32385C1347019AF4FE85E" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D4132723B7E32385C1347019AF4FE85E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_4A271E1CC6DD5495AD997019AF4FAB12" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_4A271E1CC6DD5495AD997019AF4FAB12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_C8305C80C103EB4C98CD7019AF4FFB1D" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_C8305C80C103EB4C98CD7019AF4FFB1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_C10B2807FA58FCDDAEBF7019AF4FB932" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_C10B2807FA58FCDDAEBF7019AF4FB932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92AD923AFDC71CC88EB47019AF4F9041" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91F1472261FD84ACD03B7019AF4F9720" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92AD923AFDC71CC88EB47019AF4F9041" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4AA1BEB45AD87A0061706F399D6F65C5" xlink:type="locator" />
    <link:loc xlink:href="biib-20191231.xsd#biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_99EE89616A02560779E66F399D6FCC22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4AA1BEB45AD87A0061706F399D6F65C5" xlink:to="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_99EE89616A02560779E66F399D6FCC22" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>acquirediprd.jpg
<TEXT>
begin 644 acquirediprd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M*ZNM3OH;F6Y-]JVI2N;E_D"S_P""8&F^,/A)H/P?_:'^.'B/XS>&OA[\"U^
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M&W]GD?M2?!MO!_Q8LOB=+J7PHAUCP/H^HV_CR"/PIX23POXNT^3XE>"IXO\
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M_P#@UU?_ .3Z -^BL#_A&=)_YYW?_@UU?_Y/H_X1G2?^>=W_ .#75_\ Y/H
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MS@ZD71K5*#NX.4?>=-R5GLU?4#0HHHKV "BBB@ HHHH **** "BBB@#\0/\
M@I/_ ,I)/^"%/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"*_$/_@I/_P I)/\ @A3_
M -G6_M0?^L<_$&OV\C_U<?\ N+_Z"* 'T444 %%%% !1110 4444 %>2^(_B
M[I'AK6K[1+G2=4N9[%H5DFMVL_)?SK>&Y4H);A)!A9E4[E'S XR,$^M5\4?%
M3_D?O$/_ %UL?_378U\-Q]GF8Y!E.%Q>6U84J]7,:6'G*=*%5.E+#8JJXJ-1
M2BFYTH.Z5[)K9L#V'_A?6@_] +6O^^M/_P#DJC_A?6@_] +6O^^M/]2/^?KU
M!'U!':OETND8,DI"Q1@R2LRLZK%&"\C,B/&[JL:LS(DD;NH*I)&Q#K^2G[%_
MQ*^,/CGX@_&[X6^)?CWK.O?$_P 6&/Q9X+^(-OKGP@_:!_9TNM&LM%_9\L/$
M7Q"^#VA^%8/!/B[P#:QK\0K=O#?PM^(-G9>!+D>([,K=>._%'P_^(LFM?F.%
MXZXNQ5#%UXYC@Z<<'"E.:J8*DW*-2HH2DE3H3DXTHIU*K49245=1:<I1?W;V
MZ^7GM_F_E_09_P +[\/XW?V)K.W&<[]/QCUS]KQB@_'OP^" =$UD$] 7T\$_
M0?:^:_ _7/'OQTO_ /@E5X<^+N@?&_Q'X?\ B9HO[/EQX_\ %WQ.N-'T'7OB
M+XQN/#[:NGEVFLW$-GX?\*:YXCU"UTUO$?BFQ\*ZA<0:(-4TSPEI7AK4-0L-
M<T/V_P#:M?QVOBR?1OA)\:OB79?'/7M$TFW^ OP1^']YH>F>"=#U/2O%=ROC
M'XR_M!VTVE:Q'XA^#$=C>66C^)9_'\^EZ#8:7HTOA'X5V&M?%SQ99WEKLN->
M+O:JE+-<#%_6L;A92^HQ<:<L#*A&I5J2^K<L*/+65:51RY:="G5G4Y9*-.9]
MS[>>J\]_Z6EFOV!/Q[\/J,MHFLJ.F2^G@9].;NE'Q[T C(T/6B#T(?3R#^/V
MNORH_:@T[QSXYU7X0^"OA+X^@T*^U#XC^.;7Q'I.C?M):G^SIK6M0Z1\,M9O
MM)T>;Q-X-T3QK\1=2M_#NJ:GHOBCQ'X&\+^'[[7?[-.DZ[KHMO#EI=7Y]&_9
ML\>6'Q,^!?PV\9Z;#XBAMK_1M1TF0>+/&@^)6O2ZAX,\3Z_X$UF[N_B2%C'Q
M%MK_ %KPQJ-]H_CX16__  F.AW&F>(&M+)]0>RM^6?'W%T,)2Q?U[#.-22BX
MK!X1RIN4JZIJI&W.G46%JRC^[Y'&/QN3<4;=->N_^?EKZVMH?HM;_'30[B>"
MW30]9#3SPP*S-8;5:>5(E9L71.U2X+8!. < FO<:_/73/^0EIW_80L/_ $L@
MK]"J_1/#SB/->(*>:RS.M3K/"3P:HN%&G1Y56CB743]G&/-?V4+7VL^[#HGY
MO\$CB_B+_P B-XG_ .P3<?R6OAQNI^I_G7W'\1?^1&\3_P#8)N/Y+7PXW4_4
M_P Z^+\6?^1SEO\ V+/_ ':Q =%ZO\HGQ=^W7\'?&7QG^"KZ#X#\ :-\0?$V
MDZJ=5TRQ_P"%H>*_@K\0=%N+BW32WUKX6?$WPO;W46B:^+"ZU#3O$>C^(X1X
M?\3^$[[4+.:87UE8V=_YWXN\%?M3:-J'[)D[?"NP^/\ XM^#GC&_\>?%;XK#
MXV?"_P $:MXN6Z^'7Q^^'.@^#3=^,M \/>(_&FJ^#;+XJ:!<W/CG5M%\/Z5X
MMDL_$WB.VT'0_$'B*^TT?HI17YY2S.M2PU+"^RH5:5*>)E'VOM^9K%471J0Y
MJ=>DXPY6Y<M/DYI\LJOM'3I<A?;I;^E\UW/SD^)GPP^/W[0WQ$\7^!?BO\'E
M\(_ >VMOBEX2^$/B3P9\9OA??V.AZEX\^&'C7X>+^TG\1_!02Q\=^*O'>G6W
MCGQ'!X#^%^D0Z?H/@/\ MN^\4:QJ7C'QK=P:YX5[3PAX+_:-LO%>C_&'Q'\+
M/ 47C?X2?LUZ=^SQX-^'N@_&:R_L/XJ:OK7Q"^&WB'QYX\F\5R^#8K/P!X)T
MW2OAWIMY\/O"WB'1=3\6O=7OB+3M9MM#>33+J^^YZ*'F=5TX4OJ^%C2IP5.,
M(K$)1B[JO9O$R?-BHMQQ$KN3NYTG2JOV@)VV_3O==._Z=CX*TOX _%:T\3>$
M_AM<:9X</P@\ ?MG>+OVO=*^+L?C9/\ A*_$.F:MXX^)7Q4\/_#&?X;)HD>K
M:9XKA\=_$J\T#Q3XMNM?G\*7WPVT<R6#7GB'Q!<Z!I?WHJ[55>NU0N?7 Q2T
M5S8G%5,4XRJ*"<5)MP4ESU)R<ZM6?-*?[RK)\TU#DIK14Z<%H%[_ ->27Z'T
M#\ O^/[Q-_UZ:9_Z.O:^EZ^:/@%_Q_>)O^O33/\ T=>U]+U_1_AS_P DCEO_
M %\Q_P#ZGXD04445]P 4444 %%%% !1110 4444 ?B!_P4G_ .4DG_!"G_LZ
MW]J#_P!8Y^(-?MY'_JX_]Q?_ $$5^(?_  4G_P"4DG_!"G_LZW]J#_UCGX@U
M^WD?^KC_ -Q?_010 ^BBB@ HHHH **** "BBB@ KXH^*G_(_>(?^NMC_ .FN
MQK[7KXH^*G_(_>(?^NMC_P"FNQK\O\6/^1!@?^QQ1_\ 4+'@>? D$$$@@@@@
MD$$'(((P000""""" 0<UY&?@#\"SI_Q)TEO@W\+VTKXQZO%KWQ8TP^!?#8L/
MB-J\,.F0PWOC*T73EAU]X?['TZXBBOTEMX]0@EU9(1JM]J-[=^N45^!0JU*=
M_9U)PYN7FY)RCS<DE.%^5J_+.,9QO\,DI*S28TVMCYR'['O[)8\'O\/1^S%\
M 1X!DUX>*7\#CX2^"/\ A$'\3+I;Z&OB!O#?]C_V0VL+HTDFDB_-H;C^SG>S
MW^0S(8;O]C3]D2_?2I;[]ES]GV[FT/2=/T#1IKGX1^"9IM+T+2-2U/6-)T6Q
MF?1S+;Z5I6KZUK.J:;IZ/]DL-1U?5+VTBAN-0NY)?I.BMOKF,W^MXF]W+^/5
M5Y.UY/W]6[*[W:T$>::_\%O@WXKT[Q)I'BCX2_#+Q+I7C'Q8OC[Q;INO^ O"
MVLV7B?QTNEZ;H:^-=>M]1TJYCU3Q>-$T?2=%_P"$ENUDUHZ-IMCI+7IT^WCM
MAZ#86%AI5C9:7I=C8Z7IFFVEMI^FZ9IEG;:=ING:?90I;65AI^GV44%E86-G
M;116UI96D$-K:V\<<%O%'#&B+:HK&52I**C*I.48N\8RE)Q3LHW2;:3Y8Q5T
MMHI;) 7M,_Y"6G?]A"P_]+(*_0JOSUTS_D):=_V$+#_TL@K]"J_:?"+^%GW_
M %\RW_TG&CZ+U?Y1.+^(O_(C>)_^P3<?R6OAQNI^I_G7W'\1?^1&\3_]@FX_
MDM?#C=3]3_.O(\6?^1SEO_8L_P#=K$!T7J_RB)1117Y4(**** "BBB@#Z!^
M7_']XF_Z]-,_]'7M?2]?-'P"_P"/[Q-_UZ:9_P"CKVOI>OZ8\.?^21RW_KYC
M_P#U/Q(!1117W !1110 4444 %%%% !1110!^('_  4G_P"4DG_!"G_LZW]J
M#_UCGX@U^WD?^KC_ -Q?_017XA_\%)_^4DG_  0I_P"SK?VH/_6.?B#7[>1_
MZN/_ '%_]!% #Z*** "BBB@ HHHH **** "OBCXJ?\C]XA_ZZV/_ *:[&OM>
MOBCXJ?\ (_>(?^NMC_Z:[&OR_P 6/^1!@?\ L<4?_4+'@>?4445_/X!1110
M4444 7M,_P"0EIW_ &$+#_TL@K]"J_/73/\ D):=_P!A"P_]+(*_0JOVSPB_
MA9]_U\RW_P!)QH^B]7^43B_B+_R(WB?_ +!-Q_):^'&ZGZG^=?<?Q%_Y$;Q/
M_P!@FX_DM?#C=3]3_.O(\6?^1SEO_8L_]VL0'1>K_*(E%%%?E0@HHHH ****
M /H'X!?\?WB;_KTTS_T=>U]+U\T? +_C^\3?]>FF?^CKVOI>OZ8\.?\ DD<M
M_P"OF/\ _4_$@%%%%?< %%%% !1110 445%-YGDR^2Z12^7)Y4DL;31QR;#L
M>2)98&E1'PSQK-$SJ"@EC)#J 2;ESMW#=Z9&?RZTM?DMX_\ CGX1\)?$Y?#U
M]\=OVN=6\6:?\1;CP#XJ\2^$8_@SIGPR\$OI-U\"_#^O^)KCP/KVAP:?K'@/
M0?&_[2'PE\%7L-AH'C7QO)J^JZV;0:SI_A/Q'X@MOU:TJ&^M],T^WU2^BU/4
MH+.V@U#48;)=-AO[V&%([J\BT];BZ6R2YG5YEM5N;A+</Y232*H8@'XE_P#!
M2R40_P#!2'_@A4[+(X'[5_[3JD11O*_S_L>^/TW!(PSE4W;G(!VH&<C"FOVB
MCU^+RT_XEFO?<7_F#7OH/^F=?C#_ ,%)_P#E))_P0I_[.M_:@_\ 6.?B#7[=
MQ@>7'P/N+V']T4 8O]OQ?] S7O\ P37O_P ;H_M^+_H&:]_X)KW_ .-UNX'H
M/R%&!Z#\A0!A?V_%_P! S7O_  37O_QNC^WXO^@9KW_@FO?_ (W6[@>@_(48
M'H/R% &%_;\7_0,U[_P37O\ \;H_M^+_ *!FO?\ @FO?_C=;N!Z#\A1@>@_(
M4 87]OQ?] S7O_!->_\ QNC^WXO^@9KW_@FO?_C=;N!Z#\A1@>@_(4 87]OQ
M?] S7O\ P37O_P ;KX_^)<XN?'&O3K'/$));(B.YA>WG7;IMDO[R&0*Z$[<J
M& RI5AP17V[@>@_(5\4_%3_D?O$/_76Q_P#378U^7^+'_(@P/_8XH_\ J%CP
M//J***_G\ HHHH **** +NG-MU"P;#';?6384%F.VZA;"J.68XPJC)9B .37
MW:=?A!/_ !+->/N-&O<?^BZ^$],_Y"6G?]A"P_\ 2R"OT)P/0?D*_;/"+^%G
MW_7S+?\ TG&CZ+U?Z'FGCW68KCP9XCA%AK$1DTN=1)<:7=PPJ3M&9)70)&HZ
MEF( '4U\:'J?J:^XOB* / _B?  _XE-QV_W:^'6ZGZG^=>1XL_\ (YRW_L6?
M^[6(#HO5_H)1117Y4(**** "BBB@#W3X(7RV-[XB9K:^N?,M=. %E:37;+MF
MN^9%A5B@.[Y2V V&QT-?2MCJ"7WF;;6_MO*V9^W64]IOW[O]7YRKYFW;\^W.
MW*Y^\*^=_@'S?>)L_P#/IIG_ *.O:^E\ = !7],>'/\ R2.6_P#7S'_^I^)_
MX;Y %%%%?< %%%% !1110 4C=#@9.#@>O'3C)Y^AI:K7MU%8V=U>3^<(+2VG
MN9C;VUQ>3B*WB>:0PVMI%/=7,NQ&\NWMH)KB=]L4,4DKHC 'Y.:WH.GZ[^UK
M\4]3\2^#]&\$:A'\7/@W#9ZKHW[!?QF^)Z_%'0O UIX!\3>!?%7B;]I"RT%?
M!+ZYX<\:K=P6]W%)'H_PHO/#OAC4=5DU"]T33=>/ZUCI^)[8[G_.>_7O7X??
M$#PQ<^(OVH-1U[2["YNM;\9_'/X"_$/P=^T7J_PN_;&M_BY\'/ -AIOPUN[_
M ."WA#1=-_9PO_A9)X-\06-AX@T?5I;_ .,?@CP78P?%#Q?+\8/ ^L^(O#GB
M"/Q'^X(Z?G^')X' X'0''(P: /Q!_P""D_\ RDD_X(4_]G6_M0?^L<_$&OV\
MC_U<?^XO_H(K\0_^"D__ "DD_P""%/\ V=;^U!_ZQS\0:_;R/_5Q_P"XO_H(
MH ?1110 4444 %%%% !1110 5\4?%3_D?O$/_76Q_P#378U]KU\4?%3_ )'[
MQ#_UUL?_ $UV-?E_BQ_R(,#_ -CBC_ZA8\#SZBBBOY_ **** "BBB@"]IG_(
M2T[_ +"%A_Z605^A5?GKIG_(2T[_ +"%A_Z605^A5?MGA%_"S[_KYEO_ *3C
M1]%ZO\HG%_$7_D1O$_\ V";C^2U\.-U/U/\ .ON/XB_\B-XG_P"P3<?R6OAQ
MNI^I_G7D>+/_ ".<M_[%G_NUB Z+U?Y1$HHHK\J$%%%% !1110!] _ +_C^\
M3?\ 7IIG_HZ]KZ7KYH^ 7_']XF_Z]-,_]'7M?2]?TQX<_P#)(Y;_ -?,?_ZG
MXD HHHK[@ HHHH **** "LO7,?V-JQ)E &F:@28;74KZ;_CSGSY5GHTD6K7<
MG_/.VTN1-1N'Q#8NET\+#4I&Z'Z'H<'IZG@?7M0!^'_A#X5ZOX9^)/@2TO=3
M\2W,EGXG\ ZD[Z;^S#_P5MET=X=0NM"UN!)/%FN_M#>(?AWI<BVM[%%K$_C"
M'4M#\+ZBM_8^/--SI&O:7'^X _J>Q'<^O\^AZCBOQ,U&X^'LW[:GQ>A\7WW[
M-$WB2V^/GPW&@0?'SXN^*;SXS6T4GA#X;_V=%\,_#GAZ.;PQH'A-M0CD_P"%
M<^#GE6]3Q2OB#5/%!2^\1-%#^V8_J>GU/^3[T ?B#_P4G_Y22?\ !"G_ +.M
M_:@_]8Y^(-?MY'_JX_\ <7_T$5^(?_!2?_E))_P0I_[.M_:@_P#6.?B#7[>1
M_P"KC_W%_P#010 ^BBB@ HHHH **** "BBB@ KXH^*G_ "/WB'_KK8_^FNQK
M[7KXH^*G_(_>(?\ KK8_^FNQK\O\6/\ D08'_L<4?_4+'@>?4445_/X!1110
M 4444 7M,_Y"6G?]A"P_]+(*_0JOSUTS_D):=_V$+#_TL@K]"J_;/"+^%GW_
M %\RW_TG&CZ+U?Y1.+^(O_(C>)_^P3<?R6OAQNI^I_G7W'\1?^1&\3_]@FX_
MDM?#C=3]3_.O(\6?^1SEO_8L_P#=K$!T7J_RB)1117Y4(**** "BBB@#Z!^
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MEI_Q45S]Q?\ F&Z5Z#_IUK\8O^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\
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M:[&OR_Q8_P"1!@?^QQ1_]0L>!Y]1117\_@%%%% !1110!<TX%M0L &VDWUD
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MH+>/_A6WQY^>5\;5X^$Y;GG[JL?8U\M'_@N)_P $HR2?^&S/!?)/_-./C_\
M_.@KRO$_+,RQV;9?4P67X[&4X9=R3GA<)B,1",_K-=\DI4:<U&5FGRMIV:=K
M.X=%ZO\ 0_5FBORE_P"'X?\ P2C_ .CS/!?_ (;CX_\ _P Z"C_A^'_P2C_Z
M/,\%_P#AN/C_ /\ SH*_,_[ S[_H29Q_X;,;_P#*//\ /LQ'ZM45^49_X+C?
M\$H%*AOVS_!"LY*HK?#OX^*TC!6<K&K?"$-(P16<J@9@B.Y 1&8._P"'X?\
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M<AP+BUGE@D^\CL,FOI_(&,D#/3W^E% #/+7T'_?*_P#Q-'EKZ#_OE?\ XFG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>amortofacquireintang.jpg
<TEXT>
begin 644 amortofacquireintang.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MB0:8?"]C\0].U3Q#X7U'4O"_A:XM;_4F\%#57\)>+M1O;0^-M'U[3M'L]-<
M\,'_  4;DUKP%J7QM\'?!?4+_P"!_P -?AA\"/BG\?M>\2^,X?#?C[X?:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 9'KUZ>]%?D#^W_P#%_P"*_P /_P!O+_@C
MKX#\!>._$_AKPA\8OVD?VA?#7Q1\):3KUYH_A[XAZ!X>_9;\:>*M$TCQA:6L
M4\>KZ?H_B"PMM;TZUNH)HH-4MX;E%65$EC_6-+CQ"40G3-&)*J23KM]DY Y/
M_%.4 ;=%8WG^(?\ H%Z-_P"#V^_^9RCS_$/_ $"]&_\ ![??_,Y0!LT5C>?X
MA_Z!>C?^#V^_^9RCS_$/_0+T;_P>WW_S.4 ;-%8WG^(?^@7HW_@]OO\ YG*/
M/\0_] O1O_![??\ S.4 ;-%8WG^(?^@7HW_@]OO_ )G*//\ $/\ T"]&_P#!
M[??_ #.4 ;-%8WG^(?\ H%Z-_P"#V^_^9RCS_$/_ $"]&_\ ![??_,Y0!LT5
MC>?XA_Z!>C?^#V^_^9RCS_$/_0+T;_P>WW_S.4 ;-%8WG^(?^@7HW_@]OO\
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MG3E4?+I?RO\ ?;_/7IYG[_'X]>'%&3HVM >I_L\#\S>4O_"^?#O_ $!M;_\
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M/^0EIW_80L/_ $L@K]"J_;/"+^%GW_7S+?\ TG&CZ+U?Y1.+^(O_ "(WB?\
M[!-Q_):^'&ZGZG^=?<?Q%_Y$;Q/_ -@FX_DM?#C=3]3_ #KR/%G_ )'.6_\
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MI)/^"%/_ &=;^U!_ZQS\0:_5+XX?\BAI?_8;M/\ TWZA7Y4?\%+1,W_!1_\
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M*** "BBB@ KZZ^"7_(EM_P!AK4O_ &A7R+7UU\$O^1+;_L-:E_[0K]$\,/\
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MO\HB4445^5""BBB@ HHHH ^@?@%_Q_>)O^O33/\ T=>U]+U\T? +_C^\3?\
M7IIG_HZ]KZ7K^F/#G_DD<M_Z^8__ -3\2 4445]P 4444 %%%% !1110 444
M4 ?B!_P4H('_  4C_P""%)) '_#5O[4')X'_ "9S\0:_5#XX.G_"(:7\R_\
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M31]1[T_O+_WT/\:-Z?WE_P"^A_C7RK_PX_TK_I*C_P %F/\ Q-/0?_G-4?\
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MHMO$/PR\37MO8:/J6KS?#?QEXQC\!^*'N+J+[1X)\9OI>L/%]M?2)-8D\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>anticd20revenue.jpg
<TEXT>
begin 644 anticd20revenue.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %N 3T# 2(  A$! Q$!_\0
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M^//Q \2_M6_%;X$>(OAK9^#O!G@SX5^#/'_@GQ->>);35_%7C?\ MOQ]X_\
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MDC +*"06&;__  4I56_X*1_\$*0RA@/VKOVGF 8 C<O['?Q 96P>ZL RGJ&
M(P0#53_@O!:VT'[)OPR:"W@A8_'WPV"T4,<9(/P]^(A()10<$JI(Z$J/05^H
M^"G_ "=7@C_L<P_]1\0?A/TF_P#DPGBA_P!DW4M_X680_DZHQG^7U."<#U.
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M3_\ GQL__ :#_P"(K\L/W@@_MK2/^@IIW_@=:?\ QZC^VM(_Z"FG?^!UI_\
M'JG_ +.T_P#Y\;/_ ,!H/_B*/[.T_P#Y\;/_ ,!H/_B* (/[:TC_ *"FG?\
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M^"D__*23_@A3_P!G6_M0?^L<_$&O%?\ @Y39E_8D^$!5F4_\-.>$N49E./\
MA5_Q5.,J0<9 ..G K[[PMS'^R/$'A7,O8_6/J>9QJ^Q]I[+VEJ-:/+[3DJ<G
MQ7OR2VM8_*O'#(7Q/X3<=9 L4L$\TR6>&^MNA]9]A?$X>IS^P]M0]I\%N7VU
M/>_-I9_S,45^>GGS?\]9?^_TO_Q='GS?\]9?^_TO_P 77^A?_$7E_P!$^_\
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M'_?Z+_XNO]"?:4W;WH^6JZV_S7WG^0"IUE>T*BO:]HRUU35]-=;->=GV)
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MZ%E.UE93@\,"#@@BOS_PA_Y*+'_]B6O_ .IV7GZ=XY7_ -5LL?\ U/\ #_\
MJNS-K\C\LZ***_HH_EB[[O\ K_AE]P4444!=]W_7_#+[@HHHH"[[O^O^&7W'
MH/PE_P"2K_"O_LJ/PT_]3WP[7^JY']T_[\G_ *,:O\J+X3$+\5OA8S$*H^*'
MPU))(  'CSPZ223P  "23P "3Q7^J4-:T="Z/JNFJRR2JRM?VBLK"5P0RF8$
M$$8((!!X(K\*\9/XV0?X,S_/ ?\ !/Z-\!K^PXF_Z^Y4O_),?H?'W_!1QE3]
MAK]J!F(51\(O$I+,0J@8MN2S$  =R2!7\(3W$&]_WT/WF_Y;P^I_Z:5_;M_P
M5>U73+G_ ()P_MEQ6^H6,\C? ;QD!'#>6TKG<EHB@)'*S'+,J@ '+$*,D@'_
M #@9?];+_P!='_\ 0C7ZK]'3C>7"_#.>86.6K&_6,]>(=1XOZOR6P&"I\G+]
M5K\UU"_-S+>RCI=_S[]+WPCAXB<9\,9C//I90\!PR\&J4<K6/]JI9IC:[J>T
M>88/D^/DY.2>U^97LOU>^#_QQ\:_ _Q,WB?P+J>DK-<VPL]6T;7].TGQ%X9U
MZTC=IK:WUK0=6CN;&\^PW96^TZY5(KW3[Q!+:74*R7"3=='^U3\49?#VK^&-
M;NO 'B[2=>\47/C/6$\9_#CX>>)KK4/$T^FP:-;ZE<W>H:*TKKHND6\6E>%M
M/_Y!?A#35:Q\+V6D6LDD3?C?17[AB/$#*<7B9XS%<&9=7Q=14(U,35Q-&=>:
MPS;H7JRRQSO2<I>S=[QO%)VA%+^:<%X&<0Y;@Z678#Q3SG"8"@\3*E@J&5UJ
M>%IO&*FL6XT(\0*G;$*FO:1<7&3NVKRFW^KV@?'/XE>&_#^K^$]/\;ZA<>%]
M>;PN-7\.ZU?)X@T.^MO!^L)KFBZ;-I6M37U@-'%\BIJ6C) NF:WI^=*U>UO-
M-8VQZKQ=^TUX^\<^++;QUXDL_A5>^+8+^^U&XUI/A-\,H9M6FO\ 1+CP\]OK
MEL-!:PUG3++2[@Q:+I%]:2Z7H$MO87&BVEA+IMB;?\=Z*<O$'*IUY8J7!F6O
M$3593K_6*"JS6)I4*&(4YK*^::KT<-0I5E)M5*=&C"2<:4$E3\#.(:>$A@8>
M*F=K!TWA73PO]FXAT*3P5>MB<(Z5*7$+A2>&Q&*Q=>@Z:BZ57$UYP<95JCE^
MN5Q^T1\2+KPK/X3EUOP\8+OPE9> +_Q(GA/P3'\0=2\":?;6=C9^#=2^(T>C
MKXUOO#D.G:=I^D&PN-:=[C0[&ST&ZN)]$MH=/7Q<W$)))FAR>3^^A_\ CE?G
MK175A?$_#8)5%@^%L)A56G[6JL/C:=%5*EHQYYJGEL>:7+%13=VHI):11Y^/
M^CMCLU="69^(N89A+#4O8T)8S)JF)=&ES<[ITG6S^;A!S<YN,;*4Y.3O)MG]
MD_\ P;\R1R>.OVF=CH^/"/PMSLD1R,Z]XVQD(S8S@XSC.#C.#C^GFOXZ_P#@
MV+N[2T^)7[7[W5S;VRMX"^"V&GFBA#;?%'Q'!PTKH#@R(#SP74'!90?[";:^
MLKW?]CN[6Z\O;YGV:XAGV;L[=_E.^W=M;;NQG!QG!Q_#?C9G+S_Q(SW-7AUA
M7B*.41=!5?;<GL,GP%"_M/9TN;G]GSV]G'EYN76UW_IM]&OA9<%^#O#'#D<<
M\R6!KY]+ZX\-]4=7ZUG^98IKV'M\3R<CK>S_ (TN;EYK1ORJW1117Y0?NP44
M44 %%%% !63KUN+O1-7M6MDO%N=+U&!K26VM;R.Z6:SGB-O):7MS9V=TDX;R
MGM[J[MK:=7,5Q<00N\J:U5[NUMKVUN;.]M[>\L[NWFMKJTNX8[BUN;:XB>&>
MWN8)5>*:WGB=XIHI$9)(G9'5E8@@'X=^$/@WX^N?B9X"\0>)_P!FW3!J%EXH
M^'K77B/5?V./V'-,U;3;#PY<:!INDW/_  D>D_MH^(O$^C)X=T+2["VTG4]#
MT?7=7T+3M-LI- TO4YK*QL9_W+']3Z>I]/7KZGOS7XIGX?\ @OQ-^UEX_>'X
M7V4UK\,?C5\-O"7AC4O@U^Q'\#O%W@_0=+\->#?AE>:;HWC#XQ>,_ U]XULO
M&?A;S4C\0ZGX2U*PT;P!X7;PCIGA.6#5=!OY(/VL']3VQW/^<]^M 'X@?\%*
M &_X*1_\$*0P!'_#5W[3QP0",K^QW\0&4\]U8!@>H(!'(KP__@Y1MX(?V)?A
M"8H(8C_PTWX3&8XT0X/PO^*A(RJ@X)5<COM&>@KW'_@I/_RDD_X(4_\ 9UO[
M4'_K'/Q!KQ3_ (.5?^3)/A!_V<YX2_\ 57_%6OJ^!O\ DK<B_P"PU?\ IJH?
M%^(G_)$\1_\ 8OE_Z=I'\1-%%%?UJ?Q&%%%% !1110 5_=G_ ,&Z%O!-_P $
M\I3-#%*1^T%\8B/,C1\$OX7!(W*<9"J#CJ%4= ,?PF5_=Q_P;F?\H\IO^S@O
MC#_Z'X9K\U\5_P#DE/\ NJ8+_P!-XH_6?!?_ )+/_ND8[_T]@S]W6L;+!_T.
MUZ'_ )=XO3_<K_.X_P""UZJG_!3W]J=4544:S\-R%4!0"WP8^'+$X  R6))]
M223R:_T46Z'Z'^5?YV'_  6Q_P"4G_[5'_88^&W_ *I?X<5^?^$/_)18_P#[
M$M?_ -3LO/T[QS_Y);+/^Q_A_P#U79F?E?1117]%'\L!1110 4444 >@?"4
M_%;X6 @$'XH_#0$$9!!\>>'01CW'%?ZJBV=HVYFM;9F:25F9H(BS,97)9B5)
M))))).2>37^59\)?^2K_  K_ .RH_#3_ -3WP[7^JY']T_[\G_HQJ_"O&3^-
MD'^#,_SR\_HWP&_@<3?]?<J_](QY^=G_  5AM;:+_@G!^V8T5O!&W_"AO&8W
M1Q1H<!+1@,JH/#*K#T95/4 U_F\S?ZV7_KH__H1K_2-_X*R_\HWOVS/^R#>,
M_P#T5:U_FY3?ZV7_ *Z/_P"A&O9\'_\ D2YE_P!C27_J)A3P/'3_ )*'*?\
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M_K[E7_I&//@[_@K+_P HWOVS/^R#>,__ $5:U_FY3?ZV7_KH_P#Z$:_T=_\
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MP4G_ .4DG_!"G_LZW]J#_P!8Y^(->*?\'*O_ "9)\(/^SG/"7_JK_BK7M?\
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M2:7XP3PTUUXAU'4[F#0Y/$VB:5K%SI=O+%9W5Y91/<0R;I _W^!RW&X)T?\
M::>(]G3Q5*3FZ\5R8G&4:ZDJ?M)1]I1IPJ)3;56K*KRU:LO9JI+\US'-\#F"
MKVPD\-[6K@JT53AAI2C+!X&MAG%U?9TY>SKU*E-NFDZ-&-)SHT8NJZ<?T3^,
M6@Z9#\"_"WQ!\5_LX:3??$'P)^TAJ?@KQ=\)!^SUKG[+@\/P7'PE\3:KIOP,
M\+S> YM3\7?M#> /#GBGPR_B+QAXUU'7[?XC:!;Z9INCWE[%IWQ0N_%%OWNN
M?#3X?^#?VA/^"B?BJZ^'%WHVJ?##Q%X&N?A1X"\%_LZ^'OB?=:)X.\:>-(]%
M\=>)/A3\%?'<-M\.[JW\-LGA[PU;>(?$5IK7ACX?Z3XJU"XM["\\1W>CW%O^
M3Y^)7Q(.H:!JQ^(WQ#.J^$[66Q\*:HWCWQ@VJ>%K*>#[+-9>%]2;6S?>&[.:
MV_T::UT.XT^WEM@+>2-H%$8GN?BG\4;S7M-\57?Q.^)5WXIT:TGL-&\3W7Q#
M\:W'B;1["Z,AN;#2/$4VO2:WI5A<M-,US9:??VUI<-+*TT,ADD+9_P!CXE14
M%BTH\E6,N7GY&IXS"8KV2HR<J"IRCAJN'J2]GSU*6)FJWMI4^:KJ\]P;G[1X
M*3DIT91<O9N:E3P&,P;KRQ$5'$NK">*I8JE#VKITJ^#@Z'L(U5&A]@>-?V<=
M.O?VPO$_A#QS?>$OA?\ "-_&FHW6M^++328/@;X&C33?AUX=^*6N?"7PK#XY
MUZ_\*?#[XTWNEZ_I?A2Z^&%_XSO+;X=>/M?GCEF@\*:/:)6!^WKX2T_PW\5_
MAYJFD^&/A)X*T_QM^S?^S[XN/A+X,^(_!WB'PCHNIW_PZTQ-8$4W@_4]3AF:
M]ND2>'Q-J4S7OQ 19/&@N]3_ +4FOY/C6?6M9NK(:;=:QJ]SIPU2]UT:=<ZK
MJ%SIXUS4XH8-2UL6,]S):?VUJ4%O;PZCK'D_VGJ$,$$5Y=3QP1*E:[OKV_:!
M[Z]O+U[:SM-.MGO;JXNWM]/T^%;:PL+=[F65H+&QMT6WL;*(I:V=NJP6L,42
MJ@[J."Q,*^$K5<6JD<-@_JDZ:IRA&K+W.;$:5>6,ZCIP<XRA445'EIN*E/F\
M[$9AA*F&QU"E@G2EB\?'&PJNK&;HP7/RX9WI<TZ=/VM10E&=-R<W*K&;C!1_
MJ+_X-@_^2F?M?_\ 8A?!7_U)_B57]A=?QZ?\&P?_ "4S]K__ +$+X*_^I/\
M$JO["Z_F[Q+_ .2RS3_KWE__ *K\*?U?X2?\D'D__7W,_P#U:8P****^#/TD
M**** "BBB@ HHHH **** /P\_P""EDL4'_!2'_@A5)-)'%&/VKOVG@9)'6-
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M_P"O>7_^J_"G]C^$G_)!Y/\ ]?<S_P#5IC"2BBBO@S])"BBB@ HHHH ****
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M#?P.)O\ K[E7_I&//SS_ ."LO_*-[]LS_L@WC/\ ]%6M?YN4W^ME_P"NC_\
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M+]7AT:36(#.=/BU*?XB6,UZEOC:+B2TMWDZF)/NC^Y8@'KZ@_B""/R(!KDO
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M6VJ:=.\,OQ.:*98+ZTMY6AE5HY50QR*R,P/ZV_\ ##W_  6%Y_XWBQ<EF/\
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M;+_+_J'\OS[N_P#&Q_Q"??$C_I*GXG_\0O\ A5_\]"C_ (A/OB1_TE3\3_\
MB%_PJ_\ GH5_9/11_K5Q-_T4.=_^'3&__+O)?<'^IW"7_1+\/?\ AFR[_P"9
M_+\^[/YA_P!E;_@@U^VS^Q5JGC36OV<O^"P^I>#-1^(.G:'I7BN?5/V ?@1X
MM74+'PY=ZG?:/%#%XA^(=[%9-;7.L:@[R6JQO.)E68LL487]H?V0/@;^V+\&
MG\?G]J_]N9/VRT\0CPR/ J+^S%\+OV=/^%>'2_[<_P"$C);X;ZSJY\7?\)3]
MOT; UC[/_8?]A'[#YO\ :EUL^UZ*\C%8O%8ZO/$XW$U\7B*BBIU\35J5ZTU"
M*A!2J5)2G)0A&,(IM\L8J*LDD>U@\%@\NP\,)@,)AL%A:;FZ>&PE"GAZ$'4F
MZDW"C1C"G%SG*4YN,5S3E*4KR;;****YSJ"BBB@ HHHH **** "BBB@ HHHH
M *IZAJ%CI-C>ZIJEY:Z=ING6ES?ZA?WT\5K965E9P27-W>7=S,R0V]K:V\4L
M]Q/*Z10PQO)(RHI(N5GZM+J$&EZE-I-C;ZGJD5A>2Z;IMY?'3+74+^.VE>SL
MKG419ZB;"WN[E8K>:]%A?&TBD:X^QW7E^1( ?(&B?M[_ +.>KZ+XDUZ\UGQO
MX3L=#\':)\1M)A\<?"OXC>$-6^(/P^\4^(--\(^$_%WPNT+6O#=OK?Q#L?%'
MB[6] \+:+I7AO3[OQ1-X@\3>$M,N?#]I/XN\,#5Y]8_;Q_9P\*_#+6/B=XX\
M4:[X"M?#OCZQ^%?B#P3XR\%^*=$^*>D_$?4;70-4M?"$OPUETV7Q5>ZA)X;\
M3Z%XU-]I-CJ.@)\/[]?'\FLIX.@N];M_CS1_V=_VP?C#%XZ\=?'CX>_"_P &
M_M &\^!GCCP#XHT_XU7/C_X4Z'/\!OCOX3^./A_]GWPYX7T[X2^$_$OAGX:^
M)=;\,++X[^*NK7'BGQ_XL\0RZ?XHO]!BTSPCX#\!>%9?C/\ LW_M6>+OA/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZEI%[8ZA<^AT %%%% !1110 4444 %%%% #7) &/[R#\"Z@_F"17^=U\4_\
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MO1?&N@^"_#H\9_%?Q/X;\0Z_\7M)\2>+_P!G+XZ7VMZU>6>@KX:U?5-%\/\
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MQ:^(/P(\/^$M3\<6WQ4\!>#K'1?CK\/_ (U^-;BW*^,O".B^)O&>J?"M?A+
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M5]8N7\/3KX(^$O@'5/%"ZEJ]TMI/<)ID^D^!_ WAZT9;9K4 _;RBOQR\7_\
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M#4?P#\!>!M*^$/Q!\3? 3X&:3:Z5H:WEO\=/^$^/PG@6#P_XPU#Q[XB\'?\
M"?\ C7XDV6D:#XI^&>BP=M^R_P"-/'VC_&KX=>!;OXZ^)?V@O"'QH_8WTO\
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MKK2_$-O\)/#&C_!GP%=_&J_<>"/ EY^V3^T#\6?&'[-&F^,=.U74!X;\3O\
MLG^,/"/[-J_%/3))=,T'2O$%_P"%/"GBNX\&:3>WUS\F?M=_#S7_  /=:/\
M#_QQX"T[X5? KXFR_M1>)_!/P7\=>.O ,UG\!?!?B/1_V:O"6EI\'VU[XO>
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MT=%L;+^T;B(W=VT+7/F+ UY=M L;75P9?2Z* /+M.^"/P=TCQEJWQ#TOX7>
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>avonex.jpg
<TEXT>
begin 644 avonex.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !5 .(# 2(  A$! Q$!_\0
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M0JJ.PJ6N&M5=27,Q-B8HI:*R$(.E+2#I6=X@U-='T.ZO6(!B0E<]V[4TFW9
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M*** $'2O./BUJVV"TTN-N7/G2 >@X'ZYKT?M7.:OX$TK6]0>\O?/:5@!Q)@
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M&JS<?$;48,7;>'[A=-)XF?()'KTQ6TJ4IPAR]@/0**Q7\5Z:GAO^V_,)M2.
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>benepalia04.jpg
<TEXT>
begin 644 benepalia04.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                    ]M8  0    #3+4%$0D4
M                                          ID97-C    _    '1C
M<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L
MH@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W
M*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R
M                                                         '1E
M>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:
M(        +5:  "\9P  DC!M9G0R      0#"0   0
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M6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9:
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MZ*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&* 0KNUG3=P3;9
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M1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J
M@ "#OLH2M<5U1</%L.IF9+V3K/)6\K>CJF9&PK(EJ-\UB*U6I#(B9:G;ET$+
M1ZBPAZ   (J(@ #RAGM&>8K:]WN<>:7"_7OV>=&J?7Q8>AR1<'S#>HIWNWT[
M>Q9<]GW#>ZH_UGYX?%P;%G_1?0_P7'F0A._9.GH'@^C!<7J @P2I%7K^@DZ0
M'7N%@<AV>7P7@61;NGRR@0H^EWUG@-09=7Y?@-ON:G@FD'37:'BLCE&_UWDW
MC%&GDGG,BI^.O'IIB25U-WL1A]5:D7NZAI4]=GQKA8D7]GSOA1CLF';XG ;5
MGW>%F-.^('@:E=&F 7B\DPV-4GEOD*9S]7HGCFM9=7K;C$T\;'N%BH(6FGN(
MB-_J\'8%IZ/4 ':3HVR\BG<MGV^DA7?7F[F+[WB1F$9ROGE:E2Q89WH7DCD[
M=7JWC]459'I7C!3I@G5+LU+2F775KB*[*79LJ2BC-7<9I'Z*O7?:H")QF'BG
MG!-7;'EKF&8ZEGH"E:X45GEGC<#H4'2YOQW1;74]N/2Y_G7.LO^B$W9ZK62)
MN7=#J"QPLW@6HTY6D7C8GNLYUGEFG"H3<GBFC2;G5W1,RPO0>73*P^JY!G52
MO0"A&77YMG:(S';$L&AOZ'>>JN%5YWADIAPY,WCCH=$2N7@(C*CFD70#URG/
MN'1YSPRX.G3VQS&@1764O\B'_W9<N/=O+W<XLNA51G@ KBTXIGAWIDT2)7>+
MC$3AXX0N=^7,,X.C>#NU\H,N>)B>_H+1>0R'6H*+>9UN\()=>DM58()/>P(Y
M)H*9>],3WX2=?([@'X*@@KW*]X(I@?>TW8'%@4V=WX%Y@,R&(X%#@'1MLX$I
M@$!4'H$P@!XW[H&#@"P2>(,@@*;>A(%*C:O)3H#AB]ZS48"'BB^<9X!1B,.$
MU( RAXQLAH NAH%3#(! A8XVYX"-A.(1/(&RA'/<YX JF)?'I'_%E=6QJG]V
MDSJ:ZG]&D-2#?'\\CL)K6'](C-Y2"']DBR0U^G^LB>$0*X!UA\';8'\]HY+&
M)'[8G^JP,GZ0G&N9@7YIF22"+WYAEA=J.GY^DVA1%7ZCD/,U(7[BCTH/0']E
MBE#:#7Z%KJW$VGX@JB2N[7W5I;V82WVQH8^!%7VPG:EI,GW+FAM0.'WYEPLT
M7GXRE5\.>WZ B<K8\WWSN>K#R'V.M(&MVGT^KS&7/'T8JB" (WT>I6]H87T_
MH2=/?'UGG8PSN'V9FV8-V'W#B5S8$'V%Q5G"ZWT?OPZL\GS(N->64'R9LN-_
M1'R@K6UGG7S+J)5.VGSWI-DS+'T;H%@-4WTHB0+79'TUT1?"/'S0R>>L,'QN
MPL:5@GPTN_=^A'PXM<UF]WQEL)=.5'R7K)8RNGRWHDP,Z'RMB+K1P8U1=I*]
MM8OK=P:I XJI=WZ3?HF.> E],8B7>+)F!8?%>7I-GH<H>DDR.(<E>S$,UHDD
M?'G0/(OQ@,>\?(J9@#ZGVHEC?\Z2:(A5?WY\'X=N?U=D^X:N?U%,E(8>?UPQ
M-88:?Y@+[(>+@%K.XHJIBQN[(8E?B9RFK(@KB#>1+X<PAPUZ\H98AA-CXH6I
MA49+CX4FA)8P1(4AA$0+'H8D@\+-?HF/E76YL8A)DQ>E)H<ED-J/S88NCL]Y
ML85LC0MBQX3,BW9*G(11BA4O;H1&B5D*:X3LAK?,)HBPG]JX5X=LG*NCSH9.
MF9Z.@85=EL)XA(28E!YAPH0(D=%)P(.3C] NKX-^CO$)TH/AAJ3*]H@ JFBW
M+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48,
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MA-\;K:T=A80%$JJ;@VX  (,?@ ![6\;LD&5M9<%PCH!>_KP$C.A0 K;"BZ5
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MO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (
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MI+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$  (
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MI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (
M@ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L
M#ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR
M>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ
M9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%
MA[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE
M2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (
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M/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4  (
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M2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(  (
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MFI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL  (
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M/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<  (
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MPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (
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MZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (
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MM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (
M@ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,
M )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*
M<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT
M4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=
M>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=
M-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (
M@ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@
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M,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<  (
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M.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (
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M#X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (
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M:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70  (
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M<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0  (
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MH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (
M@ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$
M4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\
M>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U
M:)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<P
MB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J
M@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (
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M.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (
M@ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4
M )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP
M?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 V
MV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_G
MC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?
M5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (
M@ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X
M"X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$
M9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8M
MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R
M<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5
M);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (
M@ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D
M ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00
M@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M
M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(
MD'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4
MNZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (
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M6G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (
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M/&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (
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M 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (
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M-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (
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M^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (
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M='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (
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M>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (
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M\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (
M?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0
M+Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"
M<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(Z
MF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"
M?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB
M?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (
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MIJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP  (
M@ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8
M (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>
M=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PP
MM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX
M@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7
M&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (
M@ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H
M (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);
MD>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG
M+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ
M9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-
M2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (
M@ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP
M (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)=
M=RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\F
MDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U
M@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,
M$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (
M@ !68J<TDGY,#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD
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MU7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (
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M3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,   (
M@ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6
MG6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2
MD;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0IGX1DV676G)Q3
MV&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!)WE27 ERMWGA
M7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (  =@F-4G7A8;J
M$':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8  (
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M=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW   (
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M.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L  (
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MSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (
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MH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (
M@ !Q?8%"=^!EN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,"
M;H%$>\   (  @ !PIG^0?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I
M?^48,W[S?^@"C7^]?_@  (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[
M<GV;A@LK*7U]A=07]WTJAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T
MCF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC
M:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (
M@ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<
M (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<
M:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STT
MC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)
M<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:
MEHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (
M@ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"__B?1!)
M0T-?4%)/1DE,10 "$H<2?;4  ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@
MA"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (  @    (  @ !CWH> C$59
M#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(  (  @    (
M@ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L
M (  @    (  @ !<X)[Q5=]20IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-
M8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K
M49@490P:4)D19;0&WYC=9>,  ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]
M9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0
M.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (
M@ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X
M (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M
M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI
M+HZE@,X9((ZI@.L'4(P<@.   (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_F
MA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5.
M"9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (
M@ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P
M (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R
M8@<  )UL914  (  =?@  (  @ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@
M$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V
M:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$
M*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D  (  @    (
M@ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0
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M7F"Q8&1]VF,G8S5M0F5^9>9;A&>W:'=(DFFV:N0T%VL#;0$;9VI-;B   (
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M/U,&C5]W0U9/C"MG/UE:BO)60EPKB=1$*UYNB.8PJ5\4B%(8_&!-B$D  (
M@ "3@4VXF!J%>U%MED1VB%3%E$EFD5?;DE)5G5JWD)-#C%SZCRTP+%UXCGP8
MN5\YC.T  (  @ "2]$QWH9>$[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&
ME8TOR5P3E/L865YFD'8  (  @ "16&FL4V*#GFM,5R]T\VSP6LQE&VZ07C=4
M$' C87A!K'&89( M=7*E9PD3T7/&9\<  (  <>2/RF7#7+Z"4V? 7[=SMFFA
M8HED VMO93=3&6TG9\! V&ZN:AHLQV^2; (387#G;%(  (  =I6.2V(J9B"
MW61R:$ERCV:,:E=BZ&B!;$-2*6I6;A= %FOK;\4L.6RE<143$FY=<0\  (
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M,5CMDR=M$5N5D8Y=[%X"C^I-OV VCGL\6V'.C7$I;V%NC4D1@F:JBF(  (
M@ "'V52ZG9EZJE>]FY]L@EIGF59=7ES2EPA-15\#E18[^F"/D],I"5_ODV@1
M)&7OBY<  (  @ "%,'&24T!X:G*65O-JI7.S6GA;I7387<E+7G7W8.<YEW<.
M8[LEF7?Y9=<+NGK$9@(  (  =<*#QVW27 YW-V\P7P-I@7"$8<Y:I7'-9'-*
M@G,&9NTXX70B:20E"W3(:K8+C7?W:JH  (  >>&"<&I=9-UUTFP!9Q=H6&V#
M:3)9C6[N:RE)F'! ;/\X(W%>;IXD@G&\;[(+976";XH  (  ?8"!#F<S;;!T
M<&D,;S=G &JV<*%8E6Q <?)(O6VN<R(W?6[,="LD%V[A=,L+3G->=+,  (
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M,E^HF"!BVV&EEDI4A&-DE&%%*63EDM8T>&6^DALAR61BD5$*:VYDAPL  (
M@ !X_7GN4OYM!'IB5H]@#7L 6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$
MA(#I9.T  (  >2!WLW9@6TAK]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'
M9^H<B'L%:/$$FWXI:;(  (  ?,!V?7,-8Y=JL'079=1=_'4)9_-/_'7J:>M
MN7:_:[@OQ7=];34<$'?+;=8$G'O%;KD  (  ?^]U1' %:]]I<W$Z;7U<NG)/
M;OY/$'-%<& _XG0N<9HO(73?<I8;IG2Z<N($GWFQ="@  (  @ !T$VU7=#=H
M2VZP=3I;HF_>=AU.!7#G=MX_/''6=XPNF7)[>!(;6''N>"($K7@9>;,  (
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M@H+-5>=52(+T62Q'RX,Y7#TXUH.A7P$GV81X82P2](:[894  (,Z9:X  (
M? -KEG^$6DY@D'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K9D02UX+[9E\
M ($):F(  (  ?S9JA'Q38B-?;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*
M:V<2E'^):S\  (  ;WH  (  @ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@V
MOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E
M<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<
M<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (
M@ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D
M (  @    (  @ !F$G%)B9I;-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)
MAYL12W1JAL$  (  @    (  @ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T
M"W)^C@(D+W(ACC81$7,_BO   (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI
M5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5
M*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (
M@ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L
M (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D
M;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\L
MP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?
M>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0
MUWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,  (  @    (
M@ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\
M (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9
MBS()3'LJADD  (  @    (  @ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HD
MSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G
M7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](
MW)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<  (  =N0  (
M@ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0
M (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^
M;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B
M:8AH==<1XHD?=8@"1895>$H  (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4
M>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%
MB(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74  (  @    (
M@ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P
M (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;
M6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P9
M19ZA7-@(IY]S75D  ([<9'X  (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO
M7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\
MA)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP  (  ?8   (
M@ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\
M (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I
M<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7
M:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z;9'V?>TP,I%/
M??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @    (  @ !#@)$$A,8Z
M)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@    (  @    (
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M0UUA4B!V6U_]5CEF?6**6B]5@63Y7?M#/6<788\O3VA 9+$6JFEU9E0  (
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MA$FX?DUO>DW$?G)@9E%V?HQ03E2_?JD^]%<=?M0K]5; ?PD4AUYD?U@  (
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M2%^+6G=K8V'^7;9<>V118--,669R8\,ZS&@I9G4G0FB':)0.0VX1:/\  (
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MCDX\A'AE6U'*A!E7&%3X@[!'P%>E@UDW&5DF@RDDIEB1@T0-/&FA@Q,  (
M@ !^$T?UC:5QTDP*C,-DJD^VB[)6=U+XBIQ')U6JB;@VA%<*B2LD-U;"B6(-
M)6G(AS8  (  @ !]@D8@EF=Q2$I3E/)D'TX1DS95\U%;D7I&NE0+D!<V,55/
MCU$CWU50CV0,X6H\B+4  (  @ !\E6ES3A-P!FL-4?QBNFRW5=)486Y868-$
MQF_=7/LSCW$K8!,?U'&L8CD',W>V8Q   (  =89ZLV2R5I%NG&:W6=QA@VBI
M70M36&I]8!5#XFPA8NHRTFUE96@?1&U/9PH''W3J9[\  (  >:UY'6!%7RMM
M%V*F8<E@263:9$Y2-V;:9J]"\6B9:.0R$&G*:LX>NFE-:_<'#705;*4  (
M?5)WDEPN9]-KFE[::;Y>Y&%$:Y=1.V-R;5A"%V5+;NLQ;69E<$4>6&7><0$'
M#G03<<X  (  @ !V(UB'<'AJ7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[
M==8=N&+[=CT&YW15=X0  (  @ !T\U53>2%I0EAI><=<L%LK>DY/$5V6>KQ
M5%^)>R(P!V!8>X,=3V")>[L&UG1R?.H  (  @ !S_5*1@;EH8%7/@<9;X5BQ
M@:9.4%LR@7,_H%TF@4\O=5W$@4L=#%Y^@8@&V'1O@6D  (  @ !S/5!#BCEG
MKU.CB;E;-E:>B/A-LUDJB"<_!UL6AX8NWEM\AT$<G5SDA\4&TW1XA)T  (
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M^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD \WYE<98  (
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MQ5H CC-0]UQ>C39$(EXRC"(V(%\_BVHF9UYABXD3L&0XB?,!#WXU@+@  (
M@ !DXWH,35I9W'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z 70T,S("@77@
M (  99T  (  >[1C177"5-]8J';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG
M8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P
M^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7
M:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5
M VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (
M@ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\
M (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=
M?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,M
MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1N
MB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (  @    (  @ !8\X-<3&!.
MJX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(  (  :34  (
M?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X
M (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[
M9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHF
MB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4&G0Y:4=**752:LX_578O
M;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)
M0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\  (  @    (
M@ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,
M (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z
M?[ $7'BB@"<  (  @    (  @ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D
M$6UDA=L4$&ZDA;@$47BU@NL  (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#
M46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (  ;*T  (  @ !+DXG+491"
M.(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\  (  <8X  (
M@ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H
M (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W
M9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;
ME8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV
M;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @    (  @ !&^'DQ=%T]
ME7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<  (  @    (
M@ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@
M (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU
M@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2
M>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.4=DL+)69
M5&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^09(657@U
M.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (  >70  (
M@  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8
M (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%
M:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$/
M/XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W
M<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ
M78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (  @    (
M@  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @
M (  @    (  @    /__  #__P  __\  &UF=#(     ! ,)   !
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M^27N)N,GV"C,*<$JMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y"SH
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MQ&)_=FXOO8Y^U6"TMIQ^B%-;KW!^BT9)I_9^T3G9H!U_/"Y#E\=_]"0SCOR
MZ8DSRAJ'(GN7PVJ%H&X(O).$5V"'M96#<%,TKF&"RT8VINJ"8#GEGQ>"$BZ
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M?"B&!*SM?&"% IA2?*F$*(-E?0&#:VY<?7""PEEQ??&"&$2X?IB!<#"1?W6
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MKER#36KYJ7Z"C5XMI(N!_%%*GX.!F$2BFE:!33B;E/2!$2UOCUN \B/-B9Z
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M>IY\E#(E?+E]I-;O;AB#!<-;;[^"4:]$<52!KII[<MZ!-857=&^ UW 2=A2
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MA;J%8(TIA.&$H7R8A!Z#YVN6@W&#1%J$@MN"J4FQ@EB"#3DU@?:!:2G&@:B
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M?<U]/RK(?PE^):]&=WJ"2Y_0>!&"!X^A>*6!KG[/>42!46V%>@.! EPG>MV
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MNXH>DE=\77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^
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MG73KJ5!CZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C
MCDAVV2 BB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET
M;C+=D4]VO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TAT
MF"-VK3U?E"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQY
MN5-6FJ)Z3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C
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M5$LTH(%]=T%DFZA]Q#?.EK!^+B[\D9=^IR<+C'9_-B"%AXU_RFBWK)F#8U\
MJ'J"^547I!6">TL>GV^!_D%/FI^!ES?4E;"!3"\9D+"!$R=!B[" YB#3ANZ
MPFB.J\J)6U[QIYZ(?E4.HS"':DL2GHN&14%#F<2%,3?7E.*$,2\WC^F#1"=R
MBPF"8B$4AFN!DVANJR^/&U[OIO"-R54/HG6,&TL-G<J*14$XF0B(@3?-E#F&
MT"]!CT^%-R>8BG^#JR%(A@&"06A:JKZ4H5[VIF*2V547H=B0B$L/G2>-_4$\
MF&>+@S?;DZ.))"],CLV&WR>JBA2$MB%RA:V"S<+/: Y@X+%*:DYCOY]1;'EF
MC(S";IEI37G#<,-L$V:6<PAN\%.?=7)Q\D#H>"!U/"\(>RQY L#N945K?Z_3
M9\AM19X&:BIO!XN?;(!PS'B\;N-RFF6N<61T?U+8= IV?$!5=O5XL2[!>CU[
M.;\I8MAV!*XB989VMYR5:!AW;(I%:IMX-G>/;3!Y$&2Q;^9Y_%(1<L1Z]S_,
M=>=\$2Z!>65]4[UI8+" 6:QJ8X. #IKJ9C9_S(C=:.-_EG92:ZE_>6.N;I!_
M9U%.<:%_63]+=/A_4RY*>*5_3+O/7MF*C*KF8<F)69EQ9)N()8=V9V:&]'4O
M:D^%SF*\;6:$NU";<*6#G3[9="B";RX:=_Z!'+J!75Z4JZFI8&.2EYA#8TB0
M;(969BN..W0I:3",#V'H;&2)YT_^;\R'M3YT<W>%6RWR=VZ"O[EW7"V>IJBN
M7T&;KI=-8C"8B85K92.54W-3:$&2(6$W:Y&.YT]\;Q2+DCXC<N&("RW0=O:$
M,+BQ6T2H;J?P7F&DC):+85.@:(2J9$R<)7*;9WN7YV"8:N63GT\';H*/+3W<
M<F:*=BVU=I*%;;@S6J2QZJ=P7<*M"Y7[8*ZGW(028Z2BC7(-9MB=0V @:E*7
MZTZ?;@*28CV1<?Z,CBV?=D*&=[5^;ZY@7J6C<29C8Y46<IUF0H/'=!AI"W'U
M=:-KVE_T=TENQ4XQ>1%QV#RX>Q9U."PM?7!Y%[08;1-J>:24;LYL<)09<'1N
M4H+><AAP+W$?<\]R%5\[=:AT%$V>=Z=V,CQ4>>EXB2P$?'Y[-K*9:K]T;J+\
M;*9U9I*M;G1V5(&)<$5W1F_\<BMX1EY*=#AY6DSB=FMZ?SO;>.![Q2O@>Z9]
M-K$,:*]^-*%L:K9^1I$H;*9^3(!&;IE^46[?<+!^95UE<NI^ADPZ=4U^K3MS
M=_1^WRO >N9_%*^;9NJ'X: -:0R'&H_2:QF&/'[_;2J%4FW>;U^$;ER/<<>#
MF$N@=%6"NCL7=R:!SRNE>D" R:YO97Z1?Y[J9[*/X(Z\:=&.&'WX:_F,.FSP
M;DB*6UO5<,J(?DL9<X"&F3K&=G>$CRN.>;*"4:V!9%B:^9X!9IJ8?XW7:,*5
MQWT?:OF2\&PL;6&0%ELW;_Z--$JL<LJ*.CJ&=>.'$RM[>3N#J*S08WBD0)U/
M9<"@YXT=9^R=.7QH:BB98&N ;*"5A5JA;UB1GTI"<CV-F#I.=6F)5"MK>-F$
MSJQ?8MZM/YS092:H_HR-9TJD4GO2:8.?<FKX; *:DUHT;L>5ITGC<<*0E#H*
M=0>+02M?>(J%PZB'=XA@!IHN>#!C&XKX>.]F WKB><)HT6H_>J9KIUEM>Z-N
MGDCE?+UQP#BP?@UU-2E]?Z1Y*:=J=1%IA)D?=?YKGHG<=NAMGGGA=]]OE&E>
M>.QQE5BS>A9SLDA6>V!U[3A:?.1X92ER?JU[,:8X<M-R[9?;<_%T'(C4=0)U
M.WC;=AUV4VA_=TYW>5@!>*5XM4?8>A]Z!3@2>]=[>"EH?=)]&:3:<--\*I9]
M<A%\B(=F<T-\SG>M='Y]"F=T==]]45<K=V-]I$<]>0I^ 3>[>NY^:BE@?1!^
MW:.2;R.%3I4]<'B$XH8Q<<6$4W:)<QN#KF:4=):#"U9R=D6"<D:[>!2!UC=T
M>B&!,"E9?&F >**%;<>.9Y0W;RV-+X4V<(F+PW6=<?6*-F7 <XB(I572=4V'
M$T9+=T"%?#<W>7*#Q2E3>]J!YJ&O;*V76Y-A;B"5581E;X63!737</Z0C&4.
M<JB."U5%=(6+@47P=HR(Y#<(>-Z&'BE.>V.#):$/:]2@'9*[;4^=1(.X;K>:
M"W0P<#26G&1Q<>V3)52\<^2/HT62=@*,!C;=>&2(-2E*>P&$-J"E:SRHG))"
M;+FD[8,M;AN@PW.C;Y6<5V/U<5.7YE1;<U>3:$4^=8J.RS:C> 2)_"E'>K.%
M%YOH?YU?T8[#?WIBXX"^?X-ES'':?ZEHGV)M?]YK?E+6@"1N@4.7@']QL32Y
M@09U-R;X@<1Y-YKZ?4=HOXW3?6MJZ7^_?9]L^G#S?>)O!6&F?CAQ'E(W?J5S
M5$,C?RIUJS2 ?]YX02<,@,9[*IGP>R9QAXRD>WMRX'Z\>\YT)F_Z?#)U9V#9
M?*MVM%&8?4%X%D*X??%YCS1.?M)[+B<=?^5\^YC/>39Z/XMW>:UZTWV,>B%[
M3&\8>I][P6 4>S]\.5$%>_Q\P$):?-5]4C0E?>-]]2<L?Q]^II>O=YB"W8I\
M>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!3$'F>^6 \3/N?1> DB<Y?G6
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M@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^*
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MNX;P@6U:A'N"@3A=_&]<@3)A7&)^@41DM54O@5YH($?.@8AKMCKA@<=O?BZ
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M?X^ 'F'[?W" (5:^?TV "DMM?SY_]$ S?U!_[S5I?X1_]2M5?]U__"*U@$V
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MAL*#P%CLA=>#64Z]A-J"UD22@^R"6#JS@Q"!YC%N@D:!@RBR@;V!'"%Q@5&
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MBG!\L#7_B')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6>
MWT>^BVV ICZAB7: ?C78AXV ;BV[A;. ;B9(A!2 :2 W@JF 7V(JC\^&\%F.
MCE.&A%";C(Z%P4=]BIB$USYNB*B$ #6FAM6#/2VIA0F"DB9H@WV!W2!F@C:!
M)&'ECQB,TUEOC:>+^%!_B^.*A$=FB=V(RSYRA^2'.#7&AAB%QRW,A&R$<2:%
M@P:#$2"+@=J!Q5N3I%Q8^5-0H91<,4KEGJ9?D4)(FVEC)CF<E^!F^#$GE"QK
M"RE?D&MO3")>C+USTQREB5YX:%K:HJQ?<%+4G_1B'DI]G/9D^D($F:MH!CF%
MEB!K1S$]DGQNP"FDCM-R8"+/BT=V.AT^B ]Z%EIKH*)EM5)>G?UGYDHAFQ1J
M.$&XE]9LOCE>E&1O;3%!D.!R32G7C5IU2R,MB?AX=QW"ANQ[G%H*GI9KU5'S
MG 1MBTFOF3%O6T%PEA-Q4CDQDL)S<3$\CV-UM"G\C =X#B-ZB-%ZBQXTA?)\
M^%FEG,MQZ%&5FE-S)DE>EXYT<D$CE']US3D6D4QW5#$ZCA)X^BH;BMUZK2.[
MA])\=AZ4A1Y^+%E&FU1W]%%+F/%XODDEECAY?$#ZDS-Z/#CZD ][&#%%C.A\
M%RHZB=A](R/QAO=^-A[DA&Q_-5CVFB)]T%$1E\]^)TC\E1U^44#9DB%^<3C?
MCPQ^J3%"B_I^^RI<B/A_8"0BACY_PA\F@]F %EBUF2^#>E#GEN>#6TC>E#B"
M[D#%D3V"93C0CC&!]3$PBSB!GBI?B$N!7R1*A:6!&A];@V. T5B+F&^(]5#-
MEBF(84C)DWZ'4T"YD(6&&3C6C7J$_#%%BHV#_2ITA[:#%21CA2R"-!^%@P2!
M::Q_7.-5*YTR7_U9)HV%8Q%=%7U,9C!@^VR?:71DYUO$;.IH[TL[<)5M*#L0
M=)EQNRP'>/IVY:J+6.U?89NP7&]B8(PS7]]E5WPG8U=H3&N<9O1K25KH:L9N
M84J,;M!QHCJE<S1U-"OW=_)Y/JB]56=I@)G]63YK@(K$7/]M?GK18,-O@VIX
M9*]QEEG\:-5SP4G>;3=V##I <?5XEBOJ=P=[=J;R4CUS<YA+5F-T@HDF6F1U
ME'F 7FQVJVE38J9WTED49QMY#4DZ:\YZ73GE<-Y[V2O>=C=]B*5"3W=]0I;+
M4^!];H?%6")]F7@T7&1]Q&A;8-Q]^%A)99M^/DBK:I9^CCF6;^Q^]"O3=8-_
M;J/432"&\96+4<*&/8:O5CB%?W<]6K&$NV=]7UV#^U>H9%&#14@X:8V"DCE4
M;R"!W2O*=.F!(J*I2RF0<Y2)3_N.UX7/5)N-*G9Z64"+=6;-7AZ)Q%<:8T.(
M$4?>:*V&5CDB;G2$ARO#=&F"H:'$29>9L)/"3HZ7)(4A4TV4@G7B6!"1VF9$
M71./-U:?8F6,C4>$9_N)SSCY;>:&ZRN]= "#Z:$K2'"B@9,W37N>]X2@4DN;
M7'5P5R&7Q67G7#N4.%988:J0G4=$9V*,Y#C*;7*(^BNY<ZN$^Z#58_-5-9+4
M9FE9.H1):.==)W49:WAA!F5Q;BQD[E6B<1!H^48O="AM-S<K=Y5QUBE;>UAW
M"I\K8#!>Y9&C8P]A^X-%9>!E G0\:+QH F2T:[UK"E4*;O5N,47#<F5Q@C;S
M=B]U*BEC>DMY29V*7,YH>9 !8 !JI8';8QMLQW+N9D%NYV.;:8]Q$U0J;1ES
M6D4A<-UUPC:>=/AX:REJ>5M[99OJ6<1QY8YO73US-(!=8)=T>G' 8_UUNV*6
M9YAW!U-?:VUX:$27;WYYX398<^5[ABEO>(E]6YIH5QM[-8T/6M![KW\77F=\
M&7"-8@5\>6&X9=M\WU*J:?A]6$0=;DY]W#8=<O9^=BET=]-_)9DH5-^$:HOM
M6,2$#WX37(N#FF^C8%Z#%6#H9&:"D5(9:+:"&$.Z;4F!IC7K<BN!-"EY=SB
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M?;A^I2'9?RQ_5VYF='B!?F3P=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@.
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MC8U^>D,?C!)^H3O]BC5^NC3YB$5^]"XXAG5_12@XA+I_JB+=@U!__QZ.@CJ
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M;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F
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M6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6 Q"V =4R M"2A>>2
MH'F;5BZ)&6])6D"(;F1Q7C^'?EDI8E&&<$VI9IN%;D(^:R>$>3>/;]2#D"U]
M=+*"H"2Z>7.!K7D>5+202F[66.V._6/^70Z-15B^84"+8$U59:N)B4(':EV'
MP3=@;S>& BUC=$"$/B3.>1B"BG=L<P91!6SQ=%=5*V(<=<Q99%;5=U5=L4M"
M>/!B'3^R>K%FO32O?)AKF"I7?L1PX"%D@1-VF778;QA8O6O/<-5<3&$N<IY?
MXE8;='-CA4JV=F)G0S]6>'YK,#2&>L%O3RIL?41SRR&]?]IXG72':W%@@FJ4
M;9)C:F T;ZUF5E5!<=%I2TH.=!-L6#[C=H9OC#1/>2%R["IU>_)VEB(*?LAZ
M>W-,:!YH.6EG:I)J=5\7;/ELM51\;V1N^TEL<?QQ4SY[=,)SRS0A=ZYV92I_
M>LEY.")-?=E\+W(?92EOXVA29^5Q<UX@:I!S %.B;4)TBTCV<!YV*3XJ<S)W
MX30$=F9YL"J0><1[J2*%?0Q]MW$A8IQW=F>"99=X85UP:']Y-U+Z:W!Z!$A>
M;HEZWCW1<=A[TC/5=4M\V"J0>.9]\B*U?&!_#W!38&M^TF;%8YQ_&5S'9KE_
M-5)E:>!_0$??;3%_5SUY<+5_@C.Z=%=_O2J9>"A__2+<>]& .&^P7IF%Y68T
M8?>%C5Q!94&$[U'P:).$,T=X;!&#A#TA;\F"YS.-<Y6"62J@=XJ!QR+\>UV!
M,F\Y722,JF7'8*J+OUO69!:*95&.9XB(VT<N:R6'8#SS;P"%^3-G<OB$GRJ.
M=Q>#1B,5>P"!_VS2>LU1%6-*>X=5+EEM?&)98$\I?45=KT2D?BUB)3HP?RUF
MU3!5@$IKOB<X@9IQ#A^ @P1VLFMH=Q]856)$>#Q;Y5B5>5Y?@TZ$>H)C-40O
M>[-G"3GN?01K#S!*?G)O1R=H@!)SUA_L@;]XHFI <Z=?H&$M=1]BEU>[=HME
MF$W&=_1HJ$.E>7!KUCF:>Q)O+S P?-!RLB>*?KEV>R!)@*%Z:VDH<'IFWV =
M<CUI.%:[<^UKETT-=9YN!$,1=VAPB3D]>5=S,3 ->V%U^B>A?8UX^""9?ZI\
M"F@D;:1N"U\S;ZEOQE7D<9EQ@DQ&<XQS0T*D=95U&#CS=\YW#B_V>AMY&2>Z
M?(9[2"#>?M=]?&<[:RIU)EY?;6UV1%4M;YEW5$NW<<1X84(U= =Y?3C-=G)Z
MN2_R>/I\!B?4>Z!]9B$7?B5^P69\:0=\$5W#:X=\F%2K;>=\^$M&<$%]2T'.
M<K5]L#B$=51^+B_D> 5^OB?G>MY_3R%&?9)_UV7D9SV"N5TY:>Z"K%0O;'R"
M7$K>;OZ!\D%V<9R!G#@Z=&J!7"_ =T*!+B?U>C^ ^R%L?1J P65R9<N)'%S0
M:*2(@U/+:UB'@$J';?N&4T$X<+>%.S@7<Z6$.R^I=J6#3"?Q><B"7R&+?+J!
M@&*$@MQ0X5GT@O%4]U$4@R!9*D?3@TM=@SY;@VYB#34#@YMFUBQ-@]MKV"1B
MA$-Q-1W5A,1VQV%#?VI7MUD#?]U;3U!'@$I>^T<V@*IBQ#WT@0AFMC35@7MJ
MWRQ;@@)O."2J@K%SWAY2@W%XI6!#?!U>D%@,?.%AGD^$?9!DN4:/?BYG[#V
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M?"8H@)9_T2&:@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0     #!"$
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M=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J^KX<*-;=#B/
M\!0_K/T>5YSP+6J/Y3YYAMY.@X'87XM_U&N0>M%PE'?/=)=USG>8<\UYFG+-
M>YMQS'V;<,M_G&_+@)UORX"=;\N G6_+@)UORX"=;\N G6_+@)UORX"=;\N
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MV9&4GMF1E)[9D92>V9&4GMF1E)[9_Z0X*O^@14#_H4I3^Z9(8O*K2''HKTB
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M@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
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MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
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MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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MDIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/
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M0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN>&Q7[7QN5>R
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M/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0  )S2  "/YP(
MAO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_'DS_1B%(_TTC1?]2)4+_5R=
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M,:#,4C^5R5E,B\5@5X+#9F!ZP&QG<[YS;6R\>G-GNX)W8KJ*>UZYE'Y:N)^
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M5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0
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MC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^
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M8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8
MPK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%C
MX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??
M\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,%
M *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1
M5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5)
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M/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP
MF,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+
M_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_
MOC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](
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M)P/UE2X%ZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW>
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M=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0;
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M2T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$
ML[,! *F] @"?QP4 EM() ([:$@"(VR0"@-HR"'C9/A!QV$@8:M=0'V366"5?
MU5\J6]1G+U?4;C-3TW8V4--_.4S3B#M*TY0^1].@/T74KD!$U+]!0]780$33
M[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@  ,.E  "UK@  J;@
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M)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT  'G:  !P\@@
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M O]X* /_?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5
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M5%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@(
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M.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@,
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M$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP  4_T& $W_#@!(_Q8
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M3V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $
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M1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0
MF;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUFM%HB8K-A)EZR:"M:
ML6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>NXSQ&K?,]1JO^/D6K
M_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0  *6K  ":L@  D+H!
M (;!"0"!PA@ >\(H G7"-09OP4 ,:<!)$F2_41=?OE@<6[Y?(%>]9B14O&XG
M4;QV*DV[?RU*NXHP2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S=
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M(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X# &76!P!=XPX
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M<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@
M 'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL ,/\0 "S_%@ I_QP
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M17!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@
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M0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF
MIYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQH
MD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)
M_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(
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M-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(  'RY @!VNA$
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ME TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*
M )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8 1>D/ $+I&0! ZB0
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M @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0
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M_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'+ +_1S8#_T9
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M.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0
MVG # -!U!0#*> < PWH/ +M['P"S>B\"K'@\!Z9U1@VA<U 3G'!8&)=N8!V3
M:V<AD&IN)8UH=2B*9WPKAV:$+H1DC3&!8Y8T?V.A-GQBK3=Z8KLY>6+..7AC
MZ#AX8_@W>&3_-GAD_S5X9/\U>&3_-7AD_S5X9/\U_U<% /]B 0#A;   U',"
M ,MX! #%>P4 OGT- +9^'0"O?BP"J'PY!J%Y1 R<=TX2EW16&))R71R.<&0@
MBFYK)(=L<BB$:WHK@6J"+GYIBC%[:)0T>&>?-G9FJCAT9KDY<V;+.G)FYCER
M9_<X<F?_-W)H_S9R:/\U<FC_-7)H_S5R:/\U_UD" /9E  #=;@  SW8! ,=[
M P# ?P0 N8 , +&"&@"J@BH"HX W!9U]0@N7>TL1DGA4%XUV6QN)=&(@A7)I
M)(%Q<"=^;W<K>VY_+GAMB#%V;)(T<VN<-G!JJ#AN:K<Z;6K).FQJY#IM:_4X
M;6O_-VUK_S9M:_\V;6O_-FUK_S9M:_\V_UL  .MG  #9<0  S'D  ,-^ @"[
M@@, M(0) *V%& "FA2@!GX0U!9F"0 J3?TD0C7U2%HE[61N$>6 ?@'=G(WQU
M;B=Y='4J=G-]+G-RAC%P<9 T;7";-FMOISAI;[4Z:&_'.F=OXCIG;_0X:&__
M-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P  +^! 0"WA0$
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M,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD  (^;"P"*G1@
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MEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8
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M!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0
M?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ N
MYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWK
ML@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT
M &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL
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M1V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI
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M)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0
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M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @#
M< 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC
M<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__
M+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P(
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M+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(  )F##@"4A!T
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MF"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\
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M%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@
MEYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(
MN$,"1KA+ T2X4@1!N%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*W
MP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(
M (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL 0,,G #_#,@ ^Q#P
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M 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@
M2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4
M[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GV
MV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](
M #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D
M"OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP
M_\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A
M   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C
M  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(
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M$ZX\\12K//T5J3S_%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H
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M((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0
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M)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U6/\A_TT  .57  #37P
MR&0  +]G  "W:   L6<' *EH% "C:20 GF@R 9EG/02494<'D&1/"HQB5PV(
M85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:
MU25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<
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M)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$:P  N7$  +!U  "G=P
MGG4  )9V#0"0=QD BW@G (9W,P*!=CT$?'5&!WAS3@MU<E4.<7%<$6YP8Q1K
M;VH6:6YQ&69N>AQC;8,>86R.(5]KFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ
M_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D
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MA1  >88> '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5>
M<QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_
M($M[_R!+>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X
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M'0!;GBD 6)XT 56>/0)2G44#4)U-!4V=5 =+G%L)2)QC"T:<:PU#FW4/09N
M$3Z:C1,\FIL4.IJK%3F:O14YFMD5.9CO%CF7_!8XEO\7.)7_%SB5_Q<XE?\7
MNWH  *^%  "DC   F)$  (V5  "!F@  =9T  &B@  !;I   5J4, %.F%P!1
MIR, 3Z<O $RG. %*IT$!2*=) D:G4 1#IU@%0:=?!C^F: @]IG(*.J9]"SBF
MB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((
M *B,  "=D@  DI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P
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M !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@
M=:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5
MV!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@
MI  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4
M %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ(
M#>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE
MZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%
M  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82
M  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4
M />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   W
MT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^
M$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2
M  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H
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M.[P/H#O-#YX[YA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]
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M%HI%W!:(1O 6AD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P
MSU,  ,95  # 4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B6
M3F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*
MUAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@
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M&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K90
MHV(  )QB#@"68QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==9 UU
M7&L0<UQR$G!;>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV'&5:
M_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4
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M&E=F_QI79O\:VUD  ,=B  "Z:@  KW   *9S  ":<P  CW   (=Q!0"!<A$
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MC!-$@9H50H"I%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH
M +5U  "J?0  GX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB<
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M""Z@LP@NH,D(+I_G""V=]PDMG/\*+9O_"BV;_PHMF_\*KX   *.)  "7C@
MC9,  '^5  !RF   9IP  %N@  !/I   1:<  #ZI#  \JA0 .JH? #FJ*0 X
MJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $OK&8"+:QQ BNL?P,JK(X#**R>!">L
ML 0FK,4$)JOD R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D
M 'B>  !KH@  7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD
M*K8R "FW.@ HMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<
MN< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF
M  !BJP  5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F
M !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D
M#\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8
MM   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1
M(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7
M  '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0
M/\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !
MWB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #E
MP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@
M "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8
M .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0
M]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6
M   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2
M  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8
M /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_
M %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L
MK #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_
M .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D
M_P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S
M ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&
M_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@
M /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X
MZPFV .@)P #F"<T Y GB .(*\ #?"_L W@S_ -P-_P#<#?\ VPW_ =L-_P';
M#?\!_Q\7 /\>$P#_&Q( _QP9 /\;(@#_&"P _Q4X /\31 #^$E  ^1%; /40
M9@#S$&\ \!!W .X0?P#L$(8 ZA", .D0D@#H$)@ Y@^> .4/I0#C#ZP X0^T
M . /O@#>#\P VA#A -41\ #2$OL SQ+_ <X3_P'-$_\!S1/_ <P3_P',$_\!
M_R(2 /\B#P#_(0\ _R(4 /\B' #_("< _QTR /@;/@#R&4L [AA6 .H78 #G
M%FH Y!9R .(6>@#@%H( WA:( -P6CP#;%I4 V1:; -86H@#4%JD TA:Q - 7
MNP#.%\D S!C> ,@9[@'%&OL!PQK_ L$;_P+ &_\"P!O_ L ;_P+ &_\"_R8.
M /\E"P#_* P _RD0 /\H%@#^)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4
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M!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<,?\(_S   /\U  #O.
MXCH  -LY! #6-0D SC03 ,8V(@"_.#$ NC@_ +8X2@&S.%0!L#== JTW9 *K
M-FP#J39S!*@V>02F-8 %I#6'!:,UCP:A-9<'GS6@!YXUJ@B<-;8(FS7%"9DU
MW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(
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M$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\  -])  #-3P  P5,  +A4  "Q4@
MJTX% *1.$0">3R  F5 M )50.0&23T,!CDY, XM-4P2)35H%ADQA!H1+: B"
M2VX)@$IV"WY*?@Q\28<.>DF1#WA)G!!V2:@2=$FV$G-)R!-R2N,3<4KU$G%*
M_Q%Q2_\1<4O_$'%+_Q!Q2_\0[$,  -E,  #(4P  O5<  +18  "L5P  I5(!
M )Y3#P"85!P DU0I (]4-0"+4T !B%-( H524 2"45<%?U!>!GU09 A[3VL)
M>4]R"W=.>PUU3H0.<TV.$'%-F1%O3:43;4VS%&Q-Q11K3N$4:T[T$VM._Q)K
M3O\2:T[_$6M._Q%K3O\1Z$8  --0  #$5@  N5H  +!<  "F6@  GU8  )A6
M#0"25QD CE@F (E8,@"&6#T!@E=% G]630-\550%>51;!G=480AU4V@)<U-P
M"W%2> UO4H$/;5*+$&M1EQ)I4:,39U&Q%&91PQ5E4MX595+R%&52_Q-E4O\2
M95+_$F52_Q)E4O\2Y$H  ,]3  # 6@  M5X  *Q@  "B7@  FED  )):"P"-
M6Q8 B%PC (1<+P" 6SH!?5M# GE:2P-V65($=%A8!G%87P=O5V8);5=M"VM6
M=0UI5GX/9U:)$655E1)C5:$48E6O%6%5P19@5=L68%;Q%6!6_A1@5O\385;_
M$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=80  E5T  (U>"0"'7A,
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MC1%/9YH23F>I%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H
M +QC  "P:@  I6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P
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M#CQ[LPX\>\@./'KF#CQY]PX\>/\./'C_#CUW_PX]=_\.O&@  *]R  "D>0
MEGH  (AZ  !\>@  <'P  &-_  !<@@  5X0+ %.%% !1AB  3X8J $Z'- !,
MASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1 AFP&/H5V!SN%@P@YA9$*.(2@"S:$
ML0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X
M (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@
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M 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$  &^4  !CF
M5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$ (+ I !^P,0 >
ML#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.Q
MZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@
M $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X
M$+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (
MOO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV
M   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL
M  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(
M ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   F
MP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7
M*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>
M  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP
M$\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@
MYB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #N
MQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L
M  />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH
M /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP
M_J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\
M;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U
M /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\
M_Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#]
M ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H
MN@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48
M /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\
M\@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #?
M ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5
M$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R
M .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L
MT ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_
M& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-
M=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/
M ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@
M_Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)
M%'< QQ5] ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8
MX@"S&?(!L1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0'
M /<A# #L'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\'W$
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M!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT  ,8\  # -P(
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M"FM&_PIK1O\*Y4   ,])  #!3P  M5(  *M2  "A3P  FTH  )1*# "/2Q<
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MC0M95)H-6%2G#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T
M ,!6  "S7   IUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX
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M#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)8/\+Q%@  +5@  "J9@
MFV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H&@!=:24 6VHO %EJ. !7
M:D !56I' 5-J3@)1:E4#3VE=!$UI9 5+:6T&26AX!T=HA E&:)(*1&>A"T-G
ML0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD
M (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T
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M<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C $5_+ !#@#4 0H ] $&
M10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$,G^:!3%^J@8P?KT&,'[:
M!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4=0  AG4  'EV  !N=P
M8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R()P [B3  .HDX #B)0  W
MB4@ -HE/ #2)6 $SB6$!,8EL 2^)> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&
M[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$
M %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$
M+)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@
MD/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.
M  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y"
M "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/<
M%IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \
MG   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J
M0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\
M  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP
M*ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 '
MMT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U
M]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4
M !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD
M ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@
MQ.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"
M   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X
M  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T
M>Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "
MT    -0   #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E
M-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@
M &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0
M .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P
M]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'
M&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![
M /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,,
M[ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_
M 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /,
M?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#,
M .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A
M_P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H
M '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -(
MW0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2
M /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L
MVP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#%
M .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.
M% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\
M ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D
MMPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R
M#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-
M?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z
M *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X
MV0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q
M%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;
M_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1
M ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I'V8 J!]L *8?<P"E'WD
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M WPQ_P-\,?\#[2\  -LW  #)/0  OCX  +,\  "L.   IS,$ *(R$0"=-!T
MF34J )4U-0"2-4  CS5) (TU4 "+-5< B35> 8<U9 &%-&L!A#1R H(T>0*
M-(("?C2+ WTTE@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W
M_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF
M (T[,0"*.SL ASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#
M=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L
M//\%XCD  ,Q"  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5
M+0""0#< ?T!  'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$
M!&P_D 5K/YP&:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%
MW#X  ,=&  "Y2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![
M130 >44] '9%10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#
MC09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$
M ,-)  "V3@  IT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23
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M"%%0L0E04,0)4%#A"5!0] A14/\'44__!U%/_P913_\&R4L  +E3  "K5P
MG%8  (]5  "%5   ?%   '51  !P4@D :U,2 &A4'0!E5"< 8E0Q &!4.0!>
M5$$ 7%1( 5I43P%95%8!5U1= E9490-45&X$4E1X!5%4A 9/5)$'3E2@"$Q4
MKPA,5,()2U3?"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D
M (M8  "!5P  =U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\
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M!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D  *MA  ":80  BV$  ']A  !T80
M:6$  %]B  !99   5&8) %%G$0!.9QH 3&@D $MI+0!):38 2&D^ $9J10!%
M:DP 0VI4 4)J7 % :64"/FEO CQI>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H
M[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8
M %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D
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M B)]_P(B??\"I7$  )-Q  "#<0  =G$  &QR  !@=0  5G@  $Q\  !#@
M.X,  #.&   MB0H *HH1 "F+&0 GBR( )HLJ "6,,0 DC#D (XQ" "*-2@ A
MC50 ((U> !^-:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(
M_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P
M "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T
M%9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0
ME/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::
M   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10
M  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L
MC8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7
MJ   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P
M4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD
M 'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M
M"[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2
MOE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5
M  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(
M  #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD
M ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;
MIP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0
M    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+
M  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@
M1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?
MWP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T
M30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8
M /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (,
M]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G
M /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\
M'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$
M .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P
MV #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_
M "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .
MA0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U
M ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "
M\0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #.
M (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L
M_0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E
M .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($
MP "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N
M O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#
M*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:#
M +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\
MH0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@#
M##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</
MA0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_
M )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD
ML!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9
M%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<
M_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO
M *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".((0
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MCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(
M ,DY  "[/@  K#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4
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M UL_KP1:/\$$6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2
MG$<  )%&  "(1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F
M0D, 9$)* &-!4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#
MK0150[\$5$/:!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H
M (U)  "#1P  ?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\
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M!$9/[01&3OP$1D[_ T=._P-'3O\#O4P  *Y2  "<40  C5$  (%1  !W4
M;DP  &=.  !B3P  75 - %I0% !741X 55$G %-1, !14C@ 4%(_ $Y21@!-
M4DT 3%-5 $I370%)4V4!2%-O D93>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3
M[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$
M &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL
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M C)@_P(R8/\"KEP  )M=  "*70  ?%T  '!=  !F70  7%X  %)@  !,8@
M164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L .&DR #=J.@ V:D$ -6I) #1J4@ S
M:EL ,6IE #!J< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG
M_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L
M #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E<
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M8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X
M (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@
M&HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,
MD6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS
M  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<
M  Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(
M )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H
M>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF
M!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH
M  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA
M58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R
MLP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X
M;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8
M $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@
M +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@
MR74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK
M   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P
M  #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<
M .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   D
MO   &+\  !##   (QP   ,H   #-    T0   -4   #8    V0   -L   #=
M    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K
M  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P
M_P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q
M (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .(
M_P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T
M /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H
MY0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1
M /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0
M.P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+
M -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\
MP0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C
M $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4
MC ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_
M +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L
MS0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U
M (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8
M_P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^
M +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D
MIP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9
M!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %
M0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF.
M )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\
M]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B
M#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1
ME "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H
M -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX
ME!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!
M&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I
M  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y!
M (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9<
M=2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W
M,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF
M1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\HB !N*)0 ;"BA
M &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\  ,(V  "O-@
MH34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\ =RPX '4L0 !S
M+$< <2Q- ' L5 !N+%H ;2QA &LM: !J+7  :"UZ &<NA0!E+I$!9"Z> 6(O
MK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH
M ) X  ")-0  @S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4,
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M DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,  ()"  !Z0
M<ST  &T\  !H/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4
M/TT 4S]5 %) 7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"
MZ ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T
M &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL
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M 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J3   8$H  %E+  !43
M4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0/0! 440 /U%+ #Y14P ]
M4EP /%)F #I2<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390
M_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(!
M $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH
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M:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@
M (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H
M+&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?
M;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<
M  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(-
M "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X
M%75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O
M80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]
M#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X
M  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90
M868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -
MB0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)
M@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP
M %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP
M I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@
ME8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY
M   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.
M  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0
M **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   X
MBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L
M#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.
M  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0
M)IX  !RC   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y"
MN@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$
MEP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T
M !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8   #'    R00
M ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@
MVYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^
M   $P@   ,4   #)    S0   -    #2    T@   -4   #6    V0   -L
M  #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\
M /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_
M $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L
ME0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_
M -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@
M] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #<
M )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L
M_P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!,
M .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )(
MR0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\
M /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -(
M4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4
M +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\
M_P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_
M %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L
MF "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P
M /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P
MK@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"<
M )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+
M  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!-
M *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D
MC@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*
M%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)
M3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB
M ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0
MKQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "(
M$$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3
MK@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,
M )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH
M?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K
M'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H
M  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+
M '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@
M82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%
M*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E
M30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK*
M %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P
M>2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?
M*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(O
MY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$
M &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT
M5S!3 %8P6P!4,6, 4S%L %(R=P!1,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,
M-/8 3#3_ $PT_P!,,_\ NSD  *8Y  "5.0  ASD  'PY  !T-P  ;C0  &DS
M  !E,@( 83(- %XR% !<,QX 6C,F %@S+@!6,S4 530\ %,T0P!2-$H 4310
M % U6 !.-6  339J $PV=0!+-X( 2C>0 $DXGP!(.+ !1SC# 4<XX0%'./4!
M1SC_ 4<X_P%'./\!MSL  *(\  "1/   @SP  '@\  !P.@  :C<  &0V  !@
M-@  7#8+ %DW$@!6-QH 5#<C %(W*P!0-S( 3S@Y $TX0 !,.$< 2SA. $HY
M50!).5X 2#IH $<Z<P!&.X  13N. $0\G@!#/*X!0CS" 4(]WP%"//,!0CS_
M 4(\_P%"._\!LST  )X^  "-/@  ?SX  '4^  !L/0  9CH  & Y  !;.@
M5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$
M/EP 0SYF $(_<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X_
M_P$^/_\!KD   )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX%
M $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH
M/D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y
M0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E#
M# !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A
M #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\
MID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!
M2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,
M:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<
M (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X
M.4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L
M474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*
M  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02
M #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W(
M)5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U
M3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;
M%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^
M !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40
M9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A
M8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5E
MBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8
M %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!,
M%FT: !5M(0 4;2D %&TP !-M.0#_XGT024-#7U!23T9)3$4 !Q(2;D( $6Y,
M !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\
M@ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD  "1L   =
M;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP "7='  AW
M4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "=/P >UT
M &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU   7>0
M$GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()   ""3
M@ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD =&(  &AB
M  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1@P  #88
M  B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".1   CE$
M (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8
M:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP  !I(   "5
M    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7
M  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO  !1<@
M1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *    "B
MHP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L
M70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0
M #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P    L
M +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!  "]4@
MO60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9
M   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_    OP   ,
M  #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #110  TE<
M -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(  "6H   :
MK@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0   ,\   #0
M    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.   Z$H  .E=
M  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_ "8
M_P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K
M (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8 V0#W -@
M_P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L
M /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X >@#= '\
MVP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q ,< _P#&
M /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P [  G .D
M,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_
M ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +< ^P"V /\
MM@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A -4 +0#1
M #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +<
M@ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_
M *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,( )@"_ #$
MO  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G
M ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T F #_ )@
M_P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P "L K0 U
M *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L =0": 'L
MF "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P",
M /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0 H  N )X
M-P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^
M (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\
MZ T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G )( ,0"0
M #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$
MA !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14
M ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C,
M@PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R
M#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>
M  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V
M '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD
M9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?
M)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7
M. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2
M %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*
MBR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C
M'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0B
MG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3+   ABT
M 'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8
M6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,
M**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3   '<O
M  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y
M %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H
M12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K
M,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM
M/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[
M #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F-0
M83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$
M,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HV
MT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C-P  738
M %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT
M/C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V
M.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@  63D  %,V
M  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M"
M #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH
M,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P  $XZ  !)
M.P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #-
M2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y
M "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^  !$/P
M0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M
M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%
M_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _1   .T4
M #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G2DL
M)DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B
M2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2   -TD  #)+
M   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A4$@ (%!2
M !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\
MBD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0   H
M4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A7
M60 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D
M '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6   D60
M'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]* !%?50 0
M7V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.
M  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?7P  &6(!
M !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT
M!V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=
M4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P  $VH   ]M
M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P2@  <%<  '!E
M  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8  &-6  !95@
M45<  $=8   ^6P  -E\  "YB   F9@  'VH  !EM   3<   #G,   MV!  %
M> L  7@/  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z
M<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P
M $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@
M (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':
MAWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI
M   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)
M  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(
M )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K
M>0  (7\  !F$   1B0  #(T   :1    E    )@   ":    FP   )P"  "=
M!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]
M  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP
M&8T  !&2   +EP  !)P   "@    HP   *8   "H    J0   *H   "L
MK00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "X
MB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT
M  RB   #IP   *L   "N    L@   +8   "X    N    +H   "[    O0
M +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@
MS9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q
M    M@   +H   "^    P@   ,8   #(    R    ,H   #+    S0   ,X
M  #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(
M .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #]
M $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0
MBP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_
M ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X
M[ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0
M (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\
M_P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!"
M -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8
MO0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P
M /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,(
M10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"(
M *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\
M_P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O
M $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P
MBP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P
M .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $
MG@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"-
M (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,
M  #! 0  M    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!!
M (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H
M?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R
M#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (,
M0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2
M '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@
MFA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W
M!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)
MG0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@
M (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X
M; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<
M$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=
M  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_
M &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D
M4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P
M(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D7
M00!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX
M $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0
M9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0
M'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,B
MS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<
M %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D
M2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]
M*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H
M  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=#
M $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8
M."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0
M*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL
M2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W
M #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0
M1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U
M,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S
M_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(
M #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P
M+S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J
M-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV
M @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3
M "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\
MC38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R
M.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "-
M6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D
M '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004
M*D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <
M164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]
M  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<*
M "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V(
M%4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A
M00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/
M#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M
M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1
M4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 1
M5PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8
M>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@
M $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P
M"F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P
M8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,
M   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.
M  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8
M &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X
M5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q
M$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..
M  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7
M*F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@
M?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  "
MG0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH
M !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T
M (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0
MCJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\
M   .@0  "(4   ")    C0   )    "2    DP   )0   "6 P  EP@  )@,
M  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(
M )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &
MD    )0   "8    G    )\   "A    H@   *0   "E    IP   *@$  "J
M"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L
M  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP
M *0   "H    K    *\   "Q    L0   +,   "U    M@   +@   "Z
MO 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(
MKP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,
M  "W    O    +\   #!    P@   ,0   #%    QP   ,D   #+    S0
M ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@
MXJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /,
M4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3
M -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\
M_P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@
M %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8
ME@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P
M /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T
MQP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R
M )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T
M  #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!.
M +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0
MH0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>
M    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *(
M30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9
M )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'
MN@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2
M $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 ((
MH "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@
M *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $<
M@P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T
M *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$
M  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!'
M '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8
M9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!
M"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L
M1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S
M %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0
M<PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A
M!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,
MQP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0
M &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44
M5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)
M$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7
M  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)'
M $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^,
M0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7
M&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $87
M2@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU
M #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@
M3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^
M'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A
M_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22
M $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP
M-R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q
M)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D
M!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3
M # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\
MC2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y
M* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL
M6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL
M '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D
M,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E
M,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O
M  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$-
M "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6,
M'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C
M,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W
M$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN
M !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0
M538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >
M/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !-
M?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD
M $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q
M%T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -
M18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\
M  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2
M !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X<
M!4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]
M/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1
M%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6
M  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@
M-$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@
M61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9
MI0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD
M "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$   810
M &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH
M8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3
M   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5
M  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+
M &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   6
M8   $&0   QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W
M%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!
M  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P
M"V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0
MAA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'
MT0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT
M  "!    A0   (@   "*    C    (T   "/    D 0  )((  "3#   E1
M )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP
ME]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1
M    E0   )@   ":    FP   )T   "?    H    *(   "D!0  I@H  *@.
M  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L
M168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A
MI0   *@   "K    JP   *X   "O    L0   +,   "U    MP$  +D'  "\
M#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(
M #)X   G@   '(@  !*0   *EP   )T   "C    J    *T   "R    M@
M +D   "[    O    +X   #     P@   ,0   #&    R    ,L   #.!0
MT0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\
M  #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9
M .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$
MS "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_
M    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$
M60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F
M +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X
M[0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\
M %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@
MK0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP
M ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %,
MIP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6
M +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<
M @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2
M )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\
MA0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">
M  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (<
M40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z
M '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  (
MBP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X
M %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H
MR0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P &
M 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L
M:P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!>
M .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$
M"0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !,
M %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H
M4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F
M! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!
M3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M
M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04
M70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,
M"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-
M^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X(
M %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\
M1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [
M$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1
M"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4
M #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\
MCAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#
M%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #08
M6P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX
M '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P
M.QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M
M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C
M  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X.
M #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F(
M)B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C
M)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB
M$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M
M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0
M5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G
M)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK
M>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP
M $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!(
M("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5
M,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N
M  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5
M !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D
M$#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^
M,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X
M&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9
M  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P
M-C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 .
M/AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_
MJ  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4
M "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D
M"$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I
M1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY
M   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<
M  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4
M $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B
M00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3
M'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*
M  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P
M%TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@
M7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:
MY   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,
M  Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP
M &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@
M9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@
M   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=
M  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P
M3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K
M;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$
M'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX
M #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0
M ($   "#    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@
MEB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9
M   O70  )&,  !II   2;P  #'4   1[    @    (4   ")    C0   )$
M  "3    E    )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<
M *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G
M:@  '7   !-X   ,?P   X4   "+    D0   )8   ";    GP   *(   "D
M    I0   *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8
M  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>
M%H    V(   %CP   )8   "<    H@   *<   "L    L    +,   "V
MMP   +D   "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5
M&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P %
M /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X
MW@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#"
M ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /,
M"P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!>
M ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,(
MK@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2
M  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$
M70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2
M )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P
MM@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"=
M %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P
MZ "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 .
M )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4
MBP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\
M /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T
M$0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4
M 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T
M;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\
M !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T
M5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X
M &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O !
M;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@
M %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8
M_P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1
M &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$
M50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!,
M /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@
M$P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5
M $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\
ME0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/
M 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($
M6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA
M 'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$
M1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y
M"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5
M  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2
M #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V(
M,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D
M&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0
M%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L
M "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0
M5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P
M%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9
M>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R
M $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0
M*1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P =
M'8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B
M  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7
M "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H<
M%R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^
M)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB
M&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8
M !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@
M-B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7
M)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJ
MJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@
M "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P
M$2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )
M+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ
M   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@
M  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8
M C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F
M+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X
M)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*
M   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,
M'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0
M/B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]
MY   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8
M !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120
M $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP
M0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_
M   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH
M  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O(
M4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +
M20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7
M+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP
M $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40
M %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@
M8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_
M   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X
M  !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH
M &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U
M1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M
M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N
M  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3
M)5   !Q5   46P  #F    =E    :@   &X   !R    =@   'D   !\
M?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2
M,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP
M !5B   .:   !VX   !T    >0   'X   ""    A@   (D   ",    C@
M )    "2    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0
MICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P
M   '=P   'X   "$    B@   (\   "4    F    )L   ">    GP   *(
M  "D    I@   *@   "K    K0   +    "S!   MPP  +L2  "['P  NS
M +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F
MB    (\   "6    FP   *$   "F    J@   *X   "P    L0   +0   "V
M    N    +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X
M  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$
M^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3
M &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D
M_P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6
M -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &(
MN@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E
M /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,,
M&P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A
M *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\
ME0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H
M !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ),
M8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_
M (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D
MDP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"!
M &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0
M_P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ;
M (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H
M< !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G
M /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '
M'0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!;
M &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\
MJ    )4   "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C
M !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8
M7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G
M (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D
M5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!*
M &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '
M  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ;
M $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\
M0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J
M#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0
M' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H
M #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$
M61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [
M AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'
M<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0
M $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D
M- D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G
M#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7
M  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T;
M "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0
M'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _
M&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80
M'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125
M !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P
M-AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?
M$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8
MI@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T
M "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X
M&1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /
M'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>
M   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB
M !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4
M"R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F
M'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B
M)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'
M  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0
M(2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *
M)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $H
MX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,
M !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@
M RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX
M+/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG
M   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M
M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?
M5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2
M+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y
M,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L
M $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P
M#34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P
M0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O
M   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P
M  4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4
M $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V
M,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&
M    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\
M  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0
M+S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/
M40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<
M1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD
M ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<   !:    7
M %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/
M:DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$
M   620  $$T   I1   $50   %H   !=    8    &,   !F    :    &H
M  !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44
M 'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   0
M5   "ED   )>    8P   &<   !K    ;P   '(   !U    =P   'D   ![
M    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.
M  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80
M 6<   !M    <@   '<   ![    ?P   (,   "&    B    (H   "-
MCP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B
M60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<
M  !]    @P   (@   "-    D0   )4   "8    F@   )P   "?    H0
M *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@
MMV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/
M    E@   )L   "@    I    *@   "K    K    *\   "R    M    +8
M  "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL
M ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q
M "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D
M;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_
M )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0
MT@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q
M &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )(
M_P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G
M +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &<
MG !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P""
M /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\
M*0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H
M (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\
MU@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"(
M "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8
M:0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P
M *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0
M=0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E
M &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D
M  "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E
M &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &<
M5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\
M    <0   &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D
M)0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M
M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P
M9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !-
M "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $
M=0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<
M %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "
M0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V
M ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,
M  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A
M #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T
M+0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !#
M#@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$
M(@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&,
M "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0
M.1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I
M R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'
MG0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(
M #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2
M(@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7
M#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3
M   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC
M !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+,
M$ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G
M%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80
M*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%
M  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@
M(18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1
M%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6
MW0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@
M !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H
M#!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $
M&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9
M   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO
M  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P
M6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6
M&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B
M-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T
M $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@
M$1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@
M)ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A
M   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,
M  TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D
M "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X
M)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ
M @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"
M   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P
M+2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 "
M,@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z
M3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD
M "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(
M #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P
M0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J
M   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _    00   $,"
M  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$
M $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;
M,0  %30  ! W   -.@  "#T   )     0P   $8   !(    2@   $P   !.
M 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>
M  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.
M$3P   Q    '1    $<   !*    30   %    !3    50   %<   !9
M6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D
M:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8
M  9*    3P   %,   !6    60   %P   !?    80   &0   !E    9P
M &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P
M<WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7
M    7    &    !D    :    &L   !N    <0   ',   !U    =P   'H
M  !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(
M (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F
M:P   &\   !T    >0   'T   "     @P   (4   "'    B@   (P   "/
M    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!
M  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '    !W    ?0
M ((   "&    BP   (\   "3    E0   )<   ":    G0   *    "C
MI@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "Q
MC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")    D    )4
M  ":    GP   *,   "F    J    *L   "N    L    +,   "V    N@
M +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0
MRI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .(
M-@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X
M +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\
M]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #
M #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *<
M>@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z
M -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$
MI@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1
M 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   /_B
M?1!)0T-?4%)/1DE,10 ($LT   "[    K@   *4   "?    G  ) )D #P"9
M !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L A@!0 (4
M50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_
M &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0 # "" !$
M@@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R
M %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_ &$
M_P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O  X ;P 2
M &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &, 2 !B $X
M80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4
M /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L 7P / %\
M$P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0
M %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H _P!* /\
MD@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ , %( $ !2
M !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $, 2 !* $8
M4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!  /\ A0
M '0   !G    70   %4   !/    3    $H   !(  0 1P * $< #0!& !$
M1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [
M %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\ ?    &L
M  !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]  X /  1
M #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #, 20 R %,
M,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$  &0%  !7
M!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P -  / #0
M$@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J $\ *0!:
M "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)  !2"P
M2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  - "P $  K
M !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L (@!7 "$
M9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-#0  0PX
M #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4##@ D 1
M) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4 !H!80 :
M 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0
M   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >!@X '@41
M !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX
M$P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41   O
M$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)
M$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R
M  X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3   L$P
M)Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2
M#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/
MDP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I%   )10
M "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q(
M#1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $
M$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@  (A4  !X4
M   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5
M  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5C@  %:,
M !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18  !P6   9
M%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A  !A83  46
M&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C   &*(  !BW
M   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7   8%@
M%14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@
M&QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*   !RV   ;
MT   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7&   %!<#
M !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @%   (1H
M "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V   ?T0
M'^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$ $QD! !$9
M 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@  )A@  "<?
M   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   DT0  (^X
M1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P   X=   -
M'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14  "T<   M
M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT   *>\ 0"
M #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB   *)
M!B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48   U(
M-2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\ /",  #(D
M   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %*P   2X
M   P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^'   /B8
M #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<  "\G   H
M)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P   #4    X
M    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P  2"$  $@L
M  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G*
M(B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X   !!
M0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P  %,G  !3
M-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F*P  'RP
M !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,    3@
M %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?  !B+
M83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,   &C,  !,W
M   ..P  "#\   %$    2    $P   !/    4@   %4   !8    6P   %T
M  !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S)0  <C0
M ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P   Y!   '
M1P   $P   !1    50   %D   !=    80   &4   !H    :P   &T   !O
M    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'   B"L  (8]
M  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.    5
M %H   !@    9    &D   !N    <@   '8   !Z    ?0   (    ""
MA0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$  )\S  "=
M1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<    8P   &H
M  !Q    =@   'L   "     A@   (H   ".    D0   ),   "6    F0
M )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH  "W/
MM%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =    'P   "#
M    B0   (\   "4    F@   )\   "B    I    *<   "J    K@   +$
M  "T    N    +P   #!    QP   ,T   #4!0  V!   -4>  #3,0  T$@
M ,U?  #+=@  R(X                       $#! 4&" D*"PT.#Q$2$Q06
M%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$149'24I+34Y/
M4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]?H"!@H.%AH>(
MBHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6VN+FZN[V^O\'"
MP\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P\?+T]?;W^?K[
M_/[______________________________________________________P
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M______________________________________\
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M_VUF=#$      P0A   !                     0
M  $    ! @,$!08'" @)"@L,#0X/$!$2$Q05%A<8&1H:&QP='A\@(2(C)"4F
M)R@I*BLL+2XO,#$Q,C,T-38W.#DZ.SP]/C] 04)#1$5&1TA)2DM,34Y/4%%2
M4U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM;F]P<7)S='5V=WAY>GM\?7Y_
M@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6FIZBIJJNL
MK:ZPL;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.S]#1T]35UM?8V=K;
MW-W>W^#AXN/DY>;GZ.GJZ^SM[N_Q\O/T]?;W^/GZ^_S]_O\  0$" @,#! 0%
M!@8'!P@("0D*"PL,# T-#@\/$! 1$1(3$Q04%186%Q<8&1D:&AL<'!T>'A\@
M("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C] 0D-$149(
M24I,34]04E-55UA:7%Y@8F1F:&IM;W%T=GE\?H&#AHF+CI"2E9>9FYV?H:.E
MIZBJK*VOL+*SM;:WN;J[O+V_P,'"P\3%QL?(R<K+S,W-SL_0T=+2T]35UM;7
MV-G9VMO;W-W=WM_?X.'AXN/CY.7EYN;GZ.CIZ>KKZ^SL[>[N[^_P\/'R\O/S
M]/3U]O;W]_CX^?GZ^_O\_/W]_O[_  $! @(# P0$!08&!P<(" D)"@L+# P-
M#0X/#Q 0$1$2$Q,4%!46%A<7&!D9&AH;'!P='AX?(" A(B(C)"0E)B8G*"DI
M*BLL+2TN+S Q,C(S-#4V-S@Y.CL\/3X_0$)#1$5&2$E*3$U/4%)355=86EQ>
M8&)D9FAJ;6]Q='9Y?'Z!@X:)BXZ0DI67F9N=GZ&CI:>HJJRMK["RL[6VM[FZ
MN[R]O\#!PL/$Q<;'R,G*R\S-S<[/T-'2TM/4U=;6U]C9V=K;V]S=W=[?W^#A
MX>+CX^3EY>;FY^CHZ>GJZ^OL[.WN[N_O\/#Q\O+S\_3T]?;V]_?X^/GY^OO[
M_/S]_?[^_]K+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.E
MA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&P
MHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5
MK9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+
M"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(
MV:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OH
MS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=
MB=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZ
MZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJ
MG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P0
M8-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>
MJ)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(
M#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-
MX:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++
MNC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9
MC^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*L
MQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0
MM,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S
M:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[
MKGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$
MM:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(
MR[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.E
MA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&P
MHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYMG+"1OGS@TYZ,T08-S)#9++NS"KQKA/M,"S9[V[KGO$M:F(R[*FA]&OHX?5
MK:"(V:N>B=RIG(K>IYN,X*69C^.AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2A
MF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y-G+
M"1KDS@TYY\X.8-K*#)++O"ZKQ;E-M,"T9KVZKGK%M:F'R[&FA]&NHX?5K*"(
MV:J>B=RGG(K>I9N+X**:C>*>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_C
MGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/X]C+"1KA
MSPPYY<\.8-G*#)'+OBRKQ;E,M;ZT9[VYKGO%M*J'S+"FA]&MHX?5JZ"(V:B>
MB-NEG8G=HYR*WY^:B^&;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.
MXIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XMC+"1K<T LY
MX] -8-C+"Y'+ORNKQ+I,M;VS9[ZXKGO%M*F'S+"FA]&LHX?5J:"'V*:?B-NC
MG8C=H)R)WIV;BN"8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:
MC>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X=?,"1K:T0LXWM$,
M7];+"Y'+P"FLPKE-MKRS:+ZWKGO&LZF'S*^FA]&JHX;5IZ&'V*2?A]JAGH?<
MGIV(W9J<B=Z5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5
MFXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X-;,"1G9T0LXVM,,7]3,
M"Y')P"FMP+E.MKJS:;^UKGS&LJF'S*VFAM&IHX;4I:&&UZ*@AMF?GX;:FYZ'
MW)>=B-V3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>
MDYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WM7,"1G8T@LWV-,+7M+,"Y/'
MORNMOKA0M[FR:K^TK7S&L*F'S*NFAM"GI(74HZ*%UI^AA=B<H(79F)^&VI2>
MA]R0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*
MW9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W=3-"1G6T@LWUM0+7M#+"I7$OBVN
MO+A1N+>R:L"SK7S&KJF'S*FFAM"EI(73H*.$U9VBA-:9H878E:"%V9&?A]J.
MGHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>
MB=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)V]/-"AC5TPLVU-0+7\[+"9?!OC"ONK=3
MN+6R;,"PK7W'K*J&RZ>GA<^BI831GJ2$TYJCA-66HH36DZ&%UX^@AMB+H(G9
MBZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+
MH(G9BZ")V8N@B=F+H(G9BZ")V=+."A?3U LUT=,*8LO,"9F^O3.QM[=5N;*Q
M;<&MK7W&JJJ&RZ2HA,Z?IX30FZ6#TI>D@].3HX34D*.%U8RBAM:)H8C7B:&(
MUXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7
MB:&(UXFAB->)H8C7B:&(U]#/"A;1U LWSM,*9<;*"YVYO#BRM+98NJVQ;L&J
MKGW&IZN%R:&IA,R<J(/.EZ>#SY.F@]&0I832C:6%TXJDAM.'HXC4AZ.(U(>C
MB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(
MU(>CB-2'HXC4AZ.(U,[0"A7.U HZRM,*:,#(#Z&UNSZTK;5;NZFQ;\&FKWW$
MHZV$QYVK@\J8JH/+DZF#S9"HA,Z-IX3/BJ>%SX>FA]"%IHC1A::(T86FB-&%
MIHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86F
MB-&%IHC1A::(T<S0"1C*U H^Q=,*;;C%%J6NN42UI[5>NZ.R<,"AL'W#GZZ$
MQ9FM@\>4K(3)D*N$RHVJA<N*JH7+B*F&S(6IA\V#J(G-@ZB)S8.HB<V#J(G-
M@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#
MJ(G-@ZB)S<C1"1O%U0I"O],*<K'$'J>EN4FVH;9@NYZS<+Z=L7W!F["$PY6O
MA,21KH3&C:V%QXJMAL>(K(;(AJR'R(2KB<F"JXK)@JN*R8*KBLF"JXK)@JN*
MR8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)
M@JN*R<32""# U@E(N-0*>*G/%YB>OD>NFK9BNIBU<;R7LWR^E[*$P)*QA<*-
ML(7#BJ^&Q(BOA\2&KXC%A*Z)Q8.NBL6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&N
MB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+
MQ;_4!R6ZUPE.KMH+<*#;$X>7S3F:DL-8J)&\;+*1MWJYDK2#O8ZSAK^+LH?
MB+&'P(:QB,&$L8G!@[&*P8*QB\* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
ML(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PO?
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MPH2I=,*%JG/!AZMRP8BK<L"*K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MEXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N@*+4K("CTJR
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MEZV$QI.MA,>/K(3(C*N%R8FKALJ'JX;*A:J(RH.JB<N!JHO+@*J,RX"JC,N
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M-VF%Z49T?^13>WS?8(%XW&B%=-IMB7#8<8MNUG6-;-5XCVK4>Y!ITWZ19].
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
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MR)2'K,63AZ[#DH>PP)*'L,"2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[#
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
MJL1QP*K$<<"JQ'' JO^1$@'_E2<+_Y4['/^32R__CUE#_XQD5/N,:V/RBG)Q
MZHA\?>.&A(?>@HJ/VG^/EM9]E)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,URJ:G,
M<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1Q
MP*K$<<"JQ'' JO^1$@'_E2<+_Y4['/^32R__CUE#_XQD5/N,:V/RBG)QZHA\
M?>.&A(?>@HJ/VG^/EM9]E)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,URJ:G,<:VJ
MS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$
M<<"JQ'' JO^1$@'_E2<+_Y4['/^32R__CUE#_XQD5/N,:V/RBG)QZHA\?>.&
MA(?>@HJ/VG^/EM9]E)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,URJ:G,<:VJS'"R
MJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"J
MQ'' JO^2$@'_EB<*_Y8['/^42S#_D%E#_X]C5/J.:63QC7!RZ8MZ?N*)@HG<
MA8F2V(*.F=1_DY[1?9>BSWN;ILUYGJC,=Z*JRW:EK,ITJ:W)<ZVNR7*RK\EQ
MMZ_(<;ROPG.]KKYTO:^^=+VOOG2]K[YTO:^^=+VOOG2]K[YTO:^^=+VOOG2]
MK_^3$@'_ER<*_Y@['/^52S#_D5E$_Y%@5?J09F3PCVUSZ(UW@.&,@(O;B(>4
MU86-G-*"D:'/?Y:FS'V9J<M[G:S)>:&NR'>EL,=VJ;'&=:VRQG2RL\9SN;/"
M=;JSO'6ZL[AVNK.X=KJSN':ZL[AVNK.X=KJSN':ZL[AVNK.X=KJSN':ZL_^4
M$0'_F"<*_YD['/^62S#_DEE$_Y)>5?J29&7PD6ITYX]S@>".?8S9BX66U(B+
MGM"%D*3-@I2IRG^8K<A]G+#'>Z"RQGFDM,5XJ+7$=JZVQ'6TML%VM[:\=[>V
MMW>WMK-XM[:S>+>VLWBWMK-XM[:S>+>VLWBWMK-XM[:S>+>VLWBWMO^5$0'_
MF2<*_YD['/^72C#_DUA$_Y1<5?J4867PDV=TYY%P@M^/>H[8C8.8THN*H,Z'
MCZ?+A).LR(&7L,9_F[/$?9^UPWNDM\)YJ;G"=Z^YPG:UN;QXMKBX>+:XLWBV
MM[!YM[>P>;>WL'FWM[!YM[>P>;>WL'FWM[!YM[>P>;>WL'FWM_^6$0'_FB<*
M_YH['/^72C'_E%5$_Y995?J67F7PE61TYY-L@MZ1=H[8CW^9T8V(HLV*CJG)
MAY*NQH26L\2!FK;"?I^YPGNDNL%YJKK!=[&ZO7BUNK=XM;FS>;6YKWFVN*QZ
MMK>L>K:WK'JVMZQZMK>L>K:WK'JVMZQZMK>L>K:WK'JVM_^7$0'_FR8*_YL[
M'/^823'_EE-$_YA75?J86V7PEV%TYY9H@MZ3<H_6D7N:T(^$H\N-C*O'BI&Q
MQ(:5ML.#F;C!?YZZP7NDN\!YJ[R_=[.\N'BSN[)YM+NN>;6ZJWJUN:A[MKBH
M>[:XJ'NVN*A[MKBH>[:XJ'NVN*A[MKBH>[:XJ'NVN/^7$0'_FR8*_YPZ'/^8
M23'_F%%$_YI45/J;6&3PFEUTYYAC@MZ6;8_6DW>:T)& I,J/B:S&C8^SPXF4
MM\*$F+K ?YZ\OWNEOK]YKKZY>+*^LGFRO:UZL[RI>[2ZIGNUN:1\MKBD?+:X
MI'RVN*1\MKBD?+:XI'RVN*1\MKBD?+:XI'RVN/^8$0'_G"8*_YPY'/^92#'_
MF4]$_YQ25/N=56/QG5ISYYM?@=Z9:8_6EG*:SY-\I<J1A:W%D(VTPXN2N,&%
MEKN_@)V^O7NEP;MYK\&R>K# K'NQOJA[L[VE?+2[HGVUN:!]MKB@?;:XH'VV
MN*!]MKB@?;:XH'VVN*!]MKB@?;:XH'VVN/^9$0'_G28*_YTY'/^91S'_FTU#
M_YY/4_N?4F/QH%9RZ)];@-^=9([7FFV:T)=WI,J4@:W%DHJUPHZ0N;^'E;V]
M@)S!NWNGQ+-ZK<2K>Z_"IGRQOZ-]LKV@?K2[GG^UN9Q_MKB<?[:XG'^VN)Q_
MMKB<?[:XG'^VN)Q_MKB<?[:XG'^VN/^9$0'_GB8*_YTX'/^:1S'_G$M"_Z!-
M4ORB4&+RHU-QZ:-7?^"A7HS8GF>8T)MQH\J8>ZW%E86TPI*-NKZ*DK^Z@9O%
MMWRIR:M\J\>D?:[#H'ZPP)U_LKV;@+.[F8&UNIB!MKB8@;:XF(&VN)B!MKB8
M@;:XF(&VN)B!MKB8@;:XF(&VN/^:$0'_GB8*_YXX'/^:1C+_GDE"_Z)*4?VD
M36#SIE!OZJ=4?>&F6(K:I&*6TJ%KH<N==:O&FH"SPIB*NKR.C\*V@YG+K'VF
MSJ)_JLF=@*W$FH&PP)B"LKZ7@[.\E8.UNI2#MKB4@[:XE(.VN)2#MKB4@[:X
ME(.VN)2#MKB4@[:XE(.VN/^:$0'_GR8*_YXW'/^;1C+_GT=!_Z1(4/ZG2E_T
MJ4QMZZM0>^.L5(?<JUR3U*EEG<ZF;Z?(HWJPPY^$N+N6B\2PC)G.H(.DT9F$
MJ<J6A:W%E(6OP9.%L;Z2A;.\D86TNI&%M;F1A;6YD86UN9&%M;F1A;6YD86U
MN9&%M;F1A;6YD86UN?^;$0'_GR8*_Y\W'/^;13+_H45 _Z9&3_^J1UWVK4EK
M[;!,>.:S3X/?M%6.V;5?E].U::#.M7:GP:M\MK"?A<2AE9+.E(ZCTI"+J,N/
MBJS&CHJOPHZ)L;^.B;*]CHBTNXZ(M;F.B+6YCHBUN8Z(M;F.B+6YCHBUN8Z(
MM;F.B+6YCHBUN?^;$0'_H"8*_Y\V'/^<1#'_HT,__ZA#3O^M1%OXL45H\+9(
M=.F[3'[CP%&'W\9;CM;(:Y3&O7&FM;-XM:6H@<.4GXW-B9RBTH>4I\R(D:O'
MB8^NPXF.L,")C;*^BHRSO(J+M+J*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+J*
MB[2ZBHNTNO^<$ '_H28*_Z V'/^>0C'_I4 ^_ZM 3/^Q0%GZMT%D\[U$;^[%
M27?ESE)\W=9B?\S.:)*\Q6ZDJ[MVM)JQ?\&*JHK+?Z>=SX"?J,R"F:O'@Y6M
MQ(23K\&%D;&_AH^SO8>.M+N'CK2[AXZTNX>.M+N'CK2[AXZTNX>.M+N'CK2[
MAXZTN_^=$ '_HB8*_Z U'/^@/S#_IST]_ZX\2O^U/%7ZO3U@\,9"9^;12FS>
MWDYVS=I7A[[08I:NQ6ZEH;QYLI6T@[V&K8C&>ZJ4RGBKJ,E[HJO'?IRMQ("9
MK\*!EK# @I2ROH.2L[R#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[R#DK.\@Y*S
MO/^>$ '_HB8*_Z$T'/^B/"[_JCH[_[(X1_R[-U'RQ3I8YM%!7-O>0FG-XD9\
MOM=1C*[,7YNAPVVHF+QYLI&UA+N%L8G"?*Z1Q7BNG\5UK:S%>*6NQ'J@K\)\
MG+# ?IFQOG^6LKU_EK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKU_EK*]?Y:RO?^>
M$ '_HR4)_Z(T'/^E.2W_KC4X_[@S0O3#,TKGT#A.V=XY6LOF/6Z^X$* KM10
MD*'+7YV8PVVHD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[#
M>9^QOWN<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO?^@$ '_
MI"0)_Z,R'/^H-"O_LR\T^;\M/.G-+T#9WB]*RN<T7[WJ.G.OWD&#H=-1D9?+
M8)V0Q&ZFC+]ZK8:[@;-_N(>X>K:-NW>UE;QUM9^\<K2HO6ZSLKYQK+*^=*>R
MOG:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO?^A$ '_I2,)
M_Z0Q'/^M+B?_N2DO[L@F,]K<)C?*YRQ/O?(R8Z_H.76AW4*$EM13D(_-8IJ*
MQW"BAL-ZJ("_@*U[O86Q=KN+M'.YDK5QN9JV<+FCM6VYJ[9JN+2X:[*VN&ZL
MMKANK+:X;JRVN&ZLMKANK+:X;JRVN&ZLMKANK+:X;JRVN/^C$ '_IR()_Z4O
M&_^S)R+TPB$FW=@=),OG(SR]\BI3K_,R9J'G.W:5WD:#C=96C8?09):$RW&<
M?\AXH7K%?J5VPH.I<L&)JV^_CZULOY:N:[Z=KFJ_IJYHOZZN9;VXL&6YN[!E
MN;NP9;F[L&6YN[!EN;NP9;F[L&6YN[!EN;NP9;F[L/^E$ '_J" (_ZPF%_R[
M'1KCT1,9S.49*;WR(D&O_2I5H?,T9I;I/W2,X4M_A=M9B(#59H]\T6^4=\YV
MF7/+?)QPR8&?;<B'H6K'C*-HQI*D9L69I63%H*5DQ:BE8\:RI&#$NZ9@Q+NF
M8,2[IF#$NZ9@Q+NF8,2[IF#$NZ9@Q+NF8,2[IO^H$ #_JAX(_[,=$>S)#@_.
MXPX5OO(8+:_^(D.A_RU5EO0Y9(SL16^$Y5%Y?N!<@'G<9X9TV6Z*<-9TCFS3
M>9%ITG^39]"$E63/BI=BSH^88,V5F5_-G)I>S:*;7<VKFUS-M)I<S;2:7,VT
MFES-M)I<S;2:7,VTFES-M)I<S;2:7,VTFO^K#P#_K1H'\L -",[3"@:^\ X:
MK_X9,*'_)$.5_S)2B_@_7H/Q2VA][%9P=^A?=G'D97ILX6Q^:=]R@6;=>(1C
MW'V&8=N"B%_:AXE=V8R+6]B2C%G7F(U8UIZ-5]:ECE;5K(Y6U:R.5M6LCE;5
MK(Y6U:R.5M6LCE;5K(Y6U:R.5M6LCO^O#0#_MPX#S<D( ;[8"0FN_1 <H?\<
M+Y7_*3^+_S=,@OY%5GSY4%YU]%ED;O%?:6CN9&UDZVIP8>IP<U_H=75=YWIW
M6^9_>%GEA'E8Y(E[5N..?%7BDWU4XIA^4N&>?E'AI7]1X:5_4>&E?U'AI7]1
MX:5_4>&E?U'AI7]1X:5_4>&E?_&T" #.P 8 O<X' :[@!PN@_Q(<E/\@*XK_
M+SB!_SU#>O])2W/_4E%L_E=79?M=6V'Y8UY>]VA@6_5M8ECT<F16\W=F5?)[
M9U/Q@&A1\(1I4/"):D_OCFM.[I-L3.Z9;4OMGVY+[9]N2^V?;DOMGVY+[9]N
M2^V?;DOMGVY+[9]N2^V?;M&Y P"\Q04 K=8# 9_X"PN3_Q88B?\D)(#_-"]Y
M_T$W</](/FC_3T-B_U5'7?]:2UG_8$U6_V504_]J45'_;E-/_W)43O]V54S^
M>U9+_7]72?V$6$C\B%E'^XU:1ON36T7ZF%Q%^IA<1?J87$7ZF%Q%^IA<1?J8
M7$7ZF%Q%^IA<1?J87+V] P"MS0$ GM\  9+_#0B'_QD2?O\I&W7_-2-L_SPJ
M9/]#+U[_2C18_U W5/]6.E'_6SQ._V ^2_]D0$K_:$%(_VQ"1O]P0T7_=$1$
M_WA%0O]]1D'_@4= _X9(/_^,23W_D4H]_Y%*/?^12CW_D4H]_Y%*/?^12CW_
MD4H]_Y%*/?^12J[%  ">UP  C_4  8;_#P1\_QL+<?\D$6?_+!=?_S4<6?\]
M(53_129/_TLI3/]2+$C_5R]&_UTP1/]A,D+_9C- _VHU/_]N-CW_<S<\_W<X
M._]\.3K_@3HX_X8Z-_^,.S;_DCPV_Y(\-O^2/#;_DCPV_Y(\-O^2/#;_DCPV
M_Y(\-O^2//^#$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z
M@&_N=XAWZG6/?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:Z
MD=QEP9+<9<F2VV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1
MSFC2D?^#$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z@&_N
M=XAWZG6/?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:ZD=QE
MP9+<9<F2VV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2
MD?^#$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z@&_N=XAW
MZG6/?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:ZD=QEP9+<
M9<F2VV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D?^$
M$P'_A2(&_X8U%/^$1B3_@%4T_X1=0_^%95#_@VU=^(!U:/)]?G'L>H9YZ'>-
M?^5UDX7B<IB)X'"=C-]NHH[=;*:0W&NKDMMIKY3::+65VF>[E=IFPY;:9LR6
MTVC/ELQISY7(:L^6R&K/ELAJSY;(:L^6R&K/ELAJSY;(:L^6R&K/EO^%$@'_
MAR(&_X<U%/^%1B3_A%0U_XA<0_^(9%'^AVM>]X-R:?& ?'/K?85[YWJ,@N-W
MDH?@=)>,WG*<C]QPH9+;;J:4V6RJEMEJL)C8:;:9UVB]F==HQIK3:,R:S&K,
MF<9KS)K";,R:PFS,FL)LS)K";,R:PFS,FL)LS)K";,R:PFS,FO^&$@'_B"$&
M_X@U%/^&1B7_AU,U_XM;0_^,8E'^BFI>]H=Q:O"$>G3J@(-]Y7V*A.)ZD(K>
M=I:/W'2;DMIQH)78;Z68UFVKFM5KL)O5:K><U&F_G=1IR9W,:\J=QFS)G<!M
MR9V];LF=O6[)G;UNR9V];LF=O6[)G;UNR9V];LF=O6[)G?^'$@'_B2$&_XHU
M%/^(1B7_BE(U_XY:0_^/85'^CFA>]HMO:N^'>'7IA(%^Y("(AN!\CXS=>921
MVG::E=ASGYG5<*6;U&ZJGM-ML9_2:[B@TFO"H<ULQZ'&;L>AP&['H;MOQZ&X
M<,>AN'#'H;APQZ&X<,>AN'#'H;APQZ&X<,>AN'#'H?^($0'_BB$&_XLU%/^)
M1B7_C5$U_Y)80_^27E'^D&5>]HYL:^^+=7;HAWZ XX2&B-Y_C8_;>Y.4V'B9
MF=5UGIS3<J2?T7"JHM!NLJ/0;;JDSFS$I<9OQ*2_<,2ENG'$I;5QQ*6R<L2D
MLG+$I+)RQ*2R<L2DLG+$I+)RQ*2R<L2DLG+$I/^)$0'_BR$&_XPT%/^*1B7_
MD$\T_Y160_^46U'^DV%>]I%H:^Z.<';HBWN XH>#B=V#BI'9?I&7U7J7G--W
MG:#0=*2CSW&JILYOLZ?-;KVHQW#"J+YQP:FX<L&IM'/!J:]TPJBM=,*GK73"
MIZUTPJ>M=,*GK73"IZUTPJ>M=,*GK73"I_^*$0'_C"$&_XTT%/^+1B;_DTXT
M_Y930O^76%#^EEY>]I1D:NZ2;';GCW:!X8R BMR'B)+8@H^9TWV5G]!YG*/.
M=:.GS'*KJLMPM*O(<+^LOW.^K+=TOJVR=;ZLKG:_K*IVOZNH=\"JJ'? JJAW
MP*JH=\"JJ'? JJAWP*JH=\"JJ'? JO^+$0'_C2 &_XXT%/^-12;_EDTS_YE0
M0?^:54__FEI=]YA@:>^5:'7HDG" X8][BMR+A)/6AHR:TH"3H<Y[FJ;,=Z*J
MRG2KKLARN*_ =+ROMW6\L+!VO+"K=[ROJ'B]KZ5YOJVC>;ZMHWF^K:-YOJVC
M>;ZMHWF^K:-YOJVC>;ZMHWF^K?^+$ '_CB &_X\T%/^/1"7_F$HS_YM-0/^=
M44[_G5=;^)Q<:/":8W3HEVI_XI-UBMR/@)/6BHF;T820H\U^F*G)>:*NQW6M
ML<1TNK.W=KFSKWBYLZIYNK.F>KJRHWN[L:![O+"??+VNGWR]KI]\O:Z??+VN
MGWR]KI]\O:Z??+VNGWR]KO^,$ '_CR &_Y T%/^20R7_FD@R_YU*/_^?3DW_
MH%-:^:!89O&?7W+JG&5]XYAOB-R3>I+6CX2;T(B-H\N!EJO'>Z&QQ7:PM;IW
MM[:O>;>VJ'JXMJ-\N+2@?+FSGGVZLIQ^N[&;?KRPFWZ\L)M^O+";?KRPFWZ\
ML)M^O+";?KRPFWZ\L/^-$ '_CR &_Y$T%/^40R3_FT8Q_Z!(/O^B2TO_I%!8
M^J159/.D6G#KHF%[Y)]IA=Z:<Y#7E7Z9T(Z(H\J%DZS$?:"TO7BPN:]YM;FF
M>[:XH7VWMIU^N+6;?[FTF7^ZLYB NK*7@+NQEX"[L9> N[&7@+NQEX"[L9>
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M*"G_ERDH_Z J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*J'"  "1T0
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MB]:+=HO6BW:+UHMVB]:+=HO6B_]Y$0'_>!H"_XP9 _^>(P3_JB8&^+0E".O
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M=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?> 6$CXC5I%^)M<0OBK7D'WOE]
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M2#7_W4DT__!)-_[X23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X2<FK  "VM
MJ,$  )O/  ".WP$ A_\1 7[_'01U_R<+;/\O$F3_-QA<_SX=5O]%(E#_2R5+
M_U(H1O]8*T'_7RT^_V<O._]O,3C_>#,V_X(T,_^--C'_F3<P_Z4X+_^R.B[_
MP#LN_],[+?_K/"W_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/+BP  "HO   FLD
M (S9  "!]0, >?\0 6[_%@-E_Q\&7O\G"U?_, ]1_S<32_\^%T;_11E!_TP;
M/?]2'3G_6!\V_U\A-/]F(C'_;B0O_W<E+?^ )BO_C"@I_Y<I*/^B*B?_K2LF
M_[DL)O_)+2;_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+:JW  ":Q0  B],  'WB
M  !U_P4 :?\, 5__$0)7_Q<#4/\?!4G_)@=$_RX)/_\V"SO_/0TW_T,/,_])
M$3#_3Q(N_U43+/];%"K_8A4G_VD6)?]R%R/_>Q@A_X89'_^1&A[_G!L>_Z4<
M'?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'9S   ",S@  ?-X  '#U  !E
M_P  6O\& 5'_#0%)_Q$"0_\7 SW_'P0X_R8%-/\M!C#_,P<M_SD'*O\^""?_
M0P@E_TD)(_]."2'_5 D?_UH*'?]A"AO_:0L9_W(,%_]\#1;_A@T4_X\.%/^:
M#Q3_F@\4_YH/%/^:#Q3_F@\4_YH/%/^:#_]<' +_5R8#_U$R!O]./ C_5T40
M_UM.&?]<6"+_6V,K_UEO,O]7>CC_5(4]_U*00?]0F47_3Z!'_TZG2?]-KDO_
M3+1,_TN[3?]*PT[_2<U/_TG=4/](Z5#_2/)0^TGV4/9+^5#P3?M/ZD_[4.=/
M_%#G3_Q0YT_\4.=/_%#G3_Q0YT_\4/]<' +_6"8#_U(R!O]1.@C_6D,0_U]-
M&?]?5R/_7F$K_UQM,_]9>3K_5X0__U2.0_]2ET?_4)])_T^F2_].K4W_3;1/
M_TR[4/]+PU'_2\Y2_TK?4O])ZE/]2O)3^$OV4_%-^%+K3_I2Y5#Z4^)1^E/B
M4?I3XE'Z4^)1^E/B4?I3XE'Z4_]=&P+_628#_U,Q!O]4.0C_74(0_V)+&O]B
M52/_8%\L_U]K-/]<=SO_68) _U:,1?]4E4C_4IY+_U&E3O]0K$__3[-1_TZ[
M4O]-Q%/_3,]4_TO@5?]+ZU7Z3/)5]$WV5>Q0^%3F4?A5WU+Y5MQ3^5;<4_E6
MW%/Y5MQ3^5;<4_E6W%/Y5O]>&P+_6B4#_U0Q!O]8-PC_84 1_V5)&O]F4R/_
M9%TM_V)H-?]?=#S_7']"_UF*1_]6DTO_5)Q._U.D4/]1JU+_4+-4_T^Z5?].
MQ%;_3=!7_TWB6/Q,[5CV3O)8[E#U6.93]EC?5/=9UU7X6=-5^%G35?A9TU7X
M6=-5^%G35?A9TU7X6?]?&@+_6R4#_U4P!O]<- C_93T1_VI'&O]K423_:5HM
M_V9D-O]C<#W_7WQ#_UR'2?]9D4W_5YI0_U6B4_]3JE7_4K)7_U&Z6?]0Q5K_
M3]);_$[D6_A/[5SP4?);YU3T6]Y5]5S55O9=SECW7<M8]UW+6/==RUCW7<M8
M]UW+6/==RUCW7?]@&@+_7"0#_U8O!?]@,@C_:CL0_V]$&O]P3B/_;U<M_VMA
M-O]G;#[_8WA%_V"#2_]<CD__6IA3_U>@5O]6J5G_5+%;_U.Z7/Y1QE[\4-9?
M^5#G7_)2[E_G5?%?W5?R8-)8\V'+6?5BQ5OU8L-;]6+#6_5BPUOU8L-;]6+#
M6_5BPUOU8O]A&0+_72,#_UHM!?]E+PC_;S@0_W1!&?]V2R/_=50M_W%=-O]L
M9S__:'-&_V1_3/]@BE+_7956_UJ>6?]8IUS^5K!?_52Z8/Q3QV+Y4MQC\U/H
M8^E5[F/>6/!DT%KQ9<A<\F;"7?)FO5[R9KM>\F:[7O)FNU[R9KM>\F:[7O)F
MNU[R9O]B&0+_7B,#_UXJ!?]I+0C_=#4/_WH^&/]\2"+_>U$L_WA:-O]S8S__
M;6U'_VEZ3O]DAE3_8)%8_UV<7/U:I6#[6+!B^E:[9?A5RF;U5.!G[%;J9]]:
M[6?07.]IQEWO:K]?[VJY8.]JM6'O:K-A[VJS8>]JLV'O:K-A[VJS8>]JLV'O
M:O]C& +_8"(#_V(G!?]N*@?_>3(._W\\%_^"1B'_@D\K_W]8-?][8#[_=6E'
M_V]T3OMJ@57X9HQ;]6*77_-?H6/P7*MF[EJV:>Q9Q&KI6-IKX5KJ:]!=[&W%
M7^QNO&'K;[9B[&^Q8^QNK63L;JMD[6VK9.UMJV3M;:MD[6VK9.UMJV3M;?]D
M& +_82(#_V8E!/]R)P?_?C -_X4[%O^(11__B$TI_X95,_^"7CW[?69&]G9P
M3O)R?%7N;8=<ZFB28N9DG&;C8:9JX%^R;=U=OV_:7=-PTE[J<,1@Z7*Z8NAS
MLV3H<ZUEZ7.I9NERIF?J<:1GZG"D9^IPI&?J<*1GZG"D9^IPI&?J</]E%P+_
M8B$#_VDC!/]W)0;_@B\,_XHY%/^.0QW_CTPF_XU3,/F*6SKSA6-$[7]L3>AY
M=U7C=()=WFZ-8]EIEVG39J%NSV.L<<MAN73(8<IUQ6'E=KEDYG>P9N5WJFCF
M=Z5IYG:B:N=UGVKH<YYKZ7.>:^ESGFOI<YYKZ7.>:^ESGFOI<_]F%P'_8R$#
M_VT@!/][(P7_ARX+_X\X$O^301K_E4HC^I11+?.163?LC6!!Y8=I2M^!=%/6
M>GY=SW2(9<IOD6S%:YMQP6BF=;UFLGBZ9<)ZMV7=>ZYHXWNG:N-[HFOD>IYL
MY7B;;>5WF6WG=IANYW68;N=UF&[G=9ANYW68;N=UF&[G=?]G%@'_9" #_W >
M _]^(@7_BRP)_Y,W$/^80!C]FD@@])I.*>R853/EE5T\W8]F1].(;U/+@7E>
MQ7N#9K]UC&ZY<99TM6ZA>+!KK'RM:KM^JFK2?Z1LX'Z>;>%]FF_B?)=PXWJ5
M<.1YDW#E=Y-QYG>3<>9WDW'F=Y-QYG>3<>9WDW'F=_]H%@'_9" #_W,< _^!
M( 3_CBL(_Y<U#O^=/A7XGT0<[Z!+)>>?4BW?G5HWTY5C1LJ.;%/#AW5>NX%^
M9[5[B&^O=Y%UJG.<>J5PJ'ZA;[:!GF_*@IMPWH&6<=^ DW+A?I%SXGR0<^-Z
MCG/D>8YSY7B.<^5XCG/E>(YSY7B.<^5XCG/E>/]I%@'_9AX#_W8: _^$'P/_
MDBH'_YLT#/Z@.Q+SHT$8ZJ9((.*G3R?8HE8VS)I@1<.3:5*[C7)>LX9Z9ZR!
MA&^F?8UVH'F8?)MVHX"7=+&#E'3%A)%UW8./=MZ!C7;@?XMWX7V*=^)[B7;D
M>HEVY'F)=N1YB7;D>8EVY'F)=N1YB7;D>?]I%0'_:1T#_W@9 O^''@/_E2@&
M_YXR"OJD-P_OJ#T4YJQ$&MVM2R30IE0UQI]>1+R99E*TDF]=K(QW9Z2'@&^>
M@HIWF'Z4?9)[H(&->JV$BGG A8AZW(2'>MV"AGK?@(9ZX'Z%>N)\A7GC>H5Y
MY'F%>>1YA7GD>85YY'F%>>1YA7GD>?]J%0'_:QL"_WL7 O^*' +_F"8%_Z(P
M"/6H,PSKKCD0XK-!%-:Q1R/*JU(TP*1<0[:>9%&MF&Q<I9)T9IV-?6^6B(9V
MCX61?8J"G(*%@*J%@7^\AH" VX6 @-V#@'_>@8!^X'^ ?>%]@'WC>X!\Y'J
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M64?0]UQ)R/=>2L'V8$N]]F!+O?9@2[WV8$N]]F!+O?9@2[WV8/^)  #9G@
MQZP! +FV @"NP0, I<X& )SD# "5[QT#C>\L"X7O.15\[T$><^]))VKN4"]B
M[E<U7.Y?.E;N:#]2[G%"3>]\1DGOB4E&\)9+0_"F34#QN4X_\MM//O#W3D+F
M^T]#W?M11-3\4T7/_%1%S_Q41<_\5$7/_%1%S_Q41<_\5.&5  #+I@  N[
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M+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8  (;3  !YX0
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M9E6D\F98G_)F6IOS95R7\V1<E_-D7)?S9%R7\V1<E_-D7)?S9/]P#0#_A 0
MW98  ,ZC P#$K@0 N[<$ +3"!0"NS0P I\X@ I[-,0J5RSX6B\A)(X+&4BYZ
MPUHX<L%B0&O :D=DOG--7KU\4UF\B%=4NY5;4+NE74Z[N5Y-O-M=2[GW7TZQ
M]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W" #KC   TYL
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M1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P  *>V  ";P0
MD,P" (;9!@" \A( >?(? G'R*P9J\C8,8_,_$EWS1QA7\T\=4O-7(4WT8"1)
M]&DH1O1S*D+U?BT_]8LO//:9,3KVJ3,X][XT-OCA-3;U^34U\_\T-^S_-CGE
M_S@YY?\X.>7_.#GE_S@YY?\X.>7_.,B>  "VJ0  J+(  )N]  "/R   @]0
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M%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4  %'_ 0!*_PL
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M866)]U]GAOA>:83Y7&J"^EIK@?M::X'[6FN!^UIK@?M::X'[6O]B$ #_<@<
M^((# -N/ @#/F@4 R:,& ,.L!@"]LA  M;(D JRP-0NCK4(7FZI,(Y*F52Z*
MHUTX@Z!E0'V=;$=VFW1-<)E]4VN6B%AFE91<8I2A7U^3LF!=D\E@79/M7UZ0
M^%YAC/E<8XKZ6V2'^UIEAOM998;[666&^UEEAOM998;[6?]F#0#_=P, XX<
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M4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<  +ZB  "SJ@
MJ;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C9\5<*F'$9#!<
MPVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%N?]*1[/_2TFM
M_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G  "JKP  H+@
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M+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T  ''8  !GY@8
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M!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\" "K_"@ F_P\
M(O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"!_]) @/_4P(
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MXGT024-#7U!23T9)3$4 "A*18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A,
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M2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0
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M24Z@]4E.G_])4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P
MRHT  +Z8  "SH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=Q
MM5(>:[-:)66R8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK
M]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,
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M*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@
M@[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"
MYEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D
M_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8
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M!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P
M,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!$O\X 1#_0 $.
M_T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0, _^P# /_L P#_
M[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\
M "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<!
M /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$ _[L! /^[ 0#_NP$
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M,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!, _U00 /]<$@#_81<
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M.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8 W7@( -I["P#1?A<
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M1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0
MUGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B
MEE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B(
M[418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX
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M-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@
MFZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.7K=2$UJV6AA6
MMF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U L/XO/Z__,3ZM
M_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH
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M%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@
M3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J
M[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J
M_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T
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M 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P
M$?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00
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M*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$
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M/&UKZ3MM;/XY;6S_-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P
MWFH  ,US  ##>@  NWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*
M?5@;AGM?((%Y9R5]=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=P
MYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X
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M-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP
MJ)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUF
MDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")
M_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0
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M)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP
M:;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*NED*1[IB#42Z;!!!
MNG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R
M_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P
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M!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP
M)>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1
M]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC
M  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L&
M !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP
M O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]
MM0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_
M"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I
M  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP
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M+GU9YBU\6OHL>UK_*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@
MXUP  -)C  #':   P&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4
M:%H4D&9B&(UE:AR*8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>
MXB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\
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M+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P
MKWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_?%$1>WI9%G=Y8!IS
M=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQU#!=<?(N7G'_+%YP
M_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX
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M)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP
M>I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T36)-E%U63;AI1
MDG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&B_\D1HK_)$:*
M_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T
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M%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4
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M !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0
MA*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4
MZ0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?R
MH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(
M &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H
M"_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C
M_*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$
M  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)
M  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT
M /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _
MU@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_
M!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,
M  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#
M_PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_
M *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT
M /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4
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M ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT _R8H /\C- #_($
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M&Y-&YAN11_D;CT?_&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P
MZTL  -U1  #15   RE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB
M45\,GU!G#YU/;Q&:3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+
MXAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5
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M(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@
MLV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,A&5;$(%D8A-^
M8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I7NXD:5[_(FI>
M_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP
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M'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P
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M$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748*
M&DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<
M27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!H
MCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*
MBAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_
M&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0
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M""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP
MG)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 S
MMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2Y
MM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<
M (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0
M(L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7
MR,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE
M  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1
M !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X
M"=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !D
MM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?
M$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(
M  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@
M2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0
MZ1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #V
MT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P
M "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L
M /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@
M_\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=
M   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P   /\&
M  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\
M /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_
M $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\
ML #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_
M +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D
M_P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3
M /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +
M^@"Y /< Q #U -( \P#F /( ] #Q /\ \ #_ .\ _P#O /\ [P#_ /  _P#P
M /\ \ #_ /\>'0#_'AD _QP7 /\7& #_$QX _Q$H /\.- #_#$$ _PI. /\(
M6P#_!V8 _P9Q /\&>@#_!H, _@:+ /P&D@#Z!ID ^ :? /8&I@#T!JT \@:U
M / %P #M!<X ZP7D .D&\P#F"/\ Y0K_ .0+_P#D"_\!Y O_ >0+_P'D"_\!
MY O_ ?\A& #_(1, _R 1 /\;$@#_'!H _QHD /\6+P#_$SP _Q%) /\050#\
M#F$ ^0YK /8.=0#T#GX \@Z& / .C@#N#I4 [0Z; .L.H@#J#JH Z ZS .8/
MO0#E#\P X0_C -T0\P#9$?\!UA+_ =03_P'3$_\"TA/_ M(3_P+2$_\"TA/_
M O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL
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M!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0
M_S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU7P*Z
M-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*"J4U
MY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH
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M%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5
MN50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24458&D5!>"8Y/9@N,
M3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+S1AY3.L8>$S^%W=,
M_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D
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M%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580
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M%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T
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M$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0
MJGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/
MD#, 39 ] 4N010))D$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.
MLPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(
M )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L
M0YDV $&:0 ! FD@!/II1 CR:6@(ZFF0#-YIO!369?08SF8P',9F=""^9L @N
MF<H(+ICM""Z6_PHME/\*+9/_"RV2_PLMDO\++9+_"[9U  "J@0  GH@  ).-
M  "&C@  >(\  &N2  !?E0  5)D  $F=  ! H   .J(- #BC%P WHR( -J0M
M #6D-P TI$$ ,Z5+ #&E5 $PI5X!+J5J 2RE> (JI8@#**6: R>EK00FI<8#
M)J3K!"6B_P4EH/\&))__!B2>_P<DGO\'))[_!Z]^  "CB   EXX  (V3  !^
ME0  <)@  &.;  !7GP  3*(  $*F   XJ0  +ZP# "JN#@ IKA@ **\C ">O
M+0 FL#< );!! "2P2P CL58 (K%C "&Q<0 ?L8( 'K*4 1RRJ0$;LL$!&['G
M 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP
M:*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6
MO"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]
M^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP
M %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT
M!\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0
MS/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y
M   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>
M  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<
M -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   L
MQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E
M&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y
M  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T
M%=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$
M\Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_
M]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(
M  /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P  _PT
M /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0
M_]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\
M90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z
M /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\
M_@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_
M &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P
MP #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &<
M_P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q
M ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8
M&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L
M /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,,
MY #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_
M&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"
M< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70
M -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L
M_QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>
M#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81
MZ0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R
M /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT
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M!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0
MRC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!I#5E J(U;0*@
M-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0->P(CC;^"(PV
M_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$
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M#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$
METL1 )--( "/3RX C$\Z 8A/10*%3TX#@T]6!(!.709^3F0'?$UL"7E-= MW
M3'T,=4R'#G-,D@]Q2Y\1;TNM$FU+OQ)L2]P2:TSU$6I,_P]J3/\.:DO_#6I+
M_PQJ2_\,:DO_#/ ]  #;2   QU   +I5  "P6   I58  )Q3  "73P  D5 .
M (Q2' ")5"L A50W ()40@%_5$L#?%13!'I36@9X4V((=5)I"7-2<0MQ47H-
M;E&$#VQ0D!!J4)P2:%"K$V90O!-E4-@39%#S$F10_Q!D4/\/9%#_#F5/_PUE
M3_\,94__#.Q!  #43   PU0  +99  "L7   H%H  )=7  "15   BU4, (97
M&0"#6"< @%DT 'U9/P%Z64@#=UA0!'186 9R5U\';U=F"6U6;@MK5G<-:%6!
M#V95C1%D5)H28E2I$V!4NA1?5-,47E3R$UY4_Q%?5/\/7U3_#E]3_PU?4_\-
M7U/_#>=$  #/4   OU@  +-=  "H7P  G%T  ));  "+6   A5H* (%;%@!]
M7"0 >ETQ '==/ %T748"<5U.!&]<505L7%T':EQD"6A;; ME6G4-8UI_#V%9
MBQ%>69@27%BG%%M8N!196= 465CP$UE8_Q%:6/\06EC_#EI7_PU:5_\-6E?_
M#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$
M=6(N ')B.0%O8D,";&%+ VIA4P5G85H'96!B"6-@:@M@7W,-7EY]#UM>B1%9
M79825UVE$U5=MA147<X45%WN$U1=_Q%57/\055S_#E5;_PY66_\-5EO_#=Y,
M  #'5@  N%\  *UD  "@90  DV0  (EC  !_80  >6(# '5D$0!R91X ;V8K
M &QG-P%J9T "9V9) V5F401B95@&8&5@"%UD9PI;9' ,66-[#E9CAA!48I02
M4F*C$U!BM!-/8LP33V+M$D]A_Q%/8?\04&#_#E!@_PY08/\-4&#_#=E/  ##
M6@  M&,  *EI  ";:   CV<  (1G  !Y90  <V<  &]I#@!L:AL :6LH &=L
M- !D;#T!8FQ& E]K3@1=:U8%6FI=!UAJ90E6:6X+4VEX#5%HA ].:)(03&>A
M$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@
ML6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !>
M<3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5N
ML!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P
M *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8
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M!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@
M=G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P W
MDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0
M^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4
M &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@
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M  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K
M-;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P
MPC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##
M_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H
M !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H
M -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P
MUO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'
M   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G
M  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\
M .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "
MV    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T
M)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT
M '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0
M .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0
M_R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+
M( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V
M /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L
M_P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_
M"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\
M>@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9
M /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4
M_P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z
M 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D
MY@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/
M /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@
M[0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8
M /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+
M# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z
M -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T
MQP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_
M#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$
M>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O]
M +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8
M^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_
M#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5
M_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4%
M -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@
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M X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L
MIR\7 *(Q)@">,S0 FC1  )@U2@"5-5, DS5; 9$U8@&/-6D"C35Q HPU>0.*
M-8(#B#6+!(8UE@2$-:(%@C6O!8$UP 9_-MP&?3;T!GLV_P5[-O\%>C;_!'HV
M_P1Z-?\$>C7_!/4M  #D-P  T#\  ,)#  "W1   K4   *<Z  "C-@8 G3<3
M )DY(@"5.B\ DCP[ (\\1@",/$\!BCQ7 8@\7@*&/&4"A#QM X(\=02 /'T$
M?SR'!7T\D@9[.YX'>3NL!W<[O AV/-4(=#SQ"',\_P=R//\&<CS_!7(\_P5R
M._\%<CO_!?$R  #>/0  R40  +Q(  "P20  ID8  )]!  ";/0$ E3T0 )$_
M'0"-02L BD(X (=#0@"$0TL!@D-3 8!#6P)^0F(#?$)I!'I"<05X0GH&=D&$
M!W1!CPAR09L(<$&I"6]!N0IM0= *;$'N"6M"_PAJ0O\':D'_!FI!_P9J0?\%
M:D'_!>TW  #60@  Q$D  +=-  "K30  H$H  )A'  "30@  CD,- (E%&@"&
M1B@ @T<T (!(/P!^2$@!>TA0 GE(5P)W2%\#=4AF!'-';@5Q1W8&;T> !VU&
MC EK1I@*:4:F"V=&M@MF1LP+94;L"V1'_PED1O\(9$;_!V1&_P9D1?\&9$7_
M!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0
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M#%53L U44\4-4U/F#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4
MM5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G
M6ST!95M% 6-;30)A6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8
MK@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP
M *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH
M8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*
M7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A
M  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#< 6F1
M 5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)1V*:"D9BJ@M$8K\+
M1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",
M8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J
M10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>
M"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P
M>V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*
M<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN
M]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL
M &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0
M07A- 3]X50$]>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q
M=/\%,7/_!3%R_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q
M  !<<P  47<  $IZ  !"?0, /WX. /_B?1!)0T-?4%)/1DE,10 +$CU_&  \
M?R, .X M #J -@ Y@3\ .(%( #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!
MH0,J@;8#*8'2 RE_\P,I??\#*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78
M (5U  !X=0  ;74  &%W  !7>@  3'X  $.!   [A0  -8@) #*)$0 QB1L
M,(DE "^*+P NBC@ +8M! "R+2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$B
MB[,!(8S. 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z
M  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  DE!, (Y0<
M "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7F0 7EZX
M%9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L
M@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A
M&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+
M  NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP
M6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &
MK1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "N
MU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H
M $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X#@  N10
M +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q
MO.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM
M   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84
M  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH
M ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   D
MO   &;\  !'"   *Q0   LD   #,    T    -$   #2 0  TP@  -4-  #7
M$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F
M  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP
M#\H   ?.    T0   -8   #<    WP   .    #B    Y    .8#  #H"0
MZ0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #Y
MY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@
M  #=    X0   .0   #H    ZP   .T   #O    \0   /,   #V    ^ ,
M /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP
M_]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\
M7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O
M /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\
M\ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_
M &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /<
MM #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_
M /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\
M^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H
M +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-
M$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B
M .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0
MU0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_
M# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X
M90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[
M ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@
M_PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#)
M &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0
MQP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\
M /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$
MN05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F
M"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09
M  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C
M *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X
MEQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*
M)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;
M90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J( DAZO ) >OP"/']@ C"#Q
M 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@  VBT  ,HP  "^+@
MM2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7)%$ E219 ),E8 "2
M)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K 80GNP&#*-$!@"CN 7XI
M_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4  ,$X  "T-@  JS$
M *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-+4P BRU4 (DN7 "'+F,
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M V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10  E4,  (Y   ")/
MA#P* ( ]% !]/B( >C\N 'A . !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J
M07 #:$%Y V=!A 1E09$%8T&?!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU
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M \Y$  "\3@  KE0  )Q3  ".4@  @U$  'I0  !R30  ;$\  &A0"P!E414
M8U(A &%3+ !?4S8 750_ %M41P!:5$X!6%16 59470)45&8#4E-O U!3>P1.
M4X@%3%.7!DM3IP=)4[H'2%/5!TA2\P9(4O\%2%'_!$E1_P1)4/\#25#_ \I(
M  "Y4@  JE<  )A6  "*50  ?U0  '93  !L40  9U,  &)4" !?5A( 75<>
M %M7*0!96#, 6%@\ %991 !564P!4UE3 5%96P)/6&0"35AM TM8> 1)6(8%
M1U>5!D57I09$5[@&0UC2!D-7\@9#5O\%0U7_!$15_P1$5/\#1%3_ \9,  "U
M5@  I5H  )19  "&6   >U@  '%7  !F5@  85@  %U9! !96A  5UL; %5<
M)@!373  4ETY %%>00!/7DD 35Y1 4Q>6 %*7F$"2%UK T9==@-$78,$0EV2
M!4!=HP8_7;8&/EW0!CU<\04^6_\$/EK_!#Y:_P,^6?\#/UG_ \%0  "Q6@
MH5T  )!<  ""6P  =EL  &U;  !A6P  6UT  %9>  !28 T 4&$7 $YB(@!-
M8BP 3&,U $IC/@!)8T8 1V-. $9C5@%$8UX!0F-H D!C<P,^8X$#/&.0!#IB
MH00Y8K0%.&/-!3AB[P0X8?\$.&#_ SA?_P,Y7O\#.5[_ [Q5  "M7P  G&
M (M?  !]7P  <E\  &A?  !=8   56(  $]D  !+9@H 26<2 $=H'0!%:"<
M1&DQ $-I.0!":D( 0&I* #]J4@ ]:EL!/&IE 3IJ< (X:GX"-FF- S1IGP,S
M:;(#,6G+ S%H[0,Q9_\#,6;_ S)E_P,R9/\#,F3_ [=;  "I9   EF0  (9C
M  !X8P  ;6,  &1D  !990  4&@  $EK  !#;00 0&X. #YO&  ];R( /' K
M #IP-  Y<3T .'%% #=Q3@ V<5< -'%A 3)Q;0$Q<7H!+W&* BUQG (K<:\"
M*G'( BIPZP(J;_\"*FW_ BIL_P(K;/\"*VS_ K%A  "D:0  D&@  (!G  !T
M9P  :6<  %]H  !5:P  2VX  $-Q   \=   -W8* #1W$@ S>!P ,G@E #%Y
M+@ P>3< +WD_ "YY2  L>E( *WI< "IZ:  H>G8 )GJ' 25ZF0$C>JP!(GK%
M 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@  BFT  'ML  !O;
M96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G@A0 )H(> "6")P D
M@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$E0 :A*D &(3! !B#
MY@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,
M %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB<
M%XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .
MC?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^
M  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF
M  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?
M IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [
MC0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F
M*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\
M  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6   RF@
M*)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#   LA$  +(7  "S'P
MLR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T
M_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P
M !:P   /M   ";<   &Y    O0   +X   "^!@  OPP  , 0  #!%@  PAT
M ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@
MQ_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]
M   &P    ,,   #'    R0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;
M  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\
M -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4P@  #,8   /)
MS    -    #5    V0   -H   #<    W@   .    #B!0  Y L  .<0  #J
M&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T
M &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@   -(   #7    W
M .    #E    YP   .D   #K    [0   .\   #Q    \P   /8'  #Y#@
M_!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\
M& #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M
M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\
M_0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_
M !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\
M< #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#'
M .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X
M_P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S
M '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .
MTP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P &
M /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P
MX@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#)
M .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\
M! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M
M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L
MMP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V
M  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P
M;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K
M *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!
MV@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L
M &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&
M^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T
M ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH
MGPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",
M$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1
M  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L
M )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\
M?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D
M%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>
M;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_
M '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$
ME1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![
M)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI
M_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0  F#(  )(M  ".*0  BR<,
M (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\
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M =0W  # 00  KT0  )U#  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@
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M TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3
MHDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!6
M3"\ 54TX %--0 !234@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-
MGP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\
M (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P
M3U$U $Y2/0!-4D4 3%)- $I25 !)4ET!1U)F 452<0%#4GX"05*- C]2G0,^
M4J\#/5+& SQ2Z0(\4?X"/%#_ CU/_P(]3_\"/4[_ KY+  "N4P  FE(  (E1
M  !\40  <5   &A0  !>3@  6%$  %12  !14PP 3E04 $Q5'P!+5BD 258R
M $A6.@!'5T( 1E=* $174@!#5UH 05=D 4!7;@$^5WL"/%>+ CI7FP(X5ZT"
M-U?$ C=7YP(W5OT"-U7_ C=4_P(W4_\".%/_ KI/  "I5@  E54  (54  !X
M5   ;50  &14  !85   4E8  $Y7  !*60D 1UH1 $9:&P!$6R4 0ULN $)<
M-@!!7#X /UQ& #Y=3P ]75< .UUA #I=; $X77D!-EV( 31=F0(S7:L",5W"
M C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P
M:5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y
M8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2IC
MXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L
M %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34
M+VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C
M:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@
M  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W
M "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?<
M&G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(
M:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\
M.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_
M !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<
M.70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .
MASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#
M_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT
M "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,
M ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P
MC_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-
M   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U
M  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\
M )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2
MG@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O
M-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_
M (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K
M!*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P
MP#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-
M  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X
M  #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL
M -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@
MG@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/
M    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ
M  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0
M2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
MXP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_
M+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2
M /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@
M_P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X
M /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\
M#P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y
M /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X
MZ0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_
M !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L
M>@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X
M -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T
M_  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5
M 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\
M_P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1
M .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ',
MP !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M
M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -,
M%0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T
M *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\
MG@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"]
M !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$
M=0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_
M )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !(
MK  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3
M W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+
M_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46
M )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0
MA@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W
M$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0
M&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X
M 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\
M;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$
M&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @
M?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_
M . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX
M>",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E
M*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L
M  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE
M &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0
M7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "]
M.@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q
M*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360
M 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0
MHSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>
M-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZ
MG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\
M (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X
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M 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P
M:T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%
M2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,
MW0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H
M %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L
M/E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O
M4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-
M  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_
M #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4
M*57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.
M4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<
M0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_
M "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@
M0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E
M8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@
M_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX
M #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T(
M&FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3
M:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G
M   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&
M  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\
M#'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D
M<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_
M2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_
M (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?
M%H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P
MBU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M
M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P
M  N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<
M )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O
M<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<
M    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,
M  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P
M67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
MK@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z
M4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L
M $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[    O@
M +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1
MT%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA
M   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0   ,X
M  #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D
M .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   F
MN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .    #B
M    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/
M  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8
M_P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_
M (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /,
M_P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P =
M /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (
M\@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B
M /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\
M) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"
M .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\
MRP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M
M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H
M@ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_
M +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ",
MT@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U
M ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4
M_P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H
M +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H
MI "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7
M /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L
M+ "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!]
M )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\
MB #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0";
M #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (<
M@0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_
M /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D
MC0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z
M"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6
M  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM
M ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8<
M;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&
M)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84
M,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0
M &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@
MJ"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K
M'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HB
MG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX
M )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$
M8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1
M*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR
M  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV
M %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@
M22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![
M-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q
M.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y
M $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.
M;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,
M-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TY
MTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH
M &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP
M1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W
M/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]
M  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!!
M $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?
M,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4
M/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%
M1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_
M "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P
M2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S
M2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)
M_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@
M #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@
M*U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B
M3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.
M   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9.
M ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\
M'%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q
M50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=
M50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_
M )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P
M)5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  0
M95T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5
M  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4
M !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E<
M!FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T
M6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q
M   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>
M  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P
M8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (
M?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$
M:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,
M %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@
M (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P
MDG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM
M   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F    )D
M  ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD
M **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W
M?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@   "I
M    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S
M  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@
M(Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
MNP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*
M?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4
M !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+    S
M ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P
MYHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\
M    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X    .(
M  #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H
M /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_
M #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P
MC0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_
M -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$
M_P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L
M (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D
M_P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V
M /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@
MU "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V
M /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$
M.P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP")
M +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\
MIP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$
M #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H
MBP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_
M /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #<
MK0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8
M (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P
M  #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z
M )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D
MB "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@
M"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T
M/ "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0
M 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$
MN1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_
M #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"
MF@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<
M )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@
M<PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B
M#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=
M  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [
M &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z<
M5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!
M(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7
M/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW
M $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P
M<B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7
M'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<B
MS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H
M &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X
M3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _
M*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M
M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M"
M $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L
M.BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8
M+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q
M1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_
M #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P
M4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \
M-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U
M_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0
M $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH
M-3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K
M.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z
M   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0
M "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\
M)CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y
M/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$
M6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_
M )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10
M,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @
M2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"
M  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL
M "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T
M%U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![
M1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3
M P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H
M  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@
M9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   5
M7 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =>
M<P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX
M %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P,
M#&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0
M9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12
M  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)
M  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D
M '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&
M5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X
M"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(
M  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P
M-6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@
MA0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+
MF0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX
M "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2    E 4
M )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0
MFZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!
M   2AP  #(P   21    E0   )D   "=    H    *$   "B    I    *4!
M  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$
M *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,
MF    YT   "B    I@   *H   "N    L    +$   "S    M    +8   "X
M    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O
M  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0
M *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
MS0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #A
MO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\
M  #$    R    ,X   #1    U    -4   #8    V@   -T   #?    X@
M .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP
M^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\
M2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7
M /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\
MP@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#]
M $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0
MF@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_
M /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8
MZ !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#(
M )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\
M  #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!(
M ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8
ML@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_
M    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4
M2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP":
M )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
MY    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@
M $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P
MH0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0
M +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $,
MC@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\
M *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!
M  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !#
M 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4
M;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3
M"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ',
M1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R
M &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0
M@ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G
M T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'
MQ@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8
M '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$(
M7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-
M$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:
M  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)%
M %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@
M11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?
M'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T9
M2 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\
M #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@
M5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%
M($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B
M_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,
M $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H
M/293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R
M)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF
M  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0
M #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\
M+2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!
M*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P
M6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_
M )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,
M.C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J
M-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q
M  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4&
M #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\
M(SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_
M-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P[
M"P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I
M !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.
M:CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D
M0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$
M=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT
M %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P
M&TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .
M2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9
M  !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U .
M !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($
M!5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*
M1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8
M$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1
M  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P
M0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@
M7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?
MH@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP
M #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\
M &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0
M:;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6
M   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0
M  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$
M '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =
M8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!
M$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)
M  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<
M#G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0"P
MD0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3
MZ@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0
M  ")    C@   )(   "6    F    )H   ";    G0   )\   "A P  HP@
M *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0
MI_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":
M    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0   +@%
M  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\
M +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
ML    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H   #-
M @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR
M $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^    P@
M ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
MY@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\
M!@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5
M /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8
M[@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_
M    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0
M5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K
M -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M_P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #;
M %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T
ML@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P
M /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F
M +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\
M  #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/
M *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +(
MD@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z
M    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0
M3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^
M (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
MH    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20""
M $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '(
MSP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0
M (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D
M<P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D
M .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X
M  ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!)
M &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$
M6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O
M!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P
M2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T
M $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@
M8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3
M"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,
M_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$
M %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT
M2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]
M$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3
M  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12
M $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\
M-Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+
M%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:
M6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_
M )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' (
M0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S
M(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB
M  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$)
M #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X
M*R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  "
M)P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F
M#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII
M "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@
M;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N
M+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O
M=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X
M %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1
M)S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8
M-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q
M  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382
M " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80
M$3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+
M-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]
M%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5
M  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P
M03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 1
M0Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#
MI0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH
M #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0
M"TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0
M2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]
M   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7
M  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4
M %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J
M0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9
M&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1
M  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@
M'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0
M8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A
M\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4
M !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8
M ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P
M;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD
M   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6
M  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\
M 'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M=@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0
M%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_
M %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@
M (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B#P
MI!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA
M  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F    )T
M  "A    I    *4   "G    J0   *L   "M    L    +(   "U"   N X
M +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y
M<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +    "S
M    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04  -$.
M  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@
M(X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
MR@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%  #K
M#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $
M /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X
M_P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F
M .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\
M  #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!>
M .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X
M_^)]$$E#0U]04D]&24Q%  P2R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_
M /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L
MW0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\
M )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\
M  #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ]
M +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H
MHP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V
M    YP   -,   #&    O0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8
M/0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ".
M (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,   #C
MS    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1
M #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P
ME !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+    MP
M *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$ A  I (( , !_ #<
M?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L
M )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(   "X    I0   )<
M  "-    A@   ($   !\  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W
M &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8
M70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_
M @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P 8P R &(
M. !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C
M %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P
M; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6
M #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@
ML@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\
M %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4
M30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^
M \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82
M  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX
M $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,<
M-0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-
M%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X/
M/  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L
M "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;  !'&@
M1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V
M%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5
M_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P
M #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T
M+AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B
M&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>
M   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]#
M "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\
M'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \(P  .",  #4B   S
M(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D
M2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_
M (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E   N)
M*R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;
M*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E
M  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD
M "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E
M%"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J
M*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK   F+   (BX  !\O
M   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;
M  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0
M6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(  !LS   7
M-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX
M90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$
M $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P  &S8  !<X   3.@(
M$#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80
M/G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T
M   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(
M  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T
M $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [
M-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"   -10$ "$<'  -)
M#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]
M  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@
M,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (3    D\%  !0"@
M4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4
MCP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX
M "=    @0P  &48  !-)   /3   "T\   92    5    %<"  !8!P  60L
M %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0
M7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(
M   :2P  $TX   Y2   *50   UD   !;    7@   &    !B @  8P8  &4*
M  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T
M &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L2@  (TT  !M1   3
M50  #ED   A=   !80   &0   !G    :@   &P   !N    <    '(%  !S
M"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S
M  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<   -80
M!F8   !J    ;P   '(   !V    >0   'P   !]    ?P   ($   "# @
MA@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(
MSP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %<    '8
M  ![    ?P   (,   "'    B@   (T   ".    D0   ),   "5    F
M )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@  "=P0
MF^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[    @0   (<   "-
M    D@   )8   ":    G0   )\   "A    I    *8   "H    JP   *X
M  "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(
M +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".    E    )H   "@
MI0   *H   "N    L0   +(   "U    MP   +H   "\    OP   ,,   #&
M    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO
M #=Q   I>   '8   !&)   (D0   )H   "A    IP   *T   "S    N0
M +X   #"    Q0   ,8   #)    S    ,X   #2    U0   -H   #>
MX0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\
M  #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+
M /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T
MZ0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_
M    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\
M30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B
M ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_
M_0   /H   #X    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#-
M $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T M ": +$
MJ0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@
M .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4
ML0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8
M +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D
M  "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$
M )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@
M@P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0   +$   "F
M    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4
M0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S
M '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X   "3
MC    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R
M $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$
MP@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#    ?
M '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T
M8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4
M -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\   !U    ;@   &D
M  !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ]
M %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X
M20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;
M    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P
M/@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J
M #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0
M4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!"
M $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8
M^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q   $X0  !*#@  2 T
M $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X
M.@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M
M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .
M  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM#
M #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\
M)PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _%0  /!0  #H2   Y
M$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P0
M2P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_
M (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46   T%
M,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D
M%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7
M  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L  #$:   O&0  +A8
M "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$
M'1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K
M'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=   K'   *1L  "<;
M!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY;
M !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P
M62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @
M( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C
M9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,
M $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P  (",  !TD   ;)0<
M&28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,
M*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G
M   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+
M !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7
M!"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \
M*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ
M#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_
M   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+
M,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0,@( #C0'  HW#  '
M-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X6   .&@  #A\   W
MD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X
M "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X
M #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP
M/:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO
M   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0
M  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0
M $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R-   +3,  "8T   @
M-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(!P  2@L  $L.  !,
M$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\
M  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/
M%3\  !!"   ,10  !T@   )*    30   $\   !1!   4@<  %0+  !5#@
M5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8?P  5YH  %:W  !5
MXP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X  !Q!   51   $$@
M  M+   %3@   %$   !4    5P   %D   !;    70(  %X&  !@"P  8@X
M &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0
M8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*   03@  "E(   -6
M    6@   %T   !@    8P   &4   !G    :0   &L!  !M!0  ;PH  '(.
M  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<
M &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )6@   5\   !C
M:    &L   !O    <@   '4   !W    >0   'L   !]    @ ,  (,(  "&
M#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__
M $9+   Z3   +D\  "-3   86   $%X   ED    :0   &\   !T    >
M 'P   "!    A    (<   "(    BP   (X   "0    DP   )8   "9!P
MG0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2
M   R50  )EH  !M@   19P  "6T   !T    >P   ($   "&    BP   )
M  "4    EP   )D   "<    GP   *$   "D    IP   *H   "M    L08
M +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K
M80  'F@  !-P   +>    (    "'    C@   )4   ":    GP   *0   "H
M    K    *T   "P    LP   +4   "X    NP   +\   ##    QP   ,L%
M  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<
M%GD   V!   !BP   ),   ";    H@   *@   "N    M    +@   "]
MP    ,(   #%    R    ,L   #.    T0   -8   #;    WP   .0   #H
M!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_    _P
M /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4
M_ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#?
M -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_    _@   /P
M  #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4
M .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4
MO0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R
M    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,(
M4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#<
M *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\   #/
MR    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F
M %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X
M\ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0   +\   "S    J@
M *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H
MC@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y
M /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<   "=    E    (X
M 0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![ $, >0!(
M '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8
M9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")    @@   'L   !X
M  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@
M2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_
M %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y    <0   &T   !I  $
M9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8
M $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T
M_P!- /\ 30#_ *H   "4    @@   '4   !K    9    &    !=    6@ %
M %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $,
M3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!#
M /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!  !2    4  " $X
M"0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!%
M $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\
M.0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$
M  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@
M20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_
M (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @
M/ $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O
M %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,
M  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@*
M #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX
M)P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M
M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0   P#P$ , T& # +
M"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8
M " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P
M6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I
M#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D0
M9@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<
M $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0  )A0! "42!  C$@L
M(A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16 !049  2
M%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;
M   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18-
M !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7(
M#1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \
M'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<
M$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z
M  <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P
M,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0
M(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $B
MD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$
M "HA   F(   (B   !\?   <'P  &2   !8A   2(P( $"0'  XF#  ,)A
M"R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP
M)J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C
M   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3
M  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0
M "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C
M)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q
M%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\
M   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G   A)@
M'"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/   W$@
M.!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   V
MY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H  "0I   >*@  &2L
M !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH  #T-   ^$   0!0
M $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP
M//P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M   :+P  %3$  !$S
M   --@  "3@   4[    /0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6
M  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P
M $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6-0  $3@   T[   (
M/@   T$   !#    1@   $@   !*    3 0  $X'  !/"P  40X  %02  !5
M&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_
M $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0  #$$   =$    2
M $H   !-    4    %,   !5    5P   %@"  !;!@  70L  %\.  !B$P
M8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\
M   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL   !/    4P   %8
M  !9    7    %\   !A    8P   &4   !G 0  :@4  &T*  !P#@  <Q4
M '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y
M/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=    80   &4   !H
M    :P   &X   !Q    <P   '4   !X    >P   'X#  "!"@  A0\  (<7
M  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$   S10
M*$@  !U,   34@  #%<   -=    8P   &@   !M    <0   '8   !Z
M?@   ($   "#    A@   (D   "+    C@   )(   "5 0  F0D  )X0  ">
M&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,
M !59   -8    V<   !N    =    'H   "     A    (H   ".    D@
M )4   "7    F@   )T   "@    HP   *<   "K    KP   +0)  "X$
MMQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5   D6P  &&$   YI
M   %<0   'D   "!    B    (\   "4    F@   )\   "D    J    *D
M  "L    KP   +,   "U    N0   +T   #!    Q@   ,L   #1"@  TQ0
M -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$   =[
MA    (T   "5    G0   *,   "I    KP   +0   "Y    O    +X   #"
M    Q0   ,@   #,    T    -0   #:    WP   .0   #J    [@P  .T:
M  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_    _P   /P  0#\  @
M_@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V
M &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H
M_P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@   /,   #S    ]@ )
M /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L
MU@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G
M /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<   #G    Y  ! .
M"P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9
M +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\
MBP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&    OP   +D !@"W
M  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L
M5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_
M '8 _P!S /\ <@#_ .    #0    Q@   +8   "I    H0   )T  0"9  H
MF  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "#
M %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D
M_P!G /\ 90#_ ,P   "^    JP   )T   "3    B@   (4   ""  4 @  -
M '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X <@!# '  20!O $\
M;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!;
M /\ 6@#_ +T   "I    EP   (D   !^    >    ',   !O  $ ;0 ) &P
M#@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/
M %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\
M3P#_ *T   "8    A@   '@   !N    9P   &,   !@    70 % %P "P!;
M !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X
M40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_
M )\   ")    >    &P   !B    6P   %8   !3    40 " $\ " !/  T
M3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !"
M %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),
M  !^    ;@   &$   !8    40   $P   !)    1P   $4 !0!$  L 0P .
M $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %
M-P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V
M P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P  P [  @ .@ - #H
M$  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7
M "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"
M7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q
M !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D /P H $D )P!4 "8
M8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T
M $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0, +08( "P$#  K @\
M*@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 >
M 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0
M  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0
M "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L
M%@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]
M$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-!P A# L ( L. !\+
M$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^
M  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%
M,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9
M#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0
MD  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8
M "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A(
M$A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $
M%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8
M   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5
M  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$
M !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R&@  *QH  "4:   A
M&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;
M&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR   <B   '*   !NY
M   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P
M'!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #
M(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   AA@  ()X  ""X   ?
MW@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP
M !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D
M "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W   DWP
M(_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?   ='@  &AT  !8>
M   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=
M   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH  "JU   IWP  *?L
M "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <(   %R   !,A   0
M(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S
M(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_
M $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F   .*
M"RH   <L   #+P   #$"   S!   -0<  #<*   Y#0  .A   #L5   ['0
M.R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I
M   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H   XL   *+P  !C$
M  $T    -@   #@    [ 0  /00  #\'  !!"@  0PX  $41  !%&   12$
M $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X
M+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT   $-P   #H    \
M    /P   $$   !$    1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G
M  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR   U,0
M+B\  "DN   @+@  &3$  !(S   .-P  "3H   (]    0    $0   !'
M20   $P   !/    40   %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>
M+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(
M "0S   ;-@  $SD   X]   (00   $4   !)    3    %    !3    5@
M %D   !;    70   &    !B    90   &@%  !K"P  ;Q   &\8  !N)0
M;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[
M   5/P  #D0   =)    30   %(   !6    6@   %X   !B    90   &@
M  !K    ;0   '    !S    =@   'D   !]!   @0L  (41  "$'0  @BP
M ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /
M2P  !U$   !7    7    &(   !F    :P   &\   !T    >    'L   !^
M    @    (,   "&    B@   (T   "1    E@,  )L,  "=$P  FR$  )HS
M  "720  E&(  )-_  "0H   CL4  (SS #%$   E2   &DT  !!3   (6@
M &$   !H    ;@   '0   !Y    ?P   (0   ")    C0   )$   "3
ME@   )D   "=    H    *0   "H    K    +(#  "W#0  MQ<  +4H  "R
M/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL   IB    :@   ',
M  ![    @@   (D   ".    E    )H   "?    I    *8   "I    K0
M +    "S    MP   +L   #     Q0   ,L   #1!   U0X  -,=  #0,@
MS4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T    ?0   (<   "0
M    EP   )X   "D    JP   +$   "V    N@   +P   #     Q    ,@
M  #+    SP   -0   #:    X    .8   #K    \08  / 3  #N)P  [#\
M .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T  4 ]@ , /H $0#_
M !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$
M:@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_
M )8 _P"0 /\ C #_ /H   #R    [    .D   #I    [  % /( # #X !(
M]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#*
M &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@
M_P"# /\ @ #_ /    #E    W@   -H   #;    W    -@ !P#1  X T0 5
M -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$
MK !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V
M /\ = #_ .(   #3    R@   ,<   "\    M@   +   0"O  L K  1 *T
M& "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A
M (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\
M: #_ ,\   #!    N0   *T   "@    F    )0   "1  8 D  - )  $@"/
M !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@
M8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_
M +X   "Q    H    )(   ")    @@   'P   !Z  $ >  ) '< #@!X !0
M=P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C
M &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +
M  "?    C0   '\   !T    ;@   &H   !F    90 $ &, "P!C !  8P 5
M &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P
M4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-
M    ?    &X   !E    7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0
M%@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A
M $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0   !_
M;P   &,   !9    40   $T   !*    2    $< ! !'  H 1@ . $8 $0!'
M !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@
M:0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T    90
M %@   !/    2    $,    _    /0   #P  @ \  < .P , #L #P [ !(
M.@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M
M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\   !L    70$  %$"
M  !( P  0 ,  #L"   W    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3
M #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X
M) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E!   5@8  $L'  !"
M"   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D "P I  X *0 1 "@
M%0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\
M !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P
M-0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @
M !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4
MCP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T
M "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0
M&008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0
M :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/
M   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6
M !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\
M"@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$  "40   A
M$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,
M&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT
M  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2   >$0
M&Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,
M$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .
MU   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0  "$3   <$P  &1(
M !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH
M"!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T   1UP
M$?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5   :%   %Q0  !03
M 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?
M  (6)P  %S   !<[   72   %U@  !=J   6@   %ID  !6T   5V0  %/<
M !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2
M$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;
M)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_
M %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P  %18! !,5!0 1%00
M#Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9   @(0
M(2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9
M   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!
M  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$  "86   F'@  )R<
M "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \
M'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;   -'   "QT   @?
M   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3   N&@  +B,  "XN
M   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0
M+B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +(0  !R,   ,E
M)P   "D    L 0  +@,  # &   S"@  -0T  #81   V%P  -A\  #8I   V
M-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T)   *R0
M "0C   ?(0  &R   !8@   1(0  #B,   HE   &*    BH    M    +P
M #(    T    -P   #D#   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0
M0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E
M   ?(P  &"0  !(E   .*   "BH   4M    ,    #,    V    .    #L
M   ^    0    $(   !% @  1P8  $H*  !-#@  314  $P?  !,*P  2SH
M $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;
M*   %"H   XM   *,   !#,    W    .@   #T   !     0P   $8   !(
M    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&
M  !76@  570  %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM   6+P
M$#(   HV   #.@   #\   !"    1@   $D   !,    3P   %(   !5
M6    %H   !=    8    &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G
M4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT
M  )"    1P   $P   !0    5    %@   !;    7P   &(   !E    :
M &L   !N    <0   '4   !Y    ?08  ((-  ""%@  @"0  'XU  !\20
M>V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)    +10   DL   !1
M    5@   %L   !@    90   &D   !N    <@   '8   !Y    ?    'X
M  ""    A0   (D   ".    DP   )@&  "<#@  FQH  )@K  "60   DED
M )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "5    %L   !A
M:    &X   !S    >0   'X   "#    B    (P   "/    D@   )4   "9
M    G0   *$   "E    J@   +    "W!P  N!$  +4A  "R-0  KTT  *II
M  "HB   IJ@  *+1 "-(   83@  #E0   1<    9    &T   !U    ?
M (,   ")    CP   )4   ";    H    *,   "F    J0   *T   "Q
MM0   +D   "^    Q    ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%
M?   PIT  ,&] !Q5   17   !V4   !N    =P   '\   "(    D    )@
M  "?    I0   *T   "S    N    +H   "^    P@   ,8   #*    S@
M -,   #:    X    .<   #M    \P   /0.  #R'@  [S8  .Q1  #H;@
MY)   -^Q                       ! P0%!@@)"@L-#@\1$A,4%A<8&AL<
M'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!24U15
M5UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/
MD)&3E)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(
MR<O,S<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^____
M__________________________________________________\
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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M      ,$(0   0                    $                    !
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M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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M6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEO4SPH
MQ.T2 K7[)@VH_S89F?\[(XS_02R _THT>/]3.G'_7S]L_VE#:/]O167_=$=C
M_W=(8O][26'_?DI?_X%*7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_
MA$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$O_GR(%_YTM
M#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2Q
MPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>
M.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(
MN;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_
MJ$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(
MC+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>
M_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z
M@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)
M*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%
MMW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V
M4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7
MR[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_
MN%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]
MH,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/
M^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F
M8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT
M;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?B
MK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)
MV*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[
MF<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_
MGR(%_YTM#/^?.!7_JD >_[-)*_^Y4CS_NUQ/^KIE9.VX;7CAL'.+U:AYG,R?
M?:K%EX&UOY&%OKJ,B<6VAX_,LH.6TJ^!H-:G?J+3IWZBTZ=^HM.G?J+3IWZB
MTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^HM/_GR(%
M_YXM#/^@-Q3_JT >_[1)*_^[4CS_O5M0^KYD9.R\;'G@M7*-TZUWGLJD>JW"
MG'ZYO):"P[>0A\JRBXS2KH>5V*:#G=JA@J'5H8*AU:&"H=6A@J'5H8*AU:&"
MH=6A@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=7_H"(%_YXM
M#/^A-Q3_K$ =_[9(*_^]43S_P%I0^L%C9>S!:GK>N7"/TK%UH<BH>+# H7N\
MN9M_Q[26A,^PE(W5JY&7VJ")G-R:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(H->:
MB*#7FHB@UYJ(H->:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(H-?_H"(%_YXM#/^B
M-Q3_K4 =_[=(*O^_43S_PEI0^<1B9>O%:7O>OFZ0T;9SH\:N=K.^IWG N*-_
MR;2AAL^LG(W5HY:4VIJ1G-R5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8
ME8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]C_H"(%_Y\M#/^C-Q3_
MKD =_[A(*O_!4#S^Q5E0]\A@9NO*9WS=PVV1S[QQI<6T=+6]L'G MJQ_R*ZG
MA<^EH8K5G)R1VI69G-R/E)_8CY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?
MV(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?V(^4G]C_H2(%_Y\M#/^D-Q3_L#\<
M_[I(*O_#4#O[R%A0]<M?9NG/9GS<R6N2SL-OIL&Z<K6VLG; K*Q[R*2H?\Z<
MI(74E*"-V(V?F=N*G)_8BIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8BIR?V(J<
MG]B*G)_8BIR?V(J<G]B*G)_8BIR?V(J<G]C_H2(%_Z M#/^F-A/_L3\<_[M(
M*?[&3SOXRU=0\M!>9N?49'W:SVF3R,5MIKJ[<+2MLW._HZUVQYJH>LV2I7_2
MBJ*&UX2@D=F$HIS7A**<UX2BG->$HIS7A**<UX2BG->$HIS7A**<UX2BG->$
MHIS7A**<UX2BG->$HIS7A**<UX2BG-?_H2(%_Z M#/^G-A/_LS\<_[U'*?S(
M3COUSE9/[M5=9N3:8GW3TFB2P<9LI+.\;[&FM7*\G*]TQ).K=\J+IWO/@Z2!
MU'VBB]9[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75
M>Z.5U7NCE=5[HY75>Z.5U7NCE=7_HB$%_Z M#/^H-A+_M#\;_[]'*/G+3CKR
MTU5/ZMQ;9N#@87W,TV>1N\AKHJR^;J^@MW"XE;)SP(VN=L6%JGK*?JA_SGBF
MA]%UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2=:6/
MTG6EC])UI8_2=:6/TG6EC]+_HB$%_Z$L"_^J-A+_MCX;_<)'*/7-3CGNV51.
MYN-99=CB8'O%U6:/M,IJGZ7!;:N9NF^TD+5RNXBQ=<"!KGC%>JQ]R72JA,MQ
MJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&I
MB\QQJ8O,<:F+S'&IB\S_HR$%_Z(L"_^L-1'_N3X:^<5')_#133CIX%),XNE7
M9,[D7WJ]UV:,K<QJFY_$;*>3OF^OBKEQM8.V=+I\LW>^=K%\PG&O@L1NKH?&
M;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9N
MKH?&;JZ'QFZNA\;_I"$%_Z,L"_^O-1#_O#X8],E&)>K833;BYT],W.]58\;F
M7WBTVF6)I=!IEIC(;*&-PV^HA;]QKGZ[=+)XN7>V<[=[N6ZU@+QKM(6^:[2%
MOFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^
M:[2%OFNTA;[_I2$$_Z0L"_^S-0_[P3X7[<]&(N'?2S38ZT],S_-48KSH7G2K
MWF2$G=1ID)'.;9F'R6^@@,5RI7K"=*ETP'BL<+Y[KVN\@+)HNX2S:+N$LVB[
MA+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$
MLVB[A+/_IB$$_Z@K"O^X- WSQST4Y-A%'M;F237+\4Y,Q/=37['L77"AXF1]
ME=MIAXK5;H^"T'&5>\UTFG;+=YUQR7F@;<=]HFG%@:5FQ(6F9L2%IF;$A:9F
MQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$
MA:;_J" $_ZXJ"/R_,POISSP0U^%"'LKM236_^$U*M_M26Z;Q76F8Z65TC.)J
M?8/=;X1\VG.)=]=WC'/5>H]OTWV1;-& E&C0A)9ESX>79<^'EV7/AY=ESX>7
M9<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY?_
MJB #_[4I!O#(,0?:W3,,R^I"(;[V2#6R_TQ&J?]159OW76".\&5JA>ML<7WG
M<79WY'9Z<^)Y?6_A?']LWX"!:=Z#@V?=AX5EW(F&9=R)AF7<B89EW(F&9=R)
MAF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B8;_K1\#
M^;\E ]_6(@++Z#(/OO1!(K#_13.D_TI!G/]138_^75:%^69>??1N9';R<VAR
M[WAK;NY\;6SM?V]J[()P9^J%<F7JB7-CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/I
MC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'3_MAP"Z,T4
M <SF'02^\S$2L?\^(J/_0B^6_T@ZC?]01(3_7$M[_V=1=/YN5F_\<UEL^WA;
M:?E\76?X?UYF^(-?9/>&8&+VB6%A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A
M]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&+SQ \ SMH+ +WS
M'0>Q_S(4H_\Z'Y7_/RJ)_T8S@/]/.GC_6T!Q_V9%;/]M2&C_<TIF_W=,9/][
M36+_?TYA_X)/8/^%4%[_B5%>_XM17O^+45[_BU%>_XM17O^+45[_BU%>_XM1
M7O^+45[_BU%>_XM17O^+45[_BU%>_XM17O^+45[_BU',RPD ON8, :__'@FD
M_S 3E?\U'(?_/"1\_T0K<_]-,6S_6#7_XGT024-#7U!23T9)3$4 #1)G_V,Y
M8_]K.V'_<3U?_W4^7?]Y/US_?$!;_W]!6O^"05G_AD)8_XA"6/^(0EC_B$)8
M_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_
MB$+_F1\%_Y8K"_^5-A+_H#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_
MA]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__
MF1\%_Y8K"_^5-A+_H#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2
MA934BXR>SX61ILN E:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%
M_Y8K"_^5-A+_H#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934
MBXR>SX61ILN E:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K
M"_^5-A+_H#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>
MSX61ILN E:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5
M-A+_H#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61
MILN E:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_
MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MNF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"&=_?1RC3Z4Q
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M2%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$C$QP<
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MM*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;#
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MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>+PW_JC@3_[5
M'/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!YLIZK?KJ5IX3
MCJ.+Q(BADL>#GYK)@*"GRGV:K,9]F*_!?9BOP7V8K\%]F*_!?9BOP7V8K\%]
MF*_!?9BOP7V8K\%]F*_!?9BOP7V8K\'_F!L#_Y8G"/^@+PW_K#<2_[= &_W!
M2"CVRTXY[]-43.;96F+8U&%WQ\MGBKG#;)JMO'*GH;9WL9BQ?;B/K8*^B*J)
MPX*HD,9]IYG(>J>ER7>BK,5XG[#!>)^PP7B?L,%XG[#!>)^PP7B?L,%XG[#!
M>)^PP7B?L,%XG[#!>)^PP7B?L,'_F!L#_Y<F"/^B+PS_KC<2_[D_&OG$1R?Q
MSDTXZMM32^#?66#0VE]VP=!EB;/):YFFPG"EF[UUKY&X>[:(M8"\@;*&P'NP
MC<-VKI;%<ZZAQG*MK<1RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFP
MP'*IL,!RJ;# <JFPP'*IL,#_F1L#_Y@F"/^D+@O_L381_KT_&?3(1R7KU$TV
MY>-02=GC5U_)WUYTNM=DAJS/:9:=QVVCD<!QK(:[=;-^MWJY=[1_O7*RA;]M
ML8W!:K"7PFFQI<%LM+*];+2RO6RTLKULM+*];+2RO6RTLKULM+*];+2RO6RT
MLKULM+*];+2RO6RTLKW_FAL#_YDF"/^G+0K_M38/^<$_%^[.1B/DW$PRW>=/
M2<_H5E[ Y%URLMYD@J/4:9&5RVV<B<5PI7_ <ZQWO'>Q<+E\M6NW@;AGMH>Z
M8[60NV&UF[QCMZ:Y8[>FN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y8[>FN6.WIKEC
MMZ:Y8[>FN6.WIKG_FQL#_YLE!_^K+0G_N34-\L<^%>751A_:XTDSS^M.2<;M
M5%VWZEQNJ.)C?9K9:8J.TFV4A,QQFWO(=:%SQ'BF;L)\J6G @:QEOH>N8KV.
ML%^]E[%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ
M7KR>L5Z\GK'_G!H#_Z D!O^P+ CYP#0+Z<\]$-K?0AW.Z4DSQ/%.2+OR4EJM
M\%MIGN=C=I+@:8&'VF^)?M1SD'?1=Y5QSGN9;,Q_G&C*@YYDR8B@8<>.HE[&
ME:1<QIND7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;
MI%S&FZ3_GAH#_Z4C!?^W*@7PR#('W-LU#,[G0A_"\4@TN/E,1J_W456B]5MB
ME>UD;8KG:W: XG!]>=YU@G/;>H=NV7Z*:]>"C&?5AHYDU(N08=.0DE[1EI1<
MT9N57-&;E5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1
MFY7_H1D"_ZTA _B_)@/BU"4#SN4S#\+P0B&V^D<SJ_Y+0J+^4$^7^UM:B_5E
M8X+P;&IZ[')P=.EX=&_G?'=LY8%Z:..$?&;BB'UCX8Q_8."1@5[?EH)<WIJ#
M7-Z:@US>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH/_
MHQD"_[8= >G,%P'/XQX#PO S$K7Z0"*I_T0PG?])/97_4$B+_UM0@OUE5WKY
M;5UT]G-A;_1Y9&OR?F=H\8)I9O"&:F3OBFQB[HYM8.V2;EWLEW!<ZYMQ7.N;
M<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW'_K!4!
M\\,0 -':"P#![Q\&M/LS$ZC_/"";_T(LD/](-H?_3S]__UI&>/]E2W'_;4]L
M_W-2:?]Y56;^?E=D_8)88OR&66'[BEI?^HY;7OJ27%SYEUU;^)M>6_B;7EOX
MFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFU[ZN0X S<L)
M ,#F#0&R_" (I_\S$YK_.1V-_S\F@O]&+GK_3C5S_U@Z;?]C/VG_;$)E_W)$
M8O]W1F#_?$=?_X%(7?^%25S_B$I;_XQ+6O^03%C_E4U7_YE-5_^935?_F4U7
M_YE-5_^935?_F4U7_YE-5_^935?_F4U7_YE-5_^935?_F4W-P08 OM ' +'V
M#@*E_R$)F?\N$HS_-!F _SL@=O]#)VW_3"QF_U0P8O]@,U[_:35<_V\W6O]T
M.%G_>3E8_WTZ5_^ .U;_A#M5_X<\5/^+/5/_D#U2_Y,^4O^3/E+_DSY2_Y,^
M4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSZ]Q04 L-<% */_$ .9
M_R()B_\I#W[_,!5S_S@::?] 'V+_22-;_U$F5_]:*%7_8BI2_VDK4?]O+%#_
M<RU/_W<N3O]Z+D[_?2]-_X O3/^$,$O_B#!+_XLP2_^+,$O_BS!+_XLP2_^+
M,$O_BS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS#_BQP$_X@H"/^$- [_CSH4
M_Y="'/^>2R?_GE<T_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A
M=*.*WW&HCMUOKI';;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QE
MRYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="
M'/^>2R?_GE<T_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*
MWW&HCMUOKI';;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,
M9<N;S&7+F\QERYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="'/^>
M2R?_GE<T_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*WW&H
MCMUOKI';;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;
MS&7+F\QERYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="'/^>2R?_
MGE<T_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*WW&HCMUO
MKI';;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+
MF\QERYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="'/^>2R?_GE<T
M_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*WW&HCMUOKI';
M;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QE
MRYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="'/^>2R?_GE<T_YUB
M0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*WW&HCMUOKI';;;.4
MVFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,
M9<N;S&7+F\QERYO_BQP$_XDH"/^%,P[_D#D4_YA"'/^>2R?_GU8T_YYA0O^:
M;5#_E7==]X^!:/&)BW+K@Y)[YWV8@N-XG8C@=*.,W7*HD-MOK9/:;K.6V&RZ
MF-9KPIO1:<J<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<
MRF;*G,IFRIS_C!P#_XDG"/^(,@[_DS@4_YM!'/^B2B?_I%0T_Z)?0_^?:E']
MFG1?]91^;.V.B'CGAX^!XH"5BMU[FI#:=Z"6UG2FFM1QK)[2;[*AT&VYH\]L
MPZ;%9\.FP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'
MH<!IQZ'_C1P#_XHG"/^*,0W_EC<3_YY &_^E22?_IU,T_Z==0_^D:%/\H')B
M\II\<.J4A7WCBXN(W822D=A^F)C3>IZ?T'6DI,URJJC+;["KR6VXKL)IO+"\
M:\"JMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$I;=M
MQ*7_C1L#_XLG"/^,, W_F#<3_Z! &_^G2";_JU(T_ZM<1/^I9E3ZI7!D\)]Y
M<^>8@H'?CXB-V8B/E]*!E:#.>YNGRG:AK<=SJ+'%<*^UP6VWM[EKN+6S;KVN
ML'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&HL'#!J+!PP:C_
MCAL#_XLF"/^., W_FC82_Z(_&O^I2";_KE$T_ZY;1/^L9%7YJFYE[Z5W=N6=
M?X7<E(62U(R,G<Z$DJ?)?9BOQ'B>M<)UI[G!=+&[N'"SN[%OMKBL<;NQJ7._
MJZESOZNI<[^KJ7._JZESOZNI<[^KJ7._JZESOZNI<[^KJ7._JZESOZO_CAL#
M_XPF"/^0+PW_FS82_Z0_&O^K1R;_L5 T_[%91/RP8U7VKFQG[:IU>..A?(C9
MF(.6T9")H\J'CZW%@I>TPG^@N+Y\J+N[>K"]L72RO:ERM+NF=+FSHW:^K:-V
MOJVC=KZMHW:^K:-VOJVC=KZMHW:^K:-VOJVC=KZMHW:^K:-VOJW_CQL#_XPF
M!_^1+@S_G382_Z8^&O^M1R7_LT\T_[181/JT85;SLFIH[*]S>N&F>HO6G8":
MS92&I\:-C:^_AY2UNH*<N;5_I+RR?:R^JWFQOZ-VLKV@>+BUGGF]KYYYO:^>
M>;VOGGF]KYYYO:^>>;VOGGF]KYYYO:^>>;VOGGF]KYYYO:__CQL#_XTF!_^3
M+@S_GC41_Z@^&?^O1B7_MDXS_K=71/>W8%;PMFAIZ+-P>]ZJ=XW0GWR=QY>#
MI[^0BJ^XBY&VLH:8NJV#H+VI@:F_I7ZPP)QYL;^:>[>WF'V[L)A]N["8?;NP
MF'V[L)A]N["8?;NPF'V[L)A]N["8?;NPF'V[L)A]N[#_D!H#_XTF!_^4+0S_
MH#41_ZD^&?^Q1B3_N$TS_+M61/6[7U;MNV=IX[5N?=:L<X_*HWJ=P9N I[B4
MA["QCXZVJXJ5NZ:'G;ZBA:7 GX2OP99^L,&4?[:XDX"[LI. N[*3@+NRDX"[
MLI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LI. N[+_D!H#_XXF!_^5+0S_H341
M_ZL]&/^S1B3_NDTS^KY51/._75;JOV5JW[AK?M"O<8_%IGB<NY]^I[*8A:^K
MDXNVI8Z3NY^+FKZ;B:+!F(BLPI""K\*/@[6YCX2ZLX^$NK./A+JSCX2ZLX^$
MNK./A+JSCX2ZLX^$NK./A+JSCX2ZLX^$NK/_D!H#_XXE!_^6+ O_HC40_ZP]
M&/^U12/_O$PR^,%40_##7%;GPV-JVKMI?LRR<(_ JG:<MJ)\IZV<@J^EEXFV
MGI.0NYF/F+Z4C:#!D8RIPHN(KL**B+2ZBHBYM(J(N;2*B+FTBHBYM(J(N;2*
MB+FTBHBYM(J(N;2*B+FTBHBYM(J(N;3_D1H#_X\E!_^8+ O_I#00_ZX]&/^W
M12/_OTPR]L530^[(6U;CQF%JU+]H?L>V;HZ[K72<L:9ZIJ>@@*^?FX:UF)>.
MNY.5E;Z.DIW!BI*GPH:.KL*$C;2[A8RYM(6,N;2%C+FTA8RYM(6,N;2%C+FT
MA8RYM(6,N;2%C+FTA8RYM(6,N;3_D1H#_X\E!_^9+ O_IC0/_[ \%_^Y1"+\
MP4LQ],E20NO-657?R6!JS\)F?<*Y;(VVL7*;JZMXIJ*E?JZ9H(2UDIV+NHR:
MD[Z'F)O A)>EPH"6K\)_DK.\@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU@)&X
MM8"1N+6 D;BU@)&XM8"1N+7_DAH#_Y E!_^;+ K_IS0/_[(\%O^[1"'YQ4LP
M\<Y10>?26%3:SEYIRL9E?+V]:XRPMG":I;!VI9RJ?*V3IH*TC*.)N8:@D+V!
MGIF_?9ZBP7N>K\%YF;.\>I>XM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU>I>XM7J7
MN+5ZE[BU>I>XM7J7N+7_DAD#_Y E!_^=*PK_JC,._[4\%?R_1"#TR$HN[=-0
M/^/85E/3TEUHQ<IC>[?":8NJNV^8G[9THY6Q>JR-K8"RA:J'MW^GCKMZII>^
M=Z:@OW2FK;]SH;2[=)ZXM72>N+5TGKBU=)ZXM72>N+5TGKBU=)ZXM72>N+5T
MGKBU=)ZXM72>N+7_DQD#_Y$D!_^?*PG_K#,-_[@[%/C#0Q[OS4HLY]I//=W>
M55'-V%MGOL]B>K#(9XFDPFV7F;QRH8^X>*F&M7ZP?[*%M7FPC+ATKY6[<*^?
MO&ZOK+QMJ[6Y;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT
M;J>YM&ZGN;3_E!D#_Y(D!_^B*@C_L#(,_KPZ$O+'0ASHTTDIX>%,.]3C4U'&
MW5IEM]5@>*G/9H>=R6N4D<5PGH?!=J9_OGRL>+R$L7*ZB[1MN9.V:KB<N&>W
MI[AGM[>V:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ:+*[
ML6BRN['_E1@#_Y4C!O^E*0?_M#$*^,$Z$.O.0AC@W4<EU>5+.\OG45"]XUEC
MK]Y?=*+898.6TVJ/BLYOF7_(<Z%UQ'BG;L%]JVF^A*YEO8NQ8;R3LE^\G;)?
MO*RQ8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_
MOJW_EA@#_YDA!?^J* ;_N3 (\,@X#>'80!/4XT4FRNM+.\'L3T^SZ%=@IN5?
M;YKB9GR.W&R&A-5QCWK0=95SS7J;;,I_GV?'A*)CQHJD7\21IES$F:=:PZ2G
M6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*?_
MF!<"_YX@!/^O)@7XP"X&YM S"-7A/!3)ZD4HO_)*.[7Q3DRI[U9;G>U?:)+J
M9W.'XVU\?MYR@G;:>(APUWV,:]2"D&;2AY)CT8R57\^2EES.F9A9SJ*96,VK
MFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFEC-JYK_FA<"
M_Z4> _^W(P/MR28#UMXI!LGI.Q>^\T0IL_A).JCW34B?]E55E/5?8(GQ:&B
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M;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC
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M?E3AN'Y4X;A^5.&X?E3AN'Y4X;A^5.&X?E3AN'[_F!,!_ZT4 ?/##P#2V L
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M ^W'+ 3?U3$&T]XY%,;81"BYT4X[K,Q63*#'75J5PF-GB[]I<8*[;WEZN':
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M'C3_EQXR_Z ?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!^FP
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M/$;_O3U%_\P]1/_F/D3_YSY$_^<^1/_G/D3_YSY$_^<^1/_G/D3_YS[+K
MN;8! *S" 0"@T ( E>4' ([_& .$_R0&>O\L"W#_-!!H_SP58?]$&5O_2QU6
M_U,@4_];(E#_8R1-_VLF2_]S)TG_>BE(_X(J1O^**T3_E"Q"_YXM0?^G+D#_
ML2X__[PO/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3"[L0  K+P
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M<6J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0
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M85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8 OL$% +?/"0"PXQ$
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M$B7_D!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@
MC<L  '[:  !PY@  9_\  %W_"@%4_Q !3?\5 D?_'0-!_R0$//\K!3?_,@8T
M_S@',/\]""W_0P@J_T@)*/]-"2;_4@HD_U<*(O]="R#_8PL>_VL+'/]S#!K_
M? P8_X0,%_^.#17_E0T5_Y4-%?^5#17_E0T5_Y4-%?^5#17_E0W_4B4#_TTO
M!/]1,@;_5S4'_UH\"O];10[_6D\3_UE=%_]8;1O_5GL?_U6)(O]3E27_4J G
M_U&H*?]0L2K_4+@K_T_!+/]/RBW_3M8N_T[D+O].[2__3O,O_TWX,/]-_##_
M3/\P_$S_,/E,_R_X3/\O^$S_+_A,_R_X3/\O^$S_+_A,_R__4R0#_TTO!/]4
M, 7_630'_UTZ"O]?0P[_7DX3_UU:&/];:AS_6GDA_UB&)/]6DB?_59TI_U2F
M*_]3KBW_4K8N_U*^+_]1QS#_4=(Q_U#A,O]0ZS+_3_(S_T_W,_]._#3[3O\T
M^$W_-/5._S+T3O\R]$[_,O1._S+T3O\R]$[_,O1._S+_4R0#_TXN!/]6+P7_
M7#('_V X"O]B00[_8DP3_V!8&/]?:!W_778B_UN#)O]9CRG_6)HL_U:C+O]5
MK##_5;,Q_U2[,_]3Q#3_4\XU_U+>-O]2Z3?_4?$W_U'V./M0^SCW3_\X]$__
M-_%0_S7P4/\T\%#_-/!0_S3P4/\T\%#_-/!0_S3_5",#_U M!/]9+07_7S '
M_V,V"O]F0 [_9DH3_V55&?]C91[_87,C_UZ */]<C"S_6Y<O_UFA,?]8J33_
M5[ U_U:X-_]5P3C_5<LY_U3:.O]4YSO_4_ \^U+V/?91^SWR4?\][U+_.^Q2
M_SCK4O\XZU+_..M2_SCK4O\XZU+_..M2_SC_52,#_U(K!/]<*P7_8RX'_V<T
M"O]J/@[_:T@3_VI3&?]H81__9G E_V-]*O]@B"__7I,S_UR=-O];I3C_6JTZ
M_UBU//]7O3[_5\<__U;30?Q5Y$+Y5>Y#]53V1/!3_$3L5/]!Z57_/^95_SSE
M5?\[Y57_.^55_SOE5?\[Y57_.^55_SO_5B(#_U4I!/]?* 7_9RL&_VPR"?]O
M/ W_<$83_W!0&?]N72#_:VLG_VAY+?]EA#+_8H\W_V"9._Y>H3[]7*E!^UNQ
M0_I9N47Y6,)']U?.2/56X$KQ5NQ+[E7V3.E6_$KE5_]&XEC_0]Y9_T#=6?\_
MW5G_/]U9_S_=6?\_W5G_/]U9_S__5R(#_UDG!/]C)@3_:R@&_W$P"/]T.0W_
M=4,3_W5-&?]U62'_<6<I_VUT,/UJ@#;Z9HH\^&.40/9AG$3T7J1(\ERL2_%;
MM$WO6;U0[5C)4NM7VE/G5NE5Y%?U5.%9_4_;6O]+U5O_2-!<_T3/7/]$SUS_
M1,]<_T3/7/]$SUS_1,]<_T3_6"(#_UPD _]F(P3_;R8%_W8N"/]Z-PS_>T$2
M_WM+&?][52'^=V,J^7-O,O9N>SKR:H5![V:/1^QCETSJ8)]0Z%VG5.5;KU?C
M6;A:X5?#7=]7TE[:5N9>UEGS6M)<_%7-7O]0R5[_3,5?_TG$7_](Q%__2,1?
M_TC$7_](Q%__2,1?_TC_62$"_U\B _]J(03_="0%_WLL!_]_-0O_@3X1_X)(
M&?V"4B'W?E\K\GEK->US=3[I;H!&Y6F)3>%ED53>89E9VE^B7-9=JE_37+-A
MT%N^8LY;S&/+6N)CR%SQ8,9?^EK!8/Y5O6'_4;IB_TVY8O]+N6+_2[EB_TNY
M8O]+N6+_2[EB_TO_62$"_V(@ _]N'P/_>",$_W\K!O^$,PK_ASP0_HA%%_>(
M3B'PA%LKZGYF-N1X<$'?<GI+V6V#4M-IC%C/9I5<S&2=7\EBI6+&8*YDPU^X
M9L%>Q&>_7MAHO%_K9KIC]U^V9/M9LV7^5;!E_U"O9?]/KV7_3Z]E_T^O9?]/
MKV7_3Z]E_T__6B "_V4> _]Q' /_?"(#_X0I!?^),0G_C#H.^8Y#%O&.3"#J
MBE@KXX1B-]M^;$/3>'9,S7-_4\AOAUG$:Y!>P&F88KUFH&6Z9:AHMV.R:K5B
MOFNS8LYLL&+E:Z]F]&2L9_A=J6C\6*=I_U.F:?]2IFG_4J9I_U*F:?]2IFG_
M4J9I_U+_6R "_V<< O]T&@+_?R #_X@G!/^.+P?]DC<,])1 %.R521[DD%4J
MVXI?-]&$:4/*?7),Q'A[5+]T@UJZ<8M?MFZ39+-KFV>O::1JK6>M;*IFN&ZH
M9L=OI6;?;Z5J\6BB:_9AH&SY6YYL_5:>;/Y5GFS^59YL_E6>;/Y5GFS^59YL
M_E7_7!\"_VH: O]W&0+_@Q\#_XPE!/^2+0;YES4+[YD^$N>;1AS>EE(ITI!<
M-\J)9D+#@V],O'YW5+=Y?UNR=8=@KG*/9:IPEVBF;9]LHVRI;J!KM'">:L)Q
MG&K7<9QN[FN:;_-DF6_X7I=P_%B7</U7EW#]5Y=P_5>7</U7EW#]5Y=P_5?_
M7AX"_VP9 O]Z& +_AAT"_X\C _^6*P7UFS,)ZY\[$.*@11G7FU HS)1:-L2-
M8T*\B&Q,M8)T5+!^?%NK>H1@IG>+9:)TDVF><IQMFW"E<)AOL'*5;KUSDV_0
M<Y1RZVZ3<_)FDG/V8)!S^EJ0<_M9D'/[69!S^UF0<_M9D'/[69!S^UG_7QT"
M_VX7 O]]%P+_B1P"_Y(B OV:*03QH# 'YZ0Y#=ZE0Q?1GTXGQYA8-;Z284&V
MC&E+KX=Q5*F">5ND?X!@GWR(99MYD&J7=IEMDW6B<9!SK'.-<[ITBW/+=8QV
MYW",=_!HBW?U8HIW^5R*=_I:BG?Z6HIW^EJ*=_I:BG?Z6HIW^EK_81L"_W$6
M O]_%@'_BQH!_Y4@ OF>)@/MI"X%XZDV"MBI0!;,HTPFPIQ6-+F67T"QD&=*
MJHMO4Z2'=EJ>@WY@F8"%991]C6J0>Y9NC'F?<8EXJG2&=[9UA'?'=H5ZY'*&
M>^]JA7OT9(5[^%V%>_E<A7OY7(5[^5R%>_E<A7OY7(5[^5S_8QH"_W,4 ?^!
M%0'_CAD!_YD> ?:A(P+JJ2H$X*\R!]*L/A7'IDLDO:!5,[2:7C^LE65*I9!M
M4IZ,=%F8B'M@DX6#98Z"BVJ*@)-NAGZ=<8)]IW1_?+1V?7S%=GU^X'-_?^YK
M?W_S97]^]UY_?OA=?W[X77]^^%U_?OA=?W[X77]^^%W_91@"_W43 ?^$% '_
MD1<!_YP; ?*E( 'FKB8"V[0N!LZO/13#JDDCN:13,:^>7#ZGF61)H)1K49F0
M<EF3C7E?CHJ 9(F'B&F$A9%N@(.:<7R"I71Y@;)V=X'"=G:"W71YA.UL>8/R
M9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1 ?^'$P'_E!4
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M7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08 T;$( ,N[" #&QPL
MO<<@ K+%,@NHP4 9GKY*)Y2Z4S2+MEH^@[1A1WRQ:$]UKV]5;ZUV6FJK?5]E
MJ89C8:B09UVGFVI9IZAK5Z>X;%:GS&Q8J.EH6J?T8UNC^%Y<H_E=7*/Y75RC
M^5U<H_E=7*/Y75RC^5W_> T _XL) -^< P#2J08 R;0' ,*^!@"\S @ M<T<
M :O++PFAR#T6E\5((XW"42^$OU@Z?+Q?0W6Z9DION&U0:;=T562U?%I?M(5>
M6[./85>SFF14LJ=E4K*W9E&SS&92L^EC5++W7U6N^EM6K?M:5JW[6E:M^UI6
MK?M:5JW[6E:M^UK_?@D \I$" -:A @#*K04 P+<% +C"!0"RSPD J]07 */3
M*P:9T#H2C\Y%'X7+3BI]R58T=<==/6[%941HQ&Q)8\)S3E[!>U-9P8165<"/
M65*_FUQ/OZA=3;^X7DS S5Y,P.I<3K_Y64^\_E50NOY54+K^55"Z_E50NOY5
M4+K^55"Z_E7_A0( W9@  ,VF @#!L0, M[H# *[&!@"GTPH H-T5 )G=* 20
MVS<.AME"&7W62R1UU%0M;=)<-6?18SQAT&M!7,]R1EC/>TE4SH1-4,Z/4$W.
MFU)+SJE32<ZY5$C/SU1(SNM32<[X4$K+_TY*RO]-2LK_34K*_TU*RO]-2LK_
M34K*_TWGCP  T9\  ,.K 0"WM ( K;\# */+!@";V0H E.4: 8WE*P:$Y#4-
M>^,_%G/B2!YLX5(F9N%:+&#@8C);X&HV5^!R.E/?>SU0WX5 3=^/0TK@FT5(
MX*A&1N"X1T7AS$=%X.A'1=_V1D7>_T1%WO]$1=[_1$7>_T1%WO]$1=[_1$7>
M_T39EP  QZ8  +BP  "LN0$ HL4" )C1!@"/ZPT B>X? H#N*P9X[30,<.T]
M$VCM1AEB[4X>7>U7(UGM8"=5[6@J4NUQ+4_M>2],[8,R2NZ--$?NF#5%[J4W
M0^^S.$+PQ#A!\-\Y0>_O.$#M_3A [/\X0.S_.$#L_SA [/\X0.S_.$#L_SC+
MH   NJL  *VT  "AP   ELP! (O9!0"$^!$!?/@? G3X*09L^#(*9/@[#U[Y
M0Q-8^4L74_E3&E#Y6QU-^F0?2OIL(4CZ="-&^GXE1/N()D'[DRA ^YXI/ORK
M*CW\N2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J
MKK   *&\  "5R   B=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/
M_T<12_].$T?_5A5$_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_
MK!\S_[D?,__('S+_XB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<
M )7$  "'T   >]T  '+]"0!J_Q$!8?\9 EK_(@-4_RH%3O\R!TG_.@E%_T$+
M0?](##[_3@X[_U4/./];$#;_8A$T_VD1,O]R$B__>Q,M_X84*_^2%2K_GA4I
M_ZD6*/^S%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,
M  !ZV@  ;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O]
M"#/_10@P_TL)+O]1"BO_5PHI_UT+)_]D"R3_; PB_W8-(/^ #1[_C X=_Y<.
M'/^A#AO_K \;_ZX/&_^N#QO_K@\;_ZX/&_^N#QO_K@^7O   B,D  'G6  !K
MXP  7_8  %;_  !._PH 1_\0 4'_%@(\_QT"-_\D S+_*@,O_S $*_\V!2?_
M.P4E_T %(O]%!B#_2@8>_U &&_]6!QG_7 <7_V0(%?]M"!/_=P@1_X$)$/^+
M"1#_E0D/_Y@)#_^8"0__F D/_Y@)#_^8"0__F G_22<"_T0Q!/]+,03_4#0&
M_U(Z"/]20PO_44X/_T]<$_]-:Q;_3'D9_TN'&_])DQW_2)T?_TBF(/]'KB'_
M1[4B_T:](_]&QB/_1M D_T;@)/]&ZB7_1O,E_T;Z)?]&_R7_1O\E_T;_)?]&
M_R3]1O\C_4;_(_U&_R/]1O\C_4;_(_U&_R/_22<"_T8O _]-+P3_4C(&_U4Y
M"/]50@O_5$T/_U)9$_]0:!?_3W<:_TZ$'?],D1__2YLA_TJD(O]*K"/_2;,D
M_TF[)?](Q";_2,TF_TC=)_](Z"?_2/$H_TCY*/](_RC_2/\H_DC_*/M(_R?Y
M2/\F^4C_)OE(_R;Y2/\F^4C_)OE(_R;_2B<"_T@M _]0+03_53 &_U@V"/]9
M0 O_6$L/_U56$_]49AC_4G0;_U&!'O]/CB'_3I@C_TVA)?]-J2;_3+$G_TNX
M*/]+P2G_2\HJ_TK9*O]*YBO_2O K_TKX+/]*_RS]2O\L^DK_*_=*_RGU2O\H
M]4K_*/5*_RCU2O\H]4K_*/5*_RC_2R8"_TLK _]2*P3_6"X%_ULT"/]=/@O_
M74D/_UI4%/]98AC_5W$=_U5^(/]3BB/_4I4F_U&>*/]0IBK_3ZXK_TZU+/].
MO2W_3<<N_TW3+_],XS#_3.TP_$SV,?I,_C'W3/\Q]4W_+_)-_RWP3?\K\$W_
M*_!-_ROP3?\K\$W_*_!-_RO_2R8"_TXI _]6*03_7"L%_V Q!_]B.PO_8D8/
M_V!1%/]>7QG_7&T>_UIZ(_]8AB;_5I$I_U6:+/]3HB[_4JHP_U&Q,?]1N3/_
M4,,T_D_.-?M/WS;X3NLW]4[U./)._3CP3_\U[E#_,^M1_S'I4?\OZ5'_+^E1
M_R_I4?\OZ5'_+^E1_R__3"4"_U$G _]:)@/_8"@%_V4O!_]H.0K_:$,/_V=.
M%?]E6AK_8F@@_U]V)?]=@2K_6HPN_EB6,?Q7GC3[5:8V^52M./A3M3KW4KX[
M]5')/?-1VC[P4.@_[%#S0.E1_3[H4_\[YE3_..-5_S7A5?\SX57_,^%5_S/A
M5?\SX57_,^%5_S/_320"_U0D _]=(P/_924$_VHM!O]M-@K_;D ._VU+%/]K
M5AO_:&0A_F5Q*/MB?2WX7X<R]ER1-O-:F3KR6*$]\%>I0.Y5L4+L5+E$ZU/$
M1NE2TDCE4>5)XE+R2-]4_$3=5O] VUC_/=99_SK26?\XTEG_.-)9_SC26?\X
MTEG_.-)9_SC_3B0"_U@A _]A( /_:B,$_W K!?]S- G_=#X._W1(%/]R4AO[
M;U\C]FML*O)G=S'O8X(W[&"+/>E=E$'F6IQ%Y%BD2>)6K$S@5+1.W52_4-M4
MS5#74^)1TE3P3M!7^TK.6O]%S5S_0LE<_S[%7/\\Q5S_/,5<_SS%7/\\Q5S_
M/,5<_SS_3R,"_UL? O]E'0+_;B$#_W4I!?]Y,0C_>CL,_WI$$_IY3AOT=ELC
M[G%G+.EL<C7E:'P\X6.%0]U@CDC979=,U5R?3]):IU'/6;!3S5BZ5,M8QE7)
M5]I6Q5?L5<-;^4_"7O]*P%__1KU@_T*Z8/] NF#_0+I@_T"Z8/] NF#_0+I@
M_T#_4B$"_UX= O]I&@+_<Q\#_WHF!/]^+P;_@3@+^X%!$O. 2QKL?%<CYG=C
M+>!Q;3C:;7= TVF 1L]EB4O+8Y%/R&"94L5?H57"7:I7P%RS6;Y<OUJ\6\Y;
MN%OE6[=>]56W8O]/M6/_2K)D_T:P9/]#L&3_0[!D_T.P9/]#L&3_0[!D_T/_
M51\"_V$: O]M& +_=QT"_WXD _^$+ 7^AS4)]8@^$.V'2!CE@U0BWGY?+M1X
M:3C.<W- R6Y\1\1KA$S :(Q1O6645+ICG%>W8J5:M&"N7+)@N5ZP7\=>K5_?
M7ZQB\5FL9?Y3JF?_3JAG_TJF9_]&IF?_1J9G_T:F9_]&IF?_1J9G_T;_5QT"
M_V08 O]P%@+_>QP"_X,B O^)*@3YC#('[XX[#>>.1!;>BE$AU(1<+<Q^9CC%
M>&]!P'1W2+MP@$VW;8A2LVJ05K!HF%FL9J!<JF6I7Z=DM&"E8\)AHV/58J)E
M[5VB:?M7H6K_49]K_TR>:_])GFO_29YK_TF>:_])GFO_29YK_TG_61P"_V<6
M ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M
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M6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0
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M4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T
MQ[(B KVO,PJSJT$7JJ=,)*&B53"9GETZDIID0HN7:TF%E')0@))Y57N/@5IV
MC8E><HR28FZ*G65KB:EG:(FX:&>)RVAIB^EC;(WY7&V,_5=MBO]2;8K_4FV*
M_U)MBO]2;8K_4FV*_U+_:Q !_WL+ /^*"@#BF 8 UJ,( -"L"0#+M0L P;8?
M ;BT,0FNL#\6I*Q*(IRH4RZ4I%LXC*!B0(:>:4B FW!.>IEW4W66?EAPE(=<
M;).08&B2FV-DD:=E8I"V9F"1R69BDN=B993X7&>2_5=GD?]29Y'_4F>1_U)G
MD?]29Y'_4F>1_U+_;@X _W\) /&.!0#9FP4 SZ8' ,FO!P#$N0@ N[H< ;*X
M+P>HM3T3G[%(():N42N.JEDUAJ=@/H"E9T5ZHFY+=*!U46^>?%5JG(599IN.
M76*:F6!>F:9B7)FT8UJ9QV-;FN5@7YOW6V":_E9AF/]289C_4F&8_U)AF/]2
M89C_4F&8_U+_<@L _X,% -^3 0#1GP0 R:H& ,&R!0"[O00 M+\8 *N^+ 6B
MNSH1F;A%'9"U3RB'LE<R@*]>.GFM94)SJVQ(;JES36FG>E%DIH-67Z2-65RC
MF%Q8HZ1>5J.S7U6CQE]5I.1=6*3V6%JC_U1;H?]06Z'_4%NA_U!;H?]06Z'_
M4%NA_U#_=P< \(D  -:8  #+I , P:T$ +FV P"RP 0 J\44 */%* 2;PC<.
MD<!#&8F]3"2 NE4N>;A<-G*V8SUMM&I#9[-Q2&*Q>4Q>L(%06J^+5%:OEU93
MKJ-84*ZR64^NQEE/KN184:[V5%.N_U!4K/]-5*S_352L_TU4K/]-5*S_352L
M_TW_?0  WX\  ,Z=  ##J ( N; " +"Z @"HQ 4 H<P/ )O,(P*2RC,*B<@_
M%8'&21]YQ%(H<L):,&O!83=FOV@\8;YP05R]>$58O(%)5+R+3%&[ED].NZ-1
M3+NS4DJ[QE)*N^113+OV3DVZ_TM.N?])3KG_24ZY_TE.N?])3KG_24ZY_TGO
MA0  U)4  ,>C  "ZK $ L+0  *>_ P">R08 E=0+ )#5'0&)U"X&@-(\$'C0
M1AEQST\A:LY8*63-7R]?S&<T6LMN.5;*=SU2RH! 3\F+0TS)ET5)R:1'1\FS
M2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0
MRYP  +VG  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-H
MW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<
MR#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,
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M&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S
M==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V
M_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_
MP1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(
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M/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y
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M1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\- .>8#0#;GPX
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M4U.?P%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0
MX(8  ,^3  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\
MM5 B=;-8*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJ
MP$U-JMQ-3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP
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M,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0
MEKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-
MY%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC
M^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(
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M"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0
M1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=
M_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_
MN@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\
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M-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/ /"%$0#CB18
MUHLC <N(-0;"A$,0NH!/&K-[62.M=V(JJ'1J,:-Q<3:?;GD[G&R!/YAJB$*5
M:9%%DF>:2(]FHTJ-9:],BF6]38EET4Z)9^Q*BFG[0XMK_SZ,;?\ZC&[_-XQN
M_S>,;O\WC&[_-XQN_S?_61  _V4+ /]Q"P#_>@L \8(, .B)#0#=C@X SX\@
M <:-,@:]B4$/M81-&:Z 5B*G?%\JHGAG,)UU;S:9<W8ZE7%]/Y)OA4*.;8Y&
MBVR628AJH$N%:JQ-@VFZ3X%IS$^!:NA,@VWY181O_S^%</\[AG'_.(9Q_SB&
M<?\XAG'_.(9Q_SC_6P\ _V<( /]S" #S?0@ WH8' -F,"0#5D0L RI(> ,&0
M, 6XC3\.L(A*&*F$5"&B@%TIG7UE,)AZ;#63=W,ZCW5[/HQS@D*(<HM&A7"4
M28)OGDQ_;JE.?&VW3WMMR5!Z;N9-?''X1GYS_T%_=/\]@'7_.H!U_SJ =?\Z
M@'7_.H!U_SK_70X _VH& /]V!@#D@ , V8D& -*/" #/E H Q98; +R4+@2S
MD3T-JXU(%Z2(4B">A5LHF(%C+Y-^:C6.?'$YBGIX/89X@$*#=HA%?W6127QS
MFTQY<J=.=G*U4'1RQE!T<N-/=G7V1WAW_T)Z>/\^>WG_.GMY_SI[>?\Z>WG_
M.GMY_SK_7PP _VP$ /5Y @#>@P( TXL% ,V2!P#)EP@ P)D9 +>8+ .OE3L,
MIY%'%I^-4!^9B5DGDX9A+HZ#:#2)@6\YA7]V/8%]?D%]>X9%>7J/279XF4QS
M=Z5.<'>R4&YWQ%!M=^!/<'GU2')[_T-T?/\^=7W_.W5]_SMU??\[=7W_.W5]
M_SO_80H _V\" .A\  #9A@$ SXX$ ,B5!@##F@8 NYP6 +.<*@.JF3D+HI5%
M%)N13AV4CE<FCHM?+8F(9C.$AFTX@(1T/7N">T%W@(1%='^-2'!]ETMM?*-.
M:GRP3VA\P5!G?-U0:G[S26V _T-N@?\_;X'_/&^!_SQO@?\\;X'_/&^!_SS_
M9 @ _W(  .%_  #3B0$ RI(# ,.8! "]G@0 MJ 3 *Z@)P*EG38)G9I#$Y:7
M31R/DU4DB9%=*X2.9#%_C&LW>HIR.W:(>4!RAH)$;H6+1VJ#E4IG@J%-9(*N
M3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0
M]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*
MF5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)
MO4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH
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M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP
MK*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUONDD4:KA1&F6W61]@
MMF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:RN3I%LM$Z1K'M.4>P
M_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY   +N<  "NHP  I*H
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M&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP
M8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX
M[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK
M_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X
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M PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P<
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M1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708
M_VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'H(I"#IJ&3!:3
M@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P=*!";7.M1&MS
MO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X_S'_7P( ]VP
M -YW  #0@0  QX@! ,"- P"YD0, LI,1 *N3(P&CD3,&G(Y #96+2A6/B%,<
MB89;(H2#8BB @6DM?']P,7A^=S5T?( X<7N)/&YZDS]K>9Y":'BK1&9XNT5D
M>-%%9GGN0&A[_3IJ>_\V:WS_,FM\_S)K?/\R:WS_,FM\_S+_80  ZF\  -EZ
M  #,A   PXL  +N1 0"TE0$ K)<. *67(0&>EC$%EY,^#)"02!2*CE$;A(M9
M(7^)8"=[AV<K=X5N,'.$=31O@GTW:X&'.VB D3YE?YQ!8GZI0V!^N41??L]$
M8'_L0&* _#ID@/\V98'_,V:!_S)F@?\R9H'_,F:!_S+_9   Y7(  --^  #'
MAP  OH\  +:5  "NF0  IIL, *"<'@"9FRX$DID["HN61A*%E$\9?Y%7'WJ/
M7B5UCF4J<8QL+FV*<S)IB7LV9HB$.6*&CSU?A9H_7(6H05J%MT)9A<Q"6H7J
M/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C
MN9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_FDP7>9A4'7277")P
ME6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-MD!3C<M 5(WI/5:-
M^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L  ,B'  "]D   M)@
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M*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@
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M"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D
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M 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP
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M-X)>PC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8
M_UT  .=G  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<
M<%<8F&U?'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IB
MOCEY8M4Y>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V
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M-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P
MP((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[
M?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V
M^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4
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M*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@
MCIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519EF%P:89=C'EZ6:B%;
ME7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1]2U-D?\J3I#_*$Z0
M_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<  )V;  "3GP  AJ0
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M&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@<
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M R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@
MF*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K
M[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?T
MD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T
M '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!,
M'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*
M_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_
M  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3
M !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT
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M)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@
M_U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ
M6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1
MPRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,
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M+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0
MQ'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1;E$/C6Q9%(EJ8!>%
M:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!BMB]O8LDO;F+F+F]D
M^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\  -=I  #*<   P'4
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M(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8   *V$  "DA0
MFH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q?5X8;GME&VMZ;!YH
M>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV\RI;=O\F7'?_(UQW
M_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80  *B(  "?B0  E(H
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M4(/_'U"#_Q_>:0  R74  +R   "RB   _^)]$$E#0U]04D]&24Q%  \2J(T
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M&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?EP  E9P  (FA  !]I@
M<:H  &2N  !:L0@ 5[$4 %6R(P!3LC !4+([ DVR1 -+L4T%2+%5!T6Q70E#
ML64+0+!O#3ZP>@\[L(<1.:^6$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K
M_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(
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M A?:_P*@G   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP
M*=D  "'>!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1
M[6< $.YW !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK
M_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$
M !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<
M _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+
MJP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z
M   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3
M  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_M
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M ?(3_P'Q$_\"\!3_ O 4_P+P%/\"\!3_ O 4_P+_*A\ _RP< /\L&P#_*QT
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M";HS_PFZ,_\)NC/_";HS_PG_.1  _ST+ /] "0#_1 T _T81 /]%&0#W1",
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M_Q3_1P  ^$\  .17  #570  S&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY
M Z%<2P>=6E0*F5E<#I989!&35FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?
M@U&J(8%1N")_4<LB?E+G(7Y3^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_
M2@  [E(  -Y;  #/80  QF0  +]E  "Z8P( LV(/ *QC( "F8S !H&(] YMA
M2 :67U$*DEY9#8]<81&,6V@3B5IO%H99=AB$6'X:@E>''']7D!]]5ILA>U:G
M(GE6M2-W5L<D=E;D)'97]Q]W6/\;=UG_&7=9_Q=W6?\6=UG_%G=9_Q;_3
MZ58  -E?  #+90  P6@  +II  "T:   K6<- *9H' "@:"T!FF<Z Y5E10:0
M8TX*C&)7#8EA7A"&7V43@UYL%H!=<QA^7'L:>UR#'7E;C1]V6I@A=%JD(W):
MLB1Q6L0E;UKA)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D
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M)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL5P  V6(  ,=K  "\<@
MLW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W.P1\=44'>'1-"G1R50YQ
M<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<(UQKJB5::[LF66S3)EIL
M[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL
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M&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-C0
M?(T  '6.! !OCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3
MBV@24(IQ%$V)>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&
M_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94
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M#2^E_PVVA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@
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M !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@
MD:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5
MV@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F
M@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D
M '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP
M"_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0
M\H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ
M  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!
M  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT
M /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/
MS0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_
M    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K
M  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2<
M_Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_
M *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T
M_P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I
M /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP
M_P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W
M _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5
M+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ?
M /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\
M[0S_ >T,_P'M#/\![0S_ >T,_P'_)1L _R88 /\E%P#_(1@ _R A /\>*P#_
M&C< _Q=% /\440'_$EX!_Q%I ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0
MH0'W$*@!]A"O ?00MP#S$,( \1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_
M >(2_P'A$O\!X1+_ >$2_P'_*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S,
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M!Z<S_P?_-P< _SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$
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M%(]#NA6-0\T5BT3H%8I%^A*)1O\0B4;_#HA&_PV(1O\-B$;_#8A&_PW_0
M\D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0(@"L43( IU$_ J)02@.>
M3U,%FTY<")A-8PJ53&H,DTMQ#9%*>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(
MM1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L
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M'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  # 9
MMV<  *YH  "G9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?5@EZ
M7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1'65:
M[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH
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M%E=H_Q189_\36&?_$UAG_Q/A6   RV,  +UK  "R<@  J78  *!X  "6=P
MB',  (%S"P!\=!< >'0F '1T,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?
M;VH07&YS$EIN?!57;8@756R4&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L
M_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@
M 'IY!P!U>10 <GHC &YZ+P%K>3H":'E# V1X2P5A=U((7W=9"EQV8 Q9=6@/
M5W1P$51T>A-2<X863W.3&$URH1E,<K$:2G+&&DIRY1I+<OD73'+_%4QR_Q--
M<O\237+_$DUR_Q+48   PFL  +5T  "K>P  HG\  )>!  ",@0  >GX  '-_
M @!N?Q$ :X > &B + !E@#<!8H!  U]_2 1<?E &67Y7"%=]7@M4?&8-47QN
M#T][>!%,>X,42GJ1%DAZGQ=&>J\817K$&$1ZY!A%>?@61GG_%$9X_Q)'>/\1
M1WC_$4=X_Q'-90  O7   +%Y  "G@   G(0  )*&  "&A@  =X8  &N&  !F
MAPT 8X<9 &"()P!>B#,!6X@\ EB'10-6ATT$4X94!E"&6PA.A6,*2X1L#$F$
M=@]&@X$11(./$T*#G11 @JX5/X/"%3Z"XA4_@?<3/X'_$D" _Q% @/\00(#_
M$$" _Q#&:P  MW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD
M6I 4 %B0(0!6D2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM
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M!2VDEP8LI*D&*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@
MI8L  )J1  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  S
ML!4 ,K A #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22Q
ME (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$
M ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T
M(KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7
MP*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>
M  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+
M !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI<
M"<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !Q
MK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9
M#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=
M  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0
M6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P
MXPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #N
MH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8
M #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L   #K    [04
M .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0
M_:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4
M   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V    ]P   /@
M  #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT
M /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_
M $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\
MJ #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_
M /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T
M_P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_
M *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /,
M_P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5&
M /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *<
M^ "N /4 M0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I
M ?\ Z0'_ .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,
M3@#_"5H _PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J
M .T&L@#J!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\
MW S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\
M$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.
MKP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_
M <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\
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M!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@
M_S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V
M,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z R
MO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@
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M$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5
MO54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'
M2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)
M[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H
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M#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9
MD%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%;%Q<!VI;8PEH
M6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;6OD26UK_$%Q:
M_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J  "7:   BV(
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M#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\
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M9   MVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %>
M( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ(
M"SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0
MLG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-
MB28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'
ME0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H
M **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\
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M !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0
M=9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7
MMR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VY
MQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8
M %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14
M"<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@
MQM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T
M  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6
M  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\
M -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   Y
MP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?
M%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%
M  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@
M(,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0
M[1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #Z
MP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H
M  W?   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D
M /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP
M_[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P
M /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\
M^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L
MM #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_
M /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P
M +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4
M_P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B
M /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0
MX@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_
M'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$
M9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[
M - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P
M_R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=
M#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00
MR #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,
M /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6,
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M Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0
MS#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<
M,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT
M\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0
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M"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4
MF4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y2E@#=TI?!'5)9@5S
M26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)Y UF2?@+9DG_"69*
M_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D  *18  "<50  DTX
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M"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q(
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M"DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6
MNF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!:
M:BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41I
ME0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8
M *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< < 6' 1 %9P'0!4<2@
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M!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P
MB(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  V
MC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,
MQ@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP
M ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT
M*9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!'9BL 1R8PP$<
ME^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5
M  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M
M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.(
M$:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8
MH0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ
M*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O
M  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP
M0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@
MOBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]
M]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8
M "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(
M ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP
MSO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["
M   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?
M  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H
M .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,
MT0  !-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M
M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??
M  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP
M .(   #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$
M_!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_
MOP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M
M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T
M_P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_
M$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\
M<@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@##
M /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0
M_P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[
M '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@
MRP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$.
M /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '
M[0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6
M -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/
M!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R
M -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -
MQ0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_
M$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%
M<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE
M +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@
M]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]
M#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4
M]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$
M -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X
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M G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0
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M!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4
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M!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P
MOU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B
M5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4
ME =-5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<
M *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P
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M!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P
MD7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !'
M:CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35J
MQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<
M ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@
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M 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP
M6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >
MD4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2.
M_P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4
M $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC<
M$9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +
MFO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@
M   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX
M  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\
M *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   F
MJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X
M.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_
M  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@
M$[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@
MR#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(
M_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,
M  /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT
M -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !Y
MH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
M    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK
M  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@
M7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B
MY@   .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_
M*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7
M /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L
M_P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\
M .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\
M$P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^
M /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q .,
M[P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_
M !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0
M?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M
M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P
M_P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E
M (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P
M]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P .
M /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H
MT "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[
M /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!
M$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z
M +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L
MJP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #=
M Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(
M>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_
M )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L
MQPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B
M$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7
M_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0
M +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W<
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M 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP
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M EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P
MPT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K
M03( :4$[ &=!0@!E04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"
ME -70J,$54.S!%1#R0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH
M +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X
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M!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@
ME6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/
M4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4
MP00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4
M (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP
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M BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@
M9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S
M;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J
M_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<
M %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0
M*71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?
M<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^
M  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W](
M !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\
M%GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \
MB   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*
M3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_
M  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@
M*I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (
MEU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2
M_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT
M !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@
M *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1
MB@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J
M   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),
M  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D
M?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "
MN    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##
M3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT
M &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0
M ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800
MV%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL
M  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4
M  #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,
M .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^
MO   +\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
M    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&
M  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !<
M_P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_
M (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@
M_P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7
M /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8
M^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J
M /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\
M'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"'
M .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\
MUP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[
M "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P
MAP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_
M ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\
MZ@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#&
M (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +(
M_P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E
M -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($
MM "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B
M /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0
M*@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"#
M *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\
ME G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R
M!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,
MA@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_
M (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R<
MH1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")
M%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9
M_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM
M )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88
M?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H
M*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B
M,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:-
M &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@
MRS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y
M*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8M
ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P
M +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#,
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M DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4
MEU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7
M/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"
MO@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50
M (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT
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M 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@
M:5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _
M44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313
M_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX
M %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD
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M 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P
M.FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >
M;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK
M_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@
M "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8
M$WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?
M<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"
M   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=
M  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0
MD'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5
MC@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/
M90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4
M (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@
M"IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7
MG6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0
M  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@
M  "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,
M *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?
MG   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
M    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK
M  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0
M1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"
MPP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2
M<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,
M "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@
M -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9
MZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W
M   1Q   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4
M  #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH
M /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_
M #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\
MDP#_XGT024-#7U!23T9)3$4 $!+_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y
M .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\
M#0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U
M /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4
MZ@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_
M  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T
M=@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D
M -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0
M_P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#:
M '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,
M[P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  '
M .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\
MPP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N
M /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\
M# #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O
M +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /(
MG0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#&
M !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *(
M;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\
M (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H
MM  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3
M V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,
M_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D-
M *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H
MA0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T
M$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/
M$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L
M '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\
M:AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%
M&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>
M< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_
M &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!(
M=R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B
M)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH
M_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9
M &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W(
M62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*
M-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M
M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z
M %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@
MMD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:
M,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LV
MA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4
M *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R(
M4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$
M.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.
M  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG
M $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$
M/D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "7
M5   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D $9
M+ !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@
M #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "46
MBUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _
M13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)
ML0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T
M 'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX
M.4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L
M3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA
M  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R
M #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4
M)E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M
M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7
M-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE
M !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P
M76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B
M7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?
M^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X
M $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4
M&&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 0
M9O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T
M   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X
M  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\
M"6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U
M?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\
M/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_
M  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP
M(X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@
MB4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$
M_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(
M !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD
M )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+
MA@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?
M   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\
M  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0
M>)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K
MK0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W
M/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@
M %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@
M +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@
MRT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F
M  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L
M  #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4
M .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   X
MM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4    V    -P   #=
M    WP   .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX
M  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !
M_P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_
M (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0
M_P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2
M /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T
M]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C
M /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\
M&0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!]
M .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\
MRP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q
M "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X
M? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_
M +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D
MVP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y
M 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4
M_P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ?
M ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4
MIP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5
M /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +,
M(P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V
M )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\
MA@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A
M "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@
M=P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_
M '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\
MD0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z
M"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T.
M_P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB
M ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'<
M;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6
M)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83
M)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^
M &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@
MO3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I
M&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?
MAP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8
M *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28
M7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/
M)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_
M  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K
M %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y
M1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "9
M10  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L
M+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&>
M $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620
MC$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!'
M,3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LV
MKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX
M (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\
M0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U
M.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0
M  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT
M #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\(
M+S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q
M4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_
M.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B
M "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P
M85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O
M13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(
M]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@
M %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL
M)TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >
M3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);
M  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%
M "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\
M&%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"
M7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A8
M10 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_
M !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@
M,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /
M84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?
M_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X
M "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T<
M!6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7
M;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV
M   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.
M  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0
MB7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0
M@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""
M50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($
M 'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@
M H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030
MD%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+
M  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T
M  "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0
M *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9
ME@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J
M    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:
M  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP
M/Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W
MN    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&
M8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP
M "2O   6L0  #;0   .W    N@   +T   #     Q    ,8   #&    R
M ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5
MX6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y
M   -O    ;\   ##    QP   ,H   #/    TP   -8   #7    V@   -P
M  #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP
M /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_
M "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X
MB@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_
M .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "<
M_P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O
M (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D
M_P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N
M /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0
MVP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^
M /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0
M,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$
M ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\
MK #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#*
M #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\
MA0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_
M )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$
MM  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"<
M (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T
M_P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T
M *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (
MBP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N
M"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ),
M-0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$
M 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0
MS1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"#
M #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"
MBP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"
M +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#
M= @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B
M#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K
M  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R
M &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I(
M5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?
M,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5
M- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ?
M $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.
MD#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4
M'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4A
MK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T
M (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3,
M2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ]
M)\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _
M  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V
M $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\
M-RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S
M0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK
M.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'>
M #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10
M94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU
M]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4
M %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P
M,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H
M.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&
M  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI!
M "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\
M(SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*
M2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_
M2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_
M !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@
M/4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =
M14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&
M_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$
M "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P
M%4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">
M5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6
M   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4
M  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70
MD60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =
M70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;
M7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL
M (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@
M$68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@
M9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U
M  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$
M  9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0
M &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S
M?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]
M!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO
M  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P
M784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*
MB08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")
M?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT
M $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8    EP
M )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P
MF(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9
M   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4
M  "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX
M *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @
MHP  $Z4   NG   !J0   *L   "N    L0   +(   "R    LP   +0   "U
M    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-
M  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0
M"[    "S    M0   +@   "\    OP   ,$   #!    PP   ,0   #&
MQP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<
MF0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L
M  "_    PP   ,8   #+    S@   -$   #1    U    -8   #9    VP
M -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB
M]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\
M00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2
M /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\
MR0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#]
M $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .<
MDP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_
M +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $
MZ0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#.
M )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T
M_P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!#
M ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X
MMP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_
M    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L
M10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1
M *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]
M\0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G
M $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$
ME0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP
M -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\
ME0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_
M )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-
M  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!
M (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4
M< "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M
M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '<
M0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"?
M &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P
MFQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I
M D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(
MK0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4
M (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH
M70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,
M#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I
M  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [
M %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X
M0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X
M*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6
M/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO;
M #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@
M:BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!
M'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A
M]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(
M %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T
M.2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O
M)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS
M  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9"
M #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\
M*BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.
M,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__
M "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0
M030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G
M,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R
M_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL
M #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T
M(#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C
M1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]
M   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6
M !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P
ME5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G
M0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !-
M8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8
M (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2
M&T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -
M1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@
M  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$
M !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD
M!$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z
M:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6
M"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W
M  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@
M;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #
M8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>
MAP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4
M %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL
M &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@
M:)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[
M  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-
M  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(
M '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _
M@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "#
M#0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D
M  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0
M)XT  !N-   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2!P
MD@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1
MM@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<
M !&8   )F0   )L   "<    G@   *    "@    H    *    "A    H00
M *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK
MI,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC
M    I0   *<   "I    K    *X   "N    K@   *\   "P    L0   +(
M  "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L
M +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O
ML0   +0   "X    NP   +P   "\    O@   +\   #     P@   ,0   #&
M    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$
M  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@
M ,(   #'    R@   ,P   #,    S@   -    #2    U0   -@   #;
MWP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #Q
MQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1
M /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T
M\ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_
M    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /(
M4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@
M -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_
M_P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#<
M %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,,
MI0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P
M /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X
MP@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L
M *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /
M  #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!.
M *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *,
MEP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/
M    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L
M3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J
M (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^
MM@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P")
M $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4
MM !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0
M *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $<
M>0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E
M ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+
M  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !&
M &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P
M6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%
M#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\
M1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2
M $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&
M=1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3
M!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,
M[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL
M &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4(
M2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [
M$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=
M  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%%
M #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\
M-!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4
M'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<6
M2@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_
M "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0
M1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O
M'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@
M_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4
M #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X
M*2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F
M.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F
M P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96
M "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@
MF$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L
M* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK
M8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<
M (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8
M)"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6
M,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/
M  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+
M !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L
M$#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^
M5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X
M#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ
M  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P
M<EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0
M/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!
MB@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&
M &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX
M"$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@
M2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F
M  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1
M  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@
M $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3
M:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:
M$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K
M  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<
M/VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0
M9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@
MP0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8
M "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$
M ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO
M:^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_
M   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1
M  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H
M 'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /
MB0  !XH   "+    C    (T   "-    C    (P   ", P  C @  (T-  "-
M$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO
M  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0
M )8   "8    F@   )L   ";    FP   )L   ";    G    )T%  "="P
MGA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<
M^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,
M  "E    J    *D   "I    J0   *H   "K    K    *T   "N 0  L D
M +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !D
MDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T
M    M@   +@   "X    N0   +H   "\    O0   +\   #     PP   ,4'
M  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP
M2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##
MQ@   ,@   #(    R@   ,L   #-    SP   -(   #5    V0   -T   #A
M!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P
M /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L
M^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G
M +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\
M  #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !<
M .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0
MS #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_
M    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X
M7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^
M +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O
MY@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V
M %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *
MRP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP
M ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4
MH@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP",
M .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4
M 0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3
M (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\
M>0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@
M  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\
M4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G
M &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4
MC0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O
M %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P
M]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ %
M 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P
M8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0
M /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$
M" !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!-
M %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L
M1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A
M! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D
M3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_
M #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0,
M4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^
M"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-
M_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \&
M $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E
M- Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J
M+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1
M"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7
M "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0
MFC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U
M% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "87
M8  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H
M (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H
M+!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?
M'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!
M  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT-
M "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H
M&")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_
M1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A
M$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y
M !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@
M=$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9
M)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XK
MBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\
M &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!
M$RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (
M,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2
M  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3
M  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID
M #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;
M50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[
M%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL
M   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7
M3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0
M0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"
MPP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T
M #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@
M $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P
M2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A
M   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;
M  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(
M %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E
M:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?
M'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW
M  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<
M$V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0
M:B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D
M_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H
M  1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H
M '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^
M?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&
M    AP   (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<
M  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA
M:H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3
ME0   )8   "6    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":
M'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT
M %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\   "A    I
M *4   "D    I0   *4   "F    IP   *@   "I    J@0  *P,  "N$P
MKB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28
M   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P    L@   +0
M  "S    M    +4   "W    N    +D   "[    O0   +\!  ##"P  Q14
M ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   I
MI@  &:@   VK    K0   +$   "T    MP   +H   "_    P0   ,0   ##
M    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;    X P  .$8
M  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $
M_P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R
M &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P
M[@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P &
M /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &,
MW !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#
M /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T
M# #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B
M ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /(
MJ@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #.
M !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P
M80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_
M )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T
MLP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7
M %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V ((
M_P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0
M )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D
MA !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P
M /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9  , DP , (X
M$@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8
M '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\
M80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\
M !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0
M60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_
M %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !
M;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6
M %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D
M_P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1
M %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8
M20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R
M&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %,
M$P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!:
M #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(
MGR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!'
M !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$
M80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH
M ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q
M.P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K
M"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR
M  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1
M #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH
M(@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  "
M-P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0
M$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X
M !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P
M=#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08
MB0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\
M &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /
M'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"
M  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5
M !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID
M"B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<
M1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B
M&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L
M  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2
M4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,
M*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   K
MP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH
M $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL
M!2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP
M,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-
M   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@
M   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N
M #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U
M3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^
M)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU
M   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50
M)5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@
M1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"
M_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH
M !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<
M $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%
M90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@
M   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM
M  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;
M>7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ
M:@   &D   !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D
M-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<
M &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0
M '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+
M<CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^
M  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,
M  "#    @@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(
M ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+
MAP  /(D  "Z*   @BP  $XL   J+    C    (T   "/    D0   )(   "1
M    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X
M  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D
M,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP   *    "@
MH    *    "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I
M0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP
M !2=   *GP   *$   "C    I@   *@   "L    K@   *\   "O    L
M +    "R    LP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P
MP$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG
M    J@   *T   "P    LP   +8   "[    O0   ,    "_    P0   ,(
M  #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL
M -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_
M !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D
M;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_
M ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4
M\P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#.
M &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0
M_P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  :
M -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@
MM@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P";
M /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T
M'@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G
M )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\
MA@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E
M "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T
M9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_
M '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L
MD  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y
M &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &<
M_P#3    PP   +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P =
M 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$
M: !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%
M    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X
M'@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D
M %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@
MK T  * -  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!?
M !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P
M: !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10
M )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H
M40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _
M &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=
M  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P :
M $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L
M- !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$
M)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P
M&P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V
M "H B  H )P )P"P "8 R0 E .H )0'[ /_B?1!)0T-?4%)/1DE,10 1$B4!
M_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+$   0PP"
M #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#.P I!$,
M* 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?
M*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.
M!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A"D  ( I*
M !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0
MD#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@  #03   M
M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT &0Y' !<.
M4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4
M (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:   J%0$
M(Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1
M$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\
M  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H'   (!@#
M !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP
M#!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT  (!   !W
M00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P  'Q\  !<:
M"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI
M  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$  !U10
M;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24  !0A!  /
M'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A
M>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T2@  :TH
M &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H!  -) H
M"2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E   F=P
M)HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P  :D\  &!.
M  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *+ H !2L.
M  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L=0  +(H
M "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0  %]3  !6
M40  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD  #(-   R
M$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@  ,H<  #&>
M   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9  !55P
M25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,   Z#P
M.1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4  #B<   W
MLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !27   1%@
M #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !##0  0A
M $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9   _L0
M/M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80  /EX  #);
M   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#   2PX  $L2
M  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'KP  1LT
M $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0  "IB   ?
M8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P  %40  !4
M%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP  4,H  $_O
M  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J   7:0
M#F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-  !@$
M8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4  %KM  !9
M_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0<@  !W$
M  !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M#   ;1$
M &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y
M>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0   'T   !]
M    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@  ? P  'P2
M  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S@
M98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D   "*
MC    (T   "-    C    (P   ",    C    (P   "-    C00  (X,  ".
M$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!HA@  6H@
M $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9    FP
M )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#  "B#
MHA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0  39   #^3
M   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H    J@   *L
M  "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W 0  N0T
M +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<   C
MH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0   +L   "Z
M    O    +T   "_    P    ,(   #$    Q@   ,D   #-    T@$  -0/
M  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\   #_
M_P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G
M %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L S0"] ,L
MX #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_    _
M /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D
MRP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T +0 S0"R
M /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q    Z    .
M!@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V %, M !8
M +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\ P "= .8
MFP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@   ,8  0"_
M  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P GP!1 )X
M5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0") -, AP#W
M (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$   "K  <
MI0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ")
M %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K ',
M_P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":  ( E  +
M )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X
M=@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B
M /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",    A@ ' ($
M#0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!.
M &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\
M5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 " ', "@!O
M  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $( 60!' %<
M3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_
M $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@ !0!C  P
M7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!" $L 2 !)
M %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_ #P
M_P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9  @ 50 -
M %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L
M/0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F
M%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0 3  * $@
M#@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T $8 ,P!/
M #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A'
ME2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  & $  "P \
M  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $( *@!+ "@
M50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28
M (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T  P
M,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!' "  4@ ?
M %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M
M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M"0D *04-
M "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP
M%@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W
M,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0 (PP) !\)
M#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI
M  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@
M;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! % !D."@ 5
M# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0
M>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P  :SH
M &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3!@ 1$ L
M#@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E  03=@ #
M$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P  :C\  & ]
M  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0%0D #!,.
M  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D
M !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,  %]"  !6
M/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD "1D-  89
M$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@  '8<  !R=
M   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&  !51
M2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -  $?$
M'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4  "&;   A
ML@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !420  2D8
M $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F#@  )1(
M "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9   FL
M)<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P  2DP  $%)
M   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@  +1$  "T6
M   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   LKP  *\L
M "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$  #M-   P
M20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\  #04   T
M&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0  ,<H  #'N
M   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92   J3P
M($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1   \&
M/"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@  #CM   W
M_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D50  &5,
M !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&%   11P
M $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L   __P!^
M80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70  $EL   M9
M   "6    %8   !6    5    %,   !2!   40D  % -  !0$   3Q@  $\B
M  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(_P![:0
M=&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60   -B
M8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(  %L<  !:
M*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y<   <W0
M &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M    ;0
M &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5  !G(0
M9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z
M  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y    >@   'H
M  !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W&   =R8
M '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%
M@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B    (D   "(
M    AP   (<   "'    AP   (<   "(    B    (@'  ")$   B1P  (DL
M  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(   YB@
M*HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@   "6
MEP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$  )TA  "=
M,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   MDP  'I4
M !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F    IP
M *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5  "T)P
MM#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0  $9\   6A
M    HP   *8   "I    K    *\   "S    M0   +<   "V    MP   +@
M  "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,  #.&@  SR\
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M_________________________________________________P
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M]_CY^OO\_?[_;69T,0     # 2$   $                    !
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M________J#4          %S3____________________________?0T
M     %36___________________________N?44          $34________
M___________________\JF0O @  !"(W25C.________________________
M____Z:1K02@_8W^5I[K:_______________________________5LJRRS.3Z
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________ENY=W8LC_________________
M________________VYYG-@H  HS________________________________(
M?S\%     %[/_____________________________]F!.0       #RJ____
M_________________________YY,         ".0____________________
M________W&\:         !!]^?__________________________KT@
M      !O[O__________________________A!,           !DYO______
M___________________L40            !7WO______________________
M__^X%0            !(UO________________________]T%
M   XS_________________________FB6A,            CQ?__________
M_______________?FUPL           -NO__________________________
M[[%]53DB$0<! A$BLO______________________________W[^EF9B:H*R]
MVO__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____X[Z=@'S[________________________________\K>$5S . !VL____
M___________________________2BDP5      !R\___________________
M_________]9_-@        !+R?__________________________^I$^
M       OJ___________________________P%H            :E?______
M____________________C20            (A/______________________
M___G7@              =_________________________^T)0
M    :O________________________]]                6_3_________
M______________TK                3.O______________________Z4
M                /.'______________________S ,
M+=G_____________________F8IA)P              )]?_____________
M_________^V^B54G            )=S__________________________LJ=
M=EU*/#(M+# Y1][_______________________________WFW=;2T-/9Y/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________OU+O6____________________
M_____________^>XCVI++Q5O_______________________________DH6<T
M!P     \R?___________________________]:".P         2E_______
M____________________[84Q            ;_______________________
M____ID(             4.'________________________L:0
M    -\G_______________________^S+P              (K;_________
M______________]Y                $*?_______________________(T
M                 )G______________________ZD
M (S______________________T8                  '______________
M________WP                   '3_____________________EP
M             &K_____________________S@                   &/_
M_____________________RDB 0               &'_________________
M_____[FC@%<W%P           &C___________________________K3KI2&
M?'5Q<')W@93_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________V[J=@FEIT_______
M________________________R)-E/1D    =GO______________________
M_____]N.3!,         ;O__________________________VWPL
M    1=?_________________________BRH             (K3_________
M_______________"1                Y?_______________________]]
M 0               '_______________________^<V
M &K______________________YT                  %C_____________
M_________T8                  $?X____________________Z0
M             #7I____________________E@                   "7;
M____________________O                    !C.________________
M____ZP                    _"_____________________P
M          JY_____________________R<                   JU____
M_________________W                    VY____________________
M_^"<C'!50C,F&Q0/#0X2&B:_____________________________^>38TL[,
MR\S/UN#\____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________Z].\X________________________________]*IA65(
M+!(!A?____________________________&K<3P/        3^#_________
M________________U7\U            '[+________________________C
M=1T              (G_______________________^0(P
M &?______________________]5#                 $CV____________
M_________XH                  "[=_____________________S@
M             !?(____________________O@                    2V
M____________________G                     "E________________
M____N@                    "3____________________W
M          ""_____________________P                    !T____
M_________________Q,                   !H____________________
M_T(                   !@_____________________WH
M      !=_____________________]$                   !A________
M______________\D                  !F_______________________)
MK)F)?79Q;&EG9F=K<'J,________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________XL6JD7EA=___________________________
M___=IG=0+ P     ,<3_________________________X)).$P
M (_________________________2<!T              &#_____________
M_________^YO#P               #?B_____________________Y8<
M             !3 _____________________T                    "C
M____________________K@                    ")________________
M____G@                    !R____________________O
M          !?____________________V@                    !-____
M________________^@                     [____________________
M_PX                    J^?___________________S,
M       ;Z?___________________UX                    /V_______
M_____________X\                    &T/___________________]
M                    RO____________________\K
M    R/____________________^                     R___________
M___________W%@$%!0,!       !!@T8R________________________.OA
MV,_,S<_0TM37W.+J____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________':
MQO______________________________\<:CA&A-,A@ %:O_____________
M_____________[E\1A@          ''________________________7?"\
M             #OC_____________________]]D"0                RU
M_____________________W0#                  "-________________
M____Q14                   !J____________________F0
M          !+____________________M@                     P_?__
M________________UP                     9Y___________________
M]@                     %T____________________PX
M        P?___________________R\                     K_______
M_____________U(                     GO___________________WD
M                    CO___________________Z4
M    @/___________________]@                     =/__________
M__________\V                    ;?____________________]\
M                :?_____________________7#0
M:/______________________<                   8?______________
M_________U \1DY465UA9&AL<'9^B?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____[]6[HXMS6I7___________________________B_CF1!(04      %+\
M_______________________WG588             !?!________________
M_____^5L%@                "-_____________________V,
M          !>____________________G0                     U_/__
M________________H0                     1V?__________________
MR@                      N___________________[@
M        H?___________________PP                     BO______
M_____________RT                     =O___________________TT
M                    9/___________________V\
M    4O___________________Y0                     0/__________
M_________[P                     ,/___________________^H.
M                (O____________________]$
M%?____________________^!                    "_7_____________
M_______("P                   NS_____________________7@
M             .7_____________________R1P                  -K_
M_____________________YT!              <.%\7_________________
M_______5N;S!Q\[5V^'F[?3[____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________XW\__________________
M____________[,:EB&U4.R$' #+>________________________UY)9*0
M          "@______________________^)-@                !G____
M_________________V8                    R]O__________________
ME0                     #R/__________________IP
M        H/__________________UP                      ?/______
M_____________P                      7O___________________R4
M                    0____________________T@
M    +/___________________VH                     &/__________
M_________XL                     !?/__________________Z\
M                 .'__________________]4
M ,____________________\D                     +[_____________
M______]4                     *[___________________^+
M             )_____________________+#@                   )+_
M____________________5P                   (;_________________
M____J@H                  'G______________________VT
M         &;_______________________=5                 $7_____
M____________________:B,K-3]*56!J=7Z'D9S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^C/MIV#:4ZY____
M_____________________^RR@UPZ'0(       ![____________________
M___%;2D               ! _____________________X,;
M       'R___________________D@                      F/______
M____________I                       :O__________________W0
M                    0?___________________PX
M    '?___________________SD                      .C_________
M_________V                       ,[__________________X4
M                 +?__________________Z@
M */__________________\L                      )#_____________
M_____^\6                     'W___________________\^
M             &S___________________]I                     %K_
M__________________^9                     $G_________________
M___2%@                   #G_____________________6
M         "G_____________________H@                   !G_____
M________________]58                   3_____________________
M_[LO                  #X______________________^K*0
M      #/________________________R4<     !Q,@+CY2:(3M________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________]-7)____________________________^M*PDG==
M0B@,  !*________________________Q7U%%P             1V/______
M_____________\10                    G___________________H@P
M                    :/__________________E
M    -O__________________V@                      !^S_________
M_________Q4                      ,3__________________T@
M                 *+__________________W4
M (/__________________YT                      &G_____________
M_____\,                      %+__________________^</
M             #[___________________\S                     "O_
M__________________]8                     !C_________________
M__^!                      7___________________^L
M          #____________________>(@                    #R____
M________________7                     #?____________________
MGP                    #,____________________Z$H
M      "W_____________________Z 6                  "<________
M______________]Z @                !W________________________
M>@L               5,_________________________Z)7:'2 C9RKO-#G
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^WC________________________
M___2HWI8.BDC'!8.!@  G_____________________^L4@X
M    :?__________________Y$,                     -/__________
M________>0                       ./_________________S0
M                 ++__________________Q,
M (7__________________T\                      %W_____________
M_____X,                      #K__________________[(
M             !S__________________]L#                      +_
M__________________\J                      #[________________
M__]/                      #G__________________]T
M          #4__________________^;                      # ____
M_______________$!P                    "M___________________P
M,P                    ":____________________9P
M      "&____________________HP                    !R________
M____________XT0                   !<_____________________Y$&
M                  !!_____________________^M?
M   =_______________________*2P                  ____________
M____________RU<   P8)#$_3F!TBZ?'___________________________7
MY_+_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________KU,W'PKZZM[.PK:FHI?___________________]U^4S\P
M(QD1"0(          -O_________________=@
M *?_________________N@                       '7_____________
M_____P<                      $;__________________TX
M             !K__________________XP                       #]
M_________________\$                       #;________________
M__$9                      "^__________________]$
M          "D__________________]K                      "-____
M______________^1                      !Y__________________^W
M                      !F___________________>(0
M      !3____________________2@                     _________
M____________=P                     K____________________K H
M                   6____________________YT4
M    _____________________XH                     ____________
M_________]9-                    _?____________________^G+@
M                U?______________________F"H           88+45@
MX/_______________________ZAC=(&/G*N[S>+Z____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^(S@$E#0U]04D]&24Q% !(2________________________________
M_______________________________GR[>IG96.B82 ?'AT<&QH99#_____
M____________O&I(+1D*                 #'__________________P
M                      /__________________T(
M      #<_________________XX                       "R________
M_________\X                       "-__________________\I
M                  !K__________________]:
M  !.__________________^&                       T____________
M______^N                       >___________________4%P
M               *___________________Z/0
M____________________90                      ________________
M____C@                      ____________________O!D
M            [___________________\4X                     V/__
M_________________XL                     O___________________
M_\Q#                    H?____________________^1&0
M        >O_____________________R= H                17_______
M________________Z'03'RPX15-B<H6;M-+U________________________
M___7Z/3_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________OW\_'N
M[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$________
M_________TLE"P                    "2_________________X@
M                  !F_________________]<
M   ]__________________\S                       8____________
M______]L                        __________________^=
M                ___________________)#
M]O_________________Q-0                      W_______________
M____6P                      R___________________@@
M            M___________________J08                     H___
M________________TR\                     C?__________________
M_UX                     =____________________Y,'
M        7O___________________\U#                    0/______
M______________^'$                   '/_____________________8
M7@                   /______________________OTX       X<+#Y2
M:H:ER/_______________________\)\C)JGML76Z/W_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^[AU\_)P[ZZMK&MJ:>F
MIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4____________
M_____]<%                        __________________\T
M                ]O________________]V
MTO________________^P                        LO______________
M___A)                       EO__________________40
M            ?/__________________>0                      9O__
M________________H                       4?__________________
MQR,                     //__________________[DL
M        )____________________W0                     $/______
M_____________Z,6                     /___________________]A,
M                     /____________________^(#P
M     /_____________________+4P                   /__________
M____________I3@           D=-$YKC/_______________________YDY
M0U%?;GV.H+7+Y?_____________________________K^?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________KS+FLH9F1BX:!?'AT<&MH9F9H
M\?________________]A13(C& X&                GO______________
M__]^                        =?_________________#
M            4O_________________[-P                      ,O__
M________________:@                      %O__________________
ME@                       /__________________OQL
M         /__________________YD(                      /______
M_____________VD                      /___________________Y "
M                     /___________________[DL
M     /3__________________^A<                     -G_________
M__________^1&                    +S____________________*4P
M                 )W_____________________F"X             $"E&
M9L3_____________________[G\=#!HH-T97:7Z5K\SN________________
M_________^>@JKG(V.G\________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________?7PZ^;B
MW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV,B\N,?__
M_______________2)1$#                     /__________________
M0@                       /__________________?0
M         /__________________L L                      /;_____
M____________W3D                      -S__________________V(
M                     ,7__________________XD
M     *___________________Z\B                     )G_________
M_________]9(                     (+___________________]R
M                 &G___________________^A*
M $[____________________37                    #/_____________
M________EBX              !4R4G?_____________________X'(3   !
M#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________^>#2R,"ZM;"LJ*6B
MGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00  -3_____
M____________D@                       *W_________________S!X
M                     (O_________________^U(
M     &W__________________X                       %'_________
M_________ZD;                     #K__________________]!"
M                 "/___________________5H
M  S___________________^/%                     #_____________
M______^X/@                    #____________________E;0,
M              #_____________________GS<              ! O4'3_
M____________________W7(4      87*D%:=92VVO__________________
M_____[Q81%1D=8::K\CC_______________________________2S>'Q____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________\^_K[_?______________________[KFHG9:/BH:"?WMX=G1R
M<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_________
M_________VD                       #__________________YL*
M                  #__________________\@Y
M  #___________________!C                      #_____________
M______^*#@                    #___________________^P-
M              #____________________56P                    #_
M____________________A1H                   /L________________
M____L4D              !@Y78'_____________________Y7L>       ,
M(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?__________
M__________________^SGK3%U^O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________Z[^?A
MW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;65A75UE>
M97'__________________[\Q'Q80"@4               #_____________
M_____^U6                      #H__________________^"!
M              #,__________________^K+P                    "S
M___________________25P                    ";________________
M___W?!                    "%____________________HC<
M        !2N4____________________RV$"            #"Q0=I[1____
M________________]8TP       -(SM7=IF^Y?______________________
M_\-C&"H[3%]TC:?&Y_____________________________^H?Y:HN]#G____
M_________________________________?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________=SL6_O+FV
MM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&2$M066:A
M__________________^G)@X' @                !6________________
M___.4                      Z___________________T>0L
M           A____________________GS(                    .____
M________________Q%@                (,5J$____________________
MZ7\?           &)TMQFL+I_____________________Z=)      (7+TIH
MBJ[5_/_______________________]-U'B8X2EYUCZO+[_______________
M______________^N<H68K,+;]O__________________________________
MW^__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________O[*JIJ.AH)^?
MH:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.66E]____
M________________GBX&                    ____________________
MPU8                  !5!____________________YWL:
M  DT8(NT_____________________Y\_          0E2G&9PNO_________
M_____________\9F#P   !,J1&*#I\WU_________________________^N.
M-2L^46B!G;S>______________________________^^=G^4J<'<^?______
M____________________________TMCS____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___V\O#O[^_Q\_C]____________________________^+"?FI>6EI:8FY^D
MK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I________
M_____________Z9! 0          !S9CC[KA_____________________\9E
M"@      !"=,<YS$[/_______________________^6(+P  $RI$8H*FS/3_
M__________________________^K4#9*87N6M-;Z____________________
M___________2AWR8L<OI____________________________________U,[M
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________M
MY>/CY.;H[?'Y______________________________VQE)*2E9F=HZFRO-#M
M__________________________^=4T=)35%68'.*K];\________________
M__________^R5@ :-5!MBZ[2]______________________________-;SY?
M>YFWU_G________________________________NGX.FPN'_____________
M________________________X\[K________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________
M
M
M          #_________________________________________________
M____________________________________________________________
M____________________________________________________________
M_P   /_; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)
M"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(
M!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( ( !*0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M6^+QC\1^)(YH/#4;_N( 2CZFPX//58P1@D<DY QR1YI^S=\'Y/CA\7--T/\
M>+99-Q?R+P8[=,%^>Q.0H/JXK]+=+TNWT33;>SLX8[>UM8UAABC7:D2*,*H'
M8  "O)\,^"J69U'F&.5Z4'91>TI;Z]TM-.K=MDT\<OPJJ/GGLANBZ)9^&]*@
ML=/M;>RLK5 D,$,82.-?0 <"K5%%?TI&,8Q48JR1[P4455U?5[/P[I%UJ&H7
M5M8V%C"]Q<W-Q*(H;>) 6=W=B JJH)))P "35>2 DOK&'4[.6WN88KBWG4I)
M%*@=)%/4$'@@^AJGX3\+6G@O1(M-T]9([&V)$$+.66!"<A%)YVCL"3@8 P
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M>I6Y*M#=EA]I4-TW+<!G*\_),F<AJ_0W]C;]M7P/_P %B/V?X?#NM75GX?\
MC#X=MS-=6:IM!884W5N"3YEN_P H= =T9.#QL=OD?%C@%Y[EL<PP"]^*YEZM
M>]%^MM^DEK9,\G$TO;1Y'\2V.T_X)C_$.*P\1^(/#,\@5M0B2^M03C<T>5D
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M;%7C8'(92.00>01SFM'Q!XZUSQ7!'%JFL:KJ4<3;T2ZNY)E0],@,3@U],_\
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M!LXI\?G,3QQS]:[<1AX5<ZIM[Q@W^+2_,MI.JO0\_P#^":W[!E]^W_\ '_\
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M &B/9G>%.%;A0>>E>CD.)HX?&QK5W9*^NKW373U.BC)*5V?D?_P3@_:^TO\
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MXQUL()?Q_P!;7[1_L2_LHV'[%7[.6B_#W3]4N-;CTF2XFDOYXA"]R\TSRD[
M6"@;@H )X7/4FOP:_P""IGB#_A)O^"AOQ<N./W?B&:TX7;_J0L/_ +3Z]ZX^
M&8TGF56=#X$G;?:ZMOJ30M[1N.Q[3_P2)_X*>^!?^"?'@WQQ8^*O#_BC5KWQ
M-<07%O)I,4#J/)1U5)#)*A )D8Y ./0YX\I_X*5?\%%-:_X*%_%:PU2;3O[
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M (-F/$C^(O+O_BOHD.D C]_!HLLERWMY;2JH[C.\^OM7TY=?\$#O@F_[.?\
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M?VSXI\4>'H;[4[W[/%;_ &F9BV6\N)4C7.!PJ@>U>^T %%%% !1110 4444
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M!?\ V!9O_2RXKC?^"'TD=WXN_;+N)IIIM4;]HWQ3#+YK,S+;I]G$ &?X0-X
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biogenlogo2020a01.jpg
<TEXT>
begin 644 biogenlogo2020a01.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "  8$# 2(  A$! Q$!_\0
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MY!90&WTQ) EQJ4J_NHAC) &06;&,*.Y&2H.1P5Z\**=6L[(Z*<'*T(*[.F^
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M=&O]8DB ,BV%J\Y3.<9V@X!P<9]#5/4--O-'OI;._M)[*\A($EO<QF.1"0"
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MW_)*_&/_ &![O_T2]?DY7ZZ>.M#G\3^"=?TBU:..ZO[">UC:4D(&>-E!8@'
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MNGZE9R>9#<0D90C@Y'.002"""""01@D']=;_ $^VU:QGL[RWBNK2XC:*:"=
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M^&=)FMX+^],!CDNV98ALGCD.2JL1PAQ@=<?6OD+_ (8*^(G_ $$_#G_@3/\
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biosimilarsrev.jpg
<TEXT>
begin 644 biosimilarsrev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M.KY,^[-^BL#_ (1G2/\ GC<_^#/5?_DZC_A&=(_YXW/_ (,]5_\ DZ@#?HK
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M,]5_^3JOV.F6>G>;]E25/.V;_,N;NXSLW;<?:IYMF-[9V;=W&[.!@ T****
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MAQLZ;\E&\'>,693N8\%D4_4?6O,/^"D__*23_@A3_P!G6_M0?^L<_$&O8?\
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MNP>.PBRZ6&C56-CAXN;Q2K.'L_J^(Q":C["7-S./Q1MS:M87_",:!_T#+?\
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M*/\ AIOQM_T!/"__ 'XU7_Y:5\XT4?7L7_S_ )_^2_Y!_9N _P"@:G_Y-_\
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M_7I?#/AX*H.AZ.2  2-.M "<<D#R> 3VH W**Q/^$:\._P#0"TC_ ,%UI_\
M&JNV>F:=IWF?8+"SLO.V^;]EMH;?S-F[9O\ *1=^S>VW=G;N;&,F@"]1110
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MS?Y,:;]NYMN[.W<V,9.?Y6O^#<W_ )*'^U5_V)7PA_\ 4B^(%?U8U^8<3_\
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M/\^S#^QLW_Z%68_^$6)\O^G?FCZ K^TG_@@?_P F)3?]ES^*W_H7AROX-O\
MAJ/X'?\ 0T^(/_#6?%[_ .8*OZA?^"0?_!9[_@FO^S5^R3)\.?C;^T;-X$\:
M-\6/B%XB&A7_ ,%/VB+^?^QM9.AG3+X3Z-\(]2M/+NQ:W&U#<"5/*/F1KE<_
M/<38S"5\LY*.*PU:?UBD^2E7I5)V2G=\L)RE975W:RV>I]9P9EV88;./:XG
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M..#R.#Z'T_&C(QG(QZY&/SZ4 &![_F?\:,#W_,_XT$@$ D GH">3]/6EH 3
M]_S/^-&![_F?\:6B@!,#W_,_XT8'O^9_QI:* $P/?\S_ (T8'O\ F?\ &EI"
M0!DD >I.!^M #67(&,\,AZGHKJQ[^@KYG_8R^&?BWX.?LK? 3X6^/+*#3O&/
M@/X9>&?#/B2QM-0M=3MK75],M#%=P0ZA8RRV=Y&CG"W%O(\4@Y1B*^FB0" 2
M 3T!/)^GK2Y&<9YZX[X]: $P/?\ ,_XT8'O^9_QH!!S@@X.#@@X/H?0^U+0
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M/[&G[&?P2^-4_@?1=/\ A^OA+XL_%CQ-X:^*?BKQ0/B=9+H&JV?B;0/%NJ>
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M7-J\4=YXCUJVF>WU35[F&6]O8A%'/*ZP0", ^)?@?XZ_:#U+Q!\$/#7AW]I
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"
M0 22  "22<  <DDG@ #DD]*X+_A:OPR_Z*)X%XX/_%8>'.HZC_D)]JZW5_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>bubbles20192.jpg
<TEXT>
begin 644 bubbles20192.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &A JL# 2(  A$! Q$!_\0
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MVVWHFTO1:!1117BGL!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1535-7L=#LWN]1O;?3[5/O
M3W4JQHOU9B *\K\0?M;?";PXSK-XPM;N13C9I\4ESGZ,BE?UK6G1J5?@BWZ(
MRG5IT_CDEZGK]%?-5U^W_P##&WSY<&O77_7*R0?^A2"F6O\ P4#^&=QCS+/Q
M#:_]=;.(_P#H,IKJ^H8K?V;.;Z]AO^?B/IBBO%M _;&^$NO[57Q2MA*W_+/4
M+:6''U8KM_\ 'J]6T'Q/H_BJS%WHNJV6K6I_Y;6-PDR?FI-<U2C5I?Q(M>J.
MB%:G4^"2?HS3HHHK$V"BBB@ HHHH **** "BBLGQ+XLT7P;IKZAKNJV>D62]
M9KR98U)]!D\GV'--)R=D)M15V:U%?,7C;]O[P#X?:6'0K/4?$]PI(5XT^S6Y
M_P"!O\W_ (X:\9U__@HAXUO-RZ1X>T73$/1KCS;AQ]#N4?\ CM>I3RO%5->2
MWKI_P3S:F986GIS7]-3] Z*_,JZ_;B^+=QGR];L[7_KEIT)_]"4T6O[<7Q;M
M\>9K=G=?]==.A'_H*BNK^Q,3W7WO_(YO[8P_9_=_P3]-:*_/S0/^"B'C6SVK
MJ_A[1=30=6M_-MW/U.YA_P".U[-X)_;^\ ^(&CAUVRU'PQ.V 9)$^TVX_P"!
MI\W_ (Y7+4RO%T]>2_IK_P $Z:>986IIS6]=#Z=HK(\,^+M%\9Z:NH:#JMGJ
M]DW_ "VLYED4'T.#P?8\UKUY;3B[,])-25T%%%%(84444 %%%% !1110 454
MU35['0[-[O4;VWT^U3[T]U*L:+]68@"O*_$'[6WPF\.,ZS>,+6[D4XV:?%)<
MY^C(I7]:UIT:E7X(M^B,IU:=/XY)>IZ_17S5=?M__#&WSY<&O77_ %RLD'_H
M4@IEK_P4#^&=QCS+/Q#:_P#76SB/_H,IKJ^H8K?V;.;Z]AO^?B/IBBO%M _;
M&^$NO[57Q2MA*W_+/4+:6''U8KM_\>KU;0?$^C^*K,7>BZK9:M:G_EM8W"3)
M^:DUS5*-6E_$BUZHZ(5J=3X))^C-.BBBL38**** "BBB@ HHHH **** "BJV
MH:E::1:/=7UU#96L?+S7$@C1?JQ.!7EOB']J_P"%'AMG6X\965S(N1LT])+K
M)] 8U9?UQ6L*52K\$6_1&4ZM.G\<DO4];HKYMO/V_/AA;$B./7;K!ZPV2#/_
M 'U(*@M?^"@GPSN,>99>(K7_ *ZV<1_]!E-=7U#%;^S9S?7L-_S\1],T5XEH
M/[9GPEU[:I\3'396_P"6=_:2Q8^K;2O_ (]7JOAOQCH/C&U^TZ%K-AK$&,F2
MQN4F ^NTG'XUSU*%6E_$BUZHZ(5J53X))_,V****P-@HHHH **** "BBB@ H
MHHH **Y+Q;\6O!G@1BFO^)]+TN8?\L)[E?-_[]@[OTKR_6?VXOA-I4FR'6+S
M5".IL["7 _&0+G\*Z:>&K5=80;^1SSQ%&GI.:7S/?:*^8Y/^"A'PU20*--\2
M2+_?6SAP/SF!_2M/3?V\OA7?2*LUSJVGJ>KW-@2!]?++'\A6SP&*6OLV8K'8
M9_\ +Q'T317G7AC]HCX:^,)$BTOQGI<DTGW(;B;[/(WL%E"DGVQ7HBL'4,I#
M*1D$=#7).G.F[337J=<:D:BO!W%HHHK,L**** "BBB@ HHHH **** "BBB@
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M3V;X9_%/P_\ %K09=5T">9D@F:VN;6ZA:&XMIEP3')&W*G!!_&KOQ \$Z?\
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M\*CW:/@,725&O*"V3"OK#]D?]K"3P7<6?@KQA=&3P](PBL=0F;FQ8G 1R?\
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M3S"%)#;NK+$LBK\H499ACC ]IU?2K;7--N;"[0O;SIL;:2K#T((Y!!P01R"
M:\F\$>+M7^'&N:CX5\8PH--21KC3=;@_U<L3,2WF)U3!.21E5)(.U=F?E:4W
M*BX)7:_KYGU-2*C4YWU/08O#=[<:3%&GBK6@S/YPNFCM5F*E>$(,& ._W=V>
M_:M;5-(AUBQ6TN7D*++#-N4@-NCD613T_O(,_C4MOJ5I>6@NH+J&>U8;A-'(
M&0CUW XKSSQI\2;;5)$\->&[ZWGU74%D1;K[0(HMJX\R.&4@J\Y!PJC.TG<W
M P>6,9U):=/P.B3C!:C_ (13IJ6H>)M1MY!+:3W;"-U(*G,T\HQC_8EC_,5W
M/B+4%TCP_J=\^-EK:RSMN&1A4+?TKSGX4QMX,T^.T@MQ/H-]=,JR6L)66SN=
MP0I<1 90MA2Q'"ONZ*5Q@_MH?$:'X?\ P#UZ(3B/4M<3^R;2,'YG\WB4_01>
M8<^N!WK:5-U*ZA'JS%5%3HN4NB/R[L?^/=:L5';KLB45)7Z4MC\[>X4444Q'
MT%^QE\:C\,/B5'I&HW'E^'M?9;:;>WR0SYQ%+[<G:3Z-D_=%?I=7XGU^J_[+
MWQ2_X6Q\'](U&XE\W5K(?V?J&3\QFC &\^[J4?ZL?2OD<ZPMFL1'KH_T/JLG
MQ-TZ$NFJ_4]9HHHKY4^F"BBN4^*_BD^"?AGXHUU6VRV.G3S1'_IH$.P?BVVJ
MC%SDHKJ3*2C%R?0_,+]HSQ\?B1\9O$^LH^^T^TFUM>>/)B_=H1_O;=WU8UYO
M117ZE3@J<%".RT/S2I-U)N<MV%%%%:$!45Q$)HBI&:EHH ^[OV%_VEK?Q+H5
MM\-_$EVD.O:9&(]*FF?'VVV4<1#/62,#&.Z@'^%C7V%7XBS021S17-M+);W4
M+B2*:%BKQN#D,K#D$'D$5];_  5_X*):EX;M8M)^)FFSZS!& D>N::B_:,=/
MWT9(5_\ >4@\?=8\U\;F&63C-U**NGT/KL#F47%4ZSU74_0.BO'?#O[7WP=\
M36\4MOX]TJT+C_5ZDYLV4^A\T+_A1XB_:^^#WAFWEEN/'NE7A0?ZO37-XS'T
M'E!O\*^?]C5O;E=_0]SVU.U^9?>>L76EV=\MPMQ:0S"XA-O-OC!\R,YRC>J\
MGCW-?'G[9_Q]T[X<^"(?A+X/N5?4[BT6ROG20R&QLPH41%L_ZQUXYY"Y)^\I
MKB?C5_P42U+Q';2Z3\,M-GT>"12DFN:FB_:,'C]S&"53_>8D\_=4C-?),,,L
ML\MU=327-U,YDEFF8N\CDY+,QY))YR:^AR_+:DI*=;1+H>%CLQ@HN%'5OJ26
MT(AB"U+117V)\F%,ED$4;N>B@FGU3U:3R[)_]H@4T2S!9BS%CR2<FEBD,4BN
M.JG--HK<P.J5@ZAAT(R*6JNF2>991^J_+^56JP-PJ*XB$T14C-2T4AGW=^PO
M^TM;^)="MOAOXDNTAU[3(Q'I4TSX^VVRCB(9ZR1@8QW4 _PL:^PJ_$6:"2.:
M*YMI9+>ZA<2130L5>-P<AE8<@@\@BOK?X*_\%$M2\-VL6D_$S39]9@C 2/7-
M-1?M&.G[Z,D*_P#O*0>/NL>:^-S#+)QFZE%73Z'UV!S*+BJ=9ZKJ?H'17COA
MW]K[X.^)K>*6W\>Z5:%Q_J]2<V;*?0^:%_PH\1?M??![PS;RRW'CW2KPH/\
M5Z:YO&8^@\H-_A7S_L:M[<KOZ'N>VIVOS+[SV$*%)( !/7CK7R!^W3^TI;^&
M=!N/AQX;NTFU[5(S'JLT+9^Q6S#F,XZ22 XQV4D\;E->>?&K_@HEJ7B.VETG
MX9:;/H\$BE)-<U-%^T8/'[F,$JG^\Q)Y^ZI&:^288999Y;JZFDN;J9S)+-,Q
M=Y')R69CR23SDU[^7Y9.4U4K*R70\/'9E!1=.B[M]22VA$,06I:**^S/D@HH
MJ*ZD\FWD?N%.*!&!>S>?=2/VS@?2H58JP8<$'(I**Z#G.HBD$L:..C &GU3T
MF3S+)1W4D5<K!FZ"F2)YB$4^BD,^MOV$_P!I2W\,S)\,O%%TEM8S2L^B7L[[
M521VRULQ/ W,2R_[1([J*^^J_$6^LDNHR"*^E?@3^WIXD^&=K;:%XYM)_%6@
M0*(X;Z$C[? HX )8A9@/]HAO]H]*^1S'+).;JT5ONCZK+\QBHJE5>VS/TEHK
MQ'PK^VA\'?%EK'+'XSM-+E;AK?5E:U=#Z$N I^H8CWK6UK]J[X0:#"\ES\0]
M#F51N(L;D7;?@(MQ)]J^;]C53LXN_H?0>VIM7YE]YZQ7SQ^V!^TK;?!;P?)H
M^CW4<GC;5HS':PHP+6<9X:X<=L=%SU;GD*:\@^,'_!1^WEM)=.^&.D337;94
MZUK$06.,?WHH<Y8^A? &.5:OC._O]2\2ZU>:UK=]-J>K7DAEN+JX;<\C'^G8
M <   5[>!RN=22G65EV/'QF90IQ<*3N^Y#9PF&/YCECR2>IJQ117VR5E8^.;
MOJ%%%17,GDV\C]PIQ3$8%]-Y]U(_;.!]!444ABD5QU4YIM%=!SG5*P=0PZ$9
M%+573)/,LH_5?E_*K58&X4R1/,0BGT4AGUM^PG^TI;^&9D^&7BB[2VL9I6?1
M+V=]JI([9:V8G@!F)9?]HD=U%?67[0OPMU#XR?"O5/"VF:N-&NKIXG\Z12T<
M@1PQC?'.TX[>@X-?D;?62W49!'-?2OP)_;U\2?#.UMM"\<VD_BO0(%$<-]"1
M]O@4= 2Q"S ?[1#?[1Z5\KC<!4A5^LX??>WF?3X/'0E3^KU]MKGO,/\ P3_\
M,7G@OP=H^I:S=+>:3-+/J-Q9H%74#*5+KSR@ 155AS@=,]/J'2M+M-#TRTTZ
MPMX[2QM8E@@MXAA8T4850/0 5XYX5_;0^#OBRUCEC\9VFERMPUOJRM:NA]"7
M 4_4,1[UK:U^U=\(- A>2Y^(6AS*HW$6-R+MOP$6XD^U>#6GBJ[4:MW:_3N>
MY2CAJ2YJ;2^9W>FZ%<6?C#7-5=XS;WT%K%&JD[P8O-W;AC&/G&,$]^E>*_M@
M?M*6WP7\'R:/HUU')XVU:,QVD*,"UG&>&N'';'(3/5N>0IKR#XP?\%'[>6UE
MT[X8Z1--=ME3K6L0A8XQ_>BASECZ%\ 8Y4U\9ZA?ZEXEUJ\UK6[Z;4]6O)#+
M<7=PVYW8_P"< #@  #BO2P>6U*TU4K*R70\W&9C3I0<*+NWU(;.$Q1\DECR2
M>I-6***^U2LK'Q[=]0JAK$WEVNP=7./PJ_6+K4FZX1.RK_.KCN1+8SJ <<CK
M116QB=/;S>? DG]X9J2L_1I-UJ5_NM6A6#T9NM@K2\'>--5^&7C32/%>B.$U
M'39O-16SLD4@AXVQ_"REE/L:S:1E#+@UG."J1<9;,TA)PDI+='Z]?!_XN:#\
M:O!%EXCT*=6250MS:,X,MI-CYHI!V(]>XP1P:Z?6M!T_Q%:"VU&U2YB5@Z;L
MAHV'1D88*L/52#7X\_#?XG>*_@GXH_M[PC?_ &6=P$N+65=]O=(#G9(F>1UP
M1AADX(K[C^&/_!1;P'XCM[>V\8VUWX/U7 664Q-<6;-ZJZ N ?\ :7 S]X]:
M^$Q66UL//FIJZ_$^UPN84J\;5'9_@>V3? G0)KKSOM%UUSMD@M96_&22%I#U
MZEL^]=%:_#GP];6%S:/IRWBW*".:6\8S2NHY WL20 >0!@ \C%<K;?M/?"2[
MM3<)\1O#:H/X9=1CC?\ [X8AOTKA/'?[>WPD\'6["QU>X\57N/EMM&MV<9[9
MD?:@'T)/M7$HXFH^5)G:Y8>FKMH]0T_06\"W%_K6I:['!I=O&3<W5V^/.MU3
MY'G8X DCQM\W.70 ,"0"/S<_:@^/4G[0'Q'^T619/"ND;[?2XV!!D!(WSL#T
M+E1@=E51US5?X[?M1^,_VA9C97@70?"J2>9%HUHY(<@_*TTG!D(^@4<$+GFO
M,(85A0*!7U&7X"5.7MJWQ?D?-8_'1J1]E2^'\Q_2EHHKZ,^?"BBB@ KZS_X)
MZ>/#I/CS6_"D\F(-7M1<P*3QYT.<@#W1F)_W!7R97?\ P!\5'P5\:/!VK[MD
M<6HQQ2MZ12'RI/\ QUVKCQE+VV'G#R.O"5?8UX3\S]<:***_,S]%"O"?VV-:
M.C_L[^((U.U[Z:VM5/UF5S_XZC#\:]VKYH_X*!3F'X&6JCI+K5NA_P"_<S?T
MKNP,>;$TUYHX\9+EPU1^3/SFHHHK]*/SL***T-!\.ZMXIU!;#1=,O-7OF4LM
MK86[SRD#DD*H)P*3:2NQI-NR,^BMAO!NOKXC_P"$?;0]2&O;@O\ 99M)/M6X
MKN \K&[.WGITYJ>Y^'_BBS\06^@W'AO5X-<N%WPZ9)82K<R+@G*Q%=Q'RMR!
M_"?2IYX]RN678P*BDMTE^\N:W_$G@GQ%X-:W7Q!H&J:&UP&,(U*SDMS+MQNV
M[U&<9&<=,BK&E_#GQ9KBV;:;X7UK4%O(GGMC:Z?-*)XT8*[IM4[E5F4$C@%@
M#UHYX6O?0.65[6U.-DT>!^=HHCT>!#G:*Z30O"NM^*&N5T;1[_5VMH_.G%C:
MO.8D_O-M!VCW/%9=+EA<?-)(BCMTB^ZN*EHHK0S"BBB@ K,UQOW,:^K9_3_Z
M]:=96N_\L?\ @7]*J.Y,MC)HHHK8Q-G1&S;R+Z-G]*^B?C#^R?JWPC^&>D>+
M)M5&HO.T,>HV*6NPZ?))'N +[VW@-\N<+R5]:XW]COX>CXC_ !JT>SG7.G:>
MXU2\SC'E0G< <]F?8I]F-?:Z^(OA=\=/^%@^$?#_ (VN-9UGQ=!YZV-[;2+;
MVT\$2HDD.Z%,X\N)B-[$^7D8Y->!CL7.C6C&&RUEI?1_EU9[N#PL*U%RGN](
MZVU_7HCXXF^ M[)\$_#?CS3KV?5+[7-6;2H="M;%GDW 3?,KJQ+D^3]T)_%U
MXYY;4_A'XZT73Y[[4?!?B&PL;==\US=:5/''&H[LS( ![FOI3_A&/$]Q^RA\
M-- T/[1I_BH>-9+6$PRF*2WF4WJL=ZG*[<,21T -;_[36I>,_ OPCMOASI5K
MXI\3Q+:K<^(O%]Y;W,T3C.]HUF;("Y&6^;"H I))?&4<94]I[--.\FO1)_UZ
MFDL)3Y'-IJT4_5M?UZ'@_P 9/V7_ !+\,_%DFD:-;:KXRLX;..[GU&QTB41P
M[B_RMM+@8"9R3T/2O+?#_@/7O&[7":#X?U+77MPIF73;.2X,8.<%MBG&<'&?
M0U^@?CCQYXAL_P!MKP/X;@UB\@T";3&>;38Y2()6,=R2SIT8Y1,$]-HQBJVE
MQV$/PKOX]'7Q@ERGC;4EO5^'GD_;1,+J;RQ<;_\ EGY?DYSQC9GY:PAF%6-.
M/M$FVEKZWW^XWE@:4JDN1M)-Z>EMOO/A_P !?!2T\9V_BQM1N]2T>ZT&U:?[
M/!H5Q?%Y%#YCE,8_T< I@M)P.?0UEZ;\#?&.H0VTUEX*\07<5U"+B"2#2YW6
M6(XQ(A"?,IW#YAQR/6OO8ZE;:IX\^.4\6CW.AWO_  B$2W]M>/;/*9Q%<?,W
MV>61 3'Y?5L^PXK+C\9:WH<G[+6D:=J=Q9:;J6GQ?;;>%RJW(%O H5P/O !V
MX/&3GJ 0?79N3<8KY]/=OT#ZG!)7E_7-;J?#/_"O_$%KX=.O-X=U2/0E;8=4
M:RD%L&#[,>;MVYW_ "]>O'6I[/P!XHU#P_)KMKX;U>YT2-6=]2AL97ME5?O$
MR!=H P<\\8K[AU#Q/JWB#7/VH],U#4;FZTW3]%86EG)*6AM\6DW^K0\(25!.
M ,GD\UWLU]!IWBSP1<>'M.\=ZMHZ:(GV*R\-M9KX?EA,;#$QE=%W[2"-S#HF
MWN*N693BK<B^_P D_OU(CE\):\S^[S:_0_.C1OAEXQ\16%O?:3X3US5+*X+"
M&YL]-FFCD*DA@K*I!P00<=,&NJ\1?!,Z/\,?#/B:TU@ZIK&KZB^E3>'H+0^?
M9W"EAY3$.6,APGR%%;YQ^/O/Q)\=W_A#]DS0[KP7?W?ARVO?%E_'"VGW"QR)
M;?:+QTC$D3$8^5.48@[>"0>?(?V<_'GC ?%+PA%I6G1^+)]&2\-AHMQ>0V>[
MSE<S,LCX!D.[)8[F*H!T48ZU7K5(2JJR46_G:^[>VMCF=&E3G&F[MR2^5[;+
MKU/,?$G@/Q+X-2!]?\.ZMH:7!(A;4K&6W$A&,A=ZC.,CIZBN7U9MMBX_O$#]
M:^X/C]I&L^(_@IXMUNVU7QGHFC6NJ++=^&O'=I$[2R-)$%-G.Q,B1)N.%#L&
MP0,9.[X;UH_Z(O\ OC^1KJP==XB',]T_Z_K4Y<515"7*MFC$HHHKTSS38T-O
MW,B^C9_3_P"M6G65H7_+?_@/]:U:QEN;1V"N\^!_PM_X7+\1K#PK_:?]C_:H
MY9/M?V?S]NR-GQLW+G.W'7O7!U[S^Q!_R<7H'_7O=_\ HAZY,5.5.A.<=TF=
M6'BJE:$);-H/#?[)^I:I\>=5^&FIZS_94EG;/>0ZFMD94N81MV,J%U^\'YPQ
MVLK+SBO)M,^&OB/Q5<W\6@^'M5\0)9R^5-)IMA+.$.2!NV*=N<'&?2OT2^ O
MC+2_B]XBNM5O1&GC7PA/=Z--(HPUQ9/(?*8\\_ZL<\X97/&^N6\%R6<?P4^'
M+Z%'XYF5=4F,\?@;R<M=^>VX7OFD?NBV[[Q"8QNXVUX:S"M%N,UJK+ROJ[_.
MR/:> I22E!Z.[\[::?*Y^?5OX!U+5-'O-8M=&OKK2;-@MU?0VSO! 3C >0#:
MI.1U(ZBK5C\)?$5]#IEQ:^&-6N8=39DL9(;"5UNV4$L(B%PY 5LA<XVGTK[N
M\66X\=>"OVA--\.:%>P:Y-=64UQH?[B6X6;RXBY"P/(K%O+=L!B2P<=>*O>!
M?#NH^$_#/[.&EZM:26.H0W]V\MM,I62/?;7#A64\JV&&0>0>#6LL>N7FY5?M
M_P!N\W_ ,E@7S<O,[=_^WN4^$K_X6^*?#T=J^H>%=9T]+J<6MNUUITL0FF)(
M$:%E&Y\@_*.>#3/$G@CQ'X,-N/$&@:IH1N-WDC4K*2W\W;C=MWJ,XW#..F1Z
MU]A?"/QYJ'B[]KCQY::UJ\MY>6']J0^&[*^N"UO;SI*(P(8V.%?R5;.T<KYA
M-9FF_P#"7_\ #./Q2'QI.I"V:^@72VUG?]I6[W?,8=W/E@^7MV?)CS<9&ZM_
MKLXR4917V?7WNW>W4Q^IPE%N+?7T]WOZGQM17L7QG\,_!C1/#MG-\-_%VL>(
M-8:Z"7%OJ,3(B0;&)8$V\?.X(.IZGCN/':]2G456/,DUZJQYM2FZ<N5M/T=P
MJGJS;;%Q_>('ZU<K/UK_ (]%_P!\?R-;+<Q>QB4445N8&SHC9MY%]&S^E:59
M6A'B8?[O]:WM,TN]UK4(+'3K2>_OKAMD-M:Q-))(WHJJ"2?85A+1NYO'5(K4
M5L:OX-U_P_J\&E:IH>I:;JEP%,-C>6DD4\FYBJ[48!CD@@8')&*7Q)X*\0^#
M7@37]!U/0VN QA74K.2W,@&,E=ZC.,C./45GSQ=K/<OEDKW6QC4R2%9!\PI]
M%624)-)ADR2HIL>BP(<[16C14<D>Q?-+N0Q6L<7114U%%40%%%%, KG=2;=?
M2GWQ^E=;JFCW^AW0MM1LKC3[DHLHANHFC?8RAE;# '!!!![@@UQ]X<W<W^^?
MYU<-=41/31D-%%%:F1J:&WS2KZ@&M>L71/\ CZ?_ '/ZBMJL9;FT=@HK2\/^
M&-9\67QLM#TF^UF]"&0V^GVSSR! 0"VU 3@$CGW%+XB\+:UX1ODLM=TB_P!%
MO'C$JV^HVSP2%"2 P5P#C((S[&L^:-^6^IIRNW-;0RR,]:KS6,4W515FM2/P
MMK4OA^374TB_?0XY/)?4EMG-LLG'R&7&T-R.,YY%#MU!7Z',G1(,_=%30Z7#
M#T45I6-C<ZI>V]G9V\MW>7$BPPV\"%Y)78@*JJ.222  .236C'X-U^73-0U)
M-#U)]/TZ3R;V[6TD,5L^0-DCXPC9(&&(/(J;0CN5><C&50HP!BG44L<;2.J(
MI=V. JC))]!6AF)16EX@\,ZQX3O_ +#K>E7VC7NP2?9M0MG@DVG.&VN <'!Y
M]JS:2::NAM-.S"BBBF(*=#,]O,DL;%)$8,K#J".0:;10!^T.@:H-;T+3M148
M6\MH[@#V=0W]:OUR'P=N/M7PC\$3_P#/30[%_P [=#77U^537+)H_38/FBF%
M?-G[?MOYWP)B?&?)U>W?_P <E7_V:OI.O&?VPM$_MS]G?Q8@7=);1PW:>WES
M(S'_ +YW5U8*7+B:;\T<^,CS8>HO)GY:T445^EGYT%?0?["G_)P6G_\ 7C=?
M^@5\^5Z#\"?BU_PI7XA6_B?^RO[9\F"6'[+]H\C.]<9W[&Z?2N7%0E4H3A%:
MM,Z<-.-.M"<MDT?:VH:#:Q_$VW^.4Z1'3K/P?/<S!1EA?1 QD#U^1F3_ ("/
M7AGQ"^*GACX8_M-ZP/$5X^AOJOA6"TM->BMQ,]D_G3'A=C<$[3RI7,:[ABOE
MF\_:@O[OX&:O\.!I'E1WUY)<)J*7A!BA>Y^T-#LV?-EBP+;AD-TKK+[]MN\O
M/B3J/B ^#[.?0=6TR+3-3\/WMSYZW*1F4JPD,8 _US @HP()!'((^?\ J%>_
MO1NDFEJEII;OY_J>[]>HV]V5FVGLWKK?MY?H=S^T%!X]U[X*:NR>-/"GQ=\*
MVES#/=:Q96D<>H:=*& Q&L#F((%(RQR^V9\@*,CMOACJ"^'?VC+3PA!(TT'@
MWX?I921XV@W!>WED;IU8-'GTQ]:\,U[]LBRDTFVT?PQ\-='\(Z-+>PW6JVUA
M*BM?1QR(_E I"@3<$*EBK\-T'?E_"'[3ESX;^-'BWX@W6A?VE+KUM/:BQ%YY
M7V='>,I\_EG=L6-5^Z,]>.E:+"5Y47"4+;VV6KMVT[[&?UJA&JIJ5]K[[*_?
M7L?6'@3P3I*^*/&/Q'\*.DWA3QEX;END\O'[B[#'SHR ,*2><9SN$@XVUYW\
M,_V5?#W_  @O@.YO? =YXW?Q);)>ZGKB:T+$:1'*B-$(X-Z^:%5R3U.5)YR$
M'C/P1_:IU/X/^"=<\+3Z2=?TN^#FV5KPPFS9U*OM^1\J>#MXY!/\1I_AO]I;
M1_\ A%?#.E^-?AWI_CB]\,QO;Z3?7-ZT"1P$*%CFA",DVW: -W& .-V68>%Q
M=-R4'IIUU:2=NJVTOK]X+$X6:BY+77IHFVK]'OKT^XZ;Q[^S[X=^'_P5^)%Y
M+:M>>(-!\4KIUEJ;SR!OLK);.BL@81EMLQR=N<D^@QV?@K]GGX?ZMK7P6@N]
M \V+Q%X<N;_4U^VW"_:)TA@97XD^7!=CA<#GITKQWP3^TA8Z3X5\4^&/$_@3
M3O$7AW7=1&J'3K"Y;2X[:7Y/EC\I3A!Y<> ,'@Y+9KK1^VE''XO\$ZW#X%M[
M.'PSI]SI\>GVNH[(I%E2-1L_='RU41\+\W7KQ6TZ>-LXJ]]=;_W;+KW^XRA4
MP=U)VMII;^]KT[%_PO\ #WX6>/O$?B^^B\)W6A^%/A[;W$^H);:M+<W&ME6/
MEYWX$0*P2DA".9 -P R,76/A9X.^+WP:?QM\/?#=SX2UFPU:'2)]#DU%KN&Z
M::2-(RLLI!!)FCY.T## CHU>??"_X[ZA\,O&&NZG%I=KJVC:\)(M4T6].8KB
M%V)*;L<'#,H)!&&.5.<5K>-OVB(K[P39^$/ OA:+X?:!#>+J,JVM_)<W,UPK
M;D<SL%88(0CJ047!  %;NCB(U%R-VTUOI;JFKZM_TT8JM0E3?,E?72VM^EG;
M2W]7.3^)'P1\:_".&PE\6:+_ &3'?,Z6[?:H)MY4 M_JW;&-PZXZUYEK@^2$
M^YKL/$GCSQ+XR2!-?\1:MKB6Y)A74KV6X$9.,E=['&<#IZ"N4UE=UH#_ '6!
MKUJ//9>TM?RV/*K<EW[.]O,PZ***ZSE.K\"^*M;\+?;WT;6+_2&ND$,YL;IX
M/-3GY6VD;A['BKFCZUJ'AW4H=1TJ_NM,U"$DQ75G,T4L>00=KJ01D$C@]":P
M]%7;:LW]YJT*YY15WIN=$9.RUV.E7XF^,$\G;XKUQ?)NGOHL:C-\EP^_?,OS
M<2-YDF6')WMD\FK&H?&#QYJ]C<65]XV\17ME<(8YK>XU:>2.1",%64O@@CL:
M[W]CSP_I?B;X]:)I^L:;::M82071>UOH%FB8B%R"58$'! /2O<_#WC;X5?%[
MXG:A\*[[X0Z1H'VB:ZLX-8TL0I,)8"S!LI%&T8(C8\,W.%(*DD>57KPHU''V
M5[*[>FB_I'IT:,JL%+VEKNR6NK/D&X^(7BF[\06^O3^)=8FURW3RX=3DOY6N
M8UP1M64MN PS< _Q'UI='^(7BKP[>W]YI7B76-,O+]_,N[BSOY8I+ELD[I&5
M@7.68Y.>6/K7O^L_ ^\7X(:/I=L/#DFH3^,F\/Q7IT@Q7SR?:)H09+L2,3%E
M<[/+X&.3CGGOB=^S+X?^'MGKT$7Q.TZY\3:+$D\^B:E8/IS3(REO]'DD<B=L
M#@(#GH2"0#<<3AY/E^6W9^FB(EAZ\?>^>_=>IXU8^-/$.ER:G)9Z[J=I)J@9
M;]H+R1#=AL[A*0WSYW-G=G.3ZT]O'GB5Y-(D;Q#JK/HZ[--8WLN;)< 8A.[]
MV,*H^7'0>E>UZ+^R3;W%OX>TS6O'VGZ#XX\169O=+\.R6,LH=2A9!+.IQ$3M
M8<J>5(7<1BL+X;_L[6/BF2YM/$WC6U\,:V-2?2[?0K*S;5M0DECW^:SP0/NC
MC4H?G.0=K$X&TM?UG#6<NWD_3335>A/U?$74>_FO7OI\SS(>/O$ZS:M,/$>K
M"75T\O49/MTNZ]3!7;,=W[P8)&&SP33K/XA>*=/\/R:%:^)=8MM$D1XWTV&_
ME2V97SO4Q!MI#9.1CG)KVS3?V-]0_P"$Z\<:-K'B:#3=(\*V\5W-JEM8R7<D
M\4JNT3+;H0V=L;[ADE2N!O!W5SR_LVQ^(OB%X=\.^"?&NC^+[/6K=KH:A#F)
M[.-%#/\ :(,LT1P1A6Y)XP#G"6)PTM+[:[:;7WM;;Y@\/B8ZV\M]=[;7ON>3
MS^)M8NM!MM$FU:^FT6VD,T&G27+M;Q.<Y98R=JD[FY S\Q]:HVMU-8W,-S;2
MR6]Q"XDCFB8JZ,#D,I'((/.17L'Q!^ .FZ%X$O?%_@WQM:^.M%TN^_L_5)(K
M)[-[60[0C*&9A*A+ ;E.,E<;AN*G[3VB:7X+\4>'/".G6=C;7.AZ%:0:G-:V
MRQ/<7C)OD>0@98D%.I.,UK"O3FU&'6_EMO=/U7WF<Z%2"<I]+>>_9_)GG7B+
MXA>*?&%M%;:]XEUC6[>)_,CAU&_EN$1L8W .Q ."1GWKD=:'^AC_ 'Q_(U?J
MIJB[K&3VP?UKKC%1T2L<LI.6K9S]%%%=!SFOH8^68^X_K6I5#1EVVA/]YB:O
MUC+<VCL%7]#\0:IX9U*/4-'U*[TF_C!"75C.\,J@C! 92",@D=:]C\ _LXZ1
MXG^#[?$37O'4?A;2(;UK2X632WNB@W*JLNQ]SDLRC:%X&3GBNVF_8@L;/QG#
MX7O/B;I\&KZE"USHMJNFR/)>Q)'N=I!OVQ8(8 ;GW!6(Z$#SIXW#Q;C)[7OH
M^F_3IU/0A@Z\DI16]NJZ[=3YNT;QEK_AS5I]4TG7-2TO4[@,LUY9W<D,T@9@
MS!G4@D$@$Y/) -6/#_Q"\4^$UN%T/Q+K&C+</YDRZ??RP"5O[S;&&3[FNV\;
M? :?P/\ "+2O&EUJZS7-WK%QI$NF);X6%XGF1G$N_P"8$P'C:/O=>.>]7]C&
M\G^*=CX1@\4(]K)X?3Q!=:BVGMOA1I'C$20K(QD;<H_B7@GN &)8C#6;DU;7
MIV_R_P"&%'#XBZ45KIU[_P!?YG@>@^+M=\*ZA+?Z)K6H:/?3(8Y+JPNI()74
MD,5+(02"5!QZ@>E7V^)WC%I+20^+-<,EG-)<6SG4ILPRON\R1#N^5FWMEAR=
MQSU-=SXD^ ^FMJ7ABU\#>.M,\;G7;P6"P"%K.\MIMY4F6V8M(D8P27(' )QC
M!/1>,OV7='\.^'?%USIGQ)TW6-;\)I&VL:7+9/:I$SY&R.=G*R/N!4*!RV%.
MUB 6\1AVU?=^3]-=-.VH*A7L[;+S7KIKKWT/"GU>^DU9M4>]N'U-I_M)O6E8
MS&7=N\S?G.[=SNSG/-7_ !)XW\1^,C;GQ!K^J:Z;?=Y/]I7DEQY6[&[;O8XS
MM&<=<#TKUKQ-^S#_ ,([\;/"7P]_X27[1_;UG%=_VC]@V^1O,HV^7YIW8\KK
MN'WO:NQN/A7H_@W]FWXT6\]I8ZKK.@>(XM/M]:DLD6X"+/:J=C'<R AF^4-_
M$?6IEBJ'N..K=K>C=BHX:M[REHE>_JE<^6J*^F/#O[&^G^+M+NDT+XDV.M:_
M:V7VF:WT_399].27:#Y)OT<Q[N>F-V.=N*Q;7]FGPWI_PK\->.O%'Q(7PYI^
MM(1'#_8DETZR_,5C&R3+ A&)8A0, =ZKZ]0VOY;/_(GZG6WMY[K_ #/ :H:U
M_P >@_WQ_(U?JIJB[K&3VP?UKO6YPO8Y^BBBMS UM#'RS'W']:]B_9E_Y+[X
M&_["4?\ 6O(M%7;:LW]YJ[;X9>-/^%<^/M"\3?8_[0_LNY6X^R^;Y7F8_AW;
M6Q]<&N/$1<X3BMVF=E"2C.,GLFC]"/&W@&'XH?%GP%XP<0B#POJNH6NI[ARH
M@9I+<Y]F53@_WS^//_%;P+I/[1GC#X5W6J3S6V@MX<NO$%S'#\LLL1^RD1@_
MPY,JY[X!Q@X(^>H/VQ+^UTGXF6$'A_RD\8SSW,,BWY#:>\L(B<@^7^\.%0C[
MF"M5H/VOM7TF[^'=QI&B0VC>%='_ +%N8[BX\Z/4H"D*MD;%,>3"K#!;!QU
M(/S$,#BH-..CBFEJM+IO\W8^CEC,-)-/[33?R:_17-RQ\'_"WXM^ ?%GBCPG
MX0N_"]UX+D2]GTV?5)KB'5;,G=MD9B6B<K%*,1GY2W5L@KV#_LU>!+/XI:GX
MDET]Y_A)#X7'B&*,7,VPDI@1B0/YA/RM)][/('(XKQ_QE^T5IMYX&U?PIX&\
M"V?@/3=<G\_5GAOI+J:XPRE41BJ^6@PP* %<,0 H+;F77[3FJW7[/D/PP.GX
M*E8GUC[4=[VRR&18?+V\ <+G<1M&,<UW.CBFO<;2;M9N[2=KN]][WMK?4XU6
MPR^))M*]TK)M7TM;;OTT/<?AK^R_X<N/ G@S5;KX?7'C6?Q-MO+^\AUHV,6B
MV\FTH(XS*&EVJV<$L3M//(%9,GP#^'7PK\"?$_5/%.AW7BJ3POKD5O9LE]);
M2S0R1VKQ1.4;8/\ 7X9PN<;B,' 'F'A?]I32(_!OAO0_&_P]L?'4GAMF&DW<
M]ZUOY49QB.2,(RRJ-H&&X(5002,G'D_:">X^$OC3P6_ANRM6\2:HFI?:--*V
MMO9A6A(BCMU3&T"$#.[/.3DY)A4,8YOFD[777I?IKV\E\RO;8107*E>W;K;K
MIW\W\CZ'N/@S\&=/\>?#W3_^$)OKJ+QY9_:(8)-8G6+3 L(DRN#OD9RX!#/@
M;<CT.7X0_9-T?1?#OB/5#X,O/B9J":]=Z98:2^LKIJPVL,SQB:24,N7.SD#/
MWEPHY->67G[57VKQ9\,-;_X1?;_PA-F;3R/[0S]LS$L>[=Y7[O[N<8;K3V_:
MFT_7[7Q)I/C#P';^*?#6I:O)K-GI[ZG);2V$KL2P69$RP^8] I^9NH.!'L,:
MDK-^>OF]M5TMU7K<OVV#;=TO+3R7D^M^C^X]ATW]E/P!H/Q6\<Z9K6GW=[H$
M.@1:Y8PM<ND]B'>970,CX<J8FV[L\8!W<D\]X3\(_#37O!/@SXF:%X(FT*6Q
M\4P:;=Z4VL3SI<;V54?S&Y!1WBD& H.UE((((\W\,?M11>&?$WCC4[;P1I=E
M9^(K#^SK?3=)*64-C& P5CMB/FO\V68@$GI@84<]X>^/4WAOX,?\();Z,KSK
MK4>LQZF]S\JLC(P0Q;.1F/KO'7I6GU?%/XI-_#UZ6][2_P#70CZQAE\*77IU
MOIK;^NIW'[>&I:5<_&J>SM-&^QZI:PQF]U+[4\GVT-%&8QY9&V/8 1\OWLY/
M2ODN]&+R;_?/\Z]W^/WQDTOXW>(+37;?PF/#FL;"E_<KJ+W(O,*BQ_(558]@
M1ONCG=STKPW5%VWTGO@_I7KX&$J="$)*S2]?\SR<;-5*TIQ=TV5****] X#1
MT3_CX<_[']16U65H:_ZYOH*U:QEN;1V/K70/&VI_ ?\ 8Y\->(?!D<%AKOB;
M5YH[_57@69T\N29450X*_=A  8$ -(0-S;AJ:3XTU/\ :*_9=\6W?CM(;^_\
M/ZA UEJRP+"[EG3<AV@*#M?8=H'#KD9Y/D'P7_:9N_A?X9O_  KK?AVQ\;>$
M+I_._LC4F $<NY6RI9'79E0VPJ?F 8$'.=/XD?M177Q(TO2/"&@>&-.\$>$4
MNHI9-,T_#>;()2_)5$4)N(;:$SN&23G ^>EA:GM'[FO-?FNMNW?;2VQ[\<33
MY%[^G+;EMU[]M];[GL/BKX6_!30_CMIWPP_X0.\\[6+8.-7BUFX'V*1D?8$C
M9B'^X#EB<%NA Q1I>CZ!\+_V7_'VE^)M+G\3:3HOB^>U^PI=&U-WLEA2,M(@
M)0'ACMYXQ5S]I7XZ:+\*/C>+IO -AK7BRPTY6TS7)KR2+R/,1P!)"H(E"DD]
M5."0"O6OG*__ &AKO5_@[XB\$W^E?:;[6]:?6KC6!<A?WCR([+Y(3N5/.X=>
MG%<]&C7KTZ<G>WNMW?GJUKIIZ,WK5:%"<XJU_>2LON3TUU]3ZI^$?@/P-X+^
M,/@/6_#'A^>PB\8>')+^VAFOI)/[/98T=\;B2^]9 IW'@KD=<5B^'=;\(W'P
M=^.5_<>&IK7PY!KF9]'M]0=FN9$,.1YS*6199 ,X&5#G;T!KQ+3?VLI]*UOX
M6ZA!X:7_ (HG3'TQXFOLB_5X%B+9\O\ ='Y=P^]S^L&N?M*Z1=>!?'?A?1?
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MV7RHRYV#]V05V&OCNBL_[-H)67>_3_+7YW+_ +1K-W?Z_P">GRL?9/B/XX>
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M&]9Q^3:Q)C!"\U-116!N>]0?$[PRG[']QX(.I8\3OK NEL?(EYBWJ=V_;LZ
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M%S]_>=__ 'R*XW7/A_XH\,:9!J.L>&]7TG3YV5(KN^L)88I&92RA790"2 2
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MVV[MC#.,G&>F37L5OH<'CSQI\"IO&^CVFJZS?>'+]]2AU2RC8NRQV[(7C9<
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MV(X(Y%??8'&PQD+K22W7]=#XC&8.>$G;>+V9!14*R$>]2*X;ZUZ1YPZBBB@
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MZGGIQXK%4\)3YY_)=SKPV&GBI\D/F^QZ#^Q[\'[/X5:2_BGQ#;2MXHU&+;#
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M<GNQYPHY/L 2/U!^%WPOT+X1>$K;0- MO*MX_GFG?!EN)"!NDD/=CCZ   8
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M'T"FOHOP[X7TWPW9VVCZ#IUOIT#,$C@MXPBY/\1QU/J3S7@XG.:5-<M!<S_
M]O#Y14F[UGRK\3S']G?]D?3O!MU%JNJ21ZMKD6"USMS!:'TB!^\_^V>G8#O]
M5Z=I-KI<>RWB"GNYY9OJ:=INGQ:79QVT(^5!R>['N37G_P 2O'&N?\))IO@?
MP8MN/$^H0->7&H7:&2#2K,-M,[)D;W9OE1,@$@D\ U\K.=7&5.:;N_P2/IX4
MZ>%I\L%9?F>E45Y/#^S7X6U)?.\6W.K>.=08?O+C7-0E>,GN%@1EB1?]D+QQ
M27'[.FC:/FY\$:MJ_@34UYC?3KR2:U8CH)+65FC=?8 'T(J>2CMSO[M/SO\
M@5S5=^7\=?RM^)W^O>%;'7K>9)84$DBE&8J"K@C!#+T8'WKX:^.?[&4UM?7>
MH>#%6*<?O)-%D;"MGO YXP?[K>^".%KZY^'/Q"U:\UZ^\&^,;2WL/&%A"+E9
M;//V74[4MM%S!GE<-\KQG)4D<D$&NI\7:/\ VEIK31+FZMP73'5AW7\?YUM2
MKUL#4O!_Y,QJT:.,A::_S1^-NI:;=Z/?36=_:S6=W"VV2"="CH?0@\BJV<=*
M_37QQ\,?"_Q0T]8=>TN*[8+B*Z7Y)XO]UQR/IT]0:^;/'7[$.H6K//X2UF.^
MBSD6>I?NY0/02*-K'ZA:^KP^<4*NE3W7^'WGR^(RFM2UI^\OQ/F)9,\'K3ZZ
MWQ-\%_''@]V&I^&=0C1>LT,7GQ?]]IE?UKC_ )HV*2*58'!##!%>W"I"HKP=
MT>/*$J;M-6'T4459 45T_ACX7^+_ !I(B:'X9U34P_22WM':,>Y?&T#W)KW?
MP!^P'XZ\131R^)+JS\+6?5E+BZN/P1#M_-^/2N6KBJ%'^)-+^NQTTL-6K?PX
MMGS",G@<FOI+X#_L5^(_B4UOJWB<3>&?#C$,%D3%Y<K_ +"$?(I_O-[8!%?7
MGPF_94\ _"1XKNST\ZQK*8(U/5-LLB'UC7 5/J!N]S7L5?-XK.G).&'5O-_H
MCZ'"Y0HOFQ#OY&%X+\$:)\//#UMHGA_3XM-TVW'RQ1CEF[LS'EF/=CR:W:**
M^6E)R=V[L^E2459;!1112&%%%% !1110 4444 %%%% !1110 5'<6\5U"T4T
M231-PR2*&4_4&I** .6NOA7X+O\ /VGPAH-QGKYNF0-_-:RM3^'?@7PU9[[7
MP9X=@G;Y8UBTJ!>?7A.@S^M=ZS"-2S'"J,DGM7G.M:D=4OWEY\L?*@]%K3VD
M]N9F?LX;\J,RWM8;./9;PQP1YSLB0*OY"I***S- JM?,QB$:G#R,$'U) JS5
M.ZF6&^TYGY1;J(L/;>N: /7;:W2UMXH(QA(T"+] ,"O/_%$/AJ_AU*32X[:[
MUV:[%B5M[AXRMTWR;GV,""H4L3UQ&><BO1:^=O'B7[>-KW6] TRYTDV=Q) +
MT@J&N1'+N94*D-Y@!4#!&65\[GQ77AX\TGK8YJ\N5+2YW'@?X:6>EW6H:;JR
MW=[)&_F#S5"VMU&>$8A  Q&,&-LJASM4 @GKO!_@FS\&V5]:6S>;;W4YE$3(
MJI&FU56-5 QM"J!5_P +I<1^']/%UJ:ZS,8E8WZQA!.#R&"C@<$=*U*SJ59R
M;39<*<8I-(\F@^'%OX9\:)-J$HO-&U2:2VM;>'?"MDQW21I@/@I@.H  4-@@
M9<FN^\*?V$MI=Q: ]N\$5RR7!MVW?O@%W!CW;!7KVQ7FWQ>M]<U;Q39Z79:F
MT]G,+>3^REQ#^\\W*_O0"PRJ2OVXA(Z&NM^$/E0^%#:#3IM/NK2<P77G1E#-
M*$0F09[8*C X7;M4E5!K>HG*FIR=V94[1FXI"?$.$0WFG70X+[H6]^A'_LU8
M-=%\4)0MCI:?QM> CZ!&S_,5SB_=%<)UBU'<6L-Y"T4\4<\3=4D4,I_ U)10
M!2T?P/X,:Z\K4?"6@W=O+P?M&FPOM/KRO2M[7/ 7@CP_:B*P\(>'[:XD'R^3
MI<"[%]>%_*LR218HV=CA5&34%GJCZEN,K%I%X&?[O0?E6GM)[<S,_9PWY42V
M]M#:1"*")(8EZ)&H4#\!4E%%9F@4Q81>:A8VA^[-.JM_NYY_3-/I--E$?BW1
MMWW3,1^)5@/UH ]7KQ/6/%S_ !>^(%QX&ATK58-%T;53'K=P!)!%<0K:LZH9
M !\K3/%A58EU4DX7K[97!_$7Q!>Z.RZ-X6T^&?QCKT,OV>9ML<<"QJ%-S.^"
M2L9= %P2Q8 <9(Z:#M)V6O3R\_D85E[NKTZ^?D><3:9X6^#.OZ!K6FW=OX>M
M+CQ%<:7J+,TEI;/ 8)W"RK*Y5V5XX\2C&23C@D'5\?\ Q&L/"$=Q;>'O$?AF
MSN?$NHV(AFANHS<PBX98IKPHS,LV%$97A5P"3D#EFE_L_P"E:/%;ZU:Z9-_P
MDNBZC=7L=]JDBWEUJ>898P&DSD([.&"G)&T#CMD>#?A_9^*? ?@S1=*\,V<F
M@WIL];US7+A82EW,K>;+#Y8R[2-*NU@RA54D#H%KT+TI-3E)NV][>;_KOL<5
MJD4XI6OM^"_KL=+I?P]U?3+FQU?5[36/%-Q81M=P6E]XB%PD5T)-J%(S%%&S
M>62X=B-IX S\U>NV=Y!J-G!=VLT=S:SQK+%-"X=)$895E8<$$$$$5X_\/O'4
M/@O[=X1O$N+RSLS?OH=U:A[E[FVMY#OM=A4/YT(94"\AU *L<&O5/#-I/8>&
M]*M;J59[F&TBCED6 0!W" ,1&.$!(/RC@=.U<6(YK^]\O0ZZ/+;W?F<=XTA%
MKXF20=+F$,?]Y<C^6VLRM7XD3 :YI" ?.(I2WT)7'\C657&=(4R:&.XC:.6-
M98VX*.H(/X&GT4 )X?\ !/@V\F^QZEX3T*Z60_(UQIL+X/IRO?\ SUJ?Q#X!
M\$:.HL].\'^'[64C+M!I<"%1Z#"=_P#/6JMS<"UA:3NO3Z]J;:7[:C&99&W3
M$_.3W/K6GM)[<S,_9PWY4%I9V]A"(;:".VB'2.% JC\!4U%%9F@58T&$7GBB
MPB;[L9:8_P# 1D?KBJ]6_!LJKXV56&2UK(%^N4/\@: /2ZXCXT?#EOBQ\-]6
M\,)>KI\MYY3QW$D/FH&CE20!TR-RDI@C/0UV]<#\=O&FL?#WX5:[K^@VJ7>I
MVB1F-98FE2,-(JO*R+\S!%9F(']VMJ//[6/)O=6]3*KR^SES[6U/F?P-XRM/
MA3\8HI/'YL?#4GAZ+4=*3^QO#TUO9WL<TD#Q3Q^2K("1&VX$@_=Z]N\^*'QZ
MT7XN:?IGA'X?V\/B75=2U*WB>76/#\MQI]M%N^>5Q,JJ2HY'.>#BO+?A5X"\
M-?$;XCPV]UXAFU^^\1'5-8O_ !!X=N;W2BDT<L %N(68# \UCRN?F7!P*[WX
MT?L]^#?AEX5L?%%OXIOM%UG3=5M;BTUCQ'=7>J1I(KY$8B4G.XCL*^CJ+#^V
MASWY^FFE]>F]K_,\2FZWLI<MN7UU^_;8]S^"/PR?X1?#NQ\-RWT>HS0S3W$D
MT,'DQ;Y96D*QQY.U 6P!GH*[RO._@#XZUKXC?"S2=>U^VCM]1N&F0O#"\,<Z
M)*R),J/\RAU4-@^M>B5\[7Y_:R]I\5W?U/;H\OLX\FUM#S+7H19^*+^(?=D(
MF'_ @,_KFJU6O&4P;QLR*/NVL8;Z[F/\B*JU@:A39(TFC9)$5T88*L,@_A3J
M* +?A_P7X.U@&TU'PKH=U,.4>?3H7+#N#E>M9_B#X?\ @>RF^R:;X.\/VHC/
M[Q[?2X$.?3A*2ZOVTZ,31MLF!^0CL?6G6UP+J%9>[=?KWK3VD]N9F?LX;\J&
M66GVNFPB&TMH;6+_ )YPQA%_("IZ**SW--@K2\&0BZ\3LYY%M"6'^\3M_ENK
M-K4^',H_M_54/WC#&1] S9_F* /0J\A^'=U'JG[0'Q2O+<_;;:*WTRP%ZB_N
MX98UF,MMN[LI=6('3> >:]5U&&XN-/NHK2X%I=21,L5P4WB)R"%;;D;L'!QG
MG%>5_LP[]/\ AW>Z#<00IJ&@:O>:7?7<,A<7]PCAY+DE@"&D:3)!S@Y&<8KJ
MIZ4IR]%^-[_A;YG/4UJ07J_T_4]=HKB_BE\5M'^$VAV^H:I%=WDUW.+2RL-/
MA,MQ=SM]V-%'4FL_X6_&W2/BA>:IID>G:IX?U_3-K7>CZU;&"YC1ON/CH5/U
M_H3FJ-1P]HH^Z7[6"GR7U,KXH*(_C1\'YH!B]:]U&%ROWC;FR=I ?]G>L1^H
M%>LUX]\/YC\5/BIJGCU06\.:/#)H>@.1Q<L7!N[I?]DLBQ*>XC8]Z]AK2O[O
M+![I:_>W^I%'WN::V;_1+]#R>:$66J7]H/NPS,%'^R3D?H13J76)A)XQUC:/
ME$B#\1&H/ZYI*Y3H"J&I:!I>L$&_TVTOB.GVF!9,?F#5^BFFUJA-)Z,M^'?A
MMX!UB/;<^"?#<EY"/]8^DVY9ATSG9U]:Z[3? ?AG1Y%DL/#NDV,B_=>VL8HR
M/H0HKCK&\?3[J.>/[R'./4=Q7I-K<I>6\<T9RCC(JW4F]')D*G!:I(EHHHK,
MT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,+Q=J'V73Q
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M\ZZ*C[J?*/ZU+HUQLF:(GA^1]:SB<\GK3HY#%(KCJIS0!U%%(K!U##H1D4M
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MIW'^?4UR=7-(O/L.I039PH;#?0\&@#T?-&:**H S1FBB@ S1FBB@ S1FBB@
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M+:[FD:6XMO+:)79",JK-@'#,.<GTHU+6(->U[QK>VHD^S2:2/+:1"A<#RQN
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MB?2/^$0&LF\$X,WVSR]HCR,_<[8SG/%>O_$CPK=^,/#RV%G)#%,)UDW3L0N
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MAW.RR.@8^I56 )]>.:Z2B@!L<:0QI'&BQQH JJHP !T 'I3J*55+,%4$L3@
M=30!+:6+ZE<+;(NXR<'/0#N34FH:.=#N/LW6,#*-_>'K]:['P[H@TN R2#-S
M(/F_V1Z58UK24U:UV'Y95YC;T/I]*=A7//**=<0R6TS12*4=3@J:CS188ZBF
MYHS18!U%-S1FBP#J*;FC-%@'44W-&:+ .HIN:,T6 =13<T^"&2YF2*-2\C'
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MPZG;F&9<CJ&'53ZBN!U729])GV2C*'[D@Z-_]?VKTBHKJUBO(6BF021MU!H
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MBBBH+"BBB@ HHHH **** "BBB@ HHHH **** "J&H:+9ZES-$-__ #T7AO\
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MJV*?G-14H.VBPR2BD5@U+4V*"BBBBP#:*1C@TFZF0.HINZC=18!U%-W4;J+
M.HINZC=18!U%-W4;J+ .HINZC=18!U%-W4;J+ .HINZC=18!U%-W4;J+ .HI
MNZC=18!U%-W4;J+ .HINZC=18!U%-W4;J+ .HINZC=18!U%-W4;J+ .HINZC
M=18!U%-W4;J+ .HINZC=18!U%-W4;J+ .HINZC>*+ 6J***@U"BBB@ HHHH
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M6_\ DW7P_P#]?S?^C)Z!V/2)?C;H%O<6PFM]2AL[AML=_);8MVYP2&SD@=\
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M@5R3<*3S*910%QV^C=3:*8A=U&ZDHH T****Q.@**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6FL<*: (ORJ&\L;;4K5[
M:[MX;JWDX>&9 Z-SGD$8/-3&DJR##/@/PS_T+ND_^ ,7_P 35C_A%=%^P?8?
M['L/L6_S?LWV5/+WXQNVXQG'>M2B@10O=!TS4H8(KO3K2ZB@_P!4DT"NL?&/
ME!''0=*==:+I]]>07=S8VUQ=0<Q3RPJSQX.?E8C(Y]*MYHW46 J:EHFG:RJK
MJ%A:WRK]T7,*R ?3<#2Q:;:061LX[6&.T*E#;K&!'M/4;<8P:M9I*8BMI^F6
M>DV_D6-I!909+>5;QK&N3U. ,9KSBY3QA#K%S<3^"-#U>Y4XMM0@>.)EQT9M
M[%CVX&.E>H4E,#@_A;\/I/"_A6YLM82&YGOI3+<0,!)&!@ *<\'IS]:ZR3PW
MI,FFQZ>^EV3V$;;DM6MT,2G).0N, Y)[=S6A29I6 J7NBZ=J5G':W=A:W5K&
M04@FA5T4@8!"D8& 2/QKF/'EMK[_ &.+2M"TG7=,4#SK.^4!P0?X=S!0,<=#
MBNRS1FBP'E>C>#-:UGQ]IVNZEHUMX<T_38?+@L;>9),GYB/N<=7)/ Z"O4Z*
M0]:>PKE74-(L=7C5+ZRM[U%Z+<1+(!^!%&GZ/8:0A2PL;:R1NJV\*Q@_D*LY
MHS0(JC1M/&I'418VPU C:;KR5\W&,8WXSTXZU:N+>WOK=H+N".Y@;[T<R!U/
MU!HS1F@"/3=#T[1T==/T^UL5?[PMH5CS]=H%1ZAHNGZLT+7UA:WK0DF(W$*R
M%"<9*Y''0=/05:60K[BG;@>E(JY4NM%T^^O(+NYL+:XNH"#%/+"K/'@Y&UB,
MCGGBGZAIMIJMN8+VUAO(,Y\JXC#KGUP1BK.:,TQ&8OAG1U^R8TFQ'V0YML6R
M?N3G=E./EYYX[U/=:-I]]>07=S8VUQ=0<Q3RPJSQX.?E8C(Y]*N9HS0,AO+.
MWU"VDM[J".YMY!AXID#HP]P>#265C;:;:I;6=O%:V\>=D,*!$7)R< <#DD_C
M4^:,T"*,VAZ;<:A'?RZ?:RWT>-ET\*F5<=,-C(ZT[3]&T_26F-C8VUD9CND-
MO"L>\\\M@<]3U]:N9HS0,H:EX?TO6&1M0TVTOF085KF!9"OTR#BK*V<"6OV9
M8(UMMNSR0@";>F,=,>U39HS0(R!X/T%8'A&B::(7(9H_LD>UB.A(QR:MW>CV
M%_:):W-C;7%J@ 6&:%61<# PI&!Q5S-&:!E/3='L-'C:.PL;:Q1CEEMH5C!^
MH %7*,T9H$%%&:,T %%%(6 ZF@!:*9Y@I/-]!3 DHJ'S&I-QHL%R;</6D\P5
M%FC/M3L*X\R&DW'UIN?:C/M0(7_/6BDS[49]J8"YHS29]J,^U "YHS29]J,^
MU "YHS29]J,^U "YHS29]J,^U "YHS29]J,^U &E1117.= 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)/NT44"9&U)11
M5F;"BBB@H:W6DHHJB0HHHH **** "F444 %%%% @IK=:**!(**** 84444""
MFQ_ZQZ**8$E%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** &OTJ/\
MBHHJD2Q:***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>cogs.jpg
<TEXT>
begin 644 cogs.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M/XC'Q'X3_::UCX26GPENO$_BKQUK]_\ &?P#\,['58?"'[=R>*OA];6UU!X
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MOB5XS\*:MK*Z)XBM=.\27%E867B;Q!I>G:OXDO+5 #[5HHHH **** "BBB@
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MB(UX5>:%*564HM7II584XU%"I.G5G"E*E^:47@_PM\._@W\ O$'B&R\.:?X
M^(WB?7_B?\2OA'KOQIU7X0>'=6U?XG^!['7? &BZ;X[\7>);?3(])^#6AVMK
M;_\ "$:]XMT.T\57T6H>-K :UXTTJST;4?%=9\3_ !&M/AK9ZMXIUN+Q!\7]
M8^#6G7G[-OVGXU^*?"OCKX?Z[!X_^)6F^ =7T_X<ZF-*\7?&[5?B?HY^&^_7
MK70_$OB77]/L&\._%;2/!_A>]N=7O/V9>.*2)H)8HI;=O*WV\L4<MNX@=9(
M\$BM"P@D1)(=R'R94CDBV21HRO;YY(YI ))H6F>&:11)- ]RGEW+P3.&DA>Z
MB_=73Q,C7$7[N8NGRUYM7A_GTI8QT(K#QH14<-2E[WL</1=:5Y+GG%T95J,9
M>Y0KUJE>@J>)E*O+V</Q=[+6MERQ,WBWB93GC:\'R+$8C$0PT.6%Z=.7MXX>
MO.#53$X6A1PN)E6P<(X2'R7^T/\ %/\ 9WL-)L(OBKXZT[4X]!^(NH^!I?A-
MH7Q.L/!-MX[^+$7A"SUUOAWXHU ^(?"=M;)X4T#7++QO*VO^+-"\)>%-/O\
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MGM<T"WUW]K;XHZEXH\'V_@K4(_BW\&DTS5_#G[ ?Q-^)EM\4?#_@>R\#^)/
MGBKQ5^T?%X-N?#EQKOA7QH-3MH-3COK71?A)/HGAR_:6XO-&M?$+_K2/\>OU
M]_Y]^O>OQ%^('@6\\2?M/:GX@TSP[J=UJ?C;XY_ 7XE^%OVD-9^ 7[9:_&?X
M-^"M'T[X<7-]\%_!CV'[-U]\,(O!.N6>E:WHVKW6H_&+P+X-\/VOQ.\<Q_%[
MP!K^OZ'XD'B#]NEX'Y_AR>!P.!T!QR,&@#\0?^"D_P#RDD_X(4_]G6_M0?\
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MJ%",*5&C&G24YU.51HTZ<7><YR<FG)N5KV22_1[_ ()U_P#(P_%3_L"^$?\
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MEU9/!["RL=/N(?[8U$E[K5+BSE#GR-R^5%I-ZFT?POYV6YRB]_E:OKKX)?\
M(EM_V&M2_P#:%?HGAA_R4[_[%N+_ /3V%'T?JOU/1/M'B'_H%:/_ .#Z\_\
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MPS/H7_0VZW_X*]+_ /CU'_#,^A?]#;K?_@KTO_X]7TO11_Q'OQ=_Z+3%]/\
MF5Y#TM_U*?[J_$/^(4>'O_1,X;I_S&YMTM_U'_W5^)\T?\,SZ%_T-NM_^"O2
M_P#X]1_PS/H7_0VZW_X*]+_^/5]+T4?\1[\7?^BTQ?3_ )E>0]+?]2G^ZOQ#
M_B%'A[_T3.&Z?\QN;=+?]1_]U?B?/>B_LW:-;:SH]S%XJUF22VU?2KF..33M
M-1)'M]1M9DC=U=V1)&C".ZHS(K%E5B I_8+S_$(_YA6CGD_\QZ\[G/\ T+M?
M!^F?\A+3O^PA8?\ I9!7Z%5]WP9QWQ;QO#,)\59S5S>66RPL<"ZN&P&&^KQQ
M4:[Q"BL#A<*I^T>&HM^T4W'D7)RIRO\ 29#PKP_PQ#$QR'+:>71QDJ3Q*IUL
M56]J\.IJBV\57KN/(JU3X'%/F]Y.RM\[?M)3:VWP'^*HN=.TR*$^#-5\R2'6
M+JXE5=L>2D+Z);*[ 9(5IHP2,;AG(_!ENI^I_G7]"'Q]T:]\0_!GXD:)IWD"
M]U/PKJ5G;&YE,-N)I50+YLH20HG!RP1B/0U^,S?LZ_$+)_>^&NI_YC$WK_V#
MZ_HW@+CG@_A;+<9@^(N(\JR;%8C'/$T*&88JGAZE7#NA1I>VA&6LH>TISAS;
M<T6NC/PCQKX5XBS[/\JQ&39-C\QH4<H5&K5PF'G6A"K]<Q,_9RE%-*:A*,K;
M\K3MJ>#T5[O_ ,,Z_$+_ )Z^&O\ P<3?_*^C_AG7XA?\]?#7_@XF_P#E?7W7
M_$8/"_\ Z+OAO_PY4?\ ,_&?^(<\=?\ 1*YU_P"$57_+^K/ROX117N__  SK
M\0O^>OAK_P '$W_ROH_X9U^(7_/7PU_X.)O_ )7T?\1@\+_^B[X;_P##E1_S
M#_B'/'7_ $2N=?\ A%5_R_JS\K^$45[O_P ,Z_$+_GKX:_\ !Q-_\KZ/^&=?
MB%_SU\-?^#B;_P"5]'_$8/"__HN^&_\ PY4?\P_XASQU_P!$KG7_ (15?\OZ
ML_*_TY_P3V>_3Q!\438VUI<L=%\)^8+J]FL@H&HZ]LV-%87Q<MEMP98]NT8+
M[B%_5"SDU&3S/M]I9VV-OE?9+^:]WYW;_,\[3K#R]N%V[?-W[FSLVC=^?7[#
M_P -/$G@+6_B)/KK:6T>I:5X:AMO[/O7NFWVE[K4DOFA[:#8-L\>P@MN.X$#
M&3^B5?B_&.=93Q#Q!C,UR3,<+FF6XB&%C0QN#JQK8>K*A@\/AZRA4CI)TZU*
MI2FKOEG"479H_K?PJRS,,GX'RK+\TP=? XVC6S.57#8F#IUH*KF>+JTW.#U7
M/2G"<>\9)]0HHHKY<_10HHHH **** "@G )]!FBJM\EQ)9W<=I(T-S);7"6\
MJ&$/%.T+K#(IN(+J#<DI1E\ZVN(L@>;!-'NC8 ^+O^&J]:U+XU^.OA7HVC_
MO2(/A]\0_#7@/5XOB9^TC'X(^*.JIKN@>%O$*^)/#GPHTOX9^+Q<Z-JEOXDF
ML? RZKXPTF]\9:EHNI1O;Z%;>3<-]M__ %_?O_G/H>*_(=/ GC^V^(NE:OXJ
ME_:F\7>.[/Q#HFK7=E=_LD_L7:G:>(WTF\LK@)/\:='^'=EX6L+:\CMDMTUE
MOB!X<UW3K=Q=6J:1?6R+:_K3I5Q>W>F:?=:E8?V5J%S96UQ?:7]JAOO[.NYH
M4DN+$WMNJV]VUI*S6[7, \F=HS)$6C96(!^)_P#P4G_Y22?\$*?^SK?VH/\
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MNHDGM;RSO+62:UN[2Z@DCGM;JVEEM[F"2.>"62*1';[!^"7_ ");?]AK4O\
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MG%8Q>S2_=WQTL0J\U":J1YU1KJC3<U-*%"A[2-10:D7_ *U/#_V:-)\7:#\
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M?#?@33M5UC0? .D2^(YTNKJ^T;0]4ZKPW\>_#GB[XR?$KX*:#X:\:RZW\,_
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MU]+6-A]B\W_3+^Z\S9_Q^W37.S9N_P!7E%V;MWSXSNVKZ5_2/AS_ ,DCEO\
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M.-U/U/\ .O(\6?\ D<Y;_P!BS_W:Q =%ZO\ *)YW\4OA)\,?C=X.O_A]\7?
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MCKVOI>OFCX!?\?WB;_KTTS_T=>U]+U_2_AS_ ,DCEO\ U\Q__J?B0"BBBON
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MPL2W#6X_9Y_:H-PMN\CPI<-;CX'>>MN\T<D*7#1B%YHY(DD:2-U4_P!7L_\
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MX)=PWME-)^TMJJQQ7EI+(W_#.?[5ORQQ7,4CM_R0OG"*QP.3C K[%_XB'/\
M@D#_ -'7ZI_XC5^UM_\ .'K]@\+,OQ^ I9TL=@<9@G5GE[I+%X:MAG44(XSG
M<%6A!SY>:/-RWY>97M=!T2\V_O2/UT^(O_(C>)_^P3<?R6OAQNI^I_G7R1XS
M_P"#@O\ X)&:OX5UW3;#]JK59KR]TZ:"VB'[-G[6B^9*^-J[F^!"JN?4D 5\
MKG_@N%_P2^))_P"&E=5Y)_YMS_:M_P#G%UY?B?E>9X[-LOJ8++L=C*<,NY)S
MPN$Q&(A&?UFO+DE*C3G&,N5J7*VG9IVL[AT2\W^-C]7J*_*#_A^#_P $OO\
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M53J* &[1ZM_WV_\ \51M'JW_ 'V__P 53J* &[1ZM_WV_P#\51M'JW_?;_\
MQ5.I"0HR2 /4D ?F: &,F0,;LAD/+MT5U8]3@\#IWKYI_8U^&/BOX-_LL? 7
MX6^.[6WL?&'@/X9>&?#/B.SLM1@U.UMM6TVU,5W%!J%F[VMY$DAPMQ S1N.4
M. *^F20" 2 3P 2 2>N!Z\>E+D9QGGKCOCUH ;M'JW_?;_\ Q5&T>K?]]O\
M_%4H(.<$'!P<$'!]#Z'VI: &[1ZM_P!]O_\ %4;1ZM_WV_\ \53J* &[1ZM_
MWV__ ,51M'JW_?;_ /Q5.HH ;M'JW_?;_P#Q5&T>K?\ ?;__ !5.I,C.W(SC
M.,C./7'7'O0!\Y_&7X<>)_&7Q6_9)\5:%:P3Z-\)/C?XS\;^-9IK^&VFLO#^
MM?LQ_'WX96%Q:6\SB74IY/%OC[PW:/:6@>>*VN;B_91;6=PZ_1>T>K?]]O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !44T\%NGF7$T4$98*'FD2)"Q!(7<[*-Q ) SD@'T-2UXY\<@#X
M-MP0"/[=L." 1Q;WQZ'->7G68RRG*L?F4:2KRP>'G75&4W351QM:+FHS<4[[
MJ,O0#U3^U=+_ .@E8?\ @9;_ /QRK4,\%PGF6\T4\>2N^&1)4W#JNY"RY&1D
M9R,\U^=>U?[B?]\+_A7US\$ !X*8  #^VM2X  'W;;L*^(X5X_K<1YJLMGE=
M/"1^K5L1[:&+E6=Z4J4>7D>'I*TO:-WYM+)6=[CLM;-Z>7FEW?<]@HHIK'"L
M1U"D_I7Z6(-Z;MNY=W]W<-WKTSGISTIU?BAIGBW]IOQ/^UQ\?]2\!:C^T9<Z
M/\*_VPO"GAG6M8U;QE\,1^R5H_[.N@_ KX)^,_B9X(/@/4]<N_B+<?$&^3Q1
MXCN- U7POX&AU-/'6M:%>R^+T\)Z?XBMEZ+2/^"AOQWD\ Z3\1=>^%/PATVQ
M\,_L]_LZ?M1?%;PT?B%XIB\0S_#W]IG7-;T/PEX-^%=Q<^&X]/\ $_CKPS!X
M3\07^MZEJ,=MX7U[Q;>^&OA?X=_TR^U#QK8 '[&Y'3/)Z#UQUHK\1/B#^WG\
M<M(\7^$_B[!H?A#3OA'-X$_;?UKPO\.;3Q5J[^(O$%M\!?CE\!/@=::G\6[2
MZ\/PPZ'K.CW.M^,O%$]GX;OI;?P;+J;^#]=?4[VUG\0-]">-OVWOB'+\9?BA
M\$?A;X7^$$^O_#;QI\5UN?$_Q.^(NI^$O!4W@GX(? ?]E;XL^,=/U#6-,TG5
MAI'CG4]=_:9LM"62Z7^P/!/A/PQK/CGQ#;:N]F/#UX ?IO17Q#^R!\4/CK\2
M_&O[8,/Q=U3P!?\ A3P!^TE-X'^#5KX,L;^#4-(\!R?"3X5>/;?3O$FJ3O\
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M?MBZ_P#"_P"+WPWA\9OHNE?$3]DS2;"Q\<PZ5XH\?:-H>F^/"/$-WJUK!?\
MA3PU)X=\,:WX?;2!XB\>6=R==AZWPQ^V]\?_ (80_&;Q-\>=/^'_ (Q\#VW[
M7O[4'P"^%USX0M]3\-Z[I=]X.T$Z[^SO\/-8M[OS[/6-7^)^KZ5JWP^L=4C$
M-S-XOUOP991R:C)KR+; '[&45E:&^KR:-I4GB"&PM]=?3;!M:@TN6>?38-7-
MI"=3AT^:Z5+F:QBOOM$=G+.BS2VRQ/*H=F%:M !1110 4444 %%%% !1110
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>collaborationprofitshare.jpg
<TEXT>
begin 644 collaborationprofitshare.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3\>^*/^$(\$>,/
M&7V"35?^$3\+>(O$W]F13"WEU'^P-&OM7^PQSF*80R7GV/[,DIAE$;2A_+DV
M[&_.W]G[_@H_X1\>_"[P[\5?BOKOP M]/\>Z7X<U#P7X4_94^*GQ$_; \>VM
MW=>"I?B!XTT;QWX/\!_!#1=>\,WOP_\ #$VG:CXAN++3];L+""2YDU:XTDOH
M\>K_ **>.O"T'CGP5XN\%W-Y/I]OXM\+^(?#%Q?VJ12W-E#X@T>]TB6[MXY\
MPR3VT=ZT\*2@Q/)&JR#837R=JG[&YT[PS^SU#\*?BSXA^%'Q#_9V^'-Y\)_#
MOQ#TCP=X&\0-XB\#^(?#'@7PYXQL?$GA#Q!IDWAVYU#5[OX;>"?%FE:K"(YM
M!\3>'+ -'JWANXUGPYJX![)\-OVE_@M\8/%VO^"_AAXR'CC5O"_ASPEXKUR_
M\.Z#XEO_  G9:'X^\)^%O'?@:Y7QTFCCP9=S^+_!WC+0_$OAO3;+7;C5-7T:
M2^O[2R>WTG4WM?COPW_P5+^#>MMX&UG5_ WQ<\#>"?%L7[8*WVI>,?A9\4K7
MQII5S^R)\3/AWX \27FG_#32? >K>*?$?A;5M-\:ZKXOU?Q9IL TSP#9>$=9
MT/Q.8_$-CK5AHWU/^S=^S'X-_9AT7Q+X7\!ZMKE]X:U<_#*VTC3]>>TNKO0M
M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MB0:8?"]C\0].U3Q#X7U'4O"_A:XM;_4F\%#57\)>+M1O;0^-M'U[3M'L]-<
M\,'_  4;DUKP%J7QM\'?!?4+_P"!_P -?AA\"/BG\?M>\2^,X?#?C[X?:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#=I_Z;]0K\K?^"DX)_X*2?\ !"G S_QE;^U ?P'['/Q!)/X#D^U?JE\<,_\
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M\7)_@"WP;^'FE?V%XPC.B_'SP;\ -8\7:1X0\1W.J^'5MO"MYH":19ZA/?\
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MD>_Y'_"@!:*3(]_R/^%&1[_D?\* %HI,CW_(_P"%&1[_ )'_  H 6BDR/?\
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MQLJ&$K87ZE+#QFJTX3YWB%6:Y>1*W+[%WOO=6ZA_7]?>8'_",:+_ ,^0_P#
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MP<?Y/'YTM(QPI((& 3D]!QU/(X'?D?6@#\U9O@_\:=._:0^(?BR?PI\4]?\
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M)/\ @A3_ -G6_M0?^L<_$&OU1^.  \(:7@ ?\3NT[?\ 4/U"OE^-?^25SO\
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M^R;:HRS8NX3M4<98XPHR,D@9K[L_MT_] ?7?_!:?_C]?"FF?\A+3O^PA8?\
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M0'Z=[T_O+_WT/\:-Z?WE_P"^A_C7RK_PX_TK_I*C_P %F/\ Q-/0?_G-4?\
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MF/\ Q-/0?_G-4?\ #C_2O^DJ/_!9C_Q-/0?_ )S5?FG_ !"7-O\ H:9;_P"
MXK_Y5_5GY7#ZJWI_>7_OH?XT;T_O+_WT/\:^5&_X(@:4 #_P]0_X+,'YD'_)
MZ>@C[S!>WP9SW[<^A!YKYT_9&_X),7WQV_9E^!_QB\7_ /!4O_@K_!XG^(_P
MX\.>+==A\/?ME:/9Z''J6KVOG7*:7:3_  DOIK>S5Q^YBDO+EE4@-,YRQ/\
MB$N;?]#3+O\ P'%?_*@/TVWI_>7_ +Z'^-&]/[R_]]#_ !KY5_X<?Z5_TE1_
MX+,?^)IZ#_\ .:H_X<?Z5_TE1_X+,?\ B:>@_P#SFJ/^(2YM_P!#3+?_  '%
M?_*OZL_*X?7&F.G]I:=\R_\ (0L/XA_S^0>]?H5O3^\O_?0_QK\/U_X(@Z8C
MI(G_  53_P""S*/&ZR(Z_MIZ"&1T8.CJ?^%-9#*P#*>Q -;7_#F6]_Z2U_\
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MXU\(>(='\5^,M=N8=7^).A^&O$7@_4+JSU*71++2_$9,NE7L44]K/^DE% "
M!1@>I/KR22?U)I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>equityinlossofinvestee.jpg
<TEXT>
begin 644 equityinlossofinvestee.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
M_86TW1-9UB=OBCXCO/#HT7]LGPWX,T$^'= M9_"NA?MI>-O!/Q,\>V=UK<$A
MN/$DWA;QUX7U2^\'WEY:64Z:+KZ:+K?]J3Z-;ZO=@'MFE_M9? 36_B#IGPUT
M?QR=4U[6-0TC0].U?3_#/B^\^'USXH\0>!;7XG:!X*3XJ0: _P -%\>:W\/+
MVR\:Z5X'?Q8OBF^\,WVGZK!I30:A8_:?,?C)^V#/\&OBY+\%]9^'$NH^+?B%
MX5\-ZG^R\+7Q,EO:_'GQG=>(3X8^('P^:2?1"?!VI_"-;_PQ\1?'&H)_PDL4
M/P8UK6OB'9V<L'@/Q;I]EY)\*_\ @F%\(?A3\9O"_P 7M-O/#NN7^A2^!_$=
M[<>(_@Q\(M7\>:AX_P# _P )?#'P@M-;TSXLZCX;O?&WA3PW?Z5X2TCQ3<>$
MO#UQ:W-AXR6\N-#\4:7X9U"\\+3_ &)\3/@9H7Q.^(?P,\?ZMJ=Y:R_!#Q)X
M\\1:?I%O:V<MIX@/CWX4^+_A1J%CJ%W*%OM/AM=*\7W=_#/I4L-S+<VT5M*_
MV6692 >:Z1^W-^SAK^EZEJN@>*?%WB*.RL](U32K3P]\'OC-K6J>/=!UZ]O]
M+TGQ=\)M'L?A_+JOQ:\!WNIZ;>6D?CWX=V?B/P9"JVU]=Z[;:9J.EWU]5N/V
M^_V3+:V%])\6;<Z?'\+KOXT:EJ$?A'Q[+8^'?AM8Z[XT\)W?B#Q=<Q^%G3P?
M/!XS^'_BGP*_A[Q,-*\3GQYI\7@F/19/$]_8:7<?'OAC_@CU\(_ OA2W\*^"
MO$WAK0[/PQ+X/TKP5&G[/'P*-GK'@/P<NH0VG@OX_6]EX9TR]_:*LKV&ZTC4
M+U_&FJZ9IDGB[P-\/_'S>'Y/&7AV;6=3][^$7_!/3P7\%_A]X]^'GA+XA>($
MTSQM\([GX21SW7@;X37-IHNE3_&S]H7XU_:8/!=YX*O/AIJ-A_:'[0>M>%I?
M!NH>"'\%2>%]"L-/BT.WCO;M$ /KWP-\8? OQ \'ZGXZTJ[US0= T*XU2U\1
M?\+%\&^,?A3K'AJ?1+.'4-6'B3PY\3-!\)^(-"@LM/N(=1:^U'38-.GTN6+5
M+2[N-.ECNF\%C_;Z_9=DT72]<;QOXF@@U_7_  )X<\,Z9=_"/XQ67B;Q?>_%
M/3?&&K?"Z^\%^$;SP%;^*/%_ASXE6G@+Q:G@+Q7X;TC4_#?BJ_T._P!+TG5)
M]3A>T$WP8_8]\+?#/X(_%'X'^(_$5YXR\*?&"Y\7_P#"4:%I>DVOP^\"^&M$
M\:>"M+\ ZUX/^$_@/P_>7FG?#'PA=:3ID^M3:'HFH3POXV\0^*_%4+VUQK;6
MMMX5\%?^"9'PV^"USX%OM!\0Z)9W_@'XF?#/QO97O@SX)?!SX77GB;1_A-X,
M^*?@[PSHWCR^\ ^'-)U#Q=K>I1_%;6-8\3>*+Z\2UN-6L+67PSX6\)Q:AKT>
MJ ':_&#_ (*.? 7X?_#"3Q[X(O=4^*6KW/A30_&&E^%](\*_$73UL])U_P")
MLOPEL!\1=<3P)J=M\';^Z\=:7XI\(Z?I/Q.MO#.KWWC#PAXG\+Q6*ZGH&M)I
MWK,_[:_[-=E<^.XM2^(<FDV7P\TWX@ZMK?B#5O!WCW3/"6K6OPH\1VO@_P")
M<7@'Q??>%H/#7Q0U+P+XMOK'PGXHT?X;ZGXJU72_%-Y;^'GLY-5D%L/F_4?^
M";.G'2/$WA_P[\>/B!X9T7XDQWMK\6+.V\,^!]2D\96.G?M$?%?]H[P!#87>
MI:=-/X4G\+^(_C%XN\):S=Z:UR_C'P4=.M;N/2==L8==7'TG_@E!\#]'U?XJ
MW>F7^GZ';>.+GQSK/A'6_#7PF^$>A_%;P)XI\=?%'3OC,?$-S\8QX6O?&GCM
MO!7C[2K*?P1H_B65-';P]&/#_P 0;3XAQPV=Y: 'U;\(/VHM#^,5I^T7JNA>
M%]?TS2O@'X]C\#[?$FE^)?"7B37[A?@5\+?C-?/J_@[QGX9\-^)?!&HV,WQ(
M?PQ)H^L:?<2R+H\>NQW#6NK0VUO\Y_"W]O[6H?"WP@\:_M2_#KP-\$?!OQV^
M >H_'_P%XT\$?%+Q!\4_#FFZ3HGA+PGX[UKP+XZAU?X4_#;Q!HWC>/PCXOL]
M5\/IX<TGQ?HWBJXTG7]#LKVSU^+0--\2?3?PC_9\O_A]I7QM_P"$M^).M_$?
MQ7\?O%D7C3QSXEO?#_A_PQ%:ZM'\(/A_\&DLO#6@Z#&;'2]$MO#OPZT>YL;.
M[N-4ODO9[V2^U749)C.WQW8_\$O['Q?\(_#OP@_:)^.OB3XS>'_AQ\#X?@3\
M(H+'X<^ /A_I7@?188_ *#QMJ.@0Q>+;'QW\0VB^&7A#3FO?%,LW@X:"GB/0
M4\$I8^+_ ! +L ^H-4_;F_9MT30X=:U?Q9XLTZX;5_$FC:AX0NOA#\8D^)?A
MRX\&>'M!\7^,K[QC\+!X#;XB>#?#WA/PAXI\,>*_$'BGQ/X:TOPUIWAWQ/X8
MU9]5>T\2Z"^HV-;_ &X?V8O#E[X]MM8^)+6=C\-]"\?:]XE\4?\ "&^/9_ <
MD7PJ\*77CCXEZ/X9^(5OX7E\#^-O%W@/PE8WVO>*?!7@WQ!KOBO2;'3M7,^D
M"?0];ATWP3P;_P $Z;#X9V&A:M\(_BK;_!/XG6MW\2K37_&7P:^!'P/^'^@:
MKX2^+.G?#'3/%>A6'PZT_P ,7&@V&L:>WP;^'>N^$?&^M7OBSQ+HGB'1[E-0
MFU_P=J!\&6_+:M_P2A^#=]XA^.^K6.LZ9I<7QJT']H1!K*_!WX/ZA\5?#7C/
M]IGPUXM\/?$GQ2/C7?\ A>7XAZ[9)<>._%^N>'_#L^HZ:;*Z\07^B:GK>L^#
MDL/#5B ?20_;J_9WO-3E\,Z-XHURZ\9/KNH^#;+PYK'PZ^*'A0CQW'X+N/B%
MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MB0:8?"]C\0].U3Q#X7U'4O"_A:XM;_4F\%#57\)>+M1O;0^-M'U[3M'L]-<
M\,'_  4;DUKP%J7QM\'?!?4+_P"!_P -?AA\"/BG\?M>\2^,X?#?C[X?:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 45^/W_!0+XJ_$OP9^WC_P1U^'?A#Q_P"+
M_"W@;XR_M(_M#>&OBMX5\/>(-1T?1?B%H/AS]EKQKXLT'2/%MGI\\ UG3M(\
M26%GK=A:73-!!J5O%=!#+&C+^BWQ/=_"_AZPU'1I+B&ZGU2WMI&FU#5KE3!)
M9WDS($EU%@"9(8SOY8!2 ?F.>#,\QH93@,5F.)C5G0PE/VM6-&,957'F4;0C
M.=.+=Y+24XJU]0/:Z*^'/^%@^*/^?T?]_+__ .3ZK7GQ-UO3K2ZU#4M:L=-T
MZPMI[R_U'4M0ET[3K"RM8VFNKV_U"^U6WLK&RM84>>ZO+RX@M;:!'FN)HHD=
MU^#7BKPXVDL+G#;T2^JX1N[MI_OWG^'I=V\_S\O+^K>E_NRBOREN_P!N7X)6
M'@/PG\4;[]HKX/V?PW\=SSVG@SQS<?$'3E\+^)[RUB6>[L-'U9-;>WN=2LXG
M22]TTLFH62N@O+:!G53O)^U[\,I(OAY.GQT^%'D_%VRM=2^%4C_$70XE^)&G
M7]Q'9V&H^!_.\21'Q+I]_>RQ6&GWVEBXM;_498M-LY9]0ECM7V?B7DJ=GEN?
MJTIP=\!05IT[^TB[XSXJ?++GCO'DG=+E86\_S\O+S_#TO^GE%? ^O_%^\\*:
M'K?B?Q1XFTGPWX:\,Z1J>O\ B3Q#K^J2:/HGA_0M$LY]1UG6M;U74-4M['2]
M*TG3[:XO=2U"]G@M;*U@FGN)8XXV86M/^*.LZMI^GZMI6M6FI:5JUA8ZKI>I
M6%W=75CJ6EZG:0W^FZC8W4.HO#=65_8W%O>6=U"[PW-M/%/$[QR*QR_XBIP[
MR\WU3.>5OEYOJN%Y>9)-J_UZUTFFUO;7JKEO/\_+R\_ZTO\ =U%?#G_"P?%'
M_/Z/^_E__P#)]?0?PR4^)_#1U/6)+F:\&I7MMOAU'5K=/)A,7EKY<>H!<C><
MMU/&>F:]?(N.<GXAQW]GX*CF%.O["I7YL31H0I\E.5.,ES4\56ES-U(V7)9V
M=VM+EM+_ -:_T_N]+^P45@_\(WI?I??^#C6O_EC1_P (WI?I??\ @XUK_P"6
M-?9B-ZBL'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&@#>HK!_P"$;TOT
MOO\ P<:U_P#+&C_A&]+]+[_P<:U_\L: -ZBL'_A&]+]+[_P<:U_\L:/^$;TO
MTOO_  <:U_\ +&@#>HK!_P"$;TOTOO\ P<:U_P#+&C_A&]+]+[_P<:U_\L:
M-ZBL'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&@#>HK!_P"$;TOTOO\
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M^@QKO_@R/_QB@#>R/4?F*,CU'YBL'^PC_P!!C7?_  9'_P",4?V$?^@QKO\
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M*=_]BW%_^GL*/H_5?E(]>HHHK^C!!1110 4444 %%%% !1110 4444 %%%%
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MBL'^QKG_ *&#7/\ O[IG_P J:/[&N?\ H8-<_P"_NF?_ "IH WJ*P?[&N?\
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M&_$/A[Q)X/\ %OA_Q%X>U[1]3EANK._EL-1MM*U_2]9T;3@#W6BBB@ HHHH
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M;W_I+7_P6H_\38T#_P"<O1_PYEO?^DM?_!:C_P 38T#_ .<O0!^TV]/[R_\
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MTC2] T+2+6*QTK1=%T^TTK2=,LH%VP6>GZ;80V]E96L*_+%;VT$4,:\(@%?
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M?B,F72KV**>UG_22B@!  HP/4GUY))/ZDTM%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>fampyra.jpg
<TEXT>
begin 644 fampyra.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  C 'X# 2(  A$! Q$!_\0
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MM@''\S110T@N%I:01VT>V-1\H_EBG?8;<.7\I=Q&,_Y^@HHH458&W<<;2!@
M8EP.F.,=_P"M2A0%VXXQC%%%.PC#U#PIHMR&EDTZ'>3DE<K_ "(K.M_!VAM,
M U@I&>AD?_&BBLY15]C*45?8WK70=,LHFCM[&!$?AAMSG\34,GAS26<$V,0/
MMD#\J**)PBUJC>$G'X78M6>E65B=UM:Q1M_> Y_.KE%%:122T$VV[L****8@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>finhighlights.jpg
<TEXT>
begin 644 finhighlights.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &Q 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S3XS_ !#_
M .%1_"'XI_%3^R&\0?\ "M?AQXZ\?_V$EY_9SZU_PA?A75_$W]DI?_9KW[$V
MI?V7]B6[^R77V8SB?[-/Y?E/\/?"'_@HGX%UGX=VGQ#^+_B_]GZ2S\0VC:GX
M:TW]DKXE_$;]K[4K+3-!\,:9XL^(]WX_L/ _P5T74_!EK\.=(\1>&+SQ1JLV
MG7NBZ3:ZYI[ZQJ.F7.J:%::K]T?%WX>6?Q;^%7Q+^%>H:E=Z-8_$KX?^-/ %
M[J^GQ6\]]I=IXS\,ZIX:N=1LH+L-:S7=C!JDEU;17*FWDFB1)@8V85\Z^/\
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MX2^$OAWP[H6M^.?&>LV.C7_C?Q?>6\4&H'P[H-EX:\.^$-+MKVPU#Y[\>?\
M!*GP'\0?&GQ,\9ZS\4O$']J>/--_:<TBTUW_ (0#X;7'Q"L=*_:F^'WCKP-X
MJT;Q)\4[G1I/'7CKP]\/(?&[1?![PWJ^JV6@^"_#'A_P[X0N=.UNRTC3=0L@
M#ZOB_;6_9WN+97M_%7B>?5I/B#;_  RA\&P?"GXLR_$:Y\477@Y_B-;O9?#6
M/P0WCR]\.3?#B.3X@Q^,;7P]+X3;P;'+K@UG[/$ZBM\/OVCO&GQ:_93^#_[0
MWPR^#TGBSQ5\9O!_PS\4Z%\.1XXT_1]'T6#XB-I<L^I^)/'VI:,'M?"/A#2K
M^XU[Q!JVE^$-8\276EZ?+;^'O!VL:Y=66E2\MXR_8R76?C1KO[0'@_XM^*O
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MGXTPVM_(OA>STZ+Q$_C9O#M]K6G7?@#2OB WAP>&=1^)4!\*Q2I!=:=K5_\
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MR^'WA?5?V:_AGXHU/0O"\WBCQ)J^H:;I5_XBU/4=:N;".\:U;4;VXN(XHV?
M /VNHK!_X1O2O[EY_P"#;6/_ )84?\(WI7]R\_\ !MK'_P L* -ZBL'_ (1O
M2O[EY_X-M8_^6%'_  C>E?W+S_P;:Q_\L* -ZBL'_A&]*_N7G_@VUC_Y84?\
M(WI7]R\_\&VL?_+"@#>HK!_X1O2O[EY_X-M8_P#EA1_PC>E?W+S_ ,&VL?\
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M@(5*='VU2%:K*=:JW[.C2H8>G6KUJLE&4N2E2G)4X5*DDJ=.<H_LK17YA?\
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MS?M?>#[Y8V\$_"C]ICXB)+_JI_#W[/'Q,T'3YATS%K/Q+T;P!HC+O#)O&H[
MRL68*I:OI_2M$T?0[1+#1=+T[2+*/&RSTJRM=-M4"C:H6WLHH(E 7"@!
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M865FOBIO%MNUYIGC>YM&TF[N=&T_]'5(9589PP!&>N",\^] #)O]5+_US?\
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M;XDU;P=KNLZ59"46&G^()M)E6UUR+3Q,\>GW&HVD^H6-OMM+6\BLT2W7WO\
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MNEZ?;C]E'X42F&QTZRLX+.TC::669UMX(P\TT\S[I9I7?]UIO]5+_P!<W_\
M037XD_\ !+[_ )/F_P""X?\ V?=\,O\ UDWX2T ?M)_8.B?] C2__!=9?_&*
M/[!T3_H$:7_X+K+_ .,5K44 9/\ 8.B?] C2_P#P767_ ,8H_L'1/^@1I?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^D?%&^^%T.MQ_#^]^(^D^%K"QT/3_&-SX>DU>VM].TF[68ZKHVD:A8_1@
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M$E\._P#0=TC_ ,&-I_\ ':/^$E\._P#0=TC_ ,&-I_\ ':VZ* ,3_A)?#O\
MT'=(_P#!C:?_ !VC_A)?#O\ T'=(_P#!C:?_ !VMNB@#$_X27P[_ -!W2/\
MP8VG_P =H_X27P[_ -!W2/\ P8VG_P =K;HH Q/^$E\._P#0=TC_ ,&-I_\
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M-A0X;:;-_, V[X\[Q*EU\=XV#2:#\)KM,$&*/Q;XST]\G&'$[^#-14[>08S
M-V<B1=NUP#UVLJZUW1+*=[:\U?2[6XC"F2"YU&S@F0.H="\4LZ2*'1E9=RC<
MI##((->>'6?C7;D&7P%\.;U&R-EG\3M?MY$8<AF-[\,@C(1E<(=X8@XVY(_,
M;]N3PQJ6MZO8>/M3\+:-H.OZ/;6?A[Q7!I.IMK\,VGW)%QX>U&?4Y=)T<W#V
MCW$ME-*=/@:&*^M+61YDLXI6X\7C\+@I82.)JJD\=BX8'#-IN,\55IU:M.DY
M)-1=149Q@Y64JCA!/FG%,/U_L]9TC4)6AL-4TZ]F5#(T5I?6MS(L:LJF0QP3
M2.$#.JER H9E!.6 .E7YI_\ !/[P=;>%['5=8N])M8]=\::4NHK?NA6]L_#M
MA=0)I6G1)L"Q1:A+<W&KW1SOFW:<K@BUCV_I91@L?A<PA6J82JJT,/BJ^#J3
M2DH^WPT_9UHQ;24XQG=*<;PE:\9-:@%%%%=@!1110 4444 %%%% !1110 4A
MQ@YX&#DG@8[Y/:EJK>F\%G=G3X[:6^%M<&RCO)98+22[$+FV2ZF@AN)X;=Y_
M+6>6&":6.(N\<,KJJ, ?!>NV/[&>O_'WQ#J8^%7B+QS\8='\>^%M%\9>.O!7
MP<^-/C/1M"\?Z;IWAW4="TWQ5\0?"/AV_P# FGZIX:TC5?#U[J-OJ&L"'PMI
M]W;G6UT]?/C7[^'MZG^?/7W_ /K<5^=4O[/GQY3XU7?Q'TQ-$T#2_%WB?P)X
MJ\<Z?X=_:S_:$T/0[[5M)T7PUIOB:ZLOA99?"_\ X02Y9ETN?34C>[TQO&FE
MZ?I#^+;BTN)I8M/_ $5'^/\ .@ I"0,9(&3@9(&3Z#U/M2U^1G[9GQD^.UA\
M:_B3X6\":U\5O"?@/]GS]FCP=^T7KM_\+_$7P6\'ZA?PZ_XJ^,MEXI\4W-Q\
M8M"\3:9\2&^'6B_"2RBTGX22?\(5X,UFY\4:O/\ $OQMI2WOP_FB /UR) &2
M0 .I)P/S-!(&,D#/ R1R?0>OX5\#_'+XB^)_'7CG]DCX1^#OB+XI^&_@S]H&
M3X@:WXI^(7@^'3="\>WH\%_"BU^(/A+X<Z)<>(-'UY?!>M^,XM3O?&VHQOI+
M>(O^$5^''B'1[-K6"_O[V/X%TG]I']H#XF?#KX\:]JO[1VK^!-4_9+_9E\>?
M%CP)XN\,Z5\.M-T+]H?7O OQM_:_^&NG?&+XC:7>>&]8L?$'PTU?PY^SE\/Y
M];\(>"(_"&BR7WQ.\2ZII\NFKJ7PRO-" /WRR,[<C.,XR,X]<=<>]+7XU:7\
M??CGK=^OQ^OOB#XG\):Y9_MR?"#]E>X_91O+?PL_A*W^'OCW5/A;X8U_1]5L
M9M"'BJY^*5CX?^(&I?M'6WC6T\3VTMMX9T?3=&^PGP)%K,5_^R:G*J<@Y .1
MP#D=0,G /4#/2@!LW^JE_P"N;_\ H)K\2?\ @E]_R?-_P7#_ .S[OAE_ZR;\
M):_6[X@?%/0/AZ]E:ZSH7Q*UA]4MKN6W?P'\)?B9\2885MVCB=-0N/ 7A7Q%
M;Z7,[3*;:#4I;2:Z19)+=)(X973\9_\ @E-XPTW7/VR_^"V&O6FF^++2SU7]
MN;X97-O::WX)\6^'];@0?LI_"J';J?A[6]&L-<TB8M"SI!J>GVD[P/;W*QF"
MY@D< _>2BL3^W[3_ )]-;_\ ">US_P"0*/[?M/\ GTUO_P )[7/_ ) H VZ*
MQ/[?M/\ GTUO_P )[7/_ ) H_M^T_P"?36__  GM<_\ D"@#;HKY7\3?%CQ?
MI_B#6+*PNK>&QMKZ6&TBNM(5+F.%50JLZ7/ESK("QR)8T?&"5&175?#GXE:S
MK-WJL?B!Y;U(+:U>R@TG0[F><RO+,LV\6$4^U-B)M:=HH\AMK$A@/B,-Q_D6
M)S7^QU'&TL0L1B,,ZM>E0IX95,,JOM+U%B92Y9.C*--^SO*3BN5.6CMI>ZV3
MMK?6WEYH]^HK@I?&UX9&BL_!GBV4J<&:\TU[&V/NKK]JG8?[ML3UXXJ/_A(/
M$DYXL;?2E(Z2:'XOUJ5?J(M*T>'(]!*P[D]J^H_M&C*WLJ.-K-VY>3!8F$)7
MM9QKUZ='#M:K7VR7F(]!HKST2ZA/G[=X@\4A6ZQZ3X.N=-0>P>YTG5+M1]+H
M-_M=,)_9_AV48OX/&&JGO_:4'B^YC/?'V;RDLP/9;<#VH^L8Z?\ #R]TWU^N
M8NC27HGA%CV_FH^=@.QO-9T?3CB_U73K)N?EN[VVMV..P661&)]@"2> ,UD_
M\)AHLF19'4=48=!I>D:I?(?I<0VAM,>YG ]ZKV;>&M/(-CX>N;-ACY[;PCJ<
M,AQT)D32P['W9B?>M7^W[3_GTUO_ ,)[7/\ Y HY<SGJZV"PZ?V(X>OB9)>5
M:6(PL6UW>':\@*7]N:S/C[#X3U+!./,U6]TS3(^_)2.YU"\ Z=;0-R?ER,4?
M\5E<'D^&]+0XZ#4M:F7/7OHD6X?1ESQR.:N_V_:?\^FM_P#A/:Y_\@4?V_:?
M\^FM_P#A/:Y_\@4+!59:5LPQM6+WA%X?#1O_ '9X;#T<1%>7MV_,"E_8>L3@
MB^\6:F5/6/2[/3-,C(ST$C6M[>*,<$K=JW<,*^9_BC\+-9\2:QX@T\>']2\0
M^']4LK6SGDO;E+PW\+V-NES'+/<727)VS(RKC882B"#:$3'U+_;]G_SZ:W_X
M3VN?_*^OR]_:L_:U/B47_P -/A=J$\/A\^99^*_%5OYUI<:TP)CN- T9R(KB
MWTE&#0ZMJ*^7-J;A[&T*Z<)Y[[?#^&CX^K8;*L-7Q^$6%Q5#'5LTAB:U>>!A
M252$9NMBWB)1;=1RHTJ3A4J5J<7&48PG.'RO%W&&5<&954S+,I\]2?-2P.!I
MR2Q&/Q*2DJ5)._)"%XRKUY)PH4VFU*I.E2J?9OP@\'^(O#WB*XN-4T6YTVR_
ML2:TADE%NL0<7%CY,")#-(5Q%"VQ0@54CQD8 KZ0K\S_ -E+]K7STT[X8_%*
M_GEO<V^G^#_%<R3W=QJ3.R6]GX=UHQ)+/+J99H[?2-3*L=0&RROF%\L-Q>_H
MK_;]I_SZ:W_X3VN?_(%="X%K^'JGP_5G7KTXUJN)H8NMR2CBJ=:2_>TITZ=*
M+C>-I0<54ISYH5-4;<+<595Q?E5+-<KJ7B[4\5A9M+$8'$J*<\/B()NTHWO"
MHKPK4VJE-N+TVZ*Q/[?M/^?36_\ PGM<_P#D"C^W[3_GTUO_ ,)[7/\ Y H/
MI#;HK$_M^T_Y]-;_ /">US_Y J[9ZA#?>9Y4-]%Y6S=]LTZ^L-V_=CR_MMO!
MYN-IW^7NV97=C<N0"]1110 4444 %%%% !69K3ZE'H^JR:.^G1ZNFG7SZ7)K
M#3II*:BMK*UD^J-:E;E=-6Y$37[6S"X6T$Q@(E"&M.F21QRH\4J))'(K))'(
MJNCHX*LCHP*LK*2K*P(8$@@@D4 ?BCX17_@J-XBN/AGXE\0S7&CZOX1U/]G_
M ,"7.C37&CVWA'QOXJU'Q/J'B+]KKXH>-;/PU+?V&K_"&/P$#X-^#5U%<Z7?
M6FKV&GZCX2T%=6UNVU.7]J[:>&ZMX;FWFBN()XDEBGAD2:&5'4,LD<L3/'(C
M Y5T9E8'*D@YKYSNOV1_V?[N^DN7\"20:?/<F[N/"%AXO\>Z9\.+F9VWR&Z^
M%VF>*K/X;W23-N,T,_A22"8/(LL3K+('^A["PL=+LK33=,L[73].L+:"SL;"
MQMX;2RLK2VB6&VM;2UMTC@MK:WA1(H8(8TBBC18XT5%  !;KRKXC_ SX,_&&
MZ\.7WQ5^%?P^^(M[X1NI;SPQ=^-?".A^);C0YKA[>6Z&G2ZM973V]O=SV=A<
M7EF";*[N=.TZYN;>6?3[.2#U6B@#PC7OV9/@-XL?XFMXP^%G@OQ@GQ@\7>'/
M'?Q @\4^']+UNWU_Q7X0\&>'? 'A?6IXKRU<)J.@^%/"^CZ3I>H(1J%I;0/'
M'=B*4QC3\2?L[_ 7QA#X MO%/P8^%NOVWPJ%HGPTMM5\!^&+RV\!6]@EBEE9
M>$;:;3&M]!TZT_LG1Y+?3-.C@TZ*?1=%N4M1<:1ILMK[)10!Y?-\$_@_<?$Z
MV^-%Q\,? <_Q;L]/.EVOQ)E\*Z+)XVM[(V4NF"&+Q&]F=41DTJXN=)CG%Q]I
MBTB[N]*BG33KJXM9?4*** (I@#%+D _NWZC/\)_P%?B5_P $O@!^W+_P7" &
M!_PW=\,N!_V:;\):_;:;_52_]<W_ /037XD_\$OO^3YO^"X?_9]WPR_]9-^$
MM '[=4444 %%%% 'S%XJ^$_B[6/$FMZI9II9M+_49KFV,M^T<IB=4"F2,6KA
M&RIRNXX]37:?"SP+K_A"^UB?6%LEBO;2SA@^RW37#%X9KB23>##%M 61=IYR
M21@8KSG]H[]J+1/@C!;Z'HUM9>)?B!?"WN4T2>XDCL-'TMY%9K_79K4F>!KR
M)9(]+L8\75R[?;'5+*$M/ZW\(?B_X3^,WA.W\3^&)RDJ%+;6]#N'0ZGX?U0Q
MAY+"_C0X9&&9+*^C'V74+;;<0,")8H?$H>%%/*9X;C583,X4J^,Q-:CB*M:E
M+#NKBE5C*<J*HJK"A5]O4CAZDG&$Y0M&<FES>!A^*LAQ6>8KANAF6&J9S@Z,
M*U?"1D^9)WYZ<*EO9U:]",8SQ%"G.56C"I&4X)<_)ZI17"^(?B=\//"CM#XB
M\:^&=)NE;:+"ZUFQ&I2-S\D6F1S2:A,_!^2*U=L\8R:Y<?&2RU+:/!_@;XD^
M,Q*F8;NP\(W7AW278@%<:SX[E\*6$D9R,RVLETH7YP&!&?J:>68^K"-6&$K1
MHRVKU(>QPUDD]<16Y*$59KXJB_ [*V=950J2HSQ^&EB(NSPE&HL3C+WM:.#P
M_M<5)WZ1I-^1[%1D#J<5XY_:WQQUD Z?X0\">"H-X4S>*O$NI>*M3"DY+MHO
MA?3].TW*KQY8\5MEOXPO)/\ A7WC_5]__"4?&+Q"D4AW-8> ] \/^#+,$CF-
M;V\@\4>(P@SC?'KD$C$!@4/%:++Z</\ ><PP%!K5PA5J8R;6E^26!I8G#\VN
MBG7AYM69C_:U6KK@\HS7$Q:TJ5*-++:<6U=<\,TK8+%\NZ<J6%K6Z*5SUV>X
M@M8I+BYFBMX(5+RSSR)##&@ZM)+(5C11D9+, .YKS'4/C=\*]/N?L*>,]+UG
M4<LITOPJMYXQU4.IVF-M-\*6NLWD;[L+B2),,<'%5H/@7\,O/BO-8\/R^,+Z
M/#&]\=ZSK?C>6249_>F'Q/J.IV43$DD+;VD$:_P1H  /3M.TK3-(M4L=)T^Q
MTNRB $5IIUI;V-M& , )!:QPQ( . %0 46RFGN\PQC[)8?+XI]6I/^TG--ZJ
M].D[;V87S^OM'*<N6Z<I8O-I26C2E!+)E2E:Z=JE9)[75K^5'XG>*-54CPG\
M(/'FH_-@7OBHZ+X TS:3A6=->U&3Q&%SRX3PU)(J\A&;Y*4V_P =M;+"74/A
MMX#M90"HL;+7_B#J\0QG:MU?3>"](CE/*EFTV^B7@A9!P?8\#THH^OT:?^[9
M=@Z36U6LJN,J-:.TX8FK4PDG=;K"1OV0_P"R\15_WS.,RK1>LJ.'G0RZC?\
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M#'CJPP,$]Q@8/%0&RM#=K?FUM_MR6[VB7GDQ_:EM9)$FDM5N-OG"V>:..5X
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M_P#Z":_$G_@E]_R?-_P7#_[/N^&7_K)OPEH _;JBBB@ HHHH **** "BBB@
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MR7-QILD#I$D45PLCRQ?B1X3_ &(O^"MOP:_:)_;&^-W[._QY_8%\#:'^U_\
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M*_%__A7G_!?7_HZ#_@EK_P"(E?M-?_1'UYK\9IO^"]'P;^$'Q5^+NI?M'_\
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MX7^.M-^&WCSXG>'_  [XQU%?#<DFF72ZI/;:%#XSUF7P[X+N/&6MV&G7F@>
M[;QIX@M[C0O!MSXWU7P];^*]9MKC3- DU&\@EA0 [OXL?"SPA\:? .O?#7QY
M:7E]X5\2+IBZK:V&I7FD7<HTG6M,U^R\K4+"2*ZM]FI:392/Y3KYL:/ ^8I7
M4^B !1@=,L?Q9BQ_4FO"M)_::^!.N?%C4/@AI7Q)T"[^)FFS:O93>'D&I)#<
M:QX>T^WU;Q)X9TOQ!-I\?A;6_%_AC2;J'5O%'@W1M<O_ !5X:THOJ6NZ/I]E
M%--'5M?VJ/V>-0^'GC/XL:;\7?!>J?#GP!XSU;X<^*?&&EZH=4T6R\?:)K=A
MX9OO!EG<Z?#='7?$Q\3ZIIWABQT;P]'JU_JWB2]MM!TB&^U:5;,@'T!17G/P
MO^+/P_\ C+X:;Q9\.?$47B#2(-2O-%U!7L-7T36-$UNP2WEO-#\2>&O$>G:/
MXE\,ZW;V]Y97DNC^(=(TS4EL+_3[_P"RFRO[.>;T:@ HHHH **** "BBB@ K
MC/B/X!\.?%7X>^.OAAXQM[F[\)?$;P;XH\!^*+2SO;G3;NY\.^,-"O\ P[K=
MO:ZC9O'=V%S-I>I744%[:R)<6LK)/ ZRQHP\V^+G[4/P%^!.K:5H7Q7^)>@^
M#]5U;2KOQ$+.\CU6^DTCPG87L&FZAXV\5OHNFZG%X*\!Z?J%Q%8W_COQC)H/
M@^RO"UM=:Y%-'*D<U_\ M,_ K2_BOI_P2OOB3H%O\2M4N=.TZTT%AJ36O]O:
MQH4WBG1?"=SXDCT]_"=CXVUOPO!)XHT3P/?:];>+]9\,[/$&EZ)=Z1+#>2 '
MM.FZ?;:3I]CIEFK)::=9VMC:H\C2NMO9V\=M KR.2\C+%$@9W)9R"S$DFKM>
M(6_[2?P%N]*^,FO6OQ:\"7&@_L]ZS<^'?C3KL6OV;Z)\-]>LO#.C^,+_ $;Q
M/JZN=-L]3L/#VOZ1?7]E'=3W%D]]#87,<6IB2R3<^%'QJ^&?QMTC5=9^&OB:
M/7H-!U<Z#XAL+G2]=\.>(O#>M?8++5HM+\2^$_%>E:%XI\.WUUI&I:;K-C;Z
MWHUA)J&C:EI^KV(N-.OK6YE /4Z*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *_-#]JC1?C3\1_B>/@_9_LJ^/O$7[,
MGB&+P1KGQD^(WPS\3?LZVGB/XX7>FZK;W%M\)]9L_B#\8/A[XF\*?#;0K?2;
M&/XC^(3HGBGQ1XT\.WUSX!\"VGARPGU3Q+/^E]% 'Y,6'[.OQR&K?#?X2ZY\
M-WO_  '\&/VOOC_^U;<_&.W\9^![JT^*OA7XF:Q^T)XVT?X;:-X-N]1LO$MA
M\1O$]]^T#-\//B;_ ,)=I&C?#R?PKI/BK4;#QAJ*>*+#1;#QN/X&?M%^.?@7
M^T%\(4_93\?_  7T7Q9^U1X?^-OA>VD^(7[.VA^)K/X5:5XF^&=]INE? 3Q%
M\,OC!XPT[X2?M!>!3X%M=>^&_B#6K71/"OA&[TJRDT7Q7IVM'3KW3?W+HH ^
M&_V%OA1\4?A1X2^+5K\1K3QA9V7C'XQ:IXW\$K\7/&'A;XC_ +0$OA[4O!7@
M?2;T_&_XB^";[5?"_B_Q!8^(M#U;1/ DECK.OW?AOX/Z1\/?!NHZY>R^'HH+
M+[DHHH **** "BBB@ HHHH _.C]M>V^/7B[49/@_\./V;O'GC+X1_%CX=7GA
MSX^_&CX6>(_V?=/^)-UX-FO-=TR3X'>#M/\ B[\6?A?>Z/?>(=*UO7[G4OB9
M=MKVG^!-%\27X\":'=>/=:;7_"/ETW[-GQKBU+QC\%M*^&\=K\./B+^V;\$_
MVL-/^-;>,/!MC#\.O!/PY\4_!;XE7_PTU+PI;:C>>+[OXF:%J/P83X2^!9/#
MNCZMX C^'VJ>'=7OO&=G+X?OO#=U^M%% 'XX:#\&_B9XJMOVVOA]??L:?%3X
M0?#[XJ:W\//B'\%&T7XD?LM^#++2M;^#'P^^$>G^%K#PU_PA/Q#^*-KX)\6+
M\3?A_+XR\&CQ!\.-9^'UR+&T/CY+6VU34M(D^EOV.O@]\8_#'Q _: ^-OQKN
M_%Z^)?C&?A-X?T[2/'UY\-I/%MOHGPD\.^)+!-;U?1?@U?ZQ\+?![:YJOC/5
M8+'PQX7\1>+[B/2]%LM>U_Q5<ZOX@GT'PY]\T4 %%%% !1110 4444 %%%%
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M\TF*:"XMXHH$W37$D=HKSK_07A/X/<%\:8#/<3FW%L,;6P$J=.G3R"KB,#'
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M\ ].\.:OK?B3PGX^4^%O GC#XA?#[XT7^L>'_@7XWUW7O!=Q\5XO$.C"UO\
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M\A-)VND[.ZNKV?==F%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
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M4^=:7'DR(TEO,!+"Q\N55D5E&O7SR/AS\>P !^T7:@   #X->$P !P !_;'
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MWK\S/B]\ OB[XD_:F\0^/+?P)<^-K?6_#_PEL?@7\9H_BC#X2MOV4]1\*_\
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M'7]G62U^#VF>/;;P_8?$;]D_X=? 3X+^%?&GP2\))?:U9>$_ ^CS?%KPQ?\
MC+4/!FL77AKP_P#%2;P'9^'/&^K+X5\30WEOXMJ7[!/[1NL^&/&=Z_A6\TWQ
M!IWPNT7_ (9VTFW^-ETVH_!#6#^VG\8?BOX<\!Z'XCM_$=M%8^(?A1\ O%_A
M;P?;>,+&>YTJTL!?_#CPAKNJ>%-/7^T@#]^ 01D9_$$'\B ?TI-XQGYOIL?/
M_?.W./?&,\=:_.7PW^S9\9?!_P"S_P#MR?!SX6:A#\);WQ_XW^,4_P"RI<V?
MBJ]_LCP-H/C?X/\ @*UT:ZT:YTZXU75?AW8S?%H?$#5W@TV!=1\-ZEJM_P"*
MM'TOSKFRBE^.=1^ 'COPUX@\!+)^RKK>E_!;QU^T'X:N++]C>V^+>@ZZAM?"
M?['/[26D_$_Q/JNL6WBJY^%%M9_$?QAJ7P]:+P5XB\;:?X8\7ZE\/+3QYXON
M]+^(/C&;27 /W@W D#GG_9; ]B<84^H)!'<4;P.S=<?<<_R7ISUZ?D:_ ;X;
M?L,_MD:!\6_@)X@^(WC+QGK\/@_3OV99-%\2>&O%'PL\0P_!GPU\-=?N-5^)
M'PCU3Q]\2GF^+UY9:[H_F>%/$FN_#OPWK[?'SP_J<VE>/-5\'OIFF:W;<Q\6
MOV!_VG]0^!>@^ _!'P]M8?'VI?#[]I?7O^%@Z7X[\ :Y\0/"7[2/BSQO?ZI\
M(==USQ/\7[_Q#HOAKP-I7A.#0-+\/^-/A/X9\1_%[P$^GZ=X8\+WG@KPY:7-
MW= '[S-\3O K:DFD6GB"VU;4?^$[/PTO+;0;;4/$+:)XX7PL_C5] \3/H=GJ
M,7A6XC\,"#59;GQ+)I6GQ1:CHL$EXEWKNC6]]W6\$9PV/='!]>A7/Z>W6OQB
MTG]C/XP^%_&GQSF^%GP_T;X0^*OBK^U'??'Z;XZ>']6\'06VJ'QQ^PW\1?A5
M;ZEK^C:9K3>*M9\2?"[]HW79?%VLZ1J^B2Z-JQ\56_BOPMJ&LW1URUT3A_!?
M[#GQ9\0>(OA7!K?P3N/A9\&+#Q]^SC<_%SX/W?QT3QG:^,O$GPX^$W[46A?&
M7XT:K=:1XDNX?%6B_$O5_B/\(?"6JV>L74?C?XOV7AJ7Q)\5_!^G?V;':W0!
M^ZNX<<-ST^1^_K\OR_\  L8[TZOP@MOV0_VHO#NK?L^ZIIOPXN?%'B[X97EK
MX;\-WGC?XE>$/%'PM^'?@/PS^UE\3?%WAV$._BOPU\:/ACK%C\ ]<\):19^+
M/@_KOQ+D^(>E:5X2^%?Q:^'9\.> T76OW>4$#!P.3C'ID[?QVXR!P#D#C% "
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1RQ13QO
M#/''-%(-KQ2HLD;K_=='!5A[$$50_L71O^@3IG_@!:__ !JM.BLYT:51IU*5
M.HTK)SA&32WLG)-I7Z ,BBB@C2*&..&*-0L<42+'&BCHJ(@"JH[   4^BBK2
M222222222LDEHDDM$DMD 4444P"BBB@ HHHH **** "C_/\ GU_&BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHI&!*L%.UB" V =I(X.#P<'G!X/2O S\/?CEDX_:#4#)P/\ A4GA X&>!DZA
MDX'&3R>IKKPN&HXCG]KC\)@>3EY?K4,=/VO-S7Y/J6"QEN2RYO:>SOS1Y.?W
MN7@QV,Q&$]E[#*L?F?M.?G^HU,KI^QY>3E]K_:699??VG-+D]C[6WLY^TY+T
M^?WF::*WBEGGECA@AC>6::5UCBBBC4O)))(Y5(XXT5G=W9515+,0H)'P_'^W
M+\/7^*Y\(&$+\/R!ID?Q",S"V;7//*&\:T*?+X3;BV36"WF^:/[1: :0PN1H
M?&OX,_'_ ,5_#C7]'LOC*WBN26))YO"L?@O0?!__  D=K;L9)](;6M,O))E^
MTJ,QV5QLL-0ECCL[^2.VF=U_'%]-U)-2;2'L+Y=76^.F-I;6DXU)=2$_V0Z<
M;#R_M7V_[5_HWV/RO/,_[D1ER!7ZCP3P7D.<X7,:V-S*CF-6,7AX4L#+%4/J
M//%2CC)K%X?"UIU&TU1YJ,L*E"HI.O)N-'\-\3/$GBOAS&Y/ALMR7$Y/0J3C
MBZM?,Z>!Q7]INE/EGEU-X#%X[#TZ*BXO$^SQ4,>W4I.G]6IJ,\1_2]%+'/''
M-#(DL4J))%+&ZR1R1R*'22-T)5T=2&1U)5E(9200:DKXI^"/P?\ V@_#?PWT
M#2M2^,;>$9(HGEM?"LW@O0O%\OAVQG(DM=*DUG5+R*8O;(3OL(/-LM-9S8VD
MTD,"FO6#\/?CG@X_:$4''!_X5'X/.#ZX_M&O@<7E& P^*Q&'I\1936A1K5*4
M*JI9PU4C"3BIWH97B*+NE=NE7K4WKR5:D>64OU?+^(,UQ>!P>*K<'Y_AZN(P
MU&M4H/$</+V4ZE.,Y4[8G/<+B4HN325?"X>LDOWM"E.\%[]TKY_U7]J?X :'
MJ/QPTG5OB;H=CJ?[-USX'M/C;836^L?:_ $GQ(T72O$'@:74[=-,:2]L_$NE
MZU8RZ=J&B+JE@UR+_39[F'4])U6SLO?$5UB5))/-D$:J\FT1^8X4!GV E4WL
M"VT$A<[0<"OR _:V_8W^,WQ!T_X^^._A5X>T74_B3XT^,7AK0[7P]JOB72]&
MT[XD?LT^)M _9?L?'MA>:I,WD:+XH^'_ (P^&&N?$;X=KK!#'4-"\2>&H38Z
M;\6-3OSX/X_UYGU2VVMY.UUY.S:^YM>9^LGB;Q3X;\&>'M:\6^+M<TOPSX7\
M.:==ZQK_ (AUV\ATK1M'TJPB>>]U'4M2O6AM+.RM84>:>YFE2&.)6D9P@S2:
MWXGTCP]<>'K;4Y+Y9?%.OP^&='%EH^LZM&^KSZ;JNJQQW\VDZ??0:)9?8]&O
MR^L:W)IVC17*VUA+J"7^H:?:W7X!>)/^"<?[1/Q%TK]L/PK\2([OQS>_%;P#
M^UCID.I^+9O@G;_#+XS:Q\1/B(OC?]GNVUN?2+;5OB_K4_PRM-/\-6_A2;XF
M6_AC2_@5?:')X=\#/XR\(7\LI_5/X@?#?QIXJ\$_LM6OP^^'L_PSL/ 'C2PU
MG7_AM+KGA;3&\ >#K?\ 9^^,O@?3?",R^$]=U7PGJ\/A_P 1^*/"&BKI?AS5
MM9T54BCU&PGN+'3/M,0!]D;A_M=OX&!YXX&W)]\#COBC<,@?-SC^%N,^IQA3
MZ@X(XSC(K\(-"_85^./@#P-\)_#^G?#B;Q7X(L/@'^PO'^TG\'Q\6K(3?M ?
M$WX0R_$_2OC5H.MZUXB\2)I7B+Q&T'B'X;^(KS7/%.KZ=X4^+.F_#[3OA]XF
M\0_V"MHECVH_9,^/DGQ#\%:G:_"<^'YX=9_9/UOX0^.U^/\ =>+D_8X^'GPL
M\<VVO?&[X*>9KE_:>*O&Y\>>%;77M)%YX7TC7_#_ ,0X_'W_  K;QUJ>D_#W
MX9^%-7O0#]JMXZ8;J!]Q^_OMQCU/0=S2[AG'.?=2!^!(P?P/KZ''\^=C_P $
MZ?CCIOPE6RT_P)]E^(T/[&.G6L$D?QAN#=Q_MF>$?B7-K/@'QJNMMXF,0\:>
M#O!]U=:3X7^)P<)H>B3OX6MKQ-&$>E1_2'[-G[)_[1/@']L7QS\5_B+XA\:7
MVGW?CS]H[Q%?^-;>_P#@[;>%/B7X#^)?C/4=5^#7@#5)-,M]2^-OB6#X5>$;
MSPOI&DZ#XUMO"?A[X9ZAX'-IX$UOQ/H&N7=O> 'Z]E@#@YXY^ZV.F>N,=O7K
MQU(%</X<^)WP[\83Z%:^%?&_A;Q'<>*/!.G?$KPY!HNMV&I3:[\/M7E@@TKQ
MKI,=I-*U_P"%M2FNK>*QURV$FGW;SQ+!.Y=<_E#\9OV4_P!H+XE?MGZ9\2_^
M$$TA/ MC\;/!,>L^(--U;X9CP_X]_9:U/X0+X&^)'@KQS-XH_MOXS:AXBO/$
M6HZU!K/PI\,Q^"?@?J?A*'2/$I'BKQ]<ZRES\G:/_P $T?B/X7^&WPHT/P=^
MRYX;\%>/-)_87M_V0-?\7^"/&GPT\*Z[X8\9^"?B/X8\1Z_\2=(\6:+XEL->
MB\*?&S1SXTN?#>K>'S'\0-$U74S'XW\,^&WU*:[L@#]^I_C+\.;7Q]I_PON_
M$$EGXZUC5-8T?1M!O=#\1V;ZU?:!X.T3Q]K:Z+?W.D1:5K%MI?A?Q%I-]>ZA
MIM_=:?!=SS:*]T-=L-1TRT].R/?M_"W?\/S].^*_&SXQ?L9>+)OBI!K]G^S_
M *3\8/@5X)^*7B[5-!^"UM\0]!\,#6O GB+]CWX*_!G1[30=/\2ZUI7AR"WT
M?XE>%O$]]J.A>)-9T6"**WD\>:;_ &GXFAT.VU'B_#G[)W[7OAS2_!/PK\7>
M'H_BK9^(OB7_ ,$_?B1\5OBU>_%VRNM&AT?X#^"OA1\/?CKX1U+2?$T\'CGQ
MIK6L#X=7VK17;:2FB?$/P_XBOM1\0:A9^+DO/#^N '[4^&?%7AOQIX>T?Q;X
M1US3/$WACQ#I\&JZ%X@T&\AU71]8TRZ026U_INHV336M[9W"$/!<6\CQ3(0\
M;,O-<;#\:?AA/X'\?_$F+Q;9/X'^%U]\2]-\>^(A:ZH++PY>_!_4-9TGXDV]
MVC6 NIV\*:CX>UJTOFL;>[2>73Y_[/>]4QL_\_&O_P#!/W]J/3?V8_A=\ OA
M=\!/#WPUUWX,_ ;Q[X+^''C/P#XL^"MG<:?^T=8:]+?6/Q>_M3Q??>(T\">!
M/'D%GH&L^&/%OPU\$V/[0T7B-M<TCQO?> ]#L=%U&\][\5?L/_'B[U;XX6WA
M'X56'A_Q1XV\1_\ !0KQ=JGQ@M_B_:+8_%SX<?M(^#?C9IGPA^ .H>%3?K?6
M%W8?$3QW\._B%JHU_2+3P)X(N_ $VL^'_$6I>(?%^O6D !^ZMK=V][;V]W:R
M>=;74$5S;S*KA)8)XTEBD4LJ\/&ZL 0&&<$!@0,BS\5>&M0\0:YX3L=>TF\\
M3^&K'0]3\0^'[6^MY]8T73_$O]JCP]>ZGIT;M=65MK?]AZS_ &5-/&B7W]EZ
MA]G,GV2;9^2?P>_9)_:+\+_MNZI\7?&FN^,9_#G_  M'X@>,;;Q?I5W\&+?P
MUJ_P?\1?#FZ\-> _@7K-VT6H?'#4-(\!W]UHT2_#S^SM'^'-AXA\&Z?\4M#\
M:76LZCJ'AZ_=^T#^QOX_U']H?]I;XJ?#/X/Z#K#_ !T\#?LE3^)_%FB^(_"O
M@C7/B5X5^!/Q8N=1^./[-_BKQ#<:IIOB[2I_C?\ #3_A'].T36(+:X\!:[:>
M''\'_$'7O"FFM#<WP!^L/C7QGX8^'7@SQ;\0?&FK0Z#X.\"^&=?\8^+-<NHK
MJ6WT7PUX7TJ[US7M5N(;2"YO)(-.TJPN[R6.UMI[F2.%E@@FE9$;POX<_MA?
M #XK27%KX*\5>([O5;2]\"VEUX<UOX5_%WP;XNM;;XEZCJ6D^!_$-UX.\:^
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M/QA\7X?%WPL_:C^,?A'XD7'C3X@_'WXRZNWB_0='T7X8>(_#?A_Q)I>J:_\
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MB@ HHHH **** $(SZ^O!(Z?0C\NA[T 8&.?Q))_,DG_..E+10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>flixabi.jpg
<TEXT>
begin 644 flixabi.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                    ]M8  0    #3+4%$0D4
M                                          ID97-C    _    '1C
M<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L
MH@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W
M*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R
M                                                         '1E
M>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:
M(        +5:  "\9P  DC!M9G0R      0#"0   0
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M6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9:
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MZ*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&* 0KNUG3=P3;9
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M1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J
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M+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48,
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MA-\;K:T=A80%$JJ;@VX  (,?@ ![6\;LD&5M9<%PCH!>_KP$C.A0 K;"BZ5
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MO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (
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MI+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$  (
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MI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (
M@ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L
M#ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR
M>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ
M9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%
MA[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE
M2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (
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M/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4  (
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M2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(  (
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MFI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL  (
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M/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<  (
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MPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (
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MZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (
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MM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (
M@ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,
M )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*
M<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT
M4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=
M>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=
M-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (
M@ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@
M )F0@    (  @ !I*;A_D?Y=%+1'D,A0/[ 8CX)"E*P;CFPS\:B;C>$CIZ8R
MCD40(J99BND  )C?@    (  @ !I#;?SF5E=%[.>E^901*]9EE5"DJM-E0@S
MY*?'E+8CG*5>D\P0/Z59BOP  )A(@    (  @ !H^K>/H.M=([,3GTE04:ZU
MG7Q"EJJ;G"4SZ:<+FVXCL:24F"(05J2#BPP  )>R@    (  @ #-4&QM9D2Y
MYVXP:'6ETV_8:I"0X'%C;)1[#G+?;HUD571/<'U,;'6D<E QK7:I<]8-QW@Q
M<[;+7&GN<52X6&OG<F>D;6VV<W>/GV]G=(9YXW$&=9=C/G*6=J5+87/Z=YLP
ML73<>%4,YG9T=^7)B&?)?&"VD6G<?%RBX6O+?%^.)FV9?'UXD6]6?*IB$G#_
M?-Y*67)O?00OQG,K?00,(73N?(/'NV7BAU"TPF@*AE"A&VH+A6",FFORA(=W
M*FW-@]-@VV^,@R])5'$%@HTNZ7&9@>L+=G.;@+C&&&1&DC2S*69\D%2?@VB-
MCGZ+#VJ#C+MUUVQNBQ=?LFY#B:)(8&_"B$$N'G KAQ\*Y')XA%+$Q6, G2&Q
MW64_FG">.&=5E[6)RFE3E0ITIFM'DH5>I6TAD#-'@FZFCBDM:6[FC,4*:'&$
MAPG#MF']J!.PU&1 I)>=*F95H/J(NVA4G6MSJ6I2FA-=R&PSEO]&QVVQE%0L
MTFW+DO,* G"YAL3"[6$\LPFP#6-_KL2<4V6-JDR'VV>%I=MRRFF$H;A<_VMM
MG@5&)&SJFOTL3VS9F%P)KW 4AHS":F"[O?ZOA6+ZN.>;LF3XLY.')6;BKDYR
M%VC:J7-<76K"I3Y%BVPWHCXKQFP G*@);7 2AE^^KW2.96"M!'6"9[Z:;'9Q
M:>^&OG=::_UR#WA";?M<6GDL;^Y%4WH/<;LK WK?<QD'@'T6<WV]1G(];_"K
MZ7-F<3N96G1U<G"%MG5V<YAQ#G9S=+U;:G=Q==]$=GA==N0J.'D%=Y &]7M;
M>!2[P' N>FNJ/G%R>K:7TW*:>OF$/W.V>T)OP73/>Y5:1'7D>^Q#<W;6?#(I
M6'=.?#\&>GG6?&RZ*6Y=A,JHFF^RA#.6,7#L@Y:"UW(;@OYN>'-/@H!9)W1X
M@@Y"A75N@9\HD76W@2X&#WB%@#&XKFS1CRFG)VXRC<.4OV]\C%"!;'"XBM]M
M1G'WB818&G,TB%)!J'0MASLGWG1$AGD%M'=D@VRW>&N6F9JE]&S_EVV3CVY-
ME2. 0V^1DMIL,'#9D*]7*7(6CK= XG,3C1(G/G+[C%8%9W;>@Z>V@FJ;I!2D
M_&P(H222DFU4G@5_26Z:FN9K1V_KE_E68'$NE59 /G(?DS@FO''>DB,%)W=*
M@WRURVG?KI>D/FM,JN>1Q6R1IOA^=FW/HP9J=V\BGV%5HW!NG#<_IG%=F?,F
M27#JEN($]'>A@UFU5FEBN22CN&K)M+>1(VO^K_A]QFTOJSYISVYZIO)5#V_%
MHV<_&'"NH0TEQW 5F8L$RG?G@SVP<'S_9*R@37T=9QV/$7U4:5=\EGV<:V=H
M_GWQ;6541'Y6;U,^$7[5<0\D '^K<B8!]X%G= &O4WK1;J"?,WLG<!.-WWMZ
M<6A[=7O5<JEG\WPZ<^-34WRO=10].'TL=ATC0WW)=I\!MG^N>'&N'7C5>)&=
MX'E->1F,OGFV>9%Z2WHF>@!FY'J<>G929GL?>NT\<'N=>TPBG'P">U0!?7XK
M?%>LN'<0@F><<W>8@B6+-W@6@<]X^GB6@7)EKGDG@2916GF\@.4[CWHZ@*,A
MYGID@%8!2WW1?[JK9G67C$";('8JBT")Y7:TBB5WL7<_B0!DG'?7A^M09GA]
MAOLZQWCZABLA27CHA<P!('X8@,.J3W1IEC*:"74#E'B(T761DI9VI'8CD*EC
MH7;!CM9/DG=CC3<Z&7??B_D@OW>8B[8 _7Y5@*NI<'-XH"^9)707G;Z'ZG2C
MFQ9UP74UF&5BS'7:E>).VW: D[$YBG;KDB@@479SD,P WWZ'@)>HRG+!JCF8
M<W-BIQ:'*W/HHZQT_W1RH#EB#G48G1-.*W7'FG@X_78LF1 ?[W5ZE/0 QWZP
M@(:H7')$M%B7\'+BL(J&CW-;K&)T6G/7J#AA<W1VI(%-I74BH; X?'6#GX8?
M=W2HE48 M'[1@'FB?X7%9!F3H(469HF#EX2<:,)R/X1':M%?N(0+;,I+\8/R
M;JPV@80@<$@<985A<.8  (!,=KJAF(.X;8.2IX-%;PF"@(+H<&UQ-8*?<;Y>
MPX)K<P1+%X):=#LUP()]=3@;R(-O=68  (  >KF@BX'9=M619H&(=XN!78$[
M>"MP$H$#>,!=P(#>>55*.(#7>>0U!8#S>D\;-X&:>BP  (  ?CJ?9H 9@"60
M,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<  (
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M.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (
M@ "4T8\,8Y*&\HV=9?%W\(QY:"!GGXN):B=6&XJ[;!5#/8HJ;>$N=HHI;T<3
MR(R;;Q0  (  >D"4$(TM;'J&*XOW;?YW#HKE;VAFRXGT<,!568DE<@M"D8B3
M<S\MWXA]=!X38HI]<ZP  (  ?;:3,8M?=4>%'(I-=@YV&(E(=L1EU(AD=W!4
M?8>?>!I!UX<3>+DM28;N>1\3 XA_>)H  (  @ "2+(FX??N$"XBR?B1T\H?!
M?C5DZH;B?CM3J88N?D=!+H6I?E4LRX5V?E02N8:@?@8  (  @ "1,(A,ALR#
M#X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (
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M:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70  (
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M<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0  (
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MH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (
M@ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$
M4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\
M>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U
M:)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<P
MB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J
M@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (
M@ !VLYI%F>MJ2Y@&F(-<W96NELM.<Y-AE0P_'I%ED]8N8X_[D](;,(^,D3T$
MU8P<@T4  (  @ !V:YG6HBMJ I>-H'M<BY4GGEQ.')+,G$0^TI#$FQDN)X]+
MF? ;!X[-DD8$V(M2@T8  (  @ !N!JTY89-B ZI=8Y)5.J>W98-'::4[9U<X
M3:,=:/<G-J(7:AL2*J1_::<  )C3;F(  (  @ !M@ZP0:3]ANJD;:H]4_:9&
M:^%'0*.@;2HX-Z%@;E,G/Z Q;QL2<:(M;HH  )<M<VD  (  @ !M%ZJ!<+-A
M.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (
M@ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4
M )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP
M?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 V
MV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_G
MC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?
M5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (
M@ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X
M"X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$
M9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8M
MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R
M<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5
M);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (
M@ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D
M ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00
M@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M
M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(
MD'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4
MNZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (
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M6G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (
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M/&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (
M@ "=Q&J6HM..BFOCH%=^6&T%G9%M-6X=FKQ;-F]"F"M(,'!2EADST7#4E1\;
M.F\UD7H  (  @ "=5&GQK)>."&L]J7)]P6Q4I?)LEVU?HFM:I6Y]GTU'M6^*
MG0,S5F__FW@:Q&Y'DAD  (  @ "84'^77EJ*27]P849[&']X8_AJEG^>9G98
MV'_7:-5%QH N:PTPY8"^;-X6M8(];30  (  =ER74WT;9YB)1GTY::1Z 7UD
M:X=ID7V<;4U7[7WC;OY$^WY!<(\P.7Z]<<D6-G^S<;L  (  >F>6.7K7<+Z(
M 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (
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M-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (
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M^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (
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M='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (
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M>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (
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M\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (
M?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0
M+Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"
M<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(Z
MF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"
M?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB
M?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (
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MIJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP  (
M@ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8
M (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>
M=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PP
MM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX
M@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7
M&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (
M@ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H
M (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);
MD>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG
M+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ
M9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-
M2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (
M@ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP
M (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)=
M=RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\F
MDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U
M@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,
M$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (
M@ !68J<TDGY,#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD
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MU7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (
M<AV9X6V'8HV+HV[N90]\,7!!9VEKHW&,::%9Y7+1:[Y&YG0';;HR.'3U;V 8
MTG3);]P  (  =LB8A6JA;""*/VQ ;<=[$6V];U5JA6\F<,98[G"#<BA&&'')
M<W0QF7*E='P88W(F=),  (  >N*7!&@%=9F(P6G+=GYY@VMG=T9I.FSL=_E7
MOFYL>*-%%F_">4$PQW")>;<7RF_L>8P  (  ?G&5H&7&?PZ'9V>F?SQX,VE>
M?T9G^&KY?SE6QFR(?RQ$.6WM?R@P&FZ>?QX74FX&?O   (  @ "4>V/JB)*&
M3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,   (
M@ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6
MG6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2
MD;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0IGX1DV676G)Q3
MV&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!)WE27 ERMWGA
M7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (  =@F-4G7A8;J
M$':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8  (
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M=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW   (
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M.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L  (
M@ !^F'FF<<IR#GH-<O=DEGIH= 56+GJ[=/=&6WL@==,U%WN'=H@A='O4=M (
MLGUP=PL  (  @ !]@'>)>DMP^7@+>MQCC'AY>TE5+'C:>YE%M'D_>^$TBWFI
M?!LA&7G ?" (JGNA?)8  (  @ !\CW77@MYP+'9K@M]BS7;A@JU47W=&@EQ$
MY7>L@A S\G@"@=\@GW?C@=4(@WH?@5P  (  @ ![RW1QBVIO9G40BMYB#'6)
MBA!3I77QB2A$-'98B%TS7':@A]D@2G8[B \(<GC8A54  (  @ ![,7-2D_!N
MSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (
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MH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (
M@ !Q?8%"=^!EN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,"
M;H%$>\   (  @ !PIG^0?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I
M?^48,W[S?^@"C7^]?_@  (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[
M<GV;A@LK*7U]A=07]WTJAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T
MCF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC
M:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (
M@ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<
M (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<
M:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STT
MC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)
M<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:
MEHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (
M@ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"__B?1!)
M0T-?4%)/1DE,10 "$H<2?;4  ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@
MA"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (  @    (  @ !CWH> C$59
M#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(  (  @    (
M@ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L
M (  @    (  @ !<X)[Q5=]20IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-
M8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K
M49@490P:4)D19;0&WYC=9>,  ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]
M9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0
M.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (
M@ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X
M (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M
M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI
M+HZE@,X9((ZI@.L'4(P<@.   (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_F
MA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5.
M"9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (
M@ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P
M (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R
M8@<  )UL914  (  =?@  (  @ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@
M$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V
M:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$
M*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D  (  @    (
M@ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0
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M7F"Q8&1]VF,G8S5M0F5^9>9;A&>W:'=(DFFV:N0T%VL#;0$;9VI-;B   (
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M/U,&C5]W0U9/C"MG/UE:BO)60EPKB=1$*UYNB.8PJ5\4B%(8_&!-B$D  (
M@ "3@4VXF!J%>U%MED1VB%3%E$EFD5?;DE)5G5JWD)-#C%SZCRTP+%UXCGP8
MN5\YC.T  (  @ "2]$QWH9>$[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&
ME8TOR5P3E/L865YFD'8  (  @ "16&FL4V*#GFM,5R]T\VSP6LQE&VZ07C=4
M$' C87A!K'&89( M=7*E9PD3T7/&9\<  (  <>2/RF7#7+Z"4V? 7[=SMFFA
M8HED VMO93=3&6TG9\! V&ZN:AHLQV^2; (387#G;%(  (  =I6.2V(J9B"
MW61R:$ERCV:,:E=BZ&B!;$-2*6I6;A= %FOK;\4L.6RE<143$FY=<0\  (
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M,5CMDR=M$5N5D8Y=[%X"C^I-OV VCGL\6V'.C7$I;V%NC4D1@F:JBF(  (
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M<&D,;S=G &JV<*%8E6Q <?)(O6VN<R(W?6[,="LD%V[A=,L+3G->=+,  (
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M,E^HF"!BVV&EEDI4A&-DE&%%*63EDM8T>&6^DALAR61BD5$*:VYDAPL  (
M@ !X_7GN4OYM!'IB5H]@#7L 6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$
MA(#I9.T  (  >2!WLW9@6TAK]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'
M9^H<B'L%:/$$FWXI:;(  (  ?,!V?7,-8Y=JL'079=1=_'4)9_-/_'7J:>M
MN7:_:[@OQ7=];34<$'?+;=8$G'O%;KD  (  ?^]U1' %:]]I<W$Z;7U<NG)/
M;OY/$'-%<& _XG0N<9HO(73?<I8;IG2Z<N($GWFQ="@  (  @ !T$VU7=#=H
M2VZP=3I;HF_>=AU.!7#G=MX_/''6=XPNF7)[>!(;6''N>"($K7@9>;,  (
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M@H+-5>=52(+T62Q'RX,Y7#TXUH.A7P$GV81X82P2](:[894  (,Z9:X  (
M? -KEG^$6DY@D'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K9D02UX+[9E\
M ($):F(  (  ?S9JA'Q38B-?;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*
M:V<2E'^):S\  (  ;WH  (  @ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@V
MOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E
M<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<
M<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (
M@ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D
M (  @    (  @ !F$G%)B9I;-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)
MAYL12W1JAL$  (  @    (  @ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T
M"W)^C@(D+W(ACC81$7,_BO   (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI
M5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5
M*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (
M@ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L
M (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D
M;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\L
MP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?
M>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0
MUWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,  (  @    (
M@ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\
M (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9
MBS()3'LJADD  (  @    (  @ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HD
MSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G
M7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](
MW)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<  (  =N0  (
M@ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0
M (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^
M;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B
M:8AH==<1XHD?=8@"1895>$H  (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4
M>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%
MB(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74  (  @    (
M@ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P
M (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;
M6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P9
M19ZA7-@(IY]S75D  ([<9'X  (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO
M7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\
MA)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP  (  ?8   (
M@ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\
M (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I
M<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7
M:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z;9'V?>TP,I%/
M??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @    (  @ !#@)$$A,8Z
M)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@    (  @    (
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M0UUA4B!V6U_]5CEF?6**6B]5@63Y7?M#/6<788\O3VA 9+$6JFEU9E0  (
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MA$FX?DUO>DW$?G)@9E%V?HQ03E2_?JD^]%<=?M0K]5; ?PD4AUYD?U@  (
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M2%^+6G=K8V'^7;9<>V118--,669R8\,ZS&@I9G4G0FB':)0.0VX1:/\  (
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MCDX\A'AE6U'*A!E7&%3X@[!'P%>E@UDW&5DF@RDDIEB1@T0-/&FA@Q,  (
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M%V*F8<E@263:9$Y2-V;:9J]"\6B9:.0R$&G*:LX>NFE-:_<'#705;*4  (
M?5)WDEPN9]-KFE[::;Y>Y&%$:Y=1.V-R;5A"%V5+;NLQ;69E<$4>6&7><0$'
M#G03<<X  (  @ !V(UB'<'AJ7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[
M==8=N&+[=CT&YW15=X0  (  @ !T\U53>2%I0EAI><=<L%LK>DY/$5V6>KQ
M5%^)>R(P!V!8>X,=3V")>[L&UG1R?.H  (  @ !S_5*1@;EH8%7/@<9;X5BQ
M@:9.4%LR@7,_H%TF@4\O=5W$@4L=#%Y^@8@&V'1O@6D  (  @ !S/5!#BCEG
MKU.CB;E;-E:>B/A-LUDJB"<_!UL6AX8NWEM\AT$<G5SDA\4&TW1XA)T  (
M@ !RLTYPDIIG+5'MD:):L%3UD$M-+U>"CN(^F%EAC=(NBEF4C7D<0%N>C1D&
MG733A'D  (  @ !PT7%S3>)E!G*34:18>'/-555*T74&6-X[S78M7" JYW=#
M7MD6G7@P8!8 IW[F8EH  (  >-IO#VSK5=QCNVYJ61-77V_<7"Y)Z7$V7R$[
M#7)J8= J4G-:9 ,60W0)9-< SGZD9R$  (  ?(1MEFBG7?=B4FIX8)%6-FPC
M8Q%(V&V=96DZ)F[=9X@IFF^?:3<5QW!]::T X'Z&;"H  (  ?[QL-62T9A=@
M^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD \WYE<98  (
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MQ5H CC-0]UQ>C39$(EXRC"(V(%\_BVHF9UYABXD3L&0XB?,!#WXU@+@  (
M@ !DXWH,35I9W'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z 70T,S("@77@
M (  99T  (  >[1C177"5-]8J';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG
M8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P
M^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7
M:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5
M VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (
M@ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\
M (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=
M?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,M
MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1N
MB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (  @    (  @ !8\X-<3&!.
MJX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(  (  :34  (
M?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X
M (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[
M9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHF
MB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4&G0Y:4=**752:LX_578O
M;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)
M0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\  (  @    (
M@ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,
M (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z
M?[ $7'BB@"<  (  @    (  @ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D
M$6UDA=L4$&ZDA;@$47BU@NL  (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#
M46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (  ;*T  (  @ !+DXG+491"
M.(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\  (  <8X  (
M@ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H
M (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W
M9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;
ME8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV
M;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @    (  @ !&^'DQ=%T]
ME7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<  (  @    (
M@ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@
M (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU
M@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2
M>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.4=DL+)69
M5&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^09(657@U
M.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (  >70  (
M@  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8
M (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%
M:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$/
M/XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W
M<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ
M78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (  @    (
M@  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @
M (  @    (  @    /__  #__P  __\  &UF=#(     ! ,)   !
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M^27N)N,GV"C,*<$JMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y"SH
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MQ&)_=FXOO8Y^U6"TMIQ^B%-;KW!^BT9)I_9^T3G9H!U_/"Y#E\=_]"0SCOR
MZ8DSRAJ'(GN7PVJ%H&X(O).$5V"'M96#<%,TKF&"RT8VINJ"8#GEGQ>"$BZ
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M?"B&!*SM?&"% IA2?*F$*(-E?0&#:VY<?7""PEEQ??&"&$2X?IB!<#"1?W6
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MKER#36KYJ7Z"C5XMI(N!_%%*GX.!F$2BFE:!33B;E/2!$2UOCUN \B/-B9Z
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M>IY\E#(E?+E]I-;O;AB#!<-;;[^"4:]$<52!KII[<MZ!-857=&^ UW 2=A2
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MA;J%8(TIA.&$H7R8A!Z#YVN6@W&#1%J$@MN"J4FQ@EB"#3DU@?:!:2G&@:B
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M?<U]/RK(?PE^):]&=WJ"2Y_0>!&"!X^A>*6!KG[/>42!46V%>@.! EPG>MV
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MNXH>DE=\77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^
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MG73KJ5!CZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C
MCDAVV2 BB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET
M;C+=D4]VO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TAT
MF"-VK3U?E"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQY
MN5-6FJ)Z3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C
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M5$LTH(%]=T%DFZA]Q#?.EK!^+B[\D9=^IR<+C'9_-B"%AXU_RFBWK)F#8U\
MJ'J"^547I!6">TL>GV^!_D%/FI^!ES?4E;"!3"\9D+"!$R=!B[" YB#3ANZ
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M>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!3$'F>^6 \3/N?1> DB<Y?G6
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M@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^*
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MNX;P@6U:A'N"@3A=_&]<@3)A7&)^@41DM54O@5YH($?.@8AKMCKA@<=O?BZ
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M?X^ 'F'[?W" (5:^?TV "DMM?SY_]$ S?U!_[S5I?X1_]2M5?]U__"*U@$V
M W:G?FB'(FQA?G.&M&&-?EN& %90?CR%(DL ?D&$1S_<?F^#>35,?K6"LRM:
M?S.!X2+<?\>!#78I?7*.%VOH?8N-#V$8?7J+HE7I?6*)^DJE?72(5S^)?;J&
MO34=?A6%+"M??J>#BR+\?UJ!['7(?+:4RVN(?->3+V"X?,J1!%60?+2.C4I@
M?,N,&S];?1V)M#4 ?8Z'52M7?CN$[B,5?P."HW!UDEY:'F:LD-I=<%QMCW-@
MRE&SC@1D-D:YC'IGQ#O/BN-KAC%ZB4UO>"?9A\MSQ1^9AG%X6F^ID#1A8&84
MCN!D#5ODC8EFQE%,C"1IDD9TBJYL?3NQB3EOES&&A\ARV2@4AG!V92 )A3YZ
M(V[VC?YH@&55C-=JDEM,BYQLK%#$BE%NV$84B/UQ'SM\AZ]SC#&!AF=V&RA"
MA3MXXB!JA#%[QFX[B_!O@F23BN9Q %J)B<ER?U WB)UT"D6EAV]UJ3LZADIW
M9#%OA2UY.2ABA"M[-2"^@TA]0&V%BBQV<&/HB3UW7EGFB#9X04^?AQ]Y($5)
MA@UZ$CK]A0][&3%<A!A\,"A]@SU]7R$%@H%^D6SDB+I]36-9A^)]KUEHANE]
M[T\MA>%^'D3LA.%^53KF@_%^HC%<@Q]^_"B7@FY_6B% @=I_MFQ:AX6#\F+4
MAL*#P%CLA=>#64Z]A-J"UD22@^R"6#JS@Q"!YC%N@D:!@RBR@;V!'"%Q@5&
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MBG!\L#7_B')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6>
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M6,2$#WX37(N#FF^C8%Z#%6#H9&:"D5(9:+:"&$.Z;4F!IC7K<BN!-"EY=SB
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M?;A^I2'9?RQ_5VYF='B!?F3P=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@.
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MC8U^>D,?C!)^H3O]BC5^NC3YB$5^]"XXAG5_12@XA+I_JB+=@U!__QZ.@CJ
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M;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F
M-$2W9C> /#<5;/J 4RKH<\V >9?B0$R)O8L-1F&(PGVD3#Z'R6^14AN&T6$/
M6#&%W%*#7I6$ZD1T94&#]S;S;$."_"KL<TJ!_I;?/A^2LXHY1'J0QGS]2I:.
MX&\/4*N- V"B5OJ+*U(?79F)3$0L9'V'8C;8:ZV%7BKO<MZ#2Y8H/'6;(8F>
M0P"8.WR!24>5:FZR3X:2LF!A5?Z0 U'T7,>-0T0$8]>*:S:[:S2':BKR<HB$
M89=D765/_HH98&%4:7QM8W-8T6X[9JE=-U^<:A!AJU#=;;9F14*)<9EK&#2T
M==QP5B@O>F=V,)5Z6,=9:HC'7$E<_WM;7\U@CVU;8VMD'E[B9SMGM5!,:TYK
M;D(F;Z%O6#2+=%ASJ"A,>4]X?9.Z5)IBS(<86))E@WGN7'QH-FP-8'UJZEW,
M9+-MJD]R:3%PBD&/;?!SDC1&<PUV["AE>%=ZII((4-)L$(5_53)M['AS67=O
MR&KI7=%QI%S28FMSBDZU9TMUBT$4;&UWJS00<>9Z""A[=WU\II!V375U-X0<
M4C!V/W<S5LYW0VG!6WMX0UP(8&AY34X39:1Z;$"L:QY[GS/F<.A\^2B.=L%^
M>8\C2HY^/(+U3Y=^<78X5(-^FFCH67Y^O5M*7K5^Y4V:9#A_'4!=:?]_8C/$
M<!!_MRB>=B& &8X/2!2'"X(&36.&:'5M4I"%LF@[5\V$]5JQ74>$/4TF8PJ#
MC4 D:0R"XS.N;UF"-2BK=9V!A(TY1@R/BX%+2Y..$'3+4/:,>6>S5F>*V%H[
M7!:)0$R\8A2'JS_?:$J&%C.<;L.$;BBU=3""NXRB1'J7EH#!2BN52'1.3[22
MSV=)54N03EGK6R&-VTR&84>+9C^O9ZJ(Z3-\;DZ&42B^=-F#O(R^9%U08X!P
M9LE4MW.Z:519#F9^; %=:%C>;MAAU4LE<>AF;3W@=3%K/S$E>-=P@"7 ?+UV
M6(KL7_A9,G\78N5<R'*19=M@6F6':.AC[E@0;"1GD4J&;YYK6SUV<U)O6#$!
M=U]SMB7Q>YMXBXE46_%B#7VG7U-DV'%]8JEGH&219A%J:%=/::AM/TGZ;81P
M-CTD<9US5S#K=@MVRB8<>IQZF8?"6%%JSGPO7!1LSW 37\!NSV-Z8WUPS59@
M9W=RU4E(:[)T^CRS<"AW/S#"=.MYP29!>;Q\?H9851IS='KD62UTL&[G72MU
MXV)J83IW$56J98-X2DBX:A=YF#Q=;N!Z_#"H<^U\B29A>/Q^-H4J4E-[_'G7
M5JU\=&W\6O)\V&&:7TI],E3X8]I]DDA*:+%^!3P;;<-^B#"3<Q1_'29[>%E_
MO80V3_>$37C]5(R$ FT\60V#DV#R7:2#%%1D8G2"G4?=9XB",COM;-"!TC")
M<EN!<B:1=]&!$(-Y3@:,5'A44LV+1FR@5W^* F!K7$6(IU/K84F'5T=T9I:&
M$#NM;!"$T#!_<<2#@R:C=V*",(+T3(*3]'?747*2,&PG5D:0%E_\6R^-W5.5
M8%>+LD<Z9<N)D#MZ:W*'<#!?<5&%0B:Q=PJ#'X(;:XY0PW:V;6U4_FKN;W!9
M0UZK<8]=E%(.<\YA_D5E=CYFESD\>-]K:BVM>])PKR-[?OAV>X!B9V%9 '5Q
M:;A<DFG?;!M@)5W.;I-COU%=<2]G;D3D= )K1SCO=P=O4RVC>EESP"/ ?<QX
MEG[O8XMA2'059DYD(VC/:0IF_ES>:]=IW%"C;LQLSD1@<?UOXSBF=6!S(RV:
M>0EVL2/\?,-ZBWV(8 UIB7+"8RUKJ&>:9CMMQUP.:59OZD_[;*1R%D/R<"MT
M8#AS<^1VS"V;=]]Y=B0Q>]U\5GPZ7/QQL7&I8&=S&6:58\!T>EL,9R9UUD])
M:L!W/T-D;IUXP#@?<J1Z6"V(=N1\&21=>Q9]]7LG6E-YNW"M7?UZ<&6U89A[
M#EI&941[H$ZD:2%\/$,";3Q\[3?J<8E]KRU_=@A^A22">F]_8WI(6 Z!CF_E
M6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6 Q"V =4R M"2A>>2
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MWRQ;@@)O."2J@K%SWAY2@W%XI6!#?!U>D%@,?.%AGD^$?9!DN4:/?BYG[#V
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M?"8H@)9_T2&:@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0     #!"$
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M=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J^KX<*-;=#B/
M\!0_K/T>5YSP+6J/Y3YYAMY.@X'87XM_U&N0>M%PE'?/=)=USG>8<\UYFG+-
M>YMQS'V;<,M_G&_+@)UORX"=;\N G6_+@)UORX"=;\N G6_+@)UORX"=;\N
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MV9&4GMF1E)[9D92>V9&4GMF1E)[9_Z0X*O^@14#_H4I3^Z9(8O*K2''HKTB
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M@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
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MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
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MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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MDIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/
MJK=SP*JW<\"JMW/ JK=SP*JW<\"JMW/ JK=SP*JW<\"J_X\M#O^//A[_DDHM
M_YA-.?^;3T7_G5-1_YU87/B;7FCQF65RZI5M?.21=X;?C(&.VX>)E=:!D)K3
M?9:?T'F=H\YUHZ;-<JNIS'"SJLMOO:O%<K^KO7._K+9TOJRQ=;ZML76^K;%U
MOJVQ=;ZML76^K;%UOJVQ=;ZML76^K;%UOJVQ=;ZM_Y M#O^0/A[_DTDM_YE,
M.?^=3D3_GU%0_Y]66_F>7&;RG&)QZYAI>^64<X3@CWV-VXJ&E-:$C9O2?Y6@
MSWJ<I<UVHZC+<ZNKRG&UK<9QOJV^=+VNMG6]KK!VO:ZL=[VNK'>]KJQWO:ZL
M=[VNK'>]KJQWO:ZL=[VNK'>]KJQWO:ZL=[VN_Y M#O^0/A[_E4DL_YM*./^>
M3$/_H4]/_Z)46OJA667SH%]O[)UF>>:8;X/@DWF,VXZ"D]:'BIO2@9*ASWR:
MILIXHJK'=:NMPW.TK[]SO+"W=;RPL'>[L*IXN["G>;RPIWF\L*=YO+"G>;RP
MIWF\L*=YO+"G>;RPIWF\L*=YO+"G>;RP_Y$M#O^1/A[_ED@L_YQ(-_^@2D+_
MHTU-_Z126/NE5V/TI%UM[J%C=^B>:X#BF'6)W))^DM.,AYK,AH^AQH"7I\%\
MGJR]>::ON7:OL;=VNK*O=[JRJGFZLJ5ZNK*B>[NQHGN[L:)[N[&B>[NQHGN[
ML:)[N[&B>[NQHGN[L:)[N[&B>[NQ_Y$M#O^1/A[_F$<L_YU'-_^A2$'_I4M,
M_Z=05ORH56'UJ%MK[:=A=.6D:7[>GW.'U)A]D,N1A)K$BHRBOH23J+B FJVT
M?**PL'JKLZUYM;2H>KFTI'NYM*!]N;.=?;JSG7VZLYU]NK.=?;JSG7VZLYU]
MNK.=?;JSG7VZLYU]NK.=?;JS_Y(M#O^2/A[_F$8K_YY&-O^C1T'_ITE+_ZI.
M5?JK4U[RK%EHZ:Q@<>*I:'K9I7.#S9QZC\65@9J]CHBBMXB0J;&$EZZL@)^Q
MJ'ZGM*5]L;6A?;BVG7ZXM9I_N;29@+JSF8"ZLYF NK.9@+JSF8"ZLYF NK.9
M@+JSF8"ZLYF NK.9@+JS_Y(M#O^2/A[_F44K_Y]$-?^D14#_J4A)_ZQ,4_BN
M4ESOL%AEYK%?;=ZP:7;2J7&"R*!XC[^8?IJWDH6BL(R,J:J(E*ZDA9RRH(*D
MM9V!KK::@+>WEX&WMI6"N;24@KFSE(*YLY2"N;.4@KFSE(*YLY2"N;.4@KFS
ME(*YLY2"N;.4@KFS_Y,M#O^2/1[_FD0J_Z!#-?^F1#[_JT9(_ZY+4?6R4%GL
MM5=AY+=>:=JT:7/-K&^"PJ1VC[F<?)FQEH.BJI&*J:.,D:Z>B9FRF8>AM9:%
MJ[>3A;:WD82WMY"%N+60A;FTD(6YM)"%N;20A;FTD(6YM)"%N;20A;FTD(6Y
MM)"%N;20A;FT_Y,M#O^3/1[_FT,J_Z)"-/^H0CW_K45&_+%*3_*U3U;INE9=
MX;U@9-2X9W+(KVV!O:=TCK2@>IFKFH"BI)6'J9V1CJZ7CI:RDHN?M8^*J+>,
MBK.XBXFWMXN(N+6+B+FTBXBYM(N(N;2+B+FTBXBYM(N(N;2+B+FTBXBYM(N(
MN;2+B+FT_Y,M#O^3/1[_G$$J_Z- ,_^I03S_KT1%^K1(3/"Z3E/GOU99WL)@
M8,^[9G'#LVR!N*MRCJZD>)BEGGZAGIJ$J)>6C*Z1DY2RC)&<M8B/IK>%C[&X
MA8ZVMX:-N+:'C+BUAXRXM8>,N+6'C+BUAXRXM8>,N+6'C+BUAXRXM8>,N+6'
MC+BU_Y0L#O^4/1[_G4 I_Z0^,O^K/SO_L4)"^+A'2>V^3D_EQE=3VL9>7\N^
M9'&^MFJ LZ]PC:FI=IB@HWRAF)^"J)&;B:V*F9*RA9::M8&5I+=_E:ZW?I2W
MMX&1M[:"D+BU@I"XM8*0N+6"D+BU@I"XM8*0N+6"D+BU@I"XM8*0N+6"D+BU
M_Y0L#O^4/1[_GC\H_Z8],?^M/CG_M$% ]+Q&1>O$34GBSEA+T\I<7L;"8W"Y
MNFA_KK1NC*.N=)>:J7J?DJ6 IXJAAZR$GX^Q?YV7M'N<H;9XFZRW=YNWMGJ7
MN+5\E;FT?)6YM'R5N;1\E;FT?)6YM'R5N;1\E;FT?)6YM'R5N;1\E;FT_Y4L
M#O^5/1[_H#TG_Z@[,/^P/#?]N#\\\<%$0.C+3D+>TU5*SLU;7<#&86ZTOV=^
MJ+EMBIVT<I64KWB>BZM^I82HA:I]IHRO>*25LG2CG[1QHZJU<*.XM7.>N;1V
MF[FS=INYLW:;N;-VF[FS=INYLW:;N;-VF[FS=INYLW:;N;-VF[FS_Y8L#O^7
M/![_HCHF_ZHY+O^S.C3YO3PX[LA#.>/54#?7VE)(R-)97+K+7VVMQ65\H<!K
MB9>Z<).-MG:<A+-\HGVP@ZAWKHJL<JV3KVZLG;%KK*BR::VVLFRHN[%OH[NQ
M;Z.[L6^CN[%OH[NQ;Z.[L6^CN[%OH[NQ;Z.[L6^CN[%OH[NQ_Y<L#O^:.QW_
MI#<E_ZTV*_^W-S#SPSHQYM!#,-S?2C7/WU)'P=A86K/17FNFRV-ZFL=IAH_"
M;I"&OW28?;QZGW:Z@:1PN(FH:[>2JVBWG*UEMZ>N9+>TKF6SO:YHK;VN:*V]
MKFBMO:YHK;VN:*V]KFBMO:YHK;VN:*V]KFBMO:YHK;VN_Y@L#O^=.1S_IS0C
M_[$S*/F],BKJRS<IW-T^*=#C1CK%XDU+N-Y56JS97&B>TV)WDL]G@HC+;8Q^
MR7.4=L=YFG#%@9]JQ(FB9L.2I6+#G*=@PZ:H7\.TJ%_!PJAANL&I8;K!J6&Z
MP:EANL&I8;K!J6&ZP:EANL&I8;K!J6&ZP:EANL&I_YDL#O^@-1K_JC$@_[8N
M(_#%+2+?V#,<T.,Z+L3H0D"XY4E0J^%.7Y[>56R2VUQWA]AC@7[5:HEVU'&/
M;]%YE&O.@)AGS(B;9,J0G6+)F)]@R:&@7\FKH%_)N9]<R,.B7,C#HES(PZ)<
MR,.B7,C#HES(PZ)<R,.B7,C#HES(PZ)<R,.B_YLL#O^D,!C_KRP;^+XG&^31
M)A?1XBT@Q.LW,[?K/D6JZ454GN=,8I+E4FZ&XUAX?>!@?W;<:89PV'&+:]5X
MCVC3?Y)ET8:48L^-EF#.E)A>SIN97<VCFES-K9I;S;>:6\VWFEO-MYI;S;>:
M6\VWFEO-MYI;S;>:6\VWFEO-MYI;S;>:_YTL#O^H*Q3_MR05Z\H<$=/@'A/$
MZRLFM_$T.*KP/$F=[T17D>Y+8X;M4FU]Z%MU=>-B?'#@:X%KW7*%:-IXB&39
M?HMBUX2-7]6*CE[4D)!<TY616M.<DEG2I)-8TJR36-*LDUC2K)-8TJR36-*L
MDUC2K)-8TJR36-*LDUC2K)-8TJR3_Z$K#?^O(P_TPA<,UMT0!\7K'ABW]BDK
MJ?<S/)WV/$N1]T18AO9-8GWP5FIVZUYQ;N=D=FKD:WIFXG)]9.!W@&'??8)?
MWH*$7=V'A5O<C(9:VY&'6-J6B%?9G8E6V:.*5MFCBE;9HXI6V:.*5MFCBE;9
MHXI6V:.*5MFCBE;9HXI6V:.*_Z@C"?VY%@?6T0L#QNH0"[;W'AVI_2DNG/XT
M/I#_/DN&_D=6??A17G;S665N\%]J:.UE;F3J:W)AZ7%T7^=V=EWF>WA;Y7]Y
M6>2$>ECCB'Q7XXQ]5N*1?E3AEW]3X9Q_4^&<?U/AG']3X9Q_4^&<?U/AG']3
MX9Q_4^&<?U/AG']3X9Q__[$5 ]3'"0'&U@H#MO<2#ZC_'R";_RLPD/\V/87_
M0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN>&Q7[7QN5>R
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M/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0  )S2  "/YP(
MAO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_'DS_1B%(_TTC1?]2)4+_5R=
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M,:#,4C^5R5E,B\5@5X+#9F!ZP&QG<[YS;6R\>G-GNX)W8KJ*>UZYE'Y:N)^
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M5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0
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MC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^
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M8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8
MPK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%C
MX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??
M\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,%
M *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1
M5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5)
M[?%10.WQ44#M\5% [?%10.WQ44#M\5% [?%1U*4  ,2R P"VO , J\D% *#8
M" "7]!,!C_4D!X?U,0]^]CL8=/9"(&SV2"=E]D\M7O=5,5GW6S55]V(X4?=H
M.TWX;SU*^'8_1_A^043YAT-"^9%%0/J;1C[ZID<\^[%(._N^23K\STDY_.-)
M.?SC23G\XTDY_.-).?SC23G\XTDY_.-)QZT  +>W @"JPP( GM $ )/C"0",
M_1@"A/XG!WO_,0]R_S@6:?] '&+_1B)<_TTF5O]3*E+_62U._U\P2O]E,D?_
M:S1$_W$U0?]Y-S__@3@\_XHZ.O^3.SC_G3PV_Z<]-?^Q/C3_OCXS_\H_,__*
M/S/_RC\S_\H_,__*/S/_RC\S_\H_N+(  *J]  "=R@  D=@" (C[#0%__QD"
M=O\D!F[_+0QF_S427_\\%UC_0QM3_TD>3O]/(4K_521&_ULF0_]@)T#_9BD^
M_VLJ._]R*SG_>2TV_X$N-/^*+S'_E# P_YPQ+O^E,BW_KS,L_[<S+/^W,RS_
MMS,L_[<S+/^W,RS_MS,L_[<SJ[@  )[%  "0T@  @^   'W_#P%R_Q8":/\>
M!&'_)PA:_R\,5/\W$$[_/A-)_T061?]*&$'_3QD^_U4;._]9'#G_7QTV_V0>
M-/]I'S+_<" O_W<A+?]_(BO_AR,H_Y D)_^9)2;_H28E_Z<F)?^G)B7_IR8E
M_Z<F)?^G)B7_IR8E_Z<FG\   )'-  "#VP  >/8" &__#0%D_Q("7/\9 U3_
M( 1._R<&2/\O"$/_-@H__SP,//]"#CC_1P\U_TP0,_]1$3#_5A(N_UH3+/]?
M%"K_910H_VL5)O]Q%B/_>1<B_X$8(/^)&![_D1D=_Y<9'?^7&1W_EQD=_Y<9
M'?^7&1W_EQD=_Y<9_U8G!/]1,@7_5C4'_U\]#O]D11;_9DX?_V18)_]A8B__
M7FXU_UIY._]7A#__5(]#_U&81O]/H$C_3J=*_TVN2_],M4S_2[Q-_TK$3O])
MSD__2=Y/_TCI4/](\E#\2?90]TOY4/%,^D_K3OM0ZD_[4.I/^U#J3_M0ZD_[
M4.I/^U#J3_M0_U8G!/]1,@7_6#0'_V([#O]G1!;_:4T?_V=6)_]C8"__8&LU
M_UQW._]8@D#_58U$_U.61_]0GTG_3Z9+_TZM3?]-M$[_3+Q/_TO%4/]*SU'_
M2>!1_TGK4?Y)\E+Y2_=2\TWY4?_B?1!)0T-?4%)/1DE,10 %$NU/^E'F4/I2
MY5#Z4N50^E+E4/I2Y5#Z4N50^E+E4/I2_U<G _]2,07_6C('_V0Z#O]J0A;_
M;$L?_VI4)_]G7B__8F@V_UYT//]:@$'_5XM%_U252/]2G4K_4*5,_T^M3O].
MM$__3;Q1_TS%4?]+T5+_2N)3_TGM4_M+\U/U3/=3[D_X4^A0^5/A4OI4X%+Z
M5>!2^E7@4OI5X%+Z5>!2^E7@4OI5_U@F _]4, 7_73$'_V<X#O]M0!;_;TD>
M_VY2)_]J7"__968V_V%Q//]=?4'_68A&_U:22?]4G$S_4J1._U"K4/]/LU'_
M3KM2_TW$4_]-SU3^3.!5^TSK5?A,]%7P3_=5Z5'X5>)2^%;;5/E7V53Y5]E4
M^5?95/E7V53Y5]E4^5?95/E7_UDF _]7+@7_8"\'_VHV#?]Q/A7_<T@>_W)1
M)O]O6B[_:F,V_V5N//]A>D+_785'_UJ/2O]7F$W_5:!0_U2H4OY2KU/]4;=5
M_%# 5OI/RU;X3]Q7]4_I5_)/\U?J4O97X5/W6-I5^%G15OA:SU;X6L]6^%K/
M5OA:SU;X6L]6^%K/5OA:_UDF _]:+ 7_9"T'_VXS#?]U/17_>$8=_W=/)?]T
M6"W_<& U_VIJ//]F=D+_8H%'_EZ+2_M;E$_Y69U2^%>D5/96K%;U5+17\U.\
M6/)3QUGP4M5:[%+F6NE3\EGA5/5;UU;V7,]7]UW(6?A=QUGX7<=9^%W'6?A=
MQUGX7<=9^%W'6?A=_UHE _]=*@7_9RH&_W(R#/]Y.Q3_?$4<_WQ-)/]Z52S_
M=5XT_V]G//QJ<D+Y9GU(]F.'3/-?D%#Q79E3[UNA5NU9J%CK6+!:ZE>Y6^A6
MPUSF5M%<XU;D7-]6\%W55_5?S%GV8,9:]F# 6_9AOESV8;Y<]F&^7/9AOESV
M8;Y<]F&^7/9A_ULE _]@* 7_:R@&_W<P"_]^.A/_@4,:_X)+(O]_4RK_>ULS
M^79D.O5P;D'Q;'E([6B#3>IDC%'G8955Y5^=6.-=I5KA6ZU<WEJV7MQ9P%_:
M6<Y@U5GB8-%9[V'*6O1BPEST8[Q=]&2W7O-DME_S9+9?\V2V7_-DME_S9+9?
M\V2V7_-D_UPD _]C)@3_;R8%_WLO"_^".1'_AD$8_X=)(/^%42CX@EDP\GU@
M..UW:D#H<G5'Y&Y_3>%IB%+=9I%7V6.96M5@H5W27ZA@SUVQ8LU<NV/+7,=D
MR5S;9<5=ZV6_7?)FN%_Q9[-@\6>O8?%GKF+Q9ZYB\6>N8O%GKF+Q9ZYB\6>N
M8O%G_UTD _]F) 3_<B0%_WXN"O^'-Q#_BS\6_XQ''?F+3R7RB%8M[(-=-N9^
M9S[@>'%&VW-[3=5N@U/0:HQ8S&>47<EEG&#&8Z-CPV&L9<%@M6>_7\%HO5_0
M:;I@YFFU8>]JKV+O:JMC[VJG9.]IIF7P::9E\&FF9?!IIF7P::9E\&FF9?!I
M_UXC _]I(@3_=B,$_X(L"?^+-@[_CSX4_9%%&_213"+MCE,JYHI:,M^%93O7
M?FU%T'AV3<MT?U3&<(=:PFR/7K]IEV*[9Y]EN&6G:+9DL&JS8[MKL6/*;*]C
MX6RK9.UMIF;M;*-G[6R@:.YKGVCN:Y]H[FN?:.YKGVCN:Y]H[FN?:.YK_U\C
M _]K( /_>2($_X4K"/^.- S_DSP2^)9#&.^62A[GE5 FX)%8+M>*83K.A&I%
MR'YS3<)Y>U6^=8-;N7&+8+5NDF2R;)IGKVJC:JQHK&RI9[9NIV?$;Z5GVF^B
M:.MOGFGL;YMJ[&Z9:^UMF&OM;9AK[6V8:^UMF&OM;9AK[6V8:^UM_U\C _]N
M'@/_>R$$_X@J!_^1,@O_ESH/])I!%>N;1QKCFTTAVI95+<^/7CG(B6=$P8-O
M3;M^=U6V>7];L7:'8*USCV6I<)9HIFZ?;*-LJ&Z@:[)PG6O <9QKTG*:;.EQ
MEVWJ<)1MZW"2;NQODF[L;I)N[&Z2;NQNDF[L;I)N[&Z2;NQN_V$A _]P'0/_
M?B #_XLI!O^5,0G[FS@-\)X^$>>@1!;?H$H=TYI2*\J37#C"C61#NX=M3;2"
M=%2O?GQ;JGJ$8:9WBV6B=)-IGG*;;9IPI'"7;Z]RE6^\<Y-OS7.2<.9SD'#I
M<HYQZG&-<>MPC''K<(QQZW",<>MPC''K<(QQZW",<>MP_V,@ _]R&P/_@!\#
M_XXG!?^7+PCXGC8+[:([#N2E0!+:I$8<SIY1*L676C>]D6)"M8QJ3*^'<E2I
M@GE;I'^ 8)]\B&6;>9!JEW>8;9-UH7"0<ZQSC7.X=(MSR76*=.)TB73H<XAU
MZ7*'=>IQAW7J<(=UZG"'=>IPAW7J<(=UZG"'=>IP_V4? _]T&@+_@QX"_Y F
M!/^:+0;TH30)Z:8W"^"J/0[4IT0;R:%/*<";6#:XE6!"L)!H2ZF+;U.CAW9:
MGH-^8)F A664?8UJD'N6;HQYGW&)>*ESAG>U=81WQ7:#>-]U@WCH=()XZ7."
M>.IQ@GCJ<8)XZG&">.IQ@GCJ<8)XZG&">.IQ_V<= _]W&0+_A1P"_Y,D _^=
M*P7QI# &YJHS"-RN-PS/JD,:Q:5.*+R?5S6SF5]!JY1F2J20;5.>BW1:F(A[
M8).%@V6.@HMJBH"3;H9^G'&"?:=T?WRS=7U\PW9\?=MV?'WH='U\Z'-]?.ER
M?7SJ<7U\ZG%]?.IQ?7SJ<7U\ZG%]?.IQ_VD< O]Y& +_AQL"_Y4C _N@*03N
MJ"P$XZ\O!=>R- O+K4$9P:A,)[>C532OG5U IYED29^4:U*9D')9DXUY7XZ*
M@&2)AXAIA(61;8"#FG%\@J1T>8&Q=G>!P'9V@=9V=H'G='>!Z'-X@.ER>'_J
M<7A_ZG%X?^IQ>'_J<7A_ZG%X?^IQ_VL; O][%P+_BAH!_Y@A OBC)@/JK"<#
MW[0I ]*U,@K'L$ 8O*Q+)K.G4S.JHEL^HIUC2)J9:5&4E7!8CI)W7HB/?F2#
MC89I?HJ.;7J)F'%VAZ)S<X:N=7&&O79OA])V<(?H='&%Z'-RA.ER<X3J<7.$
MZG%SA.IQ<X3J<7.$ZG%SA.IQ_VT9 O]^%@'_C1@!_YL> ?2G(@+FL" !VKHA
M <VX,0G"M#X7N+!))*ZK4C&EIEH]G:)A1Y6>:$^.FVY7B)AU78*5?&-]DX1H
M>)",;'2/E7!PC:!R;8RL=&J,NW5IC<YU:8WH=&N+Z7-MB>IQ;8CJ<6V(ZG%M
MB.IQ;8CJ<6V(ZG%MB.IQ_W 7 O^!%0'_D!8!_YX: ?"K&P'BMA8 T[T= <B[
M+PB]N#P5L[1'(ZFP4#"@JU@[F*A?19"D9DZ)H6Q5@IYS6WV<>F%WF8%F<I>*
M:FZ6DVYJE)YQ9I2J<V23N'-CE,MS8Y3F<F62ZG%GC^IP9X[J<&>.ZG!GCNIP
M9X[J<&>.ZG!GCNIP_W,5 O^%$P'_E!0 _*,5 .JP$@#9O@P S<$; <+ +0>X
MO3H3KKE&(:2U3RV:L58YDJY>0XJK9$R#J&I3?*5Q67:C>%]QH7]C;)^':&B>
MD6MDG9QN8)RH<%Z<MG%=G,EQ79SD<%Z:ZW!@ENMO897L;V&5[&]AE>QO897L
M;V&5[&]AE>QO_W<2 ?^)$0'_F1$ \Z@. ->U"@#/P0H QL48 +S$*@6RPC@1
MI[]$'IZ[32N4N%4VB[5<0(2R8DE\KVE0=JUO5G"K=EMKJGU@9JB&9&*GCV=>
MIIIJ6Z6F;%BEM6U7IL=M5Z;B;%>D[6Q:G^UL6I[M;%J>[6Q:GNUL6I[M;%J>
M[6Q:GNUL_WP0 ?^.$ #VG@T V*T) ,VX"0#'Q @ OLH4 +7*)P2KR#8/H<5!
M&Y?"2RB-OU,SA;U:/'VZ845VN&=+<+=M46JU=%9EM'Q;8+*$7URQCF)8L9EE
M5;"E9E.PLV=2L<9G4K'A9U&O\6A3JO!H5*GP:%2I\&A4J?!H5*GP:%2I\&A4
MJ?!H_X(. /^4# #;I08 SK$' ,6[!P"]QP< M= 0 *S0(P.CSS,,F<T_&(_*
M2"2&R%$N?<98.';$7S]OPF9&:<%L2V3 <U!?OWM46[Z$6%>]C5M4O9A=4;RD
M7T^\LV!-O<5@3;W@7TR\\&%-M_5B3;;U8DVV]6)-MO5B3;;U8DVV]6)-MO5B
M_XD+ .&< P#0J@4 Q;4% +N_! "RRP@ J]@- */9( *:V"\)D-8\%(?41A]^
MTD\I=M!6,F_/7CEHS60_8\QK1%[,<TE:RWI,5LJ#3U+*C5)/RIA43<JE5DO*
MLU=*R\572<O@5DG)\%A'Q_I92,7[6DC%^UI(Q?M:2,7[6DC%^UI(Q?M:]Y$$
M -2B @#'KP0 NKD# +#$!0"GT D G^$0 )CA(0./X# )AN [$GW?1!MUWDTD
M;MU5*V?<7#)BVV0W7=MK.UG:<C]5VGI#4MJ#14[:C4A,VIA*2=JE2TC;LTQ'
MW,1,1MS>3$;:[4Q$V/E/0]C[3T/8^T]#V/M/0]C[3T/8^T]#V/M/VYH  ,JI
M @"[LP( L+T# *7)!0";U@D E.@4 8SI)02$Z#,+>^@\%'/H1!MKZ$LB9.=2
M*%[G62U9YV R5>=H-5+G;SA/YW<[3.> /4GGB3]'Z)1!1.B?0D+IK$-!Z;I$
M0.K-1$#JY$1 Z/5$0.?X0T#G^$- Y_A#0.?X0T#G^$- Y_A#S:,  +VN 0"P
MN $ I,0" )G0!0"/X0H B?$: 8'Q* 5X\C(,</([$VGR0QEB\DH?7/-0(U;S
M5R=2\UXK3_-E+4ST;#!)]',R1O1[-$/TA#9!]8XW/O69.3WVI#H[]K [.O>_
M/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP
MF,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+
M_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_
MOC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](
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M)P/UE2X%ZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW>
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M=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0;
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M2T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$
ML[,! *F] @"?QP4 EM() ([:$@"(VR0"@-HR"'C9/A!QV$@8:M=0'V366"5?
MU5\J6]1G+U?4;C-3TW8V4--_.4S3B#M*TY0^1].@/T74KD!$U+]!0]780$33
M[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@  ,.E  "UK@  J;@
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M)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT  'G:  !P\@@
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M O]X* /_?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5
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M5%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@(
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M.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@,
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M$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP  4_T& $W_#@!(_Q8
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M3V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $
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M1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0
MF;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUFM%HB8K-A)EZR:"M:
ML6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>NXSQ&K?,]1JO^/D6K
M_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0  *6K  ":L@  D+H!
M (;!"0"!PA@ >\(H G7"-09OP4 ,:<!)$F2_41=?OE@<6[Y?(%>]9B14O&XG
M4;QV*DV[?RU*NXHP2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S=
MM_\W0+?_-T"W_S= M_\WSHL  +^8  "RH0  IZD  )RP  "1N   AL " 'O(
M!P!TRQ( <,PB 6O+, -FRSP'8<M%#%S*3A%8RE855,I=&5')9!Q.R6P?2\ET
M(DC(?B1%R(@G0\B5*$'(HBH_R+$K/LG$*S[)X2H^Q_(K/<;\+3S%_RX\Q?\N
M/,7_+CS%_RX\Q?\NQ),  +:?  "II@  G:X  )*W  "&OP  >\<# '#/!P!G
MU@T 9-<: &#8*@%<V#8#6-A!!E382@I0V%(-3=A:$$K78A-'UVD61==R&$+7
M?!I V(<</=B3'CS8H1\ZV; @.=G#(#G9WR YU^\@.-7Y(C?4_R,WU/\C-]3_
M(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X# &76!P!=XPX
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M<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@
M 'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL ,/\0 "S_%@ I_QP
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M17!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@
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M0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF
MIYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQH
MD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)
M_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(
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M-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(  'RY @!VNA$
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ME TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*
M )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8 1>D/ $+I&0! ZB0
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M @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0
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M_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'+ +_1S8#_T9
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M.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0
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M-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P  +^! 0"WA0$
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M,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD  (^;"P"*G1@
MA)TG 7Z<- 1YFSX(<YI'#6^93Q)JF%879I==&V.58QY?E&HB7)-R)5F2>RA5
MD84K4I&0+E"0G3!.D*LQ3)"\,DR0TS),C^TR3([Z,DR-_S%,C/\Q3(S_,4R,
M_S%,C/\QW'$  ,A^  "[B   L9$  *:6  "<F@  D)\  (>B!@"!HQ0 ?*0C
M 7>D, -RHSL&;:)$"VBA3 ]DH%038)]:%UV>81M9G6@>5IUP(5.<>210FX,G
M39J.*4J:FRQ(FJDM1YFZ+4::T"U&F.LM1I?Y+D:6_RY&EO\N1I;_+D:6_RY&
MEO\NT7<  ,&$  "VC@  JI4  *";  "5GP  BJ0  'VI  !WJQ  <ZL> &^L
M+ %JJS<$9:M!!V&J20M=J5$/6JE8$U>H7Q93IV894*=N'$VF=A]*I8$A2*6,
M)$6EF29#I*@G0J2X*$&DSB=!H^HG0*+X*$"A_RE H/\I0*#_*4"@_RE H/\I
MR7X  +J+  "OE   HYH  )B@  "-I0  @JH  '6P  !LLPP :;08 &6T)P%A
MM#,"7K0]!%JT1@=6LTX*4[-5#5"S7!!-LF,32K)K%D>Q=!A%L7X:0K"*'4"P
MEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8
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M!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0
M?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ N
MYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWK
ML@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT
M &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL
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M1V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI
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M)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0
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M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @#
M< 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC
M<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__
M+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P(
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M+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(  )F##@"4A!T
MCH0K 8B#-@2#@D (?H!)#'E_41!U?5@4<GQ?&&Y[91MK>FP>:'ET(F5X?25B
M=X<G8':2*EUUGBQ;=:LN6G2[+UEUT2]9=.PN673Z+5IT_RQ:=/\K6G3_*UIT
M_RM:=/\KYF$  -%M  ##=@  N7T  *^#  "FA@  G(8  )2(# ".B1D B8DH
M 8.)- -^ASX'>89'"W2%3P]PA%83;8)=%VF!8QIF@&H=8W]R(&!^>B-=?80F
M6GR/*5A[G"M6>ZDL5'NY+5-[SBU4>NHM5'KY+%1Y_RM5>?\J57G_*E5Y_RI5
M>?\JX64  ,QQ  "_>@  M((  *N'  "AB@  E8L  (V-"0"'CA8 @H\D 7V/
M,0)XCCL%<XU$"6^,3 UKBE019XE:%62(81AAAV@;7H9P'EN%>"%8A((D582-
M)E*#FBE0@J<J3X*W*TZ"S"M.@N@K3H'X*D^ _RI/@/\I3X#_*4^ _RE/@/\I
MVVH  ,=U  "Z?P  L(<  *:,  "<CP  CY$  (:3!0" E!( >Y4A '>5+0%R
ME3@$;91"!VF32@MEDE$.8I%8$EZ07Q5;CV886(YM&U6.=AY2C8 A3XR+(TV+
MF"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\
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M%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@
MEYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(
MN$,"1KA+ T2X4@1!N%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*W
MP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(
M (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL 0,,G #_#,@ ^Q#P
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M 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@
M2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4
M[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GV
MV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](
M #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D
M"OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP
M_\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A
M   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C
M  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(
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M$ZX\\12K//T5J3S_%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H
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M((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0
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M)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U6/\A_TT  .57  #37P
MR&0  +]G  "W:   L6<' *EH% "C:20 GF@R 9EG/02494<'D&1/"HQB5PV(
M85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:
MU25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<
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M)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$:P  N7$  +!U  "G=P
MGG4  )9V#0"0=QD BW@G (9W,P*!=CT$?'5&!WAS3@MU<E4.<7%<$6YP8Q1K
M;VH6:6YQ&69N>AQC;8,>86R.(5]KFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ
M_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D
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MA1  >88> '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5>
M<QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_
M($M[_R!+>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X
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M'0!;GBD 6)XT 56>/0)2G44#4)U-!4V=5 =+G%L)2)QC"T:<:PU#FW4/09N
M$3Z:C1,\FIL4.IJK%3F:O14YFMD5.9CO%CF7_!8XEO\7.)7_%SB5_Q<XE?\7
MNWH  *^%  "DC   F)$  (V5  "!F@  =9T  &B@  !;I   5J4, %.F%P!1
MIR, 3Z<O $RG. %*IT$!2*=) D:G4 1#IU@%0:=?!C^F: @]IG(*.J9]"SBF
MB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((
M *B,  "=D@  DI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P
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M !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@
M=:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5
MV!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@
MI  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4
M %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ(
M#>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE
MZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%
M  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82
M  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4
M />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   W
MT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^
M$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2
M  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H
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M.[P/H#O-#YX[YA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]
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M%HI%W!:(1O 6AD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P
MSU,  ,95  # 4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B6
M3F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*
MUAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@
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M&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K90
MHV(  )QB#@"68QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==9 UU
M7&L0<UQR$G!;>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV'&5:
M_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4
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M&E=F_QI79O\:VUD  ,=B  "Z:@  KW   *9S  ":<P  CW   (=Q!0"!<A$
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MC!-$@9H50H"I%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH
M +5U  "J?0  GX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB<
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M""Z@LP@NH,D(+I_G""V=]PDMG/\*+9O_"BV;_PHMF_\*KX   *.)  "7C@
MC9,  '^5  !RF   9IP  %N@  !/I   1:<  #ZI#  \JA0 .JH? #FJ*0 X
MJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $OK&8"+:QQ BNL?P,JK(X#**R>!">L
ML 0FK,4$)JOD R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D
M 'B>  !KH@  7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD
M*K8R "FW.@ HMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<
MN< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF
M  !BJP  5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F
M !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D
M#\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8
MM   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1
M(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7
M  '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0
M/\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !
MWB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #E
MP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@
M "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8
M .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0
M]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6
M   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2
M  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8
M /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_
M %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L
MK #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_
M .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D
M_P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S
M ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&
M_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@
M /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X
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M /\E"P#_* P _RD0 /\H%@#^)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4
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M!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<,?\(_S   /\U  #O.
MXCH  -LY! #6-0D SC03 ,8V(@"_.#$ NC@_ +8X2@&S.%0!L#== JTW9 *K
M-FP#J39S!*@V>02F-8 %I#6'!:,UCP:A-9<'GS6@!YXUJ@B<-;8(FS7%"9DU
MW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(
M ,Y" 0#)/@8 Q#L/ +L^'0"U/RP L3\Z *T_10&I/T\!ICY8 J,]7P.A/6<$
MGSQM!9T\= :<.WL&FCN"!Y@[B@B6.Y,)E3J<"I,ZI@N1.K(+D#O #(X[U0R,
M/.P-BCS[#8D\_PV)//\,B#S_#(@\_PR(//\,_S<  .H_  #<10  SDD  ,5)
M  "_1@( ND,, +-$&0"M12< J$8U *1%00&@14L"G413 II#6P.80V(%ED)I
M!I1!< >2078(D$!^"8Y A@J-0(X+BT"8#(E H@V'0*X.A4"\#X1 SP^"0>D/
M@4'Y#X!!_P^ 0O\.@$+_#H!"_PZ 0O\.^CL  .5$  #32P  QTX  +Y/  "X
M3   LDD) *M)%0"E2R, H$LQ )Q+/0&82D<"E4E/ Y))5P202%X%CD=E!HM'
M:P>)1G()B$9Y"H9%@@N$18H-@D64#H!$GP]^1*L0?$6Y$7M%RQ%Z1>81>4;W
M$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\  -])  #-3P  P5,  +A4  "Q4@
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M$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=80  E5T  (U>"0"'7A,
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MC1%/9YH23F>I%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H
M +QC  "P:@  I6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P
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M#CQ[LPX\>\@./'KF#CQY]PX\>/\./'C_#CUW_PX]=_\.O&@  *]R  "D>0
MEGH  (AZ  !\>@  <'P  &-_  !<@@  5X0+ %.%% !1AB  3X8J $Z'- !,
MASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1 AFP&/H5V!SN%@P@YA9$*.(2@"S:$
ML0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X
M (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@
M0I!  $"01P$_D$\!/9!6 CN07P(YD&@#-X]S!#6/@ 4SCXX&,8^>!S".KP<O
MCL,'+X[A!R^,] @OB_\(+XK_""^*_PDOBO\)L'8  *5_  "8A   BH0  'V%
M  !PAP  98H  %J.  !/D@  1I4  $&8#  ^F!0 /9D? #N9*  ZFC$ .9HZ
M #>:0@ VFDH -9I2 3.:6@$QFF0!+YIO BV:>P(LFHH#*IJ: RF:K 0HFL $
M)YG> R>7\@0GEOT%)Y7_!2>5_P4GE?\%J7X  )Z%  "2B0  A(H  ':,  !J
MCP  7I,  %27  !)FP  0)\  #>B!  RHPX ,:,7 #"D(0 NI"H +:0R "RE
M.@ KI4, *J5+ "FE5  HI5X )J5I "6E=@$CI84!(J66 2"FJ $?I;L!'J77
M 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$  &^4  !CF
M5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$ (+ I !^P,0 >
ML#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.Q
MZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@
M $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X
M$+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (
MOO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV
M   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL
M  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(
M ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   F
MP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7
M*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>
M  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP
M$\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@
MYB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #N
MQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L
M  />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH
M /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP
M_J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\
M;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U
M /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\
M_Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#]
M ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H
MN@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48
M /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\
M\@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #?
M ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5
M$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R
M .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L
MT ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_
M& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-
M=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/
M ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@
M_Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)
M%'< QQ5] ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8
MX@"S&?(!L1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0'
M /<A# #L'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\'W$
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M!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT  ,8\  # -P(
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M"FM&_PIK1O\*Y4   ,])  #!3P  M5(  *M2  "A3P  FTH  )1*# "/2Q<
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MC0M95)H-6%2G#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T
M ,!6  "S7   IUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX
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M#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)8/\+Q%@  +5@  "J9@
MFV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H&@!=:24 6VHO %EJ. !7
M:D !56I' 5-J3@)1:E4#3VE=!$UI9 5+:6T&26AX!T=HA E&:)(*1&>A"T-G
ML0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD
M (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T
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M<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C $5_+ !#@#4 0H ] $&
M10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$,G^:!3%^J@8P?KT&,'[:
M!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4=0  AG4  'EV  !N=P
M8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R()P [B3  .HDX #B)0  W
MB4@ -HE/ #2)6 $SB6$!,8EL 2^)> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&
M[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$
M %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$
M+)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@
MD/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.
M  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y"
M "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/<
M%IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \
MG   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J
M0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\
M  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP
M*ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 '
MMT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U
M]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4
M !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD
M ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@
MQ.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"
M   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X
M  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T
M>Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "
MT    -0   #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E
M-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@
M &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0
M .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P
M]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'
M&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![
M /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,,
M[ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_
M 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /,
M?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#,
M .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A
M_P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H
M '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -(
MW0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2
M /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L
MVP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#%
M .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.
M% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\
M ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D
MMPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R
M#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-
M?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z
M *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X
MV0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q
M%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;
M_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1
M ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I'V8 J!]L *8?<P"E'WD
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M WPQ_P-\,?\#[2\  -LW  #)/0  OCX  +,\  "L.   IS,$ *(R$0"=-!T
MF34J )4U-0"2-4  CS5) (TU4 "+-5< B35> 8<U9 &%-&L!A#1R H(T>0*
M-(("?C2+ WTTE@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W
M_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF
M (T[,0"*.SL ASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#
M=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L
M//\%XCD  ,Q"  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5
M+0""0#< ?T!  'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$
M!&P_D 5K/YP&:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%
MW#X  ,=&  "Y2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![
M130 >44] '9%10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#
MC09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$
M ,-)  "V3@  IT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23
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M"%%0L0E04,0)4%#A"5!0] A14/\'44__!U%/_P913_\&R4L  +E3  "K5P
MG%8  (]5  "%5   ?%   '51  !P4@D :U,2 &A4'0!E5"< 8E0Q &!4.0!>
M5$$ 7%1( 5I43P%95%8!5U1= E9490-45&X$4E1X!5%4A 9/5)$'3E2@"$Q4
MKPA,5,()2U3?"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D
M (M8  "!5P  =U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\
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M!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D  *MA  ":80  BV$  ']A  !T80
M:6$  %]B  !99   5&8) %%G$0!.9QH 3&@D $MI+0!):38 2&D^ $9J10!%
M:DP 0VI4 4)J7 % :64"/FEO CQI>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H
M[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8
M %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D
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M B)]_P(B??\"I7$  )-Q  "#<0  =G$  &QR  !@=0  5G@  $Q\  !#@
M.X,  #.&   MB0H *HH1 "F+&0 GBR( )HLJ "6,,0 DC#D (XQ" "*-2@ A
MC50 ((U> !^-:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(
M_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P
M "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T
M%9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0
ME/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::
M   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10
M  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L
MC8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7
MJ   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P
M4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD
M 'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M
M"[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2
MOE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5
M  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(
M  #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD
M ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;
MIP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0
M    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+
M  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@
M1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?
MWP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T
M30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8
M /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (,
M]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G
M /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\
M'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$
M .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P
MV #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_
M "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .
MA0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U
M ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "
M\0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #.
M (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L
M_0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E
M .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($
MP "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N
M O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#
M*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:#
M +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\
MH0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@#
M##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</
MA0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_
M )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD
ML!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9
M%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<
M_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO
M *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".((0
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MCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(
M ,DY  "[/@  K#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4
M?S,^ 'TS1@![,TT >3-4 '<S6@!V,V$ =#-G 7(T;P%Q-'<!;S2! 6XTC )L
M-)@":C6E FDULP-H-<8#9S;B V8V]0-F-O\"9C;_ F8V_P)F-O\"V#<  ,0^
M  "U0@  ID$  )L_  "3/   C3@  (@V!P"$-Q$ @#<< 'PX)P!Z.#$ =SDZ
M '4Y0@!S.4D <3E0 ' Y5P!N.5T ;#ED 6LY:P%I.70!:#E^ F8YB0)D.94#
M8SJB V(ZL0-A.L,#8#O@!%\[\P-?._\#7SO_ U\[_P)?._\"T3L  ,!"  "P
M10  H40  )5#  "-0   AST  (([ @!].PX >3P8 '4](P!S/2T <#TV &X]
M/P!L/48 :SU- &D]4P!G/5H 9CUA 60]: %C/7$!83Y[ E\^A@)>/I,#7#Z@
M UL_KP1:/\$$6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2
MG$<  )%&  "(1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F
M0D, 9$)* &-!4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#
MK0150[\$5$/:!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H
M (U)  "#1P  ?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\
M7T5' %U%30!;150 6D9; 5E&8P%71FP!5D9V E1&@0-31HX#4D><!%!'JP10
M1[T$3T?6!4]'[P1/1_T$3T?_ T]'_P-01_\#Q$4  +5-  "C30  E4P  (E+
M  !_2@  >$8  '%'  !L1P< :$@0 &1(&@!A220 7TDM %U)-0!;23T 64E$
M %=)2@!625$ 54I9 51*80%22FD!44IT D]*?P-.2HP#34J;!$Q+J@1+2[P$
M2DO3!4I+[@1+2_T$2TK_ TM*_P-+2O\#P4@  +)0  "@3P  D4\  (5.  ![
M30  <TD  &Q*  !G2P0 8DP. %],%P!<32$ 6DTJ %A-,@!633H 5$U! %-.
M2 !23D\ 4$Y7 4].7P%.3F<!3$YR DM.?0))3HL#2$Z9!$=/J 1&3[H$1D_1
M!$9/[01&3OP$1D[_ T=._P-'3O\#O4P  *Y2  "<40  C5$  (%1  !W4
M;DP  &=.  !B3P  75 - %I0% !741X 55$G %-1, !14C@ 4%(_ $Y21@!-
M4DT 3%-5 $I370%)4V4!2%-O D93>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3
M[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$
M &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL
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M C)@_P(R8/\"KEP  )M=  "*70  ?%T  '!=  !F70  7%X  %)@  !,8@
M164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L .&DR #=J.@ V:D$ -6I) #1J4@ S
M:EL ,6IE #!J< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG
M_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L
M #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E<
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M8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X
M (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@
M&HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,
MD6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS
M  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<
M  Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(
M )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H
M>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF
M!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH
M  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA
M58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R
MLP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X
M;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8
M $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@
M +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@
MR74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK
M   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P
M  #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<
M .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   D
MO   &+\  !##   (QP   ,H   #-    T0   -4   #8    V0   -L   #=
M    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K
M  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P
M_P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q
M (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .(
M_P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T
M /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H
MY0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1
M /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0
M.P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+
M -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\
MP0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C
M $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4
MC ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_
M +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L
MS0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U
M (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8
M_P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^
M +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D
MIP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9
M!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %
M0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF.
M )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\
M]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B
M#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1
ME "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H
M -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX
ME!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!
M&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I
M  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y!
M (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9<
M=2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W
M,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF
M1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\HB !N*)0 ;"BA
M &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\  ,(V  "O-@
MH34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\ =RPX '4L0 !S
M+$< <2Q- ' L5 !N+%H ;2QA &LM: !J+7  :"UZ &<NA0!E+I$!9"Z> 6(O
MK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH
M ) X  ")-0  @S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4,
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M DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,  ()"  !Z0
M<ST  &T\  !H/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4
M/TT 4S]5 %) 7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"
MZ ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T
M &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL
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M 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J3   8$H  %E+  !43
M4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0/0! 440 /U%+ #Y14P ]
M4EP /%)F #I2<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390
M_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(!
M $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH
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M:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@
M (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H
M+&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?
M;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<
M  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(-
M "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X
M%75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O
M80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]
M#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X
M  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90
M868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -
MB0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)
M@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP
M %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP
M I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@
ME8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY
M   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.
M  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0
M **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   X
MBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L
M#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.
M  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0
M)IX  !RC   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y"
MN@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$
MEP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T
M !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8   #'    R00
M ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@
MVYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^
M   $P@   ,4   #)    S0   -    #2    T@   -4   #6    V0   -L
M  #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\
M /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_
M $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L
ME0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_
M -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@
M] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #<
M )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L
M_P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!,
M .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )(
MR0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\
M /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -(
M4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4
M +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\
M_P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_
M %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L
MF "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P
M /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P
MK@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"<
M )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+
M  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!-
M *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D
MC@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*
M%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)
M3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB
M ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0
MKQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "(
M$$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3
MK@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,
M )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH
M?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K
M'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H
M  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+
M '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@
M82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%
M*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E
M30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK*
M %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P
M>2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?
M*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(O
MY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$
M &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT
M5S!3 %8P6P!4,6, 4S%L %(R=P!1,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,
M-/8 3#3_ $PT_P!,,_\ NSD  *8Y  "5.0  ASD  'PY  !T-P  ;C0  &DS
M  !E,@( 83(- %XR% !<,QX 6C,F %@S+@!6,S4 530\ %,T0P!2-$H 4310
M % U6 !.-6  339J $PV=0!+-X( 2C>0 $DXGP!(.+ !1SC# 4<XX0%'./4!
M1SC_ 4<X_P%'./\!MSL  *(\  "1/   @SP  '@\  !P.@  :C<  &0V  !@
M-@  7#8+ %DW$@!6-QH 5#<C %(W*P!0-S( 3S@Y $TX0 !,.$< 2SA. $HY
M50!).5X 2#IH $<Z<P!&.X  13N. $0\G@!#/*X!0CS" 4(]WP%"//,!0CS_
M 4(\_P%"._\!LST  )X^  "-/@  ?SX  '4^  !L/0  9CH  & Y  !;.@
M5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$
M/EP 0SYF $(_<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X_
M_P$^/_\!KD   )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX%
M $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH
M/D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y
M0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E#
M# !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A
M #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\
MID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!
M2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,
M:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<
M (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X
M.4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L
M474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*
M  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02
M #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W(
M)5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U
M3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;
M%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^
M !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40
M9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A
M8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5E
MBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8
M %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!,
M%FT: !5M(0 4;2D %&TP !-M.0#_XGT024-#7U!23T9)3$4 !Q(2;D( $6Y,
M !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\
M@ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD  "1L   =
M;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP "7='  AW
M4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "=/P >UT
M &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU   7>0
M$GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()   ""3
M@ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD =&(  &AB
M  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1@P  #88
M  B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".1   CE$
M (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8
M:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP  !I(   "5
M    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7
M  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO  !1<@
M1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *    "B
MHP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L
M70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0
M #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P    L
M +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!  "]4@
MO60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9
M   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_    OP   ,
M  #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #110  TE<
M -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(  "6H   :
MK@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0   ,\   #0
M    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.   Z$H  .E=
M  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_ "8
M_P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K
M (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8 V0#W -@
M_P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L
M /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X >@#= '\
MVP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q ,< _P#&
M /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P [  G .D
M,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_
M ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +< ^P"V /\
MM@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A -4 +0#1
M #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +<
M@ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_
M *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,( )@"_ #$
MO  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G
M ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T F #_ )@
M_P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P "L K0 U
M *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L =0": 'L
MF "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P",
M /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0 H  N )X
M-P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^
M (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\
MZ T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G )( ,0"0
M #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$
MA !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14
M ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C,
M@PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R
M#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>
M  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V
M '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD
M9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?
M)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7
M. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2
M %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*
MBR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C
M'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0B
MG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3+   ABT
M 'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8
M6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,
M**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3   '<O
M  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y
M %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H
M12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K
M,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM
M/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[
M #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F-0
M83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$
M,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HV
MT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C-P  738
M %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT
M/C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V
M.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@  63D  %,V
M  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M"
M #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH
M,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P  $XZ  !)
M.P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #-
M2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y
M "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^  !$/P
M0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M
M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%
M_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _1   .T4
M #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G2DL
M)DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B
M2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2   -TD  #)+
M   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A4$@ (%!2
M !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\
MBD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0   H
M4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A7
M60 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D
M '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6   D60
M'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]* !%?50 0
M7V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.
M  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?7P  &6(!
M !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT
M!V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=
M4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P  $VH   ]M
M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P2@  <%<  '!E
M  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8  &-6  !95@
M45<  $=8   ^6P  -E\  "YB   F9@  'VH  !EM   3<   #G,   MV!  %
M> L  7@/  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z
M<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P
M $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@
M (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':
MAWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI
M   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)
M  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(
M )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K
M>0  (7\  !F$   1B0  #(T   :1    E    )@   ":    FP   )P"  "=
M!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]
M  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP
M&8T  !&2   +EP  !)P   "@    HP   *8   "H    J0   *H   "L
MK00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "X
MB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT
M  RB   #IP   *L   "N    L@   +8   "X    N    +H   "[    O0
M +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@
MS9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q
M    M@   +H   "^    P@   ,8   #(    R    ,H   #+    S0   ,X
M  #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(
M .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #]
M $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0
MBP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_
M ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X
M[ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0
M (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\
M_P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!"
M -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8
MO0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P
M /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,(
M10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"(
M *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\
M_P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O
M $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P
MBP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P
M .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $
MG@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"-
M (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,
M  #! 0  M    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!!
M (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H
M?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R
M#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (,
M0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2
M '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@
MFA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W
M!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)
MG0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@
M (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X
M; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<
M$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=
M  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_
M &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D
M4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P
M(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D7
M00!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX
M $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0
M9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0
M'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,B
MS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<
M %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D
M2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]
M*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H
M  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=#
M $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8
M."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0
M*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL
M2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W
M #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0
M1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U
M,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S
M_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(
M #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P
M+S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J
M-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV
M @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3
M "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\
MC38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R
M.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "-
M6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D
M '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004
M*D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <
M164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]
M  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<*
M "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V(
M%4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A
M00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/
M#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M
M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1
M4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 1
M5PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8
M>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@
M $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P
M"F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P
M8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,
M   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.
M  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8
M &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X
M5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q
M$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..
M  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7
M*F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@
M?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  "
MG0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH
M !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T
M (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0
MCJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\
M   .@0  "(4   ")    C0   )    "2    DP   )0   "6 P  EP@  )@,
M  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(
M )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &
MD    )0   "8    G    )\   "A    H@   *0   "E    IP   *@$  "J
M"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L
M  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP
M *0   "H    K    *\   "Q    L0   +,   "U    M@   +@   "Z
MO 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(
MKP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,
M  "W    O    +\   #!    P@   ,0   #%    QP   ,D   #+    S0
M ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@
MXJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /,
M4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3
M -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\
M_P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@
M %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8
ME@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P
M /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T
MQP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R
M )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T
M  #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!.
M +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0
MH0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>
M    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *(
M30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9
M )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'
MN@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2
M $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 ((
MH "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@
M *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $<
M@P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T
M *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$
M  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!'
M '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8
M9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!
M"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L
M1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S
M %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0
M<PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A
M!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,
MQP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0
M &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44
M5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)
M$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7
M  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)'
M $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^,
M0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7
M&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $87
M2@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU
M #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@
M3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^
M'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A
M_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22
M $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP
M-R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q
M)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D
M!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3
M # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\
MC2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y
M* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL
M6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL
M '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D
M,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E
M,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O
M  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$-
M "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6,
M'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C
M,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W
M$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN
M !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0
M538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >
M/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !-
M?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD
M $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q
M%T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -
M18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\
M  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2
M !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X<
M!4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]
M/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1
M%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6
M  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@
M-$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@
M61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9
MI0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD
M "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$   810
M &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH
M8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3
M   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5
M  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+
M &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   6
M8   $&0   QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W
M%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!
M  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P
M"V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0
MAA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'
MT0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT
M  "!    A0   (@   "*    C    (T   "/    D 0  )((  "3#   E1
M )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP
ME]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1
M    E0   )@   ":    FP   )T   "?    H    *(   "D!0  I@H  *@.
M  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L
M168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A
MI0   *@   "K    JP   *X   "O    L0   +,   "U    MP$  +D'  "\
M#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(
M #)X   G@   '(@  !*0   *EP   )T   "C    J    *T   "R    M@
M +D   "[    O    +X   #     P@   ,0   #&    R    ,L   #.!0
MT0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\
M  #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9
M .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$
MS "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_
M    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$
M60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F
M +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X
M[0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\
M %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@
MK0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP
M ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %,
MIP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6
M +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<
M @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2
M )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\
MA0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">
M  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (<
M40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z
M '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  (
MBP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X
M %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H
MR0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P &
M 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L
M:P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!>
M .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$
M"0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !,
M %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H
M4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F
M! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!
M3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M
M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04
M70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,
M"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-
M^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X(
M %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\
M1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [
M$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1
M"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4
M #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\
MCAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#
M%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #08
M6P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX
M '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P
M.QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M
M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C
M  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X.
M #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F(
M)B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C
M)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB
M$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M
M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0
M5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G
M)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK
M>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP
M $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!(
M("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5
M,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N
M  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5
M !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D
M$#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^
M,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X
M&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9
M  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P
M-C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 .
M/AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_
MJ  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4
M "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D
M"$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I
M1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY
M   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<
M  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4
M $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B
M00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3
M'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*
M  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P
M%TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@
M7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:
MY   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,
M  Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP
M &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@
M9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@
M   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=
M  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P
M3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K
M;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$
M'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX
M #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0
M ($   "#    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@
MEB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9
M   O70  )&,  !II   2;P  #'4   1[    @    (4   ")    C0   )$
M  "3    E    )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<
M *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G
M:@  '7   !-X   ,?P   X4   "+    D0   )8   ";    GP   *(   "D
M    I0   *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8
M  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>
M%H    V(   %CP   )8   "<    H@   *<   "L    L    +,   "V
MMP   +D   "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5
M&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P %
M /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X
MW@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#"
M ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /,
M"P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!>
M ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,(
MK@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2
M  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$
M70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2
M )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P
MM@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"=
M %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P
MZ "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 .
M )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4
MBP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\
M /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T
M$0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4
M 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T
M;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\
M !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T
M5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X
M &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O !
M;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@
M %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8
M_P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1
M &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$
M50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!,
M /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@
M$P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5
M $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\
ME0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/
M 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($
M6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA
M 'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$
M1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y
M"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5
M  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2
M #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V(
M,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D
M&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0
M%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L
M "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0
M5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P
M%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9
M>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R
M $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0
M*1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P =
M'8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B
M  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7
M "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H<
M%R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^
M)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB
M&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8
M !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@
M-B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7
M)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJ
MJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@
M "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P
M$2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )
M+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ
M   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@
M  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8
M C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F
M+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X
M)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*
M   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,
M'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0
M/B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]
MY   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8
M !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120
M $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP
M0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_
M   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH
M  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O(
M4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +
M20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7
M+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP
M $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40
M %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@
M8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_
M   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X
M  !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH
M &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U
M1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M
M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N
M  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3
M)5   !Q5   46P  #F    =E    :@   &X   !R    =@   'D   !\
M?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2
M,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP
M !5B   .:   !VX   !T    >0   'X   ""    A@   (D   ",    C@
M )    "2    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0
MICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P
M   '=P   'X   "$    B@   (\   "4    F    )L   ">    GP   *(
M  "D    I@   *@   "K    K0   +    "S!   MPP  +L2  "['P  NS
M +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F
MB    (\   "6    FP   *$   "F    J@   *X   "P    L0   +0   "V
M    N    +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X
M  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$
M^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3
M &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D
M_P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6
M -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &(
MN@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E
M /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,,
M&P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A
M *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\
ME0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H
M !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ),
M8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_
M (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D
MDP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"!
M &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0
M_P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ;
M (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H
M< !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G
M /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '
M'0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!;
M &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\
MJ    )4   "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C
M !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8
M7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G
M (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D
M5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!*
M &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '
M  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ;
M $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\
M0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J
M#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0
M' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H
M #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$
M61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [
M AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'
M<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0
M $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D
M- D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G
M#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7
M  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T;
M "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0
M'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _
M&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80
M'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125
M !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P
M-AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?
M$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8
MI@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T
M "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X
M&1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /
M'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>
M   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB
M !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4
M"R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F
M'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B
M)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'
M  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0
M(2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *
M)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $H
MX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,
M !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@
M RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX
M+/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG
M   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M
M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?
M5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2
M+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y
M,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L
M $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P
M#34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P
M0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O
M   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P
M  4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4
M $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V
M,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&
M    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\
M  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0
M+S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/
M40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<
M1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD
M ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<   !:    7
M %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/
M:DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$
M   620  $$T   I1   $50   %H   !=    8    &,   !F    :    &H
M  !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44
M 'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   0
M5   "ED   )>    8P   &<   !K    ;P   '(   !U    =P   'D   ![
M    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.
M  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80
M 6<   !M    <@   '<   ![    ?P   (,   "&    B    (H   "-
MCP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B
M60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<
M  !]    @P   (@   "-    D0   )4   "8    F@   )P   "?    H0
M *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@
MMV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/
M    E@   )L   "@    I    *@   "K    K    *\   "R    M    +8
M  "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL
M ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q
M "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D
M;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_
M )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0
MT@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q
M &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )(
M_P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G
M +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &<
MG !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P""
M /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\
M*0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H
M (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\
MU@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"(
M "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8
M:0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P
M *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0
M=0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E
M &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D
M  "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E
M &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &<
M5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\
M    <0   &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D
M)0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M
M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P
M9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !-
M "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $
M=0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<
M %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "
M0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V
M ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,
M  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A
M #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T
M+0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !#
M#@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$
M(@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&,
M "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0
M.1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I
M R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'
MG0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(
M #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2
M(@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7
M#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3
M   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC
M !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+,
M$ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G
M%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80
M*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%
M  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@
M(18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1
M%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6
MW0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@
M !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H
M#!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $
M&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9
M   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO
M  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P
M6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6
M&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B
M-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T
M $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@
M$1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@
M)ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A
M   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,
M  TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D
M "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X
M)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ
M @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"
M   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P
M+2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 "
M,@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z
M3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD
M "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(
M #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P
M0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J
M   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _    00   $,"
M  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$
M $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;
M,0  %30  ! W   -.@  "#T   )     0P   $8   !(    2@   $P   !.
M 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>
M  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.
M$3P   Q    '1    $<   !*    30   %    !3    50   %<   !9
M6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D
M:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8
M  9*    3P   %,   !6    60   %P   !?    80   &0   !E    9P
M &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P
M<WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7
M    7    &    !D    :    &L   !N    <0   ',   !U    =P   'H
M  !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(
M (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F
M:P   &\   !T    >0   'T   "     @P   (4   "'    B@   (P   "/
M    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!
M  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '    !W    ?0
M ((   "&    BP   (\   "3    E0   )<   ":    G0   *    "C
MI@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "Q
MC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")    D    )4
M  ":    GP   *,   "F    J    *L   "N    L    +,   "V    N@
M +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0
MRI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .(
M-@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X
M +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\
M]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #
M #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *<
M>@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z
M -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$
MI@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1
M 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   /_B
M?1!)0T-?4%)/1DE,10 ($LT   "[    K@   *4   "?    G  ) )D #P"9
M !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L A@!0 (4
M50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_
M &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0 # "" !$
M@@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R
M %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_ &$
M_P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O  X ;P 2
M &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &, 2 !B $X
M80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4
M /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L 7P / %\
M$P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0
M %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H _P!* /\
MD@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ , %( $ !2
M !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $, 2 !* $8
M4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!  /\ A0
M '0   !G    70   %4   !/    3    $H   !(  0 1P * $< #0!& !$
M1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [
M %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\ ?    &L
M  !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]  X /  1
M #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #, 20 R %,
M,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$  &0%  !7
M!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P -  / #0
M$@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J $\ *0!:
M "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)  !2"P
M2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  - "P $  K
M !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L (@!7 "$
M9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-#0  0PX
M #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4##@ D 1
M) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4 !H!80 :
M 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0
M   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >!@X '@41
M !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX
M$P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41   O
M$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)
M$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R
M  X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3   L$P
M)Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2
M#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/
MDP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I%   )10
M "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q(
M#1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $
M$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@  (A4  !X4
M   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5
M  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5C@  %:,
M !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18  !P6   9
M%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A  !A83  46
M&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C   &*(  !BW
M   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7   8%@
M%14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@
M&QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*   !RV   ;
MT   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7&   %!<#
M !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @%   (1H
M "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V   ?T0
M'^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$ $QD! !$9
M 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@  )A@  "<?
M   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   DT0  (^X
M1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P   X=   -
M'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14  "T<   M
M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT   *>\ 0"
M #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB   *)
M!B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48   U(
M-2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\ /",  #(D
M   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %*P   2X
M   P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^'   /B8
M #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<  "\G   H
M)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P   #4    X
M    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P  2"$  $@L
M  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G*
M(B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X   !!
M0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P  %,G  !3
M-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F*P  'RP
M !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,    3@
M %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?  !B+
M83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,   &C,  !,W
M   ..P  "#\   %$    2    $P   !/    4@   %4   !8    6P   %T
M  !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S)0  <C0
M ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P   Y!   '
M1P   $P   !1    50   %D   !=    80   &4   !H    :P   &T   !O
M    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'   B"L  (8]
M  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.    5
M %H   !@    9    &D   !N    <@   '8   !Z    ?0   (    ""
MA0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$  )\S  "=
M1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<    8P   &H
M  !Q    =@   'L   "     A@   (H   ".    D0   ),   "6    F0
M )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH  "W/
MM%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =    'P   "#
M    B0   (\   "4    F@   )\   "B    I    *<   "J    K@   +$
M  "T    N    +P   #!    QP   ,T   #4!0  V!   -4>  #3,0  T$@
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M_/[______________________________________________________P
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M______________________________________\
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M_VUF=#$      P0A   !                     0
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MQ;_4!R6ZUPE.KMH+<*#;$X>7S3F:DL-8J)&\;+*1MWJYDK2#O8ZSAK^+LH?
MB+&'P(:QB,&$L8G!@[&*P8*QB\* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
ML(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PO?
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MPH2I=,*%JG/!AZMRP8BK<L"*K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MEXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N@*+4K("CTJR
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MEZV$QI.MA,>/K(3(C*N%R8FKALJ'JX;*A:J(RH.JB<N!JHO+@*J,RX"JC,N
MJHS+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,R]K%
M" KKR0TB[L@20N_&%6C0T@J'L;XOKJ6X5+B?M6B\G;-VOYNQ?\&9L(3"E*^$
MPY"OA<2-KH7%BJZ&QHBMAL:'K8?&A:V(QX.MB<>!K8O'@*R+QX"LB\> K(O'
M@*R+QX"LB\> K(O'@*R+QX"LB\> K(O'@*R+QX"LB\> K(O'@*R+Q]7&" G9
MS H@Y<\-0-C5"U^]U@N(I<0TIIRW6KB9M6N[E[1WO9:S?[Z5LH7 D;&%P8ZQ
MA<&+L(;"B;"'PHBPA\.&L(C#A:^)PX.OBL2"KXO$@:^+Q(&OB\2!KXO$@:^+
MQ(&OB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q-+(" ?3SPH=
MU=0+/<+9"V.KWA"#F\XSF93$4Z:1OF>OD+ITM)"W?;F1M82\CK.&OHRRAK^*
MLH? B+*(P(:QB,&%L8G!A+&*P8*QB\&!L8S"@+&,PH"QC,* L8S"@+&,PH"Q
MC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PL[*" ;.T0H<QM<*
M0:_J#F&=YAQXD-HRB(O23)2)RU^<B,9NHXC#>*B%P'RK@[]_KH"]@;!_O(.Q
M?;R$LGR[AK-[NX>T>KJ(M'FZB;5XN8NU>+F,MGBYC+9XN8RV>+F,MGBYC+9X
MN8RV>+F,MGBYC+9XN8RV>+F,MGBYC+9XN8RV>+F,MLG+" ;(T@DBL]\)0J#\
M%5J3\"AJB^8Y=X3?28*!V%N+@--ID7S0<99YS7::=LMZG73*?9YRR7^@<<B!
MH7#'@Z)OQX6C;L:&HVW&B*1LQ8JE;,6+I6S%BZ5LQ8NE;,6+I6S%BZ5LQ8NE
M;,6+I6S%BZ5LQ8NE;,6+I6S%BZ5LQ8NE;,6+I<3.!PJWV0<FH_L./9;_'DZ-
M^B];AO(_9X#K3G%[Y5MY=N!E@''=;(1NVG*(:]EWBVG7>HUGUGZ.9M6 CV74
M@I!DU(218].&D6+3B9)ATHN38=*,DV'2C)-ATHR38=*,DV'2C)-ATHR38=*,
MDV'2C)-ATHR38=*,DV'2C)-ATHR38=*,D_^Q& G_L2,>_ZXQ.O^I/EGMHDMY
MV9I<E\B5<K#%E7VUPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y
M@9G'N(";R+A^GLFW?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[
MJ<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<
ME\B5<K#%E7VUPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'
MN(";R+A^GLFW?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT
M>ZG*M'NIRK1[J<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5
M<K#%E7VUPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";
MR+A^GLFW?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*
MM'NIRK1[J<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%
ME7VUPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^
MGLFW?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NI
MRK1[J<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VU
MPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW
M?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[
MJ<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VUPY>%
MN,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW?:+*
MMWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT
M>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VUPY>%N,&7
MB[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW?:+*MWRG
MRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*
MM'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VUPY>%N,&7B[N_
MDXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW?:+*MWRGRK1[
MJ<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NI
MRO^Q%PG_LB(>_ZXP.O^I/5GLHTIYV)M;F,>5<K'%EWNUPYB#N,&9BKN_E8N^
MO9&,P;N.CL.ZBI#%N8>2Q[B$E<FW@IC*MH";R[9^GLRU?:/,LWRGS:]\J,NO
M?*C+KWRHRZ]\J,NO?*C+KWRHRZ]\J,NO?*C+KWRHRZ]\J,NO?*C+KWRHR_^R
M%PG_LB$>_Z\O.O^J/%GLI$EZV)M:F<:6<;+$F'BUPIF!N<";B+R^EXJ_O)2+
MPKJ0C<6YC(['MXB1R;:%E,NU@Y?-M(&:SK1_G\^S?J3/KGVFSJM]J,RK?:C,
MJWVHS*M]J,RK?:C,JWVHS*M]J,RK?:C,JWVHS*M]J,RK?:C,JWVHS/^R%@G_
MLR$>_[ N.O^K.UGLI$AZUYQ9FL:7;[+$F7:VPIM_N<"<A[V]FHG NY:*P[F2
MB\:WCHW)MHJ/S+2'DLZSA);0LH&:T;* G]*N?Z/2JG^ESZ9_I\VF?Z?-IG^G
MS:9_I\VF?Z?-IG^GS:9_I\VF?Z?-IG^GS:9_I\VF?Z?-IG^GS?^S%@G_LR >
M_[ M.O^K.EGLI4=ZUIQ9FL:8;;+$FG2VPIQ]N;^=A;V]G(C!NYB)Q;B4BLBV
MD(O+M(R.SK.(D=&QA973L(.:U+""H-6J@:+3IH&ET*.!I\VC@:?-HX&GS:.!
MI\VC@:?-HX&GS:.!I\VC@:?-HX&GS:.!I\VC@:?-HX&GS?^S%0C_M" >_[$M
M.O^L.5GKI49[UIQ8F\:9:[+$G'*VPIU[N;^?@[Z\GHC"NIJ(QK>6B<JUDHK-
MLXZ,T+&*C].OAY36KH6:V*N#G]>F@Z+4HH.DT)^#ILV?@Z;-GX.FS9^#ILV?
M@Z;-GX.FS9^#ILV?@Z;-GX.FS9^#ILV?@Z;-GX.FS?^T%0C_M!\>_[$L.O^L
M.5GKID5[U9U8F\>::;+$G7"VPI]YNK^@@KZ\GXC"N9R(Q[:8B,NTE(G/L9"+
MTZ^,CM:MB9/9K(>;VZ:&GMFBA:'5GH6DT9R%ILZ<A:;.G(6FSIR%ILZ<A:;.
MG(6FSIR%ILZ<A:;.G(6FSIR%ILZ<A:;.G(6FSO^T% C_M!\=_[$L.O^M.%GK
MID5[U9U7G,>;9[+$GFZVPJ!WNK^A@+Z[H8C#N)Z'R+6:A\VREXC1L).*U:V/
MC=FKC)/=J(J;WJ*(GMF>B*'5FX>DT9F'ILZ9AZ;.F8>FSIF'ILZ9AZ;.F8>F
MSIF'ILZ9AZ;.F8>FSIF'ILZ9AZ;.F8>FSO^T% C_M1X=_[(K.O^M.%KKID1[
MU9U7G,><9;+$GVRUPJ%UNKZB?K^[HX?$N*"'R;2=A\ZQF8C3KI:)V*N3C-RH
MD)+AHXZ:WYZ,GMJ:BZ'5EXJDT9:)ILZ6B:;.EHFFSI:)ILZ6B:;.EHFFSI:)
MILZ6B:;.EHFFSI:)ILZ6B:;.EHFFSO^T% C_M1X=_[(J.O^M-UKKIT-\U9Y5
MG<>=8[+$H&JUPJ-SNKZD?+^[I(7$MZ*'RK.?A]"PG8?5K)J)VZF8C."EEY/F
MGI2:WYF1G=J6CZ#6E(VCTI.,I<^3C*7/DXRESY.,I<^3C*7/DXRESY.,I<^3
MC*7/DXRESY.,I<^3C*7/DXRES_^U$PC_M1X=_[,J.O^N-EKKIT-\U9]3G<>>
M8++%HFBUPJ5PNKZF>K^[IH/%MZ6'R[.BA]&OH(?7JIZ)W*2;B^"=F8[CFIN9
MX)66G-N3DZ#7D9&CTY"/I<^0CZ7/D(^ESY"/I<^0CZ7/D(^ESY"/I<^0CZ7/
MD(^ESY"/I<^0CZ7/D(^ES_^U$PC_MAT=_[,I.O^N-EKKJ$)\U:!1G<>?7K'%
MI&2UPJ=MN;ZI=[^[J8'$MJB(R[&EA]&KHH?7I9^(VYZ=B-V7FXO@DIN3WY*<
MG-R/F)_7CI6BTXV3I-"-DZ30C9.DT(V3I-"-DZ30C9.DT(V3I-"-DZ30C9.D
MT(V3I-"-DZ30C9.DT/^U$PC_MAT=_[0I.O^O-5KJJ$%\U:).G,>A6K'%IF"T
MPJIIN;^M<[Z[KGW$M*J'RZVEAM&GHH;5H*"&V)F?AMN2G8G=C9V.W8R>F-N,
MGI_8BYJBU(J7I-&*EZ31BI>DT8J7I-&*EZ31BI>DT8J7I-&*EZ31BI>DT8J7
MI-&*EZ31BI>DT?^V$@C_MQP=_[0H.?^P-%KJJ4!]U:1)G,BD5;#&JENSPZ]C
MM\"S;+VVKGS%L*F'S*FFAM"CI(74G**$UI6AA=B/GX?:BI^+VX>?DMJ(H9S7
MB)^AU(><I-&'G*31AYRDT8><I-&'G*31AYRDT8><I-&'G*31AYRDT8><I-&'
MG*31AYRDT?^V$@C_MQL=_[4G.?^P,UKJJCY]UJA$F\FH3Z_'L%.RQ;A9M;FS
M;;^QK7W&K*J&RZ6GA<^?IH31F*2$TY*CA-6,HH;7B*&*UX6ACM>#HI;6A*2?
MU(2BH]&$HJ/1A**CT82BH]&$HJ/1A**CT82BH]&$HJ/1A**CT82BH]&$HJ/1
MA**CT?^W$0?_N!H<_[8E.?^Q,5KJJSQ^UZP[F<JM1*W)N46NO;A9N+*R;\"L
MKG[&J*N%RJ&IA,V;IX//E::#T(^EA-**I(;3AJ.(U(.CC-2!HY'4@*29TX"F
MH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:A
MT?^X$ ?_N1D<_[<D.?^S+UKIK3E^V;0OELRX,JG"O4"PL[9=NJRQ<<&GKG[%
MI*R%R)VK@\J7J8/,DJB$SHVGA,^)IX;0A::(T(*FB]& IH[1?J:4T'VGFL]]
MIYK/?:>:SWVGFL]]IYK/?:>:SWVGFL]]IYK/?:>:SWVGFL]]IYK/?:>:S_^Y
M#P?_NA<<_[DB.?^U+5KLLS!ZW< ?D,G#(:BUNDBTJ[5BO*:R<\"CKW[#H*Z$
MQIFL@\B4JX3)CZJ$RHNJA<N(J8;,A:F(S8*HBLV J(W.?JB1S7RIELU\J9;-
M?*F6S7RIELU\J9;-?*F6S7RIELU\J9;-?*F6S7RIELU\J9;-?*F6S?R[#@?\
MO!4;_KL?./^W*5KPO21TW],.AKG!*JJJN4^VI+5EO*"R=+^>L7_"FZ^$PY:N
MA,61K83&C:V%QXJLALB'K(?)A:N(R8*KBLJ JXS*?JN/RGRKDLI\JY+*?*N2
MRGRKDLI\JY+*?*N2RGRKDLI\JY+*?*N2RGRKDLI\JY+*?*N2RO&]# ;YOA(:
M^KX;-_RZ)5KGSA-HR-D+B:W#,J>AN%:XG;5HNYNS=;Z9LG_ F+&$P9.PA<*/
MKX7#C*^&Q(FNAL6&KH?%A*Z(QH.MBL:!K8O&?ZV.QWVMD,=]K9#'?:V0QWVM
MD,=]K9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0Q]_ " 7UP@\9]L(6
M-N[(%5#-W QFM=H/B*+)-J":OE:PE[=JN96U=KR4M'Z^E+.$OY"RA<"-L8;!
MBK&&P8BQA\*&L(C"A+")PH.PBL.!L(O#@*^-PWZOC\-^KX_#?J^/PWZOC\-^
MKX_#?J^/PWZOC\-^KX_#?J^/PWZOC\-^KX_#?J^/P]G"!P7DQPL8[\@0--':
M"T6ZZ0YHIMX8@IC1-Y61R%.AC\)EJ8Z^<JZ-O'NRC+J!M8FX@K>'N(2XA;>%
MN8.VAKJ"MH>Z@;6(NX"UB;M^M8J\?;2,O'RTC;U\M(V]?+2-O7RTC;U\M(V]
M?+2-O7RTC;U\M(V]?+2-O7RTC;U\M(V]?+2-O=3$!P36RPD5T]0+)[WB#$FI
M]!1EF>8E>([<.8:(U$^0AL]@EX3,;9R#R76@?\=XHGW&>Z1ZQ7VF><2 IW?#
M@:AVPH.I=<*$JG3!AJMSP8>K<L")K'&_BZUQOXNM<;^+K7&_BZUQOXNM<;^+
MK7&_BZUQOXNM<;^+K7&_BZUQOXNM<;^+K<_&!P+0S0D2P-D)+*SW#TB;^AY<
MC^\Q:X;G0G: XE!^?MU?A7O9:8IWU6Z/=--SDG'1=Y1PT'J6;L]]EVW.?YEL
MS8&9:\V#FFK,A9MIS(><:,N)G6?*C)UGRHR=9\J,G6?*C)UGRHR=9\J,G6?*
MC)UGRHR=9\J,G6?*C)UGRHR=9\J,G<K(" '"T@<3KN8)+9W_%4&1_RA0A_HY
M7('S2&9\[51N=^A>=7'D97IMX6M^:M]P@6C>=81FW'B%9=M[AV/:?HABVH&)
M8=F#BF#9A8I@V(>+7MB*C%[6C8U>UHV-7M:-C5[6C8U>UHV-7M:-C5[6C8U>
MUHV-7M:-C5[6C8U>UHV-7M:-C<3*!P.QV@05G_\-*)+_'3>)_RY#@O\]3GS]
M2U=W^%9?;_-=96CP8FID[6EN8>MO<5_I<W-=Z'=U7.=[=EOF?G=:YH!X6>6#
M>5CEA7I8Y(AZ5^2+>U;CCGQ6XXY\5N..?%;CCGQ6XXY\5N..?%;CCGQ6XXY\
M5N..?%;CCGQ6XXY\5N..?/^J' 7_JB<7_Z<V+_^B1$KZG5)EZI=??MR3;I//
MDGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]@)O!O7Z>P;Q]
MH<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FO
MPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B1$KZG5)EZI=??MR3;I//DGBE
MQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]@)O!O7Z>P;Q]H<*\
M>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAY
MK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B1$KZG5)EZI=??MR3;I//DGBEQI*"
MM,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"
MO'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X
M>:_"N'FOPO^J' 7_JB<7_Z<V+_^B1$KZG5)EZI=??MR3;I//DGBEQI*"M,22
MB;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"O'JH
MP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"
MN'FOPO^J' 7_JB<7_Z<V+_^B1$KZG5)EZI=??MR3;I//DGBEQI*"M,22B;;#
MD8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QY
MK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FO
MPO^J' 7_JB<7_Z<V+_^B1$KZG5)EZI=??MR3;I//DGBEQI*"M,22B;;#D8ZX
MP8Z0NL"*DKR_AY2]OH26O[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X
M>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J
M&P7_JB<7_Z<U+_^C1$KZG5%EZ9=>?MN4;93/DG>FQ9*!M,23B+;#DHVXP8^/
MNL"+D;R_B).^OH66O[V"F,&\@)O"O'Z>PKQ]H<.[>Z3$NWJIQ+IYK<2U>:[#
MM7FNP[5YKL.U>:[#M7FNP[5YKL.U>:[#M7FNP[5YKL.U>:[#M7FNP_^K&P7_
MJR87_Z@T+_^D0TKYGE!EZ9A=?]J5:97-E'2HQ91^M,25AK;"E8RYP9&.N[^-
MD+V^B9*_O8:4P;R#E\.[@9K$NGZ=Q;I]H<:Z>Z7&N7JJQK5ZK,:Q>JW$L7JM
MQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ/^K&@7_JR47
M_ZDT+_^D0DKYGT]FZ)E<@-J69I;,E7&IQ95\M,26@[?"EXNZP).,O+Z/CK^]
MBY#!O(>3P[J$EL6Y@9G&N7^=Q[A]H<BX?*;)M7JJR;![J\>L>ZW%K'NMQ:Q[
MK<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ?^L&07_K"06_ZDS
M+_^E04KYGT]FZ)E;@=F88Y;,EF^JQ99YM,.7@;?!F(FZOY6+O;Z1C<"\C8_"
MNHB2Q;F%E<>X@IC)MW^=RK9]HLNV?*C+L'NIRJQ\JLBH?:S%J'VLQ:A]K,6H
M?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H?:S%J'VLQ?^L&07_K"06_ZHR+_^E
M04OYH$YGYYI9@=F989?+EVVKQ9=WM,.9?[?!FH>[OY>*OKV3C,&[CH[$N8J0
MQ[B&D\FV@IC+M7^=S;1^H\ZQ?*;.K'VHRZA]JLFE?JS&I7ZLQJ5^K,:E?JS&
MI7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&I7ZLQO^L&07_K2,6_ZHR+_^F0$OX
MH$UGYYQ7@=F:7I?+F&JLQ9ETM,.:?;?!FX6[OIF)O[R5BL*ZD(S%N(R/R+:'
MDLNT@Y?.LX"=T+)_I-&L?J7/J'ZGS*1_J<FA@*S&H8"LQJ& K,:A@*S&H8"L
MQJ& K,:A@*S&H8"LQJ& K,:A@*S&H8"LQO^M& 7_K2,6_ZLQ+_^F/TOXH$UG
MYYU5@=F<7)?*F6BLQ9IRM,.<>KC G(.[OIR)O[N7B<.YDXO'MXZ-R[2)D,ZR
MA);1L8&=TZR HM.G@*70I("GS:"!J<J>@:O&GH&KQIZ!J\:>@:O&GH&KQIZ!
MJ\:>@:O&GH&KQIZ!J\:>@:O&GH&KQO^M& 7_K2(6_ZLQ+_^G/TOXH4QGYYY3
M@=F=69?*FV6LQ9QOM,.=>+C GH&\O9Z(P+N:B,2XE8G)M9"+S;*+C]&PAI75
MKH2>UZ>"H=2C@J31GX*GS9R#J<J:@ZO'FH.KQYJ#J\>:@ZO'FH.KQYJ#J\>:
M@ZO'FH.KQYJ#J\>:@ZO'FH.KQ_^M%P7_KB(6_ZLP+_^G/DOXH4MHYY]1@=F?
M5I?*G&*LQ9ULM,.?=;C H'Z\O:"'P;J=B,:WF(C+LY.)S[".C=2MB939J(:=
MVJ*%H=6>A:31FX6FSIF%J<J7A:O'EX6KQY>%J\>7A:O'EX6KQY>%J\>7A:O'
MEX6KQY>%J\>7A:O'EX6KQ_^N%P3_KB(6_ZPP+_^G/DOXHDMHZ*%/@=F@4Y?*
MGE^LQI]IM,.A<KC HGR\O:*$P;F@A\>UG(?-LI>(TJZ3B]BJCI/?HHN<W)R)
MH-:9B*/2EXBFSI6(J<J4B*O'E(BKQY2(J\>4B*O'E(BKQY2(J\>4B*O'E(BK
MQY2(J\>4B*O'E(BKQ_^N%P3_KB$6_ZPO+_^H/4OXHDIHZ*)-@-FB4)?+H%RL
MQJ%EL\.D;K? I7B\O*6"PKBDA\BTH(?.L)V(U:N9BMVEEY/FFY&;W9:/H->4
MC:/3DHRFSY&+J,N0BJO(D(JKR)"*J\B0BJO(D(JKR)"*J\B0BJO(D(JKR)"*
MJ\B0BJO(D(JKR/^N%@3_KR$6_ZTO+_^H/$OWHDEHZ*1*@-FD39;+HEBKQJ1A
ML\2G:K? J72\O*E^PKBHA\BSIH?/K**'UZ2=B=V:FHWAE9J;WI&5G]B/DZ+3
MCI"ET(Z/J,R-CJK)C8ZJR8V.JLF-CJK)C8ZJR8V.JLF-CJK)C8ZJR8V.JLF-
MCJK)C8ZJR?^O%@3_KR$6_ZTN+_^I/$OWHTEIZ*9(?]JG2)7,I5.JQZA<LL2L
M9+;!KFZ[O:]XP+:LA,FNIX?0IJ.&U9V@AMF3G8G=C9V4W8V=G]B+F:'4BY:D
MT(J3I\V*D:G)BI&IR8J1J<F*D:G)BI&IR8J1J<F*D:G)BI&IR8J1J<F*D:G)
MBI&IR?^O%03_L" 6_ZXN+_^I.TOWI$=IZ:A$?MNK0Y3-J4RIR*U4L,:S7+/"
MMV:YM[!WPK"KA,FIIX;/H:2$TY>BA-:.H(?9B)^/VH>AFMB'H*'4AYNDT8>8
MILZ'E:G*AY6IRH>5J<J'E:G*AY6IRH>5J<J'E:G*AY6IRH>5J<J'E:G*AY6I
MRO^P%03_L" 5_ZXM+_^J.DOXID1HZJM ?=RO/)+/KT*FRK5)K<:\4K&YM6>[
ML+!XPZNLA,FDJ83-G*:#T).DA-.+HX;5A:*,UH*BE-:#I)W4@Z*DT8.>ILZ$
MFJC+A)JHRX2:J,N$FJC+A)JHRX2:J,N$FJC+A)JHRX2:J,N$FJC+A)JHR_^P
M% 3_L1\5_Z\L+O^K.4OXJ4!GZZ\[>]ZV,X_2NC2AS,(YJKNZ5;6PM&J]JK!Y
MPZ>MA,>?JH3+F*B#S9"GA-")I8;2A*2*TX"DD--_I9?2?Z:@T'^EILZ H*C+
M@*"HRX"@J,N H*C+@*"HRX"@J,N H*C+@*"HRX"@J,N H*C+@*"HR_^Q$P3_
MLAX5_[ K+O^L-TSZK#ME[;4T>.*_*8G8S""8OK\]KK"X6;BILVR^I;!ZPJ*N
MA,6;K(/(E*J$RHZIA,R(J(;.@Z>)SX"GC<]^IY//?*B:SGRIHLU\IZC+?*>H
MRWRGJ,M\IZC+?*>HRWRGJ,M\IZC+?*>HRWRGJ,M\IZC+?*>HR_^R$@3_LQT5
M_[$I+O^M-DS\L35B\;TJ<N;-'X#(S"&;L;Q%LJBW7KFCLV^^H+%[P9ZOA,.7
MKH3&D:R$QXRKA<F'JH?*@ZJ)RX"JC,Q]J9#,?*J5RWJJG,IYJZ3*>:NDRGFK
MI,IYJZ3*>:NDRGFKI,IYJZ3*>:NDRGFKI,IYJZ3*>:NDRO^S$03_M!L4_[,F
M+O^O,TS]N2M=Z\H?:=+?$7^YS"><I[U,L:"W8KF=M'&]F[)\OYJQA,&4L(3#
MCZ^%Q8JNAL:&K8?'@ZR)QX"LB\A^K([(?*R2R'NLE\AYK9['>:V>QWFMGL=Y
MK9['>:V>QWFMGL=YK9['>:V>QWFMGL=YK9['>:V>Q_^U$ /_MAD4_[4D+?^T
M+$GRQ1]4UMT28L'?$X&LS2Z:G\!/JYJX9;>7M7*[EK1\O96R@[^1L87!C;&&
MPHFPA\.&KXC#@Z^)Q(&OB\1_KHW%?:Z0Q7NNE,5ZKYG$>J^9Q'JOF<1ZKYG$
M>J^9Q'JOF<1ZKYG$>J^9Q'JOF<1ZKYG$>J^9Q/^W#@/_N!83_[<@+?F_'T'<
MV1%$Q.L29K'?&(&@T#.5E\90HY/ 8ZV1NW&SD;A[N)"V@KN.M(6]B[.&OXBR
MA\"&LHG A+&*P8*QB\& L8W!?K&/PGRQDL)[L97!>[&5P7NQE<%[L97!>[&5
MP7NQE<%[L97!>[&5P7NQE<%[L97!>[&5P?2Z"P/]NQ(2_KL;+.70#S+(Z0]*
MM/(59Z+B(GV6UC>-C\Y/F(S(8:"*Q&ZFBL%XJH>_?:V$OH"P@;R"L7^[A+-]
MNX6T>[J'M7JYB;5YN8NV=[F-MG:XC[=TN).W=+B3MW2XD[=TN).W=+B3MW2X
MD[=TN).W=+B3MW2XD[=TN).W=+B3M]R^!@+XP X1[L@.(LO;"RZV^!%,I?4=
M8Y?H+'6-WSV!A]A0BX/38)*"SVR7?\USFWS+=YUYR7J@=\A]H77'?Z-SQH*D
M<L6$I7#%AJ5OQ(BF;L2*IVW#C:=KPY"H:\.0J&O#D*AKPY"H:\.0J&O#D*AK
MPY"H:\.0J&O#D*AKPY"H:\.0J-? !@';Q@@.R],*%;CH##*F_Q5*F/HF7(WP
M-VF%Z49T?^13>WS?8(%XW&B%=-IMB7#8<8MNUG6-;-5XCVK4>Y!ITWZ19].
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
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MR)2'K,63AZ[#DH>PP)*'L,"2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[#
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MD*'+7YV8PVVHD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[#
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M>[:XH7VWMIU^N+6;?[FTF7^ZLYB NK*7@+NQEX"[L9> N[&7@+NQEX"[L9>
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M*"G_ERDH_Z J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*J'"  "1T0
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MB]:+=HO6BW:+UHMVB]:+=HO6B_]Y$0'_>!H"_XP9 _^>(P3_JB8&^+0E".O
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M=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?> 6$CXC5I%^)M<0OBK7D'WOE]
M]]]@0^[L8$?C\5](V_%A2=+R8TG2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8_Z5
M  #4J0  PK4# +7! P"JSP4 H.<+ 9C]&@:/_BD0AO\U&W[_0"5T_T8M:_],
M-6/_4CI<_UD_5O]@0U#_:$=,_W%*1_][3$/_ATY _Y10/O^A4CW_L%0[_\-5
M._[A53SY\%5 \/150^?W5$/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5-NA  #%
ML   M;H" *C' @"=U@0 D_P. 8O_'0:#_RL/>O\U%W'_/!]H_T(F8/])+%G_
M3S%3_U8U3O]=.$G_93M%_VT]0?]V/S[_@$$[_XM#.?^813C_I$8V_[)'-?_$
M2#7_W4DT__!)-_[X23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X2<FK  "VM
MJ,$  )O/  ".WP$ A_\1 7[_'01U_R<+;/\O$F3_-QA<_SX=5O]%(E#_2R5+
M_U(H1O]8*T'_7RT^_V<O._]O,3C_>#,V_X(T,_^--C'_F3<P_Z4X+_^R.B[_
MP#LN_],[+?_K/"W_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/+BP  "HO   FLD
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MCX61?8J"G(*%@*J%@7^\AH" VX6 @-V#@'_>@8!^X'^ ?>%]@'WC>X!\Y'J
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M64?0]UQ)R/=>2L'V8$N]]F!+O?9@2[WV8$N]]F!+O?9@2[WV8/^)  #9G@
MQZP! +FV @"NP0, I<X& )SD# "5[QT#C>\L"X7O.15\[T$><^]))VKN4"]B
M[E<U7.Y?.E;N:#]2[G%"3>]\1DGOB4E&\)9+0_"F34#QN4X_\MM//O#W3D+F
M^T]#W?M11-3\4T7/_%1%S_Q41<_\5$7/_%1%S_Q41<_\5.&5  #+I@  N[
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M+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8  (;3  !YX0
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M9E6D\F98G_)F6IOS95R7\V1<E_-D7)?S9%R7\V1<E_-D7)?S9/]P#0#_A 0
MW98  ,ZC P#$K@0 N[<$ +3"!0"NS0P I\X@ I[-,0J5RSX6B\A)(X+&4BYZ
MPUHX<L%B0&O :D=DOG--7KU\4UF\B%=4NY5;4+NE74Z[N5Y-O-M=2[GW7TZQ
M]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W" #KC   TYL
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M1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P  *>V  ";P0
MD,P" (;9!@" \A( >?(? G'R*P9J\C8,8_,_$EWS1QA7\T\=4O-7(4WT8"1)
M]&DH1O1S*D+U?BT_]8LO//:9,3KVJ3,X][XT-OCA-3;U^34U\_\T-^S_-CGE
M_S@YY?\X.>7_.#GE_S@YY?\X.>7_.,B>  "VJ0  J+(  )N]  "/R   @]0
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M%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4  %'_ 0!*_PL
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M866)]U]GAOA>:83Y7&J"^EIK@?M::X'[6FN!^UIK@?M::X'[6O]B$ #_<@<
M^((# -N/ @#/F@4 R:,& ,.L!@"]LA  M;(D JRP-0NCK4(7FZI,(Y*F52Z*
MHUTX@Z!E0'V=;$=VFW1-<)E]4VN6B%AFE91<8I2A7U^3LF!=D\E@79/M7UZ0
M^%YAC/E<8XKZ6V2'^UIEAOM998;[666&^UEEAOM998;[6?]F#0#_=P, XX<
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M4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<  +ZB  "SJ@
MJ;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C9\5<*F'$9#!<
MPVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%N?]*1[/_2TFM
M_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G  "JKP  H+@
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M+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T  ''8  !GY@8
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M!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\" "K_"@ F_P\
M(O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"!_]) @/_4P(
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MXGT024-#7U!23T9)3$4 "A*18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A,
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M2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0
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M24Z@]4E.G_])4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P
MRHT  +Z8  "SH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=Q
MM5(>:[-:)66R8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK
M]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,
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M*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@
M@[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"
MYEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D
M_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8
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M!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P
M,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!$O\X 1#_0 $.
M_T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0, _^P# /_L P#_
M[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\
M "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<!
M /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$ _[L! /^[ 0#_NP$
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M,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!, _U00 /]<$@#_81<
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M.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8 W7@( -I["P#1?A<
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M1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0
MUGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B
MEE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B(
M[418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX
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M-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@
MFZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.7K=2$UJV6AA6
MMF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U L/XO/Z__,3ZM
M_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH
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M%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@
M3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J
M[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J
M_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T
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M 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P
M$?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00
M_TT  /]<  #_;0  _X(  /^6  #_J   _[H  /_#  #_PP  _\,  /_# /\D
M+P'_)2\!_R@O ?\G,0'_)#8"_R ^ O\:20/_%U8#_Q5D _\3<@3_$G\$_Q**
M!/\2E 3_$IT%_Q*D!?\2K ;_$K,&_Q*Z!O\2PP;_$\X'_Q/?!_\3ZP?_$_8'
M_Q/_!_\3_P;_$_\&_Q3_!_\4_PC_$_\(_Q7_"?\5_PG_%?\)_Q7_"?\E+@'_
M*2T!_RLL ?\K+@'_*3,"_R0[ O\?1@/_'5,#_QMA!/\9;@3_%WL$_Q>'!?\7
MD07_%YH&_Q>A!O\7J0?_%[ '_Q>W"/\7P C_&,H(_QC;"/\8Z C_&/0(_QC]
M"/\9_PC_&?\(_QG_"?\9_PK_&/\+_QK_"_\:_PO_&O\+_QK_"_\F+0'_+"D!
M_RXH ?\O*@'_+2\"_RDW O\G0P/_)% #_R)=!/\@:@7_'G<%_QZ#!O\>C0?_
M'I8'_QZ>"/\>I0G_'JP)_QZS"?\>O K_'L8*_Q[3"O\>Y0K_'O$*_Q_\"OX?
M_PK]'_\+_!__#/P>_PW\'_\.]R'_#O<A_P[W(?\.]R'_#O\J*@'_+R8!_S(D
M ?\S)0'_,BH!_S$T O\O/P/_+4P#_RI9!/\H9@7_)G(&_R5^!_\EB0C_)9()
M_R6:"O\EH0O_):@+_R2P#/\DN S_)<$,_R7.#?\EX0W\)>\-^2;Z#/8F_PWU
M)O\/]"7_$/0E_Q'R)O\2[2?_$NTG_Q+M)_\2[2?_$O\N)@'_-"(!_S<@ ?\Y
M(0'_."4!_SDO O\X.P+_-4<#_S-4!?\Q80;_+VT'_RYY"?\MA K_+8T,_RR6
M#?\LG0W_+*4._2RL#_PLM _[++T/^2S)$/8LW1#S+>P/[RWX#^TM_Q+K+/\4
MZBS_%>DL_Q;E+?\6X"[_%N N_Q;@+O\6X"[_%O\R(P'_.!T!_SP; ?\^&P'_
M0"(!_T$K ?] -@+_/D(#_SQ/!?\Y7 ;_.&@(_39S"_LU?@SX-8@.]S21#_4T
MF1#S-* 1\C.H$O SL!+O,[D3[C/%$^LTUQ/G-.H2XS3W%.$T_Q?>,_\9W#/_
M&MLS_QK4-/\:SC7_&LXU_QK.-?\:SC7_&O\V'P'_/!D!_T$6 /]$%@#_1QX!
M_TDG ?](,@+_1CT#_T1)!?I"5@?V0&()\C]N#.\]>0_M/(,0ZCR,$N@[E!/G
M.YP4Y3ND%>,ZK17B.K86X#O"%M\[TA;:.^@7U#KV&M Z_QS-.O\>RSK_'LHZ
M_Q_$._\?P#S_'L \_Q[ //\>P#S_'O\Y&P'_0!4 _T41 /]*$P#_3AD _U B
M ?]0+ ']3C<"]DM#!/!)4 ?K2%T*YT9I#>-%=!#@1'X3W4.'%=M"D!?809@8
MU4"@&=- J1O10+(<ST"]'<U S!W*0>0>QD#T(,) _R*_0/\CO4#_([M _R.V
M0?\CLT+_(K-"_R*S0O\BLT+_(O\]%P#_1!$ _TH. /]0$ #_5!4 _U8= /U6
M)@'S53$!ZU,] ^522P;?4%@*VDYC#M1,;A/02G@6S4F!&<M(BAO(1Y(=QD>:
M'\1&HR'"1JPBP$6W([Y%Q22\1=PDN$;P);5&_R>R1O\GL$;_)ZY&_R>J1_\F
MITC_)J=(_R:G2/\FITC_)O] % #_2 X _TX+ /]5#@#_61$ _UP6 /1='P#J
M7"H!XELW MI:1@725U,+S%5>$,A3:!7$47(9P5!['+Y/A!^\38PBN4V5)+=,
MG2:U2Z<GLTNQ*;%*ORJO2M$JK$OK*ZE+_"RF2_\LI4S_*Z-,_RJ?3?\JG4W_
M*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$
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M/&UKZ3MM;/XY;6S_-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P
MWFH  ,US  ##>@  NWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*
M?5@;AGM?((%Y9R5]=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=P
MYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X
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M-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP
MJ)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUF
MDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")
M_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0
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M)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP
M:;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*NED*1[IB#42Z;!!!
MNG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R
M_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P
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M!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP
M)>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1
M]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC
M  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L&
M !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP
M O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]
MM0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_
M"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I
M  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP
M8<D  %+3  !#VP  ->$  "GF   >Z@  %>X  !#X   ._P  "_\   C_   $
M_P8  /\*  #_#@  _Q$  /\5  #_&P  _R,  /\K  #_-@  _T,  /]3  #_
M90  _WH  /^1  #_I@  _[@  /_/  #_SP  _\\  /_/ /\<+P'_("P!_R$L
M ?\>+@'_&C,!_Q0\ ?\/1@'_#50"_PMA O\);P+_"7L"_PF& O\)D +_"9D"
M_PF@ O\)IP+_":T"_PFT O\)O '_"<4!_PG1 O\)XP+_">\"_PGY ?\*_P'_
M"O\!_PK_ O\*_P+_"O\"_PO_ _\+_P/_"_\#_PO_ _\?+0'_(RD!_R0I ?\B
M*P'_'C !_Q@X ?\40P'_$5 "_Q!> O\.:P+_#G<"_PZ# O\.C0+_#I4"_PZ=
M O\.I +_#JH"_PZQ O\.N0+_#L$"_P[- O\.WP+_#NP"_P[X O\._P+_#O\"
M_P__ _\/_P/_#_\$_Q#_!/\0_P3_$/\$_Q#_!/\C*@'_)B8!_R@E ?\G)P'_
M(RL!_QXS ?\;0 '_&4T"_Q9: O\49P+_$W,"_Q-^ O\3B0/_$Y$#_Q.9 _\3
MH +_$Z<#_Q.N _\3M0/_$[X#_Q/) _\3V@/_%.D#_A3V _L4_P/Y%?\#^17_
M!/@5_P7X%?\&^!7_!O@5_P;X%?\&^!7_!O\F)@'_*B(!_RP@ /\K(@'_*"8!
M_R<P ?\D/ '_(DD"_Q]5 O\=8@+_&VX#_QMZ _\:A /_&HT#_QJ5 _\:G 3_
M&J,$_QNJ!/\;L@3_&[H$_QO%!/P;TP3Y&^<$]1ST!/(<_P7Q'/\&\!S_!^\=
M_PCO'?\)[QS_">X<_PGN'/\)[AS_"?\J(@'_+AT _S ; /\P' #_,"( _S L
M ?\N-P'_*T0"_RA1 O\F70/_)&D#_R-U!/\C?P3^(X@$_2.1!?LCF 7Z(Z %
M^".G!O<CK@;U([<&]"/!!O(DSP;N).0&ZB7R!N@E_@CF)/\*Y"7_"^,E_PSC
M)/\,XB3_#.$D_PWA)/\-X23_#?\N'@#_,Q@ _S46 /\U%0#_.!T _S@G ?\W
M,P'_-#\!_S)+ O\O6 /[+F0$^"UO!/4L>@7S+(,&\2R,!N\LE ?M+)P(["RC
M".HLJPCI++,(YRR^">8LS GB+>((WBWQ"MLL_@S6+?\.U"S_#](L_Q#1+/\0
MSRS_$,XM_Q#.+?\0SBW_$/\R&0#_-Q0 _SH1 /\\$@#_/QD _T B /\^+0'_
M/#D!^CI% O0X4@/P-UX$[#9J!>DU= ;F-7X(Y#2'".(TD G@-)@*WC2?"MPS
MIPO:,[ ,V#.[#-4SR0W2--\-SC3P#\HT_1+'-/\3Q33_%,,T_Q7#,_\5P#3_
M%;\T_Q2_-/\4OS3_%/\V%0#_.Q  _SX- /]##P#_1A0 _T8< /]&)@#V1#(!
M[T(_ >E 3 /D/UD$WSYD!ML];PC8/'D*U#R"#-$[BPW/.Y,/S3J:$,LZHA')
M.JL2R#JU$\8ZPA/$.M44P#OK%;PZ^Q>Y.O\8MSK_&;8Z_QFU.O\8LCO_&+$[
M_QBQ._\8L3O_&/\Y$@#_/PT _T,) /](# #_2Q  _TP5 /5,'P#K2BH Y$DW
M =U)1@+51U,$T$9?",Q%:0O)1',-QD-\$,-"A!+!0HP3OT&5%;U!G1:[0*87
MND"P&+A O!FV0,P:LT'F&J]!]QRM0?\=JT'_':E!_QRI0?\<ID'_&Z5!_QNE
M0?\;I4'_&_\]$ #_0@D _T@% /]-" #_4 L ^5$/ .M0%0#A3R  V% Q ,]0
M00+)3TX%Q$Y:"<!,9 V]2VT0NDIV$[=)?A6U2(<7LT>/&;%'EQNO1J <K4:J
M'JM%MA^I1<8?IT;@(*1&]""A1O\AGT?_()Y'_R">1_\?FT?_'II'_QZ:1_\>
MFD?_'O] #0#_1@0 _TP  /A2 @#H500 X54( .)5#0#551D S%<L ,57/ *_
M5DH&NE55"K937PZR4F@2KU!Q%:Q/>1BJ3H$:J$V*':5,DA^C3)P@H4NF(I]+
ML2.=2\ DFTO8)9E+\"663/\DE4S_))1,_R.33/\BD4W_(9%-_R&13?\AD4W_
M(?]""@#_20  _U$  .97  #=6P$ U5P% -);"0#+7!0 PUXH +Q>. *V748&
ML5M1"JU96P^I6&03IE9L%Z-5=!J@5'T=GE.%'YM2CB*949<DEU"A)I50K2>2
M4+PHD5#0*(Y0["B-4?XGBU'_)HM1_R6*4O\DB5+_(XA2_R.(4O\CB%+_(_]%
M!P#_2P  \%4  -];  #38   S&$# ,AA!@##81$ NV0D +5D- *O8T(%JF%.
M"J5?5P^A76 4GEQH&)M;<!N867@>E5B!(9-7BB205I,FCE6>*(M5J2J)5+<K
MAU3+*X55Z2N$5?PJ@U;_*(-6_R>"5O\E@5;_)(%6_R2!5O\D@5;_)/]' P#_
M3P  YU@  -E@  #-9   QF8! ,%F! "[9@X M&D@ *YI,0*H:#\%HV9*"I]E
M5 ^:8UT4EV%E&)-@;1R07G4?CEU](HM<AB6(6Y HA5J:*H-9IBR 6;0M?UG'
M+GU9YBU\6OHL>UK_*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@
MXUP  -)C  #':   P&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4
M:%H4D&9B&(UE:AR*8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>
MXB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\
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M+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P
MKWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_?%$1>WI9%G=Y8!IS
M=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQU#!=<?(N7G'_+%YP
M_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX
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M)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP
M>I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T36)-E%U63;AI1
MDG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&B_\D1HK_)$:*
M_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T
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M%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4
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M !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0
MA*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4
MZ0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?R
MH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(
M &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H
M"_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C
M_*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$
M  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)
M  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT
M /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _
MU@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_
M!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,
M  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#
M_PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_
M *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT
M /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4
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M ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT _R8H /\C- #_($
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M&Y-&YAN11_D;CT?_&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P
MZTL  -U1  #15   RE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB
M45\,GU!G#YU/;Q&:3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+
MXAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5
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M(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@
MLV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,A&5;$(%D8A-^
M8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I7NXD:5[_(FI>
M_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP
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M'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P
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M$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748*
M&DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<
M27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!H
MCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*
MBAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_
M&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0
M7)<C %J8+P!7F#H!5)A$ U*73 5/EU0'3)=<"4F690Q'EF\.1)5Z$4&5B!,_
ME)<5/92H%CN4O18[E-\6.I+X%SJ0_Q<ZC_\7.H[_%SJ._Q<ZCO\7.H[_%\5N
M  "V>P  JH4  )Z+  "4CP  B)(  'N4  !NEP  8IL  %>>  !2H X 4: ;
M $^A* !-H30 2Z$^ 4FA1P)'H5 #1*%8!4*A80<_H&L)/:!W"SJ@A0TXH)0.
M-J"F#S6@NQ TH-T/-)WW$#.<_Q(SFO\2,YG_$S.9_Q,SF?\3,YG_$[UW  "O
M@P  HXL  )B1  "-E0  @9D  '.<  !GGP  6Z(  $^F  !'J0@ 1*H2 $.J
M'P!!JRL 0*LW #^L00 ]K$H!.ZQ3 CFL7 ,WK&<$-:QS!3*L@08PK)$'+JRC
M""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP
MG)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 S
MMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2Y
MM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<
M (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0
M(L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7
MR,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE
M  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1
M !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X
M"=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !D
MM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?
M$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(
M  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@
M2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0
MZ1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #V
MT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P
M "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L
M /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@
M_\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=
M   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P   /\&
M  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\
M /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_
M $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\
ML #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_
M +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D
M_P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3
M /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +
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M O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL
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M!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0
M_S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU7P*Z
M-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*"J4U
MY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH
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M%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5
MN50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24458&D5!>"8Y/9@N,
M3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+S1AY3.L8>$S^%W=,
M_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D
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M%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580
MCV(. (MD' "'92L @V4W 7]E0@-\9$L&>&-3"'5C6PMS8F(.<&%J$&U@<A-K
M8'L5:%^&%V9>D1EC7I\;85VN'&!=P1Q?7>$<7UWX&E]=_QA?7?\78%W_%F!=
M_Q5@7?\58%W_%>M*  #45@  PUX  +9E  "L:0  HFD  )AG  "/90  B68,
M (5H&0"!:2@ ?FHU 7II/P-V:4D%<VA1"'!G60IM9V -:V9G$&AE<!)E9'D5
M8V2#%V!CCQE>8IT;7&*L'%IBOQQ98M\<66+W&EIB_QE:8?\76V'_%EMA_Q5;
M8?\56V'_%>=-  #/60  OV(  +-H  "I;0  GFT  )-K  "):0  @VL) ']M
M%0!\;B4 >&XR 75N/0)Q;D8$;FU/!VML5@EH;%X,96ME#V-J;1%@:78476F!
M%EMHC1A89YL:5F>J&U5GO1Q49]P<5&?V&E1F_QA59O\7567_%E9E_Q569?\5
M5F7_%>)1  #*70  NV8  *]L  "F<0  F7   (YO  "#;@  ?7 % 'AR$@!U
M<R$ <G,O 6]S.@)L<T0$:7),!F9R5 AC<5L+8'!C#5UP:Q!;;W036&Y_%55N
MBQ=3;9D946VH&D]MNQM.;=D:3FST&4]K_QA/:_\74&K_%E!J_Q50:O\54&K_
M%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T
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M$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0
MJGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/
MD#, 39 ] 4N010))D$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.
MLPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(
M )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L
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M 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP
M:*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6
MO"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]
M^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP
M %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT
M!\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0
MS/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y
M   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>
M  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<
M -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   L
MQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E
M&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y
M  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T
M%=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$
M\Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_
M]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(
M  /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P  _PT
M /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0
M_]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\
M90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z
M /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\
M_@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_
M &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P
MP #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &<
M_P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q
M ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8
M&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L
M /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,,
MY #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_
M&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"
M< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70
M -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L
M_QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>
M#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81
MZ0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R
M /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT
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M!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0
MRC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!I#5E J(U;0*@
M-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0->P(CC;^"(PV
M_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$
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M#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$
METL1 )--( "/3RX C$\Z 8A/10*%3TX#@T]6!(!.709^3F0'?$UL"7E-= MW
M3'T,=4R'#G-,D@]Q2Y\1;TNM$FU+OQ)L2]P2:TSU$6I,_P]J3/\.:DO_#6I+
M_PQJ2_\,:DO_#/ ]  #;2   QU   +I5  "P6   I58  )Q3  "73P  D5 .
M (Q2' ")5"L A50W ()40@%_5$L#?%13!'I36@9X4V((=5)I"7-2<0MQ47H-
M;E&$#VQ0D!!J4)P2:%"K$V90O!-E4-@39%#S$F10_Q!D4/\/9%#_#F5/_PUE
M3_\,94__#.Q!  #43   PU0  +99  "L7   H%H  )=7  "15   BU4, (97
M&0"#6"< @%DT 'U9/P%Z64@#=UA0!'186 9R5U\';U=F"6U6;@MK5G<-:%6!
M#V95C1%D5)H28E2I$V!4NA1?5-,47E3R$UY4_Q%?5/\/7U3_#E]3_PU?4_\-
M7U/_#>=$  #/4   OU@  +-=  "H7P  G%T  ));  "+6   A5H* (%;%@!]
M7"0 >ETQ '==/ %T748"<5U.!&]<505L7%T':EQD"6A;; ME6G4-8UI_#V%9
MBQ%>69@27%BG%%M8N!196= 465CP$UE8_Q%:6/\06EC_#EI7_PU:5_\-6E?_
M#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$
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M$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@
ML6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !>
M<3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5N
ML!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P
M *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8
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M!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@
M=G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P W
MDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0
M^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4
M &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@
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M  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K
M-;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P
MPC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##
M_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H
M !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H
M -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P
MUO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'
M   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G
M  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\
M .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "
MV    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T
M)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT
M '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0
M .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0
M_R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+
M( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V
M /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L
M_P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_
M"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\
M>@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9
M /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4
M_P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z
M 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D
MY@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/
M /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@
M[0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8
M /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+
M# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z
M -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T
MQP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_
M#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$
M>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O]
M +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8
M^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_
M#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5
M_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4%
M -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@
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M X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L
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M!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0
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M#%53L U44\4-4U/F#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4
MM5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G
M6ST!95M% 6-;30)A6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8
MK@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP
M *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH
M8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*
M7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A
M  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#< 6F1
M 5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)1V*:"D9BJ@M$8K\+
M1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",
M8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J
M10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>
M"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P
M>V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*
M<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN
M]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL
M &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0
M07A- 3]X50$]>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q
M=/\%,7/_!3%R_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q
M  !<<P  47<  $IZ  !"?0, /WX. /_B?1!)0T-?4%)/1DE,10 +$CU_&  \
M?R, .X M #J -@ Y@3\ .(%( #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!
MH0,J@;8#*8'2 RE_\P,I??\#*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78
M (5U  !X=0  ;74  &%W  !7>@  3'X  $.!   [A0  -8@) #*)$0 QB1L
M,(DE "^*+P NBC@ +8M! "R+2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$B
MB[,!(8S. 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z
M  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  DE!, (Y0<
M "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7F0 7EZX
M%9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L
M@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A
M&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+
M  NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP
M6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &
MK1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "N
MU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H
M $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X#@  N10
M +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q
MO.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM
M   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84
M  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH
M ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   D
MO   &;\  !'"   *Q0   LD   #,    T    -$   #2 0  TP@  -4-  #7
M$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F
M  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP
M#\H   ?.    T0   -8   #<    WP   .    #B    Y    .8#  #H"0
MZ0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #Y
MY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@
M  #=    X0   .0   #H    ZP   .T   #O    \0   /,   #V    ^ ,
M /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP
M_]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\
M7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O
M /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\
M\ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_
M &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /<
MM #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_
M /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\
M^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H
M +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-
M$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B
M .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0
MU0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_
M# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X
M90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[
M ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@
M_PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#)
M &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0
MQP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\
M /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$
MN05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F
M"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09
M  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C
M *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X
MEQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*
M)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;
M90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J( DAZO ) >OP"/']@ C"#Q
M 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@  VBT  ,HP  "^+@
MM2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7)%$ E219 ),E8 "2
M)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K 80GNP&#*-$!@"CN 7XI
M_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4  ,$X  "T-@  JS$
M *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-+4P BRU4 (DN7 "'+F,
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M V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10  E4,  (Y   ")/
MA#P* ( ]% !]/B( >C\N 'A . !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J
M07 #:$%Y V=!A 1E09$%8T&?!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU
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M \Y$  "\3@  KE0  )Q3  ".4@  @U$  'I0  !R30  ;$\  &A0"P!E414
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M!4!=HP8_7;8&/EW0!CU<\04^6_\$/EK_!#Y:_P,^6?\#/UG_ \%0  "Q6@
MH5T  )!<  ""6P  =EL  &U;  !A6P  6UT  %9>  !28 T 4&$7 $YB(@!-
M8BP 3&,U $IC/@!)8T8 1V-. $9C5@%$8UX!0F-H D!C<P,^8X$#/&.0!#IB
MH00Y8K0%.&/-!3AB[P0X8?\$.&#_ SA?_P,Y7O\#.5[_ [Q5  "M7P  G&
M (M?  !]7P  <E\  &A?  !=8   56(  $]D  !+9@H 26<2 $=H'0!%:"<
M1&DQ $-I.0!":D( 0&I* #]J4@ ]:EL!/&IE 3IJ< (X:GX"-FF- S1IGP,S
M:;(#,6G+ S%H[0,Q9_\#,6;_ S)E_P,R9/\#,F3_ [=;  "I9   EF0  (9C
M  !X8P  ;6,  &1D  !990  4&@  $EK  !#;00 0&X. #YO&  ];R( /' K
M #IP-  Y<3T .'%% #=Q3@ V<5< -'%A 3)Q;0$Q<7H!+W&* BUQG (K<:\"
M*G'( BIPZP(J;_\"*FW_ BIL_P(K;/\"*VS_ K%A  "D:0  D&@  (!G  !T
M9P  :6<  %]H  !5:P  2VX  $-Q   \=   -W8* #1W$@ S>!P ,G@E #%Y
M+@ P>3< +WD_ "YY2  L>E( *WI< "IZ:  H>G8 )GJ' 25ZF0$C>JP!(GK%
M 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@  BFT  'ML  !O;
M96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G@A0 )H(> "6")P D
M@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$E0 :A*D &(3! !B#
MY@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,
M %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB<
M%XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .
MC?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^
M  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF
M  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?
M IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [
MC0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F
M*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\
M  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6   RF@
M*)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#   LA$  +(7  "S'P
MLR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T
M_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P
M !:P   /M   ";<   &Y    O0   +X   "^!@  OPP  , 0  #!%@  PAT
M ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@
MQ_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]
M   &P    ,,   #'    R0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;
M  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\
M -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4P@  #,8   /)
MS    -    #5    V0   -H   #<    W@   .    #B!0  Y L  .<0  #J
M&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T
M &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@   -(   #7    W
M .    #E    YP   .D   #K    [0   .\   #Q    \P   /8'  #Y#@
M_!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\
M& #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M
M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\
M_0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_
M !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\
M< #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#'
M .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X
M_P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S
M '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .
MTP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P &
M /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P
MX@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#)
M .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\
M! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M
M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L
MMP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V
M  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P
M;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K
M *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!
MV@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L
M &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&
M^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T
M ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH
MGPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",
M$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1
M  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L
M )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\
M?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D
M%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>
M;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_
M '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$
ME1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![
M)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI
M_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0  F#(  )(M  ".*0  BR<,
M (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\
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M =0W  # 00  KT0  )U#  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@
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M TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3
MHDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!6
M3"\ 54TX %--0 !234@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-
MGP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\
M (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P
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M C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P
M:5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y
M8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2IC
MXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L
M %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34
M+VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C
M:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@
M  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W
M "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?<
M&G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(
M:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\
M.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_
M !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<
M.70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .
MASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#
M_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT
M "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,
M ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P
MC_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-
M   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U
M  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\
M )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2
MG@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O
M-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_
M (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K
M!*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P
MP#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-
M  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X
M  #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL
M -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@
MG@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/
M    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ
M  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0
M2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
MXP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_
M+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2
M /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@
M_P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X
M /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\
M#P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y
M /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X
MZ0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_
M !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L
M>@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X
M -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T
M_  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5
M 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\
M_P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1
M .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ',
MP !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M
M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -,
M%0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T
M *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\
MG@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"]
M !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$
M=0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_
M )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !(
MK  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3
M W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+
M_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46
M )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0
MA@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W
M$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0
M&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X
M 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\
M;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$
M&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @
M?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_
M . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX
M>",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E
M*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L
M  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE
M &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0
M7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "]
M.@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q
M*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360
M 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0
MHSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>
M-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZ
MG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\
M (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X
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M 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P
M:T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%
M2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,
MW0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H
M %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L
M/E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O
M4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-
M  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_
M #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4
M*57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.
M4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<
M0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_
M "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@
M0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E
M8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@
M_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX
M #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T(
M&FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3
M:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G
M   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&
M  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\
M#'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D
M<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_
M2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_
M (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?
M%H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P
MBU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M
M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P
M  N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<
M )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O
M<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<
M    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,
M  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P
M67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
MK@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z
M4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L
M $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[    O@
M +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1
MT%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA
M   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0   ,X
M  #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D
M .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   F
MN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .    #B
M    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/
M  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8
M_P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_
M (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /,
M_P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P =
M /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (
M\@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B
M /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\
M) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"
M .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\
MRP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M
M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H
M@ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_
M +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ",
MT@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U
M ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4
M_P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H
M +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H
MI "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7
M /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L
M+ "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!]
M )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\
MB #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0";
M #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (<
M@0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_
M /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D
MC0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z
M"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6
M  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM
M ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8<
M;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&
M)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84
M,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0
M &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@
MJ"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K
M'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HB
MG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX
M )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$
M8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1
M*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR
M  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV
M %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@
M22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![
M-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q
M.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y
M $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.
M;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,
M-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TY
MTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH
M &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP
M1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W
M/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]
M  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!!
M $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?
M,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4
M/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%
M1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_
M "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P
M2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S
M2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)
M_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@
M #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@
M*U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B
M3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.
M   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9.
M ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\
M'%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q
M50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=
M50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_
M )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P
M)5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  0
M95T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5
M  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4
M !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E<
M!FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T
M6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q
M   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>
M  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P
M8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (
M?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$
M:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,
M %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@
M (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P
MDG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM
M   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F    )D
M  ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD
M **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W
M?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@   "I
M    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S
M  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@
M(Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
MNP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*
M?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4
M !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+    S
M ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P
MYHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\
M    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X    .(
M  #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H
M /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_
M #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P
MC0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_
M -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$
M_P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L
M (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D
M_P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V
M /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@
MU "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V
M /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$
M.P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP")
M +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\
MIP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$
M #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H
MBP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_
M /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #<
MK0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8
M (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P
M  #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z
M )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D
MB "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@
M"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T
M/ "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0
M 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$
MN1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_
M #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"
MF@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<
M )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@
M<PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B
M#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=
M  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [
M &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z<
M5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!
M(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7
M/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW
M $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P
M<B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7
M'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<B
MS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H
M &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X
M3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _
M*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M
M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M"
M $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L
M.BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8
M+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q
M1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_
M #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P
M4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \
M-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U
M_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0
M $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH
M-3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K
M.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z
M   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0
M "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\
M)CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y
M/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$
M6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_
M )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10
M,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @
M2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"
M  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL
M "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T
M%U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![
M1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3
M P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H
M  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@
M9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   5
M7 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =>
M<P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX
M %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P,
M#&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0
M9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12
M  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)
M  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D
M '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&
M5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X
M"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(
M  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P
M-6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@
MA0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+
MF0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX
M "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2    E 4
M )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0
MFZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!
M   2AP  #(P   21    E0   )D   "=    H    *$   "B    I    *4!
M  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$
M *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,
MF    YT   "B    I@   *H   "N    L    +$   "S    M    +8   "X
M    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O
M  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0
M *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
MS0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #A
MO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\
M  #$    R    ,X   #1    U    -4   #8    V@   -T   #?    X@
M .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP
M^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\
M2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7
M /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\
MP@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#]
M $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0
MF@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_
M /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8
MZ !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#(
M )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\
M  #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!(
M ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8
ML@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_
M    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4
M2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP":
M )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
MY    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@
M $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P
MH0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0
M +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $,
MC@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\
M *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!
M  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !#
M 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4
M;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3
M"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ',
M1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R
M &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0
M@ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G
M T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'
MQ@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8
M '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$(
M7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-
M$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:
M  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)%
M %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@
M11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?
M'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T9
M2 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\
M #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@
M5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%
M($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B
M_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,
M $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H
M/293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R
M)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF
M  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0
M #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\
M+2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!
M*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P
M6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_
M )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,
M.C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J
M-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q
M  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4&
M #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\
M(SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_
M-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P[
M"P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I
M !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.
M:CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D
M0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$
M=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT
M %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P
M&TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .
M2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9
M  !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U .
M !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($
M!5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*
M1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8
M$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1
M  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P
M0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@
M7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?
MH@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP
M #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\
M &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0
M:;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6
M   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0
M  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$
M '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =
M8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!
M$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)
M  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<
M#G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0"P
MD0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3
MZ@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0
M  ")    C@   )(   "6    F    )H   ";    G0   )\   "A P  HP@
M *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0
MI_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":
M    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0   +@%
M  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\
M +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
ML    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H   #-
M @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR
M $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^    P@
M ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
MY@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\
M!@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5
M /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8
M[@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_
M    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0
M5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K
M -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M_P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #;
M %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T
ML@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P
M /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F
M +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\
M  #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/
M *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +(
MD@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z
M    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0
M3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^
M (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
MH    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20""
M $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '(
MSP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0
M (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D
M<P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D
M .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X
M  ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!)
M &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$
M6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O
M!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P
M2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T
M $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@
M8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3
M"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,
M_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$
M %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT
M2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]
M$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3
M  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12
M $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\
M-Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+
M%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:
M6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_
M )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' (
M0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S
M(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB
M  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$)
M #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X
M*R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  "
M)P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F
M#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII
M "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@
M;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N
M+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O
M=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X
M %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1
M)S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8
M-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q
M  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382
M " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80
M$3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+
M-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]
M%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5
M  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P
M03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 1
M0Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#
MI0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH
M #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0
M"TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0
M2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]
M   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7
M  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4
M %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J
M0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9
M&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1
M  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@
M'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0
M8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A
M\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4
M !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8
M ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P
M;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD
M   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6
M  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\
M 'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M=@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0
M%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_
M %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@
M (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B#P
MI!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA
M  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F    )T
M  "A    I    *4   "G    J0   *L   "M    L    +(   "U"   N X
M +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y
M<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +    "S
M    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04  -$.
M  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@
M(X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
MR@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%  #K
M#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $
M /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X
M_P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F
M .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\
M  #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!>
M .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X
M_^)]$$E#0U]04D]&24Q%  P2R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_
M /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L
MW0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\
M )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\
M  #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ]
M +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H
MHP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V
M    YP   -,   #&    O0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8
M/0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ".
M (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,   #C
MS    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1
M #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P
ME !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+    MP
M *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$ A  I (( , !_ #<
M?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L
M )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(   "X    I0   )<
M  "-    A@   ($   !\  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W
M &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8
M70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_
M @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P 8P R &(
M. !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C
M %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P
M; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6
M #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@
ML@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\
M %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4
M30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^
M \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82
M  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX
M $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,<
M-0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-
M%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X/
M/  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L
M "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;  !'&@
M1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V
M%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5
M_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P
M #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T
M+AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B
M&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>
M   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]#
M "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\
M'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \(P  .",  #4B   S
M(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D
M2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_
M (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E   N)
M*R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;
M*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E
M  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD
M "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E
M%"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J
M*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK   F+   (BX  !\O
M   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;
M  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0
M6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(  !LS   7
M-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX
M90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$
M $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P  &S8  !<X   3.@(
M$#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80
M/G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T
M   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(
M  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T
M $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [
M-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"   -10$ "$<'  -)
M#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]
M  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@
M,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (3    D\%  !0"@
M4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4
MCP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX
M "=    @0P  &48  !-)   /3   "T\   92    5    %<"  !8!P  60L
M %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0
M7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(
M   :2P  $TX   Y2   *50   UD   !;    7@   &    !B @  8P8  &4*
M  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T
M &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L2@  (TT  !M1   3
M50  #ED   A=   !80   &0   !G    :@   &P   !N    <    '(%  !S
M"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S
M  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<   -80
M!F8   !J    ;P   '(   !V    >0   'P   !]    ?P   ($   "# @
MA@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(
MSP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %<    '8
M  ![    ?P   (,   "'    B@   (T   ".    D0   ),   "5    F
M )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@  "=P0
MF^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[    @0   (<   "-
M    D@   )8   ":    G0   )\   "A    I    *8   "H    JP   *X
M  "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(
M +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".    E    )H   "@
MI0   *H   "N    L0   +(   "U    MP   +H   "\    OP   ,,   #&
M    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO
M #=Q   I>   '8   !&)   (D0   )H   "A    IP   *T   "S    N0
M +X   #"    Q0   ,8   #)    S    ,X   #2    U0   -H   #>
MX0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\
M  #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+
M /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T
MZ0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_
M    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\
M30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B
M ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_
M_0   /H   #X    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#-
M $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T M ": +$
MJ0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@
M .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4
ML0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8
M +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D
M  "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$
M )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@
M@P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0   +$   "F
M    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4
M0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S
M '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X   "3
MC    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R
M $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$
MP@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#    ?
M '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T
M8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4
M -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\   !U    ;@   &D
M  !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ]
M %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X
M20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;
M    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P
M/@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J
M #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0
M4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!"
M $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8
M^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q   $X0  !*#@  2 T
M $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X
M.@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M
M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .
M  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM#
M #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\
M)PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _%0  /!0  #H2   Y
M$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P0
M2P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_
M (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46   T%
M,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D
M%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7
M  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L  #$:   O&0  +A8
M "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$
M'1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K
M'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=   K'   *1L  "<;
M!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY;
M !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P
M62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @
M( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C
M9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,
M $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P  (",  !TD   ;)0<
M&28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,
M*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G
M   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+
M !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7
M!"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \
M*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ
M#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_
M   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+
M,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0,@( #C0'  HW#  '
M-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X6   .&@  #A\   W
MD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X
M "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X
M #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP
M/:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO
M   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0
M  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0
M $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R-   +3,  "8T   @
M-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(!P  2@L  $L.  !,
M$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\
M  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/
M%3\  !!"   ,10  !T@   )*    30   $\   !1!   4@<  %0+  !5#@
M5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8?P  5YH  %:W  !5
MXP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X  !Q!   51   $$@
M  M+   %3@   %$   !4    5P   %D   !;    70(  %X&  !@"P  8@X
M &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0
M8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*   03@  "E(   -6
M    6@   %T   !@    8P   &4   !G    :0   &L!  !M!0  ;PH  '(.
M  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<
M &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )6@   5\   !C
M:    &L   !O    <@   '4   !W    >0   'L   !]    @ ,  (,(  "&
M#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__
M $9+   Z3   +D\  "-3   86   $%X   ED    :0   &\   !T    >
M 'P   "!    A    (<   "(    BP   (X   "0    DP   )8   "9!P
MG0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2
M   R50  )EH  !M@   19P  "6T   !T    >P   ($   "&    BP   )
M  "4    EP   )D   "<    GP   *$   "D    IP   *H   "M    L08
M +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K
M80  'F@  !-P   +>    (    "'    C@   )4   ":    GP   *0   "H
M    K    *T   "P    LP   +4   "X    NP   +\   ##    QP   ,L%
M  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<
M%GD   V!   !BP   ),   ";    H@   *@   "N    M    +@   "]
MP    ,(   #%    R    ,L   #.    T0   -8   #;    WP   .0   #H
M!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_    _P
M /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4
M_ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#?
M -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_    _@   /P
M  #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4
M .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4
MO0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R
M    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,(
M4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#<
M *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\   #/
MR    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F
M %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X
M\ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0   +\   "S    J@
M *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H
MC@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y
M /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<   "=    E    (X
M 0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![ $, >0!(
M '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8
M9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")    @@   'L   !X
M  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@
M2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_
M %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y    <0   &T   !I  $
M9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8
M $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T
M_P!- /\ 30#_ *H   "4    @@   '4   !K    9    &    !=    6@ %
M %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $,
M3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!#
M /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!  !2    4  " $X
M"0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!%
M $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\
M.0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$
M  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@
M20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_
M (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @
M/ $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O
M %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,
M  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@*
M #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX
M)P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M
M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0   P#P$ , T& # +
M"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8
M " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P
M6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I
M#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D0
M9@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<
M $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0  )A0! "42!  C$@L
M(A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16 !049  2
M%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;
M   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18-
M !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7(
M#1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \
M'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<
M$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z
M  <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P
M,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0
M(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $B
MD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$
M "HA   F(   (B   !\?   <'P  &2   !8A   2(P( $"0'  XF#  ,)A
M"R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP
M)J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C
M   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3
M  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0
M "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C
M)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q
M%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\
M   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G   A)@
M'"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/   W$@
M.!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   V
MY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H  "0I   >*@  &2L
M !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH  #T-   ^$   0!0
M $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP
M//P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M   :+P  %3$  !$S
M   --@  "3@   4[    /0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6
M  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P
M $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6-0  $3@   T[   (
M/@   T$   !#    1@   $@   !*    3 0  $X'  !/"P  40X  %02  !5
M&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_
M $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0  #$$   =$    2
M $H   !-    4    %,   !5    5P   %@"  !;!@  70L  %\.  !B$P
M8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\
M   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL   !/    4P   %8
M  !9    7    %\   !A    8P   &4   !G 0  :@4  &T*  !P#@  <Q4
M '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y
M/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=    80   &4   !H
M    :P   &X   !Q    <P   '4   !X    >P   'X#  "!"@  A0\  (<7
M  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$   S10
M*$@  !U,   34@  #%<   -=    8P   &@   !M    <0   '8   !Z
M?@   ($   "#    A@   (D   "+    C@   )(   "5 0  F0D  )X0  ">
M&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,
M !59   -8    V<   !N    =    'H   "     A    (H   ".    D@
M )4   "7    F@   )T   "@    HP   *<   "K    KP   +0)  "X$
MMQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5   D6P  &&$   YI
M   %<0   'D   "!    B    (\   "4    F@   )\   "D    J    *D
M  "L    KP   +,   "U    N0   +T   #!    Q@   ,L   #1"@  TQ0
M -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$   =[
MA    (T   "5    G0   *,   "I    KP   +0   "Y    O    +X   #"
M    Q0   ,@   #,    T    -0   #:    WP   .0   #J    [@P  .T:
M  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_    _P   /P  0#\  @
M_@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V
M &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H
M_P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@   /,   #S    ]@ )
M /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L
MU@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G
M /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<   #G    Y  ! .
M"P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9
M +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\
MBP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&    OP   +D !@"W
M  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L
M5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_
M '8 _P!S /\ <@#_ .    #0    Q@   +8   "I    H0   )T  0"9  H
MF  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "#
M %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D
M_P!G /\ 90#_ ,P   "^    JP   )T   "3    B@   (4   ""  4 @  -
M '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X <@!# '  20!O $\
M;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!;
M /\ 6@#_ +T   "I    EP   (D   !^    >    ',   !O  $ ;0 ) &P
M#@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/
M %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\
M3P#_ *T   "8    A@   '@   !N    9P   &,   !@    70 % %P "P!;
M !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X
M40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_
M )\   ")    >    &P   !B    6P   %8   !3    40 " $\ " !/  T
M3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !"
M %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),
M  !^    ;@   &$   !8    40   $P   !)    1P   $4 !0!$  L 0P .
M $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %
M-P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V
M P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P  P [  @ .@ - #H
M$  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7
M "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"
M7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q
M !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D /P H $D )P!4 "8
M8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T
M $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0, +08( "P$#  K @\
M*@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 >
M 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0
M  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0
M "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L
M%@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]
M$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-!P A# L ( L. !\+
M$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^
M  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%
M,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9
M#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0
MD  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8
M "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A(
M$A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $
M%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8
M   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5
M  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$
M !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R&@  *QH  "4:   A
M&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;
M&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR   <B   '*   !NY
M   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P
M'!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #
M(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   AA@  ()X  ""X   ?
MW@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP
M !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D
M "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W   DWP
M(_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?   ='@  &AT  !8>
M   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=
M   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH  "JU   IWP  *?L
M "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <(   %R   !,A   0
M(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S
M(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_
M $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F   .*
M"RH   <L   #+P   #$"   S!   -0<  #<*   Y#0  .A   #L5   ['0
M.R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I
M   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H   XL   *+P  !C$
M  $T    -@   #@    [ 0  /00  #\'  !!"@  0PX  $41  !%&   12$
M $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X
M+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT   $-P   #H    \
M    /P   $$   !$    1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G
M  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR   U,0
M+B\  "DN   @+@  &3$  !(S   .-P  "3H   (]    0    $0   !'
M20   $P   !/    40   %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>
M+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(
M "0S   ;-@  $SD   X]   (00   $4   !)    3    %    !3    5@
M %D   !;    70   &    !B    90   &@%  !K"P  ;Q   &\8  !N)0
M;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[
M   5/P  #D0   =)    30   %(   !6    6@   %X   !B    90   &@
M  !K    ;0   '    !S    =@   'D   !]!   @0L  (41  "$'0  @BP
M ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /
M2P  !U$   !7    7    &(   !F    :P   &\   !T    >    'L   !^
M    @    (,   "&    B@   (T   "1    E@,  )L,  "=$P  FR$  )HS
M  "720  E&(  )-_  "0H   CL4  (SS #%$   E2   &DT  !!3   (6@
M &$   !H    ;@   '0   !Y    ?P   (0   ")    C0   )$   "3
ME@   )D   "=    H    *0   "H    K    +(#  "W#0  MQ<  +4H  "R
M/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL   IB    :@   ',
M  ![    @@   (D   ".    E    )H   "?    I    *8   "I    K0
M +    "S    MP   +L   #     Q0   ,L   #1!   U0X  -,=  #0,@
MS4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T    ?0   (<   "0
M    EP   )X   "D    JP   +$   "V    N@   +P   #     Q    ,@
M  #+    SP   -0   #:    X    .8   #K    \08  / 3  #N)P  [#\
M .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T  4 ]@ , /H $0#_
M !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$
M:@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_
M )8 _P"0 /\ C #_ /H   #R    [    .D   #I    [  % /( # #X !(
M]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#*
M &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@
M_P"# /\ @ #_ /    #E    W@   -H   #;    W    -@ !P#1  X T0 5
M -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$
MK !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V
M /\ = #_ .(   #3    R@   ,<   "\    M@   +   0"O  L K  1 *T
M& "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A
M (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\
M: #_ ,\   #!    N0   *T   "@    F    )0   "1  8 D  - )  $@"/
M !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@
M8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_
M +X   "Q    H    )(   ")    @@   'P   !Z  $ >  ) '< #@!X !0
M=P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C
M &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +
M  "?    C0   '\   !T    ;@   &H   !F    90 $ &, "P!C !  8P 5
M &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P
M4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-
M    ?    &X   !E    7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0
M%@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A
M $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0   !_
M;P   &,   !9    40   $T   !*    2    $< ! !'  H 1@ . $8 $0!'
M !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@
M:0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T    90
M %@   !/    2    $,    _    /0   #P  @ \  < .P , #L #P [ !(
M.@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M
M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\   !L    70$  %$"
M  !( P  0 ,  #L"   W    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3
M #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X
M) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E!   5@8  $L'  !"
M"   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D "P I  X *0 1 "@
M%0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\
M !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P
M-0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @
M !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4
MCP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T
M "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0
M&008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0
M :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/
M   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6
M !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\
M"@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$  "40   A
M$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,
M&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT
M  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2   >$0
M&Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,
M$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .
MU   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0  "$3   <$P  &1(
M !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH
M"!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T   1UP
M$?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5   :%   %Q0  !03
M 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?
M  (6)P  %S   !<[   72   %U@  !=J   6@   %ID  !6T   5V0  %/<
M !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2
M$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;
M)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_
M %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P  %18! !,5!0 1%00
M#Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9   @(0
M(2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9
M   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!
M  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$  "86   F'@  )R<
M "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \
M'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;   -'   "QT   @?
M   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3   N&@  +B,  "XN
M   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0
M+B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +(0  !R,   ,E
M)P   "D    L 0  +@,  # &   S"@  -0T  #81   V%P  -A\  #8I   V
M-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T)   *R0
M "0C   ?(0  &R   !8@   1(0  #B,   HE   &*    BH    M    +P
M #(    T    -P   #D#   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0
M0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E
M   ?(P  &"0  !(E   .*   "BH   4M    ,    #,    V    .    #L
M   ^    0    $(   !% @  1P8  $H*  !-#@  314  $P?  !,*P  2SH
M $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;
M*   %"H   XM   *,   !#,    W    .@   #T   !     0P   $8   !(
M    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&
M  !76@  570  %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM   6+P
M$#(   HV   #.@   #\   !"    1@   $D   !,    3P   %(   !5
M6    %H   !=    8    &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G
M4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT
M  )"    1P   $P   !0    5    %@   !;    7P   &(   !E    :
M &L   !N    <0   '4   !Y    ?08  ((-  ""%@  @"0  'XU  !\20
M>V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)    +10   DL   !1
M    5@   %L   !@    90   &D   !N    <@   '8   !Y    ?    'X
M  ""    A0   (D   ".    DP   )@&  "<#@  FQH  )@K  "60   DED
M )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "5    %L   !A
M:    &X   !S    >0   'X   "#    B    (P   "/    D@   )4   "9
M    G0   *$   "E    J@   +    "W!P  N!$  +4A  "R-0  KTT  *II
M  "HB   IJ@  *+1 "-(   83@  #E0   1<    9    &T   !U    ?
M (,   ")    CP   )4   ";    H    *,   "F    J0   *T   "Q
MM0   +D   "^    Q    ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%
M?   PIT  ,&] !Q5   17   !V4   !N    =P   '\   "(    D    )@
M  "?    I0   *T   "S    N    +H   "^    P@   ,8   #*    S@
M -,   #:    X    .<   #M    \P   /0.  #R'@  [S8  .Q1  #H;@
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M__________________________________________________\
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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M      ,$(0   0                    $                    !
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M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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M6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEO4SPH
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MNF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"&=_?1RC3Z4Q
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M2%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$C$QP<
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MM*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;#
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MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>+PW_JC@3_[5
M'/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!YLIZK?KJ5IX3
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M_Z4> _^W(P/MR28#UMXI!LGI.Q>^\T0IL_A).JCW34B?]E55E/5?8(GQ:&B
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M;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC
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M?E3AN'Y4X;A^5.&X?E3AN'Y4X;A^5.&X?E3AN'[_F!,!_ZT4 ?/##P#2V L
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M ^W'+ 3?U3$&T]XY%,;81"BYT4X[K,Q63*#'75J5PF-GB[]I<8*[;WEZN':
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M'C3_EQXR_Z ?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!^FP
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M/$;_O3U%_\P]1/_F/D3_YSY$_^<^1/_G/D3_YSY$_^<^1/_G/D3_YS[+K
MN;8! *S" 0"@T ( E>4' ([_& .$_R0&>O\L"W#_-!!H_SP58?]$&5O_2QU6
M_U,@4_];(E#_8R1-_VLF2_]S)TG_>BE(_X(J1O^**T3_E"Q"_YXM0?^G+D#_
ML2X__[PO/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3"[L0  K+P
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M<6J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0
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M85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8 OL$% +?/"0"PXQ$
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M$B7_D!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@
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M9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1 ?^'$P'_E!4
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M7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08 T;$( ,N[" #&QPL
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M*CW\N2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J
MKK   *&\  "5R   B=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/
M_T<12_].$T?_5A5$_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_
MK!\S_[D?,__('S+_XB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<
M )7$  "'T   >]T  '+]"0!J_Q$!8?\9 EK_(@-4_RH%3O\R!TG_.@E%_T$+
M0?](##[_3@X[_U4/./];$#;_8A$T_VD1,O]R$B__>Q,M_X84*_^2%2K_GA4I
M_ZD6*/^S%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,
M  !ZV@  ;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O]
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M ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M
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M6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0
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M4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T
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M2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0
MRYP  +VG  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-H
MW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<
MR#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,
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M&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S
M==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V
M_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_
MP1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(
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M/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y
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M1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\- .>8#0#;GPX
MSI\B <2=- BZF$(4LI--'ZJ/5BJCBE\RG(9F.I>#;4"2@'5%C7Y\2HE\A$Z%
M>HQ2@GB55GYWH%E[=JM;>76Z7'=VS5QX=^I8>WKZ47U\_TM]?/]&?7S_17U\
M_T5]?/]%?7S_17U\_T7_81 !_V\+ /]]"P#UB H WY,( -B;"@#3H@P R:,?
M ;^@,@>VG$ 3K9=+'J635"B>CUTQF(MD.9*(:S^-A7)%B(-Z2H2 @4Z ?XI2
M?'V357A\G5AU>ZE;<GJX7'%ZREQR?.A8=7[Y47> _TQW@/]'=X#_1G> _T9W
M@/]&=X#_1G> _T;_9 \ _W() /]_" #EC 4 V)8' -&>"0#.I0H Q*8= ;JD
M+P:QH#X1J)Q)':"84R>9E%LPDY!B.(V-:3Z(BG!$@XAX27Z&?TUZA(A1=H*1
M57*!FUAO@*=:;'^U7&N R%QK@>59;H/W4G&$_TURA/](<H3_1W*$_T=RA/]'
M<H3_1W*$_T?_9@T _W4' /:#!0#<CP, TI@& ,RA!P#(J @ OZD: +6H+06L
MI#P0I*!'&YR=4264F5DOCI9@-HB39SV"D&Y#?8YV2'F,?4QTBH50<(B/5&R'
MF5=IAJ599H:S6V6&Q5MEAN-9:(CV4FN*_TULBO](;(G_1VR)_T=LB?]';(G_
M1VR)_T?_:0L _W@$ .6'  #6D@, S9P% ,:D!@#!JP8 N:T7 +"L*P2GJ3H.
MGZ9%&9:B3R./GU<MB)Q?-8*99CM]EVQ!>)5S1G.3>TMND8-/:H^-4F:.EU5C
MC:-88(VQ65^-PUI>C>!88H_U4F20_TUFD/](9H__1V:/_T=FC_]'9H__1V:/
M_T?_; @ _GP  -Z*  #0E@( R)\$ ,"G! "YK@, LK(4 *JQ* .AKS<,F:Q#
M%Y&H32&)I54J@J-<,GR@8SEWGFH^<IQQ1&V:>4AHF8%,9)>+4&"6E5-=EJ)5
M6I6P5UF5P5=8E=Y66Y;S4%V7_TQ?E_]'8);_1F"6_T9@EO]&8);_1F"6_T;_
M< , ZX$  -:/  #*F@$ P:,# +FJ @"QL@$ JK<1 *.W) *;M30*D[) %(JO
M2AZ#K5,G?*M:+G:H835PIV@[:Z5O0&>C=T1BHG](7J&)3%J@E$]7GZ!15)^N
M4U.?P%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0
MX(8  ,^3  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\
MM5 B=;-8*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJ
MP$U-JMQ-3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP
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M,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0
MEKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-
MY%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC
M^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(
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M"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0
M1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=
M_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_
MN@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\
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M-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/ /"%$0#CB18
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M3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0
M]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*
MF5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)
MO4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH
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M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP
MK*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUONDD4:KA1&F6W61]@
MMF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:RN3I%LM$Z1K'M.4>P
M_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY   +N<  "NHP  I*H
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M&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP
M8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX
M[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK
M_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X
M $[S"@!*]Q, 1O@= $/X)P$_^# "._DX CCY0 ,U^D<$,_I/!3#[5P4N^U\&
M*_QI!RG\= @G_(())?V0"23]H HC_K *(O[$"R'_X LA_?(*(/S\"B#\_ H@
M_/P*(/S\"B#\_ JBIP  E;$  (>[  !YQ@  ;,\  %_9  !2WP  2.@  $/_
M"  __Q  ._\9 #?_(0 T_RD!,/\P 2W_-P(J_SX")_]$ B7_2P,B_U,#(/]<
M QW_9@0;_W($&?^ !1?_CP46_Y\&%?^O!A3_P 84_]8&$__I!A/_Z083_^D&
M$__I!A/_Z0:7KP  B+H  'K%  !LSP  7MH  %#@  !$Y@  //4  #?_!  S
M_PT +_\3 "O_&@ H_R$ )?\G 2'_+0$>_S(!&_\X 1G_/P$6_T8"%/]- A'_
M5@(0_V "#O]L @S_>P,+_XL#"O^: PK_J ,)_[4#"/_" PC_P@,(_\(#"/_"
M PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P<
M(_\. "#_$@ <_Q@ &/\= !7_(0 2_R8 $/\L 0[_,0$-_S<!"O\^ 0C_1@$%
M_T\! ?]9 0#_9@$ _W0! /^" @#_D ( _YP" /^F @#_I@( _Z8" /^F @#_
MI@+_+B\"_S,L O\W+0+_.# "_S<V _\T/P3_,4L&_R]8!_\L9@C_*G0)_RF!
M"O\HC0O_*)<+_RB?"_\HI@S_)ZT,_R>T#/\GNPS_)\0,_R?.#/\HW@O_*.D+
M_RCS"_\H^PO_*/\*_RG_"O\I_PK_*?\*_RC_"O\H_PK_*/\*_RC_"O\H_PK_
M,"T"_S8J O\Y*@+_.RX"_SHT _\X/ 3_-DD&_S-6!_\Q8PG_+W$*_RU^"_\M
MB@S_+)0,_RR<#?\LI W_+*L-_RRQ#?\LN0W_*\$-_RS+#?\LV@W_+.<-_RSQ
M#?\L^@W_+/\,_BW_#/TM_PS]+?\,_2S_"_TL_PO]+/\+_2S_"_TL_PO_,BL!
M_SDH O\]* +_/RH"_SXP _\].@3_/$8&_SE3"/\W8 G_-6T+_S-Z#/\RA@W_
M,9 ._S&9#O\QH0__,:@/_S"N#_\PM0__,+T0_S#'$/\PU!#_,.00_S'O$/XQ
M^0_[,?\/^3'_#_@Q_P[W,?\.]S'_#O8Q_P[V,?\.]C'_#O8Q_P[_-2@!_SPE
M ?] ) +_0R<"_T,L _]$-P3_0D,&_T!/"/\]7 K_.VD,_SEV#?\X@@__-XP0
M_S>5$?\VG1'_-J02_S:K$O\VLA/_-;H3_S7#$_\USQ/\->$3^3;M$_8V]Q/S
M-O\3\3;_$O V_Q+P-_\1[S?_$>\W_Q#O-_\0[S?_$.\W_Q#_.24!_T A ?]%
M( '_1R("_TDI O]*- 3_23\%_T9+"/]$6 K_0F4-_T!Q#_\^?1'_/8<2_SV1
M%/X\F17]/* 5_#NG%OH[KA?Y.[87^#N_%_8[RACT.]P8\#OJ&.T[]ACJ._\7
MZ#S_%^<\_Q;F/?\5Y3W_%.4]_Q3E/?\4Y3W_%.4]_Q3_/2(!_T0> ?])' '_
M31X!_U F O]1, /_4#L%_TY&"/]+4PO_2& ._T9L$?M%>!/X1((5]D.,%_1"
ME!CS09P9\4&C&^] JAON0+(<[3^['>L_QA[I/]4>Y3_H'^) ]![?0/X=W4'_
M&]M"_QK90O\8V$+_%]A"_Q?80O\7V$+_%]A"_Q?_0!\!_T@: ?].& '_4AL!
M_U8C O]8+ /_5S<$_U5"!_]230OY4%H.]4UG$O%,<A;N2GT8ZTB&&^E'CQWG
M1I<?Y46>(.-$IB+A1*XCX$.W)-Y#PB7<0] FUT/E)M-$\R301?XBS4;_(,Q'
M_Q[*1_\<R4C_&\E(_QO)2/\;R4C_&\E(_QO_1!L!_TP6 ?]2% '_6!@!_UT?
M ?]?* +_7C(#_5T]!O9:20KP5U4/ZE5B$^92;1CB4'<<WTZ!']Q,BB+92Y(D
MU4J:)M-)H2C12:DISTBR*LU(O"O+2,DLR$C?+,5([RO"2OPHP$O_);],_R*^
M3?\@O4W_'[U-_QZ]3?\>O4W_'KU-_Q[_1Q@!_T\3 ?]6$0#_7A4 _V(< ?]E
M) '^92T"]&0X!>UA0PGF7U$.X%Q=%-I8:!K45G(>T%1[(LQ2A";*4(PHQT^4
M*L5.FRS#3J,NP4VL+[],MC"]3,(QNTS3,KA,Z3&V3O@MM%#_*K-1_R>S4O\D
MLE+_(K)2_R*R4O\BLE+_(K)2_R+_2A4!_U,1 /];#P#_8A( _V@7 /]J'P'V
M:R@![&LR ^1I/@?<9DP-TV)8%,U?8QO(7&T@Q%IV),%8?BB^5H8KNU6.+KE3
MEC"V4IXRM%*F,[)1L#6P4;PVKE#+-ZQ0XS>J4O0SJ53_+JA6_RNH5_\HJ%?_
M):A7_R6H5_\EJ%?_):A7_R7_31, _U8. /]?#0#_9Q  _VP3 /MP&0#O<2(!
MY'$L MMP.@71;$@,R6A4%,-E7QN^8F@ANE]Q)K9=>2JS6X$ML%J),*Y8D3.K
M5YDUJ5:A-Z=6JSBE5;8ZHU7%.Z%5W3N?5O WGUC^,I]:_RZ>6_\KGES_*)Y<
M_RB>7/\HGES_*)Y<_RC_4!$ _UD, /]C# #_:PT _W 0 /5T$P#H=AH W7<E
M =%V-@3(<D0,P6Y0%+MK6QNV9V0AL65M)ZUB=2NJ8'POIU^$,J1=C#2B7)0W
MGUN=.9U:ICN:6;$]F%F_/I=9TSZ56NP[E5W[-99>_S&67_\MEF#_*I9@_RJ6
M8/\JEF#_*I9@_RK_4@\ _UP* /]F"0#_;@H ]G0, .]X#@#A>Q( U'P@ ,I[
M,P3!=T$+NG1-$[1P6!NN;&$AJ6II)Z9G<2NB97@OGV2 ,YQBB#:989 XEE^9
M.Y1>HCV17JT_CUV[0(U=S4&,7N@_C6'Y.(UB_S..9/\PCF3_+(YE_RR.9?\L
MCF7_+(YE_RS_50X _U\& /]I!@#T<@8 XG@& -M\"0#9?PP S8$= ,1_, .[
M?#\*M'A+$JUU51JH<5XAHVYF)I]L;BN;:G4OF&A],Y5GA#:298PYCV25/(QC
MGSZ)8JI AV&W0H5AR4*$8N1!A63W.X9F_S6'9_\QAVC_+H=I_RV':?\MAVG_
M+8=I_RW_5PP _V$$ /YL P#D=0$ VWL% -. " #0@PH QX4: +Z$+0.V@3P)
MKWU($JAY4AFB=EL@G7-C)IEP:RN5;G(OD6UY,XYK@3:+:8DZB&B2/(5GG#^"
M9J=!@&:T0WYFQ41\9N%#?FCU/']J_S> :_\S@6S_+X%L_R^!;/\O@6S_+X%L
M_R__60L _V,! /1O  #?>   U'\$ ,Z#!@#*AP@ PH@8 +F'*P*QA3H(JH%&
M$:-^4!B=>ED?F'=A)9-U:"J/<V\OBW%W,XAO?C:%;H8Z@FR//7]KF4!\:J5"
M>6JQ1'=JPD1V:MU$>&SS/GEN_SAZ;_\T>W#_,'QP_S!\</\P?'#_,'QP_S#_
M6P@ _V8  .=R  #:>P  SX(# ,F'!0#$B@8 O(P5 +2+* *LB3@'I85$$)Z"
M3AB8?U<>DWQ?)(YY9BJ*=VTNAG5T,H)T?#9_<H0Y?'&-/7EPET!V;Z)"<VZO
M1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708
M_VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'H(I"#IJ&3!:3
M@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P=*!";7.M1&MS
MO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X_S'_7P( ]VP
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M/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C
MN9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_FDP7>9A4'7277")P
ME6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-MD!3C<M 5(WI/5:-
M^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L  ,B'  "]D   M)@
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M*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@
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M"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D
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M 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP
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M-X)>PC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8
M_UT  .=G  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<
M<%<8F&U?'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IB
MOCEY8M4Y>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V
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M-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P
MP((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[
M?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V
M^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4
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M*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@
MCIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519EF%P:89=C'EZ6:B%;
ME7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1]2U-D?\J3I#_*$Z0
M_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<  )V;  "3GP  AJ0
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M&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@<
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M R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@
MF*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K
M[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?T
MD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T
M '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!,
M'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*
M_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_
M  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3
M !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT
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M)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@
M_U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ
M6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1
MPRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,
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M+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0
MQ'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1;E$/C6Q9%(EJ8!>%
M:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!BMB]O8LDO;F+F+F]D
M^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\  -=I  #*<   P'4
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M(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8   *V$  "DA0
MFH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q?5X8;GME&VMZ;!YH
M>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV\RI;=O\F7'?_(UQW
M_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80  *B(  "?B0  E(H
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M4(/_'U"#_Q_>:0  R74  +R   "RB   _^)]$$E#0U]04D]&24Q%  \2J(T
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M&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?EP  E9P  (FA  !]I@
M<:H  &2N  !:L0@ 5[$4 %6R(P!3LC !4+([ DVR1 -+L4T%2+%5!T6Q70E#
ML64+0+!O#3ZP>@\[L(<1.:^6$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K
M_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(
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M A?:_P*@G   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP
M*=D  "'>!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1
M[6< $.YW !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK
M_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$
M !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<
M _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+
MJP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z
M   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3
M  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_M
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M ?(3_P'Q$_\"\!3_ O 4_P+P%/\"\!3_ O 4_P+_*A\ _RP< /\L&P#_*QT
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M";HS_PFZ,_\)NC/_";HS_PG_.1  _ST+ /] "0#_1 T _T81 /]%&0#W1",
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M_Q3_1P  ^$\  .17  #570  S&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY
M Z%<2P>=6E0*F5E<#I989!&35FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?
M@U&J(8%1N")_4<LB?E+G(7Y3^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_
M2@  [E(  -Y;  #/80  QF0  +]E  "Z8P( LV(/ *QC( "F8S !H&(] YMA
M2 :67U$*DEY9#8]<81&,6V@3B5IO%H99=AB$6'X:@E>''']7D!]]5ILA>U:G
M(GE6M2-W5L<D=E;D)'97]Q]W6/\;=UG_&7=9_Q=W6?\6=UG_%G=9_Q;_3
MZ58  -E?  #+90  P6@  +II  "T:   K6<- *9H' "@:"T!FF<Z Y5E10:0
M8TX*C&)7#8EA7A"&7V43@UYL%H!=<QA^7'L:>UR#'7E;C1]V6I@A=%JD(W):
MLB1Q6L0E;UKA)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D
M --B  #':   O6P  +9M  "O;   IVL+ *!L&0";;"H!E6LW I!I0P6+:$P)
MAV94#(-E6Q" 8V(3?6)I%7IA<!AX87@:=6"!'7-?BQ]P7I8B;EZB)&Q>L"5K
M7L$F:5[>)FI?]"%K8/\=:V'_&VQA_QEL8?\8;&'_&&QA_QCU40  XEP  ,]E
M  ##:P  N6\  +%Q  "J<0  HF\( )MO%P"6<"< D&\U HMN0 6&;$D(@FI2
M#'YI60][:& 2=V9F%'5F;A=R978:<&1^'6UCB!]K8Y,B:6*@)&9BKB5E8K\F
M9&+:)F1C\B)E9/\>9F3_&V=D_QEG9?\89V7_&&=E_QCP4P  W5\  ,MH  "_
M;P  MG,  *YU  "F=0  G7,% )9S% "1="0 BW,R H9R/@2!<$<(?6]/"WEM
M5PYV;%X1<VMD%'!J;!=M:G,::VE\'&AHAA]F9Y$B8V>>)&%FK"5@9KTF7V?6
M)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL5P  V6(  ,=K  "\<@
MLW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W.P1\=44'>'1-"G1R50YQ
M<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<(UQKJB5::[LF66S3)EIL
M[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL
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M&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-C0
M?(T  '6.! !OCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3
MBV@24(IQ%$V)>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&
M_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94
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M#2^E_PVVA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@
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M !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@
MD:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5
MV@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F
M@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D
M '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP
M"_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0
M\H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ
M  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!
M  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT
M /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/
MS0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_
M    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K
M  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2<
M_Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_
M *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T
M_P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I
M /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP
M_P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W
M _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5
M+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ?
M /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\
M[0S_ >T,_P'M#/\![0S_ >T,_P'_)1L _R88 /\E%P#_(1@ _R A /\>*P#_
M&C< _Q=% /\440'_$EX!_Q%I ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0
MH0'W$*@!]A"O ?00MP#S$,( \1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_
M >(2_P'A$O\!X1+_ >$2_P'_*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S,
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M!Z<S_P?_-P< _SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$
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M%(]#NA6-0\T5BT3H%8I%^A*)1O\0B4;_#HA&_PV(1O\-B$;_#8A&_PW_0
M\D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0(@"L43( IU$_ J)02@.>
M3U,%FTY<")A-8PJ53&H,DTMQ#9%*>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(
MM1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L
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M'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  # 9
MMV<  *YH  "G9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?5@EZ
M7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1'65:
M[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH
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M%E=H_Q189_\36&?_$UAG_Q/A6   RV,  +UK  "R<@  J78  *!X  "6=P
MB',  (%S"P!\=!< >'0F '1T,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?
M;VH07&YS$EIN?!57;8@756R4&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L
M_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@
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M$$" _Q#&:P  MW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD
M6I 4 %B0(0!6D2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM
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M!2VDEP8LI*D&*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@
MI8L  )J1  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  S
ML!4 ,K A #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22Q
ME (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$
M ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T
M(KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7
MP*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>
M  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+
M !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI<
M"<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !Q
MK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9
M#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=
M  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0
M6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P
MXPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #N
MH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8
M #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L   #K    [04
M .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0
M_:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4
M   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V    ]P   /@
M  #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT
M /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_
M $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\
MJ #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_
M /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T
M_P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_
M *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /,
M_P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5&
M /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *<
M^ "N /4 M0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I
M ?\ Z0'_ .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,
M3@#_"5H _PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J
M .T&L@#J!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\
MW S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\
M$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.
MKP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_
M <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\
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M!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@
M_S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V
M,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z R
MO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@
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M$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5
MO54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'
M2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)
M[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H
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M#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9
MD%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%;%Q<!VI;8PEH
M6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;6OD26UK_$%Q:
M_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J  "7:   BV(
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M#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\
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M9   MVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %>
M( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ(
M"SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0
MLG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-
MB28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'
ME0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H
M **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\
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M !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0
M=9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7
MMR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VY
MQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8
M %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14
M"<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@
MQM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T
M  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6
M  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\
M -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   Y
MP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?
M%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%
M  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@
M(,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0
M[1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #Z
MP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H
M  W?   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D
M /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP
M_[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P
M /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\
M^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L
MM #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_
M /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P
M +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4
M_P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B
M /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0
MX@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_
M'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$
M9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[
M - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P
M_R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=
M#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00
MR #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,
M /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6,
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M Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0
MS#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<
M,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT
M\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0
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M"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4
MF4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y2E@#=TI?!'5)9@5S
M26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)Y UF2?@+9DG_"69*
M_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D  *18  "<50  DTX
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M"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q(
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M"DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6
MNF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!:
M:BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41I
ME0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8
M *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< < 6' 1 %9P'0!4<2@
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M!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P
MB(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  V
MC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,
MQ@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP
M ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT
M*9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!'9BL 1R8PP$<
ME^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5
M  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M
M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.(
M$:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8
MH0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ
M*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O
M  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP
M0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@
MOBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]
M]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8
M "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(
M ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP
MSO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["
M   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?
M  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H
M .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,
MT0  !-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M
M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??
M  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP
M .(   #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$
M_!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_
MOP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M
M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T
M_P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_
M$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\
M<@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@##
M /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0
M_P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[
M '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@
MRP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$.
M /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '
M[0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6
M -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/
M!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R
M -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -
MQ0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_
M$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%
M<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE
M +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@
M]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]
M#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4
M]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$
M -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X
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M G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0
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M!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4
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M!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P
MOU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B
M5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4
ME =-5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<
M *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P
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M!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P
MD7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !'
M:CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35J
MQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<
M ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@
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M 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP
M6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >
MD4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2.
M_P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4
M $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC<
M$9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +
MFO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@
M   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX
M  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\
M *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   F
MJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X
M.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_
M  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@
M$[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@
MR#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(
M_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,
M  /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT
M -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !Y
MH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
M    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK
M  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@
M7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B
MY@   .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_
M*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7
M /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L
M_P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\
M .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\
M$P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^
M /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q .,
M[P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_
M !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0
M?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M
M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P
M_P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E
M (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P
M]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P .
M /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H
MT "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[
M /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!
M$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z
M +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L
MJP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #=
M Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(
M>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_
M )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L
MQPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B
M$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7
M_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0
M +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W<
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M 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP
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M EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P
MPT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K
M03( :4$[ &=!0@!E04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"
ME -70J,$54.S!%1#R0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH
M +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X
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M!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@
ME6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/
M4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4
MP00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4
M (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP
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M BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@
M9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S
M;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J
M_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<
M %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0
M*71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?
M<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^
M  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W](
M !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\
M%GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \
MB   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*
M3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_
M  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@
M*I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (
MEU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2
M_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT
M !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@
M *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1
MB@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J
M   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),
M  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D
M?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "
MN    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##
M3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT
M &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0
M ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800
MV%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL
M  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4
M  #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,
M .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^
MO   +\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
M    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&
M  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !<
M_P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_
M (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@
M_P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7
M /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8
M^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J
M /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\
M'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"'
M .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\
MUP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[
M "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P
MAP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_
M ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\
MZ@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#&
M (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +(
M_P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E
M -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($
MM "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B
M /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0
M*@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"#
M *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\
ME G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R
M!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,
MA@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_
M (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R<
MH1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")
M%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9
M_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM
M )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88
M?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H
M*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B
M,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:-
M &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@
MRS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y
M*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8M
ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P
M +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#,
M;S [ &TP0P!K,4H :3%1 &<Q5P!F,5X 9#%F &,R;P!A,GD 8#*% 5\RD@%=
M,Z$!7#.Q 5LTQ@%:-.8!637[ 5DU_P%9-/\!633_ 5DT_P'2.   P$   +-%
M  "H2   GD@  )5&  "+0   @CL  'DU! !S,Q  ;S0: &PT)0!I-2\ 9S4W
M &4V/P!C-D8 8C9- & V5 !?-EL 73=C %PW:P!;-W8!63>" 5@XCP%6.)X!
M53BO E0YPP)3.>0"4SKY 5,Y_P%2.?\!4SG_ 5,Y_P'-/   O$0  *])  "D
M3   FDP  )%+  "'1@  ?4   ',[  !L. T :#D7 &4Y(@!C.BL 8#HT %XZ
M/ !=.D, 6SI* %H[4 !8.U@ 5SM@ %8[: !5/',!4SQ_ 5(\C0%0/9P!3SVL
M DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4
MEU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7
M/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"
MO@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50
M (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT
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M 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@
M:5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _
M44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313
M_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX
M %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD
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M 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P
M.FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >
M;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK
M_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@
M "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8
M$WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?
M<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"
M   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=
M  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0
MD'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5
MC@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/
M90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4
M (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@
M"IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7
MG6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0
M  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@
M  "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,
M *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?
MG   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
M    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK
M  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0
M1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"
MPP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2
M<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,
M "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@
M -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9
MZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W
M   1Q   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4
M  #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH
M /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_
M #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\
MDP#_XGT024-#7U!23T9)3$4 $!+_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y
M .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\
M#0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U
M /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4
MZ@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_
M  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T
M=@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D
M -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0
M_P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#:
M '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,
M[P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  '
M .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\
MPP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N
M /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\
M# #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O
M +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /(
MG0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#&
M !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *(
M;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\
M (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H
MM  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3
M V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,
M_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D-
M *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H
MA0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T
M$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/
M$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L
M '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\
M:AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%
M&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>
M< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_
M &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!(
M=R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B
M)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH
M_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9
M &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W(
M62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*
M-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M
M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z
M %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@
MMD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:
M,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LV
MA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4
M *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R(
M4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$
M.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.
M  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG
M $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$
M/D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "7
M5   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D $9
M+ !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@
M #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "46
MBUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _
M13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)
ML0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T
M 'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX
M.4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L
M3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA
M  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R
M #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4
M)E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M
M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7
M-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE
M !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P
M76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B
M7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?
M^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X
M $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4
M&&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 0
M9O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T
M   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X
M  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\
M"6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U
M?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\
M/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_
M  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP
M(X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@
MB4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$
M_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(
M !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD
M )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+
MA@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?
M   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\
M  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0
M>)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K
MK0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W
M/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@
M %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@
M +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@
MRT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F
M  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L
M  #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4
M .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   X
MM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4    V    -P   #=
M    WP   .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX
M  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !
M_P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_
M (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0
M_P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2
M /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T
M]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C
M /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\
M&0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!]
M .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\
MRP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q
M "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X
M? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_
M +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D
MVP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y
M 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4
M_P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ?
M ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4
MIP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5
M /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +,
M(P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V
M )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\
MA@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A
M "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@
M=P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_
M '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\
MD0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z
M"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T.
M_P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB
M ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'<
M;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6
M)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83
M)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^
M &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@
MO3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I
M&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?
MAP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8
M *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28
M7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/
M)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_
M  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K
M %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y
M1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "9
M10  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L
M+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&>
M $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620
MC$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!'
M,3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LV
MKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX
M (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\
M0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U
M.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0
M  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT
M #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\(
M+S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q
M4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_
M.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B
M "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P
M85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O
M13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(
M]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@
M %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL
M)TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >
M3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);
M  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%
M "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\
M&%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"
M7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A8
M10 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_
M !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@
M,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /
M84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?
M_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X
M "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T<
M!6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7
M;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV
M   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.
M  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0
MB7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0
M@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""
M50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($
M 'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@
M H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030
MD%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+
M  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T
M  "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0
M *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9
ME@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J
M    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:
M  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP
M/Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W
MN    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&
M8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP
M "2O   6L0  #;0   .W    N@   +T   #     Q    ,8   #&    R
M ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5
MX6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y
M   -O    ;\   ##    QP   ,H   #/    TP   -8   #7    V@   -P
M  #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP
M /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_
M "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X
MB@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_
M .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "<
M_P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O
M (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D
M_P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N
M /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0
MVP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^
M /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0
M,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$
M ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\
MK #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#*
M #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\
MA0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_
M )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$
MM  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"<
M (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T
M_P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T
M *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (
MBP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N
M"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ),
M-0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$
M 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0
MS1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"#
M #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"
MBP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"
M +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#
M= @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B
M#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K
M  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R
M &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I(
M5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?
M,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5
M- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ?
M $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.
MD#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4
M'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4A
MK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T
M (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3,
M2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ]
M)\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _
M  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V
M $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\
M-RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S
M0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK
M.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'>
M #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10
M94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU
M]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4
M %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P
M,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H
M.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&
M  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI!
M "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\
M(SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*
M2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_
M2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_
M !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@
M/4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =
M14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&
M_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$
M "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P
M%4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">
M5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6
M   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4
M  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70
MD60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =
M70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;
M7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL
M (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@
M$68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@
M9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U
M  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$
M  9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0
M &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S
M?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]
M!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO
M  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P
M784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*
MB08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")
M?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT
M $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8    EP
M )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P
MF(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9
M   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4
M  "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX
M *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @
MHP  $Z4   NG   !J0   *L   "N    L0   +(   "R    LP   +0   "U
M    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-
M  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0
M"[    "S    M0   +@   "\    OP   ,$   #!    PP   ,0   #&
MQP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<
MF0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L
M  "_    PP   ,8   #+    S@   -$   #1    U    -8   #9    VP
M -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB
M]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\
M00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2
M /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\
MR0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#]
M $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .<
MDP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_
M +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $
MZ0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#.
M )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T
M_P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!#
M ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X
MMP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_
M    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L
M10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1
M *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]
M\0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G
M $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$
ME0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP
M -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\
ME0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_
M )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-
M  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!
M (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4
M< "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M
M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '<
M0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"?
M &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P
MFQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I
M D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(
MK0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4
M (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH
M70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,
M#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I
M  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [
M %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X
M0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X
M*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6
M/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO;
M #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@
M:BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!
M'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A
M]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(
M %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T
M.2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O
M)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS
M  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9"
M #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\
M*BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.
M,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__
M "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0
M030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G
M,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R
M_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL
M #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T
M(#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C
M1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]
M   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6
M !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P
ME5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G
M0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !-
M8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8
M (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2
M&T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -
M1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@
M  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$
M !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD
M!$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z
M:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6
M"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W
M  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@
M;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #
M8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>
MAP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4
M %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL
M &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@
M:)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[
M  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-
M  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(
M '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _
M@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "#
M#0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D
M  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0
M)XT  !N-   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2!P
MD@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1
MM@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<
M !&8   )F0   )L   "<    G@   *    "@    H    *    "A    H00
M *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK
MI,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC
M    I0   *<   "I    K    *X   "N    K@   *\   "P    L0   +(
M  "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L
M +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O
ML0   +0   "X    NP   +P   "\    O@   +\   #     P@   ,0   #&
M    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$
M  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@
M ,(   #'    R@   ,P   #,    S@   -    #2    U0   -@   #;
MWP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #Q
MQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1
M /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T
M\ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_
M    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /(
M4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@
M -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_
M_P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#<
M %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,,
MI0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P
M /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X
MP@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L
M *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /
M  #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!.
M *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *,
MEP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/
M    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L
M3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J
M (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^
MM@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P")
M $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4
MM !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0
M *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $<
M>0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E
M ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+
M  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !&
M &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P
M6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%
M#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\
M1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2
M $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&
M=1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3
M!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,
M[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL
M &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4(
M2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [
M$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=
M  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%%
M #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\
M-!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4
M'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<6
M2@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_
M "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0
M1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O
M'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@
M_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4
M #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X
M*2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F
M.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F
M P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96
M "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@
MF$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L
M* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK
M8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<
M (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8
M)"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6
M,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/
M  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+
M !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L
M$#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^
M5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X
M#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ
M  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P
M<EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0
M/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!
MB@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&
M &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX
M"$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@
M2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F
M  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1
M  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@
M $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3
M:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:
M$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K
M  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<
M/VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0
M9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@
MP0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8
M "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$
M ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO
M:^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_
M   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1
M  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H
M 'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /
MB0  !XH   "+    C    (T   "-    C    (P   ", P  C @  (T-  "-
M$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO
M  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0
M )8   "8    F@   )L   ";    FP   )L   ";    G    )T%  "="P
MGA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<
M^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,
M  "E    J    *D   "I    J0   *H   "K    K    *T   "N 0  L D
M +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !D
MDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T
M    M@   +@   "X    N0   +H   "\    O0   +\   #     PP   ,4'
M  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP
M2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##
MQ@   ,@   #(    R@   ,L   #-    SP   -(   #5    V0   -T   #A
M!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P
M /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L
M^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G
M +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\
M  #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !<
M .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0
MS #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_
M    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X
M7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^
M +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O
MY@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V
M %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *
MRP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP
M ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4
MH@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP",
M .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4
M 0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3
M (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\
M>0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@
M  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\
M4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G
M &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4
MC0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O
M %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P
M]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ %
M 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P
M8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0
M /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$
M" !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!-
M %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L
M1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A
M! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D
M3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_
M #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0,
M4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^
M"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-
M_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \&
M $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E
M- Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J
M+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1
M"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7
M "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0
MFC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U
M% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "87
M8  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H
M (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H
M+!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?
M'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!
M  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT-
M "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H
M&")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_
M1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A
M$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y
M !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@
M=$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9
M)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XK
MBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\
M &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!
M$RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (
M,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2
M  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3
M  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID
M #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;
M50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[
M%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL
M   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7
M3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0
M0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"
MPP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T
M #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@
M $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P
M2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A
M   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;
M  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(
M %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E
M:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?
M'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW
M  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<
M$V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0
M:B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D
M_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H
M  1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H
M '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^
M?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&
M    AP   (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<
M  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA
M:H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3
ME0   )8   "6    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":
M'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT
M %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\   "A    I
M *4   "D    I0   *4   "F    IP   *@   "I    J@0  *P,  "N$P
MKB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28
M   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P    L@   +0
M  "S    M    +4   "W    N    +D   "[    O0   +\!  ##"P  Q14
M ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   I
MI@  &:@   VK    K0   +$   "T    MP   +H   "_    P0   ,0   ##
M    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;    X P  .$8
M  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $
M_P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R
M &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P
M[@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P &
M /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &,
MW !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#
M /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T
M# #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B
M ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /(
MJ@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #.
M !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P
M80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_
M )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T
MLP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7
M %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V ((
M_P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0
M )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D
MA !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P
M /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9  , DP , (X
M$@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8
M '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\
M80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\
M !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0
M60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_
M %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !
M;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6
M %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D
M_P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1
M %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8
M20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R
M&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %,
M$P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!:
M #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(
MGR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!'
M !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$
M80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH
M ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q
M.P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K
M"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR
M  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1
M #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH
M(@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  "
M-P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0
M$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X
M !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P
M=#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08
MB0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\
M &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /
M'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"
M  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5
M !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID
M"B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<
M1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B
M&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L
M  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2
M4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,
M*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   K
MP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH
M $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL
M!2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP
M,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-
M   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@
M   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N
M #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U
M3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^
M)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU
M   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50
M)5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@
M1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"
M_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH
M !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<
M $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%
M90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@
M   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM
M  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;
M>7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ
M:@   &D   !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D
M-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<
M &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0
M '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+
M<CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^
M  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,
M  "#    @@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(
M ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+
MAP  /(D  "Z*   @BP  $XL   J+    C    (T   "/    D0   )(   "1
M    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X
M  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D
M,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP   *    "@
MH    *    "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I
M0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP
M !2=   *GP   *$   "C    I@   *@   "L    K@   *\   "O    L
M +    "R    LP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P
MP$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG
M    J@   *T   "P    LP   +8   "[    O0   ,    "_    P0   ,(
M  #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL
M -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_
M !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D
M;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_
M ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4
M\P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#.
M &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0
M_P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  :
M -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@
MM@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P";
M /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T
M'@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G
M )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\
MA@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E
M "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T
M9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_
M '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L
MD  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y
M &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &<
M_P#3    PP   +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P =
M 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$
M: !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%
M    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X
M'@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D
M %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@
MK T  * -  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!?
M !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P
M: !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10
M )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H
M40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _
M &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=
M  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P :
M $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L
M- !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$
M)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P
M&P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V
M "H B  H )P )P"P "8 R0 E .H )0'[ /_B?1!)0T-?4%)/1DE,10 1$B4!
M_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+$   0PP"
M #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#.P I!$,
M* 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?
M*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.
M!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A"D  ( I*
M !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0
MD#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@  #03   M
M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT &0Y' !<.
M4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4
M (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:   J%0$
M(Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1
M$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\
M  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H'   (!@#
M !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP
M#!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT  (!   !W
M00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P  'Q\  !<:
M"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI
M  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$  !U10
M;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24  !0A!  /
M'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A
M>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T2@  :TH
M &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H!  -) H
M"2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E   F=P
M)HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P  :D\  &!.
M  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *+ H !2L.
M  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L=0  +(H
M "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0  %]3  !6
M40  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD  #(-   R
M$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@  ,H<  #&>
M   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9  !55P
M25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,   Z#P
M.1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4  #B<   W
MLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !27   1%@
M #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !##0  0A
M $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9   _L0
M/M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80  /EX  #);
M   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#   2PX  $L2
M  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'KP  1LT
M $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0  "IB   ?
M8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P  %40  !4
M%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP  4,H  $_O
M  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J   7:0
M#F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-  !@$
M8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4  %KM  !9
M_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0<@  !W$
M  !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M#   ;1$
M &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y
M>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0   'T   !]
M    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@  ? P  'P2
M  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S@
M98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D   "*
MC    (T   "-    C    (P   ",    C    (P   "-    C00  (X,  ".
M$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!HA@  6H@
M $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9    FP
M )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#  "B#
MHA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0  39   #^3
M   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H    J@   *L
M  "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W 0  N0T
M +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<   C
MH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0   +L   "Z
M    O    +T   "_    P    ,(   #$    Q@   ,D   #-    T@$  -0/
M  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\   #_
M_P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G
M %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L S0"] ,L
MX #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_    _
M /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D
MRP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T +0 S0"R
M /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q    Z    .
M!@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V %, M !8
M +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\ P "= .8
MFP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@   ,8  0"_
M  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P GP!1 )X
M5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0") -, AP#W
M (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$   "K  <
MI0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ")
M %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K ',
M_P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":  ( E  +
M )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X
M=@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B
M /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",    A@ ' ($
M#0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!.
M &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\
M5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 " ', "@!O
M  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $( 60!' %<
M3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_
M $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@ !0!C  P
M7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!" $L 2 !)
M %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_ #P
M_P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9  @ 50 -
M %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L
M/0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F
M%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0 3  * $@
M#@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T $8 ,P!/
M #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A'
ME2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  & $  "P \
M  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $( *@!+ "@
M50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28
M (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T  P
M,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!' "  4@ ?
M %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M
M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M"0D *04-
M "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP
M%@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W
M,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0 (PP) !\)
M#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI
M  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@
M;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! % !D."@ 5
M# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0
M>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P  :SH
M &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3!@ 1$ L
M#@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E  03=@ #
M$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P  :C\  & ]
M  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0%0D #!,.
M  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D
M !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,  %]"  !6
M/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD "1D-  89
M$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@  '8<  !R=
M   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&  !51
M2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -  $?$
M'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4  "&;   A
ML@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !420  2D8
M $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F#@  )1(
M "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9   FL
M)<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P  2DP  $%)
M   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@  +1$  "T6
M   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   LKP  *\L
M "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$  #M-   P
M20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\  #04   T
M&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0  ,<H  #'N
M   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92   J3P
M($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1   \&
M/"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@  #CM   W
M_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D50  &5,
M !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&%   11P
M $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L   __P!^
M80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70  $EL   M9
M   "6    %8   !6    5    %,   !2!   40D  % -  !0$   3Q@  $\B
M  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(_P![:0
M=&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60   -B
M8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(  %L<  !:
M*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y<   <W0
M &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M    ;0
M &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5  !G(0
M9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z
M  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y    >@   'H
M  !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W&   =R8
M '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%
M@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B    (D   "(
M    AP   (<   "'    AP   (<   "(    B    (@'  ")$   B1P  (DL
M  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(   YB@
M*HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@   "6
MEP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$  )TA  "=
M,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   MDP  'I4
M !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F    IP
M *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5  "T)P
MM#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0  $9\   6A
M    HP   *8   "I    K    *\   "S    M0   +<   "V    MP   +@
M  "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,  #.&@  SR\
M ,](  #08@  T(   -"=  #0N                        0,$!08("0H+
M#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R,S0V-S@Y.SP]/D!!0D1%
M1D=)2DM-3D]04E-455=865M<75Y@86)C969G:6IK;&YO<'%S='5W>'EZ?'U^
M@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.DIJ>HJJNLK:^PL;.TM;:X
MN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>W^#BX^3FY^CIZ^SM[O#Q
M\O3U]O?Y^OO\_O______________________________________________
M________                      $#! 4&" D*"PT.#Q$2$Q06%Q@:&QP=
M'R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$149'24I+34Y/4%)35%57
M6%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]?H"!@H.%AH>(BHN,CH^0
MD9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6VN+FZN[V^O\'"P\3&Q\C)
MR\S-S]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P\?+T]?;W^?K[_/[_____
M_________________________________________________P
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M]_CY^OO\_?[_;69T,0     # 2$   $                    !
M             0    $" P0%!@<(" D*"PP-#@\0$1(3%!46%Q@9&AH;'!T>
M'R A(B,D)28G*"DJ*RPM+B\P,3$R,S0U-C<X.3H[/#T^/T!!0D-$149'2$E*
M2TQ-3D]045)35%565UA96EM<75Y?8&%B8V1E9F=H:6IK;&UN;W!Q<G-T=79W
M>'EZ>WQ]?G^ @8*#A(6&AXB)BHN,C8Z/D)&2DY25EI>8F9J;G)V>GZ"AHJ.D
MI::GJ*FJJZRMKK"QLK.TM;:WN+FZN[R]OK_ P<+#Q,7&Q\C)RLO,S<[/T-'3
MU-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_'R\_3U]O?X^?K[_/W^_P !
M 0(" P,$! 4&!@<'" @)"0H+"PP,#0T.#P\0$!$1$A,3%!05%A87%Q@9&1H:
M&QP<'1X>'R @(2(B(R0D)28F)R@I*2HK+"TM+B\P,3(R,S0U-C<X.3H[/#T^
M/T!"0T1%1DA)2DQ-3U!24U576%I<7F!B9&9H:FUO<71V>7Q^@8.&B8N.D)*5
MEYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_ P<+#Q,7&Q\C)RLO,S<W.S]#1
MTM+3U-76UM?8V=G:V]O<W=W>W]_@X>'BX^/DY>7FYN?HZ.GIZNOK[.SM[N[O
M[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\_?W^_O\  0$" @,#! 0%!@8'!P@(
M"0D*"PL,# T-#@\/$! 1$1(3$Q04%186%Q<8&1D:&AL<'!T>'A\@("$B(B,D
M)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C] 0D-$149(24I,34]0
M4E-55UA:7%Y@8F1F:&IM;W%T=GE\?H&#AHF+CI"2E9>9FYV?H:.EIZBJK*VO
ML+*SM;:WN;J[O+V_P,'"P\3%QL?(R<K+S,W-SL_0T=+2T]35UM;7V-G9VMO;
MW-W=WM_?X.'AXN/CY.7EYN;GZ.CIZ>KKZ^SL[>[N[^_P\/'R\O/S]/3U]O;W
M]_CX^?GZ^_O\_/W]_O[_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________3_________________________________________
MZ]'_________________________________________]^G^____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________X<W7____________
M___________________________=KY:W]/__________________________
M___________%C&BGY______________________________________,G(FD
MY______________________________________ZSKO&]?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________W,6]]?____________________________________^_DWJ%
MQ?___________________________________]N06SUEJ/;_____________
M_____________________KQU- !4F^O_____________________________
M____TY1^22Q.FNS________________________________8U,JS?F5MI?G_
M___________________________________TQ:ZOR?__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________\-;&[/______________
M_____________________^:[D71CJ_?_____________________________
M___VQ)IS128T?<S_______________________________^U@%4P"@ 98++_
M_____________________________\]T-0L    *4J?_________________
M_____________Y8T        3Z?_____________________________]FD=
M   )# 8)4K'_____________________________RSL.$S5,6TU,7L/_____
M________________________J6 V8(:?MJRIN-G_____________________
M________X)>-ON7______________________________________^WY____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______KV<J\Q___________________________________SYJ!;5I&B.K_
M_______________________________$?#XF$   5+#_________________
M_____________^"#/       +H?M_____________________________ZQ3
M$       %VW6____________________________^X Q        "6',____
M________________________TEH"         %W,____________________
M________J#4          %S3____________________________?0T
M     %36___________________________N?44          $34________
M___________________\JF0O @  !"(W25C.________________________
M____Z:1K02@_8W^5I[K:_______________________________5LJRRS.3Z
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________ENY=W8LC_________________
M________________VYYG-@H  HS________________________________(
M?S\%     %[/_____________________________]F!.0       #RJ____
M_________________________YY,         ".0____________________
M________W&\:         !!]^?__________________________KT@
M      !O[O__________________________A!,           !DYO______
M___________________L40            !7WO______________________
M__^X%0            !(UO________________________]T%
M   XS_________________________FB6A,            CQ?__________
M_______________?FUPL           -NO__________________________
M[[%]53DB$0<! A$BLO______________________________W[^EF9B:H*R]
MVO__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____X[Z=@'S[________________________________\K>$5S . !VL____
M___________________________2BDP5      !R\___________________
M_________]9_-@        !+R?__________________________^I$^
M       OJ___________________________P%H            :E?______
M____________________C20            (A/______________________
M___G7@              =_________________________^T)0
M    :O________________________]]                6_3_________
M______________TK                3.O______________________Z4
M                /.'______________________S ,
M+=G_____________________F8IA)P              )]?_____________
M_________^V^B54G            )=S__________________________LJ=
M=EU*/#(M+# Y1][_______________________________WFW=;2T-/9Y/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________OU+O6____________________
M_____________^>XCVI++Q5O_______________________________DH6<T
M!P     \R?___________________________]:".P         2E_______
M____________________[84Q            ;_______________________
M____ID(             4.'________________________L:0
M    -\G_______________________^S+P              (K;_________
M______________]Y                $*?_______________________(T
M                 )G______________________ZD
M (S______________________T8                  '______________
M________WP                   '3_____________________EP
M             &K_____________________S@                   &/_
M_____________________RDB 0               &'_________________
M_____[FC@%<W%P           &C___________________________K3KI2&
M?'5Q<')W@93_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________V[J=@FEIT_______
M________________________R)-E/1D    =GO______________________
M_____]N.3!,         ;O__________________________VWPL
M    1=?_________________________BRH             (K3_________
M_______________"1                Y?_______________________]]
M 0               '_______________________^<V
M &K______________________YT                  %C_____________
M_________T8                  $?X____________________Z0
M             #7I____________________E@                   "7;
M____________________O                    !C.________________
M____ZP                    _"_____________________P
M          JY_____________________R<                   JU____
M_________________W                    VY____________________
M_^"<C'!50C,F&Q0/#0X2&B:_____________________________^>38TL[,
MR\S/UN#\____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________Z].\X________________________________]*IA65(
M+!(!A?____________________________&K<3P/        3^#_________
M________________U7\U            '[+________________________C
M=1T              (G_______________________^0(P
M &?______________________]5#                 $CV____________
M_________XH                  "[=_____________________S@
M             !?(____________________O@                    2V
M____________________G                     "E________________
M____N@                    "3____________________W
M          ""_____________________P                    !T____
M_________________Q,                   !H____________________
M_T(                   !@_____________________WH
M      !=_____________________]$                   !A________
M______________\D                  !F_______________________)
MK)F)?79Q;&EG9F=K<'J,________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________XL6JD7EA=___________________________
M___=IG=0+ P     ,<3_________________________X)).$P
M (_________________________2<!T              &#_____________
M_________^YO#P               #?B_____________________Y8<
M             !3 _____________________T                    "C
M____________________K@                    ")________________
M____G@                    !R____________________O
M          !?____________________V@                    !-____
M________________^@                     [____________________
M_PX                    J^?___________________S,
M       ;Z?___________________UX                    /V_______
M_____________X\                    &T/___________________]
M                    RO____________________\K
M    R/____________________^                     R___________
M___________W%@$%!0,!       !!@T8R________________________.OA
MV,_,S<_0TM37W.+J____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________':
MQO______________________________\<:CA&A-,A@ %:O_____________
M_____________[E\1A@          ''________________________7?"\
M             #OC_____________________]]D"0                RU
M_____________________W0#                  "-________________
M____Q14                   !J____________________F0
M          !+____________________M@                     P_?__
M________________UP                     9Y___________________
M]@                     %T____________________PX
M        P?___________________R\                     K_______
M_____________U(                     GO___________________WD
M                    CO___________________Z4
M    @/___________________]@                     =/__________
M__________\V                    ;?____________________]\
M                :?_____________________7#0
M:/______________________<                   8?______________
M_________U \1DY465UA9&AL<'9^B?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____[]6[HXMS6I7___________________________B_CF1!(04      %+\
M_______________________WG588             !?!________________
M_____^5L%@                "-_____________________V,
M          !>____________________G0                     U_/__
M________________H0                     1V?__________________
MR@                      N___________________[@
M        H?___________________PP                     BO______
M_____________RT                     =O___________________TT
M                    9/___________________V\
M    4O___________________Y0                     0/__________
M_________[P                     ,/___________________^H.
M                (O____________________]$
M%?____________________^!                    "_7_____________
M_______("P                   NS_____________________7@
M             .7_____________________R1P                  -K_
M_____________________YT!              <.%\7_________________
M_______5N;S!Q\[5V^'F[?3[____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________XW\__________________
M____________[,:EB&U4.R$' #+>________________________UY)9*0
M          "@______________________^)-@                !G____
M_________________V8                    R]O__________________
ME0                     #R/__________________IP
M        H/__________________UP                      ?/______
M_____________P                      7O___________________R4
M                    0____________________T@
M    +/___________________VH                     &/__________
M_________XL                     !?/__________________Z\
M                 .'__________________]4
M ,____________________\D                     +[_____________
M______]4                     *[___________________^+
M             )_____________________+#@                   )+_
M____________________5P                   (;_________________
M____J@H                  'G______________________VT
M         &;_______________________=5                 $7_____
M____________________:B,K-3]*56!J=7Z'D9S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^C/MIV#:4ZY____
M_____________________^RR@UPZ'0(       ![____________________
M___%;2D               ! _____________________X,;
M       'R___________________D@                      F/______
M____________I                       :O__________________W0
M                    0?___________________PX
M    '?___________________SD                      .C_________
M_________V                       ,[__________________X4
M                 +?__________________Z@
M */__________________\L                      )#_____________
M_____^\6                     'W___________________\^
M             &S___________________]I                     %K_
M__________________^9                     $G_________________
M___2%@                   #G_____________________6
M         "G_____________________H@                   !G_____
M________________]58                   3_____________________
M_[LO                  #X______________________^K*0
M      #/________________________R4<     !Q,@+CY2:(3M________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________]-7)____________________________^M*PDG==
M0B@,  !*________________________Q7U%%P             1V/______
M_____________\10                    G___________________H@P
M                    :/__________________E
M    -O__________________V@                      !^S_________
M_________Q4                      ,3__________________T@
M                 *+__________________W4
M (/__________________YT                      &G_____________
M_____\,                      %+__________________^</
M             #[___________________\S                     "O_
M__________________]8                     !C_________________
M__^!                      7___________________^L
M          #____________________>(@                    #R____
M________________7                     #?____________________
MGP                    #,____________________Z$H
M      "W_____________________Z 6                  "<________
M______________]Z @                !W________________________
M>@L               5,_________________________Z)7:'2 C9RKO-#G
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^WC________________________
M___2HWI8.BDC'!8.!@  G_____________________^L4@X
M    :?__________________Y$,                     -/__________
M________>0                       ./_________________S0
M                 ++__________________Q,
M (7__________________T\                      %W_____________
M_____X,                      #K__________________[(
M             !S__________________]L#                      +_
M__________________\J                      #[________________
M__]/                      #G__________________]T
M          #4__________________^;                      # ____
M_______________$!P                    "M___________________P
M,P                    ":____________________9P
M      "&____________________HP                    !R________
M____________XT0                   !<_____________________Y$&
M                  !!_____________________^M?
M   =_______________________*2P                  ____________
M____________RU<   P8)#$_3F!TBZ?'___________________________7
MY_+_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________KU,W'PKZZM[.PK:FHI?___________________]U^4S\P
M(QD1"0(          -O_________________=@
M *?_________________N@                       '7_____________
M_____P<                      $;__________________TX
M             !K__________________XP                       #]
M_________________\$                       #;________________
M__$9                      "^__________________]$
M          "D__________________]K                      "-____
M______________^1                      !Y__________________^W
M                      !F___________________>(0
M      !3____________________2@                     _________
M____________=P                     K____________________K H
M                   6____________________YT4
M    _____________________XH                     ____________
M_________]9-                    _?____________________^G+@
M                U?______________________F"H           88+45@
MX/_______________________ZAC=(&/G*N[S>+Z____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^(S@$E#0U]04D]&24Q% !(2________________________________
M_______________________________GR[>IG96.B82 ?'AT<&QH99#_____
M____________O&I(+1D*                 #'__________________P
M                      /__________________T(
M      #<_________________XX                       "R________
M_________\X                       "-__________________\I
M                  !K__________________]:
M  !.__________________^&                       T____________
M______^N                       >___________________4%P
M               *___________________Z/0
M____________________90                      ________________
M____C@                      ____________________O!D
M            [___________________\4X                     V/__
M_________________XL                     O___________________
M_\Q#                    H?____________________^1&0
M        >O_____________________R= H                17_______
M________________Z'03'RPX15-B<H6;M-+U________________________
M___7Z/3_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________OW\_'N
M[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$________
M_________TLE"P                    "2_________________X@
M                  !F_________________]<
M   ]__________________\S                       8____________
M______]L                        __________________^=
M                ___________________)#
M]O_________________Q-0                      W_______________
M____6P                      R___________________@@
M            M___________________J08                     H___
M________________TR\                     C?__________________
M_UX                     =____________________Y,'
M        7O___________________\U#                    0/______
M______________^'$                   '/_____________________8
M7@                   /______________________OTX       X<+#Y2
M:H:ER/_______________________\)\C)JGML76Z/W_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^[AU\_)P[ZZMK&MJ:>F
MIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4____________
M_____]<%                        __________________\T
M                ]O________________]V
MTO________________^P                        LO______________
M___A)                       EO__________________40
M            ?/__________________>0                      9O__
M________________H                       4?__________________
MQR,                     //__________________[DL
M        )____________________W0                     $/______
M_____________Z,6                     /___________________]A,
M                     /____________________^(#P
M     /_____________________+4P                   /__________
M____________I3@           D=-$YKC/_______________________YDY
M0U%?;GV.H+7+Y?_____________________________K^?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________KS+FLH9F1BX:!?'AT<&MH9F9H
M\?________________]A13(C& X&                GO______________
M__]^                        =?_________________#
M            4O_________________[-P                      ,O__
M________________:@                      %O__________________
ME@                       /__________________OQL
M         /__________________YD(                      /______
M_____________VD                      /___________________Y "
M                     /___________________[DL
M     /3__________________^A<                     -G_________
M__________^1&                    +S____________________*4P
M                 )W_____________________F"X             $"E&
M9L3_____________________[G\=#!HH-T97:7Z5K\SN________________
M_________^>@JKG(V.G\________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________?7PZ^;B
MW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV,B\N,?__
M_______________2)1$#                     /__________________
M0@                       /__________________?0
M         /__________________L L                      /;_____
M____________W3D                      -S__________________V(
M                     ,7__________________XD
M     *___________________Z\B                     )G_________
M_________]9(                     (+___________________]R
M                 &G___________________^A*
M $[____________________37                    #/_____________
M________EBX              !4R4G?_____________________X'(3   !
M#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________^>#2R,"ZM;"LJ*6B
MGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00  -3_____
M____________D@                       *W_________________S!X
M                     (O_________________^U(
M     &W__________________X                       %'_________
M_________ZD;                     #K__________________]!"
M                 "/___________________5H
M  S___________________^/%                     #_____________
M______^X/@                    #____________________E;0,
M              #_____________________GS<              ! O4'3_
M____________________W7(4      87*D%:=92VVO__________________
M_____[Q81%1D=8::K\CC_______________________________2S>'Q____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________\^_K[_?______________________[KFHG9:/BH:"?WMX=G1R
M<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_________
M_________VD                       #__________________YL*
M                  #__________________\@Y
M  #___________________!C                      #_____________
M______^*#@                    #___________________^P-
M              #____________________56P                    #_
M____________________A1H                   /L________________
M____L4D              !@Y78'_____________________Y7L>       ,
M(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?__________
M__________________^SGK3%U^O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________Z[^?A
MW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;65A75UE>
M97'__________________[\Q'Q80"@4               #_____________
M_____^U6                      #H__________________^"!
M              #,__________________^K+P                    "S
M___________________25P                    ";________________
M___W?!                    "%____________________HC<
M        !2N4____________________RV$"            #"Q0=I[1____
M________________]8TP       -(SM7=IF^Y?______________________
M_\-C&"H[3%]TC:?&Y_____________________________^H?Y:HN]#G____
M_________________________________?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________=SL6_O+FV
MM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&2$M066:A
M__________________^G)@X' @                !6________________
M___.4                      Z___________________T>0L
M           A____________________GS(                    .____
M________________Q%@                (,5J$____________________
MZ7\?           &)TMQFL+I_____________________Z=)      (7+TIH
MBJ[5_/_______________________]-U'B8X2EYUCZO+[_______________
M______________^N<H68K,+;]O__________________________________
MW^__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________O[*JIJ.AH)^?
MH:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.66E]____
M________________GBX&                    ____________________
MPU8                  !5!____________________YWL:
M  DT8(NT_____________________Y\_          0E2G&9PNO_________
M_____________\9F#P   !,J1&*#I\WU_________________________^N.
M-2L^46B!G;S>______________________________^^=G^4J<'<^?______
M____________________________TMCS____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___V\O#O[^_Q\_C]____________________________^+"?FI>6EI:8FY^D
MK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I________
M_____________Z9! 0          !S9CC[KA_____________________\9E
M"@      !"=,<YS$[/_______________________^6(+P  $RI$8H*FS/3_
M__________________________^K4#9*87N6M-;Z____________________
M___________2AWR8L<OI____________________________________U,[M
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________M
MY>/CY.;H[?'Y______________________________VQE)*2E9F=HZFRO-#M
M__________________________^=4T=)35%68'.*K];\________________
M__________^R5@ :-5!MBZ[2]______________________________-;SY?
M>YFWU_G________________________________NGX.FPN'_____________
M________________________X\[K________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________
M
M
M          #_________________________________________________
M____________________________________________________________
M____________________________________________________________
M_P   /_; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)
M"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(
M!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( (<!  ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
M     0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q
M008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+C
MY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&
M!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R
M@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR
M\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH **** "BBF33);0M)(RQQQ@L
MS,=JJ!U)/I1>VX"7%Q':6\DTTD<<,:EW=VVJBCDDD] /6O"Q^T5=_M!_%7_A
M#_ <TEOHMC^]UG7U'S&('!CM_P"Z6/RB0\]2HPNX^'_MC_MBS?%:\F\,^&II
M(?#<+[9YU^5M48'](@>@_BZGL!])?L>_ Y?@E\(;6*XBVZUK 6]U D89&(^6
M+_@"G'^\6/>OS6GQ)//<V>6Y9*V'IZU:BWEVA%]$WO):M)V:6KXE7=6IR4]E
MN_T1ZG#"MO"D:YVQJ% )SP/>GT45^E+31':%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R3_P % _VFW@:3
MP%H=QMW*#K$\;=CR+<'Z8+_4+_>%>\?M)_&>'X%_">_UH[&OG_T;3XFZ2W#
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MO_!-+XF^,O'W[:W@O3]0\6>)KZPWW4]Q#/J<TL3JEI,X#*S$$%@HZ=Z^U/\
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MG?Y^/>N/,*GL\+4J/I&3^Y'H910]MCJ-%?:G%??)(_#FOT1^'G_!$[P_XP\
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MKEYIUVGEW5A.]M,G]UT8JP_ @UZE^PWXK'A7]I;0-[[(=2\VQDY^]OC.P?\
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M\ T8X)X-U7K)2O9=$U;\3[JMXR8N>;0S58:-X4Y04>9M>]*+;O9:^[8^!?\
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MH_\ !7GX.>/?BS^U!I]SX?\ !7B[7M,T_0+>T6YT[2+FZ@+^=/(PW(A7</,
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MZZ>D%%%% !7P9_P6&_Y.O_8A_P"ROP_^D[5]YU\&?\%AO^3K_P!B'_LK\/\
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MR<$[6,%U)-;3Q[ASM>*1@1T/RGJ!72?LK?\ *<C]K#_L4_!O_HBZH_X+J?\
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MV"?^"5_B+_@GUX\^)_AWPAXNT&;X(>.FEU"QT>ZTZ:77=/OWMH+?+W9EV21
M1,3E-SEP21@Y**FXSA?V5O\ @E3\=/\ @F3\)M+TG]G_ .)'PZU::\M5_P"$
MIT+QMI-Y'HNJ:@A95U&UDM9#-:3/"(8I%(D1_*5\9&*];_9'_8"\>:)^U%J?
MQZ^/GCK1_'?Q2FTHZ#H5AH%E+8^'O"%@Q#S16D<C-)))*XRTLGS8RO(Z%%4(
(^MZ*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>fumaderm.jpg
<TEXT>
begin 644 fumaderm.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_P 8H^N4?YG_ . 3_P#D0^L4OYOPE_D'_"56'_3Q_P" EW_\8H^N4?YG_P"
M3_\ D0^L4OYOPE_D'_"56'_3Q_X"7?\ \8H^N4?YG_X!/_Y$/K%+^;\)?Y!_
MPE5A_P!/'_@)=_\ QBCZY1_F?_@$_P#Y$/K%+^;\)?Y!_P )58?]/'_@)=__
M !BCZY1_F?\ X!/_ .1#ZQ2_F_"7^0?\)58?]/'_ ("7?_QBCZY1_F?_ (!/
M_P"1#ZQ2_F_"7^0?\)58?]/'_@)=_P#QBCZY1_F?_@$__D0^L4OYOPE_D'_"
M56'_ $\?^ EW_P#&*/KE'^9_^ 3_ /D0^L4OYOPE_D'_  E5A_T\?^ EW_\
M&*/KE'^9_P#@$_\ Y$/K%+^;\)?Y&U:W45Y$EQ VZ.55=#@C*L RG! (R"#@
M@$=QFNV,E-*<=4TFO1ZHZ4U)*2V:NOF<9XID*W5H.PF8_P#DO<#^M>9COX</
M\:_])F<&+^!?XE^3*GFBO!/&#S10 >:* #S10 >:* #S10 >:* #S10 >:*
M#S10 >:* #S10!J^#Y"VF6^>T,0_)!7U5#^#3_P0_P#24?24O@A_AC^2,KQF
M_E3VK>DS?^B)JXL?I3C_ (U_Z3,Y,7I37^)?DSG_ +:/6OGKGAW-_P /2I<2
MR!@C;8F8>8 4!!')ST [GTS7J85*4:LFH7BE9S7NK??LNYV89*53E:37++1J
MZZ%PJE[,(6-MA8GDS:$=1CAR0?P'ZT2@JGM&^3]W2<U[+X6[[2\_NT:.CD52
M<*;]G9\W\+?1=?T^9'8V$-S'"[LX\Y96;!''E],?+^?7\*I8>G92DY)>Q=1V
MMNG%::;6;T_$SHT8U%!MN\IRCI;HFUT\B6*RLY?)*R3 7081@A,AESDMVQZ
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MT4 'V2+^Z* #[)%_=% !]DB_NB@ ^R1?W10 ?9(O[HH /LD7]T4 'V2+^Z*
C#[)%_=% !]DB_NB@ ^R1?W10 HM(O[HH O1(J#"C H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>fvremeasurementcc.jpg
<TEXT>
begin 644 fvremeasurementcc.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MB0:8?"]C\0].U3Q#X7U'4O"_A:XM;_4F\%#57\)>+M1O;0^-M'U[3M'L]-<
M\,'_  4;DUKP%J7QM\'?!?4+_P"!_P -?AA\"/BG\?M>\2^,X?#?C[X?:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 9'KUZ>]%?D-^WS\7OBAX!_;V_X(Y^ O!7
MC_Q9X6\%?&/]I']H?PU\5/"VA:S=:?H7Q"T#P]^RSXU\5Z%I'BW3X&$.M:?I
M'B.PM-:T^UNP\5MJ4$5VBB:.-U_7>,DHA/)**2?4D"@!U%%% !1110 4444
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MY'_JX_\ <7_T$4 9/_".>'O^@%HW_@KL?_C%'_".>'O^@%HW_@KL?_C%;-%
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M:@_]8Y^(-?MY'_JX_P#<7_T$4 8GVOQ#_P! 6Q_\'C?_ "GH^U^(?^@+8_\
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MZB3^9)]Z .AHK!_X1O2_2^_\'&M?_+&C_A&]+]+[_P '&M?_ "QH WJ*P?\
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M'0]U-?&C=3]3_.OP3Q9_Y'.6_P#8L_\ =K$#Z+U?Z"4445^5""BBB@ HHHH
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M!^(=MIT5SJEM'^TX_J?7U/K_ /J].,4 ?B#_ ,%)_P#E))_P0I_[.M_:@_\
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M#:EIOAJ*3XB>)M>\.>$[2Q^-OAS6?C)#H6C^#O$OBFU^.'B[X+Z7X1GF\,?
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M^8HR/4?F* %HI,CU'YBC(]1^8H 6BDR/4?F*,CU'YB@!:*3(]1^8I<@]"#0
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M_M^W_P"@?KO_ ((M4_\ D:C^W[?_ *!^N_\ @BU3_P"1JW,#T'Y"C ]!^0H
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M2_'WC?3-<OYI3<Z]<:;%-*TB:)"EM^K/_"DO">",SX+B0_N+/F08(D/^C\R
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MQ7NL:GH_A_4?L>*6.:-)8G5XY%5XW0AD=' 9'1APR.I#(PX92".#0!)1110
M4444 %%%>)_&#XL>)/AQ)X7TKP;\&OB1\9O%'BVYU5;/2?!"^&-'T;1=/T*V
MM+K4M4\7>.?'>O\ ACP=X;CN#>V>E^'=,NM5EUWQ1K=Y';:3IDFF:=XCUC0@
M#VS_ #^72LO1-#T7PSI&GZ!X<TC2] T+2+6*QTK1=%T^TTK2=,LH%VP6>GZ;
M80V]E96L*_+%;VT$4,:\(@%? EQ_P4<^&5WX2L?B1X0^''Q7\9_#/1O@]X)^
M//QF\7Z9I_A/3V^!7PS\>GQ2-+U/QCX=UKQ98:]XDU?0[3P1XO\ $?C+P_\
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gazyva.jpg
<TEXT>
begin 644 gazyva.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  4%!0@%" P'!PP,"0D)# T,# P,#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T!!0@("@<*# <'# T,
M"@P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#?_$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^_9:WC/HS\ZS#()X=.MA/?ANX]5Z=SVY'5P&4@J1D$<@CVK4^&:<79Z-=!U
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MH0!V/>L)QMJC]1R+,_:Q^IXF7O17N2;W7:YXC_9]S_SRD_[X;_"LC[?VE/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P!V/)_I5G@2WT.OH)"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?$;7=/4)#<O@>H#?SJ^9H\:IE."JN\Z6OD[%UOBKXA88-R1]%4?THYF8K),
MO^77_DS.<U#Q9JFI_P#'Q<2,/0,5'Z8I79Z-+ X;#_PJ<5ZI,YYG+G+$DGKF
MI/0VT6B[(85S03*-]#IO"7@B[\6W2PPJ5A!_>2D?*H[\^OM6D5?8^7S'$4\#
M!RFUSOX8]3[7\/Z#;>'+-+&S4*D8Y/0L>['W-="5M#\DK595YNI/=_@;5,YP
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2^=CIHWO>]/0X]2[&;GO2T*U+J&3O2 G%(84 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 &* # H ,"@ QB@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M^A4]?TS7H+5'F[.W8^SO VO#Q!I4-P3F55"2?[X'-<$X\KL>C!W5SKZS- H
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MES+S.2<>1V6QZ9\%O$7^LTB4_P#32/)Z8X*C\>:QJQ^T;4I?9/H6N4ZPH *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M/S'^\.2,>E>EBY^QKQFDG9;'S&3T'C,!4P[DX\TOBZHD_P"%=X_Y>3_WS_\
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MA^-?+SBX2<'T=C]6HU57IQK1VDDRU4'0% !0 4 % !0 4 % !0 4 % !0 4
M% 'DGQ%E)N8(.VS=^9D']*^AR]6C*7JOP1^;\1RO4I4NEHO[Y27Z'I>DPBWM
M(HUX"H/Y5XE5\TY/S9]YA8*E0IP6RBCB/B+ &MXINZO@?C7J9?*TW'NCY+B2
M"="%3JI6^\Q=3F,_AZW8]G _(UU45RXJ21Y>,FZF4TI/H[?<=IX)_P"09'^-
M>7C/XK/J\E_W.'S,KXB1!K.-^Z2?H1@UT9>[5&NZ/,XC@I8:,NL9?H8MR^_P
MNG^R<?D3_C72ERXQV/,G+FR:%^FA#;_\BU+_ -=#_.KG_O:]#&A_R)I?XCI/
MA[_QXO\ ]=&_G7%F'\7Y'M\._P"ZO_$R;Q\H-@">SC'Z5. TJFO$"_V1OLS!
MM3_Q2\O^Z?YBNJ7^]Q]3RZ/_ ")JG^%FC\./^/6;_KK_ (UEF/\ $CZ'5PW_
M +O/_$OR-+Q[_P @IO\ ?3^=88'^,O1GH9]_N,_\4?U(/ G_ ""3_P!=)?YU
M>._C_)&&0_[A_P!O3.1\,?\ (<?ZO_,UZ&)_W:/HCYS*_P#D95/5GI_B+_D'
M7'_7,_TKPJ'\6'J??YA_NM;_  ,XCX:_ZN?ZI_Z#7JYCO#T/D>&?@K?XD=5X
MO_Y!DOTKSL+_ !8GTF;?[G4,+X=_\>DG^^:[,P_B+T/%X<_W>7^)G1>)M7&C
MV;2 _O'^5![G_"N+#4O;5%'HM6>[F>+6!P\JGVFK17FSB? 6D&:1M2G&<'"9
M[DXRWY\5ZF.J\J5"'S_R/D\@PCG*6/K+6[Y;^>MREXX_Y"<7T'_H2UK@OX,C
MFSS_ 'VC\CUVU_U*?[B_R%?.R^)^K/TJE\$?\*_(\>\3_P#(>3_>B_\ 9J^C
MPW^ZR^9^99G_ ,C6'_;GYB^)O^0Y']8_Y&C#?[M+YAF?_(SI_P#;OZ'LB_<'
MT_I7S74_3U\/R_0\8\&<:T__ &W_ /0J^FQG^[Q_[=/R[)M,RJ?]Q/S/2?%0
M_P");-_NUXF&_BQ/N\T_W2IZ'+_#HX@E]-W]*[\P^./H?.<-_P &?^(U=5\<
M6>FR&) 9V4X.T@ 'TR>*YZ6"J55S/W5YGI8O/,/A).G&]22W4>C.&\3^+DUJ
MU%NL+1$.&W%E/3/'%>KAL(\//G<D]+61\EF><0S"A["-*<'S*5Y;:$EW_P B
MW!_UV/\ Z%1#_?)>@ZW_ ")J7^/]3OO!7_(+B^IKQL7_ !I'VN3?[G#YF1\1
M(0]I$_=)/YC%=67NU1KNCR^(X*6&C+K&3_(U_!<IDTN('^ 8KEQ:Y:TK'J9-
M/FP=-/HK%JPCO8KV=[AA]G)'EC/3_"HFZ?LX*"]_J=%".(CB*TJTE[%VY%?;
M_(WA*A.T,,^F1G\JY+/>QZW-&]DU?M=7,*"*]74I'=A]E*#:N>_TKJ;I^R22
M]^^IY4(XA8N<I27L.5<J\_0W1*F=H8;O3(S^5<MGO;0]7FC?E35^UU?[AS,$
M&6( ]^*7H4VHZMV7W&=J5^MG:2W,95C&A8<C&1VK:G#GG&#NKNQQ8FNJ%"I7
M@TW"+:U6YD->7.JZ4)K1E2XD4$<CCU^E=/)"C6Y:B;@F>:ZU;&8)5,.U&M))
MK78W+(O#;1_:2/,"#><\9QSS7).SD^1:7T]#UJ/-"E#VS7,HKF=]+]2VKJPR
MI!'J#Q46MH="::NFK>0WSD!QN7)Z<BBS[,7/%:77WHDI%A0 4 % 'D7Q%C*W
M<$O;RPOY-(?ZU]%E[]R4?-_DC\UXCC:M2J=.6*^Z<G^IZ?ID@EM8G7H47^5>
M%47+.2\V??X:2G1IR76*_(XGXB2A;6./N7S^5>KEZ_>-]D?)\1R2P\8=7*Y@
M:C$8?#MNIX_> _F:ZJ3OBY-=CQ\7%T\HII][_>=MX)_Y!D?XUY>,_BL^MR7_
M '.'S,SXAR!+%%[M)_(9K?+U>H_)'G<124<+%=Y6_ P9TV>%U/\ >8G\,FNM
M.^,?D>3*/+DT/-W([?\ Y%J7_KH?YU4_][7H94/^1-+_ !'1_#W_ (\7_P"N
MC?SKBS#^+\CV^'?]U?\ B98\>_\ (/'^^/YBIP'\5&V?_P"Z/U,"T_Y%>;_=
M/\Q75/\ WN/J>31_Y$U3_"_T-#X<?\>LX])?Y@UEF/\ $CZ'7PW_ +O4_P 2
M_(T_'O\ R"G_ -]/YUA@?XR]&>AGW^XS_P 4?U(/ G_()/\ UTE_G5X[^/\
M)&&0_P"X?]O3.1\,?\AQ_J_\S7H8G_=H^B/G,K_Y&53U9Z?XA_Y!UQ_US/\
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MTB5[BY5WD(PN%)QZG/J:Z<51J5DH4](K<\S*L;A\#.5?$:S>WEYG>CX@6?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
8 * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>imraldi.jpg
<TEXT>
begin 644 imraldi.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                    ]M8  0    #3+4%$0D4
M                                          ID97-C    _    '1C
M<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L
MH@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W
M*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R
M                                                         '1E
M>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:
M(        +5:  "\9P  DC!M9G0R      0#"0   0
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M6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9:
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MZ*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&* 0KNUG3=P3;9
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M1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J
M@ "#OLH2M<5U1</%L.IF9+V3K/)6\K>CJF9&PK(EJ-\UB*U6I#(B9:G;ET$+
M1ZBPAZ   (J(@ #RAGM&>8K:]WN<>:7"_7OV>=&J?7Q8>AR1<'S#>HIWNWT[
M>Q9<]GW#>ZH_UGYX?%P;%G_1?0_P7'F0A._9.GH'@^C!<7J @P2I%7K^@DZ0
M'7N%@<AV>7P7@61;NGRR@0H^EWUG@-09=7Y?@-ON:G@FD'37:'BLCE&_UWDW
MC%&GDGG,BI^.O'IIB25U-WL1A]5:D7NZAI4]=GQKA8D7]GSOA1CLF';XG ;5
MGW>%F-.^('@:E=&F 7B\DPV-4GEOD*9S]7HGCFM9=7K;C$T\;'N%BH(6FGN(
MB-_J\'8%IZ/4 ':3HVR\BG<MGV^DA7?7F[F+[WB1F$9ROGE:E2Q89WH7DCD[
M=7JWC]459'I7C!3I@G5+LU+2F775KB*[*79LJ2BC-7<9I'Z*O7?:H")QF'BG
MG!-7;'EKF&8ZEGH"E:X45GEGC<#H4'2YOQW1;74]N/2Y_G7.LO^B$W9ZK62)
MN7=#J"QPLW@6HTY6D7C8GNLYUGEFG"H3<GBFC2;G5W1,RPO0>73*P^JY!G52
MO0"A&77YMG:(S';$L&AOZ'>>JN%5YWADIAPY,WCCH=$2N7@(C*CFD70#URG/
MN'1YSPRX.G3VQS&@1764O\B'_W9<N/=O+W<XLNA51G@ KBTXIGAWIDT2)7>+
MC$3AXX0N=^7,,X.C>#NU\H,N>)B>_H+1>0R'6H*+>9UN\()=>DM58()/>P(Y
M)H*9>],3WX2=?([@'X*@@KW*]X(I@?>TW8'%@4V=WX%Y@,R&(X%#@'1MLX$I
M@$!4'H$P@!XW[H&#@"P2>(,@@*;>A(%*C:O)3H#AB]ZS48"'BB^<9X!1B,.$
MU( RAXQLAH NAH%3#(! A8XVYX"-A.(1/(&RA'/<YX JF)?'I'_%E=6QJG]V
MDSJ:ZG]&D-2#?'\\CL)K6'](C-Y2"']DBR0U^G^LB>$0*X!UA\';8'\]HY+&
M)'[8G^JP,GZ0G&N9@7YIF22"+WYAEA=J.GY^DVA1%7ZCD/,U(7[BCTH/0']E
MBE#:#7Z%KJW$VGX@JB2N[7W5I;V82WVQH8^!%7VPG:EI,GW+FAM0.'WYEPLT
M7GXRE5\.>WZ B<K8\WWSN>K#R'V.M(&MVGT^KS&7/'T8JB" (WT>I6]H87T_
MH2=/?'UGG8PSN'V9FV8-V'W#B5S8$'V%Q5G"ZWT?OPZL\GS(N->64'R9LN-_
M1'R@K6UGG7S+J)5.VGSWI-DS+'T;H%@-4WTHB0+79'TUT1?"/'S0R>>L,'QN
MPL:5@GPTN_=^A'PXM<UF]WQEL)=.5'R7K)8RNGRWHDP,Z'RMB+K1P8U1=I*]
MM8OK=P:I XJI=WZ3?HF.> E],8B7>+)F!8?%>7I-GH<H>DDR.(<E>S$,UHDD
M?'G0/(OQ@,>\?(J9@#ZGVHEC?\Z2:(A5?WY\'X=N?U=D^X:N?U%,E(8>?UPQ
M-88:?Y@+[(>+@%K.XHJIBQN[(8E?B9RFK(@KB#>1+X<PAPUZ\H98AA-CXH6I
MA49+CX4FA)8P1(4AA$0+'H8D@\+-?HF/E76YL8A)DQ>E)H<ED-J/S88NCL]Y
ML85LC0MBQX3,BW9*G(11BA4O;H1&B5D*:X3LAK?,)HBPG]JX5X=LG*NCSH9.
MF9Z.@85=EL)XA(28E!YAPH0(D=%)P(.3C] NKX-^CO$)TH/AAJ3*]H@ JFBW
M+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48,
MADS)^8=RM1FV-X8QL$ZAL84/JY>,=80@IQIVIX-FHO=@%X+2GT=(58)8G'4M
M>X(XFDD(YH)&A@3)+(<#O_^U;87%NF>@WX2?M-Z+H8.IKY)UWH+OJL)?9X)F
MIJ1'QX'MH_DM!(&ZGG (CX&NA<G(D8:NRSVTS85TQ-B@+X1)OGJ*ZH-+N&AU
M-8*.LP!>U8(&KK5'2H&3JM8LEX%>GB8(2H$UA9O"!Y:]=82O692*=@N<#9*#
M=I>'\)"N=S9R^(\'=_-=!HV4>,M%N8QR>:8K XQ.>HP&J8S_?)S O)5]?RRN
M4Y-0?LN;%)%3?GZ' 8^(?E-R"8WM?D]<'(R(?FU$SHMO?IDJ)XM#?OH&+(ML
M@!>_CI17B-BM&)(TAYV9^Y VAG6%Y(YXA8EP_XSJA,9;*(N2A"]#\8J!@[HI
M8XI-@[D%OHH*@R:^;Y-!DJ>KY)$HD)F8N8\WCJ&$R(UPC.-OZXOTBV9:,(JH
MBAQ#&8F>B1$HJHEEB.<%7XC7@Z&]1Y)GG(6JSY!.F;*7F8YAEP.#E8RJE(5N
MV8LHDD%90(GKD%)"4XCDCL<H"(B@CLH%#8?0@VJ\/)&_IH:IQ8^IHOB6D(V\
MGX>"EXP'G$IM\(J'F5%8;8E EKM!IX@\E-\G?(?PE#L$R(;S@SR[6Y$YL*>H
MZ8\EK%^5M(TUJ"R!P(M^I#1M+(H$H)A7QHB]G8-!&8>IFY4G"X=5F+X$CX8\
M@Q6ZI)#/NP&H-HZ]M@"4^8S*L0^!!(L.K%YL>8F4J#!7*(A7I-= G8= HMPF
MJH;6FB0$8(6F@O:Z&I!\Q;JGIXYMP .46XQXNE* 8(JVM/)KXHDWL$Y6IX?[
MK1) +8;LJ,0F2(:!F>($.X4O@MVRPZ!Z=,.A2)V(=4Z//)K'=>)\:)@]=HQH
ML97I=U-3Z)/:>#(]H9)%>0PC9Y))>=0!2I!9?+JQL)]@?>:@?9QK?9B.?)FL
M?6-[JI<D?5%G[)38?693))+2?9T\VY% ?>$BN9$S?E0!+([,?]VPNYY&APZ?
M>9M<A?2-CYB;A/EZMI8@A#-G!9/=@YQ24)'A@S$\'9!3@NXB'I U@SL!$8UO
M@+FOO)U3D#&>:)IMCF",;I>TC+9YMY4PBS-F$Y+ZB?I1?I$%B/,[;H]XB#DA
ME8]*B+, ^HQ @*FNU9QPF8J==IF3EP2+<I;BE*=XLY1EDG-E,9(;D()0MI S
MCNXZRHZGC=PA%XYMCB\ YHL]@)RM\YO,HPB<K)CNG]&*J98XG+YWX).\F>5D
M8Y%]EU=/_X^*E3TZ.(W^E!(@J8VWDN  UHIC@)&M,IM-K*";[)AOJ,&)Z)6W
MI/YW)9,ZH7YCNI#_GF9/;H\*F_$YPHUJFP(@58T6E=P R(FN@(>LD)KKMFJ;
M4)@-L>.)2)51K75VA9+.J59C()"3I<M.YHZGHTHY68T H5L@#(R0E:L O8D;
M@("L%)J<P)V:TY>^NV^(OI4 ME9U]Y)XL:)BGY YK<U.>HY,JUTX_(RNIF4?
MOHP^E78 M(BE@'JD":J1=#F3GZ;L=+R"L:-\=4]Q!:!%=?Q><YU*=L5*O)JH
M=Z(U5YB^>&L;0)EK>.P  (V>?Q&C,*F6?..3"Z7G?)N")*)P?'-P=I\T?'!=
MVIPY?)=*(IF;?-XTOY>M?2T:T)@U?9@  (QL@ "B<ZB*A8B2/Z3DA(6!;*%F
M@Z1OLIXQ@OY='YL\@HA)>9BC@D0T+):R@BL:;9<9@L8  (M@@ "AL*>5CB^1
M8Z/VC(. ?:" BOYNVYU$B;)<59I9B*M(RY?%A^$SH971AW@:$Y8:B#@  (IW
M@ "@XZ;4EN:0EZ,UE)I_J9_"DG]N IR(D)];G)F)CO9(+);]C;\S)I4"C2\9
MR)4MC.T  (FO@ "@.J8BG]Z/[:*)G/-^_)\6FC5M5IO:E[9:^)C:E89'H)8Y
MD^4RNY0[DXD9A)16D.H  (D'@ "?G:6AJ/*/9Z(%I6=^=YZ*H@9LR)M&GO-:
M;IA.G%M'*I6RFI,R8I.=FA 94).BD1T  (A\@ "?%J5#LC2.YJ&DKA!]])XC
MJA5L2)K:IGI9]9?@HY1&OI5,H@XR$9,NGW09)I,0D0$  (@+@ ">JJ3YN]Z.
M?:%4MR%]A)W0LHMKUYJ#KGI9D)>&JX-&;)3OJ4(QSI+8H:P8]Y*UD.$  (>P
M@ "5\;4(<\2&?;"X=#=VD*RB=,)E[ZC%=6Q49Z4K=C%!HJ((=P,L\)_X=ZP2
M;J(<=ZP  (E^@ "55;0B? &&'Z_%>[1V-*N>>Y!ECJ>R>Y93^Z01>\A!.*#I
M?!HLCY[)?&D25*"=?*\  (C$@ "4U;,9A"R%C*[#@S1UL*J3@F5D_*:I@=A3
M;Z,'@7] O9_@@5LL+YVT@6<2/Y\_@@D  (@A@ "43K(?C%.$[*W/BL)T^ZFD
MB6!D6:6QB#]2UJ(8AVA /9[RAM@KTIRZAL$2*YX&ALH  (>3@ "3N[%3E)*$
M5*T$DG!T6:C<D(ACLJ3ICM]22J% C80_R)X?C*$K@9O;C*@2&YSNBN(  (<9
M@ "3*K"WG/F#RZQFFDMSU*@XE]5C+Z1!E:U1SJ"4D^4_9IU9DL,K0)L+DQ,2
M$)ORC#8  (:S@ "2OK EI86#8*O5HDMS:*>EGTIBQJ.MG*=1;J !FHX_&YR_
MF7HK$)I&F)02"9L,C#(  (9>@ "24Z_%KD6#&ZMLJGAS)J<LIN-B>*,?H\E1
M'9]MH8T^SIP]H+HJVIG*G/D2!YI=C#$  (89@ "1^Z]ZMVR"RJL7LQ%RU:;0
MKO%B*J*_JWQ0W)\)J7,^GIO4ILTJO)EDG.42!IGFC#   (7B@ "(=K_E<U%Y
MX;KU<ZUJV;9#="M;)['*=,Q*BJV>=8<XDZH4=D8D4J@K=K<*6*H'=Q<  (8,
M@ "('K\%>RYYN;H(>M1JKK4\>JQ:]+"K>K9*3ZQN>NXX7ZC5>T,D-*;'>X$*
MGZ@N?&(  (6V@ "'WKWR@NEY8KC]@?1J7K0F@2Y:EJ^/@+5)]JM,@'0X&J>L
M@&PD$Z6!@)0*WZ:#@28  (5K@ "'E[SGBIAY ;?UB1MIY[,BA]1:+*Z!AM=)
ME*I!ABTWSZ:=A=4C\J1;AA@+%Z4'A5$  (4I@ "'/KP*DF!XI;<6D&)IA+)!
MCJ99P*V>C3-)/ZE.C!PWCZ6LBY8CUZ-6C#X+2J.YAZ(  (3Q@ "&W[MBFE-X
M4+9GE]9I-;&(E9Q9=:S?D[U(^:B,DE4W7:33D<8CPZ)KD>@+=**4A[\  (3"
M@ "&A[K>HE]X";7:GV1H];#OG*Y9.:P^FFM(PJ?LF-LW.:0LF*HCNJ&8EJ,+
MG*&4A]D  (2:@ "&3;IBJI5WU;5:IQYHQK!KH_99#ZNSH65(FJ=>G^4W%*.F
MGPHCJJ#\F!T+P*"TA_(  (1[@ "&#;H1LSYWP+3XKSEHMZ_SJX-8]:LCJ*A(
MB*:]ISDW$Z+]I \CPJ!@F"T+\: =B!,  (1A@ ![;LLQ<OUMF<6V<S=?6,!_
M<YI0<[N"="= GK;?=,LO1;,A=60;!K'X=6L#;[!-=XD  (,D@ ![:,I >HAM
MJ\3">A%?7K]K>=E0<+I)>=I F;6'>@TO4K&H>E8;1[ Q>E\$"ZXO?$8  (,B
M@ ![<LD2@=EME\.>@-A?1[X]@ ]03KD+?Z! ?;0Z?VTO4+!'?W<;?:Z2?ZL$
MEZQ)@'4  (,A@ ![<,?HB11M?<)SAYY?%[T1AF=0);?4A85 7K,!A0(O2J\"
MA-\;K:T=A80%$JJ;@VX  (,?@ ![6\;LD&5M9<%PCH!>_KP$C.A0 K;"BZ5
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MO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (
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MI+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$  (
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MI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (
M@ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L
M#ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR
M>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ
M9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%
MA[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE
M2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (
M@ !R,+]0F--E/[IBEN!7KK5_E0I)8[#/DXTZ/ZR0DL(IMJDXDP<68*@MCR$"
M1Z&T@8H  (  @ !R$[[3H&!E/;G,GAI7L;35F^Y)9+ 6FCHZ.JO2F;8IMZA]
MF'D6A:=-CSH"C:"S@;H  (  @ !Q_KYVJ#9E0[E0I:)7N[1#HRA):Z]WH6LZ
M1:LIH%$IT*?*G$46J*:/CU("NI_S@=@  (  @ #9M7&!;*K%#G+7;C>OOW0;
M;[>9FW5)<2V"K'9K<J-JZW>*=!M2!7B@=8(V>GF@=L 2 GIY=JW7MV]7=][#
M<'#<>$>N27)!>+>82W./>32!='32>;YIQW8.>E%0ZW<T>M8U:'@A>SX0SGC"
M>JW5XFV$@QW!I&\;@F>LM7"9@<*6S'( @4F ''->@.IHDW2R@)Q/V77E@$HT
M;':\?^\/P'=!?R+4&6OJCDJ_U6V.C)"J[F\9BO"5.G"7B75^L'(.B#%G5W-V
MAP1.S'2TA>(S@'5RA-L.UG7S@S#2>FJ4F6^^.VQ ELRI5&W6E#^3KF]>D=5]
M4G#BCY1F)7)>C9%-SG.DBZ@RI71'BA@.#G34AJC1)FF*I)V\ZVLXH2.H FS/
MG:J286Y<FE%\'&_HERIE"G%HE#],XW*VD:8QX',_C\X-97/CB0[0%6BYK]2[
MW6IGJXJFZVOYIRN126V%HN=[&&\8GN9D)G"?FS-,&7'HE^\Q.G):EA0,V7,;
MB+#/1V@?NQ6[$&G+M@&F#&M3L,.07FS6JYAZ+VYJIL9C5V_XHFU+<'%#GL@P
MJG&7FY ,9W)YB&+.N6>\QF"Z@&EAP'VE86K:NF./G&Q-M&!Y;6W:KL]BIV]H
MJ>]*SG"NIE P&G#KG^X,#''WB"7*6GGD:XNW?7ID;4NCP7KF;NN/ GMH<'1Y
M57ON<?IBM7Q\<W]*TGT5=.XOX7W0=AX+.7]D=C?(Z7?H=CRV5WB1=N2BI'DM
M=X.-['G$>")X0GI=>,IAKWK_>7I)V7NB>AHN]7Q)>I *:WVQ>JC'978J@.2T
MKG;F@(>A''>5@"R,<WA#?^AV\GCU?[E@A7FM?YA(SWI:?W,N!WKE?T )MGPS
M?M;%TW2EBWJS"W5KBC.?>'8GB/*+ W;DA\1UHG>NAK]?7WAXA=!'U7DMA.\M
M,'F<A#0)&7KH@G?$6W-=EA.QEW0JD_:>!'3PD=F)EW6WC\UT97:)C>%>2'=F
MC"U&[7@@BITL;'ARB8H(DWG,A9/#)');H,*P8G,LG=><SG/RFMZ(:'2^E_1S
M2G67E3-=2W9TDJY&&W<TD(LKO7=KCWH((GC=A8#"*W&/JWZO9G)AI\R;S7,C
MH_F':'/NH#-R773/G*Q<?76QF79%:G9IEM$K+':'E5<'Q'@7A4#!;G#XMDVN
MI'''L=F:^G*!K3&&CG-$J)-QAW0FI$U;O741H(Q$SG7)G< JKG7'FB,'>'=V
MA0W \'"4P3:N%W%>O .:4G()MHF%UG*^L1YPU7.9K"M;'G2$J A$.W4[I1 J
M*G4CG(('.W;VA.2[;H*4:IRJ,8(X;'B7ZX'Y;BJ$>8'1;[]O_(&Y<4U:<(&X
M<ME#@('==$<I!(*!=5,%/(.[=HVZ3("]=+.I$("-=8V6LX!E=E:#3X!+=Q=N
MY8!"=]U9<(!0>*9"DX!X>5HH+H#\><@$R((,>M*Y''\.?LVGPG[Y?K>5F'[?
M?IR")'[8?H9MSW[<?H-8>7[X?HU!NG\G?I(G;G^.?GP$8H"1?I*WO'V4B-6F
M7'V&A^Z4#GU\AOZ R7V!AA5LD'V?A4Q787W,A)A S'W_@_8FJ'Y$@X0$"7](
M@=2V;7Q9DN&E"WQ0D3B2OWQ0CW]_A'Q=C<AK=WR C"U6:'R^BL<__GSTB9 E
M_WT8B08#OGXO@HBU57MBG0RC\WM>FJ.1J'M>F!Y^=7MNE9MJ>7N5DSQ5BGO/
MD1X_1GP)CW4E:'P/CP #?GU!@ERT=7J>ITFC#7J=I":0O'J9H-5]BGJGG8AI
MH'K4FG54SGL2E[\^K'L^E<8D['LJE" #27Q]@CFSS'H+L:"B6'H,K<:/^'G_
MJ:]\PGH$I9EHW'HQH=U4&GIYGKH^&7JCG.0D?WIJF%(#'GO=@ARS7'FGO""A
MTGFGMYB/5GF-LKY\%'F#K>EH.7FHJ9=3C'GNID$]EWH:HWPD"WG-F%\"_'M>
M@@2LV(N]:=J<^8J :[N+_8E^;7!YP(BI;PAF:8?Q<)A1[(=B<B0[Z(<@<X4A
ML8?U=$X  (>!=R2K\XH"<V6<!XCX=%6*[H@,=3)XN8<_=@AE<8:-=N)1!X8&
M=[P[$87 >'@@]H9J>,<  (65>Q6J\(AJ?-N:U8=[?/F)V8:8?0MWG87:?2%D
M<84T?490*82X?74Z481R?9D@583T?9   (/F?HJIT8;VAEJ9I(8/A;>(D(4^
MA0!VBX2&A%-C>8/M@\-/7(-Y@TDYIH,X@N,?QH.8@K@  ()O@ "HI87#C]N8
MF(3@CHJ'@X07C2)U8H-GB[9B;X+6BF1.:X)UB4HXX8(RB&X?,H)FB'L  ($N
M@ "GJX37F7Z7EH/ZEWZ&@8,PE5QT;X* DS-AC('QD3!-JH&&CW@X18%%CE(>
MM8%8C=T  ( @@ "FXH0<HS*6R(-%H(B%K8)VG:QSF8'"FLI@Q($WF"9- (#-
ME?(WQX!VE+H>48!LDE<  (  @ "F2H./K0B6(X*^J;J$^('GIB9RX8$FHHQ@
M$H"7GU9,4X YG-DW-W_?F[4=^'^GE$0  (  @ "EXX,MMQJ5I()@LS.$7H%\
MKNMR/("IJJ!??( 0IN]+UW^OI'HVS7]8H7D=GG\-E <  (  @ ">II4>:4Z/
MU),F:R-_[I%Y;-1NS) #;FI<C8ZP;_9)#XV=<70SUHT0<K(9AXZB<O8  (,6
M>KR=[).4<EJ/%I'(<TU_%) G=#-M^HZL=11;Q(U8=?E(58Q%=MDS*(NM=XH8
M_8T =X,  (&A?A^=&)(3>TZ.$)!B>WU^(8[&>Z=M (U8>]A:X(P-?!A'CHL!
M?%\R?HIC?)$8?HM\?&P  (!:@ "<&9"WA"N,_8\+@[-\]HU^@S5L"8P0@KA9
M^HK6@EA&SHG3@@DQY8DP@<T8$8H2@=D  (  @ ";)H^$C2R, (WBC!![^(Q>
MBNEK"(KVB;]9+8FUB+)&'(B^A]PQ68@7AU 7L(C&AU@  (  @ ":4HZ@EE&+
M/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4  (
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M2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(  (
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MFI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL  (
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M/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<  (
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MPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (
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MZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (
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MM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (
M@ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,
M )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*
M<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT
M4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=
M>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=
M-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (
M@ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@
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M,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<  (
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M.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (
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M#X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (
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M:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70  (
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M<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0  (
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MH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (
M@ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$
M4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\
M>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U
M:)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<P
MB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J
M@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (
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M.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (
M@ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4
M )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP
M?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 V
MV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_G
MC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?
M5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (
M@ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X
M"X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$
M9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8M
MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R
M<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5
M);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (
M@ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D
M ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00
M@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M
M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(
MD'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4
MNZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (
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M6G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (
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M/&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (
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M 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (
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M-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (
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M^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (
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M='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (
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M>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (
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M\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (
M?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0
M+Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"
M<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(Z
MF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"
M?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB
M?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (
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MIJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP  (
M@ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8
M (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>
M=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PP
MM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX
M@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7
M&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (
M@ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H
M (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);
MD>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG
M+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ
M9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-
M2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (
M@ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP
M (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)=
M=RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\F
MDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U
M@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,
M$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (
M@ !68J<TDGY,#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD
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MU7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (
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M3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,   (
M@ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6
MG6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2
MD;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0IGX1DV676G)Q3
MV&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!)WE27 ERMWGA
M7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (  =@F-4G7A8;J
M$':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8  (
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M=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW   (
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M.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L  (
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MSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (
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MH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (
M@ !Q?8%"=^!EN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,"
M;H%$>\   (  @ !PIG^0?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I
M?^48,W[S?^@"C7^]?_@  (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[
M<GV;A@LK*7U]A=07]WTJAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T
MCF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC
M:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (
M@ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<
M (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<
M:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STT
MC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)
M<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:
MEHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (
M@ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"__B?1!)
M0T-?4%)/1DE,10 "$H<2?;4  ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@
MA"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (  @    (  @ !CWH> C$59
M#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(  (  @    (
M@ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L
M (  @    (  @ !<X)[Q5=]20IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-
M8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K
M49@490P:4)D19;0&WYC=9>,  ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]
M9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0
M.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (
M@ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X
M (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M
M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI
M+HZE@,X9((ZI@.L'4(P<@.   (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_F
MA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5.
M"9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (
M@ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P
M (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R
M8@<  )UL914  (  =?@  (  @ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@
M$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V
M:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$
M*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D  (  @    (
M@ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0
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M7F"Q8&1]VF,G8S5M0F5^9>9;A&>W:'=(DFFV:N0T%VL#;0$;9VI-;B   (
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M/U,&C5]W0U9/C"MG/UE:BO)60EPKB=1$*UYNB.8PJ5\4B%(8_&!-B$D  (
M@ "3@4VXF!J%>U%MED1VB%3%E$EFD5?;DE)5G5JWD)-#C%SZCRTP+%UXCGP8
MN5\YC.T  (  @ "2]$QWH9>$[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&
ME8TOR5P3E/L865YFD'8  (  @ "16&FL4V*#GFM,5R]T\VSP6LQE&VZ07C=4
M$' C87A!K'&89( M=7*E9PD3T7/&9\<  (  <>2/RF7#7+Z"4V? 7[=SMFFA
M8HED VMO93=3&6TG9\! V&ZN:AHLQV^2; (387#G;%(  (  =I6.2V(J9B"
MW61R:$ERCV:,:E=BZ&B!;$-2*6I6;A= %FOK;\4L.6RE<143$FY=<0\  (
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M,5CMDR=M$5N5D8Y=[%X"C^I-OV VCGL\6V'.C7$I;V%NC4D1@F:JBF(  (
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M<&D,;S=G &JV<*%8E6Q <?)(O6VN<R(W?6[,="LD%V[A=,L+3G->=+,  (
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M,E^HF"!BVV&EEDI4A&-DE&%%*63EDM8T>&6^DALAR61BD5$*:VYDAPL  (
M@ !X_7GN4OYM!'IB5H]@#7L 6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$
MA(#I9.T  (  >2!WLW9@6TAK]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'
M9^H<B'L%:/$$FWXI:;(  (  ?,!V?7,-8Y=JL'079=1=_'4)9_-/_'7J:>M
MN7:_:[@OQ7=];34<$'?+;=8$G'O%;KD  (  ?^]U1' %:]]I<W$Z;7U<NG)/
M;OY/$'-%<& _XG0N<9HO(73?<I8;IG2Z<N($GWFQ="@  (  @ !T$VU7=#=H
M2VZP=3I;HF_>=AU.!7#G=MX_/''6=XPNF7)[>!(;6''N>"($K7@9>;,  (
M@ !S#FL8?)YG;VR/?1-:VFW/?5I-,F[B?7X^:F_.?9PN '!2?;T:X6^(?<($
MF'@\?H(  (  @ !R.FDSA/EFH6J^A.1:%FP*A)%,>&TEA"(]NFX0@\0M;FYU
M@Y<:F&V(@]X$FG@X@H,  (  @ !QDF>GC49F &E#C+%9>&J6B\U+Y&NPBLX]
M*&R3B@8LW&S?B;H:*VOVB<P$F7@Z@QP  (  @ !Q%69QE8UEA&@:E(Y8]VEP
MDR)+96J#D9X\O6M8D( LBFN%D%\9T&JTCH@$;'B'@OT  (  @ !LQ8+94GMA
M@H+-5>=52(+T62Q'RX,Y7#TXUH.A7P$GV81X82P2](:[894  (,Z9:X  (
M? -KEG^$6DY@D'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K9D02UX+[9E\
M ($):F(  (  ?S9JA'Q38B-?;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*
M:V<2E'^):S\  (  ;WH  (  @ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@V
MOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E
M<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<
M<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (
M@ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D
M (  @    (  @ !F$G%)B9I;-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)
MAYL12W1JAL$  (  @    (  @ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T
M"W)^C@(D+W(ACC81$7,_BO   (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI
M5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5
M*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (
M@ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L
M (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D
M;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\L
MP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?
M>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0
MUWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,  (  @    (
M@ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\
M (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9
MBS()3'LJADD  (  @    (  @ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HD
MSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G
M7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](
MW)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<  (  =N0  (
M@ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0
M (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^
M;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B
M:8AH==<1XHD?=8@"1895>$H  (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4
M>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%
MB(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74  (  @    (
M@ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P
M (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;
M6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P9
M19ZA7-@(IY]S75D  ([<9'X  (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO
M7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\
MA)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP  (  ?8   (
M@ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\
M (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I
M<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7
M:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z;9'V?>TP,I%/
M??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @    (  @ !#@)$$A,8Z
M)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@    (  @    (
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M0UUA4B!V6U_]5CEF?6**6B]5@63Y7?M#/6<788\O3VA 9+$6JFEU9E0  (
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MA$FX?DUO>DW$?G)@9E%V?HQ03E2_?JD^]%<=?M0K]5; ?PD4AUYD?U@  (
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M2%^+6G=K8V'^7;9<>V118--,669R8\,ZS&@I9G4G0FB':)0.0VX1:/\  (
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MCDX\A'AE6U'*A!E7&%3X@[!'P%>E@UDW&5DF@RDDIEB1@T0-/&FA@Q,  (
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M%V*F8<E@263:9$Y2-V;:9J]"\6B9:.0R$&G*:LX>NFE-:_<'#705;*4  (
M?5)WDEPN9]-KFE[::;Y>Y&%$:Y=1.V-R;5A"%V5+;NLQ;69E<$4>6&7><0$'
M#G03<<X  (  @ !V(UB'<'AJ7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[
M==8=N&+[=CT&YW15=X0  (  @ !T\U53>2%I0EAI><=<L%LK>DY/$5V6>KQ
M5%^)>R(P!V!8>X,=3V")>[L&UG1R?.H  (  @ !S_5*1@;EH8%7/@<9;X5BQ
M@:9.4%LR@7,_H%TF@4\O=5W$@4L=#%Y^@8@&V'1O@6D  (  @ !S/5!#BCEG
MKU.CB;E;-E:>B/A-LUDJB"<_!UL6AX8NWEM\AT$<G5SDA\4&TW1XA)T  (
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M^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD \WYE<98  (
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MQ5H CC-0]UQ>C39$(EXRC"(V(%\_BVHF9UYABXD3L&0XB?,!#WXU@+@  (
M@ !DXWH,35I9W'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z 70T,S("@77@
M (  99T  (  >[1C177"5-]8J';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG
M8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P
M^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7
M:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5
M VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (
M@ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\
M (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=
M?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,M
MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1N
MB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (  @    (  @ !8\X-<3&!.
MJX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(  (  :34  (
M?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X
M (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[
M9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHF
MB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4&G0Y:4=**752:LX_578O
M;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)
M0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\  (  @    (
M@ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,
M (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z
M?[ $7'BB@"<  (  @    (  @ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D
M$6UDA=L4$&ZDA;@$47BU@NL  (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#
M46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (  ;*T  (  @ !+DXG+491"
M.(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\  (  <8X  (
M@ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H
M (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W
M9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;
ME8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV
M;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @    (  @ !&^'DQ=%T]
ME7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<  (  @    (
M@ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@
M (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU
M@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2
M>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.4=DL+)69
M5&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^09(657@U
M.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (  >70  (
M@  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8
M (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%
M:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$/
M/XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W
M<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ
M78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (  @    (
M@  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @
M (  @    (  @    /__  #__P  __\  &UF=#(     ! ,)   !
M             0                    $   $   (   (D!!T%V@=I"-D*
M-@N%#,<-_P\Q$%X1BQ*W$^(5"Q8R%U<8>1F8&K4;TASO'B4?62"'(;(BVB/_
M)2,F1"=F*(8IIRK'*^@M""XH+T@P:3&),J8SPC3>-?LW&#@U.5$Z;3N)/*4]
MPC[>/_A!$4(I0T)$7$5U1H]'J4C#2=U*]TP232Q.0T]94&]1AE*<4[)4R57?
M5O98#5DC6CI;45QF77A>BE^;8*UAOF+/8^!D\68"9Q)H(VDS:D)K4FQ>;6=N
M<6]Z<(-QC'*4<YQTHW6J=K%WMWB]><-ZR'O-?,Y]S7[,?\N R8''@L6#PH2_
MA;N&MX>SB*Z)J8JDBYZ,F(V1CH:/>Y!PD6226)-,E$"5,Y8FEQF8#)C_F?*:
MY)O6G,B=NYZMGY^@CJ%\HFJC5Z1%I3.F(*<.I_RHZJG7JL6KLZRAK8^N?:]K
ML%FQ1[(VLR2T$K4 M>VVVK?(N+6YH[J0NWZ\:[U9OD>_-< BP1#!_L+LP]K$
MQ\6UQJ/'D<A^R6S*6<M$S"[-&,X!SNO/U="^T:?2D--YU&'52=8QUQC8 -CF
MV<W:LMN8W'W=8MY'WRS@$.#TX=CBN^.>Y'OE5^8SYP[GZ.C!Z9KJ<>M([!WL
M\.W#[I;O=O!5\3/R#_+J\\/TG/5S]DGW'O?S^,;YE?IA^RG[Z_RG_5S^"_ZT
M_UK__P   >@#IP4L!H0'OPCG"@0+%@P<#1X.' \9$!<1%!(0$PL4!!3\%?,6
MYA?8&,P9UAK>&^$<X1W?'ML?UB#1(<LBQ".^)+@ELR:N)ZHHIBFB*J KGBR=
M+9HNE2^1,(TQB3*&,X,T@35_-G\W?SB .8(Z?SM^/'P]?#Y\/WU ?T&"0H5#
MB42-19)&F$>:2)M)G4J?2Z-,IDVJ3J]/M%"Z4<!2QU/.5-55UU;95]M8WEG@
M6N-;YUSJ7>U>\5_U8/AA_&, 9 -E 67_9OQG^FCX:?5J\VOP;.YMZV[H;^5P
MX7'><MISUG3-=<-VN7>O>*5YFWJ0>X5\>GUO?F1_6(!-@4&"-8,IA!R%$(7^
MANV'VXC*B;B*IHN5C(.-<8Y@CTZ0/9$LDAN3"I/ZE.F5V9;)E[J8IYF3FH";
M;9Q:G4B>-I\EH!2A!*'UHN:CV*3*I;VFL:>FJ)NID:J'JW^L=ZUOKF>O8+!:
ML52R3[-,M$FU1K9%MT2X1;E&NDB[2KQ.O5*^5[]=P&/!:L)RPWO$A,6*QI#'
MELB=R:7*K<NVS+_-R,[2S]S0YM'QTOO4!M42UA[7*M@WV43:4=M>W&O=>=Z&
MWY3@G.&BXJCCK>2RY;;FNN>]Z,#IP^K4Z^7L]>X$[Q+P(/$L\CCS0_1.]5GV
M8_=J^&[Y;_IL^V3\5OU$_B__%___   "!0/8!6@&Q@@&"3(*4@ME#'(-> YZ
M#WH0>A%Y$G43<!1H%5X64A=%&#<9*1HT&ST<0!T_'CH?-" L(2,B&2,/) 0D
M^27N)N,GV"C,*<$JMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y"SH
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MQ&)_=FXOO8Y^U6"TMIQ^B%-;KW!^BT9)I_9^T3G9H!U_/"Y#E\=_]"0SCOR
MZ8DSRAJ'(GN7PVJ%H&X(O).$5V"'M96#<%,TKF&"RT8VINJ"8#GEGQ>"$BZ
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M?"B&!*SM?&"% IA2?*F$*(-E?0&#:VY<?7""PEEQ??&"&$2X?IB!<#"1?W6
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MKER#36KYJ7Z"C5XMI(N!_%%*GX.!F$2BFE:!33B;E/2!$2UOCUN \B/-B9Z
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M>IY\E#(E?+E]I-;O;AB#!<-;;[^"4:]$<52!KII[<MZ!-857=&^ UW 2=A2
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MA;J%8(TIA.&$H7R8A!Z#YVN6@W&#1%J$@MN"J4FQ@EB"#3DU@?:!:2G&@:B
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M?<U]/RK(?PE^):]&=WJ"2Y_0>!&"!X^A>*6!KG[/>42!46V%>@.! EPG>MV
MO$L5>]* =SI>?/B ,"JN?E1_VZX$=A6+H9Z/=KJ*CHYF=V")7'VD>!*(%VR5
M>.2&U5M>>>&%G$J#>O6$5CH'?#R"]BJ7?;>!:ZSZ=/B4\)V(=:B3#HUF=E:0
M^'RP=Q:.QFNX=_B,CEJP>06*4DH$>C>(!SF\>YN%C"J$?3&"T*PF=!2>'YRQ
M=,R;:XR/=7V8;'OA=D2516K^=S>2%EH:>%6.V$F=>92+?#F >Q.'YRIU?,&$
M!ZN'<VBG))P)="2CF8O==-.?JWLR=9F;A6I9=I:75EF+=\F3%4DW>1F.KCE+
M>J2* 2IH?&6%$*L?<O*O\9N.<ZZKB8M-=%2FHGJ<=1&A=6G2=@^</ED>=TN6
M]DC;>*V1@CD+>DR+S"I>?!R%[*6+A7QE.Y=_A,AGR(B-A$1J+'BV@]YL>VA1
M@X-NV%>]@S-Q5T=R@O!S_C=R@LQV]"AJ@M1Z7*2O@XAN4Y:5@Q)O[X>,@J]Q
M='?&@EQR]F=^@AATB%<-@>5V-$;J@<%W_#<C@<!Y^2AK@>A\/J.P@<!W195H
M@7!X"89_@2-XNW; @.EY;V:?@+]Z+U9:@*U[ T9H@*I[YC;;@,U\Y"AK@19^
M :*;@!B (Y1(?]^ ((53?ZZ  W7<?X=_XF7:?WI_RU7'?X9_OD8%?Z9_M3:F
M?_%_K"AK@%Y_H*%_?L*([Y-+?I:(+X19?G.'273,?EV&2F3Z?F2%354)?I*$
M6$5]?L^#639??S6"1RAK?[^!&*"6?;*1LY)<?9&0,8-Q?76.=G/T?6J,EV0Y
M?7Z*L51V?;>(QT46?@^&T38H?I.$L2AK?SB"99_9?-F:4I&>?,*8#(*U?*>5
M=G,^?*"2L6.5?,*/X%/U?0J- 43%?6N*"S7^?@F&XBAK?L>#AI]*?#2BR)$&
M?"2?NX(4? :<0W*B>_R8C&,#?"24R%-S?("0\D1J?/&- #78?9B(U"AK?FN$
M>Y[H>\"K#)"1>[.G-(&.>XVBT7(:>WF>'F*->Z&97U,7? 24CD0>?(>/GC6G
M?4**>2AK?B&%19B=CC%DZ8NIC*YG;'W=BVAIT&\ZBD%L*& =B1QND5#>A_EQ
M($'ZAM=SV3-RA<EVYB7_A-5Z89?HC&IM>8KPBR%O&GT0B?)PKFY_B--R15]Z
MA[QS[U!9AJ]UN4&8A:AWH3-&A+AYQ28A@^!\,)<7BK1UWXGUB9)VN7PQB'1W
MBFVFAVMX7U[#AFMY1D_+A7IZ1$$VA)%[53,=@\%\AR8^@P=]W98BB2-^&HCY
MB!!^1WLFAPQ^7VS9AA!^<5X2A2Y^CT]*A%M^N$#F@Y%^ZC+]@N-_)298@DE_
M9I4UA\N&5X@0ALB%TGI'A=*%*VP"A.6$;EU\A R#L4[;@U:# T">@JN"4#+@
M@A^!DR9N@:: R)1KALF.CX=CA=&-6GF@A-Z+[&M)@_:*5ES/@RF(O$Y:@GR'
M*4!'@>J%CC*Y@7F#U": @1R" )/'A?N6GX:WA0V4MGCUA!F2>FJF@S.0"EPW
M@G&-DTWC@="+&$ (@4.(D#*@@.R%W2:/@*F##)-'A5^>@88RA'F;XGAH@X&8
MTVH?@I.5?ENY@=22(4UN@4:.O#^X@,:+2C**@'B'J2:<@$N#[Y+LA.^F.H7)
MA ZBY7?O@PV>]VFE@A.:KUM3@4^69$TC@,>2%#^#@%F-M3)M@!Z)+2:F@ "$
MJ8PHEP-DK8 >E-!G('-9DM1I@V7?D.AKXU@$CNMN5TH9C.%P]CR@BLUSP"^<
MB+QVWR/,AK=Z8XN.E7ALPG^1_^)]$$E#0U]04D]&24Q%  ,2DVYN8'+!D7=O
M_659CX=QIE>2C8]S9TG"BY=U3#QGB9AW4R^5AZ%YF20.A;5\(8KFD]ITI'[$
MD?!UB7(0D 9V;V2LCB5W85<%C$!X:TE:BF%YD#PIB'UZS2^-AJ-\,B1(A--]
MNXH>DE=\77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^
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MG73KJ5!CZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C
MCDAVV2 BB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET
M;C+=D4]VO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TAT
MF"-VK3U?E"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQY
MN5-6FJ)Z3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C
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M5$LTH(%]=T%DFZA]Q#?.EK!^+B[\D9=^IR<+C'9_-B"%AXU_RFBWK)F#8U\
MJ'J"^547I!6">TL>GV^!_D%/FI^!ES?4E;"!3"\9D+"!$R=!B[" YB#3ANZ
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M>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!3$'F>^6 \3/N?1> DB<Y?G6
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M@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^*
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MNX;P@6U:A'N"@3A=_&]<@3)A7&)^@41DM54O@5YH($?.@8AKMCKA@<=O?BZ
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M?X^ 'F'[?W" (5:^?TV "DMM?SY_]$ S?U!_[S5I?X1_]2M5?]U__"*U@$V
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MAL*#P%CLA=>#64Z]A-J"UD22@^R"6#JS@Q"!YC%N@D:!@RBR@;V!'"%Q@5&
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MBG!\L#7_B')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6>
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M6,2$#WX37(N#FF^C8%Z#%6#H9&:"D5(9:+:"&$.Z;4F!IC7K<BN!-"EY=SB
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M?;A^I2'9?RQ_5VYF='B!?F3P=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@.
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MC8U^>D,?C!)^H3O]BC5^NC3YB$5^]"XXAG5_12@XA+I_JB+=@U!__QZ.@CJ
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M;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F
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M6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6 Q"V =4R M"2A>>2
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MWRQ;@@)O."2J@K%SWAY2@W%XI6!#?!U>D%@,?.%AGD^$?9!DN4:/?BYG[#V
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M?"8H@)9_T2&:@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0     #!"$
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M=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J^KX<*-;=#B/
M\!0_K/T>5YSP+6J/Y3YYAMY.@X'87XM_U&N0>M%PE'?/=)=USG>8<\UYFG+-
M>YMQS'V;<,M_G&_+@)UORX"=;\N G6_+@)UORX"=;\N G6_+@)UORX"=;\N
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MV9&4GMF1E)[9D92>V9&4GMF1E)[9_Z0X*O^@14#_H4I3^Z9(8O*K2''HKTB
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M@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
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MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
M95'T@&51](!E4?2 95'T@&51](!E_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@
M]9AA;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)
M=Z6OR'6IL,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%U
MN[+!=;NRP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA
M;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6O
MR'6IL,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!
M=;NRP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5
M:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6I
ML,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR
MP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GE
MDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=T
MKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[
MLL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$
MWX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=TKK''
M<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%U
MN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$WX]\
MCMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=TKK''<[.R
MQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!
M=;NR_Y8S%/^50R7_DU$W_Y=31?^95E+]F5M@]9A@;>V69WGEDW&$WY![CMJ-
MA);5B(J<T820HL^ E:;,?9FIRWN=K,EYH:[(=Z6OR':JL<=TKK+'<[2RQ'2Z
MLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JR
M_Y8S%/^60R7_E5 W_YE11/^;5%+^G%A?]9M=;.V99'CFEFR#WY-VC=J/@);4
MC(B=T8>.H\V#DZC+@)BKR7V<KLAZH;'&>*6RQG>JM,5UL+7%=+BUO7>XM;AW
MN+6X=[BUN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BU_Y<S
M%/^60R7_EDXW_YI/1/^=4E'^GE5>]IY::NZ<8';GFF>"X)9RC-J2>Y74CH2=
MT(J+H\V&D:G*@I:MR'Z;L,9[H+/%>::UQ'>LML-VL[>^=[>WMWBVN+)YMKBR
M>;:XLGFVN+)YMKBR>;:XLGFVN+)YMKBR>;:XLGFVN+)YMKBR>;:X_Y@S%/^7
M0R7_ETTW_YM-0_^?4%#_H%-=]Z!8:>^?777HG62 X9INB]N6=Y35D8"<T(Z)
MH\R)CZG)A)6NQX":LL5]H+7#>J>WPGBNN<!WM;FX>+6YL7FUN:QZM;FL>K6Y
MK'JUN:QZM;FL>K6YK'JUN:QZM;FL>K6YK'JUN:QZM;FL>K6Y_Y@S%/^80R7_
MF$PV_YQ,0_^@3D__HE%<^*-5:/"B6W3IH6%_XIYJB=R:<Y/6E7R;T9&%H\R,
MC*G)AY.OQH*9L\-^H+?">JBYP7BQN[EXL[RQ>;.[JWJTNZ=[M;JG>[6ZIWNU
MNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6Z_YDS%/^80R7_F4LV
M_YY+0O^A3$[_I$];^:539O&E6'+JI%Y]XZ)FA]V><)'7F7B9TI6!H<V/B:G)
MBI&OQ8.8M,)_G[B]?*>[NGJPO;)ZLKZK>[*]IGRSO*-]M+JC?;2ZHWVTNJ-]
MM+JC?;2ZHWVTNJ-]M+JC?;2ZHWVTNJ-]M+JC?;2Z_YDS%/^80R;_F4HV_Y]*
M0O^C2T[_IDY9^JA19?*H5G#KJ%Q[Y:=BA=^C;([9GW67TYI^G\V3AJC%C8VO
MOX>4M;F#G+FU?Z.\L7VLOJQ\L;^E?+&_H7ZSO9Y^M+N>?K2[GGZTNYY^M+N>
M?K2[GGZTNYY^M+N>?K2[GGZTNYY^M+N>?K2[_YDS%/^90R;_FDDU_Z!(0?^D
M24W_ITQ8^JI09/.K5&[MK%IYYJQ@@N"J:8O:IG.4SY]\G<:7@ZB^D(JPN(N1
MMK*&F+JM@Z"]J8&HOZ6 L,"??[# G("RO9J!L[N:@;.[FH&SNYJ!L[N:@;.[
MFH&SNYJ!L[N:@;.[FH&SNYJ!L[N:@;.[_YHS%/^90R;_FT@U_Z%'0?^E2$S_
MJ4I7^ZQ.8O6O4FSNL%AVZ+%>?]^P:(C5K'20RJ-ZG<";@:BXE(>PL8^.MJN*
ME;NFAYV^HH6EP)^$K\&9@:_!EX*ROI6#L[R5@[.\E8.SO)6#L[R5@[.\E8.S
MO)6#L[R5@[.\E8.SO)6#L[R5@[.\_YHS%/^90R;_G$<U_Z)&0/^G1TO_JTE6
M_:],8/:R46KNM%=SY;=>?-VV:H//KW*0Q:9XG;N>?J>RF(6PJY.+MJ6.D[N?
MBYJ^FXFBP9B(K,*3A:_"DH:QOY&&L[R1AK.\D8:SO)&&L[R1AK.\D8:SO)&&
ML[R1AK.\D8:SO)&&L[R1AK.\_YHS%/^90B;_G$8T_Z-%0/^H14K_K4=5_K%*
M7_6U4&CKN59PX[U>=]F[:H#+LG"0P*EVG;:B?*>MG(*OI9>)MIZ3D+N9CYB^
ME(V@P9&,J<*-BJ["C8FQOXV)LKV-B;*]C8FRO8V)LKV-B;*]C8FRO8V)LKV-
MB;*]C8FRO8V)LKV-B;*]_YLS%/^:0B;_G44T_Z1$/_^J1$G_KT53_+1)7?*Y
M3V7IOE9LX<-@<M.^:8#&M6Z/NZUTG+"F>J>GH("OGYN&M9B7CKN3E96^CI*=
MP8J2I\*(D*["B(ZPP(B-LKV(C;*]B(VRO8B-LKV(C;*]B(VRO8B-LKV(C;*]
MB(VRO8B-LKV(C;*]_YLS%/^:0B;_GD0S_Z5"/O^K0DC_L412^K=(6O"]3F'F
MQ%9GWLEB;<[!9W_!N6V.MK%RFZNJ>*:BI7ZNF:"$M9*=B[J,FI.^AYB;P(27
MI,*"EJ_"@Y.PP(21LKZ$D;*^A)&ROH21LKZ$D;*^A)&ROH21LKZ$D;*^A)&R
MOH21LKZ$D;*^_YLS%/^:02;_GT(S_Z9 /?^M0$?_M$)/][M'5^W#35WDS%A@
MV<U@;,G%9GZ\O6N-L+5QFJ6O=J6<JGRMDZ:"M(RBB;F&H)"]@9Z9OWV>HL%[
MGJ_!?9FPP'^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6
MLKY_EK*^_YPS%/^:02;_H$$R_Z@_//^P/D7_MT%-],!%4^K)3E;BU5I7TM%>
M:\3)9'VVP6J,JKMOF9^U=*26L'JLC:R LH:IA[=_IXZ[>J:6OG>EH+]TIJV_
M=Z&QOWJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZ
MG;*^_YTS%/^;02;_HC\Q_ZH\.O^S/$+[NSY)\,9$3>;23TW<W%=6S-5=:K[-
M8WNPQVB+I,%MEYF\<Z*/N'BJAK1^L'^RA;5YL(RX=*^5NW&NG[QNKZN]<:JS
MO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\
M_YTS%/^;0";_I#PP_ZTY./^V.3_UP3Q#Z<Y$1-[=34?2X%-8Q=M<:+?387JI
MS6:)G,AKE9'$<9^(P':G?[U]K7B[A+%SNHNT;[B4MVRWG;AJMZBY:;:VN&VO
MM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y_YXR
M%/^=/B7_ISDN_[$V-?N\-CKMR3H\X-I$.M+B1TS'XDU>N=Y4;JS96WR?U&*(
ME-!HDXK,;YN"QW>B?,-^J'; A*QROHJO;[R1L6V\F+)KNZ&S:KNMLF>ZMK1G
MNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T_Y\R%/^@
M.B3_JC0L_[4R,?/#,C/CU#@PT^$\/\;H0E*YY4ACK.)-<I_?5'^3V5V*B=)G
MDX/-<)I]R7>?>,9]I'3$@Z=PPHBI;L&.JVS E*QJOYNM:;^EK6B_KJUHOZZM
M:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM_Z P%/^C-B+_
MKS H^[PM*^C-+"C5X# PQ^DX1+GL/E>LZ45GGN=+=9+@4X")V5Z)@M1HD7S0
M<99XS'>;=,I]GG#(@J%NQX>C:\6+I6G$D*9HQ):G9L.>J&7#I:AEPZ6H9<.E
MJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H_Z$O%/^H+Q__M2HB
M\,8D(=C=(R#(Z2TUNO(U2:SQ/%J>\$-IDNA,=8CA57^!VV&'>]=JC7;3<9%R
MT7>5;\]\EVS-@)IJS(6;:,N)G6;*C9YER9*?8\F8H&+(GJ%BR)ZA8LB>H6+(
MGJ%BR)ZA8LB>H6+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA_Z,M%/^N*1KXOR :WM88
M$\GH(B6Z]"LZK/@T39[W/%R2\49IB.E0<W_C67MZWV2"=-QKAG#9<8IMUG:-
M:M5[CVC3?Y%FTH.29-&'E&/1BI5AT(^68,^4EU[/F9A>SYF87L^9F%[/F9A>
MSYF87L^9F%[/F9A>SYF87L^9F%[/F9A>SYF8_Z<H$O^W'Q+FSA$-R^85%KOT
M(2JL_BL^GO\T3I+Z/UR(\DIF?^Q5;WGH7G5RY&1[;N%K?FK?<(%HWG6$9=QY
MA6/;?8=BVH&(8-J$B5_9AXI=V(N+7->0C%O6E(U;UI2-6]:4C5O6E(U;UI2-
M6]:4C5O6E(U;UI2-6]:4C5O6E(U;UI2-_[ >"^W&#@C-VPL(N_,5&JS_(2Z>
M_RP_DO\W38?]1%A_]D]A>/%9:''M7VUJZV1Q9^AJ=&3G;W=BY71Y8.1X>E_C
M>WM=XWY\7.*!?5OAA'Y:X8A_6>",@%C@CX%8X(^!6."/@5C@CX%8X(^!6."/
M@5C@CX%8X(^!6."/@5C@CX%8X(^!\[T-!,S/"0&]Y0P,K/\7'I[_)"^2_R\]
MA_\]27__25)X_%1:</A:7VGT7V1D\F5G8?!J:5[O;FM<[G)M6^UV;EKL>6]8
M['QP5^M^<%;K@7%5ZH1R5.J(<U/IBW13Z8MT4^F+=%/IBW13Z8MT4^F+=%/I
MBW13Z8MT4^F+=%/IBW13Z8MTS,8( +W4" .M]0X/G_\:'Y/_)RV(_S0Y?O]"
M0W?_34IN_U-09_]956+\7EA>^V1;6_EH75GX;%Y7]W!@5O=S857V=F)4]7AB
M4_5[8U+T?611](!D4/.#94_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF9/
M\X9F3_.&9D_SAF9/\X9FO<L& *[;!@2?_Q 0D_\='8C_*BA^_S@R=O]$.FW_
M2T%E_U%&7_]725O_74Q8_V).5?]F4%/_:E%2_VU24/]P4T__<E1._W543?]W
M54W_>55,_GM62_Y^5TK]@5=*_8%72OV!5TK]@5=*_8%72OV!5TK]@5=*_8%7
M2OV!5TK]@5=*_8%7_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOO
MC7)VZ8E\?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)M
MLZ'1;+FBT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&
MHLANQJ+(;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)V
MZ8E\?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1
M;+FBT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLAN
MQJ+(;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)VZ8E\
M?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FB
MT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(
M;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)VZ8E\?^2%
MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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MDIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/
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M0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN>&Q7[7QN5>R
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M/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0  )S2  "/YP(
MAO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_'DS_1B%(_TTC1?]2)4+_5R=
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M,:#,4C^5R5E,B\5@5X+#9F!ZP&QG<[YS;6R\>G-GNX)W8KJ*>UZYE'Y:N)^
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M5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0
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MC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^
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M8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8
MPK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%C
MX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??
M\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,%
M *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1
M5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5)
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M/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP
MF,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+
M_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_
MOC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](
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M)P/UE2X%ZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW>
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M=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0;
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M2T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$
ML[,! *F] @"?QP4 EM() ([:$@"(VR0"@-HR"'C9/A!QV$@8:M=0'V366"5?
MU5\J6]1G+U?4;C-3TW8V4--_.4S3B#M*TY0^1].@/T74KD!$U+]!0]780$33
M[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@  ,.E  "UK@  J;@
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M)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT  'G:  !P\@@
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M O]X* /_?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5
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M5%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@(
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M.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@,
M@L\' 'C9"P!SWA@ ;MXF FC>,P5BWCX*7=Y(#UG>4!15WE@74=Y@&T[>9QY+
MW6\@2-YX(T;>@25#WHPG0=Z8*3_>IBH^W[4J/>#(*CW?XRH\W?$K.]S[+3K<
M_2XZW/TN.MS]+CK<_2XZW/TNP)\  +&G  "DL   F+H  (W#  "!S0( =M<'
M &[H#P!IZ!L!8^@G E[I,@58Z3L(5.E$#$_J3 ],ZE,22>I;%4;J8A=$ZVH9
M0>MR&S_K>QT\ZX8>.NR1(#CLGB$W[:PB-NV[(S7NSR,T[N8C-.OU(S3K^",T
MZ_@C-.OX(S3K^",TZ_@CLZ4  *:M  "9MP  C<$  (#+  !UU0$ :>$& &3S
M$0!>\QP!6?0F E3T, 1/]3@&2_5 "$?V1PI$]DX,0?=5#C_W7 \\]V,1.OAJ
M$S?X<Q0U^'T6,_F(%S'YE!@O^J$9+OJO&BW[OAHL^\\;*_OG&RO[ZQLK^^L;
M*_OK&RO[ZQLK^^L;J*H  )JT  "-OP  @,D  '33  !GW@  7O(( %G^$0!3
M_QH!3O\C DG_*P-%_S,$0?\Z!3[_008[_T<'./]."#7_5 DS_UH),?]A"B__
M:0LL_W(,*O]]#2C_B XF_Y4/)?^A$"3_KA$C_[H2(O_*$B+_T!(B_] 2(O_0
M$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP  4_T& $W_#@!(_Q8
M0_\> 3__)@(Z_RT"-_\S S/_.0,P_S\$+O]$!"O_2@4I_U %)_]6!B3_708B
M_V4'(/]N!QW_>0@;_X4(&O^2"1G_G@D8_Z@)%_^S"1?_MPD7_[<)%_^W"1?_
MMPD7_[<)D+H  (+%  !TT   9]P  %CC  !-\   1_\" $+_#  \_Q$ ./\8
M 33_'P$P_R4!+/\K BG_, (E_S4"(_\Z B#_/P,>_T0#'/]) QG_3P,7_U8$
M%?]>!!+_: 01_W(%#_]^!0[_B@4._Y0%#?^>!0W_H@4-_Z(%#?^B!0W_H@4-
M_Z(%_SDO O\\, /_03$#_T0T!/]$.@;_1$4(_T51#/]#71'_06D6_SYV&?\\
M@1S_.HP>_SF6(/\XGB'_-Z4C_S>K(_\VLB3_-KDE_S; )?\URB;_-=<F_S7E
M)O\U[R;_-?@F_S;_)OXV_R;\-O\F_#;_)_HV_RCZ-O\H^C;_*/HV_RCZ-O\H
M_SDO O\^+P/_1"\#_T8R!/](. ;_2$,(_TA/#?]'6Q+_1&<6_T)S&O\_?QW_
M/8H?_SR3(?\[FR/_.J(D_SFI)?\YL";_.+8F_SB^)_\XQR?_.-,H_SCC*/\X
M[2C^./<H^SC^)_DY_R?X./\I^#C_*O8X_RKV./\J]CC_*O8X_RKV./\J_SHO
M O]!+ /_1BP#_THO!/],-P7_34$(_TQ,#?]+6!+_2&07_T9P&_]#?![_08<@
M_S^0(_\^F"3_/: E_SVF)O\\K2?_/+0H_SN[*?\[Q"G_.\\I_CO@*OL[ZRKX
M._4I]CS^*?0\_RKS._\K\CO_+.\[_RWO._\M[SO_+>\[_RWO._\M_SPM O]$
M*0+_2BD#_TXL!/]1- 7_4CX(_U)*#?]051+_36$7_TIM&_](>!__18,B_T.-
M)/]"E2;_09TG_T"C*/] JBG^/[$J_3^X*_P_P2OZ/\LK]S_<+/4_Z2SQ/_0K
M[S_]+.T__RWL/O\OZS[_,.<__S#G/_\PYS__,.<__S#G/_\P_T J O]()@+_
M3B8#_U(I _]6,@7_5SP'_U='#/]541+_4ET7_U!I'/]-="#_2G\C_4B))OM'
MD2CZ1IDI^$6@*O=$IROU1*TL]$.U+?-#O2WR0\@N\$/7+NQ#YR[I1/,MYD/\
M,.1"_S'C0O\RX4+_,]Q#_S3<0_\TW$/_--Q#_S3<0_\T_T,G O]+(P+_4B("
M_U@G _]<+P3_73D'_UY##/];3A'_6%@7_E5D'/I2;R#W4'HD]$V$)_),C2GP
M2I4K[TF<+>U)HR[L2*HOZD>Q+^E'NC#G1\4PYD?2,.)(Y3#?1_(RVT?[--A&
M_S751O\VTD;_-\U(_S?-2/\WS4C_-\U(_S?-2/\W_T8D O]/( +_5A\"_UTD
M _]A+ 3_8S4&_V1 "_]B2A#Z7E06]5M?'/%8:R#N574EZU-_*.A1B"OF3Y$M
MY$Z8+^)-H##A3*<QWTRN,MU+MS/;2\(TV4K/-=5+Y#702_ VS4K[.,I*_SK(
M2O\ZQDO_.\%,_SO!3/\[P4S_.\%,_SO!3/\[_THA O]3'0+_6QP"_V(B O]G
M*0/_:3(%_VH\"?EH1@_R95 5[6%;&NA>9B#D6W$EX5A[*=Y6A"S;5(POV%*4
M,M11FS324*,UT$^J-\Y.LCC,3KPYRD[).LA.W3K$3^T[P4[Y/;Y._SV\3O\^
MND__/K90_SZV4/\^ME#_/K90_SZV4/\^_TT> O]6&@'_7QH!_V<@ O]L)@+_
M;RX$^7 X!_)O0@SK;$L2Y6E7&=]E8A_:86PEU%UV*M!;?B_-68<RRE>/-<A6
MEC?&5)TYQ%.E.\%3K3R_4K<^O5+#/[Q2TS^Y4N@_M5+V0;-2_T&Q4_]!KU/_
M0:Q4_T&L5/]!K%3_0:Q4_T&L5/]!_U < ?]:%P'_9!@!_VP= ?]Q(P+]=2H#
M\W8S!>MV/0KC<T</W&]3%]1K7A_.9F<FRF-Q*\9@>3#"7H$TOUR)-[U:D3JZ
M69@\N%B@/K97J$"T5K)"LE:]0[!5S$.M5N-$JU;S1*A7_D2G5_]$I5C_1*)8
M_T2B6/]$HEC_1*)8_T2B6/]$_U,9 ?]=% '_:!8!_W : ?]V( 'W>B8"[7PN
M ^1\. ?<>D0-TG5/%LMP6A[&;&,FP6AL++UF=3&Y8WTUMF&$.;-?C#RP790_
MKER;0:M;I$.I6JU%IUJX1J59QT>C6MY'H5KO1Y];_$>=6_]'FUS_1II<_T::
M7/]&FES_1II<_T::7/]&_U47 ?]@$@'_:Q0!_W07 /]Z' 'R?R(!YX$I MZ"
M,P33?T ,RWI,%<1V5AZ^<6 EN6YH++1K<3*Q:'DVK6: .JIDB#VG8H] I6"7
M0Z)?H$6?7JE'G5ZT29M=PDJ97=9*EU[L2I9?^DF57_])DV#_2))@_T>28/]'
MDF#_1Y)@_T>28/]'_U@5 ?]C$0'_;A( _W<5 /M^& #M@QT XH<C =:'+@/,
M@ST+Q7])%+U[4QVW=ETELG-E+*UO;3*I;74WIFI\.Z)HA#Z?9HQ!G&641)EC
MG$>78J9)E&*P2Y)AODR08=!,CV+H3(YC^$N-8_]*C&3_28MD_TF+9/])BV3_
M28MD_TF+9/])_UH3 ?]F$ #_<1$ _WH2 />"% #HAQ< W8L< -"++ /'B#L*
MOX1'$[A_41RQ>UHDK'=B*Z=T:C&C<7(VGV]Y.YMM@#^8:XA"E6F019)HF4B/
M9J)*C&:M3(IENDV(9<Q.AV;F3H9G]DR&9_]+A6C_2X1H_TJ$:/]*A&C_2H1H
M_TJ$:/]*_UP2 ?]H#P#_=!  _WT0 /.%$ #DBQ$ UH\7 ,N.*@+"C#@)NHA$
M$K.$3QNL?U@CIWQ@*Z%X:#&==6\VF7-V.Y5Q?3^2;X5"CFV-18MLEDB(:Z!+
MA6JJ38-IMTZ!:<A/@&KC3X!K]$Y_:_],?VO_2W]K_TM_:_]+?VO_2W]K_TM_
M:_]+_UX0 ?]K#@#_=@X ^X - .J(#0#;CPP T)(5 ,>2)P*^CS8(MHQ"$:Z(
M31JHA%8BHH!>*IQ]93"7>FPUDW=S.H]U>SZ,<X)"B'*+1H5PDTF";YU,?VZH
M3GUNM4][;<90>F[@4'EO\DYY;_Y->6__3'EO_TMY;_]+>6__2WEO_TMY;_]+
M_V / /]M#0#_>0P [H,+ -N+"0#4D0H S)43 ,*5)0*YDS0'L8]!$*J,2QFC
MB%0AG81<*9>!8R^2?FHUCGQQ.8IZ>#V&>(!"@W:(17]UD4E\<YM,>7*F3G9R
MLU!U<L-0<W+=4'1S\$]T<_U-='/_3'1S_TQT<_],='/_3'1S_TQT<_],_V(.
M /]O# #\>PH WH8& -6." #/E D QY@1 +Z8(P&UEC(&K9,_#Z:021B?C%(@
MF(E:*).&82Z.@V@TB8%O.85_=CV!?7Y!?7N&17IYCTEV>)E,<W>D3G%WL5!O
M=L%0;G?94&YW[T]N=_Q.;G?_36]W_TQO=_],;W?_3&]W_TQO=_],_V0- /]R
M"@#P?@8 VH@% -"0!P#*EP@ PIL0 +F;(0&QFC &J9<]#J&41Q>:D5 ?E(U8
M)XZ+7RV)B&8SA(9M.("$=#U[@GM!>("$171_C4AQ?9=+;7RB3FM\KT]I>[Y0
M:'S54&A\[4]I?/M.:7S_36I[_TQJ>_],:GO_3&I[_TQJ>_],_V8* /]U" #A
M@0( U(L% ,N3!@#$F@8 O9X. +6?'P&LGBX%I)L[#)V81166E4X>CY-6)8F0
M72R$CF0R?XMK-WJ*<CQVB'E <H:!1&^%BD=K@Y5*:(*@366!K$YC@;Q/8H'1
M3V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $
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M1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0
MF;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUFM%HB8K-A)EZR:"M:
ML6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>NXSQ&K?,]1JO^/D6K
M_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0  *6K  ":L@  D+H!
M (;!"0"!PA@ >\(H G7"-09OP4 ,:<!)$F2_41=?OE@<6[Y?(%>]9B14O&XG
M4;QV*DV[?RU*NXHP2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S=
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M(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X# &76!P!=XPX
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M<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@
M 'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL ,/\0 "S_%@ I_QP
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M17!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@
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M0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF
MIYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQH
MD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)
M_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(
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M-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(  'RY @!VNA$
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ME TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*
M )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8 1>D/ $+I&0! ZB0
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M @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0
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M_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'+ +_1S8#_T9
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M.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0
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M-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P  +^! 0"WA0$
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M,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD  (^;"P"*G1@
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MEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8
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M!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0
M?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ N
MYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWK
ML@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT
M &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL
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M1V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI
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M)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0
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M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @#
M< 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC
M<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__
M+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P(
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M+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(  )F##@"4A!T
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MF"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\
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M%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@
MEYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(
MN$,"1KA+ T2X4@1!N%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*W
MP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(
M (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL 0,,G #_#,@ ^Q#P
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M 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@
M2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4
M[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GV
MV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](
M #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D
M"OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP
M_\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A
M   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C
M  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(
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M$ZX\\12K//T5J3S_%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H
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M((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0
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M)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U6/\A_TT  .57  #37P
MR&0  +]G  "W:   L6<' *EH% "C:20 GF@R 9EG/02494<'D&1/"HQB5PV(
M85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:
MU25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<
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M)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$:P  N7$  +!U  "G=P
MGG4  )9V#0"0=QD BW@G (9W,P*!=CT$?'5&!WAS3@MU<E4.<7%<$6YP8Q1K
M;VH6:6YQ&69N>AQC;8,>86R.(5]KFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ
M_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D
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MA1  >88> '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5>
M<QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_
M($M[_R!+>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X
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M'0!;GBD 6)XT 56>/0)2G44#4)U-!4V=5 =+G%L)2)QC"T:<:PU#FW4/09N
M$3Z:C1,\FIL4.IJK%3F:O14YFMD5.9CO%CF7_!8XEO\7.)7_%SB5_Q<XE?\7
MNWH  *^%  "DC   F)$  (V5  "!F@  =9T  &B@  !;I   5J4, %.F%P!1
MIR, 3Z<O $RG. %*IT$!2*=) D:G4 1#IU@%0:=?!C^F: @]IG(*.J9]"SBF
MB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((
M *B,  "=D@  DI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P
M1+$G $*Q,@!!LCL /[)# 3VR2P$[LE,".;); S>R9 0ULFX%,[)Y!C&RAP<O
ML98(+K*F""VRN DLLM (++#L"2NO^0HKKO\+*JW_"RJM_PLJK?\+K8L  *"2
M  "5F   B9T  'VC  !QJ   9*T  %FQ  !-M   0K@  #NZ"@ XNQ, -[P>
M #6\*0 TO3( ,[T[ #*]1  QODP +[Y5 2Z^7@$LOF@!*KYT BF^@@(GOY$#
M)K^B R2_M ,CO\L#([[H R.\]P0BN_\%(KO_!2*[_P4BN_\%I)(  )B8  ",
MG@  @*4  '.K  !GL   6[4  $^Y  !$O   .L   ##$!  JQPL *,@3 "?)
M'0 FR2< )<DP "3*.0 CRD( (LM+ "'+50 @S%\ '\QL !W->@ <S8H &\V<
M !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@
M=:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5
MV!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@
MI  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4
M %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ(
M#>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE
MZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%
M  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82
M  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4
M />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   W
MT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^
M$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2
M  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H
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M.[P/H#O-#YX[YA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]
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M%HI%W!:(1O 6AD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P
MSU,  ,95  # 4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B6
M3F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*
MUAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@
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M&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K90
MHV(  )QB#@"68QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==9 UU
M7&L0<UQR$G!;>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV'&5:
M_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4
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M&E=F_QI79O\:VUD  ,=B  "Z:@  KW   *9S  ":<P  CW   (=Q!0"!<A$
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MC!-$@9H50H"I%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH
M +5U  "J?0  GX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB<
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M""Z@LP@NH,D(+I_G""V=]PDMG/\*+9O_"BV;_PHMF_\*KX   *.)  "7C@
MC9,  '^5  !RF   9IP  %N@  !/I   1:<  #ZI#  \JA0 .JH? #FJ*0 X
MJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $OK&8"+:QQ BNL?P,JK(X#**R>!">L
ML 0FK,4$)JOD R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D
M 'B>  !KH@  7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD
M*K8R "FW.@ HMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<
MN< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF
M  !BJP  5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F
M !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D
M#\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8
MM   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1
M(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7
M  '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0
M/\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !
MWB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #E
MP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@
M "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8
M .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0
M]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6
M   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2
M  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8
M /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_
M %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L
MK #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_
M .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D
M_P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S
M ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&
M_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@
M /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X
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M /\E"P#_* P _RD0 /\H%@#^)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4
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M!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<,?\(_S   /\U  #O.
MXCH  -LY! #6-0D SC03 ,8V(@"_.#$ NC@_ +8X2@&S.%0!L#== JTW9 *K
M-FP#J39S!*@V>02F-8 %I#6'!:,UCP:A-9<'GS6@!YXUJ@B<-;8(FS7%"9DU
MW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(
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M$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\  -])  #-3P  P5,  +A4  "Q4@
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M$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=80  E5T  (U>"0"'7A,
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MC1%/9YH23F>I%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H
M +QC  "P:@  I6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P
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M#CQ[LPX\>\@./'KF#CQY]PX\>/\./'C_#CUW_PX]=_\.O&@  *]R  "D>0
MEGH  (AZ  !\>@  <'P  &-_  !<@@  5X0+ %.%% !1AB  3X8J $Z'- !,
MASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1 AFP&/H5V!SN%@P@YA9$*.(2@"S:$
ML0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X
M (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@
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M 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$  &^4  !CF
M5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$ (+ I !^P,0 >
ML#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.Q
MZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@
M $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X
M$+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (
MOO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV
M   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL
M  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(
M ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   F
MP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7
M*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>
M  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP
M$\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@
MYB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #N
MQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L
M  />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH
M /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP
M_J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\
M;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U
M /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\
M_Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#]
M ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H
MN@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48
M /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\
M\@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #?
M ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5
M$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R
M .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L
MT ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_
M& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-
M=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/
M ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@
M_Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)
M%'< QQ5] ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8
MX@"S&?(!L1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0'
M /<A# #L'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\'W$
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M!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT  ,8\  # -P(
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M"FM&_PIK1O\*Y4   ,])  #!3P  M5(  *M2  "A3P  FTH  )1*# "/2Q<
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MC0M95)H-6%2G#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T
M ,!6  "S7   IUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX
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M#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)8/\+Q%@  +5@  "J9@
MFV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H&@!=:24 6VHO %EJ. !7
M:D !56I' 5-J3@)1:E4#3VE=!$UI9 5+:6T&26AX!T=HA E&:)(*1&>A"T-G
ML0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD
M (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T
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M<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C $5_+ !#@#4 0H ] $&
M10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$,G^:!3%^J@8P?KT&,'[:
M!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4=0  AG4  'EV  !N=P
M8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R()P [B3  .HDX #B)0  W
MB4@ -HE/ #2)6 $SB6$!,8EL 2^)> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&
M[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$
M %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$
M+)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@
MD/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.
M  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y"
M "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/<
M%IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \
MG   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J
M0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\
M  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP
M*ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 '
MMT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U
M]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4
M !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD
M ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@
MQ.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"
M   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X
M  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T
M>Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "
MT    -0   #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E
M-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@
M &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0
M .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P
M]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'
M&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![
M /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,,
M[ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_
M 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /,
M?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#,
M .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A
M_P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H
M '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -(
MW0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2
M /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L
MVP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#%
M .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.
M% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\
M ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D
MMPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R
M#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-
M?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z
M *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X
MV0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q
M%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;
M_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1
M ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I'V8 J!]L *8?<P"E'WD
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M WPQ_P-\,?\#[2\  -LW  #)/0  OCX  +,\  "L.   IS,$ *(R$0"=-!T
MF34J )4U-0"2-4  CS5) (TU4 "+-5< B35> 8<U9 &%-&L!A#1R H(T>0*
M-(("?C2+ WTTE@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W
M_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF
M (T[,0"*.SL ASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#
M=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L
M//\%XCD  ,Q"  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5
M+0""0#< ?T!  'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$
M!&P_D 5K/YP&:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%
MW#X  ,=&  "Y2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![
M130 >44] '9%10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#
MC09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$
M ,-)  "V3@  IT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23
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M"%%0L0E04,0)4%#A"5!0] A14/\'44__!U%/_P913_\&R4L  +E3  "K5P
MG%8  (]5  "%5   ?%   '51  !P4@D :U,2 &A4'0!E5"< 8E0Q &!4.0!>
M5$$ 7%1( 5I43P%95%8!5U1= E9490-45&X$4E1X!5%4A 9/5)$'3E2@"$Q4
MKPA,5,()2U3?"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D
M (M8  "!5P  =U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\
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M!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D  *MA  ":80  BV$  ']A  !T80
M:6$  %]B  !99   5&8) %%G$0!.9QH 3&@D $MI+0!):38 2&D^ $9J10!%
M:DP 0VI4 4)J7 % :64"/FEO CQI>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H
M[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8
M %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D
M/7%1 #QQ60$Z<6(!.'%L C9P> (U<(8#,W"5 S)PI@0Q<+@$,'#0!#%O[ 0Q
M;OL$,6W_!#%L_P0Q;/\$KV0  *%I  "/:   @6@  '5I  !K:0  8&L  %5N
M  !-<0  1G,  $)U"P _=A( /7<< #QW)0 Z>"T .7@U #AY/0 W>44 -GE-
M #5Y50 S>5X ,7EH 3!Y= $N>8,"+7F2 BMXHP(J>+4"*GC, BIWZ@(J=OD#
M*G7_ RIT_P,J=/\#JFH  )IM  ");   ?&T  '!M  !F;@  6W$  %!U  !(
M>   07L  #I^!0 V?PX -( 6 #.!(  R@2@ ,($P "^".  N@D  +8)( "R"
M4  K@EH *H)D "B"<  F@G\!)8*/ 22"H $C@K(!(H+) 2*!YP$B?_<!(G[_
M B)]_P(B??\"I7$  )-Q  "#<0  =G$  &QR  !@=0  5G@  $Q\  !#@
M.X,  #.&   MB0H *HH1 "F+&0 GBR( )HLJ "6,,0 DC#D (XQ" "*-2@ A
MC50 ((U> !^-:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(
M_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P
M "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T
M%9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0
ME/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::
M   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10
M  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L
MC8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7
MJ   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P
M4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD
M 'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M
M"[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2
MOE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5
M  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(
M  #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD
M ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;
MIP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0
M    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+
M  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@
M1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?
MWP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T
M30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8
M /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (,
M]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G
M /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\
M'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$
M .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P
MV #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_
M "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .
MA0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U
M ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "
M\0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #.
M (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L
M_0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E
M .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($
MP "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N
M O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#
M*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:#
M +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\
MH0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@#
M##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</
MA0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_
M )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD
ML!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9
M%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<
M_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO
M *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".((0
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MCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(
M ,DY  "[/@  K#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4
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M UL_KP1:/\$$6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2
MG$<  )%&  "(1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F
M0D, 9$)* &-!4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#
MK0150[\$5$/:!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H
M (U)  "#1P  ?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\
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M!$9/[01&3OP$1D[_ T=._P-'3O\#O4P  *Y2  "<40  C5$  (%1  !W4
M;DP  &=.  !B3P  75 - %I0% !741X 55$G %-1, !14C@ 4%(_ $Y21@!-
M4DT 3%-5 $I370%)4V4!2%-O D93>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3
M[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$
M &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL
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M C)@_P(R8/\"KEP  )M=  "*70  ?%T  '!=  !F70  7%X  %)@  !,8@
M164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L .&DR #=J.@ V:D$ -6I) #1J4@ S
M:EL ,6IE #!J< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG
M_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L
M #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E<
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M8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X
M (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@
M&HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,
MD6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS
M  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<
M  Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(
M )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H
M>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF
M!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH
M  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA
M58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R
MLP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X
M;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8
M $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@
M +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@
MR74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK
M   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P
M  #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<
M .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   D
MO   &+\  !##   (QP   ,H   #-    T0   -4   #8    V0   -L   #=
M    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K
M  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P
M_P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q
M (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .(
M_P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T
M /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H
MY0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1
M /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0
M.P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+
M -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\
MP0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C
M $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4
MC ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_
M +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L
MS0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U
M (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8
M_P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^
M +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D
MIP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9
M!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %
M0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF.
M )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\
M]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B
M#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1
ME "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H
M -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX
ME!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!
M&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I
M  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y!
M (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9<
M=2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W
M,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF
M1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\HB !N*)0 ;"BA
M &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\  ,(V  "O-@
MH34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\ =RPX '4L0 !S
M+$< <2Q- ' L5 !N+%H ;2QA &LM: !J+7  :"UZ &<NA0!E+I$!9"Z> 6(O
MK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH
M ) X  ")-0  @S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4,
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M DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,  ()"  !Z0
M<ST  &T\  !H/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4
M/TT 4S]5 %) 7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"
MZ ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T
M &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL
M3D-2 $U$6@!,1&, 2D1M 4E%> %(184!1T64 45%HP)%1K0"1$;) D1&YP)$
M1?@"1$7_ D5%_P)%1?\!ND8  *9(  "42   AD@  'M'  !R1@  :D(  &-#
M  !>1   6D4+ %9%$@!41AL 448C $]&*P!.1C, 3$<Z $M'00!*1TD 24A0
M $A(6 !'2&$ 1DEK $1)=@%#28,!0DF2 4%)H@) 2;,"/TK' C]*Y0(_2?<"
M0$G_ D!(_P) 2/\!MDD  *)*  "12@  @TH  '=*  !N20  944  %Y'  !9
M2   54D( %%*$ !/2A@ 3$HA $I+*0!)2S$ 1TLX $9,/P!%3$8 1$Q. $--
M5@!"35\ 04UH $!-= $^38$!/4V0 3Q-H $[3K$".D[& CI.Y ([3?8".TW_
M 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J3   8$H  %E+  !43
M4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0/0! 440 /U%+ #Y14P ]
M4EP /%)F #I2<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390
M_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(!
M $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH
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M:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@
M (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H
M+&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?
M;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<
M  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(-
M "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X
M%75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O
M80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]
M#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X
M  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90
M868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -
MB0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)
M@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP
M %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP
M I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@
ME8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY
M   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.
M  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0
M **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   X
MBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L
M#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.
M  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0
M)IX  !RC   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y"
MN@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$
MEP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T
M !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8   #'    R00
M ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@
MVYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^
M   $P@   ,4   #)    S0   -    #2    T@   -4   #6    V0   -L
M  #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\
M /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_
M $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L
ME0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_
M -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@
M] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #<
M )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L
M_P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!,
M .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )(
MR0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\
M /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -(
M4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4
M +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\
M_P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_
M %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L
MF "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P
M /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P
MK@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"<
M )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+
M  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!-
M *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D
MC@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*
M%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)
M3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB
M ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0
MKQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "(
M$$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3
MK@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,
M )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH
M?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K
M'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H
M  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+
M '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@
M82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%
M*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E
M30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK*
M %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P
M>2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?
M*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(O
MY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$
M &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT
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M 4(\_P%"._\!LST  )X^  "-/@  ?SX  '4^  !L/0  9CH  & Y  !;.@
M5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$
M/EP 0SYF $(_<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X_
M_P$^/_\!KD   )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX%
M $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH
M/D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y
M0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E#
M# !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A
M #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\
MID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!
M2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,
M:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<
M (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X
M.4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L
M474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*
M  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02
M #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W(
M)5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U
M3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;
M%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^
M !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40
M9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A
M8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5E
MBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8
M %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!,
M%FT: !5M(0 4;2D %&TP !-M.0#_XGT024-#7U!23T9)3$4 !Q(2;D( $6Y,
M !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\
M@ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD  "1L   =
M;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP "7='  AW
M4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "=/P >UT
M &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU   7>0
M$GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()   ""3
M@ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD =&(  &AB
M  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1@P  #88
M  B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".1   CE$
M (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8
M:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP  !I(   "5
M    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7
M  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO  !1<@
M1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *    "B
MHP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L
M70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0
M #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P    L
M +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!  "]4@
MO60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9
M   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_    OP   ,
M  #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #110  TE<
M -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(  "6H   :
MK@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0   ,\   #0
M    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.   Z$H  .E=
M  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_ "8
M_P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K
M (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8 V0#W -@
M_P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L
M /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X >@#= '\
MVP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q ,< _P#&
M /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P [  G .D
M,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_
M ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +< ^P"V /\
MM@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A -4 +0#1
M #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +<
M@ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_
M *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,( )@"_ #$
MO  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G
M ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T F #_ )@
M_P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P "L K0 U
M *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L =0": 'L
MF "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P",
M /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0 H  N )X
M-P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^
M (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\
MZ T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G )( ,0"0
M #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$
MA !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14
M ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C,
M@PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R
M#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>
M  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V
M '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD
M9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?
M)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7
M. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2
M %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*
MBR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C
M'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0B
MG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3+   ABT
M 'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8
M6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,
M**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3   '<O
M  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y
M %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H
M12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K
M,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM
M/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[
M #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F-0
M83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$
M,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HV
MT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C-P  738
M %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT
M/C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V
M.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@  63D  %,V
M  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M"
M #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH
M,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P  $XZ  !)
M.P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #-
M2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y
M "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^  !$/P
M0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M
M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%
M_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _1   .T4
M #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G2DL
M)DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B
M2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2   -TD  #)+
M   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A4$@ (%!2
M !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\
MBD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0   H
M4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A7
M60 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D
M '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6   D60
M'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]* !%?50 0
M7V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.
M  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?7P  &6(!
M !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT
M!V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=
M4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P  $VH   ]M
M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P2@  <%<  '!E
M  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8  &-6  !95@
M45<  $=8   ^6P  -E\  "YB   F9@  'VH  !EM   3<   #G,   MV!  %
M> L  7@/  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z
M<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P
M $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@
M (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':
MAWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI
M   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)
M  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(
M )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K
M>0  (7\  !F$   1B0  #(T   :1    E    )@   ":    FP   )P"  "=
M!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]
M  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP
M&8T  !&2   +EP  !)P   "@    HP   *8   "H    J0   *H   "L
MK00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "X
MB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT
M  RB   #IP   *L   "N    L@   +8   "X    N    +H   "[    O0
M +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@
MS9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q
M    M@   +H   "^    P@   ,8   #(    R    ,H   #+    S0   ,X
M  #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(
M .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #]
M $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0
MBP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_
M ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X
M[ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0
M (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\
M_P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!"
M -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8
MO0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P
M /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,(
M10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"(
M *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\
M_P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O
M $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P
MBP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P
M .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $
MG@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"-
M (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,
M  #! 0  M    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!!
M (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H
M?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R
M#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (,
M0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2
M '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@
MFA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W
M!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)
MG0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@
M (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X
M; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<
M$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=
M  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_
M &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D
M4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P
M(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D7
M00!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX
M $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0
M9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0
M'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,B
MS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<
M %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D
M2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]
M*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H
M  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=#
M $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8
M."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0
M*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL
M2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W
M #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0
M1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U
M,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S
M_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(
M #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P
M+S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J
M-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV
M @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3
M "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\
MC38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R
M.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "-
M6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D
M '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004
M*D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <
M164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]
M  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<*
M "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V(
M%4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A
M00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/
M#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M
M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1
M4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 1
M5PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8
M>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@
M $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P
M"F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P
M8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,
M   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.
M  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8
M &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X
M5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q
M$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..
M  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7
M*F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@
M?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  "
MG0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH
M !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T
M (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0
MCJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\
M   .@0  "(4   ")    C0   )    "2    DP   )0   "6 P  EP@  )@,
M  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(
M )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &
MD    )0   "8    G    )\   "A    H@   *0   "E    IP   *@$  "J
M"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L
M  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP
M *0   "H    K    *\   "Q    L0   +,   "U    M@   +@   "Z
MO 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(
MKP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,
M  "W    O    +\   #!    P@   ,0   #%    QP   ,D   #+    S0
M ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@
MXJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /,
M4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3
M -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\
M_P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@
M %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8
ME@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P
M /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T
MQP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R
M )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T
M  #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!.
M +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0
MH0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>
M    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *(
M30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9
M )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'
MN@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2
M $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 ((
MH "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@
M *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $<
M@P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T
M *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$
M  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!'
M '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8
M9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!
M"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L
M1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S
M %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0
M<PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A
M!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,
MQP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0
M &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44
M5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)
M$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7
M  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)'
M $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^,
M0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7
M&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $87
M2@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU
M #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@
M3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^
M'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A
M_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22
M $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP
M-R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q
M)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D
M!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3
M # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\
MC2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y
M* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL
M6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL
M '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D
M,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E
M,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O
M  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$-
M "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6,
M'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C
M,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W
M$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN
M !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0
M538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >
M/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !-
M?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD
M $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q
M%T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -
M18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\
M  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2
M !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X<
M!4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]
M/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1
M%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6
M  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@
M-$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@
M61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9
MI0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD
M "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$   810
M &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH
M8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3
M   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5
M  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+
M &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   6
M8   $&0   QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W
M%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!
M  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P
M"V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0
MAA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'
MT0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT
M  "!    A0   (@   "*    C    (T   "/    D 0  )((  "3#   E1
M )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP
ME]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1
M    E0   )@   ":    FP   )T   "?    H    *(   "D!0  I@H  *@.
M  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L
M168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A
MI0   *@   "K    JP   *X   "O    L0   +,   "U    MP$  +D'  "\
M#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(
M #)X   G@   '(@  !*0   *EP   )T   "C    J    *T   "R    M@
M +D   "[    O    +X   #     P@   ,0   #&    R    ,L   #.!0
MT0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\
M  #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9
M .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$
MS "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_
M    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$
M60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F
M +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X
M[0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\
M %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@
MK0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP
M ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %,
MIP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6
M +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<
M @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2
M )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\
MA0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">
M  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (<
M40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z
M '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  (
MBP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X
M %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H
MR0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P &
M 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L
M:P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!>
M .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$
M"0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !,
M %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H
M4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F
M! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!
M3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M
M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04
M70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,
M"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-
M^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X(
M %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\
M1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [
M$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1
M"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4
M #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\
MCAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#
M%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #08
M6P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX
M '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P
M.QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M
M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C
M  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X.
M #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F(
M)B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C
M)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB
M$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M
M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0
M5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G
M)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK
M>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP
M $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!(
M("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5
M,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N
M  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5
M !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D
M$#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^
M,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X
M&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9
M  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P
M-C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 .
M/AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_
MJ  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4
M "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D
M"$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I
M1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY
M   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<
M  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4
M $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B
M00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3
M'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*
M  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P
M%TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@
M7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:
MY   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,
M  Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP
M &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@
M9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@
M   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=
M  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P
M3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K
M;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$
M'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX
M #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0
M ($   "#    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@
MEB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9
M   O70  )&,  !II   2;P  #'4   1[    @    (4   ")    C0   )$
M  "3    E    )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<
M *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G
M:@  '7   !-X   ,?P   X4   "+    D0   )8   ";    GP   *(   "D
M    I0   *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8
M  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>
M%H    V(   %CP   )8   "<    H@   *<   "L    L    +,   "V
MMP   +D   "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5
M&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P %
M /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X
MW@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#"
M ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /,
M"P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!>
M ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,(
MK@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2
M  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$
M70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2
M )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P
MM@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"=
M %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P
MZ "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 .
M )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4
MBP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\
M /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T
M$0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4
M 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T
M;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\
M !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T
M5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X
M &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O !
M;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@
M %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8
M_P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1
M &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$
M50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!,
M /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@
M$P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5
M $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\
ME0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/
M 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($
M6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA
M 'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$
M1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y
M"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5
M  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2
M #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V(
M,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D
M&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0
M%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L
M "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0
M5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P
M%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9
M>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R
M $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0
M*1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P =
M'8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B
M  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7
M "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H<
M%R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^
M)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB
M&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8
M !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@
M-B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7
M)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJ
MJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@
M "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P
M$2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )
M+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ
M   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@
M  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8
M C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F
M+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X
M)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*
M   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,
M'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0
M/B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]
MY   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8
M !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120
M $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP
M0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_
M   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH
M  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O(
M4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +
M20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7
M+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP
M $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40
M %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@
M8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_
M   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X
M  !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH
M &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U
M1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M
M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N
M  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3
M)5   !Q5   46P  #F    =E    :@   &X   !R    =@   'D   !\
M?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2
M,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP
M !5B   .:   !VX   !T    >0   'X   ""    A@   (D   ",    C@
M )    "2    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0
MICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P
M   '=P   'X   "$    B@   (\   "4    F    )L   ">    GP   *(
M  "D    I@   *@   "K    K0   +    "S!   MPP  +L2  "['P  NS
M +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F
MB    (\   "6    FP   *$   "F    J@   *X   "P    L0   +0   "V
M    N    +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X
M  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$
M^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3
M &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D
M_P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6
M -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &(
MN@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E
M /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,,
M&P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A
M *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\
ME0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H
M !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ),
M8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_
M (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D
MDP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"!
M &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0
M_P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ;
M (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H
M< !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G
M /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '
M'0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!;
M &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\
MJ    )4   "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C
M !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8
M7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G
M (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D
M5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!*
M &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '
M  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ;
M $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\
M0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J
M#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0
M' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H
M #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$
M61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [
M AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'
M<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0
M $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D
M- D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G
M#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7
M  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T;
M "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0
M'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _
M&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80
M'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125
M !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P
M-AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?
M$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8
MI@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T
M "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X
M&1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /
M'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>
M   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB
M !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4
M"R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F
M'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B
M)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'
M  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0
M(2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *
M)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $H
MX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,
M !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@
M RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX
M+/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG
M   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M
M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?
M5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2
M+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y
M,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L
M $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P
M#34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P
M0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O
M   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P
M  4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4
M $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V
M,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&
M    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\
M  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0
M+S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/
M40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<
M1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD
M ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<   !:    7
M %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/
M:DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$
M   620  $$T   I1   $50   %H   !=    8    &,   !F    :    &H
M  !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44
M 'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   0
M5   "ED   )>    8P   &<   !K    ;P   '(   !U    =P   'D   ![
M    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.
M  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80
M 6<   !M    <@   '<   ![    ?P   (,   "&    B    (H   "-
MCP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B
M60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<
M  !]    @P   (@   "-    D0   )4   "8    F@   )P   "?    H0
M *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@
MMV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/
M    E@   )L   "@    I    *@   "K    K    *\   "R    M    +8
M  "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL
M ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q
M "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D
M;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_
M )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0
MT@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q
M &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )(
M_P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G
M +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &<
MG !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P""
M /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\
M*0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H
M (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\
MU@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"(
M "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8
M:0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P
M *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0
M=0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E
M &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D
M  "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E
M &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &<
M5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\
M    <0   &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D
M)0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M
M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P
M9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !-
M "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $
M=0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<
M %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "
M0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V
M ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,
M  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A
M #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T
M+0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !#
M#@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$
M(@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&,
M "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0
M.1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I
M R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'
MG0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(
M #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2
M(@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7
M#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3
M   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC
M !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+,
M$ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G
M%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80
M*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%
M  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@
M(18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1
M%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6
MW0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@
M !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H
M#!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $
M&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9
M   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO
M  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P
M6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6
M&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B
M-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T
M $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@
M$1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@
M)ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A
M   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,
M  TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D
M "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X
M)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ
M @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"
M   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P
M+2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 "
M,@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z
M3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD
M "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(
M #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P
M0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J
M   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _    00   $,"
M  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$
M $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;
M,0  %30  ! W   -.@  "#T   )     0P   $8   !(    2@   $P   !.
M 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>
M  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.
M$3P   Q    '1    $<   !*    30   %    !3    50   %<   !9
M6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D
M:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8
M  9*    3P   %,   !6    60   %P   !?    80   &0   !E    9P
M &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P
M<WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7
M    7    &    !D    :    &L   !N    <0   ',   !U    =P   'H
M  !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(
M (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F
M:P   &\   !T    >0   'T   "     @P   (4   "'    B@   (P   "/
M    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!
M  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '    !W    ?0
M ((   "&    BP   (\   "3    E0   )<   ":    G0   *    "C
MI@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "Q
MC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")    D    )4
M  ":    GP   *,   "F    J    *L   "N    L    +,   "V    N@
M +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0
MRI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .(
M-@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X
M +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\
M]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #
M #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *<
M>@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z
M -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$
MI@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1
M 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   /_B
M?1!)0T-?4%)/1DE,10 ($LT   "[    K@   *4   "?    G  ) )D #P"9
M !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L A@!0 (4
M50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_
M &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0 # "" !$
M@@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R
M %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_ &$
M_P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O  X ;P 2
M &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &, 2 !B $X
M80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4
M /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L 7P / %\
M$P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0
M %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H _P!* /\
MD@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ , %( $ !2
M !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $, 2 !* $8
M4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!  /\ A0
M '0   !G    70   %4   !/    3    $H   !(  0 1P * $< #0!& !$
M1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [
M %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\ ?    &L
M  !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]  X /  1
M #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #, 20 R %,
M,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$  &0%  !7
M!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P -  / #0
M$@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J $\ *0!:
M "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)  !2"P
M2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  - "P $  K
M !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L (@!7 "$
M9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-#0  0PX
M #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4##@ D 1
M) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4 !H!80 :
M 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0
M   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >!@X '@41
M !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX
M$P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41   O
M$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)
M$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R
M  X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3   L$P
M)Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2
M#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/
MDP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I%   )10
M "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q(
M#1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $
M$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@  (A4  !X4
M   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5
M  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5C@  %:,
M !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18  !P6   9
M%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A  !A83  46
M&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C   &*(  !BW
M   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7   8%@
M%14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@
M&QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*   !RV   ;
MT   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7&   %!<#
M !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @%   (1H
M "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V   ?T0
M'^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$ $QD! !$9
M 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@  )A@  "<?
M   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   DT0  (^X
M1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P   X=   -
M'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14  "T<   M
M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT   *>\ 0"
M #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB   *)
M!B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48   U(
M-2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\ /",  #(D
M   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %*P   2X
M   P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^'   /B8
M #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<  "\G   H
M)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P   #4    X
M    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P  2"$  $@L
M  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G*
M(B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X   !!
M0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P  %,G  !3
M-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F*P  'RP
M !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,    3@
M %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?  !B+
M83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,   &C,  !,W
M   ..P  "#\   %$    2    $P   !/    4@   %4   !8    6P   %T
M  !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S)0  <C0
M ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P   Y!   '
M1P   $P   !1    50   %D   !=    80   &4   !H    :P   &T   !O
M    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'   B"L  (8]
M  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.    5
M %H   !@    9    &D   !N    <@   '8   !Z    ?0   (    ""
MA0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$  )\S  "=
M1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<    8P   &H
M  !Q    =@   'L   "     A@   (H   ".    D0   ),   "6    F0
M )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH  "W/
MM%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =    'P   "#
M    B0   (\   "4    F@   )\   "B    I    *<   "J    K@   +$
M  "T    N    +P   #!    QP   ,T   #4!0  V!   -4>  #3,0  T$@
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M_/[______________________________________________________P
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M______________________________________\
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M_VUF=#$      P0A   !                     0
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MQ;_4!R6ZUPE.KMH+<*#;$X>7S3F:DL-8J)&\;+*1MWJYDK2#O8ZSAK^+LH?
MB+&'P(:QB,&$L8G!@[&*P8*QB\* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
ML(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PO?
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MPH2I=,*%JG/!AZMRP8BK<L"*K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MEXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N@*+4K("CTJR
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MEZV$QI.MA,>/K(3(C*N%R8FKALJ'JX;*A:J(RH.JB<N!JHO+@*J,RX"JC,N
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M-VF%Z49T?^13>WS?8(%XW&B%=-IMB7#8<8MNUG6-;-5XCVK4>Y!ITWZ19].
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
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MR)2'K,63AZ[#DH>PP)*'L,"2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[#
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MD*'+7YV8PVVHD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[#
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M>[:XH7VWMIU^N+6;?[FTF7^ZLYB NK*7@+NQEX"[L9> N[&7@+NQEX"[L9>
MN[&7@+NQEX"[L?^-$ '_D" &_Y$T%/^70B3_G4,P_Z)%/?^E2$G_J$Q5_*E1
M8?6J5VSNJ5UWYZAC@>&D;8O6GGF6RY6#HL"+CJVV@YJVKGZJNZ1\L[R>?K6Z
MFH"WMYB!N+66@;FTE8*ZLY2"NK*3@KNQDX*[L9."N[&3@KNQDX*[L9."N[&3
M@KNQDX*[L?^.$ '_D2 &_Y(T%/^902/_GT$O_Z1"._^H14?_K$E3_JY.7O6P
M4VCLLEIRY+-A>]NO;H3,IG:4P)Q^HK22B*ZIBI2WH(6DO9F"L;Z5@[2[DX2V
MN)*$N+:1A+FTD(2YLY"$NK*0A+JRD(2ZLI"$NK*0A+JRD(2ZLI"$NK*0A+JR
MD(2ZLO^/#P'_DB &_Y,T%/^:/R+_H3\N_Z= .O^L0D7_L$90^;-+6O"W4F/H
MNUEKW[UD<M&V;(+$K'.3MJ-ZH:J9@ZZ>DI"WE(V?OHZ+L;^,B;.\C(FUN8R(
MM[:,B+BUC(>YM(R'NK.,A[JRC(>ZLHR'NK*,A[JRC(>ZLHR'NK*,A[JRC(>Z
MLO^/#P'_DA\&_Y0T%/^</2'_HSPM_ZH]./^O0$+_M$1,];I)5>R_45SDQEIA
MV,5B;\F\:8&[LG"2K:IWH*"A@*V3FXNWB9:;O8.5K[^$D;.\AHZUN8>-MK>'
MC+>VB(NXM8F*N;2)BKJRB8JZLHF*NK*)BKJRB8JZLHF*NK*)BKJRB8JZLO^0
M#P'_DQ\&_Y4T%?^>.R#_I3DK_ZPZ-?^S/3_[ND)'\<%(3NC)45+?T5M9S\I@
M;<'"9X"RN6V0I+%TGY>J?:N*I(BU?Z"7NWB?K+Y\FK.\?Y6TNH&2MKB#D+>W
MA(^XM82-N;.%C;JRA8VZLH6-NK*%C;JRA8VZLH6-NK*%C;JRA8VZLO^1#@'_
ME!\&_Y8S%?^@.!__J#8I_[ X,O^X.COVP#]![,I'1>/65$76V5=8Q]!>:[C(
M9'ZJP6N.G+IRG(ZT>JB KH6R=JN4N&^KJ;IRI;6Z=YVUN7J9MK=]EK>V?I.Y
MM'^1NK* D+NQ@)"[L8"0N[& D+NQ@)"[L8"0N[& D+NQ@)"[L?^2#@'_E1\&
M_Y<S%?^B-1[_JS,G_[0T+_F^-C7MR3TXXM9(.-G@347-WU96O]A<:;#08GNA
MR6B+D\-OF86^=Z1XNH.M;KB3LVBXJ+9ILKBV;Z>WMG.AN+5VG+FT>)FZLWJ6
MN[%[E;RP>Y6\L'N5O+![E;RP>Y6\L'N5O+![E;RP>Y6\L/^3#@'_EA\%_YDS
M%/^E,!S_KS C_;HO*?#&,BWCU#LLUN! .LOE2$S X4Y<L]U6;*7877J8TF6(
MBLYME'W)=I]SQ(.G;,"1K&>^H:]EOK:O9K2[L6NKN[%NI;NQ<:"\L'.=O:]T
MFKVN=)J]KG2:O:YTFKVN=)J]KG2:O:YTFKVN=)J]KO^4#@'_F!X%_YTQ$O^I
M+1G_M"H>]<(I(N31+2'5X#,LR>@\/[[H0U&QY4EAI.)/<)??5GV*VF"(@--K
MDGC-=YIPR(*A:L6.I6;#FZAEPZRG8<*]JF.XOZMFL+^L::J_K&REOZMMHL"J
M;:+ JFVBP*IMHL"J;:+ JFVBP*IMHL"J;:+ JO^5#0#_FAX%_Z(L$/^M*!7[
MNR,8Z,T@%]7?)1W(Z# QO.\Y1+#L0%6CZD9DE^A-<8OC57V!W&&&>=5LCG+1
M=Y5LS8&:9\J+GF3(EJ!AR*.A8,BSH5W'PZ-?OL2E8;;#I62PPZ5EK,.E9:S#
MI66LPZ5EK,.E9:S#I66LPZ5EK,.E9:S#I?^7#0#_G!X%_Z8F#?^T( _OQA</
MUMT6#LCI(R*[\RXVK_0V2*+R/EB7\49EB^M/<('E6'IZWV2"<]IMB&W6=HUH
MTW^29-"(E6#/DIA>SIV97,VIFEO.N9E9S<B:6L7*G%R]R9U>N,F>7KC)GEZX
MR9Y>N,F>7KC)GEZXR9Y>N,F>7KC)GO^:# #_GQT%_ZP?"/B^$PC8U@L$R.@5
M$[KT(B>N^BTYHOHV2I;Z/UB+]4AC@NY2;7KH7'5RY&1[;>!M@&C==85DVGZ(
M8-B&BUW6CXU:U9B/6-2BD%?4KI%6U+R05M3-D%;-T9)7R-&35\C1DU?(T9-7
MR-&35\C1DU?(T9-7R-&35\C1D_^<"P#_HQT$_[42 ]3)"@+(V@L&N?06%ZS_
M(RJA_RX[E?\X28O_0E6"^$Q?>O)69W/N7FUKZF1R9N=L=V+D='I?XGQ]7.&#
M?UK?BX)7WI.#5=V<A53<I892W*^&4MR[AE'<S(52VMJ%4MK:A5+:VH52VMJ%
M4MK:A5+:VH52VMJ%4MK:A?^@"@#_K1,!U, ( ,;." "YXPL(J_\7&9__)"J4
M_S YBO\Z18'_1D]Z_5%8<OA87FOU7F-E\F5H8.]L:UWM<FY:ZWEP5^J <E7I
MAW13YX]V4>:6=U#FGGA.Y:=Y3>6O>DWDNWI,Y,5Z3.3%>DSDQ7I,Y,5Z3.3%
M>DSDQ7I,Y,5Z3.3%>O^D!P#8N 0 Q,0& +?3!P&J\PT+GO\:&I/_)RB)_S,U
M@/\_/WG_2D=P_U%.:?]74V+]75=>^V1;6OEJ7E?W<&!4]G9B4O1\9%#S@V5.
M\HIG3/&1:$OPF&E*\)]J2>^G:TCOL&Q'[K=L1^ZW;$?NMVQ'[K=L1^ZW;$?N
MMVQ'[K=L1^ZW;-VO  #%O 0 M<H$ *C;!0*<_Q +D?\=%X?_*B-^_S8M=O]!
M-FW_2#QF_T]"8/]51EO_6TI7_V%,4_]G3U'_;5%._W)23/]X5$K_?E5(_H16
M1_V+6$7\DEE$^YA:0_N?6T+ZIUQ!^JQ<0?JL7$'ZK%Q!^JQ<0?JL7$'ZK%Q!
M^JQ<0?JL7,BV 0"UP0, I]$! )GK!0*/_Q()A?\@$GS_+!MS_S4C:O\]*F+_
M1#!<_TLT5_]2.%/_6#M/_UX]3/]C/TK_:$!'_VU"1?]R0T3_=T1"_WU%0/^#
M1C__BD@]_Y!)//^723O_GDH[_Z-+._^C2SO_HTL[_Z-+._^C2SO_HTL[_Z-+
M._^C2[:Z @"FR@  F-P  (S_" &#_Q0%>/\>#&[_)A)E_R\97?\W'E?_/R)2
M_T8F3?],*$K_4BM&_U@M1/]=+D+_82] _V8Q/O]K,CS_<#,Z_W4T.?]Z-3?_
M@#8V_X8W-?^,.#/_E#@S_Y@Y,_^8.3/_F#DS_Y@Y,_^8.3/_F#DS_Y@Y,_^8
M.:?#  "7U   B.0  (#_"@%R_PX"9_\3!5__'0E7_R8-4?\O$4S_-Q5'_SX7
M0_]%&4#_2QL]_U =._]5'CG_61\W_UXA-?]B(C3_9R,R_VPD,?]R)2__=R8N
M_WTG+?^$*"O_BRDK_Y$I*_^1*2O_D2DK_Y$I*_^1*2O_D2DK_Y$I*_^1*?]V
M%0+_<R $_W(Q#/]Q0QG_<5 F_W59,_]U8C__<VI)_W!T4_]N?EO\:X=A^6F/
M9_9GEFOT99QN\F.A<?%BIG/O8:MU[F"P=NY>M7?M7KMX[%W#>>Q<RWKK6]AZ
MYEW>>M]>X7G88.-YU6#C>=5@XWG58.-YU6#C>=5@XWG58.-YU6#C>?]V%0+_
M<R $_W(Q#/]Q0QG_<5 F_W59,_]U8C__<VI)_W!T4_]N?EO\:X=A^6F/9_9G
MEFOT99QN\F.A<?%BIG/O8:MU[F"P=NY>M7?M7KMX[%W#>>Q<RWKK6]AZYEW>
M>M]>X7G88.-YU6#C>=5@XWG58.-YU6#C>=5@XWG58.-YU6#C>?]V%0+_<Q\$
M_W0Q#?]R0AG_=$\G_WA8,_]Y8#__=VE*_W-Q5/]Q?%S[;H9C]VN.:?1IE&WR
M9YMQ\&6@=.]DI7;M8JIX[&&P>>M@M7OK7[Q\ZE[$?>I=S7WG7=E]X5_>?=I@
MX'S18N%]SV+A?<]BX7W/8N%]SV+A?<]BX7W/8N%]SV+A??]W%0+_=!\$_W4Q
M#?]S0AK_=TTG_WM6-/]\7T#_>F=+_W=O5?YS>E[Z<8-E]FZ,:_-KDW#P:9ES
M[F>?=^QEI7GK9*I[ZF*O?>EAM7[H8+U_Z%_%@.A>T('B7]J VV'>@-)BWX#+
M8]^!RF3?@<IDWX'*9-^!RF3?@<IDWX'*9-^!RF3?@?]X% +_=1\$_W8Q#?]T
M0AK_>DPG_W]5-/^ 74#_?F5,_WIN5OYV=U_Y=(%F]7"*;?%MD7+N:YAV[&F>
M>>MGI'SI9:E^Z&.O@.=BMH+F8;V#YF#'A.5?TX3=8=J$TV/=@\QDW(3&9=R$
MQ67<A,5EW(3%9=R$Q67<A,5EW(3%9=R$Q67<A/]Y% '_=AX#_W<P#?]V0AK_
M?DLG_X)3-/^#7$#_@F1,_W]L5OUZ=&#X=W]H\W.(;_!PCW3M;99YZFN=?.AH
MHW_G9JF"Y66OA.1CMH7D8K^'XV')A^!AU8?59-J'S67:B,=FV8C!9]F(OV?9
MB+]GV8B_9]F(OV?9B+]GV8B_9]F(OV?9B/]Z% '_>!X#_WDP#?]X01K_@4DG
M_X92,_^(6D#_AV),_X-I5_Q^<6'W>WMI\G>%<>YSC7?K<)1\Z&V;@.9JHH/D
M:*B&XV:OB.)DMXKA8\&+X6+.B]ADUHO-9M:+QF?6C,!HUHR[:=:,NFG6C+II
MUHRZ:=:,NFG6C+IIUHRZ:=:,NFG6C/][$P'_>1T#_WHP#?]\/QK_A4@F_XI0
M,_^,6$#_BU],_XAG5_R$;F'V?WAJ\7N"<NUWBGGI<Y)^YF^9@^1LH8?B:JB*
MX&>OC-]EN([>9,2/VV32C\YGTX_&:-.0OVK3D+IKTY"U;-.0M&S3C[1LTX^T
M;-./M&S3C[1LTX^T;-./M&S3C_]\$P'_>AT#_WLP#?]_/AK_B48F_X].,O^1
M5C__D%U+_XYD5OR):V'VA'-K\']^<^Q[AWKH=I"!Y'*7AN%NGXK?:Z>.W6BP
MD-QFNY+;9<J3T&C1D\9JT)2^:]"4N&S0E+-MT)2O;M&3KF[1DZYNT9.N;M&3
MKF[1DZYNT9.N;M&3KF[1D_]]$@'_>QP#_WPO#?^#/!G_C44E_Y--,?^54S[_
ME%E*_Y)@5?V/:&#VBG!J\(1Y=.M_@WSF>HR#XG65B-]QGHW=;:>1VVFQE-EG
MOY;49\Z7QVO-F+ULS9BV;LV8L&_-F*QPSI>I<<Z6J''/EJAQSY:H<<^6J''/
MEJAQSY:H<<^6J''/EO]^$@'_?!P#_WXO#?^&.QG_D4,D_Y9+,/^84#S_F%5(
M_Y9<5/V38U_WCVMI\(IT<^N$?WSF?HF$X7B2B]USG)#:;J:5V&JSF=9HQ9O)
M:\N;O6[*G+1ORIRN<<J<JG++FZ9SRYJC<\R9HG3-F*)TS9BB=,V8HG3-F*)T
MS9BB=,V8HG3-F/]_$@'_?1L#_W\O#?^).AC_E$(C_YE'+_^;3#O_G%)&_YM8
M4O^97UWXE69H\9!N<NN*>7OE@X2$X'R/C-QVFI/8;Z:9TFNUG<YJR)^^;LB?
MLW''H*QRQZ"G=,B?HW7)GJ!VRIV>=LN;G7;+FIUVRYJ==LN:G7;+FIUVRYJ=
M=LN:G7;+FO^ $0'_?AL#_X O#?^,.!C_ET B_YQ$+?^?23G_H$Y$_Z!53_R>
M6UKUG&)E[I=J;^B1='GABG^#V8.*C,][E97(=:"<PW"NH;YOOZ.S<L6CJG3%
MHZ1VQ:.@=\:AG7C'H)MXR)Z9><J=F'G*G)AYRIR8><J<F'G*G)AYRIR8><J<
MF'G*G/^ $0'_?QL#_X$O#?^/-Q?_FC\A_Y]"+/^B1C?_I$Q"_Z123/>D6%?O
MHU]AYZ!F:^":<775DWR!RXJ%C<."CY:[>YJ>M7:GI+!TN*>H=L*GH7C#IIUY
MQ*6:>L6CF'O&HI9[QZ"4>\F>E'S)G91\R9V4?,F=E'S)G91\R9V4?,F=E'S)
MG?^!$0'_@!L#_X(N#O^1-A;_G#P@_Z% *O^E1#3_J$H_^JE02?*J5E+JJEU<
MXJEF9M>B;W++F7B!P9"!C;B(BI>O@96@J'RBIJ-ZLJF>>L&IF7S!J)9]PZ:4
M?L2DDG[%HY%^QZ&0?LB?D'[)GI!^R9Z0?LF>D'[)GI!^R9Z0?LF>D'[)GO^"
M$0'_@1L#_X0N#?^4-1;_GCH>_Z0^*/^H0C+_K$<[]J]-1.VQ5$WELUM5W+!E
M8<ZH;''#GW2 N)9\C:Z/AIBEB)&AG8.=IY> K:N3@+^KD8'!J8^!PJ>.@<.E
MC8'%HXV!QJ*,@<B?C('(GXR!R)^,@<B?C('(GXR!R)^,@<B?C('(G_^"$0'_
M@1H#_X8M#?^6-!7_H#D=_Z8\)O^K0"_[L$4X\K1+/^FY4T;AO5Q-T[9B8,:M
M:7"[I7%_L)UYC*65@I>;CXVADXJ9IXR'J:N(A[^LB(? JHB&PJB(A<.FB(7%
MI(B$QJ*(A,B@B(3(GXB$R)^(A,B?B(3(GXB$R)^(A,B?B(3(G_^#$ '_@AH#
M_X@K#/^9,A3_HC<;_ZDY)/^O/2SWM4(S[;M).>7"4C[:PEA,S+I@7[^R9V^S
MJVY^J*-VBYV<?I>2EXF@B9*6IX*/I:M^C[JL@(W JH&+PJB"BL.F@XG%I(.(
MQJ*$A\B@A(?(GX2'R)^$A\B?A(?(GX2'R)^$A\B?A(?(G_^$$ '_@QH#_XLJ
M#/^<,1+_I30:_ZPV(?ZS.BCSNT MZ<-(,>'+43?2QU9+Q<!>7;BX96ZLL6Q]
MH*ISBI2D>Y6*GX:>@)N2I7F8HJITF+>K=Y7!J7J1PJ=\C\.E?8W%HWZ,QJ%_
MBLB??XK(GW^*R)]_BLB??XK(GW^*R)]_BLB??XK(G_^%$ '_A!H#_XXH"_^?
M,1'_IS(7_[ S'?FY-B+NPCTFYLU')MO33#7+S%1)OL5<6[&^8VRDN&IZF+)Q
MAXRL>9.!J(*<=Z2/HW"BGZ=LHK2H;I_"IW*9PZ9UE<2D=Y+&HGB0QZ%ZCLB?
M>H[)GGJ.R9YZCLF>>H[)GGJ.R9YZCLF>>H[)GO^&$ '_A1D#_Y$F"O^A+P__
MJRX5_[4O&?2_,ASIRSH<W]E$'=':2C/$TE)'M\M:6:G&86F<P&=XD+INA(2V
M=H]YLH"8;Z^-GVBMG:-DK;*D9:K%I&JBQ:-MG<:B<)G'H7*6R)]TD\F==9/*
MG763RIUUD\J==9/*G763RIUUD\J==9/*G?^'#P'_AQD#_Y4D"?^D*PW_KRD1
M^KLI$^S(+!/>V#<0T^%!'LG?23"\VE%$K]-85J'-7V:4R&5TB,1L@'S =(IQ
MO7^3:;N,F6*YG)U>NK&>7;C)GF*NR)]FILB?::')GFN=RIUNFLN;;IG+FVZ9
MRYMNF<N;;IG+FVZ9RYMNF<N;;IG+F_^(#P'_B1D#_YHC!_^H)PK_M2(,\<0@
M#.#5) G1X3 4Q^8])+WC1C2RX$Y$IMQ64IG776&,TF-O@,]K>G3,<X1KRGZ+
M8LB,D5S(G)59R+&65\C.EEN[S9A>LLR98:O,F62FS9EGHLV89Z#-EV>@S9=G
MH,V79Z#-EV>@S9=GH,V79Z#-E_^*#@'_BQ@#_Y\A!?^N( ;XO1@&X]$3!-#A
M'@G%ZBX9NNDZ*;#G0SFDY$I(F.)05HS@5V* W5]L=MMH=6S:<GUCV'Z#7-B,
MB%?8G8M4U["-5-C-C%7+TX]7P-*16KC1DURRT9-?K-&38*K1DV"JT9-@JM&3
M8*K1DV"JT9-@JM&38*K1D_^,#@'_CQ8"_Z4> _^U%0/:R@L"T.$. L3K'@VX
M[RP=K>XW+J+L0#V7ZTA*C.E/5H'H5F!VYUYI;.=E<&3F<'=>XWQ\6>")@%;>
MEX-3W::$4=RXA5'=U(13T-J'5,;8B5:_UXI8N-:+6;;6BUFVUHM9MM:+6;;6
MBUFVUHM9MM:+6;;6B_^.#0#_EQ(!_ZT5 =F_"0#,S@D P^L.!+;U'A&K]2PA
MH?0W,);S0#Z+\TA*@?-05'?S5UUM\UUD9?!F:E_M<&Y:ZGIR5N>%=E/ED7E1
MY)Y[3^.L?$WCO7Q-X]E\4-C@?%'.X']2QMZ!4\3>@5/$WH%3Q-Z!4\3>@5/$
MWH%3Q-Z!4\3>@?^2# #_H T V[<& ,K#!P# T@D M?00!JG['Q2?_"PCE/PW
M,8K\03V!_4E'>/U14&[]5U=E^EY<8/9F85OT;V56\7AH4^^":U#NC&U.[)=O
M3.NC<4KJL'))ZL%R2.K8<DOCY').V.9S3M7G=$[5YW1.U>=T3M7G=$[5YW1.
MU>=T3M7G=/^6"@#>K ( R[H% +W'!@"RV @!I_\2")S_(1:2_RXCB?\Y+X#_
M0CEW_TI";?]0267_5DY?_UY36OYE5E7\;5I2^G5<3_A^7TSWAV%*]9%B2/2<
M9$;SIF5%\K-F1/+!9T/RU&=%[N=G1NOH9T;KZ&=&Z^AG1NOH9T;KZ&=&Z^AG
M1NOH9^ZB  #-M ( O+X$ *_-! "DW@<!FO\5"9#_)!6'_S @?O\[*G3_0C)K
M_T@Y8_]./UW_54-8_UU'4_]D2E#_:TU-_W)/2O]Y44?_@E-%_XM40_Z45D']
MGE= _:A8/_RS63[\OUH^^]%:/?O;6CW[VUH]^]M:/?O;6CW[VUH]^]M:/?O;
M6M*M  "]N ( KL4" *'5 @"6]PL"C?\8"(3_)A%\_S$:<?\X(FC_/BE@_T4O
M6O],,U3_4S=0_UHZ3/]@/$G_9CY&_VU 1/]T0D'_>T,__X-%/?^,1CO_E4<Z
M_YY).?^G2CC_L4HW_[Y+-__"2S?_PDLW_\)+-__"2S?_PDLW_\)+-__"2[^S
M  "NO@  H,T  )+>  ")_PT!@?\:!7?_(PQM_RH39/\Q&5S_.!Y5_T B4/](
M)DS_3RE(_U4K1/];+4+_82\__V<Q/?]M,CO_<S,Y_WHU-_^"-C7_BS<S_Y0X
M,O^<.3'_I#HP_Z\[,/^R.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.["X  "@
MQP  D=@  (3O  !\_PT!;_\1 V;_&09>_R$*5O\I#U#_,A-+_SH61O]!&4+_
M2!L__TX=//]3'CG_62 W_UXA-?]D(C/_:2,Q_W D+_]W)2W_?B8L_X<G*O^/
M*"G_ERDH_Z J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*J'"  "1T0
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MB]:+=HO6BW:+UHMVB]:+=HO6B_]Y$0'_>!H"_XP9 _^>(P3_JB8&^+0E".O
M* CAS3 'U-(W%,C-12>[R$\YK\)72J.]7UB8N&9EC;-M<8.O=7MZJWZ#<:B)
MBFJFEH]EI:>28J:]DF.CTI%GG=.0:IC4CVV5U8UNDM:,<)#8BG"0V(IPD-B*
M<)#8BG"0V(IPD-B*<)#8BO][$0'_?!<"_Y 7 O^B(0/_KB $\KL=!.7*'@/:
MVR0#S-DU$L#30R2TSDTVJ,E51YS$7561P&1BAKQK;7NX<W9RM7Q^:K.'A6.Q
ME8I>L*6,6[&\C5NOU8U?I]6-8Z'6C&:<UXMHF=B*:I;9B&J6V8AJEMF(:I;9
MB&J6V8AJEMF(:I;9B/]\$ '_@10"_Y45 ?^G'0+\M18"Z\80 =K;#P#-X"4$
MP]\V#[C;02&LU4LSH-%30Y3-6E&)R6)=?L9I9W3#<7!KP7MX9+^&?EV^E()8
MO:6%5KZ[AE6]VX98L]J'7*O:AU^FVH=AH=N&8YW;A6.=VX5CG=N%8YW;A6.=
MVX5CG=N%8YW;A?]^$ '_AQ$!_YH1 /^M% #:O@H T<T* ,OD$ '!Y"4'M^,U
M$ZWA0"&CWDDOE]M2/HO764N U&!7=M%H86W/<&EES7IP7LR&=5C,E7E4S*9[
M4<V\?%#,XGQ3P>!_5;??@%BQWH%:J]Z!7*;?@5RFWX%<IM^!7*;?@5RFWX%<
MIM^!7*;?@?^ #P'_C@X!_Z(- -NU" #.P0@ QM ) +[I$@*TZ24*JN@S%Z#F
M/B66Y4<RB^-./X#A54EVX%U3;=YF6V7=;V%>W7IG6-R&:U/<E6]0W:9Q3=Z[
M<DW?X7%.T>=T4,;F=U*^Y'A3N.1Y5;+C>E6RXWI5LN-Z5;+C>E6RXWI5LN-Z
M5;+C>O^##@'_E@L W:L$ ,VX!@#"Q 8 NM0) +'O% .G[B4-GNXS&I3M/2>*
M[$8S@.M./G;K54=LZEM.9.IC55WJ;5I8ZG=>4^J#8D[JD65*ZZ%G1^RS:4;M
MT&E(YNAI2]GK:DS/[&U.Q^MO3\#J<$_ ZG!/P.IP3\#J<$_ ZG!/P.IP3\#J
M</^)"P#IH $ T+$$ ,&\!0"WR08 KMH) *3U%P6;]2<0DO4T'(CV/B=_]D<R
M=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?> 6$CXC5I%^)M<0OBK7D'WOE]
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M2#7_W4DT__!)-_[X23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X2<FK  "VM
MJ,$  )O/  ".WP$ A_\1 7[_'01U_R<+;/\O$F3_-QA<_SX=5O]%(E#_2R5+
M_U(H1O]8*T'_7RT^_V<O._]O,3C_>#,V_X(T,_^--C'_F3<P_Z4X+_^R.B[_
MP#LN_],[+?_K/"W_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/+BP  "HO   FLD
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MCX61?8J"G(*%@*J%@7^\AH" VX6 @-V#@'_>@8!^X'^ ?>%]@'WC>X!\Y'J
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M64?0]UQ)R/=>2L'V8$N]]F!+O?9@2[WV8$N]]F!+O?9@2[WV8/^)  #9G@
MQZP! +FV @"NP0, I<X& )SD# "5[QT#C>\L"X7O.15\[T$><^]))VKN4"]B
M[E<U7.Y?.E;N:#]2[G%"3>]\1DGOB4E&\)9+0_"F34#QN4X_\MM//O#W3D+F
M^T]#W?M11-3\4T7/_%1%S_Q41<_\5$7/_%1%S_Q41<_\5.&5  #+I@  N[
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M+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8  (;3  !YX0
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M9E6D\F98G_)F6IOS95R7\V1<E_-D7)?S9%R7\V1<E_-D7)?S9/]P#0#_A 0
MW98  ,ZC P#$K@0 N[<$ +3"!0"NS0P I\X@ I[-,0J5RSX6B\A)(X+&4BYZ
MPUHX<L%B0&O :D=DOG--7KU\4UF\B%=4NY5;4+NE74Z[N5Y-O-M=2[GW7TZQ
M]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W" #KC   TYL
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M1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P  *>V  ";P0
MD,P" (;9!@" \A( >?(? G'R*P9J\C8,8_,_$EWS1QA7\T\=4O-7(4WT8"1)
M]&DH1O1S*D+U?BT_]8LO//:9,3KVJ3,X][XT-OCA-3;U^34U\_\T-^S_-CGE
M_S@YY?\X.>7_.#GE_S@YY?\X.>7_.,B>  "VJ0  J+(  )N]  "/R   @]0
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M%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4  %'_ 0!*_PL
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M866)]U]GAOA>:83Y7&J"^EIK@?M::X'[6FN!^UIK@?M::X'[6O]B$ #_<@<
M^((# -N/ @#/F@4 R:,& ,.L!@"]LA  M;(D JRP-0NCK4(7FZI,(Y*F52Z*
MHUTX@Z!E0'V=;$=VFW1-<)E]4VN6B%AFE91<8I2A7U^3LF!=D\E@79/M7UZ0
M^%YAC/E<8XKZ6V2'^UIEAOM998;[666&^UEEAOM998;[6?]F#0#_=P, XX<
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M4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<  +ZB  "SJ@
MJ;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C9\5<*F'$9#!<
MPVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%N?]*1[/_2TFM
M_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G  "JKP  H+@
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M+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T  ''8  !GY@8
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M!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\" "K_"@ F_P\
M(O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"!_]) @/_4P(
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MXGT024-#7U!23T9)3$4 "A*18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A,
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M2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0
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M24Z@]4E.G_])4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P
MRHT  +Z8  "SH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=Q
MM5(>:[-:)66R8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK
M]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,
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M*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@
M@[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"
MYEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D
M_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8
M &O/  !?U@  5-X$ %'P$ !-\!L 2O F 4;Q, )"\CH#/O)#!#OS2P4X\U0'
M-O1="#/T: DP]70++O6!#"SVD0XJ]J(/*/>W$"?XUA$G]O01)O/_$2;Q_Q$E
M\?\3)?'_$R7Q_Q,E\?\3)?'_$ZVA  "@J0  DK,  (2\  !VQ@  :<\  %W8
M  !1WP  2>X$ $;\#@!"_1< /OXA #O^*@$W_S,"-/\Z C#_0@,M_TH#*_]3
M!"C_7 4E_V8%(O]S!B#_@P<?_Y0('?^F"!S_O @;_^()&O_Y"1K__PD9__\)
M&?__"1G__PD9__\)&?__":*G  "3L0  A;L  ';&  !IT   6]H  $[@  !#
MY0  /OL! #K_#  V_Q, ,O\; "__(P K_RH!*/\Q 23_-P$A_S\"'_]& AS_
M3@(9_U@#%O]C Q/_< ,2_X$$$?^3!!#_IP0/_[T%#O_@!0[_]@4.__\%#O__
M!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P
M,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!$O\X 1#_0 $.
M_T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0, _^P# /_L P#_
M[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\
M "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<!
M /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$ _[L! /^[ 0#_NP$
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M,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!, _U00 /]<$@#_81<
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M.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8 W7@( -I["P#1?A<
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M1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0
MUGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B
MEE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B(
M[418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX
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M-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@
MFZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.7K=2$UJV6AA6
MMF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U L/XO/Z__,3ZM
M_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH
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M%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@
M3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J
M[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J
M_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T
M #CD   U]@P ,_<4 ##W'@ N^"< *_DP "CY. $F^D !(_M) 2'[4@$>_%T"
M'/UI AK]>0,8_HL#%_^> Q7_LP04_],$%/[T!!/\_P,3^O\#$_G_ Q/Y_P,3
M^?\#$_G_ YVE  "/K@  @+@  '+"  !DRP  5M,  $G:   ^WP  -.0  "[T
M   K_PH */\0 "7_%P B_Q\ '_\F !S_+0 9_S0 %_\\ !3_1 $2_TX!$/]9
M 0[_9P$,_W<!"_^* @K_GP()_[4""/_5 @?_] ('__\"!___ @?__P('__\"
M!___ I&M  ""N   <\(  &3,  !6U0  2-T  #OB   PYP  )^X  "/_   @
M_P0 '/\, !G_$0 6_Q8 $_\; !'_(0 ._R< #?\N  K_-@ '_SX !/](  #_
M5   _V(! /]S 0#_AP$ _YT! /^R 0#_R@$ _^H! /_S 0#_\P$ __,! /_S
M 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P
M$?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00
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M*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$
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M/&UKZ3MM;/XY;6S_-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P
MWFH  ,US  ##>@  NWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*
M?5@;AGM?((%Y9R5]=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=P
MYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X
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M-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP
MJ)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUF
MDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")
M_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0
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M)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP
M:;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*NED*1[IB#42Z;!!!
MNG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R
M_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P
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M!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP
M)>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1
M]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC
M  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L&
M !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP
M O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]
MM0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_
M"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I
M  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP
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M+GU9YBU\6OHL>UK_*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@
MXUP  -)C  #':   P&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4
M:%H4D&9B&(UE:AR*8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>
MXB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\
M ,UG  ##;   NV\  +5P  "O;PH J'$: *-R*P&=<CD$F'!%"9-N3PZ/;5@4
MBVM@&(=I9QR$:&\@@6=W(WUF@"9Z9(HI=V.4+'5CH2YR8J\O<&+!,&]BWS!N
M8_<N;V/_+&]C_RIO8_\H;V+_)V]B_R=O8O\G;V+_)_]-  #K6   V6,  ,EJ
M  "_<   MW,  +!T  "I= < HW87 )YW* &8=C<$DW5""(YS3 Z)<543A7!=
M&(%N91Q^;6P?>VQT(WAJ?29T:8<I<6B2+&YGGBYL9ZPP:F>^,6EGW#!I9_4N
M:6?_+&EG_RIJ9_\I:F;_*&IF_R=J9O\G:F;_)_]0  #G6P  TV8  ,5N  "[
M<P  LW<  *MY  "D> , G7H4 )A[)0&3>S0#CGI !XEX2@V$=E,2@'5;%WQS
M8AMX<FH?=7%R(G)O>R9O;H4I;&V0+&ELG"YF;*HP9&R\,6-LV3!C;/0O8VS_
M+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P
MKWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_?%$1>WI9%G=Y8!IS
M=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQU#!=<?(N7G'_+%YP
M_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX
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M)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP
M>I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T36)-E%U63;AI1
MDG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&B_\D1HK_)$:*
M_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T
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M%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4
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M !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0
MA*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4
MZ0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?R
MH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(
M &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H
M"_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C
M_*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$
M  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)
M  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT
M /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _
MU@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_
M!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,
M  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#
M_PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_
M *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT
M /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4
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M ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT _R8H /\C- #_($
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M&Y-&YAN11_D;CT?_&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P
MZTL  -U1  #15   RE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB
M45\,GU!G#YU/;Q&:3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+
MXAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5
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M(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@
MLV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,A&5;$(%D8A-^
M8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I7NXD:5[_(FI>
M_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP
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M'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P
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M$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748*
M&DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<
M27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!H
MCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*
MBAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_
M&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0
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M""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP
MG)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 S
MMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2Y
MM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<
M (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0
M(L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7
MR,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE
M  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1
M !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X
M"=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !D
MM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?
M$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(
M  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@
M2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0
MZ1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #V
MT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P
M "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L
M /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@
M_\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=
M   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P   /\&
M  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\
M /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_
M $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\
ML #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_
M +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D
M_P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3
M /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +
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M O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL
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M!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0
M_S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU7P*Z
M-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*"J4U
MY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH
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M%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5
MN50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24458&D5!>"8Y/9@N,
M3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+S1AY3.L8>$S^%W=,
M_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D
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M%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580
MCV(. (MD' "'92L @V4W 7]E0@-\9$L&>&-3"'5C6PMS8F(.<&%J$&U@<A-K
M8'L5:%^&%V9>D1EC7I\;85VN'&!=P1Q?7>$<7UWX&E]=_QA?7?\78%W_%F!=
M_Q5@7?\58%W_%>M*  #45@  PUX  +9E  "L:0  HFD  )AG  "/90  B68,
M (5H&0"!:2@ ?FHU 7II/P-V:4D%<VA1"'!G60IM9V -:V9G$&AE<!)E9'D5
M8V2#%V!CCQE>8IT;7&*L'%IBOQQ98M\<66+W&EIB_QE:8?\76V'_%EMA_Q5;
M8?\56V'_%>=-  #/60  OV(  +-H  "I;0  GFT  )-K  "):0  @VL) ']M
M%0!\;B4 >&XR 75N/0)Q;D8$;FU/!VML5@EH;%X,96ME#V-J;1%@:78476F!
M%EMHC1A89YL:5F>J&U5GO1Q49]P<5&?V&E1F_QA59O\7567_%E9E_Q569?\5
M5F7_%>)1  #*70  NV8  *]L  "F<0  F7   (YO  "#;@  ?7 % 'AR$@!U
M<R$ <G,O 6]S.@)L<T0$:7),!F9R5 AC<5L+8'!C#5UP:Q!;;W036&Y_%55N
MBQ=3;9D946VH&D]MNQM.;=D:3FST&4]K_QA/:_\74&K_%E!J_Q50:O\54&K_
M%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T
M;'DK &EY-P%F>4 #8WE)!6!X40===U@)6W=@#%AV: Y5=7$14G5\$U!TB!9-
M=)<72W.F&$ESN1E(<]4927+S&$EQ_Q=*<?\62G#_%4MP_Q1+</\42W#_%-1:
M  # 9@  LV\  *AV  "=>0  CW@  (1X  !W>0  ;WP  &I]#0!G?AD 9'\F
M &* ,@%?@#T"7(!& UI_3@57?U4'5'Y="5)]90Q/?6\.3'QY$4I\AA-'>Y05
M17ND%D1[MQ9#>](60WKR%D-Y_Q5#>/\41'?_%$1V_Q-$=O\31';_$\U?  "[
M:P  KG0  *1\  "7?@  BGT  ']^  !R?P  9H,  &&$" !>AA, 7(<A %J'
M+@!8AS@!58=" E.'2@-0AU(%3H9:!TN&8@E)A6P+1H5W#4.$@P]!A)(1/X2B
M$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0
MJGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/
MD#, 39 ] 4N010))D$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.
MLPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(
M )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L
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M 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP
M:*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6
MO"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]
M^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP
M %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT
M!\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0
MS/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y
M   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>
M  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<
M -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   L
MQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E
M&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y
M  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T
M%=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$
M\Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_
M]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(
M  /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P  _PT
M /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0
M_]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\
M90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z
M /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\
M_@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_
M &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P
MP #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &<
M_P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q
M ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8
M&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L
M /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,,
MY #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_
M&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"
M< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70
M -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L
M_QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>
M#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81
MZ0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R
M /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT
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M!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0
MRC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!I#5E J(U;0*@
M-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0->P(CC;^"(PV
M_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$
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M#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$
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M#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$
M=6(N ')B.0%O8D,";&%+ VIA4P5G85H'96!B"6-@:@M@7W,-7EY]#UM>B1%9
M79825UVE$U5=MA147<X45%WN$U1=_Q%57/\055S_#E5;_PY66_\-5EO_#=Y,
M  #'5@  N%\  *UD  "@90  DV0  (EC  !_80  >6(# '5D$0!R91X ;V8K
M &QG-P%J9T "9V9) V5F401B95@&8&5@"%UD9PI;9' ,66-[#E9CAA!48I02
M4F*C$U!BM!-/8LP33V+M$D]A_Q%/8?\04&#_#E!@_PY08/\-4&#_#=E/  ##
M6@  M&,  *EI  ";:   CV<  (1G  !Y90  <V<  &]I#@!L:AL :6LH &=L
M- !D;#T!8FQ& E]K3@1=:U8%6FI=!UAJ90E6:6X+4VEX#5%HA ].:)(03&>A
M$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@
ML6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !>
M<3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5N
ML!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P
M *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8
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M!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@
M=G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P W
MDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0
M^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4
M &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@
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M  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K
M-;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P
MPC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##
M_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H
M !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H
M -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P
MUO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'
M   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G
M  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\
M .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "
MV    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T
M)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT
M '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0
M .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0
M_R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+
M( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V
M /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L
M_P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_
M"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\
M>@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9
M /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4
M_P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z
M 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D
MY@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/
M /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@
M[0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8
M /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+
M# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z
M -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T
MQP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_
M#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$
M>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O]
M +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8
M^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_
M#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5
M_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4%
M -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@
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M X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L
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M!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0
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M#%53L U44\4-4U/F#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4
MM5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G
M6ST!95M% 6-;30)A6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8
MK@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP
M *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH
M8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*
M7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A
M  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#< 6F1
M 5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)1V*:"D9BJ@M$8K\+
M1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",
M8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J
M10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>
M"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P
M>V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*
M<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN
M]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL
M &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0
M07A- 3]X50$]>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q
M=/\%,7/_!3%R_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q
M  !<<P  47<  $IZ  !"?0, /WX. /_B?1!)0T-?4%)/1DE,10 +$CU_&  \
M?R, .X M #J -@ Y@3\ .(%( #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!
MH0,J@;8#*8'2 RE_\P,I??\#*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78
M (5U  !X=0  ;74  &%W  !7>@  3'X  $.!   [A0  -8@) #*)$0 QB1L
M,(DE "^*+P NBC@ +8M! "R+2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$B
MB[,!(8S. 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z
M  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  DE!, (Y0<
M "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7F0 7EZX
M%9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L
M@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A
M&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+
M  NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP
M6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &
MK1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "N
MU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H
M $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X#@  N10
M +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q
MO.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM
M   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84
M  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH
M ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   D
MO   &;\  !'"   *Q0   LD   #,    T    -$   #2 0  TP@  -4-  #7
M$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F
M  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP
M#\H   ?.    T0   -8   #<    WP   .    #B    Y    .8#  #H"0
MZ0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #Y
MY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@
M  #=    X0   .0   #H    ZP   .T   #O    \0   /,   #V    ^ ,
M /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP
M_]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\
M7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O
M /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\
M\ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_
M &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /<
MM #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_
M /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\
M^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H
M +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-
M$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B
M .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0
MU0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_
M# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X
M90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[
M ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@
M_PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#)
M &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0
MQP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\
M /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$
MN05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F
M"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09
M  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C
M *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X
MEQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*
M)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;
M90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J( DAZO ) >OP"/']@ C"#Q
M 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@  VBT  ,HP  "^+@
MM2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7)%$ E219 ),E8 "2
M)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K 80GNP&#*-$!@"CN 7XI
M_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4  ,$X  "T-@  JS$
M *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-+4P BRU4 (DN7 "'+F,
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M V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10  E4,  (Y   ")/
MA#P* ( ]% !]/B( >C\N 'A . !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J
M07 #:$%Y V=!A 1E09$%8T&?!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU
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M \Y$  "\3@  KE0  )Q3  ".4@  @U$  'I0  !R30  ;$\  &A0"P!E414
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M!4!=HP8_7;8&/EW0!CU<\04^6_\$/EK_!#Y:_P,^6?\#/UG_ \%0  "Q6@
MH5T  )!<  ""6P  =EL  &U;  !A6P  6UT  %9>  !28 T 4&$7 $YB(@!-
M8BP 3&,U $IC/@!)8T8 1V-. $9C5@%$8UX!0F-H D!C<P,^8X$#/&.0!#IB
MH00Y8K0%.&/-!3AB[P0X8?\$.&#_ SA?_P,Y7O\#.5[_ [Q5  "M7P  G&
M (M?  !]7P  <E\  &A?  !=8   56(  $]D  !+9@H 26<2 $=H'0!%:"<
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M 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@  BFT  'ML  !O;
M96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G@A0 )H(> "6")P D
M@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$E0 :A*D &(3! !B#
MY@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,
M %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB<
M%XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .
MC?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^
M  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF
M  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?
M IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [
MC0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F
M*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\
M  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6   RF@
M*)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#   LA$  +(7  "S'P
MLR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T
M_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P
M !:P   /M   ";<   &Y    O0   +X   "^!@  OPP  , 0  #!%@  PAT
M ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@
MQ_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]
M   &P    ,,   #'    R0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;
M  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\
M -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4P@  #,8   /)
MS    -    #5    V0   -H   #<    W@   .    #B!0  Y L  .<0  #J
M&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T
M &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@   -(   #7    W
M .    #E    YP   .D   #K    [0   .\   #Q    \P   /8'  #Y#@
M_!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\
M& #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M
M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\
M_0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_
M !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\
M< #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#'
M .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X
M_P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S
M '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .
MTP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P &
M /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P
MX@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#)
M .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\
M! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M
M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L
MMP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V
M  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P
M;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K
M *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!
MV@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L
M &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&
M^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T
M ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH
MGPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",
M$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1
M  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L
M )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\
M?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D
M%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>
M;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_
M '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$
ME1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![
M)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI
M_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0  F#(  )(M  ".*0  BR<,
M (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\
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M =0W  # 00  KT0  )U#  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@
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M TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3
MHDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!6
M3"\ 54TX %--0 !234@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-
MGP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\
M (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P
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M C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P
M:5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y
M8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2IC
MXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L
M %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34
M+VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C
M:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@
M  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W
M "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?<
M&G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(
M:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\
M.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_
M !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<
M.70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .
MASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#
M_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT
M "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,
M ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P
MC_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-
M   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U
M  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\
M )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2
MG@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O
M-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_
M (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K
M!*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P
MP#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-
M  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X
M  #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL
M -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@
MG@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/
M    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ
M  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0
M2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
MXP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_
M+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2
M /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@
M_P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X
M /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\
M#P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y
M /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X
MZ0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_
M !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L
M>@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X
M -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T
M_  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5
M 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\
M_P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1
M .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ',
MP !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M
M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -,
M%0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T
M *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\
MG@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"]
M !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$
M=0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_
M )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !(
MK  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3
M W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+
M_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46
M )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0
MA@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W
M$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0
M&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X
M 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\
M;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$
M&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @
M?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_
M . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX
M>",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E
M*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L
M  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE
M &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0
M7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "]
M.@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q
M*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360
M 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0
MHSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>
M-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZ
MG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\
M (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X
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M 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P
M:T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%
M2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,
MW0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H
M %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L
M/E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O
M4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-
M  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_
M #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4
M*57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.
M4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<
M0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_
M "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@
M0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E
M8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@
M_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX
M #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T(
M&FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3
M:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G
M   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&
M  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\
M#'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D
M<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_
M2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_
M (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?
M%H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P
MBU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M
M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P
M  N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<
M )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O
M<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<
M    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,
M  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P
M67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
MK@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z
M4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L
M $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[    O@
M +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1
MT%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA
M   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0   ,X
M  #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D
M .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   F
MN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .    #B
M    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/
M  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8
M_P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_
M (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /,
M_P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P =
M /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (
M\@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B
M /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\
M) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"
M .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\
MRP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M
M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H
M@ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_
M +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ",
MT@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U
M ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4
M_P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H
M +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H
MI "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7
M /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L
M+ "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!]
M )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\
MB #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0";
M #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (<
M@0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_
M /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D
MC0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z
M"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6
M  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM
M ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8<
M;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&
M)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84
M,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0
M &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@
MJ"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K
M'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HB
MG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX
M )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$
M8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1
M*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR
M  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV
M %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@
M22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![
M-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q
M.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y
M $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.
M;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,
M-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TY
MTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH
M &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP
M1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W
M/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]
M  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!!
M $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?
M,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4
M/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%
M1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_
M "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P
M2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S
M2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)
M_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@
M #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@
M*U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B
M3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.
M   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9.
M ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\
M'%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q
M50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=
M50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_
M )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P
M)5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  0
M95T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5
M  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4
M !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E<
M!FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T
M6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q
M   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>
M  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P
M8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (
M?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$
M:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,
M %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@
M (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P
MDG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM
M   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F    )D
M  ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD
M **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W
M?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@   "I
M    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S
M  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@
M(Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
MNP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*
M?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4
M !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+    S
M ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P
MYHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\
M    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X    .(
M  #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H
M /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_
M #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P
MC0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_
M -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$
M_P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L
M (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D
M_P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V
M /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@
MU "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V
M /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$
M.P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP")
M +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\
MIP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$
M #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H
MBP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_
M /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #<
MK0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8
M (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P
M  #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z
M )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D
MB "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@
M"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T
M/ "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0
M 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$
MN1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_
M #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"
MF@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<
M )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@
M<PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B
M#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=
M  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [
M &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z<
M5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!
M(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7
M/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW
M $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P
M<B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7
M'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<B
MS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H
M &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X
M3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _
M*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M
M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M"
M $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L
M.BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8
M+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q
M1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_
M #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P
M4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \
M-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U
M_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0
M $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH
M-3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K
M.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z
M   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0
M "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\
M)CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y
M/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$
M6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_
M )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10
M,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @
M2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"
M  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL
M "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T
M%U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![
M1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3
M P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H
M  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@
M9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   5
M7 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =>
M<P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX
M %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P,
M#&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0
M9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12
M  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)
M  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D
M '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&
M5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X
M"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(
M  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P
M-6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@
MA0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+
MF0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX
M "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2    E 4
M )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0
MFZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!
M   2AP  #(P   21    E0   )D   "=    H    *$   "B    I    *4!
M  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$
M *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,
MF    YT   "B    I@   *H   "N    L    +$   "S    M    +8   "X
M    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O
M  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0
M *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
MS0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #A
MO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\
M  #$    R    ,X   #1    U    -4   #8    V@   -T   #?    X@
M .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP
M^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\
M2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7
M /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\
MP@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#]
M $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0
MF@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_
M /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8
MZ !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#(
M )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\
M  #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!(
M ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8
ML@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_
M    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4
M2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP":
M )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
MY    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@
M $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P
MH0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0
M +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $,
MC@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\
M *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!
M  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !#
M 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4
M;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3
M"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ',
M1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R
M &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0
M@ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G
M T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'
MQ@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8
M '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$(
M7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-
M$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:
M  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)%
M %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@
M11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?
M'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T9
M2 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\
M #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@
M5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%
M($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B
M_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,
M $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H
M/293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R
M)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF
M  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0
M #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\
M+2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!
M*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P
M6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_
M )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,
M.C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J
M-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q
M  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4&
M #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\
M(SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_
M-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P[
M"P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I
M !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.
M:CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D
M0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$
M=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT
M %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P
M&TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .
M2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9
M  !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U .
M !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($
M!5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*
M1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8
M$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1
M  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P
M0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@
M7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?
MH@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP
M #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\
M &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0
M:;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6
M   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0
M  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$
M '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =
M8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!
M$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)
M  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<
M#G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0"P
MD0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3
MZ@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0
M  ")    C@   )(   "6    F    )H   ";    G0   )\   "A P  HP@
M *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0
MI_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":
M    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0   +@%
M  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\
M +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
ML    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H   #-
M @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR
M $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^    P@
M ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
MY@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\
M!@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5
M /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8
M[@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_
M    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0
M5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K
M -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M_P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #;
M %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T
ML@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P
M /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F
M +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\
M  #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/
M *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +(
MD@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z
M    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0
M3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^
M (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
MH    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20""
M $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '(
MSP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0
M (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D
M<P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D
M .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X
M  ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!)
M &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$
M6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O
M!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P
M2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T
M $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@
M8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3
M"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,
M_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$
M %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT
M2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]
M$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3
M  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12
M $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\
M-Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+
M%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:
M6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_
M )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' (
M0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S
M(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB
M  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$)
M #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X
M*R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  "
M)P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F
M#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII
M "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@
M;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N
M+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O
M=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X
M %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1
M)S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8
M-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q
M  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382
M " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80
M$3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+
M-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]
M%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5
M  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P
M03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 1
M0Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#
MI0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH
M #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0
M"TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0
M2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]
M   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7
M  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4
M %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J
M0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9
M&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1
M  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@
M'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0
M8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A
M\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4
M !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8
M ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P
M;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD
M   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6
M  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\
M 'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M=@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0
M%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_
M %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@
M (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B#P
MI!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA
M  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F    )T
M  "A    I    *4   "G    J0   *L   "M    L    +(   "U"   N X
M +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y
M<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +    "S
M    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04  -$.
M  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@
M(X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
MR@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%  #K
M#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $
M /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X
M_P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F
M .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\
M  #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!>
M .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X
M_^)]$$E#0U]04D]&24Q%  P2R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_
M /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L
MW0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\
M )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\
M  #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ]
M +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H
MHP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V
M    YP   -,   #&    O0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8
M/0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ".
M (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,   #C
MS    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1
M #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P
ME !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+    MP
M *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$ A  I (( , !_ #<
M?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L
M )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(   "X    I0   )<
M  "-    A@   ($   !\  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W
M &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8
M70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_
M @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P 8P R &(
M. !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C
M %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P
M; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6
M #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@
ML@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\
M %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4
M30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^
M \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82
M  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX
M $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,<
M-0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-
M%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X/
M/  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L
M "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;  !'&@
M1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V
M%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5
M_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P
M #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T
M+AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B
M&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>
M   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]#
M "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\
M'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \(P  .",  #4B   S
M(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D
M2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_
M (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E   N)
M*R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;
M*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E
M  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD
M "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E
M%"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J
M*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK   F+   (BX  !\O
M   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;
M  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0
M6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(  !LS   7
M-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX
M90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$
M $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P  &S8  !<X   3.@(
M$#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80
M/G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T
M   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(
M  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T
M $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [
M-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"   -10$ "$<'  -)
M#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]
M  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@
M,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (3    D\%  !0"@
M4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4
MCP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX
M "=    @0P  &48  !-)   /3   "T\   92    5    %<"  !8!P  60L
M %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0
M7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(
M   :2P  $TX   Y2   *50   UD   !;    7@   &    !B @  8P8  &4*
M  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T
M &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L2@  (TT  !M1   3
M50  #ED   A=   !80   &0   !G    :@   &P   !N    <    '(%  !S
M"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S
M  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<   -80
M!F8   !J    ;P   '(   !V    >0   'P   !]    ?P   ($   "# @
MA@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(
MSP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %<    '8
M  ![    ?P   (,   "'    B@   (T   ".    D0   ),   "5    F
M )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@  "=P0
MF^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[    @0   (<   "-
M    D@   )8   ":    G0   )\   "A    I    *8   "H    JP   *X
M  "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(
M +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".    E    )H   "@
MI0   *H   "N    L0   +(   "U    MP   +H   "\    OP   ,,   #&
M    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO
M #=Q   I>   '8   !&)   (D0   )H   "A    IP   *T   "S    N0
M +X   #"    Q0   ,8   #)    S    ,X   #2    U0   -H   #>
MX0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\
M  #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+
M /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T
MZ0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_
M    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\
M30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B
M ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_
M_0   /H   #X    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#-
M $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T M ": +$
MJ0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@
M .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4
ML0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8
M +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D
M  "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$
M )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@
M@P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0   +$   "F
M    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4
M0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S
M '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X   "3
MC    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R
M $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$
MP@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#    ?
M '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T
M8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4
M -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\   !U    ;@   &D
M  !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ]
M %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X
M20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;
M    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P
M/@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J
M #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0
M4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!"
M $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8
M^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q   $X0  !*#@  2 T
M $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X
M.@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M
M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .
M  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM#
M #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\
M)PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _%0  /!0  #H2   Y
M$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P0
M2P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_
M (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46   T%
M,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D
M%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7
M  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L  #$:   O&0  +A8
M "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$
M'1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K
M'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=   K'   *1L  "<;
M!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY;
M !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P
M62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @
M( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C
M9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,
M $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P  (",  !TD   ;)0<
M&28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,
M*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G
M   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+
M !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7
M!"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \
M*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ
M#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_
M   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+
M,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0,@( #C0'  HW#  '
M-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X6   .&@  #A\   W
MD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X
M "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X
M #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP
M/:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO
M   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0
M  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0
M $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R-   +3,  "8T   @
M-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(!P  2@L  $L.  !,
M$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\
M  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/
M%3\  !!"   ,10  !T@   )*    30   $\   !1!   4@<  %0+  !5#@
M5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8?P  5YH  %:W  !5
MXP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X  !Q!   51   $$@
M  M+   %3@   %$   !4    5P   %D   !;    70(  %X&  !@"P  8@X
M &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0
M8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*   03@  "E(   -6
M    6@   %T   !@    8P   &4   !G    :0   &L!  !M!0  ;PH  '(.
M  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<
M &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )6@   5\   !C
M:    &L   !O    <@   '4   !W    >0   'L   !]    @ ,  (,(  "&
M#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__
M $9+   Z3   +D\  "-3   86   $%X   ED    :0   &\   !T    >
M 'P   "!    A    (<   "(    BP   (X   "0    DP   )8   "9!P
MG0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2
M   R50  )EH  !M@   19P  "6T   !T    >P   ($   "&    BP   )
M  "4    EP   )D   "<    GP   *$   "D    IP   *H   "M    L08
M +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K
M80  'F@  !-P   +>    (    "'    C@   )4   ":    GP   *0   "H
M    K    *T   "P    LP   +4   "X    NP   +\   ##    QP   ,L%
M  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<
M%GD   V!   !BP   ),   ";    H@   *@   "N    M    +@   "]
MP    ,(   #%    R    ,L   #.    T0   -8   #;    WP   .0   #H
M!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_    _P
M /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4
M_ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#?
M -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_    _@   /P
M  #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4
M .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4
MO0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R
M    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,(
M4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#<
M *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\   #/
MR    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F
M %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X
M\ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0   +\   "S    J@
M *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H
MC@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y
M /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<   "=    E    (X
M 0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![ $, >0!(
M '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8
M9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")    @@   'L   !X
M  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@
M2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_
M %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y    <0   &T   !I  $
M9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8
M $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T
M_P!- /\ 30#_ *H   "4    @@   '4   !K    9    &    !=    6@ %
M %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $,
M3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!#
M /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!  !2    4  " $X
M"0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!%
M $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\
M.0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$
M  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@
M20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_
M (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @
M/ $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O
M %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,
M  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@*
M #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX
M)P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M
M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0   P#P$ , T& # +
M"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8
M " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P
M6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I
M#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D0
M9@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<
M $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0  )A0! "42!  C$@L
M(A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16 !049  2
M%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;
M   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18-
M !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7(
M#1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \
M'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<
M$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z
M  <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P
M,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0
M(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $B
MD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$
M "HA   F(   (B   !\?   <'P  &2   !8A   2(P( $"0'  XF#  ,)A
M"R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP
M)J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C
M   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3
M  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0
M "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C
M)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q
M%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\
M   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G   A)@
M'"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/   W$@
M.!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   V
MY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H  "0I   >*@  &2L
M !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH  #T-   ^$   0!0
M $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP
M//P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M   :+P  %3$  !$S
M   --@  "3@   4[    /0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6
M  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P
M $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6-0  $3@   T[   (
M/@   T$   !#    1@   $@   !*    3 0  $X'  !/"P  40X  %02  !5
M&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_
M $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0  #$$   =$    2
M $H   !-    4    %,   !5    5P   %@"  !;!@  70L  %\.  !B$P
M8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\
M   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL   !/    4P   %8
M  !9    7    %\   !A    8P   &4   !G 0  :@4  &T*  !P#@  <Q4
M '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y
M/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=    80   &4   !H
M    :P   &X   !Q    <P   '4   !X    >P   'X#  "!"@  A0\  (<7
M  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$   S10
M*$@  !U,   34@  #%<   -=    8P   &@   !M    <0   '8   !Z
M?@   ($   "#    A@   (D   "+    C@   )(   "5 0  F0D  )X0  ">
M&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,
M !59   -8    V<   !N    =    'H   "     A    (H   ".    D@
M )4   "7    F@   )T   "@    HP   *<   "K    KP   +0)  "X$
MMQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5   D6P  &&$   YI
M   %<0   'D   "!    B    (\   "4    F@   )\   "D    J    *D
M  "L    KP   +,   "U    N0   +T   #!    Q@   ,L   #1"@  TQ0
M -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$   =[
MA    (T   "5    G0   *,   "I    KP   +0   "Y    O    +X   #"
M    Q0   ,@   #,    T    -0   #:    WP   .0   #J    [@P  .T:
M  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_    _P   /P  0#\  @
M_@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V
M &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H
M_P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@   /,   #S    ]@ )
M /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L
MU@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G
M /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<   #G    Y  ! .
M"P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9
M +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\
MBP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&    OP   +D !@"W
M  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L
M5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_
M '8 _P!S /\ <@#_ .    #0    Q@   +8   "I    H0   )T  0"9  H
MF  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "#
M %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D
M_P!G /\ 90#_ ,P   "^    JP   )T   "3    B@   (4   ""  4 @  -
M '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X <@!# '  20!O $\
M;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!;
M /\ 6@#_ +T   "I    EP   (D   !^    >    ',   !O  $ ;0 ) &P
M#@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/
M %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\
M3P#_ *T   "8    A@   '@   !N    9P   &,   !@    70 % %P "P!;
M !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X
M40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_
M )\   ")    >    &P   !B    6P   %8   !3    40 " $\ " !/  T
M3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !"
M %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),
M  !^    ;@   &$   !8    40   $P   !)    1P   $4 !0!$  L 0P .
M $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %
M-P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V
M P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P  P [  @ .@ - #H
M$  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7
M "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"
M7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q
M !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D /P H $D )P!4 "8
M8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T
M $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0, +08( "P$#  K @\
M*@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 >
M 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0
M  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0
M "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L
M%@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]
M$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-!P A# L ( L. !\+
M$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^
M  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%
M,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9
M#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0
MD  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8
M "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A(
M$A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $
M%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8
M   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5
M  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$
M !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R&@  *QH  "4:   A
M&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;
M&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR   <B   '*   !NY
M   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P
M'!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #
M(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   AA@  ()X  ""X   ?
MW@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP
M !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D
M "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W   DWP
M(_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?   ='@  &AT  !8>
M   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=
M   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH  "JU   IWP  *?L
M "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <(   %R   !,A   0
M(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S
M(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_
M $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F   .*
M"RH   <L   #+P   #$"   S!   -0<  #<*   Y#0  .A   #L5   ['0
M.R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I
M   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H   XL   *+P  !C$
M  $T    -@   #@    [ 0  /00  #\'  !!"@  0PX  $41  !%&   12$
M $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X
M+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT   $-P   #H    \
M    /P   $$   !$    1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G
M  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR   U,0
M+B\  "DN   @+@  &3$  !(S   .-P  "3H   (]    0    $0   !'
M20   $P   !/    40   %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>
M+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(
M "0S   ;-@  $SD   X]   (00   $4   !)    3    %    !3    5@
M %D   !;    70   &    !B    90   &@%  !K"P  ;Q   &\8  !N)0
M;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[
M   5/P  #D0   =)    30   %(   !6    6@   %X   !B    90   &@
M  !K    ;0   '    !S    =@   'D   !]!   @0L  (41  "$'0  @BP
M ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /
M2P  !U$   !7    7    &(   !F    :P   &\   !T    >    'L   !^
M    @    (,   "&    B@   (T   "1    E@,  )L,  "=$P  FR$  )HS
M  "720  E&(  )-_  "0H   CL4  (SS #%$   E2   &DT  !!3   (6@
M &$   !H    ;@   '0   !Y    ?P   (0   ")    C0   )$   "3
ME@   )D   "=    H    *0   "H    K    +(#  "W#0  MQ<  +4H  "R
M/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL   IB    :@   ',
M  ![    @@   (D   ".    E    )H   "?    I    *8   "I    K0
M +    "S    MP   +L   #     Q0   ,L   #1!   U0X  -,=  #0,@
MS4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T    ?0   (<   "0
M    EP   )X   "D    JP   +$   "V    N@   +P   #     Q    ,@
M  #+    SP   -0   #:    X    .8   #K    \08  / 3  #N)P  [#\
M .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T  4 ]@ , /H $0#_
M !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$
M:@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_
M )8 _P"0 /\ C #_ /H   #R    [    .D   #I    [  % /( # #X !(
M]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#*
M &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@
M_P"# /\ @ #_ /    #E    W@   -H   #;    W    -@ !P#1  X T0 5
M -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$
MK !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V
M /\ = #_ .(   #3    R@   ,<   "\    M@   +   0"O  L K  1 *T
M& "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A
M (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\
M: #_ ,\   #!    N0   *T   "@    F    )0   "1  8 D  - )  $@"/
M !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@
M8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_
M +X   "Q    H    )(   ")    @@   'P   !Z  $ >  ) '< #@!X !0
M=P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C
M &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +
M  "?    C0   '\   !T    ;@   &H   !F    90 $ &, "P!C !  8P 5
M &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P
M4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-
M    ?    &X   !E    7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0
M%@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A
M $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0   !_
M;P   &,   !9    40   $T   !*    2    $< ! !'  H 1@ . $8 $0!'
M !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@
M:0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T    90
M %@   !/    2    $,    _    /0   #P  @ \  < .P , #L #P [ !(
M.@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M
M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\   !L    70$  %$"
M  !( P  0 ,  #L"   W    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3
M #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X
M) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E!   5@8  $L'  !"
M"   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D "P I  X *0 1 "@
M%0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\
M !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P
M-0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @
M !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4
MCP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T
M "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0
M&008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0
M :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/
M   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6
M !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\
M"@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$  "40   A
M$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,
M&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT
M  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2   >$0
M&Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,
M$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .
MU   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0  "$3   <$P  &1(
M !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH
M"!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T   1UP
M$?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5   :%   %Q0  !03
M 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?
M  (6)P  %S   !<[   72   %U@  !=J   6@   %ID  !6T   5V0  %/<
M !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2
M$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;
M)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_
M %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P  %18! !,5!0 1%00
M#Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9   @(0
M(2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9
M   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!
M  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$  "86   F'@  )R<
M "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \
M'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;   -'   "QT   @?
M   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3   N&@  +B,  "XN
M   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0
M+B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +(0  !R,   ,E
M)P   "D    L 0  +@,  # &   S"@  -0T  #81   V%P  -A\  #8I   V
M-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T)   *R0
M "0C   ?(0  &R   !8@   1(0  #B,   HE   &*    BH    M    +P
M #(    T    -P   #D#   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0
M0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E
M   ?(P  &"0  !(E   .*   "BH   4M    ,    #,    V    .    #L
M   ^    0    $(   !% @  1P8  $H*  !-#@  314  $P?  !,*P  2SH
M $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;
M*   %"H   XM   *,   !#,    W    .@   #T   !     0P   $8   !(
M    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&
M  !76@  570  %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM   6+P
M$#(   HV   #.@   #\   !"    1@   $D   !,    3P   %(   !5
M6    %H   !=    8    &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G
M4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT
M  )"    1P   $P   !0    5    %@   !;    7P   &(   !E    :
M &L   !N    <0   '4   !Y    ?08  ((-  ""%@  @"0  'XU  !\20
M>V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)    +10   DL   !1
M    5@   %L   !@    90   &D   !N    <@   '8   !Y    ?    'X
M  ""    A0   (D   ".    DP   )@&  "<#@  FQH  )@K  "60   DED
M )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "5    %L   !A
M:    &X   !S    >0   'X   "#    B    (P   "/    D@   )4   "9
M    G0   *$   "E    J@   +    "W!P  N!$  +4A  "R-0  KTT  *II
M  "HB   IJ@  *+1 "-(   83@  #E0   1<    9    &T   !U    ?
M (,   ")    CP   )4   ";    H    *,   "F    J0   *T   "Q
MM0   +D   "^    Q    ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%
M?   PIT  ,&] !Q5   17   !V4   !N    =P   '\   "(    D    )@
M  "?    I0   *T   "S    N    +H   "^    P@   ,8   #*    S@
M -,   #:    X    .<   #M    \P   /0.  #R'@  [S8  .Q1  #H;@
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M__________________________________________________\
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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M      ,$(0   0                    $                    !
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M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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M6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEO4SPH
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MNF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"&=_?1RC3Z4Q
MRO%15;[R6&BMYF%WGMUGA)+5;(^'SV^6?LMSG'C(=J%RQGFD;L1\IVG"@:EF
MP(:L8K^-K6&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_
MCZYAOX^N8;^/KF&_CZ[_HAT#_Z8G!_^W+PGRQS@-X=A!%-+F1BK'\$Q OOA0
M4[+U5V.BZV%PE>-G>XK=;82!V'&+>M1UD'32>9-PT'R6;,Y_F6C,@YMDRXB=
M8<J-GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@
MR8^?8,F/GV#)CY__I!T#_ZTF!?N^+0;FT#0(T^(\%L?N1BN[^4H^L/Y/3Z;Z
M5UR8\6%HC.MH<8/F;GA[XG-]==]X@7'=>X1MVW^':MJ#B6?9AHIDUXN,8=:0
MCF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.
M8-61CF#5D8[_IQP#_[4C ^[))@/5WRD'Q^P\&;KX1"NM_T@[H_]-29K_5U2-
M^6%=A/1J97SP<&IV[79N<>MZ<6WI?G1KZ()V:.:%=V;EB'ECY(QZ8>.1?&#C
MDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2
M?&#CDGS_JQL"]\ = =G<$@''ZR@*NO<[&JS_02F@_T8VE?],08W_5DN#_V%2
M>_UK5W3Z<5QO^'9?;/9[86GU?V-G](-D9?.&9F/RBF=A\8YH7_"2:5_PDVI?
M\)-J7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_P
MDVK_MQ4!UL\+ ,?J$P*Y]RD-K/\Y&I[_/B:2_T0PA_]+.8#_5$!X_V%&<O]J
M2FS_<$UI_W909O][463_?U-C_X-48?^&56#^B59>_HU77?V26%S]DUA<_9-8
M7/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUC6
MQ @ QM0) +CW% 2K_RD.GO\T&)#_.B&$_T$I>O]),'+_4C9L_UXZ:/]H/63_
M;T!A_W1!7_]Y0U[_?41=_X!%7/^$15O_AT9:_XI'6/^/1UC_D$A8_Y!(6/^0
M2%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$C$QP<
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MM*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;#
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MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>+PW_JC@3_[5
M'/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!YLIZK?KJ5IX3
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M_Z4> _^W(P/MR28#UMXI!LGI.Q>^\T0IL_A).JCW34B?]E55E/5?8(GQ:&B
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M;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC
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M?E3AN'Y4X;A^5.&X?E3AN'Y4X;A^5.&X?E3AN'[_F!,!_ZT4 ?/##P#2V L
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M ^W'+ 3?U3$&T]XY%,;81"BYT4X[K,Q63*#'75J5PF-GB[]I<8*[;WEZN':
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M'C3_EQXR_Z ?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!^FP
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M/$;_O3U%_\P]1/_F/D3_YSY$_^<^1/_G/D3_YSY$_^<^1/_G/D3_YS[+K
MN;8! *S" 0"@T ( E>4' ([_& .$_R0&>O\L"W#_-!!H_SP58?]$&5O_2QU6
M_U,@4_];(E#_8R1-_VLF2_]S)TG_>BE(_X(J1O^**T3_E"Q"_YXM0?^G+D#_
ML2X__[PO/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3"[L0  K+P
M )_)  "3V0  B?P+ 8#_%P)V_R %;/\H"63_, U=_S@05_] $U'_1Q9-_TX8
M2O]6&4?_7!I$_V,<0O]I'4#_<!X__W@>/?^ 'SO_B" Z_Y$A./^;(C?_I"(V
M_ZTC-?^X(S7_N2,U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2.MM@  G\0  )+2
M  "$X0  ??\- 7+_$P)H_QL$7_\C!EC_*PE1_S,+3/\Z#4?_00]#_T@10/].
M$CW_5!,[_UH4.?]?%#?_914U_VL6,_]R%C'_>A<O_X(7+O^+&"S_DQ@K_YP9
M*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQFAOP  DLP  (3<  !X
M]P  ;O\* 6/_$ ):_Q4#4O\=!$O_) 9&_RP(0?\S"3S_.@HY_T +-?]%##+_
M2@TP_U -+O]4#BS_60XJ_UX/*/]D#R;_:@\E_W$0(_]X$"+_@!$@_X@1'_^1
M$1__D1$?_Y$1'_^1$1__D1$?_Y$1'_^1$1__D1'_7"(#_U<M!?]8,P?_7S8)
M_V,]#?]E1A+_9E 7_V5>'/]D;B+_87PG_U^**_]>EB[_7*$Q_UNJ,_]:LC7_
M6;HV_UC#-_]8S3G_5]@Y_U;@.O]5YCO_5.P\_U/Q//Q2]3WX4OD]]5']/?-1
M_SWS4?\]\U'_/?-1_SWS4?\]\U'_/?-1_SW_7"(#_U<L!?]:,@?_834)_V4\
M#?]G11+_:$\7_VA<'?]F;2+_8WLH_V&(+/]?E"__7I\R_UVI-?];L3?_6KDX
M_UK!.O]9RSO_6-4\_U??/?]6YC[_5>L^_53P/_E3]3_V4OE \U+]0/!2_S[P
M4O\^\%+_/O!2_S[P4O\^\%+_/O!2_S[_72$#_U@L!?]<, ?_9#,)_V@Z#?]K
M0Q+_;$X7_VQ:'?]J:B3_9W@I_V2%+O]BD3+_89PV_U^F./]>KCK_7;8\_UR^
M/O];R#__6M)!_UG=0O]7Y4/]5NI$^57P1/54]47Q5/I%[E3^1.Q4_T+L5/]"
M[%3_0NQ4_T+L5/]"[%3_0NQ4_T+_7B$#_UDL!?]?+@;_9C()_VPX#/]O01'_
M;TP7_W%7'O]N9R7_:W4K_VB",/]ECC7_9)DY_V*C//]@JS[_7[-!_UZ[0O]=
MQ$3_7,Y&_UK<1_Y9Y$CZ5^I)]5;P2O!5]DKM5?I*Z5;^1^=6_T7G5O]%YU;_
M1>=6_T7G5O]%YU;_1>=6_T7_7B$#_UDK!?]B+0;_:C (_V\V#/]R0!'_=$H8
M_W55'O]R9";_;W(M_VQ_,_]IBSC_9I8\_V6@0/]CJ$/_8;!&_V"X2/]>P4K_
M7<M+_US:3?I:XT[U6>I/\%?Q4.M6]E'G5_M.Y%C_2^%9_TGA6?])X5G_2>%9
M_TGA6?])X5G_2>%9_TG_7R #_UHK!?]E*P;_;2X(_W,U#/]W/A'_>$@7_WE2
M'_]W8"?_=&XN_W![-?]MASO_:I)!_V>;1?]EI$G^8ZQ,_6&T3OM@O%'Z7L93
M^5W45?5;XU;O6NI8Z5CR6>59]U;@6OM3VUO_3]=;_TW76_]-UUO_3==;_TW7
M6_]-UUO_3==;_TW_8" #_UTI!?]H*0;_<2L'_W@S"_]\/!#_?487_WY0'_]]
M72C_>6HP_W5V./]Q@C_\;8U%^FJ72_AGGT_V9:=3]&*O5O-@N%GQ7\%<\%W-
M7NU<X&#H6NQAX5KR8-I;]EO37/I7SUW]4\Q>_U',7O]1S%[_4<Q>_U',7O]1
MS%[_4<Q>_U'_81\#_V G!/]K)@7_=2D'_WPQ"O^!.A#_@T07_X1-'_^#62C_
M?V8R_'IR._AU?D/U<8A+\FV24>]IFE;M9J);ZF.J7^A@LF/F7KQFY%S(:>%;
MVFO=6NIKTUSP9LU>]6'(7_E<Q&#\6,%A_E7!8?Y5P6'^5<%A_E7!8?Y5P6'^
M5<%A_E7_8A\#_V,E!/]O) 7_>2@&_X$P"O^%.0__B$(6_XE+'O^)5BCZA6(S
M]8!N/?!Z>4?L=8-0Z7",6.5KE5[A9IUDWF.D:=M@K6W77[=OU%[#<-%>TG'-
M7>=QQU_N:\)A\F:^8O9ANF/Y7+=C_%BW8_Q8MV/\6+=C_%BW8_Q8MV/\6+=C
M_%C_8Q\#_V8C!/]R(@3_?2<&_X4N"?^*-P[_C4 5_X])'OJ/4RCTC%\T[H9J
M/^E_=$OC>'Y5WG*&7MAMCV73:IAJSV>@;<QEJ'#)8[%SQF*\=,1AR77!8>!V
MO&/J<;=D[VJT9?-EL&;V8*YG^5RN9_E<KF?Y7*YG^5RN9_E<KF?Y7*YG^5S_
M8QX#_V@A!/]U( 3_@24%_XDM"/^/-0S_DCX4_)1''?663RCND5LTYXMF0>"$
M;T[9?7E8T7>"8,QSBF?';Y-LQ&R;<,!IHW.]9ZQVNF:V>+AEPGFV9=5YLF;F
M=O_B?1!)0T-?4%)/1DE,10 .$JYH[&^J:?!IJ&GT8Z9J]U^F:O=?IFKW7Z9J
M]U^F:O=?IFKW7Z9J]U__9!X#_VL@ _]X'@3_A"0%_XTL!_^3- O_ESP2^)E%
M&_";32?HEUDTX9!B0M>);$[.@W58R'U^8<-XAFB^=(YMN7"6<K9NGG6R;*=X
MKVJQ>ZUIO7RJ:<U]J&KC>J5LZ7*B;.ULH&WR9IYN]6*>;O5BGF[U8IYN]6*>
M;O5BGF[U8IYN]6+_91T"_VT> _]['0/_AR,$_Y J!O^7,@K]G#L0])]#&>RA
M2R7CG%8SVI9@0<^.:4['B')8P()Z8;I]@FBU>8INL762<ZQRFG>I<*-ZIFZL
M?:-MN'ZA;<=_GV[@?IQPYW6:<.MOF7'P:)=Q\V27<?-DEW'S9)=Q\V27<?-D
MEW'S9)=Q\V3_91T"_V\= _]^' /_BB($_Y,I!?^;,0GYH#D/\*-!&.>F22/>
MH50QTII>0,B39TW C&]8N8=W8;."?VBN?8=NJ7J.<Z1WEGB@=)][G7.H?IIQ
MM("8<<*!EG+8@95TY7B3=.IQDG7O:Y%U\F:1=?)FD77R9I%U\F:1=?)FD77R
M9I%U\F;_9AT"_W$; _^ &P/_C"$#_Y8H!?^>+PCVI#<-[*@_%>.K2"#8IE(P
MS)Y<0,.794V[D6U7LXMT8:V&?&BG@H-NHGZ+=)U[DWB9>9Q\E7>E?Y)VL(&0
M=;Z"CG;1@HYXXWJ->.ASC'CM;(MX\6B+>/%HBWCQ:(MX\6B+>/%HBWCQ:(MX
M\6C_9QP"_W,: O^"&@+_CR #_YDF!/ZB+@;SJ#4+Z:T]$]^O1A[2J5$OQZ):
M/[Z;8TRUE6I7KH]R8*>+>6BAAX%NG(.(=)> D'B2?9E\CGRB@(MZK8*(>KN#
MAWK-@X=\XGR'?.=UAGSL;H9\\&F&?/!IAGSP:89\\&F&?/!IAGSP:89\\&G_
M9QP"_W49 O^%&0+_DA\"_YPE _NE+ 7PK#0)YK([$-NS1!W-K4\NPZ99/KF?
M84NPF6A6J)1P7Z&/=V>;BWYNEHB&<Y"%CGB,@I9\B("@@(1_JX*!?[B#?W_*
MA(&!X7V!@>9V@8#K;X" [VJ @.]J@(#O:H" [VJ @.]J@(#O:H" [VK_:!P"
M_W@7 O^'& +_E!T"_Y\C _BI*@3LL3$'XK<Y#=6W0AS)L$XMOJI7/;2C7TJK
MGF=5HYAN7YR4=6:6D'QMD(V#<XN*BWB&B)1\@8:>@'V$J()[A+6$>83'A'J&
MX'][A>9W>X7K<'N$[FM[A.YK>X3N:WN$[FM[A.YK>X3N:WN$[FO_:1L"_WH6
M O^*%P+_EQP"_Z,A O2M)P/HM2X%WKTU"M"Z0!O$M$PLNJY6.Z^H7DFFHF54
MGIUL79>9<V:0E7ELBI*!<H60B7=_C9)\>XN;?W>*IH)TB;.#<HK$@W2,X']T
MB^5X=8GJ<7:([6QVB.UL=HCM;':([6QVB.UL=HCM;':([6S_:QH"_WT4 O^-
M%@'_FAH!_Z8> ?"Q(P+DNRD#V<(P"<N]/QG N$HJM;)4.JJL7$>AIV-2F:-J
M7)&?<62*FW=KA)A_<7Z6AG9YDX][=)*9?G"0I(%MD+&":Y#!@FV2W7]ND>5X
M;X_J<7".[6QPCNUL<([M;'".[6QPCNUL<([M;'".[6S_;A@"_X 2 ?^0%0'_
MGA<!^ZL: >RW'@'@PR$!TL8M",;!/1BZO$DHK[=2.*6R6D6<K6%1DZEH6HNE
M;V*$HG5I?I]\;WB=A'1SFXUY;IF6?&J8HG]GEZZ 99B_@669V']HF.5X:9;J
M<6J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0
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M85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8 OL$% +?/"0"PXQ$
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M$B7_D!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@
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M9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1 ?^'$P'_E!4
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M7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08 T;$( ,N[" #&QPL
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M*CW\N2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J
MKK   *&\  "5R   B=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/
M_T<12_].$T?_5A5$_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_
MK!\S_[D?,__('S+_XB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<
M )7$  "'T   >]T  '+]"0!J_Q$!8?\9 EK_(@-4_RH%3O\R!TG_.@E%_T$+
M0?](##[_3@X[_U4/./];$#;_8A$T_VD1,O]R$B__>Q,M_X84*_^2%2K_GA4I
M_ZD6*/^S%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,
M  !ZV@  ;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O]
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M ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M
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M6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0
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M4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T
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M2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0
MRYP  +VG  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-H
MW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<
MR#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,
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M&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S
M==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V
M_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_
MP1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(
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M/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y
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M1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\- .>8#0#;GPX
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M4U.?P%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0
MX(8  ,^3  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\
MM5 B=;-8*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJ
MP$U-JMQ-3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP
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M,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0
MEKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-
MY%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC
M^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(
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M"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0
M1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=
M_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_
MN@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\
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M-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/ /"%$0#CB18
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M3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0
M]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*
MF5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)
MO4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH
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M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP
MK*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUONDD4:KA1&F6W61]@
MMF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:RN3I%LM$Z1K'M.4>P
M_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY   +N<  "NHP  I*H
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M&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP
M8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX
M[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK
M_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X
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M PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P<
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M1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708
M_VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'H(I"#IJ&3!:3
M@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P=*!";7.M1&MS
MO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X_S'_7P( ]VP
M -YW  #0@0  QX@! ,"- P"YD0, LI,1 *N3(P&CD3,&G(Y #96+2A6/B%,<
MB89;(H2#8BB @6DM?']P,7A^=S5T?( X<7N)/&YZDS]K>9Y":'BK1&9XNT5D
M>-%%9GGN0&A[_3IJ>_\V:WS_,FM\_S)K?/\R:WS_,FM\_S+_80  ZF\  -EZ
M  #,A   PXL  +N1 0"TE0$ K)<. *67(0&>EC$%EY,^#)"02!2*CE$;A(M9
M(7^)8"=[AV<K=X5N,'.$=31O@GTW:X&'.VB D3YE?YQ!8GZI0V!^N41??L]$
M8'_L0&* _#ID@/\V98'_,V:!_S)F@?\R9H'_,F:!_S+_9   Y7(  --^  #'
MAP  OH\  +:5  "NF0  IIL, *"<'@"9FRX$DID["HN61A*%E$\9?Y%7'WJ/
M7B5UCF4J<8QL+FV*<S)IB7LV9HB$.6*&CSU?A9H_7(6H05J%MT)9A<Q"6H7J
M/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C
MN9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_FDP7>9A4'7277")P
ME6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-MD!3C<M 5(WI/5:-
M^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L  ,B'  "]D   M)@
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M*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@
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M"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D
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M 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP
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M-X)>PC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8
M_UT  .=G  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<
M<%<8F&U?'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IB
MOCEY8M4Y>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V
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M-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P
MP((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[
M?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V
M^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4
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M*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@
MCIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519EF%P:89=C'EZ6:B%;
ME7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1]2U-D?\J3I#_*$Z0
M_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<  )V;  "3GP  AJ0
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M&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@<
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M R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@
MF*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K
M[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?T
MD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T
M '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!,
M'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*
M_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_
M  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3
M !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT
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M)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@
M_U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ
M6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1
MPRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,
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M+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0
MQ'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1;E$/C6Q9%(EJ8!>%
M:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!BMB]O8LDO;F+F+F]D
M^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\  -=I  #*<   P'4
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M(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8   *V$  "DA0
MFH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q?5X8;GME&VMZ;!YH
M>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV\RI;=O\F7'?_(UQW
M_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80  *B(  "?B0  E(H
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M4(/_'U"#_Q_>:0  R74  +R   "RB   _^)]$$E#0U]04D]&24Q%  \2J(T
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M&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?EP  E9P  (FA  !]I@
M<:H  &2N  !:L0@ 5[$4 %6R(P!3LC !4+([ DVR1 -+L4T%2+%5!T6Q70E#
ML64+0+!O#3ZP>@\[L(<1.:^6$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K
M_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(
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M A?:_P*@G   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP
M*=D  "'>!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1
M[6< $.YW !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK
M_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$
M !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<
M _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+
MJP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z
M   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3
M  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_M
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M ?(3_P'Q$_\"\!3_ O 4_P+P%/\"\!3_ O 4_P+_*A\ _RP< /\L&P#_*QT
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M";HS_PFZ,_\)NC/_";HS_PG_.1  _ST+ /] "0#_1 T _T81 /]%&0#W1",
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M_Q3_1P  ^$\  .17  #570  S&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY
M Z%<2P>=6E0*F5E<#I989!&35FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?
M@U&J(8%1N")_4<LB?E+G(7Y3^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_
M2@  [E(  -Y;  #/80  QF0  +]E  "Z8P( LV(/ *QC( "F8S !H&(] YMA
M2 :67U$*DEY9#8]<81&,6V@3B5IO%H99=AB$6'X:@E>''']7D!]]5ILA>U:G
M(GE6M2-W5L<D=E;D)'97]Q]W6/\;=UG_&7=9_Q=W6?\6=UG_%G=9_Q;_3
MZ58  -E?  #+90  P6@  +II  "T:   K6<- *9H' "@:"T!FF<Z Y5E10:0
M8TX*C&)7#8EA7A"&7V43@UYL%H!=<QA^7'L:>UR#'7E;C1]V6I@A=%JD(W):
MLB1Q6L0E;UKA)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D
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M)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL5P  V6(  ,=K  "\<@
MLW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W.P1\=44'>'1-"G1R50YQ
M<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<(UQKJB5::[LF66S3)EIL
M[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL
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M&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-C0
M?(T  '6.! !OCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3
MBV@24(IQ%$V)>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&
M_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94
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M#2^E_PVVA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@
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M !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@
MD:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5
MV@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F
M@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D
M '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP
M"_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0
M\H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ
M  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!
M  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT
M /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/
MS0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_
M    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K
M  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2<
M_Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_
M *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T
M_P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I
M /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP
M_P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W
M _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5
M+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ?
M /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\
M[0S_ >T,_P'M#/\![0S_ >T,_P'_)1L _R88 /\E%P#_(1@ _R A /\>*P#_
M&C< _Q=% /\440'_$EX!_Q%I ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0
MH0'W$*@!]A"O ?00MP#S$,( \1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_
M >(2_P'A$O\!X1+_ >$2_P'_*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S,
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M!Z<S_P?_-P< _SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$
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M%(]#NA6-0\T5BT3H%8I%^A*)1O\0B4;_#HA&_PV(1O\-B$;_#8A&_PW_0
M\D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0(@"L43( IU$_ J)02@.>
M3U,%FTY<")A-8PJ53&H,DTMQ#9%*>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(
MM1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L
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M'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  # 9
MMV<  *YH  "G9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?5@EZ
M7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1'65:
M[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH
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M%E=H_Q189_\36&?_$UAG_Q/A6   RV,  +UK  "R<@  J78  *!X  "6=P
MB',  (%S"P!\=!< >'0F '1T,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?
M;VH07&YS$EIN?!57;8@756R4&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L
M_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@
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M$$" _Q#&:P  MW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD
M6I 4 %B0(0!6D2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM
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M!2VDEP8LI*D&*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@
MI8L  )J1  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  S
ML!4 ,K A #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22Q
ME (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$
M ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T
M(KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7
MP*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>
M  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+
M !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI<
M"<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !Q
MK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9
M#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=
M  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0
M6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P
MXPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #N
MH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8
M #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L   #K    [04
M .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0
M_:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4
M   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V    ]P   /@
M  #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT
M /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_
M $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\
MJ #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_
M /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T
M_P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_
M *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /,
M_P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5&
M /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *<
M^ "N /4 M0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I
M ?\ Z0'_ .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,
M3@#_"5H _PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J
M .T&L@#J!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\
MW S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\
M$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.
MKP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_
M <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\
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M!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@
M_S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V
M,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z R
MO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@
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M$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5
MO54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'
M2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)
M[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H
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M#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9
MD%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%;%Q<!VI;8PEH
M6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;6OD26UK_$%Q:
M_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J  "7:   BV(
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M#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\
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M9   MVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %>
M( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ(
M"SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0
MLG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-
MB28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'
ME0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H
M **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\
M09,J $"3-  _DST /9-% #N330$ZDU8!.)-? C:3:0,TDW4#,I*#!#"2DP4N
MDJ0&+9*W!BR2T08LD>\&*X__!BN._P8KC?\'*XW_!RN-_P>S>   IX(  )R(
M  "1C   AY   'J3  !ME0  89<  %69  !)FP  /YP! #F=#@ WG1< -IXB
M #2>+  SGC4 ,IX^ #&>1P PGU  +I]: "V?9 $KGW$!*9Y_ B>>D (FGJ$"
M))ZU B.>S@(CG>X#(YO^ R*:_P0BF?\$(IG_!"*9_P2L@0  H(@  )6.  "+
MD@  ?Y8  '*:  !EG0  6:   $ZC  !"I   -Z8  "ZH!0 IJ0\ **D8 ">J
M(@ FJBP ):HU "2J/P CJD@ (JM3 "&K7@ @JVH 'JMY !VKBP ;JYT &JNQ
M !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0
M=9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7
MMR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VY
MQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8
M %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14
M"<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@
MQM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T
M  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6
M  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\
M -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   Y
MP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?
M%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%
M  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@
M(,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0
M[1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #Z
MP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H
M  W?   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D
M /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP
M_[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P
M /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\
M^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L
MM #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_
M /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P
M +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4
M_P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B
M /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0
MX@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_
M'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$
M9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[
M - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P
M_R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=
M#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00
MR #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,
M /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6,
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M Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0
MS#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<
M,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT
M\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0
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M"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4
MF4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y2E@#=TI?!'5)9@5S
M26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)Y UF2?@+9DG_"69*
M_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D  *18  "<50  DTX
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M"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q(
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M"DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6
MNF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!:
M:BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41I
ME0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8
M *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< < 6' 1 %9P'0!4<2@
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M!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P
MB(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  V
MC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,
MQ@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP
M ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT
M*9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!'9BL 1R8PP$<
ME^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5
M  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M
M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.(
M$:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8
MH0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ
M*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O
M  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP
M0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@
MOBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]
M]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8
M "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(
M ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP
MSO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["
M   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?
M  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H
M .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,
MT0  !-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M
M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??
M  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP
M .(   #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$
M_!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_
MOP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M
M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T
M_P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_
M$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\
M<@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@##
M /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0
M_P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[
M '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@
MRP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$.
M /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '
M[0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6
M -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/
M!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R
M -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -
MQ0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_
M$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%
M<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE
M +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@
M]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]
M#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4
M]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$
M -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X
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M G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0
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M!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4
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M!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P
MOU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B
M5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4
ME =-5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<
M *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P
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M!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P
MD7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !'
M:CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35J
MQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<
M ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@
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M 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP
M6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >
MD4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2.
M_P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4
M $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC<
M$9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +
MFO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@
M   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX
M  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\
M *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   F
MJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X
M.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_
M  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@
M$[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@
MR#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(
M_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,
M  /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT
M -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !Y
MH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
M    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK
M  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@
M7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B
MY@   .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_
M*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7
M /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L
M_P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\
M .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\
M$P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^
M /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q .,
M[P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_
M !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0
M?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M
M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P
M_P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E
M (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P
M]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P .
M /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H
MT "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[
M /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!
M$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z
M +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L
MJP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #=
M Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(
M>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_
M )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L
MQPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B
M$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7
M_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0
M +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W<
ME!M_ )(<B "0')( CQR= (T=J0"+';< BA[* (@?YP"&(/H A"#_ 8,@_P&#
M(/\!@B#_ 8(@_P'U)   Y2P  -,Q  #&,P  O#$  +8M  "P)0  K!T, *8>
M& "A("8 G"$R )DB/0"5(D< DR-/ )$C5@"/(UT C21D (LD:P"))'( B"1Z
M (8D@P"$)8T @R68 8$EI & )K(!?B;% 7TGX@%[)_<!>2C_ 7@H_P%X*/\!
M>"C_ 7@H_P'O*P  W3,  ,HY  "^.P  M#H  *TV  "F+P  H2@' )LG$P"6
M*"  D2DM (XJ. "+*T( B"M* (8K4@"$*U@ @BQ? ( L9@!_+&T ?2QU 'LL
M?@%Z+(@!>"R4 78MH %U+:X"="W  G(NW0)Q+O0"<"__ F\O_P)O+_\!;B__
M 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP
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M EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P
MPT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K
M03( :4$[ &=!0@!E04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"
ME -70J,$54.S!%1#R0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH
M +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X
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M!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@
ME6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/
M4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4
MP00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4
M (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP
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M BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@
M9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S
M;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J
M_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<
M %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0
M*71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?
M<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^
M  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W](
M !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\
M%GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \
MB   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*
M3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_
M  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@
M*I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (
MEU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2
M_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT
M !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@
M *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1
MB@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J
M   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),
M  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D
M?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "
MN    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##
M3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT
M &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0
M ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800
MV%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL
M  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4
M  #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,
M .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^
MO   +\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
M    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&
M  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !<
M_P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_
M (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@
M_P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7
M /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8
M^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J
M /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\
M'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"'
M .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\
MUP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[
M "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P
MAP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_
M ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\
MZ@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#&
M (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +(
M_P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E
M -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($
MM "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B
M /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0
M*@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"#
M *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\
ME G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R
M!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,
MA@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_
M (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R<
MH1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")
M%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9
M_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM
M )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88
M?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H
M*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B
M,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:-
M &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@
MRS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y
M*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8M
ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P
M +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#,
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M DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4
MEU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7
M/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"
MO@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50
M (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT
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M 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@
M:5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _
M44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313
M_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX
M %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD
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M 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P
M.FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >
M;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK
M_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@
M "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8
M$WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?
M<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"
M   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=
M  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0
MD'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5
MC@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/
M90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4
M (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@
M"IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7
MG6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0
M  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@
M  "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,
M *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?
MG   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
M    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK
M  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0
M1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"
MPP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2
M<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,
M "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@
M -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9
MZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W
M   1Q   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4
M  #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH
M /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_
M #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\
MDP#_XGT024-#7U!23T9)3$4 $!+_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y
M .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\
M#0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U
M /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4
MZ@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_
M  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T
M=@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D
M -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0
M_P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#:
M '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,
M[P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  '
M .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\
MPP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N
M /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\
M# #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O
M +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /(
MG0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#&
M !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *(
M;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\
M (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H
MM  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3
M V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,
M_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D-
M *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H
MA0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T
M$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/
M$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L
M '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\
M:AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%
M&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>
M< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_
M &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!(
M=R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B
M)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH
M_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9
M &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W(
M62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*
M-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M
M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z
M %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@
MMD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:
M,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LV
MA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4
M *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R(
M4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$
M.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.
M  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG
M $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$
M/D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "7
M5   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D $9
M+ !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@
M #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "46
MBUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _
M13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)
ML0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T
M 'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX
M.4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L
M3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA
M  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R
M #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4
M)E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M
M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7
M-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE
M !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P
M76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B
M7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?
M^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X
M $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4
M&&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 0
M9O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T
M   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X
M  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\
M"6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U
M?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\
M/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_
M  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP
M(X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@
MB4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$
M_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(
M !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD
M )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+
MA@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?
M   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\
M  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0
M>)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K
MK0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W
M/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@
M %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@
M +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@
MRT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F
M  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L
M  #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4
M .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   X
MM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4    V    -P   #=
M    WP   .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX
M  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !
M_P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_
M (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0
M_P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2
M /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T
M]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C
M /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\
M&0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!]
M .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\
MRP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q
M "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X
M? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_
M +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D
MVP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y
M 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4
M_P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ?
M ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4
MIP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5
M /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +,
M(P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V
M )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\
MA@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A
M "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@
M=P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_
M '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\
MD0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z
M"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T.
M_P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB
M ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'<
M;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6
M)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83
M)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^
M &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@
MO3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I
M&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?
MAP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8
M *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28
M7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/
M)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_
M  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K
M %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y
M1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "9
M10  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L
M+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&>
M $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620
MC$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!'
M,3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LV
MKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX
M (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\
M0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U
M.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0
M  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT
M #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\(
M+S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q
M4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_
M.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B
M "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P
M85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O
M13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(
M]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@
M %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL
M)TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >
M3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);
M  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%
M "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\
M&%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"
M7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A8
M10 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_
M !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@
M,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /
M84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?
M_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X
M "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T<
M!6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7
M;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV
M   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.
M  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0
MB7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0
M@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""
M50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($
M 'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@
M H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030
MD%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+
M  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T
M  "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0
M *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9
ME@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J
M    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:
M  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP
M/Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W
MN    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&
M8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP
M "2O   6L0  #;0   .W    N@   +T   #     Q    ,8   #&    R
M ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5
MX6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y
M   -O    ;\   ##    QP   ,H   #/    TP   -8   #7    V@   -P
M  #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP
M /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_
M "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X
MB@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_
M .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "<
M_P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O
M (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D
M_P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N
M /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0
MVP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^
M /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0
M,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$
M ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\
MK #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#*
M #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\
MA0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_
M )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$
MM  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"<
M (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T
M_P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T
M *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (
MBP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N
M"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ),
M-0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$
M 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0
MS1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"#
M #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"
MBP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"
M +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#
M= @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B
M#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K
M  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R
M &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I(
M5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?
M,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5
M- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ?
M $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.
MD#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4
M'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4A
MK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T
M (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3,
M2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ]
M)\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _
M  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V
M $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\
M-RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S
M0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK
M.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'>
M #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10
M94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU
M]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4
M %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P
M,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H
M.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&
M  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI!
M "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\
M(SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*
M2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_
M2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_
M !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@
M/4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =
M14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&
M_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$
M "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P
M%4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">
M5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6
M   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4
M  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70
MD60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =
M70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;
M7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL
M (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@
M$68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@
M9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U
M  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$
M  9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0
M &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S
M?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]
M!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO
M  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P
M784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*
MB08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")
M?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT
M $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8    EP
M )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P
MF(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9
M   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4
M  "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX
M *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @
MHP  $Z4   NG   !J0   *L   "N    L0   +(   "R    LP   +0   "U
M    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-
M  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0
M"[    "S    M0   +@   "\    OP   ,$   #!    PP   ,0   #&
MQP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<
MF0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L
M  "_    PP   ,8   #+    S@   -$   #1    U    -8   #9    VP
M -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB
M]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\
M00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2
M /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\
MR0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#]
M $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .<
MDP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_
M +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $
MZ0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#.
M )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T
M_P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!#
M ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X
MMP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_
M    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L
M10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1
M *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]
M\0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G
M $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$
ME0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP
M -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\
ME0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_
M )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-
M  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!
M (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4
M< "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M
M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '<
M0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"?
M &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P
MFQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I
M D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(
MK0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4
M (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH
M70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,
M#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I
M  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [
M %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X
M0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X
M*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6
M/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO;
M #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@
M:BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!
M'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A
M]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(
M %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T
M.2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O
M)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS
M  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9"
M #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\
M*BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.
M,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__
M "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0
M030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G
M,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R
M_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL
M #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T
M(#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C
M1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]
M   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6
M !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P
ME5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G
M0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !-
M8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8
M (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2
M&T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -
M1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@
M  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$
M !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD
M!$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z
M:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6
M"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W
M  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@
M;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #
M8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>
MAP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4
M %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL
M &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@
M:)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[
M  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-
M  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(
M '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _
M@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "#
M#0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D
M  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0
M)XT  !N-   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2!P
MD@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1
MM@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<
M !&8   )F0   )L   "<    G@   *    "@    H    *    "A    H00
M *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK
MI,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC
M    I0   *<   "I    K    *X   "N    K@   *\   "P    L0   +(
M  "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L
M +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O
ML0   +0   "X    NP   +P   "\    O@   +\   #     P@   ,0   #&
M    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$
M  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@
M ,(   #'    R@   ,P   #,    S@   -    #2    U0   -@   #;
MWP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #Q
MQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1
M /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T
M\ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_
M    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /(
M4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@
M -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_
M_P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#<
M %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,,
MI0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P
M /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X
MP@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L
M *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /
M  #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!.
M *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *,
MEP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/
M    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L
M3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J
M (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^
MM@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P")
M $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4
MM !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0
M *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $<
M>0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E
M ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+
M  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !&
M &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P
M6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%
M#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\
M1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2
M $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&
M=1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3
M!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,
M[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL
M &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4(
M2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [
M$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=
M  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%%
M #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\
M-!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4
M'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<6
M2@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_
M "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0
M1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O
M'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@
M_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4
M #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X
M*2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F
M.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F
M P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96
M "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@
MF$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L
M* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK
M8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<
M (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8
M)"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6
M,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/
M  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+
M !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L
M$#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^
M5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X
M#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ
M  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P
M<EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0
M/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!
MB@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&
M &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX
M"$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@
M2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F
M  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1
M  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@
M $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3
M:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:
M$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K
M  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<
M/VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0
M9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@
MP0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8
M "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$
M ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO
M:^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_
M   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1
M  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H
M 'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /
MB0  !XH   "+    C    (T   "-    C    (P   ", P  C @  (T-  "-
M$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO
M  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0
M )8   "8    F@   )L   ";    FP   )L   ";    G    )T%  "="P
MGA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<
M^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,
M  "E    J    *D   "I    J0   *H   "K    K    *T   "N 0  L D
M +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !D
MDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T
M    M@   +@   "X    N0   +H   "\    O0   +\   #     PP   ,4'
M  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP
M2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##
MQ@   ,@   #(    R@   ,L   #-    SP   -(   #5    V0   -T   #A
M!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P
M /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L
M^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G
M +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\
M  #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !<
M .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0
MS #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_
M    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X
M7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^
M +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O
MY@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V
M %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *
MRP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP
M ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4
MH@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP",
M .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4
M 0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3
M (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\
M>0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@
M  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\
M4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G
M &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4
MC0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O
M %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P
M]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ %
M 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P
M8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0
M /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$
M" !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!-
M %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L
M1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A
M! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D
M3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_
M #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0,
M4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^
M"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-
M_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \&
M $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E
M- Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J
M+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1
M"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7
M "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0
MFC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U
M% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "87
M8  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H
M (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H
M+!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?
M'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!
M  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT-
M "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H
M&")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_
M1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A
M$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y
M !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@
M=$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9
M)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XK
MBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\
M &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!
M$RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (
M,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2
M  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3
M  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID
M #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;
M50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[
M%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL
M   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7
M3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0
M0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"
MPP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T
M #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@
M $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P
M2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A
M   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;
M  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(
M %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E
M:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?
M'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW
M  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<
M$V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0
M:B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D
M_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H
M  1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H
M '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^
M?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&
M    AP   (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<
M  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA
M:H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3
ME0   )8   "6    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":
M'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT
M %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\   "A    I
M *4   "D    I0   *4   "F    IP   *@   "I    J@0  *P,  "N$P
MKB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28
M   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P    L@   +0
M  "S    M    +4   "W    N    +D   "[    O0   +\!  ##"P  Q14
M ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   I
MI@  &:@   VK    K0   +$   "T    MP   +H   "_    P0   ,0   ##
M    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;    X P  .$8
M  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $
M_P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R
M &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P
M[@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P &
M /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &,
MW !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#
M /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T
M# #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B
M ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /(
MJ@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #.
M !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P
M80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_
M )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T
MLP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7
M %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V ((
M_P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0
M )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D
MA !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P
M /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9  , DP , (X
M$@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8
M '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\
M80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\
M !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0
M60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_
M %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !
M;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6
M %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D
M_P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1
M %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8
M20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R
M&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %,
M$P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!:
M #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(
MGR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!'
M !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$
M80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH
M ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q
M.P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K
M"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR
M  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1
M #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH
M(@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  "
M-P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0
M$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X
M !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P
M=#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08
MB0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\
M &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /
M'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"
M  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5
M !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID
M"B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<
M1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B
M&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L
M  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2
M4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,
M*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   K
MP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH
M $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL
M!2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP
M,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-
M   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@
M   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N
M #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U
M3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^
M)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU
M   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50
M)5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@
M1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"
M_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH
M !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<
M $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%
M90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@
M   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM
M  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;
M>7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ
M:@   &D   !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D
M-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<
M &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0
M '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+
M<CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^
M  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,
M  "#    @@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(
M ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+
MAP  /(D  "Z*   @BP  $XL   J+    C    (T   "/    D0   )(   "1
M    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X
M  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D
M,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP   *    "@
MH    *    "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I
M0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP
M !2=   *GP   *$   "C    I@   *@   "L    K@   *\   "O    L
M +    "R    LP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P
MP$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG
M    J@   *T   "P    LP   +8   "[    O0   ,    "_    P0   ,(
M  #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL
M -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_
M !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D
M;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_
M ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4
M\P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#.
M &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0
M_P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  :
M -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@
MM@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P";
M /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T
M'@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G
M )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\
MA@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E
M "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T
M9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_
M '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L
MD  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y
M &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &<
M_P#3    PP   +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P =
M 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$
M: !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%
M    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X
M'@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D
M %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@
MK T  * -  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!?
M !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P
M: !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10
M )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H
M40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _
M &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=
M  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P :
M $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L
M- !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$
M)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P
M&P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V
M "H B  H )P )P"P "8 R0 E .H )0'[ /_B?1!)0T-?4%)/1DE,10 1$B4!
M_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+$   0PP"
M #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#.P I!$,
M* 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?
M*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.
M!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A"D  ( I*
M !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0
MD#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@  #03   M
M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT &0Y' !<.
M4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4
M (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:   J%0$
M(Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1
M$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\
M  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H'   (!@#
M !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP
M#!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT  (!   !W
M00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P  'Q\  !<:
M"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI
M  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$  !U10
M;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24  !0A!  /
M'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A
M>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T2@  :TH
M &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H!  -) H
M"2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E   F=P
M)HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P  :D\  &!.
M  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *+ H !2L.
M  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L=0  +(H
M "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0  %]3  !6
M40  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD  #(-   R
M$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@  ,H<  #&>
M   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9  !55P
M25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,   Z#P
M.1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4  #B<   W
MLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !27   1%@
M #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !##0  0A
M $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9   _L0
M/M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80  /EX  #);
M   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#   2PX  $L2
M  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'KP  1LT
M $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0  "IB   ?
M8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P  %40  !4
M%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP  4,H  $_O
M  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J   7:0
M#F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-  !@$
M8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4  %KM  !9
M_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0<@  !W$
M  !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M#   ;1$
M &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y
M>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0   'T   !]
M    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@  ? P  'P2
M  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S@
M98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D   "*
MC    (T   "-    C    (P   ",    C    (P   "-    C00  (X,  ".
M$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!HA@  6H@
M $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9    FP
M )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#  "B#
MHA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0  39   #^3
M   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H    J@   *L
M  "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W 0  N0T
M +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<   C
MH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0   +L   "Z
M    O    +T   "_    P    ,(   #$    Q@   ,D   #-    T@$  -0/
M  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\   #_
M_P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G
M %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L S0"] ,L
MX #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_    _
M /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D
MRP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T +0 S0"R
M /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q    Z    .
M!@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V %, M !8
M +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\ P "= .8
MFP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@   ,8  0"_
M  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P GP!1 )X
M5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0") -, AP#W
M (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$   "K  <
MI0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ")
M %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K ',
M_P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":  ( E  +
M )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X
M=@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B
M /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",    A@ ' ($
M#0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!.
M &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\
M5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 " ', "@!O
M  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $( 60!' %<
M3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_
M $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@ !0!C  P
M7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!" $L 2 !)
M %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_ #P
M_P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9  @ 50 -
M %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L
M/0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F
M%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0 3  * $@
M#@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T $8 ,P!/
M #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A'
ME2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  & $  "P \
M  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $( *@!+ "@
M50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28
M (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T  P
M,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!' "  4@ ?
M %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M
M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M"0D *04-
M "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP
M%@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W
M,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0 (PP) !\)
M#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI
M  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@
M;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! % !D."@ 5
M# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0
M>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P  :SH
M &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3!@ 1$ L
M#@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E  03=@ #
M$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P  :C\  & ]
M  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0%0D #!,.
M  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D
M !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,  %]"  !6
M/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD "1D-  89
M$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@  '8<  !R=
M   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&  !51
M2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -  $?$
M'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4  "&;   A
ML@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !420  2D8
M $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F#@  )1(
M "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9   FL
M)<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P  2DP  $%)
M   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@  +1$  "T6
M   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   LKP  *\L
M "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$  #M-   P
M20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\  #04   T
M&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0  ,<H  #'N
M   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92   J3P
M($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1   \&
M/"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@  #CM   W
M_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D50  &5,
M !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&%   11P
M $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L   __P!^
M80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70  $EL   M9
M   "6    %8   !6    5    %,   !2!   40D  % -  !0$   3Q@  $\B
M  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(_P![:0
M=&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60   -B
M8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(  %L<  !:
M*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y<   <W0
M &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M    ;0
M &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5  !G(0
M9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z
M  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y    >@   'H
M  !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W&   =R8
M '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%
M@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B    (D   "(
M    AP   (<   "'    AP   (<   "(    B    (@'  ")$   B1P  (DL
M  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(   YB@
M*HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@   "6
MEP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$  )TA  "=
M,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   MDP  'I4
M !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F    IP
M *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5  "T)P
MM#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0  $9\   6A
M    HP   *8   "I    K    *\   "S    M0   +<   "V    MP   +@
M  "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,  #.&@  SR\
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M_________________________________________________P
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M]_CY^OO\_?[_;69T,0     # 2$   $                    !
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M________J#4          %S3____________________________?0T
M     %36___________________________N?44          $34________
M___________________\JF0O @  !"(W25C.________________________
M____Z:1K02@_8W^5I[K:_______________________________5LJRRS.3Z
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________ENY=W8LC_________________
M________________VYYG-@H  HS________________________________(
M?S\%     %[/_____________________________]F!.0       #RJ____
M_________________________YY,         ".0____________________
M________W&\:         !!]^?__________________________KT@
M      !O[O__________________________A!,           !DYO______
M___________________L40            !7WO______________________
M__^X%0            !(UO________________________]T%
M   XS_________________________FB6A,            CQ?__________
M_______________?FUPL           -NO__________________________
M[[%]53DB$0<! A$BLO______________________________W[^EF9B:H*R]
MVO__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____X[Z=@'S[________________________________\K>$5S . !VL____
M___________________________2BDP5      !R\___________________
M_________]9_-@        !+R?__________________________^I$^
M       OJ___________________________P%H            :E?______
M____________________C20            (A/______________________
M___G7@              =_________________________^T)0
M    :O________________________]]                6_3_________
M______________TK                3.O______________________Z4
M                /.'______________________S ,
M+=G_____________________F8IA)P              )]?_____________
M_________^V^B54G            )=S__________________________LJ=
M=EU*/#(M+# Y1][_______________________________WFW=;2T-/9Y/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________OU+O6____________________
M_____________^>XCVI++Q5O_______________________________DH6<T
M!P     \R?___________________________]:".P         2E_______
M____________________[84Q            ;_______________________
M____ID(             4.'________________________L:0
M    -\G_______________________^S+P              (K;_________
M______________]Y                $*?_______________________(T
M                 )G______________________ZD
M (S______________________T8                  '______________
M________WP                   '3_____________________EP
M             &K_____________________S@                   &/_
M_____________________RDB 0               &'_________________
M_____[FC@%<W%P           &C___________________________K3KI2&
M?'5Q<')W@93_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________V[J=@FEIT_______
M________________________R)-E/1D    =GO______________________
M_____]N.3!,         ;O__________________________VWPL
M    1=?_________________________BRH             (K3_________
M_______________"1                Y?_______________________]]
M 0               '_______________________^<V
M &K______________________YT                  %C_____________
M_________T8                  $?X____________________Z0
M             #7I____________________E@                   "7;
M____________________O                    !C.________________
M____ZP                    _"_____________________P
M          JY_____________________R<                   JU____
M_________________W                    VY____________________
M_^"<C'!50C,F&Q0/#0X2&B:_____________________________^>38TL[,
MR\S/UN#\____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________Z].\X________________________________]*IA65(
M+!(!A?____________________________&K<3P/        3^#_________
M________________U7\U            '[+________________________C
M=1T              (G_______________________^0(P
M &?______________________]5#                 $CV____________
M_________XH                  "[=_____________________S@
M             !?(____________________O@                    2V
M____________________G                     "E________________
M____N@                    "3____________________W
M          ""_____________________P                    !T____
M_________________Q,                   !H____________________
M_T(                   !@_____________________WH
M      !=_____________________]$                   !A________
M______________\D                  !F_______________________)
MK)F)?79Q;&EG9F=K<'J,________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________XL6JD7EA=___________________________
M___=IG=0+ P     ,<3_________________________X)).$P
M (_________________________2<!T              &#_____________
M_________^YO#P               #?B_____________________Y8<
M             !3 _____________________T                    "C
M____________________K@                    ")________________
M____G@                    !R____________________O
M          !?____________________V@                    !-____
M________________^@                     [____________________
M_PX                    J^?___________________S,
M       ;Z?___________________UX                    /V_______
M_____________X\                    &T/___________________]
M                    RO____________________\K
M    R/____________________^                     R___________
M___________W%@$%!0,!       !!@T8R________________________.OA
MV,_,S<_0TM37W.+J____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________':
MQO______________________________\<:CA&A-,A@ %:O_____________
M_____________[E\1A@          ''________________________7?"\
M             #OC_____________________]]D"0                RU
M_____________________W0#                  "-________________
M____Q14                   !J____________________F0
M          !+____________________M@                     P_?__
M________________UP                     9Y___________________
M]@                     %T____________________PX
M        P?___________________R\                     K_______
M_____________U(                     GO___________________WD
M                    CO___________________Z4
M    @/___________________]@                     =/__________
M__________\V                    ;?____________________]\
M                :?_____________________7#0
M:/______________________<                   8?______________
M_________U \1DY465UA9&AL<'9^B?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____[]6[HXMS6I7___________________________B_CF1!(04      %+\
M_______________________WG588             !?!________________
M_____^5L%@                "-_____________________V,
M          !>____________________G0                     U_/__
M________________H0                     1V?__________________
MR@                      N___________________[@
M        H?___________________PP                     BO______
M_____________RT                     =O___________________TT
M                    9/___________________V\
M    4O___________________Y0                     0/__________
M_________[P                     ,/___________________^H.
M                (O____________________]$
M%?____________________^!                    "_7_____________
M_______("P                   NS_____________________7@
M             .7_____________________R1P                  -K_
M_____________________YT!              <.%\7_________________
M_______5N;S!Q\[5V^'F[?3[____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________XW\__________________
M____________[,:EB&U4.R$' #+>________________________UY)9*0
M          "@______________________^)-@                !G____
M_________________V8                    R]O__________________
ME0                     #R/__________________IP
M        H/__________________UP                      ?/______
M_____________P                      7O___________________R4
M                    0____________________T@
M    +/___________________VH                     &/__________
M_________XL                     !?/__________________Z\
M                 .'__________________]4
M ,____________________\D                     +[_____________
M______]4                     *[___________________^+
M             )_____________________+#@                   )+_
M____________________5P                   (;_________________
M____J@H                  'G______________________VT
M         &;_______________________=5                 $7_____
M____________________:B,K-3]*56!J=7Z'D9S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^C/MIV#:4ZY____
M_____________________^RR@UPZ'0(       ![____________________
M___%;2D               ! _____________________X,;
M       'R___________________D@                      F/______
M____________I                       :O__________________W0
M                    0?___________________PX
M    '?___________________SD                      .C_________
M_________V                       ,[__________________X4
M                 +?__________________Z@
M */__________________\L                      )#_____________
M_____^\6                     'W___________________\^
M             &S___________________]I                     %K_
M__________________^9                     $G_________________
M___2%@                   #G_____________________6
M         "G_____________________H@                   !G_____
M________________]58                   3_____________________
M_[LO                  #X______________________^K*0
M      #/________________________R4<     !Q,@+CY2:(3M________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________]-7)____________________________^M*PDG==
M0B@,  !*________________________Q7U%%P             1V/______
M_____________\10                    G___________________H@P
M                    :/__________________E
M    -O__________________V@                      !^S_________
M_________Q4                      ,3__________________T@
M                 *+__________________W4
M (/__________________YT                      &G_____________
M_____\,                      %+__________________^</
M             #[___________________\S                     "O_
M__________________]8                     !C_________________
M__^!                      7___________________^L
M          #____________________>(@                    #R____
M________________7                     #?____________________
MGP                    #,____________________Z$H
M      "W_____________________Z 6                  "<________
M______________]Z @                !W________________________
M>@L               5,_________________________Z)7:'2 C9RKO-#G
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^WC________________________
M___2HWI8.BDC'!8.!@  G_____________________^L4@X
M    :?__________________Y$,                     -/__________
M________>0                       ./_________________S0
M                 ++__________________Q,
M (7__________________T\                      %W_____________
M_____X,                      #K__________________[(
M             !S__________________]L#                      +_
M__________________\J                      #[________________
M__]/                      #G__________________]T
M          #4__________________^;                      # ____
M_______________$!P                    "M___________________P
M,P                    ":____________________9P
M      "&____________________HP                    !R________
M____________XT0                   !<_____________________Y$&
M                  !!_____________________^M?
M   =_______________________*2P                  ____________
M____________RU<   P8)#$_3F!TBZ?'___________________________7
MY_+_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________KU,W'PKZZM[.PK:FHI?___________________]U^4S\P
M(QD1"0(          -O_________________=@
M *?_________________N@                       '7_____________
M_____P<                      $;__________________TX
M             !K__________________XP                       #]
M_________________\$                       #;________________
M__$9                      "^__________________]$
M          "D__________________]K                      "-____
M______________^1                      !Y__________________^W
M                      !F___________________>(0
M      !3____________________2@                     _________
M____________=P                     K____________________K H
M                   6____________________YT4
M    _____________________XH                     ____________
M_________]9-                    _?____________________^G+@
M                U?______________________F"H           88+45@
MX/_______________________ZAC=(&/G*N[S>+Z____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^(S@$E#0U]04D]&24Q% !(2________________________________
M_______________________________GR[>IG96.B82 ?'AT<&QH99#_____
M____________O&I(+1D*                 #'__________________P
M                      /__________________T(
M      #<_________________XX                       "R________
M_________\X                       "-__________________\I
M                  !K__________________]:
M  !.__________________^&                       T____________
M______^N                       >___________________4%P
M               *___________________Z/0
M____________________90                      ________________
M____C@                      ____________________O!D
M            [___________________\4X                     V/__
M_________________XL                     O___________________
M_\Q#                    H?____________________^1&0
M        >O_____________________R= H                17_______
M________________Z'03'RPX15-B<H6;M-+U________________________
M___7Z/3_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________OW\_'N
M[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$________
M_________TLE"P                    "2_________________X@
M                  !F_________________]<
M   ]__________________\S                       8____________
M______]L                        __________________^=
M                ___________________)#
M]O_________________Q-0                      W_______________
M____6P                      R___________________@@
M            M___________________J08                     H___
M________________TR\                     C?__________________
M_UX                     =____________________Y,'
M        7O___________________\U#                    0/______
M______________^'$                   '/_____________________8
M7@                   /______________________OTX       X<+#Y2
M:H:ER/_______________________\)\C)JGML76Z/W_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^[AU\_)P[ZZMK&MJ:>F
MIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4____________
M_____]<%                        __________________\T
M                ]O________________]V
MTO________________^P                        LO______________
M___A)                       EO__________________40
M            ?/__________________>0                      9O__
M________________H                       4?__________________
MQR,                     //__________________[DL
M        )____________________W0                     $/______
M_____________Z,6                     /___________________]A,
M                     /____________________^(#P
M     /_____________________+4P                   /__________
M____________I3@           D=-$YKC/_______________________YDY
M0U%?;GV.H+7+Y?_____________________________K^?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________KS+FLH9F1BX:!?'AT<&MH9F9H
M\?________________]A13(C& X&                GO______________
M__]^                        =?_________________#
M            4O_________________[-P                      ,O__
M________________:@                      %O__________________
ME@                       /__________________OQL
M         /__________________YD(                      /______
M_____________VD                      /___________________Y "
M                     /___________________[DL
M     /3__________________^A<                     -G_________
M__________^1&                    +S____________________*4P
M                 )W_____________________F"X             $"E&
M9L3_____________________[G\=#!HH-T97:7Z5K\SN________________
M_________^>@JKG(V.G\________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________?7PZ^;B
MW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV,B\N,?__
M_______________2)1$#                     /__________________
M0@                       /__________________?0
M         /__________________L L                      /;_____
M____________W3D                      -S__________________V(
M                     ,7__________________XD
M     *___________________Z\B                     )G_________
M_________]9(                     (+___________________]R
M                 &G___________________^A*
M $[____________________37                    #/_____________
M________EBX              !4R4G?_____________________X'(3   !
M#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________^>#2R,"ZM;"LJ*6B
MGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00  -3_____
M____________D@                       *W_________________S!X
M                     (O_________________^U(
M     &W__________________X                       %'_________
M_________ZD;                     #K__________________]!"
M                 "/___________________5H
M  S___________________^/%                     #_____________
M______^X/@                    #____________________E;0,
M              #_____________________GS<              ! O4'3_
M____________________W7(4      87*D%:=92VVO__________________
M_____[Q81%1D=8::K\CC_______________________________2S>'Q____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________\^_K[_?______________________[KFHG9:/BH:"?WMX=G1R
M<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_________
M_________VD                       #__________________YL*
M                  #__________________\@Y
M  #___________________!C                      #_____________
M______^*#@                    #___________________^P-
M              #____________________56P                    #_
M____________________A1H                   /L________________
M____L4D              !@Y78'_____________________Y7L>       ,
M(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?__________
M__________________^SGK3%U^O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________Z[^?A
MW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;65A75UE>
M97'__________________[\Q'Q80"@4               #_____________
M_____^U6                      #H__________________^"!
M              #,__________________^K+P                    "S
M___________________25P                    ";________________
M___W?!                    "%____________________HC<
M        !2N4____________________RV$"            #"Q0=I[1____
M________________]8TP       -(SM7=IF^Y?______________________
M_\-C&"H[3%]TC:?&Y_____________________________^H?Y:HN]#G____
M_________________________________?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________=SL6_O+FV
MM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&2$M066:A
M__________________^G)@X' @                !6________________
M___.4                      Z___________________T>0L
M           A____________________GS(                    .____
M________________Q%@                (,5J$____________________
MZ7\?           &)TMQFL+I_____________________Z=)      (7+TIH
MBJ[5_/_______________________]-U'B8X2EYUCZO+[_______________
M______________^N<H68K,+;]O__________________________________
MW^__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________O[*JIJ.AH)^?
MH:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.66E]____
M________________GBX&                    ____________________
MPU8                  !5!____________________YWL:
M  DT8(NT_____________________Y\_          0E2G&9PNO_________
M_____________\9F#P   !,J1&*#I\WU_________________________^N.
M-2L^46B!G;S>______________________________^^=G^4J<'<^?______
M____________________________TMCS____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___V\O#O[^_Q\_C]____________________________^+"?FI>6EI:8FY^D
MK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I________
M_____________Z9! 0          !S9CC[KA_____________________\9E
M"@      !"=,<YS$[/_______________________^6(+P  $RI$8H*FS/3_
M__________________________^K4#9*87N6M-;Z____________________
M___________2AWR8L<OI____________________________________U,[M
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________M
MY>/CY.;H[?'Y______________________________VQE)*2E9F=HZFRO-#M
M__________________________^=4T=)35%68'.*K];\________________
M__________^R5@ :-5!MBZ[2]______________________________-;SY?
M>YFWU_G________________________________NGX.FPN'_____________
M________________________X\[K________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________
M
M
M          #_________________________________________________
M____________________________________________________________
M____________________________________________________________
M_P   /_; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)
M"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(
M!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( (<!! ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MU.*E'9GI87%4L31AB*#O":4D^Z:NGKW044451T!1110 4444 %%%% !1110
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MWSFOH6OB[]I;X@ZW^RG_ ,$7]#O?#6H7&B^(M)\+^'K&UO+==LD4KM:)*W<
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M,Z;IL>WR]/M8K9=J[5PB!1@=AQTJ_117L15E9'ZPE9604444P"BBB@ HHHH
M**** "BBB@ KR71?VZ?A3XA_:XU7X$V7C"UN/BOHFG#5K[05M+C=;VY2)P3,
M8_(W;)HF\L2%]K@[<9->H:WK-KX<T:[U&^N([6QL(7N+B:0[4AC12S,Q[  $
MGZ5^)O@C2KGP!X,^#_[?VI6DEKJWC+XX:AJFOSRXA>R\(ZRW]CP1O_"T4,4%
MO(@DR0;@G<,T ?MY117@/[3W_!4'X&_L?^/+7PGXX\<1V_BZ\B6>/0=+TV\U
MC4Q&1D.]O9Q2O&I )#.%! XSQ0!Z-\7OVC?!OP'USP;IOBS6/[)O?B#KD?AS
M0(_LD\_V^_D1W2',:,(\K&YW2%4&.6!(KN*_.']N/]JWX=_MA^+/V-/%?PU\
M5:?XJT1?CK86LTMN'BFM)ULKHM#/#(JRPR@$$QRHK $''(K[1_:B_;(^&/[%
MG@B'Q#\4/&6D^$=+O)3!:FYWR7%](!N,<$$:M+,X'.V-&/(XY% 'IM</\2/V
MC/!OPC^)?@7PAXBUC^S_ !%\2;NXL?#EI]DGF_M&:WA,\R[T1DCVQ@MF1E!Z
M D\5Y3^SK_P5F^ 7[4OQ+M_!?A/QT4\87L)N+71=:T>^T2]O8\,VZ!+R&+SO
MD4OB(L0HR0,''F/_  4@_P"4E'[#?_8V>(O_ $S/0!]2:?\ M&^#=5_:&U'X
M56^L>9X^TG1(O$=WI?V2<>582S-"DWG%/).9%*[0Y<8R5 YKN*\,\._#_P"%
MEK_P44\1^)[/7I)/C+=>!K73]1T;[4"D.C+>.\-QY6W()F++NW'/(QQ4OQC_
M ."C_P #_@#HVM7WBSXC:'I:^']9_P"$>O+=%FNKP:CY:2_98[:%'FEE$<B.
M5C1B%<$\&@#VZBO _P!F;_@IY\#?VN'\20^"_'EF^H>#;=[O7=/U>TN-&O=)
M@09>:6&\CB<1*,;I "BY&2*X70/^"Z/[*_B+QI8:+#\5+:W_ +6NS86&J7FB
MZC::->S@L&CCU"6W6U;&!\WF;3N7#'L ?6U%<W\4_B[X9^"/A5=<\6:S9:#I
M+7=O8BZNFVQF>>5888\X/S/(ZJ!W+ 5TE !17*^$_C7X4\=7OBJWT?7+'4)O
M!%ZVFZZD3$G2[E8EF:*3CAA&Z-]&%>*?$O\ X*_?LY_"OPQX?U6^^)FG:E'X
MJLGU+2+;0[&[UF]O;5'=#<"WM8I)4AW1NHD=50E& ;@T ?2M%>#^!_\ @I[\
M ?B+^S?J7Q<TKXJ>%W^'FCS_ &6_U:YE>S^PSG&V"6&94FCF;<NV-D#MN&T'
M(K#_ &=O^"N_[/?[4GQ3M_!'A+Q]_P 5;?1F:PTK6-'O]%N-4CVLP>V%Y#%Y
MV55FPF6"@D@"@#Z4HKC_ (Z?'[P7^S+\-[[QA\0/$VD>$?#.GE5GU#49Q#$K
M,<*@[L['@*H+$] :\$^$_P#P6R_9G^,?CK2?#>F_$8Z7JGB*41:,/$&A:EH<
M&KDE57[//>6\43EF8*J[M[-P%Z9 /<_CK^T;X-_9IT/1-2\;:Q_8MEXBURS\
M.:?)]DGN?M%_=OLMX<0HY7>PQN8!!_$P%=Q7Q'_P74_Y(=\%?^RW>$/_ $L:
MNP^*/_!;7]F/X/\ CC5- UCXF1S76@SFUU:ZTK0]1U73]*E#;#'/=VMO)!&P
M;Y64OE3][;0!]645B?#GXD:!\7O VE^)O"NLZ;XA\/:U +FPU'3[A;BVNXST
M9'4D$=1[$$=16W0 4444 %%%% !1110 4444 %%%% 'R#_P7(^+NH_#S_@GK
MXD\,^'I8E\8_&*^L_AOX>A=]IN+K59A;2*N.=PMC<,, G*BNN_:B_82T?XC_
M /!+?Q-^S_HUO%]AA\#KX?T13"&5+BTMT^Q2%><D3PPOUSD9SGFOG'_@HQX4
M\;?MQ?\ !5SX0?"+X>>,K/P1<?!70+CXGZEK5UX>37+6TOI9EL["-[=Y8E:5
M5$KH"P($A?#;?E]>_P"&1_VP?^CQO"__ (9:S_\ EA0,[/\ X)9_M3Q_M/\
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M"MG_ (*0?\I*/V&_^QL\1?\ IF>O%O\ @IC_ ,$UO@;^QK^RK8^)/"GA%/\
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M[\"_^P+-_P"EEQ0,\-\._L>>#_$7_!QOXXFNK&&70[7P'IGQ"DT-X]VGW/B
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MR]$L?!FABY0,!<3C3I99!G&"R,S*P'0!/6ONR@ HHHH **** "BBB@ HHHH
M**** /E/]@?]E3QE\//VHOVD/B[\1=/M+'Q%\5/%45KH<<5ZMVT/A[3X!#8Y
M*DK&TFYV>,<@@9)XQ]6444 ?)_QG_91\9V'_  5G^$?QT\%Z=9W.A3^%=3\$
M?$!FNU@F2R++=6$J1L1YI6ZSNQ\P51UXQY#X2^'GQP_X))_%_P"(L7@+X;P_
M&;X _$#Q#/XIT^RLO$=KI.L>"+ZZ(-S;A+QEBFM7D *!&!7))Y)+%% ',_%;
M]BK]H[]L_P#;-^!?QT\>>%]&\&0_#?QK9MI_@NW\007\GA[10LDE[>7-PN(I
M[R>9;1?+@+*B6X +$DUW_P :?@Q\8/V$_P#@H#X^^/GPG\"Z?\5O WQETW38
M/''AN/6;?1]4TJ]T^(P6]];27#+#)&8G8/&2&+NQR.M%% 'F_P"WM^SO^U-_
MP4[^#=GXB;P#H/PWM_ASJ=CXI\&^!+OQ/;WVH>*]2@NHV\Z^NH?]%MXQ:&X6
M*%9&S)/NDD3: />_C5\"?BI^TI^T-^R/\1M4\%Z?X5G^'>M:SJ?B_2TUZ'4!
MHR7%@]M"L<P6/[06;:3L08R?3)**!G3>$OV9O%VD?\%>O&'Q=FL[=? ^L?#&
MP\,6UT+E#*U]#J$D[H8L[PHC<'<1@G(K2_8>_9W\4_!'XR?M%:SXBL[>UL?B
M+\0F\0Z(\=PDK3V?]GV< 9@I)0^9"XVM@X />BB@1F_MF?LR^+OC)^VG^R[X
MTT&RM[C0/A?K^L:AX@FDN4C>VBN-.-O$41B#(3(<$*#@<U[+^TQX*U#XE?LW
M_$#P[I,2SZMX@\-ZCIME&SB-9)IK62.-2QX4%F R>!110!\L:Y_P39\3?&;_
M ((A^%?V?=6U"'PI\0-$\)Z1!;WD<XEAT[5]/:&>(ETW!HS+"$9E!(5B5&X"
MJWA/]L+]L;Q'X='@.Y_9M\.:/\4(K807'BJ[\<V$GA6(XV_VC]GB9KTQLWS"
MV";QN +CD@HH&B__ ,$NO^"?_C3]BCX<?'WP[XDOYO$%UXY\5W.MZ?K-S<1-
M<:\\^G6Z3W<JH<0M+=K.VP\J&'7K7I__  2;_9X\4?LH?\$[OA;\._&EI;V/
MBCPMILMKJ$$-PEQ'&YN9G&'0E6RKJ<@]Z**!&9X2_9F\7:1_P5Z\8?%V:SMU
M\#ZQ\,;#PQ;70N4,K7T.H23NABSO"B-P=Q&"<BM+_@J)^SOXI_:?_9=@\+^#
M[."^UB/Q7X?U8Q37"0+]GL]5MKF<[G(&1'$Y ZD@ 444 >:?MV_LW?%KX>_M
MM>"?VG/@?X;TCQ[XBT7PQ/X'\6>$+W5DTJ77='>X^U1-;7,O[F.:*<LY\S[P
M"CG&*\S_ &Q?AQ^TI_P6"_9H\2>!5\ V/P'\!7VEW%T6U7Q-::IJ_BV_B0O8
MV8%F9(K6S^U+&TTCNTC"/:J $DE% R']I[]AKXQ?MY_\$HOA/\(_&'P]M/!/
MB+P]XG\/V>N:?;^)[6^;^Q[*(07%ZDZJ(UD9"[+"-Y4X^9N:[W1_VF_VOOV?
M/"-C\.=8^ &F_%CQI9Q'3=&\;:=XUT[3-(\2I$@ OKJVG9;FVD"[7EB17#-N
M$;8( ** /5/^"8?[%OB#]D+X2>)M0\?ZW9^)/BO\4_$-QXP\9ZC9J1:+>SA0
;+6VW?-]G@10B;NY8@*"%'TM110(**** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>incometaxprovision.jpg
<TEXT>
begin 644 incometaxprovision.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %2 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3\>^*/^$(\$>,/
M&7V!]4_X13PMXB\2_P!F1S?9Y-0_L#1K[5_L,<_E3^2]W]C^SK+Y,OEM*'\J
M3;L;\Y/V>O\ @I+X4^('PK\/?%;XK:]\ #9>.])\,7_@SPC^R5\3OB+^V!X\
MM+^]\!Q_$?QMHGCKPEX%^"^D:]X:NO 'A:_TG4=<N[33M6LK2UN'GU:72&NM
M$@U;]'O''A:W\;^#/%O@R[NI[&U\6>&=?\,W-[;)')<6D&OZ1>:1-=0)+F)Y
MK>*\>:))/W;2(H?Y2:^4M<_8\,'AK]GR#X8?%KQ3\*_B!^SO\.;OX3>&?B'I
M'AKPAX@GUKP'K_@_P/X/\6Z;KWA?Q%87.A37VHCX<>"?$^B:G!Y<GA[Q1X8T
MIW@UGPW)K/AK6 #U[X:?M+_!?XQ^+_$'@KX8>+V\;:IX7\-^$?%FN:EH.@>)
M+OPA9Z)X_P#"7A7QYX&N$\=?V0G@Z\N?%W@WQGH7B7P]IMCK=QJFIZ/+>WUO
M9M!I6I/;?&_AO_@J9\'];3P%KFK> _BYX,\&>,(?VPUOKWQ3\+/BI%XVTF[_
M &0_B;\/OA_XBN]/^&NE?#_4O%'B3PKJ]AXRU7Q5JWBW3;<:5X%M?"NJ:+XB
MD_MNSUJVT;ZQ_9R_9F\%?LRZ/XD\-^ ]1UF[\/:R/AE:Z;8ZV]I<W6C:5\+/
M@E\-/@?H-D=2MX+:759KK1/AII^LZE?WD4<\^L:GJ)CCBM1!$GC7A_\ 87T?
M1-8UJ:;XE^(M1\.?V7^V+X?\$>'Y= T*WE\'>'_VT?&7@KXD?$+3)=:@?[3X
MD/AWQWX9U;4O"5[J%M;7D6C>(1H>L2:H^CVVJ70![+IO[6?P%UGXBZ;\,=)\
M;2ZGKNKW^C:)IVM6'A?QA=_#JY\5>(O UK\3M \$)\5H= ?X:#QYK?PZO[#Q
MOI7@EO%:^)[[PUJ&G:G!ICQ:C8+<^8?&?]L"]^#/Q>D^"VJ?#:35O%_Q'\*^
M%]0_996R\2&"V^.OCB\\2-X7^(7P]G>XT/\ XI#4_A+!J'AGXD^,[ZW_ .$F
MBC^#.J:[X_MK8Q>!O%%A:>7?"[_@F-\'?A9\9O#'Q>TV;PWK=]H-SX*\47,O
MB+X+?!S6?'E[\0O!'PA\,_!JSU[3?C!J?A2^^(GA?P]?:%X3TCQ'<^$M U.U
MDLO%\=Q<:)XDTKPS?:AX4N_L+XD_ _0?B9\0?@AX^U?4;RWF^"7B+QWX@TW2
M8+>TDM-=/CWX6>+?A7J-CJ%S(!>V4%OI7BV[OH9=-DAN)+JWA@E?[,\HH \Q
MT3]N3]G7Q-INI:EX8\0>-_%"VEMHVI:-9>'/@U\8]8U;X@^'O$.IWFBZ-XS^
M%&CV'@2?4?BGX O]6L+BS7Q_X!@\0>"[17LKS4->M--U72+W4*C_ +?7[**V
M\5Y_PM'?8_\ "J[KXTZC?1>#?'TUEX=^'%EKOC3PG=:WXMN8?"[IX3O8?&GP
M_P#%/@7_ (1KQ"-.\4R^.["+P9;Z+-XDO['3;CY'\-?\$@/A!X)\*P^%_!OB
M'POH-MX<E\%:5X0\C]G3X 1V^M^!/!$FIFP\&?'Z#3O!VF7G[1EG=I?Z;>7D
MWCG4[&R?Q1X(^'WCX:*?'GARX\1:O[K\(O\ @GGX%^"_P[\<_#GP=X]\16VF
M>,O@_<?!V*[?P=\+)H]#T2?XR_'_ .,IGM/"-YX,O?AQ>61U'X_ZWX:E\(WW
M@J3P5)X9T33M.308(+FZA0 ^N/ GQB\#?$'P9J?CS3+C7O#OA_0;G6+3Q'_P
MLGP=XO\ A1K'AJ;0+9+W5SXC\/\ Q*T/PKK>BVMG82QZB=0O["'3+C2Y(]3M
M+VXL'6Y/@</[?G[,,^B:=KH\7^+88=<\1> _#/AG3+OX/_&*Q\3>,+SXJZ9X
MPU;X6ZAX,\)WW@.V\3>+/#7Q*M/ /B]/ ?BO0-*U#PYXGOM!O],TW4Y=1B-L
M+WP6_9 \)?"[X)_$[X(:[K<_BWPK\7;[QA-XHT+2-%T_X<^!?#NC^-?!FE^!
M=9\'_"KP!X6N'TCX8^#I])TR;6)-$T*[E23QGX@\5>*EGBN]<D@M_"_@G_P3
M*^&/P5G\#W>A:UH-K>^ ?B/\,/&>F7?@SX(_!?X57.O:/\(O!OQ1\&^$]&\<
M7?PX\*:#?>,-:OH?BIK.L^)?%&JW9@NM:L[:Y\-^&?"<=[K,.I '7_&#_@HW
M\"_A_P#"^3Q[X)GUCXG:S<^#] \:Z5X5TWPE\2--2STKQ#\4O^%06$7Q%UQ/
M 6JVGP?U*Y\<Z?XM\+V6D?$R#PWJM[XJ\$^+/#,5D-3T#5X['U:?]MG]FRRN
MO'T&I>/[G2+/X=:=\0M4UGQ!J_@GQ_IGA'6[;X3^)+?P=\2X?A[XNO?"T/AS
MXI:GX&\7WEEX2\2Z+\-]1\4ZOIWBF\M_#WV*;5'^S#YYU/\ X)MZ.^E>)= \
M._&_Q]X9T'XC0W%G\5M-M?#G@G4?^$SLM*_:)^*/[2'@&.TO-2TV:]\+W'A;
MQ/\ %WQ=X6U.YTR>?_A*_!<UE9W<.F:W86FNP8^E_P#!*3X&:3JGQ8N=.N=*
MT2V\>M\0=1\)ZSX:^$/P:T/XJ^ O$OQ%^*NF?&J[U^7XSIX-N_'WCN3PE\0M
M'L+KP7I?BJ]DTDZ"C>'_ !_:?$*%+.ZL@#ZC^#O[4>C?&6R_:+U?1/"GB'2-
M*^ OCV/P.L7BC2?$W@_Q/K\H^!/PL^,UY+K7@SQIX:\-^)?!&HV<WQ(?PT^C
M:OI]Q,\>D0ZXDYM]5BM+?YV^%G[?FNV_A7X/>-OVJ/A]X!^"?@SX[_ +4_V@
M/ ?C/P-\3_$?Q0\/Z9I>A^%/!WCK6? GCBUUCX5?#OQ!I7C5?"?C2RU+PZ/#
M6F>+M)\5W>D:]H-I<:?KZ^'=-\3?3?P@_9ZN_AWI'QK'BOXC:W\1_%GQ]\7#
MQOX^\47VA:#X9C36C\)? 7P@-MX=T'0D-CI.B6_A[X>Z/-86-Q<:E>PW,ER;
MW5=2ED:Y?Y!LO^"8.E>+_A)H7P?_ &AOC?XF^-'AKX?? P? /X2V</P]^'_@
M?2/ OAX0^ 8#XPOM!2T\6V?CKX@R6_PQ\'Z9-?>+I;WP>^@0Z_H*^"$L/%_B
M9=1 /I?4_P!NG]G#1M MM=U7Q'XUL+B36O$VA:AX/N/@Y\8Q\3/#5SX)\/\
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MB_OKB:ZN)96 /QS_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\
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M$'Q/^T)J'@[54ELCI>NV&C?!KQGX)TG4YH#+H_C74=/U:TDDN=(MO,_0X22
M "20!4EB4!W 6*8@SQ+@C;%.0#/&,),0#(K$"FDD\GD^I]N/Y<4ZN<<]3!UJ
M6'EAZN!IJG1E3Q,N6T:"ITTTZ2FXQJ0A5<)5)<\76I593]JJD'?\O)7VOY>F
ME]GT*UG:6MA9V=A86L5C86%I:V%A8P&1H+*PL;>*TLK*%IGDG:&SM88;:)IY
M99VCB5II992\C?7WP/\ ^1,F_P"PY?\ _HBRKY)KZV^!_P#R)DW_ &'+_P#]
M$65?3^&6O%,;MM_V?B[MN[?OX?5MZM^;)/8J***_HX HHHH **** "D;H?H>
MG/Z#!_(@^A!I:0]#@ G!P#T/L?8]Z /QC\.^ ?BSK'QJ^,OP]D^*O[1/Q2^'
M>B_M2:'X@\7:?\0OCE\&OA3%!]N@^%GQ$MO#7ASPKH?P8O/B5>_";2!;Z9_8
MEOHGC?X<VWCO[-XGT.STF+0=1U35?$W[.#@?B??N>?QZX[=*_"SXM^&OC:_[
M?NJM8?LU:#XBBU[7? ]_X1\9S?LR_![Q!\/9K#P]\2/V:[G2_&7B?]H6\\%7
MWC_1_&*?#)_VI(_$%GK_ (PTG5?#E_X*\!#X8^$]4O9-+OO&/[IC..??\>>"
M>!R1R>!S0!^'O_!2V:&W_P""D'_!"J6>6.&)?VKOVG5:25U1%,G['GC^- 68
MA1N=E09(RS =Z_:2/Q-X>\M/^)WI?W%_Y?;?T'_32OQ?_P""D_\ RDD_X(4_
M]G6_M0?^L<_$&OV\C_U<?^XO_H(H QO^$F\._P#0;TO_ ,#;?_XY1_PDWAW_
M *#>E_\ @;;_ /QRMRB@##_X2;P[_P!!O2__  -M_P#XY1_PDWAW_H-Z7_X&
MV_\ \<K<HH P_P#A)O#O_0;TO_P-M_\ XY1_PDWAW_H-Z7_X&V__ ,<K<HH
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M7O$%AJ]GX8T_PSX(^'7A[Q5X;U'7I[::+XM:KI?AE)9K[]:.V,G )(7)VY.
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M -%7U?-M?27P!_X]O%/_ %\:3_Z*OJ^EX J.MQIE]6480=6695'&G'EIQ=3
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M/1+!4GT_4;N#5EN&T#2HHM/TC3(/L5S&]PVJ:JW]HZI?"21("[&SMUB=WCL
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M2UMK>VC:9X[>&*"-[BXN+NX>.%%B1YKNZEGNKF5U0-)<7,TT\SEI9I9)&9R
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M7AQ'K-JMXD1%]/;7$V]B)+6UEM(MF!M4Q37EZY<'=N?S@&! "+@DV:**_HX
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M* "BBB@ HHHH 0C/KQZ$C\\$9_&C ]_S/^-+10 F![_F?\:,#W_,_P"-+10
MF![_ )G_ !KY:^+?PM\8>+/VB_V5/B)HEE;W'A;X5ZA\;[CQE=RZC:VUQ8Q>
M-OA<?"_A\VUE-(MSJ)N=8Q#,MHDAM(_](GV1?-7U+D$D @D=1D9&>F1U&: 0
M<D$$#()!!P1U!^G>@ P/?\S_ (T8'O\ F?\ &@D  D@ XP21@YZ8/?/;UI:
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MM]^5I^C .A)4.I89RH8$C'7(SD8[^E*&4]&4\ \$'@]#QV/8]#7\_'A'Q?\
MM:-^SY^V=^T=H7B'XXZ5XY\'Z;^VL_PK^('Q5^-/ASQE^SOJ$O@K]H'XI^#M
M"'AGX$^&KVX\2>&]1\#^!/"5M'X/F\2:)!I4&K:5$^IVVJV][>1WNGX<_:"_
M:O\ V:?'/C7P?X]U'5/CEXN\0_&[0?V8?A+;:##\=?BKX8\#>&?AE^S#X?\
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M:WZ*]7/.*LYXBIX>EFF(IUH86=2=%4\/0H-2JQA&;;HTX.5U3CHVTNAX?#/
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M#LK&WN+QK6VM;07,R/*EG:6EG&R6MK;PQ>BT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>interferonrev.jpg
<TEXT>
begin 644 interferonrev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU+_Y)J&:#Q'/#+ \^B!)HWB<QC589 LBE&V30WD<T3[6.V2*2.6-L/&Z.JL
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M(U,>;_:+V#9V>3]B2Y3'WM_F?:)9,Y^39LQC#;LY&$,OT444 %%%% !1110
M4444 %%%% 'X@?\ !2?_ )22?\$*?^SK?VH/_6.?B#7[>1_ZN/\ W%_]!%?B
M'_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?MY'_JX_\ <7_T$4 /HH) &20 .I/
M'XTFY?4'G&!R<^F!SD#DC' Y/% "T49&,YXZY[8]:3<, YZ].N3]!U/K].>E
M "T4F1QR.>1[CKD>WO\ 3UH) Z]^GJ?H.IH 6B@$'D'(]110 444F?K^1_PH
M _,7]M#]K/XP_L]_'7X$>&M-;P1\/O@EXKN[=O$_Q4^)/@#XC>+/ _B/5Y-"
M^*U]K?@/6_'O@*Y:P^ 4/A6R\)^#_$+^/_&VCZQHVK1^+6NQ%#X?\"^-([OT
M>Z^,?[0WA;]I[X:?#7Q+J/P=\1:%\6/&/Q,AC^$?@CP[XNN?B/\ ##X%^#=
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MM<9^@'))X  Y))/  '))Z5V%_P##WQUI8\,G4/!_B6T/C.**7PHDNBZB)?$
MN)Y+:"+3(A;F6YNYI(]T5BJ?;9+>6WNUMS:75M/+_4]3#Y92<(U:.!IRJ<ZI
MQJ4Z$'4=.#J34%))SY*<)3GRWY81E*5HIL_FN%?,:JG*G6QM14U%S<*E>:@I
MS5.#FXMJ*G.481O;FG)15VTA_P#PL?XB_P#10O'O_A:^*/\ Y:T?\+'^(O\
MT4+Q[_X6OBC_ .6M2CX9_$0ZZWA@>!_%1\0I8+JK:.-%O/MRZ6[B--3*>7Y?
M]G/,1;QWXE^R27)%JDS71\FL2T\+^)+_ %#5-)LM UFYU30[/5M0UO38M-NV
MO]'L=!1I-;O-4M#$L]A;Z0JL=1DNDB%IP)=K%0<XPR>:<H1RV<8TXUI./U62
MC2G\%635TJ<[>[-^[*SLWJ7*>:Q:4I9C%RJ2I14GB8MU86YZ23LW4A=<U->_
M&ZYDKHUO^%C_ !%_Z*%X]_\ "U\4?_+6C_A8_P 1?^BA>/?_  M?%'_RUK+\
M/^%?$GBN>YMO#6B:AKEQ9VXN[J+3XDE>WM6D$2SR[Y(E6(R,$#;C\QZ8YJEK
M&C:MX>U2^T37=.O-(UC3)S;:CIFH0-;7MC<A$D,%U _SQ2A)$<HW(5U/<5HL
M/E<JLL/&C@'7A'GG04,.ZT(>ZE.5)+GC!N4%S.*BW):^]K#KYBJ4:[K8Y49R
M<(5G/$*C.:YKPC5;Y)27+*\5)OW9:>Z[=_X5^(GQ"E\4^%HI?'_CJ2.3Q/X<
MCDCD\9^)GCDCDUNP22.1&U4J\<B,R.C@JZ,RL"I(K^H8=/Q;^9K^4?PF WBO
MPJISAO%/AM3@E3AM<T\'#*0RG!X92&4X*D$ U_4[_P (_IS%F+:H2S,2?[>U
MT9)8D\#40!SV Q7\Y>/E"C1Q'#"HT:5)2I9OS>SA&%[2RVU^5*]KNU]KONS]
M\\$:U:M2XC]K5JU>6IE?+[2<IVO''WMS-VO97MOUV/$_VM/^3;?C/_V(>L_^
M@Q5_-@W4_4_SK^CG]JS1;&U_9R^,DT3:AO3P)K! EUC5[B,X$+ /#<7TL,BY
M4$K)&RG&"""17\XS=3]3_.OIO 3_ ))W./\ L=2_]0<$?.^-O_)095_V*%_Z
MF8D^A_V:M*T+4O'DK:_X;DUVVM;",VM[/X:O?%^@>'KVYN3&-0\2:#I]]9W$
MME>VL=UIEC?LM_;Z;J=Q;R2:9=SSVKP:%I9#P1>_%Q];\&_#:\TCP-#9FWTQ
M_"L>MV\_B;Q[':6/A'3;#5_%4#>+]/T*Q@EO_%4NBZA/!K&F_P!D2Z%>?9[F
M2[*> :!XAUWPKJUKKOAO5]1T/6++S1:ZEI=U+9W<*SQ-#,@EB8;HI8W*R12!
MXG^4LA9$9:9U+43!>VIU"_:VU*YM[S4H'O;J2+4;RT:X:UO-0225A?7=LUY=
MO#=77G7$;W5RZR![B8O^K8G*,1B,QQF)EBD\)BL/E]%8:3J/D>&Q2J8F5-\R
M5&57"NM2IU*34HU<1[6"HU*=2IBOS.AFE"A@<+AXX:V*PV(QU;ZQ%4USK$8;
MDP\9WBY58T\3&E5J4ZEXRIT%3FZT*E.GA?J31_"GA;Q7H?AOPM# /#<]EX&^
M'WB+Q;JNL_"C1])-QIEYXAT33_$6JV7Q0NKI]<^WZFFM1WFAZDVFIX>U:&(Z
M+:W)E!WXGQ?\,:6VFW=QX6\/Z-:#PY\3M=\!SVVD?#_7?!^L1R6NF7M[:Z5;
M-<ZMJ[^/=+LK32+BZN_$>JV6G>+K6];[1JELFDZW8I!X)+XF\23:)%X9F\0:
MY-X;@E$\'AZ75]1ET.&8.\HDBTA[EM.C<2R22J4MALEDDE0+([L;DWC;QG<W
M.E7MQXO\57%YH5O+::)=S^(M8FNM'M;BW:TN+?2KB6]>;3X;BT9K6X2T>%9[
M8_9Y@\("#"EDV8T<7#$QQZE3I5L15AAY<JA/VL(*]6<,/&I4E5E&TG*3GAXN
MWM<5!2I3VJ9K@*N%EAY8'EG4I8>E*O'F<XJE*3:I1G6E""IQE>*453KR3?LL
M+-JI#T!M0AL_@VMWJ/ASP;->^)]=D\)^%=2A\):+:Z]8Z;X2ATO5O%7B*77[
M>W35+W5+RZU?1/#MK<3W#H+>379I5DG^R-#XQ5E[V\EL[/3Y+NYDL-/:Z>PL
M7GE>SL7O6B>]>SM6<P6S7CV\#730(AN&@A:8N8D*UJ]S"85898C5.5?%5\1+
ME3C!*4E"C&,&VHM4*=)5>6T:E?VM:RE5D>/B<1]8=!6:C0PU&A'F:<FX1YZL
MI26LE*O.JZ?->4*'LJ5[4XI?J=_P2]_Y&;XP_P#8!\%?^G/Q)7[%5^-/_!,F
MQM[[Q)\7EG-R F@^#,?9KZ]LB=VJ>(20[65Q;M(,HI <L%(.T#<V?V(LM.MK
M#S/LYNCYNS?]IO[^^^YNV[/MMS<>7]\[O+V;^-^[:N/XY\8O^2_SG_KUE7_J
MHP!_6/A1_P D-E/_ %^S/_U9XLO4445^8'Z,%%%% !1110 445%.)##*(9$B
ME,4GE2R1F:..38=DCQ+)"941\,T8EB+J"@D0G> "3<N=NY=W]W(S^76EK\D?
MB#\<?!GA+XH)X>O?C1^V!K/BS3OB-/X$\5^+?"NH?"32/ASX*&D7OP(\-Z]X
MJD^'VLZ;:Z-KG@C0_'7[27PH\$W5G8>#O&'C.YU2_P#$$UE#KNF^%-<UX_J_
MI4%];:9I]MJ=^FJ:C;V5M!?ZE'9IIZ7]Y#"D=S>+812SQ68N9E>;[+'-+'!O
M\N-V15- 'XG_ /!2?_E))_P0I_[.M_:@_P#6.?B#7U+_ ,%+?^2&^#?^RF:/
M_P"HOXJKY:_X*3_\I)/^"%/_ &=;^U!_ZQS\0:^I?^"EO_)#?!O_ &4S1_\
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M_P"3=F_[*#XQ_P#0M+K\'J_>'_@G%_R;LW_90?&/_H6EU^5^-_\ R1*_['&
M_P#3>*/TGP=_Y+'_ +I&._\ 3^"/O9NA^A_E7\Z7[;?_ "=#\5/^OSPU_P"H
M9X<K^BUNA^A_E7\Z7[;?_)T/Q4_Z_/#7_J&>'*_+? ;_ )*W,_\ LG<3_P"K
M/*C]*\;/^29RW_L>T/\ U7YB?*Z[=R[F95W+N9%#.J[AN=%9E5G499%9E5F
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M6M_L_I#9C5RS@_*:]&G3J3GQ+A:3553<5&65YO-M*$X.]Z:6KM9O2]FO<?\
MAH_X&_\ 12="_P# ?6__ )4T?\-'_ W_ **3H7_@/K?_ ,J:_&W)]3^9HR?4
M_F:_MG_5+ _]!.,_\"H?_*/ZN_*W\=?ZVX[_ *!L'_X#7_\ E_\ 5WY6_9+_
M (:/^!O_ $4G0O\ P'UO_P"5-'_#1_P-_P"BDZ%_X#ZW_P#*FOQMR?4_F:,G
MU/YFC_5+ _\ 03C/_ J'_P H_J[\K'^MN._Z!L'_ . U_P#Y?_5WY6_9+_AH
M_P"!O_12="_\!];_ /E31_PT?\#?^BDZ%_X#ZW_\J:_&W)]3^9HR?4_F:/\
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M .21XB_[*.7_ *K,O/@OI-?\E9D/_9/J_P#X<<;^GK^@VBBBOZA/YM"BBB@
MHHHH _HK_P"#>?4+/3_'_P"U*]W,L*GP5\)2"RR-G;XC\=J>(T<\&5!T_B]
MQ']3MCJECJ7F_8KA9_)V>9M25=OF;MF?,CCSG8W3/3G'&?Y;_P#@W;&?B%^U
M-_V)?PC[D?\ ,Q>/O2OZH,8]?Q)/\Z_SB^D)_P G6XB_Z\9';_PP99_70_T&
M\!;?\0OR"W_01G5]>O\ ;>8>2MZ:^H4445^*'[$%%%% !1110 5E:YC^Q=7W
M"1A_9FH9$-GJ&HS$?8YLB*PTJ6#4[V0CA+33IHK^Y;$%G+'<R1.NK2-]UNO0
M]#@].Q['WH _#SPC\(9?"_Q,\"6MU#K%Q/9>)_A_J1N-*_8O_P""FL>C^7?W
M&@ZW;J_C'6OVJ?$7@?1)K>WO88-9O/%-CJVD>$M3BU"U\9:5/_8^LZ97[AC^
MI[$=SZ_SZ'J.*_$?47^'DG[:GQ?C\8G]F%O$L/Q_^&[>'Q\>?$?B[Q/\:%@?
MP?\ #5-,;X;'0S_PC'A?PP;^"2/X=>"@9+C1_$T.N:QXDE6\\2M:VO[<#^I_
MF?\ /\J /Q!_X*3_ /*23_@A3_V=;^U!_P"L<_$&NP_X+6?%;6/A#^S!\.O$
M.BZ7I6K7-_\ &_P]HLEOJSWJ6\<$_@7Q[>M-&;&:&4S+)91HH9C'L=R5+!37
M'_\ !2?_ )22?\$*?^SK?VH/_6.?B#7._P#!P+_R:#\+/^SA_"__ *KGXDU^
MC>$=*G7\2>#Z-6"G3J9M",X.Z4DZ-;1M-/[F?G_BI5J4/#SBNK2FX5(98W":
MM>+]O15U=-=>J:/YV?\ AMWQ_P#]"9X*_P"__B+_ .3Z/^&W?'__ $)G@K_O
M_P"(O_D^OBZBO]+?[#RG_H!I?^!5?_EG]7?E;_.S^W,V_P"@VK_X#3_^0\OS
M[L^T?^&W?'__ $)G@K_O_P"(O_D^C_AMWQ__ -"9X*_[_P#B+_Y/KXNHH_L/
M*?\ H!I?^!5?_EG]7?E8_MS-O^@VK_X#3_\ D/+\^[/M'_AMWQ__ -"9X*_[
M_P#B+_Y/H_X;=\?_ /0F>"O^_P#XB_\ D^OBZBC^P\I_Z :7_@57_P"6?U=^
M5C^W,V_Z#:O_ (#3_P#D/+\^[/M'_AMWQ_\ ]"9X*_[_ /B+_P"3Z_JI_P""
M-GQ,U;XK_L?2>*M9TW3-*O!\7?B+I8M=*:[>U\FP;0_*ES>RS3>;)YS>8-^S
M*C:!SG^(6O[,_P#@@U_R8O)_V6_XI_\ H7AVOP3Z1^68#">'*JX;#0I5/]8,
MKASQE4;Y71QUU:4Y+5I/8_</H^YECL7X@.EB,3.K3619C+DDH)<RKX!)W44]
M$WULWJ[L_:1NA^A_E7\)/_!77_E(I^TC_P!A/X??^JF\!U_=LW0_0_RK^$G_
M (*Z_P#*13]I'_L)_#[_ -5-X#K\=^BU_P EYG7_ &2.-_\ 5SD1^L_28_Y(
MC)_^RJPG_JHSH_-ZBBBO[R/XA"BBB@ HHHH [;X9_P#)2_AK_P!E(^'W_J9Z
M'7^E O0_[S_^AM7^:_\ #/\ Y*7\-?\ LI'P^_\ 4ST.O]*!>A_WG_\ 0VK^
M,OI7_P"]\$?]>.(/_2\E/Z[^B]_NW&7_ %_R/_TWFA\,?\%,_P#DP7]K#_LC
M'BO_ -%V]?P)/]]O]YOYFO[[?^"F?_)@O[6'_9&/%?\ Z+MZ_@2?[[?[S?S-
M?6?17_Y)'B'_ +*.7_JLR\^6^DS_ ,E9D/\ V3Z_]6.,&T445_4)_-H4444
M%%%% ']''_!NW_R4+]J;_L2_A'_ZD/C^OZH*_E?_ .#=O_DH7[4W_8E_"/\
M]2'Q_7]4%?YQ?2%_Y.MQ#_UXR/\ ]4.6'^@W@+_R:_(/^PC._P#U=Y@%%%%?
MBA^Q!1110 4444 %!. 3Z#-%5;Y+B2SNX[21H;F2VN$MY4,(>*=H76&13<07
M4&Y)2C+YUM<19 \V":/=&P!\7?\ #5>M:E\:_'7PKT;1_@7I$'P^^(?AKP'J
M\7Q,_:1C\$?%'54UW0/"WB%?$GASX4:7\,_%XN=&U2W\236/@9=5\8:3>^,M
M2T74HWM]"MO)N&^V_P#Z_OW_ ,Y]#Q7Y#IX$\?VWQ%TK5_%4O[4WB[QW9^(=
M$U:[LKO]DG]B[4[3Q&^DWEE<!)_C3H_P[LO"UA;7D=LENFLM\0/#FNZ=;N+J
MU32+ZV1;7]:=*N+V[TS3[K4K#^RM0N;*VN+[2_M4-]_9UW-"DEQ8F]MU6WNV
MM)6:W:Y@'DSM&9(BT;*Q /Q+_P""EIF7_@I!_P $*S!''++_ ,-7?M/;4EE:
M&,@_L>?$ .3(D,[*50LR@1-O8!"4#%UY+_@OU+JC_LB?"T7UG8VT7_#0OADJ
M]KJ4]XY<?#KXC[5:.72[%54@N2XE8J54!&#$KV/_  4G_P"4DG_!"G_LZW]J
M#_UCGX@USO\ P<"_\F@_"S_LX?PO_P"JY^)-?I7@]_R<[@S_ +'%/_TS6/SO
MQ9_Y-QQ;_P!BM_\ J10/Y"****_T^/\ -L**** "BBB@ K^R/_@A)+JJ?L-.
M+*RL+B+_ (7=\4\O=:G<6;@Y\.<".+2KY2,Y&3*#P#M&<#^-RO[,_P#@@U_R
M8O)_V6_XI_\ H7AVOY]^DO\ \FU7_9193_Z9QY^[_1U_Y.'+_L09E_ZD9>?L
M4UQXAP?^)5H_0_\ ,>O/3_L7:_A>_P""MS3M_P %#_VCS<QQ0SG4_ &^."9[
MB)<?"CP(%VS206SON0*S9@3:Q*#<%#M_=VW0_0_RK^$G_@KK_P I%/VD?^PG
M\/O_ %4W@.OP_P"BU_R7F=?]DCC?_5SD1^S_ $F/^2(R?_LJL)_ZJ,Z/S>HK
MV+X=_L__ !B^+/AKQCXN^'?@/6?%&@>!;5;G7KVQ^S*\DIGTZ.72]!M+B>&[
M\3:[:6VJ6FJWVAZ%#?:E::0_VZ6 &:RAN^2U'X<^.](\!^&OBAJOA/6M,^'W
MC+7-7\.>$O%=_:&TTKQ+J^@V-IJ.L6^AF=H[G4K:PM+ZV:;5+6VDTAIWDLH;
M^6^M;RVM_P"YHYCE\ZT\-''8.6(IUX86IAXXFBZT,34H2Q-/#RI*?/&M/#PG
M7A3<>>5&$ZD4X0DU_%CR_'QHPQ,L%BUAZE&>(IUWAZRHSP\*T</.O"KR<DJ,
M,1.%"512<(UIPIMJ<XI\517JW@+X'?%?XGZ5>:WX#\&7OB'3;/4Y-#CFCU/P
M]IDNL>(8=)?7IO#'A6QUW6=*U#QIXJAT.,ZO-X8\'VNNZ]%I[V]Q)IZK>60N
M''X%_%L>!;3XDKX(U&3PA?Z=I&MVMW!?:%<:U+X>\0ZXOACP_P"*#X,@U:7Q
MS#X3U[Q))%H&B^*I_#47A[5-8GM;&QU*>6[M!/,LTRR%65">8X"%>-:CAI49
M8S#QJQQ&(YG0H2INHIJM749NC2<>>JH2<(RY96J.6YC.DJT,OQTZ,J-7$1K0
MPF(E2E0H<OMZ\:D:;@Z-'GA[:JI>SI.<>>4>97\GHKU3XA_!+XI?"FVMKSQ]
MX3?0K:XU>\\.231:[X6\0)I?B?3K9;S4/"?B+_A%M>UP^%_%MC:-]IN_"_B0
M:3KL,,=P[6!%G>?9YM3^!7Q;T;P&GQ+U/P3?6G@QM,T#79M0;4_#LNI:?X>\
M5W2V7A7Q-K/A.WUJ;QEH7A?Q/=O#;>'_ !+K?A[3]#U>:ZL5LK^4:CIYNB.:
M99.GAZL,QP$Z6+JJAA:L<9AY4\37<U!4</.-1QKU7-J"ITG*?,^7EOH$LMS&
M$Z]*67XZ-7"TG7Q5.6$Q$:F&HJ/.ZV(@Z:E1I*"YW4JJ,%'WN:VIS7PTS_PL
MKX;;0"W_  L?X?[0Q*J6_P"$RT/:&8!BJDX!8*Q49(5B,'_2($_B %@NEZ0R
MAY-I.N7BDKO;!*CP^P4D<D!F /&3UK_-X^&?_)2_AK_V4CX??^IGH=?Z4"]#
M_O/_ .AM7\@?2O\ ][X(_P"O'$'_ *7DI_5WT7O]VXR_Z_Y'_P"F\T/@3_@I
M9-K+?L%?M7"ZT_3(83\&?%6^2#5[JYD4;;8$K$^BVJL0NX@&9 6 4E02R_P3
M/]]O]X_S-?WV_P#!3/\ Y,%_:P_[(QXK_P#1=O7\"JJ'G5&:!%>=$9[EG2U1
M7E56:Z>,B1+502UT\9$B6XE>,API'UGT6';A#B)]N(Y/_P Q>7Z?UW/EOI,Z
M\69 O^J?2_\ ,CC!C*RB)F5E6:'[1"S*RK-;F:>W%Q"6 $UN;BVN;<3QEXC/
M;7, ?S;>9$8K*P#(RNK#*LI#*P/0JRDA@>Q!(/:OV1_:XL/%>M>&OV:O$/AW
MP/X;UKQ;!97-OX%_9UN]"^$?Q:\*ZG \GQCU!-8^$6O?"_\ L3Q!XS^$/A1=
M*T6Y/A7Q1H\/@V^BN?AW=7-YXJ\0V_CVTN?EK]JWX0?$+4/VM/CEJ=WX3;0?
M#C^-K7Q[JGB7Q#IEMI/@K2_ .M^*_"/@R?Q[J,%B+2*?P!;>*]=M].UAO#5I
M*D$4US;6=I;Q1[H?VW)^,</F;PT<13PF#EB,-F=9J.94\3RU<OS+#9?'#4FJ
M%%8IXAXE2A7PSJ4)5J=3#8>>)E"I.'XYFW"5?+EB94*F+QD</B<MHJ3RZIAU
M*GC\NKX^6(J+VU66%5#ZO*,Z.(4*\:,Z>(Q$,-&<(S^#Q<6Y#,+BW*HNYV$\
M15%R5W.P?"+N!7<Q W!ESD$ ,\ 7>9X FXIO,T>S> 24W;MN\ $E,[@ 20 #
M7]!WB!]!U'X@Z/XBU+1/&NCIX7^.?C_5/!_A+XLR_"6YU#QKHK_!+XAZ=I>@
M?L"-I%U;Z-X<T&WU:WL];\ :7XXD\2>'M,\33?!/4HO$.NZUI&HZ)KGC6MP:
M[>:VVG^")?C=X1^,7B/]G7P$Z>,+[P_\-_B'^UYX#D\)_&+Q;%XBL?BCH^D^
M)_!;ZW%\5++5="70/%?@]-'\3^'?AIX7\&Z?\0]#B\'W6M:S<^10\1(U_9<V
M54J//1H5:DZF:<]*C*M7J0GS3HY?4G5HX>A3=>O7P]*M^]:P-&E5QG+2GZU?
M@"5'VELSJ5N2M7I0C#+7"I65*A2G!QC6QU.%.M7K551HT:]6DG37UVK5I812
MJP_%H$, RD,I4,&4AE*D;@P(R"I7D,"01R#BA65@&5E92,JRD,K ]"K*2"#V
M()![&ON'XY>%KZX_:;\8>./@;\+M*^)/A2_^(>H^&O".C_V#H/C'PEXJ^+'A
M?X6^'-;^)%E;>$_"%_#HNOQ:/XMU#5?&#6&D6[_#V]G"16/]M>&!+I]SR7[<
MGA?Q'X<_:G^-%[KWAV_T&U\6>.];\2^')KG2X=+L-=T>Z-K"^KZ%%:0P:=-I
M+ZC%>01OID,>GQ312V]O'$D0B3ZK <04<=B<JPRITJ4\TR6IFRISQ=*6)P]2
ME/ PJX&KA5'VGM*3QDU4J-P49X:M35.3A4=+YC'9#6P6'S/$.=2K#+<XAE<J
MD,+56&KTZD,9.GC:>);Y/9U?JL'3II2<H8FC4<TITU4_7K_@WF>^3X@?M2&Q
MMK6Y8^"_A+N6ZO9;-1CQ%X\V[6BL;XMD%R<JFTJH&[>2G]3UG)J,GF?;[2SM
ML;?*^R7\U[OSNW^9YVG6'E[<+MV^;OW-G9M&[^6S_@W;_P"2A?M3?]B7\(__
M %(?']?U05_ ?TA/^3K<1?\ 7C(__5#EA_='@+_R:_(/^PC._P#U=Y@%%%%?
MBA^Q!1110 4444 %%%% #=B9W;5W=<[1G/KG&:=110!^('_!2?\ Y22?\$*?
M^SK?VH/_ %CGX@USO_!P+_R:#\+/^SA_"_\ ZKGXDUT7_!2?_E))_P $*?\
MLZW]J#_UCGX@USO_  <"_P#)H/PL_P"SA_"__JN?B37Z5X/?\G.X,_['%/\
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MC(__ %0Y8?Z#> O_ ":_(/\ L(SO_P!7>8!1117XH?L04444 %%%% !1110
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MET]47=(QVHO]F'"KG"C)P !D]:_S>_AG_P E+^&O_92/A]_ZF>AU_I0+T/\
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M/[6=? RA2]OB</2I>TG&$Y1AS<TE&32:3/ZYVZ'Z'^5?PD_\%=?^4BG[2/\
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M_&:*2YF2&2X>&VCD^'RO<2I;PS7#Q0+)(EO#-.RB&&5TE_X:@^"__0;\8_\
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MM>!#;:OJ?@F[T'ZQB^*WQ8\#_M)?M,S_ !2^+-AIGPQ\._L=^%_CEX:\.R>
MR/"WP3M[/QI\:K/5=6UVUT?4=6\8?$/Q)!HOA>PNO',]OK]K8ZNFAVVE^"/"
M_AS%W<:Q]4#]E_\ 9U,7PQBE^"/PNN5^"]M:67PH>]\$Z#?S?#ZSL+B&\L;7
MPI<WUE<7&D6]E?VMGJ5G#;2K':ZI966J6ZQZC9VMU#B6G['G[+MA\7KCX^V7
MP&^&%M\:KO4[[6;KXHP^%-/3QO<:CJ4-];WUQ/KX3[=-]IBU/41+#)(UN6O[
MR00B2YF=P#X._P""?'Q7_:5U/XEZ?X$_:3?XL^']=\<_LWZ+\8-(TOXKZ_\
M"_Q[8?%'7=,\4>']$^(?Q.^$FK?"72]-M?A3X$TQ?&/@JWNOA%\0+?3/$B_\
M)SX:N-$\.Z4?#'C&\U?]@Z\@^&?[/WP-^#%[K>H_"7X0_#?X;7_B18(]=O?!
M'@SP_P"&;K4[:TDDFL[&ZGTBPM96TVQGGN)['2T9--LIKFYFM+2&6XF=_7Z
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MO;>&[L[B"[M;B-98+FVFCG@FB<962*:)GCD1A]UT9E/8FOY*E@@R/W$'4?\
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>lossondivestitureofdenmark.jpg
<TEXT>
begin 644 lossondivestitureofdenmark.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3\>^*/^$(\$>,/
M&7V"35?^$3\+>(O$W]F13"WEU'^P-&OM7^PQSF*80R7GV/[,DIAE$;2A_+DV
M[&_.W]G[_@H_X1\>_"[P[\5?BOKOP M]/\>Z7X<U#P7X4_94^*GQ$_; \>VM
MW=>"I?B!XTT;QWX/\!_!#1=>\,WOP_\ #$VG:CXAN++3];L+""2YDU:XTDOH
M\>K_ **>.O"T'CGP5XN\%W-Y/I]OXM\+^(?#%Q?VJ12W-E#X@T>]TB6[MXY\
MPR3VT=ZT\*2@Q/)&JR#837R=JG[&YT[PS^SU#\*?BSXA^%'Q#_9V^'-Y\)_#
MOQ#TCP=X&\0-XB\#^(?#'@7PYXQL?$GA#Q!IDWAVYU#5[OX;>"?%FE:K"(YM
M!\3>'+ -'JWANXUGPYJX![)\-OVE_@M\8/%VO^"_AAXR'CC5O"_ASPEXKUR_
M\.Z#XEO_  G9:'X^\)^%O'?@:Y7QTFCCP9=S^+_!WC+0_$OAO3;+7;C5-7T:
M2^O[2R>WTG4WM?COPW_P5+^#>MMX&UG5_ WQ<\#>"?%L7[8*WVI>,?A9\4K7
MQII5S^R)\3/AWX \27FG_#32? >K>*?$?A;5M-\:ZKXOU?Q9IL TSP#9>$=9
MT/Q.8_$-CK5AHWU/^S=^S'X-_9AT7Q+X7\!ZMKE]X:U<_#*VTC3]>>TNKO0M
M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MB0:8?"]C\0].U3Q#X7U'4O"_A:XM;_4F\%#57\)>+M1O;0^-M'U[3M'L]-<
M\,'_  4;DUKP%J7QM\'?!?4+_P"!_P -?AA\"/BG\?M>\2^,X?#?C[X?:/\
M&_P3X>^*%QIGA;P-9^&/$&E>.-8^$_PM\5^'_'_Q)AU'QIX+MY-(U.WT_P #
MW'BK7%FL8_>+?]JW69?B[^T+\,I/@/\ $E+?X'?!G3_BUH%[#-HMYXN^-;3>
M)/BEX:O=#^&_P^MKJ2_CMKG4?AJ+'P3K/B;5=%N/'NHZV&T_0]/T&SL-?UWB
M/%W[#;^.[O7QXA^,?B*WT'XS>&_AQHG[5OA+P[X1\,:-X?\ CM>?#;2[/18=
M3TY9Y-5U/X5KXW\.V-GX&^(5AX<U'5X];^'VG:3H&D7'AW6+$^)[C,\;_L5_
M$KXD?&7XP^./&'[25TWPS^-GPEU;X">*OAGX:^$OA_POKUA\)KI_B3=:3I_A
MSXKV?BRX\1:5XOTG4?B9JUVWB_\ L:=;_P"P:<CZ#;R)/<2@&M^Q=^W#I?[7
M<_B*+1K#X8:C9Z-X*^'_ (WD\3_!'XQQ_&[P9H4WQ CU>YA^%_C_ %T^!_ ,
M_@_XT>&M/T^SU;Q+X%_LW55L]'UC3K^34+5YX[27T?Q9^V]^S;X"O/B#:^.O
M&NM^#8OAIX7\=^-?$>J>*/AK\4-"T*\\*_"_5++1_B/KG@[7M3\&VND?$*P\
M#WVI6"^))? EYXA%C!=)>KYUBDUU%D? C]DH_";XEZS\7?%'Q$?QUXUO/AQH
MOP?TIM#^'/@+X1^'+'X>^'M<?7]*M]6\-_#VQM+/Q1XCM[PI!:ZUJLJ:9X=T
MTW^F>!O#7A&R\0^)H=9^8?$/_!*#P%XF\4?$#Q7JGQ5\0RZWXS\/_M!^%8?$
M[> ?AR_Q$ET#]H?7-+\2ZU:>._B:^DGQK\3F\!ZEI<&D_#&/Q%J=OI7A?P9#
M8^&GTF_ETVTUA0#ZTU+]MO\ 9ZTW3YKA_$WB=]9C\:Z]\/CX)'PJ^+G_  L6
M#Q-X;\'Z5\0M9_M+X<1^!)?'ND>'-.\ :_X=\<WOC/4?#<'A.W\(>(_#VO'5
MWM==TD7EOPS\?/'GQ&_9D^!GQS^%WP>/B_Q=\=? OP<\9Z7X%G\<Z?H7AKP;
M;?%3PSHWBK4=3\8>/KG1[J]'A/P1I>HW4FHZEX<\$Z_XFUZ:WL;/0?"$]YJJ
MI9\'XO\ V+VU7XO>+OCGX)^,/B[X=_$?Q7XVU#7GU;3O#OA+Q!9V/A#Q1\'/
M@Q\'O''@1-*\1V=W975OK4'P+\"^-M'\0W"#5O#?C'34*IJWAJ?5/#VJ[7B[
M]EOQE_PR7\./V6_@Y\?_ !C\'&^'G@GX7_#9/BCIOAS1O$'C#7/ WPZ\/Z=X
M;OM&N?,OM"?0[SQMI.EP6.N>)/">J:'XFTF"YOY?">K:%J<MIJEB >1>'_VY
M?B9X_O;OX??#+]G[0_%?QN\'GXZW'Q)\)W7QE31_ -G8? KXB6OPQN1\//B4
MGPYU.7QKJGQ)\7RZEH7@.TUWPAX&L=+UCPCX^TCXC:IX/U?PE+8:CZ)X+_;:
MTKXD?$O]F?POX)^%OC*X^&W[2OPCU?XL^'OB_P"(KW1/#^DVT,7@/PI\0M#\
M*:1X9CN=4U_Q+K;Z)XED3QCJ 31_#O@W5+.WT2/5?$6L7MW9Z/R.B?L.>*_#
MNB>!+GPK\=X_AG\2?!7@CQ3\&T\8?"'X*_#_ ,%>'+GX(>)]8TKQ!!X,LOAO
MJE[XOT'1O$G@O7M+;7/ 7CN'4+NYTC5M8\0RZSH7B.RUW4-/EEUG]BKQ[IGQ
M!_9SUKX/_'NS^&'PS_9A\%6OP^^&WPON?@SX=\=,OA>;PKX?\%Z_::OXXU?Q
M=INN7MSJ7A_PY8PV-\EE!<:9>27%Y<G6/,\D 'HW@#XV?'W6?VEO$?P1\9?#
M+X,6OA3PWX'G\>:SXR^'_P 8_'7BWQ!X9L-?\1W>B?"G2/%'A;Q%\#O ^C6V
MO?$*TT+QEK#V.C^,M7/AVQ\'WUQ=M=6FL>';G5/L:O(/AS\(=,^'OC;XY>.X
MM6O=9UGXX?$/0_'.IM?6UI /#]GX;^%?P^^%VB^$]*DM0KS:+8VW@:Y\01-=
MYN?[8\4ZXS$QO&3Z_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXB^&]<\(:O\ #OX,^/\ P+?>,M<T[4?!.M_&+XO_  TUOQS\/;*W\,WWP_\
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M_P"2G?\ V+<7_P"G<*/H_5?J>@_\(QX>_P"@/8?^ Z?X4?\ ",>'O^@/8?\
M@.G^%;M%?T8(PO\ A&/#W_0'L/\ P'3_  H_X1CP]_T![#_P'3_"MVB@#"_X
M1CP]_P! >P_\!T_PH_X1CP]_T![#_P !T_PK=HH PO\ A&/#W_0'L/\ P'3_
M  H_X1CP]_T![#_P'3_"MVB@#"_X1CP]_P! >P_\!T_PH_X1CP]_T![#_P !
MT_PK=HH PO\ A&/#W_0'L/\ P'3_  H_X1CP]_T![#_P'3_"MVB@#"_X1CP]
M_P! >P_\!T_PH_X1CP]_T![#_P !T_PK=HH PO\ A&/#W_0'L/\ P'3_  H_
MX1CP]_T![#_P'3_"MVB@#"_X1CP]_P! >P_\!T_PH_X1CP]_T![#_P !T_PK
M=HH PO\ A&/#W_0'L/\ P'3_  J]9:7IVF^8;"SM[3SMGF^1&(_,V;MF['7;
MN;&>F35^B@ HHHH **** "BBB@ J&X@BN8)K>:,2Q3Q20R1L2%DCE1HW0D$$
M!U8J2"",Y!!YJ:D/0\XX/.<8]\]L>O:@#\A/B)XF_:'T_P")^M_"#X?_ +,7
MA6S^#WA#XK>%K.XT@?L[7^N>#/B3\//&/B#X >$] TQ/&KW2>#MU_IWB_P#:
M/^)/Q"\9Z3I$\?PCL_A=X*\/^-+'[1K[2^,OULTG2]/T33+#1])LK?3M+TNT
M@L-.L+6,16UG8VD:P6MM;Q#B*&""...*(<1HJH,!0*_&;Q/<^"M"_;'^)5YX
MH\,?!WXGVU[\?/A5I\'Q/^('AW]I+7KOX-^)]<T'X<:?H?PNN?BEI'P9\0?
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MH;UM)\8ZW_9=CH-_I!^(=MIT5SJEM'^TX_J?7U/K_P#J].,4 ?B#_P %)_\
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MXA_Z#5C_ ."-O_EQ0!O45@_9/$/_ $&K'_P1M_\ +BC[)XA_Z#5C_P""-O\
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M R< 5\J5]=?!+_D2V_[#6I?^T*_1/##_ )*=_P#8MQ?_ *=PH^C]5^4CT?\
ML#0_^@-I7_@MLO\ XQ1_8&A_] ;2O_!;9?\ QBM>BOZ,$9']@:'_ - ;2O\
MP6V7_P 8H_L#0_\ H#:5_P""VR_^,5KT4 9']@:'_P! ;2O_  6V7_QBC^P-
M#_Z VE?^"VR_^,5KT4 9']@:'_T!M*_\%ME_\8H_L#0_^@-I7_@MLO\ XQ6O
M10!D?V!H?_0&TK_P6V7_ ,8H_L#0_P#H#:5_X+;+_P",5KT4 9']@:'_ - ;
M2O\ P6V7_P 8H_L#0_\ H#:5_P""VR_^,5KT4 9']@:'_P! ;2O_  6V7_QB
MC^P-#_Z VE?^"VR_^,5KT4 9']@:'_T!M*_\%ME_\8H_L#0_^@-I7_@MLO\
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M +Z'^-?*O_#C_2O^DJ/_  68_P#$T]!_^<U1_P ./]*_Z2H_\%F/_$T]!_\
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MG(+$ _HP#(H"AEPH 'S#H!@=Z7>G]Y?^^A_C7XL_\.9;W_I+7_P6H_\ $V-
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M '[3;T_O+_WT/\:-Z?WE_P"^A_C7XL_\.9;W_I+7_P %J/\ Q-C0/_G+T?\
M#F6]_P"DM?\ P6H_\38T#_YR] '[3;T_O+_WT/\ &E!!Z$'Z$'^5?BQ_PYEO
M?^DM?_!:C_Q-C0/_ )R]?:?[(/[&,_[)#>/FF_:W_;5_:C_X3P>&E5?VOOC;
MI_QA7P5_PC9UPEO (L?!7A#^P#X@_ML#Q,93?_VF-'T/8+7["WG@'VK1110
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MT6*+0O#NO>$S>ZCJ<WU_10!^8WB#]AGXAZQX>\8^%O#GCOX4?"_PK^T)\"O
M/P#_ &D/!_@SX8:]<:%IGA;P'X:\5> XKO\ 9T2\\;V,'@"\U7X9>*9?AP+3
MQCIGC'2=!LM$\(^)-)L5O-!U'1_$N_JW[-7[3NJ_M#_$;QW9?$WX/>"/A7XY
M^"B_L\Z2G@3PM\1],^-7@'P+HU]\1=7\(^+?"7BZ_P#&5]X*MOB)HFJ^.X)X
M9[CPC-HEK)H-I<VELKRO"OZ-44 ?G5^R5^PY<?LW?$F_\?0S?!/PE:R?#3_A
M6FI>&/V>/A-KGPDT;XN7T.N:#K>G_&'XZ6^K?$'QI%XU^*^C#3-<T_PYKQB.
MNZ;:>/\ XA_V_P",/& \0:?%H/Z*T44 %%%% !1110 5^;FL_LM?M"?$?]HG
MQ7XY^.'B[X$?$OX,ZE'X]\$^!/!__"*?%30O$_PI^$?CGPKJ?A'6++PI%%X]
MO? ]S\6_%.D:C=:?XV^+VJZ-<:S<Z!JFJ>$/"%EX/\)W5_H^J_I'10!^=W@;
M]EG]H#P(WA;Q1/\ %KX7>._'_P "/@=??L^_LYS:[\-_%&A:!'X8\0:O\+KG
MQAXY^,G]D^/-0U?Q)\0/$FB?"7P=I#)X'G\'^&-,O-/UK5;72WMO%3Z+H&9\
M-?V0?C-%^QQX1_90^+OQ ^%E_;>$=>^"6C2:]\.?!_C?2-.\6_!_X;>/? /B
MSQKX0\0Z/XK\9:[<PZO\2=#\->(O!^H75GJ4NB66E^(R9=*O8HI[6?\ 22B@
M!  HP/4GUY))/ZDTM%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>marketedproductsrev.jpg
<TEXT>
begin 644 marketedproductsrev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '\ IH# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *"<?F!^9Q12'^H_F* /Q,^&'_!67XK>(?@'\*?VQ
M/BI^QHGP[_9#^*7B3X<Z,?B=X4_:0\*_$SQY\/\ 1/BM\3M/^$/A/QS\0/A+
M<?#CP#<P>%+#QGKOAY/&1\'^+_%^O^&M%U*YUR/0]6LM&U0V_P"J=G^T+\!M
M0\2ZCX,LOC3\)[OQAI%GX[U#5/"=O\1/",OB73]/^%VKVV@?$O4+W0AJ_P#:
MEKIWP]UV\L]&\;:A/:QV7A;5;RUT_6[BRNKB.)OQ"_X)A_\ !.:'QQ^P;^Q^
M_P"TQ\3?VM->\/\ A_3O!OQ+NOV0?B9XETOP5\&/#GC7X=_$;4?&W@'3-?\
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MG:6=A;W U";PG)JD:I:Q&VBO8[60R20/-)X7I?\ P4%\'ZC_ ,%"=:_8,E\
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MQE_P39_9N_8M_P""</@VS\5/\:/!W[*7P<\$^,_VI[O]G3]HKXQ_LZ?!O0?
M7A;2_AYK?BZPTKX0_#KQ+>_%GXHZQK'A_6;GX9_ V'4_"=FFEV]MXD^*?C#P
MCX9BTS3?%8!]B6G_  4Y\&^)?AC\/K[P'\(?'OB#]I#XD_M!?$K]D[2OV5]3
MUKP;H/C3P[^T%\$K?Q5J?QMT+QOXYBU37/ >D?#SX8>&/!FM>.=9^*>B7WB?
M1=;\'7?A6X\(:;X@\1^,O#OAB\]^_9I_:KN?C5XQ^+OP7^)/POUCX&_M$_ @
M>!]1^(OPQU+Q)I/CG0[[P5\4++6[SX;?$_X:_$+1+32['QS\._%MQX6\8^&X
M]1NM"\,>(=$\9>"/%GASQ#X8TR6QL+O5?RD\._"KX9?"F+_@GC^UE^S5IWQ\
M^.7P:_9J^+_[7&F?M.^)]=^$7Q5_X:0\;:Q^V#X3FE^*G[5GBCX9^)O /@GX
MC_$'7K;XXV'AS6O'UEX$\ 3'3O /C3Q#=_#?PM=>&_ =MX>M?M/]F"QUCX[?
MMU?M%?MM:5X0\=^#/@QJG[-G[.O[+7PFO_B+X'\4?#3Q%\6KSX=^/OC=\8_B
M!\2;/P+X\TGPWX\TCP+IE[\8/#?@/P=J7BSPUHMYXDU;1/'6JZ/92>&/[&UC
M6P#'_;9_;Q_:S_91^)?@?PWX*_8.T/XW?#;XJ?%3X6_!'X9_$IOVNO!'PPU#
M7_B=\4;"ZDL-(U;P#K7PP\1:CX=T?3=4T[5--N->EUJ_2YCM8[^&R2.Y$$7H
M?AG_ (*#:5X2\=R?#?\ ;&\*?#K]CSQ#HW[/?P\^./C+6O'/[0_@/6OAQX<U
M+XE?&#XQ?"_0/AY!\0M0TGP/HFLZM)8?"<>+%U2);.*>+7WT:/3?-T&]U"XS
M?^"D_A;Q/XH_X8-_X1GPWX@\1_\ "/?\%*/V3?%&O_\ "/Z)JFM?V%X9T>]\
M<-J_B/6O[,M+K^R?#^E+<0-J>MZA]FTO3UGA-Y=0B6,MFM\&].\3_P#!6?QI
M\3/%?PXDUW2-&_X)U_![P-X7\7Z]X8N=2\+6FJ:_^T=^T!<^.?#FE:EJ-E/X
M<;Q%=>'U\//K=G!(^N6WA^^MDG6#2-:E6^ /N/XB?M _ CX0^$=$^('Q7^-'
MPG^&?@3Q+-I]OX=\:?$#XB^$/!_A37KC5K,ZCID.B^(?$&L:?I.K2ZAIRMJ%
MDFG7=RUS8(]["'M$:8'BK]H+X$>!?#VA^+O&WQH^%'@_PGXF\,ZOXU\/>*?%
M'Q$\(Z!X;UOP;H&CV?B+7/%NE:_JFKVVD:AX8T;0-0L-;U37[6\ETJQTF]M-
M0N+N.UN8)7_DW_9^^!7[0GPVT7_@G%\7/B-XO_:7_9X^$G@']@WXF_L_^&O%
M/@3]DFQ_:=\1?!3XH)^TKXAU"[\*>,?A-XU^#/Q@\6_"32?BE\'K7X;>'?!_
MC?P[\/[*SO[#X9P> ]>\0:/I]WX4TKQ#]T?"3]C_ $R'Q;_P21\+^(OAO\=_
M&'PO\*?%;_@H?\9[S1/VD?A#X#\*7O@2]^(6A^)/%?@2/QG\)_A9HD'PM^$_
M@R3Q)XCG\3_!7X2:QI7A^Z\ POX-T2X\+>&?&W@R/P_X? /W$O\ ]J?]F32O
MB-H7P?U3]HCX&Z;\6?%*Z2WAGX8:A\6? 5E\0O$*Z_;6-[H/]B^#+G7X_$6I
M-KEEJ5C>:-'::=++JUI=0W.GQW,$BR&3QK^U'^S3\-M<D\,_$3]H3X(^ O$4
M7B;3?!;Z%XU^*O@7PIJZ^,-:T31O$NC^%?[.U[7=/N_^$CU;P]XBT#6]-T81
M?;[W2M;TB_@@>VU.RDG_ )?OVX=&_: ^('P=_;X\#>&/ ?Q.^$WQ.M/VB?'_
M ([\,?LM? G]@6TN/#_Q+\'>"/C+I6L>!?VJO&W[7GB?X>^*K?QYXO\ 'WAK
MPUH?Q;MM?^$WC[PI\0?"VLVVC_"'P=X4N/%?@PFY^D_'/C3X0^'/VT/^"Z'A
M?XH_L\_$GXW7GQ9\,?LS_#+PIIG@3X!>+_CDOQ)O/$/[$&CVR_ =+CPEX>\1
MVG@K5?$&I75AJ2S^/I_ _@74+?58M5NO%Y7PSK#Z" ?T ?%#]HGX _!"^\-:
M9\9OC?\ "+X2:CXSGGM?"%A\3?B3X-\!WOBFYMI((KFW\/6OBG6M*GUB6WFN
MK6&=;".<0SW5M#*4EN(4?O!XW\&MXP/P^'BOPX?'8\-1^,CX,&M:<?%0\(S:
ML^@1>*#H N#J@\/R:Y')H\>L?9O[/?4T:Q6X-RIC'\FGA+]F;]ICX >.]>M_
MVMOB?^TOX<UGQ[^P%^PC\$],U;X0_L9> /V^M#^,>I_"']G*'P'\>OV>M6\2
M^+/@;\<[SPOXFO\ XWP^.O&A\*Z_-X+^'OQ2L/B7#XQ;6->U"#Q1)X;_ $"^
M%WAS4_V(?CY^R/XA\=>!OVJ_$OPP'_!+_P  ?LP>&O%.K_##5_CE\6+#XL_#
M?XJ>'?%>E?"CXTG]GG2O'&@>'_B3K/A'7(K33O$?GQ?##7-:\)^*;6V\;HUC
M:SZB ?>?C3_@I_\ L/\ @7XY?L^?L_ZK^T#\,KSQI^TQI'C?6/AGJ6D_$#P#
M>^%)8O!?B&R\'066K:P?%,,UOJ?CGQO-JW@CX=V6GV&J/XK\7^$/&GA^V:'4
MO#=[!7LN@?M.^!+/P/\ %GXC?&'Q;\&OA'X(^%7QA^('PNU3Q?>?';P)K_A&
MRMO"/B2+P_I%]XU\49T'1_AYXTUI[BU&L_"[7KF7Q)X/U:Y@T'4+F_OY(V?^
M?K]ECPAXX^ '@[_@CI\9OC;\'/BIX.\*_"NW_P""GWPY^,*6GPF\<_$+Q!\)
M?&OQ[^-,.K?"BP\;^'?AWX6\5^(['0M:NO"NMZ=9^.K/2+KP4M_/HURFN)I?
MB;1]1O.K\/\ P\\>?#_XQ^%_CW\3/A%\3?$W[._P>_X*_?\ !2GXB_$?0=+^
M%WCGQSJ?AUOB9X$U7PO\!/VEK?X5:#X9UKQ1X_\ !'A/69_$6@VOBSPEX;\3
M/X8/Q'M?'MA'_9.AZKK>D '])?@[QMX-^(OA;1_''P^\6>&?'?@OQ%9_VAX>
M\7>#=>TKQ/X8UZP\R2);[1=?T.[OM)U2S:6&6-;FQNYX3)')'OWHZK^2FI?\
M%.OCK%HW[6?Q9\/_ +$;>,OV<OV//BU^T!\-_B-XR\-_M)^$5^,FNZ5^S5J$
MT7Q+\6^"O@AKWPYT72=6:'1K+4M>T7PQ=_%S3]8UJ&Q.FV,DFJWEA:W/VC^Q
MC_P@=_\ #WXA^+OAE^SSXN_9R\%?$+XW_%/QSH^@^-=(U+P=K7Q'EUG4K.'5
MOC@/A?K1M];^%5A\7-;L-2\56'@[7=#\*^(;V"=?'/B/PQI&O>--0CD_+/\
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M'&L?$77O%FH6/P1T_P <^)?#GBO3_@AX5\<S32^&%T:QTV+30#^B#PY^T7\
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M3W&.#G(_#&#R.:6B@!,#.><XQU/3WYY]LYP>1S1@>_;G)!XZ9(.3U/4FEHH
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M3+CZ]/A+XW^//C-\&M-\=^!W\-^$_A!^S:WBG^U?"5SI2_#Z/]J/QZT?P_\
MM7AC3Y]35KF'X-^#-(\;7'A:SOK98(+#XHV5XF_5K*SDL #ZZ\'_ !A^$_Q!
M\0^+O"7@/XF^ /&GBGP#>C3?''ASPKXQ\/>(==\'WYGN+46?B;2=)U&[O]#N
M#>6=[9>7J,%N1?6-]8G%Y974$,5Y\:/@_IWQ%T_X07_Q3^'5E\5]6M?MVE_#
M2[\:^&[?Q]J-E]DFOUNK+PA-J2:_<PR6-M=WL3Q6#>=965[>0B2VL[F6+\F_
M@1X4^+WPY/[,6M7G[,GQ>\,7G["O['7Q8^%_QDM_#ND_#Z\O_COXLNM!^$T>
MG^"/@6\?C2V/Q6M_&WB;X::_\6;+7M6N?#<$6NW_ (7TO7+NQ\9>)O%NF:%V
MGQ-URY^('[4'A_X2K^R1\=?AY\,-&^/OP?\ CEXZ^+6B?!*PUB'XZ_&_PM9>
M$=7\!ZJOQ'TC4[S2/ WP\^'-SHG@W1_B5\1=?O6\7>([/PI=?##0M'TKX>6^
MN:_KH!^OE%8 U35% '_".7W  _X_]%[#';4 /R 'H!2_VKJG_0N7W_@?HO\
M\L* -ZBL'^U=4_Z%R^_\#]%_^6%']JZI_P!"Y??^!^B__+"@#>HK!_M75/\
MH7+[_P #]%_^6%']JZI_T+E]_P"!^B__ "PH WJ*P?[5U3_H7+[_ ,#]%_\
MEA1_:NJ?]"Y??^!^B_\ RPH WJ*P?[5U3_H7+[_P/T7_ .6%']JZI_T+E]_X
M'Z+_ /+"@#>HK!_M75/^A<OO_ _1?_EA1_:NJ?\ 0N7W_@?HO_RPH WJ*P?[
M5U3_ *%R^_\  _1?_EA1_:NJ?]"Y??\ @?HO_P L* -ZBL'^U=4_Z%R^_P#
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M $+E]_X'Z+_\L* -ZBL'^U=4_P"A<OO_  /T7_Y84?VKJG_0N7W_ ('Z+_\
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M*L1@T 24444 %%%% !1110 4444 %%%% 'X@?\%*/^4D7_!"K_LZ_P#:=_\
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M_P"(E;]AW_HEW[4/_A%?#?\ ^>K7\/U%?JG_ !"SA+_GSC__  NG_P#(>O\
M2U_&O^(R\;?\_P#+O_#?3_\ DS^X'_B)6_8=_P"B7?M0_P#A%?#?_P">K1_Q
M$K?L._\ 1+OVH?\ PBOAO_\ /5K^'ZBC_B%G"7_/G'_^%T__ )#U_I:G_$9>
M-O\ G_EW_AOI_P#R9_<#_P 1*W[#O_1+OVH?_"*^&_\ \]6C_B)6_8=_Z)=^
MU#_X17PW_P#GJU_#]11_Q"SA+_GSC_\ PNG_ /(>O]+4_P"(R\;?\_\ +O\
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M /A=/_Y#U_I:G_$9>-O^?^7?^&^G_P#)G]P/_$2M^P[_ -$N_:A_\(KX;_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q _X*4?\I(O
M^"%7_9U_[3O_ *QU\0J_;R/_ %<?^XO_ *"*_$/_ (*4?\I(O^"%7_9U_P"T
M[_ZQU\0J_;R/_5Q_[B_^@B@!6Z#_ 'D_]#6O\M?]J3_DYS]I+_LX3XX_^K5\
M75_J4-T'^\G_ *&M?Y:_[4G_ "<Y^TE_V<)\<?\ U:OBZOV?P<_WS/?^P;!?
M^G<0?@?CQ_N'#W_85F'_ *:PAX31117[R?S6%%%% !1137+K'(T:&618Y&CB
M#!3+(J,R1!V^5#*X"!F^52VX\ T .HK]-OBG^RS^SEX%^#/[.7Q8L?$GQ<\0
M_#OQ5JD</Q8^.GP_G^&WQ \'7MG=3W<U]HUGX-M]5T[Q)\)O'6G7]C=^#?"6
MD>-EOM.U&XT[7+GQE+;:UI"66H_+W[0'PR\#^"?#/P4\9>"](\=^"+SXM^"O
M%'BZ_P#A/\3?$.C>*O%GA31]+\3'1_ OC ^(=%\+>"I)_"7Q;T<76O>%H=8\
M(Z3JBVNBZAJ]@^L>%M8\-ZG<^;ALUPV*E3C25;][5KT(RG3Y4JN']JYTYKFY
MHR<*,YN+BI4DZ<,0J-6M2IS];%Y-B\%&K*M*A^YH8;$RC"KSMT,5[!4ZD&HJ
M$X*>(ITU*,G&LU5J85UZ%&M6A\U45^DOPX_9C_9P^,-CX;N_#/B3XQ>!/#DO
MQJ\ ?"#2/B)\0K[P%8V?[0VH:QX1\6:_X_TOX7>$;W2-%@^'WC/PSJ_A[0M%
MTRTUKQGX_P##&FCXA^#;3QYK6F>);^ST[4M7Q'^QIX+\*_#B']H3QKX&^-_P
MS\$:9\./'WB+Q/\ L^>,_%?AF#XR0^-O#/Q;^%'PE\):2?&4_P /M+/AKP;X
MRF^,6A>*K_4_$'PL_P"$FT>Q\-:[9:5I>KV7B#PQKBXRSS!1JQH3]K"M.I"C
M&E.,8U)5JL92HTHQ<U>=50DGKRT)KV.+EAZS5,WCP]F$Z,L3#V$\/"E4KSK0
MJ3E3AAZ,J<<17DXTW:G1=6#U]_$TW[?!0Q6'3JK\Q:*^F_B-^S]/_P +F^'?
MPX^"EOXA\6VGQQ\$_"'XB?"C2?$+:>/%5MI7QB\,6^O67A[QA?:7:VFC"[\&
M7L>NV/B'Q5:V6G:-+X?T1_&4UCI-C+<6EI8_:C^#_P .OA'??!O_ (5?K_BG
MQ9X<\??!;2_&E_XI\26L5E;>(?%-I\1/B7\/O$&L^$;!-.T^XTOP-K4_@*#7
M/"&EZNU_K]OH.J6-SK-\]U>?9[?LAC\/4GAJ<92<\73=6G'E=XQ4)3_>K_EU
M*2A445*SG*E54;^SG;AGEN*IT\95E&"IX*JJ567/%J<W.$/W'_/Z,74I2G*%
MU"-:BYM>UIJ7RY11178< 4444 %%%% ']G__  ;(?\FT_M)?]G!Z;_ZJCP97
M],-?S/?\&R'_ ";3^TE_V<'IO_JJ/!E?TPU_)_'W_)89Y_V$4?\ U$PY_:WA
MI_R0_#__ &"U?_4K$!1117QY]T%>;ZU\8_A+X;U2\T/Q#\3_ (>:%K.GO''?
MZ3K/C?PMI>IV4DL,5S$EWI]_JUO=VSR6\T,\:SPQL\,L<J@QR(Q]&?[C?[K?
MR-?YS'_!9^TLY/\ @IY^UH\EE92NWBWP.6DEL[661B/@_P##D L\D3.Q   R
M3@ #H*^OX,X8I\59CB<#4QD\%'#X&>,52%%5W)QQ&&H^SY'5I))JNY<W,_AM
M;6Z^&X^XOJ\&95A,RI8&GF$L3F%/!.E4Q$L,H1GA\37=13C1K-M?5U#EY4K3
M<N;W;/\ T#?^%_? S_HLOPI_\./X+_\ EY1_PO[X&?\ 19?A3_X<?P7_ /+R
MO\K+[%8?] _3O_!?9_\ QBC[%8?] _3O_!?9_P#QBOTG_B#F%_Z'U?\ \-\/
M+_J,]?ZV_)O^(\XW_HFL-_X=*OE_U >3^_R/]4W_ (7]\#/^BR_"G_PX_@O_
M .7E'_"_O@9_T67X4_\ AQ_!?_R\K_*R^Q6'_0/T[_P7V?\ \8H^Q6'_ $#]
M._\ !?9__&*/^(.87_H?5_\ PWP\O^HSU_K8_P"(\XW_ *)K#?\ ATJ^7_4!
MY/[_ "/]4W_A?WP,_P"BR_"G_P ./X+_ /EY61K_ ,7OV;_%>BZIX;\4?$KX
M)^(_#VMV4^FZSH.O>-?A]K&C:MIUTABNK#4]+U'5;FPO[*YB)CN+6[MYH)HR
M4DC93BO\LG[%8?\ 0/T[_P %]G_\8H^Q6'_0/T[_ ,%]G_\ &*/^(.87_H?5
M_P#PWP\O^HSU_K8_XCSC?^B:PW_ATJ^7_4!Y/[_(_P!)2^^!/_!,C4?A!X=^
M 5YX;_9<G^#?A74)=6T?X>/XI\%+X;35;BQ_LVZU74;2'Q'"VN:G>606"]U#
M7)=1N[Q(X?M,LI@A,>9K?[.?_!+WQ%>>']1UGPY^S-?:IX7\':?\/M#U:3QU
MX=35['P1I6O:WXHTSPH-6@\8Q:C<Z#8>(O$>N:W::;>75S;P:GJEY>1JLTI8
M?YOWV*P_Z!^G?^"^S_\ C%'V*P_Z!^G?^"^S_P#C%'_$',+_ -#ZO_X;X>7_
M %&>O];'_$><;_T36&_\.E7R_P"H#R?W^1_I@:SX'_8"\36GC*S\5WG[._BN
M'QY\3=1^,/B)O$7B[X?:A<2_$75/#F@>#[SQ/87?]KPW>D:G-X3\+Z'X;FN=
M,GM9[S1K'['J$MVES=^??U[PG_P3X\3VWP_LM>TO]D_4[#X5VT%A\.M.N+GX
M3?V=X-TNUFBN;;1M T^.\CLK'0X+RVM+^+0UMVTA-1LK'4ELA?V=M<Q?YF'V
M*P_Z!^G?^"^S_P#C%'V*P_Z!^G?^"^S_ /C%'_$',+_T/J__ (;X>7_49Z_U
ML?\ $><;_P!$UAO_  Z5?+_J \G]_D?ZD^F_$K]F'1_$WB7QEI?Q#^"5AXK\
M90:!:^*O$-KXY\"PZQXAM_"UO?VGAR'5[]-:$]]'HEKJFHP:8L[,+2*]N4BP
M)G!\>_X0C_@GD=/^%FE-I7[*4FF_!*QL=+^$UE+J'PNFMO &EZ9/;WFFZ7X9
MBFU&1=/TO3]1L[#5;'31YEC::QIVFZQ;V\>J:?97D'^9S]BL/^@?IW_@OL__
M (Q1]BL/^@?IW_@OL_\ XQ1_Q!S"_P#0^K_^&^'E_P!1GK_6Q_Q'G&_]$UAO
M_#I5\O\ J \G]_D?ZIH^/OP,'3XR?"G_ ,./X+_^7GYT?\+^^!G_ $67X4_^
M''\%_P#R\K_*R^Q6'_0/T[_P7V?_ ,8H^Q6'_0/T[_P7V?\ \8H_X@YA?^A]
M7_\ #?#R_P"HSU_K8_XCSC?^B:PW_ATJ^7_4!Y/[_(_U3?\ A?WP,_Z++\*?
M_#C^"_\ Y>4?\+^^!G_19?A3_P"''\%__+RO\K+[%8?] _3O_!?9_P#QBC[%
M8?\ 0/T[_P %]G_\8H_X@YA?^A]7_P##?#R_ZC/7^MC_ (CSC?\ HFL-_P"'
M2KY?]0'D_O\ (_U3?^%_? S_ *++\*?_  X_@O\ ^7E'_"_O@9_T67X4_P#A
MQ_!?_P O*_RLOL5A_P! _3O_  7V?_QBC[%8?] _3O\ P7V?_P 8H_X@YA?^
MA]7_ /#?#R_ZC/7^MC_B/.-_Z)K#?^'2KY?]0'D_O\C_ %<O"_Q+^'?C:[N;
M#P=X\\&>*[ZSMEO+NS\->*M UZ[M;1I5@6ZN+;2=1O)H+=IF6%9Y42(RL(PY
M<A3V]?Q2_P#!LE;VT/[5O[1+06MK S?L[Z0&:"V@@9A_PL_1N&,4:$C@'!)&
M0#C-?VM5^5<5Y%#AO.:^50Q,L7&C1PU3VTJ2HN3KT8U6N15*B7+S6OS:[V6Q
M^S\%\25.*\AP^<U<)#!3K5L32>'A6=>,?J]:5)2]I*G2;<U'F:Y%9NRON%%%
M%?.'U84444 %%%% !1110 444=.M !169I^M:1JS:BFE:II^I/H^HS:/JR:?
M>VUX^F:M;PV]Q/I6HK;22M9:E#!=VL\UA<B*[BAN;>1X52>)FL?;[+[&NH?:
M[7["T N5O/M$/V0V[*'$XN=_D&$JRL)1(8RI!#$$9 +=%07-S;V=O/=W<\-M
M:VL,MQ<W-Q*D-O;P0(TDT\\TK)%###&K22RR.L<:*SNRJI(K0ZKIESIT.KV^
MH6,^E7%K'?6^IPW=O+I\]E-&LL5Y#>I*UK+:RQ.DD=S'*T+HZLKD,,@&A16?
M<:MI=I?:=IEUJ-A;:CJYNQI5A<7EM#>ZF;"$7%\-/M)95N+TV=N1/="UCE-O
M$1)-L3YJ-3U;2]%M3?:QJ-AI5DLMO UYJ5Y;6-HLUW/':VL+7-W+#"LMS<S1
M6]O&7#SSR)%$KR.JD T** <\_P"?\^U% !1110 4444 %%%% !1110 4444
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M_)#\/_\ 8+5_]2\0;-%8WD>(?^@IHW_@BOO_ )HZ/(\0_P#04T;_ ,$5]_\
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MY@L]9E=K294CTF[N;BTMK74Y&(33[FXNK:"WO##-+<01HTJ?A=_Q$*_L"_\
M0Z?$[_Q'7QQ_\U%'_$0K^P+_ -#I\3O_ !'7QQ_\U%'^I_%/_0@S7_PBK^7]
MSS_JZN?Z]\&_]%-DO_APPWE_T\\_P?8\Q_8P\-> ? &A_M;^&/B#X'\::5\
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M]_PH7X8_] ?4/_![JO\ \DT?\*%^&/\ T!]0_P#![JO_ ,DT?ZPX'_GWBO\
MP72\O^G_ )O[O,7^K>._Y^87_P #J?\ RGU_IZ? -%??W_"A?AC_ - ?4/\
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M,7LUNEJ%%%%?+'V8U_N-_NM_(U_G/_\ !9W_ )2=?M9_]C9X'_\ 50?#JO\
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M  0J_P"SK_VG?_6.OB%7[>1_ZN/_ '%_]!%?B'_P4H_Y21?\$*O^SK_VG?\
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MC.,'./7'I0 E%*00<$$'T((/Y=:"".""#Z$8H 2BBB@ HHHH **** /Z8?\
M@AN0/@C\:LD#_B\-GU_[)_X:K]OLCU'YBOPQ_P""(FGF\^"?QG87VI6FSXOV
M:;+*[^SQM_Q0/AIMSIY3[G[$Y'"H,?+S^V']A'_H,:[_ .#(_P#QBOZ=X(_Y
M);)_^O%3_P!2*Q^L9!_R)\#_ ->Y_P#IZH;V1ZC\Q1D>H_,5@_V$?^@QKO\
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MN71U.]OI]4O+Z>[U.ZN'N[K4KFZN)M0N;N1!%)=7%[(6NIKF2(")[B25IGC
MC9R@Q5JBC_B/WB'_ -!&4O2W_(KI;.UU\>SMK_P%9_V+@DK6JVNG;VKM=;/;
M=7=GTN[&6+&559%,:(\?DNB%D1X=P?R9$5 LD.]0_E.&CW@/MW $3E-0,?DF
M]G,.SR_)-Y=F'RP<B/R2WE>6#R(]FP'D+GFKM%'_ !'[Q#_Z",ITM_S*Z72W
M]_R_K2Q_8N![5>W\5[=MOZN_*V8;.<^:"ZD3J$GR\A\]%?S%2?*GST5_G5)M
MZJ_SJ _S4GV*7^]'^;?_ !%:E%"\?_$-?\Q.4_\ AKI>2_G\OZTL?V+@?Y:O
M_@Q_Y>OWORME_8I?[T?YM_\ $4?8I?[T?YM_\16I11_Q'_Q$_P"@G*?_  UT
MO_D_ZN_*R_L3 _RU?_!C_P OZN_*V7]BE_O1_FW_ ,11]BE_O1_FW_Q%:E%'
M_$?_ !$_Z"<I_P##72_^3_J[\K']B8'^6K_X,?\ E_5WY6R_L4O]Z/\ -O\
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MU'Q!J'C3XB:0Z^'?A7HFJVT\;>&[[QB@FO$$]UJ-II5C:SW*]O-\?O"-Y?\
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M &-J7_J'C3Y/C#_D7X;_ +#(_P#IBN?"U%%%?@I^=A1110 4#DX]?7I^-%%
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M_P#\*\1_\L\OS[L_,/94O^?=/_P"/^7DON&[$_YYQ_\ ?M/_ (FC8G_/./\
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MY]T__ (_Y>2^X_1__@DRJ#]NGX6$(@/_  CGQ1&0B@_\B%J_0@ U_8#7\?\
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M31_PJOXB_P#0G:W_ -^;?_Y)H_XA]Q]_T0O&?_B+9[_\P>:^\/[5RO\ Z&6
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M^0J/^&<?%7_0P>'/RU7_ .0J/^)??&7_ *('-O\ PHRK_P">'FOO#_6?(?\
MH94?_ *W_P J/GJBOH7_ (9Q\5?]#!X<_+5?_D*C_AG'Q5_T,'AS\M5_^0J/
M^)??&7_H@<V_\*,J_P#GAYK[P_UGR'_H94?_  "M_P#*CYZHKZ%_X9Q\5?\
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M/_#/?C__ )Z^&_\ P;S?_*^C_AGOQ_\ \]?#?_@WF_\ E?7VM11_Q*)X1_\
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MGLW5AG&)H+V4.2/)'!X":O'FEKS5):WVLN@4445\@?IH4444 %%%% !1110
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MC_F&V7J/^F%?R\_%!53XF_$A$541/B#XW1$10J(B^*=65515 5550 JJ %
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M0HP/0?D*6BBR[+^O^&7W ?M!_P $QY88OAG\21)+%&3\0;<@.Z(2/^$5T89
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M,"W$303K 3")X&9':&81;1+"7CC<Q2;D+1HQ4E5Q\UEW#\LLJ0J8;$T&Z?\
M:48JI@I.4:>8XG#8ETXU8XM3Y:4L+3;=3VKJ2E4Y72I?5Z6&]_'YW',:<Z6(
MH5TJG]GRDX8R*3G@,-7P_/*E+"RA>K'$U$O9NDJ<8T[JK5]O5Q'Z,:KXQT.U
MODU#[39S16WC+X9-X?U+4/B=X8O/"?CN/2M'O?#']L?#CPI<7MY;_ Z72%OO
M^$Q675(+O2;6XLK'0-=ETB4FU/G][;:SJ3>"/!_A?X@7MCXRT_PK\0$\=^.O
M&7BGPI>^-=.\#:KXB\/WVE:-!JFC>)M4(U^YN+/5/[&\+>'?&%[K\VEZQ/%J
M.I:+HNMW]O8_$@5068*H9\;V"J&?'3>0,M_P(FFF.,J$,<909PAC0H,]2%QM
M!/<@#J?6N.APC##.$J6-BYTTN5U<&Z\.>&#J8*BYTZV*G&I3I0KUZ_L9/V4L
M3*CRQIX/"X;!4NRMQ1/$<ZJ822C4;YU2Q7L)<D\72QE90J4<-"4)U)4*-#VR
MO4CAXU4W/%8G$8NI])^($\;ZW\7;;Q1H$6E:%K5EKG@WPOI%_P",/%7@2XU-
M]5L_"*V^F>+O%ET^IWNCSZIJ-CHUQXCU_P 11"]TS2==D@MFO9M:&GB\Q/C9
M)JMJO@CPWJE]J7B.3PQI6N6O_"<ZUJ]EJ^I^++C4M974KTVS0ZMK&J6?A?19
MI4L_#%MX@N4U>>*XU'5)[73QJ/\ 9=AX0(XPNT1QA<$;1&@7!()&-N,$@$C&
M"0#C(S0J(@(1$0'DA$5 2.A.T#..<9Z9->Q0RCV-?+ZCJ89TLNPT,/1IT\'.
M%5N&'J8>$GBIXRK5Y*=.M75.A/VM-*O5E452LJ5>EY-;,W5HXZGR8A3Q^(E7
MK3GBXSI^_7I8B<?JT<)2IN=2I1HNI7@Z=1NC24.2BZM&JZBBBO9/*"BBB@ H
MHHH _:3_ ()B?\DS^)/_ &4*W_\ 45T:OTTK\R_^"8G_ "3/XD_]E"M__45T
M:OTTK^&_$[_DN^(O^PJA_P"H.%/[)\./^2*R'_L&J_\ J57"BBBO@S[<1NA^
MA_E7\Y7[:7_)SWQ9_P"PMH?_ *A_AROZ-6Z'Z'^5?SE?MI?\G/?%G_L+:'_Z
MA_AROW'P$_Y*G-O^R>K_ /JSRL_&_&S_ ))K+/\ L>4?_4#,#Y=HHHK^KS^8
MPHHHH **** /HZS^*'@R/X&S> =13Q)K.LF[>+3=&UNST+5-%\,WTUFX7QAX
M5\0O##K^A6]E=237D/A>S99)]5N;NTN;^;0;ZX(QM;NOA;XD'PLT-/&/BNSL
M?#.D7'A?Q!JM_P""=/L/+T^X\1^,/%LVNV*CQCJ8N+E)M=M--72IU1[J43W2
MWRR-%;/X517C0R3#T9U*F'Q&+P\ZF+Q..;A*A**Q6*H3P\JBC6P]17A"I4<>
MLYRYJ\JW)34/6GG%>K"G3KT,-7A3PN&P24XUXMX;#5Z>(C3YJ5>FTISIP4DO
M=A&-J,:7-/G^J=&^/.CZ/X*TK0HAKDUEI'@W2=(M/AS<Z#H;: GC32M5M?$$
M7C-OB$-5_P"$O2SE\3VY\33^&H]/%K]ID;0EA_LI$NJ77?CUH+:I!K]IINI^
M-M0C\>:AXWT*P\9Z=IGA^R^'%O>Z7K-JGAOPK?\ A:_FOKY+75=4L=:@NS'I
M.DIJ'A30-5_L)]6FOYA\JT5SKA?*/:U*OLJG-5G7G5Y9JFZGUE157FJ4HPK>
MTGRKVN*558S$Q_=XO$UZ3Y#=\1YI[.G35:*C1A0A2O%U%#ZNVZ3C3JRG1Y(7
M?LL,Z;P>'E[^%P]"I[Y[AXC^(?A#5M8\%^)M&T74_#VK_#[P=\/K72+%KF[\
M0V&M>*/"6NVM[/:ZQ?ZSJKWUIH4%D+N2UU>VAO-7U:\=8]3LX=_VN*GXU\9^
M$+O0O$NC^#T\1R#QQ\0HOB%K)\1VNFV@T);*V\11Z9X9TU]/U&_.M-!=^*]7
MEO?$,\6DK=VUKI<,6DPRO>L/&Z*[*63X2BZ'++$RCAI)TX5*\ZMU"I"M2C4G
M4YJU2-'$4UB*3G4<HU)2CS.BU27)4S3$U%7YHT(RKIJ<Z=&-)Q<J<J-25.%/
MEI4W5P\WAZBA3494U&7*JR]JRBBBO5/-"BBB@ HHHH _2G_@F/\ \E7^(O\
MV3RS_P#4GLJ_:^OQ0_X)C_\ )5_B+_V3RS_]2>RK]KZ_C7QG_P"2[Q__ &!Y
M9_Z@T#^M/"/_ )(G!?\ 89F7_J94"BBBORD_3 K\+?\ @I/_ ,EZT#_LE_A_
M_P!2+Q=7[I5^%O\ P4G_ .2]:!_V2_P__P"I%XNK]<\$_P#DN*7_ &*\P_\
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M /\ ">^*?^?ZW_\ !?:?_$4?\)[XI_Y_K?\ \%]I_P#$4?V%C?Y\-_X,J?\
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M 6/_ (0S07(*Q*H8EV8[B,\XS@"OUJK^!_%:A/#>(/$U"HXN=/%X=-Q;<7?
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M\&2_S.[_ .%C>(_33/\ P"D_^2J/^%C>(_33/_ *3_Y*KA**/[.P/_0+1_\
M %Y?Y(/KV,_Z":W_ (,E_F=W_P +&\1^FF?^ 4G_ ,E4?\+&\1^FF?\ @%)_
M\E5PE%']G8'_ *!:/_@"\O\ )!]>QG_036_\&2_S.[_X6-XC]-,_\ I/_DJC
M_A8WB/TTS_P"D_\ DJN$HH_L[ _] M'_ , 7E_D@^O8S_H)K?^#)?YGZ0_\
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M_%&CG4TN_#8U&RAGU1+G55@M-.L(96URXTFY1K8<)XN\"Z]X*31KK5I-!O\
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MS>2DMX,U)1M@M(IYV )^8K&0HRS$*":_J!_MVQ_YX:S_ .$YXA_^5=?S"_\
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MG;TXH _$#_@I1_RDB_X(5?\ 9U_[3O\ ZQU\0J_;R/\ U<?^XO\ Z"*_$/\
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MV5G#IUK9:_KKP:SI_P#95WYAX^U+X=>+9K?2/#WC)]'\">!? GC*Y\#>'?\
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ML8IV2;=O[6R97LO/3U/P#Z1,HQX1R9R:BO\ 66@KMI:O*\U[GS%17$_\+)\
M?]#GX;_\&D-'_"R? '_0Y^&__!I#7]N^SG_)/_P%_P"7FOO/XZ]K3_GA_P"!
M+^NOY]F=M17$_P#"R? '_0Y^&_\ P:0T?\+)\ ?]#GX;_P#!I#1[.?\ )/\
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MI'_W\3_XJ@!U%-WI_P ](_\ OXG_ ,51O3_GI'_W\3_XJ@!U%-WI_P ](_\
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MLP)_HWX-_P#)M.%/^P*O_P"I^+,'[7XA_P"@+8_^#QO_ )3T?:_$/_0%L?\
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MF*K9 ?RTW 9V+G DHK^<3^@@HHHH **** "BBB@ HHHH **** /Q _X*4?\
M*2+_ ((5?]G7_M._^L=?$*OV\C_U<?\ N+_Z"*_$/_@I1_RDB_X(5?\ 9U_[
M3O\ ZQU\0J_;R/\ U<?^XO\ Z"* %;H/]Y/_ $-:_P XW]HS_DX;X_?]ER^,
M/_JR/$]?Z.3=!_O)_P"AK7^<;^T9_P G#?'[_LN7QA_]61XGK^M?HI?\C3C'
M_L RG_U(QA_+7TG_ /D6<)?]AN;?^F<">-T445_:9_'@4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% ']97_!O-_R;_\ '[_LN5A_ZK3PG7]!U?SX
M_P#!O-_R;_\ '[_LN5A_ZK3PG7]!U?YD^-?_ "='B_\ [#L+_P"JS G^C?@W
M_P FTX4_[ J__J?BPHHHK\M/TT1NA^A_E7\'/_!6/_E(=^TW_P!C/X/_ /56
M> Z_O&;H?H?Y5_!S_P %8_\ E(=^TW_V,_@__P!59X#K^F/HL_\ )=9Y_P!D
MGBO_ %<9*?SG])C_ )(O)?\ LJ,-_P"JG-S\[J***_O _B,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#]^/^#>O_DY;X[_ /9"]*_]6)I5?UP5
M_(__ ,&]?_)RWQW_ .R%Z5_ZL32J_K@K_.OZ1G_)T<U_[%^3?^JS#G]_?1__
M .39Y7_V,,X_]6%8****_"S]J"OXY/\ @OO_ ,GI^#/^S>/!7_J<_$NO[&Z_
MCD_X+[_\GI^#/^S>/!7_ *G/Q+K]\^C;_P G,H?]B7-?RPY^%_2'_P"3=U?^
MQQEG_I54_$*BBBO]##^"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /U0_X(M_\I%/@[_V*OQ?_ /5<:W7]Q%?P[_\ !%O_ )2*?!W_ +%7XO\
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MC'.?3%!!'4$?4$?SKW;XRZEX TCXO:GXB^$FA>$-:\&Z%'X/2[M],T/4]?\
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MB?XA_P!-/UZCJ.17^=5^T2&7]H/X]J[^8Z_'#XOAY-@C\QQ\1_$P9]BY5-[
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MO!Q->&G"B:L_J6(_]3\67:*I?VC8?\_MI_X%6_\ \=H_M&P_Y_;3_P "K?\
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M_P#!+XA_^:6OV$HI679?U_PR^X=WW?\ 7_#+[C\>_P#AP)_P1Q_Z1]?L^_\
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MO_@E\0__ #2U^PE%%EV7]?\ #+[@N^[_ *_X9?<?CW_PX$_X(X_](^OV??\
MP2^(?_FEH_X<"?\ !''_ *1]?L^_^"7Q#_\ -+7["44679?U_P ,ON"[[O\
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M_P ,ON"[[O\ K_AE]Q^/?_#@3_@CC_TCZ_9]_P#!+XA_^:6C_AP)_P $<?\
MI'U^S[_X)?$/_P TM?L)119=E_7_  R^X+ON_P"O^&7W'\[?[:'_  0C_P""
M6WAC]F'XPZ[\)O\ @GU\'A\1-.\,13^%6\)^%_%^I^(EU%M;TB%CI5AINNW5
MY<W(LY;IMD%M,PB$C,AC62OIY/\ @@+_ ,$<B"3_ ,$^?V?0=SC_ ) OB+H'
M8 \^)3U !].>,# K]AB,\?R)'ZCFBBR[+^O^&7W!=]W_ %_PR^X_'O\ X<"?
M\$<?^D?7[/O_ ()?$/\ \TM'_#@3_@CC_P!(^OV??_!+XA_^:6OV$HHLNR_K
M_AE]P7?=_P!?\,ON/Q[_ .' G_!''_I'U^S[_P""7Q#_ /-+1_PX$_X(X_\
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M\$<?^D?7[/O_ ()?$/\ \TM?L)119=E_7_#+[@N^[_K_ (9?<?CW_P .!/\
M@CC_ -(^OV??_!+XA_\ FEH_X<"?\$<?^D?7[/O_ ()?$/\ \TM?L)119=E_
M7_#+[@N^[_K_ (9?<?CW_P .!/\ @CC_ -(^OV??_!+XA_\ FEH_X<"?\$<?
M^D?7[/O_ ()?$/\ \TM?L)119=E_7_#+[@N^[_K_ (9?<?CG=_\ ! ?_ ((Z
MQVMQ)%_P3X_9^>1()GC0:)XD)9UB=D4"/Q,LA+,  $8/D_*0V"/!?V3/^"#G
M_!*KQ#^RQ^S7KWQ._P""?GP9?XDZW\ _A!JWQ!?Q1X9\5Z?XE?QMJ/P^\/7?
MBI_$-A?:[:WMCKCZY-?-JUI=6MM<6U^;B&:W@D1HD_H&H_SZ_P Z=EV"[[O^
MO^&7W'X]_P##@3_@CC_TCZ_9]_\ !+XA_P#FEH_X<"?\$<?^D?7[/O\ X)?$
M/_S2U^PE%*R[+^O^&7W!=]W_ %_PR^X_'O\ X<"?\$<?^D?7[/O_ ()?$/\
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M++3;&75O$'B'5M0U&X@TO3-*T338YH=)T#2-'T+3]-TJS]0H **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^UYKWCB^TSQK8?LA:!XGEO-*\*_L^>-O!WA+XH7_ (4_9Z^&WQ&ENH_BU?\
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M64?_ #_W'^S7UE^P;'&/VH_AV5CC4BS\;8*QHI&?!>MYP0H(SWP:_HC.O!+
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MJ7X3^._P7\=^(=?\)^#/BK\/O%'B;PM<^(;3Q!H6A>+=$U+5=)N/".KOX?\
M%D5W96UX\Z-X6U^-M#\2E4==!UC&F:LUI>LD#8.N?M/?LZ^&O#O@[QAKOQP^
M%FF>#_B%H5EXH\#>+KGQQX?'A3Q;X9U%;)]/\1>'_$J7SZ)JNAW\>HV$EEJU
MI?26%U'>6TD$\B3QLWYP:;^Q1^TA86+6+^,K:^3Q%>?MR:1H,6I7GA*XT[]G
M=_VG/VG]4\26'Q"\$PZ'H/A37?';ZG\!O%7B3^T_#GC#Q/K&H>'O%]EI.F:-
MJ5G!K.K:CIF]X6^ 7[1OPQC^&_P&UKX<Z?\ %/\ 9L^%WQ8\>_%+2V^&.L^
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M\M5;<3^4O_#]']HW_HCWP1_[_P#C_P#^7U?1?_!>>2./P;^S49)8XP?&GQ&
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MP5JWC?1O#WAE/A;^R]\.?V8470-7354^(EQX%U87T_C2/[.L+Z5X3MH+4?\
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M8J,5&*48Q2C&*5DDE9)):)):)+9!1112&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'SU)^R/^RI+))++^S/^S])++))++))\%_A
MJ\DDLKM))([MX9+.\DC,[NQ+.[,S$L23T/A+]G7]G_P#KUEXJ\"_ WX/>#/$
M^G+=)I_B/PG\,?!'AS7;!+ZUELKU+/6-&T*RU&U6\LIY[2Z6"YC%Q:S2V\P>
M*1T/LE%=,L;C)1E"6+Q,H23C*,J]5QE&2LXRBYM--:--6:T9R1P&!A*,X8+"
M0G&2E&<<-1C*,HM-2C)034DTFFFFFDUL%%%%<QUA1110 4444 %%%% !1110
M 4444 %%%% !01G_ #@_F.1110  8_SD_B3R:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>nci.jpg
<TEXT>
begin 644 nci.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MB0:8?"]C\0].U3Q#X7U'4O"_A:XM;_4F\%#57\)>+M1O;0^-M'U[3M'L]-<
M\,'_  4;DUKP%J7QM\'?!?4+_P"!_P -?AA\"/BG\?M>\2^,X?#?C[X?:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 9'KUZ>]%?D-^WS\7OBAX!_;V_X(Y^ O!7
MC_Q9X6\%?&/]I']H?PU\5/"VA:S=:?H7Q"T#P]^RSXU\5Z%I'BW3X&$.M:?I
M'B.PM-:T^UNP\5MJ4$5VBB:.-U_7>,DHA/)**2?4D"@!U%%% !1110 4444
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MM&-*LX.I%T:U2A)MP<H^]*FY*S>C5];@%%%%>P 4444 %%%% !1110 4444
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M7P ^*]EXC\(?#.XTK0#\)?A_^VOXQ_;!T[XPQ^-+<^(_$6C:QXY^)OQ6\/\
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MV=N[RW;;NP<;L9P<9P:^:?@5:VUU>^(UN;>"<):Z:4$\,4VPF6]!*^8C[=P
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M!^(=MIT5SJEM'^TX_J?7U/K_ /J].,4 ?B#_ ,%)_P#E))_P0I_[.M_:@_\
M6.?B#7[>1_ZN/_<7_P!!%?B'_P %)_\ E))_P0I_[.M_:@_]8Y^(-?MY'_JX
M_P#<7_T$4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B
M_B+_ ,B-XG_[!-Q_):^'&ZGZG^=?<?Q%_P"1&\3_ /8)N/Y+7PXW4_4_SK\$
M\6?^1SEO_8L_]VL0/HO5_E$2BBBORH04444 %%%% 'T#\ O^/[Q-_P!>FF?^
MCKVOI>OFCX!?\?WB;_KTTS_T=>U]+U_3'AS_ ,DCEO\ U\Q__J?B0"BBBON
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M-Z7Z7W_@XUK_ .6-'_"-Z7Z7W_@XUK_Y8T ;U%8/_"-Z7Z7W_@XUK_Y8T?\
M"-Z7Z7W_ (.-:_\ EC0!O45@_P#"-Z7Z7W_@XUK_ .6-(?#ND@X/VT'T.LZR
M#_Z<:+I;NP&_17/_ /"/:3ZWG_@YUC_Y8T?\(]I/K>?^#G6/_EC2NNZ^] =!
M17/_ /"/:3ZWG_@YUC_Y8T?\(]I/K>?^#G6/_EC1==U]Z Z"BN?_ .$>TGUO
M/_!SK'_RQH_X1[2?6\_\'.L?_+&BZ[K[T!T%%<__ ,(]I/K>?^#G6?\ Y8T[
M_A&]+]+[_P '&M?_ "QHNGLTP,GXB_\ (C^)_P#L$W/\A7PXW4_4_P Z^R_'
MNA:?;>#?$=Q$+OS(M+N'3S-4U69-P P6BFOI(I .NV1'0]U-?&C=3]3_ #K\
M%\6?^1SEO_8L_P#=K$#Z+U?Z"4445^5""BBB@ HHHH ^@?@%_P ?WB;_ *]-
M,_\ 1U[7TO7RU\$-.M=0O/$2W(F(BMM.9##=WEH<M+>!MQL[BW,@.!@2%PI!
M*A26S]+6.FVNG^:;83CS=F_SKR]N_N;MNW[9<W'E_>.?+V;N-V["X_ICPY_Y
M)'+?^OF/_P#4_$@7Z***^X **** "BBB@ JK?6D=_9W=E,$,5Y;3VLH>&WN4
M,=Q"\,@:WNHI[:=2CL&AN(9H)1E)HI(V9&M44 ?FY9?L.Q^'O$>EW'A;X4?L
M#V":/=66H:/\06_9!TZP^(&BW^F30W&FZE;:3X?\6:5X:?Q#87,$-Y;:WI^H
M^'[*'4((KN#P[ @%LGZ)Z3:7ECI>GV>H:E-K-]:V=M!>:M<6UG9SZE=10HEQ
M?36FGPV]C;27<JO.\%G!%;1-(8X8UC516A10!^('_!2?_E))_P $*?\ LZW]
MJ#_UCGX@U^WD?^KC_P!Q?_017XA_\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MY'_
M *N/_<7_ -!% #Z*** "BBB@ HHHH **** "OBKXINX\>^(0'8 2V. &('_(
M+L>P-?:M?%'Q4_Y'[Q#_ -=;'_TUV-?E_BO_ ,B# _\ 8XH_^H6. X'S)/\
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MYZ/_ -]-_C7QY/\ LV^+M9_:#\%_&?Q)XK^%CGX=^+?$^NZ+XQ\)?".;P?\
MM!>,_!.LZ#XO\/Z)\#?BG\0K#Q3)X9U[X3^'+7Q/IEY?6=CX82X\9ZKX%\':
MO=Z;X;UJSO=6N_L <#U]SU_&N+&+"Q^K?59QD_JT?K#A[?D]O[6K\/M[3UI*
MC*5E&/,W:G2UIQ3M^7GT7ZWTZ;79H::[G4M.!=R/[0L/XF_Y_(/>OT(K\]=,
M_P"0EIW_ &$+#_TL@K]"J_7_  B;]EGVO_+S+?\ TG&AT7J_T.+^(O\ R(WB
M?_L$W'\EKX<;J?J?YU]Q_$7_ )$;Q/\ ]@FX_DM?#C=3]3_.O(\6?^1SEO\
MV+/_ ':Q =%ZO\HB4445^5""BBB@ HHHH ^@?@%_Q_>)O^O33/\ T=>U]+U\
MT? +_C^\3?\ 7IIG_HZ]KZ7K^F/#G_DD<M_Z^8__ -3\2 4445]P 4444 %%
M%% !1110 4444 ?B!_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?MY'_JX_\ <7_T
M$5^(?_!2?_E))_P0I_[.M_:@_P#6.?B#7[>1_P"KC_W%_P#010 ^BBB@ HKS
M'XR?%KPI\#?AOXE^*'C3^T6\/>&(=/:Y@TJWMKC4+R\UG6M,\.Z+I]K]OO=,
MTJUDU+7-8TS3_P"TM;U71_#^E+<MJGB#6=(T6SO]3M?E3PM^W+>^+?A_\(-6
MTW]F[XPK\7?C5::UJOA#X(RZM\+8]4N/#'A3PWX4\4^+/'T7Q%E\=)\,;KX>
MZ9:>-?"NBZ?XCB\1K=ZMXN\1Z-X8.BV%^VJOI(!]\T5YE\&_BUX1^.GPQ\&_
M%?P.^HGPWXTTA-3L[76;$Z9KND745Q<:=K'A[Q#IAEG_ +,\1^&M<L=3\/>(
M=-%Q<#3];TN_M%N+A(5GD]-H **** "OBCXJ?\C]XA_ZZV/_ *:[&OM>OBCX
MJ?\ (_>(?^NMC_Z:[&OR_P 6/^1!@?\ L<4?_4+'@>?4445_/X!1110 4444
M 7M,_P"0EIW_ &$+#_TL@K]"J_/73/\ D):=_P!A"P_]+(*_0JOVSPB_A9]_
MU\RW_P!)QH^B]7^43B_B+_R(WB?_ +!-Q_):^'&ZGZG^=?<?Q%_Y$;Q/_P!@
MFX_DM?#C=3]3_.O(\6?^1SEO_8L_]VL0'1>K_*(E%%%?E0@HHHH **** /H'
MX!?\?WB;_KTTS_T=>U]+U\T? +_C^\3?]>FF?^CKVOI>OZ8\.?\ DD<M_P"O
MF/\ _4_$@%%%%?< %%%% !1110 4444 %%%% 'X@?\%*"!_P4C_X(4DD ?\
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MH#]-MZ?WE_[Z'^-&]/[R_P#?0_QKY5_X<?Z5_P!)4?\ @LQ_XFGH/_SFJ/\
MAQ_I7_25'_@LQ_XFGH/_ ,YJC_B$N;?]#3+?_ <5_P#*OZL_*X?7&F.G]I:=
M\R_\A"P_B'_/Y![U^A6]/[R_]]#_ !K\/U_X(@Z8CI(G_!5/_@LRCQNLB.O[
M:>@AD=&#HZG_ (4UD,K ,I[$ UM?\.9;W_I+7_P6H_\ $V- _P#G+U]_P3PI
MB^%X9C'%8K#XEXV6%E#ZNJJY%AXUU+G]I"/Q>V5N6_PN_2[OI;S;^^W^1^N7
MQ%=/^$&\3_,O_()N/XAZ+[U\.,Z9/S+U/\0]?K7S7-_P1?GN89;>X_X*S_\
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MTB\:_%?1AIFN:?X<UXQ'7=-M/'_Q#_M_QAXP'B#3XM!_16BB@ HHHH ****
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>ocrevus.jpg
<TEXT>
begin 644 ocrevus.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "D A\# 2(  A$! Q$!_\0
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M000I'(Z<+@ZV)J*C0BY2?1?UIZF=2I&$>:;LCZ#=UC1F8A549))X KYN^/\
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M%8G_  N/PC_T-7AO_P &</\ \53C3G)7BFQ<R6YTE%<W_P +C\(_]#5X;_\
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M3KXY_ 'PG^T=X%N/#WB[2;?4[&96\IV4">S<C EA?&8W'J.O0@@D'\3?VO\
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M^:]@')0^K+U7\1W&/4^CCX_XC(\72X5X@J.6#F^6G.3UHR;LHMO_ )=MZ:_
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MB\5&X81*JJL;$<;B6(!.-IP1F_M2_P#!&?5OV>_@EK'C#2?&G_"6-H:K/=6
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MZQ^]?YH_=;0/$%CXKT6UU+2[RUU'3[V,36]S;2K+#.AZ,K*2&!]0:N5^2?\
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MAYUZL:-/XI-)>K=D?7'[*OP07X#_  3L8;J+R_$'B18]2U0E,/"I4^3!_P
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M$LSMU&YVQQBN,^)/Q<\5?&?7EU+Q5X@U?Q%? %8Y+ZY>8Q G.U 3A5S_  J
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MW^S_ /\ "G/V3[77+JW\O6/'DO\ :TI8?,+8#;;+_NE,R#_KN:_4>*,53R_
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M@%RH!9O=LFNCK%^(WQ$T?X3>!]2\2>(+S^S]%T>$SW=QY3R^4@(&=J*S'J.
M":/AS\1-'^+/@?3?$GA^\_M#1=8A$]I<>4\7FH21G:ZJPZ'@@&N2<:LX^VG=
MJ]KN^_:_<T3BGRK[BQXM\':1X_\ #UQI.O:5INM:3=[?/LK^V2YMYMK!UW1N
M"K89589'!4'J*Y/1_P!E3X7^'=7M=0T_X;^ ;&_L9DN+:YM_#]I%-;RHP9'1
MUC!5E8 @@@@@$5WU%$,15A'EA)I>38.,6[M!1116)1YW-^R%\)KB9I)/A?\
M#N220EF9O#=F68GJ2?+KJ/ ?PS\-_"S2Y;'PQX?T/PY93RF>6WTNQBLXI)"
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MNI-&9HX,G SNCC7OT+@GL#7TI\&OC;X7_: \#6_B/PCJUOK&DW!*>9'E7A<
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M .W_ (UY2MT/N\_I0CBO:4_AFE)/R>R^7P_(****^X/$"BBB@ HHHH ****
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M>#/$T%TB/#>:=.&,<BE2&4_,C#K@\J0>Q(KZ,/B*R_9=^,4?B#3;%M4^%WQ
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M)[<X*GAA[@$?.?AKX*_M;_LY6::%X5\7>#/'WANT416#ZTK)<V\2\*K9PPP
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ME>BVTLDEHK66Q:P\$DET=PKP']M#]@W2_P!JB73?$&F:I<>$?B!X?VG3-=M
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M 3L/(85M(^/NN>$M9_M+PG=6%XUQ)YES!%:?9)+O_KXLU)BW8'W[;!QRS9)
M_%O$SP-S'.,+*OP[BG1K2C:4)-NC57]Z+3Y)_P![EWW7,Y3/L.'.,,/A*BAC
MZ7/!.ZDOCCZ-6NO*^W6UD?HIX9^._BCPGA+;59YK=>!%=8G4#TRW(_ BNZT7
M]LN^A55U#1;6X/=K>9HOT8-_.OC/]GK]KNQ^-]V^GS:7-INJ01>8X6=)(I1T
M.P$B0GO@*V!U->MVNIV][(T<4T;R)]Y,_.GU7J/QK^&,RSCQ X(QLLJQM:I2
MG32;C)QJ12>S5^>*3Z6/VBA@LASFBL52A&2EU2<7?SM9W]3Z1M?VQM"<?O\
M2]6C]=@C?^;"DN?VQ]#7=Y.EZK)Z;_+7/Y,:^=J*V_XCWQ?R\OM87[^SC?\
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MFY;@6W[:IMT_S)J***_+3W@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>otherincomeexpense.jpg
<TEXT>
begin 644 otherincomeexpense.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3\>^*/^$(\$>,/
M&7V"35?^$3\+>(O$W]F13"WEU'^P-&OM7^PQSF*80R7GV/[,DIAE$;2A_+DV
M[&_.W]G[_@H_X1\>_"[P[\5?BOKOP M]/\>Z7X<U#P7X4_94^*GQ$_; \>VM
MW=>"I?B!XTT;QWX/\!_!#1=>\,WOP_\ #$VG:CXAN++3];L+""2YDU:XTDOH
M\>K_ **>.O"T'CGP5XN\%W-Y/I]OXM\+^(?#%Q?VJ12W-E#X@T>]TB6[MXY\
MPR3VT=ZT\*2@Q/)&JR#837R=JG[&YT[PS^SU#\*?BSXA^%'Q#_9V^'-Y\)_#
MOQ#TCP=X&\0-XB\#^(?#'@7PYXQL?$GA#Q!IDWAVYU#5[OX;>"?%FE:K"(YM
M!\3>'+ -'JWANXUGPYJX![)\-OVE_@M\8/%VO^"_AAXR'CC5O"_ASPEXKUR_
M\.Z#XEO_  G9:'X^\)^%O'?@:Y7QTFCCP9=S^+_!WC+0_$OAO3;+7;C5-7T:
M2^O[2R>WTG4WM?COPW_P5+^#>MMX&UG5_ WQ<\#>"?%L7[8*WVI>,?A9\4K7
MQII5S^R)\3/AWX \27FG_#32? >K>*?$?A;5M-\:ZKXOU?Q9IL TSP#9>$=9
MT/Q.8_$-CK5AHWU/^S=^S'X-_9AT7Q+X7\!ZMKE]X:U<_#*VTC3]>>TNKO0M
M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MB0:8?"]C\0].U3Q#X7U'4O"_A:XM;_4F\%#57\)>+M1O;0^-M'U[3M'L]-<
M\,'_  4;DUKP%J7QM\'?!?4+_P"!_P -?AA\"/BG\?M>\2^,X?#?C[X?:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 9'KUZ>]%?D-^WS\7OBAX!_;V_X(Y^ O!7
MC_Q9X6\%?&/]I']H?PU\5/"VA:S=:?H7Q"T#P]^RSXU\5Z%I'BW3X&$.M:?I
M'B.PM-:T^UNP\5MJ4$5VBB:.-U_7>,DHA/)**2?4D"@!U%%% !1110 4444
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MCX D*=$/C6W\.1>&))O%4?CL']C1\2_BO@;O#@W8&<>&M7QG'./WW3-?0_\
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M_!XW_P IZ/M?B'_H"V/_ (/&_P#E/6]10!@_:_$/_0%L?_!XW_RGH^U^(?\
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M (_O$W_7IIG_ *.O:^EZ_ICPY_Y)'+?^OF/_ /4_$@%%%%?< %%%% !1110
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M $,=]_X :+_\KZ -ZBL'^RM4_P"ACOO_   T7_Y7T?V5JG_0QWW_ ( :+_\
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>otherrev.jpg
<TEXT>
begin 644 otherrev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
M'EI?WO@./XC^-M$\=>$O OP8TG7?#=UX \+:AI.HZY=VFG:M96MK<//JTFD-
M=:);ZO\ H]XX\+6_C?P9XM\&7=U/8VOBSPSK_AFYO;9(Y+BT@U_2+S2)KJ!)
M<Q/-;Q7CS1))^[:1%#_*37RGKG['A@\-?L^0?#'XM>*OA9\0/V=OAS=_";PQ
M\0]'\-^#]?GUKP'K_@[P/X/\6:9KWA?Q%876A37NHCX<>"?$^B:G!Y<GA[Q1
MX8TEV@UCPX^L^&M8 /7?AI^TO\%_C'XOU_P5\,/%[>-M4\+^&_"'BS7-2T'0
M/$EWX0L]#^('A+PKX\\#7">.O[(3P=>7/B[P;XST+Q+X>TRRUNXU34]'EOKZ
MWLC!I6I/;?&_AK_@J9\(-;7P#KFK> _BYX,\%^,(?VPTOKWQ3\+/BG%XVTJ[
M_9#^)OP]\ >(KO3OAKI7@#4O%'B3PKJ]AXRU7Q5JWBS3;<:5X%MO"NJ:)XBD
M_MNSUFVT?ZQ_9R_9F\%?LRZ/XD\-^ ]1UF[\/:R/AE:Z;8ZV]K<W6BZ5\+/@
ME\-/@?H-D=2MX+:;59KK1/AII^LZE?WD4<\^L:GJ)C2*U$$2>->'_P!A?1]$
MUC6IIOB7XBU'P[_9?[8OA_P1H$N@:#;R^#O#_P"VCXR\%?$CXA:9)K-NWVKQ
M(?#OCOPSJVI>$;W4;:VO(=&\0_V'K$NJ/H]MJET >RZ;^UI\!=9^(NG?#'2/
M&LNIZ[JU_HVB:?K=AX6\7W?PYN?%7B+P-:?$W0/!"?%:'07^&@\>:W\.K^P\
M;:5X);Q4OB:^\-:AIVIP:8\>HV"W/F'QG_:_OO@S\7I/@MJGPV?5O%WQ'\*^
M%[_]EA;/Q(8+7XZ>.;SQ(_ACXA?#VX>XT/\ XI#4OA)!?^&?B5XRO[?_ (2:
M-/@SJFO>/K:U:/P-XHL+3R[X7_\ !,?X._"WXS>&/B]ILWAS6K[0;GP3XHN9
M?$7P7^#>L>/+WXA>"/A#X9^#5GK^G?&#4O"E]\1/"_AZ^T+PGI'B*Y\)>']4
MM7L_%\=Q<:+XCTOPS?ZAX5N_L+XD_ _0?B9\0?@AX^U?4;RWF^"7B+QWX@TW
M2;>WM7M->/CWX6>+?A7J-CJ-S(!>64%OI7BV[OX9=-DAGDNK>&&5_LSRB@#S
M#1/VY?V=O$VFZEJ7ACQ!XW\3K:6VC:EHMEX=^#7QCUC5OB#X>\0:G>:+HWC/
MX4:/8>!;C4OBGX O]6L)[-?'_@*#Q!X+M%>QO-0UZTTW5=(O=0JO^WU^RDEO
M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M'Z_X-\._$2PU#PCX:OI!XZU")=;7QIX6T+0-#O8=0\1>)O" !^E%%?E)I_\
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M7UU\$O\ D2V_[#6I?^T*^1:^NO@E_P B6W_8:U+_ -H5^B>&'_)3O_L6XO\
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M35#:A8*P#*U_9*RD @JUW"K*0000RD@@@@@D$$$U]Y_\(_H7_0%TG_P6V/\
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M_P $*?\ LZW]J#_UCGX@U^J7QP_Y%#2_^PW:?^F_4*_*W_@I/_RDD_X(4_\
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M%N\N&)46BOY_ ECN+B&198;BXAE5/+2:*>:.5(P HC25'5UC"@*$5@@4!0,
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MU%R\T94ZE.2D^;2?Z_K^O4^@?@%_Q_>)O^O33/\ T=>U]+U\T? +_C^\3?\
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MY$MO^PUJ7_M"OT3PP_Y*=_\ 8MQ?_I["CZ/U7Y2/7J^*/BI_R/WB'_KK8_\
MIKL:^UZ^*/BI_P C]XA_ZZV/_IKL:^\\6/\ D08'_L<4?_4+'B//J***_G\
MHHHH **** +VF?\ (2T[_L(6'_I9!7Z%5^>NF?\ (2T[_L(6'_I9!7Z%5^V>
M$7\+/O\ KYEO_I.-'T7J_P HG%_$7_D1O$__ &";C^2U\.-U/U/\Z^UOBMJ-
MCI/PY\8ZEJ=U%96%EH=W<7=U/N$4$,84O)(45V"KD9PK'GI7YS-\6?AKD_\
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M]=?!+_D2V_[#6I?^T*_E\_X?Z?L0?]#S=_\ AE_VI?\ YR-?9_P%_P"#@_\
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MGC]NG_@EU::1;Z''\8/B'IMQ<^);WQ./$5GX2_;ATCXC:UXIOM#71=5U*_\
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M W:/5O\ OM__ (JC:/5O^^W_ /BJ=10 W:/5O^^W_P#BJ-H]6_[[?_XJG44
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M?X]L/BCKNF>*/#^B?$/XG?"35OA+I>FVOPI\":8OC'P5;W7PB^(%OIGB1?\
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MJI/X D^G'/%?H(A=RDE006')&1D ]"1U&:7(Z9Y'4>F>E?A-I7QY_:,?X:?
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M3/#3ZWHFJ:?!XST30;'3-*LM2O+&\BGTG3+/1-2MK[18VL'V/@Y\)_"WP/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>plegridy.jpg
<TEXT>
begin 644 plegridy.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "6 /H# 2(  A$! Q$!_\0
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MMO#:P+%;":2<'!9L!<>W?K66FL^,[E4ECTRW2*3!''8_C5/XH_\ 'QIOT?\
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M[:>ZB/\ L28_I4I-$Q4HZ&U6?J6LV^GH06#S=HP>?Q]*GFL_.B"-<3@ 8RK
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M@>QR*W:* .-3X9:4'!>XNV4?P[@/Z5T^FZ7::3:BWL85BCZG'4GU)[U;I"<
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M]MCTSXA7;78D1;N"-(6"$ACQZ?2@#-@N],URYO[G6=3>&19FCMXA,4\I1T8
M=:CGU>\N_ -O*+E_M$=ZL/G \L!T)]>"*M:5>:=X<;4+'680LJSM+"SP[O-4
M] IQST_6EUK[9<>#+62ZM4@FDNT?RHDQM7G&1ZT 6]=T5=+\):O(;F>XGN(U
M,KR-D%LCH.U5=1D&B>&M-MX+R: 7[1B29WSY:[06P>U;WC!6?PGJ"JI9C&,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>researchanddev.jpg
<TEXT>
begin 644 researchanddev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %M 3T# 2(  A$! Q$!_\0
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M:=ZS/^VQ^S797'CN+4OB%+I-E\/--^(6JZSX@U;P;X^TWPEK%K\)_$=MX/\
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M6FZ#9V&O:[Q/B_\ 8;;QW=Z\?$7QC\2PZ%\9?#GPXT7]JSPEX>\)^%M'\/\
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MCG9X7E\*^'_!>O6>K^-]:\46&O7MSJ7A_P .6,-E?):PW&F7CW%Y<'5C)Y(
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M<L/1JUYQJ1A6E4C*U*4+<EU-I225VG;^ON_SL>]T5C_\)#H/_0:TG_P96/\
M\D4?\)#H/_0:TG_P96/_ ,D5]\(V**Q_^$AT'_H-:3_X,K'_ .2*/^$AT'_H
M-:3_ .#*Q_\ DB@#8HK'_P"$AT'_ *#6D_\ @RL?_DBC_A(=!_Z#6D_^#*Q_
M^2* -BBL?_A(=!_Z#6D_^#*Q_P#DBC_A(=!_Z#6D_P#@RL?_ )(H V**Q_\
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M_P""D7_!"I64,I_:M_:@R& 8'_C#KX@GD$$<'D>AYZU^V\=O;^6G[B'[B_\
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M\(?^_2?_ !-'V>W_ .>$/_?I/_B:\S_X7)X$_P"@A>?^"R^_^,T?\+D\"?\
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M:_Z&'0__  ;6'_R16'U[!?\ 09A?_"BE_P#)@:WV>W_YX0_]^D_^)H^SV_\
MSPA_[])_\363_P )/X:_Z&'0_P#P;6'_ ,D4?\)/X:_Z&'0__!M8?_)%'U[!
M?]!F%_\ "BE_\F!K?9[?_GA#_P!^D_\ B:/L]O\ \\(?^_2?_$UD_P#"3^&O
M^AAT/_P;6'_R11_PD_AK_H8=#_\ !M8?_)%'U[!?]!F%_P#"BE_\F!K?9[?_
M )X0_P#?I/\ XFC[/;_\\(?^_2?_ !-9/_"3^&O^AAT/_P &UA_\D5I6E[97
M\1GL;NUO8 YC,UI<17,0=0"R&2%W3>H925SD!@2.15T\5AJLN2EB*%2=F^6G
M5ISE9;OEC)NRNKNUE<"PJ(@VHJHN<X50HSZX  S3J**W **** "BBB@ I&QM
M;/3!SC.<8YQCGIZ<TM(Q(4D$# )R> /?)X'X\>M '\XG[0WAKX?S_MD>++[P
M%??%WPK?:;\>/!_Q'\0?$1? ?[.7_"M](^)>E_$']E+POX@M_%FO^*/B!X1^
M-_COX::9X]MOV?TUCPG9VUG]C?5]?N/#.JWUE#X3U;P7^\GP*^%EK\$O@]\.
M/A-9ZS>>(XO 'A'1_#+Z_?PK:W6M7>GVX6_U5[)+B[BTY+^_>ZNH-+AN;B#2
M[>6+3H)YH;5)&_)>YT+XB_$KXW^*]$^)G_#,FM^+? W[6&@ZYHWQ#^#G[&7[
M0/Q?\2^ K.SL_A'J.F:%XE^(D?A.]^$6E?%>3PCHOAS3?$FM>,];UZ/X?64/
M@/Q1J0-]X(\+V>D_M^HP,?7MCN>.W Z ]QSDYS0!^(/_  4G_P"4DG_!"G_L
MZW]J#_UCGX@U^K7QL_Y$BU_[#.G?^DUY7Y0?\%+IX+;_ (*/_P#!"R>YFC@A
M3]JW]I[?+,ZQQIN_8[^("+N=R%7<S*HR1EB .2*_4[XPZQI-_P"#;:"QU.PO
M)AJVGR&*VNX)Y BV]V&<I&[,%4LH+8P"0">17S7&/_)+YY_V 5?_ &T#Y \4
M7FM:?X8\3:AX:L=,U3Q)8>&_$%]X;TO6]4&B:+JGB.ST:^N?#^EZSK120:-I
M&I:S%8V.J:N4<:787%Q?[3]GQ7YQ_L]?&[]H3XF^"_BSX>\;?%[PM\-OBCX%
M^(.J:OX\E^+7[/<OPO\ $/P6^#NF^._B#H'C'5] L=2\;^(_@[\2O#^EW?A!
M_!G@GQ_=^+=5\*>"M2TCQ:?BAJ_BZ_TS1+/5/TKU32]-US3-2T36M/L=7T;6
M=.OM(UC2=3M(+_3-5TG5+2:PU/3-2L+J.6UOM/U"QN+BSO;.YBEM[JUGE@FC
M>*1E/R*/V!?V6QX'\1?#R/P+XAM?#GBGQYIWQ"UEM/\ BI\5=-\07&JZ#XFU
MKQ?X3T(>+++QG#XE'@'P9X@U_4M3\+_#U]4E\'V5^\&J7NDZCK5M%J@_FC X
MC TL/B*>*IR=6I6PLZ56&$P^)<(4YR=9/ZQ4BN5Q?\**BJT^15JCI1<)/I:]
MK_=\^_Z=+W.R^ GC3XP?$?X$ZSXINO[ UKQA<:U\4M-^#WC/Q!X2USP)X>^*
M/@S3M9U33O@A\5_%_@32OM.M^#],^(EE'I^L:CHNAK;7&K^'U@\2^&-,T.#Q
M1IFC:7\@>./VB_VB/ \'CKP_X7\?:3\=[73/B5^S]\,++XG^!?@GX=_X3J\^
M(_BW5O'[?M'?"+X$?"S2=>E\"?'#QS\(/!OAKPWXYM[:^U-X?A_IFI^.M#^(
MFL>-/$_@"[L$^U+G]FWP+>6&@Z/>^)/C'J>DZ'H'QA\/.NM_'7XQZYXBUBS^
M-F@Z7X:\52ZQX[U3QS<>-;N\TO2=.F_X0J^?6CJ/@74]1N=9\'7V@ZD//EYK
MPQ^QG\!O"7@ZS\ :7I_Q+N?">BMX;E\':9KGQY^.&OR?#2\\(VVK67A[4OA)
MJ>J?$"?5OA3JMC8:[K.FSZAX OM N-7TO4[_ $K7&U/3;RZM)^BCB\LIU*U6
MI0]K&M6C5CA_J.&<*,(XCGY/:2JJ6M*G%.E1C2H35:I3FN6$$GUT:T\GY?/3
M[^JU9\U?!W]H'X^_M :MH/PF\-^.]/\ AAXWTOPU^T#XR\3>*O&_P2TE?B-$
MWPV^+'@?X7?#3X>?%7X*:MJEEH'PQ\:W"^-K7QM\;-,\/7DEQ%X1O?A_<> -
M1\,CQZ]_IO?>)/VJ/'.M?LN_LF?%/P;X:U'0/'W[6VM?"#POIEIHWA!_B+<^
M$=2\;?#[Q;\1?%K>$O#6KZAHFC^*-4-CX!UW1/AW)XSUO2O",4NMZ)XK\;WS
MZ%I>I6=_[?>_LE_ *_T#3_#L_@K4XHM/U/QEK#:_8?$3XH:7X^UF^^)%IIVG
M?$D^*_B9IOC2T^(GC&T^(VF:/HNF>.=,\4>)]6TSQ%IVA>'[&ZM%M_#N@IIG
M3ZK^SW\(M9LM?TV\\+7,6F^(+;X7VPTW2O%7C'0=/\*M\%["XTWX77_PSL]"
M\0:;!\)]9\&VERR:=K7PT3PKJET\5J^KW6I?98%1U,9E,JM.<<'*,(5_:^R^
MK89+E=2JY0FX5E[>$HU*4XTJJ]G2^JK"P_=8BI6@7B^EM5^2Z[]]N]]U8SOV
M=/'6O^._A_J$GB[6-1U?QGX/\?>./A[XOB\0?#VP^%WB_0]9\,:C;RV_A_QQ
MX/T+Q%XK\(0>+;+P]J^@WM_K_P /]>O/A[XSL-2TKQ?X.BT_2M:73+/[L^ _
M_(P:W_V!8O\ TO2OE?P!\//!_P +_#B^%?!&D-I&D'5-8UZ\-SJFLZ_K&M>(
MO$-Z^I>(?$WB7Q)XCU'5_$?B?Q/K^H2->:SX@U_5=1U6_F$:2W7V:VM8(/IW
MX)7]CI^NZQ)?WEM91R:/&D;W4\<".XOD8HK2LH9@O)4$G'.,5Z?"$Z=3C/*9
MT8N%*>.K2A%PA!QB\-B';V=/]W32Z0@Y1A&T5*5N9KOZ+\T?5]?/'Q^_U'A;
M_KOJ_P#Z*T^O;/\ A)?#O_0=TC_P8VG_ ,=KP7XY:GIVHP>&A87]G>F&;53*
M+6YAN#&'CL0AD$3ML#%6"EL9*G'0U^V^(7_)'YQZ8'_U9X(%O\I?DSY\HHHK
M^8A!1110 4444 %?27P!_P"/;Q3_ -?&D_\ HJ^KYMKZ$^!NIZ=IUOXD%_?V
M=D9I],,0NKF&W,@2*]#F,2NN\*64,5S@L,]17VWAW_R5^5?X<?\ ^J[%C6TO
M3]4?2E?+/QY /B'0\@'_ (DTHY /_+])7T7_ ,)+X=_Z#ND?^#&T_P#CM?-7
MQMO['4->T:6PO+:]CCTB6-Y+6>.=$<WDC!&:)F56*D-M)!P<XQ7ZYXE_\DIB
M_P#L(P/_ *ET1'P?^U/\=Q^S;\%/%'Q87PW!XEN-)EM=+L;;5-8_X1GPGIFI
M:M;:B=.UWX@>+%T[5V\*> ]/O;*&WUW78]+OIUN=0TK2;6.&ZU>"]M/-M5_:
M3^*\?P9T?XRZ!\$_ .I>'+'X,>+/C;\0_$FH_M$^%H_AG9Z#X/@GO'\/_#?X
MA^%_"?BZW\8:_P"+-'L-2\2Z#J?B31_!'A+PSI<=EI/CC6+#Q1=S:18^]_&W
MX:ZG\6_AGXK\!:+\0O%?PPU7Q!HVLZ=9>+O"8TJZFMGU70-9T":P\0:%KNG:
MIHWBOP?J5KK,\/B+PQ?VT1U&W6"XTW4M'UJPTS5K/Y,O/V$M7M?#OPX\(^#_
M -H76/#_ (1\&:YXC^(7BCP1XB^"/PN\>> /B9\9O$WB&#Q/+\3O$G@F&Z\"
M>'+.+POJL"S^ /AO9:;+\-_#.HJGBVX\/:QX\C@\46_X-@O[)^JTEBE1CB8X
MN<JKJQQ\U/"J@N6"CA7&,?WJ2A).51U&G44*,'[1JUG?Y;=U?L^[7IUU:^L-
M?\<>-KSP#X'\3_"OX87OC'Q'\0AX(FTOPYXPU@?#VT\&Z5XST)?$4^O_ !,N
MUTOQ-KNE6WA6S:+2M9\.^%?#7BGQ9?>++W3O#FEZ:(Y[W6M+^)/$/[?>N6*^
M%[6T\)_ _P ':C+!\=8_'6J?%GXM_$9/ 5A?_ ?XQ1_!KQ%JGP]\4_"GX(^/
M[[Q?\.[O58-5\17/Q(\3>'O OAWPKHUHEEXHET[58[]+;Z-^*_P3^-OQ5T'Q
MWX4C_:=\1?#S1?%%Y\+ELKWPE\-_"%SK(T'PYX6O[+XM^'+R[-_H>N6&E?&S
MQ5>6NJ:U-HWBR#Q+X6T+3+KPUX1\2:5IWB/4/(;%^S[\2+7P!X?\!:-^TCKG
M@FPTWP+X@^%NLVOPX^!_P=\'^#]1^'NL_P"C:?I_A?X>RVFO:/\ #?Q1X6T5
MI] T/Q3H.HZEIDVG3F37/!>K7UKI]S9F&654X0^LK#5I2J\UHSS&G*G2EAW)
M*I4CA9TYN%6<(*-/#N2JT7S2E1J.4#3^OETZ^5[)_>C+^(G[3.M?#WXM?#/P
M#=>#?AWJ6A?%'QK\._!/A!+/XV:/-\9?'</CJ.U&L?$WX9?!VQ\,Z@OB3X3_
M  PGN+JY\<ZQJ_C+0-;?PQH/B7QCI6F#2=-TV+Q#2_:-_:VTSX&^*],\#6%I
M\,KCQ"_P]O?BGKEW\6?BVGPA\*V'AA/$%UX8T#1--UN+P;XXN;OQ;XQU?1_$
M[VE_JNF:+\/_  1H/A;5/$_Q"\6Z/I=QIT=SIZM^R98ZI!X+\&M\5O&R? WP
M+KGP5U_0?@W=:!X(U:?1Y?@%+X&NOA_H'A7XPWND?\+*\(^#FU'X>>']4\1Z
M-I]U=ZWJE[<^)(=-\6:#I7B;4M,JYXC_ &;/$FOZE'XQA^/7BK1/BKJ/PZ\>
M?!;QM\3K#X8_"6YU'QI\%_&WCW7/'5AX&E\,7^B2^&?#NH> I-:ETCP=XNTN
MUN)+B 7NH>-/#WBZ[U1XK.J?]C*>%=14Y1A3G&O%?7H1J3<4Z-2LXTZDZ<H\
MLE6IX;VE-572E2G5HRJPPQI_P^NWW73\[:7TO:_T]IUU]OT[3K]K8VC7^G:?
M?M:-<V%^UHU]9P7;6C7^EW%YI=^UL9C ;_2[R\TN^,?VO3;NZL9K>XD^P_@?
M@>#)L #_ (GE_P! !U@LO2OB?P?X4T3P'X0\)>!?#-M+9^&O!'A7PUX+\.6=
MQ=37UQ:>'_"6AV'AW0[:XO;@F>\N(-*TRTBGNYCYMU,CSR -(0/L?X-:QI-A
MX1F@OM3L+.8ZS?2"*YNX()"C0685]DDBMM8JP#8P<'!XKZCPS4?]:O<OR_4,
M9RZ6?*IT+-J\K/EM=<TK;<SM<1[G15:TO;._B,]E=6]W"':,RVTT<\8D7!9"
M\;,H=0P)7.0",CD59K^C0"BBB@ HHHH *1NAX)X/ ZGCH/?TI:0]#@XX/.,X
M]\=_IWH _!KXB?M%^$? '[>?CKP'9R^.M&UC7O'7@VZNOAWH'[4WB_PMXR\;
M>+;/QQ^RE\.QK^G?L\Q^';GPO=>%_%W@_P".#^(/#9TBYFO/B7I/P6\>R^*]
M>T.SLI)O#O[RJ<@'Z_S[>W]T^F*_(CQ+J'Q&\4_M'_$_PAX<^(/@-/%&F_M&
M?"?6-(^)OB3XO2^"_%OP9^'>C:1\/[_7_@Y8_ S5O"ZZAXQT?QUHJ^+;'2;O
MPYK<O@7XHW7Q&FUOQ#KND^(_"'V#3?UW'3GG]?PR>3CID\GJ: /Q!_X*3_\
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M% !7TE\ ?^/;Q3_U\:3_ .BKZOFVOI+X _\ 'MXI_P"OC2?_ $5?5]MX=_\
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M7Q@^+GAWQ]\6?B3X\^$NG?M??#9?%/@KXL?ML^%?!GQ/UG6O&>J_!K6]"NO
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M!&1ZC@^HXK]6OC9_R)-L<DDZSIV<DG/^CWAYR3WK\I?^"D__ "DD_P""%/\
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M^PY?_P#HBRK]"\,?^2HC_P!B_%_^EX<#V+&/_P!9/\Z***_HX HHHH ****
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M ,C!K?\ V!8O_2]*\+KV?X*:A:Z=KFL2W<CQI)I$<:%(+B<EA>JQ!6WAF90
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M ?\ CV\4_P#7QI/_ **OJ^;:^DO@#_Q[>*?^OC2?_15]7VWAW_R5^5?X<?\
M^J[%C6TO3]4?0U?+7QY_Y&'0_P#L#2_^ETE?4M?+7QY_Y&'0_P#L#2_^ETE?
MKGB7_P DIB_^PC _^I=$1X91117\V@%%%% !1110 5];? __ )$R;_L.7_\
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M#K:&!;T.-6L'S<:7JEE&56WNP<37MG;Q%CN&V/?YC#)52%;'S7&/_)+YY_V
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M_P!D^'OBW;:IHWC?P5JWP^\&WOAGP)+87-OIN@^2?\/'_B7_ -(C_P#@L/\
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MEFDD>79C9YCNS-)LPNS>6V;5VXVC#7>21B\DCR.< O([2.0!@ LY9C@  9/
M  X%?F!_P\?^)?\ TB/_ ."P_P#XB?X%_P#GZ4?\/'_B7_TB/_X+#_\ B)_@
M7_Y^E/\ U,XHZ9'C_P#P4O+^]YK^D'S7X_Y?U9^5_P!/:^DO@#_Q[>*?^OC2
M?_15]7X8?\/'_B7_ -(C_P#@L/\ ^(G^!?\ Y^E>N?##_@JWXS\&1:TFJ_\
M!(O_ (++R'49;%X/L7[(_P /YPHMDN5D\SS?CY 5),R[=NX$ YQCGZS@?AK/
MLNXFR[%XW*L7AL-2CC/:5JM-1A#VF Q%.%W=_%.I"*TWD@Z/7=?JG_7IZ'[\
MU\M?'G_D8=#_ .P-+_Z725^?_P#P^1UW_I$-_P %I?\ Q$'X=?\ T0E>+_$S
M_@J=XX\8ZKIM]I?_  2,_P""RD<5II\EK*M[^R3X A<R-<M,"BQ?'J<%-K $
MEE.<C;WK]+X]P&,S+AS$X7 8>IBL3.O@W"C27-.2AB:4YM+32,8MO79"/O6O
M-_BC\'?A1\;O#D?@_P",7PY\'?%#PI%?#4X_#?CC1H->T0:@+.[T_P"UOIUR
M?L\TIL+Z]LV6=)8I+:ZGADB=)"*^"O\ AX_\2_\ I$?_ ,%A_P#Q$_P+_P#/
MTH_X>/\ Q+_Z1'_\%A__ !$_P+_\_2OPJ'"'%E.<:E/)LQISBTXSA!PG%Z6<
M91DFGJM4T]1_-?C_ )?U9^5_L1OV6?V:'TOPEHDW[/\ \'[K2/ :W4?@O3K_
M , Z!J=KX9@OM5N==O+32UU.UO'&G7&MWEWK$FE73W6E'5;F?4%LENY&E/KN
MA^&?#OAC4O&.L>&M#TSP]JWQ#UN/Q+X^U/1+6/2[_P :^(8?#^D^$XM<\4W5
MGY,VN:K'X7T'0_#J7VH/-.NBZ/ING!_LUG"B_F]_P\?^)?\ TB/_ ."P_P#X
MB?X%_P#GZ5SVF?\ !4SQ)K.N>)O#&D_\$KO^"N>H^(O!DND0>+-%M/V6/ DN
MH^'9M?TQ-9T6+5K<?'(&U?5-*DCU"S7<WF6KHYVE@M7/A3B^HN6IE.:U$[Z3
M4YI\\HU):2FU[TU&I+O-*;O)7#YK\?+RW\]]/2_Z31_#+X<Q:39:"G@3PDNB
M:;X"A^%FG:2="L&T_3_AI;O8R6_@"PM6B:*S\(02:7I<D.A6RQ64<FEZ7*D:
MR:98/;]/I&CZ3X?TK3M"T+3+'1M%TBSAT_2M)TRUBLM.TZQMUV06EG:P*D4,
M,:YPJKEF+R2,\KN[?FG_ ,/'_B7_ -(C_P#@L/\ ^(G^!?\ Y^E'_#Q_XE_]
M(C_^"P__ (B?X%_^?I4RX1XMFN6639E).7-:4&US/[5G.W,^;??5Z[A\_P _
M+RZ?IZ7_ $]KZV^!_P#R)DW_ &'+_P#]$65?@9_P\?\ B7_TB/\ ^"P__B)_
M@7_Y^E>Y?#C_ (*T^+?"/A^32M2_X)%?\%FY+A]2NKP-9_LC?#V:+RIH[=$!
M>3X_0MO!B;<NS &TACDX^S\/^'<\RSB&.*Q^68K"8?ZEB:?M:T.6'/.5&48W
MN]9*+L(_>.BOF[]EG]HNZ_:>^&ES\1[O]GW]I']FN6W\4:MX8'P\_:F^'NC_
M  T^)=PFE6FE78\26_AW1/%WC2SD\+ZF=4:TTG4CJZ375WIFJQ/90+;1R3_2
M-?N@!1110 4444 %%%% !1110 A56^\H..F0#UZ]:;Y<?_/-/^^5_P *?10
MSRX_^>:?]\K_ (4>7'_SS3_OE?\ "GT4 ,\N/_GFG_?*_P"%?/'Q*^"^J^-_
MCE^SG\5+'5=)L=*^#%[\6KK6]*NK6ZDU#6D^(7P\/@[3DTN: ?98&T^](O+T
MWO$MM\EO^^KZ(W#)&<8[D$#IG@D '@$\$\4!@<GD8XY!4]<#@@'D\ XP>V:
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MV>F>'?'_ (BTWX^^*;XQ^#KVZ\:>,-/^%=K=_#_2=.U&3Q8NF@'[S_Y]/YT
MY&>?Q!!_(X-?F7XL^-'CCX9?LX?L.VMOX\\/_";2OBE;_"GPC\3OCS\2]/M_
M$FC_  VTRW^ 6L>.;:35Y/$FMZ)HMKK_ ,1_&GA;0_AS8>(_&6I?V5;:GXHE
MC6&]\5ZGX<M9OSB_9Y_;8_:<\(P_LS_"K3G\*ZCH][X5^$NMP:A\0/$W@OPS
MJ'QTN?C#^T%\3O#_ ,29=(@^)_CZ'XO2Q^!/#6E6=GX%T/X:^%O'6K^'_%DE
MK'\3Y'\+7FE6M ']*-&><?CT./SZ?AUK\(_B#^WK^U!H/P]N39VGA.'5OA?\
M8O"W[)/[0OQ!;3/"'A+0/!GQ9L/^%N>(O'7Q*M-0^+7BWPM\-] T7Q'X)\)?
M .7P%9^+_%$/A*SU?]J#P]#>WVOZCH=AX>U2"Q_:Q^.:S:)\3/%'B7P'\/M4
M^(?PJ_98\$^-_B9;W]KX[^#7PH\&^+/VCOVR?#!^/9L=/\27/@5KCQ?HO@_X
M?:,-3B\3:G\/?"WBOXAZ#<ZWXG\4^ O"UO-JH!^\=%?@;XI_X*"?'K3/"5UJ
M4?Q;^#>E:_X8^$?Q6\??#"SNOA;JDL/[9WB'X7_M'_$KX2_"_1?AU;2^+UET
MR#]ICPCX9\)7>@Z3X*O?$GB.?6?%EEXL^&Z:UX'MY(M0[7Q)^U5^V 8?$5]H
M_P 0/AQHL.O:1_P4KUWP[I][\'VU>[\#I^PC^T!?>$O!&D37,?C>Q@\5W'C_
M ,,75IH/Q NKM-.BC_LP:KX*.DZE<3WLX!^WM%?@4?\ @HS^TYK7Q8\<:?9Z
M%\./"VB:-X5\07>E^"-6\0_#8ZU-X/M/V11\=M-^,&A^';SQR/C7XGNKKX@7
M$4-@$\!6WPGO/AQ:WFAS^((_B%:7-^*OQ!_:'_:NF3X-6GC/]I71/ACI6G^(
M_P#@GC\<OB9\2_"7PW\/>$_"VF>#/VH+;]H#POXV^&7BR3Q=XDUC1X/AAI?B
M_P"%7ABYT?Q-K=Y8ZW->^-8M"U^2\^Q:-<2 '[_T5^4W_!0_]K;XY?L\>*OA
M-X6^&-GX/\-Z#XK\"?%?QMJ?Q)\?Z[\+] \/W'C?P%>> ;/P5\*I;WXM>/\
MX?:));>)X/%FO>(O$MAX6OM6^*>I>'O"]P? .D(UEK^JZ=XQ\0OV]/C]X(US
MXRZ9K.J_#[PM:^$O _@OQIX%U^Y\&ZUXR\+:AXNU_P 3? [1/CM\))=6T672
M9O%5]^R'!XSN]8\2ZAHD&FZI\1-&^*7A^SMH-)U[X(?%9' /W HK^>7XE_\
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MA2JD %00UK2U:6&=K>%IK=I7@E,49DA:?(G:%RNZ)IPQ$S1E3,I(E+CBK%%
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M<!DX!^#B$@9X!/\ PG@S@<9P,]<"OG_]J'PS\8=/^!_C2[\4_%'PWXDT*,Z
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M66*W4S"WU6YTK4(;1KJ72+Q;;T'Q!\</@KX.UWP?X8U[XF> -(\5^/AX?M_
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MM;F*>TUS3;/4%>*=#++$R7'G0S7$4OY^>"?V,_B5\/?VFO#'Q$\':SX&\/\
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3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>researchanddevelopment.jpg
<TEXT>
begin 644 researchanddevelopment.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *U 3T# 2(  A$! Q$!_\0
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M'["VF:'K.L7#?%'Q)>>'AHO[9'AOP9H)\/>'[6?PKH?[:7C7P1\2_'UG=:U
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M?B:[S<_VQXIUQB3&\9/K] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 45^>'[3_ .VSXB^ W[0_P,^!^D^"OA]+:?%&ZL6N?$_Q
M:^*$WPEL/%9U73/B:L/@CX-:S?>$M9\(^)?B9H^J^"=#N-:T#Q3XB\-++%XU
M\"Z#I:75SXR?7O"O<WG[1/QF\+?'CX;> /'_ ,(/!OA_P#\:/B7\0OAG\.'T
MOXH2^(?C"EKX \(>.?&B_%KQ7X%L_":>%=/^&7B/3/!<<,BZ5XZU/Q'X(D\:
M?#F/Q;:1:UXHU'PYX8 /M:BOSD_:._;'\7_"#]H'3?A;I\OP9\+^!]-\%_##
MQGXT\;?%>?XRH;*R^(OCKQYX5DG-_P##OX>^)_!/@CP[HEMX' E\9?%'Q1X5
M\-S:YKMIITUY:06<]S+G^'?V\-;UCXG>$=#OO"GPSTOP'\5?VA/C%^RU\.85
M^)^I7WQHTKXI_!V'XK&ZU;XF_#%/!D-CX;\'^)KGX3:P((M,\3ZGXB\,Z9K_
M (#U76;.Z'BB]L_#8!^E=%?%W[-GQ=_:'^('Q(^,W@[XM>'O@:GA_P"$\OAG
MPQ/XJ^$/B;XCZJDWQ.U;3(O%.O\ @BYL_'?A+0(I/^$3\&ZQX+U?5M7TR\N[
M>/5/&%MX<,:ZKHFO16,=U^T1\9?#'QX^&OP_^(/PA\&^'O ?QI^(_P 1/AO\
M.&TOXH2>(?C!#:?#WPCXX\9CXL>+O MGX47PK8?#/Q)IG@R&%VT?QUJOB#P/
M/XV^&UOXMM8];\5ZAX>\+@'VK1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 &1Z]>GO17Y"_M]?%WXH> OV]_^".7@/P5X_\
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MG?$G5+'5/&OP^O=!\1W^@QI9+<VNO:?X5\4^%LOP%^R3X\\$_M(>+?VA;_\
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M&>!M1^)?C2WOM(\*^+G\-0^'O&-OK(!^T7_"06__ $#M>_\ !'J7_P CT?\
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MJ.H^'/A9X>\,V3/X@\&?#CX&^&OA3H^B:'H7@;P -(O](U/48O#;Z/K'@/\
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M %CGX@U]>_\ !1/_ )(OX1_[*-I/_J->)Z^0O^"D_P#RDD_X(4_]G6_M0?\
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M26T\4>)%\=>/+.;198])UEX],CT=?$?B^6!;A_$EPEM]+44 %?MO_P $^_\
MD@;?]CWXL_GIM?B17[;_ /!/O_D@;?\ 8]^+/YZ;0!]P-T/T/\J_ /\ ;(_Y
M.2^)O_7WX>_]1#P_7[^-T/T/\J_ /]LC_DY+XF_]??A[_P!1#P_0!\R4444
M%%%% !1110!N^%O^1I\+_P#8S^'/_3Y85_3T.GXM_,U_,+X6_P"1I\+_ /8S
M^'/_ $^6%?T]#I^+?S- '@?[4O\ R;S\7O\ L2-7_P#08Z_GE;J?J?YU_0U^
MU+_R;S\7O^Q(U?\ ]!CK^>5NI^I_G0!\4?MX66G7?P55]8UZ/1M(L=;6\OK/
MQ!X=\::_\-/$1:S>RL]'^)D_@.ZM-:\/Z;;W5XFN>%=9NFNM$_X2W2;&QO\
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M.=C_ -!RPK^G<.F/O+U;^(>I]Z /!?VI?^3>?B]_V)&K_P#H,=?SRMU/U/\
M.OZ&/VI64_L\_%X!E)_X0C5^ 1_=C]Z_GG;J?J?YT )1110 4444 %%%% 'Z
M8?\ !-K_ )&3XL?]@/P?_P"G+Q#7ZT5^2W_!-L@>(_BQD@?\2/P?U('_ #$O
M$/K7ZT @]"#]"#_*@!:*** "BBB@ HHHH **** "BBB@#\._^"EL$-S_ ,%'
M_P#@A7#<0Q3PO^U;^T]OBFC26)]O['?Q 9=T;AD;:RJPR#A@".0#7ZE?&32M
M+L?"VF366FV%G*^LVR-+:6=O;R,AT^_8HSPQHQ0LJL5)VY4'&0*_+K_@I/\
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MB#9$0)9,L /+B) E?[D9(#LI(S1LOV:? 6IF0:9\1[S5#$ 91I<WA74S$#@
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M%D&'+YO-,NYMS9^;][LX&U5YR >VU\7?%'_D?/$'_76Q_P#378U];?V3>_\
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MJEI9WK1*;JVM=2DLM->_MX9B\<-V^G6+W$:K*]I;,YA0 _$__@I/_P I)/\
M@A3_ -G6_M0?^L<_$&OU4^-W_(I:5_V&[7_TW:C7Y5_\%)_^4DG_  0I_P"S
MK?VH/_6.?B#7ZJ?&[_D4M*_[#=K_ .F[4: /EJBBB@ HHHH **** "OK7X*_
M\B8W_89U+^<%?)5?6OP5_P"1,;_L,ZE_."@#UNOB[XH_\CYX@_ZZV/\ Z:[&
MOM&OB[XH_P#(^>(/^NMC_P"FNQH X"BBB@ HHHH **** +NF_P#(1T__ *_[
M'_TL@K] AT_%OYFOS]TW_D(Z?_U_V/\ Z605^@0Z?BW\S0!QOQ#_ .1*\3?]
M@BZ_DE?$;=3]3_.OMSXA_P#(E>)O^P1=?R2OB-NI^I_G0 E%%% !1110 444
M4 >^? ;_ )"'B7_KSTO_ -'WU?2E?-?P&_Y"'B7_ *\]+_\ 1]]7TI0 4444
M %%%% !1110 4C8(((R,'('4C'(_&EIDKK'')([(B(CNSR,$C544LS.S$!44
M EF) 5022 * /QBU[X9^!?B'^U7\:+?2_#L5O:Z=\9/A_IGC#1?'/[4/AOP%
M=/?3ZK\ ?B]XSUCP)\'[?X0>,_$-QX/^+NL_"WX3_P!N'6O'>E7_ ([N/AK/
MI/A%O VA:MK=QK_[/@8&/<_B2223P.2>3QP<U^+'Q/\ #_Q!OOVH_$>NV/@R
M[U?QO=_'?X-7WPJOM-^'7[*NI_LZZG\$4'PXE\6ZY\5/B/XB\/7GQGLOB-96
M@^(%Y!Y/BS2?&MOK]K\/H_A3H.J^';R3_A)/VG7H/Q^O7OCC/KCC.<4 ?B#_
M ,%)_P#E))_P0I_[.M_:@_\ 6.?B#7ZJ?&[_ )%+2O\ L-VO_INU&ORK_P""
MD_\ RDD_X(4_]G6_M0?^L<_$&OT9_:N^(.D?#CX=Z!K6M6FHWEM=^++#3(X]
M,2V>=9Y=&UFY5W%U<6T?E!+616*N7W,F%(R1YF<YSE?#^68W.LZQM'+LKR^B
MZ^-QM?F]CAJ*E&#J5.2,Y\O-**]V,G=K0SJU:="G.K5FH4X+FG.5[15[7=K]
MSQ6BOF;_ (:I\!?] +Q;_P!^-'_^6M'_  U3X"_Z 7BW_OQH_H3_ -!7T!/T
M!/:OS'_B/_@T_P#FX.1??C/+_J%\_P 'V/._MO*O^@VC_P"3_P#R/G^?9GTS
M17S/_P -4> \9_L'Q=CU^SZ1C\_[5Q2?\-4> ^O]@^+<'H?(TCG'7_F*T?\
M$?\ P:_Z.#D73KC.MO\ J%\_S#^V\J_Z#:/_ )/_ /(^?Y]F?3-%?,W_  U3
MX#'70?%O_?C1_P#Y:TI_:G\"#KH'BX?6WT@?SU6C_B/_ (-?]'!R+[\9Y?\
M4+Y_@P_MO*O^@VC_ .3_ /R/G^?9GTQ7UK\%?^1,;_L,ZE_."ORQ_P"&J? 7
M_0"\6_\ ?C1__EK7Z-?LL^.M+^(7PP?7](M=0L[0>)]<L/)U)+9+GS;3[)YC
MXM;BYB\MO-78?,W'!W*O&?H.&O%;P[XQS+^Q^&.+,LSG,_JU7%_4\(\0ZWU:
MA*E&M6_>T*<>6G*M3C+WKWDK)F^'S+ XJI[+#XFG5J<KGR1YK\L;7>L5HN97
M]?4^CZ^+OBC_ ,CYX@_ZZV/_ *:[&OM&OB[XH_\ (^>(/^NMC_Z:[&OT$[C@
M**** "BBB@ HHHH NZ;_ ,A'3_\ K_L?_2R"OT"'3\6_F:_/W3?^0CI__7_8
M_P#I9!7Z!#I^+?S- '&_$/\ Y$KQ-_V"+K^25\1MU/U/\Z^W/B'_ ,B5XF_[
M!%U_)*^(VZGZG^= "4444 %%%% !1110![Y\!O\ D(>)?^O/2_\ T??5]*5\
MU_ ;_D(>)?\ KSTO_P!'WU?2E !1110 4444 %%%% !6/XA2"30=;2Y6-[=]
M(U-9TF&FM$\+6,ZRK*-95M(,;1E@XU13IQ4D7P-J9@=BH;B&&Y@FM[B**>">
M&2&>&>-9H9H94:.6*6)U9)8I$9DDC=65T9E92"00#\$O"OAG11\7OA[=>)-
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MX5TF\O;EHHGGF\J"&R9RL,,<DTTC;8H8D>65TC4L,L?M$?%D@$>([0@C(/\
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M%_PL722CV=_=74AD_P"$;\3X4QSZ;9J$*[B7\UF#!0$(8LORK_P4G_Y22?\
M!"G_ +.M_:@_]8Y^(-?77_!1;_DBOA#_ +*/I'_J,^**_'_'[_DS?B!_V(Y?
M^I>%/+SK_D58W_KR_P#TJ)^,E%%%?XS77=?U_P .OO/RL****+KNOZ_X=?>
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M7%>1QDE*+QT4TTFFN2>Z>Y\+XF-K@/B=IV?]FRU7_7ZD?D%Q_=7_ +Y7_"O
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M._&6I^(O#GC'Q#IOAC1T\23>&_$MWI/PFUVTU#5(;[Q-HOQ$U'35\.>']/\
M$>K3:C>R^$_$6G:?FWW[(]A_PM+2OB1H'QI^.V@)!+^T#J>J:)_PL)M2B_X2
M7X]Z;HMEJ&O>'+BYT59=&;0KG28KV"TNY=465-+\):=92Z;IWABVMI>5T/\
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MRER*3?M+).:E!-NSDN5:W2@HJQ]N\+?V[_PBW_"0Z+_PE T[^V#X8_M[1_\
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M** "BBB@ HHHH _$#_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K[,_X*!?\D=\)_\
M90=*_P#4=\25\9_\%)_^4DG_  0I_P"SK?VH/_6.?B#7V9_P4"_Y([X3_P"R
M@Z5_ZCOB2OJN"/\ DK,B_P"PZ'_I$SX7Q,_Y(+B?_L6R_P#3U(_(*BBBOZN/
MX)"BBB@ HHHH *_9S]@O_DA3?]CQXJ_GIM?C'7[.?L%_\D*;_L>/%7\]-K\X
M\4_^25_[J>"_]-XD_9/ O_DN7_V)<P_]/X$^U*_"']KS_DXKXD?]?6@?^HGH
M-?N]7X0_M>?\G%?$C_KZT#_U$]!KX'PD_P"2AQ__ &)J_P#ZG8 _5_I ?\DC
ME7_91X;_ -5F:GS;1117]"G\B!1110 4444 ;GAC_D9_#/\ V,GA_P#]/-C7
M]*8Z?BW\S7\UGAC_ )&?PS_V,GA__P!/-C7]*8Z?BW\S7X?XP_Q<@_Z]YE_Z
M5@3^G?H[_P #BO\ Z^Y/_P"D9D>&?M,_\D"^+'_8EZM_Z!'7X"-U/U/\Z_?O
M]IG_ )(%\6/^Q+U;_P! CK\!&ZGZG^=>SX1_\B/,O^QK+_U$PI\[]('_ )*7
M)O\ L2+_ -3L4?&O[</A5?$WPAM;D:+XWU6Z\,:Y)K.GW7A#P'H7Q8L='O+O
M3IM -SXQ^%NLL]UXOT&[LM6O;.RNO#MK)X@\+:^VFZM;7VC64M_J"^)>//[)
MU7P]H'PD\;? '7?A]XO\>_#_ ,(:3\4OB-X*_9]^)?BW0? /@;PUXWUV\\(^
M"_A,O@WP]\0;+PC\1[BW$GB2'0K?Q-9:!\!=0\22:GJWB#QCXGT/P[8W/Z;=
M"""01R""00>F01R."1QV)%*"5&%)4>@.!QTX'I7W^)RB&(Q6(Q/M5%XFA2P]
M6G.C&K!TX<\:C3YX3C.K2E[%U*4J=6-*56*J.]%X?\HP/$53!X+!X+ZNYK!8
MJOBZ-:GB9T*BJ573G23C[.I2J0H5X?651K0JX>I6A0DZ,4L2L7^;/Q,\#?M/
M^(/VC;#Q=:_#;PS!J&K:#^UIX+\!_%+2_BK+?6/PX\&>(/A99Z'\*X[S2#\/
M[6[\+ZE>>*7;QIKJ/XEFG\6>,]1N;*SU2WL?!>@RIUGP*74OADSZS<?#OQW+
MX8\+? ;P/X9\4P1?LY6/@OQMX;\>:9XHT/34^%7PXM_"NC:9XC^+7@S3K?4M
M=\2:SJ5S/X]M]$N+"+Q=:?$G6IO%WB"RM_OFC_#'X#.!].3^9J:>30I8J>+I
MXJNZLZU6O>KRR2J5:5&F_=IJE"47*BI352,W*+4(2IN%.I%U.)*E; PP%3 X
M2-&&%H83]PZL)2HT,1B:Z]^M+$5(24<3.%/V,Z<8R3G4C6A.I1E^?GA#P3X_
M\/?&6--6T+4?$/BJ7]J7XE^-M<O+SX,:%-X!7X3>))/&$/A[XK:/\>[C2GUV
MV\>:'X(N_"G@#1?#FF^-I%6"QN_AS)\,;;PX9?%D7Z!C.!GKCGZT8'IWS^.,
M9^N.,^G%%=V"P4,%"K"%2I.-2JZB]I*4G'W8Q2YI2E)R:BG-IQ@Y7<:<+M/S
M,SS.IF<Z%2I2I4I4:"H_NHQA&7ORFVHPC",8IR:@FIU%&T9UJEH\OZ/?\$Z_
M^1A^*G_8%\(_^G'Q!7ZI5^5O_!.O_D8?BI_V!?"/_IQ\05^J5?S?XE?\E?F7
M_7O ?^J["']E^#'_ ";O)?\ K_F__JWQH4445\&?J84444 %%%% !1110 44
M44 ?B!_P4G_Y22?\$*?^SK?VH/\ UCGX@U]V?MP>%M>\6?"KPQI_A[3WU*\@
M\<:;=RPI-;0%+=-!U^)I2]U-!&0))HEVJY<EP0I )'PG_P %)_\ E))_P0I_
M[.M_:@_]8Y^(-?JE\</^10TO_L-VG_IOU"N;%\1XWA+#5N),NHX6OC<GC];P
MU'&PJSPM2I%J"C7A0K8>M*%IMM4ZU.5TO>MH_)SW)L-Q#E&/R7&5*]+#9C0>
M'K5,-*G"O"#E&5Z4JM.M34KQ6LJ4U:^A^)W_  I7XG_]"I<?^##1_P#Y8T?\
M*5^)_P#T*EQ_X,-'_P#EC7Z#5^?/[7'[07QE^"?Q7^"\.EW6A?#[X$ZM=3R^
M-/BGXC^$WC+XL^$K_6+7PK\6-;USP;\0M2\!:_9^(O@IX7\/:+X4\*>+(_B"
MOAS6+&:#5-<U[6-8TOPQ\._$>BZ_XF#^E/XC8VLJ%')."E4<*DTIX+/?>]E"
M4W"$89[.I4J24;0A"$I-N[2BI2C^0_\ $O\ PA_T-.)/_"K*_P#YT!_PI7XG
M_P#0J7'_ (,-'_\ EC1_PI7XG_\ 0J7'_@PT?_Y8U+!^V /%W[9?@SX+?#_Q
MK\)+OX976F_M(>!-2M+OQ#H&I>-?%_QP^#NF^!+]DTB?3M>?4-&\(>$M=UW5
M_AS>V-IHE]J_CSQ=I7C:XT@Q:9X-TJ369?A[\8?VD[GXL_%7X+ZK=^!/&7C7
MP_\ "G0?&/A>X\??"GQO^S1X:D\;2?$E_ ?C5O GGWWC;7_C1^S[X3T^XL=<
M3QWI,'_"3G6IO#7@W4?$?VKXAV.J>$^E_2<\3(1O4R3@BE+ZK2Q?LJF#SZ$U
M1JUYT$Y-YY[.#IRAS554J0<(M+6:G"#_ .)?N$?^AIQ(M;:XK*T^G3^R+O?I
M=E7_ (4K\3_^A4N/_!AH_P#\L:/^%*_$_P#Z%2X_\&&C_P#RQKV+X1?'#7M6
M_8J\$?M)^/[2TUWQ(O[,D?QO\<67A/36T.PUC5]&^&][XXU^R\/:7+=ZNVAV
MVKW&FW-II%E/?:HVF+=6\,MWJ+PM+/S'P9^*?QB/Q)^''@+XN:]X)\9#XU_L
MSS?M%^'[_P #^"Y?!]K\/-8T'7?AAIGB[X<M-_PD?B(>,?!SV'QA\+3^"/&N
MKC3?%-[>^'O$::RE[!J^E1:/B_I1^)"^M)Y)P3S86I5I3C]3SWFJ3H)RK^R_
MX7+-4J<74DZCIMPMR*4WR)?\2_<(?]#3B3:_^]97L[?]2GS1PG_"E?B?_P!"
MI<?^##1__EC7ZS?L5^&];\+?!EM,U^P?3K__ (3'Q)<_9WEMYF\B<V'DR;[:
M::/#[&P-^X8^91D9\?KZZ^"7_(EM_P!AK4O_ &A59=X\<6>(F(_U=SG+.'<)
M@_9RS#VN68;,J6*]MA90ITX<^*S7&4O9R6(FYKV/,VH\LXI-/Z;A/PIR#@[-
M7G.6X[.,1B?JM;">SQU?!5*'LZ\J4Y2Y</@,-4YTZ,>5^TY4G*\6VFO7J_"'
M]KS_ ).*^)'_ %]:!_ZB>@U^[U?$OQ5BB;Q_XB+0PLQEL<LT,3,?^)58]69"
M3Z<GIQTKZ*'B5'PN;SV63/._KJ_LE859@LN]FZS6,^L.N\%CN?E^I>S]E[*-
M_:\_M%R<LO3\0>"GQUE&$RI9DLK^K9E2S#V[P?UWG]GA<7AO9>R6*PO+?ZUS
M\_M)6Y.7D?-S1_&FBOU56"!F5?(MQN8+G[-&V,D#.U(G=L9SM1'=NB(S$*?D
M/X!_M=>#?COH7Q,\>1> O$7@#X1^ #=:I8?%SQ;?_#^[\%Z_X2L/!OA;QMJ6
MKZNWA?Q-KFK?#SQ'I6B>)EU;4_ GC+3[/7-/T2SN9;R6#Q%IWB'PMH/72^EM
M.M3K5:7AU4G3H>S]K)<5TTXNK+DIQC%\/*4Y3DG:%-2E:,I6Y8R:_(/^)=I_
M]%?'_P ,+_\ GR?,U%?3/@_]J:;XA?"Z/XD>"_@%X]O+J3XL_%#X57'A3Q3X
M@^&7P[_X1EOAAKNJ:-<^+OB)XQ\6ZW:^&_ >D>)EL;%O#^AW0U?Q6-;U[3O"
MNIZ39:C::U=:92UC]M'X::;\-?V>/B/:>"_&6I']HWQ#\.=+\.^#7L?#VE^*
M_!_A[QU\1_"OPKU3Q[XW6XU"YTBV\(^"_&/C3PQI-U?Z+J6K1>-+O7M"C\!7
M&MVVKP7T71_Q-;BN=07AO4<_;RP_+'BVA*2K1523A)1R!\EXTJDHRE:$HPE*
M,FHMC_XEUFK/_6Z-GL_[!?\ \^>G5=#YSHK]#/B)XP\0^$G\+Z7X*^$/BCXM
M^*?%^M7NCZ9HWAR[\+^%]%TJ/3=.DU*]U?QGX[\73VWASPGILVVVTG08IUU#
M5O$_B/4++1]&TR9$U34-*3X/_$OPQ\:_AEX-^*GA;3=0T_0_&>FW=[:Z9X@T
M_3[37-)O-*UK5?#6NZ-JL6GW6IZ8][HOB/0]8TF6\TC4]4T74OL2ZGHFIZCI
M-Y97L_,_I<-45B'X>3]C*:@I+BRDVI2]IRJ4%P^YQ4_8U>24HJ,_9U%!R<)6
M7_$NL_\ HKX_^&%__/D^$/#'_(S^&?\ L9/#_P#Z>;&OZ4QT_%OYFOSRTR"#
M^TM-_<6_&HV!&((1R+R#'(3-?H=7-/Q<CXK6JQR"61?V'>FXO-%F?UG^T+23
M367X#V/LOJ=K6J\_M+WAR>]^H>'7AX^ J>:P>;K-?[4G@Y)K ?4O8?5(XE6L
M\9B_:>T^LWO^[Y>3[7-[OA?[3/\ R0+XL?\ 8EZM_P"@1U^ C=3]3_.OZ!OV
MB["]U3X'?%#3].M9[V^N_"&J06MI;)YD\\SJ@6.),C<[8.!D9Q7X:M\+OB+D
M_P#%%>(NI_Y<??\ ZZU^S^&>?Y#E.48^AFN=Y/E=:IF+JTZ.8YG@L#5J4GAL
M-!5*=/%5Z4YT^>,H<\4X\T9*]T[?DGCME.:YAQ%E%7 97F..I0R94YU,'@<5
MBJ<)_7<2^24Z%*I&,[-/E;4K-.UFC@J*[S_A5WQ%_P"A*\1?^ (_^.T?\*N^
M(O\ T)7B+_P!'_QVOTC_ %TX-_Z*[A?_ ,2#*/+_ *C/-'X=_JUQ'_T3V>_^
M&C,/_F?S7WG!T5WG_"KOB+_T)7B+_P  1_\ ':/^%7?$7_H2O$7_ ( C_P".
MT?ZZ<&_]%=PO_P")!E'E_P!1GF@_U:XC_P"B>SW_ ,-&8?\ S/YK[S@Z*[S_
M (5=\1?^A*\1?^ (_P#CM'_"KOB+_P!"5XB_\ 1_\=H_UTX-_P"BNX7_ /$@
MRCR_ZC/-!_JUQ'_T3V>_^&C,/_F?S7WGW%_P3K_Y&'XJ?]@7PC_Z<?$%?JE7
MYG?L#>$_$WAO7OB7+K^A:EI$=WI'A6.V>_MQ"L[PW^N/*L?SMN,:RQL_3 =3
MWK],:_G[CW'X',N)\?C,NQN$S#"5(8)4\5@L31Q>&J.G@,+3FH5\/.I2FX5(
MRA-1F^6<91E:46E_97A#A<5@N <HP^,PV(PF(A6S1SH8JC4P]:"GFF,G!RI5
MHPJ14X2C.+<5S1DI*Z:84445\:?I@4444 %%%% !1110 4444 ?B!_P4G_Y2
M2?\ !"G_ +.M_:@_]8Y^(-?JE\</^10TO_L-VG_IOU"ORM_X*3_\I)/^"%/_
M &=;^U!_ZQS\0:_5+XX?\BAI?_8;M/\ TWZA7R_&O_)*YW_V!O\ ].4QQW7J
MOS/E2OGOXM?LM_!3XW^+/"7C/XB^%[W5=9\*&2VE73_%'BOP]I7C/06T;Q;H
ML/@_XD:-X?UK3-+\>^#[2/QOXCN[;0?$=K>VZS:EJ&GRM-X=UGQ!H>K_ $)1
M7\N4:];#S]I0JU*-3EE#GI3E3GRS3C)<T6FDT[.S\]TA7M_7S/%M:_9R^ _B
M'QUH?Q*U;X1?#N?QMX>L/B!IECKL'@[PYIUU<6OQ1TS3]&\<'6#INEVAUN\U
MG3=,M[6/4M4>YU+3%FU%]+N[274[]Y^:TC]E;X4^'[?55T/4/B_IFK:AX2T[
MX?Z=XPA^/'Q=O/'W@CX?:5K6F>(;7P%\,_&VL^+-5U[X>^$9=5T;2I]4TOPW
M=6DVO1:;I]IK][JEMIVG16GT=15K&8M14%B<0H148J"K5.51C.52,5'FMRJ<
MYR4;6YI2=O>=R_\ 7]>B/GOX9_LQ_#/X3>&/A_X,\*ZI\6KWPM\+]1O+WP5H
M7C3XU_$KQSIFG6%[X&O_ (=MX1U"S\1Z]=VWB7X?6GAO4KMM,\ ^)H=7\+Z;
MXA:'Q7::?'X@M;6_AWOA=^S_ /"SX.7ES?\ @/1=8M+J3PWI7@C39?$'C/QC
MXU_X1/X>Z#>W&I:%\-/ 8\8:YK8\$?#?1=1NI;[3/!?AS[#I$-PMH98YXM*T
M:+3O9J*)XO%5/:*>(K25;^*G5FU5M.51.HKVF_:3G.\KOGG*6\FV7_K^M@KZ
MZ^"7_(EM_P!AK4O_ &A7R+7UU\$O^1+;_L-:E_[0K[SPP_Y*=_\ 8MQ?_I["
MCZ/U7Y2/7J^*/BI_R/WB'_KK8_\ IKL:^UZ^*/BI_P C]XA_ZZV/_IKL:^\\
M6/\ D08'_L<4?_4+'B//2"00&="00'B95E0D$"2)G21$E3.^)GCD19%5GCD4
M%&_-#PW_ ,$[H=0\8_'3Q/\ %KXI7.HM\6M1TN.;5/@7X3TO]GCQ=XQT_1+_
M ."GBK2O$WQIU3PK<ZQH'C;QK8^,/A#O@L[#POI7A#[!XJ\?W$NERQ_$75=
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M*1_\$*B2 !^U;^U!DD@#_DSGX@]SQ_\ 7XK]4?C>Z-X1TL*Z,1K=ID*RL?\
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M'ZK\I'M7G1?\]8_^^U_QKXK^*9!\>^(2""#+8X(((/\ Q*['N.*^P/\ A'M
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M$#_@I/\ \I)/^"%/_9UO[4'_ *QS\0:_5+XX?\BAI?\ V&[3_P!-^H5^5O\
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M/\XQ_#_!O$&<Y95C1Q^7X%U\+5G2IUHPJJK2@I2I5HSIS5I/W9Q:^=F?&/\
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M7_S#T?\ $+K^PE_T</\ \%%/_$N]2_\ F'K^DRBC_6/B'_H?YW_X=L?_ /-
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M /#MC_\ YH#^P,B_Z$F4?^&W!>7_ $X\D?S=6O\ P:__ +#=C=6M]9?M'_\
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MMU<127Z/]8^(O^A_G?\ X=LP_P#F@/[ R+_H291_X;,%Y?\ 3C79?<?S9_\
M$+K^PE_T</\ \%%/_$N]2_\ F'H_XA=?V$O^CA_^"BG_ (EWJ7_S#U_2911_
MK'Q#_P!#_.__  [8_P#^: _L#(O^A)E'_AMP7E_TX\D?S_?#;_@W=_9S^#5S
MJUY\(?VVO^"JOPNN]>@L[77+KP#^W-XK\*W&L6VG2W$UA;ZG+H_A&U>]ALIK
MNZEM8[@NL$ES.\84RR%OTL_9"_8JLOV0F\?-:?M0?MI?M'?\)ZOAI9%_:Z_:
M.\2_'Y?"/_"-'7"I\!+X@TZP'A9M<_MQAXE-IYIUD:5H@FV?V9%N^U:*\W$8
MG$XRM+$8O$5\57FHJ=?$UJE>M-0BH14JM64YR48I1C>3Y8I15DDCT,/A\/A:
M4:&%H4<-0AS<E'#TJ=&E'FDY2<:=.,81<I-RDU%<TFY.[;84445@;!1110 4
M444 %%%% !1110 4444 %4=3OX]+TZ^U*6"]NHM/L[J]DMM-L;K4]0GCM()+
MAX;'3K**:\O[R5(S':V5I#+<W=PT=O;QR32(AO50U5-3DTS48]%N;&SUA[&[
M32KO4[.?4-.MM2:WE%A<7]A:WNFW-[90W9ADN[2VU"PN+FW66&&]M)72XC /
M@5_V^8/#DFJZ7\4/V??B_P##;QC?>#/!7COX8> M1N_A_KWBOXBZ=\2/BGX3
M^"G@SPI<P:#XLN-+^'GQ*N?B=X\\%>&M9\,>.-3T_1M'_P"$A.I1>+M3L?#/
MC:3PRWQ7_P % M$^'WPR^)/BGQQ\$_BQ9_$GX/\ CC0O GQ&^$7AB'P]XTO_
M  ]+XD\/^%O&6D^.+CQ]H^J)\/[/X77/@KQ=I_B)/&6NZOH4]Q=V6L>"+#0;
MWXB64?A.Z\\\%?L.?'G4/#OQ"MOCI\;_ (5>,OB=XQUGX5_$.S^/7@SX0>-]
M$^(%O\6/@?\ $G2?B=\)KB^T/QI\9?&_@VU^#/@O7--GM=-^!_@W3O"6BC2M
M8\1/)KTGBKQ3XH\7ZU>^*?[$WQT\=?"SXZZ'IGQD^#MI\6OVH/$?AJ^^,?CC
M6?@OXVN_!^F>%/ OA?P]X:\"^#OAEX+TKXU:9K6CVV@CP\VJ7FI^+?&WBN?6
M-:\1^*+];;3+6\TS2]) /:OC=^V=I7P=\4?$G3(/AAXR\;^$_P!G_P  :+\5
M?VDO'>B:QX+TC3/A-X \0P^*=0LM5@TCQ+KNEZUX\U#3/#G@OQ'XS\2:/X:@
M$VF^%K.W.G7.M^)]0LO"TWVE#+'/%'-$ZR12HLD<B$,KQNH9'1AP4="'4]U(
M/&:_,_X\_L(>+_VFY=!NOBUXM^!ZW^M_#<?#+XO:QX7^"7BVU\2:KX>GUOQ%
M?:I:^ M8U'XT7.G165UI6OS6WAG3/C+X<^,MA\,?%DM_\0_ $&F:]J5];7'Z
M76UO%:00VT""."WBC@AC7.V.&)%CBC7))VQQJJ+DDX49).20":BBB@ HHHH
M*\0^,?Q1\;?#]O"^E?#WX*>-_C-XF\4W&K>7:>'M0\-^%O#'AW3M"MK2YOM0
M\7^.?%]_8:%HDNH27UGI/A;1HEU'6_$NLW+K:V-OHFD^)->T/V^OD+]KWX,_
M'OXY>%O#?@KX0?%WP5\,_"=SJ6HM\7M%\4^"_'&NWOQ,\+R6,<.G>";'Q?\
M#WXH_#+Q7X$T&ZOFN)_&<_A^_P#[=\4:0L/AJTUKP]IEWK9U4 \>N/\ @I#X
M%U#P=:?$[P/\*?B=XS^&'ASX+^"/V@/CAXH@;P=H]_\ !3X9^/D\47&G76K>
M'-1\2?;O&_B+P_I'@GQ9XO\ &&@> I]8_L_P1HT/B'0=1\3R>)?!VE^(O>-
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M#\??^'6VO:QXOUGQCXY^/-IXTUN^\*>+? K>(-:\!>*-3\4^*O#WB?\ :/\
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M"D,OBKPSI)U1-7\1>&(I?$6BV%]HT;7H]ZZ]* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^6/CN"?$NCX!/\ Q(QT!/\
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M;:-^T3\-M<^%^F_#OXG?%6?7?A%H]Q\,?VG++PW;:)X<FTX>(M2M-4\.W7]
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M?GU&T\,>%-)^-WQ;T&W\*ZWKK6'A[XYZO\/OA;=PZ1XIN;3Q/%>_#S4-?O\
M1M)/BIHIOO*B@#\Q_'G_  3W\1>._''QSU!?C@G@+X=?'#P=\=O#'B7P=\,_
M!?B3PQ=>)9_CIX#U_P #W6I?$C39_BOJGP=\6ZOX*FU6S\5:+XU\/_!OP-\3
M?$FM:/I<'C'QOJEE)XI'B_FOB=^P+\7_ (H^/_#_ ,7/'GQI\)>-O%'@[QM\
M%OBYH?AS_A"_'^C:38>,/@O!X::?P!X#?6?C-XM\(^ _A=\3-2\-W>N^(;K6
M/AWX]^(VG^)?&'B&XO?&GB7PQ;:!X9T?]7:* /YR/@)_P3H_:%\:>#/"/@#X
MPZ+?^#K[X3Z3\(_$/A;XI_$B;Q FK1>-?@WX5\>_#GPM\%=)T3X._MF^+M8U
MGX ^'_!WQK^+VJ^&=>\$^+OV<KOPSXRU73-3TWPIXGTJ^U'P[H?Z9^.OV3=?
M\/\ [#E_^S+\*)M"/B<76FW]EJFDZ,-+T7_A(M8^-^F_%/Q=XG@T+X@^+O&\
M]T/[1O-?\0S:;XN\;^)M2U^Z66#5_$.HZEJ4U[)^@E% 'YS:7^P.^O>-OB9\
M0_C!\2K/Q;XE^-OA/]HKPI\3D\$>"I_ 6F)9_'3X>?LS_!^P'P^&H^+?&FL>
M%#X1^&?[-.A6%[=:GK'B34_%?B?Q!?Z]->:3IFGZ;X=A^4?VAOV(?VG;#3/A
MMXZ\,_$'4/B-\3?"%W\'?A^?%OP/^'VA_#7Q?X*^$'P1\ ?M$Z;X>U/P[X4U
MC]H7X<R:]XY\<^)_C7>Z7\0[SPQ\;_AKH]CX/U&YT/PYX)U#PM-XK\.^)?W'
MHH _)7X5_L0_%.[^!'C;2[CQ!IO[.'CKQ_I?P$\,6/@_P;9:W?:/X:\ _LS>
M)=9L/"G@CQ9JGA_XMWWC.^T#XN^ 5LD^(_A_PQ\:[G7_  E>>*O%VD:-\6/%
ML[S^(]6@\.?\$M(?#G@/XO\ @BU^+>F00?%;X,?MH?"C.F?#F^M-*\,R?MA^
M)/AQXFU"^TW3]5^(/B#5;W0_ \_@6;3H=$U?Q'J&I>*;+4H)=7\1QWEE-+>_
MKC10!^;_ ,7?V$-;\?>*OB1XT\.?$;PEI&N^.?BUX7^)NE7'B+P-X\FU#P5_
M8GP"\#_ J]B\)>-OA5\:?@Y\3?"WB*ZM?"$NMKXA\*>-M$M-0TS5;GP9XET'
M6].CM=2M/NOX;>%=5\#?#OP'X*USQAKGQ"UKPAX-\,>&-7\?>)TLX_$GC;4]
M T2QTJ_\6^($T^*"P36_$=U:2ZQJBV,$-HM]>3BWC2(**[6B@ HHHH ****
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M6TUQ'J-UKG@FU>\\6Z5)IEU;6^HV-]X=ME675[?4;6T>R%Q9K* ]]9I/ZU0
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M?"_QDUOP9KWQB^+7Q@^*>G_$'P[I%YI^H^%3\5/BG<_$B;PU+!IGB?2M:O\
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M1I&M7VA07VBQZ_<^'8M4O-'TH7T>I>*K31M3U#PM8:M96SRJ ?8M%?//B?\
M:O\ V=?!^DZ3K6N_%OPA;V&O:'X,\3:"UI>7.KW.NZ!\0=-\1ZUX1UC1=/T6
MTU'4M6T_5]!\(>*?$2W.GV=S'9>'- U;Q#J9L=%LIKY>8N?VQ_@KH]_\37\5
M>*-)\-^%OA]JGPNTG3?&4VK6>L:3\0KOXL^!+;Q_X7@\!6?AX:IJWB6YNM&N
M))K:RT:RU*\U&SM+W6+&&72+2XNX@#ZMHKYQF_:[_9F@U3P+H[?&[X=RWOQ+
MLO >I^!C:^((+VR\1Z7\4K[4-)^&VJV.JV:3Z4NE>/M<TN]\/>#]3N[ZVL?$
M7B6-/#>E7%SKMQ;:=-R$7[>_['4R7DJ?M#_#00:=+I2WUS)K,L-K:6VKZUJ'
MAN/5KBZFLX[>+0--\0Z5J&A^(_$;R#P_X2U>TETWQ5J>BW@6%@#Z]HKYWUG]
MK/\ 9P\/:W\1?#VM_&+P3I>I_";PWXH\6?$-+W4WAL_"^A^!M+BUSQQ<W^JM
M;_V3+<>"-&GMM5\9Z98WUYJWA/3[JUO/$%AIT%S \GG>J?M^_LM6'B7X1>%;
M#XB_\)3JGQI^,NI_ CPJ?!WA_P 1^);73/B#I?@?4?B$UKXOGT[293X8TS4/
M#EII]UHFK:C&MEKEKXCT+7]+DNO![ZIXETH ^S**\=\<?M _!?X:^-O!OPX\
M=?$GPIX8\;^/I;6+PMX<U74A!J.HG4-7@\/:3+,JQR0Z5:ZYXENK7POX?O-:
MFTVS\0>*+FW\-Z)/?ZY-'I[<;#^V'^S!/<?$:UC^./P[,_PHM[FZ\<HVOQ)_
M95O9^(?^$/O);1WC6/Q"MGXV:/P+=GPP^M?9O'<]MX*G$?BJZMM(E /I2BOC
M>U_;X_9<OOB3\._AA9?$9+G5OB5\-/BQ\5]'\0?V'K]KX'T3PO\ !/6-+T/X
MB0^-_%VH:;9:3X%USP_>WVH?VIHWBN72;O0E\.:U%XE&AWLN@6FN^Z?"?XV_
M"SXXZ-J6O?"SQGI7B_3M'U,:/JYL5OK2]TG49+&TU6UMM4TG5K/3M7T\ZAH^
MH:?K6E2WEA#!J^BZA8:QI<MYIE[;74H!ZI1110 4444 %%%% !1110 4444
M%%%% 'RY\= 3XET? )_XD9Z G_E_N?2O$G1]C?*WW6_A/H?:OT.*JWWE5OJ
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MOBEX2\.>$5M?VB](4:?H-C\5=5^'EA+\>%_:%U<^'="\*:_?ZM?^+;/Q%?\
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MBT+XV:%\*?#]G?V/PD\&^(VM/$WP?\>ZYX9\06VKR>&_$D%MJFG1^'/UYHH
M_'W4O^"4-B=!\#0Z=\7UU+Q/\+?B!\1)_AU?>*O#7C^T\/:'\#?%'A_P[X#\
M _!F^M?A+\:_A'XZU"7X0?#WP7X/\/\ AKQ=9_$328-;FM/$UQKGA5H/%]U!
MIWK>D?L!ZCX!E\":W\)/B;X:\(>)?A%KWPCUGX6V>J_"^ZUOP!H]G\-_V7]>
M_99U?PSK7A+3?B%X=U2\T3Q#X-\3:GJNB2:'XMT+5?!>JPZ9;P:AK>D)K6GZ
MY^D]% 'Y'Z1_P3U^(%GJ&N?#"/XG6%I\$=;\ ?LT:3\0-:O_  -I-[XQ^)FO
M_#O]H7X__M%_$J3P;)I'BK2(?A))KGC+XE6VFV\=_HOC70?#WA/7A;^"+2Q\
M3:!+K]SUDW_!.&>;X::GX ;XP1I<:E^Q]^TE^RJVM1^ ]B0S?M$?$/3_ !Y?
M^.(]-_X2L_N-%-@NF7?A;[8$\1@QW=UK-H85@/ZB44 ?C_XD_P""3OAS6]5_
M:!^S^/M!BT+XPV7[5>H^%KC6/"'Q#\1>,O 'CG]K?2/B)IOCO6VN=3^.4GPM
MU#2-'D^)WBZ+3;3PW\'O!7B;6?#>HVOACQ#XMNDL]0U37_I;Q-^R!XCN?CE>
M?'CPA\3-'TCQ"OQN^%?Q<TK0M?\  M]K>A06/@K]G?XC_LU^*?"^H-I?C7PW
M?W;^(?!WQ1\0Z_X>U>UN+.'POXHL=%:_T?Q+I":CIU[]U44 ?)_C7]GOQQJ7
MQWNOC%X ^*>C^#]/\;>%O@YX'^+?A?7OAI8>.[O7_#7P0^(7CKQ_X5/@;6M1
M\2:;IW@O6-67XD>,O"WB6^UOPQXXMAIFHZ;KGA>R\->*]#AU6\^9;'_@G+K$
M7A;2/ VK_%WPEXF\'_"OX7>._@U\ ="\2?!2'5;;0? _C[XF_"_XC:A_PN1C
M\1K:X^*>OZ9#\(?!'A;1O$/A"X^#^MV#:==_$2WU*+XGS:/XF\._J510!^:_
MA#]AGXD^&[7PK)K'Q^LO'FH6W@S]IOX9^*]/^(/@'Q%\1_"<?PV_:4D^%VL7
M/@[P-IOQ/^*WCGQ"-,\!>)?A)H$VD6?Q?\4_&#3-?\/^(O&GA?5-/L]%NO"U
MEX4]L_9._9N\8_L[:?XYLO$_Q8D\=6'BG5-"N?#O@S1=/\>:3\-_AMI^@:1)
MHS6?@31_B=\5_C7XQT5/$:"UU#7-'@\>)X,TZYL;*#PIX5T(_P!KWNN_7E%
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M%I#X?OM86PT_P]+!I<$T_P"FE% 'Y[?L3?L&Z1^R"U_-_P )#X;\77]O\.O
M?PD\-Z[IOAOQ_I/B&+P'X DO9=.MO$>H>._C)\5[>6\OYKBVNKK2/ =C\/?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>reservesdisandallow.jpg
<TEXT>
begin 644 reservesdisandallow.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %( 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MB0:8?"]C\0].U3Q#X7U'4O"_A:XM;_4F\%#57\)>+M1O;0^-M'U[3M'L]-<
M\,'_  4;DUKP%J7QM\'?!?4+_P"!_P -?AA\"/BG\?M>\2^,X?#?C[X?:/\
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MX2.MVUW<^&--\:7_ (?UVP\%:UKFF>++[1=4M=%EL+C\ROV>/B_X8\1_LQ>
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MF_A;2?$>K:IJ"SZEH-MJ+7%E^ZP_J?YGV'_UNF3UK\>M3\4V]I^T_J_@._\
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MQN\0:)_PDOB2.^\.>&9O!/@6P^(WA_4O"5]->:/!H6B]7^P]\//BW\+OA?\
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MXWZM\1]&AT/339^&].N],U&^\)KHO@ K-<VNG3:9;&T7]AP<CC'4]/J?<_\
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M5\1MU/U/\Z &D!A@@$>A&1UST/OS]:  H(4!0>H48!Z=0, \@'GN >H%+10
MA52""H(/)! P3UR?7GUI/+3&-B8SG&T8SZXQUX%.HH 0 #H .,< #CT^GM2_
MY_/K110![C\$4OWO_$7V"YL[9A::;YAN[&:]#@S7FT(L.H6!C(.[<6:4,"
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M)5?4'PBN]2@\)%+32_MD7]K:@WG?;[:V^<F+<GE2HSC;@?-G#9XZ473V:?S
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MCF2+>@Y:OQ8\-?LD_M22Z7\9/!VC:5JGP?\ AGH_Q'^$WCOP)\*'^/5CX_\
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MPP.'S/!8C 8N,I8;%4W2K1A.5.3@VG:,XM2B[I:IW!:-/L?SH_\ #97[7_\
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M"%2FFYTVI-<E6:<;V;:;5T@3MV?KZG\Z/_#97[7_ /TAG_X*'?\ A1_LE?\
MS\J/^&ROVO\ _I#/_P %#N>O_%1_LE?_ #\J_HN\F+_GE'_WPO\ A1Y,7_/*
M/_OA?\*^8_XAIPI_T"XK_P +L3Y?]//)_?Y!?R7W>G^7XON?SH_\-E?M?_\
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M##.D9^.>Q78<,RJ&8<$FF_\ #97[7_\ TAG_ ."AW_A1_LE?_/RK^B[R8O\
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MLQ2"VDMUG,;B,J0#=# Y^]P,\JP/X @$_AGMZC*[A@'D9.!D$$GV!&3T)Z=
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M7CT)'YX(S^-+10 FT''7C_:8=\\@'!_'/''2C SGG\SC\LX_2EHH 0*!TW=
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M8_CPG@*32D_;Y?\ X*9^%O\ A%!X4.M_\+G/PG7XA?!@^,F\;KHV;X_L_)\
M3\3_ /A)3XS!^'R^'&E_L4CQBWAK/]#=)@9SSZ_>;'ITSC\,8!Y'->L!^#W@
MK]I[XL?#_P 0?LO:'!XGT[0? ?BJS^'%I%\$_AWX!\)V'CWQ%J?CO]HSXB^"
MO%NJW'@;QMX7TJ^\:^#X/#TGAO4[O4/@7\4-)\5_!&/2O&?Q!^*_@7QCX?U/
MP_8WG1>&_P!KGXWWOPATWQ3JWQ\2/Q!XB\4? S3_ -IIT_9]338?V )_'/B'
MQI9_$W0TU.]TE]"UQ?".K:-HGPR^S?%*Q\6ZW\/_ +8GQ]\>7NI_#+6--T:/
M]OBH/K_WTV.#GD9P??(Y'!R.*-HY^]SS]YO7/!SQUYQC(X/'% 'X)^(?V\/V
MA_ OPM^)^L^)?& ;4M0_9\^(U]^RQXG?X.RVMW\=/&GP]_:2^,/@;1?B1HGA
MBVT.YCO[WQ;\%+;X-^/]9\,06]IX:31-:F^)6@Z3I7@?5)VTBK^T#\8/VR]<
M^%'QNT[1?B[XQM+SXJ:5_P %9?A_X$TOX<_"SP]HWBSX<C]EKQI\4;;X%:CX
M'\11:%J_B'4/&OBGP[X.M?!VI:GJ*W"Z_::W9Z[X$M?#GC73+7Q+JW[[;1QR
MW' ^9OUYY^IR:7'U[]SW_'\O3MB@#\<-,_:M^(>F?M0?!/P7I7[0,'QM^$_C
M2W^#OAWPQ9^!/"7@"_\ &/C[2/%O@F\7Q%\7O'GAN3P3X'U/6O#C>*_+UW4_
MBY^SGXLG^%_PMT6QO_#?CGX1P:EI>LZC!^QZG*J>>0#@C!Y&>1S@^V3BC:,@
M_-Q_M-CCU&<'WR#GO2T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 45AZWXDT/PY'!+K>H1:?'=2/%
M TJ3.))(T\QU'DQ2$%4.XE@!CH<\5SW_  L_P%_T,EI_WYO?_D6@#O:*SM*U
M;3M;L8M2TJZ2\LIVE6*XC615=H97AE 65$<;)4=#E1DKD9&"=&@ HHINX9QS
MZ9VG&?3=C;VQUZ\=>* '4444 %%%% !1110 4449[?T/OWZ=OY>HH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /!/CO_P @WP]_V$;W_P!(EKYJK[6\<^"(O&UOI]O+J4NG"PN)K@/%;)<&
M7SH1"4(>6,*% W @G)XQWKSC_A0MI_T,]W_X++?_ .2J .V^$7_(AZ3_ -=]
M4_\ 3I=UZ77.>$_#J>%="M-$CNWO5M7NG%S)$L#/]IN9;D@QH[JNPR[ 0QW!
M=QP3@='0 C?=;[WW3]W&[I_#GC=Z9XSUK\1/!US\/M/^,7Q7O?BAI/Q%\1?M
M]:?^V%\6-1^$VB>';_Q9I7C76/@Y;:EK%[\ M'LM2CSX>LOV2-2^!,/AK3/B
M;<.K_#6#QS-XPDU:-OC4B"OV\INT9SS],G;W_ASM[YZ=>>O- 'X)^"_VMOVI
M_&R_"_1?"?QJ7Q0?B1K?[(5M\3_&'_"BM$TJ7X"?$KXM>+O&NF?&_P#9[M-#
MN='MK>'4_#7AG1XK_3=*\>+KOQ"^$.JZ/:W7Q.U?Q18>-M$TD\5XN^/O[4OA
M#Q;XV^)E]\?O%]KXHT+]DW]N'P!\)_!6M^ _"%K\-?BM\8OV8/VI_BE\//#W
MCF\\&V?AB.[U/XBS?#3PUX4^)?B_0O"&LZ+9ZEI_VVX\,Z78^")KO2[?^B$*
M!TS^+,?YDX'L.*7 ]^_<]^O?\O3MB@#\4/BE^U+^TA\*OVI?!'PG\/>/-1^(
M\/AGXJ_ ?X6^/O"'C'PMX$\&WWC_ $+XOVFCOK/Q/\(>%_"/PSU[Q9JOA#0=
M3\7:?H%O\5O^%C?"SX;^%/%6AZEX#UGP[X]US0M5U77O+(OCW\7?B%X5_9.^
M)GB+]LGQGH%MH_[0'[.WB7]I_1_#/P>\-?#WPW\$M:^(WPS^-]EXW^ _Q%\3
M:WX.O]-E\(:)\0[7P5X";P/XK%Q\3OA]K>J:7X@^(?B[4+SQC\-;SP]_0%M&
M<\Y_WFQ^6<?I2;0.[<D'EW/3ZMP/4#@]Q0!^%-Q^WS\9K7PEH6F:OXGU6+Q_
MX8^"O[2DGQZM] ^%NE&Y^&/Q7\-?M9_LY?"'X<W7BJ]\1:;;^$? ^G^%O 'Q
M$\9>)/$U]JTFKZ-I/P\BNOC5K7AOQAX:T'3;?7.T_8Y^-GQE^-'QU^&5Q\6+
MV+Q!<_#N?]M_X=Z1XUT-GO-%\?\ A"QM_P!BSQ=X-\6W&MZ3\//A-X0\4S7E
MOXSU73M)\3^&OAUX5\.ZY8Z6UWX?L[N)K[5;_P#:+:.>6YZ_,WKGCGC\,<<=
M*4#'K^))_F30!^)'Q<_;3_:5\+_M8Z[X/^$]E<>.]'TCXA_$7X7W'P.\4:;H
M6A:W-=:+^REX_P#BQ\.O%6A^'-%^'FI>.F\(>/OBQX3\/>$M ^+WB_XV>&?"
MGBL^(+_PIX9^&-QJ2:=KZ?/NE_&3XH:Y\9]-\9^#_BQ'^T-XC\6>$?V5=$T+
MQEJ_P:TOPG8Z5\68_@)_P5;\:W7@KPGH3:=I>@Z;XM\,>/[;P9I5W:R07'C?
MPWI>K1?#?XA:MJVII>W+_P!'.T9SS]-S8Z8^[G;^GOU->?>(?A5X \5^-_ G
MQ&\2>&K/6_&'PQ_M]_ .K:E-?W0\*W?B?3QI&M:KI&FR7ATB#6[O1VN='37G
MT^36K+2=0U;3-/O[2QUC5;>\ /QMUO\ ;G^+OC/PKK.K^ ?C+X2\,^&M ^$?
M["^I^,/'>O>$4\':9I7COXE3_M-Q_'_0]$^(OB[X8^-/AMX%\917_P /_AOH
M]U<?%;PIJ?PX^'VJ0:CX'US_ (1?QMXJTZ:P\NU3]I;]HU/&&B?%S1OCA\5?
M#&J?%O\ 9=_9'T3X>?#/XD?"?P'8>$O$7C&Y_;.U7X5?';Q]X=\"Z9:ZTNIZ
MWI/PXUO3/'-U?^%OB#-H^J>#_&_A?Q@D@\$1>#[;PY_1'M&,9;_OIL\>^<_7
MGGO2[1QUX&/O-^O/)]SD^] 'X2>*?VHOVW_AGI_C;5O#VO-\<?$/A?QA^W5\
M%?!OP^U;X0Z1I'_"=:O\ O@_XN^+7P?\=ZG>^"-.TS5Y?&.LZ[H=KX-UG3_#
M,>G^"?&/AZ18/#?A'2O&LL.HWFC\%_VA_P!KSXNZW\(? D'QJ\.6WA;X@?'/
MQ?X,F^,/@BR^&?Q>\1S>%='_ &6?&OQ'U73)-:TKX0>"/@UIVMZ!\3](\,3:
M+J&F^%O$*6&B:KJ'@#QW;7?C#2S>W/[E8'OW[D=>.Q_+TZC!H"@=,_BS'MCN
M3Z?GSU)H _GH\"_M$?M'SQ?%CXQ:_P#M&7/@OQM\4?V,OV$?BMX5^&GCSPWI
MNE_";PDVM>)M2\*_M%>-OAU:Q?#;QMK_ (1NM(G+Z??>*/&<'C;P!\,O%'Q%
M\.:Y\:M(U3P!X?\ #LFF_K1^Q9\7-;^-/P'T;Q?XAOO$NM:I;^*/'WAB3Q1X
MCT7P?IH\6VOA;QEK&D:;XET'5OAW,WP_\<>&=2TV&T&B_$/P59Z%X<\;PV\F
MNV/A?PL]S/X?T_ZN*@^O3'WF'\CU]6ZD<$XI0,#'/XDD_F23_G'2@!:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO/_ !]\4_ /
MPOMM-O/'OB2T\.6VKW,UGITMW!?3K=7-O!]IFB06-I=LK1PD2$R*BD<!BW%>
M9?\ #6W[.W_14-&_\ /$'_RGKTL/DV;XRE&OA,JS+%4)N2A6P^!Q5>E)QDX2
M4:E*E*$G&:<96;M).+U5CQL7Q'P]E^(GA<?GN38+%4U%U,-B\TP.&Q%-3BIP
M<Z-:O"I%3A*,XN45S1DI*Z:9]&T5S'@_QEX9\?:!9^*/"&K0:WH-^]U'::C;
MQW,4,[V5U+972JEW!;S@PW,$L+;XE!9"4++ACT]<-6E5H5*E&M3J4:U*<J=6
ME5A*G4IU(-QG"I":4H3C)-2C)*46FFDT>I0KT<31I8C#5J6(P]>G"M0KT*D*
MM&M2J14Z=6E5IN4*E.<&I0G"3C*+4HMIIA112;AG'/)Q]UL>O)Q@#W)QGC.:
MS-1:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#\Y?^"B9(\+?#'!(_XJ?7>G'_,#
MCK\JLGU/YFOZ#/C!\#O!GQNL=$T_QE+KD4&@7UUJ%B=#U*/3I#/>6HLYA</)
M9W@EC\H H@5"K_,6(XKPC_A@;X'_ //YX^_\*:U_^4M?M?!W'F09)P_@\MQS
MQJQ-">)E4]CAHU*=JN)JU8<LW6C?W)J_NJSNNES^:_$7PKXKXGXLS#.<K66_
M4L33P,:3Q&-E1K7P^!PV'J<U-4)I)5*4^7WG=)/2^G6_L5_\F\>#?^O_ ,6_
M^I5JU?5M<'\-?AUH'PJ\(:;X)\,OJ,FCZ7+J$UL^JW27M\7U*_N-1N/-N(X+
M97 N+F01 0KLC"H2Q7<>\K\HSS&4<PSG-<=A^?V&,S#&8FCSQY9^RKUYU(<\
M;OEERR5U=V>EV?O'#&7XC*>',ARO%\GUK+LGRW XGV4W.G[?"X2C0J\DVHN<
M.>$N63BKJSLB.7_52_\ 7-__ $$U_-P_@3XEZ#^T[XX^,FD?"WX<V-E?_P#!
M2;XC:+I_QQT&7QW8_M(ZCJOA?X;R>(? GP8\0W\NEV7A&T^"'QP\4>'[/X$7
M>KWNOZ_H.F6?CC2+*/PK#KVKVGB;PG_2728_SD_YQ[=*\L]P_FMTO]I7]L#X
MS? ZS\7?$'X[S_"+1_!?Q2_88^(7Q5\:?"S4_AYJGB+X377B;XV6VD_'7X<>
M/=-F^!NF>'O 7PK\(>'[FUUG6_!/Q(O/%OQ:\%/X4OK7XP:WK'@+Q+=>9]#_
M !5_;F^/>AZ)XO\ "?@KQ98O\8?!:?\ !3/4?$&C3?#.36(O#.E?"6?QGKG[
M'UYXD@ATJ*VCL=>\$7'P^\3:$D%_%>_%KPY/>:G97%^4U2YLOW*VCD9;G'\;
MYX.>#NR/?&,C@\<4NT9)YY_VFQ^ S@?@* /R$U#XN?M7^!/C1XRL-1^+]QXT
M\%?"[]JK]D#X"#PS=?!WPAIL?CSPQ^T!X/\ A>/B1XJUK7]#TRWU.QN/"^M?
M$*\UOP8?"<VGZ?H<V@OI'C*7Q79WLO\ 9G:?\$__ -I+XI?%SQ?\1_!7Q2\=
M?\+/UO0O"'@_Q5?^(_!OACP[!\*O#?B#5=>\5:1KGA'2=1LO#7@+XC?#S6MM
MCIU^GP+^/G@V[^+?@O28&U'5O'_C!;ZZ73/U'Q]>QZGM^/YCH>] 4#.,\^K,
MWKZDXZ]OZ"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
IHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>rituxan.jpg
<TEXT>
begin 644 rituxan.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!<17AI9@  34T *@    @ ! ,"  (
M   6    /E$0  $    ! 0   %$1  0    !   7$E$2  0    !   7$@
M  !0:&]T;W-H;W @24-#('!R;V9I;&4 _^(,6$E#0U]04D]&24Q%  $!   ,
M2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M245#('-21T(               $  /;6  $     TRU(4" @
M                                                   18W!R=
M 5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA9
M6@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P
M9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@
M   4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M!#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@
M2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#
M-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                         %A9
M6B        #S40 !     1;,6%E:(                     !865H@
M    ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@
M   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                        9&5S8P         N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="                             &1E<V,         +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ                                  !V:65W       3I/X
M%%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE
M87,          0                        */     G-I9R      0U)4
M(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
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M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\  $0@
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M,"#P?4'U![BK_LZ,H7C*_P"1'UZ2E:4;'UA/J%E:S1PW%Y;PRR?<224*S=N
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MCF?;\O\ ,.5=_P RQ15?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y3_XFCF?;\O\
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HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>rituxanhycelalogo300x87.jpg
<TEXT>
begin 644 rituxanhycelalogo300x87.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        !(     0   $@    !  .@ 0 #     0 !  "@
M @ $     0   2R@ P $     0   %<     _^T .%!H;W1O<VAO<" S+C
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M\SGP;9Q$0>4]-BQPN=N+IMXWRX'H&NCNGJ.G]L;H^'#TT)8A*5\NSH_\=S#
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M0A#R'#[J6_A;E*/#IP\U$47\.3-=[FH&\IKX9#D0KV[U<1( 2#'>6$ <@B/
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M=!#P '/B4%D_,:"(EQQXL%"01(A_7_'".J Q> A?[O !\!_%"8HJH9F0Z^*
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>Q5X9LX" 0E6/-E!(M0E%Z#W<0B< C(X&_P#[(?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>sellinggeneralandadmin.jpg
<TEXT>
begin 644 sellinggeneralandadmin.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MB0:8?"]C\0].U3Q#X7U'4O"_A:XM;_4F\%#57\)>+M1O;0^-M'U[3M'L]-<
M\,'_  4;DUKP%J7QM\'?!?4+_P"!_P -?AA\"/BG\?M>\2^,X?#?C[X?:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q _P""D_\
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MLM=$FF_X0SQIILOBH?L_20WOC'2_A?X7T_3-,\,>)]-M+&VU+P7P=X%\<?\
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MV%G_ %\O\U]Y^K%%?#MCXY\8/>V2R^)]9,1O+02@WLI5HC<Q"16 R2K(6#*
M202,'.*^P_\ A)]$/_+Z/_ >\_\ D:OIN%^*\+Q1#&RPV%Q&&^I2P\9JNZ;<
MWB%5:Y?9RE\/L97O;=6OJ+I?U_"W^9OT5@?\)/HO_/Z/_ >\_P#D:C_A)]%_
MY_1_X#WG_P C5]6!OT5@?\)/HO\ S^C_ ,![S_Y&H_X2?1?^?T?^ ]Y_\C4
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M7A6S^#WA#XK>%K.XT@?L[7^N>#/B3\//&/B#X >$] TQ/&KW2>#MU_IWB_\
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MK -=PC*L.589RK#E6 (Y%?=W_"/V_P#T$-=_\'NJ?_)-?MGA%_"S[_KYEO\
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M*** "BBB@ KZZ^"7_(EM_P!AK4O_ &A7R+7UU\$O^1+;_L-:E_[0K]$\,/\
MDIW_ -BW%_\ I["CZ/U7Y2/7J^*/BI_R/WB'_KK8_P#IKL:^UZ^*/BI_R/WB
M'_KK8_\ IKL:^\\6/^1!@?\ L<4?_4+'B//J***_G\ HHHH **** +VF?\A+
M3O\ L(6'_I9!7Z%5^>NF?\A+3O\ L(6'_I9!7Z%5^V>$7\+/O^OF6_\ I.-'
MT7J_RB<7\1?^1&\3_P#8)N/Y+7PXW4_4_P Z^X_B+_R(WB?_ +!-Q_):^'&Z
MGZG^=>1XL_\ (YRW_L6?^[6(#HO5_E$2BBBORH04444 %%%% 'T#\ O^/[Q-
M_P!>FF?^CKVOI>OFCX!?\?WB;_KTTS_T=>U]+U_3'AS_ ,DCEO\ U\Q__J?B
M0"BBBON "BBB@ HHHH *0]#CK@X_R>/SI:1CA200, G)Z#CJ>1P._(^M 'YJ
MS?!_XTZ=^TA\0_%D_A3XIZ_X/\5?%7PEXGT#7?"/[5$OPH\':9X;LM!\):3>
M6FL?!/PPFFZ;XEGTZ\TC4;O6=5\0/K/B7X@V5S#I6M7<>F:9H>F67Z5C^I[Y
M[_YX[=*_.NZN_C_=_M!^-$\3Q?M:3>!K?XE>%1\,[_X00_LQZ9\#I/AU)HOA
M4W%IXGA\3Z[??%S4KJT\3KXID\=:O/;VMS?Z9=P0^#;:&&TBL;/]%!^/4]?K
M_+T]NM 'X=?\%+FF3_@H]_P0L:WB2>8?M6_M/[(GF^SJV?V._B &S+Y4VS:I
M+?ZIMQ 0;=VX?J-\99M4D\*Z<M[I]M:0C6;4I)#J?VUB_P!AOP$,?V"UX*[F
M\T2$ KMV?."/R_\ ^"D__*23_@A3_P!G6_M0?^L<_$&OU2^.'_(H:7_V&[3_
M --^H5\OQK_R2N=_]@;_ /3E,<=UZK\SY4HHHK^5Q!1110 4444 %?4WP>GU
M:/PBRV6G6UU!_:^H'S9M3-H^\^3O7R1I]S@+P WF_-R=J\9^6:^NO@E_R);?
M]AK4O_:%?HGA?_R4[_[%N+_].X4?1^J_4] ^U^(?^@+8_P#@\;_Y3U\@?$MK
MA_'&NM=0I;SF2Q\R&.?[2B'^S+(#;/Y-OO#+AC^Y0J24.XKN/V[7Q1\5/^1^
M\0_]=;'_ --=C7WGBQ_R(,#_ -CBC_ZA8\1Y]1117\_@%%%% !1110!=TW(U
M&P*@,POK(JI.T,PNX2JEL-M#' +;6V@YP<8/W;]K\0_] 6Q_\'C?_*>OA/3/
M^0EIW_80L/\ TL@K]"J_;/"+^%GW_7S+?_2<:/HO5_H>9^/;G6W\&^(UN=*L
MX8&TNX$LJ:N9GC3 RZPG2XO,(X^3S8]W3<*^-&ZGZG^=?<?Q%_Y$;Q/_ -@F
MX_DM?#C=3]3_ #KR/%G_ )'.6_\ 8L_]VL0'1>K_ $$HHHK\J$%%%% !1110
M![I\$);^*\\1&PLX+QFMM-$HFO39"-1+>;2I%I=^86.01B/8%!RV[ ^E;&;4
M9?-^WV4%GMV>5Y-\;WS,[M^[-G:>7MPN/]9NW'[NWGYW^ 7_ !_>)O\ KTTS
M_P!'7M?2]?TQX<_\DCEO_7S'_P#J?B0"BBBON "BBB@ HHHH *JWUI'?V=W9
M3!#%>6T]K*'AM[E#'<0O#(&M[J*>VG4H[!H;B&:"492:*2-F1K5% 'YN67[#
ML?A[Q'I=QX6^%'[ ]@FCW5EJ&C_$%OV0=.L/B!HM_IDT-QINI6VD^'_%FE>&
MG\0V%S!#>6VMZ?J/A^RAU""*[@\.P(!;)^B>DVEY8Z7I]GJ&I3:S?6MG;07F
MK7%M9V<^I744*)<7TUII\-O8VTEW*KSO!9P16T32&.&-8U45H44 ?B!_P4G_
M .4DG_!"G_LZW]J#_P!8Y^(-?JE\</\ D4-+_P"PW:?^F_4*_*G_ (*6S0V_
M_!1__@A7-/+'#$G[5O[3Y>6:1(HUS^QW\0%&Z21E1<L0HRPRQ"C)(!_4CXSZ
MGIU[X4TV*SU"QNI4UFU=H[:\MKAU06%^I<I#*[; Q +XVY*C.6&?E^-?^25S
MO_L#?_IRF..Z]5^9\Q4445_*X@HHHH **** "OKKX)?\B6W_ &&M2_\ :%?(
MM?5?P;U73++P>T-WJ%C:S?VQJ+^5<7EM!)L;R=K>7+*C[6P=K;<'!P37Z)X8
M?\E._P#L6XO_ -.X4?1^J_*1[;7Q1\5/^1^\0_\ 76Q_]-=C7V!_;^A_]!G2
MO_!E9?\ Q^OCKXFSP7/CG7I[::*XADDLC'-!+'-$X&F62DI)$SHV&!5MK':P
M*G# @?>>+'_(@P/_ &.*/_J%CQ'!T445_/X!1110 4444 7M,_Y"6G?]A"P_
M]+(*_0JOSTTTA=1T]F(55O[%F9B JJMW 69B< *H!))(  ))P*^]/^$@T/\
MZ#.E?^#*R_\ C]?MGA%_"S[_ *^9;_Z3C1]%ZO\ 0POB+_R(WB?_ +!-Q_):
M^'&ZGZG^=?:/C_6=(N/!?B2"#5--FFETNX2.**_M)))'(!"I&DS.[''"JI)[
M"OBYNI^I_G7D>+/_ ".<M_[%G_NUB Z+U?Z"4445^5""BBB@ HHHH ^@?@%_
MQ_>)O^O33/\ T=>U]+U\O? V^LK&]\1M>WEK:+):Z:L9NKF&W$A66\+!#-(F
M\J""P7.W(SC(KZ5M=0L;[S/L5[:7?E;?,^RW,%QY>_.S?Y,C[-VUMN[&[!QG
M!Q_3'AS_ ,DCEO\ U\Q__J?B0+E%%%?< %%%% !1110 4444 %%%% 'X?_\
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M110!^('_  4H('_!2/\ X(4DD ?\-6_M0<G@?\F<_$&OU0^.#I_PB&E_,O\
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MHWI_>7_OH?XU\J_\./\ 2O\ I*C_ ,%F/_$T]!_^<U1_PX_TK_I*C_P68_\
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M>LJY_P"")%E>3/<W?_!5?_@LY<W$FWS)I?VU-!:1]B+&FX_\*9&=J*J#CA5
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MF/\ Q-/0?_G-4?\ #C_2O^DJ/_!9C_Q-/0?_ )S5?&_\0ES;_H:9;_X#BO\
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M$U[;V&CZEJ\WPW\9>,8_ ?BA[BZB^T>"?&;Z7K#Q?;7TB36)/#_BN+0/L^@
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M2WU;X@^-(O&OQ7T8:9KFG^'->,1UW3;3Q_\ $/\ M_QAXP'B#3XM!_16BB@
MHHHH **** "OS<UG]EK]H3XC_M$^*_'/QP\7? CXE_!G4H_'O@GP)X/_ .$4
M^*FA>)_A3\(_'/A74_".L67A2*+Q[>^![GXM^*=(U&ZT_P ;?%[5=&N-9N=
MU35/"'A"R\'^$[J_T?5?TCHH _.[P-^RS^T!X$;PMXHG^+7PN\=^/_@1\#K[
M]GW]G.;7?AOXHT+0(_#'B#5_A=<^,/'/QD_LGQYJ&K^)/B!XDT3X2^#M(9/
M\_@_PQIEYI^M:K:Z6]MXJ?1= S/AK^R#\9HOV./"/[*'Q=^('PLO[;PCKWP2
MT:37OASX/\;Z1IWBWX/_  V\>^ ?%GC7PAXAT?Q7XRUVYAU?XDZ'X:\1>#]0
MNK/4I=$LM+\1DRZ5>Q13VL_Z244 ( %&!ZD^O)))_4FEHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>spinrazalogonewa01.jpg
<TEXT>
begin 644 spinrazalogonewa01.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[@ .061O8F4 9      !_^$0C$5X:68
M $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    )    '(!,@ "    %    ):':0 $
M 0   *H   $N  K\@   )Q  "OR    G$$%D;V)E(%!H;W1O<VAO<"!#0R R
M,#$U("A-86-I;G1O<V@I #(P,38Z,3 Z,C@@,#@Z-# Z-#,   >0 P "
M%    020!  "    %    1B2D0 "     S P  "2D@ "     S P  "@ 0 #
M     0 !  "@ @ $     0   >"@ P $     0   /      ,C Q-CHQ,#HR
M." P.#HT,#HP,  R,#$V.C$P.C(X(# X.C0P.C P      8! P #     0 &
M   !&@ %     0   7P!&P %     0   80!*  #     0 "   " 0 $
M 0   8P" @ $     0  #O<         2     $   !(     ?_8_^T #$%D
M;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5
M#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !0 * # 2(  A$! Q$!_]T
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M[1AB4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M.$))300Z      $+    $     $       MP<FEN=$]U='!U=     4
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q 4@            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ !(     0 ! $@    !  $X0DE-!"8       X
M/X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          $X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300        "   X0DE-! (       (
M #A"24T$,        0$ .$))300M       &  $    ".$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      U<
M   &              #P   !X    !$ 4P!0 $D 3@!2 $$ 6@!! %\ ; !O
M &< ;P!? &X 90!W     0                         !
M  '@    \                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    \     !29VAT;&]N9P   >     &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   /      4F=H
M=&QO;F<   '@     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 4 "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M300A      !=     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    %P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 0P @
M #( ,  Q #4    ! #A"24T$!@      !P (     0$ _^$20&AT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED
M/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX-"CQX.GAM<&UE=&$@>&UL
M;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E
M(#4N-BUC,#8W(#<Y+C$U-S<T-RP@,C Q-2\P,R\S,"TR,SHT,#HT,B @(" @
M(" @(CX-"@D\<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@T*"0D\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B('AM;&YS.G-T4F5F/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C
M(B!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S
M:&]P+S$N,"\B('AM<#I#<F5A=&]R5&]O;#TB061O8F4@4&AO=&]S:&]P($-#
M(#(P,34@*$UA8VEN=&]S:"DB('AM<#I#<F5A=&5$871E/2(R,#$V+3$P+3(X
M5# X.C0P.C P(B!X;7 Z365T861A=&%$871E/2(R,#$V+3$P+3(X5# X.C0P
M.C0S+3 T.C P(B!X;7 Z36]D:69Y1&%T93TB,C Q-BTQ,"TR.%0P.#HT,#HT
M,RTP-#HP,"(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!X;7!-33I);G-T86YC
M94E$/2)X;7 N:6ED.F-C,3)E8V$S+38W.3<M-#1A,RTY8C)B+6,T,3(R-3,W
M9C(U."(@>&UP34TZ1&]C=6UE;G1)1#TB861O8F4Z9&]C:60Z<&AO=&]S:&]P
M.C(V8S1F93DP+61D.6$M,3$W.2TX9# X+3@Q83$Y8C!E9F4X-"(@>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/2)X;7 N9&ED.C P,V4P-60R+38Y.3(M-&5E
M-2UB.61F+6%D83!F8C8V9&$X-R(@<&AO=&]S:&]P.D-O;&]R36]D93TB,R(@
M<&AO=&]S:&]P.DE#0U!R;V9I;&4](G-21T(@245#-C$Y-C8M,BXQ(CX-"@D)
M"3QX;7!-33I(:7-T;W)Y/@T*"0D)"3QR9&8Z4V5Q/@T*"0D)"0D\<F1F.FQI
M('-T179T.F%C=&EO;CTB8W)E871E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP
M+FEI9#HP,#-E,#5D,BTV.3DR+31E934M8CED9BUA9&$P9F(V-F1A.#<B('-T
M179T.G=H96X](C(P,38M,3 M,CA4,#@Z-# Z,34M,#0Z,# B('-T179T.G-O
M9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#0R R,#$U("A-86-I;G1O
M<V@I(B\^#0H)"0D)"3QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%
M=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HW9# R.68U,BTT,6$P+30R968M.&0P
M-2UD,S@Y8V0P,#(T83DB('-T179T.G=H96X](C(P,38M,3 M,CA4,#@Z-# Z
M,S4M,#0Z,# B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO
M<"!#0R R,#$U("A-86-I;G1O<V@I(B!S=$5V=#IC:&%N9V5D/2(O(B\^#0H)
M"0D)"3QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N
M8V5)1#TB>&UP+FEI9#IF.&9E,39D-2TQ-F8U+30X8C<M868W8BTW,#4X.#@P
M,3AA,6(B('-T179T.G=H96X](C(P,38M,3 M,CA4,#@Z-# Z-#,M,#0Z,# B
M('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#0R R,#$U
M("A-86-I;G1O<V@I(B!S=$5V=#IC:&%N9V5D/2(O(B\^#0H)"0D)"3QR9&8Z
M;&D@<W1%=G0Z86-T:6]N/2)C;VYV97)T960B('-T179T.G!A<F%M971E<G,]
M(F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G
M92]J<&5G(B\^#0H)"0D)"3QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)D97)I=F5D
M(B!S=$5V=#IP87)A;65T97)S/2)C;VYV97)T960@9G)O;2!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+VIP96<B+SX-"@D)"0D)
M/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$
M/2)X;7 N:6ED.F-C,3)E8V$S+38W.3<M-#1A,RTY8C)B+6,T,3(R-3,W9C(U
M."(@<W1%=G0Z=VAE;CTB,C Q-BTQ,"TR.%0P.#HT,#HT,RTP-#HP,"(@<W1%
M=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-#(#(P,34@*$UA
M8VEN=&]S:"DB('-T179T.F-H86YG960](B\B+SX-"@D)"0D\+W)D9CI397$^
M#0H)"0D\+WAM<$U-.DAI<W1O<GD^#0H)"0D\>&UP34TZ1&5R:79E9$9R;VT@
M<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI9#IF.&9E,39D-2TQ-F8U+30X8C<M
M868W8BTW,#4X.#@P,3AA,6(B('-T4F5F.F1O8W5M96YT240](GAM<"YD:60Z
M,# S93 U9#(M-CDY,BTT964U+6(Y9&8M861A,&9B-C9D83@W(B!S=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z,# S93 U9#(M-CDY,BTT964U
M+6(Y9&8M861A,&9B-C9D83@W(B\^#0H)"0D\<&AO=&]S:&]P.D1O8W5M96YT
M06YC97-T;W)S/@T*"0D)"3QR9&8Z0F%G/@T*"0D)"0D\<F1F.FQI/F%D;V)E
M.F1O8VED.G!H;W1O<VAO<#HP-C9A93<T."UD9#DY+3$Q-SDM.&0P."TX,6$Q
M.6(P969E.#0\+W)D9CIL:3X-"@D)"0D\+W)D9CI"86<^#0H)"0D\+W!H;W1O
M<VAO<#I$;V-U;65N=$%N8V5S=&]R<SX-"@D)/"]R9&8Z1&5S8W)I<'1I;VX^
M#0H)/"]R9&8Z4D1&/@T*/"]X.GAM<&UE=&$^#0H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_^(,6$E#0U]04D]&24Q%  $!
M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(               $  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
M10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R
M +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!
M,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1
M =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"
MH@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M S@#0P-/ UH#9@-R WX#B@.6
M Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^!(P$F@2H!+8$
MQ 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86
M!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'
MK >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$ DE"3H)3PED
M"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+
M:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.
M#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0
M"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C
M$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5
MFQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BABO
M&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:' (<
M*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_
M'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0C
MPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<
M* TH/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL
M;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2
M,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV
M-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK
M.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!
M*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P
M1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-
M2DV33=Q.)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J
M4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:
MIEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@5V"J8/QA3V&B
M8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/VB6:.QI
M0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@
M<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV^'=6=[-X$7AN>,QY
M*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K
M@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*
M9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1J)(1DGJ2XY--
MD[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<
M]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+
MIOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[  L'6P
MZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LN
MNZ>\(;R;O16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&
M1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\
MT;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=
M$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\
MZ4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.] [\SP6/#E\7+Q__*,\QGSI_0T],+U
M4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @("
M @(" @(" @(# P,# P,# P,#_]L 0P$! 0$! 0$! 0$! @(! @(# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\
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M>W/Z>QY[ZC_D+;5_TL4_ZLS]9(_W9'_3[>>/_%1N/^[EM?5.'\I_CY-[T_\
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M 2B#$3.B_I#GW+?L/S-#[.>UUCR1>V;7V\Q7-U*9(B$@;QYGD05D/B JK!6
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MYD_Y[I?^/=?3U]WG_IQ?LQ_XKMA_U:7K:(_EL?\ ,H?C7_X@7$?^X-'[Q_\
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M\BYID<ZQ2HH/*M;'O[O-CO'NU]Y;:N:ELVCL;.Y>_G\Q!;PQ-#:Q,PQK:0Q
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MK(6=_EZ]S^4;?EC>9_H!_B1N9XOD'AD9"1Z!U :G &M,4 )5_.@_[=_=F?\
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M2]0K -)FV*$#[$&3%WWBYQ_>E]_5C;Y0=OM7K,0?CF'X/]+#Y^LF*=F>V?\
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M2/\ [^+97O/+WC_Y4+<O^:]M_P!I$?4T_P!WO_XE'R=_TKMW_P"[5=]:R?\
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M,;JWCL[>VR]MY#:RMM2HPE/3;IP53D8\O0T68.7Q.19:K!UK51H9$>.-!7U
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M]1-!-63N7UL"3<RCN/-G*NQ1".]WBUB5!I$:,'84'PB./45]!4 #UZQAY?\
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MIIV9HB8G4 %0205!^*F:4X'UQY]<?DIOW([GVW\+_DG+U+WCB]B==?),;V[
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M\KAG;^6I\!6=F=S\./CCJ9F+,3_HCVI]6:Y/MCFT4YIYB X?73?]7&ZMM/\
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M3PTE'3P4M+31)#3TU-%'!3P0QJ%CBAAB58XHHU%@J@ #Z>VB2Q)8U)ZL
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..[KW7O?NO=>]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>spinrazarev.jpg
<TEXT>
begin 644 spinrazarev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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MJ$3")/2:_'?_ (77\6_^BB>*/_ V+_Y&K] ?V9_$^N^*/AL=4\2ZS>:SJ/\
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MWX5F:\TW3[N;_A*-?3S;JSMKB38K6>U=\L;MM7LN<#L*_->OTX_9'_Y).?\
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M_P#3'KE?GQ_P4G_Y22?\$*?^SK?VH/\ UCGX@U^@_P"V%_R37P[_ -CA8?\
MICURO@O%#_DW_%/_ &+)?^GJ)\YQ=_R36<?]@DO_ $N!^;]%9^K:OI.@:7J&
MMZ[JFFZ'HNDVD^H:MK.LW]KI>DZ786R&2YO]2U*^E@L[&RMXP7GN;J:*&->6
M<$@'RS1_VAO@9KWPPB^-.E?%GP'<?"F6:PM#XZD\06=IH=MJ6J7]CI>G:+?M
M=M!>:?XAOM2U33;&U\-WMG!K]Q<ZA91PZ;(+NW:3^!*6$Q=>'M:.&Q%:G[:G
MAO:4J-2I#ZQ6NZ-#FA%Q]M549>RI7YZG++DB[.W\WPH5JD>:G2JSBZD:2E"G
M*2]K.[A3O%->TG9\D/BE9\J=F>QT4VX=+-;A[N2*TCM%G>[FNYH;:WM([57>
MZFN[F=X[>U@M4BEDNKB>6."VBCDFGDCBC=U\KOOCI\&]-^'_ (;^*U[\3/",
M?PX\9I8OX-\90:C)J.C^,!JD-Y=::/":Z5;7VH^)GOK/3M0U"VBT+3]0FDTR
MPO=5$8TRTN+R*:6'Q%>WL*%:OS5(4H^QI5*KE5J1G*G2BH1E>I.-.I*$%>4H
MPFXIJ,K3"E5J6]G3J5+RC!<D)3O.2E*,%RIWE)1DXQ6K49-)I,]6HKQK5?VB
M?@+H;>$%U;XQ_#FS7Q]I>CZ[X.G_ .$GL;JQU[0/$5ZNF>'O$$&IV#7>EV'A
MW7]49=)T/Q#K5[I>B:QK&[1].U"YU2.6S3L?'OQ&\!_"W2(M>^(OBS1_!VDW
M&I1:-:76LR7(EU#69X;JYBTC2]-L;:^UC5]5:TL;Z];3M)TZ]O(K"PO[^>&.
MRLKNXAT>!QRE1@\'BU/$2G'#P>&K*=>4'RSC1CR<U64)>[)4U)QEH[/0MX?$
M)PBZ%92JMJG%TI\U1Q=I*FN6\W%Z-13:>CU.TK]./V1_^23G_L:O$/\ Z%95
M^6.@Z]H?BG1-)\2^&=9TKQ%X=U_3K36-"U[0]0M=6T;6=)U"%;BQU/2]3L99
M[._L;N!UEM[FVFDBD4\-N#*/U._9'_Y).?\ L:O$/_H5E7[!X#QE#CZ4)QE&
M<<ES*,HR3C*,HU\$I1E%V:DFFFFDTU9ZGW'ARG'B249)J2R_%IIIIIJIATTT
M]4T]&GJF?4%?)_Q%_:C@^'_C/6_"#^")]6;1I+-#J">((K-;C[7IUI?@BV;2
M;EHO+%V(B#/)N*;\J&VK]85^2O[1W_):?&__ %\:/_ZCFCU^]^,G%&><)\-Y
M?F&0XU8'%U\[P^#JU7AL+B>?#SP.85I4^3%T,13C>I0I2YXP4UR\JERRDG^C
M<<YOF&395AL3EU?ZO6J8^G1G/V5"MS4I8?$S<>6O3JP5Y4X/F45)6M>S:?T)
M_P -JVO_ $3>ZXZ?\53!_P#**C_AM6V_Z)O=?^%3!_\ **O@VBOYL_XC1XD?
M]%!'I_S*<D\O^I;Y/[V?E7^OG%/_ $,U_P"$67?_ #)Z_P!+7[R_X;5M1_S3
M>Z_\*F#_ .45'_#:MM_T3>Z_\*F#_P"45?!M%'_$:/$C_HH(]/\ F4Y)Y?\
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M?_*6ORL_:&-PWQC\:&[CABN#<:1YD=O-)/"O_%/Z3MV2R0V[OE-I8M"F&+*
M0 Q_7"OR5_:._P"2T^-_^OC1_P#U'-'K]7^D-_R1V5_]E)A?_59FQ]EXF_\
M(CPG_8TH_P#J+C/\_P $>(T4 $D  DD@  $DDG   R222   220 ,UY5IOQT
M^"NKI\0Y=,^+?PUO8?A+=367Q/G@\;>'&M_ ,]O;VMS.?%5P=1$.D6T27L$#
M7]PXT_\ M'S]'6Z.L6EY80?Q_2PV(KJ;H4*U94^3VCI4IU%3]K4C2I\[A%J'
MM*LHTX<UN><HPC>32/Q"%*I44G3ISFH<O,X0E)1YY*$>9Q3Y>:;48WMS2:BK
MMI'JM%>*:A^TE\ -+\(Z5X_O_C'X!@\%:YK=UX:TGQ.FLM>:7>^([&W-W>Z
MIT^VN[JVUFTM0+BYTR^M;2\@A>&22%5N+<RW;?\ : ^!=U:_#V]@^,'PX:T^
M+-M#>_#&=_%FEVR>/;*YOQI-K>^&1=S0/?6=YJ[)H]E=NL%M?:U)%HUE+<:K
M-%9ON\MS%7;P&-24YTVWA:_\2G&<JE/X/XE.-.I*I#XH1IS<DE"36GU7%?\
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M_P#!2?\ Y22?\$*?^SK?VH/_ %CGX@U^@_[87_)-?#O_ &.%A_Z8]<K\^/\
M@I/_ ,I)/^"%/_9UO[4'_K'/Q!K]!_VPO^2:^'?^QPL/_3'KE?!>*'_)O^*?
M^Q9+_P!/43YSB[_DFLX_[!)?^EP/S?HHHK_/P_FH**** "BBB@ K]./V1_\
MDDY_[&KQ#_Z%95^8]?IQ^R/_ ,DG/_8U>(?_ $*RK]I\!?\ DO'_ -B3,?\
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M32[;0?'4S^)?"OA_P%+KVI?&GXSZMXST#P!X6\0V?BK0O /@?QUJGCZ\\8>
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M_P# *U_^,U9M[.UM=_V:VM[??MW^1#%#OVYV[O*1-VW<<;LXR<8R: +%%%%
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M110 4444 %?U=?\ !&/_ ),ZD_[*]\1_YZ#7\HM?U=?\$8_^3.I/^RO?$?\
MGH-?H/AG_P E-_W3L5_Z=PI]+PG_ ,C9_P#8)7_]+HGZRG@$^@-?RX_\% ?V
MLOBI\.?VO?C'X,\/0>#WT?1+[PG'9-J>@7-Y?%;SP#X5U&;S[F/5[9)2)[N4
M(1!'MC"(=Q4L?ZCFZ'Z'^5?QK_\ !3[_ )/J^/?_ &$?!/\ ZK/P77V7B[A<
M-B^'L!3Q-&G7A'.:,XPJ14HJ:P.814DGU2E)7[-GM\:T:5?+,/"M3C4BL?3D
ME)72DL/B4GZV;7HSDO\ ANGXV_\ /KX!_P#"7N__ )?4?\-T_&W_ )]? /\
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M28Q)_P -7_M.<RABFS_ACWQ_YG"$,6\O?LY"[]N[Y<UL?\%J?[6_X9@^'?\
M:!TXQ_\ "[] V_8UNP^__A!?'6W=]H8KLV^9G'.=N.-U?-<8_P#),9S_ -@C
M_P#3E,\G/?\ D48[_KS_ .WP/YBJ**^]/V6?AMX#\=_#3XDV.H^!=%\1_$C7
M&&C^#Y_B"OQ T+PMK$;^)OAAI5AH7@#X@>$8[K2/"GC^'6_$,]OJT^OZ;>#9
MK_@\75S9^$9/%<5S_,^!P<\=7^KTYTZ<G3J5$ZCEROV<'+E2A&<G.;2C",8M
MRDTHIR:3_*Z%&6(J>SC*,9<LY)RO9\J;LN52;;T223;;25VTG\%X.,X./7M^
M=+@\<'GIP>?IZ_A7WG#\,?A?XB^&_BD:#HWP^NAX4^!'@#QYHEYI&N>)V_:#
MUGXKSZ[X"T;Q9X6\9^&Q=7EIIF@>*=;\1^(?#7A15\,V^A74$G@;4?AWJOB/
M4[K48[JKK&A?#*^\ ^&?B=H?PJ^'.KR>'?B=XC\,^//#'A.W^-.FZ#\-]$G\
M"7&K:#HWQLM=8NYO%_C74_!^I:?K'B77_$_@M=.T[4]*\.ZKH/B35;>;5M,M
MX.QY/5BKO$897I1K)<U5N5/VTJ-24%&E*514G'VLW34KT'[:-X*3CJ\'-;U*
M2O!37O3UCSN$G%*#<E"W/+E3?L_?2<5+E^%2".",'T-&#UQP>A]<=:^E_CMX
M"T)/%?PG/PTT[PO<Z=\3_AQX/U6QU3P5_;F@?#WQ5XLO?$^O^#=8U/POI7CN
M[?Q%X&T)=>TN'0M0L_%DMC;V^LZ=J^MZ?!9^'+_3T7O?VD/@78?"SX4_"V^T
MOP9+87&G^-_B?X#\6?$22\BG;XC:EHMA\/\ 4-.U^*UCU>]AL?#TVJ:EXRL?
M ]O:6=K,_A32['4-<8ZIJ+BL999B5#'5%R2IX"-*52I#GG"HJTZ4:?LI1@XR
MBX555]HW&DZ:YHU)<])5)>%JI8B2M*.'4)2E'FE&2J2@H\C46FFIJ?.[0Y%=
M2?-#F^*Z_JZ_X(Q_\F=2?]E>^(_\]!K^46OZI_\ @CA_:_\ PQZWV Z<(_\
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MY0IQ?-&ZIM2O*:DH1E=1BHRC:=^>34Y61ZGJ/P.\+66@:WHT?B'Q0WQ:\,_
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MS;_T.7BW_P ,E\>/_G94?\-L?LV_]#EXM_\ #)?'C_YV5?S?_J_GW_0DS?\
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M&<'BZ&9^TKX7$T8?5:T>>K0JTX<SG2:7-."C=I.RO=V=C^K=NA^A_E7\:_\
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MS66293BLSC06)EAW02HRJ.DI>VQ%*@[S4*C7*JCDO==VK:7NOMW_ (23P_\
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M2DCF=XS?32W019I9';U2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>stockperfgraph.jpg
<TEXT>
begin 644 stockperfgraph.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '@ F4# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_"-Z7Z7W_@XUK_Y8UO44 8/_  C>E^E]_P"#C6O_ )8T?\(WI?I??^#C6O\
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MES<>7]XY\O9NXW;L+B_110 4444 %%%% !1110 4444 %%%% !1110!^(/\
MP7>_Y-\_9#_[2E?\$Z/_ %H31Z_;N/[I_P!^3_T8U?B)_P %WO\ DWS]D/\
M[2E?\$Z/_6A-'K]NX_NG_?D_]&-0 ^BBB@ I#T_%?YBEI#T_%?YB@#D_ O\
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M8\2_^G7PI73US%S_ ,CGH_\ V+'B7_TZ^%*Z>@ HHHH **** "BBB@ HHHH
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M71_;MC_SPUG_ ,)SQ#_\JZ -FN8\;?\ (G>*O^Q>UC_TWW%7O[=L?^>&L_\
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M-_;MC_SPUG_PG/$/_P JZ/[=L?\ GAK/_A.>(?\ Y5T ;-%8W]NV/_/#6?\
MPG/$/_RKH_MVQ_YX:S_X3GB'_P"5= &S16-_;MC_ ,\-9_\ "<\0_P#RKH_M
MVQ_YX:S_ .$YXA_^5= &S16-_;MC_P \-9_\)SQ#_P#*NC^W;'_GAK/_ (3G
MB'_Y5T ;-<OX/_Y LG_8>\6_^I7K57_[=L?^>&L_^$YXA_\ E77->$M;LX]'
MD5H=7)_MSQ4V4T#79%P_BG67 W1Z:R[@& =<[HWW1N%=64 '?45C?V[8_P#/
M#6?_  G/$/\ \JZ/[=L?^>&L_P#A.>(?_E70!LT5C?V[8_\ /#6?_"<\0_\
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MXA_Z"FC?^"*^_P#FCH V:*QO(\0_]!31O_!%??\ S1T>1XA_Z"FC?^"*^_\
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M]2TA5_MSQ4,/HEY(VX>*=9#G<NOQC:S[F1=N40JA:0J9&]0[#OJ*QO(\0_\
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M]>"?^C9:ZVN2\"_\BEH7_7@G_HV6NMH **** "BBB@ HHHH **** .2\3_\
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M5.3@X-_U; Y_,C\CBBD'3\6_F:6OY6/Z76J3[I!1110,**** "BBB@ HHHH
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M1DDYSTKJO^$8\/?] >P_\!T_PH W,CW_ "/^%&1[_D?\*P_^$8\/?] >P_\
M =/\*/\ A&/#W_0'L/\ P'3_  H W,CW_(_X49'O^1_PK#_X1CP]_P! >P_\
M!T_PH_X1CP]_T![#_P !T_PH W,CW_(_X49'O^1_PK#_ .$8\/?] >P_\!T_
MPH_X1CP]_P! >P_\!T_PH W,CW_(_P"%&1[_ )'_  K#_P"$8\/?] >P_P#
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M$GA+XG>$@A(:36/AYXCU"S4]MVJ^$[;Q-I*@GC<;X*>N<%2<QOV@O!NIEH_
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MN_\ @M/_ ,?K>P/0?D*,#T'Y"@#!_MT_] ?7?_!:?_C]']NG_H#Z[_X+3_\
M'ZWL#T'Y"C ]!^0H P?[=/\ T!]=_P#!:?\ X_1_;I_Z ^N_^"T__'ZWL#T'
MY"C ]!^0H P?[=/_ $!]=_\ !:?_ (_1_;I_Z ^N_P#@M/\ \?K>P/0?D*,#
MT'Y"@#SGQ'K)>Z\*G^R=;7R_$]M)AM.P7VZ3K0VI^_.Y_FSMX^56.>,5U']N
MG_H#Z[_X+3_\?JAXG ^U^$>!_P C7:=O^H1KE=;@>@_(4 8/]NG_ * ^N_\
M@M/_ ,?H_MT_] ?7?_!:?_C];V!Z#\A1@>@_(4 8/]NG_H#Z[_X+3_\ 'Z/[
M=/\ T!]=_P#!:?\ X_6]@>@_(48'H/R% &#_ &Z?^@/KO_@M/_Q^C^W3_P!
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M5 554        8  Z  < #@#@<5S'@\ Z-)D _\ $^\6=1_U->M4 6O[=/\
MT!]=_P#!:?\ X_1_;I_Z ^N_^"T__'ZWL#T'Y"C ]!^0H P?[=/_ $!]=_\
M!:?_ (_1_;I_Z ^N_P#@M/\ \?K>P/0?D*,#T'Y"@"A8WYO?-S9W]IY6S_C]
MMOL_F;]W^J_>/OV[?GZ;<KUSQH48 Z "B@ HHHH **** "BBB@ HHHH ****
M "BBB@#\0?\ @N]_R;Y^R'_VE*_X)T?^M":/7[=Q_=/^_)_Z,:OQ$_X+O?\
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MS3-1MK6_M+FVBZZ@#\0?^"[W_)OG[(?_ &E*_P""='_K0FCU^W<?W3_OR?\
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MP9I/Q=T'XAZ[?:=H6E:/XS\,^&M,BU"2]O1;M=Z??:=XPU6WOH+$3I<ZA;P
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MAO3ZYX/\$>%? 6D+H?A+1K71]/\ ->YG$(DEN]0O92#<:EJ^HW+S:AK&JW3
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MW[.&F>,+N.V!""2Z\:_#OPU)'"D#W,0(<I^B_P %OV3_ -F/X?:)X<UCP%\
M/A#X)U.WEL=:BOO"G@+P]H-VNK6-P\MEJ+7&G64$LEY:2H);:>5W>W?)A*9Q
M7U=@')QR1C(X./J.?UKV.,>-,#Q'B,!5PF'SG!+#4*E.K4P^=9CD^*YIU%-*
MC/*L>L-.*2UEB\-B)*6D.6-[_*<(>&6(R#"8NCC\QPV*JUL1"K2I1H2KY>XQ
MI*$GB,/5CAZ\YW7NNCBJ*Y;)W:3/S8^"-I^RQ\69B_P)_:B\*>*=9C5C=:/X
M/L?@#'XQTQX@-Z:QX7NOAVOC/1[Q-H::/5]/M;O(#2J&&:^K5^"VK$#S/C?\
M97D(Y*:WX>L$..!Y=EI_ANSLX$4858[>UBC 'W-Q8FQ\5_V9?V>_CH-_Q?\
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MX.W<>2:]'KDM!_Y&#QK_ -A/1_\ U&]*H N_V?K?_0>_\I-E_P#'*/[.UO\
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M=Q_=/^_)_P"C&K\1/^"[W_)OG[(?_:4K_@G1_P"M":/7[=Q_=/\ OR?^C&H
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M1^W?VK&'^\X',\,W:T7@JF,W[SRQX^E"V[YYQL?:%%?%O_#='PMT.*1_BGX
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M8[&XN-*&+QF*Q4:$>2A'$8BK6C1AHN2DJDY*G&R7NP45HM-$<>%R[+\#*M/
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M )Z*@^U6W_/Q!_W^C_\ BJ/M5M_S\0?]_H__ (J@">BH/M5M_P _$'_?Z/\
M^*H^U6W_ #\0?]_H_P#XJ@">N7\'_P#(%D_[#WBW_P!2O6JZ'[5;?\_$'_?Z
M/_XJN8\(7%NNC2!KB '^WO%AP98^A\5:T0?O="""#W!R* .NHJ#[5;?\_$'_
M '^C_P#BJ/M5M_S\0?\ ?Z/_ .*H GHJ#[5;?\_$'_?Z/_XJC[5;?\_$'_?Z
M/_XJ@">BHTEBDSY<D<F,9V.KXSG&=I.,X.,]<&I* "BBB@ HHHH **** "@C
M/K^!QT.?_P!8Z'H01Q110!^>>I?\$XOA3XK\4?%G5OB3\0?C%\3O#/Q'\->)
M?"WASP-XR\:MJ&F_"C3_ !GX=D\+^*I_!7B+[$OC2_OKS1W_ ++T>X\:^(?%
M$?AG10=$TRW:P.U>EOOV%?#.M^);SXF>*?C3\:O%/QU@;P(O@GXZWTOPHTCQ
MU\.++X;WOQ(N/#.E>%M&\)?"KPY\.+_3;BR^+?Q%T3Q7;>,O _BD^+]$\7:M
MI6KR&R&GP6'W/10!Y3\&_@_X9^"7@UO"'AN\UO6I+_Q'XK\:>)_%7BFZLK_Q
M7XT\;>.?$%_XH\7^+O$MYING:1IDFK:YK6HW$YM=(TC2-"TBQ2QT/P_I&DZ%
MIFFZ;:^G7=I:W]K<V5[;07EG>036MW:74,=Q;7-M<1M#<6]Q!,KPSP3PN\4T
M,J/'+&[(ZLC$&Q10!_/G_P %M_@G\&_!/P._9#UGP=\)OAEX4U@_\%0/^">%
MC_:OAOX?^$-#U/[%>?M!:(EW:?VAI>BVEV+:Y2-$N+<3>3-&/+E1T9E/[YKH
M.B,"3H^E$EY,G^S;+)/F-R?W')/<GDG).22:_%K_ (+O?\F^?LA_]I2O^"='
M_K0FCU^W<?W3_OR?^C&H R_[ T/_ * VE?\ @MLO_C%']@:'_P! ;2O_  6V
M7_QBM>B@#(_L#0_^@-I7_@MLO_C%(= T/_H#:5U'_,-LO4?],*V*0]/Q7^8H
M \_\$Z)HTOA70Y)-)TMW:Q0LS:?9LS'S)1EF,!)/'4DUU7]@:'_T!M*_\%ME
M_P#&*R? O_(I:%_UX)_Z-EKK: ,C^P-#_P"@-I7_ (+;+_XQ1_8&A_\ 0&TK
M_P %ME_\8K7HH R/[ T/_H#:5_X+;+_XQ1_8&A_] ;2O_!;9?_&*UZ* ,C^P
M-#_Z VE?^"VR_P#C%']@:'_T!M*_\%ME_P#&*UZ* ,C^P-#_ .@-I7_@MLO_
M (Q1_8&A_P#0&TK_ ,%ME_\ &*UZ* //O$NB:,EUX4":3I:B3Q1:QN!I]F-Z
M'2=:8JV(!N7<JMM.1N4'&0#75?V!H?\ T!M*_P#!;9?_ !BLGQ/_ ,??A'_L
M:[3_ --&N5UM &1_8&A_] ;2O_!;9?\ QBC^P-#_ .@-I7_@MLO_ (Q6O10!
MD?V!H?\ T!M*_P#!;9?_ !BC^P-#_P"@-I7_ (+;+_XQ6O10!D?V!H?_ $!M
M*_\ !;9?_&*/[ T/_H#:5_X+;+_XQ6O10!D?V!H?_0&TK_P6V7_QBC^P-#_Z
M VE?^"VR_P#C%:]% &1_8&A_] ;2O_!;9?\ QBN4T/0]%;7O&2G2-+*QZEI(
M0'3K+"A_#VENP4>1A079F(  +,S8R2:]"KDM!_Y&#QK_ -A/1_\ U&]*H UO
M[ T/_H#:5_X+;+_XQ1_8&A_] ;2O_!;9?_&*UZ* ,C^P-#_Z VE?^"VR_P#C
M%']@:'_T!M*_\%ME_P#&*UZ* ,C^P-#_ .@-I7_@MLO_ (Q1_8&A_P#0&TK_
M ,%ME_\ &*UZ* ,C^P-#_P"@-I7_ (+;+_XQ1_8&A_\ 0&TK_P %ME_\8K7H
MH R/[ T/_H#:5_X+;+_XQ7-^,M#T:+PCXGDCTC2T=- U=D==.L@RLMA.0RL(
M 593RK @J0""" :[NN8\;?\ (G>*O^Q>UC_TWW% %\:!H>!_Q)M*Z#_F&V7_
M ,8I?[ T/_H#:5_X+;+_ .,5K+T'T'\J6@#(_L#0_P#H#:5_X+;+_P",4?V!
MH?\ T!M*_P#!;9?_ !BM>B@#(_L#0_\ H#:5_P""VR_^,4?V!H?_ $!M*_\
M!;9?_&*UZ* ,C^P-#_Z VE?^"VR_^,4?V!H?_0&TK_P6V7_QBM>B@#(_L#0_
M^@-I7_@MLO\ XQ1_8&A_] ;2O_!;9?\ QBM>B@#A+C0]&'B_2(AI.EB-O#?B
M.1D&G604NNJ>%E5B/(P657<*3DJ'8+C<V>D_L#0_^@-I7_@MLO\ XQ6?<_\
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M %*]:H T?[ T/_H#:5_X+;+_ .,4?V!H?_0&TK_P6V7_ ,8K7HH R/[ T/\
MZ VE?^"VR_\ C%']@:'_ - ;2O\ P6V7_P 8K7HH IVNGV-CYGV*RM+3S=OF
M?9;:"W\S9G9O\F--^W<VW=G;DXQDYN444 %%%% !1110 4444 %%%% !1110
M 4444 ?B#_P7>_Y-\_9#_P"TI7_!.C_UH31Z_;N/[I_WY/\ T8U?B)_P7>_Y
M-\_9#_[2E?\ !.C_ -:$T>OV[C^Z?]^3_P!&-0 ^BBB@ I#T_%?YBEI#T_%?
MYB@#D_ O_(I:%_UX)_Z-EKK:Y+P+_P BEH7_ %X)_P"C9:ZV@ HHHH ****
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MP?M7?\%G@,?\.COV=>K'_E*/H?\ $Q/?]DP^O/;/0 <  _96BOQK_P"&K_\
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M!^RE%?C7_P -7_\ !9__ *1'?LZ_^+1]"_\ H2Z/^&K_ /@L_P#](COV=?\
MQ:/H7_T)= '[*5S'C;_D3O%7_8O:Q_Z;[BOR2_X:O_X+/_\ 2([]G7_Q:/H7
M_P!"77FOQG_;A_X*\_#KX0_%+Q_XT_X),_L_:?X0\#_#OQGXN\4WUC_P4ZT/
M4[ZS\.^'/#NHZQK5U9::/V5;)M1O(-.L[B6UT]+NW>]N%CM4F1Y5- '[NKT'
MT'\J6OQJ7]K#_@L\54C_ ()'?LZ$$ @C_@J/H1!!'&"/V3""/<$CW-+_ ,-7
M_P#!9_\ Z1'?LZ_^+1]"_P#H2Z /V4HK\:_^&K_^"S__ $B._9U_\6CZ%_\
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M<^MZ?X5FUK3(_$E]HUM*T%QJUGH+W2ZM=:9;SJT4^H06<EG#(K1R3*RD#HZ
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M_"+_ !;\:>)_'][HWCVXO?A-K7CKPQXUO_"=_P#%[7]8\ W.H^&_ ][^YE(
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MV;[5_:UY]I^S>;^]^S^?YGV?S?WOD[/,^?=7VS^P(?B<?'_CS_A5Y\!G5?\
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M:^(/%P\0V">8>B?TL[ER1N7(!)&1D =2?0#(SGUK*LM?T+4K[6-,T[6M)O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?'C7O!OQTE^.?[/_ ,3/C%XG_:+_ &3-7^ 7[/-Z_P ./!]UXH\-WNB?%O\
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M?- U;4]"UGQU+IVKZ-J%YI6J6%QX5\8B>SU"PN)+6[MI0N@,NZ*:)UW(S1N
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MI!-)<:9=7>D7]CJMK;WL<$UQIMY:7T2/:W,,K_B=\2IOVX-,^+G[2UE\)_\
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M9/!EE\7M7_:$OOB[HWB33[XGXBV6FR^ ;7P%,OPYDUV6;N/^"AGP\^(WB/\
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MB?X57/PW\2_$73EUC2O&OARR_9I>@Z]!][K^/OZ]O2@!:*** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>tecfidera.jpg
<TEXT>
begin 644 tecfidera.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !2 7(# 2(  A$! Q$!_\0
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M.BJO:4XJ75HYW5]=U/Q7JBF>1W:1]L,(.%3/8"NMM/A',]INNM2BCG(SL7D
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>tecfiderarev.jpg
<TEXT>
begin 644 tecfiderarev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3\>^*/^$(\$>,/
M&7V!]4_X13PMXB\2_P!F1S?9Y-0_L#1K[5_L,<_E3^2]W]C^SK+Y,OEM*'\J
M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
M]4M/@_J=QXYT_P 6^%[+2/B9!X;U6\\5>"/%GAJ.R74] U>.Q]7G_;:_9LLK
MKQ[#J?C^YTBS^'6G?$+5-8\0ZOX*\?Z9X2UNV^$_B.W\'?$N'X>>+KWPM#X=
M^*6J>!?%]Y9>$O$NB_#?4?%.KZ?XIO+?P\+*;5'^SCYZU+_@FWHSZ5XDT#P]
M\;_'WAG0?B-#<6?Q6TRT\.^"-0_X3.RTK]HGXH_M(> 8[2\U+3)[WPO<>%O$
M_P 7?%WA;4KG3)YO^$K\&365G>0Z9K=A::[!C:7_ ,$I/@7I.J_%FYTZYTK1
M;;Q\WQ!U'PIK/AKX0_!G0OBKX"\2_$7XJ:9\:KOQ!+\:(_!EUX^\=R^$OB%H
M]A=^"]+\67TNDG04;P_X_M/B'"EG=60!]1_!S]J/1OC+9?M%ZOHGA3Q#H^E?
M 7Q]'X'6+Q1I/B;P?XFUZ4? GX6?&:\EUKP9XS\->'/$O@C4;.;XD/X:?1]6
MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M\-V/B6YTC0)M=AT6]EETXZHVC::+R2VDF2UCC9,]W0 4444 %%(64$ D G@
MGD_YZ?4@=2*6@ HI"RC@L ?0D#J0!^9('U('6EH **,CGGIU]OK1_G_/Y&@
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M/^(#<6?]#/A[_P *<R\O^I7YO[O,/^(V<,?]"W/_ /PGR[_YY_U9^5_Z*@0
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M=V$&I?V=IYOX;6:**]-A9&Z2;[);^7T_V5FG_0MQ_P#X1XC_ .5G-_:>6_\
M0PP/_A70_P#EGFOO/@C]KCQ7#XL\3:/;? S]I?QA=_'?X@_#WP/K7[._@CX=
M_%?3O#WPG^&^C?\ "874NL?M.?&"UT6^D\.>/?A-K,=Q;:%>VOQ0B\6:'XQM
MO#7_  @GP3\-R^/M=UG5$ZDZ)I%E^VI\3/%GAOQ9^T1J&B_LZ_"NY^+7Q/\
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M]"\2^']:MK;Q!K>ER:=J5QPVC?L)?"7PY\(?"OP&\/>)?B5H/PE\ _##X4>
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MO#/?_J/:?7]7 Z?BW\S7\\_2 _WCA?\ Z]9O_P"E98?NO@;_  N)/^OF5_\
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M_P#*23_@A3_V=;^U!_ZQS\0:P/\ @X"DDC_9"^%ICDDC)_:&\,*3'(\;$?\
M"NOB2<$HRDC(!P21D D9 K:_X*6QM+_P4@_X(5(DTD#']J[]ITB6'RO,7;^Q
MYX_<@":*:,API1PT;91F"E6PR\C_ ,%^+&>U_9%^%KRZIJ%\I_:%\-*(KS[
M8U+?#OXC$.IM;"TDW*%*J&D9 ';*,2"OZ5X._P#)SN#/^QQ#_P!,5M/GM\S\
M[\6?^3<<6_\ 8K?_ *D4#^1_[3<_\_5U_P"!,_\ \<H^TW/_ #]77_@3/_\
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M[H2I5@#E2#@C_0O7H?\ >?\ ]"-?YKWPU&[XE?#=0Q4M\1OA^H9<;E)\9:&
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M^"%/_9UO[4'_ *QS\0:YW_@X%_Y-!^%G_9P_A?\ ]5S\2:Z+_@I/_P I)/\
M@A3_ -G6_M0?^L<_$&N=_P"#@7_DT'X6?]G#^%__ %7/Q)K]*\'O^3G<&?\
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M$/\ UXR/_P!4.6'^@W@+_P FOR#_ +",[_\ 5WF 4445^*'[$%%%% !1110
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M)4HU?9\OM(TDJ:GS*"4$C]N&Z'Z'^5?PD_\ !77_ )2*?M(_]A/X??\ JIO
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MK_2#:_UI7D5-##HLLH1_[6LTWJ)&"ML:(LNX8.TDE<X/(K^8OI7_ .]\$?\
M7CB#_P!+R7KM_6FQ_1_T7O\ =>,_^O\ D?\ Z;S3^O\ AT?&W_!3/_DP7]K#
M_LC'BO\ ]%V]?P)/C>V61!O.7D+"- 6P7D*)(XC09>0I'(X16*1R/M1O[U?^
M"E-YJLO[!?[5Z7.D"VB_X4QXIS+_ &C;3XS]D5OW<<:L=J,\G7G9M'S,*_@M
M61X9UFC8++#,LT3%(Y LD4@DC8QRI)%(%=5)CECDBD *2QO&S(WU?T6/^21X
MBMO_ *QRM?17_LO+[:V>GFD_1VL?+_29_P"2LR"^W^KZO;5V_M'&7TNM?)M>
MJ3N???QL_9/^&'P?N_@2UUXR^+^H^&?B-IES_:OC?1_AUX7\1^$_'E]#?>+8
M--N?@IXIT?QS=^%)Y_$L^E>&].L_#/B[5K;4- T;Q-I7CK7)_+77_"^D^#?M
M"?!2R^#'C/P9X;6X\6:*/%_@'PKXWU+0/B/8:.OB[X>/XCU36--?2/$]UX(G
MU/PYX@2&RTJ'Q/9ZGX7/FW.B:M:6%YI&G^(K6]TY>S\3_M?>(/$VC^"_#<GP
MB^!MCX6T&QD7QCX/M? LT7A/XE:U*?B+"-8U;2+?6+<^$1IUG\3O%,WAVS^'
MEUX6;PQXCU2_\2:+>6LC:5I^B\'KOQMTKQ5I:Z+KGPJ\#0:!X3^'5G\/O@]X
M6T.3Q9;Z)\,XY?BA:_$?Q/KEMJ.I>*]1\4ZUK'BEKKQ=I>J76LZQJ(\KQ7,-
M*@T---L'@_:<IH\6X>>!EFE6MBHPEBZ>-49Y?>M2KXNLL+6C%."HUJ"G1G4P
MZ]K3J8.G&K3Q>$KTJN4XW\@S2KPK7CC(Y;3HX5SCA*F$<HX]^QJ4L+0>)HR<
ME-U*5:4*T(UW[*I'%U'2J8;$T:E/,\'[AX6_9>^%'Q)MK#7OAQX[^+>H>%[3
MQM\2?"%R=:\ ^&D\6?%R'X8_"C7_ (IZKJO[/OAK3M;\[4]4OTT"W\-/X*\5
M27&J>&=0\7>$;C5M6OKZXU'P[;X&H_LK6%IXL^$VH7NK^-_ WP=^(WP\@^*W
MB'6OB/H.DZ9\0_AYX3M/B)>?##4])U'1K::UT;7?%7B7Q=;Z7I?PIBBCT9/&
MDGB[P[<76DZ5:6VL30\MXV_:A/C3Q9X,\7R?!+X3:%<> S%8^'/#^CZE\6_^
M$+TCPK;V-]:6O@WPUX5N?B4UCX&TFRN[X^(K#5_ \GA_QA:^+K:W\5/XDN=<
M:[O+NK>?M>?'!/$5OK7A3Q3=?#_2[/3_  [I,'A#PQ?ZQJ.A7.F^&?$.K^++
M-=?OO&^I>+O%'BS5[_Q-XA\1:[K7B?Q+K^H^(M1U+7+Z5=0M8$L;:SQIX7C5
MNFZ.)=)3P]2,Z695, WA^:>+A*-/%X&EBE5QEJF#Q-&O/ /"PEAJE*5&%*JZ
M#UJ8G@^*G&KAE5<,1"5.KEU/')5U&.$FG/"XVKAO98-NEB\/6H0QRQ4HXF%6
M-:56E&LJ&F? _2KSX_\ Q2^%=YXDU*T\&_"+4?CKJ/BKQ39Z?I^J>(6\#_ G
M_A)[K6[G2]*^U6.D7GBK6;;P_;Z9IUI+>6NDP:SJL<]W(FFVD\9Y3XL?#WP[
MX2L?AIXP\$ZIXAU/P+\6/!^I^)_#\/B^UTBU\7:!J/AGQ?K?@7Q?X8\0-X?D
M?0M2FTK7M#-UIFNZ3'9VFLZ+JFGSOINFWT-[:)UVH?M/>-]5^).M?%S4_#O@
M?4_'WBCQG\0_$?B_6M2TS5[R/Q=X4^)?AU_"GB#X0>(-,.N0Z=<?#*#0;G4;
M+2K:SM[#Q=;/J4UY-XMN+VTTV>S\T^(OQ(U#XAS^&86T+P_X1\,^"/#:^$O!
M/@OPJNL'0?#6B-JVJ>(=06&[\1ZOK_B+5]5USQ%K6K:[KVNZ[K6HZGJFH7OS
MRQ6=K8V=K[6$I\0/&Y?4Q<O9T(8*A#'4U5PU2C.O"AC(8ODY:4:\ZU?&2RZM
MAZ]J5)82ABJ<Z.&K34*_D8J>1+!X^&%CSUYXRO/!3=/$4ZT*$ZV"GA>?FJ2H
MQI4L+',*.(HWJ57BJV&J0JXBC#GH?OG_ ,&[?_)0OVIO^Q+^$?\ ZD/C^OZH
M*_E2_P"#>B>\@\?_ +4IM+(7C'P5\)25-U%;8(\1^.@!NE5@<JTAST'EX/+K
MC^IVPN+ZX\W[;8"QV;/+Q>0W?F[MV_\ U*)Y>S"_>SNW<8VFOX'^D)_R=;B+
M_KQD?_J@RS[_ )']R> J_P"-7Y!YXC.GNG_S.\P[;>CU-"BBBOQ0_8@HHHH
M**** "BBB@!NQ,[MJ[NN=HSGUSC-.HHH _$#_@I/_P I)/\ @A3_ -G6_M0?
M^L<_$&N=_P"#@7_DT'X6?]G#^%__ %7/Q)KHO^"D_P#RDD_X(4_]G6_M0?\
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MN<>7_4'YK[UW/?Z*\ _X:@^"_P#T&_&/_AF_C7_\[NC_ (:@^"__ $&_&/\
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MWH#*1N!!7KD$8QZYZ4 )M'JW_?;_ /Q5&T>K?]]O_P#%4I(! ) )X ) )/7
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M!'@SP_X9NM3MK222:SL;J?2+"UE;3;&>>XGL=+1DTVRFN;F:TM(9;B9W]?H
M**** "BBB@!#T/..#SZ>_P"%?EK\2O%7QP\#_M!7E[\+?BS\2/CMXC\,ZA\2
M?'WQD^$=CX<\+67P-^''P.M/A7XWUCX9?"Z8V>CSZQ8_'7Q#XXB^'#>%)K;Q
MM>?$/Q=;ZIXK\8^(?#6E_"E=%T6Q_4NOFG1OV-_V6/#OQ2NOC9H'P"^%FB?%
MF^\7:WX_OOB!I/A'3=/\3WOC?Q+!+;>(?%UYJ5K'%)=^)-;MYY(=6UFX62_O
MX]B7,\BQ1! #X<^!GC?X^ZIX@^!_AKPQ^TI/\1=5_:J_8NO_ -HG7_$OCOPQ
MX:\7^'OA+X]T_P 2_ 2VA\6> /"WAD?#^ZTWP%XZT?XN^-="\)^!-9UC5-)L
M=9^'/A[4 ;MK;XAMXB+CQEXV\7?\$Q_@-\9/&'Q8^-TOQ5C^&GPQN;/5_AWX
MUT_X;>)?C#\8OB//I'PR\":%XVU/0O#/]G6^E^,_B+XL\/C6%T'0]+LM+DO)
MM2TO38X;&VL!]\K^RG^S7'H'Q%\+VWP*^%5CX?\ BY<6UU\3=)TSP1H.E6?C
MJ>SU%]8M'\3)IEE:-J@M=7EN-6MXYW,,&J7E_J,4:WFH7LUP_P"'/[+'[./P
MB\(MX!^&7P2^&?@;P0?%WASQZOA+PUX2TK3/#D/C/P?J&C:MX4\36VCPP?8;
M76?#>J^'M"U+0[ZVABETN_TG3[RS,-Q:Q2* =M\(/!FO?#OX7^ O _BGQYXD
M^*'B;PKX5T;1/$'Q#\7RVLWB3QIK=A9QQ:KXDU=K*UL[1;G5;X3W0B@MHD@@
M>&WPQB+OZ/110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXGM+JWM(Y?%WAS5M+%CK^@>,M2MM4ET[2/J>@ K*U+7=%T8PC5]7TO2S<!S
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MH>%]!U@)! MQH?A]UOM%MOGCXT_M[_'X_#7XI:W\-_#/PR\(IXS\(_MR:+\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>tysabri.jpg
<TEXT>
begin 644 tysabri.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !W -@# 2(  A$! Q$!_\0
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M)T!2444 +2444 +2444 +2444 +1110 E+110 E+110 4E%% !1110 M%%%
M!4%X\J6<S6Z!Y@AV*3C)[444UN)['/>!M->ST^>XG&)KB0YYS@+D?SS1116E
..>3E4DV8X:"IT8Q78_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>tysabrirev.jpg
<TEXT>
begin 644 tysabrirev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M237FAZ!<Z;K6MW.N73&UFO\ ^W="T'P?HUAK7B76K^_:TTO0-;^?]6_X)_\
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MX^_\&L/_ ,AT?\-2?M&?]%I\??\ @UA_^0Z\%HH_U=X?_P"A#DO_ (:L!_\
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MLPQ5'^RL;/V6)QN)KT^>-;!J,N2K5G'FBI-)VNN9ZZN_Z!F6, G>G S]]?\
M&OR\^/\ ^WCX\^$/Q>\9?#K1_ OA#5]-\-SZ5#;:CJ6H:W#?7(O]!TK5I3/%
M:-]G0QSW\D*"/@QQHS?.6K]+3X>T#!_XD>C]#_S#++_XQ7\\O[:D$%M^TY\4
MH+:&*W@CO/#FR&"-(HDW>#?#K-LCC547<S,QP!EB2>237Y-X/Y#E'$/$>/P>
M<X&GC\-2R2OB:=&K.M",:\,?EU*-1.C4I2NJ=:I%)R<;3;:NDU^H>*V=YKD6
M08'%91C:N!Q%7.*.'J5:4:4W*C+!XZK*FU6IU(V=2E3E=14KQT:5[_17_#SK
MXG_]$S\!?^#7Q)_\51_P\Z^)_P#T3/P%_P"#7Q)_\57YH45_1W_$,> O^B;P
M?_@_'_\ S7Y+[C\"_P"(B<;?]%#B_P#P3@?+_J%\OZLK?I?_ ,/.OB?_ -$S
M\!?^#7Q)_P#%4?\ #SKXG_\ 1,_ 7_@U\2?_ !5?FA11_P 0QX"_Z)O!_P#@
M_'__ #7Y+[@_XB)QM_T4.+_\$X'R_P"H7R_JRM^E_P#P\Z^)_P#T3/P%_P"#
M7Q)_\51_P\Z^)_\ T3/P%_X-?$G_ ,57YH44?\0QX"_Z)O!_^#\?_P#-?DON
M#_B(G&W_ $4.+_\ !.!\O^H7R_JRM^H.B_\ !2WXEZGK6C:9+\-_ D46IZQI
M.FRRIJGB(R11:AJ-K9221AFVF2-)VD0-\I90&X)K]E/,3D%T!!((W $8)'//
M7CFOY2?"8#>*_"JL RMXI\-*RD AE;7-/#*0>"&!((/!!(/%?U0_\(_H!R3H
M>D$EF))TVR))+$DDF#))/4U^#^,W#61<.5^'XY)EM'+XXNGF3Q*I3KS]JZ$L
M J3E[>K5MR*K42Y>7XG>]E;]I\).(<ZS^EGKSC,*N/>%GEZP[JPH0]FJL<9[
M2WL:5*_/[.G?F3MRJUM;^&_M9NA_9M^,X#J3_P ('K/1@?X8AV/J0/J:_FR;
MJ?J?YU_1Y^U;HNC6W[.7QDFMM)TRWFC\":PR2P6%K%*C 1$,DD<2NI! ((((
M(!'(K^<-NI^I_G7WO@)_R3N<?]CJ7_J#@CXGQM_Y*#*O^Q0O_4S$B4445^['
MXP%%%% !1110!^IO_!+X@>)OC"20!_8/@KJ0/^8GXC'?W('U(K]B@RMG:RMC
MK@@X^N*_&S_@F/86-]XE^+RWMG:7BQZ#X,*+=6\-PJ%M3\1;B@F1PI;:N[&,
M[5ST&/V(M-.T^P\S[#8V=EYNWS?LEK!;>9LW;/,\E$W[-S;=V=NYL8R<_P 7
M>,7_ "7^<_\ 7K*O_51@#^NO"C_DALI_Z_9G_P"K/%ERBBBOS _1@HHHH **
M** "BBB@ HHHH _$#_@I/_RDD_X(4_\ 9UO[4'_K'/Q!KZE_X*6_\D-\&_\
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MQ4FU;5&EX2_Y&WPG_P!C5X9_]/NGU_5N.GXM_,U_*/X4(7Q7X58]%\4>&V;
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MZ/\ ^9^C_ANB+_HF$O\ X5T?_P S]'^K^<?] 4O_  ?AO_EW]6?E<_UAR?\
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MS@G&WS<YYSY>.-]?U.V']J?O?[2^P?P>3]B-T?[WF>9]I _V-FS_ &MW:O\
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M_P"JY^)-=%_P4G_Y22?\$*?^SK?VH/\ UCGX@USO_!P+_P F@_"S_LX?PO\
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MO\U_X9_\E+^&O_92/A]_ZF>AU_I0+T/^\_\ Z&U?QE]*_P#WO@C_ *\<0?\
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M ,G6XA_Z\9'_ .J'+#_0;P%_Y-?D'_81G?\ ZN\P"BBBOQ0_8@HHHH ****
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M]ER74YRFG=2E)W;_ &*;2KW!_P"*CUKH?^6.@>G_ & J_A>_X*W1O#_P4/\
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M^&#+/ZZG^@W@+_R:_(/^PC.O_5WF!H4445^*'[$%%%% !1110 4444 %%%%
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M X#_ .BVX1_\23)O_FT_S^_U#XY_Z(SBS_Q'<X_^8_-?>>_T5X!_PU!\%_\
MH-^,?_#-_&O_ .=W4(_:G^"!G:U'B+Q4;I84N6MA\(OC,;E;:21X4N6MA\/O
M/6V>:.2%+AHQ \T<D*2-)&ZJ?\1 X#_Z+;A'_P 23)O_ )M#_4/CG_HC.*__
M !'<X_\ F,^A:*\ _P"&H/@O_P!!OQC_ .&;^-?_ ,[NC_AJ#X+_ /0;\8_^
M&;^-?_SNZ/\ B(' ?_1;<(_^))DW_P VA_J'QS_T1G%G_B.YQ_\ ,?FOO/?Z
M_LS_ ."#7_)B\G_9;_BG_P"A>':_A-_X:@^"_P#T&_&/_AF_C7_\[NOZ;_\
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M,K6DF_?J*\ _X:@^"_\ T&_&/_AF_C7_ /.[H_X:@^"__0;\8_\ AF_C7_\
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MHHH **** "BBB@!" <9SQZ,P_/!&?QI-H]6_[[?_ .*IU% #=H]6_P"^W_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]X,\/V/@KQ.;"TTOP]HLEAKFFZ=HWAVXL;_3_#^B:CK;:C+K=WI^@7EOZ?X
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M4T5-&6R37HM+8Z3%JR1+?1:.?[(CG73,6E?1%% 'GVC?";X8>'?%-MXW\/\
MP]\%Z'XPL_ VG?#&U\2Z-X9T?2]:M_AUH]W'?Z/X%BU"PL[>X3PEI%[&MSI/
MA]7&EZ7*7:PM;822!\2+X _ V#Q%X^\6P_!_X91>*?BIHVH>'?B7XBC\#>&H
M];\?Z#JT$5KJVC>,-4335O?$6F:K;6]K#JEEJDUS!J4=I:+?I<"UMO*]<HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>vumerity-logoa03.jpg
<TEXT>
begin 644 vumerity-logoa03.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  D&!Q(2$A 1$A 6$! /$ X6#Q$0
M#Q -%Q,/%1$6%Q42%148'2@@&!HE&Q43+3$A)2DK+BXN%Q\S.#,L-R@M+BL!
M"@H*#@T.&Q 0%2T='QTK+2LM*RTW,"TK+2TM+2TM*RTM+2LX+2TW*S<M*RTM
M+2TM+3$M+2TW*RTW."TM+3<W+?_  !$( '@!+ ,!(@ "$0$#$0'_Q  <  $
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M&I=6EJ'5'4$'_(^<VYS54]7?$Q,7#,1$)(B("(B B(@(B("(B B(@(B("(B
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M[74%QKH/&<_Y*TG-\VNS!QKA,&57# ]A8?<_^9SYL)U:W#(QU958C@"0#PW
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M\O"0(C-<,M> 6A&WAFHKJ;@=S-<NGLRS2,.6@V5,2!5AQZFI1M LT*[S[EX
M=VIDG 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
61$!$1 1$0$1$!$1 1$0$1$!$1 __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6773632848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions Acquisitions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5,757.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,706.4<span></span>
</td>
<td class="nump">$ 4,632.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred Tax Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 852.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6630227568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Minimum rental commitments under non-cancelable leases</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the five years and total thereafter as of December&#160;31, 2018, were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>87.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>80.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>75.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>601.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(26.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(25.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(23.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(58.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(182.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>418.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6979078768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 5,888.5<span></span>
</td>
<td class="nump">$ 4,474.0<span></span>
</td>
<td class="nump">$ 2,670.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and impairments</a></td>
<td class="nump">680.6<span></span>
</td>
<td class="nump">1,016.6<span></span>
</td>
<td class="nump">1,081.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">182.3<span></span>
</td>
<td class="nump">157.5<span></span>
</td>
<td class="nump">128.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">67.1<span></span>
</td>
<td class="nump">108.3<span></span>
</td>
<td class="nump">91.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(63.7)<span></span>
</td>
<td class="num">(12.3)<span></span>
</td>
<td class="nump">62.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax', window );">Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax</a></td>
<td class="nump">55.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">69.2<span></span>
</td>
<td class="num">(69.1)<span></span>
</td>
<td class="nump">162.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">68.8<span></span>
</td>
<td class="num">(205.2)<span></span>
</td>
<td class="num">(435.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="num">(63.3)<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="num">(232.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(19.2)<span></span>
</td>
<td class="num">(52.1)<span></span>
</td>
<td class="num">(94.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">240.2<span></span>
</td>
<td class="nump">465.5<span></span>
</td>
<td class="num">(227.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">16.1<span></span>
</td>
<td class="nump">321.7<span></span>
</td>
<td class="nump">1,303.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(43.3)<span></span>
</td>
<td class="num">(135.4)<span></span>
</td>
<td class="num">(79.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">7,078.6<span></span>
</td>
<td class="nump">6,187.7<span></span>
</td>
<td class="nump">4,551.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">6,007.0<span></span>
</td>
<td class="nump">9,173.7<span></span>
</td>
<td class="nump">5,565.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(5,252.6)<span></span>
</td>
<td class="num">(7,694.8)<span></span>
</td>
<td class="num">(5,355.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration related to Fumapharm AG acquisition</a></td>
<td class="num">(300.0)<span></span>
</td>
<td class="num">(1,500.0)<span></span>
</td>
<td class="num">(1,200.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to Acquire Businesses, Net of Cash Acquired</a></td>
<td class="num">(744.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from Sale of Property, Plant, and Equipment</a></td>
<td class="nump">923.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to Acquire in Process Research and Development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(112.5)<span></span>
</td>
<td class="num">(120.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(514.5)<span></span>
</td>
<td class="num">(770.6)<span></span>
</td>
<td class="num">(867.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(155.0)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(975.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Payments to Acquire Other Investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(462.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(676.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from Sale of Available-for-sale Securities, Equity</a></td>
<td class="nump">479.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by (used in) investing activities</a></td>
<td class="nump">470.5<span></span>
</td>
<td class="num">(2,046.3)<span></span>
</td>
<td class="num">(2,963.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(5,868.3)<span></span>
</td>
<td class="num">(4,352.6)<span></span>
</td>
<td class="num">(1,365.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Net contribution (distribution) to noncontrolling interests</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="num">(36.4)<span></span>
</td>
<td class="num">(134.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(560.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfCapitalDistribution', window );">Net cash contribution to Bioverativ, Inc.</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(302.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Contingent consideration payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(58.2)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="num">(21.6)<span></span>
</td>
<td class="num">(13.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(5,860.4)<span></span>
</td>
<td class="num">(4,472.0)<span></span>
</td>
<td class="num">(2,380.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">1,688.7<span></span>
</td>
<td class="num">(330.6)<span></span>
</td>
<td class="num">(792.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(18.6)<span></span>
</td>
<td class="nump">39.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the year</a></td>
<td class="nump">1,224.6<span></span>
</td>
<td class="nump">1,573.8<span></span>
</td>
<td class="nump">2,326.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the year</a></td>
<td class="nump">$ 2,913.7<span></span>
</td>
<td class="nump">$ 1,224.6<span></span>
</td>
<td class="nump">$ 1,573.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfCapitalDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfCapitalDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6979313904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">1,955.4<span></span>
</td>
<td class="nump">1,816.3<span></span>
</td>
<td class="nump">1,630.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">2,280.6<span></span>
</td>
<td class="nump">2,597.2<span></span>
</td>
<td class="nump">2,253.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,374.7<span></span>
</td>
<td class="nump">2,106.3<span></span>
</td>
<td class="nump">1,933.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">489.9<span></span>
</td>
<td class="nump">747.3<span></span>
</td>
<td class="nump">814.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">241.6<span></span>
</td>
<td class="nump">185.0<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">55.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(63.7)<span></span>
</td>
<td class="num">(12.3)<span></span>
</td>
<td class="nump">62.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">7,335.3<span></span>
</td>
<td class="nump">7,564.3<span></span>
</td>
<td class="nump">6,928.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">7,042.6<span></span>
</td>
<td class="nump">5,888.6<span></span>
</td>
<td class="nump">5,345.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">83.3<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="num">(217.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">7,125.9<span></span>
</td>
<td class="nump">5,899.6<span></span>
</td>
<td class="nump">5,128.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">1,158.0<span></span>
</td>
<td class="nump">1,425.6<span></span>
</td>
<td class="nump">2,458.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">79.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">5,888.5<span></span>
</td>
<td class="nump">4,474.0<span></span>
</td>
<td class="nump">2,670.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
<td class="nump">131.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 5,888.5<span></span>
</td>
<td class="nump">$ 4,430.7<span></span>
</td>
<td class="nump">$ 2,539.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 31.47<span></span>
</td>
<td class="nump">$ 21.63<span></span>
</td>
<td class="nump">$ 11.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 31.42<span></span>
</td>
<td class="nump">$ 21.58<span></span>
</td>
<td class="nump">$ 11.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">187.1<span></span>
</td>
<td class="nump">204.9<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">187.4<span></span>
</td>
<td class="nump">205.3<span></span>
</td>
<td class="nump">213.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">$ 11,379.8<span></span>
</td>
<td class="nump">$ 10,886.8<span></span>
</td>
<td class="nump">$ 10,354.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">2,290.4<span></span>
</td>
<td class="nump">1,980.2<span></span>
</td>
<td class="nump">1,559.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">$ 707.7<span></span>
</td>
<td class="nump">$ 585.9<span></span>
</td>
<td class="nump">$ 360.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationandImpairmentofAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6979083184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments Cash Flow Hedges (Details) - Foreign Exchange Contract - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember', window );">Cash flows, revenue | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in operating income for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="nump">$ 118.6<span></span>
</td>
<td class="num">$ (42.5)<span></span>
</td>
<td class="num">$ (32.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in net income of foreign currency forward contracts, excluded component</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember', window );">Cash flows, revenue | Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in net income of foreign currency forward contracts, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember', window );">Cash flows, operating expenses | Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in net income of foreign currency forward contracts, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember', window );">Cash flows, operating expenses | Operating Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in operating income for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in net income of foreign currency forward contracts, excluded component</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109977999&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6985900112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 2,541.1<span></span>
</td>
<td class="nump">$ 705.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">337.5<span></span>
</td>
<td class="nump">615.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">43.8<span></span>
</td>
<td class="nump">66.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">27.7<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,920.4<span></span>
</td>
<td class="nump">5,102.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">346.1<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="nump">$ 523.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">354.4<span></span>
</td>
<td class="nump">434.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,695.1<span></span>
</td>
<td class="nump">2,459.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,013.9<span></span>
</td>
<td class="nump">969.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">261.3<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,541.1<span></span>
</td>
<td class="nump">705.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">329.6<span></span>
</td>
<td class="nump">563.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">43.8<span></span>
</td>
<td class="nump">66.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">27.7<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,912.5<span></span>
</td>
<td class="nump">5,050.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,695.1<span></span>
</td>
<td class="nump">2,459.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,013.9<span></span>
</td>
<td class="nump">969.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">261.3<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">346.1<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">346.1<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7028192272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 2,541.1<span></span>
</td>
<td class="nump">$ 705.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">384.4<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight Reverse Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">368.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">1,628.5<span></span>
</td>
<td class="nump">279.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 159.4<span></span>
</td>
<td class="nump">$ 194.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6888969808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 118.1<span></span>
</td>
<td class="nump">$ 144.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">835.0<span></span>
</td>
<td class="nump">1,282.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">99.5<span></span>
</td>
<td class="nump">94.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">844.5<span></span>
</td>
<td class="nump">1,258.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ComputerSoftwareAndHardware', window );">Computer software and hardware</a></td>
<td class="nump">798.4<span></span>
</td>
<td class="nump">798.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">58.3<span></span>
</td>
<td class="nump">61.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">2,084.4<span></span>
</td>
<td class="nump">1,758.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">4,838.2<span></span>
</td>
<td class="nump">5,398.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,590.9)<span></span>
</td>
<td class="num">(1,797.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">$ 3,247.3<span></span>
</td>
<td class="nump">$ 3,601.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ComputerSoftwareAndHardware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Computer software and hardware</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ComputerSoftwareAndHardware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6883479296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">$ 1,495.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">6,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Non-current portion of notes payable</a></td>
<td class="nump">4,459.0<span></span>
</td>
<td class="nump">5,936.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Note payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">2.900% Senior Notes due September 15, 2020</a></td>
<td class="nump">1,495.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,480.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">996.6<span></span>
</td>
<td class="nump">995.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">1,739.5<span></span>
</td>
<td class="nump">1,737.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">$ 1,722.9<span></span>
</td>
<td class="nump">$ 1,722.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6892189168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FinancialInstrumentsTextualAbstract', window );"><strong>Financial Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Original maturities of commercial paper and short-term debt securities</a></td>
<td class="text">less than 90&#160;days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">14 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FinancialInstrumentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FinancialInstrumentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6766508608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text">Indebtedness<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,495.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,495.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,480.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>996.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>995.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,739.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,737.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,722.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,722.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>4,459.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Senior Notes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$1.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020, valued at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>99.792%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>3.625%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2022, valued at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>99.920%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$1.75 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>4.05%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2025, valued at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>99.764%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$1.75 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>5.20%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15,&#160;2045, valued at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>99.294%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The costs associated with these offerings of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$47.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheets. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These notes are senior unsecured obligations. These Senior Notes may be redeemed at our option at any time at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>100%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued interest and a specified make-whole amount. These Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>101%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes offering due in 2020, we entered into interest rate swap contracts. The carrying value of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$14.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to changes in the fair value of these contracts. For additional information on our interest rate contracts, please read Note 9, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Credit Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we entered into a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span><span style="font-family:Franklin Gothic Book,sans-serif;">five</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we were permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility included a financial covenant that required us not to exceed a maximum consolidated leverage ratio. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2020 we entered into a new </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span><span style="font-family:Franklin Gothic Book,sans-serif;">five</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility that replaced the credit facility entered into in August 2015. For additional information, please read Note 26, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Maturity</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments due under our debt arrangements are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,500.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,000.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,500.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6,000.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our debt is disclosed in Note&#160;7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7028192272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events Subsequent Events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 112.5<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior unsecured revolving credit facility maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Term of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">five<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 635.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior unsecured revolving credit facility maximum borrowing capacity</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Term of credit facility</a></td>
<td class="text">five<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871665264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </span><span><span style="font-family:Franklin Gothic Book,sans-serif;">less than 90&#160;days</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>384.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>231.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>368.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,628.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>279.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>159.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>194.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities gains (losses) are recorded in other income (expense), net in our consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,057.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,058.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>633.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>636.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>502.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>503.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>510.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>510.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>260.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>260.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,965.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,970.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>218.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>132.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>337.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,608.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,607.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>854.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>851.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>706.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>264.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>263.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,694.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,689.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>496.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>127.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>615.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,562.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,560.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,313.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,314.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,234.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,230.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,232.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,235.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>173.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>173.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,970.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,965.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,689.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,694.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;months and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6,007.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9,173.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,565.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to impairments recognized on certain of our available-for-sale marketable debt securities, sales of agency mortgage-backed securities, corporate bonds and government securities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$393.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">  Our investments in equity securities include shares of Ionis common stock acquired in June 2018. This investment is classified as a Level 2 marketable security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effect of the holding period restrictions on our investment in Ionis common stock valuation are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends. The remainder of our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in our strategic investment portfolio for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily reflects our sale of a portion of our investment in Ionis common stock for approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$382.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as well as our sale of our investment in a non-marketable equity security, partially offset by an increase in the fair value of our remaining investment in Ionis common stock.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the June 2018 investment in Ionis common stock, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we exercised our option under our joint venture agreement with Samsung BioLogics to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>670.8 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$580.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$680.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets within our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6630370992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation Litigation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss Contingency, Claims Asserted</a></td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_BR', window );">BRAZIL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Tax Assessment</a></td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885824640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">3,674.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,601.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,674.3<span></span>
</td>
<td class="nump">3,601.2<span></span>
</td>
<td class="nump">3,182.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">1,493.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,152.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,493.2<span></span>
</td>
<td class="nump">1,152.7<span></span>
</td>
<td class="nump">1,226.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">2,162.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,442.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,162.9<span></span>
</td>
<td class="nump">2,442.8<span></span>
</td>
<td class="nump">1,948.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaMember', window );">Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">600.8<span></span>
</td>
<td class="nump">595.8<span></span>
</td>
<td class="nump">576.4<span></span>
</td>
<td class="nump">517.4<span></span>
</td>
<td class="nump">534.9<span></span>
</td>
<td class="nump">511.7<span></span>
</td>
<td class="nump">490.4<span></span>
</td>
<td class="nump">443.2<span></span>
</td>
<td class="nump">2,290.4<span></span>
</td>
<td class="nump">1,980.2<span></span>
</td>
<td class="nump">1,559.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,211.9<span></span>
</td>
<td class="nump">1,903.4<span></span>
</td>
<td class="nump">1,475.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.3<span></span>
</td>
<td class="nump">76.6<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">145.7<span></span>
</td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">160.0<span></span>
</td>
<td class="nump">292.4<span></span>
</td>
<td class="nump">165.7<span></span>
</td>
<td class="nump">147.2<span></span>
</td>
<td class="nump">108.6<span></span>
</td>
<td class="nump">164.4<span></span>
</td>
<td class="nump">707.7<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">585.8<span></span>
</td>
<td class="nump">457.0<span></span>
</td>
<td class="nump">249.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">32.7<span></span>
</td>
<td class="nump">67.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.2<span></span>
</td>
<td class="nump">96.2<span></span>
</td>
<td class="nump">42.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 2,924.8<span></span>
</td>
<td class="nump">$ 2,894.7<span></span>
</td>
<td class="nump">$ 2,880.3<span></span>
</td>
<td class="nump">$ 2,680.0<span></span>
</td>
<td class="nump">$ 2,825.7<span></span>
</td>
<td class="nump">$ 2,780.1<span></span>
</td>
<td class="nump">$ 2,757.5<span></span>
</td>
<td class="nump">$ 2,523.5<span></span>
</td>
<td class="nump">11,379.8<span></span>
</td>
<td class="nump">10,886.8<span></span>
</td>
<td class="nump">10,354.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,713.8<span></span>
</td>
<td class="nump">6,800.5<span></span>
</td>
<td class="nump">7,017.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,794.5<span></span>
</td>
<td class="nump">3,370.3<span></span>
</td>
<td class="nump">2,844.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320.3<span></span>
</td>
<td class="nump">281.2<span></span>
</td>
<td class="nump">160.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 551.2<span></span>
</td>
<td class="nump">$ 434.8<span></span>
</td>
<td class="nump">$ 332.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentsGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentsGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895698400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36"/></tr><tr><td style="width:17%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>3,306.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>1,126.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>4,432.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3,253.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,020.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>4,274.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3,294.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>920.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>4,214.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>1,426.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>675.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>2,101.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,668.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>694.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,363.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,889.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>756.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,645.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>1,041.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>850.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>1,892.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,025.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>839.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,864.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,113.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>859.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,973.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">VUMERITY</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>97.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>97.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>92.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>92.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>91.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>91.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>52.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>52.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS Product Revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>5,780.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>2,748.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>8,529.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>5,946.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,648.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8,595.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6,296.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,680.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8,977.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>933.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>1,163.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>2,097.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>854.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>870.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,724.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>657.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>226.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>883.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>486.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>486.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>485.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>485.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>370.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>370.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>184.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>184.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>68.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>68.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>43.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>43.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>738.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>738.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>545.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>545.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>379.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>379.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>22.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>22.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>39.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>39.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>42.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>48.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Hemophilia product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>63.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>74.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>6,713.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>4,666.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>11,379.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6,800.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>4,086.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>10,886.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7,017.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3,337.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>10,354.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>34%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.1%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>13.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net accounts receivable associated with our product sales, as compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.7%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15.6%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>127.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>888.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>666.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,011.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>20.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,698.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(54.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(48.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(535.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(2,242.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(2,778.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(127.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(576.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(20.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(724.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>131.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,027.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>40.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,198.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>109.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>606.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>761.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>679.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,686.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,389.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(12.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(551.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,887.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2,440.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(109.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(506.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(31.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(646.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>127.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>888.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>482.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>605.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>583.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,307.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,917.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(475.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,756.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2,232.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(69.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(442.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(23.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(534.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>109.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>606.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>761.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>197.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>176.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,001.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>874.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,198.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,431.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,316.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>748.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>548.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>242.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,290.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,980.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,559.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>13%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our total revenues in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are derived from our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(16.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development services and manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>106.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>96.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>42.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Swedish Orphan Biovitrum AB (Sobi) and royalties from Sobi on sales of ELOCTA and ALPROLIX</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>38.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>69.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>584.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>459.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>253.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>707.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>585.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>360.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic customers, including Bioverativ Inc. (Bioverativ). During the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$383.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$206.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$64.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we will license certain of our manufacturing-related intellectual property to the customer. We will be eligible to receive </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$500.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in a series of three payments. The first payment is due upon a regulatory achievement related to the customer's product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We expect the regulatory achievement to occur in 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with AbbVie Inc. (AbbVie) and Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6882954560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text">&#160;&#160;&#160;&#160;Quarterly Financial Data (Unaudited)<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,680.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,880.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,894.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,924.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>11,379.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>517.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>576.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>595.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>600.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,290.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>292.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>160.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>109.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>145.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>707.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,489.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,616.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,600.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,671.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>14,377.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,887.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,140.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,170.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,224.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>12,422.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,408.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,494.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,545.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,439.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,888.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,408.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,494.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,545.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,439.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,888.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.17</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.85</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.40</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.10</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>31.47</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.15</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.85</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.39</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.08</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>31.42</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>196.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>190.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>184.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>177.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>187.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>197.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>190.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>184.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>178.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>187.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,523.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,757.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,780.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,825.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10,886.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>443.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>490.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>511.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>534.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,980.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>164.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>108.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>147.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>165.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>585.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,131.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,356.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,439.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,526.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>13,452.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,685.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,935.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,978.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,037.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11,636.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,171.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>915.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,442.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>944.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,474.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,172.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>866.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,444.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>946.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,430.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>211.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>201.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>199.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>204.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>211.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>207.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>201.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>200.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>205.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for 2019 include:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax gains (losses) related to changes in the fair value of our strategic investments of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$376.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>($174.2) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>($4.6) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second, third and fourth quarters, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment charges related to certain intangible assets of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$215.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter. For additional information, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A total net loss in our consolidated statements of income of approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$124.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the sale of all the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This loss included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$55.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a tax expense of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$68.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this transaction. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read, Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An expense of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$63.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded in research and development expense in our consolidated statements of income in the fourth quarter as we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. We also acquired an option to extend our existing commercial agreement with Samsung Bioepis for BENEPALI, IMRALDI and FLIXABI in Europe and obtained exclusive rights to commercialize these products in China. For additional information, please read, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Losses (gains) related to the adjustments to the fair values of our contingent consideration obligations of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$11.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(20.0) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(57.8) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second, third and fourth quarters, respectively. For additional information on the valuation of our contingent consideration obligations, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A payment of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis in the fourth quarter, as we exercised our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB080. For additional information, please read, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A payment of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$38.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk in the first quarter as we entered into a collaboration and research and development services agreement with Skyhawk pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. For additional information, please read, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for 2018 include:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax (losses) gains related to changes in the fair value of our strategic investments of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(6.4) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$5.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$141.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(12.2) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second, third and fourth quarters, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax charges to acquired IPR&amp;D of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$27.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second and third quarters, respectively, for upfront payments made upon closing of asset purchase transactions. For additional information, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax research and development expenses for the second quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$486.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the 2018 Ionis Agreement. For additional information, please read, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax charge to noncontrolling interests of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the second quarter for a payment to Neurimmune in exchange for a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. For additional information, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment charges related to certain intangible assets of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$189.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$176.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third and fourth quarters, respectively. For additional information, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Losses (gains) related to the adjustments to the fair values of our contingent consideration obligations of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(5.6) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(87.9) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$79.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second, third and fourth quarters, </span></div></td></tr></table><div style="line-height:120%;padding-left:48px;padding-top:12px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">respectively. For additional information, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase to income tax expense of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$135.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the fourth quarter reflecting the impact of electing to record deferred taxes on GILTI. For additional information, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An upfront payment of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$35.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis, as we exercised our option in the fourth quarter to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize tofersen. For additional information, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6877768880">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 10) - Time-vested restricted stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RestrictedStockUnitsActivityAbstract', window );"><strong>Time-vested restricted stock units</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">903,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 303.18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">602,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 304.44<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 316.32<span></span>
</td>
<td class="nump">$ 293.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(416,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 294.71<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(151,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 311.07<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">938,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">903,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 306.55<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 303.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2019 primarily represent RSUs granted in conjunction with our annual awards made in February 2019 and awards made in conjunction with the hiring of new employees. RSUs granted in 2019 also include approximately </span><span style="font-family:Franklin Gothic Book;font-size:9pt;"><span>15,000</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> RSUs granted to our Board of Directors.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestrictedStockUnitsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestrictedStockUnitsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895835200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 6) - Cash settled performance units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CashSettledPerformanceSharesAbstract', window );"><strong>Cash settled performance shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(33,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(4,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="nump">13,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CashSettledPerformanceSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash settled performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CashSettledPerformanceSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895906640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Schedule of separately identifiable assets acquired and liabilities assumed (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Identified assets acquired and liabilities assumed</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>117.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(81.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>852.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871673328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text">Litigation<div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing on the merits has been scheduled. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. In Italy, Fresenius Kabi has surrendered the Italian counterpart of the &#8216;510 Patent and has moved to dismiss its infringement action. A hearing in the proceeding in Germany has not yet been set but is expected to occur after a decision on our pending opposition to the &#8216;510 patent in the EPO.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">'667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom (U.K.) counterpart of the '667 Patent. In January 2020 the U.K. court revoked the patent.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. Gedeon Richter filed a separate action for infringement in the same court and a hearing in both cases has been set for May 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss in the pending IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Dispute with Former Convergence Shareholders</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$200.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of our U.S. Patent No. 8,399,514 (the '514 Patent), which covers treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. Sawai USA, Inc. and Sawai Pharmaceutical Co. Ltd. were later joined as petitioners, but in January 2020 the PTAB terminated their involvement in the proceeding. A hearing on Mylan&#8217;s petition was held in November 2019 and on February 5, 2020, the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, 2018 and 2019 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shipla Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia. The litigation against Aurobindo Pharma U.S.A., Inc., Glenmark Pharmaceuticals Ltd. and Sawai USA was dismissed in the fourth quarter of 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial against the remaining Delaware Defendants was held in the Delaware Court in December 2019 and we are awaiting a decision.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial is ongoing in the West Virginia action against Mylan.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into settlement agreements with some of the Delaware Defendants and we now anticipate market entry of a generic product equivalent to TECFIDERA before the &#8216;514 Patent expires in February 2028.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we filed an action under the Hatch-Waxman Act against Banner Life Sciences LLC (Banner) for infringement of our U.S. Patent No. 7,619,001 (the &#8216;001 patent) expiring on June 20, 2020, and claiming treatment of MS with dimethyl fumarate or methyl hydrogen fumarate or a combination thereof. In January 2020 the </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware Court entered judgment that Banner&#8217;s drug product does not infringe the &#8216;001 patent. We have appealed the decision.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the EPO revoked our European patent number 2 137 537 (the '537 Patent), which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing has been set for March 2020. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for June 2020. For additional information regarding this matter, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish '263 Patent), corresponding to our European Patent Number 1 485 127 (the E.U. '127 Patent) and covering administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. No hearing on the merits has been set in this matter.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and a hearing has been set for July 2020 in our appeal in the German action. No date for a hearing on the merits has been set in the Italian action.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. EMD Serono and Pfizer filed an appeal in the U.S. Court of Appeals for the Federal Circuit and oral argument is scheduled for March 2020. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We are cooperating with the investigation and have participated in preliminary discussions with the government regarding potential resolution of aspects of the matter. We have accrued the amount of our best estimate of the minimum probable loss in this matter.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties. We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending. We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6982373840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred tax assets, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103.7<span></span>
</td>
<td class="nump">$ 38.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.50%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(11.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,158.0<span></span>
</td>
<td class="nump">$ 1,425.6<span></span>
</td>
<td class="nump">$ 2,458.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries', window );">Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,381.6)<span></span>
</td>
<td class="num">(544.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Net impairment on certain tax assets</a></td>
<td class="nump">$ 48.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in Unrecognized Tax Benefits is Reasonably Possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Totaldeferredchargesandprepaidtaxes', window );">Total deferred charges and prepaid taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243.8<span></span>
</td>
<td class="nump">239.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefit</a></td>
<td class="nump">64.3<span></span>
</td>
<td class="nump">122.7<span></span>
</td>
<td class="nump">109.1<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Net interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">$ 13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember', window );">2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Transition toll tax liabilities</a></td>
<td class="nump">989.6<span></span>
</td>
<td class="nump">697.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">989.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Income tax expense (benefit)</a></td>
<td class="nump">184.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductionindeferredtaxliabilityundistributedforeignearnings', window );">Reduction in deferred tax liability, undistributed foreign earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherTaxExpenseBenefit', window );">Other tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | Domestic Country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,773.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_PrepaidtaxesMember', window );">Prepaid taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Net impairment on certain tax assets</a></td>
<td class="nump">$ 142.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember', window );">Earnings in the form of cash and cash equivalents | 2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TransitionTollTaxRepatriationTaxRate', window );">Transition Toll Tax repatriation tax rate</a></td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember', window );">Other Foreign Earnings | 2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TransitionTollTaxRepatriationTaxRate', window );">Transition Toll Tax repatriation tax rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecorded tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting', window );">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting', window );">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxAssetLiabilityTypeAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred Tax Liabilities, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred tax assets, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 754.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredtaxliabilitiesGILTItaxcalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, GILTI tax calculation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredtaxliabilitiesGILTItaxcalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductionindeferredtaxliabilityundistributedforeignearnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in deferred tax liability, undistributed foreign earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductionindeferredtaxliabilityundistributedforeignearnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Totaldeferredchargesandprepaidtaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total deferred charges and prepaid taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Totaldeferredchargesandprepaidtaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TransitionTollTaxRepatriationTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transition Toll Tax Repatriation Tax Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TransitionTollTaxRepatriationTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_PrepaidtaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_PrepaidtaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxAssetLiabilityTypeAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxAssetLiabilityTypeAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-20191231x10k.htm": {
   "axisCustom": 9,
   "axisStandard": 44,
   "contextCount": 908,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-20191231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20191231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20191231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 1156,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 36,
    "http://www.biogenidec.com/20191231": 15,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 56
   },
   "keyCustom": 141,
   "keyStandard": 591,
   "memberCustom": 112,
   "memberStandard": 92,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Divestitures Divestitures",
     "role": "http://www.biogenidec.com/role/DivestituresDivestitures",
     "shortName": "Divestitures Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:ScheduleOfMarketStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421406 - Disclosure - Share-Based Payments (Details 4)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
     "shortName": "Share-Based Payments (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:ScheduleOfMarketStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421407 - Disclosure - Share-Based Payments (Details 5)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5",
     "shortName": "Share-Based Payments (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421408 - Disclosure - Share-Based Payments (Details 6)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails6",
     "shortName": "Share-Based Payments (Details 6)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:PerformanceunitsactivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Share-Based Payments (Details 7)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails7",
     "shortName": "Share-Based Payments (Details 7)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:PerformanceunitsactivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:PerformanceStockUnitsSettledinStockTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Share-Based Payments (Details 8)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
     "shortName": "Share-Based Payments (Details 8)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:PerformanceStockUnitsSettledinStockTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:PerformanceStockUnitsSettledinCashTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Share-Based Payments (Details 9)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails9",
     "shortName": "Share-Based Payments (Details 9)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:PerformanceStockUnitsSettledinCashTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Share-Based Payments (Details 10)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
     "shortName": "Share-Based Payments (Details 10)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421413 - Disclosure - Share-Based Payments (Details 11)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails11",
     "shortName": "Share-Based Payments (Details 11)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421414 - Disclosure - Share-Based Payments (Details Textual)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual",
     "shortName": "Share-Based Payments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422402 - Disclosure - Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Revenues",
     "role": "http://www.biogenidec.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422403 - Disclosure - Income Taxes (Details 1)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails1",
     "shortName": "Income Taxes (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422404 - Disclosure - Income Taxes (Details 2)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails2",
     "shortName": "Income Taxes (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422405 - Disclosure - Income Taxes (Details 3)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails3",
     "shortName": "Income Taxes (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2016Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOther",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422406 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-8",
      "lang": null,
      "name": "biib:Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423402 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423403 - Disclosure - Other Consolidated Financial Statement Detail (Details Textual)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual",
     "shortName": "Other Consolidated Financial Statement Detail (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424402 - Disclosure - Collaborative and Other Relationships - Genentech (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails",
     "shortName": "Collaborative and Other Relationships - Genentech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "biib:PercentageoffuturedevelopmentcostsrelatedtoEisai",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424403 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Eisai (Details 1)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
     "shortName": "Collaborative and Other Relationships Collaborative and Other Relationships - Eisai (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember",
      "decimals": "-5",
      "lang": null,
      "name": "biib:Expenseincurredbythecollaboration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424404 - Disclosure - Collaborative and Other Relationships - AbbVie (Details 2)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
     "shortName": "Collaborative and Other Relationships - AbbVie (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424405 - Disclosure - Collaborative and Other Relationships (Details Textual)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
     "shortName": "Collaborative and Other Relationships (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember",
      "decimals": "-5",
      "lang": null,
      "name": "biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToMinorityShareholders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425401 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426401 - Disclosure - Litigation Litigation (Details)",
     "role": "http://www.biogenidec.com/role/LitigationLitigationDetails",
     "shortName": "Litigation Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427402 - Disclosure - Commitments and Contingencies (Details Textual)",
     "role": "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
     "shortName": "Commitments and Contingencies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OtherCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:MinimumQualifyingAgeForEmployeeBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429401 - Disclosure - Employee Benefit Plans Employee Benefit Plans (Details)",
     "role": "http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:MinimumQualifyingAgeForEmployeeBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_DE",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429402 - Disclosure - Employee Benefit Plans (Details 1)",
     "role": "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1",
     "shortName": "Employee Benefit Plans (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_DE",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430402 - Disclosure - Segment Information (Details)",
     "role": "http://www.biogenidec.com/role/SegmentInformationDetails",
     "shortName": "Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2017Q4_srt_StatementGeographicalAxis_country_US",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430403 - Disclosure - Segment Information (Details Textual)",
     "role": "http://www.biogenidec.com/role/SegmentInformationDetailsTextual",
     "shortName": "Segment Information (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)",
     "role": "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
     "shortName": "Quarterly Financial Data (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431403 - Disclosure - Quarterly Financial Data (Unaudited) (Details Textual)",
     "role": "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual",
     "shortName": "Quarterly Financial Data (Unaudited) (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433401 - Disclosure - Subsequent Events Subsequent Events (Details)",
     "role": "http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails",
     "shortName": "Subsequent Events Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "D2019Q4Pfizer_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115100 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantAndEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116100 - Disclosure - Leases Leases",
     "role": "http://www.biogenidec.com/role/LeasesLeases",
     "shortName": "Leases Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117100 - Disclosure - Indebtedness",
     "role": "http://www.biogenidec.com/role/Indebtedness",
     "shortName": "Indebtedness",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Consolidated Statements of Income",
     "role": "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119100 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120100 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsPerShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121100 - Disclosure - Share-based Payments",
     "role": "http://www.biogenidec.com/role/ShareBasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122100 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123100 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124100 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125100 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126100 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127100 - Disclosure - Commitments and Contingencies",
     "role": "http://www.biogenidec.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GuaranteesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128100 - Disclosure - Guarantees",
     "role": "http://www.biogenidec.com/role/Guarantees",
     "shortName": "Guarantees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GuaranteesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129100 - Disclosure - Employee Benefit Plans",
     "role": "http://www.biogenidec.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130100 - Disclosure - Segment Information",
     "role": "http://www.biogenidec.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131100 - Disclosure - Quarterly Financial Data (Unaudited)",
     "role": "http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited",
     "shortName": "Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133100 - Disclosure - Subsequent Events Subsequent Events",
     "role": "http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents",
     "shortName": "Subsequent Events Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302301 - Disclosure - Acquisitions Schedule of separately identifiable assets acquired and liabilities assumed (Tables)",
     "role": "http://www.biogenidec.com/role/AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables",
     "shortName": "Acquisitions Schedule of separately identifiable assets acquired and liabilities assumed (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Consolidated Balance Sheets",
     "role": "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313301 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314301 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315301 - Disclosure - Property, Plant and Equipment (Tables)",
     "role": "http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:LesseeLeaseTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316301 - Disclosure - Leases Leases (Tables)",
     "role": "http://www.biogenidec.com/role/LeasesLeasesTables",
     "shortName": "Leases Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:LesseeLeaseTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317301 - Disclosure - Indebtedness (Tables)",
     "role": "http://www.biogenidec.com/role/IndebtednessTables",
     "shortName": "Indebtedness (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryOfCommonStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319301 - Disclosure - Equity (Tables)",
     "role": "http://www.biogenidec.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryOfCommonStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319302 - Disclosure - Equity Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Equity Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320301 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsPerShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321301 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003501 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322301 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:CoPromotionProfitSharingFormulaTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324301 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:CoPromotionProfitSharingFormulaTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327301 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.biogenidec.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330301 - Disclosure - Segment Information (Tables)",
     "role": "http://www.biogenidec.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables",
     "shortName": "Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401403 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:ConsolidationPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "2",
      "lang": null,
      "name": "biib:InterestInSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Acquisitions Acquisitions (Details)",
     "role": "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails",
     "shortName": "Acquisitions Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Acquisitions (Details Textual)",
     "role": "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
     "shortName": "Acquisitions (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407401 - Disclosure - Divestitures Divestitures (Details Textual)",
     "role": "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual",
     "shortName": "Divestitures Divestitures (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Revenues by Product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesByProductDetails",
     "shortName": "Revenues by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)",
     "role": "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1",
     "shortName": "Revenues Reserves for Discounts and Allowances (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 2)",
     "role": "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2",
     "shortName": "Revenues Reserves for Discounts and Allowances (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails",
     "shortName": "Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Revenues Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
     "shortName": "Revenues Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409407 - Disclosure - Revenues (Details Textual)",
     "role": "http://www.biogenidec.com/role/RevenuesDetailsTextual",
     "shortName": "Revenues (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "2",
      "lang": null,
      "name": "biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "I2019Q3Denmark",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:InventoryrawmaterialssoldtoFUJIFILM",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Inventory (Details Textual)",
     "role": "http://www.biogenidec.com/role/InventoryDetailsTextual",
     "shortName": "Inventory (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411403 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2016Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Consolidated Statements of Equity",
     "role": "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2016Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Fair Value Measurements (Details 2)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "shortName": "Fair Value Measurements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Fair Value Measurements (Details Textual)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "shortName": "Fair Value Measurements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413402 - Disclosure - Financial Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413403 - Disclosure - Financial Instruments (Details 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "shortName": "Financial Instruments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413404 - Disclosure - Financial Instruments (Details 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "shortName": "Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Financial Instruments (Details 3)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "shortName": "Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesGrossRealizedGains",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMaturityDateDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Financial Instruments (Details Textual 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1",
     "shortName": "Financial Instruments (Details Textual 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMaturityDateDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Financial Instruments (Details Textual 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2",
     "shortName": "Financial Instruments (Details Textual 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember",
      "decimals": "-5",
      "lang": null,
      "name": "biib:StrategicInvestmentPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414402 - Disclosure - Derivative Instruments Cash Flow Hedges (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
     "shortName": "Derivative Instruments Cash Flow Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414403 - Disclosure - Derivative Instruments Derivative Instruments Net Investment Hedges (Details 1)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
     "shortName": "Derivative Instruments Derivative Instruments Net Investment Hedges (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DerivativeTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414404 - Disclosure - Derivative Instruments Interest Rate Swap (Details 2)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2",
     "shortName": "Derivative Instruments Interest Rate Swap (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414405 - Disclosure - Derivative Instruments (Details Textual)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
     "shortName": "Derivative Instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DerivativeRemainingMaturity1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415402 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415403 - Disclosure - Property, Plant and Equipment (Details Textual)",
     "role": "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual",
     "shortName": "Property, Plant and Equipment (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416402 - Disclosure - Leases Leases (Details)",
     "role": "http://www.biogenidec.com/role/LeasesLeasesDetails",
     "shortName": "Leases Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4_srt_RangeAxis_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416403 - Disclosure - Leases Leases (Details Textual)",
     "role": "http://www.biogenidec.com/role/LeasesLeasesDetailsTextual",
     "shortName": "Leases Leases (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4_srt_RangeAxis_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417402 - Disclosure - Indebtedness (Details)",
     "role": "http://www.biogenidec.com/role/IndebtednessDetails",
     "shortName": "Indebtedness (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417403 - Disclosure - Indebtedness (Details 1)",
     "role": "http://www.biogenidec.com/role/IndebtednessDetails1",
     "shortName": "Indebtedness (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Acquisitions",
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2015Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417404 - Disclosure - Indebtedness (Details Textual)",
     "role": "http://www.biogenidec.com/role/IndebtednessDetailsTextual",
     "shortName": "Indebtedness (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2015Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SummaryOfCommonStockTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419403 - Disclosure - Equity (Details)",
     "role": "http://www.biogenidec.com/role/EquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SummaryOfCommonStockTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419404 - Disclosure - Share Repurchases (Details)",
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "shortName": "Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419405 - Disclosure - Equity Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Equity Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2016Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419406 - Disclosure - Equity Reclassification out of Accumulated Other Comprehensive Income (Details)",
     "role": "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Equity Reclassification out of Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420402 - Disclosure - Earnings per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsPerShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421402 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421403 - Disclosure - Share-Based Payments (Details 1)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "shortName": "Share-Based Payments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421404 - Disclosure - Share-Based Payments (Details 2)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails2",
     "shortName": "Share-Based Payments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421405 - Disclosure - Share-Based Payments (Details 3)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails3",
     "shortName": "Share-Based Payments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20191231x10k.htm",
      "contextRef": "FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - biib-20191231x10k.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - biib-20191231x10k.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 224,
   "tag": {
    "biib_A2011ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2011 Share Repurchase Program",
        "label": "2011 Share Repurchase Program [Member]",
        "terseLabel": "2011 Share Repurchase Program"
       }
      }
     },
     "localname": "A2011ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2015ESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2015 ESPP [Member]",
        "label": "2015 ESPP [Member]",
        "terseLabel": "2015 ESPP"
       }
      }
     },
     "localname": "A2015ESPPMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2016ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2016 Share Repurchase Program [Member]",
        "label": "2016 Share Repurchase Program [Member]",
        "terseLabel": "2016 Share Repurchase Program"
       }
      }
     },
     "localname": "A2016ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2017OmnibusEquityPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2017 Omnibus Equity Plan",
        "label": "2017 Omnibus Equity Plan [Member]",
        "terseLabel": "2017 Omnibus Equity Plan"
       }
      }
     },
     "localname": "A2017OmnibusEquityPlanMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2018ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2018 Share Repurchase Program [Member]",
        "label": "2018 Share Repurchase Program [Member]",
        "terseLabel": "2018 Share Repurchase Program"
       }
      }
     },
     "localname": "A2018ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ALPROLIXMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ALPROLIX [Member]",
        "label": "ALPROLIX [Member]",
        "terseLabel": "ALPROLIX"
       }
      }
     },
     "localname": "ALPROLIXMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AbbVieMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AbbVie",
        "label": "AbbVie [Member]",
        "terseLabel": "AbbVie",
        "verboseLabel": "AbbVie"
       }
      }
     },
     "localname": "AbbVieMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued expenses on funding commitment related to clinical research.",
        "label": "Accrued Expenses On Funding Commitment Related To Clinical Research",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AccumulatedOtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "xbrltype": "stringItemType"
    },
    "biib_AcordaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acorda.",
        "label": "Acorda [Member]",
        "terseLabel": "Acorda"
       }
      }
     },
     "localname": "AcordaMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional milestone payment"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Additionalreductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional reduction in royalty rate payable on commercial sales",
        "label": "Additional reduction in royalty rate payable on commercial sales",
        "terseLabel": "Additional reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Additionalreductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedTerseLabel": "Adjustments relating to prior years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AducanumabMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aducanumab [Member]",
        "label": "Aducanumab [Member]",
        "terseLabel": "Aducanumab"
       }
      }
     },
     "localname": "AducanumabMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AliveGenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AliveGen [Member]",
        "label": "AliveGen [Member]",
        "terseLabel": "AliveGen"
       }
      }
     },
     "localname": "AliveGenMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AlkermesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alkermes [Member]",
        "label": "Alkermes [Member]",
        "terseLabel": "Alkermes"
       }
      }
     },
     "localname": "AlkermesMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AmortizationandImpairmentofAcquiredIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization and Impairment of Acquired Intangible Assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "terseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationandImpairmentofAcquiredIntangibleAssets",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change in reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assumptions used in valuation of market based stock units.",
        "label": "Assumptions Used In Valuation Of Market Based Stock Units [Table Text Block]",
        "terseLabel": "Assumptions used in valuation of market based stock units"
       }
      }
     },
     "localname": "AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_AverageStockPriceOnGrantDateInDollarsMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average stock price on grant date in dollars maximum.",
        "label": "Average Stock Price On Grant Date In Dollars Maximum",
        "verboseLabel": "Average stock price on grant date maximum"
       }
      }
     },
     "localname": "AverageStockPriceOnGrantDateInDollarsMaximum",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageStockPriceOnGrantDateInDollarsMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average stock price on grant date in dollars minimum.",
        "label": "Average Stock Price On Grant Date In Dollars Minimum",
        "verboseLabel": "Average stock price on grant date minimum"
       }
      }
     },
     "localname": "AverageStockPriceOnGrantDateInDollarsMinimum",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BG00011Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BG00011",
        "label": "BG00011 [Member]",
        "terseLabel": "BG00011"
       }
      }
     },
     "localname": "BG00011Member",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB111 [Member]",
        "label": "BIIB111 [Member]",
        "terseLabel": "BIIB111"
       }
      }
     },
     "localname": "BIIB111Member",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB112 [Member]",
        "label": "BIIB112 [Member]",
        "terseLabel": "BIIB112"
       }
      }
     },
     "localname": "BIIB112Member",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_BiogenIdecInternationalNeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biogen idec international neuroscience.",
        "label": "Biogen Idec International Neuroscience Member",
        "terseLabel": "Biogen Idec International Neuroscience GmbH"
       }
      }
     },
     "localname": "BiogenIdecInternationalNeuroscienceMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Biogenshareofcopromotionprofitsorlosses": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biogen share of co-promotion profits or losses",
        "label": "Biogen share of co-promotion profits or losses",
        "terseLabel": "Biogen share of co-promotion profits or losses"
       }
      }
     },
     "localname": "Biogenshareofcopromotionprofitsorlosses",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BioverativMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bioverativ [Member]",
        "label": "Bioverativ [Member]",
        "terseLabel": "Bioverativ"
       }
      }
     },
     "localname": "BioverativMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/InventoryDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bristol-Myers Squibb [Member]",
        "label": "Bristol-Myers Squibb [Member]",
        "terseLabel": "Bristol-Myers Squibb"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "terseLabel": "Business Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_BusinessTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business.",
        "label": "Business (Textual) [Abstract]",
        "terseLabel": "Business (Textual)"
       }
      }
     },
     "localname": "BusinessTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_CashSettledPerformanceSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash settled performance shares.",
        "label": "Cash Settled Performance Shares [Abstract]",
        "verboseLabel": "Cash settled performance shares"
       }
      }
     },
     "localname": "CashSettledPerformanceSharesAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_CashSettledPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash settled performance shares [Member]",
        "label": "Cash settled performance shares [Member]",
        "terseLabel": "Cash settled performance units"
       }
      }
     },
     "localname": "CashSettledPerformanceSharesMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails6",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.",
        "label": "Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment",
        "verboseLabel": "Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment"
       }
      }
     },
     "localname": "CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_CoPromotionProfitSharingFormulaAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Co-promotion profit sharing formula.",
        "label": "Co Promotion Profit Sharing Formula [Abstract]",
        "verboseLabel": "Co-promotion profit sharing formula"
       }
      }
     },
     "localname": "CoPromotionProfitSharingFormulaAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_CoPromotionProfitSharingFormulaTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Co-promotion profit sharing formula.",
        "label": "Co Promotion Profit Sharing Formula [Table Text Block]",
        "verboseLabel": "Co-promotion profit sharing formula"
       }
      }
     },
     "localname": "CoPromotionProfitSharingFormulaTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CollaborationProfitSharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.",
        "label": "Collaboration profit sharing",
        "terseLabel": "Collaboration profit (loss) sharing"
       }
      }
     },
     "localname": "CollaborationProfitSharing",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expenses"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_CollaborationsTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborations.",
        "label": "Collaborations (Textual) [Abstract]",
        "verboseLabel": "Collaborative and Other Relationships (Textual)"
       }
      }
     },
     "localname": "CollaborationsTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercial Milestones [Member]",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones [Member]"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CommitmentsAndContingenciesTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments And Contingencies.",
        "label": "Commitments And Contingencies (Textual) [Abstract]",
        "terseLabel": "Commitments And Contingencies (Textual)"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_CompensationExpenseOverPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Compensation expense over purchase period.",
        "label": "Compensation Expense Over Purchase Period",
        "terseLabel": "Compensation expense over purchase period"
       }
      }
     },
     "localname": "CompensationExpenseOverPurchasePeriod",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ComputerSoftwareAndHardware": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Computer software and hardware",
        "label": "Computer software and hardware",
        "terseLabel": "Computer software and hardware"
       }
      }
     },
     "localname": "ComputerSoftwareAndHardware",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Option Exercise Fee",
        "label": "Contract Option Exercise Fee",
        "terseLabel": "Contract Option Exercise Fee"
       }
      }
     },
     "localname": "ContractOptionExerciseFee",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual Adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ConvergencePharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convergence Pharmaceuticals [Member]",
        "label": "Convergence Pharmaceuticals [Member]",
        "terseLabel": "Convergence Pharmaceuticals"
       }
      }
     },
     "localname": "ConvergencePharmaceuticalsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CumulativeSalesLevel": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cumulative sales level",
        "label": "Cumulative sales level",
        "terseLabel": "Cumulative sales level"
       }
      }
     },
     "localname": "CumulativeSalesLevel",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_CumulativeSalesLevelAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cumulative sales level [Axis]",
        "label": "Cumulative sales level [Axis]",
        "terseLabel": "Cumulative sales level [Axis]"
       }
      }
     },
     "localname": "CumulativeSalesLevelAxis",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_CumulativeSalesLevelDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Cumulative sales level [Axis]",
        "label": "Cumulative sales level [Domain]",
        "terseLabel": "Cumulative sales level [Domain]"
       }
      }
     },
     "localname": "CumulativeSalesLevelDomain",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current provisions relating to sales in current year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Make Whole Provision Redemption Price, Percentage",
        "label": "Debt Instrument, Make Whole Provision Redemption Price, Percentage",
        "terseLabel": "Redemption percentage for change in control provision on the 2015 Senior Notes"
       }
      }
     },
     "localname": "DebtInstrumentMakeWholeProvisionRedemptionPricePercentage",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_December2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "December 2019 Share Repurchase Program [Member]",
        "label": "December 2019 Share Repurchase Program [Member]",
        "terseLabel": "December 2019 Share Repurchase Program [Member]"
       }
      }
     },
     "localname": "December2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DeferredTaxAssetLiabilityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Asset/Liability Type [Axis]",
        "label": "Deferred Tax Asset/Liability Type [Axis]",
        "terseLabel": "Deferred Tax Asset/Liability Type [Axis]"
       }
      }
     },
     "localname": "DeferredTaxAssetLiabilityTypeAxis",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DeferredTaxAssetLiabilityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Deferred Tax Asset/Liability Type [Axis]",
        "label": "Deferred Tax Asset/Liability Type [Domain]",
        "terseLabel": "Deferred Tax Asset/Liability Type [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetLiabilityTypeDomain",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DeferredTaxLiabilitiesDepreciationAmortizationOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax liabilities depreciation amortization other.",
        "label": "Deferred Tax Liabilities Depreciation Amortization Other",
        "negatedTerseLabel": "Depreciation, amortization and other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciationAmortizationOther",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxLiabilitiesTaxCreditCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Tax Credit Carryforwards",
        "label": "Deferred Tax Liabilities, Tax Credit Carryforwards",
        "terseLabel": "Deferred Tax Liabilities, Tax Credit Carryforwards"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxCreditCarryforwards",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredtaxliabilitiesGILTItaxcalculation": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax liabilities, GILTI tax calculation",
        "label": "Deferred tax liabilities, GILTI tax calculation",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "DeferredtaxliabilitiesGILTItaxcalculation",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries",
        "label": "Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries",
        "terseLabel": "Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries"
       }
      }
     },
     "localname": "Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredtaxliabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax liability [Member]",
        "label": "Deferred tax liability [Member]",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredtaxliabilityMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DenmarkManufacturingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denmark Manufacturing Operations [Member]",
        "label": "Denmark Manufacturing Operations [Member]",
        "terseLabel": "Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "DenmarkManufacturingOperationsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Gains (losses) on net investment hedge, excluded component"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development Milestones [Member]",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DevelopmentalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Developmental Milestone Payment",
        "label": "Developmental Milestone Payment",
        "terseLabel": "Developmental Milestone Payment"
       }
      }
     },
     "localname": "DevelopmentalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DirectorsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Directors plan.",
        "label": "Directors Plan [Member]",
        "verboseLabel": "Directors Plan"
       }
      }
     },
     "localname": "DirectorsPlanMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DivestituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]"
       }
      }
     },
     "localname": "DivestituresAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "xbrltype": "stringItemType"
    },
    "biib_DueFromUnconsolidatedJointBusiness": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from unconsolidated joint business",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DueFromUnconsolidatedJointBusiness",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "Aducanumab [Member]"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ELOCTATEMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ELOCTATE [Member]",
        "label": "ELOCTATE [Member]",
        "terseLabel": "ELOCTATE"
       }
      }
     },
     "localname": "ELOCTATEMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EachAdditionalOneBillionUpToTwentyBillionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Each additional one billion up to twenty billion [Member]",
        "label": "Each additional one billion up to twenty billion [Member]",
        "terseLabel": "Each additional one billion up to twenty billion"
       }
      }
     },
     "localname": "EachAdditionalOneBillionUpToTwentyBillionMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EarningsPerShareTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earnings per share.",
        "label": "Earnings Per Share (Textual) [Abstract]",
        "terseLabel": "Earnings per share (Textual)"
       }
      }
     },
     "localname": "EarningsPerShareTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization",
        "label": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective income tax rate reconciliation manufacturing deduction",
        "label": "Effective income tax rate reconciliation manufacturing deduction",
        "terseLabel": "Manufacturing deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationManufacturingDeduction",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeBenefitPlansTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee benefit plans.",
        "label": "Employee Benefit Plans (Textual) [Abstract]",
        "verboseLabel": "Employee Benefit Plans (Textual) [Abstract]"
       }
      }
     },
     "localname": "EmployeeBenefitPlansTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenue from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Samsung Bioepis, ownership percentage before additional purchase transaction"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentsExpectedProfitShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investments, Expected Profit Share",
        "label": "Equity Method Investments, Expected Profit Share",
        "terseLabel": "Equity Method Investments, Expected Profit Share"
       }
      }
     },
     "localname": "EquityMethodInvestmentsExpectedProfitShare",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones.",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones",
        "verboseLabel": "Estimated additional payments upon achievement of development and commercial milestones"
       }
      }
     },
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EstimatedUsefulLivesOfLeaseholdImprovements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated useful lives of leasehold improvements.",
        "label": "Estimated Useful Lives Of Leasehold Improvements",
        "terseLabel": "Estimated useful lives of leasehold improvements"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfLeaseholdImprovements",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected additional milestone payments when meeting certain sales threshold.",
        "label": "Expected Additional Milestone Payments When Meeting Certain Sales Threshold",
        "verboseLabel": "Expected additional milestone payments when certain sales threshold is met"
       }
      }
     },
     "localname": "ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected license fee and regulatory milestone payments.",
        "label": "Expected License Fee And Regulatory Milestone Payments",
        "terseLabel": "Expected License Fee And Regulatory Milestone Payments"
       }
      }
     },
     "localname": "ExpectedLicenseFeeAndRegulatoryMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpectedPaymentTimelineofMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected Payment Timeline of Milestone [Axis]",
        "label": "Expected Payment Timeline of Milestone [Axis]",
        "terseLabel": "Expected Payment Timeline of Milestone [Axis]"
       }
      }
     },
     "localname": "ExpectedPaymentTimelineofMilestoneAxis",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ExpectedPaymentTimelineofMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Expected Payment Timeline of Milestone [Axis]",
        "label": "Expected Payment Timeline of Milestone [Domain]",
        "terseLabel": "Expected Payment Timeline of Milestone [Domain]"
       }
      }
     },
     "localname": "ExpectedPaymentTimelineofMilestoneDomain",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ExpenseIncurredByCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total expense incurred by collaboration.",
        "label": "Expense Incurred By Collaboration",
        "terseLabel": "BAN2401 and Elenbecestat R&amp;D expense incurred by collaboration"
       }
      }
     },
     "localname": "ExpenseIncurredByCollaboration",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Aducanumab expense incurred by the collaboration",
        "verboseLabel": "BAN2401 and Elenbecestat expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Biogen's share of expense reflected within our consolidation statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "label": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "terseLabel": "Fair value, in-process research and development, discount rate"
       }
      }
     },
     "localname": "FairValueIndefiniteLivedIntangibleAssetsDiscountRate",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_FairValueMeasurementInputs": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value Measurement Inputs",
        "label": "Fair Value Measurement Inputs",
        "terseLabel": "Fair value measurement and measurement inputs, recurring and nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementInputs",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_FifteenbillionMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fifteen billion [Member] [Member]",
        "label": "Fifteen billion [Member] [Member]",
        "terseLabel": "Fifteen billion"
       }
      }
     },
     "localname": "FifteenbillionMemberMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FinancialInstrumentsTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial Instruments.",
        "label": "Financial Instruments (Textual) [Abstract]",
        "terseLabel": "Financial Instruments (Textual)"
       }
      }
     },
     "localname": "FinancialInstrumentsTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ForeignSalesRequiredToTriggerMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign sales required to trigger milestone.",
        "label": "Foreign Sales Required To Trigger Milestone",
        "verboseLabel": "Foreign sales required to trigger milestone"
       }
      }
     },
     "localname": "ForeignSalesRequiredToTriggerMilestone",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ForeignearningsintheformofcashandcashequivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign earnings in the form of cash and cash equivalents [Member]",
        "label": "Foreign earnings in the form of cash and cash equivalents [Member]",
        "terseLabel": "Earnings in the form of cash and cash equivalents"
       }
      }
     },
     "localname": "ForeignearningsintheformofcashandcashequivalentsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ForeignearningstypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign earnings type [Axis]",
        "label": "Foreign earnings type [Axis]",
        "terseLabel": "Foreign earnings type [Axis]"
       }
      }
     },
     "localname": "ForeignearningstypeAxis",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ForeignearningstypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Foreign earnings type [Axis]",
        "label": "Foreign earnings type [Domain]",
        "terseLabel": "Foreign earnings type [Domain]"
       }
      }
     },
     "localname": "ForeignearningstypeDomain",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FumapharmAgMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fumapharm AG [Member]",
        "label": "Fumapharm AG [Member]",
        "terseLabel": "Fumapharm AG"
       }
      }
     },
     "localname": "FumapharmAgMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "terseLabel": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesAxis",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Domain]",
        "terseLabel": "Future Contingent Milestone Types [Domain]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesDomain",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future contingent payment for annual worldwide net sales that exceed $2.0 billion",
        "label": "Future contingent payment for annual worldwide net sales that exceed $2.0 billion",
        "terseLabel": "Future contingent payment for annual worldwide net sales that exceed $2.0 billion"
       }
      }
     },
     "localname": "FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future contingent payment for annual worldwide net sales up to $2.0 billion",
        "label": "Future contingent payment for annual worldwide net sales up to $2.0 billion",
        "terseLabel": "Future contingent payment for annual worldwide net sales up to $2.0 billion"
       }
      }
     },
     "localname": "FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_FutureContingentPaymentThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future contingent payment threshold",
        "label": "Future contingent payment threshold",
        "terseLabel": "Future contingent payment threshold"
       }
      }
     },
     "localname": "FutureContingentPaymentThreshold",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future royalties percentage to be received on sale of product.",
        "label": "Future Royalties Percentage To Be Received On Sale Of Product",
        "verboseLabel": "Future royalties percentage to be received on sale of ocrelizumab"
       }
      }
     },
     "localname": "FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Futurepercentageofcopromotionoperatingprofits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future percentage of co-promotion operating profits",
        "label": "Future percentage of co-promotion operating profits",
        "terseLabel": "Future percentage of co-promotion operating profits"
       }
      }
     },
     "localname": "Futurepercentageofcopromotionoperatingprofits",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_GAZYVAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "GAZYVA [Member]",
        "label": "GAZYVA [Member]",
        "terseLabel": "GAZYVA"
       }
      }
     },
     "localname": "GAZYVAMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_HemophiliaProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hemophilia Products",
        "label": "Hemophilia Products [Member]",
        "terseLabel": "Hemophilia Products"
       }
      }
     },
     "localname": "HemophiliaProductsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IPerianMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "iPerian [Member]",
        "label": "iPerian [Member]",
        "terseLabel": "iPerian"
       }
      }
     },
     "localname": "IPerianMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IncomeTaxesTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Taxes.",
        "label": "Income Taxes (Textual) [Abstract]",
        "verboseLabel": "Income Taxes (Textual)"
       }
      }
     },
     "localname": "IncomeTaxesTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_IndefiniteLivedIntangibleAssetsUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indefinite lived intangible assets useful life.",
        "label": "Indefinite Lived Intangible Assets Useful Life",
        "terseLabel": "Indefinite lived intangible assets useful life"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsUsefulLife",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "durationStringItemType"
    },
    "biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets and goodwill additional.",
        "label": "Intangible Assets And Goodwill (Additional Textual) [Abstract]",
        "verboseLabel": "Intangible Assets and Goodwill (Additional Textual)"
       }
      }
     },
     "localname": "IntangibleAssetsAndGoodwillAdditionalTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "terseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InventoryrawmaterialssoldtoFUJIFILM": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory raw materials sold to FUJIFILM",
        "label": "Inventory raw materials sold to FUJIFILM",
        "terseLabel": "Inventory raw materials sold to FUJIFILM"
       }
      }
     },
     "localname": "InventoryrawmaterialssoldtoFUJIFILM",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual",
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InventorysoldtoBioverativcost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory sold to Bioverativ, cost",
        "label": "Inventory sold to Bioverativ, cost",
        "terseLabel": "Inventory sold to Bioverativ, cost"
       }
      }
     },
     "localname": "InventorysoldtoBioverativcost",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInVariableInterestEntitiesTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in Variable Interest Entities.",
        "label": "Investment in Variable Interest Entities (Textual) [Abstract]",
        "verboseLabel": "Investment in Variable Interest Entities (Textual)"
       }
      }
     },
     "localname": "InvestmentInVariableInterestEntitiesTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_Investmentincommonstocksharespurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in common stock, shares purchased",
        "label": "Investment in common stock, shares purchased",
        "terseLabel": "Investment in common stock, shares purchased"
       }
      }
     },
     "localname": "Investmentincommonstocksharespurchased",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_Investmentincommonstockvalue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in common stock, value",
        "label": "Investment in common stock, value",
        "terseLabel": "Investment in common stock, value"
       }
      }
     },
     "localname": "Investmentincommonstockvalue",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments by third party in joint venture as per agreement",
        "label": "Investments By Third Party In Joint Venture As Per Agreement.",
        "terseLabel": "Investments By Third Party In Joint Venture As Per Agreement."
       }
      }
     },
     "localname": "InvestmentsByThirdPartyInJointVentureAsPerAgreement",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "xbrltype": "stringItemType"
    },
    "biib_IonisPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ionis Pharmaceuticals [Member]",
        "label": "Ionis Pharmaceuticals [Member]",
        "terseLabel": "Ionis Pharmaceuticals"
       }
      }
     },
     "localname": "IonisPharmaceuticalsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_JointVentureOwnerShipPercentageByThirdParty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Joint venture owner ship percentage by third party.",
        "label": "Joint Venture Owner Ship Percentage By Third Party.",
        "terseLabel": "Joint Venture Owner Ship Percentage By Third Party."
       }
      }
     },
     "localname": "JointVentureOwnerShipPercentageByThirdParty",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_KaryopharmMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Karyopharm [Member]",
        "label": "Karyopharm [Member]",
        "terseLabel": "Karyopharm"
       }
      }
     },
     "localname": "KaryopharmMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_LesseeLeaseTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee Lease Table [Table Text Block]",
        "label": "Lessee Lease Table [Table Text Block]",
        "terseLabel": "Schedule of operating leases"
       }
      }
     },
     "localname": "LesseeLeaseTableTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_LicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Fee",
        "label": "License Fee",
        "terseLabel": "License Fee"
       }
      }
     },
     "localname": "LicenseFee",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_LongtermoperatingleaseliabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term operating lease liabilities [Member]",
        "label": "Long-term operating lease liabilities [Member]",
        "terseLabel": "Long-term operating lease liabilities [Member]"
       }
      }
     },
     "localname": "LongtermoperatingleaseliabilitiesMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "MS Product Revenues"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MajorDistributorAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Major Distributor.",
        "label": "Major Distributor [Axis]",
        "terseLabel": "Major Distributor [Axis]"
       }
      }
     },
     "localname": "MajorDistributorAxis",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_MajorDistributorDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Major Distributor.",
        "label": "Major Distributor [Domain]",
        "terseLabel": "Major Distributor [Domain]"
       }
      }
     },
     "localname": "MajorDistributorDomain",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_March2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "March 2019 Share Repurchase Program [Member]",
        "label": "March 2019 Share Repurchase Program [Member]",
        "terseLabel": "March 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "March2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Market stock units activity.",
        "label": "Market Stock Units Activity [Abstract]",
        "verboseLabel": "Market stock units activity"
       }
      }
     },
     "localname": "MarketStockUnitsActivityAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum target number of market stock units granted based on stock performance in percent.",
        "label": "Maximum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent",
        "verboseLabel": "Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)"
       }
      }
     },
     "localname": "MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_MinimumQualifyingAgeForEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum qualifying age for employee benefit plan.",
        "label": "Minimum Qualifying Age For Employee Benefit Plan",
        "terseLabel": "Minimum Qualifying Age For Employee Benefit Plan"
       }
      }
     },
     "localname": "MinimumQualifyingAgeForEmployeeBenefitPlan",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum target number of market stock units granted based on stock performance in percent.",
        "label": "Minimum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent",
        "verboseLabel": "Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)"
       }
      }
     },
     "localname": "MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NetMinimumLeasePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments total.",
        "label": "Net Minimum Lease Payments",
        "totalLabel": "ASC 840 - Net minimum lease payments, total"
       }
      }
     },
     "localname": "NetMinimumLeasePayments",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments thereafter.",
        "label": "Net Minimum Lease Payments Thereafter",
        "totalLabel": "ASC 840 - Net minimum lease payments, thereafter"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsThereafter",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInFiveYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in five year.",
        "label": "Net Minimum Lease Payments With In Five Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2023"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInFiveYear",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInFourYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in four year.",
        "label": "Net Minimum Lease Payments With In Four Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2022"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInFourYear",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInOneYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in one year.",
        "label": "Net Minimum Lease Payments With In One Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2019"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInOneYear",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInThreeYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in three year.",
        "label": "Net Minimum Lease Payments With In Three Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2021"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInThreeYear",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInTwoYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in two year.",
        "label": "Net Minimum Lease Payments With In Two Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2020"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInTwoYear",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NeurimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Neurimmune.",
        "label": "Neurimmune [Member]",
        "terseLabel": "Neurimmune",
        "verboseLabel": "Neurimmune"
       }
      }
     },
     "localname": "NeurimmuneMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NewAntiCd20Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New Anti-CD20.",
        "label": "New Anti Cd20 [Member]",
        "verboseLabel": "New Anti-CD20"
       }
      }
     },
     "localname": "NewAntiCd20Member",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NightstarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nightstar [Member]",
        "label": "Nightstar [Member]",
        "terseLabel": "Nightstar"
       }
      }
     },
     "localname": "NightstarMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails",
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Noncontrollinginterestincreasedecreaseother": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncontrolling interest, increase (decrease) other",
        "label": "Noncontrolling interest, increase (decrease) other",
        "terseLabel": "Capital contribution by noncontrolling interest"
       }
      }
     },
     "localname": "Noncontrollinginterestincreasedecreaseother",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NumberOfDaysForCalculationOfAverageClosingStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of days for calculation of average closing stock price.",
        "label": "Number Of Days For Calculation Of Average Closing Stock Price",
        "verboseLabel": "Number of days for calculation of average closing stock price"
       }
      }
     },
     "localname": "NumberOfDaysForCalculationOfAverageClosingStockPrice",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_NumberOfEqualAnnualIncrements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equal annual increments.",
        "label": "Number Of Equal Annual Increments",
        "verboseLabel": "Number of equal annual increments"
       }
      }
     },
     "localname": "NumberOfEqualAnnualIncrements",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share-based compensation plans pursuant to which awards are currently being made.",
        "label": "Number Of Share Based Compensation Plans Pursuant To Which Awards Are Currently Being Made",
        "verboseLabel": "Number of share-based compensation plans pursuant to which awards are currently being made"
       }
      }
     },
     "localname": "NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfSharesOfCommonStockForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of shares of common stock for issuance.",
        "label": "Number Of Shares Of Common Stock For Issuance",
        "verboseLabel": "Total number of shares of common stock for issuance"
       }
      }
     },
     "localname": "NumberOfSharesOfCommonStockForIssuance",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_OCREVUSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "OCREVUS",
        "label": "OCREVUS [Member]",
        "verboseLabel": "OCREVUS"
       }
      }
     },
     "localname": "OCREVUSMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OperatingleaseassetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating lease assets [Member]",
        "label": "Operating lease assets [Member]",
        "terseLabel": "Operating lease assets [Member]"
       }
      }
     },
     "localname": "OperatingleaseassetsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating lease supplemental cash flow disclosure [Table Text Block]",
        "label": "Operating lease supplemental cash flow disclosure [Table Text Block]",
        "terseLabel": "Operating lease supplemental cash flow disclosure [Table Text Block]"
       }
      }
     },
     "localname": "OperatingleasesupplementalcashflowdisclosureTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating lease weighted average remaining term and discount rate [Table Text Block]",
        "label": "Operating lease weighted average remaining term and discount rate [Table Text Block]",
        "terseLabel": "Operating lease weighted average remaining term and discount rate [Table Text Block]"
       }
      }
     },
     "localname": "OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherForeignEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Foreign Earnings [Member]",
        "label": "Other Foreign Earnings [Member]",
        "terseLabel": "Other Foreign Earnings"
       }
      }
     },
     "localname": "OtherForeignEarningsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate revenues"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherresearchanddiscoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other research and discovery [Member]",
        "label": "Other research and discovery [Member]",
        "terseLabel": "Other research and discovery"
       }
      }
     },
     "localname": "OtherresearchanddiscoveryMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PLSRMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "PLSR",
        "label": "PLSR [Member]",
        "terseLabel": "PLSR"
       }
      }
     },
     "localname": "PLSRMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentTermsOfAccountsReceivable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment  terms of accounts receivable.",
        "label": "Payment Terms Of Accounts Receivable",
        "verboseLabel": "Payment terms of accounts receivable arising from product sales"
       }
      }
     },
     "localname": "PaymentTermsOfAccountsReceivable",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedTerseLabel": "Payments/returns related to sales in current year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedTerseLabel": "Payments/returns related to sales in prior years"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of co promotion operating profits first fifty million.",
        "label": "Percentage Of Co Promotion Operating Profits First Fifty Million",
        "terseLabel": "Percentage of Co promotion Operating Profits first fifty million"
       }
      }
     },
     "localname": "PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option one.",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One",
        "terseLabel": "Until GAZYVA First Non-CLL FDA Approval",
        "verboseLabel": "Until GAZYVA First Non-CLL FDA Approval"
       }
      }
     },
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two.",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two [Abstract]",
        "verboseLabel": "After First GA101 Threshold Date"
       }
      }
     },
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option one.",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One",
        "terseLabel": "Until First GAZYVA Threshold Date",
        "verboseLabel": "Until First GAZYVA Threshold Date"
       }
      }
     },
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option three.",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three",
        "verboseLabel": "After Second Threshold Date"
       }
      }
     },
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option two.",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two",
        "terseLabel": "After First Threshold Date and until Second Threshold Date",
        "verboseLabel": "After First Threshold Date and until Second Threshold Date"
       }
      }
     },
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfMinimumInvestmentReturn": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of minimum investment return.",
        "label": "Percentage Of Minimum Investment Return",
        "verboseLabel": "Percentage of minimum investment return"
       }
      }
     },
     "localname": "PercentageOfMinimumInvestmentReturn",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfRoyaltiesAsPerCollaboration": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of royalties as per collaboration.",
        "label": "Percentage Of Royalties As Per Collaboration",
        "terseLabel": "Percentage Of Royalties As Per Collaboration"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesAsPerCollaboration",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageParValueOfSeniorNotes": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Par Value Of Senior Notes",
        "label": "Percentage Par Value Of Senior Notes",
        "verboseLabel": "Redemption percentage par value of senior notes"
       }
      }
     },
     "localname": "PercentageParValueOfSeniorNotes",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage receivables of wholesale distributor accounted in consolidated receivables.",
        "label": "Percentage Receivables Of Wholesale Distributor Accounted In Consolidated Receivables",
        "terseLabel": "Percentage receivables of wholesale distributor accounted in consolidated receivables"
       }
      }
     },
     "localname": "PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Abstract]",
        "label": "Performance Stock Units Settled in Cash [Abstract]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails9",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Table Text Block]",
        "label": "Performance Stock Units Settled in Cash [Table Text Block]",
        "terseLabel": "Performance stock units settled in cash activity"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Abstract]",
        "label": "Performance Stock Units Settled in Stock [Abstract]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Table Text Block]",
        "label": "Performance Stock Units Settled in Stock [Table Text Block]",
        "terseLabel": "Performance stock units settled in stock activity"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_PerformanceUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Units [Member]",
        "label": "Performance Units [Member]",
        "terseLabel": "Performance Units"
       }
      }
     },
     "localname": "PerformanceUnitsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceunitsactivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance units activity [Table Text Block]",
        "label": "Performance units activity [Table Text Block]",
        "terseLabel": "Performance units activity"
       }
      }
     },
     "localname": "PerformanceunitsactivityTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_PeriodOfCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period Of Collaboration Agreement",
        "label": "Period Of Collaboration Agreement",
        "verboseLabel": "Period of collaboration agreement"
       }
      }
     },
     "localname": "PeriodOfCollaborationAgreement",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer [Member]",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PostacquisitionequitycompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Post-acquisition equity compensation [Member]",
        "label": "Post-acquisition equity compensation [Member]",
        "terseLabel": "Post-acquisition equity compensation"
       }
      }
     },
     "localname": "PostacquisitionequitycompensationMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential future milestone payments commitment to third party approximately.",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "terseLabel": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "verboseLabel": "Potential future milestone payments commitment, approximately"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Premiumonpurchaseofcommonstock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Premium on purchase of common stock",
        "label": "Premium on purchase of common stock",
        "terseLabel": "Premium on purchase of common stock"
       }
      }
     },
     "localname": "Premiumonpurchaseofcommonstock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PrepaidtaxesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid taxes [Member]",
        "label": "Prepaid taxes [Member]",
        "terseLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidtaxesMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PretaxProfitSharingFormulaTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pretax Profit Sharing Formula [Table Text Block]",
        "label": "Pretax Profit Sharing Formula [Table Text Block]",
        "terseLabel": "Pretax profit sharing formula"
       }
      }
     },
     "localname": "PretaxProfitSharingFormulaTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_ProceedsFromMarketableDebtSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from marketable debt securities.",
        "label": "Proceeds from Marketable Debt Securities [Abstract]",
        "verboseLabel": "Proceeds from Marketable Debt Securities"
       }
      }
     },
     "localname": "ProceedsFromMarketableDebtSecuritiesAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_PurchasePriceOfCommonStockUnderEspp": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase Price Of Common Stock Under ESPP.",
        "label": "Purchase Price Of Common Stock Under ESPP",
        "terseLabel": "Purchase price of common stock under ESPP"
       }
      }
     },
     "localname": "PurchasePriceOfCommonStockUnderEspp",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_Purchaseofcommonstock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase of common stock",
        "label": "Purchase of common stock",
        "terseLabel": "Purchase of common stock"
       }
      }
     },
     "localname": "Purchaseofcommonstock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_RatioOfNumberOfSharesReservedUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio of total number of shares reserved under the plan.",
        "label": "Ratio Of Number Of Shares Reserved Under Plan",
        "verboseLabel": "Ratio of total number of shares reserved under the plan"
       }
      }
     },
     "localname": "RatioOfNumberOfSharesReservedUnderPlan",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reclassification out of Accumulated Other Comprehensive Income [Abstract]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "ReclassificationoutofAccumulatedOtherComprehensiveIncomeAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "xbrltype": "stringItemType"
    },
    "biib_Reductionindeferredtaxliabilityundistributedforeignearnings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction in deferred tax liability, undistributed foreign earnings",
        "label": "Reduction in deferred tax liability, undistributed foreign earnings",
        "terseLabel": "Reduction in deferred tax liability, undistributed foreign earnings"
       }
      }
     },
     "localname": "Reductionindeferredtaxliabilityundistributedforeignearnings",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Reductioninroyaltyrate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction in royalty rate",
        "label": "Reduction in royalty rate",
        "terseLabel": "Reduction in royalty rate"
       }
      }
     },
     "localname": "Reductioninroyaltyrate",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Reductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction in royalty rate payable on commercial sales",
        "label": "Reduction in royalty rate payable on commercial sales",
        "terseLabel": "Reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Reductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_RegulatoryApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Approval Milestone [Member]",
        "label": "Regulatory Approval Milestone [Member]",
        "terseLabel": "Regulatory Approval Milestone"
       }
      }
     },
     "localname": "RegulatoryApprovalMilestoneMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RemedyPharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remedy Pharmaceutical [Member]",
        "label": "Remedy Pharmaceutical [Member]",
        "terseLabel": "Remedy Pharmaceutical"
       }
      }
     },
     "localname": "RemedyPharmaceuticalMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Research and development asset [Axis]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetDomain",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting",
        "label": "Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting",
        "terseLabel": "Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting"
       }
      }
     },
     "localname": "ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_RestrictedStockUnitsActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restricted stock units activity.",
        "label": "Restricted Stock Units Activity [Abstract]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsActivityAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_RevenuesFromUnconsolidatedJointBusinessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from unconsolidated joint business.",
        "label": "Revenues From Unconsolidated Joint Business [Abstract]",
        "verboseLabel": "Revenues from unconsolidated joint business"
       }
      }
     },
     "localname": "RevenuesFromUnconsolidatedJointBusinessAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues In Percentage From Anti-CD20 Therapeutic Programs",
        "label": "Revenues In Percentage From Anti-CD20 Therapeutic Programs",
        "terseLabel": "Revenues In Percentage From Anti-CD20 Therapeutic Programs"
       }
      }
     },
     "localname": "RevenuesInPercentageFromAntiCD20TherapeuticPrograms",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables",
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenues from anti-cd20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RituxanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "RITUXAN.",
        "label": "RITUXAN [Member]",
        "terseLabel": "RITUXAN"
       }
      }
     },
     "localname": "RituxanMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech",
        "verboseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RoyaltyCostofSalesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Cost of Sales [Policy Text Block]",
        "label": "Royalty Cost of Sales [Policy Text Block]",
        "terseLabel": "Royalty Cost of Sales"
       }
      }
     },
     "localname": "RoyaltyCostofSalesPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty operating profit threshold for highest royalty rate percentage",
        "label": "Royalty operating profit threshold for highest royalty rate percentage",
        "terseLabel": "Royalty operating profit threshold for highest royalty rate percentage"
       }
      }
     },
     "localname": "Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_SOD1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SOD1 [Member]",
        "label": "SOD1 [Member]",
        "terseLabel": "SOD1"
       }
      }
     },
     "localname": "SOD1Member",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SalesTriggerGrossSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales trigger gross sales threshold.",
        "label": "Sales Trigger Gross Sales Threshold",
        "terseLabel": "Sales Trigger Gross Sales Threshold"
       }
      }
     },
     "localname": "SalesTriggerGrossSalesThreshold",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Cash Settled Performance Shares Activity.",
        "label": "Schedule Of Cash Settled Performance Shares Activity [Table Text Block]",
        "terseLabel": "Cash settled performance shares activity"
       }
      }
     },
     "localname": "ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Development Milestone And Collaboration.",
        "label": "Schedule Of Development Milestone And Collaboration [Line Items]",
        "terseLabel": "Schedule Of Development Milestone And Collaboration [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfDevelopmentMilestoneAndCollaborationLineItems",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of development milestone and collaboration.",
        "label": "Schedule Of Development Milestone And Collaboration [Table]",
        "terseLabel": "Schedule Of Development Milestone And Collaboration [Table]"
       }
      }
     },
     "localname": "ScheduleOfDevelopmentMilestoneAndCollaborationTable",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ScheduleOfMarketStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Market Stock Units Activity.",
        "label": "Schedule Of Market Stock Units Activity [Table Text Block]",
        "terseLabel": "Market stock units activity"
       }
      }
     },
     "localname": "ScheduleOfMarketStockUnitsActivityTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of property plant and equipment useful lives.",
        "label": "Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Property, plant and equipment estimated useful lives"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Segment geographical groups of countries group other.",
        "label": "Segment Geographical Groups Of Countries Group Other [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "SegmentGeographicalGroupsOfCountriesGroupOtherMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SegmentInformationTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Segment Information.",
        "label": "Segment Information (Textual) [Abstract]",
        "verboseLabel": "Segment Information (Textual) [Abstract]"
       }
      }
     },
     "localname": "SegmentInformationTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.20% Senior Notes due 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.05% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "label": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "terseLabel": "2.90% Senior Notes due 2020"
       }
      }
     },
     "localname": "SeniorNotesTwoPointNinePercentDueTwentyTwentyMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeriesXPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series X preferred stock.",
        "label": "Series X Preferred Stock [Member]",
        "terseLabel": "Series X junior participating"
       }
      }
     },
     "localname": "SeriesXPreferredStockMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareBasedPaymentsTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Payments.",
        "label": "Share-Based Payments (Textual) [Abstract]",
        "terseLabel": "Share-Based Payments (Textual)"
       }
      }
     },
     "localname": "ShareBasedPaymentsTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "verboseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares issued under employee stock purchase plan.",
        "label": "Shares Issued Under Employee Stock Purchase Plan [Table Text Block]",
        "terseLabel": "Shares issued under employee stock purchase plan"
       }
      }
     },
     "localname": "SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SixteenbillionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sixteen billion [Member]",
        "label": "Sixteen billion [Member]",
        "terseLabel": "Sixteen billion"
       }
      }
     },
     "localname": "SixteenbillionMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SkyhawkTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Skyhawk Therapeutics [Member]",
        "label": "Skyhawk Therapeutics [Member]",
        "terseLabel": "Skyhawk Therapeutics"
       }
      }
     },
     "localname": "SkyhawkTherapeuticsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SobiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sobi [Member]",
        "label": "Sobi [Member]",
        "terseLabel": "Sobi"
       }
      }
     },
     "localname": "SobiMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Solothurn [Member]",
        "label": "Solothurn [Member]",
        "terseLabel": "Solothurn"
       }
      }
     },
     "localname": "SolothurnMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual",
      "http://www.biogenidec.com/role/SegmentInformationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StockOptionActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock option activity.",
        "label": "Stock Option Activity [Abstract]",
        "verboseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "StockOptionActivityAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_StockOptionsAndEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock options and employee stock purchase plan.",
        "label": "Stock options and employee stock purchase plan [Member]",
        "verboseLabel": "Stock options and employee stock purchase plan"
       }
      }
     },
     "localname": "StockOptionsAndEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StockholdersEquityTaxBenefitExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stockholders Equity, Tax Benefit (Expense)",
        "label": "Stockholders Equity, Tax Benefit (Expense)",
        "terseLabel": "Tax benefit"
       }
      }
     },
     "localname": "StockholdersEquityTaxBenefitExpense",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StromedixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stromedix.",
        "label": "Stromedix [Member]",
        "verboseLabel": "Stromedix, Inc."
       }
      }
     },
     "localname": "StromedixMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SubleaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sublease [Member]",
        "label": "Sublease [Member]",
        "terseLabel": "Sublease"
       }
      }
     },
     "localname": "SubleaseMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]",
        "label": "Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]",
        "terseLabel": "Summary of activity related to BAN2401 and Elenbecestat collaboration"
       }
      }
     },
     "localname": "SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfCommonStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of common stock.",
        "label": "Summary Of Common Stock [Table Text Block]",
        "terseLabel": "Summary of common stock"
       }
      }
     },
     "localname": "SummaryOfCommonStockTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheet"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of share-based compensation expense associated with different programs.",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]",
        "verboseLabel": "Summary of share based compensation expense associated with different programs"
       }
      }
     },
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of activity related to Aducanumab collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TGNMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TGN",
        "label": "TGN [Member]",
        "terseLabel": "TGN"
       }
      }
     },
     "localname": "TGNMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TMSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TMS [Member]",
        "label": "TMS [Member]",
        "terseLabel": "TMS"
       }
      }
     },
     "localname": "TMSMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TaxBenefitAndCashReceivedFromStockOptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax benefit and cash received from stock option.",
        "label": "Tax Benefit And Cash Received From Stock Option [Abstract]",
        "verboseLabel": "Tax benefit and cash received from stock option"
       }
      }
     },
     "localname": "TaxBenefitAndCashReceivedFromStockOptionAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_TaxcontingencyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax contingency [Abstract]",
        "label": "Tax contingency [Abstract]"
       }
      }
     },
     "localname": "TaxcontingencyAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "xbrltype": "stringItemType"
    },
    "biib_TecfideraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TECFIDERA [Member]",
        "label": "TECFIDERA [Member]",
        "terseLabel": "TECFIDERA"
       }
      }
     },
     "localname": "TecfideraMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Termofcollaborationagreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of collaboration agreement",
        "label": "Term of collaboration agreement",
        "terseLabel": "Term of collaboration agreement"
       }
      }
     },
     "localname": "Termofcollaborationagreement",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.",
        "label": "Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One",
        "verboseLabel": "Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one"
       }
      }
     },
     "localname": "ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold of gross sales to be achieved in any twelve consecutive months under option one.",
        "label": "Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One",
        "verboseLabel": "Limit of gross sale of GAZYVA to be achieved in any 12 months under option one"
       }
      }
     },
     "localname": "ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Time Vested Restricted Stock Units Activity.",
        "label": "Time Vested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Time-vested restricted stock units activity"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Totaldeferredchargesandprepaidtaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total deferred charges and prepaid taxes",
        "label": "Total deferred charges and prepaid taxes",
        "terseLabel": "Total deferred charges and prepaid taxes"
       }
      }
     },
     "localname": "Totaldeferredchargesandprepaidtaxes",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Totalpaymenttoentercollaborationagreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total payment to enter collaboration agreement",
        "label": "Total payment to enter collaboration agreement",
        "terseLabel": "Total payment to enter collaboration agreement"
       }
      }
     },
     "localname": "Totalpaymenttoentercollaborationagreement",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_TransitionTollTaxRepatriationTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transition Toll Tax Repatriation Tax Rate",
        "label": "Transition Toll Tax Repatriation Tax Rate",
        "terseLabel": "Transition Toll Tax repatriation tax rate"
       }
      }
     },
     "localname": "TransitionTollTaxRepatriationTaxRate",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_TwelvemonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Twelve months [Member]",
        "label": "Twelve months [Member]",
        "terseLabel": "Twelve months"
       }
      }
     },
     "localname": "TwelvemonthsMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TwentybillionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Twenty billion [Member]",
        "label": "Twenty billion [Member]",
        "terseLabel": "Twenty billion"
       }
      }
     },
     "localname": "TwentybillionMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_U.S.2017TaxActMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "U.S. 2017 Tax Act",
        "label": "U.S. 2017 Tax Act [Member]",
        "terseLabel": "2017 Tax Act"
       }
      }
     },
     "localname": "U.S.2017TaxActMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UndesignatedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Undesignated preferred stock.",
        "label": "Undesignated Preferred Stock [Member]",
        "terseLabel": "Undesignated"
       }
      }
     },
     "localname": "UndesignatedPreferredStockMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront And Milestone Payments Made To Collaborative Partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Upfrontpaymentforcollaborationagreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront payment for collaboration agreement",
        "label": "Upfront payment for collaboration agreement",
        "terseLabel": "Upfront payment for collaboration agreement"
       }
      }
     },
     "localname": "Upfrontpaymentforcollaborationagreement",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_VUMERITYMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VUMERITY [Member]",
        "label": "VUMERITY [Member]",
        "terseLabel": "VUMERITY"
       }
      }
     },
     "localname": "VUMERITYMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ValuationOfGrantedStockUnitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation of granted stock units.",
        "label": "Valuation of Granted Stock Units [Abstract]",
        "verboseLabel": "Assumptions used in valuation of market based stock units"
       }
      }
     },
     "localname": "ValuationOfGrantedStockUnitsAbstract",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period to recognize the cost of nonvested awards.",
        "label": "Weighted Average Period To Recognize Cost Of Nonvested Awards",
        "verboseLabel": "Weighted-average period to recognize the cost of unvested awards"
       }
      }
     },
     "localname": "WeightedAveragePeriodToRecognizeCostOfNonvestedAwards",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_WorkinprocessMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Work-in-process",
        "label": "Work-in-process [Member]",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "WorkinprocessMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20191231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "BRAZIL"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SWITZERLAND",
        "terseLabel": "SWITZERLAND"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "GERMANY"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DK": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "DENMARK",
        "terseLabel": "DENMARK"
       }
      }
     },
     "localname": "DK",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "JAPAN"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S",
        "verboseLabel": "U.S"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Canada, Dollars",
        "verboseLabel": "Canadian dollar"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Swiss francs"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound sterling"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AsiaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Asia [Member]",
        "terseLabel": "Asia"
       }
      }
     },
     "localname": "AsiaMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]",
        "verboseLabel": "Equity Method Investee, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r212",
      "r336",
      "r340",
      "r635"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails",
      "http://www.biogenidec.com/role/InventoryDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesLeasesDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesLeasesDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails",
      "http://www.biogenidec.com/role/InventoryDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r208",
      "r336",
      "r338",
      "r632",
      "r633"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesLeasesDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesLeasesDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Equity Method Investee, Name [Axis]",
        "verboseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/SegmentInformationDetails",
      "http://www.biogenidec.com/role/SegmentInformationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r211",
      "r336",
      "r339",
      "r634",
      "r642",
      "r646"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/SegmentInformationDetails",
      "http://www.biogenidec.com/role/SegmentInformationDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r214",
      "r579"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingGuidanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Previous accounting guidance and the new accounting guidance.",
        "label": "Accounting Guidance [Domain]",
        "terseLabel": "Accounting Guidance [Domain]"
       }
      }
     },
     "localname": "AccountingGuidanceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update 2016-01 [Member]",
        "terseLabel": "Accounting Standards Update 2016-01"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201616Member": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.",
        "label": "Accounting Standards Update 2016-16 [Member]",
        "terseLabel": "Accounting Standards Update 2016-16"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201616Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r24",
      "r47",
      "r215",
      "r216",
      "r337"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r42",
      "r593",
      "r618"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued Income Taxes, Noncurrent"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r30",
      "r31",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties and licensing fees"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r96",
      "r101",
      "r104",
      "r350",
      "r476"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded Status of Post Retirement Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r63",
      "r292"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r101",
      "r112",
      "r475"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized Gains (Losses) on Cash Flow Hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r101",
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gains (Losses) on Securities Available for Sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r101",
      "r522"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (Losses) on Net Investment Hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r99",
      "r100",
      "r101"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax Ending Balance",
        "periodStartLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax Beginning Balance",
        "terseLabel": "Balance, January 1, 2018",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r98",
      "r101",
      "r104",
      "r476"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r90",
      "r101",
      "r104",
      "r476"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r149",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r360",
      "r383",
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedLabel": "Share-based compensation expense",
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r149",
      "r272",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as hedge, excluded component, after tax"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r233",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r204",
      "r591",
      "r617"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r86"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r224",
      "r250"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "verboseLabel": "Marketable Debt and Equity Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Marketable equity securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Marketable equity securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-sale Securities, Current",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost",
        "verboseLabel": "Due after one year through five years, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r228",
      "r231",
      "r610"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "verboseLabel": "Due after one year through five years, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "verboseLabel": "Due in one year or less, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r228",
      "r230",
      "r609"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "verboseLabel": "Due in one year or less, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r222",
      "r225",
      "r250"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities, fair value",
        "totalLabel": "Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesGrossRealizedGains": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.",
        "label": "Available-for-sale Securities, Gross Realized Gains",
        "verboseLabel": "Realized gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossRealizedGains",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.",
        "label": "Available-for-sale Securities, Gross Realized Losses",
        "negatedLabel": "Realized losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossRealizedLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.",
        "label": "Available-for-sale Securities, Noncurrent",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "verboseLabel": "Marketable securities including strategic investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r361",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails6",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails7",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails9",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LeasesLeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r498",
      "r502"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LeasesLeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r28",
      "r291"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails",
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r444",
      "r445"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails",
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails",
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Maximum contingent consideration in the form of development and approval milestones"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r452",
      "r453",
      "r456"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent consideration obligations",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r452",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion of contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r452",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and Equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r401",
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred Tax Liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails",
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r446",
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Axis]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Domain]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "terseLabel": "Fair-value post-combination equity compensation"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r155",
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r22",
      "r59",
      "r151"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents, end of the year",
        "periodStartLabel": "Cash and cash equivalents, beginning of the year",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r152",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r34",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedge"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options.",
        "label": "Cash Proceeds Received and Tax Benefit from Share-based Payment Awards [Table Text Block]",
        "terseLabel": "Tax benefit and cash received from stock option exercises"
       }
      }
     },
     "localname": "CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassificationOfVariableInterestEntityDomain": {
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categorization of Variable Interest Entities (VIE) for consolidation and (or) disclosure purposes, whether individually or in aggregate, by: (1) VIEs consolidated because the entity is the primary beneficiary, (2) VIEs not consolidated because the entity is not the primary beneficiary, and (3) VIEs or potential VIEs that are not consolidated because necessary information is not available. In general, a VIE is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A VIE often holds financial assets, including loans or receivables, real estate or other property. A VIE may be essentially passive or it may engage in research and development or other activities on behalf of another company.",
        "label": "Variable Interest Entity, Classification [Domain]",
        "terseLabel": "Variable Interest Entity, Classification [Domain]"
       }
      }
     },
     "localname": "ClassificationOfVariableInterestEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r462",
      "r463",
      "r465"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative arrangements and non-collaborative arrangement transactions"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r77",
      "r306",
      "r603",
      "r625"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r305",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r313",
      "r643",
      "r644"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Summary of common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r46",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Accounting for Share-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r107",
      "r109",
      "r110"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncomeCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r107",
      "r109",
      "r469",
      "r470",
      "r484"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncomeCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r107",
      "r109",
      "r468",
      "r484"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncomeCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r191",
      "r614"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r471",
      "r485",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r602",
      "r626"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.",
        "label": "Construction Payable",
        "terseLabel": "Accrued construction in progress"
       }
      }
     },
     "localname": "ConstructionPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r347",
      "r356",
      "r636"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
        "verboseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Costs and expenses",
        "totalLabel": "Total cost and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Cumulative effect of new accounting principle in period of adoption"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r158",
      "r428",
      "r436"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r164",
      "r431"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r158",
      "r428",
      "r436"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r158",
      "r428",
      "r436"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Current portion of notes payable",
        "verboseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Indebtedness"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Indebtedness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r38",
      "r40",
      "r41",
      "r592",
      "r594",
      "r615"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r554",
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Senior Notes aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate on senior notes",
        "verboseLabel": "Interest rate on senior notes"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.",
        "label": "Debt Instrument, Maturity Date, Description",
        "verboseLabel": "Original maturities of commercial paper and short-term debt securities"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateDescription",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemptions percentage of 2015 notes"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r75",
      "r160",
      "r323",
      "r326",
      "r327",
      "r328",
      "r553",
      "r554",
      "r556",
      "r613"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in Unrecognized Tax Benefits is Reasonably Possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "terseLabel": "Deferred compensation liability"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r158",
      "r429",
      "r436"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r158",
      "r429",
      "r436"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxChargesMember": {
     "auth_ref": [
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rate action of a regulator resulting in capitalization or accrual of income taxes.",
        "label": "Deferred Income Tax Charge [Member]",
        "terseLabel": "Deferred Income Tax Charge"
       }
      }
     },
     "localname": "DeferredIncomeTaxChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r149",
      "r158",
      "r429",
      "r436"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total",
        "verboseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r158",
      "r429",
      "r436"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r397",
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory, other reserves, and accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": {
     "auth_ref": [
      "r401",
      "r402",
      "r422"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Assets, Net, Noncurrent",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r420"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r396",
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r396",
      "r426",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r397",
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Deferred tax assets, other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r424",
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r396",
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses": {
     "auth_ref": [
      "r396",
      "r426",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses",
        "terseLabel": "Net impairment on certain tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r402",
      "r422"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": {
     "auth_ref": [
      "r397",
      "r426",
      "r427",
      "r459",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill",
        "terseLabel": "Deferred tax liabilities, goodwill"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r397",
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNoncurrent": {
     "auth_ref": [
      "r401",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Liabilities, Net, Noncurrent",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r397",
      "r426",
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Deferred Tax Liabilities, Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "terseLabel": "Transition toll tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "verboseLabel": "Employee Benefit Plan obligations"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r344",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "verboseLabel": "Unfunded net pension"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r349",
      "r355",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "verboseLabel": "Periodic pension cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expenses related to savings plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r149",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r149",
      "r201"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation, amortization and impairments"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]",
        "verboseLabel": "Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income"
       }
      }
     },
     "localname": "DerivativeAssetFairValueNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract Type [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r87",
      "r88",
      "r500",
      "r586"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r87",
      "r88",
      "r500",
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Interest rate swap, liability, fair value",
        "verboseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r499",
      "r501",
      "r509",
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument Risk [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r495",
      "r499",
      "r509"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r495",
      "r499",
      "r509",
      "r514",
      "r515",
      "r517",
      "r520"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "auth_ref": [
      "r506",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "verboseLabel": "Net gains (losses) in operating income for the settlement of certain effective cash flow hedge instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": {
     "auth_ref": [
      "r507",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net",
        "terseLabel": "Net gains (losses) in net income of foreign currency forward contracts, excluded component"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r489",
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "terseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Forward contracts duration"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r166",
      "r488",
      "r490",
      "r495",
      "r497",
      "r516"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Completed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenue by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax": {
     "auth_ref": [
      "r2",
      "r4",
      "r6",
      "r17"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.",
        "label": "Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax",
        "terseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations, net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r13",
      "r17",
      "r404",
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Tax expense on disposal group"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration received for sale of Denmark manufacturing operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Inventory work-in-process sold to FUJIFILM"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Expected costs to sell disposal group"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "terseLabel": "Property, plant and equipment sold to Fujifilm"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": {
     "auth_ref": [
      "r149",
      "r289",
      "r294"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down",
        "terseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r21",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/InventoryDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Country"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r165",
      "r578",
      "r600",
      "r628"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from Related Parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r165",
      "r578",
      "r601",
      "r627"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r117",
      "r172",
      "r176",
      "r178",
      "r179",
      "r180",
      "r184",
      "r606",
      "r631"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r117",
      "r172",
      "r176",
      "r178",
      "r179",
      "r180",
      "r184",
      "r606",
      "r631"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r181",
      "r182",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r163",
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r405",
      "r406",
      "r435"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory rate",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r405",
      "r406",
      "r435"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "2017 Tax Act"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets": {
     "auth_ref": [
      "r405",
      "r435"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r405",
      "r406",
      "r435"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r405",
      "r406",
      "r435"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r405",
      "r406",
      "r435"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 13.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "Impairment of ZINBRYTA related tax assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r405",
      "r406",
      "r435"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "verboseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r405",
      "r406",
      "r435"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 14.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r405",
      "r406",
      "r435"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r405",
      "r406",
      "r435"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails2": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.",
        "label": "Share-based Payment Arrangement, Cash Used to Settle Award",
        "verboseLabel": "Cash in settlement of CSPS awards upon vesting"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation cost related to unvested share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "verboseLabel": "Tax benefit realized for stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails11"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Samsung Bioepis, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r60",
      "r205",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r60",
      "r143",
      "r155",
      "r243",
      "r542"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method of Accounting"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Marketable equity securities, fair value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "totalLabel": "Marketable equity securities, amortized cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedTerseLabel": "Equity Securities, FV-NI, Realized Gain (Loss)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r35",
      "r39",
      "r239",
      "r599",
      "r616",
      "r641"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "verboseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EuropeanUnionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Economic and political union of member states, located primarily in Europe.",
        "label": "European Union [Member]",
        "terseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeanUnionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r535"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, by Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r525",
      "r535"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Fair Value by Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r525",
      "r541"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r347",
      "r348",
      "r356",
      "r526",
      "r582"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r525",
      "r526",
      "r529",
      "r530",
      "r536"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Fair Value by Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedge"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r347",
      "r348",
      "r356",
      "r526",
      "r583"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r347",
      "r348",
      "r356",
      "r526",
      "r584"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r347",
      "r348",
      "r356",
      "r526",
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r531",
      "r535"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r532"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "terseLabel": "Loss (gain) on fair value remeasurement of contingent consideration",
        "verboseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Payments",
        "terseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r534",
      "r536"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring",
        "verboseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r155",
      "r537",
      "r539"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r498",
      "r503",
      "r517"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated life, (In Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "verboseLabel": "Expected future amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Expected future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "verboseLabel": "Expected future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "verboseLabel": "Expected future amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "verboseLabel": "Expected future amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r273",
      "r275",
      "r279",
      "r283",
      "r590"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r279",
      "r590"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r273",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Net change in acquired and in-licensed rights and patents"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority",
        "verboseLabel": "Outside the U.S"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r544",
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange gains (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r546",
      "r550"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Translation of Foreign Currencies"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r347",
      "r512"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign Exchange Contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan [Member]"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures, Gross",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePayments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions",
        "negatedTerseLabel": "ASC 840 - Sublease income, total"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsThereafter",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, Thereafter",
        "negatedTerseLabel": "ASC 840 - Sublease income, thereafter"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInFiveYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Five Years",
        "negatedTerseLabel": "ACS 840 - Sublease income, 2023"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInFourYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Four Years",
        "negatedTerseLabel": "ASC 840 - Sublease income, 2022"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInOneYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months",
        "negatedTerseLabel": "ASC 840 - Sublease income, 2019"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInThreeYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Three Years",
        "negatedTerseLabel": "ASC 840 - Sublease income, 2021"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInTwoYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years",
        "negatedTerseLabel": "ASC 840 - Sublease income, 2020"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r499",
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "verboseLabel": "Net gains (losses) of other income (expense) related to foreign currency forward contracts"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "terseLabel": "Gain (loss) on investments, net"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralBusinessMember": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax credit carryforwards which include, but are not limited to, investment, alcohol fuels, low income housing, alternative fuels, alternative motor vehicles, hurricane relief, disabled access, renewable resources electricity production, employer social security, orphan drug, new markets, employer provided child care facilities and services, biodiesel fuels, low sulfur diesel fuel production, distilled spirits and the advanced nuclear power facilities credit.",
        "label": "General Business Tax Credit Carryforward [Member]",
        "terseLabel": "General Business"
       }
      }
     },
     "localname": "GeneralBusinessMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r262",
      "r263"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails",
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Increase to goodwill",
        "verboseLabel": "Increase to goodwill"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r155",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r155",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r264",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "terseLabel": "Elimination of goodwill allocated to Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "verboseLabel": "Gross Profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Guarantees [Abstract]"
       }
      }
     },
     "localname": "GuaranteesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GuaranteesTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.",
        "label": "Guarantees [Text Block]",
        "verboseLabel": "Guarantees"
       }
      }
     },
     "localname": "GuaranteesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Guarantees"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r495",
      "r515"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r149",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of in-licensed patent"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r149",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of IPR&amp;D"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r288",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "verboseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r64",
      "r155",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-process Research and Development (IPR&amp;D)"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Income before income taxes (benefit):"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r115",
      "r149",
      "r202",
      "r241",
      "r604",
      "r629"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in loss of investee, net of tax",
        "terseLabel": "Equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "negatedTerseLabel": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.",
        "label": "Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax",
        "negatedTerseLabel": "Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax"
       }
      }
     },
     "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/InventoryDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r16",
      "r18",
      "r19",
      "r20",
      "r297",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual",
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "verboseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LeasesLeasesDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LeasesLeasesDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationLitigationDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationLitigationDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r410",
      "r417",
      "r419",
      "r432"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r158",
      "r203",
      "r437"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit (expense)",
        "totalLabel": "Total income tax expense",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Income tax expense (benefit):"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.",
        "label": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r155",
      "r399",
      "r400",
      "r418",
      "r419",
      "r423",
      "r439",
      "r645"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r146",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income Taxes Paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r177",
      "r182"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock options and employee stock purchase plan"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r274",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Cost and net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r274",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r271",
      "r277"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Intellectual Property"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Interest Costs Capitalized"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r113",
      "r200",
      "r551",
      "r555",
      "r607"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r141",
      "r145",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2",
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r53",
      "r260"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r23",
      "r82",
      "r256"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, current",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Components of inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventory, noncurrent"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r83",
      "r155",
      "r186",
      "r257",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r55",
      "r260"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r54",
      "r260"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "verboseLabel": "Write-downs on excess, obsolete, unmarketable or other inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r123",
      "r199"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities and Other Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r637",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r637",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: Available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "verboseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r27",
      "r62"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r574",
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Net lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r28",
      "r291"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating lease liability maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "terseLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "ASC 842 - Minimum lease payments, thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "ASC 842 - Minimum lease payments, 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "ASC 842 - Minimum lease payments, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "ASC 842 - Minimum lease payments, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "ASC 842 - Minimum lease payments, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "ASC 842 - Minimum lease payments, 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, Operating Lease, Renewal Term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r52",
      "r597",
      "r623"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as current.",
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "verboseLabel": "Liabilities associated with uncertain tax positions"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityDescription": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.",
        "label": "Line of Credit Facility, Description",
        "terseLabel": "Term of credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityDescription",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual",
      "http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of the amount outstanding under the credit facility.",
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "terseLabel": "Amount outstanding under the credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Senior unsecured revolving credit facility maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual",
      "http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Payment made to Forward Pharma"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r41",
      "r317",
      "r594",
      "r619"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Non-current portion of notes payable",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Total debt maturities"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-term Debt, Current Maturities [Abstract]",
        "terseLabel": "Current portion:"
       }
      }
     },
     "localname": "LongTermDebtCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r168",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessDetails1": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r168",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r168",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessDetails1": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r168",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessDetails1": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r168",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r168",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-term Debt, Excluding Current Maturities [Abstract]",
        "terseLabel": "Non-current portion:"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Non-current notes payable",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r306",
      "r307",
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Loss Contingency, Claims Asserted"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r308",
      "r310",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Tax Assessment"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r589"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Loss on Contract Termination"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r28",
      "r291"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r81",
      "r596",
      "r622"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distribution to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r144",
      "r147",
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r105",
      "r108",
      "r116",
      "r150",
      "r182",
      "r605",
      "r630"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc.",
        "verboseLabel": "Net income attributable to Biogen Idec Inc"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r105",
      "r108",
      "r473",
      "r483"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedge"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of world"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Long-lived assets related to operations in Denmark",
        "verboseLabel": "Long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationDetails",
      "http://www.biogenidec.com/role/SegmentInformationDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual",
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "2.900% Senior Notes due September 15, 2020"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Note payable to Fumedica"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "verboseLabel": "Number of reportable segment"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationDetailsTextual"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating Expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTerseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r568",
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r565",
      "r570"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r563"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/LeasesLeasesDetails",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r573",
      "r576"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r572",
      "r576"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "ASC 840 - Minimum lease payments, total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInOneYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "ASC 840 - Minimum lease payments, 2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInFiveYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "ASC 840 - Minimum lease payments, 2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInFourYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "ASC 840 - Minimum lease payments, 2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInThreeYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "ASC 840 - Minimum lease payments, 2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInTwoYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "ASC 840 - Minimum lease payments, 2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesLeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsThereafter",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "ASC 840 - Minimum lease payments, thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue": {
     "auth_ref": [
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of revenue recognized for the period under subleasing arrangements.",
        "label": "Operating Leases, Income Statement, Sublease Revenue",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "OperatingLeasesIncomeStatementSubleaseRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Investments and other assets",
        "verboseLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "verboseLabel": "Cancellable future commitments"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r93",
      "r94",
      "r99"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "totalLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r101",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax": {
     "auth_ref": [
      "r92",
      "r99",
      "r102",
      "r507"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax",
        "negatedTerseLabel": "Less: Reclassification of net investment hedge forward points amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": {
     "auth_ref": [
      "r92",
      "r505"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax",
        "totalLabel": "Gains (losses) on net investment hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": {
     "auth_ref": [
      "r92",
      "r99",
      "r505",
      "r518"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax",
        "terseLabel": "Gains (Losses) on net investment hedge recognized during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "totalLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r89",
      "r549"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r106",
      "r109",
      "r112",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r106",
      "r109",
      "r468",
      "r469",
      "r475"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r97",
      "r99"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r99",
      "r102",
      "r103",
      "r238"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Less: reclassification adjustment for (gains) losses included in net income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax": {
     "auth_ref": [
      "r99",
      "r102",
      "r103",
      "r496"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax",
        "negatedTerseLabel": "Less: reclassification adjustment for (gains) losses included in net income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r91",
      "r99",
      "r521"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax",
        "terseLabel": "Unrealized gains (losses) recognized during the period, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r93",
      "r99"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized gains (losses) recognized during the period, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r498",
      "r517"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r71"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "totalLabel": "Accrued expenses and other",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1",
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Payments for pre-combination equity compensation"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r343",
      "r351",
      "r352",
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Deferred Compensation Plan"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherTaxExpenseBenefit": {
     "auth_ref": [
      "r162",
      "r404",
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other income tax expense (benefit).",
        "label": "Other Tax Expense (Benefit)",
        "terseLabel": "Other tax expense (benefit)"
       }
      }
     },
     "localname": "OtherTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r131",
      "r135",
      "r167"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfCapitalDistribution": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends.",
        "label": "Payments of Capital Distribution",
        "negatedTerseLabel": "Net cash contribution to Bioverativ, Inc."
       }
      }
     },
     "localname": "PaymentsOfCapitalDistribution",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Costs associated with the Senior Notes offerings"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecurities": {
     "auth_ref": [
      "r132",
      "r223"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.",
        "label": "Payments to Acquire Available-for-sale Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r133",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Amount paid in cash",
        "verboseLabel": "Total transaction value"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Payments to Acquire Businesses, Net of Cash Acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Payments to increase investment in Samsung Bioepis",
        "terseLabel": "Payments to increase investment in Samsung Bioepis"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Payments to Acquire in Process Research and Development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Payments to Acquire Other Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Contingent consideration related to Fumapharm AG acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Contingent consideration payments"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Net contribution (distribution) to noncontrolling interests",
        "terseLabel": "Payments to Noncontrolling Interests",
        "verboseLabel": "Payment to Neurimmune"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "verboseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.",
        "label": "Pension Cost (Reversal of Cost)",
        "terseLabel": "Pension Cost (Reversal of Cost)"
       }
      }
     },
     "localname": "PensionExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails7",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r361",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails11",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails11",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "verboseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and discovery services"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r137",
      "r140",
      "r167"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r127",
      "r128",
      "r223"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity": {
     "auth_ref": [
      "r129",
      "r223"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity securities classified as available-for-sale securities.",
        "label": "Proceeds from Sale of Available-for-sale Securities, Equity",
        "terseLabel": "Proceeds from Sale of Available-for-sale Securities, Equity",
        "verboseLabel": "Sale of Ionis common stock"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from Sale of Property, Plant, and Equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r136",
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Cash received from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r105",
      "r108",
      "r142",
      "r204",
      "r207",
      "r468",
      "r472",
      "r474",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r63",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r62",
      "r291"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Total cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r36",
      "r37",
      "r293",
      "r624"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r155",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r36",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Components of property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r36",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to prospectively adopted accounting guidance.",
        "label": "Prospective Adoption of New Accounting Pronouncements [Axis]",
        "terseLabel": "Prospective Adoption of New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "ProspectiveAdoptionOfNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r43",
      "r595",
      "r620"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Future minimum batch production for Denmark manufacturing operations"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "verboseLabel": "Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable securities, excluding strategic investments"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r217",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r101",
      "r104",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts Reclassified From Accumulated Other Comprehensive Income, Net of Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Repayments of borrowings"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "verboseLabel": "Overnight Reverse Repurchase Agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r394",
      "r651"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense asset acquired",
        "verboseLabel": "Research and development expense on 2018 Ionis Agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/LeasesLeasesDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual",
      "http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r155",
      "r285",
      "r286",
      "r651"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r149",
      "r302",
      "r303",
      "r304"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 9.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r49",
      "r329",
      "r621"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r352",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r352",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r342",
      "r343",
      "r351",
      "r352",
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r342",
      "r343",
      "r351",
      "r352",
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r156",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, Remaining Performance Obligation, Amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r114",
      "r197",
      "r198",
      "r206"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Revenues",
        "terseLabel": "Product Revenues",
        "totalLabel": "Total revenues from anti-cd20 therapeutic programs",
        "verboseLabel": "Total Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r571",
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r229",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r608",
      "r611"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r444",
      "r445"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails",
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Income before income tax provision and the income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Indebtedness"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r354",
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r499",
      "r509",
      "r515"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of derivatives designated as cash flow hedging instruments on our consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of the fair value for our outstanding derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r360",
      "r382",
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r360",
      "r382",
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the details pertaining to each employee stock ownership plan.",
        "label": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]",
        "terseLabel": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails11"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r525",
      "r526"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r273",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Minimum lease payments",
        "verboseLabel": "Minimum rental commitments under non-cancelable leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesTables",
      "http://www.biogenidec.com/role/LeasesLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r33",
      "r56",
      "r57",
      "r58"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Total debt maturities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r63",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "verboseLabel": "Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Identified assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r119",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "verboseLabel": "Geographic information"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r361",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails6",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails7",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails9",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r365",
      "r375",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r78",
      "r159",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r417",
      "r432"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of beginning and ending amount of unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r480",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization of intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentsGeographicalAreasAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segments, Geographical Areas [Abstract]",
        "verboseLabel": "Geographic information"
       }
      }
     },
     "localname": "SegmentsGeographicalAreasAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SelectedQuarterlyFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Selected Quarterly Financial Information [Abstract]",
        "terseLabel": "Selected Quarterly Financial Information [Abstract]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r122",
      "r255"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/LeasesLeasesDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A description of the changes to the valuation model inputs that led to changes in fair value of the servicing assets.",
        "label": "Servicing Asset at Fair Value, Description of Changes in Valuation Inputs",
        "terseLabel": "Fair value measurements, changes in valuation techniques"
       }
      }
     },
     "localname": "ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails6",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails7",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails9"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares granted",
        "verboseLabel": "Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails6",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails7",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails9",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value",
        "verboseLabel": "Weighted Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance, Unvested, Shares",
        "periodStartLabel": "Beginning Balance, Unvested, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails6",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails7",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails9"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Beginning Balance, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails6",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails7",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails9"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of vested awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails9",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Range of expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "verboseLabel": "Maximum range of risk-free interest rates"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "verboseLabel": "Minimum range of risk-free interest rates"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails6",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails7",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails9",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Omnibus Plan number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Number of shares granted under stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic values of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r367",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance, Outstanding shares",
        "periodStartLabel": "Beginning Balance, Outstanding shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance, Weighted Average Exercise Price",
        "periodStartLabel": "Beginning Balance, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r359",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails10",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails4",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails5",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails6",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails7",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails8",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails9",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term for options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "negatedPeriodEndLabel": "Ending Balance, shares",
        "negatedPeriodStartLabel": "Beginning Balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r80",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/LeasesLeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/LeasesLeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r45",
      "r46",
      "r322",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails11",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r46",
      "r322",
      "r329",
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised",
        "terseLabel": "Issuance of common stock under stock award plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r46",
      "r322",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r45",
      "r46",
      "r322",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "verboseLabel": "Cash received under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails11"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r80",
      "r322",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "negatedTerseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r45",
      "r46",
      "r322",
      "r329",
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock options and stock purchase plans, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Authorized amount of share repurchases"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r45",
      "r46",
      "r322",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r46",
      "r50",
      "r51",
      "r218"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Idec Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r466",
      "r467",
      "r482"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteSpinoffTransaction": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.",
        "label": "Stockholders' Equity Note, Spinoff Transaction",
        "terseLabel": "Hemophilia spin-off adjustment"
       }
      }
     },
     "localname": "StockholdersEquityNoteSpinoffTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "terseLabel": "Adoption of new accounting guidance"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual",
      "http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual",
      "http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetailsTextual",
      "http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash Paid During the Year"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "verboseLabel": "Trademarks and trade names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r79",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "verboseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r46",
      "r322",
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "terseLabel": "Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r79",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r46",
      "r322",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Repurchase of common stock, at cost, shares",
        "terseLabel": "Repurchase of common stock, at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r79",
      "r331",
      "r332"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r322",
      "r329",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Repurchase of common stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r347",
      "r598",
      "r636"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "negatedLabel": "Gain/Loss on fair value of foreign currency forward contracts",
        "terseLabel": "Unrealized gain (loss) on net investment hedge in AOCI"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate net change in the difference between the fair value and the carrying value, or in the comparative fair values, of marketable securities categorized as trading held at each balance sheet date, that was included in earnings for the period, which may have arisen from (a) securities classified as trading, (b) the unrealized holding gain (loss) on held-to-maturity securities transferred to the trading security category, and (c) the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) on available-for-sale securities transferred to trading securities during the period and/or any unrealized gains or losses on investments that are separately or otherwise not categorized as trading or available-for-sale.",
        "label": "Unrealized Gain (Loss) on Marketable Securities, Cost Method Investments, and Other Investments",
        "terseLabel": "Unrealized gain (loss) on strategic investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r398",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at December 31",
        "periodStartLabel": "Balance at January 1"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions of prior periods"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "terseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Net interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]",
        "terseLabel": "Reconciliation of the beginning and ending of unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior periods"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Unrecorded tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Statute expirations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "verboseLabel": "Unrecognized tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Revenue related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1",
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis": {
     "auth_ref": [
      "r477",
      "r478",
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of Variable Interest Entity (VIE).",
        "label": "Variable Interest Entities [Axis]",
        "terseLabel": "Variable Interest Entities [Axis]",
        "verboseLabel": "Variable Interest Entities by Classification of Entity [Axis]"
       }
      }
     },
     "localname": "VariableInterestEntitiesByClassificationOfEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r569",
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r175",
      "r180"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
        "terseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r173",
      "r180"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome",
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=SL94080555-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e2646-109256"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "460",
   "URI": "http://asc.fasb.org/topic&trid=2155896"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "60",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6406278&loc=d3e26268-112671"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(k)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31958-109318"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5558-128473"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9972-128506"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9979-128506"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6228884-111685"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "c",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1),(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=117336053&loc=SL75039408-165497"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b),(c),(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77891322&loc=d3e41620-112719"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77914019&loc=d3e50824-112756"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=84167019&loc=d3e54681-109401"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "340",
   "Topic": "980",
   "URI": "http://asc.fasb.org/extlink&oid=77907324&loc=d3e43603-110378"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "405",
   "Topic": "980",
   "URI": "http://asc.fasb.org/extlink&oid=6500807&loc=d3e48068-110394"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "980",
   "URI": "http://asc.fasb.org/extlink&oid=6501382&loc=d3e54053-110423"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "980",
   "URI": "http://asc.fasb.org/extlink&oid=6501382&loc=d3e54136-110423"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r652": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r653": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r654": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r655": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r656": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r657": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6886138032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Eisai (Details 1) - Eisai - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">BAN2401 and Elenbecestat R&amp;D expense incurred by collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 348.7<span></span>
</td>
<td class="nump">$ 232.0<span></span>
</td>
<td class="nump">$ 146.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174.3<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Aducanumab expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179.4<span></span>
</td>
<td class="nump">264.8<span></span>
</td>
<td class="nump">268.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.7<span></span>
</td>
<td class="nump">234.6<span></span>
</td>
<td class="nump">268.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Aducanumab expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="nump">$ 27.3<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895786912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;&#160;&#160;&#160;Income Taxes<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Tax Expense</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>4,725.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,877.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,540.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,400.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,022.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,588.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7,125.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,899.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,128.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>947.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,131.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,201.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>59.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>57.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>84.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>140.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>108.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,090.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,317.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,367.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,143.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(62.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>241.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1,074.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>177.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(159.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>67.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>108.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>91.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,158.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,425.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,458.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2017 Tax Act</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries and collaborations to immediate U.S. taxation as GILTI or Subpart F income, and includes base erosion prevention measures on U.S. earnings and the reduced effective tax rate on income that comes from U.S. exports, called Foreign Derived Intangible Income. These changes became effective in 2018. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2017 we recognized within our provision for income taxes a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.2 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> estimate pursuant to the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 118. Our estimate included an amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$989.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax), as discussed below, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$184.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the impact of remeasuring our deferred tax balances to reflect the new federal statutory rate and other changes to U.S. tax law. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended December 31, 2018, we recognized a net reduction of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$34.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our estimated Transition Toll Tax, an expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$12.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to remeasure our deferred tax balances, an expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$135.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to establishing deferred taxes for GILTI and an expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$11.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect other aspects of the 2017 Tax Act.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Transition Toll Tax</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax. The Transition Toll Tax was assessed on our share of our foreign corporations' accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and all other earnings were taxed at a rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$697.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the Transition Toll Tax. Of the amounts accrued as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to an approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$87.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> carryforward of taxes paid in relation to the company's 2017 tax return. The Transition Toll Tax will be paid over an eight--year period, which started in 2018, and does not accrue interest.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unremitted Earnings</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At December 31, 2019, we considered our earnings not to be permanently reinvested outside the U.S. and therefore recorded deferred tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. Other than for earnings, we are permanently reinvested for book/tax basis differences of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of December 31, 2019, primarily arising through the impacts of purchase accounting. These permanently reinvested basis differences could reverse through sales of the foreign subsidiaries, as well as various other events, none of which were considered probable as of December 31, 2019. The residual U.S. tax liability, if these differences reverse, would be between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.3 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.4 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of December 31, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Article 20 Procedure of ZINBRYTA</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017 the European Medicines Agency initiated a review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury. As a result of the Article 20 Procedure of ZINBRYTA, for the year ended December 31, 2017, we recognized a net impairment charge on certain tax assets related to ZINBRYTA reflected within income tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$48.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This charge reflected the write-off of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$142.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to prepaid taxes, which was partially offset by the recognition of an unrecorded deferred tax benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$93.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our collaboration arrangement with AbbVie, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>106.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>102.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves and accruals</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>162.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>163.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,380.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,298.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>130.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>213.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>23.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>103.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>38.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(20.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,905.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,823.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(350.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(232.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1,381.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(544.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1,617.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,425.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(135.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(102.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(3,484.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2,305.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intra-entity sales of inventory. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total deferred charges and prepaid taxes were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$243.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$239.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:55%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(11.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Divestiture of Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Internal reorganization of certain intellectual property rights</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S. tax reform</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss tax reform</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment of ZINBRYTA related tax assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Changes in Tax Rate</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights and the impact of the enactment of a new taxing regime in the country and certain cantons of Switzerland. This decrease was partially offset by a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$68.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense related to the divestiture of our subsidiary that owned our Hiller&#248;d, Denmark manufacturing operations. We also had a higher effective tax rate in 2018 resulting from the unfavorable effects of </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the 2017 Tax Act and our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Although we are recognizing a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write-off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the internal reorganization of certain intellectual property rights, we recorded a deferred tax asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$754.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$603.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the enactment of the 2017 Tax Act. The effects of an overall reduction in the federal statutory rate in the U.S. were partially offset by the elimination of the manufacturing deduction, the imposition of the GILTI tax on international earnings, our recording of deferred taxes on GILTI in 2018, limits on the deductibility of certain benefits on executive compensation and a reduction in the tax benefit associated with the Orphan Drug Credit, all resulting from the 2017 Tax Act, and a change in accounting rules related to recording the tax impacts of intra-entity transactions. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Attributes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which begin to expire in 2022. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that begin to expire in 2020. For state income tax purposes, we had research and investment credit carry forwards of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$133.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that begin to expire in 2020. For foreign income tax purposes, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,773.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net operating loss carryforwards that begin to expire in 2025.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>114.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>17.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>58.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(13.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(21.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement refund (payment)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>44.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>129.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>114.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our 2017 activity reflects a refund received from a state related to the settlement of an uncertain tax position.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in the balance of unrecognized tax benefits as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$122.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$109.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$64.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize potential interest and penalties related to unrecognized tax benefits in income tax expense. In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recognized a net interest expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We have accrued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$13.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the payment of interest and penalties as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Accounting for Uncertainty in Income Taxes</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, in connection with the spin-off of our hemophilia business, we distributed all of the then outstanding shares of Bioverativ common stock to Biogen shareholders pursuant to a separation agreement. In March 2018 Bioverativ was acquired by Sanofi S.A. (Sanofi) and is now an indirect wholly-owned subsidiary of Sanofi. The spin-off of our hemophilia business was intended to qualify for tax-free treatment to Biogen and its shareholders under the Internal Revenue Code. Our 2017 tax return remains open to audit. Bioverativ and Sanofi agreed to indemnify us for certain potential liabilities that may arise. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Federal and State Uncertain Tax Positions</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6778247504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,892.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,701.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>131.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>98.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>92.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,892.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,239.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of derivatives designated as cash flow hedging instruments on our consolidated statements of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>118.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(42.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized Directly into Net Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(32.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of our net investment hedges in our consolidated financial statements:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>25.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of the fair value for our outstanding derivatives</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br/>As of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br/>As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>65.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Net Investment Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivative Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6629422032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfCommonStockTableTextBlock', window );">Summary of common stock</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"/></tr><tr><td style="width:13%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">As of December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,000.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>198.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>174.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,000.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>221.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>197.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,000.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>235.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>211.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6872405168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,158.0<span></span>
</td>
<td class="nump">$ 1,425.6<span></span>
</td>
<td class="nump">$ 2,458.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,706.4<span></span>
</td>
<td class="nump">4,632.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.5<span></span>
</td>
<td class="nump">1,080.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">$ 5,706.4<span></span>
</td>
<td class="nump">$ 5,757.8<span></span>
</td>
<td class="nump">5,706.4<span></span>
</td>
<td class="nump">$ 4,632.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">Fumapharm AG | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember', window );">Each additional one billion up to twenty billion | Fumapharm AG | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">$ 20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874342384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract', window );"><strong>Tax benefit and cash received from stock option</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit realized for stock options</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from the exercise of stock options</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax benefit and cash received from stock option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TaxBenefitAndCashReceivedFromStockOptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874872528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Idec Inc</a></td>
<td class="nump">$ 1,439.7<span></span>
</td>
<td class="nump">$ 1,545.9<span></span>
</td>
<td class="nump">$ 1,494.1<span></span>
</td>
<td class="nump">$ 1,408.8<span></span>
</td>
<td class="nump">$ 946.8<span></span>
</td>
<td class="nump">$ 1,444.4<span></span>
</td>
<td class="nump">$ 866.6<span></span>
</td>
<td class="nump">$ 1,172.9<span></span>
</td>
<td class="nump">$ 5,888.5<span></span>
</td>
<td class="nump">$ 4,430.7<span></span>
</td>
<td class="nump">$ 2,539.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">177.8<span></span>
</td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">196.6<span></span>
</td>
<td class="nump">199.8<span></span>
</td>
<td class="nump">201.4<span></span>
</td>
<td class="nump">207.1<span></span>
</td>
<td class="nump">211.4<span></span>
</td>
<td class="nump">187.1<span></span>
</td>
<td class="nump">204.9<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">178.2<span></span>
</td>
<td class="nump">184.2<span></span>
</td>
<td class="nump">190.4<span></span>
</td>
<td class="nump">197.0<span></span>
</td>
<td class="nump">200.3<span></span>
</td>
<td class="nump">201.9<span></span>
</td>
<td class="nump">207.3<span></span>
</td>
<td class="nump">211.7<span></span>
</td>
<td class="nump">187.4<span></span>
</td>
<td class="nump">205.3<span></span>
</td>
<td class="nump">213.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EarningsPerShareTextualAbstract', window );"><strong>Earnings per share (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EarningsPerShareTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EarningsPerShareTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805506096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms', window );">Revenues In Percentage From Anti-CD20 Therapeutic Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenue from major distributors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables', window );">Percentage receivables of wholesale distributor accounted in consolidated receivables</a></td>
<td class="nump">24.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.10%<span></span>
</td>
<td class="nump">27.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenue from major distributors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables', window );">Percentage receivables of wholesale distributor accounted in consolidated receivables</a></td>
<td class="nump">13.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
<td class="nump">15.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 145.7<span></span>
</td>
<td class="nump">$ 109.6<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">$ 292.4<span></span>
</td>
<td class="nump">$ 165.7<span></span>
</td>
<td class="nump">$ 147.2<span></span>
</td>
<td class="nump">$ 108.6<span></span>
</td>
<td class="nump">$ 164.4<span></span>
</td>
<td class="nump">$ 707.7<span></span>
</td>
<td class="nump">$ 585.9<span></span>
</td>
<td class="nump">$ 360.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue | Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383.2<span></span>
</td>
<td class="nump">206.7<span></span>
</td>
<td class="nump">64.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584.5<span></span>
</td>
<td class="nump">$ 459.4<span></span>
</td>
<td class="nump">$ 253.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage receivables of wholesale distributor accounted in consolidated receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues In Percentage From Anti-CD20 Therapeutic Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6879100448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 1,051.3<span></span>
</td>
<td class="nump">$ 761.6<span></span>
</td>
<td class="nump">$ 605.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">3,698.6<span></span>
</td>
<td class="nump">3,389.1<span></span>
</td>
<td class="nump">2,917.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(48.3)<span></span>
</td>
<td class="num">(12.1)<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns related to sales in current year</a></td>
<td class="num">(2,778.6)<span></span>
</td>
<td class="num">(2,440.4)<span></span>
</td>
<td class="num">(2,232.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns related to sales in prior years</a></td>
<td class="num">(724.1)<span></span>
</td>
<td class="num">(646.9)<span></span>
</td>
<td class="num">(534.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">1,198.9<span></span>
</td>
<td class="nump">1,051.3<span></span>
</td>
<td class="nump">761.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">127.8<span></span>
</td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">666.2<span></span>
</td>
<td class="nump">679.3<span></span>
</td>
<td class="nump">583.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns related to sales in current year</a></td>
<td class="num">(535.5)<span></span>
</td>
<td class="num">(551.7)<span></span>
</td>
<td class="num">(475.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns related to sales in prior years</a></td>
<td class="num">(127.7)<span></span>
</td>
<td class="num">(109.1)<span></span>
</td>
<td class="num">(69.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">131.1<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
<td class="nump">109.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">888.8<span></span>
</td>
<td class="nump">606.0<span></span>
</td>
<td class="nump">482.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">3,011.5<span></span>
</td>
<td class="nump">2,686.7<span></span>
</td>
<td class="nump">2,307.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(54.1)<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns related to sales in current year</a></td>
<td class="num">(2,242.9)<span></span>
</td>
<td class="num">(1,887.6)<span></span>
</td>
<td class="num">(1,756.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns related to sales in prior years</a></td>
<td class="num">(576.0)<span></span>
</td>
<td class="num">(506.3)<span></span>
</td>
<td class="num">(442.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">1,027.3<span></span>
</td>
<td class="nump">888.8<span></span>
</td>
<td class="nump">606.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">34.7<span></span>
</td>
<td class="nump">46.0<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns related to sales in current year</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns related to sales in prior years</a></td>
<td class="num">(20.4)<span></span>
</td>
<td class="num">(31.5)<span></span>
</td>
<td class="num">(23.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">$ 40.5<span></span>
</td>
<td class="nump">$ 34.7<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895819008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">198.0<span></span>
</td>
<td class="nump">221.0<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">174.2<span></span>
</td>
<td class="nump">197.2<span></span>
</td>
<td class="nump">211.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>biib-20191231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20191231"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20191231.xsd" xlink:type="simple"/>
    <context id="FD2019Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q4SharesOutstanding">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-02-04</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredIncomeTaxChargesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DeferredIncomeTaxChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_biib_DeferredtaxliabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:KaryopharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:AliveGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:AliveGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:KaryopharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TMSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TMSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_RemedyPharmaceuticalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:RemedyPharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="I2019Q3Denmark">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_biib_MajorDistributorAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_biib_MajorDistributorAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SobiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SobiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SobiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q3Denmark_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:WorkinprocessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_PLSRMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:PLSRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4QTD_srt_ProductOrServiceAxis_biib_VUMERITYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q1_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BG00011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q3_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-01</startDate>
            <endDate>2015-02-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-02-12</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2012Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2010Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-10-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="FI2012Q1_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_biib_SubleaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">biib:SubleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_biib_SubleaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">biib:SubleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:OperatingleaseassetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="I2019Q4creditfacility_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-28</instant>
        </period>
    </context>
    <context id="FI2015Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="D2019Q4creditfacility_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-28</startDate>
            <endDate>2020-01-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2015Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_biib_UndesignatedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_biib_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:SeriesXPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_DirectorsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:DirectorsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q2_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4QTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_biib_ForeignearningstypeAxis_biib_OtherForeignEarningsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:OtherForeignEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_biib_ForeignearningstypeAxis_biib_ForeignearningsintheformofcashandcashequivalentsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:ForeignearningsintheformofcashandcashequivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_biib_PrepaidtaxesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:PrepaidtaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DeferredTaxAssetLiabilityTypeAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD_biib_CumulativeSalesLevelAxis_biib_TwentybillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:TwentybillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SixteenbillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4QTD_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SixteenbillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_FifteenbillionMemberMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:FifteenbillionMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2012Q1Feb_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-01</startDate>
            <endDate>2012-02-29</endDate>
        </period>
    </context>
    <context id="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-05</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-29</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_StatementGeographicalAxis_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q3_srt_ProductOrServiceAxis_biib_RituxanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="FI2012Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_NewAntiCd20Member_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_NewAntiCd20Member_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2013Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-10-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q2_us-gaap_TypeOfArrangementAxis_biib_IPerianMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IPerianMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q1_srt_ProductOrServiceAxis_biib_RituxanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_biib_RituxanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-01</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_ProductOrServiceAxis_biib_RituxanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_ProductOrServiceAxis_biib_RituxanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_country_BR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-04-02</instant>
        </period>
    </context>
    <context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_biib_ExpectedPaymentTimelineofMilestoneAxis_biib_TwelvemonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ExpectedPaymentTimelineofMilestoneAxis">biib:TwelvemonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_TwentybillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:TwentybillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_CommercialMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_CH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_StatementGeographicalAxis_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_biib_SolothurnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_country_DK">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_biib_SolothurnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_srt_StatementGeographicalAxis_biib_SolothurnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_srt_StatementGeographicalAxis_country_DK">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="D2019Q4Pfizer_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="KRW">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="Plan">
        <measure>biib:Plan</measure>
    </unit>
    <unit id="Increment">
        <measure>biib:Increment</measure>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <biib:AverageStockPriceOnGrantDateInDollarsMaximum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="Fact-E1DADEECA96329DE235D6F38B875BAB9-wk-Fact-E1DADEECA96329DE235D6F38B875BAB9"
      unitRef="usd">267.88</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
    <biib:AverageStockPriceOnGrantDateInDollarsMaximum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="Fact-527FABF924E06DF975726F38B873BC9A-wk-Fact-527FABF924E06DF975726F38B873BC9A"
      unitRef="usd">346.76</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
    <biib:AverageStockPriceOnGrantDateInDollarsMaximum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="Fact-8AE57826EEE2EB0602D96F38B872E835-wk-Fact-8AE57826EEE2EB0602D96F38B872E835"
      unitRef="usd">331.18</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
    <biib:AverageStockPriceOnGrantDateInDollarsMinimum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="Fact-24E5D42CE847B29554036F38B8795FC9-wk-Fact-24E5D42CE847B29554036F38B8795FC9"
      unitRef="usd">263.18</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
    <biib:AverageStockPriceOnGrantDateInDollarsMinimum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="Fact-A7DAE5BD4AD52B2198CA6F38B86F7587-wk-Fact-A7DAE5BD4AD52B2198CA6F38B86F7587"
      unitRef="usd">279.47</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
    <biib:AverageStockPriceOnGrantDateInDollarsMinimum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="Fact-3A5DE464808C2798DA176F38B871BD09-wk-Fact-3A5DE464808C2798DA176F38B871BD09"
      unitRef="usd">228.59</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
    <biib:CompensationExpenseOverPurchasePeriod
      contextRef="FD2019Q4YTD"
      id="Fact-A03F848351BE481BF8D16F38B7A5DB76-wk-Fact-A03F848351BE481BF8D16F38B7A5DB76">The fair value of the look-back provision plus the 15% discount</biib:CompensationExpenseOverPurchasePeriod>
    <biib:EstimatedUsefulLivesOfLeaseholdImprovements
      contextRef="FD2019Q4YTD"
      id="Fact-62C72C917F54368B79356F38B7A54CBB-wk-Fact-62C72C917F54368B79356F38B7A54CBB">Lesser of the useful life or the term of the respective lease</biib:EstimatedUsefulLivesOfLeaseholdImprovements>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      id="Fact-6110EA3B8640BF0D62D66F38B8B35502-wk-Fact-6110EA3B8640BF0D62D66F38B8B35502">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      id="Fact-DCC86966D94742959D726F38B8B2452D-wk-Fact-DCC86966D94742959D726F38B8B2452D">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <biib:PaymentTermsOfAccountsReceivable
      contextRef="FD2019Q4YTD"
      id="Fact-5F142DCE72FD5134700E6F38B7A2E496-wk-Fact-5F142DCE72FD5134700E6F38B7A2E496">30 to 90 days</biib:PaymentTermsOfAccountsReceivable>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
      contextRef="FI2017Q4_srt_ProductOrServiceAxis_biib_RituxanMember"
      decimals="3"
      id="Fact-9E5D1C690A1B3B1254016F38B82B06AD-wk-Fact-9E5D1C690A1B3B1254016F38B82B06AD"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_RituxanMember"
      decimals="3"
      id="Fact-6FCE829BB6F09C994EAD6F38B89242A5-wk-Fact-6FCE829BB6F09C994EAD6F38B89242A5"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfMinimumInvestmentReturn
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH"
      decimals="4"
      id="Fact-B2C25DE9246FE9F1ADDE6F38B8279589-wk-Fact-B2C25DE9246FE9F1ADDE6F38B8279589"
      unitRef="number">0.0100</biib:PercentageOfMinimumInvestmentReturn>
    <biib:PurchasePriceOfCommonStockUnderEspp
      contextRef="FD2019Q4YTD"
      id="Fact-699918F11E4708DEF9106F38B7A47F0D-wk-Fact-699918F11E4708DEF9106F38B7A47F0D">85% of the lower of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date</biib:PurchasePriceOfCommonStockUnderEspp>
    <dei:AmendmentFlag
      contextRef="FD2019Q4YTD"
      id="Fact-601138F62D1C8D2958846F38B8C1504E-wk-Fact-601138F62D1C8D2958846F38B8C1504E">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q4YTD"
      id="Fact-06B7887BD1A8B23C3B886F38B8C441C5-wk-Fact-06B7887BD1A8B23C3B886F38B8C441C5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q4YTD"
      id="Fact-4B124B26183E6D03F6586F38B8C36512-wk-Fact-4B124B26183E6D03F6586F38B8C36512">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q4YTD"
      id="Fact-6E1016268B067DD34AA26F38B8BFB35A-wk-Fact-6E1016268B067DD34AA26F38B8BFB35A">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q4YTD"
      id="Fact-3FEAB178574D22E242196F38B8BF2AA2-wk-Fact-3FEAB178574D22E242196F38B8BF2AA2">0000875045</dei:EntityCentralIndexKey>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="4"
      id="Fact-85A1AFF0B49581B25B366F38B7D90BF4-wk-Fact-85A1AFF0B49581B25B366F38B7D90BF4"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="4"
      id="Fact-5DFC402E0126967CB4006F38B7D77431-wk-Fact-5DFC402E0126967CB4006F38B7D77431"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="INF"
      id="Fact-5EA23C2207BDD738691E6F38B83B4DE9-wk-Fact-5EA23C2207BDD738691E6F38B83B4DE9"
      unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="INF"
      id="Fact-1D0ADB12ADA663D2040D6F38B8425926-wk-Fact-1D0ADB12ADA663D2040D6F38B8425926"
      unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="INF"
      id="Fact-67D0AE3558AB50F5D08A6F38B840B179-wk-Fact-67D0AE3558AB50F5D08A6F38B840B179"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="Fact-FABA99D64585208CA56D6F38B83EB03B-wk-Fact-FABA99D64585208CA56D6F38B83EB03B"
      unitRef="number">0.029</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="Fact-81600C9A0651D20828876F38B8B223F0-wk-Fact-81600C9A0651D20828876F38B8B223F0">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-6E15AF8386CB79E957DD6F38B8B4A42A-wk-Fact-6E15AF8386CB79E957DD6F38B8B4A42A">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="3"
      id="Fact-AA88748079D9B380E8496F38B7D98433-wk-Fact-AA88748079D9B380E8496F38B7D98433"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="3"
      id="Fact-86DCC857F67C7F46C9BD6F38B7D8C446-wk-Fact-86DCC857F67C7F46C9BD6F38B7D8C446"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      id="Fact-EEE9BF4E254006CC2C9E6F38B7A29AFF-wk-Fact-EEE9BF4E254006CC2C9E6F38B7A29AFF">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      id="Fact-13C488D9E41343A8B7EE6F38B7A33BF4-wk-Fact-13C488D9E41343A8B7EE6F38B7A33BF4">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      id="Fact-153CC06D6EA62F0A52336F38B7A40C82-wk-Fact-153CC06D6EA62F0A52336F38B7A40C82">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      id="Fact-FD08B729ECF2C081B08A6F38B7A4D731-wk-Fact-FD08B729ECF2C081B08A6F38B7A4D731">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      id="Fact-FE61D96427A39BE025246F38B7A27545-wk-Fact-FE61D96427A39BE025246F38B7A27545">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      id="Fact-86BC2A4465AAC25075FC6F38B7A581F3-wk-Fact-86BC2A4465AAC25075FC6F38B7A581F3">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      id="Fact-DBE47407B1C4535086796F38B7A56FDC-wk-Fact-DBE47407B1C4535086796F38B7A56FDC">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      id="Fact-AFC93C3C3D190267E7DE6F38B7A3B32B-wk-Fact-AFC93C3C3D190267E7DE6F38B7A3B32B">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs
      contextRef="FD2018Q4YTD"
      id="Fact-2EE1844C4B58DBE8170B6F38B866C2C5-wk-Fact-2EE1844C4B58DBE8170B6F38B866C2C5">0</us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="3"
      id="Fact-6D8C27F9216C433740646F38B88A79F9-wk-Fact-6D8C27F9216C433740646F38B88A79F9"
      unitRef="number">0.356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="3"
      id="Fact-D237F246AF8DB7B950F96F38B88A1D9B-wk-Fact-D237F246AF8DB7B950F96F38B88A1D9B"
      unitRef="number">0.330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="3"
      id="Fact-4344324549D84AC1B9FD6F38B886F120-wk-Fact-4344324549D84AC1B9FD6F38B886F120"
      unitRef="number">0.324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="3"
      id="Fact-D9A4DFE51F184DEB18246F38B887C4B8-wk-Fact-D9A4DFE51F184DEB18246F38B887C4B8"
      unitRef="number">0.275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="3"
      id="Fact-6D281EE0B4EB38A5923E6F38B878089C-wk-Fact-6D281EE0B4EB38A5923E6F38B878089C"
      unitRef="number">0.336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="3"
      id="Fact-7656A5517DB6D5E1671B6F38B876F2CF-wk-Fact-7656A5517DB6D5E1671B6F38B876F2CF"
      unitRef="number">0.312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="3"
      id="Fact-3782FE58C378859235B86F38B86FCEFF-wk-Fact-3782FE58C378859235B86F38B86FCEFF"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="3"
      id="Fact-941E760E735BA19EC38F6F38B86EB083-wk-Fact-941E760E735BA19EC38F6F38B86EB083"
      unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="3"
      id="Fact-A61344F03DC3C8D92A306F38B885CF7F-wk-Fact-A61344F03DC3C8D92A306F38B885CF7F"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="3"
      id="Fact-3CD5599D57576D94FB7B6F38B87A4BE9-wk-Fact-3CD5599D57576D94FB7B6F38B87A4BE9"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="3"
      id="Fact-B5F6CE3CDF4ACECF48676F38B8707903-wk-Fact-B5F6CE3CDF4ACECF48676F38B8707903"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="3"
      id="Fact-5320006E980F782C8B846F38B87C5B0F-wk-Fact-5320006E980F782C8B846F38B87C5B0F"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-734743511DAD63D802D36F38B82ED381-wk-Fact-734743511DAD63D802D36F38B82ED381"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-99CAF33D20DB4421C94B6F38B82E7DBD-wk-Fact-99CAF33D20DB4421C94B6F38B82E7DBD"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-8A010BA93697EF84D0E16F38B7EA0C22-wk-Fact-8A010BA93697EF84D0E16F38B7EA0C22"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:TreasuryStockShares
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-ACA1E382C836063D0E616F38B7D9045D-wk-Fact-ACA1E382C836063D0E616F38B7D9045D"
      unitRef="shares">23800000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="FI2019Q4"
      decimals="-5"
      id="Fact-CC5ECDE03E80FD890D4B6F38B7D86F9D-wk-Fact-CC5ECDE03E80FD890D4B6F38B7D86F9D"
      unitRef="shares">23800000</us-gaap:TreasuryStockShares>
    <dei:DocumentType
      contextRef="FD2019Q4YTD"
      id="d50957966e1302-wk-Fact-8A0BD13F9654E1708EB06F47CA3D88E7">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="FD2019Q4YTD"
      id="d50957966e1320-wk-Fact-8AC584334697CA5AF6676F5D16084FB9">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q4YTD"
      id="d50957966e1330-wk-Fact-E2F33040799E665984FC6F52E5F164F8">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q4YTD"
      id="d50957966e1352-wk-Fact-3459CEEEFAC318EF53C96F64AD8D9C87">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q4YTD"
      id="d50957966e1362-wk-Fact-8FF2256FFD63083C31126F65B4DA690C">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q4YTD"
      id="d50957966e1371-wk-Fact-F4886CD50E944D3BFD496F66BB5F74FE">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q4YTD"
      id="d50957966e1393-wk-Fact-D5FDEF9463C34BF02A4A6F678B37A423">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q4YTD"
      id="d50957966e1403-wk-Fact-6B38EB0D7BD444EC36416F686F26055F">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q4YTD"
      id="d50957966e1422-wk-Fact-6DAE157B31DF5216E6506F693C13B591">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q4YTD"
      id="d50957966e1427-wk-Fact-27902AF61E711D4CAF786F6D76C3DCA7">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q4YTD"
      id="d50957966e1432-wk-Fact-7154533D5E89DEEF68CA6F6E0C00FF91">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q4YTD"
      id="d50957966e1437-wk-Fact-334900A350D58FFCC3E46F6ED17D95B3">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q4YTD"
      id="d50957966e1445-wk-Fact-C5C2D35F6513E1BABC0C6F6F7BCC6CF0">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q4YTD"
      id="d50957966e1450-wk-Fact-C31EF1664673F29BE8A46F6FF7852803">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q4YTD"
      id="d50957966e1509-wk-Fact-2E56A7F1386DB9728FA16F74B8D83F0E">Common Stock, $0.0005&#160;par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q4YTD"
      id="d50957966e1519-wk-Fact-8F2E3B31C107204E37026F76272291CD">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q4YTD"
      id="d50957966e1534-wk-Fact-9BE6B29D477F3BD46FA16F772CDA80AE">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="FD2019Q4YTD"
      id="d50957966e1545-wk-Fact-41EE8623BDCA627FCB916F79BEF375CE">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="FD2019Q4YTD"
      id="d50957966e1564-wk-Fact-03EB33628C68E360B7E66F7B2F40FFF8">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q4YTD"
      id="d50957966e1574-wk-Fact-86E93BC8EFB70DC13E2E6F7BF17D195D">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q4YTD"
      id="d50957966e1588-wk-Fact-FDFC56682816F3A7F6E66F7CD4C6C400">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q4YTD"
      id="d50957966e1619-wk-Fact-1D339E7308DF24AA5BC56F88ABA10583">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q4YTD"
      id="d50957966e1665-wk-Fact-452C19F066A64736E2FF6F8946356071">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q4YTD"
      id="d50957966e1691-wk-Fact-11BA7DFC965395B933626F8997BE0D1A">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q4YTD"
      id="d50957966e1701-wk-Fact-DB8A85D06B8CE086F5F26F8D70A120E1">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="FI2019Q2"
      decimals="0"
      id="d50957966e1711-wk-Fact-10A120009520C03707E26F38B7B34CD4"
      unitRef="usd">43010112437</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2019Q4SharesOutstanding"
      decimals="0"
      id="d50957966e1722-wk-Fact-F0A469027FF5A7D7626D6F38B7B72BFD"
      unitRef="shares">174064011</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d50997257e1508-wk-Fact-F1FBA38FF669B88E1D976F38B82CDF1B"
      unitRef="usd">11379800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d50997257e1527-wk-Fact-7B6205D978C9C04E48296F38B81CF51A"
      unitRef="usd">10886800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d50997257e1546-wk-Fact-A0A85755BDDAAFF80DF16F38B7A963B8"
      unitRef="usd">10354700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d50997257e1562-wk-Fact-6DB6BA0B8C715A0D0D4B6F38B8607F57"
      unitRef="usd">2290400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d50997257e1581-wk-Fact-5DE8AC0444CC0844782E6F38B82AE6AA"
      unitRef="usd">1980200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d50997257e1600-wk-Fact-3A0656DB95083450147A6F38B824BC8E"
      unitRef="usd">1559200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d50997257e1621-wk-Fact-00E0A71FFA7A5B6582ED6F38B7ACA093"
      unitRef="usd">707700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d50997257e1640-wk-Fact-F0C4D670DC0F193457D96F38B8622365"
      unitRef="usd">585900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d50997257e1659-wk-Fact-5D3FED1ADFF25AE90C656F38B87CF3D8"
      unitRef="usd">360000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e1680-wk-Fact-E32397F18F6693CE30CB6F38B869063E"
      unitRef="usd">14377900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e1699-wk-Fact-6346545FE8014FEB58A26F38B7BCE6BD"
      unitRef="usd">13452900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e1718-wk-Fact-96627728E852FC579E846F38B8727293"
      unitRef="usd">12273900000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e1801-wk-Fact-F31EB1813F669E0C4CE46F38B81939B6"
      unitRef="usd">1955400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e1820-wk-Fact-5836028879FCD1E33D2B6F38B81DC6AF"
      unitRef="usd">1816300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e1839-wk-Fact-436BEFF0AD5D83B1CFDD6F38B827BEB2"
      unitRef="usd">1630000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e1860-wk-Fact-249B537F1C6F398F9F736F38B883F9E8"
      unitRef="usd">2280600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e1879-wk-Fact-CB3AC2C9EB0A3573A6A06F38B841157E"
      unitRef="usd">2597200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e1898-wk-Fact-8C04E99A6A84512CB5786F38B83C630B"
      unitRef="usd">2253600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e1919-wk-Fact-7B2DF81CED7650C3660D6F38B7AEC578"
      unitRef="usd">2374700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e1938-wk-Fact-DC74F299D202669E73136F38B8048B00"
      unitRef="usd">2106300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e1957-wk-Fact-B05147F5608E5C0110656F38B815661A"
      unitRef="usd">1933900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e1979-wk-Fact-79F73778C54DE73C4DD76F38B881C966"
      unitRef="usd">489900000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e1998-wk-Fact-81104360B4FDD747DCD66F38B87FA895"
      unitRef="usd">747300000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2017-wk-Fact-0248BA74606E7D1238426F38B833F6BA"
      unitRef="usd">814700000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <biib:CollaborationProfitSharing
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2038-wk-Fact-18F0A3FB37E3A7A494966F38B87AD564"
      unitRef="usd">241600000</biib:CollaborationProfitSharing>
    <biib:CollaborationProfitSharing
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2057-wk-Fact-8CFFC23D5AD1C81925E76F38B80A2DFD"
      unitRef="usd">185000000.0</biib:CollaborationProfitSharing>
    <biib:CollaborationProfitSharing
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2076-wk-Fact-768B3C497523BB8A323D6F38B867F91A"
      unitRef="usd">112300000</biib:CollaborationProfitSharing>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2097-wk-Fact-2E1848792728A1D7E2B57019220BE327"
      unitRef="usd">55300000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2116-wk-Fact-7ECF992C3975B52D113870194B2D32B5"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2135-wk-Fact-D95679811100D0E7E32C70196C35ACAE"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2156-wk-Fact-1823324BEE5AA206F4236F38B832A514"
      unitRef="usd">63700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2176-wk-Fact-977CCFE1B549EEAAE2F26F38B8745977"
      unitRef="usd">12300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2196-wk-Fact-98699FC9CF903005B5E56F38B7ABD2C2"
      unitRef="usd">-62700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2217-wk-Fact-8083CD7170BB88E868B56F38B7C72176"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2236-wk-Fact-17423E27B848A85AD4AE6F38B820B150"
      unitRef="usd">112500000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2255-wk-Fact-44EAC57204C4C05B290C6F38B884AC7E"
      unitRef="usd">120000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2276-wk-Fact-5A8618CA47536F9730136F38B7B89C8B"
      unitRef="usd">1500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2295-wk-Fact-B80C88B842F78DFE31EF6F38B818E106"
      unitRef="usd">12000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2314-wk-Fact-997495A4CAD8A36FB4E26F38B826DFBB"
      unitRef="usd">900000</us-gaap:RestructuringCharges>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2335-wk-Fact-F5F281DF9D0C5B1D58116F38B805F247"
      unitRef="usd">7335300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2354-wk-Fact-7EC25CE695A7A4812C316F38B7AD746A"
      unitRef="usd">7564300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2373-wk-Fact-EB3F161724E402F63C156F38B7C88B14"
      unitRef="usd">6928100000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2394-wk-Fact-A79AB0F2F1ED0BC79F866F38B7C805F3"
      unitRef="usd">7042600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2413-wk-Fact-926F44026F3FFC9248AC6F38B800FCAC"
      unitRef="usd">5888600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2432-wk-Fact-9E58A29345FB56EB3CDE6F38B7A7E08A"
      unitRef="usd">5345800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2453-wk-Fact-30D3E4734FFCCDECF81C6F38B832E9CF"
      unitRef="usd">83300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2472-wk-Fact-1E1CCAC95E8FE4A0F3CC6F38B873F8AA"
      unitRef="usd">11000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2491-wk-Fact-0B37CAFFF87FFF67E1CA6F38B7DCE800"
      unitRef="usd">-217000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2513-wk-Fact-037FDB9132CFC80955486F38B80DC31A"
      unitRef="usd">7125900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2532-wk-Fact-CEA622036210CBAE55336F38B7C2C044"
      unitRef="usd">5899600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2551-wk-Fact-68291FC0C112D97457DA6F38B7DD4BB7"
      unitRef="usd">5128800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2572-wk-Fact-D772848546D678B1763B6F38B837CC03"
      unitRef="usd">1158000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2591-wk-Fact-2FDAAAEDBE81F99A2C786F38B89FE50C"
      unitRef="usd">1425600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2610-wk-Fact-297A0CBBF5B99106D4D26F38B7FC8B8D"
      unitRef="usd">2458700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2632-wk-Fact-2A57B951C0BA4E68F8936F38B82EF936"
      unitRef="usd">-79400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2651-wk-Fact-91D14DB26E2AF98F5DF46F38B8756C34"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2670-wk-Fact-A9714C9669A2DB1BC04A6F38B8195CF4"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2691-wk-Fact-C3E3738B6B2880EEE0C26F38B86F41E2"
      unitRef="usd">5888500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2710-wk-Fact-697504B55D319C5C89A06F38B813740F"
      unitRef="usd">4474000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2729-wk-Fact-11271C2D6390C500664E6F38B7B1785A"
      unitRef="usd">2670100000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2750-wk-Fact-1900219E0FB7A5328D086F38B7FAC097"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2769-wk-Fact-E8E5FA73540BFEE969DC6F38B88214FB"
      unitRef="usd">43300000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2788-wk-Fact-161AB1A997B7E3DA22CF6F38B89B9F1E"
      unitRef="usd">131000000.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e2814-wk-Fact-409F06146EDA2C5A1FA56F38B82DE39D"
      unitRef="usd">5888500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e2833-wk-Fact-D75E3BB69A698B5537196F38B831D83C"
      unitRef="usd">4430700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e2852-wk-Fact-029151C37D9A5DCBB4476F38B8229A45"
      unitRef="usd">2539100000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d50997257e2935-wk-Fact-A79B8DD2B8E528E3782E6F38B808C78D"
      unitRef="usdPerShare">31.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d50997257e2954-wk-Fact-EC8AD5EF20EED04CF1636F38B8861C2A"
      unitRef="usdPerShare">21.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d50997257e2973-wk-Fact-1309CB0E98D1AEAAED8B6F38B837AD26"
      unitRef="usdPerShare">11.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d50997257e2994-wk-Fact-F8BA2307E5D05CF7F3896F38B7C21B4F"
      unitRef="usdPerShare">31.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d50997257e3013-wk-Fact-5A9680F29B9835BE41B06F38B82F13BD"
      unitRef="usdPerShare">21.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d50997257e3032-wk-Fact-AC1A9E20C32DB8C75C6E6F38B7A31203"
      unitRef="usdPerShare">11.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e3110-wk-Fact-1969AB1F17EC7BCE4FB56F38B7B8CA9B"
      unitRef="shares">187100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e3129-wk-Fact-5907C0CD0AE9671001886F38B828BCF3"
      unitRef="shares">204900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e3148-wk-Fact-699EE9018111D1CC3A906F38B80EA6F3"
      unitRef="shares">212600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d50997257e3169-wk-Fact-9C26193DB3CDD8FB9C8B6F38B8899F39"
      unitRef="shares">187400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d50997257e3188-wk-Fact-4176A55C9C6E8FB2BE6A6F38B7A4B71D"
      unitRef="shares">205300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d50997257e3207-wk-Fact-BDF045D316347ECE0A996F38B87BB71A"
      unitRef="shares">213000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e1445-wk-Fact-409F06146EDA2C5A1FA56F38B82DE39D"
      unitRef="usd">5888500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e1464-wk-Fact-D75E3BB69A698B5537196F38B831D83C"
      unitRef="usd">4430700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e1483-wk-Fact-029151C37D9A5DCBB4476F38B8229A45"
      unitRef="usd">2539100000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e1623-wk-Fact-036AE0A9F02C9CF5CCE66F38B81AF793"
      unitRef="usd">11800000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e1642-wk-Fact-E2BF01DADDB2DDB253656F38B81672D1"
      unitRef="usd">-10600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e1662-wk-Fact-22620E07DDA09BF57ACF6F38B8196E38"
      unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e1684-wk-Fact-850FB1BD118ACA44C9D66F38B819DD6F"
      unitRef="usd">3600000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e1704-wk-Fact-158B897DA936D844E43D6F38B8100B61"
      unitRef="usd">-6700000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e1723-wk-Fact-186A8E31C983D57A2BE46F38B8174F8A"
      unitRef="usd">-12700000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e1744-wk-Fact-23E718C96C1F7D1EFA1C6F38B81A332F"
      unitRef="usd">8200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e1763-wk-Fact-82BCB771BD1EBE85B00B6F38B86381BD"
      unitRef="usd">-3900000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e1783-wk-Fact-980B5C73304B4432C5D26F38B8628EF0"
      unitRef="usd">9200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e1866-wk-Fact-72F9B7E4B0E1E8A262AA6F38B8187145"
      unitRef="usd">88100000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e1885-wk-Fact-768879F371477FBF53096F38B80E0DB3"
      unitRef="usd">97400000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e1904-wk-Fact-BD0BC5A2ADA7F06BF7026F38B81A5C38"
      unitRef="usd">-193800000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e1926-wk-Fact-6569365DC95E5054B5696F38B80E341B"
      unitRef="usd">115000000.0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e1946-wk-Fact-F829005F80D75D746CB96F38B8611030"
      unitRef="usd">-41800000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e1965-wk-Fact-5C1A5042825B6AB15DB56F38B86EF660"
      unitRef="usd">-31500000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e1987-wk-Fact-58F1A7C851B29908A75F6F38B80F8124"
      unitRef="usd">-26900000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e2007-wk-Fact-CAF379F238DF11937A766F38B817DB96"
      unitRef="usd">139200000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e2026-wk-Fact-F7B9347038E39989A61B6F38B885B658"
      unitRef="usd">-162300000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e2110-wk-Fact-085DEE816DF81F31649E6F38B8148634"
      unitRef="usd">28600000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e2129-wk-Fact-65E3E9BC59BCE7A697106F38B86A342A"
      unitRef="usd">5000000.0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e2148-wk-Fact-C6684478E53F26F446A76F38B861D8CB"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e2169-wk-Fact-DE48FCAAECC6C1C392296F38B81B9578"
      unitRef="usd">7000000.0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e2189-wk-Fact-EB54C7BF5C1E6F59DC676F38B80FF675"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e2209-wk-Fact-081830A5CD7E691CD34E6F38B861C060"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e2230-wk-Fact-FCA6B8EFE0F2484309866F38B8104433"
      unitRef="usd">21600000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e2249-wk-Fact-AD4CB6818D39FC290C2F6F38B81A9BFE"
      unitRef="usd">3500000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e2268-wk-Fact-AD6832FDCF7B55A0E55C6F38B8165837"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e2289-wk-Fact-77779DF3D5AEA2320E5B6F38B81A5CF3"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e2309-wk-Fact-80172A32A65847926D416F38B8168295"
      unitRef="usd">-5500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e2328-wk-Fact-C713801FE6BC787A0CFA6F38B85E8929"
      unitRef="usd">4100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e2350-wk-Fact-656A298293E90F3F8D096F38B863F838"
      unitRef="usd">103800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e2369-wk-Fact-ADE602B01FDC1A89FCED6F38B80E4CFE"
      unitRef="usd">-67800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e2389-wk-Fact-2FBD302A263A0B7D0BEF6F38B8637B5D"
      unitRef="usd">158700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e2410-wk-Fact-D065EF4A97DD7AA72ECF6F38B85F566B"
      unitRef="usd">105200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e2429-wk-Fact-3FFFEF07DFDCE1143CF16F38B81442EC"
      unitRef="usd">76500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e2448-wk-Fact-DAF3185409661071AF2B6F38B80DA8BC"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e2469-wk-Fact-A2D5BAF327BB6898B0C76F38B8158571"
      unitRef="usd">5993700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e2488-wk-Fact-13ED8A39D11AE02272036F38B86B8D5E"
      unitRef="usd">4507200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e2507-wk-Fact-72AE9FEE19B228C5CA406F38B8632119"
      unitRef="usd">2540600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e2528-wk-Fact-4A88EA1036E45A6BB6556F38B810DFBF"
      unitRef="usd">-400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e2548-wk-Fact-F24257C6912EE59FAE036F38B8144963"
      unitRef="usd">42900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e2567-wk-Fact-2E945A5EFA82EB9E24136F38B8178C5C"
      unitRef="usd">131000000.0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51001034e2593-wk-Fact-67C0C1B1314ABCDB93F36F38B8182C91"
      unitRef="usd">5993300000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51001034e2612-wk-Fact-E9FE404441B42C8D4A326F38B862B50F"
      unitRef="usd">4550100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51001034e2631-wk-Fact-E01AAF7679D745D8EFD46F38B81785C4"
      unitRef="usd">2671600000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1480-wk-Fact-1F183EDFDE14BD1665F76F38B8C78A4F"
      unitRef="usd">2913700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1499-wk-Fact-B402A4E49B32DDD763566F38B838CB79"
      unitRef="usd">1224600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1514-wk-Fact-5D3894AA12B159647C9C6F38B8C18A7C"
      unitRef="usd">1562200000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1533-wk-Fact-7805FBAA57741DCE7CBC6F38B8B5C084"
      unitRef="usd">2313400000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1553-wk-Fact-8D13454B6972B4D73FFB6F38B8B6120C"
      unitRef="usd">1880500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1572-wk-Fact-D5ADBF8AD760EE88B7BE6F38B8BECAA8"
      unitRef="usd">1958500000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DueFromUnconsolidatedJointBusiness
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1592-wk-Fact-32D40AC6CF18100B88736F38B8C7335F"
      unitRef="usd">590200000</biib:DueFromUnconsolidatedJointBusiness>
    <biib:DueFromUnconsolidatedJointBusiness
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1611-wk-Fact-74A98A29053CE4F6BDA96F38B8B662C1"
      unitRef="usd">526900000</biib:DueFromUnconsolidatedJointBusiness>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1631-wk-Fact-26F6B410F20D465D19666F38B8C27FA2"
      unitRef="usd">804200000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1650-wk-Fact-8C4A1D272C17C1AD6F426F38B8C3B56F"
      unitRef="usd">929900000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1670-wk-Fact-EFB3265B4305DF9AAD2A6F38B8AD763C"
      unitRef="usd">631000000.0</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1689-wk-Fact-349E6AD4888A84D1E7F66F38B83F1C50"
      unitRef="usd">687600000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1709-wk-Fact-4DA9948E5664D6D862B86F38B8B9AEF8"
      unitRef="usd">8381800000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1728-wk-Fact-D186B9D28E2E1CF9CC046F38B8C42A59"
      unitRef="usd">7640900000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1749-wk-Fact-2986E5682008DC2FAEA06F38B8C277D9"
      unitRef="usd">1408100000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1768-wk-Fact-C117801EC02801861D686F38B83BC1C5"
      unitRef="usd">1375900000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1788-wk-Fact-CF1C2504DA7602F237C56F38B8445161"
      unitRef="usd">3247300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1807-wk-Fact-366250CBE4B1855EC9FF6F38B83E3B1B"
      unitRef="usd">3601200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1827-wk-Fact-95391A476E38CC55D450E85D6C8B15E7"
      unitRef="usd">427000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1846-wk-Fact-A9E19B8C55ED48705AC7E85D6DCCE9E8"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1866-wk-Fact-4AD21CB6B4B90431AF316F38B8BC8BF4"
      unitRef="usd">3527400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1885-wk-Fact-0B06E7AFD52116E2A95B6F38B8B9E33F"
      unitRef="usd">3120000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1905-wk-Fact-0B1007097B5E08446E1E6F38B840631D"
      unitRef="usd">5757800000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1924-wk-Fact-E7AAD5AF93A3B138C23D6F38B839DA15"
      unitRef="usd">5706400000</us-gaap:Goodwill>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1944-wk-Fact-60EC76FA353894EECB236F38B8B6C3F6"
      unitRef="usd">3232100000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e1963-wk-Fact-AFB3FFACBACC4E72C02F6F38B84277F6"
      unitRef="usd">2153900000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e1983-wk-Fact-411CE66892D435FC7FB76F38B83D1251"
      unitRef="usd">1252800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2002-wk-Fact-C768E5E9137F08726E626F38B8B30520"
      unitRef="usd">1690600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2027-wk-Fact-0B0D7B37366B0014A0F36F38B83BECFB"
      unitRef="usd">27234300000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2046-wk-Fact-644C724D76997259EF696F38B8BE093A"
      unitRef="usd">25288900000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2148-wk-Fact-E03C31AEBF983BAF370A6F38B83EEB28"
      unitRef="usd">1495800000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2167-wk-Fact-A5C816CFC4616E30647F6F38B83C6A09"
      unitRef="usd">0</us-gaap:DebtCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2183-wk-Fact-E6307D6AD7D6708EC20C6F38B8C0EE3E"
      unitRef="usd">71400000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2202-wk-Fact-A541F02EAEEFBC121D796F38B8AEF68C"
      unitRef="usd">63500000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2222-wk-Fact-157D8C3481B5747B40DF6F38B7A2AF9C"
      unitRef="usd">530800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2241-wk-Fact-64359EE7A1009F1987726F38B83EA3DC"
      unitRef="usd">370500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2261-wk-Fact-BDC01B59134555A3997B6F38B8B552E2"
      unitRef="usd">2765800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2280-wk-Fact-90574151EADDD2E79EBF6F38B8439367"
      unitRef="usd">2861200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2300-wk-Fact-70416AC8671D942151196F38B8C37C72"
      unitRef="usd">4863800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2319-wk-Fact-725A00ED306314158A066F38B83D6A7F"
      unitRef="usd">3295200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2339-wk-Fact-95D2C560A678B1EACADD6F38B8BDFC71"
      unitRef="usd">4459000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2358-wk-Fact-CAE61D364EA39551186E6F38B8C4B9E5"
      unitRef="usd">5936500000</us-gaap:LongTermDebt>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2378-wk-Fact-3A8FA7EC9AB9E31C8A0C6F38B8AECDBE"
      unitRef="usd">2810800000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2397-wk-Fact-AF3291890E788E56CFA26F38B8B279CB"
      unitRef="usd">1636200000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2417-wk-Fact-BD941F941CAD0B19CB3BE85E0BA7189C"
      unitRef="usd">412700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2436-wk-Fact-A5C2C3DC4144BB1F5F14E85E0D615639"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2456-wk-Fact-FEE7C166F066CB6B97C56F38B8BCBDFD"
      unitRef="usd">1348900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2475-wk-Fact-020D28AEA8A1984F186F6F38B8C2FBCF"
      unitRef="usd">1389400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2495-wk-Fact-6CF1DF5B7EEDCBFB71AE6F38B8B913E1"
      unitRef="usd">13895200000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2514-wk-Fact-4C5322C471F747C960D06F38B8C872C7"
      unitRef="usd">12257300000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q4"
      id="d51001180e2534-wk-Fact-89147172F22905F20F616F38B8BB7BD3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d51001180e2552-wk-Fact-A0E43DF219EADE5F54BE6F38B8B14C7A"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2654-wk-Fact-90D450E388D8C0D2F2176F38B83BA6A3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2673-wk-Fact-830C505FAD6F5F8EA4F76F38B83C4EAB"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2693-wk-Fact-8EFD8D4FF6F2358C8A4D6F38B83A95E5"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2712-wk-Fact-473042731EFBFF89C9C76F38B839E4AE"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2732-wk-Fact-B6FD7CE60F4817CDE6D76F38B8401DD3"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2751-wk-Fact-7FC06C33EE058E10D0F86F38B8BF0E98"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2771-wk-Fact-262FECE5A3392F04B8F36F38B8C7C408"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2791-wk-Fact-85A952828CB37D9B77516F38B8B27C3F"
      unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2812-wk-Fact-61EAE81C54FFEDB4AD576F38B8B2E4C1"
      unitRef="usd">16455400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2831-wk-Fact-3AE2378285645E37DA366F38B8B87CFB"
      unitRef="usd">16257000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2851-wk-Fact-1F5E05E7ECE9B8E9663E6F38B8BC02DD"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2871-wk-Fact-B8498D34D3DCF278F79A6F38B8BEF886"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2892-wk-Fact-5784C3342553B2982B496F38B8C6A7D0"
      unitRef="usd">13343200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2911-wk-Fact-ABC0C61D4C7DF5163AEB6F38B8BBCD37"
      unitRef="usd">13039600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2931-wk-Fact-C067636497E1287B08576F38B8C365BD"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2951-wk-Fact-5A5612F8391AED46D17A6F38B8C1E160"
      unitRef="usd">-8000000.0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e2972-wk-Fact-E27B78E7E3A5AB66D9E76F38B84668E0"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e2991-wk-Fact-3CB4C3695BCE2D0BFC186F38B8B4EFC2"
      unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51001180e3016-wk-Fact-0F5AC0816DAEC603849D6F38B8BA9613"
      unitRef="usd">27234300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51001180e3035-wk-Fact-76A4EDC8B35F3DF03EDC6F38B8C1F81B"
      unitRef="usd">25288900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e1507-wk-Fact-C3E3738B6B2880EEE0C26F38B86F41E2"
      unitRef="usd">5888500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e1526-wk-Fact-697504B55D319C5C89A06F38B813740F"
      unitRef="usd">4474000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e1545-wk-Fact-11271C2D6390C500664E6F38B7B1785A"
      unitRef="usd">2670100000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e1623-wk-Fact-9F317AAA796E544D450C6F38B7C21FFB"
      unitRef="usd">680600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e1642-wk-Fact-A01969903A5AB3CDF5E36F38B7B87E83"
      unitRef="usd">1016600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e1661-wk-Fact-E48762A5362956E4A6F06F38B7B77F84"
      unitRef="usd">1081000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e1682-wk-Fact-8083CD7170BB88E868B56F38B7C72176"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e1701-wk-Fact-17423E27B848A85AD4AE6F38B820B150"
      unitRef="usd">112500000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e1720-wk-Fact-44EAC57204C4C05B290C6F38B884AC7E"
      unitRef="usd">120000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e1741-wk-Fact-1A811E630801EA6218816F38B7BEDB3E"
      unitRef="usd">182300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e1760-wk-Fact-C59DD2F2BE7B48ACB8A36F38B7C40CE5"
      unitRef="usd">157500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e1779-wk-Fact-E96F49E60A88D191F5456F38B868F049"
      unitRef="usd">128000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e1800-wk-Fact-7C31084FEFA28114DCAB6F38B864D055"
      unitRef="usd">67100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e1819-wk-Fact-15E7585669CC1C2CBDC96F38B86FDC03"
      unitRef="usd">108300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e1838-wk-Fact-AA985A4C7305479DFAD86F38B7C27564"
      unitRef="usd">91700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e1859-wk-Fact-1823324BEE5AA206F4236F38B832A514"
      unitRef="usd">63700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e1879-wk-Fact-977CCFE1B549EEAAE2F26F38B8745977"
      unitRef="usd">12300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e1899-wk-Fact-98699FC9CF903005B5E56F38B7ABD2C2"
      unitRef="usd">-62700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e1920-wk-Fact-449CB1C38658B96F0B32702A6FD27FC1"
      unitRef="usd">-55300000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e1939-wk-Fact-031FE57F4CD6143FA88D702A711D0319"
      unitRef="usd">0</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e1958-wk-Fact-4F2E88D9EA10D834AEBC702A733556A8"
      unitRef="usd">0</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e1980-wk-Fact-65A959FDD7161E1D47256F38B8745FF9"
      unitRef="usd">-69200000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e1999-wk-Fact-7538CE22CD7EF7BC1BD66F38B86F88CE"
      unitRef="usd">69100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2019-wk-Fact-862B182E47ACC274FB026F38B7BB54E4"
      unitRef="usd">-162100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2102-wk-Fact-B659C7CB89E531CB336F6F38B87048E0"
      unitRef="usd">-68800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2121-wk-Fact-CEF792B8E5CDB003A2156F38B7C658F8"
      unitRef="usd">205200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2141-wk-Fact-AEF5F9EAE45D73BAF3046F38B7C0A9E5"
      unitRef="usd">435600000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2163-wk-Fact-B06309CAA3F7B48BEAB96F38B7BBD7BC"
      unitRef="usd">63300000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2183-wk-Fact-FA9BC9B82681B1CD6BAA6F38B7BE61DB"
      unitRef="usd">-5700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2202-wk-Fact-9AEFBC358E3F4DF143156F38B8656111"
      unitRef="usd">232000000.0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2224-wk-Fact-AD27F47DE869A6583EE86F38B86751D6"
      unitRef="usd">19200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2244-wk-Fact-BFE944E2874ECC49B6BE6F38B7C40C1D"
      unitRef="usd">52100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2264-wk-Fact-20289F6533314EC2245C6F38B7B74DB7"
      unitRef="usd">94500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2286-wk-Fact-5C87F5F1B69BB7100A396F38B85FFE0C"
      unitRef="usd">240200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2305-wk-Fact-8A162E103A33BEC2464C6F38B862D580"
      unitRef="usd">465500000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2324-wk-Fact-CF31E47F5618546D9EF16F38B86C36D8"
      unitRef="usd">-227400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2346-wk-Fact-7D417649EF6FB7299BE56F38B7B51FE0"
      unitRef="usd">16100000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2365-wk-Fact-314F4041AF93F9CA4DC46F38B7B795A4"
      unitRef="usd">321700000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2384-wk-Fact-42A8F80D9CDDF989C7A36F38B8798B8C"
      unitRef="usd">1303900000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2405-wk-Fact-6470012F61FD41C52B4A6F38B7B35B70"
      unitRef="usd">-43300000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2425-wk-Fact-C8F1A4DB634CBA6DEAF56F38B7B23F03"
      unitRef="usd">-135400000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2445-wk-Fact-1DA332A1C998985B82626F38B7BC741B"
      unitRef="usd">-79000000.0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2467-wk-Fact-DD78F0561C2C078BC6C06F38B7C4DE29"
      unitRef="usd">7078600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2486-wk-Fact-F2E5DE33CB2C655CA5146F38B7C2A789"
      unitRef="usd">6187700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2505-wk-Fact-98EE686DF7096618BDFC6F38B7B9D389"
      unitRef="usd">4551000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2588-wk-Fact-9B2BAA05E503864359F46F38B864558E"
      unitRef="usd">6007000000.0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2607-wk-Fact-91236B58E7640EF128CE6F38B7B34236"
      unitRef="usd">9173700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2626-wk-Fact-D3A23249D5697F1852396F38B7BFFC17"
      unitRef="usd">5565900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecurities
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2648-wk-Fact-4C68BC47649C1BEDB6796F38B86C620E"
      unitRef="usd">5252600000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecurities
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2668-wk-Fact-43864AB7F367BEC8CB266F38B7B7DE5B"
      unitRef="usd">7694800000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecurities
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2688-wk-Fact-D4B8F07D51F93EAE064C6F38B86585D6"
      unitRef="usd">5355200000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2710-wk-Fact-5E52FA6D936ABFBDD72C6F38B7B418A6"
      unitRef="usd">300000000.0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2730-wk-Fact-A3ED243CAB7D69E02C186F38B7C799D8"
      unitRef="usd">1500000000.0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2750-wk-Fact-4D39337611F4E739AA156F38B7B4DEDC"
      unitRef="usd">1200000000.0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2772-wk-Fact-B3F3DED935484FDB31CCE85FE2E5CFE9"
      unitRef="usd">744400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2792-wk-Fact-25FA12D62D0DC4BF016CE85FE511BD49"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2811-wk-Fact-357439D0C8C388C30CD4E85FE746CDDA"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2832-wk-Fact-747B36455DA4C02BB05FE85FE7BA7257"
      unitRef="usd">923700000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2851-wk-Fact-3556A3D0E26975B63737E85FE84B02C3"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2870-wk-Fact-65BB47BFE5EAE92961F3E85FE989E27C"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2891-wk-Fact-B48678F8D726B3BD2EEB6F38B8650C01"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2910-wk-Fact-9BE248533C0B2242410B6F38B86296E1"
      unitRef="usd">112500000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2930-wk-Fact-F05C8B2C70F5E87F066F6F38B7BAABD2"
      unitRef="usd">120000000.0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e2952-wk-Fact-38E0EFAA85842E5BC05E6F38B878A308"
      unitRef="usd">514500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e2972-wk-Fact-1575B781F30213FFEAA66F38B864B389"
      unitRef="usd">770600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e2992-wk-Fact-66C0C90B949CD69B1FEC6F38B86B5B73"
      unitRef="usd">867400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3014-wk-Fact-1B13AF395A441265574E6F38B7C87917"
      unitRef="usd">155000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3034-wk-Fact-F0A85357FE625601CC2F6F38B8798D2F"
      unitRef="usd">3000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3054-wk-Fact-F052F57799815F2A29246F38B7B9D93E"
      unitRef="usd">975400000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3076-wk-Fact-EF2A48E55DCF47CD34D96F38B8787822"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3095-wk-Fact-0591D97BDE0EE9E1145D6F38B868CBD7"
      unitRef="usd">462900000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3115-wk-Fact-BE6D47613A51669C34166F38B87AECB8"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3136-wk-Fact-2B041933338397072C1D6F38B7C650A8"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3155-wk-Fact-56AE50267B9E75B542206F38B871E659"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3175-wk-Fact-2D715DE442451A4B2D5B6F38B8733414"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3196-wk-Fact-9647933C724E3158CEEAE8605DEC3679"
      unitRef="usd">479300000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3215-wk-Fact-6D0E1729EF84810FC5F3E8605FDB3FBE"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3234-wk-Fact-8C04290EE3D1C6718370E86061E63329"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3255-wk-Fact-B37D1DDBF5355A5E9D856F38B7C86378"
      unitRef="usd">-27000000.0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3274-wk-Fact-08994F80B22E8720DF866F38B7BFB5AC"
      unitRef="usd">-400000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3293-wk-Fact-41E69C07DAC08E1FFD7D6F38B7B860E4"
      unitRef="usd">11000000.0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3316-wk-Fact-C861526D9C529998F7F56F38B87B56DF"
      unitRef="usd">470500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3335-wk-Fact-2B64996FC864C4CB7F056F38B7C5C649"
      unitRef="usd">-2046300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3355-wk-Fact-64F4A50A8C7E564F686D6F38B87B1589"
      unitRef="usd">-2963100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3439-wk-Fact-DBDCE8E038F5A0BEB2896F38B7C7295A"
      unitRef="usd">5868300000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3459-wk-Fact-51A36D29CEDD709084E26F38B7C1A09B"
      unitRef="usd">4352600000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3479-wk-Fact-1EDE0510D32C1A1B87566F38B7BE982E"
      unitRef="usd">1365400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3501-wk-Fact-5541F8E1DC128D1E97CA6F38B87336D0"
      unitRef="usd">-4300000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3520-wk-Fact-36421408DAD2A68EB4B56F38B869B8F1"
      unitRef="usd">36400000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3540-wk-Fact-9DF56AB117278D77F5856F38B87733CB"
      unitRef="usd">134100000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:RepaymentsOfDebt
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3562-wk-Fact-38CA70517A8BFC890A8A6F38B8640CA3"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3581-wk-Fact-9AE83ED9BB882A5E31076F38B7BA21FA"
      unitRef="usd">3200000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3601-wk-Fact-3FDAD86BD7C7C5BB43E16F38B86981FA"
      unitRef="usd">560900000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfCapitalDistribution
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3623-wk-Fact-50CDFAC5A8F402BE1F176F38B86AEF49"
      unitRef="usd">0</us-gaap:PaymentsOfCapitalDistribution>
    <us-gaap:PaymentsOfCapitalDistribution
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3642-wk-Fact-1A8962550E6653E7B5846F38B86C9D02"
      unitRef="usd">0</us-gaap:PaymentsOfCapitalDistribution>
    <us-gaap:PaymentsOfCapitalDistribution
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3661-wk-Fact-3E089A53FF95A00D23F56F38B86DE827"
      unitRef="usd">302700000</us-gaap:PaymentsOfCapitalDistribution>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3683-wk-Fact-BC9F6486AF65F795A6A76F38B864CDBF"
      unitRef="usd">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3702-wk-Fact-1CC5D67510E7F7D718F56F38B7B3987C"
      unitRef="usd">58200000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3722-wk-Fact-8DA102F7283160FDB2F66F38B7B5A88D"
      unitRef="usd">3000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3744-wk-Fact-FF6BCD881A2410D97BEA6F38B874F541"
      unitRef="usd">3600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3763-wk-Fact-60BC6FDF615D07063CBB6F38B86D6581"
      unitRef="usd">-21600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3783-wk-Fact-39EE9C45F78744F025F76F38B7C3D0CA"
      unitRef="usd">-13900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3805-wk-Fact-F93416FD66A9D8FD7F286F38B86E7D15"
      unitRef="usd">-5860400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3825-wk-Fact-73C98F381A9A802F7CD76F38B7BD3586"
      unitRef="usd">-4472000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3845-wk-Fact-3391BFD9FEE4D4BCB3DB6F38B7BC1DB6"
      unitRef="usd">-2380000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3867-wk-Fact-DA2298296EC21724ABD26F38B7B3BE98"
      unitRef="usd">1688700000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3886-wk-Fact-B94D83286461806D9D686F38B8777B0B"
      unitRef="usd">-330600000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3906-wk-Fact-12258EE9E52A93DEB5D06F38B7C55548"
      unitRef="usd">-792100000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51007189e3928-wk-Fact-392834188991A47ED5A76F38B7C62BA4"
      unitRef="usd">400000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51007189e3947-wk-Fact-4222BFF6621838727A446F38B874BD6D"
      unitRef="usd">-18600000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51007189e3967-wk-Fact-2D564E4A9446367C189B6F38B8751D23"
      unitRef="usd">39400000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51007189e3989-wk-Fact-B402A4E49B32DDD763566F38B838CB79"
      unitRef="usd">1224600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51007189e4008-wk-Fact-80BFDA7146A775C44BE06F38B8660DF1"
      unitRef="usd">1573800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q4"
      decimals="-5"
      id="d51007189e4027-wk-Fact-906F465F35CDF3F0FBD96F38B87215EE"
      unitRef="usd">2326500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51007189e4053-wk-Fact-1F183EDFDE14BD1665F76F38B8C78A4F"
      unitRef="usd">2913700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51007189e4072-wk-Fact-B402A4E49B32DDD763566F38B838CB79"
      unitRef="usd">1224600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51007189e4091-wk-Fact-80BFDA7146A775C44BE06F38B8660DF1"
      unitRef="usd">1573800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d51023978e1843-wk-Fact-FC6BD39B73491F0771E96F38B7C48259"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d51023978e1862-wk-Fact-12411F493663665C481B6F38B7AE8F90"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e1876-wk-Fact-9C5AD0C83D1E22701F2D6F38B88FEE4B"
      unitRef="shares">221000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e1896-wk-Fact-D0D7319D5AA69096D4096F38B7BFEDA4"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e1915-wk-Fact-5A0843BFA954605F22C16F38B7C7A6EE"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51023978e1934-wk-Fact-D9A111AF560E38CA94966F38B7B8C128"
      unitRef="usd">-240400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e1955-wk-Fact-A13A847A72CA16A4EF8C6F38B88C56EE"
      unitRef="usd">16257000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e1969-wk-Fact-AAB3BBD7C2DAA204DE6C6F38B7B43D09"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e1989-wk-Fact-C25C9B8B2D2AA699B5276F38B7BBE94A"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51023978e2010-wk-Fact-ABC0C61D4C7DF5163AEB6F38B8BBCD37"
      unitRef="usd">13039600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e2029-wk-Fact-34F4954DA06ACA92FB976F38B7C02975"
      unitRef="usd">-8000000.0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51023978e2049-wk-Fact-3CB4C3695BCE2D0BFC186F38B8B4EFC2"
      unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e2177-wk-Fact-68E8E865C41C38D9112D6F38B7B94D24"
      unitRef="usd">5888500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51023978e2232-wk-Fact-409F06146EDA2C5A1FA56F38B82DE39D"
      unitRef="usd">5888500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e2251-wk-Fact-1787ACAA578B0F24D5506F38B7BA0886"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51023978e2270-wk-Fact-C3E3738B6B2880EEE0C26F38B86F41E2"
      unitRef="usd">5888500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51023978e2382-wk-Fact-9E2D38129642A883439E6F38B7B1D9D9"
      unitRef="usd">105200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51023978e2458-wk-Fact-D065EF4A97DD7AA72ECF6F38B85F566B"
      unitRef="usd">105200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e2477-wk-Fact-0F0C45BABB91FC77FB5B6F38B88D6612"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51023978e2497-wk-Fact-596E86F9CDF4F8C52B756F38B7BE1409"
      unitRef="usd">104800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d51023978e2686-wk-Fact-DCB5BFF6946C6676AF916F38B88EB503"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e2705-wk-Fact-36F7B33FA7F3FA7073BB6F38B7B41E3E"
      unitRef="usd">4300000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51023978e2724-wk-Fact-409293DD07607E05EE636F38B7B5AAE8"
      unitRef="usd">4300000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e2877-wk-Fact-16BCE9E5B23F30F172376F38B7C1AC08"
      unitRef="shares">14700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e2892-wk-Fact-32548F6D031B8B1990166F38B7B2CE43"
      unitRef="usd">3720900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e2913-wk-Fact-D6A1E3FDDFFE78444EAB6F38B7C19B99"
      unitRef="usd">3720900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e2953-wk-Fact-D6A1E3FDDFFE78444EAB6F38B7C19B99"
      unitRef="usd">3720900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e3010-wk-Fact-283DBFC1C9312B5C5DFB6F38B7B95B88"
      unitRef="shares">14700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e3026-wk-Fact-57201F8897F0F6EEB68E6F38B7B4E6D8"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e3045-wk-Fact-D0064842CD711BCAA8146F38B7B5118D"
      unitRef="usd">121500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e3086-wk-Fact-AE9EDC54A0A6ADB02B2B6F38B7BD5F2A"
      unitRef="usd">3599400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e3106-wk-Fact-8CC8973B0434B74FE4446F38B7B60001"
      unitRef="shares">14700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e3120-wk-Fact-8C55871DF7B9A306B4EA6F38B7BCA81D"
      unitRef="usd">3720900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e3140-wk-Fact-B8692957C4584F603E846F38B7B26CDD"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e3179-wk-Fact-B8692957C4584F603E846F38B7B26CDD"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e3332-wk-Fact-F3CA4D4490CE7F4C990D6F38B88E760F"
      unitRef="shares">8900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e3347-wk-Fact-8803384DCB38FFD8CD086F38B7BD1540"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e3368-wk-Fact-742DD781FD1D0934345D6F38B7C7BACB"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e3408-wk-Fact-742DD781FD1D0934345D6F38B7C7BACB"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e3465-wk-Fact-8929CB2D5485F6A69A0A6F38B7B4A367"
      unitRef="shares">8900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e3481-wk-Fact-70889EF7E1168A55BD876F38B7B90C35"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e3500-wk-Fact-1DCE07891E1F4D7631246F38B7B7E472"
      unitRef="usd">110500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e3541-wk-Fact-7926CD3F1690D7285DF56F38B7C03A33"
      unitRef="usd">2036900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e3561-wk-Fact-FDCF0305A794EC365FE66F38B7C38E2A"
      unitRef="shares">8900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e3575-wk-Fact-D0BF822130FB09F0C5FE6F38B7C33B6A"
      unitRef="usd">2147400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e3595-wk-Fact-7251DB06C6F9757CB5FF6F38B7B2B48A"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e3634-wk-Fact-7251DB06C6F9757CB5FF6F38B7B2B48A"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e3690-wk-Fact-3CA56DF928B38105CB516F38B7C66627"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e3705-wk-Fact-B8DA4CA054F4DD800C6E6F38B7B40779"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e3724-wk-Fact-2EA47AAC0D74F6302AEC6F38B7BC6F4B"
      unitRef="usd">40800000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e3764-wk-Fact-865139B6689C1E58AF48704FB84AB569"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51023978e3819-wk-Fact-35500CDAF2981EA9525E6F38B7AE4854"
      unitRef="usd">40800000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51023978e3858-wk-Fact-35500CDAF2981EA9525E6F38B7AE4854"
      unitRef="usd">40800000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e3915-wk-Fact-41366450D8ACD916761F6F38B7C7F059"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e3930-wk-Fact-3F824C5D06F4125EEDCD6F38B7B68461"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e3949-wk-Fact-FBDBAD377D97578AAE276F38B7C5D8B0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e3989-wk-Fact-94B91508B97EC4AE3DC7704FB6D6720C"
      unitRef="usd">-53800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51023978e4045-wk-Fact-F467A8211DAC2F43FECE6F38B7B81897"
      unitRef="usd">53800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51023978e4085-wk-Fact-F467A8211DAC2F43FECE6F38B7B81897"
      unitRef="usd">53800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e4178-wk-Fact-AC009E45F0FF8755A28B6F38B7C9366D"
      unitRef="usd">191200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51023978e4274-wk-Fact-AF5A93CA6CDB2ABC9CA26F38B89029DB"
      unitRef="usd">191200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51023978e4313-wk-Fact-AF5A93CA6CDB2ABC9CA26F38B89029DB"
      unitRef="usd">191200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d51023978e4334-wk-Fact-D707CBC1CE8CCE3C21EA6F38B8905FEC"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d51023978e4353-wk-Fact-53918B50FD97547ECEEA6F38B88D9C39"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e4367-wk-Fact-2CB51A211F1BF0B5F3736F38B7B13F39"
      unitRef="shares">198000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e4387-wk-Fact-3357A56FBC7ABE47C9106F38B7AF6548"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e4406-wk-Fact-3DC3833E3C7F4D639B646F38B7B1AD45"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51023978e4425-wk-Fact-27B78241165E74F361586F38B7AF85C1"
      unitRef="usd">-135200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e4446-wk-Fact-65E2CC87B286D0DBBA0B6F38B7C5E657"
      unitRef="usd">16455400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e4460-wk-Fact-F95FC732B4AFA5C8407C6F38B88CBFFF"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e4480-wk-Fact-9BEE3CB0E201DEDD1EB46F38B7BA4D6D"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51023978e4501-wk-Fact-5784C3342553B2982B496F38B8C6A7D0"
      unitRef="usd">13343200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e4520-wk-Fact-CB551408B665B05A357B6F38B7B03C36"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51023978e4540-wk-Fact-E27B78E7E3A5AB66D9E76F38B84668E0"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d51023978e5121-wk-Fact-0886C1D4B8AB865F3CD06F38B7E46B34"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d51023978e5140-wk-Fact-03DEADBCAD46914CF4F06F38B7D531CC"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e5154-wk-Fact-C13E27745B490825AA1F6F38B7CE25A1"
      unitRef="shares">235300000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e5174-wk-Fact-52639BD98AA93C0EB4036F38B7E35AEB"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e5193-wk-Fact-C750753F5AA372874A1B6F38B7E1E7E8"
      unitRef="usd">97800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51023978e5212-wk-Fact-F4A56A3A303C51E837676F38B7D955AA"
      unitRef="usd">-318400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e5233-wk-Fact-A93126C2F82E7A3B20636F38B7E6B801"
      unitRef="usd">15810400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e5247-wk-Fact-661A3C0DCE4765F146886F38B7DCFB0E"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e5267-wk-Fact-A55654119174A11F647C6F38B7DB1CB3"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51023978e5288-wk-Fact-36FECCDF9D50D85B76656F38B7E45CF3"
      unitRef="usd">12612800000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e5307-wk-Fact-D13879B48E9022EC4D7D6F38B7D89A58"
      unitRef="usd">-14700000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51023978e5327-wk-Fact-80594C8122A490FC351A6F38B7D2FC06"
      unitRef="usd">12598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e5455-wk-Fact-8C366C83E15D49CC1ECD6F38B7D3A4B4"
      unitRef="usd">4430700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e5510-wk-Fact-D75E3BB69A698B5537196F38B831D83C"
      unitRef="usd">4430700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e5529-wk-Fact-2651FB05B09233E88B256F38B7DBB4C0"
      unitRef="usd">43300000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e5548-wk-Fact-697504B55D319C5C89A06F38B813740F"
      unitRef="usd">4474000000.0</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51023978e5660-wk-Fact-2067F4D14B744B2D41076F38B7CD6912"
      unitRef="usd">76500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e5736-wk-Fact-3FFFEF07DFDCE1143CF16F38B81442EC"
      unitRef="usd">76500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e5755-wk-Fact-A480E5CE5B06849E52266F38B7E02B46"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e5775-wk-Fact-A03A1753D060A8971AF46F38B7E60287"
      unitRef="usd">-76100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d51023978e5964-wk-Fact-FB2D9D52BF31AB371CEE6F38B7D568EA"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e5983-wk-Fact-02EE46D930F1ED3557B86F38B7D90B74"
      unitRef="usd">13800000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e6002-wk-Fact-20C298F6BEB40565C4C46F38B7CDD57F"
      unitRef="usd">13800000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d51023978e6191-wk-Fact-37C43954921C599396CA70568DF5DE2F"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e6210-wk-Fact-69DC196773D870C8C1DD6F38B7D84CC5"
      unitRef="usd">50000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e6230-wk-Fact-D3ECBD278C317A2CB11D6F38B7D168F4"
      unitRef="usd">50000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e6384-wk-Fact-73305A4F4F5E62C2B5C06F38B7D67E91"
      unitRef="shares">4300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e6399-wk-Fact-25825FA2B84C8B1EE0096F38B7D15627"
      unitRef="usd">1352600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e6420-wk-Fact-4EE3A1B4E0157649FB6E6F38B7CE3806"
      unitRef="usd">1352600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e6460-wk-Fact-4EE3A1B4E0157649FB6E6F38B7CE3806"
      unitRef="usd">1352600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e6517-wk-Fact-E6BE2390B5AE4F131A8A6F38B7DEBD9C"
      unitRef="shares">4300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e6533-wk-Fact-1B2C7F775C9C1A9C472F6F38B7DE77F4"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e6552-wk-Fact-870FFFE2E908113E06636F38B7D985C3"
      unitRef="usd">92800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e6593-wk-Fact-B4ABB9396B0720B578946F38B7D024F8"
      unitRef="usd">1259800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e6613-wk-Fact-86F5951AF31EC0F490AA6F38B7D6E336"
      unitRef="shares">4300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e6627-wk-Fact-586B60655108632C7D246F38B7D5F4A7"
      unitRef="usd">1352600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e6647-wk-Fact-69633AB2142E42903C916F38B7D0B26A"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e6686-wk-Fact-69633AB2142E42903C916F38B7D0B26A"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e6839-wk-Fact-956208B46B55066FC1386F38B7DFD78C"
      unitRef="shares">10500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e6854-wk-Fact-83D923F803F5409DB02C6F38B7E57C09"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e6875-wk-Fact-D7AB953A47BC17DC8C1E6F38B7CD70FC"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e6915-wk-Fact-5238B1DADDD936CFEAFC6F38B7DD4CB8"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e6972-wk-Fact-3E3088E5F4B09DEB09966F38B7D32C08"
      unitRef="shares">10500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e6988-wk-Fact-5333541CC49EABABB9F46F38B7E20BD6"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e7007-wk-Fact-3DE131CE57525E0022906F38B7D849A2"
      unitRef="usd">171100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e7048-wk-Fact-0AAEF901F2822B0F01E37059808F2985"
      unitRef="usd">2828900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e7068-wk-Fact-74E86CC0A17E26AE2FD3705982AC16C7"
      unitRef="shares">10500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e7082-wk-Fact-2BD0EA05BF8DE4588403705985A2D9BE"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e7102-wk-Fact-EF3CCCCCAE831F3679756F38B7D71DBD"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e7141-wk-Fact-EF3CCCCCAE831F3679756F38B7D71DBD"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e7198-wk-Fact-5B54512E2377006387716F38B7E84358"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e7213-wk-Fact-4005CD58FBAB4132EDCB6F38B7DC8B03"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e7232-wk-Fact-ED8F63D55778AF7189E06F38B7E16145"
      unitRef="usd">41200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e7328-wk-Fact-E0E38D282EE87BA8269E6F38B7D38808"
      unitRef="usd">41200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e7367-wk-Fact-E0E38D282EE87BA8269E6F38B7D38808"
      unitRef="usd">41200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e7423-wk-Fact-8DC3660624E05CCBA288705A84C92515"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e7438-wk-Fact-6F141D11FC100555FD28705A8635943B"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e7457-wk-Fact-9FCF1E5EE2DD934C018E6F38B7DD1DA5"
      unitRef="usd">43800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e7554-wk-Fact-6CDAB4B7BB39BF18B3556F38B7E6AF3E"
      unitRef="usd">43800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e7594-wk-Fact-6CDAB4B7BB39BF18B3556F38B7E6AF3E"
      unitRef="usd">43800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e7687-wk-Fact-801B0D428C27F2581CC1705B8EFD6FD8"
      unitRef="usd">168700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e7783-wk-Fact-CB0C79BAA35FE78702876F38B7E3D400"
      unitRef="usd">168700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e7822-wk-Fact-CB0C79BAA35FE78702876F38B7E3D400"
      unitRef="usd">168700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51023978e7934-wk-Fact-021F31C03C5221590FED705F51A8D852"
      unitRef="usd">1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e7954-wk-Fact-A7DBCF21A5815F5F0D186F38B7CF6B0F"
      unitRef="usd">104600000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e8009-wk-Fact-EB93AA6C2C429B96187A6F38B7D618B4"
      unitRef="usd">106100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51023978e8048-wk-Fact-EB93AA6C2C429B96187A6F38B7D618B4"
      unitRef="usd">106100000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d51023978e8069-wk-Fact-FC6BD39B73491F0771E96F38B7C48259"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d51023978e8088-wk-Fact-12411F493663665C481B6F38B7AE8F90"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e8102-wk-Fact-9C5AD0C83D1E22701F2D6F38B88FEE4B"
      unitRef="shares">221000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e8122-wk-Fact-D0D7319D5AA69096D4096F38B7BFEDA4"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e8141-wk-Fact-5A0843BFA954605F22C16F38B7C7A6EE"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51023978e8160-wk-Fact-D9A111AF560E38CA94966F38B7B8C128"
      unitRef="usd">-240400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e8181-wk-Fact-A13A847A72CA16A4EF8C6F38B88C56EE"
      unitRef="usd">16257000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e8195-wk-Fact-AAB3BBD7C2DAA204DE6C6F38B7B43D09"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e8215-wk-Fact-C25C9B8B2D2AA699B5276F38B7BBE94A"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51023978e8236-wk-Fact-ABC0C61D4C7DF5163AEB6F38B8BBCD37"
      unitRef="usd">13039600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e8255-wk-Fact-34F4954DA06ACA92FB976F38B7C02975"
      unitRef="usd">-8000000.0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51023978e8275-wk-Fact-3CB4C3695BCE2D0BFC186F38B8B4EFC2"
      unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d51023978e8849-wk-Fact-8F5C3C45E1E9BD2374D66F38B7F321AD"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d51023978e8868-wk-Fact-747A0F9127B6CCE61D276F38B7F35514"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e8882-wk-Fact-ADF9AC0B6C877F0358806F38B82CC6A6"
      unitRef="shares">238500000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e8902-wk-Fact-CDB85ECA23D3AB0B68226F38B7F5C96C"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e8921-wk-Fact-B1CD54FE9F38B1C08E5E6F38B82CC11B"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51023978e8940-wk-Fact-B9875DACED8DC67D83116F38B7F5EA33"
      unitRef="usd">-319900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e8961-wk-Fact-30268C24E8A59C69E4EB6F38B83354FF"
      unitRef="usd">15071600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e8975-wk-Fact-3B53CFC6BB638AEB9FAC6F38B8324484"
      unitRef="shares">22600000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e8995-wk-Fact-BDC3DD8AD19867C6C1376F38B82BDE4A"
      unitRef="usd">2611700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4"
      decimals="-5"
      id="d51023978e9016-wk-Fact-1F045D43A0E5359FD2356F38B7F0BBC3"
      unitRef="usd">12140100000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e9035-wk-Fact-019E683D47BA697F2D0C6F38B83674BC"
      unitRef="usd">-11500000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4"
      decimals="-5"
      id="d51023978e9055-wk-Fact-5E5620C312817FB09DAF6F38B7F714F9"
      unitRef="usd">12128600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e9183-wk-Fact-06611EA785D40EC668BA6F38B82F5B3E"
      unitRef="usd">2539100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e9238-wk-Fact-029151C37D9A5DCBB4476F38B8229A45"
      unitRef="usd">2539100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e9257-wk-Fact-1D2683E70CA35B372F2A6F38B82DC2E1"
      unitRef="usd">131000000.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e9276-wk-Fact-11271C2D6390C500664E6F38B7B1785A"
      unitRef="usd">2670100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51023978e9388-wk-Fact-8C3F29C774F4A3815E606F38B829DC74"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e9464-wk-Fact-DAF3185409661071AF2B6F38B80DA8BC"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e9483-wk-Fact-DE80286E6A70EC3C59A96F38B8334602"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e9502-wk-Fact-4B79072BDE22BA60E2BE6F38B7EEBCD9"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d51023978e9691-wk-Fact-C4875D7DDBB8C97C8AB36F38B82ADF80"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e9710-wk-Fact-541D7BE3ADC98B39D4AB6F38B7F41F28"
      unitRef="usd">15800000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e9729-wk-Fact-93F094A0BF31508500566F38B82A04EA"
      unitRef="usd">15800000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d51023978e9918-wk-Fact-148DB9F0D59F9148013270653ECC95BB"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e9937-wk-Fact-E4AFDA0136EA7D8ECF1F6F38B82A9149"
      unitRef="usd">150000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e9957-wk-Fact-E65FD5FBB08404BDC3656F38B832B441"
      unitRef="usd">150000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e10111-wk-Fact-59F8879B05862FBC7F077066C880543F"
      unitRef="shares">3700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e10126-wk-Fact-B2F432CFE860D0FB1FB47066CC22A78F"
      unitRef="usd">1000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e10147-wk-Fact-061D830C94F821DDA1506F38B82DBAD0"
      unitRef="usd">1000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e10187-wk-Fact-061D830C94F821DDA1506F38B82DBAD0"
      unitRef="usd">1000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e10244-wk-Fact-687A766E726C7B24C6AA7067AA93863B"
      unitRef="shares">3700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e10260-wk-Fact-5A09E6312B71636065D67067AF9C3317"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e10279-wk-Fact-11C44FA4BE3B2C8E4CEA7067B47EE7CA"
      unitRef="usd">36000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e10320-wk-Fact-AFE9592753AA02AAABF77067BB0075AE"
      unitRef="usd">964000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e10340-wk-Fact-61B524345985C3AD6DD06F38B82F63FC"
      unitRef="shares">3700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e10354-wk-Fact-B99A8876BF4EBCEA5A1B6F38B8294D42"
      unitRef="usd">1000000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e10374-wk-Fact-594EB43D3443905048CD6F38B83112C6"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e10413-wk-Fact-594EB43D3443905048CD6F38B83112C6"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e10565-wk-Fact-F6724E09EE7FC8445EC06F38B8349C89"
      unitRef="shares">1200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e10580-wk-Fact-A68BDB24BDA277AF98EF6F38B82DBBBE"
      unitRef="usd">365400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e10601-wk-Fact-9DD635C1632F8A8B601C6F38B8352615"
      unitRef="usd">365400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51023978e10641-wk-Fact-9DD635C1632F8A8B601C6F38B8352615"
      unitRef="usd">365400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e10698-wk-Fact-6DBA67E1D2A9DD4AC8006F38B8329B6F"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e10713-wk-Fact-07CB553EE7FF10B090846F38B82C1FF8"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e10732-wk-Fact-325D6834206767B1A5916F38B7F28810"
      unitRef="usd">40500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e10828-wk-Fact-6F478638806535FF11366F38B83108DA"
      unitRef="usd">40500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e10867-wk-Fact-6F478638806535FF11366F38B83108DA"
      unitRef="usd">40500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e10924-wk-Fact-49D243369062EFA992C36F38B7EF0777"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e10939-wk-Fact-A40008494073408D69A86F38B834C45B"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e10958-wk-Fact-6914A52621E737ACAC3C6F38B830F20A"
      unitRef="usd">44800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e10999-wk-Fact-021604712AED861A6B736F38B82E2BBE"
      unitRef="usd">1000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e11055-wk-Fact-7ADCCC58C69D0AEC769A6F38B82DD6EC"
      unitRef="usd">45800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e11095-wk-Fact-7ADCCC58C69D0AEC769A6F38B82DD6EC"
      unitRef="usd">45800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e11188-wk-Fact-1388A48FDD68A817F9356F38B7F64767"
      unitRef="usd">-138100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2016Q4YTD"
      decimals="-5"
      id="d51023978e11284-wk-Fact-1B9F01A41CA665B313546F38B7F23D1F"
      unitRef="usd">-138100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2016Q4YTD"
      decimals="-5"
      id="d51023978e11323-wk-Fact-1B9F01A41CA665B313546F38B7F23D1F"
      unitRef="usd">-138100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e11456-wk-Fact-368FBF3D3A4830C37DC97071B5C5FC34"
      unitRef="usd">-852800000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e11512-wk-Fact-368FBF3D3A4830C37DC97071B5C5FC34"
      unitRef="usd">-852800000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e11552-wk-Fact-368FBF3D3A4830C37DC97071B5C5FC34"
      unitRef="usd">-852800000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <biib:StockholdersEquityTaxBenefitExpense
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e11686-wk-Fact-D3899ACF1C5DD76971FA70610ED8BD72"
      unitRef="usd">17500000</biib:StockholdersEquityTaxBenefitExpense>
    <biib:StockholdersEquityTaxBenefitExpense
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d51023978e11741-wk-Fact-54026962E7FD89FA1DEA6F38B82B0A78"
      unitRef="usd">-17500000</biib:StockholdersEquityTaxBenefitExpense>
    <biib:StockholdersEquityTaxBenefitExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51023978e11780-wk-Fact-6CCE522EFA3648933A9B6F38B83011C7"
      unitRef="usd">-17500000</biib:StockholdersEquityTaxBenefitExpense>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d51023978e11801-wk-Fact-0886C1D4B8AB865F3CD06F38B7E46B34"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d51023978e11820-wk-Fact-03DEADBCAD46914CF4F06F38B7D531CC"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e11834-wk-Fact-C13E27745B490825AA1F6F38B7CE25A1"
      unitRef="shares">235300000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d51023978e11854-wk-Fact-52639BD98AA93C0EB4036F38B7E35AEB"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d51023978e11873-wk-Fact-C750753F5AA372874A1B6F38B7E1E7E8"
      unitRef="usd">97800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51023978e11892-wk-Fact-F4A56A3A303C51E837676F38B7D955AA"
      unitRef="usd">-318400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d51023978e11913-wk-Fact-A93126C2F82E7A3B20636F38B7E6B801"
      unitRef="usd">15810400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e11927-wk-Fact-661A3C0DCE4765F146886F38B7DCFB0E"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d51023978e11947-wk-Fact-A55654119174A11F647C6F38B7DB1CB3"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51023978e11968-wk-Fact-36FECCDF9D50D85B76656F38B7E45CF3"
      unitRef="usd">12612800000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d51023978e11987-wk-Fact-D13879B48E9022EC4D7D6F38B7D89A58"
      unitRef="usd">-14700000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51023978e12007-wk-Fact-80594C8122A490FC351A6F38B7D2FC06"
      unitRef="usd">12598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D9CDBC0DC3760159B4206F38B8DB2C65-0-wk-Fact-C6AF55507CF2F2CE1EC86F38B84190AC">Summary of Significant Accounting Policies&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#x2019;s disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This standard became effective for us on January 1, 2018, and was adopted using the modified retrospective method. The adoption of this standard as of January 1, 2018, did not change our revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under the FASB Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the United States (U.S.), we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Reserves for Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#x2019;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other governmental rebates, non-U.S. pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our collaboration with Genentech is within the scope of ASC 808, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs consist of:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(ii)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech and the Roche Group. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates that are based on information received from Genentech and Roche. These estimates are subject to change and actual results may differ. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our relationship with Genentech, please read Note&#160;18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Royalty Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We receive royalty revenues on sales by our licensees of products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and other third parties and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our development and commercialization arrangements with Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Genentech and Samsung Bioepis, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Corporate Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&#160;1&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&#x2014; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&#160;2&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&#x2014; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&#160;3&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&#x2014; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;30 to 90 days&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#x2019;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We provide reserves against accounts receivable for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Marketable Securities and Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Equity Securities and Venture Capital Funds&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Evaluating Marketable Debt Securities for Other-than-Temporary Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#x2019;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Equity Method of Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our consolidated statements of income our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Capitalization of Inventory Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Obsolescence and Unmarketable Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;At each reporting period we review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are carried at cost, subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;three to five years&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;"/&gt;&lt;td style="width:50%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&#160;Software&#160;and&#160;Hardware&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-10, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-20, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Narrow-Scope Improvement for Lessors&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and ASU No. 2019-01, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Codification Improvements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis in our consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$463.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a corresponding operating lease liability of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$526.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are included in our consolidated balance sheets. The adoption of the new leasing standards did not have an impact on our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our consolidated balance sheets. Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the adoption of the new leasing standards, please read Note 11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our intangible assets consist of completed technology (comprised of acquired and in-licensed rights and patents, developed technology, out-licensed patents), in-process research and development (IPR&amp;amp;D) acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also include our rest of world license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to trademarks, trade names and IPR&amp;amp;D prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired In-process Research and Development (IPR&amp;amp;D)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;amp;D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the potential treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but is reviewed for impairment. Goodwill is reviewed for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&#160;24, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Segment Information,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Cash Flow and Fair Value Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Net Investment Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our derivative instruments and hedging activities, please read Note 9, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Translation of Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Royalty Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). Compensation expense is recognized based on the estimated fair value of the awards at grant date. We recognize compensation expense for the number of awards expected to vest after taking into consideration an estimate of award forfeitures over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of PSUs that settle in stock are based upon the stock price on the date of grant. Compensation expense is recognized for the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development expenses consist of expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses and upfront fees and milestones paid to third-party collaborators. Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Advertising costs are expensed as incurred. For the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, advertising costs totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$79.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$90.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The income tax consequences from the intra-entity transfers of inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the inventory is sold to a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16,&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, offset by a corresponding net increase to retained earnings of approximately&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;with a corresponding reduction to &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our retained earnings as these differences are related to intra-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We account for uncertain tax positions using a &#x201c;more-likely-than-not&#x201d; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#x2019;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued the new leasing standards to increase transparency and comparability among organizations related to their leasing activities. For additional information on the adoption of the new leasing standards, please read the section titled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Lease &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;above, and Note 11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based on the composition of our investment portfolio, accounts receivable and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards are not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020. The adoption of this standard will not have a material impact on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 the FASB issued ASU No. 2018-16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard became effective for us on January 1, 2019, and did not have an impact on our consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; This standard makes targeted improvements for collaborative arrangements as follows: &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard became effective for us on January 1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. The adoption of this standard did not have a material impact on our consolidated financial position, results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5FB78FAF711B145EA4916F38B8DCA3EE-0-wk-Fact-DFF35CDBD026F8F4BF2D6F38B8429FE0">&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#x2019;s disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E91CD00ED7A7C22D21D86F38B8DFDAF5-0-wk-Fact-E5F3CF50E846E415A4866F38B8417C93">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d51036666e1347-wk-Fact-B51F226A28E138CC87D36F38B84D317B"
      unitRef="number">1</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q4YTD"
      id="TextSelection-229ECB1F5983B47BEF716F38B8DA3574-0-wk-Fact-FBF4FC766C3E889E1E116F38B8413FB6">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4612B92134120E57E50D6F38B8DD3191-0-wk-Fact-6E3068D75466F10C72626F38B84EED50">e recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under the FASB Accounting Standards Codification (ASC) 606, &lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.&lt;/span&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the United States (U.S.), we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Reserves for Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#x2019;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other governmental rebates, non-U.S. pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our collaboration with Genentech is within the scope of ASC 808, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs consist of:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(ii)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech and the Roche Group. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates that are based on information received from Genentech and Roche. These estimates are subject to change and actual results may differ. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our relationship with Genentech, please read Note&#160;18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Royalty Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We receive royalty revenues on sales by our licensees of products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and other third parties and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our development and commercialization arrangements with Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Genentech and Samsung Bioepis, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Corporate Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-526A1BE0ED2E1668EBEB6F38B8DD73DD-0-wk-Fact-2D2DB7630D37A02DAC576F38B84F00F5">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&#160;1&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&#x2014; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&#160;2&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&#x2014; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&#160;3&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&#x2014; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-ED8506B883BD4310FC396F38B8DCD3DF-0-wk-Fact-E19D0E522C04F68E444A6F38B847FB6D">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E48462F90ADD8398F7FA6F38B8DD8672-0-wk-Fact-2D1A7EBD71C494030DA66F38B83F374D">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;30 to 90 days&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#x2019;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We provide reserves against accounts receivable for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="FD2019Q4YTD"
      id="TextSelection-BE13A326763589E11E9A6F38B8DFC218-0-wk-Fact-458AEEFDFC538B8817DE6F38B847F389">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. &lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-85AEF28D9ECEEC93418C6F38B8DF4F14-0-wk-Fact-82DA0B446A759DA949726F38B844B3FB">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Equity Securities and Venture Capital Funds&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Evaluating Marketable Debt Securities for Other-than-Temporary Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#x2019;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-58D6B934244A71EFA26E6F38B8DA5910-0-wk-Fact-07FB11C8245D50EF4B816F38B83F5A19">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our consolidated statements of income our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B4CD9C493290CFF5DB316F38B8DC6312-0-wk-Fact-151F6839A74ACC5887416F38B84AE9AD">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Capitalization of Inventory Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Obsolescence and Unmarketable Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;At each reporting period we review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7C6EDE1D68E5669729D96F38B8DD466B-0-wk-Fact-FEE492222B4EBF843EC06F38B83F5B62">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are carried at cost, subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;three to five years&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;"/&gt;&lt;td style="width:50%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&#160;Software&#160;and&#160;Hardware&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-0456031171C9C7B3D5BE6F38B8DD9CFF-0-wk-Fact-5747030CAADA4194E8966F38B849625D">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;"/&gt;&lt;td style="width:50%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&#160;Software&#160;and&#160;Hardware&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-03902514FE18354A67B67086E8EFD225-0-wk-Fact-2DA24DDCFAE617F81342708902278BD1">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-10, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-20, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Narrow-Scope Improvement for Lessors&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and ASU No. 2019-01, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Codification Improvements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis in our consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$463.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a corresponding operating lease liability of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$526.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are included in our consolidated balance sheets. The adoption of the new leasing standards did not have an impact on our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our consolidated balance sheets. Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the adoption of the new leasing standards, please read Note 11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d51036666e2037-wk-Fact-FD54D2082F0EC999FDCA707FE56A3FD7"
      unitRef="usd">463000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d51036666e2041-wk-Fact-4B8EB3579A1CE9B976E67083394AEAC0"
      unitRef="usd">526000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-976E879F7336CA28B7A06F38B8DD63BF-0-wk-Fact-DBEEA948824D9252F3EF6F38B84CBC03">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our intangible assets consist of completed technology (comprised of acquired and in-licensed rights and patents, developed technology, out-licensed patents), in-process research and development (IPR&amp;amp;D) acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also include our rest of world license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to trademarks, trade names and IPR&amp;amp;D prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-1702C2A0CC24C2EB85576F38B8DBB3FF-0-wk-Fact-627187BBA600F4047F7A6F38B847EF75">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;amp;D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the potential treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-3AEDFC223B7C86FBEB626F38B8DE737F-0-wk-Fact-3C5194FF93F83C8999A46F38B8489990">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but is reviewed for impairment. Goodwill is reviewed for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&#160;24, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Segment Information,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6A53B5804CA37149EACF6F38B8DD3637-0-wk-Fact-B14187411D9B66E80DE76F38B84C1F85">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-080B2420FC03FFE52B176F38B8DBEDCA-0-wk-Fact-30D34E129BB1CCA9640D6F38B84F35E6">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. &lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-347366D80B70B59701976F38B8DE0940-0-wk-Fact-C6317E04DECEEC87A1EF6F38B84FA2C4">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Cash Flow and Fair Value Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Net Investment Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our derivative instruments and hedging activities, please read Note 9, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-BCE616ABE6DD6B6A0A956F38B8DBCEB2-0-wk-Fact-6473D4BA672CF43BBFB36F38B84A2F01">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <biib:RoyaltyCostofSalesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8486721CFB427D6F63AE6F38B8DC7F7F-0-wk-Fact-E1EF5BB5CBCC1DC2E2186F38B8454ACE">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.</biib:RoyaltyCostofSalesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-512E4B81667DBEB8D0A56F38B8DA1294-0-wk-Fact-D50F80BCCF8F204446BF6F38B848EF00">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). Compensation expense is recognized based on the estimated fair value of the awards at grant date. We recognize compensation expense for the number of awards expected to vest after taking into consideration an estimate of award forfeitures over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of PSUs that settle in stock are based upon the stock price on the date of grant. Compensation expense is recognized for the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-438844A82D50452CC5EF6F38B8DD001E-0-wk-Fact-D80E11A91593CD2E313D6F38B83F700E">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development expenses consist of expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses and upfront fees and milestones paid to third-party collaborators. Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-02AF5B7D697DD27AEB1D6F38B8DC8F08-0-wk-Fact-5C7FDBE4B2431CC4EF2A6F38B84920A1">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Advertising costs are expensed as incurred. For the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, advertising costs totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$79.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$90.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51036666e2398-wk-Fact-F81F350DB92916E843356F38B84E816D"
      unitRef="usd">79200000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51036666e2402-wk-Fact-4AFAB95BD8A23F38B0736F38B84B90B9"
      unitRef="usd">90200000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51036666e2407-wk-Fact-2A967406F0C1D109E2756F38B84BA6BD"
      unitRef="usd">75200000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-0CA105AB31CC754F766A6F38B8DE2712-0-wk-Fact-F831BA4C535BA3D499A46F38B8418622">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The income tax consequences from the intra-entity transfers of inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the inventory is sold to a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16,&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, offset by a corresponding net increase to retained earnings of approximately&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;with a corresponding reduction to &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our retained earnings as these differences are related to intra-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We account for uncertain tax positions using a &#x201c;more-likely-than-not&#x201d; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredIncomeTaxChargesMember"
      decimals="-8"
      id="d51036666e2447-wk-Fact-B731234716BE94F35167FC24C706A84B"
      unitRef="usd">500000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember"
      decimals="-8"
      id="d51036666e2451-wk-Fact-AA09A7F3E7B9E543D186FC2A4A300063"
      unitRef="usd">500000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_biib_DeferredtaxliabilityMember"
      decimals="-8"
      id="d51036666e2455-wk-Fact-514B72584F113CB8EF3EFC2B76296BAE"
      unitRef="usd">400000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EE9A1C76879ADDBCD91A6F38B8DF2471-0-wk-Fact-4CC2F9186EA432BA36A06F38B84314DE">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#x2019;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. &lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-ACBB4B1562FED648703B6F38B8DE3DE8-0-wk-Fact-7573B255B5DE6D7779916F38B847B8EC">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-A4B5BC575EF4381FA2126F38B8DDD3B2-0-wk-Fact-270D728EF47334CD036C6F38B8425E79">rom time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued the new leasing standards to increase transparency and comparability among organizations related to their leasing activities. For additional information on the adoption of the new leasing standards, please read the section titled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Lease &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;above, and Note 11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based on the composition of our investment portfolio, accounts receivable and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards are not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020. The adoption of this standard will not have a material impact on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 the FASB issued ASU No. 2018-16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard became effective for us on January 1, 2019, and did not have an impact on our consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; This standard makes targeted improvements for collaborative arrangements as follows: &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard became effective for us on January 1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. The adoption of this standard did not have a material impact on our consolidated financial position, results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-CBC6979DD13E1240A2C76F38B8DF18F4-0-wk-Fact-B00139C06603A18CB7B86F38B81EF5D6">&#160;&#160;&#160;&#160;Acquisitions&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acquisition of Nightstar Therapeutics plc&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. As a result of this acquisition, we added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the acquisition, we paid NST shareholders &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$25.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash for each issued and outstanding NST share, which totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$847.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash for equity compensation, which is attributable to pre-combination services and is reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$26.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$18.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recognized as a charge to selling, general and administrative expense with the remaining &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$7.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as a charge to research and development expense in our consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We finalized purchase accounting for this acquisition in the fourth quarter of 2019. The following table summarizes the fair values of the separately identifiable assets acquired and liabilities assumed:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;700.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;117.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(81.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;852.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of the IPR&amp;amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This valuation was primarily driven by the value associated with BIIB111. The fair value associated with BIIB111 was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$480.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have recorded an additional IPR&amp;amp;D asset related to BIIB112 of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$220.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have recognized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;amp;D intangible assets, which have no tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for GILTI. Goodwill that is tax deductible for GILTI purposes is approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$35.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our consolidated statements of income. Subsequent to June 7, 2019, the acquisition date, our results of operations include the results of operations of NST.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;BIIB100 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2018 we acquired BIIB100 (XP01 inhibitor) from Karyopharm Therapeutics Inc. (Karyopharm). BIIB100 is a Phase 1 investigational oral compound for the treatment of certain neurological and neurodegenerative diseases, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Karyopharm, which was recorded as acquired IPR&amp;amp;D in our consolidated statements of income as BIIB100 had not yet reached technological feasibility. We may also pay Karyopharm up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$207.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments as well as tiered royalties on potential net commercial sales in the mid-single digit to low-teen percentages. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;BIIB104 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2018 we acquired BIIB104 (AMPA) from Pfizer Inc. (Pfizer). BIIB104 is a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Pfizer, which was recorded as acquired IPR&amp;amp;D in our consolidated statements of income as BIIB104 had not yet reached technological feasibility. We may also pay Pfizer up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$515.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the low to mid-teen percentages. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;TMS Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2018 we entered into an exclusive option agreement with TMS Co., Ltd. (TMS) granting us the option to acquire TMS-007, a plasminogen activator with a novel mechanism of action associated with breaking down blood clots, which is in Phase 2 development in Japan, and backup compounds for the treatment of stroke. In exchange for the purchase option, we made a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment to TMS, which was recorded as research and development expense in our consolidated statements of income as TMS-007 had not yet reached technological feasibility. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If we exercise the purchase option, we will make an additional payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$18.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon closing of the asset acquisition, which will be recorded as acquired IPR&amp;amp;D expense in our consolidated statements of income as TMS-007 will not have reached technological feasibility at that time. In addition, we may pay TMS up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$335.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the high-single digit to low-teen percentages. If we exercise the purchase option, consummation of the asset acquisition may be subject to the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;BIIB110 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 we acquired BIIB110 (ActRIIA/B ligand trap) and ALG-802 from AliveGen Inc. (AliveGen).&#160;BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. We initially plan to study BIIB110 in multiple neuromuscular indications, including SMA and ALS. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$27.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to AliveGen, which was recorded as acquired IPR&amp;amp;D in our consolidated statements of income as BIIB110 had not yet reached technological feasibility. We may also pay AliveGen up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$535.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development and commercialization milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;BIIB093 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2017 we acquired BIIB093 (glibencamide IV) from Remedy Pharmaceuticals Inc. (Remedy). BIIB093 is in a Phase 3 study for large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) granted BIIB093 orphan drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 fast track designation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are responsible for the future development and commercialization of BIIB093 and Remedy may share in the cost of development for the target indication for BIIB093 in LHI stroke.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We accounted for this transaction as an asset acquisition as we did not acquire any employees from Remedy nor did we acquire any significant processes required in the development of BIIB093. In connection with the closing of this transaction, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$120.0 million&lt;/span&gt;&lt;/span&gt; to Remedy, which was recorded as acquired IPR&amp;amp;D in our consolidated statements of income as BIIB093 had not yet reached technological feasibility. We may also pay Remedy certain development and sales based milestone payments that are substantially payable upon or after regulatory approval, as well as royalties on potential net commercial sales.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="2"
      id="d51004110e1301-wk-Fact-87A79CBC26146B5B02DF7ED5975AFD8A"
      unitRef="usdPerShare">25.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51004110e1305-wk-Fact-BD679BAC683C3BF72B757ED63BF7452C"
      unitRef="usd">847600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51004110e1309-wk-Fact-BCF10C77947A99F4F8DD7ED685C30FB1"
      unitRef="usd">4600000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember"
      decimals="-5"
      id="d51004110e1313-wk-Fact-CE62EAAB9B912242D46C7ED81421F20D"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d51004110e1317-wk-Fact-F67C75A789F9727D76D67ED96BC76A4A"
      unitRef="usd">18400000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d51004110e1322-wk-Fact-86B091481203272C918C7ED9B644335B"
      unitRef="usd">7800000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D6FDFA07009C738CD95E7EDAC335DFDD-0-wk-Fact-67B67180AEE82E3BCBCD7EDAF551425D">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;700.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;117.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(81.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;852.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51004110e1376-wk-Fact-A69B380F158C715F8AA57EE119CB9859"
      unitRef="usd">107800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51004110e1391-wk-Fact-258C860583CB3EAE79377EE15A9486D1"
      unitRef="usd">7500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51004110e1411-wk-Fact-82604D074397E99D730A7EE181675AC1"
      unitRef="usd">700000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51004110e1431-wk-Fact-4B28A3E3556855D1ED5D7EE1A58C5933"
      unitRef="usd">117500000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51004110e1451-wk-Fact-C8DAF36AAE5AE163FFC97EE1CA1DA9BC"
      unitRef="usd">81900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51004110e1472-wk-Fact-F996B37F911A6B9CB2797EE1EF9CF960"
      unitRef="usd">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51004110e1497-wk-Fact-CF11A036F39E4C2D297A7EE2134DB9A3"
      unitRef="usd">852200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="3"
      id="d51004110e1508-wk-Fact-F0008C0FF84DCD6358DB7EE76FBE1C12"
      unitRef="number">0.125</biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51004110e1512-wk-Fact-59D17427E05415CAE83C7EE6E2305AF9"
      unitRef="usd">480000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51004110e1516-wk-Fact-16D30E8145816579B4B67EE71C9FA449"
      unitRef="usd">220000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51004110e1523-wk-Fact-ED9FFCF1D2282A32C02D7EE7BC70BB37"
      unitRef="usd">35500000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember"
      decimals="-5"
      id="d51004110e1540-wk-Fact-2B07C6A0EAB8D12E9C486F38B8201F89"
      unitRef="usd">10000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember"
      decimals="-5"
      id="d51004110e1544-wk-Fact-61F677BF746AE3FCF8206F38B81F399F"
      unitRef="usd">207000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember"
      decimals="-5"
      id="d51004110e1557-wk-Fact-B73E9F9149B60E7A00846F38B81FA7CC"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember"
      decimals="-5"
      id="d51004110e1561-wk-Fact-32EF7D1B556445EBA9046F38B8212F8D"
      unitRef="usd">515000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember"
      decimals="-5"
      id="d51004110e1571-wk-Fact-76FF4C3B95913B1B5A2E6F38B820C94B"
      unitRef="usd">4000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember"
      decimals="-5"
      id="d51004110e1578-wk-Fact-ADD13EB686B15E95ED926F38B81E1838"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember"
      decimals="-5"
      id="d51004110e1582-wk-Fact-4FC75C2379EEC9FBCADC6F38B81F1AB2"
      unitRef="usd">335000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember"
      decimals="-5"
      id="d51004110e1595-wk-Fact-771C25E8188CAD91CD726F38B81F1A30"
      unitRef="usd">27500000</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember"
      decimals="-5"
      id="d51004110e1599-wk-Fact-0D209DC0E8BA2D277CCF6F38B8217DC9"
      unitRef="usd">535000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_RemedyPharmaceuticalMember"
      decimals="-5"
      id="d51004110e1616-wk-Fact-7C3FA50C178600D388ED6F38B820D42B"
      unitRef="usd">120000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6207EDEF5A6EDB000B1A6F38B8DFC435-0-wk-Fact-08B6D2842F607D1A44226F38B878311C">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM Corporation (FUJIFILM). Upon the closing of this transaction, we received approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$881.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash, which may be adjusted based on other contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of this transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$74.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with such guarantees and have accrued for this obligation. We may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#xf8;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#xf8;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this transaction, we recognized a total net loss of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$164.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our consolidated statements of income. This loss included a pre-tax loss of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$95.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which was recorded in loss on divestiture of Hiller&#xf8;d, Denmark manufacturing operations. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hiller&#xf8;d, Denmark manufacturing operations of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$11.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and our estimate of the fair value of an adverse commitment of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$114.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with the guarantee of future minimum batch production at the Hiller&#xf8;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. We also recorded a tax expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$68.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this transaction. During the fourth quarter of 2019 we recorded a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$40.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in our estimate of the future minimum batch commitment utilizing our current manufacturing forecast, which reflects the impact of forecasted aducanumab batches, resulting in a reduction in the pre-tax loss on divestiture from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$95.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$55.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we sold to FUJIFILM &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$41.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of raw materials that were remaining at the Hiller&#xf8;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our estimate of the fair value of the adverse commitment is a Level 3 measurement and is based on forecasted batch production at the Hiller&#xf8;d facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51007415e1296-wk-Fact-27EA9DE3604CB7A8CAFA7EF86BCE840F"
      unitRef="usd">881900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2019Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51007415e1303-wk-Fact-994A71B05DC0C10DA6977EFB1890BB20"
      unitRef="usd">74000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51007415e1316-wk-Fact-C512769E94DAD5B118357EFD5604D7D3"
      unitRef="usd">164400000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51007415e1320-wk-Fact-6206447488C50EAA0D3D7EFE82A6B7CC"
      unitRef="usd">95500000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51007415e1324-wk-Fact-34C97FE393A15D423D807F007801A7DC"
      unitRef="usd">11200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2019Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51007415e1328-wk-Fact-10A78FAED36F0E9DB584E86F82C97371"
      unitRef="usd">114000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51007415e1332-wk-Fact-7DD7E13C219FC7B4D1AE7F012B0335CA"
      unitRef="usd">68900000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="FD2019Q4QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51007415e1337-wk-Fact-680A2949DD1C33225AE8E8704D7CBB50"
      unitRef="usd">40200000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51007415e1341-wk-Fact-6206447488C50EAA0D3D7EFE82A6B7CC"
      unitRef="usd">95500000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51007415e1345-wk-Fact-25731977E8E1923A8E3DE870A27E5A14"
      unitRef="usd">55300000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <biib:InventoryrawmaterialssoldtoFUJIFILM
      contextRef="I2019Q3Denmark"
      decimals="-5"
      id="d51007415e1352-wk-Fact-7B67356AE4C6F2044AE67F01D86E0CE7"
      unitRef="usd">41800000</biib:InventoryrawmaterialssoldtoFUJIFILM>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-70BC8E95AFE27EB79C366F38B8E0B1B1-0-wk-Fact-B56C3DDD09EFB06F29DC6F38B7D41263">Revenues&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="36"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;3,306.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;1,126.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;4,432.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3,253.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,020.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;4,274.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3,294.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;920.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;4,214.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Interferon*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;1,426.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;675.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;2,101.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,668.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;694.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,363.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,889.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;756.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,645.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;1,041.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;850.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;1,892.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,025.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;839.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,864.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,113.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;859.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,973.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;VUMERITY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;97.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;97.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;92.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;92.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;91.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;91.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ZINBRYTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;52.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;52.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: MS Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;5,780.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;2,748.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;8,529.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;5,946.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,648.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8,595.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6,296.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,680.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8,977.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;933.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;1,163.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;2,097.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;854.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;870.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,724.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;657.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;226.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;883.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;486.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;486.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;485.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;485.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;370.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;370.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;184.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;184.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;16.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;16.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;68.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;68.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;43.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;43.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;738.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;738.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;545.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;545.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;379.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;379.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;15.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;15.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;22.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;22.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;39.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;39.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Hemophilia:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ELOCTATE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;42.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;48.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ALPROLIX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;26.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: Hemophilia product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;63.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;11.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;74.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;6,713.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;4,666.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;11,379.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6,800.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;4,086.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;10,886.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7,017.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3,337.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;10,354.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognized revenues from two wholesalers accounting for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, two wholesale distributors individually accounted for approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of net accounts receivable associated with our product sales, as compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15.6%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;127.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;888.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;666.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,011.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;20.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,698.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(54.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(48.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(535.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(2,242.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(2,778.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(127.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(576.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(20.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(724.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;131.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,027.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;40.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;109.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;606.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;761.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;679.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,686.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,389.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(12.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(551.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,887.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,440.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(109.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(506.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(31.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(646.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;127.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;888.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;482.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;605.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;583.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,307.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,917.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(475.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,756.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,232.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(69.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(442.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(23.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(534.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;109.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;606.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;761.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;197.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;176.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,001.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;874.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,542.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,431.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,316.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;748.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;548.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;242.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,290.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,980.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,559.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our total revenues in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, are derived from our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(16.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under our technical development services and manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;106.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;96.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;42.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Swedish Orphan Biovitrum AB (Sobi) and royalties from Sobi on sales of ELOCTA and ALPROLIX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;584.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;459.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;253.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;707.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;585.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;360.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic customers, including Bioverativ Inc. (Bioverativ). During the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$383.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$206.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$64.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we will license certain of our manufacturing-related intellectual property to the customer. We will be eligible to receive &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$500.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in a series of three payments. The first payment is due upon a regulatory achievement related to the customer's product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We expect the regulatory achievement to occur in 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with AbbVie Inc. (AbbVie) and Samsung Bioepis, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9480294ACAA90466835A6F38B8E07ED5-0-wk-Fact-0F0EADBFB6A8A6B5CF7D6F38B7CFBACB">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="36"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;3,306.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;1,126.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;4,432.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3,253.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,020.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;4,274.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3,294.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;920.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;4,214.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Interferon*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;1,426.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;675.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;2,101.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,668.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;694.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,363.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,889.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;756.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,645.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;1,041.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;850.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;1,892.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,025.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;839.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,864.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,113.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;859.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,973.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;VUMERITY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;97.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;97.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;92.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;92.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;91.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;91.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ZINBRYTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;52.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;52.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: MS Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;5,780.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;2,748.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;8,529.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;5,946.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,648.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8,595.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6,296.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,680.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8,977.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;933.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;1,163.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;2,097.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;854.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;870.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,724.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;657.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;226.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;883.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;486.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;486.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;485.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;485.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;370.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;370.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;184.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;184.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;16.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;16.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;68.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;68.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;43.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;43.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;738.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;738.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;545.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;545.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;379.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;379.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;15.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;15.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;22.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;22.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;39.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;39.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Hemophilia:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ELOCTATE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;42.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;48.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ALPROLIX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;26.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: Hemophilia product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;63.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;11.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;74.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;6,713.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;4,666.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&lt;span&gt;11,379.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6,800.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;4,086.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;10,886.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7,017.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3,337.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;10,354.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2110-wk-Fact-7178F7ECE2E8F56E08A06F38B8541ED7"
      unitRef="usd">3306500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2129-wk-Fact-7EF5073E34FA11118B256F38B837386B"
      unitRef="usd">1126200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d51031806e2148-wk-Fact-BCD410BEDDA3E97A774A6F38B89E9365"
      unitRef="usd">4432700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2168-wk-Fact-E774B0EFAAFB7BAF76E46F38B8AB1412"
      unitRef="usd">3253200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2187-wk-Fact-28E1368E449182293C046F38B850AB49"
      unitRef="usd">1020900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d51031806e2207-wk-Fact-6C076252D70E55462C066F38B8AB8BDE"
      unitRef="usd">4274100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2226-wk-Fact-69D618FB522F322CD6206F38B8489900"
      unitRef="usd">3294000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2245-wk-Fact-19AF842B0A3547F2B74B6F38B8A81C5A"
      unitRef="usd">920000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d51031806e2265-wk-Fact-8532C1CA9122300BB9346F38B855A197"
      unitRef="usd">4214000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2280-wk-Fact-C9D00A1D3DA8814BEF436F38B8A19E4A"
      unitRef="usd">1426600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2299-wk-Fact-D246160A5EBECF776B8C6F38B846D26F"
      unitRef="usd">675200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d51031806e2318-wk-Fact-BFD6B5E6012E423899A66F38B8A0631D"
      unitRef="usd">2101800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2338-wk-Fact-CF63614DF1A99675C25E6F38B83D89C0"
      unitRef="usd">1668300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2357-wk-Fact-1F34CCAADCF6D0D1A1CE6F38B8AC918F"
      unitRef="usd">694700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d51031806e2376-wk-Fact-87FEDFBFC34F2CBF19196F38B89FC4FD"
      unitRef="usd">2363000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2396-wk-Fact-7A7107DD41A37CAF21B66F38B89CE292"
      unitRef="usd">1889100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2415-wk-Fact-087395A8FEB9289E01F06F38B855013E"
      unitRef="usd">756700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d51031806e2435-wk-Fact-FDEBEBFB11DD9F83A10D6F38B846D785"
      unitRef="usd">2645800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2455-wk-Fact-6FFE0F9E1BD388E264516F38B83B0EE9"
      unitRef="usd">1041800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2474-wk-Fact-981BDCC3DC7C07AE2E736F38B8A0AFE8"
      unitRef="usd">850400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d51031806e2493-wk-Fact-7964346AAB80C3F7196E6F38B8AA2B20"
      unitRef="usd">1892200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2513-wk-Fact-893E7531F927F0336FBB6F38B84E90B3"
      unitRef="usd">1025000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2532-wk-Fact-3098CD42B17958D530796F38B83EB3FB"
      unitRef="usd">839000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d51031806e2551-wk-Fact-630F890706B31D75C9906F38B84BA5E4"
      unitRef="usd">1864000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2571-wk-Fact-44698503DF8F3807C0946F38B854904B"
      unitRef="usd">1113800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2590-wk-Fact-8CB95461A7A4EE4364926F38B842B36D"
      unitRef="usd">859300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d51031806e2610-wk-Fact-F8C2676E0917361E4F216F38B8A766E8"
      unitRef="usd">1973100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2630-wk-Fact-D1B96FC294061CE18A4DE8733EA1ADDA"
      unitRef="usd">5500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2649-wk-Fact-3A83CDE025A9577BB627E8734109493D"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember"
      decimals="-5"
      id="d51031806e2668-wk-Fact-BB343842B86CAFA0210BE873437B4DF3"
      unitRef="usd">5500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2688-wk-Fact-BEBCF796CD96EE563D2FE87345707D1B"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2707-wk-Fact-63765EBCBA2DD3A0D2B7E87347D845BD"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember"
      decimals="-5"
      id="d51031806e2726-wk-Fact-97624A8A3A23EC00C779E8734A52C620"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2746-wk-Fact-49383F53A8FA45B5AC4BE8734C4677E7"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2765-wk-Fact-47B14953EEDE7D46DA78E8734EADDF2A"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember"
      decimals="-5"
      id="d51031806e2785-wk-Fact-587520D80F04B0A3451BE87351275B96"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2805-wk-Fact-A9D93BDED7FD663918B46F38B840D5C8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2824-wk-Fact-E56C85A610C096D955846F38B84A1E45"
      unitRef="usd">97100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d51031806e2843-wk-Fact-2CD61E5D5F15DE0F701C6F38B8A1427F"
      unitRef="usd">97100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2863-wk-Fact-FBAC51A55B525C65EE9E6F38B839D35C"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2882-wk-Fact-846BC48484CE6B3755A66F38B8AB70C6"
      unitRef="usd">92700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d51031806e2901-wk-Fact-56F9563F6D3125EB88FD6F38B84F15A8"
      unitRef="usd">92700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2921-wk-Fact-48A40101726EB69A0B736F38B84C2F77"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2940-wk-Fact-0666315F19323315166C6F38B8A564C4"
      unitRef="usd">91600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d51031806e2960-wk-Fact-5CE00C2F48BBE2B5E3AD6F38B8A56504"
      unitRef="usd">91600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e2980-wk-Fact-FD1B9F4E6879A74F7D5A6F38B841269F"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e2999-wk-Fact-B85B3F4D03DE5193F31D6F38B8533CA0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember"
      decimals="-5"
      id="d51031806e3018-wk-Fact-AF7E4474FC3158821EBC6F38B84DB649"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e3038-wk-Fact-8B52002C0AA5B42EF6446F38B89C32DE"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e3057-wk-Fact-314DB7EE1940650BD3266F38B8AB5355"
      unitRef="usd">1400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember"
      decimals="-5"
      id="d51031806e3076-wk-Fact-827F967916D4315CC3E66F38B857DAD4"
      unitRef="usd">1400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e3096-wk-Fact-633898C07050AE5610DE6F38B8A24B9D"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e3115-wk-Fact-9AE66B8E642AC36F1ADE6F38B8A11AB1"
      unitRef="usd">52700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember"
      decimals="-5"
      id="d51031806e3135-wk-Fact-4650A6B5A762EBC9C2976F38B8A4B3A0"
      unitRef="usd">52700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e3155-wk-Fact-F195E1EC8ED28689E8366F38B8AC6376"
      unitRef="usd">5780400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e3174-wk-Fact-5714B817FBA2361D71686F38B84F2F94"
      unitRef="usd">2748900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d51031806e3193-wk-Fact-83E0947CDDEC5CDDBEB36F38B8A86451"
      unitRef="usd">8529300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e3213-wk-Fact-85B07E50F6083E80A3466F38B83871A8"
      unitRef="usd">5946500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e3232-wk-Fact-F808B4766C0E2E1F55296F38B837B592"
      unitRef="usd">2648700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d51031806e3251-wk-Fact-642538AB9FBB204C8D4B6F38B8ACA635"
      unitRef="usd">8595200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e3271-wk-Fact-3432B61F6A97B0B236506F38B849DEFA"
      unitRef="usd">6296900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e3290-wk-Fact-FCFCA77FD020F91DB4C86F38B840EAC0"
      unitRef="usd">2680300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d51031806e3310-wk-Fact-0138E25D800678A85E416F38B8A70656"
      unitRef="usd">8977200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e3699-wk-Fact-969824CFFEEA7B45CB4E6F38B840AA9B"
      unitRef="usd">933400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e3718-wk-Fact-10CEB08D0414FD1054166F38B8AAA640"
      unitRef="usd">1163600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d51031806e3737-wk-Fact-8E61C5D97516A10EAAA36F38B89DB152"
      unitRef="usd">2097000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e3757-wk-Fact-7E1E771E7FE7124A5A146F38B858452F"
      unitRef="usd">854000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e3776-wk-Fact-E4B225B6380CB42493526F38B89F299E"
      unitRef="usd">870200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d51031806e3795-wk-Fact-06349855CEE6CBAF9C546F38B8A6AA7D"
      unitRef="usd">1724200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e3815-wk-Fact-2838B8F012123786F80F6F38B843EAD5"
      unitRef="usd">657000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e3834-wk-Fact-95A708AD9372607553FD6F38B8490B20"
      unitRef="usd">226700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d51031806e3854-wk-Fact-21ADC2404D6F977648066F38B89E310E"
      unitRef="usd">883700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e4242-wk-Fact-1B3734F7E6FF26D8C5F76F38B84ADF6E"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e4261-wk-Fact-711EDED6F8A4F6BE32346F38B8479476"
      unitRef="usd">486200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d51031806e4280-wk-Fact-22A7D3D6C162A23114496F38B84A97EF"
      unitRef="usd">486200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e4300-wk-Fact-C63524C709AD88F7A6FD6F38B8A0F9B2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e4319-wk-Fact-3EDF123DF168D9E112546F38B84251EB"
      unitRef="usd">485200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d51031806e4338-wk-Fact-B0232DB960246F65C8F16F38B8AC3007"
      unitRef="usd">485200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e4358-wk-Fact-137970766800E834C4BC6F38B8ADDB9A"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e4377-wk-Fact-470D8EE6BC1ABE7B1F946F38B8394139"
      unitRef="usd">370800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d51031806e4397-wk-Fact-00E75C2CE55924708BD56F38B845AC1F"
      unitRef="usd">370800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e4417-wk-Fact-E4528FB59CDB06C7F6596F38B837969F"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e4436-wk-Fact-17CA8FA2624735F12D7E6F38B89C960D"
      unitRef="usd">184000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d51031806e4455-wk-Fact-7CF29032C4491FE8C4AC93CA0EE139FB"
      unitRef="usd">184000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e4475-wk-Fact-43E17EB736CBEE0D88F56F38B8AA09D0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e4494-wk-Fact-1039995D8C96C0984B326F38B848D6CC"
      unitRef="usd">16700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d51031806e4513-wk-Fact-86E344CFD95A06FA298593CA50577A1C"
      unitRef="usd">16700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e4533-wk-Fact-25C4C43A696F34DA0C5A6F38B8A2A50C"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e4552-wk-Fact-08B90C4658E140B0B2756F38B89C2507"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d51031806e4572-wk-Fact-9029280CBBA3314E11DB93CA7E35DE76"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e4592-wk-Fact-E893ECE2AD3B7E60DA1A6F38B847835C"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e4611-wk-Fact-491D22F8A9F7E4060D056F38B83D4007"
      unitRef="usd">68100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d51031806e4630-wk-Fact-B185EA9C40B4D4F5DAA76F38B89D88AF"
      unitRef="usd">68100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e4650-wk-Fact-254C46441D4F7BE1CA9C6F38B84138E6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e4669-wk-Fact-8EA51C673D11E6431F6C6F38B8561583"
      unitRef="usd">43200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d51031806e4688-wk-Fact-8502F49E7AD44B2566856F38B842DC87"
      unitRef="usd">43200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e4708-wk-Fact-C733A3C18E14F9773B5F6F38B8A78598"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e4727-wk-Fact-02AD391F6F7C94E78ADC6F38B851AF4D"
      unitRef="usd">9000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d51031806e4747-wk-Fact-CB65433CC48753DB72DA6F38B852E3C1"
      unitRef="usd">9000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e4767-wk-Fact-DC78B706D2B9E2411BA26F38B84310BC"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e4786-wk-Fact-1201F017A49BBAA608B96F38B8482900"
      unitRef="usd">738300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d51031806e4805-wk-Fact-2F917D991B1833F4ED2A6F38B850B40B"
      unitRef="usd">738300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e4825-wk-Fact-E00653BCA67F9A701C5C6F38B8584492"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e4844-wk-Fact-140266E38F85D9033E966F38B8AC5C36"
      unitRef="usd">545100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d51031806e4863-wk-Fact-8F308751B2A4931FF9196F38B8523276"
      unitRef="usd">545100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e4883-wk-Fact-E0EF5C9090DF50D179CD6F38B850B9D9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e4902-wk-Fact-0D9BF2E2D2B320A142666F38B84CC1B9"
      unitRef="usd">379800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d51031806e4922-wk-Fact-9807BBA5D0267FC5D7C76F38B8A3EE8A"
      unitRef="usd">379800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e5311-wk-Fact-868DBD07789EDFCA6D6C6F38B84CF1BF"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e5330-wk-Fact-CFAA484D6EACFCB7D28D6F38B854EECD"
      unitRef="usd">15200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d51031806e5349-wk-Fact-9EA18A071FA86CFA9C9B6F38B83EBB00"
      unitRef="usd">15200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e5369-wk-Fact-C9884796EC6F2B319DCE6F38B8A55F3D"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e5388-wk-Fact-7702DA027A7BA4C9DE396F38B8504B7C"
      unitRef="usd">22300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d51031806e5407-wk-Fact-B5D3FE6C77BB94DD7A476F38B84F4C18"
      unitRef="usd">22300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e5427-wk-Fact-BEBED064BBAF13E2161F6F38B89D3CE4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e5446-wk-Fact-BA182DF5D3411FF3595F6F38B8485735"
      unitRef="usd">39600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d51031806e5466-wk-Fact-C264FD3C1FC17E8E126B6F38B8407721"
      unitRef="usd">39600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e5854-wk-Fact-7E045E2FCCE87D5EF5216F38B8A28056"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e5873-wk-Fact-AE1B22DC7C26C1FADBF06F38B83A2E87"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember"
      decimals="-5"
      id="d51031806e5892-wk-Fact-FD5A8E196D5C96F123346F38B8A2593D"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e5912-wk-Fact-481DC4EBC294AC8261326F38B83CF5BF"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e5931-wk-Fact-50F08CF7707F3BF9C0CE6F38B8A5E86E"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember"
      decimals="-5"
      id="d51031806e5950-wk-Fact-1FDFC5717EACA77C36896F38B8467A5A"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e5970-wk-Fact-C458C2240F5FF26B82676F38B84D38D8"
      unitRef="usd">42200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e5989-wk-Fact-33566A04BE05B220B8386F38B8533D19"
      unitRef="usd">6200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember"
      decimals="-5"
      id="d51031806e6009-wk-Fact-469032FB2607D925670E6F38B8A328AC"
      unitRef="usd">48400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e6029-wk-Fact-BC4A27EADBD4713E0CAE6F38B83DABCA"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e6048-wk-Fact-15C1A916923E32CDEAD56F38B84B3AE0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember"
      decimals="-5"
      id="d51031806e6067-wk-Fact-719FBA0AF483D751A30D6F38B8A8EBF2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e6087-wk-Fact-01A174DB54FCDB30C5436F38B8A43863"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e6106-wk-Fact-F3E403AAF46FBEB1496C6F38B84DA03A"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember"
      decimals="-5"
      id="d51031806e6125-wk-Fact-099A36DE28A9D45111D86F38B852EEC9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e6145-wk-Fact-47FA694F1D66D8F80F656F38B8A656E5"
      unitRef="usd">21000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e6164-wk-Fact-C46A212B9154F02ADAAE6F38B844820C"
      unitRef="usd">5000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember"
      decimals="-5"
      id="d51031806e6184-wk-Fact-452255477FCCBAC36EDB6F38B84DACCF"
      unitRef="usd">26000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e6204-wk-Fact-51038E5E04FCB94F836E6F38B8AA1931"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e6223-wk-Fact-513B5CD79F09E8E550386F38B843F9C1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember"
      decimals="-5"
      id="d51031806e6242-wk-Fact-104590C7188B6920EE6E6F38B83D7677"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e6262-wk-Fact-1E49E52ADF04EC5D3F2D6F38B8372877"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e6281-wk-Fact-E5626ED7D6CB030440F26F38B8A414FE"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember"
      decimals="-5"
      id="d51031806e6300-wk-Fact-348EADC13053EA8A72FE6F38B83CB548"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e6320-wk-Fact-ACBC9FA87EC1ABF415CA6F38B84AF0ED"
      unitRef="usd">63200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e6339-wk-Fact-6941617A07683B02C6256F38B857FDDF"
      unitRef="usd">11200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember"
      decimals="-5"
      id="d51031806e6359-wk-Fact-1EFF99EC168CB8E933B66F38B83B205A"
      unitRef="usd">74400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e6568-wk-Fact-8B42590D2AE4D7B90D5A6F38B83ADC6B"
      unitRef="usd">6713800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e6587-wk-Fact-BCA71A3F159546C947596F38B8A552F7"
      unitRef="usd">4666000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51031806e6606-wk-Fact-F1FBA38FF669B88E1D976F38B82CDF1B"
      unitRef="usd">11379800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e6626-wk-Fact-5384BFFD347C612F45386F38B8517C44"
      unitRef="usd">6800500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e6645-wk-Fact-DA7D01CBC8D84725300E6F38B89FAAFB"
      unitRef="usd">4086300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51031806e6665-wk-Fact-7B6205D978C9C04E48296F38B81CF51A"
      unitRef="usd">10886800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51031806e6684-wk-Fact-279DB18511D84B5AD04A6F38B8A819C5"
      unitRef="usd">7017100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d51031806e6703-wk-Fact-C390E028FC22AE0CC39C6F38B840045E"
      unitRef="usd">3337600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51031806e6723-wk-Fact-A0A85755BDDAAFF80DF16F38B7A963B8"
      unitRef="usd">10354700000</us-gaap:Revenues>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember"
      decimals="2"
      id="d51031806e6737-wk-Fact-E1DC77899CA180C007446F38B7CFA906"
      unitRef="number">0.30</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember"
      decimals="2"
      id="d51031806e6741-wk-Fact-BDF0173A84F573BCAC686F38B7D399C5"
      unitRef="number">0.17</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2018Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember"
      decimals="2"
      id="d51031806e6749-wk-Fact-FDCC363E917377C951356F38B7D26F96"
      unitRef="number">0.32</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2018Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember"
      decimals="2"
      id="d51031806e6753-wk-Fact-B386C9FB6E650706AAC06F38B7D324C5"
      unitRef="number">0.18</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember"
      decimals="2"
      id="d51031806e6762-wk-Fact-3497DED074498C52B4FC6F38B7D0519B"
      unitRef="number">0.34</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember"
      decimals="2"
      id="d51031806e6766-wk-Fact-0D6484122065A63253336F38B7D1FDD5"
      unitRef="number">0.21</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables
      contextRef="FI2019Q4_biib_MajorDistributorAxis_biib_DistributorOneMember"
      decimals="3"
      id="d51031806e6781-wk-Fact-3BF5C3BCEC00B76C7AA16F38B7CE1504"
      unitRef="number">0.241</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
    <biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables
      contextRef="FI2019Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember"
      decimals="3"
      id="d51031806e6785-wk-Fact-CDBB450B5A86B10052676F38B7D05D4E"
      unitRef="number">0.139</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
    <biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables
      contextRef="FI2018Q4_biib_MajorDistributorAxis_biib_DistributorOneMember"
      decimals="3"
      id="d51031806e6789-wk-Fact-553F8ECB319EB233D11B6F38B7D58795"
      unitRef="number">0.277</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
    <biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables
      contextRef="FI2018Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember"
      decimals="3"
      id="d51031806e6793-wk-Fact-1CCE6E02877ED1F149D26F38B7D253EA"
      unitRef="number">0.156</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-65A5FD682DBB94372F2E6F38B8DF0878-0-wk-Fact-F5C1149F28E89263E7E56F38B7CF1A5D">&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;127.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;888.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;666.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,011.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;20.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,698.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(54.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(48.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(535.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(2,242.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(2,778.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(127.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(576.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(20.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(724.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;131.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,027.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;40.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;109.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;606.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;761.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;679.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,686.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,389.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(12.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(551.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,887.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,440.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(109.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(506.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(31.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(646.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;127.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;888.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;482.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;605.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;583.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,307.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,917.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(475.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,756.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,232.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(69.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(442.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(23.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(534.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;109.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;606.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;761.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e7019-wk-Fact-8A9FA3DBACC07E8F72896F38B7C91625"
      unitRef="usd">127800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e7038-wk-Fact-79A7D730F6B06E25F5666F38B89D0D7E"
      unitRef="usd">888800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e7057-wk-Fact-87C468842B59399AECDA6F38B8AD129D"
      unitRef="usd">34700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51031806e7077-wk-Fact-3E4AC112B64B6AB6576A6F38B7A3C8B2"
      unitRef="usd">1051300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e7092-wk-Fact-ADEF6A24E22C27F4C0C76F38B85A4F9F"
      unitRef="usd">666200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e7111-wk-Fact-0EF84F87EB4BE24ED5866F38B85DFC19"
      unitRef="usd">3011500000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e7130-wk-Fact-7918091EA9B0A5A90A826F38B85B3EDF"
      unitRef="usd">20900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51031806e7150-wk-Fact-4E9BC5FF9D53688268956F38B85832C6"
      unitRef="usd">3698600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e7170-wk-Fact-92DE238C7225EF4158BC6F38B859A897"
      unitRef="usd">-300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e7189-wk-Fact-28F007448A95EBC00A586F38B85CF5C2"
      unitRef="usd">54100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e7209-wk-Fact-3F84CA51FF2BB074F4E36F38B88FE47C"
      unitRef="usd">-5500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51031806e7229-wk-Fact-F016752F3BCB36A7239C6F38B8592922"
      unitRef="usd">48300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e7250-wk-Fact-001105F50119E81B8FCB6F38B85C20A2"
      unitRef="usd">535500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e7270-wk-Fact-082CC9D897975E81FBE66F38B88F6874"
      unitRef="usd">2242900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e7290-wk-Fact-BA796D8196DC485D19C66F38B88FA417"
      unitRef="usd">200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51031806e7311-wk-Fact-B4D20E61498F88F869B76F38B85C60DB"
      unitRef="usd">2778600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e7332-wk-Fact-D659A76D66CFFC23418D6F38B88EFF7E"
      unitRef="usd">127700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e7352-wk-Fact-7DD37661EA45CE932DA36F38B88D5765"
      unitRef="usd">576000000.0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e7372-wk-Fact-0CB7A2255824C17E17026F38B88DCF22"
      unitRef="usd">20400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51031806e7393-wk-Fact-6E2594A9A1686D7CFB9F6F38B859D9BE"
      unitRef="usd">724100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e7419-wk-Fact-234A584500B6138FF4426F38B85ADC81"
      unitRef="usd">131100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e7438-wk-Fact-C277ECD3C56D4DCB92896F38B85937EA"
      unitRef="usd">1027300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e7457-wk-Fact-D443961612D1F37D9C8D6F38B88CF725"
      unitRef="usd">40500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51031806e7477-wk-Fact-8FCA815A8432989B0C476F38B85D916C"
      unitRef="usd">1198900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e7690-wk-Fact-A3B5EB49BDB9642F21216F38B8AE1126"
      unitRef="usd">109600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e7709-wk-Fact-F8FB02F259A4C849D20E6F38B7B16265"
      unitRef="usd">606000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e7728-wk-Fact-725101FDAF5D5B5EE9046F38B7CFB816"
      unitRef="usd">46000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51031806e7748-wk-Fact-62C9CCF20D5EBA9BEE1B6F38B8A5EBD2"
      unitRef="usd">761600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e7763-wk-Fact-05897C73EFBDCDAB3FE16F38B8062729"
      unitRef="usd">679300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e7782-wk-Fact-78503854A7992EC92DAA6F38B845B733"
      unitRef="usd">2686700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e7801-wk-Fact-67AF24074B393E49D6EC6F38B89BA940"
      unitRef="usd">23100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51031806e7821-wk-Fact-02D8942802EF783000F76F38B843D773"
      unitRef="usd">3389100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e7841-wk-Fact-792CE882BF360DAAA1FB6F38B8AD6AC1"
      unitRef="usd">300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e7861-wk-Fact-D5F502F5FDA21EF314F36F38B84830C8"
      unitRef="usd">10000000.0</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e7881-wk-Fact-CAB62E1A5365663019476F38B80920B9"
      unitRef="usd">1800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51031806e7902-wk-Fact-002464A079952E84F1E06F38B8843652"
      unitRef="usd">12100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e7923-wk-Fact-EED2B404CCE8057BCC4A6F38B889145E"
      unitRef="usd">551700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e7943-wk-Fact-061C6E9B319E087D90566F38B810295E"
      unitRef="usd">1887600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e7963-wk-Fact-82D2367CC5432D7D9CEB6F38B7ADAF47"
      unitRef="usd">1100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51031806e7984-wk-Fact-A11AE8C60D6185A85AC16F38B8A27509"
      unitRef="usd">2440400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e8005-wk-Fact-31FE67F8A9DEDC6C90A06F38B81C0478"
      unitRef="usd">109100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e8025-wk-Fact-2FC15730D71DA76C0CFC6F38B8938B56"
      unitRef="usd">506300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e8045-wk-Fact-DA3FD5C5771E6C287EE56F38B7F6C630"
      unitRef="usd">31500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51031806e8066-wk-Fact-9CEB9913060033D680996F38B8C635E7"
      unitRef="usd">646900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e8092-wk-Fact-8A9FA3DBACC07E8F72896F38B7C91625"
      unitRef="usd">127800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e8111-wk-Fact-79A7D730F6B06E25F5666F38B89D0D7E"
      unitRef="usd">888800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e8130-wk-Fact-87C468842B59399AECDA6F38B8AD129D"
      unitRef="usd">34700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51031806e8150-wk-Fact-3E4AC112B64B6AB6576A6F38B7A3C8B2"
      unitRef="usd">1051300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e8361-wk-Fact-030F4CD51D3F6EB116226F38B7DEDF0A"
      unitRef="usd">71600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e8380-wk-Fact-A47FEFD554FC7FA2AFC36F38B7D62E13"
      unitRef="usd">482700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e8399-wk-Fact-06A1569401039B2745E56F38B7D816F4"
      unitRef="usd">51200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2016Q4"
      decimals="-5"
      id="d51031806e8419-wk-Fact-196068BFBBDD76DA0DE96F38B7DCB8F9"
      unitRef="usd">605500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e8434-wk-Fact-2E5795BE191D586CDFD86F38B7DD065E"
      unitRef="usd">583000000.0</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e8453-wk-Fact-3DC03A11EACE31EABAD36F38B7DE30AA"
      unitRef="usd">2307400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e8472-wk-Fact-6E75F5FED2995B4D47EF6F38B7DB714B"
      unitRef="usd">26900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51031806e8492-wk-Fact-B1FF02E77436FC2E279D6F38B7DA95A2"
      unitRef="usd">2917300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e8512-wk-Fact-DCFB2B6F64AFE602BB856F38B7D99489"
      unitRef="usd">100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e8532-wk-Fact-42B8D9900839DD64F6426F38B7DC2698"
      unitRef="usd">-15000000.0</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e8551-wk-Fact-1EA7F2CFFB94951B9D586F38B7D73CBC"
      unitRef="usd">8900000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51031806e8572-wk-Fact-89106EC5EE704A3F8B446F38B7DE941E"
      unitRef="usd">-6000000.0</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e8592-wk-Fact-AA68AD01E0CED3A783316F38B7D77D21"
      unitRef="usd">475800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e8612-wk-Fact-2B6335B01DBA1E84E99A6F38B7D9D2AE"
      unitRef="usd">1756900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e8632-wk-Fact-8DE44C836FEB57B07C6C6F38B7DD0BB6"
      unitRef="usd">100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51031806e8653-wk-Fact-4ADC89F64F60FC5BC1506F38B7DE84BA"
      unitRef="usd">2232800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e8674-wk-Fact-A298CC9B2B0A6D59AD366F38B7DB5A51"
      unitRef="usd">69100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e8694-wk-Fact-530018D21CF10484BF6A6F38B7D9EF65"
      unitRef="usd">442200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e8714-wk-Fact-69A47D51F11389F0DB346F38B7DB12B8"
      unitRef="usd">23100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51031806e8735-wk-Fact-5A1EE19821AB7E6631C96F38B7D6D9F0"
      unitRef="usd">534400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d51031806e8761-wk-Fact-A3B5EB49BDB9642F21216F38B8AE1126"
      unitRef="usd">109600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d51031806e8780-wk-Fact-F8FB02F259A4C849D20E6F38B7B16265"
      unitRef="usd">606000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d51031806e8799-wk-Fact-725101FDAF5D5B5EE9046F38B7CFB816"
      unitRef="usd">46000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51031806e8819-wk-Fact-62C9CCF20D5EBA9BEE1B6F38B8A5EBD2"
      unitRef="usd">761600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-729A6DC70A834596B0D76F38B8E03739-0-wk-Fact-F67DE55115249D1B05086F38B7D06501">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;197.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;176.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,001.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;874.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-5"
      id="d51031806e8957-wk-Fact-EDD2DB46CDE06F3C80E96F38B85DE649"
      unitRef="usd">197800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-5"
      id="d51031806e8976-wk-Fact-4B0FA7C18E26D6A05A026F38B85EDDE2"
      unitRef="usd">176600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d51031806e8991-wk-Fact-95236321ECF2BFF56EC16F38B85CEE98"
      unitRef="usd">1001100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d51031806e9010-wk-Fact-1FE860E51A66C4BD686F6F38B85CFD98"
      unitRef="usd">874700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51031806e9035-wk-Fact-8FCA815A8432989B0C476F38B85D916C"
      unitRef="usd">1198900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51031806e9054-wk-Fact-3E4AC112B64B6AB6576A6F38B7A3C8B2"
      unitRef="usd">1051300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-638E06587C1F10CAAFCD6F38B8E02F7C-0-wk-Fact-D5A9FB3D9AB158FBE9E46F38B7CE9A2D">&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,542.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,431.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,316.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;748.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;548.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;242.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,290.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,980.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,559.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,542.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,431.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,316.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;748.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;548.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;242.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,290.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,980.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,559.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d51031806e9230-wk-Fact-26337B82AAEF05E73A3E6F38B85F0A00"
      unitRef="usd">1542400000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d51031806e9249-wk-Fact-B6C3F88418A5E2EE809B6F38B8628501"
      unitRef="usd">1431900000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d51031806e9268-wk-Fact-2DFFF43C74572858F7716F38B862D03C"
      unitRef="usd">1316400000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d51031806e9284-wk-Fact-B81242FED25624534B936F38B8676A8A"
      unitRef="usd">748000000.0</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d51031806e9303-wk-Fact-FB06AB0BDFB9774258446F38B8615CE3"
      unitRef="usd">548300000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d51031806e9322-wk-Fact-EE4AEC4BFD0DED5E11FC6F38B85F5D20"
      unitRef="usd">242800000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51031806e9348-wk-Fact-6DB6BA0B8C715A0D0D4B6F38B8607F57"
      unitRef="usd">2290400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51031806e9367-wk-Fact-5DE8AC0444CC0844782E6F38B82AE6AA"
      unitRef="usd">1980200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51031806e9386-wk-Fact-3A0656DB95083450147A6F38B824BC8E"
      unitRef="usd">1559200000</us-gaap:Revenues>
    <biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d51031806e9399-wk-Fact-77C6EE89DB0D429BD2826F38B7D19259"
      unitRef="number">0.16</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
    <biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d51031806e9403-wk-Fact-F8CAE99BE14A27F718C56F38B7D4FDE9"
      unitRef="number">0.15</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
    <biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d51031806e9407-wk-Fact-E9F18636260A1ABA5F5E6F38B7D3E7A3"
      unitRef="number">0.13</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
    <biib:OtherrevenuesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8C0ADF7C45713CB35C766F38B8E0335B-0-wk-Fact-00ADD7CF61EF3DA1F56A6F38B7D42149">&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(16.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under our technical development services and manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;106.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;96.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;42.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Swedish Orphan Biovitrum AB (Sobi) and royalties from Sobi on sales of ELOCTA and ALPROLIX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;584.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;459.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;253.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;707.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;585.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;360.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d51031806e9655-wk-Fact-4C382510ABFD169D06076F38B81BC097"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d51031806e9674-wk-Fact-8E85EC7E039C29B352A46F38B838A94B"
      unitRef="usd">-8600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d51031806e9694-wk-Fact-F2A2DA8DFCD0FE44D3006F38B817260B"
      unitRef="usd">-16900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d51031806e9711-wk-Fact-9C6F8620EFB92534924C6F38B81B790F"
      unitRef="usd">106200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d51031806e9730-wk-Fact-D98AB683F00560D115956F38B8180CE8"
      unitRef="usd">96400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d51031806e9749-wk-Fact-451BC7676B153AC2F9D46F38B817A7C0"
      unitRef="usd">42700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d51031806e9770-wk-Fact-BC230EB7D860876E9F856F38B83772D5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d51031806e9789-wk-Fact-C57B6BD867FF7B4640876F38B8193C6F"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d51031806e9808-wk-Fact-57A6F603F561C56782EE6F38B81B5038"
      unitRef="usd">10700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d51031806e9891-wk-Fact-6DEF235C43079255766D6F38B81AFE42"
      unitRef="usd">17000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d51031806e9910-wk-Fact-3BA33591AF6A2EFEC48B6F38B81A04B0"
      unitRef="usd">38700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d51031806e9929-wk-Fact-53FF036340A563D1B1086F38B81A8157"
      unitRef="usd">69800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d51031806e9950-wk-Fact-A11D430804BAB190CC8E6F38B817B7C1"
      unitRef="usd">584500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d51031806e9969-wk-Fact-8F29895CB4BD28E2DF4F6F38B818F0BD"
      unitRef="usd">459400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d51031806e9988-wk-Fact-FB7300F2763967631B9A6F38B819D90D"
      unitRef="usd">253700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51031806e10014-wk-Fact-00E0A71FFA7A5B6582ED6F38B7ACA093"
      unitRef="usd">707700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51031806e10033-wk-Fact-F0C4D670DC0F193457D96F38B8622365"
      unitRef="usd">585900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51031806e10052-wk-Fact-5D3FED1ADFF25AE90C656F38B87CF3D8"
      unitRef="usd">360000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51031806e10076-wk-Fact-8711D748E93BCF1DE1F07F0BBDAA434B"
      unitRef="usd">383200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51031806e10080-wk-Fact-6A7B1A646BAC100755617F0C17101529"
      unitRef="usd">206700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51031806e10085-wk-Fact-4BCF78733E175B27C3217F0C543D4B61"
      unitRef="usd">64800000</us-gaap:Revenues>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d51031806e10092-wk-Fact-28D3BE14DB3FB3A79BFE7F0D47D39D08"
      unitRef="usd">500000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5A01C0CCF8D0FD9461346F38B8E0D4DB-0-wk-Fact-39E39E9D5DA713830DF96F38B7DE9329">&#160;&#160;&#160;&#160;Inventory&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;169.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;196.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;460.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;606.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;174.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;804.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;804.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;929.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;804.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2019 we sold to Bioverativ hemophilia-related inventory on hand as of December 31, 2018, with a cost basis totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$184.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; pursuant to the terms of the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$52.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$41.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$76.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM. This transaction included the sale of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$14.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of work in process inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we sold to FUJIFILM approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$41.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of raw materials that were remaining at the Hiller&#xf8;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-55ECB43DF7CEACC8FF876F38B8E04257-0-wk-Fact-7924AFE8409EAEDABF6B6F38B7DF8884">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;169.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;196.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;460.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;606.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;174.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;804.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;804.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;929.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;804.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51008168e1413-wk-Fact-90CD31E27EE2393C377A6F38B7D734CC"
      unitRef="usd">169700000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51008168e1432-wk-Fact-6AB07456E0D537CEEA996F38B7D80BDA"
      unitRef="usd">196300000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51008168e1447-wk-Fact-6591E1D4F7E20493F29F6F38B7DB76E2"
      unitRef="usd">460000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51008168e1466-wk-Fact-007259F61199871542A76F38B7DF8974"
      unitRef="usd">606700000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51008168e1486-wk-Fact-3C6C4DCD7ADE40FCA6416F38B7DEEC50"
      unitRef="usd">174500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51008168e1505-wk-Fact-28E893FE7C0BFEAE60A36F38B7E0624D"
      unitRef="usd">133500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51008168e1530-wk-Fact-DF17104FDCA763B760176F38B7D6FA5B"
      unitRef="usd">804200000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51008168e1549-wk-Fact-BF2415D4BD7E9816F0596F38B7DA7C7F"
      unitRef="usd">936500000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51008168e1651-wk-Fact-26F6B410F20D465D19666F38B8C27FA2"
      unitRef="usd">804200000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51008168e1670-wk-Fact-8C4A1D272C17C1AD6F426F38B8C3B56F"
      unitRef="usd">929900000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51008168e1685-wk-Fact-AC0DDA02A7F652BE02696F38B7D8D45D"
      unitRef="usd">0</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51008168e1704-wk-Fact-049FFF4E5B821BBC12EF6F38B7D78A2D"
      unitRef="usd">6600000</us-gaap:InventoryNoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51008168e1729-wk-Fact-DF17104FDCA763B760176F38B7D6FA5B"
      unitRef="usd">804200000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51008168e1748-wk-Fact-BF2415D4BD7E9816F0596F38B7DA7C7F"
      unitRef="usd">936500000</biib:Inventorynetcurrentandnoncurrent>
    <biib:InventorysoldtoBioverativcost
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_BioverativMember"
      decimals="-5"
      id="d51008168e1771-wk-Fact-AE180E85B6D1ADF24A22D10AC85EF07A"
      unitRef="usd">184500000</biib:InventorysoldtoBioverativcost>
    <us-gaap:InventoryWriteDown
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51008168e1781-wk-Fact-BE860C7BC2B63CB66F1F6F38B7E38CE6"
      unitRef="usd">52200000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51008168e1785-wk-Fact-28B7F0251CE7E29184A36F38B7DD62DF"
      unitRef="usd">41900000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51008168e1789-wk-Fact-B065744EEC1FFCD04F3D6F38B7DF69EC"
      unitRef="usd">76900000</us-gaap:InventoryWriteDown>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="I2019Q3Denmark_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember"
      decimals="-5"
      id="d51008168e1812-wk-Fact-B750035E8C7689BE23DD7F75AD606980"
      unitRef="usd">14000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <biib:InventoryrawmaterialssoldtoFUJIFILM
      contextRef="I2019Q3Denmark"
      decimals="-5"
      id="d51008168e1819-wk-Fact-7B67356AE4C6F2044AE67F01D86E0CE7"
      unitRef="usd">41800000</biib:InventoryrawmaterialssoldtoFUJIFILM>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-99BD60AB4ED2AABE17936F38B8E13EAD-0-wk-Fact-27CE6DFCA6B12E79B93D6F38B8B09302">&#160;&#160;&#160;&#160;Intangible Assets and Goodwill&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Completed technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-28 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7,379.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(4,881.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,497.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,187.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,607.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,580.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;965.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;965.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;476.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;476.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks and trade names&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8,408.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(4,881.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,527.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,727.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,607.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,120.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Amortization and Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization and impairments of acquired intangible assets totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$489.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$747.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$814.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Amortization of acquired intangible assets, excluding impairment charges, totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$274.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$381.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$455.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. The decrease in amortization of acquired intangible assets, excluding impairment charges, over the three years was primarily due to a lower rate of amortization for acquired intangible assets, primarily due to prior year impairments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amortization and impairments of acquired intangible assets reflects the impact of a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$215.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment charge to reduce the fair value of IPR&amp;amp;D assets associated with BG00011 (STX-100) to zero, as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization and impairments of acquired intangible assets for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflects the impact of impairment charges related to certain IPR&amp;amp;D assets associated with our vixotrigine program totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$189.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization and impairments of acquired intangible assets for the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflect the impact of impairment charges of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$176.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$328.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to our intangible &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;assets associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan. The net book value of the TYSABRI asset as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Completed technology also includes &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$155.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), following the approval of VUMERITY in the U.S. in October 2019, technology related to our AVONEX product, which we recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003, our rest of world license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below, and other amounts related to our other marketed products and other programs acquired through business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;TECFIDERA License Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.25 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;in cash, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$795.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded within intangible assets in the first quarter of 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We had an intellectual property dispute with Forward Pharma in the U.S. concerning intellectual property related to TECFIDERA. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$328.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute and continued to amortize the remaining net book value of the U.S. intangible asset in our consolidated statements of income utilizing an economic consumption model. The U.S. Court of Appeals for the Federal Circuit upheld the U.S. Patent and Trademark Office&#x2019;s March 2017 ruling and in January 2019 denied Forward Pharma's petition for rehearing. We evaluated the recoverability of the U.S. asset based upon these most recent developments and recorded a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$176.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment charge in the fourth quarter of 2018 to reduce the remaining net book value of the U.S. asset to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have an intellectual property dispute with Forward Pharma in the European Union (E.U.) concerning intellectual property related to TECFIDERA. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2018 the European Patent Office (EPO) revoked Forward Pharma&#x2019;s European Patent No. 2 801 355. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for June 2020. Based upon our assessment of this ruling, we continue to amortize the remaining net book value of the rest of world intangible asset in our consolidated statements of income utilizing an economic consumption model. The remaining net book value of the TECFIDERA rest of world intangible asset as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$36.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the dispute with Forward Pharma in the E.U., please read Note 20, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Litigation,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life and amortize these amounts based upon an economic consumption method. The carrying value associated with our IPR&amp;amp;D assets as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, relates to the various IPR&amp;amp;D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Limited (Convergence), Stromedix Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN) in 2019, 2015, 2012 and 2010, respectively. IPR&amp;amp;D balances include adjustments related to foreign currency exchange rate fluctuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long-range planning cycle, which was most recently updated in the second quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of NST in June 2019, we acquired IPR&amp;amp;D programs with an estimated fair value of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$700.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on our acquisition of NST, please read Note 2, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;BG00011&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of idiopathic pulmonary fibrosis (IPF) due to safety concerns. As a result, we recognized an impairment charge of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$215.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the third quarter of 2019 to reduce the fair value of the IPR&amp;amp;D intangible asset to zero. We also adjusted the value of our contingent consideration obligations related to this asset resulting in a gain of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$61.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the third quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Vixotrigine&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the potential treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR. As a result, we recognized an impairment charge of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the third quarter of 2018 to reduce the fair value of the related IPR&amp;amp;D intangible asset to zero. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN as we awaited the outcome of ongoing interactions with the FDA regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy. We reassessed the fair value of the TGN program using reduced expected lifetime revenues, higher expected clinical development costs and lower cumulative probability of success. As a result of that reassessment, we recognized an impairment charge of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$129.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the third quarter of 2018 to reduce the fair value of the TGN IPR&amp;amp;D intangible asset to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$41.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The IPR&amp;amp;D impairment charges were included in amortization and impairment of acquired intangible assets and the gain resulting from the remeasurement of our contingent consideration obligation was recorded in (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income. The fair value of the intangible assets and contingent consideration obligations were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues, costs and probabilities of success.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our most recent long-range planning cycle was completed in the second quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;260.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;225.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;230.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,706.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,632.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;117.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,080.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Elimination of goodwill allocated to Hiller&#xf8;d, Denmark manufacturing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(69.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,757.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,706.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase to goodwill during &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase to goodwill during &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent milestones achieved (exclusive of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$119.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in tax benefits) and payable to the former shareholders of Fumapharm AG and holders of their rights. In the fourth quarter of 2018 we achieved the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$20.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cumulative sales level threshold and accrued the final contingent payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$300.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to FUMADERM and TECFIDERA (together, the Fumapharm Products), which was paid in the first quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The elimination of goodwill represents an allocation based upon the relative fair value of our Hiller&#xf8;d, Denmark manufacturing operations at the divestiture date. In connection with the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, our remaining goodwill was reviewed for impairment, and based upon this review, no impairments were recognized. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill. &lt;/span&gt;&lt;/div&gt;Other includes changes related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C939E9154435C068A8E46F38B8E16AAA-0-wk-Fact-35165718CDEE76B7403A6F38B8312EEA">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Completed technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-28 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7,379.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(4,881.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,497.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,187.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,607.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,580.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;965.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;965.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;476.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;476.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks and trade names&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8,408.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(4,881.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,527.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,727.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,607.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,120.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51024678e1635-wk-Fact-5045C1667BFDB7F4A6446F38B7E197CC"
      unitRef="usd">7379300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51024678e1654-wk-Fact-20A8E4232234AAE424EB6F38B7DC7954"
      unitRef="usd">4881400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51024678e1675-wk-Fact-53F472F6525C248BDD756F38B80BCEEE"
      unitRef="usd">2497900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51024678e1694-wk-Fact-B71A68581363D3A4EC056F38B7E217EE"
      unitRef="usd">7187300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51024678e1713-wk-Fact-DDF87F45F2B80791E2666F38B8857B3B"
      unitRef="usd">4607300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51024678e1734-wk-Fact-34E907057BF3D13FBA226F38B83C3DA7"
      unitRef="usd">2580000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51024678e1759-wk-Fact-8C410B396EF78F024FDE6F38B8749112"
      unitRef="usd">965500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51024678e1778-wk-Fact-0FFBD3D5F524EC2262766F38B7E92401"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51024678e1798-wk-Fact-8C410B396EF78F024FDE6F38B8749112"
      unitRef="usd">965500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51024678e1817-wk-Fact-5EAFAAB3B2572C26BBA06F38B7EA7D38"
      unitRef="usd">476000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51024678e1836-wk-Fact-F86AF0E3D50420C8D0CC6F38B80D6733"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51024678e1856-wk-Fact-5EAFAAB3B2572C26BBA06F38B7EA7D38"
      unitRef="usd">476000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d51024678e1886-wk-Fact-143ECF7427AA746C048C6F38B8464756"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d51024678e1905-wk-Fact-10ABBE83A8CD22353A3D6F38B84E6240"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d51024678e1925-wk-Fact-143ECF7427AA746C048C6F38B8464756"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d51024678e1944-wk-Fact-1F10FFA1F2C8C13051306F38B8206FF5"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d51024678e1963-wk-Fact-F1D7727F1F9A9CBF64B26F38B7E00E1F"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d51024678e1983-wk-Fact-1F10FFA1F2C8C13051306F38B8206FF5"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51024678e2018-wk-Fact-FC57B6818DAB358EB31C6F38B86B69CD"
      unitRef="usd">8408800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51024678e2037-wk-Fact-20A8E4232234AAE424EB6F38B7DC7954"
      unitRef="usd">4881400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51024678e2058-wk-Fact-4AD21CB6B4B90431AF316F38B8BC8BF4"
      unitRef="usd">3527400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51024678e2077-wk-Fact-99E7A6571B58CD4405F86F38B7BBCE7A"
      unitRef="usd">7727300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51024678e2096-wk-Fact-DDF87F45F2B80791E2666F38B8857B3B"
      unitRef="usd">4607300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51024678e2117-wk-Fact-0B06E7AFD52116E2A95B6F38B8B9E33F"
      unitRef="usd">3120000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51024678e2139-wk-Fact-79F73778C54DE73C4DD76F38B881C966"
      unitRef="usd">489900000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51024678e2143-wk-Fact-81104360B4FDD747DCD66F38B87FA895"
      unitRef="usd">747300000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51024678e2147-wk-Fact-0248BA74606E7D1238426F38B833F6BA"
      unitRef="usd">814700000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51024678e2164-wk-Fact-D74A6CDB288794BC843EE882FF86C7CA"
      unitRef="usd">274000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51024678e2168-wk-Fact-80A6F7EEED667976781BE88369CFD305"
      unitRef="usd">381200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51024678e2172-wk-Fact-2C139FCC0AA67C2038C4E883A392B032"
      unitRef="usd">455300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51024678e2196-wk-Fact-C90610768443E1F0F6317F831C0B9606"
      unitRef="usd">215900000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51024678e2207-wk-Fact-6D50742932615A5BE2716F38B844A09D"
      unitRef="usd">189300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d51024678e2222-wk-Fact-A4EB1ECE5775B27307D9E884A2D18D59"
      unitRef="usd">176800000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d51024678e2226-wk-Fact-7597E590B93FBF39E3386F38B81E1927"
      unitRef="usd">328200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-8"
      id="d51024678e2244-wk-Fact-A9F80EBA5C2DA997D16C6F38B8AF1792"
      unitRef="usd">1800000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="FD2019Q4QTD_srt_ProductOrServiceAxis_biib_VUMERITYMember"
      decimals="-5"
      id="d51024678e2251-wk-Fact-FAF3E384D38C467CBFA2E884F0FC95D7"
      unitRef="usd">155000000.0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="FD2017Q1QTD"
      decimals="-7"
      id="d51024678e2261-wk-Fact-13472D8C1D1B9AD94363E88565015CFA"
      unitRef="usd">1250000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q1_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d51024678e2265-wk-Fact-8C83B763FE15C49AD3ECE885D34DF5DF"
      unitRef="usd">795200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d51024678e2275-wk-Fact-7597E590B93FBF39E3386F38B81E1927"
      unitRef="usd">328200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d51024678e2279-wk-Fact-A4EB1ECE5775B27307D9E884A2D18D59"
      unitRef="usd">176800000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d51024678e2293-wk-Fact-E4C1FC14499CDABFA6306F38B81DCCAE"
      unitRef="usd">36100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51024678e2329-wk-Fact-82604D074397E99D730A7EE181675AC1"
      unitRef="usd">700000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51024678e2343-wk-Fact-C90610768443E1F0F6317F831C0B9606"
      unitRef="usd">215900000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member"
      decimals="-5"
      id="d51024678e2347-wk-Fact-96B220D7911BA8C5D11B7F8F096174C3"
      unitRef="usd">61200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_PLSRMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51024678e2357-wk-Fact-6B94FF0E1EF87647F2456F38B81FA37B"
      unitRef="usd">60000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51024678e2364-wk-Fact-62518CD3536763C588746F38B8229656"
      unitRef="usd">129300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q3_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51024678e2368-wk-Fact-92077CE971E61FD7333E6F38B8AF7674"
      unitRef="usd">41800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9C8568245F5583FE04CA6F38B8E0A841-0-wk-Fact-4F83D5382DABAFFA03906F38B8B1EE25">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;260.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;225.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;230.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51024678e2443-wk-Fact-200089F11B8DA6B74B1D6F38B7F70E07"
      unitRef="usd">260000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51024678e2458-wk-Fact-0F163071339723968F596F38B7F8F5C1"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51024678e2478-wk-Fact-395237A1C58F7524DD016F38B7F70B84"
      unitRef="usd">225000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51024678e2498-wk-Fact-61656FE5DD1FDCA426E56F38B7F85E81"
      unitRef="usd">230000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51024678e2518-wk-Fact-747F3B69343A6D3953D56F38B7F78A97"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7EB297BCF3C73DE434486F38B8E1B425-0-wk-Fact-3D58A57FA90251447EE66F38B7C59CA4">&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,706.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,632.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;117.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,080.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Elimination of goodwill allocated to Hiller&#xf8;d, Denmark manufacturing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(69.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,757.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,706.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51024678e2665-wk-Fact-E7AAD5AF93A3B138C23D6F38B839DA15"
      unitRef="usd">5706400000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51024678e2684-wk-Fact-0953C5B7CA793B642E7F6F38B875B561"
      unitRef="usd">4632500000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51024678e2699-wk-Fact-71020C1F7736B6CF6FC66F38B7AFB71D"
      unitRef="usd">117500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51024678e2718-wk-Fact-E0120A450E5719C33F066F38B87FFF71"
      unitRef="usd">1080100000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51024678e2738-wk-Fact-70778140A835211D559A6F38B8C700DB"
      unitRef="usd">69500000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51024678e2758-wk-Fact-3F4BF4DDAF919884DABA6F38B7A73815"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51024678e2778-wk-Fact-666206ACF5FD1CF8210E6F38B7AF1BAD"
      unitRef="usd">3400000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51024678e2797-wk-Fact-3BE55DA4EB7A677936746F38B7A3DB52"
      unitRef="usd">-6200000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51024678e2823-wk-Fact-0B1007097B5E08446E1E6F38B840631D"
      unitRef="usd">5757800000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51024678e2842-wk-Fact-E7AAD5AF93A3B138C23D6F38B839DA15"
      unitRef="usd">5706400000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember"
      decimals="-8"
      id="d51024678e2876-wk-Fact-B14BB1896D500B5349FE6F38B8285E65"
      unitRef="usd">1200000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember"
      decimals="-5"
      id="d51024678e2880-wk-Fact-B7E679FB7C54BDBC9E4C6F38B8383EBD"
      unitRef="usd">119900000</us-gaap:IncomeTaxExpenseBenefit>
    <biib:CumulativeSalesLevel
      contextRef="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember"
      decimals="-8"
      id="d51024678e2884-wk-Fact-52F3177A7113406F4A0D6F38B8263878"
      unitRef="usd">20000000000.0</biib:CumulativeSalesLevel>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember"
      decimals="-5"
      id="d51024678e2888-wk-Fact-00B4683AD08C54F6AB9A0C84CED65C99"
      unitRef="usd">300000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="FI2019Q4"
      decimals="-6"
      id="d51024678e2906-wk-Fact-75282F562CB5B1A31AA16F38B8685406"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-17926427357AC9421FAF6F38B8E1A3F8-0-wk-Fact-39C1B03C36FAA051D4B46F38B8682FFE">Fair Value Measurements&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&#160;1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&#160;2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,695.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,695.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,013.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,013.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;261.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;261.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;337.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;329.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;43.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;43.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,920.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,912.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;354.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&#160;Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,459.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,459.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;969.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;969.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;615.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;563.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,102.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,050.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;434.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There have been &lt;/span&gt;&lt;span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or transfers between fair value measurement levels during the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our collaboration arrangements with Ionis, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies - Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,509.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,489.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,038.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,897.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,745.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,107.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,802.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6,553.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,037.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence, Stromedix and BIN in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;523.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(63.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(12.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(101.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$197.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$265.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of IPF resulting in a reduction of our contingent consideration obligations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$61.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, partially offset by changes in the probability and expected timing of achievement of certain developmental milestones, a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of achievement of milestones related to the TGN program and an increase in discount rates used to revalue our contingent consideration liabilities, partially offset by the passage of time. For the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, payments and other reflects an &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$81.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment made to the former shareholders of Stromedix. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of the contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read Note 1, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Convergence Pharmaceuticals Holdings Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$274.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$244.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$246.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon net cash flow projections of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$400.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, probability weighted and discounted using a rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net decrease in our contingent consideration obligation was primarily due to changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones, partially offset by a decrease in discount rates used to revalue our contingent consideration liabilities and the passage of time. Accrued expenses and other in our consolidated balances sheets include &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$148.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as we expect to make the payment within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Stromedix Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Stromedix in March 2012 we recorded a contingent consideration obligation of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$122.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF due to safety concerns. As a result, we adjusted the fair value of this contingent consideration obligation to zero, resulting in a gain of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$61.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the third quarter of 2019. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$83.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Biogen Idec International Neuroscience GmbH&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$81.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$101.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$80.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon net cash outflow projections of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$335.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, probability weighted and discounted using a rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net increase in our contingent consideration obligation was primarily due to changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones, a decrease in discount rates used to revalue our contingent consideration liabilities and the passage of time. No amounts are reflected as a current liability in our consolidated balance sheets at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as we do not expect to make a payment in the next year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of the acquired IPR&amp;amp;D assets were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. These assets are tested for impairment annually until commercialization, after which time the acquired &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D will be amortized over its estimated useful life using the economic consumption method. In connection with our acquisition of Stromedix, we recognized a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$219.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; acquired IPR&amp;amp;D intangible asset. During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF due to safety concerns and recognized an impairment charge of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$215.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reduce the fair value of the IPR&amp;amp;D intangible asset to zero. In connection with our acquisition of Convergence we recognized a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$424.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; acquired IPR&amp;amp;D intangible asset. During the third quarter of 2018 we recognized impairment charges related to certain IPR&amp;amp;D assets associated with our vixotrigine program totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$189.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on our IPR&amp;amp;D intangible assets, including a discussion of our most significant assumptions, please read Note 6, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D18453EBD284594A49C06F38B8E12CD3-0-wk-Fact-382434371F926A3C1E126F38B8842AE2">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&#160;1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&#160;2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,695.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,695.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,013.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,013.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;261.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;261.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;337.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;329.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;43.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;43.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,920.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,912.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;354.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&#160;Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,459.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,459.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;969.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;969.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;615.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;563.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,102.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,050.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;434.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1538-wk-Fact-EC9258146D77A8509D4A6F38B85AB46E"
      unitRef="usd">2541100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1557-wk-Fact-C0EDD3E1836D4F554E976F38B8512EB6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1576-wk-Fact-F6993B6A07451D31C2816F38B852F514"
      unitRef="usd">2541100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1596-wk-Fact-D9D82276CB0A34D035ED6F38B84D887D"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1693-wk-Fact-EE2725F5ABCD06330BDB6F38B850343B"
      unitRef="usd">1695100000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1712-wk-Fact-7DDF33C226B4FEA28B356F38B890358B"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1731-wk-Fact-C1B61E94DB40BA9C1EF86F38B84FA38C"
      unitRef="usd">1695100000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1751-wk-Fact-0AB90965DA3A51E629136F38B8520920"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1771-wk-Fact-BB81D28A818D61B7F9C56F38B853BBCB"
      unitRef="usd">1013900000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1790-wk-Fact-ECE628EF0E7F5557F9EA6F38B85436D4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1809-wk-Fact-C47E75F1901532A2D33E6F38B88DA9FF"
      unitRef="usd">1013900000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1829-wk-Fact-73A593FB899D23F0F6FA6F38B85E868A"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1849-wk-Fact-CDC833E9D8E5798F6C086F38B85A1A4E"
      unitRef="usd">261300000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1868-wk-Fact-0E0227789BD7E61B7CBE6F38B85350F1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1887-wk-Fact-38B96DB4487EB6D0D6506F38B88F5211"
      unitRef="usd">261300000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1907-wk-Fact-AFA9B75D9FCFA0C4CD4E6F38B855801F"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1927-wk-Fact-75BD645E58686BC7DF086F38B88E19D3"
      unitRef="usd">337500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1946-wk-Fact-148D6A4A23ED02B89C5F6F38B84C8D5C"
      unitRef="usd">7900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1965-wk-Fact-82305A531B9DADFE49596F38B892A48C"
      unitRef="usd">329600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e1985-wk-Fact-8080A8035109E43370386F38B8563DF1"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2005-wk-Fact-FC186D031C3543E76EDD6F38B85939A1"
      unitRef="usd">43800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2024-wk-Fact-27E2FED8EF080B4CEF2C6F38B852EDCE"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2043-wk-Fact-569815B4283E15978A5D6F38B8507840"
      unitRef="usd">43800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2063-wk-Fact-D382C2D4C27C1B6563F36F38B88FD6DC"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2083-wk-Fact-F49B5B9071D0CE36CFCB6F38B851A3D9"
      unitRef="usd">27700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2102-wk-Fact-152F682FD573AD841C476F38B84C7C97"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2121-wk-Fact-7C26DE24B15654FB9BA76F38B88F8D37"
      unitRef="usd">27700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2141-wk-Fact-5F904C78B213E79C53C16F38B8911ED8"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2166-wk-Fact-BBAF8FE2318EE27C5ECB6F38B85B60F7"
      unitRef="usd">5920400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2185-wk-Fact-C689AE60EC7AFC7E85BC6F38B84ED892"
      unitRef="usd">7900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2204-wk-Fact-FFDDF10B2C1E2AAA6A206F38B84F3259"
      unitRef="usd">5912500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2224-wk-Fact-4D7CEA22B015CD4196D66F38B85209EB"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2327-wk-Fact-8C6CF39828C652CAA4A06F38B88EF8CD"
      unitRef="usd">8300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2346-wk-Fact-6334288060FBC89E46266F38B85A34FC"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2365-wk-Fact-0FD9268BA3776F2B89016F38B851368A"
      unitRef="usd">8300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2385-wk-Fact-E76ACDF87C147D10A42C6F38B854110E"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2400-wk-Fact-A10F6A8B85523CF3F7F86F38B84D8473"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2419-wk-Fact-C12EE914E4EAC5A9C0656F38B84C0FE8"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2438-wk-Fact-67DE65816E41FA577CCB6F38B851EBC9"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2458-wk-Fact-98019CA6F4F46E58F06A6F38B84EAD9F"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2483-wk-Fact-C330140DBC1BE65A98526F38B8540F0A"
      unitRef="usd">354400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2502-wk-Fact-BE5B60068B92D653D43A6F38B851DCA9"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2521-wk-Fact-55BFF459F1207C4E5E6B6F38B8501D48"
      unitRef="usd">8300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2541-wk-Fact-51F232D0E20F8EB1419C6F38B85416BC"
      unitRef="usd">346100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2782-wk-Fact-7066379BD1A122AE212C6F38B7FF4D18"
      unitRef="usd">705500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2801-wk-Fact-1FC555EC02578EFE4E236F38B7A5D468"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2820-wk-Fact-A18D399B01FAF16D4A736F38B7F4F29D"
      unitRef="usd">705500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2840-wk-Fact-AEC23130A93B349F00636F38B7FA8322"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2937-wk-Fact-DC0AECE32297AC1D00136F38B8153FBA"
      unitRef="usd">2459200000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2956-wk-Fact-632D7F1114B4609849D36F38B80FE9AF"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2975-wk-Fact-CB17C242A467DB7596436F38B8853B59"
      unitRef="usd">2459200000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e2995-wk-Fact-F0814ACED7E8DBD5D5436F38B810DDE0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3015-wk-Fact-FD6242F3725B6137E3E96F38B8B9F6F1"
      unitRef="usd">969600000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3034-wk-Fact-655F2172AC92567F2F5B6F38B7ADB408"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3053-wk-Fact-EDBEA891E156890AEE0B6F38B7B2B15A"
      unitRef="usd">969600000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3073-wk-Fact-4614A717FC48F3D890BE6F38B8B0297B"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3093-wk-Fact-8DFC21527B6A71EF8CC56F38B809EA4D"
      unitRef="usd">260500000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3112-wk-Fact-A3C922C7F774CC6E33986F38B8B528FB"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3131-wk-Fact-1EEBD29C1636DC3AD73A6F38B7F6FC21"
      unitRef="usd">260500000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3151-wk-Fact-3C29A0E494BD1CCE09066F38B7B0DAB0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3171-wk-Fact-02629FE4358DD9094CCE6F38B7ACADD3"
      unitRef="usd">615400000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3190-wk-Fact-18F308766DE279481A656F38B7A8867C"
      unitRef="usd">51700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3209-wk-Fact-C615210C0C666FD0FB676F38B866E20F"
      unitRef="usd">563700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3229-wk-Fact-EDB6E812C8742BD336E46F38B7B2ABA8"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3249-wk-Fact-61EC83DAACBFB9B470886F38B7E4DB90"
      unitRef="usd">66900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3268-wk-Fact-544258B85EA2A94192166F38B8839BA6"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3287-wk-Fact-140AE2CF9DDD5779CDA56F38B80F5E13"
      unitRef="usd">66900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3307-wk-Fact-2CC73AD2FCBFD5E279876F38B7AECD84"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3327-wk-Fact-2F2C777FB878339C66176F38B7B3A968"
      unitRef="usd">25400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3346-wk-Fact-FA109492FEBA88B300696F38B8116A5C"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3365-wk-Fact-C22AADAA8DBB01CE21DE6F38B813B895"
      unitRef="usd">25400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3385-wk-Fact-F4AF2B25A8E7DCC31D826F38B8BE8F7B"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3410-wk-Fact-AA67EA863E25380A58166F38B7A76C3B"
      unitRef="usd">5102500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3429-wk-Fact-BE71513E9CA27ADFC3866F38B810644A"
      unitRef="usd">51700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3448-wk-Fact-81EDECD226AA6FBF647F6F38B7B3CF78"
      unitRef="usd">5050800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3468-wk-Fact-30E8FDFFD51F491BA6236F38B7B5B93D"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3571-wk-Fact-03E95DF04DD8C94FACFC6F38B7AC6B61"
      unitRef="usd">24600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3590-wk-Fact-24A4920ADE5088A089046F38B80D45A2"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3609-wk-Fact-5D8FBC53D5A9017C794D6F38B7E5F1B1"
      unitRef="usd">24600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3629-wk-Fact-E78A97B2CE06EC055E3D6F38B7AB700A"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3644-wk-Fact-4CBE27413C3EDEA117916F38B7AB7C4F"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3663-wk-Fact-C6760C7C98C35A581B576F38B816A4D7"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3682-wk-Fact-9EA89F642293CDE2C3466F38B7A8EB74"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3702-wk-Fact-A7480D911796580F012E6F38B883744D"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3727-wk-Fact-E21BB8206966B528A1A96F38B7B96660"
      unitRef="usd">434400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3746-wk-Fact-F33FB8DF7F99068F43606F38B7A7707B"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3765-wk-Fact-1B00161C63AA6B85F13F6F38B80E7CA4"
      unitRef="usd">24600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e3785-wk-Fact-581739A6C39ADF7DBDB96F38B800E5CF"
      unitRef="usd">409800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs
      contextRef="FD2019Q4YTD"
      id="d51035532e3803-wk-Fact-4D4C5D0C76D36F50A349F0A34ECC1A00">no</us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-BE2A1D4443B5D4661F4F6F38B8E1C53A-0-wk-Fact-B0702C79A1D818C1BAF56F38B7E83F89">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,509.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,489.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,038.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,897.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,745.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,107.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,802.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6,553.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,037.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d51035532e3955-wk-Fact-C42B399BF1898948B2D86F38B891F112"
      unitRef="usd">1509600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d51035532e3974-wk-Fact-B3B52DE23849508B0B4E6F38B8913386"
      unitRef="usd">1489500000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d51035532e3989-wk-Fact-D2B809557FDB244752996F38B8947CAC"
      unitRef="usd">1038900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d51035532e4008-wk-Fact-05177D675BB7590DA7426F38B89015AE"
      unitRef="usd">1000400000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d51035532e4028-wk-Fact-4E62F59C14B398A4E6BD6F38B89235A4"
      unitRef="usd">1897200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d51035532e4047-wk-Fact-BDFDE0697E29B5C39B0B6F38B8901FF9"
      unitRef="usd">1745100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d51035532e4067-wk-Fact-D76875A72D97919255A46F38B8928CA8"
      unitRef="usd">2107900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d51035532e4086-wk-Fact-739E99003183BF386DF16F38B8901AF8"
      unitRef="usd">1802600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51035532e4111-wk-Fact-B67478805A82134060856F38B892A4C8"
      unitRef="usd">6553600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51035532e4130-wk-Fact-69AB32B1F3AAD4D403D96F38B890B442"
      unitRef="usd">6037600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F8B83E8D25CA0D0309176F38B8E19FEE-0-wk-Fact-C60548148E5F11FC19416F38B81DD489">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;523.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(63.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(12.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(101.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e4271-wk-Fact-4CBE27413C3EDEA117916F38B7AB7C4F"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e4290-wk-Fact-E13D65BE0BFFDEB212A06F38B83B8926"
      unitRef="usd">523600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51035532e4305-wk-Fact-1823324BEE5AA206F4236F38B832A514"
      unitRef="usd">63700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51035532e4325-wk-Fact-977CCFE1B549EEAAE2F26F38B8745977"
      unitRef="usd">12300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51035532e4346-wk-Fact-1C082769A24C4F5A17026F38B83DA9E5"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51035532e4365-wk-Fact-6B14B2072094EAE02A5D6F38B83CD501"
      unitRef="usd">101500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e4391-wk-Fact-A10F6A8B85523CF3F7F86F38B84D8473"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d51035532e4410-wk-Fact-4CBE27413C3EDEA117916F38B7AB7C4F"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-5"
      id="d51035532e4438-wk-Fact-0107656A82B694AD32DF6F38B8315091"
      unitRef="usd">197700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2018Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-5"
      id="d51035532e4442-wk-Fact-572C4D0ED257CDB07A6E6F38B81D2A82"
      unitRef="usd">265000000.0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member"
      decimals="-5"
      id="d51035532e4456-wk-Fact-96B220D7911BA8C5D11B7F8F096174C3"
      unitRef="usd">61200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember"
      decimals="-5"
      id="d51035532e4471-wk-Fact-920EF404A5465C38E5D86F38B824C4C0"
      unitRef="usd">-81500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember"
      decimals="-5"
      id="d51035532e4488-wk-Fact-30E2D56393376CCAD3CF6F38B82E36B2"
      unitRef="usd">274500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember"
      decimals="-5"
      id="d51035532e4500-wk-Fact-BE914F8B9FEE22331A776F38B81E88FB"
      unitRef="usd">244600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember"
      decimals="-5"
      id="d51035532e4504-wk-Fact-867A7DC3CFA3B0DF94256F38B8226B63"
      unitRef="usd">246600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember"
      decimals="-5"
      id="d51035532e4509-wk-Fact-54A6AF67038662FE8BCE6F38B8A1038C"
      unitRef="usd">400000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <biib:FairValueMeasurementInputs
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="INF"
      id="d51035532e4513-wk-Fact-1D4B0CA927D10DE2CE256F38B8246AE3"
      unitRef="number">0.021</biib:FairValueMeasurementInputs>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember"
      decimals="-5"
      id="d51035532e4528-wk-Fact-06F8823C5C30121355FB6F38B859ABAE"
      unitRef="usd">148500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="FD2012Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember"
      decimals="-5"
      id="d51035532e4538-wk-Fact-724C1824631E20BDD6C76F38B86D0976"
      unitRef="usd">122200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member"
      decimals="-5"
      id="d51035532e4542-wk-Fact-96B220D7911BA8C5D11B7F8F096174C3"
      unitRef="usd">61200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember"
      decimals="-5"
      id="d51035532e4550-wk-Fact-793CC6F3B179192134706F38B88D3F53"
      unitRef="usd">83000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="FD2010Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember"
      decimals="-5"
      id="d51035532e4561-wk-Fact-B8D8A4EABED9B5C813466F38B84B025D"
      unitRef="usd">81200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember"
      decimals="-5"
      id="d51035532e4573-wk-Fact-9F894064E55EE73F5EA86F38B7E64F02"
      unitRef="usd">101500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember"
      decimals="-5"
      id="d51035532e4577-wk-Fact-49A54CE2D062190C77266F38B85A20C6"
      unitRef="usd">80200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember"
      decimals="-5"
      id="d51035532e4582-wk-Fact-DB35B8C424CD465606046F38B82E6ED4"
      unitRef="usd">335000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <biib:FairValueMeasurementInputs
      contextRef="FI2019Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="INF"
      id="d51035532e4586-wk-Fact-8A658ABCA5EFAB81986B6F38B82A37A9"
      unitRef="number">0.023</biib:FairValueMeasurementInputs>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="FI2012Q1_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember"
      decimals="-5"
      id="d51035532e4614-wk-Fact-FE43F80CB27D3FFF9E0D93D1315B1342"
      unitRef="usd">219200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51035532e4618-wk-Fact-C90610768443E1F0F6317F831C0B9606"
      unitRef="usd">215900000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember"
      decimals="-5"
      id="d51035532e4622-wk-Fact-76351957F1E1DE2032BB6F38B7E3ACBA"
      unitRef="usd">424600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51035532e4626-wk-Fact-6D50742932615A5BE2716F38B844A09D"
      unitRef="usd">189300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C333F93EB0D11B0846F16F38B8E2A9CE-0-wk-Fact-E143E08BEEF1049774636F38B8B46C63">Financial Instruments&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of &lt;/span&gt;&lt;span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;less than 90&#160;days&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;384.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;231.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;368.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,628.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;279.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;159.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;194.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities gains (losses) are recorded in other income (expense), net in our consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,057.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,058.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;633.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;636.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;502.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;503.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;510.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;510.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;260.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;260.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,965.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,970.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;218.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;132.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(13.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;337.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,608.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,607.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;854.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;851.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;706.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;264.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;263.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,694.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,689.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;496.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;127.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;615.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&#160; Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&#160; Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,562.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,560.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,313.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,314.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,234.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,230.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,232.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,235.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;173.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;173.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,970.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,965.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,689.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,694.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;months and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6,007.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,173.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,565.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily relate to impairments recognized on certain of our available-for-sale marketable debt securities, sales of agency mortgage-backed securities, corporate bonds and government securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$393.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which are included in investments and other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;  Our investments in equity securities include shares of Ionis common stock acquired in June 2018. This investment is classified as a Level 2 marketable security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effect of the holding period restrictions on our investment in Ionis common stock valuation are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends. The remainder of our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The decrease in our strategic investment portfolio for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily reflects our sale of a portion of our investment in Ionis common stock for approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$382.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as well as our sale of our investment in a non-marketable equity security, partially offset by an increase in the fair value of our remaining investment in Ionis common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the June 2018 investment in Ionis common stock, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2018 we exercised our option under our joint venture agreement with Samsung BioLogics to increase our ownership percentage in Samsung Bioepis from approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investment in Samsung Bioepis totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;670.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$580.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$680.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), respectively, which is classified as a component of investments and other assets within our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B5F7DFAC0C3D284D63E56F38B8E196EF-0-wk-Fact-E55C97626BB3026608AC6F38B8B75180">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of &lt;/span&gt;&lt;span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;less than 90&#160;days&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;384.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;231.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;368.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,628.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;279.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;159.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;194.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="FD2019Q4YTD"
      id="d51044137e1304-wk-Fact-8231AA510DC926D15A2D6F38B8B1428F">less than 90&#160;days</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-5"
      id="d51044137e1424-wk-Fact-BD1F39C0A6E101800CF06F38B8029320"
      unitRef="usd">384400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-5"
      id="d51044137e1443-wk-Fact-DF3C5F781F9601E153906F38B7FE33BE"
      unitRef="usd">231200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember"
      decimals="-5"
      id="d51044137e1458-wk-Fact-DD6060CCFB1172CE3C8A6F38B8047EC4"
      unitRef="usd">368800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember"
      decimals="-5"
      id="d51044137e1477-wk-Fact-4D359C9051066803D9AE6F38B7FC0023"
      unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      id="d51044137e1497-wk-Fact-995379A87E623A9C8B356F38B7FF1B2D"
      unitRef="usd">1628500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      id="d51044137e1516-wk-Fact-BC251230685EC89EFFA16F38B7FEA342"
      unitRef="usd">279500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember"
      decimals="-5"
      id="d51044137e1536-wk-Fact-8E93462D8487551B1DC66F38B803C15B"
      unitRef="usd">159400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember"
      decimals="-5"
      id="d51044137e1555-wk-Fact-A22A1FC75E3FB4DD217E6F38B8030BA2"
      unitRef="usd">194800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e1580-wk-Fact-357953AE9799FBE6CE586F38B7FD6616"
      unitRef="usd">2541100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e1599-wk-Fact-72F8FDC4D34E0E09E26F6F38B7FD5F30"
      unitRef="usd">705500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5A72E2605693FD043BEE6F38B8E2854D-0-wk-Fact-C5D1DA78D6A047029F2B6F38B8B5AECD">The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,057.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,058.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;633.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;636.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;502.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;503.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;510.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;510.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;260.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;260.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,965.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,970.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;218.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;132.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(13.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;337.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,608.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,607.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;854.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;851.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;706.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;264.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;263.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,694.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,689.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;496.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;127.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;615.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e1847-wk-Fact-499BCBCDFA7161162B7B6F38B8C2A23D"
      unitRef="usd">1057200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e1866-wk-Fact-E1640AC93A688483020D6F38B8BB439D"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e1885-wk-Fact-2BF9EE5393947905DEF16F38B8BD1C98"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e1905-wk-Fact-72BE606195F640491DD36F38B8B733F8"
      unitRef="usd">1058200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e1920-wk-Fact-DCA62FB5A695DF208DC96F38B8BE8ABF"
      unitRef="usd">633900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e1939-wk-Fact-F2F305B920B30862AAA46F38B8BB8F9D"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e1958-wk-Fact-0EAED0B47CFCBAD00CCC6F38B8BE2693"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e1978-wk-Fact-8BFED5455B9C725819236F38B8B8CD8D"
      unitRef="usd">636900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e2080-wk-Fact-B5ECD264FC84041711ED6F38B8B78097"
      unitRef="usd">502900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e2099-wk-Fact-D9610289F4D33C55FFF56F38B8B603A4"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e2118-wk-Fact-0125DCCA5F45BBCC43246F38B8B6FCFA"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e2138-wk-Fact-AC67B65856A432CC36C66F38B8BB83A8"
      unitRef="usd">503300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e2158-wk-Fact-61A5E1A99439DE57C5E36F38B8BC9487"
      unitRef="usd">510100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e2177-wk-Fact-FADD5F5B48CAB54CDBE86F38B8BDC234"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e2196-wk-Fact-B4D502692B65FBEA76216F38B8B9F58E"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e2217-wk-Fact-399A53AA1C7B57A139E36F38B8BD97DD"
      unitRef="usd">510600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e2319-wk-Fact-037C5769F3CB157047D56F38B8BC38A5"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e2338-wk-Fact-EEDBF86DFD6E6DF594F16F38B8B72B9E"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e2357-wk-Fact-ADF496AAE7893D618D8C6F38B8B8FB8F"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e2377-wk-Fact-B48911120D075BFD3A9D6F38B8B815DB"
      unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e2397-wk-Fact-D451502CBFF668E854066F38B8B6FB61"
      unitRef="usd">260200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e2416-wk-Fact-FFDB8024DA8C692EDFF96F38B8B7614D"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e2435-wk-Fact-A025048BE07F39FDF5336F38B8BA1A78"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e2456-wk-Fact-0BB584C0303018C7AD6C6F38B8BC7BC3"
      unitRef="usd">260600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e2481-wk-Fact-F9D36A0CB178A1F1D6766F38B7EC70D8"
      unitRef="usd">2965000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e2500-wk-Fact-A6EDAB71C71AC15906D46F38B8BACFAD"
      unitRef="usd">6000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e2519-wk-Fact-8750CE4F362D33737E1C6F38B8BA7F39"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e2540-wk-Fact-09218CCAD46CA9CF6A4C6F38B86B23BF"
      unitRef="usd">2970300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d51044137e2561-wk-Fact-CDB6C6B5B81A1C186FCB6F38B8B865A5"
      unitRef="usd">218400000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d51044137e2580-wk-Fact-C5F1FB95DB08B92097976F38B8B8D668"
      unitRef="usd">132100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d51044137e2599-wk-Fact-B5A9831670533F21DE9C6F38B8BCD2CB"
      unitRef="usd">13000000.0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d51044137e2620-wk-Fact-26E2C7EA882598294EFC6F38B8BA256B"
      unitRef="usd">337500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e2846-wk-Fact-80F3CAB0D5F744F370C36F38B89EE9AD"
      unitRef="usd">1608400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e2865-wk-Fact-360611FC5D942991413A6F38B89E8CA6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e2884-wk-Fact-E89DE0338FD1F58C5B656F38B89893ED"
      unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e2905-wk-Fact-CB2E3F7E5FE62BF1896A6F38B8A20697"
      unitRef="usd">1607500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e2920-wk-Fact-F1D6C18E812A0BF007336F38B89ED934"
      unitRef="usd">854900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e2939-wk-Fact-81D0D887B4A7804D91F06F38B89D15D5"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e2958-wk-Fact-DC230E025AEB8132D23C6F38B89F5719"
      unitRef="usd">3900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e2979-wk-Fact-45B824EA7434337FF27B6F38B892D649"
      unitRef="usd">851700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e3081-wk-Fact-FA72D75A8CCEEF7E57196F38B89E2253"
      unitRef="usd">706100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e3100-wk-Fact-1BC4EBAA2F4F4EA705906F38B892D761"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e3119-wk-Fact-6ABEA62478C33DF326A56F38B89611FE"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e3140-wk-Fact-4F0323AC2FDD3D7A3BF56F38B8940D02"
      unitRef="usd">705800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e3160-wk-Fact-38F396ADBA1C8634B5636F38B89C4151"
      unitRef="usd">264000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e3179-wk-Fact-5868C1668606EF0682106F38B89389A2"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e3198-wk-Fact-B46981E1891E0618C6D36F38B89BD766"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e3219-wk-Fact-27B11F2D7A6A920E511A6F38B8953529"
      unitRef="usd">263800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e3321-wk-Fact-EEAED65C2D12FC36748A6F38B898A436"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e3340-wk-Fact-904214979D307A17D3416F38B895E2A7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e3359-wk-Fact-20A25FC23E278823D8DC6F38B896123C"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d51044137e3379-wk-Fact-CDEA0C0C71658E6E63056F38B8972AF7"
      unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e3399-wk-Fact-54D22EFA48C2C609B7FA6F38B8A0B5B8"
      unitRef="usd">260500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e3418-wk-Fact-200BCC83220232E9105C6F38B895A6C8"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e3437-wk-Fact-2918168DB16D901EFC366F38B897C5E2"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d51044137e3458-wk-Fact-7F1A94F3577CE236BC216F38B8A0EB34"
      unitRef="usd">260400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e3483-wk-Fact-8011E5D75A472C102B556F38B86C2B35"
      unitRef="usd">3694000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e3502-wk-Fact-9658045F6AE0A83E6BCA6F38B896BA8B"
      unitRef="usd">1300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e3521-wk-Fact-344C4E37506D463167EE6F38B893B426"
      unitRef="usd">6000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e3542-wk-Fact-DA378162924C6E8185866F38B867BA25"
      unitRef="usd">3689300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d51044137e3563-wk-Fact-9A1781D4961FADC5DD8F6F38B8A04118"
      unitRef="usd">496200000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d51044137e3582-wk-Fact-1F943AC009C6CA9CB8306F38B89C969E"
      unitRef="usd">127700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d51044137e3601-wk-Fact-EA583EB5D882938547046F38B89F85AC"
      unitRef="usd">8500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d51044137e3622-wk-Fact-4A497BE42A7A0770B68A6F38B89F6DDF"
      unitRef="usd">615400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E99A927E3431E726A7196F38B8E24431-0-wk-Fact-D097DFA1546017030E2A6F38B8B62ED1">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&#160; Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&#160; Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,562.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,560.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,313.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,314.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,234.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,230.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,232.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,235.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;173.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;173.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,970.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,965.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,689.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,694.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e3860-wk-Fact-8E7C177DAA02C71040B26F38B86AD9EF"
      unitRef="usd">1562200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e3879-wk-Fact-88C164EEF8973C79F5206F38B86A35F6"
      unitRef="usd">1560800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e3898-wk-Fact-EBE178038FF6C4118D6D6F38B86B3749"
      unitRef="usd">2313400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e3918-wk-Fact-DAD4020BCE622F9576F56F38B8674CC9"
      unitRef="usd">2314600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e3933-wk-Fact-4945B89ECB0F351F61A36F38B86B73CB"
      unitRef="usd">1234500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e3952-wk-Fact-CEE7E030A0D8B5A888B56F38B869CCA1"
      unitRef="usd">1230400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e3971-wk-Fact-E25B7DE7CFEC25358FB16F38B8603BE6"
      unitRef="usd">1232700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e3991-wk-Fact-7937243CF0F75852BFF56F38B8691A7F"
      unitRef="usd">1235900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e4011-wk-Fact-6A0F20E0E0A5CDFE5E426F38B86912AC"
      unitRef="usd">173600000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e4030-wk-Fact-1D77144E73C658D1A2126F38B7EDDC04"
      unitRef="usd">173800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e4049-wk-Fact-59F5101A3A2879A604296F38B86CC09D"
      unitRef="usd">143200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e4069-wk-Fact-0166A7986CBB236C34DA6F38B8658555"
      unitRef="usd">143500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e4094-wk-Fact-09218CCAD46CA9CF6A4C6F38B86B23BF"
      unitRef="usd">2970300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044137e4113-wk-Fact-F9D36A0CB178A1F1D6766F38B7EC70D8"
      unitRef="usd">2965000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e4132-wk-Fact-DA378162924C6E8185866F38B867BA25"
      unitRef="usd">3689300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044137e4152-wk-Fact-8011E5D75A472C102B556F38B86C2B35"
      unitRef="usd">3694000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="FD2019Q4YTD"
      id="d51044137e4179-wk-Fact-F3EC85F2D74FFA7E1C696F38B8B296F4">P14M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="FD2018Q4YTD"
      id="d51044137e4183-wk-Fact-9217D82551BA1B54B6CE6F38B8B48AE5">P12M</biib:AverageMaturityOfMarketableSecurities>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-021208C0A949526AE3736F38B8E1D49E-0-wk-Fact-0B7A6EB4995D768455936F38B8B379DB">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6,007.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,173.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,565.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51044137e4359-wk-Fact-9B2BAA05E503864359F46F38B864558E"
      unitRef="usd">6007000000.0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51044137e4378-wk-Fact-91236B58E7640EF128CE6F38B7B34236"
      unitRef="usd">9173700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51044137e4397-wk-Fact-D3A23249D5697F1852396F38B7BFFC17"
      unitRef="usd">5565900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51044137e4418-wk-Fact-3B95433C7554C0E3DCC46F38B7B110E9"
      unitRef="usd">6000000.0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51044137e4437-wk-Fact-FCAFA4592669D8A91F486F38B7B0CD63"
      unitRef="usd">3200000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51044137e4456-wk-Fact-E33EA6F236DF1BABE4076F38B7B2BDC5"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51044137e4477-wk-Fact-4CCC5518040988ACF0376F38B7B359BF"
      unitRef="usd">1500000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51044137e4496-wk-Fact-BE272356E0A1EA689E236F38B7B03644"
      unitRef="usd">11700000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51044137e4515-wk-Fact-976E7CF53C8B41C98F856F38B7B0841C"
      unitRef="usd">22400000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
    <biib:StrategicInvestmentPortfolio
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember"
      decimals="-5"
      id="d51044137e4561-wk-Fact-21A754B118FC5CD829BA6F38B8B7A9E2"
      unitRef="usd">393900000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember"
      decimals="-5"
      id="d51044137e4565-wk-Fact-281E4FDF61B6472841496F38B8B5CBBA"
      unitRef="usd">676300000</biib:StrategicInvestmentPortfolio>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51044137e4586-wk-Fact-4585A0C5F296BA0EF92B7FC68D2C8F95"
      unitRef="usd">382000000.0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d51044137e4604-wk-Fact-DAB0787A25553AB213926F38B8B69EFC"
      unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d51044137e4608-wk-Fact-A46E758D060B3483184A6F38B8B7D2D3"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d51044137e4612-wk-Fact-1D9B164B83DF3A938B3E6F38B8B5E5B9"
      unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51044137e4616-wk-Fact-5DB725E3C58F19FD80EA6F38B8B392CA"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d51044137e4631-wk-Fact-8B25F35DD4B8B6D130EE7FC9A21CE66B"
      unitRef="KRW">670800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51044137e4635-wk-Fact-F7C51D85CEA56380D0337FC9E125D2A2"
      unitRef="usd">580200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d51044137e4639-wk-Fact-D54A0203BB298D1A86707FCA1DE4971F"
      unitRef="KRW">759500000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51044137e4644-wk-Fact-17DCA88187EFC9B166DA7FCA47FC4B95"
      unitRef="usd">680600000</us-gaap:EquityMethodInvestments>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-31C5FA1C9BF71F15525D6F38B8E26774-0-wk-Fact-68D27276F7646A4F03CE6F38B7BFB595">Derivative Instruments&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had durations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,892.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,701.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound sterling&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss francs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;131.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;98.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;92.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,892.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,239.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$27.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$113.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We expect the net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to be settled over the next &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of these gains are expected to be settled over the next &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;118.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(42.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized Directly into Net Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(32.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interest Rate Swap Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, as described in Note 12, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements, we entered into interest rate swaps with an aggregate notional amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$675.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. The carrying value of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$14.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In order to mitigate these currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had remaining durations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$7.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of our net investment hedges in our consolidated financial statements:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;25.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency contracts as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$793.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$735.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts were recorded as a component of other income (expense), net, for the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance&#160;Sheet&#160;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;Fair Value&lt;br/&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;br/&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;33.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;65.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="d51044295e1309-wk-Fact-322A8E363F8F4AC741F86F38B84945FB">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="d51044295e1313-wk-Fact-9DA025E88F4CEAA204886F38B7C1912E">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="d51044295e1317-wk-Fact-4445A6B770DAC40FBF306F38B8191CC7">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="d51044295e1322-wk-Fact-B166FDEC738C790EC53B6F38B7C0A4E8">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4EC23AA84A35C9473B546F38B8E28F6E-0-wk-Fact-6C8EE6B0C078BAD9BD196F38B8142FD2">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,892.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,701.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound sterling&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss francs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;131.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;98.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;92.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,892.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,239.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e1450-wk-Fact-01060BEB3FFC6FDD9D0E6F38B7E66D87"
      unitRef="usd">1892400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e1469-wk-Fact-C8FBC61236F0662265186F38B7E5606D"
      unitRef="usd">1701400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e1484-wk-Fact-D465D1CEFCFF502D43D06F38B820F35C"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e1503-wk-Fact-28316E0CC9131D1BDF7D6F38B821B736"
      unitRef="usd">215300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e1523-wk-Fact-10DB29D0D2ACF88E58236F38B7ED0212"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e1542-wk-Fact-55B3847AAA7DF49559B56F38B7E6409C"
      unitRef="usd">131400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e1562-wk-Fact-5959E939060246CD68866F38B7EBB0F9"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e1581-wk-Fact-77897E8B689D13A798146F38B81D01B8"
      unitRef="usd">98800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e1601-wk-Fact-774F3E6DE4491836CC566F38B7E5EC7A"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e1620-wk-Fact-FBC0DBD746BC13CDDEBB6F38B7E99DEE"
      unitRef="usd">92200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e1645-wk-Fact-5B690B9CCC4A5E092FFA6F38B81CDF26"
      unitRef="usd">1892400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e1664-wk-Fact-D25A1ADD28720BAD4E6A6F38B81C5438"
      unitRef="usd">2239100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51044295e1683-wk-Fact-D75AFD411EE46F08ACAC6F38B8993659"
      unitRef="usd">500000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51044295e1693-wk-Fact-7D74CD4B51C415DEDD1E6F38B8115C73"
      unitRef="usd">-27300000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51044295e1701-wk-Fact-98A1BCDDBBC2EE8EA0286F38B89FD15D"
      unitRef="usd">113000000.0</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51044295e1710-wk-Fact-D75AFD411EE46F08ACAC6F38B8993659"
      unitRef="usd">500000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q4YTD"
      id="d51044295e1714-wk-Fact-96309B39BDAAF66576016F38B89A9A52">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2019Q4YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember"
      decimals="-5"
      id="d51044295e1718-wk-Fact-A5F8F43BA2744D4183DC7FDF53B0299B"
      unitRef="usd">-2400000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q4YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember"
      id="d51044295e1722-wk-Fact-E09D9C5760AA1B45491D7FDFC94A9A06">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8FCDEE5F9B9BEF14AB586F38B8E2E680-0-wk-Fact-BB404B549937FA3C058E6F38B89BA2E3">&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;118.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(42.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized Directly into Net Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(32.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d51044295e2087-wk-Fact-5260522B2CD0BCFADAAF6F38B895D3B4"
      unitRef="usd">118600000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d51044295e2106-wk-Fact-D42E285B8893C20236697FE3A907F9B8"
      unitRef="usd">-42500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d51044295e2137-wk-Fact-A036F55C47EED3316C056F38B89704D2"
      unitRef="usd">2900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d51044295e2156-wk-Fact-C7119B5AA91BF351B91F7FE42522B7A5"
      unitRef="usd">10800000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d51044295e2181-wk-Fact-A63AA220535E48DF3CEA6F38B89740CE"
      unitRef="usd">-3300000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d51044295e2201-wk-Fact-DA2F3E9D47228ED394387FE3AE7DD78E"
      unitRef="usd">200000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d51044295e2231-wk-Fact-423CCDCB7D50A90D707D6F38B8989411"
      unitRef="usd">200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d51044295e2250-wk-Fact-1DC9C850823BA1BB48A87FE42A290F7E"
      unitRef="usd">-100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d51044295e2472-wk-Fact-9D4CBD668A22CCF2DF1A6F38B7B8ABB3"
      unitRef="usd">-32500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d51044295e2502-wk-Fact-5C003B6F019CF448767C6F38B7B897A5"
      unitRef="usd">8900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d51044295e2527-wk-Fact-6A8CECD39C48F1B630B26F38B7BB5B4E"
      unitRef="usd">600000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d51044295e2556-wk-Fact-814B4029D7DAE9F381136F38B7BE2A46"
      unitRef="usd">-200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="4"
      id="d51044295e2585-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d51044295e2593-wk-Fact-91634FBD8864B002F6BA6F38B805EA5A"
      unitRef="usd">675000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="4"
      id="d51044295e2597-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="4"
      id="d51044295e2601-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember"
      decimals="-5"
      id="d51044295e2614-wk-Fact-9D14185955890E7019747FF3DD7958FA"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember"
      decimals="-5"
      id="d51044295e2618-wk-Fact-318271C910C842B5982C7FE5B4A322B8"
      unitRef="usd">14500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="4"
      id="d51044295e2622-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d51044295e2632-wk-Fact-DAB0787A25553AB213926F38B8B69EFC"
      unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d51044295e2636-wk-Fact-A46E758D060B3483184A6F38B8B7D2D3"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d51044295e2640-wk-Fact-1D9B164B83DF3A938B3E6F38B8B5E5B9"
      unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51044295e2644-wk-Fact-5DB725E3C58F19FD80EA6F38B8B392CA"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:DerivativeTermOfContract
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      id="d51044295e2655-wk-Fact-DF2BDBB8970976C6E4F26F38B89F1AE7">P10M</us-gaap:DerivativeTermOfContract>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d51044295e2659-wk-Fact-3178A6E613BDE080179B7FE8DCDCECF4"
      unitRef="usd">1500000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d51044295e2663-wk-Fact-82EFE079072AC128382F6F38B7C47C93"
      unitRef="usd">3800000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d51044295e2676-wk-Fact-2BB9F9545D64078F5B5D7FE90C425A93"
      unitRef="usd">2900000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d51044295e2680-wk-Fact-A89E9C631799C85213276F38B80E93D7"
      unitRef="usd">7300000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E571C744E817334A4F746F38B8E260E2-0-wk-Fact-CEC27C0A941BCE574AD36F38B7C21D85">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of our net investment hedges in our consolidated financial statements:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;25.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d51044295e3212-wk-Fact-29FEB4AE3F94AEBB937F7FEDB1AE4E7B"
      unitRef="usd">25300000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d51044295e3231-wk-Fact-3CBA00191B363CB2E3E57FEDE96562ED"
      unitRef="usd">-3800000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d51044295e3262-wk-Fact-A5C28CFDE1FB3632C9D07FEFA6057756"
      unitRef="usd">3300000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d51044295e3281-wk-Fact-C1157379E3EC9063E8B47FEFCDE19CE6"
      unitRef="usd">0</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d51044295e3311-wk-Fact-9C67F2B02D3E94F8D9B87FF069EFBCB1"
      unitRef="usd">7000000.0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d51044295e3330-wk-Fact-546CFE2C88A2882395047FF08CC03A8C"
      unitRef="usd">1500000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d51044295e3363-wk-Fact-FA3AF1C953859101D3A56F38B80C7CD9"
      unitRef="usd">793800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d51044295e3367-wk-Fact-ADB46BC448BE107A13646F38B8096BC5"
      unitRef="usd">735100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51044295e3371-wk-Fact-83B9DCA80B7E3348A6D16F38B7BF4413"
      unitRef="usd">5900000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51044295e3376-wk-Fact-5CD833AC352FD4AABED36F38B817E110"
      unitRef="usd">2000000.0</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51044295e3380-wk-Fact-6113D2CEAC14628723796F38B818ABC0"
      unitRef="usd">4500000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-821FDF2E9F0DAD91AAA66F38B8E23A78-0-wk-Fact-E0008F9442FAD27741DD6F38B7C8BB93">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance&#160;Sheet&#160;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;Fair Value&lt;br/&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;br/&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;33.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;65.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember"
      decimals="-5"
      id="d51044295e3573-wk-Fact-5B3355CCF2387046704F6F38B8360FD9"
      unitRef="usd">33800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember"
      decimals="-5"
      id="d51044295e3592-wk-Fact-131E482AD083DEA7EB927FF47BCE3FF8"
      unitRef="usd">65800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember"
      decimals="-5"
      id="d51044295e3627-wk-Fact-58E214ACCAB56FD047A76F38B834C61C"
      unitRef="usd">2000000.0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember"
      decimals="-5"
      id="d51044295e3646-wk-Fact-8C9312E633030F7ACD497FF483800B72"
      unitRef="usd">6900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember"
      decimals="-5"
      id="d51044295e3681-wk-Fact-C968C9C18AA1750428DDE8A9A2526617"
      unitRef="usd">1700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember"
      decimals="-5"
      id="d51044295e3700-wk-Fact-3B20DED08C9C19115855E8AA194DA7A2"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d51044295e3791-wk-Fact-4DE8D84271D5CA1BA8CEE8AB1620F687"
      unitRef="usd">2000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d51044295e3810-wk-Fact-89880E7343C312FC8187E8AD626F7892"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember"
      decimals="-5"
      id="d51044295e3901-wk-Fact-9D14185955890E7019747FF3DD7958FA"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember"
      decimals="-5"
      id="d51044295e3920-wk-Fact-ECBD79681239A276DA737FF487B5E566"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember"
      decimals="-5"
      id="d51044295e3955-wk-Fact-8C2D3ACDED3B8964DCB96F38B8360841"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember"
      decimals="-5"
      id="d51044295e3974-wk-Fact-318271C910C842B5982C7FE5B4A322B8"
      unitRef="usd">14500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d51044295e4066-wk-Fact-108A7C9507D9361A6F876F38B8361CC2"
      unitRef="usd">8000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d51044295e4085-wk-Fact-FC5D1258F8E394E7C27F7FF48C686004"
      unitRef="usd">1100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d51044295e4120-wk-Fact-0B8B27042BA58742D28A6F38B83688AC"
      unitRef="usd">2400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d51044295e4139-wk-Fact-A1DB114E40FC36CD7ADF7FF490D291B6"
      unitRef="usd">3200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5A065778407496A902036F38B8E3209A-0-wk-Fact-583FED3EF6F479C4F2FC6F38B86D775F">Property, Plant and Equipment&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;118.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;144.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;835.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,282.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;99.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;94.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;844.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,258.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Computer software and hardware&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;798.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;798.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;58.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;61.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,084.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,758.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;4,838.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,398.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1,590.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,797.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,247.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,601.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation expense totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$190.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$269.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$266.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we capitalized interest costs related to construction in progress totaling approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$68.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$54.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$30.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. The increase in capitalized interest costs is primarily due to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to this facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM. This transaction included &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$631.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of property, plant and equipment, which was primarily comprised of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$312.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for buildings and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$287.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for machinery and equipment. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-BBDC0E14965AF1D1D8FF6F38B8E3C430-0-wk-Fact-2EBF8AF6C6A2C7F240776F38B86C9010">Components of property, plant and equipment, net are summarized as follows:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;118.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;144.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;835.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,282.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;99.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;94.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;844.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,258.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Computer software and hardware&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;798.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;798.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;58.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;61.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,084.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,758.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;4,838.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,398.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1,590.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,797.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,247.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,601.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044285e1414-wk-Fact-4B49484BBFA4A6FCA3D36F38B805104F"
      unitRef="usd">118100000</us-gaap:Land>
    <us-gaap:Land
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044285e1433-wk-Fact-6BE2BD1A669AEE9100D16F38B7FB8F25"
      unitRef="usd">144500000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044285e1448-wk-Fact-7BDD6D60FC8F781E52FC6F38B7F9578F"
      unitRef="usd">835000000.0</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044285e1467-wk-Fact-1A742A393FBFA7C01FE16F38B809798A"
      unitRef="usd">1282800000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044285e1487-wk-Fact-D24E333490A428E38D996F38B8063617"
      unitRef="usd">99500000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044285e1506-wk-Fact-0DC1EF657D2F114AF7AA6F38B8074924"
      unitRef="usd">94400000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044285e1526-wk-Fact-3B68992FE1A598E60B6D6F38B7FE701C"
      unitRef="usd">844500000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044285e1545-wk-Fact-B217FB97E6FF9A3C46F06F38B8061029"
      unitRef="usd">1258100000</us-gaap:MachineryAndEquipmentGross>
    <biib:ComputerSoftwareAndHardware
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044285e1565-wk-Fact-621204C2730CA9AC6A346F38B804A4D8"
      unitRef="usd">798400000</biib:ComputerSoftwareAndHardware>
    <biib:ComputerSoftwareAndHardware
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044285e1584-wk-Fact-50185CBC3B73771789F46F38B80554E0"
      unitRef="usd">798700000</biib:ComputerSoftwareAndHardware>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044285e1604-wk-Fact-6B928379857C30DCD69F6F38B805F28B"
      unitRef="usd">58300000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044285e1623-wk-Fact-F9184F78DDE45846EE276F38B7FFFE0F"
      unitRef="usd">61600000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044285e1643-wk-Fact-3F3D01122035916260A86F38B8074B57"
      unitRef="usd">2084400000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044285e1662-wk-Fact-D750FA2C509ABF560CDD6F38B7F8299B"
      unitRef="usd">1758500000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044285e1682-wk-Fact-A988179B5A4A50D9029E6F38B7FA7DF9"
      unitRef="usd">4838200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044285e1701-wk-Fact-18F5FDAB35FE9A151BE46F38B8000255"
      unitRef="usd">5398600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044285e1721-wk-Fact-48854B5A0D08098CE00C6F38B7FC4889"
      unitRef="usd">1590900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044285e1741-wk-Fact-31CD5C9D5B66334623C96F38B80A11EF"
      unitRef="usd">1797400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51044285e1768-wk-Fact-CF1C2504DA7602F237C56F38B8445161"
      unitRef="usd">3247300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51044285e1787-wk-Fact-366250CBE4B1855EC9FF6F38B83E3B1B"
      unitRef="usd">3601200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51044285e1806-wk-Fact-E6AC2228D96AB11FAC5A6F38B86EDBA5"
      unitRef="usd">190600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51044285e1810-wk-Fact-4167CA96464ED73233176F38B86F4840"
      unitRef="usd">269400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51044285e1814-wk-Fact-5A0679B5555AF4201F236F38B8703906"
      unitRef="usd">266300000</us-gaap:Depreciation>
    <us-gaap:InterestCostsCapitalized
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51044285e1846-wk-Fact-54FA55EDE8C97A3A61D66F38B86CF92D"
      unitRef="usd">68800000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51044285e1850-wk-Fact-9168C76B52E9B46B008C6F38B86E3F8B"
      unitRef="usd">54000000.0</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51044285e1855-wk-Fact-20FD69DACAAEE20F65066F38B86FE9EA"
      unitRef="usd">30700000</us-gaap:InterestCostsCapitalized>
    <us-gaap:ConstructionInProgressGross
      contextRef="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnMember"
      decimals="-8"
      id="d51044285e1873-wk-Fact-DCA742D8727EF6C110DC6F38B86E4271"
      unitRef="usd">1900000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnMember"
      decimals="-8"
      id="d51044285e1877-wk-Fact-03000C2CA37F755F47206F38B871C590"
      unitRef="usd">1600000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51044285e1894-wk-Fact-8A855AA40548BDD58AFE7FFA8BDE6119"
      unitRef="usd">631500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-5"
      id="d51044285e1898-wk-Fact-45EE7F87D5BEF4AA169D7FFAD1A78A2C"
      unitRef="usd">312500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      decimals="-5"
      id="d51044285e1902-wk-Fact-5C77A015F4A117A204F97FFB16A4C7A0"
      unitRef="usd">287300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-43A723FF06F4D4F7BD9BD256EB02EA17-0-wk-Fact-0E7EE0AC3F393CD7E015D25831F6E61D">Leases&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We lease real estate, including laboratory and office space, and certain equipment. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our leases have remaining lease terms ranging from less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;six years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;nine years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Our subleases do not include an option to renew as they are coterminous with our operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All of our leases qualify as operating leases. The following table summarizes the presentation in our consolidated balance sheets of our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance sheet location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;427.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;73.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;412.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;486.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of lease costs in our consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the year ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;84.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(25.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other (income) expense, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;86.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Variable lease cost primarily related to operating expenses, taxes and insurance associated with our operating leases. As these costs are generally variable in nature, they are not included in the measurement of the operating lease asset and related lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The minimum lease payments for the next five years and thereafter is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;87.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;81.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;75.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;72.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;69.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;158.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;544.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;58.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;486.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the five years and total thereafter as of December&#160;31, 2018, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;80.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;75.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;601.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(26.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(58.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(182.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;60.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;156.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;418.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average remaining lease term in years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our consolidated statements of cash flows is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the year ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;93.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;35.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember"
      id="d51053068e1291-wk-Fact-98B103000C2354954A1DD25B8DAA9804">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember"
      id="d51053068e1295-wk-Fact-C747ECF84F93AF17D27BD25D069E9418">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember"
      id="d51053068e1299-wk-Fact-F49053B600A739414845D25E634C5BBA">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember"
      id="d51053068e1303-wk-Fact-43DC8C4EC87A088951D9D25EC9CD3C9E">P6Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_biib_SubleaseMember"
      id="d51053068e1310-wk-Fact-325DF0C214489ABB5100D25F33858CEC">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_biib_SubleaseMember"
      id="d51053068e1314-wk-Fact-F31E080003FAE333EF0DD25F8FEF399A">P9Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <biib:LesseeLeaseTableTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4732EE9A28730427D90FD2605903A336-0-wk-Fact-421B44518408CD64825AD262FABA93E2">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All of our leases qualify as operating leases. The following table summarizes the presentation in our consolidated balance sheets of our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance sheet location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;427.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;73.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;412.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;486.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:LesseeLeaseTableTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember"
      decimals="-5"
      id="d51053068e1421-wk-Fact-FF6A7E1776F83C7A2D34D2657F134BC1"
      unitRef="usd">427000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember"
      decimals="-5"
      id="d51053068e1513-wk-Fact-138158BBE8B16C663BCCD267F943D212"
      unitRef="usd">73600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember"
      decimals="-5"
      id="d51053068e1538-wk-Fact-F0E5F5917B249CC4F8E6D268506563F2"
      unitRef="usd">412700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51053068e1573-wk-Fact-AD7CC2919CAEAFB3317ED27287CE9B7B"
      unitRef="usd">486300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B1E6980692F0814E3037D269F5909227-0-wk-Fact-6BF9C981D75DC0B63261D26A17861D93">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of lease costs in our consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the year ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;84.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(25.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other (income) expense, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;86.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d51053068e1684-wk-Fact-E7EAB52CF08ACA66B1C8D26B5E4DA964"
      unitRef="usd">6700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d51053068e1709-wk-Fact-EB31B3B8CD8116B07A1CD26B639EFDC0"
      unitRef="usd">84600000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d51053068e1739-wk-Fact-D1B3F6139ED547983EB6D26C3EB4AD33"
      unitRef="usd">1200000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d51053068e1769-wk-Fact-5438E2817981411124A4D26C3E806F38"
      unitRef="usd">23700000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d51053068e1799-wk-Fact-F4FFEA457BF335D62736D26BB07929EC"
      unitRef="usd">25600000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d51053068e1830-wk-Fact-0737D4062FEBE63A8C49D26BB3B5066E"
      unitRef="usd">3900000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <us-gaap:LeaseCost
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51053068e1866-wk-Fact-9B475C9DE28C7BFC7248D26D3E7D7D59"
      unitRef="usd">86700000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EBE2C51FF2B1DE2D897DD296468B3FE6-0-wk-Fact-C6B8F51C34C0FCCE69DFD29655E67564">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The minimum lease payments for the next five years and thereafter is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;87.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;81.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;75.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;72.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;69.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;158.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;544.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;58.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;486.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51053068e1929-wk-Fact-325DB683CCCC3F3A1E95D27278B22168"
      unitRef="usd">87600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51053068e1944-wk-Fact-A33843634D22D121E0C5D27279CD6129"
      unitRef="usd">81500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51053068e1964-wk-Fact-C94182E27AD58B92D66AD2727AFBC849"
      unitRef="usd">75700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51053068e1984-wk-Fact-C7CED10EF6BF06225152D2727C8E2D24"
      unitRef="usd">72500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51053068e2004-wk-Fact-436B831B80AD7C621E1BD2727E11D345"
      unitRef="usd">69000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51053068e2024-wk-Fact-663AE6F5A00DA383205AD272819532B1"
      unitRef="usd">158300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51053068e2049-wk-Fact-20D97C274D5756C7D9CED27283C357EA"
      unitRef="usd">544600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51053068e2064-wk-Fact-34DE3CB4391A7D254B13D27285EA5ECB"
      unitRef="usd">58300000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51053068e2089-wk-Fact-AD7CC2919CAEAFB3317ED27287CE9B7B"
      unitRef="usd">486300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1A6A5459CD9F15B3F0D4D298717E3CE7-0-wk-Fact-95D18213C26B3A8A4F26D29880FC7251">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the five years and total thereafter as of December&#160;31, 2018, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;80.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;75.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;601.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(26.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(58.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(182.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;60.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;156.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;418.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. &lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2296-wk-Fact-F448D524BB6C29BABB0BD285F180843C"
      unitRef="usd">87000000.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2315-wk-Fact-BD37721BE5760CE16941D285F4B3E6C5"
      unitRef="usd">80700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2334-wk-Fact-E65DF6F80C316715AC2ED285F8103315"
      unitRef="usd">75900000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2354-wk-Fact-C134D2DCDEC1D134EC69D285FB29E17F"
      unitRef="usd">71700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2373-wk-Fact-26034169EA8E41FECE04D285FE6987A5"
      unitRef="usd">71000000.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2393-wk-Fact-C72105749996343CBEBBD28601A28DAB"
      unitRef="usd">215300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2412-wk-Fact-D27ADF44B904D08F9065D286050BB5C7"
      unitRef="usd">601600000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2429-wk-Fact-197543281BAF214CAE83D286070B363C"
      unitRef="usd">26800000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2449-wk-Fact-A1F3A611D2BEA4BB0093D2860B6CF75E"
      unitRef="usd">25600000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2469-wk-Fact-905C9AF2725D9142C22AD2860E8FDA55"
      unitRef="usd">23700000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2490-wk-Fact-F260C39FC952F5A5D6DDD2861135FC79"
      unitRef="usd">24000000.0</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2510-wk-Fact-563B5CB3AC9659E0D256D28613061385"
      unitRef="usd">24300000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2530-wk-Fact-20388E6104F2DEBAE0A8D28615AA9673"
      unitRef="usd">58400000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2551-wk-Fact-BA7D0A8595160868FD70D2861884AB31"
      unitRef="usd">182800000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions>
    <biib:NetMinimumLeasePaymentsWithInOneYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2577-wk-Fact-1A8B7EFC82003ABECC8DD2861A412721"
      unitRef="usd">60200000</biib:NetMinimumLeasePaymentsWithInOneYear>
    <biib:NetMinimumLeasePaymentsWithInTwoYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2596-wk-Fact-97E7DE7EA108EC818068D2861F2B04F5"
      unitRef="usd">55100000</biib:NetMinimumLeasePaymentsWithInTwoYear>
    <biib:NetMinimumLeasePaymentsWithInThreeYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2615-wk-Fact-2509EC043A89283223F5D2862057FC94"
      unitRef="usd">52200000</biib:NetMinimumLeasePaymentsWithInThreeYear>
    <biib:NetMinimumLeasePaymentsWithInFourYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2635-wk-Fact-487E6DB50BB15185A1ABD28622049F3C"
      unitRef="usd">47700000</biib:NetMinimumLeasePaymentsWithInFourYear>
    <biib:NetMinimumLeasePaymentsWithInFiveYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2654-wk-Fact-507288293ED2543D7FECD28623850110"
      unitRef="usd">46700000</biib:NetMinimumLeasePaymentsWithInFiveYear>
    <biib:NetMinimumLeasePaymentsThereafter
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2674-wk-Fact-8AD4395FFBA587A8A1F2D28625FE405F"
      unitRef="usd">156900000</biib:NetMinimumLeasePaymentsThereafter>
    <biib:NetMinimumLeasePayments
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51053068e2693-wk-Fact-3B65BBB1394F99B9E0A0D28628C87F37"
      unitRef="usd">418800000</biib:NetMinimumLeasePayments>
    <biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-220A65F40BB0FEFF642BE8B0D9C0447A-0-wk-Fact-254228B0E2533195F093E8B132B665C6">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average remaining lease term in years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q4"
      id="d51053068e2748-wk-Fact-B185DDB0D8D082FEC49EE8B1DEBE1587">P7Y25D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q4"
      decimals="INF"
      id="d51053068e2763-wk-Fact-02809B82CC15FE28F9A8E8B1E03EA9CA"
      unitRef="number">0.032</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-3D28474708AB7D3C55F2E8B2F25F7C0F-0-wk-Fact-A9B0DC1A734E72159153E8B30CBA9305">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our consolidated statements of cash flows is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the year ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;93.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;35.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51053068e2843-wk-Fact-3424A5BA918C9E081E4CE8B3C067116C"
      unitRef="usd">93800000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51053068e2863-wk-Fact-E88D20030A558670E804E8B3C22CE54A"
      unitRef="usd">35900000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6283D8B98CF253E607C86F38B8E3BDCC-0-wk-Fact-22BA89BB527A24EDD0C16F38B8C5857B">Indebtedness&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our indebtedness is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Current portion:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,495.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of notes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,495.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Non-current portion:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,480.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;996.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;995.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,739.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,737.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,722.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,722.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of notes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;4,459.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2015 Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following is a summary of our principal indebtedness as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$1.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2020, valued at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;99.792%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;3.625%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2022, valued at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;99.920%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$1.75 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;4.05%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2025, valued at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;99.764%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$1.75 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;5.20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15,&#160;2045, valued at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;99.294%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The costs associated with these offerings of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$47.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheets. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These notes are senior unsecured obligations. These Senior Notes may be redeemed at our option at any time at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued interest and a specified make-whole amount. These Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;101%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes offering due in 2020, we entered into interest rate swap contracts. The carrying value of the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$14.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to changes in the fair value of these contracts. For additional information on our interest rate contracts, please read Note 9, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2015 Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2015 we entered into a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year senior unsecured revolving credit facility under which we were permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility included a financial covenant that required us not to exceed a maximum consolidated leverage ratio. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; outstanding borrowings and were in compliance with all covenants under this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2020 we entered into a new &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year senior unsecured revolving credit facility that replaced the credit facility entered into in August 2015. For additional information, please read Note 26, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Subsequent Events&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Maturity&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total gross payments due under our debt arrangements are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.24561403508771%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,500.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,000.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2025 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,500.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6,000.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our debt is disclosed in Note&#160;7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7D284A2F47DAEF2676396F38B8E36381-0-wk-Fact-E12F5BC37DE0C6DC1B686F38B8BFDEF5">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our indebtedness is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Current portion:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,495.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of notes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,495.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Non-current portion:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,480.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;996.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;995.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,739.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,737.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,722.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,722.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of notes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;4,459.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:NotesPayableCurrent
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember"
      decimals="-5"
      id="d51046405e1455-wk-Fact-B15F90F1B71E3C1809497FFD88156156"
      unitRef="usd">1495800000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember"
      decimals="-5"
      id="d51046405e1474-wk-Fact-A1047D9C168DA653CB937FFDAB2CD98D"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51046405e1494-wk-Fact-E03C31AEBF983BAF370A6F38B83EEB28"
      unitRef="usd">1495800000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51046405e1513-wk-Fact-A5C816CFC4616E30647F6F38B83C6A09"
      unitRef="usd">0</us-gaap:DebtCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d51046405e1569-wk-Fact-FC236BB80FF0F420C1A16F38B80A1E2A"
      unitRef="usd">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d51046405e1588-wk-Fact-EB614431FC5BD5386DF06F38B8084B73"
      unitRef="usd">1480800000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d51046405e1608-wk-Fact-D3B5F99A599AE23341726F38B80DC998"
      unitRef="usd">996600000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d51046405e1627-wk-Fact-8370C4172702E53DEADA6F38B811BADE"
      unitRef="usd">995500000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d51046405e1647-wk-Fact-9DCC3C01439D32D6DE5C6F38B80FEFB5"
      unitRef="usd">1739500000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d51046405e1666-wk-Fact-140B7DF2A89B4109EED76F38B8165890"
      unitRef="usd">1737800000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d51046405e1686-wk-Fact-20CAA2D36A64BED55F856F38B8063F0C"
      unitRef="usd">1722900000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d51046405e1705-wk-Fact-22DA3FF05C0248C3F3526F38B806CC70"
      unitRef="usd">1722400000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51046405e1730-wk-Fact-95D2C560A678B1EACADD6F38B8BDFC71"
      unitRef="usd">4459000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51046405e1749-wk-Fact-CAE61D364EA39551186E6F38B8C4B9E5"
      unitRef="usd">5936500000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-8"
      id="d51046405e1781-wk-Fact-0F42613126F00D906B776F38B8C2BD33"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="4"
      id="d51046405e1785-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d51046405e1789-wk-Fact-02689282C3EF9AFEBEB06F38B8C2F271"
      unitRef="number">0.99792</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-8"
      id="d51046405e1798-wk-Fact-E934BAB45B9706213CE06F38B8C18FB2"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="INF"
      id="d51046405e1802-wk-Fact-E0443512FEBBE52824A96F38B8C29E2A"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="INF"
      id="d51046405e1806-wk-Fact-DFD920FC86A191811D876F38B8C46C9D"
      unitRef="number">0.99920</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-7"
      id="d51046405e1815-wk-Fact-E4527FF9ED756B4B100B6F38B8BE51E3"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="INF"
      id="d51046405e1819-wk-Fact-FC4C4141291E4F6C42D66F38B8C68612"
      unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="INF"
      id="d51046405e1823-wk-Fact-0A3388434B06C530B3286F38B8C8DBAD"
      unitRef="number">0.99764</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-7"
      id="d51046405e1832-wk-Fact-AF1FE49802A1E6EA17C86F38B8BE8C1B"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="INF"
      id="d51046405e1836-wk-Fact-8565C05E209F8F450DC66F38B8C7F518"
      unitRef="number">0.0520</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="INF"
      id="d51046405e1840-wk-Fact-A90FDA8FE1B2A18A5CB56F38B8C111DF"
      unitRef="number">0.99294</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="FD2015Q4YTD"
      decimals="-5"
      id="d51046405e1847-wk-Fact-163EE2E3AC8A618105F46F38B8C5BA76"
      unitRef="usd">47500000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d51046405e1854-wk-Fact-92E9208DA2B62EF6ECD56F38B8C7003F"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d51046405e1858-wk-Fact-27C3C0642E3C19801B0C6F38B8BF4F0C"
      unitRef="number">1.01</biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="4"
      id="d51046405e1866-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="4"
      id="d51046405e1870-wk-Fact-C0A6F33E3B668F989F5C6F38B89853D7"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-5"
      id="d51046405e1882-wk-Fact-605D61DB6321AE9F9AD86F38B8C4442A"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-5"
      id="d51046405e1887-wk-Fact-F1581EDDBFA2F3E913D06F38B7A2983A"
      unitRef="usd">14500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="FI2015Q4"
      decimals="-8"
      id="d51046405e1901-wk-Fact-C446A5D9C854BCD587A26F38B8C4C209"
      unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityDescription
      contextRef="FD2015Q4YTD"
      id="d51046405e1905-wk-Fact-76841EF437B0D8571B3E6F38B8C67A4D">five</us-gaap:LineOfCreditFacilityDescription>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="FI2019Q4"
      decimals="0"
      id="d51046405e1914-wk-Fact-934F02061E603F0702F96F38B8C626F3"
      unitRef="usd">0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="I2019Q4creditfacility_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-8"
      id="d51046405e1921-wk-Fact-73DC378EC219BD1563FAEC7E7FAC4555"
      unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityDescription
      contextRef="D2019Q4creditfacility_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="d51046405e1925-wk-Fact-8D917A5C058323C8C36FF1EE60E38D68">five</us-gaap:LineOfCreditFacilityDescription>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-BCD0F32A7FDF8AAFDCF76F38B8E39766-0-wk-Fact-1C5AD54819A016628FCD6F38B8C5F69B">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total gross payments due under our debt arrangements are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.24561403508771%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,500.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,000.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2025 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,500.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6,000.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51046405e1994-wk-Fact-20533A4401F8EC49847A800D03B9F56E"
      unitRef="usd">1500000000.0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51046405e2009-wk-Fact-684DEFAC9641121FE678800D0382D985"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51046405e2029-wk-Fact-BE2FA3CFE945C192DCF2800D03D830E9"
      unitRef="usd">1000000000.0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51046405e2049-wk-Fact-0B54A89F822A9A5D659A800D04042FC7"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51046405e2069-wk-Fact-084EC2EC01BD47FFFFBD800D03A0B35B"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51046405e2089-wk-Fact-DBA1BA49741A60135A9A800D03F4D263"
      unitRef="usd">3500000000.0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermNotesPayable
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51046405e2114-wk-Fact-9F59954044E7007AB12B6F38B872D031"
      unitRef="usd">6000000000.0</us-gaap:LongTermNotesPayable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4E5D23502DD4F5C1360C6F38B8E31FA6-0-wk-Fact-8C61B09CC6F7BC2443C46F38B839FB10">Equity&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;shares of Preferred Stock authorized, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are authorized as Series A, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are authorized as Series X junior participating and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.25 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table describes the number of shares authorized, issued and outstanding of our common stock as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="27"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;As of December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,000.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;198.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;174.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;221.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;197.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;235.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;211.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2019 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (December 2019 Share Repurchase Program). Our December 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our December 2019 Share Repurchase Program will be retired. We did not repurchase shares of our common stock under our December 2019 Share Repurchase Program during the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (March 2019 Share Repurchase Program). Our March 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our March 2019 Share Repurchase Program will be retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts paid to repurchase shares in excess of their par value are allocated between additional paid-in capital and retained earnings, with payments in excess of our additional paid-in-capital balance recorded as a reduction to retained earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(243.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(240.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;11.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;88.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;28.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;103.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;230.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(115.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(7.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(125.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(26.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;21.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;103.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;105.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;25.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(32.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(139.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(135.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(318.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified, net of tax, upon adoption of ASU 2016-01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(316.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;97.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(67.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;139.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(67.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(243.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(240.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(32.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(334.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(319.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(193.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;158.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(42.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(162.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;158.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(318.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(19.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;118.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(42.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(32.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;125.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(44.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51051987e1303-wk-Fact-D79D91C6A2D5A75569146F38B8A8B83F"
      unitRef="shares">8000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember"
      decimals="-4"
      id="d51051987e1307-wk-Fact-98CAA0605D2A84C43ADF6F38B8ADCEE9"
      unitRef="shares">1750000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_biib_SeriesXPreferredStockMember"
      decimals="-5"
      id="d51051987e1311-wk-Fact-3733D51B55A8696C85946F38B83A4F7F"
      unitRef="shares">1000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_biib_UndesignatedPreferredStockMember"
      decimals="-4"
      id="d51051987e1315-wk-Fact-BE42894C1739BB2ED9D66F38B8A983FF"
      unitRef="shares">5250000</us-gaap:PreferredStockSharesAuthorized>
    <biib:SummaryOfCommonStockTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-3C10B2DCA2989F75F8C26F38B8E3A568-0-wk-Fact-D5E7A39AA0E2E248B9506F38B83DCCA9">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table describes the number of shares authorized, issued and outstanding of our common stock as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="27"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;As of December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,000.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;198.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;174.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;221.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;197.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;235.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;211.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryOfCommonStockTableTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51051987e1676-wk-Fact-5A92707C43F82506E5216F38B8540FA0"
      unitRef="shares">1000000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51051987e1690-wk-Fact-31883891660A7A0437D46F38B855FD64"
      unitRef="shares">198000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51051987e1704-wk-Fact-CC50B950451110D3CA3B6F38B85396AF"
      unitRef="shares">174200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51051987e1718-wk-Fact-EDA8A7A0D4281E431C636F38B85B8528"
      unitRef="shares">1000000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51051987e1733-wk-Fact-0A2980EE743D28411E9B6F38B85BC10E"
      unitRef="shares">221000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51051987e1747-wk-Fact-B10B4F9BBC03C6C5C4EE6F38B85552EA"
      unitRef="shares">197200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51051987e1761-wk-Fact-F2D81868B89E4B71DD6A6F38B85501DD"
      unitRef="shares">1000000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51051987e1776-wk-Fact-14AB024F22AD87BD1CA36F38B8586D04"
      unitRef="shares">235300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51051987e1790-wk-Fact-AF25FA45AF16B77A2FF56F38B8537A6C"
      unitRef="shares">211500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d51051987e1812-wk-Fact-7B9C0D8AF720AFE79E1CE8B6319F5D57"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d51051987e1823-wk-Fact-5B658F307BDA3C44B4BA6F38B8AD1B06"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51051987e1827-wk-Fact-FB6AC0B45C6B499F86096F38B8ACCC32"
      unitRef="shares">14700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d51051987e1831-wk-Fact-2B4E10B158798D3B3F006F38B83E2D0F"
      unitRef="usd">3700000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-8"
      id="d51051987e1842-wk-Fact-13436D827A1A1F4478DC8010EDBAF4B4"
      unitRef="usd">3500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51051987e1846-wk-Fact-8706F5DAD179D43BBC086F38B8AB2700"
      unitRef="shares">8900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51051987e1850-wk-Fact-8832B6AD62AFCD028A2D6F38B847A986"
      unitRef="shares">4300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-8"
      id="d51051987e1854-wk-Fact-DCD343A2BEB5045F50DD6F38B8A7CF3E"
      unitRef="usd">2100000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-8"
      id="d51051987e1858-wk-Fact-12342286F9FC1F7EA0356F38B8442EEF"
      unitRef="usd">1400000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-8"
      id="d51051987e1874-wk-Fact-817AE393230274773B806F38B8A7A489"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51051987e1882-wk-Fact-89EC87E59F7C976A5D63801782306245"
      unitRef="shares">10500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d51051987e1886-wk-Fact-6057C9D23FA36429E6178017EF6CDAF8"
      unitRef="shares">3700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-8"
      id="d51051987e1890-wk-Fact-56FF7E99664C2BB0C436801817D23142"
      unitRef="usd">3000000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-8"
      id="d51051987e1894-wk-Fact-F562C0311FCAEA2C9214801890A383BD"
      unitRef="usd">1000000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1512C5E42CC278C4647E93D9D84794A2-0-wk-Fact-9B50A09A9D9096764B8F93DD504B60FF">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(243.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(240.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;11.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;88.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;28.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;103.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;230.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(115.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(7.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(125.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(26.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;21.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;103.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;105.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;25.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(32.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(139.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(135.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(318.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified, net of tax, upon adoption of ASU 2016-01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(316.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;97.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(67.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;139.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(67.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(243.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(240.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(32.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(334.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(319.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(193.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;158.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(42.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(162.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;158.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(318.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e2087-wk-Fact-178748512BCFA1C379B693E2D4388F8E"
      unitRef="usd">-4000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e2107-wk-Fact-7B69EC771B3E6E1AB62093E2D750DBF1"
      unitRef="usd">34700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e2126-wk-Fact-6843D6299757B934C99693E2D9ED6021"
      unitRef="usd">3500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e2146-wk-Fact-895AC5822916CE06895193E2DCFD2C2F"
      unitRef="usd">-31300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e2166-wk-Fact-5BA8F3C93A182973AC7893E2E042F1A6"
      unitRef="usd">-243300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51051987e2187-wk-Fact-85A952828CB37D9B77516F38B8B27C3F"
      unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e2203-wk-Fact-C51E95C1BF0FF19CB4EE93E36D6DEEE9"
      unitRef="usd">11800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e2222-wk-Fact-F2474D0E574279166C0593E36FBDBB18"
      unitRef="usd">88100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e2241-wk-Fact-D9215D63C3DBA9AD82AB93E371DB0ABD"
      unitRef="usd">28600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e2261-wk-Fact-A242EA9CEEFD24B9AE4593E373CFA97E"
      unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e2281-wk-Fact-0766AFC4E6DE932685A393E376C294D5"
      unitRef="usd">103800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51051987e2300-wk-Fact-57B9F76C4674F2C06D0B93E378B8B805"
      unitRef="usd">230800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e2321-wk-Fact-F788E9346BE01BFAEAF393E3797F6784"
      unitRef="usd">-3600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e2341-wk-Fact-F65A959DDC48207B00EA93E37B725000"
      unitRef="usd">-115000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e2361-wk-Fact-E32B640B4EE06960ED0693E37D62A5F9"
      unitRef="usd">-7000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e2382-wk-Fact-0F82510384CB56A7178393E37F55C521"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e2401-wk-Fact-DB1DA0462637EB3A4D6393E381484D63"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51051987e2420-wk-Fact-72B63C63D1CDE0E9F72B93E3833F3516"
      unitRef="usd">-125600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e2442-wk-Fact-5F015F13891E413F21BA93E383FB7A17"
      unitRef="usd">8200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e2461-wk-Fact-0C117B8A724C9C861CE393E3861182F4"
      unitRef="usd">-26900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e2481-wk-Fact-7757B0D69E90628D878793E3881F758F"
      unitRef="usd">21600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e2501-wk-Fact-BAA061D55CC34503AEE193E38A123643"
      unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e2521-wk-Fact-9C0560EF60F68E76FC1C93E38C14D2E7"
      unitRef="usd">103800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51051987e2540-wk-Fact-D065EF4A97DD7AA72ECF6F38B85F566B"
      unitRef="usd">105200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e2566-wk-Fact-70A9DB0651B9F60974E193E30D7A671F"
      unitRef="usd">4200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e2585-wk-Fact-8D884594A5A5D95C1A9893E30F9F0DB2"
      unitRef="usd">7800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e2604-wk-Fact-2C52629334D62FF5AB8393E3119854AA"
      unitRef="usd">25100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e2624-wk-Fact-FDDEACAFB6D66B0144E193E313862167"
      unitRef="usd">-32800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e2644-wk-Fact-6A7C963BF18DF642FC6B93E3157BCD7A"
      unitRef="usd">-139500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51051987e2665-wk-Fact-262FECE5A3392F04B8F36F38B8C7C408"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e2842-wk-Fact-07D495ABFF6039A18136941B494B2A22"
      unitRef="usd">-1600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e2862-wk-Fact-FE977B54EDE7A9CF2098941B4BB9E5D4"
      unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e2882-wk-Fact-895997288D6D64219932941B4E2EF4CF"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e2902-wk-Fact-5018F694E1B8D5355537941B50C8F979"
      unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e2922-wk-Fact-C0FB69BC90E1B56F1934941B53628DDB"
      unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51051987e2943-wk-Fact-A6E46D76F34C55D88CC8941B55CC5CBE"
      unitRef="usd">-318400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e2959-wk-Fact-658A94750EB1D69E11F39418DE48866E"
      unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e2978-wk-Fact-BD6FF3399C6562B753F89418E4C27318"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e2997-wk-Fact-E9ADEE488E668494B9C69418E8FB17B0"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e3017-wk-Fact-731C1B94716F134C85649418ED587143"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e3036-wk-Fact-F2610B0C258F502051619418F14551E9"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member"
      decimals="-5"
      id="d51051987e3055-wk-Fact-563DC78A92E8A93225719418F52CCDD8"
      unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e3076-wk-Fact-9D3C39963A95A1DD3CD2941930EC3140"
      unitRef="usd">-100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e3096-wk-Fact-CD08B7F90C0778171626941933A31A3B"
      unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="0"
      id="d51051987e3116-wk-Fact-A0134F9E1C741E7A8DD4941936409639"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e3136-wk-Fact-6A379A6848F3D361526194193A26C373"
      unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e3156-wk-Fact-F4BC8557A2A2ECD85CE094193CC09493"
      unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate"
      decimals="-5"
      id="d51051987e3176-wk-Fact-618AB2E321B713DEA5B094193F5B390F"
      unitRef="usd">-316900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e3198-wk-Fact-CB2E2D178F3FADBA9E02941982488C02"
      unitRef="usd">-10600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e3218-wk-Fact-C5CFFF4684CF6B7677A2941984B2CBDC"
      unitRef="usd">97400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e3237-wk-Fact-40D1C6E26CE2E33CB6AF9419872A8673"
      unitRef="usd">5000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e3257-wk-Fact-9CCBFDEDEE603CE47D679419899735E2"
      unitRef="usd">5500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e3276-wk-Fact-573F5569E4722D7E112194198C1019FF"
      unitRef="usd">-67800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51051987e3296-wk-Fact-6F3EC5CAB9A43FF0240B94198E754933"
      unitRef="usd">29500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e3317-wk-Fact-F00ECF603588EE58C33F94198F6F5869"
      unitRef="usd">6700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e3336-wk-Fact-116C306A7E5739C4A5189419923EB93C"
      unitRef="usd">41800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e3355-wk-Fact-47F7CF754C6ED8994F629419952ECB4E"
      unitRef="usd">-1500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e3376-wk-Fact-561639E1D23D773BC3E694199796B125"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e3395-wk-Fact-5BB19077D2110F8FD86694199A6429E5"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51051987e3414-wk-Fact-0201F6255D9B9731182594199CC726A6"
      unitRef="usd">47000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e3435-wk-Fact-B95F34D42CB9B0EF443094199DFF21A4"
      unitRef="usd">-3900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e3455-wk-Fact-2BED97F6EBE772FF736D9419A12FBEFF"
      unitRef="usd">139200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e3474-wk-Fact-5843D0CA8CF34CA20D3B9419A3F62F1E"
      unitRef="usd">3500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e3494-wk-Fact-C9A8CA2C87EC6AEBE5E99419A68B17D7"
      unitRef="usd">5500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e3513-wk-Fact-E6B5E760AFD0AE23BD0D9419A9D29DDA"
      unitRef="usd">-67800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51051987e3533-wk-Fact-3FFFEF07DFDCE1143CF16F38B81442EC"
      unitRef="usd">76500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e3559-wk-Fact-178748512BCFA1C379B693E2D4388F8E"
      unitRef="usd">-4000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e3579-wk-Fact-7B69EC771B3E6E1AB62093E2D750DBF1"
      unitRef="usd">34700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e3598-wk-Fact-6843D6299757B934C99693E2D9ED6021"
      unitRef="usd">3500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e3618-wk-Fact-895AC5822916CE06895193E2DCFD2C2F"
      unitRef="usd">-31300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e3638-wk-Fact-5BA8F3C93A182973AC7893E2E042F1A6"
      unitRef="usd">-243300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51051987e3659-wk-Fact-85A952828CB37D9B77516F38B8B27C3F"
      unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e3836-wk-Fact-4C8A5B38537622477E78941AC9E38458"
      unitRef="usd">-10800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e3856-wk-Fact-E814EC0FF67BAE36ABB8941ACC4EB86D"
      unitRef="usd">57800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e3875-wk-Fact-7C5196AA257EEF081E92941ACEE68D4E"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e3895-wk-Fact-0FD8D50BF909B9016CA0941AD181454F"
      unitRef="usd">-32700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e3915-wk-Fact-07F183B7054D476CE03C941AD3FAAEFF"
      unitRef="usd">-334200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2016Q4"
      decimals="-5"
      id="d51051987e3936-wk-Fact-C4A62DEFE59259832965941AD69B964B"
      unitRef="usd">-319900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e3952-wk-Fact-BB6EFE3D3423D6C7AAC5941B804FBB3D"
      unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e3972-wk-Fact-6EC5CCE9F62338099816941B82BD6151"
      unitRef="usd">-193800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e3992-wk-Fact-C651569856E77135970C941B86514330"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e4012-wk-Fact-E660B6217267DBFFD1DA941B896B64D4"
      unitRef="usd">-4100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e4032-wk-Fact-8600E5F798A22BE2810C941B8C0AB6DA"
      unitRef="usd">158700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51051987e4051-wk-Fact-0A0F554323ACF9A4EAED941B8EC35849"
      unitRef="usd">-42700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e4073-wk-Fact-72D9BB3271867555F035941B8FC3E386"
      unitRef="usd">12700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e4092-wk-Fact-CB2589EEF05F68ABD3EE941B9259B117"
      unitRef="usd">31500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e4111-wk-Fact-FEAD22787E7E02DA1BCC941B94F1938A"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e4131-wk-Fact-88ABB94E91FD5450E00A941B978C9CF4"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e4150-wk-Fact-E89B250F169BB85C81EE941B998063A6"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51051987e4169-wk-Fact-DBF10CB8F64B5205176D941B9C1C2D58"
      unitRef="usd">44200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e4190-wk-Fact-441A06FDCFC0868D2CFD941B9D1662EF"
      unitRef="usd">9200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e4209-wk-Fact-FC48A91DD98C59EDCC8D941B9FB0FC14"
      unitRef="usd">-162300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e4229-wk-Fact-978715A59DD6FD7E26BA941BA24B9275"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e4249-wk-Fact-3047E24625691847B508941BA4E5079A"
      unitRef="usd">-4100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e4269-wk-Fact-493FD0DBE7F972326F32941BA75D7BA2"
      unitRef="usd">158700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51051987e4288-wk-Fact-DAF3185409661071AF2B6F38B80DA8BC"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e4314-wk-Fact-07D495ABFF6039A18136941B494B2A22"
      unitRef="usd">-1600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e4334-wk-Fact-FE977B54EDE7A9CF2098941B4BB9E5D4"
      unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e4354-wk-Fact-895997288D6D64219932941B4E2EF4CF"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d51051987e4374-wk-Fact-5018F694E1B8D5355537941B50C8F979"
      unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d51051987e4394-wk-Fact-C0FB69BC90E1B56F1934941B53628DDB"
      unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51051987e4415-wk-Fact-A6E46D76F34C55D88CC8941B55CC5CBE"
      unitRef="usd">-318400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EE9F3D043A73CF2A447793E031A34F76-0-wk-Fact-6792ECB53088202F5AFE93E09F0C81BE">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(19.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;118.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(42.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(32.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;125.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(44.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e4712-wk-Fact-54D121CA477BAEB35479941F6A66B57D"
      unitRef="usd">4500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e4731-wk-Fact-C5204CAB23A4798797FC94275EAD3512"
      unitRef="usd">-8500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e4752-wk-Fact-4A2DBD7C2A0336E1F6D794280378C462"
      unitRef="usd">-19500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e4783-wk-Fact-7385455619DEF5D6A684941F6E54BBCF"
      unitRef="usd">-900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e4803-wk-Fact-BB01F54623AC0F97231C9427619B3D80"
      unitRef="usd">1800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d51051987e4823-wk-Fact-5072DC54AB4D9CAA7570942806BBA88F"
      unitRef="usd">6800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e4935-wk-Fact-BEC66000A2CB4EC06261941F72938A2E"
      unitRef="usd">118600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e4954-wk-Fact-16F49252555A74CF249D942764AC84FB"
      unitRef="usd">-42500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e4975-wk-Fact-090B19977163AF3B35A794280AC485D1"
      unitRef="usd">-32500000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e5011-wk-Fact-1982D6C33B97D658B64F941F76081F9D"
      unitRef="usd">3300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e5031-wk-Fact-7460358F3BD45B4ACA36942767F03A6C"
      unitRef="usd">200000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e5051-wk-Fact-A259D465D8968892612094280DCC3480"
      unitRef="usd">600000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e5086-wk-Fact-8F22CC3A412CF24B3781941F796F4C93"
      unitRef="usd">300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e5105-wk-Fact-BCC500546C941AE8E3AB94276B94A7FE"
      unitRef="usd">300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e5125-wk-Fact-8FE747E8CB16B2D41B32942810791F76"
      unitRef="usd">300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e5160-wk-Fact-870CD408467ABBCF2A36941F7CCCB813"
      unitRef="usd">-600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e5180-wk-Fact-075E5B7B1449DEB324D194276F23BEA1"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d51051987e5200-wk-Fact-9CDF945993C2E9EEFA4E9428146187F4"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e5313-wk-Fact-38282520213A514E8E9E941F82324BDB"
      unitRef="usd">7000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e5332-wk-Fact-8F568474A86415FD9337942772AE1CD9"
      unitRef="usd">1500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d51051987e5352-wk-Fact-03675CE962CB85DAA68F9428174DA493"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51051987e5469-wk-Fact-9DB89B1746185ECA2275941F8AC37E3B"
      unitRef="usd">125600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51051987e5488-wk-Fact-5F31DEE26DCD4B5BD70794277ACD107E"
      unitRef="usd">-47000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d51051987e5509-wk-Fact-7410252D9B358428F6CB94281D5D5C54"
      unitRef="usd">-44200000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-34F97D9F7E1A61E404CA6F38B8E3153C-0-wk-Fact-45F9DB28866826D2B1426F38B7E62D2F">Earnings&#160;per Share&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,888.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,430.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,539.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;187.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;204.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;212.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;187.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;205.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;213.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Earnings per share for the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflects, on a weighted average basis, the repurchase of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock, respectively, under our March 2019, 2018 and 2016 Share Repurchase Programs.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B2C9529A0DAD009DF57A6F38B8E329D7-0-wk-Fact-10B42F0A0DC7EA5039D56F38B7E2F72A">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,888.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,430.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,539.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;187.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;204.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;212.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;187.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;205.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;213.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51046400e1523-wk-Fact-409F06146EDA2C5A1FA56F38B82DE39D"
      unitRef="usd">5888500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51046400e1542-wk-Fact-D75E3BB69A698B5537196F38B831D83C"
      unitRef="usd">4430700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51046400e1561-wk-Fact-029151C37D9A5DCBB4476F38B8229A45"
      unitRef="usd">2539100000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51046400e1639-wk-Fact-1969AB1F17EC7BCE4FB56F38B7B8CA9B"
      unitRef="shares">187100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51046400e1658-wk-Fact-5907C0CD0AE9671001886F38B828BCF3"
      unitRef="shares">204900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51046400e1677-wk-Fact-699EE9018111D1CC3A906F38B80EA6F3"
      unitRef="shares">212600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d51046400e1760-wk-Fact-3E14C3A9898CA93B736F6F38B89AB3DC"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d51046400e1779-wk-Fact-3F82DD404E7B8472DFC26F38B8925F13"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d51046400e1798-wk-Fact-39F40B3990A378800B306F38B89C5615"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d51046400e1819-wk-Fact-45FECC33B84B76ED5B986F38B8A0D460"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d51046400e1838-wk-Fact-AEAA52268159CD4CE5626F38B8A5391F"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d51046400e1857-wk-Fact-3162A1744EC5226544156F38B892BD57"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d51046400e1878-wk-Fact-2C548FA9FA0FAE820D7F6F38B85284AE"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d51046400e1897-wk-Fact-BA6B4E84300F981C201C6F38B89B836D"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d51046400e1916-wk-Fact-63F28142EBF3663844A96F38B895BA00"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d51046400e1937-wk-Fact-37CC05F29D372DD5E8A16F38B8A5FF8B"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d51046400e1956-wk-Fact-2C8A010A4389F3969E5E6F38B8AC985D"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d51046400e1975-wk-Fact-8F202F0C15B8A7A4ACE96F38B8AB9848"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51046400e1997-wk-Fact-8CA2D641896DAA16E2CE6F38B7A837D6"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51046400e2016-wk-Fact-7183DAA7FA0ADDEAD2616F38B84BC9AA"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51046400e2035-wk-Fact-5F0CB5C6EF0AB00189616F38B8AA7909"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51046400e2056-wk-Fact-9C26193DB3CDD8FB9C8B6F38B8899F39"
      unitRef="shares">187400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51046400e2075-wk-Fact-4176A55C9C6E8FB2BE6A6F38B7A4B71D"
      unitRef="shares">205300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51046400e2094-wk-Fact-BDF045D316347ECE0A996F38B87BB71A"
      unitRef="shares">213000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51046400e2134-wk-Fact-8D6FF6737C2327B196A56F38B7E32E9B"
      unitRef="shares">23600000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51046400e2138-wk-Fact-A7D6E527CFE244BE3DAA6F38B7E7ED8F"
      unitRef="shares">14800000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51046400e2143-wk-Fact-D404ED6D582D89FFF6656F38B7E0ED7E"
      unitRef="shares">3700000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-876DD46AAABEEFFF4F7D6F38B8E61073-0-wk-Fact-DA6DF5E033A0759F17856F38B7CE8464">Share-Based Payments&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;77.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;75.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;74.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;148.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;105.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;95.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;225.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;181.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;169.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(8.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(11.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;216.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;170.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;160.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(35.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(27.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(42.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;180.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;142.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;117.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;30.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;134.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;126.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;107.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;15.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;11.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NST stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;225.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;181.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;169.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(8.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(11.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;216.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;170.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;160.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, unrecognized compensation cost related to unvested share-based compensation was approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$210.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Directors Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2006 our shareholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2006 Directors Plan. We have reserved a total of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a &lt;/span&gt;&lt;span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;1.5-to-1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Omnibus Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2017 Omnibus Equity Plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2008 Omnibus Equity Plan as of June 7, 2017, or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017, are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&#160;&lt;/span&gt;&lt;span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;1.5-to-1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a 10-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, all outstanding options were exercisable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;27,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;53.82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(15,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;50.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;12,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;58.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total intrinsic values of options exercised in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. The aggregate intrinsic values of options outstanding as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The weighted average remaining contractual term for options outstanding as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;years. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax benefit realized for stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received from the exercise of stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Market Stock Units (MSUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;MSUs awarded to employees prior to 2014 vested in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;150%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on actual stock performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;MSUs awarded to employees in 2014 and thereafter vest in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;200%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on actual stock performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The vesting of these awards is subject to the respective employee&#x2019;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our MSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;180,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;371.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;147,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;378.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(101,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;356.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(43,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;388.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;183,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;378.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;MSUs granted during 2019 include awards granted in conjunction with our annual awards made in February 2019 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2019 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2018, 2017 and 2016.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price on the date of grant for MSUs, expected volatility of our stock price, risk-free rates of return and expected dividend yield.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assumptions used in our valuation are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of expected stock price volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;31.2% - 33.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.5% - 32.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.0% - 35.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of risk-free interest rates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.46% - 2.53%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9% - 2.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9% - 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 calendar day average stock price on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$228.59 - $331.18&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$279.47 - $346.76&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$263.18 - $267.88&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average per share grant date fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;$378.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$378.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$382.59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of MSUs vested in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$32.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$26.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$31.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Cash Settled Performance Units (CSPUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;CSPUs awarded to employees vest in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#x2019;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;200%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs are classified as liability awards and will be settled in cash based on the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our CSPU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;50,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(33,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;13,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The cash paid in settlement of CSPUs vested in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$10.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$15.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$16.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Performance-vested Restricted Stock Units (PUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;PUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;200%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;48,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(33,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;11,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All PUs that vested in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; were settled in cash totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$10.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$17.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$11.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Performance Stock Units (PSUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;PSUs Settled in Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the first quarter of 2018 we began granting awards for performance-vested RSUs that will settle in stock. PSUs awarded to employees have a three-year performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#x2019;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of cumulative three-year performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Participants may ultimately earn between &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;200%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PSUs that settle in stock activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;60,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;317.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;77,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;316.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(26,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;318.11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;111,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;316.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;PSUs settled in stock granted in 2019 include awards granted in conjunction with our annual awards made in February 2019 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;PSUs Settled in Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the first quarter of 2018 we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have three performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#x2019;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of three annual performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Participants may ultimately earn between &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;200%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs are classified as liability awards and will be settled in cash based on the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through the vesting date, once the actual vested and earned number of PSUs is determined. Since no shares are issued, these awards do not dilute equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PSUs that settle in cash activity:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;40,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;63,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(20,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;82,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;PSUs settled in cash granted in 2019 include awards granted in conjunction with our annual awards made in February 2019 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Time-Vested Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;RSUs awarded to employees generally vest no sooner than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;one-third per year over three years&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;903,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;303.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;602,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;304.44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(416,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;294.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(151,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;311.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;938,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;306.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;RSUs granted in 2019 primarily represent RSUs granted in conjunction with our annual awards made in February 2019 and awards made in conjunction with the hiring of new employees. RSUs granted in 2019 also include approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;&lt;span&gt;15,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; RSUs granted to our Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;RSUs granted in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; had weighted average grant date fair values of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$316.32&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$293.41&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of RSUs vested in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$131.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$111.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan (ESPP)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2015 our shareholders approved the 2015 ESPP. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our ESPP activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 2015 ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;204,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;170,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;167,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 2015 ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;40.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-ABA33A557B4D9126332E6F38B8E55CC0-0-wk-Fact-5D446A58D85E6810F4FB6F38B7E4DAB3">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;77.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;75.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;74.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;148.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;105.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;95.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;225.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;181.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;169.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(8.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(11.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;216.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;170.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;160.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(35.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(27.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(42.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;180.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;142.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;117.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d51064427e1463-wk-Fact-C922D916B58FEFA23D0E6F38B8143DBF"
      unitRef="usd">77100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d51064427e1482-wk-Fact-D618F66F3E981AC7924D6F38B81B169A"
      unitRef="usd">75800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d51064427e1501-wk-Fact-FFDA31967CDBE4C30AB96F38B80717D8"
      unitRef="usd">74000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d51064427e1517-wk-Fact-9A5F370A85DDE8BE45FF6F38B81CF3D1"
      unitRef="usd">148300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d51064427e1536-wk-Fact-562BBC3F1D7C8933A7B36F38B82ED00D"
      unitRef="usd">105800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d51064427e1555-wk-Fact-C6FA636FBAB903C58E386F38B827DD00"
      unitRef="usd">95700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51064427e1576-wk-Fact-8B3171C4274A546EDCA86F38B7F9C16D"
      unitRef="usd">225400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51064427e1595-wk-Fact-54510C3888EE45A844256F38B825BBE9"
      unitRef="usd">181600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51064427e1614-wk-Fact-EE0CD247BF1D9F82DECD6F38B7F5FC51"
      unitRef="usd">169700000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51064427e1635-wk-Fact-7061327E7AB7741ACFB96F38B81BB062"
      unitRef="usd">8900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51064427e1655-wk-Fact-9AE20A75B8882ADFEE256F38B823558A"
      unitRef="usd">11500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51064427e1675-wk-Fact-5C646CC93220E93D672D6F38B7F35D70"
      unitRef="usd">9600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51064427e1697-wk-Fact-D021E3ABEB7B41FE371E6F38B80DF396"
      unitRef="usd">216500000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51064427e1716-wk-Fact-FF777E45E6F8CA8C999B6F38B7FDE5A6"
      unitRef="usd">170100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51064427e1735-wk-Fact-9F6535C3ECBA176AA3296F38B80811D8"
      unitRef="usd">160100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51064427e1756-wk-Fact-1F24B9F99EB57A66D2026F38B83053AA"
      unitRef="usd">35700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51064427e1776-wk-Fact-BA23EDC78AD5FF4D46166F38B7FA3BE4"
      unitRef="usd">27500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51064427e1796-wk-Fact-978A75625295FF7309116F38B82B2963"
      unitRef="usd">42800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d51064427e1823-wk-Fact-915F4D8C6F2550003B5A6F38B810B047"
      unitRef="usd">180800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d51064427e1842-wk-Fact-434297DF9F7949D844786F38B821D069"
      unitRef="usd">142600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d51064427e1861-wk-Fact-748B8BE3668FE4F546886F38B82B162A"
      unitRef="usd">117300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6995D26B5C680CBF9C8C6F38B8E55A68-0-wk-Fact-6C83D6D43AD797CE8B906F38B84DE68A">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;30.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;134.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;126.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;107.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;15.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;11.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NST stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;225.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;181.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;169.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(8.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(11.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;216.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;170.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;160.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d51064427e2046-wk-Fact-FF47A0BFFBB40E31C4026F38B81578C5"
      unitRef="usd">30400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d51064427e2065-wk-Fact-6818B27E3D83AD21D0136F38B7E79A5B"
      unitRef="usd">27200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d51064427e2084-wk-Fact-5786DECBF34BD272D8326F38B824693D"
      unitRef="usd">22400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d51064427e2100-wk-Fact-9A72D65EA029C2FC982D6F38B7D439CB"
      unitRef="usd">134000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d51064427e2119-wk-Fact-4D16389809F0FC61C29F6F38B7FC6C47"
      unitRef="usd">126600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d51064427e2138-wk-Fact-4576FE68CEDDBACB358C6F38B7CB61F8"
      unitRef="usd">107300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d51064427e2159-wk-Fact-36D505C37F9F0707642A6F38B7FE04C6"
      unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d51064427e2178-wk-Fact-4B8EBC42050D315BEDB26F38B7CB53D4"
      unitRef="usd">7800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d51064427e2197-wk-Fact-28AB811D140475E2C4BD6F38B80C61E4"
      unitRef="usd">18400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember"
      decimals="-5"
      id="d51064427e2218-wk-Fact-BD786C5ABD9928B3C47C6F38B815A558"
      unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember"
      decimals="-5"
      id="d51064427e2237-wk-Fact-CBE4A395CF0D8EA9B5EB6F38B7D3BDEB"
      unitRef="usd">3100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember"
      decimals="-5"
      id="d51064427e2256-wk-Fact-2DD72CA6169948AF943A6F38B7F3C293"
      unitRef="usd">12300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d51064427e2277-wk-Fact-D1D3D736F620F31C599C6F38B7E5734E"
      unitRef="usd">15500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d51064427e2296-wk-Fact-6063A14C11004029EA6F6F38B808052F"
      unitRef="usd">4700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d51064427e2315-wk-Fact-41207B4540E34DF84C486F38B7F45ED8"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d51064427e2336-wk-Fact-0DF50BC8476D2B886F5C6F38B81C0B06"
      unitRef="usd">5500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d51064427e2355-wk-Fact-A8D151C6E31CC0E810D66F38B7F70E5E"
      unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d51064427e2374-wk-Fact-7EC347940DCD48F3C2666F38B7E8B381"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d51064427e2395-wk-Fact-527A592769461A2B136A6F38B7E6A3B0"
      unitRef="usd">11500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d51064427e2414-wk-Fact-17A3EA923FAE9471A1F96F38B7FA5F52"
      unitRef="usd">10500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d51064427e2433-wk-Fact-305C7119B0B0D6B630346F38B7D4070F"
      unitRef="usd">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51064427e2454-wk-Fact-172F3F921774D1B166F0944CD0F65A4E"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51064427e2473-wk-Fact-B71F2CC8992DBEF8A2DA944CFB29F2E1"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d51064427e2492-wk-Fact-BAED40554C69D9A61B7E944D219E0221"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51064427e2513-wk-Fact-8B3171C4274A546EDCA86F38B7F9C16D"
      unitRef="usd">225400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51064427e2532-wk-Fact-54510C3888EE45A844256F38B825BBE9"
      unitRef="usd">181600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51064427e2551-wk-Fact-EE0CD247BF1D9F82DECD6F38B7F5FC51"
      unitRef="usd">169700000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51064427e2573-wk-Fact-7061327E7AB7741ACFB96F38B81BB062"
      unitRef="usd">8900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51064427e2593-wk-Fact-9AE20A75B8882ADFEE256F38B823558A"
      unitRef="usd">11500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51064427e2613-wk-Fact-5C646CC93220E93D672D6F38B7F35D70"
      unitRef="usd">9600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51064427e2640-wk-Fact-D021E3ABEB7B41FE371E6F38B80DF396"
      unitRef="usd">216500000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51064427e2659-wk-Fact-FF777E45E6F8CA8C999B6F38B7FDE5A6"
      unitRef="usd">170100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51064427e2678-wk-Fact-9F6535C3ECBA176AA3296F38B80811D8"
      unitRef="usd">160100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51064427e2702-wk-Fact-D9E9FBC431D1B18C74466F38B85E9C3B"
      unitRef="usd">210400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards
      contextRef="FD2019Q4YTD"
      id="d51064427e2706-wk-Fact-E60D91BBE3EEFA7A68576F38B7ECABBB">P1Y10M24D</biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards>
    <biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d51064427e2716-wk-Fact-97DECEBFF0902871C1296F38B8386AD7"
      unitRef="Plan">3</biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade>
    <biib:NumberOfSharesOfCommonStockForIssuance
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_DirectorsPlanMember"
      decimals="-5"
      id="d51064427e2726-wk-Fact-A322F0C7CAE044925A296F38B85F2046"
      unitRef="shares">1600000</biib:NumberOfSharesOfCommonStockForIssuance>
    <biib:RatioOfNumberOfSharesReservedUnderPlan
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_DirectorsPlanMember"
      id="d51064427e2734-wk-Fact-BB4E9B18885D67C0ED356F38B838ED01">1.5-to-1</biib:RatioOfNumberOfSharesReservedUnderPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="FI2017Q2_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember"
      decimals="-5"
      id="d51064427e2745-wk-Fact-0BA892FD0CEDA877082B6F38B81C320F"
      unitRef="shares">8000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <biib:RatioOfNumberOfSharesReservedUnderPlan
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember"
      id="d51064427e2749-wk-Fact-A906DDC7957F1D33F7A46F38B858BCF5">1.5-to-1</biib:RatioOfNumberOfSharesReservedUnderPlan>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8829F4033081A42157536F38B8E64402-0-wk-Fact-B6F20196A0837ED1F79C6F38B7E8E186">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;27,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;53.82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(15,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;50.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;12,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;58.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q4"
      decimals="INF"
      id="d51064427e2850-wk-Fact-53E39B02B39DBEE7CE5F6F38B85C8EF0"
      unitRef="shares">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q4"
      decimals="2"
      id="d51064427e2869-wk-Fact-70E2D2874738ECA713326F38B859CB3D"
      unitRef="usdPerShare">53.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d51064427e2884-wk-Fact-98A5FEF334055CFE47C66F38B7EA7C84"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d51064427e2903-wk-Fact-340D89B8336E79B114656F38B7E8ADE8"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d51064427e2918-wk-Fact-0EC02343C5D0A7CEF6616F38B85E2ECF"
      unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d51064427e2938-wk-Fact-A0CE7062B0440F70C8796F38B84907C8"
      unitRef="usdPerShare">50.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d51064427e2953-wk-Fact-C1DE462F7D6C535647B16F38B7EBEAC2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d51064427e2972-wk-Fact-DEE1F8947598FD74DDF46F38B88B25B1"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q4"
      decimals="INF"
      id="d51064427e2987-wk-Fact-19A652CBBED3248EC4606F38B834021F"
      unitRef="shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d51064427e3006-wk-Fact-5D8C7A679D3329FE4F406F38B7E9A0F6"
      unitRef="usdPerShare">58.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51064427e3037-wk-Fact-E157BCB3B37F5CE45CC76F38B85BAAE6"
      unitRef="usd">4200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51064427e3041-wk-Fact-2EE2E28457B6C059D2586F38B7E4D7D7"
      unitRef="usd">4000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51064427e3046-wk-Fact-3E4FD9FE67DE98FAF6E96F38B8438607"
      unitRef="usd">3400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51064427e3054-wk-Fact-19AEAF3E0F2B812115816F38B846FAEC"
      unitRef="usd">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2019Q4YTD"
      id="d51064427e3062-wk-Fact-B1F40E8EE87ED50C35CC6F38B8573C0A">P0Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-2DEAF2173AF6230F8FE76F38B8E5E40F-0-wk-Fact-CB345E0D3830958CA2D46F38B8646B64">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax benefit realized for stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received from the exercise of stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51064427e3234-wk-Fact-28D2B8E36C08CD93F5766F38B8C1ADCC"
      unitRef="usd">2500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51064427e3253-wk-Fact-C1A6D9DBA8BF960DD6CA6F38B8C1CA41"
      unitRef="usd">2200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51064427e3272-wk-Fact-D8FAFC9B199E2B4C98666F38B7CFE133"
      unitRef="usd">3400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51064427e3293-wk-Fact-CB7AEAEA5B4BE251E8EC6F38B8BF2C86"
      unitRef="usd">400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51064427e3312-wk-Fact-508DF8FC6ECB1FA135E86F38B8C53B8E"
      unitRef="usd">800000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51064427e3331-wk-Fact-025DF0FDFEB2A4098D636F38B8C44F30"
      unitRef="usd">700000</us-gaap:ProceedsFromStockOptionsExercised>
    <biib:NumberOfEqualAnnualIncrements
      contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="INF"
      id="d51064427e3355-wk-Fact-2722D1624C9AE10CA4F26F38B860466D"
      unitRef="Increment">4</biib:NumberOfEqualAnnualIncrements>
    <biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3359-wk-Fact-BA4D3214B32D3F463ACE6F38B8627507"
      unitRef="number">0</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3363-wk-Fact-F0C4380BDBC9E3CC22516F38B80777E5"
      unitRef="number">1.50</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:NumberOfEqualAnnualIncrements
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="INF"
      id="d51064427e3370-wk-Fact-E5040A4CD8DE00B2D2646F38B7E5979E"
      unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
    <biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3374-wk-Fact-E78332A274D2E5AB26286F38B8158F1C"
      unitRef="number">0</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3378-wk-Fact-60B47D9C51EB6837B1506F38B865647C"
      unitRef="number">2</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:ScheduleOfMarketStockUnitsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5D5DB79CBAA1942BC12D6F38B8E56EF8-0-wk-Fact-549075D5A0002475A3156F38B7E8CE9F">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our MSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;180,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;371.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;147,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;378.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(101,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;356.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(43,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;388.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;183,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;378.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:ScheduleOfMarketStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="INF"
      id="d51064427e3464-wk-Fact-1C8395DA70B2A9104F6C6F38B7E39853"
      unitRef="shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3483-wk-Fact-DA5044E573BB62D9089F6F38B8998C4A"
      unitRef="usdPerShare">371.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="INF"
      id="d51064427e3498-wk-Fact-4F1B1F369F645FCAB5E06F38B89EFA30"
      unitRef="shares">147000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3517-wk-Fact-9ECB7064E915716669C46F38B829E7BC"
      unitRef="usdPerShare">378.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="INF"
      id="d51064427e3532-wk-Fact-68A3733CE3D50B1519A06F38B8A24461"
      unitRef="shares">101000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3552-wk-Fact-E2AB938B33018F780EE26F38B7E57340"
      unitRef="usdPerShare">356.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="INF"
      id="d51064427e3567-wk-Fact-54ED05CD4563CEC483C36F38B8A269E7"
      unitRef="shares">43000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3587-wk-Fact-279307FF36F0573DAB476F38B89304F1"
      unitRef="usdPerShare">388.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="INF"
      id="d51064427e3602-wk-Fact-F19F4A496734EDDC4E0A6F38B7E70EF0"
      unitRef="shares">183000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3621-wk-Fact-476D467B761CD93FB37D6F38B82F7637"
      unitRef="usdPerShare">378.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <biib:NumberOfDaysForCalculationOfAverageClosingStockPrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      id="d51064427e3665-wk-Fact-53EFE783EAD85B76A8FA6F38B84686AF">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
    <biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B18DDD8B61AFC145F5636F38B8E479EE-0-wk-Fact-3CB94B70ACB531D0F5D36F38B85A0F70">he assumptions used in our valuation are summarized as follows:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of expected stock price volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;31.2% - 33.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.5% - 32.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.0% - 35.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of risk-free interest rates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.46% - 2.53%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9% - 2.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9% - 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 calendar day average stock price on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$228.59 - $331.18&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$279.47 - $346.76&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$263.18 - $267.88&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average per share grant date fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;$378.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$378.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$382.59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3765-wk-Fact-C39F45D35190FA2BD9026F38B8301A32"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3775-wk-Fact-64501121A84C9DC23BF66F38B82DAF77"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3785-wk-Fact-BF42A68D25A45EDE267B6F38B82A4F0F"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3889-wk-Fact-9ECB7064E915716669C46F38B829E7BC"
      unitRef="usdPerShare">378.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3899-wk-Fact-D8DDCF53FD3C69463D566F38B82F9D06"
      unitRef="usdPerShare">378.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="2"
      id="d51064427e3909-wk-Fact-4C7CBB88ADB7D61992006F38B82C0ACA"
      unitRef="usdPerShare">382.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d51064427e3936-wk-Fact-86B7CEB9A6E8E900FC9B6F38B817E463"
      unitRef="usd">32500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d51064427e3940-wk-Fact-98EA283ADA24D4CE984E6F38B856134F"
      unitRef="usd">26900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d51064427e3945-wk-Fact-C679A98255842BC995FF6F38B85F718E"
      unitRef="usd">31400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <biib:NumberOfEqualAnnualIncrements
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="INF"
      id="d51064427e3956-wk-Fact-0BB7C67757E825523A406F38B7D1EB26"
      unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
    <biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="2"
      id="d51064427e3960-wk-Fact-34E10E045B53C0EB4EC06F38B7E746D4"
      unitRef="number">0</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="2"
      id="d51064427e3964-wk-Fact-01E3912C107ABBA133496F38B7E8C8C7"
      unitRef="number">2</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:NumberOfDaysForCalculationOfAverageClosingStockPrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      id="d51064427e3968-wk-Fact-A7629355C3DC0E0A65F86F38B7CEA480">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
    <biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4677AB063A3DF49666826F38B8E5E47A-0-wk-Fact-51210B2110A2D5878D766F38B7CCB113">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our CSPU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;50,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(33,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;13,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="INF"
      id="d51064427e4027-wk-Fact-A7477ACA4DFB73072E4F6F38B888235E"
      unitRef="shares">50000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="INF"
      id="d51064427e4042-wk-Fact-B2AB1654C6C9E45C3FE56F38B8955470"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="INF"
      id="d51064427e4057-wk-Fact-97444E16795C011BA1C76F38B890091A"
      unitRef="shares">33000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="INF"
      id="d51064427e4073-wk-Fact-AB693AAE5A6B8FBB6B7A6F38B88669D7"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="INF"
      id="d51064427e4089-wk-Fact-B6FC8A90A77461C6DABE6F38B8866FCF"
      unitRef="shares">13000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d51064427e4128-wk-Fact-C1C8D2FF47C7358C64D66F38B85ECBD0"
      unitRef="usd">10600000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d51064427e4132-wk-Fact-A7625857EA260083E9D66F38B84AD16E"
      unitRef="usd">15100000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d51064427e4137-wk-Fact-D77CC0E80F4F8EF7262A6F38B7E639D2"
      unitRef="usd">16600000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <biib:NumberOfEqualAnnualIncrements
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d51064427e4147-wk-Fact-45F705999FB7B255551C6F38B85DB2B3"
      unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
    <biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="d51064427e4151-wk-Fact-0E629A35D8D2FDBAC23F6F38B85222AC"
      unitRef="number">0</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="d51064427e4155-wk-Fact-44EC9332C926D2A9E2696F38B7CB1EAC"
      unitRef="number">2</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:NumberOfDaysForCalculationOfAverageClosingStockPrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="d51064427e4159-wk-Fact-E0B08A77A7EB951769686F38B7EC1EDA">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
    <biib:PerformanceunitsactivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-A0F47EC8AF36F08713846F38B8E6D5CE-0-wk-Fact-CDBCF06F669C0DFF78F96F38B83FEAE7">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;48,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(33,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;11,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:PerformanceunitsactivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d51064427e4212-wk-Fact-5D738431E6B0640650D36F38B7EADB64"
      unitRef="shares">48000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d51064427e4227-wk-Fact-178A9FB5811957F1E3206F38B7E913F2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d51064427e4242-wk-Fact-8F65EFFE6EA0B59DEC0F6F38B7E4ED2E"
      unitRef="shares">33000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d51064427e4258-wk-Fact-88944F7E8428361225D86F38B7E27EBB"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d51064427e4274-wk-Fact-17A4AD567165210541106F38B7EAD75D"
      unitRef="shares">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d51064427e4308-wk-Fact-E6C051DE16452B467AA76F38B85D31B8"
      unitRef="usd">10400000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d51064427e4312-wk-Fact-06AF65B25DDDD5332C616F38B7CA0D0D"
      unitRef="usd">17000000.0</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d51064427e4317-wk-Fact-62E533FC673DF438DAFF6F38B7D0D5BB"
      unitRef="usd">11500000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="2"
      id="d51064427e4334-wk-Fact-BC58F528399BE8E673F76F38B8586123"
      unitRef="number">0</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="2"
      id="d51064427e4338-wk-Fact-6815093DD9E2225A7F9A6F38B84A0A04"
      unitRef="number">2</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:PerformanceStockUnitsSettledinStockTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5EDAC8FB81402AE3095C6F38B8E409A2-0-wk-Fact-F8EEEEF5C04CDFEC70C76F38B7D309ED">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PSUs that settle in stock activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;60,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;317.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;77,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;316.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(26,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;318.11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;111,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;316.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:PerformanceStockUnitsSettledinStockTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-3"
      id="d51064427e4415-wk-Fact-DC74A22A9C5CF874E2F86F38B80B280F"
      unitRef="shares">60000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="2"
      id="d51064427e4434-wk-Fact-3E1BDE3778C9B8846FE66F38B7FF16CB"
      unitRef="usdPerShare">317.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-3"
      id="d51064427e4449-wk-Fact-E6B44BF27A8218CBDB316F38B80A7BFE"
      unitRef="shares">77000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="2"
      id="d51064427e4468-wk-Fact-B089A6B821E5A82ACA5F6F38B8043D78"
      unitRef="usdPerShare">316.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-3"
      id="d51064427e4483-wk-Fact-07D417C2DD6D2349C2236F38B8088D4C"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="2"
      id="d51064427e4502-wk-Fact-FECA44E5E9369A58A6256F38B7FE4D65"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-3"
      id="d51064427e4517-wk-Fact-0E27AC6844410186DF816F38B8076183"
      unitRef="shares">26000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="2"
      id="d51064427e4537-wk-Fact-5FF072EA40E53B412D436F38B805956E"
      unitRef="usdPerShare">318.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-3"
      id="d51064427e4552-wk-Fact-21D9EEB57C8B81975A986F38B800B160"
      unitRef="shares">111000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="2"
      id="d51064427e4571-wk-Fact-D81570F131E4F91864A86F38B7FD1CDE"
      unitRef="usdPerShare">316.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="2"
      id="d51064427e4601-wk-Fact-EE467F4818885B4ABCF36F38B83ECE7D"
      unitRef="number">0</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="2"
      id="d51064427e4605-wk-Fact-4D3365D46D74B763092D6F38B8172E7B"
      unitRef="number">2</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:NumberOfDaysForCalculationOfAverageClosingStockPrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      id="d51064427e4609-wk-Fact-6E902BEBB4BDC065C59B6F38B7E80670">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
    <biib:PerformanceStockUnitsSettledinCashTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6ADE1629F8D3A4FE9C616F38B8E5FD05-0-wk-Fact-84254DC1F5EF703F54DB6F38B83EC749">&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PSUs that settle in cash activity:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;40,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;63,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(20,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;82,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:PerformanceStockUnitsSettledinCashTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-3"
      id="d51064427e4652-wk-Fact-BA919EE2C778FB1C8D9C6F38B8BA7660"
      unitRef="shares">40000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-3"
      id="d51064427e4667-wk-Fact-D2C5B78117DF5BA6F4CA6F38B7F2C88F"
      unitRef="shares">63000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-3"
      id="d51064427e4682-wk-Fact-10D174C5D09D544C3BDF6F38B8C0F09A"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-3"
      id="d51064427e4698-wk-Fact-0AC9D94E1AD28EE9A91E6F38B7F4B6F9"
      unitRef="shares">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-3"
      id="d51064427e4714-wk-Fact-2F35CB83578AA6D9E5A96F38B7F8EA50"
      unitRef="shares">82000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9672EAFAA506674613B46F38B8E5D6E0-0-wk-Fact-001C065AE58F8BD532A16F38B845CF13">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;903,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;303.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;602,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;304.44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(416,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;294.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(151,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;311.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;938,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;306.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="INF"
      id="d51064427e4825-wk-Fact-C19263F98BEC96BACF586F38B8745AD2"
      unitRef="shares">903000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="2"
      id="d51064427e4844-wk-Fact-BE97DDD53A99867F18FD6F38B8753E52"
      unitRef="usdPerShare">303.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="INF"
      id="d51064427e4859-wk-Fact-E86D1CE0A120BCF496176F38B80DB12E"
      unitRef="shares">602000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="2"
      id="d51064427e4878-wk-Fact-A2BEB14B74EE13ECC3C46F38B87B88DB"
      unitRef="usdPerShare">304.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="INF"
      id="d51064427e4893-wk-Fact-62D4F9FF93274D5C52236F38B891CA64"
      unitRef="shares">416000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="2"
      id="d51064427e4913-wk-Fact-71C2C55015FC332ED5E86F38B87103B2"
      unitRef="usdPerShare">294.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="INF"
      id="d51064427e4928-wk-Fact-8DD013F8BFBBCE2336496F38B8104318"
      unitRef="shares">151000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="2"
      id="d51064427e4948-wk-Fact-B90C1DAA899DC8E99CEF6F38B8BDFDF5"
      unitRef="usdPerShare">311.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="INF"
      id="d51064427e4963-wk-Fact-E5DE6EEA546C5EDF1D2A6F38B863D9D8"
      unitRef="shares">938000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="2"
      id="d51064427e4982-wk-Fact-AC8802F47110652E27396F38B812ED68"
      unitRef="usdPerShare">306.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="INF"
      id="d51064427e5013-wk-Fact-607BA5807AAC7AE99C9D6F38B7FC34A8"
      unitRef="shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="2"
      id="d51064427e5036-wk-Fact-58BFCB2553BA5BFAF57A6F38B7F6F569"
      unitRef="usdPerShare">316.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="2"
      id="d51064427e5040-wk-Fact-F976A3B9036513CD33B76F38B8562CC1"
      unitRef="usdPerShare">293.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d51064427e5064-wk-Fact-A0904F4433BD188763D16F38B857A591"
      unitRef="usd">131500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d51064427e5068-wk-Fact-839FD07AFB0F8759459B6F38B84773F1"
      unitRef="usd">111700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d51064427e5073-wk-Fact-2166256C00BFAC597E046F38B7D08B93"
      unitRef="usd">100000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51064427e5083-wk-Fact-D2767D36571F6FA495C26F38B85B0C8F"
      unitRef="shares">6200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EA3C3CEDF4D2A42EC1DA6F38B8E5EF55-0-wk-Fact-950AE6A3F1EB56C83D656F38B838C717">&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our ESPP activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 2015 ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;204,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;170,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;167,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 2015 ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;40.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember"
      decimals="INF"
      id="d51064427e5250-wk-Fact-47B389D096C1443776C66F38B8107F60"
      unitRef="shares">204000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember"
      decimals="INF"
      id="d51064427e5269-wk-Fact-CB390249688740D2237E6F38B8148ACA"
      unitRef="shares">170000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember"
      decimals="INF"
      id="d51064427e5288-wk-Fact-34461C5F12C3B31864C56F38B815B731"
      unitRef="shares">167000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember"
      decimals="-5"
      id="d51064427e5314-wk-Fact-CA41435A97D666695B0B6F38B80E0ADB"
      unitRef="usd">40400000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember"
      decimals="-5"
      id="d51064427e5333-wk-Fact-4139C1C3B3EE90400BE26F38B8147EF1"
      unitRef="usd">40500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember"
      decimals="-5"
      id="d51064427e5352-wk-Fact-4C50BA076A1732EB37C66F38B813E0A6"
      unitRef="usd">39800000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4DA6B191511715A8114C6F38B8E60B13-0-wk-Fact-88AC1A04F8B2F4BD38796F38B7A6D37A">&#160;&#160;&#160;&#160;Income Taxes&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Income Tax Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income before income tax provision and the income tax expense consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income before income taxes (benefit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;4,725.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,877.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,540.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,400.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,022.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,588.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7,125.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,899.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,128.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income tax expense (benefit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;947.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,131.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,201.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;59.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;84.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;140.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;108.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,090.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,317.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,367.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,143.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(62.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;241.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1,074.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;177.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(159.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;67.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;108.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;91.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,158.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,425.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,458.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2017 Tax Act&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries and collaborations to immediate U.S. taxation as GILTI or Subpart F income, and includes base erosion prevention measures on U.S. earnings and the reduced effective tax rate on income that comes from U.S. exports, called Foreign Derived Intangible Income. These changes became effective in 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the fourth quarter of 2017 we recognized within our provision for income taxes a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; estimate pursuant to the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 118. Our estimate included an amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$989.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax), as discussed below, and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$184.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the impact of remeasuring our deferred tax balances to reflect the new federal statutory rate and other changes to U.S. tax law. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the year ended December 31, 2018, we recognized a net reduction of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$34.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our estimated Transition Toll Tax, an expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$12.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to remeasure our deferred tax balances, an expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$135.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to establishing deferred taxes for GILTI and an expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$11.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect other aspects of the 2017 Tax Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Transition Toll Tax&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax. The Transition Toll Tax was assessed on our share of our foreign corporations' accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and all other earnings were taxed at a rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have accrued income tax liabilities of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$697.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under the Transition Toll Tax. Of the amounts accrued as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, no amounts are expected to be paid within one year due to an approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$87.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; carryforward of taxes paid in relation to the company's 2017 tax return. The Transition Toll Tax will be paid over an eight--year period, which started in 2018, and does not accrue interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unremitted Earnings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;At December 31, 2019, we considered our earnings not to be permanently reinvested outside the U.S. and therefore recorded deferred tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. Other than for earnings, we are permanently reinvested for book/tax basis differences of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of December 31, 2019, primarily arising through the impacts of purchase accounting. These permanently reinvested basis differences could reverse through sales of the foreign subsidiaries, as well as various other events, none of which were considered probable as of December 31, 2019. The residual U.S. tax liability, if these differences reverse, would be between &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Article 20 Procedure of ZINBRYTA&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2017 the European Medicines Agency initiated a review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury. As a result of the Article 20 Procedure of ZINBRYTA, for the year ended December 31, 2017, we recognized a net impairment charge on certain tax assets related to ZINBRYTA reflected within income tax expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$48.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This charge reflected the write-off of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$142.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to prepaid taxes, which was partially offset by the recognition of an unrecorded deferred tax benefit of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$93.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on our collaboration arrangement with AbbVie, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Significant components of our deferred tax assets and liabilities are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;106.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;102.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory, other reserves and accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;162.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;163.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangibles, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,380.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,298.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net operating loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;130.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;213.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;23.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;103.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(20.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,905.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,823.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(350.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(232.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;GILTI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1,381.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(544.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1,617.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,425.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation, amortization and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(135.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(102.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(3,484.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,305.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intra-entity sales of inventory. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the total deferred charges and prepaid taxes were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$243.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$239.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(11.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Divestiture of Denmark manufacturing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Internal reorganization of certain intellectual property rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;GILTI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;U.S. tax reform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss tax reform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Impairment of ZINBRYTA related tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;16.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights and the impact of the enactment of a new taxing regime in the country and certain cantons of Switzerland. This decrease was partially offset by a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$68.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; tax expense related to the divestiture of our subsidiary that owned our Hiller&#xf8;d, Denmark manufacturing operations. We also had a higher effective tax rate in 2018 resulting from the unfavorable effects of &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;the 2017 Tax Act and our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Although we are recognizing a loss on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, the divestiture required us to write-off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of the internal reorganization of certain intellectual property rights, we recorded a deferred tax asset of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$754.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a deferred tax liability of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$603.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the decrease in our effective tax rate was primarily due to the enactment of the 2017 Tax Act. The effects of an overall reduction in the federal statutory rate in the U.S. were partially offset by the elimination of the manufacturing deduction, the imposition of the GILTI tax on international earnings, our recording of deferred taxes on GILTI in 2018, limits on the deductibility of certain benefits on executive compensation and a reduction in the tax benefit associated with the Orphan Drug Credit, all resulting from the 2017 Tax Act, and a change in accounting rules related to recording the tax impacts of intra-entity transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Tax Attributes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which begin to expire in 2022. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; that begin to expire in 2020. For state income tax purposes, we had research and investment credit carry forwards of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$133.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; that begin to expire in 2020. For foreign income tax purposes, we had &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,773.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of net operating loss carryforwards that begin to expire in 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at January&#160;1,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;114.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions based on tax positions related to the current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions for tax positions of prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;17.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;58.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reductions for tax positions of prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(10.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(13.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(21.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statute expirations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlement refund (payment)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;129.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;114.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our 2017 activity reflects a refund received from a state related to the settlement of an uncertain tax position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Included in the balance of unrecognized tax benefits as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$122.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$109.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$64.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize potential interest and penalties related to unrecognized tax benefits in income tax expense. In &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we recognized a net interest expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We have accrued &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$13.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the payment of interest and penalties as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, in connection with the spin-off of our hemophilia business, we distributed all of the then outstanding shares of Bioverativ common stock to Biogen shareholders pursuant to a separation agreement. In March 2018 Bioverativ was acquired by Sanofi S.A. (Sanofi) and is now an indirect wholly-owned subsidiary of Sanofi. The spin-off of our hemophilia business was intended to qualify for tax-free treatment to Biogen and its shareholders under the Internal Revenue Code. Our 2017 tax return remains open to audit. Bioverativ and Sanofi agreed to indemnify us for certain potential liabilities that may arise. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Federal and State Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E043A5C322EBAC858C606F38B8E619A0-0-wk-Fact-0C585A59587886FFB97F6F38B8B0B584">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income before income tax provision and the income tax expense consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income before income taxes (benefit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;4,725.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,877.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,540.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,400.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,022.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,588.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7,125.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,899.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,128.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income tax expense (benefit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;947.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,131.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,201.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;59.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;84.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;140.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;108.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,090.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,317.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,367.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,143.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(62.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;241.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1,074.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;177.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(159.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;67.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;108.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;91.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,158.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,425.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,458.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e1525-wk-Fact-97DD3255C2BDF679F11A6F38B7A57D74"
      unitRef="usd">4725300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e1544-wk-Fact-3975C9AC3921344880396F38B87C828C"
      unitRef="usd">3877000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e1563-wk-Fact-E83BB60678D8829947466F38B86601AB"
      unitRef="usd">3540400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e1579-wk-Fact-56B0163FA259911C6FE06F38B8B81FD7"
      unitRef="usd">2400600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e1598-wk-Fact-D255D63334B1DCF5C8996F38B8B15215"
      unitRef="usd">2022600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e1617-wk-Fact-74EFDB175FE9C6843B4A6F38B8B52700"
      unitRef="usd">1588400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e1643-wk-Fact-037FDB9132CFC80955486F38B80DC31A"
      unitRef="usd">7125900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e1662-wk-Fact-CEA622036210CBAE55336F38B7C2C044"
      unitRef="usd">5899600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e1681-wk-Fact-68291FC0C112D97457DA6F38B7DD4BB7"
      unitRef="usd">5128800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e1826-wk-Fact-DE3A2A0A5EE9C325988B6F38B7AA7A89"
      unitRef="usd">947400000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e1845-wk-Fact-EBDE76E464C0C13C53EB6F38B8BDF2C5"
      unitRef="usd">1131800000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e1864-wk-Fact-2DCE46EB8C1E141938FC6F38B889B028"
      unitRef="usd">2201400000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e1880-wk-Fact-31413CF7A9812FDE308A6F38B7A8C876"
      unitRef="usd">59100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e1899-wk-Fact-9F8604320F39675BA1CD6F38B860D1FF"
      unitRef="usd">45500000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e1918-wk-Fact-6A7640C2E516651606786F38B8AFD467"
      unitRef="usd">57000000.0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e1939-wk-Fact-3A59225FB2492EB6E06E6F38B8B076B9"
      unitRef="usd">84400000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e1958-wk-Fact-C7EFC5F1F7C7AAE1C0516F38B87E3338"
      unitRef="usd">140000000.0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e1977-wk-Fact-CA8B8708EFFE5E90A0056F38B887B516"
      unitRef="usd">108600000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e1999-wk-Fact-93A2CA0144A6EBF443CA6F38B8B055D5"
      unitRef="usd">1090900000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e2018-wk-Fact-6B0573C592FE253693E36F38B86B9C7C"
      unitRef="usd">1317300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e2037-wk-Fact-ECDCAE5C5D0D0B6542466F38B879CBB3"
      unitRef="usd">2367000000.0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e2125-wk-Fact-646EEB59905489B571E26F38B869ED88"
      unitRef="usd">1143900000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e2144-wk-Fact-2B3F15C20007669E5F5B6F38B7A98384"
      unitRef="usd">-62000000.0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e2164-wk-Fact-DF212C12FCD728BF21B16F38B8B941BE"
      unitRef="usd">241000000.0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e2180-wk-Fact-A2272F18AE1DA0F204C86F38B7A83B36"
      unitRef="usd">-2300000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e2200-wk-Fact-6047BEF02B04CC40CB696F38B8C3F563"
      unitRef="usd">-7400000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e2220-wk-Fact-73AA159C8BDE75BD6B376F38B7C353EE"
      unitRef="usd">9900000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e2241-wk-Fact-98E81378DDE2B9FBC91A6F38B87B20BA"
      unitRef="usd">-1074500000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e2261-wk-Fact-CFEB7783D75421F028966F38B8C0B521"
      unitRef="usd">177700000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e2280-wk-Fact-29B2E5C7B4902366CBDC6F38B7A60D13"
      unitRef="usd">-159200000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e2302-wk-Fact-7C31084FEFA28114DCAB6F38B864D055"
      unitRef="usd">67100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e2321-wk-Fact-15E7585669CC1C2CBDC96F38B86FDC03"
      unitRef="usd">108300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e2340-wk-Fact-AA985A4C7305479DFAD86F38B7C27564"
      unitRef="usd">91700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e2366-wk-Fact-D772848546D678B1763B6F38B837CC03"
      unitRef="usd">1158000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e2385-wk-Fact-2FDAAAEDBE81F99A2C786F38B89FE50C"
      unitRef="usd">1425600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e2404-wk-Fact-297A0CBBF5B99106D4D26F38B7FC8B8D"
      unitRef="usd">2458700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e2427-wk-Fact-70B479AAC24A525935106F38B88111E8"
      unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="2"
      id="d51060145e2431-wk-Fact-964C41E5BAFF81993B036F38B7B1194F"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="-8"
      id="d51060145e2438-wk-Fact-F4F0D1C36591CEA9D6F06F38B8AFC00D"
      unitRef="usd">1200000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="-5"
      id="d51060145e2442-wk-Fact-5EAC5E8CB8B583D310216F38B7B4551F"
      unitRef="usd">989600000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="FD2017Q4QTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="-5"
      id="d51060145e2446-wk-Fact-DD89308EA5D44145ED3D6F38B8B5EB64"
      unitRef="usd">184000000.0</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <biib:Reductionindeferredtaxliabilityundistributedforeignearnings
      contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="-5"
      id="d51060145e2453-wk-Fact-F28A34897708EEE639296F38B7A48216"
      unitRef="usd">34600000</biib:Reductionindeferredtaxliabilityundistributedforeignearnings>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="-5"
      id="d51060145e2457-wk-Fact-95CA1639175DCBB9B9D96F38B8B0DCA0"
      unitRef="usd">12700000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <biib:DeferredtaxliabilitiesGILTItaxcalculation
      contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="-5"
      id="d51060145e2461-wk-Fact-570282B9EBEE8CB3C20D6F38B8C7A8FD"
      unitRef="usd">135800000</biib:DeferredtaxliabilitiesGILTItaxcalculation>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="-5"
      id="d51060145e2465-wk-Fact-2606B358E0C2B7C076B26F38B8B0033F"
      unitRef="usd">11000000.0</us-gaap:OtherTaxExpenseBenefit>
    <biib:TransitionTollTaxRepatriationTaxRate
      contextRef="FI2017Q4_biib_ForeignearningstypeAxis_biib_ForeignearningsintheformofcashandcashequivalentsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="INF"
      id="d51060145e2475-wk-Fact-32F7BCF55DD8411DDF826F38B8B078DE"
      unitRef="number">0.155</biib:TransitionTollTaxRepatriationTaxRate>
    <biib:TransitionTollTaxRepatriationTaxRate
      contextRef="FI2017Q4_biib_ForeignearningstypeAxis_biib_OtherForeignEarningsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="INF"
      id="d51060145e2479-wk-Fact-ACD03A6750E57F9BB4846F38B8B514BE"
      unitRef="number">0.080</biib:TransitionTollTaxRepatriationTaxRate>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="-5"
      id="d51060145e2494-wk-Fact-52C5D7094068BA7F90B96F38B8C0633D"
      unitRef="usd">697000000.0</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:IncomeTaxesPaid
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e2502-wk-Fact-AD9B60635BB64EC20E84D152089FDEEB"
      unitRef="usd">87000000.0</us-gaap:IncomeTaxesPaid>
    <biib:Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries
      contextRef="FI2019Q4"
      decimals="-8"
      id="d51060145e2513-wk-Fact-D59DFCF02A0901DBDA23FC2E91368956"
      unitRef="usd">1500000000</biib:Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries>
    <biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember"
      decimals="-8"
      id="d51060145e2517-wk-Fact-B45BDA5E60CF0C82C39AFC2FB25DFB6A"
      unitRef="usd">300000000</biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting>
    <biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember"
      decimals="-8"
      id="d51060145e2521-wk-Fact-6DD37D671D9965452540FC308A139EBF"
      unitRef="usd">400000000</biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51060145e2531-wk-Fact-0221C7625B0B85BB983B6F38B7A389F9"
      unitRef="usd">48800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses
      contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_biib_PrepaidtaxesMember"
      decimals="-5"
      id="d51060145e2535-wk-Fact-436D63CDAA4F7906CCF36F38B7ADEE47"
      unitRef="usd">142600000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember"
      decimals="-5"
      id="d51060145e2539-wk-Fact-455C43561EC0E646D11C6F38B7B0B5DB"
      unitRef="usd">93800000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4973455FAB516DAF7FD36F38B8E63C6B-0-wk-Fact-20837A0D7F89FFF497D76F38B7C4D61B">s&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Significant components of our deferred tax assets and liabilities are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;106.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;102.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory, other reserves and accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;162.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;163.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangibles, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,380.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,298.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net operating loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;130.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;213.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;23.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;103.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(20.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,905.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,823.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(350.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(232.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;GILTI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1,381.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(544.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1,617.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,425.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation, amortization and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(135.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(102.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(3,484.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,305.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e2713-wk-Fact-16EC0A3CF085551C5B626F38B858FBF7"
      unitRef="usd">106600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e2732-wk-Fact-C9F59C72AADD891E9AD26F38B7ECEA92"
      unitRef="usd">102800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e2747-wk-Fact-5B4EA01EFF58A89270CA6F38B8446C16"
      unitRef="usd">162000000.0</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e2766-wk-Fact-397664E3A5D081A2263B6F38B84B841F"
      unitRef="usd">163900000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e2786-wk-Fact-5EB6015C5472673176836F38B849C5C9"
      unitRef="usd">3380000000.0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e2805-wk-Fact-E4BE326B0E89DE253EBE6F38B8387ED3"
      unitRef="usd">2298600000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e2825-wk-Fact-A09602DEA5E5C954519A6F38B8421746"
      unitRef="usd">130400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e2844-wk-Fact-0C5DA9D442BC1C5923146F38B7EB5297"
      unitRef="usd">213100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e2864-wk-Fact-16A6C004B9B328EA998A6F38B85F0908"
      unitRef="usd">23800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e2883-wk-Fact-68850645CAF9CCDC748B6F38B8673B71"
      unitRef="usd">25800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e2903-wk-Fact-19EEBCCCAB42517C84F06F38B84812E1"
      unitRef="usd">103700000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e2922-wk-Fact-5170640CB73AD2784A096F38B84A8965"
      unitRef="usd">38900000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e2942-wk-Fact-762A01BA35E74570BB0D6F38B86CE6C8"
      unitRef="usd">1100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e2962-wk-Fact-9A23ACC46298D163A6FC6F38B868F978"
      unitRef="usd">20000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e2988-wk-Fact-940B6E43E7B37D8C63466F38B841C6DC"
      unitRef="usd">3905400000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e3007-wk-Fact-6AACC70561E6F97141D86F38B7EB650B"
      unitRef="usd">2823100000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e3069-wk-Fact-F262955AB6A852EE15D36F38B85CD285"
      unitRef="usd">350300000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e3089-wk-Fact-1B1976732BFA422CBF826F38B7E86C9E"
      unitRef="usd">232800000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <biib:DeferredtaxliabilitiesGILTItaxcalculation
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e3105-wk-Fact-6497D6494E0F1755C7D06F38B849922C"
      unitRef="usd">-1381600000</biib:DeferredtaxliabilitiesGILTItaxcalculation>
    <biib:DeferredtaxliabilitiesGILTItaxcalculation
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e3125-wk-Fact-707B18E38D5CA08D1CD76F38B7ED988B"
      unitRef="usd">-544600000</biib:DeferredtaxliabilitiesGILTItaxcalculation>
    <biib:DeferredTaxLiabilitiesTaxCreditCarryforwards
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e3146-wk-Fact-FBEE45F2DF7CB9BACF906F38B7EB9D05"
      unitRef="usd">-1617200000</biib:DeferredTaxLiabilitiesTaxCreditCarryforwards>
    <biib:DeferredTaxLiabilitiesTaxCreditCarryforwards
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e3166-wk-Fact-9ABDCFC10A5A1DEA25226F38B85F9F10"
      unitRef="usd">-1425700000</biib:DeferredTaxLiabilitiesTaxCreditCarryforwards>
    <biib:DeferredTaxLiabilitiesDepreciationAmortizationOther
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e3187-wk-Fact-3EF9DF482D4D62B2DCBC6F38B8393EE4"
      unitRef="usd">135000000.0</biib:DeferredTaxLiabilitiesDepreciationAmortizationOther>
    <biib:DeferredTaxLiabilitiesDepreciationAmortizationOther
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e3207-wk-Fact-377CE05F36C5E2F93FAF6F38B8596798"
      unitRef="usd">102300000</biib:DeferredTaxLiabilitiesDepreciationAmortizationOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e3233-wk-Fact-02014614BD7DDA3BF39D6F38B85349B7"
      unitRef="usd">3484100000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e3253-wk-Fact-030A1BEE9F279EE71D176F38B85E2855"
      unitRef="usd">2305400000</us-gaap:DeferredTaxLiabilities>
    <biib:Totaldeferredchargesandprepaidtaxes
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e3281-wk-Fact-31EFDE55C1D24E1AF2686F38B7A818B9"
      unitRef="usd">243800000</biib:Totaldeferredchargesandprepaidtaxes>
    <biib:Totaldeferredchargesandprepaidtaxes
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e3285-wk-Fact-AABC1E5B8E2DAEF3C49D6F38B8B8779D"
      unitRef="usd">239200000</biib:Totaldeferredchargesandprepaidtaxes>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F289736B160DA1D44C266F38B8E6496B-0-wk-Fact-7D4E93A70ED5F331F7D46F38B7A99968">e&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(11.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Divestiture of Denmark manufacturing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Internal reorganization of certain intellectual property rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;GILTI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;U.S. tax reform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss tax reform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Impairment of ZINBRYTA related tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;16.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3420-wk-Fact-5AB65E54E6ED753A97286F38B86A45C8"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3435-wk-Fact-83B09769B7AA78058C616F38B85EC330"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3450-wk-Fact-70B479AAC24A525935106F38B88111E8"
      unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3466-wk-Fact-926B9BF83222A3F446966F38B89E5835"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3480-wk-Fact-601B8D2D7BC01C5C097E6F38B8A14DE9"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3494-wk-Fact-88651EC52BC6F05A0CB86F38B870AF05"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3509-wk-Fact-FA9A558EA5E6EC27C8356F38B871AA63"
      unitRef="number">-0.045</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3524-wk-Fact-721359E7B2C9C9CE6AED6F38B7B251BD"
      unitRef="number">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3539-wk-Fact-7EAAFEDA265C69E49F126F38B85E8045"
      unitRef="number">-0.111</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3555-wk-Fact-FB124E6754FDDC88CC316F38B8A8D8D5"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3570-wk-Fact-3F01D31134776FD9A2F86F38B88929F0"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3585-wk-Fact-356D6DDC944080E81DA56F38B8611998"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3601-wk-Fact-F8790B0E4C4645295FB46F38B87DB9C1"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3615-wk-Fact-68C383DCBFF43CA7388F6F38B7C18A2B"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3629-wk-Fact-1A5EB239771B15E719CA6F38B891F4B5"
      unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3644-wk-Fact-2F34BDE0C6F486007D3AFC325A1748A8"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3658-wk-Fact-4D33A815C2D29FEF8597FC325C90EF02"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3672-wk-Fact-5A71A2B2EE69CD85BEE1FC325FD1B0D6"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3687-wk-Fact-72B56EE923FD022F1F74FC32D923FB70"
      unitRef="number">-0.021</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3702-wk-Fact-39FFF3CC878998F488F0FC32DBE4D9E3"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3716-wk-Fact-621794DC7AED53291CD8FC32DDCC458B"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3731-wk-Fact-2EC086FEB0B7B5DC78596F38B869E74B"
      unitRef="number">0.015</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3745-wk-Fact-D7D73339E6424F8F42F96F38B85D5EE8"
      unitRef="number">0.016</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3759-wk-Fact-2F5C0605538ED33785C76F38B861D7D5"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationGILTItax>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3774-wk-Fact-6742C652BCD109F261216F38B7B7FA52"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3788-wk-Fact-AF9608F45B0981A225756F38B87AC347"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3802-wk-Fact-D4C9E1BD8D5DE1F1C1AD6F38B896F7BA"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3818-wk-Fact-0587D865B836AC81849B6F38B8A6E562"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3832-wk-Fact-93BA252969E48801D5856F38B887FAC7"
      unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3846-wk-Fact-D89EE90BA083174049A76F38B855DABD"
      unitRef="number">0.229</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3861-wk-Fact-AC75FDDA482AD23E414DFC334FAFC7FA"
      unitRef="number">-0.008</biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent>
    <biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3876-wk-Fact-B0FE0CA0B791ED99366FFC3351AAE511"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent>
    <biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3890-wk-Fact-2B90E70AF63F58C74900FC335343371E"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent>
    <biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3905-wk-Fact-B8B4A1514F45B78096346F38B86D71E5"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
    <biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3919-wk-Fact-DB85FF57400AB512649E6F38B894C141"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
    <biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3933-wk-Fact-1E6F9F929AABB17352746F38B8972549"
      unitRef="number">-0.019</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3949-wk-Fact-949FC4CC836E235F807B6F38B87ACE77"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e3963-wk-Fact-F82628F3EED443F7ADDA6F38B86AE879"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e3977-wk-Fact-AFC434AE531F81CD46C06F38B864B8BD"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e3992-wk-Fact-AA6623E1119A08930BE86F38B8A4875B"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e4007-wk-Fact-EDFBDE8B3772D65674456F38B89A5C63"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e4021-wk-Fact-35E969BC343232E771F06F38B874509C"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d51060145e4036-wk-Fact-90B8848C5FD113D9C68C6F38B865B932"
      unitRef="number">0.163</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d51060145e4051-wk-Fact-AF4164AAC639B94B05996F38B862D248"
      unitRef="number">0.242</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d51060145e4066-wk-Fact-FA643C28819C0460819D6F38B8675469"
      unitRef="number">0.479</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51060145e4098-wk-Fact-7DD7E13C219FC7B4D1AE7F012B0335CA"
      unitRef="usd">68900000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2019Q4_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember"
      decimals="-5"
      id="d51060145e4111-wk-Fact-61163ADE25D807E7EECDD15B0AD703FC"
      unitRef="usd">754100000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="FI2019Q4_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember"
      decimals="-5"
      id="d51060145e4115-wk-Fact-B877199C18D25F0A7EBFD15B4BC95EE9"
      unitRef="usd">603300000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember"
      decimals="-5"
      id="d51060145e4144-wk-Fact-51A20F9CC38DFBED4FD06F38B7C5053C"
      unitRef="usd">700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember"
      decimals="-5"
      id="d51060145e4148-wk-Fact-F6AFC41F5586E1D0A7FE6F38B7A3F0E6"
      unitRef="usd">1300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember"
      decimals="-5"
      id="d51060145e4152-wk-Fact-668DE660CDCA76B2D6026F38B8B30549"
      unitRef="usd">4600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"
      decimals="-5"
      id="d51060145e4156-wk-Fact-3531BEBE380FD43695086F38B7AFD27A"
      unitRef="usd">133800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember"
      decimals="-5"
      id="d51060145e4161-wk-Fact-0A3DC3D42DA6B4D28F736F38B8C75622"
      unitRef="usd">1773800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5B11A01FC9DD37801EBE6F38B8E6679A-0-wk-Fact-1D21FF544C3C654959B96F38B7A585EE">s&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at January&#160;1,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;114.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions based on tax positions related to the current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions for tax positions of prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;17.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;58.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reductions for tax positions of prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(10.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(13.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(21.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statute expirations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlement refund (payment)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;129.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;114.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e4350-wk-Fact-AB10E54D109DDBC561266F38B7FA3A6B"
      unitRef="usd">114200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51060145e4369-wk-Fact-FF0F2B63D3EA661B77306F38B7FB01CC"
      unitRef="usd">66800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2016Q4"
      decimals="-5"
      id="d51060145e4388-wk-Fact-349189CE5FAC281F17B06F38B7F703AD"
      unitRef="usd">32400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e4404-wk-Fact-FC2880A8916EC8F47B286F38B7FB4716"
      unitRef="usd">5300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e4423-wk-Fact-9539A77778B89AEA65556F38B80A3E15"
      unitRef="usd">500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e4442-wk-Fact-1DF81E43CEB65862627B6F38B7FACB6C"
      unitRef="usd">5700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e4463-wk-Fact-CFDC88F42BD89B0B03906F38B7F94E41"
      unitRef="usd">17200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e4482-wk-Fact-A9F96A2C9665D9D8203C6F38B7F8727E"
      unitRef="usd">58700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e4501-wk-Fact-0F1FFBF057F3650EFA2C6F38B80B836E"
      unitRef="usd">7300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e4522-wk-Fact-0721083B9094C73C03466F38B7F9A81D"
      unitRef="usd">10300000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e4542-wk-Fact-DBE683CF335380DC296E6F38B7FBB64B"
      unitRef="usd">13600000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e4562-wk-Fact-53BE0118CF50045ECCFB6F38B80C1CBD"
      unitRef="usd">21800000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e4584-wk-Fact-2406579DE5E709708ADC6F38B7FE50F0"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e4604-wk-Fact-598DCA08D826185F05806F38B809916A"
      unitRef="usd">2900000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e4624-wk-Fact-F198E84EBF9574B45FEC6F38B808171A"
      unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e4646-wk-Fact-EC584DDDBDA72427591F6F38B7F9EDC2"
      unitRef="usd">3600000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e4665-wk-Fact-8F3F5AD37C6546D383D06F38B809C121"
      unitRef="usd">4700000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e4684-wk-Fact-26EC59C24555B8E11E636F38B7F9820F"
      unitRef="usd">44600000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e4710-wk-Fact-EF493EE8E9EC92C2670F6F38B7FDBD03"
      unitRef="usd">129900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e4729-wk-Fact-AB10E54D109DDBC561266F38B7FA3A6B"
      unitRef="usd">114200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51060145e4748-wk-Fact-FF0F2B63D3EA661B77306F38B7FB01CC"
      unitRef="usd">66800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e4781-wk-Fact-2935EEB95A1B81FE0A1E6F38B7A6C75D"
      unitRef="usd">122700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e4785-wk-Fact-D3DF7A5C2F4B3465B44E6F38B8B9D34E"
      unitRef="usd">109100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51060145e4790-wk-Fact-28D1D158D54CD3FE56CD6F38B7C2C2BB"
      unitRef="usd">64300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51060145e4809-wk-Fact-0EA46F30C069CC16D83D6F38B7A856F2"
      unitRef="usd">4700000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51060145e4813-wk-Fact-98651094EB3215501A816F38B7A603BB"
      unitRef="usd">2200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51060145e4818-wk-Fact-75EB74161C54271B76AB6F38B7A2B406"
      unitRef="usd">4800000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e4822-wk-Fact-C308FA8DC5FEA9337AD06F38B7A672DB"
      unitRef="usd">20000000.0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51060145e4826-wk-Fact-D0DE7D0BFD688FF2DF686F38B7A6F1F2"
      unitRef="usd">13800000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51060145e4853-wk-Fact-E768FD74A6B755573EABFC37B29ABA00"
      unitRef="usd">75000000.0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-AF019DEBDCA1085723246F38B8E64AB0-0-wk-Fact-65BD57164ED9C0FB3C376F38B7F44A23">Other Consolidated Financial Statement Detail&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information for the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:51%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid during the year for:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;244.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;243.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;281.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,064.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,007.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,066.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-cash Operating, Investing and Financing Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2018 we accrued &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$300.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon reaching &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$20.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total cumulative sales of the Fumapharm Products, which was paid in the first quarter of 2019. In the fourth quarter of 2017 we accrued &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$600.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon reaching &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$15.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$16.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total cumulative sales of the Fumapharm Products, which was paid in the first quarter of 2018. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our consolidated balance sheets as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. For additional information on the construction of our manufacturing facility in Solothurn, Switzerland, please read Note 10,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Property, Plant and Equipment,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;120.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;78.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(187.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(200.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(250.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;204.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;119.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(7.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;83.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(217.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;200.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;127.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(19.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;50.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unrealized gains (losses) recognized during the period on equity securities held as of December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;150.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(19.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,001.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;874.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;309.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;320.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;281.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;261.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;220.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;224.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;148.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;444.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;78.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;125.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;726.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;609.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,765.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,861.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,348.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,389.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and include accrued income taxes totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$803.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$791.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-301BC8F1DE83051280B46F38B8E6DF41-0-wk-Fact-81160F6F89BF21BE54416F38B8C6E41D">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information for the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:51%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid during the year for:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;244.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;243.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;281.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,064.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,007.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,066.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51055572e1538-wk-Fact-3B03BC9A70F88E7B20476F38B88AD059"
      unitRef="usd">244200000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51055572e1557-wk-Fact-AA66E144B518F61D07CE6F38B88BFA64"
      unitRef="usd">243200000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51055572e1576-wk-Fact-4428291704869D02AFA16F38B88B806E"
      unitRef="usd">281700000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51055572e1597-wk-Fact-2FA61DF1A7D45D46FC286F38B889CA04"
      unitRef="usd">1064500000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51055572e1616-wk-Fact-1D84891FFEFF3D3240466F38B88A79AF"
      unitRef="usd">1007100000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51055572e1635-wk-Fact-8120DA83F7CCE87809186F38B88A8A5F"
      unitRef="usd">1066400000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2018Q4QTD_biib_CumulativeSalesLevelAxis_biib_TwentybillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember"
      decimals="-5"
      id="d51055572e1658-wk-Fact-756B1B0E00D6B85859926F38B8BF2B5A"
      unitRef="usd">300000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <biib:CumulativeSalesLevel
      contextRef="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember"
      decimals="-8"
      id="d51055572e1662-wk-Fact-52F3177A7113406F4A0D6F38B8263878"
      unitRef="usd">20000000000.0</biib:CumulativeSalesLevel>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2017Q4QTD_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember"
      decimals="-5"
      id="d51055572e1666-wk-Fact-1D13164F44F2C95774536F38B8BEBD1E"
      unitRef="usd">600000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <biib:CumulativeSalesLevel
      contextRef="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_FifteenbillionMemberMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember"
      decimals="-8"
      id="d51055572e1670-wk-Fact-59063DE70B104946D9C36F38B8BF6A8D"
      unitRef="usd">15000000000.0</biib:CumulativeSalesLevel>
    <biib:CumulativeSalesLevel
      contextRef="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember"
      decimals="-8"
      id="d51055572e1674-wk-Fact-24FF9E356FF94A2E12036F38B7EF18C9"
      unitRef="usd">16000000000.0</biib:CumulativeSalesLevel>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnMember"
      decimals="-5"
      id="d51055572e1681-wk-Fact-944BD814856D14F96A656F38B8BDDC7D"
      unitRef="usd">50000000.0</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnMember"
      decimals="-5"
      id="d51055572e1685-wk-Fact-5FE6F3423667647EBE6B6F38B8C5666A"
      unitRef="usd">100000000.0</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F41A9DF256F315AB85696F38B8E6EAFE-0-wk-Fact-AE6B3FEDFFFFD7EBD0506F38B7EE3024">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;120.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;78.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(187.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(200.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(250.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;204.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;119.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(7.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;(47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;83.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(217.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51055572e1872-wk-Fact-85B874E7E62A9101904F6F38B8742F9F"
      unitRef="usd">120000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51055572e1891-wk-Fact-0A117E36A421D3D76EF96F38B83810FF"
      unitRef="usd">112500000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51055572e1910-wk-Fact-5A1406495907EB020B106F38B86F6156"
      unitRef="usd">78500000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51055572e1926-wk-Fact-3EA70472CEE6A4EE94E56F38B875ACBE"
      unitRef="usd">187400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51055572e1946-wk-Fact-1534B4E7B5A8B2A414996F38B8363E97"
      unitRef="usd">200600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51055572e1966-wk-Fact-5F35E4DFA17CCF71225D6F38B882F056"
      unitRef="usd">250800000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51055572e1988-wk-Fact-BB569C88A55CBE4E87686F38B875D085"
      unitRef="usd">204700000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51055572e2007-wk-Fact-4FA1482C5BA6E328AEE56F38B82F9734"
      unitRef="usd">119500000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51055572e2026-wk-Fact-0F3B9152E08008909C026F38B8318B83"
      unitRef="usd">-36300000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51055572e2048-wk-Fact-639D520FEB7E6862ECF76F38B835B8C4"
      unitRef="usd">-7000000.0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51055572e2068-wk-Fact-37145F1FC591319D816E6F38B832153E"
      unitRef="usd">-9900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51055572e2088-wk-Fact-90ADE57319FE76E8F42E6F38B83AD9B6"
      unitRef="usd">6300000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51055572e2109-wk-Fact-FF9550E5E3EF2F8D02966F38B8337367"
      unitRef="usd">-47000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51055572e2129-wk-Fact-53E4E27123F2766429F76F38B872AF63"
      unitRef="usd">-10500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51055572e2149-wk-Fact-B08A6FF70F6D2A4FDE4D6F38B83380E3"
      unitRef="usd">-14700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51055572e2176-wk-Fact-30D3E4734FFCCDECF81C6F38B832E9CF"
      unitRef="usd">83300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51055572e2195-wk-Fact-1E1CCAC95E8FE4A0F3CC6F38B873F8AA"
      unitRef="usd">11000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51055572e2214-wk-Fact-0B37CAFFF87FFF67E1CA6F38B7DCE800"
      unitRef="usd">-217000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-3187FB28D55B05D13E26D1452B029EF1-0-wk-Fact-994621E207C2B0E41975D145970D4E3F">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;200.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;127.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(19.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;50.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unrealized gains (losses) recognized during the period on equity securities held as of December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;150.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(19.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51055572e2408-wk-Fact-13F44DF9426E85BDF0F6D146DA277C3B"
      unitRef="usd">200100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51055572e2427-wk-Fact-2EBB35116AEFBCF728C2D14710567E67"
      unitRef="usd">127900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51055572e2446-wk-Fact-2C9CA874145B994202FCD14730C1B823"
      unitRef="usd">-19800000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51055572e2468-wk-Fact-645143363FDF2D8BECE5D146DBFEC6BC"
      unitRef="usd">-50000000.0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51055572e2487-wk-Fact-01E54A92BB165870A1DED1471152634C"
      unitRef="usd">600000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51055572e2507-wk-Fact-97AE98E6E634AD3CC1F8D14731EFFB4B"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51055572e2528-wk-Fact-605E5B86437522F7BCB6D146DD6CDC58"
      unitRef="usd">150100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51055572e2547-wk-Fact-759879636059F1182545D1471250FB18"
      unitRef="usd">128500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d51055572e2566-wk-Fact-6697C3D3636FA7224390D147330E7F6F"
      unitRef="usd">-19800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6E9449BBA1D866400F4F6F38B8E6752B-0-wk-Fact-7C621D6B5EE7DA477DB86F38B8C613BA">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,001.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;874.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;309.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;320.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;281.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;261.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;220.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;224.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;148.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;444.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;78.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;125.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;726.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;609.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,765.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,861.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d51055572e2701-wk-Fact-95236321ECF2BFF56EC16F38B85CEE98"
      unitRef="usd">1001100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d51055572e2720-wk-Fact-1FE860E51A66C4BD686F6F38B85CFD98"
      unitRef="usd">874700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51055572e2735-wk-Fact-414B60AB8BD95FAE15316F38B868EF90"
      unitRef="usd">309100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51055572e2754-wk-Fact-78C6956C594728149DC36F38B8734A5B"
      unitRef="usd">320900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <biib:Collaborationexpensesaccrual
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51055572e2774-wk-Fact-04C37D51933A184113346F38B8735F30"
      unitRef="usd">281600000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51055572e2793-wk-Fact-DB9DFDEEA8CEDBEE297C6F38B7D3A399"
      unitRef="usd">261600000</biib:Collaborationexpensesaccrual>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51055572e2813-wk-Fact-35921CBA415099C6A3106F38B86DCDBA"
      unitRef="usd">220900000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51055572e2832-wk-Fact-E1E091172F781958E9146F38B7EBAB19"
      unitRef="usd">224700000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51055572e2852-wk-Fact-92247D7B4EA77638028E6F38B87B4117"
      unitRef="usd">148400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51055572e2871-wk-Fact-01C21F6EE35A9311D0D66F38B86E4C71"
      unitRef="usd">444800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51055572e2891-wk-Fact-74FE5404FACBD8A74C016F38B7D43993"
      unitRef="usd">78000000.0</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51055572e2910-wk-Fact-4932976258F68F1A43716F38B87250C8"
      unitRef="usd">125200000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51055572e2930-wk-Fact-89BE674B1B83BA3AD10E6F38B7D351E2"
      unitRef="usd">726700000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51055572e2949-wk-Fact-582F5182862F03E22FF36F38B8701293"
      unitRef="usd">609300000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51055572e2974-wk-Fact-BDC01B59134555A3997B6F38B8B552E2"
      unitRef="usd">2765800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51055572e2993-wk-Fact-90574151EADDD2E79EBF6F38B8439367"
      unitRef="usd">2861200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51055572e3021-wk-Fact-FEE7C166F066CB6B97C56F38B8BCBDFD"
      unitRef="usd">1348900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51055572e3025-wk-Fact-020D28AEA8A1984F186F6F38B8C2FBCF"
      unitRef="usd">1389400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51055572e3037-wk-Fact-B1FECD0EAF4155BDE1806F38B7F44DF3"
      unitRef="usd">803300000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51055572e3042-wk-Fact-15E26C14508A094955CA6F38B7F063DE"
      unitRef="usd">791400000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-0248CB847CE55149846C6F38B8E8AA98-0-wk-Fact-FF17E955EB440724F2546F38B826C590">Collaborative and Other Relationships&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depending on the collaborative arrangement, we may record funding receivable or payable balances with our collaboration partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaborative arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Genentech, Inc. (Roche Group)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our collaboration arrangements will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#x2019;s offer or purchase Genentech&#x2019;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;RITUXAN&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN, as well as all development and commercialization activities as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Canada&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;OCREVUS&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FDA approved OCREVUS for the treatment of RMS and PPMS. Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and increasing up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if annual net sales exceed &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$900.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. There will be a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we receive a gross &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS has been approved for the treatment of RMS and PPMS in the E.U. and certain other countries. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Profit-sharing Formulas&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;RITUXAN Profit Share&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share on the first &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until GAZYVA First Non-CLL FDA Approval&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;40.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;39.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;37.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;35.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First Non-CLL GAZYVA FDA Approval&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the FDA&#x2019;s first approval of GAZYVA in an indication other than CLL.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First GAZYVA Threshold Date&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;Second GAZYVA Threshold Date&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$500.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share of RITUXAN pre-tax profits in the U.S. decreased from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12-month period exceeded &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on certain events.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;GAZYVA Profit Share&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our current pretax profit-sharing formula for GAZYVA provides for a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share on the first &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of operating profits earned each calendar year. Our share of annual profits in excess of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until First GAZYVA Threshold Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;39.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;37.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;35.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share of GAZYVA operating profits in 2019 and 2018 was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; our share of operating profits on GAZYVA was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,542.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,431.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,316.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;748.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;548.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;242.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,290.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,980.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,559.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Ionis Pharmaceuticals, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2012 we entered into a collaboration and license agreement with Ionis pursuant to which we have an exclusive, worldwide license to develop and commercialize SPINRAZA for the treatment of SMA. SPINRAZA was approved for the treatment of SMA in the U.S., E.U. and Japan in December 2016, June 2017 and July 2017, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized product revenues of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2,097.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,724.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$883.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, on our sales of SPINRAZA. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$293.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$238.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$112.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we made milestone payments to Ionis totaling&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;related to the marketing approvals discussed above, which were capitalized in intangible assets, net in our consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Antisense Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three gene targets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, Ionis is responsible for global development of any product candidate&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$70.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$130.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;if we successfully develop the product candidate after option exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$30.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis and agreed to make potential additional payments, prior to licensing, of up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 we recognized this &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; developmental milestone upon the selection of BIIB080 (tau ASO), which is currently in Phase 1 development for the potential treatment of AD. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2019 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080. In connection with the option exercise, we made a payment of&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$45.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;to Ionis, which was recorded as research and development expense in our consolidated statements of income. Future payments may include additional milestone payments of up to&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$155.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;and royalties on future sales of in the low- to mid-teens if we successfully develop the product candidate after option exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2018 Ionis Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2018 we closed a &lt;/span&gt;&lt;span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year exclusive collaboration agreement with Ionis to develop novel antisense oligonucleotide (ASO) drug candidates for a broad range of neurological diseases (2018 Ionis Agreement) for a total payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, consisting of an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$375.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and the purchase of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of Ionis common stock at a cost of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$625.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon closing, we recorded &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$375.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment as prepaid services in our consolidated balance sheets and recognized the remaining &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$324.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as research and development expense in our consolidated statements of income. The amount recorded as prepaid services represented the value of the employee resources committed to the arrangement to provide research and discovery services over the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of Ionis common stock were purchased at a premium to their fair value at the transaction closing date. The premium consisted of acquiring the shares at a price above the fair value based on the trailing 10-day weighted-average close price prior to entering into the 2018 Ionis Agreement in April 2018 and the effect of certain holding period restrictions. We recorded an asset of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$462.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in investments and other assets in our consolidated balance sheets reflecting the fair value of the common stock as of the purchase date and a charge of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$162.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to research and development expense in our consolidated statements of income in the second quarter of 2018 reflecting the premium paid for the common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our investment in Ionis common stock is remeasured each reporting period. Changes in the fair value of our investment in Ionis common stock, including the effect of the holding period restrictions, are reflected in other income (expense), net in our consolidated statements of income. For additional information on the fair value of our investment in Ionis common stock, please read Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have the option to license therapies arising out of this agreement and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$125.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$270.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for each program, depending on the indication plus an annual license fee, as well as royalties on potential net commercial sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we incurred milestones of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$30.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the advancement of neurological targets identified under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2017 SMA Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2017 we entered into a collaboration agreement with Ionis to identify new ASO drug candidates for the potential treatment of SMA. Under this agreement, we have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of such therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$25.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment to Ionis and we may pay Ionis up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$260.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development and regulatory milestone payments if new drug candidates advance to marketing approval. Upon commercialization, we may also pay Ionis up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$800.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2013 Long-term Strategic Research Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2013 we entered into a &lt;/span&gt;&lt;span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the potential treatment of neurological diseases.&#160;Under this agreement, Ionis performs research on a set of neurological targets identified within the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ionis is eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us under the terms of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For non-ALS antisense product candidates, Ionis is responsible for global development through the completion of a Phase 2 trial and we provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$70.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$130.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2018 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (tofersen), an investigational treatment for ALS with superoxide dismutase 1 (SOD1) mutations. In connection with the option exercise, we made a payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$35.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis, which was recorded as research and development in our consolidated statements of income. Future payments may include potential post-licensing milestone payments of up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$55.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and royalties in the low to mid-teen percentages on potential annual worldwide net sales. We are solely responsible for the costs and expenses related to the development, manufacturing and commercialization of tofersen following the option exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the years ending &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we incurred milestones of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$18.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$12.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to the advancement of programs under this agreement, which were recorded as research and development expense in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BAN2401 and Elenbecestat Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates for the potential treatment of AD, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor (the BAN2401 and Elenbecestat Collaboration). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2019 we and Eisai announced the decision to discontinue the global Phase 3 studies (MISSION AD1 and MISSION AD2) of elenbecestat in early AD. As a result of this decision, in the third quarter of 2019, we accrued approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$48.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to our share of the termination of various clinical trials and research and development contracts incurred under the BAN2401 and Elenbecestat Collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. Upon marketing approval we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for early AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;348.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;232.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;146.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;174.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;116.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;74.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;32.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and Elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;16.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Aducanumab Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, the two companies will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early AD. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;study met its pre-specified primary and secondary endpoints. In October 2019 we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of aducanumab development expense incurred and beginning January 1, 2019, is reimbursing us for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of aducanumab development expense incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$45.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the termination of various clinical trials and research and development contracts net of the expected &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. We will receive a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the potential profits (losses) in the U.S., a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the potential profits (losses) in the E.U. and a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The two companies will continue to share equally in the potential profits (losses) in rest of world markets. Sales and marketing expense incurred before commercialization are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;179.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;264.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;268.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;98.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;234.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;268.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;27.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;15.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Anti-Tau Option&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Alkermes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes for VUMERITY, a novel fumarate for the treatment of RMS. In October 2019 the FDA approved VUMERITY in the U.S. for the treatment of RMS. In November 2019 VUMERITY became available in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we received an exclusive, worldwide license to develop and commercialize VUMERITY and we pay Alkermes a royalty of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on worldwide net commercial sales of VUMERITY. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Alkermes is eligible to receive royalties in the high-single digits to sub-teen double digits of annual net commercial sales upon successful development and commercialization of new product candidates, other than VUMERITY, developed under the exclusive license from Alkermes. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$28.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment to Alkermes representing our share of VUMERITY development costs already incurred in 2017. Beginning in 2018 we became responsible for all &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;development expenses related to VUMERITY. In December 2017 we also recognized a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; expense, which was paid to Alkermes in 2018, enabling the continuation of the agreement to develop VUMERITY. Both the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$28.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; continuation payment were recorded as research and development expense in our consolidated financial statements during the year ended December 31, 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the fourth quarter of 2019, following the FDA's approval of VUMERITY, we paid Alkermes &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$155.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments, which were recorded in intangible assets in our consolidated balance sheets and will be amortized over the useful life of the product. For the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$53.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$68.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$80.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in research and development expense in our consolidated statements of income related to this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Alkermes currently supplies VUMERITY to us pursuant to a supply agreement with Alkermes. In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes pursuant to which we have the election, following a transition period, to manufacture VUMERITY or have manufacturing transitioned to a third party in exchange for an increase in the royalty rate on worldwide net commercial sales of VUMERITY that is manufactured by us or our designee.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Bristol-Myers Squibb Company&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for the development and potential commercialization of BIIB092 (gosuranemab), an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we received worldwide rights to gosuranemab and are responsible for the full development and potential commercialization of gosuranemab in AD and progressive supranuclear palsy (PSP). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2019 we announced that the Phase 2 PASSPORT study investigating gosuranemab in individuals with PSP did not meet its primary endpoint. Based on these results, we discontinued development of gosuranemab in PSP and other primary tauopathies. We will continue our ongoing Phase 2 TANGO study of gosuranemab for mild cognitive impairment due to AD or mild AD, given differences in disease pathology.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$300.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to BMS and assumed all remaining obligations to the former shareholders of iPierian, Inc. (iPierian) related to BMS&#x2019;s acquisition of iPierian in 2014. In June 2017 we recognized a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; developmental milestone payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 PASSPORT study of gosuranemab for PSP.  Both the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$300.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment and the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; developmental milestone payment were recorded as research and development expense in our consolidated statements of income for the year ended December 31, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may pay BMS up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$360.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments, and potential royalties, and we may pay the former shareholders of iPierian up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$370.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestone payments as well as potential royalties on net commercial sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$144.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$97.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in research and development expense in our consolidated statements of income related to this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acorda Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and we may pay potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. The next expected milestone would be &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, due if ex-U.S. net sales reach &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; over a period of four consecutive quarters. Royalty payments are recognized in cost of sales within our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;agreement between Acorda and Alkermes Inc., who acquired Elan Drug Technologies, the original party to the license with Acorda. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ending &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$42.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$36.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$34.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;AbbVie Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with AbbVie for the development and commercialization of ZINBRYTA, which was approved for the treatment of RMS in the U.S. in May 2016 and in the E.U. in July 2016. The collaboration began selling ZINBRYTA in the third quarter of 2016. In March 2018 we and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for RMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we and AbbVie conducted ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories, where development and commercialization costs and profits were shared equally.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We were responsible for manufacturing and research and development activities and recorded these activities within their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures received from AbbVie.&#160;For the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the collaboration incurred &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$32.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$39.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for research and development activities, respectively, for which we recognized &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$16.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$19.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Co-promotion Profits and Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the U.S., AbbVie recognized revenues on sales to third parties and we recognized our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share of the co-promotion losses on ZINBRYTA in the U.S. for the year ended December 31, 2019, was immaterial. For the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net reduction in revenues from collaborative and other relationships, a component of other revenues, of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$8.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$16.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, to reflect our share of the overall net losses within the collaboration for each of those years.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Research and Discovery Arrangements &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Skyhawk Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments as well as potential royalties on net commercial sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this agreement, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$74.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Skyhawk, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$38.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as research and development expense in our consolidated statements of income and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$35.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as prepaid research and development expenditures within investments and other assets in our consolidated balance sheets and will be expensed as the services are provided. In October 2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$8.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as research and development and approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$7.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as prepaid research and development expenditures within investments and other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we entered into several research, discovery and other related arrangements that resulted in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$30.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$22.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, recorded as research and development expense in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;Samsung BioLogics contributed &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;280.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$250.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for an &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;85%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; stake in Samsung Bioepis and we contributed &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$45.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for the remaining &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ownership interest.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflected the effect of previous equity financings in which we did not participate, to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics.&#160;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership percentage remained at approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$675 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, consisting of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$115 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to inventory, approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$615 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to developed technology and approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$170 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to IPR&amp;amp;D. A deferred tax liability of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$225 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years, respectively, one quarter in arrears.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized losses on our investment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$79.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These losses reflect our share of losses totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and amortization of basis differences totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$78.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investment in Samsung Bioepis totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;670.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$580.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$680.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), respectively, which is classified as a component of investments and other assets within our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2019 Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this transaction, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Samsung Bioepis in January 2020, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$63.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as research and development expense in our consolidated statements of income and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$37.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as an intangible asset in our consolidated balance sheets. Additionally, we may pay Samsung Bioepis up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$210.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development, regulatory and sales-based milestones, including a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; development milestone that we may pay in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also acquired an option to extend the term of our current European commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and obtained exclusive rights to commercialize these products in China. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2013 pursuant to our rights under the joint venture agreement with Samsung BioLogics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, 3 anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of BENEPALI, Japan.&#160;As discussed above, we have an option to extend this agreement by an additional five years. Under this agreement, we have made upfront and clinical development milestone payments totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$46.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which were recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$25.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept biosimilar referencing ENBREL, received regulatory approval in the E.U. in August 2017, May 2016 and January 2016, respectively, and we capitalized the related milestone payments totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as intangible assets, net in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2018 we and Samsung Bioepis announced an agreement with AbbVie related to the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. We began to recognize revenues on sales of IMRALDI to third parties in Europe in the fourth quarter of 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We share &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net profit-sharing expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$241.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$187.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$111.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, to reflect Samsung Bioepis' &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration profits. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development and analytical development. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Following the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations in August 2019 FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under the technical development services and manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$106.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$96.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$42.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues under the license, technical development services and manufacturing agreements, which is reflected in revenues from collaborative and other relationships, as a component of other revenues in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts receivable from Samsung Bioepis related to the agreements discussed above were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$85.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;116.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Amounts payable to Samsung Bioepis as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, consisted of the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment related to the 2019 transaction we completed in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as discussed above. Amounts payable to Samsung Bioepis as of December 31, 2018, were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$31.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_RangeAxis_srt_MinimumMember"
      decimals="3"
      id="d51071008e1342-wk-Fact-664E32782AC86EDCCA856F38B89A2198"
      unitRef="number">0.135</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_RangeAxis_srt_MaximumMember"
      decimals="2"
      id="d51071008e1346-wk-Fact-3B2DD34F96F98E3539906F38B8791AF3"
      unitRef="number">0.24</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember"
      decimals="-5"
      id="d51071008e1350-wk-Fact-449A12C7A3815C3873996F38B8A37D3D"
      unitRef="usd">900000000.0</biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage>
    <biib:Reductioninroyaltyrate
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember"
      decimals="INF"
      id="d51071008e1354-wk-Fact-1C035B2428FED589E6CC6F38B89625E2"
      unitRef="number">0.50</biib:Reductioninroyaltyrate>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_StatementGeographicalAxis_us-gaap_ForeignCountryMember"
      decimals="2"
      id="d51071008e1361-wk-Fact-57062AC12104FB9BD0076F38B83059B0"
      unitRef="number">0.03</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:PeriodOfCollaborationAgreement
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember"
      id="d51071008e1365-wk-Fact-2F94F8439CB3688155EA6F38B8324FC8">P11Y</biib:PeriodOfCollaborationAgreement>
    <biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_RituxanMember"
      decimals="2"
      id="d51071008e1381-wk-Fact-E793B5096FFC945F0D926F38B880CC0D"
      unitRef="number">0.30</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="-5"
      id="d51071008e1385-wk-Fact-9CBF23E3E580D390FD5D6F38B8860C7A"
      unitRef="usd">50000000.0</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionProfitSharingFormulaTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-18A47850A3E822186C736F38B8E83241-0-wk-Fact-4CF2A4C620AD6776B3E56F38B7A4CA60">Our share of annual co-promotion profits in excess of &lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until GAZYVA First Non-CLL FDA Approval&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;40.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;39.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;37.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;35.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First Non-CLL GAZYVA FDA Approval&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the FDA&#x2019;s first approval of GAZYVA in an indication other than CLL.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First GAZYVA Threshold Date&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;Second GAZYVA Threshold Date&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$500.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/span&gt;&lt;/div&gt;</biib:CoPromotionProfitSharingFormulaTableTextBlock>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="-5"
      id="d51071008e1393-wk-Fact-9CBF23E3E580D390FD5D6F38B8860C7A"
      unitRef="usd">50000000.0</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_RituxanMember"
      decimals="3"
      id="d51071008e1422-wk-Fact-7359C2203FF6BF4198606F38B879CBC4"
      unitRef="number">0.400</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_RituxanMember"
      decimals="3"
      id="d51071008e1438-wk-Fact-8B0154F97582BA43BDE56F38B87FE35E"
      unitRef="number">0.390</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_RituxanMember"
      decimals="3"
      id="d51071008e1454-wk-Fact-E7B224C78A4F9ED8640D6F38B87EB52D"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_RituxanMember"
      decimals="3"
      id="d51071008e1470-wk-Fact-7D85B91793C9E93100B56F38B8720B03"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="-5"
      id="d51071008e1487-wk-Fact-A737849F68ECB6E002456F38B89A84D5"
      unitRef="usd">150000000.0</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
    <biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="-5"
      id="d51071008e1491-wk-Fact-986DB9D28CA2E91154136F38B80BDF48"
      unitRef="usd">150000000.0</biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne>
    <biib:SalesTriggerGrossSalesThreshold
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="-5"
      id="d51071008e1500-wk-Fact-A7874FAF6F77A9CADDCA6F38B8A45B84"
      unitRef="usd">500000000.0</biib:SalesTriggerGrossSalesThreshold>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
      contextRef="FI2016Q1_srt_ProductOrServiceAxis_biib_RituxanMember"
      decimals="2"
      id="d51071008e1515-wk-Fact-4EAA23903F08FD6756A76F38B896B796"
      unitRef="number">0.39</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="FI2017Q3_srt_ProductOrServiceAxis_biib_RituxanMember"
      decimals="3"
      id="d51071008e1519-wk-Fact-93DD129F7CEFE369F6786F38B8946116"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="-5"
      id="d51071008e1523-wk-Fact-A737849F68ECB6E002456F38B89A84D5"
      unitRef="usd">150000000.0</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
    <biib:Futurepercentageofcopromotionoperatingprofits
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_NewAntiCd20Member_srt_RangeAxis_srt_MinimumMember"
      decimals="2"
      id="d51071008e1530-wk-Fact-DF3F625F69C63173D78B6F38B892663B"
      unitRef="number">0.30</biib:Futurepercentageofcopromotionoperatingprofits>
    <biib:Futurepercentageofcopromotionoperatingprofits
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_NewAntiCd20Member_srt_RangeAxis_srt_MaximumMember"
      decimals="3"
      id="d51071008e1534-wk-Fact-C34BEA8AC19A84FDE2836F38B82231D1"
      unitRef="number">0.375</biib:Futurepercentageofcopromotionoperatingprofits>
    <biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="2"
      id="d51071008e1544-wk-Fact-91A763299E1F13047A5E6F38B82A1F99"
      unitRef="number">0.35</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="-5"
      id="d51071008e1548-wk-Fact-9CBF23E3E580D390FD5D6F38B8860C7A"
      unitRef="usd">50000000.0</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PretaxProfitSharingFormulaTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-060EC7F63A0E7D21888D6F38B8E7E87A-0-wk-Fact-2EFA8F144910027FBE2C6F38B8846E8A">Our share of annual profits in excess of &lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until First GAZYVA Threshold Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;39.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;37.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;35.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:PretaxProfitSharingFormulaTableTextBlock>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="-5"
      id="d51071008e1556-wk-Fact-9CBF23E3E580D390FD5D6F38B8860C7A"
      unitRef="usd">50000000.0</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="3"
      id="d51071008e1583-wk-Fact-4D81637F5B65639300426F38B825BC36"
      unitRef="number">0.390</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="3"
      id="d51071008e1599-wk-Fact-BA91171A3F17E1E48BC86F38B82C8787"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="3"
      id="d51071008e1615-wk-Fact-F68E5E429E6096D786666F38B825D8ED"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="3"
      id="d51071008e1634-wk-Fact-BA91171A3F17E1E48BC86F38B82C8787"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion
      contextRef="FI2017Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember"
      decimals="2"
      id="d51071008e1642-wk-Fact-6B1F43032B2FD7F291C36F38B8A30846"
      unitRef="number">0.35</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d51071008e1821-wk-Fact-26337B82AAEF05E73A3E6F38B85F0A00"
      unitRef="usd">1542400000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d51071008e1840-wk-Fact-B6C3F88418A5E2EE809B6F38B8628501"
      unitRef="usd">1431900000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d51071008e1859-wk-Fact-2DFFF43C74572858F7716F38B862D03C"
      unitRef="usd">1316400000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d51071008e1875-wk-Fact-B81242FED25624534B936F38B8676A8A"
      unitRef="usd">748000000.0</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d51071008e1894-wk-Fact-FB06AB0BDFB9774258446F38B8615CE3"
      unitRef="usd">548300000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d51071008e1913-wk-Fact-EE4AEC4BFD0DED5E11FC6F38B85F5D20"
      unitRef="usd">242800000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51071008e1939-wk-Fact-6DB6BA0B8C715A0D0D4B6F38B8607F57"
      unitRef="usd">2290400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51071008e1958-wk-Fact-5DE8AC0444CC0844782E6F38B82AE6AA"
      unitRef="usd">1980200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51071008e1977-wk-Fact-3A0656DB95083450147A6F38B824BC8E"
      unitRef="usd">1559200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2115-wk-Fact-742BB14C0FCC481D8AB66F38B82D0ED2"
      unitRef="usd">2097000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2119-wk-Fact-2E407703B7BA9CD6B5516F38B8C79046"
      unitRef="usd">1724200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2124-wk-Fact-1CFE1EA12F70B469F5D56F38B7CBFF41"
      unitRef="usd">883700000</us-gaap:Revenues>
    <biib:PercentageOfRoyaltiesAsPerCollaboration
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="INF"
      id="d51071008e2128-wk-Fact-97EF098C978E67239F5E6F38B88B6DA7"
      unitRef="number">0.11</biib:PercentageOfRoyaltiesAsPerCollaboration>
    <biib:PercentageOfRoyaltiesAsPerCollaboration
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="INF"
      id="d51071008e2132-wk-Fact-279649C450172DB898E46F38B897EA2C"
      unitRef="number">0.15</biib:PercentageOfRoyaltiesAsPerCollaboration>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2149-wk-Fact-A219CFD621E22B7F12AF6F38B7F3E17F"
      unitRef="usd">293000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2153-wk-Fact-7A519F41BC3ACB0F79206F38B87D1FE0"
      unitRef="usd">238000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2157-wk-Fact-86F65F329274A9652C786F38B7C6EEA6"
      unitRef="usd">112400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2168-wk-Fact-D8DAE9CEDFCC00FF18426F38B8967349"
      unitRef="usd">150000000.0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <biib:LicenseFee
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2190-wk-Fact-AA7FA5569A6872F3C7156F38B881416F"
      unitRef="usd">70000000.0</biib:LicenseFee>
    <biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2194-wk-Fact-7748D63CFAE1FF483FC36F38B88BF578"
      unitRef="usd">130000000.0</biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments>
    <biib:Upfrontpaymentforcollaborationagreement
      contextRef="FI2012Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2205-wk-Fact-4FC046DF40102C366D1C6F38B7FCF597"
      unitRef="usd">30000000.0</biib:Upfrontpaymentforcollaborationagreement>
    <biib:AdditionalMilestonePayment
      contextRef="FI2012Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2209-wk-Fact-4E5EB29B68A37C265D6F6F38B7C60A78"
      unitRef="usd">10000000.0</biib:AdditionalMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2213-wk-Fact-F2B8134F1C39001A0A416F38B7B96561"
      unitRef="usd">10000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2220-wk-Fact-5B5420AD288ECBE73C13EC7114B5ABC1"
      unitRef="usd">45000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <biib:AdditionalMilestonePayment
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2224-wk-Fact-25DC7FFD4791A31458DCECA062432E53"
      unitRef="usd">155000000.0</biib:AdditionalMilestonePayment>
    <biib:Termofcollaborationagreement
      contextRef="FD2018Q2QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      id="d51071008e2234-wk-Fact-B3665494D7856B968E2B6F38B82EDF2F">10</biib:Termofcollaborationagreement>
    <biib:Totalpaymenttoentercollaborationagreement
      contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-8"
      id="d51071008e2239-wk-Fact-076A2D6FE46F438716566F38B8A3F008"
      unitRef="usd">1000000000.0</biib:Totalpaymenttoentercollaborationagreement>
    <biib:Upfrontpaymentforcollaborationagreement
      contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2243-wk-Fact-A31264209A135F8935066F38B8980997"
      unitRef="usd">375000000.0</biib:Upfrontpaymentforcollaborationagreement>
    <biib:Investmentincommonstocksharespurchased
      contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2247-wk-Fact-6D745E4F584CBC62896A6F38B89ADA6C"
      unitRef="shares">11500000</biib:Investmentincommonstocksharespurchased>
    <biib:Purchaseofcommonstock
      contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2251-wk-Fact-4764836B123DE4FED2616F38B8A63CD0"
      unitRef="usd">625000000.0</biib:Purchaseofcommonstock>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="FI2018Q2_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2258-wk-Fact-04DBE02A65A3F7BD798F6F38B7C4730B"
      unitRef="usd">50900000</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:Upfrontpaymentforcollaborationagreement
      contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2262-wk-Fact-A31264209A135F8935066F38B8980997"
      unitRef="usd">375000000.0</biib:Upfrontpaymentforcollaborationagreement>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q2QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2266-wk-Fact-258760E5EE54092130EA6F38B7BEE376"
      unitRef="usd">324100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:Investmentincommonstocksharespurchased
      contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2273-wk-Fact-6D745E4F584CBC62896A6F38B89ADA6C"
      unitRef="shares">11500000</biib:Investmentincommonstocksharespurchased>
    <biib:Investmentincommonstockvalue
      contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2277-wk-Fact-342A2C8FE26F3A83D8CF6F38B8A7FC04"
      unitRef="usd">462900000</biib:Investmentincommonstockvalue>
    <biib:Premiumonpurchaseofcommonstock
      contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2281-wk-Fact-65A5C54CC3B28292F9056F38B87A34EC"
      unitRef="usd">162100000</biib:Premiumonpurchaseofcommonstock>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2295-wk-Fact-4011947F1F92C272DDBC6F38B80BA3F1"
      unitRef="usd">125000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2299-wk-Fact-D60C6251150446495CCD6F38B87F5A52"
      unitRef="usd">270000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2310-wk-Fact-115C3D81A706BBC517E4F1F9B0DB81D5"
      unitRef="usd">30000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2324-wk-Fact-E7BEC9109BD1FCC29A616F38B896409D"
      unitRef="usd">25000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2328-wk-Fact-E33B7AB296AC4150F7ED6F38B87DCC9B"
      unitRef="usd">260000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2332-wk-Fact-32D4211CDCB16562773D6F38B8A4A03B"
      unitRef="usd">800000000.0</biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold>
    <biib:Termofcollaborationagreement
      contextRef="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      id="d51071008e2342-wk-Fact-7A316ACB9A0063AC60446F38B81E01DC">six</biib:Termofcollaborationagreement>
    <biib:LicenseFee
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2353-wk-Fact-AA7FA5569A6872F3C7156F38B881416F"
      unitRef="usd">70000000.0</biib:LicenseFee>
    <biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2357-wk-Fact-7748D63CFAE1FF483FC36F38B88BF578"
      unitRef="usd">130000000.0</biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2364-wk-Fact-F1B44D408396DB2DB4B46F38B8357A14"
      unitRef="usd">35000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2368-wk-Fact-324AFBEA52048AAC06456F38B89B269C"
      unitRef="usd">55000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2387-wk-Fact-095BF1856EBFD7DA54A56F38B7BEA159"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2391-wk-Fact-9D3CB2C3CD0078914B146F38B899B336"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51071008e2396-wk-Fact-F732D92A9D3C624DC4A76F38B81C117B"
      unitRef="usd">12000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:LossOnContractTermination
      contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2413-wk-Fact-D5DA5C521F4F7074EC20D19B904E5B8B"
      unitRef="usd">48000000.0</us-gaap:LossOnContractTermination>
    <biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B088616852F49CBD7EEC6F38B8E74EAB-0-wk-Fact-FCA19E4AF57F2B41E7526F38B86E6E2F">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;348.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;232.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;146.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;174.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;116.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;74.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;32.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and Elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;16.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2588-wk-Fact-08C727694376BA512CAF6F38B7E96617"
      unitRef="usd">348700000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2607-wk-Fact-C1D31F1EB158B04C54696F38B7E8453A"
      unitRef="usd">232000000.0</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2626-wk-Fact-8E638E97A4C4DB13850F6F38B7EE4C5B"
      unitRef="usd">146200000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2647-wk-Fact-8F25270C0284E5A65D036F38B7EA96A3"
      unitRef="usd">174300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2666-wk-Fact-934314B5FF60EA4C86A86F38B7F59D8E"
      unitRef="usd">116000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2685-wk-Fact-881149773F0324EB5F9B6F38B7EB20A5"
      unitRef="usd">74300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2768-wk-Fact-221F350006AE51CE2502F1FB21DE5FF9"
      unitRef="usd">32400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2787-wk-Fact-49AD674CE0EEF2F1C14DF1FB2849667E"
      unitRef="usd">10700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2806-wk-Fact-C20AACFDAEEAED825894F1FB2D2CC43A"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2827-wk-Fact-B84B0CAB357B865CF6FCF1FB31305DAB"
      unitRef="usd">16200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2846-wk-Fact-9F4F135F6E08C7180AEEF1FB37B733D2"
      unitRef="usd">5400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2865-wk-Fact-61A7790C60DA35C33F84F1FB3C4213F6"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d51071008e2891-wk-Fact-27475C4DD98D739E17186F38B88B53D7"
      unitRef="number">0.15</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d51071008e2895-wk-Fact-C993143E7D1D855941D46F38B89D8ABE"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:LossOnContractTermination
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e2902-wk-Fact-012BCC0F7C02381025AFD19F5113AAD6"
      unitRef="usd">45000000.0</us-gaap:LossOnContractTermination>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d51071008e2906-wk-Fact-C993143E7D1D855941D46F38B89D8ABE"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="2"
      id="d51071008e2914-wk-Fact-1E94605F3E4F72190F746F38B7AAB657"
      unitRef="number">0.55</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="3"
      id="d51071008e2918-wk-Fact-A658ABD84A392E0E1B5B6F38B89CC72F"
      unitRef="number">0.685</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="2"
      id="d51071008e2922-wk-Fact-B8D56377C0E6C7C837C86F38B8A2F806"
      unitRef="number">0.20</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-20FB1F64C46A96A4AEB56F38B8E70C33-0-wk-Fact-06154BE7726237EF17B06F38B8297C5A">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;179.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;264.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;268.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;98.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;234.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;268.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;27.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;15.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e3088-wk-Fact-8730AA714286FEFCB36F6F38B7CD4B14"
      unitRef="usd">179400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e3107-wk-Fact-8185424F24C92C16B9CF6F38B7EACB8C"
      unitRef="usd">264800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e3126-wk-Fact-8EA7422CDF24C79C4D0D6F38B7EB078E"
      unitRef="usd">268700000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e3147-wk-Fact-A94D14CE5744FEBB5F906F38B7CFDCCB"
      unitRef="usd">98700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e3166-wk-Fact-2FD63AB0181A85FE3C676F38B7ED1818"
      unitRef="usd">234600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e3185-wk-Fact-9EC598074DF125146F4D6F38B7CE7BF7"
      unitRef="usd">268700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e3268-wk-Fact-0D328B3AAF9E457C39B66F38B7CC2A40"
      unitRef="usd">27400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e3287-wk-Fact-971A1F6FEF7C4FFE050E6F38B7D209E6"
      unitRef="usd">50600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e3306-wk-Fact-C0660FEE6809279BC14B6F38B7ECE569"
      unitRef="usd">23600000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e3327-wk-Fact-9608C93BECBFCEBAD20F6F38B7D1B610"
      unitRef="usd">15100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e3346-wk-Fact-8ED2F2BE7D52C6B05AA26F38B7EA4A1C"
      unitRef="usd">27300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d51071008e3365-wk-Fact-8182FAF2A9369FF03EC56F38B7D59AF8"
      unitRef="usd">23600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageOfRoyaltiesAsPerCollaboration
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember"
      decimals="2"
      id="d51071008e3400-wk-Fact-EA384A9F7FD60A71FCC5F1FCECA48C09"
      unitRef="number">0.15</biib:PercentageOfRoyaltiesAsPerCollaboration>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember"
      decimals="-5"
      id="d51071008e3410-wk-Fact-03E5BA08D7A20108DD7B6F38B8808AC3"
      unitRef="usd">28000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember"
      decimals="-5"
      id="d51071008e3418-wk-Fact-A06FB396768E5D3CD6A46F38B87DCC49"
      unitRef="usd">50000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember"
      decimals="-5"
      id="d51071008e3422-wk-Fact-03E5BA08D7A20108DD7B6F38B8808AC3"
      unitRef="usd">28000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember"
      decimals="-5"
      id="d51071008e3426-wk-Fact-A06FB396768E5D3CD6A46F38B87DCC49"
      unitRef="usd">50000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember"
      decimals="-5"
      id="d51071008e3433-wk-Fact-FCE856802EFC015AD7B46F38B891AD08"
      unitRef="usd">155000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember"
      decimals="-5"
      id="d51071008e3449-wk-Fact-1ADE24E20015E7D5646ED1AB7ECBA186"
      unitRef="usd">53500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember"
      decimals="-5"
      id="d51071008e3454-wk-Fact-66FF91986D5968388DC16F38B829FAF5"
      unitRef="usd">68700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember"
      decimals="-5"
      id="d51071008e3458-wk-Fact-821E328A9F393893776F6F38B87E92C2"
      unitRef="usd">80300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember"
      decimals="-5"
      id="d51071008e3480-wk-Fact-00C45A5666966A71BAE06F38B8711AD1"
      unitRef="usd">300000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:DevelopmentalMilestonePayment
      contextRef="FI2017Q2_us-gaap_TypeOfArrangementAxis_biib_IPerianMember"
      decimals="-5"
      id="d51071008e3484-wk-Fact-0A3D2802844EB1BB9FF66F38B8A7E063"
      unitRef="usd">60000000.0</biib:DevelopmentalMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember"
      decimals="-5"
      id="d51071008e3488-wk-Fact-00C45A5666966A71BAE06F38B8711AD1"
      unitRef="usd">300000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:DevelopmentalMilestonePayment
      contextRef="FI2017Q2_us-gaap_TypeOfArrangementAxis_biib_IPerianMember"
      decimals="-5"
      id="d51071008e3492-wk-Fact-0A3D2802844EB1BB9FF66F38B8A7E063"
      unitRef="usd">60000000.0</biib:DevelopmentalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember"
      decimals="-5"
      id="d51071008e3499-wk-Fact-B0DEA4B56A9D4FB261FBF20168391F57"
      unitRef="usd">360000000.0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_IPerianMember"
      decimals="-5"
      id="d51071008e3503-wk-Fact-43C971A8EAD8F70AD746F2021F2D7827"
      unitRef="usd">370000000.0</biib:AdditionalMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember"
      decimals="-5"
      id="d51071008e3518-wk-Fact-9AA1A01020D70ED8B5616F38B89730ED"
      unitRef="usd">144000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember"
      decimals="-5"
      id="d51071008e3522-wk-Fact-859993C783D50BEBF8ADD1ACD753209C"
      unitRef="usd">97000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember"
      decimals="-5"
      id="d51071008e3536-wk-Fact-EA5A1C060FDD0C7B4E366F38B897B4F5"
      unitRef="usd">15000000.0</biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold>
    <biib:ForeignSalesRequiredToTriggerMilestone
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember"
      decimals="-5"
      id="d51071008e3540-wk-Fact-F1A66207600FA29F87416F38B822EB42"
      unitRef="usd">100000000.0</biib:ForeignSalesRequiredToTriggerMilestone>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember"
      decimals="-5"
      id="d51071008e3565-wk-Fact-404E03712136CD77DE8C6F38B8316AE4"
      unitRef="usd">42000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember"
      decimals="-5"
      id="d51071008e3569-wk-Fact-B78CCBC6AB2F035AA4EC6F38B8819922"
      unitRef="usd">36500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember"
      decimals="-5"
      id="d51071008e3574-wk-Fact-4AAD0D6C41920063614E6F38B87670E0"
      unitRef="usd">34000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember"
      decimals="-5"
      id="d51071008e3602-wk-Fact-6C7BA2D242BBD1C886F06F38B7B55975"
      unitRef="usd">600000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember"
      decimals="-5"
      id="d51071008e3606-wk-Fact-811A9D6FFBA7E278CE7E6F38B8AD05DB"
      unitRef="usd">32400000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember"
      decimals="-5"
      id="d51071008e3611-wk-Fact-838CE9149DE37C8CB94B6F38B7BCA4D3"
      unitRef="usd">39900000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember"
      decimals="-5"
      id="d51071008e3615-wk-Fact-86F35087C76273AF20236F38B8851B4E"
      unitRef="usd">300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember"
      decimals="-5"
      id="d51071008e3619-wk-Fact-0989A631126306480E926F38B874BEE7"
      unitRef="usd">16200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember"
      decimals="-5"
      id="d51071008e3623-wk-Fact-F48B96524831F4EC11236F38B87D93D8"
      unitRef="usd">19900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember"
      decimals="INF"
      id="d51071008e3633-wk-Fact-2191C1A3A8C54C5C63EE6F38B8258F6C"
      unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d51071008e3649-wk-Fact-A7E4C562D06F7A04E3316F38B825053D"
      unitRef="usd">-8600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d51071008e3653-wk-Fact-BCDA72483413293F7B436F38B827A94C"
      unitRef="usd">-16900000</us-gaap:Revenues>
    <biib:AdditionalMilestonePayment
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-8"
      id="d51071008e3674-wk-Fact-7C46030F7669AFFAE93DD20C8E341E38"
      unitRef="usd">2400000000</biib:AdditionalMilestonePayment>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d51071008e3681-wk-Fact-F5DEECDD7C73D0E65496D20CEDFEAD5D"
      unitRef="usd">74000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d51071008e3685-wk-Fact-675472E800A67B0C8E6ED20D97FD89D3"
      unitRef="usd">38500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d51071008e3689-wk-Fact-2A81369EB46647C60CEBD20DF59D652B"
      unitRef="usd">35500000</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d51071008e3693-wk-Fact-362EF62B33BE7B5BF910F2039EC4019E"
      unitRef="usd">15000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d51071008e3697-wk-Fact-BBE3B55DE6D14BDAF8C7F203E0AB050F"
      unitRef="usd">8000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d51071008e3702-wk-Fact-2675EAA9CC3E6040330BF20421FBD7E2"
      unitRef="usd">7000000.0</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember"
      decimals="-5"
      id="d51071008e3724-wk-Fact-6D4B8D7E8024F3B20AD66F38B87AFA9E"
      unitRef="usd">30600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember"
      decimals="-5"
      id="d51071008e3728-wk-Fact-3085C0C30A9779E2D0CA6F38B871232E"
      unitRef="usd">22000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember"
      decimals="-5"
      id="d51071008e3733-wk-Fact-2123162CC5D7890D21F26F38B899081F"
      unitRef="usd">10000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement
      contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d51071008e3746-wk-Fact-8D87ED9DE334715630F56F38B8772C98"
      unitRef="KRW">280500000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
    <biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement
      contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3750-wk-Fact-852C58676DA1E4B247F16F38B80BF322"
      unitRef="usd">250000000.0</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
    <biib:JointVentureOwnerShipPercentageByThirdParty
      contextRef="D2012Q1Feb_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d51071008e3754-wk-Fact-D55A9A2E83B0312B678D6F38B89A2E7D"
      unitRef="number">0.85</biib:JointVentureOwnerShipPercentageByThirdParty>
    <us-gaap:EquityMethodInvestments
      contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d51071008e3758-wk-Fact-D24397B89D145D635BB66F38B8C6A74C"
      unitRef="KRW">49500000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3762-wk-Fact-DBCF0FB220053BD05F626F38B87E87D7"
      unitRef="usd">45000000.0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d51071008e3767-wk-Fact-6CE8293C111EFE1740776F38B87F1A04"
      unitRef="number">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d51071008e3771-wk-Fact-DAB0787A25553AB213926F38B8B69EFC"
      unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d51071008e3775-wk-Fact-A46E758D060B3483184A6F38B8B7D2D3"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d51071008e3779-wk-Fact-1D9B164B83DF3A938B3E6F38B8B5E5B9"
      unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3783-wk-Fact-5DB725E3C58F19FD80EA6F38B8B392CA"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d51071008e3792-wk-Fact-A46E758D060B3483184A6F38B8B7D2D3"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-6"
      id="d51071008e3803-wk-Fact-771D05291C8CC40C81F7D21AA9F83E54"
      unitRef="usd">675000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember"
      decimals="-6"
      id="d51071008e3807-wk-Fact-081E3F1AC50849F244ACD21B53D44884"
      unitRef="usd">115000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d51071008e3811-wk-Fact-AAE6B857D798A53D01CDD21A418C492A"
      unitRef="usd">615000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d51071008e3815-wk-Fact-F4F967EFE1EE2E9ABF6AD21BC7A877F6"
      unitRef="usd">170000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember"
      decimals="-6"
      id="d51071008e3819-wk-Fact-0A7EE883B67066DBBBEED21C263442F3"
      unitRef="usd">225000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember"
      id="d51071008e3824-wk-Fact-E0D08ADEFD56849B949BD21D8B30E561">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="d51071008e3828-wk-Fact-DAB312106952D76CA981D21DF6687E5D">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3842-wk-Fact-23936DA0DC5001F1DADAD220C9D581A5"
      unitRef="usd">79400000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3846-wk-Fact-66154A9606CEC9C41FE3D2217F28B5AE"
      unitRef="usd">1200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AdjustmentForAmortization
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3850-wk-Fact-CAB0D45948C3549C78A5D2228CB00F92"
      unitRef="usd">-78200000</us-gaap:AdjustmentForAmortization>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d51071008e3865-wk-Fact-8B25F35DD4B8B6D130EE7FC9A21CE66B"
      unitRef="KRW">670800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3869-wk-Fact-F7C51D85CEA56380D0337FC9E125D2A2"
      unitRef="usd">580200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d51071008e3873-wk-Fact-D54A0203BB298D1A86707FCA1DE4971F"
      unitRef="KRW">759500000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3878-wk-Fact-17DCA88187EFC9B166DA7FCA47FC4B95"
      unitRef="usd">680600000</us-gaap:EquityMethodInvestments>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3891-wk-Fact-8D6B653F907874A6E197D22634175528"
      unitRef="usd">100000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3895-wk-Fact-5B7F3DDADDBB4C47F3B2EC6DE68C4672"
      unitRef="usd">63000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3899-wk-Fact-6791AF70FA77FE74B14AF2095DC411E0"
      unitRef="usd">37000000.0</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3903-wk-Fact-C0B4C53773E14CED851CD22804A64D7A"
      unitRef="usd">210000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:AdditionalMilestonePayment
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3907-wk-Fact-6828886166CEFE3ED2D5F20AAF8C3EF6"
      unitRef="usd">15000000.0</biib:AdditionalMilestonePayment>
    <biib:ContractOptionExerciseFee
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3914-wk-Fact-A432E54702AD34B8591ED22D5CE08289"
      unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2013Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3924-wk-Fact-56AFCE20C54A6CC5AFB76F38B81D22A3"
      unitRef="usd">46000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:AdditionalMilestonePayment
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3928-wk-Fact-A1667191ABA6F8419ED26F38B80703C6"
      unitRef="usd">25000000.0</biib:AdditionalMilestonePayment>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3932-wk-Fact-66EB9FA5174B08DB1DB86F38B87381C7"
      unitRef="usd">75000000.0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="INF"
      id="d51071008e3946-wk-Fact-48EABB5BCC628031C5326F38B87E15F5"
      unitRef="number">0.50</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:CollaborationProfitSharing
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3962-wk-Fact-C2712DE5284CD67B98766F38B81C2AA2"
      unitRef="usd">241600000</biib:CollaborationProfitSharing>
    <biib:CollaborationProfitSharing
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3967-wk-Fact-B982771564D71C98A85B6F38B8931CE6"
      unitRef="usd">187400000</biib:CollaborationProfitSharing>
    <biib:CollaborationProfitSharing
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e3971-wk-Fact-788368E24B5EC46BB2316F38B86F0577"
      unitRef="usd">111000000.0</biib:CollaborationProfitSharing>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="INF"
      id="d51071008e3975-wk-Fact-48EABB5BCC628031C5326F38B87E15F5"
      unitRef="number">0.50</biib:EquityMethodInvestmentsExpectedProfitShare>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e4016-wk-Fact-BC915FE1FECB54CF4E056F38B87E9E6F"
      unitRef="usd">106200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e4020-wk-Fact-EBD00976BEE6C60D674C6F38B7FF634D"
      unitRef="usd">96400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e4025-wk-Fact-4921D7BE0122CF1814FF6F38B8C44381"
      unitRef="usd">42700000</us-gaap:Revenues>
    <us-gaap:DueFromRelatedParties
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e4032-wk-Fact-2B38C81BAE0E01F3BCE0F21A9F57496B"
      unitRef="usd">85000000.0</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e4036-wk-Fact-00A318E352F4AC8DCCEEF21B6D75E60E"
      unitRef="usd">116900000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e4053-wk-Fact-9A423FB5FF6E75EB561CF21C3A27ADBA"
      unitRef="usd">100000000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51071008e4061-wk-Fact-9F81F1F89FD292CA48CEF21E1C5BAE54"
      unitRef="usd">31500000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7B876764000A21D7A8636F38B8E81C06-0-wk-Fact-265CB486E69B573024BF6F38B8333118">Investments in Variable Interest Entities&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab, our anti-amyloid beta antibody candidate for the potential treatment of AD (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all licensed products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2017 we amended the terms of the Neurimmune Agreement and made a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune in exchange for a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additionally, under the terms of the Neurimmune Agreement, we would be required to pay Neurimmune a milestone payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the regulatory filing with the FDA for approval of aducanumab and a milestone payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if aducanumab is launched in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amounts reimbursed were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai. For additional information on our collaboration arrangements with Eisai, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$22.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$28.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d51057336e1314-wk-Fact-DB65AC15292FB71121BAD13ADCB80CEC"
      unitRef="usd">150000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Reductioninroyaltyratepayableoncommercialsales
      contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember"
      decimals="2"
      id="d51057336e1318-wk-Fact-1DCD443E7C1D275CAD15D13A87F52F6D"
      unitRef="number">0.15</biib:Reductioninroyaltyratepayableoncommercialsales>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d51057336e1322-wk-Fact-C19630D92012165D1FC7D13BABFED104"
      unitRef="usd">50000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Additionalreductioninroyaltyratepayableoncommercialsales
      contextRef="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember"
      decimals="2"
      id="d51057336e1326-wk-Fact-FBC8A0F6B8DBADA5A65FD13B517B54B9"
      unitRef="number">0.05</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d51057336e1333-wk-Fact-3D02CF3B8FE89CC2BA34E8C5607DA162"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d51057336e1337-wk-Fact-E00CAFA5C5E3AF54FE19E8C6DE164BFA"
      unitRef="usd">100000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51057336e1392-wk-Fact-2F8ED388D78B448BDED46F38B881BB49"
      unitRef="usd">22700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51057336e1396-wk-Fact-A285A36E7B203AE01A146F38B83D8AC9"
      unitRef="usd">28700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8876274B241FF251AD046F38B8E896C5-0-wk-Fact-4953CBD6F753103A31DA6F38B7ABCE40">Litigation&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing on the merits has been scheduled. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#x2018;510 Patent, and against Biogen GmbH in the D&#xfc;sseldorf Regional Court relating to the German counterpart of the &#x2018;510 Patent. In Italy, Fresenius Kabi has surrendered the Italian counterpart of the &#x2018;510 Patent and has moved to dismiss its infringement action. A hearing in the proceeding in Germany has not yet been set but is expected to occur after a decision on our pending opposition to the &#x2018;510 patent in the EPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;'667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2019 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom (U.K.) counterpart of the '667 Patent. In January 2020 the U.K. court revoked the patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. Gedeon Richter filed a separate action for infringement in the same court and a hearing in both cases has been set for May 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An estimate of the possible loss or range of loss in the pending IMRALDI patent litigation described above cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#x2019; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Dispute with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$200.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for alleged breach of the contract under which we acquired Convergence. We dispute the claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Petition for Inter Partes Review&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of our U.S. Patent No. 8,399,514 (the '514 Patent), which covers treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. Sawai USA, Inc. and Sawai Pharmaceutical Co. Ltd. were later joined as petitioners, but in January 2020 the PTAB terminated their involvement in the proceeding. A hearing on Mylan&#x2019;s petition was held in November 2019 and on February 5, 2020, the PTAB issued a final written decision upholding the patentability of the &#x2018;514 Patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2017, 2018 and 2019 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shipla Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia. The litigation against Aurobindo Pharma U.S.A., Inc., Glenmark Pharmaceuticals Ltd. and Sawai USA was dismissed in the fourth quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A trial against the remaining Delaware Defendants was held in the Delaware Court in December 2019 and we are awaiting a decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A trial is ongoing in the West Virginia action against Mylan.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into settlement agreements with some of the Delaware Defendants and we now anticipate market entry of a generic product equivalent to TECFIDERA before the &#x2018;514 Patent expires in February 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2018 we filed an action under the Hatch-Waxman Act against Banner Life Sciences LLC (Banner) for infringement of our U.S. Patent No. 7,619,001 (the &#x2018;001 patent) expiring on June 20, 2020, and claiming treatment of MS with dimethyl fumarate or methyl hydrogen fumarate or a combination thereof. In January 2020 the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Delaware Court entered judgment that Banner&#x2019;s drug product does not infringe the &#x2018;001 patent. We have appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2016 the EPO revoked our European patent number 2 137 537 (the '537 Patent), which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing has been set for March 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2018 the EPO revoked Forward Pharma&#x2019;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for June 2020. For additional information regarding this matter, please read Note 6, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;TYSABRI Patent Revocation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish '263 Patent), corresponding to our European Patent Number 1 485 127 (the E.U. '127 Patent) and covering administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. No hearing on the merits has been set in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and a hearing has been set for July 2020 in our appeal in the German action. No date for a hearing on the merits has been set in the Italian action.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. EMD Serono and Pfizer filed an appeal in the U.S. Court of Appeals for the Federal Circuit and oral argument is scheduled for March 2020. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We are cooperating with the investigation and have participated in preliminary discussions with the government regarding potential resolution of aspects of the matter. We have accrued the amount of our best estimate of the minimum probable loss in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$70.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; including interest and penalties. We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending. We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51059462e1346-wk-Fact-5F60A55BB9859C24F44DEC440B3F8272"
      unitRef="usd">200000000.0</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_country_BR"
      decimals="INF"
      id="d51059462e1435-wk-Fact-9A0003D48F79424514B26F38B7ACECC8"
      unitRef="usd">70000000.0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-2EB05FD7772AEE7F87646F38B8E8B06E-0-wk-Fact-D65571CBE05A3241BE026F38B8B0601D">Commitments and Contingencies&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Royalty Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on annual worldwide net commercial sales up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on annual worldwide net commercial sales that exceed &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net commercial sales of SPINRAZA using a tiered royalty rate between &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are recorded as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;VUMERITY&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes, we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are recorded as cost of sales in our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. For additional information on our collaboration arrangement with Alkermes, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As the acquisitions of Convergence and BIN occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue the remaining obligations each reporting period. We may pay up to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$735.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestones related to these acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Fumapharm AG&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired the Fumapharm Products. We were required to make contingent payments to former shareholders of Fumapharm AG and holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement, until such time as the cumulative sales level reached &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$20.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, at which time no further contingent payments were due. During the first &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we paid the final &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$300.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment as we achieved the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$20.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Development, Regulatory and Commercial Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based on our development plans as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we could make potential future milestone payments to third parties of up to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$6.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, including approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in development milestones, approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in regulatory milestones and approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$430.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of milestone payments in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, including &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the regulatory filing with the FDA for approval of aducanumab and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if aducanumab is launched in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Funding Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$24.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our consolidated balance sheet for expenditures incurred by CROs as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$514.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cancellable future commitments based on existing CRO contracts as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of the sale of our Hiller&#xf8;d, Denmark manufacturing operations to FUJIFILM, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$74.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with such guarantees and have accrued for this obligation. We may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Related Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$136.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of net liabilities associated with uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have accrued income tax liabilities of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$697.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under the Transition Toll Tax. Of the amounts accrued as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, no amounts are expected to be paid within one year due to an approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$87.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; carryforward of taxes paid in relation to the company's 2017 tax return. The Transition Toll Tax will be paid over an eight-year period, which started in 2018, and will not accrue interest. For additional information on the Transition Toll Tax, please read Note 16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$52.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the construction of this facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion
      contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember"
      decimals="2"
      id="d51064727e1301-wk-Fact-EBD6EC500D1CE98116AF6F38B88CA3B4"
      unitRef="number">0.18</biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion>
    <biib:FutureContingentPaymentThreshold
      contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember"
      decimals="-8"
      id="d51064727e1305-wk-Fact-B00C4DF317BBBD5BD22F6F38B891ABDD"
      unitRef="usd">2000000000.0</biib:FutureContingentPaymentThreshold>
    <biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion
      contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember"
      decimals="2"
      id="d51064727e1309-wk-Fact-4BF71588B4E62170C4756F38B8B2396A"
      unitRef="number">0.25</biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion>
    <biib:FutureContingentPaymentThreshold
      contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember"
      decimals="-8"
      id="d51064727e1313-wk-Fact-B00C4DF317BBBD5BD22F6F38B891ABDD"
      unitRef="usd">2000000000.0</biib:FutureContingentPaymentThreshold>
    <biib:PercentageOfRoyaltiesAsPerCollaboration
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="INF"
      id="d51064727e1323-wk-Fact-97EF098C978E67239F5E6F38B88B6DA7"
      unitRef="number">0.11</biib:PercentageOfRoyaltiesAsPerCollaboration>
    <biib:PercentageOfRoyaltiesAsPerCollaboration
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="INF"
      id="d51064727e1327-wk-Fact-279649C450172DB898E46F38B897EA2C"
      unitRef="number">0.15</biib:PercentageOfRoyaltiesAsPerCollaboration>
    <biib:PercentageOfRoyaltiesAsPerCollaboration
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_VUMERITYMember_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember"
      decimals="INF"
      id="d51064727e1341-wk-Fact-1F987F6C8DFF43FB8511EC47C08D492A"
      unitRef="number">0.15</biib:PercentageOfRoyaltiesAsPerCollaboration>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51064727e1358-wk-Fact-48B032DD5B2856DA9FB16F38B889F3F1"
      unitRef="usd">735000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <biib:CumulativeSalesLevel
      contextRef="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember"
      decimals="-8"
      id="d51064727e1369-wk-Fact-52F3177A7113406F4A0D6F38B8263878"
      unitRef="usd">20000000000.0</biib:CumulativeSalesLevel>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember"
      decimals="-5"
      id="d51064727e1380-wk-Fact-00B4683AD08C54F6AB9A0C84CED65C99"
      unitRef="usd">300000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <biib:CumulativeSalesLevel
      contextRef="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_TwentybillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember"
      decimals="-8"
      id="d51064727e1384-wk-Fact-A9129AACC76F7855A4456F38B8AF7A68"
      unitRef="usd">20000000000.0</biib:CumulativeSalesLevel>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4"
      decimals="-8"
      id="d51064727e1398-wk-Fact-0776212560941C81146F6F38B8AD1A2F"
      unitRef="usd">6800000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember"
      decimals="-8"
      id="d51064727e1402-wk-Fact-ED218F9DC433A7A7EB2E6F38B8B287BD"
      unitRef="usd">1200000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember"
      decimals="-8"
      id="d51064727e1406-wk-Fact-D116F0DF4FB64DA0B1EC6F38B8B06C4A"
      unitRef="usd">1400000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_CommercialMilestonesMember"
      decimals="-8"
      id="d51064727e1410-wk-Fact-21D2290D413A9581BC386F38B8AECE53"
      unitRef="usd">4200000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_ExpectedPaymentTimelineofMilestoneAxis_biib_TwelvemonthsMember"
      decimals="-5"
      id="d51064727e1422-wk-Fact-640ECF8E8C001804904AEC60BE836EFD"
      unitRef="usd">430000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d51064727e1430-wk-Fact-3D02CF3B8FE89CC2BA34E8C5607DA162"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d51064727e1434-wk-Fact-E00CAFA5C5E3AF54FE19E8C6DE164BFA"
      unitRef="usd">100000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51064727e1448-wk-Fact-6ECB94B0B79FC17F81356F38B8AF3F26"
      unitRef="usd">24000000.0</biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch>
    <us-gaap:OtherCommitment
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51064727e1456-wk-Fact-427D34D688E05363331A6F38B88A5E5F"
      unitRef="usd">514000000.0</us-gaap:OtherCommitment>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2019Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51064727e1467-wk-Fact-994A71B05DC0C10DA6977EFB1890BB20"
      unitRef="usd">74000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51064727e1481-wk-Fact-C7E36954AFAACB148FC26F38B8AF9E42"
      unitRef="usd">136900000</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="-5"
      id="d51064727e1497-wk-Fact-52C5D7094068BA7F90B96F38B8C0633D"
      unitRef="usd">697000000.0</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:IncomeTaxesPaid
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51064727e1505-wk-Fact-AD9B60635BB64EC20E84D152089FDEEB"
      unitRef="usd">87000000.0</us-gaap:IncomeTaxesPaid>
    <us-gaap:OtherCommitment
      contextRef="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnMember"
      decimals="-5"
      id="d51064727e1524-wk-Fact-8304BC3025AB413DB9796F38B8B439C7"
      unitRef="usd">52000000.0</us-gaap:OtherCommitment>
    <us-gaap:GuaranteesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-319FC8E7471B5DC248EB6F38B8E902D0-0-wk-Fact-736467A969D1A652D48D6F38B8AB41C1">Guarantees&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we did not have significant liabilities recorded for guarantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:GuaranteesTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-BF963FD87C8E6D8ECE9C6F38B8E98819-0-wk-Fact-C4CF9E5CCC7ECA210AA06F38B8246515">Employee Benefit Plans&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;401(k) Savings Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#x2019;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expense related to our 401(k) Savings Plan totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$44.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$42.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$42.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Deferred Compensation Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, totaled approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$114.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$109.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.00%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#x2019;s contribution. Minimum employee contributions are based on the respective employee&#x2019;s age, salary and gender. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the Swiss plan had an unfunded net pension obligation of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$42.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$48.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and plan assets that totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$127.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$93.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. In &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we recognized expense totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$14.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$14.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$12.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to our Swiss plan, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, was included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The obligations under the German plans are unfunded and totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$59.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$45.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net periodic pension cost related to the German plans totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, was included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <biib:MinimumQualifyingAgeForEmployeeBenefitPlan
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember"
      id="d51065270e1301-wk-Fact-D99AE47FEDE29B147F406F38B828E78F">P21Y</biib:MinimumQualifyingAgeForEmployeeBenefitPlan>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember"
      decimals="-5"
      id="d51065270e1308-wk-Fact-2E5F4C79981B241F8DCE6F38B829D7C0"
      unitRef="usd">44800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember"
      decimals="-5"
      id="d51065270e1312-wk-Fact-41354BEFF3BB0C99A1536F38B8201A0D"
      unitRef="usd">42200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember"
      decimals="-5"
      id="d51065270e1316-wk-Fact-2D32663DAD4837DDFA396F38B827A668"
      unitRef="usd">42600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-5"
      id="d51065270e1347-wk-Fact-E889EFC3A3310103639E6F38B822557A"
      unitRef="usd">114600000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-5"
      id="d51065270e1351-wk-Fact-A132796A6954B3C105286F38B8263E5E"
      unitRef="usd">109300000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <biib:PercentageOfMinimumInvestmentReturn
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH"
      decimals="4"
      id="d51065270e1364-wk-Fact-9A1CA8ED200CCB8610066F38B81E6760"
      unitRef="number">0.0100</biib:PercentageOfMinimumInvestmentReturn>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_CH"
      decimals="-5"
      id="d51065270e1389-wk-Fact-E2A045DD696104A293146F38B829807C"
      unitRef="usd">42900000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_CH"
      decimals="-5"
      id="d51065270e1393-wk-Fact-988C1184F51B0AB919FE6F38B826B7E1"
      unitRef="usd">48600000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_CH"
      decimals="-5"
      id="d51065270e1397-wk-Fact-2F546F8BE84A22804D5A6F38B8227E61"
      unitRef="usd">127100000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_CH"
      decimals="-5"
      id="d51065270e1401-wk-Fact-1F7B5CD82F6ED33806C66F38B829E39D"
      unitRef="usd">93100000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:PensionExpense
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH"
      decimals="-5"
      id="d51065270e1418-wk-Fact-8FCD4D08FB01F06A3CE86F38B8264779"
      unitRef="usd">14700000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH"
      decimals="-5"
      id="d51065270e1422-wk-Fact-7D10F49F8A3712EE94F06F38B8216318"
      unitRef="usd">14800000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_CH"
      decimals="-5"
      id="d51065270e1426-wk-Fact-467FA76AD3EFD859682F6F38B826458B"
      unitRef="usd">12300000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_CH"
      decimals="-5"
      id="d51065270e1431-wk-Fact-9D388FF5167A764EC2316F38B8252FCC"
      unitRef="usd">1200000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_CH"
      decimals="-5"
      id="d51065270e1435-wk-Fact-4B7F8E051E7FA2E3E7606F38B82B5093"
      unitRef="usd">1300000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_CH"
      decimals="-5"
      id="d51065270e1439-wk-Fact-CEECC964429512646C546F38B8276795"
      unitRef="usd">1100000</us-gaap:PensionExpense>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_DE"
      decimals="-5"
      id="d51065270e1446-wk-Fact-59C31D551F404845C4406F38B81D04CC"
      unitRef="usd">59600000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_DE"
      decimals="-5"
      id="d51065270e1450-wk-Fact-37EB30B842EC92FC31EE6F38B82BA711"
      unitRef="usd">45300000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_DE"
      decimals="-5"
      id="d51065270e1462-wk-Fact-C4E45D0B969CFFBC14D96F38B81FE739"
      unitRef="usd">5100000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_DE"
      decimals="-5"
      id="d51065270e1467-wk-Fact-587FF54E95EAF8EC9EE66F38B82314C9"
      unitRef="usd">5300000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_DE"
      decimals="-5"
      id="d51065270e1471-wk-Fact-6677DE611C0506DF504F6F38B82CEB12"
      unitRef="usd">5200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_DE"
      decimals="-5"
      id="d51065270e1487-wk-Fact-A43A4B6D95C63703CB7C6F38B826825B"
      unitRef="usd">1400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_DE"
      decimals="-5"
      id="d51065270e1492-wk-Fact-8A580C55F0C7511AF4206F38B82B4512"
      unitRef="usd">1500000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanSponsorLocationAxis_country_DE"
      decimals="-5"
      id="d51065270e1496-wk-Fact-9F4E6AA1D7C74586523A6F38B824591B"
      unitRef="usd">1400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-53DB1FAEA6598AC06C406F38B8E94F53-0-wk-Fact-34D95C94DA9019DD33176F38B7EDB16C">Segment Information&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;adjacencies. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables contain certain financial information by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6,713.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,794.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;320.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;551.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;11,379.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,211.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;78.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,290.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;585.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;9.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;112.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;707.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,493.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,162.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;12.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,674.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,800.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,370.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;281.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;434.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,886.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,903.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,980.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;457.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;96.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;585.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,152.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,442.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,601.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2017 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,017.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,844.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;160.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;332.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,354.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,475.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;83.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,559.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;249.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;67.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;42.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;360.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,226.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,948.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,182.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2,028.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,748.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,215.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$646.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$707.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our long-lived assets were related to our manufacturing facility in Hiller&#xf8;d, Denmark.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read Note 10, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Property, Plant and Equipment,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="FD2019Q4YTD"
      decimals="0"
      id="d51067797e1295-wk-Fact-5427CEDDEB92B1321B7E6F38B7EE85C9"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F8710783B40C5BD386EA6F38B8E9268A-0-wk-Fact-471B90E542382DD739876F38B7E92817">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables contain certain financial information by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6,713.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,794.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;320.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;551.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;11,379.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,211.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;78.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,290.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;585.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;9.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;112.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;707.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,493.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,162.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;12.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,674.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,800.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,370.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;281.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;434.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,886.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,903.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,980.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;457.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;96.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;585.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,152.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,442.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,601.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2017 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,017.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,844.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;160.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;332.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,354.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,475.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;83.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,559.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;249.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;67.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;42.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;360.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,226.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,948.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,182.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51067797e1484-wk-Fact-8B42590D2AE4D7B90D5A6F38B83ADC6B"
      unitRef="usd">6713800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-5"
      id="d51067797e1503-wk-Fact-D1ADF5271EB4D920B3206F38B7EF8761"
      unitRef="usd">3794500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember"
      decimals="-5"
      id="d51067797e1522-wk-Fact-5CC1C47027CEEF72393D6F38B8800726"
      unitRef="usd">320300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"
      decimals="-5"
      id="d51067797e1542-wk-Fact-24E1AAE4BDA8525977496F38B883BD1B"
      unitRef="usd">551200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51067797e1561-wk-Fact-F1FBA38FF669B88E1D976F38B82CDF1B"
      unitRef="usd">11379800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51067797e1581-wk-Fact-302877AADF4727E157716F38B7F2F23B"
      unitRef="usd">2211900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-5"
      id="d51067797e1600-wk-Fact-0329A2785D6301B120826F38B8839B92"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember"
      decimals="-5"
      id="d51067797e1619-wk-Fact-A5FDB089B5DEB2A7936B6F38B7F1490C"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"
      decimals="-5"
      id="d51067797e1639-wk-Fact-ABD1723A5EDA5BDEBBAA6F38B7F51F9F"
      unitRef="usd">78300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51067797e1658-wk-Fact-6DB6BA0B8C715A0D0D4B6F38B8607F57"
      unitRef="usd">2290400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51067797e1678-wk-Fact-9F4CABFBF61C08C7E87A6F38B7F6DA17"
      unitRef="usd">585800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-5"
      id="d51067797e1697-wk-Fact-7A3EB7F7BE97023681FB6F38B7EF2D8F"
      unitRef="usd">9700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember"
      decimals="-5"
      id="d51067797e1716-wk-Fact-1D2439D2FBE31142DE6F6F38B7E96A09"
      unitRef="usd">112200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"
      decimals="-5"
      id="d51067797e1736-wk-Fact-095C88231DD51BB72BFC6F38B7ED5F77"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51067797e1755-wk-Fact-00E0A71FFA7A5B6582ED6F38B7ACA093"
      unitRef="usd">707700000</us-gaap:Revenues>
    <us-gaap:NoncurrentAssets
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51067797e1775-wk-Fact-5F5DB3E2272AB8BEF9F96F38B7F78461"
      unitRef="usd">1493200000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-5"
      id="d51067797e1794-wk-Fact-1A401C3F874F7BFDEBD76F38B881CC25"
      unitRef="usd">2162900000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_srt_AsiaMember"
      decimals="-5"
      id="d51067797e1813-wk-Fact-91065B372CF805CC59FF6F38B7EF344F"
      unitRef="usd">6200000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"
      decimals="-5"
      id="d51067797e1833-wk-Fact-76AAB65B2A55E8CEFC946F38B7EEB45D"
      unitRef="usd">12000000.0</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2019Q4"
      decimals="-5"
      id="d51067797e1852-wk-Fact-94DC29CEE3F92F740CE96F38B7EFC59F"
      unitRef="usd">3674300000</us-gaap:NoncurrentAssets>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51067797e2076-wk-Fact-5384BFFD347C612F45386F38B8517C44"
      unitRef="usd">6800500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-5"
      id="d51067797e2095-wk-Fact-275AB4FFDCA5EF8F689B6F38B7CD7319"
      unitRef="usd">3370300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember"
      decimals="-5"
      id="d51067797e2114-wk-Fact-CD016954D7E8676A16366F38B7F9715C"
      unitRef="usd">281200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"
      decimals="-5"
      id="d51067797e2134-wk-Fact-61E59191AAEF81EB2BA06F38B7EBAD21"
      unitRef="usd">434800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51067797e2153-wk-Fact-7B6205D978C9C04E48296F38B81CF51A"
      unitRef="usd">10886800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51067797e2173-wk-Fact-5EF752A227592086471A6F38B87F0557"
      unitRef="usd">1903400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-5"
      id="d51067797e2192-wk-Fact-15A53D11F6DA96A745546F38B7DC71EE"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember"
      decimals="-5"
      id="d51067797e2211-wk-Fact-DE1BAE8DA3A43AE8551F6F38B88B779F"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"
      decimals="-5"
      id="d51067797e2231-wk-Fact-6C130D9355AF505EBF086F38B882B79C"
      unitRef="usd">76600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51067797e2250-wk-Fact-5DE8AC0444CC0844782E6F38B82AE6AA"
      unitRef="usd">1980200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51067797e2270-wk-Fact-264EFC1D21AB90A284476F38B7FB0CF4"
      unitRef="usd">457000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-5"
      id="d51067797e2289-wk-Fact-3C1DF127DC9DD578F87F6F38B88664AA"
      unitRef="usd">32700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember"
      decimals="-5"
      id="d51067797e2308-wk-Fact-A2A68834ABB36C86D7606F38B88EEA07"
      unitRef="usd">96200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"
      decimals="-5"
      id="d51067797e2328-wk-Fact-1A0C6809BDA4753FC6A96F38B8811066"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51067797e2347-wk-Fact-F0C4D670DC0F193457D96F38B8622365"
      unitRef="usd">585900000</us-gaap:Revenues>
    <us-gaap:NoncurrentAssets
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51067797e2367-wk-Fact-7562A42A473089BD40D56F38B7F97076"
      unitRef="usd">1152700000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-5"
      id="d51067797e2386-wk-Fact-652DA8F43F88D798C7256F38B7ECEA29"
      unitRef="usd">2442800000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_srt_AsiaMember"
      decimals="-5"
      id="d51067797e2405-wk-Fact-BB01A963345C013E206E6F38B884948F"
      unitRef="usd">3900000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"
      decimals="-5"
      id="d51067797e2425-wk-Fact-027982AD79AD29EA6B406F38B88477E9"
      unitRef="usd">1800000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2018Q4"
      decimals="-5"
      id="d51067797e2444-wk-Fact-9E56EA3F4D5FC1518D1A6F38B7F207CD"
      unitRef="usd">3601200000</us-gaap:NoncurrentAssets>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51067797e2669-wk-Fact-279DB18511D84B5AD04A6F38B8A819C5"
      unitRef="usd">7017100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-5"
      id="d51067797e2688-wk-Fact-642975C3D6C28123A4726F38B7F0826F"
      unitRef="usd">2844800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember"
      decimals="-5"
      id="d51067797e2707-wk-Fact-C77115557CCAA3ADDCF76F38B8826FEB"
      unitRef="usd">160100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"
      decimals="-5"
      id="d51067797e2727-wk-Fact-DBCBE5F70B3B9DB8CAED6F38B7F35AE4"
      unitRef="usd">332700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51067797e2746-wk-Fact-A0A85755BDDAAFF80DF16F38B7A963B8"
      unitRef="usd">10354700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51067797e2766-wk-Fact-F9ECA47F2C0B0325F8336F38B7EFDED1"
      unitRef="usd">1475600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-5"
      id="d51067797e2785-wk-Fact-D75FB3B1F832C8532F786F38B7F0CFC4"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember"
      decimals="-5"
      id="d51067797e2804-wk-Fact-4532B72CFBDDC394485E6F38B7F43FC2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"
      decimals="-5"
      id="d51067797e2824-wk-Fact-B3FA4B00BA644CBFEC916F38B7EBF4EC"
      unitRef="usd">83000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51067797e2843-wk-Fact-3A0656DB95083450147A6F38B824BC8E"
      unitRef="usd">1559200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51067797e2863-wk-Fact-C53B45C269C2189708726F38B7CCB94E"
      unitRef="usd">249500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-5"
      id="d51067797e2882-wk-Fact-3863DF20D8ACF33505CF6F38B7CB577F"
      unitRef="usd">67800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember"
      decimals="-5"
      id="d51067797e2901-wk-Fact-28CEEDFEA5E04BAE6DA36F38B8832E29"
      unitRef="usd">42700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"
      decimals="-5"
      id="d51067797e2921-wk-Fact-11818BB1ECD914C093916F38B7FBFD70"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51067797e2940-wk-Fact-5D3FED1ADFF25AE90C656F38B87CF3D8"
      unitRef="usd">360000000.0</us-gaap:Revenues>
    <us-gaap:NoncurrentAssets
      contextRef="FI2017Q4_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d51067797e2960-wk-Fact-62338B2EAF4D1924647A6F38B7EDF103"
      unitRef="usd">1226900000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2017Q4_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-5"
      id="d51067797e2979-wk-Fact-3CB99C6F8CFD6C286D416F38B886F312"
      unitRef="usd">1948200000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2017Q4_srt_StatementGeographicalAxis_srt_AsiaMember"
      decimals="-5"
      id="d51067797e2998-wk-Fact-88452907363C618AE3066F38B7EF3679"
      unitRef="usd">5200000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2017Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"
      decimals="-5"
      id="d51067797e3018-wk-Fact-B29D8B95A58F749477E56F38B7CC2615"
      unitRef="usd">2100000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2017Q4"
      decimals="-5"
      id="d51067797e3037-wk-Fact-541578B691FC636CFB606F38B7F05BBB"
      unitRef="usd">3182400000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_biib_SolothurnMember"
      decimals="-5"
      id="d51067797e3077-wk-Fact-85205AFED49CBF44EB4F6F38B7F6230C"
      unitRef="usd">2028800000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_biib_SolothurnMember"
      decimals="-5"
      id="d51067797e3081-wk-Fact-4278D722BE0FAE4D2DE56F38B7EE3A42"
      unitRef="usd">1748500000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2017Q4_srt_StatementGeographicalAxis_biib_SolothurnMember"
      decimals="-5"
      id="d51067797e3086-wk-Fact-EBA944AC55EF018982E26F38B7ED4E8A"
      unitRef="usd">1215700000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_country_DK"
      decimals="-5"
      id="d51067797e3101-wk-Fact-BFF966C5B2B9276781EE6F38B7E9DCB8"
      unitRef="usd">646500000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="FI2017Q4_srt_StatementGeographicalAxis_country_DK"
      decimals="-5"
      id="d51067797e3105-wk-Fact-67CE26E1B85ECCC0E5F36F38B7D53E68"
      unitRef="usd">707100000</us-gaap:NoncurrentAssets>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-0E9B45DD7372ACAFCAF06F38B8EB6324-0-wk-Fact-301FD8665A37A02D43E26F38B87A2460">&#160;&#160;&#160;&#160;Quarterly Financial Data (Unaudited)&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,680.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,880.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,894.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,924.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;11,379.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;517.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;576.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;595.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;600.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,290.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;292.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;160.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;109.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;145.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;707.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,489.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,616.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,600.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,671.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;14,377.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,887.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,140.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,170.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,224.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;12,422.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,408.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,494.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,545.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,439.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,888.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,408.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,494.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,545.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,439.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,888.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;31.47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;31.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;196.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;190.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;184.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;177.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;187.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;197.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;190.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;184.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;178.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;187.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,523.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,757.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,780.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,825.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,886.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;443.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;490.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;511.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;534.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,980.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;164.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;108.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;147.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;165.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;585.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,131.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,356.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,439.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,526.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,452.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,685.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,935.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,978.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,037.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,636.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,171.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;915.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,442.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;944.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,474.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,172.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;866.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,444.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;946.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,430.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;211.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;207.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;201.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;199.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;204.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;211.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;207.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;201.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;200.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;205.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for 2019 include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax gains (losses) related to changes in the fair value of our strategic investments of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$376.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;($174.2) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;($4.6) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$2.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the first, second, third and fourth quarters, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Impairment charges related to certain intangible assets of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$215.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the third quarter. For additional information, please read Note 6, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A total net loss in our consolidated statements of income of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$124.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the sale of all the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM. This loss included a pre-tax loss of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$55.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a tax expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$68.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this transaction. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read, Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$63.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded in research and development expense in our consolidated statements of income in the fourth quarter as we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. We also acquired an option to extend our existing commercial agreement with Samsung Bioepis for BENEPALI, IMRALDI and FLIXABI in Europe and obtained exclusive rights to commercialize these products in China. For additional information, please read, Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Losses (gains) related to the adjustments to the fair values of our contingent consideration obligations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$11.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$(20.0) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$(57.8) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$2.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the first, second, third and fourth quarters, respectively. For additional information on the valuation of our contingent consideration obligations, please read Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$45.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis in the fourth quarter, as we exercised our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB080. For additional information, please read, Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$38.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Skyhawk in the first quarter as we entered into a collaboration and research and development services agreement with Skyhawk pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. For additional information, please read, Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for 2018 include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax (losses) gains related to changes in the fair value of our strategic investments of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$(6.4) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$5.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$141.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$(12.2) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the first, second, third and fourth quarters, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax charges to acquired IPR&amp;amp;D of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$27.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the first, second and third quarters, respectively, for upfront payments made upon closing of asset purchase transactions. For additional information, please read Note 2, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax research and development expenses for the second quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$486.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the 2018 Ionis Agreement. For additional information, please read, Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax charge to noncontrolling interests of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the second quarter for a payment to Neurimmune in exchange for a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. For additional information, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Impairment charges related to certain intangible assets of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$189.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$176.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the third and fourth quarters, respectively. For additional information, please read Note 6, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Losses (gains) related to the adjustments to the fair values of our contingent consideration obligations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$(5.6) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$1.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$(87.9) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$79.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the first, second, third and fourth quarters, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:48px;padding-top:12px;text-align:left;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;respectively. For additional information, please read Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net increase to income tax expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$135.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the fourth quarter reflecting the impact of electing to record deferred taxes on GILTI. For additional information, please read Note 16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$35.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis, as we exercised our option in the fourth quarter to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize tofersen. For additional information, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C3B13C8C0EC18BE3BCAD6F38B8EB31A7-0-wk-Fact-D70888FD5EA151BDDD0A6F38B88310D2">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,680.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,880.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,894.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,924.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;11,379.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;517.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;576.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;595.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;600.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,290.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;292.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;160.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;109.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;145.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;707.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,489.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,616.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,600.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,671.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;14,377.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;2,887.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,140.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,170.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;3,224.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;12,422.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,408.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,494.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,545.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,439.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,888.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,408.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,494.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,545.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;1,439.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;5,888.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;31.47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;7.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;8.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;31.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;196.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;190.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;184.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;177.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;187.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;197.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;190.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;184.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;178.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;span&gt;187.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,523.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,757.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,780.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,825.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,886.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;443.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;490.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;511.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;534.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,980.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;164.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;108.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;147.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;165.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;585.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,131.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,356.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,439.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,526.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,452.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,685.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,935.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,978.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,037.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,636.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,171.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;915.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,442.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;944.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,474.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,172.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;866.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,444.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;946.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,430.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;211.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;207.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;201.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;199.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;204.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;211.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;207.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;201.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;200.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;205.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for 2019 include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax gains (losses) related to changes in the fair value of our strategic investments of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$376.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;($174.2) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;($4.6) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$2.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the first, second, third and fourth quarters, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Impairment charges related to certain intangible assets of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$215.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the third quarter. For additional information, please read Note 6, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A total net loss in our consolidated statements of income of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$124.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the sale of all the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM. This loss included a pre-tax loss of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$55.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a tax expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$68.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this transaction. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read, Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$63.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded in research and development expense in our consolidated statements of income in the fourth quarter as we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. We also acquired an option to extend our existing commercial agreement with Samsung Bioepis for BENEPALI, IMRALDI and FLIXABI in Europe and obtained exclusive rights to commercialize these products in China. For additional information, please read, Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Losses (gains) related to the adjustments to the fair values of our contingent consideration obligations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$11.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$(20.0) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$(57.8) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$2.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the first, second, third and fourth quarters, respectively. For additional information on the valuation of our contingent consideration obligations, please read Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$45.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis in the fourth quarter, as we exercised our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB080. For additional information, please read, Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$38.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Skyhawk in the first quarter as we entered into a collaboration and research and development services agreement with Skyhawk pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. For additional information, please read, Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for 2018 include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax (losses) gains related to changes in the fair value of our strategic investments of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$(6.4) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$5.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$141.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$(12.2) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the first, second, third and fourth quarters, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax charges to acquired IPR&amp;amp;D of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$27.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the first, second and third quarters, respectively, for upfront payments made upon closing of asset purchase transactions. For additional information, please read Note 2, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax research and development expenses for the second quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$486.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the 2018 Ionis Agreement. For additional information, please read, Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax charge to noncontrolling interests of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the second quarter for a payment to Neurimmune in exchange for a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. For additional information, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Impairment charges related to certain intangible assets of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$189.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$176.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the third and fourth quarters, respectively. For additional information, please read Note 6, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Losses (gains) related to the adjustments to the fair values of our contingent consideration obligations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$(5.6) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$1.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$(87.9) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$79.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the first, second, third and fourth quarters, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:48px;padding-top:12px;text-align:left;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;respectively. For additional information, please read Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net increase to income tax expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$135.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the fourth quarter reflecting the impact of electing to record deferred taxes on GILTI. For additional information, please read Note 16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;&lt;span&gt;$35.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis, as we exercised our option in the fourth quarter to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize tofersen. For additional information, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51074274e1572-wk-Fact-AD5FB9CCB325CF9421AD6F38B7ADD3B3"
      unitRef="usd">2680000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51074274e1591-wk-Fact-3C99DBEE0A70FF128ED76F38B7CACC9F"
      unitRef="usd">2880300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51074274e1610-wk-Fact-FDA2283986F94F8989176F38B7AB9F87"
      unitRef="usd">2894700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51074274e1630-wk-Fact-EBC222CFB76BCEF4797C6F38B7A77F5E"
      unitRef="usd">2924800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51074274e1649-wk-Fact-F1FBA38FF669B88E1D976F38B82CDF1B"
      unitRef="usd">11379800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51074274e1669-wk-Fact-D841D758A9AE1491D7356F38B7C01877"
      unitRef="usd">517400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51074274e1688-wk-Fact-F3EA7407820C3A25AB6F6F38B7CA41D9"
      unitRef="usd">576400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51074274e1707-wk-Fact-22090CFFFD2F9FA335B86F38B7BB91AA"
      unitRef="usd">595800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51074274e1727-wk-Fact-FCD514F0CFE43F1D8E326F38B7A99E9C"
      unitRef="usd">600800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51074274e1746-wk-Fact-6DB6BA0B8C715A0D0D4B6F38B8607F57"
      unitRef="usd">2290400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51074274e1766-wk-Fact-4DC688EC5AC5B079BF716F38B7CD1745"
      unitRef="usd">292400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51074274e1785-wk-Fact-0A77A8237921432958FA6F38B7C77344"
      unitRef="usd">160000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51074274e1804-wk-Fact-FCC559336DD4CB3730296F38B7BCDB0F"
      unitRef="usd">109600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51074274e1824-wk-Fact-433EF916C4F31B981FF06F38B7A95047"
      unitRef="usd">145700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51074274e1843-wk-Fact-00E0A71FFA7A5B6582ED6F38B7ACA093"
      unitRef="usd">707700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d51074274e1863-wk-Fact-E66159CAA272F56A28B96F38B7AC2603"
      unitRef="usd">3489800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d51074274e1882-wk-Fact-9D67E0FD29235C9445926F38B7CC811D"
      unitRef="usd">3616700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d51074274e1901-wk-Fact-6D5131DB8D61F9BDE8A06F38B7AC54F3"
      unitRef="usd">3600100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4QTD"
      decimals="-5"
      id="d51074274e1921-wk-Fact-08548BD7E3A5566F20A56F38B7C55A3A"
      unitRef="usd">3671300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51074274e1940-wk-Fact-E32397F18F6693CE30CB6F38B869063E"
      unitRef="usd">14377900000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d51074274e1962-wk-Fact-25F8D9680520642A20556F38B7A877D9"
      unitRef="usd">2887800000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d51074274e1981-wk-Fact-F03991FB13B63561F4C96F38B7CC50F3"
      unitRef="usd">3140400000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d51074274e2000-wk-Fact-F1ACA004E23D51D9B4726F38B7B6E740"
      unitRef="usd">3170100000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2019Q4QTD"
      decimals="-5"
      id="d51074274e2020-wk-Fact-9E8DAB667FD08FF8AE916F38B7ACD38A"
      unitRef="usd">3224200000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51074274e2039-wk-Fact-90B4B0BBDC335E1D98E66F38B7AEC3AF"
      unitRef="usd">12422500000</us-gaap:GrossProfit>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d51074274e2061-wk-Fact-5CB2738E0B2538DCF1A06F38B7BDC8F2"
      unitRef="usd">1408800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d51074274e2080-wk-Fact-ECEAB4B119829BAB3C906F38B7CB668E"
      unitRef="usd">1494100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d51074274e2099-wk-Fact-F395A257B7F590399F956F38B7C9A1C5"
      unitRef="usd">1545900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4QTD"
      decimals="-5"
      id="d51074274e2119-wk-Fact-C434E596792007D163776F38B7CBD190"
      unitRef="usd">1439700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51074274e2138-wk-Fact-C3E3738B6B2880EEE0C26F38B86F41E2"
      unitRef="usd">5888500000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d51074274e2160-wk-Fact-83DF4A1F2393A5ED88726F38B7AD3519"
      unitRef="usd">1408800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d51074274e2179-wk-Fact-36F36E7386F02C65EC8B6F38B7C94661"
      unitRef="usd">1494100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d51074274e2198-wk-Fact-1986ED84E54A9B7C58D26F38B7CDA200"
      unitRef="usd">1545900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4QTD"
      decimals="-5"
      id="d51074274e2218-wk-Fact-4471A1E7D022C2980A646F38B7CAF15E"
      unitRef="usd">1439700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51074274e2237-wk-Fact-409F06146EDA2C5A1FA56F38B82DE39D"
      unitRef="usd">5888500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d51074274e2359-wk-Fact-3BDD6A35F238782207506F38B7CDF5F9"
      unitRef="usdPerShare">7.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d51074274e2378-wk-Fact-DA7D41C4F4E182D8EF5C6F38B7AB5E58"
      unitRef="usdPerShare">7.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d51074274e2397-wk-Fact-3C2FC0561FB7CC6CFDC56F38B7AAB1AE"
      unitRef="usdPerShare">8.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q4QTD"
      decimals="2"
      id="d51074274e2417-wk-Fact-4AD7D09A973C86BFE6946F38B7C98EE1"
      unitRef="usdPerShare">8.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d51074274e2436-wk-Fact-A79B8DD2B8E528E3782E6F38B808C78D"
      unitRef="usdPerShare">31.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d51074274e2457-wk-Fact-47CFB0CD5C2C762DBF116F38B7ABFBA2"
      unitRef="usdPerShare">7.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d51074274e2476-wk-Fact-37082D66FD70F1D412346F38B7CDBE64"
      unitRef="usdPerShare">7.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d51074274e2495-wk-Fact-7FD2F26F5947521C8BE36F38B7A7294D"
      unitRef="usdPerShare">8.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q4QTD"
      decimals="2"
      id="d51074274e2515-wk-Fact-A048BB136DDC540916CA6F38B7B1E593"
      unitRef="usdPerShare">8.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d51074274e2534-wk-Fact-F8BA2307E5D05CF7F3896F38B7C21B4F"
      unitRef="usdPerShare">31.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d51074274e2651-wk-Fact-C6761C1F1CA74A16822D6F38B7C91E98"
      unitRef="shares">196600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d51074274e2670-wk-Fact-6A2AD75D2054CFC71F016F38B7A72D25"
      unitRef="shares">190300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d51074274e2689-wk-Fact-BE3C899C712E77415DE86F38B7C5EB92"
      unitRef="shares">184000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q4QTD"
      decimals="-5"
      id="d51074274e2709-wk-Fact-35A1AFB52B56E89DDAA56F38B7C9F202"
      unitRef="shares">177800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51074274e2728-wk-Fact-1969AB1F17EC7BCE4FB56F38B7B8CA9B"
      unitRef="shares">187100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d51074274e2748-wk-Fact-DBEA22B774F16B3CFEF86F38B7A9DC71"
      unitRef="shares">197000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d51074274e2767-wk-Fact-BF07F8E164232369C7C36F38B7AAABC9"
      unitRef="shares">190400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d51074274e2786-wk-Fact-AD5DBA1463EBDCBB74A26F38B7B6C73D"
      unitRef="shares">184200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q4QTD"
      decimals="-5"
      id="d51074274e2806-wk-Fact-7ECACBA61073B2ED940C6F38B7C845F8"
      unitRef="shares">178200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d51074274e2825-wk-Fact-9C26193DB3CDD8FB9C8B6F38B8899F39"
      unitRef="shares">187400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:Revenues
      contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51074274e3097-wk-Fact-30F3E12D536F79AABFFC6F38B808B357"
      unitRef="usd">2523500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51074274e3116-wk-Fact-AD919574D17CAEC27DA66F38B811E3DB"
      unitRef="usd">2757500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51074274e3135-wk-Fact-68103C672778227924356F38B80874D8"
      unitRef="usd">2780100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51074274e3155-wk-Fact-8B326E9A26F264AC12086F38B818E2B6"
      unitRef="usd">2825700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d51074274e3174-wk-Fact-7B6205D978C9C04E48296F38B81CF51A"
      unitRef="usd">10886800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51074274e3194-wk-Fact-28863BD8E6798AE49A656F38B80C388D"
      unitRef="usd">443200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51074274e3213-wk-Fact-E59C624DCFB464B0C7676F38B7F81774"
      unitRef="usd">490400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51074274e3232-wk-Fact-60E3C8FDE3B55903D8066F38B7FDB782"
      unitRef="usd">511700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51074274e3252-wk-Fact-0AA8E5171B27F12CD62A6F38B810AB32"
      unitRef="usd">534900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d51074274e3271-wk-Fact-5DE8AC0444CC0844782E6F38B82AE6AA"
      unitRef="usd">1980200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51074274e3291-wk-Fact-9011AE068F8ECE15B8D66F38B7FA7F68"
      unitRef="usd">164400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51074274e3310-wk-Fact-5E718DE99528EB752B886F38B7EAD1AF"
      unitRef="usd">108600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51074274e3329-wk-Fact-EFD2F43A1450A1C22FFB6F38B8169DE3"
      unitRef="usd">147200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51074274e3349-wk-Fact-34D2C07DC74D44E6CFF26F38B80B737A"
      unitRef="usd">165700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d51074274e3368-wk-Fact-F0C4D670DC0F193457D96F38B8622365"
      unitRef="usd">585900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q1QTD"
      decimals="-5"
      id="d51074274e3388-wk-Fact-1EA16D36EE1AE4411D1A6F38B8049268"
      unitRef="usd">3131100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d51074274e3407-wk-Fact-078C4341C813F11836146F38B80DCE38"
      unitRef="usd">3356500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d51074274e3426-wk-Fact-EAF9B9FE03252FD9A1A96F38B80F27BB"
      unitRef="usd">3439000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4QTD"
      decimals="-5"
      id="d51074274e3446-wk-Fact-9CB27597215A4E7FAA6E6F38B8076EFC"
      unitRef="usd">3526300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51074274e3465-wk-Fact-6346545FE8014FEB58A26F38B7BCE6BD"
      unitRef="usd">13452900000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="FD2018Q1QTD"
      decimals="-5"
      id="d51074274e3487-wk-Fact-AD7947C887768A97332A6F38B805214D"
      unitRef="usd">2685100000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d51074274e3506-wk-Fact-18648B692AB2CAE6B5BE6F38B8007958"
      unitRef="usd">2935500000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d51074274e3525-wk-Fact-7D710B0C70644267D7476F38B819CD33"
      unitRef="usd">2978200000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2018Q4QTD"
      decimals="-5"
      id="d51074274e3545-wk-Fact-D6A590AF10C4643FB6FE6F38B80C7506"
      unitRef="usd">3037800000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51074274e3564-wk-Fact-E3357B8FDA69C56A09186F38B7FDB839"
      unitRef="usd">11636600000</us-gaap:GrossProfit>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q1QTD"
      decimals="-5"
      id="d51074274e3586-wk-Fact-B3AB723FE175911FB07E6F38B7F0F805"
      unitRef="usd">1171200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d51074274e3605-wk-Fact-B068B7126E3159FA2C536F38B7F131A2"
      unitRef="usd">915000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d51074274e3624-wk-Fact-9BCABB355017EF845B056F38B805C907"
      unitRef="usd">1442900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4QTD"
      decimals="-5"
      id="d51074274e3644-wk-Fact-15605FE8BC1CD2C9C6FB6F38B7F481A7"
      unitRef="usd">944900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51074274e3663-wk-Fact-697504B55D319C5C89A06F38B813740F"
      unitRef="usd">4474000000.0</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q1QTD"
      decimals="-5"
      id="d51074274e3685-wk-Fact-5EF51A0A02802EFFDD366F38B7F6849E"
      unitRef="usd">1172900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d51074274e3704-wk-Fact-3C07468CEC439713990D6F38B7F382D1"
      unitRef="usd">866600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d51074274e3723-wk-Fact-9CD666CAB27461A1B8E16F38B7FA6F36"
      unitRef="usd">1444400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4QTD"
      decimals="-5"
      id="d51074274e3743-wk-Fact-DA01565E8E45737ED7AA6F38B8073EB8"
      unitRef="usd">946800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51074274e3762-wk-Fact-D75E3BB69A698B5537196F38B831D83C"
      unitRef="usd">4430700000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q1QTD"
      decimals="2"
      id="d51074274e3884-wk-Fact-49623268A504D41A981F6F38B7F8EAED"
      unitRef="usdPerShare">5.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d51074274e3903-wk-Fact-7651DAC439D825E8B7696F38B80AB9B3"
      unitRef="usdPerShare">4.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d51074274e3922-wk-Fact-42ADC5E897592FF8E0116F38B7FBE91C"
      unitRef="usdPerShare">7.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q4QTD"
      decimals="2"
      id="d51074274e3942-wk-Fact-C5188F0B4EB3254B954E6F38B7EE313D"
      unitRef="usdPerShare">4.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d51074274e3961-wk-Fact-EC8AD5EF20EED04CF1636F38B8861C2A"
      unitRef="usdPerShare">21.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q1QTD"
      decimals="2"
      id="d51074274e3982-wk-Fact-63A9F4036D89356E74106F38B80D5031"
      unitRef="usdPerShare">5.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d51074274e4001-wk-Fact-AB60636A4671D09F83616F38B7F7151E"
      unitRef="usdPerShare">4.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d51074274e4020-wk-Fact-B7F190E431DEB44184906F38B7F65C34"
      unitRef="usdPerShare">7.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q4QTD"
      decimals="2"
      id="d51074274e4040-wk-Fact-765F9120D917446BE64C6F38B7FFE2A9"
      unitRef="usdPerShare">4.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d51074274e4059-wk-Fact-5A9680F29B9835BE41B06F38B82F13BD"
      unitRef="usdPerShare">21.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q1QTD"
      decimals="-5"
      id="d51074274e4176-wk-Fact-FC7932016DEFEE7A5FE56F38B7F71979"
      unitRef="shares">211400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d51074274e4195-wk-Fact-FAC98350780596AD28B36F38B7FEEF4D"
      unitRef="shares">207100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d51074274e4214-wk-Fact-1404B31D802E46C921166F38B7FC8939"
      unitRef="shares">201400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q4QTD"
      decimals="-5"
      id="d51074274e4234-wk-Fact-CCE787442430278832B76F38B809CE0D"
      unitRef="shares">199800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51074274e4253-wk-Fact-5907C0CD0AE9671001886F38B828BCF3"
      unitRef="shares">204900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q1QTD"
      decimals="-5"
      id="d51074274e4273-wk-Fact-FCC9E03DC1CC9B6D20486F38B7FFF632"
      unitRef="shares">211700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d51074274e4292-wk-Fact-8E0B84ECF7BC81FC318B6F38B8068B61"
      unitRef="shares">207300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d51074274e4311-wk-Fact-29B19561644BD9FBA27C6F38B80EB30B"
      unitRef="shares">201900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q4QTD"
      decimals="-5"
      id="d51074274e4331-wk-Fact-ED85616D28DB679E267D6F38B7FE4555"
      unitRef="shares">200300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d51074274e4350-wk-Fact-4176A55C9C6E8FB2BE6A6F38B7A4B71D"
      unitRef="shares">205300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d51074274e4389-wk-Fact-155FE2BAD93CE4C5E7FFEC6A378D9D8B"
      unitRef="usd">376100000</us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments>
    <us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d51074274e4393-wk-Fact-D8CC00D4F94E0F4E5663EC6A6676F50F"
      unitRef="usd">-174200000</us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments>
    <us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d51074274e4397-wk-Fact-9E1231F3AE2514DA1497EC6AD45D429C"
      unitRef="usd">-4600000</us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments>
    <us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
      contextRef="FD2019Q4QTD"
      decimals="-5"
      id="d51074274e4401-wk-Fact-D64BD4428891C56FC7E5EC6B140B2265"
      unitRef="usd">2800000</us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51074274e4412-wk-Fact-C90610768443E1F0F6317F831C0B9606"
      unitRef="usd">215900000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51074274e4427-wk-Fact-DE24E0AAB8C57FA871FDEC6C42D0446D"
      unitRef="usd">124200000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51074274e4431-wk-Fact-25731977E8E1923A8E3DE870A27E5A14"
      unitRef="usd">55300000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d51074274e4435-wk-Fact-7DD7E13C219FC7B4D1AE7F012B0335CA"
      unitRef="usd">68900000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d51074274e4450-wk-Fact-5B7F3DDADDBB4C47F3B2EC6DE68C4672"
      unitRef="usd">63000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d51074274e4465-wk-Fact-E98DDFB941B88644DF5AEC6F35091D0E"
      unitRef="usd">-11500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d51074274e4469-wk-Fact-091B0E5A2669AC634033EC6F6FBA0AFD"
      unitRef="usd">20000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d51074274e4473-wk-Fact-9AADE74D209FBE4C7C31EC6FA9A4D575"
      unitRef="usd">57800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q4QTD"
      decimals="-5"
      id="d51074274e4477-wk-Fact-39B3894DFAD25F5F286DEC6FDFEFE899"
      unitRef="usd">-2600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51074274e4493-wk-Fact-5B5420AD288ECBE73C13EC7114B5ABC1"
      unitRef="usd">45000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d51074274e4509-wk-Fact-675472E800A67B0C8E6ED20D97FD89D3"
      unitRef="usd">38500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
      contextRef="FD2018Q1QTD"
      decimals="-5"
      id="d51074274e4536-wk-Fact-2D6CDBC84B55379E429B6F38B87C088F"
      unitRef="usd">-6400000</us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments>
    <us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d51074274e4540-wk-Fact-4C456391CD220B575E856F38B87EAF3F"
      unitRef="usd">5400000</us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments>
    <us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d51074274e4544-wk-Fact-B32F5C599F3E116FB95D6F38B87D1AC5"
      unitRef="usd">141200000</us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments>
    <us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
      contextRef="FD2018Q4QTD"
      decimals="-5"
      id="d51074274e4548-wk-Fact-B8B418E02662408D4B7B6F38B883B16D"
      unitRef="usd">-12200000</us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember"
      decimals="-5"
      id="d51074274e4561-wk-Fact-2B07C6A0EAB8D12E9C486F38B8201F89"
      unitRef="usd">10000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember"
      decimals="-5"
      id="d51074274e4565-wk-Fact-B73E9F9149B60E7A00846F38B81FA7CC"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember"
      decimals="-5"
      id="d51074274e4569-wk-Fact-771C25E8188CAD91CD726F38B81F1A30"
      unitRef="usd">27500000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q2QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51074274e4587-wk-Fact-8669B37D8C8580A46D1C6F38B8809639"
      unitRef="usd">486200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d51074274e4611-wk-Fact-C19630D92012165D1FC7D13BABFED104"
      unitRef="usd">50000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Additionalreductioninroyaltyratepayableoncommercialsales
      contextRef="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember"
      decimals="2"
      id="d51074274e4615-wk-Fact-FBC8A0F6B8DBADA5A65FD13B517B54B9"
      unitRef="number">0.05</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d51074274e4636-wk-Fact-6D50742932615A5BE2716F38B844A09D"
      unitRef="usd">189300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d51074274e4640-wk-Fact-A4EB1ECE5775B27307D9E884A2D18D59"
      unitRef="usd">176800000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q1QTD"
      decimals="-5"
      id="d51074274e4655-wk-Fact-EB896C80A9671BCA5721D12053D79915"
      unitRef="usd">5600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d51074274e4659-wk-Fact-0E6A160C0EA0B920DE1CD1208205BF21"
      unitRef="usd">-1900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d51074274e4663-wk-Fact-911C3BA01E60604047B3D120EB28908F"
      unitRef="usd">87900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q4QTD"
      decimals="-5"
      id="d51074274e4667-wk-Fact-04824CD0E3AC2599621AD121286C67CD"
      unitRef="usd">-79300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <biib:DeferredtaxliabilitiesGILTItaxcalculation
      contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember"
      decimals="-5"
      id="d51074274e4704-wk-Fact-570282B9EBEE8CB3C20D6F38B8C7A8FD"
      unitRef="usd">135800000</biib:DeferredtaxliabilitiesGILTItaxcalculation>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d51074274e4725-wk-Fact-F1B44D408396DB2DB4B46F38B8357A14"
      unitRef="usd">35000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-60D6DDE9EC14655A4F336F38B8EB7E1B-0-wk-Fact-21BB5138DD21BD5FC02D6F38B81FA1E9">Subsequent Events&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2020 we entered into an agreement to acquire PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer. In particular, we plan to develop the Phase 1 asset for the treatment of sundowning in AD and irregular sleep wake rhythm disorder in Parkinson&#x2019;s disease. In connection with the closing of this transaction, we will make an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Pfizer, which will be recorded as acquired IPR&amp;amp;D in our consolidated statements of income as PF-05251749 has not yet reached technological feasibility. We may also pay Pfizer up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$635.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This transaction will be accounted for as an asset acquisition and is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S. We expect the transaction to close in the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2020 Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2020 we entered into a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility entered into in August 2015.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="D2019Q4Pfizer_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="d51065666e1294-wk-Fact-DEDB8924A8ADBD1698EDEC78CD31B93A"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="D2019Q4Pfizer_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="d51065666e1298-wk-Fact-7DD6B4AE19422BE7FF2AEC7C94B46FE3"
      unitRef="usd">635000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="I2019Q4creditfacility_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-8"
      id="d51065666e1311-wk-Fact-73DC378EC219BD1563FAEC7E7FAC4555"
      unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityDescription
      contextRef="D2019Q4creditfacility_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="d51065666e1315-wk-Fact-8D917A5C058323C8C36FF1EE60E38D68">five</us-gaap:LineOfCreditFacilityDescription>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#d51074274e3506-wk-Fact-18648B692AB2CAE6B5BE6F38B8007958"
          xlink:label="d51074274e3506-wk-Fact-18648B692AB2CAE6B5BE6F38B8007958"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl" xlink:label="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51074274e3506-wk-Fact-18648B692AB2CAE6B5BE6F38B8007958"
          xlink:to="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51074274e1962-wk-Fact-25F8D9680520642A20556F38B7A877D9"
          xlink:label="d51074274e1962-wk-Fact-25F8D9680520642A20556F38B7A877D9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51074274e1962-wk-Fact-25F8D9680520642A20556F38B7A877D9"
          xlink:to="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51064427e3498-wk-Fact-4F1B1F369F645FCAB5E06F38B89EFA30"
          xlink:label="d51064427e3498-wk-Fact-4F1B1F369F645FCAB5E06F38B89EFA30"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-7DBF3EF78F81D359A1B66F38B8E4EC02-0-wk-Footnote-7DBF3EF78F81D359A1B66F38B8E4EC02_lbl" xlink:label="TextSelection-7DBF3EF78F81D359A1B66F38B8E4EC02-0-wk-Footnote-7DBF3EF78F81D359A1B66F38B8E4EC02_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:10pt;"><xhtml:span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted during 2019 include awards granted in conjunction with our annual awards made in February 2019 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2019 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2018, 2017 and 2016.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51064427e3498-wk-Fact-4F1B1F369F645FCAB5E06F38B89EFA30"
          xlink:to="TextSelection-7DBF3EF78F81D359A1B66F38B8E4EC02-0-wk-Footnote-7DBF3EF78F81D359A1B66F38B8E4EC02_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51064427e5013-wk-Fact-607BA5807AAC7AE99C9D6F38B7FC34A8"
          xlink:label="d51064427e5013-wk-Fact-607BA5807AAC7AE99C9D6F38B7FC34A8"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-6E4BA122DC3EE32976BC6F38B8E4D29B-0-wk-Footnote-6E4BA122DC3EE32976BC6F38B8E4D29B_lbl" xlink:label="TextSelection-6E4BA122DC3EE32976BC6F38B8E4D29B-0-wk-Footnote-6E4BA122DC3EE32976BC6F38B8E4D29B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:10pt;"><xhtml:span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2019 primarily represent RSUs granted in conjunction with our annual awards made in February 2019 and awards made in conjunction with the hiring of new employees. RSUs granted in 2019 also include approximately </xhtml:span><xhtml:span style="font-family:Franklin Gothic Book;font-size:9pt;"><xhtml:span>15,000</xhtml:span></xhtml:span><xhtml:span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> RSUs granted to our Board of Directors.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51064427e5013-wk-Fact-607BA5807AAC7AE99C9D6F38B7FC34A8"
          xlink:to="TextSelection-6E4BA122DC3EE32976BC6F38B8E4D29B-0-wk-Footnote-6E4BA122DC3EE32976BC6F38B8E4D29B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51074274e3525-wk-Fact-7D710B0C70644267D7476F38B819CD33"
          xlink:label="d51074274e3525-wk-Fact-7D710B0C70644267D7476F38B819CD33"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51074274e3525-wk-Fact-7D710B0C70644267D7476F38B819CD33"
          xlink:to="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51074274e2039-wk-Fact-90B4B0BBDC335E1D98E66F38B7AEC3AF"
          xlink:label="d51074274e2039-wk-Fact-90B4B0BBDC335E1D98E66F38B7AEC3AF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51074274e2039-wk-Fact-90B4B0BBDC335E1D98E66F38B7AEC3AF"
          xlink:to="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51074274e2020-wk-Fact-9E8DAB667FD08FF8AE916F38B7ACD38A"
          xlink:label="d51074274e2020-wk-Fact-9E8DAB667FD08FF8AE916F38B7ACD38A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51074274e2020-wk-Fact-9E8DAB667FD08FF8AE916F38B7ACD38A"
          xlink:to="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51064427e3517-wk-Fact-9ECB7064E915716669C46F38B829E7BC"
          xlink:label="d51064427e3517-wk-Fact-9ECB7064E915716669C46F38B829E7BC"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d51064427e3889-wk-Fact-9ECB7064E915716669C46F38B829E7BC"
          xlink:label="d51064427e3889-wk-Fact-9ECB7064E915716669C46F38B829E7BC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51064427e3517-wk-Fact-9ECB7064E915716669C46F38B829E7BC"
          xlink:to="TextSelection-7DBF3EF78F81D359A1B66F38B8E4EC02-0-wk-Footnote-7DBF3EF78F81D359A1B66F38B8E4EC02_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51064427e3889-wk-Fact-9ECB7064E915716669C46F38B829E7BC"
          xlink:to="TextSelection-7DBF3EF78F81D359A1B66F38B8E4EC02-0-wk-Footnote-7DBF3EF78F81D359A1B66F38B8E4EC02_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51064427e4878-wk-Fact-A2BEB14B74EE13ECC3C46F38B87B88DB"
          xlink:label="d51064427e4878-wk-Fact-A2BEB14B74EE13ECC3C46F38B87B88DB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51064427e4878-wk-Fact-A2BEB14B74EE13ECC3C46F38B87B88DB"
          xlink:to="TextSelection-6E4BA122DC3EE32976BC6F38B8E4D29B-0-wk-Footnote-6E4BA122DC3EE32976BC6F38B8E4D29B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51074274e3487-wk-Fact-AD7947C887768A97332A6F38B805214D"
          xlink:label="d51074274e3487-wk-Fact-AD7947C887768A97332A6F38B805214D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51074274e3487-wk-Fact-AD7947C887768A97332A6F38B805214D"
          xlink:to="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51064427e4468-wk-Fact-B089A6B821E5A82ACA5F6F38B8043D78"
          xlink:label="d51064427e4468-wk-Fact-B089A6B821E5A82ACA5F6F38B8043D78"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51064427e4468-wk-Fact-B089A6B821E5A82ACA5F6F38B8043D78"
          xlink:to="TextSelection-7DBF3EF78F81D359A1B66F38B8E4EC02-0-wk-Footnote-7DBF3EF78F81D359A1B66F38B8E4EC02_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51074274e3545-wk-Fact-D6A590AF10C4643FB6FE6F38B80C7506"
          xlink:label="d51074274e3545-wk-Fact-D6A590AF10C4643FB6FE6F38B80C7506"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51074274e3545-wk-Fact-D6A590AF10C4643FB6FE6F38B80C7506"
          xlink:to="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51074274e3564-wk-Fact-E3357B8FDA69C56A09186F38B7FDB839"
          xlink:label="d51074274e3564-wk-Fact-E3357B8FDA69C56A09186F38B7FDB839"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51074274e3564-wk-Fact-E3357B8FDA69C56A09186F38B7FDB839"
          xlink:to="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51064427e4859-wk-Fact-E86D1CE0A120BCF496176F38B80DB12E"
          xlink:label="d51064427e4859-wk-Fact-E86D1CE0A120BCF496176F38B80DB12E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51064427e4859-wk-Fact-E86D1CE0A120BCF496176F38B80DB12E"
          xlink:to="TextSelection-6E4BA122DC3EE32976BC6F38B8E4D29B-0-wk-Footnote-6E4BA122DC3EE32976BC6F38B8E4D29B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51074274e1981-wk-Fact-F03991FB13B63561F4C96F38B7CC50F3"
          xlink:label="d51074274e1981-wk-Fact-F03991FB13B63561F4C96F38B7CC50F3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51074274e1981-wk-Fact-F03991FB13B63561F4C96F38B7CC50F3"
          xlink:to="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d51074274e2000-wk-Fact-F1ACA004E23D51D9B4726F38B7B6E740"
          xlink:label="d51074274e2000-wk-Fact-F1ACA004E23D51D9B4726F38B7B6E740"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d51074274e2000-wk-Fact-F1ACA004E23D51D9B4726F38B7B6E740"
          xlink:to="TextSelection-6F163E72375E5461C67C6F38B8E93EE0-0-wk-Footnote-6F163E72375E5461C67C6F38B8E93EE0_lbl"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6892990176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text">Investments in Variable Interest Entities<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab, our anti-amyloid beta antibody candidate for the potential treatment of AD (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all licensed products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of the Neurimmune Agreement and made a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune in exchange for a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, under the terms of the Neurimmune Agreement, we would be required to pay Neurimmune a milestone payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the regulatory filing with the FDA for approval of aducanumab and a milestone payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if aducanumab is launched in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai. For additional information on our collaboration arrangements with Eisai, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$22.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$28.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div>We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6630211312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract', window );"><strong>Reconciliation of the beginning and ending of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1</a></td>
<td class="nump">$ 114.2<span></span>
</td>
<td class="nump">$ 66.8<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current period</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior periods</a></td>
<td class="nump">17.2<span></span>
</td>
<td class="nump">58.7<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior periods</a></td>
<td class="num">(10.3)<span></span>
</td>
<td class="num">(13.6)<span></span>
</td>
<td class="num">(21.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Statute expirations</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 129.9<span></span>
</td>
<td class="nump">$ 114.2<span></span>
</td>
<td class="nump">$ 66.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6873658656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Genentech (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-cd20 therapeutic programs</a></td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542.4<span></span>
</td>
<td class="nump">1,431.9<span></span>
</td>
<td class="nump">1,316.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 748.0<span></span>
</td>
<td class="nump">$ 548.3<span></span>
</td>
<td class="nump">$ 242.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract', window );"><strong>After First GA101 Threshold Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaAbstract', window );"><strong>Co-promotion profit sharing formula</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne', window );">Until GAZYVA First Non-CLL FDA Approval</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract', window );"><strong>After First GA101 Threshold Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-cd20 therapeutic programs</a></td>
<td class="nump">$ 600.8<span></span>
</td>
<td class="nump">$ 595.8<span></span>
</td>
<td class="nump">$ 576.4<span></span>
</td>
<td class="nump">$ 517.4<span></span>
</td>
<td class="nump">$ 534.9<span></span>
</td>
<td class="nump">$ 511.7<span></span>
</td>
<td class="nump">$ 490.4<span></span>
</td>
<td class="nump">$ 443.2<span></span>
</td>
<td class="nump">$ 2,290.4<span></span>
</td>
<td class="nump">$ 1,980.2<span></span>
</td>
<td class="nump">$ 1,559.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from unconsolidated joint business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesFromUnconsolidatedJointBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871631600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text">Share-Based Payments<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Expense</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>77.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>75.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>74.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>148.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>105.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>95.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>225.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>181.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>169.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>216.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>170.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>160.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(35.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(27.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(42.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>180.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>142.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>117.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>134.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>126.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>107.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NST stock options</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>225.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>181.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>169.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>216.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>170.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>160.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, unrecognized compensation cost related to unvested share-based compensation was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$210.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.9</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Plans</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>three</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP). </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Directors Plan</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2006 our shareholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2006 Directors Plan. We have reserved a total of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a </span><span><span style="font-family:Franklin Gothic Book,sans-serif;">1.5-to-1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Omnibus Plan</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2017 Omnibus Equity Plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2008 Omnibus Equity Plan as of June 7, 2017, or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017, are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&#160;</span><span><span style="font-family:Franklin Gothic Book,sans-serif;">1.5-to-1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;ratio.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a 10-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all outstanding options were exercisable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:67%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>27,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>53.82</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(15,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>50.03</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>12,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>58.46</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total intrinsic values of options exercised in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic values of options outstanding as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The weighted average remaining contractual term for options outstanding as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;years. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Market Stock Units (MSUs)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees prior to 2014 vested in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>four</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>150%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on actual stock performance. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees in 2014 and thereafter vest in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>three</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>200%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on actual stock performance. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:67%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>180,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>371.32</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>147,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>378.08</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(101,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>356.71</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(43,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>388.68</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>183,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>378.09</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted during 2019 include awards granted in conjunction with our annual awards made in February 2019 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2019 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2018, 2017 and 2016.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price on the date of grant for MSUs, expected volatility of our stock price, risk-free rates of return and expected dividend yield.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assumptions used in our valuation are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:44%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:18%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;%</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.2% - 33.6%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.5% - 32.4%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.0% - 35.6%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.46% - 2.53%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9% - 2.3%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9% - 1.6%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$228.59 - $331.18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$279.47 - $346.76</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$263.18 - $267.88</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>$378.08</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$378.85</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$382.59</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of MSUs vested in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$32.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$26.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$31.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Settled Performance Units (CSPUs)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CSPUs awarded to employees vest in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>three</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>200%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs are classified as liability awards and will be settled in cash based on the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:82%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>50,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(4,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>13,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cash paid in settlement of CSPUs vested in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$15.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$16.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance-vested Restricted Stock Units (PUs)</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">PUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>three</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>200%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:82%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>48,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(4,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>11,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All PUs that vested in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were settled in cash totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$17.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$11.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance Stock Units (PSUs)</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">PSUs Settled in Stock</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018 we began granting awards for performance-vested RSUs that will settle in stock. PSUs awarded to employees have a three-year performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of cumulative three-year performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Participants may ultimately earn between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>200%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PSUs that settle in stock activity:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>60,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>317.26</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>77,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>316.28</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(26,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>318.11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>111,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>316.39</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PSUs settled in stock granted in 2019 include awards granted in conjunction with our annual awards made in February 2019 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">PSUs Settled in Cash</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018 we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have three performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of three annual performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Participants may ultimately earn between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>200%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs are classified as liability awards and will be settled in cash based on the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through the vesting date, once the actual vested and earned number of PSUs is determined. Since no shares are issued, these awards do not dilute equity.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PSUs that settle in cash activity:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:83%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>40,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>63,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(20,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>82,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PSUs settled in cash granted in 2019 include awards granted in conjunction with our annual awards made in February 2019 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Time-Vested Restricted Stock Units (RSUs)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs awarded to employees generally vest no sooner than </span><span style="font-family:Franklin Gothic Book,sans-serif;">one-third per year over three years</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:67%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>903,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>303.18</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>602,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>304.44</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(416,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>294.71</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(151,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>311.07</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>938,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>306.55</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2019 primarily represent RSUs granted in conjunction with our annual awards made in February 2019 and awards made in conjunction with the hiring of new employees. RSUs granted in 2019 also include approximately </span><span style="font-family:Franklin Gothic Book;font-size:9pt;"><span>15,000</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> RSUs granted to our Board of Directors.</span></div></td></tr></table><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs granted in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> had weighted average grant date fair values of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$316.32</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$293.41</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of RSUs vested in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$131.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$111.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015 our shareholders approved the 2015 ESPP. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>204,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>170,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>167,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>40.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>40.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>39.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>908</ContextCount>
  <ElementCount>732</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>224</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Divestitures Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDivestitures</Role>
      <ShortName>Divestitures Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Leases Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesLeases</Role>
      <ShortName>Leases Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2127100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Guarantees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Guarantees</Role>
      <ShortName>Guarantees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2129100 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2130100 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2133100 - Disclosure - Subsequent Events Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents</Role>
      <ShortName>Subsequent Events Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Acquisitions Schedule of separately identifiable assets acquired and liabilities assumed (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables</Role>
      <ShortName>Acquisitions Schedule of separately identifiable assets acquired and liabilities assumed (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Leases Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesLeasesTables</Role>
      <ShortName>Leases Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/LeasesLeases</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2317301 - Disclosure - Indebtedness (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessTables</Role>
      <ShortName>Indebtedness (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Equity</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2319302 - Disclosure - Equity Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Equity Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2323301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2324301 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2327301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2330301 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformation</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2331301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2401403 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Acquisitions Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails</Role>
      <ShortName>Acquisitions Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Acquisitions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsDetailsTextual</Role>
      <ShortName>Acquisitions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AcquisitionsScheduleOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - Divestitures Divestitures (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual</Role>
      <ShortName>Divestitures Divestitures (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DivestituresDivestitures</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Revenues by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesByProductDetails</Role>
      <ShortName>Revenues by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Revenues Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2409407 - Disclosure - Revenues (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesDetailsTextual</Role>
      <ShortName>Revenues (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Inventory (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetailsTextual</Role>
      <ShortName>Inventory (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Financial Instruments (Details Textual 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1</Role>
      <ShortName>Financial Instruments (Details Textual 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Derivative Instruments Cash Flow Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails</Role>
      <ShortName>Derivative Instruments Cash Flow Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Derivative Instruments Derivative Instruments Net Investment Hedges (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1</Role>
      <ShortName>Derivative Instruments Derivative Instruments Net Investment Hedges (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Derivative Instruments Interest Rate Swap (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsInterestRateSwapDetails2</Role>
      <ShortName>Derivative Instruments Interest Rate Swap (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Derivative Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual</Role>
      <ShortName>Derivative Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Property, Plant and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual</Role>
      <ShortName>Property, Plant and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Leases Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesLeasesDetails</Role>
      <ShortName>Leases Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/LeasesLeasesTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Leases Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesLeasesDetailsTextual</Role>
      <ShortName>Leases Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/LeasesLeasesTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2417403 - Disclosure - Indebtedness (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails1</Role>
      <ShortName>Indebtedness (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2417404 - Disclosure - Indebtedness (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetailsTextual</Role>
      <ShortName>Indebtedness (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2419405 - Disclosure - Equity Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Equity Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2419406 - Disclosure - Equity Reclassification out of Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Equity Reclassification out of Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2421404 - Disclosure - Share-Based Payments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails2</Role>
      <ShortName>Share-Based Payments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2421405 - Disclosure - Share-Based Payments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails3</Role>
      <ShortName>Share-Based Payments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2421406 - Disclosure - Share-Based Payments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails4</Role>
      <ShortName>Share-Based Payments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2421407 - Disclosure - Share-Based Payments (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails5</Role>
      <ShortName>Share-Based Payments (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2421408 - Disclosure - Share-Based Payments (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails6</Role>
      <ShortName>Share-Based Payments (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Share-Based Payments (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails7</Role>
      <ShortName>Share-Based Payments (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Share-Based Payments (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails8</Role>
      <ShortName>Share-Based Payments (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Share-Based Payments (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails9</Role>
      <ShortName>Share-Based Payments (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Share-Based Payments (Details 10)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails10</Role>
      <ShortName>Share-Based Payments (Details 10)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>2421413 - Disclosure - Share-Based Payments (Details 11)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails11</Role>
      <ShortName>Share-Based Payments (Details 11)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>2421414 - Disclosure - Share-Based Payments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual</Role>
      <ShortName>Share-Based Payments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>110</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>2422405 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>2422406 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>2423402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>2423403 - Disclosure - Other Consolidated Financial Statement Detail (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>2424402 - Disclosure - Collaborative and Other Relationships - Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails</Role>
      <ShortName>Collaborative and Other Relationships - Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>2424403 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Eisai (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Eisai (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>2424404 - Disclosure - Collaborative and Other Relationships - AbbVie (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2</Role>
      <ShortName>Collaborative and Other Relationships - AbbVie (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>118</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>2424405 - Disclosure - Collaborative and Other Relationships (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual</Role>
      <ShortName>Collaborative and Other Relationships (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>119</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>2425401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>2426401 - Disclosure - Litigation Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationLitigationDetails</Role>
      <ShortName>Litigation Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>2427402 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>122</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>2429401 - Disclosure - Employee Benefit Plans Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>2429402 - Disclosure - Employee Benefit Plans (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1</Role>
      <ShortName>Employee Benefit Plans (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>124</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>2430402 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>125</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>2430403 - Disclosure - Segment Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetailsTextual</Role>
      <ShortName>Segment Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>126</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>2431402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>127</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>2431403 - Disclosure - Quarterly Financial Data (Unaudited) (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>128</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>2433401 - Disclosure - Subsequent Events Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents</ParentRole>
      <Position>129</Position>
    </Report>
    <Report instance="biib-20191231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - biib-20191231x10k.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - biib-20191231x10k.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="biib-20191231x10k.htm">biib-20191231x10k.htm</File>
    <File>biib-20191231.xsd</File>
    <File>biib-20191231_cal.xml</File>
    <File>biib-20191231_def.xml</File>
    <File>biib-20191231_lab.xml</File>
    <File>biib-20191231_pre.xml</File>
    <File>biib-20191231xex21.htm</File>
    <File>biib-20191231xex23.htm</File>
    <File>biib-20191231xex311.htm</File>
    <File>biib-20191231xex312.htm</File>
    <File>biib-20191231xex321.htm</File>
    <File>biib-20191231xex44.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>acquirediprd.jpg</File>
    <File>amortofacquireintang.jpg</File>
    <File>anticd20revenue.jpg</File>
    <File>avonex.jpg</File>
    <File>benepalia04.jpg</File>
    <File>biogenlogo2020a01.jpg</File>
    <File>biosimilarsrev.jpg</File>
    <File>bubbles20192.jpg</File>
    <File>cogs.jpg</File>
    <File>collaborationprofitshare.jpg</File>
    <File>equityinlossofinvestee.jpg</File>
    <File>fampyra.jpg</File>
    <File>finhighlights.jpg</File>
    <File>flixabi.jpg</File>
    <File>fumaderm.jpg</File>
    <File>fvremeasurementcc.jpg</File>
    <File>gazyva.jpg</File>
    <File>imraldi.jpg</File>
    <File>incometaxprovision.jpg</File>
    <File>interferonrev.jpg</File>
    <File>lossondivestitureofdenmark.jpg</File>
    <File>marketedproductsrev.jpg</File>
    <File>nci.jpg</File>
    <File>ocrevus.jpg</File>
    <File>otherincomeexpense.jpg</File>
    <File>otherrev.jpg</File>
    <File>plegridy.jpg</File>
    <File>researchanddev.jpg</File>
    <File>researchanddevelopment.jpg</File>
    <File>reservesdisandallow.jpg</File>
    <File>rituxan.jpg</File>
    <File>rituxanhycelalogo300x87.jpg</File>
    <File>sellinggeneralandadmin.jpg</File>
    <File>spinrazalogonewa01.jpg</File>
    <File>spinrazarev.jpg</File>
    <File>stockperfgraph.jpg</File>
    <File>tecfidera.jpg</File>
    <File>tecfiderarev.jpg</File>
    <File>tysabri.jpg</File>
    <File>tysabrirev.jpg</File>
    <File>vumerity-logoa03.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871700688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of property, plant and equipment, net</a></td>
<td class="text">Components of property, plant and equipment, net are summarized as follows:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>118.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>144.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>835.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,282.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>99.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>94.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>844.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,258.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>798.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>798.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>58.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>61.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,084.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,758.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>4,838.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,398.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1,590.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,797.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,247.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,601.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895833152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AccumulatedOtherComprehensiveIncomeLossAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(31.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(243.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(240.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>88.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>103.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>230.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(3.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(115.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(125.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(26.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>21.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>103.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>105.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(32.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(139.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(135.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(318.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU 2016-01</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(316.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>97.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(67.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>29.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>41.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>139.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(67.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>76.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(31.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(243.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(240.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>57.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(32.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(334.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(319.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(193.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>158.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(42.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>44.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(162.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>158.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(318.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(19.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>118.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(42.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(32.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>125.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(47.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(44.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccumulatedOtherComprehensiveIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated Other Comprehensive Income (Loss) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccumulatedOtherComprehensiveIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6896670592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83.3<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="num">$ (217.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,158.0<span></span>
</td>
<td class="nump">1,425.6<span></span>
</td>
<td class="nump">2,458.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">14,377.9<span></span>
</td>
<td class="nump">13,452.9<span></span>
</td>
<td class="nump">12,273.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,439.7<span></span>
</td>
<td class="nump">$ 1,545.9<span></span>
</td>
<td class="nump">$ 1,494.1<span></span>
</td>
<td class="nump">$ 1,408.8<span></span>
</td>
<td class="nump">$ 946.8<span></span>
</td>
<td class="nump">$ 1,444.4<span></span>
</td>
<td class="nump">$ 866.6<span></span>
</td>
<td class="nump">$ 1,172.9<span></span>
</td>
<td class="nump">5,888.5<span></span>
</td>
<td class="nump">4,430.7<span></span>
</td>
<td class="nump">2,539.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.6<span></span>
</td>
<td class="num">(47.0)<span></span>
</td>
<td class="num">(44.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Securities Available for Sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(19.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.6<span></span>
</td>
<td class="num">(42.5)<span></span>
</td>
<td class="num">(32.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (Losses) on Net Investment Hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6880883424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="nump">69.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584.5<span></span>
</td>
<td class="nump">459.4<span></span>
</td>
<td class="nump">253.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">$ 145.7<span></span>
</td>
<td class="nump">$ 109.6<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">$ 292.4<span></span>
</td>
<td class="nump">$ 165.7<span></span>
</td>
<td class="nump">$ 147.2<span></span>
</td>
<td class="nump">$ 108.6<span></span>
</td>
<td class="nump">$ 164.4<span></span>
</td>
<td class="nump">707.7<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(16.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.2<span></span>
</td>
<td class="nump">96.4<span></span>
</td>
<td class="nump">42.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Sobi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 10.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SobiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SobiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6987369328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues by Product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,432.7<span></span>
</td>
<td class="nump">4,274.1<span></span>
</td>
<td class="nump">4,214.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,101.8<span></span>
</td>
<td class="nump">2,363.0<span></span>
</td>
<td class="nump">2,645.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892.2<span></span>
</td>
<td class="nump">1,864.0<span></span>
</td>
<td class="nump">1,973.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.1<span></span>
</td>
<td class="nump">92.7<span></span>
</td>
<td class="nump">91.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,529.3<span></span>
</td>
<td class="nump">8,595.2<span></span>
</td>
<td class="nump">8,977.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,097.0<span></span>
</td>
<td class="nump">1,724.2<span></span>
</td>
<td class="nump">883.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486.2<span></span>
</td>
<td class="nump">485.2<span></span>
</td>
<td class="nump">370.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.1<span></span>
</td>
<td class="nump">43.2<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738.3<span></span>
</td>
<td class="nump">545.1<span></span>
</td>
<td class="nump">379.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ALPROLIXMember', window );">ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_HemophiliaProductsMember', window );">Hemophilia Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">74.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 2,924.8<span></span>
</td>
<td class="nump">$ 2,894.7<span></span>
</td>
<td class="nump">$ 2,880.3<span></span>
</td>
<td class="nump">$ 2,680.0<span></span>
</td>
<td class="nump">$ 2,825.7<span></span>
</td>
<td class="nump">$ 2,780.1<span></span>
</td>
<td class="nump">$ 2,757.5<span></span>
</td>
<td class="nump">$ 2,523.5<span></span>
</td>
<td class="nump">11,379.8<span></span>
</td>
<td class="nump">10,886.8<span></span>
</td>
<td class="nump">10,354.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,306.5<span></span>
</td>
<td class="nump">3,253.2<span></span>
</td>
<td class="nump">3,294.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,426.6<span></span>
</td>
<td class="nump">1,668.3<span></span>
</td>
<td class="nump">1,889.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,041.8<span></span>
</td>
<td class="nump">1,025.0<span></span>
</td>
<td class="nump">1,113.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,780.4<span></span>
</td>
<td class="nump">5,946.5<span></span>
</td>
<td class="nump">6,296.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">933.4<span></span>
</td>
<td class="nump">854.0<span></span>
</td>
<td class="nump">657.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">42.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | Hemophilia Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,713.8<span></span>
</td>
<td class="nump">6,800.5<span></span>
</td>
<td class="nump">7,017.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,126.2<span></span>
</td>
<td class="nump">1,020.9<span></span>
</td>
<td class="nump">920.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.2<span></span>
</td>
<td class="nump">694.7<span></span>
</td>
<td class="nump">756.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850.4<span></span>
</td>
<td class="nump">839.0<span></span>
</td>
<td class="nump">859.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.1<span></span>
</td>
<td class="nump">92.7<span></span>
</td>
<td class="nump">91.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,748.9<span></span>
</td>
<td class="nump">2,648.7<span></span>
</td>
<td class="nump">2,680.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163.6<span></span>
</td>
<td class="nump">870.2<span></span>
</td>
<td class="nump">226.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486.2<span></span>
</td>
<td class="nump">485.2<span></span>
</td>
<td class="nump">370.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.1<span></span>
</td>
<td class="nump">43.2<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738.3<span></span>
</td>
<td class="nump">545.1<span></span>
</td>
<td class="nump">379.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Hemophilia Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,666.0<span></span>
</td>
<td class="nump">$ 4,086.3<span></span>
</td>
<td class="nump">$ 3,337.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_VUMERITYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_VUMERITYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ELOCTATEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ELOCTATEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ALPROLIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ALPROLIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_HemophiliaProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_HemophiliaProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6878611152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Costs associated with the Senior Notes offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemptions percentage of 2015 notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage', window );">Redemption percentage for change in control provision on the 2015 Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior unsecured revolving credit facility maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Term of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">five<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Amount outstanding under the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.764%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.294%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | 2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Interest rate swap, liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior unsecured revolving credit facility maximum borrowing capacity</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Term of credit facility</a></td>
<td class="text">five<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Make Whole Provision Redemption Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6987332496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="9">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 7,379.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,187.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,379.3<span></span>
</td>
<td class="nump">$ 7,187.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">8,408.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,727.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,408.8<span></span>
</td>
<td class="nump">7,727.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,881.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,607.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,881.4)<span></span>
</td>
<td class="num">(4,607.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,497.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,580.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,497.9<span></span>
</td>
<td class="nump">2,580.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,527.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,527.4<span></span>
</td>
<td class="nump">3,120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489.9<span></span>
</td>
<td class="nump">747.3<span></span>
</td>
<td class="nump">$ 814.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274.0<span></span>
</td>
<td class="nump">381.2<span></span>
</td>
<td class="nump">455.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent Consideration</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">$ 57.8<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="num">$ (11.5)<span></span>
</td>
<td class="num">(79.3)<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.7<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="num">$ (62.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117.5<span></span>
</td>
<td class="nump">1,080.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Payment made to Forward Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">965.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 965.5<span></span>
</td>
<td class="nump">476.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="nump">155.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 36.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">795.2<span></span>
</td>
<td class="nump">$ 36.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of in-licensed patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BG00011Member', window );">BG00011</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_PLSRMember', window );">PLSR | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationandImpairmentofAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets and goodwill additional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_VUMERITYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_VUMERITYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BG00011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BG00011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_PLSRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_PLSRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6984545280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 2)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StockOptionActivityAbstract', window );"><strong>Stock Option Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance, Outstanding shares | shares</a></td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 53.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised | shares</a></td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 50.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Cancelled | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance, Outstanding shares | shares</a></td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 58.46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6986619632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>March 2019 Share Repurchase Program</div></th>
<th class="th">
<div>March 2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>March 2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>March 2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>March 2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>2018 Share Repurchase Program</div></th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>2016 Share Repurchase Program</div></th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>2011 Share Repurchase Program</div></th>
<th class="th">
<div>2011 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 12,128.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (319.9)<span></span>
</td>
<td class="nump">$ 15,071.6<span></span>
</td>
<td class="nump">$ 2,611.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2016</a></td>
<td class="nump">12,140.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning Balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(238,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">2,539.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,539.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">131.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,670.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Capital contribution by noncontrolling interest</a></td>
<td class="nump">15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interests</a></td>
<td class="num">(150.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000.0)<span></span>
</td>
<td class="num">$ (365.4)<span></span>
</td>
<td class="num">$ (365.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 36.0<span></span>
</td>
<td class="nump">$ 964.0<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock options and stock purchase plans, value</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">40.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(45.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(44.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Hemophilia spin-off adjustment</a></td>
<td class="num">(852.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StockholdersEquityTaxBenefitExpense', window );">Tax benefit</a></td>
<td class="num">(17.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="nump">12,598.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">97.8<span></span>
</td>
<td class="num">(318.4)<span></span>
</td>
<td class="nump">15,810.4<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="nump">12,612.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(235,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">4,430.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,430.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">43.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,474.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">76.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(76.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Capital contribution by noncontrolling interest</a></td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interests</a></td>
<td class="num">(50.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="num">(3,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,352.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,352.6)<span></span>
</td>
<td class="num">$ (3,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,300,000)<span></span>
</td>
<td class="num">(10,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 92.8<span></span>
</td>
<td class="nump">$ 1,259.8<span></span>
</td>
<td class="nump">$ 1,352.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 171.1<span></span>
</td>
<td class="nump">$ 2,828.9<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock options and stock purchase plans, value</a></td>
<td class="nump">41.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">41.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(43.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(43.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="num">(168.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(168.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Adoption of new accounting guidance</a></td>
<td class="nump">106.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">104.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="nump">13,031.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(240.4)<span></span>
</td>
<td class="nump">16,257.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="nump">13,039.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(221,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">5,888.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,888.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">5,888.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">105.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">104.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Capital contribution by noncontrolling interest</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,720.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,720.9)<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,700,000)<span></span>
</td>
<td class="num">(8,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 121.5<span></span>
</td>
<td class="nump">$ 3,599.4<span></span>
</td>
<td class="nump">$ 3,720.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 110.5<span></span>
</td>
<td class="nump">$ 2,036.9<span></span>
</td>
<td class="nump">$ 2,147.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock options and stock purchase plans, value</a></td>
<td class="nump">$ 40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan, shares</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">$ (53.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="num">(191.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(191.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">13,339.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (135.2)<span></span>
</td>
<td class="nump">$ 16,455.4<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">13,343.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(198,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StockholdersEquityTaxBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity, Tax Benefit (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StockholdersEquityTaxBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6978056576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 5,888.5<span></span>
</td>
<td class="nump">$ 4,430.7<span></span>
</td>
<td class="nump">$ 2,539.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) recognized during the period, net of tax</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Less: reclassification adjustment for (gains) losses included in net income, net of tax</a></td>
<td class="num">(3.6)<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">8.2<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) recognized during the period, net of tax</a></td>
<td class="nump">88.1<span></span>
</td>
<td class="nump">97.4<span></span>
</td>
<td class="num">(193.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax', window );">Less: reclassification adjustment for (gains) losses included in net income, net of tax</a></td>
<td class="num">(115.0)<span></span>
</td>
<td class="nump">41.8<span></span>
</td>
<td class="nump">31.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(26.9)<span></span>
</td>
<td class="nump">139.2<span></span>
</td>
<td class="num">(162.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Gains (Losses) on net investment hedge recognized during period</a></td>
<td class="nump">28.6<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax', window );">Less: Reclassification of net investment hedge forward points amortization</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax', window );">Gains (losses) on net investment hedges</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">103.8<span></span>
</td>
<td class="num">(67.8)<span></span>
</td>
<td class="nump">158.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">105.2<span></span>
</td>
<td class="nump">76.5<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">5,993.7<span></span>
</td>
<td class="nump">4,507.2<span></span>
</td>
<td class="nump">2,540.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(42.9)<span></span>
</td>
<td class="num">(131.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 5,993.3<span></span>
</td>
<td class="nump">$ 4,550.1<span></span>
</td>
<td class="nump">$ 2,671.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109974929&amp;loc=SL110061190-113977<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph c<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109978405&amp;loc=d3e80720-113993<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983964800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 427.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 486.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessTextualAbstract', window );"><strong>Business (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentTermsOfAccountsReceivable', window );">Payment terms of accounts receivable arising from product sales</a></td>
<td class="text">30 to 90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedUsefulLivesOfLeaseholdImprovements', window );">Estimated useful lives of leasehold improvements</a></td>
<td class="text">Lesser of the useful life or the term of the respective lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PurchasePriceOfCommonStockUnderEspp', window );">Purchase price of common stock under ESPP</a></td>
<td class="text">85% of the lower of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CompensationExpenseOverPurchasePeriod', window );">Compensation expense over purchase period</a></td>
<td class="text">The fair value of the look-back provision plus the 15% discount<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">$ 79.2<span></span>
</td>
<td class="nump">90.2<span></span>
</td>
<td class="nump">$ 75.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Deferred Income Tax Charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CompensationExpenseOverPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation expense over purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CompensationExpenseOverPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedUsefulLivesOfLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated useful lives of leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedUsefulLivesOfLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentTermsOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment  terms of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentTermsOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PurchasePriceOfCommonStockUnderEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Common Stock Under ESPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PurchasePriceOfCommonStockUnderEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredIncomeTaxChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredIncomeTaxChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_DeferredtaxliabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_DeferredtaxliabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871700688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaTableTextBlock', window );">Co-promotion profit sharing formula</a></td>
<td class="text">Our share of annual co-promotion profits in excess of <span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:82%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>40.0</span></span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>39.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>37.5</span></span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>35.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</span></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$500.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PretaxProfitSharingFormulaTableTextBlock', window );">Pretax profit sharing formula</a></td>
<td class="text">Our share of annual profits in excess of <span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:82%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>39.0</span></span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>37.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>35.0</span></span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,431.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,316.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>748.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>548.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>242.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,290.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,980.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,559.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,431.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,316.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>748.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>548.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>242.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,290.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,980.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,559.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock', window );">Summary of activity related to BAN2401 and Elenbecestat collaboration</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>348.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>232.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>146.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>174.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>116.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>74.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>32.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>16.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of activity related to Aducanumab collaboration</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>264.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>268.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>98.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>234.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>268.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>27.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pretax Profit Sharing Formula [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885239792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness (Details 1)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Total debt maturities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 1,500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2021</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2022</a></td>
<td class="nump">1,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2025 and thereafter</a></td>
<td class="nump">3,500.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total</a></td>
<td class="nump">$ 6,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6878944336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual 2)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Sale of Ionis common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 479.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">676.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 676.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393.9<span></span>
</td>
<td class="nump">$ 676.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Sale of Ionis common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Samsung Bioepis, ownership percentage before additional purchase transaction</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Samsung Bioepis, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580.2<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 670.8<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">&#8361; 49.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6878991648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments Derivative Instruments Net Investment Hedges (Details 1)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 29, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedge in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="num">(27.3)<span></span>
</td>
<td class="nump">$ 113.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Forward contracts duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedge in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as hedge, excluded component, after tax</a></td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in net income of foreign currency forward contracts, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Samsung Bioepis, ownership percentage before additional purchase transaction</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Samsung Bioepis, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109977999&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7047695056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 6,553.6<span></span>
</td>
<td class="nump">$ 6,037.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,509.6<span></span>
</td>
<td class="nump">1,489.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,038.9<span></span>
</td>
<td class="nump">1,000.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,897.2<span></span>
</td>
<td class="nump">1,745.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 2,107.9<span></span>
</td>
<td class="nump">$ 1,802.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6878513984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">$ 2,965.0<span></span>
</td>
<td class="nump">$ 3,694.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">2,970.3<span></span>
</td>
<td class="nump">3,689.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">1,057.2<span></span>
</td>
<td class="nump">1,608.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">1,058.2<span></span>
</td>
<td class="nump">1,607.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">633.9<span></span>
</td>
<td class="nump">854.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">636.9<span></span>
</td>
<td class="nump">851.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">502.9<span></span>
</td>
<td class="nump">706.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">503.3<span></span>
</td>
<td class="nump">705.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">510.1<span></span>
</td>
<td class="nump">264.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">510.6<span></span>
</td>
<td class="nump">263.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">260.2<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">260.6<span></span>
</td>
<td class="nump">260.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Marketable equity securities, amortized cost</a></td>
<td class="nump">218.4<span></span>
</td>
<td class="nump">496.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable equity securities, gross unrealized gains</a></td>
<td class="nump">132.1<span></span>
</td>
<td class="nump">127.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable equity securities, gross unrealized losses</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities, fair value</a></td>
<td class="nump">$ 337.5<span></span>
</td>
<td class="nump">$ 615.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6752516624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 190.6<span></span>
</td>
<td class="nump">$ 269.4<span></span>
</td>
<td class="nump">$ 266.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest Costs Capitalized</a></td>
<td class="nump">68.8<span></span>
</td>
<td class="nump">54.0<span></span>
</td>
<td class="nump">$ 30.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">2,084.4<span></span>
</td>
<td class="nump">1,758.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">$ 1,900.0<span></span>
</td>
<td class="nump">$ 1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment sold to Fujifilm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 631.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment sold to Fujifilm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment sold to Fujifilm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871629920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,695.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,695.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,013.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,013.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>337.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>329.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,920.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,912.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>354.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,459.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,459.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>969.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>969.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>615.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>563.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,102.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,050.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>434.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </span><span><span style="font-family:Franklin Gothic Book,sans-serif;">no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or transfers between fair value measurement levels during the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our collaboration arrangements with Ionis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,509.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,489.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,038.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,000.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,897.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,745.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,107.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,802.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6,553.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,037.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix and BIN in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>523.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(63.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(12.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(101.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$197.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$265.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of IPF resulting in a reduction of our contingent consideration obligations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$61.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, partially offset by changes in the probability and expected timing of achievement of certain developmental milestones, a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of achievement of milestones related to the TGN program and an increase in discount rates used to revalue our contingent consideration liabilities, partially offset by the passage of time. For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, payments and other reflects an </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$81.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment made to the former shareholders of Stromedix. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of the contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Convergence Pharmaceuticals Holdings Limited</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$274.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$244.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$246.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash flow projections of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$400.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.1%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in our contingent consideration obligation was primarily due to changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones, partially offset by a decrease in discount rates used to revalue our contingent consideration liabilities and the passage of time. Accrued expenses and other in our consolidated balances sheets include </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$148.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as we expect to make the payment within one year.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Stromedix Inc.</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Stromedix in March 2012 we recorded a contingent consideration obligation of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$122.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF due to safety concerns. As a result, we adjusted the fair value of this contingent consideration obligation to zero, resulting in a gain of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$61.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter of 2019. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$83.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen Idec International Neuroscience GmbH</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$81.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$101.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$80.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash outflow projections of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$335.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.3%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in our contingent consideration obligation was primarily due to changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones, a decrease in discount rates used to revalue our contingent consideration liabilities and the passage of time. No amounts are reflected as a current liability in our consolidated balance sheets at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as we do not expect to make a payment in the next year.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired IPR&amp;D</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of the acquired IPR&amp;D assets were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. These assets are tested for impairment annually until commercialization, after which time the acquired </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D will be amortized over its estimated useful life using the economic consumption method. In connection with our acquisition of Stromedix, we recognized a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$219.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> acquired IPR&amp;D intangible asset. During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF due to safety concerns and recognized an impairment charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$215.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reduce the fair value of the IPR&amp;D intangible asset to zero. In connection with our acquisition of Convergence we recognized a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$424.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> acquired IPR&amp;D intangible asset. During the third quarter of 2018 we recognized impairment charges related to certain IPR&amp;D assets associated with our vixotrigine program totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$189.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our IPR&amp;D intangible assets, including a discussion of our most significant assumptions, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6876060096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payment to Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.3)<span></span>
</td>
<td class="nump">$ 36.4<span></span>
</td>
<td class="nump">$ 134.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.7<span></span>
</td>
<td class="nump">$ 28.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payment to Neurimmune</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones | Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryApprovalMilestoneMember', window );">Regulatory Approval Milestone | Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInVariableInterestEntitiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6896574464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_DE', window );">GERMANY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Employee Benefit Plan obligations</a></td>
<td class="nump">$ 59.6<span></span>
</td>
<td class="nump">$ 45.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Periodic pension cost</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_DE', window );">GERMANY | Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Periodic pension cost</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CH', window );">SWITZERLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfMinimumInvestmentReturn', window );">Percentage of minimum investment return</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Unfunded net pension</a></td>
<td class="nump">$ 42.9<span></span>
</td>
<td class="nump">$ 48.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Employee Benefit Plan obligations</a></td>
<td class="nump">127.1<span></span>
</td>
<td class="nump">93.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">Pension Cost (Reversal of Cost)</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CH', window );">SWITZERLAND | Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">Pension Cost (Reversal of Cost)</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EmployeeBenefitPlansTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EmployeeBenefitPlansTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfMinimumInvestmentReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum investment return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfMinimumInvestmentReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871687440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures Divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM Corporation (FUJIFILM). Upon the closing of this transaction, we received approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$881.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, which may be adjusted based on other contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$74.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees and have accrued for this obligation. We may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this transaction, we recognized a total net loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$164.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated statements of income. This loss included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$95.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded in loss on divestiture of Hiller&#248;d, Denmark manufacturing operations. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$11.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and our estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$114.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. We also recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$68.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this transaction. During the fourth quarter of 2019 we recorded a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$40.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in our estimate of the future minimum batch commitment utilizing our current manufacturing forecast, which reflects the impact of forecasted aducanumab batches, resulting in a reduction in the pre-tax loss on divestiture from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$95.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$55.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sold to FUJIFILM </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$41.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the adverse commitment is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895866672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease real estate, including laboratory and office space, and certain equipment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our leases have remaining lease terms ranging from less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one year</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>ten years</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one year</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>six years</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one year</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>nine years</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our subleases do not include an option to renew as they are coterminous with our operating leases.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All of our leases qualify as operating leases. The following table summarizes the presentation in our consolidated balance sheets of our operating leases:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:41%;"/><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>427.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>73.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>412.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>486.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of lease costs in our consolidated statements of income:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:41%;"/><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the year ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>84.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(25.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>86.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Variable lease cost primarily related to operating expenses, taxes and insurance associated with our operating leases. As these costs are generally variable in nature, they are not included in the measurement of the operating lease asset and related lease liability.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The minimum lease payments for the next five years and thereafter is expected to be as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>87.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>81.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>75.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>72.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>69.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>158.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>544.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>58.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>486.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the five years and total thereafter as of December&#160;31, 2018, were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>87.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>80.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>75.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>601.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(26.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(25.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(23.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(58.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(182.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>418.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:83%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term in years</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.07</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our consolidated statements of cash flows is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the year ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>93.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>35.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7008064080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details Textual) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 05, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments', window );">Unrealized gain (loss) on strategic investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="num">$ (4.6)<span></span>
</td>
<td class="num">$ (174.2)<span></span>
</td>
<td class="nump">$ 376.1<span></span>
</td>
<td class="num">$ (12.2)<span></span>
</td>
<td class="nump">$ 141.2<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="num">$ (6.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,381.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(544.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,381.6)<span></span>
</td>
<td class="num">$ (544.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="num">$ (11.5)<span></span>
</td>
<td class="num">(79.3)<span></span>
</td>
<td class="nump">87.9<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.7<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="num">$ (62.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,280.6<span></span>
</td>
<td class="nump">2,597.2<span></span>
</td>
<td class="nump">2,253.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
<td class="nump">36.4<span></span>
</td>
<td class="nump">134.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
<td class="nump">131.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,158.0<span></span>
</td>
<td class="nump">1,425.6<span></span>
</td>
<td class="nump">2,458.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense on 2018 Ionis Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember', window );">Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144.0<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember', window );">iPerian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DevelopmentalMilestonePayment', window );">Developmental Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember', window );">Alkermes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.5<span></span>
</td>
<td class="nump">68.7<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense on 2018 Ionis Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Premiumonpurchaseofcommonstock', window );">Premium on purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of in-licensed patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember', window );">Karyopharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember', window );">Remedy Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember', window );">AliveGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember', window );">2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Transition toll tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 989.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 989.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164.4<span></span>
</td>
<td class="nump">124.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95.5<span></span>
</td>
<td class="nump">55.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredtaxliabilitiesGILTItaxcalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, GILTI tax calculation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredtaxliabilitiesGILTItaxcalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DevelopmentalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Developmental Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DevelopmentalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstocksharespurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, shares purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstocksharespurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Premiumonpurchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Premiumonpurchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Development Milestone And Collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net change in the difference between the fair value and the carrying value, or in the comparative fair values, of marketable securities categorized as trading held at each balance sheet date, that was included in earnings for the period, which may have arisen from (a) securities classified as trading, (b) the unrealized holding gain (loss) on held-to-maturity securities transferred to the trading security category, and (c) the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) on available-for-sale securities transferred to trading securities during the period and/or any unrealized gains or losses on investments that are separately or otherwise not categorized as trading or available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IPerianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AlkermesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871665264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pfizer Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2020 we entered into an agreement to acquire PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer. In particular, we plan to develop the Phase 1 asset for the treatment of sundowning in AD and irregular sleep wake rhythm disorder in Parkinson&#8217;s disease. In connection with the closing of this transaction, we will make an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Pfizer, which will be recorded as acquired IPR&amp;D in our consolidated statements of income as PF-05251749 has not yet reached technological feasibility. We may also pay Pfizer up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$635.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This transaction will be accounted for as an asset acquisition and is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S. We expect the transaction to close in the first quarter of 2020.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2020 Credit Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2020 we entered into a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span><span style="font-family:Franklin Gothic Book,sans-serif;">five</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility entered into in August 2015.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895843184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 11) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember', window );">2015 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">204,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="nump">167,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Cash received under ESPP</a></td>
<td class="nump">$ 40.4<span></span>
</td>
<td class="nump">$ 40.5<span></span>
</td>
<td class="nump">$ 39.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2015ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6877877424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 7) - Performance units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="nump">48,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(33,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(4,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="nump">11,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6630230096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenue by product</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36"/></tr><tr><td style="width:17%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>3,306.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>1,126.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>4,432.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3,253.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,020.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>4,274.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3,294.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>920.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>4,214.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>1,426.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>675.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>2,101.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,668.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>694.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,363.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,889.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>756.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,645.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>1,041.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>850.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>1,892.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,025.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>839.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,864.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,113.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>859.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,973.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">VUMERITY</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>97.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>97.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>92.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>92.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>91.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>91.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>52.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>52.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS Product Revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>5,780.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>2,748.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>8,529.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>5,946.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,648.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8,595.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6,296.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,680.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8,977.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>933.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>1,163.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>2,097.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>854.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>870.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,724.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>657.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>226.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>883.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>486.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>486.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>485.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>485.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>370.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>370.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>184.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>184.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>68.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>68.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>43.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>43.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>738.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>738.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>545.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>545.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>379.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>379.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>22.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>22.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>39.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>39.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>42.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>48.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Hemophilia product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>63.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>74.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>6,713.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>4,666.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>11,379.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6,800.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>4,086.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>10,886.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7,017.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3,337.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>10,354.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change in reserves</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>127.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>888.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>666.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,011.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>20.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,698.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(54.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(48.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(535.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(2,242.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(2,778.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(127.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(576.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(20.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(724.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>131.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,027.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>40.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,198.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>109.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>606.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>761.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>679.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,686.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,389.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(12.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(551.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,887.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2,440.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(109.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(506.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(31.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(646.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>127.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>888.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>482.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>605.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>583.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,307.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,917.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(475.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,756.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2,232.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(69.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(442.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(23.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(534.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>109.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>606.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>761.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheet</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>197.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>176.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,001.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>874.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,198.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,431.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,316.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>748.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>548.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>242.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,290.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,980.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,559.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,431.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,316.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>748.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>548.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>242.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,290.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,980.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,559.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(16.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development services and manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>106.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>96.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>42.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Swedish Orphan Biovitrum AB (Sobi) and royalties from Sobi on sales of ELOCTA and ALPROLIX</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>38.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>69.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>584.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>459.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>253.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>707.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>585.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>360.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874347568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Payments</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net commercial sales up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net commercial sales that exceed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net commercial sales of SPINRAZA using a tiered royalty rate between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recorded as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">VUMERITY</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes, we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recorded as cost of sales in our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. For additional information on our collaboration arrangement with Alkermes, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence and BIN occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue the remaining obligations each reporting period. We may pay up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$735.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestones related to these acquisitions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired the Fumapharm Products. We were required to make contingent payments to former shareholders of Fumapharm AG and holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement, until such time as the cumulative sales level reached </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$20.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments were due. During the first </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we paid the final </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$300.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment as we achieved the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$20.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2018.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$6.8 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.2 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in development milestones, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.4 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in regulatory milestones and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.2 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$430.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of milestone payments in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the regulatory filing with the FDA for approval of aducanumab and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if aducanumab is launched in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$24.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated balance sheet for expenditures incurred by CROs as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$514.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cancellable future commitments based on existing CRO contracts as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$74.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees and have accrued for this obligation. We may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$136.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net liabilities associated with uncertain tax positions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$697.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the Transition Toll Tax. Of the amounts accrued as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to an approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$87.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> carryforward of taxes paid in relation to the company's 2017 tax return. The Transition Toll Tax will be paid over an eight-year period, which started in 2018, and will not accrue interest. For additional information on the Transition Toll Tax, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Manufacturing Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$52.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the construction of this facility.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6747808384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - AbbVie (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,335.3<span></span>
</td>
<td class="nump">7,564.3<span></span>
</td>
<td class="nump">6,928.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 2,924.8<span></span>
</td>
<td class="nump">$ 2,894.7<span></span>
</td>
<td class="nump">$ 2,880.3<span></span>
</td>
<td class="nump">$ 2,680.0<span></span>
</td>
<td class="nump">$ 2,825.7<span></span>
</td>
<td class="nump">$ 2,780.1<span></span>
</td>
<td class="nump">$ 2,757.5<span></span>
</td>
<td class="nump">$ 2,523.5<span></span>
</td>
<td class="nump">11,379.8<span></span>
</td>
<td class="nump">10,886.8<span></span>
</td>
<td class="nump">10,354.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,713.8<span></span>
</td>
<td class="nump">$ 6,800.5<span></span>
</td>
<td class="nump">$ 7,017.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6882954560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text">Other Consolidated Financial Statement Detail<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Supplemental Cash Flow Information</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>244.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>243.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>281.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,064.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,007.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,066.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-cash Operating, Investing and Financing Activity</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2018 we accrued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$300.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$20.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of the Fumapharm Products, which was paid in the first quarter of 2019. In the fourth quarter of 2017 we accrued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$600.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$15.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$16.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of the Fumapharm Products, which was paid in the first quarter of 2018. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information on the construction of our manufacturing facility in Solothurn, Switzerland, please read Note 10,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Property, Plant and Equipment,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>120.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>112.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>78.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(187.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(200.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(250.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>204.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>119.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(47.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>83.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(217.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>200.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>127.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(19.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period on equity securities held as of December 31</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>150.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>128.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(19.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,001.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>874.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>309.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>320.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>281.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>261.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>220.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>224.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>148.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>444.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>78.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>125.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>726.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>609.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,765.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,861.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,348.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,389.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and include accrued income taxes totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$803.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$791.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6872336880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of deferred tax assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">$ 106.6<span></span>
</td>
<td class="nump">$ 102.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory, other reserves, and accruals</a></td>
<td class="nump">162.0<span></span>
</td>
<td class="nump">163.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles, net</a></td>
<td class="nump">3,380.0<span></span>
</td>
<td class="nump">2,298.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">130.4<span></span>
</td>
<td class="nump">213.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">25.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred tax assets, other</a></td>
<td class="nump">103.7<span></span>
</td>
<td class="nump">38.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(20.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">3,905.4<span></span>
</td>
<td class="nump">2,823.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Purchased intangible assets</a></td>
<td class="num">(350.3)<span></span>
</td>
<td class="num">(232.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="num">(1,381.6)<span></span>
</td>
<td class="num">(544.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards', window );">Deferred Tax Liabilities, Tax Credit Carryforwards</a></td>
<td class="num">(1,617.2)<span></span>
</td>
<td class="num">(1,425.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther', window );">Depreciation, amortization and other</a></td>
<td class="num">(135.0)<span></span>
</td>
<td class="num">(102.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">$ 3,484.1<span></span>
</td>
<td class="nump">$ 2,305.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation amortization other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesDepreciationAmortizationOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Tax Credit Carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredtaxliabilitiesGILTItaxcalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, GILTI tax calculation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredtaxliabilitiesGILTItaxcalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6877195808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Equity Securities, FV-NI, Gain (Loss)</a></td>
<td class="nump">$ 200.1<span></span>
</td>
<td class="nump">$ 127.9<span></span>
</td>
<td class="num">$ (19.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Equity Securities, FV-NI, Realized Gain (Loss)</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Equity Securities, FV-NI, Unrealized Gain (Loss)</a></td>
<td class="nump">150.1<span></span>
</td>
<td class="nump">128.5<span></span>
</td>
<td class="num">(19.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash Paid During the Year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">244.2<span></span>
</td>
<td class="nump">243.2<span></span>
</td>
<td class="nump">281.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">1,064.5<span></span>
</td>
<td class="nump">1,007.1<span></span>
</td>
<td class="nump">1,066.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
<td class="nump">78.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">187.4<span></span>
</td>
<td class="nump">200.6<span></span>
</td>
<td class="nump">250.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (loss) on investments, net</a></td>
<td class="nump">204.7<span></span>
</td>
<td class="nump">119.5<span></span>
</td>
<td class="num">(36.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(9.9)<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(47.0)<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">83.3<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="num">(217.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue related reserves for discounts and allowances</a></td>
<td class="nump">1,198.9<span></span>
</td>
<td class="nump">1,051.3<span></span>
</td>
<td class="nump">$ 761.6<span></span>
</td>
<td class="nump">$ 605.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">309.1<span></span>
</td>
<td class="nump">320.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses</a></td>
<td class="nump">281.6<span></span>
</td>
<td class="nump">261.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">220.9<span></span>
</td>
<td class="nump">224.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">148.4<span></span>
</td>
<td class="nump">444.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Accrued construction in progress</a></td>
<td class="nump">78.0<span></span>
</td>
<td class="nump">125.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">726.7<span></span>
</td>
<td class="nump">609.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,765.8<span></span>
</td>
<td class="nump">2,861.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue related reserves for discounts and allowances</a></td>
<td class="nump">$ 1,001.1<span></span>
</td>
<td class="nump">$ 874.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6875518064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Preferred Stock</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares of Preferred Stock authorized, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.75 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are authorized as Series A, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are authorized as Series X junior participating and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.25 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Common Stock</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"/></tr><tr><td style="width:13%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">As of December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,000.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>198.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>174.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,000.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>221.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>197.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,000.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>235.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>211.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (December 2019 Share Repurchase Program). Our December 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our December 2019 Share Repurchase Program will be retired. We did not repurchase shares of our common stock under our December 2019 Share Repurchase Program during the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (March 2019 Share Repurchase Program). Our March 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our March 2019 Share Repurchase Program will be retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.7 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.1 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.4 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts paid to repurchase shares in excess of their par value are allocated between additional paid-in capital and retained earnings, with payments in excess of our additional paid-in-capital balance recorded as a reduction to retained earnings.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(31.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(243.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(240.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>88.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>103.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>230.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(3.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(115.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(125.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(26.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>21.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>103.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>105.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(32.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(139.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(135.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(318.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU 2016-01</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(316.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>97.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(67.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>29.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>41.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>139.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(67.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>76.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(31.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(243.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(240.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>57.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(32.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(334.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(319.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(193.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>158.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(42.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>44.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(162.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>158.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(318.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(19.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>118.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(42.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(32.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>125.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(47.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(44.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895936832">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AllocatedShareBasedCompensationExpense</td>
<td class="num">$ (138,100,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>129
<FILENAME>0000875045-20-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-20-000005-xbrl.zip
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M,-F7<_E!T3"WASHTNN!^>--+Q/$BQCD9H/1T4GCT7JQV?&VL)3V9I>\=PK(
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M2?>2:$*K)):A6)EPE;IZQS3+ %:NK\%?J\4](:V2%QK8VZG"K.Y6JNI9)AS
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MEVXD;P39374A'OWDC8]#"&NE"J3/D_R1X57PG0>D,O?LA;BNXT1@7 8H6Y2
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M677\L9XS3T_OT1.]/W/X"V-3=Y]@_*<;GR.O9/5>O*C^ 7_KYN&'ZZ]2MLB
M!I<MJLCGPU1>XM$VHVLB+VGWPT/NM8Q9:2L+[]I@M.:3Q^71#0;W=5XUYD@*
M:(3T-C<X*X0;1OVL$C.&'\^C((WU/R?ECRVH;(S\%^P92>>!]>PAB-IACM2$
M!LL9&:!7**)@EU>%<&'C.AD@C'QY;0R_T1%U5YP(G*$2FV7 @;<Q"#+[V>*+
MM&F8/:;#H/)R%F5 9M^7;R>M-XS_NDXN4<+6ELA;SH@UD&6A&CQ3( /NGD?6
MBPOA2JU\GW\[Z8=H]*MCJ[07Q(2Y-?ULT!59M65,RDV77LM9E*YF4.&/%WG(
M*>[?[G]@/>$_&\F@2;>\VTD.8QRM:%>]X;O)Z$7B].CIFM ;TJ\Z*VHTF-O7
MKWG@J:]&^+<EO)KQFO@1"H261"*JJ?MT)H4@:!6G?(=?V%LH ^Z? FV6T[8R
M1D&EK057OXV=XV^9QY[\M&LH]NS[8][7A^[[*A5F!61LS\CZ$1CI_UA*2$"T
MF_I;DBA3=Q&SO).E\1>1^#O:;DE)\JP1RP_DSL\B,.T**QRK(XQ=*:5%_O;8
M1D>PUR&I0NVF2]ZA;-W3'[Y[L-_Q[.V.S1>LD>4-7,E!T?0'C.>L35=MT (R
M@!=XA U)!N'(?\NI$1*B#8U^9TJ;Z:*JE+4(S\4AT%\Z%O>WIVCH"'@CN=J*
MM>E\->O%K%D$;^7MHOZ?7IY_^=DA\=3=_:SC[U626NT)1]Y/K([]'%K%KOY:
M'3C=YS%(Y+Z4$'XO^QPZ-#O][L-C"LC(D\K-Q@I^D@'M?S(<6:Y#CM!MJ"\#
M7ALA*K7_#55:*J#R60>0G(NM7[G._<"_#:.(O3I[]QK61@A-Z/>*'_8SW4\-
M?/1W&U4T,RM]\=O0D)__T4W,U,^_<$*"URUZ[9YR_#H]?3='$#6T;I>S:<%W
MJ)'/S+OCRS/3(9";!X2-GR,J7% 3^\%6*OEEA90&J@[+A-%LH%S?ER\'65TC
MGQ00!P^VV1$46"_X[;KE'[06PYP-:6#!+(>UOB?2VU+YHX9K/VWRU#B<__X+
M]5W,_ PAF:MJLRM<@!V,=^^O?*F<6TYLH>HC'9@]&#6-\-%.246Y="=9'U1)
MR@7[OL@ 'C/!XK35PL]LV-LDGFP7<$:@@O%$-D"(B;/1#D UH[7;H/CZY?:4
MVGT"1;&3*,Z:0DTVN5;/BT#I9^@"8KO_J:<"S9C_C.I8!F$=^80,^%74A)_O
M:Y4!KI<MEZCIF*\;ZI&F0D"3W@NHGYW86L"FU__)MG4EU%<N1Q'>3DR69MD1
M[IU<FOSKC"@P@=#8SI[\C"C (J'3OW4EVO^T@1'1_ED9^$?(NJLCV?9'PI]T
M'2L/*DOQM:XRP#\G4'J]CE$\^9GVUX+[5]P=0*P77?TS897:^G=),LO4SP'!
M.=>,]4X?62;"LW3<R?S,S3Y5'^BS[X9<?K742V[:LS/;35GEB.,8)?E>P_@$
M">/?(P=3^>C$:'8293.LWK7H 9F]R:*8@&N+9DJD;_"@YT!$5/*QFHZJY^IN
M6B'L2JL4BL'X);/R*?<0#;C1P,4>9!4P%W VW>%%(8-^U.?RR_E-43AV^[V)
MO8RFMXY"_A2WNK1YC$R(%5FX"ER(-+I*RS54:WLZ:ULM_#9T7;XJ3)3D:7/P
M:TG1^VIWW26Y5BF.()U=.&_T-M&CV52@XM&\$EM[J-->=![_8'P>/R+J0 G0
M_U(@$%*HX''JDK.)6+54^HZY<%<&].V#XPG,7V5 &4V"T'B' X#[ZS/X?U ,
MT]%PH:!43!O>* ,>5^.70RH8;>)3",16H:2MZZCSRH8H.D) 8BFB=HY]&_]:
MJ@W9_/]<JAW7N.IVU^1Z[?%>EY'G-_Z8-ML<=#%_D!_ZR6XU:33H[*FS[N'Z
MU9]N',\H(!4E_*)041MSZRKY9WJ52:HE,4.Z'S[#GU$D&S^K@*,@90YE1?]%
MG!&EHV]8 4ZF6++1L&]38!-+'_8^!PXU=UW059FGI_IW-] >DIX=JH6R2@LF
M*K94T\Y6]\_&%A.NQ_/[TP7P[1(2K04/LFM/0UKM38-K&=3 *)$2I:TFKS5U
M2R=QZN(F9]S>,98*5>&]\F^A =5,""7>,8UQ[PJ(>%F=_7U-)>$9A17LI9V=
M<YX>=3]XIHA[VGO(;SCXDM^0OW/)1S<E%]L$YN70+<4]69?,?5^'!6^N[K8)
MW:S>IK$Y0PZF_Q_%^C^O6!T BP*-&VEN?K=UVA^'Y42N.X;BCXK751BZP=M0
M8M4' ;?O!7S3?\EO'#+?;_^F_P*/;?%R&]X0M*BYQ?XBX3=Y0N6N\6AV%AUR
M]_N6WK]=O(U(P#[V>C:O2 9\O>$&;W23Y!&GD6KT*!Q:Q28:R0 OC"@=T65I
M $?:UBL#QGY\@<BKB[=EP*M*ZKD)&3"WR^];^3LB T9\N 57O\,_G:<NKW],
M!7V+J5_-, /1;,D:+SQLUL5>TF*.W5V#GJHC2)-,Z6*M<8(XW6G!GR$#[#7;
MI<H1#*E#^?)6>7D1UDL&W$L;12!5@WRWJ5.2789047,X4OD^FB*\$D)) ^K_
M:DW55U33\T_)K;ISX1\L>\K,\D7)U[?F'(P8VJ/0JK39I>HPX5?'@R.?4DVF
M)_Z?TM7;O5H].X#0(JXW4+_B1.[] S^LU]SBO$9.0?T[.X4TT?/QZ H3Z7;3
M?/:<2A=M<L$_A&_[+_DL^0YIT:VG "2FC.3Z/7^1&O&BK;[/.L)E>V91H;-*
MS:M[R3J.G@9V I:EK5O/?Y/GYOYSS8RA-RB'E.6VJRF?/NBRHKHF[/+UX3[>
M'VOZ8^R5?QM1TE"(NZKQ_(N)/.;(^\%AWROL"SW%/593 Y]]?7R7?*,NM@[\
M2*.('T>-7NQDZNQ;$OX5P'.MR?BOAS^QYV<Q,N !_ M28UF\O[YCBVY"P]OP
MXJ*;4D4/&1#H*SI&G=07VS&&7LF WE8IHOC'-K&1_N6_@;_8/\7CGX/L#GE(
MG6:0J_M],1++]_V#\__PKD8VC,B>36O0DNM;9<"$E@T:5Y!FNB3^TSSEP4!Q
M0N6,2/$4=?RLYK(F(;_F+Q/5) ?Q#I&4=8Z]?-0B]EMBA_VS6#R7;D(PF"F@
MBA0^4+<PDO4>+--'_9W2\5_WM5&GO&7 RU-7$77_20TA _%]N[\A"]6!_PL)
ML(+@E3( ,VR,D("KN0QP\N_OFI?LXK>+;R#L0D;TV@1E,V(YXSGP%ZJ4A^3_
MM4!D-.'_93BN8O[=NCOKWSG:AK?:[EN\N_+_T/$_I>/_[C--\0+"4H$X*S)6
MDD/]"0\;85IG,J7;W%:0-\#!(G=*9Y1T/U37]RMC4C<J::J*/>#5@M/O^H(M
M)UL5AUB7F7VN>OC^U,'J0?*7<_28AW;K9AVF4V4 "HVLJA>W 5\]&G]-Z2X-
M]N0:6E]%0&-1<!5_(8C13(-3XJ6*0PB*7O!FQ'NXAOBE'G<9H*9*;="CCBW:
M&,B I"$A@BGK-$"R1U(4R4CQQ\!88:@+W[.*[RHO4(QW> *R"H5F;HZ=<\\>
MA!@:=UJ$E08OTU+5B2IV LF%/NFH [@"SAJ>X83#B\? WFKVN9C"MS'!5B.M
M4TQ(*#1I-5->^$E"CV33\!B;U0*BZCA78YZ;QMH+,1,IRN-43*BEFP)Y!XP2
M,I+9:^;:-8/R#2%&(T9C@#1D#[^-@J(Q.N/#.ME-T8PX\=;A=?VA4Y;[,5K.
MD0P!'L:.BM7,6W0-'_!I6M)^KHJ-.[_\TKO0_;[@8@I+C7RA;\XVX.ASN8L[
M+%U-/&#[R#/WO?VV#MF6?ZSM.%)KK4:P'6>#)_&PE<9A&'^7TKY,;:%=_9EL
M#-;-5S/OP0849?*%/=&4JI5%.8'BS:^_@X_5/(.39MVR)H_TD%W-)B>667GA
MU.*)J,4L*Z^LIU<IG12DJ&J2ST"%"\'P&4BYM?L4%V:>J(!6W7P4LGPZP^?\
M;>$^&P,A7AW>U"]8^VO)T#.?]\$8M9]LK(*%=3O_Z,S,*T].*><]4P[ZY?[R
M=;;:'!7>:R159/"GC5PZ+-!#1OPOJ?>"HB.OTPK&:IP:Z9G+YV\6!5N?>^3I
M<S&[)+B/H,A[]J2[4K1W8^73IY5)>B$N03_&*1:F6=@5_E=Q+RU@:^$%F]"P
M$5%B.!K/!H?()!DPZNXD/H30L$(H(H<_@%%2/2(-(Y[8*K^0_P\)C[#&/P&:
MUQN*+<)$4PA&MU2U:TWJ/LX3!9%V^^Y_8>:C@^90:7>?I#7VH41LQ3S2#1/]
M7>.3A-])>?$M 9=L-'=H:6BD/] ?S'3V:.PH2WFP?H?QGIV7$M<?/:)T/,,O
MQ_VHN^O'N_@C8XP_"# %(U:G26GF#53X(@XO V;O%DHQR8CEB,>%;T""5(]&
MDP'B,5.P?6J-2)IPIU6JMXLM+FR?G:J7^!2PMU'Y,!4\@E^V:5])+T7L&I$2
MP/O[2AAB;3WIZ@,3#,PTG9>J=O4L26H@)M^P\NB\<5BJ^M0Z_\TCNZD@:7T[
M>\PY5P;PG^E]D@%';?KG?L.4W?+ZA!7CT=+53LB6W.&QQ588I$8N=2#)A^8@
MFX)\[?Q,PLH E58D"M*(==0? KESF]_AP8%,A$H,J?3SJ$E'I!/9:+9?VJB%
M6?9>24GTFL6>0R31:^3Z8W8Q@1;T:F*\PL_#/D=&R%:P#&AT"%]W_0I\ *54
M]/7 _(9PP@]T>.^WJ-R4 3K_$1;Z9TJ5")WXVQK*JJS+%<]W^*OT/LBN<=%.
M*D^.7&>4,3IR\AYJIW_0["5N=HY55<<RUFL9\_B?5;P;M8@U*!027H-YJM+D
M8&CV]#/>^,X9B_&[3)I4D]E*S_=JZ17R]UV\(GK8^KZ_S4FJ_.WO\0HWT^&?
MVE=^=1-W_RTP?T#X'6\J!JH)'BNSA16W^-F7CI+\C(W4%-LG+;F;BQU_[SEW
MGFX:/% :LC_9 5&<]O/GT\3%,B"9C]P<*>MCLS8(RR8)D28"@;02_C_BB83E
M.?QM]ET<V_S?0_4[%8F4#/C#1@;@WCA-]&HN.5)YS[G@D97;]1;:P8//;MPO
M!V>$@LH,S=\?7> JVA]NT/S]X:H?4KX<.'1^[7]]TR?F,\OJYY%,^*EEB=I-
MLY08H[XM[O)?1IP#(JKG%G7N2KZR#."$0=_6R5N)>:^S*%EM3A/O": N.=%'
M!ZZ)F/_PY&-I$D;67?D%6=>!Y#/C=_.4I,I&;\6P[ZGB%Q@5J6W>S!JFV88E
MJ;K3HJ?#/IW).)2/!"?YA<HKH%:43H])\;0%%YA;2 Z@)G(X)JWQSF _C8PD
MJR((T19&Q4;GPX7$U? /IV7 !6KCOO(KU(&2Q5<B90EC2AK*SI.HU>\E.VHG
M/EU>_U#S22_?0W?42>U(L=*3XRV"+=K;(P-T6G/,CEBEU?K<J F^ME"%%-ZS
M?TKI/\<*396,Z\E&5W_^V?&*0J#";-_-( 3L5!CI:8"/A>)$&2 (&L2_(DB-
M\QP J[\=6XIRA0.$RL0A\Q:,]N=N/D'N M)'8CF,I#[K^ST[=*^03R/!2:=K
MDKT?OM]SR]@ZX5A# :G0X87ODEG6'U$O8H+.QZ1?Z<+?_[IO)*QA])Z!W5RS
MSK^+G-$#JRNIO[#%KGI.2T@XFKJ?KMI]H-V-6OQ_8XYK^AA^!ND\!,%SQ^1M
MJN8PBW_( ,CB2LC?I]51'K1RX%!GW"K@%:G= 1/9FSIF+9>_;^XSZYPD@Z(#
M,WF+4V6@,I]*JQR+8.C &OSD)!M+P6EKY4D53STS@FOE+G_?YOOC71_>#V^^
MI*^<[OTISJWV.L>817^U_K6\K:WTUC^_=7W\[ZIA#0UCL2IF@'D; 2%R,M)F
M:;C\NY,([5_LE![\=DF^SS):] GQ)G8=T&X6BY)\18X;_GU21Z?ERN1U>/XN
M.E=J+K:&W#)P.RBO6-LZ=FQ\V8G3$(=!C$QR6/B6Z<RR\7R#/NIY]* \OSAQ
M9$__[F9<\>9A+#2:9+%0V2U\7I-F.F"Y^D=?/=,7]Y:M_L,DMU>VZ*/HBKFB
M'7?//KT:K7X !5D W'^PA+0A(T[15G$$TX+87F_] [4>Z0Q3B^4QTKOX7]95
M'OLKP/X^3E1M8<?BEBP>3$U'6CU[X6H]ZOZ,?NP)DQVTV7<?XZ=01L1D[M#A
MQ]\?]QOTG= R_]#XU$[ETZ,;.Z"/CR2^1[KGWV+=.R-##A/GZOP;9[_O>?18
M+@B[PU(Y^*>9T/,GM[>8I@<7)QW0<7;Z0='$0@YN*R=[2@JDF&;A*[&!R(G$
M$; Y5QC40&R\_RY)@4TD#YU<[:\'$J=70N$+OX$FC=A4PXWP*@NWU4'^>CUD
M(W#VVV\0V3C=)]%<^_'\'\4VH$G3;V0Y_DG(^&79F Q87YD;3#$3GY+<IV#(
MFR65M08\0N9R^1ONT_XF6J)Y,'Y];2"O78G$$#B^X+'U22@^C5:%36B/*@D>
MU@%/X'9W6M+5_ 8F\O?VVJPNGU C8Z'+UP*U?I-:GX2:2X?9:Q -3A\PXGVA
M,>!P/KL>GYRO#;:GV:BR5:IFE ;'S?U)'NZ@PKDU%)7LQN6JSX5WG?BO>K7V
MSOUF,1:JOG&D*$1MZSG(:@HO,H9;^2P:F-Q$EZ,87J"K6-B&'X,LL^,^=6V)
M/WBSR;KRO)F';\]TZ,[I(;_>2,V-#,;\ZTC3W <!2<%%5T)YI*LX,TF-U(K2
M04")G2%V"P73S]H5A,/ )T%E9_@VB/H>#N91%>%2OAM-:C3V%>'Y8PB))K&#
MJ>HAPSJ]%VMUBOT=BDC[[3O,JMS4Q7NZ+;%K)G+>W0.Y389F<)'V]V#[9-ZM
MKWZ#/A]<%+*>MA/7=/FZO*G^ZJ+[:N&KP</O?S%?3]]>>DG_ZB54NZKT%>:9
MOKEX[TLJTM>L91!9ZJ<&@MGH2!4O3M_RNV)^.=ZE[W&M2^' T 7K%RQ6+;/3
MQB4F4N"J9.8I/.:*;K)2G\RQ?C_QN#]Y7/<_?FMA9&;PW:Q[I]B4+Z&,"MNO
MLY1@\^][&/?ZYF82<&L[:CV@7$%V:I7IX7+R2AXV6=X7'*5MH9]XWNMUC(W3
M +D<24R3U+*.V14Q-F^@Q[E,,8D_M=Q2BQ$2III!C87TW 8F05>J3?(5;)GA
MM-5=$M4/)M41(R(QJX=)N4?3G2"5=_'WW_N?X@8_"_'Y?EOQ!#'TYZ39H[O?
MOV4-!A?\(O^UK8FK*P-")C%)>%VR-V0D0-BET2V#4$&?"@$]A!?+> 8F!V&R
M5 -F0KY-PUIPJ1"[;E!\K)I^L%_# YQ)_8+#!,N 5=-S]$2I,3B<5P!/XS9,
M#*OU8G?Z-NP>XWK:0S%"5#P>X=1!=Y:)^"@HO0F^Y."?HI)8^V G3I2_ J(X
M\*@?JR!F2ZZ9AP^4-YSW8"+_.VB898%5#O:B[!.MJB@.7L4]E.X,>B5%M"6P
M^VKMYHKH3ZE37!OJ&O59'ILS[<Q:\_Y],'U-:6\M/J1LF.1TM&OF3*_%2Q5K
MT0G1N9%JGXL5(8'EXWTU&8L=IR:K/:T_%?T\L7"YOR+ E])">*9";S%M'UPQ
MQ.M/"(!?W^=R)ZQD@"JYSE5L=P57NK9PY5S4\;8'MN7-">-E$QD1#T(Q+LY5
MRD,I4S=B[IS] 9W*_@&=P:Y\S(:,CH(FTUMD@'(R)V<FDWI>@A)JY16*@PCQ
M@ST85;'3.4&HLCT<+YRY5E-:+]G>V%9/5YYS%[ 5[>Z3L7!C#K;9P 86-D2I
MD:SLI&U0Z#!C><;?%&0N7(+50)=C?56$!/9J\DIP\3BDH+7@4[Z82-Y7.FX5
M/G[9P[8Y*=F@26WU3[6VI1]<+%OR^$.K*CLB1*DE^6VN<=YG+R\\_#LP[7_7
M__8*1%6TDJ.]/HTVH_7(5^ 8:,&7 9"]H/Y6 \(!-DP3?JNV"G-4!=C>#38'
MVQ:HW10MTJP/PAS*;SW[[6HA"AWJ;S:TJH!C40FEV8(MBZG2#08!+?X;L^MU
M"8UO=_?A52@%D9,$;!"^@CCU@D]-6Y0!^C;[0-^&0>UF5Z^6FM&F6*\6Z^^M
M;R<5/H!GF_J>>I/BFP=O:0W>BCXG93_R?KW@*SDRT>B;GDXJ+XC:%GQA(P!W
M\^B(L@R:_!8C5; O4V3O(S[<R[[ ?M^WN)!:UT^^PF.LF1S6AFV%Y29-5&!3
MMC]HDERKAN&$^A"2#'=WX"Q(N:Y@<IS8E3%I;E=.M@'GOI*NNT<*R]X>W2>.
M@32:J>#W[=?H>K6^$$UXFM$<Q%HOWM/CZP6?*2.9U%,VPV^A&(%&,&$M&<UG
M:+I@.9*H UT6[?H(D[DEGV'C]$ I+;30A=*_',M\/U70S?VR%W_6;2"_[0"<
MR8\UY]$Y'[4/PI4+F=#:U@,=/X P=/#4A:<AU7N8_=9&P8N_O/<.B=+.>5N2
M6_K!.[AO\''APPO?^11_+KO_-M**XS:P'\$#GE<!3O*9C>A5))?Z"IC3.(QG
M@OFYI6\&5;(SR!H/@W*X"9$2_-&ZFI?Q1UG@< 6_3OE$IVO<D'WIA.[IO(^U
MVVQ\7Z'NBC>!V:EB%,BIIZA #%HD-PV'!?L3(T(QS1@U&Q?#[+5,(5[5>Z#5
ML$)@"EN<-G?JFN9Z]. ZPU2J\G-#-.O*[.0<;UAEN3G^#_R#IO_)(1OX7U!+
M P04    "  /A$90U07G#Y1&  #&3@  &    &%M;W)T;V9A8W%U:7)E:6YT
M86YG+FIP9]2Z>5036;LO7+8B($*841 B3J@(:95!$1(5%14Q*@H*0E14)I&F
M 0D04@I"&,WK2(L-41$B(D1E%$,BA$%Q8!)04$(2D5FJ!$)!*LFM?L_I]]QS
MNN^Z=]USOS^^L/9B):GL[.?9S_,;=D7Y4=D':._=M6<7,&<. ,S!_@!E#^",
M/?OO/?Z8Y+\[QQSE2T!'#8#F.,V=LPSX26?.7)TYRCH CZU3Y=\N /[],>>G
MN?-4YJNJJ2_0P"XHTP9^FC-W[D_SYJJHS)N'O1N'O0_,TU'1-5^_;;[>P9.J
MR\+T-URZ>D]M^?:G-0:'6J$5&T_]&J^^P-!HT6+CE:LL5J]9:V-K9[]ILX/S
MCIV[7';OV>M^^(B'Y]%C7GZGSYSU#P@,"H^(O!!%C8Y)N)R8Q$A.2;UV_<;-
M6YF_W<ZZG_L@+Y_]L.#1LY+2LO**RN=5M8*Z^H;&5Z^;VMH_='1V??S4+1)+
MOO9_&Q@<&H9_3$Q.2:>1F=D_XIH#S/U7Z'\;EPX6UT_SYLV=I_I'7'-^BOKC
M IUY*N;KY^MN.ZAZ,DQOV89+:OK;K]Y[6J.^?.,AR.#4KZT+#%?8B%;"?X3V
MS\C^SP*+_[^*[%^!_4=<W<#"N7.PS9NK Y  A6+U_53@__7XBL:*F<AV1QT)
M;G%<O)NG0H>D04VK$WZZNL^J_P/XQ"9XC#*Z_OVIWYQ7#GQ4O+WVVQF=TGOH
M<[O1T/?"3S+% I((;X9:0^/UE-39\9<:<:3&*@K#%J>"N$L/(P6PGO0E/%;T
MI2L^#[DD<3-II.,@?(VFD2_T;ER@!!:ZL8.(YI7/VJ=>:*BM>'[=H[+-=1 >
M5@+W<QR@4K/-D&<:UR@\FL@*%0LU$(; R$A:H%]A=P!)<*EN6_FBX@I-L$+:
MVEL*/;A;]V-7X=*/;K3L1_2&@?U0\^@4KI:51C1'#L(XZ04D/!IB"?C:DTQ5
MJDF=II@P%YO-3 4:2#]'VR/":0=>IUX8.-#Q76%"M:C/\BA4NQ*B6M>[Y(FF
M69'H18:_(*M2]1G-3IZGT*"=@"_P^_A)9AO,-G5P":)F=2KG.!_ZGB#V5@+J
MGP+H1(B5R(WJ"[X)MP5(:C+#$7Y-[X86U%54;??&I[+#-L[8=43F:E'1%FE?
MAHP+0.@P/R&FAVIRK /5A,-?]JK#YRCE"X1!ONN18_#>KH:L(\VC*?!&D?"B
MXYYH-FK31E,MI++KZ(8=I4+C81ZA SV6_]*F&?A$=3G6@N[W@S6OE)W,C2/+
M[.EOZ9KRWR(HN@CE94SY\SA1T7%T0WF;C3QZS+IXTLI2%/I2"221YD:X+B_H
MJ0FUXSA]3X,:R9U33MNEBP;N>';8SDO==*ZM<S4:NE6>6/I%[UBG16@J<3D7
M&FP%S[$TD8W;B*8M5OY0<:(LD-I30])SC/6/+*HQKX17]!K"78E3KN.JO;Y>
MQ_9G6?.RK"OD!<2,T,(O%V//9LJ.T>9U*I8.L30CP"79[KZ=MIK+G=O+XD@"
M(H&+Q(6+F=I4PR[QA4M]#Y""^1>5@*918Y90\*:'8#SDJPH:$E)#N1OCV,-/
M MWFW_.3LM8CKV4GFJ%@\5>^RA2+H3M,M$(2113-8? 95 9O\.Y&H^'LKF1R
M$G$IC1AHT:H.76!#&:'H>MBHT3@>K'75)\VW+0H6FV;__H2*JZ^*R[Q&LU0"
M\2=IYH@[?*=6"1B5]C1KC63.ZO-48=.QQF3%0MJR#C3Z(54)8%E4IZV'XMN]
MVXGKAHDFU7!%HJ,]F$=UW0V[-5[F.H4%AY^4K.16MJ '\Q#_ URH5 F<HNU#
M%M^C[4<8T,;&V7)V=#"A!J=+G:CSHE\-#?:W8B?CF'1]A"_:=<_OH4^3H8R<
MU+47CON";APZ) BW>E?JT<;_=.;V;M6L(7R%_:B(,Q1SJ_ NE5W?N^Q*4_/N
M#IM",HYFAKPK"LIQ:HD<Z9$3]L!1M2%FC2*TBE//F=,['!/2_X#NA$3YBTGS
MMQ>&Q$45]P1F7<F,B_.02&7RZU9%B9,LPY#W+'SM"#_#^-8]_&5:K!6303<Y
M.L*S@;*%R8X^X?C$;$>\H]E&!!2S?N(SN/ML.'HLLT"8NLK)D*PG_!@8A3=#
M_!1J4Q#S)4^_ N+$<]U$15K- EV$M!<Z'"ASI"VPBVF\B"ZINFR7HX'(0\^(
MLC=,2U.?52>-[/Y H#1D%=_.WR,>GTLCP1-4.GDQ]4*(O_LT_S(%(I-54",D
M3B)DY.@BB>)Y[8XAT)4!T8KP+U03D>V[_+0\,EPB342ZI+\Y&D7W%38G964P
MI(PQU2*J%V7^L)D:J+)'%+= 0$YSKK@B'=.>.R*<2SL)$>IPJL-TA[;BJ7>J
M6UN*;5TI.F!M/12:3M<?,3-F[2AA'.A@I#ANAC=N@UC)-JO7E<J2(PUY'R(^
MV@Q-/C_5867]W6;(KRI4A2F=E6>>;HVH#N.&B@.6=DTI@9^HX0*',\):4KJ'
M[RHX;KS>R;[!N*)V9%P%V37QTD.Q&@89Q)5>5(WZ@CZ" 1*Z^P-J+RZ4:RD!
MU[;(/5.;?%O<(#^I$U0A(,63].FJ"+/.,V<#Q&[08!DI@=J#]P)CW#B"\9^0
MX!TP.[Z4#XSXXA!R'PG7ZQLH7$@SCWPP='W$/2!FU3U'@B14&^'4'Z@N:RCO
M+.\U@#P5ZE>AGKZRYDNAI7CMP5M1BCG(;:BY0>K)6XBLA,)%D0,II>#EWH4(
MNV]\X6"O(P_",6RRG>N[>_/P]2%^1V'[5 )'MU/B\:0L4T TA'[W2JHV>SBG
M&SV!-=(5F@H"0K5D,V39]&$DK_ SXNX,)V6*XI;7\G4BIDK:(I5 RC-TY1.\
M3F0=M(H= EU0C#1Z45)IR]E#)+TB[L9"(550:V8!<3TL"P:-VP)[2TAC')GM
MI^/(=RM7\9(LMTS!.WNQ5E$1DN !13$CFM6#.OD+'%V"^["9PZBJ]=.]A@D"
MBKXMX2>D?+:QEKZZ56$R3%_;$<'7[_5&HD>_=IPV%'R3NRC42]BFR^MZ\=!X
M(S/9;'$K?45C;#!\ZGV/@*CZX0%\\TJV; ?-4Y[+G:.9V)O'=B,E6D#\9,5Z
MZHM:KW>]65T$"5[%U*'SNY.%SU.&S_$X"X7Z-HCDTJ%8^V4H<Y;.")&DL9:,
M$'4Z45OHCLB, 7N_S%D#=]6;;I&LAS6;&]:+@H7&U#&N@61L;1,X+T"Q\J;-
M!6C2#R-,[1"B>:-F=O]=U0Z^&BG("B<Q8(\9/1KT->J:?&?9AV?Z042A;B!]
M)9298BM+1 R@"HGMQ+!""V8ET>S%E'E!=AMIN\&%>W)'C./JGEDSS5Z8"KR&
M6WJ\T0&H0JKHO =5U.*,%1_X6EQ-R*6&;\J;,TS"HRH2\CS:(5BUGJ056+4_
M14101\:](,*5>QT*?=0.GI\AH:++Q3(G3\&0Z)U%_:Q]:K%--NC\K+JD2]QB
M(]2-LX>84AH?B<NCA2B!RQ7B_14POA[$<X\993B&B[V%. 04Z'@-MZ)+L3()
M7,>UO3NX_HXI84<Y-"XH,OO6\/Z[Y##/]=/X:5Y'Y.)5&RL:+Y @5QG>"%T.
MC=?BNBTDG!3B1BHH:GR)T.>AR^(;1<T7B7B,*UI/,E^N=@QY.*A=+^[!FZ+.
M ;S%5.?]P4+]-_8)2?$YRUO<:];XB;'4:CS!/;0E]]R1AK3:;(HLHM3GK&LO
M-O&$5V4\I&X?$>$:5B"9HC?,^=38;3"8SN'Z04^HFKQE5'M!KQ[$2*6M%_.U
M,6)6&+>AMFQJ5)UB40?K2"Q9=Y#P\&.G$CB/_Y0FR.0YE7<25Y1E,P5Q&HW=
MTRFT@TI +93I#RVY2EL+Y75=(:X<5"Q&$D-%T32<)-2(BJOUL.^>3J49] FU
M@WF6;><BQHXW/U"?=#IO:E_C:*($Y@T]0?Q/W@L2JBG6]J!Z2'9P%+RVG0)G
MUG NX><J\(/&G,N\=4/"A1'-!H,>>"V,>Q8>#[ S;L@1SE>8CO!T8%Y9K+A9
M=S#'O/6[^X$[%.C"7=KBT#=!0F@O/B&JUQP9+SPZXG VTZBA2%5Z>=MC3HTP
M89913]&D-DMO0UUI-"?8HGZYQ$<))/8CC.)/*QNOH)1B*B@H&78(?%8%JRA2
M"D9BFA.N"00>2_%[<#V%TBCNAW[H?88XX]>1!G+Q,%'S&?3M*30B9B2JP9_I
M&I48=S/5@F?9R5R]D_E4YT-(1I\,1'8K%O%3BFT^TI</7JE0J(;0;,+V--'6
M8NC"H#?SM14Z5$^Q!^=QL)ENEZV0 ?Y$BXR$?E!44 Q%C\02QE38 R\=H@2F
ME@KM6$U0<C:;0[W67&=F &'X0%P\:/S]=G$0W;@S:V.P:6)K@G\]Y:D_P_&(
MA&Q(;1III*^LR*SGF_%PZ(47[??;)U.L0J;PEREJ$<V7/7R7)!TS:HZS]&F?
MK.LL,WFN_L&J;+&OI9WWZ7TT61%88^DX1]P\;]!7'U8"=>_"Q4>Z!'AUF@%6
MZ [38M6+Q"74Z\X0*9ZN IZS3YID+D)625S2!*"AM:-7UI24!1L=A!<:^PW/
MGLE/IEFIQD^-67&=8^9(71+XP61,&FD[!HL(#+H6?(%=C+0WT!=U</WR$'K/
M2QXI2;8/&F>@!\6LN=34Z893T[72IZC3'4'.9@@3L:!V8,X64"NHRCY]["14
M)$]W&)-G9#1FTD[)B[BN4(*$*1 F&;,$S3_Y#.)U4!":%HTG+F-)V(S'/ >D
M'PTM".CVY4N$22 PQMWX2$AEBQIKUT0>*\.EQI0_E9 6C&39)SF2)'C#HX-&
M67:7V&_$^YG2*#D3-94Y!'MD-2=&>A]X2EOW# D+NSMH-A<R$G#4BUXAA?!R
M\;<BL:E%K1 WZ:/AW+KB ^H,$PZ7&$<6W4@\MVY=\92;JS>L\KZH:%B?:*UX
MG<5OH"SQ\J7F2L#TK\@!OC9Q">U@)>*+L9K^;-)M,2>1;@XQTQRQMC017VH]
M"6,R9/%#)+/&85>9.,/P4YG;!<4W69W'K$4:S3Y_9%7#A[F%B*G,)0A<I%A-
MBT.B'J)K8'O!4?K"8+-YSUK'N91'@00.=6 77,&8<O/"Z9%%/FLX*R"?M-Z
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MU3?6%W""%#S]YX+T:8?_6)"LCK1!"10]_>-'1EM?X&,0@6+)FUAL(S&TB/\
MBL\%X-'^D;4#"K6K9Z(W?OZ"K?.($N@KR;37#9E8E2G]T.+E\C'-^#P)RM]U
MX?XCK4U'YI;%X1=#WY:G//M,5-5,OI=4X&)*UA_P.?S+C>7.>COK8S<U'>\J
M6FQ9Z+6A4^J&/_C?R3D=RY1VIIT2N)>/*:.+8OZ,YY1__R^SA3%@-#A^3V$3
M^N^3\PZ'(LOFWP!(T!0.65<S\P_P]=#@\O&??87SPX45Q,MFP0/D3R8*]?5Q
M<(_T#(*'T^J5 '28CUBB9A8($Y((<JRZ3D+38S=S/PV&#7M5<[)_S?)YH 34
M"?D5)9[XYZFN;VX=66KS_M>Z/\O;^M_*^R&N/>3/R%JK25S^=(L2,)[Q5"P!
M\\"VPV!?"1[)BL$I@<V/2']3[[D*<VM,E#KOPVAQ3CWX@S/<W"2::OAM2)['
MIOV!'AHX,7YB1K6:GOAGK'Q<ET(M(7_Y@Q0L?^Y_]&-NP\@R!T5WC-KIB!.#
MPZ#([?2&)PO93X'.+G3SK6G%M2[L0JP"ZSZVD&;>= DA\H)3B._B]+"CCXDK
M)6<2;Q"+'Q7O9&1$6H.!:JCO)V\,137XKB^&0NT4,O#J;#]LT*[0#M7[ \V6
MWF&*S=+&*5H;\\EOJ\DPCE)$Z[)'=>BQOYVIJ,06@Z%O36!^_.F ?&QY(1G
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M)P2!\S)U\W*RV37A(!C1VE#;V]34&_OB>:IW=XW-#Q<3P.=Q7DOICLYO\-J
MV4/4*P.NY2W?;:?:'W=YL7:6<%]\6#>94G90C9_I6L;G\WCE[;VBHJ7<:FP"
M@YQO_F"B$A#Q2DW5@FY1].CST'"$(B[DS*>2&H6:7'6QZ<:7W:QTHL6@4)N^
M$G'M&TA G?(#%4M@7F%@7W-R%U^/&]<7JA[4NP!A/J0>G-3@& Y59':_.#KD
M^S-+H F347V]&CJ !,(:];V.R!XXS04>KV4M"1#B%$MI2UHC0N8VY*R!I&Q.
M@)D^?"5;G,8WH'K7&3,$P92D9\CR!F/_-._&K(JTTFS'GI[A',/4-DIR.0E*
M;)HS+3> V0VA/00!7Q5UAW&[0Y/XVMP0$?,2?7Z+8A6]E>@$E?(6)&Q#;/O(
M.L[BV!'-T$/MZ!YQM4:=[_K*]DF<ZDCO!G@5LR_$POM#*4GU4R/]5'6GK1->
M,,O\"+LN:7WPU('[ZUKN^<L;'#8MO)*^Z72D^57&P@<Z-7?5_^-W>5RR1+6>
MJ4O;=+UVUC.!KDG;C;P3,PT_#Q?Z/T#,:>MS![NM6?>\O7R"O-AIW'!)-2@P
MTX(^1\V7-KM"WV]'/GI3C.1Z<Z_T[&E?T6XSKC-BK*U:#K+>Y)T9S#)+$V4O
M)[<X;GX0&#,_\8%7O5]>0)4U*S OT.',#8UR#2>2VY,DK!PZ#69.593'K_;S
MU0$XEZQ)?;FLA<7H2C]X>2U>BVB)-(MR,J#8&I(9?2.5OZ\=M6!7O.0DT9V(
M:XQ]V1*\UHCONB==W#V%@Q=RU& P&3V#R7.&1XX5K\711-3#TGTY^]BK*V$4
M=1N;-1KS[J-HTR@('[K6+B#I%.4A&R&)&W*U&'ES #K+/B,"]8:FZ>8P.VG*
MR5[T06\9DMOHZ6OVP5'GX<Z'055&##;44! 9YY>'D(_#9@6AC[N'MN(/'*0L
MHK_EEV<FD@(S]G:1VQQ5)+CY3&W4KH6W 5DVXM5)-*/>[ZDC+>2ZQ8:>S!WV
MX@HUT3.21:BJF%%9E39FI@[?&8H1U$N[VE9TKH"40*JXA=C\3^7\;V/[+^HU
MF^;U+;Q^Y644,9[GB#7\.4U"+46W5+B .B#"UU-^HCET\98BF2(7!M$.*6^O
MS7))*&.9(NZUOAM@7GXK]2Q%KZ+N#F&.3P =@(,"*+KC*#Y4%/+KQ(ZLX<XS
M$._>783E"<PVR':V3FUYAS_P(:+(3H$A7L7$<)7*V%ABT9=>1L'GH?_1JOD'
M)7V'<=R-C$J4$)-6"::F-B5:H>Z,H#;+2HW4*0Y_<-E5_CBCC4J:!)FBXB]V
MN<G2$VN:>GG(*M BXHN@TF5%_N3$)8+SIID'5.KW#''?_FK_[+_]\?SYW.=S
MG_?G>9[7^^ZA5_-9;3-+>WL#C*<7^@3MKQ6DI5JJ:X\BH[4M^^V1T?RNW?VM
M# 3;?W'.)A+XE4]!0WL]E\C^G.#E".D"IVU<]V\UG>0]H\X]G)!'HPX?\Q,Y
M93T[U2R63!'0LV*";,3IY]@7=];\=[E,@NE1[! )'?B"MNC-5*]>\Y48P&A*
M&>&=(928Y$BMZ1HWP$[@*YF3!4P!V>\E"2HD,TV[/]',N]9LF]:7+?@D]BWK
MRTFQ3L]W'(JKK-;X)G+MP_9Q^E'WY\.8I9\XN)R?8?.1(2^<GNQQ&EACZU>+
M*0:EFX500@<JE?@F=NV2&HM_,'B.0S7O#*O_6CH499A^*26\O]4^UDV,X;DW
M_&4?3[N!3^^Q/17,_.(2?\CK/R/Y4H>B?99^/8N5DCH7=Y*MB%V6/'X^>L.C
M)>^VMV=.^&A^>'Z^]\Y+)W.?X,_-GSO=Z:ES?8;><ZR.> (^'51$R10:]_5L
MB>C9R:4X:&"8!5?!#1E1H3@'!ITD$*?FH40]BSPT>0TG85#UI2-XJ-E&JR+[
M0EUG0+4&^JY_*.5%DZ8B*W%[_BD)*#PQ3*(53#6BP5)=9!50;KK+FT=]M$%8
MXO,@"U7]P+G;.:SRLTETO7KT',-#Y8_\G,WJ-B&5068K D1K>!ZDB&9'-!5U
M?Y9P,RV7+I9: #0C7"(!FWIHR8OTY,:5FN84;EO\ 9P(P$)>F8IU#DF;_H0,
M+5S]:M<'" +=A!J@RB@M5N$<"16IPPZRT5!F[9"0\*' 9FB ;0#O4[><+>LP
MV\@B^U W#O4>@FK55X]&N+[LA GG7-+CESM6]LD[RU],N*5LC':5Q7<C<J_?
MU6X(_>'P;4&F?U729YDI_'[/HV'[/XE >X*3K[IH&HU[IW!\!V%27VCRY.)
MF!93U_&[Z>.QWMDX%";=;N6[5YZ?G4#8#-6JK6R])B, +&C-B1A, RKE5Q"-
M7CG&T/BL#!^#,I!YT><X4SIS$_F,N9&KI6Q<$"+9.LW$-KM)(^0[-ZW<(KNR
MX9.X^>V3JRYK.;L-'43\7LT$S&8H5\(WF=[,B,01=XO4F#JIEN#5;YNDLW6Q
M]NJ:FV-98I0]L":SJ\ZCJ0D4\9)7ZH#L5[3%4K!JZA%! ,"5*)M41W'%+%X>
M3%2+O4%A"R?'ABR\D&LM4P#%G%0S <, GW[H3C:AB'$TW7DJ8@F+JH^2UQR4
M/91UTGXU,P;N!,/>M2\>6RG=13EC%40XR27,:UQ/>8VYU1$2%Z/%W==I\ECF
MP"K[C\L^K(.CD "5%!_\ K.,3*SH S:]/]F26\<K#9M"&2Z,4W$0TICLI97P
M,B(HPPW0@S\U," BK'$L=[$8%'Z( J%+;R.EV_PMC.Z&8Q0L&*060XQ>G&AI
MX5MX?,HZ!\N<3M5$]HKX?A6Z+A7\(=AE:?"/5PPY\NP%20,=8?4-L.]&2-O-
M;@0X>/SUJDOT".\(]/POK#!N/T4&+]RJF0ANM!@T5A\0XJ]H]9QU;&F159\.
M,BU5;@>$6JSOB!.3!FIUE"\H]SB7VW*< 6"A)0YM)A3)2J@P/:03(EM4QY7?
M,<XR\RRM Q<0^A+@'K(O"S@E7.=\BL-P?3FA0*>M^K$MYG!-!LB",K;.;LFO
MX"(=X7;K5<[W4XQU[-)H.Z-2/O[;19X@$E>B/#2Y\LUK?8(HZMZ@XW"L(NE-
M/#67,KO#R^6JZV9L\_+;HT$+@;7_7BW\_P.V.O8/4$L#!!0    (  ^$1E")
M9GD\B*D  !:U   3    86YT:6-D,C!R979E;G5E+FIP9\RZ>SA4>]PWO$J9
M<IH00DPE5 [3@1333*52"9408G;9Y12SA0S&3'(F9K>%-C&5$&*24VG,Q QV
MQW$6RIPJ9]8JM#*G9_;[OM?]7/?UWN]U/=?SW'^\LZ[?'VO-;_W6^G[7]_LY
MS"SY1SD?6'?RV(ECP(H5 +!"L0'R4<!1L?=_]OEWD?_3-5;(7P&::U:$KSB@
MM&(+L%)SA9+F"CD'0"GN<_7_/0'X?SXK5BJM6JV,6+-6154QH7$=L'*%DM+*
M54JK5Z]:I?@V0?$]L$ISM=;F78>4M<]<1&R)6+\[\?:#-2:'Z]ITSO: 6_=<
MNG9SK8JNW@9] U,S\VW;=]C8[K7;M]_>\<C18T['3YQT/^?AZ77>VR?@]\M7
M H."0R*CHJ_'$&/CDI)34M/2,S+_RKV3EU]P]^_"AZ6/RLHK'E=6/:MO:&QJ
M?OZBI9W-Z>CL^N?UF]Z^_H'!H8_#(P*AZ,O7;^,3DU/0]Q\+BTL_X5_+_\:U
M E#ZC]#_R[@T%7&M7+5*:17BW[A6K(SY=X+FJM6;=REK'3J#N!BAO65WXIKU
MAV\_J&M;:[+G+*ASZ5J/BNY6&X$I]&]H_U=D_VN!W?S?BNP_ ON?<8T :DHK
M% ]/21/  3+9MH>9P'_W^"*)%U+APQA-$5(_(7'1#3Z*L1*BM>3 %2>[X2_]
MN*<VH;/XF5W<KVY?6GD?91^>_=K]*VP;98?+2\,?N4NQ<N#F7["[$-'.0I(\
MX1HZ"=CK[]!+VD7A<]?(7N.UF5MD'XT/-+!:P8T434G80^)TN_]J&/THE&G0
M E,$H5+SLT/6LS:S/F]Z!P7C V4](^-'DKRDQE!72HTD@L_5A7?/384:XG6)
M@7CP_?O99TZF'8\,9+?C'[E$KW065Q2..706;LW]&;9E!^N-"ZFL1M:5BE23
M<?\D[80;A=04VCI*("7-CK*6L0="'@>'DC&']C;R72AM8PB0DF7S.;Y];$O=
MB^YR9K\3F[H*IAWI%WS_ O[,Q.PJ<VA[ H>[!+)]7B'H)!MIF4Q5$@!1TC$Z
M(+MCO'.Y(D6R7X#4#2W,3[P/__6C?6\<BH-<2_3J*E%^[K91#OQNGD2WQOCQ
M>?I!_J;@7%% [860PG*JU>)BZ^WFWFCS)EC$IH#GN$G+(T35"P,,!!395J(*
M):.:#'AX8H4@L.,X(^S19]D_%&TRBH2#=,9HX-!)F%))K."4Z S,8"Y7P=6>
M4'C151OZRA'8ZUP/Z8C(MWZP)HI0+0<"T<,%;91Z:ZK031U&GAD,EQQX0DWU
M; G+:5IJMO.QS@/K^05LM\1E]=O]-?RF H_"Z2-P<,6T?9[TRYGWV+K**>,+
M$3Y9Q-Q."4ZL.FE@5E?SWH[#73>%-9*]E=:1<'PJ\JU JC*&1Q I2SU0P4WF
M5M+A/M/!^Y1&XI]P3%>)_L B>JW_E.Y@<T30V!8#W3JSQ\L'FBJC5LRT$&8#
M03UO.*M<LKN7%&9=43OU<WEO1L7T=6-=*(7'KJ;I$+->#=*T&Y"KS#N"HA!P
M$":V1F+/>@HQ\_CYD ]<*&;[I!97MI5C?+)O?OJ5UDD97?F3S^V8Q*J&T-0?
M#3#P$*J=J=>/NYSW#-I\<U1$ST%CCH_IP2G@4LSS;CD@_+-?IG6((J!E8/<P
MF^5 <N$VF=I4RSQUMJ80K41\V,Y]2]:CM.UB(DE6,%= RQJY.F8P.!]E2%\%
M/_R&UR3IP@Y/B$L_A*B;V'5P('^@I+5<\EL_PR(!0K;+C)G=$O-'Q)SQ=A_E
MBE#3@BS1\^<]F!-EQ"MRX#18P_M(T2(C)G#:V$V2== 2_?&8[WO0F>/O "D7
M/6H+"S4M9Y#BP?H.ELJBH='A;P?1EK\U]S)\8Q+46J[>OG BFJ"FQ1HN.7/0
M.. A^1.MGI[1\-GY+-B5C@D31C4T]31:&7#9+&7FKFG[9@X*"2>=;>V)(NA+
MMO7,8-9&/):< Y4?5)^_X&-.E2@ATC'Z(?3+L8]#!PO#JQ_A0W102\O2.V?'
M++BPS^89BL#C,RFXG_ 0)%#+GX'S["RKF,X2[99!B7<$,J488QZ+O"5#$2M>
M5;#]-QL0,B]#GY/]59M[S"!3:4X1[A^9@0(?#DHV@TXI%\'F),Q108+R*/LO
MV.(DF)BT% 4K&3%?\-U6G:@R1*Z64-)<0?+?L>)CWI_+9'_'QMKEV#JHZD%N
MB8HKP$%I7>2-SR$-^AQK#8M?4J+ $'"^"Z=!,A+Q-'V#F;OA Q'@=8L7&".P
M*:CA@!;E%@LEV_WW+,8DEO^6EZ:7[W0&E@,U< A^#8^X7:)GGAKEXN!*/7S3
ML/IN + L>D7;P%"'$&V%-*K-V^)X-A/5'6Z;Y:8I!]I?@S%9LO6AQOI%!YMR
M?GIA34 YP&E%MK>,981=OF@9E]&/GMG<9VWSVJ1_%AUN\TOW"[P5USP^TX;-
MJ @M[9!9I1I%<OR50&YJU%M6DAS8,$-R$:ER,PL#;]E24EK2DC"F\7P'BC:Q
MF8W7JL$H"1= 5*8$]VC*>"-T="F)4AY<>*_EELM5:XFN]$^,*?B27\"9OVDP
MUXS+(EE <>).;6*%8\^""T[0E4AR*(6'V@KQB;9TA&0[B$BIW=I+WD"T3S _
M570^]T@WW<P+HJ5C/(1E)0ZM8?QFD'Z3 IZBI^)6!X)'OZ74!.UM9JZ J2"[
M,RZ,EX1=0]*#W2/I07)@#<D0<FIC:O>0(F) 47N+CARX95O]D;DCU)Z;03I3
M-6:CY_.^N)&;*MDEV#??^+AQDP9;* <DZPE\/%L.I,R+>*NX3TBN@[4,U'UX
MZ"186R1 IR^'>$_Z;X)+Y8#*S4YT>HN0J.K1 .,J+Q#'W:# E)D&:L:?1()'
M*X2_2?(6W'V26G$_!/JXS) #3=R9X<O1HHEH'.K3I"Y%HV$^W:>\7JB.;_/'
M]6%,:D9)YI 1*XEIR@9_=@PQ==/8M/6-N)4P\_O;=G^S'J;A%';[P,+\^C%?
MF#CL7,4:3N,:%$BT"4X)%IP61!K3#A:S[9$<8KBES"(XG[D1='T@!]86Y^>)
MCTC.2!]AE(R*OY65OX\5Q%-5B47"^2R&5>6GR=P/&&_^ZR<UUOS>Q9>J+M<W
MAJ%E:YW /2<&L):?)H?L73-"18-PTF/8S1L<:D<E^: Z\ !<($1W^.T1>8RQ
MT)U18!B/2HHV3V9N#M:U(ZOU83QBS?X:45'TL6Q(N'[7\.=A(.$$&+-4VD/>
M/4SNB6-F"-S6!1MXO<(;=_&CLSH,W#(8*&%"G >L#=:+;+^T#"5A @5T=;C@
MU7+V/3F@M17LFQAATB+V=)6R:[=^XWED#O+&"2FTYF\O"0)\DFROM J+(B+X
MM"2L@V1EOQP(0JZ N:]XVI(3D!-[^4K! ]B];<Q^$(,09?D%"-S8K923T#/8
MK?.Z3T$:16#81_)[!-?.'Q]J,'3.QG%4!9_M.'+ E;196E(K,YI$&71ERDQ"
M\9H2;^AG![M3AH4.+"7=AZ_L6RP%"U[A$;+W@L^(PXX!94'Y8\9P?.G[BY<C
M(RK].R)-W^)#6NX\LWTK2;PL!U:U]4KP8.YA&"=VE! @="=5G82%-[  F=9P
M&_CSE3&B%Z,N$"!O_(;=R>K6'>UH(CO B:8L-@HQF>L/-_ER$<Q$9+J-#GCX
M/)'%89\!EO'NTA9*H+KAP::A:+P6L;<]UI:E'62?EC2'U2 %H+0QMI%\&I)(
MZ9#M84'4]G[04.((4M(8Y@*4+NS6X;\)PF5@[,KA>%>%@)!85#'+E\9,NT=D
M@\WB"-D[LA$3DM;2(5U?7U1JBQ['*IY3LD/!GE.B5^X5[82UG^%Q87B&@)"^
M5V:0VX;=!U$2,:87*;5P41M9?6B1MWXR/R[\Z;/@8R+'H4U]))-V"NA:XR 8
MI#V88JE@=SB"OL*$LGG.RX283I8R=K5$#28\"/'7@9L?2?;U,+P?!/,T&M!K
MZ6D+G]U=\<DEP!#&2.1R:;[#WZR;X?3P98B7L0F8)X+MK0D>"M!V)^FR(%27
MWR7NZ9Z&CTS;($K#1L(3=!LKJ8"GPS@@G!_!M\O,0!Z'JFG79<A3>0W9^?<]
MS.WTWS[(L!.,%@>ZA:JRUH7$8:MKITN0?FBVSWE$-T3^S*H?+*UBI=K@UQ'_
M(FQX30\U5F\ 92RP3UB0]!=ZXPC1>KI+9@!6I$<K -'<M5=BD@"9M%]GXV%O
M='JMY6:XJ/2?@C$EPKKY3/U8MQ0<> 9U [6.N0[&"UT;*T/'D$.-]#3*2DQD
M-#A'6"DYU4]RKW01'PK>;G<C2@%#<;ZPGNL0<U]PRWSZ+..0P$6)PU*+LJ(X
M#T;CU*9/&7RP,"Q%'!52/KYL9YI#M$Q&0+0(M:X-ERES(&V&)V,NJN<7#@XN
M5[2CD^,([5:X@ZE.TA_!<1\**JRK*=?&9Y_B3T$^M,V>S+@!%C^/AY2X\Q,,
MV\DX^/83TJGG<*@ GSBV$C:,AE0%\VR<-DQYY;\67K7,D.ET2[SXOJUK26CH
M(L/%["4E&%HI!SIT!]U#1L)J,Q0 S""K#C640SH3B(\EJM(:\FJ2(U21C#4F
MVG48?'@A0AO 7EY0>=']-CXZ7?=GG%,:Z8"0MA[6X\24V-HQ-S2F"1:[TD@Q
M?-XZHJ%_'R;2/*W1S[PS_T_8Y_N; ^&RSC<4:_BUV)>8RY<#7?@TG&JCVTK2
M =HA.$\D!](4H9B&14-O#]?!\R(N[!)M9.(,Z5&9^B1$$\BLCA=2TO!KPJ,C
MXR$GCT',14%"P EP+$F$6C\\43]IKYMGGAE'&18M'03Q,]-/O$.Q.OUA,8?
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M<<IGZ4'YH:7MN#]Q,!$_^T*1? <H4&%.FUB2VE*9L9XXG-+S0>(M!]IFZ7+
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MH?' _/LRVH]=1\EQL3\H7&_*_ )+XF=,XOT8Q(NE:#F@AY_ 2XY^E0-'Q'*
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MD.9^A(JX189I"[''C\S^_0Z/(&:^IO(N%;Z;$MNN<N?)=<WHM,++H;O@'3Y
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MELLC#E\O'(@ISG2J[O?Y;GD@_B?F_8ETJGT'ZL/[.+@(6M!2HFCWPDBG4VI
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MWKE14N;)ZX3FW[N!4M?R"/ G"=:K-8Z1OTOCY7".^[NN/?IP[/B]?W_BR 8
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M%X$@_XF##V,.Y/!A/T]S8H!.=9H$<D$3#Q50IRX(0<F &0&,V698<=50D.P
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MHMT&RC^I0;*%(@;0\X[S85\!W8%69+QN(IIYL[ES-9Z'Y!8@#LARI*8ZC:N
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MG ?TG^"N\2YE";?L'LR>0)>P'/6;E4KF[Q@SQ)H?K%Y&V3('F>YM_6FSA9-
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MH,W0EH6;K,L/QG9$AE:[%R;7G;?\@WVIP%:1;SO[_HRG]#<B[LB>=+>7NVL
MVVWGJFZK:[6NKGYOM2'#)S9B(TZD3FW=&QW^\Z&XJO?PPU)X]W4@NU:VGOCS
MCZ]QLK1)]?;$Z%)GGWQO^OG#IPO._E58$W'R%P=%]?8B^\LG-ZBD_,6:$&8*
M\K5*^H#Y.\E5Y$$G AA)KP5]^+,LWK>MO:&O3D! 490AN8V3BZ%5=6]-*P_/
MA+0_KLLONS(Q /Z]_3NQ;S&I"I6]PF7U?Q:=Y#C@K2[_V8FG9_;_ZX*CO[?(
M=<_C/9=Z3&/7Q#QP2MO^?0D]LL[A\(EWAT^2:ZK_&#]*#NRN7+]3AO.4/7<:
M*5MSV?BX]"K3V7:'&>,"L52B!><N_U059HGS._S\ZE N);1T4UYT)/70@;J]
M,8/%YU=>6^.!^N>A"9.:>R+?I29<II:X!DY1E^4R-FH,AI#=K'(6DS%YJE6X
M\]#NL.+P@-EK##>M*<LF"6L?[]JF\*+-Q7E(N5@%(] 0.KDBEV':W+O#<9XQ
M<&'"U:H1<4%"_WN.#/^3;JM%J'J_PZO]#O+ZC(2Q,OYAQ )BS3CJ3C$"80&?
M80-ZR+P\99C5>E?&X:5'C#5/X"_R*Z=$F^#&FDDF>BF?8:H+OLAU:(*.%C\D
M9T1\*1*AD?U0O.!NN,;KZ#L!]9QR\+M^Y+Q[#7_"=8MP*,OD.\-\Y"*I,!5,
M[VRE25EYBXDW1-OIM8#JHTL-[!8)GN\M96[PZV$.MV*E+YVF3\(W 949_8"/
M=9)R-GN>?YT9 !D_3  ULD\8IT,:GW5T6FB V2")LG6%+BZ$F69(24&+C%.*
ML6:8J4O"U0L<\',XQI01!AEIJ.-%?.'):OKC5^,'X!X#<LEND@'BRJE%[U^?
MC(S P],=S<P]C43G>DX=''F@M0W4BZO?T:^?HS_W*<&T1'6K\O6;X%\>7#30
M1%,6+6R0E<1:8P@ML]G46$(!DP!Y5VG:T]7I;'T07*Q!%S%,U$'F7Z16=%+7
MF,,+A:]+H,35QHE3:'!\!:G_>:G*\SWD\?H]:NG[>^+-J6AXF\^-38-<0@%I
M93T.H^GAKYTTT$ 3T:0GZ['DJ\E+OSXC\L7*9Z[(#PQ?2GUYUH^VYB5H3;K5
MM>A>FWB?U("<@'T>T%\-2A9?M=7$AOS)P!N&NE#?)R(,B%RC]W]ELO506#>_
M@/ -C@!X$>5V*EO<*O6TB[V6+UE&E3#]GK=X:GU63XC<(6X-6,>TZE#R"AF>
M9S'9^,UOZ-EOX/@ODI:G8\'_6*'S#&$>GA2#QV=M(L!!37JQ@,7FF@_XS>:S
MUNFM*-@K:,V[HQ'H*#A',ZN<U8Y__$4SXQ$Q5)_Z#C\O]#,I8)J.3(NLN+$.
M\Z--$/7VS=IH>=;Z PR^&:LS3/0MO7E<H[\+\$=N26,>7+\WL8QJ.L);F_^,
MK)EE#RO+"I@HY#AF[=R2?3?+ DF[2R:8":[JMZO"'B4M!K5(VA.BVL#S2Y7L
MZX+9F0B:U"ZF\JG)]-*&#3>R5[__P2(T;.7EB0R%H</FRZB+G *"->M";ZFK
MSX 8,![$^R);BS51^1%YX_E,'SCAX ".!LP:O8$5729RL3ES&QQF6.VLA!CW
MJBHZ6^*T4 WDXS>T\ X,??0CFM-[I $7^)04>X/564919I6>0&\7%;L/8OX"
MT K+O[ 16]WZD225%2,1,NEF)A;C YEOQS;T/4F-&O8F20;YV7@KV.0$=& J
MIGU 2?RQ_(=%XG7$#)@.C;T@0"T)[XG7"TD&@K>& 2"65AC#(*W1VU+B-R]Q
M\1C]4#P![O$3ER(GJ0#/>D3_!W<[O$.T89!I,V4)IQQKC0B7QZ^!&Z8I]D5J
M"HO-LVQRB>J*W] *N>17^C>F+7ATS2HCI2U*U@S17A:!Z8A?]YIUP<=2O# F
MN$^OBBWK4'#7OF:N@R.UI25U28OU-0!4.X%ULF<+3RQZW-B2<VAXAW31MK<@
ME<Y5'>/L?XK2N6?O<]R,"KC5@2EA[H3#]&NQT&@WTVM0;S6*.("_\*0\2R1L
MB3L79!0%[82+U4035I>I+A39NU3-(-^#_WV1N[U?#><]8G4YI^OV3H%"Q:)/
M;C7T,K^.MI!ETJ',/A.2.*X4S\AUH?#H"0C?OAV.ZB*L:5*]:92/[8+"<I!M
MCY.4K-*/>APC8*F&$:4CT-E1($'ZW[E?S?@YR=ZX[;2Y&C^2>>5A5;"HA#9'
M%Z1G=JS0/8^.NKWAFQ_7;/B!F\,='[B5D3SZ(IV5_N.[_R82JIFGZ0K-^ W"
M18SR>X5ZGB\EEI :>B7H=?I>EC73*X:2(!DVR(,P4\O"T .UZPAF\Q'_!/3N
M=-+WW,] 65>$E9>UC)30,@B #TOOPCR@S0"(/8_I20.J([P/AH1'CL)UZ!PQ
ME:!D[5]Z@E T9K2%?X)?/D(UR(;F?F_?2L)"%MQ]N5;?HS)BNC_(5ZU.GIG/
M#$;/;-2*U\=/*&,F\1O+9!E'1'O[=P@=^=V/R<H392B,T-'1\^;S=3=O_H0^
M$';&:87)G@UJM3HG9^)RG^)]2S?1A4&%4R"2G+L-#H1(&MK,"@V)'8.=L82<
MM1S)BSF.61B([H@W'A!9&/0=VT&\7AY1_\O=NK_$<B),Y'31[=!H6'(,FBT0
MNACZ_U5.-H^0G=!%3,>)IU=4#88+N*PJ),D J+'B4M&6I3O"C5#5 G9@&45F
M65#&MK+0\:PN#VT9Q+J>&N<3 _[ =>E//8@00)WVZ"]:DO4[.*%SL&ZAN*JE
MJ_@A*'YC1[1TV6<T-^BVX8<?YEQ>!6@G0YB.=.+"STLOTL0%>*-^[[39W-;Q
MPGF",E:_-EIMYA9R@\[N(J"WP"F@\4R3./\F/!<]6:XH3(L@[1]J&KETR1U$
MKGQ^-[DHN"VHC2.1E%.F5R=9ZPCJ!Z*]<#NT&_A4!M!&M-V'P"]24YTO.=YS
M2-./R^2'5R6)FSB=1#;/20QL$, Y9X%,GSQ_KA,<]X 1 ;ZZ^61B;..P[S+*
M'GX?K(DC=0U?(8PXA=[2_(A^L]T3PLJ646 D\888K5_!"(*!>H8'S'I,FN(U
M?F#KHI$#\%EU9;"&4"P, 7RRQ[9PCKIB.">@(\SU \(U@&==M)<P-H6F$5M2
MRDX-3I5OZ<UO(JV<7FC%MVD]F2I-+V+#DV-6:>%"[:P%8RO(OH&W@\,U]C,D
MD!/>CS/5EAS]HIE1E+ N\-FN.)A/KIEV6E]N]J'P(9W676YRC3\7$;^9:[#M
M91D/V;CC 5.+[@+WB@<H9GO?P?4_H^9Q:7LPOVJG2;^25BVCJ.(BIC<T*V&Q
M6=9X-%&=*;9%HJ!$R5)D=X"8S71C! TD-[WS6,B [.6F<>$2PQ!555W$[\H>
M/S3$"'P$$V)8%N2%Q://SE)H6L*ZL1YRS9F)19->EHGX$D_IHPWI+4+2-!7\
M59,D8X2H)L%;V*5,9WHB,+,@J(9')>4/9\@039*!+<I3E7@\$S9#/OG)=[,.
M!(ZBGV)F*NU,(\R[9@\ZU3<^LD"/EGMJ>".!"S_!UW7[8D;HC=VN&#@:4!DS
M0D&OA]V$O/*H?-&F,Q26U1QGM8I><0*<<XJ2BE<G!9POCIWJ[TP\F_YH6N1<
M3D.3X[>\4. Q+UVZ9_/O0/:%^.'_XTW3QBW[]7^S)BBD\?,017^8+UU&Z;;J
M@Y910VW1_+FC;H1_$VZN9&U'3D,8Q$*^$ -A"])FK4B,4'C>=K8@[65"O+!(
M(75=$7ZQ7E!W=/;$BZ)W/\"9.XII-E_^&?;-[SL:5I]<^?-_@/NT"565P7#Y
M *]\BCPO^UTZ[W#A.>/Q;4O@V[2=R=]WG90?;FDZH?SQ4-3#/U3=Z=1?$>J<
M&(PL%5[HH3N;=CI<:K.,VB@;?_T9/;-.5DIRB)3W_5$#M-]ZS!/\\[95RRY.
MQ[]BX9OP[F74RJ?+J%M+2P84_?@#1-+7$IVCOCCP+K/>D=Y[_LU98!K(8S_S
MU3*JD2?#K&0D@;12T:XID3OHLE#%JB;KMPP+'=/NONVIN1A3?WU7D@59M'I@
M]GZ)EU]FX3D[Q<*?WFYYE6,;H$.+K<8HHZ=&?_/MY6-!P*P%W+C])9Q<O[T>
MO4;RAM':](P>#23MB,#)=TG_V/GP>,O6[:<?$RLOOO_+%N2%S!T&*V[@,.IU
M7]C/!_)-T+\FP&+'WP#@FOQ[^<!M8U'$3?7=;2?O_^MLY*AZIV6J2ECET$/>
M2"F'V#G"+=IEE%F2WAQ2Y:=B'.EA)(%_P'@^CECUAK)H_.S"#Z6DAJD,_$-:
M>D*62:5-Y(YTN[^W1]A$NH^<*U%4\_,)-#/G:(70&0P/'Q#:/F:$-CU?>J"W
MP%C3K0^_9CV[#Y%R-^'=RZ3E6][]]?)E?J%?R<)O#2'^'$T=\2#(+ES?#?3:
M3"U>**R-CP^&SRX=S7RK:BS[N'3Y?V_AJE#SNR9Q1NK*1+T5T03VA=&2*@G3
M 3+WLRV+ZVM*&SS5&SY<7W9Z.$$T5+>I:!EU/"+A5*D^\Y?7/K<UXP5Z4X;I
M:\;.^@F1)QP'#NBZ LJR<3YJEN5DZY=<7" ^)PW4 2^''];1L9(80?/=<\,$
ML!AV6D:=>"W@K'MSYO&DWK&]O7VHZ=GYRSMN*=Z;<W1K]7V-L+.\O%+!KF\2
M6XPBFT$9!TSLB&(Y\=_2W3K*>,W$&2,H489I#*W0N@2>'#+)1XXNHQI8-W!N
M.G]^=]"N0ZDO30Y#!@W)PVW3M'&,R=@6!<&=J6"A_9911N\,R(U&+JN] H&H
M#GYA@X%V/$!B)\N%/MVQ.QI9!9(*YE@CM5TQ,0P,-5/SY9K>I$<7P>J*!&@W
M2%9,1QC=J;+4;[VH6C>G*FPMS;E'=S[5SPC6!([N0T\Z=Y#,\%;T3;UAK7"B
MFK@"CB4*P&IVOJ\S9R5,"1ZX!( Q25C]YL'4"&^J^2O3RT#_X^F8VVV4Q"29
M+"+X5/MKFZ"7R.<_>VT09SA$2T/#;5W<;^'S:I(-G2)??-=2B%#O3(]9]@NH
M'MW,S8U-_9=V&'[;U'G4<68^*$,V*&%B6IX->_?/!V[N:\IK>I'7-!J,?A_U
MM?Q92+!*I;+D"RQC@0M+0L*PR!1Q(7?3P/PDSNPR1)+P5LQSLLO-6KJR/ ["
M9&@TAJW^PJ[#[=06%_?P"ER_@3ZQ-6;$SK*_I\>V@1S)$D5>=:2]X8-^O;Z+
MT/2;WA6^7(.0!NJ18"A0\O6I$GMPA#KZ V+1*45&KL@9CB6GJ57*!0=!4&#4
MP&U-KTR,GJ<F2O3^I4%X&;'8R>5M1JHR^>Y"IF>@!7KDG35@TD4RBZ?[' -G
M)805$UB5.>+)ISL#2V,EZG>FX<]!0@XN,OW.&%S6Q;4IEQ^]CNP%WC$_=^F=
M6X>;J#N4Y,5*V?7[Q$R:;WE:8_<K>N!"TA*7Z7J5!%Y'S.%P=:];=_,8+D=O
M26.+;/IP'*?3D\I7-PUVBM P5TOR.#,XQ[.DM)[B/0IKSB)$#*>%.[NW",2M
M1:3?T39,F:J)R(X$_@%B)($\RVG,.@.&BR3 %G8A<Q-,C('#P-'.=%(SMA3O
MQG"EAA-%4$N.R!/Q*(Z /=+4[:8'X3P#0;9TX_V?@M3?,*L946#5,? +FYHZ
M$_;E4N+Z^9Z,N;>7%:..']%&WUS#[3Z]]&]6(L:BYQZQ'C&!]S_I!1Y IO0,
M:B2@R)W]J]^Y6^1^2\;UH'J'5VX/:\!O@!@#\,,H_X^\9,BF@9+R::CR4\P0
MJY'U\;^N+R!3:2U( #R0S1B[IG?A8?#=)U@)?[6H"D(?&CZ?G95X!*H>*@\.
MU\01HKE*9=:YWBCLE<7V;D&[[*'+VP7P/]S7(:BKJNMZ2X:7(<@GF1@#:J2K
M^2MA)_645PJ ,:4G'NQ#@M+<^0[L4[=G#P_6;6AJXT7FKA:L^72NG/*?+OGE
MS06/[PD-]D-O\>YB_!:P72%!L[_@G: R]AQA+;UEWW,P/P=?K*&MHR<>T7>#
MLVS!S"Z*XPX!U?G  'HAF?- M3_H045",67/O8)5KK^&H.A+91]UH&<$^#'>
M:E!OCNQJ (6NQE"89(\PB*)FF<=._ Y^EBWF.K7<0*Q\)YK>"_#V4'(=U;A6
M0[6]1W')C"ST,SOEV=9Q(>@E/UN(24C3M(T2#$,\_%D>&?.6/O#!#$,LI=D1
MS]\9H<>\(ED=]/I<=X@"U&&)?1NH83/&04Y_*(Z<B>Y<[SG8O\]UH[IWA+>0
M#J=\7=96FW2H<D6F>OEKWW;:89HI P\V9R]>>79W%&X>_&[HH^K(P$SYF"ZT
M$9HMN317\>B/EP]&Z'RIW96(5?6UZ>MN^_F,]*CMGK:N3>*MTMM/K0'H"!7-
M/C7;,;:^,C6651CU>4IL06WJ6[RJ\^*7S,?^*B#9*KN;5:2A-TD!OT79/Y,'
M9 ;9K/B L1*M05SA'O+]TXQ8.!;4::BEUQ\=JKUXFQL$LMA(-/7^5*1LXPOA
MX%U%JF[BX[BPY:7@\[Y'/C/A,6-UW8T.G&U9.B_FRT5>]T'\GB3"-TPK%4)J
MOK6/J]*<G+W&\$O3[DD6>I*->4#QA&"Z!!_^9AYM?CIF]/1$0-%!GR;*GHW-
M@\G4>T5^I(Q[U_#)H/QCIFX'[*DYHW) -NKPR"90WAW(LZ)7R;!X?!_.]"X9
MO^TYE%CR4D>72Q5.[;\\P>ZFZ+=G11XKD\8(GR@6_U2T[";UXAH:>:'P53 1
MP'2%0FZ(ET$O,6RBUNQ0&L<6FXUSNP/'"4,>>RC7I2O[^R]=$C<E;\*F4TW/
M_+?8*#ZNR=0Y[HQCEG<1ZN^90#6G\YV;+*9%&N0#I%]+74:Y4)1U"VUU=%%/
M5X972\%\!.U$WR6AUV.*O5+H3[YZ^?$4UVDP=<8H<NB'7_A^+F[$9X.S%[C*
M@=5:></2;X3$F<!N5U-(P.XT4'S\MW *4.?1.;8""OE:)3$-YL.[N\I7Y9:?
MR@%4ZY)^KRZ>L0[KFWOQ*?6=G9S(79U:@O][H>=H;&SLZ/,'"^5;C22,<-U.
M_2ON;@&8QREFKF)L@KQX7[_II9IC%#,M-D<\:F/AX$Z%$R/FQ)@M^!Z[> *:
M='7-"AA3#NJ<?C\W^+,SY<?;4WW?_?ZK>G:$I [+1HA:DO,(8R_(K=.R"IS$
M4J\PZ9@?A,['[7X,-^B.PKPGS2T:\9I#&N/^LT,/0>IK^2TRACV;V-I"]1\>
MELW/;FKA8 Y\O?US7K=-_V<Y+?L?,/6L838=&F$65=.&<1F%O4<!7LY=\$^\
M[Z#EV4%AE.N-\CU/219O8C>='IG^!M,22W[4^L/N![_=&VCQ6D8E\J_[E[/9
M:;%?]Y[/"'S6T(G[0$R^#U5H#4QG5AIUQMM IVYI>6MAXJ';SBLI&',X09;A
M>DO#-Y\ ;9_V"8//4FLGC\60-O[:7E2$^LQ;Q=@ GP15T1"[0(1A8$&?[+39
M@H :!2[M"1S956[/GB?:3YM=OGI%65;H,U?K'%MW 3),YN'_/A3?3J?,A'\O
MVCR6A&U\F^'W_ZAEAQ*.9MQ$6I?07P]:;CR6\6DB;%V/8FE@[UQ0V+EM%_\/
MCO__U=#+(_\+4$L#!!0    (  ^$1E#VK)5?=Q4  "86   *    879O;F5X
M+FIP9YV795047+?'9P 92KI349$4*>DP:!%I' <&&"0<Z1I:"4$Z! 611D1*
MNAT:I+MAF*%[AAQR+L^[;GRY']Y[]UGGT][KK/-;>Y__WH<P15@$T&JI::H!
M@$ @(/EZ 0BS@*< "A"('$1*04Y&3DE)047#1DM#34W#S<Q"SW;W%M^].[?N
M\/*+R#[D%WPDQ'M'_)GX(WE%%145OH=JVJI*6K+**HK_' *DI*2DN4G#14O+
MI2AP1T#Q_VR$9@ =&< (@"$&\@*(Z(#$=$!".X '  #> /[+ /]I0")BDAND
M(#)R"LKK@"I: !&0F)B(A/C&#1*2:Z__M1] 0G>#_K;88U(&/4L0KPNC^(?X
M++([3\I:F/2'L7<EK%R#R"F865C9V._QW><7$)24>B0M(ROW])FJFKJ&II:!
MH9&QB>DK,,SZC8VMG?U;-W</3R^$MT]P2.C'L/!/$0F)GY.2OWQ-2<W.R<W[
MD?^SX%=Y1655=4UM77UK6WM'9U?WWYZ1T;'QB<FIZ1DT9FEY975M?6,3MW]P
M>'1\@C\]^X<+"" &_I?]KUQTUUQ$)"3$)*!_N(!$7O\$T)'<N"U&2O]8#V3I
MPL K_H&,\4E\5ED+^1T)?2R3E>LP!?-=2?0]W#]H_R+[]\""_E]D_PWV/UPS
M "IBX'7RB.D RH#CES(YC-2?*X$WQ]L]D\L'1<G9DV';0FO1QI=5.L:;1V>#
MM]_Y4(]O01FJ8K<) &K_!.GVR>@*KF-JW4.F-26J(5"XQWCU%Z4GM[W)+I7!
MA\[Q+X,+>.-MT:M%[H-,*E%3'[=.'B@.SE_"9W%06?/7.GEO$U__,8;;:PS6
M*K"?./"8^)NTT:)F?B;;A,F3=T(\>+[^[&RSSZR:+HT0,W=%,3KJ3?,\5^EQ
M?AR'#134Q8,3"8"A1\KG^,#61A2<8?BJJX, $,7$JG>PELH0 *$%RI?$, (
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M\6T#!X:CHZ7((ED'C,;08=7^@LY'\_=+^AC*E@F F\AECRH"P%7WDK0^-I(
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M%J.C]0V5:5C0L*!A0<."A@4-"QH6-"S\T"P8&D+=S,U_FP5^G.U]FJ_^R6+
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M8 PQAA@$!< Q!FBT"=C ! DUPD #C=%@-,S,\'?8KW0&_M[K,'A0(!)A%&0
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MHC&B,:(QHC&B,:(QHC&B,:(QHC&B,:(QHC&B,:(QHC&B,:(Q\JT/LQ6D:'1
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ME#,JB)515<'5FVK\:CWK5M>O:G!LM&NR;;9IL6VU:W-H=]KBTN'>Z;-U_;:
M[9N[L#OB=G)WB7?+]R3OS=Q7N+_R0%/WUH-[#QT[?.'(S:-/COUR8NA)W5,S
M3R\Y8WS6YIS;^0T7PGXB7^1?2KJ<<27O:LFURNMU-YINMMWJN+WMSHZ[)^[=
MN/_SP\&/=!_K/=%_BGQF_=SE9]\7 2\WOXI\'?4F_)? M][O;-X;?IC4P__
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M76M37$A15[ +QH4:E@S.'>(S/_]$5HJ-2<[P3$?#G1F/,Q9.FI!1DI .H+0
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MH#A1XE13+HJEN%4+A>G@%-,- 3^+;<#Q[Z_7557PH8&WM;_Y_C/'5ZT9?B4
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M? \\O\TQ-HH0U>RR9 G!V\H='T7\Q'^P&\FM@EH[@KGA<++Q.><K<@F?PKF
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M^ <]TQ52\.(.@AR;U]MR7Y:SJ;B1(LU9[5$'EEB6%M>X2<!N%VT#$MX8;],
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ML(%*ZBW=)0PE%U3@\:V4&97?2]]0+D% *0[4:MC.<!FM$K'?XS0]"GGI_S,
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M9^S*O^$)E) [N6X0-I@\NZ8*_C;ZB]6"] AF54]%S?'ZPW(0I9_,L,)1#@"
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MNNV4S5!633]L(JS&NB7_#WB]^792*\)FO!BY 5ELZ/&=B9R@!SJWHC42>QV
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MS1$WY 0 >).A[$4AW'52Q@-ZKWT@VPKBF=0IVD%2'7W)23!XVEM[,$-I28-
M 1'ZDF/%;_W72Z(A#%=G\5/HW;4I$FW8.9,HJ0K6H&,N?%/:/NU=S]BO1&_1
ML=+4\! 1%%[I5R+\C-CA@A'*D(V6]X7",G_C7Z+]R$<ZCGQ\^73>C3;3.YG
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M4+!"YOE!6UB+9JA%X1\E':@+,8;B(\#>^)VB[6FXI"_"^G";U%[!+D]VNJ'
MWLHK[;"@<)XU]!AO)C-+88995()1$5')ZG= \SACE6?J^\1L!3%L3XJ1W-33
M-35>EKCV=FJ"##CW+LR/O^,O1=9 T7&+RO1+YB7^*-Q3.I)Z(:4 D9')"IE
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M-<485M8=,R1I*?*K6IKJ/D^NVJ/(K5BDF"_]EE$GU8B;HU'Q1.&Z]2_Q<L&
M(Q,=0B;V4:H[ZV[43='W60KDRS67C%^YYU6+=?7EN7) G9PQ0_)=_BMZJ8@N
M4:[OPU[C[QP):#3Z9^^>:M=V9FV2WKO93U:B2:W[EVNCM)@'RL[+IQNHV]02
MH<8VZICPA[QK/80AHB^.)<@[P;3>U<;S_3]K]NDN=[V07E:_:]W/42M]&O"R
M3;(FR^9M5A)7P]0HEK!9A:W/P)PD1QWSD [!I9X.(SA*JXG0X4.@=+.ZL2>=
M,T_QH&U9Z5598OV]]#/B6R99E(]PAW;&>G?!.UF48Q9"P!BMX]M&*8?TO*:;
MU QL5_T*VBRZR4*EW2]:;SQ/?[SEJ&XQ<UE$O2J<Q?"Y*POC.-J["7_R-K5X
MMA[ESM#]VWB7<P'SJ5O.V4E?8B9S3A4.&_[BSMP2I;7C,B)\E5F\\3YMT@K>
M2?L8X3K^7\W\E@-HH&YMPT/$3R"M70%OI96:.%!7X7S] \@Q]9 F$CP=_I="
M K)\&)).,-8^'Q>!_DW'FR](,[2%]=_%-6A_S0;1.&I'M1&7%13IYV 1J;YJ
MKF!N.%%^$1GSB17_@GOM6=@["&V:U/R[ME334A^D^HR\LJ"*9LH3XP,9,?^D
M+EH2O7FWZJ3(/WRYW ;_T\=>G(\^MY=B!+BS,:\ISR+73*TS5.<@">;;^HV4
M>&. 9GU^@+9%Z;LY6K58MB[LL@P6V_E,$UW'/MB;L?%(5\.%QD?-.K6H;E%]
M$WS9O,4R1+Y@Z#6>SSNN7:-]E_*/LE8U/4POFR ;Y_U:5"2\8-\N:$&%#?&-
M>#=+_7OMSK:#\';3N\8/Y.V&B%JGO&S-:'51BD$9HE6$Y4A;%3KO,=%,<:7]
MD"!#$%K_M#%H>).JI[:T=Q?TT53?_HOT6?^N:4/>=$U!#9:2IGAE.!"V5IJM
MNNI]5'A!<MI^KV"EX+JQ:Z"<4B(.Z#Y!^<JQM/M1NROV-PW2)%E]=4OHEH0&
M4P[C?O!/'8V5X'E3&<:9;_-1O),78%S2+^8$B!YUW>2,YT2WA;+?5Y0T]G/^
MS-I2NXA#2DBJSN-\"SZ@!;B-GG\I,G@2VP#1 _Z(H;Y/"#\7;>^\#WUD7VH-
MA1S+GS8,@9;M]VI6@1OB_S72P2G!D*86N.]Y0BX"GMBR1 [@7,.:7IV8+3S5
M\5XXQG9MV8;GEJ?7G\"6;L^U! DFQJL,]>CXX$CU962*YP'9)7BE;:\0AR+U
MAI[SZHG"@ XWQ2C+W*R7Z<M.U$^1Z#+_,5-%_?%^^H?XO> _U*NQJ9Z[9*ZH
MF^U-_"><H9_;XUTMP/>WJ_4*EE73)\U066I=@?)])F:Z+ ^->Z/WEBB#GJNX
MPFN>@](:;*[=!%R$Q.@ZNYOKW^#;VJ?4A#,/-Y56MY5^J;VF7YZYSA2M-L;M
MTO4H9@:=4SZ6E'KV29?AHW:K<4=TD2ZR.Z+=%U_25M=TEBEH_%"77CI<FV1Z
MF_&A^K#>&,?3^:G7!74J8=DASU[)'I&GG3]V$SVL?=_UO6\'=K$MKM.!&=AH
M;KY<2JSY4"?(.%!=8$J*VZ:]K9L?9%!Z*4[\1S'%Y78)F$40*_U];S)E&;]A
MY &ECK2P'Z$FY>=W+:+Y;C&W\.F;-[VHZV%T^N^M-K <W=PU5IP)UN.E43QW
MR8$]##;$YXZ,9X<2W_1)V?[YZSMGLZNV5#27L^]L.EYKX:#^G48Q-]8M66W%
M2[.NE.3S:R3(:"4TP'<=^@6>(+;W(N"LO&<=$X#J+;9-><#V39H:,Q#G;S!H
M@<UN!%40(+$^)[8 SR0AN\N%^WE7AL;CWL2@'I'@1IZL?0(ZFGJUL1*YN"G;
M,H",]T?U.^$@-Y&2"IEM5HK>0K^+7^_2*O;SH$%'F8'PI'M 4I?GV>8DNI2J
M:5 ([3=YF!]@!G^:[KU@BEN#XC@"V^2+LN$%8OW.M_I=/*\!ON8-H;Y[O"HF
M]]]6AOQ4:D;];6G6ICEF!]$O_U)=)&YV&U&X" )L:H4/X8_B\)V$&@GWW_Y/
MIJ6$DJXJ_?[< RUW-?Q4]_I8Y9;(]R:SS,F_0-LK^N1V4MZ&';$Y+^0C0^*Y
M(Q^;/;G'^CGUOQ&".M^:/^::6K(-_Z;.K3NGG1AYP^2@G.V?J0V0SG6[+O<6
M_F'S0>B")HLNC[1T[N/V]Z]H^9O@T0G6W\A%F\?,7U,GU 49-D9>KZY7*_Q+
M-7_+;KN]D;T0N=G.QU^@?X&SC^>3/U)$![TH^44_1R=39V:4#'91_XV_V3V5
MOB04:IG)X/L<J1EBS7$ZK7O$_K F7#;"LP&G'N.SOE",!Q)8K<63=D]AU604
M#2A98_'7.F^RLT+%33<YRWT>6##N..<EVE,\QS57I0?Y&#CW: [81\'V^P.'
MBM[L? G,SHCNK^#WQQ_I&.$K0H6-^_G-/C_-%/[_G',TYP!_JU3)<^ 8^-N1
M,-R70MBW2C!:='SD$DK)<.A+1"CQ7>T-\% HVK 37N"[T,2%1,XUZC>0C=5!
MR5KP#O#M<(JLEY*QUU'26-0W?%5T(6-6[Q:A2WQ=6PNV.U18?TY0X.M6W83^
MZ?P_M3O\V'J9V #]#[AY2*-=28G9DZ/B%74,3U),SYC= TH/Q]>U_D]L"-74
M?1?"OM'&QQC59:I*@K*MB\4+X0Y@W\$OIEQ*\.BHP:JH8RA%.SGCC^[SJKGQ
M[:U.<N_0IKIMDGS? N-&H=YEK6J\X)9UJZ@+R01J#_+J293UHVLMDJ+>P</&
M/1G+NKUU<^('6_0J,'2@]JKLJR_'<%K,=-FJ5.!SK&^(4I'7 '9P<6LB9=WN
M@PV#1:.#834K,ERZ!HQ#\:=:%FA)H1=JMRL#?:L->=(_7!C*0.$TFPFBW]&"
MQSMI_>3BOU+IZO]V$S (5*]F/^8FFJ.LGF5-7T]_S?Z-4; C@?,;LR/Z C>0
M;>_5R]O#^?5PF'*51[XP2+W'<QK]C7:7^[7Q'_H8]XF4P!CCOJ?=8#[G+<E)
M8<_A14=]XF3S=%Y3N-]XW^\_(L<)1>?>4DKP);M0*E]PM(%+TZ)M$B?Z(-)+
M/<"X#Y_)SF?90O>CO-A:\,-: C<6>'C/GOA=(SV[EFREFC9RF1(A;Z[[025*
MRT37:%WB4DH=_9.0G,5EIF$EFP#6/33 \R6G%QJXHR$\K66=;B']8?IW.(8<
M8L!K)12&-E0HIQY5+2*+Z8[R&=L;& WB*Y%CK(UXMB>+8XUDW0XA_-&1>BJ=
M&-1\=6@"J;)^1TT\N<LR!2=0)QD.DC :7</)O,J8HO@S,H*Y5[S%<S&[&WUP
MRZFJ8GCQR6B"H;=YX#7Q<,<J2PAY0E,[QJ<4U$82]U ?&Z]DVM%!C4W$26:T
M;(''*78DYG\SN?+? Z,G:(2EN^,&?B=N&!@Q9Y*878L%3>1[S3+B1"JAYEU&
M-?U/P[B(3,8+A<9#P/H7+QP;K&P^;77\1M7QPP/].PBW]DPPF4ES!OW1YV1J
M)X^00YW1V)KQ!VV?B1[^B6%6'?=(8O4*=UQ=Q5] 6G*DFK^8O+X7X-M3XJM/
M\8.IQ6@'/Y^F)^3R=?1'&6OYUYCQ$2N #:P/'CS@-N?'E49N(<=XF,05<ZI[
MBKF#G$;C+NY]SB&DAK>"\ZVJA%?!3=B6Q/N+.Q!>R-_.\_48!ZSF/;QLQ?X7
MFW_P*L=>,*GK'TX..L&0S&E'[.$"[GBXK#*32X .IQ.Y;Z$_PW;Q#"#!7<FG
M D.7:E@#2LJ!,-9K>4EG#MM;6JG[P):()9 K9[SP<D4J1XC;;*WEV@@*PY9S
MGR!B=S?>3:CH+U=FF^GXOEO,YX9S[3]9Z[6WM TLB^H[.)F]7.%2GL$^**6D
MW>*01?J-"FXL!KK=X*7"GRY\85QOF;>WB[F\P;WM$K.B)E0#,Z]5;P,FL/)U
MW#(Z>Z[*G.;"OBZKV?@'YZ0HRDW%O8_N./^#X=T7NV>0P>KDMEYEG&B1J&5,
MKWH-WXYYQMQ2>HB%Z)NW&-A;5!6AG9PTR76W-"XHJ#V_GKYWM'CT-6/<4$?K
M-$9D3X]J+Z.WS<3;P8QID)4N9OUAKMCR)^NM;E)H,ONKW,'-ENN.]9_KI9<>
MS1K-I'?M:VG)IC\=T:BF,<)[MW%W,^ZV69<(F;UU_TMM8E4; T)^L?N4KJZ_
M.*]Q[<GIV"7BY!$_P5-21.-.P4HR34%#JRBM_R5VGOJF^ [B3\],M8'[&<]#
M,'@C:Z\K&_K"^7+\IB"2]6C8"^6Q5S:T(J?8V^04Q('=S#X'FS@SBL?#JSGB
MS=G0$'=5\"NHD'O3U0[RXYTY-HC<0TX/C4-<D GU#3 (A\JV01^@&M8QB DM
M*5H*+0*[4FK!TV!8\ [0 CQVN0W* /CH-KA9)ALP0N\E#^O60.GB .DL\*:P
ME5D+\G&?0CMPG>!\\GUP(IH5=!MX!5]SL0 ?H15'YD!-AN#^>/"C=G_-7;!
M[2,> ]XI^AA:H$;F4Q #$,5_)_L#2<+DH H@15#G4@@08>VA#^!8_8<^?]"S
MQF2Y!#28K$5C@)>^B=['?Z9QR,?Y!Q4]2>W\G=*E0=/YYX5^+K[\7\C#0_/
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MQX0>MY!X#M34AC+NQZ*XFG+NO^DKJW-X"V(FZT)XVP(KE%]Y ^YB*<Y?:[,
M?\S_6U[=GH.^@1*;LY!OE-[Z;&1YX5'+#CA_:XNQ +H0W:7=#,4%^BN7@U?<
M19(#(-$F"?<!E\I_:Z-)MX*'FYCB(Y2E=7Q14*&'&<;/;?4UP!@Q.ET#"VP"
MYRC2D<O_47/^&Q"L%@J4R5J/:':#D8VG5#"YJ?:,(J9@G^F<;&G:1?TY\;OH
MA>K#PK,!+^4M6*.[1$Q"RVUZL-6PG\REU=KT#;C?Z&Y<0=Y0ZZ%S*L@P>:H]
MTSAZ;X5?U"VUBS0@X*I\DFBMNUST!%MF<TFP"_E=>K5E7^-BH+OA1*V2/*5F
ME^E2P:+J!OVW-%]=G<8URJ+J4F0'],JT$H&[0L3!#3:O!'G(,:FZA=0Q#RAM
M(#5?(>VO2:\/RC]?'6C&MGS5^>KO1!%586K? )W,3R9REX@\A)=M)PM6HFG(
MGI&(R@[&CGZXZD;9\:Z31-NL9ZVO2;JD%PUW*![ADRQJZJ]UK899] _.[U7K
M6(%K&B1VG$L(.%Q)6\B([C/2&&6=G?OIT[+.M9RCGTBZ6#_(V!7VP5S&O+ZN
M2_>"O=3%1FG'L5@M$+OS4I#8H3BN/_UK+Y?SMJRXHYIS/@MM;N8\3=+4*;AN
M81=-J=R:=2W:^SQ;EWC%6MZ8%4.TE=^+3!RT1USIIIY,.*[T2SL/DF:Y-(G!
M[TG1M3!H"&NHW@+&K3-IWH._NU3),X!W5N>$-< 3N/N_4_F=OK&[6%A3:FZ3
MXA';SS968U.2IM4HT"=A-",%N;U.H5GUGZU)9#707>N%^"_P&YS>3U6^I'WJ
MZI0_+DUI/2U]M%W0<%G\;^(9RQG1'V$IAG8\>!VNSA=4N31)/R/UULDX"WH*
M_];WR%!#&^U:J!M7NJ3529VX/;[!3=&0J+<XRB:&^1AFBXO78:H#^%F746F)
MP,T:P6?# ]#MOI+:%31)I\%TK^1%2ZN!LWU5?8MV=F*EN4[9$?:[7B&+6,=2
MA8H>NUR0O,8PZVYL"$F'>OJ6-4,TM-._OJ[D;HNWI63[Q/JEQL6)6\W3-2_"
M9NE^*$ZO@Y47),,N]R4FO,7Z'%:!W&,N.>A>65#!'3U3!>PX/QQ-.+%E1B]
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M\7^':#L%;+4);'G)KC8\U[:PVW5V\"7V174"\1!GH8*<W<@!I*JX:]P9(E/
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MQGPHH)LK# =SVE(9@X"AX6;Q"F".)3>MC;]??RNRC2]4>:V;QX<E&QT,?)W
MH?Z19GYIO/JU:D)Y$.JB<*G\DVJ6T:I>%N@EAXA74BO$T\F/PW7"6-H*G^F8
MGM%B1T.?L4WUWJIJ\GCU!L4P91I2('M%G4FY*_6C+<Y_+I;2@S;?$#YFH.$K
M\4#F8^\3@EHVSPY'IW'3Z\J5#FRI*DJ>PSX&"Z2-[)^4\>)?G/!\>U$^IW%S
M 'Z%^V=8!Q;&-7M+T(.\ #L]$LS[5,N2C\&OE9MDBV$21)%40J_(UJ)+4&E>
MOC 1_);2C%T#=6$;!=F@EW<Z\@FX8M<$*P%2C58V)-FJR)3\$EN!8G&V<(P4
M++R H[G#>"+FD[)8\!;]=^-#5(DT>3LC&^&-=GW05_"DY9STAN: O$WBJOH;
MN"&2*?814>$XF2QW,B:69"8K!.XBQXTH\A![[O4#[D(ANU&(!7VP.$C=+!-D
MW\6BZ@S 1?A43R+<QM,UN3L(@I?*V.0EJ%'FM#$ B1.]\QJ#G3"AW6%H+OS9
MW"[I;5XFHXKGUH_P+<)BRWM",O:7\4O./X)"[8>D%G2-\G[H2_B.=,1K/W1(
MF&)W$MR-_&U.D*1T_R&;)=K9]I)O)9S:%%)U!2NHC<T!T??524DIR) V*K0;
M!A2V7@:(+/J?W3F0C&*:!Q;KDA_86/7VLH<L%_W)B@-E5[4;JVJVKU(-$'7Q
MJ8JYY%U!;Z49M/$>7T1&ALG&"3O%UFM23;=(:[&M1G=R(-.H,U/BR^(T\ZB$
MS"8E3.N->RW[AS$OJ$42P51YW!?JV;$V.P1CW'#USFJ0M4Z@U;]@08Q7V@S6
MWZ5UJIML_\RYB@SV_CB.]#HG,VB;.)([R^,LWLN]8Z,0S.!=5'TS^D&+T*.Z
M'G"8,5OC J:4O% . [\R"/)HX&#<1,DM0!DT6[0#*/88QNX"L3:[T<W .I6?
MP5EX%YVN;<%OT)/5+MCI$F?%/L'(MJ>R1+0EUB#^@K1L."=4PC4>39@])+<9
M0W:"3&6U?I-R$"G27%1,I/6KTF5>Q0;Y,TGBMCPI*"J+#1';X:(-1ORRH,%#
M*Q @#39?D+606KE 5V_,@S]HW/4S:4'* 0VE>)G<3[D[_9GDNNQ'S'V16!*X
MH0A?)ZSR$* _!8#M[_!Q&%%TZNSJ'L,"]2[+'>III5<UIZA#-J![F Y(DM71
M,8AHKKQU@P-V5/S1@XDJ\#6VUG YDJ#8KCW?%@2[J;.:!-0BQ5]U,441LG#3
MF71'\5U]5$R8L%YU*/ ;EB=S\<A#@X6 K1=L@[S'@9;RDE9.4L/G,K"JL;:Y
M8GLNS1Q5%9DZV7":F!BIU3J04;]Z92'UOJN_E,]06*T6 FPU/J\YC5C._E[_
ME$2NBJR!R-)<*]-"RI'->_4:VK+(;/4WNL4/46QD;G!-D%2QEUDQ<83K@=4U
MS6"\8Y?5=3##*\]:PIB=.]J,MUB>F]-TA:SKD8M4M]D-?CGR=1S -5/,XF)6
MQ[$V7A>VL.$H$,TZ5UL.C*M<99['/[!CE6& KTNYKXWCXQ''E=?X<C]?622_
MT;5 5,<_8SU-\ R8($#K!S$E*Z F3]!;(3;-1<_D2/2#R(L4IB8)61%!5[R!
ML_SF2HE0G6NY\"[XV#I8$ %Z"B;7W9.=9QZVZ*6;*Q94AXB/Y/RI>RBR3YFG
MAG%%1*!BF>#G^D^27K3"E2Q<!U^RKD+W0OYH0YV+]C$ST_Q"?:&\RZA1"K,'
M=3YRQ^2]JNN24Q&3Y0Q1P?KGD@G8#U<>WHSBUCHT!EZ&)M:.F*\RG<V4:H=R
MEG&.?E4V16M0/TIFJ7P4?>%'9,^D_/4'Q*@HSA7$W;%IUL/(:_@Z.J]V1Z.9
M\<J\H"ZFW,O0:*9G.VFM#;G)@<K]FK1P@XRL2%[?*EXI27#E86-XA/5YI!DA
M<?;WOB@)(L9T7BV;62!N/5S^-)W3"%7>B=M4.XGP/<2M.I8<Y=VJS:,><#RO
M"&,@J]/$L]A23D7O1(*%:--QC6@I*&ZQD ZEYS:$4F;&^5KV4,$0%^,,NHWW
M'HTSXX733/E*UJO5YT7CN2LY-MT'Z%V$D^U&QN2"E<U;&9ST)77?F=9Q$\Q<
MYKN0>?J;K*?>!]6_L;\X!<J6<+W7^ @7\\3L\UU$'D+(:DOBQ>6W-2WF.6X]
M7'N4YQR[VY3*2PE^ICO.4WOO4\WF/7(JE'KR-Z^1XXG\2VQ"9RH:11C7&H"(
M\B,;I\%_;]U>,P+;Q;*JHR%#\$'M!6BE]TZE ]CEA$F*P*@U8U@S\"][<0=/
M,J5JL*5 M#_O9X.S,'_K0LLU?'JLO[%*L">X7O,.Y7H/*K*0<*=&\0C\N]42
M;"'X#^MB^U65KHK9O$=Q).]X/4MV*.VF9:6D.W:288^H,1C6A.,-WCOE78)F
MIWWBY4B+5;R@'CK$JFU/,+RNBFEVTXGRU'5/U;?2VLVX<E;,%8.U+#0X3;U7
MS/%ND]O@!YVNBLR"R58,00A,9%':OM3:5L4UG3*OSY/7E1M.I,E,[[2+8H[H
M(244O$6]4C;.>U#6)E(Z/1,%8PY6U>@'9!P1W-U8?+.P<WA2J2KC6)]'>47B
MZ8Y?E83PB\TEA ;_V;4@>:;[.^-6JMFN4?6,P5IY6$)B8\2P70^KKA9V#LTC
MG,RXW#N!^#;Q87L'.3[\;=,TR@/_P!H;6I>'MV$*PV@_0]G#.KHJ39S&G4VT
MW]E (Q<" Z=IIS)&N_OHL8EGVQ(8?X2_:!ADSO"/-]]F>7CDZ2ZQ:?;9"BWG
MZ:JKHEQ>!7'JR$;.A<+8_BI.0P:S*X-C3&QLG<@Y$GZIGL)=Z9]@&N":/%#M
M7IZ;?8O<PGNX.ERHX+<2;@_/A^<7VO:%0H2,I$XW\&XBI7D,+ H_5)<"_NF?
M6-T"//5HU!P'CM@_D!T%=JYNQ&\#HX1=0\["Y,(_>A-PGXS0#F_L]\2\IGOH
MA_"^VASDC7^J<2<RV6._^@7LZ+!(-@W*6OT&WP2V$O2#3'E.X<P>L?1DQH;V
M0LGTQ(RFN:*0\/8:/2[QWV;X+'CF<5WMCJ8Z1$A+X4MKW+'S4!6!-_!!ZULX
MN_N->G5&:-M>Q<'$],9L67AXK>69^*;_9D.F$/5XK*K#-CJ429Z@\];D8Z7P
M D+%@*[Z>N&B;I(A,".NS5GKD9C9<$+Y/;S1DB*[Z9^CORB^[/%&98<_<N!*
M$,&B-5)L&6PZ7U_Q9^'7/4\K7Y8$M@T3NLN(FN>DK HS,$R95W6^? OU!FG1
MUE7T Q1^V'+F';J=^RE..FO#V?VE0\1CHZ7EAT@/6W,JNRE3U/L)8JH[OXE4
M22LJRZ44T0?3HF@\YKR-%,8%ELD]E\W@Y)[^4MS*X>T:*KW$ 9N?EC_D2%59
ME8\Y(SP"X1WGW]),\B)NR!8*-8.K"[U*O\']YCZ5U<4K/^5?>!6;/?*Y9*E@
M1M/ZLC!TH>)%13'BS76H,L.TDGCB<^A :C-E*S0Q-)SV"PQTV\G\!&PYT5J0
MJ&0/$XM:Y.*&D9)'TAHYIWR%> _[0V65\&EQ+.$!;K_Y/IDJ2 DY1 M&MKF1
MF%NAI<>S\Y>9_C?D6<@U3JSG%A_7+9'%E<U5N['N55 4L47Y53^EI9O7D@9$
MC) 8JAF+<EO'N  /'<O(LVV9-^A=(&_(J.,6W:PA29-*7:L9S!_ES3I!87-5
MF I/J27-DN4'/Z?.$_YTF\;(1)<?->82^E8-T/)O=H*U T4V+1H)4$*O1YAK
MRSZ;F06?*[OTN2DKB4+5'\%Z2IVDRO4N_8<@]>B2'9]VO^A_GY\SE%R[N+"V
M)TU\K?AIFPM#65;6,+6@HM+!=#&YE;A FQD<1 F625P/TONP;0<ARJ]"KUXY
M]>=_Q?N(]JOT@YC!&%_ASA QYU21"\I8KL2+R1QV"24QZ"CG?_3Y+G_S%*R8
M W:DDP1V#TC^1;QL?D"U(J\0(;2(_[)MI%.H^_(MC/UTQZ0++!M&3U X^R@K
MUT7&[>5LW==+^(M5V_6<9,=Z9R*32]G!0GM*+]M(8] F<R;F-=*9''[25.8,
M[J0-HZR_N6:79,Y#WJ:]]E6+$&-G.@&"?QJ?$6_!6=@8.1 Z1$VDC$+^N7VT
M%'!O8B)C)ABP(83Y#1AQ6<YQ!_X<W5-1*V.W?ZY:*IUDD!+$8I9 2AHG?$H)
M(JOQK!UGJ4F"^PDM="=T<^!EY@:XS?DU6PT>WJTJIQI2VBY7?->-TU=54=4"
ME$WXJOA"CB35R<IWC*<0Q;<2YM+*A$&!%(9%4.I\BCT;#M[54H8WS&Q]6K&P
MYJ8.JE29RA$=8:7^%HE!O*:)RTDC[U7TQJNI)R6O VT9"_"WSNTL"R+?^:GT
M:J>AU:N\J!77'JJXU[@,OEQ540,1#Q#=C8^R=Y,=M>OC5U&C%-D!]^G-8A]G
M.2L8[=TI*-TQ]+1EL.R?WG^T#A69'1S8L_)NTP6B Z&Y=E5V *G#F!,W0KFA
M+@_0TJ.E#LXLY@=!S< 5[NJ"ID8J-ZS86;V>"Y8*H67<B^47" 2>:]7*+!7/
M0I3%ON&OIJSY3[XNT,<[30-&6:G]1]FSJF(:2MDEA NJI>P3I W@'QQ/<FL5
MPNFF+M]^FAM,ZXI-X#YG;/9?PSO,<G%\S+_"B>TS,^T9]^H=F9U,DG(VRYKY
M!9C ZF3Q*K7L,/;\[9/97]E[8T8Y9S@DOR/<<]P@QY/\Z3R;W@@Z"XJIO<CX
M'9HJKV<T@SV\"\PP,*D"94T$)V3:L6X!>V,6L"\!=+\LSF? W;&'MYD_UC.)
MMD!<7R.GC8IDLD)ZCC"3V\28AR\JUS(>"JYD9#'OH>9HF/4!V>(WE1, ?734
M<W>"95U?*9\U;RPXM4T]1UI(VZ+XS.FC+Y0=+]M%_RR1;>MC3A8E1T]B^>)3
MU^]EFU")XW]."5WLLJ7,KUEI[J><-95)Y%2NH9Q]CQ:F#2_]2?=5+=RVA)$J
MNQ9E86K$G/4 ^P_LB2.5<PB9VHF1BUNMS=,IUHU&\2W*W[6=;$^JT826IM-T
M^BWI8OHI]8(H7^9B6<_Z&%:3:+QC,:< G=NYDO2N]ZU)1N[I%(KC*)M;&EAF
MZN_UU))+M-_,&])7T&-T'S>-,;J5T/J9K%CQ6<<LSC+T9;,8Y13XZ_G(R:*3
MN!0)*W5FC,"WR]G%23!<>2UM'[R6F!9)@MZ0?_J2H+.T]_:ET&569E,OC%>F
MZ+3PO*K7F 3J)5+HQZ%,TL<B'O0G!4^;#3ZB>44\!P_1O_M:@0>97^S+P*><
M#8U]X$%ZN+88)#"F"_B@%6,/[2#PC%E56 L<8+EMV09TLR=&% ,=[,<^8\ Y
MSL/_J(6\\0TFX$_ 2K.)?P=8A:;P>X")U)M\C'^_X :?Q3^3>H(OX.^/F,QO
MX0_[M/#?\KOLRX L?ET]GW<8?ZV.X>EP-R2=1\:B*&=YVP71^5]Y^6A<ZG2>
M"MD:SN5=@--]LOG>4*1]&?\ ^&>=CCN@'%1E<I4*#YC(I<IHY/?<4HD^?SV7
M)^K?3./NQ$^$+^3])OC+QYZG1OK_H]9!!;77.=>KDY4UG,.&6= PIU5+(V_@
MU*GZ\[2<P_*[*1^X,Z3CPXYQRT0SO7_RI@ONVY?Q3L""VFB.5\-)Y12.=>T>
M:#YGBGDCJ8']W2#)F\BQUIQ,(7, Q;NP4LY;Z3CO:UP#?OD_J@QAUSQE'^R<
MI5"R!UN]0!E;VO 7:0F;6;,B5\JN-V:G+.),TLC"5G P>8UW*S=4Q/R/6HV&
M&RPRC_QGXG9)3U$Y]Y:XN.1BE9\HI-P^9[EP6:4R\3;VA;@JY*O@*OGZ6A)Z
MBO;8YA=RA;5#_U126L$4O1&OKEK"G2M\1^BIY.-_D\*S6=A>\NO$=$$O=7>(
M 6VCUZ^-0'8QC]FNAN]RW/6+1$/4.\(/0A5M-\<#I]!%%2U8&2,[ZXB@C!F1
M< 9EL<)"?! E.W7M<O@0![/= $_EWM*M$5KQEN!?\+F\2+8M-HN777Y=,)='
MS)J'NO+D"=%(!F]7\&-8R7ON^0-ZP+>QW0I%\0NUWM@901H^5W 2O<2*1"^A
M3N43D$=(Y78.,@ONCQ^#M\ 3@VN@3BC1\RZT$E3;5H(MP$E-F>"43([EH7])
MMS'KD-OBEV51\$?1ELP+L .^-WX;Q,$<@B/!YZC,<S?(A"_; N R:)SZ!/I-
M5RO8B<[6C# ^((M5K-(6>*UB1J8O1)2JXQZ %\5_!D\#-^(*SSK@)7K+5@ZT
MP[/4D6AV#2CP1)BF^XQB&#3\7;H24FMY&;O!RZK5<95@A&QOT"[@N#C:4P0P
ML'9;,Q #OU:]1%ZW^*&GD#D-C^BOX=DUGTJ:H3^J>S-2P 1=?IP5<$(U/P@&
MTJ7#GA7 "J&+;0LP#FF7V.LGYG<#*S07BU:1TU672^"".XJG90^V3I*]J$R+
M7BRY1_@84"<Z1S[H9L;WTNY8G17L9.6)95I&^6&^\O]_1)\X3UU9F4,ZI*17
M_2A(EV/$EC255$XNBCHLUE-C XJ$!GJ*FQ:K9QJMYZ##G-6BQ^H;E";>4>4;
MJI T5S&%5I7?);.A[TB;+ EFE$5M$^U@*@(<<"[KG)M4T,CQM-Z$_,W=(UJA
M2N-LYSY3<#@U1#M9*^=*WD?)9>Z\+27BF=RL3<^%$=R]_D\P'L_6#4 /\YJM
MF<@<OH<P5;D0F<!UD$?"S80R*1OVR/,5#T/]J4^$[Z"UFU \"CSAWRTP@5O=
MZ,A7X*5U$UP \/!NQ6_B#@XDBQ>U5YV4"(7<W";1$=PSM5 X7?!PD_]_%U'K
M#Z+G__.W"B0.GFA]$OH?V(#;R"/5+IQ94I524K59?$)>DVLG_"8%-[_ H\6Y
MD3<$0\)P_U34"K-RRX='D8?6CZ <R(+ME@U6\]@UTO&&=97WQ!Y:=,>H,$NE
MW(QBO?+J2([ 3E+OOQAI$#:[;8=#!4+K'] XN HKED74U[ C)-J:@4J^:*_)
M<T<Z?D>_?;,7YJS&(D/1=GF_WUMDK?B:6QST!'MN,Q<<1)8"H76S\C,H'RWK
M"@^46%=#):LSS^@/ETD3732W*A=LU"C'"&=\ =D!<J?S1+&6=GOU-;R2E<\?
MK1DM^T%1F-Y7&(OW&3VK0C)INGS"KX07:C[IYL92A8ARWY<L!>@SG*U%%4SR
MFG58-F<>W\?B2<XCOZV&*2G%?OH3U/B,S]H)M!T)0I4S7;G121['>.";(<E@
MQ3MO$.:Q'ZV1"$A<,Z_&-,PRD:.,?[#^+<)TQ>S8#(*ZCSV<L$CQCN,5>E?F
MQ#GEZR].X58Y)^ ,GON:*V@3[Q=O4C4-/$3JU]\%\<+7VD P=-M-E13X&#\H
MOP[L"=5)'0&%[Q)1"5#JG(FU XE6\Y /@#^7:^3AMTA>NK?XO$*&)@%;LZU8
M62=8&1\G>X.N""V0!"/VOE.%>GB=<XG@ Q1B%8'L ..Y\PP]\O/$$SI'67GA
M3+50<F[;.,68>%;<!YFG<%.HBUB""7PGX'?0$\Y,03K\PXH /X'6<_89ENNT
M1+VV1M-6,*9ZK8I//ZYPE _'C4JYTC4AKT3_B P^U_!4?($S@(ZAH)4*1J ?
M'(Y^R&)/3-,Z5[<4:%5DO22=+V_1K(X#)1\5^T-.B$JE!3Y'L/NB1<X@RA4<
ML>J!O6$+Y45[8M[3TH3F!X6!V3D-I.+ZS2MK+I:MV+2[^E7%_L JW76"PG._
MJI8LL3\HVT2[OFJ-\#,KET)M\RZS*IW;M*M\--NEWKJR,N67I900MJG=")-"
M RE:)J72\Y8R@;;/8:IT#C-V50T^QIE(6="RES2_I+8QBCP[ZWKM,&592K_I
M!S5E$\5@1>L.S-:X,MP]7RB6,,\[A(H_LDVK9V#WN3QR5W, XZ\2N_K+S*"L
MM)I8YNZ4+=4-K(1-+KJ;[,F!?JJ?[/]YOI)/XNQU((A^< ^M+L)F\OXF!S=^
MY'.*#];I^47;WU@6\A.2_S&2^'Z1K[0C_)# ^<K7_"S/E[(Y?-1!)[+F[U\]
M+$CE_R+=:_@F6%%<65N'HML;S<N1"\F-AO^Z(;)7<QC>%O!9\0O:Y?E2NA9:
MY3 D+ 9EJS^A>\%))%6#KT1>[%8S)J9N+S4EBY8E%^L[\)9(FOHKYA=P71&"
M7O=\+Z$AL,,E_#CLN,8%#03OD=+KC:IC1=]J I1KMGM6]\JMDSWT$R0?(\/4
MFT47 MKEG7BOYR/Q0T&]PQL\"%&L24>N0D:24[V[X4K1#\M)W;[M;M6VFDG)
MRW0YBN^1_JH6V:R (?E$L9?G1W$63G6<A-U =Z_A("CL5CI]X&I>:?;WGJ<%
M[:GW.G87SX[I:[$N-84 ]4X56WV%IJ>$.-= '85<9K-/<9WV]XHZ<28KI\30
M_ZXT./MJ]Z6R,ZG_:R^I$,:,-O57,4+,M3U$D^_N:@KY7U=4^QN-8&LOES+M
M5_J(W-D?2C+Z$,+A;'57#G%/:E?K.])8C+'1F^(;HJH)H![R/6-<0&>Y[E*?
M8";90K(\]I:5.X5.W/P2ZYXO]&G9"1UC=#@UNX7&6!)35G^2<2>$9K['O.A[
M3G^)]<#UEJJ6,\?VK#23F['*#H_A=10_[V[@KL]>UB[FAJ2Z-#MP-\=XU8%<
M>DB^J8U[U/>\KH_GZOI=J>>UVLV4T/@^JU!,RC]=O+/+".=ECVMC05]2%S4M
M@-@Q*VJKP)\A"=6UH-[WLK8/C'5;K.@#_[ +$?<!CU?]+7@%'"Z6=9X69F2]
M;:W!>:ES&MVQTIAY-6)!>,A&XU'4P_>JYC[BX>8K?P:'V9'$TZ'<U?,%9:"Z
MN++33;XTZW7+&^FIU-\:J)*E,;,MIT7A(>N,TW#0]YQFO>"BV_]1=([M<2T,
M%ZY.VU/;C>TT5F/;3L:V9\_V'D\FMJHDM=M3IK;MIK9[:IWW>7_#?:VUKOO3
MBJW+UH6XMIL18JU]BGXX'LLJ6[.O>5G5EP%*X\W"V<MNU!O3)_>X6G_'1K8S
M+43([:85)B??C-JS^GNN:\PSM/_82W3K\;.'SK,FD>YO3N-D4?<OR>6I&34U
MAP0=[$SU8=%AWG1&JW2LX'W^$KE$_#'FN<I.'ND[5N.E'G'@+3V1BVR\S#S!
M3^P=S?$0CK$LX:&B,ZJ]@D>23OH&,4V&Y-V0C5. ,86*SZK-/@>!*$W8?G?*
M#<6H#0YTO6)'=PMKCI)G3N1TJ8*5=7P_]13:9N%3]:^\J9(CP-?H,_)GX%0?
M3$V'\@?9I$UHZ3H.E4 G=;YD!"-GC'=9CY!611YW-:*F;A#4(\S<+/$RI#0Z
M7?8-R?=)4_4C&7O.5]TTUZQY2CYI*NT0T[J,S@8%DZ'_)/?E9.O.4?;R&=H]
M.5VB?J)G\4V9&R[TF:?\@RW8C556-:]=O9I$;6QKCZ>FU//T10S/V@B9.]NO
M9C+Y.8]F>I;]1WC&L'VQ3*K4E7M_5 KP_;N4%=Z] ZLV5,=V;6C+I/BUFW1<
MNF-+OC2?%=MH3P[A-M0^RP:%,RR-BQTE#XSCO2\HOFC]=FXN3U@E6/F^BMQ7
MTVHAYR]E:=?0,KJ=)5U,3=LS4COG2=.2[#$"O,X[ZHZ$859X;U<TZO@[ \KZ
M-K]<*:H\M'Y\RT_2AI5WM-.H?<NMDHF,&SWQ)#M.7MNKK"6"$8V4J ;QGYI:
M[R6*.+UR.RS<0*KJ7R%VH5);9DEZ&''$<=D<]GCQ9_D*[JWJ3\I4P=$L?_54
M\8W(G9I9\E O;TBDGKUM#G\Z1]W7+#C'$S7/%<D$>?B09([(5VPK/2^961TA
M7R6;D=FK7*E8%%F@?J$R>8T"84WPE@[.?IE@^2_>@)S1N%X@4Q1@)E&B,DGX
M2^*I2JI*DX6JRS(>*K@ $G%;=5]SU/.^9@ *WCR!M1$.7,;C_ ,G-;CQ!N ,
M-$G0 ><*[HDVP?1*NN0EK,\(EV?"ZR.DRD_P/<\#P%-DQL8NQDO#@Z43V1,,
M\^HN<>?J(^'_^!ZZ//Z0L%HKJ*@3'R?:TY?*"O'=$;.5+MAYSWX@!CVY04B'
M&Y#>E\PM=?=K][(OULZ!OG&_UX3SW@M2S.7E5T6GC'#Z7"FJ[P@_IE!JZSQK
MU5OPW/48K:3S>^]P1F<[8KW..M1R'++E?&]\S_/BD^MGE8<(_U@#T]9)3IG#
MP_7R1X;IGAIU!+%JW06JJB^F)YM^8.DSZT+FZYXPD,5QZR!Q4=[2%EW9,F%)
MPY*T.$F4M3T\2\XV%7AR53>UY]954X;61W=?H+NL^E-C9:;UY6DNL8DE$LXW
MWHC.IK) P?&6E:F/Q(?JF\/'R<=88CVK56;=X54&I9$TNO-_BTB=;_ZF>L<8
M"3Q4'V)=Y$0# ]R5I7S-"D%ORA-P4'P@=!,\41[D#B%]:O>5'/E4MK;#5OZ'
MVVNZHWC.[U4_4-X3-K.K5*_%+25;@5G2+2E%&I+\36@9^%A%=Y? ZS7^ Z&2
MRY(W;;>E'V0+C%?D(^01JMN*A8I\%J+,4JI+AJOZ5=N3;P"VP%^ATS37-2IW
M%G0)FMMW2W09]&B%)%-!HX$AC0?/*=?+8&@<4R:_!^46>RJI4%]RE'H</#QD
M#_ 6YKB3H"GPW16-0D==5DN42*5]J/<7']7F*TS2^<0&1K.LE1A?)%$DXI*D
M/:H9V+40&6"/^;F7@FQ4M5S'/U[+; X1>EM]=<$BD^6PO$?\V1Q,/R U&OL+
M+\DS#=.3TI4Q.C D1"TACKKG:VYA3Y=MY*UO*V\B"^Q:"K5TH:[I+]EUT9_Z
M&OHDR:K:\86),IT%2WROJ#$^#AFK&M+;N&=IJ(3SLLG<*TL7-N[A9_<D$#L%
M.SK'R_Q$@:W=-+'X39-SP5[IX[H5B8V*$36C@^^J:,8@]S3-<&WPTGYNY*KN
MQCC>KKXWA+=@_M+#TA7"ENYBZF=Q?MO3@G)I<1,K<;'<7'LZ>(5JE.F7>S*P
M53>[ZSG24WVQ]C "4!ZA^Q""?D9\"UG-6D+A(T-<..\:ZB3 XMM01+PY<!<V
M6A[B\@T[H@[I_ $EL_9;+T-<S@MD/[2$]T/T+_10^!=Y  X5V^2%P/W2@GA'
MQ$.^-A!%AE2QKA/08QJ/CO<:%[&AID^CD=R']VK.R5R$/\!%<B;I)KA6L2VW
M'8I5S8K;"7U0UP5FP9<T/JX+D2?@S_;SZF @VJ)4KP<N0S6 O29#. =8HCE(
MFJ&)!L-R_]+\ @_$E8%7H;Q 9^@1]-G5"[&%!]HV*MOQNV90Y8SO!AM5FW&!
M8(HZ!?^[.@T8A@WD5 )/L8S8IYHGZ(> M]!LM-$U#):C[JW[%5D6H<FB>&FV
M:M8H"9.8'Z;R-"ZJ,JN^Z5]G7U)_T*V,-6JF:JL"#H(,_)=K//080UO^D\<V
MW3">D;]L# (^*,SUB3RS<G&M2^4;E8WE=W:)VLMT)C8.J#!8 U9H+N@\73,@
M'KZZA2<3=T\V!LD=.U8#A?*CK4/<+PI-T_5*JI)5?S1K2%5G'8AYK[YD5@3H
M-(6&^:[YT-]$?\MHZ:V^T8:#LL:E0^HK<K\>?ZY"_K CO.*+XE)+:)9%-:K!
M(V:UNL(Z.J 8^&H<="T%=VOE=6V&=]6K":5A*F6CPJAGTUM99W6W6<*R=ET>
MMR0C47M>P%Y<KBT6#_@](7[+(YWZB=/JN-K3NI.L*?@6G0\G1KY3.\"K8LW2
M>@DTI?\1NT5KTB\2)9(?BR<3(^4\OPOX196=TS7\L,;>^H(X(,K%UA%%X@.R
MJ_@KJ3TS$K?*L-),/$+^(3T=^ZU41^W&SJOG^?V#'0&>. _';H%W:MY@[U0B
M=#G6J_:1'L1RU#<8'&PLH"YI1V]IG-..H0<U0U%L="<XX->-7H$(9U=L$BRQ
M_$!S4 S9@\Y%FR5/D(>HCMZ";$6K2A8@S6A$&A]9BMI'A2%[T7%^3<A_R&?G
M)+0:N6=Q0^8:ZY#1\$?#9TDX?-C@2'L!=^D]BWEP@\XG]3V\01L:^11^3L3X
M29$,/-B9C)S&[,P(/*]> )=!_]4YBYNA*U8++0O:;CE8=!?:8WJ;2D OC+,C
M-\'^^C _*KQ%&^VL1'+P(-,/J*!]%G05BFM=()X$S6G:2;T ?FN85L2"QM92
M4N="&98UD7RHS_C2KQ .U/_M;()?$S:F=O#P$BW$ __IOB/J!HT=_5022&U=
M4#0!E#8:4ZZ!!VO?1H9 WI84OQ#HBL'LW 9W$T-$?WUWM5155C>.0N4QK6OI
M2=6G:\I8[GD7S+^Y]HDG3)V"A+ (8XBXV3M2_T2^V,&DVZA.Q]_4KF>6*/=:
ML]E:[O&:X=SUU8GFG?Q[>7035^2:B!B=),UAL_7WY"[>:;I-RM\.U[1=FMFX
M?\T^X4S%$XM%5,^=;BZ0_%W59;*7FG+O&][);1(=]"<4YT.?ZP94/=XYVBZ@
MTW$>L0K<CY',7Q0;%&--MY5&CJ]QGZJH\I-AJ=HUMT!?!XQ(.*(S Q]"=VEK
M-!^]\XD!:(IC(7X5CD6;3&+83YYK9,$2-F&H@#LJX_1Y\(:<-[I,^'@"H.7"
M'T/;B%K$P;L,/X-4.!IP.Z0#&3*&Z=;+!@SQN@S6 WVT=K!BMRY4.S%'K8TC
M2A+2"1:^/13!U^%SO"OQR9C$<1-F1(\C&88DZU^R('U5S3B64E=FWE\1K<TV
MQ63_)IB&@_$O\&7ZK- R[)WVGG<9)B:*'2]CX[!3\ U]3;.K]*!N;6,]:X2V
MOUY7?H5HJPW,[L:W6I[&6_#AIMY0.ZS*4.5=BK[5#7=\AZ[ 5\"(?GC7#"E=
MY]#^F+E$.[MU6KF<&-GX-#L;7U!W,+X8$]?TAXY$[YOJO/-1HY[A]!>:2Q2J
M CH8U>[\_6V+*&,I!UOL:2^*PYO^8EY+%]8?X0Q%;ZSE"68'0C5CQ9#["],:
M>93=&@-+G:.L;=O)6,)/:NEG':5D-=5SOA8];.#S(],7U04(ET37UWR0> 7"
MYI6R>QZSC6SE+?MI^B3-1,77E@?\![R.IG=".OE0PRO1^R)2W35)0]IEZU99
M6G2)I5;A%B@QT56.'I&&-"#?GJ]+ ?L46<UVLN_<AXVQ\A?D$?4%BAN%EVJ+
ME)?3R#6YJOO1T\SIP)C 4F.")MZC4)\!KK#?H^7#T^4#C2O!8=R8^IL@F42O
M_0YN+8RPC@%_I_YGF0$5+SYK\H6.!$8:DN H#X9. )^P_T-L1LKDTQM@_!=G
M5]T^_'SU"^LC7%-PU/(%GY+:89Z$K5F\W.B+%09ZZFG8> ^Y=@-ZP"&(F($J
M95WU>M,I3GSM%=/X:F7-;^.$@E++#/VSU"A3L.[P8J:!J5T3Z*E;0G1Y&+5_
MXY@#%6_$.++(NHOU/,[86O<ZM^KHFC2KK,#&G&V!4O\V"DV-B[WU.PS_!([4
MC=:]\&@F,.UX!R/NA@=)/]:EMEYC'[3VMHRM^FS9U=B9?].TJ^YZRF7##:O#
MXO%Z9S,2\$6K-[SVZ"+FZO(<!K#+^&U^W')AU2:J:DD?&2TMZ[Y&HV8][;C%
MI"1DM"[G&,(N-L7R'_I^KCLI9KN<KTF7Q]F.,7Y4%_!6+_U%'Z0NZ UD/BR=
MW)7#<<SZISV!1R0$MTP0C@N[T;!7?-!O06VYK-?5UOQ3N<_6:#BD&<'S7Q+.
MLU(ZNG6"A27K.M8)#V55M:X6F^+_-.FDHK"C]=ERS,_?.D&YV95L.@_,L/VJ
MWP6:N=M[0*D?96KG#5E8R<+VJ?*,S%\M#@IE_+;&N<I]8<OKAJL=_<(L0\!2
MUQ;C43#6KEAW%7K)#>T>ICY,[N[@ 6G%ZULW F<RK4VG-3GQBOK+FK=AL/46
MV.\79KX*<5P'#4-PHMUJW73$@7.J\QJ:3HYJST#SBDM:&M'PS)C&+>B,^."Z
M(\BO,%;-9>277Z3I%3K6=<@P"YUO]T8K0OTX_(X7^C[2OVT,O5?Q[.8U.EGF
M\(:3VMZX[[5/B,MA234CB;E^R29[7.#ZYW^FO-_>F7B!S>2X=GC4["=M:5UG
M.5QTK>F]F9UQK&&B\5[<\5IO0U783$NE[I5?B%&KK76ST=TE/.WS"!"[PG[7
MOKQQ"VEEJT-#:M'IIM*ZB(PM]:2:.W%'K7)S1YB'>;U1ZI=C^*1GN@7KA-HR
M>P7AC(LHZ]:>JII7"JV2DJ[GA/0]H@XF75SZ@7$ABMW=SYD;&-J^D-_CN;U)
M*<YT_%%[7)ZXL,5<H"ZDS%Q33SM8ZKO2@?$@9]0*)MLO:7!)!7=CE+AKG( 2
M6-U:*T[W_-7P4U;FQ+*RE"MLO$VS@&_DP55#7*>2*_TRWM[LH\L."%1)EIZ=
M(DY498=28@CDMTR77?7RK^]6QC@=K?%2W[399!P!2LFBE?/$1270BKT2:39[
MZ4SIZJ3\;D?YWU$1;3\4C8'\INVJ**_BNFI@N/-4RTS-4UL[PTSH*-FQOU&I
M*@E='JNRSW;O7:ZZG#2]<Y>Z.<JYM1^  WF-D$;OI:A-!GN<<\V.T"E;1)\.
MOR/=[:N$&DO&+9L$G<H>W2.&WB1^ZK#"4Z(FMFCAM$!Y QON\VJQYB*3G(VF
M/ 2W/:];@;PGK5C!((#BETMG$K%9[[OE^,7$^^W->';DS^96[$&@O-Z"F;RV
MU<!8HO,NXW)LM-T4W1ST%$FQ?)7)H_C&DFPCFO6D:Y5!E7BM[8@^+?)MTQF=
M;R"K[KK6PVNOY3:QV/F^<2I>;)>@784AI-+E<VK[BB_W;K0:LAYV_F=YD'BY
M;;9Y6.2_3?;&P$!U78B>\#IER=&^<?YL6$*P[03:+'SJCE+*CK(7 U_I554E
MK9[,+^1=VG,<*WVBY \_G,4D#Q--Y-[.3I).%*JC[BC*I2QO,3!.^6B[I)I#
M+^B'*33FKN;[]'C.;&(=RX8G%__D3A7<)MD*O,7E635BE?1G5*5\NN*^=Y)Z
M$N"U=74%)NQ;<:YZEWAXDYAR55*!%]%?28^*+K/GRR.K/7F XD3F)=$X%2_R
MF?0-$.-MK_($"S<_+GVA/K9\;F41X-EPEK0,:$&_4U]IQ@B7,\LTUJI@SA?0
M,=-&< P\&JF6O(!P[V%**ER^*;9X+7%D:5MY(I%03ZK:BQ]$EE!\\1A!,_T,
M=K*RB-V'T3(@_GKT3^1<R5BTQ^NQ8AL:LN%)X67KZB7EI74U*751E2[F:W 3
M:9^IDK^,AAF>5W2S$+TF_1-O4#<^XJ@XE3!XG5'88H_6GRO(;F/T5I:XMMC6
MYI=?:=P![:DVU,?S[E+YULOE/YGUENIT/?>#\5:$5K1*'^BU2[Z<*%_W,]]^
MZ;.>[N+Q/5NLG67'.K.AB57&UMN\2(JAB5_.9YRM^Y)NP\VIH49DB!R-75ZK
MY1':WG72O-0U$WKF%$7VW[!.+_VV3 H:*_?W#.<>)9]N;R^?R'!I=D@[Q3E<
MIX^8+-QN7N_5+7NN6[?F#F="V;JN']S?54$U"OX'<B\8*7Q+^Y>KE8QBY90M
MDT5S3Z>-5_0)96&7U/E2N<<&L$PU;'49XSVMJ?,N.Y"YP*+DTMA-FG)^!V\$
M9Z_PN0 H_2&AB2>EUL@G2X^%Z53C%,<]EFC* +^59VC.@J*.6,: \)5Y(GNB
M6 Z,XP*2_]A+!*-E;:731(<4"2E#T@VJ"6&VBA? 7QX-@ *,'@@AKU*^:=M,
M*U4M,UH9;]6IJDMLL_H-JY:7"RPI"1>F:,@IB1(QN"CTA/P%9.NA4Z^#W?OV
M5V,8NS6?4H8E&Z+I<[')RA;F7?0TLY=S'JTMEO'_H*3D/>(J-"@4DH]')WL
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M8"M?T4_IW_'FLC+UH=6'.(]UU?D!_(U:0](6T0YB6_@)Z1O\N2]3R<-G.+.
MKU@(KB=?K?-4YM*TUI]<@FE3HZ@.9Y\U'\G;P=MIFIZ4)'QF8(3KI3&Z0=]R
MQ1WM<&<-8,:C\:FDXZU=BKM4<_->[GC&HD9FU0G6N[KK>>7<-]:TI-'"8/.A
M\"S))F.H;YA"J%OJ; $"B#GP)0 L7"(;I1E>"K&Z-)LJ<ROJ0"G9.<<.BJ=/
MB5\%>[$]0C8C@7R-5S$JEP0ZE&#/E-70@#*MLD<Z7>5).L[<KYY%?5Y^%YC(
MG)C=IIG%28Y/!V/XJT.TD$4<[D5!ILIM'?K0074)6"/+H]>)/\I1UFC&)<4
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MF\XK6?Q(H1?6!&:K[26O/>2:CXI6AW'P"4 CS6#9L,+83$XC1UX]F_>=M[T
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M7-?=H%Z38C<$7X= 9@370^Y25<WG*Q(*O84=RH+T'>(C*G)<D&R,&@H]JY
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M%R0<4MDK_H^]NXIJ.UT;_M^]9S\C>USVS-X=:Z?33F?J[@+%W=W=7>)N)"%
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M6<(KJ*96,/5$-M>(94E-:%:-"55F,F%+3 VX8K-Q/OUIJ-JW$LCW; #5>W>
M>JO]]UKL;*_VN#J>&0MPGAH*">OKBLYH;$I U]2GT24U.>5<%4S E&$45!%9
M2Q 4U:'YY?7P2E$#A*<UY?-,#;!RLQ'!:JR?3X!E,; L!N&>7X!RUWJ@V[WM
MN7G?[MN=-OLO#;M9GYSR=1H;#0[MZ(M,JV^/1RD;4ZG\^BQ662VDBJ9!R0A*
MHAHII]="I"Q]CD10GRE1&S,D9F-V56-]'J_1,)\ VV(HW_T#$.]< =26_=^P
M<_/CUMW;;PP<V'%VVF/;X5DOAX')P)"FX?#4ZMY8A*@CN:"\*:.TL"&ODF!
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MX+?'&X3L]P 15FX@YH +2+!Q LFVCB#-\H4GT\X>Y-C;@3P'6P!UL $(QP,
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M*\ZE2BL1I94</)=51A46E3!E5(;E;2F4:O#T6BVVL%6+H[=K\-0.%9[:^=H
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MV+8*!JPV9P#[70G U2H2^-B&@"#' !#N[ MB7;U DKL'2/-T UE>+B#?VQG
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M-Y.XN=?CA9!KL3+8U1@UXDI4[?]A[[ZBFEK#ME%/FMA[[QV[B(@TI?=.()!
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M-L*JCGS!:(X>HIV+':1VQ3VE/HB[PW@8U\7JB[_@^B#AK-N#A#;WF8$0S1"
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MSQ/^V'2Y_+*Y2_QI/4C\9OV:.&4S3GR/F2".V7TDCF G_^K_9J"H+0 /[97
M-=D$WC:[@8M7 D^J.K \=8#N9P3D4 MPB;<!IPP[P.4[@$,9#K U3F#?[ QV
MIPE_,)TNOVV[B+]L[I-^6+\@?;%Y3?IH^Y[TUNX#Z27V(VG(8?*O@(QF<$8S
MT%47 %MK!?"--H&/]2[@.QX"+[(ZN+OI %-@#-00"R#%V@(AS1[P>8[@6(H'
MAQKG/]@FE]]VIXF_,9VD7Y@;Y!^V#RG?;$8H4[9O*.-V[RFOL!\H@XX3E">.
M'ZE_ Q0T ^'@+&"J+ #N\17@:[@1_"QW@2_V$/")ZL!FZ8 ;SQ@8099 B<8
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M*2'>X4G1ON+X9%% ;&ZP;TRYA!]](M0[^E*H=TQ_*"_Z>0@_<D#L$S$8_#?
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MP&89/5"0U8(#<NJ@/.LHJ,L?!BUY1="??0!,YNP#RSF[ 3-7 1SG[@"7>=N
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M@$6[%07MG)XH7[3K!2O.AC"U!;\C=)9_#C=9]UYBLW4T$+]GR(^F])3'5G_
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MS?;N**>#ET)I:NU!'CJG_?G&)WQ$E@W>89@:3JQ#A6>J4ZE[KDN16QDIG]5
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M*4H8*M,"4)O-&XTYW-&*B]3G10[HQF>'WOPV&"AHB>%"%AB[V!131(PQ6]0
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M&[H3+!,.]+7D0G]G?O3S%47?2"EDI2J@1X$*NM9HH%.+-CHLUT7[87UDKC5
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M%QJ2?#,U"M()2\UO[X,(&QK27=G1/( #36,XT3B#&XV*>=&@C@\-6OA1OT<
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M<:_G<N7='BM5=KJ/JVUWGU;?ZKY=8XO;$<U9M]\U-[H_UMK@_D%[O3MJK_-
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M)=J]D2VZW1$]!AWA*XW:PB9,6L+F3)>%'3);&O:[66/X,[.&\'G3A@@TJ8]
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M-G:M:\,<FM=F.#2N'R)N<*C_]9Q3[>I'+K4K7[F_-SY,[@#);R'Y520_=R]
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MUBD,!#0K+0_H5NGQ'U+K\ENKWN&W6;/-;[]6J]\%K6;_1UK+_#]J-@6@YM(
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ME9XW4%G,,JI?6%)'ZV(#S4>BJ)'F0C.-P[F /]E"MR[ROSW N*7 B!6 X2I
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M@X=$[H.7R?,B]X'/1>[]OXK=^^1B]]X%3K*?N]JY)K3Q>.1C%VF@=BFUL_N
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MXOXLBMT_09'[+T3^-T_Y<1X$</P5UYZ0:<7>!V,98BQ]C*7'50.=KOIH=;-
MLYL3&MV]4.\>A%IW"6K<XU'EGH9*CVQ4>!2BS*,"I9X-*/;L1)'7, J]5J'
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M+,-WD9E8C@/ICEW8?ZEF/DH92P%CRHU21F:T#J311DB-MD)RC!.28CR1$!.
M^)APQ,7&(38V%3&Q.8B.*T%47"TD\9V(C%^&B/BU"$_8C;"$4T)8PDTA-.%-
M/GXGA,7_1>3SG(SC,<DR?)H,D@Y23\H91P')X<\SXD1(C=="4KP^$A+,$9=@
MC]@$=T0G^B$J,122Q&A$)B4C(BD+X4F%"$NN1FAR&T*2AQ&<,H.@E)T(3#E)
M;B @Y3]\_!:!R7\25FM)<AQ-X)J8"$RR#.]3[ &1:KXNYOLY1,K7*<FL-Y,U
M$)NBB^A44TA2;1&9ZH+P-&^$I04C-$V"D/0$!*=+$92>CT!I)0*D+?"7#L!/
M.@U?Z7;X9!R'=\8CY#5X2[^!C_1/^*3+X4L.L/WU*< 8Z28-+,7+%?L_1,KG
MR6GT'.FLN:4JB,C005BF$4(RK1"<Y8B@+ \$9 7 /SL<?MEQ\,U.@T].+KQS
MRN"5TPC/G#YXY*R$>^Y6N.4>)=?@FOL*W'*^AEOV'W#/EL,]2XX]U)@AP]1I
M)[6T:"4DAZ2P)(_/ B2T2V&Y(@3E:2% I@\_F1E\\^W@G>\*KWP?>!:$P(,3
MQ[T@"6X%67 M+(9+81V<"WO@5#@!Q\)-<"@\#/O"*^1%\B4<"GZ#0SXK5[*-
M.BL5]X*19E))33:##.HFYK+_>=0OH.\HHO\O48-'Z1*XEQK!M<P*+F6.<"[S
M@%-9 !S+P^%0'@_[<BGLR@M@6U$-FXH.6%>,P:IB RPK#L"BXA+,RY^'1?EG
ML"C[%9:E\GD4WPLTIK@7C-11LY3D4C=-!L06TG?1M@:5TOM5T/M4B>%8HP7[
M6CW8U9K"ILX6UG4NL*KSAB47$XOZ*)C7)\.L/@>F]>4PJ6^!<?TPC.K7PK!^
M'PSJST.__AGHUWT"@]J?85@CGT=Q/=(@+6$KJ5)<!T2RJ)U$;4D9$$Q[Y%L#
MN-71_S;2?[6HPJQ-!Z9M!C!N-X=1NQT,V]V(+PS:P_Y__R.ZJKY^1QST.J30
M[2C"DHYZZ'3T0;MC%=D%K?8'H=E^"YIM[T&K]0=HM_X)[18Y)JG>0QI(&8VB
MC*0QFEA&$U8+^-' NM/0.]) 6G4")G3L^GWJ6#*P!#H#AL0"V@,.T!IPA^9
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MX)C>#H?T9;!/GX6=] %R'K;2V[!-_QAVZ3_#/DT^SUP\YP)U.DE=HN*J(.:
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M:>$\OW6:X[=!L_VW:9;_+9H1<! \J^F!O]7TH&\T/?@'<%P/.JUR^Y4L-9>
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M*2 NSI(='6[D)R _ _GYR"]#>@WRFW0R=JS CN78 <M&_B2B<P:>6*"%7%W
MM^9C_5Q:-8<6SO96T7X*/@#?:";Z#1Y@2MM-*G %R]_%X&RFVM.YMI8E8#7S
MQ<F*1(\''4G8G(F. G24HZ,&'4WH&*5YV#&'?IE-?,PB3F?R;#J?G*93>'4N
M$7,IUFW'4V9'T6/@'2*:]9)Q:GZG:C]3V;5,[QM8:M:!4\!R7B]E^5D<%J!%
M@1'H<J(G%CTIZ,A&1R&M+4='+2.T"3WMFNS7K4E^ YKH/T'C_6=H.&"AA@).
MUKC LS00N%EC@VY0?]!^]04=46_P,?6&? [^!H[K9G1N)1T[EREU3;15^UC
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M+8HNVPGN4U39L^!W//^+/*7'O7NB%J-S&I1DL,2J 8T"C:"&:^6@".26PGM
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M#:M72WB;FL.[U10^3@T14U0?,5]UMI-58SM7U;:MJK+O4J7]/E78GP4?@F_
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M"WPOBVL?"U\_OAC+1#9@BMUY5L/&8O  _3$PA>=+K9]^[2=;Z[^#[Y!!]GW
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M3QSUA;8)^QM]PWVS=RH(Q4X',J-!(JPU$]D%>+B,WC;W@30BNPW97<CN0=8
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ML0XEQ;J5$!NK^+@4D*6X^"+%QE<I)J%9GH1N12<.*RIQMMQ)*^5*.D_.I*O
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M(7\ZH3$7^8L)DY.]=UQ<1S!MTQ6ZFJM7>JLRYK22KP@MZPR,2\"%P)P#:O:
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M +%Q?O+$^<L='RAG8H@<B3;9DYRR)44I(BE>X4FI"DO.56ARJ4)2ZA6<TJ'
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MT:.;I5I4&U^-[&"ID)U4):I[Y.T!1H[K1<I)O0@YK1>NX/; 5=*N.PEX'I@
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MI&EM12I-6X%6VWK"J&O-M^E;\EWZEN,!?6-^1)\X$='=KO\7JK\-_X\,=,C
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M80=<K&FMY>H;D"QC L4P1]$T:QA#M0>Q%(?_=@$A9)"-&-Z= 22+Y@#UPH7
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MC7W+.!'WEGX^X8W+]817+@\3'C*?)O2PGB9>8S])O.CZ)/'\OP#!F$,0YB#
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MG,+J7T4HOA<A03]"WB"!7&&Q$!56"#M@O;#%<K\YR,XQ N5YNJ"Y0!,,%AT
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M2 )OSF((E%@(L1(+(!.C%*-Z1L!FLS"8[Q$! V4Q,%83!S-M"; R70S6=JO
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M=,'PI!X87#0 @UN&H/_2$/0^855_&('^+Z.?1F#TV12,/IB#\6L+,'EF.3.
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M+&L:[!$!RUTB@-\M"@XR8N"H+ $DO47@;+4"B([K@<#:"CB?76 =+@,6R?O
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M:_^+O78^%X<=O"Z-.7I<.N'H>>DQU^W\%Q>7L^CF=A0]W/>CI\=N]/K>C9D
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M9L@"0Q0$710#35H/551D%%&-D:6Q2*$^(XXFC"A:,<+HP!)$=Q8?^K.H-+(
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M*AJT+R]<Y5A:L,VIN."T4U'!(\>BPJ\.185H5UR(-L4%:%V<CY:3823 FU2
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M(Z(6I[:+F9_Z4<S\Q!MQTV,H97($98P/HZS1(92;;%</[<$"@"64WT_Y;1L
M:K=2_FZ M(.43Y4PX!0+W,[S ?<'47#X00GL?]0'NQ]MP/8G-["^$LA878EF
M+'Y.8YG]7,@V^:6>8W2UB\?PZC"/_J];>/6NG>?5^^4YK^Y/**#S PII7T9A
MK4LH,MD877_+Z/S-H_7OH/PZ6OO"O91//3SJ!'7PLP NEP!LKG# Y(8@&-^6
M J,[:F!PUQ#T[]F WCU7T+T? -H/HD'K03JC\;"847_8Q%+]HX^E\F@E2^G1
M/I;BXSLLQ0>?60KWD:UP#SGR=Y%GLA64/Y_R9U)^_7;*WT_K?PP@\@QU\ L
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MS#[N)[G=7)3?R46%'60[/=_JB/);)D&'B;E/Y%/G\Z/N&4CC"9*!MT%J\"3
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M>I.\P^J3\@ZK'LO;KT!%NQ%4LEN&RG9+OW6LEM: SL!:RA^F2C:'YMZQE/:
M>FCQ&H ,JFC1FP'"MHI"R%8E"![7A\!Q&_ ?=V5\QOU97N,1'/?Q1%[7\2Q^
MI_$20>YX@[#=>*>HS=8A,:OQC>*6X\?%+;<^$K?8_%72? RES3:BC-D&E)UL
MXG[D&.W_".7/I_Q9-/>I5,G*J(=F;P*(WP80LI,ZX#X><-LO :[[5<'E@!$X
M'; %QX/NX' PD+$[&,6R.93*LCJ4S[$X5,-C=JB#U^30 CZC0^OX#0\?X3<\
M])#/8/\70?U]**RW!T7T=J/H9%N[ 5;1^B^D_)X1@.91@'*JR3GC  E4#4/W
M GA1'^4>8X'Y:7XP/2,!)F=4P/BL 1B=M0&C<VY@>#X ],_'@-Z%=-"]4,)H
M7VAFM"[VLS0NKF*I7]K/4K]XCZ5V_B-;]2QR5,\@C\IIY)UL#>4OIOP^RI].
M:U])<\_= 9"XC^9_B.9_%,"!ZK+9.0"]2QQ0^UD0E*Z)@])OBJ#XFRXH7K<
MA1M.('_##^1_CP:YFQD@>ZL<9&ZU@_3M(9"ZLP4D[UX$R5MO0/)W9"1ND-^0
M-=D2RI]#^6UK_[D'E4=S3Z1YAQP#\#@%8$?9)I< M*\ *%,GE[G) ]*/1$'R
ML31(/%$!\2>Z(/JG.8@^Y8+(,Q\0>A8)@L\S0.!%)?"_G 5\KY8!SZL]P'EY
M#U@OOP#K.0+[Z;<&*+]C[3_WH*;LH?PC ,&4[4;9UI<!#'\&T*!LA5L DO<
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M#H^M>ML\#NAO]3BCWNSQI'K0XQWU!H_[!NL\)8.!8=1K/"7]1]'H:U++G_D
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M=VF<[](D/R-!N/,W&S=P+&[A?*3) 1T"LEGG6.H&4'<.=9VH.YZZUK< DSN
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M7OB$:G;[1ZK9;;^K9K=*JMDMDJY[\]\\SOYW@G7>VPQL:-&< P+:2'4KD+^
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MDP-B6V>= F*H[<OZNK"^$ZEK35WCYP#5BX#X*C7?).^2#XCF/,K'(WF)S[6
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M85)?&2;TM0KV?7W"^+YM@EW?:<%VQ;."[?)OA7&]DCBNFRR51-L1#M=RMEP
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M(=1..B[43+XN5$U^1ZB8_)-0/ED2RAXR:9A/N.0_SZ7EFCO]WFSZ#%=J\_N
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M&3P+WSV5]$66^"-@-V'Q)FQ:C2W+\,LBL*!HIL:*O312$J*ADC@-EJ:KOZQ
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M[ [*[J&\(5VH,5I@$;UA)5/:1BS8I7VV<R#';;M3=C.XS.FE,WLPSN <8/;
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MMZ6:I[68)^>:I\9TRYR2^8'!:6XK_1\4T#=TUJ]01N:VTD]1GQ_3<!_28/_
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M:328NL,^1Z)6(]"RPV#!;K!R-VA^*#T5YH+=Q,B#S$2^41=3OQ__H0B8"\S
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M#++!(Q/1^BY$\&EXMT.X5^8T6H@_5T>4]^ YB&AQ'H*?2O&MV)R.TI\G8Y1
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MZCRA!_7L ]I6D&N"][HP:W745QERY4;^1>9$H6.#\@#$RL)\R&Q)##)P-A:
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ML(!4!+ZD+(@B)4$**0B*25YPF.0$]X'?2$X-XS;*G@UYX^$&NR$\<0'L@9X
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MH]M5? ]>_1!$+0C-7=%T??"WARW?AP8[$*]!4N\MRO\H0*ZT"V2B>3&1X[L
MSX?PO(0P'X))?AQX3% 237R3-45)U\E\T1.^/ GM,8D_"G@ET43TC0E%XGU!
M[X2GM0R!^?;EZW#ZB/:"F0'Z>*_AQ-?_0#[D2@IS/V*9H\7.#7=R)HD='F$^
M!#J9#<=C+G@LX),0VF0AC&DA*K, Q.>C/>;!0YP+CVGV'M')M3-^%:Y%&=!/
M?$(/N'03[P/3A/I4(5=^F-")^E-F9_ZE,Q<B7(LB=CRY$RC,3\#9\ 6/ ('H
M23JK8&#^$.#/'Y&$+ZQ<C7L01'LCDO!Z@N\Q<H4\1]371KP/BZ_!445]Y;A<
MGO>9*I;)UZ(L_*LL$N5">&XB4.R(=^Z3B8:-Q(#'9MC&)F/1X^,VP#;7(>9>
MAR]%(GI86T$4_A71ZM_)%?6UP\<6J+,NJ*J-AWRN7YYGFB^6Z4U_KD/I7!,2
M*79$T>7_R(5T[I'A>SAVP4:RT6?YAF'^])HL*'DW*I:& G>N)TK!F+T=0?O6
M5^2 .G?G^Z!09P'T+#]7[-RNH#_S(+QN?/%UYZFMG7+^6'M"?^9!_KI.HPX\
MFM!GFS#9-*"3U:&R-5!J)916@?8HKR<J_H%ZPJY,H"(--)4BK_-*L5YY/6/I
MSY-*_IX'X0OS__HDW\Z30_A:$)B;,"\AS(%(BYX:<PUM<AE&=V&\Z.F]I[80
MM:. M@ZR@&R=)?S)3.C[O,Y\?0]?A\)_^.7!5ZY8)@\&^:8 'I1V[K_ALOC)
M))UK0?BB@<X<R+<D.BGU&? +^LM+M,E/Z*O/87!/(?3Q6@3XV;BOY?^3?_@-
ML<0;4J8/PC48^F+/UTZ\%F2P,#+ZA$[R <;Z%M'(:QCJ*_COOT"!/R'R?(YH
M] GBJA_06-^A<>Y2'2*KBW05I;:1:.]+KCCWT7DRINBI**(]&$_$> X>OX+'
M.\0S;^$-OX;'_!(>_#/X[8\0T3P C[N(Y&ZBLUY#I[D,X[T XST''F? XR0B
M[G9$Y*V0= C&T41'J9Y^%#Z598]8-M__L5&<@WA)HNU#]^C/!Q+SIZ3<)#FZ
M@ECB"N*(JXAE.N"[GT0T<0P\CD ?AS!@-6'@:,! 58>XK@:#136,N1)1?3D,
MJA1&7 3CS4>M<W%'-MV Z7X2UIN??1$ISD'P9P_S VYY[H.O03@M;N9&H9E)
MT'[$=Y5HDRK$_56(M\L0N12!1QXFC#T8M+,1\?%(=C<&DG0,7CLQ<(GVHJR$
MK-7HJAM1WS1TVU*\:H?LE\+\!\]]\/T?_,S;%0 W(Y[*:Q:;..]>&>)ND$JR
MT)L*H(%R]=$]S"D)/.+!(P[VL4FXFM\-^AR%H6(\RI\*:YB#X6,)ZNB'.JY!
MRR10$!@'H#7\Z;YPWPG/>_ <Q$)Q'J)5;.Y<]@[Z<PT&7Y:V%KJ(( 7AZ9P1
MB#'#$16%@D<PVB40,=4J1'_\A$Y?\0F=*Q")>V,"\<*@NA3_]\1=B] F"Z&A
M!6BA^;"6>; P_BQHO@>$YR'X.10U]+][0$+%0]-*\?"XC*11GA(@ +0!0Y1M
MCK*M4:X=RG6$1!?4?C#*'@$+'0_KF(9_\R%C!:PV'!:30!Z0,A%6- %6/YY$
M^S\ZSZ H$,N/$LOF4P&?%OB4Q(?K&=#%=-CG-+3)--C&=-)!V8;@;XZRK5"V
M+<IU0+DNT,)@E#T2Y4[ E#X3KSR%6:+A%(.I?C=:;3^F_:^%^S^&B'LZ_YLF
MKC^?"I:*9?/I@D]7_.<*_K/%:.AB-&)N=[2).WB,!H]19 09YBC?"N7;HGP'
ME.>"<H? 6D?#4B93?VC>%:WD@E;M!XOJ"]OL*SSMYK7P7")G\:@3+]8_KS_/
M?TP2R^4_UW!7A;L.@T@2D*.!&#,&DAJ@ 1FZD&&$\LU1OA7*LA-F'YQPU0&L
M[*&9/M!%;^&9JB'X-![( ]L6X*EP!9RM>/3C.N YH 5P0:9(BEPBGOL8B-?<
M=>*N&V8\E"X#*  JD"$ -"%'#W*,(<,"9=F@S-[4$VSXRA ;:,P:&K5"RW9'
M*W>#I5L*GT%T '??$XZ^_(RD;L2$2T&785J9B2%]/-RQX?)PV>1%KJH]KO6"
M2V('3K8DA?+E4+X2H JH0XXVY.A#C@GD=,._GBC7 >7WAW9&8$3Q(%-8K G:
MPQ@69X3^88@1QQ"C*G]6%M\9:00$0L8B>=$:&'>>?P'Z O: +:[9P'7OCL^[
MR4F2I;0L64HJD(6$,N2H08X&Y.A CB'DF$&.%<KLC7?]T(N'@MTX:&H66LT;
M=T6 <3)0@EY^'/A)F)7G9U?YHOQYD#=16;1<F[OH#H"="L][(-; =7/ 5$F"
M3!1ER%A>GHQEE<A(1H6,I 5D**U%^M)Z@ GI25N2KK0MZ4@[D;;T(-*2'DV:
M4M-)0VHIJ4NM)H%D(@DD"H1G1*MAAE"CS\)5DLLA?Y8*/_<$;C;"E+Y ;\ &
MZ(9K9H Q8*@B0?HJTJ2G+$=Z2@JDJZ ,J)*.@@9I*^B0EH(A:2I ,PHV@#VI
MPQD6*(PB-86II*K@22H*(:0L'T]*\GM)4:Z)%&5ODZ+,&U*49K04\J=!ACL/
M3_C:%W51V,9S+^: ,6  /GIJ$J2C*DW:JG*DI:) FBI*I*FL0AK* E)7UB*!
MLCY@2FK*UJ2JTH=45/J3LLHH4E*90@HJBTE>)8AD5>)(1F4/22O7DY3R59)4
M_H4DE9CPY\C)D#,"<ETU$&< -H"E!L^[H/Z 'J M0-POD"$-@1RIJRF00$V1
M!*K*I*JJ2JIJ&J2BIDO* F.@&RD*[$A!T(_D!<-(5N!!,H(%)"4(( D!G$$!
M8EXU^'"J<'94X;&H8LZ _(F0YP8WIY\X!V0%F..]$:"/SW0 +74ITE"7)75U
M>1((%$E5H$0JZDJDK*Y"2AKJI*BA30H:!B2O84ZRFCU(1M.)I#2'D*0FW[ /
M)U43(X F9B(-^$X:X*#^-? :8#0;Y8^%S,%\'1#"9EN@&\__  :XK@MH:4J0
MIH8TJ6O(D4!#@50!%4!)4Y$4M%1(3EN-9'4T25I'CZ1T3$E2!SZ;KCV 8$&7
M'R6)T4\7,Y#.!@ .L#8X:'^#@M^"%Q/N2W.'W %P?>W%.2 +<?Y''] !%TTM
MZ$!3E@2:<J0&J&C)D9*V/"GH*)"LGC))&:B2A $:S$!'E+#@"R8,$3P:(B@U
M1,!@A#C/<#D 9]403JH!'&!]>$MZ[\$-<R>^-@)R7?C^*P.T V"F_V?^1UL'
M.M"6(75M:5(#5'2D24E7AA3T94G60)XDC3"(F,"PS="H9IJB+YLAGC#O*<[%
M# <0*)EY ?!C3=,!> LFX& ,3Y(_U5M?M![)V4BT!ZL;8(+W!N"B"QY:NI*D
M 0CT)$A%7X*4#"1)WDB*9(RE2=(4 ZDY!AA+=/#N,&XKZ,**)_1,1!MYK.'+
M6V/6L4*L:;48P*C<'5Y*M_WX#CQ'"WC3YHS&\/5(^(J#>!V0!6 ,'OK@H0,>
M,#,2X+4*KBGA7GG<)XUJ2EAB0NF.0=X:/'I@,+53%@TLO35%"N6+:GHC@.X-
MF^B-&;@7/U0@&/<A6+%% -3S^A]YF)%FZ)/BO6!6@!G>&X&''N1I 0*\5H5<
M)7PFAV*E$,)BDL#W 3M,=+VE1!.+$]JD+U_<!UWT0R/V,Q4=<M,/070_OK$!
MWDA?!*?.\-0<$8@YP(NT_R!<#S-4O!;(MIMH'QC/ 1F"APZ@CM>JN*8(N;((
MU231Q)@D\3WA1"J:5/GDVI]/M. Q1%&TT7(8WW3)-QYV%QT!S(]>Y9L+AL N
M!Z-_#H+G-  >=/]W4 !B?Y1M#_3@^[#P%5/(U ,?C>ZB_(\BY,IPN?;B2?R/
M' R \%&8EX#9T2BTS6CP& <>$U5%!V!-,!5MNN*/0QHW 8,  MDQ_#&D&"-&
M'45G>"7<$]1/O ['NH=H+YBA> V0*N0J0JZTD[BN \0.C1O][WJ4\?27M2$2
M(B> GU,R#_UD'C]!MKOH$>6S\859&*MFP&.:CF!Y*C^Y]JGPQ%HG>U$:CZ_#
M,8%<G3Y\#QCDH[Y2 \3.U'"QS+_F7Z:2:"T*=[[^OD]F.7CX*HN.C/>%0?FB
M<!]48#F^Y(VQR@LVX8D =M$=X5-['%!/.S29!=^'Q=?@]!?MOY(<3J*\3V?^
MI7--",^]\'4H?\^%=*X+X6M"A'D0\(B%C<:BKVY XZY#X5&H1"3:(P+>6QB\
M^9!31(%OR0'UM4+[&J%]-:!G)9BPY'BQ8SM3+'.Q6)Z/6-;?SR;I?)(P_V'V
M?TXU!8\<V$8V[#,##;X+ G; :TX-@3./L2H)[1'_(]G"KLSX/BC4607M*CE=
M+/>O>9 0L3PNB^=<N"/,-^3S]1F=:T(Z\R#\A^K.<SMX\-(D)SH7I &=K ZZ
MV \A%:A,&0HI01\MN$*6L"L]?@[-=/&IP'R!M[]8IU%BF0EB>9TGI^:1:&W&
M7_,@/%CK7 O"@S>>E^!!+#^CXQ;ZRE=HDZLP_(NH\#D(.HG"VT&Z[8AP.E''
M);EEXCIS)W>]N*X\#\*#S[WBNG6>#2)\0C#]N1:D\^14OA^&!]"=.1"^D(%O
M;! F-M FO\(^?T;C/T=#_PAAWT/ ?4[^?_^3D)*6D9574%124553U]#4TM'5
M,S T,C8U,[?HUMW*ID=/VUZ]^]@[.CGW<W'M/W#0X"%NPX:/'.4^>NRX\1,]
M)DV>.FWZC%FSY\R;OV#A8L\E2Y=Y+_=9Z>NW*B P*"1T=7C$FK51T>LVQ,1N
MW!RW)3XQ:>OVY)34G6GINS(RLW+VY.[-+R@L*BDMJ]A76;6_IO9 ?4/CP>9#
M+4=:C[:U'S]QZO29LQWG+URZ?.7J]1M???W-K=MW[]W_]L'#[Q\]_O')L^<O
M?GKYRZ^_O7[S]OV'CY\^LW_ZWY?Z_S]>?PE)7F,Y7F5EU%G *ZV-6NOS:IOP
M>ENBXM:\YG:\Z@ZH>U]>^0&\]D-1_1&\_F.@@ E< U.X"F9"!W.Y$A9Q+7A!
M#2NX'ORY(H*AB3"NBDCH8CU7QB:NC02H8QO7QPZND-W02#9721[723&44LZU
M4@VUU'&]-''%'(9FCG'5G.2Z.0?E7.3:N<;5<Q/ZN<,5]!TT] -7T5.NHY^A
MI%=<2^^XFG[_S/R]0QUXNTL)';"_&\/_S_O_Q_5%$A*2DE)2TM"!K)R<O+P"
M]*"DK*P"5:@)!.K0AJ86]*&C"XWH&T G4 JT K5 +U ,UXQ0-2+=_$TY0MU
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MVS"+&C;*J8B-&Y;#IDQ,_KQ@YN;WW@NC?UOE%?9KR(K@GR-\5_T4Y>_W8GW
MRN>Q@<N?;@Y>]C0A9.F3K:'_%JS12/+'"UH2YQ\92[>^<M"H94,L"MGP/KO8
MF ';V.21F]C\\9%L^930SZMF!GP*F>/W,6*>S_NH!<O?K5_H_6[C(J^W<8N7
MO$GP]'RS=<F_Q:L3:G3QEA(=>64L5\L<M0K9 --T-K1G G-WVL F#8A@\]R"
MF/<H/^8_9@4+&>?-PB=XL<B)2]AZ#T\6.VDQVSQY(4N8LI E_6N<[U"@UD?*
M$ON9B4(1L]=,9WV-MK!!W:+82-L0-M'!C\WN^_<GHJMH+&=+^R]EO@,]6=#@
M16SUD 5LS=#Y+,IM'EL_;"Z+'3:'Q0V?S>+_-5BFJ0S;9:O$TC%ZYPTQ8&6C
MK5CU%&>V?]XH5K5LUKOR@!4O"B/6/,Q>O^7VCLUIUY.VYE[:G%K2L2&]\G14
M9NW)-;D-[6&%S<="*PX?":IK;0ZH/=I5?.'PA<,7#E\X_%_/83<X[ :'?'"H
M<._.:B8[L]JYHUB-UZRWE?X^STO#([_+C4[\9M?&W5>V)Q1TQ&_?=SIV9^V)
M=;N;VM;FM+2&%QP]O+JBO2&H^OB!X/UM786(0T]%EM%7@Q4.-F"5X'!@DC.K
MG^/.ZI?.?E/KY_NT:G7T_<+(;3>R8W(N[(@K.YV46-N^.;GYZ(:TUI:HK./-
M:_)/-X25GZM:77EJ7UC5B:Z"99E*LPQPR'+68,6#]5DU.#1X.+.FV>ZLR7/.
MZX:5?D_J0M;?+8M(N;9W7=ZY7;&5)[9O:?HS*Y+141^5?VE?1/&EXC459XK6
M5)[J*O[@D.VLSDK 8?^H[JP)' [-<F<MB^?\UNSC_[@Q*.9.9=C.RT61A6>R
MUM<>V[GI<,O6A)--\2D=]7&9%^OBBJX4115=V1M=?BXWNN),5\&RP2$3''+
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M.'1?>WU ]?'JX .']X4T'NP*6+J1B$,Z..2!0_EP4U8SKA>KGSZ8U2_T^/W
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MP?:NG/)[5NBBUVGK_%YLCX]XO"4YYL&&],2[D5DIM\+S=GT56I)U/:@R]VI
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M)*JN)32RN>YO^1\'">I0<'@!5"G]NP?B>Z?>P0\73=5>#MI8/+CHX';EO$O
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M719+4IH2E).7("A.CQ55)(D2:\3"S/KHB.+&R(BZIC!^4WV8H*TL3-!5\#=
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MS'GL>"OH-FZ$>Q7W,'# 8=3_3P ;=6"BZQ<6NH[[M1<D2G$IB-770*+A=DC
M' (QX12(O'0A(L#B9VB8_9<@L>L'_Q3JI$\V[95W(?.%1T7 ,W)=T%-2:_ 3
MUPO\1^B#_+;C?R*NX&^']3F.\+J='G+^! 2@[>^'.K#WS?YW+T@,VED)9]9
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M<,1YIWLAK82'@8TN8\P&EZ<^TP&,?V3 Z]>[H!TS( QMO9BC"R#QU')(T=H
M:<:[(<7V^)<D%XT/8D_3-Y'^N!>AH6YC@5'TA\R$@+O>Z:$W*'G"JV[EHD%B
M8TP_L2NVS_6:N)UP([K9]79X'7&$5T5ZS*YP>^(W'>"#.GAODP/.]AD0L6<V
MQ*&M)U%>#AF:ZR';</>W+)OC4VE.FF^2*>;/8GP='X=Q/.X$"?R'6-'!@XRD
M\(M>F5$]U*+8\^3JN';WUH1S[OT)#:2K\=7N-Z/*R'?Y192'G$+*8_9T_.M
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MLF"]?!+LGQ<)1Y?Q0'DM$]2W>(+^+C<PWT\ >P4\N!ZS X\3&/!1LH; 4Y;
M/VT&(E432%(SAJPSAE"L80"U&GK0IJD+5[5TX-ZT7*M D/9F&:2F1P8IO"F'
MI/U8(!T/F^3#T>8.A$.+&7!R)1G4UA) 9Q,.3+9B +,##;O=:&3M16-G/QH<
M!XP@Z* !A!W2@YC#NI!\1!NRCVA!R5%-J#VF#NW'U:%G6CIK$:2F31K)'Y!"
M)",R2 PLEN;#>CE_V#[;"_;-)\+1)7@XM0(#FJLMP&"M"5BL-P2[#7K@O$D'
MW#=K@=<636!N50?.MC/ WZX*HATJD+CC-&3L5(;"G4I0M4L)ZJ:EMDD*R;^
M($DW$43X1E8J!)9(^\)J60ILFN$,N^9@X=!\"SBQR!A4E^B!]C)M,%JA 98K
MU0"[2@7PJT^!ZVHEH/RCB,;2"?!;<QR"UAZ%L+5'('K=84A:=PBRUA^"O&DI
MZ$#'OXP@X?<1A ,SI.BP4)H$RV1PL$;."K;,-(8]LW5!8:X&*,Y7!=4%RJ"U
M\"08+#H.IHN.@M7BPX!=<@CP2PZ"R]+]X+YT'W@MVPN^R_9 P+)=$+Q\)PA1
M1-,"+AMD +]+#O *,X%T= Y0E1> E^8RH)FL 9K]9O"D[ 0J^P"XAQ\!4N()
M<,U6!I<2%7"N40.G9G7 G]<$ASXML!_4!NP-7;"]K_?-YHG^)^L7^A^LWAA,
M6KXWF+#X/"W_SS@XH@Y.!V>"^Y$YX*FT &@:RX!AM 9\[#8#C;P+/%D'@2(X
M"N[QBD#*/ W$(C5PJ=( YR8M<.K0 7RO+N &],'NNL%W['W#+Y@G1E,V+XS?
M6K\Q>67UP>2YU1?CZ0!7=-W@A#H0#LP$JL(<H)]< +YGEH&?X1I@8;: +W$W
MT'T4P"OD!%!C3@,Y]0RXY6L!L5P77!OT@=!F"$X]QH#O-_V!&S+_8C=B\<'V
MB>4DYH752^M)ZW'K*:M1FZ_FTP'$7PX[Y8"X;P9X'9H-OL<7@+_:,@C07P.!
MUEO WP6]Q&A'@!ZD!%Z1:N"1I 7D;#UP*S$"8HTIN+:8 Z';\J?C)>LO#M<P
M4_;WL)/8)W8O,"_MG]J\Q3W&3-G>L_UB-1U 0M<NSJB#^]X90$?7U/['Y@-'
M=1EP==< SV(K<)SV@;_G46"R3P$C7 .\XO7 (\,8R 7FX%9A_8/8:/O=I</N
MJ_-%ARG\5<=)^WM.+[!CA#';"9?[F$FG8=L/#M?L/MM.Q[\.A!UR0-T] YC[
M9@/GZ'P(/KT40K77@,!L*X0X[(<@\G%@^ZD",U3G)SW&^)N7Q/(+-0?SV;T$
M]Y%8X_C!I87PWKF'..EXU?T%;H0R:C=.O6O[@G(=^X8X:/_>N0_W"3<=X(8Z
MN* .7FC?^*/-&WQD'@A.+84(K7\@TG@KA-OMAU#2R1]<AOI7=I#!)Z;0X@,M
M ?O6(]WQ#3G?]16IW/VE2X/',Z<.[Z?X <:HPP/?6]@GS,OVS[TOXEY1NATF
MB>V.'YRF ]S7RH KNJ:G;Y<'SNZ9($";-U)I"41K_ .QAELA&G/@N]!%\3/?
M2_,]EVWRABW 3/C$.#[S2B:-D;,\'Q&+&/>=JUAW'<\&#N-[.3?P=SC]N$>!
MW?@QWW;'Y]XM3J\H#<YO7:<#R*B#&[JF]]TF#SRT-R/0YHU17 QQ9U9#HOZ6
M'PE6!S[%.BJ]BZ3H3/"9YN,<+NXQ,X)TSUOL?8N2PAQRRV%?=BWE]+O4<2\2
MVH-[G2^'=#J-!)]U?LS^]8ZEQO6%5P7QC=MT  5=UY/1[F:AA*+G0X3V9OR)
M19"LM@I2=;=\3C4_\"X)I_Q2[*8W%D&SOL]C.]]DAU*O^$0Q+GDGL"Y0TP.[
MR/F\=K?*D'.D9OY98J^@D7A'4$V\SRTGC;**W9_1"]PG* 7D5[_E7P?J9ED(
M0'LS#.W-6/3>2#Z^$-)45G[+U-G\(=MT_ZMTK/)8HHO^B,@#<UW ) QPN=0+
M_N$^G;ZQ_JTT25"39W9(/;5$4$.I"Z\D=T:4DX<BBLCW0O,ICP)SJ&.^F1XO
M/:<#J*B#UR99X*"]*42OB7BT-U./+8"LTRL^YVEMG"PTVO<L!Z/\(-7)X$8\
M&=,?R2!T\P,\VH)"?9K84>Q:9@*WDI$>6NJ='U[D52G,]VR)S/7LC\KRNAV6
M[O6 F^K]A"6A/?>>#O#X]2X([3P>B@B])I+VS83,H_-_Y)U:]J%(<\-$F<'>
MT4)KI=M9>/W!9#>;GEAOPCDAB]H0RO.I"@H/* V(Y17Z2?BYOCD1F8S2J#1Z
MHRB%?B$ZF7%+F.@S$ASO\Y@=YS-.%_L\^RVH@S0PULM""$K,5CE(V3L3<H[,
M_5JDO/1MF<:Z9U7ZNQ^46BD.Y>'T^M*(-NT)'LZ-T;[4J@B.3TDH/R"/*^)E
M!B8*4OTSA$E^1:)X9FVTF'D^)I9U,RJ:=3=4Q'H4&,5ZZC,=X(DZ^*!S!!]M
M[SC4(7W/#,@_/.=3J=+BU]5GUHS5Z>V\4VEQ<K#(7O=\EHMU<PK%N3J.02T1
ML7UR(X(#,OA"GH07)X@/2A7&!.:+H@*J8B("VF(C.->CPP/O",("'W $@6.^
MT_&O Q.]/\-0CX0M:'OOEH>B0[,_5)Y<]+)>;?6C)MWM-VK-3O258G7:\IRM
MZC+<G<J2O2EY<7Z,#!&7G2P,XXD%,8*H4(DP/#A'Q.=5Q ;S6F-YP9=C@X-O
MA_%X#[@\WA,_%.;O *_5TO_N7XQ /9+0^R-GI]SWLH.SWM:>6/#LK,J*D5;M
MK5<:3(]W5=IJ-Q<Y6E;FN#D6IGF2,Y-\&<EQ@6QQ#)\7&242""*2A,%A62*.
MH#26+6B.]1?TQ[+#AL,#!/=Y ?PG+!2_W_&O _O7;\2@'BF;9"!_A^R7ROTS
M7C<=F_ND_?32X0[-+9?.&A]KK[71JBO#6Y04$/'9V51W21J#+DYF^T<F!'/Y
M8B&?&Q,O9(LR1,RHXAB?R(98>E1?K(]H.,(W<H3G&S'*F@[P1ATXJZ0A&CTG
MZ>AZIGB;S,?:O7(OSAV9]?""TL*A;O7-/>>,CIQMM-:LK,:9YY>Z.*054-SB
M<VBTR P6BY_*#0I*#@]E)8K#&?&I4=YQ!=$><74QE/B>&,^$X0A/\4BP5\RH
M_W0 #1V?A[:W&'7)6B\-Y5NDWS7MDGW:=5#^[L"1!0-]:AL[SAL<KFNU5"]N
ML#?-K':V3RQS)XJ*O;SX^4PF)X<3Z)<E"*:G1X=YI$F$[JEY4<34&I%KZGD1
M*7TXPDTRPG-/'/6?#J"C#J'+I"%Q)=J=:Z2^U6R0>M6^5?K1P"Z9&]<.S>L=
M4%U_ME?_8$6GN5IN*]98TNB(C:DEN0BJ/*A!Y3X,OY( ?UI12!"E("J4F)\4
M1LC+C7#,JQ(ZY'4*'0MNASGEW.<2,D99TP$^*Z4A'&WOE.524+Q2ZF/3/U+C
MO:NE[MY>(S5XZ\"<CJ'3:^L&=?<7]9F>3N_"&(C;\=;A+:Z.04T4=[\&NI=W
MK;\ON3J8[5H5&>18F1AL7Y'-QU94"C"5[0+;JCLA=F4/.?:%8\SI !9Z#$1H
M^V<N0:!J"?*F8R%R^\9<Y/*#-5+=(_MG-=]67EU^77M/]A5CQ81^:QUA+\Z<
MUTVP]SM/=O'N\":[M[&\7<[Q?/ M0A:V)2' YFPVQ^IL99!%2WN01>MMCF73
M*,NZ9IR!0O\=$(2.'[\0@8(%R&C3'&3HPFQDX#]SD*[1==+-CP_.KGRHO#)O
M1'.[Y+;AL:@;ENK!U^R,6%><K;T'W7#N_=X$PB4_-X>+/ _;BT)OJ[Y$AGE?
MCJ]I7R73Y&('T_C275^3"\]HIATO/4S;)WX+".9+0>H\Y$'%#.1JZTRD]^),
MI//N'*3QV0:9\O&#\_*>*J^2/%'?)GJLKQ#RT/R4_WVL%FW$R<C]GILEX8XW
MUN$.R\'V=K"SU>U(5[/;26[&MW/)AK>K*09WSE/T[]XC&PQ/N!E>F72=#HB>
M@SS/DT6NU<DC/>WR2.NO[S">SY<J>;U)+N>UPORD5XJKHB;4M@2_U-GG_\+L
M*.TY]A3YN;.ZZW.RCN,SNH'],[8)YEFHN>4SD:79\V0;D^>Y&,/G55B#%VU8
M_9=#=GHOGMOICK['3L<7B0QRHTP:Z6F419J[Y)"JH9E(X<=%4AE36^03I@[-
MCY@ZN8([I;J!.:6]W7/*>)_;!\QAP@>GXPX?W)7LINBG;:;8:E93(>KF4U&:
M)A^3M(T^9NL:?"S3T_O4K*_[J<] Y_-# ^U/[U$^_)8[N0C26RV--+7((.47
M99'<VS.0E!]+I<4_ML\0_-P_+^#GL:5T./T/&;0VN(#A5@>PVHD%A[TV0#I@
MB0:)&3 /FT#042,(/V8 XA-ZD'92!PH4M:%:21/.*6O @+(Z/#VE#N._I;\,
M09H;I)"R\U)(UE5I)&%L!B*"E3(AL$6>!7OF>,+AA4106H8']56VH+?6$LPV
MF('M)F-PVF( [MOT@+9=!U@[M='%J"9$[/[U[8<:9.Q5A<)]*E"][S2T[C\%
M@P>FHZ4:0<I:$23S(H+$W4:0\.]SI()@A;0/;) CPXY9SG!@GAT<7V@%*DM,
M0&NY 1BNU 7+55J 7:T.3FO4@+16!3S7G0;F.F4(6J\(81M.0NS&XY"ZZ1CD
M;3H*Y9N/0!-*\V\I;T#'[T80\1""A#Q"D "8)^4-2Z2)\(\L#C;+6\/N62:@
M,$<?3L[3 M4%9T![D0H8+E8&\R6*@%EZ G!+CP%AV1%P7ZX WLL/ FO%?G3R
MWP?"E7L@;N5N2%NU"PJG);L='7\ '?\>@C _(0@59DLYP4)I#"R3,86ULGKH
M.=&$/3-506&6$IR<?0)4YAP!C;F'0'?> 3">MP_,Y^\!F_F[P'[!#G!>L W<
M%FP%KX6;@;EP$P0MV@!AB]9#[+0 %GU>6^V5 VN%&8 [.@N<E.<!07,QN!BO
M (+]&G"F;@(\>SO@(G:#?>(^P&8?!-L2!<#4' &;LT?!NNL86 ^> *OA$V#Y
M\"18/%4$\PDE,'NK]-UT2OFSZ1?E*9,?RN]-X+?\E\,>.< <F@'X([. H#0/
M7#46 ]%H!1"Q:\&%L@F<_'< /FP/X.+W@WWF(; K/@*VU<< TWP<,)TGP:9?
M$:QO*H'5 V6P?'H*+%Z>^F$^>?J+V=3ICZ9?5-Z;_E"9-(53OP/L-LJ ->J
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M"*V$IF62T/D_@;<R":BZ7.!EP /^QKP08"4 @<["$. I#JR@E<!,E &__+7
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M=7@AVD@ XFR$(9XL#G$^TA 3NA:B4I0AO% #0FIT(;C=$-CK32!PDQD$;+4
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MT?U!GS/YP;B+RX.]KLX/+[@Z/WCFZGQ_SL7Y'CC]+[>Z$3H]BM#>;0AMV4=
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MGX5?W5NU#,VU"Z%[0_SHYH0 NC:S#)V>42 >G#84V+'9?N7D&$5IPT:&7N]
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M[H-@+MHD<#7@ A<K'G F\X$C0Q#LPY:!;8HH6!>*@56M.%BV2X!EOR18C*P
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M?6RM14U,FU5E=+]M6=28?4G43L>BJ)-.!5$/'8MB/EL5QX%I23P8EB: [F+
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MHM,61S21^E0D$-<@"N MYJV;F#O_4T"'"\4L.%<B"$=+96!?J1ZUO=B6N:G
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MV32_H,LB)W_9M,R\M3;I>3MMT_+.V*;E/YJ64?#)+*N0&&87$3VD,Q6)P;V
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M'$C8I0BQNPRHJ%W6M/!=,YG!N[P% G8&"_ONC.9XC2=QW<>S)%QVE$C/W-'
M=]S1*6>_8YF"W8X-"K8[#BK:[+BA8+/MC8+-5J)@,T;D;;;\TR$\%VQ?B&N
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ME5M!^R(W0OLLMX'V46X[[8/<!.V=W$G::[E?:"_D'M.>RK^G/9(GM(?RA/Y
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M9";SCP_=O??'-(ZG^-]"*?A/* NN! G#F6!9.!*B#_M"[*CQ( _&6& 0>V-
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M6'\1SKUE.>9?S,%Y:P&2-@"$;P;PW@HP8P<+',9Y8#^N!';CNF"[TP)L=CK
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M'JD.YW-2[2X/I>:Z?A)O<R-<Q&EU(Z)333[:?H7SOX.U?\3<=R84X&@(P,$
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MG8@P$IKM1 1GSR "WY'I?U[F?L7:9_'4?B0 <R=FT)V>%(RY<6"]AP(,>QK
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MN/]?B*;TM\83("J)-M]#%8<C\2:1)(T4D5HRCW1KUF+4ZP^J/2D/L9,Z^_$
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M<H^H9K&:@\SW"-N\GMK]RYB#/OK_%4#92OK_5<S!:OI_6D5WXK 6L!G0A]6
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M:"]9",620<A[]D':<PFRQ>^2GR!?)$+1K68KVSFPD#E8PNO#,J!A.><$S;U
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M'=B'QT,%X/H;24.7H0^T35.P1R>^:BYS47VICVI+@U1=&J6JTB15E&:JO*Q
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MQ.)&^B6D%:E"\I D[D>LE_P1$^+">VUPEM:3^*WW0>"6ZTG"UC/8KV>P7<_
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MTIE?C4\.\LW]E+ /B^W!D[NQ]I7K+PSYS#ZM:#2UIV2;"GW VAUY8B\_\"+
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M//1+IJA(;!3(][W1RWV:FQRGD?@,,,@/,+ -,, -,, ,,/ -T/$.$,@#!/<
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MZ&N5$GV/DF.>5E+,^US_K908BU5NI]ZGP3U,^KFKUG8ZZW(HRER#(A227^5
MB]*E>O0HCW%5492W\J/\E1<5JIRH&&5')2DK.E.9T07*B"E7>DR]TF+'*C5V
MHI+C9BHI;KD2XW<H/OZDXA+N5FS"4XI-?$]QB3_PWJ)XQ$CW3H%_$#Z[@_1S
M73VQP.O9W)O*9UWHV$*,U!*O)4F.RHWW4E:<KS+B@I06%ZG4N'BEQ*<I.3Y7
M20FE2DRL54)BJ^*3)B@N:89BDY<J.GF;HE*.*S+E3H6G_@]R61&IWRDRU<)]
MQC#J? +,_5"!;?#\M<8Z%%[/0I?)Z#$>'S41*U7XK)!8S4AQ5TJRCY*3 Y28
M'*:$Y%C%IR0K+B5+L:E%BDFM5G3:&$6E=2LR?9K"(4AA&5L4FG%,P9FW*RCS
M">1M7G^KD$R+0I'KL?\Q,/?!J;>V$X_&.A3C3]7H,K'>.(M$:JPDUR-F\HF1
MM&P7)628%)OAIYB,$$5G1BDJ,U&1F1F*R"I0>%:%PK(;%9(]7L$Y_0K*6:#
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M%/S^(&G&#E+A=5R7\'YV[I5K0*0ZZ$-YL+,* TS*\_=5;D"PL@,BE160H(R
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MN;B3;>M0YB+3D%[4;^-^#?2H<"PF0]<8_!.,W<S$CV>MDYQJ/' 4@TJ5+\*
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M%.S=I2#O007X+)&_>;O\S"?D:[Y'9O,EY#WD.]Y;=!*\ Q#&[21@:TOMIY/
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M%[VA\UN:SX.^B65<<%GCH$]B85"+!5G$$I_I >'&G 4LA/E1]5#F..(*==I
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MVD>YB@(@:2A ,1IP'@7X@ :$H9E$ \A<$'84@,P_V( "[$$#CJ$ =FC &Q2
MW$<1)P7L)P,\OY=X.MC/ZZ";RWX7]\/'_KCLM43_0=13?3<^P'&QT!ZH(_WH
M-NGY\%J^:I'LKG.F?VMN''E^X^'?QP<RG25\\V3Y7>-4>]" ! $2E>1X@@:L
M1VGU353^?50^V2!U#0TX@@*@9W_$ 05H0P.VH@#3:( FNA7,*,!:]%JN(@K
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M\T$N$G5 FS]A'TKC[%'YJ-4%!%%&,7$##6!#;2^\0 .0$E+ -S+ #103C&C
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M@&"% D2B 7?I20$!: #!@Q1 ODPR94$"T"<#0(>(22GK&EOL.> ;<C+^ZB*
M)?HWZ$M#07*XFRG9DCC04&[X;@W!GV<D \FRJSW6_-Y5Z$F/$,Y/VMFTJ(CU
M'%HCD<ND@%MD %0$TD$&T$/Q0!8="*( ZF1%?"$%["$#H'8P(L@ A:2 VV0
MU$)+'1D =6!MA L-"$8U0P<-.(@"N*$!-B@ 63!GA (THIE01P$(NU" -6A
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M!Q637"<#F),":L70 "V4I$W0 $E2 /G*"BL*<)-L<P<%>+?E7P (I] +Q&A
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MWYNPTV'W\M5-.*=<:DSGXO\FZNYMJG-6".-5^G'=T!!! G*BLM<S/.^J%.:
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MPY,"*_G>J4/+\97&M8_6E.<\HRO5)?\(0^UTG=2\_OBDV>Q$X;P0)A*!#."
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M':%VZT-Z(:ZVJ.K*_UY+""?_"U!+ P04    "  /A$90#DJYU48H   S^P$
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M"1Z]QMX::2Q&^:JCQ:X,9R=;>6RDHP&.HP?,;M'22!TIB$;RHTSRV>DG(7B
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MM;WOJ;;!FT/C?*@9ASX=.E6E0VHE#2\9^A0AAH(0FVBB *--?$Y^420^.?"
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M+;"0:\I"\D_9$ 7>9+U!A(DF=#%V(; %^U"]VR[CIA>H;0,GEP18PRTG?+H
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M1 QRYR6_Q4S.FE:G=KHWW_N4SIE<.)MXV)4W'P9Q9.]_QA&CW"483$5%608
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MTJ>07GWYK\G5Y/JFQJ6VJ?6,QA3G)>[=PG51;8ULFX8N<1?O%YP$0'6(W55
M?;K<BEJ'*"#QC,>8X:S2L2?2Q?(1L:\(5 KLI:;D4NS"+51@^-$?L:SK:&Q8
M+H<F=AK];!]0"]QL2K;<H@'BYF+?N;RR(RNWX=69;&G]#+XDKN=.-340^E"\
M'*VEC65]5L$:/]O.5H1YMXB%VTD@SX%^A><1@^ 'LI'QDF&\KG@S<U#+!-%A
M\/+F(=@\;+L!67>J9$(#PK6U1[4M]A^*%?N>//YP7S[^4.BH*4=F(+8%RO\/
M1@25BW!E/2F>[U\[UQC2*"RWGL>9DS+K:FUE19*5;Y_.Z"X^L2T$;.Q US18
MBC LFR;WA> +I;/*_:I[<_NFK&[NRQ4_*ZPUO[:0E<K!MN(R=L,[BQ>NJQ27
MEZH;W]JH%HA:NY8<[=K82C:_XS"_'WHLSC6+REZ5>*A#.^M"H"K--9VIW^[?
MN29W\LX06^+P<R3H2N\FSNF5U]EB3][O/0WB4\'Y%5V3H%+'8<<X][VXG%S=
M^]^0-I/%%GK/>"DNLU8< <\$8 )AP?G*A-[==H+=XK0M@KZA+%Q"H#\./%DC
M5T[UGR'W._9:%K9[05IHS;NPT;3TW1=X__;R,PZ3GBU3C>HQR>;7UFX7:B!Y
M!FK!:!'F2NO2\*5Q^8V$JTEP11YPL>I_U\8OE%L:L>[<YHU?)K?3H+MJ\[8O
MDU>Q/;$[M\76+Y3?1]J=VZRM;;PVNEAQ 3M9KZ-J.4_%<_OB@\_X<1R$Y-P[
M&56IK[^PD'Q9.PV472&^]MB"D(2*-="04=^'5(,D"P?5 LJT> F$&8AUA9=S
MUI.\X@)M.218Y_D5!M/%6*RN+_&Y3SGP&.<6X@*:3 ;]8"U(UU+*+_\2*[ER
MW_U$J*X<B;8TZL^'Z"Y+S';&AIS(DBE@\1Y(65+M-F(\ K,YH]]6Q%V-Y94<
M8X:3O,#?GF'0SPWR:EK=%5++Q,3%]=%BG5CV2>BV$RYXJ??JUM8_<GF\G\6-
MUF)QH'ZA@>J%=1. T_.[RZ]?[LO>HOK0/C>774 N%V20W*]8X4'78O_.KTP>
MCS:;N 58\^1V>H]P%^QXQ!H6#I^%P8I%Q3('CUC$*-A#L0\#BP]R)O'Z&PH\
M+RDA !"=!/(<=/N43G.7%U%-<I8VK:Y<Z?*Z%A:.84&NFUX*RI2KE"UM+&4*
MW P6RUUI/X,NN%7PI6UF@8F*:8Q%WC#DM$WL,#)%$A<,1".2N(N3D7B.-G)7
MSR9>@^1*MMIAK,LS&GOG[?7]7;DCEI[LO\^EYU7!2$,0.([O*N/Q 4Y!6D9V
M>[N][P]-YW'N<!BQ@(_!01/LC9=(S*FTW<:JN--UA_ALVZ^S&YE!JDO9SB16
MQ&:OO J5H,_%%;_Q*> L%(IK ?,KPG@HR@")@I?%<_'/@-_SB?B.E']B6 0.
M,W"R-2:F\G;?:5YY9\<X+2L4M3/N9H^TFNO^(-S[M^$[Y.L^FO^X'E?'_^\R
M/HN<R:6?'RJ[] O_EM)[I#]6=A*_19)+5M7R@PIQ(* 20G/3?6_C*E*9%3B1
M)TV4!8*[-[>'L5L45UN<+NYQ %'79QKF!^S:FUG3X_+\ Y*2;RL*_R(?%S<G
MQXF*.$]_7CC^5X"K<[T;I-;(B"X6LGZ-E]],(,Z1<B8";^R%5-ZV4Q=#9SC;
M=MP5-@;F&PCO<1CZXFK9<\17BF"J.X1U*PKMU%=F(+JWMV!^HI58]419#S@K
M)Z'U?,A'9KVY"O+"NK-\9-*?RP"V=VCYJ$^/5@/:WJ451R :WUJENDB0AI+S
M)JWZTK>V8M;^5@*(W*00L]8.9;>VVM^FE^;NMB#_K!;HKCRSH&OY*(B+ %U1
M=H$78C6DM"$E*Y!^D:TQ9\ST@WTI1^5O(>A$[E\1X;( %);WD[D%]BJJ[=S<
M JU#/A6$!/EQA<G:W4AB3PZ1R?&,YL?$QYL-HT_RTBU_F[.]"U2V[7C-)<7P
MFD3PD?04HZC!F97!R(30UNK%]'F&-XAXH2AN5^G>JC<6]&0&TGG*+T*$P!",
MT3KR48-S[-[>SAB&45&VF<>W@(JS:H+&"SPOE.BLQ>5F,/N?BL\.#!,7ES8(
M?@D\S"[Y9I.QUJFI-1RIC<?+L!D9,W>"W^FBO(\S657UI-B+)TT[M[8N'[S#
MKH\X)PL2W^1#HY"*#0B1L!8ACL\%BG"'X94H+)!>]ET=?CO L_<.?)=>3TY$
MM5 9Z($93<MC;*/ 2V<IL;<HWP*1B^$Y**Q=ER^PQ>0D_)85KDUJ?+OO*7DU
M81NT%5116>HKOC]63$&K=-@-RK8IVOP^4!F!/A2N3BV'.UT:VK<G47'=*6_B
M2]'"1H;6V-N6ZW)5&=*TL)&A?"=HOKXA-ZT7:]VT-[.X[(V&^'(%G"X-[50A
M!"\+<2*+K](+[VKC3-]H_YD34$B\"/E??K[_N>B(:2#VPS*PX'2A<-20*] @
M\<\\+;5,\L*6*%ZCA'Y5$,4/_Y!EL;*N[\"8$]>_ME<9ZMC6PK@YWDXMTLUR
M\5M9DO LX@2<3BU+-0>S("J.2<[*P* E%N2/DTWDLWP3^6UEXWD_T/U'C9UV
MRJNG7OH"6SD/4V7&]93,5)V"&9"%O@\^_U2]U*/ZT$*RJ;O"\MN?<  ML5O9
MFJ!K8(&KCG.M<PKQ^D)>6G8+MM'=UH=8AX96K/HEA%;NL K3R\O [:_(<B4<
M8"'-S QEA=W^6&R;56CLP/?3B^-RCRT]L6_$W=]./M^-_U&Y_*OV=/]C*[X/
M,;YR%S[)>7)!8N6ZO?9F+^=LV#WXF"A8GA'*R9KX*"]D7M%6>SL+] >&VXO$
M97\BT4JVI12WK,@)Y[%VQ\0S<5@9H.0\7>2I=3;G,PZ\TE:*:XBM!0F\+A)3
M<.OR$3-69L7#A_U .T_-K+;"&T5SO.NI&07O335KVT9$9S@KXHJ<;LB: #K<
MBM6E$#1U^5=$I/K2"\T>FHXZ/Q.'G=8 +T6#3UAD&)N5F"25Q,CZ*Z(X L%<
M/I"+414WT _6PI@D9F022+LN1ZSZFIHN#>TS<_E)"5$ \E9,FLP>:3*]<!'A
MV2/\N[VBT*%%@ZJ2>T+;J.:<%1HQR<H_,*.2KPH_"5=:<?3 8;50Y,$WR=$]
M>0(=-_,$+QO%T@^+W8*!_BX8^@S1C)J59FET![4@9,;"9/]QRY))=\76=GT3
M"UA0%D^[?!(_Q?8)/_+B4U)<7N:9O,BCV][@+V?&(&,Q*X/<X.PZ--S[3+LD
MLG2 ];9\5;JN@769>9DM+FK>)7NAT@+\<4''=',;?*PA5.T/;V>8NH+X0M3M
M E;( \#7_+*F@86^A3R%& ?S^!AUA1/U.PN9^+Y=H<?OA06IRJJ&KH&%[- Y
MJ=!??&(CP3X-5Q&K]I_:8PM)%U8HKAC0M,BM;V)?DI63*P.#)G-;T94IE 4!
MEJ!-S&QCQB_E4989>DJNA4G"H1)WK4TM=L*R-.22N'E)B%OP,@L*ACGG4=OF
MI6P_4;!1->:Z%C9:& CW0/M/-2XJCRTD/9K+\J45RJM/+3 %T7H-/504WXL-
M]%U<B&%&2[/?XA*#^";L[:4HR%J..!OBUQ^"VHZ9Z)2UPIF4%B'H6MK%D[JB
M7C%QSG=OG<66['Z%<=@TX[Y[O':F-RF?VOF',>?4)8)%T>\OR&*!14''=!M8
M+8+:,=+]Y_HQ0[1J%$(ZALZ!0$5H7E]W:^I4ST!C91^:??I<]AC%!_9YN=E-
MI>)\\8&%Y&:1JUC<17P5UU;"GMB;6<Q5*H.P!YQUN0WP(*Y< =0X<&N)6N-;
M^_C [H) ,H(J':_V>/^AE:AJ+(Y]%JP0JI:^:&FS=W.=[8&:+O*-4=/%C)[A
ML;LBX,K!<=\R& ^>J+;[B/T'+/PX=B,Y?0>=:L7EY&6M9N:/06UO)JKDM\SM
M.-@^7X2]45HL.K+&7R%A%=7PFH]-J".%GK!VA@=:7BH6L5M;"\PD#9&?'A%R
M5^+"7HX";U,H29'QU*FI9?,U948W\3)<2,4^=-;B' P K&6:H2"NF3,#TB'.
MN -=07=,@O*GN\)YZHYM+:O''9O7M;2IE2&H>F-A6"RW,"C7L=2O+&1AR]&<
MD62&H<*#^IU]3(@CE">CX_?0T\=5)AK>[=]ZBRB"DV4@DF_=GI,.[2Q@9K-@
M5&X&K56Z$O?QE28N'T0=XS H<-@3V+9-)U5I) YH05N\5??FEOFJQ@'Y]<O-
MY=UD]F>Y)]>>VF=)1%D^"27R A24(]Y*ZM^Q[=XST6_)17#)W:AQS<@9O<,N
M70;DGUALYYHN/E.YL@7-Y+6:*9-]@2TL//F-LN\DV(BJ7[P2;ZA?V=<]_S'Y
M?';WYZQR?*SV]%]'^&]'@F[NKO :_?ZW_P]02P,$%     @ #X1&4(/)<ZD\
M.   &X8" !4   !B:6EB+3(P,3DQ,C,Q7V-A;"YX;6SM?=N6&SER[;N_HD_[
M.:9QOWAY["6II!Z=U=V2);7'YRD7KA(]+%)#LJ26O_X$2);JHB*99&8B6?+T
M@[I42@"!C8U !! (_.N__W$Y_>%36BPG\]F??Z1_(C_^D&9A'B>S]W_^\?>W
M\.3MLY<O?_SW?_NG?_T_ /_U],TO/US,P]5EFJU^>+9(;I7B#Y\GJP\__#6F
MY=]^R(OYY0]_G2_^-OGD #:%?EC_,)W,_O8OY0_OENF'/Y:3?UF&#^G2_3(/
M;K5N^\-J]?%??OKI\^?/?_K#+Z9_FB_>_\0(X3]]+;7SB_(WN/X,RJ^ ,N#T
M3W\LXX\_8 ]GRW7;+1JY_OR/;[[_S-=?4VOM3^M__?KI<O+0AU@M_>F_?OWE
M[;J?,)DM5VX6TH__]D\__+"!8S&?IC<I_U#^__N;EW<J\9/Y^S2;Q!3^%.:7
M/Y5/?GH2_GXU64X*7$ML?%W'AT7*?_[13R8>^TTM99M>__-#WZZ^?$Q__G$Y
MN?PXQ7[^U(\@MW^^2"LWF1XEVY[B@XB[;>-=^F-UY:;'2/IPR4&$+)2)5]/T
M*K]-']T"9]GTR\N(<VZ2)\Y/TY/E,JTVT"U2?#*+O^"O)U,LG);X;S@]X[OR
MW5$CT7NCO4'S;#Z=.C]'D2:?$C;\:O4A+=ZDZ5IQ+#],/A[L9_L:*@K]Q/M/
MD[2E%>O>A8?KJ]BAPU\\GRS=9"LA[=[C$QNL",EQZN;4^BIVZ.<T0Y60PH>6
MNO[T&BMVJIVR/+:>'CMP>3E9%9MKB<T^FZ-*GN%'8=)&YH-%:XAY[#0XLJ(:
M76C+D985]"CR;#F?3F(QQ9^Z:3$QWWY(N%(?%O5 P>%%?.T6B-2'M)J$-JPX
MII9!A'^[PC_7@_LJ/W/+#R^F\\]'X;RW@N%%GE]^7*0/:;9$!?82O;S+=++P
MNZL:HQO/W#2TL*!.JV_P#CU'DWKUY53Q[Y8>7-ANO!F,*I_2XK5[WT*N>Q_V
M)L)%6DP^K4V#E^CI+]9;) =UP]Y"PXIVK7[^DN+[U-9S/[ZF83OQX"]_2ZN7
MLT]IN5Z&[PAUT.7HM9&ANWZ,275$%<.*_1)-_07"]@9UPMO/[F-;]_>DRH;M
M2CN+L$71_L2<%$9.5E<(RNV?#\IXH-S@ AY)YJ-JZ4WXYVXQ0VM^^3HMWGY
MF_.0F+N^'TR@EDK\0+'!Q&LW7_:7ZD\XK&'^):6G:9;R9/4:_8G#HNTI,ZA@
M;9>O-F4'%72/ *?(WJ*Z_KK3R@@?R-C>5/LDA*O+JVFQF==[2P\X)K_,EZT!
M[5#G.!UKJ2!.K[+G;ATU$,,B_":%J5LN)WFR.4Y]=;5ZE5M@=%07>FJDYZX?
MPYJ!Z/#"31;_Z:97Z=?DEFB)M/+]]A8:5K26H]ZF;!5!#RY\K0I7$?6@(].J
M<!516UK;1U0QK-CM)GJ+HOV).9FY69BXZ1%;/OO*#"I8VTE_N&@-,0]/^19E
M:PAZ>,*W*%M#4-Y!4%Y3T*U2Z<* ^U54%+L+'^Y7,:C8+=7IP9*]"?GSE5NX
MV2H=%NK;+WL38F.QOG-_');B@4^'$*.EWMY=8D"A#L[1/44&%.O@'-Q39$"Q
M#FK@/44&%*NE'7BPX! BME-2.POT*%),'EW<65JVD.;;;P<1I+5FV%ED2+%:
MZ(;=9884K#7?#Y4<1,BVC-]5HD>A5F[V?G(3^3N+/\_G\?-DV@*Z@T5KB-EZ
M?K2MH:+0+69/ZRIJB-V6MBTKZ%'D3VBRSA<'=_:_^;!_$5KS\>'O!Q.HM4+<
M6ZQ_\=IRZL'/>Q5G$^:Q?#G[3[=87X:XCCQX/ENM+T"T$;)U)75%/X*5Q];5
M6T=^26Z9EIL_#PGZT+>#"-(2N#U%AA2KY:0^7'(0(=M-[=TE^A,*>?M^?9IU
M4)AOOAQ B)N?VK+K<-'>Q-R>[]U$=G[='/H:XKEI^I#01U=4OPLMX3^UOM$Z
MU%(M=*RV?O?:*903J^NM.Z\7\X]IL?I2(EE6:/R64^F/I=5#@A\L.+R(+6=$
MV_+5!&[)^".K&5[\=HQN6;PW<?_CRBW0YIM^^3IS+MS*_3YS5W&"\^F0N"V+
MUQ*W):>/JZ6R\"WY?5)EM;K2CNM'5=*;Z&\2^I=7AZ6[_UWO CS]@I,]7H6V
MFOA0N=X%/(Z0^TOU+MSVMNZ=-MN*N*]L[X*^2<NT0%_[Q7QQ,5F&^=7F+NF3
MZ73^N5QZ;+V_?G*%HW7IX+G=R14.T*7-_U\LYI=/9JO)L\C(.V2)^YBN5I.
M,^[]PET>2[33:NV]<^W4\<-?]R;,V_2^V#$O9WF^N&SEH>\N,:!0+4?X8,'A
M16RIE]N6'U#@=OP[5*X_ <L]E*=NF>)K]Z55D-_N$@,*U9:)APH.+^+!I>MP
MR0I"DM.E)!7%[ !F130/+NV'2PXOY,$ G<,EAQ=2G"RDJ">D/%E(64](=;*0
MJIZ0^F0A=3TAS<E"FGI"VI.%M/6$;&NDM2P_H, MC;0#Y?H5\$WZ>+4('XXX
MG3U0K#_QKOPR_?T* 7A>PA66]_]^4,Z6Y:L)W!;?XZKI4?S+2[?X\BJ_G;R?
MK6\LSE9/PGJG8#)[_WH^G;1)GW9<+96%;ST")U16N2O]CL?(X])2,9Y0U\Z.
M!#<-5]-M&,#L;]O/B\Q'Y9V]VPZN)&D6RZ%,_RT=3/L[9./[ELHAVQTHPV[?
M(A^;++=^^_LRW=:7IE,6VOKBUF1_U^RO7^4ITES+,YV'.[IU*\,ZGWMV2[_.
MOGZUA/?.??RIZ-R?TG2UO/[-6@L#H=OT\/^\_75S__@.Y4[3/_^(C37W/VD$
MDRXZ;B%3*\ Q;4%H%R!&8D,VUF9_;YBG)<W]?'&-ZT\/ 5L)\3HJI&7:V8H-
MU^7]46E@^V^^56K7BK-KL[3MF5N;#QJJ4^994! L:Y L$ C>4; \Z402I52Y
M?3.K1B^>72T6MR*O=G9F^UU#//>1*PI16@;,$@6H,1(P99@2.L?(=)L^W2+$
MDT7X8;Z(:?'G'U'1?$Z3]Q]6ZQ\WM;A%^(8G=Y^[V'[QT[)8H:5&F*S2Y77Y
M\HQ']^&9]PL*BEQED+_>)_@M[1OCVY\U(6A&LA @@B4@70C $!'PQB1#,G.9
MF<<QQ">-S[Q7:&H-=,E;6K0S_J]$S7URT[6^7CUSB\47U-?K+")[&-"J?$-C
MTH9@KZTB&J)S'(A/$0@/QKADA5;V=&JP1T:-H3"KQ9DGG]"&*"OXB_GB+0K_
M-H6KQ=I!:[$J'"K;)"V,"CJ#\"*#\CAA7/86%#?,N.R4RAVXPA\95X; JQI/
M-CLYRS<I)&0Y=@)U80N*["G6(%;!)VM!Z\@@>D: !TM!2R*--88&W8$=XK&Q
MHU^H#A/CVRV\\IOFXBJ5:*W?9^&6T?U_YY/9ZNG5<G([!\"M\6Y9LN$TV6B9
M VL0EDBH!BHS$CQSDYP/3'MV^I#+1S+DPZ%52QVLO?"VWL.W'S?:<$8,2Y#+
MKH,PN#0Z)24P80,EN%SZ+@N#>B0\Z!6@\2V&W^:ST,%HN"G>Y&"-LU*#(=$!
MXVAMZQ31VO8RL" -C[J5USR^C=G-PQP&JUI,V7F59[\CNJ]8(YA0*3 !U(D
MU,8(4@<+G$7A3"*(;0=FU+0H.S&C9XRJ+1LHM"M;A^LKT&\*TJ_R[\O-0=&^
M%61?N2:&S&,F$1A%#<EE5J"IC&"XLSY8_-?L'X<=V8D3?8-4;W_J;@X5I/#S
M/\+TJCS9>S_+SH/[5H>+-\88=+V5!V,R*LDH$_#B6#%N? @Q6VD[;%G6M#L[
M460@K&HQI04;OO:":R\$20R45 &\0G5(E#'@=<C*4#2?S-XCK?.Q,#N-> <\
M:HWJ1<H)39GXSOVQZ?"M* $D:"NKLG4=C>4Q6IT#<.XR+HD.O2M.-&A!F%6*
M"&GSZ;S0CX470P(V@A/:BB0/?M_X:*20,4'(@177FH+/N#JB#1T%H2QPV6%I
M,(^%$'V!4VOP;X<2S>+;U3S\[<-\BI@O[SYI\@ /#A5MHL[41<)!I8C>%%&N
M[+L$2"YI*V)*.!7&.[3]5N"7L^T:_GJ^6/-OM5I,_-6JN([OYF4XY[,5$@I%
M>7^=X6H//OTTT#!%9'84EQAD$00==3$[ S@7DN#.!.S>N9\A]DN5^9G@7&N.
M'C4K'P!7>&N)P$Z9M;D2O0=G!5JB-F<6LB'&G?TI]!B#?)!G)R!;;]-H:YFL
MI3YT9/W UXUE)C&"MDK2W(!P+ *1'D'+Z-"D2*F5_/&QYK@A^V:[J ^8JL4Q
MS"\OY[-6XW__TR83Z3P3$IB/%+11$ON7(E"AJ)-.42D[F/=U=HY['OP>,*IV
MMA#C.K+<35^[27PY>^8^3E9NG[^_HT3#HW0D. 4D2PM*)P4N>@G*I1 9\\KR
M#GN"=?:)>^9!?U!5##IH\R8>^JNO,CJR^^,0CJFIL<8$RH4"+X0 9Y2&G R!
MS!$4*@1B)DZG3YTMY;[I,SB$M6CUI@1.SU*\?IGU5L\N4IZ$R3[GZ'#A1C%.
M9#09HB$:9U4R$(GS@! SS]%9(/<3%9S?9G//Y!D$M5I\>;=8O[SVI95%\NW'
M35)$V6 BQ)P"")E+?!?/H' .4":C]*R?8 =X/(3H!:9:!/AU,ILOUI[;P;V3
M^Y\VG&B2O.+@<7D%FM&%<XQE"$&*@A9C\>S#9<_ A^T!UQ%V)MMM0C9"&,71
M#H?@@P#O\(^$W0/BL%^64R%-!VNC#D<&W2GK!M8( W\X*.[;CY'2,3A)(CCM
M(_KAF0 2V4&)X$D&=2/^V[EO7)P\4KM'_'1X:@='OW9?B@)L'Q9]MT"#JY^Q
M: >!+N'?P6#GO/<<_?1@L[<NVBP?$0%.&K@=4=&=D:IF+)9'VUH3X8&O&Z&Q
M:\)2D#(HH,E;B"Q'T(YY;ZP@,H5'M!KTP8)^8*IZ+GW48K"C1).\%X%FM)AD
MS&@G>0(I68*]M31'1D.V'<+EZ^QB]4R%_J"J%]_B6]R4N?550P75G)=8/9LM
M!)$L..\5,&--1*V7%>EP@E%G]ZGG8>\&3S4+<#Y[_RXM+HNT^VR_6Y\UCJ$Q
M9$,"3K#"@&!#%,: XMRC+\.(BH])W7>S^KH!,T+$VNVPJ2,#U1XLVK@4C/*&
M J7.@9'E"HF3B*9@6?@8##'J$:G\3G08 *QQ(MVOI?_2+D[M4-DF4I.MM@&4
M$!%LL@S_,!;*,A<II\R*#H$1U1>(3B09 JVQ+,7V88P/SP<3C"14< B1!"#9
M2+"$&TC41A-$UC@ASOWDH3=>] G3#2$&376T(\O-:U?$_I!6DS!\HI\;&;X^
M(;9\E4N"@Q?3^>?Q,NX\G&GA=5I,YO'E+)3SA'21-O__>JD!?_C@9N_3&^S)
M\YQ3V#>Q>FJAB5D[ZY@!S0P'GCB#K'@ GZA0Q%,15:OMW&%P++?*L8>O%_-/
M./3QZ9??EPF[MWV":/;^25A-/AW:O6Y?24-3CI8' KZD,V!."7#6:N!.$Y>=
MX[G+C;TZFUJC,&->$?)JT7W;G,DOYHN;',6H76Y"E/8%^QTLW/!LB&#854L=
M-FZY!2DH>IS<>L6,";;+O7):YZAUJ)&^'Q0X!)RUB?1N?GTRN$Y\O3UR:D&B
MAPLV2<><",V 1D$$21R')%T"*3.55JMB>?3BC7]'!.H-RGH!0!^WHK_*![9J
M[G_:H+? 4A 2A(H4$J<)K#<&T&24,=L019<,)OR[(D@/X-76)\7278=%7DR6
MFY"&6Z]N[5$G#Y9KT$61Z*]PL K=3VN"1TVJ)" $01&JO&UG"1[TT[\#LO2-
M9/V5:)OH>OLX94E7>RA)Z,&RC=,\&E8B9:(4(),SP&()<Q%$2.$U5;R#02._
M2P;UB6;%7"DAI;A^*/&68;;>Q#C.-3NRIH;'& E#L'FD#EA2#"15Y0ZIB<R0
MR+/OL.%<YZ)\+8(-#FTMNNT K"0Z7:XZ;@(\4$E#,M'.$ 6.10>X^!MPZ I#
MU%QD%VGFGO1B5O_OW 3H!_(Q=%U):X6@_NI6);/5EU=Y=\ZKECKOB!H;PT-6
MTDFT*J@"KX4!&A7:%RP3KZ-3J4LNVSI[4T-18H_N&Q;BT0RWTZC7OI;&6VU<
MTN4B3-80O,"1R"E!9ER@24NS3_UHP1&,N=[Y-BBNHW%L;2MT\1 >K*!!'\@*
MIM&=U@YM&9TS$(:FC:)<$G26E/ =0H?'W948G%E]03H:J:X3QJ;-[;NUH;)]
M=.D8:NVIIE'.%\O$@L:Y!IRPB%-,>8@^!V.R5CYWV/8:=R=C<(+U"^Q89MJK
MO#/KY!&FV9Y:&A5QJK& IG#)3"B$#L ]4Q"X5"(&Z<G^9XC.(7QA)'.L7UA'
MTV0O9^N.+9=OTC*A%,7ANDB?TG1^D&='5M48)80J>;6-<0RL08?,!!&!,A6-
ME3HXT^&DI]*MS+$T6O_@CKE=>[Q2:UT)PFYB1K<>C* 98<\2T"7BD 01-G*E
MA.S@8NKOFV9]PCJB3KN;=/4X)7:W;)-=R3+O&9"R;VTR3>!M0.N!&DFYD,KK
M#A%^YONF4P]HCNLX;A!:_\/1/N.MLHTP7%,>#21)"/AD(T2J.2@O$_HX5*$C
M?3J+[/?-HA[0'(U%F[O8OZ;5A[)G?1*9=E31$!6=$2* 2HD FI012'*HF[,T
M.*>89S2=SBE*OF]2]8?J>.[A[AVZ@\D?CZ^L"<([I24!1UPLZSX#340&)[BE
M-M*47)<T?]_UYOT@\(X00WJ[7[?4<NNC\N-J:KP,60FOT*NQ%J0K=Q>9<2 R
M<9PREW@7XXM^GQOXPX$[\F'YUXM'70[+'ZBD"8E$75+;./1CP ?K0=M4,C42
M:V@2S.0.*VF=*X!G?%C>#^05E]D\697,>ON7S^U'C?'2,"YPHBJ6(,3LL3N2
M0T1[07C!$K$=]E!'714[#]RWJ^+IJ-6[:_QQD<)D#1O^/$WK$9G%)Y<E\];_
MN /QJ6V*-\FGS 3JVN@8!<5U!!MQSO$H6,Z6)),Z'.[4B<ZIQ)F!\*S%IG6
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M9N[-PG6S8MWJZU!VS+&--=QJ)[3T0%R6D'GRD&U)DBRI"=:1D+L\%CV^!3,
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MVNLZAQ2G#<-\('Q.WBM:ZZO%MB^EEZY,C@M&5C>3X^-V<NP:Z&/J:+(,,9I
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MX*;XGC9,1/)O;]/%_;OKC_GG^>;%XGRE)AM/03[__+Z8Y4VRC9TVRL#$-Y9
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M2#GF'2&FMK*HQ:K]/M3;&]?>D-]_67 21L/% '[)YNN##Q:K)HDQ!AA"O >
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MO;0= N3VLW_K['HSGZS+-)[Z_A%4Q=XBP(=[)0$>H9BACBHC-.0J&&L50LB
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MP"X]LKP^:I, ITIN./0.*6@(E:J^,C2 C^BZ9]C%M3U&[65W:DI6@T30G7!
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MWV2!_6W#T"J[JQG8'XG39=3$>N.Y H%GSPE"$@!07XY2TZ%(:?0MHB^5&13
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M+!KRLKEE-%%L2;]4I#PJB)U>41^F9F_4R$G]$\2)(%Q!IC5QBAH(E=CQ@TW
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MB'%CM8:8![JE15ZXRD$8EAW9/K#L]'+.(S2](\$65<R'S:O]/1+-I/;48,&
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MQ>*W8I4MK[X6[XL RF_Y/-M%-]MU=O4U_'F__>\13\CI0R5,\[(J(=546Z>
M-\[B'9?0>S BHRZ>P(I!,3MGY$#72G_6"XD--\P[II! &'M5<<J9;>]V.3UT
M^/(-C6@X#Z]1\>JV2>(%14(3IXB$X12M435)(35$CMWTB"'$4PJXM</K-6O(
M2 V2L2G&>12BG\I^P@3K#DEO,(4$$%0^]JIX5<0W"HX9466_QJ([J;+?:2 -
MI1!OYJMLD2U7'])5]O%K>G=4$U[ND# KC (:4<NH$UH X"ON4$"S?=3. *\C
M(ZI %'0&SNSPR(0Z8HN^W"$Q"% E'=$"*XH\Y\&8K[@+1G_["_G3'QQ=NA4:
M!>'SZ4_3Q"#?=4DX$X ;C E27%& $.65 Q\%MD>>2J:KV(YJ02>47J,^C-+*
M'(L:G.NPL:4SFVZ?NFT2N57&]E&[HD'O1%J)&)(.*ZFEA6$/Q94/$1FJ1I3C
M-YX(OSMSQ(9I*/7XK9A/:^*/IP?ZOG6",'58*RT44ZY,1$E$-8\P@;K]0_G>
M;,SHXN\.RS_KJW@+C0526,/8)DVE\^%_.Y2"/3[J[$ Q'Q@,!N'P/JX/68EK
MF2AK%Y\)#^XW^[LE0B(# 960*VV91[A,%5F!:T7[C6: TVQ,98D(TGGN7I^<
MQ\N,H=-&6:&:#Q)6<D^)DF615:0QU)IS4J$ H6"M566 S#YQ5:4GR(9?1WXK
MMIG0M@\T&ZTA3[LD6EF E:'!YM>8*JBM(MXB8 C@&G2H+#U 2I]^UH]. )WK
M1>MS;][NA>NS"*.+?]L:)AT0-DA!4<S"Y P'U-V# P>DTHWJ9?1T7?'*WK8B
M!0+&L/0!>DM4^ NI3F8Z3(8A+THZO&UMK"_#O6T]#=B>WK:^KI3R88<&R'D.
MB <><V8,X-Y"[AD50+'V570N]S5M8RV+DT+^- D,[.6-E ]<(8.L\E &$]"*
M8 P&:V+'HZ9<^7'[_?L6;./$X.U@?)TJ,\JK@8O1E/-HB$F7-WY6?&V:/?[%
M]HD3$C,KB4= &ZO#*47#P)M0$&*'Y$4ECF\LIR(^,H-="40N',"X8U@2"P1$
M!!M+-0.!2V6=-)QU2 #2]P5!1/E'@V>PD+3*7FNJ "]W2 AG'%N%I+ <(,"!
M@R9P9P#%DDG1_AE=;XZX^,*/ DV?KR.K*X8#204>-TD,T,@+ I473 !&O"=5
M')9& 9@!9_2E'D(Z8MI,&Y85<LML\I?/Q9>?)[LO;E6B^NFY2E2_3]1LMJ,Q
M#Y#MLPT/-4\$ Q)08BU3&D@&"?>55]EX2=DX3Q+MI5/TALFK$?FH3@+GE?0Y
M).Q^_W!(HN&?$P")XUH[P3 V92T9CTU%-B-X1)'C<=!_+LK3,1A&=+_H]X=$
M%_XY";:D=Y '.U(*'DP*RDVU#QF(!]V:SR*ZTS$81G3FW_PAT85_3AB#@5<J
M,'; ><&)(K+6. ;;/QN,;BKW([K3,1A(=,H>%)VR0>,XUV4!KF#]A;,< )SO
M[EZL-:)#DI?H-\L]B>YD#(81W;^___LAT85_3CR7!M' ,,82!AL>N7J_MPZ*
M]N&+T>NR]".ZTS&XY*?9U%/NPFF;6"RH(,1(A2I..>KP(.IR<\#$O#YKB?,E
M/[PE6(39$R:,L8 PQ:5U-:>..S/. VY<(9[R K<=7J]90T9U'AZO8IS)#][+
MTVQ=9F;S'%);%KU'*&S;H.)50=W>*WZ>I]F-17?2T^S30+JTI]DHF%EEU43(
M&-.">2U=]3[$!39'E%^P5Q7X_]E[UR4W<N5J]%V^![!QOYPXWP]<QW)H)!U)
MXQWV'P1%5DOTL%F]BZ0TVD]_ )+%OJA)%NL"5DMCQQY)W044L'(5D)E(9/:"
M3B[9/Z=PG=%&CS4)PB*/F#!"PPB:<]"YVK_D%.Q0>_;E)@EJJXGVA/$U6716
MPSC>*#!C%!#,<$6EQBY""&K3SSENT+@UT.[":\"&3DC]K+P8I=XY)CI<AP9O
MUU^*:N??6:O5JEBOSJH8QYH$IC1"QD)/@:", 2E<[9-SPN7-&=Y,R>A#7.4@
MZ.22OYI.JTTQ>SV??)HO(N[%>?D?:Q*BXJ0$Y%)H2B1DQ.H#9-Y+,\(;DP/(
MOR=TLG[_;\KESD.[OH0'YYH&F5908H#@5%-@+.6F7D0]MJ9]EKC!HK&&6@_Z
M0RESN';GO% ,I1=P 0WPR;MOY6'5\QITN.WT<O-"M34\>D'X>OQIGP>(,2D$
MV>;$8(@+8%*M@/T,(W9DW"9'5[$U30C4#J6?D0^C-#7&0H-KG70,G1=*6ZH<
MB*H43J7"&;6."F\!BWLUQG&/'9_QT5V$+?)"7093MDL@G?-"84D$CF85HP "
M:U+Q'U;?1^;>MM<S\N>%:BO^[K"\R#0;4D5[2G*O!<" 2R6<]A9!'DUM!]P(
M[WL-<[&^)X#R4V#K)#D \:98JT^KK1;=B U'6P?E.>):1QP%P8PPJD@-)/2R
M0]6,*^5OZDZ,OK#*SY'#H-_>/)E.(Y(<;QX(MXP10 EUR%& J 6JGKFU6>N%
M7\R2'N1YE"N]0382LM1^E^_M"7/H(DCJK%+0<28$5IX P@_P*HM'G>@\.VG:
MPG9/G+P)G[9.FM7CL1S2.^T'U/6]:8E?S]>;JE@]_/M57KI/:/4QOFXS61P9
M0HY(ESC279ZX)(:'KC:UG*G9;+[3:NQ\E=+UI)'K[_$?=^5JLOBM*C=WJ]C%
M8C-+.G5\IERNY\M-,7M[5U2[J[6O&R3)RCB*X)G D'(1[2[A 45(R70!R"M/
MJ8:R42SX2Y7%N?Q;F480&)=02>"<4 1!"8P]R(!(C7,6LCF9C&N4O/PAN&J,
M,IN,.<_7\)"=.;7),X" I%:.(R,P4PIH[[FEM<B,1>T5IH'SB(V.TMD_N1;B
MRZ;Q7S*/9@58V_48()$26^:!$S3"DY(RL1H?!)D>]P'5V$CTU+S(*I2_R?L4
MIU&>IOVBG+V4JT?J&=MB>3NI_OQ]LMS<1,M_4\6QW8_G= 'C)FT#HQA)(X0D
MJ=ZS] #APWYF#<F:GJ^A@V1HB97#8GB5=>LT3";.93[;_Z/IPG5!E\%%6 B$
MTFCF-?6">F]J0X4PV;[FW& L>PEF7"9QY"+LNTTU_3)9%::\O9UO$^+=E[&(
M_[W=W.[.R7:_7R=WVU&F7MQ7@,!)2J!A4B@ "'=('# !%K4O C"8I_@E4'1H
M.61<3'_$YUU5?ITG)<B754H,FQ+$OEW6"+\IUF]O3A=(ZM!K\! +;03!"'HO
ME2$:H!HGPV'[$/[!0G9? E_S2>0J:L";<OWL#.]G]8]JOHX:T[?&:L %708B
M"0;,)/V+>TZ%0-;O$6)*HO8WCP8KM/)".)M#'"/46[<1^^ZONVB*GJP/U:['
MP#V*=J0!5F\_9>@,XC4^P)/V2VSO*8!>+%T'D\95%8.X&[B;FV(:-X9G?W^I
M2G"NOT"55H()9JU@Q%*,$;O'QL#V<=;L%V?JX+)H[1E*:<.748K?J\FWVXAB
M-9\L5JMR,5N7_H__?.5?O?[]F&.H0=. *)+8RQ0SY 2%EE%3*S,,\0Z1^_Q7
M9-1 L&<(O'&3*AEKJW=%]>'+I"H>#Z#GP)>G+]L'O%PMTD5%"LSFBTV*._I0
M3%,ES7FQ<G\EEA0S'RD8[=:[S7JW6=T\'?[K!F$L?;TB6$V14P(Y;#@AW@*C
M*/-82@^U@>Z*,2H?IE^*V691O+WI.-ESH2C]OBAX9!%17CO/,<3>"T_='E&E
MG,MY%'XRXB0_A<H1X3[JJ)&.>.COSW=P)E1DP+<&&/49K34QWBEI(='*JUHX
M$+B<A;DOB@^Y%D>?YAP8C6BRI:UX=L"-SLG/-0V((&4-%PI2+*S#D@E3S]@Q
M(,<=S3$*+C3B9V?(?P6RC3+ZXJ?D6$\6](=U.?WS[=TNAF0Y<[=WB_)[46Q_
M7)];O8M&Y.DHB\MZ"8H@8;E#4#C@%1+::E+/S<HQ9E[J3UQE+MA:4^)C_+#^
MJUBMB]G[^-]J/HU_VP[ICXCWF7";)FV#5<!"+RQ2#A(A ?2ZQDH+*T98\VX8
M\0\ 5FNA_SZI_BS63<7\_--!0\8\(5I""00"7&MCZ[%JR$>806D8P?8"3VM1
MQGWKIJQNMXZ_PQ ^%.OUHIC-E]L?G99NXPZ"UHA@9XASEC!MO!7&W1O+JOV7
M/-A9YC "'PJQUAS0D]5\&K<4FZ9:S)ZJ-"?NK%_2/#B/ +->8\2)A-1@IM%^
M-D91,J):6%?W$PV(:VN6O-G<)K=^69WCPP\/!@R9@$!CJQRR'F&CTR7_W0BC
M@M(^>6+ODA\&^+)'=+*EK4EU=M/Y4(J#.&$%/GHN<)<R[F"&D0"$ N0!.4 "
M!1E1IJ*NPGBN+'%+&+K$NI>W\V63C_*91X."0A,J##=">FL\%L =YAHMU?&H
MUL-_EMWQR?5A_J.8?_Z2\F!]C=3]7$0*1\C>WFPQ6+W=K%?KR3*=R&[A.O'A
M7M1/(,!Z*J,BJCGVDA"K#NY;ZSEK7]QKF ^[DSC+?$#E"[KYP2'5(!/1T4;!
M<$]97!P59Y18J*$CM75BD=<CLLI[IT-OJ.22?=R7JNU)WF21@L;+Y8ZY:KVN
MYI^B\OII47PL=\[+R:J8O9M\3P^KJDJ59+9I0TYPI'OGP3,*&4$<:"*]XH)#
M3@ZHN0Z%5@>\4-6= C_>=LZ+XU6WJ_T6_L,2JF;_NUFM=X?-EVU<YWL,2BGL
M@5#&Q)$RP7C\[&M\&!UC&L4!>)8'O"OK0L?F<[DV=*RG0!012%DOF &28D+-
M 0]GL6ZO#_7NO<RE#_4$U14B]#)DQ:I/:W2QC'VLTSE-_A?N@P/AD1?GR&,7
MIU/,'HSI/K3T=8/0OT;M@\-,(B3C_T5CF<?_\R19] 9ZB[05C:+0AH[K^W$F
MJP=1MLW#]AKT$YP15BA@!5-,F;A58"UJ/"B$.7TR)Z/R>I;NT9"[_C$;=43=
M^V(]WZF6::H?[LKE*EW*:U1S[VS;@ T7GB##&;+*:>:D=D!3ZM/RSEG.; @M
MH]MZI4,Y+'ZY]*J3XSX;&-2@==!20*Z$M<! (!F1W$?#A3-NO),$C;S47H]R
MO80QG;#[=;@SRKBR<5/F.E395RT^&3)V]-F0\G$HJEF<U389A^3*)*^K88IP
MGC6PNJ$]WZNDGJ\ W1J?9C)?U2BLHK'QN?SZ[].4BZ+ZGF3.ZW\D<?,'XM[_
M.%CWC'SO?QDX]AY1C G@D'ACJ56R'C#D;D2'ASV 7G:<?@9YF?\X(2_S'T$J
MZ9!T0@@)":!2 :@/<Y5ZA%4(^I/7Q=//Z.U_>*FSH:)_HE40S"#&M$,NSL\X
M(XDZ*+\<=(C>N%S,(U3Q^T/NR@PYJYJ=;!<7,,JX!M)[2('PWKN(YGZN@/J7
ME2>TG12;,:,37C\W1T:IN(^/&M>A1%WLM=S=[D_UU](D]LE&&E?4/=4\:.HT
M=XB(J/52KP2RA!_P5'*$%6MZDN21PKH]@M4ZR.RYDX1]08US06<-F@;J#0;0
M<@4B3,98 YRK9R'<.&N<#>&G'@BP+A<#IBD<X7/4G_:)!U,ZCM4^)>%Z4SVW
M#S1M&DP$!#,"M%:1K )QY_'ARXB#&8_8^Q=,.2A6V4+*?O@,_":=(Z:U<+-Z
M>Y-^<M%9WH_- _. 66* YQX0@(&"@-4SMPZ;\5B8@[%D0+RNQY3]7]]^6LP_
MG\WO=;YU0!CYE)(:,V^!TI@+<MAG&6#M-Y%AHC'R\J0K7+EH\FZGD)_/3OCX
MP8"5D=(8Y BEW"D-E#PHX1B-*4?FX,+OA,SUEH,WQ3KN@_-R-I_N?VK*U>GR
ME\VZ" QQPB#RF@K+H1&*QW5QBX!#U)+VOJO>$U)>86'H!;,<\5K/H'(BONG:
MX4VF7.Z"=E,BY+8Q3@TZ"8"G;+08<*9E7- -L\IN:TX:!07EC3(.9D7B7%S3
MJ6;!"2N=3WY921D1"CLA]K,%Q)O1)!<;0H#/?\I]X/2"0I<^Q@%?%*]4-PC
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MG:#+2)NBJM+@;Y.3=5<J:#[Y-%_,U]_-8K):S6_FQ>Q-N9QNXG,G;S)?W%<
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MU.2L ]\X5V(>>O3$RE8XYV+ET5)E)PAWM$V0S"K&+! 2\ BFP_QP6X=AIEX
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M](C5K\*44<;PCXL@UR%&M")OX[H;-<1WD[@ G^7"L\\'*1R!0AC&K""2:,Z
MJ#=LZGS[F\J#6>Q]"NR'Y%G=(<HE_O?%W?Z 7GVNBIT==)8#QQL%XYV6<68:
M6H%=LO2\K6?)20<-=#![>4 B](93+C;\7BZ+[[]/JC^+M=\L9^>9\'R#8 @A
M!HBX7J;T^4);P0_Z>]3F<V;TO#X+>L$H9W3VAQ3.T"P[VG./!P681Y9H"R%%
M E.HB#RL=*Q#"NC!0@<'E'X/"&53!1[;4&IM)E7U?;[\O/64J4^K=369GHJ9
M;M9!<(A::Q4$,(6!<:X-JW="R;W(JBLVS)PWD+]B$,#&09?6- F&2X,T0TX
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M.>368>[9DH_,_G>S#U#T9?6F^*:FTW*3? *?WU7E,OYUNK^4?]H&OJB?0 Q
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M3G9I/^O-\/U\]>?9V,/CS0)SUB-OK!9"4T*$5,[4.A=5H+TG]W(C\&HJ08\
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M\6AIHZZJ]0/[-/[KJ6T:?Q3>5>5L,UV_K3X4U=?Y]%CJKF./!HGB/+AP6$(
M%$2$RGI!\$" ]MKMP%=O!]1N>\(J@]330<9^@*NC"L_)Y].'$,T[Y9SF!&,/
MI7?R,"<[UIQ=W47THZQ[ ^?G$/RH%-R1R+NOC??[:O*IFN_'<68/?N;9( 21
MUF-@!:34<845KD]^ (99,W&>V8Y[PKOL%Y'6DONO/WYW[U]]_._3,GO\5#!(
M26\=MY@H)!"ENO:A">"1;7]AJ'?]=@!I=<*B_0W"=Z_>O%?_H\[<#'ST5*"&
M>!WU0<\5@@(S!#BLQR:CT30>)7< .77"HKU5/R]7\]OY8E(=+W'X_(/!.2LP
MU])1;A6Q'A%P8!)'J+UUW_O-BP&DU16.]EM7,;V91Y@F9W:MQX\%!)B%"A D
MO:94&4,!J4?'(![178@A-JQ.8.0ZX$RA8#?'32G]_??)_Y:5640K^DS<Q(4]
M!<,A%AY1!YAP2ENOA#VL-9:VS^1P^9<\%A,T#Y0CH=;]'!HE$&K16Z"> *48
M-=!:X:@U3NT]:@+"T>>>'(P%E[&M1V3_9EZ-SZC,[)^!<-<B6E0:HIZPJEW/
M47>P]Z[G!LDP&[0/'&GAH,66"8^]8YS16LF#41%I[ZP=+,)D4 G_P*;^,<S%
MGX_59%;<3JH_D]*Y_4<"Y'S=]Y/M(I+( (^9L<XIS&RTO74]5\K0"(M]Y^1+
MG]@-Z?-]'R$X=:YS^'V -!HG&$!%% ,&4JRD/8R9L_;KP^5FUE@TZ2X #2[4
MHY_WDR>"0]PP$&>J&#*<(H[@8='B&(WXE*8%]D\EUPF#ER/#46F">4673V2_
M1_AN-[<GA?;HF9#NY@%@N?$(>8LH%NAPRT:C#O?M!SEK:85ZV<_<!Y7;[JKV
M:;D]?"8X+;"%@$H5E0)K()>^GCT2<$SY07N16X>YY[.1'F_H;XJU^VNZV*2K
ML?5US :5A2_I)ACJ.,;46<T0$D+*Y'7=(R&Q&*'%-.C5OP&QR\6BX_C\L2IN
M-HO7\YM3ET6;- ]QN9-:2>2UT A"9:E0A^_'J!'>Y!A&L.7@V+4^B#IC*)[D
MPF4=!,<8M!H# +3BFBD$=*W]8#ZJ\_LL;!@4O>NO(JO?JG+5\LK]MFG02G,N
MB*7$<><QDD+A>L91BVX?G3-84L@KKQZM<!O)$<(/.+4_/_BAJR"E(0HIY2E5
MECE&C;Y'Q-GVVLM@V26S,&E@'*^E#V^_@LOXU*2#$*?(3337D''<6J()I8<5
M&#C0_G[%8(DH,[%H /1&L'^IZ71SNUFD/,OJMJS6\W]-SJ0'N[RSD"X^1-6.
M&PPD<P@:;&KO.&:\0QF%P1)87GN/ZP?)$? K M>.2[%A(#1N[%XP)0PDEB,B
M0#U;PAEH?ZURL.R5U^;-Y:B-R9_3T8\3HK'@(& ">4O212LIJ*MG[J1N'SXQ
M6.+*J^Q=/6 W@I7E75'-R_C3:55,5H4M=G^V6VR>[RLX*C$5U@ #'79,,BMJ
M39!( ANE0LMKRP_J#QP:P-;NG8=;Y&0Y>W5[-YE7*8JCO-EG*/EAP,<</2VZ
M"H)+2SC7D$-'P3:Y=!W^3J+MT'[9&<R$'X0FF?#+MF$=AO[VYNF0=_@M$GZG
M]JQF/005IPPP\("SN&UK"*+U<%AZ 6\?>#.8X3[LL<,@L(V!-O>NB.T,+M)_
M.G0;H)(<.Z(E((AR(! X6*44$=;^]LM@-OW5"-8SEKE8]W#9_7%2)WAUNF%<
MFJ'&UBIAM068HI3\I9ZM QWJV@UFN0_*G%[1RL6-.F^;*6\_S9?;L;\OIN7G
MY?Q?$:-9_ SF-_/) ]?#;IM6RUE='&%>K.+O-K<)TI/.U!-$RSB*$,TASZ"E
MF!#EM/0"ZSJB@5+4(4?,8'Z#05D[7NBSF9%UGO7?HUFRJ;8)A?\Q7W_Y8UE^
M6A75US3Y5\N[S7J5@%FFY.PU3)NJBLN_GJSFJT.MD-^B2%^7J[A9I-TAH> F
MU3(^=O(D,-<8@L002H(-$@ 09J6-2\]ABU*Z_1'T8&Z08<W6D0+?(9KA:()Z
M-9MMA399?"S^6F\FIT*D6O<5I-22:44$%A3&21,M:DE0[D5[@@U6 60X@S<#
M@"-PMCU4?-Q?=\5R5;R)<_KXK5A\+7XOE^LO+8,@&G0<F,,81_..*0\(,1 Z
M41MZE+@.J1:&2<TW+",N.$/J'=IQ$O&_BTGU\5O9&__V_04,L+<"8^^ $,*F
M=#'X'ALTHLJ\8Z==.T1'S+;X^I8G#:=Z#$Y:"C%/<2=1>\960E$KSTRZ#GZ:
M81(GCIUQ+3 =+^=\N3EUM;-=AP%9CHFV@G&BD:<24%#'WS*K;<YL&C\!XUI
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M[9@S6BM6@V,1S!D]=MDQ4$L9G[YCV &:*]VJK4=\UK=^LEV 2! ,*4%$ ,Z
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M.:\\1![603H.<9%11F4&K#<@TF?-G7R1Z3=@\N31@*!]\4#O&^1+MG]Y,$1
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M_#$+B/U2I;7<:"</53JRF<PN[S<Q:)^NM]7&S:Q<3N<WFRV\F!XWJ9SRKH!
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MU0YQVYZ;B-S CY'+8Y^F(94]ZF-,QI,4MLE^6"Q(O=+:5=_*<SI]ATH& ]1
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M<C'5.);7F^(?^>IRLQ=VN<F?2".;U;Z/Q[\MU_>K?5X'_9N\JC[E58WY.H?
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M"==/E X;UWNR96X<]0 &)G![% 9T5IV! >(H16?8!G<',%2SZI+>\ SBEMJ
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M=]0C3CW,1<)]3N1SDR2)XGT<#W&L]E6^_M-'9*<4I0<$@%<P=MJQ29^=4L]
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M/P#RP#V=)WHT\GB%/;K.J,+G<O,EKW;-_4MDO6X.F#O]HXY\#/N(Q[['PBC
M7H0Y]?8#J+JWP&+5%MQ0-'L5ZT2-[#&OU^VAMR=_/%D#K^9=3Z4S;/X\:J#I
MI$JK+RRL;I(O6;&N9^I%N?V8K?./^?)^6^R*O&+YY]W/V:[]W4%&0 CEKL_#
M*$6AGZ8H<L.##"_U8/=C&P\/J;9:]UY_O+^]S;8/]2)<VE[!>9^MG:/4?W$.
M2;V1PZ(W=5K.,2]8S\-\\:A!=-)R@>'TL=O58[<OG%KO2>E,AE:HHSV0M58X
M\\"MO?3*D5YR.PC^:[&[*3;O-OG?\FPKLF+[EVQ]GR](C&D<Q)3$*<>N[XE(
MB$Y41-S(#I UQ5C',[O/Z\T/Y29W'J0R^;8ZZ[R2'.#5KKAM]D+4:IU&KAT6
MZY:363*/4$ P3C<@/B7S<W!?=*!^:#K&-8=D>3471!2;:PGV[J\=)O_FPOG:
MY-B<#5!G>:%2M)/"_>5",8#Z@:7]?8%_:+*:S8 1CZTV"N2VOKGX'_DJ+:O=
M(B8>CJC+J>]YW&,>=U%T:*U2UQVA88 )FJYQ..AT:J$C- O DK+8--@KHODU
M#XK%/)\FXE'AF&XF]$K^.VXJ-!,VT5P,\=KX5,[5+J\/I/ETLRWOKV]$\:61
M6!V;-#]@!/LA\XB?!(%LPT+LM_JB)*7"TAS/8%VC-"!9+?/8ANSV:ITK*;?Y
MDU''&@;*TO"$T*B%.'D3LW\9ZA:F3=BI,VZ:FVK^PY%7"\O$))2Q%^+[:GD,
MYJT[;678^;':H<=MI<]\X@L6UCN)TI@1Q*)NV2/B(O;';8M@VN;2'HTQO#%4
MFN.T1O:*<>8MTO<P E(J-(LMD][+\<_1.FGF;KB%&E("2E^0@02^T'!B%E D
ML,=(G&(N/)=2]]AP1HJ-TBA21FR#S R!QBF@_G9F=B4#:U8.RATIW7FR >'9
MBGBC_Z25F&F) 3Y FU/)Z7V,]NFFJ)QBE]\ZV_Q._ERS*VQWDSM7==E\J576
M.U!6=5%6)_V'KS?%\L;)MKF3?[O+EW7]VY7.;9WQ\UJZ/_2E?NKG;-U\RU'=
MY/G.J;_A;7H8QZ?5O8[K<MOT'#9YT6Q8RRKG)E^OWNS*-[=='V13GYFZS5;U
M1R)'74,_.1]8GB_T%49]36;PY=QHJ9835$/K#?_C_@CV(^*EJ2M?TY@RGS'L
M=[.W$>*AX@ZXT>1,U '0&7..5T36FG][93-J%V#>I6>]*V"O% UV!YXU_MG.
M64J]%[*%WM6]@VSU7_?=CO+;;"4[#_LS8K;Y_FO-;)]E^^UF63?J;W8WV>:-
M#%1?_[Y]<(K;.XGC=J]ZW26XR5?7LG&_< KY_,W#_]_C./O:F.UUZ+V1WVW/
M0S/=X;V/(3[K3I#7>H[J'BF@6554"Y>Z/!:AX*%@4I!4$W7[3J,8QWBQ*W?9
M6F\&?'!P"/V..F%3I(\H=VB:EH,GLX<[KS=?/:KI%J:DYS2-_)J7@)EB8\4R
MS\E@<^F],M]KV$<S"X_'WRTBFGB("^[QV/4\Y*5$L"Z\\ 09PE/MH&-PM+]>
MFUP8A+AM8LW/DM'&V3FG);?C[[17TS1LGR<;AZ<%6@/3]NTU%E;;W>+C4H[2
M[M?YNRO^]WLY1OHYW]V4J^,WI<__-,]_R6[S_=7)U,48Q23TXM /&8G2*(Q$
MA%.<(!;A1.4\".LB0*R$'Q>QU^;LQ3F=N@NGU@>Z(-U^:?2S<U8% 6/I4:":
M[RK\E':<L%/^[BDWA_KU D='*X)IN3I>FN7(K[8Z=\^%:V]-YD$H?!HD,<&Q
MFX0R=L"Z@"YV [5U P.!K*\(]/,3=!^Z"5]?9^2(A@ZEX&ON&>-@OR=G2&?(
MR.E99BJ1TOA+!ECM_)C=5O>;:UJ457$K>Z-;<KW-\_IM:B_4#!G&;H(\STN]
MD/DRM.MV,5/7#95/Q1X<R7*/KM7G2('Y70$Y3'FXAPIKC:/:!R/0B7.M-N<@
M3N=6X>%^ E;_1O55;VFO\_=S4;[I#,XZE4.7L5[+_]P:E3'?9K  92Z7TL:;
M!3U*;5G>YA_E.];$>EL;*]^VID-+(Y<(PKV(4<:$;$MP&A\:D# 5D),<A\2Q
MC/*]-.>@S>G$F1@A:IR8=M:HGDDU$_;.8Q[-2";/#D0SY<[ :M7VS-)88(\P
M1% D:"+[:=R/NIC<<Y7N#C$3:;JJ96+88:IRG1V!F#5YUA4,FHM:%=-R2+62
M_9+OCL/9/^_W$;6-I<^QAT(F7!)Z.(IH$)&V5A/DQS2"U+ !82Q7+ZGLY)1/
MI]8&7',;8J':*MM([L'&("\85V_W>G7T805*YQWJ(9(!6^>!(Q.)E,9?.<AE
MVB_.%+_[NI'U^::X.][W0O.K<IN3U:JHR9BMW\N7\R:K\D_;;%-ERV;PR;$;
M8,)<$9#8$XS3V.>=/DX25_V:[3%5C3O7<N&471JG=P]_;A)QLD,FSEV;2KV=
ML\L%<B_TJ 6K,*DSVS*%P?>ER?S]A/0AE=/[LO;).,=LG"X=Y]-W4*Z0F\#G
M6KZ:=X2/6LZ*UX<;M/C<7-<DQ3B#>;%I\BZGKD"P,8NRQ(6@L@!0G'CUT,GU
M7=J<!+F/'Q,.NH+-7-0Y-/6P(8Y!Q]5&/-.8;;,-'G<\I.Q?S_#(?!G,8[1D
M(:_2]ML+ ^3[[*'Y.NQ32992RC9_65"UB%)&/)S@. Y=^2:1*$7H,)3S"8?P
MT5A0RWCL=-9?Q!6;Y3:O>T?%<2*CV#A:"]/FS5=#Y22^PTAY:GDKTCE'3^6+
M>\V 4M6]'DX:+X!Y8-)\6J7E%Q<&299OBR]R-/8E_Y1O;]]==1?'+)*$\MC#
M/$J#D 4$TY2G73B4!#X$BMI!+$-0E-NOV;;^6F^OIW)6]]M,?1)@N(EJ<!O%
M/QC,CI(NG%K4Z:5#X[+KG#D]K!KLYSS8-#R-TO![!F//KQO9[5C7G]_]E!6;
MMV55O=O(*ID7UYOT?KO--\N'HZ+JEWRW'VQ_RKXM*!,X"@)"0XI3/W(%"0Y#
M:C<4 81.%F58YM=1N7,MI3M_7$OQ?W+*37/,PDEOKCX:H;E?@+Q++V%LLUE(
M:O2;2?G ^'A2-#\U1?.V*YI6NM-I=T[$7SA2_D6W "$S&!>E^D[WP':$XIL'
MCL=(M!R]:@"_<RZ7Q3'B?]Q+<5</Q>::5,V6 OYMN;Y?U9];W]Z5&TFFYH2+
M1@X5-(RH$%X0D2#QW8#C2'"2!A'F:9!"@&Y-A&6<'S4[?S^(WI\L(V5?.'DK
M7/976^7=F;J['E*,7$YJ3)]%$<&(7C>=%R>P=O[C41G]>5]&G7(G?5I&H]-<
MU^,>EELOMGF0W'Z:3[_('L=758HWBU?K_<[6PT%=LEUYMATFEW_R[DH*>2_%
MU],5^XE$EN__?R'E\!2[',6>1U&2\#!*I#Q&W40V-PA$]=%$6:9\W5)7^ZYZ
M?KZS#L/Y> 6FAO=9EI7N!$?EW%<2Z+(3_](NR:;+7L]^R"0NG'T:3I>'\\<N
MDS^-RWY3!=#3%HQ>QO-H&\9/NYRX;@%V,)Y4FKK.%!N)MB/9&K#)/RFO9'^U
MZ\P>^K+=*M2JT^=S2D+*7(Q8&H8^B=,DE?H$"1D72:*T;6%\5;-H/5X:*P#V
MM8U;C/U-RKQ+<'B;\G+QM<>D[NHVY7E1'E=L_[AZM7V9NG@!VQ9G6\QZVQ8G
M*6ZUW8LFG3ZW>W&2TIS![L5I\BZGKD>P(>:[[76V:0]X3LM-5:Z+U;Y/LUF]
MWQ\CW?SVW94H-MEF663KPR=A%?E<[=>E(DHXB=P B9BD-*3<]0D6OE1%_ C%
MJE\6C2/&7KMRJO_">91!<W3U:0XU9PY9'+^GK)S?ND1&_FC)B/D]XY1Q"W<>
M@Y21<RZGK$[ !8K#3NU#[,O-5;F]W7]D6E1+V;6^W^:?\F\[*BW]?>'2D$6(
MXM3U I&X+"8L['0$W V!MSP:CP_!BM:16>^: ^Z/!5E?G/4<( [+=UFQ!BY#
MF"\-Q?6'28L!N/!P_([EZ/N)6N<HU_FM%NPTBD?&.-C1OF4&:Z4S#SQ;S._I
MPH)E)Y7.?.T0\5->7F^SNYMBF:V;$S.\)$ I#Q(1^FZ$B"_B).1QY =>3%E
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M7>7E\)< @#Q!?G[_MP^D#9"B)"$^9RR)J? ]+/NE!Z:FGH^4B0=[K&7@M6(
M]1KHB@+N[!D"HUVK0P=V0%, K+-GCA[JE$U2(]VC],Z!3L^#&7!.4W@YN/P!
ME/L_E[_0#W_[U$6@'@^%SSWY7XIDYU%@0KH(/J;JW\D"GVN9<YT:0)V&&J-
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MX?@#:;EI;FG[)$/1A_JVZ6)SS?*JN-XT/_LI^[S.%QY!)/3=5 Y_! N(_$5
M12I"ES.:AEQI3^D,9-I>Q).9.?O4G)/<+IPV.Z=)S^GRNW ^/YS\G-/EZ-1)
M.K\U*2GV\&?@K6)OX#LI?>!RY9@%;X7:]HJEIQV8P;LPCY9E#D:4LZNGL-8O
MS:H;L2Z_ME&[#2EQXLLA9" \1%-&<<"I*Y@;$]?UN9=$D(9++X+E-J<6Y=2J
MG%I6#FLN-#U3([U]NV"0?NR45#312/!%7WHH.<S'>0!N8 ZER3=+LU/].%@0
MX<AGQ$MB%B%/#DJYF\I@*0K]!">QTG$E T.,UIG5(8NN;<!.I#W'=#N $\/E
M96=4^F!Z5LX#+T.3.-?W&>*)RB68Z?UVFV^6#\T=FRFBGH@#EX@8QP@'0@2L
MZQ9YL:]\AR[HH;9[)ZT6\)6Y,&?ZJ6'5%& ?1-$/8Y=8GN;] @6TK9G^JDH]
MV>7 5T+Q0LKVT0NR7K=A"CF0VM]]&6.4H#!@#!.*$NP&D0C:4*E(0J6]38,"
MV-[DM%X[1TW "VZ'.=?/@=%,@S$!ZI?2M9=MJGM =+]["H@^0UZ A1'_)KX<
MTT@*I<'W"0@4_NN'!7(#'E'*8^S[:;TE2?AI]V@<^'3Q)=]^+I41HO)(R-M_
M&EVY$O#[;0DDA)(5BD0P[0&, '7RSKZ3Z:3-':Q%/7G<ZXD%"D@3^FH]Q*.9
MU'*0Y*>U&IZO<BW^B;Y?<.P+[D9^RI(XDF.),$J[6=#4]=6Z^Z '6F[VZ;;8
M%=6-<R=?X)53R2?(?W<-K--*QBC6:=.>P.KTKYMBEZ^<_RT]6)6W%\[[VA;0
M4OS0ZBSS[ZO.$'MF4IU!DI]69WB^RM4Y_;-88.S*=CZ,?9\C+N(H($%R( 5V
ME3;M@AYHN3I__%I4E7.US39+Q<VY,#L4*[%I)V"56)JP^X<$6;9973BBWPL+
M-5@FWU>#(=[,I :#)#^MP?!\U6LP81(.4409IS&1K7P2(!1%;OMHEL8! 7:K
M51YIO5N=9IML560;9U6NU]D66I%57%&MR(;M@*[]21^R"X<U-HQ;B0GKK<0
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M12**F)^ZJ8]CU^5N%XW'/H).%^E%L=X-NI1]G<^[?+7)*_"<D*9Q.HBQX]A
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M1DG-!!(C)?M\86X\C^'7M#6A:1WZ5-S)6U_1A^//M/+(UVR[VE^;Q+TXP5%
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M*2-5R,VN8*!@?'YKU85S2,)ILWBV8'9F_#8V44VXWTOA48MW+N0>-^EGM)_
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MN8 P/H_=U=R#:(Z$X.IK-20NA&<GU/(8C?V48&JQF-(A<2&>-T=B ,%G/$'
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M<I_7C./\711BJJM-L19%)/ZS*LI=LJ^+,J_K84,JC&Q"8B=P"0DIB8+4"MD
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M!L!$+:/3PV%7(SL(K%N3JFZJ$Z5M#=UZ&$486\0GKH]='#B441O;;M^<G8;
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MD._K>I^O:5/!KD723E6.=B?K'LQZY3L139PP<L3&I,6GG=0*>B .H\ K508
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M98689<6V:3AY:LXYDDU6U\W.46H%.++CP(^")+43YKHI3]%=XEB.%2;,@F3
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MNERUCB!Q(BZ,A)'(MUV'A@ZQ[?[[?NI+EBV ?]?XMN0\!>)DS5Y"1U7"?;)
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MCS.@TM9/(+*ZS1^*/6_A\=46L>-:EA4[04H9#5+7MQ@>6O0 #U:,;,?\@KM
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M#0-">S !<=W5EWQ[7<$E6BL(B#8<XY5?:1-HN_IYZ*>\!?GS!2ISX":.*2]
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MSX!HXW )!T+T&5,:Z6>ZY#\I^8K\*O9HX+)@$SIQG,1!Y%-D=\UZ=FP%>@*
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M%6"&H2Q<\Y7N*C3M/;.Z;\!QTRK_+'<FCF/;@/I+NO'[UG]98S5% "6.3<>
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M4@,*W#[S5:/-?BU[C$0/K8+K[9,S*KGP\P(?U\.>WKF?'A)B[E+942OSRU!
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M*W3Z+JDL88[C2_W)ONU#M6V/"ETWAPW<@TT_QBR*TA"Q.(VS+'"3J+=)O#@
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M-,9A@#%*W-CUHLCO/?'BS 7M])PC_FGRR77KEQ@YMM\UTC/GI^MB4]R4S=^
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M3Z/$)UY&0I=XOHMZ&R[V@T"M4-7[;.L5Z $18.P,ITAA]L$J-S"A.D#1F5F
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M<YYFGNOZ?I;YM#? O=17>MQ0XV,M*U\/!E!$ UE1& +9(P0F1ST.G6-:0%(
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M$?_IW.>;W4V^;-I@.M7^YGR]^M=0H&"5\?0QTIT.Z)&*(,FC'_NI%XE6!F[
MVZZ.7T8SE;A4$%&S,9F7JAKV[83,VF 0JKOMK?1#0F=%]]\%90'%/L<1<E/F
M^X&\MJFWZ8<H EV-.,Z295W5>#EM)',PX;-/FJ[0=>]7[$O!GP9P?[N,JKU)
ME(**C2-X7JHUTI<3*F6"(?"$0IIRAM*,$3>+@\ C"4^"X>,QR?Q^0H%O5L#I
MA/<^&#Z=,&#0Z$/%9O4C3".H<C:OWJ .^]0T LSO]]IXO6T6_\C7N[;X)IO5
M_][EZ_+F2=3D9+FL=INF9F6]7%?U;EMTNS#2E(41"=.04$R(AZGG1MV&X(2Z
M!"<J6=B\5=O[LWCJ#-M2KAP7_XR2*V?O07MT[N"#,SCA'+R ;>:R$)7S&?ZR
M 8%E>_NQ4-$VP=B1KHGO7FH:F-(W1,]>6"ZKBA;]JFPW:%CM<,"P7E=_Y8*5
M6J 93N!_$Y]%OI?U(O!\CR&?HR3R ^RAC'FT-YZ&. 5=$&O(Y&45]8"][= #
M>D?"=_Z0#@ WK9D*A-I(Z0(Q,"JB8^BW4AFJ$7JF;C0<D7E4E::=JJRV8I/*
MR:K[O-PLF/B?+,#4CRGS0U$ 4YP,ICE.05/O1@S.4S7_Z- ;E4S5")@03 OD
M3R*7[_)^ :WL(&DK)3 4/X).0ET"J:067ZK':*6%FVJ;YO6=+&?;NK9_Q#5%
MHGP-HCAA-$,QY2Z+TL&@&Z9$11D-F+&LAWLXL..;8W@[KV<34P93L1Z7W(7H
M2&3.'MK[+ST;YQ%V_G4B/K4/OFKSJGSV]30#;VBY0=KF<=K5A".5\28%4.NT
MVK1G9W?YFJS^8U<WLID-]KR$(Y*XOAM&.(FX[WJ<#_8\GBA=H3+>BF6M/L+F
M'($#*,XX#A6$>S+Z8+I]@CD=T1Y'(4"S)Z-23[*/*<T/^,;>47#.ZU,R;82I
M&:BT&3\JTVT(> =!OB[J+T6SVVYD%7\HZ7NKOA]EV(NH*^_0(MQ%U/-[JPQG
M5&GURY0MRWK=(P->/S"6/[7I@BFI \X42&1.#ZV=#3B:'(!6@X;N)3A/UIFI
M %,TSV,6P)@W+^\K,,J2R17[CX<ST"X7%GV4^7X0N03[F SS#XPP;GS57MWR
M_%?N/T(O2K 4(G-+^':B,_DRODI@)E_+_WCFM@:[,?IQUO0U?--8U]=E4+56
M_+5Z+&1%^F%S?@KXV9%'1-*(<I_Z" 6,IBF+AK4R%A$_AM2/-NQ?0HT'/^0Q
M:(4U%;4#P--%3*UBO72P#(BSE3A9J7@UR#Y3!=L,W3PJ8ZL>5M-U!),[#&B^
MEC]:9!G-0NY'J1M[H1^G68"&>08FKR*#GR(W8Q?2^;6/F-/]P?+K#M:<5K)[
MIK27LJ%,SZ.O&O8)M)BMQYC:^DAWW_3G;?58UO(@Z+=*?+W:+9LOQ6.QV15[
M79"GTD2+[(ZEU1\V_5_^>Y%O%RAFJ9?0( A3*B^RP3SM7S1*>$98JKZ0,@D<
MVRLN_<LN#WLONHNW9']N*J=NIZI$,A]>@'D2F"%K"=.$3&7=9G;1 B[P] $X
M..!\JYS>!:?WX5!:#5[(7^KF&S]LG.$S_GV6082L',TNF)I+3*][G^AT#WU0
MMWU0MT-0W^V9H]>F3/!Z<A%KTJ#-8;5K6H>KBW400 X_6J13AO195*9;":A>
M>*F/4^:Z88PP9AF+."(#H@C%T6)3W+8'TA5SN&4X2@J2= KR"KFRBARO]Q]+
MQ(,$VNH"9 >%[0@IY.HY1$4K21]' IR=6P_:W#RG< &R\HS"II>.C\,'SL-'
MO6UL&AY'Y*G\.U%X9I!XI_*TFK[Q U+MY_RIA3,L.S\\K,MB16[S<E,W[R%\
M5@8$,0Y8&&99ZH>8I,3-W $;"B(7FG0G S9-^AW<^>=MOZ/CZ.;JL>/GZ6*H
MD);G%3>M!#VXL-]]TSOA]%ZHI6S-<?1TP00D[5D&52]][SNB,_3$O(]NWD=7
M*:.;'%";8O=43I\\>C/([M/[7%VROTR5\??%R(*G*/$X=J,,93X-7<PS-""C
ME(23YGMU6#/*]GHC[ZG"9SO5&P[9!1/]84@^PS!.E>3MA/.B*?[0/R^:X/?,
M6DGO\+C]Z,E=PV-CJ5V7;;,[4?S08Y@':8@8#G'&<!3&@VT><PR]?M",5?@^
M%/#=A.(/_IMO05$E^4?:@J+LD]86%!ACJATQK>I&6N/?'XI-7=2+E&(694$8
M>'$0\BB@4<:S- M<837Q/*5K%+0_W/;V$(FGW;19](BF[5HO^3C3B[2IFT>'
MT8=?&6I"L&[0[Z67SRQ4ZW)9BAXX//V<B)&L'V$L'UN(?9(RY-%(Q)=D?I9$
M&"ENAQYAP>(*WQZ4,Z!2>2'>2N<X3="9;F* U7ET&!..5,9;'&"V9K@L_].C
MR%IE\5=K\^E;\;VAPL\_%Z*+\LS+,L0C[/$P0\1E@TF&B=(;PT8,6<XQ^Z<E
M!GR L?9H#A7F0J:D#R9&KYAS_NC .1*=T\*#W/PPFDW E,24K.K--;"B7F[+
MZ_;0BE,-# _/,E;W#_GFJ2V-2E$B'5ZG&3NC\ XQIZ8*3/$Y@SD 8ZY4%MH;
M=+"PJ86A5=LT7II$:11$;N*W-V"2*)079 XF0\\#/?H\RI#U0<01-MAIO''\
MJ=69DU$'$_=GL*Z<7M@A F]I1'::K;.C,P,DSZ/P-./*JU&;,7Y4M>GWNOAT
MP^NFO,\;,4QTLX1&D?APBJ/0I1&3NY!Z(YFH>R%J!/QHR_HCT,BTO<<#DR H
M36JB8Y$AF,R\)&<^2O.<HC/:HLGE/-1$%WQEI#W!%&._^+&L;C?E6TKENB%/
MW2CRLHAD3-CUZ5ZI(E%@041DO#7+NG)8.MXCA$F+ 3[5U&9:*F$"-+!X<;UY
MEZ0S$F2.X'FHDD%_*EM-$:9=65YNY;*1D,FLW.2;99FO/VSJ9MO.#-0=B$7*
M"8^#E&21%\4T\#A.]KH9<)]#],N,1<L:)D&V-W44SJ]%+J_$ =RX:IA;-2V;
MGE:8GATQ*NJJ/43G".-\:BPE,L_HGME@S$/[#/M4V6R^P-FHO+XCFY7\#__/
M7?F8KP\F#_H;9F$8(>PC434F418D218-MF/L,M"TE!&+MN>GY'WL<B*W_>((
M)W"NR@R[BI-6DQ,+G+TZQ>E\M$^)PG-36D9#, _M,^S3RTDN"XRICUV7A;!X
MO2Y>&_1)$H=)G* @3?T8QYCNQ3;%$8(-6K7-6%:Y_?68!XC0T:H^@ZK#U$G(
M@XY/!U"7EZS3!)T=FXYF=1[B9,*15Z-10]P %@27A;RR7HY\OY3UG^FV6)6-
M_&H1QCR*4^H%%/E)1G'"Q8!WF+3+(M#%GV/LV%\./$"38Z0.FB.Q@5<']<E4
M7AR<A$?PVN 1A1+,U3&+,ZJQ3M-W?K%P-.GSD"PCGKQ>*C3$CJIH?=@\%MW=
M!B]%$B,?H9@AST-1X),T\-U@L(<R%_0HL;X5RX+U:[[]LVC:"N!KL=QMRZ;L
M;[+]U-P56^< '#AB',&KFGI-0RE,NPZ8YB-3)WDZ(U+CN9V'1!GPHS+=ZF#R
M),>2S=.O17-7K8[Z8C^5QK'/$TS"+*)" '' 8[27Q"2 O9L^SI)EF>K .1TZ
M65<=MC/#9&DDGVK2-!V5,'EZSN(1LLNKU%G*SBB5&:KGH5:&?*EL-$9X4;41
M5#Z]VNWE,]^CON>2A 5!2&F8X/W T\TB:$VE9<2R5NUQP0LF/<[4ZR7K=,'+
MI1;2O*JEMUAZIU@:1>P\U&>\&V^42@9X4=6<SUMY3J%Y^BR:6"//" K=>WBK
M4 LS,8)TW2P.@BS#*$@#A/9[,%P:0#3(F%'+FC3@%!U-(FT'>'NL,)TRQ[.:
M;EV$8IB.G65W/MJFRN09K3,>C'EHGWFW*LN-&*:-'XNZ+HJ/15Z_7@L(DB2-
M,$'(]_THX0R'KE#C.$$8\=#-0'(XQHYE!>Q P:1N%&UJZC858S!!ZU!=.1VN
MRRO7&9;.B)4);N>A3T8\J<RW/)@*_5)5J[_*]5KHWX=-(]I;>;TNB$#1U"^_
M[T>GU T"3'!,(AR'?A)%0@/WVR5("#I%:-ZZ]7'D@,KI8,'$RP+;:I)V6:)A
M0C=@;4NV5X1?O?6CN51S8)K/**6]D,U#/RWZ5TW5^*$S<*+D7 J)EQ='B3^2
M>]-8\5BLJZ.R<^&&*7:3,$49XEX6,DI<;S_[EQ&E9['-6K2^44P4WMM"]O6?
M'SJXSH"WU8 CQ,Y/'SY_^:?\_N%?V-^@4WE&R%>=UYN:=^@DG_/Y':;G(ZI*
M9)Z="S09C'F(IV&?7LT2FF?,0$$Z_%-OGX41X3SC$46AYP9$ -@/RX/ ]PP5
MHD"KEL5R0&.L[H22.KK>M,BGV3IS^/?Y**$RJWIEI69DYJ&(%OQ2+R-',:=<
M/MX_Y.56"O"G+2OKAZK.UY]N/E:;VX_E8[$Z+F"/=L!X"?/\!,5>A''L1A$_
MB+2'? RJ)FT L#U@WV.6.U0DUI];L%K#=SL14"PI+TT^L,(\XGWK#(#?C,%\
M]%6'XW.%I\V0S4-U[;KXLBRUSZ>J%@^WNZ75_76YZ2[B&X[2QKZ//(\$;A@D
MF$:(Q.%^M2CT0&LW(\Q8UM6T:C?ZR?XMKY(J5_UUA#!!'4.CFFQ.Q"!,'/?W
M:!ZCFHT*GJ;LC-89X'D>BF;"D<IX&X2I$RNVY:.P\_AZ%2F.DL G"+N>S[R,
MTP#Y_MX@\D"'[4>8L:Q.!V3'UV"T [U_+5:W\C9MLA3_W)ZL@$G6&&[5)&LB
M6F&2=01J/O7:::;.*)4!>N>A5"8<J8PW/> M2=6V*&_[1^"%N6V^J?-EJY!B
MF-U^NSX6S .>A,69AUV,&$5)0 /,O7U=AWD*>@7#'@K+.G<$K;W\I_.C?R]T
M"=8VB]%0D[YY! *FC"](%W)XA+I-.<>X9Z.=VE2?D5;[X9N'\D[@Y\M;G"9B
M5NDAB2_54[YNGN3#+]5-^[3X2Z,4HP0G-.0NQBQTHSA%^W-W).;J3TF,-V59
M@7N CD0H);C%"'@"P0"7YZ7U C3"]/--!D<^+&& 5<#3$M.RJ_>XQ'B6U5Z3
M>)>+-]*'81)G\**$06<J*PT->HG,O7S;J[L HGM^N'WUZY5U$N D1H01EN$@
M\-.4)_MUKR@%W69JRJ;US4O[][ENJJWS]2[?%C_3O"Y6SK$'T'MF#/&M5G5?
M@FI8CCA&Z/006RF;T62$(HMGRF?3<9A'L6S<JU?7T]A@3?V:OVZ'U-'V*'GC
MH,"T$VKRM;II_A**\!(+\S(?LR@BF" >Q3'AP?Z$-_?#%'8#H T$MLOF4_L[
M^7O/?DX9!37YO'P @ 5WC_?J^7;/]O+4'K0SH)Z/O&JQ?$9L[49M'M)KV<=7
M=QO:9U15EK\6:_&OM[\4FV*;RQU;9'5?;LJZO<7LL1A4YA48W_5PA#T:<0][
M<9"ZWGZ2F\<!J("U!,&R,/>HKYP>=RL+SY%K:K2MD*B)] RB 5-I2"#FH])Z
M-)^1:<MQFX=.VW:RFK0O0 ]%+:O[XEO^_:4YG^#(Y6Z:AHP%?A(0ENSK=4)=
MV,Y572.V=Z>VN!P!#*JF^K2IZ>4DC,$4\4#6?/3N%$WG=H6.978>FC7>C5>'
MCHSP IC3O"^[:]?:*K7?SB@7S5\"2&,/!6F,4A=YG/II$J>'Q^TH\($2<V:G
MVN$)WT=@DEOE*<Q+T J>Q1Q ]J/M(YCST31U+L_/99H.R#QTSX9CKV<T[7"G
M?,%MOMT(D_5G,6R_>V/,+JQ1'*,H(T&<I8P13O=C=IIXH-)LK"W+*CC <QZ*
M?G4'>+?M6"K5]&]*%F&BMR?P\T#@?)3N'=;.R)LION>A:<:\>7G-K5&65-7K
MM^*OPZKLYVVU$5\NBZ,+=E]MD<*BI,0>R5@:B3(SCH62[@^R(Q_T$KEQXY;U
M3> ]NK?;>8X8)G7F>5?3OHM2#A/#LVS/1Q>AC)X12FO!F8=RVG.OFJB1 ]=5
MEG?%:K<N/MV\_;;>-_EJR8+Z+ FRB) @8)AZ2<8C$F9>DG :X30&'8$T8]'V
MJDD/LGU=ZM1+E,X?+5;%?8R&&5=<)9F<;."BB!&>[:Q\J%!W;J'#*/7S4$?#
M/KU<QK# &/R%JF_B[\CWLE[X$4<QI7[L!T&*@\SG63(8\D2-J_<TE?+'6U^I
M&! Y$I+SAP0%E#(=TE17*ZSR!5VG %%E^8&I@9"S*Q+:[,U#9\8X</(M*4TN
M]!0DS9OBMMJ6_]5N8_RUN+\NM@LO2E/L8R]D'O5PX 99B@?#'/N@=0<#YB96
MF.<8G3]8=9^7FU&2H\>RC@19)UA7DNKWB9Q D-ZB1UF@1G$[1\$:Y]!9 3/
M%61!M=@NRWS].7\HMKVM).:^&\=I&++83WP:A2CN;<4!S[S%8[&]KB"KIW ;
MD'YU# >TL-?!<EI<\-52#>+4%T;M,@9? SVFROFC@W2!-<Y7M+RSG*E/XSQ$
M9Z0/;RQ2CF5$_9#%@VA.=WE=D-MMT<UZ]0;3C--$&*$NBST>Q0G)V& P\N,
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M[A05RS1M!B2JS>#<+5"I&# 9:9*A=J%:).7"6^(CSX>"VHRJB"ZD9U^D:^,
M13$(W2B&%" 7^]3MC]Q3%V*LM^2R!&J:!5G?18+WC!R.031US=8H28O@G".C
MKY@C]%<+.J12(U5,6BT/V.)TV+:_YT5[$J:%6JV]#NI,\53JHC -W AF((M0
M3"&.^PB3^BX5?\[!J%7+&=CSJB!=<6B;_LL2/2_SIJ1X<:1+]$>;C7RUGF@&
M!T&L*9H,/Z^$-'L<+Z#YF1V_:MM?IW8HPL7#KEAW]\C@?;W;E__JWIKE9:8K
M%*5QF"0AR0(4AI#Z40)Z&*D?N!)["VL8IME*C#%>.?D(97NTU%;E:FNDYF H
MQZ<)!L!HF'+&@)TQ8N=F"0.A';.F&Q#-T,43A>,.69OQP#R9)>T,T6WKJ<"6
M7" S0_QBXYDA]]X.:R9YU$NEK4*V=8LS'P,4XABF/L(H[(UE64844_<R)J9/
MWBO?+%8E42=]990_4QNA]Q?*U"?,0DFGEH3)7'*^2-P)H220)">B@O-[Q1M"
M?JG*?[4&^\*,H4OHAZ+*M^VEX#;Y5/ W48XU'<,UX2!&$+LT(%X<A2@":99&
M%-$0X-1S"?)D"O2FP&,Y&_2L1TM]Y[" X=P67\JJXJ6Z?*U=5!O^2_9GAY'#
MK>S='EV6T[Q)QE%,()<VA')J.D;?*NJIXF[4(7GPH;^@TGK1U^W-UH#! /47
MQ'K*@5V&LD_J<3W?-#(2,U8X !%(?)>ZV$W#+'5QXO;6@CAV5P_%KJPWG_;Y
M;J\5#=ZT)",/ST$)*T7?J#'?._\SKPZ\<R8P(MIO$ZDEQ$;9,R2NBY!)>>D3
MIG+1<B;NA9A$2;*BOU3=%7E3-!^+YK#EMUTH<QP=V!*ZVG]H)S=7R[HIVQ:)
M*YAF*$K2Q(,4!6'BNB1)>W# #Z"9U:I12)87K'"SZ8 XW6T"MFCE"]&''I^S
M*[8\Y>SLZW8IN^X<<3KE-+5.-3N(NDO5V<;/Y&JU=<(9G'"X(CA'-YS.CVXU
MVWNR"!F69%]IP6IE>!<M\M:<%EZV6N3<2@CYP$#M7H%&(DA@!E,<P!!D<18G
M !^A^<C#0H^\3PIHLO!Q5^^>18[ZSGG@J(^QPEA2P^1P60@54XR4]4#1.O&C
MA8DSS)L*$KH#^P.&"&V7=0*$&;XUPP,N9*!!+_ ]X/J4Q@E!<9H![/?0HC2$
M"K7LD^":I@;E8[$YK">-%H9'3RM:S#!BIJ-%[\(/%BVDF)>/%G8&=M'1PI++
M8M'")M^:T>*D<$^PO<L?FN+F#CX\;,LU;X+_:9_O#WOV6^_*^[*K76I6@1NX
M:11%?@1<#\5QEL1]YLP/?9*8"QY684X32X[0G.+[0[E3>0!EEA'4"B#SCYKI
M>#)X]#R@M#[Q)<')*Z<?<?:[(\<6$6!T1D8^WDSR'2PZ_$S#@%@TFG TK&QE
M/A7[_;9H7_/[1[G_ROX^^P-XV'^M=UWMD9NEV$M!FB"$8<CA):#'&$ D]1+*
MM,@LY[Y&^"QN5O3'Q\*N9=*AL;Y]&7GC_,7<<3I_G)%#BP@S:F-A:D-C;,P7
M'5IL^ZZSQ3$\ KHE/TD<!(@D"*,TR$(<^VD2]M:(YX7'DA]2;?0*?MZR(U_P
MTT-2*?=A0U/<WQ8[QS]?\+/PPA510A<]4<6]$"Q<D6-%=/*<'L>&U;[<E-O#
MOOQ6?.+/X[5SEGQ?;P^;8M.>B-;W#X=N:7AS1_(=KQAN/A2[ME->^]KCBGK8
M"R#-"(U]X%.:T)"T#^11 "%A.TR)Q=C$T&ROQH[>M+O&D3_.R2&G]^A8#''R
MB?]+O5<\C]DUV#P^L7F^CG<1(RZVO%OP8,NM[^889RMZ;G9$+H2!F89^&=%C
M+N?K14P_N5BE"2U[?/T'P.]ELP*^[V59%B!*8(I!D$$*>\3 )4 F<,V)TW8]
MC1E%NW)N'\^JXQ_<4<F@-NNG(1;A?I2O0B[<*0ZBE8AED>$+X6L)X[J,6+8(
M)NKES3H34>Y]?E_@^CXOJY47>!"C.($@]!-,_#1*4&^61*[4*V?:QN:)-U<.
MA^C\T8$T$BMD"-81?$O<&E%M45HG5.\37=(2K,#TDG54Q1TA,53F2:@MUJ=]
MO?[SYJ$]3X35AMP_;.O'HFA_N^\?^X%]G+^U6<L5#+P$Q\0#"7$I])(,9T&/
M *>4K+X5N]M:J!F68<LRLW$,4J)DA %SZ@YP=Q/_"-EIVC]Z.()V'MB_)]&#
MR?007):_N;F73-=(D>[\T0$6C#A6V)=H?C7C**CUO9(;#=UN5W+TO!)_;)*\
M@!Y7MCRK[7^BDR:6WI55<;TO[IL5SD*/P,0C/HJ#@&(7P? (+T. 2-6B3 ;J
MQT@939H/DAC129(_=@;33*9'^C"#.^.TWBQBAR$_"/:20?+CO.0=BTVWS:9Y
M5'D7V@%E>5.N66S#'%^Q>6Y[:(A#J.=&F&:^%P<I")$?9=[1- ,19!);'U,F
MK>]Y6J#M0F_3076*7C$>F&(TXLIOEFJ!+<X<',LI=D<N@^@<,;XJQV^W [/(
ML\1F9@Z^U78Q(A^U[MY%D(USFQ;39"Y@MV+<I=KBQR<1/MZS+W#':1V,^"!*
M@)OY&!(/4\]'613W1MC.*)0(%/(_W'I(&"#]AX0@*9 D(/%VV9$3\P&+FF(K
M$"2AS7:)4E/A 9.NU+YP[IRHJK.P /G4 %\;^1*DGMJHZONR>F(&@B0+P@3%
M*$DI1M1/7#*8\3V9U;/*C[<NBR-0,L*H1)6 --KF2$X<1VC4Y%&))JEG*.S2
MI?K,Q(!*_^6(%PZ>DTD=+A8@E%KP:T/?A%Q^^Q]%^>4K6[9"ICSYEX)I]&VQ
MN[EKEZ[-S6'?[/.VYW>[RET%+J9AFGAN%OLT#0(,A^)-3.-(*HEMUK+E3'4/
MULD[M$[5PN5YS'5]?U]7W=:M<>H3\&DSF%)T7DA3VAF69>0B+?E63_%A2S[(
M\K(LK=<1%-,P8DLM&$=A@$$&2(![@Q[-8K'5D %#UM=%Y.ZN6+>O@@^'$\T
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MRQ<R.[;';1FI'NM>UM/.!LDGC\\:_'57-\W'(M^6_RHVO^9EU:RR*$5N1OT
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M ::$D]SKK\7FL&6:BIG,5L7FJ+=MJ\A3*[FF?71J15""$^CB)((11" #?L8
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MYX5I*L'&,J:I#.!:>>3E5M\O<[BG%.X[]B?7^^*^61$_2CTO9?_Q?!"S_]
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M$45>$/DH"E(JU47'C$7+R?+1N[H#2J>#Z7"<O[B>W F>(9[%3O.FIUAN22S
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MQ8H!J7.] ,)E+MG/1+SBA7O)+U[[$KXX.^="BPV"%Q!EK+A56_XP978A?6N
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M$D@]ZGE,S=.81!3Y$$#LIS!-Y?14\H=;ETKXZ1/Y_$DRZRA)D&#NT!XSDAG
M%HCS1P]E8I%ZRL.E))P:8<N0%E7PSQ-B.AS("0+J&DV<;!%*@P11ZD(W24!
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M0&D*D4M[^Y2D4BW\S5F5RG7)MU_H@3K\Z+6-+W*[5(/TBFU5YV%6;K\ZD,I
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MUI8&RVZ<L#=.4\<)[LF/%R>>\&\A3JB-[X\=)Q1]-A0G=!C7SYT\1;E*:1:
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MVO#_XY7\W_(MU^X/Q:[D=WN>O@I(OJ^WAPU#Q7[QE7WGQ4>V125W=\5ZOR*
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M=LECRW6G^PM/*I.2V)5*ZN;BLOK7OV NU)8+DR"95-JW3Y=E&0 #$0\"$8%
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M&_U(VU,_Q@(Y8HAVR7X7+.-I8-NGH!,^_S6XK^HMUAJLW:E4,Z J=&V.S*Q
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M,\@PF\Z?+(CPMY>+(?PJ^3#XKWQJ%K-Y?A?$N.-JZ/:&"1;<$\:505 &&U)
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MGZ;9S<2LZ#P8W][6/ F;J46\"-]S:2QDK%@@FYD%'G5YTM)F.+M9:#3(TJ[
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M$\N@0=( QPRV%*GRR@'%/JK.]]$'#V<.R38D4EL=[K[;M$OG[>X1_"'AG*!
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M46H(U AX 'RPG*"0KI*[W@[_/@]OT]%BO'P=*'K97 ZNQOOR?9K_6,(1MQ)
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M8GZ;3[/YPX%PQO8."952<<0-!(@9@;PG4):S,W'/!?9'^W<>SVB$VZ?#TL[
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M7&8E\%AKEF#>;_7&Y_"KM<UUA?SJ">>AN/9[L8[#+Z9NLES,%I]7)XGU=H,
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MN\.4J$:12GWM[N>5\G,:147%:*.< U(3D!Q:]R.R5&4Y (S/D,F6Z_'B?>W
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MQ>F,0[Y9IJU^L*I#)Y_%]ZWT9#Y9W!<?OQ3%FU=BSY,$UA=KMEA%$W+[[*F
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MF/Y>K&<[X[M53;86;PE16Y%,(@29U=Y@31'?.;9HZS!AC>X<^\'B0RJ9LAW
M-D#^0QE[7(]D+ZV610/.?65P/-T1.<40T8X"(ZT'%4I4JYNY<>N502\3/0TC
MC LN(_O@0/@3+2<T'?-YC"V*M" 6 \T0T-A ;Y'6IM'1?]_ZAXT"6A33'R3U
M%+7>/$2PP7N",\(*!:Q@BBD#-<1:5'A0" ==./HWEGMARI&J0UWC/Y1!_01,
MZO7'K^5BE7)]W>^ .QZY=[)MP(8+3Y#A#%GE-'-2.Z I]<GJB@K>;7&N)SZ4
M_:(^"J:=C)-KT#JD,HY<"6N!@4 R(KGG0'/&C7>29&59&R';.N1!&X:=A?50
M'//ELIA]7AR-@COX;/!.6&.C >H@(LARJ&@:$^:0<RCHC?B=]"+ELEMLF_%E
M51%F%=7?S^6W_[A/V5B7WQ-?>/5-H@I_1I7]CX-U;W#CZ9=!$(($Q-A9+;7V
M2O"(L:8BE<8D**MLXPC)D"&P,A.Z 61M_G%$UN8?@2M./,-IYS6 1(T/1V-.
M4X8I@)ZAG("T$=XC=2?KUM -Z ST/$580WWV2*L@F$&,:8<<U, X(XFJM34.
MLASB1TB18339[O"^,*].:J]'V\4EDS*N@?0>4B"\C]-156,%U-]V):;SI-Z,
M26?A.Q27MD>-[\M%N4L[N/B\&\0^^^I)];5)\Z"IBZLZ(B(J;C1NQ,@27N.I
M9([[Z_4PJRT+RMZ!'LR;^M7B_;1V_]H@)+91^^!P.G.7\1^$H\+ N2>P/CZS
M(B>UV B3^0^S-?:!_/G>6V]<*#3UX#K=-%!O,("6*Q GIS'6 .>J40CG!EVD
M!O&,[E:V9:]PYR2(N$\2^1QGRKY:2LJ+N]K745EOEF\I3$V;!A,!P8P K55<
M8 7BSN-Z-8^=N172="_6LE>D+[>U^4VZRDR[_V9U]Y!^TFIG>]T\, ^8)09X
M[@$!&"@(6#5RZ[*.@,87/-0'QWI$^W(\VW]Y]\=\]OED<8'3K0/"R*?JG9AY
M"Y3&7)!:+V6 Y6Q_H\J&= &6Y8(]%,GV_B>GB[+\^&# RDAI#'*$4NZ4!DK6
MVB5&MU)6J'?B9*%ZN87H?;&.^_>LG,[N]S\UY>IHG&S#5P2&.&$0>4V%Y= (
MQ>.*O$7 (6I)SF%GZQH^-[8D=8+X!1W)CCB7_42^9<HS*!PQU"M#O*<* >&-
MI]!(CR2[8'[Z/>-,N=@%Q:8J?E%&IUS)CC4+3ECI?#J[D)01H; 3^]$J0+RY
ML=SQO?#@[76A"[@OX[[S*7YV*^^PJD$ AFOJXOI)42H/F:X7034Z9>F@F:7Z
M)U,W@C[JGW,FLI?C34M?KZ<F03)!HY4(,*0"4JZ, #5@BH@;2^>?*^:3K#D+
MU<'TW?*Q6*UG]XU\N5X_'(@U<5S2.8'C7\9@(LQ^5% H>V-Y\_.%^W*'RD5T
MT&O4-R,V]KKI<PV\V:UJN[<%0860$'*LK9&<:BB0JG"!3-Y8X?;.F=8_Y .;
MZ"\W^[/N7!N\) ">2A%CP)F6R!/#K++UA*0\)[Q\A,3K197J#>VS[\WVUS#_
M9S.9SQZ^IR0QGPM?+M^PNP]=GS5_0X#( V@9UTI[):E#V\"YW9C8P,&$%V-0
MEK#+(8"_\ *63JA^+^[+SXO9_Q33]FO7C^T#ME9* ;7"T#--(2",UM@BFD.Z
MZUFVNB!=G[ /2+FMM)Z?NOPZF_PQF\_6W\U\LEK-'F;%]'VYN-\LE\>3GK5^
M5P ,>@<QM]9Z "SDR%;;!A+$YAB4(W1=&H:*O8I@J)/O_][$_E[L0'OW\4V2
MK_SP8  ."4>0ABQEK(NX>KW+&F9<%*17ESN6WN;H^5+.X]18[3K]OEP7[5(F
M-'Y'8-Q8H32W3%%C"3#:\3T. BIY>VE5SJ3!RWCFG@ >=-*J^_O-XV8^61>[
M9 YI)5H67](5[[?B*>GZ^7=6!_3VAI][RF&RY6L"LT JK)34"%D<;5\0[:"T
M?#IBK-.-7 #ZF?(-1W+J9JK-:X(PFF.*/4=<62:AXDQ4:'"+;R0"N%^BO"RL
MTQ_^0^F83VE65]$<>U_\&<>4(MBBA?9A62[BE_>[],"G*A6W>4_@1 BQO1BD
MV$9#+R[*L,("^JQCP1%QL5^:O.1BCP(8BHSIQ/3N04W+;370DP?2;ST>4GDL
M9X#:W313IB1&^Y%9%@V[&Z-6/U(O.P=ZL/6L'O_'E,=WLIRN_OEU&J=>?)X!
M>))3C=H'ZKQ47$. (("&&^RPJL9.J1A4B>Z?9'GB?[UG=@[P4.2JP^=VZG1:
MQ\M%@\WQ:+M@E=*81>/>,\F\XP![5HW5*W9C9WZ#;(9= CX4N5YT]:0GR)O/
M!R> A@13[Y!1R&,F2#TVH8;-FCI P&$W<BZ[1W; _:Z:3N^+]3\7RV(R3T?:
M3Z%*O\3.IQG59.MK]:IH-ADOF >6$>,(\DKNG1X<<5!F%7,=(=<R67'8=.P#
M[ O0K^IO'(Z9K+[X>?GG/XKIY^+#%MTV[&ORIH -B>JKL%IC%6>W!!14P#O*
MZ: !:%=,OAZPO@#WCI]F+F??)JF4S;/+Y]5VD%7MVQK7V"K^(!E/Y7)+BA_*
M)Z6;F70_5,[GVU0'4>QQKK9A]N7[&227!$E,C#4:0>&8 _4ZPLRP(757/&^N
M3I(7F)5O)(%X.J]H,VT:O"A01*!%0"F,'.3,>H%LA0:/7V7P>D3Q?KWSNGNH
M+T"\3\O8[5UID_,(=^0%P?@X\&B22H@]%AH97A]\>.>$RR!:ZP# *R9:=Q"/
M3-_XM8$C:]M7!<[B9%-6B B$TT@A:&I$", Y%R8CW+6'N3#I5P8C8V74[^\>
M/DW^RB=E]:: E$$6&RNY0L B@V%]:^J]Y8-&JWW=Q@U_7$^6ZS$P\PS2G,?.
M,X4Q%#G-;@RQR^[AH;B/?7UQ135;W,^^SN. =H'?3[<,1WAZ_DN#(=0"((5U
MBBG/L*>&5BC!N)'=UJ'!8&0=3"(_P:)J*4!">>>)0@*Y* R;\J]$0"RP,L>,
MN=Z-_@++:2LQ#!K/=Z#KNG@HE\7OQ?W>D7B7W[,)13/>&JBR.-H #C&&M5?&
M,\@K>1@+<XRA$5K=@]%U.)$,%^K^8W]]!+<!G&;G";_;-AIPN<N/"03&!< B
MXB06$DC*O5;UWN1$3ICT""W]P<A]01F-8:&NNO[F@>_NVN7,Q;K!FP, 6F$N
M@-'8$*FU1&(77)=*]&&<XVS"?F).#RN6VU># 1#:<H<T%I!1;!TAL,(CPI-S
MML#/.UMPB^EM4+5?48PQGN7LPN'C"F>1B$  #$0>\6B2>&85D=@:[XWR1#0J
MA=&37V2=][V-1-H5#S_KS2%Y+'B@/:3$>8&)397>L$W6'?>8W$A6I'[I=+"R
MYQ BN91]<K=9-QI@8R9W\P$!6J"-T0Q0"CTEQEB.)79 .N@XYC?B]C0HH2\B
MF4'WR4LG(3TW9MLR8("VP!$)G#%2ZN3[#S1 RD%-&\7R]'2Q43X^EHMM4/#[
M3;JSOGOX^"52>A7U^?^<S#=%52_]6=639GE6SWYMH,2Z:/YBP@T&Q DDHTV\
M1\M;=F-!=>=2Y>75Q7"(#W;I]C2DW5#49OVE7)[(3W.D5=#"(H[2 8OER"G)
MHY%:C9/R9BE]KX=9PU#B, \SX;\8S=ZM5IMV%-NU"(Y1**DRT&C +&+$ U2-
MCQ"<$T<P(IUF7/0Z"_J+42NJ9*L4+3A;?&[#KV?- A9.&D:I<4@PPYRU7%0C
M-58VRO]R/1>KXR#9^?@/JAZ?:P!TGB?E94?*S;ILTI%3)TVY[PU2$XJCY#1G
M GF<ZO6!_5DCYK)9&<,1VNU]F>M!6FQ%M#PQQ$I2!#WP5: ]ELK=B,(T,+>Z
M--M;2NBZ \P1TXP8)363<;UE!'+B]V,EFO*<K6]$;!R8%ZTBSMM)X+HBS@W@
MT< &FF"!L%?."EK-7V(AN9&UKF,Y-XHX;X?LSQ!Q+BQGP#E'M$;&0N\)>4*$
M\!NKV9W)BMR(\W9@WW[$N070PX@ ETRG!,&,R[V/!J$:D4;WK]=S3-$;^7K
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MCJ4S$88I=Q38"*C9C](@S',\'4=XT=X?KSJ#>+C\%U4FWY:KUO&&01 J+)8
M2RX\(]$T)=6-G:%.Y00:C-+:[X]2G0(]F+U2+HO9Y\6N_OK]=Y/2@T80MBBU
MXUG+-P5D#=1",X@CVM@J&6&O\( <Y-QTMK:^KYMX_2)_FHD'@J _S">+_:#+
MI=V+(X71%XO55F+-^'7VNX)#DD"L@5!Q@F'F#4 5GL90E>.@T3J?P74R;"CL
M+VZ0GF.(!D:%D5!%39-:@#&T)&J>^S$R9W-RQK.?@U]=8SP4CYX9WN>=;C1[
M04 &2>RQ)CBNK!8:ATT5PF.L1CDG<]=P(WB9(XY>9'-A?6Y5#>I[)TK=T=<%
M! 6S7!*+M(L+O\.:5@:4=1P,&KL\!&N[)DPS]:Y+&0S%3KU9S1;%:A6UAS]F
MBZUPTW#BU(TPQZ]6L^DVP59*L+ ?W!%RGO&V #DE<0OAPGBIL'(JQ6OL<6$.
M#YJ[_P:XV;\(QK&EG[V5!V:<(,9XCJ1VCL5ANRHBR%JAAW7H+=>3^373K5.L
M1Y#ZY<59XI7G?L&"TFCQ.2'CG\13K+AS@F-EI9*PF3W4SVB3:^&[1>SF)J%_
M*HO+&T\');23G&!*L. &:LHC3?=CLTH,>J-SX7PLC<5<=@WK4'O!CST]$<OQ
M^N'@I6!> N"I]]()+RCFU:B 4SG)6D=(EBRY'N7(&6!>AB+O)PW*]!QJ$I 7
M0F*%!824&0@L<; :(5'#WA8/39=V(C[*EK,1/?N$^V/<Z\OE^W)=K#[]67XH
M9[$341W^4"SO8W_LIOCT9_S[^^[/@SZYY[XJ*(8<MH)1CZ"*ZK1EN%Z(J<\J
M\3%ZWIPC[')0O#MA57RPV';NX^ROV$\_^W:@B_&7S0G6_JV!8^  981;!#3T
M2"?G]PIDHAOE];L>OX/^N-8[]%W0SI>;Y;:3_Z]8'NEB^DUCTK5^9U!06.Y2
M_@P*.)2&JFC5[<?-HQP&M9ROEW)] ]\)X5*W4A_36ORB>[Y<MJ5:\[<%0PA$
MREJ!-&:$"N45J=&E/N<\<(0Q /V1K#?(+Z/0_]H@&.5 BR YM"[I"-!8KJ7W
M"M98.F9SKC]&OU5V:?V=B^A0C-D2_\/D^]:+L-61\8F6 2-G((22.L,51A Y
M^S0;C<IQ+!CE!5JVW%_5-NL2WQ&<$[]PFK_R<V+/%*.,<X.LU5#IJ%7L,K0[
M);B7C?;<?D;[\?Y+,=W,B[N'ZF)+W?_W9K::)8&N]/=GWQVXYCIUMMS1)P1F
MX]*JB*"(2FL\I9''>PRETN16DS)GT:D<@RAN)^>?-C8.#R+&&;* 4@BUK<9M
M!;VQ8\O!V7)&QK]V$KF=C'\8<TTT\Q ";17G0'I5C9MCG1/(/4(F=LJ$,S+^
MM4/[EC+^"8X<4T(9B[%ASDN"035R \BM%N7H@@OGY/MK!_?0/FRG%_PFAPAG
MO"U8YXPP BK/L,; (&RJR:U2V=/;.F"X],;;OX1^'N]+9CQ2@E$.I85< VH=
MK'!1U@X:LO^U6,[*Z<?U9+GNE;^]\J<#=\QV,KGD=OZOV?K+JRQ,JQ_3,/W^
M(DO'?I2_Q,TJE55]M[B?;Z;%]-W"39:+^%@C(ZCO/@0JJ 5(V6C%:LZI-+PV
M814#<M#,;_VOZ$/.B+'*\$KGT<=BO9[_6(>T_XGS[$-#RL%')>2,>2TU1P2R
M"F6-*<]QK6M^*?QC'?2_YTK78OMY%"+A/";8889XJD@#M-N7'8ZX4&USW&I:
M7S_O%"*WN!U"]R^1$=P-I<JWF\G\QWY=^0V18$!9[023D"HB*7-P?X$L%#&@
MD9WPL]\0*>XMQM'8I8+X"*$UKL90<G9C3NC=T*FG&Z)VHCC;H>KW**S8^,MD
M,9VFHE3EU[1.3%(H]8'KGB;-0EP0*7)1A?54(D:H9@)6O5?TUMR,!Y=YV9LH
M^B#2P?N:9@V#0H8C![21E@@<IV'$IAZ!,H.> /5'IFZ%V9 A9R%\-D?T+P
M>+BFZNN'0NR.URE $UJ%O*,":5/U#-(LQ[@KDGU;,94=X3F44?5,1=T:BY_B
MIY_P-CC4) !#J",RPJ2PMDY #G&]B *;<[$[PG.Q2VT]'8OADD0[Z4YPN%&
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M!Z X0,QX8XQ%U"+DTC&I)L!(!U76/9X1EE;I>><^$]WA[^T\2;1U@?=V+,/
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MTY=$JQ_1+*@$E$*M=?S\OVH%\-;I*&A)F4^'5]9RKAW T/ *$4_Z=7>.*"M
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MTR7KFG07B(-<0,FA)4YIYHPG<O_2:YJ5)>GLA W_$+D5*0W+WY>@;"68,WC
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M6;%Q^/YKNKJ-S\<_J/7JMER<RH31ZN<$H*5%$DIAC%4TP2A@A251)L?/.L*
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MQD>;ML1\@#T9R ZQ_-1<; +35 GN(29*V;@,:^JK$VGA'<A);3["I:5CCC1
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M%S^*6?D].84G:7T\L-'4:1:(CAJWYAP@0PE#%FI5+:H)FIRT^2-TD'2XVW2
M=A=<.;B'U&L8G.&"4$AE<NI(I P0L)H!UC0GR&]$2TB[PJS)D$8(-^:(_@,
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MS85=!Q[_OI@IH/S E&4YNUZ5]^R_*I>GHU)>:A2@M9(!2KB5E((4+*' ?N0
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M-5> W(6=?K<B]7I,:H1O7UQ*Q4GB9]VJ^;4M?A2S\GL:^JX Z\%S\3-:!V*
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M49XI]NV+H?>EXOZ[7>!S@[7CP/;X9?+WU;T\CKSJ1YX.RDAMG91$ \@,Q19
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M*9&#[%,S% [WJ*1L.PW;5JY/FK@VH>K^%P/71F-&/"4J^A=.$(Y81("ZZ&-
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MQ\7QWGVY06HMUYPY2HX/DYO#+F+++X8(BM?$"HM4U245$FW]!A]B@$GI%#K
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M,ALRI!7"K3GR];</^]>0[0-!6N T489[#Q#QS"M4KYC2Z*26NF>D\V/54W:
M93XG\[*XFLZGJ^+]]$=Q^2Z*/+^>1C.H*LF7^O[WR?^6"S.+0!R,9([Z4H#4
M>^H@0< :)1E%AMH-'LIREM+6>T#=H4X0XO2IAH'0\E&&1AN.+;X6J'<Q2K#,
M((8XEI1R7L]V930>6=?YWEAS'#L[T$0^AGY:E!?%<EDO''$:/YW=A\K\&KT?
MU/JHG3,!M =.&"BV5D 1D'?+.T<R3J_\^(F+W6L@%_OTW7(ZCT-7%_^ZFRZG
M>^Y+./!&T%BL#X$!MM13(RTR]3ZJB@M/2EG[T4FK(UJ&NX'[E'2J_K@H#B^N
M!]\-E I/G*AN7#1.4,F-K#U?K:P=2>>$SC3?@$DI^+:.&_]KLK@O;[]/%C?[
MP\>7S\7Q,2B,9H1J[A15-OZK'I_C24WVST3_+?55=H=JPH[237%Y_ZGZQ9.+
M=<..R>Q06Y5=;P3,.6)* $4,U/%?BGJ\'3-1*=?1#NA8JV<F=(9O:TY\NIK^
M>T_WDY^>"0(JHRP ADIJJXMVG:_#!2VD3@FF!K3CW+/>$Q!MK6DUBV[X;\6!
M*WF>/Q4$%MY19X!CUE(-/!>L'AL7<&1]OWO2=A*F+?W&+&WY(!=1E"JYB' M
M.430RHTDQDN3L@8<7=DT@H"C(YPS,*:#5GT$,.^U8H0+0J/+@[RO0WW#J!E)
MDG>Z2ANUZCL.S/;'3<7%U31"/#EPZ/3\L0"U0<("+353##@E#*Z/V T1>B07
M^'6DH;(S('/M./QCLIA6]JZ^P\?-5W'IK%)8U]M[TZOIQ:;ETOIO#J71M?E<
M4-%C4E@IH+QA&B& 7'V,6W7"SEKI.(*5**,N<K'TY8!?%>UP6MXQGPF60V>-
M98(8"X@65+#M? 71]QN'X<M#EI?7//6GA];+XX?B;C&]N;F;%_O7QY?/!8<
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MVNU=S:/BN?=[+E)(^5RPR%/M(.">,>FYB5[\5EK,74H0(X?#K;Q%='ETD2O
M_F.^*":SZ;^+R]\FTWG5_?;C_/?)XL]B52'TI;BX6ZRW.DVYC)[WZGMY^6[^
M(XI:3^#UE39/?K0G N_Z5P6)D-=,:"D$0$)#&=6Y031"+4:2LI>'=.6@=)6+
M_:\GU;N_;XOY<M]]H'O?"UA HYQFAG@-+"1*@3H-QC.2E$@VJ+[_)V%FE]"W
M7M[M1@6K27QX\FTZ6T^&W]Z]__HN_BBZ&Q=WL[6\NQ;TQA^H"D=P]%F@@-SQ
M.(LDV;:0\9237[<.OCV5>M5 +M/E)]/%/R:SN^+W8E+UU:JP^N=T]?V/>?EM
M62Q^/)P[W=ZMEI^+BW)^$05<B_.YLMV+31/?Y?N-Z/>UF7_HFE05-=5MJ/>8
MP6QC"$9##)GE!L3_]\@*S.M,4F\0'$GH?!*#.E0E#L('<']OFHAMLF4OM_5X
ME>?3UD/8_]6 .")Q[4*(62\1 9#!6I/><I'25VM05S0,SW_H5#'M*Q?B))S>
MW91QTE6]'I9%>751WL3_CI!<_+FSEF'O6P$HHJVP1"-@,.90(KA=Q:(X*5L!
MYYW1G.A'= I[^QW);:@UG3_Y]<MU@_1Z9*]=\7'$VX$*2C#BE %-I?"60:4>
M9%' 8_[KIB(F4J@7^$^[?&[MYM%+Y/;- (%'@%CI!&+>*>R5];6\<2ZEA-'G
MG?[3UR+8%OI<5/LTN5]O)GTM?Y_.USWSUA= ?"]G4:E[[]K;^V) !C!,E$%>
M" :%$!!L)Q90-&4?\;QWR=.)UBGR[4]KMWVHHQKNUN=+T_FBO)_,5O=1TN)V
M<E]%.>7:^A:+ZJ:"Y63VZDVP2=\+F&J%+6,&>*(A(=(B6<OK/$IJ,@!^4:KE
MU$@N2_?NYC9&Y15@'Z]>MI?QZ\XS5>'EOBO;&GXA: HTDYQBC%F,;!S32-3R
M"T.3.DC]ZH<H_>A@"!Q\[("TEF ;-O]6EI=_36>SEL0\]-G K2=86H"8-M(Z
M!A2B-5+*6I#"U@%ET0V.K1TK)A>%7^W\'WW<']-E_(,O%]5&9;5A^7%>WQWP
MH8CB?YW\O8?!"5\-UJ"XWD37QDNG!,3.@TUFHH*6XJ1[XW_5XYS\>LG(W\<+
M+3Z4JU<E?)3JG]&_+FSY5^-K;8[X9*A*<Y&F7DEKH=(*1;>]1LC)M.;\O_H1
M3":EG-3LQEGFKJZ*BU5U>^,K?W^LP3WTO0",BHZ5)(ZJ:K\,8B5=C8U&,LG4
M#BBQ<CBFMF.-)"1G/';&GFU!V.Q$[$[(V/-24$PR#"(\VG( /7&6P'KD*(:/
M*5SZI4]/NH0]EWF+3L/#[1V515:KU6+Z[6Z=%O>U_%!M,,Q7$>KX6Z_KLM\]
MINWH;P6&7)P[&L5YI(2GT6'!VTDD(4ZJ-?M53V%R::.U2?O<R;;E<5\),@Y!
M$PTHLPY#H3D$6^?"2))4 ?NK'L#TKX?6'/OC-F(RKZYM?&F'E[]/+N,4> +!
MC_A7B]5\SPU/;3X6)*4."N  XA:Z&(/I;12&XKQ*ZA;QJY[$9%-'MGW)^N:L
M3<Z.+N;%U73?(KOCC: QHC[*9BS3 L9?!Q2KY5- I2REZ%<]C>D6\VP1ZT93
M<;SO'Y.!_YA?3I</3D!QZ<M%,;UNDA5[_,<" Q!)"&)DI)'7&B'MMS.M2C=.
M8>*O?@K3NSH>2?K__N=/FHCC_W/]5Z_^S>8[/X'[;5I>%_/I97'Q'W$:/:CE
MO^^B62X6LWL_G4_FE7M@)ZO)'_/)W>5T58GW[8GK]S"RXN]5,;\L+O^?_F?0
MSZ-[-[\J%S=K41]O?U;?(NB3BWW6^L@O!>$! PH" 0C" A.$I&$>2^F%8H@V
MBLW[P>21Z7ME6FON:]25GKV>WIGTO: @5< K;YV $DEA#)8U/E0FU8 .\G:6
MWOA3YM=&)M/R.1KB^=T)K<=F #XJTU11=M1+58)@[N*:$&.A!E:CX1>"U]A;
M836A,")N.5&>K_%W'CI&&C4N/ D&30Q$TT\$X+USQ ILM*6(2&4UJ%'0MAD*
MPZ^<[8T;/V53]@)[YLFO[S<]?FVQFDQGIS,&T49/KJ\7Q?6FB^)F@ V,P($W
M Q5 <<(D(Q(:HB7QVCC!H\T7RD/8*/TNJ\SKQ>-X@1^Z&W"MD&;0>^ET#-ZM
MCBYM+2UD.ND ;'B3O#/=_WS4U17$+:/91NWKOT0=K4OW?BO*Z\7D]GO5]&3/
MK0<[GP\QP@'&$>DIAAPH[(6D&YFBC=(IL>CYT.9(]9;= ]LK68KKER/<>]?!
MSN>#8U92)CGWT"!-J3'&UC(Q#49R:UI'>BV[1[092Y8U399QX;\N?_SG17D7
M_93[BBF\_H^**/P)438_#G]\>845CW\9?)P8U#&J%(#$6NN4W@Z8@*2]JZ%1
M(%UI92)\V<ZXR_D?AWOJ/GDJ2 \<@UH@PSTE',2 FF_D,$RIE&V& 67F=DN#
M=!S[7"52[U"RC%(6/2Z.K;0:^NHVR:TD7J0D:P^($;TY$AU@FH$='=R7I*E@
MR%*F/0",4XJI);5,6"=UN!G8 I*FTD;W)1T'9NMD@9;W)2$JO=0JBHH8)<P2
M86 ].F?,2.ZK[TA#^^Y+.@[(A+8"$:6(:7FHR?&+YX*TC!@"**0$&5%MHTNW
M&9]5U+IQV/X>%)V(9/L)?;^<?%M,-](<F-6O/!L\QU 938U%7&!).(5D.TYL
M4G:;!E38TL?43D>SM=;_\<?O[O.[K_^S7]_/GPI$8>BH \XQ[(@"#.@U(P5D
M$"&54BX_H$*0'C2=A&-K'7OU^Z?_^:SVJ_C90\$ *15VUDJA/48LVIXM^PS"
M*9[[@"HG>M!P"HRM%?Q_WWW0G__GZP$-/W\J:.2HQP[%?S2()L;'V+(>&V9)
M7<<'5-#0@XJ3<&RMX]^_;,2H3^OV*WO'X\$Y"J*PUDC $#0Z!AR^'FW\G2G^
M]X!J!WK0>C> ME;_ET_O/GQ6__? %'_^5- 81_^!0""%(M9Q:%R]&V4AD2D^
M^(#2]WM0=A*.K76LW0?W2;U_=^!^H6=/!4RTYI(Z;2 "DBHE71T'NOA/REW3
M TJ8[T''23BV]\7>O_O_E#Z@XF</!:2Q=]2*R#S$$5?Q'[(=F2<IS4"'U#*H
M#V<L <?V.R:_?U;O[0$-/WLH5-%=% ]21 &/T3WR0M<C0S1I#@^I!4\?FR4)
M.+:WT]LKZ0XX83\]&!RG<>GP$BG&! *>,BKJ$7)@DM+NQKTMEHIE>XO]Q^_*
MNL^_'S#9SYX*'$D.).,:,PXY0=+".M?(12&39O2X-\.2@&RM9/?^H_FJOKK]
M2G[^5/#6<AU=?$N4P-9I2BG;CHW@%/=Z2 U1>E!R$I"ME:S>?_K\,;H$!Z[L
M>_94X,)+H!5P,:J/ED;9]:#68_,Q*DAJ_##NK; D(%LK^?\4-^7M]^J*@EJ<
M_>K>]7Q@'&L@K?2$60DMAY#7I[+> 9QTM]2X-\@Z@C17IM.A$Z]7GPO:,"LL
M<%A(8VP$/+H<M2Q6@J2<A='NI'4!9;:*X-?3>=[ON:FQZ:O!"\6A%,H:@! E
MWA!5X^8!5R,Y*NTE,:HGC'.QZF6AW>X:KB@!U%4.(59>08L1(Q[7VXX^0C:R
M&JWN%/IZ<=:Q>&8NOMK47%6E8G>3V?.AC*+TRBN,M-#.02]05"(TP@I@,"30
M(JA.6*7=1^F5E)) 08C@UEGE-9>&U-(2 T:2$]^Y[H\IO3H.XB'G23-, =.$
M*&8Q<T38Z%#5DG"+DG;XSX8L1RKU4)[T<9B>1YXT!4XS;:6S@,?0"0)LZVGD
MC$X[)Q@.3])5VBA/^C@P,P>CC\-=WZ/<-#9]];6 @,8.(.VMU4X; S0QM:0R
M.E&CHTV*ME^/5+L MO66UOI77I2+VZHC4K%HE/^S[YW@E#-.:F80(,9IZ# !
M];B%2KI7ZVP.H8XE1->H]KGB_#[YWW)1-Y]8[O%&?GXP> "M508QI2%Q$"!J
M>"V%<DF-00;$C=Y\D61$^^3%A\E-\?'JV1#W>B([GP\:0FNT-XQJ0X7PDEBZ
MY3I-:IPXL"4E1:%E]U"F)"W\6+=A_W$P9^'9<T$!19!BPC'%'8:&"5Q+ZR&6
M6;N']:OJ#G14=H=D^TSA2@!;]S8L%SOL_\YG@XJ#$1X!RAWWO+H)TM9VSQNA
M4R;WN>U.'[L$= 5J9\K?:=_W/!TP(PY0!YT34D-E"? UW3U5=B36O0-=[=-Z
M*RQ;Z_W)+_XX+_:;^->>#8(")16T$COI.(]N,5'U.+EP21>K#5SGQVJJ[!;+
M+G3^]:^RL<ZWSP8?8Q7FO'38J3BN:.RX>!@G H[QI*;#OX;.VV(YAD-L"9DP
M"/EH$TE<'G64'-<2>YET)<Z LM]Z<1-ZPGB(A]C*0P&1T=)@[W!5!2FV$F@.
M\O@2\H$E\V)UVB/LQNK<=81]')KMTV'GJ^GJ_I_3R^)3L;BHH+\NMN)474Y?
MFM.= <;Q7PH, RB0YU)93#TB$ F^E9'9D?21ZHTS>6!O3:W'\7PN+HKICW73
M^H]7__P>(:MNNWGJBU^LNZ05E^_FIIPOR]GT<A+_Z\E[NUC7Z2\)" DMO=:0
M2X^<4)Q852,C-<6_1#R<2,A3:J0U5VNS^V[^./QJ\J@XNZI$Q:_?B\7DMKA;
M32\^+:I><*\Z5&T_%9SG,0YUC&GHN(.$1M@W4L*(?,K2>3X.5B+O^L<]L]/U
MN:@"E^G\.LJSOF)@?E%\_#:;7A^Z0[71^\&2&*T*Q+WU0!CO(T2REAU+EI+6
M/*!JAUP.6Z=@9TY(7)]UOLA./%E:8L;K(1@EUG-A,:'&6<JL=>L._58X('FC
ML_'S25/4<;F$0AL0@PGFJ<):^5I:(=+J48<WW3OGP#'IBL=!G6M5^1I_V\<K
MM5A,YM?KYM8[3HOV/A^$!49Y3RDE,2[U!# G-[)YKL5(S@B[57/9/;"Y2/-D
ME%5FS8=R/GG\R=?XI^5D?;OIX?[11WXI, *]YAI4IZC20VDH,34>7B;M6 ^0
M:(F<*'-BG8M[S^XI?2+20:KM?S$80SVTEA/BE''1%Y,*U]):!Y.*N8?'K-ZX
M4/8(^I!3^+GEDB/M%>.H<A\T!:"6! B=DII]/IN6[5; CC ]CQ1^XP&#AEH!
MG>6 2T84>Y!) DG)2%(KTE7:*(7_.#"S;=0\W.A^<$%Z]EQ@@BA$+(^3Q3"C
MH*.8U[+$-7XD^1<=Z?/E;DL"DL/)RA?858V D;184&&\I%+5XR:"\W$L(=TR
MH&M4S[G,1QBM-4>0JFA@(47.,[WE/;,I6[<#.J;JQX)T".Q0"SNTX118XY1#
M$1V-N%.;L%%" GE*/YL!T:,W#S49T?,H["">0\6(59HJ  R**V>]>$+E?5*[
MJ^&P)%6AC0H[CH.RM1^BOGW[Q_1 QN_39P*QQ%JA$=):$&\4-LC6XXJA_8A4
MW(%NRFY0;*W=+Y.;Y=W\^K'[I8I&;?^&5Z/W@A>>$*>QBW]P&C#D!:S'#[!*
M26H9F+?9,0LZ1K8],\IOTP,<V#X1+)-Q#,XK$+W?Z!%COK5LR)JD*SH'M/CW
MH>VV&(XAPYMY8PP# GJJ+6:*46MJB24P([GGI]=CO8XQ'F2&=XR"D(%$1MN&
MN?$(65Q+0(#*>G+RHUA\*T^=--18I3NSO(]"-'->T.?XB<6/8NG7^</K5,TJ
M$%>S6?E7E=]4YPJ]L(?MDX4:14#_F,SN'M@SO_SON\EL>G4_G5]O4DF7>_*#
MFK\<'-5<*JX<L#%$ -A2M]F\EAK#9B5RN22N5#,KEW>+G?E!1W\C&&,95\PP
MI9&J.GIA6"^@&BHTHJO>NR9$F0?R7*O#HPS;21^EJ0U#E;5P((NHV0<"Q01;
M0-8Y5Q1AX"VN-]X,0V8D?=%Z9$69 ?9AD&[G=M<QKP<;_\]3I(G0EC!,D$:U
MBV\<&ELZ9-=T.(IMK1!/J.18_]:K&!1.EM^W?LO^^'GO2\& ..DH%]6%;T!H
M!RVOO3P#6=)UMV?'E6.56?:$<FM^U.G T?2JR_^]6Z[6F5'[Z;'OG8"E ZK:
M-6;5#2:.0.Q</6[LY$BVU_IG1X<@YUJHODQF592TNEO,GP=&!X]W#[P9".$>
M8:ZKBZ%C& B!QF0CKT5>ISC@ ]K%ZY54_4#=Y]E>4]=PWXY?J^\$#UV4F !/
M".71KR1HN^%IE74I=!N0#>O?_<Z!?B[C]GOY8WW6\6Z^?WI^+F<S7R[^FBPN
M]QB\%E\+ BC#M2.: $"MCLK@M3MJN1I3!F6/G"ESZV$84:*>S*H?M0X3-^\'
M[[5GCG #!69$&$]![7A8SWC69,W;8C$M+[^L)HM^FYOTRI&C0L=V6F@?&]PM
M*GP^+<H?TV55$_&U?'X5^%;R8A8'/;_^6JZ]BW?SS9O_4TQV!Q%=?#P 80V6
MFE)F-'=6(F?0!@GGE4TYJ!O02IV3B2=33OL\H,?PJ/$P/T73L:@&N;-O1=I7
M S8$&0LA$P AZRV/ 5LM.P<B):>Y><2R[?YT7?41^3H>?F953ON./Y/[]1#K
M:.OV=C8M+M5U#-^6JT.C;F!"N_I^ %0@:AGSWA"&E%'0UXD[#M"DXM+FZ0ZC
M)>N)U'0:VFYG62^DW7X]. ,D=@AR'WU^S2!ROCZ!=%HWNU0KN5W+&V6[5-*X
M(B7"L$6.&@8L8LA;Q)FH97?"I72&./H2W8=(R<TOSYZ=?>I@H.E$+T8Y@G0B
M =<J5XCH: <XIQ1II[UFE&*+2:.@K:<3C*C2ATX !WH+/7\P&&@!Q<11Z1$A
M"'G^*!$B?B3=.?I0\<O3B11<<RT@&_/RY7M1K-Y7NJS@V)_WL^N50!QRD#H?
MO3HA!/41'K.5T(&19/JDJK?L!<U3\N5@VL[NEP(TEG()'4*8<^Z18,!MI"02
MB90C]@%R)EW9#=C3"MEL7:<VUO6Q$>SA]E([7@G840J$5QA")&#TRJV"M82*
MC.6&DRY5_;*95#?(YN+.NIQ[LXGP?CKY-IU-5],&&1E[WPL :4FQ D8Z DST
MI"'UM:P:)?D[ ]QV[X%%7<*;+;VG7KS?-RBQ^OGAX)&GT583#@BC7E&(L-A.
M$(Y'EAG6D:N3C..X=E4$)\91S"BF<2)HB[6OUWQ*!!U)LZ NE-]JP^0X>+-O
MF#S\>]O%_/+5+N:_3L=FHTU4$K),&J6LT$HQ^:"MZ&XPUJC^L!\,^NC83+E"
MT%MCF/"H:J-6)3INI.5<CRQ2[IP#QW1L/@[J/G- 4[M3$D!L],HUP-A$LR:M
M8K"6A$43.B[2=*/40]TIC\,T SLZZ$[).+/<0F$)A!+1ZKJ#>AHY(Y(2S ?$
MDW25-NI.>1R8":5-#_Y )=\D^@,7T1]8/?H#MQM_X%"ITQ$?"51A"YPB7&"C
M+.92$%Y+!KT;R>Y)1]I][3::/F >:M\YSYRO\HLH9P8@@2@WN)8"&?9K7.?6
M?NU)1O0\^LXA(8T7SD5 +.#<:D]J:)Q,N^MJ8"8E1:&-^LX=!V7[=:>\^%[\
MMBCO;G\KYE'FXN+[@35FUPM!$HL@YPY*K.,,(59KNAFQ%UR,R.WH0&ME#Y".
MH5F5=,0@#91VW'" K..<U!(SSE-BG $61W:ZSO2$<?O6=M\C!A^O3)73?%-6
M8XE_N)JN=F:I[WPA6 I1E7T!XG"!@DPKBNH1&R:SIJ0,HCE58Q66/>#;FA'K
M@Z+%"^^YNK_Q%>]Y%TF.^4;PGG(<A6-20&BI$P:IS18PD$J.I/:U7];T"/@0
M^^#1Z,%)+BT%RBDMA=8(UQ*(AOE\G2U Y6HR.R_*).*9^13FZ[/[I\=\NL)$
M5"%BSC*O==1AM/0/R<.<FH8]0/.?KGR-NM#QU_[9\IAE^WZP%BA (5?82^V4
MD=3[6GY-T<A:0G7.BB/.6]IBWKYB<CZ9W2^GRX]7ZJ9*9HK_GE^:[]4=956=
MW&OE'0?)U<V'@W)$>,\%PQ1AHK1';(N 83SEE&^ [D=?K#N),MI'/7<W-Y/%
M_<>KUP?U;GXQNXNKR[MYQ&A9SJ:75;75TZ2LANSL^O<$@BW2S$ D8S  A9.(
MNQH?&C4TKLB[5[*>6#>='4+M\/*;$;35QX)'QGHG-7 :4$]]U?ZIEA1 DI(3
M-<!FY;VR,(<"NMD*:$:H/:\$&L&!2E*%L=$HQAH*U1.$&2E3NI<WKZ =!VVZ
M@SE3,/>EN'ZHU+PJ%S?K+YPLH-L,Y7-Q6RZJ^N$&$=RN5P*%$@%MH.):ZJ@P
M8L7#1#10:M*,TGFD?-)9K4' UN#M8+ DWL?001EN!$':"[J171%GLAXEY=CO
M32?!RTSKSD$^V60^=0ILEW,Z6N.XJ"(:_3F,F)2(H0>#[+$!4C?:ANA)RHOO
MQ>7=K/AXY:*KL+K_9U3+9IG1]\\/N_7]5K"-H,N#%<;I7P\>8B(Q,%IP$I<A
MJ<7F0MB('?0HI0G1 +=PTBGTTB)D5\&04VD%AUH)++S'UFBC,>>VEB3B.;;2
MBYRZ/Y1Q>QSTYY%QBP2$1E'.='2(094(M F:HHS6V)'0*5VEC3)NCP/SG#)N
MB=(:.F0=!5A9ZRV@JI8,DJ3;&H=)DQ3MML^X/0[F7(?0?5P6;C#4PA &$/)Q
M\1>2"5U+ZDC2U7X#.F#HEE ] )N90DTY4\O"H<0,,T/71QX:1[0VLC@"4,H5
M)P/:V.^5)*V0[--UV1;3_E94IN_V^_1B,MOC!.]\/F#OG(>>>6@H-Q3I&$/4
M,CF95 4R(!-R:D^X*_Q[Y=2#E$]'N-<=WOE\,,H*:23FT%=M0^+<8[*620"9
MLBP-S,_I0*]E]X@V8\FRILFRN/B/Z_+'?ZY[P2SN*Z;P^C\JHO G1-G\./SQ
MY156//YE<%5/0JL-A!A45ZT8P5 ]8&/M:*Z3[4AM92* ?=H%=[<H;W=W:7KY
M2'!,4$N!DQ9;*1$Q M7,]P8@.XX5I5O%)X+8I_K5<CK9J_S'!Z*#I"C6,?J'
M56\88#B!M=L<%T:1DF8W,%>S6]6WAK!]FM+/XU]7("VK^H#*"$V+Y?H'^Z/4
MUM\*W AA%:@RBQF*TA&TC; \9=CG3/0XGP4B%]ZY(MJ?O/!G/OC[!A5E#;\0
MJ(+,<8X!B%/+$,.M%+7\@.N4O;<!F:93QCG]:F2(M2(6:DH0K0H])18"6<3Q
M=DXI-[++8SO7ZZZ2D>-@S46,>G(\B_06Q61?'_'&[X:X"!@ I"!::0 5JN;8
M@\P$*.]3XJ6CG>8<&2]]DZEKQ'.Q[$,YOWCHI*F6R^+56ME=CX8X82 @2")F
M+!($.%UO3\8_Q\5_+#%W#SHN.X7VU+E258[7W63V?%!GFC)ED-3.1^_#2&=!
M]%P%?5"A<8YIV\AORY<R]4073Y)T781^,9_,GOA<KQQ5M$FB2OY]@;+J-A%(
MJLF!%4:"4E?CZS$?R9ET=S1KD%:56RGG<=!D %'"0<VUYL)@Z)!4M4R*F)1M
MP2$2[;2\:'3T=)Q&SN/H"3/N!8CA@Z76<X8<,*:6"5GP2QP]-=9KHZ.GXQ!M
MOR%9SLK5][O%_,!>X_/' L:\RC=C G&#!+;*2+(9G1=6CJ2PNR,-E9T!F>&$
MT?[7GA-&^U]!.,.<%8H**PQU'(NZ-,)Y8Y+NI#N;8Z9C-=\:OOS[P<T6R^-V
MB(_\9M 2$:<B2M&&8H"UH5;6&%% 4\XH!D2Q8;DLN;5V#AL[>GU/+D0$(@<)
M (R3APU1XX'S?&2E+QDT?VB[YSC 4P]AGXBYV;G9LV'2[,6 $#*$$8>9H)P"
M+G&]G'O @"=CVT_N++#O!=]L1N:N\N6JACP5#)7]K?=(]YF;G2\%BRAPEG%'
M 9"62V6YJJ6LFOF,94>Y:Z6_M"]=(7RRC>43-TKK<D-9&!@=C^CQ2B"!L(!)
M0S<]#*#7JA&G^]Y0WN=KJ=5J,?UV5]W17OIR44ROY]NL#WW_&"14)R&-ZO'[
M^ZT1:V"TE(X00PWA'BB!:ZR505EO+#GI*M28=#NWET^MG%RFI^I1JR?+XO+3
MY/[9RI7=Z#SV3*CRJFYNB_ERXXK.JGY-IERNENOA?GLZW :F*>W#P4)&&#12
M0BJY=3J&5'4F%Z$:-]KX.#%BSQ3<L,MCRI>#I@)6"24(Q1FH/3 $@RUF&&4M
MT,W40#H+Q7YN#)E132<S2:=N23)4R^2A8]1)R8F0JKK#6EOMC:?5E;*6-"N#
M[_VL_N9V5MX7Q6:7ZE&Y3^6M[I6\V#8WO2BOY]-_1WF+Q;1\ .&(L_KN?E^@
MB$E+B%= &B4T]S&VW>"+L3<CVP?*1<;=)_HG4UVN_8)W\VCEBL>;69_<2+^'
MW'O>"DI$>:@@C&&M"078$5C+"2P<6SK):;E2]J67$_-OY]E_H_>" )I3J 25
MWE<[*@93OL6/TY'<0M6IUILQJ16^^1+WET7\7=_5_-+&6'E6WE9#=W]7LV]W
M]>(1;P<@!05><P<$P%9)#ZFHY>8F;_N6'$%$1RSX*<V_:Z3S50#,XC>OJTNZ
M%I-9'+^ZO)G.IY6_L9K^*#8B[.X8U.H[07"FA/75W@R1S,9H2->K 5&29KW#
MYGQ9UR?FV=J_K/$[W/WER6-!*4$,\5X#XJ 4#'E0KP!$ )6UJ_OYLB<!TFR9
M,YTXH.^;Y--T^YM"M.Q48^&()5ARZGSUSP9/"<%($KF&&3*<5I?9%NX#8E57
MB<PFR^7T:OKP@W=S/YU/YA?3R6QK2AK5^77ZBX*'QB&&K/+2"82<!1'+#9K<
MT-'M6I^,C2^=A5.J,=>DV(A37+XN[<8CVD/V9A\(,<Z457=0$ V1UH@1OXU!
MJ81)/0J;DU@^D'A>75FU>;8W W\B\I09M#,L;GXH5A^OOD[^3N9H_:% %8 H
M+ID&(A1]12FU5#4:Q"3M' TRUCHKKK;4TGDYX&9R.UU-9M5/'RXZZ]T1_^DW
M!L 98 XIB(&@S%B!)*[Q1<#FZ>+TW&)_[=\O'\94&(9.VV<T[YO 3^\]6ZY+
M!>IMEYUYSNT^%[0G)G) :$@Q@\YAK.LXGVH@4G9J!WB+V(FIFU%3@[+E<2G2
MQ;RXFJX>+N(ZQG?NYA<$@"230$+"A4;& H(%W:+G8$J6?_-KSWX]W_HDVCMU
MMA-\2W=ZD6&B 8[+JA5> .<,(T:RA[O1D142TV&T)CGC="?B)4%*&N(8IE R
M4\W3!WSC?*4PP;H-\!P_%QFSI#L=I[I<R[J^6T[GQ7*I+OYU-UU.&Z0Z[7@C
M( H%%<9YJ*S6Q'%@7"T?1V1D*28GYDC9ATY.R;GJCXNB.)CF=/#=P)"@F" .
ME-'5D69THV$M,Y;-BIG.AX?)FF_ I!1\6X?-'Z;7WU?+U>1 H^47CP5ND85>
M0$DBE@IKK!G>C$XY0T:6#]RAMLK.0,VV(_[79''Y-?[* PO6L^<"P1ARQXS1
M"!/%!5**UK(HRD=R/]0PEZD439SX8'RQF,RO'V)E??]30+@6[%&Z^>6GV63^
M87)S>#WKX]>%J!9?790 #&-,8>4M\C6RQ+N1=/Q*9%6S ^Z<BLB^E;<J+_[\
M>%O)>3"#;N<[@3*@.<3"0J@4,-P#H;>+ U<C6W%/2Y-=FVZ)2LF6K;D1^\""
M_?2Q@+P13D+GJ44"&6D!9AM)M$,@Q9T?]B4% UBO$Q21FU('%]H74\Y[1#!7
MBF'CG6, *5?[Q1K*I&9  [1:[12Y@PVM$&P=!_X^6?Q9K-86[H_Y='7@\N'7
MGP[1GG*%932JP-!(?\D%J,=J%$LI&!ADUF!;595=0]E:[5^G-\4_BN6JN/P<
M_W<QO:A281J2H,F[ 3CF*04<4TDE(DP"RS=R&)5V'C[(O*8N*-$#L*T)8B;+
M[U^*U6JV7N_679GFFV7R #T.OQFLA4@2R*'QC$IBH>3UAH?!#J;DWP_0Z>B"
M&IV#VIH83WY] UOQ^M.!RK4[3KWA" JI$&=;$E/M4_*]!I@MTP4!.@&R"Z4_
M&J0-'Z?S]8\:\V#_!X+7TD*!-2#"(.,0)L;4$DF/4LZYFB>8G"LU.L6V)[94
MIBR%+(_O!V4UU3'R%A!: ( &>NLL&1"CL@2NL%^1*ZVA;4V59ULLG^X6%]]C
M#%X)NI\A!UX+D>+68V<)5E 21: &;FL6A=,)Q.!C]3Z[Q710>9.#+$(%F!HA
MD8ZVF#&"G,=;1]Z*&/6-RP<:UL[;:779/M?][N9FLKC_>+4W]UDME^7%M,K@
M^N=T]=U.KR(1HH8^+:JFG#?[LA2[_R7!0^N(B$A@57FIPIJM*;+<P*P9=>=8
M4-J86>5 5#BL@KU]>0O-RA4=$C[B3#05DCLOG$>U(V2-Q5D/>_MO2'X:XK0K
M)#U.,[FS[^*(OTWGZP%_*2+T49[9_>-D_[J81'$NJK]>UJ4I:G[YOES&/SP^
MUB!5KYM?%*KK)VA<2KWUW@$FC!6J1M,[E7*5ZX 2=P;$\I/J;UA6NH>R:J20
M(=AJ)1U7##&-W18-F72Y]:":$ V(S[UJZ+S"R2&45&LOK,*RL@)81M?1>U$?
M!SAG6<H,:!Y>YBJI'M T&(8^S[V<FFEE,:G^WSFO/$0>UFF&#G&1I\ST5_!&
M,FKIY.6D+[9AWNI) \113](KJQGD1%H%N7VX"\HZ2OT@VN>W3PEM7D.:^#L"
MQX9)[HW2&'NIL*):;'#T$)B1I;OE(MW.NM&\ZAIVP0V*5ETZ;V'$$2 J,(*X
MEH4 E#7W+N<Q0C8.["VR.0[]MR*;YDG[ !ML!+/::4 @19+(+;(.YCTXR%UD
MTYA5.8ILCE/$<#-2J5=5Q9('BGKAB*$1Y<VUK  [D+6 _H2=]C*1X>B\UN/4
M,QA+N@O#)AD%Z1\/A@C( 8>25X5,C)@J^W.#&@4X)8E@0+OVPUG]LZNLM3U]
M;:JIB]7TQW1U?R@%H,F[ 6A.XF0EG#.!3)R\ -E:#@ODZ$[V<ZJ^[%<9@[>>
M[E]W4;IW\RC=W7HV?UQ]+Q9?OT_F#V68RP_E_,=Z17FXZ+H/(WOL& )'&FAB
M'>'.:V&YXF)C4QQ4.%/;Z<V$N%UO)7]931:K_G8NNV5F5Y:V9[V-:.[\LZ@:
MD127*IK/R77Q6_STRDY6A9],%_^8S.[V[IT-8'@! N^0-Y@S+8T7&/#(LHWF
MM+<IM?%'>S]O,^X$*CW_R;B&8/EN_G#V=Y()]WP( <4X3@".,;:.5[>Y6$]K
M#7B6-*F&ESIQIA,J265CFS3#7,:.'&/ "CNC" 8&,4PQUA)L#1_6/B6<.KH<
MX&W:G4*GYS\O'S;Y3KJ8/1]",":Z$]1#P!@"R'@@D=EJP/*40N-!M2L_YUF5
MI+*Q39IA+F9'CC%(Y1WFT>QQQZUB!%.W#:DCSU+J+X\NS'U;S$ZAT_.?E[Y<
M7!734Z]G/XTB6"HU<AA+YSAR !+!:B8A!D7*-F/SVN:W):U7K8UF]MQ%H@US
M23MF@$%PR(DCPAA@'/=<6UK;/A0#[)3< ?&VG@U>H><_'8=X7A9I*:#6F"B*
M@28RVD12ZX"(I-:CLMWNO9N_+67=:FU$,V>8R]@11RM&,,FX=AX@Y+A1'FM6
M:PX0E+(74I56O$VX@6OTY/4W;_>YO2R%D A[#C"WW'K+!'3 @+4"K57:-^M3
MU7?]S?,NZ'_-B\7R^_2VR@MU7SY^>@2@S95MC3X9K(HST0,OH30<DAA),;=!
M25,J1E;BD(M2AV]EZT,[N1R"-KWP*:;&.2-=!$UJR(%UI)8$FJ1=RP'RK'^%
M[VMW?QS6N5ES;+M[X(VVA@*BE4#,6H?-%A+B[<@L5#M%[F]W?QR"K;.B5?P1
M=5\^?=I?4/+BL0"=K6XM9]X9'(TK@WBS]QU'Q]-R8@:LWV-54W:&8/9V'X<L
MW_MC&D0V_E@00"M>);PACQTSCA '-Z@8;&3*BC/H\HU,*T[O&LFVO5$)\&ZY
MO"LN[=UB.K]^.%5XZ/^^LW'KWMJC=E\,U&&-O3;5Q>&<0@;K K"(C\%Z9'>?
M]4F@E_YW%H6<F+#K;8N=PAQ/U_W?"SJN6M6^"'1">R\(K$*B#38T^@4YS6O6
MYJ,GHVNG"CGUAM6+*S/>]JL"(908C$U4(K2*$ RQ6NO/:4@-:]4O9E<CJL=+
M]YJ6+>YY)7BHJ5GW1@)&  $8L:@>N84TJP>?PQ3D4G39"_Z#/S;:[-5_O*ON
M<9Y?1OO7W\'JKM\5!,-4 >6IQ''U-]@[8&M,@:%9.QID*7_JA&!='>1TI)8S
MI/J+@RGW=[&XF,85?C&]Z.40]+@1! :YJKI12* LE\)3K6&-/T,\):]@F%6!
M Y\6'2KK7"9+_U5]KQ>"216-CJ':N:ARC+R7'FS01!1QF[-VK^^VF0,D?9(V
M!L/MG:U3FE1!=;88=#>*@"5GR@IA(+6*6V*EH;4>5 Q&1U5:=Y)Y<3)E#6(#
M]@GDRUJ8O4;_Z(\%BH35B(LJQ<Z N"Y:P&I4D+<IW;R'5\?6"X7[QOQLS'<M
MX,DM^%$#"0A2Z1TQD$LO*/&06%YK R.:XM4/KZ1LD$:\3WT-9O8<P.!)D4$&
M[_Z5WQ8LM 8 P[%Q6#%CH+>XQM4!D>+B#Z_\:XA.?KI2!D/V0S/^%5%/M5@<
M.91 K(482HF0\)A%VE&^C;T,3=KO'U[%UB"7BWXU-I@Y-.@3 N.]L9A2[Y@$
MEFLDE=]@B@7V>&0E5D-<+E*5<H9$'_CY &?*(2FPMII)#!W5O([K,)=)=PL-
ML@YJX+.B0UV=.F'DQ=1]2Q@)C%% #>.($FPI4\+YASP"[[Q0OE6!TZX+!"9_
MZV)>7$U7:GYI)LOOGXN+8OJCN/1Q.CR= P>R2([]3M .*0HM!S)Z+=(39B&O
M9601@+?4DG:4*/,I)7N^^;[+ 1]EK82K[>''JZ>[E$W2T%-_1P"602P% D00
M3F#T4L1#VK7W  H^FALS>F98FPLB>]!/MAJJ17E1%)?+%[@U.ADY^&Y 7 (F
M!-!44J(ML-3*6F8@2<KVUZ!2>O-RLFO<3^V(D3='[&5"I^".>(915:-'#("
M/P2='@*%&6OCB/V*-ST*KP#$P@ID%3&<>HEPC:,V(&5'98#U+[E(U]M-C\>I
M*]<2V>ZF1T8Q!B@:<NN4M 9A"=E&%HBI4>.BW@DXL/>FQ^/0'\RNW1G<].@P
MII@K[C7"&*NH+@1J9"'-F\:>^Z;'QJS*<=/C<8IH78/_^V3Q9[%J>K?CZT\'
M+[R+KJUF6A,I'%!>J'JL0)J4.&!0L>DP%%YVK9#!V,<3W]^(615.><,%DL X
M:!736]1LWG#V5UC3LZNL,RO9M CRT'N!$:>-TP0:CE&5V(CU9H\@#@#8K!7\
M@["<':I\GYU,5,3@+>99]J#E7%C'#%>&.D*HE%;4=@0!BE'.R9"E5JP[5I[N
MOL:C=#:B>7/V'6BQ1%Y+)A#2PF"IXJ*-:LT1Q;)Z.V^S+;,ZSW\B#N^N1N^5
M-IH[HA%5Q%%JI*DU4'4#REGOV?MIV!E.IB1UC6W"#'/Y.O9./XN4DP1;+9"3
M3"/A;:U##+1.:?4YO&+2LY]R7>OS_.?D\.YHQ!9+;8#EW#L"N*9F4_$;-8 Q
M3UG$AE?;>H8S*DE=8YLPPUS$CKW+SUM,J)< <:VLD! :!6L=(M[LWH&S*:8]
M^RG7M3[/?TX.]6Y&2C5T%!J,$/<" \?D5@_>)K5I&%YQ[AG.JU2-C6;FC.1>
M1H2)UPZ#J#>#A7"*H*TOHK5*.<L:7I7O^<ZW/I1Y_E-QB.=AQC%"D8TDXHQZ
MY8$R=18'=MRFG(<-L6#X#*=4FL9&-&N&N7P=<7P" /0$"$N!5\AS!SFICT\(
M TD7>0^R#OF<)UO7VCQU@<R+^L>W IG )'?*4P&,I<(8[+7?9!40"BUIU=K^
M5RR0D4!&'TXQ"9B6S#F #:EQ)%1GK88>?(%,8]+U5B!SG+H&7B#CA%;6DSAN
MP@60OKZ*SA.F!4_9?1D@]4[ @?T%,D>A/QA'] P*9"2$ "L,&8 ZQL56T3HP
M)@Q;/S)>MV15C@*9XQ1QV@(9K"01T$KO7?RW5$P#7H\U>J:C:=XP#(4W*) Y
M3B$M[>-RL7IB&^-_O;2+\4?A<P7)CI7UV=\'235B2GMM&7#$$&K%9G><<"5\
MUJLTQKRBIJ#>.U-VFI\73P1"'?!2,FNHY ([RHVMQVT8&4EM?$M=O=1T*\SZ
MU/7OT_GTYNYFK[:?/1,D!Y HPQFP@F HM8>B'CNU>C1+3&N=E=T@UZO6)W\?
MUOK39T(T;1"A&*E&0V80$%;!FO'".942X ^J T\G6D] ;C 1THE+9*5"P%."
M<?3\O6& 2%_[8"+:WI2$VP'=:71Z'^1D*FL=)U4;[^O!?;Q:;\@7ET\.%PZ4
MR39Y-WB%D>1:(>N%@$1P2F0MAR<P:\>50<10':J^[%<9@[>>VY,CM5S>W=3M
MUFZ+BRB]G?Z87A;SR\^352^GF$U_=W .06=PM!;: 4Z-@UL_13CJ1^/A]<#"
MKJQJ3[HZZ_GQCW(6/S.;KNY/,4.>__88 6*,D;,81.259M6=937N7,&4FR8&
MM$=RIC,D25=G.4<^3Y=_^D51O(OJB:Q:57)O@L]<$V7/$(*GR!B/ <:>6>D0
MTW33<HA( 6A6;_YM1>E!9>.9- ^Q^TDGS<,0@J <&XT@U0Q9)P'%6Z=:6FI3
MMER&5W-ZYI.FE<I:A\";?+0U0NL;,S[.M[EI[^:VG,TFB^5N\W_T-P(FSD.-
M#8Q37PE&"7!;N:#1*2%Q\V+-LZ9BWYCWS*6=5O'H;P0MI'>.2F.J'51%N/(U
M<A)XGV+6AE>%>&HNM<)\\(OY+]F"PD6U^:A 4K7@!X1P .I(7THE4VQP\RK#
M7SGB/+%&3YT\_N*R@+?D\4 =-50@[K"@<4E&EH-UHWM5'?,RVRCSX2UY/,X#
M)"3C1'$A-4!5-=/#&>L:1Y'4#G= &22Y2==;\OAQZAIV\K@"C&BE,0." H4E
ML$[5LD"=]ZSOG(Z9&W-@;_+X<>@/QBT]@^1Q!9"A"BGC/7#,.[2Y)*Q"5D*0
MM=US[N3QQJS*D3Q^G"):1_'5-6%?BM5J%@=6+*[*Q<UDOKEE[D B^>$W ^0V
MQHL$$.B9=%@#R;<R:,<:%<F=#YE.2X.R3]4,QH*>.+F, >8TDR*&6Q&T&#<J
M7_M044DHI1'6@ YOA[/J9U=9+W;T4')9DW>#(H)#0+QRF"C@075I2BT'P&0T
MN36G4'U3V]E2&8.WGF?9>Z:J[L-.&B !H H22P!ZU %,20T8YET,W3+S9!UH
MCM/;^<^=X;6!E\@2K)B%4A&O"=&<TXT&6-3)N"Y%/M-9DZ2R\Y\TPVL[C8#P
M%%,JD/)(1[<585-K0"*8LC'2/!,M5Z_.,YTT22H[_TDSU#:WB@/#F.>$0>6-
MHI38V@]GCKJ4AA3-\]'>IDZO6CO_V3/$&(<+3*Q&"DG#-<7*2*NWR[YW*<4"
M1Z?/96CY=Z9S)TUKIT[/>#&<M_2,P!PVB$A(';.2(Z^(>VBSIJVLFJ^]I6<T
MV_7E""DE276[@.0&40,YW^"H#$!9;\L<?'I&8]+UEIYQG+J&G9[A$&!622&%
MC:N$TMHQ6,NB%6?CHMX).+ W/>,X] ?C.IY!>@9VQ&B ->/5IBE!5$!5(\NU
M&$G/I$16Y4C/.$X1N2C>/(7CP!M!0,"UEE )+@&6?-MJ-LH'(!S9VGU:BI1]
MJ&0P5O7$*1M:0<:B:T6)PAHZ 2B@&]2T$?JM)V''GD!VE0V>Z&>Y\R28HM9S
M!J CU"$AE':U#N(*G-6![OMT_134/=WQ^U&*/?_)-;SC=RZI)LX J['5U"DH
MR%8#%L*4J36HX_=13ZLDG9[_K!K>^;Q"SA*OH0;:$F81)$9L-&"T$BG5X8,Z
MGQ_UK$K2Z?G/JJ$>X%L'?31L0,A(<2QB4"M,K0<&DXXA!W6 /^JYE:K6\Y]>
M0XRS*'?2(0<$1 +$F-LR7CL.AJ*D7,R!G?"/>G*EJ?74*0 OZA7>4@""TYIH
M5>698%W=SZ@1W?10T@X@T&C%>TL!*$+TWJ@"&'D+G)> 4_J0"E/A:"U)\1P&
M>(R0BW2]I0 <IZYLIUJ;<Y4#&0!/'PM><,"H!D@H(S5P5O):$@\%>$L 2&7
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M5N;ED XOM-D7Z3I+L3I-7(,N>H\!(%CQ=($ 4YQB9-AV)"3^FV."#I!X9V#
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M2JM7OA( E23II#-D@/#X>>=0<><]ZB6_ZW.1K%,)#?_X-P8FSAR-)$%:4"6
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M&B/P,.>B*?DI"-06M'W1)RV[J2C.\L?LYKGOQVWP@^V"0\1)I%@Z,,8%HDZ
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M,VL4EW]1*VR-\]$X9\X[@Y3."<D@4P!1!CB7CE5C-P9=V,WT;9!@=A[H:RB
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MAX+Y'R7N'5TI>@_\@#!>+.SR[TLN%[WKS]B)EB5O2ZX5Z?YK&0-I:#@]U_$
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MV*$K>SPK0&B_\1VO9!:D>%Q) #S=R:77OC*]N'9@)=:G<$8A+)H:2 Q)\:0
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MPL!_@\!/N+G#Q8R7S;*1UBE%AV99T15!8*%UXJ@LW.087F8VR=&A@0D;N1X
M\7X6@!2)=\XK!&,Y*^'%!CD)'02E&"S/2XK*4R:O4U)6<>0H:)(W@#PT,.$D
M*S ]8"549<3(*Q@X%K.P0?Z9BJK(LBYPO,0SE*0IO) !C#54BMT4O@X-3/C'
M'%N_3)+(6\M[2C-']%LV=5%,JUE:4"FLIT@PLJ8T6:%@O -?*C$PCEN521C6
MI#;^[<# L\\WC'1DM%1$8YJK-4(CC)IXQ92@J=54439D'H9.V:=S"LQA\^'5
MWH&01JZ,Q -U@MIARDW2#!N :547KBA0(IQ$B;(NJZQ$&1(GKP(0B6/93:WZ
MP,#4A=-'%D1J!RJU"94$5-OC11.&'Z+)"9JLZMGWHWQCXR(.#3Q Z#L5<VW8
M;@(?)JG1$E4N(L6;&G_&3E(\5I?KR9C56#5V7+2I4C'N2Y]4"'O#,&08>!JH
MXD4)FL9H\KI\*,-0=3,'?F @@CW5H&J_FTMH&B>&1GP]I@EVT:S&29(N&QS-
M<BQ,9$5CQ066S4?ZAP9"=O%]XI89!U YXP# <:;SBGX*&V$8SVH:!7V=H0B,
M22D\P[*K A*E29LD\-! R#"Q3PR[M.P9C#""97Y<$QPS86BEBHQL:":C43!+
M7$5:D!$P%=AD68<&(F?;I$;FG6WG=LLT!%J7!8Z!^B2K!L7P#+<R1R+/;<I.
MAP9"+M%-:N*[N702NR4)JL8HT)WQBJ(Q/"7RIK::=Y5HD\VYP_T#(;O8/G'K
M5'9+5PU.Y&#Z36L<S_*4)(CRB@^"J6N;*<0# QLV].]FV,GLEF)J,JO!_Z?3
M,L4(HB'J:X^GLLPF%3HT\"B.25OER14%Z70:-#E)W*]$IN4$2<2H@] .G'3&
M\%&;(1Z'%QZZE$P677A0!?/%5\8P:(GC-$[E)2AQB18I->O,$6 HM#$WAP;"
M<++!*=A<SU=5'U>[OV?-2Q1AJU8(IOD&&24(T$M3L&V&9#/=R<O63(="B.<)
MST/45V.C\-UWX6-<)UK>;D\K"#IJ]#%EAA8TF&Y #1.RR0])$64S5Y@X,#"9
M>N3K-""^D^N%&HH)UW6&%4WH'V%^JZNB*O.4*:^8";WH1H</#4RXSI;.;![+
M=6F06.=8CF,9CN=D7>(4C59E,ZLH2()),YORRJ&!"=<9KCVN8XUU&8;)IL'3
M)C38NJ'2$K,R'"(TW](&ZP<&(JXSS?:&')&[8,)U06<DVC HE3-45E)XF6&S
MB0U1HB19R]GU_0-3"].X7:\9>6'"=5'@!87G:5%7!9TW:$&DLZA$%&#RN*GR
M'!J8<)VN,^]4QYOVBZNW3OC=# #(3P6\71# BA(#C8.DP1\DA%)>E58]VYJ1
M*Z =&IAV S4.Z/<VOG?(6IFC#5&@#!&R2J%E0T/=,"G'#)62-DGKH8'IY I[
M(EN!(VL5@8:QA$FQ.DS$)%UF%);*?!JOF>(&M8<&IJQMW/GA8Q#>KFG0=)Z7
M99T7>1$U%ILP/LY,J,*IN3G^0P/3F8?2*<'A&X0WK%5Y4] ,R#<31K^&9G*2
ML%H%0HDRM3$(AP:FMK9QUN)C$-ZPEF<9BJ($0Y8H$SHJ#4WL9QS3>)7:&(1#
M ^L;A.TV@*1-,RQN-6^,3U>)!*\?DZNA\FPY+NJ_-_T@6;64CYQ83N18GD8K
M0 56ERA&SQ:K,8;.2IMJ_*&!N<)/<SPIF!)N@2>RK"DFB]II=)7C&%J3.75%
M*@P<<UWU!P:>A"<%L\<M\$12*)I2%9D59-$P89Y(&=G:+D.A-&8SSW5H8#V>
MG/-'PN0^ %88!\O$%-UE-V[" TVA#19I-RM0$,V4(=#K/D6.WTCXT,"SSPPK
MH>[-YHDJD/-^HC2--S3=H%@#FBY=DBD]0Z.HPQ!<WA!U:. ^HCYN+XM?;U86
M?OX9;;V8[!8WMR 5DV3?TD^S9&LJY!O.$4WHW)X/KVB=9GH9[<L&>>#,%RY:
M?O]Q^QGIZ_+O2'X-_3A(?DNVLON4<2YE1*Z5-]E,(!T"DE9>](?57YPI^MNC
M@QKGT>M X4XYVL4_MIMS=V].WO%Q]R79.](&_OQ;P\@*DC6CGU<;+*#.B]UK
MN1M VH^>#L^ZQ[>OY#Y@_;[5'S+.%#$J0U@*HNLX0GO^H;G+/G(MW9$P^HQ.
MJ$);_5#<^I'9E2.9D.D9TV^B$5"$<U1L;H;HW'12#^G>4A&IGHI(C:I(+E'K
M/:/$>HP23\6H\M5^N;E<=#%+#-KBZYIIX D%/\F?TK]-X9M?%ZYC.]DW3:8.
M')*>\0>I^51$S=GGW!SRAIR?/Q8^,?V CV^^8#3"5KQI=O4:;:TX,-D74C<:
M*$@$"OV 0O>^LB84!B;[D0E;)GK?#[WO-(VL!(5THP?P#+P8A.CD8YB]./:4
MH1"OK 6(X6^+P'\*K'F(.S"2S0IJT4I@0MS#\(1]*$,@-J$'-J'_V0.!20]@
MTFVPN9H+Z6$);JM&NT5T$X5IJ?=$2\T3+?:>:+%YHH7>$RTT2W1!,TDR$W4+
M%NM]OA)#M]598L_0;<4#\3#^6Q/VA<1F;J 2M:,()E?;"*YQ@I;%(Y*,Y.!D
MU/#@>_#7[?TW;T%D.1Z8&E;@.=X3)K'!&A[[:-QD%L5$G@X5I[7\<FTA;V^:
M,$@1%Y'8BH ;CF=.9?!K(F:K@08SP)S<932/W@)VC\)G%:&]$CYS^]5AALYJ
M@'A#WRC@<%P(0[P;-N'+T?I^8Z'M9X<IVQQIH]'R^C$LSA%)#X. 7D6P"K(T
MHRA7'*1T%!;@%! 9D3DY*<@PMVL]1WDE;"K3J8,6D5CNC>5,+SS-6CB1Y6*&
MTFK@V$OK:&'2LC'$O B,F3ULNQK=(ZP?%_I?^1YZ2N"[+N37:ODR9B"MAHU]
MI(XD&3A%.7O@!JZ'%>T1&[FCXSYBY\8#DN-*W8IMQ_/8A4.G2?\\&A: &1+"
M,[B +)V#0<*E,MTX%L6/"XHP=VG]]"+M!D)$SB1:Z$/ZC^]D.F:9/YG5'T>!
MOH=U\7;G]%LV8,,HF&-FS$CE_L@<;A!@[35&^I:KX1M@]2ZN&7RI&E^L8%BE
M'F= WA.D#\,18HAZ$KD=WYI#"O!=%>![!)_C G]\/7OOG&G? OQAN+)>>X^3
M;R%!)NO[-5G?.QTGKK\'<^\G2/HEL@"U/YEQ]_MU'@4'LCZ1@("$!",'"5GE
MV+-5COV#",DF^Y%-]APF9#%L/VP1YDT_^*-<&(V_W$LI@0AI)!NL220AP"F,
MX[B6&9S4PC8/^4[7.XP>Z_C6;C&#.2DB=X3PH2=T/<+X6!.Z[ R"$0&SAW@X
M[6D+]<4[C/RIUVE+[T1.VB)ZT!;1"RB0^<^1"1SSHD$_<_73";D'B<DP @3,
M4A128#UZ*IY8. (,$O;V*^SM$7R."YO(@25##YG(YLRX3D837TAV(AL!S,<Y
M,W><N\87E+W#PLE/AR:B[8%H3W &MD@6976]*$NL9[K%YH,3@2RFZ'^A3Z@'
M$^%4,&E-M/@RZBBCBGDZBD$6V+VAW05&A2R0)MUKE?/ O;QJ-P_LKGL-2Y23
MY4CCA@B).'L8<6(*$](M-6Z0D$4O?7!76-?<>H3PX^JO9"8<FRKL<0(FL5";
M"P):*+R_MQ2 C<Q/FLB/W.SC7.#I85VE=Q: +&7%,G(EQ<#1Y%0DE3E%X8_T
MA/>B)[Q_\"&;^0S8;8YXLOBX\)]4OK%-"(X3..;VJ)]FH&]")M%/'S:"&%X!
M8!@E9,QBFM'/ZZ=G!-%? 91#?K[*#Q? CJ!F*U-_@3AT_7@%7J -\&-(GO<$
M1WCP1SOA\1L#F0V"0O"F5C -ORVF\!N1Z"D&+T ?PXDMFWF8%:W8RYV#!-]I
M+].CQ&CE[IN5,041E3-E?\1AE/##](-&<$,+.T95M5P+/N9N!D#TU;<M]!$#
M"L9JL; BX%8\;,C$EDF@%Z&B-#J\Z]G\>QJ*W5NO&O2R3X#@OGW<[Q<%AOA_
M<W9DIXA/PN\5CR/KU76L!\>%S"%0;PWJ23!?+H.6,-YX#I@=EAT&T>^WEO<$
M$KRAWRZM5V<>[V9V4$[P%='R!K(I4KPI2C86B"AU>;]<@"WP7UKV##K#8)D?
MAP=B(0,^K=EQ]AG]NL6/AM!6@9L;-=C#SI;RMMX<[5Z 5L=[)UK5V($<])[P
M!6B>!5T =)N#!)/OQZ09PS0BB@, QYG.*_H)D^BVC_@LYR;!ZON]/?[VLVL'
M3^QGTYA$1? X @&)/M\-SA)6$I2^W\L/"*5=NWB"TI/9TF'%HEV;4Q*+GM*B
M#JSRU+55'7GE*>T88*Z<IUF$WIQ+>4+(EC!4;,B4T-DNUZ^'XX&[31)22%-6
M_]XAJJV)?.&<$ILL>DN_T+_D&I_VRO$?5K#T%S,KP&R=XWY![E+5DA[7WB66
M8AO?!YFM+'K%=9[!%^ -2?#;-+4G=K&>V.5SECJ5^4YD>PM"8*%N/&\Z!<_
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MB ,F#KA7YJI2ZS8Q5\,&@42R6I+5]KH]KRI*2:Y <@4L$4U*QR,2-LD)2$Z
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M@D*N!XK[%S]ARY7CE;!D>%BH2G,K$#CQ(FAB%W"T"R=>7$OL0O_M0@]<PRP
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MP?3)\9YT$#I/GA5!KNVT7Z1_!U,ES(9N6(@'!I 'R?/A[/.*$9\@(_9)N ;
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MC1TD@[]T5R...14">_$FNOO5]Y[0!*:_!7%W>*).%+DBM;B*7=K?E+'IL(E
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M)6[2WD/X1O:U*!]%::5@ HY "#<(=3\))M>'$(X[I51"2 ?[QG9?MS_"AA
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M60#)(MX01)X*D=BZXGZ[O!/W7!-AMBG,$RQKR=?$5<M-&\@!B%"*O7U"PTT
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MURE%M()H!59:T<-^LPHZ9#J/;V! -*F6)I6SD.A3;[U,EKWLQ_C=M4[O3DO
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M6]Z"9^#%('P,_#E\H6-/&0H9%VN1'-6Y"!!OYJM-OX:&@7T;OM5AS#N#AI[
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MOFIK@_'*B?O39=7]>F!2 1E-!00'0Y(&XK[K1[,XP.3(]$J![39).!J7>IY
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M)L_0@B'P%#1!,JO1K,K+]%L3I$RG 0C#[#]?X3?3+>6F,'>>J([G@>7D+@H
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M>-!ZIV<E%60W^S[(JB&HC*QSHFBRJLX)J9L0&4U7)$HI=!,K=[V_K>Q-OP2
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M?(',F25_VJ(%3<6ZJ*LC]"%1UIJ*Y&\/648RF5K+/<R9^R%J;$.=O.XRM>4
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M]-TIFB\N+M9-8FD%N :2Q[IY"2:'7S*G/_SR[78"^XN*/3C\<G7X3O+C+-B
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M5N-P>$&EWJL.RLU:M]ZMU/OU<KM<KL#2E*KUP:!6[M:?G1>T#H85O.329I+
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MKU3;\&>MT:GUS4&C7^H\O]A9+AW,;?22:]MS D'QD ;K?Q-63+;IR\G$L1)
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MU?E L+' 7^;<%FP1!R'&>&>5XOU;)\P7P+T*G%N$SF6IG]@9_#.5=>BO!8+
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MZ/QQ@(2VKVCR3,C37 2.>T\4B8S@<-VX .P)^,*QX7ZC)%<BQ)+UF&$+C9U
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M)#F.4U92'!&5K;YS0,5,V1 R,]^;^KBT29\WYL6'R^QRSD]I(@L+H?Z=8+!
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M,Y"#_U;*+!E6$'[ %K RODW$#'*"E$LRZ3[.I(-%3ME9!.+$@H4F!PE./OU
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M&S&>P#$G&HY#ZBWD,K-1/N/+J81:_"Z PD.?P2N%K5-^U)]:(7E2\7P64LW
M3'*##(@>IL*#)ZV0^(:B%OB [P3Q-#W,*E?- D\CY9JQH6,^'B,MDJLW-TP8
M^@R/[BDSF>V$5AR&*FE=LM"!$WZ53<>>^DZN+'(()$$^F> -E2T$2P[P#RZ(
MD\^' R,81F+.RN;I"S #=@VS90-8=#_8 C>XQYTN#PE?V0!73.$^R/, NDED
MYJ'B,4"W5&@%SAA^Y&/8];4U1.""I.7G12_\_^Q]>5,;2;;O5ZGPQ)W&-X2:
M?9E^TQ$"A*V^; '8W9[_2J645$VI2E,+M/K3O[/D5HL VX ER/M>3!NIE)7+
MR;.?WYF[DQ:'?_I]?.+\A7NPRA8*M*[:^F_P]:!UOA<._OTN.]Y87]_H'NSN
M= [VMS>Z:P='W;W-S>/-;J>SV=WH$A*27]J>;U..'=K=3W"IIY&/V7RT;_TH
M"6Y^\2S(JI]*CP^CQ,]Y&SUEDE6>>4#QWBOKU1M/1H4;)M-N>W=O?7^'ORSC
MKR LJLC#.N[*8^>_\X/M!FL!2KNJ:^DPEP)TN1GR650@8U AD(>#XHLPF6DR
M0>D] P6L2$FK94:$4KZLW)/(+H^-RK,?8T3 .\4QI$H2R'DE*/(M%>UN#"\C
MQ1!L1=2N<N"!H*V/L*<U"%C-%ULPI?1&H"F @CD3?HI6 TQ@(&Y%E$Q)Q<*_
M63+#(SQ[%/4Q&@.#I$40>'=)>B,-&OE3E.<TAY)A9&DC6K=-I/G$>WR+%@9(
M*#8Z[H2<(MD-\"(Y.F59P+SD&^(,;(R4KB8"ZH'V@!8>[ 9I.KE/<PO@S&D[
MP;P%W4VKH7W<-WS 4DU85<)G$S6!RIEH?="SP -;1!SVBC7B;T6%3NYBHX\9
M,TSOCC[B* +QG>*LI#873@7>%O6H%\"G(6,&HNX5BQ'9$W#>(5 -/" M 51F
M];@U"[ N_Y;#IO\=39PH!*I01JZYJ[A=D0!K,\W&X51=7?NB]OT,MA\>A:L)
MHA+I@BU>=1WIJ$%/%:C?!T+23 RDP6_(@$+!'(;_B@S=(2&\"7>5M5YS<VR=
MUF!$Y^,T*4;CN5</\X?@G<$8UZ?,'=]>DQJ+C9&!F HTX>%:C9  BBG27H&J
M?ABA44?4_!=</.FB4&0.ES@(Q)0,,5;L,R'-329'F&$1$<$0)RM-F :Z]>$R
MR[?@))6);W0PBWF V007$VTG_ &YI^#QD-;<0M,L2^)8P*S,E149<REC 2D6
MH%D8&"PQ[_:-@!N<3<D&&<*+)_*"5YE, T6D(DB+,%>#IT(Q!]QT_&\6A(CW
MF>69H900%A@#)Z@2(W O8Y]G18!V^+"(**$LS\FI5'M/=A-&B"6*GQI>-E#O
M'<*ET!NTK)?6%JC^)+'8D.&)0V5_(U,#@YVN:DL^SL>,!SA"_U!<-S,5=Q1#
MV#$_0!^"/Q3H2P!I<2MBVM6?!W!:8&K/\-*%))7!H HE';?*5,VF-#Q5X?AP
M$>"JP=M3IGS@P'=SA 4J!LK;0#(%UT84 JP:C! ?><;@%O[CHR\!=G0DJ4(-
M4+FF<I@,W@;3Z@1!DN(I1S,61.QG1#U@"@8CRU7V P-E@MS0LKKL!R0_'?Y>
MWCJV195$E+Y!=A 5TRDLW@@\#VX]HN&&VEW%QTI.0UHI*/Y <TC'N%HIHB2;
MLN^G3K)<4AJ_)L:2\P9('8 H0TOXU!(S98604( M#<S\5'IE*[]%UY"E#)*C
M#)ZW:A;0!U#D=;%?GP5S>B(^F% J2$+:4A4O)AX6TYZMT:D;PB^ F:+:(8^V
M]C3+MH95PO! %<P$<M18^<LIBTSD"D#_ S\=$(4%J!2B_@COXD8+M'EAAA//
MR@XT&@T6"'])SW:0%!&PV0@D8NQ+HI>BK_1+[-\ 5Q6?R_FAW# %N!D14+,Z
M9.!/29.ZJ?:MKK?54M.K!J.T^O[G%\^R!7_215_5Q_DA<IU]J\7XHV]/R;W:
M0(?(("2%2>,J;[AOTCOJ 8O/.'I0<HQ:+E-\NGXY+/7NFYVH5QB(*<&%R]@)
M^Z$SL)%!&:A8:E%R1TICJ&VM/NS@H&0J,"-'LK08*OR6Z=OK)V1$"1Y%ZR,X
M ;*3T&,X1CVQ2IB95NINDZB8E/5 &"&#':F(P+LQQA^JV\V7H7Z9PJQB$P+K
M(U'8,BEP/@6Q8'\0S1M96$#[0KL4YD4N%03[/K$:16NGX!UPEKA@*0HR9PSB
M%16G,!G@A/)P(JK7;FDN1Z>Q+$VR>&F :G9-!]_,K_ERU:#FGTOB5MU03[LM
MY8+/NO^YP3%UBB8-:#O>51")%'A!]IW^J9=2+10R;\OK?#X_Z_[1\A1"9<N[
M_G+5.;CLT77X_.FT>]F[_@(Z*K *I@KI7J&+B5V)4KJ@%#&D5B[S&*"ZW&7&
MJ5DK#I+9K.Y?7W&[YGN+E[ [P1.U'MA\-S_3QLCT=[5$EH=["*RY'@+V0/,]
MUG 37#<!1Q%V#"-)%QP^3[Z%&%WM%8_=S6<5S:"_?#KH?.B=>RLY/AT5<3()
M!^*K\O->^R5S!%-"(?/C9!AZ'T3\]VS2U&/5W<"OV]"#[G7GJGMY?O8S_NL8
M_^6MJ*R[)%[MB]Q?7>^[*^DH:!X%^3.1>A_2I)@N^'U<D T[/+_H_ '&VGRS
MZ(=-;66$88+4GZ _*Q"8*^5N_ENFU6MQZWL7I1!6YO4X2HKAAI-\,+<J8$%N
M_3+PT.X?UYW/O<XB<@2G"RP(1U@&.CY+;C&W/O,Z'QQ7^.[=_- [Z9Y]Z7@K
M0Y@[3'"2#-S=<]2R]'=O03;LPTGG&E1QSRF]BW+-%H0PKOQXD/S=HJ*;VU %
ML)?G?BT#MSKIGEY?=H[@]OF1F.3%W\7$=YJEHQ?G^'VA#3WM?.Z>'9YTCKR5
M(/(':=@/8R?W'+W,=5&<'GE7Z 9(W.5[@LOWY3_=LVMO)0NG2>P,.T<LK\*P
M6X;=/#^\['[^=.6M) %6>#B]TY'+O4X"@= @(AB[J_?=>WG9/>@=+T6,PS$$
M1\3?K <W-1%ZNHH"?. 9,\IEOUO&+AA@,1-6H&:>;U5@Y8FJR_+N_(@JZK&T
M8E!$.9:[A(2N0KGEIU<(0:#*_=3#@S"S2RG#C)/.PS3+[;=@N0)L3<J%;H30
M4L03K)44 RJGBG4IXT!,DICPL^ 35>B)DYJ*!-/ZZ2$_B@Q\UNE5V[/6&A1I
M*JAH!J>2Q/R/U)_.3)E/\[*K"WZ^6I)G/OD&; LX/EE7:J L).I5)\+J6UIS
M@4!>7EQ,^@@J-S08%?/P('#5LFI%'S=7Q<$+-714&;VL7+)0T*.F@/ \%J6:
M UGDY%M%6G(X['&)_]Y86]]5N _X.3:%DY_OX6JEFM@J$3Y.\1)>C+^[N%"3
MQ=?(I3'*F-89VM[O8\3%4]7?OE4$3S)'9%@);%[6!-!@+5150/L#++; TC'&
MU\+E#1M+!Y<+PVCG^S&,'!31LD 1-?&[9R0N9?<%\$5(Y8 (FXHX+';I?(N*
MCH<25L"^>JIL4M8:VD76532:M IU\QR0:N6JA/93P[:!)F#S(L+RPS)<0I&L
MX,J\Q *??GW]V3+.^I[B9KNHV2YB9D6&2OH?K'-.TF^N;WXKM:)7<,E!?I\6
M65!@W6,'#F,ZGGW;\A\$-'MFI>]W(7%+;5@'+*)G\!*D+*T(/UJW.@5F 7K4
MO@9AL, ;AM[5::?M=;0*B @EJAK]SN<:5(V4),O$XQ(Z!+Z_A4S:X.A$,TL#
M,Q@E6%".G*ND/*I&]FK6,!\I FS@C6F"@A05M20M87P=5U0T/=Q\W:P_NP<,
M3!<8FE>\E9MTD25IZ']_L?6/,I4_G7:.NI>GBKRD"9@!(2+)#,(A 5?GQNC4
MG%C1WE3M@%)")!;5!Y$B1*!-D$2&V2S+Q018O4;U!GMXG,#]^@M!2PC(9!9$
M23:%<6/Q9GCR@9%KRTE+!]VS[D7GI-?R>J>7G9,CKMH_/NG]T3GH,813#H:%
ML ON;2@.X[\HH\];K0 ,G+_N"T ,^LJ?9 40&.RAF(82^$ES2WASB! :$H/=
M0AWIGAU<=D]:WL=/I[W+#LWWLGO:.X0[0=A!"+I&6F++!@]@UE[10QCAL?Z2
MM\,*M<O NR2DKB1&4#\ZJG/:L1X[X_"+9=Z3[<V]C<WMACUY]^ME[_K3'YVS
MEB?_X7W\<M@]8<+ZT/G/E\\DL<_C@,!1E_.:/V*-I=MGN]5JPB.16]&@O5Q?
M=CMGF%S7%_' GQ2HY0OOX^')^Y;7N?Q/]Q(N[$HR]/-B0O%/9#L'EY\^P^WU
M5L)^6L#S8?\]S>L_7XZZ)[T/\/D 2#,*,_AB:9V<"DT*\125*DO-,! &Z)Y3
M(=0ZB3X5(JQ>^9S4#YM/IHJ15-%V$>MI]?!H8\V;))$ HZ*&"5SE^*TFE?C1
M&C%#G37-_X&[U[BT)G0[OV'2A#+(D'(2B,D"_R.T)N5YCM$90^JULA]2$0G$
M0E1CM8PD*?=! $U+XD,EJ'Q)Z:61:6"3;#PM.I<SV!2Z8F2QX()_@R$1G75C
M#8ZD2=XJ086GLQ1X;<_/T8"H$<_,+^)@7#$(&4.,H+Z0[JKVD40F$ZNY_Q=N
M\3!LPCPF5*L4)C>2X/U$MEIJ*@PT>@7=#B"(N/XN'G057C-):$SUPHH%*_WP
M,P$*RE(KT0_+6USNY5B &,B3<.!U4M S@5$MJ1ZM%O7M)EEJ]L)7>U&7L"7X
M6>#'>>KKF):$G%R=)/"^&7F$D</+@6$5[*)3%AQ8="F\#0:YUY9K>==GQS"!
M<=B7.._GE]VSPQYFT/?]W$<T6)3NA]?=4Y3N>8*0RIS>1(/]T3WYK7/V'_P&
MX999PC\;INH+R/%4RO(Y;J-F&=HL.\F==(_/J"+?[Z&1!LU(-]98VSW8V=A9
M6SOJKA]N=W<W]X_6MH[WCX_WUKM[6P=;1]7&&H\[BA_;TN'2QO\^LK;U(DU&
M*9B6R\E'2 ^?A#K?0<.<PT$C8KF/7W!3 $)4#*DS3]L[)[Q)^:P8(I8BQX>&
M25!(A/F^R+'W GG5"<%6.NGYDV@F"9;;R0T-@BV0N@)K#C-NX<8H\81<;8?2
M21VDB#,)5^W*)-#W&XQ#P[.&'0:Z<QN.E,E^>%96PQ@.J2'W A2H \J/X#ES
M-P%JIY71B+P(]%81_#U\/4H95C#PIYP!(AEO-L'D#*7^MHAA9IAMT"JYH.5?
M8F!@V27^=PFX&'8I1SS3'-&N P)*+TT;44I3BLHKC':)-BQ/QMI)/#K\C:C"
M'"P3IZ3,#>X,)8.?DKII%\MZN(7,SWM(T9XY_4"P'5^:%S&?(^]J3O\;9A4-
MGZF',G9P%'[6)U%H\(^!9K,ZR?8%$2!:-$I^4Q2J[74RZN6F.VE(O.6Y\Y47
MLJ43,N#+!%<X=P]@P\@RL5&<LQR$"G]-$.VR&V033'=SHY!*8PG56Y&LTBA)
M10E7>EZ;#KJR2*@RHXI2YS+8K%FB&S4:KV E5 -&$2C6(GJ^9A_/[7NGYI&-
MX+<29GP^$0"+BHE!F?9?M89A5ILP. !X-)D +YI&R(F1>0ZX\=SND\?=FS3U
M4VI)@K/Y*?..3!\X7%D'EC_#  ),\U@G%QT"#9C.)Y<2R!T>.0?VS%[$IP]-
M/ZZ?VC+F)>VZO*0?E9?T\&Z])-M!9Q>C!1,^-LLE;DQ)+(3Y[7S>,Y5*L4QN
M33E T]"-BN+%<C20(MR(0&4XTA!M[PAEISUZ&-\F$2IP/FML S'"D!$VOL'.
ME9SM"-_GW%U'O0=Y'>9PYMC[8%1N]XJK:EP SMWJ/QV,T373]GJZ>\F0^V2J
M7DR-KA\:O;H*6VN632^9IZA6GR_!<G](J\^G\JI+AEF_!]: I83]!<3.!FMZ
M%,8\/43^5Q]PL0!]\D3PVOL/PFO?@ZZ]N37_N_4G_]GN/2/._VKG45_9JP<K
MC?=F<UV?7:4H9!(.!I%XVKH/_N K*C]JA/ZDX,\-8=PJ%#2PJ ^P66 B=S R
MU%Q5HW=S^X'-[/O!#5C(13Q8E>_>6O.!'3[M+M,@"[/)#=LJ$^S/1)$FX612
MQ T!W[==D:6 UY^77A8%<?U\BHVDT)'MK9 G_:1W]N'\O;?JG5Z]3:JP6D-\
M+85(;O;,%/(BC'E(_X=YA*0@;[Q!6GATUXZ76*A4%K>_R@1[>J[HENJ6ZI;J
MENJ6^B:DCE/ GUT!/^CU#M9VUKT5JD%(Q62&?><IC/"6M?"O)(W=77\HMEZC
MYKWNSM^M;\G6MU RS*DH;JENJ6ZI;JFO?*D+)7462SU^O9;3/EA.!]?_9W+W
MG='DC"9G-+GU+=WZ7EA\?4W"@M-=W%+=4MU2W5+=4E_K4AM3-/>_.JFP#QKU
MFTLJ[$1_PRE-1,HE-%3'PR6K$ZHG6U#*6BQK[$DII[SP%Z2$01'X,IVP\\]_
M[&_M_.)-.J8'R+.]^/]EQ73.CB/$_CT53=/\W:__"_,KIK\^^RR97%8]Z\*\
MS;NADRRWOCK)<CW8]G<'K]%KL?GCK<*%$,5NJ:]TJ8^^]:]HV0MU@9W&\_11
MB,[9QM;:NE-WG+KCU!VG[C@=P"W5+=4MU2UUB9:Z4%+GS>CH/SIS:,-;&259
M 8,)PO%T>JJK?7:USPO($9W <TMU2W5+=4M]Y4M=**GC]/"7T<-W=R3R4.X7
MY#QWBKC+Y/_%9?*[]2WK^A9*C#DMQ2W5+=4MU2WUE2]UH:3.8JG'K]=XVEOS
M5M!NZER=.[O)V4W.;G+K6][UN0KH13QQMU2W5+=4MU2WU%>^U,8*Z%W75N4Q
MQACU4YD465!@,_LCU3&R-;_IU(^<K>G=?'7:X4Z')PXRZVT#J>WL4O-R["%'
MP--OEB)<K8ZKU7'J@%NJ6ZI;JEOJPBUUH:3.FU%.7U@9W=WS5GKG9[VKU</]
MEZBE[]^_U0^4TU_^A?7T_5^??::+CBOPCY?&%7BK-HH+<[HPIUO?DJYOH308
MIZ"ZI;JENJ6ZI;[RI2Z4U%DL]?C5!G76U]>\E4Z07_9ZG9\//)@&QOKRU)]B
MA.?JM+.@5V*QR,-93V_I_-WZ%GM]"R7'G)KBENJ6ZI;JEOK*E[I04F>QU./7
M:SVM@?7TQ\7:>KFYJ LZ.;/)G;];WW*M;Z$$F--/W%+=4MU2W5+=4E_+4ANK
MY^;":+O^H;:U=0IGAIU"EZAP[L)/;\(X2V+3\G1!Z7^QK,+7"\6SO>6M!&$\
M->T$+!IYF[3AV@FX=@+.^G1+=4MU2W5+=4MU0;LWH(:_L-J]OT6E@GO;^ZXZ
MKEP=]^;-#Q>P= %+M[XE79\# UW$$W=+=4MU2W5+=4M]Y4M]HG#FFP0#/9^.
M\[$?36 +1K,%):/%,KU>;P[Q^KJWDH>35$S#D8B%)R93/[V%TP@P0GCX\?1M
MTH<#V70@FT[,NJ6ZI;JENJ4NW%(72NHX5?6%5-4-;^7RXL.E1XIJ#EOI3V>H
MI?YQ<GFQH/?!);#]@ 2VGYL4U==.#0O%$IW$<TMU2W5+=4MU2W5+7;JE-@97
M-M8>B*X\:1"%/UB8*$I9:6ZP4+H3D8Y@)=X'V+!\['52X<]):_N>ZKO^(-A]
M:^&JWF12Q!2K\G[VSM'N6]#;N5B.@">EE45Q!!SYTS %.OV[F/A];RI&2>2M
M^'$>KAX>;:V=O/]?Q T]Z;Y- G'> %?.YGP!;JENJ6ZI;JENJ2XHYW3Q9T>5
MV)?Z]\'186>#<L9.NC\[%=RIX$X%=^5!BW;B;JENJ6ZI;JENJ:]\J0^+W[DQ
MEH$8;@9K;RS&<B:*- F241SFX:TP.(<+2D6+9=T]*<4LDG6WOK;EK71.+SID
MU_4Z;[2Q@#/JG%'GC+JWKE*XI;JENJ6ZI;JE+H)1IY/H=ET2W6/4^4Y0Y,(C
M,\^A/OSXJ-T+1^GV-[V5413V11Q$,.Y >+W/:-.=?.PM."CE/_^QO_7+BP)3
M7N5I<O-&FR4XV L'>^$T#;=4MU2W5+?4A5OJ0DD=IZL_N0)Z?7JUNK:VN^ J
M^4OCQ+/IVLN"L9C .$X_=Y$H%XE:)$G@!+U;JENJ6ZI;ZBM?ZD))G3=C?_RX
M'+ S/_=5K?VJUYV&D9AF;S1VY%1OIWHO'A-T,LXM]46XVNM:]EM9ZD+Q*J>P
M_=ADCX/4AZ$/X5=%%B;Q@MZ,16%X3HU[W;2P4*S123ZW5+=4I[&Z$V[,\=[^
MZASO-UG$>P'ZW8)2SV+I_J^V8'=M=\M;N0W_2G*87Q@+5/NOX9]B$L9^1.G_
M?C0*_;=))4[W=[J_T_W=4MU2W5+=4MU2G3/>*>0_0"&_FOA1Y!V'?9%R0>[4
MS\<NJ\*IY$XE7Q#FZ&2?6ZI;JENJ6^HK7^I"21VGDK]0?LRVMW+FWWKK[5U4
MQ[4*#@.Z",HCJ6-WUQ^*K=>H?*^[\W?K6[+U.5S213QQMU2W5)?IY$YXH9CV
MX_IJ+X1PGIO<Y0?X_Y9;^6PR3L(D"V$HW[5=>)0-\C)D\,(6ZM7!^KJWDHJA
M2$4<P!R]DT^'W;/KWM7[MTD4#I)R,2$IOTN>.&W"+=4MU2W5+=4MU2UUZ99*
MJL;/N=^/A/Z<_M>:6@U$\H5TZG>__J]WF$21#PJ*GX=)[$W39)3ZD_(Z%F*F
M__#.IS1%?Y0*,0%%<@$G20C\WHF?CH3W44S";(KD$GB]>.BG 4U_Y>1C[_WC
MIVX3_CH2=74M]'<8 T7G_]K<^"IB?OSJY$C'2>J%\3!))TPM0#=%[@5PA;%:
M/AEZ29&:\\F\NS ?HU$B"2Q),\^/!QZ\3:0>O#(=>%,?[K_(6MXT$JBMI\(?
MP%?"RXI^)GC+8*PPC\3 >SH855H0_XG#_"M$\*8 '0M%!D>09=ZEB&B1V3B<
M9D_\XG>_>GT!K(AVXRS)A;?1>HG%=8+_%F$6TK*>?$DM7LGZWHLLQ6);MX+V
M\9RHJG1LK:<_-WC3"ZSNJ7?PW:]\-OLO<C:]^%9D.;, &.BSGX8H_H +@O$/
MWWA=O-!XZY_^?/*$F%  %( VMI\#VQB&L1\'H1_!*^ #-;$@*@;P+8P.8V?
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M4XY HC%E,]M?Z!VNU-O1_.-H?E+D!?DQ@F0DHROW$;ZL;"" ($VB98JLB?]
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ME0F&YEB )0'#&>)KR%K%NTQB*5%&KEX$4"?8=L3Y-)J^ANJ@.3#LG&RAP+%
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MK^U(U_?WY\JX[^A;X3!QO@839^/=?-5"@MO,AZ+9WV[&HK%&GT/ $[@\D:A
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MB7V@29&BNP'F<PV\,P->F=Z_T\-*]&+'$B.8&@HF"@Q26VV58_J8(:'\_3!
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MU3SDKBY82V;S<:LU*9;VM3)$'OUZ:&6#( =![E\)S'\&/1M@R-'KJ*(+[3E
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MN5J[;_*[2_?'38UKO>9 "'(C"-*<=!![+'!6MF&NH&0LO5.3I.6B,0\/2LM
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M1RQ/ISN&K%+=.)&(1R,RK@Q6RD1]YEHE)!C8-\&0&?+VCE\9L]'U$1J=J=I
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M/##YS>PT/1]P!#"- ,Y0H O"*6:&4+U*8WA8\<YO?9>RH'WF^7UF!MSZ,@E
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M>E'(,U8)V,1!!$^=IF<W6'$G,V^HI,([_ZO52E]5B*65X= &GHM==G92]"O
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M8H_-D,E1X]@0PR\ 7Y..XYKG$"Q@IK(=?* _X0XAL<V+98I#2<!D]:'\=KP
M7(!'#3EKHH\VO"BV/V Y!S</!4AJ/6;Y] 5P<K'*\,8P:7=!^T>#?_7S>K]R
MI'-\[30T_4@S%URJ;\3Z$Z[4);NS^XY,DGUQ\:$^5FIH8+QV+TGRR2((TI71
MI6R('Y;Y[%%!@ 3>\^8/3Y@&M=:"F-!^0W,P5I>K*N$&?!:?KHQAXPL9U<XQ
M$EF(Q4L4AAJ4>Y]B$C[;L3>.:2&38DQ,UAV(V-N7C6C). @M&4^/-WSI@7U
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MTW>CW;=:18R.SH[?OWL.*F%_N4KX!88%G1,CSJEM8=Q8Q? K-*6:=KJA?=^
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M2N!Q'X,(:"E[V+V]+S!T_.5/1[N[.V^F;55D]4RE^//H#7+. 'N'_#W+[=^
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M^!Y"RG FPYD,9_*^*K.'.]\T'RV<R7 FPYF\;[3$_GV0=C^E,WE[(NH1#Z=
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M.EA9*.KV%^O%&+P-7/(IZZO$-,6@ST^_@P2=O4QK+&/')=Q8%VS'%E-!M6%
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MSGJ],\,PPG A%4G*=,AJ2B8\DPAY_MLU[J/+L,7TD,N(+\A)7?OS%&;WC13
MLBT2^$)@@0^I@7<??C",6DB+MB2(C O3TFPG1O"-CT#83F(Q%>W#[<VOMZE#
M_)BWP,J/+UKBGU>W-XEAQ&+S%R72)4GR.XGYYTQ\[_!S=LW.7VUQ_IF6[%GN
MF#%SB,PJ6'<"/B^":[ZKU$OU,N4+4:0>0?48'8\7R+A&DNVCWX?'&$8HW[5J
MS3C0<:B*(.&AX3;_!JO%D&2EUOHTU+4+;F,8%\'D$R7(BPU5]UX[=()Q +[+
MHGX0O9+$S?:SBH$2S(*^9PY--&9)0#F/ME0S?5.8<UZF8CN--[)DAT'"77[]
M=^^R=W5=TK[FUE\A'"LLW1/ @\0!(.4YP41DPFNMEI&NPQ]0G#Y&%T<LP"$V
M\L9@!Y,:+%UWCDDFQ'Y97'");YZ8L?:N9B3Z><%L7?8806UX(4XY69F(W4'E
ML0(G(;4="$DC@6S3ZQ\2(.;B)APJ5]Z!N@Y@W6>FPV=F<=@LRIE<9#26/#?I
MLJ57*;HHX%61Y$O^'>P1#_TJD>,D4#\2.-ID&<6:.67;)),OP]Q,7;L#6R!$
M)2,HPZNOY]W/]SWI:IT9]=2WW;^NNAVRFZ;L;X*4E6 :(:AG%B@(,ZAT[9S9
M;,AT"=2A@_>+>XQOZ 28K6V93/A=",L9U9(QM,Y";#("J19R)<+G2B:29YS?
MS$ZBTCOK?N[>=*YZNM:[ONU<7?1H I=7O3\[9[T8O5(H1 +-Q9[5SV\Y68PQ
MM+FMG4_ Q%GN>F5EUE-.JE$N9[S4],(.E=_12"VWRJ!9:?.ZWW&_/5Y<ON=R
M!8*")5D338CRX131L20_112HAQVQ3ON<D2*%O:*:1Z +::(O(!H+YP6V4A<Y
ME63<C"6,;<)T1P;I7!PJ.=V,X&&WJ!'"2GDQ0FAG8D%"9FHWEZ?E>J5N-&MM
M]#1M!W&2SS_?G<[ ST/!XV=#<HA'TB=<(W10_P^<W&<\O'30KL\G[,%TP@*<
M5 S/FT]GOC-%+][%8L<'H%HG %_<FP\F)O-=V(F%'X6!/Q$D$P='LI2*ZF#*
M3$!,S2QF)PD_KE TA/L>K2,U>Q">0[!019@2*%[ U=[]<7M!+B^H,]/V'#L&
MD133D=TUDAH;_DQ@S0] CSE3/*_01(OADK,ZD7^?F6X4))1P>D"H=*WPR$S2
M;;)5:1!Y?K_!^D_O!H[OG]XZ,):C=?#BP44SOC<EGUD$6CHBX=EH-QLQGM\=
MZ5<) I=50[0 RQ%Y\0(,S(51_P'Z\[D;PEH> "!5*V\)*M?Y('.=LR)[[_"H
MQ'7I__$Y6 LQFMQAWMC]_O6Z>]N[_ZLPVC=U#8,B\?*B$X<FP^7DZYC;:Y"V
M2T)VH<DF[+34)5_:@^E8W^!W> $6N@BP%C#>')N''H),'D1M\<ZHU]..0OC[
M&)<E7,8/7@S?"K,*UT)*]C-JD6C=T3+[?(#ML]D# _>1:F1BO7*8!-L!;PX,
ML"GK%Y-D'WF4#)8F,S2C;'BJ:WK,U!"G$^&-AV%(*K*KZ-J8)S%'(Z(94;)1
MN#\I&T,45<E05GA#T@4J^K6KB;814ZSB\\/>9'.LK)LY)MJE$T&E+(6]#!9O
M(.TM.[[@&=)E#B>;IL\MDQ-L.?,C)$W145MT@DE;K7*VT=P^_]J)YO8X<>((
MHA>,8 ZF["3E8/^,L &F-D1;*;$%V.K20?1VDR*D\OUBW0+E&69L>I(U1Z9%
M8.11G!$[A#S"WC%K[IF4G67CJD4Z!R9_P)I8,HI ?*Q3B%:SL$V-BQ%!1E9O
M",J:V7T\&;E8/QN$I'MC 71*KTRD&L;2@R&^M0A&AC,MB#/U?'(<$KT7'0W2
M]_-TG\Z&PQW?QUNJ+6XK,9?@3?03?;PC.EFGR.HD3E^B/,,-D=5;JY"NQ6U0
MG!S3M(K!**!$[OC,3T>N7JI&TK(N(5I$OI#E].'L0^&$<A=S8SY<]^[N>E\^
M@T=NT!OCORL?0]LI&[VBJ,-9Y[R;"&+PQ*:+@N)DM((SUYJO'^?:-PI[,AF\
M.)<D"76#A';F,'=(#2<(,MQQP5X-_(GCBIY6JZ7"IW(09,('TF.<T:\%,_S@
M'=K-_?BB+INU7]*^K)A\/W0X9E[X MB=V<DXSY  QCN6)7$OXVEX+TSQ)UCR
M/@]+$5X=L7VKF/AJ)YW^S8X.>[67;N"\5WS1TT>^$'YAFCG\^<1KG%^6F]7Z
MV5G]S*@WR\99R^BT+EN5RVK;,+K-YDDR>K,RW60D7F5C9%))2+QFRV@W\D(F
M3X+8%FPEHL']1KSG$(!\EY7\$7@1$JT73+%V%KF6A1$'[Z?5U[8XS\33J2JU
M<D9NX=_)X6PT[:WT2<MRNA?5]27W)EO&EYEM(H39IT2]4S*59A[_*?S'0J@C
MKOR#1W"7?CXQ6F')7TZEGRP,K+]/U 6FOS.>^.JI[S;^5<%?5GZC$9\O[^P[
MON],TT6;E4PSS.3?XOG41^1-TB<GRRYI\B\N-G61$#J[>36A,2<8)YH+ H3^
MJ)P\O1V2Y>1BC=EWC4IEM'^5Z7]K;=?2S9$W6%O:GAPU<2GCRW^!Y^)I7:P$
M6"I5WW*>R=YP^:>[\H%N@[ZQ* ([5/PT,8>@-EZ@%V7F<EYY\PJ47#]JXGVO
MG5/3XV7UQDK:27[8F+#KL\&WL>N AW$J+= A_6]#VRA?3T;5PKO?B.YR+E[3
M5$B^51(--MG!3LFHC=+?X9)9/F&ULH25;:;W(EFWF]U]$UF8LWT?>G9X7^U1
MEB.?$5X#GB,;<^_C,W1;W6]9N<_B\"4]60Y0XKV6<@I-($L$F2()11)IDLA3
M98=.$BOUV-JQ'MYXY/9&E*I$&*LZ=G',@P9\$8/L4ION6$H<-,F_Y) /8*V'
MOCYUEH>SOJ2+KH3OL1]RT=>ZAFUE%,^X^FI3FY,[;,WF[8BBE[+_&^U".@9Q
M\LN[-?;A69&VS@V(2*;=V;H;>M.HEM9QK;=^HDO95Q9O':,DWOCZWDP(K<-P
M>\Q7R$FM<KE47V-9BF$4PQPAPS3ULM$L&8IABL,P&W7B]L4$^F"4JMO8B_A
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M7/+-HTRWRW9'[O!2R@)J%;$E^"J*/@I"X5YX'I[GX.'"(Q3C#>.<ECGB@_G
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MQ!],9]'YF*GS,>-C870LHD'[%#&XDOUH%YZ3C>]3-<@2:DO7.K]_^=S]4X\
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MD]SA)%XPN5=4_AO,RC*";S'!_Z^[CJ,5@C91CXR[$EF*O5VL!?X7'L!_57H
MOD<\P3S0!D*A1.2E@E^.$&(3^\XB\("U(Y9SOY1W37,M%/&@<J%?S,2E"(7L
MRP4CD-JX&SEH$=!"^V&L=BO/6&;[>V6N%ZQ+6N-N)9GKO6O0S7.,A1LBQL*T
M[FPM\= \XBI$HV6^XC^^W0\1=PI4S"^S*?BI#=?8*R&^^G7'#(M7?*]QO3M#
MZ]XOQ]XEP&<E@.EDI#'<4&9"0XLT%.CRM,H0  \2;+,D2]6J9%KGQX-!:W)R
M>C+I'_<Q5'/:'?3.SB;=]K@W.7Y8E<PH3SZ=G9%/QQ+XPU%[/"B+7S# Q@7S
MTILSKL9]VW ^B >&*RC)S[PI:WNMH,6V/^X)\>#6J1M[UDEG>F2%LOL8)'6D
M:B&D#'LC#^-MOL)5UD&H5#9VL6"R,V&$-Y&\S?5 Q!(DA9I3;RO84/-U/&DK
M,DO,HR"(KE5-KCN+5NK=$X]2>OBG+XA-0""[OZ^HL>'-Y,OO;QF[M]4>'+7:
M!Q$CYYJG+T+83<8[.'+DG"[GS9=L"C0 #Q]U^D?MUMN?0>>:\T1)^#Z?9C-/
MM)( YI?O3&IR]_6OSB>[4]@^>1)-B3SS8H.3=<]WNV,J@?;D$$8QT[ +RQ6B
MXH<)TJHB2H(1;"#9W:$"J)R@>' <MY7GA@JIXFU68%RAS3 7.< *G)5T"6L*
M=2G2OK)T!ZA[K4AU#4-O<4ZP&J41/%---F;YX1;9VI#8?<IEU:+6R%7J%D09
M][K3ZC6'VEZW.$Y2K$WDA1SJ@F<=$?T*,'5D3=!,3%.>RB>K&^QS+EM"NSVV
M0JCP,#P[[N$Q'[=69LTW70NL/PQ1,>S\L!7@-SL>"O5[#W>Z<5/%.I."(/*+
M-X._N8A"GS%*<?AB&GG?V!$LPI:/ME>;Z.;132K0X#TT4LX:BG;K(JS+XL'9
MLC++FDN;Z$ZAPL 8NRZLO -!H@:! 2R'XC!FO[JLO94Z[%F(4GY-S.3 Y)U=
MP+/@%I(;&V!,U2\3Z-70#R\PVW^8<:ZONZ..B<JQ:HVH:HG"Y0E->P+!025E
M=I6]'ZIA(>V1#J?;0O=E2)?7W7;'F"A5U2H?RHRI79EYFCJ>!1G(!FYI-]]L
MCG&;?L'S=,(H/.)YTR2?Y,')\UKOJ=VV]'SVXX:XJ<Q&(724!%%SM;V^"5'P
M>C2T_ P>$8XVC3Q/:1L66L=O"%&>C%O=X[/1Z>BD/^J?#$;CD]/6>-(=#GN3
MX]%9=U+%$*4,3GYUO^,(B2L_>7#;';N$J?M]I9YCQ2:W_3$?F^QV1]4<%4&]
MRSH>B?WN&+!QYD&&^(I8J$_,1W(*1!S]URK3O@RB*2+IN'9C;A$Z!;MQHUBV
MS-%@1"OF@UEB&?4I7XI"0+.#E]B6[UZ#M\SSP[DL7#('^&J1EYM%#1]GL<(H
M;(F<6;S$]O\5_/[?(&62F>_)?C0Y%R>3?=@XAQ&6!\?W9^ZI6^>/R\A"8LUT
M3_+-/;)UFT.)'E;K48^;G:\QPY;)8C YQ8=6I#_VJ.GS9Z7QDLK&P^PPP1:.
MV]J4877&JIB"SP.]<1Y]%%^ZH<4DBMZWS-FDL>FZ\\S =O ,<13KGQ$-<2DA
MJ_2Z:74E09E]@*7L%RG&!KK)H<:4PAUL1WF^-YZ5 MVAH=C. FY";!&][,L4
MAB5PSPR->6:Y2M],%$E0K07>W\1+=>N'"LF@Y1>"-E@S-=(1T-=II"!5/>"J
M: *C3L7*Z>2K6- $=/@2XX(^Q=J( SJJ&]E#[$B_X3JIQ5K>T(ARWAG>A/[
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MK,M.GJAM\+P(]$VGMY>JJ&K%ZG=5.UO9FI.ICM8_E?35LXP+O8QJDG&_][#
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M''6J.WO'QL1PQQZ\N[/7-!P/F-:%;R1PE/X<V#=,&302Q6CB7(M8.&[BS*,
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M)>4T^[BHU_U1J]G97\89+^CU8&25Z#70WL4,!\4<F@Y84L6-PO]S43)?D=4
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ME\F#Y>57MKJVK4#SW,T++;*:91D\6Z[Z0][["=][-1GJCP+Q C',Q)QP'$!
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MA!IJB5!+A%HB/ ^)T&^,6KV7(A-R4Z.W#/:=^<DJ</'A-'AF&D3>-S6REZ;
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MB*[Q7,P=NL$/";WB3=9B[X?$7L%=4?4419FQ.=#U?G'K78J(4;'0E?YW$9L
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M6PDCLNQH\?P]PO;GZ9$\6]I-"#-)7I%-;<HR,PVW&M=S 5(6D6Y"XQ^DY2?
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M>76?"G*W=&U'VMV!_;N@_)0*V>JF=7%3G/U^88'Y_C([MT?^"2Q0E&-F=]1
MU$&E)Z_OA0_%DA+1];'X:/7,\F8=SUP9SGV%NX^5?V\8+:V+AQMBK]$CWDJ
MHY&KC_58V<CZ&EM>AGX[W//X+?+'?>FXNR#6)+U,2Q^-/_P[>_BQ/_SV\(?)
ML @=G%ZFJ=>(=O*@$W_0EUD^R2^#V!XQ?^1W\<A3?^27CGR9I-.3X^"/>YO'
MG>WK<3\>3\NJP$?=MCTY%_[<MWGN;S<>V)MS7_>]OE@O_.Y!L$,@$+=#Z4O=
M!N\N2'ANU6?' 2L];P+LID//.P?FLZMZ;.ED7$Y+W=DY)@\G7+U&;X(ZIKN]
M,<FTCDH/L[J WJ7O5 NKXOGV<KX'9Y;=1F4OAG)D9]4]"-ULJ?3@<,Z#1I!S
M[$KX)Z,LO[PWXEF/";GQL=FHS@"K7O3P],_USB(1/3N+K_&;+I(&7OH(SB^_
MV.=QT6CQ?-X U)[$'\43CGF*'A0#QZCS\3'NX;K.OWBP\<;;X[OFW;ZJ!+5!
M4V.].QX_.G??4+;%<)F"#Z2C&J1#"@'#4%&JL11&<>E:AE&D11SK+4]K8?=G
M;L3V)@<0O/U;<%J,9_NQG0?Q^,8)NVNGMR"I#[;8"(P@ #0U!&.J=*PBK6(0
MJCC&3'&\-,#;)_6UE]3WD!I8G3%[.8.W]E$WD?Y].1;QQPLRA?F?7X["H\_!
MT7%D_J>^!5N48&1OG]5MRLM+9M-Q_4!I8!2/;"P'";+[\XP>2$'B?(T4I%U*
M,2J^]]R-<RA$_ONBTY,[5^Y\-K79X]MRO ]V:I>WZJ8AT[^U;SCIZ*&#$J7Y
M8))=+_<+V1_7%CJ$15$'Z<M)V2-OU?_.\FEV\>..)28W7GWGZ:VDM$L3C..;
M&D)EY,]UI,OI]/K]NW>N.9Y]V>&7\==W:C*X='-RWZ7G7Y+).VL6)>\$IX#0
M=^X3RU\A=K]#\"ZY3@XOIU=MGCOEYGX$'V?V.A)KP2DWU*%LM' U'GVIZBJ#
M([OTNGN^6[^UV'ZQH'9>B0_3\\.#P+BR]X^7B=4A;KWN@QN940T:;KQJD,Z*
MC<X/7+*1_832(BS;C<?IV63F)@+1HB\X/K0V>)6@7<F4P.*E;HNH9Y-)Z0>N
MIR(6QI%X^[=WJG9ZC!:?"5'UH7<HC7M$-W<EP7F>V6^>X46V,W^7?D?PW_E\
M!-?WI&:%MMGG=#'F:\$\9^GTF^O87W./I8>"/>S?7]V@<GMOB\>:C/'79%2
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M8$7IH%1_JD30O><=XGFGAVO?2MYA;?/.A]3-[&R0RB2UE^3N8?"SLBI9HS^
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M*_&$T9L$6$\8_2:,AGL$4X+>G3$.F#B_L(0QJ!D#4M1]8LG'A5GS-K0TX72
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M]/7YFWD$(!W,)MDT2UW^ZN#2&<EU& !*3 ZJ#W49.4Y%+S3V\]GP1S!(9FZ
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M$;V!(1L"]\-9[.5K#^3K'D9W"5_(7VB@MKJKI$;$AB@08UT!EN-8J"7Y^Q3
MMIA([+,N/"ZW'Y>/E=H2"1>-CT/,M8KC6'#[@W&+4U4JQI$V8GETSE. V7ZE
M'()\HQ#=_B+:O5#'*]_O66J/3EJKY=/D>YW8429Y_&>637_89ZO.'Q?V5]<
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MJ4SAZ*%)%Z/SKMWS<#/N^7Z.S/:R_WEK[27X5X4[62@&*B(Z9%8[B+",-9)
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M*6]\'>"U(RW1 ;;J=IN-6;RT[/0LJL&@B%<'DW206MW*'IJB/9,7F.L*3+K
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MB$ EJ@5'>BGO]V$ MR2;T8%EI Z[A]X!8)^[]&(=I\975UECJH$[5/;2TM'
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ML85OO&C>.='\*,KE N6"*DF10$*'F$<RY%9PSSM+:+Q4F/-\E#]!9J^"<D1
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M"8<M6>OX &!YR/Q@GUVH'72=T.QCD[&UT$=?@LP>&6N=3WUSJ\[,<MEPTFG
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MUUOM5HPO*K,7_O4Y:B',1P^$$(?4EVQN,?-VL;ZM2C#H,6VL2A1HD?S$)*>
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MNZ'ZE@?N>;W32\A-2D@!%Q(24L.IH(Q)K:%&.HRTK&N?(@WNB-0_%7;M*:!
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M?JN6*<':UXO4J(@])K!!P8)G?=D36[U1.J5M2%$[I]0A2P@C#*,U#).?#<>
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M1' N6=79RRFI[VDPM!W'K]?E^/<6,>=P;Q&D.;CY+413MI&92P$WY3(&0;A
MV#D2;^>9>A*;0'1S X,A$0= [1-0^290.8E<2JT5YI$8H@F['6*@Z>[^7WL
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MWKV]970G>;R<%2U;D[G9<OS[:CP!". #!; @]2U%CIR/QG&C(D/$!ARQK!C
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MUK7)%E$5$ T0S:L3#<3I/30<W,Q>;H:#FP$W\VPWTZ?JDF7:X47,!=4EX,%
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M01%XYKU?9S"G+/*NLO06WA=B A9&B"YSY"W6\U6,0\HG\RA+<UB;D[>7+\T
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M?<\QUU=ZHVB<$>,J;$N+[LXHN.QQB<;4"RX_>>_2,_KC:;56.72_[#)\/!\
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MT^M9T^WB7?]>V[OUG!\> $,@O6FZ7+$DI1;76H*2JK1EZ(GJ@GD387$6,?J
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M5962INLU,@Y\CN;Q=<JAJ47XF0$ _"C#+L$H)IX:1[KOGQO"(BQ_EUE-G3Q
M>>!BKX>7TQ[L$8'?^7J&6.SQ>BS-D40#F;_*&T&(?$()6YT6CI/EFNJOM+=D
MF%QS$VR1!#WE[BNV=[/2Y/!$^J+A =HHID39E%J'Y38I!R7L%8# RJSM]73;
M"D\HJ1)E-]N?G_/MW #:;;X+3RR>7/MXVB]&>E>+]9;:U)^RCU+,$)KSO/&:
M @I$\3U,0)(QLRO[D01&*1^@_83BI+/H"L>78N\L)(* \W.T&<F!<_+41=J0
M1X:5*?0649A;^(5)%DV1%R?./V^L%+A,J[DF-U*L:0Q388' Q72:'T!?A((D
ML"^?[;32 $@;.&?<8!ZLVA"\M5,2#GF%GH^T; A[<)$36"#%";5PM?E53PM?
MG70KG#4!6<BDW4%%2QUR+PH;K7UN)>]&R;FKB-+=YTD1KE6.<Z*XI"!_4$N%
M>%;#C,1.#G<,=:2^-NH6D 3+,;Z",4Y8F$GDR"LXB3!C..SY"GX1&>01^LTH
M?<#UI3#Q1PJ>6B)53HK)N>I]L^#1(B')TT_'*&?(09+[R%"K,^_2^L(_U],K
M16,6P6JG=^598[J<RPS/8R(@,(U%T'HS-,4_!0U/\R3L"VHRTY]"J[)?)7H[
M@.?<L#P^3^ DK T+Z]^BZ14N=Z!;RAS ZC;OVR=B6V^TZZW6 &SO=K77[+;A
MJ<KJ'E:[C:IE=?=;=;\]K#8&P_YPV.^T U_7]X^"6K_QS5;W#X]A[J,^'X$^
MY^ZB>$7_H"M:OK??ILR^M^_A<+M@$>W43"ZV#RZ(C9AK0G4,V.$$=.S_?5AE
M[C5JMXW$-6-)T(A>1'-%%)OB^*=8M57PS^6IQ+(0@4;)^>F$USC!A-Y++',G
MXQ!MJT3C(5DOE0R(\<<HFYE0("??BKVL:[CI#N@/3Q+1"N0IAU97=TN:[\8G
M&3#)5/YW$JC5YJ4*'^?NRLA*,@4=C.:*K*U\V[?YI1ANCA;LKP@\CKH]8S8!
M.PIMVP92Y5G(Z\1V@3) E^L,([U'6T?S9Z2Z3(46OR>K<(KYI\E5BO,FHJ/*
M_6?$<LX56NM:E("UY7RTKV%1D&= -PS!NS2;H56H$>U6'L=L:^K$X96"WMCC
MZ L7H=.=4ZTI8#:(+D>WTU 3;9F*FD%8-@=SN/0$R(Q81=+X42(+A1OOM&=T
MO/+8#*MPT_>C_[;O!%$^R'VP2IZM)5* 4D-BR!N'*Q7!6C,\W<R6("A4!\<U
M[V,5I^9X"SR]HBUTCCW*3;?@I,HFYGHW=*/<;> OF!W@W""WM^2%6B?(04;2
MT%G(U!C,3%6;%_S_HK!\K O[O37YNPAA$& :,;SO)]/?PMN8YB:2I1B;9W1P
M86!X[4EJ@+!8(PF$A!03*;'3:Z-*#L"L9R_I,ESD:SBFO3B-EG%N 31@?BFS
MZ8H\T+2GJ8C#D!_VZ>SR#'3+'#RIBA2SH+L63L%]RB-!<$JII_59.\9$C/]J
MD&?>)P*+E0LHNG$$%)6+C3-$A) U2Y51)8)D^->5BD>RU,KO7;D"*1[K8LL,
M*+R/1G*O$55QK:C*ON1\8CRXFH&DWI(RP3)^!;SY*G-(*FU89U@A.UM]9,KQ
M<T@Q"LH%Y\)P6'F\@-7!X.+%^MI^#JH#A2WBGMQJ.DZAL9NF<)?M#9NLM+[I
MB%I"5]A]$HC;;D'^H[ 7_IP!#FJM.=<@F9%(RS[K@,,$->2A\LR[CY:M'"13
M:P3[Q#QZ_6'+;P6]86LP:/5:037H-E6FL3_LU>SRWD:[/FCT@E:[UA\UZKW>
MJ%>7F$=0&U5WIY+O?<_Q<AI^I.J%9")R0^M[(@=.F4L!I8=2G1C_BZ=QF%$Q
M8RYH(=@@Z\O,+DTZ&A:/U+_S-8:DR<ZSG5$VA)TFQ_8V!BLY0XQ#4O:P9A+7
MNE-@<6[#94YIGK->4A6I6']%NJ'D^63F8\SX*M)KI&?P$\.<NL\PIV>8TS/,
MZ2E@3K4'PISJ>W$G[:'C'J;5'E$@.?Y0;E*2DJ *+*1!"6!WY9H]Y.B4=:HO
M:$(I=*!4+!:#HW[B:A!64KEX\<+IKE\W+8*1V5?2&L<IRMS;MZM0'Q-5$J_[
M2:#"([^?=;*CAF_A6>+7E6E?!QY>5+1<%F-U&W(,@ HI_@4,8162Y[6GLEX)
M;8.CI[%2EGFC)/C%24FI.L,IZ)K4V^MXCHV)O_:].XP$'75]3#NA_-C:YK@-
MEM'Y6V<W-YJ''< S_X5XVR_2NW"^N@,US3;O)2)NCC,4\'6.V3B.QZ]D]CCY
M=$93W\/[ZC0ZX$WY_1&HG/:@-6K5@Z%HC'Y[Y%3?#OWAJ-GK-?N]?M\?]&O#
MFM\1[ZO9"/K#HOOT9\1-SC+9%8.(3)&U9HWM_B2*:)IN",.#(M[%%N*J[-1J
MWU'$YI00#Y<2ZRI<Q\:0Z*[?+1%0A4W&%%D!$US@948S!Z_]B?HJ7O>72JX0
MM$OI%D/4E[B(SKLHS$2[?$3OR7X4%>LP43)SNH3"M4)=EG =II'\6VK\*>V"
MCW011*L46V:9HA$>FK #D@"C0EHMH(;XF'^M8928=Y%?<\MU74&SSN2Q:L0%
M]"FKG_F<AZ/223H$2\O/R1,SM)#+2<P03?$.[YD9$_^]N!,8"M;O--SE]&%6
ME-&7$/%+E-@E_8;X):6L^:%$K4 ;'B%W"#_,]+8B76;ODJP]_AX_6M$MZ"1_
MQA+9GA:FJ1*")XE65'%2_KZS=V868QP/4E9;+S\K.I\/QNG]J'(\<+-PE]=P
M/4][M%)]9(A*\D.!XNW'77#:#N7G/I*SZ=>&C5[';[7:@]X0Y&4U4+9VX->Z
M#;L71[,ZZE1!;(XZHUJUT6BT>@JKTQF.JL?+6X#=(W+:'3['$VLY#=<X_'^\
M\+?4Q-3PA6A#!_35Y+-J#%DA"G;8PI7^"Y87RQ<Q<V,A[^C/PD%#AMWG!(%\
M8:YIS:P'G+R]_(0X$NOSI_B\:+KSE83[C'12_Z1_^8$>@V2G]WS_Y.*;WBC-
M$OC%4_WF5-9:*QJ$*.M5.,%1*2,5+$+.;F>1[1'9IYW$]-LP":6-JDW\")];
M8#VAAOST4LP8P0\#,-&%%ZYD4CO63O8XDT7\</E)<E@R)<*T*(8J?*6 (2.U
MR9KR C&M)\/+#Q]>GKD3TM:[DT[?(F WP?)R/L.5G%==&&%TV:3L=4H!&H-&
MGF27>M*YY1XM*RY,$%9#&Y5?J%JEQ^#C9Y$@XK7NR"*V=?"09#?( :+UMLH"
M,Z\\6C/X!7R_7;GP)[F-:LI9Q"WHR99"KP^=$K1 T#5UOPJ'F@J:$ZY1KH@#
M&A;1$3QX_*[@Z?$D,GS6BT!8"9_D2]?2<$T'M<(N*2(#3;33:C9+%R#HI+$Z
M0DS\DV^.X7BKH3\Z0!TM$E#$<<C":N;"-)&@W%9X4@@%SUL=>F]137K],)NG
M"*I>LZ?*G12X4R3%+D#I9>($@]0:K^V6!E*W+%WHMBD#M9?Z"%L<;NX9UD56
M.!>!U[L <3$017(4*JH1,Q-1ZQAUN0S#DW56=%4 X?VR"-UY/C1&BA"+C8+(
MTS2I%:0 K&D,+.OXG3_94;I01\FY?J)7'4"HR'8KL -_H+7>(J%QA^GQKJAV
M>P#=?U*.=<$?[7+9]$W*>,8-(I.EXGWXQ'$T5+YEMDUE!Y.4+GCA/9-J"!T5
MHS[>L_(Z.4]5!NJ;RJ]ER%#I 2GZ]WM.P#JNNL)2S >'*,NH:KF_I2*$U34C
M3LM*5=A6DW(LVPB=9#$2C(;L&8Z),$N_>Q5F5Y%4)*;KE3BEQ0F+IMM\9&&H
M4GN&M8BFT,R.,SJ!Z,CR]6V!5H0G%9;,Z!(8,(-]9L41GBK0(TC=J13&XBF<
M&Z' 47L>DL4,348@F[H$\RR=MJ+/6#"): F3!OREPKY\V8&R: DM@8/$GA*'
MWEA]L8W4%B+I<Y;_5$*^[!;QUM]SC;Y"TKL"?M-4?KY_RJ!XOF1;+]G/A+FH
M59\Q%\^8BV?,Q5-@+G;W.+[_^XV?BEIF:YN7H72G/T X7;W#>GR03-$R6,.!
MO4QG*Q#XT1[!]4:]TVDT@DYMT*PVFK5^OSG4U(75JC^T@^N=ZM#W@RYL8;T_
MJ WK?EWH9^JC=K6ZD98\FN#ZQ3UT\D[7:OT[Q2OOQ0X[^_8^,!9<7(*'T@YU
M4HP6CZ,DFL58R3$+)QJ(D3#OP35BS-4H*H:> EQ:)*E0PZ,Z]"C":LQXR@VM
MI I*CS#-KL)$2#=RD!L7[S&&KA^8K\5WGGI@OZRQ504G-\W+D0TO.L7J/,X$
M(S< 5@^0Q8C=2"U+Q>YF0-E :6DFL4Q%FC /UXE>/6U6K5*KSHP;$B-=B")9
M9O@&V',8AW+78+V<93!S7@N:BV&T44M#B?%33""CP36?AV/DSZ'>*/>?#:D^
MXCX'H3D7V(J$7^V\U:3"*1*\Z^U;'PV34C%8*BYADL82?I&W6]XJ@>*-;P@O
MH=5VPBIJF=IA<=5H6'>PGFD[6C,!\8Z>>1\T2X4 %= ]V7I/)/24FU9LY!:I
MWXXCOF4)!QS=!NITX&A7=[#L%YJB*Q29O=#.&_&/N#QPM*8<L,5>QN%D E).
MBF]R ;Q)6:Q[)TL)<#AA5^#T5U"WB*J/K:))]NA8:E 450HOA0)+]\<1P>'T
MCF<4W23.I5Y3'SOULL*[E/N'(SQ6)WQ$20N:?4K_R]D/-.8X'^0(9@-WB1/#
M*D-!0'/-)8YO+B@5>L.E3:+,I@S3%PU^CH@$E#(H? I+OJN1;+%D'4WUL1DB
MGS "9E #*\/,NELZ58CO>TD@$-SB=2ZURX:,V^\\2:52WYD[#O<]R6S" J#^
MN8Z7^7>EYS[S>M+.D1KMQ-020XB!<;FOPYQO*0M+N9-C&(AW<?[QT]^#=S2M
MWX/_^<<?0:7$3AC?>;]'B#.-2/?3)BN)46B+M?E '3.PA=W]VX\- 6#-<:6Y
M\QGG$=0Y@XF@G>$\-'0!L6YC-]3:IV#\54D,@;&';<*U/#M:<9$ZEQ.M(;KN
M-C6946@YX9QNN>Z8A27L,9@R<Y(R(@><YG6L)> 4Y,M4F#4T\3O?;3X/,>G%
MI1 ?4':&(;+[<]6=ZZ'A:=DZO.+[RV0+3>"7J><#GVA.? 6_<T*?-BZ8(C44
MYLMH1P[HP<GKY&7@O+FO4F_:PX6KUH)1L]<>M+KMP:#6#H8]?Z"0I9U1M6.Y
M<,U^>S3H#1N]6J/N]_N-X:BFVG9V:]7@> OS].9=69L7NIOG6.QP*19A%L\Y
MPIK%PLN]U17;9*ECT"$Y1YBII;>S7@&Y>[U>,-NC8D:;1U=X >U*XT)S1_9A
M"F.&6YJG21+-*]J[L5Y'! *KF'$'B-O'E[CN#S]UQZK0]3]6P1U8"R!R;*LW
M-DH-'#3W&/5Y<'MC $;?PNF6@P+@$0JR#_Y(&&?G\.87'KC'&&K[$98TW#A,
MA,5^C&-"3_KM/T1SC#+%I@.R?=KTJ_46_!?5ZMV.EMRCCC^J-ZN#7K?6]5O#
M3J->%Q!L8]CQ6QOJQ;H9HDI>;-=,F!RDWZ[SZ0MR%A?@MO[UQ6GSA9<C9/NO
M+UHO/)9<?WT1?UF]2M:+:;J23[[XK=T]JRG30,WF-XQYS&WT\(]_"?;;ET:U
MIO>E$8R"7K?9&W2"6AWWH]I6E?*];K77_:9]Z1QJ7[K5[[ OCW/I]]V:MMZ:
M6M!MM1O5UJC:]P=^M3NLM=65Z06MWK==F?;!KDSSNUP9XU[,[WX9TUXJ#S^&
M7PYBNO/CX&G[&.?]P*\V@QZ:V^UF8]1NM0)%-%IK^S;IQJA3]WM!H]^L-WM!
M?="PFB[ZG59M=V'SO>\Y7MM>@*DW',%D4#3MYPKWT^H'$"' &RQE<HPK4F4K
M?+Q40DI?T(6H_/4PBXJ-&!/5N]UT)#*H/,8+GGF#:!916 <>LZMVM@258X'C
M.7Z+CT#7GJB")\)=&"V0Q3^[LYKJY4YSRI(@5K&9D8X^N($%?!_"CO+]IZ%Q
MB(QRCI*0T2KP+:['M0$L#+K$T%OX17B9;2Y"J?TR\>PMDU6VO(6+D<9-'"#7
M.!MD=62<<209",X.:2 S,SJ5SQ1V \88(ZC1HC /Y_/TEM($A/6,B3QP@=AE
MZGYPQTPK'&+!RK/YG-N^6^C\LA<2 $>W"N.X4J'VP?Y:"7D^3N5JGHXI.*G[
MH<%@3_'S4UW#_/OYFX_G+_EH294E\;8=J:>'0L!<>_>VZ!*%&#.<IQ'VJ+_C
MBO(9!MB=U*04%FY$TZB36X7CN:K"77K0T794-E)-H4XVX8A2ZX1-KA'[YA99
M&'3N?C1OMZ9OMAHZG, <F6FIK-<4\Q;U^-'LZ7FBFLNBE]RBV8Z"RYZJ40HN
M/WGOTC/ZXZG?JK!3_03)"MM>\$X^IDMX#%B2+U^!ZL 3-N03]E%.&.Z:-.GF
MI,9'E WG:M\.;L5AK0:>!;C]4RS^B>8Q9_*DES$=PW"N$DEX.BU:1^>2L(:S
MKHIAD=+GCEJYA@)XK,B9_):;R*TZY)UE;U*MW97 L^@6"U+1 !GU]=(7QKP.
M.6B/5N)AHGF:+DGW.=L-VN6_PV2-VI+C2YV*U3QZD8(*C:GP<96E6N6SV5+1
M0BBT&J:<"F.(@=,R9A;QO@2F%29Q1>\1JIJ]3TLBV^""4IU=D/VP^!6Q#+Q,
M&^)YP&3:%S*'YG>/<L'W=AT;QG7LM>M^K=YH^ZW>L(O-M?Q6>]2O-?KM:BL
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MP++U9[#L,UCV&2S[<+#L'L;0@VRI^D-LJ<>V)3[I3CM(8:-+P8NJEGIL@#7
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MO!^9AZ;F\LAF5I0.A.'5VX)FKX9?AIEN.9I\?3O/5-GPBNA.^S)XXB_8ZW;
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M(X9Y! A1CD7=V@KF@''\097NV?CWL&^3Z;=I_VLY!VD65S6?E&OZ7OY5$ZH
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MQF;._7;CK;^6 RO/+T>#Z60VG/5^^/7\QY]>*UY-!EA?M9-;!N N=V5/F.>
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M2M,ST@*@H,56"0&)=I[@0DV TI%UU(258KO5Z6W?$($G!+%3=M11X$/.7DG
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M_0ED?_8IN )IA70/)770&>$L$DQ()W#I.C*Q^6C3P95?SXO'RC?:P>B-$RY
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MCZ'KAG;OW4?U[BP5X&Y2@$L0J48B0XTY)IX[YCUB5ACJ>9&@J:QGZ^1^K52
M6Q[=%I*G_SD(WZ(_NXE@$0BBGX^Z2/>0#?>$^)<0SZH1JQQ"9YUE7BCBF788
MX:)&B7!)^#ISV9I'?#LIV42P9L>W)?0G].\1^D4UE1$AQ2VVS$"&%,(0$B++
M^UYRMTZ)_P;H3UA.=1='77=!,*BP:!BFB!@.I+)">*Y861RE@)=ZG>8W*U4+
M'XCNG8"9@-D",&'5BA([ZR'"X2\FK'00HK*,GR *W3JM*)L'9ELJ,DUE_PFD
M70<IKEI':H PLEHR@ (X&37"E_/%3;AE>;L@39!+D#L.R-%:MU;,)0><,0&
M$Y@8HDT!.1N0J)HN%$X*:P)F N9SP.15XT;"@17.,6V@THYKZ&6AL&))()8[
M!68["BOFX%0DD":0=ANDL@)IN#,Y-<@X2B4*B!7:TL*JI,K =5RO&X T0>ZX
M<B3.?OVDWMF4(K%9R(1 7NN\2I'PFDIC-6"&!UNS")D$=9C)QD,FQ<GMN=*[
M?W&5%",]9L#CJM4RY$8)KQ +MS2F'B++BTE$TD@&UNGBVCC@6YI)(IIMAY[
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ML%-@[H%RG!":$-H"0A&MKDXI%6;6(:&D)11":,M8$'+.K!,+V@"A"6\);T>
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MG?:U VKM'(.VQ)G[28VKDB&JR)!B0;3W%A-N&$2>T,4,/<@-(0V6I'3 FR
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M#K3@.$1,BUHG,T$!%I0H+B5R1B*K5(YI0C7'N.N8;KU3/A.LT7Z,"=0)U&V
M6H"JVS/CRB,".-%88D>D9:X8\R6#FDU AT&]Q<9>N-$V#0G7"=>MX!I5N ;(
M"DF0 ,AY+C  P!=%5 1;SK=Y63< 0'R"A3P,#!Z'15U3L!Z8TLTU4=]'_+[4
MJ$Z0"L!<(N.$0-IC!H*FK: O'5Z6*0/;G;_98=,9-&HX/\5,E_W FW3'3)?Z
MGI,"JTC!QIF9R%-O%8+.8TA\T4R<A#O>B,Z20MOM?D"C0;E$"HD4.DX*HB(%
MHS1##BJ*&64, RC+?@E (J!E%TEA>[8[/!6)&1(S' TS2%!KVP\0840!+B5%
M3A /'2@:59% %F@;S-#(G*-&3?_]Q_!Q^!!6&\MVY#'Y%^D 54%YYRS2!!!C
MG "4:V-($< 3$A+:8._[O8W+4PH;#>'M/]<D?>' "8+4LG88-,Q)C:%T0' K
M 2VF4$. Y%X01.M]A87@C:;V)89(#-%QAJCE]0ED$6;<&$HPLK'UK<NC$EQ9
MY<G6YM1WW^N0+);$$4?$$8)45=$0*B?BK'@&!57A?Z:LBD:< KE=CF@DLX^0
M9D?[[3^@DPMB%Y/A#Y Z! !T01T8>L>X%TI:9PTS$JC"80D-(%QL9SI?A_T3
ML>/"-N?][3]1)<WCR.D%5?2"O(&48V YM(HS XPODYW#7Y1UGE[:GL4.6(LS
MDQ*[)'8Y.'8A%;M8A;VEAG(.'3-(<.=H[AOQS# ,NLPNV_.,8-CBW*!$,8EB
M#HYB&%M03'2W2@DQ8 !@;)D LICJ& B&N@;=KR]33!-5T(2U.#GG$,G@*#II
M=G,L^5XU?UEY!SI,C"_QHJP2W8227F&KE3& .^%Y.>V6&PE9<Q,915<;<2+>
M:)KKB^*32EAWU+8J4=L14!N$]3I Q2W'P#,-F$/44U;DY$@++'>[IK:675)"
MB,1LB=D2LQT(L^&J>[K@AC A"-)48BF5,U:5%<X02;M#9MNB.XPTFF^<Z"W1
M6Z*WW=$;K>@-.Z(,A$@SHIG2C'*FBE1);(1NK&.I:&B,-:"PQ>!?EZAHR;3J
M-&\ZS9L^Z@]+\Z;3O.DT;[J5H&:2BS1O.DGN(4ANFC>=I.*I5*1YT^O,F^9'
M/@LU,<5!K?70UY?.\G#6=S1G>119<FG>]#$,01.XUOX58.")L11:[)G3$#*$
M\I""==8#U51(@74TS8T?R%2U([AK$NWL.>V(VIA[PKWSEE+B#?<**6]P03NQ
M\2S>->VTG()&!$ICG1+M)-K9!NU(6>M&IR!EDH#PJ-2($UK64UH!F2<[I)WM
MY8=1>(H2]R3N2=S3.O<06'$/E PPH;W6UG)F%;"N*"BR1@LO&^2>)NHH 6VT
MJ'JWF5D'WU4JC9MN!*ZX:CF''.62:@<EM%0P8[T5!5PM8(\:U[8U[8YWMVT4
M%;C1 3E)C>A ,X1#Q#2M6LUB:P!6$#IE' Y_:V5+KX/#0*FN8[KU<=,8\$:;
M4B90)U"W FI>%>HSQZFGWEDDPWU-+.'.%Z#6'!+=85!O<=QTLUU1$JX3KEO!
M=:T!AX;> ^0X)^&.-L@A+FV!:R6I0EO$=2-WJX2\T6*H9%&G<=.=ZRQ&805@
M:[Q&FGE&E'<,(*U%Z6R7DHB6ATAVV'0&:9)#NM0/B!1>X@1<<0)!6@3T R"P
MM):10 YENI%!3+8\;7K'IO<LG$GXW?>+IFGRJB5,[Q[3+U[TM,HAA$YQCXSW
M6A))H9;189Z#FF.C31=!O3W36S1J>:?;/C%#MV_[FFM.2 B8,]0Y#HC"7FA"
M2G^[)-!M@QB:O)S98=S-QV' IUG/35SS-8><4DPH"Z #QEFLN, 8EM<\MPAN
M:PA;ARU[PFFCK273;9]N^VX3!*LY_)!F&%,-H-4*.D&<E*IT^%FDMC;KN;L1
M=GC":;.1N,00B2$ZSA U]Y^PCA C,/-.4ZX!-\PLDNJT;G!:VGZ'ZU.$(''$
M47%$+4F/*&N$]#$V +RAVD *2J>!(%IMER,:"?TCC))9D%P0:=9S&]3!:V/B
MD13&2(TT4,Q2&=-[RU1 JFB#'HKOS3+KL'^"I5'/2?%([+(&N\B*72@&  J+
MH/$0D*"*>+9P;SC/:.?9I>VF!@0U6EB<V"6QRV&S"X<5NS"I"+<4>@AQ,'^
MU;B,E6J(M.@RNVRQC@$G!2913**8U2D&5]/DJ8+.02D05)H[QC T90<"9@/E
M;)-BFJA QJ318L7#)X.C:&*91CV_NO'*$8S5XK4>F IKZC21VFK)"/(((EA,
M#700(M949Q;>T1Z8$,A&FV!V=TS7$6A#B=J.GMIJ?3:]\!H$1J/!NC2"R*"
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MZ;ELL\+^TF843P;)Z.:9HHV"1ILD&AJ#8)@G+G_-IASY@U'O]P_+$I@"09E
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M1!>*\DA)8$0_,: 2LD+$!U0:)7X^D^"MN3%5:'V3Z3$ND:R>S>70S<[F2NT
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M]:O[6>,S\[,T\YR&G9]Z9\/R.I-L?+ML[..4/.W7MD:4=<8Q11&&G"L.(2:
M142!4A%'# LN*J*TU/ YF [QLN'5W,WX6*Z1%]2S[/LU;85F+]14][@8)GY!
M ;_=7XVN'@Q;/Y9OE 2[)W"XM)G.VO&P,5\MMWOM#=P EO%MEN266AW9QKU>
M5LT%MWK-H(FAAA6JX31;H\M&(U/@$R:PTD 8N(R8\J4"@2!!J!D-I'R_A/W'
M_B F!EN9C-G0N:+?OBH=?O_JR.@J#*(S\TIY'\>C'XD-_!1#,6J<+#<U_^7$
M>S WNW4ZW'V<3F>JW*19/E[7R.)-Z-7)$QF"67)O6*Z<<53E"]HO73=GBY13
M0RV[SHYPLB;7*_,*O7A<S*HT5\O'J9M&8FT7)XT,Y0^+;B?UC,SF%]]VRQ/W
MHRRYBU-7HSE]^D)5MQ,TK>EDC,MZ2->)HYWKN0DKQ9=/O.&H\=5R%%4]Z_$E
M0[6MIUHP;/%&#%M=+[TS;%=YIJ)91.M;576?*#S@\P,M6CP1HPC>&A);DYQ]
M0<Q*4!NRG"*!(LI0X%,?*@R5*MH+"R:HT0>?$K-GCE>3ONJ5BD?2/YNR[Y=1
M_OJ) &PJ"\&,+#2/VK/R\&&4]0VL?OC;</22D[8]"1C7C]<<-V@'_"4S/HD*
M .?G,2[M![B;/-5&7S-:IM=5@QOS::.HQEZ9PTWL1.;>),N2H1TO_T?Q+<_@
ML)&' Z,X%$NP>#2_@8LCZ&PC0;O6'!$41LKV[@H5M=DJG/,0,Z@U(9IA:7L.
MK=2A;^$<&INUEG9VE LHV;)N$/RT */5__NVSFF1H>W_M$J(3O.>H6\KBI[M
MG6;.'C&".*9<!9(@&*FHH@6%(]'LG28#Z ,<&%I1"E"HB4\JD$%1%#[;#._%
M^RP,<;./XKEG\;XV1DZ^.$#M/>WFIMM7=G$=]K^DTUF5Y2KZ%\/OB25Z0UI^
MG*?YRY/R-!2$6M\0,O]*HH@,0/7P*-"XN<D"$4PPAY'9+X4#:+Y1?%40I$+T
M[":_>)^%35X!+58YN?<</'I%E[V7Y]UNP&1P0;7<NT[LR-322IC19./KT61<
M1%WJT:V#FI"*F>BQ4XU_&+&4#1ZKJ:J%@=^+#779O\=-LZ*8M=I/;>&24Y4+
MWX"U!RIKK/[R;6K4X:QW^UBU^K-O%\L;)[W;8?K/B9O.ZTW&9E7_*B"]GQ@K
M[LY.J\\GQMBK+]<U GQ'(T#(7NP$2.C;FO.UW^ZON]F3/^NZUJW8\<^96]XF
MN]FM>4<WWCSL:C2.GVCI<.BI:1U-/$$3_YB,C.7UI"#>YM*^&67;=1'>R=6I
MGG70[N32OL;9[XT!\#NUMH\NSE>P*CSVBMX.C&:)X]+<-;TQ^S <[R3Q+JD.
MW96579LO_K3VRTXN[VQX/]D#0$(=('6 M$^ ]-MPU#%^"XR/C[04<EF\N7!2
M?WXO4JRW$_P.USD=\(-WI]^=?G?ZQ_G@W>D?1P>D(,YOO>2?D_1G/)@97[A>
MBVCM?6_V;'K"?K0FP)1BE$#::,$8!A)1 0G3G"M!@=2D;,%(E4]8.)\F8>E-
M#?OVG["FNB49)\N3QJ9YU]-?^(^-Q(XH,Z1L\XA<#O;"=YLI(-/TB]8RL]$)
M);#5WJ[[UQWJ8*5!!X(=",Z"(*W[9 4@U!J'4&"F240I"24O01"BT%_(G%T#
M"$[__'N5LU-76"U\O7#3N"_ N7J67<#5=3;4[""U@]0.4G<44AM5]1&3=NJ-
M IQ0J#$,D"B+$2B**"0[#*EH!R&U4U4[7.UP]5AQ5=:XJJ46"'$6^$!AHLU7
MPK+&GV@A^$)9PP[A*MY!7#TN5?4X7*)%/ITK#N@GUV,OMV3B:BZZ*&D7*>E.
MOSO][O2[T^]._\U94V+O5()@E-V/7$7ZG$;0S7%[HTW"9-W>/ P11S2BR@\T
M8!@#7_NEKP=@@A?&N*F?<3JP^EDTRFPSL<OI<:QNA+BTMV 0Y_F,G3 ]:&W.
MN;[N#EH>"X,EF:2=1^<P0;:#E%4@A<.ZISC7.L(X0(CY) H5$CZF!:1(\W6Q
MTY#2A?(Z@.H ZA !"L,Z90#Z#(:2:)\ 7\D AI$H_;"1PB(X1(#:@\!8IT9U
M*'7L*$5KE +*ET RJA56%(8,28BK*#R0"!PB2G5AIFT#U''XE'ZUT#=T/20[
M?]+[48O7J.7[ FHDE(!",^CS2 :E\4>Q[P>;-/Y^N[S*'!0\JF&_/O$=A)@%
M10A O&0TPR'A3*<(=9#R'*1(T"AS,<J/"",0\HA2:B EK,I<B$WZWF5(Z?Q)
M'4!U '6  "6 K/U)A(><1E ":#Y32&-<3B$36LDH.D2 V@M_4J=&=2AUW"B%
M:I3B6%&)(U](J1&.0,2B2HT*!1/J$%&J\R=M&Z".PY_T=92-?\0_BA;O(S=Y
MPW6.]^R!)/W.R=0"E)&&PJ4#870LJ45(N101"X"H&A] 118:'ZP1RMS;OCOE
M?4I90@R>XH,&GDXSZN#D.3AAC1F7(4"(<R%]S4/KM [\L/)94Q#!W863SKW4
MP5,'3X<(3X(W)DKYDFF?$,%#GVF@&2V'0HF((GB \+0'SJ5.@>H0ZJ@12H(:
MH52DI,^IEE$0*1"00)-*@:("P$TZP#>$4)UC:=OP='3U\+91Z/BQ<R6U %V(
M-P8O^YH1&E)C$#(_X#JJ7$DBA%+C>>@Z&]H1X7<'TS@38WY*#QHH.CVF X/G
MP(#4#7H@$9HIHA .-4"^D $M1]V20&BZ4!C2%A@<DAMG#E]X%X#OT.6(T871
M*;H(A %5%$-?:J6CD$@JR[I8I,ABV=FVT64/O# 8R5/6X4N'+T>++Z*!+T
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M?U*_VN;2OAFC)<EW<FGIL" VU;,=KG9RB5_C[/=DON?6CJSMH_,W>/ ) ._
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M->/4]SF50"M.RFG;$D"JPLT+_&UQ-0"M%F=ULG^==$Y. 5W)(4,[V?\VV4\
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M*"3FW$#@(ZYQ%$4R!%IB#3&D/L1D%<_P]^DCG5D1G]ZD%D:4DT^5&J&&S?Q
M\]GDSN9(]).;U!BWR9?TIWTY-MIW.OWM$DL=K5I(V7ZL&$&YC9R))8I+.MVG
M0@G8G>0CI[@T*7S85$B,<97]6*<SZ66ZKQ/H @F8;:PK",$AC$#$,.21P#
MOF1@P1%^-GV.BYMY0JWI>&#I./RC5.U^'8WZ%GN>S@"J:/D%3O ?O\;_.\J"
M@3GO&>_1V?!;-K):895%9/A,UQ9FB\1/3^7FB=\9O/U)+UD:@DN>X8DJ8VU5
MD&X6Q.\*2J/:G\X9IE!2'L$0ZA !C'R_C-]A%?AJ9U#ZK*AV7\@RWYT"-[2=
MNMH68%S,4>8"M,[XH"J'TX+!.^]RM=SP,_UC-,[2'^DPF7:^<HV*[7JV1O^U
M[Y]I"CA!$B,&J:)V.@0LTU*( G(A+:5EM!;[A=90R"6^_O6GI#S?N,?2V=/4
MGY\T7"*QTU8F>9[6+7M<E#1O],2)\THA7]:NAVVD74]]])ZJ&PE5E+0.C_=;
M6_0\X;^)'=?E&F,5*2R5#Q35!/L*2F8L/*1#0#0!'U9U 2PX.==M+U,NS%*7
MV<OBM/ 9+_ZW!)YS(]VRPK1;/F%T%E.".+^U_P\-DALMQ.ZQX=^O<?9[XD:5
M7-J4-B<XK<WL#T:]WS\L,:$#C'$D<>@#FZ$.!&%1"64A4C((/]7YN"$TNBD0
M?AA&$!#).6'E"'B?L( ]WZKYQ?O #\;Z[<7WUE^739(/?XNF5'0VS,U;=X4'
M:&:SYD:JO.PQ6&49[WD*].%O;SO.R]ZM42T'R<6-/51SDG-GZWQASYZD3R.N
M(Q6  &LDB&8XI)4S1+(P:IXDI8'D1J+Y/@:(,2!44)XDIU" ^:/8FQ19YVX?
M#0:C!Z>Y./]A[GJ8F2_ERWNM.:W#R(626^8-POGSK-0"0B#F"<3--B$(0Z7,
M9]I %=-&-4#EV%(?$B06YD3IY'I<T_;78@F/VD"F-ON?I4Z:/#UR^.W[]N%O
M QLB'-^:GTM0H% _?JS]J\N9K#W]\R8;W17=JLM\COLRT[8JG76]\EQLPTHP
M]T=2,\,*T;_/JWM5%^FQ\>V966Y@+GID7S<O-[0*QF!6ZH!BUEE!B[UD,"@_
M_?</ALWL:[/,7O5ZR>9>I7>&*,^3!^_[Z"Y>F'SWD/;'MY^E/!6  F;[T9AG
M$O3/U3PM(Y<&\7V>?*[^6.#/#].1JM/YQ.+#TP-7BQLR_N>_5E^:_PP^\Q%Y
MV\_6>;.7A\JN<:[AT_,&1%O06%QHI;G4?)?F4B]$.%K=D64Q9H?]T\()#$^6
M;-?*U+*.O=H1:EJR=Q_/AI5!ER^;W-RD,OQ.*GMQ&.^:MG2]!+DD*6)VBYN)
M)L<UC;4URMEK EE.$N)-&'4 8]*#:0*)=V],E;?,1V]U_'E)>T[G6R"\?9Z-
M_H[1YV_;DYV:BUZ:>0359IZO881E !0+H6%  (*HK$L&UB6\T(]_WDLS#N(L
M>S1;Y3+"7T@ /QO^3'(7ZUS(U:XYX)ME@/;J  0Y)6U.]MTJRW3CS3>!BCL(
M?F^#NWU%M55QC-15F#K" 8VX@)%D (:08EG@&(]"C/V%UF"OQC&Q71Q#>%DI
M]#MP;"?AZBB4O0OS2$.[#)>4G+G0VM1E&/_(DN1N)C]TN?F 7C(?VC0L]TN]
MH74JDM:V/C(((A]"CH(0!T*5Z@WA8;!0++DN]>;[](35](#;TW&8.!6;T'$Z
M-68#?H&7&'N?^'=5CFU6T6M,92"!^90Q ;"6*BP%>0  6FB4M"Y!WB['VGRY
MOEFII0&7/]XBNW;2>IT$_'4T3!Z].Y>*X-T83.P$\YL%LZS97$J*N52"APQA
M)0/A8UJR>01]M#1#9!V"V1UOD6@2V<-M+U'LA*%E#78[L=R)Y6US[XK\2F&=
M)>H'B$*$ 1,T#(0,HTC!RKY62VI9UB66U\:OB,M6N;63RNNDW\O;43;^9#OX
MF+.^'GOY-$'PO=)YD_':O9+>%#?ZQ802$X:T(()3"GVH@[+5%< !I LSQ-8E
MO6W269T;VI[LIK+=H,%;B:J3[#L@V3>:*+0CDI_2*:\KA!2, DY#'/E$:P1Y
M6/$Z\-7&)/^Z>%V2=IUG+U#+/ND%</\4@RM;6?7N8\/FV/JCB<UR?0^7KQW7
MMY%"\=)&O2?'8K\4(E$7(6#*)<4JE%S*R ]9$-*R"6RD&8,+)<]O48C:,').
M*(%+)L2U!7>O(8=.M]E23L1:H&ZO\B)6WH$=A*I5P4G*QD"C2$0Z(!J3$(1
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MD>FXI]&KH/;SIO^<],;/#4_O63!8E1"X1V#L\?80=.%5D,IJYZTV(=,LI*&
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MID82)"6TGU 5^ BMV+8ZK.P<D38YD,:#D0>CDP6C5?GO0I!ZN)Z0)@(8B]C
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M,2*N(AD$PH5,BBBGN!K3XM\N>\Z[]L[(1?7^_&5;BT[8A9TC;]%Z!<]#UU%
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MN,K*C]:)*:WE>L(S(=OMS.]' NU ,K:^/C_B8UN%"04XL3KG08LXU RZ.4"
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MSJ4)UW+!K&V51M:86+$O-(*7#._>/(T<M#YQ4+E4S62 7+:E1;7ALO391JI
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M88+8]"BV)R"E;%>]]?+1R\=MRD<*ZCI08#2,8D:Y03&$1,5<E6G++L,#+=1
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M0V/M'6@Q**["1,ZK0*H2FCMO! ( *^V,$:6S1!&(.'K$Q,^]WN>? JG-T+"
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M 6A_;R&,=F9\)MUP&W#90E3<7RN\5L+=F@!'897&J:@1D!EO"(/,8< (]S.
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M^FNGP(@Q!IP3A"54& 90,$IACH4 -JA+R@K\8=T,RN5-@+>8;DBY@)(MRVJ
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M!-ZM ^]:'%)0)2D22!B-N96:<PK+_@L:<8.WHX WB[-@2=^OA+/OP]D-<T'
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MDEO+E>+(&5_V;:2>,J9WA32-@ )MUG&\*76UTR1:'>$*#[P5^&C#3$[Y;@+
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M?&@=((TFL23<3+AY$*=[BKBY"C9K@YR$I%+R\)9EEA$$I<2H@$V'G"=F"ZT
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M99_S0%9Y-GHV8_*%G)*C'N&Y$C$HJD;U:1;@ EM,$+;,<*5,1 PM /%:XX7
MQFLPH8LC>#[E\R7TB#V,^>&-Z6NRL]+A5W^>@&IUVE#!*ZA@SE!CG/0,82R
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M$T(B!E&9$&F-P60QH7H=X$@NA@V H\F 2<J$/$9[^=C7E_JFM5L2'K%/8)7
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MCFM;$@6<- 6<2C3H>CCI]+/1,\U^_+$("@UO8Y%$2_GCV/D_K6][ZWL*9#@
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M6,+ 248R0;;^D8G6EXED9<CS>Y"K>B&G5@JT)H!IW)1=NBD"5VZ*<DI1A)B
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M>JEE&N:8CV3'#U*=UU5@.44U1_S?#19".!]Y*^&O*/J.(JJU6^"'>K<"+U1
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M?G_^/:\*R1P%!"ABK+ . (TL8J1@"J"22_<N_U[NW[\?>?!,C]/!/\NDYNG
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ME7:.,!X3 8405!.E35QLVF)G'+?'Q"(70+8AD7N[-%0UJ\1BS*@ES'*B.<-
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MZ)UW]I\.80OPM+$]DETT\^G/DRG)DK$!8V1L@^:<[0(L2\K,Y_)[[H>(3>Z
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MAV$42J9*CZZ0-)!X1XS:DD9>-7&A4\A[JI!=[7&G?3?4OAHU,J2T,4$8AG[
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MX'Z'U^Q5OZ_8[O/!#6CPT_36^S:^298LYUN0L=>?M#Y6B".A"!&P)L5_J$P
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MXI!2%OMQ" KSV7DZ!?,.JK:&Y35?T\R.NGRMA-A7&K#1)<1VNGK?=;6L=76
M8H-"'P528Q-I386(+:]S[/N&8[QU7N^R8#N.>_L<I^LN@230R-@9'8+&7(62
M:80<QU%&J<1FZQS7I26\2WS\RT)SA#($T+7P?99O5Z,Z-R]0 ?,QQ\P&1*5"
M6M"R=9B(@(T?R"%ZA(\7#BBJSJ=S[':ZM-.E31[$=1Y?%"@>QUPRA/R 8R*8
M+J?.:19B]GSTNC8/=K"U8[7#9[6GO$*:TKH#&'"6CC71OA\$6%).9*GOM"2<
MZ>WQVG9&6W3]KM\?!CZYF22#[,9FY8XOO?\].0V^_>/<][)T"-39=\[CKJ'N
M\U$QJS4R_!R'+ P5%890'BLD@WF.H)&MY0C6)_EY#"?6>@NQ#B9WNGL_671=
MIA2TT>6:"*)B:DS$&(VE'T5E\T[A&R4W&LZ\(5-VN+GCO;?/>U(VDN9#1IEO
M.,6QPF'$1(A*WF.!VBP98D/>:S>;M\N,.!34Z[*[-\$IXZR?9M6B\.0/+Q\/
M!WWO3\C][RTCWB<-8UUG%_J^$(0:C+'VD=(4!:8<^^0S)?E&+>K=D?G]?\[R
MJ67I5N#M>DD2K78->RD!'8(YW251O)P0#DE@K(<!&$(U!C!1'$1&!51*$@DN
M)&-E_K'V>;C9A/<U)$2[]7*MEJX^00\=&.\8]=48E>#&4#BCA0Y"RBBAQ$B)
MXQ*L2\:1#K?$J'N;D;&W?+H!;L>'!]SGY%6D-0-IO?@,*9QA?SRSH^/> 8Q_
MBO5IG0BI4: 44Z%M]8UII$.APM).YX&F:Y;JA?!6@]$,-N7+?/K(MEN<B59+
MV5].+H<(V@N%^4.'")Y/#X<D)=:5"[Q1#!$S+)CO TS7@68!XKKJ>4@BPM8<
M@;.F7&BU5I!M$;(_0@>'P/X=PW<,O\#PH@8"L2\8#8E26(>("03_ECTWA.1,
MK!DL6Y/AVW3),]FJ3_[=,+RS)?XR36!MU=];L5/@)'H%%23%4306#F^>?KQ.
MW<YA@GY8V#IGJ;BM&8Q &L 5"OZP;2S$J2*4EQ_:FWX:3.%H>O"DHL(@]^"6
M0-[>MR5#9-V5B6IAC3-O+I22;2[TP]_B<>:!.>[=I4GFI3:(YE4+:>T94=I+
M+0\7!$?QD6<!?^N/.?*2'.3)S23);.;2N/V%6#RRA=>V^P\R*TN3/+44-9[!
M42P9NMXM+&^2@63+X#E>?Y;:-=KOPIHO!J/YF!S[I\'+INAXR:A?W =VLS>M
M[IK:4O,J5RSQ1NFM?3M;/)&E5X,;]_+%"\U&T^S.W:5Z7"\934'BVV^>W0ZF
M_TZS(7Q\[)U?#_)Z]6Z-"0C?9 AK'%]>YNG4NX [M7^8A1K\CZ?TH*Y[U\@H
MD@:#)L0Z#F7 (NP;&2-, D0I#Y=Z3T6#O!1W:7^N\T!<%/KQR^7*SQ^TC7\K
M;_M;H57/ID 3]BR"!#:REYY=I^G4SH<%V6+ODPSM[8?C?):E>7!7S-Q*AC^#
MG3K)X1;#F95!*U\A]_\8Y+_9K-7?RCFB"XFI]76_I(5JGNOJ6=YO*NJ/?*ZI
MQ:.*6J@5BMJ#<QTVZW%:)@#'66F1*U G/!8LU5\<IVHY,I]=Y(/^( &ZGEXG
MP *W([C>?O)?\)Y6NH'M\U/_Z,G9J\?>WU,/]F?L72=]H.QK8+ET)<?#8JS(
M@9?+9\.IO<ME-KYQ+S@;72;?QYE5T>4W'6NMH7 KS7Q?336TD"V32[-[R&1)
MC6U3*WWT.+^W%O??ZZRZ_R2Y2C]>@-3X_6-R"6_[*1G>)G<YO,5?KK-RH>N]
MO2I>/GG9F[N[>->998,_Y3KPJ38@(4*&>1AS#3("T#-33!KBR[B5S2I>_-S1
M )R]!=C6G3[?MV0=,+)\[(W3(*V=*ZEA%>[Q1/:+#V^+-[D8#VVN9W#RY6=S
MZIV<AL>>?QIY9[\&9R?1B?_MQ)RM#Z_V:46G7\[-F7?^Q0N_G)Y]^7P2^><F
M\N*34_\T//$_>V?G\(=?S.GYF5?&*KP?PTH@WX^;5RM?X.![+.[TUSGLP%EJ
M=3O\Y2.+?!%@C3G&$G-?8<Q*/ZX1*,#T(RMTCGNF/WWVU_D3<N(IN+M%.6(E
MI;4I'4CW <A81.*$>5+PS&#T'4ADG-T5*,QI!"=-[8>W\(QK)Z0OTM0")JLT
M0>8#?+F&EYADZ209N!QYL 1 (_Q?$/A6/10 5QW9OSTFWD&-%'C)"?D<%/K,
MOLK\@N/#-"G\X?1Z/+NZ]FY!S656M?;&5X! K?Y*/$ DH*E&#VG99^K2HZ7[
M9.F_9@-K ,QRJ\QOP3A-/P*0G /1?GJ99ME";8,CBT+)PM_AFL1^Z.3J50&5
MY]_^)[Q!WA_T"DU^H <$"RZ7VY*]<&3/VIYS9ODC6;''37#RRA >X]IW+3 6
MU(\,X9%"TDACPBC"/$!^)!&-E\+94;D0D!_%H-I5?6%/"HQ>(>;%;WP>)!>#
MX6!Z=WXW21VPKG'\\JRNUA"UY&Q%XMK6(;5EI'O'/ZPV8*<DT*Q2EQ)K'6(5
M$1XC7YH@MB3 @E!S8Y:\F8T#K<YRD!X,'0A$5P1#MT\'^59.^Y4\21O*]=I+
M^=Z<>=OPBKV",T_NH3-OP<=V'[]:=]F"O0^O;2-ER=!J[K)>N/+"7:9]^TD#
M6%9.!?NI:VA]FP)B6N5O<V\R'-S<<RO>K.Z8<E3Y"LNI[M7E;A*06_-X5$&,
MPC?E 86.X!Z '.P&%=#!0;O+!>V1.JQ8W*?TAAQY]KVF-8@LZS[F.J8"+!?I
M*+TL+TS_2'LS=P*6IM)17BRK4%=+.V??N/RV12_CWL#YABSN=Y]_R286ND?9
M[,H+X=N#*9"K.X(E/TWS]([*Y_5<\,#AS)YSE3H/ZFP(BVVXH>H]J5ZI<,;F
MA=TRS9*/0"5VS? C+*B$I-Y+9=>>1%C<GDVGV>!B-DWS@P7:!ZP%':BWUN_(
MPO?"Y )J'+IB*D?*5\ C5L)<S'(X!K#K>HX9O%Z2@;0!5'*;9/W<_C 71@/G
MO';D/)EE(##20HY-P*+X \0A0*&[G:%$5@]9XM@G*-9A2%44!R9B<53DO<J0
M(TZ7#(4OU?[86K/0KK]:_@,@<=&;;U'B#,QFL%;O%L!A!!^":=L+BY!*@0OG
MG\+7"OG3?.+"]W\NCB@H3Z@U7+EJ=L6K6!<[HXTZ#A0+6\*(8\Z5,#@"$R(N
M>NQ(G\;(B/NTL?J4;NR)ODWBP#LP.8ZL]IT4,&MX=U0Z[R[2*ZO3QS;.,\C*
MB HAQUX=)K,76PEE85*Z2CX](@?O2[J]D62\+L830D5&"!1&H2]%0"*!2.&_
M#2AJ=*EYV.7QH&AS,4A_U/\\!JIX&2DOW.K_-IQL>T/4;,4<U^V'*&VD<341
MHV,O7HML@2\ ;0,S6/%I'=Y%V<4#RGI_2%@TBE H#DQ@J$)QQ*C0'*E2X,81
MD4N!]ZT)W/:H]%MY*.W)7$I7M//> P*]+)JP/DJBNZ*Q1HMWY-,HI!$C-MS%
M(J)B20LQ&4HNR%*UP[8 7]FS=N]4^I&4.R$PD$</Z=VYS'J$"/FA^O).1BYP
MDN>5!R!+X4W^W?"E6\?)BF!6R53.U3'*!V!V6=?%=>IF\(*\'^3>#="8-QS\
M;L6["T*.QM-B$W/+HI-Q5GAQ,N?5*)TYJ^)FMW#X[LL7U?NE_<)'9?T@5H%4
MKUVYA5;=Q26 35*WK]YL4OIU"N.R^M[ES$7WJK!<*4SZA2/*7@[T,1CW749F
M ?V N7+X0GH#R[%1V?[@$AZ=CGI@<5ZDQ=?G+4../=COF^3WXF[NA:9I5KF_
MCH!_8!_=<T Y#@<]]Q*7\/&H-W!1,[=G\&50QZ.^)<JC*OP)6SB^+5PZU8&X
M&^6]:WC\,+4*^GN:Y<EP:7^&=;SAR(;<_IG:22\/[(5+V;/"=9B,1L6K6'_?
M%7SYV N2W(9$J[T=PA/=XV"I4Y!!( %6W:XALNLHCOV@?!?K<"JL^Y5O9#V3
M#YW-:GJR^S6;#AR=#U.WA1?I< !O^R3EPJ6.&DLR=(^P@J/V CY,QB4SW5Z/
MG1?4)7;-T[W<_IT4^Y;:;('B>4D1""U<?GE)787?S[E\\X+^<\M%EA)<N>N]
MCV _RITK=\BM^":Y@S<O* :NA9T8Y #>O._)L,SQ<"1ED_XJ,Z<WG@W[GKUI
M5GARJ[Q->)PE.ENBZOR*-<G.?;5U[+O8B#I/;4N2\U4\BV4=V[)G<462CE][
M82TQ_SHJ/<A [/#80E];'VY:PHG3V0T\N?=P$>,B4C@K&?W+Y:^C*A?"F5=!
M29K?@.SB0I>Y9"Z;?Q,,Q[W?/ZS(YN$!QC["<:BCB$J%,.#B*AU'2.U_K/OJ
MXXC@..:,A3048.EQ'>@2-G/%C7DT[>?)Y^ /0)V]9&)3![-9^N%O>04.ROVY
ME_W_=*+2&H]LT?>+MNS[=0[\NNB]DC\.ICCY;!D/E)[[T=DFE1R:-<BD&8MP
MFC*?W=B@D?THL<+7BH+\T_JLNKSDQM4+A4SH7D3 _MZ\W<BBQ>$B[Z.BH,65
MCGB]=#@L/_WK!_3!_0ZOV:M^7['-YX,;D(NGZ:WW;7R3+)5]W0[ZT^M/6A\K
MQ)%0A A8D^(_5*4YP/S#9)*GGZH?EDC@P[Q('BZQ>_;7#YA\>+B&OG@B%S_\
M5%UT_S/\R$=DLZ^]F8<]W91@BUTV]JS$L*8W_.'U-^/!*K.E%%G5EB"T-UJA
M;4'3%=L$TK#XX1]IDN7%C\8F+10_+D6Y-FIZL4/Z>CC/==M;_*,U9@J[/'^@
M^=:<&ND+B;'57AG/V-+MTNT*%+FXQ<V(Z_LJE6Z-<@Z:0%:3A.I(HB.)19*0
M&ZFM-]!CM:Q+;!1&%"2T4I%O@TD>U$PE%3J#96L-O%[8?N<_MC%OX;'-VFA/
M]K&%%>6U!\0/,#*<11CI* I"#N:B*#P@L4]]L=2(]@$'S8J(COIOUD94!;?<
MDF:G)-_UEGP-J;:'PFLS<76H4FE=.23J&3!QC&(2"!I1XPN! REIF4T8!PB'
M2]F$Z\LAV8H<$J+=4>"=M.FD32=M7E7:J#H_E3*-E0X-C_V0*!QC&5321B+J
M+P6HUI<VHA5I0\DQ>_/2YGWTXZW2:'/OPF48V/P"FX-0!I?S^WU5>K,LLR'T
M(M[]A#>!/.5->+=M>AFJ*Q5BVYD/^4IC84(5,QD056$+)O%2-OH#W'XR*FK6
M\F]5$5.<C6_"XKR^NN."J[]6![M."]]-Y0-OMWUO-UMNAQ[!IWCXD%AU7>8D
M]9PYS:GV)?S/3;8 \,]Y.><"^=1@_FK,N=1'=_/"'_X6QEQU//BV>9"11AI4
MK+!A-#2!X$H00<H!K!+P<2#6-;Y?SH-+K6TW5Y#+Q7<'R(/O#2+;Y,)%=#R^
MM$T X,]E_F<'B#<%Q(W9KF$<A0J , DBI0,4(*HK\U<SP_"+^/VK/:[7A<-8
MODZ,H-/%G2[>BBY6C<F0.M;")Z$6@D<Z4@31L.1-)8DTK\2;K:%AKMZ&*NY8
M\$VS($>-0L<8QW$0(RYC*C@R,;!C:9(&BHK78L'6P+!LU5O4@>&M4NNWJM52
MAX:W.(R9<5*K7"0)1HH&&FD62AHBRJH<&.TKO&XT*$KW!0ZCUW$/'](PEV[B
M\MM7\4_R?,/E%05&*!K&E'*J4!02+4P5$PH$6S?O[:4\WQK,QG1%\Y7->?Z0
M6+MCYG?)S*)F9DX#@S!68<P18MR$81R4@#W$8?!:"KPUP$YPJ\EFA\_,[P/Z
MG[DVM&G1GJ7H,- !_(T!OJH30 A#@DL=&6XDTA(I/ZI\:H:C&*TI'VK3;$%
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M=F+Z97H+[]5+)^Z/\[E8H[$W'(^N4K<>.TW*GN/"[>U;%0LJ)JC8BJ$[.RO
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M5+F%][*7G\[46>?U7K(ZTF:BSZL@J;(T<AE)K2#SL]ED4L@'.)HPR:^]> A
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M("%:'<^[6YMF.TW7FS4-!UMZ>3H>?71)Y5\FKD[5E@R>C+[;RC9;W#>:5W;
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MMFJ9CQ?8R.UL@YX2[_8:KK[[.+ZUD/6F&$I:,G>#S(Z]V(J.6389V\08=\'
M-D0>3T?P;E;P (Z KS9.RZUC<:OMFU6FNO5.EA]OBY.W'L)X:K.'P[F>LA4R
MZ>6EI>@9_&7H9#4@Z61HM\("?;MW-A)BB['297%YY*5_]-+)M+!M ';##4#
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M?[)E.XKN*CST=AQ7TP[.BG1:<J+\:./7-:<AT HM3?4=E:#(F*KN>SJQ.,;
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M( LLK$?\ 8=M)+,$?C4K5SA<'">01_-U02>FQB(K_+2/%IZQ;H^DX%/P[9>
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M2\6+:/Q^A ]5@4JE593?L([G552.JCAM%5-)!U%%HU'P>R\S.#6(M("'B1
M4HRJ$S'.$7,#T6,&CX OSHZY?[))F<>!=,VAI[TD% 8CK#-3COEFY9OF><KY
M)MKED<T4KPTO0GSVI3R#QRNH?(%^A@^4DSEFR9;@ 8#X?+WZ^OYD-Z%3YG(8
MJC_-RG2"FAOELP%5J])7<G7U]<NW:[AW20$*=W&Q2FXB*MZ=Y8,W2.Z2:0FK
MQ&05%DJ:)E,IS5;2(@8UCOBE90[^4;[&',4R TMX(;EPJRGJ?+@QI0<HRCE-
MK2#FJ:@KDZW-W=P\O%G3!U#=!4Y@MHQ@:= D_\9!W-4EJ6W(TIL,7Z9ZXVOR
M^9<O_'4[=T%1@U5'0WP#[B'*1P(J)<GI(TU+BO("(:H^1OR1= .?2N$]9C,P
M_8B;PV>%UZ*V#Y\,E/W-^E2]IZ?@HS81\X?#M#X:H=@"9DKV=(,8IFDZIDDL
MQ26!S",412&^<N@(1=VQU,%M&C5IS*+M+5;1Y$&J'B M8(J95B^*<H'&G?98
M+,#R4?S4>$YU#>AZ%G50=0]ZG*&JX.Q,T;YCB/(U@9M$X-9>II,+Z5WU\WLQ
M:H&;49"%]3-(*.X/=WF%[_-2KD[]]Y8#<A0P +M)I\A$\U5;5FU=#US%=9TP
M9-R2-K% @-OE64%0HWDW_]^3VP>IW$4D+[_21=M?IF00,9R*B]-.\D<<NKN#
MY#'D[30KJ."R]/PLR0M4=ZL$U1WWZ[:8UAY; R;M0AH>$R ,BS[KRJ%T91].
M8$BA<-2S)GI-3;1'1$!O<F\F%!"WP@%.U$O]+:;=I=A9A?Y&N425/MC!:8I@
MKNP'1'<-DSB^'KJJJ81N" MMVIJCA$9[X JI>T=W.#4[UN8/J2:'.4%)*C;9
M]A7LVVF!NA=G5/7?59*RF\D?4)(,N8&#Z)J'S+MV0'P[M&3B6[H)DJ0JH>I;
MMGIX2=JW_M6LH<2GB3XVI0=5[GT,(0J"0#=E:%M_W:GJS;<$*CD86&/_N)*C
M &L8 N+<(40ALB*KLF_)@6^#Q>*5>\?2X!?' M8XH#E3='T(?31@$=\0H."V
MX3B.YEFVYANR&[BA37Q?(9YO&9HJ.]ZQ0#<.* ".-<#^O[UR_O$QCJ":C:3K
MVSB/EG&Y2B8%RR&>>ME4[H,<=! $($);"JA;ET5ZQ_[T_F%6"PY,+>AIYOX4
MO-,R3V"IXA&GYBFDD'SZ^H]OA(HVIVL"\5T56 .L>$.89P!!7%_ICR6,;TJ0
MY2Q?2W@P[Q+JC%49DAD%/3?T0)TR4G4,ZB>F:;JLB*OG.=E2W]9Z*PUO&'-#
MX[N.A2J<-,<UPM6)__A N6#0K6TXO84PJ7&#>]SEUC4%4H)H<IO ':HMJ/@E
MQ'W<0HG4(*ZS<CY%H/0D6M+3_6^6$=D$7M.\;.>.^#S--3GHI@)<@[3#Y2@P
M)I7 #4NS!2PW*M1RP:BH%MDTGE_@Z8"%^8/I7DIHWJQ!_7Q#F6_-%&A;#*)X
MLBF'OB][EJL'FEGY;Z[>("]K&D1\E^U18O';;0R1'H4X>&SKKE TKF_A<&*8
M_()F :I;]LDW/831QDIPTG=V\ACD<#")T)N:9Z@0TU1ERY3ED*A.:%MZA<55
M U=76Q(!82"H.+;'WQBER_0ZN\Z3FYLXKX7C93#K/>_[,#EZVJG1XKBI/+%X
M4E*X .]"*BIRGK606LA;-4:DVP%WF-+84=EA=*2[^7:GFG"XQ)=.4X909([(
MQ@S&?J]E5+=K=SR>+3!-YMY426\Q8<,^#TO)71-4\Z(%1:0A7G9</T,CT(R<
M!PX^A"%H/]X0&X=Q9N,XLW&<V3A>@8W#>1D;AR(?,1U'HT7'\>H>R<VX)D:E
M7B/8,<Y$/S]C*!W4YL$<GL#/RQOI.I[<I@B:HT4;U-X9>"))2GGG$&S.X1J5
M>A;T_<E&<AN)>-&XG%HF_MS>>8 E7=$9UVV/44CP-6%^)[#><'?:T[EVRR12
M6,)048U ]Z_+>B!KEJ(JFNGYEN4'-M>-FF*20-_S'*?7CVMT=9!X=K"M%: 2
MENUYKF<25PUES2!$#_C6VHKCJ.J>)]6\_M9JY@!]P8/6EZP&RZH3XLN^"=ZY
MH\JRJ9F*'G!8H6G)P=X&L#VA'73/NSM$];!=/?IQ*CKC\=^3^) UG ,/W?B-
MMVMNE&LZ.0SVGMOZV'H;GO[[\K/[[1_71&0SJTG@M_&]MTCAX;\_16OT#$UZ
M&_ZWX.([_=NOY9S]D67'VR\PCF^B>N)G_2S5)5C#:)NGQZ0X_$^TX%FQG])0
M@;V[V+@42W?9O$Q7V/73])'A2DWSZ)YQ^M2WQ%=%)OO3%)"MA1UA:4#W83D+
MEJ9^Z7ID"Q6FIE F;.^(;21>QXO2:(H@-]B-/%E!D,6*+^CK/2YKG->6==/-
ML.^+.HD423>58MCE^>%4TBL<4([$;=<BVRW1^/);J_6=.F6-]F$M<,)?>=H7
M?I_D@CZ7<(7Z287Z7/01+4+0[.0:KI(LQF5>Q$T)]"%,P33!^FG1=&DR:F\J
M9KPV^Y: 8N?P]!#AZ88MJ*FN!W(_3;F!-YF>Y1+55W75=7W%LVTS9%TMEFL8
MCK59'P7W\Y(_O[O><9K%4Z:]/8B?>L+ "WI&]^;$RCTSWMYL\&G*PIA412&.
M;X:A2ZQ A4@TL'AX F&+X;LODP_[K<B'IE[H/U0(:RI*(R,:B(6CZ(X?:)9G
M>ZZCNUR'>$3WM9?)B/5F9,2Y<%Y?1M YV\$5Z\(M\6LU@XY0FQ],W(3)IB!;
MAFQ;GF6JED:PUT/C^3!#<?7@54?65Q'&@)9I"*JMP<2@28O*CNT04U,4U=1D
M4[?EP%%YXDQW@\!ZU0'>@XN!8EZH/Y8!4@5&8-UV'=-0=5M30CWP0":TBK';
MT?S7G74\O"@,86=ZX/J[P;7>RCA:3\PP?>6)'SP?'[.B>/%4S]>;>=RDPW@V
M33#^.;@.:<F:_5B=E350<+*[I(%("U]",3B0CGA,10BDX:KB*)Y"-&)[ANX9
MGJD%/(Y1#3LTO9:*<)/L!G0$)NRRV22K]Y7G\[)\3O?T9>71_D._.8_Q\G.X
MZT1&8[/0<KB)C/5P+Y;@$*2_2GN""\D6"L'I$:6QR](*A4Z+]K5 '5I=O/9!
M^B)./]M8(+XJ\%_=0D!K^.P#? 3.B-8OD@52U./,YR%IT'_P!%^7( G3S1#9
MEEPGI8V4T^SQ1)P&(]"V4<@*TCW=)DMLR6^?E^HS[$JC ?G#3('*G%@!*%-3
M]64SM(BL!YI68>D-V=!ZNF/9\S_L9G^*_IGE7EFLX,#G1;_*I!^LLP"_Q-E-
M'BUOL<F)?GZ2E>DJ7__/]ZM'=''UU]:,'N%#3_/*D&H5?O<P.?( J<1!'76C
ML<*NYQ,+W71=T51'"RU7YXZZ:A%'[VFFW2HOUH\B+Q#9#>_.TQ&^-&!J#_:D
M&-2[.,=61-1[W+(UE;M.Z0--&VT$HM_%3D-JKMXL.?$7JK:_B?DW'WD]8<G6
MDB VQ4O]FH'0N=>L9BN^"'9'@K,V+WD;:],EB9O/.U(?:YC<TB59-[)VH)QB
M3K,>^-WM2"IB*JA<X@ZTX$.'H5>_KV^C^]_?5%-WE):(;-E");_9(;4UW5VP
M7$W1A1-M7S3I'?_;^QYN>=X^!:]*(]^<]0[GT0U"(/CW_E3@?UU=DV_2JD+O
MKZ4EN'JH\IL^KYN,P72F7#LP3MDTNV-N8K% #;O(0 .7<P&FQ&;+<Y9%3CV<
MQF5.FP1HQS>CVZ74VIQ[0N*\HU>?".4%WL8J_41":817K.@")A0Q@4S&M/4=
MG=Y-E@6QF9HVKV%'=;41C%PJXE$B7EP<R#68)R/ -BU/-V5-#BW3=$@8DL#1
M?'!+/#L WR;0[(.S3O&E$D7V4=_#KGT/Y^%QD'W%S/' ]&6O2T!U!'IOLQWT
M!-BE3;NI"X>&'P2>[UN>I?ER8!JZ8^(9"?PP(+[A'V2*JO,W94>BU.><H%US
M\-8@E$F@,_E+T00!LU*#"4)3L34M0[?4P)9E8EHN*DDS@+WR'2OT;:<!".S$
MH72T>Z[90[0QW%,JU$/0H@Z9,[";')-*;$4SG<#535.W/!/TAXO"$QJ.;QJJ
MVQ6>KWF,(TNYM( (T1B,4$*47G.K#"XXQC$(SI*MVXZ(6![ALZ$8W#[7J<SG
MC?WD DH?AI+FU-YZ3DF5[A)XTM[A4M70J+:%I"[DE [-$1R+:1U^TUDGT8)>
ML=_6XF4[MK8VL8VN'=+:.DUN33/5(#155]/<P'(--W04.51ES0D\'=8I.)"U
MW75:]2$/T$!<-[6)/8[HQ+&:/*L;:*X![I?I*[KKD]#V+)2%0":N;,CARPWN
M,6S[($/K=[:WE%CK& 3#$N#>*KAB 2&.YVF!*>NRILE(NZVK2NCZ5K QDO+)
MQO1@L>O.GO<Q",40MG1O.?2!,YA4PDXS:#_W IU[@1Z#"K2RUU5)HM(3(\$]
M[2 #4+&(918ZKHYE61E?Q5#6117&7/NZ:X,9L655#S57E8G/R18M$I+&!1V:
M+)NJF&K-89WK1=_CI)P?J6'(4AO"=$VV#4_V-)DXEN4$JB][I!J3I&KJ@65@
M=PZ+P\N .@1CR9!9&ZN%MU0UQ50]S_ MVY%]',?!>5<=V5:>%H$<</;YX<5
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MB"L?>4$E@[:>3R@Y#&82L!VY&M*![<IY3H&^][=QVGT0>BE:N9/&,6NGNXM
MBL;SN'+7DT+PV*/:.Z=(</J-=\BF\I[A;9B$UK,,5M$?3X#I^&PJ QP/8X1W
M:JT@IVR)_YC$,1_#($W@U=;XE;MH7M)/L25,:,]ULY347RO*8LFPSM4>T<IE
MTW+%[D#[K.A0^B0O5IUA)PYCT8+'SU>="[4>MK-O?VHM55R\'U5I8S9OI?5
M;,@YYRM(:TZ1<53 3DP3")?R.)UL<A?@ [3]UF8!3O5 ?5]F:6L?'Q/]G V_
MAI-"21\3?,IDQE#*T7R.+-QQ:Q&K(9=TQZ,D[XI2?1KQ"@_)',O25 1Y]*#.
MZ>?P*/#N"'[@JF-"XQ((13:W%L6HF79/*6+8>)%ZUOT\F;'O<_*)[C6:N4%#
M9YUMN?%"+4OQ94-U%,_V/%WV;"4$TZH0XH2V%A@[9AC]^BU=MGL>WQ.R0#D@
MZ?1[O?SL"IL)2'!2^2$=WE$U=W947[__=D05-Q^6?2P,)[;<)*UE6PFT4"&>
M(=NZ$ZJZ3CP0*=?0?%VW[;<L4C5P. 3%]7=41^Z:]KQY<U X+1XXO$'*)D3M
M31R5GHSXX7'CJ[K,2G/8[+76HR,13&'<!"&!Z=J&Y5N.34 :9<7S4=?IBNWI
MCKH1<?^8@LE1]/&T'AJ]_H;.R/[$U!Q>3*?52XKD6D?3>&L+0RM"/71,"ZM_
M0: &#G%#DZ V]2QB6U9HGH66:5/>U]'?#K(_#6L-T9G3$MW+K]_^3[18_NQ?
M2 1>81;3B6 8U\V3:)S,T1,?CEC"%@=M$"L(;%MS34LV3=]UW2  T?544]-U
M-=PQ??-619=>Q^?[!]M7[][>A%55!V*'J9'(PH#4B'=@59$7;4.]C;!R2(67
MADLL?NH+K.N43.U@B%U(;3U>\<+4\9J8_1BU@C?PHA?TRF41S\HY'*&[^#"9
MWE;R\W.Y@$]--@Z/T!(;R+YL$S\(?<,$-]IUX']P>'S;U>3 ,)6>$CJ+OYL(
MF:YCLXQB'H.1FSX\N^@H3LD#[K(@^;#HDS]/RQS[YT%)-S4FOM#_=3!Q9QW[
M!^R=?$QB;!%TH2FJ(IN.H?J6Z1''5E!B0M.TK:##FO?V)>91/W:[_+RR^'1[
M+ONSQ:>:,?RR 7I:,E:H45\3"[*]XGR_= 7N=U&._XE0%,228.KU)L.<QR0'
MT4CK=')RPS*SU*!PW"]VB.&W%EF*4Y@OI-]NDWG,R+G:WYIDY7PJ)8MEA/=!
M4O*F$+"9-F;3NY%SNBQPEG!!\]AL\#BFD8MJJO:6E.46M++XR.-XC@36['4V
M<Z!-MI)=D")Q, 5?L,0]/!O:NC'L"OO2J8I-N#G+Y'2KK^U)'\T4EXYX#.BV
MZP+5D^9HID]DWS-D60D5G\#_JZKL.;YA*\3HNNULL"9.JPKS;+$%E? Y7GV9
M^0E2\:73XDON)P4+:O"D#6U5]L$>Y0PPQ[4J5W"!ZAVTP/]&:Q('!#4_+F!-
MBYYI*H9.'%,VO<!S/%T) PT$3+%"U78-LL'TL9. O0$94H::Q-BN<,YZ K#!
MQ4?HTO.(*_NZX>BVIQFZXUDV,4!\5-MS93ET-JCHR/2?)=MEL"E$>-53$9E=
MAKU8]@#"<ZJ^Q6F#N0Y&7+9_CK71@P7ZA]QBJG &Z]RS36%JM*L:H6;X2%'F
MFKZBR4%@A9Y#5,4+3'.#1GHW^S08Y.RYT%W3DB_L'QBZ:YM-8CNT/$/Q;<,+
MB&%JMNS+FH8B$2@J6"*R88&.7"2>ZZ\8MCR T7G_"MFVK4)@:4(GN$YD5=9<
M5W5L7R$VG! 0 J+X@>Y8FT1ENPO!(!U+9TC_,_6"U61@%<OWB&TKMA6 -G 5
M$\)H% D=_J&[SD;D?.0B\6SXOCT$B>7[;AJU!LM.,#><S!*&ENW,1WV0/)D3
M+!^&0+D[6GAH?B6*IA5Z*4_4N;],FZ''%4"X:26+VFUF'2JE.B-;Q),RK_HA
MD42RP&%J.:T?8)96'&062ZO[3)@LE2UO5[?1?,&*D3U,2B/IRE443-?0\!H]
MXX_?O>#S]26?K^8J1NNOP3\^!@0'L4D+G%C*29I /+-\/KU/IK$XI*V9P^Y%
M:32-1E)0YMD2/O-KA&N,=R 0$.?P[-'%QMM7Q=/N8+<N0SW]7%$NEW-X1]B:
M^NUP><J3K59L&^DA2,V1#M"R'44@P3)=T]!"![NP=6(&BF/Y*N(N%,LP5'OH
MD1ZOD$N3AR JZG20T0.5B(,H57GX 5NVTP2WAFN%FN\3WW==W0,_17/5P#/]
MP+0]W;0V(ID#SOMX!;]$.X81#V]BSI;M--&P:3D*"2TY))85!I;N*CH)5=DQ
M?$]7E$!^I=$@AY<?[2A&A$38?[."!:"FF3JJNPSYD!K>#.H<LP&J='9JMZ6-
MSE =2+ <H3?%DT$G&9IE:8&B>X%O&XH'5LR6P:+IOD7:@)8*RB7P@W KACU+
MI)D+_64FJ"X0/Z_VY6K[]T UZ3A$41V$'+PS:E507AA[W93SJ ;FT1&J']AH
M[D6]K**?&@TG8@+!DJW:MFU"I.X%8: %ONH;H+L(#K[2@@9=_;QIO%0:0CJX
MG)$EWZ ,5-]%"6I!01NX<KU@'=33P#[5$,1<+1-92U*-]JF4&%P1O:OG3F<?
M/.[ <=HXS+J!R:85=Q0H8WB0F'<[KN)\4950.%**!WA1*LXP;IBE,'IS@\_!
M5_+Q<B1=?OI&/OJ7])"&'R__'W$OI?&Z,^MPAM$NQZ8)("PAR&D>K^*[DF9Q
M/&#XXRBZP!N@J8&A6[)*?$UW;<-1X&3#T?8"&0Z\TSK5>#+QFE_HZP3\;<)X
MBSM[/#; '&8^!$V2C5>,-&*'W A%J-3) ;B5=YNDT9L: 6%UWN4\ N(\ F(G
M$W1,;_3Y)$9 *"\< :$^803$$2;H-:F)5M[ " 0Q4:\A$UQ11HP+$]T;;E(:
MBI6G3D38F*F0/O E#CMIFR_>+11)BOR!(I'1_1I)&EQJE7Q8E0OPK=)XDF<(
MF,,Y"O#SN^O/X?N>O+\T =-)@W-J!IG3QA#E*<?)%%0[-LX:S=@W#%0X8ZJD
M(/-H#,\E@,][G<763.L'?+P+Z3M?8O$;S=5IKKM*=%.\.FQS,FE'@()OSMW$
MX5&#CM!/99@D] )5]@R=F)YGD-#E5+H*N(9DHQEQOW/%M&/*@^KF((YCQ1>:
MQX?*A[+Q[WP\._UAS5L'\5RP9D.08)8*FK92%MCV?1?-+Z0Z$,-EIQV'"^29
M%PY.CZ /&/8(#6!$,4U+<13B$C.T=<6!H(>/K[!DS7M!,N.DX ?J(&D*RD;:
M(U&5<@\NOE_04#P&^:LZ>5;@A,?,EH#1>-AF7%2A^X@I<M"LBW(1C<5OB47C
MOWS_=/F-C*H@?\02Q[-Y@NP&6[_U+?ATZ1$_8'%>8XEPGM J2I%!;[G:]N7@
ML_LM^$B'!L;)EA/66@_X;U+>E,4*'0!K)'V*Z#0DD]Z\J9HI9A?;4<UXB);4
M._HW+]57?<+':(LT56B "%PG)(9BZ:YL^Z[BNS:G===LQ=N@^@^10"W^B$MZ
M6:?^6<'D*VW+O.3,X>!/T7]OGVQY,J?8&N041\5&<:5@W>.'AP$-YX:399[,
M:P)["D'9P,2D60FO.NWQH<EX_/<D%GOTJ3,KN-%U8PG78(W#R?*9-0^;X'SR
MJX(E3UE_?N]S(=<X/ ?$1^@J%#7;0%G$=1E"N''C=V.7+86"E>DJ7W\8KS_P
M_V3-+[6&H<8_S];1?+46E4GU?'"5<7P;S6<]W:+4F6!\@O"%AH<R!^\#XE?:
M 4CK).(3TN5+\BEC4V^%"EQSSD .8=G;/(CVJ0)N*$,GZUOK79>',]=]JU69
MSNIRV\_OUJHZ\T];)F4"CCU^JG[(NLHES,U#^\+=UF+W.[(3D^2"C9-PTR10
M^HN&);2(Z4,P+D+X*B;_IQ?2MP>%<T.^HKS5BYJD]9NQCVZ#/.XRQ_>4A(XU
M2 X#(W>$9DC=#HCK&J[GF:HM:XIG:/78'\4(C1U&9108E2(9+,2@LV1UA6_V
M6L6+30;CR\_ASJ,N-BW\ 0>XS*KH$-9( CN!G;%=LM_> EI?IJC%Q=L^3358
M+DNKNW%"7I0Y5!&[GR^Q"[XX^3;XTVA:.UA_G76(I$I+FT?4U#&A^U!)6Y5'
M&3!)(8PY\U1+4?W 4&W=\TW+=6R+#\)3/)4TO5.\-BL<ID:[P5L=>W%6U94!
M>B .<,1VW>$&4P-;JEHX>E?W+<5S;&(;+A^1J6'+Y/-WV#ZF'59L:P#*AR%!
MGXXPX<NR;<VT U5WC<#33==5-3XJUPQEP[*>O\G646VRH@R2*V]GNVCTR&*D
M#1[[@3Q88:S6V8-]K8FWW*!S3Q9-?9^W6;P\+#N2@C<%ADM7<7Z73.+B---K
M5\FBG&/F'.?H\7ZBF(L4SXIMAA:\!M4N7C.*RXVZ:\&71TR>1=(B2DNL1[,!
M'DTL0^E>JGS9(S'.R8;W8G9QUR6[IZ$A\E-M@@)Z+T+'3S2DH[1!; :WK2Y>
M1X@4\1R/I'&YHMD7K$'.02NQL',D3>+Y7)J D""HH86I7L+NS>#&U>&F+&^M
M3Z <884%/]!]N"B-YNM5][G?P*9ND6W>U%#]+6Y@"HQCKX[L_X4@DX2F"Y'L
MJ)S_+DWS\@:1KA"%8T(??[W9MTFSRQL9: &T,N%0TA)N0O/:'+IQHBL>@G')
M[JN>TFE">1/IRG+\\5_ #<*T@:K;/T]'DA^GF ;M[(] J-@J]SE2^/W7R_#R
MXR>LLY0+6B[D/:>,Q;I*YHM["G=^C6VEJ?LTD^89N!9Y7^Y^\^$H-V73:(Q(
MSXV%PUR/ &AZ3#W1Q'*OL!=;-#8FC 2L0I(*EB;=TSZ"8IK3.<5Y'$VESQF\
MDK;WR+//'_";1R\.X'2S/#Q-LPN).3[T%A:S2=&=:K&ET:$;'@#5GE6U;;/\
M)R"]JZ_2/F^P:UQT1ZUSVCZ;>'+Z3AY6JVDAM:<+#<>ZXD\W<5W2^8!!$5I$
MP?#2Z6#P<+<8!%3Y,$0?2'B!.<K[3;+B);R$%9<B;''O>9R&37SC\?N>\52E
MX)Q4/B>5GY!4'B;;I,M*4R1S/4<QPD ) \\U="_4 ]FH4@Q.8&YP+7WC5OK8
ML\2*; [ H#54EEB7U8;%,W!]678LTPT"TS-EW[1T!M6WPM#4=/\)6WI4:6''
M_+&RPK"I0BK0417?<@-9454O5&Q%A\VDY]33=<U6GK"I1Y4&UM4+:_ L<)(V
MT4?9=>1&+XDE>@?+BK>CXTPG(@V,P)5%2^@8%]PFRV+40[%5?8Q?[+GHDI-N
M$;0[[W)N$3RW")Y;! _2(OB4%K_!8S$VQ*S@02L5?JILN^%P!UTKY($Z36&L
MP68H7T  N:NN9GNVXI) !G\@U%POD$-5(4YH6+JSR9OLES'2^W]C+_J5X3F/
MF@_('@:B#H;W?P]2]87M;4(R62::8@>:H88Z\6S?\X( MM<U?<L(3'ECB,.N
MVVL?S?8JBGGA#-*"<":G?XV43-N_!AO-5?$R6E,]W,/E=]I[4T\.QPGV#$,P
ME)TP&I8OA^BJ%KH&1(H!J [7,!4/%(FG$=4BOKLQE1D4R7765B,>X\$AZ?1S
MEG)2G*.V' .Q4W;)2CM.!2W*M>AQ1>9<N-'I"GZTX2<]X;S7+ 7\ >W1L$Z6
MV<#PG-!60B6TG=!7'=4CX!NC%0X4SP#'R]#W=WB.QRYK2A_A_('/SL5.N8B(
M[E5A8C0B>X3806B UVM[,L[BM!P?AW-:SD^[AK,;H<JA8S_#LA7'[(O]%(>#
M&;;]LS.H=$OBO2N0?X_R!$_?)84Z%:L 2_AK'\[J/"O*/,;@SYUGD]]_ZHD%
M+=>V3,O497!&,?%(;%.K8D'%D\T/3;I9-0W/U6TS,!W7L#2((EV>F=0T35'L
M!VEE'KV/\I,4@^PN,?&4ES$V53:L\K 'U5M*U6M* 8<J;)TTNF,XO,NCO>3-
M]AI,OPJ>4(7M'4<]^($>H?;$'.1#FW2*R,,OW21K'Y*A@J<Q5&+] 7C]<LZ2
ML7?5LB35LL05S 8>IB+UH,@VUE\%6AK;:.,TGB5PL7S-IGK/:C01G4R(,PIA
M62B^#4E]MM[EQ57V(P&S?HY+6)I%F<;253G^ O\BOYPH@."WBG:H@S_&V&\+
MM+3O[:5WS6_?UX"J+HRQMY$<D5[C;)H(0*QF ,,*4245427Q6Z2STQ+$#6DS
M1E0$*?5&M%C/LV0*(KN*JBNO&^:-Q^\@O<.BQX(B*=C(,^%U:P?H/2.7R3=G
M*W1>>]0MU&Q=A?F\6N]IC6+!T]9B?H(?XMF,]Q57M^/ -AX&3LN\ON@DSI'<
MD;?6\\PC!0%F#7*XOATV4BHJAY+0S"53)'FQ$K%Y51]^E*[K;S*$3U$B]4]S
M75HY*M/IR>)4?VOAQW@/>:U-!<$ F;G'?4>D*"73K#AM'U"EG4N,XTF$5 <5
M4Q>3TGM:&LRS\N:64S&(AQ2V<9KD,1]WC>[S'=/F]/8+; 87%/-\+0['ICIY
M37/[UL\@5O"BV0(691GGU&%'D"4G3F!RSLELX9XSV%,) IC_J&1N*^\3:W*O
M&MS1R."8D2Q?5=]LO<_)RLEE*GV9K#+.?F?1-6,J9),7HT^=\(HNCB%Y]4@4
M7"S-C!5-X-SU7=,@GF) &!JZEJ*HBDM\12.^Y]JR%W@;4P X7<%U]BE)LQS$
MBG;]W()C%N>=Q##' ]3Q9V_0 "+LKCT^ZHEAYK_,6#C1A*?-0NZ1%7N07$Z5
MPX&C)4A'TF AJ:H_F&@\*AG"5#3?\W5="RQ/\57+\$ L#)0,VPH--33]5G_8
MMQAM UPQ23GK"ASSF*=HLK0Q*92M8@ QV6P74W=M%E,VTQ:':Q;+JX6L:&.6
M>7R79&4!&CV-;S+P8S FJ*AM<DI+6:7"LK0/%-N 3OKTD>AF-6A;\8JU^]1Q
M#*B::SPSBNCE3&"V.&M)P+4/I?!4H9%=<4Q-]AUX2E4Q0:)#SP*Q=HD;!KXB
M;Z3>GJKP[+^IS3(?I^H[)LU'78R<(XU EN+3$OK1)D'K0)I;;6J\H>O91 Y-
MU_;!F!.#F$:((FXHEFOHKK.%4#)_H0Y_1<E_@39_165^(6$NYY!2VW?5G24W
MS>ZEG+D<50!X"TYWJP&#TE(5Y?C#*H8X[T(B!:LN[1 H43SZBG>*\'$"%=<5
MJ^NL\F1<LA:SBKV+8]?AXPO\$+A$^4U,'R)%"4Q7.001C(N'B5/Q(+V:Q=H]
MX<\%!CW3+OL:@STNEQ#&XOJ=*!5@>T14V<_1UR]0L$7W63F?LM&13=B'LUG$
MF'>3FG,(7II*UVE-&5KS9=4+-=<. ]OQ/-4EFA[8GF'*ED\4L\U+\[4Z&VRX
M3Y=!MT"2]H0FB*ZS:^2GPUK;FB %ZA]T2M5\O8^10=]J>M5/VR8&'96_, RG
M)V7F9=JE9J.=)?3PU_WXH4]8O%2QU+94'.^:/R[1;0AW EGV2$@,SP@T$AIZ
M&"@.B*[I!XJINR$Y;M$E?,GK3QZS! \$W$A:TI@4TCPJ4V3QK8P6#OP]T3S8
MMX?S@'@JZR)3'B>+<9D7+2O$,HVMMH4],<I?2#[+P+>Z)0]"(GUNESS==LFH
MQG!SZ9PR?!#()\@4:*_YJ9Y-K-LR$FQ>VXLH-0.G6.B<0>0U$4NZ-:5F;PEZ
MF14)*SGEHMLOL$4@%S>M7D7;3W26WT0IKXC1\AHM@W B%QSW4-V1U:^$)V9-
M2:O;*!63! *#QWS=.+)\AT]U&YNV?])8D18IF^C*!TD1)71:1FNL#"/,Y?:&
ME:2J FVQ0BG))BR[4CM5=6A9Y0,V0'@_2[?9/6QG7MUUFK 9'12@\OA=Z:TX
MBI>.ODGXKL;MV@K(6)U0W'RJ>C0)CK07JEULUU$J.;$6XW&-B_=/B8_QN<:<
M;Y@O#GW7Q[@ZV-EIE=<;P%TA7*B'C@,#TE?@X_ V.@(98]<WL2/PF(@Z3KJ%
MT.F\R[F%\-Q">&XA?$8+X0Z@QQ=A)K4WC9G\GD[>,FJR\B%;7>W,VB)&$5D<
M'T!$5A">:4;=&#&_S> ^\VCRNPC3>1",LQV'4P%OBG)"20%9;K:(&]0D8BZ+
M[FM48,^D#4^N(%_C)!,8#1&)!<YU7"75N0O>\4GJ1M23!>*0DV[J.JF&.S;E
M,L_7&(_=1?.RIJ![HD3F\1(%DF89!4^\;.NFAPXJC@,;@-RH2M\Z0J-T: >^
M9MN^9;NZ;KM^X.O,GMB*Z^KM*FO36'"9NN+B>-7:7(/F('GLU[C"Z\R-VTI[
M6TJU/[&[#S;\(?A3!B'%J?>WJ:(3U3:(9@:6J\H:"62%*'Q_-=\FWK#[:^]G
M?^W!^7%8C7P1_8%3$3'32]N'T,!VY[PP0_E06T,A\//NIK-VB3-/PQKNPW_6
MA!:!#1[K1QT)YFQ5%N"!?;J_Q2SK-JQQ=8%6/T'M8%7^4?]?JQ%;Z"SMMZ3
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MFAD-#[UBCD5]BJMUY:,\T VA5>7T!LZBF)9J(@5^LNB1%E"!(@Z"'^51TR
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M<<>I%,;CG#Z+,:*/,VJ>AV>\(HH_FDOW>0)JJG$DI7*)YKX"Y[+ KP/DJNM
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MN;C1DI=IZ(36QXH?/E$>ZU4D>"=>1;?KUNSUP09JJ'S3YHT:9[N2:-SH2=@
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MR='B'FKM,H<-7<S"N\[0]]O4JY.>$;6[YB\8;+C'L]\_-Q.GMY:KUU^8RVZ
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M!<+]M6.4V4A"J""15"1B3<2:;6 -!TTYBN8<0DHIUUHIK(S1&:\;2;+,IGN
M-9VFCCJICCI-Q)F(,]O &=3@C$EU:FG&08I39T,)K:RI=!I,E7U*I[5-X,PN
MTTQQ[(@4(2E"TG8@B335= HH03FEJ3%*99D )H,E)/D*F51L&I*ZX5/#E!P&
M>KP*5W+D4WOU",0:!,JDU8KP#&F0 HQH)C"NZGDS8\U32&8?0J!]YU,CG,;.
M_%$)BA"T#0@235&?X31S)AETT(.TH!AE7-2^9IWI+NVRE\&G%D$H@E $H<V#
MD !-R1]QN)-RI#-GBFDL"1'45B!$<*;1OH-0Y%.+"!01Z,4A$&H0*,69(BD
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M^XX@LFG5(P2A2 *.&=8,"F4Q8'4%%V;\1SB1'H<@G3IS:<2.B!T1.S:/'1C
M!CM2)(U()5549)Q(SZ%&ZV09Q.!*,\%.L&.7R<(H=MZ),!-A9ALP@YO..Y1
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M'3P\$=B*5BK##9!*<JP%2S/+9)U (86U*VFFCX>GU42*Y\$3C/ 4X2G"TRN
M)\P6\*2X3(4Q*!66(F&=W8=LF4P!A.9B)9GB"?"TDE3Q''C"\)@<MO/I=?C3
MS6 XGQ7]Z%&/J-8UJM&6TL5UE@)MJ$::,V32#-8=FM,L52O%VK=1K9+2[?C4
MH],JJET1H%X!0/%&[<(<"&08RPP'&30$(EQ;A2:UC#P'H*)7/0)4!*@(4$\'
M*$D7 ,4=F&2(95023A'4(K6XTJ XDN1!N_ ^@.K:KXYC86($J A0AP]0%#8
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M49F)@+ %0* M+G4H&!$IDTBE2"NGOM"T-FT EW3%[?D0('3D^41'$M/H^8R
M$ %A&X#08F3GAD/@FX4 1@AB[B7A56:HU :O9(8^! @=.3\=(' 1$SPC($1
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M@4H*F%7.6F&576GR8ROY^51,SKST!*EZ9&"W_DW;,$,+NPS<3X]P3&.'CQ>
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M/(87#L0&O56WTZPGO&;L)_I;"A%GKIU"W$VCQ$W_4^6Q =F>K>+9<O5^"/1
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M)LGK9W?*V9W2+'S.Z:0 /XFJYR-.Q[#5NF;-M%7=T7TW\J/("7PC #.9RZK
M]IRZ12:%TD-L79VS,:Q])@!QPHK?+CY?7\!'0(!1.>L:AW'!L?#:+(SK^*=7
M+J>4Q%'[L['#-5QNX[>C P8J#/.H\WW;S<L!>9&R$%V]DSF(!.K5PJJ/,]%-
M'5Z6;SIR##K8X.FXX?L&L%_* T[,?8U+/>T8]2X6R"N7X0> 6P\#G:T_[Q\&
M;O6?!K?,T]=G.S#C3CKO "0_$,VV;?K+SB!9JQIY<8VK-Y+7-+_?#_NJ8[A6
MZ.NAW_=%@9AAVHUY9Z1Q?^?K]M+QEV3&BF66,ID!^24>L^NLE;%\!=HE177Y
MN%#R]\M0XPKWZ)GKQE&[)S[8)[%[',GS=T]<9H #"O;@D*LNQ7_.G.]&!+N*
MW!9JH)_&=+P+D'^Z!M+.UOI]TS4LWW154W,#1XM"W?.=-[NZM5K(P9'(X1E]
M0*;M:*[5Y0/2K0]_^3?-4C\^_*<0=U]+X$]XZCVS[]9=\=_+8<'^66+ES"WE
M<,-O_%DV^O&F0\%88(>$8>2"FL+ K=<?&(94,':D^>_KC!Q=\WU3,YPPA+^%
MYB!0]; JN=4B]T'TL/4YVAN%@<Q:H-LY+]F;3_5K*/P]I* 2V_&IS6C;=>D.
M2]B#@2KO4)*.875_UZPV1QU6NPJ.PB&>P[A#,G3P&*])IOY>NSM*FZ]H=?B_
MFF]LZ,_YQFCD*/\5 SGSE:*KNKK9:3%MM$VL&PXH5X/WJJF;FMUW0<,H:0:B
M7@F^?G^_8"G#$M7E>FO#))TFPV294;'<" 0[K/('R#:0=UJO,B[KG.>J%2)>
MWVZ$.&33^#8! 3T3_=<:?1&+U7RQS.8%K#3':;"WH*&RLE 6Q6HT3>(EGO&-
M'\EFBER!<:)^ *K"<Q&9EK,X[^'6+&9QVM1LN.(KJLK51)FN?(_6ZHLR'6=W
M*2]44;R0%I" (7R#=U:*&6,+Y2[^ ;INNEI.Y[@>'#Z6X^4 A&";BBPE1[7]
ML9"KI07"<4Q98TX8M:ZL:X?7ITK26V "ES+'Q\4'0Y,/,MD68&F9EF4Q37?[
MC<G2H>^X>M]SO- /-<MUHC *;"<(#<UWC8U!IWN5J@NISLE<P<,UB8YHL96&
MNO;]*^]# $S,W[\G>IX24PQ9/?<N+KJZB^P\Z0Y^WI 1"AP2$!)+905G!([&
M:(I.(-DWE<[@!'@ZX8%I&O@VCU=\Z!MPIE@K,"LN_&C\Z30'\5I^WXLTMZ_K
M?F0/!KH'_!FX9 !%1LOPB8HE36IO3,:5AL_OBRSU0"X!S_*LV@;W B\'%6JN
M3*:3YF7K.+9.TJR5:5@3S0KN=2.$ YBYW-:J!X.PE^ PP/]!Z>15S4]2]U><
M@C)74,;.< CO3<+S!XMR^'[)P!!Z)!;H#(:])!BX7M,6E5"(1Z.L3,D:R:@A
M,\("TG=QW>R!:[4"M^$/4$E4%5'"YLX17$B=A-D6B1A\TAX'R7XN$IE8.>'I
MF8L%P"[R6][%";F2%[#PK%E8]9^@H-]_'V7+Y?MO&=PK4SPL*\KAP<K%?)%G
MMT(R>=PIK;FV):F([GF4-!BZP/5.6\TU:/VPZGIH9ZLK-=P+ =.327VJR);0
M8 #<GRP5$'DDEW]1B'LLA6(T:H=M(PP,VXEPM#L 'M,R!JA00+-X0=\T-W)X
M/\..7TXX?21YOL0_DWDY][,\S^Y@]X,8/?O+55MC7'"-,:*?3L1/GTUS.)7F
M<+=D>';HC>%+9GA^6G,$;!"K=GLZH:O9GAFHIF/HZ( &$W>@19&E1F"Y6\XN
MQ K!$,^3Q6:$,7P&^CQ^T]Y\FB2WK*) MW/@8!1YOV)H#[$TP>Y(J1QPG+/;
M;'9+ZH,+)+DM0A$(!,NH53^HB'FR%%G^XSR^4R9P%>_<<I>A+06WB1<H^4AC
MW8#!FE.-;;Y GQ_#5DL+D/O%!^4:50+<KY JZ?Z5B*;>($UJAQTV_$]ILL T
M1MA+:+I02@Z%:7+QB-&\YSD_NFU<+88.,(74(JXF*1Y80<[ /!V)>=#W7]:2
M?6B.EC>H+('KS*UNQ><)@B3I%-BAZQ<\W^I58JD_Z]J?U>?[I*4=&X=T+_VU
MI 6[3T\+%K$&RPPPF-AW+$,U(R=R#34,W<!U0]MPC<%&K.&Q8N?7SR_>RD1[
MB9FC)^U^BZXNOUTKEP/EXFL8747PQ]=KY5OTV\7WZ^A;%"I7O_N?+P+%"X++
MW[]>7WS]31E<?/OR!$'U\F]_?[CJFA<@^EF<CY'L(6"%T3++>>%MLS,0?ML8
M+/*H#.WGSE/84TZ_V,IVLGTO%TG*JSJYY3^H$-WWVM6)5*%>)NAIPC.:9S,%
M)SPU+O_& %*BX^($=^)T:?3FT_\R91IC[+T$Z"H0+?J@<"372KB1:IP\C&>P
MWTPIIDPTW&B.W2&OU)+<4D4R3N(<_7AO\8Z4OJ1^#/AMZ5_:QW?HWL+CQT9D
M.RF&UD-P[-*-,/VD)[J[LJJ<>*LWO$?CQ.  LQ03**I/T2( 2$Z^R;B8*I-9
M=L<M%7212Z-C"=J'*6@:50Y(X0=C*7KJ-Y:Z[EJ3ZP2K ]\=9Z?)G'A,WQ0I
MF1EY/.M]V9J%('>,G&CDJM\@FMC;OQ:\0UM*1E'CJ-2WS>51N6__>T!G2E])
MP:2!!^1)K+ "<QF28DKVS NU16B?^/<D!&YRVB5XP)RAD:F\A24;[Y[!U5T4
M);+\2FXOV;J$$[XOD&"4CW.9W\2I\'%7MNLU)M( *.._*@KT2+U]$UQ^OWP#
M)%1.4A"<KHBZ2$4B%:F*GI@9N.7$M$_;$(X =ADK,#Z!C0>P+S1F75%XECA\
M)AN%%#WA@Y8W763"ZRZH*T[:7M*K*&="2N'_%J*O05&)S$/+)-P@] &BS*-H
MM8@KD&<?&'>4++"YF?#(@'""[]EBR0\W>>Q3DBRDA6GA'CFBX@^*A^(GZ:")
MW)=YC*V9@&'&#^TQFTRX9#S+JV>15R!LSGCUR?F)]; WKSY 5]4!.L'7.-T-
M?O/)HXR:45D4_%3R5%/9$&:K3&^+&=Y2E O8>9RF/(>'.ZB3I11X7)[.>,X1
M?%])Z%U^5A==,?G!,H_?,^K(R2.8$V$ERA9TE+ZZA*71]+\4K,J5>*QS/HX'
M-Q^IRP)11AJ2)_@FI[O'F(?0M!S@/,0\85^A^$>!.)<:DXEDNUTRIGF&H00!
M*"\?H>I[HD%$3N@(#U=1R*0Y2F&0M\2A)]SZV_G.(GY$$NA+]<95SI^7IF7E
M4$!,L;/K =,H1)H^CY9=P)8HKO=!N2SS>CM%%*O@82E$I84$4I4?I&$ITZ*V
MXUW<K_:/]S(%*P2%L([LRH(;FSD&VA8E8*E1$T1.DGP./[])"A[CJE(BK_BE
M4DHWU.8E/+M +A>>M[<MC/E.>7L5>)?^.WH3?*R(XA&"'R+OC-F"40"!/TU@
M2:D^Y!,1<HXPLXX\%=6Z* 5EPL84@2RJJ7K*++XK*H70R(/)2P3(?-SYC2A0
MK0R\>BH?71')_M8->T_>DE[J+/KW]DIA^E(Y6HHJ&LZ1]]$6CD$Z!I:JZ,,W
M7;F>8E)1_:W@*!XDEDG&2"@PJ&B6//$ ?U1=FH,UV%D:BT:S94[/!I.RA'M,
MF5#XNYBDR-23G+L0*HL(^45>TJMN."ZIZALL6,SBAB.;P[*X4)27/,: NHN+
MAGEVKW5V]E'LN[++FD<%"VYGATH/">[CMGDV8N,R%S,'2>]Q%T)2_"CN99R=
M'[H3A]VS'IY9@4I,M'7$PT7K^J!\+P$^-RZNWHW]A!U-2>^B4%26V(]\B+"M
MI[#;!*3Y""7]#9Q/Z4.-YQR!TV0@,!=F62'NN=L[<G4KJ!%S;X5<#?:;C*L*
M^FZG2(F:$!^.K;6H$3^.)1*9Q6)RV'#5 $NM1-:U1^!1Q#,FG$^MK,M]WF0O
MC%._,!=AA$U2#DI(&HJ:A7W@&+%BY>8&JG.&B&N&O&/Q#X)C[">@@D*XOW#C
MZ/$;NS]FN,$<N'"/6!,KW@OL*J1"%*1E8>(2K.@!PC=8ND!6Y79:@V%YZ:;L
M.HH>?(;E##$WWXA:23XJY[A](\:QT9#-,)V<;T1#2V$N;$()2@W5,:Q,E8;C
M;)_\Y;.<?>V9'8[ZO W?S@D:^R1HG)8G(^0-^Z7E\#F9)\O:YCA'OY_)(:F,
MU@SM/71L@88QKWH3NHS;JE+\=]H-;:B3,]D1:85D[HQY"#L2 ,0BKJLV.A$E
MA8Y^BA>0N;5=1E-'W*<3"WU0GK1#7/L6 BHN .N,I,F\#BS?)N]XD?A"C/<0
M5CU9*YC:.R(!P&OF^&\HNM38Y#&#'\YZ^"8E!EUF/-S/PWVR>=)Z[4D%,V64
MKP+P]5 1CM5H%S["0JN5/D1G>JGV<_)VR5\-,)!G*)5Z)R(_@9PR(DE ?L22
MA4#9U%$,H N1H_W"M.PAP_L0\,W26:>+)>8]N1J!\(8SD6^Q3+):WU'\%G9U
MIVVMCP_.C$)'/.X4&.#)'.D-+"!*=.$A92H71?M154_U$.'W\%<-LJ^MJN)V
MP06T9["CL['(O*AA+T>L$I#NT$/B1&3?Z4IEGXWBDC>XXTX?P.K(1K-:*?;V
M$$-8WHI5 ()CB/#$)RT3NN"1[1Y*IC_8J&)C/ /2<.%LTC91X/!.2CPY(BK/
M#WJC,J]M+XG5%K2J(:/X$JQYS/Y98D'$L'[U41U[;);RD2,^7@H+ZD:XDY!M
M096TO&*5O,U:E@X^&-\_3Z@&X\R<!\=R ;J&L=#:(\O]2[S$]M8G^#:GN\\\
M,C62&\E=('/:2*HM+E.<CXCI#FR6W7$L)KZ.X;!1A (;3)!(+W,2'R)KIG*G
M[.:EX[[BN&@_-LO7PQ.MK^74$WK4J$H=J[0OH!V1*LC]?#+HS'52Y?'B'I:<
MU<IFUU"Y5*KO, R=S6Z%&YW\NPDA!1 OLQE+;\B[(\05=9S*<BY-V$_ECW)\
M(V3C];3YBD(2=M('P'#&>-U5/%OR\#H*4<R':[@^I,+<)>H?_V IU4(K=]-L
MQH0?G >GX#D]=,<U%B? =3?W$,/T!$@G@*T4''2QC:5UW@ ].&G3?;A)MJS.
M)Q!4/D4I*_+D)Q,5_J,>@]2DZ?06VI69@VU(\EN1EO&%C8%."??:\I#N6 F0
M.[ZQ(1VRPZ=;G> ^G3 )>>X/%>(.Z]R? IOY ,GZCTP!0G/J)B5\3]BN%'WQ
MQ(!8,<$U94MN.G*.::9LMQAG+AAGQ"TU8IP/"D[]X.E?><G&LOFRB+>C%QF[
MR2TE#@5CKZ3.&/6X*Q[.X$KAW[6>JML?#-FGX[Z,1E&!*M/MP8*;@UJ;K6J3
MFN1702!UXP1TO4BK$T-UM?R22ZFU2'IE \G8Q[@UAPO;</#L4)[LT,RXS%DR
M'Y9Y(<R_NA&DT"3K3ZB](*V7D<LCM[P8.5X'8O#2T2Q.YE)1\O4TFB[)%E$2
M 8B.$CWYLPDA8ZR EC-(^)W(Q!LR4#KUJU-1,TEUGMN5)2-6]=JA:\FDON59
MK_1U47W47&N%2^Y]<G7'!6P"5W9QO11JTE7/*VYL@.PA0H8Z3U>3*6CT/8_+
M2$X C;6$TUB2,D=C(V7 N,M&<O&'2I:V. DL*Y%)W<4L:RS"I[U0<R\\>C4G
M+W@/4#2"4C8A]8K/RC'X?,]C,8E:'' >SL'#\9['@VZR>,93C^;8Z6M59VUS
M;Q-2J^JG3H8DAKZS.XKF*&_Y!7"HA/_@G4 \=7/RRBV$@@ V7ORSXZPI=')%
MD&J-<)P;L54+RZLM&Y94:;,@?)'6V2C\C45BD<Q+:8H9\3S$+F^+=P*(LCA'
M1R29PW'K<DY9L',+"5=XOG SDHG/O5^8U(=/NM- 3 &#$4I"T9@G&-#M52>N
M)1137K)3$D<*^"RD.N'2">B1'VEVE\)#\Q\@M<E>%_L!MQN3[![#]L'O04?$
M,DD,C.:"JH/$SLH=)=*+;FMR=T\1B9VTXK[FH@I=B%S+U7,9ZW@F.13FH+!Y
M/Y\IER,=602D::I6]?=AN&X-A@9 -R:/*:F'Y8PLM6;<7IHP;3Z7V0^4/-2X
M>E[/!0&M)B9-4\L)843!OHE65\+*H*ZY$EB(JJ[JO<AW6DF"HBCG"[YMC<'U
M9*ON<8KV/#<;[,^1!>J ,D^5F2B0X7VV:G\2[2Y016Y?PT24971L,L$$2;3N
M0#JMNNA<6<(%:[[^^0CNBYW'X[R1?2&8OF+*[I.VEG'!STN5<I-L-K24]R C
M7:2M[&NL@_*^)G)WY0+)7)#.!-[*,=J4$*W3M).4:*+[ZI:D"T5,ISJ#E.:#
M&5!2/<O3S'6J>.J'S?=I99;T$-_CIJ'X@:>C9Z<A(0@KUGFKZU!@[6$HI "/
MS9+_X]LDH9/0=HTS)2V<,8--@$5L?H]X1KB0N59O==>IY(98 =SO)H_GXM*&
M."*]2Q*A!3D$[%Q(4KS:E SMG)+Q)TS)>/-I;;[TY#X=6X5AN,!IJ%<>"N8!
MP[R:R=-UV.$\SC?K#.37O3H 6DG(CE-6UR&CN=44<VMI=0W;5MC-(/!7C9[%
MC1=MR81U2TXLHFI*_>AFFUWM@)Z1M'\K_G:%XN\.G>;3#.1\D&&"8:%\_GQU
MDOK=S[ S:@_LWJ*(1U-8\7*Y1[SH.44D&^;8SY&#(ZM'?1V/Z4P]G5C8GV(E
MLCT(X9.Q-'#J B-I)P V!;RAJZJQ*21>"Q30.Z# O\A_#+/QZM._@M9?SF>?
M_A]02P,$%     @ #X1&4#\!_IC+"0  4/8  !8   !B:6EB+3(P,3DQ,C,Q
M>&5X,C$N:'1M[9UK<]JX&H _M[]"RT[/-#/<TW9/"<T,@21E2P,#I)WVF[ %
MUD26O)(<0G[]D63,)2'3TYW3/:W\=J80^2+)>A[+PI:E]F^]87?Z972.(ATS
M-+H^&_2[J%2IU3X?=VNUWK2'WD\_#M"K:KV!IA)S1345'+-:[?RJA$J1UDFK
M5ELNE]7E<57(16TZKMFH7M68$(I40QV63I^W[:+3Y\_:$<&A^7[6_JU203T1
MI#'A&@628$U"E"K*%^AS2-0-:J!*9;-E5R0K21>11LUZLXX^"WE#;W&^A:::
MD=/SNXC.J&[7LJ!)K+9.K3T3X>JT'=);I/2*D7>EN>"Z,L<Q9:O6E,9$H2NR
M1&,18W[BUBEZ3UJ->J)/;.[-GJ=MC#B.S;ZJU_VCV:R_J1_WCO]X_?K-Q=F_
MSYNO+GK'%\=G;YIOWUR43MLU;/Z[O?*//&5&.:E$Q!Y+J]&LOWB<7-LN.931
M"U/\-V9_="ET1 -T)L1-61DD%44DG1^(:29--NSB/#<[>7+KOID[3>YT!3.Z
MX"U7_C\NNRZXS)*>"1::J-=$4;.Q?Q3_988#HQ:1_VP!_^VL-?]G66L>+LRS
M_O#R_ KUK[I5WTJ3D?D/%+-T.HT(F@O&Q-)63U0AC!A5&HDY4NE,T9!B24T=
M8L)G5"P(1WT>5!%V2WHD(/&,2'3<*)O:J_&VC$1,M;91*1&3_2B6)D-1&07"
M5+0AD:9.-/G4)GV\6$BR,+5D&2U%RD+$A7:;F=HNU68]4J8HZ)P&V!YU'N?J
M.V#_C&B?M&YG_P2'H2G-BM6@54_NLOTI#\V^+KR; !<RQNPDWT>+Q$9Y9Z/4
M>,8("@ACZ[7O2O62"ZL$!WGX^Z\@,98+RK/LX52+?(&K4+,E2QKJR&QM#GXF
MI %?"8QO.%&DE?_Q2'B;8U.J.C0:V!SR=Z5C>^G1H?V0F[7K#&=)O'K[XB3?
MZ.&ZQM.K7M>WZP[$?4ND-N*Q=?9F0FL1YT>2A5J-Y,[XSFB(?J^[?R=[W)J&
MP2Z4W? ZAMU%6=DU,W [+OQCM<*!&G9R?3;I]_J=\9<'%]W]$CU<6#^B,(1)
M:FYJK59$0W,R?$=A4!Z9@SY0?/_ZO?&F?O(WCJ]P,DP[TW,T'*/A]/WY&/UY
M/>Y/>OWNM#^\0L,+>QD>CD?#<2=;8#8;7W:N^E]=^$#Q?OND,^7T:Q>B::)D
M%\\+D?(0VY\9[CH*)Y-7D#]BI7 0I8IHK0IN^L<.&.X?7#!\:_B88*97J"MD
M(J2KTT%VKSB#[(]D'U#S^][\<A]AJ3F1*J()2.\5;Y!^*_UU=5*%^MU;RJ#Z
M ]6A=@?EBZ/\R_%T=+1IV RZH+I7E'N$X266I."6=R.B<$+P#0''O6,,CCO'
MWPMF<X3ZH+AWB$'Q?<7!<?\8@^/9(R/,TSD.="JMZ;GQH+MON$%WI[OM5/6)
M<*,[4?"LU#_,H+G3?#(>@MW^T06[G=U3XP1.2&J.#BIQ#S&#YMO'0R,<V$[X
MT"+WCC)8OK7\,U$:'OI[B[KHJG<%G]OWA/9;+N"[K[R+[OM$2Q&3D-Z5H7GN
M']VBVWUELZ TEF"WAW2+;G?>4:LCS9>F'!^AR7@ DGL%>0.WX)9W4J6E21&C
MT?0+&N@0//<*\X8O>*ZEL?PRGKT'Q;TBO$9;<,'/"%O0-$97U4_5VJ3:@5:Y
M9Y@SO@6WO&\'+^(X&S%OVUDK>X,(C/<+.9%Q&A:^7I=8489&4H2I%@I=8!GC
MP-U -Z'!M-<![?WB+O$]906WOHLY#C'<7?0/<$:VZ'I'E!$T20Z5 \C]Z^)U
M7 ONMOG2)(BX8&*Q0B\G$>:+"-,CU!75LKW#"#6Z7]R-](6_C=XUML<SBI&]
M\S(!P_V"G-,MN.0ON_>F8D=CDJ0S1H,CI*JR*D!VOV#O0RZZ\CW"8RQOCE"G
M-@'1O4*\1@N&KPW??Q&ZDX#O?@$'WW>'M.B,P&^_ (/?^_6Y?=,?ZG2_H8/S
M;GX+RAGF(1K"/#%^\5V#+;K>9K^ P*U%'Q%G; LN.'3*]8[L)9$QYJN"B]T/
M26!^<9JF]P<!_10]9;WA6W#9WZ=\@>4*?;B8@N%> 5Z3+;C?KC)?]VY!?1[:
M=^9N=16ZM/A'W-$%W0/TLB^)_05^!);[!WK-MJB>;T:Q0.>I% F&YKF7F+]A
M><U-4K]9[C[=QTSN!7<R;U(GE2B;G+K1K+_XD;G/LK&7=?<9R3SZ!"](928)
MOJG@N2:RA=D2KU3IY\SWXZ)],G<[C@3$OO=W()6=_?<TK1OCW/Z4FW,G"^\F
MP.U@9&S/Y$8]L]3Y@ +"V'KMNU*]Y,(JP4$>/E!&4QH3Y9ZZC46,'YVP,98+
MRK/LX52+?$%VBK@E2QKJR&QM#GX]NWL@&,.)(JW\CY.'9TYI4U&;34P.^;O2
M<>GI:CQ+XM7;%R>E1^?^.OFG5[VN;]<5XA*1-X6T&R$#1H'QC:\%6_2?M7]B
M4VE \]X_O@YLP>7^($S#"+SV"NU33(OD]2"](_%,I'([8]&D \T3SV!O*1=<
M]X_DC@8"3:JH=X[&U8'[[E8_09/%+]P99Y#=R4[D+0VH4&7P'KSW^>CSF>F^
MVJ>K260'.(+?H_YAMG=&OQ)<Y$=.N>E"+O$*=>!M#+_P9EP++O=(N'<Q)DD5
MW5=%]=!5#1S_=2EG> OON-3I C,T$0$E(0[)[KB,N(RN.4V(4@*S,AJ$&)HR
M?FF0\R_X:?!R8O*#$R')$1II M,'> =Z [C@ID^8N,4W%,.01SY"SNC"F$?K
MQHV[ U-&\ZQ%<ZO5#48FFIGM^N[&=;0+0IG>S\P7-/&]\\">#H07O@/\),&4
MVYOO ZCO_0+LR!;=[B4)[;Q(9^"V5W@SK@67>W^:&!A>P#O.DR75]T3"K<@'
MJE^15 H54&('C 'OO8,.WF]ZR6".%R0F)M:LIPQ1(+Q_M$'X;8.=*F6J^UNB
MM-4>=/>0->B^K_O^^*4@O'>T0?@=X?.20)U+T-PKQJ#Y(<W7KRY!2\9#W&#\
MZ3D-B3VDG6[M(+IWE$'TO&J?8KJT0PG ,$H>,L[@%MSP,WCUSC>RTXB@*Z*C
MK 97!1=\IR1 =O\H@^Q[CT[M"*?PHJEW>*^Y;7^B#R8[H8A!\@"-B2)8!A'8
M[A]GL-W&U!7<'-3"]7O).K"OW\5C"J3W#S=(_RWI-_?6P7[ON(/]-J8A"Q%4
M^R!^X<0?84X%#-GK(5GP.WOIG)F#0IW@KY0J:GNVFWH>YEGRD#3X;F/:3D0S
M-7+@Q+5@%#Q']1(V*+^O/%CN(U^PW#UN2_E":=MO@(:! -6]A RJ/WS:="W3
M18I7:-(!U;V"O ;[G5/IY4G_?Z>?"W_Z.?V>Y8&9"%>GS]NU2,?L]#]02P,$
M%     @ #X1&4!&71E@3 P  G@D  !8   !B:6EB+3(P,3DQ,C,Q>&5X,C,N
M:'1MU59M;^(X$/[<_HI93G>ZE1KR!B70'-)"DAZZEB*:574?33(A5H,=V::4
M^_5G)U!UNZN]O96Z+Q\(GA?/\\QX/$GX)KJ9IG\O8BC5IH+%^\G5; H=R[;O
M_*EM1VD$?Z;75]#K.BZD@C!)%>6,5+8=SSO0*96J1[:]V^VZ.[_+Q=I.E[8)
MU;,KSB5V<Y5WQJ>A48U/3\(22:[_3\(WE@41S[8;9 HR@41A#EM)V1KN<I3W
MX()E/7E.>;T7=%TJ\!S/@3LN[ND#.7HHJBH<QX\E75$5VJVHP>P#6KCB^7X<
MYO0!I-I7^$>GX$Q9!=G0:C]*Z08ES'$'2[XA[**Q2?H/CERG5A>&O=XY#@DP
MLM%[93(81GXP[ 7G2=!/^I-WPY[OG<=1%,2#Q#GO=\:A3?2OV75\')$KRM J
MT>0R<CWGUX_A0J/Y%%'*2A14?6+'2F@XHSZB/L-N;/_)0N&CLDA%UVS4U/E_
MT$IT5]SK@'#)54DSF'!^?R9UIUA2TRU>1FK$70N]XE6N0Q].#CS_PRP^1[@F
M>:Z;Q5IQI?AFY'OUXY-.\;I5/,LJTWV&XO72:J!RS+@@YH*,MBQ'85AKC.G-
M_#:>IW"3P&P>Q8M8/[2XC"]GMVF\C*/CO7LWG=Z\GZ>S^24DL^7U5U<C^##W
M"HM7/-#.^ Y!=R:N]I!Q)LV%5AQ4B4"9KD=]* EHN\!".[+,F!J/):ZI5 >'
M6Z6G@!D($K24<+&!6RN W^=<=L'W?<MS@\%P>-:NG;[7[[5KUPM\_Z!W^UZO
M?WY8]YS '0!A>2L.'-?WWP(O8$+Y&AG,6-8U(M\*S4TS59 WDRC!E=@2L0<=
MJ1DY BM-4D^G0VH%981EE%2Z@D^L#9 Q8E%@IN@#,I32Q*>F^?34- 52@E?
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M_VZ_<7I.+=BM5B2>D%NEQY*S(2]GAIQ;,--PGDH#7X89*"Q U82DRIF4@QS
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M69!V"]/7#=.#38-I?\ZFW[\[;M0_G-H<B'D^A0%)AZ& XH[=]0;?(]1P#RV
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MZE:LC?0ZT!B<RH@4<"$5L>9>O,A!6<[8J8A'2HZ *&K,A_GK(SJ/PA E4DT
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M==:87S&L>P2RP$(V^YYI]4N11^.!#_WJZM6TX#XZ>]UR7\.=_1=02P,$%
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M-#M *6_9/F5[I,_I83=XLY$<=\!8G XBJ"PM[",:1-7.(F,8%01$-_P<8O6
M<,DRQ@4*YA1'39XA8U^@_3M635;;]D(!P$UG'40IAQ&[TP)$IRV6ZF;I=1N0
MME@?SQ<(8=F71(\3>'=L\7H<P#WWSZJ:,<+L">@"_*)WA@RFEV[T,%G ')[B
MJMO*H?8<1J_'4<;81XJ;.'6]'<XD1C6Z&X-9>UJ==UIPH%"=?7EQUF<+]?A
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M;#>Q9OS>MNKGDGL9?&*FZT&3^UKE5DT-5/DB)=V+9/V"0CXS>"VCX2F$MU/
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M<;07M*9%I1\U;-<1BPB>^]"@PU@0-3B.UU0^H4?4(YO0AEF3:DGAB0G^=,R
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M-\BLG7[14HC@;ZM"'49KB&CSJ7L+T>K^>/05=BU6T@/JXTFNA:W12(']C4B
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M[#+5^1T&!6;R[XD@AQL:Q][7@^@&SJQ*GG"=U2?7;^=A9ZT?&M2BE61Y009
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MMU9GS(Q%VQK3/F2IUS7S&E,:;4?1=+L'0A:%7K;ZB B*&^6X!_2I^C++ F0
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MZNI2>N8D1&QK>K[<"PDY/Q^_PZT?KU^_7\B?WQQ$LY)Z2/Z)$#J1&=9C$_%
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M9&D=ZL+L)ZO K:9YSU_&D/P=*!:,L"C4..+4>++OLJ%<P_%IS/8),DORX>X
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MU_)S4;L1%A&)JCV)UV%(*U5"S!2 T'+'>=BGK-("'@E:KQ"R9.HROK\7MOG
M]:;9/I6A9-A0+K2"H6<V=5YHVJUT=2+0;EXQGAG]S#X\KD;+9W$>=UN+N_J/
M@5<=W.W!D,N:QVS=8')V@"8FP =V3<##^DV3@WO__AWM,$A]EJU>"NPN=5R"
MN8\[1"E<_RP &82C/)=!]<K1SFVZ+SWZD!BR5KO/&(_X\M2G?7ON"687P[.]
MVQL[._6]9/:.NS]%UJ29IKZ,HB0T^?6K^Y% %(UPE)IPPCD]@98(8%XX0M@"
M]98>%+YI>1*0MN6Q[T2S.A#V6_;7=36PXN60\+X"!Q^>4/*N1X(Y=>UG0A%[
M.]ST"8.%<3T]V.>V]>P$P3D2&(#E"+2D[2-4^#_^1-;^00Z@)FY/$N#AK*3$
M>IQZ9"A&!!!"ITJH0=PH07"!Q)IIISY$P!Y.F+>>8[R(GN\LN#:L7(=Q;N%S
M/N0NN#'2$%3P,.'\>= :[TS2 D:;T1].DBI/I85B4"Q"Z.NXL/HZ+PY(D'=V
MN'$D8O471\]-EEA^S8A3[)B *U[YXA.)VC5[-%SB/F^+6D>;M\^Q[HC$_%-L
MGE_;:>$3J]TF/5*6N$2[V%8Y\VP9&6+HU81ULP^TXT$]HF@KLJT*\CHY48(_
MU0&[P#A20_Z-!2@2%J#^MGE@_]'F&2?PG160A*$/XB\7I&#F3WE&B< E_-39
M_7-!(M#7@H-N/B<"Q7[0NLFD\%[XOF<[Y]DL$5A_.+YU=)KB3#BWP5O@AZ84
MX*?<CXA AU#?9?ES!SCINHI-4AHN]IY<1>Y-KD.W7Q*!JYM+R*H20B8:EH-"
MPTJ\GY\G$8$N(@ *5^^=WU<H(5">UAU6')/J7(;_'G*"5 QOK2)=D#P7*41@
M>394^H@D=D>:*Z8V#P0&+HX;<<6GB)IE(K OBR;5 7 ZG<2'UM')_VR__'=3
MG3EQ?O\6GB0U[$-0%VQ'I^JPZ@*-GVM8<)3_A<AX8<H&H3/DP;2%'E7@E*X#
MV=<^0;*E=I+U<72XEZ/G$#0"QPXF KS(GX$P^<Z%1_<=Q <"*L/O]@39*5ZO
MT%\L:P;E#PGA0K AW2BZY-.]!N3%:Z_6&A]"*D?[X^\S\ EI1_Z9CQH7TI](
MMVS%-1*!FW[PA7;2.B=#26O&P(EE)T2%DQ#W:QD1P'T7VNL LYP1 3><'\D3
M+J0P5SY2]CEE#&K)#!(3'T?BJ+N'!P(SF._<_5!N(/TAX,(43. [6)J'X$QR
M22GT&(%_TCK:-2<S$>I6WEY<O=%H77]P26NSS"33HKNA] >G[N/.4L E0IH4
M[(M1[2+PG_]I8!6<% D=X-8[_C+S,P7BHTK?OE)=K8DSJ>W-BV,0G4F13UJ;
MSM<:$.D\/\QSP!<B%Z*J[W8%=F]M2O8%#4"Z$;+6UD.ELS?=W1FR5>^V='-<
M?_\\[5=$>3D9*/T&<,E8E/,,0I(7O'_+!;H^\6Z<$I:I1'P:><SI*.2Z^)OZ
M"C1=X89+*!O3$T@,N(XZNIUY]FJQ,\=T=<O[B#'D+\4>WAN/^ !.S8.H7P&4
M+]20CY )0W5';XIO,E614 B.)S\TY5E\Z6QQ-B$Y5S@50 J*4)++*4D:(!5!
M1@2:P_#;FYB6"Z:+<@* 2\0\F^,+H]J\T\CWY/=+U&>Q--6@N&M? D1==@36
M!/4#A?#7(5W@,UJ<-WSF>^]?[Q?V*89R<<O&\HVSI:-6A]*69%*O=Z^.2P\7
M_;:M/Q7=_44$QL5_0KN$&M8Z5(>/(C$75\F/Z5<?U!LM)2WQMLAT'=)AZ *!
MZ]2@MK#.Q'J.8(;[[IOT898](9H#@=7;LJ*N'QOSR8M>H!DJ2TJ%TZ(G<_"[
MUP:EG)LR[?A.;(?/&CPR1[]_\F*\:SA\[((YRO]]%C;&;5G7Y^Y/7ED#H<\,
MG#62ZO^ZITM.P>)+QGG$'8WR0K+\.;.PQL6CL]J%O]R6FKOI=ZRW -#ZTRS4
MJ*O;%N8!TDA<V3GUU)/G?O,X;HM48QEN/M/W;0O4PFRU^!^%O&I24^) 9(36
M3;.+E'89JSD3"CN!E&.EI]>ZVRZ:DGM+F44:=,J9Z\/?W^5/=[D.807E[.[4
MK\#W73#W]@E7ODGU/7(@(5>FG_C^)-:@MT=NAI^TW=D_NQW>T>D!,[BI&K&M
MV.<7-[WQ:V9H>BAZZ5WIPSR6!Q6<2+($[J:W(K%\5D[VY2]H'X,6 &I0QM=+
M;;MHH1JAKBI?!V7Z$&;FKFHR]YGBM(2,/G.F/6]%-&??[ES[1YSXN13.9>%B
MY$FM$6D7O8C*M#E_TUDDO'958E]/P-Y3++>4@DJDML#K]?*8K19G[E;]^52]
M5JKF$):N6@-KNU(RRPX^OH.[1 1H0Q5ED94B"+8-;%F6BFZN6G"E\-%O7WH,
M^15#3?++\<=9.%7N'KEXI ='S?0FGY_R;-(^)=T#249V>5X:3!G%HTR>-4_F
M:F@'N.%YSX5)E]WUMCV5?-]/N)#;S[A-/$_/'^(8;KX*WW+"N+A8F!K9HEBS
M+_Q4!L==;XVB%,/2"97AR3D7-T7[YBX7R=%;R>Y.8IL/;N_5MXYT;L46^L;T
M+(Z]\O;N-Q)-H0&Q?@/=>X!\!W>"108+]5QS?_@%RYH>IFJ4(G9.8<&#/\D>
M)'L[%D>FQQZ9W)7B7:3:]/T<P(D5=FF<O! -)^'YH],@/91Q-Y:*GMIVL6+^
MK?7.M%"Z?:#C]<'KF]SQC3)(Y[!G.HQGPSCH+&QO=YX._G.@DI24Y0@B91OP
M/4@^DXV%$A'@W%"9%/!(7YU3?^7WX][3H;4'LE?[9R8L20QN-2[+_,.B)9D(
M;"^'YBZ@$@ARN" 9N<5=5MAZ6M?@YM/T[$:9KU'67/WR'1O0*#(>8=:3H:WY
M<P-KO.?(CH><??0=K%A"Q4/KWJL63EI!-5%^C<\IG+;[E_/18!J\'0Y2@>?'
M)N4PE0__H*/=]GQ_GLV2?B/4_VZF<-D?W0Y1AF=$P$6(XV&@"<8KQG.[P\<G
M3#"F9E>J.D-(8IG\AVH<@,VDKC?PR+8_T.*HN6>QVJC@7M4"WM1=#FK0%!\4
MC:F>EW93:\\'5W@&EVSG[RFLH74D<GOYM'-58LNNNQ,!"0;K6?:H9>!ZK9-@
M+UC]:5JS[ND0NEUTK%6\VLI=0WNY);S81?PM8Q?(F69AV>^5[M\7>Z\,:*F/
M)H@ I&&\TJ6NM3%A8V1))<%5_,:ZR'6TM"2/<)0N-5)Y']$M]TNG]UY3TY@6
M8]G5E"UNSPQXNY&JTR7+AW7O>DQI0C,B/S_;\_44*>2CITZ=<BW8F'U[.$4$
MZ!PN7\'4SLY5/1W=28%WPO?,I#?O:,S-=]EQF6Q^M@"UU;3LQ\1KA:^_QB0Y
MQ2TO1ZA=*B$YR*O-Y=[HX_J]H?A'P]5"4HTG&1?O,V^E9:8^*?4V$JYQ7H@J
MT0J:*S[GQT,_M6?1:&ES%;()7!NOQU]2IRYEVOAU5JKL=^,B(5QBT^);8[!_
MRHMR,NB8G'GT.;/X(/@-YWH8-%[DHE$I9";W$+402 1LEYI[-_!UV^&PB?GD
M(<;65H192\'&1I"L9TE:<5907MVW+=_!0>,^<5"Z\0_COQUO1UA$=CLPZAD*
M6Z+1&:I\\DG&LB&YR=CCJ9'C*L."XJMX-XK2&[24;PUZ.U"_YM$PAB,CY7S+
M[59(E4W?JDV?C-T]ENM_!KAL9-6OO,D38"'C1;ZGDOXZ%!C%4PZ_UX$7A(4\
MLS,<\YZGO]<Q?K8#QN5S>ZFN!@[]BV&VEY G5?]^0W:$'&=.+0#&PB5")2;P
MRD7?O2@OUB-ZQ684NE0@ O%B]U\L,EW7P&S"A$GUCC+T'R+P#A$/WKL*)RC:
M_E;,>73]@?%HUQW]9MB>87X/KX&F4$KL0V55B=)B7-TZXM<NX<Y,9\G<ORGH
M,5(;1[W :+@8WYG,CK;^/'$ F^(=3'4=',X_Z!/N<+8(],E+:3Z;? _M<"PW
MJ):M7-C)RX6IA",R1_,%&.GN<Q;S=(.;L(B_7:*9;MBN-7S]H?)IV2:,1!R7
M\62E>#.<>17.Q3AGCOY\E"S%I,'YQ=,"=:9;%:R= O;^O1/M>O^F(2*@"V:"
M+]PF OC'[2=Q?K>OTM-J!+XL;90FT.#120I) 6!!NJ8GGN;F)EB7$43MM4%+
M5)U77$G^A(0#=\J^^M?[W'?9C+?DK7S#?UH?; Q(K5^?FJD?4S%S;4S3^/W[
MNQ*]ECQ_,B[*D;],8EB!RN+CH_R!WZ',./>@O9,%0N:BH$^5G.RUB459RF:7
MV GCHM!+_47)U604P4>;#R5QY$O\7FS*XRGOG9F*LLV'O#"2OR&EO7Q6B>8"
MK[3$G&=Y3M\,OOO">PEYUG*J/H:^WSV9-SOJ4;)!!) ZO=,&!2HIU/2FZ6[=
M^N O9_L[)'Q%NX1*D+R&G\?)_=5C$N5">UUP!M1:SSE)=,/PKM4I#W-;2=IW
M7Q'%$A!_=*!]EB"!?*/S[?_V[YP0<U@V^#,\5I8D->NZ&QK%\FQAQG"&CPKO
M,7EO#13')!V*4A22-'W.DNT,L9O' </A:FY[QB"T$9;Q';U7>2_7P<K:54EN
MT>!]HV5.QU?>5C;K@7"%.)N$M8J]/JO3((1@-Z_^[7G*/D-,8LO!OL[E"X2.
MIAV>$7NOT6%^>_KJ.[9K!L/>(&>+@%:G0__?OR@6HUE\7@V<N,2@W%+C"'*C
M%CM"G _<AF+GW<MO-]06<E)4"T3\^D&K-_#*^TZH/"9URF4)&EGLI8K>W^3Z
MTBDVD9R;Z0O5$KYL3_[*1)CW\E+KD.5P/2,==EM9FK]*9UW-U?.]:U[8_0CP
M&^1/^;>6M@60F>&RW?H*ZXL_^$:R_-56=>8*R^(=\<\9H\,(9,/DQ&06=H@"
M^YTC@=<I&2U-_C-*K7>D&<81:K\'C9I>U7;OYK--[F[A!=6'O%:,H I\(;AE
M] < '7\/AQRLVP0+1>(-EU[8>0BASSY6L0E6B26_SI!"Z-V'Z(QCX&6'I>='
M-9=WBU%W_X G^X^RKPHQ[@;/[]5J"QV_QWUWQ^8N43SG,WKM&OSTZL3P*O_M
M-1\YE1&%]^UF9*!%LBO&4LHHQ]2X ]S,TNS'"AGZJVF+>+N'B@5:2SPW"JDU
M&Y,)B"_"1[R_<2[G3#A45_:GH:7>5+2&==.!B!67>S,T*B!6C%TX+0L4I6"6
M@G(/U<8]?Q\JM_=;0RA^*S8_S^E+^G-CI7C^ @.M.@'F=P # +0.J78L>,.F
M<+Q^FM877S;'WRZ?,FDJ#'*YO.G-M#L.:1PUG2LQU^> KE)O+>ISF)'];R8U
M<>J_ %!+ P04    "  /A$90%#?.+6EX   L@0  $@   &)I;W-I;6EL87)S
M<F5V+FIP9^R\>SQ4[=\O/A)R/A-B*D4EE!R*,7-+"&EN%$5,)SE,FH0,QDSE
M?)Q;DF_$)#D?)CE%FHEQN#M(SD7,J7+.6A56+#-[[N>WG[U_^WD]O]=K__;>
M?^[QNOY8,]>ZUOI\/M?G?6 6X4<A!Z'DXNCLB! 30R#$1#\(X03"7G3TO_?Z
M9Y'_W37$A*\0REO$S,1LQ<5V(C8IBXDKBPF[$$C1?4K\/Q,0__4EMDE\LX2D
MU!9I&5G1A"8EQ"8Q<?%-F\4E)#9O%GT:)_H<L5E90F7'03M)5?<+4CO#U,QN
M9Q=OT3]:WZ'N,0#L.G3QQAUI&0W-K5K:NPT,]^S=9VYA:77XB+7],0='I^/.
M+IZG3GMYGSGK<^ERP)7 H."0\(C(FU'$Z)CXA,2DY)34M+LY]W+OY_WK0?[C
MDB>E9>45E57/&AJ;FEN>M[9ULKJZ>WK_?OUF<&AX9'3LXZ=Q+H__Y>NWZ9G9
M.?#'SU_+*ZO0[[5_XA)#B/^WT/_3N)1%<6W:O%E\L]0_<8EMBOIG@O)FB1T'
M)57LW*4NA*GN-+N]1>UH=G%]A[3^(0] _>*- 1F-7>;<W> _H?U;9/]S@=WY
M7XKLOP7VW^,:1\B)BXF*)ZZ,P" $@CV/TQ#_I\<7.)9'A8ZBE/F*6G&WE[&0
M \J89ZHB1%QQLOKT91CSU!R_B%LXV/\5^^4E^Z/@_;/?9K]#]U#VN;W0^9FS
M$BU$W+E+].1)=3(525Y0+9V$P)OJSJ*W,H' !,IE>BI3F8(7(O1\<%.0 B9%
M8#F BN2:;H*W#D:RY2>)XIWC23D5\WDW\V_6!N#QUW_.#0;+1S[VG1,B2J8.
M TW,3%B+QY;TF\1>PO/ZY>8%6JTOFX]_>=X8CQLT-4^M>^0<KMI'4.?WJ3BO
M-V>K8=ZXD<KKR+U)BO+D_K](!Z$F'CV1IH0))"1;4:3;#X**3@ [?OGW,EUL
M7J  8.+ALV7X*4U0/7$TT>+[8_0VHF'7FD&Y5)YA<KL[-W/WN/PE%K4&PI]!
M++.3:(W,#DH&V70,5@=8W8O\4,].@0Z0G&[1YVKW >4<Q96U5>1));0;\?O%
MSQEF,9^I=HSEH4T 0L8O4Q4H]L2ST>\6;EBG^VMK4W]WE(9@0T%F$I-32=MB
MT00HM%83%7G3\2A-_A;*57/&2Q#;V9\61IQP>;'QE\  M@6D4NI^+26U>=^R
M,%4CYG2VO4S.:,*IATSM'PKMR>7X$F3F\@U3G@@F&D9#&RDUE$#33P4=N 83
M*@\K#RFZCUZ#;6NH25YMH5G-*RU6/B:Y0 ,GCX6]O2:?/5S+:2XXG3]_# HN
MG[?.W?CBWH^NKYPS,$\;ME,ACB4+$1?BD,=&+2K+H#R>L1.+^8G2;)H,*S]R
M?11D^0.R80D1S=2,=G50GZ?QP*#A&CL$W $L9<&'JD/\E5\.A];2=PRTVV\D
MU[A6H:FA57Z(6)."=1^2Q"AYYRQ;+H*J_;9ROJU)D/DX>&TR.;$=%P5\F^[V
MWPE8E'=-BG=(@SZZ$@)M13T\18&^@ HM)>YN/\4P8 "CQ>4AUX.I>B7G6] 7
M0-H*DP$= F.P=\;+68$C[7X@LI.AR=RXK]'?E22+RRHZT@[J0Y=XFJR)Y.<?
MA C>7\,,%3L*EY;J;\9L$2(2\LVA0U7X*71S4Q LSTN7Q9I ."%B<R]D [3P
MK9+0IL$-Q' ?QH=K)%5>^@.2 X#C3-7SW[)3_+= ]EQ:O%>,H!",]P!*5[NP
MLE#,^E&@*)MG1),F4DXUQ6(T>\/"'D-45Z!/4,SU93YE[((5/Y -2';0#OXB
MSKV]I8"3E](>Q9.W<FYI:8IU(T*KW,!TLOJ<I77FNUO^9^T(I<3F[P*MB$\[
MBERKB1=R!>]^I"%^RJNN?-TH;'<KF_/)2T+9\2FJM:7-F95!S?ZZD 5(/3/"
MV [%=FD7?DLO(?9S':D7.+Z9KCS:+=-EO/3"6*]@4WR7GFRC=WW[L,6\F]7I
M0=-(&?IZ'/F-,T%W&C;>M*+/]1OK*71<,Y6$UO"F"O#A9V.D8*Y-+:&[Y0#D
M-]0954\<X@H1:219(6++6(IC(>\!*>J"9KSQK[/M3G&7RK$_,$E"!.<OS!:4
M*O<,R93#5B9>LFL!%A@R@_#.\QN%F$!HL8FYB;C3#;N@)P>M2Q9R)LV65C(:
M7[AN6'[_0=$-N>D5RJ-N)J%!8(!*15F%\8QQDV1E2H<M2A; <:>SR-L@FUZ&
M?O,0*@ @\SD+W@2.$)'8X%0\DX?4(F/@@$.?()>?'7E,^:7][TM (<(7&&8H
M,X 313)Y+&N#PG*#^,V:5G\^DAK3VPQU<P@I:+D15'399_R4+B"(#ZOQ(5(%
M&MCX=AQ0<@9X-R[1&-76 2*3!;N#R.JCOWQ]C:0O#9\LH5S2>!!6YJQ7'AP;
M=G[^!DD!.?%SY4+!L:&F 9X0H6FOT,HS%8,"6=8![ XA(L,+;0 F3G?['>K1
M;NF<M.\H4GT)Z+:DMI_ETE.]BL3 &$BQ.T8RMX(8WK7:)B\H*)N[$7+0XNE+
MP'OE#X#:N70'I\K8@L__+# &Z-T32UO=>)F*QP?,EY+1DL!W*A\G&4S>/$K:
M 52_TE,O;*0DH15ISD,&H[L&S'4J/;!:\X*]X)]%-GTWCF\'F'=HP EZ$E(B
M$'"82JP-\FIAB$%4@-63'\J.)V^!U2'/<'HP<DN[#NC4,:4VT$Z( MB=,1*K
M&18%'\G[\-:]J2CWJLE&*^N^W-K^9)0%]_A2Y+\BE11>\*5@-0(G4 0/B3^(
M/SM4YS&JD=4TJ1FTQ2!L5$YTXCD^O._CG8+>2^E\5)_.LVQ%WEIVQ<:O%?9F
M10@1&I#_V^/0 ZFD9=]^=:)^=Y%VUNM(6W'OK-Z1Z8UFYI6W1G0]5B4DF#[>
M $66DXZ.6%"5Y@0RH. !U_C:!!>3L@CK@B;(Y"*3ET C6A<JK2)J=J_>]U<!
M3=(!MCMXDEX.E?U@LSK?A+H+WJ-CAIF<@IA#L_Z[/J!L06;OE-8'LKY]6"#H
M>Z(16+ICH0B=6&BDCQORJ(L[.%L732V,S6+9LI^)OEVB\I+\N*$NTR>*") +
MK&616_C%^DK+A>"ZCLQ2(:)C+UIBUIK>75!H/>TR$-I.8BM%(F7P:&W('@@\
M"E5S3%5@!ZBRC!3R MS,U-8' L:H[5&F"8P=02N:9-E!^&R<R=T(-8(B)!CB
M;=L;&'E9;!G9T3].=83>!JP[S*T9)J+L2V9Q8J0XY.U14[5@M % 26V:=7I%
M2Z1IT7>/MFOQ,?*BC<38,GSU&_270#L.Z37TW>"NK9YQF*'E6HW7?2'"&MZ_
MP;28H,C >F#+HB>P_@HC@=("V1R-RO4_B(H]19)0(0^;IBWYH#2(K 9$9351
MQ2#>V!GH-/ 3-PB',%3!TJ(2;C_DV,C6#$8;M0]:+$J.QF%P.(5@AL%:%%=J
M83D*6#H.#:.\01U?B,KKIS),]*S U3337\92K#WY Y KQS1!<H+5II&(_!A1
MJ,)FL14CHFOV7S,<IE]HO?^5'NGGXJS-%=@]$RF.\[/^)I!K,6G[1C'#"BK@
M.R4QD"0YW"V:]%4N%">Z_36GVR344TA2G"\[*;$?/AO IZ>H^,(' ?(#B]7T
MKPP@=D9I?DT&VG$5A>,%#-]"WQ]F7J-]ZG7\8-S4Y]U%MGCZ/,<'M$RL(*+Y
MG.F>'> AEC=:!EA-AOWX-D+$5M@8NPG392H%Q7:2E4%" GR:IZ@*45DQ4<F-
M0H0BD=[95AU"".7YR=,7YBDMA@N]W DA CDNTC7* 4U/H=!BTM&Q=F=>J2B7
M=2@):])NH)"=13:8*=* X@G<2I(ZG[J5J-KII;FVE-JNR9F,/0>>+ @LP\L:
MW!NSUFB5+.#JJ8H2$3'+5&C<D#T-N8,>IG>8JK6FY-T==<0Q3N\KYFV*_"]C
MUTZ:QB]:LK95NKFN%7<TD:L.K#RH"IX%<EY9L^/;@ZLGB>5=:YHIOX)U/%I!
M9,(2LF,@O*T%5BG@U H1J6AKO&5,$K7, 2P_NO&H),X/K4#284#5W"4-P:!
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MJ!"/P%A@R*MQB&2H4%OZF?A^Z,SP]A$X7"K%HM;K _$A%!8QJ>JV9O6*IA@
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M.[SD=KF'^;1'6-FTS+]FGK?]=:=:O?K/2@D+K9]VY$$AHO.02&.N24Z0;U#
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M3V6&5DU=N"*3.!.T%WMA4""#49" ,0/QEUNI^,2752M7!E?K^9!]E/(O\TW
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M9!O;%3<AS0SB)341?X(9W&N$M2;>@X"M+&XKCM8" RRGDZ=KIE=D@3[Z^(H
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M^?CODK:^=FT+^E9PL:< '[,B>%%/<%[7^9#U8Q]PP'_ ,6>0*S#=_H;\XY*
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M+M#WNCR]OR)Y/AP_WV<[WVYR!L#Q/FH0!2H[&3WAJ0-V:66^!HX0V;H<8S#
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MJ%6M>G_%NV!*SKOQ<7PZ]8*R4_J4N? ;C&*.K+&YB]B9T](_N4W+C]@G75$
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M#VS>((HUQVYNU@8HOT7L]G"HODB@'J7KB%E$S!W!7WWU0^D@-PMWG2R]!&5
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M4$V0:3%-R$A*'S2,6D.%&SO]KEFM,/^9^Z01=07HO$N_XA)43)!#X;L:R^J
MRF$]BU%3.(,OP- _]Z<ZK#XR/OO4."ELXYM.PWG':$S50^HZ9S=UC%(^022
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MZ%KC^: &V[4M!CMGJI)752W51L+\+P!TGW61+CY'HZ+I&F[["C.K<9>D3P+
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M@V52,6G=A.Q4O 6:>66!55M13IWA?+5VJ\Y6C!W:S)\N/3LP."+>7S,:VBI
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M5/^FK]L2(]\-W;>-XQ0G+?Y(*DM9UQ+87Q$A6SBW0=HX:HSYG6?Q2IX;Y(%
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M83E?NDC\MMCC(%\83C6#Y0=\VJ6)B(BRN2LKP_$ML\/':OW*\ND\<?23YP6
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MVG/HGV]S",">.Z\GV2C.*Y;T'F/\59S6/+0N<5H4JZAXS&Z>GO +4)^1!2X
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M ))<=P%@TUTNINU&1B[R F^-C)^D]B06%.9SICD+K9AZ_1F\X7M?H!WTT.5
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MVL-WQ+<--YZK*[C65/B)L6M]MF>-LB59GA&@0'H&*R(%(@&L5;Q5PMQOKO>
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M;"[&IQM8.W6O_"2OT]P&C\$TU0N&0,(Z7_T_]9JPHI:4O<*SI [C4"K[SN.
M#.JCDB;J/Q!NLXF-$-<8HH!EV:>IG0RJ)[^?_^:7?71$4 ]@(5T"T>'X4$&8
M]6H0%E#L#D-@.W"NQ7!H&N93!HD? 0_ME$2*[=F:V%'L8%L],^8^R*C>"7?)
MP$?%2\9TM)"..Q\__]3G29N4+X+5BV[J.V$8D/];\ [=LHX0[#-%?X5L#\@%
M \MW/QR,SJ8) 4F&\H^FM%[&D0\O56V(SJ2:;84QLYJ4X]?BO_ T[F,XWK(
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MRE[U&&""T2U0@L.R%6.RG>3T?U-&M:5>XDB9L+->'KAI9W(+-/]O/U+/V'B
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M9O#ZA07X/Y>?/B91%?_O" HX+Y@WE@<D9H#LV<\G^::139<O!*(%LM4&#Y4
M !>&2:V:RGUR57W]+L:NSA)B@3__M<#4,G.;\K#54#>8>&*,R'=LS*&;!FVV
ML^;E:D#=I_N>SC1##AM</]HFMA-OR9UJ<8/2WWJ5+Q2+\E_HH'1S;P@1@2,%
MA1E=>G^*E_O#G_ICLSU*/:.1H]&?Q-!KK0KI:";?@/G/]VG"7=#$$]9)<:_^
M?A.,"A6<10&NG^>GFIPG-H"7UH\"YN5>H-L<@$)E=S23&Y1\]C$7LL#>F9UC
M4LWIZZ[;C:-$JKCL0_:CC/CDFA27K'TW/=<LK,2DF@H>]8^O.N@Q _"U\ @_
M&KO=C654E@!?L)M-.==I]735[/EOXT= ,AUBTJ-NIX$?NY^BU+7&[9W9Y3>4
M)]G-*YIKO\6U<2<X?YD--/8,_.]4K_TGU9:UTMSA069LQ\JZF)Y49TH89ZI2
M )+_'6H?'A^H5H74DF"PZXX[+T"=U*LG2EYY-BX4DK%\B31/"_O[*&O\K'')
M3:VVK*PF\>)BK=-1 B?1S706P]C99X2N<@C6/D R[?(S>J?K0QZN0Y]%SK=0
MS_([IAML2N:1[HW7@4'+%9[TK=C?TSE<]5TL\^Z&[@$$5<K^8MADX(9CXQ8V
MOEQW*KP/_B?=WU<//_\0E3/M=N 1$X,P2Z"V5@7/]&,9\W*?G9X=[$32O3$1
M7MTQ):#P<)K$6:X=.R[]R:,55Y$>J6T%3)-C#CEG\6>W9+[!QK^)\O%!DM(8
MV_MZ7(IMJ>05>E)[-M+]3'\S"FMB@RY;4^4VZAG/RYHF,M,0%IQCF02.!N!;
M;M(F7%[VW /\^(S)JKKKJS7*D5)_ON(&4W\J$CS)N3@3?4!Z.(K98-2%$&]_
M1LBBT)H]ZK;1-O%9$E[^=>!L]---[143Q[)NR0,Y]IGS452D!0%$;@'2_/LQ
M*4ZO3+-L*?7! ]H)_@^K^>1!<JCT^(N)<$!B3G6 _D$!&+KA?L3D^-)1.O?W
M;"H L"]7  9;3G+\J:T)5H@(^\7@^"DW[=_"9KRQK<]#)BN]?!Y%$Q)#XDB3
M.N,XP' E2EM_NI+O;O!1-]Z.R.Z/V,K)^F>&PXL<9)#"DQZ[DK.1.=,UN]\(
M8#NA6#:U\CI45?/87 I+/##!7\F#("<:N@\HK=RH#?0"(CO^:@O1K/RV]J4\
M/4-O1[ZP?__R16!_[$G9F5BFUJ(0;99#5MRP 6U*\,K.IWG:++O<]&$5;,-L
MMQ/82&Y8\=OEI59/IZ.-D'PJHRY.YYL")&<([(8>9K1[#?VO[//1Q6+7T?\[
MV:];?8V)/%CE#>F"OUK4OW(U8JR29"^=-9'%%M/(.-S)VL^YE4#1=]+23-XP
MEQA8>U2GUI!?P&MDS2GH%ST><D]H@QXD$*+H=8U;\C4D#.TVV?F>\9!YO0?8
MT\-XWY39)>RE.^S_OP:(#\%:LN9332VK7 U0^"$T;H?E)R@6\$?3FN)MP& /
M "-.T=L7S7,W",WI ZW#R.;B"S;EON3*U[]/'Y=M73DS7MMWW^L)[U)O5]_)
MZ',30LQ:K_^S@CKT(#ST1/B,K&G%W;$B\:N@ZU'2[&5_32DK_$YKXSMJL:X!
MV)>5&[XUV&W4OO@'E[0\B*FJB,Q]XN/F&HV_E6DQ[[C&^9D1IM%!4M[%="'G
MK$EL#WC&Q;T94I\6X61?SG $%>SEK?>;<0V1A-)0RK9A.75Y*8ITEW!Q/C]O
M.1@HO^#EOE;K*,)5L+T9Z;L'<'E;3\'IJN@.]]P0PQ>&EI_"]5=P!N=Z!T1C
MF8^ 1=?\J^YM8G1Q0MI+8U"\3Z3R=KNHY$E+23M2TM]?P\/,1*\*20.=H8-2
M_P=F'P*F=)MQ]V3?]^4-B/:W?<N"3 T;1V[!X_6GIY<R7^$!)-[*XC9);;X!
M/J]12^NA9\VT9.'#?$\NU6*?!4\1?O,LW\$1%/M+#%3Q(??B'&TA@L@OB(^R
M-Q5#[MSSO2CM&%[9Q7U<BA;S SP!P%YP#9*1B?SP0=\06G+^%?E<OX/@[%Q"
M7(:<W0-P=EV%Q!)L$SU<(MFPGC-+:5+0J>\K,YSJ\:@:/UFP.T2;Q6E)2)&H
M4:A*D0#^A?8O+_O;#*\/R &9Y_OEU*)ZC]],:-6J[GR\Z[N[MD0IMSP5F<D?
M>^B20FH/75+:A;4[QX"I]/>5(#+^PAWIVZ8HD:1=P:^GP/=J"DY2W118QHRB
MODWL\3)S,C(WKM9.=+T.*JF949%Q K_]&4?Y0T@H/3.PC?34LHMP%MAFQ)WH
MN8(_POG=Y9F8_5LLXKGX>X!!V&/?U7> .[BW!;E09!+':]U+F8'U;^[,0Q)+
MKI8[4J1'RWRW$6(L*-$M" _DYJ-%&O,X$S$Q\"#ER^F9NA%O"<1)"W'83:.M
MT#S!A/U$>, MJ'(O^%%+<)J'9L)>WX>V0NE<9IM8J^$'M>#T/(\GQ:?:8KS]
M6"VEKZ(Z^<C^:@?+?.'D43-Y>VLE9Z<RF:WSJ-D$^\*=_GXD^]]+%A_?/A!5
M0N&X=B%#E/5XH>8\D>U)>U?#C#;B<LTM]([9)F! 8F+9!9MX22XA &/_>-3[
MB=PAOK?"*N$L3&)LG@U&LD\,2L+MJZH=Y%N]?G&Y<&J<ZXV?N\='2S?QIV*B
M9+6LXOM7 ?:-I^&B?C!,TC3U@*W,4O29Z**8JJ"8S=% K?I@R].[82%@>^M;
MAR?5Z^[!$Y ]?UH9-N*,!E&=$_== 5@.CS&.Q-="]E[]B-*FD^(SNLDI9<P]
M";!2]MN["[LW(XA\V,9-N>;=:\@V(>&N4,#>=5KX0>R5-4U3'%M#I5#DE3O6
M#VH!V,_4_:]%3HI+E7MK.!#(MS9=^HH_=81$J/:])MS<)=U]AUG03.*H80_X
MI:0N\^./0C*T%*>IEMC['^J<KNFZP!\-D62IE[5$$%_9VDC>!07<I_FN'[];
MTP!=Y]XN/'LL@Z=3@T'U(@Z,"24Y]&C>BFK)>A:^SI@ G-\7"ZGVND)+^ S.
M,W>")!SY#H1WNQ>\M4B>R-X2JW:?C2A]=Z5G%H.NCU I9*(:.Z;S]J=7Y!MT
M:?=U$4_>/Z+9],MF\'8*WV<_?B<B\14.=K3WM6923:?$"O66ECCXQ*@6&*4C
M_#[5>EHI=6KLBA3)N7H<UD*Z_X3&HB]Y+.7Y/MEJ<U.K= _V;7P@W$#1IPS4
MP( KNAWK:T^S58Q'4?I<2(%R[X<T(2K\ZGB=\-!R+8-(CGTEA&,+L;7@M6+9
MDV:K7!%?[W0H2Q/DK40N]/T_ -:G^Q#6MT/^#\'[7O(5I >]A1(C\N= ,I\!
MW^<W+&:.V?< VP7.FYKQ1<4,%#;A/2!ZYM>*M=OUNV7-VX2NGQFGP^M,4:UO
MV':MIW-UC5+C1=[^M%%S3=6C__/CY0DKR/0!Q[]678JUA!XT!G]L_IR!T<#M
M@%6R](T?3!Z1<5B+).R2YA?BOQ"M]!T JW8*7.=S/KS'-"^;^A^8FARU>K9:
M<=6;N<VY$3UX"^4-+9*_"_Q)(EN7R H:5OVL31_B XU61M,SS[?DHKS1E!!0
MQ_A'MW7A>B\IUSK[2O_-!<Q=#9HAU ]"1Z-;D#4H>U;&WMJ>-#>'K4; 1#S4
MSQ5'X%&+)VF:)%L202FZ.<8-/WY8.;FQ CZYVO+L;B29OQTUS2X(K#I'!W5>
MI^YC/CXB<2H7K6>.C._RQLU&V<TH:'YK\1YQUW$6ZZB66*.A1P.5=#<-# WP
MX>E%S4DGMZ!OXD/46.!(:4Q3 ;$Z6'RAFDO>CNI2Y;[U1!!+@83NZTGM9X@.
MZ1GG\I(:V+I"E#/O1/>?M:QXT^+GPWF\M'JU ^CXM%_[3DHHI\R#9*F+NFM8
MJ(NH!7_=_ LU6;XK?PGK5R?UT6\H6*).)"2=3LWJU55;FZIN/N4M52T>N- P
MS6C$F'=*W+YT&#CC7<V@\;5L)E]G3&XK>AT ER#3:\(1F44?VA]SHID7 _#=
M?&DW9@B#SN9XE(F74'8?BW46^AA_JE;%A=E]#<6K$\!T%\#<_HL=N=,4K\#?
MP*UK/'11Z)6KR_$(:W'UVYIO2+HC2E.B/SS*2G[P-\OT=J[ $EW<"DG+4U3*
MFN@I1[Z5'<^T[<?"A4>CP,S_E.(;;L'21ZW:'"5:FO43QYG1YFI?$UDUN 4N
ML0.>PIZB@M T$/4N;D6W+$7F8'OC# [24W:Y>T"I64 K@AAP!BMHWU&-V^ID
M$]N]*E%29K@J$"X=1+F8'=KHG<>0^?0;/V_B&!<1,O!8*CI+^?Q3D/ZN/E7,
MQV\F:5^((S=S\,MD%1HJ]GFUQP7ST]SU>](SGH/Q$IB27#J^/"^KL$:$E ?+
MGUHNG*B<P[==N4';Q?RQIB#1Q=;% &[X%891S)KQ7-(Z<P2?D!6W=>*#[&8_
MER9;]?U+.'+%;JI6+21_SA +%=)\VRC)GJYK:-RQ$K1,CTHKPF7'5G:??*G@
MPJ3U%+NX5>*,DKF,]YS3#_BU&5O&JK1)O4"NU("3:7SE_4+@KO**_9!/PAE3
M6NX<Q%,IN$>A(KA_6H1!:WKLN^HA@'3U:V61@T$5Z8I/2&-(/S/SD.&<Z[[[
MSE_@7(P\RNWM8)"+/1'W'5KM]_O$?8\2A1NQW^B>]$#_LYJD+#UK-G3.$H=@
MPI7I'5T0DW].:4R^#!EV:H<S='_I'H Q7K*OEY >8RH*OYWDXW/@N++C8"#Z
M=RUCYRHAU"M!KYIM)-T.GJ&NE,K2$8?31V8%RZA:F=]?T)@Z#RUIPEY7=)*I
M;$WN7M%&G#FN=+ELD>*M:09BG+)NT.,UG2I/ T&\8T?.A79W-*ABF=$CV%IY
MW723Q"/KBXMET\>$IUSLT3F.?T6F[P%J,,]O=RP]!QI@'_O!BR5UR:JII,MR
M>!+*7(G"-V;#B A9O"H6A:0:U $YNO,C"_GTH W^;WR1"ND%OG@OJ2[AG)H5
M,SPHSJJ#.L[#?$.DP8(L0[34N196@%B"L?&XMLY$3@3@<RN/XNY2*^9X?9;@
M6 8/33)_ZFLMD0KMSS?I*"B"N?,>\*QT#@9O6<BI_,JN-B47UHSI)GT!].?=
MT;RN,U48<'^=SNAB8AK'2O[JXE6@$0V2\ *("(G(23R6=A?A\KE9G_JX\&+_
M*X/IW2/Q"UCQ VA!2<]+T+ 3,=,7\7UB-@1WGU%?'E K?WY,[M/G^]R+^T04
M^EWH_ &U2C_)'E!;0RWVE^ID2%U\R@O(&J$QP<FS,\RW]!?Y\MKKK_:8>J?:
M?\&6U&I/C9V4Y4_XXM^W3/%EA5 HAPMK)U_BR6*_APP.N2D*YXP3YVZ8[OF-
M;CG\1MC1W&[E9$7MS9SX><=:Z#6FKD:Q4ERS'.,^"$?SK? #;JWU[W 1M,U(
M7&U%?HF)O-8Z!GMSBNC7MSNF[3'0!][ .1OSN9S+ %6KY2VO&F#K?--%.-KK
M8T$GGM<2@3@..EO!GUNPNB9(L\\7'R3^1QSJ@9V.D]?Q0Q"!U.T$W@$))^#?
M"\25E%SCM%<Q4J3GPNTV]NSXR9)4T7Z<3#$HUJ1Z>+'-ROL-]C$0;9EO(GRK
MG6_-UV#@R;Z.XUF_E;)O/6^7099D25-%OR71=]13S[MS#R!N<BSU;9?+0]&U
M1=B)*!>(SR11!<U3OAHOZ0!_J#"S=[5/>/&*^)D(IC&;X%2WQG9*XPVQ6#K)
MWIKU29NNCV6NJI$RX>',&EC.ZYAL<7]9<)+"YV3#8)(1TG=$AF4>1G[[H\E1
MSA$M9#4O9N=%5&QSAS7YT Z5FN) 6O29<=-:5DO>?MBCX>GRPDZMC<K#]P!_
M@RFWK1N7&R@J[:YY39_&8]DLD818-I<R/*#T:1M>,P6=!PJTD7%HSEM]OIRU
MVJ633]<4+Q5;!DU'"&Y@HZ'' 0)ZUSMK(YWL>J=&+0C[2##[H<B7+T_K=6U/
M+PR5)FO&G)ZX&_#W(U,3&+Y)/&G((+>Z!\SK@12)M_<7R3^[?%GRI=O15X/I
M8ZHA?#<';<:R(X/R6H?HHAH24]RR5Q0M?4&\:8OL-;+,DM$AHX&]17,]\K>\
MR)X..MP;E8EI&D^%<'C .EON%7/$[<S+F'QE%=#V"(U/IU!0L<@=\;1I2X0@
MF4?2T1;FJ&PVB*Y [[I)S%&R-$%T!N6],[#.G3Q9G7_,V7D59C:"#15K6'GA
M18[L"5P*SE]+D^0QJOQ(GD%^>_';>+KN'I#,Q_HFP<3A(QZ1T>);R3]--&,;
M_<1Y<-XO9ZI2NAA2SG<4*./U>P"5;%@6RE)CLN,L;GELGNO(F%K\DJEYY2]=
M&5UTDQ3/-U3<_DC[M+>N0D1Q3-MS^,U*C/Q6<7B6#"I>X?K0>;Q#"WHC4./5
MS@UYF7RML H\U%X'ABG:%T-2%=<R"+CPR#YU;?7? \J^>X7[-BW/8FG/9#QK
M-5<&W#! 2@_/3DM K &\HNJV%:_/HQQ(Q3+M+GD/-4\A)7M] E^FFE9V8[+:
MMW X4YX?;WZ!<+91,7>,$.I;I=--K$\X+SB>=%%LI31^H-6-<15)7OH3?F4M
MU[?46+FGIJJE_YA$5?:+%(D*QO\W5!?UNUQPI7CD>!0[&,(IE2>IXL(!6Z4M
MI"B.>P#0&A$<Z)C>8O<;TY>W!*J\MN+OQ6O9,M.63A/@>F6J4U5 GF'T(G/D
MP/#@?90"5WM!'W.U^W!U(8W:[=;. -U;0BFH:,[%MH7/,/5)-O?R-+7 A7['
M2Z(=X3?BQ5<X<>%L'\2+9@:[7U.EBD0^]Y9[5#(E7)A(#1?,^*E?$$$(/D@&
MG"^ G*MKPY]V$_,\;15_SS9RHTH8#%N;S!G?J&F<L6@D8P0?T7+7*I[8>4<^
M?4M2+NI(N?.FF:S%%;EN7!L%<VG&_%P_KIC6^0-W'">XGFB@/@'GQ[+)8_$V
M2G.O(R]M(UJ1<8_9;1B'1E7](H1N+3<]R:7 NJ%B:;F/^BIP2*6F5C6=*%0<
MDRB28N%MB+#&HV<'372K*< G<\9Z^OPI]BZ"/S_U%L7F36E&:>"!<3(U[P&X
MN9T^=!-=TWD-@]V,IC[EWU\$]IID^[?1L*E5%FI] _,9L':S\L0P!:YUM09[
M6<7;$$<,46LD*X#T(6[M-9_=Y*A,Q'!,A/P *K.OS/M*T>T9LPK6;F1^%\=8
MVN^2GBS5^J >+U)<VI(>+)!NKY!#SX?TN_@\#!/S)N8&V3?O^@T^HD?XV="C
MN'A%\K=UWZ.#&U:^BVF(D? %*J4H-U2EMKGL2*L,L7QBDDB???M>P+!1(T$%
MY!'6GYR:-I<@+&W'^@Q)0(2_G>8LP-E =KDK<S>DPSOFI?*3/3HQHWO&+R93
M>N24=)ASB;3=)4)U4:_#'5=*1'7DA8L<"7?&W\F?*H_9Z?[>X8%@;*J(Q$ W
M>TYL.)4M9]7U23.;IP&"/$ $:/.F#!$2 B]EH..,S_W;2#X3=%/,+4?&,C>[
MIF$V2>:1O:\?6:(GM6J);L;>TO.4@P\.WJ;R;WVJN1B=__0F@"&8<3>V0 6(
MH:8J96%%TO7=R(:,+^1H2*C8MS'=]_/$'L_<)Q_VL5KO"2ZZ,"W,\TQ";=B+
M:1&#>P!YRRL#"!4-FV:@U%BU.FVM ]8/*4><^<HB2@ =VV?D%\TP%S4E<EB-
M-C:2O).\09@C:@TL1GEC"OO(.;<-+N]YU)VE.'@<(-]M"# @[O)[:1:=3##N
MJG=V<GI%H65T!%-J\9%)5<R#Z*\.MV:"],!+K2%0#A$IQ]S]=T.,N95_3=+:
M^ROJM<TA&YW9E P; 1)3R'M )XCPJ8PC>.V8"&4QO-/9$!4:;&67S?\^(E@G
MKXEE<("/1%H[R."1DOA6\C_/JEPKI/Z!5H/9"B)NMR%JZM!M/B?"W:5PF](4
M(V=84EC ))\!C!D]1XN/\K5<S\! ?9 :;_I@R13H87O>[&10IR-O. C='B!,
MY(;3RS?J< =I,A#X@T:;67D%Y1KM/=U;#UIZ2(ND!')!<!3G0?GXGB^ABS?W
M=H_V%)PWAF111WK&0<\8$FK H"VI6*#V@42UTMVLSI7>>A7O9NJ@YG]9!<\/
MT0R5($O*%7%#Y(B"-1-"L)Y+8&G'W(@A)\5PT6[?[8G73X8'5UI"7&QHMX[
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MLN[4=Z 4_9$D?*,H=11;5>I-F0N>$%&L@OACF;4T<:L[X>KEA2_-TC6,#79
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MIOT_K7UU6%1OM_8&) 0$@ZY!05*Z<P@I$>E6 >D8>N@0^$EW*BC=," M)<V
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M6N3'51X_EZ/J$XBV),]R8,.,:6BQYQ,]XCT#K0I[P/4JD;/,=N0>ZQ$R8NT
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M#%??=?#.9HVC]XI?M"H8'O($-2]=[U74VFW!W0/]&]K_$ME_6V!Q_T.1_9?
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M"@9VL+2$ME(CP-*;]1&N?7CPB.3M7U<'YJ6)E<D[8!2?+F.4Q].S?6^:'DK
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M;N6;ASY]8#TO=]94B-$-4WWXL^I4N9+C0!PA7_SC9<@4T^,<$KP[@USJG)(
M<M$,"6 LG>KF#_<D #J,"@962H ?D23Y(;WV.W=7.53ZTLQ WS 7+]2@\B@O
MP"A!-KRAAB&5*YHSU"U",R*1A]TJW .?@;IP<#!$:</!QRAVXR$4;!U\B^^K
MP#1==Y[V-ZF3PJ1*T/C&P17V'D8*>F<4%Z%,"F@W^ 4N?M)=*@H%USV&]DL
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MW/#X 4C91CNYMF<[@;*[J1%R3@F[]*K_KO^VW@@1EIT+(*N/R)?J+(BI/1+
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M&9_F5WRBYNQOR(:&(A/P YU;1=.9@),=7H 997?%AHV0XR2CW)=T?8P-C4B
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MS?UF!*292[]%,HAY$)%Q=MG'/*.$$/VL8&X%8BR8@+8\9RDQ;2<?@E!L.NS
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MP_:?S8K_?/1S6+8M[J3<M? U>D#%R"R&..+O_>,F<<GLV0+$NODYMG)SU%1
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MQ\$<FXC"DZZ1 ;*6NJ>^9J5%_*=JWCNHJ77_%XX5%"$@38ID*R(B3;K2LBV
MP,8(*$B-BD@3$0$)$A)%>HNBP!:$" @H+=(50@*$(J*B5 $A3>G(6DA9DI#<
M>.XY9^XYO_T[][TS[WUGWC\>F%FSLM;W*=]/>=9WGBF$GYAKZOLYC1]Z3Y3/
M%.\W*-QIGR_K)AI;86!I,,LR>_C"*:7TJ$V%/Z5/-^>\W_M/+WHM+$6F/%",
MN(9*K!O0VQ[HT^$IEM??BM,A@\[Q869ZS+"X1# ]:K>;]N[/,_0=9#O0$37<
M-^8*G2^Q8EF+3CY$Q 1J<\]F.Z5G?RG@*53X<Z:?'H%]97BIOECG?+((M:=]
MHC56/G+W\$^K<#Z<<?C80'#*L2>E'P(C7R95^_G5?:<KJ<HE=)3N)+-5X@J>
MGTU1LR^4#WTTY9AAF6H<'/YD2O7@DYP,TI7T_U/N)/T;=Z+^(W>JJ[MWK6J1
M7IVF<?3.OHGK/3MP57D^Y(K%I2+;[261^Q15BG/UG=<T$S2^I4V>S@WS4_C>
MX!F?WSKS>=5\>1,4P43$Z$)HEL]=S>OY0UJJU2"2MG'ZBQ^Z"L^5&C)#]%!?
M?0QK"L/OF4/7H1+(\ *[H*#(7?+OIY*NA04JM[D^<8TEI=2^$.3B2JXN]4;7
MBEG"]R@\\>1 ,#IA/9EK^G!U *(B4E#S;1,J\6P^C'8+@* ?+*0LAL@^T<*#
M0_[97EA#XU^% %YMO#U&@#6"1MJV1:63P/(->^_5GEXQE>@Z-+S*P#MR>W_R
MSFV"(OFP;9IZVERI>SQAIXMIQP2@'U>Y45+_K+I6YS[>JS=A4_>#?;F/2F6\
M-Q^<:-EW:$\CKQ![->L<?J=?]/K;MM%]Y:X9D1XVK*43?-A%2ENMPXS3X>?G
MJK0.7I8[\?.*CC>W63!;#_FPM]9(1BQR-8Q:)\2KZFV7WW" !+"V/RZ+#[O4
MA-HPFI5>X@8(T+(R7/ <@4L]XZ@8[EGVP_Q<09+Z3_?C%E)G-_UJZ'-<Q2PG
ME-#+ZJK^[_MXGP>L(RL<6!_.3KWY0CGG:C<;B&CCW7)[4K#VTY72"*D(WN"&
M_QS@P(>-2J^KQB&6'*D<&0$S+:]*12%*-U"G.%8)^&EI 6,QUG_P88]'N=W0
M"J#;U8F0(:-99K:>U+[%.K7E^KS.MHD/O ]?QJ9=/0J$KW\OK,F[=.#6C/IC
MS4(U9;*_G(0']9PZBY!$7$)BXGF-G_FPF<I.ZD6VF#;KC$C/RY_$75<S=)_<
M4E9 ;7&3L(F3E#C\I_7']LNJ%C2%^/8^F_,O!U3?[SF<V&]M9]&-E#5ESN<D
M'JE]Z3*Y62Y.)FW_T=)S_N?;[<^VG\BUL7]>%%=Q(K TK)26T=WZHI[]KF!8
M8-R!=^NR&Z*-=-[.92K/S(JK9Q[+AYV\WB 8_&9M/HS@W+?L/(4$E;@>?%A!
MOVP_SSL";HL?*.&4@>;.O'U6\=3E/YB-^'?7 _OH*XB-08BHCZ?I3:.7#>?P
MD'J?@,17$/_Z#K3M)RNN%546/UW;L2P8.L^3@E^J\6:Y)_^_>)S9-+7F5FI@
M^?2:#J;,)=TV$&WS.NV8_H+!;JN&@<"KI\<'QQ\<\&TS*=7;7^7M])O:1O0/
M[@GDI'1A'HK;13)YPH=];$(+S1"7=O=3Y_==XL.*[CM/GX^B;P^FRX!DO1V@
M4XBS4::;AL8-K4J%37'KY&#[2G"G^I;8MA<<J[@">JUC\%?W)R_>"IS^?8 $
M!]IU=-[<'(T(#4Y_!A[.O78^R!^8]4\.DO9L(NRO<&0$HW(FSKREF^#Z' ,"
M 03K^>O^VC?YYKL&L=W[AK0J5<Z/*=F<6%>I;MJ4+EV<LEOGE8\RX-U(?,$+
MVQ#&1GTB84\"/BS+Q)*(S6N.0&61S[7KWD?&$HO.B4R^W7TBL;5GZV4S49R>
MT?P<***Z1I&?Q4_J&)$V[LVM&]UY-74/<M/LO @E)RR5YT@G=)G:[92+.YRG
M5.1NDF^951_C79Z_H/9!<2S$HC*%J]Q)D69I<)!OJ^0,[0CO?.W?2LO7W?@S
M8BCF\$:()-)'S4*_./_0V[&EVH47C&7G)@$$&7,%J9]'D>?#6MOI7%(A3VZ8
M)<M= 89Y8@<%,CHJ:IAK"1<1Z,@F)I5[S)X/TP.)4+RI ,%/50K^Q)S']ZS7
M+%%C[#T7!8I0T />;4B !$*2^"4* ?)!)Z!_#-/0T-$</BQC&=]^$:#RDBD"
M.47+0/R _]]\4#\10/E04>)8>T/#H2R-4/2.G]&SJP&_/?4W7GV?*AT+WAP)
M;,TT:[(4^;X/?T[CZ\"5'^9T/Y_ 5(KSB/9D,SUWC-MK<N;ETBKSUL*/\._7
MYD>-<%$X&A\F:FK-T QB'5B?\PM4*BK"^"L$S7.&&P-7LQH'TG_F+SS];-BK
MU"9RW>3N%CEDP7F(NF?*!24.;M<SZ-93U/++9.V+3=UU7:P\X-+LVS@X/+X\
MW\'8NK_"IDBMC.+29G_+E]< E&F\T\4)O:WF]@NAMZ06NNEEN!L>%,OU/?PZ
M3ZO"Z*B9LYE:6_"BG.K K]WSD.6S_RA@>/ID<]1VW]*&[F"5W"^WTO6-=-W<
M5<C/+\&E%D3*==5>1<^*=JM9HHU'61IW)UOU(PLOPI.IS-*5"ELV.HTB/3V*
M;&G>#X^GBW,-&&:>VHG$VA2<,%186MST%./6KLY"B6$/]?'D(++[]&@1-?%@
M%: [2SG2%X3U?N';^"@H*-\MPDATE2Y0VG3JS]Y\%G5??TL>LAY*+O+G'<Y:
M+0;#T^:Y)PO\AV\YXZM1\QXO1C&IRSD]ZG<><OT^\?:.8%S;1I=,KC38>5-^
MPX1X]%=\\7 M?A!U+3E@O;_(W7-\)CMJJ.C21L9S]Q$W=[0?WC^.PS'^[NM@
MFRP9>;TLZ-90>HU;W;LMW;F%NJ=<#9U^0R0*P-4!_]-:E2M>POO0L/J4#QLZ
M!MU#EZ(5D5_/"J!LWLB/#RO>./%+?_R5S:2>HQS%O\D7.*C/U_OY,+OU6"Q5
MD"S=ZKF"*X+EU_^H:^]P*;<WX]#S;YD*F*(\EF_@ B/)^KN6UM6DT=$)8?NB
M;-;D))/=4-\0?2#"YU7>:4:T5,35!\J6P6_\$!*_=CA:5NF2H=I*D/H%*"C"
M2Z8D$!0Z SK%AC$>A\Z0]O<7-"L=3N-.![<>+#*5]Z\=KFI8?03X=5C,?QIK
M6'H;\_5UX0[K$$M9^\"0WIQT69LO_=^R-,*S-,IS_RSGX-']5CX6IZML^A)D
MU%Q#]B6<J&KZPWO7N<[]L-?WCQQVO,XXOO6*/+,.G8@6T]<6L@ EW:%$QEY9
MYC(XVA/$'D=W3LCV<25"I)<7 [U4&I(75P+P8N,J*^]NCHT84$H.D;/5O.IU
M:QVV*<O9%0F_M7NK8Z/6_?H,M\I:-<(VT_V%__Q\[I\NJSQJ<=I0TA)<EO>1
M",,A_(W//&#3TZC;3>&E<^OGXYJ?SE"TH0H&0A0=D"U3IMY:-)=M4%_'4E"K
M\U!PS#ZVOS\LT$PK=&[-RLWD<=*3\#Q-D'"/NRE_')/31=$$&NZ2#;PTFYL7
M$\A^+#/9-E?1HHXOQ0JV ;D^[4:CUW.VO1]HZ0@(5.GK#=[?>%+AT8W:Z4'W
MQ+[GN<[^X3%4S/>,_!+*][[:H#*/CWOW1H4!MKQ3]0(5.B28]%IU]IQ;F=N<
M6\"8@N"?^AA&6X-TK?(BN;JYIC%1M8Y<0ZY+#W!KLGU^("W2K<S/N^%U].FI
M:)?]#_926O]-P0C%R0>;H/#S7]"\O#9"X0KZ$<&3E&1^&/]F@X58GQ-XZ.(F
M>8XGY1 DD)#*:PGXN0H"+WL^8-'T A_V8+L0KTL*OR*BI-S[O"")A_]'P=+F
MU<=\V#Y-$UZ;#&+=91LNUGFJ\M^O+.1)X$7,!2[S<1#O82K"8I8/._0$W8[^
M*4%&"01;#N%K'< .0SIRY[XC$ZA+RA@BK]4(T1W [)S%E?P<?L#JY:;=I'-D
M\-^'?C/6=OYYRN90 ?6P^#]L\#*\11OB@48;M_V(Z\:KE"Q2MODF?-=:(G6N
M7^!G/PW7+3?C_\"$_++3;@)L$#C[=6*B('CU[_]R*-_U]@\+94V5MU*FAH^^
M-_Y/M5@KMNR[0FWRGL)(T*16D(2X?'0&$G!XPZ5#:G"N>)'1&R*8(9@]]O7$
M=T%+N"X*,JHIW@1]O6O+HK+N5Q_E%3C[X.-5Y,Z9] VJ0^-XN6M)5@1F6&+7
M9[3ARHGD>(4;"J9JE[CN?YWJ=Y&^VL*N$(<Q3,#NC6)2Y2!*CV?_<G(D"8XU
M?0T44=.T\ZL%MFL%CZ2)8Q;BH^N:4=8/[0BN2A+@Y5[FHN*H7X/GCL%KBPNF
M)U5BA]EAU#M8J^<" C:J"Q+AGMYXPHUB$:4G_)64!G&;1C'*J^Z@:CPWA$60
M<H/0S/EAJ@1%$RL#V6DGDH\)5+@$Y#F% F5CN1*@=I>K<WPQ*%IYMQ#*0@%=
M,>2SV1[?^+#%?%BT\!M3\=L2TW["NZR#_DRWUORQ&^5@W7U@Y4"Z]==L7F#+
MY. -_?-[^AU2@FMU/J6_, Y)F2X[JF8Y8UEJ'VNG:8P%LQ^N.A:H%E%)/3RY
MV8H*'@[$=U!CD>+EIK:"*&2X9A"['-)SAR)]0,?V/,6@>PB9>=/CI9#0>:@H
MA+$(G:K$*A2."-!6<JPS?&W=[/UJ!3"HKQZ%M@>V?)G-^CB!N<XY6_?P!XKI
M$VOJ$PFXK4KJ81"K]R$O)F*D@8;?8RH$FM H2AL9*PK$)-YF$)^JGVN,C,/I
M0&B@E^5SQV#<Z,+'Y2"Q5A8)AL;TMM+%3",1=RM,0T-3S8=/U T:+ 2=VBB3
MZ)3[T_+N8WNYMM]NG>ZI5CZJ\%CBV8,'>S(LTT_<_2/-Y5:E3EWP\)X]O22;
M)X:77SZ:LLF0._JVI-:FR-M!YV;;Y2-AFF?.1>4\F6:5>MY,7F,>?_56ZLM!
M=!V/UQB!HP)X)%D=6&/!$R@(G$#9[Z3LPZKUZ8ONG$#OQO2P\S*>823;\A2!
M"4(A5KZ:#,);"?'F^P%Z+-$>R+IW%;K+3@UH4=("?6AT4?07C.7>R!;>$0"7
MAJ9U:R8WK:96@6@"3A6K +ZG9(!S)Z P -U)K(5'8\.?8Q",ZQF@+"NL(9EL
MQ5B,'YK8!O4 6:T\C8]8O#>+M'7"A: (;8<GN3K3Z+)H/R*0,9<YBLO*_^P)
MQ;<W^DR+"2F*&4=&F:D)"ST7>K*T:6IXSE'Q;8"$HE75LR=..I'ZU'!L:-5.
M\L#!4JM<^\KG_2&.-E*'(D\/G/6WX,,J4/"-;'VBK"\29KY[.L\4J"0P"#)^
MGN)Q74Y 7BRS%XXQ07TLC#\WB*Q:0+?R)!HI0%9,6"0!OE?9 32*-56/"&&2
M1*%2CMNG4+GM&5X!BO@B]-8$@:+3?(U8DA\0J-7AG3\52FS6<QBK6:N]PG(X
M^HLQ+^<!QY[:Y@ ,!:T\^5GY6I//Y+4?7=*K$_(#8:_JZWSV= RV>I6^:C40
M;OPS1?_+Q9Q BV.N:O7S&6.WXZUFJ6I*[ >S2!VTU*]]AP><=N3*4)> Y6\9
MK'2MPC<L5NA<>20?)D^Z;Z[2NAJD&/#Q9TUOM1MRXLN;JX_7_.H#?[SY73-U
MS#E-ZO#J^ZBN9,32;RT"L& 1>/E>[5@+T''UV2>> M8'"@=,_H""0#@K* 7K
MXR-#K72#1+$J*O1[Y+V1Q5S+QGZLE4PL2UO*UWB-H)(YQXQ/<G;X2-Y1,B>[
M?O!A2?<+]!L#DT51*+P]BAI+,<$$=/!A"I3]6-$^,I+M:T"(H^SZA/5Z 5%=
M@84/L0R2Q,$*-G(W1OZ'+6#PO30P#"U-$)OSE'\=[P*:Q652Q%Z]>FV'I(U.
M-H5=*LM%3@GH:6[U!(A8.,["QS:(L(E;ISUW W$E+SS0^"#LX7ZR!:C:8I3E
M"0<[X_),(!%0B^8!+":8*K!'ZN#B$&[VZ$JW 55LVG4J%GN,W7SX@]U)BV:
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MVAVS]9?9:;V-5/ZH>N\SF<;8FR7IPA_._8C>-"6]YO?Q-1(T&L8#5_DPKK\
M4Y(AE[4-; ]^^8EOJ"=I*?$A*'6/@9=DW./#=N>D\6'?AVD5?_M*44V.+-P@
MME(.Y'!0%W)Z^J:"#D<=_Q8+-GQ+UY./<_SBDPT-K" =/:V2D4O'>O#S+GQ8
MTX4[T\WH;Q)J.V!W3F]=WKJ$RZL#NKA2(AW$/:;J@-,0^IZY&@58;8JL=,<'
M78#T.I!BIJH@L=U3OG]YZ,]1KAP9>A$8SE0?#[(9KM0W0W6Z!MO:^>.WB*(X
MRDY]76.>;#8?EHBN4^TRNZHMCOT=$H!<*L\0\@:R&"@:208SUX63!@3RBQZ_
M;M6*5[1FHQ/$L98@>D%PQ_F/8>,!K,E$Q%VR+O9X.$-[Y*'#8$6MF7JKN5;@
M]L[>LR#^GJF]4.LE77=+/;BMQ)EZ>?$RIR+U<T]8,V]UB\XH];FG2825GO]6
M)&ONGV;Z*,.&-)*O_GUABOJ-9/4M:N$U!_7@R16?2KT/9L&V#])U=8W3V&9Z
M*Z1NJ8TBG.8T<J\V3QE#<H&JJ=7-] 4KT(1YZP$8@+K7TC@U/U6*V=)&V0L:
MQ!& FM\ALT+(/VC4<)A]#2EA:E".,=1.EH]I\!0&G5/(ZJ7)<'$Z%-1A+@<4
MA!.KD O7D+[(5'QM7,9SKE,_^>2ORB+T/ C:MB)$*JY57JLPWX4)Z1Q%MP=H
MAK>R'9J!R62M,I:(1 D6F<6R+'H^:QR- A%.0PNF1Y2!]QG9ED[=.H]NK 1K
M]N4>WG/;8-;XS+.?*DYD7U/3A3,#H)2*%M;".$TL9??Y8_YGGAQPZRVX-<(S
M^>FZMC"V3+OM<_W;>+]"7,A,RF0N6KZC %/,6>WDO17,21<B;0GCU3*QC0^+
M?0TZ,K]7L'.%'" /S>$.D45)C#I3EJ8IV:;<LCJ:1B@4B!!A L%<Q?\F4=+=
M_XAV''E?,2U<I9):6KV1X1EVV[RCSQW,>6&9>S4]/</ X?N1['3/'_&:%UZ]
MMCPW>\)ZO/8A'Z;=LVQ^%Q+J6$NLX</,LWUX:<VDHB7X"5%L'7"B:Z&!LA]=
M-S'Z\U:CW_N,[@;MQ@#*@7UN-]RQA8I7UH?[A@P1EW_@^[6_D]\304[HL(GA
M=3[,^9%'3@,6$EB;&72?N:+ 4"AG"J3,.SROA/4[U4+*^0OL[T;J'VT3=/>O
MBP+7BT :ST)4FT>[15P/&E!?:OCO_5$\-TD>O1&W@%RF/W?N$;!J^FOZQEWJ
MQK$_@L=OD][]=$@Z1/H6O$W*_O>_M7^WO5]=U^<86=S$0#[L4H4M'^;K/)VW
M!]]]A@^;=TL6>*'/]LNXLJ4'<X.@50?J)X)\D@_SN(9?'O9"!PQW(*217W$@
M?".L2G"G1VK4U+\*HX@5*7MT+T/*W@+VJWGV([^JE. _GZ#Q8;:_D3Z6<E?^
M_<I&39LVTX>^\D.3#^L++OP%&)+)D""._4:)@H@D@[F9%,6_?1"-Z@)E>:>"
M) 4O.\C^J8G]>_WRDJD :AY\$+C/R[T;H^U"?[/ >>&@+5.5ADB=$*/^JGQI
MR=L#)3+>GW%S2R;!H;+3M8/EL>./>LR*5G+<VW_,9*<VE1UP3<LQ*%H:LPOS
M6254>WJT&@HEXGT(=SQU![ &99@R!K$M%W\6"(S+?88Y$VC5DK<70T86^J[!
MPPJF7:-B#(_,$ '"=/B9-5?9^,KYREHSL6_94Z?[RTNNWN=(2_^,T3F:%)SB
M-UQQYDC((Z^==?OVO"U(\3_ZO/O K*5$RFC-$R]I]6?W"9H"]&TM0R<L<2_5
M0\X,$7Q2O\<7_]U8BWB:_!6<EG'1>.',6G;?;)FP+]DBHJ3[(#&2Y>M%:,^J
MWVWM'5YF%W#@?GUO$D\.:PJ.-Z24<P,95#&HL9^EF153NXAPPQ!0'JX(N0N8
MG:M1MBVKN -I,U_\,WD2 UJ505B3O9V6CT."33,Y?Y#R)I/.-(<?ZAXJ_2;<
M)O[PA=&A$T\>S;3IWB1[[>C4BW&TV9WTR,%/9[Q"NU!7<UET]S :%$I:J,TU
MATMBJC7%Z.WK7*=/Q14L85,]F1)X_*7!Q=]_!'E]9 [586IK'SVXFIT[VRXT
MBC!>MG>I__I][/JGU+' I<[#.J[+*9<+I:N3K%T.Q$1M 41X2+(='^;Y]W2=
MFR3<08,;K*#UY7[D<MA"E#:ZC_=O>7>H((ES9^>A@G]I2''D_\,]0)PVOO6J
MN2[6;.,),H .*:,7=H $IP&N-H!G.B\@.:?\T>)8;R^F]A[H+6+7YP!Z]:^C
M09^Y3\PH;?]H:LO:D<[Q&"S7AYQZK!L?OGOR;KI^:$V/5@:B>"(_^+"MCP6&
M7T-#'S_Z\'QC8_RYAM>9.APCW)#]0IR)R9O':\B6#*'=-LEW4.[+I">L=8,J
M18,G9VF?RCSK_E!.-=;W^U#AFKYZ'_NR9)M:]XB1;_'\GT-S@SB?+_K.WX2X
M2"'>CB@^S$J]E ]C'>,-4KFL:3XLGB$@0&WJ]+<P--<*.=K ASWQP.OS864C
M?-B&\ \BUX!-_?GK8)C89O.5C3 N1V\%E\1]^M<_%  Q_(T DMSE4E]N%"^^
M;VMO$+V.]"&./OVBV?0&***Y$>Y.W!XC?^K>Z:Y_63;[V'YK^=/C @/F+ #=
M=8DI)!30A5\B('MK1&Y'S:W/_5SUF5.1_BF8#7BKX+%H_*>WLU0H#5\G8*VC
MC4@FA 1L%]>/>3CS81*]JQ5\V)2LU7HSD0_[2#C&A]$\301(^NO4%K?^1?0P
MNK<&Z3PW1XI&+ZDT;,35:6_DHWN-_FI8YJ9) O<"H!>A Z1XTR.A"^C5XL'
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MFY[;TLQJ33D!HVW]@>@05#,KZ;D/U31BC"1=;$VF!N39P#9ER8WBL:BBB*!
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M+,1F4E?4M%'MR21!2]J"+^+-86E#+5D"*9#-HVM4UKH9F!)V^7_NCL8G18A
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M!04-C]#UM*: /-8- ;C8/410U$'ZTAGIF 3,=^X55TN!T%)G0JX ]1'&]H3
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MNY2.^&VO3?)?LC1US9N=SURU=K@:+3Q@,9)>5&":U[6\2=:I-AS=RVDY62G
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MOR \B=>A"4D]7W*W<./W.K^OE%8//;_)%PGIJ^XM^CE8KY"5,I,"P0\1>Z5
MG_ZD3?P!Z*R-/[JLY<V/734I"R%[S()Z;I\[;PM_/DURL0EN=LIW*KIZH^%M
M-?E?=!BW5ZQ52+&LH?](!<=*:9+<;Q%C$^9-^&F]=C;D$2\%WIE28N'UIPU;
M728_>:MWIIUBOEYV:?Q^B/CV,;]C.H>"7 _;MKD?\KJI>&GW-L8 N5QFFSI&
MG+U*"HP:N'HJQU[\];3Y%?DO?[2G^6Y:%[/YE^#U&QZ.G[C\UC#W7NO7YMH_
MB>^PO8Q!NW$,A&G%&KL&D@9)0 #9<L(O6PHT@A7<!*H3\HIXF:Y-"2$=@39%
MD=+,5#I8:\BA!SOP)TKM.5J(9^ML3+!)Y_NZZ&)NV<$PP_5;'U+P$#YUQJYC
MU!IZZN149G33,M-\5Q2\ITBU_'&AL-LE_<'SK!W6GS865P[Y>+W)+#[PY7%N
M3,WU5S.=U#'WR=#MXAR<*T*?/2_.H2Y! Q O@?<+*1"Z>3PJ0@I@*%8+>T=9
MJCW4%:.Q5..N*+XR91M$&%>"IAI<L)E4H[>#_0PM\@-.(+3FT# >>N;P*3ZT
MQY7@>#.)),@Z:TW_<$?X%%2KQ"ZJN2A1&^-KWT-\CD#\>GZE,24 N70/Z9P-
MN\Z1X)$,(2;E0O;5PG"66F<D;G4$79EI(]+0Y+HC.0(?O(#6A$G/MVN;&<&M
M?H*<:]89*!H+TA^H^'86.;#*LY^K^UHI[;+;H]%NAHV!U<%7506;+/E5>XIV
MLJON;[^QRE#RE,EDLDM)DT5-6!7T9#=N-8I#W@GXBF1SOVZ)$IDM_)'L:C\X
M[BV,&U:#28-2H'E"CH)_SH:C>:DY]0$W[T ,X?8T$5>YWXU]>:@#W7-_ "'X
M=.^A^(3'"8-<N#X38"@AJ8_1P$V4&$/.J=$VS@?@#:-20(L2*GQ;IQY,TRS*
MH*Y!?X5SFD'=$=:2H)VK'!6AEK0R\L"".[0PT.__Z=-(0&39_=B0(]'G'6^P
M:_8$Q_\:M/,6^<C+\)8;SDIF'BNM]Y'3&FU>OC[[Y!;3QV?%G1LG'GU<W9ZT
M8CYP?@09$4?$]86BERLG%I0/@B/'].?UB?FYI\'*4TY7C,=G [T7O3$>_VU\
M[;WBXTH*CX^OE9/[_2Z-R:1I28&V?=NE0(/^#RG@$+U@>)G8R&6/?0V4 H]$
M[@]FP/L5'B'GS99+@7N%63+<L)Z0A U/NLI0?JO/SV?N?GRTG?<MP2GL*>D?
M"\G,,Q4<7OT0'$Q?D *Y+D#O@_)_7BWJG^>5/Y'>\D]SMW\FIT@2<ITER@SV
MW,-[&KG6QG_ &+&B PG5)H)3GGZ1YEVZ?R[$=]]X'S-'//8L_^T)9]*4Z[CG
M[BEG2FW,7.!OO?P7D<#+_ZC__>>K_NRY$/PPEF1B?RC@0_"AK?IO@U8R*[9&
MKBWWW'RPCSBPUG:X9'5E.?.E]DVGV1Q[A60?56[WO1<O.V:LXPBK/A&.G-=X
MEO]U\KW\&9O*\D;+VLY>N_$'4_Z4MQF6@2]T-_2ORS-?)@]]7S@DZRE-Q.Q7
MIQ^:)<9A95B-_HKL$8&FZ*8J.&6\5L!.9MDB.0_HBMM=0\I07)TX_7#;=SN'
M+'!+1]FRYSG"T 147G3;=;6 JT7Q:3_\J@Y>!7Y:7]]:&+^03]A%V#>13PA
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MDES/PGK(9*O[-416ABN<TV1,0O<,>I-E<KIH%,R+KX,UA4J09]H-JZ1;(\[
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ML35#$N6KQ\_;?_PDL_. 3 E7Y#CK1$Y9YLQVM05X?L@P.HV'"K?'/'BBN?&
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MJ7VKUC)CUVI[2H8Y;_GG_?'>^]YS_[KWW',^YPJ&!=. E .>@ = (!"0N5>
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M-'LXF&TXO3V =1YMDJ%)J.2-I\0(&+(S088X,X?V<>E1 7:++ZY@^]#5L4'
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MQHY6?)S^RS6ONQQZ-/&V)L).T&XX5*J[Q-P7($E;_N'+'T3WR:TJ**1HB&4
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M%MK"32 ]M=Z"PG@J- +H:2A50BB/GH62 ',PKF@+&Q##LI&&@D '#&B;O?3
M0CN\>?SQ.3YZ6WAN6,%8&H!/83\7"B0%4!*!>!"CA$Y%ZH)H >)&](2ZT':
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MNO5"G!RVCFF/%#*]+4!B@.:9T3C[7!MH+C-ZI"JL?D\BZ6'W .=PN?O:4>F
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MJJXTIH_#$,^Z+]M/?S.%/U16!G<4$3K0=HAY%%FIQ?S]Y;@IIC7*BO@3]%*
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MD#J):-(LJ)5-&&\!DZXBM<[>F;O4V#)E3!^1;218"0(R]B9:9:\&9-J@E3M
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M$*S):B3K0>XA(T@O/F7C#!#=JI]M8_@J,11Q8F3?-8\8<O7L02_;^H7RSHU
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M^_"FZ=[#=?L6S0K'.2FW3#**U^Z\>=VP4[95]@X+0UEXQ.'^>8M4X>+QQC;
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MS&'KN;D.DYI!2M_=Q5\V;YX&3:E_WR"_=?3]OU.?BY!/_#]02P,$%     @
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MT7BT#1J/L0 :%\P #+0L$\^>Q@4SA<"6@A&F,+"9X>]DOU 1%1@:1/ZD &D
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MM=0Z#.'A'1Z-\8WPT]&*\8]T@F(B$2LW1Z_TB8@V"HV.B2'@L&BCV"AWP*=
MK1UMK-R R'#SM;4&Z/?O\5.(K8V5M:V'LY>MG9>[2XACL!\IV,^6K*,5Y>]
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MT#00$@ V1J+!!E!CN)$!'.H/-? '!T(,H @T)C H"!GD#\'T*OP:^Z5*FZ@
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MF)C^+^[T+H*:H@-ZS%L$1$7&8K!X3&#/E7U1WD<:T(B.P%D$]00#.CHZ/#0
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M")R^GF-DP#(0:(VOG]Y'5*,?"+0E& 12@"."\+V7-'C0"-!'GW]Q_,%WX/]
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MDHKB%]SRP:\ZH'V$C-^_XV[K4()[!RAW"N%U4ZRP.W9G34C4;6)6V16O6Z3
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MX 2^&6="6X'\</N $B-91Q,HZ;5T?^UHUF#)J(H-X6114@G89Y'0I^"T9:;
M,N_"@C+^J;1Y@S?QBM@OVJ;*J;O:BHME$=L&):V5DMK<F9O$30U/PZZ*C&M<
MO(L%OU3J6AKP[Y?L7.# 9Z5>';R<9\C^J6Y'#@6_(]<A4TAP23!+VT.X2@U1
MF\=*0VI5=X@>'K>5YTA0\UR%+7GDW&"%(_G$ ">Y+[6MMB9[$^UF#BTCC*:6
M45,K: %Q92GS:&[!]Y/.T((\YBF.T3+-SB=:TJ[,:4V$T3T'Z,NZ&3_5M&?9
M"49ED]/7\9[')ZC3N:\I3<EZ7%CP$.5/G QWU\0K'(C9#+D'^^&<F7($9_F
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MRBOR\%V81R6[".&>P85+8R&HO+SAQ$'ZC[-?$2MT(_.F$RN >M$!E%?#'.H
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M;#G3RL/+2+@%Q?I%U_Q)^;/R][G-R([(C;<XE&&>T[;D7.K^C->ZP]+62R$
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MV=79/8\)%86VP3\)[-0K_><)@^M]MKXDS@[=TJTFTKTUG6)BSY1Y72>(/@"
M54)?8%=MN[%T6&'ISDJZ1ZIH>R'M:<R[7A+M=FA UPS:&V]=^SO:ERF@CGNT
MZP! -9A5;U?47<$\5N&* 6_NGZE9VV9RDV+Z>_PYUT)G=.SD6+RKV@2<FBGM
M[4&<'@#  F<#["IE:)5T=Z''CGF2DZFQ?0#QS9B:;B>Q2\B/=HU(ZVUKC10=
MF/*HM5,XO,<SJ_]3?H,LS:_"&?WQZA.IT5O=5-R8JJZY2GC(V[9JQ5WOUI;E
MR@TN"UIRI4\! -.=_Y33SO?FW,)9VVN,CU)C>W,-F3':SF2]8\B#UN-5 ][6
MYB+=&9?HYESICV&U\5\%_K935?>\T'O[]-J$U"T].VST&$-'M751R-/62=5(
M[[ZF*M,"EZPFGFPR &#<]J\ZFPI'5,8./48&@0G-EU#7H6KUWYAR>!7-&7L'
MJ:C(Q&]&,S;!"4W8U.!N8CONJM-Q<C!NX'0!Y!4F8S ']A@+:D(@!G D52T*
MA!=2[F,<",;R-5@#L3FI%/>-5!W4A[])SIS\B(@G/3PI!IVDEPQH(#?I!0UW
M8:?IQ4H?A)G.(&M06?2.LFGHW_3;B;E8%&/LLF,X?\;8R?/QK^B\X[N!]T2I
M_8? $X6I]7.ADP0E<@OL'5]$6H(XR[M4\A=*SEN6D($9QU4$/L68.<\G$7'5
M[,%C;A5QVM#M?I5T=48M#ZQ0,F53H#SY;L(U.%(VJW@;<KVD86,)ZI!X7: '
MVE_D.?$!ELQ/.W*T'&";WW<+&&U!UX2#,HT[)*<@Z?J)^!98O%90U(R8KPZ)
MYR);E'X!$.0C^=&)8 Q?-.'P0.G/MNE;+U>L;3+:EE1FUGT3[P9GV&"X=FB:
M97KA"7B(X7?<<41?5<;2BXC3VO<31Z.'A$<.O2Q=M7W"5J=R5L\1:SI0T;%)
M]!=(T/P7]A2$7S]8\!N&J!D7MQ#^S/)SZ6;X#5/!A%[T#*'\$+1D]]Y?O8*R
M;X./J[=5?-FN$RVJO->3@IT%_K,=5U (/=2\9H,,OK)AC?\Q.,#:-@&!GB8L
MWM>+5P)+NL<2N*!]%C@1 WDMW$?*@_W$3B''(+X7Y%&6HEYM2*=.P>SV'T.]
M@YL]GLUPQ3'VQF%7H]YT/L558J+,>7@"%BT8(!!Q)HPS$8??FP\E80AW8HGD
M0N*#)>&4<22UPT=:/GG&[@/H0"JL8PT&2QTP7L):J%_YT;@!6@SJ(/X\39\7
M2WA >[$>1[Q*7^Z70TJA1SM0*5?I\%U^R$+^J38+:AL_Q!",?L$S<*]AYW)_
M(<FXS5QVKB^>S'6.$1"0G-K%&L).3J##%+* '3S8 [^@\FOU12Y7'*[:CZ++
M4SEP]*#T#B(.\UG"SYF#"Q6GK6O#!XBB?&_C8X64<?VD"AY\)QEF,%N:/\!_
M&Q$Z%3)9[\U>C])H_X0'H6^H>[/]L*[*G6OOX:8KIOFNP7Z79XT#$6_S6@>X
MT.JF&4T_X([U"[5:1$;-.%8"TF)Y!(M'/3=^S2K!!.JSUJ[!>NK"??9@;FN]
MQ_F2$GGT':<A=WJ,36M@FSH>:X["-2U?F$3$^48'* FUH+8TLQ&-M*Z,;L$4
MFM_[)*"?&>Z-_4"JY^7NR(*4#2UL'(2>[-^I\8;]ZOW".(98UKD&<AY);7F7
M.05UM!$4[8;NJ7=:=!P]TRP;>XKTF+=Z*YK^NZ*K+IGA#G)7365D0++I!H85
M!@+_8KQ% #-BF5FH]#53F5<P4Q8"6)U8GU&?.2#\J-YTZ@5D76T(S1<]77&'
M1L6 :03:%6P[Z#T]$G<_/9W>2YBQ.IRQE.CNO9YQDE@[:H#50\;TN).OD#6V
MORG)E-GR?90!BH::1/6A BH?4*U48EHES9/Z<A6:9J-M6F"ECZ9EC&(P_>G9
M78,D%R[(BB.9N(MD*\FNG//D;V0#!POLH?AR?+;D4?:P'T:IJ)'LQOF/J!7L
MK%%)C NL79V5!*-\;;47<8ELK>0AL5^ZB-1'BI8 *JRD:Z+GJ95DAO![Y''R
M-Z'__ 3R$\&945Y,-_;ACLUXB&&Y90)A3!59?(&@T1J(341O=7MY/?&@\NIF
M+:E<L3)R-NF.[*O7?I))-@#XR<QD=[:C<>2Z9>9%^%FV?:)G^,9J5\)!P@H3
ML.P,X4_]O92_B&Q=7X24^%R[V&L+$:<^ [C#%+&-;:>P!SLB3#A<6:NKR!_W
MI+$+_QN/K8LH<R:XV::G^!..6\CA/XE+S2Z>KPG4J@^ X\RM;&%; 3:V/\?X
M!GMOJU2HPN5WE>'S<-?:PDMQ>&(3)[F9L*!^:SB=P*L5>I+P;?HX0#_S IO2
MP!(<K9BMJQ.X5DIX1KX5? @;S8^'7B@>Y$^"GTIZRWN'[ KC\+W0&^<!!:7_
M7V?9FXB[ZDV\001/V\K;@)K 97.?H!&8%=Q:S+ZBPUP8;FS2+&X>/FK% 2Z#
M$#[W! ]%J/S_ZD =JI-Q;A"O:"HY8I*,4\B)(ONCIW'&D \4'F#?IF0FAK.O
M41ZL&,=^3]T\=R7'0EWZ?\6,K*UDSV8O4H>P;K$7L&>Q6MEC4--9%-;M@K]8
M%:Q#"6Q6):L[E,QBLJKFG&+=9=D31TT4<ZN$H5K(9(C/L\8S4T6_$0^8_B+W
M_*M,#V'B1@USN< <LHT9(W":$\',%4P>4;98AEK[2KF0 =3HF1,9D>HI\'>,
MV4I2WD>&L_Q+_#7&;%E?R#S&0NFMV<?IWZ65(\K*H'=808I<NM "8:RF9YL"
MX3[T4/V#O%!ZH.YD?"@]7#MQ>3/=7^,S&T,[KOPWT3^D?6]^+Q^@W6S,I"MI
MK74P&(E&L6%S)32,Y62<BL8S'5[N24,8O\[VHAY1_[0K!HW56RN/H)5U(6D_
M://;;D!O4Q\TK\KY1;W8X!XWF_IWW9S@7NHQ6ZW;(.6=>N>(JKJ@FERN%;Y3
MV(!O26_D%+ 7J%8F@?IFS97NAL]<OUJZ!'$WD"CU0\5//R&O1LWX9[S65KDH
M N!4H;_L,^(7R5GZ$ 6N/"WY@#Z0F2M9A)T4HQ'K<-$!=\0,O,?T,BD#U_5/
MRA[0!<N*"?&">=)DHC/13;*1> 1X65Q!0F<P1+7D.>NNB::3AP(2A*\HGM/'
MB%EDRT@+M4LE@XSO_$GB;<R%^'>B@\P5%<^$]YA1Z>W"0&;\ND!!.S-SZ6D!
MD9DQ;4A8Q[0G#DV0>)/P#&^**%V8C?LAA D.EW\4: 7N:1_Y-_B<M59^ 7_R
MTGR^%V__-!+_"4]HKQYDBZ)4^[@9PD3E-MQZ08F"5+Z +Y#[IBWDG9&^B7['
MBY4"_"]R?TIJIGGR0.)(>QV@35AFVL&Q",C&65@!7Z*/* /QVG5Q6Q#<=QII
M="87J([Q1W&^J]VG/N1ZR&?;E9=@3_T^S@3^C5H#YBGOKFUNZ1GN!XLL]0IW
MI2EOS1!GF^'#DC><2$/<U&V<J3+[2;%RGV!#QV>VD0]LR\:4\\J:-Y1&<\L:
MYJ?F<(RUIC59G(DUP"75;&7UBJD8]@;9Z1$EHIMLY3.I$(,)F N/K;H/(A?<
MU55 L)L2M%-@R9%A&B_XQT4W-.'(49-6Z?0(_#_C%2>\8O@)DU+.ZST1HV%F
M'00)*MB@^0NU/VF/FH9QB-BGXF!]%Y%51.R)28$:-^R&D6<)O?0;<7^17^G$
M^&;H1<T-0D4^3;V%Z)$T6?F1>#DB4/&-A%_DK+A,VCUIGO($B3&B!!MU6^FN
MI%^:'_1-D#/J0CHNKT7Y)]V8F*20TP^$:^15](<+K?(<^J-)H^1[&/:ODH_2
M%O)S24O4??SQX"\J-UY][C&%A1><T"9?QST9/DZVA2M:&"[]Q05-?"E]RWEE
MKP/LTL3+3Q"QJC;9:W"T<HKT0ZZ;7")YGN @"Q3_7&F5+A+G>S^7'!##)MZ0
M@(0S[,I'C=?'$MXJ;^G>@/8HHK1E.4)9F_KH1I@T605>.4,2HS1YUXBW*8]-
M/"9V%R78ZP!]JJNV<P2B,L8Z#A0I-YI?YXR5?C*>B7\FT1GFA*G$<CW,.U3T
MM&KFQ &1BVB-7>6I*EKX!%?%N:;\RM/R6?7'LS524.VR>+[XLRTM;)7HH16]
MX)4HPE@S42^,$]EK7U1U0W,9&CF]SJ="7])I>U59E^95_1@LC<FQ>$!3@NZ9
M?L$.S^.8#\*CQ]PQU</W_5^Q_J#\J%\'I2'J:L[ [I6$6EF(=5N&+(5(?<PH
M$QMU,:C1F(B^/*_2>!XS?JR7P05C/VVGP&H;L#GP5[88W/QBF^4#[M&6^:8+
M^*YU7,,[ C@H5M]'^#4OS#".\'ULFNXH*7E$D8_4N%#=X<NK=U-+B\Z:R51K
M*MV80[VY]H6>0W-?=JEJ%6WSW,]5(%KP6+SF 'V37<VU[N>\AHDM6,Y0D8=I
M!8>X^81A.B=@+;@JE/UE687V-?OFW!W:C^SK8Y6JGVS;B"()JW=)[D"_F7&2
M\$*=,4A,V!RIGR#JCKZG6R :OVRV9DC8-U>EL8E<Q[8IB3P?NYIJN:6Y!F6;
M:M1'"F<:<E3"E%U5_LJ-T0CM6D5*X!'U*?F'N4(U4-XT]KC"CQ=EKQYLMVPP
M/X<FF1Q,O();^A[#Z12<KE0_.=I# ]1=#2Q7?===G!NDDFM6C[TBG\>S?RE$
MF/EJ@S]TM%%11RN0Z7UK"E+F:<]88]=<5!^IGAWHJTHROYD[7GE6&S?VNBR-
M%S>BD [=$:6ZLC$=A>7:S,C6G4!>/*0Y"I0=GMSH#O[L&]8P"SIWVI(F%J1U
M.+5=0I:-* 2ORP427;JK?2Y4E?&S)0YV-WYM8QUB2?C*^A)DNF]T73!J[C1,
M0P!2.IS: G 0NYK5P4%O+XUHU6%P&::F?NS*N-L-8W"C5KZL'<+M\IU;@\4'
M3M/63<>9  !]'3EH1,'KVYZ1'4MZ6\:0T]-_-BXE6^.@=53RZY62FA#*.I];
MUIL4^#1CS7+R1P"@*HA>;E>+6]4L>$EX4R\K-9U3?X/EO^%^K0]K[,I@ZQ_,
M#SZV:C3SW32M5<B\#P!HG_R;*V%[6T3"=\4W&IN%I/1%=<<%#S8(:B8)4L.N
M5W?R'_J@+(OY5Z9IJ\?PA_.RYMA_JJ)YIY)1K&FXJ.A-NU/[6+YM0Z3-0[8[
M3&C9(YOK$V5>)$N<UFQNDPQG>?5?_ZF%S5,,+L49#3Y5'].LM2&ZVMCWUF)M
M;MA:\P?-]D5/3:6:/=.XIFXY;UCY_JN@;YKJ;?>+L^J;K&UIYAJ3Y7/L]>H&
M<U98B'F6Z?RB'T:HX?&T#F.[O 8P225E.XZHTNV#]!))YH<=]+*TA/IMZ@JW
M5:6]AX&' W9WRT&+YFF[8T&#C@4]32 8 *#+P=KO'I0&[=2 _LH\WK\9,CI!
MVS<3&KX*U3,)5AGPL+,67C'O3>=$^"['MUT3X,/CJYU%0HZHDF<#DY O,DG;
M]J.T"86]6/2&5>N[MF#&!UQM/X=I=9_1/@YS<D)!>S-F^,M2WZ6Q[:JCOX)P
M/7-1WQSB[(T_N_\@EJX:V]%)W!70T>9%FN0^JW4YR6%"6RN5% X J/:S7.T*
MO.TC_6+&T]XN^OZ-^[H*Z=U10^VA=&N LD5/;W"?W:RDFR<\:Q8SAE=)Y<%_
M^[ DL.]/WMN,XST<GG%C8^="WI*HZM:WW(,!J.:-7)[[HB87;MU$W\8SW @
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M&]OF53)+<E._K:Q%O(,+ 4X6&9%IH#*A,G<%1"UHC7D,B^"?]9/ 9O/G.,[
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M&QK :Q/OZKTA7Z(&=,]@O"6].B2\TS5(/PM>!5BFWH<<&'D6>K-I.CRFHL$
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M3:XS^QEE05(A>R?%M,K,UE%^^#]AMU-CW#:R?U.GC_X?6V<!U007/GQ*%+#
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MR*+<]!IEF5M^=[5%X?6"CLJH%'814%T0:@M\J+SB@0?M5YJM.0XL5"0:EB"
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M9UY+(A4PF:=3'Z=&,#]D.H2?9'GG^&^\PFK)U[:YQL87.)A\X.XMT/R)I'Q
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M79V4W:W-5'?D3I]H!)_9J4AN5/U,WQPYJ@K)O+-I7-F5D^O&5X;DU5F!E7Q
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M>!$WEW@$.#MI5>FVXG5IIKEU$._,%[%I,*=<A6][R13@M<V[TNJBGOFJLN=
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MW!5>#"H+79T!NH72GCT?LP@UDQ' KLW@E>%A>=E(U+[<'7D&Y2\3=  I&.U
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M=(JKA%_49Y(]^6_DF  7[FO11<??[$GNH8GOE<"A \,6JH&!M.:K"O.>69)
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MY!^*&%0">"8;MTI^<1"VWP3AK.-;7O;^K/U8#^NLK+HDZFV-5#\F#C<N5SI
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M'CF_-J)J-^6QX4J&#0U46X6?8$1)%[B=9$5@OC>3*M[O'SU.)2S=%3OP9U7
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M<%;["/R\[G@U%5Y@/BMD01NKA8Q7H$ZWN'@].$?5N$4/M,K7;$P#-HGA=97
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MD,"6W,LR4.G4R>R)N8TT!IN7.)4Q@S,I8)3Y#\?DE,1^R-VXQ[9R$6+H3"-
M\"_#LZI;<"8V1O*'#E(2R*.0;TX?-1G<DY! GPGZ!00SO@,C3LO9KL#?H[O+
M:Z6L]B^52R63]!*"2,3D2XCC!$_)@205GKG]#"61?S^^A>: ;O*_S B VQQ?
MLU3@H5W*,HH^N>UR^0_M.%UE)47%1UF$;_*OI ABG;1L^WARE>A6_%QJJ2#0
MGTPW\TL<3[)FPT$[6TKQAIFM3\L7UMS40A5*8QFB):S4W2+2JZZI8[-327OD
MO7$JR@GQ:W]K^@+\K6,[TXS(=GPNN=JI;_4H*VS%-0?+[S4N@R]7EM= 5?NK
M7 V/LG:1[#7KXU91(N59?O=IS2(O1QDS".W=P2_9/O2T9;#TW]Y_-7;E&1UL
MV+WB;M/Y*CM"<^VJ+#]BAR$[=H1\0U7FIZ%%2>P<F8R/_)J!*YS5^4V-%$YH
MD:-J/0<L$4#+.!?*SA,(7.?*E9E*KKE*&O.&MYJ\YC_Y.D\;[S -&&6F]!]A
MS:J,;BAA%1/.*Y>RCA,#P+_8[J362H3=35F^[10GB-H5$\]Y3M_DNX9[B.ED
M_YAWA1W39V+8TN_5VS,Z&43%;*8EXRLP@=G)Y%9H6*&L^=LFL[ZQ]D2/LD^S
MB3Z'.6<Y@?8G>-.Y5KWA-"8477N!_B<T559/;P9[N.<9H6!B.<J<"$[(L&'>
M O9$+V!= F@^F>PO@*M]#W<3;ZQG$G6!J+Y&1AT52J4%M&Q!!J>)/@]?5*:A
M/^1?2<]DW$--43#S([+99RK;#_IDK^/L $N[OI&_J-^8<4J;:HZD@+I9_H7=
M1ULH/5:ZD_9%+-W:QY@L3(J:Q/3&IZ[?PS*B8OO_G!*ZT&5-GE^STM1//F,L
M%<LH''T9ZQXU5!-6\HOFK5RX=0D]17HMTLQ0B]CK =9?V!-["OL@,K43(Q6U
M6IJFDRT;#:);Y']J.UGN%(,1+4FC:G6;TT2TDZH%D=Z,Q=*>]=',)N%X^R)V
M/CJW<R7Q7>];HY34TRD0Q9(WM30P390_ZRG%EZA_F +25M"BM9\VCM&[%=#Z
MF<P8T1G[3/8R]&6S"&7G^^IXR(G"$[@$"2UQI(_ M\M818DP7'$M=2^\MBHU
M@@B](?WR)D)GJ!]L2Z#+S(RF7ABO2-9JX'F5KS$QU%M%IAV#,HB?"KG0WV0\
M=3;XB.H1_AP\2/OA;0$>8'RU+06?L@,:^\ #M#!-$4B@3^?S0 OZ;NH!X!FC
MLJ 6V,]TV;P5Z&9-#"\".EB/O<: L^R'_U$+N>,;C,#?@(5Z(^\.L I-YO4
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MJ KC>3<MS=XMM*E['WM8DE3C%5@I'S0FNF6JJ[4EC1O4Y#*C/E-]IVJ*V@%
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M-,TZ3E8;O,A\56'P7F/L4W4ZW]$W #=LJ=HMT'RJM*E8%E"VJ6&Y/#6WL^Z
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MU.HP"EZ"LOAWI(N,:32A3&HX66:2F_4?<K(4;;K7B3^49[0?(LZK@[4C%U4
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MI^U*JH-]F*^C4/@"-SZP':D1G/0J0RLD"J>'6+:";+,/3P7*JPO4D^A5Q0[
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MUKC*3S:@C-3UJI.-7=K<IC8-LKU)C>]M4)*']'+RA$9,GI%6%1SG<HM._]6
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MC#&M89;/"JF5QWD%@B-O&I!LMQAL]P.AB\]3J7/T;:5S]@6-"_Y$M4?)(6U
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M]K<7S<O7GYU<O&;PTK=6#0^7!<FNK4UGG]Z-IA]QIY$GPTL)HRD5V*&<*M0
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M,K053=#Z,HNJQ$!L>WD;@*BC=&-K:+W(ZN(^6'6Y)>Z" ]+-/P&1U3:@VG,
M&':X/F[;YGME9&?@L1.[HH;/[\MO/NI0H!GSYPC[8J6<CDQM:3/,4&S&FNE&
M@F5_);41]04=V#I:)TI7U 77E77#=.P%]\H@V;L55.^P N;-#K?Z-KF>.KK5
M8_3\UOBV<[O@U8<=Z,+1@(KROG@ILS-+PVB%Z^@OGPB8\2:"B=B(,U*:T?74
M5H2AL UF*&F'&4H7')!O_ G(=VX&^DU['G:LM3XWN<YJ_-Q:W_:;FY)K3^]"
M"6><"MECP17% XDB>G>VLJ #KB6UH6MQ+5@]IIE@0#:1C/!&2@/43#/EFXK,
M^:;BQH4&%!M^ MI-&T#CJJU71E9LG3R]PJKSYNH@W?5-::+3>]"LPZ[TPHDP
M=L%P,I_4GR/&]\#DZ&ZD"M&)T< Z<%IH.Z$ZOXU4F]M6H,MNI==EMQ8N.*!:
MNQ08?EMUI_>GU3,GOUO3?7V9O?[QJE#QM:WIK#/62-JL%X5X**(8-Y'"1HUD
M\^!#^5600;@P;P ESNG'2++[<-+,7H(LHX<L3^NA*M*Z:0L.:'];\J3UQY^.
M'_WBV]ZKBS?5/UGF)'F\-HQU8W<J];PC%'_*#X>:C2F S:0P\J8R2[(G<\LR
M)Z"L]'%X>>H8BI,RAJE('L5QDT8)O,01<F7""&7!@88?_GUNXI,O!RY_OL3X
M^-MM,K#"N?S)YA#:;>L$W!7W+,3Y8%C^Z1ATULDD?-KQ#%+*L1Q*TM'\@H2C
M4%K\$00M[C"*'CN#*8R9P3&BIXE%46_0Y?Z//QJ:_?!3T\,O?E: [W=PP"I'
M^HN=_O@'CI&(6[Z)N=?"TM,N1^<D74S,CS^?!HT]EP6//IN+B#J3CXP\ T5%
MG(:CPT\CT>%S:$S8' X;>@J_X(8G/GBGZ<R'7RK!5RNX8.FV0K#!E@#V>R">
MN07D//(/3[T7&A-_)RH^^E9"4N2-E)3PZQFIH=>STD.NY:8'7\O/"+H*S0RZ
M"LL,O(+("KB"?EGV0@.5VQ<#KMT:4.YI!;C>[B\J?</N5P:E7..%P\Y5Q)./
MLS.9TZ7PRO%B@G280=<,4(MUO>2R^FX"Q]2%Y35VHJN:.I'BY@ZXO*4#JFEM
MA^A;FR&&!?76\-;PUO"_U,!_:;!="\H]K #/TQWP?4+O5P4D7^.'0L_Q8DC'
M.6G,:1:D<H*)E0X7%6CZ"XOJ>@M*C=W$<G,7CMMD,31W(,6M[7!%6SNTNJT9
M4M?6 -4OJ#\-'/>7-Q+<@, KY('0-^FZ, AR7A!!/%&95#+#R>9-L)#28291
MTU]46-=#+VGH(K,:._$5S>UH?EL;4MS>"E-VM$!K.^NANDX=3->QD !_VV+
MLQ@JW%[>!G #(H_@AV+OQ!L2__P+XE#\24%<T>'*=.Y!#E0RS,)I^ID%=3V,
MHH:N@M*F=@*GM17#[VA!2KJ:X>J>>EAU3S6\IEL-K^U<2*#JI<%F+>"ZOKP-
MX K$;L$/I9X)-V6^N1=E0;A3DJC"(\)DSF1EKFBD J4:8)%T/<S"ADYZ27,;
MB=W>@JWL;D))>TT(37\U7-.G0%3W2)$UW0OI3P//Y>5M %<@=0UZ)'>/OZ7T
MSKFD],?,*<+HL]($]I0H4S#&ARD&*_"UO2RJL;.HJ+FU@-791.3W-."D_3J,
M>D"!5 ^(4=I> ;JF>R']::ATW@=$3BY YASX6.D6=UOMF7U9XXL^HPFF'E/%
MEDW+T_CCDGS9D "C[:T@U;>7TEO,A:6=^H**WAJ2:$!-4 V*,*JA2JRVCX>M
M[EE(H&KK8E#YTN"T#X@=78#<*?"QRB7VMM8]\TJ-#_)L;2#E1$U4R4QU,O>@
M.E<\+$-J.OGX^D9V08N^I+A32V?W*0KX Q*R?(B'5PYS\)I^-J&Z=R'];CBP
M%O =]P&)@S-0. 8\T3C'W*EQR[A:YP4_9_ GGJJ/8!PU)+$/UN56]2GAFA8A
MMM[ );=HRPJ[Y,5E?<)"WF E33K,)BN'2\F: 299V[N0@. /0Y6#Q6#O#)0.
M_D^K':/OZES2K]5[0"^8_?"GF\-HL\U)S-'Z[*I.#51MDJ+K:_B$%CF'VBDL
M*^GCEG &V46BX1*Z<J2(JAY@4+5]"^E_#/9[@=3.":CM_)[5.$3=,SBGWC"[
MYU]J]46?[@PCS72D, 9,F?S6FGRU7H&L5XEPS:)*2B>74]17QF8/%I<)ANE,
MY0BU2#U(96C[%M*?!H'=7B"S=0(:6]]G.KO(!PV.R;=:W'(N=OG"3PU$8@YV
M)Q7V-&7PS?I<5;4&;I#(,,T\$:FSC%_8R^"5#5 K^$.D"N4PJ4P]2&)J^A82
M$&Q9#/C6:X'0=@]0V#B"Z@,^+PPVX0^;[!-N=KIFG!_TRST^%@,;Z4LL;&M+
MJ]0WY"@5.JB^2H-J8LD)'0P)K8<B8O83!-Q!C$ QA.6J!W <3=]" L(_#"*;
M/4!I[0!JK;Q!@W7HPS:[V&O]KLEG)P-29Z8B8?U#\?3&KE2>MB5+(6K(K^/4
M(1N+JG%M%'5!-TY9W(=45 S %+)!N%@S@*S2]BVD/PUBZ]U O=\>Z/=Z/F_:
M'WBWVR;BTKA;]*GC@?'C1R*@'>-Q5/U ,E?>E2'GM>35EICAI@(CM@6G)W<@
M=8QN2 V[-Z]:U)>KU?;ERZM[%Q(0;EX,JJS6 NG^74"[QQ88=[D];-_K>VW8
M)O#TK'O0H5.>*7VS04CS5!1-,Y;($?1E2ED=^=6,9E0]V81OQ-:36Q%Z>CNT
MKK0S3\?KRM')N[)TU0L*B#:]-*P#BCT[@6[G@>=-VYUN]>UR/SMMZS9]VBY\
MX(QS9M,)+ZQV.KA(,!+'8_=E2(LZ(!IJ"[J.T(@W8DQD,Z*!U@RM+V[)KR]O
MS:L7M>889&T+"8@M!N'>M4"]8QNHW[+O0<<6FXOC.VP/G]KM,7C1*J;YO%V>
M]K@;43 5Q&2-Q%<R+'.@=D'5Q'94#<;R3EAV_WI8([4AW\PPYYI*&[--7$O"
M!04D&Q<#R<[5H&;SYA=-&W9>'UJ_:_;$QGU#%[?[MES;DUA]W@8J..9&+IL*
M81:.)/ H UDB0@]4CNE"JA$=V&IH&[$VOY6BRVFAZ;.:BPT9S:SZ]";N@@+2
M]8M?W5"I7[?^7O=O&TX>6;5FY,):V]8[6X*J;^Q*$9RS@9<>\R33#H45D\:3
M.+CA;/[+6PFP/H0TOP?S\C;"JYL(F9T%FO2.0FUJ![,ZI9VUH(!LW6)0O6;Y
MLY9?5IZ?6/KSV+F?-[7=7NU4\VA3J/#ZGM32<_8PZ@D?(OYP)!T]F<*$CV>5
MYX_F<W.&X9590ZBJC$&L,&V ($KM)XN3^ZB2Q#Z&-*&W1+:0@&+U8F!<_N.U
MP<7?39SYS]+V6S]MKWV^RE7X:$M8Z0VKE((+KOG8N0 ,\G@,"7(DF98]G<G(
MF,HM29N$EJ8<1)0E3:#9B>.X\H1Q(B=NC%(1.TKGQHPR%A2H^?GK^YW??'7H
MU">?==S\]PK=\V6[16"-6]GCG:$%M^T3L%>],F$70B$Y9V*0&:>2L:DG,@A)
MQW-("<<@E+A9>$'L420UY@B&%G4$3X^<(19&S!0PPJ=I"^I%X]<?'YK\\-VN
M&Y]\7??L/[^)P?(]96"C2\&S_8'8!ZY1L%L!B=G7PM-3+L=D)UQ,RHL[GPZ-
M.9<-BSJ;AX@\"T5&G(&CPD^C4&&G,>C0.3PF9(Z(#3Y%65"'!CYXI^?P/]_3
M/_WL/Q+PW2H66+F+"K8[8(&M%^R95U#6P\"(Y'MA,7%W8A*B;B4F1=Q(30F[
MGID:<CTG+?A:7GK0-6A&X%5X9L!59.;+YP_^5W#9?I<)"ZIG]/V_U9]X_T,I
M^&)Q.?CQ-QI8NQ4+]EA!@9-C)O#R2 0!OM'/0P/"GT8'ASR.#PUZE!P>\# M
MPO]A9J3?@YQ(WP=Y43[W\Z.][T.CO>\A8KSNH6(\[V%B%Q)@;_H*L XL!TS/
M;:#<VQ94^'L_KPB.N,^)3+W.2H">9V813A4A&+-T(GN:3*L\B"\6C6-8\E$D
M5S4,K](,0475@_FRVH%<E:X_IZ:N/]N@[\MNTG?F-L^[MX:WAO^UAM+_-OAY
M_6Z(2+W.CH>>+\TDG"J&,V8+">QI"K7R(*%8_-(P@JRP&/C:0:BH9N"E(4]=
M9S'H^[/K]3TY3?KVW/GWRL"V&%@>VT"%IPW@^7B]J P(O\\+3;E>$0.YP$[!
MGRK-*YPMPK /T2G\@V2&9!1?JAS&<#2#R,J: 9BHK@\BT_?EJ^M[<W7&WARS
ML37?;#0O(%#^AX'MM@UPW6T W\OS195OV(.JH*0;E1%Y%[GQN#EV%GV6"6<=
M8A#X$U2:9)14HAK"L:L'4#Q='UQHZ(7*C3WYVH;N/(.I+=]D,D$:S'KH_ ,<
MBZ'<8BAWW09XK@> P,,#"+U#'PH#$F\*0G,O\6,PI[EIM&/L_++I$DSE!*-
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MPOP?9D3X/<S^X_D#),K[/CS:ZQ[RY;.'&(^[^%CWNZ2X^=8Z_.ZBFF/O_D,
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M4C::)U$.9VLT0YG&ZK[,MNJVG-::AMS6&EU>:XTV?W[]:6 YK@8\I^V@RN4
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MUAE%2',#'V4V<M&-]168)L-\^M-08;L*"&RV *EE_U<Y. *MB_>C&J^0F[J
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MP.9 #G!S2@$^'K$@R"?B>7A Z-/8H* G22'^C]/"?!]EA?L\S(OP>@"-]'R
MC/*XCXEVOT>(<;M'CG&]2X]UN5L<-Y]ZNMY=U'#PO47*ZQ^^RP/??%D,EO](
M!!M^0X#=F[.!W:XDX&(5#;SMPD"@8Q (<_$#T6X^(,'#"Z18OGRG>[F#+&\W
MD.?C J"^S@#AZ_0"[>?X N?O\)P48/^<.J\:!O^Q2'GT'W_C@4_>*P*+/R>"
M7[Z%@TT_9X+=JQ/ @8V1P&E;,/#8Y0?\]GB#D/T>(,+*#<0<< $)-DX@V=81
MI%F^\&3:V8,<>SN0YV +H XV .%X & <K0'>:3X!W,H/ &['UP#KL!Q0W3<
MAM\>4!3B"!C1/B^H26&/B)D)=S"PC!L(?/X5" UY,8>).Y?)(9Y)YU-.IXII
M<\F*PE.)6L;)A+KB$_&FDA-QK27'8WN9QV-'F8?B#C+'$R9?VUO#_S(#WF+
MVR\'=+<-H-AW#R@)=@#%D=XO"A/"'E'2$^[@(1G743C(91@5=2&O!'\NNYQ\
M)H-/G4L3TT\E*Q@GDK3%)Q+T)<?CS:7'XMHM]9<=C9LH&T^8*!U.G"A[70#_
MRO -(-G]#!BNZT&ISVY0%F /F&'>H#@V]!$]-?X.*3?C.A8-N8PDH\Y#BPAG
M<EF4N2P>_62ZJ.A$BJ+D>+*V]%BBH6PVH8E]-+Z;?31NM'PB<8P]D#16WI,\
M^MH P6(@6 P4VY]!B<MZP/+<!=A^]H 5X@5*HT(>%R7%W:5F95PGPB&7,03T
M>3B=>":_E'HJF\LXD2$L.98J+YM-KF8?3:PO/Y+0RCD2/U!Q,'&D8C!YI*(K
M983;FCK\V@#18B!:#%2;GT&I\[I7ST$X/G:@/- #L"."'S/C8^\RTM-O%$#R
M+^.QZ',H*O$TM(1V,I=3=#Q34#J;)F<?2:GA'$YJX,XD=/*F$H=Y0\G#O*[4
MH<KFM"&^.?WUO3*0+ :ZS3+ <EH'*EQW JZG#>#ZN8.*T* G[)B8>\SDM!N%
M.7F7R2C4.2R9.(<HHIW(+R\^EEW%.I(NY\RDU'*GDQHK#R7V\8=3!OG=J8-5
M+>D# F/&@$"?^?H Z9??#8P#RT"YXUK ==X!*MT/ +Z/&Z@,"GC*C8BZSTY(
MN5F2GGN%!D6=)^*)<V@Z_02457(TA\\^E"'C3J35\$=33(+AY&YA=UJ_L#F]
M7V3,[!/59O6)M-FO#Y M!K+%4&R]S++_KP&5CMN!P,4:"#U=@-#?[VE56,0]
M7FS2=79*]L7B/,1I*H9PC%! FT*5,,<@%9S!'%%E7Z9*T)6A%W>DMTJ:,GHE
MAJQ>:4UVKU25TRN1Y[Z^5P;*]F] B=5/@&N[&E39;P4BI_U XN'T0N+K\T <
M$GI3&!5_J3(QXS0[!SI;C,0=+"#1AG"%I;U(5D4'E%_5DB<3F;.KI<8LLTR?
MU2W7YG3+%7G=<DE^CTP$>7V \H>AU&+@V:P&0MLM0.*X#\C<')XJ?#SORH."
MK\HB8LZ*$U*/\[/S#K)@N,%"'*V+3"UMP95P3<@*@1XFDM3FJ^2:/(-"E=>A
ME.9W*470+@4?UJW@P;KEK^N5H<!B8.U?"OC6JX#89C.0.>P!2A>[1VHO]YN:
M /^+FO"(.65BXB%11NYP!03;Q433FFFD,B.)P:W%L81J%%\JA\L5$IA.)82V
MJ/FP3A47T:GB(+N4;&27XG6!@C\,['U+0=7+W=MZ$U#8[7JA<;:Y7^/I<DWG
M[W.N+BSD6'5"W+@L+;>7GXMM82-HQF)\60V5QE.2F$()CBNKPHB5/)16S4&9
M-6Q4AZ8,W:$NQ70JF9BNU_;*0+48./N6 ,&^7X',:B-0V^Y\5N-H=:?.W?&R
MT<_CM"G<?[HN-G9(F9+3(<K&F+@P6FT9MDQ91.&)J47"2G*YK)P@5);A5.H2
MG%%3A&O7,/ =ZD)\I\J2\G4!JL5 LQ@J]BX!HKV6W7O_>J ]L/UQG<.^6T8W
MVXM-OLXGF\-\)NIC8GNUR=G-TDQ,716$JN*@2L6E1"ZOJ%#(IK-D)05\92%9
MH:&2]5H*N=U2AX9"ZE!12)W*U_7*0-_V#>#M^1&(7^[>^]:!&NNM#^OM=U]O
M<K4ZU^%G=[0]Q'O8%!W349N8W:!,1VO%N51I):*TDH/GLLJHPJ(2IHS*L+PM
MA5(-GEZKQ1:V:G'T=@V>VJ'"4SM?&Z!9# R+H7+WCT"RR[)[[UD#ZO9ONF>V
MW7ZEW67WF7[?_5-=05[]39'1S8;X+%UU*DJAR"ZH$L&8;#ZFHHA+$124%TL)
M91PENE2L1C"K-3!FDQ9>TJ%!%G6J4(Q.Y>L"=(NA:.O7@+_S!R#;:=F]=ZUZ
M5K]W_>V6 YLO]KIL/3GLM6^L+]"SJRTBJL$<EZ&I2T&*M%D4C@)24BQ!<0J$
MQ"H<OU""Y+$5D J!*I>C5F=7F#0YG YU?EFG"E+:I7Q=KPPE6[X&@NW? \7V
M9:!VQ\K'YMVK;W19KST_ZK+FR(3[GL%!?X^6[K (74M,NLR4A.#I,TC,ZKPB
MJ@K!QLGQE0@I390G+I5EB?B*=*%2E2HT6NI49O"Z%%D5KP\4KO@ E&W^%Q!M
M_1:HMRX%AJW+[[?M^.7*X/X5<S..*P].N^WN'O-S:Q@("5=W1:<*6A-@9>8T
M JT^IQ!?!RM#U&"YN5I*58:F1)RLXDD35')YG,H@CU-WRQ*E/;)DT>L##(OA
MY1U*R>;%H'K3#R_,&Y?<ZMVRY.S4ON^.G+1=,73,=6?KE(^+;BPX5#(8F<SI
MB<\O[$C!$EJS"A!-D.)<,YJ=WD#F)AF+^;'U7&&402:*K*\31QB[1%&U?>(8
MS>L#Q18#;\,70+[A&U"W=O'#MC6++XYM^.;HR1W_&3UKL[)KSG6[\9BWDW(Z
M,*AR(CRA>"0VFS28C$3V91)S>_)I:=VHXL1.4EE,1U%Y1 >7&]HAXP5WU/&"
M.CMYP2U#E:&F(?[K B46@V#=YT"]QK+_K_S7]8$57\P>__63D7-;O^^\L']M
MPUF'O>HY-Y>J$WZ!S-G06,I,=#KJ4!(D;S(#G3:13TP81Q=$CY$+P\>*BX-'
MN<S 45FI_YB^U&^\J]1O>*+,OW><];I J<4@6?T)T*WX]'['CQ^?FO[VO=%S
MOWS9>77S,N.5/9M4%VVM^>>=/4K.>H60S@3$(>;"TW).Q>6FG$R%Q9W,14>>
M0.)"CY.(0<>** %'.52_(R*:SQ&M)1/=^\@@S7MFYK6!\I\_ *H5_WQA_NZ#
M"V.?_]?8V6_>[[BQXIOZ6QM7*F_LVEYY_8!=R35G+](UKQ#$U<"8[*MAR4E7
M8C)B+Z7D1E[(@82=0\"#S^"1@7,TM-\I)M;W)!?O?5*,]SJA)GB>:+#4_MJ
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MU-K_[J*Z(^_]30(^>Y\#?ORJ$*Q>@@?;5L& U>8,8+\K ;A:10(?VQ 0Y!@
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M@OR=>P!\UVZ VKT3X"V1]KPND/OSNR!ORV<@_\!W ./T"R!Z;0*DP+V &.$
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M%_O6YQ;XGLG+\[V>E^W7G9?IWY.;+KR9DR:\F3V3_S)(T PI__9>M'L7:RM
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MI\+GQ"'A/?)P0#?EA>@*]47@>?I08,<,_LO 5IP' 4>70<3Q]1!GL ,2S0]
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M%B?3W1WK$[U)E;'^K.+($'9N:!0_4YSDEQ*4+4H0H8F$]9(HX=G02&%/:$3
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M6BYK\[11SNI9IX+%LY6*YL^GE,R>[U8V_>><LLD_#Y1-GKXC/OYD,SF#\6F
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MW;,F#KN/FCKNOF/BL/.-*6/'5W/[[?B3LV0&^_L!9D< )M8!K"!GT+D#H/$
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MMXEI&*!'UH\SPNNW.+#JCSNRZN\ZL!:]980O0OO_1_\1I@'<* 'XC73?0ZT
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MMSF\7L'Z\!Y%J\.7%*T/_:-H>>"3DL5^5)GO^SW<- @P1NY@_R1 ZPQ S4Z
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MD?SF,8!*TH.+UPM"_GHYR)[2H:2M-V=+7,_@C)UT7Q"YSD^ M2YT8<C::+&
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MDK5=MX)U4J^,=5>O+/R=;ED$ZI1&H#;YU/K1]Q^QKTGWOD$ZWSG2?8]G4>%
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MQL*/U \G"X!]Y+^W5E,.:LES$(OJQ&BOUT9K_0AF5IT5KZ[60;*JQD-F6G6
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MOK7GB/LC?&?\9>97PPYA^BV_#*T)Q>2]J0\VD?ZJ.90#\J!SYP,-"_BH:5=
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M]0L;&+4+QZ%V_G>HG7O)J)WYFV Y7UD\].VL/J!VU>=3H?2M0#1I^^\G_</
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MFB13%Y(IGA&<+U<57*8P/:A&J3RP2:4LL%VM)+!/O2AP4*,@<(]F?N!YK;S
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M-P\0YN.;2_?M/^@M[C_8+-X#<N\[03+IU@OQ&SWFS_/?A=&!N^BCBQ^F/Y_
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MTJ4(S4A$2(8,P1D%"))5(5#6B@#9(/QE,_"3[8!OY@GX9#Y"7H./[&OXROZ
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MZBNG]RJD_Z:-MBU3AV6%+LPK#&%680'32GN85+K!N-('1I6A,*R,A4%5.BF
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M)"ED3J:"YA0J<$Z5 N8TRV\.0N:8[2:0^#EKP'H(/D1U-H1M]L\(/OCNK*_
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M"7P"_NR])VT8/6- &V@ 5:#$U* 0DS$*[M.!_M'H1Z0#RA8Q$*"0P5#Y#['
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M;,(.P_8O81*[F-BX$"WG\^WS:,$Y>/)L(NAL_1D<_R?>]M5?[O,-N9N\0S\
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M=54*@#S[UT/@ZLFCZQ<"2%F].5 0@E!'<EY'XEU']EC[)\U&_K"I0Z&CU=2
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M6&E0.GJRT5& CC+D52.W":]TJ (OE=-39?1J*?U1PL@L)NJ+M >8$XA? 5^
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MC2(]H^3P],L1,UGVF(6RQ9ZJB-@-"H^]46$Q!Q0:\R3XE<(\7VBVJ87%6?N
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M4'B:0Z%I;@6GQRHH/5F!Z5GRSRB27X;YHWT;#8&H9$)0,B$'F:P*F60&&?L
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MOXI__>F]U&_?.H:YN+0$?F%C=?69_>C*P2Q":5\>M:BGD'ZBJY29WUG!SNN
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MK>\>^B[X:L$7;<_ &UN?XUL#*VP:=YI7;C\>DE@KHR)H_N>84"F: =4P<G^
MU6%'[P[@.E(K3%O76J5CM53H!,WE>L68 _8'[P*.)Q\&]A??!.9WUOWA?6W?
ME>9GLKJ''ZSQMKXD4 ?7627N0UZAXT20;ZL*\Z#YGVE!Q:'Y?_3^ &/$-B -
M^)$;@L9J Z6QRD!OK#1P&LN-HH:Q!IP/_!.X'G\8.&>^ 1ROK_X^^<S6_C/3
M#D6''T(8VM[DB2,;]#Q/AIOC+/"S'55!E@T9'KE!@.;_D?N#.,:,BR/-^-$;
M@AH3.0DSU24K3<QDA9F;&&O /?6?P//(0\#][!N_AI]9<GKPP>6)*]..6(<?
M0T@ZWV%Q4AOEC,AA(\U_PD[S5'KJ7+5^B@,=)-HQ89P-&\'8\)%_W1[ K>1H
MM94:J[+28Y565G2L_>B;\L\__-.F_>E_\O7/.^]_N_'+^]<XOI]^5';A>1B[
M_WTRM7U#/:GQH(20R%,1HF4Z;!AF1(7@%D2@UEKC1]EA?K2CTH=U5GCQSG(O
MT57J);M*/%1WD8<QYDZ'[OG'+Y&I#W[3./7YEE-3WG3]\N ZY4]/'>9<>KV8
M/+P0@1W82$3V'*#7=N1P:MH*^54MI<+RI@I):2-,6MQ0(R],U2H*DBAE?A*C
M/)[ J?(2!'5NG*P^%J_3C+63D7O&GTI-G-K2,WFZY]*];ZO ]#7UUU_<2[[Z
M?A;ZRY5%-9]MJ:P:/H H.YV)+AK*Q></G"#F]1>3<_K*J-F]E759/=6THSUP
M^I%N)".C&\U,[\(R#W<26(<Z*>RQUA6[9WQ;RZ2[?4,3'M?\.?4M+GAJ&07,
MWH2^OFAO]8^?I)=?W9E=^-7^X[F7#Q=F7<PJ.?IY7GG&9P65AS\M@1VZ4%Y]
MX'Q5S?YSU?"T801BWS"R=N]9#'+/&3QJ]QDR>JRU).X9Y^^Z9X+VXCU/\,!#
MKU' S'EH\-[R:K#\DW*P:=N)WW;L.79MWX&,'P^E'_H^\^C^J[G9^[X]D;/G
MZ^+<W5^7'=_U567^SBO5)W9<1A1LOXPJV/8EMG#KEX2B+9<HQ6,MT'3W./VI
M\1-Y8,HC5/#X"VCPVAO58-[[96#EXGRP_N,LL/630V#WYK0_#V[?_?N173M_
M.[9GVZ_Y^[;^4I2V^5K9_DW7*@]L_+GZX(:?$(<V_(0ZO/Y';/HG/Q(SUOU0
M=V2L <EC_P2RUQ\ D@6S@&#UAX"S8\LO]/2C7]7EE%^@%N,'*=6<+C)6UDHB
MZQH(-&L"QW3%T6Q/#,GUQA!\;[1&Y(O"I/YHI<(?J5#[(^6Z0*3,%(B4.OR!
MLK'UM^%OPW\8I)!!_AIDF \95D&&[5M^81S._(J>57&>5D@8H%;5=U)0BF8*
MR9@BUSD2!(8[CF%Y8JAZ;Q3!]T5KA/X(3!*(5"H"D"$8*3<$(V668+#,'O",
ML1N&5Q\ TGFS@'#50E"_;>LUYL&L*\PCE>?HQTG]M#)>>UVMJI&*MR2H5%><
M2'/'<$QO%,7Q16IY@4B-,!B&24+A2D4H5*$)A\J,X6"9->0ILX4<Y?;@6 (R
MR*!X!3)\ !D^7@BXD(&=EG6%=;CR'#.'W$<O%K31:C0--*PM0:.XXN0Z3Q3/
M\$4P[$"XEAL,UPA"(9@D'*Q41H+ENDBPS!+QE%LBCG)KV%QA"XXE(+]ID$$&
MT4K(L'7;-<[>K"N< U7#["QR'Z- V$JOTB7I:$>"3G+%J%1OE$CW1["L8 A9
M'P["!9$@3!(-5"IC@7)]S%MNCCG*S5%+A25BJ+2%QA)D^ =0O@P9WI\%Q)"!
MMV7;->[NK"O<M*IA3@:EEW5<V,(LUR<9M8X$D^".T2C>"*EN="<51'$B(_LH
M/TP2]U>J$KX*8])184J8*\PQ0Z4EHJFRAL<24-PTR-^##"MN&'@[LJ[P]U0-
M<P]1>CG'1"VL$D.2"7?$63AWE$'V12C4D9U4)(!FQ4;V45Z8).6MU#0X*O0-
MYDIC4E]IBJNKS%$%S!H>2Z,&U4LW#)+E"P%_\_9K@FU95P0[JX;Y:91>[E%1
M,Z?0D&17.>(<M#O*)OK#-')H9"?EQS 3(W=![FI)DZM*VVRJU#7JJ@PI%<R8
MD%>;HY)J:W@L >6(X<7[@>+=&P;!INW71%NRKHBV50Z+=I-[^>FB9NYQ0[*^
MW!'GUH[>"(68I'" 0HE[<?0&]\@NJ%K:9JY2MVEAVF9EM;Y!5F-,B&O,,2'<
M&AY+0 49U/\R+/L("#=NNR;>E'E%LJ7RG&0'N5>T7]3,/V9(\HL=<7ZU)\+'
M!H(<0L1'(R7=A+IF!XK388/+NS4UR@XY7-,B@>L;A ACDH\PQ[BUUO!8NF&8
M=3]0SIT%I)!!M'[;+]+UF5_)-E:<DV\F]4GW"%M$1PPIX0E'7%3AB8A0@0 ?
M%_.R" U.,KG=@F'W:FLE_=):1:>P5M/"0^H:N4ACDH,RQ]@H2V0L_:=AZ4=
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M>.7)8O#N"SG@PU?3P;+9:6#-W)U@X_M;P?;YF\">#]># Q^M!>F+UX#,):M
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MKJSOS]7S^HY9^'W9;D%O5EC8F]4D;#W6+$SE- DCN4W"8-ZM UC(@(<,!,B
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M7B,@RA@ 658/7.1T@"VO!=S]&N"EH ;^B@<@6$D%(I65(5Y%"5)5%2 7H_#
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MKMH*X:NW8"^C39"Q=A-DS0JXK1$&YC91H,J) T5'$ACF:\'5;@>XD>6 [7H
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MN+;;@>,D VRF,C"\-($:J@^D!%-PS+($AV(;(%3C =]( -Q1![ ][0@V5YS
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M$^E>CNUEOH3V%G^[$]W^^&.# 0Y- P%.M0,!I,I!?VKIH!^M^/V,@ _F$+\
M317.14\.B:/;[7/0U8MST(4[<]'I9\O0D:>[Q1H>JRPM?6"P)?N>Y;Z$VP2-
ML)MD8[_K+!O>-0\'UI4 "N5R%,.Q*]W-KJN,:]O5PK.^W.UA=>F3ATW',!_?
M-NQ%:!KR(M8/>SG6S P$+L;600*]J!1&=UK$T.538JCSBCAJ[YV'6OI7"M7W
M[Q8O>Z6R).>%WH:DYQ:[(Y[:*?G_0]+V>,@T8?7RK*GW ^P<[T<YVMU+)]O<
M*Z-9WF^CF_=>IYO=_T0W[QYC6Y[_XF;=\9EC>_0S!]<Z.B,0,0]]RD?H?KT0
MNGQ4!)TZ(X+:KHNC0X_GH:K!-<)%@WOF9@ZJ+$\8T-L4]LYLM]];6P7N&T<U
MYFL77<IKKC'QM;\YOC_2VOIU&M[\=0G!]$VS@_';RPY&;SXX&/6-.QK?_4$R
M[?Y!,;LX3C,_.S.0A-"3<H2N-0NA4R>$4<M%$51W6QR5OEV \D8WB*2-2L^/
M&SVP(G14=Z/OJ.E.]Q$;.?J(@Q)IA*IF/^*FC1OQUK,<#34R'4TR-?J<;Z[_
MN=Y2Y\LI*^VQ9]9:GW]8Z0U,6>OW3=D:/)C&&]Z9MIN)_CR$;M8CU(GE[Y9.
M(53=+8P*'XJAS(G%0DD3FT6C)V3G"WZJ+//ZJ;W.[:?15MJDY2ZG23L9NTF2
MO/442\E\RD/5>#I077\Z1E/[5Z:VQJ\*7;7?K?JJ<-5 !88,E:=_&:J/@8'6
M$,8 &,W$W0J$SC9C]=L1JKZ$4-X=A)+[1% L+!4*@8TB?K!G+@\4%C-!?249
M]-<Y@-EF6[#=;@'$G29 VV, ;M(ZX"VK 2'R!R!QOQ+D*RI K;(\G%"1@[NJ
MLC!Z0 ;@@#R&PO3,7#R(4.L1K/Y9A')O()3P&*&PKW-0 .;@ 6M%6+!=C (R
M\XB@O!@'FLLLP'"E"5BLT0?\.FUPVJ@!+IM5@;-%"7RVR4/8#EE(EMH+1;MV
M0\/NG7!JKQ3<E]X!H]+; 61FXT@+0C6GL/I7$8KO14C0CY W2"!76"Q$A17"
M#E@O;+'<;PZR<XQ >9XN:"[0!(-%!\!<4AELE^X'XC(YH*Z0Q@YDN\%[E12$
MKMX&26LW0^&Z35"_?@.<W+ >;FQ<#P.;UL'G&:G%UB /6X-X; T"7R#$_880
M'420(\P7LH4E0F:P2M@ -HEH@Y2H&LB(*8.B^'Y0FR,+.A)[P4AB%UC,W0&X
MN5O!<=YFH,_? -P%:R%@X2J(7;0"LA<OATK)97!XR3(XC=&U="8*SF'U;V'U
MGR'$&42(] LA.T#(',20/BP0TH0EPBJ8QWZL'[*P760/[!'= 7*B6T%);!.H
MB6T ;;&U8"B^&LS%5P).?#DXS5D*]#F2P)NS& (E%D*LQ +(Q"C%J)X1L-DL
M#.9[1,! 60R,U<3!3%L"K$P7@[7=*K"F;01+WG8P$^P!DSA9,,K<#P;%BJ!?
MK0)ZC:J@>T0-=$ZI@\Y%#="^J0E:S[5 Z[T6:'[%F-(&[%^@ UJ3^J#YS0"T
M1HQ >R;^/P=#)3$P4Q4'2TT)L#59##C<*K"E; 1K]QU@&;@7S&+DP"1= 8P*
ME<&@2A7T#ZF!7IL&Z'5H@NY%K-9-;=!YK@/:'S"^895_Z6+U=7[I@<ZX(>A\
M-@+=#R8S [:;A,%BMP@8*XJ!I;(XV*I+ ,%($NQM5@.!M EP;E)@XR<-EI'R
M8):J!"8%JF!4J0Z&!S7 H$T+]#NT0?^B+NC=T@7=%WJ@.ZP/.M\Q?ND#]F?"
M"/0^FX#^D"D8O#$#PYD '.9@B3F8[1<%&P5Q(!R0 $=]27"R7 V.Q,U@S]P)
M>&\9L E3 ,LD%3#/50/3<DTPKM<&HQ9=,#RI!P87#<#@EB'HOS0$O4]8U1]&
MH/_+Z*<1&'TV!:,/YF#\V@),GEG.#. W"H/5+A&PDA,%NWWBX*0L\?=^$,UL
M-5 (F\&9M@N('G)@)U $V[@#8)6E"18E.F!6JP>FAPW Y(01&%\T!J,>$S#L
MQYYV%'NR";,IXU]F7\S ]+TEF+^T HM_K,'BCNW,@-T&8;#9*0(X:5%PE!$#
MZGX)8&I( MMX-3!QF\&%M O(;OO R5\9[*/4 9>F#=:%^F!9;0@6329@UFX*
MIN?-P>06]J3]V%.-6$Z;_+0:,Y^V'+3Z9=UG\\OF/NZWS2T\V%ZUFQD@8 ZV
MF(/];M&_,PBFG 2XJRT&GN$JX%EO!C?'7<!D[ .:EPJ00C6!F*@'A!PCP)>9
M@FV].5BW68+5:>M?EE=M)BV?V(Y;#-F.6?ZP';29Q#W#3=G=MILF7+/_1;CH
M\)MPAC@SX(!E"IR4"#A)B0(=PUUZ#GBK+ )?O97@:[$)O.QW 9>V#]A<56 $
M:OVFQAA,.:>;_"066ORPK[+^3FBR_8IOQW_!7;0;M;U+&+8=) S@QNV?VOTD
MWK*?=.PB3CF=<9IR.ND\Y7B,-#- Q#(%?H?(WUF,*Y;_O?:(0Z#20@C660'!
M9AL@""\%OB2Y:4^VR@3'1_L;*]SPBTN2V0@EQVJ85(9[[UA/&""V.;QU.$-\
M;7_+\87]6\?']M^<;Q!_D"\X35 Z2!.48^0)2@ME@MQ$_4F:"7#$'.RQ^G0L
M]_(P_'>)09C"?(C47 91QNL@PF;[SQ!'F6\!=.41;P^M(9[ <, MUOPU,]WV
MA4LAX1FEVO$1J=FYU[F#<M?I*K7'Z26MVVG,Y1SI.[V=\HW>0OM.;W3Y[E)/
M'W>I8?R@S@0XK14&QRW"P,;VQ9_\'XRM1[3\7(A7EX1$@S4_XRVWC,78[QT.
MIRB^$W T7_GY&3[E1UCTNB?A[["SB3<9I>1K+O6TR]0CC(N4\\QSE/NLT]2/
M[*.T,783?8Q=QQQC5;&^,BM8WQBE[._TF0#G/[-![#N"@_7#']L;X=M%($%6
M E)5%TVEZZT<2S?;.)R"V_DVP7E?7Q1;K3?8R[#'/]BJVRN&T,5+<S['R:>=
M9E<R3S*;7(\S.CA'Z#?<6Q@#[@>9H^[5[%%.F>MGMV*W+ZZ%G#%V/N<K<R;
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MJ,FZ#\@Y1O><RTQO.]9;W"2V674[G+&Y:M]CV^4P8'O.X0>N@PCX-B? -Y$
MUT &7 T9;*O)8//?@#56WP&K3<=R!@_+OG[8V@AVBD#X_CD_(S46?HDP6C$4
M8K/A;:"S5)\O6_:AAY?*74ZPUDU6K,$U>KKI95J!Y05*I<U9<B.^T_D$H</Y
MBGV[\TO[HZ2O#LWD7P[UE%_V5;3?A'(:V)6Z +YX!L!F [8.6/9F83G#"_,(
MPG)WQ';A7[&R8E_C5><-Q>LM>1-KON99A,.V>P*ZW$T_GNH5?H#.!5Z$T1FW
M1/,.=I9-.Z,$?\2ESKZ%UN;81#WO=(CZP+F>-NI<[3+I5,:8<BQB3A/SF;\<
M\EB_";DS\->!C-7F_/G] >81ME8(8K<(_4C:(_(I37'.VS3-A<]33%;>B[/;
M=CV"(GLIV$WUC+^WSDGO8..CGK&6+=PT7*-;OGT#N]*QAM5$JF2>HI0S>R@E
MS"%*(7N"G.OZDY3M-N64Z3;MF.[VRP'#_K\!W'HAH&)YF_?GWCV6?:,PG\0-
M0F,9.X0'<^1$7^2ISNW--%QQ(\5VZZ4X9]G.2);J\1!/W=; 0)-&OPBK.J]$
M?)5GMD,9M]2YR+V!DL]II^6Z=;MD<P9H&>X_J&G<"7(*]R<IB3?EE,B;)B9R
M_Q>PPYZ;CM7F8UDG9"F"N.5H,FT-^I2S2>AUT2[AQT4*$K?R])9?SK3:<B;%
M4>9X'%VE)8JK<S#4UZ1:$&I5%A!G5^2;3LSS+B1E\6MI:9Y'Z"D>78PDS]?T
M!/ZX2SS_!S6._Y,<RY]TCN%/.<;PIXG_#=ACV9^)]< 'R[Q_LG?B$O0]:SEZ
M7[@&]95O%KI7+C_G6K'.LG-Y%IM/9-I+MZ305!KBW72JHKU,2L,%5ODAT7;9
M02F.:0%YY"2_2I<XWQ9&M,]Y9J3O"V:DWW=ZA-\X+<)W@A+N^Y,4[C/I%.XS
MY?C? !'KO:ODG]R+( HC=1'ZDB>)WI0M08]JUJ&;57+BE\JUEIXJ,MO8EFNW
M]U F6;DZA:U=DN!IG!<;8)49&6&7$I[H&!^238X2E+N$!34Q@X/.L 1!3UA!
M@F]T0= X31 X01$$_"0)_">=!/Y3_P,X_;D/@]4.PG)O[ (TFCD?]17/0T^J
MYZ.[]:O1U3IIL;/5&I+'RTTV-!7A=M?D.2N69C&T\M*X1AE)OI9)\:'XV-@X
M8D14)CDXHL0E(/P@TS?L%,L[O!=CC.$3-D[S#?E!\0O^2?(33#K["Z:<_AL@
M8WN!AV7.D/EH/'$NEKG$T<.RN>A>W3QTHW$%NGAHC^C)>K7%+=5&Z^K+;7:5
M%SLJY.>[:&3D< R2,KPM8M($N+#D&(>@Q#22;WP1C1];S^#%GF2ZQ][!^$SG
M18_3/")_4/@1/TG\L$EGK] II_\&J-A>X,_#]H($>I,J@AX5B*$[E7/0C8,2
M6/Y=ACH/[Q0YVJ2R\%"#P9K*6BNIPDH'^:Q2JEIRD:M^3#[?+"PGT"8P*]+>
M)R/9R2,MG^*64N/"2CG.8*3<PAAQ827]H+K&3U XL3])[M&33MRHJ?\!Z-@^
M])F#)J)%T+,,872G6 Q=KQ%'7<WBZ.Q12=1^=+MP<YO2_)K#>JM*&BVV9=<3
M9)-KR*HQE2R=L#*><4")GZ5741B>FY](9.?EDNBY551JSE$:.><ZQB<J)7."
MXI+ZD\1(GG1F)DPYL>*G'/\;8&/K$"B"WB1@V3M'"-TH%T67&K#\WRJ*VD\L
M1"TGMPC7G=@_M^R8]HK<-K/-J8?Q>V,;G17##C(T NK<];UJ?,S<JT*L697Q
M=K3R+*)S684SL:R-;%]V#6.8Y% \Z>R4-^E$RIIRI*1/$ZEITP[_#;ACZQ"*
M96\L__<4(M15(X).-PJC8\>$4/.9>:C^[ :A\C-RXOFG-9:D=1BOCVNWV1EV
MS'%?P!&:*K_539MSV,N0T20PHS3&6CL=RL01#I83< VM#K8'KSK8- PYV-1-
M.^ K?CD0BG_9.^3_MB?F_2;\-\ 710/1"-W/0NAJ&4*=]4+H*);]&D\*H>I+
M8JCT\FJ4U[5'-.W2@85Q%PQ6AYVSVN)_QG[/_R/L+H"CO+NPX9][)>[N[N[N
M[N[N"7%W$D($B)$ @1 ($"QHD.#NKFUI*87B4*"X%3W?2?OT?0-]9[[I_&9W
M*[G^=N_N=9.9%N])L<C;G6.7L;/8)7E'K6?<]NF^4=MF!X9M&PX)'A\+"]QV
M/"QP_'%8P!8,#UJ/$2&K,")L!"/"EV#X][ :X,8L@#,+  XL!QA?!["6NM>R
M?2P8/,$#_><DH.N<-JOMK!5_XVDWB:I3 8I%)R,U<X\G&:0?RS)+.EID$WND
MVB'R2(MKZ.%>C\##P]Y^A\=\? \?)X]]O Z@O_=N#/ =QT#_C1@4L/Z_'C4#
M7.X#.$+]>_LHS7\3Y>\"F'^8!=UG>:'MBC!,NZ+"U%TQX9;_Y"14^*.O5/8/
M88JIE^/5$RYGZ$9?*C *OU1E%GRQQ<K_8J^MS\5A>Z]+8XX>ETXX>EYZ[.!V
M_HN+RUET<SN*'N[[T=-C-WI][\9,@)-T#G:M %A/_7?9-H"! P!=I]@P[3(O
MU-X6ALK;RDSQ;4-VWBU;OO1;'B))MX*E8F_%R$?>2E4.O35%(_!6A;;OK28]
MKUM=AAZWAHQ=;Z\W=;ESF-PW=;KYT=S^=[2R_Q5M'"ZAG>,YM/_>^3D ^Y8!
M;%P#,+*%\O<"S#H.T'21!977>*#XB3CD/5%A,IX8L)/_M.:)_=-5,.)//]'@
M/\,E YXFR/@\S93W?%JDY/:T5L7Y6;NZP[.YFG;/5VC9O-BA8_WR!QVKYZ]U
MK/Y$'8LGJ&?Q$ TM[Z'1]PXO!MB\&F %G</YM >SC@),/0]0=A4@]P$/9+P3
MAZ3WRDSL>UU6Q'MS3O!?#CQ^'SSXO3X$"KI_C!)Q^9@DYO@I6\+N4XF4]:<&
M&8O/L^3,O@S*FWQ9IVCT]:"2(=Y5-OC\4=G@(RH;O$<EHOR]<=J#E;0'"W90
M_F& AK, )3\#9-X$2'S+ ]$H!F$HSP2B)LN'>K\'6G%<T(GK@)X\MAC(:X61
M?.:8R&^"60*&6"*DAXW".M@EHH6+Q31P3%P=CTNHX2-)5?PLJ8+X_[1Z+< @
M70>=!RG_#$#Q%8 TRH]Z"!!"W=\?1< 3I< 5E1D'U&91A699H"7;%!W8ANC.
MT4,_CC:&<C4PEJN&:3S*6,BK@'6\<MC))X.+^*1Q([\4'N67Q+OD+X("WQNB
M,]"U'Z#Q%$#13P"IMP#"'P#XO@5P1P GY =;6@L+E&9,:!P&J,GHH#ZC@:8L
M5;1F*:$C2QX]V#+HSY;$<+8X)K!%,8<CC)4<06SG".!\+C^NX?+A;BXO7B)W
M_Z-G#^W_2<K_\9_\,)J_QU, !\JW)J;( @,4 !T4!0U:#Q548!10E9&AL4BB
M'B.&QHP(6C)":,\20'<6+_JSJ#2R %-((6ED _:08;*!;/\/M*>>9VG!0FLK
M-MK9$$<.VGART3*$%\T3^=$T3QB-J\71L$T*]?ME4'^1'.JME$>]C0JHMUT1
M=0\HH>XI\I,RZMXCSU50]P/!?RFC'C&DY\:H^MGTO]"!QF!ESD([<S8ZTC@<
M[3GHX,Y%VT!>M(X30,ML$32OD$#3%FDT[I5%XT%Y-!I11*-U2FBXE7[V7A4T
M/*:*AI=4T>"V&AH\)>\)JE'N!%4T(J:H_MD<-=Y;_A<ZZM :F+'0T92%+C0.
M5QL.NCAST<F/%QVC!=$^0Q1M2R31>JHL6G;*H\6 (IHO44:S414TVZ2*9CO5
MT/20.IJ>I2-RG3S61-.WY"NAGV_V-\U/EJC]UAJU7]BBSO?0B<9@;\Q"5R,6
M>AJST<N"@Y[V7/3TYD6/"$%T2Q5#EP)I=*R50_MV1;3M4T';(36T6:&.UNLU
MT'I<$ZWV::'5"6VT^HD\T$&KE^23#E+F5VO4^6B#>J_M4/]/!]1_X(0&WT-G
M;18Z&U"^'@M]]=GH;\S! !LN!KC3\0H60M\$<?3.E4&/2@5TFZ:,+MUJZ#R@
M@4Y+M-!QM0XZCNFBPTX]=#A,SNNCPVW]KP[/]#\Y?-!_[XCZ[QS0\(4C&O_A
MC":W7='D-_?_0A<:@SNMA1_U_R!Z'DKCB+#D8K@++X;["V%HC 0&9<AB0(D2
M^C:HH7>')GKV:Z/'D"ZZ+]=']W4&7]RV&GYVVV?TR?64\5^NOQF_<7MB_,+M
MO?%3-S1]XHKF]]S1XC=/M+SLA99G??X+W2A[XM[<Q'V("'46QNBP,=Z4@_$.
MO!CO(X0QX1(8E2R'X?G*7T.JU#\'M6A_".C2>^\_8/C6=]CHM>]JDU<^8Z8O
MO'>9/?<^9O[4^T?S/WS^,+_O\\[BCC=:W_1"FQ]]T?:,']H="T"[@X%H^SUT
MUV307Y7!<.I\$[\3DD3C23-B8YH-#Z:Y"V)*L/B7Q#BYO^*RE-]$EVJ^C&S4
M?1;68?@DM,_D4?!"LX=!(Q;W@]99W@W<9G4G\)#UK<"+UK\%/K"Y$O#&[G(
M.EP(0*=C0>BT/QB==H6BT[90=/P>>F@P&$3YT=2W)O[\/9/6(T>/C7D67,QS
MYO^8XR?V)C-2]EE:JO+CY +-!PG5>G=B6XQO1G>978^<9_EK^+#-E;#5=C^&
M;G*X%+K7\4+(::>SH;>=3X:^<CD:BFZ'0M%]9SBZ;XE MXV1Z+8N"EV_ASZT
M!F&4'4]=9^(>1!YU_T+:GQ(3]H<2.]Z7Q5XB3PI"I._G)2K=S,K5O)969O!3
M<H/II<1VJW-QO7:G8Q<XGHQ>YGPL:JWKD<AM[@<CCWCLC_S9<W?D4Z\=D5^\
MQZ/0>T,,>HW&HM?*./0<B4./[Z$?94;*,)A,W3]':N)W[ZE[JC.?JO19KZHM
MN8^J703O5 1(_%82J_!#08;F^=Q"PU-9U>;'TIMM#Z7,<MR?-,=E3^*0^\[X
ME5[;X\9\ML;N]=T<>]YO8]P??NOB/OJ/QJ/?2 +Z#2>B[Z(D]%F8A-[?PT#J
MW;'4M=*I9Q10[RZ7H=ZGQ+QMT&*>3#5FWVFRY_VUP4?L4G6DPNFR%*VC17E&
M!_+++/?D-MCMR&IUWIK1[;XI;<![0\I2W[7):P-6)^T(7)ET,FAYTIW@I<GO
M@Q:G8-!@*@8,I*'_W#3TZT]#WW]]_W]$%Y#X/_\DA$Y& K6O+&JA)32R:DGX
M/%46GK>H,/?:=%F_M5EQ+[5XBIYJ#)4_7)N@N;<BRVA[:9'EEL)JAXWYS:YK
M<V=ZKLKN]UV>N2A@:<:JX,7I6T(7IAT.6Y!V/6P@_77HW P,Z<O$H-XL#.S.
MPH"N+/3['H;1SB11=AZUGXD[ O5B\*Y% AYUR,+OG6K,#YUFG-,=;B*'IP?+
M[YD:J[FM+MUHK"K?:FUYN</*D@:W985M7L/Y/7X+\Q8$#>2.A,[)V1C>E[T_
MHC?[I\CNG!?A7;D8-C,70V;D85!''@:VYZ+_]S""3D4J91<( E8)P8<F87C1
M+@)WN\3@Y]D*<*[7A'.TRUEX[XP N6VMT1H;FU(,1QMR+9?7E#@,5]:Z+2R?
MYCU0,LN_OVAN<$_ADK#._'61,_)W1[7G7XQJ*W@6V5J(X=,+,;2E (.G%6 0
M"?@>1M'I3!<"+!: +[7\\,=T/K@^BQ^NSA:$2W-EX<1<0_:!/D>A'=U^LF,S
M(]1'VY(,1Z9E62YN+')84%?E-J=FJG=O54= 9WE?2$?9HO#I):-1S24[HJ>6
MG(UI+'D2U5B*$0VE&-90@B$DN*$8 [^'L>* F=0 2WGA12,7KK=SX:=N/LKG
MAS/SI>#P GWV[GGV@EOZ?&36]H2I+9^58+"X/<-B_O1\^_[F<M?NQGKO&?6M
M :VU/2'-U8/A#54KHVHKQV.J*T_%5%7^$5U5]26RJA+#JRHPM+H<@ZO+,.A[
M&$]G(8<7L((#MYL9^'DF!R[V\5 ^'QP;DH!]BW18VP9M^3<,>$FM[ ]1'>Z-
MU9O?F6;>-R//KJNMU+5C>JU72W.+_]2I7<&U#?/#*^N71Y75;8DIJ3L>4US_
M(+JX_G-D21V&E]9@:%DU!I=58=#W,)'.PA0.O*NA%DA-]%(7&T[/Y<*QA3QP
M8(D8[%BJQ1H;MN);/>0NN71^D/+@W&C=_KX4TZZ>;-OVSB+G:3.K/!O:F_RJ
M6V<&E4^?&U8\;5ED0?-8=%[SD9C<YKO1>=,^1DYIHL^?1@PM:,#@PCH,^AZF
MT%DH9.!!/<#/'0!G9[/@V (.'!CFP*[E(K!EA3JS=KD%[\A25_&%BP,4YRR,
MU.Z:GV3</C?3NKF_P+&^M\*]JKO1I[2S/;!@9G]H[HSAB*R.#5$9'0>CTSMN
M1Z5W?(C(;,.P[!8,S6G&X-PF#/H>IM-9* &XU41K0&WXQ%P&#BYBPZX1%FQ9
M+0CKUJ@P*T9-N8M6.8O.6^XGW[TT7*-]<;QA\U"Z1=W@%/O*@3+7DKEU7OES
M6OVR^WJ#TF<O"DWI71>1V+L_(J'W]XC$GK_"DKHP-&4FAJ2U8U!Z*P9^#[.X
M\+82X!KMP]E>H#-(;70) UM642-?SPLK-BK X@U&G('U#D(]:[QE.E:'JC:O
MC-6K6YYJ6K$LQ[IH2;%CWN(:M\RA%N_4A=W^B8,+@V(7K F)7K W-&K!]9"H
M^>]"HN=A<%P?!L7W8&!B)P9\#_, [M=1&Y\!<)S:Z%YJ@UN64_[:B4;*@D7C
MTC PKL?JW6K#W['90Z)Y+$BQ=D.49OFZ)(/"-5GFN:.%-AFKJAR35S:[Q:_H
M](Q>OL W?&34/W1D3T#(\E_]0Y:]]0]9BOYA"]$_8C[Z1<U!W^]A,<#OS0!G
M>@ .4",?IT:\;I3RQ_YIA/U[Q*![CR;3OMN"IVF7BTC-#G_9LNT1*@7C"=K9
M6S,,T[;DFR5NKK".W335/G)LEG/HQOEN01M7>01LW.WI/W;5PV_]6T_?=>CE
MOPJ] I>A5_#B_WI<!? #G<6C<P%V#@-L6 FP?/T_C;!W+P/MAX6@Y8@R-!PQ
M9E<==N O.>0M/N5@J%SF@5B5E/VIFO'[\O2B]Y89A^]M, O>,\,J8,^ K>^>
M5?;>>W8Y>.WYQ=YSUUM'CQWH[#&.+EYCZ.*]]K]N304X36NP=PA@C/9@Q40C
MI4;8NQN@[3 +ZD[S0N59*2@]I\,4G+7F9I]U$T@[$RB6>"9*)O9TLD+$Z6S5
MD%,EFH&GZG5\3W7H>YV:9^1Q:J6)VZE=IJZG?S%U/?G6S/D86CH>16NG VCC
MO MMOW>9UN#0 ,#6I0"K: ^&-E'^3H!6:L6U)]E0?)$7LG\1ALRKRI!VU9B5
M>-6!$WO5AS_R:IAPZ-5X\<!?,J1]?RF4\_JE1M']ES85EZMSU9RNKE!W_'6G
MAL.U*QH./[_2M/T)=6U^0'VKRVAH<P:-OW>\#V '[<$:N@X6;P2836>@]0!
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M/X=V:/T0,EOW4O"@_OF@989G ]<:GPX8-SD9<-#T>, ELR.!?YCM#_S+8D\
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MRBI^5-E QLD^ 50Y07XD]\E+ 53]+/!5%06^J*+@9U44^JR"PO0H\E[]6VA
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M(G:Z(&SG/"%D9Y 8M#-:YK\S6>&[,T=K_HXR':\=3:JY.Y;JN^]8IW;;L<_
M=<<E0Y<=;QJX;/W)<-86R7C6$!F43![EBB8?R7;?3?U-:S@6U@.+!H&Z+8S!
M=OK/7?3_M&E!![7A?\@8?H?&PN?P5'@?GHWY1WS@=214\#@2)\XYDBZ;?:1(
M[GJD3C'SR"+E]"-KM)R.[-9V/')!9]J1U[2G'?I!=^H!235EGZ0W9:^D_RAG
MV0<.4'\+]==L )92NWD'^\!>(.L $'<$"#X.>-&3NIU5P>6L&6:=L\7,<],P
MX_QL3#_O ^<+87"ZD(!I%[*%*1<JA,D7V\2)%U>*#A>WR^POGI&-O_B";/SY
M^W*[LY+"]HRDM#TM:=F>^INC;/\=FK-8C'OO5K;!2 XHYRB0<!((/4,/>IX>
MG)YXZN,RV-_0@]T-4]@],1:V3TS!N)LN&'MS/L8\&8K1MQ)A<RL/UK?K8'5[
M*4;='H3E4\=@\=0SL+CUK6!Q4Q+,GY!$\^N2[%%VKQD^"]7'-F]GW:L/LP]0
M._$<]6E/YUVA_C5@"CVYW5/ J+MRF#RO"Z,7C&#X@A4,7W2 P8O3H7[)DP1#
MGYL0_9<+H/=*,UD)U:M[H/OJX]!Y[2/HOO(G5"])4+WP .$A0]1?Q7;OW#><
M \IGO9,> T*N,OZTZC/IQR<]#8R]!UC\BSZ<OESO=06TWU)!^;81%&];0?Z.
M/<1WG2"\-Y<+(#=$'W S] $'W(?L[!^Q@W]TB(LS*_#Q-\ GTO_%&NHOWC^<
M RI@S),>I_X3@.=M8/HS@,-S@ VMNNEK@/I-0.==0/R0OO]3)=$G1L!G]/R?
MT_-_2<__]6S@6VY*OF,YON?D]ST'_7TV] \G@!^?!W[ZGDC_P5+J-_*/"R\
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MNLE WN0-;M+ WZ11?D+Z#]:NXU@8&CZ'4TI+G$[=*-;5AW_%E7Y\,BWRV"N
M.7VYX1. [BWZ\#OTV7?I^>_2\]\S IZU)+; \U.X&>+&]$5NRE[B)N0E3CPO
M<\"]S$[U,H/YR@U" __*'T3ZB^6;.19W >4'.0XTSV&= WRIZT+=2=>!T3<!
MT]N _C. \EEJOT#^A[Q&_LURO*'B9MB0&W(SX-W1P/LT"!]R@_@QX_$))^%/
M. %_RD[_*3OU9\<);_+YU^1/(CV@79,#8EMGG0)BJ.W+^KJPOA.I:TU=X^<
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MA[;KHE1AUJ)\8<:B:L%Y48?HN*A?-FW13MF41>=DDQ>]()O<\;UL<KLDF[R
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MDOMKB)=D&FXQYF>IO3<56,>M>'<RO0:I89D*^?,<?LY(D2,EU1!):=9(2)^
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MW+D:S1W22.X"#>4NUV#>!O7GG:O>O(LL/7G76N;FW67IRON%I3/O74M'W@_
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M#;[/23,.N,AR (U[P)=!%0((@ ZQ"!]BH3G$Q'*HT[[9Z9 Y H7F/H3./(B
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M.G"7V9."(+B'X/Q>@O/[T/SWTRX/8L?#!"8/L_@]S"3S")WK$7SQ, 4^_%.
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M5_G^U__>C[($/KJ.ND"M.0?&U].GI%AX@S?#OT-RWRW-V OO 7"!3*#)!._
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M2BJJ5&)1D^*+NA57-*:8HA6**F:&+3ZB\.+K%5K\@$**?J_0HB\55FBU(;S
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MG(O9@V+;?^+(3=QZ5C[$" 2S7^.^6?;G!S^*'8^RX#[*1/<(G>QAB!YB?#R
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MHU:CU'!4C]%[W@+? >N_82:BTRS,5SHS6;, [&1!VNQ8*%?CBY7X8KF\L#<
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M$EP,SPXX5X;;_]'2[$9I!XW\7$/ 6LGOROE.&;:4!,Q4D;^'"@-\E1\0HKS
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MR;G67TZU8?;T9FV:.=X%J@"2MA896XN$K"4:J$4ZU=P)D G5V%!MM6$)7Q]
M&+7"45/HR KQ629(XGU,D<2P5R#</@@7SVI429U%LQIFRKF)1:UICGU";S$I
M9@9P"QVLA8JU\ >MR/I65%\+4K8%&=ER&=^]#2!7FE#B358;%E"W'CB:0&6)
M?6=0#KRIO,:5T@<J4*14R:<6_@94.<7.0L@Y=:!H.EGD.U'@72Q\<YG0>YC(
M>F+L:4]S[5!/K?VX2P^2N@=IUW,A@X]H;2Y1Z]R/^#NK#2-P=( Z4%Y..SBR
M0@G4.1+QRM0KGR:3$4(5=D@S*))@0>HGV!D@R!AT-?_<P,!B81ME\9EG_BG
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M>]1C"?HA9*OCLERDN+[;Q/7<(ZY;>6>]Z,]32OZZ)H0'R7P]"#_*@9\8PG_
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M_LV'C!6PVG!83 )Y0,I$6-$$6/UX$NW_Z#R#HD L/THLFT\%?%K@4Q(?KF=
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MPE=,(5,/?#2ZB_(_BI KP^7:BR?Q/W(P ,)'85X"9D>CT#:CP6,<>$Q4%1V
M-<%4M.F*/PYIW 0, @ADQ_#'D&*,&'44G>&5<$]0/_$Z'.L>HKU@AN(U0*J0
MJPBYTD[BN@X0.S1N]+_K4<;37]:&2(B< 'Y.R3STDWG\!-GNHD>4S\879F&L
MF@&/:3J"Y:G\Y-JGPA-KG>Q%:3R^#L<$<G7Z\#U@D(_Z2@T0.U/#Q3+_FG^9
M2J*U*-SY^OL^F>7@X:LL.C+>%P;EB\)]4('E^)(WQBHOV(0G MA%=X1/[7%
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M_S_O_Q_7%TE(2$I*24E#![)R<O+R"M"#DK*R"E2A)A"H0QN:6M"'CBXTHF\
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M:E).P;6X])*+<6FEY[L*$8<>BJP '*H&ZK(F<&B;X/C^[+11KR[,G?O\ZN+
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M^S!B3_RWH85;[P:7I=P.J-IY:]6!73?]#F5\Y=N>?<7G7,XY[W\.MM5(BB7
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MHV'O@F XO-P7%-9XP-E-)-#9[@ FNVP!NQ<#A -60#EH ;3#9N![Q!0"CII
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M''NMO^,';#[CKF,_V W;3F!'[%[9O,"-6;^U'[5^AYN*_W7X_SOLD >W@[.
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M\1J@V6T&#\I.H+(/@%O842 EG 27+"5P+E8&IVI5<&Q2 _QY#;#OTP2[02W
MWM !FP>ZWZV?ZGVV>JGWT?*M_H3%!_UQ\R]3\O^,@P/JX'AP)K@=G0,>B@N
MIKX,&(9KP-MV,]#(N\"#=1 H@F/@%J< I(PS0"Q4!>=*=7!JU 3'#FW ]^H
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M;/=#".G43RY#[1L[4/\S4VC^D1:/?>>>YO"6G.?RFE3F]LJYWOVY8X?7,_P
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M3ID[YP_,ZC]W9E5'H\ZNNFJS4\6E6,VL D<328XK-B;#TRD\Q<<M.(GC&9#
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M#-@J3X:]LYW@V'Q;.+W8"M27F8#^2D,P7ZT'V#7:Z"),$]S6JP%M@RJP-ZE
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MQ.T*.Q2_(^Q2PK:P)_'349\BMD1_#9J(^<$<BP6?T5CP7@H$XC7\:LZ,7^\
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M%CW7X[[F:)NOYKZ&8)/MU5&VF\N27$>+LF@;\@M]^G,JF3U9C>R.C$Y.:]I
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MAYW.,[:XG&7L<CWM>\3MI.\5MV,^?[D=\?OL?(@%=@<#P>H &\SW!X'Q[!*
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M_R%P9PV!"VL0G!>#3(0>5"%TN1VA$X,$-#M&0-MQ^TWL1FC#P66H[Z <H>.
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M]612R?*O TH6?UU7,G_R1LG\SV^*YH] :2F'!Q":'D5H&)_#;KP'=<<0*KJ
M4/I-(HI]PH\BWDH@SCLY NN=)LGWG3&WYSL;7H_W+@*N[VE"3N_]A1W><T1M
M/T0OM_Z0(F'Q(5_2[&/U"I./'5+&GS9*&W[:+FWP^>0J_<^/5NE_>B^M_WX!
M@W^9P7NP"9_#'OPZJ#^"YY]#*/4WA"+O(13\60"Q?H@CGQ]K"+0?JD3WGWHD
MYY_FW/8_[7AL%LB\E@N>_&;@+V "P8*&$"VD#RG+=*! 6 MJ132A2U0=1D35
M8*>8*IS&'HJIP =L[E_&\![T[L#S\1DH.HM0RG6$(O!\YE.$O($?44$,N8(T
MP1$4"#:@0;3 S6\*YB1#L.72 Q=N;:!R:X(OCQH$\JI .*\B)/+)0R[_6JCF
M7P.= JMA6$ 6M@O(P!'!57 3N_\O??@,-![ \T_C^=<0"L?S&8\1\OB,D MP
M(SL01I8@@4Q!AF (B@1=4"=J@AY1#8R)RF!)4@![$HY/TFJ@D58!@TL*@KDD
M(89;'#*XQ:",6Q1:>$1A/8\(3/ (PRYL]E^:9A$J/HGG7T4H#,_W?8)GOT3(
M=@$A<T#("%\+7;P.3;P.55A%4 1YPEI0)LB"!D$:= DKP(@H 19$,; CBH(+
M41AH1"'P(_)#"(D7$DA<D$,B016)"*TD JS'-OP+F&@3P5R'"#8Z)+ SP,RX
MP,:>!ZPH?& 1( !F,4)@DB4,QN4B8-0L"H:]8F"X 9M8#@;;L#W88>R,.!A<
MQ_[$7F-SR\%P 8/_1^S_$OV77VNPU"*"G18)''4Q8RYPL.$!.W<^L/$7!*O(
M96"1+@)F):)@VB &IEW+P610'$S&L"D),-F%'9  XY.28'P%>R ))B^Q3]A/
M_&?PMP53$%\P ?&?)K!\,3#%\VU^W0?!7+1)X&K !2Y6/.!,Y@-'AB#8ART#
MVQ11L"X4 ZM:<;!LEP#+?DFP&%D!%INQF95@L6\EF!_#+F!WI<#\.?91"BR^
M2_VP@)7?L'D+6/'U'Y*+@;DF$>Q_?28&<U<G@8<N%U#,><##F0_(7H+@$BP,
M3@EBX) K#O:5DF#7O!+L>J3 =@@;DP:;J55@LQL[) ,V9V3 ^J;L@O5?LM]M
MWLM^M?DF^]D&9#_:P*H/MB#]_A]2BX&U&A&<E8A_]S=-^9][,=XF/.!ESP>>
M5"&@!(B >_1R(&=(@FO)RG_N!W7(@%._+#B.K%YPW+SFI\/,VA\.LW+?'$[(
MS3M<D9^S?R3_P>&-PEN'>877#B#WTA'6OG"$U<^=0/:9$\@L!G;*1"#+$\$3
M][</?O3'UX)ER U,&S[P<Q,";X8H>(5+@&?RR@5J_JKO'E6KY]V;UWYQZY&?
M(P\J?'(=5?KH.J7\WF6WRCN7PZIOG<^KO7*^I_[,^97Z$Y>O:H]<0>4A&93N
MNX'"/3>0N^L&:Q<#1]S9E#4$\)$E @LW>) *"3AZ7,"QX(4@9T$(H(O^9 9+
M?F7$27_VR5K]P:M$_JUGG=)K:KO*2\HZ]><>&S6?ND]H/7';KO.8O%_W$?FT
M_@/R+?T_R"_T?W>;T[GA 9K7**!^A0HJEVF@?(D&BHN!ZUH"T%<1P%\*]S?N
MW7"\)U%X/Z+P?D38"WP+HXA\XK DW[(C95ZR4N2>^N4K/_:M4'_HU:A]C]ZI
M]X?G>H-;M$V&-ZE;C:]3]YA<I1PSO4RY:G:!\I?96>HGX].>H'_2"W1.>(/F
M<1]0/^8#JHN!.Y[KB[N7C;LS'#=X+-Z3!+P?B0;<\PG6_!]B785?1OE*/@D/
MD7W B5>XP\Y4N\DJUK[F7Z-WF=%B>,&WQ^2<SY#9:>\QBY->VRR/T_=;':6?
MM3Y,OV]]P.N=Y:S/#]-]###<ZP^Z>YB@C6DN!M1?UP W9PANOIA?[WVOQOVK
M3/R>KD/ZD&[&^SS5<=FC)+K$G5BV[/7(**5+82D:9SEYNJ?898;' ^M,CK#:
MS \RUUGN]]MHLY>QV78W8Y?]3M]C#C.^-QRV,5[83_G/6TVQP'1K(!AN98/>
MUB#060SH>&X GA^!NSM1 D$Z7E.V/.%3KCKQ19XA]Z,<6X%;&13QRRE,V;/Q
M84HG8A(T#T=FZNT/*S3>&U)IMBNXT6J&W6DS';C>?FO J.-FUK33!.N \QCS
M@LL(\XG+2."<W7 P6 YSP'0X! R'0T%_,?#!>Q"$Y_]J[Q3<_MDKT/<"6<*;
M8B7"XQ)MTNUB2[[+>6[+3V?ZRAQ-Y2CM3XS1W!V7HC\3G6LR'5EBL3F\QGH\
MM,5N-*3'<3AX@_-0\&;7@: ]Y/Z@4V[KV/?=UG$^.*T+ YMUX6#>%PDFF.%B
MP!#'^X";^U=[9^"UY"]'GTM7HF<5:]"]:E7"U0I3WC/%+F)'\KUD]F4%*NY,
MB]2<3D[4GTS(-!F+*[ 8CJFP&8IJL%\?T>&T+GR]:W?8F%MGZ(Q'>^A12FOH
M[Y36\+>N;9$_[=NBP:H]%LS:X\!X,?#'W1V.>R\)MW?VK_=\1="[2C'T9^T*
M=+->D7"^QICG6(6CZ&R)YZH=^2S%K=EA&N,9<?K#J:DF@TFYEOT)I;8]<34.
MG;&MSFW1Z\C-4</NC9'3E+K(@]3:R*NTVNA7[G6QWQWKX\&F(1$L&I+POSJ+
M  L_]TC<>ZE8GB!Z7R:$GM4N0W>;A-'E9CG"J48#GH.U]B*[*JC24R5^"F,%
M'(V-.=%ZZS.337K3LRPZ4PMMVY(K'9H2FUSJ$[K<:N*&/"KCME#+8V<]2V,O
M>);&/:.4)\X[5R2#;64*6%:E@MEB$(C/030?/HM\Z&,A'[I7Q8MN-?"CWUH%
MT;FV->AHBQ[WWD9;X6TU[E(3%;[R&TN"U-<71NKUY"48MV>G6S1GYMLTI)<Y
MU*35NU2F=+B5)0]0BI,F: 6)>SSS$\_2\Y+^HA:D?G4I2@?[X@RP+LD$B\4@
M"%__.!X$63SH<0D)W:KE0=>:^=#E#@%TLDL&'>C0X=K1:KUL<R-YY4B-M]Q
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M:-<)@58'UK\,M$:PS=AV;-\RT#R*'\]CM[&GV'OL&P9""]H@]//_T0+!Q<!
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M0OTR>4;C(OF YGGR6:TSY/M:)\EO-8^Y_U [X@'*ARF@<(@*<@>IL!9;\]_
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M!3-PU7: W+TX_X, $<<H\#W-!)<?1,#Y@@S,O* )3A?,P/&B/65_T9VRNQA
ML[D42;>ZE,2PN)3+-+M4R3:YU"I@=*E/T/#R.D&#R_N%#"[?$-2_^%I([X=O
MPKKGB8CN.2(ZU:8^@)6X_WJP_VU8OQI[GS>!]8\ A)_$#'X.8.8E.MA<%03+
M&URPN"$/9C>UP?26&9C<L@>CV^Y@>#N TK\=1>G=2:'IW"F@:=VMHVO>G4]7
MOS?$4+NWG:%Z[QQ#Y>Y3ALKMSPSE6X2I?/.?AO'XZ\/]U[YI\AD<0/Y^K'\<
M(.P,9O + $Y7 *Q^!3"^QP;#9US0?\X'W>=JH/U"'S1?6(#Z[]-!]7=74'[I
M!XJO(BCY5\F4[.L"BO^Z@9)YTTV3>K.:)OEV#TWB[4\TB3<O:.*OOM#$?R?_
ML 2/OPY<_SJL7W  ZY_ ^N<!/"\#V%\#,+\!H'<'0.L-$S0^BX+J%PE0^BH/
M"E_50/:;+LA\,P4I8@,29 ;PB!=P22AP2 *(D#Q*A-130F0A)4A&* &RAV*3
M']$3BD7>_<-\W/_U6+]PLOXIK'\1P.-G +O? $QN8^W[ ,J_ R@0 %DB"-*$
M Y)$ NO)@AA1 E&B <)$'P2)&;"('=")"^"-.L*+(<$3X.1?!D1PTY%5"#<:
MP2:3G_YA]H[)9X  R9/U<>[NOP#8W@0PN@>@_@A [AF U%< <1P#E]!PCH)8
M4Q0$"!<8.!:*\/%]E) &TD?F?ST'\41A\,<?T! \$1.\$!(\^,E:-/8/1%.?
M(CJZ%-%%.@8443>CB)(=C<BYTXA,*)U()=*)1#Z=B%>C%K0 ]:-!M 9MI!/>
M=K07'47GT0WTA$;$WZ%OB/R_3=;7QZQM@/0GQV%,$35K&E%QH1'%(#J1CZ,3
M?C:=R%0PB,P<U(EZ&$1Z  VC]6@,[4('Z43Z-/H%/<3_Y@WZ2O\B0VB?90A]
MTJ?_!='#VD:8M8W5D";UQW,9/4L:T9Y!(QI^=*(632<JZ0RB5,P@BO5H+NIF
M$L4E: BM01O1=OSU"70"_<CXIGB?\5GQ%>.]TF?Z6R7">(->_^75OQ CK&V&
M6=M"B2+F*O@UCLD,U\/8@48,O'",X72BG<P@6OE,HEG%)!I-J)-%-'K0 %J%
MUK.^:HRQOFCL9GW6.,+ZJ/$#ZYW&'=8KC=^9SS4_,9]I$M83]!@]^E\0,ZQM
MA5G;6A;)4\06>V)C2!%K6QJQ=*,3LR &,8G#L68QB6$IZZM!/?N301O[H_X"
M]GO]?H&W^BL$WNB/"+S6WRCP4G^'P._Z!P2>ZY\1>*)_0^"!P7.!NP:?!&X;
M$,&;Z+H!$9CTV[\02SD@MIBU[3%_.\H F:&,<%\X65#$'M?#UI?^Q3J*^<$J
MA?7&LH#]TJ)*X(7Y',%GYAV"3\P6"3TR6RKTT&RE\'VS]<)WS;:*W#';*W++
M[*3(#;-?1:Z9/16]8OY!])(Y$;U@3D3.HW,61/CLOQ ;K.\@CG4Q_[M* /'
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M;M?-S.XU2,M:9922M=4X.>NH26+6+>/D['=ZJ3E$"ZFGY1*5J=[A7KB9@NN
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M.@6/OG8EU]Y^%>?>M:HS>_>HS>B]K#:CYX7*S,7?E&8N)HK.BXC"5&<GN]*
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MOQCX+9$#GR7:X+7$##R63*?<EKA0+DM\:#.7A-"=^F,8#OVI3+O^?+9-7[7
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M\.(2C+DX!.7%HS"X^"P,+GP!Y;F_H#PK0OG$/VQG[M<Q[[W,=X=J'PZU\X\
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M<KX^SY^?FZ*-IRU,\.1D2SPQ90Y.3/7#D6F1.&B9C/V6V=AC58Q=5E78:=6
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MZS.U$ZD;O!]P/:2^,V@"]0RIIZ-:C7F"G"=/:E9'KI"K&IZB67M:&WC&@.:
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M;!)GD]\:FW+!OK,,&Y!V7%,.SV"(V<:PNQ:;+,4_PS%>FA7CKQFQD1J,3=)
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M-7H<Q"_[M9G(V*L]?+*+7^W .MN(OBU8>#/1;)P_?*7\TX,F3M?V.[.MB[M
ML[X7?6ZGO=Q(&SFC$"(]'JP,< JI2Q7U:* .K:",UV[B="=Z[$"/;?AE"_&Q
M26OQRG:M0Z,U:+R*3GT%%EVNEXGB3ZS[SI;:6[@AQJ:_YQEJ'@^%=QKS'X&V
M:?C3Z';<P8.Z^5&O<.J4"$XV.,74I0J+-X#3"LYX<'III5/QQ)"6.\S34H?E
M6CQJDQ:.VJ?YCB<TS_$6S75Z4'.<7]!LUP\UR^T'S7*W:*9=C#F8)V.D!^(9
M>I#K>7TRG-R*+O\J;P?M=#5ILU. UKM$:8UKBE:ZY6BY6XF6NE=KL7N#%GFT
M:8%'I^9[3-2PYX#F>,[6;,_%FNFU5C.\=FFZUS%-,]VD =,#ZC>]H"G>'VF*
MCT5]YI_D^5B&&X;\>QE>;D).,=P=)B7:0Q>[E91@G:^S5IA\M,04K(7>L9KG
MG::Y/GF:;2[53'.-ALR-FF%NUZ"Y2P.^D]7O.UU3?.>ISW>E)OEMTT2_PYK@
M?X-Z_.]7M_^SZ@KX4)V!%G4&66Q7Y!+X#V3A?]*.L\@QNO:K&&:V)4MKT6\I
M=IKG[ZG9_OX:"HC08$"B!@(S-36P0%,"R]47-%J3@IHU,:A#$X(GJ">X7UW!
ML]49LE3C0C:I(_2 QH:=55O8+]0:_C3R#[5$_(!8?I0GP#L/K[ZY&!LPW!_B
MNHOW&TC)EF.3^?AG*,)5_:%F]86%:%)XK'K#4]43GJ/NB&)U1E1J?$2].B);
M-3:R4^V1D]4:-4,M40LU)GJ]FJ+WJ3'F.C7$WJ/ZV"=5%W<9^1ZQ_"B/4O>[
MP;Z>8?XX''M_)38H,W;%2(MRX!EIC.T)H]0;8U)W3(#&QT2J(S918V,SU!:;
MK]:X,HV)JU%S7).:XL:J,;Y7]?'35)<P3Z,3UJ@V<;>JDTZJ*NE.528_@;RE
MRI1O$0NO;6+, ]T![AF&^*.CX?[(9E+!E<:N&#Z;CAZ3T&-\HJ?:$WW5FABJ
M,8FQ:DI*44-2MNJ3BE275*G1R?6J36Y5=4JWJE*FJC)UKBI25ZH\;:=*TX^K
M)/UV%6<\CKR!?(U8K%*"7*#.MX)_'1S_ZD;[SAQ>+^/>'/080(\>8J0MW55-
MJ3YJ2 M275J4:M,259V6H:KT?%6FEZHBO5;E&<TJRQBOTLP^E63-4E'6,A5F
M;U-!]C'EY]RJO)Q?*S?W;\A7RLNU\)Z1&3F/_6\"\R1IWT$X^ YD'7Q_,7Q_
M)GKTH4<G>C3G.FETEDG56?ZJS I7>5:<2K-359*=K>+L(A7E5*DPIU$%N1W*
MSYVDO+PAY>8M44[^%F47'%%6P2W**'P$>17Y0IF%%F466+AOL9Z4<P/XQ]N(
M!=*^;<@:4O*%Z#(=/2:BQUABI8%8K<SW5&F^KXKS0U24'ZV"_"3EYV<JKZ!
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MW>=@^<_ ,Y\FD)[2\[CS UVTGI]BF_]XP#X'<??/=/A&QN&W+GS;![Q0ZI$
M5C8XI?HCO/]%?/*<NBA[,F5/H^Q9E#V/FBZA[%74:R,AM).Z'="#=" 7K#M
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MNZQR\*!N9O""P8K6'"53GRQP"L I!Z<&U$8LT 96%U$ZF?*G4_9\6L\J[NQ
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M.5*-Y@0UF--5YYNKT;[%JO6M4HUO@ZK\VE7I-T$5?H,J\U^@4O_U*@[8KZ*
MLRH,O$\%@<\K/^B?*@BR_"CW,KS?0 IZO!CNS]"VE=1G->\7<G\F-IF"G;I)
M ]I"G-088-+H #_5!(2J.B!&E8')J@C,5'E@@4J#RE02-%K%02TJ"NY287"_
M\D.&E1>Z1CFA>Y4==EI98>>5&?X[Y$-E1EB4%6Z3NXRU.& ?A=/NK< /R$IX
M]CSTF)YM6P,RCCAIBI9JPCQ4$6I666B02D(C5106K\*P5!6$Y2@_K%AYX57*
M#6]2=L0X947V*3-RMC*B5BHM:K=2HZ]52O0]2HYY6DDQ[W/]MU)B+%:YG7J?
M!O<PZ>>N6MOIK,NA*',-BE!(?I4#+4J7ZM&C/,9515'>RH_R5UY4J'*B8I0=
ME:2LZ$QE1A<H(Z9<Z3'U2HL=J]38B4J.FZFDN.5*C-^A^/B3BDNX6[$)3RDV
M\3W%)?[ >XOB$2/=.P7^0?CL#M+/=?7$ J]G<V\JGW6A8PLQ4DN\EB0Y*C?>
M2UEQOLJ("U):7*12X^*5$I^FY/A<)264*C&Q5@F)K8I/FJ"XI!F*35ZJZ.1M
MBDHYKLB4.Q6>^C_(946D?J?(5 OW&<.H\PDP]T,%ML'SUQKK4'@]"UTFH\=X
M?-1$K%3ALT)B-2/%72G)/DI.#E!B<I@2DF,5GY*LN)0LQ:86*2:U6M%I8Q25
MUJW(]&D*AR"%96Q1:,8Q!6?>KJ#,)Y"W>?VM0C(M"D6NQ_['P-P'I][:3CP:
MZU",/U6CR\1ZXRP2J;&27(^8R2=&TK)=E)!A4FR&GV(R0A2=&:6HS$1%9F8H
M(JM X5D5"LMN5$CV> 7G]"LH9X$"<S?)/_>(_')ODV_>X\C?Y9?W#?<L5CEC
MI/_@[X&*;(;CKX1;+X!;3R?UFX >[:2B]=BI')ODXIOD(D=%YWDJ(L^L\+Q
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M;2].&_=KH"6%Z)*&GC'H$XQMS!3MV>DJY_$F.8SSI1.C,Q\7:>O,QM'!CB.
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M&%SJZ,CJ:,!U!&X=G5T=#JRC@G5]R#S;HV;KR A&0XI&DZW4DC76DD'66G3
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M.N[8B\3%)E.QQ10&]SZOG]:D3#+6I&"+232>2?AC4K/M@4<3*;07<M\+L9L
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M1B8[M&D-U+,.:A6!42(!=4E#78J+>R-RP)DL&'O2P+W4XILF[H"X -S>0C;
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M# 600@,R40!#- #M#_JB 6$H0#(:<!H%^( &$!DQ"BB "QK@AP(XH@$M](0
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M(32@! 4P0@,>_2LNXU& 6O0<%($"X$Q0@" TX $-(< 7#<"Y$ *(MTFF]Q,
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MK^Q=K-#_,BI]\B E\=[=^/A[B2D/<Y[7=:)M^Q"S??HZNS5V[53;H;934^^
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MT'XO?LX_!K3M?L([VUG^,GAJR<$[6,%U)-;3Q[ASM>*1@1T/RGJ!72?LK?\
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MX.((":3D)@@ A?Q+?PE* V(0*%0,!H7#83!1)$H4 V!HN,PNG+&XK,T%Q.Y
MN?W7T@HEE$T>-\G;]BQ@=2X&74=*;E%0W+I-176/VE[U [IZ^@:&WQTY:FIV
M[+BYQ2D[>X+#Z3..KF[NESP\O;R#0T+#+E\)C_@I)O;&S5MQ\>D9F;>SLN_D
MD(N*[Y<\*'U85DYY4E-;1WWZK+[Y54MK6_OK#GIO7__ (./MT/#[#Q.L2?;4
M],SLXA)G^0N7M\)?18N0Q6 P* RQ@0P1N[SQ/F@8?!=.7,;8!G$A4';W_FL2
M<B9IA8^;D,HZM@OR%X-Z)+=@#[Q76=R@_@WZ/V.^_E]!_\'\!S+X$D!+ !J
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MJX;;L(\00U#[4+K=2^'2<#TQZ].\IG_VA)\60>G;W(XE;#(R[#J:E:A3L,?
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M:SX9/,QAW[*PC2KA&_<2I,KQ):U$E8$:MOHL'3G =WO69-P%&\;;N'7S'7U
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M^VP/?Z?830(.T$R>3!_,U4+^6@<L,BNU)]L^?.5=H-L/+UZE#X2K[3E,;8]
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M5\1P//=1= '/U#'_(<!_Q)%:UL4UM+%9W]98-N.E%6-GN =I#5&YBRG$'35
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MVKN"VVZM67>U&]JT5$/?Q\?NK5L0N^7YAR&W<?A&*)2;V-PE,P;-HJ6FM96
M]\S6@P2U(<)!#CI)W#_M/"Y.*M"EBKYC4%?2+M6YA[^K%(^M:!1D$0]0%DPX
MZ'24MN!)#4,.4FPFRM @CR=\K5>0!B>@<EZX(\B=PA2$>@'SQ&.9K'MS^\KL
M2PG'>DDOEB=Z^'F;V[B3W?XY=U.5>V_ISR^O7Q8K954QZ_W>[&4&2,7QY6)
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MM,*59\G*!"LC*@\-%W83E1-;%\81B4A0P5-R)7'(F*$PYYQ_#,I9LP4IK9.
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M"-1VT*:YZPY"BA8R_FLOS<8OTC<<5WD"0#;137OX5K^))1[[;EC__AQJ0LF
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MX.AJR!OH6O$&+E*8BPELF:]$62BR_0Q=-;>%C@"\& 'E$,\%C,BM\OHTZX4
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MJ)^^_4WBF<"UG=*H?$\/U3'S@Y)[T;*2O\ ]ZK9,\4YN>R4ID:NTF[[[R]!
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MMB^Q0:5U#%.P=(=.B,6/1OXH*_ES81S0N#J.>]GG\FK?*B\/#[2WMD1*$-*
M<]@O)0\7^5T*+(>3<1Y_NC6/<TNL]UKVT=-!F]K[02Y23Z*.1!V)/1_LME8I
MD7)HWX)ZL8,YHK%GY]HQ.A.GONV4JH1$[!5].#JTY/@>+L!AL5N@M.Q5'MW*
M$9=/Z8G@0$(YA*5(6VMM4]4#<U>S[]T_E]CB\VU0LNTZ]1R;7U6U[50$S>#C
M7UNOEI*/JMT=#7CM*.818[RYF8=$H;[4>1B'KIF6UB?N'1D)S..1R_O%'K34
M:*Z'YB%M!4,IZENT6?(/Y.9$S;+1%U<SI)Y=(^2:UNMU_WU/+B;L%PGQ^E[6
M0)]+%,NJNB*[A[O$ER8HT5OT=3VTR9&-2QJ\K7D/J?_-0Y*?J>7V-S95HMW^
MTQIFI#*;?,7 @H'!HQ:U;]LBDBLG@C7:@^!DG1(-:B'M\M1L/$ AHY+<]8\E
M]\UDHMF<:^QD[78"=Q!L]GV3^0/ZR>.<7J*?5UYM>MY_+^XO8$.B'K 68%O<
MUYYN!R<O<J/2-0C515OLJB_>\3GB+WP+5O$0J%07H6\@3UUC@[9E3<IG270X
M2=ZW%7UU2IG[>Y+_4.S#CM(DSQHLG-,O1:TQN=I\+V5N(N!!^<3VJ&*JVKK6
M$I>ET8,L52Q;)E*4:J/YCC:28H 0NSD4/G':-5$GQSI7KZ"T;IX3M>LS/+ \
M4DM?O:LD7<&3&5=_C^UV\/\=AD>707CE/2D)P!?^WPNC&SP\9N4R+#VEW^A9
M0PEA11 6;IC(J"3G1HT3Y]TOP8RWTAO5.;545#LZ1\(GUO# HN>$-=CR"Z@V
MZ=1<T+_SA'F:IUTFQU=_T#&4JKJ2+0<'_TQ#GAICE^U'(5]1%XR^6HGZP4SZ
M,1N,![0L[1ER)\I>_,T0K@GO+L2Z5^A<M_G%E?9+@DS,C>:,EIWT+],>5T"I
M;:>H.4QZOI<=9);UKVI^G6NI?H0RQP--S0/0=11D',M1S3J1[GE"@='UIL!>
MM)_A@2#&V&W&?11X[_L1^/0<AL8#)"*L$R++,Y!%TPW(X0EX"W?;6>F[2_O/
M%4Q IMA5@VRN%N"Z%UL&4IZEEDC<)RU<V(VT_D9'82^Y]F$[@V!@KX.3<TPW
M?3,[T3V<EAV5=[9,JG944CF<&EFS_'G;6B]9[@63DT)KNYMI'EN94+[BG_*;
MV+A?#,MY.38NQ,Z8U\S>)X7E&+D[^H!QJ?Q-*<*SX.78ZF/=GC+1J!8>3W "
M.8]8AKKJ<UL[_;2&&.+J6J?;BL^XO$DO.-0;0G.&1E.'L-(#NN]YECN%F7QP
M-+ZQV_*75@:J%W:P1 ;+T5]UO7=2>"S \I<OVT?1YTS7M'97=652>5"8K:$\
MV?HP9[69SLK]N0@/CM]D7>+1[_+Y8Z$<Q0K<;U3%W5]NA0@F9[RZ)MCXOL^!
M$"8BMY2VOQ7NOLEYQ*-.?ZVUQ3W4(GY';63XZ$[++3OM$RXJH6O)'A\&$M!?
MQVX6!T7XA*(^*=TDDM:](FJI6^#_\@:6W2'#F_K5X[^L6:W36JHU(=%/1I%;
M0#:7F73Q0$A>0:1A6@Q5[,=:2<5]H2A!"FI%X\6N%HI.JE0.V);18'AP^]7L
MU>J.R/0$*TM8:6^5>_OT5OF &$T'Y[/H+\T-W"/B@H\3AV2JF%TML)$2-W8P
MFL)Y;PTMEDO150%84_NE;L>G5%062R_.\]"@]@HG11[2W<CXQ!!3O90_2&&,
M0G)E^H2I4+%RM0^0V'^O'#E5DMVOBU@*R'OAPH@R8Q9_PV8'_^6"&;</J7[;
M3@)O=-F2?;WP)/7CDQM'@DT>$7_AS6%NVQ>1XK=%/2_ZK@C-TJ,XB^-^6+-J
MY9<NXH%)6OAAF^KYRKCLN$M*_W>HA3&TGQZR&R<[_JYL&SQ)&X#3[;P4I2D\
MM4%P<^&/N40?V4/1L"!)&MQTX[G%UA<?0R&)>8S\@IRRN;IA?K>[@XJ0QP:L
M2%2'>,[W<#^NZ?-TX33O.3\ 88-TC&NQ^R4Z:\&FY&$8I18J3T>U\'UBDEPJ
M NP+_[VBE>J$:,\&'9>=:;&?NYE*H2\L8F2N2+39]U>42[#.WK$E7</JE;0O
MUHL:M$,>JU/Z)(J3^HF.MHGWM2@:YJ^WZ"0Y;])2B&?7Q9::^<1"^ZYY$QL\
M]ZK=]+/<JVW*>C8<U-(=\:50S#J_Q!);7<P16_MCDNEHN:MD!.4VRR<805\X
M0[B619#>&TVQ8"]P:M3+4%.Z5W21A3RA,NAL?KZ=B[OBA ?&2Q3$-KVB]";.
MIA>M:B]*LK+?0KWLSW^([3"1O1LQ+-S-V07+#!50O[X,*$E%3%4)'K"SRQE[
MVO,TX]'E*%YLHG(*B]]I>;AOZV(@&5";3:MCJ?-:J9_>M.($&$+%@A]53D-1
ML^=@[7'*&5EQI/U=Y?M3,1][_("5P96[8#9]S)+4$GQ'#E+C)5YH#>-*>X\'
M]%$K)R(JUR#^ZV-.'3^^N8IH Q_% @S%F%;M]\1#^A$";*5M1E/*W"U4>HL/
M#5SZ59,D.&6_>J"L'8HF-L1Y;U0-9T5Y-K]4'>F][XCU3 E[:^AJ,N[BGYUQ
MV06.>6/YW%\G_$RE+8C/<"EESHW V0K)A_O0,.M]P<.9KA>15,PO]_*FP<85
M&W+BX1V'"![K=WNY@<58'6?NG;818XM/%R/@Y8U'\?$T$W(\*AUG\.9Y\J,B
M@NO,U+VPY)6[/_R>B9,LQT^+F5^C+L'U5A""7NH>330NZLVFZ+F+&$$7C^.*
M,RFHFA^2CT=>^XV^9RYH]U:,\A$[F-NS^7>5,57U0<[=14>T\X=F"JC,CE%I
M;.S 8CPC4[@QS3XICJ$A^H!*^B-AB97,".414D5M3?NV90<*5N5Z/H&^ZXG*
M%%'0?(R5<S)VT1XXBJNIX5&G>T7TR==DG_;8*I7K@<./V4LT+C8O6;/W5JMM
M-$\O+"RL@;-?O[?B9)1+?*S3;'(KRN,%S.L"W8B:\6C:R]TO)FY/2(\2,0(%
MZ3$$7>;=[4_RO#SY$\A/%(<9U_VB*4[7X"==EY O%MXAV4Z$/50]7X4V103%
MK.,!2K=:*!D2MIIMMK1P.]+!\*,\][ P339UW(&<AAUGS^F=N3EE.;=@OAH%
M$\ [$7+AC9I8F)?9*2'"^$/(D(/Z]T[W:V1F:IVAS*U>![Y]ZPBZ@P(F62E+
M;L4F;I4I)86VC57U;# 45R^PDT^MHRT)VN<)XPTI6?T1#RTP+S_F\*8TCC1Y
M4KW6Z5P+VMIS:36Q"2NW#SY=[I9)WQH-69RJSF^;.Q"U5=I./QRJCLY:P0,1
MDARXB<;SJV1??*3EF4C3Z,Z7:FW;$TRJF]5UW V8^1>3@F"A;JRQ6KWUI>2G
MC&!97(46:U==9R[(>@7V/4$:R'I_G6A AV#CYC,P.]9T %+F=M^';IIFH!\\
M;U)_NE9K*U;@+FS7UG?1(7EKJW$RI632<$FLM"S]0_ +"$R1@[/@F$2E;[:_
M<"L410*T[I-_J^&!"RZG->@_G3_Y[@[KR^= M70>%,!OSLY('.V*'1Q4FZ/-
MX5O&L=H#A^+]WR7I-TPF4L1]@EE^7FQY1T83+1K2,$UN:,"X5*4+HU39,65+
MX.THKJGG$RF[J^U^\!9[.Z?+*"#YL:J-\HU+91QW^N47L%?5 IGV5FR]?X$N
M04UX3 FK^U<TJXL7'K%W;0T<Y;QJ)D*8O>$SE;W_'OCPWJ_^$4$G0\O3C*GK
MGJ!UMD,V@>O-W_XBQ1[+/#_&1,WTVMZ-*X> MP'532F:006C^=)^K4F#ZH/1
M.EZ7!ZUTW2( P::WCE4[;<SQ?("X"&UP^<;.,F&/&P6S>6P/?_^P<(FH^IJ'
M!)U\@AZ3I53&)<>BDWRPMU,25J2<-B&FT/7]O,M/5M-B"146KYF0?$F,]A "
MC:<[0D@#'VW3;36D,=- UMYJRD33SH/[++0BXL=GY*.1</[J.AV.'T(<BI2?
M[W%Y A8#1*W06^+/?&4*E#ABS2(_+X/"17$6.IDW#@I KJL]*,W:O;36RI@[
MY=!1Q=471^LD4 8[1>S753OQ=K6]+RV0B;.,RD\[P=MO1#;H_(8QZ1P<<IL7
M$0@>G;?KXS1-'D'_GB&5#5,J;?K& C?MS'@J^003LN2^_S '%7)R*XY19@*D
MNF0_$.BED[RN8MC?R=3_>Y[$+]]]%$5[\@Y;>D68"QH*K0WO*RRL5BMZM-73
MC]B*W/Y#=-H:># :YRH]=NY;R47R_='[)UBIXG#GLK*)]8*[Q98#IV5RHZR#
MCLQU@9_V'XL[?:*X=TYIY&"DNZR:, O6P,#;/QEX^CGN?*9WI#9[)!YL&G+F
M4/RH>:[*O%*C_&T-_.&#3I_'QL8*=!3J>C"TX&QIDU_6@BH9;[!KQP+SR1!P
M #^&.6;0K/<9]AR9@K3,RPI[+[U_OJ0=<%&=_8+210!<)X.L2KRX9D_4U9,O
MGPP&3<Y(Q".?4!7=Y21]YRF"![9T?(PH)&S\1A=WU 33)&^.(#FN^,&\#_57
MW26$:[-[4V)AUS&CQ:>/91%R7I].8PDFV!? Q?8Y\?Z#W5H7<6WBU%^9?+0^
M3F,\B,PW"@Y=T&V<7U43#-<_KMF"'>4BJ *E@M3>$[WF[)/@#F)YU+E  F"&
ME^1#5>H+7JB5D5YM!P_X[?:$[P9ZJ:V/)/$?/<G>2VOQ%MV"'K1F3\+:@0N.
MZB0A=O&&7;X!7YY]BF-0?FG'].OJB^D+:"#.39#9;4-+Q+G6U7I"\)?W?RYB
M/,8Z54.F/AG@@1L5\MB7925'Q5T&0NLX>1J'H0,\P!^$\;'A07=K.=;\N,Z,
MU%>>XNJ[.2<_3;.>'OKJNO)QK2GB9S3*<\'Y"6$E.4>LHX62[=MM=3P0V"B'
M!^ =D-U2U81CLS68*W@O:6/^\)3HXOC1JM]G%_D:@6U!>XE7U-8"+H'GTW2,
M?G;Z]GXDRA)1)#(DP.%\F/\]W.\AEAM.@FWF,"8I\;A3[?)ECPU+=<-OI[QR
MPQ9C)5_+7R8F-\5MJ[*,N_CFKU_1<9?L&O45))L+GU+\UM1TA> ";4RQ!$WS
MVM1.XML0/J_+;8UEJ3$:U#CHO@J/8X:&ELBX>DU#9':@1/812V0\=[\[GTMW
M;B]_*Y%42I@X^HHJ=J.Y]E="$,7ZZNWK' N&3-Q[8VA$R@C2$H.W(QS_D*U(
M#J4$O;?]G\O]>(SL#L2$Y8RM;Q[UJ_LG3,QS5+<DS,:<W G*ELV<E#4'IDH?
M@35F< _KUE H;P7G F;]O\H\<\KM- 9VP.*=%%'F]:B #DQ9>SJ](^FFLS3!
M@07KDD1X7 >6N-7[5M(3<61[S'1F1_U("4-3STNG6"V%!>KQ*^73&A#F"?];
MEZFEN+WI<?,\PK$Z/8H-#Y@;HEDMNZ+#U6K7?)@W%9?%I"]IMD5,F&:6<^$-
MYHE(!@ 3U\[ ;"-:/H:9"HIHQRTSAA^]1L6)3Q9K#V[/7Q/<%25VK1*QZ?^<
MC-N5)AH8E]!R]-S(QG6B^K:HDLR#U&+]+@OT-TQ$V]G@N)LM"AK()XL'W(B-
M)7_V>C\VS&/N_5+[YACVL88BQI&GX-Z:QFI[3 >)%_-6RGH^>G7;53TJB0^%
M[G%CY&U1O45!@:2J255^S->.VV>"$NA+B_=T.:_*MY]9QJ?4K[AWQAYVT$)V
M0:I;*;N."88+BJCV*5H0?;#R;22!W"#Y(+*.=PX/-!3TKYU4P^239E<EN6JJ
MXA1J;;ZLQA+?.*.1@+X<SZB0_U)69;Z]2VC?W,*@*71U3>M5++2!2/"W\$$M
M*))IM*^A3.!OI2MI@EE^.S_U714+L7B.?5X&WS**K[3OQT9S3.>NXJPI]PXV
M].T3$3_)[JG[\>LK^Q3V,2B [<?3O>\_8PR)J /;+M6:,V9P;1)'JXVJ5A\=
M%S&S$66F9F3#/E7TDQMO""G;OXNJ5KUZ18:\Y9;8N'.LW<:"DY.[E=#D&FX9
M#\QSXVB>3\SLS8<YBO.Z\SA\CF04!=<T_V0^94B65=!+H!<6R]J&W/3,&6]]
M^G5M8C&$BLW5434WLYA8]O=D>J!%=G'T%X24=0<>N",N<U&2_\6F'U4$<><;
MJ'(Y&W<3/B@X$>901,U&PQ>J0B++% H4&[E,:F',><PL,(2LCJ-KC=JY_)!@
MASN8#6NTMWZLC3B>2'HC)",YW3Z'/4S9R>7\PPW:$V;?]#H&@!Z<<P\CU5-9
MEEW-+TK'#Z\DZ")[PA&<DAK(_&6Q/\JNR,N#*9+7B9TDAMU,E>DZ5-_^>WH*
MG-*SRB2NQ3NR*MI?>B(2ZD8D=6$_$.FE!7OZIXJ6+<P'^?=3VPO=#(Y;#02C
M3DS1@OW:)I9, EF.7NEHP_97?\_FK#;>$1!VXV8M-@AS"+5T?+N%&1N93:O]
MK*D3=0YFG6Y>5RQUG?GM@KX'U4=-+$JN[E7&D(?E--L#P-5KL)//T:K+QF_2
M9OL5.1-8HH.SO_\E1??@4:)$<$=0'A5VD"D6?*PZBPTK3E&90W9KB[J N!>B
MWFR(EM/2M_@T=:)R2[;"-U)J;-8#5FWAJKZRXVTQ7Q4>@--7G]MN'48W)C@U
M"274,I4E<:E^XBHRQBW>@R4E-,$*&*W1O1X[>>L(/XH:5R9N5WNZ-P,$JP\"
MHG>B+VMK[UO4>DX2QXOQO$>G,DN[H8WE:-[2YU WVX.8B4:74T8=A[]\:->%
MZL[,VS-OSME$HA5T3MR7S2R@=TE7_/@4+VOO*Z2\L3FR9EE,-=&?S]/C7/3"
MC2Z)\A*]*);5#JVW4K:SCZK,@PO?[,Y ?_=3^@6?ED\:4,[ /KE34>Q?"2\=
MVLI *O8G5:.9G-(R_U4LB"*Q5H-3NRI*$VW*9;[K%Q_)(0^47=7=W44V"PJ*
M0[J/A^NS"P2L[=M^?SAAXBSK6)HVW[FL*EO[GA$JX9O,A]=N/CC1)B2"&%K5
M(>4O$3:+Q]+5%7T)L1K5PSLE-_C;8BD'OE]/<7C#R<SYZONPP+07#^+CO1AV
M\X/H]UH/YT(38W5*]Z]GB<[,=', -"MFP :!.6R89H.;!B:(\J/>DVQ=JOQ9
M W'7)H$LB/0ZCWIGNPUJ*Z?#EYF<?"&(7E>G1EM-4.&,TU&?/5VQM;F7I);+
M$O&J[8HM8VR/ LM9RI'[P*'R%PIJNQ1#?UE$S_<V2! YT4&>DZJK>EQT6!)T
M46@<LGZPC#N[9 )JG:#F]207?O5Q-)F1%J]UK)M, KE+P$ZK( U30IBSH[OV
M4,G*$"JK)C3!,_4Q\W0)4D9'^^JIT>")2D1>>Z&>C ]Q5\^'1A#^,CUZ+VE_
MK(>.'$)!ZAF(8A_6:F(5YFKOWMP9_(4I*1_67N\Z!)L2L>N:VQ27:?*^FOY@
MQ*Q,ZJ#LROJ/C$W5@^*PRWZD\*VYRT^/:<=,/$L<>%_:DJE)(67L,ZXQI#CU
MH/?^WZR.4;Y%]91@!@_4X@2S)5FL(4'PN[K0]AXH>A!R=-\X8-.KV]4/F0MM
M+S=!\1Z4\*&\(\Q6__7P=97:'/E"W5[K1UU=@>;S]. B=7>/YQ5NYHL&6WH"
M6TE5GQP\#?- 2_4TQ=\.&<I*AS%QK8>>P4-#8R\#;.FUC\Q_$>W14,(XWU0K
M);-.;$E2;("G])/K/UEQ:O5CR1IV5\/#H[O:XK,\_-M'*UH\&$_"*[('!"9+
M[N;?)Y'0W>,[72OFV'G <JIAW>RA0^'&^7(ET9U+82O..'H*Y)A<D(N)TQC*
M.GB#8OTHOF['2+&JOI2^@6!CHBZ%XJC]7'!0'LAN":Z",69;TLN#OP),:2?Z
MX\:N=:*KQB?&%<+35U^S?GQ/_3+X(RAH)<6OQ8.2JH3Z^E7O< =75C&Q+!2,
MPFYPR_W67.N0YM5S4 BZ1/0//UA"Q<GU7GKL#PHIJ7V/4*^,'7*J$=',(YK'
MDOTM])CW=4)R]D:/$EVN "Q9[I;;\N@2.=YD(]";K*YMDSW'R.(Z5J<UV<,F
MK *]..6F1.O+K]DAQ,(23R7S!GS=$/;[(<&64?VZ*_=U05A01=O"DH><G0'3
MZ_0G3^B=MF+T4NAU<,S#Y2V\+DX,#O1MBW%'H I%[NTP9[59N#!6&I.$!XBO
M?"$38[>')\/(V"HAM4;O<KL+9I;35!R82U?&[CS9U$"4D^@KT#TB'$GUEZE_
M,UMA16SRW*]Q49E87"RGU:Q>\RWT9.+*?-&_="U-5Z&G4!N4TJ\8*? SVKSJ
M%$Z$F3 G0AH)9%FZI!16K(K @]-OP5I."M]^>#I0;%"IL%%=D%JM_25Y&,8_
M;CX'6=3<@!RV7%8XN6J_[-HTXRZ) !R-7  >$%>].+(YCD6!NB3>^[(/0-?#
M+LMY%&C(J'E2OO00!A,7O$22MISC#;Z;OOO0&A_KJ9I%'DN76*<5]PWO^=^.
ME%ZE"MF*_C9XP L$K1WXAO4JY+@4S4((WA\^JRY,<MI5!;)?];I]^ C,U.5\
M*H7!8?F*J([$4ZW^$+<T]4OJIE0=QLM)?42_X \LU=^NUHI9J_)P098$SMUA
M$(0=!VY>/7E-N5EZ#&I)6<[CK.6.F504S[_0VTH&57P8H >5 Q:OK@S\*4E.
M8$K("I$+;A<S]@D3DXJ[X^M@B@? ?'A@_#D>& CRILA;YQX\R4G# Z!!Z,_&
MKKKVZDWNB/A_S^K[YNV'/,/UC00=V8>BVM8DJJ*S#HJG5#9GHQE*RQI=VM\7
M];ELPX.]+^D]#(2>%FS?!6]XJ6$(_]+/PY?Z6>92/W]I$,"$]*9(/&0^:#WO
M? P-_0A 5"K&%2$VRP6\/YS Y.(/TQ^-D!@2'GOJN!SW?UV?*T^MOO.WE^;Q
MP/^)FX+ )*Z4>(#K/Z_ TAKN80P]3=1M3*]*W9L'?X<TP]6,WB4].11A \E;
MEB+AU^ID<64OXO' \(L#;_./6?MKI07@<@=%$XNS.]4JW_]>CX;MAP3L^.K9
MKRH=O PX48_.]Z/X)M%J2R\L0;I*PVJ^ KV%N108S2YTQ<OWY=Q_7LUCBO:Q
M'AAWM4"4_G[TTZ;/B\4SU)+UQ8;\57^MYRF$!@V$5[R<D&M"F*$?VV(-J^S%
MEC]%8I+[SY_#UU4= @V'!7SJC;4^#CV-F5AXS4B1M\'^-*N 07D#EE='L+?)
M2_JMMK8E*1)RX_<F46.]DXKO%'?TA,;**,KC;"X/%&')O9+-T1(8B0=\P(^P
MRE:7E+_@4HTTBR:LU!3-)*E;U/7IXH%?,%6D<;BVMG@;"N7GL3?>/#_!\-RT
M[>'/*PK\(]0#_EK-(D9GH"#A@ZP!3N97?V8E0I;P0$AC>?F@WZV+U<R9=R*/
M/)GW^NR]5?K:)71GC5PEG?<:ON/ (Z;UAD%1;8N;N<70-+=.%T[&&-\B?I22
M4GQ=$%ODQ]A'K^5_]GI-VW@KU4@Z85J72BI>"OA8];S##IM_,OG&Z.U1G*]6
M5>>LE30I'PC(NJ;FU-BG!-I16G_FB 18W@''] C+B8**$8]C7!8>@%!?AD3[
MGYTU.J_7_":@CIN0PWW(!1:ZGY7@3FX]F^0ZZ_'*_MN'GU^N/R=Z O$ Y=Y.
MT?8F$W(KD%RH% DCQFW@M-;2DP7_;'SUE14>0$%G+U\V!*;BAS?U1VW+\9CO
MG+?\3TF2_E\EB==)2SW1N8M\TNN>RN7>2/+LRR0ILFW0ME07@F4>TGX\>CJ&
MMG%P7R5$??+F2+?_<2FRE_Z(;(=VAJ8(!E(.(,,;> Q1/(2]0.1O4B*U?\SV
M2!>^,&#+>;;@_S!%QUWZ4F-@S'5'6,9X+>OBQ'*<YU^F$ZT:QQKFMW^>G>TO
M:*#%^)Q3*"@PFMD7OIC<%",XU:%1,#IC&EGN@BD4*O_9!7O0&"$)PHT/]8Z8
M/YFB6B:,S?T(*7)0,2R>[?DSY0+[7">1WYDYW^P#@KHNAJ*-EP^*.SD+&-7^
M>,_^9DMC5?3: WK65[^B4]'8:/G%OZ9)AQN^5?W'8IC2]$T_.7ZR$7LNZ_SO
M'3EIE=0*&_V/1R4I;&G[+-[7ETK0\%4="/[('XQ T%:&B.$!$DFF^?V]B3.*
MO8+CAN<^8/ZWS0MM"6]^KWL]9,:H7,$ED!<@,Q5CY7-LO5D3P].-XME)\, /
M$8B&WM.YM<Y'VX5V(_%6FU/*#14$%;5&^WQ72XI%-523-!_&:5MSTS8[D-"2
M5VXEW(-]6]$Z[*Z&EX5O>"AF FJ_& GT4OZU%')[C[7'@33CB?#]#QM26:\/
MA,WWAJ7%+]+L36QYUHS[)*+[VMJXGUZK?.\0S1<$^ECV]BR%U8&RT]!7;/#M
MBFW.>_%8JAY5=643\<30_EB)4.BBWB5,H<I=NG_Z"!]38+2]*;#G18P'*%#?
M'[Q*O\0KR2UY\=J0,MAK/!!DG8$'^FL&^WD6MY<G?$W(CH29+)3<2 ,IT43,
MZ*STRTK37CK+$4@@_^PQ)[^:#9!!HA\,)\\E-##DP<Q_;"@?KORF;"+G3(E]
M.K#T>NMM1MY5L%.OB7AM\KGPL=BW9<I'L@N/?H&:R@0GW/Z]QBHX(!HO07?+
M/_B]>/=OXQMX(-#E57V-4W/#/<CV4X4+>UO59!;S&\Z5_:J%RI$7&DH!NE7V
M2HAYZF7GLZ44WYI,03<K9]N]<>FH@)MN79_D%_5=_@PLS+SF.>4W63HM ! C
MT&/8%OV#F@2Q+67WHY_1Z]Z2^M?8:ER.K9E"E6$<O*_BDJGR6H/:37-M]Y#:
M2-NW3UM![K"7I>9G<7I5?GI?#?,[:O\=5_^W]@[^OT].#8(-7U3+=:K,(@VO
MR&<*(A?RVA J>@4%8.ZT)0[3=]@C,%=)M4]3DO,<$LG5[I*Z,B;\+=^-T?RK
MF'-^64E0E&+Q@9]*[$_8NQ6L>5XO8N(T<=V^+*@_0W##E+VM2$5OQQXNDKJ4
M_WIO;B@ZUEGQ(HYYSRI/$F&CW,X5J0E6V]6*1# (<I/1FCTQU'II#$XIJU49
M1[G3K,%?_FWA?3$IR7CB6LY4=%*8@V.Q<K;7'#%HQJUX<C%7A22[TCI"AC\S
MM'"O?+>?ULI5J\7GOQXP@C;,U)F#9*_Q]4>MOSJ._N>^IIM=]G5N*& UZ8D.
M+T9]TZ!74L1*+#4N3M?,+&_4*3J,:=)(;[RI":'C);;IZM;VO_G*)2NW'"NS
MM)AF2V9VE+;W',P3])0M?S?:9KHAJ5]A3COY8[1HA3:B879,%JV1TO<J0>)A
M"EH(H9_FUBNGJ-29JM,"QARHGFTT]NCD73)%VA5?."6T!MM9Q^[G:(J0&Z?B
MDF';9=0T,V4?LR-NE,GB+%&B^!A8H/)8']57/*Q6V4!?&6/1;I3SDU5%$R<P
MGG<D4'J[E&$@U?)MSUN$@X,;<?0>>RAZ]E>NBD9@B<K) 1NU2I3^6[KX:K#S
MW1O;1^>^!C0OI#8IZ"716DR*L2>H%>N0:#"9 A>$RY:GP*S9[NE@^[I *#.X
M-9V#1J2JZ^ONQ.32HS;)P3X.IMU,FN)22^]I[C6%NP,@VZYX9$$?-[.H;IV$
M1[=<ML7Y0Y-8V2"E:I*L/(EK%G'>W'V="E(N"I/<T_376CP(75\RDB\,.SD-
M*;9(9W-P#L?&'C!Q=;ZM7;E_VT.<A,K9/7PD3T5@7&!*J993P<]QE5Z\=4(*
M6(]<*I+6J4@[IU.LYY&7]#RHS=[-7)Z[^S.<VS;M,X?EGJJ*0DE6BVR=N+K^
MI(V_9:+*K1X[%>5'LY-'$K%B$RQ7L_)N=OY&HDN^O(MWM2UN1^X7J=C^[!6H
M*IOPI>4SM&CYO3].A&"CI0C3_:D99' NPF[@0Z7PH*DV-4AMYBA/H9[2.?;C
M6MP/(SV2.>D-2QWUB-&R7_DKL;Z5'ML6!1I.+I%)'+/STN =)=7337B:S@_X
M01EOD1H>@,><-Y^KC^.\<]?E+R^67EC!L%C8G#+K]JU/Q9N(FBO>(]\4MI.S
M"S0"%-45ZHN[[ZW'#&69^QUS2JSP01)1^>L8A;4B:64C-G-B[5QB9T4%I0HT
M45VPT,'DJ.'1U4/IP)0:E=\<(XL\"@KL[@T(I:BW;8/8ZIPH\$"Z_8O!/%;/
MUG*7D;;%C>Y8A*Z<T1?>POT:K_Q?.?RUXF8_5FT/IHW;]5,-_;[:)X[7'Y6F
M@>I-F4\5Q"T/HZK7!<LRU3F3?T\L18N1L?L(CP8DCE47&:Y_M9ZU&TN4I^Z*
M@4O;VPREXFY4.FFUOLK8T<XVPTXDUM2G(:<=G[SP(_BJF:NJ)YN!B,@T.AC,
MHY?L3$UJX<7L_0GZOGK&1DPC\]K/B(M!:-@=<4ZHHVEVRV70/XOK9M3V_*R(
ML'WT\((\LKB>2Y(D]3+J=7S*\LI''$H^/!WB^KQ5/DZ:UP5O2T%+?DQ\D,BL
M3QU9-)EDS_SMO]HU0Z[3.M5M<VS1VO(C+=1/0G75"*,H.86 -U58]UMAQC\T
M5\LLPVO!O/P! [Z,9S,0A]J8>!$Q[UCY/,A0O1VF0MJX*U[[RY$DA"!.Z7$N
MNE!SOKY0^^20?4;*9>'+$<=JICA,WC#J5W0R3:$AWTC::';C=>>1H+?@5JDV
MY:&DF>5QF>+]GJ9UY7#-C>U(""/#X7?.Q+((I*O?0Q]!C6L,,5/:4*]>C$\3
M;Y%!1$28'C/C ]CZCE'"OF+@*7NK28&X8>.C1,G8(N.L5U-\!M[Q;C=OPJ_/
M9<>(6$">5#UK3BT@3Z@7:;ZKW*;8L]1BNKDB'*J)>+@P5?4</9E5L^\P43L8
MU&(=,N6Y7 4I\J+3/=!9\>/Q"W;0TO[%,>"MV"_SI<KJLCB^U8B#/SXY*48B
MT!4;GK?OXMKC:AN?GO#["BY65V F$0FQLW3O"=C8Q/<-EIPHFQ4'PUV@'YH3
M+2OX.7Q'.10%S(YTZN?5Q&46)\6?[,\8=/043A!]THQ^YQ=%YRO=RJ9B:]S4
MXXRT)*>+%)_G]$^TU_@YXD;X#>-4K$H^Z#N![O721)YSJ8?(<E.4M)B!V#@2
M_+*16V]7'4->ZH^]@9_:7Y#9?K95,U F-V9T6%QWGZ^K.A*H<U=$OI$'B[J>
MC=&!EWGEO.FW[*^)V>[*.R;W;*2PC[NZR=R/Z$Z10_=+4%1XC!>A?67LV&>Y
M*>"_%M+-DZ3)LS.[1<2*WCJ=J00=7T@58GN_*/E.'$DF;&@5;>=QU%4URJSM
M?087+B$"UYU6'5RX9V&R( ;1:PDC'S4>8D+;^&#^N2G[<VQ;-.S%6G=?G-NL
MPB<_^SZO+\SMO5XQU*H:O*TO<J#P6_7B>GF/Z[LJ\[C@+^^*_E@N"J>EJK'(
M=FJW.]QK; T[2J[\K)@XL%+'9N%FQ.&CO@;AP^VM1'KK("+@I27TV6F)[3T6
M1R!^ @WRE>5>WHA\EDM&Y0$[]8*<].,!XZ3CD LQ66@!%$T-^;FP*S!,GGE\
M5X^T]^=#.?D>[Y.=%+2I^E%]^=+7HM(#P>_%Z>ROOZ-9U0Y9H?Q9^^]M'(N6
M.Z^9/_-"T;L8ZBJ)NC'5E,WVB62&-3?MZ/.I&K=_U\<#>:HG.J<DI]6^JJ/P
MG"$,,X[F%"2U9&U:<N_JAQH>/+"K,V0:>U9>CO*W3JXL>\$R6S_+NR:U3"%8
M\?I3+%W@S3Z1>Z.F(EK75\J5/Z\S[H+IAAP4LA/KM^V[]TY39KJ&^0UI9@,Z
MV.BG#;O!ML[?$#<GCM:;9T;2%$:<B^RWYGT8*\.KSK*@%O+W7U3=>:M*H"J\
M+GQ<?#;7%W[6'36OFGR(80UKK4IHRHKDF4E#*SB:FYOLZ0[N^(^31N+T[GY8
MSMOD&]XK]J;K=X!8"V>GM^=^MHBX)K\E\' ZJF3P+*TJH()>D%OL3<@3^?A^
M9[[?);RTRNH%.?T:FS_>O"SU5/4['ZQS/*4S_T7FNL,]TAO;\EY$'&Z(!S@V
MS_#  [5<FJ_SYIV&DIM]6GR"!K4.\CZ,ZZ&^@FS!E48&+UJ5S"5(OJ_XR8_5
MOL,$A=>+QNB4+EJ)O/D1;:@"<DQ*YAFS&@_=[<O-E'KG?R@:@":Z7OU]Y"+Q
MX2LC:@G#?DIT77&:1ZTM1-/J$A\HB@QN_L&'SAM9TXT5]B9WOJG&IFJ=E<%X
MNUAA7PO,. 3)LFBJ\N1??:_><]A4H(X-7#7(6<0JRLNT.JB\:QMVBBV/YI(#
M%<N$!B(5:AP*).)0*1(_NI".KQ6&41V9(<LFO,(_%7X?N4.TL[1T<AD&IQ2>
MC$H-_!<\:P5.:?EP[8;8F]G39**CDLSNT2QV[Y+?X"_[C"7J"3R)$>>KK&>@
MI.PF[IT'49XD :<Z85J'*JJ]<*^@CPCIU#M=CY8D'_QBF&.O+5CP%]RT/"B?
M\<E:^1E+/!"DDJ]]WF.D8@X)*9HX?@=A-M+4X>%0 !D_>9NCH:B:537CGDZ,
M!SY90*.\//N7RC8/3$Z$?7M*0F.NET6=9\,SZ00'DVHU[6O$^Y@_)C(\V:+W
M#^;NWMVK@?YP.J7&"0XE\?!-'++QO$FA16:2-6(CU/' N QV<QUW7$]J ^U(
M,5D250UIW%_" ^C!QC0G*W#K*6B>' _4-.X_<00_>@JD]_&=:2X(Y-NWW+R(
M:>CY70'95^K&(7%F-0C<"5BC^U*O/["#+UK!FF$8]!=<#1Z(LOR,!Z@D0W3(
M\$!M/U;I0*#.!P_<R\$#?I TTP^X)T?6F7#HSWZLVL4+\<O.W8O# T:L.#?/
MW65L3+ ,;A$/.+Y<\>7# _?;SQH/!3?,H+-9&[#4+CRP8JDQF@Y?XCTE,H2.
M\U]P-F5B=;WAT,_0FC$\0"@,"V[<7#_+Q048%YO725#$+,(_5F%B1CT;<5*Q
M%YQ]37C@#MN0U3S*C90W!+J/9#M?J^6G6.*5:5WL/_&"AJ71AE4X94V6O\?M
MXS1!ZUC."#*E:4VUC0KKVN2E,2(*#KAM@:Q76=C>G4]6,17L;>_>):-4GLS#
M:3;-\P\0TF#(@:3JO2:1+MVS;H,&@],MYZ1HR H;[0!T0TE_H3& ^8OXY1!D
M'4BXCU\H0G\V=NCT=2_Y%UYP)/T&[Y5T[.]2XX$.+\A<!!ZP*LEJAM9TK_E;
M)E]>&P,?KZ_QAC6NB(#'("LVS=!:I35Z.#82B0>F&S.W(TZ(AL]T>MT@JB84
MW4?BYK]3[57Q@ ,>..(X>V-]7@?=&3[8_O*R*_>B!=NOL/\*#X2]F4>-AP7C
MN%1K>R&S'-Z,C<U9H:Q'LQ><C8\QRQN^ZY>>NPY=$G0S8=1#_J#[1#^I0CX$
M$ VSA:\C/N9IN4#<O-(3><6;%UF0;6B6*K6-OKLM.!YENQ&#0FY*\KM.EA+\
M[32;B]]A%)(>+$<5,0=ZZ4ZD32'?H]A_'[(;&]@H>%P&S0P8/8$'-C1E+@Z,
M XK^1)')\H7*^6^3@YL1F_9MK7B 07YJ91[U[C093'F?PI;Z1 'RN=7-$C7*
M@(+QABX@@B-KVE0/!+&T['%*H> %NF)#_=4B3E".LN0;)H$SSCN%S/7AQQX_
M38^=Y1/YA[$<#Y'GPH]XH7F#TL*A2YR*Y4FE[BLZT]BH10[J\L?].7)0CI6R
MN?:BWKN3@O[C.H\SPM%N[$P3?O$94]6[1\4YR'.6V)/=O%5IX:"(5 3KMH@.
MQ^&1T/.\M,S@W9>1.*UNZ_IR"6.;^80_3Y^'\%^E-P-.EI(RE;]MSB;-6-OI
M;%G;<O=8ZK8%A3#3,Q78O5M/?8TJWG8RL\^_S:$3H-S$7:2])F-LN%GS*F4P
M@8?EE3PSS 3A>B =]58_[.=#K^**-U;$FLT5#$,*1>Y"7!'-#N"I%X=7R-;%
MK1D/#>/*XE;T351EQK)Z25X=][H\*K;VXQVI+"Y\DDVY24%SIS)$VK8@IVA%
MJ.^94[6SM_.CLNW6?AK$^%P8^YU__0E/=O_.DZIW2M/=-T\%0L[&!RUW9^)]
MYU=@O9[13XL4<U5T2VJ<H7G(,XN/!KIIWK=-5HUI9+M%>)_ZX1@476T[W<*Q
MT6Q++)D.YK!J7YS6YNK62=2Q?.<^8VQS&Y-A\6L[/CI?L;>YL#G"TY3-[-V(
M.",8F)96]5$.W.=BW6$!?GI='C.>%(GCE*QBQ0,N(3T]F)![2K>-=]@.Z(L.
MT-ZP3I 'I8+\39HY;2PI_;!UT @>\ K#/K$O$EL&QZQTB5<+B,]V[%QBA'X2
MK@:\K@4YJ=BPE,$]'\(#E(-8"3P H\4#Q5'8K8C'.-Z.8XS'Q>AE)B2*_\&F
M?1P&9Y9+@-5T@%]"'T3CRC!.UJMQ%M*CHXD'YI8WO02@*\H:6-XC 4E&:'OA
M\I#)&MG?*&?R!^4N;:'"1D% E\G*C@?F5==U7T,CZ^DWK.=1_'C@-E2=X@JT
MXY+*C"M TXS%,'B Q?03'O@)G1X6 9-".YQP)=A>;SKXB<T9\_J3QE-Z3;1U
M+B8$)S4.1O?@ <6];] [H-SY-3"JHO%7'W@QKTE%8A@/2-%LKHDU#YR"&##V
MO+O,!?M0; #KF4Y:T&5B9_<VSFS2F5"0<[.PE:5L]T!"ZREH0P2:E; O5[$*
MGK@'HW>ZYN/E)K)*(2WS"1ZF"]_+C?0VIJH7K+00*>;F 5F%#TY]2T8OVDN0
M8PJY!HARF9L,'W""APD/-Q5Z49-G5J#(=R-9TB1='.UQF/4H%>;A#W@@D]N/
M_":&'R+:+]"F=@JJM<<A(#,F*YSKEOL0;?\X)<P[/$""A8'V(=B0N(N-QF.[
M,W&A\\(&ZS4O.#;*% ^\]3?#?,')Q%R8X^0BA<[+&TS_X%\?_*+V#-31^,X/
M@O =USA"[V$;9=K$[UX6B"H\4(D'SFC\GO)?S$&.D:?NRGB F0-^0GUHG8W)
MQ4F506N-'][%E*(E=P7P@&O>AM=X""J]6ZXV19+15!Y[,_RX])9&BT; !,:P
MIJQY=2+\^V 1;;_T^ ?7NS[H6-3J<X2!7? &.0';EMYR@6*<9EXMI]$$LN.=
M0"E?.D>=%YQ? =*PEA1]M&6O=,W&7--14.Y9.^,8'4-L@H%"96&_C&3S4%:0
M.N(:;5_"X(>_8 ^"GKF$/:UIBI-.;Q"3XRG598""-SWF2"[+O*&)AO%37LR0
MY/C#OW*@&Q/T*+I+ '7PVO]/H2^9$YH$.5YF 1G=2=*&+>8A/RB)$M+RA)/4
MO-[6"Q2L1,O(]/2L(#6QP(U#.0]HN<KL*"&\8W3TM=IFP_>8HW#TI9VZM_[4
MSH8D'E 0M0QDR%:O3GMI&<9&>C?V1N\CK>,$5FDUPP9T7:&1+]OHXY'2HTV%
M4<.HRA-55[TO.HE3QTLKU*T_:(Q_?W;[IAF?UP2>ASH_3>=Q+1@K@IZZW$EZ
M/C73']OI4(X>55^,VJ42ZAUG2VCSX]02XH"1+]2G%SAR]XFH:7XO[6'6N[!6
MJ/>H'7O::*YBD.RKYD&34BM[I84ER?$:#&'V]?NG!"5C%6U8S#Q'7&_!<#.[
ML+KFR+K#7;\H,I/F3WJV2<34PJ]J3UD.Q/S(S)4HV4<#;!T=Z[9;5T<V7F_)
MI2(LJJLV(X7+]TTS[_Y,:ZXA'/]P5)PKZ2M?%JO]\L T1->W>HF]RW H?.OK
M$5=IG%[*\$MKRZ#7>JR_5\.8-FF^R2$LDH3XU0Z$?#%3GWUOQFF./NISG]-Y
MYMM/8=2=FU4F)< ZP'=>U*\HT"(MJ*^HEI!6D^$[Z>#]65BA1B-G]3:NF]W
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M^X6@O6-$\+\7#C8,C0C^$N+L_.\!$1&?I7%X=TS0OY?&>9*C,8;N&%P4 1N
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M4PC8%([0$/5-B;*U^YHH%-S(&@5'0$P MF ((ZO^$P6%FB)@IC"8AJAOVZ+
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MS7J+)OS^3^%G]\W#K_<9"(1FX*<)OS\//["Q-<S*!HJ @*' C ,"04*L$"9
M,(*M;:V02!N3_H8?LG>_*\(4JADE:<+O/QBD@TV05F!@0&B#@IE8V=KU*_R
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M%1]?[&3J@,9YA^)"_<,QJX$I1G0/V,(.'8[[N*?P7TG\"Q6>6'0D#H@I3&0
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M9&3G1?. W\XVAHGB*FA-5D6.5M1MY^P:49A?^XAM8<#U0ZG-#=F[^]<W+DZ
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MH'E5SB_JQ0;WN-G4O^OF!/=2C]EJW08I[]0[1U35!=7D<JWPG<(&?$MZ(Z>
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M].5YE<;SF/%CO0PN&/MI.P56VX#-@;^RQ>#F%]LL'W"/MLPW7<!WK>,:WA'
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M>%TND.C27>USH:J,GRUQL+OQ:QOK$$O"5]:7(--]H^N"47.G81H"D-+AU!:
M@]C5K X.>GMI1*L.@\LP-?5C5\;=;AB#&[7R9>T0;I?OW!HL/G":MFXZS@0
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MU? ]^+EE\KR[A%A@1?Q!(@@\??D[$AA:,KN(=!:6]T]5Q-U\%R$J4\@:D:^
M4^C!Z'4@"*P1(X?4YS[$7H#MBWN$'X_8M3P<_Q%5XG81?Q)U\Y^4?<(D@-;#
MO:31\+6(X[2IB+VH3*@ Y8,^EO,*S<,NCG/#G,3A@\W89CS=K1SK@__GSBWU
MGG$L>!S!+#X(.4UD4G@P$"D.$@E_0?J:O0\))S=N<$4=HJP+.HZ64';..H5Z
M09'_4Q7!Z.N QUC.(A"HA;6*' (I8L6!OD"_LB*RCL'%K*6Q$8B7K,5!<Y U
M+(]9:4@'YIN1F:V*5OY,K!5N MX13R3Y@%I$696?(>E">>95Z$O!F?4L>(K
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ME<JV[(^&X2TD0OY#^58<QM7[G*W(Q'N[L%0#^$JK+RIM_*@I5+4:7S.');]
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M$KMI[W>T9 -HN,@4^*5H#&J2<@]:#_L<?@ON6;S/.ZR8@XA=_Z;$&,E:DH-
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M-Y7QGIT= XSK8U?&WPSF</22-WD9<FK3\M>/<AD '=,TOC S6P_-OYPUW?L
MVS ]7RO2"?2X9$HLAWXY311$9  !:$\'QMMLL_6+F-MR(Y>^9;OG!>M).7.
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MN^KVZNOF5RS.KSEI.;9VO]4NZZ%U S:]ZSMM6^V:[1L=&AQKG33.2A?IG]7
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M2&2H7YA+^-H(TTBCR-]1[Z.?Q-R(/1<W'K\[H3^Q)4GS9QV04A%I>>F)&<&
M#9GKLI9E&V1_RWF>>R/O%'!?_I:"ND(AB  N*DJ!!$%=8*OA1O OQ0]++B#V
M(WM1E:4L=$E9&B8 :UMN4OX=]P!_FK"3V$CBD9&4-.HFFC5]'OT#XSKS,*N;
M+>64<=-YOGP+P2S!,^%9T9"X6D*5%LC"Y8X*$\47Y2W56$6O6JDA5 *KPJN=
M:Y;5:M<^J[M4?Z"AM[&RB=V,;LEKC6_;W.[28=FYI&M.U\_N]SW/>N_U7=]R
MN?_<P,FM1P?'MAW>?FCHT/#A'>,[CXV<WG5Q]_4]]_>^'/VR7^^ \4&+0RZ'
M XXDC16-DR;D1SN/[3]^Y<3;4W-/VYT)/UMXCG&^Z<*!BW<NZUZQN1HSB;E6
M-S5V_?7-%;?";F/NM-P]>U_G0>S#FD>/GW@^Y3V;?&'_DO'JZAO7MXIWKS_$
M?NS]K/<E\VO?MT\_?'Z2?^W]_6<!_.-'/(JGGZ%GG*ZA=]-.#T_1:VC$^L7T
M-AJ8'4.?H''A7/HOVL'$ XQ"NK^W%M.$L>#'.(TB]GBP@U8H+#D50,OAGQJJ
MI2%Y1;63M&IN,&L9[1HG'I9)=V9#$@;H6UDM&Q<S<,Q'WT:IGI7H>]^I+A6J
M$R>IFQ1GM_M08;+<F@KJ%HD#XS5MML@2&D<K%RR*/T2?R]/R"J0_86_Y<I_B
MU#)R-Y#BWG#@N#LEMN;-X&$*MS*].I1RNV(%_20U7OX>DD8]+]D1]YI&$<9Z
M\ND0;O9G+W)AO^[M#G)1U_.CO61^F^%6(/EX(ZSR"\6^Y@MM.V6K9J0(20U6
M!L8Y47]*R!L>TC[P7G\<)9W8E7K+F71T^^*)8-*#+8L'EI,=.O,U-\@US5/4
M=HI5'0"LH1S3=,>RJ$HY<T,632G(^X G)1WIO?&"%#;J-FY RMEAN.4KJ6O
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M0-BN+/1=MUW3">1\ZR_%*?A&PQW. +S(<KJX"2(;ZC9?!V^I T/20)*4YPJ
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M%.7R47.,K$#:(6R5<,4G:#6BLZ+9>4JA YZ;>!C#!+T;$M'7R#OG8T@,//>
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M9]/Q6@L']>\TBKFQ;LEJ*UZ:=:4DGU\C048KH0&^Z] O\ 2QO1<!9^4]ZY@
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M=^(A&WD#.UG2+]"9UDF2/"A(^TUT#QQ!G(4H&$.:B?L#7[+/89. _7%GT8N
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M9Q0Q!?M,YV1+TR[JSXG?12]4'Q:>#7@I;\$:W25B$EINTX.MAOUD+JW6IF_
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MC1Q/Y%]B$SI3T2C"N-8 1)0?V3@-_GOK]IH1V"Z651T-&8(/:B] *[UW*AW
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MBMY8RQ/,#H1JQHHA]Q>F-?(HNS4&ECI'6=NVD[&$G]32SSI*R6JJYWPM>MC
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M5H\+MX7V P(?)GQ0\]EI.O(8:L,_JA* 066]ZKZFE#N@EFMN5!<"D\'$O!/
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MP=0A?HAB0GB,^+.JU?.E<HQ&,? Q+THJ;4\OHLIPDTL93=ZL1JMXBK7L?,J
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MY0N'9\@.C9=&).[C,T4WI..$ ?1!&5WTJ2Q)?EBR)2M3F2(#XSBJ#XKJD&G
M/E65%PW<!Y@=[>'+X'6@0I@A#Q)>$CU4%-#.23A*4BE/^D55E7E!ODK-C)NJ
MM )$\"MUHV:S%T]S$OSIF ]/AHO58GXI^$XX13@;8M$<10>AW24')%+HW\P
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M>\'3TM;(1U";?.VBH[!&><>=A.B!<'LZN@S<('RN_"@-9<2JSLJ("@]UL_Q
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MD%(R":L5/BE_C]731U8?PEBEJZFK,.^L!<P#Z,^XY;Q9Z(V0XZ(6](@W*L]
MMSDM4S]&EZJ[BGQ,<X6I93%& 4U<%6V 2]TIN7I1YFI&ETX0MYCKJE6'U FO
M$/7>D&P+OM1IMUJ*K5?;%&RK3Q-<*WE3^YOZIW*2-;%D'SG&0LHLI*\UF>+&
M<"H-!T-(PA#]"&^J+$:[V.F<>@YN5O*DHW/_XGV0%1=Z4A;(SY32BJXJ"RLW
MI\>IWE,61F\!-C,& S>"[=QVCV+XB.B^/0V;KNB0WQ#.*1GDGA==K<@@^TAZ
MJQ\6S9=)J;JT?Q049GQTD0KF^@7J@8/"; \>E" ];3^(W%+UR Q<,0GG-/,;
MJ1Q2H' ]HZ@P5GR1G9XV23:=5[+XD4(OK G,5MM+7GO(-1\5K0[CX!. 1IK!
MLF&%L9F<1HZ\>C;O.V][ 2BD"7ZF\L2_Q/F+-;)#TM.!]LH-"KH' IQ4ASID
M0C=!7XDMW5WXB)7'?"*65MEQZJ7#\I?SXV26E"\B&X7[8@_I(N6#P%$*AGJ3
M1[WZB&:U@PZ: .T0VU.ZE0HF3F]3D2M%+$0=DO>#*P)&I50)3,!0U$7Q#<VE
M@*OR=/"&1[WJ*?3183M(0B:+\DE<^!+C*+4;F5MQG+$+"<JCL^\C,<GW^/Y(
M<91:M!W! W;+BI%!CPZ5&_+;X8[F(AHJW%35H7O"""1_U5DK8NFQVG>Y[UE-
MVH!D%6\JH8VR%Y[$GP58I2UXJ<=2I1D[[O!+4XDM$H95.M6LH1\GK;'L+[]&
MFV6FY]8RC<;;R3Y<9P,I\E_A,-WW *;DFW:)1ZUR-I'D.%,S#/N/=PDXFSN3
MFJ8Q%/J4\D%**2G;'4JLW)C0!WM3G,/]$&_&5;]"-(V[SS44ZQ1/LD6)48HM
M7);2MJ20DJ"*+']2TJ*NJB:RM !.#4KPU6QE_AWV%AK%G>R7!DN$R:XL=)KT
MFNUK;+]J.2=&NK)Z*=E;;DMI*]ZCL-#;,X\I/[%6Q?>K1=QK89V::4)?/S_P
M@F2+JQG>I=#8I:++ "[;300P[I$62J+8H45[I&^X;9D3Y;V"4?%3E2R1*2Q*
M72SU]YNH(<M_N"Z#K*IO=AW(&G <RXG?)QA?'2!<+3Q6^%C<(<8SDJ0UTOBX
M/GF+?$[HO\ISRDF^7X#YZKFNNT&])L5N"+X.@<P(KH?<I:J:SU<D%'H+.Y0%
MZ3O$1U3DN"#9&#44>E8A 7;Y?E3] $>[7M$LA1CVLV%G^" #9(\!IU8>YAK
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MG,8W9FW]"8NOS;/[/A[?!G/QG<2>B*YUR\-]'^=M=QRW+?&]?<MPFY./;//
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MMRJ6E)YIM[R6F)33L41)*(>X?E>+?P17.\]2PN+';+TIGR4MW5M#AJ=0+)]
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M>?"O!M2;-P+Y?F>@VQ'PN'5#U,6Q-8D3<S^C&\>WE2NZO%1537%&KC&[F6-
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M7%$\D"BB=V<K"SK@6E(;NA;7@M5CF@D&9!/)"&^D-$#--%.^J<B<;RIN7&A
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M-%3:;P%BN_U 8>\,-(Y^SVM=(A[H/9-NU/MGGS>%(4XT).'':[.*>^40OF6
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M3Z-+:G+*N2J8@"G#**@BLI8@**I#\\OKX96B!@A/:\KGF1I@Y68C@M58/Y\
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MYDIR5N3ES)SPBWEYH1?@D.#S:&C@.0(LX"P%X7^6CO0[4X+R.5V.]CY=.:]
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M99Q,J"L^$6\J.1'76G(\MI=Y/':4>2CN(',\8?*UO37\+S/@+0:\_7) =]L
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M+HR_S*E,/N_9E'K.HSV]W?U:1JOG[8PFSJV,6J_;&17<V^GEWC/[OQGBU-=
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MS[-+I>_?G(=<?[E(NF-B\[RFB0-KRM^J*>2\T3V2^-I$)_R5M5G N /&>YR
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MZ1NSD+HG<Z2*8.7L=-BQ/!:4-DE <[<_VOTY8*K&!"LM(MCKX<')R![(IK;
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MK0JDX+0A@63R/8IA^TG"QK\7^9/?^(:RQKSCV*.>Z;PAMWS?I\P*X0"]0?2
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MUJDO".]P.Y* N9U,M+Z=1[:\74TUO]U&->OKI9KWO:"8WIJDFUV;9/P-I"Q
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M54,5\C55H/+8$6@^K@SGCA^&'JV_:3N!(#6=")+?@R#)#Z61J)\+I()AC;0
MML]BP_[Y##BRE B:JQQ!;QT&3#9:@M464[#?;@A.._6 I* -C-W'P7V/!GCO
M50/__2H0<D 98@X>0F]&%"'OT $H5]H/C8?WP>F_JFU#D((K"))T%T%"AQ D
M$!9)><-*:19LE"6#PFP\')QO!T<76\+Q92:@O]( 3%?K@-6:XV"_3@-PZ]6
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MFSVZ8_=[=L9>\.R(>^C9'O_!HRT>W5L3T*WE)S!L,0632-_-);V[3!C>UXG
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MQ"<_[[I/0?X+[X+\+UX%^>CY,QA'9D!Z[^=R'KC1R &7V[G@?"_I_@-"L']
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M.BY%[.12P&%N>=S +8>[N67Q%+<,7O_! +F#S;L!*HZ2_%](_A6 0)+O=@_
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M@'>6P <J5C\&?OEV2,F7;ZET$S3HV$W_P*H8@E4FGRM/B(S 2I'?%5B#Y;J
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M_9739/:<TVC&<AK^Q<O_8^LLP*.ZUG?_[IFX$7=W=T\F[IGXQ-U=B8<D))!
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ME32<5,G%<=5B'%6MQ!'5>AQ2;<5!M6[L5QO  VICV*LVA=WJZ[%+?3MV:!S
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MU5Z"'3IFV*+CA(U+?+!!-PSK=&.Q1C<%JW6SL$HW'U.ZI5BI5XU)O48LU^O
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MW(:0Y&$$I\P@*&4G E-.DAL(2/D/'[]%8/*?A-5:DAQ'$[@F)@*3+,/[%'M
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M]K#_YW]$5]77[XB#7H<4NAU%6-)1#YV./FAWK"*[H-7^(#3;;T&S[3UHM?X
M[=8_H=TBQR35>T@#*:-1E)$T1A/+:,)J 3\:6'<:>D<:2*M.P(2.7;]/'4L&
MED!GP)!80'O  5H#[M <"(#&0"34!Y*A-I +U8%** ]T0FE@.<0#6R#TT\[V
M/P*A[S4(O5] U/L3^0,CBCO$2 VS7TPRJS@S:A=VA0): 8\.ZE/7NH_Z--/Z
MR^@*QU6@/J$%Y0D]B">,(9JP@C#!4_\$3[^3P0N7(4YRFBLZ.-F$^<LN)A7_
M'?)^E@F7"-WO^"><%M^37]'+S#>1"I+'$4BE=C2U@[L KU[ :9#ZU#59#NBM
MH/XTH#:C!-%:EL1K=8@!RQ"ZWG4LT699(LWR]+N>R_YZ+C?K.>T4VT_KN\D4
MH<6?I;U>1RN][EW^[M?D)W0PS#KJ%C4K[@[CZL"/A_;SJ!@!G,>IOQ(P7@WH
MK@.T:%Y5-M$2T+5CFRJPG>7P=I;).QC'3L:QBW'L9AR[?5DF\O2X1W&9IN(6
M28KL88-[YOBS(X0.?!?M]"[F8M=W:&EG#CC..<QWT@"/#/;9;W+AJAQKZAIO
MI#XU-=@%)3IVEOH\]9)# E%A24:K<(3Y.,HR_1A+YN,L3T\RCE,L24XI+MOE
M<G":@WV:B3W-7)S>S??/$N;B%"W\R4]1I[@RA\.5/L8Q8)\#U_"H8+@VVZC/
MC^O2M*L? H1[.S**W9%SBYQ7[)2(@4MJP&5:EH<4_U2J^"=3ENV/,([K+$EN
MQ"Y\?=D-#O1-"MUDXS<.DROD:?(OE#'?V0PO82W'@'GV9'_MJ&O"C^F>H/Z]
M'9F'%#LQY,;B[HB"Q\CC]W9*E!?NV+G-G-SAV#Q'Z_ /QO$22S7%+;RO<$Q>
MX41[E4E^=3MAXZ]<)4\BG_E.W<S581=7!N;8Z3A@3ET]3E_U>YKW7YGRW.+N
MB((7[]LE^>?B%2-O<'S>YCQY3P_XP'SAFUL_"04^Y2GB,X[)YQST+SC!OF"2
MOZ38EQ<6=R0T%]']^ZZ0A6\)D4!QA\SO=+^_H(1.M88>MIENO1/?TG%^3>?[
M)<;Q!5;B,[K.3S&'C^DU/Z3S?)_>][_TWN_B$;S-P!>^(?3GO^]&^=<B__Q[
M1T)I$>WY*U3^@AU^@R=_(Q1WZ7Z_I>O\"OETRN7XA([S0SK.]^DXWV,<[S".
MMQG'FYBBQEJ\AHUTTCOIY/<S32>9KLN,X$DZZ[>9QN]PFPI/W\?M_[4CH=BA
M^67^J@Q+]L^%??-G]!+J);.%;&H44:.2J:_G$+3@'XSC><;Q+..XPSAN,XZ%
M*S.V</CV<,H<X5">8R9NS._/7&7&KC"K#U'I?N[?D?@!RM3580Z-V2\[ZGFQ
M/R'4BJ5.&C5RV:-BW&(<CS&.FXSC.L?E$?1RN@ZS_>5L<Q6]_WI.X^U4W\_#
MZ"0>Y$].,0LG\ &.X\>_K\JX=V6&0O\O\AT6OI3W7\S%"\S%;>;B%N?%H_"C
M3@3[D<"6I&P_C^T7\["LY&C7L?UFG&8<)QG'"<9Q#!-L=P:'.28'L9M1',$^
M_L9>9F8WWL N?,.1^A,[J'P/1?^_Q<(-8"_/;T(J,7/:U#/"1=BR+Q[4"6(_
MHMB')+:?P?9E.,0X#C"._8QC'^/8BPYJ]%%CA.VNX,Q<Q^5T&S;S4QOG]VH>
MP2QGR#IF>BU'?!VU[_&#"'A?=>%+B1Y56MB4/<]Y>HK'R#&84<^1.M[4">$(
MQU CF1J9;%U&C6)J5& 3XYAC'!N8CUGT4V.,1\EJ_MF$:48WQ0RMX&R8X(@N
M9[:7<SS&(?\;Q0UO+W%YNTG.<WDYSM>'N.SM%VE1TX!Z5M1R86M^U G#>B$6
MZX04K!%E8D8DPRI1,:9%E5@IKL,*<2LFQ#U8KC2,,:65&%5>CQ'E71A2.89!
ME<OH5WT&?6H?H$_]+GHUY%BZR-M<6I_D,G^>'#'F:85+W#;%/Q)H*V&SFC;6
MJQIAK;HM5JN[8THC "LT(S"A&8?EFJD8T\S"J)8,(UHE&-:JPJ!6(P:T.M"G
MW8]>[>7HT5Z'+NV=Z-0YBG:=RVC3N8/6)1^C1?=G-.O*_^8E+NW7K!=.-;OY
M?),%3Z=FP&K&MDI/%5,ZNIA88HXQ74>,Z'IA2#<8 WH2].LEH%<O#4OULM&M
M5X NO3)TZ->@7;\%K?I+T6PPBB:#&308;$.]X2'4&EU$C='3J#'^ -7&/Z'*
M1/XWM^UY^G$ 'F )LHF/,WP]:<O2@O$L8RS#1MH8,#)"K[$-NHU=T6GBBPZ3
M4+291*/5)!'-INEH,LU!@VD1ZDTK4&O6@!JS3E29#:'2? KE%IM09G$ I9;G
M4&+Y!(JMWD.1]5TB_YM'N9R?<.7IGZPEDWP]XL22B_$L92S=ENKHL-1#JZ4Y
MFJT<T&CEB7JK -1:AZ/&.A95ULFHM,Y A;4,93:E*+6I0;%M*XIL^U%@-XE\
MNSG([/<AS_X,<AT>0X[#V\AQ_)[(%W"0XYH'YZ GL)E,LQ1;QL=>=Z"3\;0R
MEF9[9338Z:#6WAC5]C:H='!!N8,/RAR"4>(@0;%C/ H=TU#@F(U\QT+D.54B
MUZD).<Y+D<4B*--E%AFN>R!U/8UTMYOD#:2Y?4?D?+[ 16\Z<47YQ=)G@@SP
M>2??:V%L]8REUD5 I8L6REP,4.)B@2)71Q2X>B#?U1]YKF'(=8M!MEL2LMPR
MD.DF0X9[&:3N]4CSZ$*JQS*D>*Y%LM<N)'F=1*+W=?(Z^8;\1>1(])+C#,N=
M7?Z<!RPWEI$>TLKWZAE+%?-2SKP4>ZJCP%,7,D]3Y'K:(MO3%9E>/LCP"H;4
M*Q)I7O%(]4I#BG<.DKV+D>13BT3?=L3[#B/.;P:Q?CL0ZW\<,?Z/(-K_5?(U
MG_])Y/.<I.8VEAG3BETAEL0=?&P@U8RKC'DI)#)?%>3XZB#3UPA2/RND^3DA
MQ<\3R7[^2/(+0X)?#.+]DQ'GGX78@$+$!%0A.K 544&#D 2M0F3P-D0$'R/7
M$![\,OF*S_\@\GF.4G=3".<BRXP^TDIJ^;J<[Q<ROKQ NJ! ,=(#M9 :J(^D
M(',D!MDC/L@-L4$^B D*1G2P!%'!"9"$2!$9DH^(T J$AS8C+*P?H6%3" G?
M2HX@./PJ@L)?Y..7Y'<$A\D10@Z&+I3B8^$<!Y;"3:22SXOY7A[CR&0\:?Q,
M4J@&$L)T$1MF@N@P&T2%.2,RS L1X8$(#X] 6$0<0B/2$!*1A^#(,@31H 1*
M>A$@68& J,WPCSH,OZB'R OD<_(;_"7R>?9%+%RA-$(Z)*SS21G)Y^M,QI+*
MGR?R>:Q$%5$2'41*C! >98FP* >$1+DC.-H/0=&A"(R.04!,"OQCLN$74P+?
MV'KXQ/; .VX"7G$;R4%XQEV&1]QS?/R,_ JO6/D\.ZFWBB7X0#3'@533(A7S
M,9>D\OT$/L;PO<A8)83%:2,D3A]!\68(B+>#?[PK_!)\X)L0#)\$";P3$^&5
MF G/Q")X)-7"/:D3;DEC<$W: )?D W!.ODCNP#GI$[@D_0+71/D\BG\HGF3Y
MO30.:"05))]DDD023;L4P;(X)(EU?[(&_%)TX9-B#.]4:WBF.L$CU1/NJ0%P
M2PN':UH<7-+2X9R>#Z?T*CBFM\,A?1GLTV=A)WV G(>M]#9LTS^&7?K/L$^3
MSS,7S[E G4Y2EZBX*H@Y(&G4C$UF_VF50E(!_W3 .T,5'IDZ<,LT@$N6.9RS
M[."4Y0K'+%\X9(? /CL:=MDIL,W.A4U..:QS6F"5,P3+G#6PR-D#\YRS,,MY
MBGP(\^R?8)$EAR590ZTA:K62*NH5D$R23-THZH;1N@9D4C\;<,T3P5&F"?M\
M7=CF&\.FP!K6!8ZP*O"$94$ + HC8%Z8 +/"3)@6%L.DJ %&17TP+%I%=L&@
M\#3T"V^1_\*@X"X,\^7SK*16+TO_!NJ5D3R23MT$6K3(+""(MM5'1N]50/]-
M&VU=J@KS<FV8ENO#I-P,QA6V,*IP@6&%-PPJ0J!?$0.]RC22#]W*&BRI[(9.
MY0IH5VXC)Z!5<9.\ >WR;Z%=]@=TRN08HU:'XNXP4J2X,HBDL,\QM&>AU/:E
M/7(OH3[MB4TE8%8CP*!>'7H-2Z#;8(@E#1;0:;2'=J,;\8=68P0T&Q.AT9@-
M]<9RJ#:V0:5Q%,J-<U!J. 11PQ6(ZU^$4OUG4*K[D?R! ?:SF7KE1$:D>4!\
M/N=A$<>@%/"HH/>JIC[MHAG]N4$+L*1=!9I=6E#KTH-JES&4NZR@U.4(<9<G
M1%U<9+MX,'4QN5WL0%<]H9'OHI'MW$=H'#MHV-I90;=_3WY%%W-<2XI)#G\E
MF=I1I0N[0MXU]/\-U*>N&?VY :VSSE) LU\)RH.:$ ;I^X=8> VQT!BB[Q^F
MOQSFB6:8"]PP)_DP$SK,AH;YB\,KR YRFI^]!0R^2[[AHO S6JA76;IPAYBT
M#(BK6M@#\FWB'&P#;/GK9KW4'Z#^"#TH_;G2! OA21:=*UA\KF ANM(0F&(<
MTRPXIGG27\63WBHN;*LXV5:Q8ZO8V"K^\BIZ[NDC_.S#Y%7^WN?D+NJI649R
MF.\DQ95!S3P.V6<W6E,[ZIKQ5_67 ]KLAMHJ0,24LGCF L\B?+TZL(%QS.DJ
M_CELX9_%-C..+6X+MP@K%I]MG&C;F(NM;' KO>[6O?PYQV,+QV/S^^1K5'.X
M"ICO-.8[NH/' ?OL,43]<>JOI/^> ;2HJ;*1NEL(T\D"G\4GV<-\[*4IV*>Y
M<*7* 7W@H"F+(L9QA'$H3HB*[6G%UZ8?92Z.CA(V<H2^_S -_6$ZFL,?SE^9
MD\5\Q_?Q.&"?O117Y;"_9M35V\2QWW[?_LLA<I30LM,R+.R)<'CQ('-RACDY
MQYR<9U%^D47Z9=O%NW5XTKG" _XJ!_IJ-V$NKC(75\_S?<Z+*R]!QBF;LHQC
M, FPW( SA\R"NOK\F-9!0*S8?SFUN/]R;R_DZB(<5MJGA3T*Q1T[CRD#CS,G
M3W!LGJ91N,,XGF51]AQ//,]S?C[/P7YAF#"I+QPFE\ACR. XQW*,@Q1W1NWD
M&L3^&K"O6NR?^/RBYL.+&K>P<$7*,_B?.W7N[8G<^_:25P3@-<[7_W!L%.9%
M\<VM[W..?LB3PD<\^#YN)>SP)]L(Y^?'YQ:OQE!>O"-#9_ZN$#D]-\^J))1^
M-!Z_TF/^B'Q\CW)ZTUI\35_W)7W=Y_2YG]'G?D+']C$=W8=T>1_07?Z7KO9=
M^LRW.%B*^S#^Q<!?X[NOXBY>@?SONU,4WQ3Z[+SO%A;]OS!_58;B"I7?Z.]^
M@BM^0  UHZB7@D^13:=8A/?I+]^EOWR;OO]-QO$?QO$ZX_@GXWB%<;Q$%_L/
MNM#GZ13OT'/?IFM^FDE\DI^XQ>@?I\M_C"H*'B4W_]<>R&_S5V4LP1<P9;\<
MJ.>-]YB+-Q''?J0S]ERV7\ST5\Y?F7%[_ALR.ME^+]L?9OO+V>XTI\=Z3I-M
MN,:)?(6Y>(A_7V*/+[#5\_3<BNR?7>3<?3'\/']5A(@9TV+N#-@?*_;%E5K^
MU(FD1B+;S\!UY'%Z%'-*5K+E.ESFN%RB[[_ .!179IQE' _2<9_FF)SD07R<
MN3C*GQQFA(<X.@<XH@?NNR+CP&(,"GW%72G_F9]B:GB"OO\&<W$-]NR#)S6"
MJ1'-]I/9=@8/$QD/S6(<X[@<Y?PX@B:VWX&#C&,_X]B'28[$6BXA6SDS'N"2
M<II945RS\B)'Z0MZ^-_GK\90H/@_F!7ZGV#ABW&>GC_41+C(7#S(>7$2EM1Q
M9A]\J1'*]F/8?C+;SV0/\]A^$;9SGFYC'%L9QV;&L8EQS&$9-G!NS/+OM?SD
M&K:RFAF;GM^Q^A K.<-78N'_@E;PY:+^XSRD+BTN.4<Y+_;S&-G+8V07;*GC
M1@U_:H0S[EBVG,+V,SC[\JA1A!G&L9IQK.*X3'%^K,  ,[&<?]9@C!&.SE^W
M<HX9NH4ASN9!SKH!'G&#U%?PC@;P))>5"UK4YN->'MH[E13;XAK4T^/L,J..
M W4\J1%(C0AJQ%$CA1J9/!KRJ%'$GE=0IXX:+6RW!_U\U<N>+V5FNCD>BGN)
M.G@4M NOHUWT%=K$OQ'Y//]0;#'K+6QY[^+C1MV%?Q*8T11CE;(65@H&F! L
M,29RPC*Q-X;%P1A4BL2 4CSZE%/0JYR)I<HR="L7HTNE$ATJ#6A7Z4"KZB!:
M5%>@26T.C>I[4:]^&G7JUU&K\4_4:GZ)&JW?B'R>)[BD/LCE?2]/-7-D%5]/
M\!0XRGB6Z:A@F88.!C6,T:=I@QY-5W1I^:)3*P3M6E%HTTI JW8:FK6ST*2=
MCT;M,M1KUZ)6IQ4U.GVHTIE I<YZE"_9@S+=4RC5O8$2W==1K/<M^9/(Y[EF
MP=.8XL)0:V"U]<+>QR#?ZV4\W5QJN_74T:FKAS9=,S3KVJ-1SQT->OZHTPM#
MK5XT:O024:6?CDK]')3K%Z%,OQ(E!DTH-NA!H>$H"@S70F:T$WE&)Y!K_#!R
MC%]!CLE7Y$\BG^<"3RO[[%D*D D'EC5\[.(2W\9XFAE+HZD2&HQT4&MLA&IC
M:U0:.Z/<V ME)H$H,8E L4DLBDR346":@7Q3&?),RY!K5H<<LPYDF0\CTV(U
M,G@23+<\BC3+JTBS>A&I5E^0WXF<K^4X[<B20'%%#,NP$1?VFX\M?-W >&H8
M2Q5CJ;#41*F%/HHMS5%H:8]\2S?(+'V19Q6"'"L)LJWBD665A@SK'$BMBY!N
M4XU4FU:DV X@V78*279;D&!_F#R$>/OG$>_P&?F-R/F:OINZFUENK' '^DD[
MJ>?K*KY?QEB*&4NAG2KR[98@U\X8V7;6R+1S0H:])Z3V 4BS#T.J?0Q2[).0
M[)"!1(=\)#A6(-ZQ&7%.?8AQ7H%HYTV(<CE$+D'B\BPDKI^27_E<SO?HNZFY
MGJ7&N!=]-VDBU9[4YWM%+ UES$N.LQ(RG;0A=3) FK,Y4ISMD>SLAD1G'R0X
M!R/>)1*Q+O&(<4E'M&L>HMS*('%K0*1[#R+<)Q#N,8<PCP,(];R $,]GR,=\
M_@N1S[.7>FM89HPH]H!\F0-2SN=%?"^/<60S1BE)===$DKL>$MQ-$.=N@UAW
M)T2[>R+*(P 2CS!$>L0@PC,%X9[9"/,J1JAW'4*\NQ#L,XX@GPT(]'T  ;[G
MX>][FWS$YS\3.0)]Z+M]%LK@ 7_Z/5)#2HB,[V7Q9^G,2S+C2?!60ZRW#J*]
M#2'QMD2$MSW"?-P0ZN.#$)]@!/M&(<@W"4%^F0CT*T2 ?PW\_3O@%S *WX!9
M^ 3N@W?@.7@%/D4^X/.?X!,@GV<KM58$*.Z*XCC0GE200C[/(>F,)8D_C^-C
MM+\R(OVU$1:@C]  ,P0'V"(PP!D! 5[P#PR$7V $?(/BB10^P?GP#JZ"5T@;
M/$-&X!&R%NZA>^ 6>@:NH4^0]_G\1[B'R.?91*UQZG:S!*X/ 4J)C&3P=3*)
MX\\D? P/%B$D1!.!(;KP#S&&7Z@5?$(=X1WJ :\P?WB&A<$C+!;NX:DD#VX1
M%7"-:(%+Q!"<(V?@%+D;CI$/PB'R%GF/S^_"*4(^SRS;7Q;*XX'6J(84L0S.
MX6,:22 2$L;W@B+H.R+4X!.I R^)(3PEYG"7V,%-X@K7*!^X1 7#.2H*3M')
M<(S.AD-,*>QCFF 7TP_;F%6PB=U)3L$Z]C'R#FQB?B!_P39:CIFPA3O$FJE1
M$;FP!Y1!DDD,"94 @2R+?6E7O&*5X1ZG!9<X/3C'F\(QWAH.\4ZPC_>$74(
M;!,B8).0 .O$3%@E%L,RL1X6B;TP3YR"6=)V<@*F23=ADO@63!._@UG"GS#_
M/^R]9YB;U?7V>T]ODD;2C*;WWGOOU>,I'GO&O?>*;6QLFNG-%4PUS;A@,,:
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M_+7(/Q/YY^EY^-US,,1GX)D_@[4^!4M_ @;_& XZHC_ J;__EY-!3]R#8?9
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M?37\G_8ZT1MV$;[?Z--G]J)LT[_N1=GAJT_L'JF)!$FWX9/;Z9L[B-,#V'&
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M">P&[+@.=KR-@7PUG/M*_G\%5FS%VLOPW*5X>(O^\2_G8)CZSUN^4#JDD7M
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M"2J,FJV"Z.7*CSY+>=&7*M>S4SF>>Y7M>0;\%OR%U_!N]*]$YQQ2P$FD7V-
M#^C@-?1)#=A2ARVUV%KM"5%5M%T5T6Z51<>J-#I9Q=&9*O(4J-!3I@)/K?(A
M07DQHY4;.ZR<N)G*BENFS'AFE_C-2H^_26GQ]R@U_F?@-SS_!L"[T;\,G3-3
MK1I0'X RJ66D[H$M5=A2@:UE\8$JB8M049Q3!7'1RH]+4&Y<FG+B<Y0=7ZRL
MA&IE)C0K(W&4TA/'*2UINE*3ER@E^70E)V]44LIV):8<4$+*3\'[2DC^6HG)
MQW4Z.A:;.A2T8%P&7 >T@T90R[5*WBO#GF(^5PCRDD.5D^Q0=K);F<FQ2D].
M!EE*2RE0:DJ%4E(;E)S:J:2T,4I,GZJ$]$6*3S]5<1D;%)MQ@V(R[I(GXTGP
M:WG2_Z28]!^\9^$LR+#V 8W)(@:S\0&/]:"*:V6\5P3RL2<'9*4'*R/=IK1T
MIU+2/4K.2%1B1CK(4T)FJ>(AIW%9[8K-ZE=,]F1YLA<H.F>-HG(ND3OG>KER
M[@1/R)GS*[FR_RAW]C^TRNR'RK+N@>H#';G$'X\UH!Q[BD$^[^> #)ZG9@<H
M.2=<B3D.Q>>Z%9<;I]C<5,7D9LN35ZSHO&I%Y;?(G=\K5_Y$N0KFR5FP6I$%
M%\E1<"W8+WO!H^ 7X LY\O^NY<B>:>[!,GN 0!N4H)['*E *"K$I%]!,I?!>
M(C0NKC!$,85V11>Y%%44(W=1DES%F7(6%X *14)6'26C9"\9!K-E*UVIB-+S
M%%YZE<)*]RJLY+!"2U[A\1.%EWRK)<B?ANQ!9'=#F9M!+2CG=;&I_X LD,:U
M1.A;7(GD*0V4NSQ<S@J'(BNBY"!@[15I(%>VBE)%5-8IO+)#896#"JV<KN"J
M90JJ.DN!E5L54+E'_I4_ 2_R_/<*K/A:"Y _J<BZ#ZL#-( J4,JU0I #,GB=
M#)6.AR9XH&_NJ@!%UH3)5F=7>)U+874Q"JU+5DA=EH+KBA185Z4 R+-_/02N
MGCRZ?B& E-6; P4A"'4DYW4DWG5DC[5_TFSD#YLZ%#I:30V(1YJB8I!O:E!<
M2T5W0B7ZJ]%?*T76!\C6&*K09KN"6IP*,)-8"Q-)"T';0J>U\(56N%7K*.N8
MU58X1>L: +=I(4MJ@20T/PO@W<U_TC1T#-*V+M $JBO,'B1\ ')XG@:%3X0R
MQD!1W(B-;(8#M08HM#U4@9TLL)TL*%UN4TP&#-YN,[B*K8T]HR#RHR"3HR!Q
MH^ 4W1<"B%D7A*B+[*GS0_ G341''^UK]]6 *LT^)$!X*X,V)S? _YO0#WV.
M;$=_%QQ\E)\"1I-H]++ ][&X]K/P#>"+,4QD@Z;8G6<U; P&#](?@U-XOM3Z
MZ=<!LK6!._@.&63_!WS_3QKG/0L(EXS4@&JM?4A9M#D%$7%0HRBH8B1NC>B%
M@T/7_&F:QI'H#,&CADD^QCNL/S),9)&;E&A--I,)I,D(G(S1DR'SDR"4DXB)
M25OY'$1Q N1L/-G\^*_43QL[0&.C=2]:,<]S:',J;HR'LD>-]M5_QL(!A] ]
M 1!FFD*B-8T$;#IVS*!/9F+';). T"?SZ)-Y.;X]*2U,0'#NN?3'7/-3+)#)
M.62/L\GB9QWC>U^HAW:VHK/!MP\HGS:GT^8$7!A%>QWH#8>;!^).C=1@"#&9
M>L@"[%B(/Q:'6OM2EF''<I.,L-B>3)^<; X%,X=2T9B5"#&'GZZ 4*^XWK<?
MA;&Q[&-UX:H6]%;S6-ACW0>62)M9>N5 ;^@,?#_'Z)-),*U:"/3=6P_Q[DD!
M:^'9IQ(?IQ,?9SJLI.C<..O>G/,8=.?1J>8@FG,P_ASZX^PKI+-N)X%]@L__
M6IWHK:>?2W%7]C@I"7.C::\#O2$,:V_-9Z5/U\C]0/_<BZ)_K8EL") VXY-+
MB=/+7=89)5<QP5_%P+Z*1EY))UY! RXG@]_*/''9@WSV1>^]6!7X.V\2,6CN
MP9J'_B7F_B?3/I].H^]"7_*_R4="S$;PD7MS3JR'F#K%3GQR,S%RJ[EYG1B]
MS9Q/P@#;BR_VHN#6LZ1;^-+-=X+'58-I1>A.YZU8AD\D_@TYW:?7W']D]KY<
MKA_OR?'JT+_60T;.*3FQ%G+0;& WOV)#OSS"XO\($]$C=/K#=/!AE!QBSCQT
M,SCH/2$Y&]T)7':>(86=+ZO&-%(',3IO]NDY\6Q80PX-01JY%V>D%D(7>\]I
M-3<1'*5O7L:.UQFSK]$GKS%67\7QK]#)+]/(%U'PPOY_JX&8^V$BX.(N_0U^
M]RU\YFLXYA>JTR?PF(_@V[^!1?R: ?JN]WZ467J# ?(ZK.L5 O4EN,11>-5S
M=-PSWC-!K\.D6_08G.((5Q_6'W08#0^!^WSW?^P[H?[P=UG[(#Z'6_U>D>B*
M05>:WH-COJU*[R^UO@#??@X[GL:.IV Y3\!\'H/+'(%)/LR@.8P=APBB!V&H
M]Q.D]Q(P=\.B[T+;?IRT#VFWT;J]OOT7I@:Q7=8YG$;WI[)^@/A5?/$\G/MI
MN6E'(GJRT%.$_&K<WJ2#,*-[L>-N[+@+IG4G$]9^F.4^)@US9\&MV&&=AW$.
M8;,1"[9Y?ZO5^H62%WGU1T(+;@6N %O!U[+J+^8<T*=\76O.X3R +^[ %[<K
M!>0BOQ39-81B$_:;?1@]N@&V>!UL[UJXW34PPJMAI%=Z]V&L1/9I],8%A/1E
M6+*=(747GGF2,/^(H?R/?YZ#<0$P>T#,5B)S#\I=OE"_28'8;4.V"]GQR$YG
M".81IF5(K-$6[-@$O]P(DUP/N[S$RVHG$ 73D#F':6,QP^IDII%U_%NO,Y!R
MNO=W7$Q/'2-JS&\/'?\GCOI"VX3]C;[AOMD[%81BIP.9T2 1UIJ)[ (\7$9O
MF_M &I'=ANQN9/<B:Q#9$[0:.U;1+RNUE%Y9P[1Z'L\N(VIW8-G=>.E9+20V
M%Z';8+$W1JTAOLVG^P+?-'@:OEB++TZ1$[DQR$T&6<@N0'89LJN90AN0WXK\
M+F3U(GN0*7T"(V4Z5LS'(RL8.6<2M1NX<BW6W<YH>A3\&IC3AX][<;M//QF.
M3&EXC6]J7B8_Y(8BUX%<-Q+C0"HC(!OY!9J-';.P8R9VS% +.KJ0V\M(&4N4
M3N+?+*Q9PNA90\1<H'%$REAZ>M![=]4KX"MPG&O'O?4G,_V>Q72R"BP!\U@.
M9W-M)KZ8SGPQE?B<0I^8^L-DQNLD[)B('>.Q8UA5Z*A'1RORNI#;KS%<[:>%
M?5C=2USTX-E11&@W_='-J.JB/[K$>JGOO+_7?153ZODATFJ6O$5@%I@:1IK!
MM0F\-\Q\,8X^&4N?#,J#_$1&0QHZ<M!1B(XR1FHU>AK0TX;,48S>04;.)*)V
M-E=.PDMGJ)D(;F(D-3&:FQ@?C7H?F-_*/JY-Z#S#9BW]L\%D, 3&<*V?E* O
MU%^]@6'HL2/=A8X8[$]"3SIZ<M!3B ?*T5.#GB;^=2*W#XN&\<X,9EA3N3H5
M*R_!8]>"VYGQC@!S%]Z7WKL2+S2W!4>2'I 23F69&S)U#]##ZRYLZ>#]]H@@
MM8=$J#7(H98 MYK\X]3HGZR&@ S5!^2I+J!8M0$5J@FL5W5@JZJ">E09-$[E
MP=-4%KQ(I2%K5!)RD8I#MJDH9)\*0QX&KX%/P;<ZQ^S!0>?L**O^8E+34:"#
MURTL>4V\W^#P4X,]6 WA-M6%.543&JWJT'A5A:6J(BQ+Y6'Y*@LK56EXC4K"
MFU4<WJVBB$$51DQ5OFVA\FQKE&N[2#GV;<JV[U.6_1%EVE\#GX)O=09ZEJ!S
M.FG@$"G8:-#!\V90SW)7BRW5V%CI#%"E(U05=KO*["Z5VF-4;$]4D3U=A?9<
M%=B+E>^H4IZC4;F.+F4[!I45.569SH5*=ZY1FO-BI3JO58ISOY*=CRK)^1:/
M7X"_>?<"+4#?Y#@K->\&K:"!U]784\%[9=A2@BW%KD 5.<-5Z'0HW^E6GC-.
M.<X493NSE.4L4*:K7!FN>J6[.I3F[E>*>Y*2H^8K*6JU$J(N5'ST-L5%[U-L
M]".*C3H&OE!<U'=:A8XYZ)P 3>HCY>E(PO\\UH *KI7R7A'V%/"YO&@_Y42%
M*#O*ILPHIS*B/$J+2E!J5+I2HG.5'%VB)$^-$CVM2HCI57S,!,7%SE5,["IY
MXIAQXZY65-QM<L<]+'?L:^ S1<5^Y]V/--/4H4C'>T!K"GU@:B^@%'L*>2\/
M6W+X7!:V9,0&*BTV7"FQ#B7%NI40&ZOXN!20I;CX(L7&5RDFH5F>A!Y%)PXK
M*G&VW$DKY4HZ3\ZDJ\!>128=EB/I%3D2_Z#(Q+]ZS\*9AKY!TJUNT$Q*7L-C
MN:F]8$\^[V6#3.Q)X[/)B7Y*3 Q1?))=L4E.Q21YY$E*5'1RAJ*2\^5.*9<K
MI4&NU&XY4\<I,FVF'&G+94\[&UPN6]H>1:0]")X'OY,M]1LM1/YD] U 5SM
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M%>;V8);^23;2&S#:I&?A5JK6%N2G5K\0Y$<@WZ$F8J.1&&UDK#0H'3W9Z"A
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M9K+L,0MEBSU5$;$;%!Y[H\)B#B@TYDGP*X5YOM!L4PN+L_8!-8-J4N%2'@M
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MX[B&<5_#&*W1#^"X=^$QB\0L\P<2%N0QH =T^EF)2RN^:,$7S?^L2+A #$A
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M7XK2-E\KV[_I6N6!C3]7']SP$^+0AI]0A]?_B$W_Y$=BQKH?ZHZ,-2!Y[)]
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MZ"D52CJ+%/*.$SI5^W&[NBTOJ&G(CVE")Z):3T%4ZRB,:LU%,8VQ**:^58
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MZ[;]KMUT\"?=CIQOM/M*+VH.(\XK<HG]HG)V"PLIBQ I1A>2YS)5Z_R**GM
M5.WT\>!N=SW"XV0CO Y6K<_.K/79&+5^ZZT"%,A @PQTR,!=\@(0+QEYP;8
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MPEHDYNA@>H("YZR1</QE8D.HBF</U+ </@3=Y4'6N=THJL>)(GOM:++/=JL
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MJ.4<0I4]"&6_0"@)%@I%P5JQ0-BVP /V+&."_!H2J&XD@,Y6&S"1L@#KW29
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M@+Q.&!PQ![R\.-@=D "RGB30S=<"G; -:%1IH'(5@12H#H[1.F"?:@AV>2:
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M"IQ4V[,9!H=3>5;U"7X.E3&AE.*(>&9>:(9[IJ#8,R6PWB<QX(1?7, MO]C
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M&&*)D!XV"NM@EX@6+A;3P#%Q=3PNH8:/)%7QLZ0*XO_3ZK4 @W0==!ZD_#,
MQ5< TB@_ZB% "'5_?Q0!3Y0"5U1F'%";116:98&6;%-T8!NB.T</_3C:&,K5
MP%BN&J;Q*&,AKP+6\<IA)Y\,+N*3QHW\4GB47Q+ODK\("GQOB,Y UWZ QE,
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M\;1ED07-8]%YS4=B<IOO1N=-^Q@YI8D^?QHQM* !@POK,.A[F$)GH9"!!_4
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M2=D^[):Q?KA8UO*/,7F+1R?D+?YX+&]^_ZN\Z3U4,KF'*L9W4.U[>V@/UJT
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MLZ3M+RZ4M;VX7L[FTE$YFXM_R%F=_Z1H<1:5S<^@JMEI5#<]]:T#M >;)LX
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M+T7*5]8!5-*F<>@"2M*81*QH'&X,\H4PR$VD\>0QR*HDS60FZ2>#9"F#S"I
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M,8&#EKL%]UN>$MQK=5MPI]5KX6U6*+J%;+9"L4UDC)Y/AM8T=SO*=V(!NO$
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MO19EJ>M&E:3LM"Y*.6%3D/*$37[*^^17J_P4R9)8%*1(9L3T(5]S#/P[ENW
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M?,5%X"L._*^7 =^P@;]AI;YYG]]_X57ZBT5[AW- >6<Y!JX @3>!V0S;E+O
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M6#_7&0.>'NCW#,0*SRAAN6>2T.N9*79[%HA=GA6RQ9X-\D[/=GF'9X^BW7-
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MO*6"4]X&85K>06%JWE5A2M[[PI3<WX0IV9(P-6N$3$DX29UMZ1R3I(UZ5:2
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M(;**W6;' ;ZV&2S'S^.@A_=-)@=$G?/6H/\WP$\Q8=LE_UUHP#UH\'U.FG'
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M!(@YEV/VAMQY5C[$Y L>1/,_3-O\C/[RN#FXSJ3\./'Y<QKZYU3P,9SWV"V
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M.'-#AQ6M:[(SWZ%EOD9/?8Z.^1CE\B%VO(?*>1OE\W=4UQMTG+^@ /^('7_
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MD R"1BE'#Y)P1.#@Z"=:TNV((,0!,[3#:0143P'$6?9,>$KR;+X[C._*$N>
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ML5DWBKOW'O$0L!TQ=Q)TD0#[C$>;;"%CH#O*MD/)CHC1787K,"(1T:Z!C43
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M]RCRYW;%P!5;)0^7!%/+-"713V3#@<%XWQ_37C]\UA=\G"5E(4,1,E11!W5
M&[(,(,L4LKI!3D_(L<?_75#V4+ :"PU-%V;/NL&Z+='++&#YYAAES-$;S=$>
M/!O.SXR*A)P5RJ(U,!X\_\)_K@1<\=X)L,=GO<&IEX(4]9*5)SMI9;*55*.>
M$AK40T*7;"2,(,L<LJPQBO6"/&>RE!A,%A+N9"XQA4PE%I")A!\92:R'-:>!
M=05P$G@FW"O)S^]>#1E>D#F#+]46B/(O_0$GH ^NV>&S'H"UB@19*\N0M:(B
M6<FK4'<Y 763U2(+67TRES4E,[EN9"IG2R9RCF0L-X",Y$>2@?PDTI>?3[KR
MOJ0C'TW:<JFD)5=*FK)'24/F>^ #P"B('^ '>7P3O;N&Z"?;?H ]8(MK-D!W
M?&X)6*A*D[F*')DK*Y&9DBJ9*FF0L9(N&2D;D:&R!1DH]R!]90?24^Y/.BHC
M2%ME$FFJS"<-%5\2J*PC-94=I*I22BK*K<"WP&N D3_*GL]_'H4K/(*O?0$<
M>>X%L,&U[H %^)CA'A-U*3(2R)"1FCP9JBF3@:J ]-6T2%?-@'34S$E;8$-:
M GO2$/0G=<%($@@FDZI@ :D(?$E9$$5*@A12$!23O. PR0GN [^1G!K&;90]
M&_+&PPUV0WCB M@#/0&$TV0!F.)S8W QT)0D?0UITM60)1T-1=+64"4M#0W2
MT- C=4T3H#L)-'N3JJ8+J6BYD;+6>%+2FDT*6LM)3BN"9+6VD;16(4EIMI"D
MYEV2T/B-)#7XTZQA"Y W1E>T]XCG@'H!-H ES[L QOC< %STM"5)1UN:M+1E
M2$-'GM1U5$B@*R!576W D%1T+4A9MP<IZ3F2@MX@DM,;33)ZTTE:;RE)ZJTF
M"3WXLKJ8$77AC.G>11#U&F#DR4_&T1/]7#[00)0#L@6Z ^8(ETSPF2&@!RXZ
MNI*DI2M%&GHR)-"7(U5#)5(V5",E0TU2Q$WR1J8D9V1%,D9]2-K(E22-X+0;
M8\0SQJAOC+C;" ZJ$7Q90W PO(>*P7,R8,)]:9,@;SC"=E<C40ZH!_Y: J:&
MHMR//KCHZDN0EKXD:1A(D<!0FE2-Y4C91(D43%5)%L8B8Z9#4F9&)&&.V-\<
M@;)Y7]%1%N9PVLT1*)@' )B5S'*!@R@<'$P09YE@[H2<\9 [%.YW7W$.R!JO
M+<3Y'T-PT<,]VH &7@N,)4G55)J4S65)P4*19"Q52+*;0&2\W?5%R1LKOH$(
ML;\5XBNK<:(?3ZTP&UDA(.F> R#N[@:GU_(]@-C?1+0>:9"Y:!V0+= =[\W
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MY?RQ]H3^S(/\=9U&'7@TH<\V8;)I0">K0V5KH-1***T"[5%>3U3\ _6$79E
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MFZ-\*Y1E)\P^..&J UC90S-]H(O>PC-50_!I/) 'MBW 4^$*.%OQZ,=UP'-
M"^""3)$4N40\]S$0K[GKQ%TWS'@H7090 %0@0P!H0HX>Y!A#A@7*LD&9O:DG
MV/"5(3;0F#4T:H66[8Y6[@9+MQ0^@^@ [KXG''WY&4G=B F7@B[#M#(30_IX
MN&/#Y>&RR8M<57M<ZP67Q Z<;$D*Y<NA?"5 %5"''&W(T8<<$\CIAG\]4:X#
MRN\/[8S B.)!IK!8$[2',2S."/W#$"..(495_JPLOC/2" B$C$7RHC4P[CS_
M O0%[ %;7+.!Z]X=GW>3DR1+:5FRE%0@"PEER%&#' W(T8$<0\@Q@QPKE-D;
M[_JA%P\%NW'0U"RTFC?NB@#C9* $O?PX\),P*\_/KO)%^?,@;Z*R:+DV=]$=
M #L5GO= K('KYH"ID@29*,J0L;P\&<LJD9&,"AE)"\A06HOTI?4 $]*3MB1=
M:5O2D78B;>E!I"4]FC2EII.&U%)2EUI- LE$$D@4",^(5L,,H4:?A:LDET/^
M+!5^[@G<;(0I?8'>@ W0#=?, &/ 4$6"]%6D24]9CO24%$A701E0)1T%#=)6
MT"$M!4/25(!F%&P >U*',RQ0&$5J"E-)5<&35!1"2%D^GI3D]Y*B7!,IRMXF
M19DWI"C-:"GD3X,,=QZ>\+4OZJ*PC>=>S %CP !\]-0D2$=5FK15Y4A+18$T
M591(4UF%-)0%I*ZL10)E?<"4U)2M256E#ZFH]"=EE5&DI#*%%%06D[Q*$,FJ
MQ)&,RAZ25JXG*>6K)*G\"TDJ,>'/D9,A9P3DNFH@S@!L $L-GG=!_0$]0%N
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M&EAZ:XH4RA?5]$8 W1LVT1LS<"]^J$ P[D.P8HL J.?U/_(P(\W0)\5[P:P
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M (4M CB_CP-:QYA@=(8*MN<H0#A/!#=U)Z!K.H"O-@XX.E@(UK.!,'UKB#3
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MH9S'_*CP>P'Q<;>8::G7Z;G9@^XE!?WDVI)>U];2"X2VD@;7SKQJ<E]ZA=N
M>"8 '^V+('1M'[I_'L0=702I:%_DJ&R"(IW]4&0N]ZO 3OM+K@OF0R;-Y76*
MO\^S&![O@2!"="LP-N4J*SFWWSN[J)=67-I%K2UO<V^IJ'5MJ:B@=!26N/=D
M%7I>3ID)_^,@0!LG 75(EUL)>2H;H41['Y29RGTOP6I/%1&LW^1YD,8RF*Q'
M"=RP6\*0Q,'@R,S>@(3\B[YI)1<8^>5-7A65]?2FJE+WIJI"C[:27%I73C;]
M4MI,@!#4(1AU"$<;)_'(0LB46P&%YS=".>I0:2+WI=)&^UVYD_5XL1OE2;87
M^Y;8+W(@.DC<'1:>U1H44]#(3BJM86575#"+JTM]ZFKR:(TU6?0+Y>G>G7FI
M/KT9,^%_'(2_O\E!';+/K(!BY0U0J;7W9ZVQW*=::^TWU8XVHV4DM_NY5,Z5
M5&9D=QQ'W"H,R:H/B2JL#$HH*PE(KRSP+ZC)]:NJ36<VU"7[-%>*?3L*$ED]
M63,!0E$'WG99B/K]/<SA!9![9CF4H@XU6GN_-QB=^="(T1YOL+=]4NGB?J/0
MG=.7X1W9)O87UXN"LRK"PPN+0F++<H-2JC*X.;6IG+(Z,;N^/M:OJ3J&W5XD
M8G=GSP0(13N+MTT6HG?/@534(?_T<BA77@]UFGN^M!B<F;Q@J3W6@K-]4.OL
M<:7$C=.90Q<VIK#$E?'<K*+HL,+L\.BRM%!QE9B761L?7%P?$UQ7+^0TU@@#
MVXHC KMR9\*_#GS4(09U2$<="D\O@TJE=="HN?M3N_[IUQ?-M9ZU86UN-SJY
M7ZH@![064(4U&4QQ<5) 5DX<OS U6EB6((RO$@G2:R/#"NO#PVH:0G@-M2'\
MUI(0?F?>3("P_W:(11TRT;FR^/12J%%:]Z-98]?'3KU3KWK-M!YWVMI<;\&[
M=56[!C06>T24YW@GYJ7Y9Z8E!14DQ(>71<?$5H5'I]2&1.;5!T=6-G##Z^NX
MX:VE@>&=>3/A7X<0U"%^UVS(1AU*3RV%.L5_OK5J['S7JW=R;,!4XT&OM?5
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M+Z2Y>]8D>+-*H_V#\\)YX1DA$=%)P7'Q\=RT)%% ?FHDNSHM(N!BFB!@($G
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MO&]72OX/MM[MIFVG^W7;(8]!FS&/7NP;UXNX]TZM]I]P30Y?K>L=?EC\"7!
M'9S0MO%$V]L/[>[@ W,@[.1"B%!< 9&:&[Y%&N_Z&(X]]H;G<NXEFZ8]PO W
M?>C)L[U#CL3?<$ETN>J<01[ %[A?<JBD]MBWT+IPE^@=N,=>+0[C'O6.;UUJ
M\!_P%4Z?[,J<OUK_"7! &X^P61KH:'=ST-X,19LW$KTN16>7_XA57S\5K[_K
M3;35L3&!D]+C(#>]NWX^%M>]N78#U##G7K<84A<IV;V=F$V]X%SBU>14QVC
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M0^Y@:FW.9$95]N[,BNS3695YC].J\M_&5>9_BJC,_QI4F3_/7@J$X[.0+D&
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M<SJ9D;PU*R!N<R$G<J(J/'2\)3IHK"^.-38>[S^V-\%O[$("<_QY3,#8I_#
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M\F9?=RF8SI]1,)G_4\'DZT<%DR\_EK1G%*&)*3Q_'YY_ J'RRPAEWT$H>4X
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MI3B5U^2X%5454_,J:KRRREH9::5]S.22L8"$XEWL^)(S[/C2)ZRD\B_>J15
M3:O /XE4@.MB$(7W(),7S>'V_J.9A*[U\* +&WC1F7$^='AB%=HUKLV]9<1*
M=&3(5:9_O9=R1R]+MZDKQ*2F/=JZK"7)L; IBYS;4$C)J*NDI]0T^R94]_K'
M5FUB157M"(RL.HG]R8JIF?..KP-J0AV0$VK!=3&(Q?N0PX6>5./V;B.AB_W<
MZ-0([O_-/&C?UI5HVQ9-KK$)"^'!46?IKHV>BLV#_MHU_1SCLMXHR\+N!/N<
MSG27]/9\CZ36<L^XYD;OJ*9N1GCC,#.D<3N+TW@\(+CQ 3.L^;-W1 M0HUJ
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MP =L[E_&\![T[L#S\1DH.HM0RG6$(O!\YE.$O($?44$,N8(TP1$4"#:@0;3
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MLY>QV78W8Y?]3M]C#C.^-QRV,5[83_G/6TVQP'1K(!AN98/>UB#060SH>&X
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M$LU**C*L\\OR[;-+*IPSBAO)*87='HD%P[2X@FV>,05'Z=$%=^EQ11_=$DO
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M((^,0)V@!WH$;3 E:H -416<B,K@05( 'Y(<L$FK(8I+!M*XI*&$>R4T<Z^
M01Y)F.:1@"/831YQ>/XOW=,(U<SB\W?RG_G!MQ&B/T#(Z2^$K#XC/)<+&<(R
MI OB2!-6(36\#F50)<B#-F$-&!!DP(P@#;:$%>!"E  J40S\B*(00A2&!*(0
MY),$H9XD .NP<1(_["+QP;%_J<.O@?SC>/XE//\.0IZ/$')XBI#)*X3T 2$M
M3!5XD2(((SE8CF1!"DG!:B2)U[(<5) H:!&$09^P#$P) F!#X ,7 C=X$@C
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MO&"$B?_EG2CUB)XM>Y]6NO8/2IW"+8\VI=_<UZE<=]N@=M5M0OTR>4;C(OF
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MCO?&5CV/C8L-73>N,G+9N,W8>>-)XYD;'A@[CWXT=!DE^B[KB>Z_7<0>'.K
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MQ#5&^8GCQGF)IXQS$^\;Y25_U,E/(1H%J405*4]%0@ >XCK\)P/@-&:N@R4
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MC7./.X3UL;8;UK8[#V"*"5WW*H#J=28H/>2 XD,ID'^D!+*/M('_V 2D']N
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MW,32V76,J;/S/E-[QT>VUC;"UMI*!*;://D<#.OW8A1L'YS\9!!  >;@E"T
MD9A%?7<"S-P+8+V? N/#@F!X1!P,CBB!_A%=T#MJ#KI'[4'GF#MH'PL$K6,Q
MH'D\'=2/EU)JQYLIE>-]E/+Q44KIQ"%*Z?A=2O'H!YK"84)7./0'QG>K%_WU
MZ:@A@ ;L>]$F@#2L'85QU ^S\,R#6/\(@#%F8JTS#%"Z( 3R%WD@=TD.9"]I
M O^R,;(%F1]=0/K' )#"FQ#)*UD@\5,UB/]G/O!^'@;NU;WH.G"OO ;N90+<
M2X3B7OS;,JR_ .LW8N]+<.[I..]HK.UW".L? YAV$L#P+( &9G*%*P!2UYC
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M!?M5G<+,52LE=JNV2Z:O.B&Q67538K/R2XG-BK^D-GVBFN5JCK'?][#M0[1
MJZG9LXHY6,,<T(_GTJHFKJ?_WT#_2V\^9Y,V'(>,X# T ?9#UI@YY(@90^ZP
MVQP V\V1F+XY&3:;<V&UN1*6F]LP=?-R3-F\19BT^:A@L?FZ8#'TF6"Q\;XP
M<8,H3%PO2AYQ@.W?SK8/TJ(O7PO,7Z>IP="BIM$>1M$3^XT +CN F;N :7MT
M,66/$2;OF8!)>ZUAL=<1$_>Z8\+> (S?&XUQ>]-@OJ\(9OL:8;IO,4SV;8#Q
MOH,PVG<-AGL_@='N/V"T2X313E%XQ$[J;V3;5PT"W=1NHATLI68F]6+IQP/W
M VZT[3,/T8,?I0>G/S4^J0/#4X9D')2G+(D]#$ZYD4#HGXJ!WJE,Z)ZJ@/:I
M=FB=6@GYJ9V0G3Q+[I)[D)]X",5Q\=]L9M[7,M\];'<KVURQ&\BF9CQM:=#H
M'AAZX%-L_Q/ .'IC(UI5@\M2:%W5A_2*,80KXSG)61)Z[:OTN%>Y"+O&"^XU
MU890GO#7V-%7V;BKAPG]]I5/R6]$_#?KV-?+V/;VG4 UVYQ+[8230/ 9ZE-S
MY@5@ZB5@+'VYX=. WK. [#EZ[=OT_+?I^6\; \\SCA<8QPN,XR4WX [CN,.+
M\<N<[%_F)/,R!_G+;.#+/.C+=\@W_/T?Y.$H?=O4^W!J#P+Y;'/B6>JSK6ZT
MY3.N 9,9NME-0'D;T'Z1VG?):T15"WE3P060/O"V$?"N.1>E4X /:!8^X@+]
M$\;Q"2]&_^+%[U^<]#YEPC]EYW[Z)!>/KY.OR<^C=.T!ZIFFPM.<!Z@=PO:Z
M/:/> V-!79.7 /U7V':5YCOD Z+:B_()^515#Y'2E.@ 7RFY.&9.OIM HV+-
MQ?H<X!?&\0L7!K]R(OZ5D]YO[/3?.+!^9P-_9SY^_W"41HZS(O9U"O,==AUP
M9YYMV=Z);*\1=74?U5\^T=1?'NT'^4ZS)^3?M1 9CZ<+W#<$'IAK[HEQTCP7
M1/5\DDK-_3";-$]*94>+UT81#2SHLR>"9RH=\61"SPTGXDNB23HI(76D[7_6
M'_[SGI@G-'M!;M.KOT^W_1T>T+$_JGW\^;]J((;T^@9C(2K,^=,X31RJ_2@>
M)(PDDWQ219I))^DA_62 .INHLWUT'\9?.$B-$_@#%_ ;KN,7O,H4?4'G_]MH
MK>.>IN9Q3\/W&D1C4XACC.GS"51,(#90[XD))'&:>E IM>JH,X\Z"_ [EN)7
MK*3.('6&V"7#//X>'O,PN^H,OF8NOL0+C.!C=N&/^!>__:_1ZI#(3]1\I&&T
M]F&D9"X,(&J-89^8\=.IC]6#(JB90KU\MJ>2.HW,;CN^89]\A674687/L8XZ
MFZFQ@\?>S^%S'.\Q%^_@!M[$VWB=4;W*H[S"H[VLJ50]CCA6GW%H,Q=RB$H]
MB/I&C(6Y$*8SOZYL9Q UXZB72:UBZE0S]F:>'AUX%XNHT$N=U3Q=UU-C*S5V
MX27FX@7FXC:NX29/YAN,]#K[XVGJ/241<4WZGX@3%8Q#\Z@;$\9AQ'PH3?&G
M[A3\H'# YU(O?"0-QWO2)+PIR\&KLE*\+*_%B_(6/"^?CUORQ;@I7XX;BC6X
MKMB$IQ7#N*;8CRN*D[BD=1D7M5_"!=W/<%;O=YPQ$'&*G%2A%'%"P^C#AR>J
MN<]3^U=S.7YC'-\HS?")GB7>TIN#N_K^>,$@&L\9I.%993Z>5I;CFK(.5Y1S
M<6E,)RZ.Z<%YPQ4X9SB()PRWXK3A'IPT.H831D_BF-'S.&S\&0Z8_HY]9B+V
MD-W_A<@I5O7(H1^L@,\YM7S$T_J]\7*\:ZB/NT;C<<MD!IXQ\\ 5\U!<'!N/
MLV,S<&9<(4Z.J\#Q<?4X.KX51\9WX=#XI3@X817V3]B O1-&L&?B0>R:^ 1V
M6-S B,6'V#KI9V'S9%$8(INFB,+&QQ"GJ[>X?>[(:7 6IW*^/L^?GYNBC:<M
M3/#D9$L\,64.3DSUPY%ID3AHF8S]EMG88U6,7595V&G5@!&K-FRW6HAM5KW8
M8KU6&++>(FRRWB-LL#XIK+.Y)@S:O"FLF7Y/6&4K2E:2%:1?C:#B_@Q.>[.!
M]WG)>\D3>-:#ES=GKK7M)3AKH\1QVTDX.,,>>V=Z8N?,$ S;QV*K?1HVV^=B
MDWT)-MA7"^OLFX0!AW9AK<-B8;7#"F&EPP;)"H<=DCZ'(Y)>AR<ERQSO2)<X
M?2U=[/1 NLA)E'1K6*CA%TZGGU+W53_Z+7KP2^0)7^ $+W^'9NEASZRQ&)DS
M'5N<7;#)V1_K7"(QX)*(U2Z96.F2+_2[E G+76J%7I<68:E+EZ3'99EDD<M:
M:;?+5ND"EP/2+I>SLODNMV4=KI_+VMS^E,US$Z6M_\4/+LP!]9^G_[X:!IP-
MYQJ7[_?SLYWN"FQQ-\$&SVD8\'+"*B\O]'N%8+E7+)9ZI0@]7MG"(J\B8:%7
MI:3+JT$RWZM-TN&U2-KFM5+6ZK5)-M=KC[S9ZY2\R>M918/W)XIZ[]_E]3ZB
MK$Z-M,Y;S==>ZGTXST8"%V/8?G(@"M@1RG6VOX!!7T.L\IN$/O^96!K@AL4!
M 5@8$(FN@ 1A?D"ZT!Z0)\SS+Y7,]:^1-/NW2!O]NZ0-_LME=?[KY37^.Q75
M_L<550%/:54$?$!^590'BG(B&R5 S6=L[\ML^[58]D$"O0Z7'KL35/4/KC$9
MQXH@ RP-'H]%(=.Q(-09\T-]T18:BM;06*$Y-$5H#,D2&D(*)74A%9*:D 9I
M54B'K#)DB;P\9*VB-&18JR3DB%91R!7MPM"WR<]:A:&BHB!4E!-9H8:/>(E_
MGGJ7J'V2E]@#:< (7S<RCI7,QY((/2R(,$-'A"7F13JA)=(339%!J(^,$FHC
M$X7JR'2A,C)/4AY1*BF+J)661,R3%44LDA=&K%;D1VS5RHTXI)T3>4D[._)U
M\J-6=I2H(/+LR%%D*MYE6V_2_U^@[K$,KO.SZ#GI00?IA7NY+%P0HXVV&&.T
MQ$Y!8ZP]ZF+=4!/KC\K8<)3'Q@FEL2E"<6RVI"BV6%(06RW-CVV1Y<8LE&?'
MK%!DQFS6RH@]H)T>>U$G+?85G=38>]JI<:(B+784^2/>X#AXADNNL]0_G,-Q
MR*7H$%G-6!8SKK8$&9H2#%&?:('J1#M4)CJC+-$')8DA*$J,%@H2DX2\Q$Q)
M;F*!)#NQ0IJ9V"3+2.R4IR7V*5(2-VDE)^[33DP\KY.8>$<G(?$[OA>UB(+(
M'W&78_ :VWPZF_V03[_%9>@&TD\OW,6XFOF[VA0E*E/'HRS5&L6ILU"8ZHG\
MU$#DID8*V:D)0E9JNI"1FB=)2RV3IJ;6RY)3.^2)J;V*^-0-6G&I>[5C4L^2
M%W6B4[_AZT.MF%110>2/>)'YOD2MXZJ]0/2_6TO9#Z27[]N8ESKV2WFF/HHS
MS5&0:8F\+ ?D9+DC*\L?&5GA2,^*$U*S4H7DK!Q)4E:)-"&K5AJ7U2:+R5PJ
MC\I<IQ69N5LK(NN,=GC6\]IA65_S]6]%>*:H0AZAX;EDC@5J'2D"=G'I29N&
M-54<BQ7, ?-1R=B*\G20FV>"[+S)R,B;@?1\%Z3F^R Y/P1)^=%"0GZR$)^?
M)8G-+Y)$YU=+(_-;9>'Y/?+0O %%2/Y.K:#\4UJ!^;?(EUJ!>0\407FB?)1<
M-=?3>4X6T/=2?Z2:YP-MR0K270LT,(Y2YB2G6([T8D.D%D]$<HD-$DMF(;[4
M$W&E@8@IC41T:8(069HAA)<62,)**R4AI2W2H))N64#)&KE?R8C"M^2DPJ?T
M)OE<X5-R7^Y3+([B6R3*5%QE#D[2 NRC_K8&]@,M22_I;.(X8"R%-?2=S$M"
MI0'BJL8BIFH:HJKM$5GMBHAJ/X35A"*T)A;!-:E"4$VN$%!=)O&K;I3X5"^0
M>E6ODGE4;Y>Y5Q^7NU4_2SZ3NU7]*7.K$F5NE?]PD?D^2HU=C>R'5IX/M",]
MI(U4S:7O:J'O8#R1C;H(:S1&2-,D!#?9(K!Y-@*:/>'?' B_YDCX-"?"NSE+
M\&PN$=R;ZR2NS?,E+LW]TCG-6Z6SFH]*G9J?)O^2.C7](75J%*5.#?^@VA-U
M@.T?G@>LGP_TT8HL7,"Q0$KY/J.3WI>?!W=(X=NAA/?\L?":/PV>\V?"H],%
M[IT^<.T,A4MG+)P[TS"[LP"S.JL%Q\XVP;YSN3"S<[/$KO.PQ+;SFF1ZY\>2
MZ?-_ETQO%T>Q;5-SG/V^A_I;J+>F&UC:0^^YA/VP%"@@222"^!*7I3J8O=0(
MLY9.@.-2:S@L<X3],C?,7.:/&<LB8->;"-O>;$SO+8=U;PNL>I=@6N]&3.T]
M($SNO4P^P.2EOPJ3>T0UB]4<9+Y'V.;UU.Y?QASTT?^O ,I6TO^O8@Y6T__3
M*KH3A[6 S8 ^K 9,8#E@@6D#-I@ZZ(0I@^Z8/!B(28-1L. $.V&P$.,'ZS%N
M<"',UPW ;-U>F Y>A,G@6S!9^PM,UX@P74U6B8**/0O4S\190^VEU&RC3M4@
MD$=KF$C+'C8$>&T&G+90G_Y\TC8)S(?U839L M/AB3 9MH;QL".,1CQ($ Q'
M8C%F)!/*D0H8C+1!?V0%](9'H#M\&CK#+T)G^[?0W?80>EM%Z&U1H[H?:Y#M
M[F,[.U4U&-K!0NJE;N<XW,$^V G,W@5,IS>>M(\>_ !@>$@.O2,&T#YL JW#
M$Z$X; WY82?(#GM"<C@4@NKB>Y@3R^%ZLIBP,8=HK \]S4F 1OG@;QR$XK_9
MR)RO&OBG!E,R J3O!J+W WZTIG/XU>E'J'\,,#T)*.G/=<X*D)RCOSTWAI@!
MYR<1&\(%Z04N2"YP,7"!D_R%4O6#D"Y0Y#P;<YX^]_QK_,X]\H"(HZQEVWN8
M[[G#G).IG<EVQM"+^Y^@_BGU'A@+?M7D F! ;ZZX2H_-YN 9^NQG](#K]-G/
M,HYG+;@8Y,+\)A>'M[R!VQ'JC:&WJ]1_HNGV!G[.!MVBN;_%7-SZA?P]RC+F
MO8TYKV2[L]G>..H&G*7^!?4>F E7 *.G #U^5:JJOSQ/7B)WR,M2X*X.\(H2
M>,V8"[+QP/_1++S#Q?G[JHW:JANV>3'\D'WR(0?\A^S@#YG(#UX@G_/]+Z-T
ML*]KF/-<MCN>VH%LZQS-'ICQ-]CWMYA[5?WE94W]Y6W5/A3ROJ8N,5H/D7-A
MS)Q\SIQ\:0Y\3</RG3U-"_.ANEGW1XZ-GSC9_<P^^9G)_IF)_?DV^7B4.J8G
MGVU/O @$70.<GZ4^=<=25WF7N7^\_O+)8_M!OM;40K[7U$)^4CTO1 '\I@_\
MR9P\L- \'U5U(W^<YGX8U5^,>?27:U3/!'EZ%%%K//WM6+K1L1K?K]J#84^\
M1CVWB%2H[P&I)BV:^H-J+\B*T?J#^IZ8;607U/?$G(!Z+\BS>(@WZ)N_QE_X
MX]_UCS\T_ ;U/2BJ/1FB'KV^W(3O5)AJXE#M1W$EP22!Y$"]'Z4>ZKT@JGM1
MEE%C)?[&(#6&J#',8^_![SC"XY^A7[]*C1='*P_W^$Y5Z_@.ZJ>4?*-Y??1>
M-*#7US'DNS%$]:JJQUB265#?DZ.J!Z51JY Z5=1IHD8'-;IYY%YJK*+&.FIL
MYC%W\)C[V57'\05S\1E=_[_8D1]3_4-&^@&/]/[_0!Q#KZ^O!U&JPY_T-;48
MU7Z4&?R6!S5#\2L2V=W9U"FA3@TU6J@QGQJ+J-%+C5746,_C;<&[[).W<8B]
M<!JO,A=W>0+=X2!ZD9$_SZ,^/UJI$G'K,40C;>9"PG'!X2'G>RA'<_$[<W$/
ML]DN/WR)*'S*<?$1\JA31HTZ:K108SXU%E%C.356\_@;>,QMN(F]' W'\ QS
M\12>PQ5&>)D9N\3>NZ@9+8\S6OO@=#?ZV%\.:5%+!W\(AM2=P#;:4=,=;W%<
MO(HX:F50IX!'+6>6ZW =<SE=S<<U+*9.'S764F,(Y]DG9SD^S_"_4XSD!(]P
M7/(=CDK_PA&YB,,*$8<>0S17/V;G=_*M$4\]3C>?*;3QOM08KTNGXB69(V[)
MO'%='HYK\D1<5F3BHJ(0Y[4J<%:K'F>T6G%*NQ,GM'MP7&<%CNJLPV&=;3BH
MNP_[=4]BG]XU[-%_';L,OL,.Y4,,*WF-&L,SZ3%4CSK^G=/;UY,YY9 W^/-=
M$PGN<(P\IV>.IPQL\*32&>>4 3@])@HG#)-QU# ;APV+<-"H$ON-&K#7:!YV
M&RW +J-EV&&\!L/&0]ANO!M;38YAL\EE#)G>Q0:S;['._&\,C.7U@:QYC/N\
MW'QO17T[:L\$GK/EY6 :<&6\'!>-#7':;#*.F3O@X%A/[!T7@EWC8[%C?"JV
M3\C%U@G%V#*A"D,3&[%Q8ALV3.S&.HL^#%BLPUJ+8:R>= @K)YW'BLG/HV_*
M%^B=>A]+IXK"$@T]&G[E9>8S!_6VPYLNP&6^GN-T?Y*7P:.3]+%_\CCLFCH=
MVZ<Y8XNE'S9:1F"]50(&K=*QUBH/JZU+L=*Z!OW6S>BSGH]>ZR58:K,:2VPV
M"XMM]@J+II\6%DZ_(2RP_43HM/U=Z+ 3A?;_XAZG]?>I_3PO,5=]N,[GU'K,
M'=C/R_ N.RULLS7!)KNI&)SAB#4S/;'2/AA]]M'HM4_&4OM,]#@48)%#.;H=
MZK# H16=#@N%^0Y]0KO#!F&>XTZAU?&X9*[C4Y)FI_<E34Z_2!IGB9(&-4*]
MAB_9[M>H>SV EW9Z\.-DOS_7=Y[TG7,$##H98M4L"_3-ML/2.2Y8[.R';N=P
M+'".0Z=S*CJ<<]#F7(16YRIAKG.CT.S<(32Z+!4:7 8D=2[#DEJ7(Y)JU\N2
M*M<WI)5N/THJW,11RA_A*DH^89M?I/X5^N_3O.0?C%#M_^#ZCI\-,#=]K@98
MXC86W>[6Z/*8A0X/+[1Y!F.N9Q2:/1/1Y)F!!L]\U'F6";6>=4*U9ZM0Z;E(
M4N&Y2E+FN45:ZG506NQU45KD?5=:Z/T]$:4%WJ+D<=YG_I\+ 2[R4G^<E]F]
ML?0ZT<"Z,*YQ&<=B;QUT>INBS6<JYOK:H]G7#0U^_JCS"T>-7QRJ_%)0Z9>-
M<K\BH=2O2BCQ:Q:*_!9("OWZ)?E^FZ1Y_OND.?[G9-G^+\JR [Z5904\E&8%
MB"HDH_B+DC>I<YUM/QNKKL'L)$,)7.,RGJ6,8WZ@ JT!1F@*M$!=H!UJ@IQ1
M%>2#BJ!@E 5%H20H$45!&2@,RA?R@\J%O. &24[P?$EV<*\T,WB#-"-XCRPM
MY(PL->0V^4J6$O*W-"5$E*:JD:BX&TSOSW:?IO:!%'H=+@,W\'4%?^[FYZUA
M$M2'*%$3.AX58=8H"W-"<9@'BL("4! 6CKRP..2$I2([/$?("B\1,L)K)>GA
M;9+4\"72E/!!:5+X+EEBQ"E90L1SLOB(+\A?1)2J2-#P(I>?E^C_3U![;X:F
M!L/77O[<R<\;&4=5I '*(LU1'#4-!5'VR(MR14Z4+[*B0I 1%8WTJ&2D16<)
MJ=%%0G)TM9 4W2I)B%XLC8]>*XV-V2&+B3DIBXZY(8N*^9S<)Z(T^C%N<1Q<
M2.)<0-U=]+^;<]D/9$D6,(_YJ&$<I7&Z*(@U06[<9&3'V2$S;@[2X[R1&A>$
ME/A(),<G(#$^0TB(+Q#BXBN%V/@6271"MR0J8;4T(F%8%IYP7!:6<%T6FOBI
M+#3A3[X7I:/$JWF6X^"L:C\2]7=PV;>1'G@E6<3WS8RK@G'D)VDA*\D(&4D3
MD9ID@^3D64A*]D!"<@#BD\,1EQ*'V)0T1*?D"5$IY4)$2J,D+&6!)#1EI30X
M99LT*/6H+##U:5E ZB?D#VE@BO@/R:+T*?;[:>9_/S6W<\FWKHSG(UG ]_7,
M1PGSD94N16JZ$DGIXY"0;HFX# ?$9K@B.L,749FAB,R,041F"L(R<X30S%(A
M.+->",SLE 1D]DO\,K=(?3,/2WVRKDF]LSZ2>F?^3D2I3\8_7&:_'Z?6GA+5
M\V X)] .+",=?%_#. J9D[0\KKES]!&38XJHW"F(R+5#>-X<A.5Y(20O",%Y
MD0C*3T1@?B;\\XL$W_Q:P2>_7>*5OUSBD3\D<<\_)'7+OR)U+7A?ZIK_J]0M
M3Y2,DJOF MMYN(CG)#4WT8.OHA583.;Q?05CR2VG]Z9=BBS606BQ$8*+)R*H
MQ!H!)8[P+W&#7ZD??$O#X%,:!Z_2-'B6%L"]M$IP*YTGN)0N$^:4;93,+CL@
MF55V2>)4]H[$J?07B5.)*)FEHEC-F7SU<WFVU]%[-ZF?Q[* -#=S+#;2=S&>
M.,837"V%;Y42WM7F\*J>"L]J.[C7S(%;C1=<:X+@4AL%Y]IDS*G-Q:S:<CC5
MML"AMD>86;M>F%&[3["KO2C8UKTIV-;\)-A6BZ/858D2%<?9QCW4V*)Z)@VM
MX5):@(X.>E^^%K8!*?PLLI7>C[]W;=;%G!8CS&Z9@%DM5G!JL8?C7%<XS/6%
M_=Q0S)@;![O6#-BVEL"FM0'6K=VP;!W M-;=F-IZ'E-:7\64N3]B2HLH3&D6
MA:E-:@[5\/K$XV_H4#V3E^?#0GK/;O8#R29Q_#F$>-(RSEH@@=T" TQ?8 KK
M!1:P6F@#RX6.F+;0G01@2G<D)G<G8U)W/BRZ:S"A>S[&=Z_"V.X=,.\^ [/N
M.S!;> _F75RQ=JH92_8RYUOG VNIMZR'\])2YJ!7?2]0*HGLH_\GSL2.3.V3
M8T*_$N/[S3"N?Q+&KI@.\Q5.,%OA =,503!9$0OCE9DP6ED&PY6M&+-R.90K
MML%@Q0GHK[@%_?ZO8;#\ 93+N7KN5;.CDSE8S!S0DBZB1@LM8=EJGH]K@5C:
MLB#Z<E<RDTQ;3P]*^VR\20'ED!(&0V;0'YI$ID-O:!9TA[R@,Q0*[:%$*(;R
M(1^JAW33(@B;^*6--+4;:60W?$3H==>+$-:IV=RCKL$LT]1@JJF5MY'^<S,0
MNI5]L UPH%VV'*;^"/5W @:[)=#:HP=A#SWNGK%D"N$B< \7(WM]221))YQH
M]G!0[6'#]O"+N^EU=[U*:%!W_D7$450UF/Y'-9@A]@$U4Z@53C_N16OJN!>P
MVD]]-L.(_EC_*" _3G][@H;D! W!"2[&3XXC]-JGN"@]Y<Q)CXN@TYR 3W/R
M/<T!?UKUAXAX\%/\\LF;Y$M^[W<BCO(?-9@=G(^H&4$];^HY\BN6U!MW$C"D
M3=8]"T@N4/^2ALN,XS+CN,(XKM(D7./"_"G5HIAQ/!/(18'J)F5.<M?G$N;B
M.AMVG0=XYO_(/7*?__8A%C.\%N:YC&W.H';4,<#G%/6I.8VI,[\(**FG]:C^
M<H.H:B&W5/M15#41.?""'O 2C=(=&J:[]/RO30?>9!QO<6'X%B\X;W,">ILG
MW=L<%V\?(=?)QX1]\O8OH\^CJ6"NLXZJG\?K>QYP>I+ZFGN0#)YE[A_57U2U
MEU<?[4/1U$/>?50/84X^IE'[E\HHT;!\Q07[MXSC.R[2ON?8N,=)X!Y/NGL<
M7/<H=(]]<H]?O/<IJMGVG!,\!]AF_\N< Z@[E;JF;*?^B\R]:O_+ZQJ]1W60
MSS2UD"\?VQ<R6@N1 #_I +\R)W]PK#ZP4M_(/_IL5-7],)R(Q7[-,T%.:9[1
M>I..TTQ3=S#5U$$>W0.BVH,12I*@O@>DG#1 O1=$77]0WQ,S2(;(,-3WQ!R!
M:B_(0[K0OYFXOQCLGX^>2?H8/VCJ#U^I/*_46%-W4&&DB4.U'\69!$!]3TX&
MU/?#J&HQJKT@'3S^(CR@[[]/W_\GUE%C,Y5VX%?LQR\XCI_H?G^@ _^>R?N.
M[[YA5%]K-%6H[DM1[<D8W8.AI?+Z!D1/4W]0U6.F$ >H]V"$\]O);$\N=<JH
M48N?Z;=_I-^^1[_]/7W_M_3]7V,]C[V5Q][%EA_B\<_@8^;B0]SE</D*[S#2
MMWFT_R-O/,;KJAAT="$*<KZ3$AU-/L93<SISIMJ#$<@VQ5(KG3H%U*C IZCG
ML)C+-G2RE8OQ'N-XAW&\B0T\YC:\@CUX&<?P(BYP*#_'4^@C9N1GGE(BKO\/
M1#V!_?'HT;O2T7S\#&-J3J&F(]OD3;TP:B6P'9G4**1&)7NZGAISJ=%)C<74
M6(YGL0;/8!.>P@BNX@"GD-/LD:=PGM\Z.[I+YB^B?IJNBE,:1FL?"HS&H7KL
MS2^,XPOVS4<8Q[;9X#6.BSOPIU84=9(9=S:/6D2-2EQF'$\RC@N,XQSC> )]
M//8 3F(+1\1N'&4N#O-?',0+'"6?8Q\55*-V#]1/MGF$ZD\N_<73^IZ2IQOC
M^5!'58Y4L!>-. 5-8MMFLE<]V*9@MB>&.JG4R<$)%%.ADF=!/7N_E3J=U%E"
MC94\[@;L9"Y&A(/8+CF+;=*;V"+_!)L5OV"3MHB-.B(V/,8#(_7CAO[%:>5-
M\B+?/Z<J06OIXHK4%.=ETW!:X83CVMXXK!.* SIQV*N;AMVZN=BI6XP1O2IL
MUVO -KUYV**_$$/ZO=BD/X -^ENQSF _!@W.8*W!#:Q6?H*5AK^AWU!$GY&(
MY8_Q&W6_X.7F34YKMVPXY5O2>W*Z?<)4P"D#)0XKQV/?&%OL,G3!L)$_MAI%
M8+-Q C8:IV.]<2X&C4LP8%*%-2:-6&72CI4FB]%ONA++33>AUVPWEIJ=Q!+S
MI[%X[/OH'O<+%HP7T:6A4\.]:9QJ9W J=N1E9Q:]A@/7V;SL')RJNBQK8\3<
M!%O&3L.&\8X8G.")-1."L')B%/HG)F+YQ PLL\C'4HM2]%C48)%%"[HG=6'!
MI%YT31[$_,DC:)]R!&U3+F/>U-<Q=]H/:)XFHLF23/N'+WFY?74V+V%NP'D/
MX!A?]W$9,&)/SV4EP;K)AE@]=2+ZI]FBU](92ZQ\L=@J% NM8M!EG8Q.ZRQT
M6!>@S;H<\VSJ,=>F#2TVB]$T?34:IF]!_?0#J+.]@%K;.T*UW7="U0Q1J'R$
MG9J/G7C9<^<EV(>7=S^NL<D.+WIO3O-KF9L^6WTLL35'MYTENF8XHF.F!]IF
M!J!U9@1:[./19)^*1OL<U-L7H]:^&C4.S:AR6(!*AWZ4.VX2RASW"J5.3P@E
M3L\+1;.^$@IG_4W$?W 2A7=<>3GV5==@CO(2MYMLX:5_P%M5_^#ZSDD;\QV-
MT>8T&2VS9J!IM@L:9ON@;G8(:N9$HVI.$BKF9*!\3CY*YY2CQ+D!1<X=*'1>
M)A0XKQ/R7'8)N2ZGA!S7FT*VZ^="EMM?1!2R7/_A54\N.ZAY)HQC@$NP$;*1
ME[F5_*R'N>EPDZ'%Q1 -KA-0ZVJ#*K=9J'#S0)E[ $K<PU'L'H="]U04N.<@
MSZ,$N1XUR/&8)V1Y] B9GFN%=,\1(<WSA"35Z[HDQ>M328KWGT**ER@DDQ0-
M+S$'ET.YI(I2UV"VDL$88#GC6, X6AA'K:<!*KW&HLS+$B7>]BCT=D6^MR_R
MO$.0XQV-;)]$9/ID(L.G$.D^E4CS;1%2?+N%9-_50J+?=B'![Z@DWO]I29S_
MQ^0/(@JC^*FY39T+;/O1./5]0$-)7.-R";:4<70P-_7\?;F?'HK]3%'@-QFY
M_G;(]I^#3']/9/@'(BT@'*D!<4@)2$-R8!X2 \N1$-@HQ =V";%!*X28H*V2
MZ* CDJC@JY+(X _(;T14(40&J;G!')REWB'JC]#_;B0KN?Q:Q)];H[G.9CZ*
M@K61&V2$K.")R BV05JP$U*"W9 4[(>$X! DA,0@/B09<:'9B DM071HO1 5
M-E^(".L3PL,V2\+"#TE"PZ](0L+?([\24840$J;FZ0@N>]GN_=3>GD'OG\FQ
M2!:F<9W+S\L91VZX'!GA8Y :/@Y)X99("+='?+@+8B.\$1,1A.B(*$1%)B(R
M,A,1D44(BZI%:%2[$!S5*P1%;1("HP]( J(O2?QCWI+X1_],1(E_E"@$:+A"
MC1/)G(^HNX5+\0'Z_%[5?3CTXW7,1S'CR(@5D!1M@/AH,\3&3$%TC!VB8F8C
M(L83X;$!"(L-1VAL/$+BTA$<5X# N&H$Q,T3_.*7"K[Q&P2?^'V"5\)%B5?"
MZ^0GP2M>5!,G"M[DR7B.A71U'6BH %A=!"PA[?3C58RK@+]+98RQ"7J(2C!&
M1*(%PA)M$)+HB.!$-P0E^2(P*10!2;'P3TZ%;W(>?)(KX)W< L^4'L$C99W@
MEK)7<$TY+[BDOB*XI/S(]Z+@FOP/YWC\0UQNCJCVXM"#K^0R?!'MT=P2]@/C
MR&5.DAA+1)H6@M,,$9@V#@'IT^"7/A.^Z<[P2?>"=T80O#*BX)F1!(_,;+AE
MEL$ULPG.F8N$.9D#PJRLW8)3UEG!,>ME<D]PRA0%IPP-Z:)PFF-@']N_C;J#
M53PGJX$NTE1)S\//,HOIO?G[D#P)?',,X)UK"L_<2?#(G0ZW/">XYKG#)<\?
MSGGAF),?C]GY&9B57PS'_'HX%"S S((UF%&P$W8%9P3;@A=A6_"=8)LO"K9Y
MHF"G(E<4CK&=N]G^S=1=4\]^:. Y2>KKU?M04AE75 40P'C<2G3@7&*$V27C
M,:MT&IQ*9\"Q= X<2KU@7Q:,F671L"M+A6U9 ::7U\"Z?#ZLRE?"LGP84\M/
M84KY;?(-II8]Q-12$5-+1&$:.52LV8O32._=PGYHY3G9JMF'T@PDT!*$,B9O
MQC2[3HH9M0:PK37%]%H+V-19P[K. 59UKK"L\\.T^G!,K4_$Y/H<3*JO@$7]
M/$RH7X[Q#5LQKN$XS!MNPKS^*XRM>X!QM2+&U:C96Z6Y'VH>SX<.]D,G^X&4
MDHSY0#0_"VAG#H@]+;3E/"U,FC<&%FWFF-@V&1/:IF-\FQ/&M7E@;'L@S-JC
M8=J>#I/V$ABW-\.H?0D,VX<PIOT(E.W7H6S[',IY]S&FE:MG%7-%[*#^1AY_
MI>JYO-WT_[3(U3WT_R21A!)/XD2LB04Q[=&!T1)#&"XQ)Y.A7&)+9L-@B1<)
MA?Z21.@MR8/.DEIH+UD(Q9)!R'OV0=IS";+%[Y*?(%\D0M&M9BO;.;"0.5C"
MZ\,RH&$YYP3-O4!1M,I^JX Y9#J9M)H>= TP9JT4N@/Z4 P80;9V'*1KIT)8
MRX706OK+ 5[\!WCQ6<N3>BT'T5HF>"T/MH;^;LT3//E?!E;1&*[ZBPT71]FP
MB"_4[J'N7.J4KZ7_'>1\L!X(W BX;@+LR&3Z<[/-U-\*Z&ZC#]W.Q>]V+H2W
MFY )A(O 82Y\AKD(&N9%9I@3SW"N^@%(VYG<[3S =AKK;?2Z6VE4M_Q)&,-F
M<;0&TTOM]@'V :UY+O]I G6"AP'W$6 &PY^RB_J[ >5>0)L>G8MH3BHRHDL8
MQR'&<9AQ'&8<1QC'42Z*CO)"=)03[5'5@\DYD(XP@4=X@",TUH=IG@_]0OXF
MHKH&LUY=@RF@+4_:R3' ?^I.K9G4FGR(_7\$,#@.*$Y2F[:=AD4#3<DYYN,\
MX[A@3+A ?I(+U$N,XS(7)E=X,;J2J7XP]17FXLH6PH-<H:&__#6AH[GT$ N9
M[T;FMIC:*?N \,,<@\>H?X+ZM.<F[$+]\X#THJKN0JZI]J%HN$Z>)3=IDIZC
M2;E%4_"\.0T"%\0O,XZ[7(R]PHOR*YQP7^6)_RH'V*MLX&N7R%OD._+;: VF
M= ^0SO9&4-?K#/7/<?Q1TYB:NM<T6C<U=9>7-'M"[FKJ(:\_JH=(@'>U@0^8
MDX_9-Y]. KZ<2;A(^HH7OJ\X$7[-D^\;-OH;CHMOV(AOWR"?H9PYS^1'4=3V
MH:X]=2<]!1BQ?3JJ>L]_[T-1U5P^TNQ!>?SY)/_>%\)Q\J,>\"O[Y@\:E;^8
MC[_]@8<<&P\Y&8H\ <5MFN>B7B7/:_8:/*H]F(QZ;I&>6[T'0_5<5-4](*IG
MDA9#_3Q0U5X0U7-!5'\C1G5/S&JR_O_S%]$-C46Z3O5=,@?PD-[P 9WG?:;R
M3X:O>C:'JA*BV@WR*]2[0515B4^AOCM$O1O#0(-24Z%1[5!Y=)>.ZBDAJJ>4
MYHU69QZBCL=OI:?NY/%[>/P^'G\-C[^!#GH;U793XS#NT:M^AZ?Q#=Y@TK[%
ME_R6JA*B>AK'YYIJR-N/*A*CU1#53@C%8Q4)U=-*9D#]E)!@ZL53)X,:A:-W
MI]Q# X\_CT?NXO%[>/P^'G\-C[^1';:=;=L[>G?*^[A(1_T\_H\M?IU1JNY,
MN:M!=8?*"U _5U9=A7A4D9"-YN,^S/D-*[9I-GY@+KY#!'.71(UL?,)>^A!5
M/'X#CS\/;S&.UQG'JXSC+M9R$&_BL4?8"P=Y_#.XP5P\PW_U%"._QBQ>A?H^
MILN/(4K^\P\2_0(M:AJQ;19LTPSJN>%=CI0W$<-VI%(CERTKP2W&<9-Q7&>_
M/,U^N<8XKC*.RQC@2-B,"^R3LSC**"[B%*,ZP4P=9\^I[J=2U=&.:E"]'_TC
M2% _#/A[S:#_$/K4-&.^+*GGQ/9X4RN4;8FC1AJ/FHOSC.,LXSC#.$XQCA.,
MXQCC.((5.(1U')G;L0_[L8?_8A>_O0,?,#L_C=;SMFO8ID&U,^8WU<UO/,$^
MY&3\ADQ5')6SC8;4G(!+L*6>,X_DAY,(ITX"1UPZ,YU+A1+V?"5;W$"=5NIT
M46,IC[N:9\D0_]O-$7*<Y]$5#/)T'V"&UW)LJNXW6RW\PY^<9+[FR?V>&2<D
MU68\53&:D^"3$EV.;&,>83(U9U+/C4<,X-D7B6$A$=LDZ=@BR<60M 0;I558
M+VW H&P>!F3=6"/OPRKY.JQ0C*!/<1B]6D]BF?;+6*K[#7KT'F"QOHA%CZ&J
MRGS$2>ZEJ>H=(1?X_M187G@X$1_4,<!N+7,,ZUAABZX3-NIY8KU^$ ;TH[#&
M(!&K##*PPB /?08E6&Y0C67*)BQ1SD>/<BD6*==BX9AMZ!IS$)V&%S#?\ [:
MC;[%/,XDK62NR3]\.5E=]+[.B?8".6X''+ "=G+2VV8BQ:8QAA@PG(A51K;H
M-W9&KXD/EIJ$H,<T!HM,D[#0- -=IOGH-"M#AUDMVLSF8I[Y0LPU7X'FL9O0
M-'8O&L8]@?IQMU$W_DO43'B ZHGB?_#1='551K4KY:0+]?FZPX'N@Y\/3.&J
M<ZP^EHTSQ^+QEE@XP0&=$]W1,=$?;19A:+6(18M%"IHF9:%Q4B'J)U6@;G(C
M:B;/1_7D9:B<L@X54W:B;.I)E$Z[@9)IGZ+8\CZ*+,7_X/^H=]V5%V5>? ][
MT?WP=3,7)@.SZ *9DT73M-$YU1AMTR9AKJ4MFBSGH,'*"W560:BQBD2553PJ
MK=-0;IV#,NL2E-C4H-BF%44VBU$P?0WRIP\CS_88<NR>)A\A>\;OR)HA_H,=
MYRLNR*YZJ:LR^P.X^"'K>?%;P87)XME<^<^4HGGZ&-3;CD>-G16J[!Q0/L,-
M93-\43(C!$4SHU$X,PGY,S.0-[, N?:5R+9O1I;# F0ZK$2ZXU:D.1Y&JM,5
MI#B]A^19OQ(1R4[_\#RUGJ3^L6 Z#]6N%+(V"%C&.#H]@&;V38V#/BH<S5#J
M. 5%3G8H<)J#/"<OY,X*1/:L<&3.BD/&K%2DS\Y%VNQ2I,RI1_*<^4B:TX=$
MYR'$.Q]$G,LEQ+F^A5C7GXFHQD7-32X\SE'_$%W_"!>G&\E*+H@6\[,VQE;'
M.$J==5#H;(P\9PMD.]L@T\41Z2YN2'/Q18IK"))=HY'DFH1$URPDN!4ASJT6
ML>YMB'%?AFB/C8CTV(\(SPM"A.=K0KCGCT14@5$\1#RM^A]B8>P'.O+M<< Z
MTL?%T$+&T<(XJAA'@8<"V>Z&R/ 8AU0/2R1[S$2BAS,2/+T0YQF(6,\(Q'C&
M(]HK'5%>!8CTKD*$=RO"?)8@U&<]0GSW"L&^YX0@O[OD!R(*0;[_!E>#U96A
M/5P8;TED/R2Q'_C:&<N5/W-#4X=L/PE2?91(\C%#@L\4Q/G8(L9G%J)\W1'A
MZT="$>X7@S"_5(3ZYR+$OP+! 2T(#%B,@(!!^ ?NAE_@6<$WZ [YGHB";Z :
MOP!1>)(Y.$J]7=0>2J4A2*,+Y6L[?ZYE/HJ8CW3&D1"HC]@ $T0%6B BT!KA
M@0X(#71!2* W@H."$104A<#@) 0$9\,_I Q^(4WP">F&=^A:>(7NA&?8&<$C
M[ 7R+1$%CU!1\%01(N)\E*8R1.T-7!2OS.+YR-=Y-"V5_#R/\:5$T@6&Z2 \
MU BAH>,1'&J)H+ 9" B; _\P3_B%!< W/ (^X0GPCLB$5T0Q/"/KX1[9!;?(
MU7"-&H%+U"DX1]W&G*AO^/H0SI'B*"[D"6H<4%6&J+V.)J4OCV.!M&2S'QA7
M3C)=(/LI/%J.P"@E_*/,X1<U&3[1T^$=[02O:#=XQOC!(R84[C%Q<(U-ATML
M(9QC:S$G;CYFQZV$4]QV.,:?@$/\<^0K.,3]#<<X$8ZQ:E1/2U8]*6<+==<6
MJ>\.ZN1K8P$=0 Y7P/Q=/&,)21+@DZ /SP03N"=,A%N"%5P3[>&2Z SG1&_,
M20S&[*1H."6EP#$Y#P[)5;!/;L>,Y#[8I6R%;<HQ3$^Y0;X@#V";+,(V2<W1
M-/5=6INHO;I<?7=0.U_K:!X+&4L:S4(T8PE@+&[IVIB39HC9Z6/AE#X%CNFV
M<$B?!?L,=\S,\,>,C C8921B>F8V;#(K8)W9"JNL7DS+VHRI64<P)>L9\AFF
M9-['U$P14S.X<B4'F?-AZJ^G]HH:]=U!K:2:[_,JZ<082S@-G$\AW7"^%#/S
M#&"79X+I>1-ADV\%Z_R9L,IWAF6^-Z;EAV!J02RF%&1@<D$)+ J;,+&P!^,+
M-V)<X2&,+7P*YH6?8&S!GQB7SS6]BCP1>WGL+=0:H%GM;02ZFM4[4\J;U#M3
MV*T(8CSN58 CX[0JU\:4\C&85&X&B_))F%AN@PGECAA?X89Q%?X86Q$)\XH4
MF%46P*2R'L:5W3"J7 ?#ROT84WD%RLJ/8%CQ.PS+Z2_*U.Q0[<YIH#FG.>NA
M<6]O_\^=*>%SF0/^;@[CLF5<DXEYHRY,&@W)6!@W3H%1DRT,FV813RB;@DD\
M#)IRH-]4!;VF^=!M6@WMIEU0-)V#HO%5:#7>@W8#5_'U:D;OD&H%EG?P?* Y
MF[N0.2!9"]4[4P(7<!R0F?S=-#*.&'7)H-^E#]TN(^ATC8=VUS1H=<V HLL9
MLBX_2+LB(71QH'6Q$[O8B*[E'.BJ1V_2TLY_@1?";\A]PI5LNSCZI.!5/.Z2
M1?Q(<W=0_C*.@UX@C%_U(H[$BDP@QL2@3X"B7Q="_QB@WY0G]$3"A4\_%P+]
MO CV<U+KBU>?Z'UUA"Y\.9WG<EKZ7MK*99\#2_\@XBBJJLQR:B_DL9OZ@1*:
MY?35=*1K =]!8#:Q)A/647\]]3< "AX.F^B^-W'AN9&+ODU<$&[B(G"3-7$B
M7 QLXD2_B;G8Q$&]J5W]*-B-=.$;:''7?TA^Y80DCK*2[5VR@N<"=2L&V ?4
MB!WBN;@%<-X*3*=AG<@T&M.QZ^\ 9#NIOYOL$0@7Y7L8AVJ7RE[&L9<+P'TV
MZNVY^WGQW\_)?C]/[/T<W/N8X'T\V%[:[3VT\7ON\3@/B(A>:K>SG=5L6RYU
MXZD51!V7W>H[@R;N8_\? '0/ 0)3R<4]+W+DY"/D7 #1&)QFOYQAOSS!?CG+
M?)SG NB\:MLN)\'S//G/,Q?GV<AS/-"Y9\BGA+DX^U!=E=G,ZS.U$ZD;O!]P
M/:2^,V@"]0RIIZ.JQCQ!SI,G-=61*^2JAJ=HUI[6!IXQH#F@4;@Y'KC-.)[G
M(NV%$/6?$GRQFK#37V127SC+USOD*_+;:%6F:!>03.U0ZKJS;;;4G,!_QB4Y
MM"YI=)[65&%458H7-/P_MLX#/*[B:O^O+%E]I57OO??>NU6M:JM8MF5+EBTW
MN??>NXT++KB "[U#'# E$##YP(10DY#\^0()$, 02H#06_;_N[LK<,CW^#F^
MNW=WYSUSSIF9\XYFYH[LU!F9(?F3H_0*1.E5?/.W8-O)K6^1G+[-H/<.G?%E
M&OEE#'\9XUZF(I?_"+%[5S,(DYX[Z ? +@8W^6'P^=C[HC3Z2?MJF&?M,R/&
M+,PK^N\=.B.S(^_99T<^(EX_]3*.-)"^3K ]XN$;DJ-O::O?T0B_Q_'? _H]
M%?SA6?O\@Y==1G:%Q,EV4JJQ*V2L;#MD^F5;'3*R.V6]?CJEPWARS#'KTU)^
M@&%^!^O\%C;Z#3SS*QBS<3;'R!-:C%-*C14AQ@D9K\EV4J=M)8:;?0["W3Y3
M8YP28NS2*99MA8JQ0V82&(.PQ;F4OQ@&O8KR-U#^-LK?0]D']2F\_V,8YT>P
MW0\)W/<)G/=PV&7^?YM?C9S.8<Q_&"LR7K#/0=CF/ARNF'\P[&',$"50IUSJ
M5 G66.K016VFV'>G#%/^$DI>1?D;*'\;9>^A[$.PZ^/4[ZQU=\J?">0_$D0O
M<?<%ZWX=&Z8Q)V7L2#'.E'W,JL-_SC]\)P_JYD>=HJE/.EC%>E>UU*$-C F4
M/Y7RAZC'/,)P">6OI/SUE+^-LO=0]M5P]I,@WT@8WZW'8>Z_)I@>T0=Z&"L^
M"(HA#\AVKLOYG^E@FX,8#:8WH1:")Q/ R@&K')P&,#H(T5[*[Z?\(<H?IOS%
ME+^2\M?K(?1X0'MU'VS_O*[#&[>BQ7U$QU-8Y4W>?6$]5^9FV=84C8B!36]E
M/0#G/?M$X,O8XCEL\;2BL)>Q*J, SU:!T42DC:/47KJG?MV#'G<1'W=JD75E
MQJWH<;.V8X&K=#VQ<9;_3Z/%*7Y]@IH<IX9&Y!ZU1O!/\CU=[B>C;0^G^M-H
MVP3E4\3%8\3%0PH"+X[Z9()3#$X-]6@&8SRE]X(Q%8P9M(:YX"P"9R7(&\#8
MJ</$QB$^.8!F5UFM\XQUYFP7K<688]QYA7Q.=_\V7<KOZ=Z>\J'[HUD_0)=W
MGG9RIWS # ,O46?PR2F5@E.+[LU8>SR>[Z4U3 5G!CASP5D,SBK*W8PU]M%R
MK^'5C=I(:1OPX+I1;VJMXQ=:.]JB-<AJ9YN\[R?].93NE6'O5PPYY^EF[^#>
M372[9T=[$EW^8$;IZE$IVN^8IWU.Y=H]NDX[G5NTW7F\MKKT:HO+5&URF:$-
MKL-:Y[I4:UW7:[7;3JUT.ZSE[N>TS/U>+?%X0HL]7]<BTY=:Z&71@BO$. S[
M68;^1Q/!1VZC>ST727Y'5WO$/$H'/+RTVR-(VSUCM<64KHVF JWWJM!:KWJM
M]FK1*J_Q6N$]4<N\^[7$/%.+S0NUT+Q*\\U;-<]\4'-]3FN.S]V:Y7M1,WU?
MUY#?EYKA;['*=+L8*V.,.9@+#/MW,.2>RX![)Y-?QI**, 1N]7/5!A]?K?$-
MUTJ_)"WSS]82_V(M"JC2@H &S0]HU7!@E^8$3M+LP$'-#)RKH:"EFAZT48/!
M^S00?%+](;=K2LBCFA+ZBB:'?:;)X?1X5\CSX/\ZQW8JR4VD0-?FDU;P?D\:
MW)NN?DV$HY8%>VE12+#FA\9J;EB:9H?E:69XF8;":S0]HDG3(MHU$-&CJ1%3
M-"5R2'V1"S4I:HTF1NW2A.AKU!-]B[IC'E)7S!_4&?NI.N,L-HFUR6^-3;E@
MWUF*#4@[KBF#9S#$;&/878M-EN*?X6A/S8KVTXR8" W&)&H@-DM38PO5%UNA
MR7%UFAC7K-ZX\>J)FZCN^$%UQ0]K?,)*C4O8IH[$(VI/NE&M21?4FOR"6I+_
MJ984"]>?Q)@'N@_<6XTYF!IL4(T-*N$9I&,K\L@OT6-&DJOZ$WTT)3%$DY)B
MU9N4II[D7'4GEZ@SN5KCDQLT+J5-[2D]:DN9JM;4V6I)7::Q:9O5E'9(C>G7
MJR'C/M5G/*OZS ]5EVFQ2GV&31ZCSK\ _R9C90P<_""R@]?KT&,)>LQ&Q_Y,
M)TU,\U)/6J ZTZ,T+CU)'>E9:LLH5&M&N9HS:C4VHUE-F9UJS)RLAJPAU6<M
M5FWV1HW)WJ^:G#.JSCVOJMS?JBKO?>3?O+;\*(^4VTZ(N1Z.?PT<_"KC9!)2
MCM5UY%?H,0,])J-'9[:G.K+]U)H=KN;L>(W-25-C3JX:<DI4EU.MVMQ&C<GM
M4$W>1%7G35=5_@)5YJ]31<$^E1=>I[+">U5:=$DE1>\AW_/:HM)"FSR([>\P
MYH%(/X^29NPE)=\,%U^!'L/H-@T])J!'6X&;QN;[J+$@1/4%,:HM2%9-09:J
M"PI555BARL)Z512UJ;RH1V7%TU1:/$\E)6M47+)'1:77JJ#T;A64/:G\LLO(
M=[RV<,\F]]?:3NF]#NS#XZ$"</V-I*'+T ?:IBG8HQ-?-94ZJZ[$6S4E@:HJ
MB51E2:+*2S)45IJOTM(RE92-47%9LXK*NU18/E4%%7.57[%*>96[E%-Y4ME5
M=RJKZC?(V\BWO"=+JK3)>7QP$W@GP3Y(ZKES K3(6)G"^R'L,0G?=! C]=6.
MJJHTJ;S23Z6582JIC%-19:H*JW)44%6L_*IJY54W*;=ZO')J^I1=,UN98U8H
M8\P.I=<>5UKM'4JMO:B4NK]S_08A2QICDWN:[?- $VPGM&R#AZ]!%O:2ZZ)'
M+_9IPT^UZ%I:ZZ["6A_EUP8KKS9:N75)RJG+4G9=H;+J*Y11WZ#T^@ZE-4Q2
M:L.04AJ7*KEQFQ(;CRFAZ3;%-SVFN*8WN'ZEA$:+51*1.SH8%XQY('#W]=,O
M#4BKN,XC#1Z82+[+9RWH6(VM"II=E#W62YEC Y0Q-D+I8^.5UIRFU.8\)3>7
M*:FE5HDMK4IHF:#XUNF*:UVLF-;-BFX[HJBV6Q39]H@BVO_*]4M%MEH4A42W
M6*P[Q:X#_S#8NTE[-P[95J;,'206T*43FM2(+N7HDMLY2JGC/)74X:O$<2%*
M&!>M^'')BAN7I=CQ18H97ZWH\6,5V=FEB,X!A7<N4&C7!H5T'5)PUTT*['I8
M 5W_R_5S!75:%#R>K!$Q3NLY,<WV1_L=<^@7YA(+R*S9Q +ZM*'+&/0KQBXT
M?25,=%5TKY<B>_T5T1NN\(EQ"IN8IM")>0J96*[@B?4*G#1. 9/ZY#]IKOPF
MKY7OY/WRF7R]S),?E-?D/\D\Z3/$(I^)-C&>&'5L%OW"/,8G*/)JJ.'"1=)T
M7O= C9K0JY+/\] Q!?M$#SHH>)J' J:9Y3\M2'[3(N4[+1')E,]@D<R#U?(>
M;)'7X$29!F?)<_I*>4S?(_?!TW(;_*5<!Y]%/I#;M!_D/F"1!W(MY1\VZ/D2
M_+#,MC)EV'Y"2L=28G$Q-D"G#'2+GP__1%>_>4[R&O:4:=A7GL,A\AB.D?MP
MBMR&<^4Z7"Z7>8T:/:]+3O,&-6H>!0_#=X<AE,.0Q[F7D'<1N/\<BU6.@[\?
MO.VK\,-::?$Z^D9D J_'(A5KI!SH:A*?1ZR4 A#OE:/DMM)=3BOAN2OAVRM)
M0E:2!*Q(1Q@ 5S#PK*!!K9ABF]Q:86S[@=@NOXV.!P*W#&*V]"L$'998=)AZ
M[UEKVQVT<K/]E-JM\&^D!BF IJ9PC>)^($)J(G=DU#82T*TD6UM) +<&(20^
M6QEDMV;9ED%NI3%O)9"WX,0MJVV/0MX,J=X$:=X$4=SXN;3!8I7]T+_M6VR[
M@Q8:NX-VTQ;VTB?MDTJNDM*1&"0(,5.,VP'P#Y+X'H+?'G1#2$ /DHP>"K;]
MX>>0D0 9JU2,K;%MMN5P!W'HP1W2 3CW@?LP/"3YJD_H#/YM79VR>[MM=]!2
M,(? F'"(.,1L9=#2S&ND6"3H./;'G:XGP8:GDTS;!3U.H\=I['$&>YS!'F?1
MXVP*R0A)T3D&@G/=B/&X>!Q\AH+/0.Y/$Q.GX?W7?8-8M&V?[4E%LP_3%L%K
M :<"=;//2'%GP3\G>6%"%_BY1E:FW'&%W DYN!._W$6"?C<)^CUP[7OQRWGT
M.$]B<)Y!YSR-^CR!?9[*GJ? 7^"/>_''O?]"?K#-P8 ]Y11] 9A5-Q*#8,7=
M"O[MX-]IWQ5TY<J4!^UB[-9Y>&1>!)O\&IL\AF\N^I.DHL=3:;;ENY>(STO3
M$0+OTE&$]G'IMWSV#O*9YE/O?NK<03UKJ&/N7;3!>XF_\Y+I?LEQ9.[%F'>Y
M:)\'N627D5TZS]I7;UCG0YRE/^*;5R (KZ''WTC$7B=!> .?O$G#?I.X>)/*
MODG!;[Z(7-8T8PZ&.M>B6C[U3*">0=:3<26'D94I(SMT1E:(&*M1_I]L)X>\
M]K.Y$.L)(OCG0^-)OL3J9\3'YR3)7Y*D?$5;_9K.YVN"^AN,_0V&_/H9_;0C
MQ,/.^Z_<%6*<$F*<4CI.MA-"C=4AQNX4XTDI([MDML,@]^H'F-WWUE,ZSL#F
M;M57<*LO88Q?6$\I_1 ^^^\?G\IRV3[_\0?D>2OG=;'/.XRRST48<S'&J:W&
M*2'&*:7&#IEF2NC6=_"Z;^"Y7\'[O]!2REZM?Z&'\;24C]'C(]C?AS"S]V&'
M[\$4+\,SW\:(?\= ;_"KD=,YC/4?QER$L4ODB?^:?W"PVR60.L6"ETE=2L"J
M!Z.=\GOU#_CV9<VD[/F4O92R5^&*C92]7:_",5^![?Z)!OP'6/V+L.7GL<6S
MW'F&$IZVXSYIG_LP3L6X\#,=Z#'0U@V[^>@#A<.2D\'*P]658#11_GC"8:)>
MT@#A-Y.ZS"-,EA":JPA1@]5NUV]@OQ=AWH_ADT=HR ]CBP?YQ@4TOP]/&7,>
MO["+L0;C]BMT^/;'.0A'ZF8"+U"_QQ;/*P.<(C!J*+]9CZN3)C*)IC) /692
M_C#E+Z;\E59V?:]VZ&[MQQ/'*?]Z(N,>W8Q&-U#B.3QW5K9G#8W(=78=C%TQ
M']A#^\_6IN:&S7S "Z,NB>#DZ'YX_WEX_SUJH?Q.RI](^?UT6T-8?2X8B\%8
M2;D;*7>G3A&C)_#)-7SK*+8X3$T.X<D?UV @5]FOQH.H_V$L^J*+><[!UOQ_
M37P^@"U^H0#PHBDE%9Q\:E4.1AT8+6!T@C$1C*DZIADZ@AY7H\=!_+)?FXF,
MO=K#)[OXU0ZLLXWHVX*%-Q/-QOG#5\H_W6GB=&V_,]NZN LTZWO1YW;:RXVT
MD3,*)M+CP$H'IX"Z5%*/>NK0 LIX[29.=Z+'#O38AE^V$!^;M!:O;-<Z-%J#
MQJOHU%=@T>5ZF2C^Q+KO;*F]A1MB;/I[GJ'F\1!XIS'_$6";AC^-;L<=W*F;
M+_4*HTX)X&2!4T1=*K%X/3@MX(P'IY=6.A5/#&FYPSPM=5BNQ:,V:>&H?9KO
M>$+S'&_17*<'-6?T"YKM\J%FN?Z@66X6S;2+,0?S9+3T0!Q##W(]KT^&D5O1
MY5_EY:"=+B9M=O+7>N=(K7%)UDK7;"UW+=92MRHM=JO7(O=6+7#OU'SWB1KV
M&- <C]F:[;%8,SW7:H;G+DWW/*9IIILT8'I _:87-,7K(TWQMJC/_),\'\-P
MPY!_+\/+3<@IAKO#I$1[Z&*WDA*L\QFM%29O+3$%::%7C.9YI6JN=ZYFFTLT
MTURM(7.#9IC;-&CNTH#/9/7[3-<4GWGJ\UFI2;[;--'WL";XW: >O_O5[?>L
MNOP_5&> 19V!%ML5N03^ YGXG[3C+'*,KOTJAIEM2=):]%N*G>;Y>6BVGY^&
M_,,UZ)^@@8 ,30W(UY2 ,O4%CM&DP"9-#.S0A* )Z@GJ5U?0;'4&+]6XX$WJ
M"#F@]M"S:@W]A5K"GD;^H>;P'Q#+C_($>.?AU3<780.&^T-<=_%^ RG9<FPR
M'_\,A;NH/\2LOM!@30J+46]8BGK"LM4=7J3.\ J-#Z]31T2+VB,ZU18Q62V1
M,]0<N5!CH]:K,6J?&J*O4WW,/:J+>5*UL9>1[Q'+C_(H=;\;[.L9YH_#L?=7
M8(-28U>,M"@;GI'*V!X_2KW1)G5'^VM\=(0Z8A+4'I.NUI@\M<26:FQLM9IB
M&]48VZZ&N%[5Q4U3;?P\C8E?HYJ$W:I*/*G*Q#M5D?0$\I8JDK]%++RVB3$/
M= >X9QCBCXZ!^R.;2057&KMB^&PZ>DQ"C_$)'FI+\%%+0HC&)L2H,3%9]8E9
MJDLL5&UBA<8DU:DFJ455R=VJ3)ZJBI2Y*D]9J;+4G2I).Z[BM-M5E/XX\@;R
M-6*Q2C%R@3K?"OYU</RK&^P[<WB]C'MST&, /7J(D=8T%S6F>*L^-5"UJ9&J
M24U056JZ*M/R5)%6HO*T&I6E-ZDT?;Q*,OI4G#E+A9G+5)"U3?E9QY27?:MR
MLW^MG)R_(5\I-\?">T9FY#SVOPG,DZ1]!^'@.Y!U\/W%\/V9Z-&''IWHT93C
MI#&9)E5E^JDB,TQEF;$JR4I1<5:6BK(*59A=J8+L!N7G="@O9Y)R<X>4D[M$
MV7E;E)5_1)GYMRB]X!'D5>0+9118E)%OX;[%>E+.#> ?;R462/NV(6M(R1>B
MRW3TF(@>[<1*/;%:D>>ADCP?%>4%JS O2OEYB<K+RU!N?KYR\LN575"GK()6
M919.4$;A=*47+5):T2:E%E^MY.*;E%3RL!)+7N'ZN9)++-RS* 6Y$YRSQCR0
M<4INI_V$6*[S>3^ /2;@FU9B9 PQ4USLJOQB;^46!RBG.$)9Q?'*+$Y31DFN
MTDM*E%9:H]329J64=2NY;$!)Y0N44+Y!\14'%5=Q@V(K'E1,Y<O(9[RV< \I
MM^@V<$Z#=QCL/1.@0+WD^ER'>3^5^UW8IQD[5>.OPNK1RJHP*:/"3VD5H4JM
MC%%*9;*2*[.45%FDQ*HJQ5<U*:ZZ4['54Q53,ZSHFK6*K-FOB#'G%#[F@L+&
M_![YE-<61=18^,RBF['[*? .391V]A&/I)U+N<[F?1^I\'ALTH1_*O!-'O0M
MM=9#B;5F)=0&*KXV4G%U"8JM2U=,7;ZBZ\L565^OB/H.A3=,5EC#'(4TK%9P
MXUX%-9Y18.-]\F]Z00&-'_/:HJ &F]P QG'P]D/)MD^C;S36H7"=V4^;A)IT
M\%D=NI2,E[+0);'%6='-7HIL]E-$<ZC"FV,4UI*LT)9LA;04*ZAEC );6Q70
MVBO_UIGR:ULAW[;=\FF[3N:V\_)J?T[>;?_DM44^K38Y@^V/3K4]K=F@IZN,
M=2C(C"%B 7V:T:4*NQ2@2QH^BNUV4&BGNP([S0KH#)1_9X3\.N/EVYDNG\Y\
MI%+FKB9Y=W7+JVNZ3-U+Y=F]71[=)^36?;=<NY_B^J[<N[Z31Z?%*M=.M9W4
MNWL.5!@*LARJ/@\9&*9-SJ8]\%DI^F5CFT3TB>#[ 7VC99[L*:_)/DBP3'W1
M\NQ+DD=?MMS[2N765R^7OO%R[NN74]\".?9MED,?_*K/V.H/49K\=^1+.4PF
MFY]DT7$P#H"]?2']PF+;.I392_ #KUNY5XT^!7R>.A?^C4[!V,AGEH,\9[K+
M9::WG&;ZRW$H3*.&C($E':&3'ZJV32P.X<RAN;:M-D/P&N./RC,>H='#-:?#
M_:>320Y:= 2,/4MLNX-6K_II'4JGL0Z%>R70HDPD#MU"^9XO8D*<E[@2.'"Z
MQ7"IQ21!BQCL%R7:!IE%=&R+".!%W;9',"VBH(5[*1R^N^ !&CY9ZSSX[CR+
M50XLHV\$=P.J+MM +&ZD7T):D$HD%TGD?OAZR0\Q(<Z\UX;1TGH2O_7>"-QR
M/4G8>@;[]0RVZQEXUU7;CF):AP/7P;G7;D<@UFL@LJLAIJL^9E""3:RT6.=@
MMFSB]E94VD:? "7MV$F?M L?0-53N$8@_M8U*.#O 7^O7?; ;_? ^:UK4M!C
M#\G&WE@$G^QE,-[;8.MT]A!L>U!^]U'[>A0(\X[WD>^L:U&,$UHV@+F(\@?W
MT2?M)PYQ'=VKTI"HP^ CIB.2$T60W-*8D1/VZW'L<1Q[G" A/H$>)]'C)'J<
M(C$Z1>=ZTIB([K<=BW,"@!,W\GT(]37$Y36PBF,6;:9>2Z^RA<P$<)K *#TI
MI6.VJ&O!OT[R/",Y0M=)TTEXD9M_)K= #FXE/FXE/FXC2;X]Q):<WLF >V>-
M?:<. 7WG9A(%"K[C/N0EOH<_;O].*\">3?TF4:]F\,K!RKA!B@;+C_(];I4<
M;C?F6Q!C+N2\?2[$$(JRK@\QYD4>,.9$G*2'L<DC).:_)AE]G,3T<=K)1>+S
M(IW,10+[(H9^ MY_\0D^>PM"\9F&L6<?V&W4L1+,+/!BP/.[&_Q?V'$NV.=<
M1G;H/&&7'W?HV.<H1N9#7L FOR=&_H0>KY"8_F^)]!=\\BIMY%6"_#4,_1J%
MO\8/7GM+4ZEW!]C5=] &[J4?I'[^8+J/G,IRY0Z=9^US+;^WRX^[<V0[K<0X
M0>0-V9YB\R[Q^@$Q\C%^^81$[%\D9Y_U2)\O0 B^SZGTYQCO<X.-N]GG'8QY
M"&,]AK%+QM@#8IP2,K)#QCBAPWABK;$7Q3BI=+Z5*?T;9O,];.<[.-6WL#OC
ME(ZO8&5?PCX_AU5_!NO^%,4_@4G_DV^-G%#ZIGW^XQG[/,!/ZR^N7(-AG!)B
MK$<Q3BDMTP]J &,<Y4^D[ '8\RS*G:^/T<-X6LJ'Z/$^+.P?,,!W883OP._>
M@@V_2?"\CM/^RK]7^:4Q]V&L/7G1CFWL!7GXO^9 9)T3^EY^X$7RJU3P"JA#
M->4WZS(\]RUX_QN:AMEGZ37T^ MZ_#_T>!D]_H >+\$,7X#K/@?+?P:>^32!
M])2>QYT?Z*+U_!3;_,<#]CF(NW^FPS<R#K]UYMO>X(50CWBPLL IT1_A_2_B
MD^?41=F3*7L:9<^B['G4= EEKZ)>&PFAG=3M@!ZD [E@W0'R"^L)H?>@^5W6
MLV1MSS@VSK8U3L@X=X4.7_S''(0G>'[Z';:XI!1*R .C@O+KJ54;=>BF[,F4
M/0#"3,H?IOS%E+\*OKY)M\+X;X8MWXA/SG'G#+^Z#NN<PJ+&#BKC?)EK['($
M^<$^__*./;R?MS8W9^KD35V"P8H%)QV;%5):)>4WZ";TN %[G,,O9]6OT_#M
M:]'C%'J<0 ]CU<-1.O.K\<E!OKF?$O9AL3UX<C?6OG+]A2&?V:<5C:;VE&Q3
MH0]8NR,/[.4+7CA8B=0C"XPBZE!%R0VT@%8P.L&8",94,&: .@S&$LI=0TO9
MIJU\N@GM-J+]>JRX5G^RSN2MEFUF<43>=0&?8>=_Z&8?XGJ/JVU*^@:-YM=>
MU"D O"@\G Q.#A@E8%2#T0!&*S7N!*=7&]!C'7JL)3Y6:YE6<F>Y5:-C6.<F
M+:1#G8]WY]&"AHEZ8Y9S1/Y"MWK)'_Q >*>Q_-#7MEGT&G0[1-^Q5V:B/5A;
M%$-]4L')I98EZ%^M%>BQ##V6:CPXO>#T:P'Q,8]7<_G&;&PQ$VO-P&/3=2]1
M_"01]+8&'+Y6_RC+C_("W>FO(VP'8]U,&G)MN'2$E&0?0\]V[++1R0-,7_#"
MP(H3K$4+'/(TSZ%4<T=5:[9C@V8YMFK(J5,SG"9IT&F:!D;/5?_H99KBO$F3
MG?=KDLMUZG6]6Q-<GU"/VYOJ]O@2L?PHE\!](('A*QG>BQSE]3Y2D6UAI![8
M9[F7HQ:ZF337U5^SW"(TY)Z@Z>X9FN:1KWZ/4DWUJ%:?9Z,F>[9IHF>W>DU3
MU&,:4K=ID3I-ZS3.:Z\ZO$ZIW>LNM7K_1JWFM]1B_@:QJ,7'8KT^3OKU"V,.
M)HLA/LMV*LA.4J$-#'G+(TF[L,E,'Q<->)DUQ3M(D\U1FFA.T@1SIKK-!>HR
MEZG39XS&^32IPV><VGUZU>H[32V^\S36=[6:_':IP>^XZOUO5YW_8ZH->%VU
M@5\CEA_E5VFV8?X<Z=<QAME]7+?P?G6:+3V<A8_Z0QS4ZV]2M[^?QON'J2,@
M3NT!J6H-R%%+8)'&!E:J*;!.C4&MJ@_J5EW05-4&SU9-\')5AVQ35>A1583>
MHO*P1U06]JK*PK]4>;CE1[E "GH;O/HZAM>K245WE1(#\-MEN? ];#+(T#L)
MWXP/<U-KB%G-H4%J"HU20VBBZL,R5!N6IS%AI:H)KU%U>),JP\>I(F*2RB.'
M5!:Y1"51FU5,,E84?9,*HQ]20<R?D<]5$&OA:E$A\DOJ?1.X)ROQ \/K#F0=
M/'LQZ>!L])B*'MW$26OL:#5$>:DVRE\U46&JBHI5972**J*S519=J-*8"I7$
MU*LXMDU%L;TJC)NN_+B%RHO?J-SX@\I)N$%9"0\H*_$/R+\0B[+M<B]8-X!_
M#=SZJEII*[*:]&LAJ> ,/IN<APU(#9N2'50=[ZF*.!^5Q0>K)#Y*Q?&)*HQ/
M5T%"GO(32I67.$:YB<W*2>I6=M* LI+G*S-YG=)3]BLM]9Q24^]72NJ+2DG[
M1*EI%MY;N&_17=3Y+/A'28'WDG)M1E;6$XO<&T2/7O1H1X\Z]"A/<5-1LED%
MR0'*2PY7;G*<LI-3E)62K:S4(F6F5BDCK4GI:9U*2Y^JU/1A)6>L45+&/B5F
MGE%"YGV*SWH>^:<2LBQ62<RTZ'9L?QK,PV/M>X&@1\N-TTG0I1\]NM&CA5BI
MP6?%6<[*S3 I.\-/F1DARLB(5EI&DE(S,Y626:"4K HE9S4H*;M#"=E]BL^9
MH[B<58K-W:.8W-.*RCNOR+QGD8]X;5$T$I-KT2W8_M18VY]#=W9 3XQU*%SG
MM!JGD\"W^'PL>E81KX6%HY29ZZFT7!^EY 8I.3=2B;GQ2LA+4WQ>KN+R2Q6;
M7ZN8@C9%0Y*C"F<JLG"%PHMV*:SH6H46W:N0XM\B'RBTV,(]F]Q(?4^ ?P!N
MOYT4?!WT; G76>@R&3W&H5\C=JH@1O*P26J)FQ**O!17Y*_8XC#%%,<JNCA9
M4<79BBPI5D1)C<)+6Q1:.D$A93,47+94@64[%%!^4O[E=\NOXA+R#U[_P#T+
MGY%#8/]CX.\CW=P*OU\SB7CD.@0]FLC]=FQ2SW=*T34;FR15CU9TI4D1E3X*
MKPQ26&6D0BL3%%*9H>"J @5652J@JDG^U5WRJYXFWYK%\JG9*G/-<7G7W"6O
M,4\B[_+Z>^Y99*ZVZ#3U/6+0,2CR9GC]2BC1_*FVO3@3>FF3Z%:#+H50QW1T
MB6N2PNK=%%3GK8 Z?_G7A\FO/E:^]2GRJ<]!RF1NJ)=WPSAY-?;+U+A GHV;
MY-%X1&Z-M\JU\3'D#5Y_*?<&,D?D%!B'P-LUS79*[;(9Q.-TVUZ<+O1I1+=R
M=,GE>\F=<"]T#FIWDD^KI[Q;?>35&H1$RM26(,^V3'FT%<F];8S<VMKDTCY9
MSNUSY=2^3J/:#\JA'>[?]BOD53FT_0NQ:%0K^13X^\'</@M:/,>V#F6.<4HL
MU*P#2C(&78H&X%Y3L 'ZA.(GWUX'F2:XR:W'2RX]?G+N"9533ZP<>U(UJH<&
MU$.'T]-L,^2$F;Q>A< U>^#^/61(W1"3;K*W+K*X+O(Y\/>"O7D^='PA8P0T
M?0;7";P?.TPL\EDN^B515 0V"N#[7NCE-LU5CM-(? 88Y <8V 88X 888 88
M^ ;H> <(Y &">X O]\/Q^B'N4R%T4R%14UY$X)I]Z-!GT2%P=H*[@:^M6(X?
M5O UKAW0Y#'<*UP,_^;S:/0*@B*9T<T=&34/'C4/;CD,IQMFD!^&;P\SL,R%
M4\W%%G.K$8)H+@:<RP_G0/#G0&IG0UIG_8[!^"/D>X+?HGU+;'N!UJZQK4.9
MCO0@36NE,B0+B>.SD-62#R9U1QP1K8)KKR+Q6XDM5IKM:U)(.E;"MU?2J:[
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MH'=@TF_#N4?.X7C)O@;C4?L<Q'_/@1AS,;;U*#_ 9[Z!8WZA"LIOH.P.RIX
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M^!)YQM?)(V&<W!/ZY9:X2"Z)6^6<>(V<$N^28^*37-]!ON(>8_D8VWZD+5"
MU<9S>9"9\.L^=!F''HVD@%7H680N&=@DGG83ADW\4EWDG6R2*<E'IN1 >29'
MR ,CN:=DR"VE2"ZI8^2<VBZGM"ER3)LOA[1-4AHC41JC8AHC=!K90MJ7.)=<
MHL&V'VD3*>]*./4"9(:Q%P?:WH%>C>A7B2YY4,>4<OR 38*PB4_.:'EF><HM
MTRR7S  Y9X5I=%:<'+/2-"J;0,K&B-G&Q 4D.0?2F@/'RB&/S2%1SR8YSGX3
M@>ME670(_)U@;NBVK4.9ATR'YT^$+K=SOQY=2J&,65#H!&P6CDW\L8E7R6BY
M%7G(J=!;#H5T'H5T(H4TXD*"II  *B*PB_AA$=R_"&)=!#$L@C050A@*2?X+
MR=@*T*' 8OU3]';C7-S)MG4H<Y%I2"_JMW*_&GI4T([)T#4:_P1A-S/QXU'C
M)*=J=QS%H%+I@S#@5=*Q5M*0*VG4E01T)5^NI'*5$/;*E;9'K59 7,HA(>5_
MD\J^L,[#[$7-K5.(1^CYXD':Q*!MZTBWL1<'74KY/ N[)*!+&/KZ8A=/]'%N
M9E ="[]L@M<U,J@T^D.6Z<@::, -!&X#G4X#RC;@W(9I&!2N6;\',@7WKR-;
MJWT-<H\.8RS61Y9LFFY?AX+)9D.#^F;AAQFT273)1Y<4=(S"3@'HXX5M7*B:
MNDA^.N';XQGDQV,+8TU*![;H8!#NH#/IP!\=Q$0'2K<#TKX(,186&(OK(6<M
M</]F=&BV: ?8Z^WK4!8LM)T)VSV/:G&O%)TR^#P64P:CIYGJN&$O$A>;3,46
M4QC<^SQ_6I,RR5B3@BTFT7@FX8])3;8''DVDT%[(?2_$;@*$L0<RUOVY=4_0
M%K#7+*9_Q%1SD,E+47,);N9>+JHGH%<HW_&A"+=A< V9:Q=LIMG&FA3TF(4>
ML]!C)CZ92:<^$UL,T8"&\,<0 3XTTW;@ZW3:YR!$<AK$<.!3ZUJ4#5"_5<8Z
M%,)V !F/U"*%J_$!$LYG/H23^PKP1F2E_;K<+LM(1)?!^9>AQU)B8RF#VU+:
MR%+B8BF-: EM= D&7,*7%Q^@$X+4+H2HSO_(>B[*.E1;NA$UD1ZZD<;-],N8
M+(V$,I*K+^*.R! CR=QVA6S]N1B)*&UEJ[?]O-@X)->V*=28 #6,OGDG 4CF
MOI'VN>$R@?"]5FZU31--(EQ:=M%D"-W,O;3#??2%B/N5ZT^NW(]S]?\AUOTY
MV.0([>4H>APE-H[BDZ/&(E%L86P&.T)?=>0$W[N/WQ"7A[[4L#%5!F8;&%6'
MZ+HH)P:7^1\#?V1^Y<HS88VYD'/Z[_TXUF?FZ*>YD5OPS6W&0QN)C=N(S]OI
M:&_'%K<39+=3L=OPQZU/\[T/-4#=QH%; UX>6'$0#'^PW*]<@S)R)NS(7IQ[
M]9_/R+GR?!)CG<B/YZBBQ^/H\3C)V$42E8OTFQ>QQ44<?Y%*7>2+C[^B+NI9
MQ]N"L[9G\@3:ST*QSKV,K$&YSU[VR!S+1?TT'_(?^W#TTUZ9D?-3_X(>K])F
M_\J@_S?B\W7:R!LTMM=Q\%\9O_[Z\W4@AACG@AAGDAK/1#'VPV3!BTOU#5G[
M%S"'SV NG\*:/J:#^ @>\P&-]!\PNW=I*)=A9&_#"/].\+R!$_^*@_X"@_P3
M[/T/>N_'9\$:,R\/V==@7'D.YT\R2M_!:;Y2 'A18*7 BO(IOX*RZ_4WF,6K
M,(U78#HOH\<?8%TOH<<+<*KGT.-W,-'?PFDNP>]^0Q!=!.4Q'/.(_A<N_Y45
M^WX[MK$&X_3/=/CIF:SN,%,?O0:/^']PNY?@_<_"<Y^&33P)FWD"-F4[$W2B
M]:_H#\-B'Z+#>L!ZPL(*:KZ1.N[&E4=PZ?6$TGE"ZK>$ZT=6W!OL\Q_'KEB#
M\;T=VYB#,/:A/&]]'JL76 '@1(*1I OPJ5_"E.Z%V=R%'G=@C]O@4[?"ZVZ&
M7]X(&[P>OGT6/<[0B5VKS32GJ_#(23CT;31;XXFUK\/CO[.>!;KOBC48UK-
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M!QX)/;@8F7+8Z^?7B@\#V]!U6NZ@+L"3".1S 4],P"?U@04SY^\$_",+D2K
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M3$@C>!:OP<MZCJP!$2M V1K0!EWHABT_7PG= 67OA++MH.R]H!*N4+XG=&$
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M>&&,\L!BR VS+1?,"EQD4P@7.<R;4&\"^&XG8&D-A'08?CX _-@17@8A1(6
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M3W-6H4/(X_Z4_QRC0T48./;U2^>_/ZZ^.+*T;BT-2-OZ<^B)GEHR_X,G[T\
M2\B2BW3>EK_"Y3Q'E@*<8/\+L._3$OE#9G\'W%EW+@%XR/$W8,M2,XC/RK\!
M:DL(XOLUF[]Y$%W*6>NZO%OF%X"Q>*E6C.:'6*J+L-*0D;.*_,D6ZRK/3+YX
MZ4K.XS_-0<NT3/\N]96E'@N>^5/N>-$)ZW5,B$#.'_(;8[8NCIXC$TOFMQ#N
M$RZ0\9+[ S].:_\:%W*WEP(\L?EK9/&>6PH0+_878,6))?(_V_\]>!'_)0 %
MJW\#'%P"$/);/F)+NE<[)_T[8"OI3DOF[_F(5@\)8!W#[P!9$C<G.<91XC>
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MO43^6\Q?NX>(T!)^=9^OP&\Z&4T*."7ZN](ZDU:PB4BKMY <Q,80J_W:#C1
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M%&@ .4I04B1%H#QK4BY1>NM# D!=5[E, D =)U72H &YQ  LR21U"=4,9S0
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M(0&X$0-L2 #;B &1) "4\442/((($@.:N=  .F+ C_4D11 #\/O_%8!45"A
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M]UKC*7/G^0V:Y^+MCHWH2\/*QJ0VQO6^C'Q6L]'?:;AXMC7H2."X^WO%A)1
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MVY4!J#NC<Q/F 7ORIN-&-X,GBN"OKE)%#IC?*ABL40#5X>V$I?PG#1&5CFV
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MNY,@2R?D!\D). <B5,\1)UN7IYI!U88XD>T7H)ZSG%4OO@IE@==:TXL= ;H
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M&:S/0'B(5T#3#MQ(T\_%ZY"E@) :4_I00$B7;).I&OLV2NUD$GHK>8"GCL(
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MP41#80+6Z-+B)8"0^><\<J2V5;(?[*Q9.4,Z,\A4A;+YUS.*0_,<6PE)Z!U
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MP$5E-Q'J0Z9IAHW@/>"E:TZ'K0[ C!>X /,\I:Y$O#;H[,B?2Q))3[F#*5X
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M>J:_% @C!ZLMU5>"RQUJ>35<3)88LK%&M/,3%NG$CX['29,E5DD^YG=5#'$
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MH>%%\U9?EH^S2J/;7UK6 :LVN(W]<$MHHNG<#?KF/51#Z7B<'_#6&.H-&C"
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MN(C6_'S9ZJ!N7>+CJ8+W+96-E.;>K[2AZ[:KC^B:9FQ0G]EI+(]U7>VLQ^F
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M?R;R5F:39[@OT1ZQ3@2U:)\#_5R >LX42!<6F9+!TQ.MHS!;6ZLKGVSO-)*
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MON&[YH6?MD_$D$M:K9)^>T_Z/@7((@>HJ">?<-M CPO5@K^8IH2MV F/!I#
M\4&+(=NQ&0S13@H_+Z46>_O'YMV6BX5>CORXPJ;TA=697WI%(^V]1G3U+%\*
M+^P-$,'9TW__'DT5W(1.9N)0W*L%F(U!'M98(E<^)[H8G/&+,,R8&Z1>>(0:
MG=+2IU]FJOVX%QT54/4F AV^QV7*]+AT(<X$M /(8YTW+))H"K@# ((!V_QY
M>FM(DYK*=:K!(RS2Z?G 1+KZM2C9#$WYMYVC7'Y-:$WH^G>O?Y85EI4]N)37
MV AT3#;\_[2?]_]2@8F'_P=02P,$%     @ #X1&4+DORFB"@0  88P  !$
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MW];_(WH?BC[;]^O+8)1R"B[TIL0S?3"IZ3&KJ(X$;8_FSFM"*$<@CRXQDDU
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MJE))>QG:/5A]6A<_)L1.R[L\E]OQ3).]^[# DR+/E%?,+VE1"ET]>ON9)1G
MRQ3AB58ZJ>D%5AOLF4+%CL.JT-$I^/!RA) G2\_L,(0E]26N;=>P,Y/TF5>Y
MGM5\_=Z_&7I^T>UITDYTU]#QO664%%;7=SUQK"]0^82A/H7?K9^-M>VI/4%W
M(*/@1)K8,KDK(D4]A.'I11>IMV?#(M9SUTFP^0*J0RHO@KJ1YTZ32Q- PQ;4
MMF.GOU0W8+&F_GII[AZ,JP5TPL!]>N&%=H'I)"-NIZ?MF1=5TM4LOLO=RK69
MS1-NE[=H;DE4P^3J!*,*K)Q:7K[;GK>@2D?6M\4&W;IZ?Z79HG!]RR[-YMDS
MX&@!):?=K.=13$[HJ\NB/GW7A%'7<P?LHRP!10$0B[%N%C\.M"T$"D;:G1]8
M]LNF<X:=*5K607XHS'JOVJ\2';VCH&RAEA"#D+#L\V.:M-U7C<MT=@_VNL\!
MT3J#SY-UV<E\!W+'?]A2\2!EY1P]@?87&R;(DL%,T%PZ7U9+CI\;E.B/2V9F
MJ)7<1XL5)>?,;?1ZI(Q]%Z!H;9""O=[KYX))38("%:6>K).U _Z1"EXI8 -B
M'4J0',)L6()@ JL=#^5L;G+YEFOOF6N1&.N0Q#/$3\WMFE^SH[*[N-*[CLB+
MJU)REF1R^_*^V73JK-$RM'TOG"XC].G 8O>#:=%Q C@*MVBF9IQPCN2OG<LZ
M]S]+&>:4YDY;B:[UNWRSNG*?)#\2?^__RZB8\S^/BK%A__NPV)Z-JV E8-V(
M/% G"VI/V44D6 ',E>9\>&CU!/D"36B]U)?&AH52!.U(G#@)-_$3?Y;&.T3?
MQR(WQJ04UF7D_< X-:Z2QWGIC)*% JJ7Z5^IWU4+71L"NQ9KJ(1]*.R#/M4N
MQ!SQ"*K5%G>0!,7$YH*%)?5&"HJ'(3/)*U<O'!!1CMBO3Q4)6C[H](NRR>WN
M6C $ZJH '5DHYKLY!_5O+_T74$,]U \JY\"8QG1UL2OO)2#W^R![[Y/M6CD+
M<JWR,YFN/9J&&A%J=)NK@V=*8R7ILD?=6Y!?E6CREX%K6![@M>Q+8"@86ZUZ
MEUXW[N=Y6R+2.NW2U.TW'U>CMLO/H/)[9O('A=K*C13_+,. -0:E)L4@!MZO
MXTB#=%4*F&B QQ"/H9JURB?JVY<C?%G=2)[:6_>I[O;MU"OE0;RC4 K#&NA"
MS53L]\/?,]:A?CLT]S.0%+7$" B AU(NOE\@(7"[,95_?:3HV!Q\K>! )=7C
M]SM@U0!T8]\[K ^ )N@)=@$CY^F<!+^)835/4[<B/^=)(L="+'5,#WGXQM#$
MZ$*U0"22/,$[.J<$IB,[S[S^Q[+V9V&B,-@D3 /FLY?_&^O]]$KQ>O[KT99K
MX9:#:9?,#YBF%-YP:'66YN<1]IN.;?DS!UW3B/_BFUO/ZFEG7VL$.Z[C"W^
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MZ0TDM6NQ9$>#<1*(QG!2DQH4PW#[@ OT@'"=P+K# .596:$R^3G8U; =%EN
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MO$69?))X1*H_TUXP*\_)L'W#@OFZ;(*#1';4W@@"%9R!;?/#/\ V\[WV6"7
MBQ0ZT9QR\Z\^'9-A27NM:VI5[QN.VJ;@<F^J)]H>:LVQ;Q=(C_;0>_SNL88I
M(72"UYO!,<'UNPX!RBY0$W[)O261VXNYYY+T]@?SBEY*409M@X143O7V##BJ
M;'Q4*_F4*6GR->M^H-UBSX[.'$X,Z'I6AGZ*X"HKY@&56RI(A['2&;_&]P =
MZ:G4B8B'EVY7TCL)7NCW+8EZ9ZZ)F[K21;7]'RU))7;25ARNBPML;)_>,UN
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M&, YH9'0Q@XJE%7'O4)01PFCIMRK@DUCXB7A+4:C7@0=;/8L.1ED;]J4*UZ
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MQTM5 66%OBK@<? ?<]K\9.>&/%-Q6>2D*!_MN0"G6)F*) GW N_1+3'[TC]
MY#I"VGGD'/ACO$/#PIGHWY@FL KP(VF"2U <W"8I(5/*N_@>@]2/[X^=G8X)
M."#,/%AY25:1U8:<4-"8KP7S^'!<J(QK.L'43I44QB.1,JK>>.YZ.!1RV=7*
M=;($A4>?M*&K)W)U>BK)"_K&"+J/G' Q1<>)R6O!M2-)>]),W*($$2F>$<:N
MM>S>]<@Z..L1X@>Y-KA"/>DTTO(@H>9T02NZ'-:2$!(W,?%P],D8ECNOB^\
MRIO:6QKQJWG\#1JEE0]?9@<FAG>P"NAF(G^])Q N^4XW\S2$0_3C:C'YY]J
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MNUU4<+.#.9&O))NI@&L?P[UP-Z34KTBK"@"I#U3 YSZV98/PR]<[6'D(#ZF
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M"_O+P;:_9@S!("UQRX *:/?!)%HE ;YMBN5Z6Q19\B=/.'U3"%NYHNN:KJB
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MT44W9&;4I8P?X&0I,56H'<XFP)QF5 ..&R3K(=:PI>:5<+$>O452F$S2I*N
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M^ZT3;^932>EX2&=O@)CIG/DH1001&XD.2(KJ/'))O86]0W.I2M!']^\1VMY
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MMOVP[\*-VY;YW83SY&:L6(55EI6"*U'*J6=JB],GJ!F<)0ZK\0BJ")*DB(:
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M6SAVN#O4;,YZ9*V":<K G*"(]!OM5/E\"$P3K;C55H04!G15:X'4_H#L6Z?
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MXW@ SH5Y(-6WV*;W>Q8B(["XL2?,I!O5NR=H2G+T%W:0#:%O\E>OTV7OB(K
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M41LH42]#8@Z]P2[)A+W6!7^T^%]3?M@9)#RD?\5YQQ6W'7F7&=UWGOR:M_O
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MX;]>@-*,8^9F#8[BLU4@^AL/2?F+/DT,Q"/%)HN'U_9.O\4I[+=LG$DR<'G
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MDEBF7/[3&,Y1\A2W!STW-[VYWDA9M;A% >XW!^('>M"-;-UV]@GFR./@;6_
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M9DJV%_U#G0\=<1!K336&;QEZ!;1*W8EX[3 *0#F.\6!W,P(:G319IDW0\$T
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MN*IE28P00=5[G^CB3/M$]BHQESGWVS ARD_M2&7,.57\P9[7;CAY%[JQ<'.
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M,([QY(00X$MSC5DJ+M4DP-Q2-JUKW0MF[9(*2CS%J3_#: 6:J_65S.\"^1O
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M@:<_+;\5D)+O>N7VQZB#^X1K9L<W,6K_5;7V9(."8'T@K!B;.=%&K8JOPQ0
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M[Y)Z4TSH#('GE_!KQ0M4^1M<:Q@3\5YB\^GO=&<;S#2-T+"?^[LD_BXI>P<
MMX>)")3\I=; Y#\TAXE(,P2/B='C4>&HE<OPM)9YN_.7>@BBP/B3Y('T0OHQ
M$*^6J>"EP](X8^D@7\^SQ6&S_.;Y.VR->?N3;IP-ZSS]"8$?R(-8:-9!U-%#
M-$6V&%EO&L;[BXWGO??V(@7#D4.%/:@*%?E"(:VMU&5G"?%.=JM,D:>ES=>.
MYND7#MY[!9.HM:G5@%]W0[W CUR,!5WF(]4/<>8[^W.QT%LAH65%AD#%+_^.
MGP?%#Z"HG\>$0K2W7:%.()XP$2>008Q=^#$HYK-<$>VNA^&PW]G;HT?N?9L@
MR+H\S;=)/KMHMSI57H4]2!D].7U%YFG?"K87%R9N4H$2Q2?=,+Y%+ZE[4E90
M4;M4'-^RF@2MHVGIL?-RC"4"!2VVR/C!1-2ET)TG-CJ8B =*X."*W#H!]M'
MFGHOE+H."3LM "NP)WH%(Y3 L23&F66Z2F?!:6B!B1C3@Q0\&=_A]DETMV\0
M4#.VV@M$"S$1OH3Y+"9" -4/X\!(V("$<4NK@]1%CKE!>%5AE,E"D%OWF@%]
M<9:_-W>F;+3#EY<#!UOI?[0_ RT"8_J0 @ W689Y\%-5U-0\GO0#.8*''EE
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M26LOQ_YR&3C0L LV8I.=H"VP'K2:-1AIK=QE@1[!ICO.WDY__,#O !-Q7I%
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MOJC]+%D38[QJ[*$>N6FE$W_<\[0BC#^N>&)%=P7S15J]I\?8;_*PZPF.K+)
M7!O;$F.:1\D7KP"">5F8KZE2ZZS0UV(F(E6@$^)./0QS!%LL J@7AA%B.1VF
M8F\M[)F(W.!@0)V7OF,)AESQ"3 (^[P31H%YLV<8Q'$G>LI' D1<]& 8Y#D
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MC-J.A^Q4B$]7F5?T-LDB00., K<':)9E!\;5)M%=+7L"H@Z]Z;ZLM[\W1N"
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M;:XYU=N(5Y2 V=>-PX(>3* 9)4_4X;ZIS_,%9'"M@#A:;H(FQ?=@9;Y BD\
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M%OI0R ;/XSEHK10U;GSW=C+=KZ3Z[JVE:X.+3\$\E@LN=F0KV%'D1O3CB-Q
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MN;B8NK B,-&^JK\2*7+6J"736J2Y!E>)3(:9[%HPSB=4XBZY]&4Q(;+1;=M
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M[U,=2LW*/N;NDGMXG,^.,U$?_:K667YPP"^JS;Z=U2\ZF*5%ESMZ/TTE6LM
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M/Q8Y*Y"7M]'@)VH5?R_L6,[KOY]E!V@6XN:+MATN+_6T_3DL:K\+6R#8X1>
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ME#98G7&J.VK-=Z\LJK723;:EL6LPAQ(K1FKN(SB6K']+WP;H%)9?.SL0>+3
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MT08YW)QWC8N0AA"UG.6K(M%-$I>X ND G?(V$!<K[TOR,E5P@)3&C1:7)K7
M=(&>5"Z<)D,VHS2>")M,B*&NLL$,=U.;:W$D/3*^G6H$J-]XB"T[@2-'M'YO
MF-X5ZLOLJ)B\##_[M<E2]CUCFPL*-AB7?''D][Z:G/:\ZN"H"\DE@7U,3H[U
M.#;<'> T596/BJ(2*9/MYL-:#QQGZ$%6WCK]%*LEN-(2S))51MOPFW8(%AST
MAE\RZI#3<S+J(G0##M\\WG6@3;6^$2Q[,(),B^@_?'(R@&XNJ\I0(LK'B$^:
MM6M8C\;P_'5&A/(<U\Y9T?_:=()X%;',H*J=]/7H[VE&_YE@['*L*S8V!LTG
MK>_R:.MJS7%N:YWW_LLIO\>]^UN7?;8 LYV=^_:MMWP287<S<L [H,+G81;W
M^*&#%*9(\=EGL+:QOO:Y7M7&8?KFTJ>?,PL;'4N?XF,^X^#-OBE4D_YS\CEM
MI348(5Z.];EDU2<OA;ZD&@KB0TRMTD((9^J$<<O6H]_Z/];3(RW)UCETT_",
MC%RO8Q-L/Y]2L]_"I =+7?W.SSJ)3:RG"T69WB\L68WY%J<V(/;K7CT_<]#.
M3G%8X8T8LJ*^=KSB:1"0^I^VK"UH64TP4*,#".)+>>O(!]JO3_S1@RJ!9E&<
M_P+S'5#$VP)$QN/3 ^=(_H)@2<[V8DR,>:?93X>"C_]#0A/?Y47T+&[#JZ\&
MYR (7X'</#XM#'C"PNGZI4;]G=E89E:0?7QD))^ :,33*_7YIR:]NRLT=Y5P
M/KD>O5GZN' XZ_QKRYH%;X=L7RB9R*?K"ASBH)J19L@T)X3^WMI>BD=%4&0#
M]O[S9_F3'T43#=&-S-+GSQJ*B7?>_E)5XEZ+M9[8<GNFU_/L<,$?!='U%X>C
MGWZ/;@Q)'F*'E1F:5)BT_=QN&VQ9F.\=F8^S?+K/T\#?Y#]\YKIF7LBH14]7
MV^=CD-,]2VAO^]I_'AE>_.BU9>T+;\O<&7%^][=#;V>G,6YUN_1:"]Z!&$7\
M*H^IL8+)CU[RU*A0\J[6Q3]&K!D2]$;E#IE7NO/PNB9.T1NYO3S'?'^M,#K@
MVYM+,XY%6K?;VAX+AM_";+= :_U.[FR76IGN#^(>N6\I_?E-8Z#IP</=.[-*
ML,YEV&"FZ6L+=76];/'5EOTQ^3<C+)Q-WNS,PA[>>13K[51,J"S&GC/P\XS=
M<NK_:ION,UV![$'?_NCG"8&<5GY467Z+_#?K@/X_V\K0?P%02P,$%     @
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M6L3+Y.QS89NR;*-!ZMH=Y@13\9OH1(PM%*'2F0.8S[AFC0#[ B= 4FTHY)M
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M:7&,VQ;:7H:^[YU)RQ3!8V>F;;,-/W2B:S@,_@@TRE4#I4!C&]I2U<<SY!@
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MJ+Z6_L/&C35S ?YAH-;KZNH),YRSZGD1KX-D'4JDWI$Q+OT![><9X:QI!YY
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MKWU3IV3&! I4R=>O3?$*?/2PSU/<SC505M;%^LM]FY] OK&*G9!0HGV)#2>
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M^Y!%ZU#+R$U)2\SK^:!F!>K''2E"4L>31[EZF*J4H#-7%^KH#R537W?PZJL
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MU3E*G= (<B<6B -!AXPY)6Y[BZ8@U+>E9Z:F+N"@TJ68_&T_EU\U2(^@"S%
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MW_CB?QO_:W><?9ZX".E[.;JYF+HX.@?3SCP+: &GZ.C^/?^O1G^:_E\[P\!
M?YKQ#"/CO\[$S,K,Q,3"Q,C(<HZ%A?4LK3$RGV<[=_;\O_&_D_P[_-]1M.=9
M)D:FL_^_&[458&<""D^!Z.F$@5/L=/3L=-1. $23_C3=?[3_5(+N%#W#Z3,T
MD5A8:1.0%VCBT].?H@E[FH&F+%T8[7N @?WTQ2NR=\YPF#@R"OM>DGN3\IE)
MY&Y5&Z?I,%94_LF+"&:6RUS</+QBXA)7KUU74%12OJ6BJG5/6T=73]_ [)&Y
MA:65M8V3LXNKVU-W#S__@)>!0<&O(M]&1<?$QL6GIKU/S\C\D)6=7U!85%SR
MI?1K=4TMLJ[^>T-C>T=G5W?/S]Z^D=&Q\8G)J>F91<S2\LKJVOK?#=S>_L$A
M_HAP?/)/+SJ GNX_V_^K7NPTO4[1;,# ^$\ONE.!_R:P,YR^(GOFXAT31D=?
M#F&Y-TR7[J9\KFIC%I$WQ7(^>3',<EE485$,]T^U_]#L?TZQB/\ES?YOQ?Z;
M7C/ 67HZFO'HV0$P0";EQU\%_O?WXUU\)Q6(>!?$AK\78:2)\2'H-=F9R:[7
MR27AW-YYBR[?+4EFDK[#<(T_^:/T^3KQ_(*[TJ9A7(<EI;D&*6^#B[=@G^8F
M%%R?<#YR3@TZU>)-H )4X+0E00LK:%T^:9/6U=@I6F:]?L?;G&]X5?3>S2 A
M6<?(/3SB%VHFDL+"BI/$ES7F"7A:>2EW["GWYKL7?:IAG0T:_&L<^E-OZ'9!
M/(Z7S"6YP%U8 LM#]8/&J4#J<9Z2B'*(*40IK!?G26$M64*S#RAHLF'G(Q=S
M='[J5_9[<#G]CMS3T8SB$RQN@>(F29= 2Y:=^CQ(MCA!\2A;H6*X+_GC6\%9
MK_93FL@E?\L9QQ?\J/,5!HEA-C^(<].KC[HLX%WB/AY4X%*3,88YM)\*L&].
MCGA+-6(HUN>-S3*<>K]"L1\VJ,#!I3$45HP*=-<\11B915CH<_O)5V.'MGEP
MC&VIDNZ"*KCH#V;<1.DJWPM+G]J_,[QLPS1'+O:0.'.6,COJDVR[? D1$^#C
MP(D;!=_/':;<[8/N-AZW7'7 W*XJ4U/6-DGU\#+4^S&\8K4KY2WE['*^3,%5
M[L[Z;9&B%T_DM@1\7B)O]8^+Z$V4"CB)AZ>%7J+9<?>OS?O?,Z3;V(#N#[;1
M8PK6+<,7-(N9;_85C*G!/8AJ"_!MB07(C*2NY]"9H!RCR<N*;#=D]>M6_PCF
M.4O%<8RNFF23Z,OF^7":10MSWFC3$476.1D3I!=VSN;![P&.5V6E#*#/B/1?
M05RGK?T<<TIDFL.&( VDY!,5I-5?#4L,]-Z8Y:KQ5B3-!RK'F]0T*F-P'F<F
M%"@B1J\&+]0_/Y^5+=;>]RG F0ZKJJ)X EXP!CU%<31=<ZL,"C&KF5#(.4"?
M'B^/T%L&.73Z"^TQM0&3JPV5^@G]:_VQR;F\XV#X^M:0'UM\B;4#V\K89'Z\
M9*_JJ?BKG_[/C@D7#Q^!L%'.Z3GAC!.;5#[_<0*[-:*2I)D.V=V"2:>#UTCJ
MNPO@W!4JT-XU<N0]"Z_^LTTBE8=K2%9G0.++!#T>%8G-::-Z>?J0MWX8Z(<.
M!>=_AT:C:E$=Z$33<@<N7$DTLC]Z;6NB\:W7<\TJMZ#=L9>5F(8-TUR5%V-&
MF@-67WKU[4]?,K%^?\E$2VDXK94_->0AG7:P#PSE-?06>K:RL'ZBY0K!87Z5
M(TXH_M#;-?%$3KOA#5ZX85N&PF*+E;%JLKI"2,HO3/H]Q(^5*+FQ?BE@Q[-1
MQ5O.9#7IFB(ZG0JDI"&,U%1DFHY4)47:H!<40+$GM\?4-2K<5;?C;A%UX($"
MOZP/_KQ-G&CV[9.6R3#X-:ZV$1%?4;:I% X:76Y"-=95(6/X5K^_U^5U?BWW
MZS:/*%LI9QP58(6U@P\4@WRHP)GG5 #W:.G!"\OX9W:]WO[O+97_R]?FI9^#
MZ@UP]Y_-N):4;!A\E$5^UX\@OTQ[\&@U?>;)JK'3W?BKY7TLUXN1B"F"=^><
MAW)==ECUNV+;K(RK;1IG5H7\K-#8[R01*J!E&4T%L&YL5(#3DM<OM<F,2\XV
M5XQS@&:B)2R,?,Z!CPJT?023S$'_9;[YE@=4DACUZP=M?DP1R0@[WP 5J,B,
M55#K+TT6B69=+TP9E&^/%L4R8VH5A]C=*=S5Q =%86XELQE,8@U9CD8]G_HO
MR+<MS7P>37WI:;(OU?_>$NR#\VFO]^NYY"".):7^;&/G,(G*ZET E%\8^5\R
MN CK+&<N^6:BS2G"(@FR(<0M4H%S:#Y[7;OA ^([>NY*'Z?XVVQ:R%CUL180
MKA*&Z4GW;[:]/Y9]X6S$R%]QV<A1-?WNYZ].S(DJL]F#[:NVO/X6;K'JG@4$
M(XR]F<6HPL0'#NX?C7KW7P=T8^03D_-JYQA[7H'B*QT$9*Q&D-<*['<RZGU_
M]35TZYGJ\8AD.PQ:K-:]^56G^#0_/B6*$U89>N=WJ&P(WLOPGT 1GSLME5/:
MB<9:T4)+D4-(*RP52*B%7Q:M*-K(#B_\]DY4*?/:S<2\K)D'\I&3(V73?7\F
M?MOUTVQWK9Z+?>;V7M\FOV]I8*":.;"<&D)G*CMF"2-,XJD 019+(5<$R,3.
M\Q+O>2%'1OR"'NZW[6DM)/KEO0^2_(\9N%-D+W_T?\Q(0E[<\7.UP[7N1SA_
MQ"4C9\DY"2MK>-/Z<$N?G_VSH\T-F?,AIR]-N1K&6NA-.R??YK%^8/YF_4Z)
M)?L7$X<[&-CLVL)NY&%_KNI13^.UQNK']2#7B_:ZWOHB;*(&/TN$EB]SMPV\
M<HML\BP@W<5NUR$^;63P=F<&_?C\HR;7-?K.5I_>TF>!)'_S]LDB3M5W[AHY
M1N+W/'0>##\=I260C]_RXTE_::FSDN9H^JZCB "9J'"Z,?52D3DOC)3%',5%
M@W=07(!I6:_CW8N/CF6C?2^^3D=?>5BP'W9QAPI4W)?ECAV.44^ 8TUD")+N
MV/'YSPL^4<KQD]@:VPT'X<1H/:;% J1Z].,79YO/G/_S\29I%H7Z/NY3W-B8
M[9F3$R-G>*/209_[8X:K>JJQBN(Y3F*R6=KBWHEF7\1DV08:?OP,EM'YQ,W&
M;I1%LHX@0-0,*L/'XHSQEE$'T]+S<JBG#:$5S=EIKYU#^=T86>A<VUC*@Q U
MFI<H[?/,A&NBXI1;H;X89\FL2N&+5K=)H2EM?2W,(OY1^VTLT2TBG<:7@T(B
M;\Y/*I6]@BV6G'.3&#4L1,P;!=OAY02Y>U;'56Y6C9;GI4# >YIB6,LV*"?I
MGI7S\,$Y4_S\8I9(@Q7+;)7=<G ,<[?&*]Q8/!Y\%MIVJTD_A$'.DW<^K:B\
M0TW(+$ T_)?<:U GV7,[6&&B)E5%\=I2@L?;RQN!?5]OS5;I,;\AW7BTA/1<
MI["UX!02Q!,60S9_VN[TWWP)$QG.? +[+$K,ILAA($66W*[C>:"8I[JLTR\:
MQR$Y=LF2AD\7?\P5'#:A.NS*6-G</QB-[>SVLAG.*6]"4S7O8]=('+8=VQ(G
M;K&*9=6?<NOP7QHTER1@/17>,B2.H;89&^7LQJ*Q$(,R.TGM;Q_W6+X-+643
MGXRV@3DK:Z.0<C8S,XBY"(LW581%V&K(&/VB6^>LJ(^T(8_Z4'KF325=",;.
M<F I:+1SRUQA);YG ^G;T9T+?^]DXK[VM*[17^W+2JC* XM'ZZ]4DR$AOM!2
MW/DJ*L!PC'4H\I[7[JXH&2"),T?J$LK?Q)&X+:]!B>R$T5:\O,Q;DH=KO=/W
MJ:&6^6O-6E=E^-;(GR/G6PXF:T'\[BG>$Z%2GE_OJFXA=>G11PR/B2F'E4K'
M"AKZ6?<"&Z46%E/-UN[\^+C&(A!VD[,%N62"R^RTB\Y/W.?I1]1TC:QXS_L]
M0%\OQ:NYM >?456V"D+LFJ:/4(%6&]*3H0'TY2[ER$,ZIZ5=NJ+:H=SZ5T&\
M]AU+Q>WQ$^4%+5=$J4!0P-<3:&LZ(8Y/?T'#!GS1[CJ7EV!05-XW8+/ZU*],
M[BVA%#20&B]Y(-\-/;=].$?K:GP:MH;?-YLO/[5%C)WA!YG_7/=<@29#OME:
M92G"3AD)]S+O0VM$W^V8JI!_O5T3J:X:(MJ?AAH0 @Y*^VI4?_=_SX:/^5ZL
M-ON1SJR,W*U0.+'_?NAG"\I;F^=]\AP;E-CH,,-:/ IYF4HBBJSTQXK6YF(R
ME)/UI@H*DLK?/K\C$(NP)[]#>?EPA_>$R]O.L:P@% Q+S9%2O(%@EQ8'.A%B
MJE/A:^?'SG(KQHI+T+AZT(4KJ9/=&6D#&$/VY<J:>B]B^E)_$Z-@N&S]KV<&
MS3.WOZ:W6QX6EHYV_5ZNX+S:^ZKX1\FQ!L\Q5*%T$/?R*7F7G 7V8&.AC*//
M;9.T%T.ZTJ(,9WFX62N43%62S;=_+S;>Y&&8S)]<@&TU$!\0TO#&A HW#.S\
MP ^W'42Y?5];Z6WC@4NOPQT;KK>RCS+B9_$!Y$\D->*#T&NC3=:+/V!*M)\9
MH@>AK08!]-G(FFO@NTR.[^Z DW'*YX:D2K>O;1K8:@[5D$%F?V_>6K&V@5Q4
MB[^:W_+H@,5!%"< BR2!0[YN9#Z<^MOXC,W/SU?>*YGI]V57IW5 ''4-Y;5+
MD"R)#Y?;.,IFZ_C1/\1"T%%ZVC++RHT4>/A"F8N_@V<K(;IG7GU;$$G#>+WD
MXLK:,+ 6P;;H#W>F6:S'R43'KQ1&21]FO'3R,FA'YU4  8I_2,X)\)E!+;U,
M6R!?HPS6WQL*"S)[-653K-ZKMYL899*2Z<+#\Y,L'_6"7_&&#+Y81;H"XIQI
M&Q"&^H7=/VNW8C9EJ@)F#&+KA'.IWW_F+R!AA1.L>'$_B3.W*=.LQ5BZ[8[&
M T-!#:-7DR0U^:7ZJ99A*L"R9KF'W^V!^Z! .\$Y-=N)DUO@5M#T4CN\!MQ!
M]#E/,+X?W3W!"=%\\>D/1(]1[A?A])_]+?G7 '!^OJJ+\,9RQI;5Z 45>'4$
M];,@&92D]60>I4[^I 23W!?8+H:*XH2J<&=@Y4%^%J_C+O/-NDNYV@D*: &^
M*1WG;RU,CL.K+$F<DUWHTP$A&ER8T^-'"4U"G3K>8IK>1<7);U+O^EU/7E_^
M&#;!/0-]T*)"HL/"MP46;&%L03_TZ\>V7"WV<M\S;_U)9'8,=546+$#<91(%
M=:)GJ #>:1SL#$^V@;\-8#XWWO38WGTRYV7"K*Y$?YI 3D0Y(UW*:]''<$^I
M@6_69.6HKE$#=P=TN</?2G1V0S^$S9)9S#1G].0/>0R+B/??Y0_R[K$:D9$Z
M/"=C^L;;R_NQU_ 0W]DR^AW)NR@5*K 0C:X='_\SL];>;+JX4E\?A4SB"H&6
M\K7_N:L1%_".[O=Q27-XHN5J<+>U^AEI*W=/+[@_K?9'KH9\\-A *BH$4X%M
M6:)!D"?>G& =B$%PV,G-=H?FV%I]<QN3$$J/EB4O1>BK7V7(.QU^AS(!PIJ
M8N%([]* <_@2I9C%8)X, 3;C](+ZO?W6#XD\.=R]T$P-3K]XVB)$%(:/3D)J
M+;?OE-EH/;?MR#N7;21R/\[JO:O.K#KE;:]PGBY6U*GNP1#I(FW%F&#X.MS
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M=HC2=,A&/C_?,$00VB5]M$P$;]F!3\S.^4.Q$,@Q7PL/%9C,^TQSO=E)%2K
M($#CP_&X&')"#!4P<$2T%% !T9)_"?>@+IB#"J3$#(3K;H312MI[^.UP'5I^
M\8$N[VU#M^QH&7&XGG,;@KV-.+X4+@Z=7(53@4]VEK0BV^;MJ@]]MLYI;5V
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M2OHR-'5SNF"L!?7J8-H>K3W>>?_E2NB!UNW)YHM4%YI3E9> &8FY\P1PRN,
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M=63E8I\+Q]P 8*&'F6[8BX+%K0--S1IM72[+UV:Z7 !&.W4R_3\ 4$L#!!0
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M*J70%>5JNA.B"&AKV&G,@_8,'9II.$BT=-/'Z? ^A,>C3*$0J?(20&UFZ38
MC&2F#[]*HY.C#6$/ ,?#5UU)JHX)'5?%QB]O.!:I01+">7[ACF51YO.FU)G]
M?6A\>T'UO4=>@@5Y$A;\1B3C-A#CHD*/+;-OX $<3E%L "4)>6E%VE"*0*'7
M-0K(F>";1X\2C?@.[QYEE>' &E$*-"CZS=7@RGA%9VI!=IHH;4ZIBAB 7SMM
MJDQ1].(GJ7)P6>X-.:(Y3?D9GCSI#(!N0RI-DYU[JI?>*>WNJG;PQFM16KD
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M,L2-!L&A!A#%I:"8_@;9KM&"0!X2HG"T J:[Q1OA;1*^C>GP8'+[?1/T3_7
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MBLJ+H?M>R5^D>)7I87VZ[:/RLW*?@E&21K(E42I:X"]ST$.K[B"^?4&)EM.
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MX'F+5%Y(O?$:3L>6L._9"F"HU/-'@B0+NQRIB<GJEQ[1SK1FO+GQKZ=R2?*
MFA3+])$A@@M"I3E-C+*9+]2K>% B(*PL]F(78^>2T/A>4V,9XK59G@PQ^"=%
M2A?LAJ>Q>E75^N$_-_<N8;4&]K7P6UEI2(JYY@\JKR=W35\QUA!3JQ#DB'<
M17BH<'4_R1T\)]6%Z P(R\7KD2P$2?)! '7N"+J5JA1>9/2\BV11.A80B5(0
M_U!PZ;[ ?W'FG=F15P.Q>$U,C0"?[NCWPU1 _\>$"_>*I_+P92$K1=\7I,2Y
M'K;S?+44.RKM(MOC=+BK 3[CD92,8#W4N@6IIOOJ]BF:?"D4:YG%/W8Y7$ D
MX:IYI%-]U56NAUA;[G0$,$6B!J>5\Q\U(<?A]5&;G]5(=%'48X,SXB:WEUU*
M B6Q+DUZ%%Y8!3C$:ZHDC[%+.>2-@W.?*--"&>(R95$+GT[Y#\\I&F[)$!54
M"5R4='D@,/^-<D$#+4"+T\?@_?'4I^-K '3Y):U<&KN,:L-_UV+B9(C3]ZF?
MZ@!A[%_"".#T*9^BX=7X %-EW#/YR2;\9RUX2<2/]WCH'I:#FU(7%L$6KK;Q
MEJ8>429GAE>"66&0H@R!&K.4(1@^,!=Z!@_V+$FV\SO%M^'=0>J0(:;)YO!$
M&"\0#S.M_ZD]:1BXQ1L:'3JHR;T2Y599S&]H=#=I0Z^[5C7_L&@XUGK6T"C]
M0O*1NP5;S"[LJ_- D"_YDSG/H,2VA*".%)8NN5FD4C+J'V&(;=.7_!HS@TPW
MM)7>LW<RO%0650I1N 5^J;0V1X,?W*]$54VM4--FB_LV9LXC-9JO!EI-%MT)
MOQ)2-B5*2"USK$F*#(U2_%)U.2HT%%,6JVN=;] ;$ Z,?!CQBM_*7%#\72OP
MIY[U_.R0$WK%\"Q,*"W>!>=DB&0JI47-<,R\Z,RJK[1W=?,5UOLJVH<% >+B
MV\\^-1&W>=/W+\NM'1U)F]L:!*6=#?%XUMXO0_S&=TN[7'*57'(=?Q/U7R_M
MV20&#-.*<.IN$5*^%E'K(!C:Z[&0*T%Z;&!)5^ZZB*T)=]2'_:N4#>?6!,P@
M7#ZL^0#S.,C^C@OL.[P6.2S^"Z0#46)3F*.W3*[">VI2#<[(U]MA17$C'-F]
M'AL)UP9R%RD D2>FE\R184!X8$N5(HU@-5EJ\D"<EOQ_819?R&Z- [P6EEE@
MX=;WZXV\7VB_*6B\)SRX[F5KS MFZZ[OKA^68S[:"/=-D^G?!S]2M"B?]H%8
M2?(E[.U!3G:?!/>-T>(*0_JM]X$RQ-E.R7 ;\N$2Y<'=(Q[DXQO_9=/*CV*4
MO2EZ$^G9*;\;W!P8#KOKDW#Q1H0%<_AXEC?[AV=_F&G-JFH$QBGUU.^,V/&=
M37B>W'FIT^8URXEU(9XP>M\%SJ8&J!FG2]AX M9%O$:&H"[H4 8?W9,A2AB1
M4PG2WX )J9=Q@Y0%NV8)JPT'F]]'Q!$/W?]WDX.N_9=2[R= _9?BLAOYKZ'X
MGS3Y+"A+AMCLE"%#S.I<%N>QC"_1IRF%21V@@?0G EQC?K 4?K<E[1K%]<D0
MSF(=+NV[\6>V:)L,,5JY>P7M]_VG S9;'.8T?,AXE8ZJ<&WB$Q-MI/8[_HV^
M2EK;8>C2S.'[7G6@PDO#]['[%UT*CXXE.:J?F/.X.=CU.M)X;L?=)\NFUD!3
MX5@*?8Q8PM%/2,NTLZMR1<-7=]QKV:#':)9>4RW S7Y?K,=+GZ\L/! <&/8K
MKS-BO*SM\HL1?-XON$O^P1\'/E/4?V?4?RQ_L^KO]%P-PRM_Y7'\_N&G#??F
MYM&SMO-FO><'SC6\8-4F"]P,58J&D\YZ7WGD5=(]WI@9&+[DEQTS>6ESGHJ=
M;]BHP6V "B?!5+SFA:8&0*F-G2K%T'Q27;+W(=>0]@"AV:&]55]^=5=O+T:F
MQ+X+#C2Z\FCS>OJK_6?SSF[.'L;EI:B\:+1^W>[XY7;6Y>Q%O[CGKX97%[4^
M'CE9)<"K/V)<X4^ 5FDZ;89QO[(V]9$PTHW==_"]3,SL"=<]C\-\2 Z)ZG*_
MZ07]\O6-^I;T9J;5AB%?WQ/G-^7F^OOO/W_^] ;_D]J5E:4[GM^&?]U6MB^(
M&/0)LJPN>!DQ53%?$$[O=[FV:-",AJ2@DR0AG+;B+&+E,PHP<I2.Y0SV3.]!
MN H<K%MLHGA#T3*$><Y?1\7;80BA9<!;P6;^?T %\6Y8!^_ $>^%'4_!BF+9
M=4K29YUMAA(F57**,H^6)MM\0<&*\-R/@Z/B84RY@,R6HOM(>#I1*-H/\K)9
MF\1;,:;],3,^^DF)L'P@8_&I"8MDVYZ%Q:B#,PD_ V//B /ZHH: XZ*7^;DQ
MEQYE! _C'J3FEE]%@"8BA+QTSXKUU*S].':C(H+0?1([%  #=SP/DGLH0WQE
M46>K8)9V61 CNBG?\;N-^GR1(M]RF*9-EJ6(,+:8P<A;[(1K^T9)+2D$2, ;
MC3I=BZ$-)?+9;8DFNF%%!MH<P8(FZ33TC)]TS"^27YKMTS/Q$]">3:_Z/=^6
MWB%R;$P=0EN^R#N,?/JX$O4/3_/\QR<]4)^V45JU.2Y#%.>LRA (>[S4KUN2
M^X32U9$D0UPU1,L0-I/R"9DMTC?]V,D0E@S1K [[*W>1<CZ"MKB=1QE?"X?A
MFQ7$V,.GE.=UN)7U"VQ 'D:RSTFH?S3ZJM/C2OE'$5FU,D2K)VDW\2NFI>07
MM<<VM^C)<@K)>Q3D;_VA]PTYZR?$IZ/64^!$-K0J2,L17XZM)K[MP*N1T *<
M]C085J3_E'JT?\G&W6%TV'\JP:.^\*(%^=>AP#V7BO?L'S0_K#18^W=OEOS-
MOJZU2WK7_V[CW^V3N_./0N(H=.EPG3<V-HWN^G1ZQ?BFJ8"UP (^OZ>'1M-Y
M,_GQCO&7[0T<OYX,XUMDM&]87Y;\5"'>5R%NXZ"9#*%*:875#P4IGOGKW.D[
MW0@(/M_V06R)5LQH[J:GM4B"+W-Q6AL:5Q/J?GQ8?F;&HR,O/-)\OJ"NSC2O
MX;XX2GI0>IY$&*>ECZV7O&#M():,PSY$ZT)I[9C-4*)P0=]+@$JG*5X,^-:\
M4L3@T[)>[LL&O<?SY]SYD@#K>5?'V'<VK<X&*9AU4"M2AYA)@+R6L&D#PT[7
MJURWTW$A36"A5)YXGX/78&E,H=1<@R[*$'KL4/S0\""74OL)5;/03LC\&5+B
M6Z7QGP^*S?B=UTTM "<.VW@XD$1\T6\Q$)M^:3')LR4!S3&A^*)TR9LBAF6(
MK%DQFA_DOG(0I22V4SX?5%EIXG]Q]GC%3<3T3XB*JT_D;_[0W#)^7!^ER$25
M#;N?*1MN>?0A,$U?Y!QW_]')H6:+/*]/F@$!PUR"ZFO7WH,SQA&&_N=N78L_
M2\IO)NVQ2KW[;,/QT-22O3<MO(UR'GT"9I:C*TCUI1%/''2W=I<=U:$ZDX<&
M?![AO^%69B#Q+2BT-(*F'H.%K#NIL2;H5JQ.?@"4#QB37$#JS27L#0HJEK=V
MFJ<]#HU8OJ(3G:3Z<8WCKV2(M)>4Z[58^;P7W;:+-*T/I!]Z;>WJ=$)WS#BS
M*@E-2N.2O#1 Z",IQH81=$@V_4RG<NB^@)WINJD,"FW&*U^XTU[/DR?K$$43
M?%QKDHT[@$NN58Z5!'=P _+%YFPC!Y792CN/I88V;YKNGW/%DP,Z_M)KXHCN
M<P"%2X59I35!X\G%&&RF#&$LCAJG&9UTO%_R_N5@FCUE*%IT \H]0S?/=[SM
M<R%*C!_'KIN6QA4-+.^P^UWT_(U(9W2/4P\*>.RZ?9" 89][]L<L K-OM_Q5
MMUU3IQQ<'3NG][C/W#M?YJZ65ODYN_U]K#6_M&Q6 *?EL^7MA^SO$C:\C+AI
M9L1]L[%HK"$A;H1179 @DI)JL:G#3(JNJP$_*)#_J"8*K.!0@,/43*PQQD)\
MB0U=B6.I#U#.=VI%\'11Q_JJI8ZX,JM4IOOX@J%8%41>8ZT9(5GC=/ 1!;[/
M'EB4+5]?E"!;M&:V2ZBK5MX5N%5[$C+?/W'J$IXO2?M@T>]D<HB@9EGRQ'-<
MA?%6"E9?@(A%.KD%>\_%Q%SQROV=UKM*31Y#,NM?U+RJ2YY^/[]AKGK.+F;.
M,3&P(O%Q\/#TV)>Q0+]4HEU4Z>TQP98CPB(EXGG?['O>0LB)OS\D9WUQCG5Q
MSJZSF2[JSKL$F>8G!9G6/1_,+WL85E[>E_FLP_#)OB>93TS1G)R-W"/'R[)>
M"R1ESK^/\0R_G_(U*]+M;0[6/;_-_>>'9:^]CF6>>G_TMM%+;W U/]\#+E*2
M?\8C9 BX(&'_6T'RPM:@V9=LDIAA[_V]=N+5R=O\!\]Z7N>>L>NVN5+_R^E-
MM_X8N3D_L6O]3&6471635SM];-I(=/%;U>R#K_7SHPVS<:+5AD^A?_*R2RY]
MK*=X\P_2=&Z=(QZL,3B:$@!=$9S_D?_YZ/&"JHR* -?J,N=C4?L>'F4:, NK
M*X?1W1YZBZ?_X]=4CM?90/95F-5CC3GS@4G.[Z=7B+/;" XN$ZD]*G86WFXN
MN.0O4NE4279*4VXN<SD^6K>A+CG\4XXCXI6_=W%81M4[P?'NQ5+0Y'U^5/''
MR!FZ?W4=)BOT2OQC_RF=B(=:%+O\2 HE*2F*WL0)V',E$1[ QNW/]S*$F@S!
M20ISUNS?QK(4JT 3 )OK%[P.H%!91D2=-N?0:W78]21<-VNCV!O(;^E4@A(/
M]HI_%";Y]K;0M!AD*^)J\YAV/U,/1!T&2B8-@FU[">BZN&<]S#/85",!#;*V
M2A;+ ;T"@RSF%>".4)\JY*5@=G6S4.+=T(\/)X>5LEV/\>=PP5VN6X0F+EP#
M\E:@(=T!F3K 5C\/>-ZT[]1OH#H0#,*=KS0T]+O:ZI6RM2Y2^&IWY1=6;(2X
MF[QZ?!H9"=$%IK_RU,F;B",<U!JQ>K'XH.0A*9$?3M);>QV(;"[:G-:V/& X
M5D:'[G 3#-*9(9?IDZ;(0>9Y@0^J>?A00WD8&5F3(^8F5D8D8-.64,\$>3^6
M>)V-)7XZ01Q5/A?S\P:3]3__,>UNIK%AO]GUW=K_#MU$6CLRR]0<NFR5LLA8
M*S:$;H'WN::VC?V^G5[ 7BC$L[LV"+NWOO9E7QW.@#C1D0 CHJL)_\6\^EQ1
M/G]TQ\R)_"!P7\,5D_H[C[P>A8^9#=AO1,+RC\T_\+;;WLV X[R/]H 8O;]G
M45UM?UUFQX'NF"!,[X&>F+?6!A?U$\CWSZC#.Z+2YBN7$*5PN)VY60Z_YA2E
MQ1.S(0@ZT"'PO($Q)OF!-(Z;T?AR,ME5? $DWZ-#.!SA&GZ=.(%TU+X)UXXQ
M&6#ZGV$0[_AUS;EJP?*C!;WER! :5:Z!20^(3IP&C,6UI9-U#*4AZ/[((GJX
MH9FU$6*#%+X%/95L%N@-A/+;[X-F06!>\?B[0V];I5:]\V)W(4Y].H' >6SI
M 7KF5#/='A/-#F<=[H]!(W'\[*/3*QW>0%&CP.THS[^NYRKFP4/6#Y)[E"BT
M*KG7,+>:5DI4:S=5-]T$1163S@,> W65)%?0HR&=O(%8(!KC>/;576$906_;
MMT-(+O)RK,&PJX[0J6<I+6N.4>I5Z<6'$RCW01)MMZ+ND7]I-\9UDG]6:=Y@
M97)U/DF1=*5*^L$0?X-E$<[2!3M;L9DL!2B60=H#HENI&J0H,(J>8D]5BL2X
M /0;S//"))^'P)\L*T*&8_":EUUB.4%?%\N"!V%XK<.?OV0X]%>^Y2>Y[P$Q
MU7)+V:*LDNGX DSQXZF * F<OP@3_3%J(R-J@:^:D,<:>^I,5">.=,^'9GK5
MOIW)UO'KC[FRL*U(+2.F"7>X]].MRH5+9_(/L=8#GG.#?+2VAUY'AE1;' 8H
M!&^!_ C@VW&Q85K*1=+Y*O$YR"^^"G+AW(H@:P,-'+? ]F"K7E=\>(78 XHK
MZ.1TZH4'H#-BO-$H*&#Y<,X/15NR6E?R*76L9T^D?^+5V1&H-+:"V$N 5R/R
MFD4\;9+' R)=@&IEI";086!2].*_I6E-.].SEVBZQ'MBBR\062W<MNY#C'JT
M7WWM;:/[C]'SBQ"F?Z/2<(Q?H=@<K&> 5OS\:ZX4!M&@#;^NCK*!&+@/M%VX
MZAIXN?0C1&L]&NEX&?\H@_&V.!@_Y>Y7DQR6)S5R>2VL;]P1\"J#GZO3_9_7
MG95S0;%^/77F75^>-@P4M((Q]Y8"$^]7[3 Y.')@FWE?5.7\Q?GY;4=G6P=_
M#1@=_OCVHD6.VF^6YW+MPQX@W^#6DKFHVOAT>T+Z43$%8@"1;5A]L5\%:3-T
MK4Q\!<!>E9JA,V:EEB1EJ*R,= (Z0O<:9QB2]L"Z4T)2@7?KF2N12BULI;&P
MO?,=@:!I\6-B]7('Q@I$YL0:4?389V6(8;,.E*K4-;P UT:[=EE\1E).\N '
M4K.*K 98)J1]I@K Q'46BHCCC&T K&Y(C8D$+RBGR"RT![_[Q4"=&YY+MF1%
M!0:"GNG55;.U5=A5J_U/)8<?7L6BR6[2UB(W"1WO^0(J$2"OO0Q:SI(:H%(H
M1G5X%1(6*M-O*(>2ZAA:O*  8H _^8<IJ1YXH<B^4RN(,YZ$%M*3,693?_WK
M=TC\$_%NH*Q),E"1^,![)3XR2J^0J?]T8XY:6$GR^D&+D%3=DX)L;^TV3\,G
M:]J>J>69WXY(^/<E8/R*C90A4K"UH>U8-0C?0I-GF8NQ@%(JVB'(@P4_=5L/
M9K/=*R%/U6@]OY>Y@<\P(3F"M!M,+V#Y4!^AM)&R(6)E \:ZO_;DPRZF"X-X
M<&S:^7<>OGLWZK>QC9)4\J894U.0FL+\4<A.0:F);5;WDE0!9#-VV+U%N@XZ
MPS@5%A":PE3B,_2(&C;LH6ZT*R%$Z2K: 9\:O"6?WUP+YMP3FECM>=[M:B;P
ML>02[$T\/4$[:=6J [GW)6,."1IUQ.%UR$BB&1^?0U9%SWXKI5]SM051!Z'^
M<=2:R4&>5BQ%&6IH#;9C@[G+R56LS6$%C)SQH@WSKF:.&9&6U\.CPR\R;%K9
M)<</*TWXS>:N:IPBO^-I$\1)ZW@*8HM(*PX.\BW(3\6&4F\,3[3Z& D^+SI_
MN5X%NW\]V3EPFJ=)"C?()MM,<@X.VL,Z&]EN5CU57X2%TB1L(7(]4C,<#,,^
MK#WR[^)%OA2)?3XXIP*B1!D@/.M=Q%?CGFWLZ\YWR6X [IHK2H90IG-]U-K@
M6H>L!4VTOJ3=B,U"JWH84 DD9#1(X#KO*XFE0R,"447)J4@GY[7E3XCNK?K!
M2*"P7TI](KT%N[]P;*TDCQ*&7..4PCR"Y3)2QEQ N!RC7AODU2S,3CB^ GA<
M0_UKJ%37/15BNT8P+8>\@W(.^G:X7^P%RK<56+7BE<+7%2G16J3K>]'VDL@3
M=3UC(US<P\D--'7*.=3-;G*'J9;D+L8.SOW^E"B^2>)X7K9E$S#1(G7JL5_0
M%Z.@*"$/ =6TLS1!#:J O2&RX8=I&4([!JM.S&I92>DO*K/+.%\&W;P74_'A
M8=$ I>> M1Q"]0<WKZ5/MW'3/K;_? K]?ZLIR8;^'U!+ P04    "  0A$90
M8Q6%1I%J  !:<P  #    &]T:&5R<F5V+FIP9\2[>503Z;HW6HB RA"9!82H
M"*@(:96AQ9BTHB B1AQ 08A*(T.$-"H2,20J\YAV@@:$J B(@!%E$ B)$(9N
M49E!0,BD(I-4R51 );GQ?&?OL\\^>ZV[UW?N6C>L]P\JE:IZWN=Y?L-;5;(/
M,@&P^J"3BQ.@H   "O(_0#8(.,K_^]]]?ASD?WL,!=EK0'.%PG:%W8H*&X!E
MF@J*F@JR1@ MOTZE_[,#\)\?A66*RY6455:L7*4JWZ%B-;!,05%QV7)%):7E
MR^7?1LF_!Y9K*FFMW[9'6=O]K,J&,)WM-VX]7&&ZMZQ>]V@'N'''N8LW5Z[2
MTU]C8&AF;K%I\Q8;6SO[GW<Z..[;[^1\P.7@L>,G/#Q/GO+R^]7_?$!@4/"E
MR^%7(BA7(Z-C8N/B$Q*3;M^Y>R\]XX_,K$=YC_,+"I\4/7WQLKRBLNI5=4T#
MK[&IN>7/O]YT=G7W]/9]Z!\0BL2?/G\9^3HZ!GV?GIF=FX<7%G_$I0 H_CWT
M?QF7ICRN9<N7*RY7^1&7PK*('SMH+E=:OTU9:X^[RMDP[0W;;ZS0V7OK85G]
M2M,=1T'=<Q<[5NEMM!&:03]"^X_(_KW ;OY?1?;WP/XKK@% 35%!GCQ%30 /
M2*6;'B4!_U^/3\@U$0/>B]44HPRB;LP2X/U8*Q%&2P:<=[;O_]2-?VY#FB1.
M;&O[3/A4Q_\@??]B8?M"R";Z%K=:H^D[<U=EP,W;E&,BE08NBNH!E[*H  EC
M/(I;PP4#8NB_LA*YFG22###Q(@[#&O@$J5T'-ER(68:LZ0SGJP]1%!L&XNX\
M&<^XDG6EU)]$^FUZK#-(/?R1]Y@,R!O^&:S@IB(&(KZRSQ#!CR1J4QN7&E37
M51[X]*H\FMB)L4E\]L#EDO8[LJ[XG9;+4N4M'?P;-VKA,UI+'$J=UO8[=1M<
M(6+%,E?C \CQ]O25[&T0RAGD1\\NS+(4QJ4:(#X:.55 &M:'=&-[8VV_/<*M
MI5@T+IH7JF18Q+/=A:EF ^I^/$8)3#H)S/+CF.7<>GH*#=.'Z(*\IDEQR+$&
MJ1$8GVS[SG5/.]8E0JBZ&R52B6%;BML43UND<5]HU_=EX*Q!<LH,1@N^=NA%
M[S=;-X)S^N+B\)_U^<&$$(@;QQ44,5?85H :U<44E&@D&JLO7D&_8,.I@P@-
M;4EAE,&#M9+?I>;(;E EX=G,5%R-YW5;C [E3D--77Q*!5$W>'AK5TCS/8$W
M>=58ED7"8^G@R]Z0<GH)/0#3GUU/?&G-$!'4891[;RBRNX01YU$3DE8Y5V7O
M97T/?"G(X!%N+*K?ZBX55&:?R!K?!P<5CCO<DWQR;\.5%8V9VR1U[]&B],7+
M@+-1Z'V]MD4%<(;(RIG'[:=78N(1S0>N#P+MOL.[>#*@DI'"UH5,17J9YB]#
M^<'0>G J#=E1'.RK6=<=4LI:W\%VE,27N#[%,4*>^@#7K+.7O*A*O;0-HWRU
MRPS#UJ+QF@IIZJ.@Q:'X6#8Q OPRTN2[ ;0M;!Q2K%\)>1DK20U1)B2Z!FL"
M&Y)/,6,?YYASP-Z'A<&_!3%,\LY4X<Y"S#DN!]X!11)N#A3R GK8/A"Z@://
ME:3KM37&J1+3<G>R(5/83Z3/&XQ_U2X#1+]W<[3VT(7,1-_MW"H9$)-E ^]X
M2AK&558$(NJB9%6"-4R4 <M;X%U@E=@^#H<)>DFYY,5I#Z5JBY(SJ?M!HF"X
M3-S*3_!= 3L*F=$>D=(<*/HHF#_?2%"%(Y?V@KFW1);,E13Z\8IK>/V6L+!'
M,,,5?"=]*/3F/N=L1%#M-'/J'GB]>)+HSJ[*%F0DL"-$ZO8N5545U]PH\+PP
M()FF.V;GD/KVNN^I/>1\2N4WJ<'E_O6YKL64L_>D;[\G =/JVG.?)3ELMX(Q
MKXPX[!XQ7;LTOS*U*+#2UQBVA1@G>SCKX&N-ACE?DO,H;4(GQEF!=ZJKB'D=
M,TM:.='7(ET6W6BB6NY9QNZV'7>S/]&)"5_%6HJBO7$A&X\@5LOF3(4^?<TY
M3HL897B1A-% ?G[11PT2[BHE-U7]!/MT-4244;J$,B")JBH#5O0E..6(,JD1
M9_6CK69.L9VC_ H)W_%Q,D#P.WX%5EMXDHH1\#4I?GNJP G.JDYDPQE)#CX
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M,2KPM0::)D2.04Z(4-HP@Q<9$5\N U 45D--<3 Y1.2CSIH8IU=93+0(!V4
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MNG%@XOG)@4".UK740]DF1LW<L@L.(TT,/20$#&CBZB&[Y$: :S3FA2R^SWQ
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M^OGSY\TR,Y-W;-MY_ORY4YF)9IF)&V^[;.S\!]LMEU>=?UK.;.'NOOS/6RZ
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M4W.L=K%(^W@6X'#DK+3*TN8U@S2V*)#$+7]E>>+UR$U37Y];54KMNUL'H9[
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M_XG1@.R<J&@"7#JW0A&!C34N^]L/C2?S#V,BEM4.C&CZQ,/I%!6T/.AX!JD
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MYM>.K"SWJFK2Q"6:I?M(C7;/\?*?_HKYV2;4%ZN@EI]6)US^N[T DF&8'"N
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M*(+HB!AY=GE^S-3)C.8^(MGU'(4.AP[ YW\L_]O8P_\'2T0P\3\ 4$L#!!0
M   ( !"$1E K;0HXBQ(   <4   ,    <&QE9W)I9'DN:G!GM9AG4)3-FH;?
M<8 A#V$ X2/GG*-DD2Q1@C" Y!PD,R@@"$A."@I*D" 9)#. DD$$)3/D+'G(
M("#.+'Y[SFYMU?XX9ZOVZ;I_=#W=77UU5W7?W=AI[#) IJ6FJ0: 0" @XZ8
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MBS*GLZJG]RS&(G:\7J0]]PV1Y'>9]0M^"C("L_PZV#7ESF],,*+AOU_$Q14
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M3+J3?C<C,^N/>]F/\Y[D%Q06%3]]7EE575/[XF5="YO3VL9]]?I-=T]O7__
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M0LZ0$R/1\H8,D2)5EJR%=(!O=GWDK:#O2<BW@,0X] P*S8>.$Y$!BPVWH /
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MHQFP_@N:V8=]^'CYF=EG:+2,;(F/,]R!BUL,FYX0,@:5CD!<\8SEER&A=HY
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MP[>XC88Z,@12[[X'H%T(UC;S%!BSC:OAP9\'4$(Z=^8:9\0\GDW!0M0G9"*
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MBS>3;%>,(3L*9JXM><_,#V\E[B+YB<9HC4:4/^GRF -D,PAC@X?5<EKC2NB
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MGS[]'19W;ZD)@XR8$'P"O,@*U2I>+53E3T#CK6(?LA] CR6'"UDK/^"A9/S
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M<V4'NFT/N_1,_WK;B6LP.E-=4K?B3-W.KWE[XQ2<MAEM3/G,RM]QIO#XKM#
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M^A \J7$VSD6D0.Z)/AO'\P+6.CR)Z-0_;_?8OZXP87J.,$5'3MQX5W7:+B]
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M&I6FU;9G>?*X^LFS!D=S[-?NIG25>/!&:T,I'?4^.:&$*14JU]"2"2!O27
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M]Y>.DDWZ]]$2&[= #>@HB1?@)QA)?4+&L@:DJNX2Y3[FKKKXE!"J@7^)<,C
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M[GZ5[O71SHB][^2=(W^F%+!4,18HV@*OUK!"X(Y9[X_9"O 2+6:5 [(MQ"7
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MC&$$=_8*8"[T!Z_WCJO2E[D@"DX@P$NY'K!A#OP,=)9!4N"2\Z/NX5U)IHJ
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MW1X,YDEQ&F$*>5CE5;9ID>G+X%M-E:^^32;J=<^O;1,,QOS>'RAF3%X0_HW
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M29B",AN(/;59SK6$4Q6D M^VEZA:O81LPY^$($F*J02AVOY9[XP&>!0.9VH
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M;K<!;U?<3O>@.6L !Q)*WY-1X <U>Y/30HH=T5)]6G"5;,AXWB-G+%HCVS0
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MUG J>7) ("0OHPZ_GQ9YTK,4N&4QEJ5&&N"#?C[=22TU#:5JMS"6HT'X(D=
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MLWR*I6*IV?G'UTY#JT)_*_[TTF'SI9"09L+7JAMJ9UBP%_9>W!>ST%:-YJX
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M!=ELN'YB:\,]K&>DZE:5W_GS]:FY9F>>_O9<JR>HEZT_4[1AL=5Y^\<23D2
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M4 ;/4;*TQG>28>3M9'H$&V0ZQ*RZ5!.FCS PD7) XT4JS\,6K=G[=]<[(%S
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M)QM6NP[%$NT<3@#WH!YGRLZH*)5,9;;B%#*%>=YV64V.?<\L*H9Z6U_\T.$
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M/"4@QG/X33 N8?0$X-XJ<N<'<,T,>9=I&_3?WBTE^?6+U6&9@TPW5\!GV5A
M^N>OH@T*<%X^'Z'@]LCA?9F"D&,>['[FR>O!!-2</"\3FT39OHA3).T#V*U8
M.:+44G6_6%YXI &8N!4B_'5U@G.*:0P#,(KC;K^^J@(2#_'6)C%(XQ,&J&E"
M97#ML?0)!RPWYZ&G*/[*,D^<0K,A67:>-;&!HRKA:GP?_^V>-#M%)9WS*YH6
MU>99>RKS?>W.Y;@4)W''G\RYME^8=%SPXWBUL14##[:Z=#^=.5^XLZ62>B#3
M=.%+XNIP+L-^JPO2SO#QPRN+%]Q8*.5DQRRYYFB\>_;4F- \>WQ,M$V"2*5
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M%X6WKK?!(I,Y@V6B7?\"&Y,21.)=T2/V9+-0&<[*^>,TL<_0]^- *D\V5>"
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MXZ@N4-5>$T*W#S-.8-'UJ3Q5]^;$-\$ORD+\GND_L0T_T:[0N9O0V_U!9NG
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M_TFKW2;K5G^E'%C);1VK)[1^<EFZ!EFNV1(Y9PA)OO)0QSC[5V(C9]B<^<<
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M@WYM3=9BX==0^2,H2)53@4OAL6X:?PZ5KH3*U:70#>"N6-TA462&>N;0#I5
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M/B-R*_0,+8A%=:"0M$AHQ"Y;Z9WL_*5R)@YECQ/CZ8.J*&:MF<AJ?-[P%3#
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M7H6/)30<KGE$3MPJ*@]#2XBKC"'Q6Z0]%*91I"&W,M7+[Z@GX2UW1361Y>H
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MQXE[6TI:W!9AI;\%FH[P/^"UR\=03\V(+Q9A*^%IN@@&!9AH9JS$>%:-"1U
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M<:_B "Q66V$)94A%U H3*$>BU8M* (HGQ(Z)HT1;L<?;AP556+!!E@,-ROY
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M5JQ7ETG<5K;'W<GM=^R0/S4!\[PZ^\\=[[Y(CW,"AN;/<?J3K9UWLCI3,$"
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M/9U5J'W#OQ*C!&D<9C20ALECE<5<5;@^(;;'PJD37=L6A8GJ1AUR'$HGB)F
ML!V;C[-.IIE%BL*'8KEKW>?7?$^Q"#M_V[DVO1;*%E2@04(F25L\LCIG([/G
M9@AXHJE28G=T>HSG\[3/&EGU#"9;X_J6 R>= .B=R!PZG/,#T2+P$%:7= @H
MSI%B#,MC?G[1S4SJ693K$N;N]KO7/GE[YE&X7B!SKN;R4=<_HHV$EW1NH2IN
M_JAM%O2_/5;[,2(K%D(^>LU] ],EU"L4 @%RH%]AFZO39Z$F(IR5"A:'&$;P
M<.8HMTJ\5Q@Y!]3_$5B:;9#BS"?#_ J2("O?NKAEOVNS;AYUZ(%95/#P[\81
M]_+N%PTN9$M$>8IP,<$@;IB:/0$L>/^^S&RIXT$W _N2 YP;TFV''AC[/(PO
M^WGJUYC<5<_97W]R,*F\UG"_JC>KYN@/MPX>/9J2O.6;?-?E-T/M#^:45O[?
MK8-KMARO/NH>/_B[>;\-6CC<EPJ=F8L_6DWFK!QT=:E;<%>ZJ051[8MY7#-H
MCV\?RJTZWF;E:LH&Q:7Q.YAK8VLY#5Y-#?%IB *2<<:C*2.(QD,[]$C8@*RY
MNO/Q5&E=U73IL;A7127W#>K^H91B=#'C=)R5TD+YI@FGN:C'C5;+:!D\C[$P
MHW[!;:#12'J@/F[ESL*+)R3D>."6CD%Q7<=]23F%/ZS=7UV LLT ;7&AC7IL
M)XEZ00VA&:[M]EIE8X/!I=,,Z!3=#C/I %2K8'H("Q7L6]QA7"'&[F/TP7F.
MQ<$O;4$.0&K!Z"A-(\BT(_HV[?3=LOGE',2RS2?N=XH*]@^BGWY+P9T[Y;>B
M^XU<_BL7N7S[NPH6XO=[I+)#O7F+PBOV9BLW24%2NMI.B44\$16CH_ 5S^?9
M._2@PA,E;E@IHYU6U(0S:80;Q(_94CN4"4NMMA@XA.5Q5G. 45$>KM.+LZ:Y
M]$ +V,'(\!BH,O2B8LZJLVCRO%\1^@ *D/W !D.N*3>/*7QNCG]A %$1+R!K
M8!%)MH)2Q1<&Z6N04:\B4MLK=@\\:=1+%B*@>R-M \NI?%V/.!3RLGC.(ET+
MO#5?6SVG P8'6@SR_Y;,9U;S0@9DK)1(1^_#C17V[,:6TEF95_"K;]!*TIT"
M_$BV+'VSF$VL_X(=FAOV+W[=D@CRI/M_'TA9>C71-N-:= B(&TYHF:>B_*,O
MU<0[>_[Q[]O!XC-W@OI^WM*;D278AD3=VO'=_N16^*,@%:RR7DV1I2J8HFTE
M]'N$"A8O25+!KJ)$.!3CC?(AF4(M0Z<WJ/4LA10 ^/$HQB0$E S&M':V<==A
M8ACZRG=<1#+2&+(\57"B6]U=U=I]X(X I^F>X,+OB5U>=P/2D>16 R*>O1Z8
M,Z#F =?] (57=,@@),+;L+D2NC])*\1H<G:IKV[_#)@(ZL%$P^T4.^VW]+OC
M$=DB,XX]-!\)$/(X)L-AT#8*=0>Q]J2WK.IR%&C;9K^^B_EFI+-7L;N6Z,=_
ME5+Y,-PO1KP2_G/@+UNY-F2O-K,&82W),4OW[(W+$_1VSN9<W?6YGB5Q$Q4X
M6\<C/FL/?GV+JK_N:X)Z_NI 85L4U VVQTK+[(Z)MSX+M DP>T8\)C@JV'KT
MWM]FSP(0166[SY9XAFXL\8S]6'2K^[:52<8^VHK!KR(%5P7[#)\6OIZ1AQBK
M8/M0HNI3_Y&Z_NXO*E@#I3TC:CRF592+T?-0^QJ<XJ=^DJ8X &XX2F0=8;UH
M2/";3=CI0XB*2:_!IQ55Y-T/>[,Z6_PF,.348'(!#AZ7=LJFH[DN_M+H=&KD
M*,Y0!6O_"$VI8#Z(' QT$&*I8'<.+8>K?3()*Z&L*<<*&F*/3?-.<)M$XCFT
M"A;8JWRC<U.6+$=7U<2S5H]?I'ACF;H?7\_FH^S>#[;WWC<D2I\2J?^4-E0N
M,N+.TUODLVY6O];1N>DMIF'E5J>2+^S'Q: :$%=IKJ5,/AO>\.I3(V4(9$XG
M!MS!CGZ=2G5*IOQ\+]^U< %+)V\E]R/4M=(Z;ZW 0!3PF"25RK932V#I7)0X
MPS7(ZWD"MB&>91P_MI'=T/CR*4"@7OS8G>RV!PLB"^H; W6.#"30_9[WN?19
M'#P;:"NK@;0E\ )3DFD/>N,4BVY\+ 1$4-T6VJJ@&W:V)\"0["?G^Q1GQM]J
M=K"\MZ)7@XABE$/U<+PE9PN I2H":B &KZ0LF(%NN#_D]R"^* ;4F1,"IK)"
M4-B)S29C5NXHW"ZK(</F)V 2 [!)NT$R$AY'ME9V )A.]ZX+*E@L(3O2!6!=
M4V.?GQA-94 K,=V8IUL7<?:!B +.!J++S_36-Y(1BH5]<R2$D^^#1+(6R ?<
MIDY!V,15U&Z@0*)3Q'1+#^[GN$]6>$,:$C@UM4(#*A]?@?-Q:]'P[RF<[4#I
MG&6]2T&C^R []!$QBM>D-.U:1.956#P'N<4+@9?N@^MU!A!FF'CZ%=QJTHEJ
M""D)X2?LY-FLS#VD/AK=C[XC<?,]#+R[+LGXE6  $2+ +]S[L:]*J1Q;*)5O
MLU+WA58)426K:\7EIL%]3SST _2_?WK*-CI/&YX8OP(Q$X!]&0%JJ\H/7PD0
M+!^^=>:Q0A^:?T!,/<4!['-JH%+!=C4\KZX!>GK%\]?.]C9&;)1]M6TQ%83(
MTBHMFH91RSF?*ZO#1Q4GY$>(.-F=E5JR$3'\IQXTC"AL]684*^T@+'_8$0-P
M2<;51*0:2(P69X@$#]PJ\GNZP9<Z;9: DH.&<QJ[12< 8=8%I:, M/R)"X;D
MQ/2@$.[@="KE/!2BWB?:/":>D$\Q)^&C+E88=2LM2+O4P+Q/LC<:B7J4[.;'
M)[M#HKIMA:4[_.^-0G3^)<6.+L;^#_O"5[S$]9E.;,:JOW\S(%RE,#%MC"+E
M%M R"Z7Y")HE,MHK[+L5)QBQY-V0&\@0N\V54MD^-?&OT 6/[RE"H<OCU^;K
MDMT"? ?JW [3G3[<\'\P[?=&+_H74-2M9@-A9I@*)B@097EC^7NW?)/LO_69
M5:6"1=45-UO<>8176CYE]9-.B /U!8,V/T?J@X@BE-/#4]ON2T3:1 H_C%Z
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M0F/Z2/J@@@NYRG>3U875D- YYR)%7D48HO6G4M-&##!B5JL6) <]9V04D%[
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M0YL.DM<08_CD55 XH%YE&T>W=W5-]91G&6;.&-3'02S[.TX#SRNVKS1'ZDQ
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MD=!FRTW;(HVA6DFYO7)>L!S"5\'60A/'\T\T/N_U>Z+\($), (CVEG0>66^
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M\8N8%UV-Y?B@+H7/2FGTP] 9Y::6'K7'QAK[B%G Y^R:^*YS'\C=9<YWP,1
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M@!S&_]JH^-SWP=UJO-2NNW"2EQC/27>SJ8P8XF41=*%0&LB0',9?$=E6B[9
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MMJ\.F+7%FNHF]G0O=_Z,;5U ?N[X06:6.L>'9<U364CETY![GVP'/J 5+*N
M/$2&4_,4V4>4@2/\QI!E&A8Z58GCG@1W1U9C#!FPAFLVWFY@?)?X4#]]!9-?
M9R^(9-9"CLF=]KAVWT GL/^FM7BFN"',3;HS9D%F.C5=6A(W^0Y&4 'MQ$W2
M:N@"0VT.I0)%H/3@Z<:\[RF1(D0'''C0X+L5=9VL0[?!O>QH">M0"-8??0=>
M]$S5\?LA1WZ)N;74V5LDF&2LH:^9:-E3QV5-H=@&YDX]#GELW$OA])0/7\L
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MM>[N5>=\7;5KG_KVWI70$^AY@.2V&D(- (% 0!KF!Z 7  M5?Z0] &AI =P
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MI-M_%\1_L]M_D3_S&B/DA5< A14_0#)  4"V^@ H.3X L<C&M(#^'K<[N$;
M]<PS9EK],^__$-#_:16<>/WP0CK\T4]%SP!NX^/I^V?;];0$L  \@!B@ &@
M1H %X 3X &%  I !% %5X#:@#1@ IH E8 ,X JZ )^ '! ,1P!,@%G@.I *9
M0 Y0")0"Y4 E4 <T 5^ +N ;\ ,8!:: >6 9V !V@2/@'+-,PD"$('(0#8@)
MQ ;B 0F#)$'R(%70'9 >R!1T'^0 <@/Y@()!CT"QH&10)B@/5 KZ"&H ?0%]
M!0V"?H(60&N@/= 9& (F %. &<#L8 &P)%@)K DV -\#.X ?@@/!C\$)X)?@
M?/ [<"WX"_@;>!0\#]X 'T( "#Z$"G(3P@>1A*A M"%F$'N()R04$@-)@^1#
MRB&-D&[(,&0>L@DYA6)#R:%P*!]4!JH!-83:0!]"0Z%QT$QH";06V@$=ABY
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MHY7VYYI/NB-3?96@4]HZ*\Y@7O.G)WF%Y:_VU(H<^%*^/N/BI:/WA*U:&?^
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M!P3^88J(BG[V+ZZT](Q_H96^_@>NOJ'Q'[ZN[G\33OP;$;GR#^31?RCG '6
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M+))DC>%-9)J;2O-J_$!\(C$.N.3$S?X74$L#!!0    ( !"$1E"K3B=*,4H
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M20<H:UP?S>C&M;W8GFWXRH#E-]TSZ@]/ /5"R5 14-^*UI4,,%7HRH!+"].
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M/2,TK,ON)'!+O]BC>*-00LW]2?'#R!!WPNL!PC<V%S_,$+0R-<F[(4HK'L7
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M! 1B,\G-1\A,(834UM]#^?G^R+\;/Q+A7P>Y=]'[;V0Z_W=WD<-("'+$'PB
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M"B0>%T,O%6-VC0U:XK<Z?.:XS:6-W'TA?C[^^O_A=[D_Q\+S_P!02P,$%
M  @ $(1&4!F@^B]BW@  >QD! !8   !S<&EN<F%Z86QO9V]N97=A,#$N:G!G
M[+L%7%7?TC"\#]U(BZ2$A-+=(E*2THUP.#0<. '2*HI*"@@J2"I=(MT*2"/2
MW8+2#=+O :Q[[_^Y]S[Q>[[W^S[7^>V]9\V:F34S*_9>PW \<#P!G+NAH*P
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M!I&U07GMWYN4//_<#KB%VS^W0L2*EU_,6@AE )\%+Y<@/\3Z9%R%N*P$1,7
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MB<XN5DY6)W ]"G[DACQ)=T)71<$!;G80=Q3<@X)9')%.=BCX)->.W EB 0>
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MK54\XP+!UN6(U)#G5&E/ '+]-_LY'VFN=\8&H3[Z"WI':=_IQ7M"-*DUDIS
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MO=C!%K %PI&Z;5\5#\9'7HU]*@WUV^J1)/.@?,N&!U1B -@:S8OV+[W(,3S
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M^&_0D,T ;"@>0.4'63^8K07OV1LKSD\P;S!?CS\YQP-Z<Y>ZKF:W.U9D]O
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M$/^5SA\\8"X/4XCR05UZ6,Q#IC+@N#<2*T:B>,#P6"=D0OVV,97?FNFP.WC
M0/;1K5)(.Z[P@';_0-F!!0CJIZG'$#/F K*[L%>,0GKF6&'C(5-"([BI./V.
M0]0Z$_6FTAD*J"#>40\DS[5WR0HZB&#]VJO]T;XZH\V][XL3451 \A]%BJ<#
M_,D2V8K-4N!NM\_BE]MP9(DC N1=6K6TM9//PUI'^)@VOH9'UU<[Y(U]G/FC
MJU_@D68PUTA6?>=!>YM;BWJSJY!IVE:*RE=KOM&E'B6:1"W0$\#$@OCU.,[T
MZF0MYQ=<NAYV#$^J:9UJ+7//[)&$]EK7&@"%8!S2O& @NX@,4V?]1!.6&,J2
M/+X;HV%L8U0WW-EW7<3<(EDUZ=[I&0'3/9"45"1NPCX6]I23TOU2LII0&%-7
MY)5?P:.;=VCCUH9:QJ;<H+=B4 DP=7J-BBR;[T..Q!XC+$@VZYA1J^%(]6]W
MS[]0Q!\Y\>A&%,MN=AW+,D[=M.G- _N=G&0Z,72C+^]72QWI]N@TB<WR]N<Z
MS1EL%.IG7L&:I0[BRD-42:0H=>5T*<A8P3$=VQMQ>YH#]AU 958TO3HMG3!;
MP]S74 \6K8A=UK>VW[(:Z42%60N8.^8;?()6/=BD%FOZCSVU7K%-\TKWFID*
MS6T:"NJL]Q1JT8?-'45^*"-\ $P[/8/#Z<%NTQ!O5CZM^'=EI=59$=6567=C
MG7-^%?Z1*10(KGA\-T\QKC,43#!DL>"1"\L4P3;^T*A#QRM[S+MX:7TV"1)?
M"JYXP9OSD*A&P*&;ZY[7R<D8?=51"SJ)9+6,]UUY_NI3]WTFZ["'+JD4;#FI
M,EOHT&Q'KVM$&^9&+&!D^<UWD/_<P9.XO- RT;4>*<])AEF*"NB^2S+A([*9
M&71Y6+\^Z>#O7@C3X1XR\!_&#.5#H6LX-?CPV1O>)V4J%^E/;I4I/& I#W'7
M<HF#,?L<A%^B_PQT>;*5>&8E*!\:^WJ39> HF_0^Y4K"=IO/,+:NE8F+]Q:O
M3KSWYP?;F?O"IQ'BE9U";N_JB@0&15G\W<T<>L=9R:G(]IP]M)K+K^S@/CIW
M$&>9SM5/6J6,UY/>.AEIUJC-A304.?#,F:#;BVH].:::\( 14?K@;V)AIP**
MLN%T&>VR%*(Q^G1E&OJ4E1)@A/3F$A#FEEW0UA97C_TXY5?&K3F#N-KSWCX;
M*OV1/"&G=_V PUSO^U74HR%?R[YR,;:R>[D?YP[\0$V_ZTP'CUP2 *PPI>F[
M %7M!"ZR2A*5J?SPDEC_5TN!31N5$9_IMWH&Z45B+PGX9^"+< 7WHC[& (=)
MVZEU8A&=\(>LQ3=QG:\9[3N:+#^"^JTS]V[&PI=I?M.*E;UQ&MPM=XB)69)*
M>3.BN2NK.VQTXF;;5C4/Z@*!BWM\9?OXG_O2;_Y\2G^@-/7K@LP">L+,![I>
M'\GJ&8+?;C5>;47)<W5&A^?E!L"#6(U7TD2AO5Z=/OVN?=UG8J;6Q^=T#3][
M9M=KP:%NXXD#G$DNKJTT)\W:Q.]^4,B7JYFS?KT*E-5^F]RY<;WITP)V;P7[
M=*AI"7@T_DOY^0A]Z<BX3*#Y0N?KG_Z'O>[L$A?)V%"HV!.]K9ON 8_@@:#$
MH7N[<A3-39[$[9[((MOJG-9#U@(RS&N)J-99A8N)@%D\0"TPN(O*'\O!<.,W
MZ_?-@S$U,3^;/<+;.XPTX3E<7L7.%T4Z;Z$^PP.8^KB01[ OET0=N+;-O)R*
MFHWIU/:^,OK9RQQK?2X[U;.]]Y)K,6?QUHX-(-<O4T>8]V;'#!7]*OR#BU'T
M4?2@EAU@U-.'*9?97ZU! &O+LGR*N,VQH_!7?_<C)8'^:YW8<O]0/G41:4I;
ML0%,SI\2XSH:C78%?V<!N**)D(GBIJEE4XG;29P+.Q:6FYDB*K*)K%K7$D"[
MQZM(_S&E^YD(4=P:=6=X*J5\S*@) <OZ6<+1.A8JFWO3S))N?P3L]5#V,!%=
MDX&,D<]>0'C.BP!'Y>X.$&PRDW:G; /E5^3HD?XU^4.8/ $;Q;,6QSIJM@11
MG6!.%SX U9J\](2LAYM-JO72@[:L/GN-)=PS)B1]Z4^J[^"J!W32R/OA/U@6
M]4-5$5X]I![B,>Q0<6=7)Q-XPIKCFU>$5+)ULH+7MO/<$H)!EP]F=/X[%1<H
MGSS'Y!VS;LFZHO>]3"J7)!5>2J3:"+71/'E0_;&\S\YYK:U!@\K9?PA:%O6N
M;D3M$";U[.OR&J8 LG4PAQ:K_,F_HHA+X:X@.W:44K 4T#_]%X-5.1N]TMLG
M9=GW\<8Q74!(,9*_S]N=5^J4(D9I0(1U0ED_0]XZ]N3[P,!:_BZM:J/>$_N@
MG0;.B@I"4.#]6<3%39>BN5E\E,'/RI+>&3TY(R-&H8=S1C/=LBJBZP@?2 U(
MLJ+OU4[=$E*MK,C4H2 A) M*^/N%<R(A85"@5ELU^S%&T$S.:Y2A!(9"##!]
M!6?ZVMO*>U$HL-0J\GI14E".\4QA_*_S,*\&EVKW8WO0RWTHH#QUWXP"3,Q[
M<WB[5O^4QF RNB(D\SG'X>SD<QZ&884=WD<O8GI/7-LVQY%/IMTAKP\2RKG?
M ?_]4>*BR[_F*010</X:>!(JU;$_T=2>UR$KY%$" VHN=I&Q-)S]42;^7K?U
MCH\IHR +*F(:_):"46&':>;GSI.5O5AXP2S+?LR8HF5:,>&O09#:X4+EZO=X
M)84AQH_(RJPPYG)]+:L@E\WSEOH4GTY@VIU3[_U2=S@WMKMGD(S[BZ6\YS1N
M_=B@J_DZ=*P]^A.G#[VH<29SB4=NF?/SJCLFLT*^7"ZGG1 5=)3&6,T12-44
M>K3^H:2HN,)0Z6I46I%=1L'-*.3[L"[L@0D!@MYI1N;'U6!<"U9F:#QH#"0)
MNFY$-='2NS;K'9$"2 $)_>%WH_7Z$CI(+866U_:G]Z\G_#E@@E*CH\-R=.Q&
MMMFOM4+LW,^T+_Z]NAIV#<[^3Y=2_=_NQIWQ+S=UVG7\N^>X6E%8%KE:6EP:
M^3+$UY;0@NM#O)!*;''O4SELXX="H0R!W42EQ )E[OLQ80]9?L3)2Q21IN<.
M)U;7,)5X!UB/K305.[\ DA[)M".GY@8:*(P,?E-:&+G9[:34P1X]D1"W+0MP
M5I"6*L_AMM'8T>,YCFN./]@$7813)Q+>3V076='GX?KAE.54^GRST2NZ\^\-
M"BU6E(@'Q%?EP=I\Z"JWV!00OU[WK[Q^KF,H"+6S$L[3O#\1)/+/<.Z\:Q)(
M6MRT:5+>[Q+ .\#?S",_/=$L1J567B'>!K-0UFOX?&+O0QAH8//#C>'Q\QC>
M;S\ +:%^+5O2NUCO;"ZVB:6"D-([.@^JH'<"-;@]_+/%GR7?>CNW"P7[33"7
MEYPCV3RKU1#K,[:I1M6\1"7[(H<?.Q0 KP+82=B% O/P^-#%XZ[:QN**:M'B
MV<R?ES5.UEHR4W"_,?YF:XV/KU\>(V8-1(XZH$MA.V3]I?M"TXE^+AX#' KV
M0E-G=D?%>(#FB@YDB=/@A*Z1;*#*TXUI31UMOQR7+,9#V^C2E)D!-W7/"V=/
M:VC7.ANU>.OP).9.A)OIM==R?^5^S';X$D5>2DZ34OGX''?J^X^(?)Z7'YIT
MB<+LOYZS4!,6I[_=7AP52-]4"?Z]?N9WBSS;<]HG6(DEL-\P?9<H\JE]F#Q0
M28-XWD-?CN:*_I3ASY3P!T4)1.C%[;98NJ^5X/<$6]D_0&IQ[=<S]OU7^@=R
M!9-%8,'CE]0/H@J/>]@\7OU9%!'Q\N*E90_)KV92/!TJEL5FIN7#6X+X0I!E
M/OZ_XF6)!>,U/,\1W+'/PR 3]#+;B CP:-9%(/K^EM?"P0?-LXGH0 \2C8>L
MM4RJQB&TYOEKCXJ1%D>653G_XPY$MQ/;BYT%9O+\G<#L*;\L1NJ/KJ/CROYH
MSI,W&>:_%4C-#DJ[(JIDN:)35#BB2% M'F0]% D:&I)R<3\/AV,SOBJ@2Z0M
MC_/WSS*%2\5HS08OD]^0O>0<T79 O[WWU*%:06<.$C@0M)]5C<G*6<'@UD!8
M(0^OF%;3MQ^@/SPAGP(TW <)[H) D]G0A#]2?WR_#<^P$U3C ;EHS5Q&+8TE
M%#WKH-T+[4;QV 94_/34AD;PB6*33Y!0=NT]@2W9M=."2['U!64W[)H.W:N=
MD8RB$P>[(LB22H'6XIH8? 8[)HOTL^=#U'LHM\50)C$MP!ZSC#$/(DP'WW7M
M=*8PU_^HV("=_$(A*VH\;P*GI;7],Z2GXRI[[+#CFXB9S#@OW=4ZX:E;DW>P
M_Y*#F8J:,JFT!!I<G=):_^O1I%;5%)>E$'@ZL-78S-CERF@J4K]"!<W8G?6T
MO$ -]B]:1"JEY:_CP0.LN\<$NZ?,XIC,JB<,TU\'98\:7T;^:'*TL1J>'N-)
MMXM18<ZOZ?MYK;M33A?PMS,%(7VS!)0M/:MD^VJWY\CM(RHOXJ[8<,8DE$_K
M\W)]6(NN;E)GRF9=8'J7.J?*>/6MR4_!KHR+C('$%A]W%";M#K&=]7M#QP4R
M"A6IH9<EYSHFF03B>VC+9K!1XS6TRW/\5*"RW:7IKV/5UK$BR_+R<\?*)7G&
MG:^1Y@O!$DC4>C@7ZR":^Y*&+I<TKN^#]YDT35!:64B&[Z,9E<2<\!26'ISK
MD\ 4B,]R3_/8:-#ZR>>5&Y8E.2<@A>,FM,H6,!_%*:_X1J6XLTL\:'^Y;>G
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M73"=O,8!+)VYM/8F1"&+!KDW-5ZD8FWM?W:'Y;6C(,ZWFPM(VG'VNC](;#H
M>&&W0$]-R/@.S.REK+@D'?3RD9,9U5%IE4L5R\LH(E]: <DVYOAP$8-_NNT
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M!8E>_HY6G$ A,F\<MV >9#P#7.(QX;U3&GHV'*2*+[*H&%6I*RX&W##:NP^
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M.+"4_1X9,+BJ"YWOUYA[S/'R-<_X)>'K 6P%W9;9]R;?8AV@$C3.6?[,9P^
M72G@:=3\@D1J^RWK#LO@D?O7DZ"BXTSX:BNF=2.0JZ$>;<ZZF!G6X/6$WN.*
MT]C.%6C_%IE",T8JV(#-M*S L9L?KR14P:PP>-YD!!MPIS(W[OA>$!U7SOFK
M@(\_256Z[)4C42:S-&#: E24F9K'PJJ!I:&((WU3FJ;][1*:;1*D!%J-WH>!
M\3&*HW.=VY%+F9Y(%9#+[Y5:3Y?M-8GAABLO[0IT9*478K?RB#;JR>%Z*Q[5
M/:SURZ2NJJRJ=MS@%O))55XJCJ"2++"*+$+UU/FVA+!_H4VSL6S00-R-YYRR
M+)C,@& ZQ0'W]:5RL,TM1Q3!"^92*K6RYR,\[#ZQ03*L%;!1>UM_NWVZZ4D-
M(/PPYK@3==>$AMIE7AHW7!ATF)'P+IDVSR2E1'4G)[ IR[RC]NTB$HT8Z)^O
M("NGY5R)4U$CGU*!^#^>;BAQL5IC &)]8V)R"^Y-*EL(T2@9NCR*CF+9I?XN
M^:K158L0BS,1=U_]G03V4M?AAH_43XT GHJ;25@2F*W65%']W(LVB5[7Q:_J
MZ]C.Q*):;0[\ ?!W5SVF[ @/'&-(P/_NH$2Q[@&P[JA"G$S_CO'F1#7BJO!D
M*\%;[ CQ):JVB/^(CSM"K/$FB/XJB\L?:S:GD5HOI+SRB&%NV4=U^_'TCS=!
M5'H=;"KG*-<#I\.)S-5.U0OZS\"44F&SS:5,][L646BQ0[L8=W09).&+BVG,
MBJ[!5<'HOVQ?&F\[/OM;N\-<3+P[RS^DKXB[H@P[J!923L5G6%5N[>BB%"?;
MKORP74"CCSR:_GAN!@VV,O[<B J]SQ"EZ!("CO=]1TQFIZHLX'+_'$2<)K:S
M2C7RB=!XJI*1[_=HW?'<9#>Q\[^G2MU6J%L: 4*;G<Y/Q9FWC4;8-EE-U!X1
MCACLU"V1T9 KZ^D!=NA+,DL""2GI:T)F6GJ(11AQPFYPY7&7I=3_5W^._@N?
M[/\7W9P6@V\,X-Z<9D?>MQ</ *X,+AW1E$\V@P.=C(4EGSA'KU\\ %[R)E#.
M>;*T&_&-LDI(+>31WQK1PXKOYA\ F@><W<AFJ3LD\=EE[6D+-%?=Z/@!T.NO
M&]2'RI=,(MH8@[5K=,65Q@FMC[XM["K4&.HGSN$$EUZS^"><([.+$27=O6M/
M6D&A_X)!0A6#-1\"?F^CA]%] (P]YR&06E9%Y-L"(JM&1OC2Z4=J'H-E3H2'
MS9'-;AMW5[(/ 'K:5R II.(J>"\2'%(8AFRQ ^V6GI%EIJ[>O;_9+DV-Y)4Z
MB'$,-*Q2;Q)IT$[S_4E$;RI\;^)2V?  &&;]1XIISQX M+1Z=G<L,,RP^2XK
MACMY:/)^U2HPHG/J 1#?-?L 4+H!__9CWP5=OSS%^-'G>]]=@>$S4L+_'GX>
M<?X ,+^3;(I!;]29@_[!C=N2U%[M R!:6%DD$J/0'G:KCHR.VN@9>EU^(WS^
M"%+$E)56O)7\05KS<1D=6TYZ25.&VP #=:@BH^53\>>!">Y8C"G"=42R.QN7
MKFVFS3'7YM;B':3_[A==TLYUU]Z=\@! 5JV+G=: $XNN5N[7SL.\7,0AUZOT
MC_WC2O,J8(WS=5KCIO3ZB-9RGO+8>"I1"YF/XW&#B]"84$K'4%O[7 _Z8CXD
M5*@'!)S@D>@ZBB UA>Y)%;46N?D;Z!5Z/)+_Q I<;0J+5\WLAQ3$6SJ"!]7$
M:Z$_.+2S*HI17\""[[I0QZ9+]\JMM]O> 2XHX#3FQ:H4=?L;NS W2_M?B8G\
M+IV5^H8Q_3K[5PTB?BV'1X\;&AIOKDH+_%)>9K^)+JG OY!ZNXI$PLQD/9*-
M!:%7VL6]/IE<'^WG'O^*M9\3U,.S:W*9=I%D4@D5Z[^):XG)7L:X'HDR9_Y[
MMZY\ 5$/@,$ SV;,Z9G9I$OWX3P<_+<.?$87^1_SXJIMC*_\C;P&>%.Q5E;J
M8P!QL,_V?SYNJCFTI#A4EYAT:KC)7Y I0L>I',KPDI+NJ20<[B5,]YD1$^4.
M_B%Z+?  :(%YWUU",4^.K;X\^EH&T   \ &X ,![ +%KS,>@QJ&-D>Z_)&&?
MNI(6-D:/_3]- !:FH2EK+^6I!1LIMWTSDT"?)_K=5'>.P;>>^MNCUQ$/@&]^
M^(H/  Z;[KL+>N3?'Q@O7\P2%,P'VFE7G3?F 'FYP*$@X@3COJJV67]$TU(Z
MA>]5%3;PLM_?CP9S2FJ(TZOSIU9W/JE!F]+:2B?R*7W7OXAED+>]JYYD06[F
M?2_ 0Y170OBLYV5+*E6Q4':C9:>3[]>\WA!8K-0]+Y@BQW+0WE5_%VT5$([Q
M?>T'3J;H1[J\?P#8B70E[Q_70*? ,77J:QG?'@"JLOOW\0^ J7ONVTPT)JKF
M 3"A?B6*+<D=X(RQ%$M'M4(OMG>:H=$%!Q+)F3<Q&0>$A[^.U<X&KP(,*ZXH
MO*V\Z497R1+C+6M:]8;UIL?^OCLD&5!7_?6+G$[K62B\S6U,//7>=*59!&%G
M/,V7RL [1<8^PB>+2\=0&,T[XZ^L.GR=O:ZO=_B24NEY95E13K"/]NRWNS9I
M[\$I6'L[AG3R[ PA[FPHNP(F$*ZZ[)'5*#O31 2(>04^866?KJL;?B<DWH^4
M!E]X,HA@$43"Y38$:M"ZG3>JJMX'Q7O%THP7.7=EXK>.FR]055"MA=B7DO+M
M$LZ5"*X#[85.*?9_P;,_.I&#DEX&2THE[OO $0WP+)A*D'*7)+^7IYCZ[-IV
M>G^?Z*\*W3I%9G)Z7L.2D<3+%]I,OG@1J8=(G]W**K*7<I/C_H)[\TZC'9N?
M9Y9E-$G_ 8/#<TF=+?DQDJ]8<C,-1&MP_2]KRBU DL>9& '0C_.8)"<,2=Q4
M]9DYJ@WQ;O'T)X;X[N@&U2))<S?W_K:LL[H).9L19N3]R: -;RQ+SJ5I597I
MJ)4_?'!N44:!G>/@^.WAOJ/2;3C;T9L?]#QNSGI>]-U>A ,@+_8H%1PZT=@G
MM8=:./8%+]ESGBLO4/=D_5G:,$[A[D@\LS@JGLR#WJ'X)'X0CTSNK,4<PW\T
MHH4ENUG\B5U/X-\ZKP$KU%*^5[8;T,N>97_P%\1B_I#LU_R4Q7FENC3?2V6J
M;S39N5'WG<:@U3O$HC WJ;E"Q$2(-CMOH$JY9LD?RWPX[9L]ED0S9\NW?<T1
M_6P".*%ICP+:A, G_0\ \79B- 5Q_Q;XW/WG;9 "9BN6^_X=\"0%GO%M=YPB
M^TKY 2#SM_W(^_16J.\!("*U=(!]L!']CPS2_P5ENKEF  )%>]Y=XD=M^Z=+
M]/0!$ /#2#:?GGA;*R?U+3P R-:HM>KRZ5E(2!(JYMN[1LB_D4*?_E0SGBU(
M05!G<\#<@/O<P/2,1?[&$96T3;:/;RMEM"2I]B<:#KDZJPY9+H@VW9WC!AG>
M>G25G3/.3I::CT\\+9/Z#^P*1/C$VW<OEV]<^.S*QDL)THT45A:D*YOX.CBQ
MY4/XG0I^5G!^D#P<+H@VV#^BN6< 0W]*C5:>OJ:=M2AY ,A*[1Q;5+MV?S1K
M'+K1B,@^R^/>NRPD \V *5</ :;957XY]=2!AC\II++=@NX? &JC\3%W'>K_
M."8A9^!;-3\(S!2#$>TT]+ZPLY]%60;<\<'4T6RTB+R]/N/+=4_&G7,P(SXX
MIJ:8%3RR.-I]L4QQ%^#AT*E]+;=O1H?]3\.K*X)V)LE4I$:J_RC-/R%Z %"U
M;>5QF9O7E_7_@PYZ.$NHP<@#X$=GY\0.G<O>2ZE=M@< T/WNMFJ0$DC]!139
M:W[F82,VV>[/7>H=HZNY*1I"T>;7YWW:U;Z$/JU#9B;(-)5=1<O7>V.HJYK6
MR!>6IH!K/9!UE$+=\A"[DZRL''ET5GBCK*8VCP\C6VUM4T?H8=I9Y0QC7<Y'
MS\<?3Y1U<$A)Z5^P_GR49,PY2?-3G+W?'E_G<SR =,MG+OOL;SI<<@KE+]ON
M/<ZM>.>R3)UO<]DD3&O0ZC()GU]*[3H?F]O,G]BYZE:?^NPU@<R%-=RD.::4
M) BVV4)GY_<?-V0[$=*H)KTS7#F!$\C]XY(XEMC81_(5<AP?9G03T[)[D][X
MERGB>7*LAMY3)N9L:W\,4HX(L@TI=BG,/2#$"$$GQ6E9/H9PKW8RUSFZBG4'
MN8B/@+U$^WPTX/<PQ>9:-)@[NVI%# =YJ1B3P,<;]\%-L.$+5;C=V<>1M>7N
MK\.UK3@6J=]T-9.U9!4!_-H"U0 ?HHI@?N6(YP:^6?3O!.XSG_WM? !,-VX<
MTI^@0RK9NZ=0O[R*0_R!R_*F* N(3[HOZ="+YGB=X ^5NML$YZ+8I92/X<WF
MU;..=8D^&\M7S>!;$^\@4V>3#Y^^JS2H1S+2@XJ5*K.78-@U7I[$%B>F\$;A
MT+YA+5U]#1!78_; GM> +O/C^AYS<<.Q0)V;;3K)/(C!D93[%5/X]-^Z&H)Q
MD"N(WW@2N^#/5/FC?\7H_LG1P2$#KCP.<<KF+/D 8CWSY%:AO&V_H>T!$# ]
MF5H%J]$!FL*")V0EO:E5-0U-P[_5SL_3.=XZLANRVB_ _\B\QGE2[:)NY>_H
MX.[ 9*?@LLO8<"9"0^ASNUU6<#9ZGU&V7/14A,X4-W!SR;@W)M #K.+I9?XJ
M8F,ML[UX32SYC?DODUEXU?>CUC.4R\JJQK9-%N1)^:3^7HVQ9(27ER--]$EP
MBXPF+4UMDA#Y5+H_^KB!99UI)H?*$:+T<R 00/R&SI*OD0RW3 5!1YG_6HPJ
M^V]^^";TM6U&D.D3"?WU[K=BT5YK_O)%;7*1)6&@T\IP.J<OWEZ7Q1L))^O-
M\(H'@)$+%^S)//1OM Q@.>)6M5H_%FH5_5F:S=X24L4%8G)$7-U7]?L(4]3?
M@X*K9<.5''WZRH[X0M3^4!Z6C&,5&41L';E7O=7^O2"K_'Q.CWWPFP)28,*U
M+S\[:7RS1D-&-WW4ZLO?>3*/I1MVOJ2YN>>JI@884:7WA660MSMEI0FS-)\A
M[K]QEQGDD"\9/_;C_=''GBP<"-[]B9WCHIYH3FVQE&2:RQUP21#H+MO"+E1H
M=A/4NS+:>'@MR"4SJ_.'99PF>ZG(\AF#Y=SN79X@-Q!;OS'?88WP=P-UP(:.
MOEX48;GBD$"AP\5A3%G3"Y_!37'VF4;2^T[;DW='><O&S=M>J]#MUZMS]&_0
M\ER+!G>73XRP9'\403WL7*YUJ*/)0_%:W'62_J[I7RG$#5-*!=3CLO\P@ERI
MBQM__]&0[A,2ZY,V3..!=ORS/_5W6X%T\(D,%9@!/#RU#:=0^Z_E"?B_,V/]
MWU0UK1MC(6RR9^6HI@< M_H>5_MA+M2#WM(YZOS,O;MY^T-O3-71M:R<OL?E
MDYU578;/#4N.:P,I94IIK<^EY66DQ116?N%93QCJ_1_EG554%%[;Q0<01011
MI)$>0+I#4KI[:.END!YB$$1TZ!1&0KHD!0;I1D(&F!D0AA1$&!UDZ.;S?_W%
M^M9Z[][W]G=YSKG8>YUG[V<U7#;WS)6F?H,J,9@TO/M),^]E'V'<6WZY&C#Y
MKLHVO  >Z'!.5L&M./B\6M'C8 UP5&E-RU%6E3&T WS!WO6"XXZ&!D'Z#"K;
MV47JEK]&.^(U!?.K@G]B4W>WJV)+J2^G5^XZY5$<2.^>F"6CT>EM<U],_4%I
MIGDD=W;\(96?A9:*<$]!X<DUO-=SVU(3T/'.8A=6QAR.K2?$&A-W:DFN_8>$
M]ANN[9W?0Z:X3@QO ,_;QL=Y7UYI.?DYU.NPA</?6293V?[U2LQ,]+M81.MJ
M#0^_HSW@>\!LYYFE:._^S"GAN I?I-3IBA*+,H413D'C]"&NWN>O*JK,[?W9
MX7?>ONSG8=QIN_*Q3#B>]S[%@'1*Z]%IT?X-X,YETK5Y9-=I^$&"S^YR''ZB
M\UK5#Y'62W>M-.N37Q'H9NJS?)8.SA-N#;9H_5@S9N34N),:6_>DI+IA:,NC
MMF>?;L<3?Z##\8=1[.!XYI.?-5DMUT\_[S3$77LZJL=J[L3Z-:"8<7-]E?MQ
M.:$Z$_/F;?!QLRDMG5(\O1Q%47%??X/!ZE?,V:MIB'!JC"*7Y V@WY-_Y<_I
M!.I4[W-WM.YE\=(%),3;MF/J.]ZZDE:0N[3#Z.0^Z6OX)ZEK)\DGOP*-U1Y+
M3PKR$F:"&#IJP"%>F>$!G[URC\>>OOH845:>0T)@YJ\-FQ"X2Q(#$O"<'"6,
M*2Q:\9WZV;I,WM% B30";!+*@HPK>M>PE]=2NSX_FWMS(*-7J_,1M^&MH=?S
MIRJH/-R[N2#ZYZZK#:L7#0]GWH/A1)^J RW'H7+JS)4!+JS0=$_>LA0Z*QO]
M/L*HT?=EAHBOLEE2M(1\H;UI8FF::J*-_,^J6<FF"<$*+4+,&$]5YXZ^[IY@
M4I$B1?XC6Z:_^H#T\6E$ZG!RP4'1O04(D8(Z+C\H((36^$3J^9\FY3RLYMSC
ML@L*Q40,^I.O38/)\PQ)A1I/3_.JRNES_0^:&7\P/K@W10YA</(FA'.ZS-X^
MZBZ5O732]*$EBZBET,YJ+6:)(-L?DD[=< J^$TVX2Y9P0'KM)U]].2V362^5
MTW^:T-3##VD>;;S@"%OCE8QR&]/#VW4UT8_7S<"; I&CDA%NN"1U7G?.^O2B
M85&G-4KQ)H2><F=NJ:WUYH2^25>'EE2>X&6HFLRK)U3)P#,Q2A)F)Z-UY4G<
M.IQ\RV;ER?C"FRYA_7MI8<AI9S=INAWK.31H])H*O2^3:_ P'R)4#U<A2==]
M.2\%KW!^0CY(XF(.G]<A.N3 2-D=8H_[?UX,(WZH,UE)^/W2&]R14<@G/3._
MG7U4X3''<FIL71-DT)<V,MR;ES#J8C3&KX_YW0@@W%Q*4YQ7N,*]O-<>>!=(
M<%'OMU=INQ6VHA/5I1[_ID/EY7/2GW7)5R-1=\'S1!#T;.JI"5QE%I9+K'5M
MAUE6O0VBS/'.V2H J>N7C-#EX8YFRZX(3KBMXZY;I;:*]F?L]H24WE+WUDG^
M*=O>(VG(?N%A9^5:6,"8^E-@;[2]QR HP>QX=3CO0\59Z-X$7!C"#J:D]20!
M+K=>@.F=E@I"F?1-],5U/F^_$D,JF>&-S.8-E71,^$'("?;,%^IG+BVKRPN[
M?06P\T=D2Q%*IW;T.&F@,Z'F%R;!E8^<7;'T/IJT:=)!9^E#T1#$R]%GYGHW
M@('$:V+G$%54+[\8!KZ^^L6GP.!2JA5,V]IQT+B^9 T)GN$8SBCKEQ=$%X(O
M??1T^0]KK:G)7ZABN6.Y>UM/5A8#2:?N(QAL<<VN3YV"BDT&NK\IM #!CV;=
MP]_Y3A-OB--R0$5A<=M/Q*Z+1TL3]XC.WFS= ')O_]P5&/ND(!HR;W5IL]B(
M"^LPV!1R0PI^TS__,J?U+C6DX'-3[<[:!-)>N-I 0X!+G\>+AX^F>"/T=1A,
MR#E_=$)G(GU!16&'K+,6BW=(PNZ]%L<Z0//1>B25A.1@8<P)RPJ[)0<\&'X;
M.LE3BWHY4F!^ _!$FW!?\M1^/Y(UH$0(]46/I$CK-*0OF?F-C?.N_.@2$</\
M*M<ZCZ"T@B!KEZ,@8<7_+("$;JE?MRQJE9U"]-4\H"<,YO$>L(!*:\8;0-<-
M(*%]HE@*1)UP'25OC8S*[@)'G*4?LOA&$JZT=V^T;TLJ0"(<1&T2T/)QS<5?
MT'JM@1;1(]_:NW+8&V1-VPHSGF<+W,&3RFA7PR1JHOAI5/S\_(3J6'M^) \P
MC= \LS1\E<Z()TQ1*O=2=M?</Z(HM(?#\]:7[#.6YEL::])_F?YU%HE,U#;(
MU0O:L[_F2FPU!I.P;C:W_/Y32<]=OX(#C/R/_=U:CQ\AA9,?)2X"?TNN&OZ.
M7'%]G<!=5#?QL_35W(R,Z@W 3U8W_;0D^]MW@8Z-C,\FN8ZKKJJ]2QP6W]M0
M]/'DNBD$;.Y\*M@G+S2T&-Q/ZF8'=(!<*TLY'M*$!L1V8H-RMSVE@UTA4[+K
M+$Z7HZ?(U@,(BU=UDR+O-?]QX?P9!WZDOKK:L7+2SR<)*>_[I::PO8[,:#??
M.;Y:34E;?6)F&IIC9??TF'JSX!SCM.RB-ZSC0^O?\HA"#3*D.%LH/I6!^BHC
MON(-[&E+ZNNS45V?OAQ]]_/Z 1_TT!(L=DVEM5=CDX\)W.I1"8WD.WO:5%6-
M+X#/=M?-%[PDMZ'9+JL ?4'C>#^&+-1GLKT<0P\#6W3,F3CM7V9U6=$#TS#^
MQ_.1^$N]>.,+S[2YOP_X-#+.-)Z.C %DUB(/C,OC5W;OY;I7SC3>AS][(+:_
M%O5L>^GR[K7+4Z&M.PLVU9;H&P"]K)=GI/HB)H)"R.SRXV^Z1Y[K%^_"R?)1
M[XL(VB05K&"94@J44*@[=\G$S)B-!I^2*;E6>8$#U-C6\4?PCPDOB<YEA[^B
M]S1G9\G1*B3' 5HD(?[T%@@4CXG>#+W+*8*164R-GY)@D;G/7D!Y ]CZ873+
M;K+HC&X4.*..VW_7E,O144OMDZP'L"^+*_LJRGD-RZ6H9IXZDWXY?GEA,H(&
MG!7\O>.81\=$L^3+EG#YM'C@7?+HY[<A"FU,)XR''+^>0^*-U2'KJKU?=XBJ
M V99Z/3?'SC,,QE2L*Q%C6%V6'ZYC7D953TW2#W>#Z)O3%&:[$3%TZD;RS P
M,*/7PI@3*'Z>K8K]7HT+1R3*AS/X&J3_=?D'IT*)RWSS+1H(V%>NJ\F-@/<'
M_A+\5I5E_6N2=:!&K>=])OUV=IH9PI9WB:^7?0:BSJ2\"I<_^:G(U8>1 [*H
MCP14]#E5@BISN?GLY]+)S6EOL:?(A67N5_#U4?*A&R[]L-JVL:=G,U=,*ORF
M5 5*J.6HN:R#?D*DBIPUM^?W8^S7QR13365%@T<$U:ER&;Y1<2<Z<TNA?%?]
MHT$'LD7'OZTONQFM^@3JZG#SL>P-OP%!])'C+K8]V#KO&L8?\$%3AC>TKF?R
MZ)<@.^S0E7SU F3I?>_9QN<;0"UEL'6:MH;2]9LB_/HTP;YB+^NN[>R2';G,
M?'.;AAWN.3&SX/LM\Y#Y8X5'/KZ"+1C9WL=GNG9JP6:*?]C')Y:7FUHV"K#-
M. $J62$_@TMU'JYQ@]1X&MQ%A-4BUY\ /V"&B*(!0S5;GH?EX]E8<:#1"V=/
M,@$#$,Q]&;8Z;)3R7;-/H@_Q2*60Z"RHXNSL]3>JH@GSWN,19!G&_\@YBH +
MW>\4<C%=,9O:L)) _[)DV,'Y Z0Q@5!R@X1GL2!6XW8FXST>YA_S[=<M/K.3
MUMB>4B,!O%>UA,0!.M-.05ZB/49R(OT!;F^;9V>_<J+*)AZ_^F%^,W7 :AM<
MY#"#_KY7,*:D''#*RQ]D>CK.W#LZ-^-X@,K2(9;$#6V(2MSNR7G/E9UFO!D[
M-U0->BN\W+,1'8([,-U\E<E"PYT(2]_V@$(90O;$L0@R92]A-AOY%3O!1#<W
M7 V9"\4!\6)GH,<N68,Y[J_Z['T0>N(>G&J)W'3-:/CH4K+-M+K/XR[IBV'O
MY%'ZW,;%QV'7[A^&#7=;0E74YYN 4.8=NDZ^ZPE"6OQO!&VG?ABM%#&Y6M08
M$-+%)(V\<?<D/!R[)8&=Z1+A=XTMI=*>S1JM8C9MT.DJQ)UV+O2*])#\84D-
MLF8,2E(+_:)+K.$:W/;HX=7H\ S<8,#UU]F)H+")$Z]4:9?X;+U@H0QTR863
M6F-9@K)9S6RVOW/1N_-0-A6:_:#@_I#4<1%S7(&<>FFL9OD+-=V<C.4%B2:5
M'&K"WH08!^A9^DC1Y%QDP+W%J+SE7FY>!T6G]D^BAXJF]#:;^&"(^FX!^O6D
MJX=1.D?<Q='BT>?%0: 7N,M'4+Q3LW&PK#+P!D#5VK3X<M<4[WP#@&74I%&<
M:PZDI@M@P99^Y\U?7ZC?G>W= >5?NU;^KE35:>%1>!IL;NOMNWZJM8KYPX-A
MS.R5'%G<Z6E;9.&^X/@DR>WUAQRS;+QYX5:^'\73$=JV]^WPO0]>-B%@HMU*
M3H(S9/A#>1$/U;<%D5@+A(#SDN]/&"*J*=D[AT94<YJ]R\&I1!-H:BY@:AAG
M1/FH[#6Y?H:,"NE;_MR\MPSFEL53ZAF:1,!\HH,ZF:<LBI+'+,&_4U-E(V1C
M!G>37"!?4]^*HNP_M02A3[%#0R>W[XFC*71 $U2SWQ\Q>#G=/@';DW9D,C[:
MOTPFNTAZRV9&(T7%.AWKQ.H,SC1 E+]S,AXH(R1+?&[.''5'.B5Q>[QA2V_!
MDN<<88_:8OQ^QTH.);:&#]RX 8Q'*#;C7VRE?,OA$6[:JA5)05'^H,GV<BLV
MTCR0(VFJJ>SMM35O-0IFM:N+1,T_'/&H32:8@DT_GNWF?#" R8\9*2-1Y\%^
MA?DC2&=[;&A62I<8G;R.YO>1[SBR,(RR[CZ(+?+] T^?<ZU?31&!GCB!SW%8
MORU.^''."&8&;:"G NWS\99G4A!ZE)K<,FLX.VC L)W\3+03JE4?GJ5:!ZR#
M6S=]X)\<T1&=]##6DN"/'..N5>UW@HL^J.$,@)$2?"0X-HX)#NSTB_2N^XZ>
M: F-GE_62Q+? ';Z^3L&)J=*.*J74P_2FX,\R+4'MA2Y"AS(&YQ^/Q+HVO/
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M]9\!_G\=R?_6 /)_%;#\9P#(_U::\9\#(/]:EO?? 4#^M0'8?P?P+_Z6_SL
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M-JYE30_N/$"7BJ9\*2(E*J'2M7 L!V-")\#G=WV$#OUHRN%ISVQ_7P0J4?Y
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M<H*WRWGV0XR5L 58.^T-++TBJ.%,0*%H3=G2+U1T:X$ZE"_Q3#55OUL<3#<
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M_(30&^L.H[-AQQ(@A!L6*[_SA@.-Y+>Y9I##O"PBCS^OV%S;@XA['6CI5^#
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M>U>CD&VD[!_AT?8&@]%[CG3SCA#.,18VCBI:V:L1$>US8N'L_<E!3&J$AY6
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ME'B STRW 89D7HV@43-[T+5I%PT%S+104+2]@-4-C@=0^TJXQCX;RE%/83R
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M(L=6N*W).&_36F[G0VEX>]GP"F#<>WO4HS:!#1\*O_?8&R*D'+&;./00O^7
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MJ,$;4P$15:'FA,"\721L+H^[Q^CDZ<[_PQD_X*5="P-+SN:(X*MF !C(:LC
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MS\:D41J5J&H[X0(RZL@@-% 4SJ=][@ LL2)-RC.%#_5P=I/1Z8KUX_257;2
M\M?VPV\F<H/X?W/<T/$VOI[U!>2=37818%3R%8?\(-*FGE"OQLG3N$M5L:Q_
M,VRH?SV:?<FV%4^C8@LDFK*SC"P[K^GA_ 9.+;FNJ37\WMH@]<=*U+\:3A_R
MU#0Y2IX[."*D#RM^W;&?=_'*M^\W'<F?PAM^?MVZ,WA9R_^L2I:+],=VN9S@
MNJ=L_R:MNEE8=VM0;/-E_PIJ:7# F9L> J.C%]T.[5SH'] ]AW;0+!HV0]$"
M$#7@6Q%*-(4C ?:!+H7:^&H:'DH2LU4F0-IA^<.S@&N+^0G[_]+<>T<UM;W]
MOG'CMB-*EQ85$!$A%A"D)#9 0(B TB%;42DQ1 0D0DA4>LT6!+8@H")=B$I3
M2D)'17J)!"$DD0Z2((0E:7=Y[WC?<\[O_=USSOWGC/O'&BMC9HTUGSG7,Y_G
M^UF9<V9<HF7B $H:%\2TR.3TMK-F+(9U!58&I(>95[DQ:>%L71OSH?SPB!UC
MG]YC:T#0$0G%D)X(*;E?NW,W<X6U;9XZSMPKU&K#Q(90'Y:JC%/]NWIA*O'Z
MDMU@&_;5A*O'YCRV'8GSHZME1)[V>$RS#JW+E6C-^I$3P)H?UD]<N.&.&LDY
MPN(M7QK\4:TCM5A^;OHSG<6WX5\Q9(S2@LZE>KADCX6XA]=4I6>-5_RE=FEI
M7^K!_G=O(0+DOP?$.>ID#6,%3=U-7'P/A(LAEQ%JM)-@"M420YZD$IMW$!<7
MB/Y20N^\.(-!8C.&^IU&4!%#1@,YZZ+G!#-R%AOZZ]#)//YFXL;=I]]GJ"N'
M.XFT/"%EZPK77-9YA?GK\'^PO?-:B!BRV5L,23-.$WU>;R/./*>M)**&:8*]
M)-&E>21?A[%7#,F-1#T'?,0034/AX%O41NB."-AV,.N,@LI5DRC4B]_XC-N\
M(8'J(@EDM_+> 26<&5XCT#G9*W5V<KU_U69Y>^<->N[#H/MXIY]-<+FA6S]_
M> \OI3IHU3\YL,>RYEA<J-Q18O'T+"'VES.7##83#MHS#ZR+(=>@FW_S)L<S
M(C/QO<<I6.P;6:Z^'RTJ*.MDTA%SZR-HB7_,K;2&M:U0E3ZU'55^SEW'..5V
M!@??KGY_DCZ0VLIR(-1@PDZF@G)A#@ ='$X!14:+U[(8DCE$; T6@%D[#P6J
M/"8L5 SIF@=&$D0X4=MGXBP*E"_-]H@3HAXP+?;I0@5;-Y9^K?N,HCCC"&7B
M#*T) =B,BR$K&R0@("^9^G-A$BK0_"&&_(I *?5;\@XY@@@N@(EVQ!%]_B+.
MRI-$$L)[ G[E(OE?+[<4&"([&+_6.%(BZ76B@$).]LWGRVB+(2\(H%SZ\P*B
M\@UB=2>HN#:)Z@D1H^O$1U3,<K*"2)]S,XHWL7D/"M?9XN3XC^#DO=3[AKGJ
M TNW5KXN),D)2E#><G^1JQ-JCA'?K<V)(7]@^^/(D^>9RX(G4 CQ*W^2*+31
M#Q/Q:2!^W!=#5D^1OS6H-E\[%ERY%MTZ\+ST2M>S8:/#/XTZ%?/#L0$^6,=5
MO:VM?2^0QWGZ+Y!9.*\ <_1*1R-Y@D:\/T54>94*BR+NN9%@=?"QZ<EBV50M
MW'>+EFNI%VX&7QM-?ZA6_4LQQ RI)3KDE@EVS''E9=0&0*9!4Q[D12'V/-B<
MQDP^#_G#B@5_<)>X0Q#I._5).-2(%+Q+HPGI@OHY28=71MF:EY^Q<BUR\@^E
MCR#D,$^Y$UK6]MWO5@L.DQ>G*OU0"U>7*K]Q&2G4*C-2$W'GW :O_":;JKB@
MMG_HASYV.P!KSMS3S8+*^#LI83KJR\S1@14+68<BB\;FE/Y,YY'#0TO]:YK9
MM2D]'<I="\5_*:J=%I9@&B30]U_/BS8#&Q,R'%KT*G&?P(;KD2L?(=W%1,96
MERWPMV6WTY'Q#8XO 9(S31^[V"5$=GCM ^Z_ A@NG'L/_T"[-1R< !51HN-'
MX6OX=B"/W=NBZ\P40V(QE'WS)[W&W3V^ 4'LK0]_-+A.CM__*W=\J7=LM?N\
M#1?Z:*U[WX"[4+U-I)H;7N,*JW(O<T27[NR":HR((3YDNK$)-H8H]1KOR@EG
M(9JAL6%Z\0:T*,IA3\&MOFJL"HYMQP6].[X<B_<[%>W'+L';<-A-]L061)%
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M'8(S?0VZKRU$AX!K!2Z^7A#@(5/Q1Q5I!TZDBFT[.38_N+"!F1PE Z:>'J.
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M7]>%Q,5L_D7\;6"<?PX@+'>N "9G.8@V[%<LTWE);K)W$TZAW5ET9+ J$9F
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M0"L##B9=IZU2Z;A_4N_$-N4]2LSW!$+@TOA3I-9UD405X'[_1?LD2;+UE8?
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M-#2'#U,^O4OY'#C,2L-VXJSV$7;3J[1"7ARR]Q-RC@J?JVKC-!O&B\A=N_V
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M#7N9-@=Q/$T#A9PPZ&-G(6[IIQMPCL&^=RT1XW7QC,:3FFSC-PBII24SX("
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MV7D$4JY%.<@0,#V&GE1@M"$HX(2G-<</%.8%&1!F"KWF69C!CM=IP;(C1-M
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M_ O0S_]SDT&@ #/HY_BC<R<@MEW.8/"^\I;5&?C_;N03MUO*75)5":$4V(P
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M>U<SIYWH]'W>=RZQ3-]#*:QC?*WM'.7E<:H/U97('/.L(!Z-R+6:5#9C=T3
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M3B!/LY\#PHGHO5N(7V0!.D]I9X6PTT!(C9TYE:^AAIVF<H0803]!&<4GFDQ
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M0+T%<!W);D$YPYD&5GS ]F2/;C\P',L8+H+D J)%$]W+'3=XF:.I+&+=*#K
MMIOW:>%'E]X**)"*+^!M4G7TQAQ?'+"M576HL@B'H#HUL,L?M1N@O_X>W4/>
M;)SIN(G4 XI(N;TNVJ21R(X;5'4@FK@0ULOKL_AZ!<6R<<BQ&X=4H0FW3\E1
M-8C;G+N6B<YU'6,[U4)3)?6YAM-%[778M/XCXU:<]];-/K$\2<S-/T&;4[AE
MJ9ZJ (XBW7ZY J<*)3'K+I<>10L+4Z:2#3V3WF5%,\XG#.@XU]>&,6)LILJ>
MYMUKB%#S3-YHX[NP?MFK:^MHPX1*<)4IDT*DM9!I/DQG_#12P?\#KUR]J@;6
MZ7_>7VN!8E4T10^/3!Z<\N#_Y)7ZR*>FCJ8_X;,HRO:1)G;OG@RRNK4)5?[X
MC^IJ.$5E>Z6\FNZ_M\-;_'__;F5,;!D1.WC_DM@R]"\[1NZ09';,)_.O)G9<
M-%T9>EH;VPE(;\#9!\1NK@MBC[X]PCU\Y7J&F$#) QH&<__2$)8=Z[8[&[NB
M2YX.%T8R Z%H1.&P41S2S^?=;<)(7*:EH,CC"8@0XOY/%_7QM?-I:QLTP2;D
M<N8MCA_H(S#R'DE#::G^8#OYZ#95,TJA!'(50'_<@#8PX[YN%XL_Q#CZ)5U=
M0)K7-24^[(E_3W49SWXP>,_JJNU.OU1'ID=JZ>5QN^RI8@Y/ ED^1HY18!KW
ML-@A EYLM=.B.%29[MY0)CE"3Z>\MJMIPVK9^7!U5=J%*4A>!E(^5;^9&I6:
MA%I^=UH_OJ>R4<' E2,CSX0MNDWL1<V0:B0=^6^"MC1?%A!,C@/JO\P$#N=^
MZV7N:9<4O"EH<2N!@*/172)%=OTZ+00";5QD',6YU<#F8C.P32KL5H=&&+^%
MP'O)L5^*>[$73=J,F3;*R,?EO_L-QV[<1+=LB3F-5>T?\]F,HC/ON%5M-!U:
M;]X1C-''3%:+UK5<WNKZ^J# ).GVW)%C@V?M6\DA:1=G0U5X0>/9:F,1CXI6
M__+]*EZ;(_9/Z>CJ'-\ML9>#XKIMG' ;&Q.=&#>=3)4H"P==JP\DQ%\5VH)W
M\&-,R]-ZVFUMV!*@=HGX#]",*J4-8B]W<&^"K[3Q$>/3=,BV^ MDWU*B7)Q$
MJ4K1AZ8XF;TEYJT"?@SIP\LJ?(#(<+R'-J6QT=NDE%(DDX'OSK'&[I91V>[0
MZ*X1F %Q5*>)4:\-A ]R#DA=UO*:Z2IDIYY7OC3U"Y/_>-?4Q,Q@FJI5V><#
M4RDF0-GMZ1.K179EWDUZRWHW:('-4XR2-;9#H'B/;9$3T/DWQTTHC\*$0RRN
M6FY9KGLI,9R#-I]K"H21P838*&4S'D1(SS/V-"?&LZ&Y=XRV4AF!"!.5"[1Y
M$JTCTW+C8-2Y 7-PZ#&[SW.:!EA V(S*.D.)/\Z#7 'J>VA:P!39C.(-M),#
M[<;V81 P@C&<'2C Z9/0L4'SN2CZ>:K)&#5P.36.5Z68V%PVW;#U=^^8Z=2P
MHICM%N<V;!V2>\JN?6LX=DM4<#E7A+.2<K>K8F1P0[B_[)[ 6W?;X"5NA84D
M%AO,5$P4CUB4M$<YTVVRCW\HV3 BFUXA,K/*:]K'%>41%/GUSLKCVW!7;"_I
M,\9V]M-!;>TD]XMCWY=NM^=+WC^<S!1CELQPK%BNO'.H_+Y#\@04)4?Y0XJZ
MW,+<RSR[OG+^WH_C-&)()Y2+JCCSX79^N6H2A)NJ-X/A>/T"JN(9SB4=EJCN
M*!F=4JK->P*"I]*;"I)'?OF $[VW5QB#J\)'L."V"RM"DBDNCG[,R$?CM#.;
M^*Z8&\-2N;/9C<(6IH.&X0;'A1(GH',\640NFUK_+FJZXH7(<M%#\2[][:6Y
MVMBCX4N*.%6X[G*%F^JN9NW*ALY\1VA/[QR[+1Y+6@#3!]TJ026$@X[?TZXH
MF3Y\ XU'U<_@P;^$7YL-5Z\4@GY"M(!G-LJXM@TBSOO^KL';_X.Z]PYK:NWV
M18.HB A1JH 0%165DJ6 *"V6)8@LB( 408B*2EL044J D"A=6E2$+$&(] XB
M31&(D  VI(. $I(HTIE3(4Q)._';]S[W<ZWUG?U\9Y^[GW/^F ^\,,L8XQWO
M;XS?F\PQM&*6L3#"(*(&TVXY40/= &>9$DG+^T9L _W$69HQR+JISQ?OKNNX
MV9@[&]RP;;/?0B!4Y.CHF'S.>4,)V6/ZY$ V7+8$^1U?_.ZLRSA8L>'U??+#
MJ\,/"K3'M"L.]Q61VHSZ1J.J; Y'+_J>COZLTINV>EKRN_KWDX;7OA1WVIV]
M]?V.!#OCS#'EM5MF9"PFM>*79"0Z4=(F6FRH/'_(K_+WY>8=HU@XKN'X\U0+
M$!M;Z;S97]\T>$"JS.'2L:>/,^>-;!Z5[ABHY;Z4C/_> S:0S.3EL*#C.'HK
M;C\R'9ZHKMQW#AM8W, K8EE$+7U.MS8[W&]&3#3163<4'?Q@V523UBO[9>KT
M7G&4U6!M,Q9=,[CD9_[&L:]NJ^P,S:[?_V)+=7/]G:O&B5;//=.EXL]??W)2
M(V?Z(>CLHFA.91\_ 0LRU9#PO4&2\3[*F6?TM;A!7*Z."]309K:#&*M2F#?1
MY6X5!QKCK"RS3YEHL-!;SIT(G#8).VOW:[;J\/*OV;[*=<F2<Q7+<M=0#>4&
M.S6RX:^0T2WKP.[V;H0W86V/@=IQ52X[**@47>J3\>E0V-7,@NT1-A'.(Q\B
MGAB0MDRWG/V-C R_@?66?WR*Y743E=OEY-A7JV,VZSA4IR6M854=WQU>XA.2
MSE%4O%8B5M#8U'A/"Z>Q-JGIR<Y/MQ[>==]+V _E=1*GA+#U)IK\LB++KT)8
MVVNP*2PNCB>NLD(Y_OAK+FB1<FK?SHY5ZT+R(YO68.C!V<G"'K/U4P)"9AG/
M8G WE%;A+>7?J%-9Y2E-OM6T-[TZWN\20+ZU,YUM4>WKG+Z7.;A,'FXZC;]_
M=2AVS29T"J(NI!4QPOEBV6/BQ_)-MF)IWLX3K?TH@EAO$#H>I=P4LO][PEW(
MBDF*GJ]#RL\HQCJ_E9LE'SIDMK5O)+JQHZ'(5>M=YAG:,'T@>9NI2MK,ZP7]
MZ>/VF9;NZ/1]+<YESRRGY3/]=HW$:LC%M=FEX1W"G,,./$ES&=2PD7Q5W'[#
M.O_S/H.M[>%]J;8)?OF!JZC6Y$-N-OUT(4QV^3DC@:#UA(A"/P/5ZBH:8O#&
MUW '(:L7G+$E'94K4INM'0%?=0VZQ]MAA+:6!CMN_AAP@H-KZ.MGA23/BV*\
M+.[>";^)[K@PZ90B-C*A!34 _V-G/UX"H+4%AW6FX%U#=I5\UO-:56M/>W!1
M-R_TBH]ZX/?!'/Y344;A=_OZ$/$QN4WJLXY^L*&[$E3"/8]+_>W!^PW2$U$N
MD":PT[?+[,K!YB*>+D7^_8<2J_ J&9_-WU\MBN ;=05QBU@SUYA>!:RT!J!2
MFGZ5PKUA#2<9J*$[*<HF(3>0]X8-W?6@$M9L!::C$<CVD@WJ+QID]VJ[KKBX
MDR_ZW'V1)80YM%[4!M^3RATPW]:1'8KLQAUJI!S:^IO[K:0WW0B^OS]<<J:)
M47EUZ\>#<\C!8NIW4M<^AX*(.MIG<EY2Q=4"99/S7]\7O;%+I;>.\%:#B&.I
MG/2UT WK:GZ,8#-&8<ML]H%^O#&(XM2"B@]VR$:460&!3HU5K=1;W]Q&7WU^
M(=!IAJBL<,,]5HM27DJ 5, "15P(NTR,Q(@9Z*#;"8H]!@@YO#TH+P5/,C/D
M_39L@(BGJC1=@KF!L]0M3=8ZD\\4T]_E3  =D:N(:/T%C;XFTXMK\JV67L*N
MK9=XE/NDXH%CUA'FU/%T*2D#;R:0<,;!KL9*SL4N6U.^\MG] (52^^C,P!QK
M%RT798>-01=OTP?*_O#8OHA62 XHGJHO'U>,WH&6C/)'IMNW]138Y<LZS#C<
MNWX!%KAUU?:DPI?L1TY_:? \/?L'V,"[/2X*)=7ASD)8?T0[+/!-3X3$UX+\
M_]B;_(_L[O\]MF37VAY%9*F+SH^\*(2UHGA.8/TPRR(>=5D(BQHE)P:=,NA6
M\&FPPX5Y!4:XTA5'&^*R@OPP;8H-0P+I0>S5]-6%\%=5/-2UX6&Y5Z933^\O
M5/5*N;KZJOJ&:VGA=+3GM\<.#0V-;IV?KZBH8#L_:FB(5#CU*'+KW9VQ6^]J
M)!B<37:0%^O^\)>W26?H'M5/G_;%(I43VLVC0_=:;(DO<]&_F/LIO]3F],/?
MR<_7*>3V_QK O#Y'%=_?_V+B&NX(RW/^@%P;T^OBY_B2X.^SK^]OGWGW-76R
M^+-6_6+9QKVYSVQ>Y";L%?O%5.*S936JD;KR4@C;&"0/Z]9%+6CROU*9-B_F
M8*N;@E;M>H^>"T;M(TX44P&K;@F164[BE9FJF1@E4BQ%6:!,%,5#S#9T@665
M%WET3^-0JJ^[#!A+6C>8O#R>&!I:Y.QC%)Q7.-Y>,J62]?R#:V?$E? 2;S+E
M#\IC)9[J;!"0RG:*)APF]&$4\6J@A WDP:IF(23P1E!H+A0IK>D"$J/K2H9_
M'3+QJ,)E:>OF]^F;^EI'N=0!XP_RB@>1%>6HNJ"K_1>?]RW#9QS_4IJ[A;*N
M8]L)\F>'@^=US<X"<LG.YNJODTI[8X(_>ME6[36JS3/<]_RX=YO]_9*GIZVI
M=SH!3:G)T$%M(4PUO:/RBDV@CU'V:-/>H9(XV^2-?R3I[]^O4&!]7/)&:TG'
MEF0'NP.V;H>W;A7"=BWOXJ:^*LA-^!XUV_:W#&:?Y(MW>OW?)RB/9B+BE/5A
MM4Z?OD2B)G(86YI.LH6P,0E:"%6*L,VRF/!."(/C ]B4C7@)$LNQ@@D?O>%
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M(X0^+AT V]DJMM[Y*RH4:=O8V%WG2NRF(U9648+]-S5S'W$=&G@_ZN,019#
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MD&]KA@$COLF-)0UO&UT7E\J9OT$/:\G*\>)@O+*-?8EU,QD5707)#90;VH[
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MJ)@NHLCA(=0I\$M<I0R5^4R@[H-:S[/$@GM$'#<$\:QLQ2D)GY?DL2VPP^;
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M351UAS1=X]J,3,*JHK$FGD&[&LQT&X'!K^C<#[C<T%V9=+ES9A5:363_^9G
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M0?4;(2SS&-\7FA3"(GN%,-H9T1$ )0I4*(+-B]!O*.9YO)D0%FTL4"#Q]F"
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MRV*1E*:=AE8:N^-Y)]KQ@>#BO&;>!V\A3-KL1\I8?QQ_$,IDH^*5J!N6T*)
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MGW)I)5-&RX=1::KDN\^N'SSU<D(F_UN'\9<"HEDC]A8*JX6(=C3Z#I+GXP)
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MNY#3FV9.4""RY1G@?5 ET04<?-VZN NL(0[GD>4YX(=&K0H5XCN2_+H6S)[
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MDI!,J%VFMQ_ 3;.973$*;X16<?6X>B^H%3=$#A=->R4G2C*@$Y-J<%SEQ&O
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MB_&RYWS_<[>*W%DW':^KG3<J. $V;]-]3V06[72->UJRL]*%F5_!L+KU^&?
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MT[JJ9M4[5E$(_FZW(G.9V&'9UPA04.*&K*ZC53\^.^G^;T-</*N!*O O>,Z
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M/8+JH,@_P>;!=>T8*"@9XF_='1;[YX9E6$??&-D%?!NZ[CRS9I&,.%HRC=F
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MDVL226EPF#<NP5N!YP&6,Q@AL';ME!B/(N(%7/ (_G""8CK]RK[OMP)!].]
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MIA,S%K(2SY&YZ J8X07&\]RBZ,Y4O 7H)XSO9*HQ;*9?TNX2#GV>P6R)DIB
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M9\I94]?;W^.Q%EW]P31Q5Q9I^')W6LUU(OVEIZ=$T@H\'(L:&*D9^RR])MG
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MO'I:\NXU/$1%9\#0BI13SAI1D1_[R8+$YOX8P_9DXOES6\A%('2QGW,B1]]
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MX0IY7:+ FR^&*CK;OEB0@F9A&.Y_$A&Y@QYI57,U^2G]EO0N]7O8JT1I_7E
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MP*YV&Y%'TUI]_F%]ET_@-9SCYE_-^;*Q94;EV+>+O/%.E2-RBH<D@-IX;K+
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MY*_4N>_F.V6 Q_:+>EE-AG5@7)>$;^Q5>60I/*K=EJ5+#[F[X270Q6TAG&N
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M$>4&9^.CEL )GEXQ:I3)> FA-_8)7&YPPW8#B^5Y-VIZ9)ZTV;:S,F@:T#>
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M?QRA! :J+/N#07<Y[N'QN%-"=W MT6HIC:@R:K^K,IRVMW^Q\8^&/T8)NMS
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M=[07QV5BPPJ/)P1I]7(2X$P4X/7W[Q315@<Q;//^#'QIOJ&PFA[&'?B0N?L
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M9"*:9^/]\.+KP[[MP;>O*37SF[8H-6E*)S-&OCZT][,Z6J9SAF*:G_G@]IO
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M\$XXM \E>)8KDO,6PT("-LZ0YG<('*B5)'89_:<C05<,"[:4R+-A#-/G9[-
M[=79U/_*0??=)YP7,1L>1G_?/\5\)B032#JP>R9O/K;DJ-U1^K[+X=(*7:"6
MZ%='ES 05%MT)1K*??96WG0I8BP<"NF<.Q57$.J9$T@\PTP[#+MS:H.D*.&(
M-QSJAE:W&.;N@SS2B?AE<"A5]$XB:"K"$!E1GD'5__ZCTU9D"I#3!"$6:0);
M3J'!B9"&^H)./[]'+\/76VV#]%-X'AO1C=DCC[)WW,#GGOZYJG@E+@";.?$V
M[MS=.^&:ZS%K2D::J>U#V1?<G3Q4JEVS,*;/OODV#._K^"TI^/!AE_F/&J7J
M^WJZMC_( VD(!8RFUUE@9=*EJ]#UE4O7?JM9I][(!^4\K6</'WY]\HPG5^GA
MF?FSRF1T&D+5.G ^QN,V,*?NK^.VX2.[[N/C(PC'\W[#8YG^A3D/2R>S;P7J
MH+8&SAV\,.=[9?KXJ]&*X=K[+MS/9JLI)<$1)#_(Y/DLT2"5X=AYR^M",>@T
M5?M\+D@#'$N)<D<X E<U+:'4SLM>H&QJK6;0P +S"<BT2.$.3[<^KMW=='=*
M-$;:W7MS=/Q<P6>N^<@.QXQS_M>K_3W"<S,2*KQ4*SP;/5[=YQ]\/N[LQ_>X
M](?HQ8@PF>J;$,$-=WVH];RERN/:L[W:0RZ]F9G\@7)\K?H(5-^1"_E'2++?
MT"#$G0*WD#7H'&'<Z8 9TVAWLQ]+4;.LA?&RVIRRBJ"P\?+"YV'YD@=_QHW@
MVZ'LQQ%?FU\7H)D(I56J'!32/K5WY(6I&O[O\!Y<:>>:K-] WNG$$[3DZ$_/
M$@Z9F5L'FG3:>5"#P]2&OCA=NBW-VELS6&-0?FAA#ZWJ82A+V^X!T!_N6>CZ
MH'*XTE_IR=,*CZC+KD]K=>XEEGDA/SS-]BW^-:6J\FA7B]>WCN.%IT_D9I5X
MJ(=[5[B&/_N#<VCD8?BU!Y4?PI_M7;SXS<45>Y<ZA8",- 4%]:3/#B!9E%PV
MQEXE3I/:CZS&Z<(_SS!O+IM0TO1_NVA0W_;Z F*A=&VQMOPT)^5LT\F3)_'4
M#P2<&'9_+^D3#T8C]JDMKAF*3@M-VEF_3$D_[N6(84.0P<K>%D2)R$<P2YP@
M_8Q"J:/FEQF8]13\37HQCQMA(+LV=E3"BM88D0-UFLH??)TQSR^ 2NWW9GD%
MX2/#\-^2<UBR^-M*EQ\;W",&HVYO.2GWX4_T-YHTZ7W 8S'L\Q$)'XP4G24^
MY(4(<@_CA.10TAS] #+@:<X6%S;,!7GGI@M?.C?H<3R XZ;DBS0REMOMOGKC
M>PU)<,>O)_]HN:?R,RS"O#M?\Q0MY4/'O/?KAI&I#P$1AD;#/S;[WKO@(KL:
M>-57<QMGQTG#%+T1?DY^K7^AD:=78K5/^]D'MQ_NOQ&]WSI:SFB?__[I92=3
M&X/M%?NU8E='4%>J[*RJ?,Y$7ZD<]+Z>]2;0-=N[O/#-]V&#VU9DRZ=M\D@U
M@4.N=ZX+6O'TV(&PW^9?7<A&.^CLGVG63/5H'D&G]];8'^!KK^Z-.*C=]?)$
MRU.7\F+LIRF9<T15@<L3K)2];HUIBU+)\UF[P@9N[^ OZ\#=_9BYEH@<2DR,
MC*B95'[.*F:-GZ_>5&'=^* _T#5!(4W_=%#(H^KFORYZ>69-K$\AV(5O]@K0
M*==<C@>X-#R="!T)AM::9'66]CD%* 1.>4*E E2&O*UUJ]<UESV+TP_\'#CT
MK5 B<\W[,Q3I'N\:$&#Y/,B%7Z"@8**K;&7#E="T]XCY0M1;A=OFUR)J+S[Z
M^5/F]=O7":.LGM?YAR9LSPY9ZVEZT@8D?55KZ3/X8_KE<-3\3-#4SP\_/_\3
MHS'VVRGI;BN/K:^*Y!C[_@B^W%\]\/#\F>QPC];=%7;[G^F%.HP//=QKCF^?
M]/?8;[YN*>M:5:;3^]#IY,T;R2$>X0^^-F>%6[_?9W*$Z=(8X5G&L?BE2Y#H
M@LM^*:25C8JQU6MV1#-!#\E8I+:+X,?Q/:K)U->]\F[/8N#-]AS8YMP[UV%[
MBF![[F*&/X.&#[(^#'Y)\8LVV+#T8:?LS#$]Q<[I),>*(M:/D5H!NC"V%[52
M4R\8$$JQ<<#K7!$MF+3N80]BQH=$[LT\E# MMD^4J$ZR41P6HI>I,RQ^]5C4
M//WS1Y[I]O?7!U%WK:^7U%AKY9E]+9[<,WJOJ[A>ZM'U+;=W1F)Z':-1WH+Y
M&<)FR53%'!+#ZH;IJ[*;\4$V8MA[AX>D3R6DN2M[QOH)1U] %3Y-_0+;TCG_
M'W6WOPOSW =KOM-:_W)4=;>L^<WDMQSC>T4NF*NAOVDS#FZIO\1!:(0WM93Q
M'W-(*N$:_MI_8OUN^2O51N)*&SQ;ZYVK/BJ6OJ"8'G#>4\^X=2E?KO3^^=(<
MJUN8$&%^]'R$:G>N4UPM/L2M?F3!H*ZU'O09?5/Z>7Y[P)="IXB:5G2)RPX:
M8KCF1T0$M23B6-/#JG=Y-IH'W*^;<DG!0'<.4O?3E]D@OPPK]/:P?%0G2AV?
M+?#D473GUTG9]G(MO<G%8>Y<^&9_Y#T%P;G[ERK:OF45F0VL!A2Z+IT<,J42
MCI2\*(V+CER_$E+T7<OTFH5BZL?]OU]RAJ?4NM;L&WD0LK^NT_7ZDV\+E?L\
MHDJ./S@[.?'@>9]V!N;SQ^4O;PW?\7[[ZZH3H:M()[I.*\-Z7V_44%+81T6M
MWM]<R_RTCC?,G\U-^;"_YOIK/V&QZ%!N>]"!U&-DIC?>K],3__NYW]]D=GJ%
MCB?%[FA:[N.'FN\>T9<*WJ-Z00PK91P\/?#1]L? 8ZBJ92R%X,)IJD<KX^,"
M^Q%G[DR>,VPNG;-S"YK85-P7VI+<^.9UNEOQK;1#6>^U<L.B9&<"X-LA7]:Q
M_L8V7US2F#?>N[U((;$]SR:DDPJJ06,==J.YAMG!W+:MY[]]+G8(V5),LT@X
M8@,LCC[.I"L&!<[GV4Q40*EQ[)X 1C5[4;53'R$: U',B!CNCO'>2G _23MT
MW.Q)D?9P[8_L[G041V> -W 15!>,UH7E^XPDLS+,*>C& N9]_R]-E&TQZ"/=
M\5<*]_^UM>@]]X#:W$BV?(?5K%>245_/_N4';5E_3)ZO\GNRY/BI_\GO<]/>
MQAVF1UT;P 9A5<GQJ%F[NB=5/I6V2FXGL[SXKUR\R0WARC>J%ZN/>YT51>5V
MB PS'3,[?T(Q09D,[W^: 'R*.\+3?6O8N'/ZKDR_N$L5?R]9W734<DO8DW]X
M5U9#78NY>KQ!V;P.LA"@=S6M5V2VVE9-063.5.;3F99L:D:K<PP/7_0Q .!7
M!P,=&QQ^3>ZL'2IU)3UJ@]($I8R/,R.>UB7,.X[^X W_\?+-K]95E'=0$R:K
M-@//],]\]A)ZXUEJ[M+N^ZS2\WGY@XF8K#F/K#=MA1[A[KW)&K\T'^=T##),
M#<I\SD8#=;6^]@,%97[C/HF)UUW\SR3M[W[8NZ-1)3G\?21]F 7M71)DL;1(
M"])LJO P=)_^>S58*I)_^#P@3+0':ETSVUT]@]PV?KGYS6N4>25W>XQ"Z!7C
M@W-2%Z6,%)[8H"XM1!\YZMRS8?)!Y-$C"FZ<I-G^F" W.B@)%JXN3#9G?_J[
M#Q3#LC _,=.HU?G]$I(["1/5 *6B4U<K1/0KI/5ZIL0[.1$O$K/^^V_GGAY[
M?ONPZ][N!TRCAZ;W'I?FN*?^059Y+_]0&>C1>K1[;JO\]D+V)O>/A6_S8M9N
M6OZ*+J.^1Z2A=A"T.189\IQY5C:B:4L]M^<(UTJT&<1D$DR>$_8,(G= QF&:
M]$WVME1\%3IUO+< 6XHMDNL71&^X$(P!]Y'"U,362[PCA5YB6*?J><<7LS2U
M,6O>.KW,(3ZB/(P_7K@>GI_=]K!!<_W!K;"*,N'7WY[%V&9>4JMG7C&_XE>P
M4-=C>AWWDW?+R?L80D+G@!?IEXN18'N%J+>97RR&C1Z&$C&2<[>[D;ZF0+:B
M#U?($DM(SZC^1OW?%NM\D>35^T@&AG^ +,JO(L2DH7Z>O $7WG$3PSP&4=NQ
M+)&2 #,@TIK5-TO@G005?U16?^YX!,[2]MH4Z8);G:M#_2X[@914W,JBMWO+
MT.6FE\.7[)*S#H3[Q5ZIK@H]^& CHKRR'))1%[XEO[L4:6_U\J^_7<OU(\N\
MKF?[/WA3J'.O6NO]X(.]QH<=(IW>'AUY5FHLANFQZUYGT95W^&K<J C:7BGG
M<79VY)M/V(<G3WQ.]9R\\.K6?9<?A=QOVO&ZD>#@*&Z+"^=&.;ZPYBM N\N9
MP&UVH<Z^!ZJ/T?M_1$WD\E#;0E^&.7;J^&6\>&%*C99;NCP\N#YT?BPZ;B(;
MZ]-\_\AN,0P*7+>N\7_Q.*(,OQ0P8(^IQDM$6E<F#Z/;3L5F!G-)V^:"M-N&
M[(VJL_?Y]N)SO0*]XN-\FUK>CN$:XI7TO+J.!!P^S;(="(KE_%-RTO-<F'%O
MF6M]1N?ON\N\GH4QAPF-WM%>I:Z>5:Q&[Z3PPRV9?RW>YH=^T[8_<:'$H]#8
M]GC2F["A!U\KN_,+7 NBP_=YB523OKD[./PL*JO%#S%LYTO&/\_8O1EJ52C^
M%%8DUSA*C<H^?J3'H?72#6Z?\ASR:$-*AT*$U\? >&?O1G=5QW@[76-Z/?O^
MSY]R2\BAN&Z6!J9;I#.X4K"T%8]S&ZV5M"5",SSV!SFB,H!6$LE]W:#^Z-!3
MVFBCI;2+^9\_PYW6F >[RQPKRI)\+9TC>2M^%V[6J(5?JJJ*C+[^,'RLQ,NG
M^O#)6KR'^M<ES^6J'V6NC9>1H;T-WWQ>Q$3FGR\Z>!94*SRU'U]U]OE84NA
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M<6RC??B7(+56VTKGYFFRVY-?3S-J7-1\2_P^<FZ-(KL$B -\'0K]#:IBOI&
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MAH>/T>9(W,"LI:03*Y+^33(PU/@B, '>+\W+ V;5V+#1[?4?S'"J_&,F@51
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M!P-E(>4W+<K5:((TXJDM?6*[P51B$/&\K839!;/!> 0_&4T?I:SNPU3J\^(
M^ &6=H,\X*(,EP2'3BVP<('B$\"1XDO"1C1EK?'?J'.9:["4;QU@HM; %+@W
M1@/=%; .^#GX$[4LF05WS!_\QW2%FT+9D5J?WS-9N09+'4>LX##A&L/AD-;<
M ]2?A4F7UQ-S_Y;E4EY!;)JD9,I=?@M18OL#M7BO=W1IO^ZR[^WOBN>"?U+H
M%(<06=I[M8;!='L*Q8YS$KI^RM'[]8']:'&R\J/IFQ4S!A;[;*5U$I_=_1$Y
MIPZ3E7J8)?Y2(;)/$CF&M.$(6'),,,6"*.Q;VMP,9$,GYR@ A_ST1^@))A][
M3(!0,XI SP;"F'9^ &T$>O(M6V0%B.\E\"6G-ZR:0<YT46(\(,%58R]W.I9U
M^>,<"RT*3(NF)2Q"Q,JI!1@?-WLR<>- [_1:Y=IWO><,GKAHL?/2O(3;U'T-
M_;N/,27?,$X^Q#):5._RFS[ ,P%(/()U:1!6B1[@,!VI1&G(@RD]7-=:)*;6
M8!CRT'E305REGWD%5'D*M$HEN4"RM(;J@-(QGZKJJFU>4EP,(\Q_D)HQ%UT6
MQB!LA3J:!^<":5C'9KV0=++"H,;\6ZV*F>)C9X[I<2SZ-3M3[O[Y[N-BE>]>
M-+F6I^=2E1DB-O=4$^.)C5D>J *1+30D[F8?'NGBHT<4;X<@>SJ'&$?6J321
M-RS]1()B[#^":G%:RJ!L"?-/6"C3TM*OXF(8DHI7K):MXN_LO0,I?TB>X4ET
MYL+JP>U):_YEQMZ4&P<3][U]I=1V-"CB\X#M-Y4)%[]A\<3^G7L/'*CT'BBQ
M-Q/"0'(JZ6(\*W7]I$WQSF/K@[(P<\Z&S\\EINDE)*_;UQ->D3]W99HY;7_G
MS<G4 U;8&I0Z#@6%J34!<E/\G7Y745NGS!F=TMB1)A/E[ :6D[485OLS6:K?
M.( Y=U53=<#5->O&<J=I]^]7/15O2C4Z"HL[W:_O_96H+S5:/S=L-MO]&IO;
M!(@4L <;1?.@(^ 1ZB!9FPRE,HG"IW-] >0=;7'LFG9TMDX9:!VQ."_E>U>.
MK-Y;=_U>SJ2)5,\=;9G1(6C>%@0B2RIF9H3(?8X6+-QN,* >+:YU$W>";AT%
M.F/#T=)0:9M-#]><A9*"<H_WXX6QU8RG>,0@?INO_AX_J7D;_AC1#C3)#V*.
M&"DJ-+K8CGXWNWYO__M*5__WG<L?P96HF*A%9'2&=C17F-W68(/U5S1BE/ S
M<[C697TJ; $B*1@3:^M#W@UJ-Y+$9FK(N4Q+UR;#\<*PP-*I@35E;[ J4SS%
MPVM8,_+KG_V!9Y2W[;\N_2LR5\/8NSG;Y%ZPX<6?+$*T:F[6]O&CZ<E1YK\J
M;QF_(Z7U16VU-+96,U9SN#W)'A61="XYRRQJKILVH+L3"AWR+K[;1NVU*=:@
M()?V-^Q(,O9Y^F9<YY<KTM@H785AH8'O-+P_1:N8&VUIG$?6%^$[Y92T(JS9
MN/M^2Q,)QL%"$2;[( ]&54GIY1,!N[NY"HP/(TVR(0Z#*\/D J#85_*RUWVK
MU." @FF7_GSK(19]$ZTE@82BNFLGZZI3UF%#3H/K(10#_2 'R@(]F@_.N*E6
MLK\]ALSJ'4U4V:F??J<RGI,T*Y';?0C%=1F6J;^?[7GW0:[GTO?%-&+%0%P8
MB7L/=$PFBTV-:0T*$%[*3%^DS ]OE$2P=8RA?RJ#( FU494,Y&5C<K!V#=:O
M3X<5S)ALZ^F"7CD)$!65OIZ?PAR&P\XLLRX\><R.:1$3:LA6&JS;;B+C\@-"
M-ZWI/V""4<FIH!%3+A)G7H*E,I9SF+ZC1YK3R+K=_BB;;F8?"]2I&NY\J/SN
M$_OF$^\,J\K70]X9O*2J?''_2P[L[6OGTO;LB)SY];[AJMSR7A_I-QR-CS<N
MLMG8MSK%IZVRKTS5X0[V'^BHNZ?N7LC1C1HXQ(A*_MP?O,]BG;QS9.!%U'+[
M@26?F@\KZ1<;S=W+)/-6#URQMRX\]^E 8*[6?:<XCEG<GX!XI2TH,;PR-,&8
M'+QI?!XGPPRSHUJ3O%.>:2SMO_.Q[OD/5YV5&QV_AP,.4R^^DTLO+O!9SHB*
M#!GL'M'\*4 ,FG$E'G]ELI;E0Q(<^C0NXORAUUL=RJ;\=ABPZ3\L?V?>T\)V
M;'QXVPI!1_Z,8'8VEGBRA!H#9+CGP$U9T<1B[/NUGNGQEO-A)T,MSE;,*5MV
M54";?I/NO?&5+^GQSK!\U%?9[GN!/% Y9SV7,4"Z%_@&\^,L4"I 0+L&N<_J
MB,NN?%@[3KHIDEI-4M N D2L]<.U)7(MC_2(%Y1:WS(#V#6'7>UXX6YE,1(T
MU" 1X7 KTN,:Y2);=)H&2A^BV%+ZX&I;3BH*VE\8YCCS0;OXSX''+WJ7+Z7;
MO7B=U9>O=E> N)IY[E,]K",)+I/ K^2'4P+$E0-\.0J]I+L.S;X@0 R;&&BI
MU@3W<=<]GY#0(-4RS!YN]Y?M&FG06R]Y]R3Q0.E<Y\=,3NU_PU,2_Y&G7/Y'
MG@(K07;N\HT/4 H[E&G=[(=AHF+(*,BW7JKJ27YGJ9?;P?[%3]:-:6N$\%VU
M[T&K6D:6D%,O'S4EY8*=L+BL[C2H^+IO:4.0SOW;V"!34+7V]2TE94B_$.M)
MGP@W.3B*)37()U&2N)@WD"5.^>4T,&*RFUT^C+4P!Y.26A*U;M:UH\SZEL*T
M[9.=N*K5CB[+*?[O?D#AQ[1\9\*.A<4L7^<5ZI"&!D^""R,X$_* L2=I:N"=
M%WYW#Q=@!FSUEF\,Q!(;,KK9I*8 D6'SH%RHLUZV:]+P07)SAYBZ7?];W4X)
M[)%+M37L^=CQFFY(@1!'%!F'Q%[C=B5\QDCL&IPU#D(W/F%.F>S!7JXS&=/J
M-U9[B55W)/ E13'1!Z<O0'8<M=.^G]#G(AKGW@[1+O%7G,E5#_WR^?4%KO'*
MF1XRY[;'/[_:<2M!3'?GZT-ISL8;6;&)NT#1;2(7 _U375*G^XH3&NV?YIR,
MED\Z\+0(4.U(%VM3KZ\)?F-ZZ)[57N:57QGG? ]'&[YX8V#]O<YX>K"!XW)Q
MTJ[ 0C0F\F+QU4.Z10TE1IBM@*<K(;9&+3S G[P+"JG/6&FBR$*$S\1-=4?>
M3N+W]-&8<O'&FDJIFW,W\6OS3JUY/M0)[928&=8.KS@6Y$RX0+ %_?Z,6%\O
MF%P+XU>+#.$['88[(Y<LK:F #'<W4WLG%M/ WP@2D_A*4\-J<2)8S$EP)=%8
MDQ[JBH*<Q+9!UBX@*5I7@)"';G0V9R,K7#U[_$FZ8MKG!X)'/8X/Z'#P(V=Y
MK\@[(37GKEXJ9FOEO*27 +'11!V:8:K-4D*9**76Z\&,9W76;[SEJXCY7/MW
M$0TK8JPY=0O0++H"K3@T,B67O;E?P=$P.^$-K3W7Y[;K\)49S$Z^@CF[X 04
MRD!'\PW95;G>]Q@$&6P/%W>^J[0"G0!(W3EV6E>!(L<U3Z8RQ@BL3Z:62)-B
MH0ACA5?8^5-=?,6DTTN:&RV8#I] L64KBDRG5('(T6&G^Q^^&=/SMSX9NM!@
M[*\55. B5:CAD?@^/[S [85+DYE^UCUW\ Y;YZE:42Y5FMUQI"2B.#8_LO'D
M;;N.3R4W;>L9RL+=3_=3M[PN-TO*$DDR/O)UJBL)IP%6[F0]Y)S@KOL(;7HS
M/'4_K9"5=9(9YMMD:% +8NJUY;C[N[6W-:13A@9KB%%+Q&V^\GDF&N\S)N5$
M/3>EMI=F:1$+?S16K64591K.S[)"7V'-,'W6R8OJG;'96R%O^GPBW@"R5HI@
MJOO940%Q8W^<OEY681.3$RM ,!0&<::OO/&Z[!NU+*3(D-G&-7$"\^B-RKZE
MS$_JKN_?=8/Z+:CHC.6H8'HM$(4_2OC,5X&22KF7P4\QL2;ZTTH:H%4!JY:R
M 4MH4%*(H?*U^G"2 7HIC*SU,XV'?89_9'1D,3$*N)/1/9T6H':"W:R#8U<+
M"=]]]SXMJLY\%UMC@":'"V4GU%,VU(6",ES7O9TQE9@-6!/4%N_Y-U[D]88;
MCWB1=4#_*#I2" *:Y/,[$RK#9#0J>%8KIET5HV:8CQF=YX]9J2\;^!GV@5(E
M(MW8V5.LQ[UI>PXWN_<Y[$D2Z=]WH:&W_FW(@,>#U/.N3]I\W*?[7H#?[QL,
MQ&PU'(HZ9W\0S#>TGL9B+0Q>>)T[ZM)A%>735SA BBM,P**+VQ2WNTNC*[R9
M^T_JL)WBQ]39?=M =4;-ST*T)!]5RDCZ:IU8<>C#YJVU3Q?TU;6._WA[&+EV
M2DQK,4VYT?!K^()$L6Q$Y8F[1HYW8]L?=OG?.+KS\3W2'RSD90X]9_=E%S"M
MJ4Q\0?-]12!__2)Z'LV/[N>V+L)E)92>,#][-**7U6H].?]JA5.] QCD$@0(
MR_&8ST2V;;O)-.J[^G+I8\N BS7VT!'F*_</!#/)HZ(WSWKXY8U\VX"X.)LJ
M/G!T]SLJ=.#LL&]DE,27/Y?,1,Z\SQ-3;CO<6/9V8<-.,>6C29Z/MM-O;#LK
MHKR!MP@KE/,"Q,]ZP!?)45:"95[WW26N\-%-+R2V['VX\9J$^48)[*[D+<:2
M]:3B-0T %H$.-)Y'>H@ <?@;I1TOAM)>?"Y /"[?12Z\M39;P>]NOH?^5# Y
M$#--F@NE:V^ T/64C2:[IBB(Q3"U>KR2N?&1(JYF/TX.%*6W-'U?VJ^-/^QS
MW^PA[CK32-&Q25Z_L5VD [.UI#,.AV'X64VT_)R:*K0$& "2>X']QYNHA.]W
M$XTYP<OCFW@K;6,[LU>BC/59H9R$,#FJB1*E#/Z,.W:TF_'PYERDG,3D\$;#
MY%RES(+V>\9IQ<&!OE=70AS+#[3_$F(6-+*"Z"/=H%S+(1K.J)M&'5M/K@;=
M:GT!^JB4><#XD_/L]J7*1?W[NA4EA32S?>\S]N^M>N'4IOR]WL]O$\^4I=]4
M<@,MH?H)5&M14@:DL?Z]#?+]@W%UCB0HF3_3L.RVKZ?.4SQ"D5_]AG;9U=NS
M<4TI]:V%]]8$Z?2[WJI=<\KZ<ZMZIU]<EZJO>3:,73J9[!%3-',5[!XO(+3?
M^O#%TN9QR>G!!O?)P?A&%YF9-JDWS ,=1X-C2=!80-8O@[>!EYX9T"_[? R[
M'Y@;5=^6AMWYGBQUAU=Q6;X[)Y[DD)@EL]_FY;N.$OD+P:,B)O/@*^V8^Z<I
MLQ16F#)]IZ%95"4QG+]G()@48WBWC,FQ(,A.UP@US2>Z*?1X@H1D?N.8ZD!E
M^\E.ZK!B9WSE,1/:F;J^Q3:#19+X"&1G97@G Y.#G:'68!X"/L"PDS=%A*OY
M"G?T+RG Z+D&2@L0Y<O%8'4#<>.=DAOCHB4',.)<%+^OK#N ">[MSZ)%5A0G
M 1PK3:W^TE<]_B\'_1U _H4ZZ _8>2'3\D.?B2[W"OE#-\DJ/[<S%$2W. 9Y
M&R:X7/ZN:&J1QL*D+,ZP/("P:_ZSPZ(1WJ'W;EY;\"^5.A>$\X1: IFB ;+6
M8 CS[=B!][V>W6^YUFJ-@#PEMD3'-Y-0^6-*=FW&-\8^YMR'VO738;I:34^K
M3_A?>UA@_TCB2[G]]I-.\?[JPL\9UXIN&$2K/_<(NFGB$5T7>*?8MM!1^&32
M>85&IO=5-U5=RL@^)KL"G^N4%I(6=,XGZO3^JPL_SE\ZS-TLETI?*/J(W[W?
M_4!/L57:@4HGYH""F*/XNX57_$)7L;BBLJ?DO@KH$,/RR#(;'(LHPAVL> ]I
M,K(\F3%QXM$Z:$EL+M5%*'H1'?D86NN9L&:_J J<SM8?Q"D$E$"A+2'H\MG2
M&FZ>-C4+-S15-5A3 U7/76=@1+T&B9N-K>G?[[AF(5L$B"V]+IE-AFBJ,UX8
M:/!E:BHTCQU@K\3J9G:&)\H/,OIJKJ55F<@]K @M,34%/Y&CR;J]\]EACA<J
M*U8;D/)0Q]!L?A5(2"CYU8LSO\?2-/0%I&?8E@40U29^BRY*SJE=]M7C86RQ
M3?C L)AI8]J\4G78ICJ)45J[]*%7_:!<'->2)>;@%](TI@(B$W3;GM&C62[@
MF8]%4()CML*UA;F7Z78#_O.D;%&O5@NL/)WJ'_EV7_S98]N-$P[E/+_^[.MJ
MWHS=YU].-VL^J4P?94Y$Y\>_!H\LE^8'8V3L),]]\K:0LWVR5N$>2V4=DFSP
M8%^"OLUHD=+'G<[MN.G5USS^++$AR?%+?F3TGE*I5]03O1=>3;HS8HI/)GI$
M1=DOQ75$X?8*7WWGU#EIQA<;K\J88 K-G2W#C'Y/H5,B/X:>?G\#!R6T1/IS
M_+*82;5G+Q?5G>54*T:A"V>,S.?J.HUL/_7ISXTL-_;V?AVI-<%\OZE13KDU
M.K[Z;+A6#S="2>N$] /XY^3F+&$&CVE \\[B $S_)F S;S?ZYTR@' _[18!8
M,DU#C?#7"Q"MI"_H664CF&N/7?EK'^T^?.,_GD.%WP7\KU>27&ELV^^/ 6B_
M$%>BR$#?#UT)S!T5(%0>GZK/_>O+8'LD0$-#1K?UUG6(XO5YA2P!@DZ1MTR-
MF4U@5[E>S[I,\<)LS?FC'5 JYXLS@A);A(."#F]X-C@NLGW=@^,:R/]I0?;,
MF__U@NPNN'N;MYZC /&NM_5V>;DVK$#BGRV0 DJ>7H.\S8?\@D6D3FJ97WIQ
M_R=Q@I9'X6;:PP/(PO=]'3CQ6X PPZP>O2U E&V^+D 4[KC'\?_;6S$I@%Y*
M64BQ'C;C-P!(RI(=5ISR\2Z[XTD$IY8<P[]:0RG@ 8/L)@%BDU^X40"T#YA#
M;71M]"[";B0]UR@WP3"L'U[SZ^E8.#?DJ38>]##JTCX1-')-$VB]EP4,*2?!
MGNHXA>]<? 97/F4U6,,5"_^U*VJ2^_-5O#KG"W_WWQ<=C0*B@05;OCRLI<Y"
M8? DLV,P4\?_]I:G$LA8H=J+@6J,FA=S0"P-V?WNK)%KLXO\"XD30AOIA5N1
MN\+7D18C37;V_/1,Z9DM;U4OX_?U1SOGW?"(HH@<-J<CA*X(R7"O+Y+^X@Z$
M-; 1M>9V#KC,DZ.,?FCC4WX":P$Z)C ?#X=+=&LX?P"U?,88-O:KN1E("B#3
MYO7_Z/)F@/IS%<=,>I=%>,7C#[7L6^H)TBQ\3N'Y J^*1YN30UL]W#])/_IR
MHEG\XB,@//UOZ\7.B_ XC\UB@=G<='[QX3^_R$_0"P[7T,O6))X3:W/W:1G>
M24#O[^O:J.X6KD*U +%7=/DU["YM!HJ?9X(F38=34M&0?G;#, <&K,H#EX3/
M$3;A]FZ/'Y_^_FA,&>R5:/<UUJ#>.7O\ZBVS[5OK*85MBH=[K?[@OY9K9Y4#
MF2'W@K(RJ^8X]HT<$X[GC=$?_AURJ FYGFU\JVI)8# QF09=:4.7%JR)T>$<
MX4;P&XZ0>)?'-\/3PL2CRC;];79_;ZA8U/_^M<1>.':>0:WLE>5;/!) 3P(J
MU)J/N=JQ*;!8C\)4"!!SDH6X$V J(;+.@[4/=\2=A&]3.LAN3@D*S<,J' >U
M8U4MYD(<WO4R7#55IZT/!QUY->+ZHQ,YT<*55>.+2L*R:(Y7($#<F$=@Y>B8
M%C^@A:S>C3\R:;*_;S$!/;2R_*SG5V773:X,*^S Q 7?)( ^]L1K2C:G>&IY
M?%^I$B/CU^7=7CV.UEVX_<WNAP4(2:R% J')_=U18Q-?D6>);H<_:>C)1^F>
M*0HJ<:M@G'NJU3/^@EG:\VG8!-G(5=5&?3:VB?C,"-S^PTU9\U9.5,.%XKC&
M06+UJ]5]7;D[^HN-5%?=A<^UUGKAE6S<U@D08B?8&'X$_I  0=4'X7C,&D6Q
M^U";!(A)?1:*>P2 4V!U=' -!@+)#0_@WBH&BFM^.(#OA^Z<7T(F Y.)S$ZN
M61"![_$'<V]^T?$!0+V DQ,@7M(2 78[UU> F BY0!@FTA]FE9C%UEWT3Y/^
MZ.O.3F =^NCJK8*U_5420YT_YI?M]3-*2_[0AO:=C_*25/R+@,;C=/2:Y@<S
M 4+J?*8 D6D*,S?BFO)1>(J2/V#H>]:9XT5""!#1+R%M >($93LLD3*A00&B
MXS<!\D&&"Q"+"B"!OX.2!'!_3PH0L0\_ XNNMPA\E>?Z H1>S%I,"WKQ3* G
M7_DC',.'5DEU*VO\;S"D1F 6KBX 0P$0[,0<[%U*).V?AIM9"X!STPRHOP%?
M_P)5[CC[0H 0-]'CA@W6B;),04>F4&QT3 CG&+\W(X_V?;BU6_QYZ'*6$+VC
M^)K4S&RUPE5]D_OW/-N3A"\ 6]=, S&B$R8H#26;QN>;?1/X8VWJ88Z:'8=G
M[ZH-V>4FVQ7/'OR041GV8B>SP,3-Z>-IO5(2Q_I!G7;CD)EBG9L?]>-OQ\A[
MJNZGKY;OS#U8[\Y[.T._+N)&VQ:3;S%L=?!%KKB_][[6O![/I8[_!F5?PB85
M$@?J=\6BP=3A E/81/T<5^!/#.EG-5_$@(/#?Z7MI/AIPQ J8R(#K32Y:;"1
M"=I<1?V8.E,_MBGK5Z3\4Q<,E;)E,KU3\74)FTR]$.DZG>$WERN:>=9"9RL8
M$Y>;(D#L7-.;,#ACWOR1K&[0?OM'KIA=5!GV/C:Q4S'J\X5"-^<J2UL==U<Y
MAU0#^U1#^P,' I]D1AFTFJ5)^2Y1\K1L,CTOH5+=W^-(A]K+=*!T4;?7*,WZ
MJX%+4UW)CIF]J=X]#3W%MCJIYRJF:A['AV>=/4WV;D+O>56W@2\?0:?P-G,]
MX(@)8&$$"*,:-..-"8P/70'-:.@&'T;;/[6DN0 H=J>0 '&Z>HL P31_ OSQ
MYH;P<\!.GN0+N%K&_@X4(+[A?>>/\>/92,@;CH*?#W0I.Z3.(I 1@'RK"ANQ
M@3%FKO9 2*5/#T9&=+WHFST?*T&Y^-*2@A,J<GJT+>0CET8Z%<*&=GV(8"P^
M:E< MJ:<G?S!2$*!$D>1_ 1_&$ :GZ@*$..PJRY $_S8#EC;-88<_>L$ [3N
M2NE$5\6_S#$SKJY0/; F!L'1O)763.&'W/DO<ZC\[SG$'1P+\V5W\L]AJ!C.
M?A0<"T>Z9GC[Y'($B'MPQ.N1%GK9VG/N;&TSL/-A99A9H]O!JMX*@@*D[]#G
M[TKO;)YP]4-;@"9/WF!^O#_-_O4KN+J\*N-JBO)7AL@9PFY[](]] D3$O_U.
MD>DN?O]PP5C :A5IN(_ME-)+-U \-K.J/J5+O.8\KAZ1_]C3V2IPI^Y.\.K>
MU!M'C>O=1YU_F;0Z8L_UIZK9#?7=Z;=RU!7^0$L=64N?_)7B>4\5E:#\XN=J
MJ8V&Y<TLQH!G.I,M7I._M6784%WNS).B0LXYW.^=7W>RQZMU I:%_KNWI%,K
MR].P)Z>!>DVR-O\+ND*?BH[!5&27,S$[L8.,F-@[2-')@_@.8N6QI\.EI/N/
M2DJ>AK@4U"LH;)&W+8G3*J5'!::GF.ER'^K/G6 [E4N60"V;XE @'%2+:OS6
MT3!T-RGN0Y *X^9R='#C#E4;MRK@0-^;\>=5&]:YE&C/SFX]5F+H5'=Z?P?1
M>*\XMJDEXW#2O&QZ.V\W%!!;7JK6ZOMS53PX\T)^2I&][_7G;D:H<UD8$G-B
MMNAB0U?QEHL_GUYOW;__]M?#E7F9*]/JG_]%8.?^B_CG)_\3*A([:=.HG0)$
M]XXF(I0\@>*VC)/_T"9)V3]YA>0MI]AFVK%U]M+IAW7TNMO8,2P=VTO?'K7>
M8H^8J5%_A<;9CNTH5=HG:RXUMJ/@N@15/8_RSY6D^Y_J"/)O583R5Q717HOX
M@[G_.Y0G0_\79:C[7Y:K_S)Q-/XM<> >.&^(_93_@LE$$: ]*UP9H^7MO%3N
M=5" N BM@$ C$?G6^#H#B#$$HDNU\>OYW37OI],SE"J9G!*'[;U4VI:E>[OT
MTM:R$A,'S=>;3T1%Y5U[I+:4^Q<UKC\%>,R/M'+QQ/<%30FDN'9V'?8:]/,2
M5P?ZR/[#D<92.0%\R=$89OJ#.BG=@#DD9*:;1?L>8ZN'N88:1EWCV!.'T0^X
MP=_>SXXT?N,HIK+8SFDB)3N?VS9?AXJV?]-TM%!I*[QX$=SND[JOO;=8N#<C
M<23J[#FIBE<]_ FVG=:WPR3QV^=E/1\V7_\^;/_GGCVLL_K?88L"BS-91;W!
M!Z%8N^)-MB\8MN(7SMUZZJG0;$ZIA,D_-Y+G](\_87AR77-02^Y!+OL,(&^9
MVT^9AVW(+.R[L.$NP4& (--@WI_KM13 F1,@H*)@:<3HWZ\I'A?39X0D^%%N
M$N2X'FD]/[!RCKP,$T6N3AE%/JG6K95)0>)<H +FJ&WW(NRRF_'#FG)-AL8@
MK2;AWJ\,5Z_O;0$'"&_6"1W=1:?3(\(-(R;-/JU[FO0Y_-/M+<W'@GH>;/OW
M^^K]^USR5=:OV[7M\\8'YC,/9UKR-1'Z_^*B IOC8L/'7/D<@'\@Z7]\IMV[
MSY@C[C]&<-L1AY[L\KAKNOO7R*N:LNE;6$6CP794&8F*DN$J\-),_CHCLS__
M4TRB\29V&]5D!ZB8E9:[N<#7K]@[+5K]P\L^C=&Y@#WFXE+,S5X_;L<@''M/
M/3BNLAZ+>"1\[-8Q[&+^EXXCG9="6DK^Y:3S-^ZD1T1$A(LC<Q9-^BK^P]!O
M_OXH6:?_7Y[V^8Z1E!>>.W:TE!JRQAZ8!$%M;%8C_S!4PE'!DDY6AH<I,-1@
M5;<#HC4_:0?$*@;<4 .4&V@"9>M;?TW-\4"]7.-L#7 E>DZII\L8=+WT _,^
MP=<H&O-J^1^G'/$"93KI+?KJ@?/3#5UI"%2.VN8'8O\T^Z<2QW>%(T^*GUB3
MM/B/"3]%&'J"*@+$86^O_W3&RG]JA3XVM+8"VNG\45>G:5OG'RT%8VY#YH7.
MPQAC*<VL]@&BV.\LS:4*.=7]!>4)%\H>3ZN$WJFK\MX(CA;)OTXO\+U_(R?7
M9]EA."VUV&ET*B.;&"IRR07CO;*\,.PV-'IBUW[=ROZW/?7&5B+FTLF)(F72
MZZ#B8NXY:)5^3+]ED+^)E\??PST+H8/#. 9<!9 XAP)%J6X;+LN=@1B@W?)S
MMEH#*9XH 7A2O1F*RE2/>B*2KP#%- 9AXU03F@&ANKV@8IW8*PB_8D]FIS>K
MVP0Q:8VD88O/P!:T'TD(VL!JB>,W<32X5I"C:@3HT62BQ!Y,(JOZFFP'"0],
MY*"5RY"V=AR_-==+ AM!S9B(<SOFVEPS&&%LPPR '$P.=U?LNU8)YAV$%JB+
M^HSJ63O.7IQ2V> B*1I57@#KG@V3_ /LVUPC4#:.,;_!*\U%MHR^=TL<O9:'
MG.WQUE>2.<LZ:W?<5WNVLMJ^VM4&L3#%5^$E -<ZM^.,N\A2$''Y#G2LA'N(
M/58&,,7D/COR-W3EL[.2:XM44J;O-TQ>[=?P[%N2U$@"PH)EFOI_)HW_L% I
M*GV)$L&/H;?ST3A5T*QY?L<D#/+-FLJG(%<.&F;LDH!G&RHJ(^2AKG94QGSC
MG!Z+N6DB\0YF.'JF\7[P>'&N-W[7DS/L])BZ(Y[%8]B0$X-U1^Z5F+%S+PSP
M#Q=6PL4",_OZ\7C/,--+:<#Y9;2S7]Z5!5<+%9\%U]I-%SHWE)^<\&K;K;*A
M";NW8#:3<WC(FLW\C7Q $4Z:;U"P\$5&ZZ\H;6(OC>?0?8TT'2;<WE6RQW)"
M/0)#"TX4^ ZF&_[.E YZVAO\\6?_(NA7:%!#ROF/4^I)*8!O;7I/G3KC4\A%
M: )49Z BWP9?/MFS0D5MY*+SIVD[R(>P%+MW9^N$Z=8Q@W(NZ/C*N*5]\XR^
MI1@V*:I./:0(6^3KNJW$UU#_X2)&=F0&==DQ%G>-E\%?A^\B,9SQ^MQ=$ ">
M8WT>E.\?C-"J\V5\0E^J8Y>TQ,Y>Z34^H1\SKY6K[V(QDW&]0OYNZ<W7,9PS
M#8<\0\9'9!,?X*VQM<R5.>]\G"XTPD3'T[;KDJ( !<##^GL+G=!\A^T6%4#?
M#L>E!W,PKLX M&X<4WO"O$&4??AFBG^HJ\Z]!$*>@[9GH!]4^HF>Z,6YRR4O
MD=8K^&'LV)9C$4N)&!FR!A:U_)CWVA/*!V]0ST,>#-KW>5B#[ZS390P9;S:+
M(@N/#$&]+/OLXF+?JAJ3W&(LE8F*V]6-TW8/9CV?6^*X*E[6,?+3KE>28X]K
M_=8E% G-4CB&S\C;F[3K45&#ZFRWX9XVAND8I':"DLE8RHIJU$_3(TM_)+__
M\*%'<Y8T=W-)_:A?OM-<L(6ZINVH1]_-.?^<Q@H> 7U]!)DPB$+=)&_ ':R"
M^D,*:;[Z&&EW]NOL;/T/?<'[ DKF2]4&&\)J BJ:"J?W.%U+*6G#C)W=+77I
MV^]U[!#N-A:3,J=>R+7HY0ISS"E-1.0,V8"7N8A)E#^3#F(P$(8U@HPW_/V<
M24!.$B7X:CB5?K+4U'T_4@-QO7<""[7)=12W!WH8\!J; C ,V/W-<8S1?9!'
MLWX&95;QGA 5/<2A!]0GC ;80!;L& :%"C-\*0W)F6KR%K9G#/=(<.&(B[G*
MP%U]NRE9V?=5F1[&*]N^3WFUOAZR# K2S<\[_./\_,PBPN:T]+^UF)R)G4IA
MQP0($6XEE,HD)2L)\5Z2M/&R7&<H!1QIQ._H,U&!."RU!B.4.-:EC1Y )3P<
M((IP ][B#D.7#Y5W3PQHX VAF!9)W-$ $4L_EF]G+%ZKNM_8D862@'PM(-L:
MK02/M72,SB2MC#);QJ#%.V(4=) /,*(ZU@GZ8UH#7" ,W&#.3LXL@+)7FOE[
MPUT#)*":/[:5R?NUN.8E(YTJAE7EM]YC:"UE6IXI5V-W"5&)&XP#P)6+H-!G
MF/5A/9:?$IE:Q1Q[?!.L\2NL*$R,(N1!==-FKS1@E*;X>R%A/V2"\3I&P%9"
MS(I+P(.ZX%SN9; TBH%>[VO87)CW?08MCCOV9L/= 9K$2./IEL0Z/^8\I(K^
M')"8?1 J VLP\64P0?,(\BR&@;"4R!YII&S''\*9$<]"U^F6HLW#V5$,XNQ,
MF'8S((ES9H!OM2)RINZZ7$I_XN/BEKE33V]@PWPJ[ZD <>/#(C*6+%<%R;"+
M6J@"A)R69BE9=<K0,UQ'\4!GB]W0M/9;%W3<D_/O*_PNN$PO_/ 9 #O&M^M:
MM/'.[!OX<^%3!D. $ >N$X9:&'*1KI_16\G"N"-L_7!D0IT!JY^='EVW-]\[
M>V=,,Q[9I^/GVI"M6M7-B)C5J^F,7L(@O5S28L+\MMI.A:Q9$>_=</]0&7\:
M,4>6P!YQ@T+8E,]N0J UP=@<-&T<DV&7)KW"1C!1";\J,QNS=09F-5@)]J!J
MZ8!#U=V$H"*:\._("ZZG'AUGCS 23].Z)_]C5^;_UW;R^,;'",1C\\^(V["6
M1OQ\TI/V9AHW-3@D0!"-*#RUM!?VPY>',:';[EHN6_*^3L#47S24<58%%4=$
M/MP8CF;HLIM/[)0 F+Y]2F*^7A0)G##3Z%>O,9IE+>R;D7!:8\8]%TH_U:_M
MLD7O^6M75X69A AIU][V1V=LC\U\2K_5N?JF_?KUB1_ RR&@I:F%^W$$N>JW
M>TX&3X')_=:2DEP>>5$V?F!8#25$UD" KE0%1BZ[F?%)TE5H@_+1HSMD>)@F
MS)DZ.?%;'?>(U(2RHQ]_[7#3/I@LZZQYX!!)0U?.WC;5_GG_G;X?+D$7QUFA
M"[5._"L,0I[>D5@L8>\7SX8/-S6"+K4)/TA3-6@ZUY.ST]+G3I93SST_79MZ
M\[:4OO#0(/5+_$&8LO.MT6\V[+HB=?@^THU['VS?(933:0-%A*,WU*^0GO"-
MH?DFI6W0!$<&&WIVL+0"$,>904.@6@/^4-F9<".TE+,W+(A76I#RDRZ:+,MM
MY15NJNS2])*AD1$+F6^#+B??_7&/QW9.</!CM)W&FUYS;]26L5LB^*I85_I
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MOW36_]+TX$\AKHS249H=I$D^2I,U,:F_8Z:L[R;5(;HAD>ZI&(BQJ:\[)GZ
M:;SYM)V,AO2A8CFUN"B9V%1T\15P>T6JFD-\NE'.+&U>^6M^>\E'3#OH'V:R
MX\NAH;Z#W<W60AI[G.[9WU&VFSGZPT1FK*C OB7%,:@G<SSP5P^W;0G#WP9L
M%B"ZAAA$+FH*S7U^6:RROW*N3O]NB,3EX1]GWM<'^>D$U>M8'7Y_6N<\^"71
M9";W<';CX,+%=R=2.+&&A%4/.1(GE:?!_[I+>Y;&=MHGDLN8CWE@O^XB\OVB
M" (A_AFQ*2P]UF1'%SVQ>A,A_X7]M^L)S3R;GL*'R3(G#L@<^%/8(A-[.Z3
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M&=]X0,GW'O-D8Y28BE6\TX.S%[X)?U;;\5DMOORTSFROZVOB#]72C%"=P3%
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MBJV/Y2^;]D+IK$[?O94X;G\<I+C^_TT 4$L#!!0    ( !"$1E#F'?88=A$
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M2P$"% ,4    "  /A$90@)X:55-   #$3   $               @ $
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M,#$Y,3(S,5]D968N>&UL4$L! A0#%     @ #X1&4%] $VXJZP$ 6=P9 !4
M             ( !D<X( &)I:6(M,C Q.3$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   (  ^$1E#MA1+$1F<! ,I"$@ 5              "  >ZY"@!B:6EB+3(P
M,3DQ,C,Q7W!R92YX;6Q02P$"% ,4    "  /A$90J(-HSIBJ!@!PR%@ %0
M            @ %G(0P 8FEI8BTR,#$Y,3(S,7@Q,&LN:'1M4$L! A0#%
M  @ #X1&4#\!_IC+"0  4/8  !8              ( !,LP2 &)I:6(M,C Q
M.3$R,S%X97@R,2YH=&U02P$"% ,4    "  /A$90$9=&6!,#  ">"0  %@
M            @ $QUA( 8FEI8BTR,#$Y,3(S,7AE>#(S+FAT;5!+ 0(4 Q0
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M<S(P,3DR+FIP9U!+ 0(4 Q0    (  ^$1E"/;TW3PG0  ,U_   (
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M;FAI9VAL:6=H=',N:G!G4$L! A0#%     @ #X1&4(]I15_S'P8 I)8)  L
M             ( !UC86 &9L:7AA8FDN:G!G4$L! A0#%     @ #X1&4!4.
M\).="0  1 P   P              ( !\E8< &9U;6%D97)M+FIP9U!+ 0(4
M Q0    (  ^$1E"%#%^]W$(  -U,   5              "  ;E@' !F=G)E
M;65A<W5R96UE;G1C8RYJ<&=02P$"% ,4    "  /A$90Z3U*S>%-  #_5
M"@              @ '(HQP 9V%Z>79A+FIP9U!+ 0(4 Q0    (  ^$1E#Z
M?3GLKR,& ,*:"0 +              "  ='Q' !I;7)A;&1I+FIP9U!+ 0(4
M Q0    (  ^$1E"B0J0(R'T  -J(   6              "  :D5(P!I;F-O
M;65T87AP<F]V:7-I;VXN:G!G4$L! A0#%     @ #X1&4+DORFB"@0  88P
M !$              ( !I9,C &EN=&5R9F5R;VYR978N:G!G4$L! A0#%
M  @ #X1&4/"9:1%U/   S$<  !X              ( !5A4D &QO<W-O;F1I
M=F5S=&ET=7)E;V9D96YM87)K+FIP9U!+ 0(4 Q0    (  ^$1E (-F?+]1\!
M &=3 0 7              "  0=2) !M87)K971E9'!R;V1U8W1S<F5V+FIP
M9U!+ 0(4 Q0    ( !"$1E"L&\P-?CP  .E%   '              "  3%R
M)0!N8VDN:G!G4$L! A0#%     @ $(1&4&,[^;W3<@  ('8   L
M     ( !U*XE &]C<F5V=7,N:G!G4$L! A0#%     @ $(1&4%II9X Y/P
M14<  !8              ( !T"$F &]T:&5R:6YC;VUE97AP96YS92YJ<&=0
M2P$"% ,4    "  0A$908Q6%1I%J  !:<P  #               @ $]828
M;W1H97)R978N:G!G4$L! A0#%     @ $(1&4"MM"CB+$@  !Q0   P
M         ( !^,LF '!L96=R:61Y+FIP9U!+ 0(4 Q0    ( !"$1E 8R9ZI
M&8T   &9   2              "  :W>)@!R97-E87)C:&%N9&1E=BYJ<&=0
M2P$"% ,4    "  0A$90RH*ALR/Z   7#@$ &@              @ 'V:R<
M<F5S96%R8VAA;F1D979E;&]P;65N="YJ<&=02P$"% ,4    "  0A$90>C1Q
MI35W  #'?P  %P              @ %19B@ <F5S97)V97-D:7-A;F1A;&QO
M=RYJ<&=02P$"% ,4    "  0A$90H3NB1RHB   !)P  "P
M@ &[W2@ <FET=7AA;BYJ<&=02P$"% ,4    "  0A$904H''1RLB  "@(P
M&P              @ $. "D <FET=7AA;FAY8V5L86QO9V\S,#!X.#<N:G!G
M4$L! A0#%     @ $(1&4*M.)THQ2@  ,5$  !H              ( !<B(I
M '-E;&QI;F=G96YE<F%L86YD861M:6XN:G!G4$L! A0#%     @ $(1&4!F@
M^B]BW@  >QD! !8              ( !VVPI '-P:6YR87IA;&]G;VYE=V$P
M,2YJ<&=02P$"% ,4    "  0A$90OSTJJHE[  #]A0  #P
M@ %Q2RH <W!I;G)A>F%R978N:G!G4$L! A0#%     @ $(1&4(NC5)KRVP
M]P0! !(              ( !)\<J '-T;V-K<&5R9F=R87!H+FIP9U!+ 0(4
M Q0    ( !"$1E"P[6XOT1L  -@<   -              "  4FC*P!T96-F
M:61E<F$N:G!G4$L! A0#%     @ $(1&4 ?YA*ST@   (8L  !
M     ( !1;\K '1E8V9I9&5R87)E=BYJ<&=02P$"% ,4    "  0A$90 Z$_
M%@ 8  #7&   "P              @ %G0"P ='ES86)R:2YJ<&=02P$"% ,4
M    "  0A$90:]5R\)R%  #9C@  #@              @ &06"P ='ES86)R
M:7)E=BYJ<&=02P$"% ,4    "  0A$90YAWV&'81   Q$@  %
M    @ %8WBP =G5M97)I='DM;&]G;V$P,RYJ<&=02P4&     #4 -0!-#0
& / L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6872150752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (191.2)<span></span>
</td>
<td class="num">$ (168.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">225.4<span></span>
</td>
<td class="nump">181.6<span></span>
</td>
<td class="nump">$ 169.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(8.9)<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">216.5<span></span>
</td>
<td class="nump">170.1<span></span>
</td>
<td class="nump">160.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(35.7)<span></span>
</td>
<td class="num">(27.5)<span></span>
</td>
<td class="num">(42.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(77.1)<span></span>
</td>
<td class="num">(75.8)<span></span>
</td>
<td class="num">(74.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(148.3)<span></span>
</td>
<td class="num">(105.8)<span></span>
</td>
<td class="num">(95.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (180.8)<span></span>
</td>
<td class="num">$ (142.6)<span></span>
</td>
<td class="num">$ (117.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7048095776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 169.7<span></span>
</td>
<td class="nump">$ 196.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">460.0<span></span>
</td>
<td class="nump">606.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">174.5<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">804.2<span></span>
</td>
<td class="nump">936.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">804.2<span></span>
</td>
<td class="nump">929.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895691056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue related reserves for discounts and allowances</a></td>
<td class="nump">$ 1,198.9<span></span>
</td>
<td class="nump">$ 1,051.3<span></span>
</td>
<td class="nump">$ 761.6<span></span>
</td>
<td class="nump">$ 605.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue related reserves for discounts and allowances</a></td>
<td class="nump">197.8<span></span>
</td>
<td class="nump">176.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue related reserves for discounts and allowances</a></td>
<td class="nump">$ 1,001.1<span></span>
</td>
<td class="nump">$ 874.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6875057872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 5,868.3<span></span>
</td>
<td class="nump">$ 4,352.6<span></span>
</td>
<td class="nump">$ 1,365.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember', window );">Series X junior participating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember', window );">Undesignated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember', window );">December 2019 Share Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember', window );">March 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 3,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember', window );">2018 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="nump">$ 1,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember', window );">2016 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874324960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </span><span><span style="font-family:Franklin Gothic Book,sans-serif;">less than 90&#160;days</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>384.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>231.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>368.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,628.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>279.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>159.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>194.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable securities including strategic investments</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities, classified as available for sale:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,057.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,058.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>633.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>636.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>502.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>503.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>510.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>510.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>260.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>260.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,965.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,970.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>218.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>132.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>337.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,608.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,607.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>854.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>851.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>706.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>264.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>263.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,694.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,689.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>496.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>127.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>615.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: Available-for-sale securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,562.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,560.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,313.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,314.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,234.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,230.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,232.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,235.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>173.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>173.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,970.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,965.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,689.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,694.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable securities, excluding strategic investments</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6,007.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9,173.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,565.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895861584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Indebtedness</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,495.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,495.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,480.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>996.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>995.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,739.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,737.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,722.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,722.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>4,459.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Total debt maturities</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments due under our debt arrangements are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,500.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,000.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,500.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6,000.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6893410384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in consolidated statements of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>77.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>75.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>74.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>148.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>105.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>95.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>225.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>181.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>169.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>216.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>170.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>160.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(35.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(27.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(42.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>180.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>142.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>117.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>134.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>126.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>107.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NST stock options</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>225.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>181.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>169.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>216.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>170.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>160.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:67%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>27,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>53.82</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(15,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>50.03</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>12,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>58.46</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock', window );">Tax benefit and cash received from stock option exercises</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock', window );">Market stock units activity</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:67%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>180,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>371.32</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>147,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>378.08</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(101,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>356.71</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(43,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>388.68</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>183,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>378.09</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock', window );">Assumptions used in valuation of market based stock units</a></td>
<td class="text">he assumptions used in our valuation are summarized as follows:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:44%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:18%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;%</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.2% - 33.6%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.5% - 32.4%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.0% - 35.6%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.46% - 2.53%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9% - 2.3%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9% - 1.6%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$228.59 - $331.18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$279.47 - $346.76</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$263.18 - $267.88</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>$378.08</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$378.85</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$382.59</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock', window );">Cash settled performance shares activity</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:82%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>50,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(4,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>13,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceunitsactivityTableTextBlock', window );">Performance units activity</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:82%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>48,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(4,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>11,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceStockUnitsSettledinStockTableTextBlock', window );">Performance stock units settled in stock activity</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PSUs that settle in stock activity:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>60,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>317.26</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>77,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>316.28</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(26,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>318.11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>111,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>316.39</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceStockUnitsSettledinCashTableTextBlock', window );">Performance stock units settled in cash activity</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PSUs that settle in cash activity:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:83%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>40,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>63,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(20,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>82,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock', window );">Time-vested restricted stock units activity</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:67%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>903,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>303.18</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>602,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>304.44</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(416,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>294.71</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(151,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>311.07</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>938,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>306.55</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock', window );">Shares issued under employee stock purchase plan</a></td>
<td class="text"><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>204,000</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>170,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>167,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>40.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>40.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>39.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumptions used in valuation of market based stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceStockUnitsSettledinCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Stock Units Settled in Cash [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceStockUnitsSettledinCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceStockUnitsSettledinStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Stock Units Settled in Stock [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceStockUnitsSettledinStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceunitsactivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance units activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceunitsactivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Cash Settled Performance Shares Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Market Stock Units Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfMarketStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time Vested Restricted Stock Units Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6878502048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="nump">$ 27.3<span></span>
</td>
<td class="num">$ (113.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">1,892.4<span></span>
</td>
<td class="nump">2,239.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 793.8<span></span>
</td>
<td class="nump">$ 735.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">15 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6982212912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="10">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs', window );">Fair value measurements, changes in valuation techniques</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">no<span></span>
</td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 101.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.6)<span></span>
</td>
<td class="nump">$ 57.8<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="num">$ (11.5)<span></span>
</td>
<td class="num">$ (79.3)<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.7<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="num">$ (62.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244.6<span></span>
</td>
<td class="nump">246.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_StromedixMember', window );">Stromedix, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember', window );">Biogen Idec International Neuroscience GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.5<span></span>
</td>
<td class="nump">80.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197.7<span></span>
</td>
<td class="nump">$ 265.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueMeasurementInputs', window );">Fair value measurement and measurement inputs, recurring and nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | Biogen Idec International Neuroscience GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueMeasurementInputs', window );">Fair value measurement and measurement inputs, recurring and nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BG00011Member', window );">BG00011</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FairValueMeasurementInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement Inputs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FairValueMeasurementInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the changes to the valuation model inputs that led to changes in fair value of the servicing assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=116651436&amp;loc=d3e122625-111746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_StromedixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_StromedixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BG00011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BG00011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895829888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ProceedsFromMarketableDebtSecuritiesAbstract', window );"><strong>Proceeds from Marketable Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 6,007.0<span></span>
</td>
<td class="nump">$ 9,173.7<span></span>
</td>
<td class="nump">$ 5,565.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gains</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses</a></td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="num">$ (11.7)<span></span>
</td>
<td class="num">$ (22.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ProceedsFromMarketableDebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from marketable debt securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ProceedsFromMarketableDebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871620128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases Leases (Details Textual)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=biib_SubleaseMember', window );">Sublease | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=biib_SubleaseMember', window );">Sublease | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=biib_SubleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=biib_SubleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983817312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details Textual) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 112.5<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 847.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Payments for pre-combination equity compensation</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate', window );">Fair value, in-process research and development, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill', window );">Deferred tax liabilities, goodwill</a></td>
<td class="nump">35.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember', window );">Karyopharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TMSMember', window );">TMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember', window );">AliveGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 535.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember', window );">Remedy Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember', window );">Post-acquisition equity compensation | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair-value post-combination equity compensation</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair-value post-combination equity compensation</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair-value post-combination equity compensation</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111 | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112 | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Indefinite Lived Intangible Assets, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=117412053&amp;loc=d3e9972-128506<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=117412053&amp;loc=d3e9979-128506<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874340944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost, shares</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6978206048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 04, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005&#160;par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,010,112,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,064,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6882991712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Geographic information</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6,713.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,794.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>320.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>551.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>11,379.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,211.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>78.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,290.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>585.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>112.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>707.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,493.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,162.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,674.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,800.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,370.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>281.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>434.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10,886.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,903.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>76.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,980.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>457.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>96.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>585.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,152.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,442.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,601.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2017 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,017.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,844.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>160.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>332.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10,354.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,475.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>83.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,559.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>249.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>67.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>42.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>360.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,226.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,948.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,182.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895851440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">&#160;&#160;&#160;&#160;Acquisitions<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. As a result of this acquisition, we added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the acquisition, we paid NST shareholders </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$25.50</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$847.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for equity compensation, which is attributable to pre-combination services and is reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$26.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$18.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recognized as a charge to selling, general and administrative expense with the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$7.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a charge to research and development expense in our consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We finalized purchase accounting for this acquisition in the fourth quarter of 2019. The following table summarizes the fair values of the separately identifiable assets acquired and liabilities assumed:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>117.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(81.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>852.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of the IPR&amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with BIIB111. The fair value associated with BIIB111 was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$480.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have recorded an additional IPR&amp;D asset related to BIIB112 of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$220.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have recognized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets, which have no tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for GILTI. Goodwill that is tax deductible for GILTI purposes is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$35.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our consolidated statements of income. Subsequent to June 7, 2019, the acquisition date, our results of operations include the results of operations of NST.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB100 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired BIIB100 (XP01 inhibitor) from Karyopharm Therapeutics Inc. (Karyopharm). BIIB100 is a Phase 1 investigational oral compound for the treatment of certain neurological and neurodegenerative diseases, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Karyopharm, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB100 had not yet reached technological feasibility. We may also pay Karyopharm up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$207.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as tiered royalties on potential net commercial sales in the mid-single digit to low-teen percentages. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB104 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we acquired BIIB104 (AMPA) from Pfizer Inc. (Pfizer). BIIB104 is a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Pfizer, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB104 had not yet reached technological feasibility. We may also pay Pfizer up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$515.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the low to mid-teen percentages. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TMS Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we entered into an exclusive option agreement with TMS Co., Ltd. (TMS) granting us the option to acquire TMS-007, a plasminogen activator with a novel mechanism of action associated with breaking down blood clots, which is in Phase 2 development in Japan, and backup compounds for the treatment of stroke. In exchange for the purchase option, we made a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment to TMS, which was recorded as research and development expense in our consolidated statements of income as TMS-007 had not yet reached technological feasibility. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we exercise the purchase option, we will make an additional payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$18.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon closing of the asset acquisition, which will be recorded as acquired IPR&amp;D expense in our consolidated statements of income as TMS-007 will not have reached technological feasibility at that time. In addition, we may pay TMS up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$335.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the high-single digit to low-teen percentages. If we exercise the purchase option, consummation of the asset acquisition may be subject to the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB110 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we acquired BIIB110 (ActRIIA/B ligand trap) and ALG-802 from AliveGen Inc. (AliveGen).&#160;BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. We initially plan to study BIIB110 in multiple neuromuscular indications, including SMA and ALS. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$27.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to AliveGen, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB110 had not yet reached technological feasibility. We may also pay AliveGen up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$535.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and commercialization milestones.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB093 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 we acquired BIIB093 (glibencamide IV) from Remedy Pharmaceuticals Inc. (Remedy). BIIB093 is in a Phase 3 study for large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) granted BIIB093 orphan drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 fast track designation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are responsible for the future development and commercialization of BIIB093 and Remedy may share in the cost of development for the target indication for BIIB093 in LHI stroke.</span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as we did not acquire any employees from Remedy nor did we acquire any significant processes required in the development of BIIB093. In connection with the closing of this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$120.0 million</span></span> to Remedy, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB093 had not yet reached technological feasibility. We may also pay Remedy certain development and sales based milestone payments that are substantially payable upon or after regulatory approval, as well as royalties on potential net commercial sales.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>147
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*FR=-GOSCXTO@ET+O^ZB^P)02P,$%     @ #H1&4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M9;H2?S)=.:IL-UX4:M]VIS-S7O>[Z_ZBU:?AGX-H_/MB]0]02P,$%     @
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M5+)D/4 [)6"K!.:^T #A<4RYA\&.@,41KC81;/&<HPT3L&-:/:YH;&XJM3:
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M<.O$U"@%4^X9E%>E!1]5C!5.W_S:=FX=_,G3=J2M$Z*1$$V$,/DO(1X)\8*
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M+W=O<FMS:&5E=',O<VAE970V+GAM;(6:W6[C-A"%7\7PO6UQ^*L@";"Q4+1
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M'-P[T<#NX\A7-%HN:.'V#6"RD 6]4?X 1@QL5(^@*^0AZ8,AQ3VD9Y\F@O<
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M_F5C_RM$!U[*YL:/4.,_V&Q(J%PX?O9G,X[9:#CLIA_$YF^<_P902P,$%
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M_M>(#KR4W8T?H=9_L,504+MPO/-G,XW99#CLYQ_$EF]<_ )02P,$%     @
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MX9[T^!52/=<8I>*_PP6$#P]*?(Y*"QM75 W6:9E8O!3)7J>=J[B/Z6:?8.L
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MQG>[MTP+:6B9)]_%ECD.7DD#%TO<H+6P/\^@<"SHGKXZGF3;^>A@9=Z+%KZ
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M2+:=3DFD7JMIDS;IU&GK9RYQ$E2(,R"7[M\/2)IF6]8O@(W?\[,QV8CFR;8
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MQP_^;*8QFPR'_?R#V/*-B]]02P,$%     @ #H1&4(56/[NU 0  T@,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL?5-A;]P@#/TKB!]0[DC:G4Y)
MI%ZK:9,VZ=1IZV<N<1)4B#,@E^[?#TB:9ENT+X"-W_.S,=F(YL6V (Z\:M79
MG+;.]4?&;-F"%O8&>^C\38U&"^=-TS#;&Q!5!&G%^&YWQ[20'2VRZ#N;(L/!
M*=G!V1 [:"W,KQ,H''.ZIV^.)]FT+CA8D?6B@6_@OO=GXRVVL%120V<E=L1
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MCZ=]S$\)WR4,;F&3V,D%\3DZGZJ<;J(@4%#ZR"#"<85'4"H2!1D_)TXZEXS
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M'D&9(:,;>@T\R;KQ(<#RM!,U_ 3_JSM9]-BL4DH-K9.F)1:JC-YM#L==P$?
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M/KQLZG^-Z"%(V=R$$6K#!YL-!;6/Q[MPMN.8C8;';OI!;/[&Q2]02P,$%
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MEXW]KXSQ@%*2*QRA!C_8;"BH?#A^QK,=QVPTO.FF'\3F;YS_!E!+ P04
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M:%PX?O-G,XW99#C=SS^(+-^X? =02P,$%     @ #H1&4)N,1BDD P  O X
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MSH-*'-1PN]#WW=A/C0,EVZE7C.:&=?,74$L#!!0    (  Z$1E >Y%[VMP$
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M8+,AH?;A>(MG.X[9:'C333^(S=^X^ M02P,$%     @ #H1&4+ELYA6R 0
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M[[UMIC6;'*?[^061Y1F7OP%02P,$%     @ #H1&4((?C)3N 0  9@4  !D
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M; 5TNI4=4E!E^'YS..X<W@->6ACU:HY<)V<I7UWPO<QPY H"#H5Q"LP.%W@
MSIV0+>/WK(D72T=<S]_5O_K>;2]GIN%!\E]M:9H,[S$JH6(#-\]R_ 9S/PE&
M<_./< %NX:X2ZU%(KOT7%8,V4LPJMA3!WJ:Q[?PX3BM)/-/"!#H3Z$+8>Q\R
M&?G*OS##\E3)$:EI[WOF?O'F0.W>%"[IM\*OV>*US5[R>'^;DHL3FC''"4-7
MF,V"(%9]L: ABR/]1*=A>ARL,/;T>$U/MF&!;5!@ZP6V_[2XOVHQA+D+FR1!
MD^2SP%UT91+"_&<G=T&374" 7IF$,/&5"5F=#@&J]O="HT(.G;^3J^QR]>ZI
M/UT?\.G>/C%5MYU&9VGL&?4GJ9+2@"TENK$--_:I6 (.E7'36SM7TX69 B/[
M^2T@RX.4_P502P,$%     @ #H1&4-R0_T_4 0  G 0  !D   !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL;53K;J0@%'X5P@,4QU%G.E&33IMF-]E-)MUL
M^YO1XR4%L8!C]^T7T%H[Y8]P#M_E' 324<A7U0!H],Y9IS+<:-T?"%%% YRJ
M&]%#9U8J(3G5)I0U4;T$6CH29R0,@H1PVG8X3UWN)/-4#)JU'9PD4@/G5/X[
M A-CAC?X(_'4UHVV"9*G/:WA#^B__4F:B"PJ9<NA4ZWHD(0JPW>;PS&Q> =X
M;F%4JSFRG9R%>+7!SS+#@2T(&!3:*E S7. >&+-"IHRW61,OEI:XGG^H/[K>
M32]GJN!>L)>VU$V&]QB54-&!Z2<Q_H"YGQBCN?E?< %FX+82XU$(IMP7%8/2
M@L\JIA1.WZ>Q[=PX3BOQ;J;Y">%,"!?"WOF0R<A5_D US5,I1B2GO>^I_<6;
M0VCVIK!)MQ5NS12O3/:2;V^CE%RLT(PY3IAPA=DL"&+4%XO09W$,O]%#/WWK
MK7#KZ-LU/=[Y!2*O0.0$HB\MQE<M^C")WR3VFL0>@=V5B0^S]YLD7I/$(W![
M9?(=$P7!E0E9G0X.LG;W0J%"#)V[DZOL<O7N0G>Z/N'3O?U-9=UV"IV%-F?4
MG:1*" VFE.#&--R8IV()&%3:3G=F+J<+,P5:]/-;0)8'*?\/4$L#!!0    (
M  Z$1E N!7?NVP$   $%   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM
M;&U4VX[;(!#]%<0'+ YQ[&UD6]IL5;52*T5;M7TF]OBB!>,"B;=_7\".UW5Y
M"<SX7&8(0S9*]:I; (/>!.]UCEMCAB,ANFQ!,/T@!^CMEUHJP8P-54/TH(!5
MGB0XH5&4$,&Z'A>9SYU5D<FKX5T/9X7T50BF_IR RS''.WQ/O'1-:UR"%-G
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MS%[.4SD'6HS+@T/65Z_\ U!+ P04    "  .A$90VQ;>0K8!  #2 P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6QM4]MNG# 0_17+'Q"#EVZ3%2!E
M$T6ME$BK5$V>O3" %5^H;9;T[VL;0E#*B^T9GW/FXG$^:O-F.P"'WJ50ML"=
M<_V!$%MU()F]TCTH?]-H(YGSIFF)[0VP.I*D(#1)]D0RKG"91]_)E+D>G. *
M3@;904IF_AY!Z+' *?YP//.V<\%!RKQG+?P"][L_&6^11:7F$I3E6B$#38%O
MT\,Q"_@(>.$PVM49A4K.6K\%XV==X"0D! (J%Q28WRYP!T($(9_&GUD3+R$#
M<7W^4'^(M?M:SLS"G1:OO'9=@:\QJJ%A@W#/>OP!<SW?,)J+?X0+" \/F?@8
ME18VKJ@:K--R5O&I2/8^[5S%?9QNLIN9MDV@,X$NA.L8ATR!8N;WS+$R-WI$
M9NI]S\(3IP?J>U,%9VQ%O//)6^^]E%EZDY-+$)HQQPE#5YAT01"OOH2@6R&.
M]#\ZW:;O-C/<1?IN3=_OMP6R38$L"F3K$FGRI<0MS-<BR:JG$DP;I\FB2@\J
M3O+*NPSL+8UO\@F?IOV)F98KB\[:^9>-_6^T=N!32:[\"'7^@RV&@,:%XW=_
M-M.838;3_?R#R/*-RW]02P,$%     @ #H1&4!M(L^3U 0  RP4  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL=51M;YLP$/XKB!]0!Y.0%P%2TVK:
MI$V*.JW[[, EH-J8V29T_WZV(8RQZQ=LGY^7.QM?VDOUIBL $[P+WN@LK(QI
M#X3HH@+!](-LH;$[%ZD$,W:IKD2W"ECI28(3NEHE1+"Z"?/4QTXJ3V5G>-W
M206Z$X*IWT?@LL_"*+P'7NIK95R Y&G+KO =S(_VI.R*3"IE+:#1M6P"!9<L
M?(P.Q[W#>\!K#;V>S0-7R5G*-[?X4F;ARB4$' KC%)@=;O $G#LAF\:O43.<
M+!UQ/K^K?_*UVUK.3,.3Y#_KTE19N N#$BZLX^9%]I]AK&<3!F/Q7^$&W,)=
M)M:CD%S[;U!TVD@QJMA4!'L?QKKQ8S_JWVDX@8X$NB"0P<AG_LP,RU,E^T -
M9]\R=\71@=JS*5S0'X7?L\EK&[WE:TI3<G-"(^8X8.@,$TT(8M4G"XI9'.E_
M=(K38S3#V-/C.3W9XP)K5&#M!=;_E!@O2L0P:]QD@YIL$('-P@3#)+A)@IHD
MB,!V88)A=KC)%C79(@+[A0F"B5>XR0XUV2$"T<($PWSPY^Q1DSTBL+QX#+.\
M>#)[3 +4U;<1'12R:WP+FT6G3O5(_6/\"Q_:W#>FKG6C@[,T]DG[AW>1TH!-
M9?5@_X_*=M9IP>%BW'1KYVKH+\/"R'9LG63JW_D?4$L#!!0    (  Z$1E"K
M9DNOQ $  #<$   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;&U4[V[;
M(!!_%<0#E 3'31;9EII6U29M4M1IW6=BGVU4,![@N'O[ 78]+^.+@>/WYPXX
M9Z/2;Z8%L.A=BL[DN+6V/Q)BRA8D,W>JA\[MU$I+9MU2-\3T&E@52%(0NMG<
M$\EXAXLLQ,ZZR-1@!>_@K)$9I&3Z]PF$&G.\Q1^!%]ZTU@=(D?6L@>]@?_1G
M[59D4:FXA,YPU2$-=8X?ML=3ZO$!\,IA-*LY\I5<E'KSBR]5CC<^(1!06J_
MW'"%1Q#""[DT?LV:>+'TQ/7\0_TYU.YJN3 #CTK\Y)5M<WS J(*:#<*^J/$S
MS/6D&,W%?X4K" ?WF3B/4@D3OJ@<C%5R5G&I2/8^C;P+XSCMT/U,BQ/H3* +
MX1!\R&04,G]BEA695B/2T]GWS%_Q]DC=V90^&(XB[+GDC8M>BUV29N3JA6;,
M:<+0%6:[((A37RQHS.)$_Z/3.#V)9I@$>K*F[Y.XP"XJL L"NW]*O+\I,8;9
MQTW2J$D:$3C<F,0PGVY,R.KB).@F/%F#2C5TH5U6T:4K'FBX^+_PJ:6^,=WP
MSJ"+LN[YA$NNE;+@4MG<N5Q:U\7+0D!M_73OYGIZR]/"JGYN4[+\*XH_4$L#
M!!0    (  Z$1E#6?"THM@$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;&U3VV[<(!#]%<0'!)MUDVAE6\JFJEJIE5:IVCZS]OBB<'$!K]._
M[X =QTW] LPPY\R98<@G8Y]=!^#)BY+:%;3S?C@RYJH.E' W9@"--XVQ2G@T
M;<O<8$'4$:0DXTERRY3H-2WSZ#O;,C>CE[V&LR5N5$K8/R>09BIH2E\=3WW;
M^>!@93Z(%KZ#_S&<+5IL9:E[!=KU1A,+34$?TN,I"_$QX&</D]N<2:CD8LQS
M,+[4!4V"()!0^< @<+O"(T@9B%#&[X63KBD#<'M^9?\4:\=:+L+!HY&_^MIW
M!;VGI(9&C-(_F>DS+/5\H&0I_BM<06)X4((Y*B-=7$DU.F_4PH)2E'B9]U['
M?9IO>+; ]@%\ ? 5<!_SL#E15/Y1>%'FUDS$SKT?1'CB],BQ-U5PQE;$.Q3O
MT'LMLRS)V340+3&G.89O8M(U@B'[FH+OI3CQ_^!\'W[857B(\,,6?G>[3Y#M
M$F21(/NGQ/1=B7LQ[U6R34\5V#9.DR.5&76<Y(UW'=@''M_D+7R>]F_"MKUV
MY&(\OFSL?V.,!Y22W. (=?C!5D-"X\/Q#L]V'K/9\&98?A!;OW'Y%U!+ P04
M    "  .A$90$( 3.\$!   W!   &0   'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6QM5.UNHS 0?!7+#U G!-HJ J2FIU-/NI.B5G?WVX$%K/J#VB;TWKZV
M(93F_"?V+K,SL[8W^:CTJ^D +'H77)H"=];V>T),U8&@YD;U(-V71FE!K0MU
M2TRO@=:A2'"2;#:W1% F<9F'W%&7N1HL9Q*.&IE!"*K_'8"KL<!;?$D\L[:S
M/D'*O*<MO(#]W1^UB\C"4C,!TC ED8:FP _;_2'S^ #XPV TJSWRG9R4>O7!
MC[K &V\(.%36,U"WG.$1./=$SL;;S(D725^XWE_8OX?>72\G:N!1\;^LMEV!
M[S&JH:$#M\]J?(*YGPRCN?F?< ;NX-Z)TZ@4-^$758.Q2LPLSHJ@[]/*9%C'
MF?]2%B](YH+DJH!,0L'Y-VIIF6LU(CV=?4_]%6_WB3N;RB?#481OSKQQV7.9
MIKN<G#W1C#E,F&2%V2X(XM@7B20F<4C^*T_BY;NHPUTHWWUQF,8)TBA!&@C2
M+P3958LQS&U<)(N*9!&"NRN1&.;^2H2L+DZ ;L.3-:A2@PSCLLHN4_&0A(O_
MA$\C]8OJEDF#3LJZYQ,NN5'*@K.RN7%>.C?%2\"AL7Y[Y_9Z>LM38%4_CRE9
M_BO*#U!+ P04    "  .A$9089%%YK<!  #2 P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6QM4]MNG# 0_17+'Q"S+.DF*T#*)HI:J956J=H^>V$
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M55VOFR 8_BO&^RD@J&VLR4[/6;9D2YJS;+NF+:WFJ#B@[=F_'Z U5NG67E3
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M8AXZ%3LHTTQT6W2W4]=1O.UOWG"X_O._4$L#!!0    (  Z$1E#8G FC100
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MNRB=GE>*\(:ZO'%FF\$,XR7(1*$(M:@[0H&\<L<.8UA>$?Y18/P)J[4]4)>
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MVM3V.U43?+BW5AHS=EW  )IV@&5GL@6G;IR%\0[$]D<L(C-0;.<-WDW;79)
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M"RC&,Z='$FQN/*A\7Z#1/*A\GW-ZU()ZDS8(J7HAW<X"BO&,II! 4WA0ZKY
M4WAD(LG1%#[5 $G2!B%5+Z3;6< IGI$1$LB( $H\%,B( $H\Y,B(%M27M&%(
MU0OI=A9P26!T@T0#!B4>"G1# "4><G1#2/5 DK1!2-4+Z786<$E@I(($4B&
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MC0%WD#B-!0^VX#46O+X+1*FT%O$;)&\0E_K(4H)909CC6$BI!@A#U%+6Z1N
M>4%H*4OU"& $4]6WIQ8C VNNLJ3/@"V74$M)QQK D(O4.#=C#'FN[UO*K%N
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M9,@G57@;B20R["NCM-F]=Z",%<?F;;\T=OR25W6HO='N1.&N.5!0QN_1;(V
M\0V:1>UYP8?Y]OCB>UP<D[PT7GDEWMV:UZL#YQ43SCN6B.S$XGUWD[)#55_Z
MXKIHCPW:FXJ?Y9&(W9W++/\'4$L#!!0    (  Z$1E#VP3EZ$P0  $X3   9
M    >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;)68[9*J.!"&;X7B H $$L!2
MJT;G4]VJJ;.UN[\9C4H=/CR XSEWOP&B TUGAOFC$)]^Z4XWW<+TDA<_RZ,0
ME?$[3;)R9AZKZC2Q[7)[%&E46OE)9/*7?5ZD425/BX-=G@H1[1JC-+&IXW [
MC>+,G$^;M==B/LW/51)GXK4PRG.:1L6?A4CRR\PDYG7A1WPX5O6"/9^>HH/X
M6U3_G%X+>6;?5'9Q*K(RSC.C$/N9>4<F&^K6!@WQ;RPN9>?8J$-YR_.?]<G+
M;F8ZM4<B$=NJEHCDU[M8BB2IE:0?OY2H>;MF;=@]OJH_-L'+8-ZB4BSSY+]X
M5QUG9F :.[&/SDGU([\\"Q40,PT5_4:\BT3BM2?R&ML\*9M/8WLNJSQ5*M*5
M-/K=?L=9\WU1^E<SW( J WHSD-?^S,!5!NZ'@?>I@:<,O+$&3!FPL09<&?"Q
M!KXR\,<:!,H@&&L0*H-PK %QKIES/DSXYR:W9)/15[FFFU!@8K>%U53J?51%
M\VF17XRBO=E.47U/DXFTDN+U:E/[S8^R6DNY^C[G/IW:[[628A8M0SL,8[S/
MK(8,N1&V=.'F!T7]6-"!/?!B.218 )C[(>/UB0=$)73[S..0X0!Y0F28WV>>
M,2;H,R\8$X*M_7)KUE\[O$$0#T^0BQ>*VPBXO8W3*'BX@M<H>-TX/+ ?BY;Q
M&R9K&)?[Q +1+#',<2P"R@'#"+= HAX0S M""_CVB&",<NC;4XNQGIH+<OJ,
M:+F,6PR4!X(1E\ X5T.,>*[O6^"J:X1S/48AMT$X2GVWP_7RS?!\LT&^N0\V
M:X4QX)9=8PS8J W&<-Q;CGO+$04?5_!Q!7_\'1+@"@'B ZC"%<; /"-,X( =
MPQA-RPYQ;T-$ 8X.C('M%F- #:Q&Z*P_U^E%5 ]G=!HZB ;3:.@F*AE?!P2?
MAG>$CJ@$# K 7%ZC$&B &Q0*-"YKY@-Q1Y0#"H'J?<2@T('!CU!:?Z'4CTLS
MM<AP;(6:^X1H&B%AWZ@(37LBP_XTG)X*Z@\"!N?=$L.<T *E<Z^P[B0C'.3A
M =&B(;4\F%/DDGS@V1,:@&^!,GI& PA@ "_H13WHVPK!?,>'OJT1C 5L,#N1
M77.YKN8TDX3X2-WJBDXS2TCPC:+3='@R;*F#HELI*.@&'+@P9VL$H\[@O]@&
MP63*-+V(:MHX1=HXUVEHVCC]1ANGFC9.AWUUN'\*"GIUY<&_@FN%=<O/8R$L
MY@V"4>9:FG\R5-/,*=8X83-74+?2F0/[]!=0ZXW=>5Q-17%H7LR4QC8_9U6=
M@L[J[>7/':T?=\'Z@DQ>"+*^(I--^VKG0[Y]T_175!SBK#3>\DH^9C=/POL\
MKX3TW;&DUT<1[6XGB=A7]:$OCXOV#4][4N4G]?;*OKU"F_\/4$L#!!0    (
M  Z$1E#&P*#J+@(  (T&   9    >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM
M;(V5VXZ;,!"&7P7Q )BC@8@@-:FJ5FJE:*MNKYW$"6@-IK83MF]?'UA*C+?J
M37SZYY]O'&NH1LI>>(.Q\%X[TO.MWP@Q; #@IP9WB =TP+T\N5#6(2&7[ KX
MP# ZZZ".@#@,(>A0V_MUI?<.K*[H39"VQP?F\5O7(?9[APD=MW[DOVT\M==&
MJ U05P.ZXN]8_!@.3*[ [')N.]SSEO8>PY>M_R':[ NEUX+G%H]\,?=4)4=*
M7]3BRWGKAPH($WP2R@')X8[WF!!E)#%^39[^G%(%+N=O[I]T[;*6(^)X3\G/
M]BR:K5_XWAE?T(V()SI^QE,]F>]-Q7_%=TRD7)'('"=*N/[U3C<N:#>Y2)0.
MO9JQ[?4XFI,TG<+< ?$4$,\!T;\#DBD@L0* (=.E?D0"U16CH\?,GS4@]2:B
M32(O\Z0V]=WI,UDME[OW&I9)!>[*:-+LC"9>:.)'Q7ZM@']-@ 28*6(G1:SC
MDP>*U&V0. T2;9 ^&&16&4:3:TVO-1$L@]PJQ:$J8?!.-:D3)G7 0 O&:. B
M30I#"\5HBH4&AG !_("2.5$R!XI5\2Y;I8GR-+!N;^]0)<E"]0 #G3#0 5-8
M,'"5I@C3P'YO:U69P/=@<B=,[H I+9C\OV#6JC(N@](-4SAABA5,'EJO86<T
MV2*-_5Z*U=.% ;0PP*(QJ$;]#;%KVW/O2(7L,;H37"@56/J%@4S6R&_#O"#X
M(M0TEW-F.J19"#I,S1_,7Z#Z#U!+ P04    "  .A$90Y'L#'5H"  !Z!P
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M,'W?"'MU0B^TH@-.=1I43X-RCM:@:0VZTZ#[\R%B$+([C.TPVQU&V32"*TW
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ML1KS_OCJ)Y*UP]'LCM\'^5]02P,$%     @ #H1&4.Y%0UH) P  Y L  !D
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M%Q_H R$4L^ =BVV.$SMR=P\Y/E!^&[/[NCUXM@^45/),;7<'^_E_4$L#!!0
M   (  Z$1E W]?:(; 4  '0>   9    >&PO=V]R:W-H965T<R]S:&5E=#<S
M+GAM;)59VW+:2!#]%8KW(,U%-Q>FRL:QX\1@DJW=?9;-V%"1$"O)=O+WJ\M
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M=L@;C[3W#^I=)16\MJ1ZQG.6%,W_T?-;46:IUE*9DL:_VM?MKGG]T/H/8K@
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M(&-0NO92@,!"=P+WJF'*EGW*3.\(DN 824!VU*#N5B2LR=L#,JTAZ(8C:V=
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M^W^KQ?JE@$^!,O.D%XUWYI[J5JC5>Y%"E(.[)AHPSST&33 SQ'Z)B(,1 I2
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M%ZF'B1KS_LCJ)Y*UPW$,QF^"X@]02P,$%     @ #H1&4.\IU"J"!   GQ@
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M5DFTIW+S:T7N0KF% ) )+7WYE9A\$I'/UP5FE?Q,C>8ITA95:0@?;E$"19[
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MA3%J<J?IG2;)*$9^+$L9)@E!*8R3@C@I@)-[.*.F>,2)4>'A+&4&)T44QLE
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MI6^GO4,UYPITBOZ-SK'5K\IJ4*B5V=[IO9AG:S84'Y9G Z]O5_X74$L#!!0
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M)('I)""=% =(88#T>D,R&""[PI!9DR\JS22/<LL/H.*)SXX<)I.#9#(<0,(
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ML^&XG7>ZYI->'\TN7GS>2MS\ 5!+ P04    "  .A$905AWI\3D#  #H#0
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M)^G^_?Q"$P)'E7X!;)Y[_-S9=[[9F8M7>6!,>6]56<NY?U"JF8:AW!Q8E<N
M-ZS6?W9<5+G20[$/92-8OK5&51G&443"*B]J?S&S<T]B,>-'518U>Q*>/%95
M+OXM6<G/<Q_Y[Q//Q?Z@S$2XF#7YGOUDZE?S)/0HO+!LBXK5LN"U)]AN[C^@
MZ2.BQL B?A?L+#O?GG'EA?-7,_BVG?N14<1*ME&&(M>O$UNQLC1,6L??EM2_
MK&D,N]_O[%^L\]J9EURR%2__%%MUF/O4][9LEQ]+]<S/7UGK$/:]UOOO[,1*
M#3=*]!H;7DK[]#9'J7C5LF@I5?[FWD5MWV?W)XM;,]@@;@WBBP$B'QHDK4%R
M-4@_-$A;@_1> ]P:X)Y!Z'RWP5SG*E_,!#][PIV')C?'#DVQWJZ-F;2[8__I
M>$H]>UI,$C0+3X:HQ2P=)NY@KHA0LU^6B*$EEO' /+Y=8#5$D.06L@8@Z2WD
M<0C!-(&%)F L$DN0=(42#!.D($%J"=*;8/9\73I,9C&U"^8D"D@O(D-43"9!
MS^,UA"+!B,\8E(P!R;W8+QV&=I8A-* ]Q0Y$.B#<EXL'<I,HR&"U!%1+AFKC
MK*>6#-3&$4W[L5L-82C#-!C9[PR4DP'!2V$""A+0^T_<!"28W!$0A\&W)R[J
MA0, D0[H1@J*X%(2#<1@2D8H1JH1NC\@"*PV#R@&-@7W2D4+ZAY%DJ"QS4=P
MN4 )L-*8OW#!0.DG_(43&$$9//!WF,()BD?]A9,/ =F7C*0O@A,&99_P%TX9
M1._QEPXK(\T&E3'LW)(5$WO;LDAOPX^U,C=)9_;2%CW83J$WOT33M6MNKC2N
MU_J1BWU12^^%*WV'VYMVQ[EB6F44Z%TYZ/;N,BC93IG/3'\+U^.X@>)-V[^%
MER9R\1]02P,$%     @ #H1&4"<HNL?,!   5Q@  !D   !X;"]W;W)K<VAE
M971S+W-H965T.#8N>&ULC9E;;^,V$(7_BN%W6^)E*"EP#"0NBA9H@<46VSXK
M#A,;*UFNI,3;?U_=XI4Y9]KU0VS)0YT9FN?C)9M+57]M#MZWBV]E<6KNEX>V
M/=]%4;,_^#)OUM79G[IO7JJZS-ONLGZ-FG/M\^>A45E$.HY=5.;'TW*[&>Y]
MJK>;ZJTMCB?_J5XT;V69U_\\^J*ZW"_5\N/&Y^/KH>UO1-O-.7_U?_CVR_E3
MW5U%UZ<\'TM_:H[5:5'[E_OE@[K;D>T;#!%_'OVEF7U>]*4\5=77_N+7Y_ME
MW&?D"[]O^T?DW=N[W_FBZ)_4Y?'W]-#E5;-O./_\\?2?A^*[8I[RQN^JXJ_C
M<WNX7Z;+Q;-_R=^*]G-U^<5/!=%R,57_FW_W11?>9])I[*NB&?XN]F]-6Y73
M4[I4ROS;^'X\#>^7\9ODHQENH*<&^MI N?]L8*8&YGN#H3>C,;.AU)_R-M]N
MZNJRJ,=?ZYSW@T+=F:XS]_W-H>^&[[IJF^[N^S8SZ29Z[Q\TQ3R.,7H6HZX1
M4??TJX1&$H^:-=>W CL>X0Q6,+ (,[2W\P156,080T/,:8BQ.@GRX#$Q3L/"
M-"Q/PP2E/HXQZ3P-I==A(F.4^_]$""9"+!%282+$$TG=6NAV!V4<D\E,%L@X
M)M.I)%@E@2H)5[%QH))PE61-V?R%)5,HF0))%4BF7%*M":MD4"4#*N&OE#&5
MA*3N4S%V> QT3&CQF MIJ1PEH$0!(1L**3:TG?#;*(B3!Z6!#(4RFM6C*)6&
MM\)849PKF76ADF%*9.W:"4J8'(JC([-)J#0&)7,EN21,!L71D-D E;LIR-W8
M29#!9%  #38+90 ;8G%P8S@H0 >*0R&.A\Y%63Q["1.:PGQ0 !"D0E5.B$2)
MY6%$*, ("F?/*<C=" D3-$:$!HB@ !$[S1&A%4GC3V-&:, (LJ&28DHN5I*E
M-,:$!I@@"I4X)E;:K5-!"6-" TR0"Y4X)E::Q)HP)C3 !(5K!\V7&"MMI(&G
M,2<TX 2%G-"<$RMM!1T,"@U 02$H- =%IR../$P*#4CA0E)H3HI5QUBI)DP'
M#>C@0CIH3H>52K4X]# ?-."#8ZMKOHAP\5IC(8,)80 A7$@(PPE!M!909# @
M# "$"P%A."!(BQ5A/AC !Q?RP7 ^V$2RDA$V)P /+L2#X7BPXCK98#H80 ?'
MMCB<#HK<6EB"&4P' ^C@0CI,0?/EBE6I-, -YH,!?'#A'@,%)<*&R6 Z&$"'
M)%SRPR!IU&$V&,"&)%R,3T'SGLN,V'&8# :0(0D7XX:3P9 T%BPF@P5D2(2-
M@\6>M]SS?/]N^<9AOH&_U<&6M]SR2@O=:K&9+3!S$FX)+#=S8GYH.VJ%@P7@
M[$2J'5O6<LN"PPEP*'!S.G&KA"UKN1N=U,G8C!;YC(T'/E6+P+38C!:9,82+
MY1.UDJ8:B[UHN1<-"2. L,L(N2SL$N+S;VI_:-P1-B:!R9AU$/')6%YN$G8F
M@<DX#0]Y""W6Q24T80,3,' J+%$(NY& &WFR?+.^,@RMT>R8MO3UZW"BW2SV
MU=MI.$Z?W;V>FC_HX9CW>_AXY/Y[7K\>3\WBJ6K;JAR.=%^JJO5=,O&Z\_7!
MY\_7B\*_M/W'I/M<CT?=XT5;G:=C_.CZOX3MOU!+ P04    "  .A$90#'O=
M;Q4"   G!P  &0   'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6R5E6UOFS 0
MQ[\*X@/4F$ "$4%J6DV;M$E1IW6OG>0(J 8SVPG=MY]M*&/)(65OXJ>[W__N
MPME9)^2;*@&T]U[S1FW\4NMV38@ZE% S]2!::,Q)(63-M%G*$U&M!'9T3C4G
M81 L2<VJQL\SM[>3>2;.FE<-[*2GSG7-Y.\M<-%M?.I_;+Q4IU+;#9)G+3O!
M=] _VITT*S)2CE4-C:I$XTDH-OXC76]I;!V<Q6L%G9K,/9O*7H@WN_ARW/B!
MC0@X'+1%,#-<X DXMR03QZ\!ZH^:UG$Z_Z!_<LF;9/9,P9/@/ZNC+C=^XGM'
M*-B9ZQ?1?88AH=CWANR_P@6X,;>1&(V#X,K]>H>STJ(>*":4FKWW8]6XL>M/
MHG!PPQW"P2$<'6CD<NF%7.3/3+,\DZ+S9%_\EMG_F*Y#4YN#W72E<&<F>&5V
M+WF:A!FY6-!@L^UMPHG-7PMBZ*-$B$J$SCV:N*_"!0Y8H("% RS^B7$&$*&
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MG0<$:J&Z.]EGYD$Q T&'Z:U$\X-=_ =02P,$%     @ #H1&4&$U+T5. P
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M6F5M%C.4+'YK?I.\_CTU9\2L#<,!M V@YP B!@-8&\#^!T2# 5$;$(UUX&T
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M2>565YO";!?-BW*SH]6A_1,@./\3L?P'4$L#!!0    (  Z$1E#KEUIT 0(
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M"Z*NHZO_QJXLD_ Z$QECQ[-*_3J[2R5XKE5D*GGRUAS30AUOS9V(:!I,P)J
M6P(*/R4032 ?A.!30J )P5@"U00ZEA!J0CB6$&E"-"!XS>ZJ=FT3D:P6);\Y
M9?/$G9/ZP49WD7P@=O6BZK^Z)SM6R=7K"OEXOO"NM9(&K1L0[H):A"?EVQ@8
MBK'&!AWW VQ,1$CZD"T "?J0!Q-"YP.91P!#HS[FR<0@G_APQ03<5:(42%_!
MLF<!J! HA:"O,-BV=0,*%:A0H-CW+8E2, R%P@SV;-V HDX8&H?Q; #;F+"
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M7XJBELISWU4^[V2R/=^D\J5N+D-U779?KKJ;NCCHKW+>^=/@_']02P,$%
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MD7I0TH'<,6A V"+\L(:+K9&X,[H[72"=(T)O"KE#(/X4<H] @@@7ZJ%F>"J
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MXK[I.LUNP%G==]'VT,IO_P-02P,$%     @ #H1&4 \@[+BY P  .A$  !D
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M<2HB%"MO&B>:[H>;G!YX<QF(ZZH[S7<WG)W[+Q7V\+ED_1]02P,$%     @
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MTCQ-LZ;V7ZC9ZP:IW\J_ZD@=*&M!> CJ$;X*WVM@2"/#$SH>"SQ-$20<0W8
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M4>K;1-WSM@UJ!Y(U78OG]WWFYC]02P,$%     @ #H1&4,:T6H'^ @  !PP
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MQ+"4\&4&5<R+VD>=39S@0X9AX#%$O-3C"%)E 4\<$XLC8F6T+CD@#1^1OB^
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MIN_W^P<EC\-9)KP>J!;_ 5!+ P04    "  .A$90(TZC!-X"  ";"@  &@
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MTZ>FO8S,==6?J_0W37D=SHS<Q\'5YC]02P,$%     @ #H1&4*OE2W!/ P
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M7!?EHZ>>L_H"JWXITGUS.6>?;PC'_P%02P,$%     @ #H1&4"F-=3;. @
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MOZR6GYX]? _GT>.7@3[_/U!+ P04    "  /A$90B*0^./ "  "U"P  &@
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M['#[#.;,5V!T!-K^6: ;U7C<$^$Z[6/ !#J#I8Y]IL!0"#HC7\R$0 N*U;]
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M=K@P8]GWRWZB13O\"LCX/\K_ 5!+ P04    "  /A$903'1W(M,"   5"P
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M04D1I$[!YB"2!#&L)06UI)"6W-'2@?*QE@ Y4B",^_+2>4X!AM5FH-H,4EO
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M([13P/TG,G]A,=Y&QOH!3$!DI'_,FB&^N$PBHN^24&N)U?6<.M\D5%3"NO[
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MSTW[T;C/U>X5K=V7IMSVKY_-]N_ G?\/4$L#!!0    (  ^$1E AO[Q$9@(
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M2>IIHN:\[S#]0K)VZ)Y@;.'Y?U!+ P04    "  /A$90/T9,0_H%  #0'@
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M<,]<WR,(W8J1#B<8K0%,JSN/"AOJ2#H&$=3&<&I#J.!1 16D@01%,DS[8)W
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MBCK".*IS^USD#YL?T^*Q:KXF]?=%^VI;^Z,J7P[:U_8&FW<'#_\'4$L#!!0
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M+.>L?<S:A:"U>:B][M]"^AM02P,$%     @ #X1&4'O)E@FU 0  X ,  !H
M  !X;"]W;W)K<VAE971S+W-H965T,3,P+GAM;'U376_;(!3]*XCW%7_$31;9
MEM9,TR:M4M1I[3.QKV-4/CP@<?OO!YAZ263-#X9[.>?X' SEJ/2KZ0$L>A-<
MF@KWU@Y;0DS3@Z#F3@T@W4JGM*#6E?I(S*"!MH$D.,F2Y)X(RB2NR]#;Z[I4
M)\N9A+U&YB0$U>\/P-58X11_-)[8L;>^0>IRH$?X!?;WL->N(K-*RP1(PY1$
M&KH*?TFWN]SC ^"9P6@NYL@G.2CUZHL?;843;P@X--8K4#><80><>R%GXT_4
MQ/,G/?%R_J'^+61W60[4P$[Q%];:OL(;C%KHZ(G;)S5^AYBGP"B&_PEGX [N
MG;AO-(J;\$;-R5@EHHJS(NC;-#(9QG%:6:61MDS((B'[1UC_EY!'0CX3TE4(
M/SD+4;]22^M2JQ'IZ6<-U)^)=)N[S6Q\,^Q=6'-IC>N>Z[0H5B4Y>Z4(>E@$
M%=>@W03*KD'W,X@X&[.7;-%+%A16UPKK985\42%?4MC<I%D$?;Y),X&* )(!
M]"G--VGBGQM'Y&*O_=E_I/K(I$$'9=UO"_O6*67!R29W3K%WUVTN.'363]=N
MKJ=#-Q56#?$^D?E2UW\!4$L#!!0    (  ^$1E#EC2MHC8<! $5 !@ 4
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M@G<_FR)SJ7U(J<V'?9I4MZ>31GHZ1G,!EPO:%HQ1[%S:62!9I38M'SDL695
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MGJ4R%;-G)",VU,)I^LB8.Z]-%+9[*4PW8#=?U0;I$>YFG+N#\9B$D+T_-U(
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M9HDO@#&9I8B0J1GH,UB12&>FS0AS%N:4QD<>K0F#3B[\9*USPT$?)'T2DSU
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M@1E&_CA(/\9:W:QM0@'9J,6>#QV_O[NGOM#&1#@M*$J!?GD!C)NHTU8WK8]
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M:A:2.C2OS(6,-JHQC]B\%1 0]0_<FI,]:FO9#9]T]&-XDS%C;(9C'5\[$+D
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MCB)&0.N\6[X#[R*Z L/*%<!GCQ\6"98.C)988.'J)[$&;C''9(M"5W52,TX
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M5]3:%N^Q-&4Q3>B#:(,$QZ^NWI\8B"QM09_^[)B-:)6]H&[Y$NIU31&B<N8
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MDG.FJM5(RHYI$'T9L!]9&+.:J87?FVB(+/91RE%S&3*J[)@G$CLBIW?AJDJ
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M2$E,^02U*RL=./[6ZS]NU(K#-ASGK#1$<^^SN;1IA+<M0S.5]J(E(A-!FTJ
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MCK^K)Q\Z3CK5%GE:AWW"+@_9[SKDPH><K0+<J-56AU2S\."X?0(7?T!Q2\,
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M[I'PGW[C+H;J7W-*OYQ7#=CN?DKNLTA-08/3*A1073M9VU6]&0.H1PQG9-4
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MK_Q3T)JBDB-:&UU&&C]"^ZM#KJG.N-OJ);79K<'7K@Z)-B==W^5U9*P_!61
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M*AB@#^GF 4U4MLS%@F!T"&"F$C6JGM"!YQ!7QEF#DPVNU1;=Q<Y L!&N!D5
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M$NG6"!+*]\+1[O*YIY]0N!_OLGP3#02<=LELU'>'.G^UZ!:!6?@[J,MW4'"
M*=YDJ;(X619&ES!*\%J7FWC#DT\CM18($ P52'&VL3F!;B2ZEC$*"F#_YO=E
ML3P-<V[40&7M2!V2]_@]ZU?DYK"&CJA8R*U8)V'JO:T>!IX9FCZ<9$':.G!9
M*'F$LT&S@I5>=J'7&<9".DK9IW-!D6)HI:0Z-ZXV>D(./,O+%*M3J:YDB=T?
M4/RXBR>*UB;]E"TKL\%Z6LNT48BH]EW &_GR8"5I$P]L3H'Q*S&HG\51TM%9
M9%"'T1Z'V%*#GK(:CJ6CK;)[;5!R*?HXE ^4)Z&%L7/BL)T8PG</2,P^)7>3
M2YU5K:BUY\L7CGC]7$LPU]74)@NC:I(9ZB**THW+&D5,71"YQ2'_.F28FHAV
MF*N,(6C_%#HJH()GH)M_AA&6WX,DJZ-.NP(PHXT-"<:K"K^&+6DB)A5"\J=R
M@ ;P4=58V0P JJM:9D%95;G*EQ)VAVO^D"V*U0/H#M9F1H8W@]Z7:([/M"FR
M@0IY7<CM*GA>Y>C5,?,/"GEL'TBO9$AG^!I1DZU2":;#W2?D@(NEZZDZTB_
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MJ!8-TAA+VFFOSF7G#LNT)';/W.J8*YV->08)A6=^5B7I&/QD9I\TQ!]_4[.
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M__ZQW.D3\?BC=M+2#NI<8S1>LWQQNUV7-J159O.YI$)J2\LZ;"#XW>]UN(E
MKYM0O5@,W4IZ')@\Q#$3#7L09.[W +Z_TP/(,0HL'S0(MC$8MWE6XU$;TT/-
M3+%1P"76V2'&P#TD*0(VA.A,"GJCRFKMJG-R*,\$*\+GUC6N->)+=?[DQB"A
MI%/5I="Y-#+*RR;\=6(*M9)*^4)VKK#VC+VRO=3&;[^[B^ZB6)IY7T+V9#K%
M#]-YR8&ZZ\N+#U>3OR"NIY1_0B$;+,X+9*>A*+7Y$YD3J\0WZ'TZ+B6@J%S*
MLW3Y\+'R8\MPSJE;\41D;L*UWIGK]Q.U)JQ)V>G-,<_KZQT[5\Y_IBNT/1PG
M,=LRB&W+G2$]M9T_<75/-;ER\Q49X'Y-E8N \WF#Z.W$;0]-.D;$!833\C(H
M1J.N5W<5E*LM+0X2X4?QI@%J,A2]8/.HFG/ET/8GY:&3>+XY-SIZG $J#^YP
M/?^?/2'*7*@X2+'F312M)"%%*^E#\PTB)8V%E''W*VI,0^]0K0[VN/!7_%I_
M#'5=JQ/_V@Q_VR,*6D]Y9]CICJJ=TSO-.3""UR]YY]BZJR;+PIZ*ZMGN:6]!
M-3&YQ_!8F)?K5@:<=:E1CBE/4LZA M@7<UW@<PG,+5072N0 2EW #!Q]!VM8
MT[*> ]7)CT;7)OG9J8,BH&UP*\A2[@-&O)7]0*_ PB#?D7H_+V[3>55H/=G;
M/(5"O1D%IQW2-40OH2\&32<%?FUVHA-MUCD[$J4R2[*%C"K&S0?Q^^9L";L"
MOV L!<CV)4 #*YXE6TG558*Q(U$!RX'1 @QG2VJU/T]XTINI$3<84L^^P!:7
M%,:B-\1N!5"W9M]V1VUOZ02.AIHV+?%B'DMI%,"L9H-C3P.I/6$O:D<H%G*
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MF;6B5Y,/G5Z;0E_G\VQY:S8/OAD8=U9F[=9'P]&/\0\GL!E8'*O87 WWH*E
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M<]W7RG# 6(V&92/OSM]>7;S^,Z;I+6=YJC)(@2V=7J84MF?&4&%3K= WP7.
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MWPQ5P95G7571%$='J*WZ<!1MU>(CS)1X4=W9LS_"]$G%@5U=;0D-'H'G6L8
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M0:AZ*&*J0X-\K2GLGUF?/4"PBQOPZ^K/YE&%2L+:><VZ:V+4J&7[2)MLMJI
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MJY*@&GE^;HJC&5D#N%;^%OQ8HL$+.B'79-=O!$PRV+P'<B=EJ, B+0FH4:7
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MUR%#5(0S%^TLZS#NJ!35BKTPWX_*42X^D! $*G;23^U;@"5I83D:T"0=V@:
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MGJJ>O&Z[4?F6A\*J$)?"OAK^]WK^VQIZ?*2.O<"&6A &+7W]T >6^4KILW<
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MY;@?MMU)DI;ABHBH@)/E#((-J9:$A*SFH^>NV&%MWH.C=6YOBAM+4F3&O9+
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M'K1Z)WYFG9_LUDO".I-CB.6>O+@)(<L4^V&C9/+%Y=6_IHO5SZ^)SVM0E3B
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MC5=TDI*OQ@T#'"W31YP79:[$\)9,$L8ES0&-$9P(?#+:D\RJFO,=1H329,F
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M'6#OMK2WU>32P*O<+O)KW+\UJ=-U]A"NGRN:X*?3L\^G!R1:'#(G1!\L)[^
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M.[),/>>6[L@)V'1SZQJB..46"1O3QEK;CA:S1@DRQ^(/*S>BC_GJ=]A[0WH
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M/N76>_VAF3^-CN*GTED(VO5K'D17[6>U_1=8."-TS]O7+'_RLD7CC$1T3JE
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MSJSDU;<F>>;NTAWWG^6<<>U%N.:C2X^BB>,Q>G':_2Z:*N:K+F'I8$_\5%V
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M]SF#S=-BMLJN^0CFRZ-Q&;-DL[[+<5E&6A8)]F/CP54TLG]P@Y4V:3$4!IK
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M,-=ZL55H*H[\J:_NY=Y<2Q!JNI17--70LG",,&ZP8_SY)U61AA,52![ $'X
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MB1?O?3<:CLFOZV9Y+$7UQI,^2^*DRS/_0M4VB'D[=@L*?S(CXK C)0=K-1M
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M0/%[WQO,)SD(/@$6S,IV./QNV^%NO140'>S[=C5[W"BR29_GO@;&BY66U G
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MKYE5W:0AR1.SG9I\".5;=!I TLZ:IL$GWM>7MGT(MK*M,R*3T!)+(YB,?Y9
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M'"\LB C5F@-:#,JB\G&($6>U;P_T.W9O='A,V[> N/82V^-]S(D#M'&#2N]
M:(RRR@7/ ]I/MSJ!& :?Z2 Z%;=F(;M45I>%#A%8=*A.I]8-^C;=4%_G&Q _
MP$J"SX!5G8E_C?>^"4=GE(@B>U62L5!)"VJ,GST)0>0 X]]0&O!'*807NX?4
MX2A*V*4.H1#ZHK_WLZ8L9U(^*R_,SN(R^<ZNE4&N?S5I%.FLYY>5O.*I?JN/
MKP!9DCRO'ZR\ZNN!+QQH/5YX]779HX70. (&ARX*"=>-(Y>>;?"T$V[$3T@=
MYS%>BG78G^LV<V5XW5^3\;-H$X9X(,2#@UD:#&<ZVTD<O4(E:!5W[ J?Q*P)
MW<I]T97'9C>YYR"H)E-MF9K;IZK</3X)EOZL<M?&CR"BJ=CQ[-]]C]Z:G'O0
MVB\P+/:DGN-HZKD%>WBV5!XN;=[NIY)F/>=B-?EQVC6FP;,X#9^RCODJ/8,Q
MBGDJ^E[L;GA1P0ESVL#]+F=I[]X.4X4K:<CH;2Y,?JR BE77>**=IV>7K6!N
M.:H]G?A^&'E^B%S648N(!@!Q<?QN^#?X^"G"1^Z#HL5@F7],?T[>J(:#)3]&
MM/8^HLS'8(]2V_PH%4I/:XTRP=9F*L1&HFZX4?F,"J7@QR[\R8]G#$89)FI]
M*,5F$-T).^W0+3H\NUH_#Q ]MP(8#P=](IEG@F-EC7!"!NB+JEN,\TY4AT2;
M^\AI?G8A@6 [)NH\;;B' E]/SB&Y^D_9\K'EQZ<S:T\TII6^B:/]>G3J=M3:
MM ^2\C0*W/@(.6L"T9=FZ("!58L1:5CP)S%FB>)E9Z30(#K!<HE=D6:/ABO?
MX)XHK!^+"K;=KJSU2P%/R4'C^Y')6@^#S-PAQO7L8 :""JBV0LJ<BU?X@.X"
MYIU*(Z"KERATIXK;CYLME^ \5->N2F:#-W]4,^:C"@R-I&3/9UA<YZ"TJ#P9
M[G,'-/ACW/ &*K7])69M#]E<6_G$G43ODB+,5#1=)>.;4Q)_P4V;3*--0I"F
MG#7:#H\\-ZTSV3_$E9H_O*)91I[,C"/)@4ZQ2R,8/S?/@&?&^]6*.1T\ 4-P
M<,1B>LC/V/>FH"O/7M+-?H[Y+M?[27$]_QN)'4S=@$ +T9VM@]B,\IKC/3W%
MSTG?(?GO$LTY=,"&LG%]2_;IQMD&WO\M-(Z@*?0[1Q, S&K:@&N@D6^]NP((
M\3VJ?0+96W#DC=AGN">S"N,)^C<T>\EK4)N$X%WO41UQVG.A2BS!U;[:HP5$
M=A\D7[-BK^X;8A"XRO2DU^]KT4]Y/V*D*\C[AAI=@ HY)O<#UL'A/KI)EM[C
M5R"VQ1YS]S#OO1_\X$[ZBP[Y;Z*'=0MRQ(: RPYR\$X#+^S5SO"MYQ)GY$_
M!>5O0\?Q;H\AR!$$S/U6UF=,,PKV[-; GAF K/[/*Y>B/F&&"D*,%HX"]&L"
M@&4^\"X#[U67#]N75,&."2UV^<)@_#3!R1X\X&3PI"_(UL ,8_06XZ<O'=0Y
MRS.@$?X5@F.,T^4RVU39(N>SV$JDIC 2'>/+&[>)O<_;F3-4S4&\M^PIXF.<
MIIM\*^5L0H[E2A"_6'?_Z)GYVDB'W6_Y0[XB/M4^@+I(W#BDP3I1__2F=SCD
M$KJ3V_WQ[#3Y<#(2C6E,/EE6HR;Q[OQ1M8B[<U0MBL064XNX\$?5(N[[W;6
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M;6Z:%=D+ADC2LS#T /R^XS^;I?V6>(+\W!)\N-Y'?[3>7)PRB<;>.RA;@[O
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ML^-$A#P0D0\:RI+/FW87;?M0M@._V;W9QD1&B(B-T'="E-[UPF5MO-I*WG<
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M%)@,<?JQ,5)*3#Y9#I(A+B922DP^70[&](Y28J24F'KP\GR4ZKTQD5AB8K'
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M'RT;VMO?4$L! A0#%     @ #H1&4!\CSP/     $P(   L
M ( !     %]R96QS+RYR96QS4$L! A0#%     @ #H1&4"?HAPZ"    L0
M !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  .A$90S!7G7.\    K @  $0              @ &9 0  9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  .A$90F5R<(Q &  "<)P  $P
M    @ &W @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  Z$1E"O
M[=(Q< ,  ,H0   8              "  ?@(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  .A$90,1+3^_L$  #M%P  &
M    @ &>#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M#H1&4%7HU4VU P  V@\  !@              ( !SQ$  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    (  Z$1E!7V)T$V@0  #<8   8
M          "  ;H5  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  .A$90W4BQ2^$!  #R!   &               @ '*&@  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ #H1&4)>M831+!@  !R$
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M965T,3 N>&UL4$L! A0#%     @ #H1&4+N .)ZV 0  T@,  !D
M     ( !?C(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Z$1E!QVE6$M0$  -(#   9              "
M 1H\  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ #H1&
M4"]K]:^U 0  T@,  !D              ( !!CX  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  .A$90#$08!+8!  #2 P  &0
M        @ 'R/P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   (  Z$1E!AS W(M $  -(#   9              "  =]!  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ #H1&4*0OIE6T 0  T@,
M !D              ( !RD,  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  .A$90_\Q$G;4!  #2 P  &0              @ &U10
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  Z$1E!@1T6;
MLP$  -(#   9              "  :%'  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ #H1&4(56/[NU 0  T@,  !D
M ( !BTD  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  .
MA$90<_8A6[$!  #2 P  &0              @ %W2P  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  Z$1E!Q^\[<L $  -(#   9
M          "  5]-  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#
M%     @ #H1&4)<B_6:U 0  T@,  !D              ( !1D\  'AL+W=O
M<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  .A$90XH5:V;4!  #2
M P  &0              @ $R40  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
M;%!+ 0(4 Q0    (  Z$1E F&WIFMP$  -(#   9              "  1Y3
M  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ #H1&4,P4
M-1>S 0  T@,  !D              ( !#%4  'AL+W=O<FMS:&5E=',O<VAE
M970R.2YX;6Q02P$"% ,4    "  .A$909HQ<R+4!  #2 P  &0
M    @ 'V5@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M  Z$1E!ZBVP?M0$  -(#   9              "  >)8  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ #H1&4#0"/?&S 0  T@,  !D
M             ( !SEH  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  .A$90XN;8+;<!  #2 P  &0              @ &X7   >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (  Z$1E";C$8I) ,
M +P.   9              "  :9>  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ #H1&4![D7O:W 0  T@,  !D              ( !
M 6(  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  .A$90
MN6SF%;(!  #2 P  &0              @ 'O8P  >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    (  Z$1E""'XR4[@$  &8%   9
M      "  =AE  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ #H1&4++G?GFW 0  T@,  !D              ( !_6<  'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  .A$90&K,,"M0!  "<!
M&0              @ 'K:0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    (  Z$1E#<D/]/U $  )P$   9              "  ?9K  !X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ #H1&4"X%=^[;
M 0   04  !D              ( ! 6X  'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  .A$90XY,-N-L!   !!0  &0
M@ $3<   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  Z$
M1E#;%MY"M@$  -(#   9              "  25R  !X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ #H1&4!M(L^3U 0  RP4  !D
M         ( !$G0  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
M    "  .A$90JV9+K\0!   W!   &0              @ $^=@  >&PO=V]R
M:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (  Z$1E#6?"THM@$  -(#
M   9              "  3EX  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL
M4$L! A0#%     @ #H1&4!" $SO! 0  -P0  !D              ( !)GH
M 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  .A$9089%%
MYK<!  #2 P  &0              @ $>?   >&PO=V]R:W-H965T<R]S:&5E
M=#0X+GAM;%!+ 0(4 Q0    (  Z$1E![8$P'2 (  #P(   9
M  "  0Q^  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M#H1&4%UEIH[> 0   04  !D              ( !BX   'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    "  .A$90!'X $>$!    !0  &0
M            @ &@@@  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    (  Z$1E!OO7GX[ $  &8%   9              "  ;B$  !X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ #H1&4-I,W-VY 0
MT@,  !D              ( !VX8  'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    "  .A$90UOP6Q[@!  #2 P  &0              @ '+
MB   >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (  Z$1E Y
M$DNUN0$  -(#   9              "  ;J*  !X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ #H1&4/$G!7#L P  2Q0  !D
M     ( !JHP  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Z$1E!]W)8JMP0  /,6   9              "
M >"E  !X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ #H1&
M4&J:ZH,4 @  )P8  !D              ( !SJH  'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    "  .A$90/^-B5E0#  !L#0  &0
M        @ $9K0  >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   (  Z$1E EZD(EZP,  *,1   9              "  :2P  !X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ #H1&4/;!.7H3!   3A,
M !D              ( !QK0  'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    "  .A$90QL"@ZBX"  "-!@  &0              @ $0N0
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (  Z$1E#D>P,=
M6@(  'H'   9              "  76[  !X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ #H1&4 2N#@-*!@  0",  !D
M ( !!KX  'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    "  .
MA$90T6K-MPT#  #L"P  &0              @ &'Q   >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (  Z$1E"\#0BPIP4  !PE   9
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M970W-"YX;6Q02P$"% ,4    "  .A$90[RG4*H($  "?&   &0
M    @ &AVP  >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (
M  Z$1E!CMBZ%8@(  +P'   9              "  5K@  !X;"]W;W)K<VAE
M971S+W-H965T-S8N>&UL4$L! A0#%     @ #H1&4.;?O<PW @  1P8  !D
M             ( !\^(  'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"
M% ,4    "  .A$900=KVU^,!  #'!   &0              @ %AY0  >&PO
M=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    (  Z$1E#=@7Y40P,
M  (.   9              "  7OG  !X;"]W;W)K<VAE971S+W-H965T-SDN
M>&UL4$L! A0#%     @ #H1&4&,RL<N6 @  20D  !D              ( !
M]>H  'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4    "  .A$90
M1-X?5# #  !&#0  &0              @ '"[0  >&PO=V]R:W-H965T<R]S
M:&5E=#@Q+GAM;%!+ 0(4 Q0    (  Z$1E"K/>5,Z@,  %84   9
M      "  2GQ  !X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%
M  @ #H1&4%8=Z?$Y P  Z T  !D              ( !2O4  'AL+W=O<FMS
M:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    "  .A$90*;B32)L"  #I"
M&0              @ &Z^   >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+
M 0(4 Q0    (  Z$1E 7$TB!R@(  % *   9              "  8S[  !X
M;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ #H1&4"<HNL?,
M!   5Q@  !D              ( !C?X  'AL+W=O<FMS:&5E=',O<VAE970X
M-BYX;6Q02P$"% ,4    "  .A$90#'O=;Q4"   G!P  &0
M@ &0 P$ >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    (  Z$
M1E"?=F'[K (  &\*   9              "  =P% 0!X;"]W;W)K<VAE971S
M+W-H965T.#@N>&UL4$L! A0#%     @ #H1&4(Y%94SW 0  O 4  !D
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M=#DS+GAM;%!+ 0(4 Q0    (  Z$1E")%T4'400  "84   9
M  "  =@: 0!X;"]W;W)K<VAE971S+W-H965T.30N>&UL4$L! A0#%     @
M#H1&4.,DI[@J!   Z!,  !D              ( !8!\! 'AL+W=O<FMS:&5E
M=',O<VAE970Y-2YX;6Q02P$"% ,4    "  .A$90L665:P\#  #6"P  &0
M            @ '!(P$ >&PO=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4
M Q0    (  Z$1E /(.RXN0,  #H1   9              "  0<G 0!X;"]W
M;W)K<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @ #H1&4*/80"]2 @
M@ <  !D              ( !]RH! 'AL+W=O<FMS:&5E=',O<VAE970Y."YX
M;6Q02P$"% ,4    "  .A$90S\3FE@@"  "+!0  &0              @ &
M+0$ >&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+ 0(4 Q0    (  Z$1E D
M:R8)V@(  ',*   :              "  ;\O 0!X;"]W;W)K<VAE971S+W-H
M965T,3 P+GAM;%!+ 0(4 Q0    (  Z$1E#&M%J!_@(   <,   :
M      "  =$R 0!X;"]W;W)K<VAE971S+W-H965T,3 Q+GAM;%!+ 0(4 Q0
M   (  Z$1E!;WL9P_@$  (,%   :              "  0<V 0!X;"]W;W)K
M<VAE971S+W-H965T,3 R+GAM;%!+ 0(4 Q0    (  Z$1E":.9N8_P$  (,%
M   :              "  3TX 0!X;"]W;W)K<VAE971S+W-H965T,3 S+GAM
M;%!+ 0(4 Q0    (  Z$1E!\7#2EC@(  ,X(   :              "  70Z
M 0!X;"]W;W)K<VAE971S+W-H965T,3 T+GAM;%!+ 0(4 Q0    (  Z$1E!/
M<CP/_P$  'L%   :              "  3H] 0!X;"]W;W)K<VAE971S+W-H
M965T,3 U+GAM;%!+ 0(4 Q0    (  Z$1E"A-7-PX0(  '4*   :
M      "  7$_ 0!X;"]W;W)K<VAE971S+W-H965T,3 V+GAM;%!+ 0(4 Q0
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M965T,3$P+GAM;%!+ 0(4 Q0    (  Z$1E!OM$6:(@,  +<.   :
M      "  :E1 0!X;"]W;W)K<VAE971S+W-H965T,3$Q+GAM;%!+ 0(4 Q0
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M965T,3$U+GAM;%!+ 0(4 Q0    (  Z$1E#E-</:*@0  "T4   :
M      "  4IE 0!X;"]W;W)K<VAE971S+W-H965T,3$V+GAM;%!+ 0(4 Q0
M   (  Z$1E IC74VS@(  'H*   :              "  :QI 0!X;"]W;W)K
M<VAE971S+W-H965T,3$W+GAM;%!+ 0(4 Q0    (  Z$1E"YH[_%7P,  '@-
M   :              "  ;)L 0!X;"]W;W)K<VAE971S+W-H965T,3$X+GAM
M;%!+ 0(4 Q0    (  ^$1E HU<R#A1   !AT   :              "  4EP
M 0!X;"]W;W)K<VAE971S+W-H965T,3$Y+GAM;%!+ 0(4 Q0    (  ^$1E"(
MI#XX\ (  +4+   :              "  0:! 0!X;"]W;W)K<VAE971S+W-H
M965T,3(P+GAM;%!+ 0(4 Q0    (  ^$1E *&3->X $  ,P$   :
M      "  2Z$ 0!X;"]W;W)K<VAE971S+W-H965T,3(Q+GAM;%!+ 0(4 Q0
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M965T,3(U+GAM;%!+ 0(4 Q0    (  ^$1E AO[Q$9@(  ,X'   :
M      "  6&7 0!X;"]W;W)K<VAE971S+W-H965T,3(V+GAM;%!+ 0(4 Q0
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M965T,3,P+GAM;%!+ 0(4 Q0    (  ^$1E#EC2MHC8<! $5 !@ 4
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    "+ (L 7B8  ,Q% P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6629477536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Income before income tax provision and the income tax expense</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>4,725.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,877.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,540.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,400.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,022.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,588.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7,125.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,899.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,128.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>947.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,131.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,201.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>59.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>57.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>84.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>140.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>108.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,090.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,317.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,367.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,143.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(62.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>241.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1,074.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>177.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(159.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>67.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>108.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>91.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,158.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,425.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,458.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of deferred tax assets and liabilities</a></td>
<td class="text">s<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>106.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>102.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves and accruals</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>162.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>163.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,380.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,298.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>130.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>213.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>23.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>103.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>38.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(20.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,905.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,823.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(350.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(232.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1,381.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(544.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1,617.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,425.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(135.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(102.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(3,484.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2,305.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text">e<div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:55%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(11.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Divestiture of Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Internal reorganization of certain intellectual property rights</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S. tax reform</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss tax reform</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment of ZINBRYTA related tax assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of beginning and ending amount of unrecognized tax benefits</a></td>
<td class="text">s<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>114.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>17.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>58.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(13.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(21.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement refund (payment)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>44.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>129.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>114.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6979360352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adjacencies. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Geographic Information</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6,713.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,794.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>320.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>551.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>11,379.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,211.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>78.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,290.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>585.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>112.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>707.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,493.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,162.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,674.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,800.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,370.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>281.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>434.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10,886.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,903.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>76.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,980.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>457.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>96.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>585.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,152.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,442.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,601.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2017 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,017.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,844.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>160.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>332.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10,354.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,475.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>83.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,559.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>249.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>67.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>42.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>360.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,226.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,948.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,182.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2,028.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,748.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,215.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$646.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$707.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to our manufacturing facility in Hiller&#248;d, Denmark.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read Note 10, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6705447056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 9) - Performance stock units settled in cash<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceStockUnitsSettledinCashAbstract', window );"><strong>Performance stock units settled in cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">63,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="nump">82,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceStockUnitsSettledinCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Stock Units Settled in Cash [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceStockUnitsSettledinCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6881172384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 5) - Market stock units - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Minimum range of risk-free interest rates</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Maximum range of risk-free interest rates</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageStockPriceOnGrantDateInDollarsMinimum', window );">Average stock price on grant date minimum</a></td>
<td class="nump">$ 228.59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 279.47<span></span>
</td>
<td class="nump">$ 263.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageStockPriceOnGrantDateInDollarsMaximum', window );">Average stock price on grant date maximum</a></td>
<td class="nump">$ 331.18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 346.76<span></span>
</td>
<td class="nump">$ 267.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 378.08<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 378.85<span></span>
</td>
<td class="nump">$ 382.59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Range of expected stock price volatility</a></td>
<td class="nump">31.20%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">27.50%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Range of expected stock price volatility</a></td>
<td class="nump">33.60%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">32.40%<span></span>
</td>
<td class="nump">35.60%<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted during 2019 include awards granted in conjunction with our annual awards made in February 2019 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2019 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2018, 2017 and 2016.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageStockPriceOnGrantDateInDollarsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price on grant date in dollars maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageStockPriceOnGrantDateInDollarsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageStockPriceOnGrantDateInDollarsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price on grant date in dollars minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageStockPriceOnGrantDateInDollarsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ValuationOfGrantedStockUnitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation of granted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ValuationOfGrantedStockUnitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6628624944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Property, plant and equipment estimated useful lives</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:50%;"/><td style="width:50%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7029617168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income before income taxes (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 4,725.3<span></span>
</td>
<td class="nump">$ 3,877.0<span></span>
</td>
<td class="nump">$ 3,540.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">2,400.6<span></span>
</td>
<td class="nump">2,022.6<span></span>
</td>
<td class="nump">1,588.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">7,125.9<span></span>
</td>
<td class="nump">5,899.6<span></span>
</td>
<td class="nump">5,128.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">947.4<span></span>
</td>
<td class="nump">1,131.8<span></span>
</td>
<td class="nump">2,201.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">59.1<span></span>
</td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">57.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">84.4<span></span>
</td>
<td class="nump">140.0<span></span>
</td>
<td class="nump">108.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">1,090.9<span></span>
</td>
<td class="nump">1,317.3<span></span>
</td>
<td class="nump">2,367.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">1,143.9<span></span>
</td>
<td class="num">(62.0)<span></span>
</td>
<td class="nump">241.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(1,074.5)<span></span>
</td>
<td class="nump">177.7<span></span>
</td>
<td class="num">(159.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">67.1<span></span>
</td>
<td class="nump">108.3<span></span>
</td>
<td class="nump">91.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 1,158.0<span></span>
</td>
<td class="nump">$ 1,425.6<span></span>
</td>
<td class="nump">$ 2,458.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6887383504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:20%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-28 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7,379.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(4,881.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,497.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,187.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4,607.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,580.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>965.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>965.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>476.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>476.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and trade names</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8,408.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(4,881.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,527.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,727.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4,607.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,120.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization of intangible assets</a></td>
<td class="text">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:<div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>260.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>225.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>230.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,706.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,632.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>117.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,080.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(69.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,757.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,706.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6601258720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text">Derivative Instruments<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,892.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,701.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>131.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>98.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>92.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,892.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,239.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$27.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$113.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We expect the net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of these gains are expected to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>118.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(42.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized Directly into Net Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(32.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Swap Contracts</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, as described in Note 12, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements, we entered into interest rate swaps with an aggregate notional amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$675.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. The carrying value of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$14.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate these currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$7.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of our net investment hedges in our consolidated financial statements:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>25.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$793.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$735.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recorded as a component of other income (expense), net, for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivative Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br/>As of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br/>As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>65.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Net Investment Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivative Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885381104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Apr. 02, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.5<span></span>
</td>
<td class="nump">$ 1,080.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Cancellable future commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments And Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liabilities associated with uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion', window );">Future contingent payment for annual worldwide net sales up to $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentThreshold', window );">Future contingent payment threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion', window );">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Cancellable future commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_TwentybillionMember', window );">Twenty billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember', window );">Each additional one billion up to twenty billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">$ 20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember', window );">Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember', window );">Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember', window );">2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Transition toll tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 989.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Minimum | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage Of Royalties As Per Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Maximum | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage Of Royalties As Per Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember', window );">Alkermes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember', window );">Alkermes | VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage Of Royalties As Per Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember', window );">Twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses on funding commitment related to clinical research.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales that exceed $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales up to $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfRoyaltiesAsPerCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfRoyaltiesAsPerCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_TwentybillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_TwentybillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AlkermesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_VUMERITYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_VUMERITYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7028821088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 3,674.3<span></span>
</td>
<td class="nump">$ 3,601.2<span></span>
</td>
<td class="nump">$ 3,182.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SegmentInformationTextualAbstract', window );"><strong>Segment Information (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 2,028.8<span></span>
</td>
<td class="nump">1,748.5<span></span>
</td>
<td class="nump">1,215.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DK', window );">DENMARK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 646.5<span></span>
</td>
<td class="nump">$ 707.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SegmentInformationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SegmentInformationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871631600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">&#160;&#160;&#160;&#160;Inventory<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>169.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>196.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>460.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>606.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>174.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>804.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>804.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>929.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>804.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2019 we sold to Bioverativ hemophilia-related inventory on hand as of December 31, 2018, with a cost basis totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$184.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> pursuant to the terms of the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$52.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$41.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$76.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included the sale of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$14.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of work in process inventory.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sold to FUJIFILM approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$41.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6877501904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments Interest Rate Swap (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 1,892.4<span></span>
</td>
<td class="nump">$ 2,239.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">793.8<span></span>
</td>
<td class="nump">735.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other current assets | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative assets</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Accrued expenses and other | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">1,892.4<span></span>
</td>
<td class="nump">1,701.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound sterling | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">215.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss francs | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">131.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">98.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedge | Foreign Exchange Contract | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative assets</a></td>
<td class="nump">33.8<span></span>
</td>
<td class="nump">65.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedge | Foreign Exchange Contract | Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedge | Foreign Exchange Contract | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedge | Foreign Exchange Contract | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative assets</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedge | Interest rate swap | Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedge | Interest rate swap | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6872215440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="num">$ (2.6)<span></span>
</td>
<td class="nump">$ 57.8<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="num">$ (11.5)<span></span>
</td>
<td class="num">$ (79.3)<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 63.7<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="num">$ (62.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(101.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 523.6<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="nump">523.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 346.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 346.1<span></span>
</td>
<td class="nump">$ 409.8<span></span>
</td>
<td class="nump">$ 523.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874348576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, Estimated Fair Value</a></td>
<td class="nump">$ 1,562.2<span></span>
</td>
<td class="nump">$ 2,313.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, Amortized Cost</a></td>
<td class="nump">1,560.8<span></span>
</td>
<td class="nump">2,314.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Estimated Fair Value</a></td>
<td class="nump">1,234.5<span></span>
</td>
<td class="nump">1,232.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">1,230.4<span></span>
</td>
<td class="nump">1,235.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, Estimated Fair Value</a></td>
<td class="nump">173.6<span></span>
</td>
<td class="nump">143.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, Amortized Cost</a></td>
<td class="nump">173.8<span></span>
</td>
<td class="nump">143.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">2,965.0<span></span>
</td>
<td class="nump">3,694.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities, Available-for-sale</a></td>
<td class="nump">$ 2,970.3<span></span>
</td>
<td class="nump">$ 3,689.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874729824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 427.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">412.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">486.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">86.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">ASC 842 - Minimum lease payments, 2020</a></td>
<td class="nump">87.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">ASC 842 - Minimum lease payments, 2021</a></td>
<td class="nump">81.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">ASC 842 - Minimum lease payments, 2022</a></td>
<td class="nump">75.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">ASC 842 - Minimum lease payments, 2023</a></td>
<td class="nump">72.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">ASC 842 - Minimum lease payments, 2024</a></td>
<td class="nump">69.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">ASC 842 - Minimum lease payments, thereafter</a></td>
<td class="nump">158.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">544.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="nump">$ 58.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">ASC 840 - Minimum lease payments, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">ASC 840 - Minimum lease payments, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">ASC 840 - Minimum lease payments, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">ASC 840 - Minimum lease payments, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">ASC 840 - Minimum lease payments, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">ASC 840 - Minimum lease payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">ASC 840 - Minimum lease payments, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear', window );">ASC 840 - Sublease income, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears', window );">ASC 840 - Sublease income, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears', window );">ASC 840 - Sublease income, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears', window );">ASC 840 - Sublease income, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears', window );">ACS 840 - Sublease income, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter', window );">ASC 840 - Sublease income, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions', window );">ASC 840 - Sublease income, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(182.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInOneYear', window );">ASC 840 - Net minimum lease payments, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInTwoYear', window );">ASC 840 - Net minimum lease payments, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInThreeYear', window );">ASC 840 - Net minimum lease payments, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFourYear', window );">ASC 840 - Net minimum lease payments, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFiveYear', window );">ASC 840 - Net minimum lease payments, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsThereafter', window );">ASC 840 - Net minimum lease payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePayments', window );">ASC 840 - Net minimum lease payments, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 418.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">7 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 93.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">35.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember', window );">Operating lease assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">427.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">73.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember', window );">Long-term operating lease liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">412.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">84.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">23.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Sublease income</a></td>
<td class="num">(25.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Sublease income</a></td>
<td class="num">$ (3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFiveYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in five year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFiveYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFourYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in four year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFourYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInThreeYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in three year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInThreeYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in two year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized for the period under subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=77891322&amp;loc=d3e41620-112719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6629591344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>100%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This standard became effective for us on January 1, 2018, and was adopted using the modified retrospective method. The adoption of this standard as of January 1, 2018, did not change our revenue recognition.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under the FASB Accounting Standards Codification (ASC) 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the United States (U.S.), we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates, non-U.S. pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration with Genentech is within the scope of ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Agreements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech and the Roche Group. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates that are based on information received from Genentech and Roche. These estimates are subject to change and actual results may differ. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Genentech, please read Note&#160;18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Royalty Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and other third parties and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech and Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Corporate Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Assets and Liabilities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounts Receivable</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within </span><span style="font-family:Franklin Gothic Book,sans-serif;">30 to 90 days</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We provide reserves against accounts receivable for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Marketable Securities and Other Investments</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities and Venture Capital Funds</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Marketable Debt Securities for Other-than-Temporary Impairments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Equity Method of Accounting</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our consolidated statements of income our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Inventory</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At each reporting period we review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Property, Plant and Equipment</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </span><span style="font-family:Franklin Gothic Book,sans-serif;">three to five years</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:50%;"/><td style="width:50%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-10, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvement for Lessors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and ASU No. 2019-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Codification Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis in our consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$463.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a corresponding operating lease liability of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$526.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are included in our consolidated balance sheets. The adoption of the new leasing standards did not have an impact on our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our consolidated balance sheets. Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the adoption of the new leasing standards, please read Note 11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of completed technology (comprised of acquired and in-licensed rights and patents, developed technology, out-licensed patents), in-process research and development (IPR&amp;D) acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also include our rest of world license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and IPR&amp;D prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired In-process Research and Development (IPR&amp;D)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the potential treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but is reviewed for impairment. Goodwill is reviewed for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&#160;24, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cash Flow and Fair Value Derivative Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Derivative Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our derivative instruments and hedging activities, please read Note 9, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Translation of Foreign Currencies</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Cost of Sales</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Share-Based Compensation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). Compensation expense is recognized based on the estimated fair value of the awards at grant date. We recognize compensation expense for the number of awards expected to vest after taking into consideration an estimate of award forfeitures over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of PSUs that settle in stock are based upon the stock price on the date of grant. Compensation expense is recognized for the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development Expenses</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses and upfront fees and milestones paid to third-party collaborators. Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$79.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$90.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The income tax consequences from the intra-entity transfers of inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the inventory is sold to a third party.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16,&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, offset by a corresponding net increase to retained earnings of approximately&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.4 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;with a corresponding reduction to </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our retained earnings as these differences are related to intra-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Earnings per Share</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued the new leasing standards to increase transparency and comparability among organizations related to their leasing activities. For additional information on the adoption of the new leasing standards, please read the section titled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Lease </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">above, and Note 11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on the composition of our investment portfolio, accounts receivable and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards are not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Debt Securities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020. The adoption of this standard will not have a material impact on our disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FASB issued ASU No. 2018-16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard became effective for us on January 1, 2019, and did not have an impact on our consolidated results of operations or financial position.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> This standard makes targeted improvements for collaborative arrangements as follows: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. The adoption of this standard did not have a material impact on our consolidated financial position, results of operations and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6887738592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,680.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,880.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,894.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,924.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>11,379.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>517.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>576.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>595.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>600.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,290.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>292.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>160.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>109.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>145.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>707.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,489.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,616.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,600.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,671.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>14,377.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,887.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,140.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,170.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,224.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>12,422.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,408.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,494.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,545.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,439.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,888.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,408.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,494.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,545.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,439.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,888.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.17</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.85</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.40</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.10</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>31.47</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.15</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.85</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.39</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.08</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>31.42</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>196.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>190.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>184.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>177.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>187.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>197.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>190.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>184.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>178.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>187.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,523.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,757.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,780.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,825.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10,886.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>443.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>490.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>511.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>534.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,980.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>164.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>108.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>147.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>165.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>585.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,131.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,356.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,439.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,526.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>13,452.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,685.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,935.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,978.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,037.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11,636.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,171.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>915.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,442.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>944.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,474.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,172.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>866.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,444.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>946.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,430.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>211.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>201.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>199.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>204.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>211.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>207.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>201.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>200.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>205.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for 2019 include:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax gains (losses) related to changes in the fair value of our strategic investments of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$376.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>($174.2) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>($4.6) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second, third and fourth quarters, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment charges related to certain intangible assets of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$215.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter. For additional information, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A total net loss in our consolidated statements of income of approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$124.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the sale of all the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This loss included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$55.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a tax expense of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$68.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this transaction. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read, Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An expense of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$63.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded in research and development expense in our consolidated statements of income in the fourth quarter as we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. We also acquired an option to extend our existing commercial agreement with Samsung Bioepis for BENEPALI, IMRALDI and FLIXABI in Europe and obtained exclusive rights to commercialize these products in China. For additional information, please read, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Losses (gains) related to the adjustments to the fair values of our contingent consideration obligations of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$11.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(20.0) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(57.8) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second, third and fourth quarters, respectively. For additional information on the valuation of our contingent consideration obligations, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A payment of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis in the fourth quarter, as we exercised our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB080. For additional information, please read, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A payment of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$38.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk in the first quarter as we entered into a collaboration and research and development services agreement with Skyhawk pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. For additional information, please read, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for 2018 include:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax (losses) gains related to changes in the fair value of our strategic investments of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(6.4) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$5.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$141.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(12.2) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second, third and fourth quarters, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax charges to acquired IPR&amp;D of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$27.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second and third quarters, respectively, for upfront payments made upon closing of asset purchase transactions. For additional information, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax research and development expenses for the second quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$486.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the 2018 Ionis Agreement. For additional information, please read, Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax charge to noncontrolling interests of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the second quarter for a payment to Neurimmune in exchange for a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. For additional information, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment charges related to certain intangible assets of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$189.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$176.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third and fourth quarters, respectively. For additional information, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Losses (gains) related to the adjustments to the fair values of our contingent consideration obligations of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(5.6) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$(87.9) million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$79.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the first, second, third and fourth quarters, </span></div></td></tr></table><div style="line-height:120%;padding-left:48px;padding-top:12px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">respectively. For additional information, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase to income tax expense of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$135.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the fourth quarter reflecting the impact of electing to record deferred taxes on GILTI. For additional information, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An upfront payment of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;"><span>$35.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis, as we exercised our option in the fourth quarter to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize tofersen. For additional information, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6896026944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental cash flow information</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>244.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>243.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>281.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,064.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,007.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,066.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>120.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>112.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>78.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(187.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(200.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(250.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>204.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>119.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(47.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>83.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(217.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>200.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>127.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(19.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period on equity securities held as of December 31</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>150.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>128.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(19.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,001.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>874.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>309.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>320.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>281.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>261.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>220.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>224.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>148.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>444.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>78.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>125.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>726.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>609.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,765.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,861.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6979541824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,913.7<span></span>
</td>
<td class="nump">$ 1,224.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,562.2<span></span>
</td>
<td class="nump">2,313.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,880.5<span></span>
</td>
<td class="nump">1,958.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DueFromUnconsolidatedJointBusiness', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">590.2<span></span>
</td>
<td class="nump">526.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">804.2<span></span>
</td>
<td class="nump">929.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">631.0<span></span>
</td>
<td class="nump">687.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,381.8<span></span>
</td>
<td class="nump">7,640.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">1,408.1<span></span>
</td>
<td class="nump">1,375.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,247.3<span></span>
</td>
<td class="nump">3,601.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">427.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,527.4<span></span>
</td>
<td class="nump">3,120.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,757.8<span></span>
</td>
<td class="nump">5,706.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax asset</a></td>
<td class="nump">3,232.1<span></span>
</td>
<td class="nump">2,153.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,252.8<span></span>
</td>
<td class="nump">1,690.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">27,234.3<span></span>
</td>
<td class="nump">25,288.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">1,495.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">71.4<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">530.8<span></span>
</td>
<td class="nump">370.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,765.8<span></span>
</td>
<td class="nump">2,861.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,863.8<span></span>
</td>
<td class="nump">3,295.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">4,459.0<span></span>
</td>
<td class="nump">5,936.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">2,810.8<span></span>
</td>
<td class="nump">1,636.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">412.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,348.9<span></span>
</td>
<td class="nump">1,389.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,895.2<span></span>
</td>
<td class="nump">12,257.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(135.2)<span></span>
</td>
<td class="num">(240.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">16,455.4<span></span>
</td>
<td class="nump">16,257.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">13,343.2<span></span>
</td>
<td class="nump">13,039.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">13,339.1<span></span>
</td>
<td class="nump">13,031.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 27,234.3<span></span>
</td>
<td class="nump">$ 25,288.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DueFromUnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DueFromUnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31958-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6985477344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures Divestitures (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryrawmaterialssoldtoFUJIFILM', window );">Inventory raw materials sold to FUJIFILM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration received for sale of Denmark manufacturing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 881.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Future minimum batch production for Denmark manufacturing operations</a></td>
<td class="nump">$ 74.0<span></span>
</td>
<td class="nump">$ 114.0<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</a></td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">164.4<span></span>
</td>
<td class="nump">124.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95.5<span></span>
</td>
<td class="nump">55.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Expected costs to sell disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryrawmaterialssoldtoFUJIFILM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory raw materials sold to FUJIFILM</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryrawmaterialssoldtoFUJIFILM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6983690160">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details Textual)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>Increment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>Increment</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedPaymentsTextualAbstract', window );"><strong>Share-Based Payments (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested share-based compensation | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 210.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards', window );">Weighted-average period to recognize the cost of unvested awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade', window );">Number of share-based compensation plans pursuant to which awards are currently being made | Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares granted under stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic values of options outstanding | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term for options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">147,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested awards | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 26.9<span></span>
</td>
<td class="nump">$ 31.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 378.08<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 378.85<span></span>
</td>
<td class="nump">$ 382.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash in settlement of CSPS awards upon vesting | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash in settlement of CSPS awards upon vesting | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 17.0<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">77,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 316.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">63,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">602,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested awards | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 131.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 111.7<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 304.44<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 316.32<span></span>
</td>
<td class="nump">$ 293.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | Time-vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">15,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_DirectorsPlanMember', window );">Directors Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSharesOfCommonStockForIssuance', window );">Total number of shares of common stock for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1.5-to-1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember', window );">2017 Omnibus Equity Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1.5-to-1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Omnibus Plan number of shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted during 2019 include awards granted in conjunction with our annual awards made in February 2019 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2019 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2018, 2017 and 2016.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2019 primarily represent RSUs granted in conjunction with our annual awards made in February 2019 and awards made in conjunction with the hiring of new employees. RSUs granted in 2019 also include approximately </span><span style="font-family:Franklin Gothic Book;font-size:9pt;"><span>15,000</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> RSUs granted to our Board of Directors.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days for calculation of average closing stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfDaysForCalculationOfAverageClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfEqualAnnualIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal annual increments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfEqualAnnualIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share-based compensation plans pursuant to which awards are currently being made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSharesOfCommonStockForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of common stock for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSharesOfCommonStockForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RatioOfNumberOfSharesReservedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of total number of shares reserved under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RatioOfNumberOfSharesReservedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedPaymentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedPaymentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period to recognize the cost of nonvested awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_DirectorsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_DirectorsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6629550096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>169.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>196.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>460.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>606.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>174.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>804.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>804.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>929.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>804.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6872550768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">401(k) Savings Plan</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense related to our 401(k) Savings Plan totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$44.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$42.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$42.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Compensation Plan</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$114.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$109.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pension Plans</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.00%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. Minimum employee contributions are based on the respective employee&#8217;s age, salary and gender. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the Swiss plan had an unfunded net pension obligation of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$42.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$48.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and plan assets that totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$127.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$93.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recognized expense totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$14.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$14.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$12.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our Swiss plan, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, was included in other income (expense), net.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The obligations under the German plans are unfunded and totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$59.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$45.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net periodic pension cost related to the German plans totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, was included in other income (expense), net.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6985610624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 8) - Performance stock units settled in stock<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceStockUnitsSettledinStockAbstract', window );"><strong>Performance stock units settled in stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares | shares</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">$ 317.26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted | shares</a></td>
<td class="nump">77,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 316.28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited | shares</a></td>
<td class="num">(26,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">$ 318.11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares | shares</a></td>
<td class="nump">111,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">$ 316.39<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted during 2019 include awards granted in conjunction with our annual awards made in February 2019 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2019 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2018, 2017 and 2016.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceStockUnitsSettledinStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Stock Units Settled in Stock [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceStockUnitsSettledinStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6880420512">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 4) - Market stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MarketStockUnitsActivityAbstract', window );"><strong>Market stock units activity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">180,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 371.32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">147,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 378.08<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 378.85<span></span>
</td>
<td class="nump">$ 382.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(101,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 356.71<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 388.68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 378.09<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 371.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted during 2019 include awards granted in conjunction with our annual awards made in February 2019 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2019 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2018, 2017 and 2016.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MarketStockUnitsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market stock units activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MarketStockUnitsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6872498720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Business Overview</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>100%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">e recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under the FASB Accounting Standards Codification (ASC) 606, <span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</span><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the United States (U.S.), we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates, non-U.S. pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration with Genentech is within the scope of ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Agreements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech and the Roche Group. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates that are based on information received from Genentech and Roche. These estimates are subject to change and actual results may differ. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Genentech, please read Note&#160;18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Royalty Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and other third parties and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech and Samsung Bioepis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Corporate Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Assets and Liabilities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within </span><span style="font-family:Franklin Gothic Book,sans-serif;">30 to 90 days</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We provide reserves against accounts receivable for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Marketable Securities and Other Investments</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities and Venture Capital Funds</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Marketable Debt Securities for Other-than-Temporary Impairments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method of Accounting</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our consolidated statements of income our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At each reporting period we review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </span><span style="font-family:Franklin Gothic Book,sans-serif;">three to five years</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:50%;"/><td style="width:50%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-10, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvement for Lessors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and ASU No. 2019-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Codification Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis in our consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$463.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a corresponding operating lease liability of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$526.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are included in our consolidated balance sheets. The adoption of the new leasing standards did not have an impact on our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our consolidated balance sheets. Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the adoption of the new leasing standards, please read Note 11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of completed technology (comprised of acquired and in-licensed rights and patents, developed technology, out-licensed patents), in-process research and development (IPR&amp;D) acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also include our rest of world license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and IPR&amp;D prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-process Research and Development (IPR&amp;D)</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the potential treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but is reviewed for impairment. Goodwill is reviewed for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&#160;24, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Contingent Consideration</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. </span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cash Flow and Fair Value Derivative Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Derivative Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our derivative instruments and hedging activities, please read Note 9, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation of Foreign Currencies</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyCostofSalesPolicyTextBlock', window );">Royalty Cost of Sales</a></td>
<td class="text">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Accounting for Share-Based Compensation</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). Compensation expense is recognized based on the estimated fair value of the awards at grant date. We recognize compensation expense for the number of awards expected to vest after taking into consideration an estimate of award forfeitures over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of PSUs that settle in stock are based upon the stock price on the date of grant. Compensation expense is recognized for the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses and upfront fees and milestones paid to third-party collaborators. Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$79.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$90.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The income tax consequences from the intra-entity transfers of inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the inventory is sold to a third party.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16,&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, offset by a corresponding net increase to retained earnings of approximately&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.4 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;with a corresponding reduction to </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our retained earnings as these differences are related to intra-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. </span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text">rom time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued the new leasing standards to increase transparency and comparability among organizations related to their leasing activities. For additional information on the adoption of the new leasing standards, please read the section titled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Lease </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">above, and Note 11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on the composition of our investment portfolio, accounts receivable and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards are not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Debt Securities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020. The adoption of this standard will not have a material impact on our disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FASB issued ASU No. 2018-16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard became effective for us on January 1, 2019, and did not have an impact on our consolidated results of operations or financial position.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> This standard makes targeted improvements for collaborative arrangements as follows: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. The adoption of this standard did not have a material impact on our consolidated financial position, results of operations and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyCostofSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Cost of Sales [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyCostofSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871687440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>118.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>144.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>835.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,282.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>99.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>94.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>844.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,258.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>798.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>798.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>58.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>61.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,084.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,758.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>4,838.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,398.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(1,590.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,797.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,247.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,601.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation expense totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$190.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$269.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$266.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we capitalized interest costs related to construction in progress totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$68.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$54.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$30.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The increase in capitalized interest costs is primarily due to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, as discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Manufacturing Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.9 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.6 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$631.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of property, plant and equipment, which was primarily comprised of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$312.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for buildings and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$287.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for machinery and equipment. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6879228480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember', window );">Domestic Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumQualifyingAgeForEmployeeBenefitPlan', window );">Minimum Qualifying Age For Employee Benefit Plan</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses related to savings plan</a></td>
<td class="nump">$ 44.8<span></span>
</td>
<td class="nump">$ 42.2<span></span>
</td>
<td class="nump">$ 42.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Deferred Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation liability</a></td>
<td class="nump">$ 114.6<span></span>
</td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumQualifyingAgeForEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum qualifying age for employee benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumQualifyingAgeForEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6879575440">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,224.2<span></span>
</td>
<td class="nump">3,170.1<span></span>
</td>
<td class="nump">3,140.4<span></span>
</td>
<td class="nump">2,887.8<span></span>
</td>
<td class="nump">3,037.8<span></span>
</td>
<td class="nump">2,978.2<span></span>
</td>
<td class="nump">2,935.5<span></span>
</td>
<td class="nump">2,685.1<span></span>
</td>
<td class="nump">12,422.5<span></span>
</td>
<td class="nump">11,636.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,439.7<span></span>
</td>
<td class="nump">1,545.9<span></span>
</td>
<td class="nump">1,494.1<span></span>
</td>
<td class="nump">1,408.8<span></span>
</td>
<td class="nump">944.9<span></span>
</td>
<td class="nump">1,442.9<span></span>
</td>
<td class="nump">915.0<span></span>
</td>
<td class="nump">1,171.2<span></span>
</td>
<td class="nump">5,888.5<span></span>
</td>
<td class="nump">4,474.0<span></span>
</td>
<td class="nump">2,670.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Idec Inc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,439.7<span></span>
</td>
<td class="nump">$ 1,545.9<span></span>
</td>
<td class="nump">$ 1,494.1<span></span>
</td>
<td class="nump">$ 1,408.8<span></span>
</td>
<td class="nump">$ 946.8<span></span>
</td>
<td class="nump">$ 1,444.4<span></span>
</td>
<td class="nump">$ 866.6<span></span>
</td>
<td class="nump">$ 1,172.9<span></span>
</td>
<td class="nump">$ 5,888.5<span></span>
</td>
<td class="nump">$ 4,430.7<span></span>
</td>
<td class="nump">$ 2,539.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 4.18<span></span>
</td>
<td class="nump">$ 5.55<span></span>
</td>
<td class="nump">$ 31.47<span></span>
</td>
<td class="nump">$ 21.63<span></span>
</td>
<td class="nump">$ 11.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.08<span></span>
</td>
<td class="nump">$ 8.39<span></span>
</td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="nump">$ 7.15<span></span>
</td>
<td class="nump">$ 4.73<span></span>
</td>
<td class="nump">$ 7.15<span></span>
</td>
<td class="nump">$ 4.18<span></span>
</td>
<td class="nump">$ 5.54<span></span>
</td>
<td class="nump">$ 31.42<span></span>
</td>
<td class="nump">$ 21.58<span></span>
</td>
<td class="nump">$ 11.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">177.8<span></span>
</td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">196.6<span></span>
</td>
<td class="nump">199.8<span></span>
</td>
<td class="nump">201.4<span></span>
</td>
<td class="nump">207.1<span></span>
</td>
<td class="nump">211.4<span></span>
</td>
<td class="nump">187.1<span></span>
</td>
<td class="nump">204.9<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">178.2<span></span>
</td>
<td class="nump">184.2<span></span>
</td>
<td class="nump">190.4<span></span>
</td>
<td class="nump">197.0<span></span>
</td>
<td class="nump">200.3<span></span>
</td>
<td class="nump">201.9<span></span>
</td>
<td class="nump">207.3<span></span>
</td>
<td class="nump">211.7<span></span>
</td>
<td class="nump">187.4<span></span>
</td>
<td class="nump">205.3<span></span>
</td>
<td class="nump">213.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 600.8<span></span>
</td>
<td class="nump">$ 595.8<span></span>
</td>
<td class="nump">$ 576.4<span></span>
</td>
<td class="nump">$ 517.4<span></span>
</td>
<td class="nump">$ 534.9<span></span>
</td>
<td class="nump">$ 511.7<span></span>
</td>
<td class="nump">$ 490.4<span></span>
</td>
<td class="nump">$ 443.2<span></span>
</td>
<td class="nump">$ 2,290.4<span></span>
</td>
<td class="nump">$ 1,980.2<span></span>
</td>
<td class="nump">$ 1,559.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">145.7<span></span>
</td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">160.0<span></span>
</td>
<td class="nump">292.4<span></span>
</td>
<td class="nump">165.7<span></span>
</td>
<td class="nump">147.2<span></span>
</td>
<td class="nump">108.6<span></span>
</td>
<td class="nump">164.4<span></span>
</td>
<td class="nump">707.7<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,924.8<span></span>
</td>
<td class="nump">$ 2,894.7<span></span>
</td>
<td class="nump">$ 2,880.3<span></span>
</td>
<td class="nump">$ 2,680.0<span></span>
</td>
<td class="nump">$ 2,825.7<span></span>
</td>
<td class="nump">$ 2,780.1<span></span>
</td>
<td class="nump">$ 2,757.5<span></span>
</td>
<td class="nump">$ 2,523.5<span></span>
</td>
<td class="nump">$ 11,379.8<span></span>
</td>
<td class="nump">$ 10,886.8<span></span>
</td>
<td class="nump">$ 10,354.7<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871665264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">&#160;&#160;&#160;&#160;Intangible Assets and Goodwill<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:20%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-28 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7,379.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(4,881.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,497.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,187.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4,607.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,580.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>965.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>965.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>476.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>476.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and trade names</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8,408.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(4,881.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3,527.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,727.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4,607.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,120.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Amortization and Impairments</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$489.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$747.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$814.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Amortization of acquired intangible assets, excluding impairment charges, totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$274.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$381.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$455.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The decrease in amortization of acquired intangible assets, excluding impairment charges, over the three years was primarily due to a lower rate of amortization for acquired intangible assets, primarily due to prior year impairments.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization and impairments of acquired intangible assets reflects the impact of a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$215.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge to reduce the fair value of IPR&amp;D assets associated with BG00011 (STX-100) to zero, as discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the impact of impairment charges related to certain IPR&amp;D assets associated with our vixotrigine program totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$189.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflect the impact of impairment charges of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$176.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$328.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our intangible </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">assets associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Completed Technology</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan. The net book value of the TYSABRI asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.8 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology also includes </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$155.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), following the approval of VUMERITY in the U.S. in October 2019, technology related to our AVONEX product, which we recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003, our rest of world license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below, and other amounts related to our other marketed products and other programs acquired through business combinations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">TECFIDERA License Rights</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.25 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$795.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded within intangible assets in the first quarter of 2017. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We had an intellectual property dispute with Forward Pharma in the U.S. concerning intellectual property related to TECFIDERA. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$328.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute and continued to amortize the remaining net book value of the U.S. intangible asset in our consolidated statements of income utilizing an economic consumption model. The U.S. Court of Appeals for the Federal Circuit upheld the U.S. Patent and Trademark Office&#8217;s March 2017 ruling and in January 2019 denied Forward Pharma's petition for rehearing. We evaluated the recoverability of the U.S. asset based upon these most recent developments and recorded a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$176.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge in the fourth quarter of 2018 to reduce the remaining net book value of the U.S. asset to zero.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an intellectual property dispute with Forward Pharma in the European Union (E.U.) concerning intellectual property related to TECFIDERA. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the European Patent Office (EPO) revoked Forward Pharma&#8217;s European Patent No. 2 801 355. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for June 2020. Based upon our assessment of this ruling, we continue to amortize the remaining net book value of the rest of world intangible asset in our consolidated statements of income utilizing an economic consumption model. The remaining net book value of the TECFIDERA rest of world intangible asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$36.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the dispute with Forward Pharma in the E.U., please read Note 20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D Related to Business Combinations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life and amortize these amounts based upon an economic consumption method. The carrying value associated with our IPR&amp;D assets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Limited (Convergence), Stromedix Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN) in 2019, 2015, 2012 and 2010, respectively. IPR&amp;D balances include adjustments related to foreign currency exchange rate fluctuations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long-range planning cycle, which was most recently updated in the second quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&#160;&#160;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of NST in June 2019, we acquired IPR&amp;D programs with an estimated fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$700.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">BG00011</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of idiopathic pulmonary fibrosis (IPF) due to safety concerns. As a result, we recognized an impairment charge of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$215.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2019 to reduce the fair value of the IPR&amp;D intangible asset to zero. We also adjusted the value of our contingent consideration obligations related to this asset resulting in a gain of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$61.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter of 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Vixotrigine</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the potential treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR. As a result, we recognized an impairment charge of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2018 to reduce the fair value of the related IPR&amp;D intangible asset to zero. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN as we awaited the outcome of ongoing interactions with the FDA regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy. We reassessed the fair value of the TGN program using reduced expected lifetime revenues, higher expected clinical development costs and lower cumulative probability of success. As a result of that reassessment, we recognized an impairment charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$129.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2018 to reduce the fair value of the TGN IPR&amp;D intangible asset to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$41.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The IPR&amp;D impairment charges were included in amortization and impairment of acquired intangible assets and the gain resulting from the remeasurement of our contingent consideration obligation was recorded in (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income. The fair value of the intangible assets and contingent consideration obligations were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues, costs and probabilities of success.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the second quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>260.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>225.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>230.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,706.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,632.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>117.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,080.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(69.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,757.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,706.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase to goodwill during </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase to goodwill during </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.2 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestones achieved (exclusive of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$119.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in tax benefits) and payable to the former shareholders of Fumapharm AG and holders of their rights. In the fourth quarter of 2018 we achieved the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$20.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales level threshold and accrued the final contingent payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$300.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to FUMADERM and TECFIDERA (together, the Fumapharm Products), which was paid in the first quarter of 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The elimination of goodwill represents an allocation based upon the relative fair value of our Hiller&#248;d, Denmark manufacturing operations at the divestiture date. In connection with the divestiture of our Hiller&#248;d, Denmark manufacturing operations, our remaining goodwill was reviewed for impairment, and based upon this review, no impairments were recognized. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill. </span></div>Other includes changes related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6629591344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text">Collaborative and Other Relationships<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depending on the collaborative arrangement, we may record funding receivable or payable balances with our collaboration partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaborative arrangements are discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech, Inc. (Roche Group)</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration arrangements will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#8217;s offer or purchase Genentech&#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN, as well as all development and commercialization activities as follows:</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">U.S.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Canada</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">GAZYVA</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">OCREVUS</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FDA approved OCREVUS for the treatment of RMS and PPMS. Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>13.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and increasing up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if annual net sales exceed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$900.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. There will be a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we receive a gross </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11 years</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS has been approved for the treatment of RMS and PPMS in the E.U. and certain other countries. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Profit-sharing Formulas</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">RITUXAN Profit Share</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share on the first </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:82%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>40.0</span></span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>39.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>37.5</span></span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>35.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</span></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$500.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN pre-tax profits in the U.S. decreased from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>39%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>37.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12-month period exceeded </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>37.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on certain events.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GAZYVA Profit Share</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax profit-sharing formula for GAZYVA provides for a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share on the first </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating profits earned each calendar year. Our share of annual profits in excess of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:82%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>39.0</span></span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>37.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>35.0</span></span></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of GAZYVA operating profits in 2019 and 2018 was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>37.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> our share of operating profits on GAZYVA was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,431.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,316.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>748.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>548.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>242.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,290.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,980.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,559.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2012 we entered into a collaboration and license agreement with Ionis pursuant to which we have an exclusive, worldwide license to develop and commercialize SPINRAZA for the treatment of SMA. SPINRAZA was approved for the treatment of SMA in the U.S., E.U. and Japan in December 2016, June 2017 and July 2017, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized product revenues of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2,097.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,724.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$883.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, on our sales of SPINRAZA. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$293.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$238.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$112.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we made milestone payments to Ionis totaling&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;related to the marketing approvals discussed above, which were capitalized in intangible assets, net in our consolidated balance sheets.  </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Antisense Therapeutics</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three gene targets. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, Ionis is responsible for global development of any product candidate</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$130.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if we successfully develop the product candidate after option exercise. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis and agreed to make potential additional payments, prior to licensing, of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 we recognized this </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone upon the selection of BIIB080 (tau ASO), which is currently in Phase 1 development for the potential treatment of AD. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080. In connection with the option exercise, we made a payment of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to Ionis, which was recorded as research and development expense in our consolidated statements of income. Future payments may include additional milestone payments of up to&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$155.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;and royalties on future sales of in the low- to mid-teens if we successfully develop the product candidate after option exercise.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2018 Ionis Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we closed a </span><span><span style="font-family:Franklin Gothic Book,sans-serif;">10</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year exclusive collaboration agreement with Ionis to develop novel antisense oligonucleotide (ASO) drug candidates for a broad range of neurological diseases (2018 Ionis Agreement) for a total payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$375.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and the purchase of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of Ionis common stock at a cost of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$625.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon closing, we recorded </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$375.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment as prepaid services in our consolidated balance sheets and recognized the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$324.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as research and development expense in our consolidated statements of income. The amount recorded as prepaid services represented the value of the employee resources committed to the arrangement to provide research and discovery services over the term of the agreement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of Ionis common stock were purchased at a premium to their fair value at the transaction closing date. The premium consisted of acquiring the shares at a price above the fair value based on the trailing 10-day weighted-average close price prior to entering into the 2018 Ionis Agreement in April 2018 and the effect of certain holding period restrictions. We recorded an asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$462.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in investments and other assets in our consolidated balance sheets reflecting the fair value of the common stock as of the purchase date and a charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$162.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to research and development expense in our consolidated statements of income in the second quarter of 2018 reflecting the premium paid for the common stock. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Ionis common stock is remeasured each reporting period. Changes in the fair value of our investment in Ionis common stock, including the effect of the holding period restrictions, are reflected in other income (expense), net in our consolidated statements of income. For additional information on the fair value of our investment in Ionis common stock, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have the option to license therapies arising out of this agreement and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$125.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$270.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for each program, depending on the indication plus an annual license fee, as well as royalties on potential net commercial sales.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we incurred milestones of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the advancement of neurological targets identified under this agreement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2017 SMA Collaboration Agreement</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2017 we entered into a collaboration agreement with Ionis to identify new ASO drug candidates for the potential treatment of SMA. Under this agreement, we have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of such therapies.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment to Ionis and we may pay Ionis up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$260.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and regulatory milestone payments if new drug candidates advance to marketing approval. Upon commercialization, we may also pay Ionis up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$800.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2013 Long-term Strategic Research Agreement</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2013 we entered into a </span><span><span style="font-family:Franklin Gothic Book,sans-serif;">six</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the potential treatment of neurological diseases.&#160;Under this agreement, Ionis performs research on a set of neurological targets identified within the agreement. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis is eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us under the terms of the agreement. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For non-ALS antisense product candidates, Ionis is responsible for global development through the completion of a Phase 2 trial and we provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$130.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (tofersen), an investigational treatment for ALS with superoxide dismutase 1 (SOD1) mutations. In connection with the option exercise, we made a payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$35.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis, which was recorded as research and development in our consolidated statements of income. Future payments may include potential post-licensing milestone payments of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$55.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and royalties in the low to mid-teen percentages on potential annual worldwide net sales. We are solely responsible for the costs and expenses related to the development, manufacturing and commercialization of tofersen following the option exercise. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ending </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we incurred milestones of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$18.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$12.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of programs under this agreement, which were recorded as research and development expense in our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates for the potential treatment of AD, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor (the BAN2401 and Elenbecestat Collaboration). </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019 we and Eisai announced the decision to discontinue the global Phase 3 studies (MISSION AD1 and MISSION AD2) of elenbecestat in early AD. As a result of this decision, in the third quarter of 2019, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$48.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our share of the termination of various clinical trials and research and development contracts incurred under the BAN2401 and Elenbecestat Collaboration.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. Upon marketing approval we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for early AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>348.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>232.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>146.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>174.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>116.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>74.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>32.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>16.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, the two companies will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early AD. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">study met its pre-specified primary and secondary endpoints. In October 2019 we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of aducanumab development expense incurred and beginning January 1, 2019, is reimbursing us for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of aducanumab development expense incurred. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the termination of various clinical trials and research and development contracts net of the expected </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. We will receive a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in the U.S., a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>68.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in the E.U. and a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The two companies will continue to share equally in the potential profits (losses) in rest of world markets. Sales and marketing expense incurred before commercialization are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>264.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>268.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>98.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>234.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>268.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>27.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.  </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-Tau Option</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Alkermes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes for VUMERITY, a novel fumarate for the treatment of RMS. In October 2019 the FDA approved VUMERITY in the U.S. for the treatment of RMS. In November 2019 VUMERITY became available in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received an exclusive, worldwide license to develop and commercialize VUMERITY and we pay Alkermes a royalty of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on worldwide net commercial sales of VUMERITY. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Alkermes is eligible to receive royalties in the high-single digits to sub-teen double digits of annual net commercial sales upon successful development and commercialization of new product candidates, other than VUMERITY, developed under the exclusive license from Alkermes. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$28.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment to Alkermes representing our share of VUMERITY development costs already incurred in 2017. Beginning in 2018 we became responsible for all </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">development expenses related to VUMERITY. In December 2017 we also recognized a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> expense, which was paid to Alkermes in 2018, enabling the continuation of the agreement to develop VUMERITY. Both the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$28.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> continuation payment were recorded as research and development expense in our consolidated financial statements during the year ended December 31, 2017. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2019, following the FDA's approval of VUMERITY, we paid Alkermes </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$155.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments, which were recorded in intangible assets in our consolidated balance sheets and will be amortized over the useful life of the product. For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$53.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$68.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$80.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in research and development expense in our consolidated statements of income related to this collaboration.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Alkermes currently supplies VUMERITY to us pursuant to a supply agreement with Alkermes. In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes pursuant to which we have the election, following a transition period, to manufacture VUMERITY or have manufacturing transitioned to a third party in exchange for an increase in the royalty rate on worldwide net commercial sales of VUMERITY that is manufactured by us or our designee.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for the development and potential commercialization of BIIB092 (gosuranemab), an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received worldwide rights to gosuranemab and are responsible for the full development and potential commercialization of gosuranemab in AD and progressive supranuclear palsy (PSP). </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we announced that the Phase 2 PASSPORT study investigating gosuranemab in individuals with PSP did not meet its primary endpoint. Based on these results, we discontinued development of gosuranemab in PSP and other primary tauopathies. We will continue our ongoing Phase 2 TANGO study of gosuranemab for mild cognitive impairment due to AD or mild AD, given differences in disease pathology.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$300.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to BMS and assumed all remaining obligations to the former shareholders of iPierian, Inc. (iPierian) related to BMS&#8217;s acquisition of iPierian in 2014. In June 2017 we recognized a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 PASSPORT study of gosuranemab for PSP.  Both the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$300.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment and the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone payment were recorded as research and development expense in our consolidated statements of income for the year ended December 31, 2017.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may pay BMS up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$360.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments, and potential royalties, and we may pay the former shareholders of iPierian up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$370.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestone payments as well as potential royalties on net commercial sales.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$144.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$97.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in research and development expense in our consolidated statements of income related to this collaboration.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and we may pay potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. The next expected milestone would be </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due if ex-U.S. net sales reach </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over a period of four consecutive quarters. Royalty payments are recognized in cost of sales within our consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">agreement between Acorda and Alkermes Inc., who acquired Elan Drug Technologies, the original party to the license with Acorda. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ending </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$42.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$36.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$34.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie for the development and commercialization of ZINBRYTA, which was approved for the treatment of RMS in the U.S. in May 2016 and in the E.U. in July 2016. The collaboration began selling ZINBRYTA in the third quarter of 2016. In March 2018 we and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for RMS.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we and AbbVie conducted ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories, where development and commercialization costs and profits were shared equally.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We were responsible for manufacturing and research and development activities and recorded these activities within their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures received from AbbVie.&#160;For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the collaboration incurred </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$32.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$39.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for research and development activities, respectively, for which we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$16.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$19.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie recognized revenues on sales to third parties and we recognized our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of the co-promotion losses on ZINBRYTA in the U.S. for the year ended December 31, 2019, was immaterial. For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenues from collaborative and other relationships, a component of other revenues, of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$8.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$16.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect our share of the overall net losses within the collaboration for each of those years.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.4 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as potential royalties on net commercial sales.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$74.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$38.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our consolidated statements of income and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$35.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our consolidated balance sheets and will be expensed as the services are provided. In October 2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$8.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into several research, discovery and other related arrangements that resulted in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$30.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$22.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, recorded as research and development expense in our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis Co., Ltd.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;Samsung BioLogics contributed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>280.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>85%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> stake in Samsung Bioepis and we contributed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ownership interest.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflected the effect of previous equity financings in which we did not participate, to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics.&#160;As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$675 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$115 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to inventory, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$615 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to developed technology and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$170 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to IPR&amp;D. A deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$225 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years, respectively, one quarter in arrears.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized losses on our investment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$79.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These losses reflect our share of losses totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and amortization of basis differences totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$78.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>670.8 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$580.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$680.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets within our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2019 Transaction</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Samsung Bioepis in January 2020, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$63.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our consolidated statements of income and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$37.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as an intangible asset in our consolidated balance sheets. Additionally, we may pay Samsung Bioepis up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$210.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development, regulatory and sales-based milestones, including a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> development milestone that we may pay in 2020. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also acquired an option to extend the term of our current European commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and obtained exclusive rights to commercialize these products in China. </span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2013 Commercial Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2013 pursuant to our rights under the joint venture agreement with Samsung BioLogics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, 3 anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of BENEPALI, Japan.&#160;As discussed above, we have an option to extend this agreement by an additional five years. Under this agreement, we have made upfront and clinical development milestone payments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$46.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept biosimilar referencing ENBREL, received regulatory approval in the E.U. in August 2017, May 2016 and January 2016, respectively, and we capitalized the related milestone payments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as intangible assets, net in our consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we and Samsung Bioepis announced an agreement with AbbVie related to the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. We began to recognize revenues on sales of IMRALDI to third parties in Europe in the fourth quarter of 2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$241.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$187.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$111.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development and analytical development. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019 FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under the technical development services and manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$106.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$96.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$42.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues under the license, technical development services and manufacturing agreements, which is reflected in revenues from collaborative and other relationships, as a component of other revenues in our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts receivable from Samsung Bioepis related to the agreements discussed above were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$85.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>116.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Amounts payable to Samsung Bioepis as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisted of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment related to the 2019 transaction we completed in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as discussed above. Amounts payable to Samsung Bioepis as of December 31, 2018, were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$31.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6878761840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(4.50%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(11.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets', window );">Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization', window );">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</a></td>
<td class="num">(2.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction', window );">Manufacturing deduction</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">2017 Tax Act</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">22.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent', window );">Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Impairment of ZINBRYTA related tax assets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">16.30%<span></span>
</td>
<td class="nump">24.20%<span></span>
</td>
<td class="nump">47.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation manufacturing deduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6876305824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Liabilities, Noncurrent</a></td>
<td class="nump">$ 1,389.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,348.9<span></span>
</td>
<td class="nump">$ 1,389.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.5<span></span>
</td>
<td class="nump">1,080.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Accrued construction in progress</a></td>
<td class="nump">125.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
<td class="nump">125.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued Income Taxes, Noncurrent</a></td>
<td class="nump">791.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803.3<span></span>
</td>
<td class="nump">791.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Accrued construction in progress</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG | Twenty billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG | Each additional one billion up to twenty billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">$ 20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG | Fifteen billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG | Sixteen billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_TwentybillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_TwentybillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_FifteenbillionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_FifteenbillionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_SixteenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_SixteenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871655184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings&#160;per Share<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,888.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,430.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,539.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>187.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>204.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>212.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>187.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>205.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>213.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Earnings per share for the years ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects, on a weighted average basis, the repurchase of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock, respectively, under our March 2019, 2018 and 2016 Share Repurchase Programs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871627328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Guarantees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesAbstract', window );"><strong>Guarantees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesTextBlock', window );">Guarantees</a></td>
<td class="text">Guarantees<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not have significant liabilities recorded for guarantees.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI http://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7014364656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details Textual)<br> shares in Millions, $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="13">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 05, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,280.6<span></span>
</td>
<td class="nump">$ 2,597.2<span></span>
</td>
<td class="nump">$ 2,253.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,377.9<span></span>
</td>
<td class="nump">13,452.9<span></span>
</td>
<td class="nump">12,273.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,955.4<span></span>
</td>
<td class="nump">1,816.3<span></span>
</td>
<td class="nump">1,630.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241.6<span></span>
</td>
<td class="nump">185.0<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Prepaid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,252.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,690.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,690.6<span></span>
</td>
<td class="nump">1,252.8<span></span>
</td>
<td class="nump">1,690.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">676.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold', window );">Expected additional milestone payments when certain sales threshold is met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments', window );">Expected License Fee And Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Upfrontpaymentforcollaborationagreement', window );">Upfront payment for collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 486.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">six<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Totalpaymenttoentercollaborationagreement', window );">Total payment to enter collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Purchaseofcommonstock', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Premiumonpurchaseofcommonstock', window );">Premium on purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstockvalue', window );">Investment in common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174.3<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">BAN2401 and Elenbecestat R&amp;D expense incurred by collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 348.7<span></span>
</td>
<td class="nump">232.0<span></span>
</td>
<td class="nump">146.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on Contract Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember', window );">Alkermes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.5<span></span>
</td>
<td class="nump">68.7<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember', window );">Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144.0<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember', window );">iPerian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DevelopmentalMilestonePayment', window );">Developmental Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AcordaMember', window );">Acorda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
<td class="nump">36.5<span></span>
</td>
<td class="nump">34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold', window );">Expected additional milestone payments when certain sales threshold is met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignSalesRequiredToTriggerMilestone', window );">Foreign sales required to trigger milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember', window );">Skyhawk Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Contract Option Exercise Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.2<span></span>
</td>
<td class="nump">96.4<span></span>
</td>
<td class="nump">42.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241.6<span></span>
</td>
<td class="nump">187.4<span></span>
</td>
<td class="nump">$ 111.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Equity Method Investments, Expected Profit Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.9<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="nump">116.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.5<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 31.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of Co promotion Operating Profits first fifty million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne', window );">Until GAZYVA First Non-CLL FDA Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of Co promotion Operating Profits first fifty million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment', window );">Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SalesTriggerGrossSalesThreshold', window );">Sales Trigger Gross Sales Threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti-CD20 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti-CD20 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage', window );">Royalty operating profit threshold for highest royalty rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyrate', window );">Reduction in royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PeriodOfCollaborationAgreement', window );">Period of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 52.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecorded tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">19.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,097.0<span></span>
</td>
<td class="nump">1,724.2<span></span>
</td>
<td class="nump">883.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,097.0<span></span>
</td>
<td class="nump">1,724.2<span></span>
</td>
<td class="nump">883.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293.0<span></span>
</td>
<td class="nump">238.0<span></span>
</td>
<td class="nump">112.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Ionis Pharmaceuticals | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage Of Royalties As Per Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Ionis Pharmaceuticals | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage Of Royalties As Per Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SOD1Member', window );">SOD1 | Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | Alkermes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage Of Royalties As Per Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 738.3<span></span>
</td>
<td class="nump">545.1<span></span>
</td>
<td class="nump">379.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement', window );">Investments By Third Party In Joint Venture As Per Agreement.</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 280.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_JointVentureOwnerShipPercentageByThirdParty', window );">Joint Venture Owner Ship Percentage By Third Party.</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 580.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="nump">$ 580.2<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 670.8<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 49.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Samsung Bioepis, ownership percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Samsung Bioepis, ownership percentage before additional purchase transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">BAN2401 and Elenbecestat R&amp;D expense incurred by collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
<td class="nump">39.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Aducanumab [Member] | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">BAN2401 and Elenbecestat expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">933.4<span></span>
</td>
<td class="nump">854.0<span></span>
</td>
<td class="nump">657.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember', window );">Outside the U.S | OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember', window );">European Union | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">JAPAN | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_AbbVieMember', window );">AbbVie | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(16.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_AbbVieMember', window );">AbbVie | U.S | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.6)<span></span>
</td>
<td class="num">$ (16.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventories | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Completed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember', window );">Deferred tax liability | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember', window );">Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember', window );">Development Milestones | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DevelopmentalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Developmental Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DevelopmentalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected additional milestone payments when meeting certain sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected license fee and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignSalesRequiredToTriggerMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign sales required to trigger milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignSalesRequiredToTriggerMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future royalties percentage to be received on sale of product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Futurepercentageofcopromotionoperatingprofits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future percentage of co-promotion operating profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Futurepercentageofcopromotionoperatingprofits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstocksharespurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, shares purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstocksharespurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstockvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstockvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments by third party in joint venture as per agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_JointVentureOwnerShipPercentageByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint venture owner ship percentage by third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_JointVentureOwnerShipPercentageByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits first fifty million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfRoyaltiesAsPerCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfRoyaltiesAsPerCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PeriodOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PeriodOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Premiumonpurchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Premiumonpurchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Purchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Purchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyrate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyrate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty operating profit threshold for highest royalty rate percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SalesTriggerGrossSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales trigger gross sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SalesTriggerGrossSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales to be achieved in any twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Totalpaymenttoentercollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total payment to enter collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Totalpaymenttoentercollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Upfrontpaymentforcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment for collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Upfrontpaymentforcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AlkermesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IPerianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AcordaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AcordaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_NewAntiCd20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_NewAntiCd20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OCREVUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OCREVUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SOD1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SOD1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_VUMERITYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_VUMERITYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6879802096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 191.2<span></span>
</td>
<td class="nump">$ 168.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (138.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">225.4<span></span>
</td>
<td class="nump">181.6<span></span>
</td>
<td class="nump">$ 169.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(8.9)<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">216.5<span></span>
</td>
<td class="nump">170.1<span></span>
</td>
<td class="nump">160.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">30.4<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">134.0<span></span>
</td>
<td class="nump">126.6<span></span>
</td>
<td class="nump">107.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_PerformanceUnitsMember', window );">Performance Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair-value post-combination equity compensation</a></td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6768748240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryrawmaterialssoldtoFUJIFILM', window );">Inventory raw materials sold to FUJIFILM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs on excess, obsolete, unmarketable or other inventory</a></td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="nump">$ 41.9<span></span>
</td>
<td class="nump">$ 76.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember', window );">Work-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory work-in-process sold to FUJIFILM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventorysoldtoBioverativcost', window );">Inventory sold to Bioverativ, cost</a></td>
<td class="nump">$ 184.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryrawmaterialssoldtoFUJIFILM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory raw materials sold to FUJIFILM</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryrawmaterialssoldtoFUJIFILM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventorysoldtoBioverativcost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory sold to Bioverativ, cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventorysoldtoBioverativcost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871572368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-cd20 therapeutic programs</a></td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542.4<span></span>
</td>
<td class="nump">1,431.9<span></span>
</td>
<td class="nump">1,316.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">748.0<span></span>
</td>
<td class="nump">548.3<span></span>
</td>
<td class="nump">242.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-cd20 therapeutic programs</a></td>
<td class="nump">$ 600.8<span></span>
</td>
<td class="nump">$ 595.8<span></span>
</td>
<td class="nump">$ 576.4<span></span>
</td>
<td class="nump">$ 517.4<span></span>
</td>
<td class="nump">$ 534.9<span></span>
</td>
<td class="nump">$ 511.7<span></span>
</td>
<td class="nump">$ 490.4<span></span>
</td>
<td class="nump">$ 443.2<span></span>
</td>
<td class="nump">$ 2,290.4<span></span>
</td>
<td class="nump">$ 1,980.2<span></span>
</td>
<td class="nump">$ 1,559.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6877166656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax Beginning Balance</a></td>
<td class="num">$ (240,400,000)<span></span>
</td>
<td class="num">$ (318,400,000)<span></span>
</td>
<td class="num">$ (319,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(240,400,000)<span></span>
</td>
<td class="num">(318,400,000)<span></span>
</td>
<td class="num">(318,400,000)<span></span>
</td>
<td class="num">$ (316,900,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="nump">230,800,000<span></span>
</td>
<td class="nump">29,500,000<span></span>
</td>
<td class="num">(42,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts Reclassified From Accumulated Other Comprehensive Income, Net of Tax</a></td>
<td class="num">(125,600,000)<span></span>
</td>
<td class="nump">47,000,000.0<span></span>
</td>
<td class="nump">44,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">105,200,000<span></span>
</td>
<td class="nump">76,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax Ending Balance</a></td>
<td class="num">(135,200,000)<span></span>
</td>
<td class="num">(240,400,000)<span></span>
</td>
<td class="num">(318,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Securities Available for Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax Beginning Balance</a></td>
<td class="num">(4,000,000.0)<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="num">(10,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(4,000,000.0)<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="nump">11,800,000<span></span>
</td>
<td class="num">(10,600,000)<span></span>
</td>
<td class="num">(3,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts Reclassified From Accumulated Other Comprehensive Income, Net of Tax</a></td>
<td class="num">(3,600,000)<span></span>
</td>
<td class="nump">6,700,000<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">8,200,000<span></span>
</td>
<td class="num">(3,900,000)<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax Ending Balance</a></td>
<td class="nump">4,200,000<span></span>
</td>
<td class="num">(4,000,000.0)<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax Beginning Balance</a></td>
<td class="nump">34,700,000<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
<td class="nump">57,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">7,800,000<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
<td class="nump">57,800,000<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="nump">88,100,000<span></span>
</td>
<td class="nump">97,400,000<span></span>
</td>
<td class="num">(193,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts Reclassified From Accumulated Other Comprehensive Income, Net of Tax</a></td>
<td class="num">(115,000,000.0)<span></span>
</td>
<td class="nump">41,800,000<span></span>
</td>
<td class="nump">31,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(26,900,000)<span></span>
</td>
<td class="nump">139,200,000<span></span>
</td>
<td class="num">(162,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax Ending Balance</a></td>
<td class="nump">7,800,000<span></span>
</td>
<td class="nump">34,700,000<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (Losses) on Net Investment Hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax Beginning Balance</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="nump">28,600,000<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts Reclassified From Accumulated Other Comprehensive Income, Net of Tax</a></td>
<td class="num">(7,000,000.0)<span></span>
</td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">21,600,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax Ending Balance</a></td>
<td class="nump">25,100,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded Status of Post Retirement Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax Beginning Balance</a></td>
<td class="num">(31,300,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="num">(32,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(32,800,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="num">(4,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts Reclassified From Accumulated Other Comprehensive Income, Net of Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="num">(4,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax Ending Balance</a></td>
<td class="num">(32,800,000)<span></span>
</td>
<td class="num">(31,300,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax Beginning Balance</a></td>
<td class="num">(243,300,000)<span></span>
</td>
<td class="num">(175,500,000)<span></span>
</td>
<td class="num">(334,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(243,300,000)<span></span>
</td>
<td class="num">(243,300,000)<span></span>
</td>
<td class="num">(334,200,000)<span></span>
</td>
<td class="num">(175,500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="nump">103,800,000<span></span>
</td>
<td class="num">(67,800,000)<span></span>
</td>
<td class="nump">158,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts Reclassified From Accumulated Other Comprehensive Income, Net of Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">103,800,000<span></span>
</td>
<td class="num">(67,800,000)<span></span>
</td>
<td class="nump">158,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax Ending Balance</a></td>
<td class="num">$ (139,500,000)<span></span>
</td>
<td class="num">$ (243,300,000)<span></span>
</td>
<td class="num">$ (175,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unrealized Gains (Losses) on Securities Available for Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unrealized Gains (Losses) on Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Gains (Losses) on Net Investment Hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unfunded Status of Post Retirement Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724394-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6889478400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,888.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,430.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,539.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>187.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>204.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>212.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>187.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>205.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>213.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895915040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,695.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,695.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,013.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,013.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>337.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>329.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,920.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>5,912.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>354.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,459.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,459.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>969.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>969.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>615.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>563.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,102.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,050.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>434.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,509.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,489.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,038.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,000.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>1,897.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,745.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>2,107.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,802.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>6,553.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,037.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>523.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>(63.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(12.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(101.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6895930688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LesseeLeaseTableTableTextBlock', window );">Schedule of operating leases</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All of our leases qualify as operating leases. The following table summarizes the presentation in our consolidated balance sheets of our operating leases:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:41%;"/><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>427.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>73.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>412.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>486.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Operating lease costs</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of lease costs in our consolidated statements of income:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:41%;"/><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the year ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>84.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(25.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>86.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating lease liability maturity</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The minimum lease payments for the next five years and thereafter is expected to be as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>87.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>81.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>75.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>72.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>69.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>158.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>544.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>58.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>486.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Minimum lease payments</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the five years and total thereafter as of December&#160;31, 2018, were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>87.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>80.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>75.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>601.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(26.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(25.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(23.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(58.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(182.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>418.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock', window );">Operating lease weighted average remaining term and discount rate [Table Text Block]</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:83%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term in years</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.07</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock', window );">Operating lease supplemental cash flow disclosure [Table Text Block]</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our consolidated statements of cash flows is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the year ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>93.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>35.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LesseeLeaseTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Lease Table [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LesseeLeaseTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease supplemental cash flow disclosure [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease weighted average remaining term and discount rate [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
